National Institute of Mental Health



The National Clearinghouse for Mental Health Information

VOL. 16 NO. 3 January 1979 Psychopharmacology Abstracts



PSYCHOPHARMACOLOGY ABSTRACTS is a publication of the National Clearinghouse for Mental Health Information of the National Institute of Mental Health. It is a specialized information medium designed to assist the Institute in meeting its obligation to foster and support laboratory and clinical research into the nature and causes of mental disorders and methods of treatment and prevention. Specifically, this information service is designed to meet the needs of investigators in the field of psychopharmacology for rapid and comprehensive information about new developments and research results. For information or correspondence with the National Institute of Mental Health concerning *Psychopharmacology Abstracts*, changes of address, or removal of names from the mailing list see the inside back cover page.

The Secretary of Health, Education, and Welfare has determined that the publication of this periodical is necessary in the transaction of the public business required by law of this Department. Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through November 15, 1982.

NATIONAL CLEARINGHOUSE FOR MENTAL HEALTH INFORMATION PSYCHOPHARMACOLOGY ABSTRACTS

Volume 16

Cumulative Index

June 1979

																			Page
Author Index		•	•				٠	*	٠		*	*						,	A1
Subject Index																			SI

Carrie Lee Rothgeb, Editor Bette L. Shannon, Managing Editor

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service

Alcohol, Drug Abuse and Mental Health Administration National Institute of Mental Health National Clearinghouse for Mental Health Information 5600 Fishers Lane Rockville, Maryland 20857

DHEW Publication No. (ADM) 80-150 Printed 1980

For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. Subscription price per year in the United States, Canada, and Mexico: \$14.00; other countries, \$17.50. Single copy \$3.50; other countries \$4.40. Index issue \$2.10. The Clearinghouse does not sell copies of *Psychopharmacology Abstracts*. Persons wishing to subscribe by the year or to purchase single copies should send their orders, accompanied by check or money order, directly to the Superintendent of Documents.

AUTHOR INDEX

[The 6-digit number is the abstract accession number. The next two digits are the issue number; digits after hypen are the category number.]

AAES-JORGENSEN T 000037 01-03
ABBAS R 001019 02-02
ABBATIELLO ER 001510 02-05
ABBOTT FS 000687 01-13
ABBRUZZESE G 000585 01-09
ABDALLAH AH 001020 02-02, 001295 02-04
ABDEL-LATIF AA 002802 04-03
ABDULLAH S 000618 01-11
ABE H 002803 04-03
ABE K 000936 01-17
ABEL EL 003151 04-04
ABERG A 000555 01-09
ABERNATHY CO 001502 02-05
ABIUSO PD 001738 02-15
ABOOD LE 000044 01-03, 000404 01-04
ABOAD ME 000404 01-03, 000404 01-04
ABRAHAM DJ 001640 02-13, 001648 02-13
ABRAHAM N 002154 03-03
ABRAMS A 000532 01-08, 000533 01-08
ABRAMS R 002516 03-11
ABT K 000913 01-16
ABUZZAHAB FS 000518 01-08, 002502 03-11, 002537 03-11
ACETO MD 000203 01-03, 001296 02-04, 003152 04-04
ACHEE FM 000115 01-03
ACKERMAN NR 01041 02-03
ADAM A 002385 03-07
ADAM K 002609 03-14
ADAMS AJ 002604 03-14
ADAMS AJ 002604 03-14
ADAMS AJ 002604 03-14 AAES-JORGENSEN T 000037 01-03 ADAM K 002609 03-14
ADAMS AJ 002604 03-14
ADAMS D 003581 04-11
ADAMS DJ 003580 04-11
ADAMS DJ 003550 04-11
ADAMS CO 002908 04-03
ADAMS KM 002670 03-15
ADAMS FR 000796 01-15
ADAMS PM 000306 01-04
ADAMS RN 00008 01-01
ADCOCK T 001961 03-03
ADELMAN HS 001877 02-17
ADELSTEIN AM 001780 02-15
ADER J 002804 04-03, 003025 04-03
ADER R 003153 04-04
ADERSON DJ 002944 04-03 ADERSON DJ 002944 04-03 ADINOFF B 000099 01-03 ADLAND ML 000562 01-09 ADLER M 000504 01-06, 001042 02-03, 001132 02-03, 001143 02-03, 001303 02-04 ADLER-GRASCHINSKY E 001117 02-03 ADLER-GRSCHINSKY E 001117 02-03
ADOLPHE A 001573 02-09, 003447 04-07, 003483 04-09
AFELTOWICZ Z 002543 03-13
AGARWAL RA 000038 01-03
AGGARWAL TN 001688 02-13
AGER IR 001000 02-01
AGHAJANIAN GK 000039 01-03, 000292 0103, 001095 02-03
AGNATI LF 002019 03-03
AGREN H 001692 02-13
AGUIAR M 001479 02-04
AHLENIUS S 000307 01-04, 000356 01-04, 001297 02-04, 001321 02-04, 002271 03-04, 002791 04-02
AHMED M 001171 02-03 AHMED M 001171 02-03 AHN HS 002805 04-03, 003112 04-03 AHTEE L 002806 04-03 AHN HS 002805 04-03, 003112 04-03
AHTEE L 002806 04-03
AIGNER TG 002188 03-04, 003154 04-04, 003155 04-04, 003155 04-04, 003155 04-04 and over the control of the control o

ALBALA BJ 000427 01-04
ALBANESE H 001739 02-15
ALBANO C 000585 01-09
ALBANUS L 000308 01-04
ALBERT DJ 000309 01-04, 003157 04-04
ALBERT DJ 000309 01-04, 003157 04-04
ALBERT DJ 000506 01-07
ALBERTINI RS 003642 04-15
ALBRECHTSEN R 001645 02-13
ALBY J 003479 04-09
ALDER KB 000040 01-03
ALDRIDGE A 001044 02-03
ALEVIZOS B 003594 04-13
ALEXANDER B 001807 02-15
ALEXANDER B 001807 02-15
ALEXANDER B 001807 02-15
ALEXANDER B 003159 04-04
ALEXANDER GJ 002337 03-05, 003159 04-04
ALEXANDER GJ 00041 01-3, 000670 01-11
ALGATE DR 003422 04-06
ALGERI S 001253 02-03, 001980 03-03
ALI MY 000898 01-15
ALKANA RL 002544 03-13, 002605 03-14
ALKUS SR 003581 04-11
ALLEN JJ 002646 03-15
ALLEN JJ 002646 03-15
ALLEN JJ 002637 01-03
ALLEN JJ 002640 03-13
ALLEN JJ 002640 03-13
ALLEN JJ 002640 03-13
ALLEN JM 002723 04-03
ALLEN JM 001740 02-15
ALLEN RP 002617 03-14
ALLIKARTS LK 001298 02-04
ALLILAIRE JF 003546 04-10
ALLIONEN H 001740 02-15
ALLEN MD 000630 01-17
ALLEN RP 000310 01-04, 002189 03-04
ALPERN HP 000310 01-04
ALTIMAN JL 001299 02-04
ALTIMAN N 000986 01-17, 002590 03-13
ALTIMER JL 003530 04-09
AMO K 001615 02-10
AMO 002417 03-09, 002443 03-09, 002465 03-09, 002473 03-10

AMIN R 003450 04-08

AMIT Z 000450 01-04, 002356 03-05, 003178

04-04, 003372 04-04

AMMA MPK 003482 04-09

AMSLER HA 001742 02-15

ANAND M 000312 01-04

ANANTH J 000519 01-08, 001743 02-15, 002486 03-09, 002419 03-09, 002456 03-09, 002474 03-10, 003586 04-13

ANDEN N 000042 01-03, 000043 01-03, 001021 02-02, 001300 02-04, 003387 04-04

ANDERSON D 000914 01-16

ANDERSON D 000914 01-16

ANDERSON B 001030 02-02

ANDERSON B 001030 02-02

ANDERSON B 001030 02-02

ANDERSON B 001010 03-04

ANDERSON B 001012 02-01, 001949 03-01

ANDERSON B 001040 02-04

ANDR S 02-03

ANDREWS C 000886 01-15

ANDREWS C 000886 01-15

ANDREWS C 0010878 02-17

ANDREWS M 001287 02-03
ANGEL A 001046 02-03
ANGEL C 000092 01-03
ANGEL C 000092 01-03
ANGEST B 002338 03-05, 002589 03-13
ANGEST D 000553 01-08, 000597 01-10, 000797 01-15, 002412 03-08, 003476 04-08
ANISMAN H 000313 01-04, 002261 03-04, 003260 04-04, 003612 01-15, 001542 02-07, 001559 02-08, 002390 03-08, 002391 03-08, 003451 04-08
ANINAU Z 000393 01-04
ANINAU Z 000393 01-04
ANINUZIATO L 001047 02-03, 002810 04-03
ANOCKHINA IP 003513 04-09
ANTELMAN SM 001301 02-04, 002359 03-06
ANTON G 002370 03-06
ANTONACCIO MJ 002138 03-03, 002811 04-03
ANOTILLA M 001254 02-03
AOKI N 000773 01-14
APARICIO N 000604 01-10
APPEL BH 003088 01-04, 001302 02-04, 001489 02-04, 002191 03-04, 003277 04-04, 001489 02-04, 002191 03-04, 003277 04-04, 001489 02-04, 002191 03-04, 003277 04-04, 001489 02-04, 002191 03-04, 003277 04-04, 001489 02-04, 002191 03-04, 003277 04-04, 001489 02-04, 002191 03-04, 003277 04-04, 001489 02-04, 002191 03-04, 003277 04-04, 001489 02-04, 002191 03-04, 003277 04-04, 003322 04-04, 003695 04-17
APPEL SH 001266 02-03
APPIL FA 000950 01-17
APRISION MH 002305 03-04, 002750 03-17
ARRIELS 000977 01-15
ARANA JV 000644 01-11
ARBUTHNOTT GW 002039 03-03, 003432 04-06
ARCHER GA 00102 02-02
ARGIOLAS A 001962 02-03
ARRISON BH 001962 03-03
ARRISON BH 001964 03-01
ARRAGANIDIS A 003366 04-04
ARROUNE M 000698 01-13
ARROUNE IC 000634 01-11
ARROUD E 001333 02-04
ARROUNE M 000698 01-13
ARRONSTAM RS 000540 01-14
ARROUD E 001333 02-04
ARROUNE M 000696 01-15
ARRONSTAM RS 000044 01-03
ARRON RC 000273 01-04
ARRON RC 000268 03-03
AVAKIAN RM 002192 03-04
AVERY D 000355 01-09
AVER

Author Index

AXELSSON JE 000687 01-13, 001258 02-03 AXELSSON R 003480 04-09 AYD FJ 001879 02-17 AYHAN IH 002257 03-04 AYINDE 0 003723 04-17

BAASTRUP PC 000663 01-11, 002420 03-09
BABA A 002961 04-03
BABA Y 000255 01-03
BABBINI M 003162 04-04
BACHMAN JA 003583 04-12
BACOPOULOS NG 001964 03-03, 002812 04-03
BADE P 000046 01-03
BADE P 0000552 01-08
BAILE CA 002193 03-04
BAILE CA 002193 03-04
BAILEY DN 003643 04-15
BAILEY J 002426 03-09, 003488 04-09, 003493 04-09
BAILEY K 001149 02-03, 001195 02-03
BAILEY K 001149 02-03, 001195 02-03
BAILEY K 001149 02-03, 001195 02-03
BAILEY R 002499 03-10
BAJUSZ S 001230 02-03
BAKALAR JB 000842 01-15
BAKER GB 003001 04-03, 003431 04-06
BAKER J 000726 01-13, 001679 02-13, 003408 04-05, 003605 04-13
BAKER SP 002813 04-03
BALAES R 000184 01-03, 000216 01-03, 001512 02-05
BALDESSARINI RJ 000047 01-03, 000314 01-04, 001641 02-13, 001770 02-15, 001880 02-17, 001881 02-17, 002328 03-04, 003102 04-03, 003366 04-04, 003698 04-17
BALDINI A 003720 04-17
BALDINI A 003720 04-17
BALDINI A 003720 04-17
BALDINI R 002837 04-03
BALLENGER JC 000645 01-11, 003481 04-09
BALLENGER JC 000645 01-11, 003481 04-09
BALLENGER JC 000645 01-11, 003499 04-17
BALDINI A 003720 04-16
BALKRISHNA V 001882 02-17
BALLENGER JC 000645 01-11, 003481 04-09
BALLETER JH 001304 02-04, 003699 04-17
BALDINI A 003720 04-16
BALKRISHNA V 001885 04-04, 003699 04-17
BALDINI A 003720 10-14, 003155 04-04, 003155 04-04, 003155 04-04, 003155 04-04, 003155 04-04, 003155 04-04, 003155 04-04, 003155 04-04, 003159 04-17
BALLENGER JC 000645 01-11, 003481 04-09
BALTER JH 001304 02-04, 003469 04-17
BALLENGER JC 000645 01-11, 003481 04-09
BALTER JH 001304 02-04, 003699 04-17
BALDINI A 003720 04-18
BALTER JH 001304 02-04, 003699 04-17
BALDINI A 003720 04-16
BALTER JH 001304 02-04, 003699 04-17
BALDAN TA 000520 01-08, 000558 01-09, 000577
01-09, 000614 01-10, 001642 02-13, 001696
02-14, 001743 02-15, 001855 02-16, 002375
03-07, 002376 03-07, 002416 03-09, 002445
03-09, 002445 03-09, 002473 03-10, 003465 03-09, 002465 03-09, 002413 03-10, 003465 04-08
BANERJEE SP 000049 01-03, 000264 01-03
BANKI CM 002545 03-13
BANT WP 003534 04-10
BARAN L 003281 04-04
BARASH PG 002546 03-13
BARCHAS J 001348 02-04
BARCHAS JD 000217 01-03, 000592 01-09, 00248 03-04, 002365 03-06, 003409 04-05, 003616 04-14, 003639 04-14, 003710 04-17
BARCHAS PR 002365 03-06
BARD RR 001951 03-01
BARDON A 001722 02-14
BAREGGI SR 002814 04-03
BARKNECHT CF 001449 02-04
BARK N 002503 03-11
BARKAI AI 002815 04-03
BARKER JL 002816 04-03
BARKER JL 000816 04-03
BARKER JL 000816 04-03
BARKER JL 000816 04-03
BARKER JL 000810 03-03
BARNET JE 000617 01-15
BARNET JE 000617 01-15
BARNET JE 000617 01-104, 001305 02-04, 001306 02-04, 002254 03-04, 002255 03-04

BARRETT RJ 001467 02-04, 002190 03-04, 002314 03-04
BARRINGER M 001788 02-15
BARRON G 003408 04-05
BARRON G 003408 04-05
BARRON S 000859 01-15
BARRY H 000413 01-04, 001396 02-04, 003163 04-04, 003266 04-04, 003617 04-14
BARTH E 001742 02-15
BARTHALMUS GT 003164 04-04
BARTHOLEMEUSZ DB 002421 03-09
BARTHOLINIG 000050 01-03, 000051 01-03
BARTICHT D 000578 01-09
BARTOLINI A 000998 01-03
BARTOVA D 003552 04-11
BARTOVA D 003552 04-11
BARTOVA D 003552 04-11
BARTOVA D 003552 04-11
BARSA MB 003165 04-04
BASSAND J 001549 02-07
BASSIME 001845 02-15
BASS MB 003165 04-04
BASSAND J 001549 02-07
BASSIME T 000318 01-03
BAUER VJ 000167 01-03
BAUER AM 000749 01-14
BAUER J 000118 01-03
BAUER VJ 000118 01-03
BAUER VJ 000167 01-04
BAUMANN PA 001960 03-02, 001965 03-03
BAUMANN T 002032 03-03
BAUMANN T 002032 03-03
BAUMANN T 002032 03-03
BAUMANN T 002032 03-03
BAUMANN D 000797 01-15, 000915 01-16
BEAMMGOLD J 000044 01-03
BEAMELA R 001051 02-03
BAUER VJ 000186 03-04
BEALE IE 002643 03-14
BEALE IE 002650 03-13
BEALER WT 002607 03-14
BEALE IE 002667 03-03
BEAUMANN R 001052 02-03, 001070 02-03
BEAUMANN R 001052 02-03, 001070 02-03
BEAUMANN R 002661 03-03
BEAUMANN R 002556 03-11, 002605 03-14
BEALE IE 002643 03-14
BEALE IE 002643 03-14
BEALE IE 002643 03-14
BEALE IE 002667 03-13
BECKER BM 001053 02-03 03-13
BECK AT 003726 04-17
BECKER AT 000513 01-07
BECKER BM 001053 02-03
BECKER L 003578 04-17
BECKER L 003578 04-11
BECKER W 001746 02-15, 002377 03-07, 002647 03-15
BECKET AH 001054 02-03
BECKMANN H 000686 01-13, 002378 03-07
BECKMER JS 000194 01-03, 002361 01-04, 002051 03-03 BECKNER JS 000194 01-03, 000361 01-04, 002051 03-03
BECKWITH BE 001309 02-04
BEDARD P 001310 02-04
BEDFORD J 001311 02-04, 001370 02-04, 001493 02-04
BEDMARCZYK B 003383 04-04
BEDWANIJR 002808 04-03
BEHBEHANI MM 002817 04-03
BEITMAN BD 000798 01-15
BELCHER G 001966 03-03
BELESLIN DB 000052 01-03
BELESLIN DB 000052 01-03
BELESLIN DB 000052 01-03
BELLER D 001084 02-03
BELLAR D 001084 02-03
BELLAR D 001085 01-07
BELLAROSA A 001493 02-04
BELLUZI JD 000455 01-04
BELLUZI JD 000455 01-04
BELLUZI JD 000455 01-04
BELLUZI JD 000455 01-04
BELLWARD GD 000457 01-13
BELMAKER RH 000543 01-08, 001666 02-13, 003063 04-03, 003529 04-09, 003587 04-13
BEN-DAVID M 002438 03-09
BENDEKIS A 000053 01-03
BENDEK O 000184 01-03 000216 01-03 BENAKIS A 000053 01-03 BENDEK G 000184 01-03, 000216 01-03, 001512 02-05 BENDER DA 000054 01-03

BENDER KI 001967 03-03
BENDING MR 000799 01-15
BENDOTTI C 001235 02-03, 001437 02-04
BENEDETTI C 001646 02-13
BENEDETTI MS 002971 04-03
BENEDETTI MS 002971 04-03
BENEDETTI MS 002970 01-09
BENGHEZAL A 002630 01-04, 002232 03-04, 002233 03-04, 003204 04-04
BENNETT EL 000360 01-04, 002232 03-04, 002233 03-04, 003204 04-04
BENNETT EL 003636 03-14
BENTET D 002636 03-14
BERCHIER P 002385 03-07
BERG JR 002340 03-05
BERG JR 002340 03-05
BERG JR 002340 03-05
BERG BERGER D 003423 04-06
BERGER PA 000592 01-09, 000820 01-15, 001695 02-13, 002509 03-11, 003618 04-14, 003699 04-14, 003710 04-17
BERGGER D 000592 01-09, 000820 01-15, 001695 02-13, 002509 03-11, 003618 04-14, 003618 04-04
BERKOWITZ D 001746 03-01, 003683 04-15
BERMANN F 003168 04-04
BERKOWITZ D 001746 03-01, 003683 04-15
BERNARD P 002373 03-06
BERNARD P 002373 03-06
BERNARD P 002373 03-06
BERNARD P 002373 03-06
BERNARD P 002373 03-02
BERNASCONI S 001946 03-01, 003683 04-15
BERNARD P 002373 03-03
BERNHEIM R 003650 04-13
BERNARD P 002373 03-03
BERNHEIM R 003650 04-15
BERNARD R 003219 04-03
BERNET HK 002846 04-03
BERRY HA 000728 01-13
BERSCH II 001230 02-03
BERSCH II 001230 02-03
BERSCH II 001240 0 BHATTACHARYYA A 001548 02-07, 003346 04-04 BHATTACHARYYA A 001548 02-07, 003346 04 04
BIANCHETTI G 000478 01-05
BIANCHI M 000016 01-02
BIANCHI R 002820 04-03
BIANCHI S 002820 04-03
BIANCHI S 002872 04-03
BICKEL MH 000095 01-03
BICKEL P 002540 03-12
BIDUS DR 002263 03-04
BIDUS DR 002263 03-04
BIDUS DR 002263 03-04
BIDUS DR 002540 03-13
BIEDERMAN J 003587 04-13
BIEDERMAN J 003587 04-13
BIELICKI L 001058 02-03
BIELICKI L 001058 02-03
BIELICKI L 001058 02-03
BIELICKI D 000738 01-17
BIERSKR R JJ 000738 01-17
BIERSER DW 002283 03-04
BIERSER DW 001705 02-14
BIERSER DW 000551 01-08, 000542 01-08

VOLUME 16, AUTHOR INDEX

BIGGIO G 000056 01-03, 000207 01-03, 002825 04-03, 002826 04-03, 002827 04-03, 002828 04-03 02828 04-03 002828 04-03 00582 01-09, 000801 01-15, 000803 01-15, 000912 01-15, 001576 02-09, 002823 02-15, 001884 02-17, 002472 03-09, 002693 03-15 002693 03-15 BIGLER AJ 000057 01-03 BIGLER ED 001885 02-17, 003171 04-04 BIGNAMI G 003615 04-14 BILKINGSLEY ML 003605 04-13 BILLINGSLEY ML 000029 01-02 BINDELGLAS PM 003526 04-09 BIOULAC B 002829 04-03, 002830 04-03 BIOULAC B 002829 04-03, 002830 04-03
BIRCH H 002544 03-13
BIRCH NJ 001644 02-13
BIRCH S 000304 01-03
BISCHOFF S 001237 02-03
BISSET GW 002792 04-02
BISSETTE G 000434 01-04
BISWAS B 002832 04-03, 003172 04-04
BITO LZ 002174 03-03
BITTIGER H 000492 01-06
BIXLER EO 000750 01-14, 002608 03-14, 003637 04-14 BIZIERE K 003406 04-05 BJERKENSTEDT L 001557 02-08, 002388 03-08, 002547 03-13 00254/ 03-13 BJORLUND A 000269 01-03 BJORUM N 000926 01-16 BLACK CA 001301 02-04 BLACK B 002894 04-03 BLACK MJ 001969 03-03 BLACK MJ 001969 03-03 BLACKMAN DE 002371 03-06 BLACKWELL B 000667 01-11, 002498 03-10, 003447 04-07, 003483 04-09 BLAIR IM 001681 02-13 BLAIR T 000939 01-17 BLAKE A 001700 02-14 BLAKE DA 001515 02-05 BLAKE DA 001515 02-05 BLAKE DJ 001293 02-03 BLAKEBORCUGH L 000010 01-01 BLANC M 001023 02-02 BLANK NK 003418 04-05 BLANK NK 003418 04-03 BLATCHCORD D 002833 04-03 BLATCHLEY RJ 002530 03-11 BLATTBERG B 002077 03-03 BLAVET N 002370 03-06 BLAZEK R 000739 01-13 BLEI 001059 02-03 BLAVET N 002370 03-06
BLAZEK R 000739 01-13
BLSI I 001059 02-03
BLISI DK 003302 04-04
BLOOM AS 001438 02-04, 002834 04-03, 002835 04-03
BLOOM D 001109 02-03
BLOOM F 000532 01-08, 000533 01-08
BLOOM F 000243 01-03, 000594 01-10
BLOOM FE 000243 01-03, 000594 01-10
BLOOM FR 003056 04-03
BLOOMFIELD MR 002942 04-03
BLOOM FIELD MR 002942 04-03
BLOSS JL 003173 04-04
BLOSSET J 002836 04-03, 003026 04-03
BLOSS JL 003173 04-04
BLUSER J 001849 02-15
BLOZOVSKI D 000320 01-04
BLUJ 001817 02-15
BLUME AJ 000058 01-03
BLONDE-BIBER MC 00166 02-03
BOARDMAN LJ 000717 01-13
BOAST CA 000384 01-04
BOBIK A 000802 01-15
BOBKIEWICZ T 001797 03-03
BOBKIEWICZ T 001797 03-03
BOBKIEWICZ T 001797 03-03
BOBKIENICZ T 001797 03-03
BOCKENHEIMER S 002377 03-07, 002647 03-15
BOECHLER N 002946 04-03
BOECKLER WH 001295 02-04
BOEHME PH 003050 04-03
BOEKLER WH 001295 02-04
BOEHME PH 003050 04-03
BOEKLER WH 001295 02-04
BOEHME PH 003050 04-03
BOEKME PH 003050 04-03
BOEKME PH 003050 04-03
BOEKME PH 003050 04-03
BOEHME PH 003050 04-03
BOEKME PH 003050 04-03

BOHRER RE 000783 01-14

BOHUS B 003174 04-04
BOIREAU A 000258 01-03
BOISMARE F 001971 03-03, 002198 03-04, 002199 03-04, 002199 03-04, 002199 03-04, 002199 03-04, 002360 03-06
BOISSIER JR 001472 02-04, 002200 03-04, 00333 04-04
BOISVERT C 003339 04-04
BOISTER A 000803 01-15
BOMBARDT PA 001857 02-16, 003084 04-03
BOMACCORSI A 000478 01-05, 000479 01-05
BOND R 002708 03-15
BONDARENKO TT 001973 03-03
BONDY GP 000210 01-03
BONNAFFOUX D 003446 04-07
BONNER HW 002075 03-03
BONTAT IL 001366 02-04
BOOKER HE 002600 03-13
BOOTHE H 002459 03-09
BORCHARDT RT 003110 04-03
BORG D 30-03
BORD S 006670 01-11, 003614 04-13
BORGMAN RJ 000047 01-03, 000314 01-04, 002793 04-02
BORISON H 001416 02-04
BORISON R 001063 02-03, 001177 02-03, 001410 02-04, 001952 03-02
BORISON R 001063 02-03, 001177 02-03, 001410 02-04, 001952 03-02
BORISON R 001063 02-03, 001177 02-03, 001410 02-04, 001952 03-02
BORISON R 001063 02-03, 001177 02-03, 001410 02-04, 001952 03-02
BORISON R 001063 02-03, 001177 02-03, 001410 02-04, 001952 03-02
BORISON R 001063 02-03, 001177 02-03, 001410 02-04, 001952 03-02
BORISON R 001063 02-03, 001177 02-03, 001410 02-04, 001952 03-03
BOSIN T 000006 01-01, 002837 04-03
BOSER LECA JF 001524 02-05
BOSCHI G 000059 01-03
BOSIN T 000006 01-01, 002837 04-03
BOSSEN LE 002824 04-03
BOSSEN LE 002829 04-03
BOSSEN T 0000748 01-04, 000776 01-14, 000920

1-16
BOULLORD AA 000279 01-03, 001091 02-03, 00139 02-04
BOULLORD NS 000144 01-03 13, 000748 01-14, 000776 01-14, 000920 01-16
BOULTON AA 000279 01-03, 001091 02-03, 001339 02-04
BOULLU RG 001064 02-03, 002201 03-04
BOULLU RG 001064 02-03, 002201 03-04
BOULLU RG 001064 02-03, 002201 03-04
BOURN WM 001364 02-04, 001977 03-03
BOUSQUET WF 000293 01-03, 001288 02-03, 002182 03-03, 003008 04-03
BOUYER J 001974 03-03
BOWDEN CL 003484 04-09, 003535 04-10
BOWDEN NJ 003176 04-04
BOWERS CY 001975 03-03
BOWERS MB 000672 01-12, 001577 02-09
BOWERS MB 000672 01-12, 001577 02-09
BOWERS MB 000672 01-12, 001577 02-09
BOWERY NG 002838 04-03
BOWNER CJ 003593 04-13
BOYDE C 001993 03-03
BOYLE R 002737 03-17
BOZARTH MA 001313 02-04
BOZARTH MA 001313 02-04
BOZZARTH MA 001313 02-04
BOZZARTH MA 001313 02-04
BOZZARTH MA 001314 02-04
BRADLEY PB 000060 01-03, 002841 04-03
BRADLEY PB 000060 01-03, 002841 04-03
BRADLEY PB 000060 01-03, 002822 04-03
BRADY JV 001349 02-04, 003236 04-04
BRABLEY PB 000060 01-03, 002822 01-03, 002114 03-03, 002115 03-04, 00114 03-03, 00214 03-03, 00214 03-03, 00214 03-03, 00214 03-03, 00214 03-03, 00214 03-03, 00214 03-03, 00214 03-03, 00214 03

BRAUMAN H 001590 02-09
BRAUN G 003075 04-03
BRAULY D 003075 04-03
BRAULZER B 001848 02-15
BREAKEFIELD XO 002941 04-03
BREESE GE 001409 02-04, 002065 03-03, 002218 03-04, 002993 04-03
BREISER GE 001409 02-04, 002065 03-03, 002218 03-04, 002993 04-04
BRENNAN RW 002705 03-15
BRESKIN ILS 003702 04-17
BREUKER E 002003 03-03
BREYER C 000805 01-15
BREYER U 000063 01-03
BREYER-PFAFF U 002842 04-03
BREZINOVA V 002609 03-14
BREIDGES JW 002809 04-03
BRIDGMAN KM 003514 04-09
BRIEN JF 001316 02-04
BRILLY M 002843 04-03
BRINKMANN R 002650 03-15
BRITTON DR 002794 04-02
BROADHURST AD 002422 03-09
BROCKLEHURST JC 002719 03-16
BRODIE HKH 000695 01-11
BRODIE MJ 000635 01-11
BRODIE MJ 000635 01-11
BRODIE MJ 000635 01-11
BRODIE NH 000605 01-10
BRODIE RO 001858 02-16
BRODY TM 000180 01-03, 003405 04-05
BROEKKAMP CLE 000341 01-04, 003381 04-04
BROMKY B 003493 04-04
BROOK P 003605 04-13
BROOKMAN S 001065 02-03
BROOK P 003605 04-13
BROOK P 003605 04-13
BROOWN CR 003493 04-04
BROOME B 003399 04-04
BROOME B 003399 04-04
BROOME B 003399 04-04
BROWN CR 002506 03-11
BROWN DA 002844 04-03
BROWN DA 002844 04-03
BROWN HW 003433 04-06
BROWN IR 000324 01-04, 003328 04-04
BROWN IR 000399 04-04
BROWN IR 000324 01-04, 003328 04-04
BROWN IR 000328 01-04, 003179 04-04
BROW BRUINVELS J 002782 03-17, 003021 04-03
BRUINBACK RA 001578 02-09
BRUNBALER 000852 01-15
BRUNIA CHM 002548 03-13
BRUNNER EA 002846 04-03, 002861 04-03
BRUNNER RL 002846 04-03, 002864 03-03, 003225 04-04
BRUNSWICK D 001658 02-13, 001859 02-16, 001869 02-16
BRUS R 002203 03-04
BRUINSWICK D 001658 02-13, 001859 02-16, 001869 02-16
BRUS R 002203 03-04
BRUZEZESE D 002718 03-16
BRYAN KS 001529 02-06
BRYANT PJ 000682 01-12
BRYANT SH 000204 01-03
BUCHAN T 000522 01-08
BUCHAN T 000522 01-08
BUCHAN T 000522 01-08
BUCKINGHAM RL 001440 02-04
BUCKLEY JP 000030 01-02, 002081 03-03
BUDHIRAJA RD 001749 02-15
BUDHIRAJA RD 001749 02-15
BUDHIRAJA RD 001749 02-15
BUDHIRAJA RD 00179 02-15
BUDHIRAJA RD 00179 02-03

BUESCHER H 000379 01-04, 001036 02-02
BUGENTAL DB 000620 01-11
BUGGY J 003181 04-04
BUICE RG 001977 03-03
BUKREYEV VI 003485 04-09
BULAYEV VM 001978 03-03
BULLAYEV VM 001978 03-03
BULLAYEV VM 001978 03-03
BULLOCK P 002863 04-03
BUNNEY WE 000756 01-14, 000916 01-16, 000941 01-17, 001560 02-08, 001712 02-14, 001870 02-16, 002610 03-14, 002733 03-17
BUOY ME 001245 02-03
BURBACH P 002887 04-03
BURBACH P 002887 04-03
BURBCS J 000326 01-04, 001214 02-03
BURBCS D 003326 01-04, 001214 02-03
BURBCS D 00326 01-04, 001214 02-03
BURGESS EL 002847 04-03
BURGESS EL 002847 04-03
BURGESS EL 002847 04-03
BURGESS EL 002847 04-03
BURGESS EL 002848 04-03
BURGESS EL 002848 04-03
BURGESS EL 002848 04-03
BURKETT CD 00075 01-17
BURKI HR 000036 01-02, 002849 04-03, 002998 04-03
BURKS TF 000065 01-03, 000089 01-03, 001066 02-03
BURNETT G 002441 03-09
BURNEY S 001687 02-15
BURNS CR 001750 02-15
BURNS CR 000064 01-03, 002423 03-09, 002476 03-10, 003645 04-15
BURSTEIN S 001999 03-03, 002850 04-03, 002881 04-03
BURT DR 000084 01-03, 002738 03-17
BUTLER LL 002851 04-03
BUTCHER LL 002851 04-03
BUTCHER RL 002864 04-03
BUTCHER RL 002864 04-03
BUTTER SR 002550 03-13
BUTTER SR 002550 03-13
BUTTER SR 002550 03-13
BUTTER SR 002550 03-13
BUTTER SR 002564 04-11
BUTLER SR 002564 04-13
BUTTER SR 002565 03-04
BUXLER SSEN J 002205 03-04
BUXLER SSEN J 002060 01-15
BUYZE G 003624 04-14
BYCK R 002549 03-13
BUTTER SR 002550 03-04
BUXLER SSEN J 002060 01-15
BYMASTER F 000114 01-03, 001686 02-13, 002017 03-03, 002919 04-03
BYRNE WL 001991 03-03

CABBAT FS 001145 02-03, 002036 03-03 CACCAMISE DJ 003377 04-04 CAFFEY EM 001600 02-09 CAGGIULA AR 002359 03-06 CAHILL M 002611 03-14 CAHN J 001979 03-03 CALILLE E 001549 02-07 CAINE ED 002651 03-15 CALDRENIN G 001980 03-03, 002852 04-03 CALDWELL J 000067 01-03 CALHOUN WH 003238 04-04 CALIL HM 001558 02-08, 002361 03-06 CALLINGHAM BA 002912 04-03 CAND DE 000070 01-03 CAMAIONI D 001094 02-03 CAMAIONI D 003361 04-04

CAMPBELL BA 000327 01-04
CAMPBELL BB 000327 01-04
CAMPBELL BB 001790 02-15
CAMPBELL BB 001047 03-10
CANOY JM 001049 02-03, 003002 04-03, 003066 04-03
CANICLARAD LA 002478 03-10
CANOY JM 001049 02-03, 003002 04-03, 003066 04-03
CANINO 1A 002471 03-09
CANINO 1A 002471 03-09
CANINO 1A 002471 03-09
CANINO 1A 002471 03-09
CANINO 1A 001319 02-04
CANINO 1B 001335 02-04, 002853 04-03
CANON JG 001335 02-04, 002853 04-03
CANON JG 000329 01-04, 000330 01-04, 002795 04-02
CAPETOLA RJ 000690 01-13
CAPONET 000804 01-15, 003704 04-17
CAPSTICK N 002477 03-10
CARCHMAN RA 001296 02-04, 002034 03-03, 003152 04-04
CARDON 1AA 002652 03-15
CARENZI A 003225 04-04
CARDON 1AA 002652 03-15
CARENZI A 0033225 04-04
CARSV RJ 001981 03-03
CARLE R 000614 01-10
CARLIN AS 002670 03-15
CARLINI EA 00331 01-04, 001320 02-04
CARLSSON K 003182 04-04, 003183 04-04
CARSSON SO 001321 02-04
CARLSSON SO 000621 01-11, 001153 02-03, 002852 04-03, 003172 04-04, 003509 04-09
CARLSSON SO 01321 02-04
CARLSSON C 000621 01-11, 001153 02-03, 002854 04-03
CARLES ND 000321 01-08
CARMICHAEL RH 001686 02-13
CARMOND J 002737 03-17
CARNATHAN G 001322 02-04
CARNEY JM 000332 01-04, 002286 03-04, 002787 04-01
CARNEY JM 000332 01-04, 002206 03-04, 002787 04-01
CARREY RM 000332 01-04, 002206 03-04, 002787 04-01
CARREY RM 000332 01-04, 002206 03-04, 002278 04-01
CARREY RM 000382 01-03
CARRER R 000690 01-13
CARRER RE 000681 01-15
CARPENTER DC 001070 02-03
CARRER R 000499 03-08
CARRILA 001071 02-03 001280 02-03
CARRER R 000690 01-13
CARRER R 000490 03-10
CARRER R 0

CATTO E 001253 02-03
CAVANAGH RL 001073 02-03
CAVAZOS LA 001315 02-04
CAVENAR JO 000753 01-14, 000858 01-15, 001552 02-07, 001607 02-09, 003572 04-10
CAVEY D 003128 04-03
CAZALA P 000334 01-04
CAZENAVE J 000236 01-03, 000238 01-03
CEDAR G 001074 02-09, 001928 02-17, 003589 04-13
CELANI T 003536 04-10
CELESIA GG 001887 02-17
CELLA JA 000494 01-06
CELICH SM 002855 04-03
CENAJEK D 002317 03-04, 002332 03-04, 002348 03-05, 002358 03-05
CERLETI C 002856 04-03
CERNAJEK D 002317 03-04, 002332 03-04, 002348 03-05; 002358 03-05
CERLETIC 002856 04-03
CERNAJEK D 002317 03-04, 002332 03-04, 002348 03-05; 002358 03-05
CERLETIC 002856 04-03
CERNAJEK D 000070 01-03
CHAJEK D 001755 02-03, 001138 02-03
CERNAJEK D 001755 02-15
CESCO G 002379 03-07
CESPUGLIO R 000070 01-03
CHAJER D 000071 01-03 001400 02-04, 002269
03-04
CHAJEL M 000071 01-03 002857 04-03 CHADHA DR 000942 01-17
CHADWICK D 001112 02-03
CHAI CY 001176 02-03, 001400 02-04, 002269
03-04
CHAIT LD 002209 03-04, 003185 04-04
CHAIFIE M 000071 01-03, 002857 04-03
CHAILIS RE 001756 02-15
CHALOUPKA Z 002858 04-03, 003069 04-03
CHAMBERLAIN JH 000461 01-04
CHAMBERS DM 000335 01-04
CHAMBERS DM 000335 01-04
CHAMBERS DM 000335 01-04
CHAMBERS G 001757 02-15
CHAMPAKAMALINI AV 000072 01-03
CHAN BH 001078 02-03
CHAN SHH 001985 03-03
CHAN SHH 001985 03-03
CHAN TL 001827 02-15
CHANCE WT 001325 02-04, 001326 02-04, 001986 03-03, 002210 03-04, 002211 03-04, 003070 04-03, 003692 04-16
CHANDA R 002934 04-03
CHANDA SK 000049 01-03, 001987 03-03
CHANG SK 000049 01-03, 001987 03-03
CHANG SK 000049 01-03, 001987 03-03
CHANG SK 000693 01-13
CHANG S 000817 01-15, 000904 01-15
CHANG SS 00087 04-16
CHAPMAN R 001546 02-13
CHAPMAN R 001646 02-13
CHAPMAN R 001646 02-13
CHAPMAN R 001646 02-13
CHAPMAN R N 001327 02-04
CHAPPUIS A 002008 03-03
CHARALLAMPOUS KD 000508 01-07
CHARLES J 003459 04-08
CHARNESS ME 000493 01-06
CHASE TN 002124 03-03, 003475 04-08
CHASEAN JB 002755 03-17
CHASSEAUD LF 001858 02-16
CHATTERJEE DK 000119 01-03
CHAIL-PHAM TT 001076 02-03
CHAU-WONG M 002779 03-17
CHASSAN JB 002755 03-17
CHASSAN JB 002755 03-17
CHASSAN JB 002755 03-17
CHASSAN JB 002759 03-17
CHASSAN JB 002759 03-17
CHARLES MD 001448 02-04
CHEC PY 002859 04-03
CHEN C 000058 01-03
CHEN C 000073 01-12, 001078 02-03, 002094 04-03
CHEN F 001176 02-03
CHEN RM 001186 02-04
C

VOLUME 16, AUTHOR INDEX

CHILDERS SR 002155 03-03
CHILES JA 002654 03-15
CHIODAROLI A 000478 01-05
CHIPKIN RE 003187 04-04, 003188 04-04
CHIPPENDALE TJ 002212 03-04
CHIU P 000006 01-01
CHIUEH CC 001079 02-03, 001486 02-04, 002862 04-03
CHMELA Z 003094 04-03
CHO A 002520 03-11
CHO AK 000074 01-03, 000498 01-05, 002970 04-03
CHODERA A 001970 03-03, 000498 01-05 04-03 CHODERA A 001970 03-03, 002317 03-04, 002332 03-04, 002348 03-05, 002358 03-05 CHOI DW 001080 02-03 CHOINOWSKI S 002296 03-04 CHOMA P 001274 02-03, 003051 04-03 CHOQUET M 001888 02-17 CHOUINARD G 000812 01-15, 001542 02-07, 001559 02-08, 002390 03-08, 002391 03-08, 003451 04-08, 003487 04-09, 003646 04-15, 003705 04-17 O03451 04-08, 003487 04-09, 003646 04-15, 003705 04-17
CHOWDREY HS 002792 04-02
CHREMOS AN 002792 03-16
CHRISTENSEN AV 001035 02-02
CHRISTENSEN DB 001889 02-17
CHRISTENSEN DB 001889 02-15, 002774 03-17
CHRISTENSEN OB 001081 02-03
CHRISTIAN CN 002863 04-03
CHRISTIAN ST 000230 01-03
CHRISTIANSEN C 002420 03-09
CHRISTIANSEN C 002420 03-09
CHRISTIANSEN C 002420 03-09
CHRISTIODULOU GN 002507 03-11
CHRISTODULOU GN 002507 03-11
CHRISTODULOU GN 002507 03-13
CHRISTODULOU GN 002507 03-11
CHRISTODULOU GN 002507 03-14
CHURYUKANOV VV 001083 02-03 CHURYUKANOV VV 001083 02-03 CHUTE DL 002753 03-17 CHWEH AY 001648 02-13 CIANCHETTI C 002508 03-11, 003620 04-14 CIANCHORD D 001111 02-03, 003085 04-03 CIANFLONE D 001111 02-03, (CICERO TJ 001084 02-03 CIESIELSKI Ł 003091 04-03 CLAASSEN V 000017 01-02 CLAESSENS J 002385 03-07 CLAGHORN JL 002486 03-10 CLAIVER RM 000336 01-04 CLARIDGE G 003706 04-17 CLARK C 000624 01-11 CLARK D 003234 01-11 CLARK D 003237 44-04 CLARK D. 003377 04-04 CLARK M. 000943 01-17 CLARK ML 001649 02-13 CLARK J. 001759 02-15 CLARK WG 000198 01-03, 001264 02-03, 002864 04-03 CLARKE DE 000075 01-03, 002893 04-03, 003016 04-03 CLARKE DE 000075 01-03, 002893 04-03, 003016 04-03 CLARKE KA 001046 02-03 CLARKE KA 001046 02-03 CLARKE KA 001046 02-03 CLAVIER RM 003435 04-06 CLAYTON AB 000771 01-14, 002612 03-14 CLEARY MF 000813 01-15 CLEGHORN RA 001650 02-13 CLEMENS JA 001990 03-03, 002866 04-03 CLEMENT JA 001175 02-03 CLEMENT JA 001175 02-03 CLEMENT A 0010587 04-03 CLEMENT A 000506 01-07 CLINESCHMIDT BV 001012 02-01, 002213 03-04, 002214 03-04, 002866 04-03 CLOPTON P 003559 04-11 CLOSE A 002940 04-03 CLOUET D 003730 04-17 CLOUET DH 000154 01-03, 001286 02-03 CLOWET GR 002550 03-13 CLOW A 000077 01-03, 002963 04-03 CLUF LE 001913 02-17 CO BT 000912 01-15 000915 01-03, 002869 04-03 CLUF LE 001913 02-17 CO BT 000912 01-15 000912 01-15 000912 01-15 000912 01-15 000912 01-15 000912 01-15 000912 01-15 CO BT 000912 01-15 COAMBS RB 003158 04-04 COBB JP 002493 03-10 COBLE P 001594 02-09 COCCHI R 001702 02-14 COCCHIA MA 000274 01-03 COCCIA P 002856 04-03 COCHIN J 000104 01-03, 001322 02-04 COCITO L 000585 01-09

CODD EE 001991 03-03
COGHLAN JP 000570 01-09
COHEN HB 002544 03-13, 002605 03-14
COHEN L 003621 04-14
COHEN S 000814 01-15, 001818 02-15
COHEN S 000814 01-15, 001818 02-15
COHEN Y 000079 01-03, 001182 02-03
COHN CK 000560 01-09, 001760 02-15
COHN D 000926 01-16
COHN M 000337 01-04, 001953 03-02,
002215 03-04
COHN MI 000337 01-04, 002215 03-04 COHN D 000926 01-16
COHN M 000337 01-04, 001953 03-02,
002215 03-04
COHN ML 000337 01-04, 002915 03-04
COIL JD 001992 03-03
COL J 001752 02-15
COLE FE 002870 04-03
COLE JD 000903 01-15, 000923 01-16, 000944
01-17, 001777 02-15, 002425 03-09, 002505
03-11, 003655 04-15
COLE SD 001329 02-04, 003189 04-04
COLELI B 001330 02-04
COLELI B 001330 02-04
COLELI B 001331 02-04
COLLAR ML 001331 02-04
COLLAR ML 001331 02-04
COLLAR ML 001331 02-04
COLLAR SD 000908 02-07
COLLETE J 001938 02-17
COLLIER B 000302 01-03
COLLINS AC 000222 01-03, 000376 01-04, 000447 01-04, 002301 03-04
COLLINS RL 002216 03-04
COLLINS RL 002216 03-04
COLLINS RL 002541 03-12
COLLINS RL 002541 03-12
COLLINS RL 002538 01-41
COLLINS RL 002539 03-04
COLLAR ML 001358 01-04, 003190 04-04, 003191 04-04, 00 CONSOLO S 000080 01-03, 002872 04-03, 003074 04-03
CONSROE P 000339 01-04, 001504 02-05
CONSTANTI A 002115 03-03, 002844 04-03
CONWAY PM 001071 02-03
CONK L 002303 03-04
COOK L 002303 03-04
COOK MA 002874 04-03
COOK WL 000035 01-02
COOKE MBD 001681 02-13
COOLS AR 000340 01-04, 00341 01-04, 001454 02-04, 001490 02-04, 001954 03-02, 003197 04-04, 003381 04-04
COONEY C 000862 01-15
COOPER AJ 001579 02-09
COOPER BR 001993 03-03, 002218 03-04
COOPER DY 002007 03-03, 002165 03-03
COOPER JR 001149 02-03, 001195 02-03
COOPER R 001149 02-03, 001195 02-03
COOPER R 001149 02-03, 001195 02-03 COOPER JR 003198 04-04
COOPER R 002417 03-09
COOPER S 001559 02-08
COOPER S 001559 02-08
COOPER S 001559 01-07
COOPER S 00159 04-04, 003708 04-17
COOPER T 000775 01-14
COOPER T 000775 01-14
COOPER H 0000652 01-11, 001315 02-04, 002407 03-08, 002714 03-16
COPER H 000106 01-03, 000139 01-03, 003378 04-04
COPPEN H 000561 01-09, 001588 02-09, 002426 03-09, 003488 04-09, 003493 04-09, 003532 04-09
CORBETT JL 000894 01-15
CORDA MG 002825 04-03, 002826 04-03, 002827 04-03, 002828 04-03 CORDA MG 002825 04-03, 002826 04-03, 002827 04-03, 002827 04-03 02827 04-03 02828 04-03 02

CORRIVEAU DP 002786 04-01
CORRODI H 002019 03-03
CORRY RJ 003510 04-09
CORSINI GU 002508 03-11, 003620 04-14,
003648 04-15
CORSON EO 001333 02-04
CORSON EO 001333 02-04
CORSSEN G 000513 01-07
CORTE LD 0022422 03-09
CORUM CR 002219 03-04
CORVILAIN J 001590 02-09
COSCIA CJ 001994 03-03, 002655 03-15
COSGROVE RJ 000419 01-04
COSTA E 000012 01-01, 000056 01-03,
000073 01-03, 000096 01-03, 000132 01-03,
000133 01-03, 000096 01-03, 000244 01-03,
000133 01-03, 000192 01-03, 000244 01-03,
00077 02-03, 001225 02-03, 001891 02-17,
002023 03-03, 002031 03-03, 002788 04-01,
002790 04-01, 002750 04-03, 002990 04-03,
002994 04-03, 002996 04-03
COSTA JL 000081 01-03, 000694 01-13
COSTA M 002086 03-03
COSTA PT 001687 02-13
COSTALES M 003385 04-04
COSTALL B 000082 01-03, 001334 02-04,
001335 02-04, 002220 03-04, 002853 04-03
COSTANZA A 000654 01-11
COSTENTIN J 001187 02-03, 002221 03-04,
002350 03-05
COSTILOE JP 001649 02-13
COSTILOE JP 001649 02-13
COSTILOE GW 002875 04-03
COTIER GW 002875 04-03
COTIER GW 002875 04-03
COTIERS GC 001957 03-02
COUGHENOUR LL 002369 03-06
COULDRICK WGR 003506 04-09 COUGHENOUR IL 002369 03-06 COULDRICK WGR 003506 04-09 COUNTS WR 001703 02-14 COUPER-SMARTT J 002621 03-14, 003629 04-COUNTS WR 001703 02-14
COUPER-SMARTT J 002621 03-14, 003629 0414
COUTTS RT 001892 02-17
COVI L 000815 01-15
COWAN A 000018 01-02, 001132 02-03,
001303 02-04, 003441 04-06
COWAND 0 001761 02-15
COWARD DM 000083 01-03, 000342 01-04
COWARD DM 000083 01-03, 000342 01-04
COWARD JK 000001 01-01
COWDRY RW 001893 02-17
COX BM 002724 03-16
COX RD 000367 01-04, 001365 02-04, 003228
04-04
COY DH 000019 01-02, 001137 02-03, 002794
04-02, 003382 04-04
COY LE JT 009946 01-17, 001128 02-03,
003406 04-05
COYNE L 000549 01-08
CRABTREE RE 000735 01-13
CRAIG JR 001087 02-03
CRAIG MILL AL 002286 03-04
CRAIN B 001088 02-03, 002040 03-03
CRAIGNILL AL 002286 03-04
CRAIN SM 001088 02-03, 002040 03-03
CRAIMS M 001088 02-03, 002040 03-03
CRAIMS D 001876 01-15, 001762 02-15
CRAYES FB 002876 04-03
CRAYTON J 001569 02-08, 001570 02-08
CRESS I 000084 01-03, 001995 03-03, 001996 03-03, 002715 03-16, 002738 03-17, 002877 04-03, 003800 04-03, 003113 04-03
CREWS EL 000818 01-15
CREWS ET 001997 03-03
CRIMI G 001806 02-15
CREWS ET 001997 03-03
CRIMI G 001806 02-15
CREWS ET 001997 03-03
CREMS H 002571 03-13, 002572 03-13 CREWS ET 001997 03-03
CRIMI G 001806 02-15
CRISP AH 002571 03-13, 002572 03-13
CRISWELL HE 001089 02-03
CROFFORD MJ 000270 01-03
CROME P 000067 01-03
CROME P 0000819 01-15, 001763 02-15, 001764 02-15, 001842 02-15, 002656 03-15
CROMAN J 000456 01-04
CROSK T 000622 01-11
CROSS JK 000324 01-04
CROSS PE 000002 01-01
CROSSLAND J 003424 04-06
CROSSMAN AR 003200 04-04
CROW TJ 000085 01-03, 000086 01-03, 003388 04-04, 003452 04-08, 003460 04-08

Author Index

CROWE R 001491 02-04
CROWLEY TJ 000087 01-03
CROWLEY WR 001090 02-03, 002222 03-04
CROWN P 000695 01-13
CRUMEY WR 001090 02-03, 002222 03-04
CROWN P 000695 01-13
CRUMMY YMT 003199 04-04
CRUNELLI V 003055 04-03
CRUPIE JE 003526 04-09
CRUTCHFIELD M 002571 03-13
CSANALOSI 1 002490 03-10
CSILLAG ER 001612 02-10, 001614 02-10
CUATRECASAS P 001947 03-01
CUBENNEC A 000320 01-04
CUELLO AC 002965 04-03
CULP R 002673 03-15
CULVER CM 001775 02-15
CULVER CM 001775 02-15
CULVER CM 001775 02-15
CUMBY HR 002864 04-03
CUMNINGHAM MR 000761 01-14
CURRAN NM 000964 01-17
CURRY SH 001336 02-04, 003590 04-13, 003649 04-15
CURTIS DR 000026 01-02
CULTIS GC 000809 01-15
CURTIS JL 003591 04-13
CURZON G 000080 01-03, 000343 01-04, 000405 01-04, 002878 04-03, 003286 04-04
CUSAN L 000019 01-02
CUSSAC M 000003 01-01
CUTLER NG 003490 04-09
CUTLER NR 001765 02-15
CWINETNIEWICZ JS 001089 02-03
CWYNAR S 002427 03-09
CZARNECKA E 001998 03-03
CZARNIAWY A 002657 03-15
CZECH K 001820 02-15
CZLONKOWSKI A 000150 01-03, 000394 01-04

D
DAFNY N 000065 01-03, 000089 01-03, 002362 03-06, 002363 03-06
DAGANI F 003127 04-03
DAGINAWALA HF 003125 04-03
DAHL JL 002859 04-03
DAHL JL 002859 04-03
DAHLBERG CC 002542 03-12
DAHLBERG CC 002542 03-12
DAHLBERG ST 001089 02-03
DAHLDFL 002879 04-03
DAHLSTROM B 001527 02-06
DAILEY JW 002880 04-03
DAILY FF 002208 03-04
DAINOW II 001766 02-15
DAIRMAN W 002053 03-03
DALLOLIO A 001283 02-03
DALLOLIO A 001283 02-03
DALLOLIO R 000416 01-04
DALTERIO S 001999 03-03, 002881 04-03
DALTON J 003600 04-13
DALY JW 002156 03-03, 002885 04-03, 003079 04-03
DAM W 001767 02-15
DAMATO MR 001354 02-04
DANIELSON K 001673 02-13
DANIELSON K 001673 02-13
DANIELSON TJ 001091 02-03, 001339 02-04
DANNESKIOLD-SAMSOE P 001035 02-02
DANSWAN GW 001000 02-01
DANTZER R 001340 02-04, 003304 04-04
DARLEY CF 900755 01-14, 001727 02-14
DANIELSON TS 000759 01-13, 000725 01-13, 001597 02-09, 001599 02-09, 002569 03-13, 003503 03-09
DAS MM 000568 01-09
DAS GUPTA B 002824 04-03
DAUNET I 002527 03-11
DAVENDON F 01888 02-17
DAVIDSON F 01888 02-17
DAVIDSON F 01888 02-17
DAVIDSON RJL 000847 01-15

DAVIES J. 002831 04-03, 002883 04-03
DAVIES JA 003203 04-04
DAVIES JE 000017 01-02
DAVIES MA 002041 03-03
DAVIS MA 002084 04-03
DAVIS BA 001091 02-03
DAVIS BA 001091 02-03
DAVIS BC 000756 01-14, 001560 02-08
DAVIS IP 003204 04-04
DAVIS JL 001341 02-04, 001705 02-14, 003205 04-04
DAVIS JL 001341 02-04, 001705 02-14, 003205 04-04
DAVIS JL 001341 02-04, 001705 02-14, 003205 04-04
DAVIS JL 000896 01-13, 000523 01-08, 000693 01-13, 000696 01-15, 00096 01-15, 000960 01-15, 001063 02-03, 001455 02-04, 001561 02-08, 001562 02-08, 001550 02-08, 001565 02-08, 001570 02-08, 001564 02-13, 001659 02-08, 001570 02-08, 001564 02-13, 001659 02-08, 001570 02-08, 001654 02-13, 001659 02-08, 001570 02-08, 001654 02-13, 001659 02-08, 001570 02-08, 001654 02-13, 001659 02-08, 001654 02-13, 001659 02-08, 001570 02-08, 001654 02-13, 001659 02-08, 001570 02-08, 001654 02-13, 001659 02-08, 001570 02-08, 001659 02-08, 001570 02-08, 001659 02-08, 001570 02-08, 001659 02-08, 001570 02-08, 001659 02-08, 001570 02-08, 001659 02-08, 001569 02-08, 001570 02-08, 001659 02-09, 001659 04-04
DEDEK J 001237 02-03
DEDET L 001974 03-03
DEE G 003526 04-09
DEFEUDIS FV 000211 01-03, 002892 04-03
DEFEAITES EG 001560 02-08
DEGKWITZ R 002377 03-07
DEGOOD DE 003622 04-14
DEGRAW JI 001040 02-02
DEHAAN RM 000509 01-07
DEHNEL L 001544 02-07
DEISENHAMMER E 000757 01-14
DEITRICH RA 000222 01-03
DEKIRMENJIAN H 000696 01-13, 001561 02-08, 001569 02-08
DEKRET JJ 001768 02-15

Psychopharmacology Abstracts

DEL FIACCO M 002262 03-04
DEL RIO J 001126 02-03
DEL VECCHIO M 003336 04-10
DEL ZOMPO M 003648 04-15
DELACOUR J 000346 01-04
DELARUE P 003650 04-15
DELAC DEL 000261 03-14
DELIAR G 001652 02-13, 001704 02-14, 002552
03-13, 002613 03-14
DELIAR G 001652 02-13, 001704 02-14, 002552
03-13, 002613 03-14
DELIAR M 002632 03-14
DELIAR D 002331 03-04
DELLIA J 003623 04-14
DELIZIA D 002623 04-14
DELIZIA D 002428 03-09
DELUCA DC 000092 01-03
DEMARQUEZ JL 002632 03-14
DEMET EM 002937 04-03
DEMARGUEZ JL 002632 03-14
DEMET EM 002937 03-09
DENCKER SJ 000524 01-08, 000567 01-09, 002392 03-08, 002393 03-08, 003453 04-08
DENIKER P 002743 03-17, 003650 04-15
DENORY D 001754 02-15
DEPOORTERE H 002207 03-04
DERAPPE C 000059 01-03
DESHAMUKH U 000647 01-11, 001189 02-03, 02092 03-03
DESDERIO D 000804 01-15
DESJARDINS D 000852 01-15
DESSEILES MF 000662 01-11
DETTIMAR PW 003461 04-06
DEUTSCH P 00315 01-04, 000316 01-04
DEVON RM 00296 04-03
DEVOSE GR 001097 02-03
DEVOS JE 002627 03-14
DEVAN RM 002968 04-03
DEVORE GR 001097 02-03
DEVOS JE 002627 03-14
DEVAL HA 001633 02-12
DEWALD HA 001633 02-13
DEVORE GR 001097 02-03
DEVOS JE 002627 03-14
DEVIN RM 00268 04-03
DEVORE GR 001097 02-03
DEVOS JE 002627 03-14
DEVIN RM 00268 04-03
DEVORE GR 001097 02-03
DEVOS JE 002627 03-14
DEVALD HA 001633 02-10
DEWALD HA 001633 02-10
DEWALD HA 00163 02-03
DEVOS JE 002627 03-14
DEVALD HA 001633 02-10
DEWALD HA 00163 02-03
DEVOS JE 002627 03-14
DEVALD HA 00163 02-04
DEVAR AJ 03408 04-05
DEVIS JE 002627 03-14
DEVALD HA 00163 02-03
DEVALD HA 00164 02-13
DILLIE LO 00298 03-03
DIAMANTAS N 003456 04-08
DIAMOND B 001063 02-13
DIAMOND B 001063 00-15
DIAMOND B 002650 03-15
DI

DIMATTINA M 000821 01-15 DIMEN EM 001524 02-05 DINGLEDINE R 002003 03-03 DIRADDO JS 001098 02-03 DISTEFANO V 002999 04-03, 003000 04-03, DIRADIO JS 011776 02-3
DISTEFANO V 002999 04-03, 003000 04-03, 003285 04-04
DITTRICH A 002540 03-12
DIVAC I 003210 04-04
DIVINETZ-ROMERO S 001223 02-03, 002004
03-03, 003064 04-03
DIXON R 001534 02-06
DURKOVIC D 002982 04-03
DMELLO GD 001337 02-04, 002315 03-04, 003202 04-04, 003367 04-04
DOAK RL 003409 04-05
DOBRIN EI 002340 03-05
DODD DE 000496 01-06
DODRILL CB 001706 02-14
DOGGETT NS 000083 01-03, 000342 01-04, 003177 04-04 DOGGETT NS 000083 01-03, 000342 01-04, 003177 04-04
DOHERTY J 001192 02-03
DOHERTY JD 002896 04-03
DOLARA P 001769 02-15
DOLFINI E 001154 02-03
DOLLER JC 000919 01-16
DOLPHIN A 000256 01-03, 001099 02-03, 001346 02-04, 002005 03-03
DOM R 003454 04-08
DOMELSMITH LN 001100 02-03
DOMINO EF 000098 01-03, 000099 01-03, 002264 03-04
DOMINO EF 000098 01-03, 000099 01-03, 0002264 03-04
DOMINI D 000933 01-16 DOMIZI D 000933 01-16 DONABEDIAN RK 001027 02-02, 001661 02-13, 002926 04-03 002926 04-03 DONADIEU A 002800 04-02 DONALD JF 002429 03-09, 003537 04-10 DONALDSON D 001619 02-11 DONALDSON IML 002897 04-03 DONE AK 001745 02-15 DONLON P 001776 02-15 DONLON PT 000822 01-15, 000823 01-15 DONNELLY EF 000542 01-08, 001582 02-09, DONNELLY EF 000542 01-08, 001582 02-09, 003492 04-09 000542 01-08, 001582 02-09, 003492 04-09 02006 03-03, 002202 03-04 00N0VAN BT 003651 04-15 00N0VAN BT 003651 04-15 00N0VAN BT 003651 04-15 001882 02-17 00REN E 000189 01-03 00RIO RE 002159 03-03 00RINBUSH R 000688 01-13, 000695 01-13, 000758 01-14, 000759 01-14, 000750 01-16, 000920 01-16, 000921 01-16 00RITY F 003429 04-06 00RSEY ER 001573 02-09 00RUSE E 000696 01-13 00920 01-16, 000921 01-16

DORRITY F 003429 04-06

DORRITY F 003429 04-06

DORSEY ER 001573 02-09

DORITY F 003429 04-06

DOSTALOVA K 002623 03-14, 003630 04-14

DOSTROVSKY JO 002890 04-03

DUIGLAS P 002737 03-17

DUIGLAS V 001895 02-17

DUISA TP 002119 03-03

DW RC 002274 03-04

DOWNS DA 000350 01-04, 002241 03-04

DOWNICK PW 001707 02-14

DOWZENKO A 002701 03-15

DOYLE WJ 001520 02-05

DRACHMAN DA 000761 01-14

DRAUS F 001648 02-13

DRAY A 000100 01-03, 002831 04-03, 002838

04-03, 002883 04-03, 003033 04-03

DREN AT 001025 02-02, 001034 02-02

DREW W 000648 01-11

DREW WG 003261 04-04

DREKLER M 000404 01-04

DREKLER M 000671 01-11

DRIES WJH 003624 04-14 DREXLER M 000404 01-04
DRIES R 000671 01-11
DRIES WIH 003624 04-14
DRIVER AG 001104 02-03
DROULLAT M 000179 01-03
DROUVA SV 003072 04-03
DRUILKOVA I 003580 04-11
DRUMMOND T 003640 04-14
DRURY K 001619 02-11
DRYKONINGEN G 001791 02-15
DU RUISSEAU P 001255 02-03
DU TOIT BM 000675 01-12
DUBAS G 003326 04-04 DUBAS G 003326 04-04 DUBE D 001948 03-01 DUBOCOVICH ML 002855 04-03 DUBUISSON D 001101 02-03 DUCHARME J 001255 02-03 DUCHOWNY M 000623 01-11

DUCOMB L 001770 02-15
DUDAR JD 000101 01-03
DUDEK BC 003211 04-04
DUFOUR H 001699 02-14
DUGAS JE 001771 02-15
DUGGAN AW 001102 02-03, 002246 03-04
DUGAY R 000595 01-10
DULSKA E 003397 04-04
DUMAS M 003005 04-03
DUMONT C 002200 03-04
DUMOVIC P 001751 02-15, 002476 03-10, 003645 04-15
DUNAL FD 001029 02-02
DUNCAN JW 002740 03-17
DUNCAN RL 001942 03-01
DUNCAN WC 00756 01-14
DUNCKIEY HG 000605 01-10
DUNDEE JW 001785 02-15
DUNHAM MJ 002628 03-14
DUNN AJ 000384 01-04
DUNN AJ 000352 01-04, 000383 01-04, 002898 04-03
DUNNER DL 000566 01-09, 000714 01-13, 000458 02-40 DUNN AJ 000352 01-04, 000383 01-04, 002898 04-03 DUNNER DL 000564 01-09, 000714 01-13, 001583 02-09, 00019 01-02 DUPONT E 003557 04-11 DUPONT E 003557 04-11 DUPONT PE 000203 01-03 DUQUE L 002672 03-15 DURHAM HD 001103 02-03 DURLOFSKY L 001132 02-03 DURLOFSKY L 001132 02-03 DUSENBERRY WE 001359 02-04 DUSTMAN RE 003171 04-04 DUTTA AS 001024 02-02 DVILANSKY A 002603 03-13 DVORAKOVA M 003533 04-09 DVORCHIN BH 001104 02-03 DVORKIN B 003112 04-03 DVORKIN BI 003112 04-03 DWORKIN SI 000322 01-04, 001305 02-04 DWOSKIN LP 002054 03-03 DWOYKIN SI 000322 01-04, 001305 02-04 DWOSKIN LP 002054 03-03 DWOYKIN SI 000322 01-04, 001305 02-04 DVORCHO 02737 03-17 DYAKOVA SD 001338 02-04 DYER DC 001009 02-01 DYKSTRA LA 001929 02-17 DZOLLIC MR 001366 02-04, 002313 03-04

E

EADIE MJ 000642 01-11, 000824 01-15
EASTGATE SM 003212 04-04
EBADI M 001105 02-03
EBERT DM 001025 02-02
EBERT DM 001025 02-02
EBERT MH 000562 01-09, 002573 03-13, 002786 04-01
EBERT SF 001655 02-13
EBNER A 002650 03-15
EBSTEIN RP 000543 01-08, 001666 02-13, 003063 04-03, 003529 04-09, 003587 04-13
ECLES R 001106 02-03
ECHAVARRIA MT 000346 01-04
ECKEL K 002380 03-07
ECKERMAN DA 003213 04-04
ECKER E 000781 01-14
ECKERT E 000781 01-14
ECKERT E 000781 01-14
ECKERT E 0001544 02-07
EDEN S 000102 01-03
EDGAR DH 002899 04-03
EDIIND PO 001527 02-06
EDMISTON S 002741 03-17
EDMONDS DE 002225 03-04
EDVINSSON L 001107 02-03
EDWARDS JD 001107 02-03
EDWARDS JD 001107 02-03
EDWARDS JD 001124 02-03
EDWARDS JG 000825 01-15, 000826 01-15, 000827 01-15, 000828 01-15, 000820 01-15, 000830 01-15, 00119 02-02
EDWARDS JM 001019 02-03
EGGERS C 000525 01-08
EGGET V 000188 01-03, 002126 03-03
EHRHARDT JA 002615 03-14
EHRLICH BE 002553 03-13
EHRHARDT JA 002615 03-14 EHARA I 001108 02-03 EHRHARDT AA 002615 03-14 EHRLICH BE 002553 03-13 EHSANULLAH RSB 002599 03-13 EICH JE 003585 04-12, 003612 04-13, 003711 04-17 EICHELBERGER RP 000103 01-03 EICHELMAN B 000947 01-17, 001348 02-04

EIDELMAN BH 001109 02-03, 001193 02-03
EINON DF 003214 04-04
EISENBERG RM 001110 02-03
EISENHARDT RH 002007 03-03
EISENHARDT RH 002007 03-03
EISON MS 001529 02-06, 003215 04-04
EKIERT H 002394 03-08, 002395 03-08
EL-AZHARY R 002283 03-04
EL-DARAWY ZI 000165 01-03
EL-FRALY FS 000004 01-01
EL-HAWARI AM 001111 02-03
EL-LAITHY AF 000165 01-03
EL-LAITHY AF 000165 01-03
EL-SOBRY AA 000792 01-14
EL-YOUSEF MK 002226 03-04
ELCHISAK MA 002227 03-04
ELGART B 003459 04-08 ELCHISAK MA 002227 03-04
ELGART B 003459 04-08
ELIAKIM M 002684 03-15
ELIASSON M 000353 01-04
ELIE R 000506 01-07, 000595 01-10
ELION R 000632 01-11
ELIZUR A 000589 01-09
ELIJUR A 000589 01-09
ELIJUR SR 000354 01-04
ELIJ ELLIOTT GC 000078 01-03
ELLIOTT GR 002248 03-04, 003409 04-05, 003616 04-14
ELLIOTT HW 001662 02-13
ELLIOTT HW 001662 02-13
ELLIOTT PNC 000077 01-03, 000355 01-04, 001112 02-03
ELLIS DG 002087 03-03
ELLIS KO 001944 03-01
ELLIS S 000227 01-03
ELLISON G 001529 02-06, 003215 04-04
ELLISON RJ 002478 03-10
ELLISON RJ 002478 03-10
ELMES PC 001896 02-17
ELO H 001505 02-05
ELROD SV 002075 03-03
ELSOHLY MA 000004 01-01
ELSWORTH JD 003652 04-15
END D 002364 03-06
ENDE W 001772 02-15
ENDERS P 003483 04-09
ENDE V 001865 02-16, 001872 02-16
ENERO MA 001113 02-03
ENEROTH P 001694 02-13, 002547 03-13, 002558 03-13
ENG N 001278 02-03, 003042 04-03
ENGEL J 000307 01-04, 000356 01-04, 001297 02-04, 001430 02-04, 002271 03-04, 002791 03-04, 002791 04-02 ENGELHARDT EL 001012 02-01 ENGELHARDT EL 001012 02-01
ENGLE DJ 001446 02-04
ENGSTRAND E 003496 04-09
ENJALBERT A 002005 03-03
ENNA SJ 000741 01-13, 002106 03-03
ENZ A 002008 03-03, 002047 03-03
EPSTEIN AN 003361 04-04
EPSTEIN PN 002341 03-05
ERBAN L 001861 02-16
ERDOS EG 003593 04-13
ERHARDT PW 002793 04-02
ERICKSEN S 000696 01-13
ERICKSEN SE 000696 01-15, 001679 02-13
ERICKSON HM 000646 01-11
ERMINI JM 002742 03-17 001679 02-13
ERICKSON HM 000646 01-11
ERMINI M 002742 03-17
EROGLU L 000169 01-03
ERVIN GN 001349 02-04
ERWIN DN 001349 02-04
ERWIN DN 002009 03-03
ESPOSITO RU 003216 04-04
ESTES LW 001523 02-05
ETEVENON P 002743 03-17
ETSCORN F 001350 02-04
ETSUN0 Y 001773 02-15
ETTENBERG A 001351 02-04
EUVRARD C 000134 01-03, 000158 01-03, 001114 02-03
EVANS BB 001115 02-03, 002080 03-03
EVANS BF 002722 03-16
EVANS G 002343 03-05
EVANS H 001569 02-08
EVANS L 003653 04-15
EVANS LE 003653 04-15
EVANS LE 003531 04-09
EVANS LE 001352 02-04
EVENITT BJ 000357 01-04, 001360 02-04, 002228 03-04
EVERS TM 001411 02-04

002228 03-04 EVERS TM 001401 02-04

Author Index

EWING JA 000831 01-15 EXNER JE 000526 01-08 EXTEIN 1 002660 03-15, 002744 03-17, 002926 04-03 EYQUEM A 003650 04-15 EZRIN-WATERS C 001506 02-05, 002229 03-04

FABBRUCCI I 002379 03-07 FABER J 000926 01-16, 002554 03-13 FABIAN I 002902 04-03 FABRE LF 000510 01-07, 000762 01-14, 001585 02-09, 002430 03-09, 002479 03-10, 003538 04-10 001595 02-07, 002430 03-09, 002479 03-10, 003538 04-10 FACCHINETTI T 001201 02-03 FACY F 001886 02-17 FADDA F 001962 03-03, 002357 03-05 FAHN S 000637 01-11, 002510 03-11 FAILINGER C 001515 02-05 FAIRMAN MD 000496 01-06 FAIRMAN F 003426 04-06 FAIRMAN KM 000415 01-04 FAKHURI LR 002744 03-17 FALLOON 1 002396 03-08, 003455 04-08 FAND 1 000040 01-03 FAND J 000040 01-03 FANG V 003009 04-03 FANG V 003009 04-03 FANG V 003009 04-03 FANG V 001192 02-03, 002096 03-03, 002582 03-13, 002903 04-03 FANG V 00309 04-03
FANG VS 000197 01-03, 000540 01-08, 001192 02-03, 002096 03-03, 002582 03-13, 002093 04-03
FANN WE 000948 01-17, 001935 02-17, 002381 03-07, 002661 03-15
FARAH MB 001117 02-03, 001118 02-03
FARB DH 001080 02-03
FARBER IJ 001586 02-09
FARSKAI 01172 02-03, 002904 04-03
FASSINA GF 002588 03-13
FAULKNER TP 002662 03-15
FAURE JMA 002632 03-14
FEDER HH 002222 03-04
FEE EA 003544 04-10
FEHIR KM 002695 03-15
FEIN G 001708 02-14
FEINBERG II 001708 02-14
FEINBERG MP 0000104 01-03
FEINBERG MP 000091 01-13
FEISE GA 002607 03-14
FELDBAN H 003624 04-10
FELDMAN S 002010 03-03
FELDMAN S 002010 03-03
FELDMAN S 002905 04-03, 003217 04-04
FELDMAN S 002010 03-03
FELDRE JA 003438 04-04
FELDMAN S 002010 03-03
FELIX D 003498 04-06
FELIX D 003590 04-03
FELIX D FELIX D 003407 03-14
FELIX FELIX FELIX FELIX D 002607 03-15
FENIX GROWN S 002905 04-03
FELIX D 003906 04-03
FELIX D 003906 04-03
FELIX D 003906 04-03
FELIX D 003908 04-04
FERMANIAN J 003471 04-08
FERNAN GROWN D 00069 01-15
FENIX O 000697 01-15
FENIX O 000697 01-13
FELIX FERNAN GROWN D 000697 01-15
FENIX O 000908 04-03
FERNEN FERNAN D 000106 01-03, 000139 01-03, 003378 04-04
FERNAN D 0C0 00008 01-03, 002878 04-03
FERNEN D 001795 02-03
FERNEN B 001775 02-15
FERNEN B 001775 02-15
FERREI R 0010138 02-02, 001119 02-03
FERRIS S 000622 01-11
FERRIS S N 0001038 02-02, 001119 02-03 CAUS 04-03 04-03 02-02, 001119 02-03 FERRIS RM 001038 02-02, 001119 02-03 FERRIS S 000622 01-11 FERRIS S 000622 01-11 FERRIS S 002794 04-02 FERTZIGER AP 001120 02-03 FESSLER R 002096 03-03 FESSLER R 000197 01-03, 001192 02-03 FEUER G 00288 04-03 FEUER SEIN A 000236 01-03 FEUER SEIN A 000236 01-03 FEUER J 002908 04-03 FIBIGER HC 000336 01-04, 002279 03-04, 002299 03-04, 003039 04-03, 003625 04-14 FICKER F 000832 01-15 FIELDING S 001462 02-04 FIELDS 1Z 002061 03-03, 002909 04-03, 003041 04-03

FIEVE RR 000714 01-13, 000949 01-17, 001583 02-09, 002445 03-09 FILE \$ 001121 02-03, 001353 02-04 FILE \$ 000358 01-04, 003218 04-04, 003219 04-04 FILEWICH RJ 000363 01-04 FINK RJ 001349 02-04 FINK RJ 001345 02-07 FINKLE RJ 001657 02-13 FINEY RJ 000923 01-16, 001589 02-09 FIREMARK HM 002520 03-11 FIRESTONE P 003626 04-14 FISCHBER JJ 00160 02-03 FISCHER RJ 001411 02-04 FISCHER JJ 00160 02-03 FISCHER RJ 001401 02-03 FISCHER RJ 00160 02-03 FISCHER RJ 002530 03-11 FISHER RJ 002550 03-11 FISHER RJ 002550 03-10 FISHMAN RJ 001029 02-02 FISK RA 000261 01-03 FIZPATRICK DF 002129 03-03 FIZPATRICK DF 00250 03-10 03-03 03-03 03-03 03-03 03-03 03-03 03-03 03-03 03-03 03-03 03-03 03-03 03 FLOM MC 002604 03-14
FLODD JF 000360 01-04, 002232 03-04, 002233 03-04
FLORA RE 001296 02-04, 003152 04-04
FLORA RE 001296 02-04, 003152 04-04
FLORVALL L 001945 03-01
FLOVD TC 001708 02-14
FOERSTER K 001774 02-15
FOG R 000583 01-09
FOLDES FF 001029 02-02
FONDREN B 003179 04-04
FONDREN B 003179 04-04
FONDREN B 003179 04-04
FONDREN B 003179 04-04
FORD DH 00108 01-03
FORD MJ 001790 02-15
FORD RD 000361 01-04, 000362 01-04, 001356 02-04
FOREMANK J 001435 02-04
FOREMANK J 001435 02-04
FOREMANE P 000178 01-03
FORREST IS 003690 04-16
FORREST IS 003690 04-16
FORREST WA 002432 03-09, 002433 03-09
FORSMAN A 00342 04-04
FORSMAN A 00342 04-07
FORSTER RM 001555 02-07
FORSYTHE A 003582 04-11
FORTIN C 003461 04-08
FORTUNE DH 000082 01-03
FOSSOM LH 001402 02-04, 002158 03-03
FOSSOM LH 001402 02-04, 002158 03-03
FOWLER JS 000116 01-03

Psychopharmacology Abstracts

FOWLER LJ 000100 01-03
FOWLER IX 000763 01-14, 000764 01-14
FOWLER R 001204 02-03
FOWLER SC 000363 01-04, 001532 02-06, 002234 03-04
FOX RA 001357 02-04
FRANCES H 001358 02-04, 002133 03-03
FRANCIS AA 001116 02-03, 002901 04-03
FRANCIS AA 001116 02-03, 002901 04-03
FRANCIS AF 002463 03-09
FRANCIS AF 001769 02-15
FRANCON F 001769 02-15
FRANGON H 003456 04-08
FRANK GB 001068 02-03, 001103 02-03
FRANKE K 000702 01-13, 001663 02-13, 001665 02-13, 001665 02-13, 001665 02-13, 002913 04-03, 002913 04-03 FRANKEL D 001123 02-03, 002014 03-03, 002913 04-03
FRANKENBERG K 002392 03-08, 002393 03-08
FRANKLIN KBJ 000364 01-04, 000365 01-04
FRANKLIN MR 003410 04-05
FRANKLIN MR 003410 04-05
FRANKS GJ 000783 01-14
FRANKS HM 000673 01-12
FRANSON M 002512 03-11
FRASER HF 001897 02-17
FRATTA W 002788 04-01, 002790 04-01, 002953 04-03
FRAFER A 000930 01-16, 001658 02-13 002953 04-03 FRAZER A 000930 01-16, 001658 02-13, 001869 02-16, 003518 04-09, 003519 04-09 FRAZIER SH 002425 03-09 FREDERICKSON RCA 001124 02-03, 001359 02-PRAZER A 000930 01-16, 001038 02-13, 001869 02-16, 003518 04-09, 003519 04-09 FRAZIER SH 002425 03-09 FREDERICKSON RCA 001124 02-03, 001359 02-04
PREDHOLM BB 002019 03-03
FREED CR 002914 04-03
FREED CR 002914 04-03
FREED CR 00198 02-04, 003338 04-04
FREEDMAN DX 0011141 02-03, 002044 03-03
FREED MA 0030323 04-04
FREEMAN GB 003223 04-04
FREEMAN GB 003223 04-04
FREEMAN GB 003223 04-04
FREEMAN GB 003223 04-04
FREEMON FR 000505 01-07, 000765 01-14
FREEN H 001267 02-03, 002915 04-03, 002916 04-03
FREUCHEN I 002616 03-14
FREY D 003712 04-17
FREY H 000186 01-03
FREZZA V 001546 02-07
FRIED PA 000766 01-14
FRIEDEL RO 000938 01-17, 001857 02-16, 003097 04-03
FRIEDMAN AH 002889 04-03
FRIEDMAN AH 002889 04-03
FRIEDMAN AH 002816 04-03
FRIEDMAN AN 00709 02-14
FRIEDMAN MA 001266 02-03
FRIEDMAN MA 001266 02-03
FRIEDMAN MA 000769 01-11, 001775 02-15
FRIEDMAN MA 000769 03-11, 001775 02-15
FRIEDMAN MA 002878 03-07
FRIEDMAN MI 000277 01-03
FRIEDMAN MI 000277 01-04
FRIES DS 001026 02-02
FRIESEN H 000328 03-07
FRITH CD 003460 04-08
FRIGERIN V 003225 04-04
FRIESEN H 000378 03-07
FRITH CD 003460 04-08
FRIEDMAR R 001290 02-03, 003146 04-03
FROMMER R 001290 02-03, 003146 04-03
FRUEDNA T 0000556 01-09, 0090906 01-15
FRUIJIT AY 000307 03-04
FRUIJITA Y 000307 03-04
FRUIJI

VOLUME 16, AUTHOR INDEX

RUBERS M. 000759 04-04

RUBER M. 000715 04-03 000112 01-03

GASPARD TO 8 00358 03-13

GASPARD TO 8 00358 03-14

GASPARD TO 8 00358 03-14

GASPARD M. 00145 02-00

COURSE 04-04 03001 10-043

COURSE 04-04 03001 10-0

GOLEMBIOWSKA K 000449 01-04
GOLEMBIOWSKA NIKITIN K 003397 04-04
GOMEN R 000478 01-05
GOMEZ-LOZANO P 003539 04-10
GOMMERN N 002677 03-03
GONCALES EG 002103 03-03, 002104 03-03
GONZALES EG 002103 03-03, 002104 03-03
GONZALES FA 001136 02-03
GOOD MI 000839 01-15
GOODED J 000540 01-08, 000754 01-14, 002582 03-13
GOODELL C 000859 01-15
GOODED I 00126 01-03
GOODMAN JT 003626 04-14
GOODMAN JE 000769 01-17
GOODWIN FK 000562 01-09, 000645 01-11, 000729 01-13, 001653 02-13, 001683 02-13, 001893 02-17, 002435 03-09, 002468 03-09, 002744 03-17, 002435 03-09, 002645 03-09, 002744 03-17, 002745 03-19, 003509 04-09, 003516 04-09, 003496 04-16
GOTTAKAN N 002669 03-15
GORBATKO LG 002339 03-05
GORCZYNSKI RJ 002793 04-02
GORDON A 003408 04-05
GORDON BK 000481 01-05, 001653 02-13, 003691 04-16
GORDON JH 003230 04-04
GORDON JL 002292 04-03
GORDON FK 000481 01-05, 001653 02-13, 003691 04-16
GORDON JL 002290 04-03
GORDON FK 000481 01-05, 001653 02-13, 003691 04-16
GORDON JL 002929 04-03
GORNEY JJ 001024 02-02
GORDON FK 000481 01-05
GORDON GORDON FK 000481 01-05
GORDON GORDON FK 000481 01-05
GORDON FK 000481 01-05
GORDON FK 000481 01-05
GORDON GORDON FK 000481 01-05
GORDON GORDON FK 000481 01-05
GORDON FK 000481 01-05
GORDON FK 000481 01-05
GORDON FK 000481 01-05
GORDON FK 0003402 02-02
GORODOTES O00568 01-14
GORDON JL 002290 04-03
GORDON FK 0003402 04-04
GORYANOV OA 001513 02-05
GORDON FK 0003402 04-04
GORYANOV OA 001513 02-05
GORBELK M 000943 01-17
GOTESTAM KG 001404 02-04, 002272 03-04, 003231 04-04
GOTHERT M 002025 03-03, 002026 03-03
GOTTORIES GG 000768 01-14
GOTTILEB JJ 001779 02-15
GOTESTAM KG 001404 02-04, 002272 03-04, 003231 04-04
GORYANOV OA 001513 02-05
GORBEL KD 000684 01-15
GOULDING R 001842 02-05
GORDON GORDON

GREENBERG DA 000219 01-03, 000283 01-03, 002029 03-03, 003118 04-03
GREENBERG G 001780 02-15
GREENBERG C 001780 02-15
GREENBERG R 002933 04-03
GREENBERG R 002933 04-03
GREENBLATT DJ 000630 01-11, 000702 01-13, 000738 01-13, 000738 01-13, 000738 01-13, 000742 01-13, 001665 02-13
GREENBLATT DI 003235 04-04
GREENFIELD AA 001644 02-13
GREENBLATT DI 003259 04-11
GREENHILL P 002569 03-15
GREENLAW P 002995 04-03
GREENLE D 002122 03-03
GREENLE D 002122 03-03
GREENLE D 002122 03-03
GREENSUD WF 003553 04-11
GREENWOUD WF 003553 04-04
GREESBACH PH 000732 01-03
GRIEFSHIT BT 001102 02-03, 002246 03-04
GRIEFTH DNW 001718 02-14
GRIFFIH DNW 001718 02-14
GRIFFIH DNW 001718 02-14
GRIFFIH DNW 001718 02-14
GRIFFIH DNW 001718 02-14
GRIFFITH SR 001499 02-04, 001715 02-14, 003236 04-04
GRILLY DNW 001368 02-04
GRINGRAS M 002481 03-10
GRINSPOON L 000842 01-15
GRIOT RG 000021 01-02
GRISANTI GC 002615 03-14
GRIFFITH SR 001499 02-04
GRUET BY 002549 03-13
GROEN WF 002303 03-04
GROEN WF 002303 03-03
GRUER WF 002303 03-04
GROEN WF 002303 03-03
GRUER WF 0020303 03-03
GRUER W 02-03 GUHA SR 002022 03-03, 003020 04-03 GUIDOTTI A 000023 01-02, 000056 01-03, 000132 01-03, 000133 01-03, 000499 01-06, 001139 02-03, 002031 03-03, 002990 04-03 GUILLEMIN R 000532 01-08, 000533 01-08 GUIRGUIS E 000527 01-08 GUILATI 0D 000263 01-03, 001240 02-03 GUILBERG B 000591 01-09, 000621 01-11, 001557 02-08, 001694 02-13, 003462 04-08

GUILEY BL. 002733 03-17
GUILIVER PA 003425 04-06
GUNGOR M 000169 01-03
GUNN RB 002591 03-13
GUPTA AK 000568 01-09
GUPTA BS 001716 02-14, 002620 03-14
GUPTA FC 000312 01-04
GUPTA FC 000312 01-04
GUPTA TK 000035 01-02, 002235 03-04
GUSSETTO JK 003206 04-04
GUSTAFSON L 000781 01-14, 001677 02-13, 002512 03-11
GUT AM 002526 03-11
GUT AM 002526 03-11
GUT SHALL PL 000682 01-12
GUYDA H 002581 03-13
GUYENET P 000134 01-03
GUZEK JW 002238 03-04
GYGAK P 002032 03-03
GYLYS JA 000461 01-04, 001073 02-03

HAAS HL 000135 01-03, 000300 01-03, 001211 02-03, 002181 03-03
HAAVIK CO 001140 02-03
HABECK D 000021 01-02
HABER B 002750 03-17
HABER LH 003251 04-04
HABER S 002365 03-06
HABIBZADEH MA 000843 01-15
HABILTZ JJ 001028 02-02
HACHE J 000003 01-01
HACHEY DL 001862 02-16
HACKETT TP 002767 03-17
HADAWAY PF 003158 04-04
HADLEY JC 001287 02-03
HAEFELY W 000173 01-03, 000226 01-03, 002128 03-03
HAEGERSTROM-PORTNOY G 002604 03-14 002128 03-03
HAGGERSTROM-PORTNOY G 002604 03-14
HAFNER J 000598 01-10
HAGGEN C 002554 03-13
HAHN EF 001029 02-02
HAILES J 001603 02-09
HAITS G 002384 03-07
HALARIS AE 001141 02-03, 002044 03-03, 002937 04-03 HAITS G 002384 03-07
HALARIS AE 001141 02-03, 002044 03-03, 002937 04-03
HALBREICH U 002438 03-09
HALIKOWSKI B 001547 02-07
HALL DA 001701 02-14
HALL JG 001102 02-03
HALL HO 101530 02-06
HALL ME 000374 01-04
HALL NR 003237 04-04
HALL RCW 001782 02-15
HALL Z 000136 01-03
HALL Z 000136 01-03
HALL Z 000136 01-03
HALLIVEL G 000002 01-01
HALM KA 001667 02-16, 002590 03-13
HALPERN FS 001867 02-16, 002590 03-13
HALPERN WI 000955 01-17
HAMPERN WI 000955 01-17
HAMMERSEN G 001843 02-15
HAMMITON J 002874 04-03
HAMMITON S 001617 02-11
HAMMER J 001807 02-15
HAMMERSEN G 001843 02-15
HAMMERSEN G 002550 03-15
HAMMERSEN G 002550 03-15
HAMMERSEN G 002550 03-15
HANGWIN G 002398 03-08
HANSEN AP 003557 04-11

VOLUME 16. AUTHOR INDEX

HARRIS RA 001372 02-04, 002166 03-03, 002242 03-04, 002243 03-04, 002244 03-04 HARRIS S 000982 01-17 HARRIS WE 002939 04-03 HARRISON DR 001000 02-01 HARRY GJ 001373 02-04 HARSTON CT 003240 04-04 HARSTON CT 003240 04-04 HARTLEY L 002621 03-14, 003629 04-14 HARTMANN BK 003105 04-03 HARTMANN E 000511 01-07, 000632 01-11, 000770 01-14, 001784 02-15 HARTMANN M 002571 03-13 HARTON BE 001374 02-04 HARVEY PA 001508 02-05 HARVEY PA 001508 02-05 HARVEY PA 001508 02-05 HARVEY PA 001784 01-14 HASEGAWA AT 000245 01-03 HASHIMOTO K 003258 04-04 HASHIMOTO K 003258 04-04 HASHIMOTO S 003527 04-09 HASKELD S 002482 03-10 HASKEY JC 001780 02-15 HASSUZAWA H 001826 02-15 HASUZAWA H 000779 01-14 00278 03-30 HASIAM RA 001826 02-15
HASIAM RA 001826 02-15
HASIOUN A 001752 02-15
HASIZAWA H 000779 01-14
HATA F 002024 03-03, 002078 03-03
HATCHELL PC 000376 01-04
HATFIELD GM 000007 01-01
HATOUM HT 001093 02-03
HATTENDORF C 000139 01-03
HATTENDORF M 000139 01-03
HATTENDORF M 000139 01-03
HAUFRECT DB 000647 01-01
HAUGAARD ES 003015 04-03
HAUGAARD ES 003015 04-03
HAUGAARD N 003015 04-03
HAUGACK W 000407 01-04, 002979 04-03
HAUGACK V 000407 01-04, 002979 04-03
HAVDALA H 001063 02-03, 001177 02-03, 001410 02-04, 001952 03-02
HAVLICK V 000437 01-04, 002245 03-04, 002958 04-03
HAWKING C 000678 05 002958 04-03 HAVSTAD JW 001130 02-03 HAWKINS C 002571 03-13 HAWKINS DR 001858 02-16 HAWKINS M 001264 02-03, 002941 04-03 HAWKINS R 002344 03-05

HAWKS R 002559 03-13

HANSEN R 000898 01-15
HANSEN S 003604 04-13
HANSEN T 000634 01-11, 002585 03-13
HANSEN T 000634 01-11, 002585 03-13
HANSON RW 000057 01-03
HANSON RW 001004 02-01, 001010 02-01
HANSON RW 001004 02-01, 001010 02-01
HANSON RW 001004 02-01, 001010 02-01
HANSON RW 002852 03-13
HANSON RW 002853 03-04
HANSSEN T 002585 03-13
HANSON RW 001004 02-01, 001010 02-01
HANSON RW 00104 02-01, 001010 02-01
HANSON RW 00286 03-13
HANSEN T 002586 03-13
HANSEN RW 000701 01-13
HANSULT C 002240 03-04
HANSEN RW 000701 01-13
HANSULT C 002240 03-04
HARANAC RW 000845 01-15
HARANACH RW 000710 01-13
HARANACH C 001132 02-03, 001143 02-03
HARANACH C 001132 02-03, 001143 02-03
HARANACH C 000845 01-15
HARANACH PSW 000975 01-04
HARAP KAC O00886 01-15
HARARASTI J 000896 01-15
HARARASTI J 000896 01-15
HARARASTI J 000896 01-15
HARARIEL C 001150 52-08
HARIULA K 001742 02-15
HARNOR RW 000702 01-13, 001663 02-13, 001669 02-13, 001689 02-14, 001781 02-15
HARRIS L 000655 01-11
HARRIS L 000655 01-17
HARRIS W 000790 02-04, 002186 03-03, 002189 02-03, 002918 04-03
HARRIS L 000633 01-13
HARRIS L 000649 01-13
HARRIS L 000649 01-13
HARRIS L 0006 OC2918 D4-03
HEMSWORTH BA OD2813 04-03
HEMDER RC 003243 04-04
HENDERSON GL 000704 01-13
HENDERSON GL 000704 01-03
HENDERSON IW 000048 01-03
HENDLER NH 003499 04-09
HENDRICK J 000315 01-04
HENDRICK J 0001577 02-09, 002560 03-13
HENKER GR 001577 02-09, 002560 03-13
HENKER B 000620 01-11, 003581 04-11
HENN FA 002943 04-03, 002944 04-03
HENNEBERG M 002657 03-15
HENRY T 002621 03-14
HENSLEY MJ 000982 01-17
HENTSCHEL F 001772 02-15
HERBERG LJ 000364 01-04, 000365 01-04, 001466 02-04 HENTSCHELF 001772 02-15
HERBERG LJ 000364 01-04, 000365 01-04, 001466 02-04
HERBET A 000134 01-03, 000158 01-03, 001114 02-03
HERBLIN WF 000141 01-03
HERBLIN WF 000141 01-03
HERBLIN WF 000141 01-03
HERMAN MM 000261 01-03
HERMAN Z 002203 03-04
HERMAN W 000142 01-03
HERMAN W 000142 01-03
HERMAN W 000142 01-03
HERMANDEZ LJ 001302 02-04
HERNANDEZ LJ 001302 02-04
HERNANDEZ LL 001302 02-04
HERNANDEZ DO0710 01-03
HERNANDEZ DO0710

HETTA J 001377 02-04
HEUBLEIN DM 002119 03-03
HEWES CR 001359 02-04
HEWICK DS 002948 04-03
HEYDEN T 002558 03-13
HEYNDRICKX A 001841 02-15
HEZRONI J 001627 02-11
HICKENBOTTOM JP 000480 01-05
HICKS TP 003006 04-03
HIDAKA H 000145 01-03
HIBB E 000616 01-10
HIEP A 002402 03-08
HIGGENBOTTOM T 001764 02-15
HILL G 002374 03-04
HILL RC 000379 01-04
HILL RC 000379 01-04
HILL RC 000379 01-04
HILL RC 000379 01-04
HILLEGERS JPM 003368 04-04
HILLEGERS JPM 003368 04-04
HILLEGERS JPM 003368 04-04
HILLEGERS JPM 003368 01-17
HIDDAMARCH I 000988 01-17, 001787 02-15, 003657 04-15
HINDAMARCH I 000985 01-16
HINE B 00109 01-03, 001571 02-08
HINES D 001414 02-04
HING GEN JN 002305 03-04
HINE F 002622 03-14 HINEK A 001258 02-03
HINES D 001414 02-04
HINGTGEN JN 002305 03-04
HINK RF 002622 03-14
HINZ G 000795 01-14
HINZED DH 002041 03-03
HIPPIUS H 000553 01-08
HIRADA J 0017793 02-15
HIRAMATSU T 000877 01-15
HIRANO M 003027 04-03
HIROSE K 000013 01-01
HIRSCH CA 001539 02-06
HIRSCH SB 000654 01-11
HIRSCHHORN ID 001378 02-04
HISAZATO T 001793 02-15
HITZEMANN BA 001203 02-03, 001379 02-04
HIXSON E 000147 01-03, 001203 02-03, 001379 02-04
HIXSON E 000263 01-03
HLAVAC AG 000203 01-03
HLAVAC AG 000203 01-03
HO BT 001043 02-03, 002280 03-04, 002753
03-17, 002903 04-03, 003150 04-04, 003359
04-04
HO IK 000093 01-03, 001055 02-03, 001096 03-17, 002903 04-03, 003150 04-04, 003359
04-04
HO IK 000093 01-03, 001055 02-03, 001096
02-03, 002336 03-04
HO WKK 002949 04-03
HOBSON GN 002247 03-04
HODSHON BJ 000498 01-06
HOEBEL BG 003279 04-04
HOFFER BJ 000299 01-03, 001538 02-06
HOFFMAN DJ 001647 02-13
HOFFMAN PL 001146 02-03, 003106 04-03, 003107 04-03
HOFFMANN D 001445 02-03, 003106 04-03, 003107 04-03
HOFFMANN G 002439 03-09
HOGARTY GE 000528 01-08
HOGBEN G 003660 04-15
HOGG MIJ 000668 01-11, 000669 01-11
HOKFELT T 001360 02-04
HOLBROOK H 002035 03-03
HOLBROOK L 000149 01-03, 001147 02-03
HOLBROOK L 000149 01-03, 001147 02-03
HOLBRO C 003444 04-07
HOLE K 000380 01-04
HOLLENDER MH 003658 04-15
HOLLISTER LE 000820 01-15, 001558 02-08, 001553 02-13, 001695 02-13, 01863 02-16, 002223 03-04, 002721 03-16, 003500 04-09, 003710 04-17
HOLLON SD 003726 04-07 O03136 04-03
HOLMAN EW 001443 02-04
HOLMAN RB 002248 03-04, 003409 04-05, 003616 04-14
HOLMABERG G 000555 01-09, 000703 01-13
HOLMGREN B 001380 02-04, 001387 02-04, 001479 02-04, 002951 04-03
HOLMGREN E 002952 04-03
HOLMSTEDT B 000187 01-03, 001157 02-03

HOLOUBKOVA E 001435 02-04
HOLTZMAN NA 003554 04-11
HOLTZMAN SG 000381 01-04
HOLZ F 000477 01-05 001503 02-05
HOLZBAUER M 002833 04-03
HONDA F 000024 01-02
HONDA F 000024 01-02
HONDA F 000024 01-02
HONDA F 000499 01-06, 002788 04-01
HONG J 000499 01-06, 002788 04-01
HONG J 002979 04-01, 002953 04-03
HONG J 002979 04-01, 002953 04-03
HONG J 002959 03-03
HONG J 002959 03-03
HONE J 00259 03-03
HOPES J 00259 03-03
HOPES J 00259 03-03
HOPES M 003572 04-11
HORI M 002046 03-03
HORINA M 001423 02-04
HORN AS 001901 02-17, 002562 03-13
HORNYAK EP 002479 03-10
HORNYAK EP 002479 03-16
HORNYKIEWICZ O 001181 02-03, 002062 03-03
HOROWITZ FD 002673 03-15
HOROWITZ HA 000569 01-09
HOROWITZ J 002674 03-15
HOROWITZ J 002674 03-13
HOROWIT HRDINA PD 001070 02-03, 001133 02-03 HRDINA V 001376 02-04, 002945 04-03, 003262 04-04 HRDINA V 001376 02-04, 002945 04-03, 003262 04-04
HRUSKA RE 002061 03-03
HSIAO W 000267 01-03
HSU CH 001400 02-04, 002269 03-04
HSU LL 002044 03-03
HUANG S 000319 01-04
HUANG SP 003143 04-03
HUBBARD JW 001149 02-03, 001195 02-03
HUBER G 000529 01-08
HUBERMAN HS 001529 02-06
HUBERMAN HS 001529 01-03
HUBERMAN HS 001529 01-03
HUBERMAN HS 001026 02-02
HUDSON P 001788 02-15
HUEY L 000530 01-08, 003559 04-11
HUFFMAN RD 002103 03-03
HUGHES IE 000138 01-03
HUGHES IE 000138 01-03
HUGHES KR 000437 01-04
HUIFW 000270 01-03
HUI FW 000270 01-03
HUIT GP 002249 03-04
HUNT F 000151 01-03
HUNT S 002956 04-03
HUNT S 002956 04-03
HUNT FW 003424 04-06
HUNTER SA 002850 1-03

HUOT S 003037 04-03
HUQUE M 001548 02-07
HUQUE MF 002554 03-13, 002566 03-13
HURT SW 000523 01-08
HURNIC MJ 000901 01-15, 002602 03-13, 003578 04-11
HUSAIN S 000228 01-03
HUSTON JP 002291 03-04, 003247 04-04
HUTCHINSON RR 002367 03-06
HUWS D 002563 03-13
HUXLEY M 002754 03-17
HVJDBERG EF 003522 04-09
HYDE JRG 001121 02-03, 003219 04-04
HYDINGER M 000087 01-03
HYMOWITZ N 002250 03-04
HYMOWITZ P 001566 02-08
HYMES M 00181 02-04, 001398 02-04, 001462 02-04
HYTTEL J 001035 02-02, 002957 04-03

IBSEN I 000567 01-09
ICHISE K 002637 03-14
IGLESIA FA 002880 04-03
IGNATOWICZ L 002513 03-11
IGNATOWICZ L 002513 03-11
IGNATOWICZ R 002513 03-11
IJIMA I 001031 02-02
IIVANAINEN M 001622 02-11
IKEDA H 000636 01-11
ILLIG R 000500 01-09
ILLIIG RPA 000152 01-03, 000242 01-03
IMAICH H 001864 02-16
IMPERATO TJ 001776 02-15
IMURA H 002803 04-03
INABA T 000713 01-13
INANAGA K 001556 02-07, 001572 02-08, 003610 04-13
INDIRA G 000375 01-04
INGLE DJ 000446 01-04
INGLE DJ 000446 01-04
INGLE DJ 000446 01-04
INGLE DJ 000446 01-04
INGRAM DL 002833 04-03
INMAN WHW 001780 02-15
INOMATA Y 001865 02-16, 001872 02-16
INTURRISI CE 001902 02-17
INUBUSHI S 001382 02-04
INWANG EE 001654 02-13
IOFFE S 002958 04-03
IONESCU E 000382 01-04
IORIO LC 000021 01-02
IPPOLITI AF 000862 01-15
IQBAL MJ 003459 04-08
IQBAL S 000257 01-03
IRRGANG U 002566 03-13
IRWIN P 001545 02-07
ISAAC L 003007 04-03
ISAAC P 000848 01-15
ISAACSON RL 000383 01-04, 000421 01-04, 000474 01-04, 002595 04-03
ISBELL H 000025 01-02
ISHIGURO T 002675 03-15
ISHIHARA T 001243 02-03
ISHII H 000144 02-03
ISHIKAWA H 000602 01-10
ISHIMARU T 001845 02-15
ISHIHARA T 001243 02-03
ISHIL M 001546 02-15
ISHIHARA T 001243 02-03
ISHIL M 0002565 03-13
ITIL T 003558 04-11
IIL T M 001546 02-15
ISHIHARA T 001548 02-07, 003610 04-13
ITIL T 003588 04-10
ITIL T M 001546 02-15
ISHIHARA T 001548 02-07, 001903 02-17, 002564
03-13, 002566 03-13
ITIL M 001548 02-07, 001903 02-17, 002564
03-13, 002566 03-13
ITIL T 003588 04-10
ITIL T M 001548 02-07, 001903 02-17, 002564
03-13, 002565 03-13
ITIL M 001548 02-07, 001903 02-17, 002564
03-13, 002566 03-13
ITIL M 001548 02-07, 001903 02-17, 002564
03-13, 002566 03-13
ITIL M 002665 03-13
ITIL M 002665

Psychopharmacology Abstracts

IWAMOTO K 000153 01-03, 001166 02-03 IWAMOTO T 002045 03-03 1WANGOFF P 002008 03-03, 002047 03-03 IWASAKI Y 002803 04-03 IWATA H 002761 04-03 IWATA H 000160 01-03 IWATA T 000160 01-03 IZARD C 002579 03-13 IZQUIERDO I 001439 02-04 IZUMI T 003373 04-04

JACKSON DB 002021 03-03

JACKSON DM 000429 01-04, 000673 01-12, 002015 03-03, 002085 03-03

JACKSON SJ 002189 03-04

JACOB JJ 003379 04-04

JACOB JD 001030 02-02

JACOB RH 000647 01-11

JACOB WITZ D 003003 04-03

JACOBS BL 001082 02-03, 001262 02-03, 001383 02-04, 001477 02-04

JACOBS JJ 002049 03-03

JACOBS RA 001104 02-03

JACOBS RA 001104 02-03

JACOBS ON S 002962 04-03

JACOBS ON S 002962 04-03

JACOBS JH 001150 02-03

JACOBS JH 001150 02-03

JACOBY JH 001150 02-03

JACQUOT C 001182 02-03

JACQUOT C 001182 02-03

JAMH-ETCHEVERRY G 000155 01-03

JAIN P 002823 04-03

JAIN P 002823 04-03

JAIN P 002823 04-03

JAIN P 002824 04-03

JAIN P 002823 04-03

JAIN P 002823 04-03

JAIN P 002825 03-03, 003083 04-03

JAIN FA 000370 03-06

JAMES IM 001718 02-14

JAMES IM 001718 02-14

JAMES IM 001760 02-15

JAMROZ G 001994 03-03, 002655 03-15

JAMROZ G 001994 03-03, 002655 03-15

JAMROZ K 2 002203 03-04

JANDALI MK 002631 03-14

JANSEN P N 000975 01-03

JANSEN P N 000975 01-04

JANSEN P N 000975 01-05

JANSEN P N 000975 01-05

JANSEN P N 000975 01-06

JANSEN P N 000975 01-07

JARSET D 00298 04-03

JANSEN P N 002965 04-04

003325 02-04, 001197 02-04, 003195 04-04, 003295 04-04, 003195

JENSEN RA 000406 01-04, 003288 04-04 JERLICZ M 001393 02-04, 002979 04-03 JERUSSI TP 000367 01-04, 001365 02-04 JESSELL TM 000240 01-03, 002965 04-03 000849 01-15 JEURING HJ 002804 04-03, 003025 04-03, 003602 04-13 JHAMANDAS K 001152 02-03, 002966 04-03 JI S 002059 03-03 JI S 002059 03-03

JIANO JB 001004 02-01

JILEK L 002161 03-03

JIMERSON DC 001870 02-16, 003691 04-16

JINKS M 000600 01-10

JOBSON K 002441 03-09

JOH TH 000183 01-03

JOHANNESSEN S 000705 01-13, 002529 03-11

JOHANNSON C 000386 01-04

JOHANSON C 002251 03-04

JOHANSON M 001677 02-13, 002512 03-11

JOHANSON M 001677 02-13, 002512 03-11

JOHANSON B 003694 04-16

JOHANSON B 001153 02-03, 002050 03-03, 00284 04-03 JOHANSSON B 001153 02-03, 002050 03-03, 002054 04-03
JOHANSSON P 0002125 03-03
JOHANSSON PR 000621 01-11
JOHANSSON R 000716 01-13, 003453 04-08
JOHN V 002451 03-09
JOHNSON B 001021 02-02, 002346 03-05
JOHNSON A 000850 01-15
JOHNSON A 003693 04-13
JOHNSON AC 00379 01-13
JOHNSON AC 00379 01-13
JOHNSON AC 003593 04-13
JOHNSON DAW 000534 01-08
JOHNSON DAW 000534 01-08
JOHNSON DAW 000534 01-04
JOHNSON HL 001040 02-02
JOHNSON HL 00318 01-04
JOHNSON KM 000318 01-04 002854 04-03 JOHNSON HR 000318 01-04
JOHNSON HR 002051 03-03, 002364 03-06,
002835 04-03
JOHNSON L 001450 02-04
JOHNSON P 000152 01-03, 000242 01-03
JOHNSON P 000152 01-03, 000242 01-03
JOHNSON RC 002304 03-04
JOHNSON SM 002052 03-03
JOHNSON WG 000637 01-11
JOHNSTON BB 001792 02-15
JOHNSTON GAR 000026 01-02, 002967 04-03
JOHNSTON EC 003452 04-08, 003460 04-08
JOHRI MBL 000257 01-03
JOLICOEUR FB 000470 01-04, 001388 02-04
JONES B 001504 02-05 JOHRI MBL 000257 01-03 JOLICOEUR FB 000470 01-04, 001388 02-04 JONES B 001504 02-05 JONES BD 003646 04-15, 003705 04-17 JONES BE 000387 01-04, 000439 01-04 JONES CN 003246 04-04 JONES DG 002968 04-03 JONES DJ 000214 01-03 JONES DJ 000214 01-03 JONES GT 001359 02-04, 003095 04-03 JONES HB 000851 01-15 JONES IC 000048 01-03 JONES RD 002451 03-09 JONES RD 001257 02-03, 002493 03-10, 002555 03-13, 002567 03-13, 002568 03-13, 002577 03-13 JONES RT 001643 02-13, 002604 03-14 JONES TA 002598 03-13 JONES VH 000007 01-01 JONES VH 00007 01-01 JONES WN 002676 03-15 JONSSON J 001005 02-01, 002970 04-03 JONSSON M 000308 01-04 JORDAN CC 002969 04-03 JORDAN LM 003251 04-04 JORGENSEN A 000037 01-03, 003488 04-09, JORGENSEN A 0 003508 04-09 JORGENSEN KA 002774 03-17 JORGENSEN KA 002774 03-17 JORI A 001154 02-03, 001236 02-03, 003411 04-05 JOSEPH C 002755 03-17 JOSEPH JA 000388 01-04, 001302 02-04 JOSHUA S 000563 01-09 JOURERT P 000957 01-17 JUJUBERT P 000957 01-17 JOUHANEAU J 003252 04-04 JUJUERT R 0000516 01-07, 003546 04-10 JUDD LL 000485 01-05, 002670 03-15, 003559 JUDIS J 000706 01-13 JUHASZ L 002053 03-03 JUHL RP 000638 01-11 JULIEN R 001699 02-14 JULOU L 000258 01-03

JUMEAN H 000898 01-15

JURASKA JM 000298 01-03 JURGENS R 001746 02-15 JUS A 000700 01-13, 002677 03-15, 003461 04-08 JUS K 000700 01-13, 000852 01-15, 002677 03-15, 003461 04-08 JUUL-JENSEN P 003557 04-11

KAAKKOLA S 002806 04-03
KABOUCHE M 002800 04-02
KADOUCH R 001666 02-13
KAFI S 003253 04-04
KAFOE WF 000159 01-03
KAGAWA M 002635 03-14
KAGEDAL B 000774 01-14, 003502 04-09
KAI Y 001572 02-08
KAIRYA DJ 001204 02-03
KAIRYA H 000160 01-03
KAIZAWA S 000599 01-10
KALANT H 001123 02-03, 002014 03-03, 002913 04-03, 003060 04-03, 003307 04-04
KALES A 000750 01-14, 001719 02-14, 002608 03-14, 003637 04-14
KALES JD 000750 01-14, 001719 02-14, 003637 04-14
KALININ VV 001155 02-03
KALIMAN RI 001022 02-02
KALLIOMAKI L 001254 02-03
KALIMAN M 001399 02-04, 003070 04-03
KALIMAN M 003254 04-04, 003692 04-16
KALVACH Z 001861 02-16
KAM R 003130 04-03
KAMMADA T 001796 02-15
KAMAL L 001268 02-03
KAMEI C 002290 03-04
KAMENETSKIY VK 003599 04-13
KAMENIKA JM 003128 04-03
KAMINKA T 003291 04-04
KAMISHIMA K 000599 01-10
KAMMERER RC 002970 04-03
KAMISHIMA K 000599 01-10
KAMMORER RC 002970 04-03
KAMISHIMA K 000599 01-10
KAPLISH D 001032 02-02, 002055 03-03
KANIB F 002321 03-04
KANOWSKI S 001905 02-17
KARTAK KM 002054 03-10
KAPLAN RJ 0010370 02-04
KARLBAN RA 001705 02-14
KAPLAN RJ 0010370 02-04
KARLBAN RA 001705 02-14
KAPLAN RJ 001397 02-04
KARLBAN RA 001705 02-10
KAPLAN RB 0010370 02-04
KARLBAN RB 0010370 02-04
KARLBERG BE 000774 01-14, 003502 04-09
KARLBERG BE 000774 01-14, 003502 04-09
KARLBERG BE 000 KAAKKOLA \$ 002806 04-03 KABOUCHE M 002800 04-02 KADOUCH R 001666 02-13 KARKISSON J 002952 04-03
KARMOS G 001390 02-04
KARMOS-VARSZEGI M 001390 02-04
KARNIOL IG 003600 04-13
KARNOVSKY ML 001208 02-03
KAROBATH M 001828 02-15, 002789 04-01
KAROUM F 001158 02-03
KASABDJI D 001057 02-03
KASAMATSU T 003045 04-03
KASE M 000877 01-15, 002690 03-15, 003673
04-15
KASSIR S 000714 01-13
KASSOUNY M 000324 01-04
KASTIN AJ 001137 02-03, 001309 02-04, 002794 04-02, 003382 04-04
KATAHN M 003714 04-17
KATAOKA K 002973 04-03
KATO H 000639 01-11

KATO R 000024 01-02 KATO Y 002803 04-03 KATSUMATA Y 003104 04-03 KATYAL SL 003149 04-03 KATZ JB 002056 03-03, 002057 03-03 KATZ JB 002254 03-04, 002255 03-04, 003365 KATSUMATA Y 003104 04-03
KATZ JB 002056 03-03, 002057 03-03
KATZ JL 002254 03-04, 002255 03-04, 003:
04-04
KATZ RJ 001391 02-04, 002255 03-04, 003:
03-255 04-04
KATZMAN R 003112 04-03
KAUFMAN N 003330 04-04
KAUFMAN N 003554 04-11
KAUMEIRS S 002620 03-14
KAWAKAMI M 002974 04-03
KAWAMURA H 000098 01-03
KAWAMURA H 000098 01-03
KAWAMURA H 000098 01-03
KAWAMURA H 000098 01-03
KAYAMAKCAIAN S 002257 03-04
KAY DC 001897 02-17, 003256 04-04
KAY DC 001897 02-17
KAY SR 003473 04-08
KEBABIAN JW 001159 02-03
KEEHN JD 000390 01-04
KEELER MH 001906 02-17
KEEPERS GA 000508 01-07
KEHNE JH 003257 04-04
KELLAMS JJ 000491 01-04
KELLER WJ 000010 10-03
KELLEY JT 003445 04-04
KELLER WJ 000007 01-01, 000162 01-03
KELLY JT 003445 04-07
KELLY PJ 000651 01-11
KELLY PH 002258 03-04, 002917 04-03
KEMP JEG 000002 01-01
KEMPF E 002975 04-03
KENNEDY LA 00298 03-03
KENNEDY LA 00298 03-03
KERNEDY LA 00298 03-03
KERNEDY LA 00298 03-03
KERNEDY LA 00258 03-03
KERNER RP 001647 02-13
KERNES SM 002886 04-03
KERNEDY LA 00298 03-03
KESSELMAN M 001741 02-15
KESSER RP 000512 01-07
KESSER RP 000051 01-13
KESNER RP 001647 02-13
KESNER RP 00051 01-03
KESSELMAN M 001741 02-15
KESSER RP 0005250 03-03
KESSELMAN M 001741 02-15
KESSER RP 0005053 01-03
KHALI SR 00036 01-03 KETY BS 000535 01-08
KETY BJ 000164 01-03, 001069 02-03
KHAFAGY EZ 000165 01-03
KHALID R 002376 03-07, 002417 03-09, 002443 03-09 03-043 KHALSA JH 000166 01-03 KHAN P 002375 03-07 KHANNA JM 001123 02-03, 002014 03-03, 002913 04-03 KHANNA JM 001123 02-03, 002014 03-03, 002913 04-03
KHAYYAL MT 002977 04-03
KHAZAN N 001328 02-04, 001476 02-04, 003010 04-03
KHAZAN V 001162 02-03
KHAZAN V 001162 02-03
KHAZAN V 001601 01-10
KHYLLVITSKIY TY 002444 03-09
KIBBLER CC 003214 04-04
KIDO A 003108 04-03
KIER LB 001530 02-06
KIERKEGAARD-HANSEN A 001599 02-09, 002559 03-13, 003503 04-09
KIKUCHI J 001865 02-16
KIKUCHI J 001865 02-16
KIKUCHI T 000602 01-10
KILBEY MM 001984 03-03
KILLEEN P 001431 02-04
KILLIAM KF 001130 02-03
KILLIAM KF 001130 02-03
KILS C 002060 03-03
KIM C 001269 02-03
KIM JK 002119 03-03

Author Index

KIM JS 003027 04-03
KIM YB 002445 03-09
KIMURA H 001812 02-15
KIMURA S 000773 01-14
KINDEL GH 003386 04-04
KINDERNAYOVA H 000517 01-07
KINEY CA 002309 03-04
KING CD 001991 03-03
KING LI 001191 03-03
KING S 002978 04-03
KINGSTON B 000853 01-15
KINLOCH N 002038 03-03
KINGSTON B 002-34 03-11, 002614 03-14
KIRAKOR SZ 0034487 04-09
KIRK L 000634 01-11
KIRKEGAARD C 000926 01-16, 002554 03-13
KIRSTEIN L 001596 02-09
KISARA K 000032 01-02, 000033 01-02
KISHI R 000258 04-04
KISHIMOTO A 901592 02-09
KITAGAWA K 001238 02-03, 002973 04-03
KITAMURA K 001615 02-10, 002635 03-14
KITANO T 001164 02-03, 001165 02-03
KITAMURA K 001316 02-04
KITSON TM 000707 01-13
KJELIMAN BF 000774 01-14, 003502 04-09
KLASSEN CD 000153 01-03, 001166 02-03
KLAGER K 002073 03-03
KLAGER K 002073 03-03
KLAGER K 002073 03-03
KLAPERNBERGER R 003104 04-03
KLASA JW 002980 04-03
KLASA JW 002980 04-03
KLASA JW 002990 04-03
KLASS D 000817 01-15, 003682 04-15
KLATZO I 003014 04-03
KLASA JW 002990 04-03
KLASS D 000817 01-15, 003682 04-15
KLATZO I 003014 04-03
KLASA JW 002990 04-03
KLASS D 000817 01-15, 003682 04-15
KLATZO I 003014 04-03
KLAB JW 002990 04-03
KLASS D 000817 01-15, 003682 04-15
KLEINE HD 001661 02-13, 002751 03-17, 003628 04-14
KLEBS K 002925 04-03
KLEIN EVD 002529 03-11
KLEIN D 001640 10-8
KLEINERGER G 001820 02-15
KLEINERGER G 001820 02-15
KLEINERGER G 001820 02-15
KLEINERGER G 001820 02-15
KLEINERGER G 00180 02-03
KLEI

KOCH-WESER J 000702 01-13, 001663 02-13, 001665 02-13, 001689 02-13
KOCHANSKY GE 001720 02-14
KOCUR J 001998 03-03
KODAMA H 001279 02-03
KODAMA H 001279 02-03
KODAMA H 001279 02-03
KODAMA H 001279 02-03
KOELA WP 001211 02-03, 002895 04-03, 002925 04-03
KOFER KB 002062 03-03
KOFER KB 002062 03-03
KOFFER KB 002062 03-03
KOHON H 000033 01-02
KOHNO K 001840 02-15
KOIZUMI S 001794 02-15
KOIZUMI T 00182 02-04
KOJIMA T 002637 03-14
KOKASAHARA S 001812 02-15
KOKETSU K 001173 02-03
KOKKEVI A 000759 01-14, 000760 01-14, 000920 01-16, 000921 01-16
KOKKINDIS L 002261 03-04, 003260 04-04
KOKKMEN E 000809 01-15
KOLB B 001033 02-02
KOLBER A 003420 04-05
KOLINOVA M 001411 02-04
KOLIS SJ 001289 02-03
KOLIVAKIS TNI. 002391 03-08
KOLTUN WA 001175 02-03
KOMARKOVA A 003630 04-14
KOMENDA S 002623 03-14, 002624 03-14, 003630 04-14
KOMENDA S 002623 03-14, 002624 03-14, 003630 04-14
KOMENDA S 002623 03-16
KOMISARUK BR 001090 02-03
KOMIGS M 002145 03-03
KOMURA K 01840 02-15
KON Y 000556 01-09
KONIG L 002400 03-08
KONIG P 002682 03-15
KONIGSHAUSEN T 001795 02-15
KONKOL RJ 002218 03-04
KOOPMAN-KOOL E 003122 04-03
KOPANDA RT 000916 01-16
KOPEL BS 000755 01-14, 001727 02-14, 002622 03-14
KOPANDA RT 000916 01-16
KOPEL BS 000755 01-14, 001727 02-14, 002622 03-14
KOPIN II 002862 04-03
KOPANDA RT 000916 01-16
KOPEL BS 000755 01-14, 001727 02-14, 002622 03-14
KOPIN II 002862 04-03
KOPANDA RT 000916 01-16
KOPEL BS 000755 01-14, 001727 02-14, 002627 03-13
KORDA W 000564 01-08
KORDON C 003072 04-03
KOPANDA RT 000916 01-16
KOPEL BS 000755 01-14, 001727 02-14, 002627 03-13
KORDA W 000564 01-08
KORDON C 003072 04-03
KOSTICKER W 00210 03-03
KOSTICKER W 00200 03-03
KOVACCIC R 001040 00-103
KOSTICKER W 00200 03-03
KOVACCIC R 001040 00-103
KOSTICKER

KOZIEL H 002515 03-11 KOZLOVSKAYA MM 001395 02-04, 001480 02-RAEMER R 001623 02-11
KRAGH-SORENSEN P 003522 04-09
KRALL MA 002628 03-14
KRAMY P 003624 04-04
KRAMY RAM 002428 03-04
KRAMER MM 002428 03-04
KRAMER MS 000571 01-09
KRAMER L 000571 01-09
KRAMER L 000597 01-17
KRAMER MS 000504 01-06
KRAMP P 003632 04-14
KRASICKA J 002701 03-15
KRAUSE G 000785 01-14
KRASICKA J 002701 03-15
KRAUSE G 000785 01-14
KRAYNACK BJ 001953 03-02
KREBS SJ 001510 02-05
KREEK MJ 001862 02-16
KREICL I 003265 04-04
KRENDAL FP 002680 03-15
KRIGMAN M 001409 02-04, 001520 02-05
KRIGMAR EC 001984 02-04, 001520 02-05
O02195 03-04, 002265 03-04, 001520 02-05, 002195
O02050 03-09
KRISHNA NR 002516 03-11
KRISHNAANR 002516 03-14
KROGH C 003633 04-14
KROGH C 003633 04-14
KROGH C 003633 04-14
KROGSGAARD-LARSEN P 000026 01-02, 002981 04-03
KROTH RS 003049 04-03
KROGTH RS 003049 04-03
KRUISKY N 002590 03-08
KRSIAK M 000171 01-03
KRUILK R 001172 02-03, 002904 04-03
KRUINKY V 000566 01-09
KRUMHOLZ A 002515 03-09
KRUMHOLZ A 003554 04-11
KRYLOV SS 002151 03-03
KRZANOWSKI JJ 002129 03-03
KRZANOWSKI JJ 003129 03-03
KUJBAK N 00173 02-03
KUJBAK N 00173 02-03
KUJBAK N 000790 01-02
KUJBICKI J 003268 04-04
KUJBE J 000546 01-08
KUJBE J 000546 01-09
KUJBE KN 001779 02-15
KUJBERSKI R 000172 01-03, 002064 03-03
KUJBI N 00265 03-03
KUJ

VOLUME 16. AUTHOR INDEX

KURIBARA H 003269 04-04
KURIYAMA K 002984 04-03
KURIAND AA 000679 01-12, 000978 01-17,
001580 02-09, 001595 02-09
KURODA S 001108 02-03
KURSAT I 002905 04-03
KURUVILLA K 003619 04-14
KUSCHINSKY K 000174 01-03
KUSUMO KS 001798 02-15
KUTSCHER CL 000396 01-04
KUTH M 001860 02-16
KUZMA R 003447 04-07, 003483 04-09
KVETINA J 001376 02-04, 003404 04-04

LA BRIE RA 001777 02-15
LA BROOY SJ 002704 03-15
LABAT J 001722 02-14
LABRECQUE G 002066 03-03, 002143 03-03
LABRIE F UUU019 01-02, 001982 03-03
LACEY JH 002571 03-13, 002572 03-13
LACOURSIERE RB 000549 01-08 LACOURSIERE RB 000549 01-08
LADER M 000603 01-10, 002681 03-15,
003594 04-13
LADER MH 003600 04-13
LADINSKY H 000080 01-03, 002872 04-03,
003074 04-03
LADURON P 000175 01-03
LADURON PM 002067 03-03, 002068 03-03,
002079 03-03, 002853 04-03, 002929 04-03, 002985 04-03
LAHMEYER HW 003654 04-15
LAHRICHI M 001669 02-13
LAHTIRA 002986 04-03
LAHTINEN U 002626 03-14
LAHTINEN U 002626 03-14
LAHTINEN U 002069 03-03
LAHTINEN A 002069 03-03
LAHTIA 0 002517 03-11, 003688 04-16
LAITHA A 000775 01-14
LAKE CR 0025273 03-13
LAKKE JPWF 003602 04-13 002985 04-03 LAKE CR 002573 03-13

LAKKS JWF 00302 04-13

LAKKS JWF 001278 02-03

LAL H 000414 01-04, 001381 02-04, 001397

02-04, 001398 02-04, 001462 02-04, 003270

04-04, 003388 04-04, 003428 04-06

LAL K 001799 02-15

LAL N 003540 04-10

LALONDE J 002070 03-03

LALUET M 000484 01-05

LAM GF 003049 04-03

LAM S 002949 04-03

LAM S 002949 04-03

LAM S 002949 04-03

LAM S 002949 04-03

LAM BP 000867 01-15

LAMBERT GS 001501 02-04, 003280 04-04

LAMBERT GS 001501 02-04, 003280 04-04

LAMBERT GS 00578 01-09

LAMMINTAUSTA R 001156 02-03

LANGE E 002400 03-08

LANGELAND J 001035 02-02

LANGER G 001867 02-16, 002574 03-13, 002575 03-13, 002576 03-13, 002590 03-13

LANGER SC 001117 02-03, 001118 02-03, 002028 03-03, 002843 04-03, 002855 04-03

LANGER LP 000383 01-04

LANSON RN 003213 04-04

LARSEN FF 0011436 02-04

LARSEN FF 001436 02-04

LARSEN FF 001436 02-04

LARSEN N 000631 01-11, 003522 04-09

LARSON JW 000200 01-03

LARSON JW 000200 01-03

LARSON JW 000200 01-03

LARSON JW 000200 01-03

LASSON M 001430 02-04

LASSON M 001430 02-04 LAKKE JPWF 003602 04-13 LAKOSKI JM 001278 02-03 LASAGNA L 000960 01-17, 003469 04-08 LASALA JM 002655 03-15 LASCHKA E 000177 01-03 LASKA E 003638 04-14 LASKA FJ 002071 03-03 LASKI E 000775 01-14 LASKY DI 002349 03-05 000397 01-04, 000398 01-04,

003271 04-04

LASTHAUS P 002671 03-15
LASZIO J 002895 04-03
LATHAM AN 001531 02-06
LATHAM AN 001531 02-06
LATHAM CJ 001312 02-04
LATINI R 000178 01-03
LAU D 000704 01-13
LAUBIE M 000179 01-03, 001399 02-04
LAUDANO O 000604 01-10
LAURIDSEN UB 000926 01-16, 002554 03-13
LAURIDSEN UB 000926 01-16, 002554 03-13
LAURITZEN AM 003362 04-04
LAVIE P 002679 03-15
LAVRETSKAYA EF 001174 02-03
LAVYNE MH 001175 02-03
LAWRENCE BE 002457 03-09
LAYCOCK JD 000415 01-04
LAYMAN WA 000709 01-13
LAZDUNSKI M 003128 04-03
LE FILOTH ML 000124 01-03
LE FUR G 002800 04-02
LE MAGNEN J 003252 04-04
LE MOL M 000139 01-04
LE POICH ML 000124 01-03
LE PINCH ML 000139 01-04
LE POICH ML 000124 01-03
LE PINCH ML 000139 01-04
LE MOL M 000399 01-04
LE POICH M 001971 03-03, 002197 03-04
LEAFER C 003461 02-04
LEAFER C 001361 02-04
LEAFER C 001361 02-04
LEAFER S 000010 01-01
LEAVENS WJ 003065 04-03 O03164 04-04
LEATHER SR 000010 01-01
LEAVENS WJ 003065 04-03
LEBEPLYA 01 001174 02-03
LEBER HW 001800 02-15
LEBERER MR 000363 01-04, 001532 02-06
LEBLANC AE 001123 02-03, 002014 03-03, 002913 04-03
LECHIN F 000961 01-17
LECRUBIER Y 000516 01-07, 003546 04-10
LEDERGERBER SA 003294 04-04
LEDERMANN H 000703 01-13
LEE C 000180 01-03, 001034 02-02
LEE CM 001985 03-03
LEE HK 001176 02-03, 001400 02-04, 002269 03-04
LEE JCM 000765 01-14 LEE HIK 001176 02-03, 001400 02-04, 002269 03-04

LEE JCM 000765 01-14

LEE JH 000588 01-09, 000866 01-15, 001831 02-15, 002407 03-08, 002699 03-15, 003450 04-08, 003680 04-15

LEE RL 002072 03-03

LEE T 001335 02-04, 002779 03-17

LEELAVATHI D 003362 04-04

LEES AJ 003560 04-11, 003652 04-15

LEFF DN 003718 04-17

LEFKOWITZ RJ 001982 03-03

LEFRANCOIS J 001971 03-03, 002197 03-04

LEGATT DF 000925 01-16

LEGATT DF 000925 01-16

LEGER RM 000118 01-03

LEGROS JJ 002385 03-07

LEHMANN E 002446 03-09

LEHMANN E 00520 01-08, 000577 01-09, 000775 01-14, 001642 02-13, 001743 02-15, 001855 02-16, 002375 03-07, 002376 03-07, 002413 03-09, 002414 03-09, 002416 03-09, 002417 03-09, 002416 03-09, 002417 03-09, 002416 LEHMANN J 001652 02-13, 001704 02-14, 002613 03-14 LEHUEDE J 000011 01-01 LEIBER L 001801 02-15 LEIBMANN S 000352 01-04 LEIBOWITZ M 000643 01-11 LEIBOWITZ SF 002074 03-03, 002270 03-04, 003272 04-04 LEICHHER P 000530 01-08, 003559 04-11 LEICHTER SB 001596 02-09 LEIGH H 000899 01-15 LEIGHTON J 001947 03-01 LEIMAN AL 000261 01-03, 003418 04-05 LEITH NJ 002190 03-04 LEITH NJ 002190 03-04 LEITH NJ 002190 03-04 LEIDHAN AL 000261 01-03, 003418 04-05 LEITH NJ 002190 03-04 LEIDHAN B 003273 04-04 LEIDHAN B 003412 04-05 LEIDHAN B 000373 01-13, 001686 02-13 LEMMER B 003274 04-04 LEMON M 001287 02-03 LENAERTS FM 000502 01-06 LENMAN JAR 000710 01-13

LENNOX IGA 003506 04-09
LENTI C 002592 03-13
LENZ G 002682 03-15
LENZER II 003355 04-04
LEONARD A 000977 01-17
LEONARD BE 000159 01-03, 000181 01-03, 002094 03-03, 002992 04-03, 003335 04-04
LEONARD MA 001608 02-09
LEPP M 000524 01-08, 002392 03-08, 002393 03-08, 002393 LEVINS NO 200524 01-08, 002392 03-08, 002393 03-08 00524 01-08, 002392 03-08, 002393 03-08 00524 01-08, 002392 03-08, 002393 03-08 LEPPIK UP 00 01670 02-13 LEPPIK UP 000525 01-03 LERNER J 003530 04-09 LERNER P 000481 01-05 LESHER GA 003275 04-04 LESLIE SW 002075 03-03 LESSES 000572 01-09, 003507 04-09 LESTER BK 003635 04-14 LESTER D 003165 04-04 LETCHER FS 01219 02-03 LEUNG KC 002949 04-03 LEVAC T 002504 03-11 LEVENE MI 002683 03-15 LEVET A 000402 01-04 LEVI MA 000108 01-03 LEVI MA 000108 01-03 LEVIN S 002673 03-15 LEVIN S 002070 3-03, 002165 03-03 LEVINE P 003068 04-03 LEVINE P 003068 04-03 LEVINE N 003660 04-15 LEVITON A 000623 01-11 LEVIT RA 000349 01-04, 001401 02-04, 003403 04-04 LEVY A 001620 02-11 LEVY M 002684 03-15 LEVY NB 003661 04-15 LEVY RA 000213 01-03 LEVY NB 003661 04-15 LEVY RA 001617 02-11 LEVY RA 001617 02-11 LEVY RA 002132 03-03 LEWINE S 001909 02-17 LEVIN S 002055 01-03, 002024 03-03, 002078 03-03 LEVINES BS 001909 02-17 LEVIN S 002055 01-03, 002024 03-03, 002078 03-03 LEVINES BS 001909 02-17 LEVIN S 002055 01-03, 002024 03-03, 002078 03-03 LEVINES BS 001909 02-17 LEV 03-03 LEWANDER T 000183 01-03 LEWIS BS 001909 02-17 LEWIS JA 001909 02-17 LEWIS JA 002316 03-04 LEWIS JM 001129 02-03 LEWIS JW 000018 01-02 LEWIS PD 000184 01-03, 000216 01-03, 001512 02-05 LEWIS SB 001705 02-14 LEWY AJ 002744 03-17 LEYBIN L 000437 01-04, 002245 03-04 LEYSEN J 000175 01-03, 001512 02-05 LEWIS SB 001705 02-14 LEWS J 000175 01-04, 002245 03-04 LEYSEN J 000175 01-03, 001512 02-05 EYSEN JE 002067 03-03, 002068 03-03, 002079 03-03, 002053 04-03, 002985 04-03 UCH 000507 01-07, 000775 01-14, 003598 04-13 U4-13 LIAKOPOULOS D 003306 04-04 LIAKOS A 000688 01-13, 000711 01-13, 000748 01-14, 000776 01-14, 000921 01-16 LIANANTONAKIS E 001802 02-15, 001803 02-O00748 01-14, 000776 01-14, 000921 01-16
LIANANTONAKIS E 001802 02-15, 001803 0215
LIANG Y 000008 01-01
LIAO H 001433 02-04
LIAO S 003148 04-03
LIBERT JA 001327 02-04
LICHTBLAU L 001402 02-04
LICHTBLAU L 001402 02-04
LIDBERG L 002386 03-07
LIEB J 001804 02-15
LIEBERMAN A 002024 03-03
LIEBERMAN JA 002404 03-08
LIEBESKIND JC 001267 02-03, 002915 04-03, 002916 04-03, 003034 04-03
LIEBMAN J 001403 02-04, 002138 03-03, 003276 04-04
LIEBSON I 001715 02-14
LIEFER M 002590 03-13
LIETMAN PS 001826 02-15
LIGHT KE 001179 (22-03)
LISBERG P 003508 04-09
LILIEQUIST S 002271 03-04
LIN SC 001180 02-03
LINAWEAVER PG 001701 02-14
LINDBERG D 002392 03-08, 002393 03-08
LINDGREN S 000728 01-13
LINDHOLM H 003462 04-08

LINDQUIST M 000161 01-03, 001404 02-04, 002272 03-04
LINDSFEDT G 001805 02-15
LINDDIP WE 003588 04-13
LINET 01 002514 03-11
LING LL 002999 04-03, 003285 04-04
LINDS MED CONTROL OF CONTROL

LOSCHER W 000186 01-03
LOSEY EG 000289 01-03, 001959 03-02, 002801 04-02
LOTTI VJ 001226 02-03
LOUDON JB 003432 04-06
LOUGHNAN PM 000644 01-11
LOUIS WJ 002873 04-03
LOVVEL J 002082 03-03
LOVALLO WR 002457 03-09
LOVEGREEN PD 000682 01-12
LOVELL D 001311 02-04, 002704 03-15
LOVENBERG W 000476 01-05, 000481 01-05
LOVENING EG 000964 01-17
LOWE DM 002207 03-04
LOVENTHAL DT 001902 02-17
LOWN B 002140 03-03
LOWY K 000404 01-04
LOWY MT 003331 04-04
LOW H 002026 03-03
LOWY KASAYA RG 001407 02-04
LUBAR JF 001625 02-11
LUCAS M 002005 03-03
LUCCHELLI A 002023 03-03, 002990 04-03
LUCCHELLI A 002023 03-03, 002990 04-03
LUCCHELLI A 002023 03-03, 002990 04-03
LUCCHELLI A 000205 03-01
LUCHONS DJ 003663 04-15
LUCOT JB 001511 02-05, 003278 04-04
LUDDEN TD 001224 02-03
LUDERS H 003550 04-11
LUJAN L 000604 01-10
LUKACHER GY 003513 04-09
LUKACS L 001502 02-05
LUKASIEWICZ K 002518 03-11
LULLMANN-RAUCH R 003664 04-15
LULLMANN-RAUCH R 003557 04-11
LUNDBERG A 001384 02-04
LUNDBERG R 000917 01-03, 001157 02-03
LUNDIN L 003453 04-08
LUSCOMBE DK 002458 03-09, 002451 03-09, 002459 03-10, 002555 03-13, 002567 03-13, 002568 03-15
LYDIC R 000914 01-16
LYKOURAS E 001690 02-13
LYNOK M 0003030 04-03
LYNOK 000118 01-03
LYNOK M 000118 01-03
LYULL M 001513 02-05,

MAANY J 001768 02-15
MAAS J 001671 02-13, 003609 04-13
MAAYANI S 000128 01-03, 000188 01-03, 000224 01-03, 000235 01-03, 001221 02-03, 002126 03-03, 002127 03-03
MACAKOVA J 002623 03-14, 002624 03-14, 003630 04-14
MACDONALD IM 000539 01-08
MACFARLAND HF 000014 01-01
MACFARLANE IR 000018 01-02
MACGREGOR GA 002686 03-15
MACGREGOR GR 000116 01-03
MACGREGOR TR 001183 02-03
MACGREGOR TR 001183 02-03
MACGREGOR TR 001183 02-03 MACK G 002975 04-03 MACKENZIE RG 003279 04-04 MACKINDON AM 002083 03-03 MACLINUGHLIN DS 001665 02-13, 003596 04-MACLAUGHLIN DS 001665 02-13, 003596
13
MACLEAN AG 001106 02-03
MACLENNAN B 000855 01-15
MACLEOD SM 000738 01-13
MACPHEE AA 002870 04-03
MACVICAR K 000856 01-15
MADER R 003571 04-11
MAEDA G 002601 03-13
MAFFEI C 002592 03-13, 002713 03-16
MAFFEI F 001045 02-03
MAGALINI SI 001094 02-03
MAGGIA 001184 02-03, 002084 03-03
MAGGIA 001184 02-03, 002084 03-03
MAGNUSON DJ 001331 02-04
MAGNUSSEN I 003557 04-11

Psychopharmacology Abstracts

MAGRINAT G 000882 01-15
MAGUIRE K 001751 02-15, 002476 03-10
MAGUIRE KP 002423 03-09
MAHIEU P 001752 02-15
MAHMOUDIAN M 003093 04-03
MAHOUDIAN M 003093 04-03
MAHOU J 002936 04-03
MAHY GE 002449 03-09
MAICKEL RP 000028 01-02, 000962 01-17, 001179 02-03, 001408 02-04, 001501 02-04, 001910 02-17, 002837 04-03, 003148 04-03, 003280 04-04
MAILMAN RB 001409 02-04, 002993 04-03
MAITRE L 000347 01-04, 001960 03-02, 001965 03-03, 002172 03-03, 002173 03-03
MAJ J 003281 04-04
MALEWSKI F 000857 01-15
MAJOR IF 000657 01-14
MAJOR IF 000657 01-14
MAJOR IF 000570 11-14
MAJOR IF 000570 10-14
MAJOR IF 000570 10-14
MAJOR IF 000957 01-15
MALINCH R 003394 04-04
MAJSKY A 003533 04-09
MAKANJUOLA R 002274 03-04, 003432 04-06
MAKANDV VV 001967 03-03
MAKMAN MH 003112 04-03
MALIEN R 003660 04-15
MALICK JB 000029 01-02, 000189 01-03, 002275 03-04, 003282 04-04
MALILAL R 00250 03-10
MALILATE A 000510 01-07
MALLINGER AG 000731 01-13, 000956 01-17, 001648 02-13
MALLOY S 001536 02-06
MALLACH H 000897 01-15, 001623 02-11
MALLETTE A 000510 01-07
MALLINGER AG 000731 01-13, 000956 01-17, 001648 02-13
MALLOY S 001536 02-06
MALLY A 000552 01-08, 002688 03-15
MALLOY S 001536 02-06
MALLY A 000552 01-08, 002688 03-15
MALLONE R 000011 01-04
MALONE R 000014 01-13
MALMORE A 002971 04-03
MALSBURY CW 002900 04-03
M **Psychopharmacology Abstracts**

MANDELL AJ 000190 01-03, 000191 01-03, 002781 03-17

MANDELL AJ 000190 01-03, 000191 01-03, 002781 03-17

MANEN C 002086 03-03

MANESS DD 000137 01-03

MANGONI A 002508 03-11, 003620 04-14, 003648 04-15

MANIAN AA 000282 01-03, 001216 02-03, 001995 03-03, 002875 04-03, 003405 04-05

MANKODI NA 00568 01-09

MANKU MS 002043 03-03

MANN J 003665 04-15

MANN SP 003430 04-06

MANNING EJ 007859 01-15

MANOGUERA AS 000860 01-15

MANOGUERA AS 000860 01-15

MANOGUERA AS 000860 01-15

MANOGUERA CO 000192 01-03, 003052 04-03

MANTONE CR 002087 03-03, 003052 04-03

MAPES REA 001912 02-17

MAPLE P 001410 02-04

MARANGOS PJ 002995 04-03

MAPCAS H 001187 02-03, 002221 03-04, 002350 03-05

MARCAIS H 001187 02-03, 002221 03-04, 002350 03-05
MARCARIA V 000016 01-02
MARCER D 000777 01-14
MARCH JD 001708 02-14
MARCO E 000192 01-03, 002996 04-03
MARCOS LR 003449 04-08
MARCOTTE E 002416 03-09
MARCUCI F 001201 02-03, 002820 04-03
MARCY R 001535 02-06
MARDER JE 001781 02-15
MARES P 001411 02-04, 002161 03-03
MARES SE 002340 03-05

MASSARI VJ. 003003 04-03
MASSIM 003207 04-04
MASSIM 003207 04-04
MASSIM 003207 04-04
MASTERS J. 001763 02-15
MASTIGLIA FL. 002653 03-15
MASUDA H. 003603 04-13
MASUDA H. 003603 04-13
MASUDA DT. 000198 01-03
MATELICEK M. 002627 03-14
MATHEW NT. 000647 01-11
MATHEW P. 001808 02-15, 003511 04-09
MATHEW RJ. 002486 03-10
MATHEW RJ. 002486 03-10
MATHEW RJ. 002486 03-10

VOLUME 16, AUTHOR INDEX

MARGETT B. 000740 09-17

MARGENI R. 000350 09-19

MARGENI R. 000351 09-19

MARGENI R. 000350 09-

MEWE F 002527 03-11 MEWE G 002527 03-11 MEYER DA 000593 01-39

MEYER DR 002283 03-04, 003167 04-04
MEYER E 000284 01-03, 003330 04-04
MEYER E 000284 01-03, 003330 04-04
MEYER IS 000047 01-11, 001062 02-03,
001194 02-03
MEYER MC 001674 02-13
MEYER MC 001674 02-13
MEYER PM 003167 04-04
MEYER BAILBURG HFL 002615 03-14
MEYER BAILBURG HFL 002615 03-14
MEYER BO 00312 04-09
MEYERSON B 001307 02-04, 001418 02-04,
001463 02-04
MEZA-RUZ G 003013 04-03
MEZERTSEVA LIN 001249 02-03
MICHAIAKEAS AC 000739 01-13
MICHAIAKEA 000412 01-04
MICOSI LG 003014 04-03
MICKEL RA 003015 04-03
MICKEL RO 003010 01-01
MIDDLETON RSW 00634 04-14
MIDDAUGH LD 001260 02-03, 003299 04-04
MILLER LD 000512 01-07, 000541 01-08, 001554 02-07
MIKHALENKON NO 002444 03-09
MIKHOV V 000514 01-04
MILLER LD 001740 02-14
MILLER LD 001740 02-04
MILLER LD 001740 02-04 MILLARESSIS E 001421 02-04
MILKMAN H 000778 01-14
MILLAR WM 000865 01-15
MILLER DG 001536 02-06
MILLER JJ 002431 03-09
MILLER JJ 002431 03-09
MILLER JJ 002431 03-09
MILLER JJ 000045 01-03
MILLER JJ 000045 01-03
MILLER L 000648 01-11, 003300 04-04
MILLER RJ 000555 01-04, 002480 03-10
MILLER RJ 001947 03-01
MILLER NJ 001040 02-17
MILLICHAP JG 003562 04-11
MILLIMAN JE 000747 01-14
MILLIMAN JE 000747 01-14
MILLINEN JW 000649 01-11
MILLINEN JW 000649 01-11
MILLINEN JW 000649 01-10
MILLER JJ 000358 01-08
MILTON F 000598 01-08
MILTON F 000598 01-08
MILTON F 000598 01-10
MIMS RB 000866 01-15, 002098 03-03
MINTAN BL 00035 01-02
MINDHAM BAE 002452 03-09
MINDHAM BAE 002452 03-09
MINDHAM RHS 000867 01-15
MINNEMA KH 001163 02-02
MINDHAM RHS 000867 01-10
MIRANDA F 001235 02-03
MINTY RB 001388 02-04
MIOCQUE M 000011 01-01
MIRABI M 002486 03-10
MIRANDA F 001235 02-03
MIRTY LESS SE 003103 04-03
MIRTY LESS SE 003103 04-03
MIRTY LESS SE 003103 04-03
MIRTAR N 002320 03-04
MISHRA R 003017 04-03
MISHRA RK 002099 03-03, 003018 04-03, 003312 04-03
MISHRA RK 002099 03-03, 003018 04-03, 003312 04-03
MISHRA RK 002099 03-03, 003018 04-03, 003319 04-03, 003319 04-03
MISHRA RK 002099 03-03, 003018 04-03, 003319 04-03
MISHRA RK 003301 04-04
MISSLIN R 003363 04-11
MITCHELL B 000848 01-15

MITCHELL BD 000127 01-03
MITCHELL CL 002239 03-04
MITCHELL D 000194 03-03, 002655 03-15
MITCHELL D 0001994 03-03, 002655 03-15
MITCHELL P 001061 02-03, 003001 04-03
MITRA C 003020 04-03
MITRA C 003020 04-03
MITRA C 000119 01-03, 003047 04-03
MITRANI L 001635 02-12
MITRANI L 001635 02-12
MITRIANI N 002800 04-02
MITSUNOBU K 001108 02-03
MITSUNOBU K 001108 000599 01-10
MIXTER RC 000249 01-03
MIVATA S 0005031 01-08, 000599 01-10
MIXTER RC 000249 01-03
MIYATA T 001157 02-03
MIYAGISHI T 000906 01-15
MIYATA T 001157 02-03
MOBLEY PL 000272 01-03, 002100 03-03, 002466 03-09
MOCCETTI T 000868 01-15
MODAK AT 001197 02-03
MODIGH K 000102 01-03, 000202 01-03
MODROW HE 003302 04-04
MOEGLEN JM 002385 03-07, 002631 03-14, 002639 03-14
MOERN NJ 003276 04-04
MOERELS H 000990 01-17
MOGENSON GJ 003341 04-04
MOGILNICKA E 000449 01-04, 001422 02-04
MOHLER HO 001198 02-03, 002583 03-13
MOHLER H 001198 02-03, 002583 03-13
MOHLER H 00198 02-03, 002583 03-13
MOHLER H 001198 02-03, 002583 03-13
MOHLER H 00198 02-03, 002583 03-13
MOHLER H 001198 02-03, 002583 03-13
MOHLER H 001198 02-03, 002583 03-13
MOHLER AT 000752 01-14
MOLLER SE 002554 03-13
MOHLER AT 000752 01-14
MOLLER AT 000752 01-14
MOLLER SE 002554 03-13
MONNA Y 001811 02-15
MONNA Y 001811 02-15
MONNA Y 001812 02-15
MONNA NO 00018 00016 01-04, 003224 04-03
MONRADIAN A 000203 01-03
MONRADIAN A 000203 01-03
MONRADIAN A 000203 01-03
MONRADIAN A 000203 01-03
MONRE BW 000125 01-03
MOORE BW 000125 01-03
MOORE BW 000125 01-03
MOORE MS 000303 01-04
MOORE RA 001359 02-04, 003095 04-03
MOORE MS 000330 01-04
MOORE RA 001359 02-04, 003095 04-03
MOORE RA 001359 02-04, 003095 04-03
MOORE MS 000330 01-04
MOORE RA 001359 02-04, 003095 04-03 001047 02-03, 002258 03-04, 002810 04-03, 002917 04-03
MOORE MR 000635 01-11
MOORE MS 003303 04-04
MOORE MS 003303 04-04
MOORE RA 001359 02-04, 003095 04-03
MORATINOS J 000227 01-03
MORATINOS J 000227 01-03
MORATINOS J 000227 01-03
MOREL P 003420 04-05
MORETON JE 000417 01-04, 001162 02-03, 001328 02-04, 001476 02-04, 003010 04-03
MORGAN KG 000204 01-03
MORGAN MG 000204 01-03
MORGAN MG 00204 01-03
MORGAN MG 002103 03-03
MORGAN MG 002103 03-03, 002104 03-03
MORGAN W 002103 03-03, 002104 03-03
MORIT J 000639 01-11
MORIN G 002066 03-03
MORIT J 000603 01-03
MORITZ V 002296 03-04
MORITZ V 002105 03-03
MORITZ V 002064 03-03
MORITZ V 002064 03-03
MORITZ V 002296 03-04
MORITZ V 002296 03-04
MORITZ V 002296 03-04
MORITZ V 002105 03-03
MORITZ V 002105 03-03
MORITZ V 001025 02-03
MOROZOV GV 003513 04-09
MOROZOV GV 003513 04-09
MOROZOV GV 003513 04-09
MOROZOV GV 003513 04-09
MORPUGO E 001236 02-03

Psychopharmacology Abstracts

MORRELL RM 000647 01-11

MORRIS LA 001930 02-17

MORRIS MD 003305 04-04

MORRISON BE 001183 02-03

MORRISON JE 002090 03-03

MORRISON JE 002090 03-03

MORRISON JE 002090 03-03

MORRISON JE 002090 03-03

MORSELLI PL 000178 01-03, 000478 01-05, 000479 01-05

MOSCHOVAKIS A 003306 04-04

MOSE H 003508 04-09

MOSES H 003668 04-15

MOSNAIM AD 000285 01-03, 001199 02-03

MOSS D 002511 03-11

MOSS DE 003023 04-03

MOSS IC 000109 01-03

MOSS IC 000109 01-03

MOSS IR 000109 01-03

MOSS IR 000109 01-03

MOSS IR 000109 01-03

MOSS RL 003220 04-04

MOTOLA NC 000001 01-01

MOYER JO 00001 01-01

MOYER SCHWING J 001158 02-03

MOYES ICA 002720 03-16

MIABAJI JP 002043 03-03

MUYES ICA 002720 03-16

MIABAJI JP 002043 03-03

MUKERIS 002946 04-03

MUKLER RA 003831 01-15, 001409 02-04, 002993 04-03

MUKLER RA 000831 01-15, 001409 02-04, 002993 04-03

MUKLER RA 000831 01-15, 001409 02-04, 002993 04-03

MUKLER RA 000831 01-15, 001409 02-04, 002993 04-03

MUKLER RA 003307 04-04

MULDES 001286 02-03, 002642 03-14

MULLS 002991 03-03, 003592 04-04

MULLS NO 002991 03-03, 003292 04-04

MULLS NO 002995 04-03, 002469 03-09

MULLGRIGAMA D 002469 03-09

MULLGRIGAMA D 002469 03-09

MULLIANEY DJ 003505 04-09

MULLIANEY DJ 003505 04-09

MULLIANEY DJ 003505 04-09

MULLIANEY DJ 003505 04-09

MULLIANEY DJ 003505 04-09 MULGIRIGAMA LD 002453 03-09, 002584 03-13
MULLANEY DJ 003505 04-09
MULLER B 002895 04-03
MULLER D 001036 02-12
MULLER M 003121 04-03
MULLER M 003121 04-03
MULLER M 003121 04-03
MULLER M 003024 04-03
MULLER M 002863 04-03
MULLER M 002863 04-03
MULCHAUSEN LL 001100 02-03
MUNCHAUSEN LL 001100 02-03
MUNCHAUSEN LL 001100 02-03
MUNCHAUSEN LL 001100 02-03
MUNCHAUSEN LL 001100 02-03
MUNRO A 002487 03-10
MUNRO A 002487 03-10
MUNRO A 002487 03-10
MUNRO M 003068 04-03
MUNRO JF 001790 02-15
MUNRAKI T 000206 01-03
MUNTHE-KAAS AW 000705 01-13
MURRHY D 00210 03-04
MURILLO LG 000526 01-08
MURPHY D 003477 64-08
MURPHY D 003477 64-08
MURPHY D 003477 64-08
MURPHY D 00081 01-03, 000501 01-06, 00068 01-17, 003585 04-12, 003612 04-13
MURPHY B 002454 03-09, 003514 04-09
MURPHY R 000969 01-17
MURRAY TF 001423 02-04, 002286 03-04
MURRAY TF 001423 02-04
MURRAY TF 001423 02 MULLANEY DJ 003505 04-09

VOLUME 16, AUTHOR INDEX

MYERS RH 001424 02-04 MYSLINSKI NR 001202 02-03, 002107 03-03 MYSLOBODSKY MS 003310 04-04 MYTILINEOU C 001145 02-03, 002036 03-03

N

NAARALA M 002495 03-10 NABRALD M 002495 03-10 NADEAU D 002162 03-03 NAFTOLIN F 002293 03-04 NAGANUMA M 000877 01-15 NAGANUMA T 002690 03-15 NAGAO T 001108 02-03 NAGAO T 001108 02-03
NAGARAJ MG 000264 01-03
NAGARAJA J 001725 02-14
NAGASAKA A 000145 01-03
NAGASHIMA H 001029 02-02
NAGATA T 001572 02-08
NAGAYAMA H 002108 03-03, 003108 04-03, 003311 04-04
NAGY A 000567 01-09, 000576 01-09, 000716 01-13, 002109 03-03, 002460 03-09, 002585 03-13 NAGY J 001343 02-04, 001344 02-04, 003208 04-04 NAGY ZM 003336 04-04 NAGY ZM 003336 04-04 NAHONEY A 002606 03-14 NAHUNEK K 003552 04-11, 003563 04-11, 003564 04-11, 003580 04-11 NAIK SR 003312 04-04 NAIM M 000423 01-04 NAIR NPV 001813 02-15, 002523 03-11, 002561 03-13 NAIR V 003448 04-07 NAKA S 001451 02-04 NAKA S 001451 02-04
NAKAGAWARA M 002110 03-03
NAKAHARA K 001243 02-03
NAKAHARA T 003027 04-03
NAKAHARA Y 001144 02-03
NAKAJIMA S 003313 04-04
NAKAJIMA S 003313 04-04
NAKAMURA J 001572 02-08
NAKAMURA J 001572 02-08
NAKAMURA K 001678 02-13
NAKAMURA M 000418 01-04, 002111 03-03
NAKANO S 002630 03-14, 002721 03-16
NAKATA Y 001238 02-03 NAKATA Y 001238 02-03 NAKAZAWA K 001592 02-09 NAKAZAWA K 001592 02-09 NAKAZAWA Y 000779 01-14 NAKRA BRS 001675 02-13 NALLAN G 003300 04-04 NAMBA M 000160 01-03 NAMBA T 003527 04-09 NAMMATHAO B 001535 02-06 NAME NAMMATHAO B 001535 02-06
NANCE DM 003314 04-04, 003402 04-04
NANCI T 001744 02-15
NANDKUMAR VK 001604 02-09
NANDY K 002112 03-03, 002287 03-04
NAPLES M 002767 03-17
NAPOLIELLO MJ 001573 02-09
NARASIMHACHARI N 001455 02-04, 003380 04-04 NARS PW 000869 01-15 NARUSE H 002860 04-03 NASELLO AG 003315 04-04 NASH JL 000753 01-14 NASRALLAH H 000521 01-08, 000732 01-13, 003469 04-08 NASRALLAH HA 000542 01-08 NATALE M 002542 03-12 NATHAN I 002603 03-13 NATSIKI R 001203 02-03 NAUSIEDA PA 000295 01-03, 000392 01-04, 001167 02-03, 001281 02-03, 001485 02-04, 002259 03-04, 002330 03-04, 002345 03-05 002259 03-04, 002330 03-04, 002345 03-05

NAVRATIL J 002624 03-14

NAYLOR RJ 000071 01-13, 000870 01-15

NAYLOR RJ 000082 01-03, 001334 02-04, 001335 02-04, 002220 03-04, 002853 04-03

NAZAR B 001204 02-03

NEALE JH 002816 04-03

NEALE R 003276 04-04

NECKERS LM 000207 01-03, 000500 01-06

NEIL JF 000956 01-17, 003669 04-15

NEILL DB 003028 04-03, 003316 04-04

NEIMS AH 000644 01-11, 001044 02-03

NELMES PTJ 003595 04-13

NELSON HL 003472 04-08

NELSON PG 001810 02-15, 002863 04-03

NELSON S 000395 01-04, 000476 01-05

NELSON-KRAUSE DC 003029 04-03
NEMETH D 002073 03-03
NEMETSOV AV 001205 02-03
NEMETSOV AV 001205 02-03
NEMETSOV AV 001205 02-03
NEVERSOV 000963 01-17
NESTOR P 001923 02-17
NESTOR P 000969 01-17
NETTI C 000431 01-04
NEU C 000718 01-13
NEUFELD AH 003035 04-03
NEUMAN TS 001701 02-14
NEUNDORFER B 000871 01-15
NEUSER V 001206 02-03
NEVINS DB 001814 02-15
NEWBERY P 003567 04-11
NEWBLRY P 001718 02-14
NEWBLB 000570 01-09
NEWLON P 003070 04-03
NEWLON P 003070 04-03
NEWLON P 003070 04-03
NEWLON P 003070 04-03
NEWLON P 003072 04-04
NEWMAN B 000819 01-15
NEWSOM WA 000508 01-07
NEZIROGLU FA 001630 02-11
NG CP 003322 04-04
NICHOLS DE 000419 01-04, 001009 02-01,
001011 02-01, 003331 04-04
NICHOLS DE 000419 01-04, 001009 02-01,
001011 02-01, 003331 04-04
NICHOLS DE 000419 01-04, 001009 02-01,
001011 02-01, 003322 01-04
NICHOLS DE 000419 01-04, 001009 02-01,
001011 02-01, 003321 04-04
NICHOLS DE 000419 01-04, 001009 02-01,
001011 02-01, 003331 04-04
NICHOLS DE 000419 01-04, 001009 02-01,
001011 02-01, 003331 04-04
NICHOLS DE 000419 01-04, 001009 02-01,
001011 02-01, 003321 04-09
NIELSEN IJ 000719 01-13, 001597 02-09
NIELSEN IL 000719 01-NELSON-KRAUSE DC 003029 04-03 NIR I 002684 03-15 NIRENBERG M 002863 04-03 NISHIKAWA M 001783 02-15, 001783 02-15 NISHIMORI T 002307 03-04 NISHIWAKI K 003108 04-03 NISTICO G 001684 02-13, 003319 04-04 NISTRI A 002115 03-03 NIU HC 000682 01-12 NIXON PA 001208 02-03

NORTH MA 002117 03-03
NORTH RA 002118 03-03
NORTHRUP TE 002119 03-03
NORTHRUP TE 002119 03-03
NORTON S 001426 02-04, 001537 02-06
NOSE P 000481 01-05
NOUSIAINEN U 001261 02-03
NOVACK B 002165 03-03
NOVACK B 002165 03-03
NOVACK B 002165 03-03
NOVIN-BAHERAN A 001210 02-03
NOVIN-BAHERAN A 001210 02-03
NOVIN-BAHERAN A 001210 02-03
NOVOTNA H 003564 04-11
NOWAK JZ 002288 03-04
NOWAK JZ 002288 03-04
NOWAK WSKA E 001970 03-03
NOWLAN R 001818 02-15
NOWYCKY MC 002120 03-03
NOZAKI M 001434 02-04, 002121 03-03, 00289 03-04
NULLER YL 003515 04-09
NUMAN R 001397 02-04
NUMMIKKO-PELKONEN A 003501 04-09
NUTT JG 003672 04-15
NYBY J 002334 03-04

OADES R 000421 01-04
0AKLEY NR 000100 01-03, 003033 04-03
0BERLANDER C 002200 03-04
0BERMAIR W 000607 01-10
0BERMAYER BD 000735 01-13
0BRIEN M 003284 04-04
0BRIEN ML 003284 04-04
0BRIEN ML 003240 04-14
0CONNELL KA 003722 04-17
0CONNELL KA 002404 03-08
0CONNOR MF 001428 02-04
0DAR-CEDERLOF I 000720 01-13
0DEA RF 003032 04-03
0DEJIDE AD 003466 04-08, 003723 04-17
0DONNELL JM 003298 04-04
0ETTINGER L 001918 02-17
0GATA M 000013 01-01
0GAWA H 003374 04-04
0GAWA N 002630 03-14, 003610 04-13
0GILVIE II 001680 02-13 0 OGAWA N 002630 03-14, 003610 04-13
OGILVIE RI 001680 02-13
OGISO T 003603 04-13
OGISO T 003603 04-13
OGIETREE AM 001720 02-14
OGREN S 000422 C1-04, 001233 02-03, 001429 02-04, 001943 03-01, 001945 03-01
OGURA C 001678 02-13
OGUSHI S 000556 01-09
OHARA I 000423 01-04
OHARA J 000605 01-10
OHARA I 000423 01-04
OHARA J 000605 01-10
OHARA E 003561 04-11
OHARA E 003561 04-11
OHGA A 002960 04-03
OHLIN GC 000157 01-03, 001386 02-04
OHMAN R 001430 02-04, 001805 02-15, 003442 04-07
OHSHIMA M 000779 01-14
OHSHIMA M 000779 01-14
OHSHIMA N 000531 01-08, 000599 01-10
OKA M 000290 03-04 OHTSUKA N 000531 01-08, 000599 01-10
OKA M 002290 03-04
OKADA F 000877 01-15, 000878 01-15, 002690 03-15, 003673 04-15
OKADA T 001198 02-03, 002583 03-13
OKADA Y 000424 01-04
OKAFOR CO 000030 01-02
OKAMOTO K 000209 01-03
OKAMOTO K 000209 01-03
OKAMOTO K 001972 03-03, 002198 03-04, 002199 03-04, 002360 03-06
OKAMOTO Y 000556 01-09
OKAWA KK 002524 03-11
OKE AF 003323 04-04
OKEY AB 000210 01-03
OKSENIKRUG GF 002586 03-13
OKULICZ-KOZARYN I 002317 03-04, 002358
03-05 03-05 OKUNO S 002973 04-03 OKUNO S 002973 04-03
OKWUASABA FK 002874 04-03
OLATAWURA MO 000721 01-13
OLEARY SG 003566 04-11
OLESEN AS 002774 03-17
OLESON TD 003034 04-03
OLGIATI SG 000849 01-15
OLGIATI VR 000431 01-04
OLIANAS MC 002001 03-03, 003324 04-04, 003325 04-04

Author Index

Author Index

OLIVARIUS BDF 003557 04-11
OLIVER JS 000879 01-15, 001819 02-15
OLIVER JS 000879 01-15, 001819 02-15
OLIVER JS 000879 01-15, 001819 02-15
OLIVER JS 001507 02-05, 002027 03-03
OLEF H 001211 02-03, 002895 04-03
OLSEN GD 002628 03-14
OLSEN RW 002122 03-03
OLSEN RW 002122 03-03
OLSEN RW 002122 02-03, 003417 04-05
OLVERA A 001735 02-14
OLVERMAN HJ 002928 04-03
OMATSUHARA K 001919 02-17
ONALI P 002508 03-11
ONEILL JJ 000282 01-03
ONEILL PJ 000208 01-03
ORME AE 000360 01-04, 002232 03-04, 002333 03-04, 002333 03-04, 002333 03-04
ONENSANZ MUNOZ LM 000211 01-03
ORME AE 000360 01-04, 002232 03-04, 002333 03-04, 003204 04-04
ORSULAK PJ 001228 02-03
ORTIZ DE ALEMAN MY 001920 02-17
ORZACK MH 000770 01-14
ORSCHOWSKI RF 003067 04-03
OSATO E 002630 03-14
OSBORNE SR 001431 02-04
OSTERGRARAD J 002616 03-14
OSTERGRARAD J 002616 03-15
OSTERGRARAD J 002618 04-15
O100171 01-03, 001214 02-03, 001487
02-04
OTTEN U 001215 02-03
OUT 5 001016 02-03
OTT T 000171 01-03, 001214 02-03, 001487
02-04
OTTEN U 001215 02-03
OUE S 003603 04-13
OVASSAPIANA A 000844 01-15 02-04 OTTEN U 001215 02-03 OUE S 003603 04-13 OVASSAPIAN A 000844 01-15 OVERALL JE 000628 01-11, 002691 03-15, 003674 04-15 OVERMIER M 002320 03-04 OVERSTREET DH 000212 01-03, 000425 01-04, 001464 02-04, 002249 03-04, 003198 04-04, 003326 04-04 OVERTON DA 000426 01-04, 000503 01-06 003326 04-04

OVERTON DA 000426 01-04, 000503 01-06, 000970 01-17, 002292 03-04, 002772 03-17, 003434 04-06

OWASOYO JO 002123 03-03

OWEN F 000677 01-12, 003452 04-08

OWEN G 001757 02-15

OWEN RT 001334 02-04, 002220 03-04

OWEN SD 002406 03-08

OWEN SD 002405 03-08

OWEN SD 002405 03-08

OWEN SD 002405 03-08

OWEN SD 002405 03-08

OWEN SD 000405 0

P. LEONTOPOULOS I 003456 04-08
PAALZOW L 001527 02-06
PACK RL 002230 03-04
PACKHAM MA 000237 01-03, 000238 01-03
PAGAN J 001921 02-17, 001922 02-17
PAGE ED 003035 04-03
PAGE J 000213 01-03, 001539 02-06
PAGEL J 000230 01-03
PAGEL ML 002773 03-17
PAGLIETI E 001962 03-03, 003327 04-04
PAKUTS AP 001052 02-03
PALFAIT 000427 01-04, 002327 03-04, 003328 04-04
PALFREYMAN MG 001007 02-01, 003037 04-03 PALL H 001820 02-15

PALLEGOIX M 003446 04-07
PALMER GC 000214 01-03, 001216 02-03, 002875 04-03, 003038 04-03
PALMER SI, 001216 02-03, 002875 04-03, 003038 04-03
PALMER SI, 001216 02-03, 002875 04-03, 003038 04-03
PALMER SI, 001728 02-14
PANAYIOTOPOULOS CP 000688 01-13, 0f /2 01-13, 000723 01-13, 000724 01-15'
PANDARINATH S 001738 02-15
PANDEY GN 000693 01-13, 000724 01-15'
PANDEY GN 000693 01-13, 000724 01-16'
PANISET JC 000595 01-10
PANKSEPP J 000428 01-04
PANTER BM 001598 02-09
PANTUCK EJ 001651 02-13
PAPANIKOLAOU G 003306 04-04
PAPPAS BA 003039 04-03
PAPPAS K 001911 02-17
PAQUIN J 002589 03-13
PARASHOS AJ 001726 02-14
PARE CMB 002453 03-9, 002469 03-09, 002584 03-13
PARESES A 001649 02-15
PARENTI M 002084 03-03
PARKI J 000881 01-15, 001821 02-15
PARK J 000881 01-15, 001821 02-15
PARK J 000698 01-13
PARKER D 003559 04-11
PARKER B 002359 03-04
PARKER M 001736 02-14
PARKER B 002369 03-06
PARKES JD 002692 03-15, 003568 04-11
PARKER B 002690 03-06
PARKES JD 002692 03-15, 003568 04-11
PARKINSON J 002093 03-03
PARKINSON J 002093 03-03
PARKINSON J 002093 03-03
PARKINSON J 002093 03-03
PARKINSON SC 000767 01-14
PARLI CJ 003040 04-03
PARSONS WD 001044 02-03
PARSONS WD 001045 02-04
PASCHELKE G 00031 01-02
PASSWAL M 001212 02-03, 003417 04-05
PATEL VD 001660 02-04
PATIL PN 001051 02-03, 001118 02-03, 001512 02-05
PATEL VD 001640 02-04
PASCHELKE G 00030 01-04, 00203 03-04
PASCHELKE G 00031 01-05
PATEL VD 001651 02-03, 001118 02-03, 001512 02-05
PATEL WD 001051 02-03, 002055 03-03
PAULLE M 001051 02-03, 002055 03-03
PAULLE M 001051 02-03
PAULE M 001051 02-03
P

Psychopharmacology Abstracts

PERALTA M 000604 01-10
PEREIRA-OGAN JA 002490 03-10
PEREI JM 000564 01-09, 002597 03-13
PERES L 001666 02-13
PEREZ FI 000647 01-11
PEREZ GO 000882 01-05
PEREZ-CRUET J 000552 01-08
PERI G 000080 01-03, 003074 04-03
PERICIC D 002124 03-03, 003042 04-03
PERICIC D 002124 03-03, 003042 04-03
PEROM-MAGNAN P 002743 03-17, 003471 04-08 PEROUTKA SJ 000219 01-03
PERRIN JH 001014 02-01, 001015 02-01
PERRIS C 002525 03-11
PERRY KW 000111 01-03, 000112 01-03, 002017 03-03, 002866 04-03, 002919 04-03
PERRY PJ 000638 01-11, 000976 01-17
PERRY PJ 000638 01-11, 000976 01-17
PERRY PJ 000638 01-11, 000976 01-17
PERRY PJ 000638 01-13
PERSAUD TVN 003659 04-15
PERSSON S 002125 03-03, 003043 04-03
PETE A 000220 01-03, 001433 02-04
PETERSE G 000123 01-03
PETERSE G 000123 01-03
PETERS D 000221 01-03, 000447 01-04
PETERSEN DR 000222 01-03, 000447 01-04
PETERSEN DR 000222 01-03, 000447 01-04
PETERSEN RP 001517 02-05
PETERSEN KP 001517 02-05
PETERSEN RP 001088 02-03, 002040 03-03
PETERSON GR 003447 04-07
PETERSON GR 003447 04-07
PETERSON GR 003447 04-07
PETERSON H 000663 01-11
PETHO B 003675 04-15
PETIT JM 000801 01-15, 000883 01-15, 001822 02-15
PETKOV V 003044 04-03
PETRONI NC 002652 03-15
PETRONI NC 001309 02-04
PETTRONI NC 002151 03-03
PETTIBONE DJ 003330 04-04
PETTIGREW JD 003045 04-03
PETTIS CW 011609 02-09
PETTY LC 001445 02-04
PEWNICK J 001550 02-07, 001714 02-14
PEEIFER R NO 00019 01-04, 002294 03-04, 003331 04-04
PEILIES AN 002103 03-03, 002104 03-03
PHILLIPS NI 002260 03-04
PHILLIPS NI 002978 04-03
PHILLIPS NI 002978 04-03
PHILLIPS NI 002978 04-03
PHILLIPS NI 002960 03-04
PHILLI 04-17
PILBRANT A 000727 01-13, 000745 01-13
PILCHER CWT 003367 04-04
PILEK E 003662 04-15
PILETTE WL 002775 03-17
PINCHASI I 000188 01-03, 000224 01-03, 002126 03-03, 002127 03-03
PINDER RM 000974 01-17
PINSKY C 000437 01-04
PINTA ER 003543 04-10

PINTAURO C 000498 01-06 PINTER K 003675 04-15 PINTO J 002352 03-05 PIOTROPAWLOWSKA-WEINERT M 001547 02-07 PIDIROPAWLOWSA-WEINER M 001347 02-07 PIPPENGER C 003550 04-11 PIRAINO A; 001682 02-13 PIRCH JH 000432 01-04 PIRES P 000700 01-13, 002677 03-15, 003461 PIRES P 000700 01-13, 002677 03-15, 003461 04-08 PISHKIN V 002457 03-09 PITA E 000479 01-05 PITA E 000479 01-05 PITA E 000479 01-05 PITA E 000479 01-05 PITA E 000554 01-08, 001611 02-09 PITA E 000554 01-08, 001611 02-09 PITA E 00057 01-02 PLACHETA P 000017 01-02 PLACHETA P 000059 01-03, 00178 01-03 PLANTEY F 000608 01-10 PLENGE P 003046 04-03 PLETSCHER A 000252 01-03, 001037 02-02 PLEUVRY BJ 001242 02-03 PLEVVAJ J 001435 02-04, 001924 02-17 PLOTKINE M 001064 02-03 PLOTINIKOFF NP 001034 02-02 PLOTISKY PM 000008 01-01 POAT JA 000301 01-03 PODDAR MK 000119 01-03, 003047 04-03 PODDOLSKY S 001687 02-13 PODDOLSKY S 001687 02-13 PODROUZEK V 003584 04-12 PODUSLO SE 000014 01-01 POFENBARGER M 000225 01-03 POKLIS A 000975 01-17 POLC P 000173 01-03, 000226 01-03, 002128 03-03 POLINGER W 000607 01-10 POLINGER W 000607 01-1 POLC P 000173 01-03, 000226 01-03, 002128 03-03 03-03 0000007 01-10 POLINIGER W 000607 01-10 POLINIGER W 000607 01-10 POLINIGER W 000607 01-10 POLINIGER W 000608 01-04 POLLACK MA 001823 02-15 POLLARD GT 001374 02-04 POLSON JB 002129 03-03 POLYAN N 001548 02-07, 002564 03-13 POLZIN RL 002130 03-03, 002131 03-03 POMEROY SL 002817 04-03 POMPEIANO 0 000199 01-03 POMSANKE K 001282 02-03 POMG SF 003048 04-03 PONTANI RB 000201 01-03, 001008 02-01, 003019 04-03 PONTO LB 000976 01-17 PONZANO M 002592 03-13, 002713 03-16 POOLE AD 001614 02-10 POPEK P 003631 04-14 POPENI MK 001782 02-15 POPPEI M 002296 03-04 POPENBERG A 000590 01-09 PORCEDDU ML 000094 01-03, 002002 03-03, 003116 04-03 PORGES SW 000783 01-14 PORCEDDU ML 000094 01-03, 002002 03-03, 003116 04-03 PORGES SW 000783 01-14 PORSOLT RD 002370 03-06 PORTOGHESE PS 001004 02-01, 001010 02-01 POSCHLOVA N 000433 01-04 POST C 000728 01-13 POST D 001800 02-15 POST F 001617 02-11 POST R 001712 02-14 POST R 000729 01-13, 001560 02-08. POST F 001617 02-11
POST R 001712 02-14
POST R 001712 02-14
POST RM 000729 01-13, 001560 02-08, 001683 02-13, 001870 02-16, 002610 03-14, 003481 04-09, 003691 04-16
POTKIN S 000542 01-08, 003477 04-08
POTOLICCHIO SJ C02526 03-11, 002606 03-14
POTTER DE 000227 01-03
POTTER LS 001361 02-04
POTTER WZ 001876 02-16, 002746 03-17, 003516 04-09
POTVIN RM 000654 01-11
POTVIN BW 003049 04-03
POULAKOS JJ 001150 02-03
POULAKOS JJ 001150 02-03
POWELL JW 003595 04-13
POWELL JW 003595 04-13
POYNTON C 000563 01-09
POYSER RH 001007 02-01
POZNIAK-PATEWICZ E 002678 03-15
POZZI E 000692 01-13 POZNIAK-PATEWICZ E UUZO/8 U3-13 POZZI E 000692 01-13 PRADA JA 000387 01-04 PRADHAN S 003346 04-04 PRADHAN S N 003346 04-04 PRADHAN S N 003346 04-04 PRANGE AJ 000434 01-04, 001609 02-09

PRASTKA GJ 003725 04-17
PRENDERGAST FG 003064 04-03
PRENNER BM 00084 01-15
PRESCOTT AM 000212 01-03
PRESCOTT AM 000212 01-03
PRESCOTT D01824 02-15
PRESCORN SH 002693 03-15
PREZIOSI P 001684 02-13
PRIANO DJ 002058 03-03
PRICE AW 002234 03-04
PRICE DD 003241 04-04
PRICE J 002458 03-09
PRICE JS 003460 04-08
PRICE J 002745 03-09
PRICE LJ 001708 02-14
PRICE LJ 001708 02-16
PRICE KM 00299 01-16, 001601 02-09
PRINTE AK 002847 04-03
PRITZEL M 003210 04-04
PROCCI WR 000582 01-09
PROCTOR J 002722 03-16
PROCTOR W 000582 01-09
PROSSER TD 001995 03-03
PROTAIS P 001187 02-03, 002132 03-03
PROTAIS P 001187 02-03, 002132 03-03
PROUDFIT HK 001142 02-03, 002132 03-03
PROUDFOOT AT 000881 01-15, 001821 02-15
PROVENZANO PM 000328 01-04
PROZIALECK WC 003050 04-03
PRUSS M 002073 03-03
PRUSS M 002073 03-03
PRUSS TD 000125 01-03
PULSEN HA 003546 04-10
PUGSLEY TA 000027 01-02
PUIG MM 00029 01-03
PUIG-ANTICH J 003569 04-11
PUIG E 002829 04-03
PUISINELLI PD 001648 02-03
PUISINELLI PD 001648 02-13
PUISINELLI PD 001648 02-13
PUISINELLI PD 001648 02-13
PUISINELLI PD 001674 02-03, 003951 04-03, 003052 04-03
PUR SK 001274 02-03, 003051 04-03, 003052 04-03
PUR SK 001274 02-03, 003051 04-03, 003052 04-03
PUITCHA LD 00010 03-03
PUITCHA LD 00010 03-03
PUITCHA LD 00010 03-03
PUITCHA LD 00006 01-01
PUR NYK 002821 04-03, 003043 04-07 04-03 PURTON WW 000644 01-11 PUTCHA L 002010 03-03 PUTKARADZE-GAMKRELIDZE NA 003443 04-07 PUVIANI R 001948 03-01 PYCOCK C 000077 01-03, 002964 04-03, 003053 04-03 PYCOCK CJ 000068 01-03, 000435 01-04, 001310 02-04 PYNNONEN S 001156 02-03 Q

QUACH TT 003054 04-03
QUADER SE 000885 01-15
QUARANTOTTI BP 001962 03-03, 003327 04-04
QUASTEL JH 000209 01-03
QUATTRONE A 001437 02-04, 003055 04-03, 003074 04-03
QUAYLE ES 000230 01-03
QUERMONNE MA 001535 02-06
QUIK M 003056 04-03
QUINTERO E 002914 04-03
QUINTON EE 000436 01-04, 001438 02-04, 003334 04-04
QUIRING K 002134 03-03
QUITKIN F 000544 01-08, 000545 01-08, 003467 04-08
QUOCK RM 000231 01-03, 001056 02-03, 001413 02-04, 002135 03-03, 003057 04-03

R

RABEY JM 001624 02-11 RABIN BS 001523 02-05 RABINER CJ 000545 01-08 RACAGNI G 001184 02-03, 002084 03-03, 003225 04-04 RACHELEFSKY GS 000730 01-13
RACHID C 001439 02-04
RACK PH 002489 03-10, 002646 03-15
RADA RT 002718 03-16
RADCHENKO LU 002353 03-05
RADMAYR E 000609 01-10
RADULOVACKI M 000052 01-03, 001440 0204, 002063 03-03
RAEBURN JM 001707 02-14
RAEVSKIY KS 001218 02-03
RAFAELSEN OJ 002581 03-13, 003632 04-14
RAFF G 001623 02-11
RAFT D 000615 01-11
RAHTZ D 000031 01-02
RAHWAN RG 00208 01-03
RAINER JM 0011825 02-15
RAINER JM 001825 02-15
RALEWSKI A 002494 03-10
RALEY JM 001825 02-15
RAMARAO VA 0024226 03-09, 003488 04-09
RAMAEKERS F 003335 04-04
RAMOS-LORENZI JR 003467 04-08
RAMPULA C 000692 01-13
RAMSEY RB 002136 03-03, 003058 04-03
RAMSEY TA 000930 01-16, 001768 02-15, 003519 04-09
RAMA KO 101882 02-17
RANDALL PJ 000327 01-04
RANDALL PJ 000327 01-04
RANDALL PJ 000327 01-04
RANDRUP A 000232 01-03, 003058 04-03
RANDRUP A 0000325 04-03
RANDRUP A 000305 04-03
RANDRUP A 000305 04-03
RANDRUP A 0000232 01-03, 003058 04-03
RANSI BJ 001665 02-13
RANSOM BR 001219 02-03
RANDRUP A 0000365 02-13
RANSOM BR 001219 02-03
RANDO NA 000056 10-15
RANGRARAJ N 003060 04-03
RANDRUP A 000056 02-13
RANDRUP A 000065 02-13
RANDO NA 000056 01-15
RANGRARAJ N 003060 04-03
RANDRUP A 000056 02-13
RANDO NA 000057 01-04
RANDRUP A 000057 01-04
RANDRUP A 000058 02-13
RANDRUP A 000065 02-13
RANDRUP A 000065 02-13
RANDRUP A 000065 02-13
RANDRUP A 000065 02-13
RANDRUP A 000067 01-15
RANGRARAJ N 003060 04-03
RANDRUP ROUTE 02-03
RAND

REICHER MA 001443 02-04
REICHMANN B 002673 03-15
REID AH 000977 01-17
REID LD 001053 02-03, 001313 02-04, 001331
02-04, 002320 03-04
REIFMAN A 002413 03-08
REIGLE TG 001228 02-03
REIM G 001314 02-04
REIFMAN A 002413 03-08
REIGLE TG 001228 02-03
REIM G 00131 02-04
REIMERS H 000236 01-03, 000237 01-03, 000238 01-03
REINA RA 002231 03-04
REINES CG 000136 01-03
REINES CG 000136 01-03
REIS DJ 000183 01-03
REMEN D 000567 01-19, 002460 03-09
REISINE TD 002909 04-03, 003041 04-03, 003132 04-03
REMEN D 000584 01-15
REMCHY NR 003011 04-03
REMOND G 001399 02-04
REMSCHMÜNDT H 002527 03-11
REMY DC 001012 02-01, 001949 03-01
REMY R 002631 03-14
REMSCHMÜNDT H 002527 03-15
RENSHAW DC 000584 01-09
RENYI AL 001233 02-03, 001943 03-01, 003071 04-03
RENZI P 003353 04-04
REFEIT D M 001013 02-01
RESELE L 002592 03-13, 002713 03-16
RESNICK R 002642 03-14
RESNICK S 003264 04-04
RESTELLI L 001748 02-15
REUBI J 000240 01-03
REUNING R 001183 02-03
REUNING R 001183 02-03
REVACDVA YA 002353 03-05
REVVELTA A 000192 01-03, 002996 04-03
REVERYBLDS JW 002479 03-10
REYNOLDS JW 002479 03-10
REYNOLDS D 000469 01-12, 000679 01-12, 000978 01-17, 003517 04-09
REININES RK 000108 01-03
RICHARDS JG 001222 02-03
RICHARDS JG 001224 01-03
RICHELSON E 000241 01-03, 00148 02-03, 0012490 03-10, 003650 04-03
RICHELSON E 000241 01-03, 00148 02-03, 00148 02-03, 00168 JA 000618 01-17
RICHEMOND S 000259 01-14
RICHESON E 000241 01-03, 00148 02-03, 00148 02-03, 00148 02-03, 00168 JA 000618 01-17
RICHEMOND S 000390 01-04
RICKELS K 000097 01-12, 000798 01-17, 002490 03-10, 003545 01-04, 003337 04-04
RILEY EU 000333 04-04
RILEY EU

RISDALL PC 001858 02-16
RISING PA 000152 01-03, 000242 01-03
RISING PA 000152 01-03, 000242 01-03
RISING PA 000152 01-03, 000242 01-03
RISING PA 000152 01-04
RITTER KS 002051 03-03
RITTLE KE 001012 02-01, 001949 03-01
RITTMANNSBERGER H 002439 03-09
RITZMANN RF 000280 01-03, 002318 03-04, 003106 04-03
RIUSECH R 000390 01-04
RIVA E 000178 01-03
RIVERA-CALIMLIM L 000489 01-05, 000542 01-08, 000732 01-13, 001871 02-16, 003469 04-08
RIVLIN RS 002352 03-05
ROBACK HB 003658 04-15
ROBBINS MS 002283 03-04
ROBBINS TW 000440 01-04, 000441 01-04, 000442 01-04
ROBERGE AG 003339 04-04
ROBERSON C 002881 04-03
ROBERTS MHT 001086 02-03
ROBERTS MHT 001086 02-03
ROBERTS MHT 001086 02-03
ROBERTS MHT 001086 02-04
ROBERSON A 001339 02-04, 003341 04-04
ROBERSON H 003066 04-03
ROBERTSON J 002980 04-03
ROBINSON M 000578 01-09, 000733 01-13, 000734 01-13, 001951 03-01, 003545 04-10
ROBINSON RG 000243 01-03
ROBINSON RG 000245 01-04
RODENS JR 001901 02-17
RODGERS RJ 000445 01-04, 000444 01-04, 003342 04-04
RODGERS JR 001901 02-17
RODGERS RJ 0000445 01-04, 001090 02-03
ROELLE 003068 04-03
ROBERD 0003068 04-03
ROBERD 0003068 04-03 O03342 04-04
RODRIGUEZ-SIERRA JF 000445 01-04, 001090
02-03
ROEL LE 003068 04-03
ROEMER D 000379 01-04, 001036 02-02
ROERIG DL 000245 01-03
ROFFMAN M 001227 02-03, 001228 02-03, 002300 03-04, 003343 04-04
ROGERS BJ 001316 02-04
ROGERS BJ 001316 02-04
ROGERS BJ 001316 02-04
ROGERS HJ 001826 02-15
ROGERS JB 003344 04-04
ROGERS PJ 003549 04-10
ROGERS PJ 003549 04-10
ROGERS PJ 003549 04-10
ROGERS RC 002851 04-03
ROGNONI G 002713 03-16
ROGNONI V 002592 03-13
ROGOLA 000542 01-08
ROGOWSKI J 003446 04-07
ROHRBACH KR 001374 02-04
ROHRBACH KR 001374 02-04
ROHRBACH KR 001374 02-04
ROHRBACH KR 001374 02-04
ROHRBACH KR 001374 04-04
ROMMELSPACHER H 000046 01-03
ROMPEL H 003470 04-08
ROMANLSPACHER H 000046 01-03
ROMPEL H 003470 04-08
RONAI AZ 001230 02-03
RONCAGLIONI MC 000297 01-03
RONDEAU DB 001388 02-04
RONIGER JJ 000512 01-07
ROOT M 003223 04-04
ROPARTZ P 003301 04-04
ROPARTZ P 003301 04-04
ROPTE H 000174 01-03
ROSE C 003554 04-03
ROSE JE 001681 02-13
ROSE F 000454 01-04
ROSEBOMH 001014 02-01, 001015 02-01
ROSECRANS JA 000372 04-04
ROSEROMH 001014 02-01, 001015 02-01
ROSECRANS JA 000372 02-04, 001323 02-04, 001325 02-04, 001373 02-04, 001325 02-04, 001373 02-04, 001325 02-04, 001373 002-04, 001325 02-04, 000376 04-03, 003188 04-04, 003254 04-04, 003692 04-16
ROSEN EF 001445 02-04

Psychopharmacology Abstracts

ROSEN M 000668 01-11, 000669 01-11
ROSEN SH 000593 01-09
ROSENBERG G 002561 03-13
ROSENBLATT M 002666 03-15
ROSENBLATT M 002666 03-15
ROSENBLATT M 002666 03-15
ROSENBLATT M 002666 03-15
ROSENBLATT M 002666 02-03
ROSENFELD GC 001066 02-03
ROSENFELD GC 001066 02-03
ROSENFELD JP 003435 04-06
ROSENFIELD JP 003435 04-06
ROSENFIELD JP 003435 04-04
ROSENOW EC 002694 03-15
ROSENTHAL M 000176 01-03
ROSENTHAL M 00176 01-03
ROSENTHAL M 00176 01-04
ROSIN J 001486 02-04, 002776 03-17
ROSIER H 000785 01-14
ROSS CA 001262 02-03
ROSS M 002724 03-16
ROSS SB 000246 01-03, 000422 01-04, 001943 03-01, 001945 03-01, 003071 04-03
ROSS M 001271 02-03
ROSS SM 002030 03-04
ROSSI S 000016 01-02
ROSSITER VS 002598 03-13
ROSSOF AH 002695 03-13
ROSSOF AH 002695 03-15
ROTHENBERG FA 002140 03-03
ROTH WT 000755 01-14, 001727 02-14
ROTH-SCHECHTER BF 000484 01-05
ROTHENBERG FA 002140 03-03
ROTH WT 000725 01-14
ROTHROSEN J 002338 03-05, 002589 03-13, 003097 04-03
ROTSZTEJN WH 003072 04-03
ROTSZTEJN WH 003072 04-03
ROUSE BA 000831 01-15
ROUTSONIS C 001911 02-17
ROWE H 000401 01-04, 000735 01-13
ROWE HW 001686 02-13
ROWE HW 001686 02-13
ROWE HW 001687 02-13
ROWE HW 001687 02-13
ROWE HW 001687 02-13
ROWE HW 001686 02-13
ROWE HW 003072 01-04
RUBEN HL 003345 04-04
RUBEN HL 003567 04-11
RUBENSTEIN A 0000880 01-15
RUBIN TEN 0007249 01-03
RUBIN TEN 007250 03-16
RUBIN RUBOVITS R 000248 01-03 (102849 04-03, 01 04-03 000249 01-03, 002849 04-03, 01 04-03 002849 04-03, 01 04-03 002849 04-03, 01 04-03 02-04 000148 02-04 000148 02-04 000143 04-03 002143 04-03 000143 04-03 000143 04-03 04 02-03 000148 000148 02-04 000148 000149 000149 000149 000149 01-03 000149 RUTHER E 001672 02-13, 002378 03-07, 0C.570 03-13 RUTHERFORD D 001619 02-11 RUTLEDGE CO 002141 03-03, 002142 03-03, 003111 04-03 RUWITCH JF 000883 01-15 RYALL RW 000135 01-03, 001966 03-03 RYAN CF 001428 02-04 RYBAKOWSKI J 000736 01-13, 000930 01-16, 003518 04-09, 003519 04-09

RYCHKO AV 001513 02-05, 001525 02-05 RYDZYNSKI Z 001998 03-03, 003570 04-11 RYE T 002665 03-15 RYMAN DH 002649 03-15 RYSANEK K 003606 04-13 RYSBERG J 001431 02-04

SAARI M 003039 04-03
SAARI O 1 001723 02-14
SAAVEDRA JM 001006 02-01
SAAYMAN GS 000402 01-04, 001734 02-14, 002640 03-14, 003729 04-17
SABA G 003123 04-03
SABIN JE 002777 03-17
SACCHETTI E 000586 01-09
SACHAR EJ 000980 01-17, 001867 02-16, 002574 03-13, 002575 03-13, 002590 03-13, 003569 04-11
SACK R 000592 01-09
SACKLER AM 001450 02-04
SACKS M 003727 04-17
SAELENS JK 002138 03-03, 002300 03-04, 003343 04-04 SAELENS JR. 002138 03-03, 002300 03-04, 003343 04-04

SAGDUYU H 000169 01-03

SAHAGIAN DE 000446 01-04, 003347 04-04

SAHGAL A 000250 01-03, 003348 04-04

SAIRG J 001699 02-14 SAIRS J 001699 02-14 SAINSBURY R 000587 01-09 SAITO H 001451 02-04 SAITO M 003027 04-03 SAITO T 000281 01-03 SAKAL F 001243 02-03 SAITO T 000281 01-03
SAKAILS G 000737 01-13, 001571 02-08, 001827 02-15
SAKATA T 003259 04-04
SAKURADA O 003073 04-03
SAKURADA O 003073 04-03
SAKURADA T 000032 01-02, 000033 01-02
SAKURADA T 000032 01-02, 000033 01-02
SAKURADA T 000032 01-02, 000033 01-02
SAKURADA T 000032 01-03
SALAMA AI 000251 01-03
SALAMA AI 000251 01-03
SALAMA M 001899 02-17
SALAZAR M 002354 03-05
SALETU B 000931 01-16, 001602 02-09, 001729 02-14, 002726 03-16, 003571 04-11
SALETU M 003571 04-11
SALETU M 003571 04-11
SALETU M 003571 04-11
SALETU M 003023 04-03
SALOME R 003023 04-03
SALOME R 003023 04-03
SALOME N 001156 02-03
SALOME N 001156 02-03
SALOMAN C 001720 02-14, 003520 04-09
SAMAAN HA 002977 04-03
SAMANIN R 001235 02-03, 001236 02-03, 001437 02-04, 002872 04-03, 003075 04-03, 003074 04-03
SAMBROOK MA 003200 04-04 SAMANIN R 001235 02-03, 001236 02-03, 001437 02-04, 002872 04-03, 003055 04-03, 003074 04-03
SAMBROOK MA 003200 04-04
SAMOYLOV NN 001513 02-05, 001525 02-05
SAMPATH-KHANNA S 001379 02-04
SAMPLES JR 000485 01-05
SAMUEL D 003145 04-03
SANBERG PR 002279 03-04
SANCHEZ-RAMOS JR 001452 02-04
SANDERS B 000447 01-04, 002301 03-04
SANDERS B 000447 01-04, 002301 03-04
SANDERS MG 002773 03-17
SANDERS-BUSH E 000276 01-03, 001251 02-03, 001467 02-04, 002226 03-04, 002314 03-04, 003098 04-03
SANDLER KR 002490 03-10
SANDLER KR 00250 03-10
SANDLER KR 00250 03-04, 002641 03-14, 003382 04-04
SANDER B 003086 04-03
SANDER A 000252 01-03, 001037 02-02
SANFACON G 002143 03-03
SANGER DJ 001453 02-04, 002371 03-06, 003349 04-04, 003350 04-04
SANGHVI IS 000253 01-03, 002372 03-06
SANGHVI ID 001882 02-17
SANGSTER B 001519 02-05
SANNITA WG 002688 03-13
SANO K 002635 03-14
SANO K 002635 03-14 SANO K 002635 03-14 SANO MC 001432 02-04 SANSONE M 003351 04-04, 003352 04-04, 003353 04-04

SANTAGOSTINO A 002011 03-03, 002907 04-03
SANTELLI S 000490 01-05, 003391 04-04
SANTOS CA 003297 04-04
SANTOS CA 003297 04-04
SANYAL AK 001968 03-03
SAPPER H 001950 03-01
SAPPINGTON AA 000513 01-07
SARAF KR 002696 03-15
SARAU HM 002798 04-02
SARGENT T 003075 04-03
SARKADI B 002591 03-13
SASAME HA 000476 01-05
SASSIN J 003569 04-11
SASTRY B 000254 01-03, 003076 04-03
SATHANANTHAN G 000622 01-11, 000624 0111, 001827 02-15
SATO K 002307 03-04
SATO T 001872 02-16
SATO Y 001830 02-15
SATOH M 001256 02-03, 003374 04-04
SATOH M 001256 02-03, 003374 04-04
SATOH M 001256 02-03, 003374 04-04
SATOH M 001256 02-03, 003122 04-03
SAVENIJE-CHAPEL EM 003122 04-03
SAVENIJE-CHAPEL EM 003122 04-03
SAVUILICH A 003439 04-06
SAWAYA MCB 000256 01-03, 001099 02-03, 001346 02-04
SAWYER PR 000974 01-17
SAWYNOK J 001152 02-03, 003472 04-08
SAXENA RC 001688 02-13
SCAGGIANTE L 002379 03-07
SCALLY MC 002167 03-03, 003330 04-04
SCARF RA 000981 01-17
SCARONE S 002592 03-13
SCATION B 000256 01-03, 001039 02-03, 001497 02-04, 002144 03-03, 003031 04-03
SCHAEFER A 000981 01-17
SCARONE S 002592 03-13
SCATION B 000256 01-03, 001037 02-03, 001497 02-04, 002144 03-03, 003031 04-03
SCHAEFER A 000981 01-17
SCARONE S 002592 03-13
SCALION B 000256 01-03, 001347 04-08
SCHAEFER JC 000074 01-03
SCHAEFER JC 000074 01-03
SCHAEFER RM 000150 01-02
SCHAMBERG SM 002665 03-03, 003474 04-08
SCHAEFER RM 000665 03-03, 003474 04-08
SCHAEFER SM 000665 03-03, 003474 04-08
SCHAEFER SM 000665 03-03, 003474 04-08
SCHAEFER SM 000665 03-03, 003474 04-08
SCHAEFER RM 000665 03-03, 003474 04-08
SCHAEFER SM 000665 03-03, 003479 04-03 SANTAGOSTINO A 002011 03-03, 002907 04-SCHAFFNER R 000173 01-03 SCHAKELAAR AJ 003624 04-14 SCHALLY AV 000019 01-02 SCHANBERG SM 002065 03-03, 003097 04-03 SCHARBACH H 002462 03-09 SCHARF MB 002608 03-14, 003637 04-14 SCHATZBERG AF 002425 03-09 SCHECHINGER SA 000354 01-04 SCHECTER MD 000448 01-04, 002146 03-03, 003354 04-04 SCHECTER PJ 003037 04-03 SCHECTER PJ 003037 04-03 SCHEEL-KRUGER J 000449 01-04, 000583 01-09, 001454 02-04 09, 001454 02-04
SCHEIKUNOV EL 002147 03-03
SCHENER U 002093 03-03
SCHIAFFINI O 003385 04-04
SCHIEF BC 001544 02-07, 0034
SCHIEF AC 001544 02-07, 0034

SCHIEF BC 001544 02-07, 0034

04-07
SCHIEF AC 001540 02-07, 0034

04-07
SCHIEF AC 000550 01-08, 000605 01-10, 003547 04-10, 003590 04-13
SCHILDKAUT JJ 001227 02-03, 001228 02-03
SCHILLER GD 000212 01-03
SCHIEF BC 000899 01-15
SCHIEF BC 000899 01-15
SCHIEF BC 000890 01-16 SCHLESS AP 002490 03-10
SCHLEY J 000927 01-16
SCHLEY J 000927 01-16
SCHLIEMAN E 000527 01-08
SCHMIDT B 003040 04-03
SCHMIDT B 003040 04-03
SCHMIDT D 002529 03-11
SCHMIDT DE 000259 03-11
SCHMIDT DE 000259 01-03, 003077 04-03
SCHMIDT DE 000259 01-03, 003077 04-03
SCHMIDT J 002956 04-03
SCHMIDT MJ 002148 03-03
SCHMIDT MJ 002148 03-03
SCHMIDT MJ 002148 03-03
SCHMIDT R 000810 01-15
SCHMITT H 000179 01-03, 001399 02-04
SCHMOLKER AM 000932 01-16
SCHMAULTZ NL 000617 01-10
SCHNEL J 002593 03-13
SCHNEIDER E 001730 02-14
SCHNEIDER FH 002112 03-03

Author Index SCHNEIDER MA 001603 02-09
SCHNEIDER NG 003631 04-14
SCHNEIDER RO 01996 03-03
SCHNEIDER RO 01996 03-03
SCHNEIDER RO 01996 03-03
SCHNEIDER RO 01996 03-03
SCHNEIDER RO 00293 01-03, 001288 02-03, 002182 03-03, 003008 04-03
SCHNIEDER H 000466 01-04
SCHOENFELD RI 002744 03-17
SCHOLZ D 002355 03-05
SCHOOBECK G 002789 04-01
SCHOOFF K 002670 03-15
SCHOOIF N 01827 02-15
SCHOONOVER S 002648 03-15
SCHOORDER N 01827 02-15
SCHOPF J 002540 03-12
SCHORDERET M 002149 03-03
SCHOTT G 000788 01-14
SCHOTT G 000788 01-14
SCHOU M 000488 01-05, 001797 02-15
SCHREURS WHP 003624 04-14
SCHROEDER DH 001038 02-02, 002381 03-07
SCHOGE JJ 000982 01-17
SCHUBERT D 003607 04-13
SCHUBERT D 003607 04-13
SCHUBERT D 003607 04-13
SCHUBERT D 003607 04-13
SCHUBERT MG 000897 01-15
SCHUCKIT MA 003701 04-17
SCHULER HW 000477 01-05, 001503 02-05
SCHULTERBRANDT JG 000613 01-10, 002459
03-09
SCHULTES RE 000680 01-12, 000983 01-17 SCHULTERBRANDT JG 000613 01-10, 002459 03-09 SCHULTES RE 000680 01-12, 000983 01-17 SCHULTZ R 001456 02-04 SCHULTZ R 001705 02-14 SCHULTZ TA 001705 02-14 SCHULTZ W 003356 04-04 SCHULZ H 000546 01-08 SCHULZECK K 000171 01-03 SCHUMANN AM 003078 04-03 SCHUSECK RC 000359 01-04, 000386 01-04, 000389 01-04, 000389 01-04, 000389 01-04, 000389 01-04, 000389 01-04, 000359 01-04, 000389 01-04, 000359 01-04, 000389 01-04, 000359 01-04, 000389 01-04, 000359 01-04, 000389 01-04, 000389 01-04, 000381 04-05 SCHUMAR M 001215 02-03, 003005 04-03 SCHWART U 003079 04-03 SCHWART U 003081 04-03 SCHWART G 002355 03-05, 003080 04-03, 003081 04-03 SCHWART G 002523 03-11, 002561 03-13, 03-09 O03081 04-03
SCHWARTZ G 002523 03-11, 002561 03-13, 003486 04-07, 003686 04-05
SCHWARTZ I 001836 02-15
SCHWARTZ I 001050 02-03, 002221 03-04
SCHWARTZ JI 001050 02-03, 002350 03-05, 003036 04-03, 003054 04-03
SCHWARTZ JI 001187 02-03, 002350 03-05, 003036 04-03, 003054 04-03
SCHWARTZ MA 001289 02-03
SCHWARTZ MA 001289 02-03
SCHWARTZ RD 002373 03-06
SCHWARTZ RD 002373 03-06
SCHWEITZER JW 000698 01-13
SCHYVE PM 002697 03-15
SCLAFANI M 000984 01-17
SCOBIE SR 003196 04-04
SCOGGINS BA 001751 02-15, 002423 03-09, 003645 04-15
SCOPES JW 001756 02-15 SCOBERS BA 001751 02-15, 002423 03-09, 003645 04-15
SCOPES JW 001756 02-15
SCOTO GM 002011 03-03, 002907 04-03
SCOTT DR 002302 03-04
SCOTT DR 001699 02-14
SCOUTEN C 002240 03-04
SCROLLINI F 002357 04-04
SCUDERI R 000460 01-04
SCUPAK CA 000891 01-15
SEABA HH 000976 01-17
SEAGRAVES E 001348 02-04, 002248 03-04, 003409 04-05
SEAMAN SF 002316 03-04
SEBASTIANPILLAI F 003605 04-13
SEDVALL G 000591 01-09, 000670 01-11, 001557 02-08, 001694 02-13, 002547 03-13, 003462 04-08, 003614 04-13
SEEMAN P 000296 01-03, 000547 01-08, 001200 02-03, 001506 02-05, 002229 03-04, 002779 03-17, 003117 04-03, 003138 04-03
SEGAL DS 000325 01-04, 000532 01-08, 000533 01-08, 001403 02-04, 002156 03-03
SEGAL N 000260 01-03, 002150 03-03, 003082 04-03, 003145 04-03, 003572 04-11
SEGAL N 000696 01-13
SEGAL N 000696 01-13 SHEPHERD M 001931 02-17, 002396 03-08, 003455 04-08
SHEPPARD G 003605 04-13
SHEPPARD H 003088 04-03, 003089 04-03
SHERMAN AD 000266 01-03, 000267 01-03, 001127 02-03
SHERMAN MC 002502 03-11
SHERRY CJ 000486 01-05
SHERWIN AL 000182 01-03
SHERWIN AL 000182 01-03
SHERWIN DW 003663 04-15
SHETH UK 003312 04-04
SHIBIATA T 001256 02-03, 00374 04-04
SHIBIYA T 001256 02-03, 00374 04-04
SHIBIYA T 001257 02-03, 003441 04-06
SHILING DJ 000968 01-17
SHIMAZONO Y 002637 03-14
SHIMIZU M 000488 01-05, 002046 03-03, 002290 03-04
SHIMIZU M 001830 02-15
SHINIONAR Y 001247 02-03
SHINIONAR Y 001247 02-03
SHORE CO 002154 03-03
SHORE PA 001129 02-03, 001191 02-03, 001196 02-03
SHORE PA 001129 02-03, 001191 02-03, 001191 02-03, 001191 02-03, 001196 02-03
SHURLEY JT 002457 03-09
SHORE PA 001129 02-05
SIEGEL RM 001520 02-05
SIEGEL RM 000259 03-15
SIEGEL NM 001520 02-05
SIEGEL RM 000259 03-15
SIEGEL NM 000269 03-15
SIEGEL NM 000369 03-03
SIMONO RM 000369 03-03
SIMONO RM 000369 03-03
SIMONO RM 000369 03-03
SIMONO

Psychopharmacology Abstracts

SINGH N 002643 03-14
SINGH RB 002700 03-15
SINGH RB 002700 03-15
SINGH VP 002080 03-03
SINTSYN LN 001083 02-03
SINTSYN LN 001083 02-03
SINTSYN LN 001083 02-03
SIRACUSA A 001871 02-16
SIRIS SG 002408 03-08
SIRACUSA A 001871 02-13
SITARAM N 003612 04-13
SIVAGEC 003640 04-14
SIVIT C 001433 02-04
SIVERS B 000685 01-13
SUOGEN C 001244 02-03
SJOURNS B 000269 01-03
SJOURNS B 000269 01-03
SJOURNS B 000269 01-03
SJOSTRAND J 002952 04-03
SJOSTRAND J 002952 04-03
SISTRAND J 002952 04-03
SKACEL PO 000799 01-15
SKACLA K 003302 04-04
KELLERN GG 003093 04-03
SKECT P 000041 01-03
SKLAR LS 000450 01-04, 002356 03-05
SKLENOVSKY A 003094 04-03
SKOLNICK P 002156 03-03, 002885 04-03, 002995 04-03
SKOLYAROVA NA 001832 02-15
SKOTT A 001805 02-15
SLAASTAD RM 001811 02-15
SLAASTAD RM 00085 01-10
SAMTH AD 001350 02-10
SMITH AD 001350 02-10
SMITH AD 001350 02-10
SMITH AD 001350 02-10
SMITH AD 001464 02-03
SMITH AD 001464 02-03
SMITH AD 001464 02-03
SMITH AD 000450 01-15
SMITH BH 000806 01-15
SMITH BH 000806 01-15
SMITH BH 000807 01-15
SMITH BH 000806 01-15
SMITH BH 000806 01-15
SMITH BH 000806

SMOTHERMAN WP 003363 04-04 SMYTH DG 001963 03-03 SNAITH RP 000988 01-17 SNEAD OC 000740 01-13 SNEDDEN W 000067 01-03 SNELL CR 001963 03-03 SNELL D 001372 02-04, 002243 03-04, 002244 03-04
SNELL JD 003236 04-04
SNELL JD 003236 04-04
SNODDY HD 000113 01-03, 000114 01-03, 002016 03-03, 002017 03-03
SNODGRASS SR 001286 02-03
SNYDER R 001833 02-15
SNYDER R 001833 02-15
SNYDER SN 00084 01-03, 000219 01-03, 000283 01-03, 000493 01-06, 000741 01-13, 001995 03-03, 001996 03-03, 002029 03-03, 002155 03-03, 002399 03-08, 002715 03-16, 002738 03-17, 002877 04-03, 003024 04-03, 003080 04-03, 003113 04-03, 003119 04-03, 003715 04-17, 003728 04-17
SNYDER SJ 003118 04-03
SO D 000877 01-15
SOB CZYK W 002701 03-15
SOBCZYK W 002701 03-15
SOBCZYK W 002701 03-15
SOBCSYK W 002701 03-15
SOBCISKI RE 003243 04-04
SOBOL MP 002614 03-14
SOBOTKA P 002152 03-03, 002858 04-03, 003069 04-03, 003083 04-03
SOBRIAN SK 002308 03-04
SOBUE I 001840 02-15
SOCZYNSKIA J 002427 03-09
SODA K 002973 04-03
SOLDERBERG U 001851 02-15
SOKOLOVSKY M 00186 01-03, 000224 01-03, 000235 01-03, 001221 02-03, 002126 03-03, 002127 03-03
SOKLONSKY M 00186 01-03, 000224 01-03, 000235 01-03, 001221 02-03, 002126 03-03, 002127 03-03
SOLDATOS CR 000750 01-14, 002608 03-14, 03-04 SNELL JD 003236 04-04 002127 03-03 SOLDATOS CR 000750 01-14, 002608 03-14, 002127 03-03
SOLDATOS CR 000750 01-14, 002608 03-14, 003637 04-14
SOLE MJ 002140 03-03
SOLLMAN KF 002123 03-03
SOLLMAN KF 002123 03-03
SOLLMAN KF 002123 03-03
SOLLMAN KF 002123 03-03
SOLDMON CA 001239 02-03
SOLDMON M 001867 02-16
SOLDMON M 001867 02-16
SOLDMON M 001867 02-16
SOLDMON M 001867 02-16
SOLDMON M 001867 02-15
SOLDMON M 001867 02-16
SOMMER E 003675 04-15
SOMJEN GG 001293 02-03
SOMMER E 003675 04-15
SOMMERBECK KW 000791 01-14
SOMOZA E 003076 04-03
SONDERGEGER T 002510 03-04
SONDERGEGER T 002556 03-13
SONNEBORN RE 000882 01-15
SONNIMEN V 001685 02-13
SONNIMEN V 001685 02-13
SONTAG K 000174 01-03
SONCMAN D 002492 03-10
SORENSON D 002580 4-04
SORENSON CA 002311 03-04
SORENSON CA 002311 03-04, 003257 04-04
SORENSON CA 002311 03-04, 003257 04-04
SORIGNED VO 101038 02-02, 002381 03-07 SOROKO FE 001038 02-02, 002381 03-07 SOUBRIE P 001472 02-04, 002312 03-04, SOUBRIE P 001472 02-04, 002312 03-04, 003364 04-04
SOUCEK K 003533 04-09
SOUILIN W 002989 04-03
SOUKUP JF 003097 04-03, 003451 04-08, 00347 04-03, 003451 04-08, 003487 04-09 003487 04-09 SOVNER R 001834 02-15, 003683 04-15 SOWINSKA H 003281 04-04 SPADARO C 002231 03-04, 002907 04-03 SPALDING E 001619 02-11 SPANIS CW 000454 01-04 SPANKOVA H 003606 04-13 SPANO PF 000094 01-03, 002157 03-03, 002357 03-05 002357 03-05
SPARBER SB 00110 02-03, 001207 02-03, 001330 02-04, 001402 02-04, 002158 03-03
SPARF B 002308 01-04, 001170 02-03
SPATZ M 003014 04-03
SPATZ M 002570 03-13
SPAULDING TC 003052 04-03
SPEALMAN RD 003365 04-04
SPEAR NE 003196 04-04
SPECTOR NH 001186 02-03
SPECTOR S 003438 04-06
SPEHLMANN R 002116 03-03 002357 03-05

SPEIGHT ANP 001835 02-15
SPEIGHT TM 000974 01-17
SPENCER PSJ 002072 03-03
SPENCER R 000974 01-17
SPERANSKAYA NP 002204 03-04
SPERK G 002789 04-01, 003366 04-04
SPETH RC 003132 04-03
SPIEGEL HE 003439 04-06
SPIERINGS ELH 002313 03-04
SPIERS P 000782 01-14
SPIKER DG 000801 01-15, 000383 01-15, 001594 02-09
SPINGLER PJ 003292 04-04 001594 02-09 SPINGLER PJ 003292 04-04 SPISSU A 003648 04-15 SPOHN HE 000549 01-08, 001933 02-17 SPRAGUE RL 001732 02-14, 001934 02-17, 002533 03-11 SPONN ME 000549 01-08, 001933 02-17
SPRAGUE RL 001732 02-14, 001934 02-17, 002533 03-11
SPRATT JL 001449 02-04
SPRATT JL 001449 02-04
SPRATT JL 001449 02-04
SPRING G 00259 03-03, 003275 04-04
SPRING G 002645 03-14
SPRING G 000571 01-09
SPRUGEL W 000275 01-03
STUBER RF 000398 01-04, 001645 02-13
ST-ARNAUD-MCKENZIE D 003147 04-03
ST-AURENT J 000614 01-10
STAAK M 000897 01-15
STACEY GJ 001024 02-02
STADLER H 000050 01-03
STAFFORD JR 000948 01-17, 001935 02-17
STAGG CJ 001039 02-02
STAHL KD 002160 03-03
STAHL SM 002596 03-13, 003608 04-13
STAHL WL 002939 04-03
STALVEY LP 002885 04-03
STAMBAUGH JE 001836 02-15
STAMBAUGH JE 001836 02-15
STAMBAUGH JE 001806 02-09
STANDING VF 000988 01-17
STANDAL JE 001606 02-09
STANDING VF 000988 01-17
STANSIK D 002096 03-03
STANISIK D 003524 04-09
STANISIK D 003524 04-09 STARK P 003538 04-10
STARMER GA 000673 01-12, 002015 03-03
STAUB RA 001319 02-04
STAUBLI U 003247 04-04
STAUBLI U 003247 04-04
STAUBUS AE 001183 02-03
STAUDACHEROVA D 002161 03-03
STAVINOHA WB 000214 01-03, 001197 02-03
STEENBERG ML 000030 01-02
STEFANIK K 000651 01-11
STEFANIN E 002002 03-03, 002357 03-05, 003123 04-03 STEFANINI E 002002 03-03, 002357 03-05, 003123 04-03
STEFANIS C 000688 01-13, 000711 01-13, 000722 01-13, 000723 01-13, 000748 01-14
STEFANIS CN 001690 02-13
STEFANO FIE 002028 03-03
STEFANOVA E 000514 01-07
STEFOPOULOS A 003483 04-09
STEG G 002346 03-05
STEIM IM. 002054 03-03 STEG G 002346 03-05
STEIN JM 002054 03-03
STEIN JW 002054 03-03
STEIN JW 002373 03-06
STEIN L 000455 01-04
STEIN S 000898 01-15, 001809 02-15
STEINBERG FA 002638 03-14
STEINBERG FA 002638 03-14
STEINBERG RM 001062 02-03
STEINBERG RM 001082 02-03
STEINBERG RM 001889 01-09
STEMPEL A 001022 02-02
STEMPIEN MJ 002652 03-15
STEPHENS DN 001466 02-04
STEPHENS DN 001466 02-04
STEPHENSON JBP 000635 01-11
STEPHENSON JBP 000635 01-11
STEPHENSON JBP 000635 01-11
STEPHENSON JD 003273 04-11
STEPHENSON JD 003273 04-04
STERANKA L 000276 01-03, 001251 02-03, 002226 03-04
STERANKA L 001467 02-04, 002314 03-04, STERANKA LR 001467 02-04, 002314 03-04, 00309B 04-03 STERKMANS P 000662 01-11 STERLING FE 002401 03-08

STERN DA 003729 04-17
STERN GM 003560 04-11, 003652 04-15
STERN HJ 003069 04-03
STERN JM 001327 02-04
STERN M 001927 02-04
STERN R 003587 04-13
STERN R 003587 04-13
STERN R 003587 04-13
STERN R 002493 03-10
STERNBACH LH 001022 02-02
STERNTHAL V 002386 03-07
STEVENS JR 002703 03-15
STEVENS JR 002703 03-15
STEVENS JR 002703 03-15
STEVENS VC 002641 03-14
STEWART JM 003187 04-04
STEWART JM 003187 04-04
STEWART RB 001913 02-17
STEWART RB 001913 02-17
STEWART RB 001733 02-14, 003711 04-17
STILLMAN R C 001733 02-14, 003711 04-17
STILLWELL DJ 001401 02-04
STILLMAN RC 001733 02-14
STOCK BH 002930 04-03, 002931 04-03, 002932 04-03
STOCK BH 002930 04-03, 002931 04-03, 002932 04-03
STOCK BH 002930 04-03, 002931 04-03, 002932 04-03
STOCKDALE S 000616 01-10, 001873 02-16
STOCK DH 000457 01-04, 002397 03-08, 003224 04-04
STOCKDAR PD 001337 02-04, 002397 03-08, 003224 04-04
STOKES PE 003662 04-15
STOLERMAN PD 001337 02-04, 002315 03-04, 003202 04-04, 003367 04-04
STOKES PE 003662 04-15
STOLERMAN PD 001337 02-04, 002315 03-04, 003202 04-04, 003360 04-03, 003440 04-06
STOLERMAN PD 001307 04-03
STOME SK 002307 03-08
STOME SK 002307 03-08
STOME SK 002307 03-08
STOME FM 0001252 02-03, 002163 03-03
STRAMENTINOLI G 001253 02-03, 002163 03-03 STRAMENTINOLI G 001253 02-03, 003102 04-STRÂMENTINOLI G 001253 02-03, 003102 0403
STRANDJORD RE 000705 01-13
STRATHDEE A 001681 02-13
STRAUSH NAB 001674 02-13
STRAUSS MJ 001951 03-01
STRAUSS MJ 001951 03-01
STRAUSS MJ 001951 03-01
STREIFLER M 001624 02-11
STREITER J 000899 01-15
STREITCH R 001469 02-04, 001470 02-04
STRICKER EM 000277 01-03, 000378 01-04, 003245 04-04
STRICKER EM 000277 01-03, 000378 01-04, 003245 04-04
STRIPLING JS 000458 01-04
STRIPLING JS 000458 01-04
STRIPLING JS 000458 01-04
STRIPLING JS 000458 01-04
STRONG PL 001622 02-09, 001828 02-15
STROCCHI P 000416 01-04
STRONG PL 001782 02-15
STROMBOM U 001300 02-04
STRONG PL 001782 02-15
STRUMPF AJ 000368 01-04
STRUNE FA 001846 02-15
STRZYZEWSKI W 002494 03-10
STUDENT JG 003109 04-03
STURDEVANT RAL 000862 01-15
STUTZ RM 002277 03-04, 003369 04-04
SUEDA K 001796 02-15
SUGREMAN AA 003523 04-09
SUGRUE MF 000126 01-03, 003103 04-03 SUEDA K 001796 02-15 SUGERMAN AA 003523 04-09 SUGRUE MF 000126 01-03, 003103 04-03 SULEMAN DE 003576 04-11 SULKOWSKI A 000900 01-15 SULLIVAN JL 001607 02-09, 003524 04-09, 003577 04-11 SULSER F 000272 01-03, 001226 02-03, 002100 03-03, 002164 03-03, 002466 03-09, 003017 04-03 SULZBACHER S 000660 01-11 SUMMA J 001837 02-15

Author Index

SUMMERFIELD A 003684 04-15
SUND A 001811 02-15
SUNDARESAN PR 000489 01-05
SUNDARESAN PR 000489 01-05
SUNDBERG I 002258 03-13
SUNDWALL A 000727 01-13, 000745 01-13
SUNDWALL A 000643 01-11, 003638 04-14
SUGNI SI 002316 03-04
SURI ML 001688 02-13
SUTAK M 001152 02-03, 002966 04-03
SUTHERLAND E 002083 03-03
SUTHERLAND E 002083 03-03
SUTHERLAND C 00180 02-03
SUTHER IM 001699 02-14
SUZUKI M 001840 02-15
SUZUKI M 001840 02-15
SUZUKI M 001840 02-03
SVENDSEN 0 001035 02-02
SVENSSON TH 000202 01-03, 001300 02-04
SVERS J 000901 01-15, 002602 03-13, 003578
04-11 SVERD J 000901 01-15, 002602 03-13, 00357 04-11 SVANSON HH 003370 04-04 SVANSON JO 02534 03-11 SWANSON JO 02614 03-14 SWANSON JW 002614 03-14 SWANSON JW 002614 03-14 SWANSON DE 0257 04-03 SWANSON DE 00278 01-03 SWANSON DE 00375 04-03 SWANSON PD 000278 01-03 SWANSON PD 000278 01-03 SWANSON PD 000375 04-11 SWEDEREGE MOB 003371 04-04 SWEENEY D 003609 04-13 SWETT C 000902 01-15, 000903 01-15 SWITZMAN L 003372 04-04 SWITZMAN L 003372 04-04 SWITZMAN L 003372 04-04 SWITZMAN L 003372 04-05 SYDOR L 002494 03-10 SYKOVA E 001384 02-04 SYNDER SH 000220 01-03 SZABADI E 002821 04-03, 002822 04-03 SZCZAWINSKA K 002317 03-04, 002332 03-04, 002348 03-05, 002358 03-05 SZEKELY JI 000351 01-04 SZEKESS S 001602 02-09 SZENTIVANYI A 002129 03-03 SZUKALSKI B 001522 02-05 SZULCT 001638 02-12 SZYBURSKI M 002427 03-09

TABAKOFF B 000279 01-03, 000280 01-03, 001146 02-03, 002318 03-04, 003106 04-03, 003107 04-03 003107 04-03
TABERNER PV 001961 03-03, 002997 04-03
TACHEY 001255 02-03, 001471 02-04
TACHIKI KH 003108 04-03
TACHIKI KH 003108 04-03
TADANO T 000033 01-02
TAGASHIRA E 003373 04-04
TAGLIAMONTE A 002001 03-03, 003324 04-04, 003325 04-04 TAGIJAMONTE A 002001 03-03, 003324 04-04, 003325 04-04
TAKAGI A 002108 03-03, 003108 04-03, 003311 04-04
TAKAGI H 001256 02-03, 003374 04-04
TAKAGI H 001256 02-03, 003374 04-04
TAKAGI H 001256 02-03, 003374 04-04
TAKAGI H 00126 03-03, 003108 04-03, 003311 04-04
TAKAHASHI R 002108 03-03, 003108 04-03, 003311 04-04
TAKAHASHI S 001830 02-15
TAKAHATA N 00906 01-15
TAKAMATSU K 001812 02-15
TAKAMATSU K 001812 02-15
TAKAMOR S 001936 02-17
TAKANO K 003109 04-03
TAKATANI Y 001794 02-15
TAKEMORI AE 001004 02-01, 001010 02-01, 001164 02-03, 001165 02-03, 001272 02-03
TAKEUCHI K 002635 03-14
TAKEYAMA E 001615 02-10
TALLARIDA J 000504 01-06, 001143 02-03
TALLEY JH 003525 04-09
TALLSTEDT L 002791 04-02
TAM YK 003574 04-11
TAMAI A 001678 02-13
TAMAKI Y 000034 01-02
TAMMINGA CA 000896 01-15, 000904 01-15, 001570 02-08, 003474 04-08, 003475 04-08
TAN EK 00220 03-08
TANAKA M 001382 02-04, 001556 02-07, 003610 04-13
TANG SH 000221 01-03
TANG FIM 001119 02-03
TANG K 000221 01-03
TANG K 000221 01-03
TANGRI KK 002823 04-03

TANI F 000303 01-03
TANIGUCHI A 002973 04-03
TANIGUCHI A 002973 04-03
TANIGUCHI A 002973 04-03
TANIGR T 000100 01-03, 003375 04-04
TAPIA R 003013 04-03
TAPP WN 000471 01-04
TARALLO P 001669 02-13
TARATSIDIS I 001911 02-17
TARISKA P 003675 04-15
TARSY D 003655 04-15
TASKER TCG 002897 04-03
TASSIN J 002005 03-03
TATSISH T 002108 03-03, 003108 04-03
TATSISH T 002108 03-03, 003108 04-03
TATYANENKO LV 001774 02-03
TAYLOR AN 001267 02-03
TAYLOR AN 001267 02-03
TAYLOR AN 001267 02-03
TAYLOR BO 002811 04-03
TAYLOR FI 002215 03-04
TAYLOR FI 002215 03-04
TAYLOR K 003441 04-06
TAYLOR K 003441 04-06
TAYLOR MA 002516 03-11
TAYLOR RH 002704 03-15
TEAGUE RS 001308 02-04, 001457 02-04
TEDESCO JL 002779 03-17, 003117 04-03
TEELEGN W 003602 04-13
TEERENHOVI L 001742 02-15
TEERENHOVI L 001742 02-15
TEITELBAUM H 003297 04-04
TELAND VG 001010 02-01
TELEGDY G 001394 02-04, 003263 04-04
TELFORD R 000747 01-14
TEMKOV IV 000514 01-07
TEOR KC 000673 01-12
TEPPER P 003376 04-04
TELRAND US 001161 02-03, 003110 04-03, 003111 04-03
TESSEL RE 001161 02-03, 003110 04-03, 003111 04-03
TESSEL RE 001161 02-03, 003110 04-03, 003111 04-03
TESSEL RE 001161 02-03, 003113 04-03
THEBOT MH 001472 02-04, 003364 04-04
TELICHMANN IK 003221 03-04
TEUCHMANN IK 003231 03-03
THEIBGOT MH 001472 02-04, 003364 04-04
THEIGOT MH 001472 02-04, 003364 04-04
THEIGOT MH 001472 02-04, 003364 04-04 003005 04-03 THOLEY G 000484 01-05 THOMAS AJ 002839 04-03 THOMAS GS 003377 04-04 THOMAS J 000011 01-01 THOMAS JE 000342 01-04 THOMAS KV 002322 03-04, 003239 04-04 THOMAS TO 001257 02-03 THOMAS TN 001260 02-03 THOMAS TN 001260 02-03 THOMAS PC 001257 02-03
THOMAS TN 001260 02-03
THOMAS TN 001260 02-03
THOMAS TN 001260 02-03
THOMPSON DM 000459 01-04, 001473 02-04, 001474 02-04, 003303 04-04
THOMPSON GD 000682 01-12
THOMPSON GD 000682 01-11
THOMPSON GD 000685 01-11
THOMPSON GD 000747 01-14
THOMPSON TO 00047 01-04
THOMPSON TO 00047 01-04
THOMPSON TO 00047 01-04
THOMPSON TO 00047 01-04
THOMPSON TO 001475 02-04
THOMPSON TO 001455 02-04
THORNBERRY JF 002148 03-03
THORNTON WE 000892 01-15, 001637 02-12, 002437 03-09
THORSTRAN C 001838 02-15
THURMAN JA 003134 04-03
THURPSON JB 002219 03-04
THUT PD 001202 02-03
THYBERG J 001258 02-03
TICE LF 002706 03-15
TICKU MK 002122 03-03
TIDMARSH S 000739 01-13
TIGANOV AS 01540 02-06
TIKAL K 001435 02-04, 001475 02-04
TIKSON HA 000461 01-04, 001073 02-03, 002054 03-03
TILSTONE WJ 003114 04-03, 003115 04-03 TILSTONE WJ 003114 04-03, 003115 04-03

Psychopharmacology Abstracts

TIMBERLAKE WH 002707 03-15
TIMSIT-BERTHIER M 002631 03-14, 002639 03-14
TINKLENBERG JR 000755 01-14, 001695 02-13, 001727 02-14, 002622 03-14
TIPTON KF 003425 04-06
TISSARI HA 003116 04-03
TITELER M 002944 04-03, 003117 04-03
TIZABI Y 003003 04-03
TJJOE SA 000282 01-03, 001259 02-03
TOAFF ME 001627 02-11
TOAFF R 001627 02-11
TOBIN JM 003526 04-09
TODD JW 002323 03-04
TODZY I 003378 04-04
TODEWS AD 003420 04-05
TOFANO G 000132 01-03
TOFFANO G 000133 01-03, 000499 01-06
TOFT A 000057 01-03
TOKUNAGA Y 000206 01-03
TOLUENAERE JP 000990 01-17
TOMINAGA H 001936 02-17
TOMINAGA H 001936 02-17
TOMINAGA H 001936 02-17
TOMINAGA H 001938 03-05
TOPESS D 002708 02-15
TOONE BK 000905 01-15
TOPLISS D 002708 03-15
TORUS CM 001839 02-15
TORUS CM 001893 03-15
TORUS CM 001893 03-15
TORUS CM 001893 03-15
TORUS CM 001891 03-13
TORUS CM 001891 03-13 TIMBERLAKE WH 002707 03-15 TIMSIT-BERTHIER M 002631 03-14, 002639 03-TOSTESON DC 000724 01-13, 001679 02-13, 002591 03-13 002591 03-13
TOUCHSTONE JC 002007 03-03, 002165 03-03
TOURTELLOTTE WW 000654 01-11
TOUSSAINT C 000662 01-11
TOUSSAINT C 000662 01-11
TOUSY SW 001734 02-14, 002640 03-14, 003729 04-17
TOVSKY NJ 002962 04-03
TOWNSEND BG 002923 04-03
TRABUCCHI M 002157 03-03
TRABUCCHI M 002157 03-03
TRAFICANTE LJ 000737 01-13, 001571 02-08, 003087 04-03 TRABUCCHI M 002157 03-03
TRAPICANTE LI 000737 01-13, 001571 02-08, 003087 04-03
TRAMIL JIN 003206 04-04
TRANSBOL I 002420 03-09
TRAPP CA 002712 03-15
TRAVERSA U 000462 01-04
TRECIOKAS LI 003556 04-11
TREMBLAY EC 003379 04-04
TREMOUROUX J 001752 02-15
TREPTOW K 002296 03-04
TRESS KH 000792 01-14
TRESVOR AJ 000193 01-03, 003295 04-04
TRIEZENBERG HJ 001959 03-02, 002801 04-02
TRIMBLE M 002535 03-11, 003611 04-13
TRIPATHI VJ 002824 04-03
TRIPATHI VJ 002824 04-03
TRIPATH VJ 002824 04-03
TROJAN S 002161 03-02
TROST RC 003398 04-C4
TROUPIN AS 001706 02-14
TRULSON ME 000463 01-04, 001262 02-03, 001383 02-04, 001477 02-04, 003279 04-04 TROUPIN AS 001706 02-14
TRULSON ME 000463 01-04, 001262 02-03, 001383 02-04, 001477 02-04, 003279 04-04
TRUSH MA 001263 02-03, 001693 02-13
TRZCINKA GP 001264 02-03
TSAI P 001450 02-04
TSANG W 002277 03-04
TSANG W 002277 03-04
TSANG W 002379 02-04, 002166 03-03
TSEVDOS EJ 002021 03-03
TSIRLIN MY 000515 01-07
TSITCIURIDIS S 003456 04-08
TSUANG MT 000638 01-11
TSUCHIYA M 001451 02-04
TSUCHIYA T 001265 02-03
TSUKAMOTO R 000880 01-15
TSUTSUI S 003527 04-09
TUCHIYA Y 000424 01-04
TUCKER AN 001266 02-03
TUFK S 001320 02-04
TULINING E 000793 01-14
TUPIN JP 000823 01-15
TURKE FW 003243 04-04
TURNBULL MJ 000710 01-13, 002799 04-02
TURNBULL MT 001024 02-02

VOLUME 16. AUTHOR INDEX

TURNER CE 000004 01-01
TURNER P 000794 01-14, 002453 03-09, 002469 03-09, 002584 03-13, 002599 03-13
TURNER PF 003553 04-11
TWITCHETT PJ 000928 01-16
TWYCROSS R 001628 02-11
TYE NC 000250 01-03, 000464 01-04, 001478 02-04 TYLER CB 003380 04-04 TYRER JH 000642 01-11 TYRER PJ 000550 01-08

u

UCHIDA M 001783 02-15 UCHIDA S 000024 01-02 UCHIMURA H 003027 04-03 UCHIYAMA M 001840 02-15 UEKI \$ 003226 04-04 UENO N 001793 02-15 UENO T 000906 01-15 UHLENHUTH EN 000661 01-11, 000933 01-16, 002716 C3-16 UKITA T 002307 03-04 ULLMAN DG 003579 04-11 ULRICH G 000934 01-16 ULRICH J 002583 03-13 ULUS I 003330 04-04 ULRICH J 002583 03-13
ULUS I 003330 04-04
ULUS IH 000284 01-03, 002167 03-03
UMANETS V\$ 001521 02-05
UMGAR B 000285 01-03
UNGRER A 003301 04-04
UNGERSTEDT U 001533 02-06, 002346 03-05, 003356 04-04
UPRICHARD DC 000219 01-03, 000283 01-03, 002029 03-03, 003118 04-03, 003119 04-03
URBA-HOLMGREN R 001380 02-04, 001479 02-04, 002951 04-03
URBA-GOLMGREN R 001380 02-04, 001479 02-04, 001254 02-03
URCA G 001267 02-03, 002916 04-03
URFO K 001254 02-03
URFO K 001254 02-03
USDIN E 002366 03-06, 002781 03-17
UTSEY E 001302 02-04
UYENO ET 001040 02-02
UZAN A 002800 04-02 UZAN A 002800 04-02

VAAMONDE CA 000882 01-15
VACCA L 003536 04-10
VACHON L 000900 01-15
VADDADI KS 002646 03-15
VADDADI KS 002646 03-15
VADDADI KS 002646 03-15
VADLAMANI NL 000201 01-03, 001008 02-01, 003019 04-03
VAGVOLGYI A 003268 04-04
VAHIA NS 001882 02-17
VAISANEN E 002495 03-10
VAKASSI MM 000893 01-15
VALASES C 002057 03-03
VALATX J 000070 01-03
VALATX J 000070 01-03
VALDES LJJ 000007 01-01
VALDIVIESO T 000871 01-15
VALDMAN AV 001395 02-04, 001480 02-04
VALE JA 001842 02-15, 001937 02-17, 002656 VAAMONDE CA 000882 01-15 VALE JA 001842 02-15, 001937 02-17, 002656 03-15 03-15
VALENTINE JL 000682 01-12
VALENTINO D 001397 02-04, 001396 02-04
VALLE RS 003622 04-14
VALLE RS 003622 04-14
VALLEALA P 002069 03-03
VAN BEVER W 002160 03-03
VAN BLADEREN PJ 002170 03-03
VAN BUSKIRK R 000377 01-04, 001375 02-04
VAN CALKER D 003121 04-03
VAN DEN BERG AP 003122 04-03
VAN DEN BROCKC WAE 002177 03-03
VAN DEN BROCKC WAE 002177 03-03
VAN DEN BROUCKE M 003454 04-08
VAN DEN STEEN N 002419 03-09, 002456 03-09 09
VAN DER DIJS B 000961 01-17
VAN DER GEN A 002170 03-03
VAN DER VELDE CD 002410 03-08
VAN DONGEN PAM 003381 04-04
VAN DUJIN H 002168 03-03
VAN DYKE C 002549 03-13, 003643 04-15
VAN DYKE K 001263 02-03, 001693 02-13
VAN ELSACKER-VAN ESSCHE M 003491 04-09

VAN HELIST ANP 001519 02-05
VAN HEST T 003454 04-08
VAN KAMMEN DP 001560 02-08, 001712 0214, 002406 03-08
VAN LEEUWEN AMH 000662 01-11
VAN LOON GR 001269 02-03
VAN NESS PC 002122 03-03
VAN NESS PC 002122 03-03
VAN PETEGHEM C 001841 02-15
VAN PETEGHEM C 001841 02-15
VAN PETEGHEM C 001841 02-15
VAN PRAAG HM 000551 01-08, 000743 01-13, 000991 01-17, 002728 03-16, 002782 03-17, 003587 04-13
VAN PUTTEN T 002709 03-15
VAN REE JM 001270 02-03, 002217 03-04, 002324 03-04
VAN RIEZEN H 000438 01-04, 000465 01-04, 000466 01-04
VAN ROSSUM JM 000341 01-04, 001292 02-03
VAN THIEL DH 001523 02-05
VAN VALKENBURG CFM 003021 04-03
VAN WEL PM 001454 02-04
VAN WILK M 002169 03-03
VAN WINGAARDEN I 002989 04-03
VAN WINGAARDEN I 002989 04-03
VAN ZWEITEN PA 000286 01-03
VAN ZWEITEN PA 000286 01-03
VAN ZWEITEN PA 000287 01-03
VANDAM LD 000992 01-17
VANDAM LD 000992 01-17
VANDAM LD 000992 01-17
VANDAM LD 001624 02-11
VARGA E 003680 04-15
VARGAS PE 000683 01-12
VARGA FE 000683 01-12
VARGUL 002002 03-03, 003123 04-03
VARME RV 003482 04-09
VARNER RV 000628 01-11
VARSOU E 001690 02-13
VASQUEZ BJ 000406 01-04, 003288 04-04
VASQUEZ BJ 000461 03-14, 003382 04-04
VECSEI L 003263 04-04
VECSEI L 003263 04-04 VAUPEL DB 001273 02-03, 002121 03-03, 002289 03-04
VECSEI L 003263 04-04
VEITH JL 002641 03-14, 003382 04-04
VELASCO F 001735 02-14
VELASCO M 001735 02-14
VELKOV V 001482 02-04
VELLUCCI SV 000288 01-03
VENCOVSKY E 002858 04-03, 003069 04-03
VENTUBLE 003207 04-04 VELLUCCI SV 000288 01-03
VENCOVSKY E 002858 04-03, 003069 04-03
VENCOVSKY E 002858 04-03, 003069 04-03
VENTURI F 003207 04-04
VENULET J 000993 01-17
VERDEAUX G 002743 03-17
VERDEAUX G 002743 03-17
VERDEAUX G 002743 03-17
VERDEAUX J 001974 03-03
VERREY K 002642 03-14, 003730 04-17
VERHEYEN J. 002177 03-03
VERMEULEN NPE 002170 03-03
VERMEULEN NPE 002170 03-03
VERNET-MAURY E 001324 02-04
VERNON S 000755 01-14
VERREAULT R 001528 02-06
VERRIER RL 002140 03-03
VERTUA R 000462 01-04
VESSMAN J 000685 01-13, 000720 01-13, 000727 01-13, 000745 01-13, 001673 02-13
VESTERGAARD P 000663 01-11
VETULANI J 002164 03-03, 002466 03-09, 003383 04-04, 003384 04-04, 003397 04-04
VIJALA D 003124 04-03
VIDAL D 002233 03-04
VIDAL D 002223 03-04
VIDAL M 001956 03-02
VIEDERMAN M 001995 03-02
VIEDERMAN M 001995 03-02
VIEDERMAN M 001995 03-04
VIJAYALAKSHMI V 003125 04-03
VIJAYALAKSHMI V 003125 04-03
VILLA RF 003127 04-03
VILLALOBOS A 002496 03-10
VILLENEUVE R 000700 01-13, 002677 03-15
VILLENEUVE R 000700 01-15, 002677 03-15
VILLENEUVE R 000700 01-13, 002677 03-15
VILLENEUVE R 000700 01-13, 002677 03-15
VILLENEUVE R 000700 01-13, 002677 03-15 003461 04-08
VILLENEUVE C 000852 01-15, 002677 03-15
VILLENEUVE R 000700 01-13, 002677 03-15
VILLOLDO A 001639 02-12
VINAR O 003528 04-09, 003584 04-12, 003630 04-14
VINAROVA E 003528 04-09, 003533 04-09
VINCENT J 002829 04-03, 002830 04-03, 003128 04-03
VINCENT M 001399 02-04
VISHNUVAJJALA BR 000035 01-02

VISWANATHAN CT 002600 03-13

VITIELLO MV 000467 01-04

VINKARI M 001622 02-11, 001629 02-11

VIVEIROS DM 002325 03-04

VLIEK RW 001655 02-13

VLKOVA A 003404 04-04

VOGEL HP 000590 01-09

VOGEL WH 003050 04-03

VOGT M 001483 02-04

VOHRA J 001751 02-15, 003645 04-15

VOINESKOS G 000527 01-08

VOITASHEVSKY A 000588 01-09

VOITH K 001484 02-04

VOLANS GN 001842 02-15, 002656 03-15

VOLAVKA J 000552 01-08, 000695 01-13, 000723 01-13, 000920 01-16, 002642 03-14, 002688 03-15, 003571 04-11, 003730 04-17

VOLICER L 001274 02-03, 003051 04-03

VOLK MAN PH 002927 04-03, 003386 04-04

VOLVAKA J 000744 01-13

VOM SAAL FS 003129 04-03

VOMACHIKA MK 002297 03-04

VON MUHENDAH KE 001843 02-15

VON WOHLENDAH CR 001801 04-02

VOROINNA TA 001213 02-03

VRANCKX S 003590 04-13

VREE TB 001016 02-01

VRHOVAC B 000994 01-17

VILLON-CACCIUTTOLO G 002194 03-04

VUOPOR 0 001742 02-15

VYBOROVA L 003580 04-11

VYSKOCIL F 001275 02-03, 002171 03-03

WACHTEL H 000042 01-03, 003387 04-04
WADDINGTON JL 000086 01-03, 000290 01-03, 002326 03-04, 003388 04-04
WADDINGTON JL 000086 01-03, 000290 01-03, 002326 03-04, 003388 04-04
WADDINGTH J 002453 03-09, 002584 03-13
WAGMAN AMI 002617 03-14
WAGMER HR 001216 02-03
WAHLIN E 001673 02-13
WAHLSTROM A 001692 02-13
WAHLSTROM G 003389 04-04
WAINAPEL SF 000888 01-15
WAINSBORT J 000664 01-15
WAINAPEL SF 000888 01-15
WAINAPEL SF 000888 01-15
WALSBORT J 000664 01-11
WALAAS I 002911 04-03
WALD D 003529 04-09, 003530 04-09
WALDMAN I 001582 02-09, 001733 02-14, 003492 04-09
WALDMEIR PC 001960 03-02, 002172 03-03, 002173 03-03, 003130 04-03, 003131 04-03
WALDRON I 000995 01-17
WALINDER J 001805 02-15
WALKER CA 002123 03-03
WALKER CA 002123 03-03
WALKER LC 002980 04-03
WALKER RF 002723 03-16
WALKER RF 002723 03-16
WALKER RF 002723 03-16
WALKER R 001763 02-15
WALLESTEIN MC 002174 03-03
WALLEY RE 001500 02-04
WALLINATU LB 00291 01-03, 001276 02-03
WALLEY RE 001500 02-04
WALLINATU LB 000291 01-03, 001276 02-03
WALLEY R 001075 02-14
WALLINATU LB 00291 01-03, 001276 02-03
WALLER R D 003221 04-04
WALLENSTEIN MC 002174 03-03
WALLEY RE 001500 02-04
WALLINATU LB 000291 01-03, 001276 02-03
WALLER R D 003201 04-04
WALLER R D 000457 01-04, 002327 03-04, 003328 04-03
WALLER R D 000247 01-04, 002327 03-04, 003328 04-03
WALLER R D 001277 02-03, 003144 04-06
WALTERS JR 001278 02-03, 002124 03-03, 003042 04-03
WALTON NY 001345 02-04
WALTON NY 001345 02-04
WALTON NY 001345 02-04

Author Index

WANG LU L 002264 03-04
WANG PFL 000140 01-03
WANG RIH 000245 01-03, 000616 01-10, 001115 02-03, 001873 02-16, 002080 03-03
WANG RY 000039 01-03, 000292 01-03
WANG SC 001844 02-15
WARBRITTON JD 002328 03-04
WARD AG 000907 01-15
WARD G 002458 03-09
WARD HK 002839 04-03
WARDHG 002938 04-03
WARDHG 002938 04-03
WARDHG MARDHG 002938 04-03
WARDHG WARDHG 002938 04-03
WARDHG MARDHG 002938 04-03
WARDHG 002938 04-03
WARNER AM 000909 01-15
WARNER AM 000908 01-15
WARNER PM 000887 01-13
WARREK PM 000232 04-04
WARNOCK JMT 003548 04-10
WARREK PM 000887 01-13
WARSZAWSKI D 002342 03-05
WARWICK RO 000293 01-03
WASSERMAN AJ 002722 03-16
WASSERMAN AJ 002722 03-16
WASSERMAN GS 01845 02-15
WASSERMAN GS 01845 02-15
WASSERMAN GS 01845 02-15
WASSERMAN GS 001845 02-15
WASSERMAN GS 001845 02-15
WASSERMAN GS 001845 02-15
WASTER GJ 003132 04-03
WATTERHEID AA 002175 03-03
WATTERHEID AA 002175 03-03
WATTERMAN LJ 003681 04-15
WATERFELD AA 002176 03-03
WATTERMAN LJ 003681 04-15
WATERS IN 000480 01-05, 001072 02-03, 001093 02-03
WATKINS JC 001116 02-03, 002831 04-03, 002901 04-03 WATERS IW 000490 01-05, 001072 02-03, 001093 02-03

WATKINS JC 001116 02-03, 002831 04-03, 002901 04-03

WATLING KJ 000301 01-03

WATSON AA 001819 02-15

WATSON D 002881 04-03

WATSON ML 001790 02-15

WATSON SJ 003616 04-14, 003639 04-14

WATT DE 002396 03-08, C03455 04-08

WATT JB 000772 01-14

WATTERS G 000644 01-11

WAUQUIER A 002177 03-03, 003390 04-04

WAXMAN D 002467 03-09, 002497 03-10

WAXMAN D 002032 01-04, 000385 01-04, 001075
 02-03, 001138 02-03

WAY WL 000193 01-03

WAY WIRE JC 002097 03-03, 003012 04-03, 003133 04-03

WAYNER MJ 000470 01-04, 001176 02-03, WAYNER MJ 000470 01-04, 001176 02-03, 001388 02-04, 001400 02-04, 002054 03-03, 002269 03-04 WAYNER M.J. 000470 01-04, 001176 02-03, 001388 02-04, 001400 02-04, 002054 03-03, 002269 03-04
WAZIRI R. 002536 03-11
WEAKLY JN. 000294 01-03
WEATHERALL JAC. 001780 02-15
WEAVER LC. 000860 01-15
WEBB GA. 000939 01-17
WEBB SD. 001938 02-17
WEBB SD. 001938 02-17
WEBB SD. 001938 02-17
WEBB WI. 003551 04-11
WEBSTER R. 002969 04-03
WEDDIGE R. 002431 03-09
WEDLEY S. 002431 03-09
WEDLEY S. 002431 03-09
WEDLEY S. 002491 03-09
WERLS JR. 001541 02-06
WEGNER JT. 001846 02-15
WEHR T. 002468 03-09, 003495 04-09
WHINT SM. 001279 02-03
WEICK BG. 003057 04-03
WEIDLEY E. 000475 01-04
WEIL AT 000684 01-12
WEINBERG AD. 001524 02-05
WEINBERG WA. 001578 02-09
WEINBERG WA. 001078 02-03
WEINBERG WA. 001078 02-03
WEINBERG WA. 001078 02-03
WEINBERG WA. 001078 03-03
WEINBERG WA. 001078 03-03
WEINBERG WA. 001078 03-03
WEINBERG WA. 001078 03-03
WEINGARTNER H. 001733 02-14, 002727 03-16, 003585 04-12, 003612 04-13, 003711 04-17
WEINSTEIN H. 002178 03-03
WEINSTEIN H. 002178 03-03
WEISS E. 003135 04-04
WEISS BL. 001847 02-15, 001848 02-05
WEISS BL. 001847 02-15, 001848 02-15
WEISS GB. 003135 04-03
WEISSMAN A. 003392 04-04, 003393 04-04
WEISSMAN MM. 002783 03-17, 003567 04-11

WEISZ DJ 000287 01-03
WELBEL L 002394 03-08, 002395 03-08
WELCH J 002300 03-04
WELCH KMA 000647 01-11
WELLBY M 000911 01-15
WELLING PG 002600 03-13
WELNER A 001608 02-09
WELSTEAD WJ 001942 03-01
WELTMAN AS 001450 02-04
WENTHAN AS 001450 02-04
WENTHAN AS 001450 02-04
WENTHAN AS 001450 02-04
WENTHAN C 00005 01-01
WERNER TE 003436 04-06
WERRY JS 000665 01-11, 002784 03-17, 003212 04-04
WESCHE D 003136 04-03
WESSELS FL 001944 03-01
WEST LG 001018 02-01
WEST LG 001018 02-01
WEST LG 001018 02-01
WESTERFIELD BT 001849 02-15
WESTERFIELD BT 001849 02-15
WESTERHOLM B 000940 01-17
WESTERMANN KH 003137 04-03
WESTEALL DP 002052 03-03
WESTLAL CV 001445 02-04
WETTERBERG L 002558 03-13
WESTLAKE KC 001445 02-04
WETTERBERG L 002558 03-13
WESTLAKE W 001487 02-04
WEATHEN ON 00303 04-04
WHALEN CK 000620 01-11, 003581 04-11
WHARTON W 001488 02-04
WHELPTON R 001336 02-04, 003590 04-13
WHIELDON D 000996 01-17
WHISTEAW 001033 02-02, 001355 02-04
WHITE BC 000371 01-04
WHITE BC 001380 02-04
WHITE BC 000371 01-04
WHITE BC 000371 01-04
WHITE BC 000371 01-04
WHITE BC 000371 01-04
WHITE BL 001580 02-09
WHITE HL 001580 02-09 WHITE FJ 001489 02-04, 002191 03-04, 003695 04-17
WHITE HL 001580 02-09
WHITE JA 001295 02-04
WHITE JA 000295 01-10, 001939 02-17
WHITE K 003685 04-15
WHITE L 001880 02-15
WHITE L 001850 02-15
WHITE R 003372 04-04, 003394 04-04
WHITE RP 001229 02-03
WHITE RP 00129 02-03
WHITE RP 000219 01-04, 001902 02-17
WHITE RP 000319 01-04, 001902 02-17
WHITE S 003572 04-11
WHITEHEAD WE 000667 01-11, 002498 03-10
WHITEHEAD WE 000667 01-11, 002498 03-10
WHITEHOUSE LW 000218 01-03
WHITILOCK EG 002091 03-03, 003292 04-04
WHITILOCK EG 002091 03-03, 003292 04-04
WHITILOCK FA 002421 03-09, 003531 04-09
WHITILOCK FA 002421 03-09, 003531 04-09
WHITINORTH UG 002123 03-03
WIDDING A 002581 03-13
WIDDER D 001842 02-15, 002656 03-15
WIDDING A 002581 03-13
WIDDERLOV E 001851 02-15, 003613 04-13
WIDDERLOV E 001851 02-15, 003613 04-13
WIDDERLOV E 001851 02-15, 003646 04-10
WIECHERT V 000804 01-15
WIEGANT VM 000472 01-04, 001490 02-04, 003197 04-04
WIEGERS U 001282 02-03
WIELOSZ M 000297 01-03 001283 02-03 003695 04-17 WIEGANT VM 000472 01-04, 001490 02-04 003197 04-04
WIEGERS U 001282 02-03
WIELOSZ M 000297 01-03, 001283 02-03
WIENER PC 000668 01-11, 000669 01-11
WIERNSPERGER N 002032 03-03
WIESEN F 000041 01-03, 001284 02-03
WIESEN RL 000616 01-10
WIG NN 000952 01-17
WIKLER A 000648 01-11, 002629 03-14
WILBUR CS 002729 03-16
WILCOX CE 001084 02-03
WILCOX GL 001285 02-03, 003241 04-04
WILCOX JB 000998 01-17
WILDER RM 003498 04-09
WILDSCHIODTZ G 002581 03-13
WILHELM M 001960 03-02
WILL S 001250 02-03, 003139 04-03
WILL JC 002537 03-11
WILLET RE 001019 02-02
WILLET TJ 002601 03-13
WILLIFJP 001736 02-14
WILLIAMS HL 003635 04-14

WILLIAMS J 003203 04-04
WILLIAMS N 001286 02-03
WILLIAMS SP 003413 04-05
WILLIAMS SP 003413 04-05
WILLIAMS WD 001523 02-05
WILLIAMS WD 001523 02-05
WILLIAMS NP 001623 02-05
WILLIAMS NP 001625 03-03
WILLINGHAM TA 002605 03-14
WILLIS WD 003251 04-04
WILLIS WD 003251 04-04
WILLIS WD 00387 01-15
WILSON BK 000704 01-13
WILSON CA 001287 02-03
WILSON CA 001287 02-03
WILSON CA 001287 02-03
WILSON CA 001287 02-03
WILSON CA 001287 02-09
WILSON ND 003408 04-05
WILSON ND 003408 04-05
WILSON MC 001609 02-09
WILSON MC 001609 02-09
WILSON MC 001490 02-04
WILSON MC 00131 02-04, 001492 02-04, 001493 02-04, 00131 02-04, 001493 02-04
WILSON MC 00131 02-04, 001492 02-04, 001493 02-04, 00131 02-04, 001493 02-04, 001494 02-04, 002331 03-04, 00395 04-04
WILSON ME 001263 02-03, 001693 02-13
WILSON MC 001951 04-04
WINDSON DA 000999 01-17
WINGER GD 000393 01-04
WINGER GD 000393 01-04
WINGER GD 000393 01-04
WINGER GD 000393 01-04
WINGER GD 000575 01-09
WINSBERG BG 000901 01-15, 001721 02-14, 002602 03-13, 003578 04-11
WINSTEAD DK 001736 02-14
WINTER JC 000473 01-04, 002180 03-03, 003396 04-04 WINSLOW WW 002718 03-16
WINSTEAD DK 001736 02-14
WINTEAD DK 001736 02-14
WINTER JC 000473 01-04, 002180 03-03, 003396 04-04
WINTERS WD 001852 02-15, 001853 02-15
WIRZ-JUSTICE A 001610 02-09
WISE CD 000455 01-04
WISE RA 000299 01-03, 001495 02-04, 002224 03-04, 003221 04-04, 003400 04-04
WISHART TB 001339 02-04
WISHEWSKI K 002101 03-03
WISWESSER G 003544 04-10
WISZNIOWSKA G 003384 04-04
WITIKOP TA 002411 03-08
WITTS DJ 002453 03-09, 002469 03-09, 002584 03-13
WODE-HELGODT B 000591 01-09, 000670 0111, 001694 02-13, 002538 03-11, 003614
04-13
WOERNER MG 002501 03-10 11, 001694 02-13, 002538 03-11, 003614
04-13
WOERNER MG 002501 03-10
WOGGON B 000553 01-08, 000935 01-16, 002412 03-08, 003476 04-08
WOLICIAK Z 002317 03-04, 002332 03-04
WOLICIAK O01496 02-04
WOLICIK M 001496 02-04
WOLISH M 001280 02-03
WOLF AP 000116 01-03
WOLF P 000300 01-03, 001211 02-03, 002181
03-03
WOLF S 003505 04-09
WOLF SM 003582 04-11
WOLFARTH S 003397 04-04
WOLFE GW 001288 02-03, 002182 03-03
WOLFE GW 001288 02-03, 002182 03-03
WOLFE GW 001288 02-03, 002182 03-03
WOLFEN 02350 03-05
WOLFING WOLF ON 02352 03-05
WOLFING WOLF ON 02352 03-05
WOLFING WOLF ON 02352 03-05
WOLKINAL 000339 01-04
WOLKOWITZ 0 001733 02-14
WOLFOR H 000286 03-03
WONG D 03-03
WONG C 002183 03-03, 003140 04-03
WONG C 002183 03-03, 003140 04-03
WONG PCL 001985 03-03
WONG PCL 001985 03-03
WONG PCL 001985 03-03
WONG PCL 001989 02-03
WONG PCL 001989 02-03
WONG PCL 001289 02-03
WOOD D 002099 03-03
WOOD D 002099 03-03
WOOD PL 002644 03-14, 002994 04-03
WOOD D N 0020644 03-14, 002994 04-03
WOODDROW KM 002413 03-08 WOERNER MG 002501 03-10

WOODRUFF GN 000163 01-03, 000301 01-03, 002884 04-03 WOODRUFF ML 000474 01-04 WOODS JH 003373 03-04 WOODRUFF ML 003376 04-04 WOODS JH 003376 04-04 WOODS SC 000467 01-04 WOODS SC 000467 01-04 WOODWARD WR 003418 04-05 WOODWARD WR 003418 04-05 WOODWARD WR 003418 04-05 WOODWARD WR 003418 04-05 WOOTTON LW 002499 03-10 WORMS P 001497 02-04 WORSHAM E 001498 02-04, 002285 03-04 WORTHINGTON C 001062 02-03 WRAY DV 001028 02-02 WRAY SR 001347 02-04 WRETIND M 000727 01-13, 000745 01-13 WRIGHT KR 00239 03-03 WRIGHT KR 00239 03-03 WRIGHT CM 001336 02-04 WRIGHT FC 001478 02-04 WRIGHT FC 001478 02-04 WRIGHT JH 002470 03-09 WRIGHT JH 002470 03-09 WRIGHT JH 002470 03-09 WRIGHT JH 00257 03-03 WRIGHT JH 000560 01-09 WRIGHT JH 000560 01-09 WRIGHT JH 000560 01-04 WUENSCH KL 003399 04-04 WUERTHELE SM 002810 04-03 WULBERT M 000671 01-11 WULFF K 000791 01-14 WURSTER RM 001499 02-04 WURTMAN JJ 002184 03-03 (003068 04-03 WYATT RJ 000457 01-04, 000521 01-08, 00213 01-30, 001380 02-06, 002413 03-08, 002522 03-11, 003224 04-09, 003663 04-15, 003711 04-17 WYLLE MG 000123 01-03, 002923 04-03, 002924 04-03 WYSOCKI CJ 002334 03-04

Y

YAFFE GJ 002263 03-04
YAGI G 000531 01-08
YAGYU M 000424 01-04
YAHABA Y 001874 02-16
YAHABA Y 001874 02-16
YAHABA Y 001874 02-16
YAHABA Y 001874 02-16
YAHABA Y 001387 01-03
YAKSH TL 001291 02-03, 002335 03-04,
003142 04-03, 003143 04-03
YAMADA K 001854 02-15
YAMAGAMI S 002561 04-03
YAMAMOTO I 002336 03-04
YAMAMOTO I 002336 03-04
YAMAMOTO K 001793 02-15
YAMAMOTO M 003144 04-03
YAMAMOTO M 003144 04-03
YAMAMITA K 000555 01-09
YAMAHITA K 000556 01-09
YAMAUCHI M 001572 02-08
YAMAZAKI H 003527 04-09
YAMAGITA T 003160 04-04
YANAI D 002318 03-04
YANAI S 003373 04-04
YANAI N 002318 03-04
YANAI N 002788 04-01, 002790 04-01
YANG HYT 002788 04-01, 002790 04-01
YARBROUGH GG 002185 03-03
YARROM A 002603 03-13

7

ZABIK JE 000028 01-02, 000962 01-17, 001362 02-04, 001408 02-04, 001501 02-04, 003148 04-03, 003280 04-04
ZABOW T 001734 02-14, 002640 03-14, 003729 04-17
ZACHARAKOPOULOU E 001803 02-15
ZAKOVA P 003404 04-04
ZACZEK R 003081 04-03
ZAGON IS 000491 01-05
ZAHAVI J 003686 04-15
ZAHNISER NR 003149 04-03
ZAKI SA 000554 01-08, 001611 02-09
ZAKRZEWSKA F 002515 03-11
ZAMAZALOVA I 003404 04-04
ZAMBOTTI F 001983 03-03
ZANDER TK 001940 02-17, 001941 02-17
ZANTONI G 001546 02-07
ZAPLETALEK M 000517 01-07
ZARCONE VP 000592 01-09
ZAREVICS P 000475 01-04

ZARZECKI P 001293 02-03 ZATZ M 000746 01-13, 003032 04-03 ZAUGG HE 001034 02-02 ZAVADIL AP 001486 02-04, 001876 02-16, 003516 04-09 ZAVODNICK S 003687 04-15 ZBYTOVSKY J 000517 01-07 ZELDOWICZ L 001553 02-07 ZELLER NH 000843 01-15 ZELLNER DA 003337 04-04 ZEMEK P 003533 04-09 ZEMP JW 001260 02-03 ZENCHOFF G 001017 02-01 ZERVAS NT 001175 02-03 ZHARKOVSKIY AM 001298 02-04 ZHUKOV VN 000795 01-14 ZIANCE RJ 001294 02-03, 002187 03-03 ZIEGLER B 001730 02-14 ZIEGLER MG 002573 03-13 ZIEGLER WE 000593 01-09, 000801 01-15, 000883 01-15, 000912 01-15, 001576 02-09, 001884 02-17, 002472 03-09 ZIEGLGANSBERGER W 002118 03-03 ZIEHER LM 000155 01-03 ZIELINSKI JJ 002539 03-11 ZIELINSKI K 001496 02-04 ZIEMBA T 003478 04-08 ZIFFERBLATT SM 002729 03-16 ZIFFERIATT SM 002729 03-16 ZIGHELBOIM I 003638 04-14 ZIGMOND MJ 000277 01-03, 000378 01-04 ZIMAN V 003022 04-03 ZIMMER R 002378 03-07 ZIMMER-HART CL 003198 04-04 ZIMMERHART CL 003198 04-04 ZIMMERMAN ANE 001519 02-05 ZIMMERMAN HJ 001502 02-05 ZIMMERMAN HJ 001502 02-05 ZIMMERMAN HJ 001502 02-05 ZIMMERMAN HJ 001502 02-05 ZIMMERMAN RL 003445 04-07 ZIMMERMANN E 002310 03-04, 003230 04-04 ZIMMERMANN RL 001544 02-07 ZIMMERMANN RL 002502 03-11, 002537 03-11
ZIPNICK J 002320 03-04
ZIRKLE CL 002798 04-02
ZISOOK S 002500 03-10, 003549 04-10
ZISSIS N 003456 04-08
ZITO T 002785 03-17
ZITRIN CM 002501 03-10
ZLATKINA GN 002444 03-09
ZOBNIW AM 001676 02-13
ZOFFUTO A 002712 03-15
ZOLLER M 001297 02-04
ZOUBOK B 003680 04-15
ZSIGMOND FK 000640 01-11 11 ZSIGMOND EK 000640 01-11 ZUCCARELLI RR 001305 02-04 ZUCKER K 002534 03-11 ZUGER PE 000036 01-02, 002849 04-03 ZUNG WWK 003524 04-09 ZUSTIAK R 001807 02-15 ZVOLSKY P 003533 04-09

ZWILLER J 002975 04-03

SUBJECT INDEX

[The Subject Index is machine generated. Keywords in the titles of abstracts appear alphabetically in the the left hand margin; under each keyword is a list of titles in which the keyword appears. The spelling of words in the titles of abstracts has not been changed; hence, two spellings of the same word may appear in this index — for example, BEHAVIOR and BEHAVIOUR.]

ON THE TREATMENT OF NEURODERMATITIS WITH A MONOAMINE-	BIOAVAILABILITY OF OXAZEPAM: ABSENCE OF INFLUENCE OF FOOD INTAKE.
OXIDASE INHIBITOR: THE CHEMOTHERAPY OF PSYCHOSOMATIC ILLNESS THROUGH A-REM SUPPRESSION. 002480 03-10	O01673 02-13 ABSENCE OF DRUG-INDUCED BETA-ACTIVITY IN THE ELECTROENCEPHALOGRAM: A SIGN OF SEVERE CEREBRAL
A-10 FURTHER EVIDENCES ON THE BEHAVIOURAL EFFECTS OF SELECTIVE A-10 DOPAMINERGIC MESENCEPHALO-CORTICO-LIMBIC GROUP LESION IN	IMPAIRMENT. 001676 02-13
THE RAT. 000399 01-04	ABATEMENT OF STIMULUS PERSERVATION FOLLOWING REPEATED D AMPHETAMINE TREATMENT: ABSENCE OF BEHAVIORALLY AUGMENTED TOLERANCE.
ABATEMENT OF STIMULUS PERSERVATION FOLLOWING REPEATED D	ABSORPTION 003260 04-04
AMPHETAMINE TREATMENT: ABSENCE OF BEHAVIORALLY AUGMENTED TOLERANCE.	ABSORPTION AND METABOLISM OF THE PHENOTHIAZINE DRUG PERAZINI IN THE RAT INTESTINAL LOOP.
003260 04-04 ABBOTT-43981 INTRAOCULAR PRESSURE LOWERING PROPERTIES OF ABBOTT-43981, A CANNABINOID DERIVED HETEROCYCLIC BENZOPYRAN WITH MINIMAL	000063 01-03 INFLUENCE OF FASTING ON THE ABSORPTION AND EFFECTS OF DELTA9- TETRAHYDROCANNABINOL AFTER ORAL ADMINISTRATION IN SESAME- OIL.
CNS ACTIVITIES. 001025 02-02	LITHIUM ABSORPTION, DISTRIBUTION AND CLEARANCE AND BODY
A COMPARISON IN RABBIT ISOLATED HEARTS OF THE DYSRHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE, MAPROTILINE	TEMPERATURE IN RATS GIVEN LITHIUM PLUS HALOPERIDOL. 000488 01-03 RATE OF ABSORPTION AND CLINICAL RESPONSE TO SINGLE ORAL DOSES
AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK NORADRENALINE UPTAKE.	OF CHLORDIAZEPOXIDE. 000702 01-13
effect of subacute diazepam administration in Mice on the	EFFECT OF ANTACIDS ON ABSORPTION OF CLORAZEPATE. 001647 02-13
SUBSEQUENT ABILITY OF DIAZEPAM TO PROTECT AGAINST METRAZOL AND BICUCULLINE-INDUCED CONVULSIONS. 002053 03-03	ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN YOUNG AND ELDERLY MALE VOLUNTEERS. 001689 02-13
TIME-RESPONSE ANALYSIS OF THE EFFECT OF STIMULANT MEDICATION ON THE LEARNING ABILITY OF CHILDREN REFERRED FOR	EFFECT OF ACTIVATED CHARCOAL ON ABSORPTION OF NORTRIPTYLINE. 001763 02-19
HYPERACTIVITY. 002534 03-11 DNA SYNTHETIC ABILITY IN CEREBELLA FROM TEMPERATURE AND	ABSORPTION AND DISTRIBUTION OF SODIUM BARBITAL IN TISSUES OF NORMAL AND DYSTROPHIC MICE.
HANDLING STRESSED NEONATAL RATS. 002934 04-03	002162 03-03 EFFECT OF ANTIDEPRESSANTS ON THE ABSORPTION OF SEROTONIN BY HUMAN THROMBOCYTES.
SELF-REPORTED ALCOHOL AND NICOTINE USE AND THE ABILITY TO CONTROL OCCIPITAL EEG IN A BIOFEEDBACK SITUATION. 003622 04-14	002586 03-1: LITHIUM NEUROTOXICITY. 1. THE CONCENTRATION OF LITHIUM IN DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS
OLFACTORY BULB ABLATION IN THE RAT: BEHAVIOURAL CHANGES AND THEIR REVERSAL BY ANTIDEPRESSANT DRUGS.	ATOMIC ABSORPTION SPECTROPHOTOMETRY. O03432 04-0 EFFECT OF A COCKTAIL ON DIAZEPAM ABSORPTION.
THE EFFECT OF ABLATION OF SEROTONIN OR NOREPINEPHRINE	ABSTINENCE 0003596 04-1:
BRAINSTEM AREAS ON HALOTHANE AND CYCLOPROPANE MAC IN RATS. (UNPUBLISHED PAPER).	AD LIBITUM CONSUMPTION AND ABSTINENCE. 000758 01-1-
O01229 02-03 ANGIOTENSIN-INDUCED THIRST: EFFECTS OF THIRD VENTRICLE OBSTRUCTION AND PERIVENTRICULAR ABLATION.	CASE REPORT: AMPHETAMINE ABSTINENCE PSYCHOSIS DOES IT EXIST?. 000899 01-1:
ABNORMAL CATECHOLAMINES AND BIOCHEMICALLY-INDUCED ABNORMAL	EFFECTS OF ANTIPSYCHOTIC AND ANTIANXIETY DRUGS ON THE MORPHINE ABSTINENCE SYNDROME IN RATS. 001303 02-0
BEHAVIOUR IN RATS. 000356 01-04 ROLE OF GLUCOCORTICOIDS IN AN ABNORMAL GROOMING BEHAVIOR IN	POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES (N) ON OPIOID ABSTINENCE SYNDROMES.
CATS WITH PONTILE OR FRONTAL NEOCORTICAL LESIONS. 000463 01-04	O01897 02-1 TIME-COURSE OF THE EFFECTS OF NATURALLY OCCURRING CANNABINOIDS ON MORPHINE ABSTINENCE SYNDROME.
PHENOTHIAZINE-INDUCED ECG ABNORMALITIES. 000812 01-15	NALOXONE-INDUCED OR POSTWITHDRAWAL ABSTINENCE SIGNS IN
MATERNAL DRUG HISTORIES AND CONGENITAL ABNORMALITIES. 001780 02-15	DELTA9-TETRAHYDROCANNABINOL-TOLERANT RATS. 002257 03-0
SOMATOSTATIN IN THE TREATMENT OF PATIENTS WITH EXTRAPYRAMIDAL DISORDERS AND PATIENTS WITH EEG ABNORMALITIES.	THE EFFECTS OF DIVALENT IONS ON MORPHINE ANALGESIA AND ABSTINENCE SYNDROME IN MORPHINE-TOLERANT AND MORPHINE- DEPENDENT MICE.
003557 04-11 PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATIENTS DURING LONG-	1NHIBITION OR WET SHAKES DURING MORPHINE ABSTINENCE BY AN
TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS: DISSOCIATION BETWEEN LIGHT AND NEAR VISION REACTIONS.	ANTAGONIST OF OPIATE ANALGESIA. 003383 04-0
003673 04-15	ABUSE PHENCYCLIDINE (PCP) ABUSE.
ABSENCE OF FORMATION OF BRAIN SALSOLINOL IN ETHANOL DEPENDENT MICE.	ABUSE OF ANTIPARKINSONIAN DRUGS BY PSYCHIATRIC PATIENTS.
MORPHINE AND ETHANOL AS DISCRIMINATIVE STIMULI: ABSENCE OF	THE INCREASING ABUSE OF PHENCYCLIDINE.
ANTAGONISM BY P-CHLOROPHENYLALANINE-METHYL-ESTER, CINANSENIN, OR BC-105. 000473 01-04	OCO892 01-1 PSEUDOCATATONIA ASSOCIATED WITH ABUSE OF AMPHETAMINE AND CANNABIS.
INTERINDIVIDUAL VARIABILITY IN DIAZEPAM METABOLISM: PRELIMINARY EVIDENCE OF AN ABSENCE OF GENETIC CONTROL.	METHYLPHENIDATE (RITALIN) ABUSE.
SLOW-WAVE SLEEP AND A STATE RESEMBLING ABSENCE EPILEPSY	PHARMACOKINETIC STUDIES ON TOLERANCE TO SEDATIVE HYPNOTICS IN
INDUCED IN THE RAT BY GAMMA-HYDROXYBUTYRATE. 001366 02-04	A POLYDRUG ABUSE POPULATION: I. SECOBARBITAL. 002662 03-1:

Subject Index

RELATIONSHIP BETWEEN ANORECTIC AND REINFORCING PROPERTIES OF APPETITE SUPPRESSANT DRUGS: IMPLICATIONS FOR ASSESSMENT OF ABUSE LIABILITY. 003236 04-04 PROPHYLACTIC LITHIUM TREATMENT OF DRUG ABUSE.

ABUSER

003564 04-11

ISER NECROTIZING ANGIITIS AND HEPATITIS IN AN AMPHETAMINE ABUSER. 000887 01-15 LITHIUM IN THE TREATMENT OF A CHILD ABUSER.

001598 02-09 THE FREQUENCY AND PERSISTENCE OF DEPRESSIVE SYMPTOMS IN THE ALCOHOL ABUSER.

003567 04-11 ARUSERS

A DIAGNOSTIC TREATMENT MODEL FOR EFFECTIVE GROUP TREATMENT OF DRUG ABUSERS. 000950 01-17

ACADEMIC
CREATIVITY IN NEW DRUG DEVELOPMENT: AN ACADEMIC CHALLENGE.
002745 03-17

EFFECTS OF METHYLPHENIDATE ALONE AND IN COMBINATION WITH BEHAVIOR MODIFICATION PROCEDURES ON THE BEHAVIOR AND ACADEMIC PERFORMANCE OF HYPERACTIVE CHILDREN. 003640 04-14

TRICYCLIC ANTIDEPRESSANTS ACCELERATE MANIC-DEPRESSIVE CYCLES.
(UNPUBLISHED PAPER).

002468 03-09 ACCELERATION

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): NALOXONE BLOCKS MORPHINES ACCELERATION OR PRESSING FOR ICS. 001313 02-04 ACCENTUATION
STRESS ACCENTUATION OF THE LSD-INDUCED DISAGGREGATION OF
BRAIN POLYSOMES.

002035 03-03 ACCEPTABILITY

A COMPARISON OF THE EFFICACY AND ACCEPTABILITY OF TWO FORMULATIONS OF INJECTABLE SERENACE IN THE TREATMENT OF STATES OF EXCITEMENT. 003576 04-11

ACCEPTANCE
BIMODAL DISTRIBUTIONS OF HIGHEST ETHANOL ACCEPTANCE
CONCENTRATIONS IN TWO STRAINS OF RATS.

003229 04-04

EFFECT OF CHRONIC COCAINE TREATMENT ON LIMITED ACCESS FOOD CONSUMPTION.

THE CONTRIBUTION OF PRESCRIBED DRUGS TO THE INCIDENCE OF ACCIDENTAL AND DELIBERATE POISONING IN THE COMMUNITY 001896 02-17

PSYCHOTROPIC DRUGS AND ROAD ACCIDENTS.

000988 01-17

THE ACCUMULATION OF P-HYDROXYAMPHETAMINE BY BRAIN HOMOGENATES AND ITS ROLE IN THE RELEASE OF CATECHOLAMINES 000074 01-03

EFFECTS OF AMPHETAMINE AND CHLORDIAZEPOXIDE ON PROBENECID-INDUCED ACCUMULATION OF ACIDIC METABOLITES IN THE CEREBROSPINAL FLUID OF THE DOG.

POTENTIATION BY RESERPINE OF THE INHIBITION BY AMPHETAMINE OF (3H)DOPAMINE ACCUMULATION IN THE RAT STRIATUM.

AUTORADIOGRAPHIC EVIDENCE FOR THE SELECTIVE ACCUMULATION OF H3-5-HT BY SUPRAEPENDYMAL NERVE TERMINALS. 001222 02-03

EFFECT OF DIAZEPAM AND PENTOBARBITAL ON AMINOOXYACETIC-ACID-INDUCED ACCUMULATION OF GABA. 002124 03-03

THE EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND 2
BROMOLYSERGIC-ACID-DIETHYLAMIDE (BOL) ON THE STRIATAL DOPA
ACCUMULATION: INFLUENCE OF CENTRAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS.

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS.

BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101 BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN RAT CEREBRAL-CORTEX.

002885 04-03 POSTMORTEM AND AMINOOXYACETIC-ACID-INDUCED ACCUMULATION OF GABA: EFFECT OF GAMMA-BUTYROLACTONE AND PICROTOXIN. 003042 04-03

Psychopharmacology Abstracts

EFFECT OF VASOACTIVE INTESTINAL PEPTIDE (VIP) AND OTHER PEPTIDES ON C-AMP ACCUMULATION IN RAT BRAIN.

THE DIFFERENTIAL EFFECT OF LITHIUM ON NORADRENALINE AND DOPAMINE SENSITIVE ACCUMULATION OF CYCLIC-AMP IN GUINEA-PIG

003063 04-03 HALOPERIDOL DEPRESSES THE ACCUMULATION OF APOMORPHINE IN THE STRIATUM OF THE RAT.

003384 04-04 ERYTHROCYTE ACCUMULATION OF THE LITHIUM-ION IN CONTROL
SUBJECTS AND PATIENTS WITH PRIMARY AFFECTIVE-DISORDER 003519 04-09

ACETALDEHYDE
ROLE OF LIVER CYTOSOLIC ALDEHYDE-DEHYDROGENASE ISOZYMES IN
CONTROL OF BLOOD ACETALDEHYDE CONCENTRATIONS.

000222 01-03 DIFFERENTIAL EFFECTS ON CONDITIONED TASTE AVERSION LEARNING
WITH PERIPHERALLY AND CENTRALLY ADMINISTERED ACETALDEHYDE. TASK-DEPENDENT GENETIC INFLUENCES ON BEHAVIORAL RESPONSE OF MICE (MUS-MUSCULUS) TO ACETALDEHYDE.

003211 04-04 ACETAMIDOBENZOATE
DEANOL ACETAMIDOBENZOATE (DEANER) IN TARDIVE-DYSKINESIA

001935 02-17

ACETAZOLAMIDE
ANTAGONISM OF THE ANTICONVULSANT ACTION OF PHENYTOIN,
PHENOBARBITAL, AND ACETAZCLAMIDE BY 6 HYDROXYDDPAMINE
202945 04 002845 04-03

ACETYLCHOLINE
INTERACTION OF GABA, DOPAMINE, AND ACETYLCHOLINE IN CAT
STRIATUM: PHARMACOLOGICAL CONSIDERATIONS.

000051 01-03 ENDOGENOUS MODULATORS OF ACETYLCHOLINE TURNOVER RATE. (UNPUBLISHED PAPER).

000073 01-03 EFFECTS OF RETICULAR STIMULATION, D AMPHETAMINE AND SCOPOLAMINE ON ACETYLCHOLINE RELEASE FROM THE HIPPOCAMPUS OF BRAINSTEM TRANSECTED CATS.

000098 01-03 THE ROLE OF THE SEPTAL NUCLEI IN THE RELEASE OF ACETYLCHOLINE FROM THE RABBIT CEREBRAL-CORTEX AND DORSAL HIPPOCAMPUS AND THE EFFECT OF ATROPINE.

000101 01-03 N.N DIMETHYLTRYPTAMINE LOWERS RAT BRAIN ACETYLCHOLINE AND DOPAMINE

000140 01-03 ACETYLCHOLINE STIMULATION OF THE SYMPATHETIC GANGLIA: EFFECTS OF TAURINE AND NICOTINIC AND MUSCARINIC GANGLION BLOCK.

INVOLVEMENT OF THE DOPAMINE NIGROSTRIATAL SYSTEM IN THE PICROTOXIN EFFECT ON STRIATAL ACETY! CHOLINE LEVELS.

ELECTROCORTICAL CHANGES INDUCED BY THE PERFUSION OF NORADREMALINE, ACETYLCHOLINE AND THEIR ANTAGONISTS DIRECTLY INTO THE DORSAL RAPHE NUCLEUS OF THE CAT.

ACETYLCHOLINE AND CHOLINE IN MOUSE BRAIN — INFLUENCE OF PERIPHERALLY ACTING CHOLINERGIC DRUGS.

000187 01-03 ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE NEUROBLASTOMA CELLS.

000241 01-03 ACETYLCHOLINE TURNOVER IN SPECIFIC BRAIN AREAS OF RATS INJECTED WITH VARIOUS ANTIDEPRESSANTS. (UNPUBLISHED PAPER). 000244 01-03

FORMATION OF BRAIN ACETYLCHOLINE FROM DIETARY CHOLINE AND THE EFFECT OF BARBITURATE ANESTHESIA ON THIS PROCESS 001074 02-03

PHARMACOLOGICAL IMPLICATIONS OF BRAIN ACETYLCHOLINE TURNOVER MEASUREMENTS IN RAT BRAIN NUCLEI.

001077 02-03 IS DEANOL A PRECURSOR OF ACETYLCHOLINE?. 001134 02-03

ENKEPHALIN EFFECTS ON RELEASE OF BRAIN ACETYLCHOLINE 001152 02-03 EFFECT OF ATROPINE ON ACETYLCHOLINE METABOLISM IN THE MOUSE RRAIN

001157 02-03 THE EFFECT OF DFP AND PENTOBARBITAL ON THE TURNOVER OF ACETYLCHOLINE IN THE MOUSE BRAIN.

001170 02-03 THE EFFECT OF NICOTINE ON THE ACETYLCHOLINE CONTENT IN MOUSE BRAIN REGIONS

001197 02-03 BRAIN NEUROTRANSMITTER RECEPTORS AFTER LONG-TERM HALOPERIDOL: DOPAMINE, ACETYLCHOLINE, SEROTONIN, ALPHA-NORADRENERGIC AND NALOXONE RECEPTORS.

001200 02-03

001577 02-09

000092 01-03

001158 02-03

MODULATION OF ACETYLCHOLINE TURNOVER IN BRAIN REGIONS AND HIGH AFFINITY UPTAKE.

001209 02-03 ELECTROSHOCK ANTICONVULSANT ACTIVITY AND BRAIN ACETYLCHOLINE ALTERATIONS IN MICE TREATED WITH SELECT BENZODIAZEPINES. 001210 02-03

BLOCKADE BY PSYCHOTROPIC DRUGS OF THE MUSCARINIC
ACETYLCHOLINE RECEPTOR IN CULTURED NERVE CELLS.

EFFECT OF NOMIFENSINE AND OTHER ANTIDEPRESSANT DRUGS ON ACETYLCHOLINE TURNOVER IN VARIOUS AREAS OF RAT BRAIN.

601225 02-03

EFFECTS THE HYPNOTICS AND ANTIANXIETY DRUGS ON ACETYLCHOLINE
(ACH) CONCENTRATIONS IN DISCRETE AREAS OF THE RAT BRAIN.

001239 02-03
ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR
MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE
NEUROBLASTOMA CELLS.

ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS. 002137 03-03

ACETYLCHOLINE ANTIRELEASE EFFECT OF MORPHINE AND ITS MODIFICATION BY CALCIUM.

002143 03-03
INCREASE OF HIPPOCAMPAL ACETYLCHOLINE TURNOVER RATE AND THE
STRETCHING YAWNING SYNDROME ELICITED BY ALPHA-MSH AND

ACTH.

002644 03-14

EFFECTS OF ACETYLCHOLINE, SODIUM-GLUTAMATE AND GABA ON THE
DISCHARGE OF SUPRAOPTIC NEURONS IN THE RAT.

O02830 04-03
COENZYME-A IS A PURINE NUCLEOTIDE MODULATOR OF ACETYLCHOLINE OUTPUT.

002874 04-03

EFFECTS OF ANGIOTENSIN-II AND ACETYLCHOLINE ON NEURONS IN THE PREOPTIC AREA.

002935 04-03

ANTAGONISM OF MORPHINE ACTION ON BRAIN ACETYLCHOLINE RELEASE
BY METHYLXANTHINES AND CALCIUM.

002966 04-0.

THE RELEASE OF ACETYLCHOLINE IN THE PERFUSED CAT SPINAL CORD IN VIVO.

002969 04-03
CARDIOVASCULAR RESPONSE TO INTRACEREBROVENTRICULAR

ADMINISTRATION OF ACETYLCHOLINE IN RATS.

002982 04-03

MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II.

O02994 04-03
CYCLIC-NUCLEOTIDE LEVELS IN THE RAT STRIATUM AND CEREBELLUM -IN VIVO EFFECTS OF DOPAMINE AND ACETYLCHOLINE RECEPTOR
AGONISTS AND ANTAGONISTS.

003051 04-03

EFFECT OF ACUTE MORPHINE ADMINISTRATION ON REGIONAL
ACETYLCHOLINE TURNOVER IN THE RAT.

003077 04-03

THE ACETYLCHOLINE RECEPTOR IN THE RAT HIPPOCAMPUS; NICOTINIC, MUSCARINIC OR BOTH?.

DEVELOPMENT OF A SPECIFIC RADIOIMMUNOASSAY FOR ACETYLCHOLINE. 003438 04-06

ACETYLCHOLINESTERASE
HISTOCHEMICAL EFFECTS OF KAINIC-ACID ON NEOSTRIATAL DOPAMINE
AND ACETYLCHOLINESTERASE.

TETRAHYDROCANNABINOL AND ACETYLCHOLINESTERASE. 003023 04-03

TIME ACTION AND BEHAVIORAL EFFECTS OF AMPHETAMINE, ETHANOL, AND ACETYLMETHADOL. 000350 01-04

INFLUENCE OF SOME NEUROPSYCHOTROPIC DRUGS ON THE BEHAVIOURAL MODIFICATIONS INDUCED BY 3 ACETYLPYRIDINE IN RATS.

ACETYLTRANSFERASE

N ACETYLTRANSFERASE ACTIVITY IN PINEAL GLAND OF RATS TREATED

WITH PARGYLINE. 000046 01-03

BETA-ENDORPHIN INHIBITS ACH TURNOVER IN NUCLEI OF RAT BRAIN. 000012 01-01 ELECTRICAL STIMULATION OF DENERVATED MUSCLES REDUCES INCORPORATION OF METHIONINE INTO THE ACH RECEPTOR. EFFECTS THE HYPNOTICS AND ANTIANXIETY DRUGS ON ACETYLCHOLINE (ACH) CONCENTRATIONS IN DISCRETE AREAS OF THE RAT BRAIN. 001239 02-03

LITHIUM: CLINICAL EFFECTS AND CEREBROSPINAL FLUID ACID
MONOAMINE METABOLITES

BROMOCRIPTINE AND GASTRIC ACID OUTPUT.

ACTOIC

EFFECTS OF AMPHETAMINE AND CHLORDIAZEPOXIDE ON PROBENECIDINDUCED ACCUMULATION OF ACIDIC METABOLITES IN THE
CEREBROSPINAL FLUID OF THE DOG.

OXIDATION KINETICS OF PHENOTHIAZINE AND 10 METHYLPHENOTHIAZINE IN ACIDIC MEDIUM.

PLASMA CONCENTRATIONS OF SOME ACIDIC AND ALCOHOLIC
METABOLITES DERIVED FROM M- AND P-TYRAMINE, OCTOPAMINE
AND CATECHOLAMINES IN HUMANS.

ILLNESS-INDUCED AVERSION LEARNING IN A DESERT SPECIES OF RODENT (ACOMYS-CAHIRINUS).

001350 02-04

COUSTIC

PSILOCYBIN: BIPHASIC DOSE-RESPONSE EFFECTS ON THE ACOUSTIC

STARTLE REFLEX IN THE RAT.

000345 01-04
PHARMACOLOGICAL APPROACHES TO HABITUATION OF THE ACOUSTIC
STARTLE RESPONSE IN RATS.

O00425 01-0
THE EFFECTS OF PIMOZIDE AND PHENOXYBENZAMINE PRETREATMENTS
ON AMPHETAMINE AND APOMORPHINE POTENTIATION OF THE
ACOUSTIC STARTLE RESPONSE IN RATS.

O03257 04-04
THE EFFECT OF ANESTHESIA ON ACQUISITION AND EXTINCTION OF
CONDITIONED TASTE AVERSION.

000326 01-04
EFFECTS OF PIMOZIDE ON THE ACQUISITION, MAINTENANCE, AND
EXTINCTION OF AN AMPHETAMINE-INDUCED TASTE AVERSION.

000373 01-04
DEVELOPMENT OF TOLERANCE TO THE DISRUPTIVE AFFECTS OF COCAINE
ON REPEATED ACQUISITION AND PERFORMANCE OF RESPONSE

EFFECTS OF METHYLPHENIDATE ON ACQUISITION AND SUBSEQUENT
PERFORMANCE OF SUCCESSIVE DISCRIMINATION REVERSALS.

O01371 02-04
ACQUISITION AND EXTINCTION OF OPERANT RESPONDING FOR
INTRAVENOUS INJECTIONS OF FENTANYL IN THE RAT.

001397 02-04

EFFECT OF P-CHLOROPHENYLALANINE ON THE ACQUISITION OF
TOLERANCE TO THE HYPOTHERMIC EFFECTS OF ALCOHOL.

COMBINED EFFECTS OF ETHANOL AND DIAZEPAM ON PERFORMANCE
AND ACQUISITION OF SERIAL POSITION SEQUENCES BY PIGEONS.
003164 04-04

EFFECTS OF MESCALINE AND PSILOCIN ON ACQUISITION, CONSOLIDATION, AND PERFORMANCE OF LIGHT-DARK DISCRIMINATION IN TWO INBRED STRAINS OF MICE.

003184 04-04
THE EFFECTS OF METHYLPHENIDATE ON REPEATED ACQUISITION OF SERIAL DISCRIMINATION REVERSALS.

O0323B 04-04

DORSOMEDIAL THALAMIC LESIONS AND AMPHETAMINE: ACQUISITION
AND RETENTION OF A VISUAL PATTERN DISCRIMINATION ESCAPE
TASK.

IN VIVO COMPARISON OF THE RECEPTOR POPULATIONS ACTED UPON IN
THE SPINAL CORD BY MORPHINE AND PENTAPEPTIDES IN THE
PRODUCTION OF ANALGESIA.

PRODUCTION OF ANALGESIA.

O03143 04-03

ACTH

POSSIBLE SIGNIFICANCE OF ACTH FRAGMENTS FOR HUMAN MENTAL

PERFORMANCE.

DO0465 01-0INCREASE OF HIPPOCAMPAL ACETYLCHOLINE TURNOVER RATE AND THE STRETCHING YAWNING SYNDROME ELICITED BY ALPHA-MSH AND

STRETCHING YAWNING SYNDROME ELICITED BY ALPHA-MSH AND ACTH. 002644 03-14

EFFECT OF NALOXONE ON MORPHINE-INDUCED CHANGES IN ACTH,
CORTICOSTERONE AND CYCLIC-NUCLEOTIDES.

O02949 04-03

PARALLEL CHANGES IN BEHAVIOR AND HIPPOCAMPAL MONOAMINE
METABOLISM IN RATS AFTER ADMINISTRATION OF ACTH ANALOGUES.
003335 04-04

000136 01-03

ACTH EFFECTS ON RESPONSE SUPPRESSION AND PLASMA CORTICOSTERONE IN THE MOUSE.

003363 04-04

002598 03-13

ACTH-INDUCED
ACTH-INDUCED EXCESSIVE GROOMING IN THE RAT: LATENT ACTIVITY OF
ACTH4-10.
000472 01-04

ACTH-INDUCED EXCESSIVE GROOMING INVOLVES BRAIN DOPAMINE. 001490 02-04 DISTINCT DOPAMINERGIC SYSTEMS IN ACTH-INDUCED GROOMING. 003197 04-04

ACTH4-10

ACTH4-IDUCED EXCESSIVE GROOMING IN THE RAT: LATENT ACTIVITY OF
ACTH4-10.

000472 01-04

ACTH4-10 IN THE AMELIORATION OF NEUROPSYCHOLOGICAL SYMPTOMATOLOGY ASSOCIATED WITH SENILE ORGANIC-BRAIN-SYNDROME.

THE EFFECTS OF ACTH4-10 VERSUS PLACEBO IN THE MEMORY OF SYMPTOMATIC GERIATRIC VOLUNTEERS.

EFFECTS OF MSH/ACTH4-10 ON MEMORY, ATTENTION, AND ENDOGENOUS HORMONE LEVELS IN WOMEN.

O02641 03-14

CEREBRAL CIRCULATION IS ALTERED BY A POTENT ACTH4-9 ANALOG -ORG-2766.

O01135 02-03

ACTING
STRESS-INDUCED ALTERATIONS OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN:
EFFECTS OF CENTRALLY ACTING DRUGS.

O00097 01-03
ACETYLCHOLINE AND CHOLINE IN MOUSE BRAIN — INFLUENCE OF PERIPHERALLY ACTING CHOLINERGIC DRUGS.

O00187 01-03

ALTERATION OF THE NEURONAL RESPONSE TO AMPHETAMINE IN THE
NEOSTRIATUM BY PRETREATMENT WITH A CENTRALLY ACTING
ANTICHOLINERGIC.

O00298 01-03
THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE HUMAN BRAIN
AS AN OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY
ACTING DRIGS

MODIFICATION OF THE TIME-COURSE OF DMPEA TOXICITY IN THE MOUSE BY CENTRALLY ACTING DRUGS.

DO DRUGS ACTING ON THE NERVOUS SYSTEM AFFECT CELL PROLIFERATION IN THE DEVELOPING BRAIN?

001512 02-05
APPLICATION OF STATISTICS TO THE METHODOLOGY OF STUDIES OF
DRUGS ACTING ON THE BRAIN.

001620 02-11
REFECTS OF CENTRALLY ACTING DRUGS ON BRAINSTEM AUDITORY
RESPONSES.

ACTION

EXCITATORY ACTION OF THE MESOLIMBIC DOPAMINE SYSTEM ON SEPTAL NEURONES.

000045 01-03

ADENYLATE-CYCLASE FROM VARIOUS DOPAMINERGIC AREAS OF THE BRAIN AND THE ACTION OF ANTIPSYCHOTIC DRUGS.

ACTION OF S-1432, A NEW PSYCHOTROPIC DRUG, ON THE CENTRAL CHOLINERGIC SYSTEM.

THE NUCLEUS-ACCUMBENS — POSSIBLE SITE OF ANTIPSYCHOTIC ACTION OF NEUROLEPTIC DRUGS?

AN EXCITATORY ACTION OF IONTOPHORETICALLY ADMINISTERED LITHIUM ON MAMMALIAN CENTRAL NEURONES.

NEW ASPECTS CONCERNING THE MECHANISM OF ACTION OF TRANQUILIZERS. THE INFLUENCE OF SOME TRANQUILIZERS ON PROTEIN AND NUCLEIC-ACID SYNTHESES.

SPECIFIC ACTION OF NARCOTICS ON REFLEX ACTIVATION OF RAT ALPHA-MOTONEURONES.

SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF PHYSICAL DEPENDENCE IN RATS: III. AUTORADIOGRAPHIC STUDIES.

EFFECTS OF N METHYLAMINO-ACIDS AND CONVULSANTS ON SPONTANEOUS ACTION POTENTIALS IN GUINEA-PIG CEREBELLAR SLICES

GRANULAR AND EXTRAGRANULAR ACTION OF PSYCHOTROPIC DRUGS ON MONOAMINERGIC NEURONS.

BRAIN CALCIUM AND MORPHINE ACTION. 000252 01-03

Psychopharmacology Abstracts

ACTION OF THE PALMITIC ESTER OF PIPOTIAZINE ON DOPAMINE METABOLISM IN THE NIGROSTRIATAL, MESOLIMBIC AND MESOCORTICAL SYSTEMS.

THE EFFECTS OF NEOMYCIN UPON TRANSMITTER RELEASE AND ACTION.
000302 01-03
TIME ACTION AND BEHAVIORAL EFFECTS OF AMPHETAMINE, ETHANOL,
AND ACETYLMETHADOL.

MORPHINE ACTION IN GROUPED AND ISOLATED RATS AND MICE.
000350 01-04
ANTISCHIZOPHRENIC DRUGS -- MEMBRANE RECEPTOR SITES OF ACTION.
000547 01-08

THE PREDICTIVE VALUE OF THE BIOCHEMICAL ACTION PROFILE OF NEUROLEPTICS.

PHOTODYNAMIC ACTION OF CHLORPROMAZINE ON ADENOVIRUS 5:
REPAIRABLE DAMAGE AND SINGLE STRAND BREAKS.

MODE OF ACTION OF: ANTIDEPRESSANTS AND CENTRAL STIMULANTS. (UNPUBLISHED PAPER).

OCO958 01-17

A BENZOQUINOLIZINE DERIVATIVE WITH A NEUROLEPTIC-LIKE ACTION ON CEREBRAL MONOAMINE TURNOVER.

001037 02-02

EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION
IN SKELETAL MUSCLE. I. CHLORPROMAZINE AND PROMETHAZINE.

A PRESYNAPTIC SITE OF ACTION WITHIN THE MESENCEPHALIC RETICULAR FORMATION FOR () AMPHETAMINE-INDUCED ELECTROCORTICAL DESYNCHRONIZATION.

CHLORDIAZEPOXIDE SELECTIVELY AUGMENTS GABA ACTION IN SPINAL CORD CELL CULTURES.

ELECTROPHYSIOLOGICAL EVIDENCE FOR A DOPAMINERGIC ACTION OF LSD: DEPRESSION OF UNIT ACTIVITY IN THE SUBSTANTIA-NIGRA OF THE PAT

MORPHINE DECREASES LUTEINIZING HORMONE BY AN ACTION ON THE HYPOTHALAMIC PITUITARY AXIS.

PREFERENTIAL ACTION OF 5 METHOXYTRYPTAMINE AND 5
METHOXYDIMETHYLTRYPTAMINE ON PRESYNAPTIC SEROTONIN
RECEPTORS: A COMPARATIVE IONTOPHORETIC STUDY WITH LSD AND
SEROTONIN

EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS.

ACTION OF DOPAMINE AGONISTS ON BRAIN VESSELS IN VITRO AND AFTER IN VIVO MICROAPPLICATION.

AFTER IN VIVO MICROAPPLICATION.

001107 02-03

SOME STRUCTURAL FEATURES GOVERNING OPIATE ACTION.
(UNPUBLISHED PAPER 001168 02-03

HALOPERIDOL AND CLOZAPINE: SPECIFICITY OF ACTION ON GABA IN THE NIGROSTRIATAL SYSTEM.

001184 02-03

THE ACTION OF BACLOFEN ON NEURONS OF THE SUBSTANTIA-NIGRA AND OF THE VENTRAL TEGMENTAL AREA.

NEGATIVE EFFECTS OF BICUCULLINE AND THIOSEMICARBAZIDE ON THE TRANQUILLIZING ACTION OF DIAZEPAM.

O01213 02-03
ACTION OF AZABUTYRONE AND ITS ANALOGS ON CATECHOLAMINE
METABOLISM IN RAT BRAIN.

ON THE MODE OF ACTION OF CENTRAL STIMULATORY AGENTS. 001232 02-03

DIAZEPAM BLOCKADE OF REPETITIVE ACTION POTENTIALS IN SKELETAL MUSCLE FIBRES: A MODEL OF ITS MEMBRANE ACTION.

001275 02-03

COCAINE AND METABOLITES: RELATIONSHIP BETWEEN
PHARMACOLOGICAL ACTIVITY AND INHIBITORY ACTION ON
DOPAMINE UPTAKE INTO STRIATAL SYNAPTOSOMES.

001286 02-03

DIFFERENTIAL TOLERANCE TO INHIBITORY ACTION OF VARIOUS

NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS

CHRONICALLY TREATED WITH HALOPERIDOL.

001398 02-04

EFFECTS OF OPIATES AND OPIOID PEPTIDES ON MOTOR BEHAVIORS:

SITES AND MECHANISMS OF ACTION. (UNPUBLISHED PAPER).

001433 02-04

EFFECTS OF IFC-45, A NEW BENZONAPHTYRIDONE DERIVATIVE WITH ANTIDEPRESSIVE ACTION, ON ACTIVITY OF THE RAT SUPRARENAL GLAND CORTEX.

001522 02-05

000253 01-03

- DIFFERENTIATION OF HYPNOTIC ACTION OF NITRAZEPAM AND ESTAZOLAM AND EFFECTS ON BEHAVIOR AND CORTICAL ACTIVITY. 001549 02-07 VILOXAZINE: ASSESSMENT OF POTENTIAL RAPID ANTIDEPRESSANT
- 001584 02-09 NORADRENALINE, DEPRESSIVE ILLNESS, AND THE ACTION OF AMITRIPTYLINE.
- 001588 02-09 ADDENDUM CONCERNING A PROPOSED MODEL FOR THE ACTION OF LITHIUM.
- 001640 02-13 A PROPOSED MODEL FOR THE ACTION OF LITHIUM
- 001648 02-13 CLINICAL BIOCHEMICAL ASSESSMENT OF DRUG ACTION IN PATIENTS. (UNPUBLISHED PAPER)
- 001668 02-13 PSYCHOTROPIC DRUGS: MECHANISM OF ACTION AT THE NEUROTRANSMITTER LEVEL
- 001684 02-13 EFFECT OF DIETARY FACTORS ON DRUG ACTION
- 001749 02-15 BEHAVIORAL MECHANISMS OF DRUG ACTION IN SCHIZOPHRENIA. 001933 02-17
- NEUROCHEMICAL MECHANISMS OF CENTRAL ACTION OF MORPHINE ON FUNCTIONS OF SINGLE NEURONS IN THE MIDBRAIN RETICULAR
- 001973 03-03
 STIMULANT ACTION OF THYROTROPIN-RELEASING HORMONE ON CAT SPINAL CORD.
- 001993 03-03 IMPORTANCE OF DURATION OF DRUG ACTION IN THE ANTAGONISM OF P-CHLOROAMPHETAMINE DEPLETION OF BRAIN SEROTONIN --COMPARISON OF FLUOXETINE AND CHLORIMIPRAMINE.
- 002017 03-03 A NEW MECHANISM OF TRICYCLIC ANTIDEPRESSANT ACTION. BLOCKADE OF PROSTAGLANDIN DEPENDENT CALCIUM MOVEMENTS 002043 03-03
- ACTION OF NOREPINEPHRINE ON MICROCIRCULATION AND PO2 DISTRIBUTION IN THE ISOLATED PERFUSED RAT LIVER 002059 03-03
- PENICILLIN IN THE PYRAMIDAL TRACT: ECTOPIC ACTION POTENTIAL 002082 03-03
- INVESTIGATIONS INTO THE MECHANISM OF THE INFLUENCE OF KININS ON THE ACTION OF AMPHETAMINE 002101 03-03
- INFLUENCE OF TRIIODOTHYRONINE (T3) ON THE RENAL ACTION OF
- 002119 03-03 DELIMITATION OF NEURONAL SUBSTRATES NECESSARY FOR THE ANALGESIC ACTION OF BACLOFEN AND MORPHINE
- 002132 03-03 MOLECULAR DETERMINANTS FOR THE ACTION OF TRYPTAMINES ON AN
- 002178 03-03 THE ROLE OF SEROTONIN ANTAGONISM IN THE TREMORGENIC ACTION OF BUFOTENINE IN MICE.
- 002236 03-04 MORPHINE-INDUCED TAIL ERECTION: SITE OF ACTION 002269 03-04
- MORPHINE AND SELF-STIMULATION: EVIDENCE FOR ACTION ON A COMMON NEURAL SUBSTRATE 002277 03-04
- MAPROTILINE (LUDIOMIL) IN DEPRESSION: A MULTICENTRE ASSESSMENT OF ONSET OF ACTION. EFFICACY AND TOLERABILITY
- 002432 03-09 USE OF LITHIUM-CARBONATE WITH RETARDED ACTION (MICALITE) IN PATIENTS WITH AFFECTIVE-PSYCHOSES
- 002444 03-09 MODE OF ACTION OF ANTIDEPRESSANT DRUGS
- 002466 03-09 BIOCHEMICAL IDENTIFICATION OF THE SITE OF ACTION OF BENZODIAZEPINES IN HUMAN BRAIN BY H3-DIAZEPAM BINDING 002583 03-13
- POTENTIATION BY NEUROLEPTIC AGENTS OF THE INHIBITORY ACTION OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE.
- 002832 04-03 REVERSAL OF THE ACTION OF AMINO-ACID ANTAGONISTS BY BARBITURATES AND OTHER HYPNOTIC DRUGS
- 002838 04-03 ANTAGONISM OF THE ANTICONVULSANT ACTION OF PHENYTOIN PHENOBARBITAL, AND ACETAZOLAMIDE BY 6 HYDROXYDOPAMINE 002845 04-03
- THE ACTION OF CNS DRUGS ON AN ISOLATED SYMPATHETIC NERVE PREPARATION OF RABBIT.
- ANTAGONISM OF MORPHINE ACTION ON BRAIN ACETYLCHOLINE RELEASE BY METHYLXANTHINES AND CALCIUM. 002966 04-03

- STUDIES ON THE EFFECT OF LESIONS OF THE VENTRAL NORADRENERGIC TRACT ON THE ANTINOCICEPTIVE ACTION OF MORPHINE.
- 002979 04-03 MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE CORRELATES WITH ANALGESIC ACTION OF MORPHINE.
- ANIMAL MODEL OF DEPRESSION: III. MECHANISM OF ACTION OF
- 003108 04-03 PHARMACOLOGICAL STUDIES OF CENTRAL ACTION OF L 5 HYDROXYTRYPTOPHAN IN INTACT OR TETRABENAZINE PRETRE/ TED
- 003144 04-03 OPPOSITE ACTION OF OXYTOCIN TO VASOPRESSIN IN PASSIVE AVOIDANCE BEHAVIOR IN RATS.
- 003263 04-04 THE CENTRAL ANTISEROTONERGIC ACTION OF MIANSERIN 003281 04-04
- LOCALIZATION OF RECEPTORS FOR THE DIPSOGENIC ACTION OF ANGIOTENSIN-II IN THE SUBFORNICAL ORGAN OF RAT
- 003361 04-04 CENTRAL AND PERIPHERAL ACTION OF TESTOSTERONE-PROPIONATE ON SCENT GLAND MORPHOLOGY AND MARKING BEHAVIOUR IN THE MONGOLIAN GERBIL
- 003370 04-04 INOTROPIC ACTION OF HYDROXYLATED CHLORPROMAZINE METABOLITES AND RELATED COMPOUNDS.
- 003405 04-05 CONTEMPORARY VIEWS ON THE ROLE OF NEUROLEPTICS IN THE TREATMENT OF SCHIZOPHRENIA AND THEIR ACTION IN THE CENTRAL-NERVOUS-SYSTEM
- 003464 04-08 DO ANTICHOLINERGICS ANTAGONIZE ANTIPSYCHOTIC DRUG ACTION?
- 003478 04-08 THE EFFECT OF CHLORPROMAZINE, SOME TRICYCLIC ANTIDEPRESSANTS AND INSULIN ON THE ACTION OF CYCLIC-AMP AND ADENOSINE
- 003606 04-13 ACTIONS PHARMACOLOGICAL ACTIONS OF INTRACEREBRALLY ADMINISTERED
 - POLYAMINES IN MICE. 000033 01-02 STEREOSPECIFIC ACTIONS OF MORPHINE ON SINGLE NEURONES IN THE BRAINSTEM OF THE RAT
 - 000060 01-03 THE ACTIONS OF CHOLINOMIMETICS AND CATECHOLAMINES ON RAT
 - SUBSTANTIA-NIGRA NEURONES 000163 01-03 PHENOBARBITAL ACTIONS IN VIVO: EFFECTS OF EXTRACELLULAR POTASSIUM ACTIVITY AND OXIDATIVE METABOLISM IN CAT
 - CEREBRAL-CORTEX 000176 01-03 ACTIONS OF IONTOPHORETIC PHENYTOIN AND MEDAZEPAM ON
 - HIPPOCAMPAL NEURONS. 000196 01-03 TRANSCALLOSALLY EVOKED-POTENTIALS AND THE EEG IN THE DECEREBRATE DOG: ACTIONS OF TRYPTAMINERGIC, DOPAMINERGIC
 - AND ADRENERGIC AGONISTS 000223 01-03 LACK OF EFFECT OF CHRONIC HALOPERIDOL ADMINISTRATION ON THE
 - PROLACTIN LOWERING ACTIONS OF PIRIBEDIL 000233 01-03
 - ACTIONS OF AMPHETAMINE AND ANTAGONISTS ON PUPIL DIAMETER IN THE CHRONIC SYMPATHECTOMIZED DOG 000265 01-03
 - PRESYNAPTIC AND POSTSYNAPTIC ACTIONS OF APOMORPHINE: DIFFERENTIATION BY ROTARY EFFECTS IN NORMAL RATS 000367 01-04
 - NEURAL MECHANISMS OF BENZODIAZEPINE ACTIONS
 - BRAIN MECHANISMS ASSOCIATED WITH THERAPEUTIC ACTIONS OF BENZODIAZEPINES: FOCUS ON NEUROTRANSMITTERS.
 - ACTIONS OF ATROPINE AND SCOPOLAMINE ON THE ENDPLATE CURRENT OF THE FROG SARTORIUS MUSCLE. (PH.D. DISSERTATION) 001042 02-03 ACTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND ITS
 - DERIVATIVES ON 5 HYDROXYTRYPTAMINE RECEPTORS IN THE 001144 02-03 THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS.
 - 001150 02-03
 - DIFFERING ACTIONS OF AMFONELIC-ACID (AFA) AND AMPHETAMINE (AMPH) ON STRIATAL DOPAMINE (DA). 001196 02-03

003430 04-06

002076 03-03

ANOREXIGENIC	AND	ANCILLARY	ACTIONS	OF	MK-212	(6	CHLORO-2-
PIPERAZINYL	PYRA	ZINE: CPP).					

CLOMIPRAMINE AND MAPROTILINE ON HUMAN PLATELET UPTAKE OF 5 HYDROXYTRYPTAMINE AND DOPAMINE IN VITRO: WHAT RELEVANCE TO THEIR ANTIDEPRESSIVE AND OTHER ACTIONS?

BIOCHEMICAL ACTIONS OF NEUROLEPTIC DRUGS: FOCUS ON THE DCPAMINE RECEPTOR

002738 03-17 MULTIPLE MEMBRANE ACTIONS OF ENKEPHALIN REVEALED USING CULTURED SPINAL NEURONS.

002816 04-03 A COMPARISON OF SOME PHARMACOLOGICAL ACTIONS OF MORPHINE AND DELTA9-TETRAHYDROCANNABINOL IN THE MOUSE. 002834 04-03

PHARMACOLOGICAL DIFFERENTIATION OF THE CENTRAL 5
HYDROXYTRYPTAMINE-LIKE ACTIONS OF MX-212 (6 CHLOR/)-2-1PIPERAZINYL-PYRAZINE), P-METHOXYAMPHETAMINE AND
FENFLURAMINE IN AN IN VIVO MODEL SYSTEM.

002868 04-03 THE ACTIONS OF DIAZEPAM AND PHENYTOIN ON A LOW DOSE PENICILLIN EPILEPTIFORM FOCUS IN THE ANESTHETISED RAT.

5 GUANYLYLIMIDODIPHOSPHATE ACTIONS ON ADENYLATE-CYCLASE IN HOMOGENATES OF RAT CEREBRAL-CORTEX PLUS NEURONAL AND CAPILL AND FOATUGUE CAPILLARY FRACTIONS. 003038 04-03

DEPRESSANT ACTIONS OF METHIONINE-ENKEPHALIN AND SOMATOSTATIN IN CAT DORSAL-HORN NEURONES ACTIVATED BY NOXIOUS STIMULI.

003059 04-03 THE NEUROPHARMACOLOGICAL ACTIONS OF AMOXAPINE.

003235 04-04 BENZAMIDES AND CLASSICAL NEUROLEPTICS: COMPARISON OF THEIR ACTIONS USING 6 APOMORPHINE-INDUCED EFFECTS.

003333 04-04 THE BEHAVIOURAL ACTIONS OF THE HYPOTHALAMIC PEPTIDES: A

003651 04-15

ACTIVATED

EFFECT OF ACTIVATED CHARCOAL ON ABSORPTION OF NORTRIPTYLINE 001763 02-15

THE EFFECT OF GAMMA-ACETYLENIC-GABA, AN ENZYME ACTIVATED IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE, ON DOPAMINE PATHWAYS OF THE EXTRAPYRAMIDAL AND LIMBIC SYSTEMS. 003037 04-03

DEPRESSANT ACTIONS OF METHIONINE-ENKEPHALIN AND SOMATOSTATIN IN CAT DORSAL-HORN NEURONES ACTIVATED BY NOXIOUS STIMULI.

ACTIVATING AND ANESTHETIC EFFECTS OF GENERAL DEPRESSANTS. 002301 03-04

REGULATORY ROLE OF GABA NEURONS ON THE ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE BY HALOPERIDOL. (UNPUBLISHED

000132 01-03 SPECIFIC ACTION OF NARCOTICS ON REFLEX ACTIVATION OF RAT ALPHA-MOTONEURONES.

000174 01-03 TYROSINE-HYDROXYLASE: DELAYED ACTIVATION IN CENTRAL NORADRENERGIC NEURONS AND INDUCTION IN ADRENAL MEDULLA ELICITED BY STIMULATION OF CENTRAL CHOLINERGIC RECEPTORS.

000183 01-03 METABOLIC ACTIVATION OF P-CHLOROAMPHETAMINE TO A CHEMICALLY REACTIVE METABOLITE.

000476 01-05 THE EFFECTS OF HYPOTHALAMIC DEAFFERENTATION ON THE HALOPERIDOL-INDUCED ACTIVATION OF TUBEROINFUNDIBULAR DOPAMINE NEURONS.

ACTIVATION OF TRYPTOPHAN-HYDROXYLASE BY DEPOLARIZATION: ROLE

MONOSYNAPTIC ACTIVATION OF FASCIA-DENTATA IN UNRESTRAINED
RATS: RESPONSE MODIFICATION BY SYNAPTICALLY ACTIVE DRUGS

001214 02-03 LOCOMOTOR STIMULATION BY L-DOPA: RELATIVE IMPORTANCE OF NORADRENALINE RECEPTOR ACTIVATION.

DIFFERENTIAL ACTIVATION BY SOME 2 AMINOTETRALIN DERIVATIVES OF THE RECEPTOR MECHANISMS IN THE NUCLEUS-ACCUMBENS OF RAT WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITING.

001335 02-04 RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION WITH A HIGH FAT/PROTEIN DIET.

ACTIVATION OF TYROSINE-3-MONOOXYGENASE IN PHEOCHROMOCYTOMA CELLS BY LASALOCID.

ACTIVATION OF AN IHHIBITORY NORADRENERGIC PATHWAY PROJECTING FROM THE LOCUS-COERULEUS TO THE CINGULATE CORTEX OF THE RAT. 002895 04-03

SUBSTRATE SELECTIVE ACTIVATION OF RAT LIVER MITOCHONDRIAL MONOAMINE-OXIDASE BY OXYGEN.

002912 04-03 REINFORCING, DISCRIMINATIVE, AND/OR ACTIVATION PROPERTIES OF AMPHETAMINE.

003231 04-04 AN IMPROVED ASSAY OF TYROSINE-HYDROXYLASE USING SODIUM ACTIVATION.

ACTIVATOR
SPECIFICITY OF BINDING OF ANTIPSYCHOTICS TO THE ACTIVATOR OF
CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE.

CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF DOPAMINE DEPENDENT CTRIATAL LEGISLATION OF THE CONTROL OF DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF C-AMP-PHOSPHODIESTERASE.

002023 03-03 BINDING OF ANTIPSYCHOTIC AGENTS TO THE CYCLIC-NUCLEOTIDE ACTIVATOR.

ACTIVE QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS OF BIOLOGICALLY ACTIVE INDOLE, I METHYLINDOLE AND BENZO-B-THIOPHENE DERIVATIVES.

LEVELS OF CHLORPROMAZINE AND ITS ACTIVE MATABOLITES IN RAT BRAIN AND THE RELATIONSHIP TO CENTRAL MONOAMINE METABOLISM AND PROLACTIN SECRETION.

000041 01-03 CENTRALLY ACTIVE DRUGS AND THE SYMPATHETIC NERVOUS SYSTEM OF RABBITS AND CATS.

000078 01-03 TYRAMINE BINDING BY SYNAPTOSOMES FROM RAT BRAIN: EFFECT OF

CENTRALLY ACTIVE DRUGS. 000285 01-03 DISTRIBUTION OF CLOZAPINE IN THE RAT: EVIDENCE FOR ACTIVE

TRANSPORT IN LUNG 001129 02-03 MONOSYNAPTIC ACTIVATION OF FASCIA-DENTATA IN UNRESTRAINED RATS: RESPONSE MODIFICATION BY SYNAPTICALLY ACTIVE DRUGS

001214 02-03 FURTHER OBSERVATION ON THE LACK OF ACTIVE UPTAKE SYSTEM FOR SUBSTANCE-P IN THE CENTRAL-NERVOUS-SYSTEM.

001238 02-03 EFFECT OF SOME CENTRALLY ACTIVE COMPOUNDS ON AGGRESSIVE

BEHAVIOUR IN SEPTAL RATS. 001376 02-04 METHYLPHENIDATE, AMYGDALECTOMY AND ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.

001500 02-04 THE ROLE OF CHARCOAL HEMOPERFUSION IN THE ACTIVE MANAGEMENT

OF POISONING 001842 02-15 BEHAVIORAL AND BIOCHEMICAL EFFECTS OF FK33-824, A
PARENTERALLY AND ORALLY ACTIVE ENKEPHALIN ANALOGUE
(UNPUBLISHED PAPER).

002744 03-17

SQUIRREL-MONKEY ACTIVE CONFLICT TEST. 002795 04-02

ACTIVE UPTAKE OF H3-5-HT BY SYNAPTIC VESICLES FROM RAT BRAIN. 002937 04-03

ACTIVITIES EFFECTS OF 3,4 DIHYDROOXAZINOINDOLES, POTENTIAL ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED ACTIVITIES.

3,4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3 AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND ANTICONVULSANT ACTIVITIES.

ON THE HYPNOGENIC AND ANTICONVULSANT ACTIVITIES OF DEMETHYLDIAZEPAM AND CHLORDEMETHYLDIAZEPAM: TIME EFFELT

000462 01-04 INTRAOCULAR PRESSURE LOWERING PROPERTIES OF ABBOTT-43981, A CANNABINOID DERIVED HETEROCYCLIC BENZOPYRAN WITH MINIMAL CNS ACTIVITIES.

001025 02-02 CATECHOLAMINE SENSITIVE ATPASE ACTIVITIES IN BRAIN SYNAPTOSOMES OF MORPHINIZED MICE.

001096 02-03

002278 03-04

SUPPRESSION OF CAUDATE NEURON ACTIVITIES BY MORPHINE AND THE INVOLVEMENT OF DOPAMINERGIC NEUROTRANSMISSION.

ALTERATIONS OF EEG ACTIVITIES AND COCAINE-INDUCED CONVULSIONS FOLLOWING PROLONGED COCAINE TREATMENT IN THE RHESUS MONKEY.

DRUGS AFFECTING THE CENTRAL-NERVOUS-SYSTEM: EFFECTS OF PEMOLINE, AND TRICYCLIC ANTIDEPRESSANTS ON NERVE TERMINAL ADENOSINE-TRIPHOSPHATASE ACTIVITIES AND NEUROTRANSMITTER RELEASE.

MAGNIFICATION OF SOME ENZYMATIC ACTIVITIES OF BRAIN-CORTEX
SUBER ACTIONS

EFFECTS OF SPIPERONE ON SELF-STIMULATION AND OTHER ACTIVITIES OF THE MONGOLIAN GERBIL.

003222 04-04
COMPARATIVE EFFECTS OF COCAINE AND PSEUDOCOCAINE ON EEG
ACTIVITIES, CARDIORESPIRATORY FUNCTIONS, AND SELFADMINISTRATION BEHAVIOR IN THE RHESUS MONKEY.

003292 04-04

POTENT PROLACTIN AND GROWTH HORMONE RELEASING ACTIVITY OF MORE ANALOGUES OF MET-ENKEPHALIN.

DOPAMINE RECEPTOR BLOCKING ACTIVITY OF THE SULPIRIDE IN THE CENTRAL-NERVOUS-SYSTEM. 000024 01-02

EVALUATION OF NALOXONE IN LABORATORY TESTS PREDICTIVE OF CLINICAL ANTIPSYCHOTIC ACTIVITY.

N ACETYLTRANSFERASE ACTIVITY IN PINEAL GLAND OF RATS TREATED WITH PARGYLINE. 000046 01-03

PHASIC ACTIVITY IN THE RAT. 000070 01-03

ACUTE AND CHRONIC EFFECTS OF TETRAHYDROCANNABINOLS ON MONOAMINE-OXIDASE ACTIVITY: POSSIBLE VEHICLE/TETRAHYDROCANNABINOL INTERACTIONS.

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES:
MESCALINE-DEMETHYLASE ACTIVITY OF BRAIN-CORTEX SOLUBLE

SUPERNATANT.

000090 01-03

KINETICS OF CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN

MOUSE BRAIN SYNAPTOSOMES.

O00093 01-03

EVALUATION OF RADIORESPIROMETRY FOR THE DETERMINATION OF MONOAMINE-OXIDASE ACTIVITY IN VIVO UTILIZING C11-OCTYLAMINE AS A SUBSTRATE.

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE.

000127 01-03

EFFECT OF CANNABINOIDS ON NEUROTRANSMITTER UPTAKE, ATPASE
ACTIVITY AND MORPHOLOGY OF MOUSE BRAIN SYNAPTOSOMES.
000143 01-03

BENZODIAZEPINE ACTIVITY: IS INTERACTION WITH THE GLYCINE RECEPTOR, AS EVIDENCED BY DISPLACEMENT OF STRYCHNINE BINDING, A USEFUL CRITERION?.

000151 01-03

EFFECTS OF MORPHINE AND HALOPERIDOL ON THE ELECTRICAL ACTIVITY
OF RAT NIGROSTRIATAL NEURONS.

000154 01-03

EFFECTS OF OROTIC-ACID AND PIRAZETAM ON CORTICAL BIOELECTRICAL
ACTIVITY IN RABBITS.

O00171 01-03
PHENOBARBITAL ACTIONS IN VIVO: EFFECTS OF EXTRACELLULAR
POTASSIUM ACTIVITY AND OXIDATIVE METABOLISM IN CAT
CEREBRAL-CORTEX.

DRUG-INDUCED CHANGES IN BRAIN TYROSINE-HYDROXYLASE ACTIVITY IN VIVO.

O00181 01-03
ANTICONVULSANT ACTIVITY OF PHENOBARBITAL AND PHENYTOIN IN
COMBINATION.

000182 01-03
PERLAPINE: RELATIONSHIP BETWEEN STIMULATION OF PROLACTIN
SECRETION AND ANTIPSYCHOTIC ACTIVITY.

ACTIVITY OF VESTIBULO-OCULOMOTOR NEURONES DURING SACCADIC
FYF MOVEMENTS INDICED BY RESERVINE

THE SYMPATHOMIMETIC ACTIVITY OF FENFLURAMINE HYDROCHLORIDE ON RAT VAS-DEFERENS.

MODULATION OF BRAIN TRYPTOPHAN-HYDROXYLASE ACTIVITY BY BRAIN TRYPTOPHAN CONTENT.

A MORPHINE-LIKE FACTOR IN MAMMALIAN BRAIN: ANALGESIC ACTIVITY IN RATS.

MAO ACTIVITY IN RAT BRAINSTEM AND CEREBRAL-CORTEX FOLLOWING ACUTE AND CHRONIC TREATMENT WITH L-DOPA AND ETHANOL L-DOPA.

EFFECT OF ALTERATION OF METABOLISM ON THE ANALGESIC ACTIVITY, TOXICITY, DISTRIBUTION AND EXCRETION OF L-ALPHA-ACETYLMETHADOL IN THE RAT.

O00245 01-03

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON
PENTOBARBITAL-INDUCED DECREASE IN CHOLINERGIC NEURONAL

THE INFLUENCE OF CAFFEINE AND THEOBROMINE ON LOCOMOTIVE ACTIVITY AND THE BRAIN C-GMP/C-AMP RATIO IN WHITE MICE. 000275 01-03

EQUAL SUPPRESSION OF CEREBELLAR PURKINJE CELL ACTIVITY BY
AMPHETAMINE STEREOISOMERS.

TIME-DEPENDENT CHANGES IN ACTIVITY, REACTIVITY, AND
RESPONSIVITY DURING SHOCK: EFFECTS OF CHOLINERGIC AND
CATECHOLAMINERGIC MANIPULATIONS.

COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMOTOR ACTIVITY,
ANALGESIA AND PRIMARY AND PROTRACTED PHYSICAL DEPENDENCE
IN SIX MOUSE STEALINS

000323 01-04
EFFECT OF APOMORPHINE ON THE ANTINOCICEPTIVE ACTIVITY OF
MORPHINE.

RAISED BRAIN GABA LEVELS, MOTOR ACTIVITY AND EXPLORATION IN THE RAT.

O00358 01-04
PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, BRAIN
SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION INTO BRAIN
PROTEINS OF DIFFERENT MOUSE STRAINS.

A COMPARATIVE STUDY OF DIFFERENT AMPHETAMINES ON COPULATORY BEHAVIOR AND STEREOTYPE ACTIVITY IN THE FEMALE

O00412 01-04
ACTH-INDUCED EXCESSIVE GROOMING IN THE RAT: LATENT ACTIVITY OF
ACTH-4-10.

ACTH4-10.

O00472 01-04

PHARMACOLOGIC ACTIVITY OF BETA-ENDORPHIN IN MAN.

000507 01-07
SULPIRIES: EVALUATION OF ANTIPSYCHOTIC ACTIVITY IN SCHIZOPHRENIC

A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY ON ANTIEPILEPTIC
ACTIVITY OF CLONAZEPAM — RELATIONSHIP BETWEEN CLINICAL
EFFECTS OF ORAL ADMINISTRATION AND ELECTROENCEPHALOGRAPHIC
EFFECTS OF INTRAVENOUS ADMINISTRATION

CENTRAL-NERVOUS-SYSTEM ACTIVITY OF A NOVEL CLASS OF ANNELATED 1, 4 BENZODIAZEPINES, AMINOMETHYLENE-IMIDAZOBENZODIAZEPINONES.

SYNTHESIS AND PRELIMINARY PHARMACOLOGICAL ACTIVITY OF
AMINOALKOXY ISOSTERES OF GLYCOLATE ESTER ANTICHOLINERGICS.
001026 02-02
ANIMAL PROLACTIN EVIDENCE FOR ANTIPSYCHOTIC ACTIVITY OF

PIPEROXANE. 001027 02-02

CEREBELLAR UNIT ACTIVITY DURING GENERALIZED PENICILLIN EPILEPSY
IN THE AWAKE CAT. 001028 02-02

CANNABINOIDS. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY
OF 8 SUBSTITUTED HYDROXY-DIMETHYLBENZOPYRANOPYRIDINE AND
DERIVATIVES.

A SYNTHETIC ENKEPHALIN ANALOGUE WITH PROLONGED PARENTERAL AND ORAL ANALGESIC ACTIVITY.

O01036 02-02

A PHARMACOLOGICAL STUDY OF THE SPONTANEOUS CONVULSIVE
ACTIVITY INDUCED BY 1,2 DIHYDROXYBENZENE (CATECHOL) IN THE
ANESTHETIZED MOUSE.

001046 02-03
ELECTROPHYSIOLOGICAL EVIDENCE FOR A DOPAMINERGIC ACTION OF
LSD: DEPRESSION OF UNIT ACTIVITY IN THE SUBSTANTIA-NIGRA OF
THE RAT

USERGIC-ACID-DIETHYLAMIDE. PHOTOELECTRON IONIZATION
POTENTIALS AS INDICES OF BEHAVIORAL ACTIVITY.

001100 02-03

EFFECTS OF DISULFIRAM ON PHARMACOLOGICAL ACTIVITY, TOXICITY AND FATE OF MORPHINE IN RATS.

001111 02-03 EFFECTS OF REPEATED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS ON ADIPOSE TISSUE LIPOLYTIC ACTIVITY IN THE RAT. 001179 02-03

ALTERATIONS IN BRAIN HISTAMINE AND HISTIDINE-DECARBOXYLASE ACTIVITY AFTER HALOPERIDOL AND IMIPRAMINE.

001188 02-03 THE EFFECTS OF METHAQUALONE ON PITUITARY ADRENOCORTICAL ACTIVITY IN MICE.

001194 02-03 ELECTROSHOCK ANTICONVULSANT ACTIVITY AND BRAIN ACETYLCHOLINE ALTERATIONS IN MICE TREATED WITH SELECT BENZODIAZEPINES.

001210 02-03 REGIONAL EFFECTS OF NEUROLEPTICS ON DOPAMINE METABOLISM AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE ACTIVITY.

001237 02-03 NONPARTICIPATION OF CHOLINERGIC MECHANISM IN CHEMICAL CONTROL OF CEREBRAL VASOMOTOR ACTIVITY.

001243 02-03 THE EFFECT OF DIHYDROERGOTOXINE ON THE ADENYLATE-CYCLASE ACTIVITY IN HOMOGENATES OF RAT CEREBRAL-CORTEX. 001254 02-03

LACK OF TOLERANCE TO THE DEPRESSION OF RAPHE UNIT ACTIVITY BY LYSERGIC-ACID-DIETHYLAMIDE.

EFFECTS OF BENZODIAZEPINES ON PGO FIRINGS AND MULTIPLE UNIT ACTIVITY IN THE MIDBRAIN RETICULAR FORMATION IN CATS.

001265 02-03 URINARY 3 METHOXY-4-HYDROXYPHENYLGLYCOL, AN INDEX 07 PERIPHERAL RATHER THAN CENTRAL ADRENERGIC ACTIVITY IN THE

001277 02-03

EFFECTS OF LERGOTRILE (LER), AN ERGOT DERIVATIVE, ON ACTIVITY OF
SUBSTANTIA-NIGRA PARS COMPACTA DOPAMINE (DA) NEURONS. 001278 02-03

COCAINE AND METABOLITES: RELATIONSHIP BETWEEN
PHARMACOLOGICAL ACTIVITY AND INHIBITORY ACTION ON
DOPAMINE UPTAKE INTO STRIATAL SYNAPTOSOMES.

001286 02-03 THE EFFECT OF SUBCHRONIC ADMINISTRATION OF LITHIUM-CARBONATE ON THE PHARMACOLOGICAL ACTIVITY OF D AMPHETAMINE.

001295 02-04 WET-DOG SNAKE BEHAVIOUR IN THE RAT: A POSSIBLE QUANTITATIVE MODEL OF CENTRAL 5 HYDROXYTRYPTAMINE ACTIVITY.

THE INFLUENCE OF ELECTRICAL STIMULATION ON THE HIPPOCAMPAL UNITS ACTIVITY OF THE RABBIT.

001314 02-04 CONTROL OF THE RAT OLFACTORY BULB ACTIVITY INDUCED BY BIOLOGICALLY SIGNIFICANT ODORS.

001324 02-04 DYNAMICS OF BLOOD NEUROTRANSMITTER LEVEL AS EVIDENCE OF HIGHER NERVOUS ACTIVITY CHANGES DURING CHRONIC ADMINISTRATION OF SEDUXEN.

001338 02-04 THE EFFECT OF BROMOCRIPTINE ON LOCOMOTOR ACTIVITY AND CEREBRAL CATECHOLAMINES IN RODENTS.

EFFECT OF D AMPHETAMINE ON LOCOMOTOR ACTIVITY OF LEAD FED

ANTIEMETIC ACTIVITY OF NABILONE, A CANNABINOL DERIVATIVE, REVERSED BY NALOXONE IN AWAKE CATS.

AN ATTEMPT TO PREDICT THE DURATION OF PENTOBARBITAL NARCOSIS ON THE BASIS OF EXPLORATORY ACTIVITY, DEFECATION RATE AND BODY WEIGHT OF RATS.

001435 02-04 EFFECTS OF METHYLPHENIDATE (M) ON ACTIVITY OF WHIRLER MICE

001450 02-04 BIPHASIC EFFECTS OF APOMORPHINE ON LOCOMOTOR ACTIVITY IN

EFFECTS OF IFC-45, A NEW BENZONAPHTYRIDONE DERIVATIVE WITH ANTIDEPRESSIVE ACTION, ON ACTIVITY OF THE RAT SUPRARENAL GLAND CORTEX.

MEASUREMENTS OF WEIGHT AND ACTIVITY IN MALE MICE FOLLOWING INHALATION OF CANNABIS SMOKE IN A CONTROLLED SMOKE EXPOSURE CHAMBER.

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION
DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND
QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY. 001535 02-06 **Psychopharmacology Abstracts**

DIFFERENTIATION OF HYPNOTIC ACTION OF NITRAZEPAM AND ESTAZOLAM AND EFFECTS ON BEHAVIOR AND CORTICAL ACTIVITY 001549 02-07

PLATELET MONOAMINE-OXIDASE ACTIVITY PREDICTS RESPONSE TO LITHIUM IN MANIC-DEPRESSIVE ILLNESS.

001607 02-09 EFFECTS OF DIAZEPAM ON UTERINE ACTIVITY DURING LABOR

001627 02-11 THE EFFECTS OF METHYLPHENIDATE ON VARIOUS TYPES OF ACTIVITY LEVEL AND ATTENTION IN HYPERKINETIC CHILDREN.

SYNTHESIS AND COMPARATIVE SKELETAL MUSCLE RELAXANT ACTIVITY OF SOME 2.4 IMIDAZOLIDINEDIONES AND THEIR CORRESPONDING 5 HYDROXYIMIDAZOLIDINEDIONES.

001944 03-01 SYNTHESIS AND STEREOSPECIFIC ANTIPSYCHOTIC ACTIVITY OF BENZOCYCLOHEPTENE-PIRIDINE.

EFFECT OF DIAZEPAM ON PULSE ACTIVITY OF NEURONS OF THE SENSORIMOTOR AND OPTIC AREAS OF THE RAT CEREBRAL-CORTEX

001978 03-03 EFFECTS OF MEDIAL RAPHE AND RAPHE MAGNUS LESIONS ON THE ANALGESIC ACTIVITY OF MORPHINE AND METHADONE.

001986 03-03 EFFECTS OF BENZYDAMINE ON THE BIOELECTRIC ACTIVITY OF THE RABBIT

001998 03-03

EFFECTS OF MORPHINE ON ELECTRICAL ACTIVITY OF SINGLE MYENTERIC NEURONS IN CAT SMALL BOWEL. 002009 03-03

DIHYDROERGOTOXINE-INDUCED MODULATION OF SPONTANEOUS ACTIVITY OF CULTURED RAT PURKINJE CELLS.

002020 03-03 THE EFFECTS OF LITHIUM ON ATPASE ACTIVITY IN SUBCELLULAR FRACTIONS FROM RAT BRAIN.

002038 03-03 EFFECT OF MORPHINE ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE ACTIVITY OR NUCLEUS-ACCUMBENS.

002048 03-03 THE ACUTE EFFECTS OF AMPHETAMINE, CHLORPROMAZINE,
AMITRIPTYLINE AND LITHIUM ON ADENOSINE-5-TRIPHOSPHATASE
ACTIVITY IN THE CORTEX OF THE RAT BRAIN.

NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: I. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY.

002096 03-03 COMPARISON OF THE EFFECTS OF METHAMPHETAMINE AND NEUROLEPTIC AGENTS ON TYROSINE-HYDROXYLASE ACTIVITY IN THE NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM.

002102 03-03 THE EFFECT OF SEROTONIN PRECURSORS ON ALPHA-MOTONEURON AND GAMMA-MOTONEURON ACTIVITY.

002107 03-03 DOPAMINE-MIMETIC ACTIVITY OF ERGOT DERIVATIVES, AS MEASURE BY THE PRODUCTION OF CYCLIC-AMP IN ISOLATED RETINAE OF THE AS MEASURED

002149 03-03

THE EFFECTS OF SP-111, A WATER-SOLUBLE THE DERIVATIVE, ON NEURONAL ACTIVITY IN THE RAT BRAIN.

002150 03-03 THE EFFECT OF AMIZYL AND ARECOLINE ON THE ACTIVITY OF NA-K-ATPASE AND THE CONTENT OF NA AND K IN RAT BRAIN.

002151 03-03 CHANGES IN MOUSE BRAIN CATECHOLAMINE CONTENT AND TYROSINE-HYDROXYLASE ACTIVITY DURING CHRONIC AMPHETAMINE ADMINISTRATION.

BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC/
ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH
NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA.

002220 03-04 EFFECTS OF NOMIFENSINE (HOE-984) UPON PSYCHOMOTOR ACTIVITY AND INTRACRANIAL SELF-STIMULATION IN THE RAT.

002256 03-04 ANALGESIC ACTIVITY OF ENKEPHALINS FOLLOWING INTRACEREBRAL ADMINISTRATION IN THE RAT.

002275 03-04 AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY AND STEREOTYPY AFTER KAINIC-ACID LESIONS OF THE STRIATUM.

002279 03-04 THE EFFECTS OF PROLONGED HANDLING, SCOPOLAMINE, AND PHYSOSTIGMINE ON THE ACTIVITY OF ISOLATED AND SOCIALLY REARED RATS

002285 03-04 THE EFFECT OF D AMPHETAMINE ON GAMMA EFFERENT ACTIVITY IN THE ACUTE DECEREBRATE RAT.

DECREASED LOCOMOTOR ACTIVITY AND ATTENUATION OF AMPHETAMINE HYPERACTIVITY WITH INTRAVENTRICULAR INFUSION OF SEROTONIN IN THE RAT.

EFFECT OF MATERNALLY ADMINISTERED HEROIN ON THE MOTOR ACTIVITY OF RAT OFFSPRING.

THE STUDY OF THE MUTAGENIC ACTIVITY OF LUMINAL AND PYRAZIDAL. 002353 03-05

RELIABILITY OF TWO ACTIVITY BOXES COMMONLY USED TO ASSESS DRUG-INDUCED BEHAVIOURAL CHANGES.

002368 03-06

EFFECT OF AN ANTIPSYCHOTIC AND OTHER CLASSES OF DRUGS ON SPONTANEOUS LOCOMOTOR ACTIVITY AND NEUROTOXICITY IN MICE. 002369 03-06

ANIMAL TEST MODELS FOR PREDICTION OF CLINICAL ANTIDEPRESSANT ACTIVITY.

SINGLE-BLIND EVALUATION OF HYPNOTIC ACTIVITY OF CHLORDESMETHYLDIAZEPAM IN NO-PLACEBO REACTOR MEDICAL PATIENTS.

ON THE ACUTE EFFECT OF SOME DRUGS ON HIGHER NERVOUS ACTIVITY IN MAN FOLLOWED UP BY THE LABORATORY LANGUAGE METHOD.

SYNTHESIS OF TWO ENZYME RESISTANT ENKEPHALIN ANALOGS
POSSESSING ENHANCED ANALGESIC ACTIVITY.

002787 04-01
STIMULATION OF ADENYLATE-CYCLASE ACTIVITY IN MONKEY ANTERIOR
LIMBIC CORTEX BY SEROTONIN.

002805 04-03

EFFECT OF MORPHINE INJECTED IN PERIAQUEDUCTAL GRAY ON THE
ACTIVITY OF SINGLE UNITS IN NUCLEUS RAPHE MAGNUS OF THE RAT.
002817 04-03

POTENTIATION BY NEUROLEPTIC AGENTS OF THE INHIBITORY ACTION OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE.

MONOAMINE-OXIDASE ACTIVITY OF MACROPHAGES AT REST AND DURING PHAGOCYTOSIS.

002902 04-03
INFLUENCE OF LITHIUM ON DOPAMINE STIMULATED ADENYLATE-CYCLASE
ACTIVITY IN RAT BRAIN.

002922 04-03

EFFECTS OF NEUROLEPTICS ON H3-HALOPERIDOL AND H3-CISFLUPENTHIXOL BINDING AND ON ADENYLATE-CYCLASE ACTIVITY IN
VITRO

A COMPARATIVE STUDY ON THE PRESYNAPTIC AND POSTSYNAPTIC ALPHA BLOCKING ACTIVITY OF A SERIES OF BENZODIOXANES.
002972 04-03

BIOLOGICAL ACTIVITY OF NEUROTENSIN AND ITS C-TERMINAL PARTIAL SEQUENCES.

002973 04-03
AROMATIC AMINOTRANSFERASE ACTIVITY OF RAT BRAIN CYTOPLASMIC
AND MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE

002978 04-03

MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID
AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE
ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE
CORRELATES WITH ANALGESIC ACTION OF MORPHINE.

002984 04-03
EFFECTS OF URETHANE ON HIPPOCAMPAL UNIT ACTIVITY IN THE RAT.
003011 04-03

CLEARANCE AND ANALGESIC ACTIVITY OF THE QUATERNIZED OPIATE, N METHYLMORPHINE (6-H3) ADMINISTERED INTRACISTERNALLY TO THE RAT.

003019 04-03

EFFECTS OF PAIN ATTENUATING BRAIN STIMULATION AND MORPHINE ON
ELECTRICAL ACTIVITY IN THE RAPHE NUCLEI OF THE AWAKE RAT.
003034 04-03

SEIZURE SUSCEPTIBILITY AND ANTICONVULSANT ACTIVITY OF CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES. 003055 04-03

THE DECREASE OF MONOAMINE-OXIDASE ACTIVITY FOLLOWING THE INTRAOCULAR INJECTION OF COLCHICINE IN THE SUPERIOR COLLICULUS OF THE RAT.

003120 04-03

EFFECT OF RESERPINE ON THE MONOAMINE-OXIDASE (MAO) ACTIVITY IN RAT LIVER AND BRAIN.

003125 04-03

EFFECT OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE.

NARCOTIC CUING AND ANALGESIC ACTIVITY OF NARCOTIC ANALGESICS:
ASSOCIATIVE AND DISSOCIATIVE CHARACTERISTICS.
003192 04-04

ACTIVITY ANALYSIS OF OPERANT BEHAVIOR FOLLOWING METHYLPHENIDATE ADMINISTRATION.

ANALGESIA AND MOTOR ACTIVITY ELICITED BY MORPHINE AND ENKEPHALINS IN TWO INBRED STRAINS OF MICE.

003225 04-04
INFLUENCE OF CATECHOLAMINES ON DEXAMPHETAMINE-INDUCED
CHANGES IN LOCOMOTOR ACTIVITY.

003239 04-04
THE EFFECTS OF D ALA2-METS-ENKEPHALINAMIDE ON BEHAVIORAL
ACTIVITY AND CYCLIC-NUCLEOTIDES IN THE RAT BRAIN. (PH.D.
DISSERTATION)

SUPPRESSION OF LOCOMOTOR ACTIVITY IN SPARROWS BY TREATMENT WITH MELATONIN.

DIURNAL VARIATIONS IN THE MOTOR ACTIVITY OF THE RAT: EFFECTS OF INHIBITORS OF THE CATECHOLAMINE SYNTHESIS.

003274 04-04
INCREASED TILT-CAGE ACTIVITY AFTER SEROTONIN DEPLETION BY 5,7
DIHYDROXYTRYPTAMINE.

P-CHLOROPHENYLALANINE PRODUCES DISSOCIATED EFFECTS ON AGGRESSION EMOTIONALITY AND MOTOR ACTIVITY.

O03293 04-04

ANATOMICAL SPECIFICITY WITHIN RAT STRIATUM FOR THE

DOPAMINERGIC MODULATION OF DRL RESPONDING AND ACTIVITY.

003316 04-04

THE RELATIONSHIP BETWEEN PIPRADROL-INDUCED RESPONDING FOR ELECTRICAL BRAIN STIMULATION, STEREOTYPED BEHAVIOUR AND LOCOMOTOR ACTIVITY.

003347 04-04

FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON LOCOMOTOR ACTIVITY
AND AVOIDANCE BEHAVIOUR OF RESERPINIZED MICE.

003351 04-04
EFFECTS OF SODIUM PHENOBARBITAL ON BRAIN STIMULATION
BEHAVIOR, BEHAVIORAL SEIZURES, AND EEG SEIZURE ACTIVITY.

CHANGES IN LOCOMOTOR ACTIVITY AND NALOXONE-INDUCED JUMPING IN MICE PRODUCED BY WIN-35197-2 (ETHYLKETAZOCINE) AND

MOTOR ACTIVITY OF RATS FOLLOWING INTRACEREBRAL INJECTIONS OF

DIRECT EXTRACTION RADIOASSAY FOR CATECHOL-O-METHYL-

TRANSFERASE ACTIVITY.

003425 04-06
CONTRIBUTION OF THE USE OF 1035MD IN A PSYCHIATRIC WARD FOR ADULTS, ITS ACTIVITY ON THE DIRECT AND SIDE-EFFECTS OF

CONTRIBUTION OF THE USE OF 1035MD IN A PSYCHIATRIC WARD FOR ADULTS, ITS ACTIVITY ON THE DIRECT AND SIDE-EFFECTS OF NEUROLEPTICS.

003446 04-07

ANTICHOLINERGIC ACTIVITY OF THE TRICYCLIC ANTIDEPRESSANTS
DESIPRAMINE AND DOXEPIN IN NONDEPRESSED VOLUNTEERS.
003447 04-07

ANTICHOLINERGIC ACTIVITY OF TWO TRICYCLIC ANTIDEPRESSANTS.
003483 04-09
PERIPHERAL ALPHA-ADRENORECEPTOR AND CENTRAL DOPAMINE
RECEPTOR ACTIVITY IN DEPRESSIVE PATIENTS.

ANTIDEPRESSANT ACTIVITY AND PHARMACOLOGICAL INTERACTIONS OF

003493 04-09
STABILITY OF LOW BLOOD PLATELET MONOAMINE-OXIDASE ACTIVITY IN HUMAN ALCOHOLICS.

003577 C4-11
THE ANALGESIC ACTIVITY OF HUMAN BETA-ENDORPHIN IN MAN.
003598 04-13
HYPNOTIC ACTIVITY OF DIPHENHYDRAMINE, METHAPYRILENE, AND

PLACEBO. 003638 04-14

SOME PHARMACOLOGICAL OBERVATIONS ON THE ANALGESIA INDUCED BY ACUPUNCTURE IN RABBITS.

001190.02-03

ACUTE

ACUTE AND CHRONIC EFFECTS OF TETRAHYDROCANNABINOLS ON MONOAMINE-OXIDASE ACTIVITY: POSSIBLE VEHICLE/
TETRAHYDROCANNABINOL INTERACTIONS.

DOPAMINERGIC MECHANISMS INVOLVED IN THE ACUTE AND CHRONIC
FFFFCT OF AMPHETAMINE

MAO ACTIVITY IN RAT BRAINSTEM AND CEREBRAL-CORTEX FOLLOWING ACUTE AND CHRONIC TREATMENT WITH L-DOPA AND ETHANOL L-

000239 01-03

EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON SEROTONIN
UPTAKE INTO RAT HYPOTHALAMIC SYNAPTOSOMES.

ACUTE DYSTONIA AS AN IDIOSYNCRATIC RESPONSE TO NEUROLEPTICS IN

000409 01-04

EVIDENCE FOR INCREASED APOMORPHINE SENSITIVE DOPAMINERGIC EFFECTS AFTER ACUTE TREATMENT WITH MORPHINE. THE EFFECTS OF HALOPERIDOL, CHLORPROMAZINE AND PROPRANOLOL ON ACUTE AMPHETAMINE POISONING IN THE CONSCIOUS DOG. 000480 01-05 CLOZAPINE (LEPONEX) VS CHLORPROMAZINE (LARGACTIL) IN ACUTE SCHIZOPHRENIA (A DOUBLE-BLIND CONTROLLED STUDY). 000527 01-08 A CASE OF ACUTE GASTRIC DILATATION IN ANOREXIA-NERVOS 000602 01-10 CONCOMITANT ADMINISTRATION OF HALOPERIDOL AND LITHIUM CARBONATE IN ACUTE MANIA. O00638 01-11 SCHIZOPHRENICS AND CONTROLS. 000698 01-13 PLASMA L-ALPHA-ACETYLMETHADOL (LAAM) AFTER ACUTE AND CHRONIC ADMINISTRATION. 000704 01-13 PSYCHOPHYSIOLOGICAL EFFECTS OF ACUTE CANNABIS INHALATION 000711 01-13 CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND ITS METABOLITES AND CLINICAL RATINGS IN PATIENTS WITH ACUTE RELAPSE OF SCHIZOPHRENIC AND PARANOID PSYCHOSIS. ACUTE VERSUS CHRONIC EFFECTS OF MONOAMINE-OXIDASE INHIBITORS IN DEPRESSED PATIENTS: TIME-COURSE OF MAO INHIBITORS. 0007:33 01-13 ACUTE EEG EFFECTS OF CANNABIS PREPARATIONS IN LONG-TERM
HASHISH LISERS ACUTE EFFECTS OF CANNABIS ON COGNITIVE, PERCEPTUAL, AND MOTOR PERFORMANCE IN CHRONIC HASHISH USERS. 000759 01-14 ACUTE ORGANIC-BRAIN-SYNDROME ASSOCIATED WITH GENTAMICIN 000808 01-15 PHENCYCLIDINE HYDROCHLORIDE: PHARMACOLOGIC ACUTE AND CHRONIC EFFECTS 000814 01-15 PROTEIN DIET ACUTE POISONING WITH MAPROTILINE HYDROCHLORIDE. 000881 01-15 ACUTE HYPOKALEMIC MYOPATHY IN ALCOHOLISM: A CLI 000888 01-15 METHODS OF ACUTE INHALATION EXPERIMENTS CHANGES IN LIVER FUNCTION IN ACUTE POISONING BY BARBITURATE, RESERPINE AND AMPHETAMINE. 001094 02-03 EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON SYNAPTOSOMAL CA UPTAKE. 001138 02-03 EFFECTS OF ACUTE AND CHRONIC MORPHINE AND NARCOTIC ANTAGONISTS ON BRAIN ENERGY METABOLISM 001163 02-03 THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE NOREPINEPHRINE TURNOVER IN RAT BRAIN REGIONS. THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS ON MHPG-SO4 IN RAT BRAIN. 001228 02-03 EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION: AMPHETAMINE LEVELS AND EFFECTS UPON SOME ARYLALKYLAMINES IN RAT BRAIN. ACETYLCHOLINE TURNOVER IN THE RAT 001339 02-04 ACUTE AND CHRONIC EFFECTS OF GENERAL CNS DEPRESSANTS ON SEVERAL BEHAVIORAL TESTS IN RATS. CHRONIC AND ACUTE EFFECTS OF BARBITAL AND AMPHETAMINE IN DOPAMINE DEPLETED RATS. 001389 02-04 FEEDING AND DRINKING INTERACTIONS AFTER ACUTE BUTYROPHENONE 001446 02-04 PHENOBARBITAL IN THE ACUTE MANAGEMENT OF FEBRILE CONVILL SIONS 001555 02-07 URINARY CYCLIC-AMP EXCRETION BY METHADONE SUBJECTS DURING GRADUAL AND ACUTE WITHDRAWAL. 001654 02-13 MODIFICATION OF SLEEP INDUCED IN ACUTE AND CHRONIC ADMINISTRATION OF LITHIUM. 001699 02-14 LOXAPINE VERSUS HALOPERIDOL PARENTERALLY IN ACUTE PSYCHOSIS WITH AGITATION: A DOUBLE-BLIND STUDY.

Psychopharmacology Abstracts

THE ACUTE EFFECTS OF AMPHETAMINE, CHLORPROMAZINE, AMITRIPTYLINE AND LITHIUM ON ADENOSINE-5-TRIPHOSPHATASE ACTIVITY IN THE CORTEX OF THE RAT BRAIN. 002094 03-03

TRYPTOPHAN AND 5 HYDROXYINDOLES IN DIFFERENT CNS REGIONS FOLLOWING ACUTE MORPHINE.

002097 03-03 EFFECT OF AGE ON ACUTE MORPHINE RESPONSE IN THE RAT 002159 03-03

METABOLISM OF 5 HYDROXYTRYPTAMINE AND LEVELS OF TRICYCLIC
ANTIDERESSANT DRUGS IN RAT BRAIN AFTER ACUTE AND CHRONIC
TREATMENT.

THE EFFECTS OF ACUTE AND CHRONIC PHENCYCLIDINE ON SCHEDULE-CONTROLLED BEHAVIOR IN THE SQUIRREL-MONKEY.

RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDROXYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN
ACUTE AND CHRONIC SPINAL RATS.

002289 03-04 THE EFFECT OF D AMPHETAMINE ON GAMMA EFFERENT ACTIVITY IN THE ACUTE DECEREBRATE RAT. 002311 03-04

PARENTERAL LOXAPINE IN ACUTE SCHIZOPHRENIA.

002404 03-08 EFFICACY OF LOXAPINE HYDROCHLORIDE INTRAMUSCULAR (LOXITANE-IM) IN ACUTE SCHIZOPHRENIA.

002410 03-08 ALUATION OF LOXAPINE HYDROCHLORIDE ORAL CONCENTRATE (LOXITANE C) IN ACUTE SCHIZOPHRENIA.

002411 03-08 ON THE ACUTE EFFECT OF SOME DRUGS ON HIGHER NERVOUS ACTIVITY IN MAN FOLLOWED UP BY THE LABORATORY LANGUAGE METHOD.

002623 03-14 ACUTE POISONINGS DUE TO DRUGS IN THE POLISH PROVINCE OF OLSZTYN FROM 1971 TO 1974.

002657 03-15 ACUTE BRAIN SYNDROME AFTER PROPRANOLOL

002672 03-15 ACUTE LITHIUM-INDUCED PARKINSONISM PRECIPITATED BY LIQUID

002685 03-15 ELECTROENCEPHALOGRAPHIC PECULIARITIES DURING ACUTE DRUG INTOX'CATIONS IN EPILEPTIC PATIENTS.

002689 03-15 ACUTE BRAIN SYNDROME AFTER PROPRANOLOL TREATMENT

002708 03-15 ACUTE PSYCHOLOGIC AND NEUROENDOCRINE EFFECTS OF DEXTROAMPHETAMINE AND METHYLPHENIDATE.

002786 04-01 EFFECT OF ACUTE MORPHINE ADMINISTRATION ON THE CEREBELLAR CYCLIC-GMP LEVEL IN TWO STRAINS OF MICE.

002975 04-03 HANGES IN BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS
FOLLOWING ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION
AND DURING POST AMPHETAMINE DEPRESSION.

002992 04-03 CHANGES IN BRAIN TRYPTOPHAN AND TYROSINE FOLLOWING ACUTE AND CHRONIC MORPHINE ADMINISTRATION

003012 04-03 EFFECT OF ACUTE MORPHINE ADMINISTRATION ON REGIONAL

THE BEHAVIORAL EFFECTS OF D. AMPHETAMINE AND CHLORPROMAZINE IN RATS; COMBINATIONS WITH ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE. (Ph.D. DISSERTATION).

003278 04-04 EFFECTS OF THE ACUTE ADMINISTRATION OF ETHANOL ON THE SLEEP OF THE RAT: A DOSE-RESPONSE STUDY.

003296 04-04 ACUTE AND CHRONIC EFFECTS OF COCAINE ON EXTINCTION-INDUCED AGGRESSION.

003303 04-04
DOPAMINE-BETA-HYDROXYLASE RELEASE FOLLOWING ACUTE SELECTIVE SYMPATHETIC NERVE STIMULATION OF THE HEART, SPLEEN AND MESENTERY.

MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA.

003460 04-08 THE USE OF PENFLURIDOL ACCORDING TO A NEW DOSAGE REGIMEN IN THE ACUTE, STABILIZATION AND MAINTENANCE PHASES OF PSYCHOSIS.

003491 04-09 THE IMPLICATIONS OF PSYCHEDELIC DRUG RESEARCH FOR INTEGRATION AND SEALING OVER AS RECOVERY STYLES FROM ACUTE PSYCHOSIS. 003517 04-09

MANAGEMENT OF ACUTE ANXIETY SYNDROME WITH PARENTERALLY ADMINISTERED LORAZEPAM.

003539 04-10

001710 02-14

001890 02-17

001937 02-17

DEPOT NEUROLEPTICS IN ACUTE PSYCHOSES.

THE EPIDEMIOLOGY OF ACUTE POISONING

VOLUME 16, SUBJECT INDEX

SEVERITY OF STUTTERING

Subject Index

000238 01-03

003102 04-03

ACUTE AND CHRONIC EFFECTS OF LITHIUM-CHLORIDE ON PHYSIOLOGICAL AND PSYCHOLOGICAL MEASURES IN NORMALS.

THE ACUTE EFFECT OF HALOPERIDOL AND APOMORPHINE ON THE

CLONIDINE BLOCKS ACUTE OPIATE WITHDRAWAL SYMPTOMS.

ACUTE EFFECTS OF LISURIDE (0.1 MG), AMANTADINE (100 MG) AND TRIHEXYPHENIDYL (5 MG) ON VERBAL ASSOCIATIONS.

ADAPTATION
EVIDENCE FOR MULTIPHASIC PRESYNAPTIC ADAPTATION: STUDIES WITH

COCAINE AND LITHIUM.

O00191 01-03
CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO
PSYCHOTROPIC DRUGS.

000729 01-13

EFFECT OF CERTAIN PSYCHOPHARMACOLOGICAL AGENTS ON
ADAPTATION UNDER STRESS.

ADDICT
NEW APPROACH TO THE REHABILITATION OF THE HARD CORE DRUG
ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY
STUDY

STUDY.

O02531 03-11

ADDICTION TO DIAZEPAM.

O00911 01-15

HEROIN IN THE TREATMENT OF MORPHINE ADDICTION.

000959 01-17

NARCOTIC BLOCKADE, LENGTH OF ADDICTION, AND PERSISTENCE OF
INTRAVENOUS MORPHINE SELF-ADMINISTRATION IN RATS.
001322 02-04

ADDICTIONS
SUBJECTS RIGHTS, FREEDOM OF INQUIRY, AND THE FUTURE OF
RESEARCH IN THE ADDICTIONS.
000966 01

ADDICTIVE
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): NALOXONE

BLOCKS MORPHINES ACCELERATION OR PRESSING FOR ICS. 001313 02-04
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): PRESSING FOR ICS BEFORE AND AFTER SELF-ADMINISTRATION OF SWEETENED MORPHINE SOLUTIONS.

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE, SELF-STIMULATION, AND PARAMETERS OF ICS. 002320 03-04

ADDICTS
PERFORMANCE DIFFERENCES BETWEEN ADDICTS AND NONADDICTS.

O00786 01-14
CLINIC ATTENDANCE AND OPIATE PRESCRIPTION STATUS OF HEROIN

ADDICTS OVER A SIX-YEAR PERIOD. 000989 01-17

LATE WITHDRAWAL SYMPTOMS IN BABIES BORN TO METHADONE

ADDICTS. 001756 02-15

NEW APPROACH TO THE REHABILITATION OF THE HARD CORE DRUG
ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY

ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY STUDY.

002531 03-11

EFFECTS OF RESERPINE AND SEROTONIN ON ADENINE-NUCLEOTIDE METABOLISM AND GLUCOSE OXIDATION OF WASHED RABBIT PLATFLETS.

ADENINE-NUCLEOTIDES

CECCTS OF ADENINE MICE COTIDES ON OVIDATION OF PHENOTULA ZIME

FFECTS OF ADENINE-NUCLEOTIDES ON OXIDATION OF PHENOTHIAZINE TRANQUILIZERS. 001059 02-03

HYPERTHYROIDISM AND A PARATHYROID ADENOMA COMPLICATING
LITHIUM TREATMENT.

002686 03-15

ADENOSINE

EFFECT OF RESERPINE ON ADENOSINE UPTAKE AND METABOLISM, AND
SUBCELLULAR TRANSPORT OF PLATELET ADENOSINE-TRIPHOSPHATE IN

WASHED RABBIT PLATELETS.

O00238 01-03

ADENOSINE MODULATES DEPOLARIZATION-INDUCED RELEASE OF M3-

NORADRENALINE FROM SLICES OF RAT BRAIN NEOCORTEX.

O02938 04-03
THE EFFECT OF CHLORPROMAZINE, SOME TRICYCLIC ANTIDERRESSANTS
AND INSULIN ON THE ACTION OF CYCLIC-AMP AND ADENOSINE
METABOLISM

ADENOSINE-TRIPHOSPHATASE 003606 04-13

IENOSINE-TRIPHOSPHATASE
DRUGS AFFECTING THE CENTRAL-NERVOUS-SYSTEM: EFFECTS OF
PEMOLINE. AND TRICYCLIC ANTIDEPRESSANTS ON NERVE TERMINAL

ADENOSINE-TRIPHOSPHATASE ACTIVITIES AND NEUROTRANSMITTER RELEASE. 002923 04-03

ADENOSINE-TRIPHOSPHATE

EFFECT OF RESERPINE ON ADENOSINE UPTAKE AND METABOLISM, AND

SUBCELLULAR TRANSPORT OF PLATELET ADENOSINE-TRIPHOSPHATE IN

WASHED RABBIT PLATELETS.

ADENOSINE-S-TRIPHOSPHATASE

THE ACUTE EFFECTS OF AMPHETAMINE, CHLORPROMAZINE,
AMITRIPTYLINE AND LITHIUM ON ADENOSINE-S-TRIPHOSPHATASE
ACTIVITY IN THE CORTEX OF THE RAT BRAIN.

ADENOSINEPHOSPHORIC-ACIDS
CHLORPROMAZINE-INDUCED CHANGES IN BLOOD
ADENOSINEPHOSPHORIC-ACIDS: TO THEIR DIAGNOSTIC SIGNIFICANCE
IN PSYCHIATRY.

001861 02-16

DENOSYL-L-METHIONINE

S ADENOSYL-L-METHIONINE (SAME) TREATMENT IN
GERONTOPSYCHIATRY: A CONTROLLED CLINICAL STUDY IN DEPRESSED
AGED PATIENTS.

THE INCREASE IN S ADENOSYL-L-METHIONINE (SAME) CONCENTRATION IN RAT BRAIN AFTER ITS SYSTEMATIC ADMINISTRATION.

DEVELOPMENT AND APPLICATION OF METHODS FOR DETERMINING THE BIOLOGICAL TRANSMETHIOLATIONS DEPENDENT ON S ADENOSYL-L-METHIONINE.

ADENOSYLMETHIONINE
POLYAMINE BIOSYNTHESIS IN RAT PROSTATE. SUBSTRATE AND
INHIBITOR PROPERTIES OF 7 DEAZA ANALOGUES OF DECARBOXYLATED
S ADENOSYLMETHIONINE AND 5 METHYLTHIOADENOSINE.
000001 01-01

LACK OF ENHANCEMENT OF DIMETHYLTRYPTAMINE FORMATION IN RAT BRAIN AND RABBIT LUNG IN VIVO BY METHIONINE OR S ADENOSYLMETHIONINE.

PHOTODYNAMIC ACTION OF CHLORPROMAZINE ON ADENOVIRUS 5:
REPAIRABLE DAMAGE AND SINGLE STRAND BREAKS.

000821 01-15

BRAIN AND THE ACTION OF ANTIPSYCHOTIC DP:JGS.

000076 01-03

HALOPERIDOL INCREASES AND APOMORPHINE DECREASES STRIATAL
DOPAMINE METABOLISM AFTER DESTRUCTION OF STRIATAL
DOPAMINE SENSITIVE ADENYLATE-CYCLASE BY KAINIC-ACID.
000094 01-03

SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION:
A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL
MEMBRANES FROM MATURE RAT BRAIN.

000230 01-03

NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN SLICES OF MOUSE LIMBIC FOREBRAIN: CHARACTERISATION AND EFFECT OF DOF. MINERGIC AGONISTS.

THE EFFECTS OF BEHAVIORALLY RELEVANT DOSES OF CHLORPROMAZINE AND MOLINDONE ON CARDIAC ADENYLATE-CYCLASE AND ON MYOCARDIAL CONTRACTILITY.

O00487 01-05
COMBINED EFFECT OF LITHIUM AND FLUPENTHIXOL ON STRIATAL
ADENYLATE-CYCLASE.

001131 02-03
HISTAMINE STIMULATED ADENYLATE-CYCLASE: BLOCKADE BY
IMIPRAMINE AND ITS ANALOGUES.

REGIONAL EFFECTS OF NEUROLEPTICS ON DOPAMINE METABOLISM AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE ACTIVITY.

THE EFFECT OF DIHYDROERGOTOXINE ON THE ADENYLATE-CYCLASE ACTIVITY IN HOMOGENATES OF RAT CEREBRAL-CORTEX.

O01254 02-03

EFFECT OF MORPHINE ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE
ACTIVITY OR NUCLEUS-ACCUMBENS.

INHIBITION BY LITHIUM OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT BRAIN.

O02357 03-05
STIMULATION OF ADENYLATE-CYCLASE ACTIVITY IN MONKEY ANTERIOR
LIMBIC CORTEX BY SEROTONIN.

O2805 04-03

EFFECTS OF SOME DERIVATIVES OF 2 AMINOTETRALIN ON DOPAMINE
SENSITIVE ADENYLATE-CYCLASE AND ON THE BINDING OF H3HALOPERIDOL TO NEUROLEPTIC RECEPTORS IN RAT STRIATUM.
002853 04-03

DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RETINA — SUBCELLULAR DISTRIBUTION. 002867 04-03

'n

MODIFICATION OF ADENYLATE-CYCLASE SYSTEMS IN MOUSE CEREBRAL-CORTEX BY CHLORPROMAZINE AND RESPECTIVE 7 HDROXY ANALOGS

INFLUENCE OF LITHIUM ON DOPAMINE STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT BRAIN.

NONSPECIFIC INHIBITION OF SOME RAT LIVER MEMBRANE-BOUND ENZYMES BY AN ADENYLATE-CYCLASE INHIBITOR, RMI-12330-002936 04-03

002936 04

EFFECTS OF NEUROLEPTICS ON H3-HALOPERIDOL AND H3-CISFLUPENTHIXOL BINDING AND ON ADENYLATE-CYCLASE ACTIVITY IN
VITRO.

THE EFFECT OF BROMOCRIPTINE ON RAT STRIATAL ADENYLATE-CYCLASE AND RAT BRAIN MONOAMINE METABOLISM.

ROLE OF SEROTONIN REUPTAKE INHIBITION IN THE DEVELOPMENT OF SUBSENSITIVITY OF THE NOREPINEPHRINE (NE) RECEPTOR COUPLED ADENYLATE-CYCLASE SYSTEM.

INHIBITION OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RAT STRIATUM BY NEUROLEPTIC DRUGS ADMINISTERED IN VIVO.

5 GUANYLYLIMIDODIPHOSPHATE ACTIONS ON ADENYLATE-CYCLASE IN HOMOGENATES OF RAT CEREBRAL-CORTEX PLUS NEURONAL AND CAPILLARY FRACTIONS.

THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE OF THE RAT CAUDATE NUCLEUS — 3. THE EFFECT OF APORPHINES AND PROTOBERBERINES.

H3-SPIROPERIDOL BINDING AND DOPAMINE STIMULATED ADENYLATE-CYCLASE: EVIDENCE FOR MULTIPLE CLASSES OF RECEPTORS IN

003112 04-03

THE EFFECT OF DIHYDROXY-2-AMINOTETRALINS (DATS) ON DOPAMINE AND BETA TYPE ADENYLATE-CYCLASES. 003088 04-03

ADIPOSE EFFECTS OF REPEATED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS ON ADIPOSE TISSUE LIPOLYTIC ACTIVITY IN THE RAT.

001179 02-03 DIFFERENTIAL EFFECTS OF MORPHINE AND D AMPHETAMINE ON SELF-STIMULATION FROM CLOSELY ADJACENT REGIONS IN RAT MIDBRAIN

001403 02-04

ADJUNCT
PROPRANOLOL AS AN ADJUNCT TO THE TREATMENT OF SCHIZOPHRENIA
000554 01-06 COUPLES GROUP THERAPY AS AN ADJUNCT TO LITHIUM MAINTENANCE OF THE MANIC PATIENT.

DIPROPYLTRYPTAMINE (DPT) AS AN ADJUNCT IN THE COUNSELING OF CANCER PATIENTS.

000978 01-17

ADJUNCTIVE EFFECTS OF CLOZAPINE, CHLORPROMAZINE AND DIAZEPAM UPON ADJUNCTIVE AND SCHEDULE-CONTROLLED BEHAVIORS.

000330 01-04 D AMPHETAMINE AND ADJUNCTIVE DRINKING IN RATS. 001453 02-04

ADJUSTMENT OF LITHIUM DOSE DURING LITHIUM-CHLOROTHIAZIDE

000956 01-17 INITIAL RESPONSE TO DRUGS IN DEPRESSIVE ILLNESS AND PSYCHIATRIC AND COMMUNITY ADJUSTMENT A YEAR LATER.

002459 03-09 ADMINISTERED EFFECT OF CHLORDIAZEPOXIDE ADMINISTERED EARLY IN EXTINCTION ON SUBSEQUENT EXTINCTION OF A CONDITIONED EMOTIONAL RESPONSE IN RATS: IMPLICATIONS FOR HUMAN CLINICAL USE.

PHARMACOLOGICAL ACTIONS OF INTRACEREBRALLY ADMINISTERED POLYAMINES IN MICE.

000033 01-02 AN EXCITATORY ACTION OF IONTOPHORETICALLY ADMINISTERED LITHIUM ON MAMMALIAN CENTRAL NEURONES.

000135 01-03 THE EFFECT OF MATERNALLY ADMINISTERED METHADONE ON BRAIN DEVELOPMENT IN THE OFFSPRING.

UPTAKE AND METABOLISM OF INTRAVENTRICULARLY ADMINISTERED PIPERIDINE AND ITS EFFECTS ON SLEEP AND WAKEFULNESS IN THE

001208 02-03 STEREOSELECTIVE, DOSE-DEPENDENT MODIFICATION OF INTRACRANIAL SELF-STIMULATION (ICSS) BY CENTRALLY ADMINISTERED LEVORPHANOL AND DEXTRORPHAN.

001280 02-03

NEUROTENSIN ADMINISTERED INTRACISTERNALLY INHIBITS RESPONSIVENESS OF MICE TO NOXIOUS STIMULI.

NARCOTIC CUEING PROPERTIES OF INTRAVENTRICULARLY ADMINISTERED SUFENTANIL, FENTANYL, MORPHINE AND MET-ENKEPHALIN. 002217 03-04

6 HYDROXYDOPAMINE INHIBITS SOME EFFECTS OF MESCALINE CENTRALLY ADMINISTERED TO RABBITS.

002231 03-04 EFFECT OF MATERNALLY ADMINISTERED HEROIN ON THE MOTOR ACTIVITY OF RAT OFFSPRING.

EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON PLASMA LEVELS
OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DEPRESSIVE
PATIENTS RECEIVING CLOMIPRAMINE THERAPY.

002577 03-13 EFFECT OF CDP-CHOLINE ADMINISTERED INTRATHECALLY ON DISTURBANCE OF CONSCIOUSNESS.

002635 03-14 POTENTIATION BY NEUROLEPTIC AGENTS OF THE INHIBITORY ACTION OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE.

002832 04-03 CLEARANCE AND ANALGESIC ACTIVITY OF THE QUATERNIZED OPIATE, N METHYLMORPHINE (6-H3) ADMINISTERED INTRACISTERNALLY TO THE RAT.

INHIBITION OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RAT

STRIATUM BY NEUROLEPTIC DRUGS ADMINISTERED IN VIVO. 003027 04-03 THE DISCRIMINATIVE STIMULUS PROPERTIES OF INTRAVENOUSLY ADMINISTERED COCAINE IN RHESUS MONKEYS.

003160 04-04 EFFECT OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE

DIFFERENTIAL EFFECTS ON CONDITIONED TASTE AVERSION LEARNING WITH PERIPHERALLY AND CENTRALLY ADMINISTERED ACETALDEHYDE

003178 04-04 **EFFECTS OF INTRAVENTRICULARLY ADMINISTERED MONOAMINES ON** SEIZURE SUSCEPTIBILITY AND BODY TEMPERATURE IN RATS

003180 04-04 MANAGEMENT OF ACUTE ANXIETY SYNDROME WITH PARENTERALLY ADMINISTERED LORAZEPAM.

003539 04-10 **ADMINISTRATION** STUDIES OF EXCRETION IN RABBIT MILK AFTER ADMINISTRATION OF CARBON-14 LABELLED AMITRIPTYLINE AND NORTRIPTYLINE.

000037 01-03 EFFECTS OF REPEATED ADMINISTRATION OF MORPHINE ON TYROSINE-HYDROXYLASE IN THE RAT BRAIN.

000062 01-03 THE METABOLIC FATE OF C14-PHENOBARBITONE IN THE RAT AND THE EFFECT OF CHRONIC ADMINISTRATION AND DOSE SIZE.

000067 01-03 EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON HEPATIC FUNCTIONS.

000119 01-03 DISAGGREGATION OF BRAIN POLYSOMES AFTER D LYSERGIC-ACID-DIETHYLAMIDE ADMINISTRATION IN VIVO: MECHANISM AND EFFECT OF AGE AND ENVIRONMENT.

000149 01-03 DEVELOPMENT AND DISAPPEARANCE OF SUBSENSITIVITY TO PILOCARPINE FOLLOWING A SINGLE ADMINISTRATION OF THE IRREVERSIBLE ANTICHOLINESTERASE AGENT, DFP.

INFLUENCE OF FASTING ON THE ABSORPTION AND EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AFTER ORAL ADMINISTRATION IN SESAME-

000228 01-03 LACK OF EFFECT OF CHRONIC HALOPERIDOL ADMINISTRATION ON THE ROLACTIN LOWERING ACTIONS OF PIRIBEDIL.

000233 01-03 ALTERED RECEPTOR SENSITIVITY FOLLOWING CHRONIC DRUG ADMINISTRATION IN MAN: THE TARDIVE-DYSKINESIA MODE

000248 01-03 EFFECT OF IN-UTERO ADMINISTRATION OF MORPHINE ON THE SUBSEQUENT DEVELOPMENT OF SELF-ADMINISTRATION BEHAVIOR

000368 01-04 RECOVERY OF AMNESTIC EFFECT OF ALPHA-AMANITIN BY POSTTRAINING ADMINISTRATION OF D AMPHETAMINE IN THE RAT.

000416.01-04 NEOSTRIATAL ADMINISTRATION OF SOMATOSTATIN: DIFFERENTIAL EFFECT OF SMALL AND LARGE DOSES ON BEHAVIOR AND MOTOR CONTROL.

000437 01-04 POTENTIATION OF THE BEHAVIORAL AND CONVULSANT EFFECTS OF COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.

000458 01-04

EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON PREGNANT RATS AND THEIR OFFSPRING.

000491 01-05

THE EFFECT OF L TRYPTOPHAN ADMINISTRATION ON THE CONCENTRATION OF PROBENECID IN PLASMA AND, CEREBROSPINAL FLUID IN PATIENTS.

000564 01-09

CONCOMITANT ADMINISTRATION OF HALOPERIDOL AND LITHIUM-CARBONATE IN ACUTE MANIA.

A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY ON ANTIEPILEPTIC ACTIVITY OF CLONAZEPAM -- RELATIONSHIP BETWEEN CLINICAL EFFECTS OF ORAL ADMINISTRATION AND ELECTROENCEPHALOGRAPHIC EFFECTS OF INTRAVENOUS ADMINISTRATION.

PLASMA L-ALPHA-ACETYLMETHADOL (LAAM) AFTER ACUTE AND CHRONIC ADMINISTRATION.

DISPOSITION OF THREE BENZODIAZEPINES AFTER SINGLE ORAL ADMINISTRATION IN MAN.

000745 01-13

MASKING OF TARDIVE-DYSKINESIA WITH FOUR TIMES-A-DAY ADMINISTRATION OF CHLORPROMAZINE.

CATATONIA AND MALIGNANT SYNDROME: A POSSIBLE COMPLICATION OF NEUROLEPTIC ADMINISTRATION. REPORT OF A CASE INVOLVING HALOPFRIDOL.

BRAIN DISTRIBUTION OF LITHIUM AND INDOLEAMINE METABOLISM IN DOGS AFTER CHRONIC LITHIUM ADMINISTRATION.

001108 02-03

EFFECTS OF NALOXONE FOLLOWING A SINGLE ADMINISTRATION OF LEVORPHANOL-TARTRATE IN THE NAIVE RAT.

EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON SYNAPTOSOMAL CA UPTAKE.

THE DISTRIBUTION BETWEEN PLASMA AND BRAIN OF GLUTETHIMDE AND 4 HYDROXYGLUTETHIMDE FOLLOWING THEIR ADMINISTRATION TO MICE.

DECREASE IN NEOSTRIATAL BLOOD FLOW AFTER D AMPHETAMINE
ADMINISTRATION OR ELECTRICAL STIMULATION OF THE SUBSTANTIA-

ADMINISTRATION OR ELECTRICAL STIMULATION OF THE SUBSTANTIA-NIGRA. 001175 02-03

EFFECT OF CHRONIC NEUROLEPTIC OR L-DOPA ADMINISTRATION ON GABA LEVELS IN THE RAT SUBSTANTIA-NIGRA.

OO 1181 02-03
THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE

NOREPINEPHRINE TURNOVER IN RAT BRAIN REGIONS.

O01227 02-0:
THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF TRICYCLIC

ANTIDEPRESSANTS ON MHPG-S04 IN RAT BRAIN.

O01228 02-03
REGIONAL LOCALIZATION OF C14-MESCALINE IN RABBIT BRAIN AFTER
INTRAVENTRICULAR ADMINISTRATION: EFFECTS OF CHLORPROMAZINE

AND IPRONIAZID PRETREATMENT.

THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDROCAMNABINOL (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HORMONE (FSH) AND LUTEINIZING HORMONE (LH) IN THE OVARIECTOMIZED RHESUS

THE INCREASE IN S ADENOSYL-L-METHIONINE (SAME) CONCENTRATION IN RAT BRAIN AFTER ITS SYSTEMATIC ADMINISTRATION.

THE EFFECT OF SUBCHRONIC ADMINISTRATION OF LITHIUM-CARBONATE ON THE PHARMACOLOGICAL ACTIVITY OF D AMPHETAMINE.

001295 02-04
INHIBITION OF DRINKING BY INTRAHYPOTHALAMIC ADMINISTRATION OF
MORPHINE.

O01325 02-04
DYNAMICS OF BLOOD NEUROTRANSMITTER LEVEL AS EVIDENCE OF
HIGHER NERVOUS ACTIVITY CHANGES DURING CHRONIC
ADMINISTRATION OF SEDUXEN.

601338 02-04
EFFECTS OF CHRONIC LITHIUM AND RUBIDIUM ADMINISTRATION UPON EXPERIMENTALLY-INDUCED CONFLICT BEHAVIOR.

O01391 02-04
PHYSICAL DEPENDENCE ASSOCIATED WITH CHRONIC METHAQUALONE
ADMINISTRATION.
O01428 02-04

FEEDING AND DRINKING INTERACTIONS AFTER ACUTE BUTYROPHENONE ADMINISTRATION. 001446 02-04

DISRUPTION OF LEARNING PERFORMANCE BY CHRONIC CHLORPROMAZINE ADMINISTRATION IN THE BABOON.

001465 02-04

EFFECT OF AGE AND ROUTE OF ADMINISTRATION ON LD50 OF LITHIUMCHLORIDE IN THE RAT.

A SLOW-RELEASE SILICONE PELLET FOR CHRONIC AMPHETAMINE ADMINISTRATION.

DIFFERENT BEHAVIOURAL PATTERNS INDUCED BY APOMORPHINE: EVIDENCE THAT THE METHOD OF ADMINISTRATION DETERMINES THE BEHAVIOURAL RESPONSE TO THE DRUG.

ANTIPARKINSONIAN DRUG ADMINISTRATION AND PLASMA LEVELS OF PENFLURIDOL, A NEW LONG-ACTING NEUROLEPTIC.

001559 02-08
INTRAVENOUS NALOXONE ADMINISTRATION IN SCHIZOPHRENIA AND
AFFECTIVE-ILLNESS.

INTRAVENOUS COMBINED ADMINISTRATION OF CHLORIMIPRAMINE AND SULPIRIDE IN DEPRESSION.

001575 02-09
L TRYPTOPHAN ADMINISTRATION IN L-DOPA-INDUCED HALLUCINATIONS
IN ELDERLY PARKINSONIAN PATIENTS.

CLINICAL PHARMACOKINETICS OF LORAZEPAM. IV. LONG-TERM ORAL ADMINISTRATION.

MODIFICATION OF SLEEP INDUCED IN ACUTE AND CHRONIC ADMINISTRATION OF LITHIUM.

001699 02-14

EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG
PATTERNS IN PSYCHIATRIC PATIENTS.

001712 02-14

EFFECTS OF CHLORDIAZEPOXIDE AND OXAZEPAM ADMINISTRATION ON VERBAL HOSTILITY.

DESIPRAMINE IN THE TREATMENT OF DEPRÉSSION: A COMPARISON OF DIVIDED VS SINGLE DOSE ADMINISTRATION.

ON LONG-TERM MAINTENANCE OF PSYCHOTROPIC DRUG THEAPY: THE COMBINED ADMINISTRATION OF ANTIPARKINSONS DRUGS.

GUIDELINES FOR NURSES: THE ADMINISTRATION OF INTRAVENOUS DRUGS THROUGH AN ESTABLISHED INTRAVENOUS PATHWAY.

001866 02-16
DRUG INTERACTIONS AND MULTIPLE DRUG ADMINISTRATION.
001913 02-17

INVOLUNTARY ADMINISTRATION OF PSYCHOTROPIC DRUGS - GROUNDS FOR SUIT. SOUDER V. MCGUIRE, 423 F. SUPP. 830, (PENNSYLVANIA). M.D. DISTRICT COURT. DECEMBER 9, 1976.

PROBLEMS ENGENDERED BY ADMINISTRATION OF LONG-ACTION
NEUROLEPTICS

PHENOBARBITAL METABOLISM DURING CHRONIC ADMINISTRATION IN RATS.

002007 03-03

EFFECT OF MATERNAL MORPHINE ADMINISTRATION ON FETAL AND
NEONATAL RAT LIVER TYROSINE-AMINOTRANSFERASE.

THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON DOPAMINE METABOLISM IN RAT STRIATUM.

THE CEREBROVASCULAR PERMEABILITY TO PROTEIN AFTER BICUCULLINE
AND AMPHETAMINE ADMINISTRATION IN SPONTANEOUSLY
HYPERTENSIVE RATS.

EFFECT OF SUBACUTE DIAZEPAM ADMINISTRATION IN MICE ON THE SUBSEQUENT ABILITY OF DIAZEPAM TO PROTECT AGAINST METRAZOL AND BICUCULLINE-INDUCED CONVULSIONS.

002053 03-03
ELECTROENCEPHALOGRAM AND SOMATOSENSORY EVOKED-POTENTIAL
CHANGES AFTER ADMINISTRATION OF SIX CONVULSANT DRUGS.
002055 03-03

THE RELATIONSHIP BETWEEN CORTICAL RECRUITING RESPONSES AND PONTO-GENICULO-OCCIPITAL (PGO) WAVES DURING PARADOXICAL SLEEP AND AFTER THE ADMINISTRATION OF RESERPINE IN THE CAT.

QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P-450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3 METHYCHOLANTHRENE.

DIFFERENTIAL REGIONAL DEVELOPMENT OF TOLERANCE TO INCREASE IN DOPAMINE TURNOVER UPON REPEATED NEUROLEPTIC ADMINISTRATION.

O02144 03-03

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN
SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC
ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS.

002148 03-03
CHANGES IN MOUSE BRAIN CATECHOLAMINE CONTENT AND TYROSINEHYDROXYLASE ACTIVITY DURING CHRONIC AMPHETAMINE
ADMINISTRATION.

002175 03-03

001517 02-05

SLEEP CHANGES INDUCED BY CHRONIC ADMINISTRATION OF S-1694 (SURVECTOR). 002194 03-04

MEMORIZATION AND CENTRAL CATECHOLAMINES AFTER A CRANIOCERVICAL INJURY CARRIED OUT IN RATS; INFLUENCE OF IMIPRAMINE ADMINISTRATION.

EFFECTS OF C'IRONIC IMIPRAMINE AND CLOMIPRAMINE ORAL ADMINISTRATION ON MATERNAL BEHAVIOR AND LITTER DEVELOPMENT.

002202 03-04 CHANGES IN THE RAT ELECTROCORTICOGRAM FOLLOWING
ADMINISTRATION OF TWO DIHYDROGENATED ERGOT DERIVATIVES

ANALGESIC EFFECT OF CEREBROVENTRICULAR ADMINISTRATION OF SOMATOSTATIN (SRIF).

A BEHAVIORAL AND AUTONOMIC NERVOUS SYSTEM STUDY OF CHRONIC IMIPRAMINE ADMINISTRATION TO CONSCIOUS DOGS.

ANALGESIC ACTIVITY OF ENKEPHALINS FOLLOWING INTRACEREBRAL ADMINISTRATION IN THE RAT.

002275 03-04 TOLERANCE AND DEPENDENCE AFTER CHRONIC ADMINISTRATION OF CLONIDINE TO THE RAT.

DECREASED RESPONSE INHIBITION DURING FIXED-INTERVAL RESPONDING IN PIGEONS FOLLOWING ATROPINE ADMINISTRATION.

002305 03-04 PRENATAL MORPHINE ADMINISTRATION ALTERS BEHAVIORAL DEVELOPMENT IN THE RAT

002308 03-04 DISRUPTION OF LATENT INHIBITION FOLLOWING SYSTEMIC ADMINISTRATION OF P-CHLOROPHENYLALANINE (PCPA)

002309 03-04 ENHANCED ANALGESIC EFFECTS OF MORPHINE AFTER CHRONIC ADMINISTRATION OF NALOXONE IN THE RAT.

THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MÂLE

OSMOTIC MINIPUMPS FOR ADMINISTRATION OF BARBITAL TO MICE: DEMONSTRATION OF FUNCTIONAL TOLERANCE AND PHYSICAL

DEPENDENCE 002374 03-06

TRIMIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF SINGLE VS. DIVIDED DOSE ADMINISTRATION. 002465 03-09

RHEOENCEPHALOGRAPHIC AND OTHER STUDIES OF BETAHISTINE IN HUMANS. IV. PROLONGED ADMINISTRATION WITH IMPROVEMENT IN ARTERIOSCLEROTIC DEMENTIA 002530 03-11

PRIMATE EEG SPECTRA BEFORE AND DURING OPIOID ADMINISTRATION 002601 03-13 BLOOD-BRAIN BARRIER DYSFUNCTION AFTER AMPHETAMINE ADMINISTRATION IN RATS.

RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D

002862 04-03 NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND L-

002942 04-03 THE EFFECT OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF AMPHETAMINE ON CEREBRAL DOPAMINE RECEPTOR SENSITIVITY

002964 04-03 EFFECT OF ACUTE MORPHINE ADMINISTRATION ON THE CEREBELLAR
CYCLIC-GMP LEVEL IN TWO STRAINS OF MICE.

002975 04-03 CARDIOVASCULAR RESPONSE TO INTRACEREBROVENTRICULAR ADMINISTRATION OF ACETYLCHOLINE IN RATS

002982 04-03 CHANGES IN BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS FOLLOWING ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION AND DURING POST AMPHETAMINE DEPRESSION.

002992 04-03 IANGES IN BRAIN TRYPTOPHAN AND TYROSINE FOLLOWING ACUTE AND CHRONIC MORPHINE ADMINISTRATION.

H3-GABA RELEASE IN SYNAPTOSOMAL FRACTIONS AFTER INTRACRANIAL ADMINISTRATION OF RUTHENIUM-RED.

003013 04-03 EFFECT OF ACUTE MORPHINE ADMINISTRATION ON REGIONAL ACETYLCHOLINE TURNOVER IN THE RAT.

Psychopharmacology Abstracts

003215 04-04

BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION OF LEVO-ALPHA-ACETYLMETHADOL IN THE RAT.

003154 04-04 ENHANCED CHOICE OF FAMILIAR FOOD IN A FOOD PREFERENCE TEST AFTER CHLORDIAZEPOXIDE ADMINISTRATION.

A REFILLABLE SYSTEM FOR CONTINUOUS AMPHETAMINE ADMINISTRATION: EFFECTS UPON SOCIAL BEHAVIOR IN RAT COLONIES.

ACTIVITY ANALYSIS OF OPERANT BEHAVIOR FOLLOWING METHYLPHENIDATE ADMINISTRATION.

003223 04-04 DIMINISHED TASTE REACTIVITY TO SACCHARIN FOLLOWING CHRONIC ADMINISTRATION OF THEOPHYLLINE IN RATS.

003259 04-04 THE BEHAVIORAL EFFECTS OF D AMPHETAMINE AND CHLORPROMAZINE IN RATS; COMBINATIONS WITH ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE. (PH.D. DISSERTATION)

003278 04-04 INHIBITION OF FIGHTING IN ISOLATED MICE FOLLOWING REPEATED ADMINISTRATION OF LITHIUM-CHLORIDE.

003282 04-04 EFFECTS OF THE ACUTE ADMINISTRATION OF ETHANOL ON THE SLEEP OF THE RAT: A DOSE-RESPONSE STUDY.

003296 04-04 **BEHAVIORAL EFFECTS OF CHRONIC NARCOTIC ANTAGONIST** ADMINISTRATION TO INFANT RATS.

PARALLEL CHANGES IN BEHAVIOR AND HIPPOCAMPAL MONOAMINE METABOLISM IN RATS AFTER ADMINISTRATION OF ACTH ANALOGUES.

003335 04-04 BEHAVIOURAL AND NEUROCHEMICAL EFFECTS OF REPEATED ADMINISTRATION OF COCAINE IN RATS

003346 04-04 SYSTEMIC ADMINISTRATION OF ENDORPHINS SELECTIVELY ALTERS OPEN-FIELD BEHAVIOR OF RATS.

DYSKINESIAS EVOKED IN MONKEYS BY WEEKLY ADMINISTRATION OF HALOPERIDOL.

THE EFFECTS OF CHRONIC CHLORPROMAZINE ADMINISTRATION ON THE ALBINO RAT RETINA.

003408 04-05 REPEATED SUSTAINED-RELEASE LITHIUM-CARBONATE ADMINISTRATION TO CATS.

003413 04-05 THE EFFECTS OF DAILY COCAINE ADMINISTRATION ON COCAINE-INDUCED MORTALITY

003421 04-05 LITHIUM EFFLUX FROM ERYTHROCYTES INCUBATED IN VITRO DURING LITHIUM-CARBONATE ADMINISTRATION.

003518 04-09 MEDICATION IN RESIDENTIAL TREATMENT: ADMINISTRATION AND CLINICAL EXPERIENCES.

003561 04-11 ALOSTERIC CHANGES IN PLASMA PROTEINS IN HEALTHY VOLUNTEERS AFTER ADMINISTRATION OF LYSERGAMIDE.

003584 04-12 DEPRENYL ADMINISTRATION IN MAN: A SELECTIVE MONOAMINE-OXIDASE B INHIBITOR WITHOUT THE CHEESE EFFECT.

PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATIENTS DURING LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS: DISSOCIATION BETWEEN LIGHT AND NEAR VISION REACTIONS.

ADMINISTRATIONS

A DEBATE ON MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY — REFLECTIONS ON THE SO-CALLED LONG-TERM SATURATION ADMINISTRATIONS.

001872 02-16 ADMISSION A DRUG-FREE WEEK AFTER ADMISSION. 001883 02-17

ADMISSIONS THE USE OF PRESCRIPTION DRUGS IN TREATMENT OF FIRST-TIME PSYCHIATRIC ADMISSIONS TO UNIVERSITY HOSPITAL, SASKATOON 003712 04-17

A SEVEN YEAR REVIEW OF COMA PATIENTS ADMITTED TO THE REGIONAL POISONING TREATMENT CENTRE, ROYAL INFIRMARY, EDINBURGH.

001821 02-15 TRYPTOPHAN NICOTINAMIDE COMBINATION IN THE TREATMENT OF NEWLY ADMITTED DEPRESSED PATIENTS. 003487 04-09

EXPERIMENTAL BARBITURATE DEPENDENCE. I. BARBITURATE
DEPENDENCE DEVELOPMENT IN RATS BY DRUG ADMIXED FOOD (DAF)

003373 04-04

VOLUME 16, SUBJECT INDEX

CHEMOTHERAPY IN MENTAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.

002735 03-17

ADOLESCENT

ADOLESCENCE

POST HEAD TRAUMA SYNDROME IN AN ADOLESCENT TREATED WITH LITHIUM-CARBONATE - CASE REPORT

000560 01-09 LITHIUM AND THE TREATMENT OF ADOLESCENT MANIC-DEPRESSIVE

000569 01-09 LITHIUM IN CHILD AND ADOLESCENT PSYCHIATRY. (UNPUBLISHED PAPER)

000657 01-11 TRICYCLIC ANTIDEPRESSANT OVERDOSES IN ADOLESCENT PATIENTS 001822 02-15 PSYCHOTROPIC DRUGS IN CHILD AND ADOLESCENT PSYCHIATRY

001939 02-17 GILLES-DE-LA-TOURETTES SYNDROME, TARDIVE-DYSKINESIA, AND PSYCHOSIS IN AN ADOLESCENT.

PHARMACOPSYCHOLOGICAL INVESTIGATION OF THE EFFECT OF SEDATIVES ON MEMORY AND LEARNING PERFORMANCE IN CHILDREN AND ADOLESCENTS

000751 01-14 CONSUMPTION OF MEDICATION AND RISK OF DEVIANCE AMONG **ADOLESCENTS**

001888 02-17 LITHIUM-CARBONATE USE IN CHILDREN AND ADOLESCENTS: A SURVEY OF THE LITERATURE.

002471 03-09 EXTRAPYRAMIDAL REACTIONS IN ADOLESCENTS TREATED WITH HIGH-POTENCY ANTIPSYCHOTICS.

A STUDY OF PHYSICIAN DRUG PRESCRIBING ADOPTION AND DISCONTINUATION BEHAVIORS. (PH.D. DISSERTATION).

001889 02-17

002651 03-15

ADRENAL

TYROSINE-HYDROXYLASE: DELAYED ACTIVATION IN CENTRAL NORADRENERGIC NEURONS AND INDUCTION IN ADRENAL MEDULLA ELICITED BY STIMULATION OF CENTRAL CHOLINERGIC RECEPTORS. 000183 01-03

TRANS-SYNAPTIC INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE FOLLOWING AMPHETAMINE TREATMENT IN THE RAT. 000284 01-03

THE AMNESTIC EFFECT OF PROTEIN SYNTHESIS INHIBITORS IS NOT DUE TO THE INHIBITION OF ADRENAL CORTICOSTEROIDOGENESIS 000352 01-04

SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT AND NEWBORN RATS.

EFFECTS OF CHLORPROMAZINE AND DL-AMPHETAMINE ON CALCIUM UPTAKE BY ADRENAL CHROMAFFIN CELL MEMBRANE.

002075 03-03 SUPPRESSION OF THE HYPOTHALAMIC PITUITARY ADRENAL AXIS AFTER ORAL HYDROCORTISONE-SUCCINATE INGESTION IN RATS

002098 03-03 ENHANCEMENT BY CHOLINE OF THE INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE BY PHENOXYBENZAMINE, 6 HYDROXYDOPAMINE, INSULIN OR EXPOSURE TO COLD.

002167 03-03 RESPONSES OF THE PITUITARY ADRENAL SYSTEM OF THE PIG TO ENVIRONMENTAL CHANGES AND DRUGS

002833 04-03 PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF NA CHANNELS IN THE RELEASE OF CATECHOLAMINES FROM PERFUSED ADRENAL

002960 04-03 DISTURBANCE OF HOMEOSTATIC REGULATION OF ADRENAL FUNCTION IN PATIENTS WITH ENDOGENOUS DEPRESSION.

003515 04-09 ADRENALECTOMY

EFFECTS OF ADRENALECTOMY ON TASTE AVERSION LEARNING 003153 04-04 ADRENERGIC

RELATIONSHIP BETWEEN THE UPTAKE OF 3H-(PLUS OR MINUS) METARAMINOL AND THE DENSITY OF ADRENERGIC INNERVATION IN ISOLATED RAT TISSUES.

TRANSCALLOSALLY EVOKED-POTENTIALS AND THE EEG IN THE DECEREBRATE DOG: ACTIONS OF TRYPTAMINERGIC, DOPAMINERGIC AND ADRENERGIC AGONISTS.

000223 01-03 BETA ADRENERGIC RECEPTOR LABELING IN INTACT ANIMALS WITH 1125-HYDROXYBENZYLPINDOLOL. 000493 01-06 Subject Index

URINARY 3 METHOXY-4-HYDROXYPHENYLGLYCOL, AN INDEX OF PERIPHERAL RATHER THAN CENTRAL ADRENERGIC ACTIVITY IN THE

ADRENERGIC MODULATION OF A CHOLINERGIC EMOTIONAL REACTION IN THE CATS THALAMUS.

HYPOTHESIZED ADRENERGIC/NORADRENERGIC SUBSTITUTION IN HABITUAL INFANTILE MASTURBATION: TWO CASES.

PARAVENTRICULAR NUCLEUS: A PRIMARY SITE MEDIATING ADRENERGIC STIMULATION OF FEEDING AND DRINKING.

002074 03-03 CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. THE IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2-METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED ANALOGS OF METHAMPHETAMINE.

EFFECT OF BETA ADRENERGIC RECEPTOR ANTAGONISTS ON D AMPHETAMINE AND POTASSIUM-INDUCED RELEASE OF H3-NOREPINEPHRINE FROM RAT BRAIN IN VITRO.

002187 03-03 INTERACTIONS OF ADRENERGIC COMPOUNDS WITH BRAIN MEMBRANE CONSTITUENTS.

002939 04-03 FURTHER STUDIES ON THE FINE STRUCTURE OF THE ADRENERGIC INNERVATION OF THE HYPOTHALAMUS.

003105 04-03 ADRENERGIC ALPHA-RECEPTORS AND BETA-RECEPTORS EXPRESSED BY THE SAME CELL TYPE IN PRIMARY CULTURE OF PERINATAL MOUSE

A NEW ANIMAL MODEL FOR SCHIZOPHRENIA: INTERACTIONS WITH ADRENERGIC MECHANISMS.

ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

003272 04-04 ADRENOCEPTORS CENTRAL ADRENOCEPTORS AND CHOLINOCEPTORS IN CARDIOVASCULAR CONTROL

002823 04-03 ADRENOCORTICAL THE EFFECTS OF METHAQUALONE ON PITUITARY ADRENOCORTICAL

ACTIVITY IN MICE 001194 02-03 EFFECT OF LITHIUM-CHLORIDE ON ADRENOCORTICAL FUNCTION IN THE

RAT 002049 03-03

ADULT BEHAVIOR AND ADRENOCORTICAL FUNCTION FOLLOWING NEONATAL MORPHINE TREATMENT IN RATS 002310 03-04

EVIDENCE FOR THE ROLE OF ADRENOCORTICAL HORMONES IN THE REGULATION OF NORADRENALINE AND DOPAMINE METABOLISM IN CERTAIN RRAIN AREAS 003062 04-03

IMPRINTING BEHAVIOR: PITUITARY ADRENOCORTICAL MODULATION OF THE APPROACH RESPONSE 003287 04-04 PITUITARY ADRENOCORTICAL AXIS AND SHOCK-INDUCED FIGHTING IN

003342 04-04

ADRENOCORTICOTROPHIC

MOUSE BRAIN TYROSINE-HYDROXYLASE AND GLUTAMIC-ACID-DECARBOXYLASE FOLLOWING TREATMENT WITH ADRENOCORTICOTROPHIC HORMONE, VASOPRESSIN OR

002898 04-03

ADRENOCORTICOTROPIN METABOLIC CLEARANCE RATE OF ADRENOCORTICOTROPIN IN THE RAT 002070 03-03

EFFECTS OF ALPHA-METHYL-P-TYROSINE, ADRENOLYTIC COMPOUNDS, PIMOZIDE AND OTHER NEUROLEPTICS, ON THE NARCOTIC CUE. 000338 01-04

ADTN THE UPTAKE AND RELEASE OF H3-2 AMINO-6-7-DIHYDROXYTETRAHYDRONAPHTHALENE (ADTN) BY STRIATAL NERVE TERMINALS

002884 04-03 ADULT OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH MORPHOLOGY AND HORMONE PLASMA LEVELS.

000315 01-04

OF ADULT MALE DOMESTIC DUCKS: 1. BEHAVIOURAL EFFECTS OF INTRAMUSCULAR INJECTIONS.	AFFECT FAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS
THE EFFECTS OF CANNABIS-SATIVA ON THE BEHAVIOR OF ADULT FEMALE	UNDER LONG-TERM TRAINING. 000034 01-02
CHACMA BABOONS (PAPIO-URSINUS) IN CAPTIVITY. 000402 01-04	DO BENZODIAZEPINES AFFECT MOTOR OR SENSORY MECHANISMS?. 000250 01-03
NEW DRUG TESTING IN THE CONSENTING ADULT.	FAILURE OF NALOXONE TO AFFECT HUMAN SLEEP.
000509 01-07 EFFECTS OF PERINATAL 6 HYDROXYDDPAMINE TREATMENT ON OPIATE RECEPTOR DISTRIBUTION IN ADULT BRAIN.	FAILURE OF METHADONE AND LEVOMETHADYL-ACETATE (LEVO-ALPHA- ACETYLMETHADOL, LAAM) MAINTENANCE TO AFFECT MEMORY.
O01128 02-03 SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE- BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT	DO DRUGS ACTING ON THE NERVOUS SYSTEM AFFECT CELL PROLIFERATION IN THE DEVELOPING BRAIN?. 000841 01-15 001512 02-05
AND NEWBORN RATS.	ANALYSIS AND CHEMICAL CONTROL OF NEGATIVE AFFECT.
O1215 02-03 THE EFFECTS OF NEONATAL INJECTIONS OF ALPHA-MSH ON THE OPEN- FIELD BEHAVIOR OF JUVENILE AND ADULT RATS.	AFFECTIVE LITHIUM AND CRISIS INTERVENTION: DAMPING AFFECTIVE OVERLOAD.
IMPACT OF AGE ON ANTERIOR PITUITARY HORMONES IN ADULT MALES. 001687 02-13	AFFECTIVE-DISORDER LITHIUM ERYTHROCYTE:PLASMA RATIO IN PRIMARY AFFECTIVE-
ADULT BEHAVIOR AND ADRENOCORTICAL FUNCTION FOLLOWING NEONATAL MORPHINE TREATMENT IN RATS.	DISORDER. 002445 03-09
COMPARATIVE TOXICITY OF CAFFEINE AND AMINOPHYLLINE IN YOUNG AND ADULT RATS.	ERYTHROCYTE ACCUMULATION OF THE LITHIUM-ION IN CONTROL SUBJECTS AND PATIENTS WITH PRIMARY AFFECTIVE-DISORDER. 003519 04-09
002342 03-05 ENTRY OF BETA-N-OXALYL-L-ALPHA-BETA-DIAMINOPROPIOIIC-ACID, THE LATHYRUS-SATIVUS NEUROTOXIN INTO THE CENTRAL-NERVOUS-	AFFECTIVE-DISORDERS PERSPECTIVES IN BIOLOGICAL PSYCHIATRY. PART 2: AFFECTIVE-DISORDERS.
SYSTEM OF THE ADULT RAT, CHICK AND THE RHESUS MONKEY. 003061 04-03	TRYPTOPHAN AND AFFECTIVE-DISORDERS. 000558 01-09
ADULTS	001579 02-09
A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE SHORT-TERM EFFECTS OF CLOZAPINE UPON SLEEP PARAMETERS OF NORMAL YOUNG	THE PRACTICAL MANAGEMENT OF AFFECTIVE-DISORDERS. 001605 02-09
ADULTS. 001734 02-14 A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE LONG-TERM EFFECTS	THEORETICAL AND THERAPEUTIC POTENTIAL OF INDOLEAMINE PRECURSORS IN AFFECTIVE-DISORDERS. 001610 02-09
OF CLOZAPINE UPON SLEEP PATTERNS OF NORMAL YOUNG ADULTS. 002640 03-14	PERSPECTIVES IN THE TREATMENT OF THE PSYCHONEUROLOGICAL DISORDERS: AFFECTIVE-DISORDERS. (UNPUBLISHED PAPER).
TREATMENT OF DYSKINETIC AND CHOREATIC MOVEMENT DISORDERS IN ADULTS.	PREDICTION OF LITHIUM RESPONSE IN AFFECTIVE-DISORDERS.
002776 03-17 CONTRIBUTION OF THE USE OF 1035MD IN A PSYCHIATRIC WARD FOR ADULTS, ITS ACTIVITY ON THE DIRECT AND SIDE-EFFECTS OF	002418 03-09 THE CURRENT STATUS OF RESEARCH IN THE CATECHOLAMINE THEORIES OF AFFECTIVE-DISORDERS.
NEUROLEPTICS. 003446 04-07 PLACEBO AND SLEEP PATTERNS OF NORMAL YOUNG ADULTS.	002733 03-17 BIOCHEMICAL AND PHARMACOLOGICAL DIFFERENTIATION OF AFFECTIVE- DISORDERS: AN OVERVIEW.
003729 04-17	AFFECTIVE-ILLNESS 003495 04-09
COMBINATION OF PHENYLPYRROLIDINOPENTANE (KATOVIT) WITH OXAZEPAM (ADUMBRAN): A DOUBLE-BLIND TRIAL WITH OPIPRAMOL (INSIDON) IN DEPRESSIVE SYNDROME.	MIANSERIN IN THE PROPHYLACTIC TREATMENT OF BIPOLAR AFFECTIVE- ILLNESS. 000561 01-09
000597 01-10	LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR
PARTICULARITIES OF LITHIUM INTOXICATION IN ADVANCED AGE. 001772 02-15	BLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE IN THE FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE PROBAND.
ADVERSE ADVERSE EFFECTS OF INTRAVENOUS CANNABIS TEA.	AFFECTIVE-ILLNESS TREATED WITH LITHIUM: EFFECTS ON THYROID
ADVERSE EFFECTS OF LITHIUM TREATMENT.	FUNCTION AND PSYCHIC STATUS. 000774 01-14
ADVERSE DRUG REACTIONS. 000874 01-15	PSYCHOPHARMACOLOGY OF THE SWITCH PROCESS IN AFFECTIVE- ILLNESS. (UNPUBLISHED PAPER).
000876 01-15	000941 01-17
TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS AND ADVERSE EFFECTS AFTER OVERDOSE. 000883 01-15	INTRAVENOUS NALOXONE ADMINISTRATION IN SCHIZOPHRENIA AND AFFECTIVE-ILLNESS. 001560 02-08
ADVERSE REACTIONS LITERATURE: A BIBLIOMETRIC ANALYSIS. 000999 01-17	LONG-TERM MAINTENANCE DRUG THERAPY IN RECURRENT AFFECTIVE- ILLNESS: CURRENT STATUS AND ISSUES.
ADVERSE EFFECTS OF CHLORPROMAZINE METABOLITES ON ISOLATED HEPATOCYTES.	001600 02-09 NEUROENDOCRINE RESPONSES TO LEVODOPA IN AFFECTIVE-ILLNESS.
001502 02-05 ADVERSE REACTIONS TO MEDICATION IN PSYCHIATRIC INPATIENTS: THEIR MEANING, UTILITY AND PROBLEMS.	O22435 03-09 CYPROHEPTADINE IN BIPOLAR AFFECTIVE-ILLNESS WITH CUSHINGOID FEATURES.
O01744 02-15 AN AUTOMATED SYSTEM FOR THE PREDICTION AND PREVENTION OF ADVERSE DRUG REACTIONS. (PH.D. DISSERTATION).	002458 03-09 CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE- ILLNESS: PARADOXICAL DRUG EFFECTS.
ADVERSE RESPONSE TO NEUROLEPTICS IN SCHIZOPHRENIA.	THE BIOLOGY OF AFFECTIVE-ILLNESS: AMINE NEUROTRANSMITTERS AND
001814 02-15 DRUG UTILIZATION AND ADVERSE DRUG REACTIONS IN MEDICAL PATIENTS: COMPARISON OF TWO PERIODS, 1969-72 AND 1973-76.	DRUG RESPONSE. 002746 03-17
PSYCHOTROPIC DRUGS IN PREGNANCY: MORPHOLOGICAL AND	THERAPEUTIC EFFECTS OF CARBAMAZEPINE IN AFFECTIVE-ILLNESS: A PRELIMINARY REPORT. 003481 04-09
PSYCHOLOGICAL ADVERSE EFFECTS ON OFFSPRING. 003708 04-17	KLINEFELTERS SYNDROME AND BIPOLAR AFFECTIVE-ILLNESS: A CASE REPORT.
DIFFERING ACTIONS OF AMFONELIC-ACID (AFA) AND AMPHETAMINE (AMPH) ON STRIATAL DOPAMINE (DA).	O03486 04-09 PRIMARY EMPTY SELLA SYNDROME AND BIPOLAR AFFECTIVE-ILLNESS: CASE REPORT.
001196 02-03	003511 04-09

 -	VE-PS	TWO IS NOT	O.F.E.

USE OF LITHIUM-CARBONATE WITH RETARDED ACTION (MICALITE) IN PATIENTS WITH AFFECTIVE-PSYCHOSES.

002444 03-09

003076 04-03

CHANGES IN HIPPOCAMPAL EVOKED RESPONSES TO AFFERENT STIMULATION DURING CONDITIONING.

000260 01-03 EFFECT OF NARCOTICS ON CONDUCTION OF AFFERENT VISCERAL IMPULSES.

001083 02-03 AFFERENT AND EFFERENT SUBCORTICAL PROJECTIONS OF BEHAVIORALLY DEFINED SECTORS OF PREFRONTAL GRANULAR CORTEX.

002962 04-03 MORPHINE AND MET-ENKEPHALIN EFFECTS ON SURAL-ADELTA AFFERENT TERMINAL EXCITABILITY

AFFERENTS

DOPAMINE RECEPTORS LOCALISED ON CEREBRAL CORTICAL AFFERENTS TO RAT CORPUS-STRIATUM. 003080 04-03

AFFINITIES OF DRUGS FOR THE AGONIST AND ANTAGONIST STATES OF THE DOPAMINE RECEPTOR. 003065 04-03

APPINITY

THE PURIFICATION OF ANTIMORPHINE ANTIBODIES BY AFFINITY CHROMATOGRAPHY.

0000015 01-01 SECOND MESSENGER RESPONSES AND REGULATION OF HIGH AFFINITY RECEPTOR BINDING TO STUDY PHARMACOLOGICAL MODIFICATION OF GABAERGIC TRANSMISSION. (UNPUBLISHED PAPER).

000133 01-03 THE ELECTRONIC AND SEROTONIN RECEPTOR BINDING AFFINITY PROPERTIES OF N.N DIMETHYLTRYPTAMINE ANALOGS

001002 02-01 ENHANCED AFFINITY OF OPIATE RECEPTORS FOR NALOXONE IN STRIATAL SLICES OF MORPHINE-DEPENDENT MICE.

001165 02-03 MODULATION OF ACETYLCHOLINE TURNOVER IN BRAIN REGIONS AND

HIGH AFFINITY UPTAKE. 001209 02-03

RECEPTOR AFFINITY AND PHARMACOLOGICAL POTENCY OF A SERIES OF NARCOTIC ANALGESIC, ANTIDIARRHEAL AND NEUROLEPTIC DRUGS. 002160 03-03 CHOLINE-ACETYLTRANSFERASE AND THE HIGH AFFINITY UPTAKE OF

CHOLINE IN CORPUS-STRIATUM OF RESERPINISED RATS 002847 04-03

ANGIOTENSIN BINDING AFFINITY AND CAPACITY IN THE MIDBRAIN AREA OF SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS 002870 04-03

HIGH AFFINITY BINDING OF H3-HISTAMINE IN RAT BRAIN.

003036 04-03 HETEROGENEITY OF LSD DISPLACING FACTORS AND MULTIPLE TYPES OF HIGH AFFINITY LSD BINDING SITES.

003099 04-03 TRICYCLIC ANTIDEPRESSANTS: THERAPEUTIC PROPERTIES AND AFFINITY FOR ALPHA-NORADRENERGIC RECEPTOR BINDING SITES IN THE BRAIN 003118 04-03

BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF HYPOXIC HYPOXIA IN RATS: STUDY OF THE PROTECTION AFFORDED BY ERGOT ALKALOIDS 001971 03-03

AFID-GC

IMIPRAMINE ITS N DESMETHYL AND HYDROXY METABOLITES IN PLASMA: MICRO DETERMINATION BY ALKALINE FLAME-IONIZATION GAS-CHROMATOGRAPHY (AFID-GC). 002597 03-13

AFTER-DISCHARGE EFFECT OF ANTICONVULSANTS ON THALAMIC AFTER-DISCHARGE IN RATS AND CATS 002046 03-03

COCAINE AND PSEUDOCOCAINE: COMPARATIVE EFFECTS ON ELECTRICAL AFTER-DISCHARGE IN THE LIMBIC SYSTEM OF CATS. 003004 04-03

AFTER-DISCHARGES

NEUROPHYSIOLOGY, NEUROPHARMACOLOGY AND BEHAVIORAL RELATIONSHIPS OF VISUAL SYSTEM EVOKED AFTER-DISCHARGES: A

INTERACTION OF IMIPRAMINE AND 3 QUINUCLIDYL-BENZILATE WITH 9
AMINO-7-METHOXYTETRAHYDROACRIDINE ON THE AFTER-DISCHARGES IN THE LIMBIC SYSTEM. 002945 04-03

AFTEREFFECTS

THE EFFECTS OF DEXTROAMPHETAMINE ON KINESTHETIC FIGURAL AFTEREFFECTS. 002620 03-14

DISAGGREGATION OF BRAIN POLYSOMES AFTER D LYSERGIC-ACID-DIETHYLAMIDE ADMINISTRATION IN VIVO: MECHANISM AND EFFECT OF AGE AND ENVIRONMENT.

PRENATAL ALCOHOL CONSUMPTION AND OPEN-FIELD BEHAVIOUR IN RATS; EFFECTS OF AGE AT TIME OF TESTING.

TRICYCLIC NEED DROPS WITH AGE

000580 01-09
RELATIONSHIP BETWEEN AGE AND TRICYCLIC ANTIDEPRESSANT PLASMA

PLASMA LEVELS OF CHLORPROMAZINE: EFFECT OF AGE, CHRONICITY OF DISEASE, AND DURATION OF TREATMENT.

000732 01-13 EFFECT OF AGE AND ROUTE OF ADMINISTRATION ON LD50 OF LITHIUM-CHLORIDE IN THE RAT.

001517 02-05 IMPACT OF AGE ON ANTERIOR PITUITARY HORMONES IN ADULT MALES. 001687 02-13

PARTICULARITIES OF LITHIUM INTOXICATION IN ADVANCED A EFFECT OF AGE ON ACUTE MORPHINE RESPONSE IN THE RAT.

O02159 03-03
TRICYCLIC PLASMA LEVELS: EFFECT OF AGE, RACE, SEX, AND SMOKING.
002472 03-09

SENSITIVITY TO APOMORPHINE IN THE GUINEA-PIG AS A FUNCTION OF AGE AND BODY WEIGHT.

003182 04-04 BEHAVIORAL EFFECTS OF DOPAMINE AGONISTS INCREASE WITH AGE 003362 04-04

THE INFLUENCE OF PYRIDOXINE ON THE PSYCHOPATHOLOGY AND PATHOCHEMISTRY OF DEPRESSIONS OF INVOLUTIONAL AGE. 003485 04-09

LITHIUM DOSAGE AND AGE OF PATIENTS.

003528 04-09 TARDIVE-DYSKINESIA: AGE AND SEX DIFFERENCES IN HOSPITALIZED SCHIZOPHRENICS.

003681 04-15 AGE-RELATED EFFECTS OF RESERPINE ON BEHAVIOR AND ON REGIONAL CATECHOLAMINE UPTAKE AND RELEASE IN THE RAT. (PH.D.

DISSERTATION) 001098 02-03

EFFECTS OF METHYLPHENIDATE ON AVOIDANCE LEARNING IN THE AGED RAT 000020 01-02

THE EFFECT OF METHYLPHENIDATE ON TEST PERFORMANCE IN THE COGNITIVELY IMPAIRED AGED.

000622 01-11 S ADENOSYL-L-METHIONINE (SAME) TREATMENT IN GERONTOPSYCHIATRY: A CONTROLLED CLINICAL STUDY IN DEPRESSED AGED PATIENTS 001045 02-03

ON PHARMACOTHERAPY FOR THE AGED. 001919 02-17

AGES EFFECTS OF ETHANOL AND PENTOBARBITAL IN MICE OF DIFFERENT AGES.
003151 04-04

AGGRAVATION LITHIUM-INDUCED AGGRAVATION OF TARDIVE-DYSKINESIA 000818 01-15

TRIPHASIC DOSE LETHALITY RELATIONSHIPS FOR AMPHETAMINE AND CERTAIN RING-SUBSTITUTED AMPHETAMINES IN ISOLATED OR

AGGREGATED MICE 001093 02-03 EFFECTS OF AMPHETAMINE ON BRAIN BIOGENIC AMINES IN ISOLATED

AND AGGREGATED RATS. 001182 02-03

AGGREGATING BIOCHEMICAL DIFFERENTIATION OF AGGREGATING CELL CULTURES OF DIFFERENT FETAL RAT BRAIN REGIONS. 001148 02-03

ON THE CONFORMATION OF NEUROLEPTIC DRUGS IN THE THREE AGGREGATION STATES AND THEIR CONFORMATIONAL RESEMBLANCE

000990 01-17 AGGREGATION OF ANTIDEPRESSANT DRUGS IN AQUEOUS SOLUTION.
003697 04-17

AGGRESSION REACTIVITY AND AGGRESSION IN THE RAT: INDUCTION BY ALPHA ADRENERGIC BLOCKING AGENTS INJECTED VENTRAL TO ANTERIOR SEPTUM BUT NOT INTO LATERAL SEPTUM.

000309 01-04 ASPECTS OF THE PSYCHOPHARMACOLOGY OF HUMAN AGGRESSION 000789 01-14

NEUROCHEMICAL STUDIES OF AGGRESSION IN ANIMALS.

ENDOCRINES AND AGGRESSION.

000947 01-17

O00965 01-17
ALKALI-METAL CATIONS: EFFECTS ON ISOLATION-INDUCED AGGRESSION
IN THE MOUSE.

EFFECTS OF L-DOPA, D AMPHETAMINE AND COCAINE ON INTRUDER-EVOKED AGGRESSION IN RATS AND MICE.

TRICYCLIC ANTIDEPRESSANT DRUGS: ANTAGONISM OF EFFECT OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON SHOCK ELICITED AGGRESSION.

PIPEROXANE REDUCES THE EFFECTS OF CLONIDINE ON AGGRESSION IN MICE AND ON NORADRENALINE DEPENDENT HYPERMOTILITY IN RATS.

602205 03-04

EFFECTS OF PROLACTIN, DEXAMETHASONE, AND CORTICOSTERONE ON MATERNAL AGGRESSION AND INFANT CARE.

002240 03-04 ANIMAL MODEL FOR STUDY OF HYPERKINESIS AND AGGRESSION. 002302 03-04

INTERANIMAL AGGRESSION AND HYPERREACTIVITY FOLLOWING
HYPOTHALAMIC INFUSION OF LOCAL ANESTHETIC IN THE RAT.
003157 04-04

P-CHLOROPHENYLALANINE PRODUCES DISSOCIATED EFFECTS ON AGGRESSION EMOTIONALITY AND MOTOR ACTIVITY.

INTRUDER-EVOKED AGGRESSION IN ISOLATED AND NONISOLATED MICE: EFFECTS OF PSYCHOMOTOR STIMULANTS AND L-DOFA.

ACUTE AND CHRONIC EFFECTS OF COCAINE ON EXTINCTION-INDUCED AGGRESSION.

003303 04-04 AGGRESSION PROMOTING AND AGGRESSION ELICITING PROPERTIES OF ESTROGEN IN MALE MICE.

003360 04-04 AGGRESSION INCREASE AND WATER COMPETITION DECREASE IN SQUIRREL-MONKEYS GIVEN PHYSOSTIGMINE INJECTIONS.

COMPULSIONS, AGGRESSION, AND SELF-MUTILATION: A HYPOTHALAMIC

003641 04-14

FURTHER STUDIES OF THE AGGRESSIVE BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN REM SLEEP-DEPRIVED RATS. 000331 01-04

EFFICACY OF SCH-12679 IN THE MANAGEMENT OF AGGRESSIVE MENTAL RETARDATES.

000506 01-07 LITHIUM AND AGGRESSIVE BEHAVIOR IN PATIENTS WITH EARLY TOTAL

000618 01-11 CANNABIS, CATECHOLAMINES, RAPID EYE MOVEMENT SLEEP AND AGGRESSIVE BEHAVIOUR.

001320 02-04 EFFECT OF SOME CENTRALLY ACTIVE COMPOUNDS ON AGGRESSIVE BEHAVIOUR IN SEPTAL RATS.

001376 02-04 THE EFFECT OF P-BROMOMETHAMPHETAMINE ON AGGRESSIVE BEHAVIOUR

001392 02-04 A BEHAVIORAL ANALYSIS OF AGGRESSIVE BEHAVIORS INDUCED AND MODULATED BY DELTA9-TETRAHYDROCANNABINOL, PILOCARPINE, D AMPHETAMINE AND L-DOPA.

001419 02-04 LITHIUM-CARBONATE IN THE MANAGEMENT OF HYPERACTIVE AGGRESSIVE BEHAVIOR OF THE MENTALLY RETARDED.

TREATMENT OF HUMAN AGGRESSIVE BEHAVIOR: FOUR CASE STUDIES OF THE EFFECT OF UTHIUM

002532 03-11 AGING EFFECTS OF DIHYDROERGOTOXINE-MESYLATE ON AGING NEURONS IN

002112 03-03 CENTROPHENOXINE: EFFECTS ON AGING MAMMALIAN BRAIN 002287 03-04

AGIOTENSIN-INDUCED DRINKING: SEXUAL DIFFERENCES.

AGITATED DROPERIDOL IN ACUTELY AGITATED PATIENTS: A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY.

000662 01-11 RELATIVE EFFICACY OF PARENTERAL HALOPERIDOL AND THIOTHIXENE FOR THE EMERGENCY TREATMENT OF ACUTELY EXCITED AND AGITATED PATIENTS.

STUDY OF SULTOPRIDE (LIN-1418) IN AGITATED STATES. 001722 02-14

Psychopharmacology Abstracts

TRANYLCYPROMINE (PARNATE) — A STUDY OF 1000 PATIENTS WITH SEVERE AGITATED DEPRESSIONS. 003507 04-09

AGITATION
LOXAPINE VERSUS HALOPERIDOL PARENTERALLY IN ACUTE PSYCHOSIS
WITH AGITATION: A DOUBLE-BLIND STUDY.
001710 02-

001710 02-14

AGONISM

EFFECTS OF CENTRAL GABA RECEPTOR AGONISM AND ANTAGONISM ON

EVOKED DIENCEPHALIC CARDIOVASCULAR RESPONSES.

002811 04-0:

AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT. 000018 01

FLA-136: SELECTIVE AGONIST AT CENTRAL ALPHA-ADRENORECEPTORS MEDIATING CHANGES IN THE TURNOVER OF NORADRENALINE. 000043 01-03

ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEDOMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR.

000086 01-03 AGONIST EFFECTS OF BETA-PHENYLETHYLAMINES ON THE NORADRENERGIC CYCLIC-ADENOSINE-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. 3,5-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. STEREOISOMERS OF P-HYDROXYNOREPHEDRINE.

NOREPINEPHRINE ALPHA RECEPTOR BINDING IN MAMMALIAN CENTRAL-NERVOUS-SYSTEM: DIFFERENTIAL LABELING WITH AGONIST AND ANTAGONIST.

000283 01-03 THE AGONIST AND ANTAGONIST PROPERTIES OF N ALLYL-ENKEPHALINS. 001029 02-02

LERGOTRILE-MESYLATE: AN IN VIVO DOPAMINE AGONIST WHICH
BLOCKS DOPAMINE RECEPTORS IN VITRO.

DOPAMINE RECEPTORS AND ERGOT DRUGS. EVIDENCE THAT AN ERGOLENE DERIVATIVE IS A DIFFERENTIAL AGONIST AT SUBCORTICAL LIMBIC DOPAMINE RECEPTORS.

002019 03-03 DOPAMINERGIC AGONIST PROPERTIES OF EPHEDRINE — THEORETICAL IMPLICATIONS.

002338 03-05 CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE ILLNESS: PARADOXICAL DRUG EFFECTS.

THE CENTRAL EFFECTS OF A NOVEL DOPAMINE AGONIST

002798 04-02 AFFINITIES OF DRUGS FOR THE AGONIST AND ANTAGONIST STATES OF THE DOPAMINE RECEPTOR.

003065 04-03

AGONISTS
ON THE MECHANISM OF THE DECREASE IN CEREBELLAR CYCLIC-GMP
CONTENT ELICITED BY OPIATE RECEPTOR AGONISTS.

000056 (000056 01-03

TRANSCALLOSALLY EVOKED-POTENTIALS AND THE EEG IN THE DECEREBRATE DOG: ACTIONS OF TRYPTAMINERGIC, DOPAMINERGIC AND ADRENERGIC AGONISTS.

NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN SLICES OF MOUSE LIMBIC FOREBRAIN: CHARACTERISATION AND EFFECT OF DOPAMINERGIC AGONISTS.

000256 01-03 EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON FEEDING IN INTACT AND 6 HYDROXYDOPAMINE TREATED RATS.

000378 01-04 DISCRIMINATIVE EFFECTS OF NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT AND SQUIRREL-MONKEY.

000381 01-04 DIFFERENTIAL EFFECTS OF THREE DOPAMINE AGONISTS: APOMORPHINE BROMOCRIPTINE AND LERGOTRILE.

000451 01-04 PARADOXICAL RESPONSE TO DOPAMINE AGONISTS IN TARDIVE-DYSKINESIA. 000809 01-15

EFFECTS OF DOPAMINE AGONISTS IN TARDIVE-DYSKINESIA 000896 01-15 IN VIVO BINDING OF H3-PIMOZIDE IN MOUSE STRIATUM: EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS.

001050 02-03 EFFECT OF DOPAMINERGIC AGONISTS UPON OXYGEN AVAILABILITY FOR CEREBRAL-CORTEX.

001064 02-03 ACTION OF DOPAMINE AGONISTS ON BRAIN VESSELS IN VITRO AND AFTER IN VIVO MICROAPPLICATION.

001107 02-03 THE EFFECTS OF VARIOUS NARCOTIC AGONISTS AND ANTAGONISTS ON DEPRIVATION-INDUCED FLUID CONSUMPTION.

001408 02-04

003385 04-04

001626 02-11

VOLUME 16, SUBJECT INDEX

ANTIPSYCHOTIC EFFECT OF OPIATE AGONISTS.	001661 02-13
TOLERANCE TO HYPOKINESIA ELICITED BY DOPAMINE AGO MICE: HYPOSENSITIZATION OF AUTORECEPTORS?.	NISTS IN
EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AG ANTAGONISTS INTO THE AMYGDALA ON RETENTION OF AVOIDANCE TRAINING IN RATS. (PH.D. DISSERTATION)	PASSIVE
NEUROENDOCRINE STUDIES WITH DOPAMINE AGONISTS IN SCHIZOPHRENIA.	002323 03-04
EFFECTS OF DOPAMINE AGONISTS ON NEURONES IN THE C NUCLEUS AND CEREBRAL-CORTEX OF CATS CHRONICALL	
WITH NEUROLEPTICS.	002829 04-03
CYCLIC-NUCLEOTIDE LEVELS IN THE RAT STRIATUM AND CI IN VIVO EFFECTS OF DOPAMINE AND ACETYLCHOLINE RI AGONISTS AND ANTAGONISTS.	EREBELLUM -
BEHAVIORAL EFFECTS OF DOPAMINE AGONISTS INCREASE	003051 04-03 WITH AGE.
AMPHETAMINE-TYPE REINFORCEMENT BY DOPAMINERGIC THE RAT.	
AGORAPHOBICS	003400 04-04
THE INFLUENCE OF PROPRANOLOL ON THE EXPOSURE IN V	IVO OF
AGORAPHOBICS.	000598 01-10
AGRANULOCYTOSIS AGRANULOCYTOSIS IN PATIENTS TREATED WITH CLOZAPII	NE. A STUDY
OF THE FINNISH EPIDEMIC.	
AGRANULOCYTOSIS ASSOCIATED WITH TRICYCLICS.	001742 02-15
AHR-2277	003642 04-15
ANTIPSYCHOTIC EFFECTS, SIDE-EFFECTS AND EFFECTIVE DO BUTYROPHENONE LENPERONE (AHR-2277).	SES OF THE
BUTTROPHENONE LENPERONE (ARR-2277).	000553 01-08
NARCOANALYSIS: THE FORGOTTEN DIAGNOSTIC AID.	
	000753 01-14
NOW RCA ATTACKS MEMORY AID DRUGS.	001915 02-17
AKATHISIA AKATHISIA DIAGNOSIS: AN OBJECTIVE TEST.	000858 01-15
AKLYLATING 3 HYDROXY-17-ARALKYLMORPHINANS AS POTENTIAL OP	
SITE DIRECTED AKLYLATING AGENTS.	
ALA2-MET-ENKEPHALINAMIDE	001010 02-01
EEG AND BEHAVIORAL EFFECTS OF D ALA2-MET-ENKEPHA THE RAT.	
DECREASE OF CYCLIC-GMP IN CEREBELLUM BY INTRASTRI- MET-ENKEPHALINAMIDE.	001476 02-04 ATAL D ALA2-
ALA2-METHIONINE-ENKEPHALINAMIDE	002828 04-03
DIFFERENT EFFECTS OF METHIONINE-ENKEPHALIN AND D A METHIONINE-ENKEPHALINAMIDE ON THE METABOLISM AND NOREPINEPHRINE IN RAT BRAIN: FACT OR ARTIFA	OF DOPAMINE
ALA2-METS-ENKEPHALINAMIDE	
THE EFFECTS OF D ALA2-MET5-ENKEPHALINAMIDE ON BEY ACTIVITY AND CYCLIC-NUCLEOTIDES IN THE RAT BRAIN DISSERTATION).	(PH.D.
ALBINO	003240 04-04
DIFFERENTIAL EFFECTS OF CONVULSANTS ON VISUALLY EVEN RESPONSES IN THE ALBINO RAT.	
BLOCKADE OF TESTOSTERONE MAINTAINED INTERMALE FI ALBINO LABORATORY MICE BY AN AROMATIZATION IN	NHIBITOR. 003176 04-04
THE EFFECTS OF CHRONIC CHLORPROMAZINE ADMINISTRA ALBINO RAT RETINA.	ATION ON THE
reserve the receive.	003408 04-05

BINDING OF PHENYTOIN, L TRYPTOPHAN AND O METHYL-RED TO ALBUMIN. UNEXPECTED EFFECT OF ALBUMIN CONCENTRATION ON THE BINDING OF PHENYTOIN AND L TRYPTOPHAN.

PRENATAL ALCOHOL CONSUMPTION AND OPEN-FIELD BEHAVIOUR IN RATS: EFFECTS OF AGE AT TIME OF TESTING.

EFFECTS OF ALCOHOL ON ATTACK AND DEFENSIVE SUBMISSIVE REACTIONS IN RATS.

	Subject Index
EFFECTS OF PCPA ON THE CONSUMPTION OF ALCOH- OTHER SOLUTIONS.	OL, WATER AND
EFFECTS OF TAURINE ON ALCOHOL WITHDRAWAL.	000469 01-04
THE INFLUENCE OF ALCOHOL ON THE PERSISTENT EF PERFORMANCE OF THE HYPNOTICS MANDRAX AND THE HYPNOTICS MANDRAY AND THE HYPNOTICS MANDRAY AND THE HYPNOTICS MANDRAY AND THE HYPNO	
PHARMACOLOGICAL INVESTIGATIONS CONCERNING EFFECTS OF ALCOHOL AND OXAZEPAM IN THE RE	000784 01-14 COMBINATION ACTIVITY PATTERN.
SIDE-EFFECTS OF SIMULTANEOUS ALCOHOL AND MA	000897 01-15 ARIJUANA USE. 000900 01-15
DIAZEPAM MAINTENANCE OF ALCOHOL PREFERENCE WITHDRAWAL.	
A BIOCHEMICAL AND BEHAVIORAL ANALYSIS OF CH CONSUMPTION BY RATS.	
INTERACTIONS BETWEEN ALCOHOL AND OTHER DRU AND TEMPERATURE MEASUREMENTS IN GERBILS	
BARBITURATES AND ALCOHOL CONSUMPTION.	001386 02-04
DOSE-RESPONSE EFFECTS OF ALCOHOL UPON RAT ST DIFFERENCES IN REACTIVITY TO ALCOHOL.	001388 02-04 TRAINS BRED FOR
ON THE INFLUENCE OF MOBILETTEN ON THE EFFECT HUMAN: SECOND COMMUNICATION: INFLUENCE UNDER ALCOHOL STRESS.	
EFFECTS OF TRITHIOZINE ON PSYCHOMOTOR SKILLS DRIVING: A COMPARISON WITH DIAZEPAM AND	
ALCOHOL. SELECTION AMONG BENZODIAZEPINES FOR ALCOHO	001723 02-14
THE EFFECTS OF ALCOHOL UPON COOLING RATES OF	001906 02-17
IN 7.5 DEGREES C WATER. MARIJUANA, ALCOHOL, AND COMBINED DRUG EFF	002541 03-12 ECTS ON THE TIME
COURSE OF GLARE RECOVERY. RESIDUAL EFFECTS OF ETHANOL AND CHLORDIAZEP	002604 03-14
FOR ALCOHOL WITHDRAWAL.	002617 03-14
TOLERANCE TO THE HYPOTHERMIC EFFECTS OF A	
ALCOHOL CONSUMPTION IN RATS TREATED WITH L OR RUBIDIUM-CHLORIDE.	JTHIUM-CARBONATE
PSYCHOPHARMACOLOGY OF ALCOHOL.	003159 04-04
DIFFERENTIAL TOLERANCE TO PENTOBARBITAL IN R	003309 04-04 ATS BRED FOR
THE FREQUENCY AND PERSISTENCE OF DEPRESSIVE ALCOHOL ABUSER.	003338 04-04 SYMPTOMS IN THE
SELF-REPORTED ALCOHOL AND NICOTINE USE AND CONTROL OCCIPITAL EEG IN A BIOFEEDBACK SITU	
ALCOHOL-BLOCKER	003622 04-14
DEVELOPMENT OF AN ALCOHOL-BLOCKER, USING C FEG.	COMPUTER ANALYZED
ALCOHOL-DISCRIMINATION	002564 03-13
ALCOHOL-DISCRIMINATION IN GERBILS: INTERACTI BEMEGRIDE, DH-524, AMPHETAMINE, AND DEL'	TA9-THC.
ALCOHOL-INDUCED	001385 02-04
DRUG AND ALCOHOL-INDUCED PSYCHIATRIC SYND	000796 01-15
INTERACTIONS BETWEEN DEPRESSANTS (ALCOHOL-	TYPE) AND
STIMULANTS (AMPHETAMINE-TYPE).	002297 03-04
ON PRESCRIBING MEDICATIONS FOR RECOVERING	000872 01-15
PLASMA CONCENTRATIONS OF SOME ACIDIC AND METABOLITES DERIVED FROM MA AND P-TYRAN	ALCOHOLIC MINE, OCTOPAMINE
AND CATECHOLAMINES IN HUMANS.	001158 02-03

LIMB REDUCTION ANOMALIES IN INFANTS BORN TO DISULFIRAM TREATED ALCOHOLIC MOTHERS.

001817 02-15

003588 04-13

000321 01-04

000413 01-04

Psychopharmacology Abstracts

Subject Index

TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDROME WITH EMD-21657. A DERIVATIVE OF A PYRITINOL METABOLITE: DOUBLE-BLIND CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STUDIES. 003571 04-11

ALCOHOLICS

A DOUBLE-BLIND CROSS-OVER STUDY: APOMORPHINE/PLACEBO IN CHRONIC ALCOHOLICS.

000621 01-11 CEREBROSPINAL FLUID HOMOVANILLIC-ACID IN MALE ALCOHOLICS: EFFECTS OF DISULFIRAM.

000645 01-11 PLACE OF CHLORMETHIAZOLE IN TREATMENT OF ALCOHOLICS 001621 02-11

A BEHAVIORAL TREATMENT OF DEPRESSION WITH ALCOHOLICS RECEIVING PHARMACOLOGICAL AVERSIVE CONDITIONING. (PH.D

002539 03-11 STABILITY OF LOW BLOOD PLATELET MONOAMINE-OXIDASE ACTIVITY IN HUMAN ALCOHOLICS. 003577 04-11

ALCOHOLISM ACUTE HYPOKALEMIC MYOPATHY IN ALCOHOLISM: A CLINICAL ENTITY 000888 01-15 PROGRAMMED FEEDING AS A MODEL OF CHRONIC ALCOHOLISM IN THE

001087 02-03 DOES DIAZEPAM MAINTAIN ALCOHOLISM? 002351 03-05

TREATMENT OF ALCOHOLISM WITH PSYCHOTOMIMETIC DRUGS. A FOLLOW-UP STUDY 003570 04-11

ALCOHOLISM: PRACTICAL ASPECTS OF MANAGEMENT 003572 04-11

ALCOHOLIZED EFFECTS OF LITHIUM ON SEIZURE SUSCEPTIBILITY IN ALCOHOLIZED AND NONALCOHOLIZED RATS.

001315 02-04

CYCLOPROPANIC PYRIDINE ALCOHOLS. 000003 01-01
INTOXICATING EFFECTS OF THREE ALIPHATIC ALCOHOLS AND BARBITAL
ON TWO RAT STRAINS GENETICALLY SELECTED FOR THEIR ETHANOL
INTAKE.

002276 03-04

ALDEHYDE-DEHYDROGENASE
ROLE OF LIVER CYTOSOLIC ALDEHYDE-DEHYDROGENASE ISOZYMES IN
CONTROL OF BLOOD ACETALDEHYDE CONCENTRATIONS. 000222 01-03

ALDEHYDE-DEHYDROGENASES
INDUCIBLE ALDEHYDE-DEHYDROGENASES IN THE HEPATIC CYTOSOL OF THE RAT 001261 02-03

DIET AND UPTAKE OF ALDOMET BY THE BRAIN: COMPETITION WITH NATURAL LARGE NEUTRAL AMINO-ACIDS.

001185 02-03

PLASMA ALDOSTERONE AND MAGNESIUM IN SERUM AND URINE DURING LITHIUM TREATMENT.

000725 01-13 PLASMA ALDOSTERONE DURING LITHIUM TREATMENT. 001500 02.00

ALERTNESS IN EPILEPTICS: PHARMACOLOGICAL AND PSYCHOMETRIC STUDY

002526 03-11 ALIMENTARY

EFFECT OF CHLORPROMAZINE ON ELABORATION AND EXTINCTION OF AN INSTRUMENTAL ALIMENTARY REFLEX IN PUPPIES.

ALIPHATIC INTOXICATING EFFECTS OF THREE ALIPHATIC ALCOHOLS AND BARBITAL ON TWO RAT STRAINS GENETICALLY SELECTED FOR THEIR ETHANOL

INTAKE 002276 03-04

ALKALI-METAL CATIONS: EFFECTS ON ISOLATION-INDUCED AGGRESSION IN THE MOUSE. 001348 02-04

IMIPRAMINE, ITS N DESMETHYL AND HYDROXY METABOLITES IN PLASMA: MICRO DETERMINATION BY ALKALINE FLAME-IONIZATION GAS-CHROMATOGRAPHY (AFID-GC). 002597 03-13

ALKALINE-EARTH
LITHIUM THERAPY AND ALKALINE-EARTH METAL METABOLISM: A
BIOCHEMICAL SCREENING STUDY. 001644 02-13 EFFECTS OF SALSOLINOL, A TETRAHYDROISOQUINOLINE ALKALOID, ON MULTIPLE SCHEDULE PERFORMANCE IN RATS. 002250 03-04

ALKALOIDS
CACTUS ALKALOIDS XXXIII: BETA-PHENETHYLAMINES FROM THE
GUATEMALAN CACTUS PILOSOCEREUS-MAXONII.
00101

BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF HYPOXIC HYPOXIA IN RATS: STUDY OF THE PROTECTION AFFORDED BY ERGOT ALKALOIDS. 001971 03-03

BINDING INTERACTIONS OF ERGOT ALKALOIDS WITH MONOAMINERGIC RECEPTORS IN THE BRAIN. 002024 03-03

INCORPORATION, AFTER SINGLE AND REPEATED APPLICATION OF RADIOACTIVE LABELLED DH-ERGOT ALKALOIDS IN DIFFERENT ORGANS OF THE CAT, WITH SPECIAL REFERENCE TO THE BRAIN.

EFFECT OF ERGOT ALKALOIDS AND OF NEUROLEPTICS ON BINDING TO PUTATIVE DOPAMINE AND ALPHA RECEPTORS.

INTERACTION OF ERGOT ALKALOIDS WITH DOPAMINERGIC RECEPTORS IN THE RAT STRATUM AND NUCLEUS-ACCUMBENS. 002157 03-03

OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINE
ALKALOIDS IN L-DOPA TREATED PARKINSONIAN PATIENTS.

PHARMACOLOGICAL AND BIOCHEMICAL PROPERTIES OF ISOMERIC YOHIMBINE ALKALOIDS. 002987 04-03

ALKOXY-3H-1
SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM EVALUATION OF SOME 5
ALKOXY-3H-1, 4 BENZODIAZEPINES.

ALKYLMORPHINOIDS
EVALUATION OF PURE DIASTEREOMERS OF N SEC ALKYLMORPHINOIDS. 001040 02-02

ALLERGY TO DIAZEPAM.

002681 03-15

002164 03-03

ALLEVIATE THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION.

ALLEVIATIVE RURAL URBAN DIFFERENCES IN THE USE OF STRESS ALLEVIATIVE DRUGS. 001938 02-17

DRUG THERAPY: ALLIANCE AND COMPLIANCE.

002749 03-17 METABOLIC RESPONSES TO ISOPROTERENOL AND EPINEPHRINE IN THE RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES AND PRETREATMENT WITH PROPRANOLOL.

000227 01-03 RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION WITH A HIGH FAT/PROTEIN DIET.

002278 03-04 ALLYL-ENKEPHALINS
THE AGONIST AND ANTAGONIST PROPERTIES OF N ALLYL-ENKEPHALINS

001029 02-02 ALLYLGLYCINE

REGIONAL CHANGES IN CEREBRAL GABA CONCENTRATION AND CONVULSIONS PRODUCED BY D AND BY L ALLYLGLYCINE. 002954 04-03

THE EFFECTS OF ALLYLGLYCINE ON GABA SYNTHESIS IN VIVO 002997 04-03 ALOSTERIC

ALOSTERIC CHANGES IN PLASMA PROTEINS IN HEALTHY VOLUNTEERS AFTER ADMINISTRATION OF LYSERGAMIDE.

-ACETYLMETHADOL BEHAVIORAL EFFECTS OF PSYCHOTHERAPEUTIC AGENTS IN RATS CHRONICALLY DOSED WITH ALPHA-ACETYLMETHADOL.

003280 04-04 REACTIVITY AND AGGRESSION IN THE RAT: INDUCTION BY ALPHA-ADRENERGIC BLOCKING AGENTS INJECTED VENTRAL TO ANTERIOR SEPTUM BUT NOT INTO LATERAL SEPTUM.

000309 01-04 BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101 BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN RAT CEREBRAL-CORTEX.

CHARACTERIZATION OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS IN MEMBRANES PREPARED FROM THE RABBIT IRIS BEFORE AND AFTER DEVELOPMENT OF SUPERSENSITIVITY.

VOLUME 16, SUBJECT INDEX

Subject Index

ALPHA-ADRENOCEPTOR

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF

ALPHA-ADRENOCEPTOR BLOCKADE BY TRICYCLIC ANTIDEPRESSANTS. 001244 02-03 ANTAGONISM BY MIANSERIN AND CLASSICAL ALPHA-ADRENOCEPTOR BLOCKING DRUGS OF SOME CARDIOVASCULAR AND BEHAVIORAL

EFFECTS OF CLONIDINE.

002138 03-03

ALPHA-ADRENOCEPTORS

EFFECTS OF BUTYROPHENONES ON THE SYMPATHETIC NERVES OF THE ISOLATED RABBIT HEART AND ON THE POSTSYNAPTIC ALPHA-ADRENOCEPTORS OF THE ISOLATED RABBIT AORTA.

NEUROCHEMICAL AND BEHAVIORAL EFFECTS OF CLONIDINE AND RELATED IMIDAZOLINES: INTERACTION WITH ALPHA-ADRENOCEPTORS 002156 03-03

TRIAL OF AN ALPHA-ADRENOLYTIC DRUG (INDORAMIN) FOR NOCTURNAL ENURESIS. 003573 04-11

ALPHA-ADRENORECEPTOR
PERIPHERAL ALPHA-ADRENORECEPTOR AND CENTRAL DOPAMINE RECEPTOR ACTIVITY IN DEPRESSIVE PATIENTS.

003489 04-09

ALPHA-ADRENORECEPTORS
FLA-136: SELECTIVE AGONIST AT CENTRAL ALPHA-ADRENORECEPTORS
MEDIATING CHANGES IN THE TURNOVER OF NORADRENALINE. 000043 01-03 MODULATION OF DEXAMPHETAMINE-INDUCED COMPULSIVE GNAWING --INCLUDING THE POSSIBLE INVOLVEMENT OF PRESYNAPTIC ALPHA-

ADRENORECEPTORS

002322 03-04

RECOVERY OF AMNESTIC EFFECT OF ALPHA-AMANITIN BY POSTTRAINING ADMINISTRATION OF D AMPHETAMINE IN THE RAT.

000416 01-04

D ALPHA-AMINOADIPATE, ALPHA-EPSILON-DIAMINOPIMELIC-ACID AND H-966 AS ANTAGONISTS OF AMINO-ACID-INDUCED AND SYNAPTIC EXCITATION OF MAMMALIAN SPINAL NEURONES IN VIVO.

002831 04-03 MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMATURE RAT.

002901 04-03

ALPHA-BUNGAROTOXIN
ALPHA-BUNGAROTOXIN BLOCKS REVERSIBLY CHOLINERGIC INHIBITION IN THE COCHLEA.

002908 04-03

SOME OBSERVATIONS ON THE BINDING PATTERNS OF ALPHA-BUNGAROTOXIN IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT. 002956 04-03

GAMMA-ENDORPHIN, ALPHA-ENDORPHIN AND MET-ENKEPHALIN ARE FORMED EXTRACELLULARLY FROM LIPOTROPIN C-FRAGMENT. 001963 03-03

ALPHA-EPSILON-DIAMINOPIMELIC-ACID

D ALPHA-AMINOADIPATE, ALPHA-EPSILON-DIAMINOPIMELIC-ACID AND
H-966 AS ANTAGONISTS OF AMINO-ACID-INDUCED AND SYNAPTIC **EXCITATION OF MAMMALIAN SPINAL NEURONES IN VIVO**

MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMATURE RAT.

002901 04-03

ALPHA-FLUPENTHIXOL-INDUCED
THE EFFECT OF BACLOFEN ON ALPHA-FLUPENTHIXOL-INDUCED CATALEPSY
IN THE RAT. 003203 04-04

ALPHA-METHYL-P-TYROSINE

EFFECTS OF ALPHA-METHYL-P-TYROSINE, ADRENOLYTIC COMPOUNDS,
PIMOZIDE AND OTHER NEUROLEPTICS, ON THE NARCOTIC CUE.

000338 01-04

TIME-DEPENDENT DISRUPTIVE EFFECTS OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE ON DEVELOPMENT OF MORPHINE TOLERANCE. 002058 03-03 EFFECT OF ALPHA-METHYL-P-TYROSINE ON THE INCIDENCE OF SPONTANEOUS CONVULSIONS OBSERVED FOLLOWING BARBITAL

WITHDRAWAL

002104 03-03
REWARD VERSUS PERFORMANCE IN SELF-STIMULATION: ELECTRODE
SPECIFIC EFFECTS OF ALPHA-METHYL-P-TYROSINE ON REWARD IN THE 002225 03-04 THE EFFECT OF NEUROLEPTICS AND ALPHA-METHYL-P-TYROSINE ON SERUM PROLACTIN LEVELS IN LABORATORY ANIMALS AND MAN. 002582 03-13

ALPHA-METHYLDOPA

EFFECT OF ALPHA-METHYLDOPA ON DOPAMINERGIC TRANSMISSION IN
THE CORPUS-STRIATUM.

HYPOTENSION AND HYPOTHALAMIC AMINE METABOLISM AFTER LONG-TERM ALPHA-METHYLDOPA INFUSIONS.

ALPHA-METHYLDOPAMINE — A METABOLITE AND KEY INTERMEDIATE IN THE METABOLIC DISPOSITION OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) IN DOG AND MONKEY. 001195 02-03

ALPHA-METHYLTRYPTOPHAN

EFFECTS OF P-CHLOROPHENYLALANINE AND ALPHA-METHYLTRYPTOPHAN

ON BEHAVIOUR AND BRAIN 5 HYDROXYINDOLES. 000405 01-04

ALPHA-METHYLTYEOSINE HA-METHYLTYROSINE

EFFECT OF ALPHA-METHYLTYROSINE (MT) PRETREATMENT ON D

AMPHETAMINE (A) AND MORPHINE (M) INDUCED MOOD IN MAN.

001714 02-14

EFFECT OF NEUROLEPTIC DRUGS ON THE CONDITIONED BEHAVIOR AFTER PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.

002290 03-04

ALPHA-MOTONEURON THE EFFECT OF SEROTONIN PRECURSORS ON ALPHA-MOTONEURON AND GAMMA-MOTONEURON ACTIVITY.

002107 03-03

ALPHA-MOTONEURONES
SPECIFIC ACTION OF NARCOTICS ON REFLEX ACTIVATION OF RAT ALPHA-MOTONEURONES. 000174 01-03

ALPHA-MSH

THE EFFECTS OF NEONATAL INJECTIONS OF ALPHA-MSH ON THE OPEN-FIELD BEHAVIOR OF JUVENILE AND ADULT RATS.

OO1309 02-04
INCREASE OF HIPPOCAMPAL ACETYLCHOLINE TURNOVER RATE AND THE
STRETCHING YAWNING SYNDROME ELICITED BY ALPHA-MSH AND

ALPHA-NORADRENERGIC BLOCKADE OF INTRACRANIAL SELF-STIMULATION BY ANTIPSYCHOTIC DRUGS: FAILURE TO CORRELATE WITH CENTRAL ALPHA-NORADRENERGIC BLOCKADE.

000475 01-04

BRAIN NEUROTRANSMITTER RECEPTORS AFTER LONG-TERM HALOPERIDOL: DOPAMINE, ACETYLCHOLINE, SEROTONIN, ALPHA-NORADRENERGIC AND NALOXONE RECEPTORS.

ALPHA-NORADRENERGIC RECEPTORS IN THE BRAIN: DIFFERENTIAL EFFECTS OF SODIUM ON BINDING OF H3-AGONISTS AND H3-

002029 03-03 TRICYCLIC ANTIDEPRESSANTS: THERAPEUTIC PROPERTIES AND AFFINITY
FOR ALPMA-NORADRENERGIC RECEPTOR BINDING SITES IN THE BRAIN 003118 04-03

ALPHA-RECEPTORS

BLOCKADE OF PRESYNAPTIC ALPHA-RECEPTORS AND OF AMINE UPTAKE IN THE RAT BRAIN BY THE ANTIDEPRESSANT MIANSERINE.

H3-CATECHOLAMINE BINDING TO ALPHA-RECEPTORS IN RAT BRAIN-ENHANCEMENT BY RESERVINE.

ADRENERGIC ALPHA-RECEPTORS AND BETA-RECEPTORS EXPRESSED BY THE SAME CELL TYPE IN PRIMARY CULTURE OF PERINATAL MOUSE

003121 04-03

ALPHA-T-BUTYLAMINO-3-CHLOROPROPIOPHENONE
BUPROPION-HYDROCHLORIDE ((/-) ALPHA-T-BUTYLAMINO-3CHLOROPROPIOPHENONE HCL): A NOVEL ANTIDEPRESSANT AGENT 001038 02-02

COMPUTER OCULOGRAPHIC DOUBLE-BLIND STUDY OF CHANGES IN VIGILANCE: ALPRENOLOL VERSUS DIAZEPAM. 001746 02-15

ALTERATION

EFFECT OF ALTERATION OF METABOLISM ON THE ANALGESIC ACTIVITY, TOXICITY, DISTRIBUTION AND EXCRETION OF L-ALPHA-ACETYLMETHADOL IN THE RAT.

ALTERATION OF THE NEURONAL RESPONSE TO AMPHETAMINE IN THE NEOSTRIATUM BY PRETREATMENT WITH A CENTRALLY ACTING

000298 01-03 CLOZAPINE AND PHENOXYBENZAMINE (PBZ) ALTERATION OF CENTRAL PHENYLETHYLAMINE (PEA) TURNOVER.

001177 02-03

002644 03-14

ALTERATION OF L-DOPA EFFECT ON BRAIN DOPA AND DOPAMINE LEVELS WITH NICOTINIC-ACID AND N METHYL NICOTINAMIDE. (PH.D. DISSERTATION).

QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P-450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3 METHYCHOLANTHRENE. 002083 03-03

EFFECTS OF ETHANOL: ALTERATION BY INORGANIC IONS AND NALDXONE.

FORMAMIDINE-INDUCED FEEDING AND BEHAVIORAL ALTERATION IN THE

002294 03-04
ALTERATION OF TRICARBOXYLIC-ACID CYCLE METABOLISM IN RAT
BRAIN SLICES BY HALOTHANE.

002861 04-03 CORRELATION OF PHENOBARBITAL-INDUCED AND SKF-525-A-INDUCED MODIFICATION OF PENTOBARBITAL HYPNOSIS WITH ALTERATION OF IN VIVO AND IN VITRO PENTOBARBITAL METABOLISM IN THE RAT. 003008 04-03

ALTERATIONS IN BRAIN 5 HYDROXYTRYPTAMINE METABOLISM DURING THE WITHDRAWAL PHASE AFTER CHRONIC TREATMENT WITH DIAZEPAM AND BROMAZEPAM.

000038 01-03 TIME-COURSE OF LITHIUM-INDUCED ALTERATIONS IN RENAL AND ENDOCRINE FUNCTION IN NORMAL AND BRATTLEBORD RATS WITH HYPOTHALAMIC DIABETES-INSIPIDUS.

STRESS-INDUCED ALTERATIONS OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN: EFFECTS OF CENTRALLY ACTING DRUGS.

ALTERATIONS INDUCED IN DISTRIBUTION AND IN VIVO METABOLISM OF IMPRAMINE BY PREGNENOLONE-16ALPHA-CARBONITRILE.

ALTERATIONS IN DOPAMINE RECEPTOR SENSITIVITY BY CHRONIC ETHANOL TREATMENT

001146 02-03 ALTERATIONS IN BRAIN HISTAMINE AND HISTIDINE-DECARBOXYLASE ACTIVITY AFTER HALOPERIDOL AND IMIPRAMINE.

ELECTROSHOCK ANTICONVULSANT ACTIVITY AND BRAIN ACETYLCHOLINE ALTERATIONS IN MICE TREATED WITH SELECT BENZODIAZEPINES.

001210 02-03 DEVELOPMENT OF DENERVATION ALTERATIONS IN SURFACE MEMBRANES OF MAMMALIAN SKELETAL MUSCLE.

ALTERATIONS OF EEG ACTIVITIES AND COCAINE-INDUCED CONVULSIONS FOLLOWING PROLONGED COCAINE TREATMENT IN THE RHESUS MONKEY.

002091 03-03 ALTERATIONS IN MORPHINE ANALGESIA PRODUCED BY CHRONIC DEFICITS OF BRAIN CATECHOLAMINES OR SEROTONIN: ROLE OF ANALGESIMETRIC PROCEDURE.

ALTERATIONS IN THE FUNCTION OF THE NUCLEUS LOCUS-COERULEUS: A POSSIBLE MODEL FOR STUDIES OF ANXIETY.

002298 03-04 ALTERATIONS OF CEREBROSFINAL FLUID 5 HYDROXYINDOLEACETIC-ACID, AND TOTAL BLOOD SEROTONIN CONTENT DURING CLOZAPINE TREATMENT.

002545 03-13
REGIONAL SENSITIVITY OF PRIMATE BRAIN DOPAMINERGIC NEURONS TO HALOPERIDOL: ALTERATIONS FOLLOWING CHRONIC TREATMENT.

002812 04-03 MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID AND TAURINE CONTENTS AND L GLUTAMATE DECARBOXYLASE ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE CORRELATES WITH ANALGESIC ACTION OF MORPHINE.

O02984 04-03
ON THE RELATION BETWEEN HALOPERIDOL-INDUCED ALTERATIONS IN DA
RELEASE AND DA METABOLISM IN RAT STRIATUM.

ALTERATIONS IN RECEPTORS CONTROLLING DOPAMIME SYNTHESIS AFTER CHRONIC ETHANOL INGESTION.

NGF-INDUCED ALTERATIONS IN PROTEIN SECRETION AND SUBSTRATE ATTACHED MATERIAL OF A CLONAL NERVE CELL LINE.

NEUROTRANSMITTER MECHANISMS DURING MENTAL ILLNESS INDUCED BY ALTERATIONS IN THYROID FUNCTION.

ALTERED

ALTERED RECEPTOR SENSITIVITY FOLLOWING CHRONIC DRUG ADMINISTRATION IN MAN: THE TARDIVE-DYSKINESIA MODE

000248 01-03 CEREBRAL CIRCULATION IS ALTERED BY A POTENT ACTH4-9 ANALOG ORG-2766.

001135 02-03

003636 04-14

Psychopharmacology Abstracts

THE EFFECT OF LITHIUM ON SEROTONIN METABOLISM IN THE BRAIN OF RATS WITH PARTICULAR ATTENTION TO ITS EFFECT UNDER THE MONOAMINE ALTERED CONDITIONS.

002110 03-03

ALTERING
DRUGS ALTERING INSULIN SECRETION: EFFECTS ON PLASMA AND BRAIN
CONCENTRATIONS OF AROMATIC-AMINO-ACIDS AND ON BRAIN 5
HYDROXYTRYPTAMINE TURNOVER.
000088 01-0

ALTERNATIVE
THE PRODUCTION OF AN ALTERNATIVE LABORATORY MODEL OF THE PARKINSON SYNDROME USING A NEW BENZYLIMIDOYLUREA DERIVATIVE LON-954.

DO00083 0

0000083 01-03 TRACE AMINES AND ALTERNATIVE NEUROTRANSMITTERS IN THE CENTRAL-NERVOUS-SYSTEM.

003698 04-17 ALTERS

RESTRAINT ALTERS THE EFFECTS OF MORPHINE AND HEROIN ON CORE TEMPERATURE IN THE RAT.

001186 02-03 PRENATAL MORPHINE ADMINISTRATION ALTERS BEHAVIORAL DEVELOPMENT IN THE RAT.

002308 03-04 DISULFIRAM ALTERS DOPAMINE METABOLISM AT SITES IN RATS FOREBRAIN AS DETECTED BY PUSH-PULL PERFUSIONS.

METHYLENE-BLUE ALTERS RETENTION OF INHIBITORY AVOIDANCE RESPONSES

SYSTEMIC ADMINISTRATION OF ENDORPHINS SELECTIVELY ALTERS OPEN-FIELD BEHAVIOR OF RATS.

003382 04-04

POSSIBLE BIOCHEMICAL BASIS OF MEMORY DISORDER IN ALZHEIMER DISEASE 003575 04-11

NEUROTRANSMITTER PRECURSOR AMINO-ACIDS IN THE TREATMENT OF MULTIINFARCT DEMENTIA AND ALZHEIMERS DISEASE.

000647 01-11

AMANTADINE
TREATMENT OF SPASMODIC TORTICOLLIS WITH AMANTADINE: A
DOUBLE-BLIND STUDY.
D0066

000666 01-11 PHARMACOKINETICS AND CLINICAL EFFECTS OF AMANTADINE IN DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS.

APOMORPHINE AND AMANTADINE: INTERACTION WITH ETHANOL IN

002605 03-14 AMANTADINE IN THE TREATMENT OF BENZTROPINE REFRACTORY
EXTRAPYRAMIDAL DISORDERS INDUCED BY ANTIPSYCHOTIC DRUGS

FOUR-YEAR TREATMENT OF PATIENTS WITH PARKINSONISM USING AMANTADINE ALONE OR WITH LEVODOPA.

002707 03-15 ANTAGONISM OF ETHANOL EVOKED RESPONSES BY AMANTADINE: A POSSIBLE CLINICAL APPLICATION

002797 04-02 ACUTE EFFECTS OF LISURIDE (0.1 MG), AMANTADINE (100 MG) AND TRIHEXYPHENIDYL (5 MG) ON VERBAL ASSOCIATIONS.

003630 04-14

AMANTADINE-HYDROCHLORIDE

AMANTADINE-HYDROCHLORIDE (AMN): ANTAGONISM TO ETHANOL
(ETOH) MEDIATED RESPONSES IN RODENTS. 002282 03-04

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON BODY
TEMPERATURE AND BRAIN AMINE CONCENTRATIONS IN THE RAT AT
DIFFERENT AMBIENT TEMPERATURES.

THE THERMAL EFFECTS OF INTERACTION BETWEEN D AMPHETAMINE AND ANTIDEPRESSANTS AMONG RATS KEPT AT VARIOUS AMBIENT TEMPERATURES.

APPLICATION OF LIFE TABLE METHOD TO NATURALISTIC DESIGNS — A COMPARISON OF EFFICACY OF TRICYCLIC ANTIDEPRESSANTS AND BENZODIAZEPINES IN AMBULATORY DEPRESSIVES. 002783 03-17

ACTH4-10 IN THE AMELIORATION OF NEUROPSYCHOLOGICAL SYMPTOMATOLOGY ASSOCIATED WITH SENILE ORGANIC-BRAIN-

002505 03-11

THE EFFECTS OF OBSTETRICAL MEDICATION ON THE BEHAVIOR OF ISRAELI NEWBORN INFANTS AND SOME COMPARISONS WITH URUGUAYAN AND AMERICAN INFANTS.

AMFONELIC-ACID

DIFFERING ACTIONS OF AMFONELIC-ACID (AFA) AND AMPHETAMINE (AMPH) ON STRIATAL DOPAMINE (DA).

001196 02-03

COMPARATIVE EFFECTS OF PEMOLINE, AMFONELIC-ACID AND AMPHETAMINE ON DOPAMINE UPTAKE AND RELEASE IN VITRO AND ON BRAIN 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN SPIPERONE-TREATED RATS.

002919 04-03

AMINE

EFFECTS OF 3,4 DIHYDROOXAZINOINDOLES, POTENTIAL ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED ACTIVITIES.

0000027 01-02

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON BODY TEMPERATURE AND BRAIN AMINE CONCENTRATIONS IN THE RAT AT DIFFERENT AMBIENT TEMPERATURES.

000105 01-03

003594 04-13

001236 02-03

NEW DIRECTION TO THE AMINE HYPOTHESIS.

SELECTIVITY OF H3-BIOGENIC AMINE RELEASE BY D.L AMPHETAMINE AND DRUGS THAT INTERACT WITH SEROTONERGIC NEURONS

001161 02-03 THE EFFECTS OF PSYCHOPHARMACOLOGICAL AGENTS ON CENTRAL-NERVOUS-SYSTEM AMINE METABOLISM IN MAN.

001671 02-13 AMINE NEUROTRANSMITTER STUDIES AND PSYCHIATRIC ILLNESS: TOWARD MORE MEANINGFUL DIAGNOSTIC CONCEPTS. (UNPUBLISHED

001893 02-17 BLOCKADE OF PRESYNAPTIC ALPHA-RECEPTORS AND OF AMINE UPTAKE IN THE RAT BRAIN BY THE ANTIDEPRESSANT MIANSERINE

001965 03-03 IN VIVO EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE IN RAT BRAIN

001987 03-03 THE EFFECT OF CLOMIPRAMINE AND OTHER AMINE UPTAKE INHIBITORS ON MORPHINE ANALGESIA IN LABORATORY ANIMALS.

002072 03-03 EFFECTS OF SUBSTITUTED SPIROISOBENZOFURANPIPERIDINES ON SYNAPTOSOMAL BIOGENIC AMINE TRANSPORT

002087 03-03 NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS

002148 03-03 THE HUMAN PLATELET AS A MODEL FOR THE DOPAMINERGIC NEURON: KINETIC AND PHARMACOLOGIC PROPERTIES AND THE ROLE OF AMINE STORAGE GRANULES.

002596 03-13 THE BIOLOGY OF AFFECTIVE-ILLNESS: AMINE NEUROTRANSMITTERS AND DRUG RESPONSE

002746 03-17 HYPOTENSION AND HYPOTHALAMIC AMINE METABOLISM AFTER LONG TERM ALPHA-METHYLDOPA INFUSIONS.

002914 04-03 THE ANTAGONISM OF THE ANALGESIC EFFECT OF DIPYRONE BY L-DOPA AND ITS RELATION TO BRAIN AMINE CONCENTRATIONS.

002977 04-03 EFFECTS OF SINGLE DOSES OF TRANYLCYPROMINE ON PLATELET MAO AND AMINE UPTAKE IN NORMAL SUBJECTS.

AMINE-INDUCED

ANTAGONISM OF BIOGENIC AMINE-INDUCED DEPRESSION OF CEREBRAL CORTICAL NEURONES BY NA-K-ATPASE INHIBITORS. 000254 01-03

BIOCHEMICAL AMD PHARMACOLOGICAL STUDIES ON AMINEPTINE (S-1694) AND () AMPHETAMINE IN THE RAT.

AMINERGIC AND THERMOREGULATORY MECHANISMS IN HYPOTHALAMIC REGULATION OF GROWTH HORMONE IN CATS. 000249 01-03

EFFECTS OF ESTROGEN AND AMINERGIC DRUGS ON THRESHOLDS OF MEDIAL BASAL HYPOTHALAMIC AXONS IN THE MEDIAN EMINENCE OF

002974 04-03 AMINES

AUTORADIOGRAPHIC STUDIES WITH SYMPATHOMIMETIC AMINES 000079 01-03

EFFECTS OF ORG-6582, CHLORIMIPRAMINE AND DESMETHYLIMIPRAMINE ON THE DEPLETION OF BIOGENIC AMINES FROM THE RAT BRAIN IN

UPTAKE INHIBITION OF BIOGENIC AMINES BY NEWER ANTIDEPRESSANT DRUGS: RELEVANCE TO THE DOPAMINE HYPOTHESIS OF DEPRESSION 000232 01-03 STUDIES ON THE INFLUENCE OF BIOGENIC AMINES AND PSYCHOACTIVE DRUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMULATION TEST IN ENDOGENOUS DEPRESSION.

STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT

EFFECTS OF AMPHETAMINE ON BRAIN BIOGENIC AMINES IN ISOLATED AND AGGREGATED RATS

001182 02-03 FACILITATION OF SIDMAN AVOIDANCE PERFORMANCE BY P CHLOROAMPHETAMINE: ROLE OF BIOGENIC AMINES.

EFFECTS OF PARGYLINE ON HYPOTHALAMIC BIOGENIC AMINES AND SERUM PROLACTIN (PRL), LH AND TSH IN MALE RATS.

EFFECT OF METABOLIC INHIBITORS AND OUABAIN ON AMPHETAMINE-INDUCED AND POTASSIUM-INDUCED RELEASE OF BIOGENIC AMINES FROM ISOLATED BRAIN TISSUE.

EFFECTS OF BIOGENIC AMINES AND PSYCHOTROPIC DRUGS ON ENDOGENOUS PROSTAGLANDIN BIOSYNTHESIS IN THE RAT BRAIN HOMOGENATES

BROMOCRIPTINE, DIHYDROERGOTOXINE, METHYSERGIDE, D LSD, CF-25 397, AND CF-29-712: EFFECTS ON THE METABOLISM OF BIOGENIC AMINES IN THE BRAIN OF THE RAT.

A DISORDER OF BIOGENIC AMINES IN DIHYDROPTERIDINE-REDUCTASE DEFICIENCY

003554 04-11 TRACE AMINES AND ALTERNATIVE NEUROTRANSMITTERS IN THE CENTRAL-NERVOUS-SYSTEM.

STEREOCHEMICAL STUDIES ON MEDICINAL AGENTS, 23, SYNTHESIS AND
BIOLOGICAL EVALUATION OF 6 AMINO DERIVATIVES OF NALOXONE AND NALTREXONE.

001004 02-01

AMINO-ACID
EFFECTS OF FLURAZEPAM ON AMINO-ACID EVOKED RESPONSES FECTS OF FLURAZEPAM ON AMINU-ACID EVENTURE REGISTRIAL CORD. RECORDED FROM THE LOBSTER MUSCLE AND THE FROG SPINAL CORD. 002115 03-03 REVERSAL OF THE ACTION OF AMINO-ACID ANTAGONISTS BY

BARBITURATES AND OTHER HYPNOTIC DRUGS. 002838 04-03 NEUROPHARMACOLOGY OF AMINO-ACID INHIBITORY TRANSMITTERS. 002967 04-03

AMINO-ACID-INDUCED D ALPHA-AMINOADIPATE, ALPHA-EPSILON-DIAMINOPIMELIC-ACID AND H-966 AS ANTAGONISTS OF AMINO-ACID-INDUCED AND SYNAPTIC EXCITATION OF MAMMALIAN SPINAL NEURONES IN VIVO

MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMATURE RAT.

002901 04-03

THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS OF MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE.

NEUROTRANSMITTER PRECURSOR AMINO-ACIDS IN THE TREATMENT OF MULTIINFARCT DEMENTIA AND ALZHEIMERS DISEASE.

DIFFERENTIAL ANTAGONISM BY CHLORPROMAZINE AND DIAZEPAM OF FROG MOTONEURONE DEPOLARIZATION INDUCED BY GLUTAMATE RELATED AMINO-ACIDS

DIET AND UPTAKE OF ALDOMET BY THE BRAIN: COMPETITION WITH NATURAL LARGE NEUTRAL AMINO-ACIDS.

001185 02-03 METABOLISM OF GAMMA-HYDROXYBUTYRATE BY RAT BRAIN: RELATIONSHIP TO THE KREBS-CYCLE AND METABOLIC COMPARTMENTATION OF AMINO-ACIDS.

002896 04-03 EFFECTS OF L GLUTAMATE AND RELATED AMINO-ACIDS UPON THE RELEASE OF H3-DOPAMINE FROM RAT STRIATAL SLICES. 003340 04-04

AMINO-6-7-DIHYDROXYTETRAHYDRONAPHTHALENE

THE UPTAKE AND RELEASE OF H3-2 AMINO-6-7-DIHYDROXYTETRAHYDRONAPHTHALENE (ADTN) BY STRIATAL NERVE **TERMINALS**

AMINO-7-METHOXYTETRAHYDROACRIDINE
INTERACTION OF IMIPRAMINE AND 3 QUINUCLIDYL-BENZILATE WITH 9
AMINO-7-METHOXYTETRAHYDROACRIDINE ON THE AFTER-DISCHARGES IN THE LIMBIC SYSTEM.

002945 04-03

DACETA

INOACETAMIDOBENZOPHENONE
ENZYMIC DEALEYLATION OF A SUBSTITUTED
AMINOACETAMIDOBENZOPHENONE AND CYCLIZATION TO THE
CORRESPONDING BENZODIAZEPINE IN VITRO.

000152 01-03 THE METABOLISM OF A SUBSTITUTED AMINOACETAMIDOBENZOPHENONE AND CYCLIZATION TO THE CORRESPONDING BENZODIAZEPINE IN THE RAT IN VIVO.

SYNTHESIS AND PRELIMINARY PHARMACOLOGICAL ACTIVITY OF AMINOALKOXY ISOSTERES OF GLYCOLATE ESTER ANTICHOLINERGICS 001026 02-02

000242 01-03

AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID

EFFECT OF 1 AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID (CYCLOLEUCINE)
ON DEVELOPING RAT CENTRAL-NERVOUS-SYSTEM PHOSPHOLIPIDS.

002136 03-03

AMINODIHYDROXYTETRAHYDRONAPHTHALENE
DOPAMINE RECEPTOR BINDING OF H3-ADTN (2
AMINODIHYDROXYTETRAHYDRONAPHTHALENE) REGULATED BY
GUANYL-NUCLEOTIDES. 002877 04-03

AMINOETHYLISOTHOURONIUM
VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF 2
AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF NAD:NADH AND
NORELEAGNINE A BETA-CARBOLINE DERIVATIVE. 000200 01-03

AMINOMETHYLATION
IMIPRAMINE DERIVATIVES: AMINOMETHYLATION OF DIPHENYLAMINE
AND IMINODIBENZYL.

000011 01-01

AMINOMETHYLENE-IMIDAZOBENZODIAZEPINONES
CENTRAL-NERVOUS-SYSTEM ACTIVITY OF A NOVEL CLASS OF
ANNELATED 1,4 BENZODIAZEPINES, AMINOMETHYLENEIMIDAZOBENZODIAZEPINONES. 001000 02-01

AMINOOXYACETIC-ACID-INDUCED EFFECT OF DIAZEPAM AND PENTOBARBITAL ON AMINOOXYACETIC-ACID-INDUCED ACCUMULATION OF GABA.

POSTMORTEM AND AMINOOXYACETIC-ACID-INDUCED ACCUMULATION OF GABA: EFFECT OF GAMMA-BUTYROLACTONE AND PICROTOXIN. 003042 04-03

AMINOPHENETHYLAMINE
SELECTIVE MONOAMINE-OXIDASE INHIBITORS. 1. COMPOUNDS RELATED
TO 4 AMINOPHENETHYLAMINE.

001945 03-01 AMINOPHYLLINE
COMPARATIVE TOXICITY OF CAFFEINE AND AMINOPHYLLINE IN YOUNG
AND ADULT RATS.

002342 03-05 REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF L-DOPA, AMINOPHYLLINE, AND EPHEDRINE.

002544 03-13 AMINOPYRIDINE

EFFECTS OF 4 AMINOPYRIDINE ON TRANSMISSION IN EXCITATORY AND
INHIBITORY SYNAPSES IN THE SPINAL CORD.

001384 02-04 **EFFECTS OF 4 AMINOPYRIDINE ON NEUROMUSCULAR TRANSMISSION** 002991 04-03

AMINOPYRINE-N-DEMETHYLATION
PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL
DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6
TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH
KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

002930 04-03 AMINOPYRROLIDINES

3,4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3 AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND ANTICONVULSANT ACTIVITIES.

000035 01-02 **AMINOSUCCINIMIDES**

NOSUCCINIMIDES

3,4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND
BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3
AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF
POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND
ANTICONVULSANT ACTIVITIES.

000035 01-02 AMINOTETRAHYDROCARBAZOLES

3 AMINOTETRAHYDROCARBAZOLES AS A NEW SERIES OF CENTRALNERVOUS-SYSTEM AGENTS.

000203 07-03 AMINOTETRALIN

DIFFERENTIAL ACTIVATION BY SOME 2 AMINOTETRALIN DERIVATIVES OF THE RECEPTOR MECHANISMS IN THE NUCLEUS-ACCUMBENS OF RAT WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITING.

001335 02-04

Psychopharmacology Abstracts

EFFECTS OF SOME DERIVATIVES OF 2 AMINOTETRALIN ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE AND ON THE BINDING OF H3-HALOPERIDOL TO NEUROLEPTIC RECEPTORS IN RAT STRIATUM. 002853 04-03

AMINOTRANSFERASE
AROMATIC AMINOTRANSFERASE ACTIVITY OF RAT BRAIN CYTOPLASMIC
AND MITOCHONDRIAL ASPARTATE AMINOTRANSFERASES. 002978 04-03

AMINOTRANSFERASES
AROMATIC AMINOTRANSFERASE ACTIVITY OF RAT BRAIN CYTOPLASMIC
AND MITOCHONDRIAL ASPARTATE AMINOTRANSFERASES.
002978 04-03 002978 04-03

AMITRIPTYLINE
STUDIES OF EXCRETION IN RABBIT MILK AFTER ADMINISTRATION OF
CARBON-14 LABELLED AMITRIPTYLINE AND NORTRIPTYLINE.
000037 01-03

A COMPARISON IN RABBIT ISOLATED HEARTS OF THE DYSRHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE, MAPROTILINE AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK NORADRENALINE UPTAKE.

000138 01-03 REINFORCING PROPERTIES OF PERPHENAZINE, HALOPERIDOL AND AMITRIPTYLINE IN RHESUS MONKEYS.

000148 01-03 CONTROLLED TRIAL OF A NEW ANTIDEPRESSIVE, AMOXAPINE, IN COMPARISON WITH AMITRIPTYLINE.

000555 01-09 AMITRIPTYLINE DOSAGE SCHEDULE, SAMPLING TIME AND TRICYCLIC PLASMA LEVELS.

000593 01-09 INDIVIDUAL VARIATIONS IN RESPONSE OF HUMAN REM SLEEP TO AMITRIPTYLINE AND HALOPERIDOL.

000779 01-14 CARDIAC EFFECTS OF AMITRIPTYLINE OVERDOSAGE

000893 01-15 UNUSUAL THERAPEUTIC EFFECT OF AMITRIPTYLINE 000908 01-15

ELECTROCARDIOGRAPHIC FINDINGS IN PATIENTS UNDERGOING AMITRIPTYLINE TREATMENT.

000912 01-15 INTERACTION OF AMITRIPTYLINE AND MORPHINE IN MORPHINE TOLERANT AND NONTOLERANT RATS.

001115 02-03 SPECIFIC RADIOIMMUNOASSAY FOR AMITRIPTYLINE AND NORTRIPTYLINE IN PLASMA.

001534 02-06 AMITRIPTYLINE BLOOD LEVELS AND RELAPSE. 001587 02-09

NORADRENALINE, DEPRESSIVE ILLNESS, AND THE ACTION OF AMITRIPTYLINE

001588 02-09 WHICH TRICYCLIC FOR DEPRESSED OUTPATIENTS, IMIPRAMINE PAMOATE OR AMITRIPTYLINE? 001589 02-09

AMITRIPTYLINE PLASMA LEVELS AND CLINICAL RESPONSE IN PRIMARY DEPRESSION

001594 02-09 YROID FUNCTION AND GROWTH HORMONE SECRETION IN

001596 02-09 AMITRIPTYLINE THERAPY IN ANOREXIA-NERVOSA.

001613 02-10 PERIPHERAL DIABETIC NEUROPATHY TREATED WITH AMITRIPTYLINE AND FLUPHENAZINE.

001705 02-14 NEUROPATHY ASSOCIATED WITH AMITRIPTYLINE: BILATERAL FOOTDROP. 001753 02-15

DOES LONG-TERM TREATMENT WITH AMITRIPTYLINE ALTER THE MONOAMINE-OXIDASE OF RAT BRAIN?.

002042 03-03 THE ACUTE EFFECTS OF AMPHETAMINE, CHLORPROMAZINE, AMITRIPTYLINE AND LITHIUM ON ADENOSINE-5-TRIPHOSPHATASE ACTIVITY IN THE CORTEX OF THE RAT BRAIN.

002094 03-03 A COMPARISON OF DESIPRAMINE AND AMITRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.

002417 03-09 AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL EFFECT: A WORLD HEALTH ORGANIZATION COLLABORATIVE STUDY.

002426 03-09 A COMPARISON OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE (1). 002428 03-09

SELECTED COMBINATIONS OF AMITRIPTYLINE AND ANTIPSYCHOTIC DRUGS AND COMPLEX LEARNING. 002434 03-09

A COMPARISON OF MAPROTILINE (LUDIOMIL) AND SLOW-RELEASE AMITRIPTYLINE (TRYPTIZOL-SR).

002450 03-09 A COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE (2).
002452 03-09

AN EXPERIMENTAL STUDY OF THE EFFECTS OF AMITRIPTYLINE PERPHENAZINE AND AMITRIPTYLINE HALOPERIDOL COMBINATIONS ON INTERPERSONAL LEARNING. EFFECTS OF CHLORDIAZEPOXIDE, AMITRIPTYLINE, IMIPRAMINE, AND THEIR COMBINATIONS ON AVOIDANCE BEHAVIOUR IN MICE PHARMACOKINETIC INTERACTION BETWEEN AMITRIPTYLINE AND **NEUROLEPTICS** 003461 04-08 CONTINUATION THERAPY WITH AMITRIPTYLINE IN DEPRESSION 003488 04-09 TRICYCLIC ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CLINICAL COMPARISON OF CLOMIPRAMINE (ANAFRANIL) AND AMITRIPTYLINE. 003501 04-09 TREATMENT OF ENDOGENOUS DEPRESSION WITH ORAL THYROTROPIN-RELEASING HORMONE AND AMITRIPTYLINE. VILOXAZINE AND AMITRIPTYLINE IN DEPRESSIVE ILLNESS: A DOUBLE-BLIND CONTROLLED TRIAL IN GENERAL PRACTICE. 003506 04-09 A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE
(SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS
(SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE AND NORTRIPTYLINE 003508 04-09 A COMPARATIVE CLINICAL TRIAL OF MIANSERIN (NORVAL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION IN GENERAL 003514 04-09 INHIBITION OF EJACULATION BY AMITRIPTYLINE. 003670 04-15 AMITHIPTY LINE JNDUCED MECHANISMS OF AMITRIPTYLINE-INDUCED HYPOTHERMIA IN THE RA 001176 02-03 THE EFFECT OF AMIZYL AND ARECOLINE ON THE ACTIVITY OF NA-K-ATPASE AND THE CONTENT OF NA AND K IN RAT BRAIN. 002151 03-03 AMMONIUM URINARY EXCRETION OF A QUATERNARY AMMONIUM GLUCURONIDE METABOLITE OF CYPROHEPTADINE IN HUMANS UNDERGOING CHRONIC 001667 02-13 AMANTADINE-HYDROCHLORIDE (AMN): ANTAGONISM TO ETHANOL (ETOH) MEDIATED RESPONSES IN RODENTS. 002282 03-04 COUNTERACTIVE EFFECTS OF NOREPINEPHRINE AND AMPHETAMINE ON OUABAIN-INDUCED AMNESIA. 000122 01-03 EFFECTS OF L DIHYDROXYPHENYLALANINE (L-DOPA) AND DL.5 HYDROXYTRYPTOPHAN (DL, 5-HTP) ON RESERPINE-INDUCED AMNESIA 000427 01-04 FAILURE OF NALOXONE TO PREVENT REDUCTION OF AMNESIA BY ENKEPHALINS. 000438 01-04 EFFECTS OF D AMPHETAMINE AND STRYCHNINE ON CYCLOHEXIMIDE -AND DIETHYLDITHIOCARBAMATE-INDUCED AMNESIA IN MICE 001438 02-04 MEMORY: MODIFICATION OF ANISOMYCIN-INDUCED AMNESIA BY STIMULANTS AND DEPRESSANTS. 002232 03-04 VASOPRESSIN IN AMNESIA 002631 03-14 DRUG CUES, DRUG STATES, AND INFANTILE AMNESIA 003196 04-04 RECOVERY AS A FUNCTION OF THE DEGREE OF AMNESIA DUE TO 003204 04-04 RETROACTIVE AMNESIA INDUCED IN CHICKS BY THE PROLINE ANALOG L BAIKIAIN, WITHOUT EEG SEIZURES OR DEPRESSION 003205 04-04 RETROGRADE AMNESIA PRODUCED BY POSTTRIAL INJECTION OF SUBSTANCE-P INTO SUBSTANTIA-NIGRA 003247 04-04 NOREPINEPHRINE ATTENUATION OF AMNESIA PRODUCED BY DIETHYLDITHIOCARBAMATE

ATTENUATION OF AMNESIA BY HYDROCORTISONE IN THE MOUSE.
003313 04-04

THE AMNESTIC EFFECT OF PROTEIN SYNTHESIS INHIBITORS IS NOT DUE TO THE INHIBITION OF ADRENAL CORTICOSTEROIDOGENESIS.

RECOVERY OF AMNESTIC EFFECT OF ALPHA-AMANITIN BY

ADMINISTRATION OF D AMPHETAMINE IN THE RAT

INFLUENCE OF THE SUSPENSION OF CONTINUED TREATMENT WITH
FLURAZEPAM AND AMOBARBITAL ON TWO DISCRIMINATION LEARNING SCHEDULES. THE EFFECT OF DIAZEPAM, CHLORPROMAZINE AND AMOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION. 000708 01-13 SPECTRAL ANALYSIS OF THE DIFFERING EEG EFFECTS OF BENZODIAZEPINES, MEPROBAMATE, GLUTETHIMIDE AND AMOBARBITAL IN MACACA-MULATTA. 001130 02-03 AMOR PSYCHIATRIC SEQUELAE OF AMOK. 002409 03-08 CONTROLLED TRIAL OF A NEW ANTIDEPRESSIVE, AMOXAPINE, IN COMPARISON WITH AMITRIPTYLINE. DOUBLE-BLIND PLACEBO-CONTROLLED COMPARISON OF AMOXAPINE AND IMIPRAMINE IN DEPRESSED OUTPATIENTS. A DOUBLE-BLIND CLINICAL COMPARISON OF AMOXAPINE, IMIPRAMINE, AND PLACEBO IN THE TREATMENT OF DEPRESSION. 001609 02-09 PHARMACOLOGICAL STUDY OF AMOXAPINE, A DIBENZOXAZEPINE 002307 03-04 THE NEUROPHARMACOLOGICAL ACTIONS OF AMOXAPINE 003235 04-04 AMP SYSTEM: LONGITUDINAL COURSE STUDIES OF PSYCHOPATHOLOGIC AND SOMATIC SYMPTOMS. AN EMPIRIC INVESTIGATION OF THE PROBLEM OF SIDE-EFFECTS 000797 01-15 EFFECT OF GINSENG ON THE BRAIN BIOGENIC MONOAMINES AND 3,5 AMP SYSTEM: EXPERIMENTS ON RATS. 003044 04-03 BIOCHEMICAL DIFFERENTIATION OF AMPHETAMINE VS METHYLPHENIDATE AND NOMIFENSINE IN RATS. 000061 01-03 EFFECTS OF AMPHETAMINE AND CHLORDIAZEPOXIDE ON PROBENECID-INDUCED ACCUMULATION OF ACIDIC METABOLITES IN THE CEREBROSPINAL FLUID OF THE DOG. 000092 01-03 EFFECTS OF RETICULAR STIMULATION, D AMPHETAMINE AND SCOPOLAMINE ON ACETYLCHOLINE RELEASE FROM THE HIPPOCAMPUS OF BRAINSTEM TRANSECTED CATS. 000098 01-03 EFFECTS OF VARIOUS NEUROLEPTICS ON RABBIT HYPERTHERMIA INDUCED BY N.N DIMETHYLTRYPTAMINE (DMT) AND D COUNTERACTIVE EFFECTS OF NOREPINEPHRINE AND AMPHETAMINE ON **OUABAIN-INDUCED AMNESIA.** 000122 01-03 DOPAMINERGIC MECHANISMS INVOLVED IN THE ACUTE AND CHRONIC EFFECT OF AMPHETAMINE O00129 01-03
INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL AND D
AMPHETAMINE. 000139 01-03 MOTILITY RESPONSE TO MORPHINE AND AMPHETAMINE DURING CHRONIC INHIBITION OF TYROSINE-HYDROXYLASE OR DOPAMINE-000166 01-03 KINETICS OF DISTRIBUTION OF AMPHETAMINE IN CATS. 000178 01-03 EFFECTS OF AMPHETAMINE, METHYLPHENIDATE AND COCAINE ON SERUM PROLACTIN CONCENTRATIONS IN THE MALE RAT. 000234 01-03 POTENTIATION BY RESERPINE OF THE INHIBITION BY AMPHETAMINE OF (3H)DOPAMINE ACCUMULATION IN THE RAT STRIATUM. 000246 01-03 ACTIONS OF AMPHETAMINE AND ANTAGONISTS ON PUPIL DIAMETER IN THE CHRONIC SYMPATHECTOMIZED DOG. 000265 01-03 TRANS-SYNAPTIC INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE FOLLOWING AMPHETAMINE TREATMENT IN THE RAT ALTERATION OF THE NEURONAL RESPONSE TO AMPHETAMINE IN THE NEOSTRIATUM BY PRETREATMENT WITH A CENTRALLY ACTING ANTICHOLINERGIC. 000298 01-03 EQUAL SUPPRESSION OF CEREBELLAR PURKINJE CELL ACTIVITY BY AMPHETAMINE STEREOISOMERS 000299 01-03

A DOPAMINERGIC BASIS FOR THE EFFECTS OF AMPHETAMINE ON A MOUSE PREADOLESCENT HYPERKINETIC MODEL.

000310 01-04

003294 04-04

000352 01-04

000416 01-04

POSTTRAINING

EFFECTS OF D AMPHETAMINE ON RESPONDING SIMULTANEOUSLY MAINTAINED AND PUNISHED BY PRESENTATION OF ELECTRIC-SHOCK METABOLIC AND EXPERIENTIAL FACTORS IN THE BEHAVIORAL RESPONSE TO REPEATED AMPHETAMINE.

PARADOXICAL EFFECTS OF AMPHETAMINE ON PREWEANLING AND POSTWEANLING RATS.

TIME ACTION AND BEHAVIORAL EFFECTS OF AMPHETAMINE, ETHANOL, AND ACETYLMETHADOL.

000350 01-04 AMPHETAMINE INDUCES ANOREXIA EVEN AFTER INHIBITION OF NORADRENALINE SYNTHESIS.

000365 01-04 POSSIBLE MECHANISMS INVOLVED IN THE STEREOTYPED BEHAVIOR ELICITED BY AMPHETAMINE.

000372 01-04 EFFECTS OF D AMPHETAMINE ON CONCURRENT SELF-STIMULATION OF FOREBRAIN AND BRAINSTEM LOCI.

LSD AND D AMPHETAMINE EFFECTS ON FIXED-INTERVAL RESPONDING IN THE RAT

EVIDENCE FOR NORADRENERGIC MECHANISM IN THE GROOMING PRODUCED BY () AMPHETAMINE AND 4,GAMMA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.

RECOVERY OF AMNESTIC EFFECT OF ALPHA-AMANITIN BY POSTTRAINING ADMINISTRATION OF D AMPHETAMINE IN THE RAT.

AMPHETAMINE EFFECTS ON BRAIN SLOW POTENTIALS ASSOCIATED WITH DISCRIMINATION IN THE RAT.

000432 01-04

THE EFFECTS OF AMPHETAMINE ON MAZE LEARNING BY GOLDFISH.

000446 01-04 CAFFEINE POTENTIATION OF AMPHETAMINE: IMPLICATIONS FOR HYPERKINESIS THERAPY.

CHANGES IN THE RATE INCREASING EFFECTS OF D AMPHETAMINE AND PENTOBARBITAL BY RESPONSE CONSEQUENCES.

ATTENUATION OF THE RATE DECREASING EFFECTS OF AMPHETAMINE ON FIXED-RATIO RESPONDING IN RATS BY HIPPOCAMPAL LESIONS. 000474 01-04

THE EFFECTS OF HALOPERIDOL, CHLORPROMAZINE AND PROPRANOLOL ON ACUTE AMPHETAMINE POISONING IN THE CONSCIOUS DOG. 000480 01-05

GENETIC ANALYSIS OF THE BEHAVIORAL RESPONSE TO D AMPHETAMINE

000482 01-05 D AMPHETAMINE INHIBITION OF PLATELET MAO FROM SCHIZOPHRENIC

000543 01-08 SLEEP-DEPRIVATION DEFICITS AND THEIR REVERSAL BY D AMPHETAMINE AND L AMPHETAMINE.

000770 01-14 COMPARATIVE EFFECTS OF D AMPHETAMINE, L AMPHETAMINE, AND METHYLPHENIDATE ON MOOD IN MAN.

000790 01-14 NECROTIZING ANGIITIS AND HEPATITIS IN AN AMPHETAMINE ABUSER. 000887 01-15

CASE REPORT: AMPHETAMINE ABSTINENCE PSYCHOSIS DOES IT

900899 01-15
PSEUDOCATATONIA ASSOCIATED WITH ABUSE OF AMPHETAMINE AND

IDENTIFICATION OF M HYDROXYAMPHETAMINE AS A METABOLITE OF AMPHETAMINE IN THE RAT.

001005 02-01 SPECIES VARIATION WITH RESPECT TO THE METABOLISM AND EXCRETION OF D AMPHETAMINE AND D.L N HYDROXYAMPHETAMINE

001091 02-03

TRIPHASIC DOSE LETHALITY RELATIONSHIPS FOR AMPHETAMINE AND CERTAIN RING-SUBSTITUTED AMPHETAMINES IN ISOLATED OR AGGREGATED MICE.

CHANGES IN LIVER FUNCTION IN ACUTE POISONING BY BARBITURATE, RESERPINE AND AMPHETAMINE.

001094 02-03 INFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3-CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN.

AMPHETAMINE LETHALITY IN MICE. (PH.D. DISSERTATION).
001151 02-03

SELECTIVITY OF H3-BIOGENIC AMINE RELEASE BY D.L AMPHETAMINE
AND DRUGS THAT INTERACT WITH SEROTONERGIC NEURONS.
001161 02-03

DECREASE IN NEOSTRIATAL BLOOD FLOW AFTER D AMPHETAMINE ADMINISTRATION OR ELECTRICAL STIMULATION OF THE SUBSTANTIANIGRA.

001175 02-03 EFFECTS OF AMPHETAMINE ON BRAIN BIOGENIC AMINES IN ISOLATED AND AGGREGATED RATS.

001182 02-03 DIFFERING ACTIONS OF AMFONELIC-ACID (AFA) AND AMPHETAMINE (AMPH) ON STRIATAL DOPAMINE (DA).

PHENYLETHYLAMINES AS MEDIATORS OF THE CNS EFFECTS OF AMPHETAMINE.

O01199 02-03

EFFECTS OF D AMPHETAMINE (D-A), PROSTAGLANDIN-E1 AND F-2ALPHA
ON H3-2-DOPAMINE (H3-DA) METABOLISM, FIXED-INTERVAL (FI)
BEHAVIOR AND RECTAL TEMPERATURE.

COMPARATIVE BRAIN/PLASMA CONCENTRATIONS OF AMPHETAMINE ISOMERS IN MICE.

SUBSTITUTED AMPHETAMINE DERIVATIVES. I. EFFECT ON UPTAKE AND RELEASE OF BIOGENIC MONOAMINES AND ON MONOAMINE-OXIDASE IN THE MOUSE BRAIN

BIOCHEMICAL AND PHARMACOLOGICAL STUDIES ON AMINEPTINE (S-1694) AND () AMPHETAMINE IN THE RAT.

A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHOXYAMPHETAMINE (DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), P-METHOXYAMPHETAMINE (PMA), D AMPHETAMINE (A), AND LSD IN MONTOLERANT AND LSD TOLERANT CHRONIC SPINAL DÓGS. 001273 02-03

EFFECT OF D AMPHETAMINE ON THE INHIBITION OF BRAIN CATECHOLAMINE TURNOVER INDUCED BY CYCLOHEXIMIDE

001279 02-03 CIRCADIAN VARIATIONS IN RESPONSES TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT.

THE THERMAL EFFECTS OF INTERACTION BETWEEN D AMPHETAMINE AND ANTIDEPRESSANTS AMONG RATS KEPT AT VARIOUS AMBIENT TEMPERATURES.

THE EFFECT OF SUBCHRONIC ADMINISTRATION OF LITHIUM-CARBONATE ON THE PHARMACOLOGICAL ACTIVITY OF D AMPHETAMINE.

EFFECTS OF D AMPHETAMINE, CHLORDIAZEPOXIDE AND PROMAZINE ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION AND STIMULUS SHOCK

BEHAVIORAL HISTORY AS A DETERMINANT OF THE EFFECTS OF D AMPHETAMINE ON PUNISHED BEHAVIOR.

PHARMACOLOGICAL MANIPULATION OF HOARDING: FURTHER ANALYSIS OF AMPHETAMINE ISOMERS AND PIMOZIDE

001312 02-04 AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOUR AND BRAIN CONCENTRATIONS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN MICE.

O01316 02-04

THE EFFECT OF AMPHETAMINE AND L-DOPA ON TETRABENAZINE-INDUCED SUPPRESSION OF INTRACRANIAL SELF-STIMULATION IN THE RAT.

001321 02-04 INTERACTION OF ARENA SIZE WITH DIFFERENT MEASURES OF AMPHETAMINE EFFECTS.

001329 02-04 COMPARISON OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE AND AMPHETAMINE IN RATS.

001337 02-04 EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION: AMPHETAMINE LEVELS AND EFFECTS UPON SOME ARYLALKYLAMINES IN RAT BRAIN.

001339 02-04 AMPHETAMINE AND CHICK BEHAVIOUR: A ROLE FOR MONOAMINES IN THE CAUSATION OF VOCALIZATIONS AND EMOTIONS.

001342 02-04 DIFFERENTIAL ATTENUATION BY ATROPINE AND D AMPHETAMINE ON HYPERACTIVITY: POSSIBLE CLINICAL IMPLICATIONS.

001347 02-04 THE EFFECTS OF D AMPHETAMINE ON PREY KILLING AND PREY EATING IN THE RAT AND MOUSE.

001361 02-04 EFFECTS OF AMPHETAMINE ON ENDURANCE PERFORMANCE AND MUSCLE WEAKNESS IN RATS.

001363 02-04 RATE-DEPENDENT EFFECTS OF AMPHETAMINE RESULTING FROM BEHAVIORAL COMPETITION.

001368 02-04 EFFECTS OF DIAZEPAM AND D AMPHETAMINE ON FOOD COMPETITION IN RHESUS MONKEY.

001370 02-04

002064 03-03

EFFECTS OF D AMPHETAMINE ON A MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE OF FOOD REINFORCEMENT IN THE CAT.

EFFECTS ON RETENTION OF POSTTRAINING AMPHETAMINE INJECTIONS IN MICE: INTERACTION WITH PRETRAINING EXPERIENCE.

EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE INTOXICATION ON EXPLORATORY AND STEREOTYPED BEHAVIORS IN THE RAT. 001379 02-04

ALCOHOL-DISCRIMINATION IN GERBILS: INTERACTIONS WITH BEMEGRIDE, DH-524, AMPHETAMINE, AND DELTA9-THC.

CHRONIC AND ACUTE EFFECTS OF BARBITAL AND AMPHETAMINE IN

001389 02-04
BEHAVIORAL EFFECTS OF NEUROLEPTICS, APOMORPHINE AND
AMPHETAMINE AFTER BILATERAL LESION OF THE LOCUS-COERULEUS IN

001393 02-04
DIFFERENTIAL EFFECTS OF MORPHINE AND D AMPHETAMINE ON SELFSTIMULATION FROM CLOSELY ADJACENT REGIONS IN RAT MIDBRAIN.

THE EFFECT OF NONCONTINGENT AMPHETAMINE INJECTIONS ON THE EXTINCTION OF FOOD AND DRUG REINFORCED LEVER PRESSING IN PATS

001404 02-04
EFFECT OF D AMPHETAMINE ON LOCOMOTOR ACTIVITY OF LEAD FED
RABBIT NEONATES.

001406 02-04

EFFECTS OF AMPHETAMINE AND NEMBUTAL ON SOCIAL EXPLORATION IN
THE MONGOLIAN GERBIL.

A BEHAVIORAL ANALYSIS OF AGGRESSIVE BEHAVIORS INDUCED AND MODULATED BY DELTA9-TETRAHYDROCANNABINOL, PILOCARPINE, D AMPHETAMINE AND L-DOPA.

001419 02-04
EFFECTS OF L-DOPA, D AMPHETAMINE AND COCAINE ON INTRUDEREVOKED AGGRESSION IN RATS AND MICE.

O01420 02-04
SUBSTITUTED AMPHETAMINE DERIVATIVES. II. BEHAVIOURAL EFFECTS IN MICE RELATED TO MONOAMINERGIC NEURONES.

VARIOUS EFFECTS OF D AMPHETAMINE IN RATS WITH SELECTIVE LESIONS OF BRAIN NORADRENALINE CONTAINING NEURONS OR

TREATED WITH PENFLURIDOL. 001437 02-04

EFFECTS OF D AMPHETAMINE AND STRYCHNINE ON CYCLOHEXIMIDE — AND DIETHYLDITHIOCARBAMATE-INDUCED AMNESIA IN MICE. 001438 02-04 LOCATION PREFERENCE AND FLAVOR AVERSION REINFORCED BY

AMPHETAMINE IN RATS.

001443 02-04

EVALUATION OF SUBSTITUTED AMPHETAMINE HALLUCINOGENS USING

THE CAT LIMB FLICK MODEL. 001449 02-04

D AMPHETAMINE AND ADJUNCTIVE DRINKING IN RATS. 001453 02-04

PASSIVE AVOIDANCE LEARNING IN THE RAT AS FUNCTIONS OF D
AMPHETAMINE DOSAGE AND SHOCK INTENSITY.

001458 02-04
PROGRESSIVE FORCE SCHEDULES IN THE SQUIRREL-MONKEY: EFFECTS OF
INCREMENT SIZE, AMPHETAMINE, AND HALOPERIDOL. (PH.D.

DISSERTATION).

001459 02-04

EFFECTS OF D AMPHETAMINE ON DIFFERENT RATES OF AVOIDANCE

BEHAVIOR IN RATS.

O01488 02-04
THE EFFECT OF COCAINE AND D AMPHETAMINE ON PUNISHED

RESPONDING.

001492 02-04

SOCIOPHARMACOLOGY OF D AMPHETAMINE IN MACAQUE ARCTOIDES II.

PHARMACOLOGICAL MODIFICATION OF SHOCK POTENTIATED

AMPHETAMINE LETHALITY.

O01494 02-04
CONCURRENT INTRACRANIAL SELF-STIMULATION AND AMPHETAMINE
SELF-ADMINISTRATION IN RATS.

O01495 02-04
A SLOW-RELEASE SILICONE PELLET FOR CHRONIC AMPHETAMINE

001529 02-06
NEFOPAM (N), MORPHINE (M), AND D AMPHETAMINE (A) IN MAN:
SUBJECTIVE, BEHAVIORAL, AND PHYSIOLOGIC EFFECTS.

EFFECT OF ALPHA-METHYLTYROSINE (MT) PRETREATMENT ON D
AMPHETAMINE (A) AND MORPHINE (M) INDUCED MOOD IN MAN.

DRUG-PRODUCED CHANGES IN HUMAN SOCIAL BEHAVIOR: FACILITATION
BY D AMPHETAMINE.

001715 02-14

A COMPARISON OF FOOD INTAKE SUPPRESSION PRODUCED BY GIVING AMPHETAMINE AS AN AVERSION TREATMENT VERSUS AS AN ANOREXIC TREATMENT.

BLOCKAGE OF PROGESTERONE-INDUCED RELEASE OF LUTEINIZING HORMONE AND PROLACTIN BY D AMPHETAMINE AND FENFLURAMINE IN RATS.

THE CEREBROVASCULAR PERMEABILITY TO PROTEIN AFTER BICUCULLINE AND AMPHETAMINE ADMINISTRATION IN SPONTANEOUSLY HYPERTENSIVE RATS.

BIPHASIC EFFECTS OF AMPHETAMINE ON STRIATAL DOPAMINE DYNAMICS.

METABOLISM OF AMPHETAMINE BY RAT BRAIN TISSUE.

THE ACUTE EFFECTS OF AMPHETAMINE, CHLORPROMAZINE,
AMITRIPTYLINE AND LITHIUM ON ADENOSINE-S-TRIPHOSPHATASE
ACTIVITY IN THE CORTEX OF THE RAT BRAIN.

MODIFICATION OF THE NORADRENERGIC CYCLIC-AMP GENERATING
SYSTEM IN THE RAT LIMBIC FOREBRAIN BY AMPHETAMINE (A) AND
ITS HYDROXYLATED METABOLITES.

002100 03-03
INVESTIGATIONS INTO THE MECHANISM OF THE INFLUENCE OF KININS ON THE ACTION OF AMPHETAMINE.

O02101 03-03
STIMULUS PROPERTIES OF D AMPHETAMINE AS COMPARED TO L
AMPHETAMINE.

002146 03-03
MORPHINE INCREASES AND D AMPHETAMINE DECREASES THE RATIO OF
DOPAC:HVA IN PUSH-PULL PERFUSATE OF RAT CAUDATE NUCLEUS.
002158 03-03

CHANGES IN MOUSE BRAIN CATECHOLAMINE CONTENT AND TYROSINE-HYDROXYLASE ACTIVITY DURING CHRONIC AMPHETAMINE ADMINISTRATION

CIRCADIAN VARIATIONS IN RESPONSE TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT.

002182 03-03

EFFECT OF BETA ADRENERGIC RECEPTOR ANTAGONISTS ON D

AMPHETAMINE AND POTASSIUM-INDUCED RELEASE OF H3NOREPINEPHRINE FROM RAT BRAIN IN VITEO.

O02187 03-03

EFFECTS OF CHLORDIAZEPOXIDE, OXAZEPAM, CHLORPROMAZINE, AND D

AMPHETAMINE ON SEXUAL RESPONSES IN MALE AND FEMALE

HAMSTERS.

002208 03-04

A DESCRIPTION OF THE NICOTINE STIMULUS AND TESTS OF ITS

GENERALIZATION TO AMPHETAMINE.

002210 03-04

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D AMPHETAMINE

ON SELECTION OF THE SUBSTANTIA NICEA AND COLUMN.

ON SELF-STIMULATION OF THE SUBSTANTIA-NIGRA AND LOCUS-COERULEUS. 002218 03-04

SOME EFFECTS OF CHLORDIAZEPOXIDE AND D AMPHETAMINE ON RESPONSE FORCE DURING PUNISHED RESPONDING IN RATS. 002234 03-04
THE EFFECTS OF AMPHETAMINE ISOMERS ON ROTAROD PERFORMANCE. 002235 03-04

THE REINFORCING PROPERTIES OF PROCAINE AND D AMPHETAMINE COMPARED IN RHESUS MONKEYS.

002239 03-04

EFFECTS OF D AMPHETAMINE, MONOMETHOXYAMPHETAMINES AND HALLUCINOGENS ON SCHEDULE-CONTROLLED BEHAVIOR.

002244 03-04

EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D AMPHETAMINE
AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY
AND SHOCK AVOIDANCE IN RHESUS MONKEYS.

002251 03-04

EFFECTS OF D AMPHETAMINE AND ETHANOL ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION.

BEHAVIOURAL SPECIFIC TOLERANCE FOLLOWING CHRONIC D OR L
AMPHETAMINE TREATMENT: LACK OF INVOLVEMENT OF PHYDROXYMOREPHERPINE

002261 03-04

OPEN-FIELD BEHAVIOR AFTER INTRAVENOUS AMPHETAMINE ANALOGUES
IN RATS.

002272 03-04
RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL
ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION
WITH A HIGH FAT/PROTEIN DIET.

002278 03-04
RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDROXYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN
ACUTE AND CHRONIC SPINAL RATS.
002289 03-04

EFFECTS OF D AMPHETAMINE AND CHLORDIAZEPOXIDE ON POSITIVE CONDITIONED SUPPRESSION.

002295 03-04

THE EFFECT OF D AMPHETAMINE ON GAMMA EFFERENT ACTIVITY IN THE ACUTE DECEREBRATE RAT. 002311 03-04

DECREASED LOCOMOTOR ACTIVITY AND ATTENUATION OF AMPHETAMINE HYPERACTIVITY WITH INTRAVENTRICULAR INFUSION OF SEROTONIN IN THE RAT.

002328 03-04

DISCRIMINATIVE PROPERTIES OF L AMPHETAMINE: STIMULUS GENERALIZATION.

002331 03-04

EFFECTS OF AMPHETAMINE ON SOCIAL BEHAVIORS OF RHESUS MACAQUES: AN ANIMAL MODEL OF PARANOIA. 002365 03-06

AMPHETAMINE PSYCHOSIS -- A MODEL FOR PARANOID SCHIZOPHRENIA?

002413 03-08

ELECTROPHYSIOLOGICAL STUDIES AND AMPHETAMINE METABOLISM IN HYPERACTIVE CHILDREN. 002520 03-11

VIOLENT DYSCONTROL RESPONSIVE TO D AMPHETAMINE. 002528 03-11

DEXTROAMPHETAMINE AND L AMPHETAMINE ARE EQUIPOTENT IN RELEASING HUMAN GROWTH HORMONE.

002576 03-13 BLOOD-BRAIN BARRIER DYSFUNCTION AFTER AMPHETAMINE ADMINISTRATION IN RATS.

002854 04-03 RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D

002862 04-03 COMPARATIVE EFFECTS OF PEMOLINE, AMFONELIC-ACID AND AMPHETAMINE ON DOPAMINE UPTAKE AND RELEASE IN VITRO AND ON BRAIN 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN SPIPERONE-TREATED RATS

002919 04-03 THE EFFECT OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF AMPHETAMINE ON CEREBRAL DOPAMINE RECEPTOR SENSITIVITY 002964 04-03

USE OF STABLE ISOTOPES IN STUDIES ON THE METABOLISM OF AMPHETAMINE.

002970 04-03 CHANGES IN BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS FOLLOWING ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION AND DURING POST AMPHETAMINE DEPRESSION.

002992 04-03 IN VITRO INHIBITION OF MONOAMINE-OXIDASE TYPES A AND B BY D AMPHETAMINE AND L AMPHETAMINE

003016 04-03 EFFECTS OF ETHANOL WITHDRAWAL, STRESS AND AMPHETAMINE ON RAT BRAIN NA-K-ATPASE.

003060 04-03 EFFECT OF () AMPHETAMINE ON THE RETENTION OF H3-CATECHOLAMINES IN SLICES OF NORMAL AND RESERPINIZED RAT BRAIN AND HEART.

003071 04-03 EFFECTS OF D AMPHETAMINE ON THE SET POINT OF THE THERMOREGULATORY SYSTEM IN RATS.

003146 04-03 AMPHETAMINE EFFECTS ON STIMULUS ELICITED INVESTIGATION IN THE MONGOLIAN GERBIL.

003186 04-04 DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE AND D AMPHETAMINE; AND ANTAGONISM BY HALOPERIDOL: A COMPARATIVE STUDY.

003191 04-04 A REFILLABLE SYSTEM FOR CONTINUOUS AMPHETAMINE ADMINISTRATION: EFFECTS UPON SOCIAL BEHAVIOR IN RAT COLONIES.

REINFORCING, DISCRIMINATIVE, AND/OR ACTIVATION PROPERTIES OF AMPHETAMINE.

THE EFFECTS OF PIMOZIDE AND PHENOXYBENZAMINE PRETREATMENTS ON AMPHETAMINE AND APOMORPHINE POTENTIATION OF THE ACOUSTIC STARTLE RESPONSE IN RATS.

003257 04-04 ABATEMENT OF STIMULUS PERSERVATION FOLLOWING REPEATED D
AMPHETAMINE TREATMENT: ABSENCE OF BEHAVIORALLY AUGMENTED TOLERANCE.

003260 04-04 LEAD-INDUCED BEHAVIORAL DISORDERS IN THE RAT: EFFECTS OF AMPHETAMINE.

003261 04-04

PENTOBARBITAL, PROMAZINE, D AMPHETAMINE, AND SCOPOLAMINE EFFECTS ON BEHAVIOR UNDER MULTIPLE AND PRIMED SCHEDULES OF REINFORCEMENT.

POTENTIATION OF HEXOBARBITAL AND AMPHETAMINE EFFECTS IN MALE AND FEMALE RATS PHYSICALLY DEPENDENT ON MORPHINE.

003275 04-04 THE BEHAVIORAL EFFECTS OF D AMPHETAMINE AND CHLORPROMAZINE IN RATS; COMBINATIONS WITH ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE. (PH.D. DISSERTATION).

003278 04-04 OPEN-FIELD AND LASHLEY III MAZE BEHAVIOUR OF THE OFFSPRING OF AMPHETAMINE TREATED RATS.

003315 04-04 EFFECTS OF D AMPHETAMINE ON TEMPORAL AND SPATIAL DISCRIMINATION IN RATS.

003349 04-04 THE EFFECTS OF D AMPHETAMINE AND SCOPOLAMINE ON DRINKING INDUCED BY A MULTIPLE SCHEDULE.

003350 04-04 INTERACTION BETWEEN D AMPHETAMINE AND ETHANOL WITH RESPECT TO LOCOMOTION, STEREOTYPIES, ETHANOL SLEEPING TIME, AND THE KINETICS OF DRUG ELIMINATION.

003378 04-04 DORSOMEDIAL THALAMIC LESIONS AND AMPHETAMINE: ACQUISITION AND RETENTION OF A VISUAL PATTERN DISCRIMINATION ESCAPE TASK.

003399 04-04 THE TRIPHASIC AMPHETAMINE LETHAL DOSE CURVE IN MICE AND ITS POSSIBLE RELATIONSHIP TO DRUG METABOLISM.

003410 04-05 A GENETIC ANALYSIS OF THE HYPERTHERMIC RESPONSE TO D
AMPHETAMINE IN TWO INBRED STRAINS OF MICE.

003411 04-05

EFFECTS OF PIMOZIDE ON THE ACQUISITION, MAINTENANCE, AND EXTINCTION OF AN AMPHETAMINE-INDUCED TASTE AVERSION.

000373 01-04 THE EFFECT OF L-DOPA AND LERGOTRILE-MESYLATE ON THE INTERACTION OF FLUPHENAZINE-DECANOATE AND AMPHETAMINE-INDUCED STEREOTYPY AND MORTALITY.

EFFECTS OF DEAFENING AND BLINDFOLDING ON AMPHETAMINE-INDUCED STEREOTYPY IN THE CAT.

UNILATERAL CATECHOLAMINE DEPLETION OF THE CORPUS-STRIATUM
AND AMPHETAMINE-INDUCED TURNING: AN ONTOGENETIC STUDY

A PRESYNAPTIC SITE OF ACTION WITHIN THE MESENCEPHALIC RETICULAR FORMATION FOR () AMPHETAMINE-INDUCED ELECTROCORTICAL DESYNCHRONIZATION.

001069 02-03 AMPHETAMINE-INDUCED INCREASE OF THE CEREBROVASCULAR PERMEABILITY TO PROTEIN.

001153 02-03 ROLE OF CALCIUM IN THE AMPHETAMINE-INDUCED STIMULATION OF CATECHOL FORMATION IN THE STRIATUM.

SPECIFICITY OF AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE AND SEROTONIN FROM RAT BRAIN IN VITRO.

001294 02-03 AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOUR AND BRAIN CONCENTRATIONS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN MICE.

001316 02-04 NORMAL AND AMPHETAMINE-INDUCED ROTATION OF RATS ON A FLAT

MODIFICATION OF THE AMPHETAMINE-INDUCED STEREOTYPY IN RATS FOLLOWING INHIBITION OF THE NORADRENALINE RELEASE BY FLA-136 001367 02-04

EFFECTS OF PSYCHOTROPIC AGENTS ON AMPHETAMINE-INDUCED BEHAVIOR IN RATS. 001460 02-04

CIRCADIAN VARIATION IN AN AMPHETAMINE-INDUCED MOTOR

EFFECT OF METABOLIC INHIBITORS AND OUABAIN ON AMPHETAMINE
INDUCED AND POTASSIUM-INDUCED RELEASE OF BIOGENIC AMINES FROM ISOLATED BRAIN TISSUE

002142 03-03 SPONTANEOUS AND AMPHETAMINE-INDUCED BEHAVIOR AFTER BILATERAL INJECTION OF ETHANOLAMINE-O-SULFATE INTO THE SUBSTANTIA-NIGRA.

002262 03-04 AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY AND STEREOTYPY AFTER KAINIC-ACID LESIONS OF THE STRIATUM.

002279 03-04

LESIONS OF THE DORSAL NORADRENERGIC PROJECTION ATTENUATE MORPHINE-INDUCED BUT NOT AMPHETAMINE-INDUCED CONDITIONED

002200 03-04 AMPHETAMINE-INDUCED TASTE AVERSICA DEMONSTRATED WITH OPERANT BEHAVIOUR.

002315 03-04 THE EFFECT OF CHOLINE-CHLORIDE ON AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR.

002330 03-04 THE EFFECT OF LITHIUM ON AMPHETAMINE-INDUCED LOCOMOTOR STIMULATION.

002791 04-02 BLOCKADE OF BOTH PILOCARPINE AND AMPHETAMINE-INDUCED HEAD-SHAKING WITH DOPAMINE RECEPTOR ANTAGONISTS

002951 04-03 AMPHETAMINE-INDUCED INCREASE IN RAT CEREBRAL BLOOD FLOW; APPARENT LACK OF CATECHOLAMINE INVOLVEMENT

003031 04-03 BRAIN MECHANISMS OF AMPHETAMINE-INDUCED ANOREXIA LOCOMOTION, AND STEREOTYPY: A REVIEW.

003189 04-04

AMPHETAMINE-LIKE EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE ON SOCIAL BEHAVIOUR IN THE MOUSE. 000433 01-04

INTERACTIONS BETWEEN DEPRESSANTS (ALCOHOL-TYPE) AND STIMULANTS (AMPHETAMINE-TYPE).

002297 03-04 AMPHETAMINE-TYPE REINFORCEMENT BY DOPAMINERGIC AGONISTS IN

THE RAT 003400 04-04

AMPHETAMINES A COMPARATIVE STUDY OF DIFFERENT AMPHETAMINES ON COPULATORY BEHAVIOR AND STEREOTYPE ACTIVITY IN THE FEMALE 000412 01-04

VARIABLES IN THE PROLONGED PREFERENCE OF HEROIN OR **AMPHETAMINES**

000778 01-14 THE AMPHETAMINES: MEDICAL USES AND HEALTH HAZARDS

000842 01-15 TRIPHASIC DOSE LETHALITY RELATIONSHIPS FOR AMPHETAMINE AND CERTAIN RING-SUBSTITUTED AMPHETAMINES IN ISOLATED OR

AGGREGATED MICE. 001093 02-03 STRUCTURE-ACTIVITY STUDIES ON HALLUCINOGENIC AMPHETAMINES USING MOLECULAR CONNECTIVITY.

001530 02-06 TOLERANCE TO AMPHETAMINES FACILITATION OF SELF-STIMULATION

RESPONDING: ANATOMICAL SPECIFICITY. 002190 03-04

AMPHIPHILIC

LIPIDOSIS INDUCED BY AMPHIPHILIC CATIONIC DRUGS.

003664 04-15

INFLUENCE OF NEUROTROPIC DRUGS ON CHANGES OF EVOKED-POTENTIALS AMPLITUDES AFTER STIMULATION OF THE **HYPOTHALAMUS**

001318 02-04

RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS. ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT LEARNING WITH D AMPPHETAMINE TREATMENTS.

AMYGDALA EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AGONISTS AND ANTAGONISTS INTO THE AMYGDALA ON RETENTION OF PASSIVE AVOIDANCE TRAINING IN RATS. (PH.D. DISSERTATION).

002323 03-04 AMYGDALECTOMY

METHYLPHENIDATE, AMYGDALECTOMY AND ACTIVE AVOIDANCE PERFORMANCE IN THE RAT. 001500 02-04

ETHANOL AND DISPOSITION OF AMYLOBARBITONE: EFFECT OF DOSE AND SIGNIFICANCE AS A MECHANISM FOR INCREASED TOXICITY.

003114 04-03 INTERACTION OF ETHANOL WITH AMYLOBARBITONE, PHENOBARBITONE AND METHAQUALONE.

003115 04-03

AMYTAL THE AMYTAL INTERVIEW: HISTORY AND CURRENT USES 002767 03-17

ANAESTHETICS RELATIVE INFLUENCE OF ANAESTHETICS ON DEPRESSOR EFFECTS OF INTRAVENOUS PROSTAGLANDINS E2 AND A2. 000110 01-03

ANAFRANIE

CLOMIPRAMINE (ANAFRANIL) AND BEHAVIOUR THERAPY IN OBSESSIVE-COMPULSIVE AND PHOBIC DISORDERS.

TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH CLOMIPRAMINE (ANAFRANIL)

A LARGE OPEN MULTICENTRE TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE MANAGEMENT OF PHOBIC DISORDERS.

002475 03-10 AN UNCONTROLLED TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF PHOBIC AND OBSESSIONAL STATES IN GENERAL

CLOMIPRAMINE (ANAFRANIL) IN DEPRESSIVE PATIENTS WITH OBSESSIVE NEUROSIS

A COMPARISON OF CLOMIPRAMINE HYDROCHLORIDE (ANAFRANIL) AND BEHAVIOUR THERAPY IN THE TREATMENT OF OBSESSIVE NEUROSIS.

TRICYCLIC ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CLINICAL COMPARISON OF CLOMIPRAMINE (ANAFRANIL) AND AMITRIPTYLINE. 003501 04-09

PROSTAGLANDIN-E2, CYCLIC-ADENOSINE-MONOPHOSPHATE AND MORPHINE ANALGESIA.

COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMOTOR ACTIVITY
ANALGESIA AND PRIMARY AND PROTRACTED PHYSICAL DEPENDENCE IN SIX MOUSE STRAINS.

000323 01-04 TOLERANCE TO MORPHINE PRODUCED DISCRIMINATIVE STIMULI AND ANALGESIA

000414 01-04 ATTENUATION OF MORPHINE ANALGESIA IN RATS BY INTRA AMYGDALOID INJECTION OF DOPAMINE.

000443 01-04 ENKEPHALIN ANALOGUES ELICITING ANALGESIA AFTER INTRAVENOUS INJECTION.

001024 02-02 BY NALOXONE FOOTSHOCK INDUCED ANALGESIA IN MICE: ITS REVERSAL AND CROSS-TOLERANCE WITH MORPHINE

001078 02-03 DELAYED ONSET OF SINGLE DOSE TOLERANCE TO MORPHINE ANALGESIA 001089 02-03

ANALGESIA INDUCED BY VAGINAL STIMULATION IN RATS IS
APPARENTLY INDEPENDENT OF A MORPHINE SENSITIVE PROCESS 001090 02-03

POTENTIATION OF MORPHINE ANALGESIA IN MICE AFTER INHIBITION OF BRAIN TYPE-B MONOAMINE-OXIDASE.

POTENTIATION OF MORPHINE ANALGESIA BY LESIONS OF THE NUCLEUS LOCUS-COFRULFUS 001142 02-03

MORPHINE ANALGESIA DOSE RESPONSE CURVES IN TOLERANT RATS: MODIFICATION BY NALOXONE.

SOME PHARMACOLOGICAL OBERVATIONS ON THE ANALGESIA INDUCED BY ACUPUNCTURE IN RABBITS. 001190 02-03

THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF THE MEDULLA-OBLONGATA IS A HIGHLY SENSITIVE SITE IN THE PRODUCTION OF MORPHINE ANALGESIA IN THE RAT

001256 02-03 THE EFFECTS OF HORMONES AND MORPHINE ON BOTH ANALGESIA AND THE LORDOSIS RESPONSE PRODUCED BY CERVICAL PROBING IN THE FEMALE RAT.

001445 02-04 HALOPERIDOL AND ANALGESIA: CASE REPORTS.

ANALGESIA FOLLOWING TRANSCUTANEOUS ELECTRICAL STIMULATION AND ITS PARTIAL REVERSAL BY A NARCOTIC ANTAGONIST

THE EFFECT OF CLOMIPRAMINE AND OTHER AMINE UPTAKE INHIBITORS ON MORPHINE ANALGESIA IN LABORATORY ANIMALS. 002072 03-03

CORRELATION OF URINARY EXCRETION OF METHADONE METABOLITES WITH METHADONE METABOLISM AND ANALGESIA IN THE RAT. 002080 03-03

NALOXONE REVERSAL OF MORPHINE ANALGESIA BUT FAILURE TO ALTER REACTIVITY TO PAIN IN THE FORMALIN TEST. 002117 03-03

ALTERATIONS IN MORPHINE ANALGESIA PRODUCED BY CHRONIC DEFICITS OF BRAIN CATECHOLAMINES OR SEROTONIN: ROLE OF ANALGESIMETRIC PROCEDURE

002186 03-03 GUANOSINE-MONOPHOSPHATE: A CENTRAL-NERVOUS-SYSTEM REGULATOR OF ANALGESIA. 002215 03-04

INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA:
EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION. 002890 04-03

IS GABA INVOLVED IN ANALGESIA?.

003084 04-03

OPIATE RECEPTORS FOR BEHAVIORAL ANALGESIA RESEMBLE THOSE RELATED TO THE DEPRESSION OF SPINAL NOCICEPTIVE NEURONS. 003142 04-03

IN VIVO COMPARISON OF THE RECEPTOR POPULATIONS ACTED UPON IN THE SPINAL CORD BY MORPHINE AND PENTAPEPTIDES IN THE PRODUCTION OF ANALGESIA.

003143 04-03 THE EFFECTS OF DIVALENT IONS ON MORPHINE ANALGESIA AND
ABSTINENCE SYNDROME IN MORPHINE-TOLERANT AND MORPHINEDEPENDENT MICE.

003169 04-04 NOCICEPTIVE STIMULATION PREVENTS DEVELOPMENT OF TOLERANCE TO NARCOTIC ANALGESIA.

003195 04-04 ANALGESIA AND MOTOR ACTIVITY ELICITED BY MORPHINE AND ENKEPHALINS IN TWO INBRED STRAINS OF MICE.

003225 04-04 BEHAVIORAL AND PHYSIOLOGICAL STUDIES OF NONNARCOTIC ANALGESIA IN THE RAT ELICITED BY CERTAIN ENVIRONMENTAL

TOLERANCE TO MORPHINE ANALGESIA AND IMMOBILITY MEASURED IN RATS BY CHANGES IN LOG-DOSE-RESPONSE CURVES.

003307 04-04 ANALGESIA BY ENKEPHALINS INJECTED INTO THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF RAT MEDULLA-OBLONGATA.

003374 04-04 INHIBITION OR WET SHAKES DURING MORPHINE ABSTINENCE BY AN ANTAGONIST OF OPIATE ANALGESIA.

USE OF THE FLINCH-JUMP TECHNIQUE TO STUDY NARCOTIC ANALGESIA

IN THE RAT. 003403 04-04

NARCOTIC CUE, NARCOTIC ANALGESIA, AND THE TOLERANCE PROBLEM. 003707 04-17

THE SEARCH FOR A NONADDICTING ANALGESIC: HAS IT BEEN WORTH

000025 01-02 CENTRAL SITES AND MECHANISMS OF THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF THE NARCOTIC ANALGESIC AGENT

000179 01-03 A MORPHINE-LIKE FACTOR IN MAMMALIAN BRAIN: ANALGESIC ACTIVITY IN RATS.

000220 01-03 EFFECT OF ALTERATION OF METABOLISM ON THE ANALGESIC ACTIVITY, TOXICITY, DISTRIBUTION AND EXCRETION OF L-ALPHA-ACETYLMETHADOL IN THE RAT.

000245 01-03 INVESTIGATIONS OF THE ANALGESIC AND MORPHINE-LIKE PROPERTIES OF AZIDOMORPHINE

000379 01-04 A SYNTHETIC ENKEPHALIN ANALOGUE WITH PROLONGED PARENTERAL AND ORAL ANALGESIC ACTIVITY.

001036 02-02

ANALGESIC BRAIN STIMULATION IN THE CAT: EFFECT OF INTRAVENTRICULAR SEROTONIN, NOREPINEPHRINE, AND DOPAMINE 001101 02-03 MORPHINE AND ENKEPHALIN: ANALGESIC AND EPILEPTIC PROPERTIES

001267 02-03 PROPOXYPHENE ON DEMAND: ANALGESIC SEEKING BEHAVIOR IN PSYCHIATRIC INPATIENTS

001736 02-14 EFFECTS OF MEDIAL RAPHE AND RAPHE MAGNUS LESIONS ON THE ANALGESIC ACTIVITY OF MORPHINE AND METHADONE. 001986 03-03

DELIMITATION OF NEURONAL SUBSTRATES NECESSARY FOR THE ANALGESIC ACTION OF BACLOFEN AND MORPHINE 002132 03-03

RECEPTOR AFFINITY AND PHARMACOLOGICAL POTENCY OF A SERIES OF NARCOTIC ANALGESIC, ANTIDIARRHEAL AND NEUROLEPTIC DRUGS. 002160 03-03 ANALGESIC EFFECT OF CEREBROVENTRICULAR ADMINISTRATION OF

SOMATOSTATIN (SRIF) 002245 03-04 ANALGESIC ACTIVITY OF ENKEPHALINS FOLLOWING INTRACEREBRAL

002275 03-04 ENHANCED ANALGESIC EFFECTS OF MORPHINE AFTER CHRONIC ADMINISTRATION OF NALOXONE IN THE RAT.

002319 03-04

A COMPARISON OF THE ANALGESIC EFFECT OF INTRAMUSCULAR NALBUPHINE AND MORPHINE IN PATIENTS WITH POSTOPERATIVE

002607 03-14 SYNTHESIS OF TWO ENZYME RESISTANT ENKEPHALIN ANALOGS POSSESSING ENHANCED ANALGESIC ACTIVITY.

002787 04-01 DIFFERENT BRAIN AREAS MEDIATE THE ANALGESIC AND EPILEPTIC PROPERTIES OF ENKEPHALIN.

002915 04-03 THE ANTAGONISM OF THE ANALGESIC EFFECT OF DIPYRONE BY L-DOPA AND ITS RELATION TO BRAIN AMINE CONCENTRATIONS.

002977 04-03 MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE
ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE
CORRELATES WITH ANALGESIC ACTION OF MORPHINE.

CLEARANCE AND ANALGESIC ACTIVITY OF THE QUATERNIZED OPIATE, N METHYLMORPHINE (6-H3) ADMINISTERED INTRACISTERNALLY TO THE RAT.

003019 04-03 DISCRIMINATIVE STIMULUS PROPERTIES OF NARCOTIC ANALGESIC

003190 04-04 NARCOTIC CUING AND ANALGESIC ACTIVITY OF NARCOTIC ANALGESICS: ASSOCIATIVE AND DISSOCIATIVE CHARACTERISTICS.

003192 04-04 THE ANALGESIC ACTIVITY OF HUMAN BETA-ENDORPHIN IN MAN 003598 04-13

ANALOESICS
PIPERIDINE DERIVATIVES: SYNTHESIS OF POTENTIAL ANALGESICS IN 3
SUBSTITUTED 4 PHENYLPIPERIDINE SERIES.

001019 02

001019 02-02 NARCOTIC CUING AND ANALGESIC ACTIVITY OF NARCOTIC ANALGESICS: ASSOCIATIVE AND DISSOCIATIVE CHARACTERISTICS.

003192 04-04

ALTERATIONS IN MORPHINE ANALGESIA PRODUCED BY CHRONIC DEFICITS OF BRAIN CATECHOLAMINES OR SEROTONIN: ROLE OF ANALGESIMETRIC PROCEDURE.

ANALOG
COMPARISON OF THE EFFECTS OF 6 CHLORO-2-AMINOTETRALIN AND OF ORG-6582, A RELATED CHLOROAMPHETAMINE ANALOG, ON BRAIN SEROTONIN METABOLISM IN RATS.

000114 01-0

000114 01-03 CEREBRAL CIRCULATION IS ALTERED BY A POTENT ACTH4-9 ANALOG ORG-2766

001135 02-03 STUDIES ON THE NEUROPHARMACOLOGY OF THYROTROPIN-RELEASING HORMONE (TRH) AND A NEW TRH ANALOG.

002185 03-03 INHIBITION OF BRAIN ANGIOTENSIN-I CONVERTING ENZYME BY BOTHROPS-JARARACA NONAPEPTIDE (SQ-20881) AND A PROLYL ANALOG (SQ-14225).

RETROACTIVE AMNESIA INDUCED IN CHICKS BY THE PROLINE ANALOG L BAIKIAIN, WITHOUT EEG SEIZURES OR DEPRESSION.

003205 04-04 SLEEP-INDUCING EFFECT OF A VASOPRESSIN ANALOG, DEAMINO-6-CARBA-ORNITHINE-8-VASOPRESSIN (DCOV) IN RATS. 003265 04-04

THE ELECTRONIC AND SEROTONIN RECEPTOR BINDING AFFINITY

PROPERTIES OF N.N DIMETHYLTRYPTAMINE ANALOGS. 001002 02-01 BREAKDOWN OF ENKEPHALIN AND ENDORPHIN ANALOGS BY BRAIN

001137 02-03 **ACTION OF AZABUTYRONE AND ITS ANALOGS ON CATECHOLAMINE** METABOLISM IN RAT BRAIN.

001218 02-03 THE EFFECT OF ANTIPSYCHOTIC DRUGS AND THEIR CLINICALLY INACTIVE ANALOGS ON DOPAMINE METABOLISM.

001250 02-03 CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. THE IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2-METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED ANALOGS OF METHAMPHETAMINE.

002141 03-03 INTERACTIONS OF PARTIAL LSD ANALOGS WITH BEHAVIORAL DISRUPTING EFFECTS OF LSD AND DMT IN THE RAT.

002264 03-04 SYNTHESIS OF TWO ENZYME RESISTANT ENKEPHALIN ANALOGS POSSESSING ENHANCED ANALGESIC ACTIVITY. 002787 04-01

EFFECT OF ENKEPHALIN AND ENDORPHIN ANALOGS ON RECEPTORS IN THE MOUSE VAS-DEFERENS.

002794 04-02

MODIFICATION OF ADENYLATE-CYCLASE SYSTEMS IN MOUSE CEREBRAL-CORTEX BY CHLORPROMAZINE AND RESPECTIVE 7 HDROXY, ANALOGS.

ANALOGUE

A SYNTHETIC ENKEPHALIN ANALOGUE WITH PROLONGED PARENTERAL AND ORAL ANALGESIC ACTIVITY. 001036 02-02

BEHAVIORAL AND BIOCHEMICAL EFFECTS OF FK33-824, A
PARENTERALLY AND ORALLY ACTIVE ENKEPHALIN ANALOGUE
(UNPUBLISHED PAPER).

002744 03-17

(-)-(E) 3,4 DIHYDROXYPHENYL-CYCLOPROPYLAMINE-HYDROCHLORIDE (ASL-7003): A RIGID ANALOGUE OF DOPAMINE.

O02793 04-02

EFFECTS OF PROSTAGLANDIN-E2 AND A PROSTAGLANDIN ENDOPEROXIDE
ANALOGUE ON NEUROEFFECTOR TRANSMISSION IN THE RAT
ANOCOCCYGEUS MUSCLE.

OCCEDED 04-03

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6

TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

002930 04-03

ANALOGUES

POLYAMINE BIOSYNTHESIS IN RAT PROSTATE. SUBSTRATE AND INHIBITOR PROPERTIES OF 7 DEAZA ANALOGUES OF DECARBOXYLATED S ADENOSYLMETHIONINE AND 5 METHYLTHIOADENOSINE. 000001 01-01

POTENT PROLACTIN AND GROWTH HORMONE RELEASING ACTIVITY OF MORE ANALOGUES OF MET-ENKEPHALIN.

6-OHDA AND ITS ANALOGUES: CHEMICAL MECHANISM OF NEUROTOXICITY: STUDY OF THE OXIDATION OF ORTHO-SUBSTITUTED DOPAMINES.

000059 01-03

DOPAMINE RECEPTORS IN RAT STRIATUM AND NUCLEUS-ACCUMBENS;
CONFORMATIONAL STUDIES USING RIGID ANALOGUES OF DOPAMINE.
000301 01-03

ENKEPHALIN ANALOGUES ELICITING ANALGESIA AFTER INTRAVENOUS INJECTION.

MONOMETHYLTHIO ANALOGUES OF 1 TRIMETHOXYPHENYL-2-AMINOPROPANE

001030 02-02
HISTAMINE STIMULATED ADENYLATE-CYCLASE: BLOCKADE BY

IMIPRAMINE AND ITS ANALOGUES.

001216 02-03
INTERACTION OF IODINATED ENKEPHALIN ANALOGUES WITH OPIATE

RECEPTORS.

001947 03-01

OPEN-FIELD BEHAVIOR AFTER INTRAVENOUS AMPHETAMINE ANALOGUES

OPEN-FIELD BEHAVIOR AFTER INTRAVENOUS AMPHETAMINE ANALOGUES IN RATS.

002272 03-04
STRUCTURE-ACTIVITY RELATIONS FOR THE NEUROTOXICITY OF KAINIC-

ACID DERIVATIVES AND GLUTAMATE ANALOGUES.

002355 03-05
IN VITRO PROFILE OF SOME OPIOID PENTAPEPTIDE ANALOGUES.

002799 04-02
INHIBITION OF DOPA DECARBOXYLATION BY ANALOGUES OF

002837 04-03

PARALLEL CHANGES IN BEHAVIOR AND HIPPOCAMPAL MONOAMINE
METABOLISM IN RATS AFTER ADMINISTRATION OF ACTH ANALOGUES.
003335 04-04

ANALYSES

ELECTROPHORETIC ANALYSES OF PROTEINS TRANSPORTED TO THE RAT POSTERIOR PITUITARY. 002920 04-03

ANALYSIS
DISCRIMINATIVE STIMULUS PROPERTIES OF FENFLURAMINE IN AN
OPERANT TASK: AN ANALYSIS OF ITS CUE FUNCTION.

GENETIC ANALYSIS OF THE BEHAVIORAL RESPONSE TO D AMPHETAMINE IN MICE.

000482 01-05
DATA ANALYSIS: COLLABORATIVE OUTPATIENT SCHIZOPHRENIA STUDY.
000528 01-08
ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND RELATED DRUGS ON

THE TREATMENT OF SCHIZOPHRENIA.

QOQ536 01-08

DRUG ANALYSIS IN THE OVERDOSED PATIENT: ITS APPLICATION TO

DRUG ANALYSIS IN THE OVERDOSED PATIENT: ITS APPLICATION TO CLINICAL TOXICOLOGY. 000802 01-

QUANTIFICATION AND STATISTICAL ANALYSIS OF ORDINAL SCALE DATA IN PSYCHIATRY. 000913 01-16 THE EXTRACTION AND ANALYSIS OF BENZODIAZEPINES IN TISSUES BY ENZYMIC DIGESTION AND HIGH-PERFORMANCE LIQUID

ANALYSIS OF A SCHOOL OF THOUGHT ON THE EFFECTS OF LITHIUM ON BEHAVIOR.

000987 01-17
ADVERSE REACTIONS LITERATURE: A BIBLIOMETRIC ANALYSIS.
000999 01-17

SPECTRAL ANALYSIS OF THE DIFFERING EEG EFFECTS OF BENZODIAZEPINES, MEPROBAMATE, GLUTETHIMIDE AND AMOBARBITAL IN MACACA-MULATTA.

PHARMACOLOGICAL MANIPULATION OF HOARDING: FURTHER ANALYSIS OF AMPHETAMINE ISOMERS AND PIMOZIDE.

A BIOCHEMICAL AND BEHAVIORAL ANALYSIS OF CHRONIC ALCOHOL CONSUMPTION BY RATS.

A BEHAVIORAL ANALYSIS OF AGGRESSIVE BEHAVIORS INDUCED AND MODULATED BY DELTA9-TETRAHYDROCANNABINOL, PILOCARPINE, D AMPHETAMINE AND L-DOPA.

THOUGHT DISORDER IN SCHIZOPHRENIA: A THEORETICAL APPROACH USING AN ANALYSIS OF SPEECH. (PH.D. DISSERTATION).

O01566 02-08

EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 2. BIOCHEMICAL ANALYSIS.

001652 02-13

FACTORS INFLUENCING BLOOD CONCENTRATIONS OF CHLORDIAZEPOXIDE:
A USE OF MULTIPLE REGRESSION ANALYSIS.

EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 1. CLINICAL ANALYSIS.

O01704 02-14
DRUG VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA
APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS.

QUANTITATIVE ANALYSIS OF METHADONE IN BIOLOGICAL FLUIDS USING DEUTERIUM-LABELED METHADONE AND GLC CHEMICAL IONIZATION MASS SPECTROMETRY.

O01862 02-16

ANALYSIS OF THE ROLE PLAYED BY THE SUBSTANTIA-NIGRA IN THE MEDIATION OF INGESTIVE, LOCOMOTOR, AND ROTATIONAL BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL MANIPULATIONS, (PH.D. DISSERTATION).

ANALYSIS AND CHEMICAL CONTROL OF NEGATIVE AFFECT.

O02367 03-06
TIME-RESPONSE ANALYSIS OF THE EFFECT OF STIMULANT MEDICATION
ON THE LEARNING ABILITY OF CHILDREN REFERRED FOR
HYPER ACTIVITY

002534 03-11
QUANTITATIVE EEG ANALYSIS OF THE PUTATIVE ANTIDEPRESSANT
COMPOUND F1-8654

AN EEG COMPUTER ANALYSIS OF CHLORPROMAZINE EFFECTS IN

O02592 03-13
ASSESSMENT OF SPONTANEOUS AND DRUG-INDUCED CHANGES IN
VIGILANCE BY MEANS OF A NEW MODIFICATION OF THE SHORT TIME
SPECTRAL ANALYSIS OF THE EEG.

002627 03-14
BI AND MULTIVARIATE ANALYSIS OF EEG DATA IN CLINICAL
PSYCHOPHARMACOLOGY.

DISCRIMINATIVE PROPERTIES OF CHLORDIAZEPOXIDE: A NEW METHOD

ACTIVITY ANALYSIS OF OPERANT BEHAVIOR FOLLOWING
METHYLPHENIDATE ADMINISTRATION.

O03223 04-04
A GENETIC ANALYSIS OF THE HYPERTHERMIC RESPONSE TO D
AMPHETAMINE IN TWO INBRED STRAINS OF MICE.

ELECTROENCEPHALOGRAPHIC CONTROL WITH FREQUENCY ANALYSIS IN DEPRESSED PATIENTS TREATED WITH SAME.

O3536 04-10

A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE
TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE
GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS.

MULTIVARIATE ANALYSIS OF DRUG EFFECTS ON ELECTROPHYSIOLOGICAL

MULTIVARIATE ANALYSIS OF DRUG EFFECTS ON ELECTROPHYSIOLOGICAL SIGNALS IN MAN.

OOGABB 04-16

002564 03-13

DEVELOPMENT OF AN ALCOHOL-BLOCKER, USING COMPUTER ANALYZED

TOLERANCE TO AMPHETAMINES FACILITATION OF SELF-STIMULATION RESPONDING: ANATOMICAL SPECIFICITY.

002190 03-04

BEHAVIORAL AND ANATOMICAL CONSEQUENCES OF SMALL INTRASTRIATAL INJECTIONS OF KAINIC-ACID IN THE RAT.

003210 04-04

ANATOMICAL SPECIFICITY WITHIN RAT STRIATUM FOR THE DOPAMINERGIC MODULATION OF DRL RESPONDING AND ACTIVITY. 003316 04-04

ANOREXIGENIC AND ANCILLARY ACTIONS OF MK-212 (6 CHLORO-2-PIPERAZINYLPYRAZINE; CPP).

002213 03-04

A NEW HALLUCINOGEN FROM ANDEAN COLOMBIA: IOCHROMA-

000983 01-17

DIFFERENTIAL EFFECTS OF THE ANTIANDROGEN FLUTAMIDE ON ASPECTS OF SEXUAL BEHAVIOR IN CASTRATED, ANDROGEN TREATED MALE RATS. 002237 03-04

CHLORPROMAZINE-INDUCED HEMOLYTIC ANEMIA IN ANOREXIA-NERVOSA.

000847 01-15

ANESTHESIA THE EFFECT OF ANESTHESIA ON ACQUISITION AND EXTINCTION OF CONDITIONED TASTE AVERSION.

000326 01-04 A DOUBLE-BLIND STUDY OF THE EFFECTIVE ANTIHALLUCINATORY DOSES OF DIAZEPAM PRIOR TO KETAMINE ANESTHESIA.

000640 01-11 THE EFFECT OF ANESTHESIA ON BRAIN MITOCHONDRIAL HEXOKINASE 001058 02-03

FORMATION OF BRAIN ACETYLCHOLINE FROM DIETARY CHOLINE AND THE EFFECT OF BARBITURATE ANESTHESIA ON THIS PROCESS. 001074 02-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL, CANNABINOL, AND CANNABINOL ON THE ANESTHESIA INDUCED BY VARIOUS ANESTHETIC AGENTS IN MICE.

002015 03-03 FLUNITRAZEPAM (ROHYPNOL) COMPARED WITH NITRAZEPAM (MOGADON) AND APROBARBITAL AS EVENING PREMEDICATION PRIOR TO ANESTHESIA: A CONTROLLED CLINICAL TRIAL.

002616 03-14 INFLUENCE OF TRANSIENT ISCHEMIA ON MONOAMINE METABOLISM IN THE RAT BRAIN DURING NITROUS-OXIDE AND PHENOBARBITONE ANESTHESIA.

002852 04-03 THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, AND CANNABINOL ON THE ANESTHESIA INDUCED BY VARIOUS ANESTHETIC

002015 03-03 **ACTIVATING AND ANESTHETIC EFFECTS OF GENERAL DEPRESSANTS**

002301 03-04 INTERANIMAL AGGRESSION AND HYPERREACTIVITY FOLLOWING HYPOTHALAMIC INFUSION OF LOCAL ANESTHETIC IN THE RAT

003157 04-04

EFFECT OF GENERAL ANESTHETICS ON HANDLING-INDUCED AND DECAPITATION-INDUCED INCREASES IN SYMPATHOADRENAL 002139 03-03

EFFECTS OF ANESTHETICS ON CEREBELLAR NEURONS RECORDED CHRONICALLY AFTER HARMALINE. 002260 03-04

MUSCARINIC RECEPTOR MEDIATED CYCLIC-GMP FORMATION BY
CULTURED NERVE CELLS -- IONIC DEPENDENCE AND EFFECTS OF LOCAL

003064 04-03

THE ACTIONS OF DIAZEPAM AND PHENYTOIN ON A LOW DOSE PENICILLIN EPILEPTIFORM FOCUS IN THE ANESTHETISED RAT. 002921 04-03

ANESTHETIZED
CARDIOVASCULAR EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN
CONSCIOUS AND ANESTHETIZED DOGS.

000109 01-03 A PHARMACOLOGICAL STUDY OF THE SPONTANEOUS CONVULSIVE ACTIVITY INDUCED BY 1,2 DIHYDROXYBENZENE (CATECHOL) IN THE ANESTHETIZED MOUSE.

001046 02-03 CENTRAL EFFECT OF SOMATOSTATIN ON THE SECRETION OF GROWTH HORMONE IN THE ANESTHETIZED RAT.

Psychopharmacology Abstracts

SUPPRESSION BY NITROUS-OXIDE OF VISUAL RESPONSES IN THE CEREBELLAR VERMIS AND SUPERIOR COLLICULUS OF CATS ANESTHETIZED WITH CHLORALOSE. 002897 04-03

MORE ABOUT POISONING BY PHENCYCLIDINE (PCP, ANGEL-DUST) 001786 02-15

NECROTIZING ANGIITIS AND HEPATITIS IN AN AMPHETAMINE ABUSER 000887 01-15

ANGIOTENSIN
ANGIOTENSIN BINDING AFFINITY AND CAPACITY IN THE MIDBRAIN AREA
OF SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS.
002870 04-03 002870 04-03

ANGIOTENSIN RECEPTIVE NEURONES IN THE SUBFORNICAL ORGAN STRUCTURE-ACTIVITY RELATIONS. 002906 04-03

INHIBITION OF BRAIN ANGIOTENSIN-I CONVERTING ENZYME BY BOTHROPS-JARARACA NONAPEPTIDE (SQ-20881) AND A PROLYL ANALOG (SQ-14225).

002818 04-03

ANGIOTENSIN-II

EFFECTS OF ANGIOTENSIN-II ON SCHEDULE-DEPENDENT AND INDUCED
BEHAVIOR AT RECOVERED BODY WEIGHT. 000470 01-04

EFFECTS OF ANGIOTENSIN-II AND ACETYLCHOLINE ON NEURONS IN THE PREOPTIC AREA.

002935 04-03 MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II. 002994 04-03

EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ, ANGIOTENSIN-II, AND SUBSTANCE-P ON MULTIPLE FIXED-INTERVAL FIXED-RATIO RESPONDING IN RABBITS.

003233 04-04 LOCALIZATION OF RECEPTORS FOR THE DIPSOGENIC ACTION OF ANGIOTENSIN-II IN THE SUBFORNICAL ORGAN OF RAT.

003361 04-04 ANGIOTENSIN-INDUCED
ANGIOTENSIN-INDUCED THIRST: EFFECTS OF THIRD VENTRICLE
OBSTRUCTION AND PERIVENTRICULAR ABLATION.

003181 04-04 AN ANIMAL SCREENING TEST FOR DRUGS THAT PREDICTS THE LIKELIHOOD OF HUMAN PHYSICAL DEPENDENCE.

000028 01-02 ANIMAL MODELS OF ORAL DRUG SELF-ADMINISTRATION.

000408 01-04 THE EFFECT OF EPINEPHRINE ON TONIC IMMOBILITY (ANIMAL HYPNOSIS) IN CHICKENS.

000460 01-04 ANIMAL MODELS FOR MANIA. (UNPUBLISHED PAPER). 000501 01-06

ANIMAL PROLACTIN EVIDENCE FOR ANTIPSYCHOTIC ACTIVITY OF

001027 02-02 THE EFFECTS OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE IN AN ANIMAL TEST OF ANXIETY.

001121 02-03 THE EFFECT OF LITHIUM ON AN ANIMAL MODEL OF TARDIVE-

001167 02-03 ANIMAL HYPNOSIS AND HUMAN HYPNOSIS: NEW EXPERIMENTAL EVIDENCE RELATING TO AN OLD CONTROVERSY.

001711 02-14 NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: I. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY.

002096 03-03 ANIMAL MODEL FOR STUDY OF HYPERKINESIS AND AGGRESSION. 002302 03-04

EFFECTS OF AMPHETAMINE ON SOCIAL BEHAVIORS OF RHESUS MACAQUES: AN ANIMAL MODEL OF PARANOIA.

002365 03-06 ANIMAL MODELS IN PSYCHIATRY AND NEUROLOGY

ANIMAL TEST MODELS FOR PREDICTION OF CLINICAL ANTIDEPRESSANT ACTIVITY. 002372 03-06

EXTENSION OF ANIMAL MODELS TO CLINICAL EVALUATION OF ANTIANXIETY AGENTS.

002716 03-16 ANIMAL MODELS FOR MANIA 002766 03-17

ANIMAL MODEL OF DEPRESSION: III. MECHANISM OF ACTION OF TETRABENAZINE.

003108 04-03

VOLUME 16, SUBJECT INDEX

A NEW ANIMAL MODEL FOR SCHIZOPHRENIA: INTERACTIONS WITH ADRENERGIC MECHANISMS. 003175 04-04

ANIMAL MODELS OF SCHIZOPHRENIA: THE CASE FOR LSD-25 003706 04-17

ANIMALS CARBACHOL ELICITED MOUSE-KILLING IN THE RAT: ANIMALS ATTACKED AND WOUND LOCATION.

000349 01-04 BEHAVIORAL EFFECTS OF PEPTIDES IN ANIMALS: FURTHER EXPERIENCE WITH PENTOBARBITAL ANTAGONISM.

000434 01-04 BETA ADRENERGIC RECEPTOR LABELING IN INTACT ANIMALS WITH 1125-HYDROXYBENZYLPINDOLOL.

000493 01-06 NEUROCHEMICAL STUDIES OF AGGRESSION IN ANIMALS.

000947 01-17 EFFECTS OF CANNABINOIDS ON UNLEARNED BEHAVIOR IN ANIMALS 001955 03-02

THE EFFECT OF CLOMIPRAMINE AND OTHER AMINE UPTAKE INHIBITORS ON MORPHINE ANALGESIA IN LABORATORY ANIMALS. 002072 03-03

EFFECT OF PSYCHOTROPIC AGENTS ON THE PHYSICAL PERFORMANCE CAPACITY OF ANIMALS EXPOSED TO HEAT AND COLD. 002273 03-04

BEHAVIOR EFFECTS OF COCAINE IN ANIMALS. 002333 03-04

THE EFFECT OF NEUROLEPTICS AND ALPHA-METHYL-P-TYROSINE ON SERUM PROLACTIN LEVELS IN LABORATORY ANIMALS AND MAN 002582 03-13 INTERACTION BETWEEN PHENCYCLIDINE AND PENTOBARBITAL IN

SEVERAL SPECIES OF LABORATORY ANIMALS. 003185 04-04

SCHEDULE-INDUCED SELF-INJECTION OF NICOTINE, METHADONE AND HEROIN BY NAIVE ANIMALS.

003321 04-04 A RELIABLE, FACIAL NOCICEPTION DEVICE FOR UNRESTRAINED, AWAKE ANIMALS: EFFECTS OF MORPHINE AND TRIGEMINAL COMPLEX

003435 04-05 ANISOMYCIN-INDUCED

MEMORY: MODIFICATION OF ANISOMYCIN-INDUCED AMNESIA BY STIMULANTS AND DEPRESSANTS.

002232 03-04

CENTRAL-NERVOUS-SYSTEM ACTIVITY OF A NOVEL CLASS OF ANNELATED 1,4 BENZODIAZEPINES, AMINOMETHYLENE-IMIDAZORENZODIAZEPINONES 001000 02-01

ANOCOCCYGEUS

EFFECTS OF PROSTAGLANDIN-E2 AND A PROSTAGLANDIN ENDOPEROXIDE

ANALOGUE ON NEUROEFFECTOR TRANSMISSION IN THE RAT ANOCOCCYGEUS MUSCLE 002808 04-03

THE OPIATE ANOMALIES - ANOTHER POSSIBLE EXPLANATION? 001660 02-13 LIMB REDUCTION ANOMALIES IN INFANTS BORN TO DISULFIRAM TREATED ALCOHOLIC MOTHERS.

001817 02-15 ANORECTIC

SUBSTITUTED TRIFLUOROMETHYLPHENYLPIPERAZINES AS ANORECTIC AGENTS.

000002 01-01 HYPERSENSITIVITY OF RATS TO ANORECTIC AGENTS AFTER LESIONS IN THE VENTROMEDIAL HYPOTHALAMUS.

000431 01-04 BIOCHEMICAL INTERACTION BETWEEN ANORECTIC DRUGS AND PIRIBEDIL. 001154 02-03 RELATIONSHIP BETWEEN ANORECTIC AND REINFORCING PROPERTIES

APPETITE SUPPRESSANT DRUGS: IMPLICATIONS FOR ASSESSMENT OF ABUSE LIABILITY. 003236 04-04

ANOBECTICS EFFECTS OF STIMULANTS, ANORECTICS, AND RELATED DRUGS ON SCHEDULE-CONTROLLED BEHAVIOR. 002243 03-04

AMPHETAMINE INDUCES ANOREXIA EVEN AFTER INHIBITION OF NORADRENALINE SYNTHESIS. 000365 01-04

BRAIN MECHANISMS OF AMPHETAMINE-INDUCED ANOREXIA, LOCOMOTION, AND STEREOTYPY: A REVIEW. 003189 04-04

ANOSEXIA-NERVOSA A CASE OF ACUTE GASTRIC DILATATION IN ANOREXIA-NERVOSA.
000602 01-10 PIMOZIDE IN TREATMENT OF ANOREXIA-NERVOSA.

000608 01-10 SUCCESSFUL TREATMENT OF ANOREXIA-NERVOSA WITH IMIPRAMINE 000617 01-10 000468 01-04

CHLORPROMAZINE-INDUCED HEMOLYTIC ANEMIA IN ANOREXIA-NERVOSA.

000847 01-15 AMITRIPTYLINE THERAPY IN ANOREXIA-NERVOSA. 001613 02-10

AMOREYIC A COMPARISON OF FOOD INTAKE SUPPRESSION PRODUCED BY GIVING AMPHETAMINE AS AN AVERSION TREATMENT VERSUS AS AN

001981 03-03 ANOREXIGEN A NEW ANOREXIGEN ASSAY: STRESS-INDUCED HYPERPHAGIA IN RATS

ANOREXIGENESIS THE PHARMACOLOGY OF ANOREXIGENESIS.

ANOREXIC TREATMENT

000962 01-17

ANOREXIGENIC PRECLINICAL EVALUATION OF DITA DICHLORO-2 IMIDAZOLINYLTHIOACETOPHENONE-HBR: A NEW ANOREXIGENIC

001020 02-02 ANOREXIGENIC AND ANCILLARY ACTIONS OF MK-212 (6 CHLORO-2-PIPERAZINYLPYRAZINE: CPP). 002213 03-04

PAROSMIA AND AROMATIC ANOSMIA UNDER L-DOPA THERAPY. 000871 01-15

ANTABUSE TOXICITY 001825 02-15

EFFECT OF ANTACIDS ON ABSORPTION OF CLORAZEPATE.

001647 02-13 CILIOINHIBITORY EFFECT OF PHENOTHIAZINES IN VITRO AND ITS

5-HT ANTAGONISTS INHIBIT NEUROLEPTIC AND MORPHINE ANTAGONISM OF THE HYPERACTIVITY INDUCED BY DOPAMINE FROM THE NUCLEUS-

ACCUMBENS 000082 01-03 ANTAGONISM OF BIOGENIC AMINE-INDUCED DEPRESSION OF CEREBRAL CORTICAL NEURONES BY NA-K-ATPASE INHIBITORS.

000254 01-03 ANTAGONISM BY CHOLINERGIC DRUGS OF BEHAVIOURAL EFFECTS IN CATS OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC DRUG AND

ENHANCEMENT BY NICOTINE. 000404 01-04 BEHAVIORAL EFFECTS OF PEPTIDES IN ANIMALS: FURTHER EXPERIENCE WITH PENTOBARBITAL ANTAGONISM.

MORPHINE AND ETHANOL AS DISCRIMINATIVE STIMULI: ABSENCE OF ANTAGONISM BY P-CHLOROPHENYLALANINE-METHYL-ESTER,

CINANSENIN, OR BC-105 000473 01-04 ANTAGONISM OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA)

LETHALITY BY CHLORPROMAZINE IN THE CONSCIOUS DOG DIFFERENTIAL ANTAGONISM BY CHLORPROMAZINE AND DIAZEPAM OF FROG MOTONEURONE DEPOLARIZATION INDUCED BY GLUTAMATE RELATED AMINO-ACIDS

001116 02-03 CENTRAL ANTAGONISM OF TYRAMINE-INDUCED SYSTEMIC HYPOTENSION BY MESCALINE

001252 02-03 ANTAGONISM OF PENTOBARBITAL-INDUCED HORMONAL CHANGES BY TRH IN RATS.

001255 02-03 ANTAGONISM BETWEEN THE EFFECTS OF L-DOPA AND APOMORPHINE ON THE BEHAVIOR OF RATS.

001298 02-04 TRICYCLIC ANTIDEPRESSANT DRUGS: ANTAGONISM OF EFFECT OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON SHOCK ELICITED AGGRESSION

001461 02-04 LYSERGIC-ACID-DIETHYLAMIDE ANTAGONISM BY CHLORPROMAZINE, HALOPERIDOL, DIAZEPAM, AND PENTOBARBITAL IN THE RABBIT. 001504 02-05

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION
DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND
QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

IMPORTANCE OF DURATION OF DRUG ACTION IN THE ANTAGONISM OF P-CHLOROAMPHETAMINE DEPLETION OF BRAIN SEROTONIN --COMPARISON OF FLUOXETINE AND CHLORIMIPRAMINE.

002017 03-03 IMIPRAMINE ANTAGONISM OF APOMORPHINE-INDUCED HYPOTHERMIA: A NONDOPAMINERGIC INTERACTION. 002133 03-03 ANTAGONISM BY MIANSERIN AND CLASSICAL ALPHA-ADRENOCEPTOR BLOCKING DRUGS OF SOME CARDIOVASCULAR AND BEHAVIORAL EFFECTS OF CLONIDINE.

O02138 03-03
THE ROLE OF SEROTONIN ANTAGONISM IN THE TREMORGENIC ACTION OF BUFOTENINE IN MICE.

AMANTADINE-HYDROCHLORIDE (AMN): ANTAGONISM TO ETHANOL (ETOH) MEDIATED RESPONSES IN RODENTS.

COMPARATIVE STUDY OF THE ANTAGONISM OF BEMEGRIDE AND PICROTOXIN ON BEHAVIOURAL DEPRESSANT EFFECTS OF DIAZEPAM IN RATS AND MICE.

002312 03-04
BEHAVIOURAL ANTAGONISM BETWEEN CHLORPROMAZINE AND NOISE IN MAN.

002621 03-14
ANTAGONISM OF ETHANOL EVOKED RESPONSES BY AMANTADINE: A
POSSIBLE CLINICAL APPLICATION.

002797 04-02

EFFECTS OF CENTRAL GABA RECEPTOR AGONISM AND ANTAGONISM ON
EVOKED DIENCEPHALIC CARDIOVASCULAR RESPONSES.

STIMULATION OF DOPAMINE SYNTHESIS IN CAUDATE NUCLEUS BY INTRASTRIATAL ENKEPHALINS AND ANTAGONISM BY NALOXONE. 002825 04-03

ANTAGONISM OF THE ANTICONVULSANT ACTION OF PHENYTOIN, PHENOBARBITAL, AND ACETAZOLAMIDE BY 6 HYDROXYDOPAMINE. 002845 04-03

MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMATURE RAT.

O02901 04-03

ANTAGONISM OF MORPHINE ACTION ON BRAIN ACETYLCHOLINE RELEASE
BY METHYLXANTHINES AND CALCIUM.

THE ANTAGONISM OF THE ANALGESIC EFFECT OF DIPYRONE BY L-DOPA AND ITS RELATION TO BRAIN AMINE CONCENTRATIONS.

EPINEPHRINE IN RAT HYPOTHALAMUS: ANTAGONISM BY DESIPRAMINE OF 6 HYDROXYDOPAMINE-INDUCED DEPLETION.

ANTAGONISM OF NALOXONE HYPERALGESIA BY ETHANOL.

DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE AND D AMPHETAMINE, AND ANTAGONISM BY HALOPERIDOL: A COMPARATIVE STUDY.

MORPHINE AS A DISCRIMINATIVE CUE IN GERBILS: DRUG GENERALIZATION AND ANTAGONISM.

O03249 04-04
ANTAGONISM OF PENTOBARBITAL DISCRIMINATIVE STIMULUS BY
BEMEGRIDE IN IMMOBILIZED RATS.

003266 04-04
THERAPEUTIC ANTAGONISM BETWEEN ANTICHOLINERGICS AND
NEUROLEPTICS: POSSIBLE INVOLVEMENT OF CHOLINERGIC
MECHANISMS IN SCHIZOPHRENIA.

ANTAGONIST
AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT.

NOREPINEPHENE ALPHA RECEPTOR BINDING IN MAMMALIAN CENTRAL-NERVOUS-SYSTEM: DIFFERENTIAL LABELING WITH AGONIST AND ANTAGONIST.

THE AGONIST AND ANTAGONIST PROPERTIES OF N ALLYL-ENKEPHALINS.

MOLINDONE: AN APOMORPHINE ANTAGONIST IN THE RABBIT.

INTERACTION BETWEEN NARCOTIC ANTAGONIST (NALOXONE) AND LYSERGIC-ACID-DIETHYLAMIDE (LSD) IN THE RAT.

O01120 02-03

ANALGESIA FOLLOWING TRANSCUTANEOUS ELECTRICAL STIMULATION
AND ITS PARTIAL REVERSAL BY A NARCOTIC ANTAGONIST.

3 BENZAZOCINE-AMIDINIUM-NITRONATES. AN UNUSUAL TYPE OF OPIATE ANTAGONIST.

INCREASED ANTAGONIST POTENCY OF NALOXONE CAUSED BY MORPHINE PRETREATMENT IN MICE.

DOPAMINE ANTAGONIST BINDING: A SIGNIFICANT DECREASE WITH MORPHINE-DEPENDENCE IN THE RAT STRIATUM.

AFFINITIES OF DRUGS FOR THE AGONIST AND ANTAGONIST STATES OF THE DOPAMINE RECEPTOR.

003052 04-03
THE DOPAMINE RECEPTOR.

BEHAVIORAL EFFECTS OF CHRONIC NARCOTIC ANTAGONIST ADMINISTRATION TO INFANT RATS.

INHIBITION OR WET SHAKES DURING MORPHINE ABSTINENCE BY AN ANTAGONIST OF OPIATE ANALGESIA.

PSYCHOANALYTIC AND BEHAVIORAL CONSIDERATIONS IN ANTAGONIST AND METHADONE PROGRAMS.

ANTAGONISTIC

THE ANTAGONISTIC EFFECTS OF 5 ETHYL-5-HYDROXY-1-METHYLBUTYLBARBITURIC-ACID ON PENTOBARBITAL NARCOSIS IN BOTH NAIVE AND TOLERANT MICE. 002336 03-04

ANTAGONISTS

OF THE HYPERACTIVITY INDUCED BY DOPAMINE FROM THE NUCLEUS-

COMPARISON OF THYROTROPIN-RELEASING HORMONE WITH
MELANOCYTE-STIMULATING HORMONE RELEASE INHIBITING FACTOR
AS PENTOBARBITAL ANTAGONISTS IN MONKEYS.

ELECTROCORTICAL CHANGES INDUCED BY THE PERFUSION OF NORADREMALINE, ACETYLCHOLINE AND THEIR ANTAGONISTS DIRECTLY INTO THE DORSAL RAPHE NUCLEUS OF THE CAT.

ACTIONS OF AMPHETAMINE AND ANTAGONISTS ON PUPIL DIAMETER IN THE CHRONIC SYMPATHECTOMIZED DOG.

SUBSTITUTED BENZAMIDES AS CEREBRAL DOPAMINE ANTAGONISTS IN RODENTS.

EFFECTS OF CHOLINOMIMETIC DRUGS AND THEIR ANTAGONISTS INJECTED INTO VERTEBRAL ARTERY OF UNANAESTHETIZED DOGS.

EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON FEEDING
IN INTACT AND 6 HYDROXYDDPAMINE TREATED RATS.

DISCRIMINATIVE EFFECTS OF NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT AND SQUIRREL-MONKEY.

O00381 01-04
INTERACTIONS OF NARCOTICS AND THEIR ANTAGONISTS WITH HUMAN
SERUM ESTERASE. VI: THE BEHAVIOR OF 14 HYDROXYLATED
MORPHINE DERIVATIVES.

IN VIVO BINDING OF H3-PIMOZIDE IN MOUSE STRIATUM: EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS.

THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN
RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED
REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS.

EFFECTS OF ACUTE AND CHRONIC MORPHINE AND NARCOTIC
ANTAGONISTS ON BRAIN ENERGY METABOLISM.

THE EFFECTS OF VARIOUS NARCOTIC AGONISTS AND ANTAGONISTS ON DEPRIVATION-INDUCED FLUID CONSUMPTION.

TOXIC INTERACTIONS OF STIMULANTS, NARCOTICS AND NARCOTIC

PRODOPAMINERGIC EFFECT OF NARCOTIC ANTAGONISTS IN RABBITS
PRETREATED WITH ANTIDOPAMINERGIC OR ANTISEROTONERGIC

PRETREATED WITH ANTIDOPAMINERGIC OR ANTISEROTONERGIC AGENTS. 002135 03-0

EFFECT OF BETA ADRENERGIC RECEPTOR ANTAGONISTS ON D

AMPHETAMINE AND POTASSIUM-INDUCED RELEASE OF H3NOREPINEPHRINE FROM RAT BRAIN IN VITRO.

002187 03-0

EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AGONISTS AND

EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AGONISTS AND ANTAGONISTS INTO THE AMYGDALA ON RETENTION OF PASSIVE AVOIDANCE TRAINING IN RATS. (PH.D. DISSERTATION).

002323 03-04

CLINICAL EVALUATION OF NALTREXONE TREATMENT OF OPINTE-DEPENDENT INDIVIDUALS: REPORT OF THE NATIONAL RESEARCH COUNCIL COMMITTEE ON CLINICAL EVALUATION OF NARCOTIC ANTAGONISTS.

D ALPHA-AMINOADIPATE, ALPHA-EPSILON-DIAMINOPIMELIC-ACID AND H-966 AS ANTAGONISTS OF AMINO-ACID-INDUCED AND SYNAPTIC EXCITATION OF MAMMALIAN SPINAL NEURONES IN VIVO.

REVERSAL OF THE ACTION OF AMINO-ACID ANTAGONISTS BY BARBITURATES AND OTHER HYPNOTIC DRUGS.

BLOCKADE OF BOTH PILOCAPINE AND AMPHETAMINE-INDUCED HEAD-SHAKING WITH DOPAMINE RECEPTOR ANTAGONISTS.

CYCLIC-NUCLEOTIDE LEVELS IN THE RAT STRIATUM AND CEREBELLUM -IN VIVO EFFECTS OF DOPAMINE AND ACETYLCHOLINE RECEPTOR AGONISTS AND ANTAGONISTS.

003051 04-03

TRYPTAMINE-INDUCED DRUG EFFECTS INSENSITIVE TO SEROTONINERGIC ANTAGONISTS: EVIDENCE OF SPECIFIC TRYPTAMINERGIC RECEPTOR STIMULATION?

AVERSIVE PROPERTIES OF NARCOTIC ANTAGONISTS IN RATS 003367 04-04

001349 02-04

001303 02-04

ANTAGONIZE TACRINE AND ITS DERIVATIVES ANTAGONIZE CHOLINERGIC

PSYCHOTOMIMETICS: BEHAVIORAL STUDY IN RATS. 003262 04-04 DO ANTICHOLINERGICS ANTAGONIZE ANTIPSYCHOTIC DRUG ACTION? 003478 04-08

ANTAGONITING

THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE. 000169 01-03

ANTEROLATERA

DIFFERENT BEHAVIORAL RESPONSES TO L-DOPA AFTER ANTEROLATERAL OR POSTEROLATERAL HYPOTHALAMIC INJECTIONS OF 6 HYDROXYDOPAMINE

MEMORY FACILITATING AND ANTIAMNESIC EFFECTS OF CORTICOSTEROIDS.

002233 03-04

ANTIANDROGEN

DIFFERENTIAL EFFECTS OF THE ANTIANDROGEN FLUTAMIDE ON ASPECTS OF SEXUAL BEHAVIOR IN CASTRATED, ANDROGEN TREATED MALE 002237 03-04

ANTIANXIETY 5 ARYL-DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES AS ANTIANXIETY AGENTS.

000013 01-01 A COMPARATIVE CLINICAL STUDY FOR THE EVALUATION OF ANTIANXIETY AGENTS, (LORAZEPAM, DIAZEPAM AND PLACEBO), IN

000599 01-10 ANTIANXIETY DRUGS: CLINICAL PHARMACOLOGY AND THERAPEUTIC

000603 01-10

EVALUATING ANTIANXIETY AGENT IN HUMANS: EXPERIMENTAL PARADIGMS.

000661 01-11 PYRAZOLODIAZEPINES, 2 ARYLDIALKYLDIHYDROPYRAZOLODIAZEPINONES AS ANTIANXIETY AND

ANTICONVULSANT AGENTS 001001 02-01 EFFECTS THE HYPNOTICS AND ANTIANXIETY DRUGS ON ACETYLCHOLINE

(ACH) CONCENTRATIONS IN DISCRETE AREAS OF THE RAT BRAIN 001239 02-03 EFFECTS OF ANTIPSYCHOTIC AND ANTIANXIETY DRUGS ON THE

INFLUENCES OF ANTIANXIETY DRUGS ON PERCEPTION

MORPHINE ARSTINENCE SYNDROME IN RATS

001840 02-15 EFFECTS OF ANTIANXIETY DRUG AND PERSONALITY ON STRESS-INDUCING PSYCHOMOTOR PERFORMANCE TEST.

002630 03-14 EXTENSION OF ANIMAL MODELS TO CLINICAL EVALUATION OF ANTIANXIETY AGENTS

002716 03-16 A MODEL FOR EVALUATION OF ANTIANXIETY DRUGS WITH THE USE OF EXPERIMENTALLY-INDUCED STRESS: COMPARISON OF NABILONE AND

DIAZEPAM. 002721 03-16

ANTIRODIES THE PURIFICATION OF ANTIMORPHINE ANTIBODIES BY AFFINITY CHROMATOGRAPHY.

000015 01-01

ALTERATION OF THE NEURONAL RESPONSE TO AMPHETAMINE IN THE NEOSTRIATUM BY PRETREATMENT WITH A CENTRALLY ACTING

000298 01-03 EFFECTS OF ANTICHOLINERGIC AND CHOLINESTERASE BLOCKING DRUGS ON APPETITIVE BEHAVIOR UNDER DIFFERENT DEPRIVATION

000306 01-04 ANTAGONISM BY CHOLINERGIC DRUGS OF BEHAVIOURAL EFFECTS IN CATS OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC DRUG AND

000404 01-04 ()- AND (-) 3 METHOXYCYPROHEPTADINE. A COMPARATIVE EVALUATION OF THE ANTISEROTONIN, ANTIHISTAMINIC,

CONDITIONS.

ANTICHOLINERGIC, AND OREXIGENIC PROPERTIES WITH CYPROHEPTADINE

PSYCHOSIS INDUCED BY DATURA-SUAVEOLENS: HALLUCINOSIS AND ANTICHOLINERGIC DELIRIUM.

001782 02-15 PHYSOSTIGMINE TREATMENT OF ANTICHOLINERGIC POISO

001843 02-15 BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA

002220 03-04 ANTICHOLINERGIC ACTIVITY OF THE TRICYCLIC ANTIDEPRESSANTS DESIPRAMINE AND DOXEPIN IN NONDEPRESSED VOLUNTEERS

003447 04-07 ANTICHOLINERGIC ACTIVITY OF TWO TRICYCLIC ANTIDEPRESSANTS.

003483 04-09 ANTICHOLINERGIC DELIRIUM IN A CASE OF MUNCHAUSEN SYNDROME 003658 04-15

SYNTHESIS AND PRELIMINARY PHARMACOLOGICAL ACTIVITY OF AMINOALKOXY ISOSTERES OF GLYCOLATE ESTER ANTICHOLINERGICS 001026 02-02

THERAPEUTIC ANTAGONISM BETWEEN ANTICHOLINERGICS AND NEUROLEPTICS: POSSIBLE INVOLVEMENT OF CHOLINERGIC MECHANISMS IN SCHIZOPHRENIA. 003473 04-08

DO ANTICHOLINERGICS ANTAGONIZE ANTIPSYCHOTIC DRUG ACTION?.
003478 04-08

ANTICHOLINESTERASE

DEVELOPMENT AND DISAPPEARANCE OF SUBSENSITIVITY TO PILOCARPINE FOLLOWING A SINGLE ADMINISTRATION OF THE IRREVERSIBLE ANTICHOLINESTERASE AGENT. DFP.

000212 01-03 ANTICONVULSANT

3.4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3 AMINOPYRROLIDINES. STREOSELECTIVE INVESTIGATIONS OF POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND ANTICONVULSANT ACTIVITIES.

000035 01-02 ANTICONVULSANT ACTIVITY OF PHENOBARBITAL AND PHENYTOIN IN

000182 01-03 EFFECT OF CONVULSANT AND ANTICONVULSANT AGENTS ON LEVEL AND METABOLISM OF GAMMA-AMINOBUTYRIC-ACID IN MOUSE BRAIN. 000186 01-03

ANTICONVULSANT INTERACTION OF CANNABIDIOL AND ETHOSUXIMIDE

000339 01-04 ON THE HYPNOGENIC AND ANTICONVULSANT ACTIVITIES OF DEMETHYLDIAZEPAM AND CHLORDEMETHYLDIAZEPAM: TIME EFFECT

000462 01-04 PSYCHOTROPIC AND ANTICONVULSANT DRUG USAGE IN EARLY CHILDHOOD SPECIAL EDUCATION PROGRAMS III. A PRELIMINARY REPORT: PARENT INTERVIEWS ABOUT DRUG TREATMENT.

000627 01-11 PLASMA ANTICONVULSANT CONCENTRATIONS DURING PREGNANCY.
000642 01-11

PYRAZOLODIAZEPINES. 2 ARYLDIALKYLDIHYDROPYRAZOLODIAZEPINONES AS ANTIANXIETY AND ANTICONVULSANT AGENTS.

001001 02-01 ELECTROSHOCK ANTICONVULSANT ACTIVITY AND BRAIN ACETYLCHOLINE ALTERATIONS IN MICE TREATED WITH SELECT BENZODIAZEPINES. 001210 02-03

THE HIPPOCAMPAL SLICE: A SYSTEM FOR STUDYING THE PHARMACOLOGY OF SEIZURES AND FOR SCREENING ANTICONVULSANT

001538 02-06 PSYCHOLOGICAL SIDE-EFFECTS OF L-DOPA AND ANTICONVULSANT MEDICATION

001801 02-15

A COMPARISON OF THE EFFECTS OF SEIZURES AND TWO ANTICONVULSANT MEDICATIONS ON LEARNING IN THE PAPIO-PAPIO BABOON. (Ph.D. DISSERTATION). 002329 03-04

RETENTION OF URINE IN THE NEONATE POSSIBLY DUE TO ANTICONVULSANT DRUGS.

002683 03-15 ANTAGONISM OF THE ANTICONVULSANT ACTION OF PHENYTOIN,
PHENOBARBITAL, AND ACETAZOLAMIDE BY 6 HYDROXYDOPAMINE 002845 04-03

SEIZURE SUSCEPTIBILITY AND ANTICONVULSANT ACTIVITY OF CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES. 003055 04-03 Subject Index ANTICONVULSANTS

EFFECT OF ANTICONVULSANTS ON THALAMIC AFTER-DISCHARGE IN RATS
AND CATS. 002046 03-03
INVESTIGATIONS OF CHILDREN OF MOTHERS TREATED IN PREGNANCY
WITH ANTICONVULSANTS. 002701 03-15 ANTICONVULSIVE HAS TRYPTOPHAN ANY ANTICONVULSIVE EFFECT? 002634 03-14 EFFECTS OF MIANSERIN, A NEW ANTIDEPRESSANT, ON THE IN VITRO AND IN VIVO UPTAKE OF MONOAMINES. TRICYCLIC ANTIDEPRESSANT DRUGS BLOCK HISTAMINE H2 RECEPTOR IN UPTAKE INHIBITION OF BIOGENIC AMINES BY NEWER ANTIDEPRESSANT DRUGS: RELEVANCE TO THE DOPAMINE HYPOTHESIS OF DEPRESSION. 000232 01-03 INHIBITION OF THE CENTRAL HYPOTENSIVE EFFECT OF CLONIDINE BY TRAZODONE, A NOVEL ANTIDEPRESSANT. 000286 01-03 OLFACTORY BULB ABLATION IN THE RAT: BEHAVIOURAL CHANGES AND THEIR REVERSAL BY ANTIDEPRESSANT DRUGS. A DOUBLE-BLIND CLINICAL TRIAL OF BUPROPION-HCL --ANTIDEPRESSANT. NOVEL 000510 01-07 ANTIDEPRESSANT EFFECT OF SALBUTAMOL. 000516 01-07 PLASMA CONCENTRATION AND THE ANTIDEPRESSANT EFFECT OF IMPRAMINE TREATMENT. APROTILINE — A DOUBLE-BLIND STUDY OF A NEW TETRACYCLIC ANTIDEPRESSANT IN SEVERE DEPRESSION.

000567 01-09 PSYCHOTHERAPY IN COMBINATION WITH ANTIDEPRESSANT DRUGS IN PATIENTS WITH SEVERE MASKED DEPRESSIONS. 000572 01-09 000574 01-09 ANXIETY STATES IN FAMILY PRACTICE: AN EVALUATION OF THE NEED FOR ANTIDEPRESSANT AS WELL AS ANXIOLYTIC THERAPY. 000605 01-10 DOUBLE-BLIND TRIALS OF A NEW TRICYCLIC ANTIDEPRESSANT (LOFEPRAMIN) AND A TETRACYCLIC ANTIDEPRESSANT (MAPROTILINE) 000607 01-10 RELATIONSHIP BETWEEN AGE AND TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS. 000652 01-11
TRICYCLIC ANTIDEPRESSANT OVERDOSE: INCIDENCE OF SYMPTOMS. 000801 01-15 EXTRAPYRAMIDAL SIDE-EFFECTS OF METOCLOPRAMIDE (CERUCAL) USED IN COMBINATION WITH AN ANTIDEPRESSANT. 000832 01-15

CARDIAC TOXICITY WITH THIORIDAZINE TRICYCLIC ANTIDEPRESSANT

COMBINATION.

TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS AND ADVERSE EFFECTS AFTER OVERDOSE 000883 01-15 TRICYCLIC ANTIDEPRESSANT AND MONOAMINE-OXIDASE INHIBITOR COMBINATION THERAPY 000976 01-17 BUPROPION-HYDROCHLORIDE ((/-) ALPHA-T-BUTYLAMINO-3-CHLOROPROPIOPHENONE HCL): A NOVEL ANTIDEPRESSANT AGENT 001038 02-02 CENTRAL PHARMACOLOGY OF A NEW ANTIDEPRESSANT 001063 02-03

POISONING WITH TRICYCLIC ANTIDEPRESSANT DRUGS

EFFECT OF NOMIFENSINE AND OTHER ANTIDEPRESSANT DRUGS ON ACETYLCHOLINE TURNOVER IN VARIOUS AREAS OF RAT BRAIN 001225 02-03 EFFECT OF TWO NON TRICYCLIC ANTIDEPRESSANT DRUGS ON C14-5
HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.

001283 02-03 TRICYCLIC ANTIDEPRESSANT DRUGS: ANTAGONISM OF EFFECT OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON SHOCK ELICITED

001461 02-04 EEG, BLOOD LEVEL, AND BEHAVIORAL EFFECTS OF THE ANTIDEPRESSANT MIANSERIN (ORG-GB-94).

FLUVOXAMINE (DU-23001), A NEW ANTIDEPRESSANT. QUANTITATIVE PHARMACO-ELECTROENCEPHALOGRAPHY AND PILOT CLINICAL TRIALS.

001548 02-07 PROTRIPTYLINE PLASMA LEVELS AND ANTIDEPRESSANT RESPONSE 001576 02-09 ANTIDEPRESSANT DRUG THERAPY IN PSYCHOTIC DEPRESSION

Psychopharmacology Abstracts

001584 02-09

IQ AS A PREDICTOR OF ANTIDEPRESSANT RESPONSES TO IMIPRAMINE 001582 02-09 VILOXAZINE: ASSESSMENT OF POTENTIAL RAPID ANTIDEPRESSANT

PIZOTIFEN AS AN ANTIDEPRESSANT.

001606 02-09 EXPERIENCES WITH USING THE ANTIDEPRESSANT DIBENZEPIN: NOVERIL, ON NEUROLOGY OUTPATIENTS.

001615 02-10 TRICYCLIC ANTIDEPRESSANT DRUGS AND CARDIAC CONDUCTION 001751 02-15

EXPERIENCES WITH PHYSOSTIGMINESALICYLATE IN TRICYCLIC ANTIDEPRESSANT POISONING.

001820 02-15 TRICYCLIC ANTIDEPRESSANT OVERDOSES IN ADOLESCENT PATIENTS 001822 02-15 THE TRICYCLIC ANTIDEPRESSANT OVERDOSED PATIENT.

001852 02-15 ANTIDEPRESSANT AGENTS. 9.3,3 DIPHENYLCYCLOBUTYLAMINES, A NEW CLASS OF CENTRAL STIMULANTS.

001943 03-01 INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS.

BLOCKADE OF PRESYNAPTIC ALPHA-RECEPTORS AND OF AMINE UPTAKE IN THE RAT BRAIN BY THE ANTIDEPRESSANT MIANSERINE.

001965 03-03 ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002004 03-03 A NEW MECHANISM OF TRICYCLIC ANTIDEPRESSANT ACTION. BLOCKADE OF PROSTAGLANDIN DEPENDENT CALCIUM MOVEMENTS. 002043 03-03

DESIPRAMINE AND SOME OTHER ANTIDEPRESSANT DRUGS DECREASE THE MAJOR NOREPINEPHRINE METABOLITE 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE IN THE RAT BRAIN.

002114 03-03 METABOLISM OF 5 HYDROXYTRYPTAMINE AND LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS IN RAT BRAIN AFTER ACUTE AND CHRONIC

002169 03-03 BEHAVIOURAL DESPAIR IN RATS: A NEW MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.

ANIMAL TEST MODELS FOR PREDICTION OF CLINICAL ANTIDEPRESSANT

A NEW ANTIDEPRESSANT BUTRIPTYLINE: PLASMA LEVELS AND CLINICAL RESPONSE.

BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS: ASSAY PROCEDURES, REPRODUCIBILITY AND RELATIONSHIP TO THERAPEUTIC OUTCOME AND SIDE-EFFECTS.

002440 03-09 CHOOSING AN ANTIDEPRESSANT.

ENHANCEMENT OF THE ANTIDEPRESSANT RESPONSE TO L TRYPTOPHAN BY A LIVER PYRROLASE INHIBITOR: A RATIONAL TREATMENT 002464 03-09

MODE OF ACTION OF ANTIDEPRESSANT DRUGS

002466 03-09

CLINICAL TRIAL OF FLUVOXAMINE: A NEW SEROTONERGIC ANTIDEPRESSANT

002470 03-09 A REVIEW OF THE RELATIONSHIP BETWEEN ENDOCRINOPATHY AND DEPRESSION OR ANTIDEPRESSANT DRUGS, WITH PARTICULAR RESPECT TO NOVEL THEORIES INVOLVING THE OPIATE RECEPTOR.

002557 03-13 TYRAMINE PRESSOR RESPONSES AND PLASMA LEVELS DURING TRICYCLIC ANTIDEPRESSANT THERAPY.

002584 03-13 QUANTITATIVE EEG ANALYSIS OF THE PUTATIVE ANTIDEPRESSANT COMPOUND F1-6654.

002588 03-13 USE OF TRICYCLIC ANTIDEPRESSANT BLOOD LEVELS.

002693 03-15 MEASUREMENT OF PLASMA ANTIDEPRESSANT LEVELS BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY. 002720 03-16

CHARCOAL HEMOPERFUSION AND ANTIDEPRESSANT OVERDOSE 002774 03-17 INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A

METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS 002801 04-02 IQ AS A PREDICTOR OF ANTIDEPRESSANT RESPONSES TO LITHIU 003492 04-09

001580 02-09

000846 01-15

000860 01-15

ANTIDEPRESSANT ACTIVITY AND PHARMACOLOGICAL INTERACTIONS OF CICLAZINDOL 003493 04-09 CLINICAL IMPORTANCE OF DOXEPIN ANTIDEPRESSANT PLASMA LEVEL 003497 04-09 A CONTROLLED TRIAL OF A NEW ANTIDEPRESSANT, WIN-27147-2. 003523 04-09 CLINICAL CORRELATES OF TRICYCLIC ANTIDEPRESSANT MEDIATED INHIBITION OF PLATELET MONOAMINE-OXIDASE 003524 04-09 ANTIDEPRESSANT DRUG LEVELS AND CLINICAL RESPONSE. 003545 04-10 EXPERIMENTAL AND CLINICAL EVIDENCE OF THE ANTIDEPRESSANT EFFECT OF A BETA-ADRENERGIC STIMULANT 003546 04-10 CARDIOLOGICAL EFFECTS OF NOMIFENSINE, A NEW ANTIDEPRESSANT. 003645 04-15 AGGREGATION OF ANTIDEPRESSANT DRUGS IN AQUEOUS SOLUTION. 003697 04-17 ANTIDEPRESSANT-LIKE INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS 001959 03-02 INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS 002801 04-02 EFFECTS OF 3,4 DIHYDROOXAZINOINDOLES, POTENTIAL ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED ACTIVITIES. 0000027 01-02 DEVELOPMENT OF BETA-ADRENERGIC RECEPTOR SUBSENSITIVITY BY ANTIDEPRESSANTS 000049 01-03 TRICYCLIC ANTIDEPRESSANTS AS ANTIMUSCARINIC DRUGS: IN VIVO AND IN VITRO STUDIES 000235 01-03 ACETYLCHOLINE TURNOVER IN SPECIFIC BRAIN AREAS OF RATS INJECTED WITH VARIOUS ANTIDEPRESSANTS. (UNPUBLISHED PAPER). 000244 01-03 NEUROCHEMICAL PROPERTIES OF DIMETHYLMETHYLAMINOPROPYL-1-PHENYLINDAN HCL (LU-3-049) AND SELECTED TRICYCLIC ANTIDEPRESSANTS. 000251 01-03 THE BLOOD (SERUM AND CORPUSCLE) DYNAMICS OF TRICYCLIC ANTIDEPRESSANTS. 000556 01-09 THE EFFICACY OF ELECTROCONVULSIVE THERAPY AND ANTIDEPRESSANTS IN DEPRESSION. 000557 01-09 INCREASED STEADY-STATE PLASMA LEVELS AND PROLONGED HALF-LIVES OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY. 000734 01-13 POISONING WITH ANTIDEPRESSANTS 000805 01-15 DYSARTHRIA: AN UNUSUAL SIDE-EFFECT OF TRICYCLIC ANTIDEPRESSANTS. 000885 01-15 MODE OF ACTION OF: ANTIDEPRESSANTS AND CENTRAL STIMULANTS (UNPUBLISHED PAPER). 000958 01-17 THE BEHAVIORAL TOXICITY OF MONOAMINE-OXIDASE INHIBITING ANTIDEPRESSANTS. 000967 01-17 EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE CONTENT AND METABOLISM OF DOPAMINE IN THE RAT STRIATUM. 001133 02-03 EFFECTS OF REPEATED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS ON ADIPOSE TISSUE LIPOLYTIC ACTIVITY IN THE RAT. 001179 02-03 ANTIMUSCARINIC PROPERTIES OF ANTIDEPRESSANTS: DIBENZEPIN (NOVERIL) 001221 02-03 THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS ON MHPG-SO4 IN RAT BRAIN. 001228 02-03 ALPHA-ADRENOCEPTOR BLOCKADE BY TRICYCLIC ANTIDEPRESSANTS. 001244 02-03 THE THERMAL EFFECTS OF INTERACTION BETWEEN D AMPHETAMINE AND ANTIDEPRESSANTS AMONG RATS KEPT AT VARIOUS AMBIENT TEMPERATURES. 001290 02-03 CHOICE OF ANTIDEPRESSANTS. 001601 02-09 SERUM GONADOTROPIN AND TSH LEVELS AFTER TRICYCLIC ANTIDEPRESSANTS IN HEALTHY MALES. 001670 02-13 GENERATION OF ELECTRONIC EXCITED STATES (EES) BY TRICYCLIC ANTIDEPRESSANTS: MOLECULAR ASPECTS.

DELIBERATE POISONING WITH TRICYCLIC ANTIDEPRESSANTS TREATED IN AN INTENSIVE CARE UNIT 001758 02-15 G OBSERVATION OF NOCTURNAL DELIRIUM IN A PATIENT TAKING ANTIDEPRESSANTS AND ANTIPARKINSONS DRUGS. 001773 02-15 POISONING WITH ANTIDEPRESSANTS. 001791 02-15 HEMODYNAMIC EFFECTS FOLLOWING TOXIC DOSES OF TRICYCLIC **ANTIDEPRESSANTS** 001838 02-15 REDUCED LEVELS OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA FROM VACUTAINERS 001859 02-16 INDIVIDUALISED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS 001863 02-16 TRICYCLIC ANTIDEPRESSANTS IN OUTPATIENT THERAPY IN VIVO EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE IN RAT BRAIN. 001987 03-03 EFFICACY OF NEUROLEPTICS AND ANTIDEPRESSANTS IN THE TEST OF APOMORPHINE HYPOTHERMIA AND SOME DATA CONCERNING NEUROCHEMICAL MECHANISMS OF THE TEST. 002147 03-03 ANTIDEPRESSANTS -- YES OR NO? 002442 03-09 CLINICAL RESPONSE IN DEPRESSED PATIENTS IN RELATION TO PLASMA
LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND TYRAMINE PRESSOR 002453 03-09
TRICYCLIC ANTIDEPRESSANTS ACCELERATE MANIC-DEPRESSIVE CYCLES. (UNPUBLISHED PAPER) 002468 03-09
EFFECT OF ANTIDEPRESSANTS ON THE ABSORPTION OF SEROTONIN BY HUMAN THROMBOCYTES. 002586 03-13 SECOND-GENERATION ANTIDEPRESSANTS AS RESEARCH TOOLS -- SOME PRELIMINARY FINDINGS WITH CLOMIPRAMINE AND MAPROTILINE. 002587 03-13 THE EFFECTS OF TWO ANTIDEPRESSANTS. IMIPRAMINE AND VILOXAZINE, UPON DRIVING PERFORMANCE. APPLICATION OF LIFE TABLE METHOD TO NATURALISTIC DESIGNS -- A COMPARISON OF EFFICACY OF TRICYCLIC ANTIDEPRESSANTS AND BENZODIAZEPINES IN AMBULATORY DEPRESSIVES. 002783 03-17 DRUGS AFFECTING THE CENTRAL-NERVOUS-SYSTEM: EFFECTS OF PEMOLINE, AND TRICYCLIC ANTIDEPRESSANTS ON NERVE TERMINAL ADENOSINE-TRIPHOSPHATASE ACTIVITIES AND NEUROTRANSMITTER RELEASE 002923 04-03 TRICYCLIC ANTIDEPRESSANTS: THERAPEUTIC PROPERTIES AND AFFINITY
FOR ALPHA-NORADRENERGIC RECEPTOR BINDING SITES IN THE BRAIN DISCRIMINATIVE STIMULUS PROPERTIES OF ANTIDEPRESSANTS.
003246 04-04 003118 04-03 ANTICHOLINERGIC ACTIVITY OF THE TRICYCLIC ANTIDEPRESSANTS DESIPRAMINE AND DOXEPIN IN NONDEPRESSED VOLUNTEERS 003447 04-07 ANTICHOLINERGIC ACTIVITY OF TWO TRICYCLIC ANTIDEPRESSANTS.
003483 04-09 TRICYCLIC ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CLINICAL COMPARISON OF CLOMIPRAMINE (ANAFRANIL) AND AMITRIPTYLINE. 003501 04-09 WHEN ANTIDEPRESSANTS DONT WORK THE EFFECT OF CHLORPROMAZINE, SOME TRICYCLIC ANTIDEPRESSANTS AND INSULIN ON THE ACTION OF CYCLIC-AMP AND ADENOSINE METABOLISM. 003606 04-13
NONMONOAMINE-OXIDASE INHIBITOR ANTIDEPRESSANTS AND EPILEPSY: A REVIEW. 003611 04-13 EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON HUMAN PLASMA LEVELS OF TSH, GH AND PROLACTIN. 003613 04-13 TRICYCLIC ANTIDEPRESSANTS: PLASMA LEVELS AND CLINICAL FINDINGS IN OVERDOSE. 003643 04-15 ANTIDEPRESSIVE ANTIDEPRESSIVE EFFECTS ON CENTRAL CATECHOLAMINE RECEPTORS 000202 01-03 CONTROLLED TRIAL OF A NEW ANTIDEPRESSIVE, AMOXAPINE, IN COMPARISON WITH AMITRIPTYLINE

EFFECTS OF IFC-45, A NEW BENZONAPHTYRIDONE DERIVATIVE WITH ANTIDEPRESSIVE ACTION, ON ACTIVITY OF THE RAT SUPRARENAL

001522 02-05

001693 02-13

GLAND CORTEX.

INTENSIVE ANTIDEPRESSIVE THERAPY BY 48 HOUR SLOW-DRIP INFUSION WITH HIGH DOSES DIBENZEPINE.

SOME OBSERVATIONS ON PATIENT COMPLIANCE IN AN ANTIDEPRESSIVE

CLOMIPRAMINE AND MAPROTILINE ON HUMAN PLATELET UPTAKE OF 5 HYDROXYTRYPTAMINE AND DOPAMINE IN VITRO: WHAT RELEVANCE TO THEIR ANTIDEPRESSIVE AND OTHER ACTIONS?

ANTIDIARRHEAL
RECEPTOR AFFINITY AND PHARMACOLOGICAL POTENCY OF A SERIES OF
NARCOTIC ANALGESIC, ANTIDIARRHEAL AND NEUROLEPTIC DRUGS.
002160 03-03

ANTIDIPSOGEN
PHYSALAEMIN, A NEW POTENT ANTIDIPSOGEN IN THE RAT

003207 04-04

ANTIDIURESIS
NALTREXONE BLOCKADE OF MORPHINE-INDUCED ANTIDIURESIS IN THE 001162 02-03

ANTIDIURETIC
SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE
(SIADH) SECONDARY TO ANTIPSYCHOTIC DRUG THERAPY.

003647 04-1

INCREASE IN SERUM PROLACTIN BY EXOGENOUS AND ENDOGENOUS OPIATES: EVIDENCE FOR ANTIDOPAMINE AND ANTIPSYCHOTIC

002926 04-03 ANTIDOPAMINERGIC
PRODOPAMINERGIC EFFECT OF NARCOTIC ANTAGONISTS IN RABBITS
PRETREATED WITH ANTIDOPAMINERGIC OR ANTISEROTONERGIC

002135 03-03

SCREENING FOR THE EFFECTS OF DOPAMINERGIC AND
ANTIDOPAMINERGIC DRUGS ON SERUM PROLACTIN LEVELS BY
RADIOIMMUNOASSAY. 002340 03-05

ANTIDROMICALLY
ANTIDROMICALLY IDENTIFIED SEROTONERGIC NEURONS IN THE RAT
MIDBRAIN RAPHE: EVIDENCE FOR COLLATERAL INHIBITION,
000292 01-03

ANTIEMETIC
ANTIEMETIC ACTIVITY OF NABILONE, A CANNABINOL DERIVATIVE,
REVERSED BY NALOXONE IN AWAKE CATS.

001416

THE ATTENUATION OF A SPECIFIC CUE-TO-CONSEQUENCE ASSOCIATION BY ANTIEMETIC AGENTS.

AN APOMORPHINE-INDUCED VOMITING MODEL FOR ANTIEMETIC STUDIES 002722 03-16

ANTIEPILEPTIC

A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY ON ANTIEPILEPTIC
ACTIVITY OF CLONAZEPAM — RELATIONSHIP BETWEEN CLINICAL
EFFECTS OF ORAL ADMINISTRATION AND ELECTROENCEPHALOGRAPHIC
EFFECTS OF INTRAVENOUS ADMINISTRATION.

DO0639 01-11

THE PROBLEM OF PRENATAL DAMAGE FROM LONG-TERM ANTIEPILEPTIC DRUG TREATMENT.

002659 03-15 ANTIESTROGENS EFFECTS OF ANTIESTROGENS ON EATING, FEMALE SEXUAL BEHAVIOR, AND THE UPTAKE OF H3-ESTRADIOL IN THE CENTRAL-NERVOUS-SYSTEM IN RATS. (PH.D. DISSERTATION).

001447 02-04

HISTOCOMPATIBILITY ANTIGENS IN LITHIUM TREATED MANIC-DEPRESSIVE PATIENTS. 003533 04-09

ANTIHALLUCINATORY

A DOUBLE-BLIND STUDY OF THE EFFECTIVE ANTIHALLUCINATORY DOSES
OF DIAZEPAM PRIOR TO KETAMINE ANESTHESIA. 000640 01-11

A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR. 003657 04-15

ANTIHISTAMINIC

()- AND (-) 3 METHOXYCYPROHEPTADINE. A COMPARATIVE EVALUATION OF THE ANTISEROTONIN, ANTIHISTAMINIC, ANTICHOLINERGIC, AND OREXIGENIC PROPERTIES WITH CYPROHEPTADINE.

MI

001012 02-01 ANTIHYPERTENSIVE THE EFFECTS OF FOUR ANTIHYPERTENSIVE AGENTS ON THE STROOP COLOUR WORD TEST IN NORMAL MALE VOLUNTEER SUBJECTS. 000771 01-14

Psychopharmacology Abstracts

BRL-13776: A NOVEL ANTIHYPERTENSIVE AGENT WITH INTERESTING MONOAMINE DEPLETING PROPERTIES. 001007 02-01

ANTIHYPERTENSIVE DRUGS AND DEPRESSION: A REAPPRAISAL 003534 04-10

ANTIMIGRAINE
QUANTITATIVE PHARMACO-EEG WITH ANTIMIGRAINE COMPOUNDS 002565 03-13

ANTIMORPHINE
THE PURIFICATION OF ANTIMORPHINE ANTIBODIES BY AFFINITY
CHROMATOGRAPHY.

000015 01-01

TRICYCLIC ANTIDEPRESSANTS AS ANTIMUSCARINIC DRUGS: IN VIVO 000235 01-03 ANTIMUSCARINIC PROPERTIES OF ANTIDEPRESSANTS: DIBENZEPIN

001221 02-03

ANTIMUSCARINICS
DISCRIMINABLE EFFECTS OF ANTIMUSCARINICS: DOSE-RESPONSE AND SUBSTITUTION TEST STUDIES. 000426 01-04

ANTIMYCIN

EFFECTS OF ANTIMYCIN A PLUS 2 DEOXYGLUCOSE ON UPTAKE AND

VESICULAR STORAGE OF SEROTONIN IN HUMAN PLATELETS.

(UNPUBLISHED PAPER).

000694

000694 01-13

ANTINOCICEPTION
MULTIPLE BRAIN SITES INVOLVED IN MORPHINE ANTINOCICEPTION 001270 02-03 CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIVITY TO THE DIRECT APPLICATION OF MORPHINE AND FOCAL ELECTRICAL STIMULATION IN THE PRODUCTION OF ANTINOCICEPTION IN THE RAT.

001291 02-03 REDUCTION OF VMH LESION-INDUCED HYPEREMOTIONALITY AND ANTINOCICEPTION BY DIAZEPAM

002211 03-04 EFFECTS OF 6 HYDROXYDDPAMINE-INDUCED DEPLETIONS OF BRAIN CATECHOLAMINES OR DOPAMINE ON MEPERIDINE ANTINOCICEPTION

002227 03-04 ANTINOCICEPTIVE
AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW
ANTINOCICEPTIVE AGENT.

000018 01-02 EFFECT OF APOMORPHINE ON THE ANTINOCICEPTIVE ACTIVITY OF

000351 01-04 PENTOBARBITAL DOES NOT INFLUENCE THE ANTINOCICEPTIVE EFFECTS OF MORPHINE IN NAIVE OR MORPHINE-TOLERANT RATS.

001132 02-03 EFFECTS OF ANTINOCICEPTIVE DRUGS ON THE DORSAL ROOT POTENTIAL IN THE RAT.

001285 02-03 STUDIES ON THE EFFECT OF LESIONS OF THE VENTRAL NORADRENERGIC TRACT ON THE ANTINOCICEPTIVE ACTION OF MORPHINE. 002979 04-03

ANTIPARKINSON
CLINICAL STUDY OF ANTIPARKINSON DRUGS USED TOGETHER WITH
PSYCHOTROPIC DRUGS.

001936 02-17 STUDY OF A DOPAMINERGIC POTENTIAL ANTIPARKINSON COMPOUND IN INTACT AND NIGRA-LESIONED RATS: N-N PROPYLBUTYLDIHYDROXYPHENYLETHYLAMINE HCL. 001957 03-02

ANTIPARKINSONIAN IPARKINSONIAN
3,4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND
BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3
AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF
POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND
ANTICONVULSANT ACTIVITIES.

000035 01-02 INFLUENCE OF THE ANTIPARKINSONIAN DRUGS ON THE PLASMA LEVEL OF NEUROLEPTICS.

ABUSE OF ANTIPARKINSONIAN DRUGS BY PSYCHIATRIC PATIENTS. 000856 01-15

ANTIPARKINSONIAN DRUG ADMINISTRATION AND PLASMA LEVELS OF PENFLURIDOL, A NEW LONG-ACTING NEUROLEPTIC. 001559 02-08 A METHOD FOR MECHANOGRAPHICAL RECORDING OF MUSCLE TONE IN THE RAT: THE EFFECT OF SOME ANTIPARKINSONIAN DRUGS ON RIGIDITY INDUCED BY RESERPINE.

002346 03-05 PSYCHOTROPIC AND ANTIPARKINSONIAN DRUG USE: AN EXAMINATION OF PRESCRIPTION PRACTICES.

ANTIPARKINSONISM

EFFECT OF ANTIPARKINSONISM DRUGS ON GASTRIC EMPTYING AND INTESTINAL TRANSIT IN THE RAT.

002010 03-03

ANTIPARKINSONS
EEG OBSERVATION OF NOCTURNAL DELIRIUM IN A PATIENT TAKING ANTIDEPRESSANTS AND ANTIPARKINSONS DRUGS. 001773 02-15

ON LONG-TERM MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY: THE COMBINED ADMINISTRATION OF ANTIPARKINSONS DRUGS 001865 02-16

A REEXAMINATION OF USING ANTIPARKINSONS DRUGS WITH PSYCHOTROPIC DRUG THERAPY -- A SURVEY OF OUTPATIENTS 001874 02-16

ANTIPODAL

ANTIPODAL CENTRAL EFFECTS OF DOPAMINE AND APOMORPHINE 000168 01-03

ANTIPSYCHOTIC

EVALUATION OF NALOXONE IN LABORATORY TESTS PREDICTIVE OF CLINICAL ANTIPSYCHOTIC ACTIVITY.

000029 01-02 3.4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3 AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND ANTICONVILL SANT ACTIVITIES

000035 01-02 ADENYLATE-CYCLASE FROM VARIOUS DOPAMINERGIC AREAS OF THE BRAIN AND THE ACTION OF ANTIPSYCHOTIC DRUGS.

000076 01-03 THE NUCLEUS-ACCUMBENS -- POSSIBLE SITE OF ANTIPSYCHOTIC ACTION OF NEUROLEPTIC DRUGS?

000085 01-03 PERLAPINE: RELATIONSHIP BETWEEN STIMULATION OF PROLACTIN SECRETION AND ANTIPSYCHOTIC ACTIVITY

000197 01-03 BLOCKADE OF INTRACRANIAL SELF-STIMULATION BY ANTIPSYCHOTIC DRUGS: FAILURE TO CORRELATE WITH CENTRAL ALPHANORADRENERGIC BLOCKADE.

000475 01-04 SULPIRIDE: EVALUATION OF ANTIPSYCHOTIC ACTIVITY IN SCHIZOPHRENIC PATIENTS

000512 01-07 CLINICAL EXAMINATION OF THE NEW ANTIPSYCHOTIC CLOZAPINE (LEPONEX)

000514 01-07 MOLINDONE: A CONTROLLED EVALUATION OF THE INTRAMUSCULAR ANTIPSYCHOTIC PREPARATION.

000541 01-08 ANTIPSYCHOTIC EFFECTS, SIDE-EFFECTS AND EFFECTIVE DOSES OF THE BUTYROPHENONE LENPERONE (AHR-2277).

000553 01-08 TREATING BLURRED VISION ASSOCIATED WITH ANTIPSYCHOTIC MEDICATION

000810 01-15 TARDIVE-DYSKINESIA AND CHANGING CONCEPTS OF ANTIPSYCHOTIC DRUG USE: A NURSING PROSPECTIVE.

000919 01-16 PATTERNS OF ANTIPSYCHOTIC DRUG USE IN FOUR SOUTHEASTERN STATE HOSPITALS

000963 01-17 ANIMAL PROLACTIN EVIDENCE FOR ANTIPSYCHOTIC ACTIVITY OF PIPEROXANE

001027 02-02 EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. I. CHLORPROMAZINE AND PROMETHAZINE

001068 02-03 EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS.

ANTIPSYCHOTIC DRUGS BLOCK LSD-INDUCED DISAGGREGATION OF BRAIN POLYSOMES.

THE EFFECT OF ANTIPSYCHOTIC DRUGS AND THEIR CLINICALLY INACTIVE ANALOGS ON DOPAMINE METABOLISM.

001250 02-03 EFFECTS OF ANTIPSYCHOTIC AND ANTIANXIETY DRUGS ON THE MORPHINE ABSTINENCE SYNDROME IN RATS.

001303 02-04 CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE

ANTIPSYCHOTIC DRUGS 001526 02-06 AN EVALUATION OF A UNIQUE NEW ANTIPSYCHOTIC AGENT, SULPIRIDE: EFFECTS ON SERUM PROLACTIN AND GROWTH HORMONE LEVELS 001554 02-07

NEW ANTIPSYCHOTIC DRUGS

001562 02-08

THE EFFECTS OF AN ANTIPSYCHOTIC MEDICATION ON THE CLASSROOM BEHAVIOR OF FOUR SCHIZOPHRENIC MALE CHILDREN.

001568 02-08 ANTIPSYCHOTIC EFFECT OF OPIATE AGONISTS.

001661 02-13 HAZARDS OF ANTIPSYCHOTIC DRUG USE IN NONPSYCHOTIC PATIENTS 001847 02-15

MAINTENANCE ANTIPSYCHOTIC PHARMACOTHERAPY, RELAPSE, AND LENGTH OF STAY OUT OF THE HOSPITAL IN CHRONIC SCHIZOPHRENICS

001911 02-17 SYNTHESIS AND STEREOSPECIFIC ANTIPSYCHOTIC ACTIVITY OF BENZOCYCLOHEPTENE-PIRIDINE

001949 03-01 BRAIN NEUROTRANSMITTER RECEPTORS AND CHRONIC ANTIPSYCHOTIC DRUG TREATMENT: A MODEL FOR TARDIVE-DYSKINESIA

002061 03-03 BINDING OF ANTIPSYCHOTIC AGENTS TO THE CYCLIC-NUCLEOTIDE

002076 03-03 NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: I. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY

002096 03-03 ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBI ASTOMA CELLS

EFFECT OF AN ANTIPSYCHOTIC AND OTHER CLASSES OF DRUGS ON SPONTANEOUS LOCOMOTOR ACTIVITY AND NEUROTOXICITY IN MICE. 002369 03-06

SERUM PROLACTIN AND ANTIPSYCHOTIC RESPONSES TO PIMOZIDE IN

002408 03-08 SELECTED COMBINATIONS OF AMITRIPTYLINE AND ANTIPSYCHOTIC DRUGS AND COMPLEX LEARNING.

ANTIPSYCHOTIC DRUGS: CLINICAL PHARMACOLOGY AND THERAPEUTIC

002658 03-15 AMANTADINE IN THE TREATMENT OF BENZTROPINE REFRACTORY EXTRAPYRAMIDAL DISORDERS INDUCED BY ANTIPSYCHOTIC DRUGS 002664 03-15

PROFILES OF PROLACTIN RESPONSE TO ANTIPSYCHOTIC DRUGS: SOME METHODOLOGIC CONSIDERATIONS.

002725 03-16 ANTIPSYCHOTIC DRUGS, NEUROTRANSMITTERS, AND SCHIZOPHRENIA. 002736 03-17

THE RESULTS OF A CAMPAIGN TO EDUCATE PHYSICIANS IN ANTIPSYCHOTIC DRUG USAGE.

002761 03-17
EFFECTS ON STRIATAL AND MESOLIMBIC DOPAMINE SYSTEMS OF A NEW
POTENTIAL ANTIPSYCHOTIC DRUG — MEZILAMINE — WITH WEAK
CATALEPTOGENIC PROPERTIES.

INCREASE IN SERUM PROLACTIN BY EXOGENOUS AND ENDOGENOUS OPIATES: EVIDENCE FOR ANTIDOPAMINE AND ANTIPSYCHOTIC

A COMPARISON OF THE EFFECTS OF ANTIPSYCHOTIC DRUGS ON PITUITARY, STRIATAL AND LIMBIC SYSTEM POSTSYNAPTIC DOPAMINE RECEPTORS.

003009 04-03 DOPAMINERGIC MECHANISMS IN SCHIZOPHRENIA: THE ANTIPSYCHOTIC EFFECT AND THE DISEASE PROCESS.

003452 04-08 MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA.

003460 04-08 LONG-ACTING ORAL VS INJECTABLE ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENICS: A ONE-YEAR DOUBLE-BLIND COMPARISON IN MULTIPLE EPISODE SCHIZOPHRENICS.

003467 04-08
DO ANTICHOLINERGICS ANTAGONIZE ANTIPSYCHOTIC DRUG ACTION? 003478 04-08

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE (SIADH) SECONDARY TO ANTIPSYCHOTIC DRUG THERAPY. 003647 04-15

WITHDRAWAL SYNDROMES ASSOCIATED WITH ANTIPSYCHOTIC DRUGS. 003655 04-15

ANTIPSYCHOTICS THE TURNOVER RATE OF GAMMA-AMINOBUTYRIC-ACID IN THE NUCLEI OF TELENCEPHALON: IMPLICATIONS IN THE PHARMACOLOGY OF ANTIPSYCHOTICS AND OF A MINOR TRANQUILIZER.

000192 01-03 ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE NEUROBLASTOMA CELLS.

SPECIFICITY OF BINDING OF ANTIPSYCHOTICS TO THE ACTIVATOR OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE.

EXTRAPYRAMIDAL REACTIONS IN ADOLESCENTS TREATED WITH HIGH-POTENCY ANTIPSYCHOTICS.

TURNOVER RATES OF GAMMA-AMINOBUTYRIC-ACID IN SUBSTANTIA-NIGRA, NUCLEUS-CAUDATUS, GLOBUS-PALLIDUS AND NUCLEUS-ACCUMBENS OF RATS INJECTED WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS.

002143 03-03

ANTIPYBENE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DRUG DISTRIBUTION AND METABOLISM: ANTIPYRENE, PENTOBARBITAL, AND ETHANOL. 001643 02-13

ANTIPYRINE
MULTIPLE ORAL DOSES OF DIAZEPAM, OXAZEPAM AND PHENOBARBITAL
TO DOGS — BEHAVIOURAL EFFECTS AND CORRELATION WITH
ANTIPYRINE HALF-LIFE.

000308 01-04 ACETYLCHOLINE ANTIRELEASE EFFECT OF MORPHINE AND ITS MODIFICATION BY CALCIUM.

ANTIRESERPINE
POSSIBLE INVOLVEMENT OF THE CENTRAL DOPAMINERGIC SYSTEM IN
THE ANTIRESERPINE EFFECT OF LSD. 000198 01-03

ANTISCHIZOPHRENIC
ANTISCHIZOPHRENIC DRUGS -- MEMBRANE RECEPTOR SITES OF ACTION.
000547 01-08

A SIMPLE AND SENSITIVE RADIORECEPTOR ASSAY FOR ANTISCHIZOPHRENIC DRUGS IN BLOOD.

RAT STRIATAL METHIONINE-ENKEPHALIN CONTENT AFTER CHRONIC TREATMENT WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTISCHIZOPHRENIC DRUGS. 002953 04-03

ANTISERA
RADIOIMMUNOASSAYS FOR BETA-ENDORPHIN: COMPARISON OF
PROPERTIES OF TWO ANTISERA.
00272

002724 03-16 ANTISEROTONERGIC PRODOPAMINERGIC EFFECT OF NARCOTIC ANTAGONISTS IN RABBITS
PRETREATED WITH ANTIDOPAMINERGIC OR ANTISEROTONERGIC

THE CENTRAL ANTISEROTONERGIC ACTION OF MIANSERIN. 003281 04-04

ANTISEROTONIN

()- AND (-) 3 METHOXYCYPROHEPTADINE. A COMPARATIVE
EVALUATION OF THE ANTISEROTONIN, ANTIHISTAMINIC,
ANTICHOLINERGIC, AND OREXIGENIC PROPERTIES WITH
CYPROHEPTADINE.

()

001012 02-01

ANTISERUMS TO NEURONS AND TO OLIGODENDROGLIA FROM MAMMALIAN BRAIN. 000014 01-01

INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY ANTITHYROID
AGENTS. METHIMAZOLE AND PROPYLTHIOURACIL.

000145 01-03 ANXIETY A DOUBLE-BLIND CONTROLLED STUDY OF CLOBAZAM FOR THE TREATMENT OF ANXIETY IN PSYCHIATRIC OUTPATIENTS.

000508 01-07 EFFECTS OF KETAMINE ON PATIENT RESPONSIVENESS DURING THE VARIOUS PHASES OF A SINGLE INDUCED ANXIETY SESSION.

000513 01-07 CURRENT THERAPEUTIC CONCEPTS: CONTEMPORARY DRUGS IN THE MANAGEMENT OF ANXIETY.

000600 01-10 ANXIETY STATES IN FAMILY PRACTICE: AN EVALUATION OF THE NEED FOR ANTIDEPRESSANT AS WELL AS ANXIOLYTIC THERAPY.

000605 01-10 LORAZEPAM IN ANXIETY WITH GLDISOPDERS

000612 01-10 MULTICLINIC CROSS-OVER COMPARISON OF TRIAZOLAM (HALCION) AND PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND ANXIETY IN ANXIOUS OUTPATIENTS.

000762 01-14 UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: IV. -- DRUGS FOR ANXIETY.

000829 01-15 THE EFFECTS OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE IN AN ANIMAL TEST OF ANXIETY.

001121 02-03 CONTROLLED COMPARISON OF TRIFLUOPERAZINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY.

001848 02-15

Psychopharmacology Abstracts

ALTERATIONS IN THE FUNCTION OF THE NUCLEUS LOCUS-COERULEUS: A

A CONTROLLED COMPARATIVE TRIAL OF CLORAZEPATE (TRANXENE) AND DIAZEPAM (VALIUM) FOR ANXIETY.

A STUDY OF THE MANAGEMENT OF ANXIETY WITH LORAZEPAM. 002478 03-10 002476 03-10

PILOT OPEN-LABEL STUDY OF BROFOXINE IN ANXIETY 002479 03-10

LOYAPINE IN NELIPOTIC ANVIETY. A CONTROLLED TRIAL 002490 03-10 A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF LOXAPINE, DIAZEPAM, AND PLACEBO IN HOSPITALIZED PATIENTS WITH VARIOUS STATES OF ANXIETY.

002496 03-10 EFFECTS OF DIAZEPAM ON PHOBIC AVOIDANCE BEHAVIOR AND PHOBIC

002498 03-10

STATE-TRAIT ANXIETY AND ANXIOLYTIC TREATMENT. 002500 03-10 ANYIETY DEVISITED 002503 03-13

THE EFFECTS OF ONE-DAY TREATMENT OF ANXIETY WITH HIGH DOSES OF HAI AZEPAM

002718 03-16 CAN SOCIAL INTERACTION BE USED TO MEASURE ANXIETY 003219 04-04

THE TREATMENT OF ANXIETY WITH A POLYFLUORINATED BENZODIAZEPINE DERIVATIVE 003445 04-07

DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF KETAZOLAM IN ANXIFTY

A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-DUMMY TECHNIQUE.

003537 04-10 NABILONE, A CANNABINOID, IN THE TREATMENT OF ANXIETY: AN OPEN-LABEL AND DOUBLE-BLIND STUDY.

MANAGEMENT OF ACUTE ANXIETY SYNDROME WITH PARENTERALLY ADMINISTERED LORAZEPAM.

003539 04-10 EFFECTIVENESS OF SCH-12679, A BENZAZEPINE, IN THE TREATMENT OF ANXIETY NEUROSIS.

003541 04-10 A PLACEBO-CONTROLLED STUDY OF BROMAZEPAM AND DIAZEPAM IN

ANXIETY NEUROSIS 003542 04-10 LOXAPINE IN NEUROTIC ANXIETY: SOME MODIFIERS OF TREATMENT

RESPONSE. 003544 04-10 A CONTROLLED STUDY OF TRANCOPAL IN THE TREATMENT OF SLEEP DISTURBANCES DUE TO ANXIETY.

003548 04-10 THE EFFECTS OF APPROPRIATENESS OF ATTRIBUTED AROUSAL SOURCE

AND TEST ANXIETY ON COMPLEX TEST PERFORMANCE AND REPORTED ANXIETY DURING TEST-TAKING. (Ph.D. DISSERTATION). 003702 04-17

ANXIOLYTIC USE OF DRL IN DIFFERENTIATING ANXIOLYTIC AND NEUROLEPTIC PROPERTIES OF CNS DRUGS.

000329 01-04 ANXIETY STATES IN FAMILY PRACTICE: AN EVALUATION OF THE NEED FOR ANTIDEPRESSANT AS WELL AS ANXIOLYTIC THERAPY. 000605 01-10

A METHOD FOR EVALUATING ANXIOLYTIC SEDATIVES 000616 01-10

DISPOSITION OF KETAZOLAM, A NEW ANXIOLYTIC AGENT, IN MAN. 001655 02-13 A VARIABLE-INTERVAL PUNISHMENT PROCEDURE FOR ASSESSING ANXIOLYTIC EFFECTS OF DRUGS.

002371 03-06 STATE-TRAIT ANXIETY AND ANXIOLYTIC TREATMENT 002500 03-10 EFFICACY OF HALAZEPAM (SCH-12041) AS AN ANXIOLYTIC

003549 04-10 ANXIOLYTICS

EFFECTS OF TWO ANXIOLYTICS ON DISTRACTION, HABITUATION AND

001353 02-04

EFFECT OF A NEW BENZODIAZEPINE DERIVATE, CLOBAZAM, IN ANXIOUS PATIENTS WITH GASTROINTESTINAL DISORDERS.

000604 01-10 MULTICLINIC CROSS-OVER COMPARISON OF TRIAZOLAM (HALCION) AND PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND ANXIETY IN ANXIOUS OUTPATIENTS.

000762 01-14

TRIMIPRAMINE IN THE TREATMENT OF ANXIOUS DEPRESSED

00245A 02.00 DOXEPIN OR DIAZEPAM FOR ANXIOUS AND ANXIOUS DEPRESSED

002482 03-10

ACRES

EFFECTS OF BUTYROPHENONES ON THE SYMPATHETIC NERVES OF THE ISOLATED RABBIT HEART AND ON THE POSTSYNAPTIC ALPHA-ADRENOCEPTORS OF THE ISOLATED RABBIT AORTA

002024 03-03

SYNAPTIC CONNEXIONS AND RELATED POSTSYNAPTIC PHARMACOLOGY STUDIED IN THE CEREBRAL GANGLION OF APLYSIA.

002041 02-03

ADNEA AFTED INTRAVENOUS DIA TERABA

000844 01-15

APOMORPHINE
HYDROLYSIS OF DIESTER PRODRUGS OF APOMORPHINE. 000047 01-03

HALOPERIDOL INCREASES AND APOMORPHINE DECREASES STRIATAL DOPAMINE METABOLISM AFTER DESTRUCTION OF STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASE BY KAINIC-ACID 000094 01-03

EFFECTS OF APOMORPHINE AND CLONIDINE ON RAT PLASMA GROWTH HORMONE AFTER PRETREATMENT WITH RESERPINE AND ELECTROCONVULSIVE SHOCKS.

000102 01-03
INCREASE IN MOUSE BRAIN DOPAMINE CONTENT BY BACLOFEN: EFFECTS OF APOMORPHINE AND NEUROLEPTICS.

000121 01-03 CATECHOLAMINE SYNTHESIS IN RAT BRAIN AFTER AXOTOMY:

INTERACTION BETWEEN APOMORPHINE AND HALOPERIDO 000161 01-03 ANTIPODAL CENTRAL EFFECTS OF DOPAMINE AND APOMORP

000168 01-03 NATURE OF RECEPTORS INVOLVED IN APOMORPHINE RESPONSES IN

000257 01-03

BEHAVIORAL EFFECTS OF APOMORPHINE AND DISOBUTYRYLAPOMORPHINE IN THE MOUSE.

000314 01-04

EFFECTS OF APOMORPHINE ON SELF-STIMULATION BEHAVIOUR IN DORSAL AND VENTRAL AREA OF LATERAL HYPOTHALAMUS IN MICE 000334 01-04

SUBCUTANEOUS INJECTIONS OF APOMORPHINE, STIMULUS
GENERALIZATION AND CONDITIONING: SERIOUS PITFALLS FOR THE
EXAMINER USING APOMORPHINE AS A TOOL. 000341 01-04

EFFECT OF APOMORPHINE ON THE ANTINOCICEPTIVE ACTIVITY OF MORPHINE

000351 01-04 PRESYNAPTIC AND POSTSYNAPTIC ACTIONS OF APOMORPHINE:
DIFFERENTIATION BY ROTARY EFFECTS IN NORMAL RATS.

DOES PROLACTIN PLAY A ROLE IN ESTROGEN-INDUCED MATERNAL BEHAVIOR IN RATS: APOMORPHINE REDUCTION OF PROLACTIN RELEASE

000445 01-04 EVIDENCE FOR INCREASED APOMORPHINE SENSITIVE DOPAMINERGIC EFFECTS AFTER ACUTE TREATMENT WITH MORPHINE

000449 01-04 DIFFERENTIAL EFFECTS OF THREE DOPAMINE AGONISTS: APOMORPHINE, BROMOCRIPTINE AND LERGOTRILE

000451 01-04 INTERACTION OF DRUGS WITH APOMORPHINE, TRYPTAMINE AND NOREPINEPHRINE. A NEW IN VIVO APPROACH: THE ATN-TEST IN

000502 01-06 A DOUBLE-BLIND CROSS-OVER STUDY: APOMORPHINE/PLACEBO IN

000621 01-11 EFFECT OF LOCAL APPLICATION OF APOMORPHINE TO THE CORPUS STRIATUM AND TO THE NUCLEUS-ACCUMBENS ON THE RESERPINE-INDUCED RIGIDITY IN RATS

001021 02-02 MOLINDONE: AN APOMORPHINE ANTAGONIST IN THE RABBIT 001056 02-03

CYCLIC-GMP AND GABA LEVELS IN RAT STRIATUM AND CEREBELLUM DURING MORPHINE WITHDRAWAL: EFFECT OF APOMORPHINE 001274 02-03

NEUROLOGICAL DISTURBANCES, NIGROSTRIATE SYNAPSES, IONTOPHORETIC DOPAMINE AND APOMORPHINE AFTER HALOPERIDOL 001293 02-03 EFFECTS OF APOMORPHINE AND HALOPERIDOL ON EXPLORATORY
BEHAVIOR AND LATENT LEARNING IN MICE.

001297 02-04 ANTAGONISM BETWEEN THE EFFECTS OF L-DOPA AND APOMORPHINE ON THE BEHAVIOR OF RATS.

001298 02-04

BEHAVIORAL EFFECTS OF NEUROLEPTICS, APOMORPHINE AND
AMPHETAMINE AFTER BILATERAL LESION OF THE LOCUS-COFFULEUS IN

MUSCIMOL A GABA-AGONIST INJECTED INTO THE NUCLEUS-ACCUMBENS
INCREASES APOMORPHINE STEREOTYPY AND DECREASES THE

001454 02-04 BIPHASIC EFFECTS OF APOMORPHINE ON LOCOMOTOR ACTIVITY RATS

001464 02-04 COMPARISON OF BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE AFTER FLUPHENAZINE-DIHYDROCHLORIDE AND FLUPHENAZINE-DECANOATE TREATMENT IN RATS.

DIFFERENT BEHAVIOURAL PATTERNS INDUCED BY APOMORPHINE:
EVIDENCE THAT THE METHOD OF ADMINISTRATION DETERMINES THE
BEHAVIOURAL RESPONSE TO THE DRUG.

001533 02-06 SCHIZOPHRENIC SYMPTOM REMISSION WITH APOMORPHIN

001570 02-08 APOMORPHINE INCREASES GLUCOSE UTILIZATION IN THE SUBSTANTIA-NIGRA, SUBTHALAMIC NUCLEUS AND CORPUS-STRIATUM OF RAT. 001976 03-03

TIME-DEPENDENT DISRUPTIVE EFFECTS OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE ON DEVELOPMENT OF MORPHINE TOLERANCE. 002058 03-03

EFFICACY OF NEUROLEPTICS AND ANTIDEPRESSANTS IN THE TEST OF APOMORPHINE HYPOTHERMIA AND SOME DATA CONCERNING NEUROCHEMICAL MECHANISMS OF THE TEST.

002147 03-03 BEHAVIORAL EFFECTS OF APOMORPHINE DURING DEVELOPMENT OF

002203 03-04 A GRADUAL SCORE TO EVALUATE THE CLIMBING BEHAVIOUR ELICITED BY APOMORPHINE IN MICE.

002350 03-05 APOMORPHINE AND AMANTADINE: INTERACTION WITH ETHANOL IN HUMANS.

002605 03-14 APOMORPHINE IN SUPERSENSITIVITY OF THE CHOLINERGIC RESPONSE TO THE STRIATUM FOLLOWING DENERVATION OR DISUSE
SUPERSENSITIVITY OF DOPAMINERGIC RECEPTORS IN THE RAT

002872 04-03 SENSITIVITY TO APOMORPHINE IN THE GUINEA-PIG AS A FUNCTION OF AGE AND BODY WEIGHT.

003182 04-04 BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC NARCOTIC TREATMENT IN THE GUINEA-PIG.

003183 04-04 DIFFERENCES IN THE DOPAMINERGIC EFFECTS OF THE ERGOT
DERIVATIVES BROMOCRIPTINE, LISURIDE AND D LSD AS COMPARED WITH APOMORPHINE

003244 04-04 THE EFFECTS OF PIMOZIDE AND PHENOXYBENZAMINE PRETREATMENTS ON AMPHETAMINE AND APOMORPHINE POTENTIATION OF THE ACOUSTIC STARTLE RESPONSE IN RATS.

CIRCADIAN SUSCEPTIBILITY RHYTHM TO APOMORPHINE IN THE BRAIN. 003311 04-04 APOMORPHINE AND L-DOPA LOWER EJACULATION THRESHOLD IN THE

MALE RAT 003327 04-04

NATAL CELL SUPERSENSITIVITY TO APOMORPHINE IN DOPAMINE LESIONED RATS CORRELATED TO BEHAVIOUR

003356 04-04 COMPARATIVE EFFECTS OF APOMORPHINE AND NALOXONE IN ACUTELY DEFENDENT MORPHINIZED RATS AND MICE. 003379 04-04

HALOPERIDOL DEPRESSES THE ACCUMULATION OF APOMORPHINE IN THE STRIATUM OF THE RAT 003384 04-04

SCHIZOPHRENIC SYMPTOMS IMPROVE WITH APOMORPHINE 003474 04-08 PHARMACOLOGY AND NEUROCHEMISTRY OF APOMORPHIA

003592 04-13 THE ACUTE EFFECT OF HALOPERIDOL AND APOMORPHINE ON THE SEVERITY OF STUTTERING.

003619 04-14 EFFECT OF APOMORPHINE ON HUMAN SLEEP. 003620 04-14

APOMORPHINE-DIPIVALOYL-ESTER TOLERANCE TO STEREOTYPED BEHAVIOUR AND TO DECREASE IN STRIATAL HOMOVANILLIC-ACID LEVELS AFTER REPEATED TREATMENT WITH APOMORPHINE-DIPIVALOYL-ESTER

APOMORPHINE-HYDROCHLORIDE-INDUCED

APOMORPHINE-HYDROCHLORIDE-INDUCED IMPROVEMENT IN
HUNTINGTONS-CHOREA.

002508 03-11

MORPHINE-INDUCED
THE POTENTIATING EFFECT OF NALOXONE UPON APOMORPHINE-INDUCED HYPERTHERMIA.

000231 01-03 EFFECT OF NEUROLEPTICS, MYDANTHAN, AND DOPA ON APOMORPHINE-INDUCED STEREOTYPY IN RATS.

001155 02-03 ASCORBATE ATTENUATES APOMORPHINE-INDUCED HYPOTHERMIA IN VIVO.

001260 02-03 APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR, LOCOMOTOR STIMULATION AND HYPOTHERMIA IN SPONTANEOUS HYPERTENSIVE RATS AND NORMOTENSIVE WISTAR RATS.

001413 02-04 APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE RELEASE: ROLE OF DOPAMINERGIC RECEPTORS IN SUBSTANTIA-NIGRA. D02084 03-03

IMIPRAMINE ANTAGONISM OF APOMORPHINE-INDUCED HYPOTHERMIA: A NONDOPAMINERGIC INTERACTION

002133 03-03 THE EFFECT OF CHOLINE-CHLORIDE ON AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR.

002330 03-04 AN APOMORPHINE-INDUCED VOMITING MODEL FOR ANTIEMETIC STUDIES

BENZAMIDES AND CLASSICAL NEUROLEPTICS: COMPARISON OF THEIR ACTIONS USING 6 APOMORPHINE-INDUCED EFFECTS.

QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P-450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3 METHYCHOLANTHRENE 002083 03-03

THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE OF THE RAT CAUDATE NUCLEUS — 3. THE EFFECT OF APORPHINES AND PROTOBERBERINES. 003089 04-03

THE PNEUMATIC SYRINGE: A SIMPLE APPARATUS FOR SELF-ADMINISTRATION OF DRUGS BY RATS.

RATIONALITY OF APPEALS USED IN THE PROMOTION OF PSYCHOTROPIC DRUGS. A COMPARISON OF MALE AND FEMALE MODELS.

001541 02-06

001439 02-04

001932 02-17

RELATIONSHIP BETWEEN ANORECTIC AND REINFORCING PROPERTIES OF APPETITE SUPPRESSANT DRUGS: IMPLICATIONS FOR ASSESSMENT OF ABUSE LIABILITY. 003236 04-04

EFFECTS OF ANTICHOLINERGIC AND CHOLINESTERASE BLOCKING DRUGS ON APPETITIVE BEHAVIOR UNDER DIFFERENT DEPRIVATION

000306 01-04 EFFECT OF PRETRIAL AND POSTTRIAL TYRAMINE AND GUANETHIDINE INJECTIONS ON AN APPETITIVE TASK IN RATS.

APPLICATIONS PSYCHIATRIC AND NEUROLOGICAL APPLICATIONS OF BETA-BLOCKING AGENTS

000596 01-10 SALIVA LITHIUM LEVELS: CLINICAL APPLICATIONS.

000718 01-13 APPRAISAL OF THE EFFECT OF IV NICOTINE ON THE CNS

002579 03-13 LEVODOPA IN PARKINSON DISEASE: A LONG-TERM APPRAISAL OF MORTALITY. 002755 03-17

AREPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE
DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON
SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR
PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION. 001787 02-15

A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR 003657 04-15

INTERACTION OF DRUGS WITH APOMORPHINE, TRYPTAMINE AND NOREPINEPHRINE. A NEW IN VIVO APPROACH: THE ATN-TEST IN RATS. 000502 01-06 Psychopharmacology Abstracts

001630 02-11

SOLID DISPERSION APPROACH FOR OVERCOMING BIOAVAILABILITY PROBLEMS DUE TO POLYMORPHISM OF NABILONE, A CANNABINOID DERIVATIVE.

THOUGHT DISORDER IN SCHIZOPHRENIA: A THEORETICAL APPROACH USING AN ANALYSIS OF SPEECH. (PH.D. DISSERTATION).

GILLES-DE-LA-TOURETTE SYNDROME: A NEW CLINICOTHERAPEUTIC APPROACH.

TARDIVE-DYSKINESIA: A PREVENTIVE APPROACH.

001740 02-15 TOWARD AN EGO-ORIENTED APPROACH TO THE STUDY OF THE EFFECTS OF PSYCHOACTIVE MEDICATION IN THE TREATMENT OF CHILDREN. 001875 02-16

SYSTEM APPROACH IN EXPERIMENTAL PSYCHOPHARMACOLOGY AND MEMORY

001924 02-17 PSYCHOPHARMACOLOGY: A BIOCHEMICAL AND BEHAVIORAL APPROACH.

001929 02-17 NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY EFFECTS OF DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF KETAMINE.

NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY THE EFFECTS OF DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF PENTOBARBITAL

002363 03-06 A NEW APPROACH TO THE HORMONAL TREATMENT OF IMPOTENTIA-ERECTIONIS.

002386 03-07 SERVICES FOR SCHIZOPHRENICS: A LIFELONG APPROACH TO TREATMENT.

002398 03-08 HORMONE RESPONSES TO METHYLAMPHETAMINE IN DEPRESSION: A NEW APPROACH TO THE NORADRENALINE DEPLETION HYPOTHESIS. 002424 03-09

ENHANCEMENT OF THE ANTIDEPRESSANT RESPONSE TO L TRYPTOPHAN BY A LIVER PYRROLASE INHIBITOR: A RATIONAL TREATMENT APPROACH.

002464 03-09 NEW APPROACH TO THE REHABILITATION OF THE HARD CORE DRUG ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY STUDY.

PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS: AN APPROACH TO THE STUDY OF BRAIN DOPAMINE BLOCKADE IN HUMANS.

002590 03-13 IMPRINTING BEHAVIOR: PITUITARY ADRENOCORTICAL MODULATION OF THE APPROACH RESPONSE.

DEPRESSION — A GOOD APPROACH FOR THE NONPSYCHIATRIST: III — HOW TO USE THE TRICYCLICS.

003719 04-17

APPROACHES
PHARMACOLOGICAL APPROACHES TO HABITUATION OF THE ACOUSTIC
STARTLE RESPONSE IN RATS.

000425 01-04 CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE FOR AN INTERACTIONIST POSITION.

000620 01-11 APPROPRIATE
COMBINED TRICYCLIC MAOI THERAPY FOR REFRACTORY DEPRESSION: A
REVIEW, WITH GUIDELINES FOR APPROPRIATE USAGE.
002437 03-0

002437 03-09 WHEN IS A NEUROLEPTIC APPROPRIATE IN PSYCHONEUROSIS? 002486 03-10

FLUNITRAZEPAM (ROHYPNOL) COMPARED WITH NITRAZEPAM
(MOGADON) AND APROBARBITAL AS EVENING PREMEDICATION PRIOR TO ANESTHESIA: A CONTROLLED CLINICAL TRIAL.

002616 03-14 ARACHIDONIC-ACID
PROSTAGLANDINS AND CANNABIS — VI. RELEASE OF ARACHIDONIC-ACID
FROM HELA CELLS BY DELTA I-TETRAHYDROCANNABINOL AND OTHER CANNABINOIDS.

THE SOCIOPHARMACOLOGY OF FENFLURAMINE (FM), METHYLPHENIDATE (MP), AND DIETHYLPROPION (DP) IN MACAQUE ARCTOIDES.

001311 02-04 SOCIOPHARMACOLOGY OF D AMPHETAMINE IN MACAQUE ARCTOIDES II 001493 02-04

ARECOUNE THE EFFECT OF AMIZYL AND ARECOLINE ON THE ACTIVITY OF NA-K-ATPASE AND THE CONTENT OF NA AND K IN RAT BRAIN. 002151 03-03

VOLUME 16, SUBJECT INDEX

Subject Index

001001 02-01

003284 04-04

001260 02-03

002978 04-03

4	-	-	ĸ.	*
-	м		м	a

INTERACTION OF ARENA SIZE WITH DIFFERENT MEASURES OF AMPHETAMINE EFFECTS.

001329 02-04

PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EMBRYOPATHIC EFFECT AND COVALENT BINDING OF PUTATIVE ARENE OXIDE METABOLITE IN GESTATIONAL TISSUE.

001515 02-05

ARGININE-PYROGLUTAMATE

ARGININE-PYROGLUTAMATE (G-278): A CLINICAL EXPERIMENT. 001546 02-07

AROMATIC

PAROSMIA AND AROMATIC ANOSMIA UNDER L-DOPA THERAPY 000871 01-15

AROMATIC AMINOTRANSFERASE ACTIVITY OF RAT BRAIN CYTOPLASMIC AND MITOCHONDRIAL ASPARTATE AMINOTRANSFERASES. 002978 04-03

AROMATIC-AMINO-ACID-DECARBOXYLASE
IMPORTANCE OF TRYPTOPHAN-PYRROLASE AND AROMATIC-AMINOACID-DECARBOXYLASE IN THE CATABOLISM OF TRYPTOPHAN.

DRUGS ALTERING INSULIN SECRETION: EFFECTS ON PLASMA AND BRAIN CONCENTRATIONS OF AROMATIC-AMINO-ACIDS AND ON BRAIN 5 HYDROXYTRYPTAMINE TURNOVER.

000088 01-03

AROMATIZATION

BLOCKADE OF TESTOSTERONE MAINTAINED INTERMALE FIGHTING IN ALBINO LABORATORY MICE BY AN AROMATIZATION INHIBITOR 003176 04-04

EVIDENCE AGAINST INVOLVEMENT OF ENDORPHINS IN SEXUAL AROUSAL AND ORGASM IN MAN

000701 01-13

A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR 003657 04-15

THE EFFECTS OF APPROPRIATENESS OF ATTRIBUTED AROUSAL SOURCE AND TEST ANXIETY ON COMPLEX TEST PERFORMANCE AND REPORTED ANXIETY DURING TEST-TAKING. (PH.D. DISSERTATION).

003702 04-17

CARDIAC ARRHYTHMIA AND HYPOPOTASSEMIA IN ASSOCIATION WITH

LITHIUM-CARBONATE OVERDOSE

000843 01-15

EFFECT OF THYMOANALEPTIC AGENTS ON THE COURSE OF EXPERIMENTAL ARTERIAL HYPERTENSION AND CATECHOLAMINE CONTENT IN TISSUES

001970 03-03

001049 02-03

ARTERIES

EVIDENCE FOR A DOUBLE CHOLINERGIC MECHANISM CAPABLE OF REDUCING THE TONE OF CEREBRAL ARTERIES.

ARTERIOSCLEROTIC

RHEOENCEPHALOGRAPHIC AND OTHER STUDIES OF BETAHISTINE IN HUMANS, IV. PROLONGED ADMINISTRATION WITH IMPROVEMENT IN ARTERIOSCLEROTIC DEMENTIA.

002530 03-11

EFFECTS OF CHOLINOMIMETIC DRUGS AND THEIR ANTAGONISTS INJECTED INTO VERTEBRAL ARTERY OF UNANAESTHETIZED DOGS.

000375 01-04 A NEW CHRONICALLY CANNULATED CAROTID ARTERY PREPARATION FOR DETERMINATION OF DRUG HALF-LIVES IN THE GUINEA-PIG.

DIFFERENT EFFECTS OF METHIONINE-ENKEPHALIN AND D ALA2-METHIONINE-ENKEPHALINAMIDE ON THE METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN: FACT OR ARTIFACT?. 001980 03-03

ARYL-DIHYDROBENZODIAZEPIN-2-ONE

5 ARYL-DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES AS ANTIANXIETY 000013 01-01

ARYLACYLAMIDASE

RAT BRAIN ARYLACYLAMIDASE: MULTIPLE FORMS AND INHIBITION EFFECTS OF LSD, SEROTONIN AND RELATED COMPOUNDS 002044 03-03

ARYLALKYLAMINES

EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION: AMPHETAMINE LEVELS AND EFFECTS UPON SOME ARYLALKYLAMINES IN RAT BRAIN.

ARYLDIALKYLDIHYDROFYRAZOLODIAZEPINONES

(RAZOLODIAZEPINES. 2. ARYLDIALKYLDIHYDROPYRAZOLODIAZEPINONES AS ANTIANXIETY AND ANTICONVULSANT AGENTS.

ON THE ROLE OF ASCENDING CATECHOLAMINERGIC PROJECTIONS IN INTRACRANIAL SELF-STIMULATION OF THE SUBSTANTIA-NIGRA.

000336 01-04

THE ROLE OF ASCENDING AND DESCENDING 5 HYDROXYTRYPTAMINE NEURONES IN CENTRAL CONTROL OF PAIN SENSITIVITY.

CHLORIMIPRAMINE INHIBITION OF MURICIDE: THE ROLE OF THE ASCENDING 5-HT PROJECTION.

ASCORBATE

ASCORBATE ATTENUATES APOMORPHINE-INDUCED HYPOTHERMIA IN VIVO.

DIFFERENCES IN THE EFFECTS OF CLOMIPRAMINE ON ENGLISH AND ASIAN VOLUNTEERS. PRELIMINARY REPORT ON A PILOT STUDY 002646 03-15

(-)-(E) 3,4 DIHYDROXYPHENYL-CYCLOPROPYLAMINE-HYDROCHLORIDE (ASL-7003): A RIGID ANALOGUE OF DOPAMINE.

002793 04-02 ASPARTATE AROMATIC AMINOTRANSFERASE ACTIVITY OF RAT BRAIN CYTOPLASMIC AND MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE

ASPARTIC-ACID THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS OF MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE

000169 01-03 **ASPHYXIA** LARYNGEAL PHARYNGEAL DYSTONIA AS A POSSIBLE CAUSE OF

ASPHYXIA WITH HALOPERIDOL TREATMENT. 003654 04-15

A NEW ANOREXIGEN ASSAY: STRESS-INDUCED HYPERPHAGIA IN RATS 000468 01-04

GAS-CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY OF SEROTONIN IN RAT SUPERIOR CERVICAL GANGLIA: EFFECTS OF NERVE GROWTH FACTOR AND 6 HYDROXYDOPAMINE

001006 02-01 A GC/CIMS ASSAY FOR THE CIS AND TRANS ISOMERS OF THIOTHIXENE IN HUMAN PLASMA. 001857 02-16

PLASMA ASSAY OF FLUPHENAZINE.

001871 02-16

BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS: ASSAY
PROCEDURES, REPRODUCIBILITY AND RELATIONSHIP TO THERAPEUTIC OUTCOME AND SIDE-EFFECTS 002440 03-09

A SIMPLE AND SENSITIVE RADIORECEPTOR ASSAY FOR ANTISCHIZOPHRENIC DRUGS IN BLOOD.

002715 03-16

RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D

002862 04-03 AN IMPROVED ASSAY OF TYROSINE-HYDROXYLASE USING SODIUM ACTIVATION.

003430 04-06 MODIFICATION OF THE RADIOENZYMATIC ASSAY FOR THE CATECHOLAMINES.

003431 04-06

EFFECTS OF PSYCHOTROPIC DRUGS ON NEUROTUBULE ASSEMBLY 000225 01-03

A SUBJECTIVE AND OBJECTIVE METHOD ASSESSING THE EFFICACY OF HYPNOTIC MEDICATIONS IN INSOMNIACS. 001873 02-16

A VARIABLE-INTERVAL PUNISHMENT PROCEDURE FOR ASSESSING ANXIOLYTIC EFFECTS OF DRUGS. 002371 03-06

ASSESSMENT

ACTION.

MARIJUANA EFFECTS ON LONG-TERM MEMORY ASSESSMENT AND RETRIEVAL

000755 01-14 EVALUATION OF THE PRISON INMATE AS A SUBJECT IN DRUG

ASSESSMENT VILOXAZINE: ASSESSMENT OF POTENTIAL RAPID ANTIDEPRESSANT

001584 02-09

000502 01-06

CLINICAL BIOCHEMICAL ASSESSMENT OF DRUG ACTION IN PATIENTS. (UNPUBLISHED PAPER).

MAPROTILINE (LUDIOMIL) IN DEPRESSION: A MULTICENTRE ASSESSMENT OF ONSET OF ACTION, EFFICACY AND TOLERABILITY. 002432 03-09

REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF L-DOPA, AMINOPHYLLINE, AND EPHEDRINE. 002544 03-13

VIGILANCE AND HUMAN ATTENTION UNDER CONDITIONS OF METHYLPHENIDATE AND SECOBARBITAL INTOXICATION: AN ASSESSMENT USING BRAIN POTENTIALS.

002622 03-14 ASSESSMENT OF SPONTANEOUS AND DRUG-INDUCED CHANGES IN VIGILANCE BY MEANS OF A NEW MODIFICATION OF THE SHORT TIME SPECTRAL ANALYSIS OF THE EEG.

002627 03-14 ASSESSMENT OF DRUG THERAPY IN CHRONIC BRAIN FAILURE 002719 03-16

RELATIONSHIP BETWEEN ANORECTIC AND REINFORCING PROPERTIES OF APPETITE SUPPRESSANT DRUGS: IMPLICATIONS FOR ASSESSMENT OF ABUSE LIABILITY.

PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT
OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC
AND CATECHOLAMINERGIC MECHANISMS BY 6 HYDROXYDDPAMINE
AND 5.6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D.
DISSERTATION).

003407 04-05 ASSESSMENT OF LONG-ACTING NEUROLEPTICS. METHODS AND PROBLEMS.

003693 04-16

ASSESSMENTS PERSONNELS OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR 003657 04-15

ASSISTED THE PEAK EXPERIENCE VARIABLE IN DPT ASSISTED PSYCHOTHERAPY WITH CANCER PATIENTS.

000679 01-12

CARDIAC ARRHYTHMIA AND HYPOPOTASSEMIA IN ASSOCIATION WITH LITHIUM-CARBONATE OVERDOSE.

000843 01-15 POSSIBLE PROPRANOLOL MYOTONIN ASSOCIATION.

O00889 01-15
THE B-MITTEN EEG PATTERN AND TARDIVE-DYSKINESIA: A POSSIBLE ASSOCIATION.

001846 02-15 ASSOCIATION OF SOME PSYCHOTOMIMETIC COMPOUNDS WITH 6 METHYLPURINE IN AQUEOUS SOLUTIONS.

001950 03-01 THE ATTENUATION OF A SPECIFIC CUE-TO-CONSEQUENCE ASSOCIATION BY ANTIEMETIC AGENTS.

001992 03-03 WORD ASSOCIATION TIMES, FELT EFFECTS, AND PERSONALITY CHARACTERISTICS OF SCIENCE STUDENTS GIVEN A PLACEBO

ASSOCIATIONS

ACUTE EFFECTS OF LISURIDE (0.1 MG), AMANTADINE (100 MG) AND TRIHEXYPHENIDYL (5 MG) ON VERBAL ASSOCIATIONS.

003630 04-14 ASSOCIATIVE
NARCOTIC CUING AND ANALGESIC ACTIVITY OF NARCOTIC ANALGESICS:
ASSOCIATIVE AND DISSOCIATIVE CHARACTERISTICS.

003192 04-04 STATE-DEPENDENT RETRIEVAL OF ITEM, ASSOCIATIVE, AND SERIAL ORDER INFORMATION

003711 04-17 ASSUMPTIONS

CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE FOR AN INTERACTIONIST POSITION.

000620 01-11 ASYMMETRY

FLUCTUATING DENTAL ASYMMETRY AS AN INDICATOR OF THE STRESSFUL PRENATAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN THE LABORATORY RAT. 001520 02-05

THE NEUROLOGICAL BASIS OF MOTOR ASYMMETRY FOLLOWING
UNILATERAL NIGROSTRIATAL LESIONS IN THE RAT: THE EFFECT OF
SECONDARY SUPERIOR COLLICULUS LESIONS. 003200 04-04

HEMISPHERIC ASYMMETRY OF VISUAL EVOKED-POTENTIALS WITH MOTOR IMBALANCE IN RATS. 003310 04-04 ASYMPTOMATIC PROVEN ASYMPTOMATIC EOSINOPHILIA WITH IMIPRAMINE.

001765 02-15 ATENOLOL
THE PSYCHOTROPIC EFFECTS OF ATENOLOL IN NORMAL SUBJECTS:
PRELIMINARY FINDINGS.
001701

ATHEROSPERMININE
PSYCHOPHARMACOLOGICAL STUDIES ON (-) NUCIFERINE AND ITS
HOFMANN DEGRADATION PRODUCT ATHEROSPERMININE. 002824 04-03

ATN-TEST
INTERACTION OF DRUGS WITH APOMORPHINE, TRYPTAPANE AND
NOREPINEPHRINE. A NEW IN VIVO APPROACH: THE ATN-TEST IN
RATS.
000502

ATOMIC

LITHIUM NEUROTOXICITY. I. THE CONCENTRATION OF LITHIUM IN

DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS

ATOMIC ABSORPTION SPECTROPHOTOMETRY.

003432 04-04

003432 04-06 ATONIA AFTER CARBACHOL MICROINJECTIONS NEAR THE LOCUS-COERULEUS IN CATS.

003381 04-04 ON THE EFFECT OF NOOTROPIL AN ATP AND ATPASE IN BRAIN OF RAT. EFFECTS OF KAINIC-ACID ON ION DISTRIBUTION AND ATP LEVELS OF STRIATAL SLICES INCUBATED IN VITRO.

003406 04-05 ATPASE EFFECT OF CANNABINOIDS ON NEUROTRANSMITTER UPTAKE, ATPASE ACTIVITY AND MORPHOLOGY OF MOUSE BRAIN SYNAPTOSOMES.

000143 01-03 CATECHOLAMINE SENSITIVE ATPASE ACTIVITIES IN BRAIN SYNAPTOSOMES OF MORPHINIZED MICE.

001096 02-03 EFFECT OF RUBIDIUM, LITHIUM AND CESIUM ON BRAIN ATPASE AND PROTEIN KINASES.

EFFECT OF PSYCHOTROPIC DRUGS ON ATPASE TRANSPORT OF THE SARCOPLASMIC RETICULUM IN RABBIT SKELETAL MUSCLES. 001174 02-03

ON THE EFFECT OF NOOTROPIL AN ATP AND ATPASE IN BRAIN OF RATS 001482 02-04 THE EFFECTS OF LITHIUM ON ATPASE ACTIVITY IN SUBCELLULAR FRACTIONS FROM RAT BRAIN.

002038 03-03

EFFECTS OF LITHIUM ON THE MEMBRANE-BOUND MAGNESIUM DEPENDENT ATPASE OF MOUSE NEUROBLASTOMA CELLS. 003087 04-03

CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. THE IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2-METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED ANALOGS OF METHAMPHETAMINE.

002141 03-03 COMPARISON OF THE ELECTROPHYSIOLOGICAL EFFECTS OF TWO NEUROLEPTICS, MELPERONE AND THIORIDAZINE, ON ISOLATED RAT

003417 04-05

ATROPHY
CEREBELLAR ATROPHY IN PHENYTOIN TREATED MENTALLY RETARDED
EPILEPTICS.
001622 02 001622 02-11

REGIONAL BRAIN ATROPHY AND REDUCTIONS IN GLUTAMATE RELEASE AND UPTAKE AFTER INTRASTRIATAL KAINIC-ACID. 002917 04-03

ATROPINE
THE ROLE OF THE SEPTAL NUCLEI IN THE RELEASE OF ACETYLCHOLINE
FROM THE RABBIT CEREBRAL-CORTEX AND DORSAL HIPPOCAMPUS
AND THE EFFECT OF ATROPINE.

000101 01

000101 01-03 DEFICITS IN PASSIVE AVOIDANCE LEARNING FOLLOWING ATROPINE IN THE DEVELOPING RAT

000320 01-04 EFFECTS OF BRAIN LESIONS AND ATROPINE ON HIPPOCAMPAL AND NEOCORTICAL ELECTROENCEPHALOGRAMS IN THE RAT.

ACTIONS OF ATROPINE AND SCOPOLAMINE ON THE ENDPLATE CURRENT OF THE FROG SARTORIUS MUSCLE. (PH.D. DISSERTATION).

001042 02-03 EFFECT OF ATROPINE ON ACETYLCHOLINE METABOLISM IN THE MOUSE BRAIN.

DIFFERENTIAL ATTENUATION BY ATROPINE AND D AMPHETAMINE ON HYPERACTIVITY: POSSIBLE CLINICAL IMPLICATIONS. 001347 02-04

002611 03-14

VOLUME 16. SUBJECT INDEX

DECREASED RESPONSE INHIBITION DURING FIXED-INTERVAL RESPONDING IN PIGEONS FOLLOWING ATROPINE ADMINISTRATION.

002305 03-04 **EFFECTS OF ATROPINE ON CONDITIONED TASTE AVERSION**

003209 04-04 THE EFFECTS OF ATROPINE ON THE TOLERANCE AND THE CONVULSIONS SEEN AFTER WITHDRAWAL FROM FORCED BARBITAL DRINKING IN THE

003389 04-04

SYNTHESIS OF SPIROISOBENZOFURANPIPERIDINES AS POTENTIAL CENTRAL-NERVOUS-SYSTEM AGENTS. 2. COMPOUNDS CONTAINING A HETERCOATOM ATTACHED TO NITROGEN

NGF-INDUCED ALTERATIONS IN PROTEIN SECRETION AND SUBSTRATE ATTACHED MATERIAL OF A CLONAL NERVE CELL LINE. 003607 04-13

ATTACK

EFFECTS OF ALCOHOL ON ATTACK AND DEFENSIVE SUBMISSIVE REACTIONS IN RATS.

000413 01-04 THE EFFECTS OF EXTENDED INSULIN DOSAGE ON TARGET-DIRECTED ATTACK AND BITING ELICITED BY TAILSHOCK.

003206 04-04

CARBACHOL ELICITED MOUSE-KILLING IN THE RAT: ANIMALS ATTACKED

AND WOUND LOCATION. 000349 01-04 **ATTACKS**

NOW RCA ATTACKS MEMORY AID DRUGS.

001915 02-17

003627 04-14

ATTENDANCE CLINIC ATTENDANCE AND OPIATE PRESCRIPTION STATUS OF HEROIN

ADDICTS OVER A SIX-YEAR PERIOD. 000989 01-17

ATTENTION CARDIOTOXIC DRUGS, WITH SPECIAL ATTENTION TO PHENOTHIAZINES AND IMPRAMINE DERIVATIVES.

000868 01-15 THE EFFECTS OF METHYLPHENIDATE ON VARIOUS TYPES OF ACTIVITY

LEVEL AND ATTENTION IN HYPERKINETIC CHILDREN. 001698 02-14 A DEVELOPMENTAL STUDY OF SELECTIVE ATTENTION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).

001709 02-14

EFFECT OF DEXTROAMPHETAMINE ON SOMATIC EVOKED-POTENTIAL COMPONENTS IN MAN WITH SPECIAL REFERENCE TO TALK RELEVANCE AND SELECTIVE ATTENTION. 001735 02-14

THE EFFECT OF LITHIUM ON SEROTONIN METABOLISM IN THE BRAIN OF RATS WITH PARTICULAR ATTENTION TO ITS EFFECT UNDER THE MONOAMINE ALTERED CONDITIONS

002110 03-03 VIGILANCE AND HUMAN ATTENTION UNDER CONDITIONS OF METHYLPHENIDATE AND SECOBARBITAL INTOXICATION: AN ASSESSMENT LISING RRAIN POTENTIALS

002622 03-14 EFFECTS OF MSH/ACTH4-10 ON MEMORY, ATTENTION, AND ENDOGENOUS HORMONE LEVELS IN WOMEN.

002641 03-14 DEXTROAMPHETAMINE AND PLACEBO PRACTICE EFFECTS ON SELECTIVE ATTENTION IN HYPERACTIVE CHILDREN.

ATTENTIONAL

METHYLPHENIDATE EFFECT ON ATTENTIONAL AND COGNITIVE BEHAVIOR IN SIX- THROUGH TWELVE-YEAR-OLD MALES.

ATTENTIVENESS PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS

THERAPEUTIC APPLICATION. 001737 02-14

DIFFERENTIAL CUE ATTENTIVENESS AND PLACEBO RESPONSIVITY. (PH.D. DISSERTATION).

LESIONS OF THE DORSAL NORADRENERGIC PROJECTION ATTENUATE MORPHINE-INDUCED BUT NOT AMPHETAMINE-INDUCED CONDITIONED TASTE AVERSION. 002299 03-04

ATTENUATED TESTOSTERONE ATTENUATED STEREOTYPY AND HYPERACTIVITY INDUCED BY BETA-PHENYLETHYLAMINE IN PARGYLINE PRETREATED RATS 003224 04-04

ATTENUATES ASCORBATE ATTENUATES APOMORPHINE-INDUCED HYPOTHERMIA IN VIVO. 001260 02-03

ATTENUATING
EFFECTS OF PAIN ATTENUATING BRAIN STIMULATION AND MORPHINE ON
ELECTRICAL ACTIVITY IN THE RAPHE NUCLEI OF THE AWAKE RAT.
003034 04-03

ATTENUATION OF MORPHINE ANALGESIA IN RATS BY INTRA-AMYGDALOID INJECTION OF DOPAMINE

O00443 01-04
ATTENUATION OF THE RATE DECREASING EFFECTS OF AMPHETAMINE ON
FIXED-RATIO RESPONDING IN RATS BY HIPPOCAMPAL LESIONS.

LITHIUM-CARBONATE ATTENUATION OF CHEMOTHERAPY-INDUCED NEUTROPENIA.

DIFFERENTIAL ATTENUATION BY ATROPINE AND D AMPHETAMINE ON HYPERACTIVITY: POSSIBLE CLINICAL IMPLICATIONS.

001347 02-04 THE ATTENUATION OF A SPECIFIC CUE-TO-CONSEQUENCE ASSOCIATION BY

001992 03-03 DECREASED LOCOMOTOR ACTIVITY AND ATTENUATION OF AMPHETAMINE HYPERACTIVITY WITH INTRAVENTRICULAR :NFUSION OF SEROTONIN IN THE RAT.

002328 03-04 DISULFIRAM-INDUCED HYPOTHERMIA IN THE NORMAL RAT; ITS ATTENUATION BY PIMOZIDE.

003085 04-03 NEUROLEPTIC-INDUCED ATTENUATION OF BRAIN STIMULATION REWARD IN RATS.

003221 04-04 NOREPINEPHRINE ATTENUATION OF AMNESIA PRODUCED BY DIETHYLDITHIOCARBAMATE.

003294 04-04 ATTENUATION OF STEREOTYPED BEHAVIOUR BY SEX STEROIDS 003312 04-04

ATTENUATION OF AMNESIA BY HYDROCORTISONE IN THE MOUSE 003313 04-04

HYPERACTIVE CHILDRENS KNOWLEDGE AND ATTITUDES CONCERNING DRUG TREATMENT. 003553 04-11

ATTRIBUTED THE EFFECTS OF APPROPRIATENESS OF ATTRIBUTED AROUSAL SOURCE AND TEST ANXIETY ON COMPLEX TEST PERFORMANCE AND REPORTED ANXIETY DURING TEST-TAKING. (PH.D. DISSERTATION).

003702 04-17 ATTRIBUTES OF DISCRIMINATIVE PENTOBARBITAL STIMULUS

IMMEDIATELY AFTER INTRAVENOUS INJECTION. 002265 03-04 STIMULUS ATTRIBUTES OF DRUGS.

003617 04-14

ATTRIBUTIONS

CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE FOR AN INTERACTIONIST POSITION. 000620 01-11

TWO CASES OF SEVERE ORPHENADRINE POISONING WITH ATYPICAL FEATURES.

001748 02-15 AUDIOGENIC

TIME-COURSE OF AUDIOGENIC SEIZURE SUSCEPTIBILITY AND PLASMA PENTOBARBITAL CONCENTRATION DURING WITHDRAWAL.

EFFECT OF P-CHLOROPHENYLALANINE (PCPA) AND PHENYLALANINE (PHE) FECT OF P-CHLOROPHENYLALANINE (PCYA) AND PRESIDENTIAL TREATMENT ON EARLY AUDITORY EVOKED RESPONSES IN RATS. 002304 03-04

EFFECTS OF CENTRALLY ACTING DRUGS ON BRAINSTEM AUDITORY 002598 03-13

AUGMENTED ABATEMENT OF STIMULUS PERSERVATION FOLLOWING REPEATED D
AMPHETAMINE TREATMENT: ABSENCE OF BEHAVIORALLY

AUGMENTED TOLERANCE. 003260 04-04

AUGMENTS CHLORDIAZEPOXIDE SELECTIVELY AUGMENTS GABA ACTION IN SPINAL CORD CELL CULTURES 001080 02-03

PATTERNS OF THE USE OF BENZODIAZEPINES IN AUSTRALIA

002737 03-17 DRUG MONITORING AT AN AUSTRALIAN DEPOT PHENOTHIAZINE CLINIC 002402 03-08

EFFECTS OF L 5 HYDROXYTRYPTOPHAN IN AUTISTIC CHILDREN 003578 04-11

AUTOANTIBODY
THYROID AUTOANTIBODY LEVELS DURING LITHIUM THERAPY 003650 04-15

AUTOMATED
AN AUTOMATED SYSTEM FOR THE PREDICTION AND PREVENTION OF
ADVERSE DRUG REACTIONS. (PH.D. DISSERTATION).
001759 0

001759 02-15

AUTONOMIC IMBALANCE: A SUBSTRATE OF HYPERACTIVITY 000783 01-14

IN VITRO AUTONOMIC EFFECTS OF FOUR NEUROLEPTICS: CHLORPROMAZINE, HALOPERIDOL, MELPERONE AND THIORIDAZINE

A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND BIOELECTRIC CORRELATES OF EMOTIONAL REACTIONS ELICITED BY CHOLINERGIC STIMULATION OF THE HYPOTHALAMUS AND THE VENTRAL TEGMENTUM.

A BEHAVIORAL AND AUTONOMIC NERVOUS SYSTEM STUDY OF CHRONIC IMIPRAMINE ADMINISTRATION TO CONSCIOUS DOGS.

THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (SECOND REPORT) — EFFECTS ON PUPIL FUNCTIONING.

000877 01-15 THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (FIRST

000878 01-15

AUTONOMOUS NERVOUS FUNCTION OF LONG-TERM USERS OF PSYCHOTROPIC DRUGS, THIRD REPORT — PUPILOGRAM OBSERVATIONS. 002690 03-15

ONE AUTOPSY CASE OF DIPHENYLHYDANTOIN INTOXICATION 001812 02-15

AUTORADIOGRAPHIC STUDIES WITH SYMPATHOMIMETIC AMINES. 000079 01-03 SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF PHYSICAL DEPENDENCE IN RATS: III. AUTORADIOGRAPHIC STUDIES

000177 01-03 AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN, III, THE TELENCEPHALON.

001048 02-03 AUTORADIOGRAPHIC EVIDENCE FOR THE SELECTIVE ACCUMULATION OF H3-5-HT BY SUPRAEPENDYMAL NERVE TERMINALS.

001222 02-03 AUTORADIOGRAPHIC LOCALIZATION OF H3-RESERPINE BINDING SITES IN 002106 03-03

AUTORADIOGRAPHY

DEMONSTRATION OF NEUROLEPTIC RECEPTOR SITES IN MOUSE BRAIN BY
AUTORADIOGRAPHY.

002950 04-05

002950 04-03

AUTORECEPTORS

TOLERANCE TO HYPOKINESIA ELICITED BY DOPAMINE AGONISTS IN MICE: HYPOSENSITIZATION OF AUTORECEPTORS?. 002221 03-04

AVAILABILITY

EFFECT OF DOPAMINERGIC AGONISTS UPON OXYGEN AVAILABILITY FOR

CEREBRAL-CORTEX. 001064 02-03

THE RELATIVE FUNCTIONAL AVAILABILITY OF BRAIN NORADRENALINE AND DOPAMINE STORAGE POOLS. 001191 02-03

COMPARATIVE AVAILABILITY OF DIAZEPAM (D) IN HUMAN PLASMA (P), PAROTID SALIVA (PS) AND MIXED SALIVA (MS) AND ITS RELATIONSHIP TO PLASMA PROTEIN BINDING. 001682 02-13

AVERAGE DEANOL EFFECTS ON PERFORMANCE AND AVERAGE EVOKED-

POTENTIALS. 001412 02-04

EFFECTS OF ID-540 ON AVERAGED PHOTOPALPEBRAL REFLEX IN MAN THE EFFECTS OF A NEW BENZODIAZEPINE DERIVATIVE, ID-540, ON THE AVERAGED PHOTOPALPEBRAL REFLEX IN MAN.

003610 04-13 AVERSION THE EFFECT OF ANESTHESIA ON ACQUISITION AND EXTINCTION OF CONDITIONED TASTE AVERSION.

000326 01-04 CONDITIONED TASTE AVERSION: A FIELD APPLICATION TO COYOTE

000354 01-04 EFFECTS OF PIMOZIDE ON THE ACQUISITION, MAINTENANCE, AND EXTINCTION OF AN AMPHETAMINE-INDUCED TASTE AVERSION. 000373 01-04

Psychopharmacology Abstracts

FAILURE TO ELICIT CONDITIONED TASTE AVERSION BY SEVERE

NACL AND LICL EFFICACY IN THE INDUCTION OF AVERSION FOR QUININE AND SACCHARIN SOLUTIONS IMMEDIATELY FOLLOWING INJECTION. ILLNESS-INDUCED AVERSION LEARNING IN A DESERT SPECIES OF RODENT (ACOMYS-CAHIRINUS).

POISON AVERSION AND SEXUAL BEHAVIOR IN THE GOLDEN HAMSTER

001357 02-04 GENERALIZATION OF THE CONDITIONED STIMULUS IN TASTE AVERSION. 001405 02-04

LOCATION PREFERENCE AND FLAVOR AVERSION REINFORCED BY AMPHETAMINE IN RATS. 001443 02-04

ODOR AVERSION LEARNING IN NEONATAL RATS. 001448 02-04

A COMPARISON OF FOOD INTAKE SUPPRESSION PRODUCED BY GIVING AMPHETAMINE AS AN AVERSION TREATMENT VERSUS AS AN ANOREXIC TREATMENT.

001981 03-03 LESIONS OF THE DORSAL NORADRENERGIC PROJECTION ATTENUATE MORPHINE-INDUCED BUT NOT AMPHETAMINE-INDUCED CONDITIONED TASTE AVERSION.

002299 03-04 AMPHETAMINE-INDUCED TASTE AVERSION DEMONSTRATED WITH OPERANT BEHAVIOUR.

002315 03-04 EFFECTS OF ADRENALECTOMY ON TASTE AVERSION LEARNING.

003153 04-04 DIFFERENTIAL EFFECTS ON CONDITIONED TASTE AVERSION LEARNING WITH PERIPHERALLY AND CENTRALLY ADMINISTERED ACETALDEHYDE. 003178 04-04

EFFECTS OF ATROPINE ON CONDITIONED TASTE AVERSION. 003209 04-04

AVERSIONS (--) HYDROXYCITRATE AND CONDITIONED AVERSIONS.

000428 01-04 LEARNED AVERSIONS TO INTRACEREBRAL CARBACHOL 001424 02-04

CONDITIONED TASTE AVERSIONS: GENOTYPE BY OLFACTORY **BULBECTOMY INTERACTION** 002334 03-04

COCAINE-INDUCED CONDITIONED TASTE AVERSIONS IN RATS 003232 04-04 METHYLPHENIDATE-INDUCED CONDITIONED TASTE AVERSIONS: AN INDEX

OF TOXICITY. 003337 04-04

ELEVATION OF AVERSIVE THRESHOLD IN RATS BY INTRA-AMYGDALOID INJECTION OF MORPHINE-SULPHATE.

000444 01-04 A BEHAVIORAL TREATMENT OF DEPRESSION WITH ALCOHOLICS RECEIVING PHARMACOLOGICAL AVERSIVE CONDITIONING. (PH.D. DISSERTATION).

002539 03-11 **AVERSIVE PROPERTIES OF NARCOTIC ANTAGONISTS IN RATS.** 003367 04-04

REINFORCING AND AVERSIVE PROPERTIES OF THE NARCOTIC CLIE 003372 04-04

PSYCHOPHARMACOLOGY OF AVERSIVELY MOTIVATED BEHAVIOR 003615 04-14

AVERSIVENESS OF ORAL METHADONE IN RATS.

003188 04-04

EFFECTS OF METHYLPHENIDATE ON AVOIDANCE LEARNING IN THE AGED 000020 01-02

FAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS UNDER LONG-TERM TRAINING.

000034 01-02 DEFICITS IN PASSIVE AVOIDANCE LEARNING FOLLOWING ATROPINE IN THE DEVELOPING RAT.

000320 01-04 PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, BRAIN SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION INTO BRAIN PROTEINS OF DIFFERENT MOUSE STRAINS.

000384 01-04 FACILITATION BY RESERPINE OF RETENTION IN AN INHIBITORY AVOIDANCE TASK IN MICE.

IMPAIRMENT OF RETENTION OF AVOIDANCE RESPONSES IN RATS BY POSTTRAINING DIETHYLDITHIOCARBAMATE.

000454 01-04

VOLUME 16. SUBJECT INDEX

Subject Index

003342 04-04

DOSE-RESPONSE AND TIME-COURSE EFFECTS OF N,N
DIMETHYLTRYPTAMINE ON DISRUPTION OF RAT SHUTTLE-BOX

000457 01-04 FURTHER STUDIES ON BL-3912A: EFFECTS ON AVOIDANCE BEHAVIOR OF RATS WITH LOW BASELINES AND ON REACTION THRESHOLDS TO FLECTRIC FOOTSHOCK

000461 01-04 INFLUENCE OF PHARMACOLOGICAL AGENTS ON AVOIDANCE REFLEXES IN A GROUP EXPERIMENT ON RATS.

001317 02-04 CORRELATED EFFECT OF CORTICOSTERONE ON HYPOTHALAMIC SEROTONIN AND AVOIDANCE BEHAVIOUR IN RATS.

001394 02-04 EFFECT OF PANAX GINSENG ROOT ON CONDITIONED AVOIDANCE **RESPONSE IN RATS**

001451 02-04 PASSIVE AVOIDANCE LEARNING IN THE RAT AS FUNCTIONS OF D AMPHETAMINE DOSAGE AND SHOCK INTENSITY.

001458 02-04 FACILITATION OF SIDMAN AVOIDANCE PERFORMANCE BY P. CHLOROAMPHETAMINE: ROLE OF BIOGENIC AMINES.

001467 02-04 THE EFFECTS OF STIMULATION AND DEPRESSION OF THE RETICULOENDOTHELIAL SYSTEM ON SIDMAN AVOIDANCE BEHAVIOR.

(PH.D. DISSERTATION) 001468 02-04 EFFECTS OF D AMPHETAMINE ON DIFFERENT RATES OF AVOIDANCE

BEHAVIOR IN RATS 001488 02-04 THE LACK OF EFFECT OF SYNTHETIC SCOTOPHOBIN ON DARKNESS

AVOIDANCE IN MICE. 001496 02-04 METHYLPHENIDATE, AMYGDALECTOMY AND ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.

EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D AMPHETAMINE AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY AND SHOCK AVOIDANCE IN RHESUS MONKEYS.

FFFECT OF BACLOFFN (BF) (LIORESAL (R) ON DOPAMINERGIC SINGLE UNITS AND SIDMAN AVOIDANCE BEHAVIOR.

002300 03-04 TOLERANCE TO P-CHLOROAMPHETAMINES EFFECTS ON SIDMAN

AVOIDANCE PERFORMANCE AND CATECHOLAMINE METABOLISM EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AGONISTS AND ANTAGONISTS INTO THE AMYGDALA ON RETENTION OF PASSIVE AVOIDANCE TRAINING IN RATS. (PH.D. DISSERTATION).

TIME-DEPENDENT EFFECTS OF RESERPINE ON RETENTION OF PASSIVE

002327 03-04 EFFECTS OF DIAZEPAM ON PHOBIC AVOIDANCE BEHAVIOR AND PHOBIC

002498 03-10 RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS: ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT LEARNING WITH D AMPPHETAMINE TREATMENTS.

003167 04-04 OPPOSITE ACTION OF OXYTOCIN TO VASOPRESSIN IN PASSIVE AVOIDANCE BEHAVIOR IN RATS.

003263 04-04 PSYCHOTROPIC DRUGS AND SIDMAN AVOIDANCE IN RATS: IRT DISTRIBUTION CHANGES.

003269 04-04 METHYLENE-BLUE ALTERS RETENTION OF INHIBITORY AVOIDANCE RESPONSES

003288 04-04 6 HYDROXYDOPAMINE-INDUCED CATECHOLAMINE DEPLETION AND PASSIVE AVOIDANCE LEARNING IN RATS.

003322 04-04 FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON LOCOMOTOR ACTIVITY AND AVOIDANCE BEHAVIOUR OF RESERPINIZED MICE.

003351 04-04 EFFECTS OF CHLORDIAZEPOXIDE, AMITRIPTYLINE, IMIPRAMINE, AND THEIR COMBINATIONS ON AVOIDANCE BEHAVIOUR IN MICE.

FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON THE PERFORMANCE OF MICE IN AN INHIBITORY AVOIDANCE TASK. 003353 04-04

CEREBELLAR UNIT ACTIVITY DURING GENERALIZED PENICILLIN EPILEPSY IN THE AWAKE CAT.

001028 02-02 ANTIEMETIC ACTIVITY OF NABILONE, A CANNABINOL DERIVATIVE, REVERSED BY NALOXONE IN AWAKE CATS.

001416 02-04 EFFECT OF SOMATOSTATIN (SRIF) AND L GLUTAMATE ON NEURONS OF THE SENSORIMOTOR CORTEX IN AWAKE HABITUATED RABBITS. 002958 04-03 EFFECTS OF PAIN ATTENUATING BRAIN STIMULATION AND MORPHINE ON ELECTRICAL ACTIVITY IN THE RAPHE NUCLEI OF THE AWAKE RAT. 003034 04-03

A RELIABLE, FACIAL NOCICEPTION DEVICE FOR UNRESTRAINED, AWAKE ANIMALS: EFFECTS OF MORPHINE AND TRIGEMINAL COMPLEX 003435 04-06

AX-A411-BS

CLASSIFICATION AND DETERMINATION OF CEREBRAL BIOAVAILABILITY
OF PSYCHOTROPIC DRUGS BY QUANTITATIVE PHARMACO-EEG AND
PSYCHOMETRIC INVESTIGATIONS (STUDIES WITH AX-A411-BS).

AXIS MORPHINE DECREASES LUTEINIZING HORMONE BY AN ACTION ON THE

HYPOTHALAMIC PITUITARY AXIS SUPPRESSION OF THE HYPOTHALAMIC PITUITARY ADRENAL AXIS AFTER ORAL HYDROCORTISONE-SUCCINATE INGESTION IN RATS.

002098 03-03 PITUITARY ADRENOCORTICAL AXIS AND SHOCK-INDUCED FIGHTING IN

AXONAL EFFECTS OF MORPHINE ON AXONAL TRANSPORT IN NIGROSTRIATAL NEURONS.

002093 03-03 BETA-ADRENOCEPTORS MODULATE NORADRENALINE RELEASE FROM AXONAL SPROUTS IN CULTURED RAT SUPERIOR CERVICAL GANGLIA. 002179 03-03

CHANGES IN SYNAPTIC FUNCTION INDUCED BY BLOCKAGE OF AXONAL TRANSPORT IN THE RABBIT OPTIC PATHWAY.

002952 04-03 RETROGRADE AXONAL TRANSPORT OF NERVE GROWTH FACTOR IN THE CILIARY GANGLION OF THE CHICK AND THE RAT.

003005 04-03

EFFECTS OF ESTROGEN AND AMINERGIC DRUGS ON THRESHOLDS OF MEDIAL BASAL HYPOTHALAMIC AXONS IN THE MEDIAN EMINENCE OF THE RAT

002974 04-03 AXOTOMY CATECHOLAMINE SYNTHESIS IN RAT BRAIN AFTER AXOTOMY:

INTERACTION BETWEEN APOMORPHINE AND HALOPERIDO 000161 01-03

EFFECT OF HYPOCHOLESTEROLEMIC AGENTS ON CENTRAL-NERVOUS-SYSTEM CHOLESTEROL BIOSYNTHESIS. III. ZUCLOMIPHENE IN COMBINATION WITH AY9944 AND TRIPARANOL. 003058 04-03

AZABUTYRONE ACTION OF AZABUTYRONE AND ITS ANALOGS ON CATECHOLAMINE METABOLISM IN RAT BRAIN.

001218 02-03

AZAPHEN IN THE TREATMENT OF ENURESIS IN CHILDREN. 002513 03-11

INVESTIGATIONS OF THE ANALGESIC AND MORPHINE-LIKE PROPERTIES OF AZIDOMORPHINE. 000379 01-04

THE B-MITTEN EEG PATTERN AND TARDIVE-DYSKINESIA: A POSSIBLE ASSOCIATION. 001846 02-15

B-TYPE DEPRENIL: LOSS OF SELECTIVITY FOR INHIBITION OF B-TYPE MAO AFTER REPEATED TREATMENT.

003131 04-03

BABIES AND TRANQUILLISERS. 000587 01-09 LATE WITHDRAWAL SYMPTOMS IN BABIES BORN TO METHADONE

ADDICTS. 001756 02-15

DISRUPTION OF LEARNING PERFORMANCE BY CHRONIC CHLORPROMAZINE ADMINISTRATION IN THE BABOON.

001465 02-04 A COMPARISON OF THE EFFECTS OF SEIZURES AND TWO
ANTICONVULSANT MEDICATIONS ON LEARNING IN THE PAPIO-PAPIO BABOON, (PH.D. DISSERTATION).

002329 03-04

THE EFFECTS OF CANNABIS-SATIVA ON THE BEHAVIOR OF ADULT FEMALE CHACMA BABOONS (PAPIO-URSINUS) IN CAPTIVITY.

ACUTE DYSTONIA AS AN IDIOSYNCRATIC RESPONSE TO NEUROLEPTICS IN BARDONS. 000409 01-04

REDUCTION OF HEROIN SELF-ADMINISTRATION IN BABOONS BY MANIPULATION OF BEHAVIORAL AND PHARMACOLOGICAL CONDITIONS 001499 02-04

PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS THERAPEUTIC APPLICATION.

001737 02-14

BACLOFEN INCREASE IN MOUSE BRAIN DOPAMINE CONTENT BY BACLOFEN: EFFECTS OF APOMORPHINE AND NEUROLEPTICS.

000121 01-03 GABA-LIKE PROPERTIES OF FLURAZEPAM AND BACLOFEN SUGGESTED BY ROTATIONAL BEHAVIOUR FOLLOWING UNILATERAL INTRANIGRAL INJECTION: A COMPARISON WITH THE GABA-AGONIST MUSCIMOL. 000290 01-03

EFFECTS OF BACLOFEN AND MUSCIMOL ON NIGROSTRIATAL DOPAMINERGIC FUNCTIONS.

000347 01-04 BACLOFEN TREATMENT IN CHRONIC SCHIZOPHRENIA: A CLINICAL TRIAL. 000521 01-08 THE ACTION OF BACLOFEN ON NEURONS OF THE SUBSTANTIA-NIGRA AND OF THE VENTRAL TEGMENTAL AREA. 001211 02-03

EFFECTIVENESS OF BACLOFEN IN SCHIZOPHRENIA

001572 02-08 **DELIMITATION OF NEURONAL SUBSTRATES NECESSARY FOR THE** ANALGESIC ACTION OF BACLOFEN AND MORPHINE.

002132 03-03
EFFECTS OF BACLOFEN ON DOPAMINE METABOLISM AND INTERACTION

002173 03-03 EFFECT OF BACLOFEN (BF) (LIORESAL (R) ON DOPAMINERGIC SINGLE UNITS AND SIDMAN AVOIDANCE BEHAVIOR.

002300 03-04 BACLOFEN (P-CHLOROPHENYL-GABA) IN SCHIZOPHRENIA

002378 03-07 EFFECT OF BACLOFEN ON TARDIVE-DYSKINESIA

002665 03-15 THE EFFECT OF BACLOFEN ON ALPHA-FLUPENTHIXOL-INDUCED CATALEPSY IN THE RAT. 003203 04-04

BACLOFEN IN PARKINSONS DISEASE. 003560 04-11

RETROACTIVE AMNESIA INDUCED IN CHICKS BY THE PROLINE ANALOG L BAIKIAIN, WITHOUT EEG SEIZURES OR DEPRESSION.

003205 04-04

WHY BAN HALLUCINOGENS?.

001632 02-12 BARBADIANS

CLINICAL EFFECTS AND PLASMA LEVELS OF CLOMIPRAMINE IN DEPRESSED BARBADIANS 002449 03-09

REGIONAL DISTRIBUTION OF BARBITAL IN THE BRAIN OF MICE DURING THE DEVELOPMENT OF TOLERANCE AND PHYSICAL DEPENDENCE. 001180 02-03

CHRONIC AND ACUTE EFFECTS OF BARBITAL AND AMPHETAMINE IN DOPAMINE DEPLETED RATS.

001389 02-04 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. II.
TOLERANCE CHARACTERISTICS. 001972 03-03

EFFECT OF SYNTHESIS INHIBITION ON THE LEVELS OF BRAIN CATECHOLAMINES IN BARBITAL DEPENDENT RATS.

002103 03-03 EFFECT OF ALPHA-METHYL-P-TYROSINE ON THE INCIDENCE OF SPONTANEOUS CONVULSIONS OBSERVED FOLLOWING BARBITAL WITHDRAWAL

002104 03-03 ABSORPTION AND DISTRIBUTION OF SODIUM BARBITAL IN TISSUES OF NORMAL AND DYSTROPHIC MICE.

002162 03-03 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL IV. INFLUENCE OF ELIMINATION KINETICS.

002198 03-04 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL III. WITHDRAWAL CHARACTERISTICS.

002199 03-04 INTOXICATING EFFECTS OF THREE ALIPHATIC ALCOHOLS AND BARBITAL ON TWO RAT STRAINS GENETICALLY SELECTED FOR THEIR ETHANOL

002276 03-04 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. I. CHRONICALLY EQUIVALENT DOSING METHOD. 002360 03-06 Psychopharmacology Abstracts

OSMOTIC MINIPUMPS FOR ADMINISTRATION OF BARBITAL TO MICE: DEMONSTRATION OF FUNCTIONAL TOLERANCE AND PHYSICAL

THE EFFECTS OF ATROPINE ON THE TOLERANCE AND THE CONVILSIONS SEEN AFTER WITHDRAWAL FROM FORCED BARBITAL DRINKING IN THE

003389 04-04 DELIRIUM-TREMENS: A DOUBLE-BLIND COMPARISON OF DIAZEPAM AND BARBITAL TREATMENT. 003632 04-14

BARBITAL-INDUCED
BARBITAL-INDUCED CHANGES IN SENSITIVITY TO THE BEHAVIORAL
EFFECTS OF NARCOTICS.

000332 01-04

BARBITAL-INDUCED TOLERANCE AND CROSS-TOLERANCE TO VARIOUS CNS DEPRESSANTS ON RAT OPERANT BEHAVIOR. 001481 02-04

EFFECTS OF CHRONIC INGESTION AND WITHDRAWAL OF SODIUM BARBITONE ON LEARNING IN RATS.

003273 04-04

SOME OBSERVATIONS ON THE MECHANISM OF BENZODIAZEPINE BARBITURATE INTERACTIONS IN THE MOUSE.

FORMATION OF BRAIN ACETYLCHOLINE FROM DIETARY CHOLINE AND THE EFFECT OF BARBITURATE ANESTHESIA ON THIS PROCESS. 001074 02-03

CHANGES IN LIVER FUNCTION IN ACUTE POISONING BY BARBITURATE, RESERPINE AND AMPHETAMINE.

THE EFFECT OF BARBITURATE AND PROCAINE ON GLIAL AND NEURONAL CONTRIBUTIONS TO EVOKE CORTICAL STEADY POTENTIAL SHIFTS.
001219 02-03

EFFECT OF BARBITURATE WITHDRAWAL ON PENTYLENETETRAZOL SEIZURE THRESHOLD.

001364 02-04 THE RAPRITURATE OVERDOSE

001778 02-15 HALOPERIDOL IN BARBITURATE DETOXIFICATION

001833 02-15 CHANGES OF TAURINE CONTENT IN THE BRAIN TISSUE OF BARBITURATE

002961 04-03 EXPERIMENTAL BARBITURATE DEPENDENCE. I. BARBITURATE
DEPENDENCE DEVELOPMENT IN RATS BY DRUG ADMIXED FOOD (DAF)

003373 04-04

BARBITURATE-INDUCED CHANGES IN TRANSMITTER RELEASE INDEPENDENT OF TERMINAL SPIKE CONFIGURATION IN THE FROG NEUROMUSCULAR JUNCTION. 000294 01-03

BARBITURATES PRODUCTION OF UNDERWEIGHT EMBRYOS IN RATS TREATED WITH BARBITURATES DURING PREGNANCY.

000072 01-03 BENZODIAZEPINES, BARBITURATES, AND HIPPOCAMPAL INHIBITION 000300 01-03

INCORPORATION OF RADIOACTIVE LABELLED CHOLINE AND PALMITATE INTO LUNG LECITHIN OF RABBITS TREATED WITH HIGH DOSES OF BROMCARBAMIDES, BARBITURATES AND DIAZEPAM.

001282 02-03 PHARMACOKINETICS OF SOME HOMOLOGOUS SERIES OF BARBITURATES IN THE INTACT RAT AND IN THE ISOLATED PERFUSED RAT LIVER.

001292 02-03 BARBITURATES AND ALCOHOL CONSUMPTION 001388 02-04

EFFECTS OF DIAZEPINES AND BARBITURATES ON HIPPOCAMPAL RECURRENT INHIBITION. 002181 03-03

REVERSAL OF THE ACTION OF AMINO-ACID ANTAGONISTS BY BARBITURATES AND OTHER HYPNOTIC DRUGS.

002838 04-03 BARBITURIC-ACID
INHIBITION BY BARBITURIC-ACID AND ITS DERIVATIVES OF THE ENZYMES
IN RAT BRAIN WHICH PARTICIPATE IN THE SYNTHESIS OF PYRIMIDINE

003049 04-03

BARRIER BLOOD-BRAIN BARRIER DYSFUNCTION AFTER AMPHETAMINE ADMINISTRATION IN RATS.

002854 04-03

RESEARCH BARRIERS IN PSYCHOPHARMACOLOGY. 000944 01-17

EFFECT OF PSYCHOTROPIC DRUGS ON 3,4 DIHYDROXYPHENYLACETIC-ACID (DOPAC) CONTENT IN THE MEDIAL BASAL HYPOTHALAMUS. 001962 03-03 LACK OF EFFECTS OF L TRYPTOPHAN ON BASAL AND TRH STIMULATED

002554 03-13

EFFECTS OF ESTROGEN AND AMINERGIC DRUGS ON THRESHOLDS OF MEDIAL BASAL HYPOTHALAMIC AXONS IN THE MEDIAN EMINENCE OF

EFFECT OF MORPHINE ON THE BASAL AND THE DOPAMINE-INDUCED RELEASE OF LHRH FROM MEDIOBASAL HYPOTHALAMIC FRAGMENTS IN VITRO

FURTHER STUDIES ON BL-3912A: EFFECTS ON AVOIDANCE BEHAVIOR OF RATS WITH LOW BASELINES AND ON REACTION THRESHOLDS TO **ELECTRIC FOOTSHOCK**

000461 01-04

MORPHINE AND ETHANOL AS DISCRIMINATIVE STIMULI: ABSENCE OF ANTAGONISM BY P-CHLOROPHENYLALANINE-METHYL-ESTER, CINANSENIN, OR BC-105.

000473 01-04

EFFECTS OF ANTICHOLINERGIC AND CHOLINESTERASE BLOCKING DRUGS ON APPETITIVE BEHAVIOR UNDER DIFFERENT DEPRIVATION

OPEN-FIELD BEHAVIOR AND GROSS MOTOR DEVELOPMENT IN OFFSPRING

OF NURSING RAT MOTHERS GIVEN PENFLURIDOL 000307 01-04

FURTHER STUDIES OF THE AGGRESSIVE BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN REM SLEEP-DEPRIVED RATS. 000331 01-04 EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN TWO INBRED STRAINS OF MICE.

000333 01-04

COMPARISON OF THE REGULATION OF ROTATIONAL BEHAVIOR BY HYPOTHALAMIC OLIGOPEPTIDES.

000337 01-04 DRUG-INDUCED CHANGES IN THE MATERNAL BEHAVIOR OF RATS. 000366 01-04

EFFECT OF IN-UTERO ADMINISTRATION OF MORPHINE ON THE SUBSEQUENT DEVELOPMENT OF SELF-ADMINISTRATION BEHAVIOR

000368 01-04 SOME EFFECTS OF NALOXONE ON BEHAVIOR IN THE MOUSE

000371 01-04 POSSIBLE MECHANISMS INVOLVED IN THE STEREOTYPED BEHAVIOR ELICITED BY AMPHETAMINE.

000372 01-04 SEROTONIN REDUCTION EARLY IN LIFE AND ITS EFFECTS ON BEHAVIOR. 000383 01-04

PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION INTO BRAIN PROTEINS OF DIFFERENT MOUSE STRAINS.

CIRCLING BEHAVIOR AND STEREOTYPY INDUCED BY INTRANIGRAL **OPIATE MICROINJECTIONS.**

EFFECTS OF METHADONE AND MORPHINE MAINTENANCE ON DRUG-SEEKING BEHAVIOR IN THE DOG.

THE EFFECTS OF CANNABIS-SATIVA ON THE BEHAVIOR OF ADULT FEMALE CHACMA BABOONS (PAPIO-URSINUS) IN CAPTIVITY.

FACILITATION OF MOUNTING BEHAVIOR BY DIHYDROTESTOSTERONE PROPIONATE IN CASTRATED ESTRADIOL-BENZOATE TREATED MALE RATS FOLLOWING PUDENDECTOMY.

000403 01-04 A COMPARATIVE STUDY OF DIFFERENT AMPHETAMINES ON COPULATORY BEHAVIOR AND STEREOTYPE ACTIVITY IN THE FEMALE

000412 01-04 P-CHLOROPHENYLALANINE PRODUCED EFFECTS ON BEHAVIOR IN INTACT AND BRAIN-DAMAGED RATS.

EFFECTS OF MONOSODIUM-GLUTAMATE ON EATING AND DRINKING

NEOSTRIATAL ADMINISTRATION OF SOMATOSTATIN: DIFFERENTIAL EFFECT OF SMALL AND LARGE DOSES ON BEHAVIOR AND MOTOR

000437 01-04 DOES PROLACTIN PLAY A ROLE IN ESTROGEN-INDUCED MATERNAL BEHAVIOR IN RATS: APOMORPHINE REDUCTION OF PROLACTIN

000445 01-04 FURTHER STUDIES ON BL-3912A: EFFECTS ON AVOIDANCE BEHAVIOR OF RATS WITH LOW BASELINES AND ON REACTION THRESHOLDS TO ELECTRIC FOOTSHOCK. 000461 01-04 ROLE OF GLUCOCORTICOIDS IN AN ABNORMAL GROOMING BEHAVIOR IN CATS WITH PONTILE OR FRONTAL NEOCORTICAL LESIONS

000463 01-04 EFFECTS OF ANGIOTENSIN-II ON SCHEDULE-DEPENDENT AND INDUCED BEHAVIOR AT RECOVERED BODY WEIGHT.

LITHIUM AND AGGRESSIVE BEHAVIOR IN PATIENTS WITH EARLY TOTAL

CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE FOR AN INTERACTIONIST POSITION.

THE RELATIVE EFFICACY OF METHYLPHENIDATE (RITALIN) AND BEHAVIOR
MODIFICATION TECHNIQUES IN THE TREATMENT OF A HYPERACTIVE

000671 01-11
INTERACTIONS OF NARCOTICS AND THEIR ANTAGONISTS WITH HUMAN SERUM ESTERASE. VI: THE BEHAVIOR OF 14 HYDROXYLATED MORPHINE DERIVATIVES.

VIDEOTAPE METHODS FOR IDENTIFICATION OF NONVERBAL BEHAVIOR PARAMETERS IN DEPRESSIVE SYNDROMES

ANALYSIS OF A SCHOOL OF THOUGHT ON THE EFFECTS OF LITHIUM ON

AGE-RELATED EFFECTS OF RESERPINE ON BEHAVIOR AND ON REGIONAL CATECHOLAMINE UPTAKE AND RELEASE IN THE RAT. (PH.D.

EFFECTS OF D AMPHETAMINE (D-A), PROSTAGLANDIN-E1 AND F-2ALPHA ON H3-2-DOPAMINE (H3-DA) METABOLISM, FIXED-INTERVAL (FI) BEHAVIOR AND RECTAL TEMPERATURE.

001207 02-03 EFFECTS OF APOMORPHINE AND HALOPERIDOL ON EXPLORATORY BEHAVIOR AND LATENT LEARNING IN MICE.

001297 02-04 ANTAGONISM BETWEEN THE EFFECTS OF L-DOPA AND APOMORPHINE ON THE BEHAVIOR OF RATS.

001298 02-04 BEHAVIORAL HISTORY AS A DETERMINANT OF THE EFFECTS OF D AMPHETAMINE ON PUNISHED BEHAVIOR.

O01306 02-04
THE EFFECTS OF NEONATAL INJECTIONS OF ALPHA-MSH ON THE OPEN-FIELD BEHAVIOR OF JUVENILE AND ADULT RATS.

001309 02-04 A COMPARISON OF THE EFFECTS OF INTRAVENTRICULAR MORPHINE AND
TWO ENZYME RESISTANT ENKEPHALINS ON OPERANT BEHAVIOR IN

001323 02-04 DIFFERENTIAL EFFECT OF NALOXONE ON FIXED-RATIO OPERANT BEHAVIOR IN STRESSED AND NONSTRESSED RATS

001330 02-04 POISON AVERSION AND SEXUAL BEHAVIOR IN THE GOLDEN HAMSTER.
001357 02-04
ENHANCEMENT OF SEXUAL BEHAVIOR IN THE FEMALE RAT BY NICOTINE.

001360 02-04 STEREOSELECTIVE EFFECTS OF DIMETHOXY-4METHYLPHENYLAMINOPROPANE (DOM) ON SCHEDULE-CONTROLLED

COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON BEHAVIOR OF THE CAT.

001383 02-04
EFFECTS OF CHRONIC LITHIUM AND RUBIDIUM ADMINISTRATION UPON EXPERIMENTALLY-INDUCED CONFLICT BEHAVIOR

001391 02-04 BETA-ENDORPHIN: DOSE-DEPENDENT SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR.

APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR, LOCOMOTOR STIMULATION AND HYPOTHERMIA IN SPONTANEOUS HYPERTENSIVE RATS AND NORMOTENSIVE WISTAR RATS

001413 02-04 DRUGS AFFECTING DOPAMINE NEURONS AND YAWNING BEHAVIO 001422 02-04

EFFECTS OF PHENCYCLIDINE ON OPERANT BEHAVIOR IN RATS 001423 02-04 THE STRUCTURE OF BEHAVIOR OF RATS DURING MORPHINE-INDUCED

HYPERACTIVITY 001426 02-04 THE EFFECTS OF SCOPOLAMINE ON THE TEMPORAL CONTROL OF BEHAVIOR

EFFECTS OF ANTIESTROGENS ON EATING, FEMALE SEXUAL BEHAVIOR, AND THE UPTAKE OF H3-ESTRADIOL IN THE CENTRAL-NERVOUS-SYSTEM IN RATS. (PH.D. DISSERTATION). 001447 02-04

THE EFFECT OF A HALLUCINOGEN, 5 METHOXYDIMETHYLTRYPTAMINE, ON PRIMATE SOCIAL BEHAVIOR.

001455 02-04 EFFECTS OF PSYCHOTROPIC AGENTS ON AMPHETAMINE-INDUCED BEHAVIOR IN RATS.

001460 02-04

THE EFFECTS OF STIMULATION AND DEPRESSION OF THE RETICULOENDOTHELIAL SYSTEM ON SIDMAN AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).

COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON ROTATIONAL BEHAVIOR IN RATS WITH UNILATERAL 6 HYDROXYDOPAMINE LEGIONE

001477 02-04 BARBITAL-INDUCED TOLERANCE AND CROSS-TOLERANCE TO VARIOUS CNS DEPRESSANTS ON RAT OPERANT BEHAVIOR.

001481 02-04 CLONAZEPAM AND DOPAMINE RELATED STEREOTYPED BEHAVIOR 001485 02-04

EFFECTS OF D AMPHETAMINE ON DIFFERENT RATES OF AVOIDANCE BEHAVIOR IN RATS. 001488 02-04

THE STUDY OF SEQUENCES OF MOTOR BEHAVIOR

001537 02-06 DIFFERENTIATION OF HYPNOTIC ACTION OF NITRAZEPAM AND ESTAZOLAM AND EFFECTS ON BEHAVIOR AND CORTICAL ACTIVITY

THE EFFECTS OF AN ANTIPSYCHOTIC MEDICATION ON THE CLASSROOM BEHAVIOR OF FOUR SCHIZOPHRENIC MALE CHILDREN.

LITHIUM-CARBONATE IN THE MANAGEMENT OF HYPERACTIVE AGGRESSIVE BEHAVIOR OF THE MENTALLY RETARDED.

001713 02-14

DRUG-PRODUCED CHANGES IN HUMAN SOCIAL BEHAVIOR: FACILITATION BY D AMPHETAMINE.

001715 02-14 METHYLPHENIDATE IN HYPERKINETIC CHILDREN: DIFFERENCES IN DOSE EFFECTS ON LEARNING AND SOCIAL BEHAVIOR.

001732 02-14 PROPOXYPHENE ON DEMAND: ANALGESIC SEEKING BEHAVIOR IN PSYCHIATRIC INPATIENTS.

001736 02-14

ASKING QUESTIONS ABOUT BEHAVIOR 001914 02-17

EFFECTS OF CANNABINOIDS ON UNLEARNED BEHAVIOR IN ANIMALS 001955 03-02

STUDIES ON THE ROLE OF FOREBRAIN CATECHOLAMINE NEURONS IN EXPLORATORY BEHAVIOR IN THE RAT. (PH.D. DISSERTATION). 002012 03-03 FEEDING BEHAVIOR OF SHEEP FOLLOWING INTRAVENOUS INJECTION OF

IMIDAZOBENZODIAZEPINES 002193 03-04

EFFECTS OF CHRONIC IMIPRAMINE AND CLOMIPRAMINE ORAL ADMINISTRATION ON MATERNAL BEHAVIOR AND LITTER DEVELOPMENT. 002202 03-04

THE EFFECTS OF ACUTE AND CHRONIC PHENCYCLIDINE ON SCHEDULE-CONTROLLED BEHAVIOR IN THE SQUIRREL-MONKEY. 002209 03-04

EFFECTS OF PCPA AND SELECTIVE REM SLEEP-DEPRIVATION ON ROTOROD PERFORMANCE AND OPEN-FIELD BEHAVIOR IN THE RAT.

002219 03-04 FACILITATION OF LORDOSIS BEHAVIOR BY CLONIDINE IN FEMALE

002222 03-04 DIFFERENTIAL EFFECTS OF THE ANTIANDROGEN FLUTAMIDE ON ASPECTS OF SEXUAL BEHAVIOR IN CASTRATED, ANDROGEN TREATED MALE

002237 03-04 EFFECTS OF STIMULANTS, ANORECTICS, AND RELATED DRUGS ON SCHEDULE-CONTROLLED BEHAVIOR.

002243 03-04 EFFECTS OF D AMPHETAMINE, MONOMETHOXYAMPHETAMINES AND HALLUCINOGENS ON SCHEDULE-CONTROLLED BEHAVIOR.

002244 03-04 SPONTANEOUS AND AMPHETAMINE-INDUCED BEHAVIOR AFTER BILATERAL INJECTION OF ETHANOLAMINE-O-SULFATE INTO THE SUBSTANTIA-NIGRA.

002262 03-04 OPEN-FIELD BEHAVIOR AFTER INTRAVENOUS AMPHETAMINE ANALOGUES

002272 03-04 EFFECT OF NEUROLEPTIC DRUGS ON THE CONDITIONED BEHAVIOR AFTER PRETREATMENT WITH ALPHA-METHYLTY KOSINE OR P-CHLOROPHENYLALANINE.

002290 03-04 EFFECT OF BACLOFEN (BF) (LIORESAL (R) ON DOPAMINERGIC SINGLE UNITS AND SIDMAN AVOIDANCE BEHAVIOR.

Psychopharmacology Abstracts

CONFLICT BEHAVIOR IN THE SQUIRREL-MONKEY: EFFECTS OF CHLORDIAZEPOXIDE, DIAZEPAM AND N DESMETHYLDIAZEPAM

002303 03-04 ADULT BEHAVIOR AND ADRENOCORTICAL FUNCTION FOLLOWING NEONATAL MORPHINE TREATMENT IN RATS.

002310 03-04 THE EFFECT OF CHOLINE-CHLORIDE ON AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR.

002330 03-04 REHAVIOR EFFECTS OF COCAINE IN ANIMALS

TAILS OF STRESS RELATED BEHAVIOR: A NEUROPHARMACOLOGICAL

002359 03-06

EFFECTS OF DIAZEPAM ON PHOBIC AVOIDANCE BEHAVIOR AND PHOBIC

002498 03-10 BEHAVIOR THERAPY, SUPPORTIVE PSYCHOTHERAPY, IMIPRAMINE, AND **PHOBIAS**

002501 03-10 EFFECT OF THIORIDAZINE (MELLARIL-SANDOZ) ON PSYCHOMOTOR FUNCTION, CONCENTRATION, AND REACTIVITY IN CHILDREN WITH BEHAVIOR DISORDERS.

TREATMENT OF HUMAN AGGRESSIVE BEHAVIOR: FOUR CASE STUDIES OF THE EFFECT OF LITHIUM.

002532 03-11 METHYLPHENIDATE EFFECT ON ATTENTIONAL AND COGNITIVE BEHAVIOR IN SIX- THROUGH TWELVE-YEAR-OLD MALES.

002618 03-14 EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE ON BEHAVIOR OF HYPERACTIVE CHILDREN.

THE EFFECTS OF OBSTETRICAL MEDICATION ON THE BEHAVIOR OF ISRAELI NEWBORN INFANTS AND SOME COMPARISONS WITH URUGUAYAN AND AMERICAN INFANTS.

002673 03-15 NEUROPHARMACOLOGY AND BEHAVIOR.

002750 03-17 NEUROTRANSMISSION AND DISTURBED BEHAVIOR.

PEDIATRIC PSYCHOPHARMACOLOGY: THE USE OF BEHAVIOR MODIFYING DRUGS IN CHILDREN.

002784 03-17 COMPARATIVE EFFECTS OF PENFLURIDOL ON CIRCLING BEHAVIOR AND STRIATAL DOPAC AND SERUM PROLACTIN CONCENTRATIONS IN THE RAT.

CHOICE BEHAVIOR IN RHESUS MONKEYS: COCAINE VERSUS FOOD. 003155 04-04

LEVO-ALPHA-ACETYLMETHADOL AND METABOLITES: SOME EFFECTS ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT.

003156 04-04

INSTINCTIVE PREDATORY BEHAVIOR OF THE FERRET (PUTORIUS-PUTORIUS-FURO L.) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE (LIBRIUM).

003161 04-04

EFFECTS OF BENZAZEPINE (SCH-12679) ON SHOCK-INDUCED FIGHTING
AND LOCOMOTOR BEHAVIOR IN RATS. 003166 04-04

NEUROLEPTIC INTERFERENCE WITH THE COCAINE CUE: INTERNAL STIMULUS CONTROL OF BEHAVIOR AND PSYCHOSIS.

003193 04-04 STEREOTYPED BEHAVIOR AFTER CHOLINERGIC, BUT NOT DOPAMINERGIC, STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.

003208 04-04 BRIEF PERIODS OF SOCIALIZATION AND LATER BEHAVIOR IN THE RAT 003214 04-04

A REFILLABLE SYSTEM FOR CONTINUOUS AMPHETAMINE ADMINISTRATION: EFFECTS UPON SOCIAL BEHAVIOR IN RAT COLONIES.

ROLE OF HYPOTHALAMIC SEROTONERGIC RECEPTORS IN THE CONTROL OF LORDOSIS BEHAVIOR IN THE FEMALE RAT.

ACTIVITY ANALYSIS OF OPERANT BEHAVIOR FOLLOWING METHYLPHENIDATE ADMINISTRATION

003223 04-04 **DELTA9-TETRAHYDROCANNABINOL ENHANCEMENT OF LORDOSIS** BEHAVIOR IN ESTROGEN TREATED FEMALE RATS.

003230 04-04 PREFERENCE BEHAVIOR AND TASTE NERVE RESPONSES IN D PENICILLAMINE TREATED RATS.

003248 04-04 OPPOSITE ACTION OF OXYTOCIN TO VASOPRESSIN IN PASSIVE AVOIDANCE BEHAVIOR IN RATS.

003263 04-04 PENTOBARBITAL, PROMAZINE, D. AMPHETAMINE, AND SCOPOLAMINE EFFECTS ON BEHAVIOR UNDER MULTIPLE AND PRIMED SCHEDULES OF REINFORCEMENT.

003267 04-04

003220 04-04

002300 03-04

ROLES OF THE VOMERONASAL AND OLFACTORY SYSTEMS IN COURTSHIP BEHAVIOR OF MALE GARTER SNAKES.

O03268 04-04

ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

IMPRINTING BEHAVIOR: PITUITARY ADRENOCORTICAL MODULATION OF THE APPROACH RESPONSE.

COMPARATIVE EFFECTS OF COCAINE AND PSEUDOCOCAINE ON EEG ACTIVITIES, CARDIORESPIRATORY FUNCTIONS, AND SELF-ADMINISTRATION BEHAVIOR IN THE RHESUS MONKEY.

EFFECTS OF METHADONE ON BEHAVIOR MAINTAINED BY FIXED-RATIO REINFORCEMENT SCHEDULES. 003299 04-04

CANNABIS INTERFERES WITH NEST-BUILDING BEHAVIOR IN MICE.

003306 04-04
SIMILAR EFFECTS OF ESTROGEN AND LATERAL HYPOTHALAMIC LESIONS
ON FEEDING BEHAVIOR OF FEMALE RATS.

O03314 04-04
INTRANIGRAL KAINIC-ACID: EVIDENCE FOR NIGRAL NONDOPAMINERGIC
NEURONS CONTROLLING POSTURE AND BEHAVIOR IN A MANNER
OPPOSITE TO THE DOPAMINERGIC ONES.

O03324 04-04
STRIATAL NONDOPAMINERGIC NEURONS: POSSIBLE INVOLVEMENT IN
FEEDING AND DRINKING BEHAVIOR.

003330 04-04
PARALLEL CHANGES IN BEHAVIOR AND HIPPOCAMPAL MONOAMINE
METABOLISM IN RATS AFTER ADMINISTRATION OF ACTH ANALOGUES.

EFFECTS OF SODIUM PHENOBARBITAL ON BRAIN STIMULATION
BEHAVIOR, BEHAVIORAL SEIZURES, AND EEG SEIZURE ACTIVITY.
03335 04-04

EFFECTS OF CHLORMETHIAZOLE (HEMINEVRIN) ON DRUG DISCRIMINATION AND OPEN-FIELD BEHAVIOR IN GERBILS.

O03371 04-04
SYSTEMIC ADMINISTRATION OF ENDORPHINS SELECTIVELY ALTERS OPENFIELD BEHAVIOR OF RATS.

EFFECTS OF NALOXONE ON SCHEDULE-CONTROLLED BEHAVIOR IN MORPHINE MAINTAINED PIGEONS.

MANDIBULOGRAM AS A MEASURE OF STEREOTYPED BEHAVIOR IN THE

003427 04-06
BEHAVIOR THERAPY AND WITHDRAWAL OF STIMULANT MEDICATION IN
HYPERACTIVE CHILDREN

003566 04-11
BEHAVIOR OBSERVATIONS OF HYPERACTIVE CHILDREN AND
METHYLPHENIDATE (RITALIN) EFFECTS IN SYSTEMATICALLY
STRUCTURED CLASSROOM ENVIRONMENTS: NOW YOU SEE THEM,
NOW YOU DONT.

003581 04-11 BEHAVIOR DISTURBANCE, PHENOBARBITAL, AND FEBRILE SEIZURES. 003582 04-11

PSYCHOPHARMACOLOGY OF AVERSIVELY MOTIVATED BEHAVIOR. 003615 04-14 STUDY OF THE INFLUENCE OF VITAMIN SUPPLEMENTS ON THE BEHAVIOR

OF PSYCHIATRIC PATIENTS.

003624 04-14

EFFECTS OF METHYLPHENIDATE ALONE AND IN COMBINATION WITH

BEHAVIOR MODIFICATION PROCEDURES ON THE BEHAVIOR AND ACADEMIC PERFORMANCE OF HYPERACTIVE CHILDREN.

DOPAMINE RECEPTOR BINDING ENHANCEMENT ACCOMPANIES LESION-

INDUCED BEHAVIORAL SUPERSENSITIVITY.

000084 01-03

BEHAVIORAL EFFECTS OF APOMORPHINE AND

DIISOBUTYRYLAPOMORPHINE IN THE MOUSE.

000314 01-04
METABOLIC AND EXPERIENTIAL FACTORS IN THE BEHAVIORAL RESPONSE

TO REPEATED AMPHETAMINE. 000325 01-04

BARBITAL-INDUCED CHANGES IN SENSITIVITY TO THE BEHAVIORAL EFFECTS OF MARCOTICS. 000332 01-04

TIME ACTION AND BEHAVIORAL EFFECTS OF AMPHETAMINE, ETHANOL, AND ACETYLMETHADOL. 000350 01-04

LONG-TERM BEHAVIORAL CHANGES IN THE RHESUS MONKEY AFTER MULTIPLE DAILY INJECTIONS OF D METHYLAMPHETAMINE. 000359 01-04

DELTA9-THC AND 11 OH-DELTA9-THC: BEHAVIORAL EFFECTS AND RELATIONSHIP TO PLASMA AND BRAIN LEVELS.

D00361 01-04 INFLUENCES OF GENOTYPE AND SEX ON BEHAVIORAL TOLERANCE TO

NICOTINE IN MICE. 000376 01-04

BEHAVIORAL SENSITIVITY TO LSD: DEPENDENCY UPON THE PATTERN OF CENTRAL 5-HT DEPLETION.

BEHAVIORAL EFFECTS OF PEPTIDES IN ANIMALS: FURTHER EXPERIENCE WITH PENTOBARBITAL ANTAGONISM.

BENZODIAZEPINES: BEHAVIORAL AND NEUROCHEMICAL MECHANISMS.
000455 01-04

POTENTIATION OF THE BEHAVIORAL AND CONVULSANT EFFECTS OF COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.

GENETIC ANALYSIS OF THE BEHAVIORAL RESPONSE TO D AMPHETAMINE IN MICE.

DO0482 01-05
BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC CORRELATES OF THE CHRONIC USE OF MARIJUANA — A REVIEW.

WITHDRAWAL OF A STIMULANT DRUG AND CONCURRENT BEHAVIORAL INTERVENTION IN THE TREATMENT OF A HYPERACTIVE CHILD.

EEG PROFILE AND BEHAVIORAL CHANGES AFTER A SINGLE DOSE OF CLOZAPINE IN NORMALS AND SCHIZOPHRENICS.

000787 01-14
BEHAVIORAL TOXICITY AND EQUIVOCAL SUICIDE ASSOCIATED WITH
CHLOROQUINE AND ITS DERIVATIVES.

O00839 01-15
SLEEP AND BEHAVIORAL CHANGES POSSIBLY REFLECTING CENTRAL
RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS
INHIBITION IN MAN

THE BEHAVIORAL TOXICITY OF MONOAMINE-OXIDASE INHIBITING ANTIDEPRESSANTS.

000967 01-17
LYSERGIC-ACID-DIETHYLAMIDE. PHOTOELECTRON IONIZATION
POTENTIALS AS INDICES OF BEHAVIORAL ACTIVITY.

THE BEHAVIORAL EFFECTS OF DIISOPROPYL-PHOSPHOFLUORIDATE:
INTERACTIONS WITH MORPHINE AND NALOXUNE IN RATS.
001169 02-03

LONG-TERM CHANGES IN THE SENSITIVITY OF PRE- AND POSTSYNAPTIC DOPAMINE RECEPTORS IN MOUSE STRIATUM EVIDENCED BY BEHAVIORAL AND BIOCHEMICAL STUDIES.

INVOLVEMENT OF CENTRAL NORADRENERGIC SYSTEM IN THE MEDIATION OF BEHAVIORAL SUPPRESSANT EFFECTS OF DIAZEPAM IN HYPERTHYPOID DATE.

HYPERTHYROID RATS.

001220 02-03
BEHAVIORAL HISTORY AS A DETERMINANT OF THE EFFECTS OF D
AMPHETAMINE ON PUNISHED BEHAVIOR

P-METHOXYPHENYLETHYLAMINE (PMPEA): SOME BEHAVIORAL OBSERVATIONS IN RATS

BEHAVIORAL EFFECTS OF BENZODIAZEPINES: A REVIEW.

DIFFERENT BEHAVIORAL RESPONSES TO L-DOPA AFTER ANTEROLATERAL OR POSTEROLATERAL HYPOTHALAMIC INJECTIONS OF 6 HYPOCYTOPPAMINE

001349 02-04
ACUTE AND CHRONIC EFFECTS OF GENERAL CNS DEPRESSANTS ON
SEVERAL BEHAVIORAL TESTS IN RATS.

A BIOCHEMICAL AND BEHAVIORAL ANALYSIS OF CHRONIC ALCOHOL CONSUMPTION BY RATS.

001362 02-04
RATE-DEPENDENT EFFECTS OF AMPHETAMINE RESULTING FROM
BEHAVIORAL COMPETITION.

001368 02-04
BEHAVIORAL EFFECTS OF NEUROLEPTICS, APOMORPHINE AND
AMPHETAMINE AFTER BILATERAL LESION OF THE LOCUS-COERULEUS IN
RATS.

A BEHAVIORAL ANALYSIS OF AGGRESSIVE BEHAVIORS INDUCED AND MODULATED BY DELTA9-TETRAHYDROCANNABINOL, PILOCARPINE, D AMPHETAMINE AND L-DOPA.

O01419 02-04

EFFECTS OF THYROTROPIN-RELEASING HORMONE ON BEHAVIORAL AND
HORMONAL CHANGES INDUCED BY BETA-ENDORPHIN.

001471 02-04
BEHAVIORAL AND PSYCHOPHARMACOLOGICAL CHARACTERISTICS OF
RATS RAISED IN HIGH POPULATION DENSITY.

DEVELOPMENT OF BEHAVIORAL TOLERANCE TO COCAINE.

EEG AND BEHAVIORAL EFFECTS OF D ALA2-MET-ENKEPHALINAMIDE IN THE RAT.

O01476 02-04
COMPARISON OF BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE
AFTER FLUPHENAZINE-DIHYDROCHLORIDE AND FLUPHENAZINEDECANOATE TREATMENT IN RATS.

O01484 02-04

REDUCTION OF HEROIN SELF-ADMINISTRATION IN BABOONS BY MANIPULATION OF BEHAVIORAL AND PHARMACOLOGICAL

EEG, BLOOD LEVEL, AND BEHAVIORAL EFFECTS OF THE ANTIDEPRESSANT MIANSERIN (ORG-G8-94).

NEFOPAM (N), MORPHINE (M), AND D AMPHETAMINE (A) IN MAN: SUBJECTIVE, BEHAVIORAL, AND PHYSIOLOGIC EFFECTS.

NEUROPHYSIOLOGY, NEUROPHARMACOLOGY AND BEHAVIORAL RELATIONSHIPS OF VISUAL SYSTEM EVOKED AFTER-DISCHARGES: A

001885 02-17 PSYCHOPHARMACOLOGY: A BIOCHEMICAL AND BEHAVIORAL APPROACH.

BEHAVIORAL MECHANISMS OF DRUG ACTION IN SCHIZOPHRENIA. 001933 02-17

SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL CORRELATES. 001974 03-03

SUBSTRATES OF ELEMENTARY BEHAVIORAL PLASTICITY.

002030 03-03 ANTAGONISM BY MIANSERIN AND CLASSICAL ALPHA-ADRENOCEPTOR BLOCKING DRUGS OF SOME CARDIOVASCULAR AND BEHAVIORAL EFFECTS OF CLONIDINE.

NEUROCHEMICAL AND BEHAVIORAL EFFECTS OF CLONIDINE AND RELATED IMIDAZOLINES: INTERACTION WITH ALPHA-ADRENOCEPTORS.

002156 03-03 BEHAVIORAL EFFECTS OF APOMORPHINE DURING DEVELOPMENT OF

002203 03-04 THE SPECIFICITY OF NEUROLEPTIC-INDUCED AND METHYSERGIDE-INDUCED
BEHAVIORAL HYPERSENSITIVITY.

002259 03-04 A BEHAVIORAL AND AUTONOMIC NERVOUS SYSTEM STUDY OF CHRONIC IMIPRAMINE ADMINISTRATION TO CONSCIOUS DOGS.

002263 03-04

INTERACTIONS OF PARTIAL LSD ANALOGS WITH BEHAVIORAL DISRUPTING EFFECTS OF LSD AND DMT IN THE RAT. 002264 03-04

SOME BEHAVIORAL EFFECTS OF SP6-11 HEXAPEPTIDE C-TERMINAL OF SUBSTANCE-P INJECTED INTO THE CEREBRAL VENTRICLES IN RATS. 002267 03-04

RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION WITH A HIGH FAT/PROTEIN DIET.

002278 03-04 PHARMACOLOGICAL AND BEHAVIORAL COMPONENTS OF TOLERANCE TO LSD AND MESCALINE IN RATS.

FORMAMIDINE-INDUCED FEEDING AND BEHAVIORAL ALTERATION IN THE

002294 03-04 PRENATAL MORPHINE ADMINISTRATION ALTERS BEHAVIORAL DEVELOPMENT IN THE RAT.

002308 03-04 SCREENING HALLUCINOGENIC DRUGS. II. SYSTEMATIC STUDY OF TWO

A BEHAVIORAL TREATMENT OF DEPRESSION WITH ALCOHOLICS RECEIVING PHARMACOLOGICAL AVERSIVE CONDITIONING. (Ph.D. DISSERTATION).

002539 03-11 STRESS AND THE HEART: INTERACTIONS OF THE CARDIOVASCULAR SYSTEM, BEHAVIORAL STATE, AND PSYCHOTROPIC DRUGS.

002711 03-15 ORIGINS AND FUTURE OF BEHAVIORAL PHARMACOLOGY.

002739 03-17 BEHAVIORAL AND BIOCHEMICAL EFFECTS OF FK33-824, A PARENTERALLY AND ORALLY ACTIVE ENKEPHALIN ANALOGUE (UNPUBLISHED PAPER).

002744 03-17 ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL TOLERANCE AND CROSS-TOLERANCE TO MORPHINE AND METHADONE IN THE RAT.

OPIATE RECEPTORS FOR BEHAVIORAL ANALGESIA RESEMBLE THOSE RELATED TO THE DEPRESSION OF SPINAL NOCICEPTIVE NEURONS.

003142 04-03

BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION OF LEVO ALPHA-ACETYLMETHADOL IN THE RAT.

NEUROPHARMACOLOGICAL AND BEHAVIORAL EVALUATION OF PROSTAGLANDIN-E2 AND 11 THIOL-11-DESOXYPROSTAGLANDIN-E2 IN THE MOUSE AND RAT.

Psychopharmacology Abstracts

003261 04-04

BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC NARCOTIC TREATMENT IN THE GUINEA-PIG. 003183 04-04

BEHAVIORAL AND ANATOMICAL CONSEQUENCES OF SMALL INTRASTRIATAL INJECTIONS OF KAINIC-ACID IN THE RAT

003210 04-04 TASK-DEPENDENT GENETIC INFLUENCES ON BEHAVIORAL RESPONSE OF MICE (MUS-MUSCULUS) TO ACETALDEHYDE.

003211 04-04 THE EFFECTS OF D ALA2-METS-ENKEPHALINAMIDE ON BEHAVIORAL ACTIVITY AND CYCLIC-NUCLEOTIDES IN THE RAT BRAIN. (PH.D. DISSERTATION).

BEHAVIORAL AND PHYSIOLOGICAL STUDIES OF NONNARCOTIC ANALGESIA IN THE RAT ELICITED BY CERTAIN ENVIRONMENTAL STIMULI.

BEHAVIORAL CHANGES AND MERCURY CONCENTRATIONS IN TISSUES OF RATS EXPOSED TO MERCURY VAPOR.

LEAD-INDUCED BEHAVIORAL DISORDERS IN THE RAT: EFFECTS OF AMPHETAMINE.

TACRINE AND ITS DERIVATIVES ANTAGONIZE CHOLINERGIC PSYCHOTOMIMETICS: BEHAVIORAL STUDY IN RATS. 003262 04-04

DIFFERENTIAL BEHAVIORAL EFFECTS OF SULPIRIDE IN THE RAT AND SQUIRREL-MONKEY. 003276 04-04

THE BEHAVIORAL EFFECTS OF D AMPHETAMINE AND CHLORPROMAZINE IN RATS; COMBINATIONS WITH ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE. (Ph.D. DISSERTATION).

BEHAVIORAL EFFECTS OF PSYCHOTHERAPEUTIC AGENTS IN RATS CHRONICALLY DOSED WITH ALPHA-ACETYLMETHADOL.

BEHAVIORAL EFFECTS OF CHRONIC NARCOTIC ANTAGONIST ADMINISTRATION TO INFANT RATS.

003329 04-04 COMPARISON OF THE BEHAVIORAL EFFECTS OF P-CHLOROAMPHETAMINE, CHLORDIMEFORM, QUIPAZINE, AND INTRAVENTRICULAR SEROTONIN

EFFECTS OF SODIUM PHENOBARBITAL ON BRAIN STIMULATION
BEHAVIOR, BEHAVIORAL SEIZURES, AND EEG SEIZURE ACTIVITY.

003355 04-04 BEHAVIORAL EFFECTS OF DOPAMINE AGONISTS INCREASE WITH AGE

003362 04-04 BENZODIAZEPINES AND BEHAVIORAL EFFECTS OF REWARD (WATER)

CHANGES IN THE BEHAVIORAL RESPONSE TO A NOVEL ENVIRONMENT FOLLOWING LESIONING OF THE CENTRAL DOPAMINERGIC SYSTEM IN RAT PUPS.

003368 04-04 BEHAVIORAL CHANGES INDUCED BY 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) IN PRIMATE DYADS

003380 04-04 PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC AND CATECHOLAMINERGIC MECHANISMS BY 6 HYDROXYDOPAMINE AND 5.6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D. DISSERTATION).

003407 04-05 BEHAVIORAL RHYTHMS IN SCHIZOPHRENIA

THE BEHAVIORAL SYMPTOMS OF HYPERKINETIC CHILDREN WHO SUCCESSFULLY RESPONDED TO STIMULANT DRUG TREATMENT

003579 04-11 BEHAVIORAL NEUROCHEMISTRY: NEUROREGULATORS AND BEHAVIORAL

BEHAVIORAL TOXICITY: THE PSYCHOLOGY OF DRUG POLLUTION.

DRUG DISCRIMINATION PARADIGMS: PROBLEMS OF TOLERANCE AND

003692 04-16 THE USE OF DRUGS AS DISCRIMINATIVE STIMULI IN BEHAVIORAL PHARMACODYNAMICS.

003695 04-17 PHENCYCLIDINE: A BIBLIOGRAPHY OF BIOMEDICAL AND BEHAVIORAL

PSYCHOANALYTIC AND BEHAVIORAL CONSIDERATIONS IN ANTAGONIST AND METHADONE PROGRAMS.

THE EFFECTS OF BEHAVIORALLY RELEVANT DOSES OF CHLORPROMAZINE AND MOLINDONE ON CARDIAC ADENYLATE-CYCLASE AND ON MYOCARDIAL CONTRACTILITY. 000487 01-05

003173 04-04

AFFERENT AND EFFERENT SUBCORTICAL PROJECTIONS OF BEHAVIORALLY DEFINED SECTORS OF PREFRONTAL GRANULAR CORTEX.

ABATEMENT OF STIMULUS PERSERVATION FOLLOWING REPEATED D
AMPHETAMINE TREATMENT: ABSENCE OF BEHAVIORALLY AUGMENTED TOLERANCE.

003260 04-04

BEHAVIORS EFFECTS OF CLOZAPINE, CHLORPROMAZINE AND DIAZEPAM UPON ADJUNCTIVE AND SCHEDULE-CONTROLLED BEHAVIORS.

MANIPULATIONS. (PH.D. DISSERTATION).

EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE INTOXICATION ON EXPLORATORY AND STEREOTYPED BEHAVIORS IN THE RAT

001379 02-04
A BEHAVIORAL ANALYSIS OF AGGRESSIVE BEHAVIORS INDUCED AND MODULATED BY DELTA9-TETRAHYDROCANNABINOL, PILOCARPINE, D AMPHETAMINE AND 1-DOPA

001419 02-04 EFFECTS OF OPIATES AND OPIOID PEPTIDES ON MOTOR BEHAVIORS: SITES AND MECHANISMS OF ACTION. (UNPUBLISHED PAPER). 001433 02-04

A STUDY OF PHYSICIAN DRUG PRESCRIBING ADOPTION AND DISCONTINUATION BEHAVIORS. (PH.D. DISSERTATION).

001889 02-17 ANALYSIS OF THE ROLE PLAYED BY THE SUBSTANTIA-NIGRA IN THE MEDIATION OF INGESTIVE, LOCOMOTOR, AND ROTATIONAL BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL

002247 03-04 EFFECTS OF AMPHETAMINE ON SOCIAL BEHAVIORS OF RHESUS MACAQUES: AN ANIMAL MODEL OF PARANOIA.

002365 03-06 ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-

MEODMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR.

GABA-LIKE PROPERTIES OF FLURAZEPAM AND BACLOFEN SUGGESTED BY ROTATIONAL BEHAVIOUR FOLLOWING UNILATERAL INTRANIGRAL INJECTION: A COMPARISON WITH THE GABA-AGONIST MUSCIMOL. 000290 01-03 EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR

OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH MORPHOLOGY AND HORMONE PLASMA LEVELS. 000315 01-04

EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: 1. BEHAVIOURAL EFFECTS OF INTRAMUSCULAR INJECTIONS

000316 01-04 PRENATAL ALCOHOL CONSUMPTION AND OPEN-FIELD BEHAVIOUR IN RATS: EFFECTS OF AGE AT TIME OF TESTING.

000321 01-04 EFFECTS OF APOMORPHINE ON SELF-STIMULATION BEHAVIOUR IN DORSAL AND VENTRAL AREA OF LATERAL HYPOTHALAMUS IN MICE 000334 01-04

DISTINCT DOPAMINERGIC MECHANISMS WITHIN THE NUCLEUS-ACCUMBENS OF RATS AND BEHAVIOUR. 000340 01-04

FFFFCTS OF EXPOSURE TO LEAD ON SOCIAL BEHAVIOUR IN THE LABORATORY MOUSE

000344 01-04 THE EFFECTS OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE FEMALE RAT.

000353 01-04 CATECHOLAMINES AND BIOCHEMICALLY-INDUCED ABNORMAL BEHAVIOUR IN RATS.

000356 01-04 5 HYDROXYTRYPTAMINE AND SEXUAL BEHAVIOUR.

000357 01-04 EFFECTS OF P-CHLOROPHENYLALANINE AND ALPHA-METHYLTRYPTOPHAN ON BEHAVIOUR AND BRAIN 5 HYDROXYINDOLES

000405 01-04 ROLE OF THE DORSAL NORADRENERGIC BUNDLE IN BEHAVIOUR CONTROL

000407 01-04 MONOAMINERGIC IMPLICATION IN DIFFERENT ELEMENTS OF SEXUAL

000411 01-04 AMPHETAMINE-LIKE EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE ON SOCIAL BEHAVIOUR IN THE MOUSE.

000433 01-04 THE INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT BEHAVIOUR IN RODENTS.

000435 01-04 EFFECTS OF PCPA ON MARKING BEHAVIOUR IN THE MALE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).

001307 02-04 WET-DOG SNAKE BEHAVIOUR IN THE RAT: A POSSIBLE QUANTITATIVE MODEL OF CENTRAL 5 HYDROXYTRYPTAMINE ACTIVITY.

001310 02-04

AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOUR AND BRAIL CONCENTRATIONS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN MICE.

CANNABIS, CATECHOLAMINES, RAPID EYE MOVEMENT SLEEP AND

LONG-TERM ELIMINATION OF VIOLENT BEHAVIOUR BY THE INTERACTION OF PSYCHOPHARMACOLOGIC AND PSYCHOSOCIAL THERAPY.

AMPHETAMINE AND CHICK BEHAVIOUR: A ROLE FOR MONOAMINES IN THE CAUSATION OF VOCALIZATIONS AND EMOTIONS.

001342 02-04 DRINKING BEHAVIOUR INDUCED BY INTRACRANIAL INJECTIONS OF ELEDOISIN AND SUBSTANCE-P IN THE PIGEON.

001352 02-04 EFFECT OF SOME CENTRALLY ACTIVE COMPOUNDS ON AGGRESSIVE BEHAVIOUR IN SEPTAL RATS.

001376 02-04
EFFECTS OF MORPHINE AND NALTREXONE ON SEXUAL BEHAVIOUR ON THE MALE RAT.

001377 02-04 THE EFFECT OF P-BROMOMETHAMPHETAMINE ON AGGRESSIVE BEHAVIOUR.

001392 02-04 CORRELATED EFFECT OF CORTICOSTERONE ON HYPOTHALAMIC SEROTONIN AND AVOIDANCE BEHAVIOUR IN RATS.

001394 02-04 INFLUENCE OF BETA-ENDORPHIN ON EXPLORATORY, SOCIAL AND SEXUAL BEHAVIOUR IN THE MALE RAT.

THE INFLUENCE OF PROGESTERONE ON THE INHIBITORY EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE

DISCRETE-TRIAL CONTROL OF COCAINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF MORPHINE, NALOXONE, AND

001469 02-04 DISCRETE-TRIAL CONTROL OF MORPHINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF NALOXONE, MORPHINE, AND CHLORPROMAZINE.

TOLERANCE TO STEREOTYPED BEHAVIOUR AND TO DECREASE IN
STRIATAL HOMOVANILLIC-ACID LEVELS AFTER REPEATED TREATMENT WITH APOMORPHINE-DIPIVALOYL-ESTER.

PHARMACOLOGICAL INTERACTIONS WITH CIRCLING BEHAVIOUR INDUCED BY THE PIPERIDINYL INDOLE DERIVATIVE RU-23686.

002200 03-04 EFFECTS OF CLOMIPRAMINE AND OTHER INHIBITORS OF MONOAMINE UPTAKE ON THE SEXUAL BEHAVIOUR OF FEMALE RATS AND RHESUS

002228 03-04 L-DOPA REVERSAL OF HYPERDOPAMINERGIC BEHAVIOUR.

002229 03-04 THE EFFECT OF CHRONIC ETHANOL TREATMENT ON BEHAVIOUR AND CENTRAL MONOAMINES IN THE RAT.

002271 03-04 THE EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY AND STEREOTYPED BEHAVIOUR OF RATS STUDIED ON A HOLE-BOARD

002274 03-04 AMPHETAMINE-INDUCED TASTE AVERSION DEMONSTRATED WITH OPERANT BEHAVIOUR

002315 03-04 ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY BENZODIAZEPINES.

002326 03-04 A GRADUAL SCORE TO EVALUATE THE CLIMBING BEHAVIOUR ELICITED BY APOMORPHINE IN MICE.

002350 03-05 CLOMIPRAMINE (ANAFRANIL) AND BEHAVIOUR THERAPY IN OBSESSIVE COMPULSIVE AND PHOBIC DISORDERS.

002473 03-10 A COMPARISON OF CLOMIPRAMINE HYDROCHLORIDE (ANAFRANIL) AI
BEHAVIOUR THERAPY IN THE TREATMENT OF OBSESSIVE NEUROSIS.

002492 03-10 THE EFFECTS OF ELEVATING GAMMA-AMINOBUTYRATE CONTENT IN THE SUBSTANTIA-NIGRA ON THE BEHAVIOUR OF RATS.

003291 04-04

ATTENUATION OF STEREOTYPED BEHAVIOUR BY SEX STEROIDS.

O03312 04-04

OPEN-FIELD AND LASHLEY III MAZE BEHAVIOUR OF THE OFFSPRING OF

AMPHETAMINE TREATED RATS.

THE RELATIONSHIP BETWEEN PIPRADROL-INDUCED RESPONDING FOR ELECTRICAL BRAIN STIMULATION, STEREOTYPED BEHAVIOUR AND LOCOMOTOR ACTIVITY. 003347 04-04

FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON LOCOMOTOR ACTIVITY AND AVOIDANCE BEHAVIOUR OF RESERPINIZED MICE. 003351 04-04

EFFECTS OF CHLORDIAZEPOXIDE, AMITRIPTYLINE, IMIPRAMINE, AND THEIR COMBINATIONS ON AVOIDANCE BEHAVIOUR IN MICE. 003352 04-04

STRIATAL CELL SUPERSENSITIVITY TO APOMORPHINE IN DOPAMINE LESIONED RATS CORRELATED TO BEHAVIOUR.

CENTRAL AND PERIPHERAL ACTION OF TESTOSTERONE-PROPIONATE ON SCENT GLAND MORPHOLOGY AND MARKING BEHAVIOUR IN THE MONGOLIAN GERBIL.

CIRCLING BEHAVIOUR IN THE RAT FOLLOWING UNILATERAL INJECTIONS OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE INTO THE SUBSTANTIA-NIGRA.

METHODOLOGICAL PROBLEMS IN THE MEASUREMENT OF DRUG-INDUCED ROTATIONAL BEHAVIOUR: CONTINUOUS RECORDING REVEALS TIME-COURSE DIFFERENCES UNDETECTED BY PREVIOUS TECHNIQUES. 003388 04-04

PHARMACOLOGICAL TREATMENT OF DEVIANT SEXUAL BEHAVIOUR. 003552 04-11

A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR 003657 04-15

BEHAVIOURAL DISSOCIATION OF THE ENKEPHALINERGIC SYSTEMS OF NUCLEUS-ACCUMBENS AND NUCLEUS-CAUDATUS.

MULTIPLE ORAL DOSES OF DIAZEPAM, OXAZEPAM AND PHENOBARBITAL TO DOGS — BEHAVIOURAL EFFECTS AND CORRELATION WITH ANTIPYRINE HALF-LIFE.

EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: I. BEHAVIOURAL EFFECTS OF INTRAMUSCULAR INJECTIONS.

000316 01-04 ROLE OF TRYPTAMINE IN THE BEHAVIOURAL CHANGES CAUSED BY A MONDAMINE-OXIDASE INHIBITOR AND L TRYPTOPHAN.

000343 01-04 FURTHER EVIDENCES ON THE BEHAVIOURAL EFFECTS OF SELECTIVE A-10 DOPAMINERGIC MESENCEPHALO-CORTICO-LIMBIC GROUP LESION IN THE RAT.

000399 01-04 ANTAGONISM BY CHOLINERGIC DRUGS OF BEHAVIOURAL EFFECTS IN CATS OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC DRUG AND ENHANCEMENT BY NICOTINE.

LONG-TERM BEHAVIOURAL AND BIOCHEMICAL EFFECTS FOLLOWING PROLONGED TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL)

OLFACTORY BULB ABLATION IN THE RAT: BEHAVIOURAL CHANGES AND THEIR REVERSAL BY ANTIDEPRESSANT DRUGS.

BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF CHRONIC REDUCTION OF CEREBRAL NORADRENALINE RECEPTOR STIMULATION.

HAVIOURAL AND PHARMACOKINETIC STUDIES IN THE MONKEY (MACACA-MULATTA) WITH DIAZEPAM, NORDIAZEPAM AND RELATED 1,4 BENZODIAZEPINES.

001336 02-04 INFLUENCE OF SOME NEUROPSYCHOTROPIC DRUGS ON THE BEHAVIOURAL MODIFICATIONS INDUCED BY 3 ACETYLPYRIDINE IN

001358 02-04 SUBSTITUTED AMPHETAMINE DERIVATIVES. II. BEHAVIOURAL EFFECTS IN MICE RELATED TO MONOAMINERGIC NEURONES.

001429 02-04 NEUROMETABOLIC AND BEHAVIOURAL EFFECTS OF HALOPERIDOL IN RELATION TO DRUG LEVELS IN SERUM AND BRAIN.

001430 02-04 DIFFERENT BEHAVIOURAL PATTERNS INDUCED BY APOMORPHINE:
EVIDENCE THAT THE METHOD OF ADMINISTRATION DETERMINES THE
BEHAVIOURAL RESPONSE TO THE DRUG.

001533 02-06 MORPHINE AND ITS BIPHASIC INFLUENCE UPON PHARMACOLOGICALLY DISTINCT DOPAMINERGIC SYSTEMS WITHIN THE FELINE CAUDATE NUCLEUS: A BEHAVIOURAL STUDY.

001954 03-02 BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF HYPOXIC HYPOXIA IN RATS: STUDY OF THE PROTECTION AFFORDED BY ERGOT ALKALOIDS 001971 03-03

BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC/
ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH
NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA. 002220 03-04

Psychopharmacology Abstracts

BEHAVIOURAL SPECIFIC TOLERANCE FOLLOWING CHRONIC D OR L AMPHETAMINE TREATMENT: LACK OF INVOLVEMENT OF P-HYDROXYNOREPHEDRINE.

002261 03-04 COMPARATIVE STUDY OF THE ANTAGONISM OF BEMEGRIDE AND PICROTOXIN ON BEHAVIOURAL DEPRESSANT EFFECTS OF DIAZEPAM IN RATS AND MICE

002312 03-04 RELIABILITY OF TWO ACTIVITY BOXES COMMONLY USED TO ASSESS DRUG-INDUCED BEHAVIOURAL CHANGES.

002368 03-06 BEHAVIOURAL DESPAIR IN RATS: A NEW MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.

RECENT RESULTS OF BEHAVIOURAL TREATMENTS OF PHOBIAS AND OBSESSIONS.

002484 03-10
BEHAVIOURAL ANTAGONISM BETWEEN CHLORPROMAZINE AND NOISE IN

A BEHAVIOURAL AND BIOCHEMICAL COMPARISON OF DOPAMINE RECEPTOR BLOCKAGE PRODUCED BY HALOPERIDOL WITH THAT PRODUCED BY SUBSTITUTED BENZAMIDE DRUGS.

DRUG-MODULATED BEHAVIOURAL RESPONSES TO ENVIRONMENTAL ENRICHMENT.

003201 04-04 BEHAVIOURAL EFFECTS OF METHYLPHENIDATE IN 6 HYDROXYDOPAMINE TREATED NEONATAL RATS.

REPEATED EXPOSURE OF RATS TO THE CONVULSANT AGENT FLUROTHYL ENHANCES 5 HYDROXYTRYPTAMINE AND DOPAMINE MEDIATED BEHAVIOURAL RESPONSES.

THE CONTRIBUTION OF TRYPTAMINE TO THE BEHAVIOURAL EFFECTS OF L TRYPTOPHAN IN TRANYLCYPROMINE TREATED RATS.

NONREPRODUCIBILITY OF THE BEHAVIOURAL EFFECTS INDUCED BY

BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE EFFECTS
AFTER INTRACEREBRAL INFUSION OF TRH IN FOWLS.

TOLERANCE TO THE BEHAVIOURAL EFFECTS OF PHYSOSTIGMINE IN RATS: LACK OF IMPORTANCE OF BEHAVIOURAL COMPENSATION.

003326 04-04 BEHAVIOURAL AND NEUROCHEMICAL EFFECTS OF REPEATED ADMINISTRATION OF COCAINE IN RATS.

003346 04-04 THE BEHAVIOURAL ACTIONS OF THE HYPOTHALAMIC PEPTIDES: A 003651 04-15

MARGARET B. -- A TYPICAL BELLEVUE CASE.

002732 03-17

000355 01-04

ALCOHOL-DISCRIMINATION IN GERBILS: INTERACTIONS WITH BEMEGRIDE, DH-524, AMPHETAMINE, AND DELTA9-THC.

001385 02-04 COMPARATIVE STUDY OF THE ANTAGONISM OF BEMEGRIDE AND PICROTOXIN ON BEHAVIOURAL DEPRESSANT EFFECTS OF DIAZEPAM IN RATS AND MICE.

002312 03-04 ANTAGONISM OF PENTOBARBITAL DISCRIMINATIVE STIMULUS BY BEMEGRIDE IN IMMOBILIZED RATS.

003266 04-04 BENEFICIAL
BENEFICIAL EFFECT OF ISOLEUCINE ON FETAL BRAIN DEVELOPMENT IN

INDUCED PHENYLKETONURIA. 002846 04-03

BENSERAZIDE
EFFECTS OF BENSERAZIDE ON TRYPTOPHAN METABOLISM IN THE MOUSE
000054 01.0 000054 01-03 A CONTROLLED STUDY OF TRYPTOPHAN BENSERAZIDE IN SCHIZOPHRENIA.

003451 04-08

INTERACTIONS OF SUBSTITUTED BENZAMIDE DRUGS WITH CEREBRAL DOPAMINE PATHWAYS.

A BEHAVIOURAL AND BIOCHEMICAL COMPARISON OF DOPAMINE RECEPTOR BLOCKAGE PRODUCED BY HALOPERIDOL WITH THAT PRODUCED BY SUBSTITUTED BENZAMIDE DRUGS. 002963 04-03

EFFECT OF SUBSTITUTED BENZAMIDE DRUGS ON RAT STRIATAL TYROSINE-HYDROXYLASE.

003018 04-03 SUBSTITUTED BENZAMIDES AS CEREBRAL DOPAMINE ANTAGONISTS IN

VOLUME 16, SUBJECT INDEX

PRESYNAPTIC AND POSTSYNAPTIC EFFECTS OF SULPIRIDE AND OTHER SUBSTITUTED BENZAMIDES.

002099 03-03

BENZAMIDES AND CLASSICAL NEUROLEPTICS: COMPARISON OF THEIR ACTIONS USING 6 APOMORPHINE-INDUCED EFFECTS.

003333 04-04

BENZAZEPINE EFFECTS OF BENZAZEPINE (SCH-12679) ON SHOCK-INDUCED FIGHTING AND LOCOMOTOR BEHAVIOR IN RATS.

003166 04-04

EFFECTIVENESS OF SCH-12679, A BENZAZEPINE, IN THE TREATMENT OF ANXIETY NEUROSIS.

003541 04-10

BENZAZOCINE-AMIDINIUM-NITRONATES

3 BENZAZOCINE-AMIDINIUM-NITRONATES. AN UNUSUAL TYPE OF OPIATE ANTAGONIST

001951 03-01

BENZHYDRYL

BENZHYDRYL PIPERAZINES: A NEUROPHARMACOLOGICAL AND PSYCHOPHARMACOLOGICAL EVALUATION. (PH.D. DISSERTATION) 001427 02-04

QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS OF BIOLOGICALLY ACTIVE INDOLE, 1 METHYLINDOLE AND BENZO-B-THIOPHENE

000006 01-01

RENZOCYCLOHEPTENE-PIRIDINE

SYNTHESIS AND STEREOSPECIFIC ANTIPSYCHOTIC ACTIVITY OF BENZOCYCLOHEPTENE-PIRIDINE.

001949 03-01

BENZODIAZEPIN-2-ONE5

ELECTRONIC FACTORS IN THE STRUCTURE-ACTIVITY RELATIONSHIP OF SOME 1,4 BENZODIAZEPIN-2-ONES.

BENZODIAZEPINE ACTIVITY: IS INTERACTION WITH THE GLYCINE RECEPTOR, AS EVIDENCED BY DISPLACEMENT OF STRYCHNINE BINDING, A USEFUL CRITERION?.

000151 01-03

ENZYMIC DEALKYLATION OF A SUBSTITUTED

AMINOACETAMIDOBENZOPHENONE AND CYCLIZATION TO THE
CORRESPONDING BENZODIAZEPINE IN VITRO.

000152 01-03

THE METABOLISM OF A SUBSTITUTED AMINOACETAMIDOBENZOPHENONE AND CYCLIZATION TO THE CORRESPONDING BENZODIAZEPINE IN THE RAT IN VIVO.

000242 01-03 SOME OBSERVATIONS ON THE MECHANISM OF BENZODIAZEPINE

BARBITURATE INTERACTIONS IN THE MOUSE. NEURAL MECHANISMS OF BENZODIAZEPINE ACTIONS

000335 01-04

000594 01-10 EFFECT OF A NEW BENZODIAZEPINE DERIVATE, CLOBAZAM, IN ANXIOUS PATIENTS WITH GASTROINTESTINAL DISORDERS.

000604 01-10 INFLUENCE OF DISULFIRAM AND DISEASE ON BENZODIAZEPINE

DISPOSITION 000738 01-13 THE EFFECT OF A NEW BENZODIAZEPINE ON THE POLYGRAPHICALLY

MONITORED SLEEP OF NORMAL VOLUNTEERS 000765 01-14 CLINICAL IMPLICATIONS OF BENZODIAZEPINE PHARMACOKINETICS.

000985 01-17 BENZODIAZEPINE RECEPTOR: DEMONSTRATION IN THE CENTRAL-NERVOUS-SYSTEM

001198 02-03 HIGH DENSITIES OF BENZODIAZEPINE RECEPTORS IN HUMAN CORTICAL

AREAS 001645 02-13 A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE
DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON
SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR

PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION 001787 02-15 ONTOGENETIC DEVELOPMENT OF BENZODIAZEPINE RECEPTORS IN THE

RAT BRAIN 002840 04-03 FACILITATION OF BENZODIAZEPINE BINDING BY SODIUM-CHLORIDE AND

GABA 003002 04-03 DIFFERENCES IN BENZODIAZEPINE RECEPTOR BINDING IN MAUDSLEY

REACTIVE AND MAUDSLEY NONREACTIVE RATS. 003066 04-03 THE PSYCHOPHARMACOLOGICAL PROPERTIES OF PINAZEPAM, A NEW

BENZODIAZEPINE DERIVATIVE. 003357 04-04 THE TREATMENT OF ANXIETY WITH A POLYFLUORINATED BENZODIAZEPINE DERIVATIVE.

003445 04-07

Subject Index

THE EFFECTS OF A NEW BENZODIAZEPINE DERIVATIVE, ID-540, ON THE AVERAGED PHOTOPALPEBRAL REFLEX IN MAN.

003610 04-13

SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM EVALUATION OF SOME 5 ALKOXY-3H-1,4 BENZODIAZEPINES.

000021 01-02 KINETICS AND MECHANISMS OF HYDROLYSIS OF 1 4 BENZODIAZEPINES III: NITRAZEPAM.

ARE BENZODIAZEPINES GABA-ANTAGONISTS?

000137 01-03

000170 01-63 DO BENZODIAZEPINES AFFECT MOTOR OR SENSORY MECHANISMS?. 000250 01-03

BENZODIAZEPINES, BARBITURATES, AND HIPPOCAMPAL NHIBITION 000300 01-03

EFFECT OF BENZODIAZEPINES ON CENTRAL SEROTONERGIC NEURON SYSTEMS.

BENZODIAZEPINES: BEHAVIORAL AND NEUROCHEMICAL MECHANISMS. 000455 01-04

WHY PHYSICIANS PRESCRIBE BENZODIAZEPINES IN ESSENTIAL HYPERTENSION: A PHASE IV STUDY.

000667 01-11 BRAIN MECHANISMS ASSOCIATED WITH THERAPEUTIC ACTIONS OF BENZODIAZEPINES: FOCUS ON NEUROTRANSMITTERS.

000741 01-13 DISPOSITION OF THREE BENZODIAZEPINES AFTER SINGLE ORAL ADMINISTRATION IN MAN.

000745 01-13 THE EXTRACTION AND ANALYSIS OF BENZODIAZEPINES IN TISSUES BY ENZYMIC DIGESTION AND HIGH-PERFORMANCE LIQUID

CHROMATOGRAPHY 000928 01-16
THE ROLE OF BENZODIAZEPINES IN NONPSYCHIATRIC MEDICAL PRACTICE.
000960 01-17

BENZODIAZEPINES

000986 01-17 HOW RENZODIAZEPINES WORK

000996 01-17 CENTRAL-NERVOUS-SYSTEM ACTIVITY OF A NOVEL CLASS OF ANNELATED 1,4 BENZODIAZEPINES, AMINOMETHYLENE-

001000 02-01 QUINAZOLINES AND 1,4 BENZODIAZEPINES. 81. S TRIAZOLOBENZODIAZEPINES BY OXIDATIVE CYCLIZATION OF

HYDRAZONES 001017 02-01

QUINAZOLINES AND 1,4 BENZODIAZEPINES. 82. 5 PYRIMIDYL AND 5 PYRAZINYLBENZODIAZEPINES.

001022 02-02 BURST FIRING OF CEREBELLAR PURKINJE NEURONES INDUCED BY BENZODIA ZEPINES.

001061 02-03 SPECTRAL ANALYSIS OF THE DIFFERING EEG EFFECTS OF BENZODIAZEPINES, MEPROBAMATE, GLUTETHIANDE AND AMOBARBITAL IN MACACA-MULATTA.

001130 02-03 HYDROXYLATION OF THREE RENZODIAZEPINES IN VITRO.

001201 02-03 ELECTROSHOCK ANTICONVULSANT ACTIVITY AND BRAIN ACETYLCHOLINE ALTERATIONS IN MICE TREATED WITH SELECT BENZODIAZEPINES. 001210 02-03

EFFECTS OF BENZODIAZEPINES ON PGO FIRINGS AND MULTIPLE UNIT ACTIVITY IN THE MIDBRAIN RETICULAR FORMATION IN CATS.

001265 02-03 BEHAVIOURAL AND PHARMACOKINETIC STUDIES IN THE MONKEY
(MACACA-MULATTA) WITH DIAZEPAM, NORDIAZEPAM AND RELATED 4 BENZODIAZEPINES. 001336 02-04

BEHAVIORAL EFFECTS OF BENZODIAZEPINES: A REVIEW 001340 02-04

SEQUELAE AFTER THE INTRAVENOUS INJECTION OF THREE BENZODIAZEPINES — DIAZEPAM, LORAZEPAM, AND FLUNITRAZEPA 001785 02-15

BLOOD LEVEL MONITORING OF BENZODIAZEPINES BY GLC USING NITROGEN SENSITIVE DETECTORS. 001860 02-16

THE BENZODIAZEPINES: PRO OR CON. 001898 02-17

SELECTION AMONG BENZODIAZEPINES FOR ALCOHOL WITHDRAWAI 001906 02-17 ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY

002326 03-04

002506 03-11

RENZODIA ZEPINES THE USE BENZODIAZEPINES IN PRISON POPULATIONS

BIOCHEMICAL IDENTIFICATION OF THE SITE OF ACTION OF BENZODIAZEPINES IN HUMAN BRAIN BY H3-DIAZEPAM BINDING 002583 03-13 PATTERNS OF THE USE OF BENZODIAZEPINES IN AUSTRALIA

APPLICATION OF LIFE TABLE METHOD TO NATURALISTIC DESIGNS — A COMPARISON OF EFFICACY OF TRICYCLIC ANTIDEPRESSANTS AND BENZODIAZEPINES IN AMBULATORY DEPRESSIVES.

BENZODIAZEPINES AND BEHAVIORAL EFFECTS OF REWARD (WATER)
OMISSION IN THE RAT.

003364 04-04 COMPARISON OF THE EFFECT OF SOME BENZODIAZEPINES WITH THE STAIRCASE METHOD. 003404 04-04

BENZODIOXANES
A COMPARATIVE STUDY ON THE PRESYNAPTIC AND POSTSYNAPTIC
ALPHA BLOCKING ACTIVITY OF A SERIES OF BENZODIOXANES.
002972 04-03

BENZONAPHTYRIDONE

EFFECTS OF IFC-45, A NEW BENZONAPHTYRIDONE DERIVATIVE WITH

ANTIDEPRESSIVE ACTION, ON ACTIVITY OF THE RAT SUPRARENAL

GLAND CORTEX.

INTRAOCULAR PRESSURE LOWERING PROPERTIES OF ABBOTT-43981, A CANNABINOID DERIVED HETEROCYCLIC BENZOPYRAN WITH MINIMAL CNS ACTIVITIES.

001025 02-02 BENZOQUINOLIZINE
A BENZOQUINOLIZINE DERIVATIVE WITH A NEUROLEPTIC-LIKE ACTION ON CEREBRAL MONOAMINE TURNOVER.

001037 02-02

BENZOTROPINE
CYCLOBENZAPRINE AND BENZOTROPINE METHANESULFONATE IN
PARKINSONS DISEASE: A RANDOMIZED DOUBLE-BLIND CROSS-OVER

000654 01-11

BENZTROPINE

AMANTADINE IN THE TREATMENT OF BENZTROPINE REFRACTORY
EXTRAPYRAMIDAL DISORDERS INDUCED BY ANTIPSYCHOTIC DRUGS.

002664 03-15

BEMZTROPINE-MESYLATE
THE EFFECT OF BENZTROPINE-MESYLATE IN THE RABBIT SYNDROME AND
TARDIVE-DYSKINESIA.

BENZYDAMINE EFFECTS OF BENZYDAMINE ON THE BIOELECTRIC ACTIVITY OF THE RABBIT BRAIN.

001998 03-03 3,4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3 AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND

000035 01-02

BENZYLAMPHETAMINE
IDENTIFICATION OF THE IN VITRO N OXIDIZED METABOLITES OF ()- AND
(-) N BENZYLAMPHETAMINE.

THE PRODUCTION OF AN ALTERNATIVE LABORATORY MODEL OF THE PARKINSON SYNDROME USING A NEW BENZYLIMIDOYLUREA DERIVATIVE LON-954. 000083 01-03

A-ACTIVITY
ABSENCE OF DRUG-INDUCED BETA-ACTIVITY IN THE
ELECTROENCEPHALOGRAM: A SIGN OF SEVERE CEREBRAL MAPAIRMENT

001676 02-13 A-ADRENERGE DIRECT EVIDENCE FOR AN INTERACTION OF BETA-ADRENERGIC BLOCKERS WITH THE 5-HT RECEPTOR.

000010 01-01

DEVELOPMENT OF BETA-ADRENERGIC RECEPTOR SUBSENSITIVITY BY ANTIDEPRESSANTS. 000049 01-03 DIRECT INTERACTION OF LSD WITH CENTRAL BETA-ADRENERGIC

RECEPTORS 002005 03-03

BETA-ADRENERGIC RECEPTOR MEDIATED CYCLIC-AMP SYNTHESIS IN BROKEN-CELL HOMOGENATES OF RAT BRAIN. 002033 03-03 CHARACTERIZATION OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS IN MEMBRANES PREPARED FROM THE RABBIT IRIS BEFORE AND AFTER DEVELOPMENT OF SUPERSENSITIVITY.

EXPERIMENTAL AND CLINICAL EVIDENCE OF THE ANTIDEPRESSANT EFFECT OF A BETA-ADRENERGIC STIMULANT.

003546 04-10

Psychopharmacology Abstracts

BETA-ADRENOCEPTOR BLOCKING DRUGS.

001925 02-17

BETA-ADRENOCEPTORS
BETA-ADRENOCEPTORS MODULATE NORADRENALINE RELEASE FROM
AXONAL SPROUTS IN CULTURED RAT SUPERIOR CERVICAL GANGLIA.
002179 03-03

STIMULATION OF PRESYNAPTIC BETA-ADRENOCEPTORS ENHANCES H3-NORADRENALINE RELEASE DURING NERVE STIMULATION IN THE PERFUSED CAT SPLEEN.

002855 04-03

LBLOCKING
PSYCHIATRIC AND NEUROLOGICAL APPLICATIONS OF BETA-BLOCKING
AGENTS.

000596 01-10 BETA-BLOCKING SUBSTANCES IN PSYCHIATRIC CHEMOTHERAPY. 002462 03-09

A-BUNGAROTOXIN

EFFECTS OF BETA-BUNGAROTOXIN, DIPHENYLHYDANTOIN AND

METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT
CATIONS AND HIGH-ENERGY PHOSPHAT? CONTENTS OF BRAIN SLICES.

000278 01-03

VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF 2
AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF NAD:NADH AND
NORELEAGNINE A BETA-CARBOLINE DERIVATIVE.

000200 01-03

A-CARBOLINES
MONOAMINE-OXIDASE INHIBITION IN BRAIN AND LIVER PRODUCED BY
BETA-CARBOLINES: STRUCTURE-ACTIVITY RELATIONSHIPS AND

SUBSTRATE SPECIFICITY 000064 01-03

BETA-ENDORPHIN
BETA-ENDORPHIN INHIBITS ACH TURNOVER IN NUCLEI OF RAT BRAIN 000012 01-01 STIMULATION OF FOOD INTAKE BY MUSCIMOL AND BETA-ENDORPHIN 000023 01-02

PHARMACOLOGIC ACTIVITY OF BETA-ENDORPHIN IN MAN 000507 01-07 CATALEPTOGENIC PROPERTIES OF BETA-ENDORPHIN

EFFECT OF BETA-ENDORPHIN ON STRIATAL DOPAMINE METABOLISM.
001269 02-03

BETA-ENDORPHIN: DOSE-DEPENDENT SUPPRESSION OF FIXED-RATIO

001402 02-04 INFLUENCE OF BETA-ENDORPHIN ON EXPLORATORY, SOCIAL AND SEXUAL BEHAVIOUR IN THE MALE RAT.

001418 02-04 EFFECTS OF THYROTROPIN-RELEASING HORMONE ON BEHAVIORAL AND HORMONAL CHANGES INDUCED BY BETA-ENDORPHIN.

001471 02-04 RADIOIMMUNOASSAYS FOR BETA-ENDORPHIN: COMPARISON OF PROPERTIES OF TWO ANTISERA.

002724 03-16 LOCAL CEREBRAL GLUCOSE UTILIZATION FOLLOWING INJECTION OF BETA-**ENDORPHIN INTO PERIAQUEDUCTAL GRAY MATTER IN THE RAT** 003073 04-03

BETA-ENDORPHIN AND THE NARCOTIC CUE 003179 04-04

THE ANALGESIC ACTIVITY OF HUMAN BETA-ENDORPHIN IN MAN 003598 04-13 BETA-ENDORPHIN-INDUCED
BETA-ENDORPHIN-INDUCED CHANGES IN SCHIZOPHRENIC AND DEPRESSED

PATIENTS 000775 01-14

BETA-N-OXALYL-L-ALPHA-BETA-DIAMINOPROPIONIC-ACID ENTRY OF BETA-N-OXALYL-L-ALPHA-BETA-DIAMINOPROPIONIC-ACID, THE LATHYRUS-SATIVUS NEUROTOXIN INTO THE CENTRAL-NERVOUS-SYSTEM OF THE ADULT RAT, CHICK AND THE RHESUS MONKEY. 003061 04-03

DETA-PHENETHYLAMINE
CHARACTERISTICS OF BETA-PHENETHYLAMINE SELF-ADMINISTRATION BY 000439 01-04

N-PHENETHYLAMINES
CACTUS ALKALOIDS XXXIII: BETA-PHENETHYLAMINES FROM THE
GUATEMALAN CACTUS PILOSOCEREUS-MAXONII. 001011 02-01

BETA-PHENYLETHYLAMINE
TESTOSTERONE ATTENUATED STEREOTYPY AND HYPERACTIVITY INDUCED
BY BETA-PHENYLETHYLAMINE IN PARGYLINE PRETREATED RATS. 003224 04-04

BETA-PHENYLETHYLAMINES

AGONIST EFFECTS OF BETA-PHENYLETHYLAMINES ON THE

NORADRENERGIC CYCLIC-ADENOSINE-MONOPHOSPHATE GENERATING
SYSTEM IN RAT LIMBIC FOREBRAIN. 3,5-MONOPHOSPHATE
GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. STEREOISOMERS OF
P-HYDROXYNOREPHEDRINE. 000272 01-03

BETA-RECEPTORS

ADRENERGIC ALPHA-RECEPTORS AND BETA-RECEPTORS EXPRESSED BY THE SAME CELL TYPE IN PRIMARY CULTURE OF PERINATAL MOUSE

RETAHISTINE

RHEOENCEPHALOGRAPHIC AND OTHER STUDIES OF BETAHISTINE IN HUMANS. IV. PROLONGED ADMINISTRATION WITH IMPROVEMENT IN ARTERIOSCLEROTIC DEMENTIA.

002530 03-11

BETAMETHASONE

THE EFFECTS OF ETHER STRESS AND BETAMETHASONE TREATMENT ON THE CONCENTRATIONS OF NORADRENALINE AND DOPAMINE IN VARIOUS REGIONS OF THE RAT BRAIN.

000288 01-03

BIBLIOGRAPHY

BIBLIOGRAPHY ON TARDIVE-DYSKINESIA SINCE CTB-TDN, VOLUME 2,

000811 01-15

MARIJUANA AND HUMAN PERFORMANCE: AN ANNOTATED BIBLIOGRAPHY (1970-1975).

PHENCYCLIDINE: A BIBLIOGRAPHY OF BIOMEDICAL AND BEHAVIORAL

003699 04-17

BIBLIOMETRIC

ADVERSE REACTIONS LITERATURE: A BIBLIOMETRIC ANALYSIS 000999 01-17

BICUCULLINE
NEGATIVE EFFECTS OF BICUCULLINE AND THIOSEMICARBAZIDE ON THE TRANQUILLIZING ACTION OF DIAZEPAM.

001213 02-03 THE CEREBROVASCULAR PERMEABILITY TO PROTEIN AFTER BICUCULLINE AND AMPHETAMINE ADMINISTRATION IN SPONTANEOUSLY HYPERTENSIVE RATS

EFFECT OF SUBACUTE DIAZEPAM ADMINISTRATION IN MICE ON THE SUBSEQUENT ABILITY OF DIAZEPAM TO PROTECT AGAINST METRAZOL AND BICUCULLINE-INDUCED CONVULSIONS.

002053 03-03

BICYCLIC PHOSPHORUS ESTERS INCREASE THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM.

000009 01-01

BEHAVIORAL EFFECTS OF NEUROLEPTICS, APOMORPHINE AND AMPHETAMINE AFTER BILATERAL LESION OF THE LOCUS-COERULEUS IN 001393 02-04

NEUROPATHY ASSOCIATED WITH AMITRIPTYLINE: BILATERAL FOOTDROP 001753 02-15

SPONTANEOUS AND AMPHETAMINE-INDUCED BEHAVIOR AFTER BILATERAL INJECTION OF ETHANOLAMINE-O-SULFATE INTO THE SURSTANTIA-NIGRA

002262 03-04

QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P 450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3 METHYCHOLANTHRENE.

002083 03-03

BIMODAL

BIMODAL DISTRIBUTIONS OF HIGHEST ETHANOL ACCEPTANCE CONCENTRATIONS IN TWO STRAINS OF RATS. 003229 04-04

MEMBRANE LIPIDS AS INTRACELLULAR BINDERS OF CHLORPROMAZINE AND RELATED DRUGS. 000095 01-03

ROLE OF PHOSPHOLIPIDS IN MUSCARINIC BINDING BY NEURAL MEMBRANES.

000044 01-03 DOPAMINE RECEPTOR BINDING ENHANCEMENT ACCOMPANIES LESION-INDUCED BEHAVIORAL SUPERSENSITIVITY.

000084 01-03 SECOND MESSENGER RESPONSES AND REGULATION OF HIGH AFFINITY
RECEPTOR BINDING TO STUDY PHARMACOLOGICAL MODIFICATION OF GABAERGIC TRANSMISSION. (UNPUBLISHED PAPER).

000133 01-03 THE DEMONSTRATION IN VIVO OF SPECIFIC BINDING SITES FOR NEUROLEPTIC DRUGS IN MOUSE BRAIN.

000150 01-03 BENZODIAZEPINE ACTIVITY: IS INTERACTION WITH THE GLYCINE RECEPTOR, AS EVIDENCED BY DISPLACEMENT OF STRYCHNINE BINDING. A USEFUL CRITERION?

EFFECTS OF NA, K, MG AND CA ON THE SATURABLE BINDING OF (3H)DIHYDROMORPHINE AND (3H)NALOXONE IN VITRO. 000180 01-03 HIGH-AFFINITY BINDING OF H3-GLYCINE AND C14-BETA-ALANINE TO SYNAPTOSOMAL MITOCHONDRIAL FRACTIONS OF RAT CNS REGIONS; **EFFECTS OF STRYCHNINE**

000211 01-03 NEUROLEPTIC DRUG INTERACTIONS WITH NOREPINEPHRINE ALPHA RECEPTOR BINDING SITES IN RAT BRAIN.

SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION: A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL MEMBRANES FROM MATURE RAT BRAIN.

O00230 01-03

OF THE CAT BRAIN.

000264 01-03 THE EFFECT OF PH ON STEREOSPECIFIC OPIATE BINDING TO MOUSE BRAIN MEMBRANES

NOREPINEPHRINE ALPHA RECEPTOR BINDING IN MAMMALIAN CENTRAL-NERVOUS-SYSTEM: DIFFERENTIAL LABELING WITH AGONIST AND

TYRAMINE BINDING BY SYNAPTOSOMES FROM RAT BRAIN: EFFECT OF CENTRALLY ACTIVE DRUGS

000285 01-03 HALLUCINOGEN BINDING TO DOPAMINE/NEUROLEPTIC RECEPTORS.
000296 01-03
BINDING OF CODEINE, MORPHINE, AND METHADONE TO HUMAN SERUM

PROTFINS

000706 01-13 THE ELECTRONIC AND SEROTONIN RECEPTOR BINDING AFFINITY PROPERTIES OF N.N DIMETHYLTRYPTAMINE ANALOGS

001002 02-01 IN VIVO BINDING OF H3-PIMOZIDE IN MOUSE STRIATUM: EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS.

001050 02-03 COMPETITIVE BINDING BETWEEN COCAINE AND VARIOUS DRUGS TO SYNTHETIC LEVODOPA MELANIN

001051 02-03 COMPARATIVE INHIBITORY EFFECTS OF SYNTHETIC ENKEPHALINS ON THE STEREOSPECIFIC BINDING OF H3-DIHYDROMORPHINE AND H3-

001076 02-03 SPECIFICITY OF BINDING OF ANTIPSYCHOTICS TO THE ACTIVATOR OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE.

CALCIUM CONTENT AND BINDING IN SYNAPTOSOMAL SUBFRACTIONS DURING CHRONIC MORPHINE TREATMENT.

PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EMBRYOPATHIC EFFECT AND COVALENT BINDING OF PUTATIVE ARENE OXIDE METABOLITE IN GESTATIONAL TISSUE.

COMPARATIVE AVAILABILITY OF DIAZEPAM (D) IN HUMAN PLASMA
(P), PAROTID SALIVA (PS) AND MIXED SALIVA (MS) AND ITS
RELATIONSHIP TO PLASMA PROTEIN BINDING.

H3-HALOPERIDOL BINDING TO DOPAMINE RECEPTORS IN RAT CORPUS-STRIATUM: INFLUENCE OF CHLORPROMAZINE METABOLITES AND

001995 03-03 NALOXONE AS A GABA-ANTAGONIST: EVIDENCE FROM IONTOPHORETIC, RECEPTOR BINDING AND CONVULSANT STUDIES.

002003 03-03 BINDING INTERACTIONS OF ERGOT ALKALOIDS WITH MONOAMINERGIC DECEPTORS IN THE REAIN

002024 03-03 ALPHA-NORADRENERGIC RECEPTORS IN THE BRAIN: DIFFERENTIAL EFFECTS OF SODIUM ON BINDING OF H3-AGONISTS AND H3-

EVIDENCE FOR THE EXISTENCE OF SPECIFIC CANNABINOID BINDING SITES.
002034 03-03 BINDING OF ANTIPSYCHOTIC AGENTS TO THE CYCLIC-NUCLEOTIDE

002076 03-03 EFFECT OF ERGOT ALKALOIDS AND OF NEUROLEPTICS ON BINDING TO PUTATIVE DOPAMINE AND ALPHA RECEPTORS.

002078 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 1. KINETICS AND CHARACTERISTICS OF IN VITRO BINDING.

002079 03-03 AUTORADIOGRAPHIC LOCALIZATION OF H3-RESERPINE BINDING SITES IN

002106 03-03 THE OPIATE RECEPTOR BINDING INTERACTIONS OF H3-METHIONINE-ENKEPHALIN, AN OPIOID PEPTIDE.

002155 03-03 DOPAMINE BINDING FOLLOWING PROLONGED HALOPERIDOL PRETREATMENT

002345 03-05

QUANTITATION OF BINDING OF H3-CHLORPROMAZINE TO SYNTHETIC MELANINS AND MELANIN GRANULES.

002354 03-05 THE BINDING OF INHIBITORS OF SEROTONIN UPTAKE TO BIOLOGICAL RECEPTORS

002562 03-13 BIOCHEMICAL IDENTIFICATION OF THE SITE OF ACTION OF BENZODIAZEPINES IN HUMAN BRAIN BY H3-DIAZEPAM BINDING

002583 03-13 EVIDENCE FOR AN ENDOGENOUS FACTOR INTERFERING DIAZEPAM BINDING TO RAT BRAIN MEMBRANES. WITH H3-

002789 04-01 THE ROLE OF SUBSTRATE LIPOPHILICITY IN DETERMINING TYPE 1 MICROSOMAL P450 BINDING CHARACTERISTICS.

002809 04-03 TWO BINDING SITES FOR H3-SPIROPERIDOL ON RAT STRIATAL MEMBRANES.

002843 04-03 HISTAMINE H2-RECEPTOR BINDING WITH H3-CIMETIDINE IN BRAIN. 002848 04-03

EFFECTS OF SOME DERIVATIVES OF 2 AMINOTETRALIN ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE AND ON THE BINDING OF H3-HALOPERIDOL TO NEUROLEPTIC RECEPTORS IN RAT STRIATUM.

SUBCELLULAR DISTRIBUTION OF ETORPHINE IN RAT BRAIN AND EVIDENCE FOR IN VIVO STEREOSPECIFIC BINDING.

O02856 04-03
ANGIOTENSIN BINDING AFFINITY AND CAPACITY IN THE MIDBRAIN AREA
OF SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS. 002870 04-03

DOPAMINE RECEPTOR BINDING OF H3-ADTN (2 AMINODIHYDROXYTETRAHYDRONAPHTHALENE) REGULATED BY GUANYL-NUCLEOTIDES.

002877 04-03 BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101 BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN RAT CEREBRAL-CORTEX.

002885 04-03 SOLUBILIZATION OF H3-SPIPERONE BINDING SITES FROM RAT BRAIN 002929 04-03

H3-CLOZAPINE BINDING TO RAT BRAIN MEMBRANES

THE EFFECTS OF STANDARD NEUROLEPTIC COMPOUNDS ON THE BINDING OF H3-SPIROPERIDOL IN THE STRIATUM AND MESOLIMBIC SYSTEM OF THE RAT IN VITRO.

002955 04-03 SOME OBSERVATIONS ON THE BINDING PATTERNS OF ALPHA-BUNGAROTOXIN IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT

002956 04-03 002956 04

EFFECTS OF NEUROLEPTICS ON H3-HALOPERIDOL AND H3-CISFLUPENTHIXOL BINDING AND ON ADENYLATE-CYCLASE ACTIVITY IN
VITRO.

002957 04-03 STRUCTURE-ACTIVITY STUDIES ON THE INHIBITION OF GABA BINDING TO RAT BRAIN MEMBRANES BY MUSCIMOL AND RELATED COMPOUNDS.

002981 04-03 CHARACTERIZATION OF SPECIFIC IN VIVO BINDING OF NEUROLEPTIC DRUGS IN RAT BRAIN.

002985 04-03 CHRONIC NALOXONE RESULTS IN PROLONGED INCREASES IN OPIATE BINDING SITES IN BRAIN.

002986 04-03 DEMONSTRATION OF AN ENDOGENOUS, COMPETITIVE INHIBITOR(S) OF H3-DIAZEPAM BINDING IN BOVINE BRAIN.

002995 04-03 FACILITATION OF BENZODIAZEPINE BINDING BY SODIUM-CHLORIDE AND GABA

003002 04-03 STRYCHNINE BINDING ASSOCIATED WITH SYNAPTIC GLYCINE RECEPTORS IN RAT SPINAL CORD MEMBRANES: IONIC INFLUENCES.

003024 04-03 HIGH AFFINITY BINDING OF H3-HISTAMINE IN RAT BRAIN 003036 04-03

H3-SPIROPERIDOL BINDING TO TWO RECEPTOR SITES IN BOTH THE CORPUS-STRIATUM AND FRONTAL CORTEX OF RAT BRAIN.

003041 04-03 DOPAMINE ANTAGONIST BINDING: A SIGNIFICANT DECREASE WITH MORPHINE-DEPENDENCE IN THE RAT STRIATUM.

003052 04-03 DIFFERENCES IN BENZODIAZEPINE RECEPTOR BINDING IN MAUDSLEY REACTIVE AND MAUDSLEY NONREACTIVE RATS.

003066 04-03 INFLUENCE OF NEUROLEPTICS ON THE BINDING OF MET-ENKEPHALIN, MORPHINE AND DIHYDROMORPHINE TO SYNAPTOSOME ENRICHED FRACTIONS OF RAT BRAIN.

003096 04-03 HETEROGENEITY OF LSD DISPLACING FACTORS AND MULTIPLE TYPES OF HIGH AFFINITY LSD BINDING SITES.

H3-SPIROPERIDOL BINDING AND DOPAMINE STIMULATED ADENYLATE-CYCLASE: EVIDENCE FOR MULTIPLE CLASSES OF RECEPTORS IN PRIMATE BRAIN REGIONS.

TRICYCLIC ANTIDEPRESSANTS: THERAPEUTIC PROPERTIES AND AFFINITY
FOR ALPHA-NORADRENERGIC RECEPTOR BINDING SITES IN THE BRAIN.
003118 04-03 H3-CATECHOLAMINE BINDING TO ALPHA-RECEPTORS IN RAT BRAIN: ENHANCEMENT BY RESERPINE.

003119 04-03 THE EFFECT OF GAMMA-AMINOBUTYRIC-ACID ON H3-FLUNITRAZEPAM BINDING IN RAT BRAIN.

HIGH-AFFINITY H3-SEROTONIN BINDING TO CAUDATE: INHIBITION BY HALLUCINOGENS AND SEROTONINERGIC DRUGS.

003138 04-03 THE IN VIVO BINDING OF H3-DESIPRAMINE AND H3-CHLORPROMAZINE TO AREAS IN THE RAT BRAIN.

003145 04-03 IMPLICATIONS OF DOSE REGIMEN AND PROTEIN BINDING FOR PLASMA NORTRIPTYLINE ESTIMATIONS.

003547 04-10 BINDING OF PHENYTOIN, L TRYPTOPHAN AND O METHYL-RED TO ALBUMIN. UNEXPECTED EFFECT OF ALBUMIN CONCENTRATION ON THE BINDING OF PHENYTOIN AND L TRYPTOPHAN.

003588 04-13 BIOANALYSIS
BIOANALYSIS AND PHARMACOKINETICS OF CLOMIPRAMINE AND
DESMETHYLCLOMIPRAMINE IN MAN BY MEANS OF LIQUID

002728 03-16

COMPARATIVE BIOAVAILABILITY OF ORAL DOSAGE FORMS OF OXAZEPAM — CORRELATION WITH IN VITRO DISSOLUTION RATE

OXACEPAM — CORRELATION WITH IN VITRO DISSOLUTION RATE.
000727 01-13

CLASSIFICATION AND DETERMINATION OF CEREBRAL BIOAVAILABILITY
OF PSYCHOTROPIC DRUGS BY QUANTITATIVE PHARMACO-EEG AND
PSYCHOMETRIC INVESTIGATIONS (STUDIES WITH AX-A411-BS).
000931 01-16

SOLID DISPERSION APPROACH FOR OVERCOMING BIOAVAILABILITY PROBLEMS DUE TO POLYMORPHISM OF NABILONE. A CANNABINOID

BIOAVAILABILITY OF OXAZEPAM: ABSENCE OF INFLUENCE OF FOOD INTAKE

FACTORS AFFECTING THE BIOAVAILABILITY OF CHLOROTHIAZIDE IN MAN.

001674 02-13 BIOAVAILABILITY OF ORAL AND INTRAMUSCULAR PHENOBARBITAI 002600 03-13

BIOCHEMICAL BIOCHEMICAL DIFFERENTIATION OF AMPHETAMINE VS METHYLPHENIDATE AND NOMIFENSINE IN RATS.

000061 01-03 SOME OLD AND NEW THEORIES IN BIOCHEMICAL PSYCHIATRY

000190 01-03 EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT BRAIN: A BIOCHEMICAL STUDY.

000216 01-03 LONG-TERM BEHAVIOURAL AND BIOCHEMICAL EFFECTS FOLLOWING PROLONGED TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL)

000420 01-04 THE PREDICTIVE VALUE OF THE BIOCHEMICAL ACTION PROFILE OF **NEUROLEPTICS**

000551 01-08 BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF CHRONIC REDUCTION OF CEREBRAL NORADRENALINE RECEPTOR STIMULATION.

001099 02-03 BIOCHEMICAL DIFFERENTIATION OF AGGREGATING CELL CULTURES OF DIFFERENT FETAL RAT BRAIN REGIONS.

BIOCHEMICAL INTERACTION BETWEEN ANORECTIC DRUGS AND PIRIBEDIL. 001154 02-03

LONG-TERM CHANGES IN THE SENSITIVITY OF PRE- AND POSTSYNAPTIC DOPAMINE RECEPTORS IN MOUSE STRIATUM EVIDENCED BY BEHAVIORAL AND BIOCHEMICAL STUDIES.

001187 02-03 BIOCHEMICAL AND PHARMACOLOGICAL STUDIES ON AMINEPTINE (S-1694) AND () AMPHETAMINE IN THE RAT.

001236 02-03 A BIOCHEMICAL AND BEHAVIORAL ANALYSIS OF CHRONIC ALCOHOL CONSUMPTION BY RATS.

001362 02-04 RELATIONSHIPS BETWEEN CLINICAL AND BIOCHEMICAL EFFECTS OF MELPERONE AND THIOTHIXENE IN PSYCHOTIC WOMEN.

001557 02-08 LITHIUM THERAPY AND ALKALINE-EARTH METAL METABOLISM: A BIOCHEMICAL SCREENING STUDY.

001644 02-13

003099 04-03

EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 2. BIOCHEMICAL ANALYSIS. 001652 02-13

CLINICAL BIOCHEMICAL ASSESSMENT OF DRUG ACTION IN PATIENTS. 001668 02-13

SOME CONSIDERATIONS ON THE BIOCHEMICAL BASIS OF PSYCHOPHARMACOLOGY. (UNPUBLISHED PAPER).

001891 02-17 PHARMACOLOGICAL, BIOCHEMICAL AND CLINICAL EFFECTS OF 2 DIMETHYLAMINOETHANOL (DEANOL): A CRITICAL REVIEW.

001928 02-17 PSYCHOPHARMACOLOGY: A BIOCHEMICAL AND BEHAVIORAL

001929 02-17 BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF HYPOXIC HYPOXIA IN RATS: STUDY OF THE PROTECTION AFFORDED BY ERGOT ALKALOIDS 001971 03-03

CLINICAL AND BIOCHEMICAL CHANGES IN PSYCHOTIC WOMEN TREATED WITH MELPERONE OR THIOTHIXENE.

002388 03-08 CLINICAL AND BIOCHEMICAL EFFECTS OF CHLORPROMAZINE IN PSYCHOTIC PATIENTS: RELATIONS TO CHLORPROMAZINE CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID.

002538 03-11 BIOCHEMICAL IDENTIFICATION OF THE SITE OF ACTION OF

BENZODIAZEPINES IN HUMAN BRAIN BY H3-DIAZEPAM BINDING 002583 03-13 BIOCHEMICAL ACTIONS OF NEUROLEPTIC DRUGS: FOCUS ON THE

DOPAMINE RECEPTOR. 002738 03-17

BEHAVIORAL AND BIOCHEMICAL EFFECTS OF FK33-824, PARENTERALLY AND ORALLY ACTIVE ENKEPHALIN ANALOGUE (UNPUBLISHED PAPER).

002744 03-17 BIOCHEMICAL AND MORPHOLOGICAL EFFECTS OF TESTOSTERONE TREATMENT ON DEVELOPING SYMPATHETIC NEURONS.

002894 04-03 A BEHAVIOURAL AND BIOCHEMICAL COMPARISON OF DOPAMINE RECEPTOR BLOCKAGE PRODUCED BY HALOPERIDOL WITH THAT PRODUCED BY SUBSTITUTED BENZAMIDE DRUGS.

PHARMACOLOGICAL AND BIOCHEMICAL PROPERTIES OF ISOMERIC YOHIMBINE ALKALOIDS

002987 04-03 BIOCHEMICAL AND PHARMACOLOGICAL DIFFERENTIATION OF AFFECTIVE-DISORDERS: AN OVERVIEW.

003495 04-09 BIOCHEMICAL AND PHARMACOLOGICAL PREDICTORS.

003509 04-09 POSSIBLE BIOCHEMICAL BASIS OF MEMORY DISORDER IN ALZHEIMER

003575 04-11
BIOCHEMICAL EFFECTS IN MAN AND RAT OF THREE DRUGS WHICH CAN

INCREASE BRAIN GABA CONTENT. 003604 04-13

BIOCHEMICALLY-INDUCED CATECHOLAMINES AND BIOCHEMICALLY-INDUCED ABNORMAL

BEHAVIOUR IN RATS 000356 01-04

THE BIOCHEMISTRY OF BRAIN DEVELOPMENT AND MENTAL RETARDATION: THE ELEVENTH BLAKE MARSH LECTURE DELIVERED BEFORE THE ROYAL COLLEGE OF PSYCHIATRISTS, 7 FEBRUARY, 1977.
002000 03-03 THE BIOCHEMISTRY OF DEPRESSION.

BIOCHEMISTRY OF MENTAL DISORDERS: NEW VISTAS. 002781 03-17

BIOFLECTRIC A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND BIOELECTRIC CORRELATES OF EMOTIONAL REACTIONS ELICITED BY CHOLINERGIC STIMULATION OF THE HYPOTHALAMUS AND THE VENTRAL

001390 02-04 EFFECTS OF BENZYDAMINE ON THE BIOELECTRIC ACTIVITY OF THE RABBIT 001998 03-03

EFFECTS OF OROTIC-ACID AND PIRAZETAM ON CORTICAL BIOELECTRICAL ACTIVITY IN RABBITS.

000171 01-03 MANAGEMENT OF THE HYPERKINETIC SYNDROME WITH METHYLPHENIDATE AND SMR BIOFEEDBACK TRAINING.

001625 02-11 EFFECTS OF MYSOLINE AND DILANTIN ON THE EEG DURING SMR BIOFEEDBACK TRAINING OF A PSYCHOMOTOR EPILEPTIC: SINGLE CASE STUDY 001657 02-13 BIOFEEDBACK TREATMENT OF TARDIVE-DYSKINESIA: TWO CASE

SELF-REPORTED ALCOHOL AND NICOTINE USE AND THE ABILITY TO CONTROL OCCIPITAL EEG IN A BIOFEEDBACK SITUATION.

EFFECTS OF 3,4 DIHYDROOXAZINOINDOLES, POTENTIAL
ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS AND
RELATED ACTIVITIES.
000027 01-0

EFFECTS OF ORG-6582, CHLORIMIPRAMINE AND DESMETHYLIMIPRAMINE ON THE DEPLETION OF BIOGENIC AMINES FROM THE RAT BRAIN IN VIVO

UPTAKE INHIBITION OF BIOGENIC AMINES BY NEWER ANTIDEPRESSANT DRUGS: RELEVANCE TO THE DOPAMINE HYPOTHESIS OF DEPRESSION. 000232 01-03

ANTAGONISM OF BIOGENIC AMINE-INDUCED DEPRESSION OF CEREBRAL CORTICAL NEURONES BY NA-K-ATPASE INHIBITORS. 000254 01-03

STUDIES ON THE INFLUENCE OF BIOGENIC AMINES AND PSYCHOACTIVE DRUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMULATION TEST IN **ENDOGENOUS DEPRESSION** 000926 01-16

EFFECTS OF AMPHETAMINE ON BRAIN BIOGENIC AMINES IN ISOLATED AND AGGREGATED RATS

SUBSTITUTED AMPHETAMINE DERIVATIVES. I. EFFECT ON UPTAKE AND RELEASE OF BIOGENIC MONOAMINES AND ON MONOAMINE-OXIDASE IN THE MOUSE BRAIN.

001233 02-03 FACILITATION OF SIDMAN AVOIDANCE PERFORMANCE BY CHLOROAMPHETAMINE: ROLE OF BIOGENIC AMINES.

001467 02-04 IN VIVO EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE IN RAT BRAIN.

EFFECTS OF PARGYLINE ON HYPOTHALAMIC BIOGENIC AMINES AND SERUM PROLACTIN (PRL), LH AND TSH IN MALE RATS.

001988 03-03 EFFECTS OF SUBSTITUTED SPIROISOBENZOFURANPIPERIDINES ON SYNAPTOSOMAL BIOGENIC AMINE TRANSPORT.

EFFECT OF METABOLIC INHIBITORS AND OUABAIN ON AMPHETAMINE-INDUCED AND POTASSIUM-INDUCED RELEASE OF BIOGENIC AMINES FROM ISOLATED BRAIN TISSUE.

002142 03-03

EFFECTS OF BIOGENIC AMINES AND PSYCHOTROPIC DRUGS ON
ENDOGENOUS PROSTAGLANDIN BIOSYNTHESIS IN THE RAT BRAIN
HOMOGENATES HOMOGENATES

BROMOCRIPTINE, DIHYDROERGOTOXINE, METHYSERGIDE, D LSD, CF-25 397, AND CF-29-712: EFFECTS ON THE METABOLISM OF BIOGENIC AMINES IN THE BRAIN OF THE RAT.

002849 04-03 EFFECT OF GINSENG ON THE BRAIN BIOGENIC MONOAMINES AND 3.5 AMP SYSTEM: EXPERIMENTS ON RATS.

A DISORDER OF BIOGENIC AMINES IN DIHYDROPTERIDINE-REDUCTASE DEFICIENCY. 003554 04-11

DOSAGE EFFECTS OF IMIPRAMINE ON THE PSYCHOPATHOLOGIC AND BIOLOGIC INDICES OF ENDOGENOUS DEPRESSIVE SYNDROMES. 002494 03-10

A NEW SYNTHESIS OF 5 KETO-DIHYDROBENZOTHIAZEPINES AND A PRELIMINARY STUDY OF THEIR BIOLOGICAL PROPERTIES.

000016 01-02 A RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF BIOLOGICAL FLUID OR TISSUE.

000496 01-06 THE BIOLOGICAL SUBSTRATES OF SCHIZOPHRENIA

000535 01-08 PERSPECTIVES IN BIOLOGICAL PSYCHIATRY. PART 2: AFFECTIVE-DISORDERS.

000558 01-09 SYNTHESIS AND STEREOCHEMICAL STUDIES ON MEDICINAL AGENTS. BIOLOGICAL EVALUATION OF 6 AMINO DERIVATIVES OF NALOXONE AND NAITREYONE

SIMULTANEOUS DETERMINATION OF CODEINE AND MORPHINE IN
BIOLOGICAL SAMPLES BY GAS-CHROMATOGRAPHY WITH ELECTRON

001527 02-06
DEVELOPMENT AND APPLICATION OF METHODS FOR DETERMINING THE
BIOLOGICAL TRANSMETHIOLATIONS DEPENDENT ON \$ ADENOSYL-L-

001641 02-13

003044 04-03

002747 03-17

PERSPECTIVES IN BIOLOGICAL PSYCHIATRY. PART 3: SCHIZOPHRENIA AND ORGANIC-BRAIN-SYNDROME.

QUANTITATIVE ANALYSIS OF METHADONE IN BIOLOGICAL FLUIDS USING DEUTERIUM-LABELED METHADONE AND GLC CHEMICAL IONIZATION MASS SPECTROMETRY. 001862 02-16

NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: I. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY.

THE BINDING OF INHIBITORS OF SEROTONIN UPTAKE TO BIOLOGICAL

IS THERE A BIOLOGICAL BASIS FOR GERIATRIC PHARMACOTHERAPY?.
002742 03-17

BIOLOGICAL ACTIVITY OF NEUROTENSIN AND ITS C-TERMINAL PARTIAL SEQUENCES. 002973 04-03 PREDICTORS. 003551 04-11 PSYCHIATRIC DIAGNOSIS: EXPLORATION OF BIOLOGICAL F

QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS OF BIOLOGICALLY ACTIVE INDOLE, 1 METHYLINDOLE AND BENZO-B-THIOPHENE DERIVATIVES. 000006 01-01

CONTROL OF THE RAT OLFACTORY BULB ACTIVITY INDUCED BY BIOLOGICALLY SIGNIFICANT ODORS. 001324 02-04

DEPRESSION: BIOLOGY, PSYCHODYNAMICS, AND TREATMENT THE BIOLOGY OF AFFECTIVE-ILLNESS: AMINE NEUROTRANSMITTERS AND DRUG RESPONSE.

BIOMEDICAL
PHENCYCLIDINE: A BIBLIOGRAPHY OF BIOMEDICAL AND BEHAVIORAL RESEARCH. 003699 04-17

BIOSYNTHESIS
POLYAMINE BIOSYNTHESIS IN RAT PROSTATE. SUBSTRATE AND
INHIBITOR PROPERTIES OF 7 DEAZA ANALOGUES OF DECARBOXYLATED
S ADENOSYLMETHIONINE AND 5 METHYLTHIOADENOSINE.

000001 01-01

REGULATION OF CATECHOLAMINE BIOSYNTHESIS IN A TRANSPLANTABLE RAT PHEOCHROMOCYTOMA.

DIFFERENTIAL EFFECTS OF RESERPINE AND TETRABENAZINE ON RAT STRIATAL SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS AND SYNAPTOSOMAL DOPAMINE POOLS.

000172 01-03 EFFECTS OF BIOGENIC AMINES AND PSYCHOTROPIC DRUGS ON ENDOGENOUS PROSTAGLANDIN BIOSYNTHESIS IN THE RAT BRAIN HOMOGENATES

002145 03-03 EFFECT OF HYPOCHOLESTEROLEMIC AGENTS ON CENTRAL-NERVOUS SYSTEM CHOLESTEROL BIOSYNTHESIS. III. ZUCLOMIPHENE IN

COMBINATION WITH AY9944 AND TRIPARANOL 003058 04-03 NUTRITION AND CHEMICAL BIOTRANSFORMATIONS IN MAN

001651 02-13 TARDIVE-DYSKINESIA DURING AND FOLLOWING TREATMENT WITH HALOPERIDOL, HALOPERIDOL BIPERIDEN, THIORIDAZINE, AND

CLOZAPINE 003656 04-15

BIPHASIC EFFECTS OF M CHLOROPHENYL-PIPERAZINE IN 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN RAT BRAIN. PSILOCYBIN: BIPHASIC DOSE-RESPONSE EFFECTS ON THE ACOUSTIC STARTLE REFLEX IN THE RAT.

000345 01-04 NONCONTINGENT DISPLACEMENT OF CATECHOLAMINES BY
INTRAVENTRICULAR TYRAMINE: BIPHASIC DOSE-RESPONSE EFFECTS ON SELE-STIMILI ATION

000364 01-04 BIPHASIC EFFECTS OF APOMORPHINE ON LOCOMOTOR ACTIVITY IN

MORPHINE AND ITS BIPHASIC INFLUENCE UPON PHARMACOLOGICALLY DISTINCT DOPAMINERGIC SYSTEMS WITHIN THE FELINE CAUDATE NUCLEUS: A BEHAVIOURAL STUDY

001954 03-02 BIPHASIC EFFECTS OF AMPHETAMINE ON STRIATAL DOPAMINE DYNAMICS.

002064 03-03 BIPHASIC EFFECT OF CHLORPROMAZINE ON RAT PARADOXICAL SLEEP: A STUDY OF DOSE-RELATED MECHANISMS. 003253 04-04

BIPOLAR
MIANSERIN IN THE PROPHYLACTIC TREATMENT OF BIPOLAR AFFECTIVE-

A PSYCHOSOMATIC TRIAD IN A BIPOLAR PATIENT.

000589 01-09 LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR BLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE IN THE FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE PROBAND.

BIPOLAR MANIC-DEPRESSIVE DISORDER: A REASSESSMENT OF COURSE AND OUTCOME.

001608 02-09 CYPROHEPTADINE IN BIPOLAR AFFECTIVE-ILLNESS WITH CUSHINGOID FEATURES

002458 03-09 KLINEFELTERS SYNDROME AND BIPOLAR AFFECTIVE-ILLNESS: A CASE

003486 04-09 PRIMARY EMPTY SELLA SYNDROME AND BIPOLAR AFFECTIVE-ILLNESS:

CASE REPORT. 003511 04-09

BITING SCHEDULE-INDUCED BITING UNDER FIXED-INTERVAL SCHEDULES OF FOOD OR ELECTRIC-SHOCK PRESENTATION.

000348 01-04 FFERENTIAL ACTIVATION BY SOME 2 AMINOTETRALIN DERIVATIVES OF THE RECEPTOR MECHANISMS IN THE NUCLEUS-ACCUMBENS OF RAT WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITING.

001335 02-04 THE EFFECTS OF EXTENDED INSULIN DOSAGE ON TARGET-DIRECTED ATTACK AND BITING ELICITED BY TAILSHOCK.

003206 04-04

LSD-INDUCED STIMULUS CONTROL: A COMPARISON OF SCH-12679, FENFLURAMINE, P-METHOXYAMPHETAMINE, AND BL-3912. 003396 04-04

BL-3912A

FURTHER STUDIES ON BL-3912A: EFFECTS ON AVOIDANCE BEHAVIOR OF RATS WITH LOW BASELINES AND ON REACTION THRESHOLDS TO ELECTRIC FOOTSHOCK.

000461 01-0

000461 01-04

EFFECTS OF DEAFENING AND BLINDFOLDING ON AMPHETAMINE-INDUCED STEREOTYPY IN THE CAT. 000456 01-04

BLINDNESS
LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR BLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE IN THE FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE

000619 01-11

EYE BLINK AND SCHIZOPHRENIA: PSYCHOSIS OR TARDIVE-DYSKINESIA? 002703 03-15

BLOCK TRICYCLIC ANTIDEPRESSANT DRUGS BLOCK HISTAMINE H2 RECEPTOR IN

000128 01-03 A COMPARISON IN RABBIT ISOLATED HEARTS OF THE DYSRHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE, MAPROTILINE AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK NORADREMALINE UPTAKE.

ACETYLCHOLINE STIMULATION OF THE SYMPATHETIC GANGLIA: EFFECTS OF TAURINE AND NICOTINIC AND MUSCARINIC GANGLION BLOCK.

000146 01-03 ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE NEUROBLASTOMA CELLS.

000241 01-03 ANTIPSYCHOTIC DRUGS BLOCK LSD-INDUCED DISAGGREGATION OF BRAIN POLYSOMES.

ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002004 03-03 ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002137 03-03 NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND L-DOPA TO RATS

002942 04-03

81			

THE BLOCKADE OF SEROTONIN UPTAKE INTO SYNAPTOSOMES: RELATIONSHIP TO AN INTERACTION WITH MONOAMINE-OXIDASE

000268 01-03

BLOCKADE OF INTRACRANIAL SELF-STIMULATION BY ANTIPSYCHOTIC DRUGS: FAILURE TO CORRELATE WITH CENTRAL ALPHA-NORADRENERGIC BLOCKADE

000475 01-04 BLOCKADE OF SYNAPTOSOMAL CA UPTAKE BY OPIATES IN VITRO 001075 02-03

NAUTREXONE BLOCKADE OF MORPHINE-INDUCED ANTIDIURESIS IN THE

001162 02-03 HISTAMINE STIMULATED ADENYLATE-CYCLASE: BLOCKADE BY IMIPRAMINE AND ITS ANALOGUES.

001216 02-03 BLOCKADE BY PSYCHOTROPIC DRUGS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR IN CULTURED NERVE CELLS.

001223 02-03

ONSET AND OFFSET OF CHLORPROMAZINE BLOCKADE OF PHENYLEPHRINE, CARBAMYLCHOLINE AND HISTAMINE ON RABBIT STOMACH STRIPS

001234 02-03 ALPHA-ADRENOCEPTOR BLOCKADE BY TRICYCLIC ANTIDEPRESSANTS. 001244 02-03

DIAZEPAM BLOCKADE OF REPETITIVE ACTION POTENTIALS IN SKELETAL MUSCLE FIBRES: A MODEL OF ITS MEMBRANE ACTION. 001275 02-03

NARCOTIC BLOCKADE, LENGTH OF ADDICTION, AND PERSISTENCE OF INTRAVENOUS MORPHINE SELF-ADMINISTRATION IN RATS. 001322 02-04

THE PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS. A TEST OF DOPAMINERGIC BLOCKADE: NEUROENDOCRINE STUDIES IN NORMAL

001867 02-16 BLOCKADE OF PRESYNAPTIC ALPHA-RECEPTORS AND OF AMINE UPTAKE IN THE RAT BRAIN BY THE ANTIDEPRESSANT MIANSERINE

001945 03-03 BLOCKADE OF THE PICROTOXIN-INDUCED IN VIVO RELEASE OF DOPAMINE IN THE CAT CAUDATE NUCLEUS BY DIAZEPAM.

001989 03-03 A NEW MECHANISM OF TRICYCLIC ANTIDEPRESSANT ACTION. BLOCKADE OF PROSTAGLANDIN DEPENDENT CALCIUM MOVEMENTS.

002043 03-03 BLOCKADE OF P-METHOXYAMPHETAMINE-INDUCED SEROTONERGIC

EFFECTS BY CHLORIMIPRAMINE. 002166 03-03
BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE

RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE

002224 03-04 MESOLIMBIC DOPAMINE NEURONS: EFFECTS OF 6 HYDROXYDOPAMINI INDUCED DESTRUCTION AND RECEPTOR BLOCKADE ON DRUG-INDUCED ROTATION OF RATS

002258 03-04 PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS: AN APPROACH TO THE STUDY OF BRAIN DOPAMINE BLOCKADE IN HUMANS.

002590 03-13 MODIFICATION OF DREAM CONTENT AFTER PREFERENTIAL BLOCKADE OF MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS. 002619 03-14

NEUROLEPTIC BLOCKADE OF THE EFFECT OF VARIOUS NEUROTRANSMITTER SUBSTANCES.

002910 04-03 BLOCKADE OF BOTH PILOCARPINE AND AMPHETAMINE-INDUCED HEAD-SHAKING WITH DOPAMINE RECEPTOR ANTAGONISTS.

002951 04-03 SELECTIVE BLOCKADE OF DOPAMINE-INDUCED VASODILATION BY ERGONOVINE-MALEATE IN THE VASCULATURES OF DOGS AND

003067 04-03 BLOCKADE OF TESTOSTERONE MAINTAINED INTERMALE FIGHTING IN ALBINO LABORATORY MICE BY AN AROMATIZATION INHIBITOR 003176 04-04

LACK OF BLOCKADE OF CENTRAL DOPAMINERGIC RECEPTORS BY NARCOTICS: COMPARISON WITH CHLORPROMAZINE 003354 04-04

POSSIBLE INDICATION OF DOPAMINERGIC BLOCKADE IN MAN BY ELECTRORETINOGRAPHY. 003689 04-16

RIOCKAGE

BLOCKAGE OF PROGESTERONE-INDUCED RELEASE OF LUTEINIZING HORMONE AND PROLACTIN BY D AMPHETAMINE AND FENFLURAMINE 002006 03-03

CHANGES IN SYNAPTIC FUNCTION INDUCED BY BLOCKAGE OF AXONAL TRANSPORT IN THE RABBIT OPTIC PATHWAY. 002952 04-03 A BEHAVIOURAL AND BIOCHEMICAL COMPARISON OF DOPAMINE RECEPTOR BLOCKAGE PRODUCED BY HALOPERIDOL WITH THAT PRODUCED BY SUBSTITUTED BENZAMIDE DRUGS.

002963 04-03

BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE.

002224 03-04

002224 03-04

BLOCKERS DIRECT EVIDENCE FOR AN INTERACTION OF BETA-ADRENERGIC BLOCKERS

000010 01-01

STIMULUS EFFECTS OF DELTA9-THC AND ITS INTERACTION WITH NALTREXONE AND CATECHOLAMINE BLOCKERS IN RATS.

BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE.

BLOCKING

DOPAMINE RECEPTOR BLOCKING ACTIVITY OF THE SULPIRIDE IN THE

CENTRAL-NERVOUS-SYSTEM.

000024 01-02

EFFECTS OF ANTICHOLINERGIC AND CHOLINESTERASE BLOCKING DRUGS ON APPETITIVE BEHAVIOR UNDER DIFFERENT DEPRIVATION

REACTIVITY AND AGGRESSION IN THE RAT: INDUCTION BY ALPHA-ADRENERGIC BLOCKING AGENTS INJECTED VENTRAL TO ANTERIOR SEPTUM BUT NOT INTO LATERAL SEPTUM.

RETA-ADRENOCEPTOR BLOCKING DRUGS

000309 01-04 001925 02-17

003529 04-09

ANTAGONISM BY MIANSERIN AND CLASSICAL ALPHA-ADRENOCEPTOR BLOCKING DRUGS OF SOME CARDIOVASCULAR AND BEHAVIORAL EFFECTS OF CLONIDINE.

002138 03-03 A COMPARATIVE STUDY ON THE PRESYNAPTIC AND POSTSYNAPTIC ALPHA BLOCKING ACTIVITY OF A SERIES OF BENZODIOXANES. 002972 04-03

HALOPERIDOL AND LITHIUM BLOCKING OF THE MOOD RESPONSE TO INTRAVENOUS METHYLPHENIDATE.

BLOCKS

COLCHICINE BLOCKS NEUROTROPIC REGULATION OF THE RESTING MEMBRANE POTENTIAL IN REINNERVATING SKELETAL MUSCLE 000262 01-03

LERGOTRILE-MESYLATE: AN IN VIVO DOPAMINE AGONIST BLOCKS DOPAMINE RECEPTORS IN VITRO 001159 02-03

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): NALOXONE BLOCKS MORPHINES ACCELERATION OR PRESSING FOR ICS 001313 02-04

ALPHA-BUNGAROTOXIN BLOCKS REVERSIBLY CHOLINERGIC INHIBITION IN THE COCHLEA

002908 04-03 CLONIDINE BLOCKS ACUTE OPIATE WITHDRAWAL SYMPTOMS 003628 04-14

BLOOD ROLE OF LIVER CYTOSOLIC ALDEHYDE-DEHYDROGENASE ISOZYMES IN CONTROL OF BLOOD ACETALDEHYDE CONCENTRATIONS.

000222 01-03 SEROTONIN TRANSPORT AND STORAGE IN RABBIT BLOOD PLATELETS THE EFFECTS OF RESERPINE AND IMIPRAMINE

000236 01-03 EEG AND BLOOD PRESSURE EFFECTS OF TRH IN RABBITS.

000319 01-04 THE BLOOD (SERUM AND CORPUSCLE) DYNAMICS OF TRICYCLIC ANTIDEPRESSANTS.

000556 01-09 ON THE DISTRIBUTION OF DRUGS IN SALIVA AND BLOOD PLASMA. 000697 01-13

LITHIUM TRANSPORT IN RED BLOOD CELLS OF MANIC-DEPRESSIVE PATIENTS

THE RELATIONSHIP BETWEEN EXTRACELLULAR AND INTRACELLULAR LITHIUM CONCENTRATION IN HUMAN RED BLOOD CELLS: AN IN VITRO STUDY.

000731 01-13 PHARMACOGENETIC ASPECT OF RED BLOOD CELL LITHIUM INDEX IN MANIC-DEPRESSIVE PSYCHOSIS.

000736 01-13 REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF BROMIDE PSYCHOSIS 000800 01-15

UPTAKE OF 5 METHOXYTRYPTOLINE (6 MEO-TETRAHYDRO-BETA-CARBOLINE) BY BLOOD PLATELETS AND ITS EFFECT ON 5-HT UPTAKE 001043 02-03 EFFECTS OF PHENOBARBITAL AND DIAZEPAM ON IMIPRAMINE-INDUCED CHANGES IN BLOOD PRESSURE, HEART RATE AND RECTAL TEMPERATURE OF RATS.

COCAINE-INDUCED CENTRALLY MEDIATED RELEASE OF CATECHOLAMINES INTO BLOOD OF UNDISTURBED RATS. (UNPUBLISHED PAPER). 001079 02-03

DECREASE IN NEOSTRIATAL BLOOD FLOW AFTER D AMPHETAMINE ADMINISTRATION OR ELECTRICAL STIMULATION OF THE SUBSTANTIA-NIGRA.

001175 02-03 INDIRECT SYMPATHOMIMETICS AND CEREBRAL BLOOD FLOW AND

001189 02-03 THE EFFECT OF STEROID HORMONES ON CEREBRAL BLOOD FLOW BEFORE AND AFTER INTRACAROTID INFUSION OF 5 HYDROXYTRYPTAMINE.

DYNAMICS OF BLOOD NEUROTRANSMITTER LEVEL AS EVICENCE OF HIGHER NERVOUS ACTIVITY CHANGES DURING CHRONIC ADMINISTRATION OF SEDUXEN.

EEG, BLOOD LEVEL, AND BEHAVIORAL EFFECTS OF THE ANTIDEPRESSANT MIANSERIN (ORG-GB-94).

001545 02-07 IE PHARMACOKINETICS OF RED BLOOD CELL AND PLASMA BUTAPERAZINE CLINICAL RESPONSE AND SIDE-EFFECTS.

001561 02-08 AMITRIPTYLINE BLOOD LEVELS AND RELAPSE

001587 02-09

DRUGS AND DEPRESSION: DOSAGE AND BLOOD LEVEL MONITORING.
001595 02-09
FACTORS INFLUENCING BLOOD CONCENTRATIONS OF CHLORDIAZEPOXIDE:
A USE OF MULTIPLE REGRESSION ANALYSIS.

001663 02-13 REGIONAL CHANGES OF CEREBRAL BLOOD FLOW DURING HALOPERIDOL THERAPY IN PATIENTS WITH PARANOID SYMPTOMS.

001677 02-13

DAILY CHANGES IN THE BLOOD SERUM LEVELS OF DIPHENYLHYDANTOIN (DPH) AND PHENOBARBITAL.

001830 02-15 BLOOD LEVEL MONITORING OF BENZODIAZEPINES BY GLC USING

NITROGEN SENSITIVE DETECTORS. 001860 02-16

CHLORPROMAZINE-INDUCED CHANGES IN BLOOD
ADENOSINEPHOSPHORIC-ACIDS: TO THEIR DIAGNOSTIC SIGNIFICANCE
IN PSYCHIATRY. 001861 02-16

INDIRECT SYMPATHOMIMETIC AGENTS AND CEREBRAL BLOOD FLOW AND METABOLISM.

INFLUENCE OF EXTRAPYRAMIDAL DISTURBANCES DUE TO HALOPERIDOL ON PHENAMINE STEREOTYPY AND THE EFFECTS OF SCHIZOPHRENIC BLOOD SERUM (EXPERIMENTAL STUDIES).

002339 03-05 BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS: ASSAY
PROCEDURES, REPRODUCIBILITY AND RELATIONSHIP TO THERAPEUTIC
OUTCOME AND SIDE-EFFECTS.

002440 03-09 EFFICACY, SIDE-EFFECTS, PLASMA AND BLOOD LEVELS OF MAPROTILINE (LUDIOMIL).

EFFECTS OF PIRACETAM ON REGIONAL CEREBRAL BLOOD FLOW AND MENTAL FUNCTIONS IN PATIENTS WITH ORGANIC DEMENTIA.

THE THIORIDAZINE LEVEL IN THE BLOOD SERUM AND SYMPTOMS OF THE PARANOID SYNDROME.

ALTERATIONS OF CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC-ACID, AND TOTAL BLOOD SEROTONIN CONTENT DURING CLOZAPINE TREATMENT.

002545 03-13 LITHIUM TRANSPORT ACROSS THE RED BLOOD CELL MEMBRAN

002553 03-13 USE OF TRICYCLIC ANTIDEPRESSANT BLOOD LEVELS. 002693 03-15

A SIMPLE AND SENSITIVE RADIORECEPTOR ASSAY FOR ANTISCHIZOPHRENIC DRUGS IN BLOOD.

002715 03-16 5 HYDROXYTRYPTAMINE AND DOPAMINE TRANSPORT BY RAT AND HUMAN BLOOD PLATELETS.

AMPHETAMINE-INDUCED INCREASE IN RAT CEREBRAL BLOOD FLOW; APPARENT LACK OF CATECHOLAMINE INVOLVEMENT.

003031 04-03 THE STABILITY AND RELIABILITY OF RADIOIMMUNOASSAYS FOR CLONAZEPAM, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN BLOOD, SERUM OR PLASMA.

STABILITY OF LOW BLOOD PLATELET MONOAMINE-OXIDASE ACTIVITY IN HUMAN ALCOHOLICS.

003577 04-11 THE EFFECT OF MARIHUANA INTOXICATION ON BLOOD PRESSUR 003724 04-13

BLOOD-BRAIN
BLOOD-BRAIN BARRIER DYSFUNCTION AFTER AMPHETAMINE
ADMINISTRATION IN RATS.

OC.

002854 04-03 SLURRED
TREATING BLURRED VISION ASSOCIATED WITH ANTIPSYCHOTIC
MEDICATION.

000810 01-15

MORPHINE AND 5 HYDROXYTRYPTAMINE INTERACTIONS IN RAT HYPOTHALAMUS AND PINEAL BODY.

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON BODY
TEMPERATURE AND BRAIN AMINE CONCENTRATIONS IN THE RAT AT
DIFFERENT AMBIENT TEMPERATURES.

000105 01-03 5,7 DIHYDROXYTRYPTAMINE LESIONS: EFFECTS ON BODY WEIGHT, IRRITABILITY, AND MURICIDE.

000430 01-04 EFFECTS OF ANGIOTENSIN-II ON SCHEDULE-DEPENDENT AND INDUCED BEHAVIOR AT RECOVERED BODY WEIGHT.

000470 01-04 LITHIUM ABSORPTION, DISTRIBUTION AND CLEARANCE AND BODY TEMPERATURE IN RATS GIVEN LITHIUM PLUS HALOPERIDOL.

THIN-LAYER AND GAS-LIQUID-CHROMATOGRAPHIC PROCEDURES FOR THE DETERMINATION OF PERAZINE AND ITS METABOLITES IN HUMAN BODY FLUIDS.

EFFECTS OF 6 HYDROXYDOPAMINE ON BODY WEIGHT: FEEDING DEFICITS OR SENSORY-MOTOR IMPAIRMENTS?.

AN ATTEMPT TO PREDICT THE DURATION OF PENTOBARBITAL NARCOSIS ON THE BASIS OF EXPLORATORY ACTIVITY, DEFECATION RATE AND BODY WEIGHT OF RATS.

001435 02-04 THE EFFECTS OF CANNABINOIDS ON BODY TEMPERATURE AND BRAIN CATECHOLAMINE SYNTHESIS.

EFFECTS OF MET-ENKEPHALIN ON BODY TEMPERATURE OF NORMAL AND MORPHINE-TOLERANT RATS.

002907 04-03 CLONIDINE-INDUCED BODY TEMPERATURE CHANGES IN RATS WITH ANTERIOR OR POSTERIOR CORTICAL DAMAGE.

002959 04-03 EFFECTS OF INTRAVENTRICULARLY ADMINISTERED MONOAMINES ON SEIZURE SUSCEPTIBILITY AND BODY TEMPERATURE IN RATS.

003180 04-04 SENSITIVITY TO APOMORPHINE IN THE GUINEA-PIG AS A FUNCTION OF AGE AND BODY WEIGHT.

003182 04-04

BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE EFFECTS
AFTER INTRACEREBRAL INFUSION OF TRH IN FOWLS. 003319 04-04

THE EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND 2
BROMOLYSERGIC-ACID-DIETHYLAMIDE (BOL) ON THE STRIATAL DOPA
ACCUMULATION: INFLUENCE OF CENTRAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS. 002125 03-03

EFFECTS OF LSD AND BOL ON THE CATECHOLAMINE SYNTHESIS AND TURNOVER IN VARIOUS BRAIN REGIONS. 003043 04-03

TIMING AND RISK OF BONE MARROW DEPRESSION BY PSYCHOTROPIC DRUGS 001770 02-15

BORN LATE WITHDRAWAL SYMPTOMS IN BABIES BORN TO METHADONE

001756 02-15 LIMB REDUCTION ANOMALIES IN INFANTS BORN TO DISULFIRAM TREATED ALCOHOLIC MOTHERS.

001817 02-15 THE BOTANICAL AND CHEMICAL DISTRIBUTION OF HALLUCINOGENS

000680 01-12 BOTHROPS-JARARACA
INHIBITION OF BRAIN ANGIOTENSIN-I CONVERTING ENZYME BY
BOTHROPS-JARARACA NONAPEPTIDE (SQ-20881) AND A PROLYL

ANALOG (SQ-14225) 002818 04-03

TOLERANCE TO ETHANOL: EFFECT OF CONGENERS PRESENT IN BOURBON 000370 01-04

003439 04-06

BOVINE

DEMONSTRATION OF AN ENDOGENOUS, COMPETITIVE INHIBITOR(S) OF H3-DIAZEPAM BINDING IN BOVINE BRAIN

002995 04-03

EFFECTS OF MORPHINE ON ELECTRICAL ACTIVITY OF SINGLE MYENTERIC NEURONS IN CAT SMALL BOWEL.

002009 03-03 BOXES

RELIABILITY OF TWO ACTIVITY BOXES COMMONLY USED TO ASSESS DRUG-INDUCED BEHAVIOURAL CHANGES. 002368 03-06

BRADYCARDIC

CENTRAL SITES AND MECHANISMS OF THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF THE NARCOTIC ANALGESIC AGENT

FENTANVI 000179 01-03

SYNTHESIS OF BRADYKININ FRAGMENTS AND THEIR EFFECT ON PENTOBARBITAL SLEEPING TIME IN MOUSE.

000424 01-04 EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ, ANGIOTENSIN-II, AND SUBSTANCE-P ON MULTIPLE FIXED-INTERVAL FIXED-RATIO RESPONDING IN RABBITS.

003233 04-04

BETA-ENDORPHIN INHIBITS ACH TURNOVER IN NUCLEI OF RAT BRAIN 000012 01-01 ANTISERUMS TO NEURONS AND TO OLIGODENDROGLIA FROM

MAMMALIAN BRAIN. ALTERATIONS IN BRAIN 5 HYDROXYTRYPTAMINE METABOLISM DURING THE WITHDRAWAL PHASE AFTER CHRONIC TREATMENT WITH

DIAZEPAM AND BROMAZEPAM 000038 01-03

LEVELS OF CHLORPROMAZINE AND ITS ACTIVE MATABOLITES IN RAT BRAIN AND THE RELATIONSHIP TO CENTRAL MONOAMINE METABOLISM AND PROLACTIN SECRETION.

INCREASE IN THE TURNOVER OF BRAIN DOPAMINE BY STIMULATION OF MUSCARINIC RECEPTORS OUTSIDE THE DOPAMINE NERVE TERMINALS 000042 01-03

BRAIN SEROTONIN TURNOVER AND MORPHINE-TOLERANCE DEPENDENCE INDUCED BY MULTIPLE INJECTIONS IN THE RAT. 000055 01-03

EFFECTS OF REPEATED ADMINISTRATION OF MORPHINE ON TYROSINE-HYDROXYLASE IN THE RAT BRAIN.

000062 01-03 MONOAMINE-OXIDASE INHIBITION IN BRAIN AND LIVER PRODUCED BY BETA-CARBOLINES: STRUCTURE-ACTIVITY RELATIONSHIPS AND SUBSTRATE SPECIFICITY

000064 01-03 THE RELATIONSHIP BETWEEN MAGNITUDE OF ELECTROSHOCK STIMULATION AND THE EFFECTS OF DIGITOXIGENIN, PENTYLENETERAZOL AND BRAIN MONOAMINE REDUCTION ON

ELECTROSHOCK CONVULSIVE THRESHOLDS 000066 01-03 THE ACCUMULATION OF P-HYDROXYAMPHETAMINE BY BRAIN HOMOGENATES AND ITS ROLE IN THE RELEASE OF CATECHOLAMINES

000074 01-03 ADENYLATE-CYCLASE FROM VARIOUS DOPAMINERGIC AREAS OF THE BRAIN AND THE ACTION OF ANTIPSYCHOTIC DRUGS 000076 01-03

DRUGS ALTERING INSULIN SECRETION: EFFECTS ON PLASMA AND BRAIN CONCENTRATIONS OF AROMATIC-AMINO-ACIDS AND ON BRAIN 5
HYDROXYTRYPTAMINE TURNOVER. 000098 01-03

KINETICS OF CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN MOUSE BRAIN SYNAPTOSOMES.

STRESS-INDUCED ALTERATIONS OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN: EFFECTS OF CENTRALLY ACTING DRUGS.

000097 01-03 THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON BODY
TEMPERATURE AND BRAIN AMINE CONCENTRATIONS IN THE RAT AT
DIFFERENT AMBIENT TEMPERATURES.

000105 01-03

STRAIN DIFFERENCES IN THE RESPONSE TO MORPHINE ON INCORPORATION OF H3-LYSINE INTO RAT BRAIN PROTEIN 000108 01-03 FURTHER STUDIES ON THE EFFECTS OF N CYCLOPROPYL P-CHLOROAMPHETAMINE IN RAT BRAIN.

000111 01-03 LOWERING OF EPINEPHRINE CONCENTRATION IN RAT BRAIN BY 2,3

DICHLORO-ALPHA-METHYL-BENZYLAMINE, AN INHIBITOR OF NOREPINEPHRINE-N-METHYLTRANSFERASE. 000112 01-03

BIPHASIC EFFECTS OF M CHLOROPHENYL-PIPERAZINE IN 3,4
DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN RAT BRAIN 000113 01-03 COMPARISON OF THE EFFECTS OF 6 CHLORO-2-AMINOTETRALIN AND OF ORG-6582, A RELATED CHLOROAMPHETAMINE ANALOG, ON BRAIN SEROTONIN METABOLISM IN RATS.

PSYCHOACTIVE DRUG EFFECTS AND SUBSTRATE SPECIFICITY IN INTACT MITOCHONDRIAL MONOAMINE-OXIDASE FROM BRAIN.

POSSIBLE SIGNIFICANCE OF CLOZAPINE-INDUCED INCREASE IN BRAIN DOPAMINE.

OCO120 01-03
INCREASE IN MOUSE BRAIN DOPAMINE CONTENT BY BACLOFEN: EFFECTS OF APOMORPHINE AND NEUROLEPTICS.

000121 01-03 A BRAIN SPECIFIC PROTEIN FROM OCTOPUS-VULGARIS, L

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE.

000127 01-03
TRICYCLIC ANTIDEPRESSANT DRUGS BLOCK HISTAMINE H2 RECEPTOR IN

N,N DIMETHYLTRYPTAMINE LOWERS RAT BRAIN ACETYLCHOLINE AND DOPAMINE

EFFECT OF CANNABINOIDS ON NEUROTRANSMITTER UPTAKE, ATPASE ACTIVITY AND MORPHOLOGY OF MOUSE BRAIN SYNAPTOSOMES. 000143 01-03

DISAGGREGATION OF BRAIN POLYSOMES AFTER D LYSERGIC-ACID-DIETHYLAMIDE ADMINISTRATION IN VIVO: MECHANISM AND EFFECT OF AGE AND ENVIRONMENT.

000149 01-03 THE DEMONSTRATION IN VIVO OF SPECIFIC BINDING SITES FOR NEUROLEPTIC DRUGS IN MOUSE BRAIN

EFFECTS OF ORG-6582, CHLORIMIPRAMINE AND DESMETHYLIMIPRAMII ON THE DEPLETION OF BIOGENIC AMINES FROM THE RAT BRAIN IN

000159 01-03 CATECHOLAMINE SYNTHESIS IN RAT BRAIN AFTER AXOTOMY INTERACTION BETWEEN APOMORPHINE AND HALOPERIDOL

000161 01-03 THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS OF MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE.

000169 01-03 DRUG-INDUCED CHANGES IN BRAIN TYROSINE-HYDROXYLASE ACTIVITY

000181 01-03 EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT BRAIN: A QUANTITATIVE HISTOLOGICAL STUDY.

EFFECT OF CONVULSANT AND ANTICONVULSANT AGENTS ON LEVEL AND METABOLISM OF GAMMA-AMINOBUTYRIC-ACID IN MOUSE BRAIN. 000186 01-03

ACETYLCHOLINE AND CHOLINE IN MOUSE BRAIN -- INFLUENCE OF PERIPHERALLY ACTING CHOLINERGIC DRUGS.

000187 01-03 MODULATION OF BRAIN TRYPTOPHAN-HYDROXYLASE ACTIVITY BY BRAIN TRYPTOPHAN CONTENT 000207 01-03

ABSENCE OF FORMATION OF BRAIN SALSOLINOL IN ETHANOL DEPENDENT

INFLUENCE OF INJECTED PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE BRAIN AND LUNG FOLLOWING MICROWAVE IRRADIATION.
000214 01-03 EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT

BRAIN. A BIOCHEMICAL STUDY

POTENTIATION BY COCAINE OF THE STIMULUS-INDUCED INCREASE IN DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL SYNAPTOSOMES. 000217 01-03 NEUROLEPTIC DRUG INTERACTIONS WITH NOREPINEPHRINE ALPHA RECEPTOR BINDING SITES IN RAT BRAIN.

000219 01-03 A MORPHINE-LIKE FACTOR IN MAMMALIAN BRAIN: ANALGESIC ACTIVITY IN RATS.

PERSISTENT EFFECTS OF REPEATED INJECTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE ON RAT BRAIN 5 HYDROXYTRYPTAMINE AND 5 HYDROXYINDOLEACETIC-ACID LEVELS.

SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION: A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL MEMBRANES FROM MATURE RAT BRAIN.

O00230 01-03
ACETYLCHOLINE TURNOVER IN SPECIFIC BRAIN AREAS OF RATS INJECTED WITH VARIOUS ANTIDEPRESSANTS. (UNPUBLISHED PAPER) 000244 01-03

MORPHINE IN BRAIN AND ILEUM. 000247 01-03 **BRAIN CALCIUM AND MORPHINE ACTION** 000253 01-03 EFFECT OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION ON EPINEPHRINE LEVELS IN THE BRAIN. O00255 01-03

EFFECT OF ETHANOL ON (3H)OUABAIN BINDING TO DIFFERENT REGIONS

OF THE CAT BRAIN. THE EFFECT OF PH ON STEREOSPECIFIC OPIATE BINDING TO MOUSE BRAIN MEMBRANES 000271 01-03 EFFECTS OF PHENCYCLIDINE ON (3H)CATECHOLAMINE AND
(3H)SEROTONIN UPTAKE IN SYNAPTOSOMAL PREPARATIONS FROM
RAT BRAIN. 000273 01-03 THE INFLUENCE OF CAFFEINE AND THEOBROMINE ON LOCOMOTIVE ACTIVITY AND THE BRAIN C-GMP/C-AMP RATIO IN WHITE MICE. 000275 01-03 REVERSIBLE AND IRREVERSIBLE EFFECTS OF P-CHLOROAMPHETAMINE ON BRAIN SEROTONIN IN MICE. 000276 01-03 EFFECTS OF BETA-BUNGAROTOXIN, DIPHENYLHYDANTOIN AND METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT CATIONS AND HIGH-ENERGY PHOSPHATE CONTENTS OF BRAIN SLICES. 000278 01-03 EFFECTS OF TRANYLCYPROMINE AND PARGYLINE ON BRAIN TRYPTAMINE. 000279 01-03 TYRAMINE BINDING BY SYNAPTOSOMES FROM RAT BRAIN: EFFECT OF CENTRALLY ACTIVE DRUGS. THE EFFECTS OF ETHER STRESS AND BETAMETHASONE TREATMENT ON THE CONCENTRATIONS OF NORADRENALINE AND DOPAMINE IN VARIOUS REGIONS OF THE RAT BRAIN. 000288 01-03 EFFECT OF COCAINE AND DESMETHYLIMIPRAMINE ON THE UPTAKE,
RETENTION AND METABOLISM OF H3-5-HYDROXYTRYPTAMINE IN RAT EXTRACTS. BRAIN SLICES. MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND NORADRENERGIC NEURONS IN NORMAL AND BRAIN LESIONED RATS. **BRAIN TISSUE SLICES** 000312 01-04 RAISED BRAIN GABA LEVELS, MOTOR ACTIVITY AND EXPLORATION IN **POLYSOMES** 000358 01-04 DELTA9-THC AND 11 OH-DELTA9-THC: BEHAVIORAL EFFECTS AND RELATIONSHIP TO PLASMA AND BRAIN LEVELS. 000361 01-04 PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, BRAIN SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION INTO BRAIN PROTEINS OF DIFFERENT MOUSE STRAINS. 000384 01-04 EFFECTS OF P-CHLOROPHENYLALANINE AND ALPHA-METHYLTRYPTOPHAN ON BEHAVIOUR AND BRAIN 5 HYDROXYINDOLES. THE EFFECT OF INTRACEREBRAL INJECTION OF CYCLOHEXIMIDE ON BRAIN PROTEIN SYNTHESIS AND ON THE HYPERACTIVITY SYNDROME PRODUCED BY A MONOAMINE-OXIDASE INHIBITOR AND TRYPTOPHAN. 000410 01-04 AMPHETAMINE EFFECTS ON BRAIN SLOW POTENTIALS ASSOCIATED WITH DISCRIMINATION IN THE RAT. 000432 01-04 POTENTIATION OF BRAIN REWARD MECHANISMS BY PSYCHOMOTOR STIMULANT DRUGS. 000441 01-04 THE EFFECT OF MATERNALLY ADMINISTERED METHADONE ON BRAIN DEVELOPMENT IN THE OFFSPRING. 000483 01-05 PROTEIN KINASES. THE SUBCELLULAR DISTRIBUTION OF PARTICLE-BOUND NEGATIVE CHARGES IN RAT BRAIN. BRAIN MECHANISMS ASSOCIATED WITH THERAPEUTIC ACTIONS OF BENZODIAZEPINES: FOCUS ON NEUROTRANSMITTERS.

EFFECT OF MIANSERIN ON BRAIN SEROTONIN TURNOVER IN MICE. 001057 02-03 THE EFFECT OF ANESTHESIA ON BRAIN MITOCHONDRIAL HEXOKINASE. 001058 02-03 FORMATION OF BRAIN ACETYLCHOLINE FROM DIETARY CHOLINE AND THE EFFECT OF BARBITURATE ANESTHESIA ON THIS PROCESS. 001074 02-03 PHARMACOLOGICAL IMPLICATIONS OF BRAIN ACETYLCHOLINE TURNOVER MEASUREMENTS IN RAT BRAIN NUCLEI. 001077 02-03 CATECHOLAMINE SENSITIVE ATPASE ACTIVITIES IN BRAIN SYNAPTOSOMES OF MORPHINIZED MICE. ANALGESIC BRAIN STIMULATION IN THE CAT: EFFECT OF INTRAVENTRICULAR SEROTONIN, NOREPINEPHRINE, AND DOPAMINE. 001101 02-03 EFFECT OF CHRONIC LEVODOPA ON VITAMIN-B6 METABOLISM IN DISCRETE REGIONS OF RAT BRAIN. ACTION OF DOPAMINE AGONISTS ON BRAIN VESSELS IN VITRO AND AFTER IN VIVO MICROAPPLICATION. BRAIN DISTRIBUTION OF LITHIUM AND INDOLEAMINE METABOLISM IN DOGS AFTER CHRONIC LITHIUM ADMINISTRATION. INFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3-CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN 001119 02-03 POTENTIATION OF MORPHINE ANALGESIA IN MICE AFTER INHIBITION OF BRAIN TYPE-B MONOAMINE-OXIDASE. 001126 02-03 METABOLISM OF FENFLURAMINE TO M
TRIFLUOROMETHYLBENZOYLGLYCINE IN RAT BRAIN. 001127 02-03 EFFECTS OF PERINATAL 6 HYDROXYDOPAMINE TREATMENT ON OPIATE RECEPTOR DISTRIBUTION IN ADULT BRAIN. 001128 02-03 BREAKDOWN OF ENKEPHALIN AND ENDORPHIN ANALOGS BY BRAIN 001137 02-03 STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT 001145 02-03 ANTIPSYCHOTIC DRUGS BLOCK LSD-INDUCED DISAGGREGATION OF BRAIN 001147 02-03 BIOCHEMICAL DIFFERENTIATION OF AGGREGATING CELL CULTURES OF DIFFERENT FETAL RAT BRAIN REGIONS. 001148 02-03 THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS. 001150 02-03 ENKEPHALIN EFFECTS ON RELEASE OF BRAIN ACETYLCHOLINE. 001152 02-03 EFFECT OF ATROPINE ON ACETYLCHOLINE METABOLISM IN THE MOUSE THE DISTRIBUTION BETWEEN PLASMA AND BRAIN OF GLUTETHIMIDE
AND 4 HYDROXYGLUTETHIMIDE FOLLOWING THEIR ADMINISTRATION
TO MICE. 001160 02-03 EFFECTS OF ACUTE AND CHRONIC MORPHINE AND NARCOTIC ANTAGONISTS ON BRAIN ENERGY METABOLISM. 001163 02-03

Psychopharmacology Abstracts

REGIONAL DISTRIBUTION OF BARBITAL IN THE BRAIN OF MICE DURING THE DEVELOPMENT OF TOLERANCE AND PHYSICAL DEPENDENCE. 001180 02-03 EFFECTS OF AMPHETAMINE ON BRAIN BIOGENIC AMINES IN ISOLATED AND AGGREGATED RATS. 001182 02-03

IET AND UPTAKE OF ALDOMET BY THE BRAIN: COMPETITION WITH NATURAL LARGE NEUTRAL AMINO-ACIDS. 001185 02-03

ALTERATIONS IN BRAIN HISTAMINE AND HISTIDINE-DECARBOXYLASE
ACTIVITY AFTER HALOPERIDOL AND IMIPRAMINE. 001188 02-03

THE RELATIVE FUNCTIONAL AVAILABILITY OF BRAIN NORADRENALINE AND DOPAMINE STORAGE POOLS.

001191 02-03 THE EFFECT OF NICOTINE ON THE ACETYLCHOLINE CONTENT IN MOUSE BRAIN REGIONS. 001197 02-03

001033 02-02 AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. III. THE TELENCEPHALON. 001048 02-03

001032 02-02

THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE HUMAN BRAIN AS AN OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING DRUGS.

PHENOBARBITAL AND PHENYTOIN EFFECTS ON SOMATOSENSORY
EVOKED-POTENTIALS AND SPONTANEOUS EEG IN NORMAL CAT BRAIN.

EFFECTS OF BRAIN LESIONS AND ATROPINE ON HIPPOCAMPAL AND NEOCORTICAL ELECTROENCEPHALOGRAMS IN THE RAT.

BRAIN NEUROTRANSMITTER RECEPTORS AFTER LONG-TERM HALOPERIDOL: DOPAMINE, ACETYLCHOLINE, SEROTONIN, ALPHA-NORADRENERGIC AND NALOXONE RECEPTORS.

001200 02-03

EFFECT OF PENTOBARBITAL ON REGIONAL BRAIN PHOSPHOLIPID SYNTHESIS.

MODULATION OF ACETYLCHOLINE TURNOVER IN BRAIN REGIONS AND HIGH AFFINITY UPTAKE.

001209 02-03
ELECTROSHOCK ANTICONVULSANT ACTIVITY AND BRAIN ACETYLCHOLINE
ALTERATIONS IN MICE TREATED WITH SELECT BENZODIAZEPINES.
001210 02-03

ACTION OF AZABUTYRONE AND ITS ANALOGS ON CATECHOLAMINE METABOLISM IN RAT BRAIN.

COMPARATIVE BRAIN/PLASMA CONCENTRATIONS OF AMPHETAMINE ISOMERS IN MICE

OO1224 02-03
EFFECT OF NOMIFENSINE AND OTHER ANTIDEPRESSANT DRUGS ON
ACETYLCHOLINE TURNOVER IN VARIOUS AREAS OF RAT BRAIN.

THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE NORPHINE TURNOVER IN RAT BRAIN REGIONS.

THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS ON MHPG-S04 IN RAT BRAIN.

SUBSTITUTED AMPHETAMINE DERIVATIVES. I. EFFECT ON UPTAKE AND RELEASE OF BIOGENIC MONOAMINES AND ON MONOAMINE-OXIDASE IN THE MOUSE BRAIN.

001233 02-0: EFFECTS THE HYPNOTICS AND ANTIANXIETY DRUGS ON ACETYLCHOLINE (ACH) CONCENTRATIONS IN DISCRETE AREAS OF THE RAT BRAIN.

001239 02-03
REGIONAL LOCALIZATION OF C14-MESCALINE IN RABBIT BRAIN AFTER
INTRAVENTRICULAR ADMINISTRATION: EFFECTS OF CHLORPROMAZINE
AND IPRONIAZIO PRETREATMENT.

001240 02-03
INVOLVEMENT OF BRAIN CYCLIC-AMP IN MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE. (PH.D. DISSERTATION).

001241 02-03
THE INCREASE IN S ADENOSYL-L-METHIONINE (SAME) CONCENTRATION IN RAT BRAIN AFTER ITS SYSTEMATIC ADMINISTRATION.

THE EFFECTS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE ON THE IN VITRO UPTAKE OF RADIOLABELLED 5-HT AND NORADRENALINE INTO RAT BRAIN CORTICAL SLICES.

001257 02-03
MULTIPLE BRAIN SITES INVOLVED IN MORPHINE ANTINOCICEPTION.

O01270 02-03

EFFECT OF D AMPHETAMINE ON THE INHIBITION OF BRAIN

CATECHOLAMINE TURNOVER INDUCED BY CYCLOHEXIMIDE. 001279 02-03

EFFECTS OF THE ISOMERIC FORMS OF PROPRANOLOL ON CENTRAL MONOAMINE METABOLISM IN REGIONS OF RAT BRAIN.

MONOAMINE METABOLISM IN REGIONS OF RAT BRAIN.

001284 02-03

CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIVITY TO THE DIRECT
APPLICATION OF MORPHINE AND FOCAL ELECTRICAL STIMULATION IN

THE PRODUCTION OF ANTINOCICEPTION IN THE RAT.

001291 02-03

SPECIFICITY OF AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE

AND SEROTONIN FROM RAT BRAIN IN VITRO.

O01294 02-03

AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOUR AND BRAIN
CONCENTRATIONS OF AMPHETAMINE AND ITS HYDROXYLATED

METABOLITES IN MICE.

001316 02-04

EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION: AMPHETAMINE LEVELS AND EFFECTS UPON SOME ARYLALKYLAMINES IN RAT BRAIN.

ROLE OF THE BRAIN MONOAMINE SYSTEM IN LEARNING ON VARIOUS EMOTIONAL REINFORCEMENTS.

001369 02-04
BRAIN STIMULATION PROVOKED EMOTIONAL REACTIONS OF CATS IN A SOCIAL SITUATION.

001395 02-04
NEUROMETABOLIC AND BEHAVIOURAL EFFECTS OF HALOPERIDOL IN
RELATION TO DRUG LEVELS IN SERUM AND BRAIN.

VARIOUS EFFECTS OF D AMPHETAMINE IN RATS WITH SELECTIVE LESIONS OF BRAIN NORADRENALINE CONTAINING NEURONS OR TREATED WITH PENFLURIDOL.

ON THE EFFECT OF NOOTROPIL AN ATP AND ATPASE IN BRAIN OF RATS.

001482 02-04
HISTAMINE H2-RECEPTORS IN THE BRAIN AND SLEEP PRODUCED BY
CLONIDINE.

001483 02-04

ACTH-INDUCED EXCESSIVE GROOMING INVOLVES BRAIN DOPAMINE.
001490 02-04
ROLE OF BRAIN NOREPINEPHRINE IN NEUROLEPTIC-INDUCED CATALEPSY
IN RATS.

DO DRUGS ACTING ON THE NERVOUS SYSTEM AFFECT CELL
PROLIFERATION IN THE DEVELOPING BRAIN?

APPLICATION OF STATISTICS TO THE METHODOLOGY OF STUDIES OF DRIIGS ACTING ON THE REAIN

MORPHINE-LIKE PEPTIDES OF BRAIN AND THEIR RELATION TO HORMONAL NEUROTRANSMITTERS.

001650 02-13
BRAIN DOPAMINE TURNOVER AND THE RELIEF OF PARKINSONISM.
001685 02-13

PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD SCHOOL CHILDREN WITH BRAIN DYSFUNCTION, ATTEMPT OF A HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS THERAPFLITE APPLICATION.

SENESCENT BRAIN: CURRENT STATUS AND IMPLICATION IN NEUROPSYCHOPHARMACOLOGY.

CENTRAL-NERVOUS-SYSTEM EFFECTS OF PEPTIDES FOUND IN BRAIN AND INTESTINES

BLOCKADE OF PRESYNAPTIC ALPHA-RECEPTORS AND OF AMINE UPTAKE
IN THE RAT BRAIN BY THE ANTIDEPRESSANT MIANSERINE.

001965 03-03
INHIBITION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS IN RATS BY PROSTAGLANDIN-E1: ROLE OF BRAIN MONOAMINES.

O01968 03-03

ALTERATION OF L-DOPA EFFECT ON BRAIN DOPA AND DOPAMINE LEVELS
WITH NICOTINIC-ACID AND N METHYL NICOTINAMIDE. (PH.D.
DISSERTATION).

001969 03-03

DIFFERENT EFFECTS OF METHIONINE-ENKEPHALIN AND D ALA2METHIONINE-ENKEPHALINAMIDE ON THE METABOLISM OF DOPAMINE
AND NOREPINEPHRINE IN RAT BRAIN: FACT OR ARTIFACT?.

001980 03-03

EFFECTS OF MAZINDOL, FENFLURAMINE AND CHLORIMIPRAMINE ON THE
5 HYDROXYTRYPTAMINE UPTAKE AND STORAGE MECHANISMS IN
RAT BRAIN-SIMI ARITIES AND DIFFERENCES.

IN VIVO EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE IN RAT BRAIN.

MULTIPLE CLASSES OF OPIATE RECEPTORS IN C57BL/6J AND DBA/2J
MOUSE BRAIN.

001991 03-03
H3-SPIROPERIDOL LABELS DOPAMINE RECEPTORS IN PITUITARY AND

BRAIN.

O01996 03-03

IN VITRO EFFECTS OF DESMETHYLIMIPRAMINE ON THE UPTAKE AND METABOLISM OF H3-NOREPINEPHRINE IN RAT BRAIN SLICES.

EFFECTS OF BENZYDAMINE ON THE BIOELECTRIC ACTIVITY OF THE RABBIT

001998 03-03

THE BIOCHEMISTRY OF BRAIN DEVELOPMENT AND MENTAL
RETARDATION: THE ELEVENTH BLAKE MARSH LECTURE DELIVERED
BEFORE THE ROYAL COLLEGE OF PSYCHIATRISTS, 7 FEBRUARY, 1977.
002000 03-03

002000 03-03
THE INFLUENCE OF DIHYDROERGOTOXINE-MESYLATE ON THE LOW-KM
PHOSPHODIESTERASE OF CAT AND RAT BRAIN IN VITRO.

OO2008 03-03
INHIBITION BY NEUROLEPTICS OF UPTAKE OF H3-GABA INTO RAT BRAIN
SYNAPTOSOMES.

002013 03-03

EFFECTS OF FENFLURAMINE AND NORFENFLURAMINE ON BRAIN
SEROTONIN METABOLISM IN RATS

O02016 03-03

IMPORTANCE OF DURATION OF DRUG ACTION IN THE ANTAGONISM OF
P-CHLOROAMPHETAMINE DEPLETION OF BRAIN SEROTONIN —
COMPARISON OF FLUOXETINE AND CHLORIMIPRAMINE.

002017 03-03
BINDING INTERACTIONS OF ERGOT ALKALOIDS WITH MONOAMINERGIC
RECEPTORS IN THE BRAIN.

O02024 03-03

ALPHA-NORADRENERGIC RECEPTORS IN THE BRAIN: DIFFERENTIAL

EFFECTS OF SODIUM ON BINDING OF H3-AGONISTS AND H3
ANTACOMISTS

002029 03-03
BETA-ADRENERGIC RECEPTOR MEDIATED CYCLIC-AMP SYNTHESIS IN
BROKEN-CELL HOMOGENATES OF RAT BRAIN.

O02033 03-03
STRESS ACCENTUATION OF THE LSD-INDUCED DISAGGREGATION OF
BRAIN POLYSOMES.

STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAMINE (DA) AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES. 002036 03-03 THE EFFECTS OF LITHIUM ON ATPASE ACTIVITY IN SUBCELLULAR FRACTIONS FROM RAT BRAIN. 002038 03-03 DOES LONG-TERM TREATMENT WITH AMITRIPTYLINE ALTER THE MONOAMINE-OXIDASE OF RAT BRAIN?

RAT BRAIN ARYLACYLAMIDASE: MULTIPLE FORMS AND INHIBITION EFFECTS OF LSD, SEROTONIN AND RELATED COMPOUNDS.

002044 03-03 INCORPORATION, AFTER SINGLE AND REPEATED APPLICATION OF RADIOACTIVE LABELLED DH-ERGOT ALKALOIDS IN DIFFERENT ORGANS OF THE CAT, WITH SPECIAL REFERENCE TO THE BRAIN.

002047 03-03 CANNABINOID EFFECTS ON PLASMA CORTICOSTERONE AND UPTAKE OF H3-CORTICOSTERONE BY MOUSE BRAIN.

EFFECTS OF DIAZEPAM ON DOPAMINE TURNOVER IN NEOSTRIATAL AND LIMBIC REGIONS OF THE RAT BRAIN.

BRAIN NEUROTRANSMITTER RECEPTORS AND CHRONIC ANTIPSYCHOTIC DRUG TREATMENT: A MODEL FOR TARDIVE-DYSKINESIA. 002061 03-03

EFFECTS OF DIETHYLDITHIOCARBAMATE ON BRAIN MONOAMINE AND PROTEIN CONTENT IN NEONATAL RATS.

002063 03-03 METABOLISM OF AMPHETAMINE BY RAT BRAIN TISSUE. 002065 03-03

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS: 3 SUBCELLULAR DISTRIBUTION OF NEUROLEPTIC DRUGS AND THEIR RECEPTORS IN VARIOUS RAT BRAIN AREAS.

002067 03-03 THE ACUTE EFFECTS OF AMPHETAMINE, CHLORPROMAZINE, AMITRIPTYLINE AND LITHIUM ON ADENOSINE-5-TRIPHOSPHATASE ACTIVITY IN THE CORTEX OF THE RAT BRAIN.

002094 03-03

EFFECT OF SYNTHESIS INHIBITION ON THE LEVELS OF BRAIN CATECHOLAMINES IN BARBITAL DEPENDENT RATS. 002103 03-03

AUTORADIOGRAPHIC LOCALIZATION OF H3-RESERPINE BINDING SITES IN

002106 03-03 THE EFFECT OF LITHIUM ON SEROTONIN METABOLISM IN THE BRAIN OF RATS WITH PARTICULAR ATTENTION TO ITS EFFECT UNDER THE MONOAMINE ALTERED CONDITIONS.

002110 03-03 EFFECT OF FLUDIAZEPAM ON TURNOVER OF SEROTONIN IN MOUSE BRAIN.

002111 03-03 CHRONIC TREATMENT WITH DESIPRAMINE CAUSED A SUSTAINED DECREASE OF 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE AND TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT BRAIN.

002113 03-03 DESIPRAMINE AND SOME OTHER ANTIDEPRESSANT DRUGS DECREASE THE MAJOR NOREPINEPHRINE METABOLITE 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE IN THE RAT BRAIN.

O02114 03-03
THE EFFECTS OF PICROTOXIN AND PENTYLENETETRAZOL IN THE DIURNAL RHYTHMS OF CATECHOLAMINES AND SEROTONIN IN THE RAT BRAIN. 002123 03-03

EFFECT OF METABOLIC INHIBITORS AND OUABAIN ON AMPHETAMINE-INDUCED AND POTASSIUM-INDUCED RELEASE OF BIOGENIC AMINES FROM ISOLATED BRAIN TISSUE.

002142 03-03 EFFECTS OF BIOGENIC AMINES AND PSYCHOTROPIC DRUGS ON ENDOGENOUS PROSTAGLANDIN BIOSYNTHESIS IN THE RAT BRAIN

HOMOGENATES.

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS. 002148 03-03

THE EFFECTS OF SP-111, A WATER-SOLUBLE THC DERIVATIVE, ON NEURONAL ACTIVITY IN THE RAT BRAIN.

002150 03-03 THE EFFECT OF AMIZYL AND ARECOLINE ON THE ACTIVITY OF NA-K-ATPASE AND THE CONTENT OF NA AND K IN RAT BRAIN.

002151 03-03 EFFECT OF EARLY EXPERIENCE, PYRITHIOXIN AND DIAZEPAM ON UC14-GLUCOSE UTILIZATION IN RAT BRAIN DURING EMOTIONAL STRESS.

002152 03-03 A LITHIUM-CARBONATE-INDUCED INCREASE IN THE MOUSE BRAIN 5 HYDROXYTRYPTAMINE METABOLISM.

BRAIN: SERUM AND CSF: SERUM RATIOS AFTER A SINGLE DOSE OF DIPROPYLACETIC-ACID (DPA),

METABOLISM OF 5 HYDROXYTRYPTAMINE AND LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS IN RAT BRAIN AFTER ACUTE AND CHRONIC TREATMENT.

METHYLHISTAMINE: EVIDENCE FOR SELECTIVE DEAMINATION BY MAO-B IN THE RAT BRAIN IN VIVO.

CHANGES IN MOUSE BRAIN CATECHO! AMINE CONTENT AND TYROSINE-HYDROXYLASE ACTIVITY DURING CHRONIC AMPHETAMINE ADMINISTRATION.

ALTERATIONS IN MORPHINE ANALGESIA PRODUCED BY CHRONIC DEPICITS OF BRAIN CATECHOLAMINES OR SEROTONIN: ROLE OF ANALGESIMETRIC PROCEDURE.

002186 03-03 EFFECT OF BETA ADRENERGIC RECEPTOR ANTAGONISTS ON D AMPHETAMINE AND POTASSIUM-INDUCED RELEASE OF H3-NOREPINEPHRINE FROM RAT BRAIN IN VITRO.

002187 03-03 EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DEPLETIONS OF BRAIN CATECHOLAMINES OR DOPAMINE ON MEPERIDINE ANTINOCICEPTION

002227 03-04 CENTROPHENOXINE: EFFECTS ON AGING MAMMALIAN BRAIN. 002287 03-04

LETHALITY OF PENTYLENETETRAZOL IN RATS AFTER DEPLETION OF BRAIN NOREPINEPHRINE.

INHIBITION BY LITHIUM OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT BRAIN.

002357 03-05 THERAPEUTIC EFFECT OF BRAIN HYDROLYSATES IN DEPRESSION-INDUCED DISTURBANCES OF INTELLIGENCE.

LITHIUM-CARBONATE AND BRAIN FUNCTION: 1. CEREBRAL EVOKED-POTENTIALS, EEG, AND SYMPTOM CHANGES DURING LITHIUM-CARBONATE TREATMENT.

BIOCHEMICAL IDENTIFICATION OF THE SITE OF ACTION OF BENZODIAZEPINES IN HUMAN BRAIN BY H3-DIAZEPAM BINDING

002583 03-13 PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS: AN APPROACH TO THE STUDY OF BRAIN DOPAMINE BLOCKADE IN HUMANS.

002590 03-13 VIGILANCE AND HUMAN ATTENTION UNDER CONDITIONS OF METHYLPHENIDATE AND SECOBARBITAL INTOXICATION: AN ASSESSMENT USING BRAIN POTENTIALS.

002622 03-14 EYE MOVEMENT. AN INDICATOR OF BRAIN FUNCTION

002637 03-14 ACUTE BRAIN SYNDROME AFTER PROPRANOLOL

002672 03-15 ACUTE BRAIN SYNDROME AFTER PROPRANOLOL TREATMENT 002708 03-15

ASSESSMENT OF DRUG THERAPY IN CHRONIC BRAIN FAILURE 002719 03-16

EVIDENCE FOR AN ENDOGENOUS FACTOR INTERFERING WITH H3-DIAZEPAM BINDING TO RAT BRAIN MEMBRANES. 002789 04-01

ON THE ORIGIN OF VANILLYLMANDELIC-ACID AND 3 METHOXY-4HYDROXYPHENYLGLYCOL IN THE RAT BRAIN. 002804 04-03

EFFECT OF MECAMYLAMINE ON THE FATE OF DOPAMINE IN STRIATAL AND MESOLIMBIC AREAS OF RAT BRAIN; INTERACTION WITH MORPHINE AND HALOPERIDOL.

002806 04-03
REGIONAL SENSITIVITY OF PRIMATE BRAIN DOPAMINERGIC NEURONS TO HALOPERIDOL: ALTERATIONS FOLLOWING CHRONIC TREATMENT

002812 04-03 EFFECTS OF SINGLE AND MULTIPLE DOSES OF DESIPRAMINE (DMI) ON ENDOGENOUS LEVELS OF 3 METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE (MOPEG-SO4) IN RAT BRAIN.

002814 04-03 DOPAMINE TURNOVER IN THE INTACT RABBIT BRAIN: EFFECT OF PENTOBARBITAL OR HALOPERIDOL.

002815 04-03 INHIBITION OF BRAIN ANGIOTENSIN-I CONVERTING ENZYME BY BOTHROPS-JARARACA NONAPEPTIDE (SQ-20881) AND A PROLYL ANALOG (SQ-14225).

002818 04-03 THE EFFECTS OF CANNABINOIDS ON BODY TEMPERATURE AND BRAIN CATECHOLAMINE SYNTHESIS.

002835 04-03 ONTOGENETIC DEVELOPMENT OF BENZODIAZEPINE RECEPTORS IN THE RAT RRAIN

002840 04-03 BENEFICIAL EFFECT OF ISOLEUCINE ON FETAL BRAIN DEVELOPMENT IN INDUCED PHENYLKETONURIA.

002846 04-03 HISTAMINE H2-RECEPTOR BINDING WITH H3-CIMETIDINE IN BRAIN 002848 04-03

002168 03-03

BROMOCRIPTINE, DIHYDROERGOTOXINE, METHYSERGIDE, D LSD, CF-25-397, AND CF-29-712: EFFECTS ON THE METABOLISM OF BIOGENIC AMINES IN THE BRAIN OF THE RAT.

002849 04-03 INFLUENCE OF TRANSIENT ISCHEMIA ON MONOAMINE METABOLISM IN

THE RAT BRAIN DURING NITROUS-OXIDE AND PHENOBARBITONE ANESTHESIA 002852 04-03

SUBCELLULAR DISTRIBUTION OF ETORPHINE IN RAT BRAIN AND EVIDENCE FOR IN VIVO STEREOSPECIFIC BINDING. 002856 04-03

MEASUREMENT OF PROTEIN TURNOVER IN RAT BRAIN

002859 04-03

EFFECTS OF SODIUM THIOPENTAL ON THE TRICARBOXYLIC-ACID CYCLE METABOLISM IN MOUSE BRAIN: CO2 FIXATION AND METABOLIC COMPARTMENTATION 002860 04-03

ALTERATION OF TRICARBOXYLIC-ACID CYCLE METABOLISM IN RAT RRAIN SLICES BY HALOTHANE 002861 04-03

PILOT STUDY ON THE DISTRIBUTION OF C14-LABELED METHAQUALONE IN THE RAT BRAIN 002865 04-03

EFFECTS OF P-CHLOROAMPHETAMINE ON BRAIN SEROTONIN IN IMMATURE RATS.

002866 04-03 BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101 BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN RAT CEREBRAL-CORTEX.

002885 04-03 SELECTIVE PURIFICATION OF A SINGLE POPULATION OF GLUCOCORTICOID RECEPTORS FROM RAT BRAIN.

002887 04-03 METABOLISM OF GAMMA-HYDROXYBUTYRATE BY RAT BRAIN: RELATIONSHIP TO THE KREBS-CYCLE AND METABOLIC COMPARTMENTATION OF AMINO-ACIDS.

002896-04-03 MOUSE BRAIN TYROSINE-HYDROXYLASE AND GLUTAMIC-ACID-

DECARBOXYLASE FOLLOWING TREATMENT WITH ADRENOCORTICOTROPHIC HORMONE, VASOPRESSIN OR 002898 04-03

CHARACTERISTICS OF MONOAMINE-OXIDASES IN BRAIN AND OTHER ORGANS OF THE GOLDEN HAMSTER.

002900 04-03 DIFFERENT BRAIN AREAS MEDIATE THE ANALGESIC AND EPILEPTIC PROPERTIES OF ENKEPHALIN

002915 04-03 REGIONAL BRAIN ATROPHY AND REDUCTIONS IN GLUTAMATE RELEASE AND UPTAKE AFTER INTRASTRIATAL KAINIC-ACID

002917 04-03 COMPARATIVE EFFECTS OF PEMOLINE, AMFONELIC-ACID AND AMPHETAMINE ON DOPAMINE UPTAKE AND RELEASE IN VITRO AND ON BRAIN 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN SPIPERONE-TREATED RATS

INFLUENCE OF LITHIUM ON DOPAMINE STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT BRAIN.

SOLUBILIZATION OF H3-SPIPERONE BINDING SITES FROM RAT BRAIN 002929 04-03

ACTIVE UPTAKE OF H3-5-HT BY SYNAPTIC VESICLES FROM RAT BRAIN 002937 04-03 ADENOSINE MODULATES DEPOLARIZATION-INDUCED RELEASE OF H3-

NORADRENALINE FROM SLICES OF RAT BRAIN NEOCORTEX 002938 04-03 INTERACTIONS OF ADRENERGIC COMPOUNDS WITH BRAIN MEMBRANE

002939 04-03 H3-CLOZAPINE BINDING TO RAT BRAIN MEMBRANES.

002940 04-03

DEMONSTRATION OF NEUROLEPTIC RECEPTOR SITES IN MOUSE BRAIN BY AUTORADIOGRAPHY

CHANGES OF TAURINE CONTENT IN THE BRAIN TISSUE OF BARBITURATE DEPENDENT RATS

ANTAGONISM OF MORPHINE ACTION ON BRAIN ACETYLCHOLINE RELEASE BY METHYLXANTHINES AND CALCIUM.

THE ANTAGONISM OF THE ANALGESIC EFFECT OF DIPYRONE BY L-DOPA AND ITS RELATION TO BRAIN AMINE CONCENTRATIONS

AROMATIC AMINOTRANSFERASE ACTIVITY OF RAT BRAIN CYTOPLASMIC AND MITOCHONDRIAL ASPARTATE AMINOTRANSFERASES.

002978 04-03 STRUCTURE-ACTIVITY STUDIES ON THE INHIBITION OF GABA BINDING TO RAT BRAIN MEMBRANES BY MUSCIMOL AND RELATED COMPOUNDS. 002981 04-03 SUBCELLULAR LOCALIZATION OF C14-METHAQUALONE IN MOUSE BRAIN: EFFECTS OF HEPATIC MICROSOMAL ENZYME INHIBITION.

CHARACTERIZATION OF SPECIFIC IN VIVO BINDING OF NEUROLEPTIC

002985 04-03
CHRONIC NALOXONE RESULTS IN PROLONGED INCREASES IN OPIATE BINDING SITES IN BRAIN.

REGIONAL LOCALIZATION OF HALOPEMIDE, A NEW PSYCHOTROPIC AGENT. IN THE RAT BRAIN.

002989 04-03 CHANGES IN BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS FOLLOWING ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION AND DURING POST AMPHETAMINE DEPRESSION.

MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING HORMONE. SOMATISTATIN MELIDOTENERS HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II. 002994 04-03

DEMONSTRATION OF AN ENDOGENOUS, COMPETITIVE INHIBITOR(S) OF H3-DIAZEPAM BINDING IN BOVINE BRAIN.

THE EFFECT OF BROMOCRIPTINE ON RAT STRIATAL ADENYLATE-CYCLASE AND RAT BRAIN MONOAMINE METABOLISM.

002998 04-03 THE EFFECT OF VILOXAZINE HYDROCHLORIDE ON THE TRANSPORT OF NORADRENALINE, DOPAMINE, 5 HYDROXYTRYPTAMINE AND GAMMA-AMINOBUTYRIC-ACID IN RAT BRAIN TISSUE.

003001 04-03 EVALUATION OF THE EFFECT OF P-CHLOROAMPHETAMINE ON INDIVIDUAL CATECHOLAMINERGIC NUCLEI IN THE RAT BRAIN

003003 04-03 EFFECTS OF PENTYLENETETRAZOLE AND TRIMETHADIONE ON FELINE BRAIN MONOAMINE METABOLISM

CHANGES IN BRAIN TRYPTOPHAN AND TYROSINE FOLLOWING ACUTE AND CHRONIC MORPHINE ADMINISTRATION.

STIMULATION BY LITHIUM-IONS OF THE INCORPORATION OF C14-GLUCOSE INTO GLYCOGEN IN RAT BRAIN SLICES.

003015 04-03 INHIBITION OF MONOAMINE OXIDATION IN SUBFRACTIONS OF CRUDE MITOCHONDRIA OF RAT BRAIN BY CLORGYLINE AND LILLY-51641. 003020 04-03

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLETHANOL (MOPET) IN HUMAN CEREBROSPINAL FLUID AND RAT BRAIN BY MEANS OF GAS-CHROMATOGRAPHY — MASS-SPECTROMETRY

EFFECTS OF PAIN ATTENUATING BRAIN STIMULATION AND MORPHINE ON ELECTRICAL ACTIVITY IN THE RAPHE NUCLEI OF THE AWAKE RAT. 003034 04-03

HIGH AFFINITY BINDING OF H3-HISTAMINE IN RAT BRAIN. 003036 04-03

H3-SPIROPERIDOL BINDING TO TWO RECEPTOR SITES IN BOTH THE CORPUS-STRIATUM AND FRONTAL CORTEX OF RAT BRAIN EFFECTS OF LSD AND BOL ON THE CATECHOLAMINE SYNTHESIS AND

TURNOVER IN VARIOUS BRAIN REGIONS

EFFECT OF GINSENG ON THE BRAIN BIOGENIC MONOAMINES AND 3,5
AMP SYSTEM: EXPERIMENTS ON RATS. LITHIUM EFFECTS ON RAT BRAIN GLUCOSE METABOLISM IN LONG-TERM LITHIUM TREATED RATS STUDIED IN VIVO.

003046 04-03 DELTA9-TETRAHYDROCANNABINOL-INDUCED CHANGES IN BRAIN

INHIBITION BY BARBITURIC-ACID AND ITS DERIVATIVES OF THE ENZYMES IN RAT BRAIN WHICH PARTICIPATE IN THE SYNTHESIS OF PYRIMIDINE

003049 04-03 REGIONAL CHANGES IN THE CONCENTRATIONS OF CEREBRAL MONOAMINES AND THEIR METABOLITES AFTER ETHANOLAMINE-O-SULPHATE-INDUCED ELEVATION OF BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS.

003053 04-03 H3-GLYCOGEN HYDROLYSIS IN BRAIN SLICES: RESPONSES TO NEUROTRANSMITTERS AND MODULATION OF NORADRENALINE

003054 04-03 SEIZURE SUSCEPTIBILITY AND ANTICONVULSANT ACTIVITY OF CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES.

003055 04-03 EFFECT OF VASOACTIVE INTESTINAL PEPTIDE (VIP) AND OTHER PEPTIDES ON C-AMP ACCUMULATION IN RAT BRAIN. 003056 04-03

EFFECTS OF ETHANOL WITHDRAWAL, STRESS AND AMPHETAMINE ON RAT BRAIN NA-K-ATPASE. 003060 04-03 EVIDENCE FOR THE ROLE OF ADRENOCORTICAL HORMONES IN THE REGULATION OF NORADRENALINE AND DOPAMINE METABOLISM IN CERTAIN BRAIN AREAS.

003062 04-03 THE DIFFERENTIAL EFFECT OF LITHIUM ON NORADRENALINE AND DOPAMINE SENSITIVE ACCUMULATION OF CYCLIC-AMP IN GUINEA-PIG

EFFECT OF L-DOPA PRETREATMENT ON IN VIVO PROTEIN SYNTHESIS IN VARIOUS RAT BRAIN REGIONS.

003068 04-03 EFFECT OF () AMPHETAMINE ON THE RETENTION OF H3-CATECHOLAMINES IN SLICES OF NORMAL AND RESERPINIZED RAT BRAIN AND HEART.

003071 04-03 EVIDENCE OF AN INTERACTION BETWEEN SEROTONINERGIC AND CHOLINERGIC NEURONS IN THE CORPUS-STRIATUM AND HIPPOCAMPUS OF THE RAT BRAIN.

003074 04-03 BRAIN AND RETINA UPTAKE OF A RADIOIODINE LABELED PSYCHOTOMIMETIC IN DOG AND MONKEY.

THE ROLE OF CALCIUM IN THE REGULATION OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN SLICES OF RAT AND GUINEA-PIG.

003079 04-03 A CONTRIBUTION TO THE NEUROCHEMICAL BASIS OF THE PYRITHIOXIN EFFECT ON THE BRAIN GLUCOSE UTILISATION DURING RELATIVE BRAIN HYPOGLYCAEMIA INDUCED BY ANTICIPATION STRESS.

TIME-COURSE OF THE INCREASE IN GABA LEVEL IN DIFFERENT MICE BRAIN REGIONS FOLLOWING N DIPROPYLACETATE TREATMENT.

003091 04-03 CHANGES IN BRAIN FREE FATTY-ACIDS AFTER PAINFUL PERIPHERAL STIMULATION (EFFECT OF PROTHIADEN).

003094 04-03 INFLUENCE OF NEUROLEPTICS ON THE BINDING OF MET-ENKEPHALIN, MORPHINE AND DIHYDROMORPHINE TO SYNAPTOSOME ENRICHED FRACTIONS OF RAT BRAIN.

CHOLINERGIC STIMULATION OF POLYPHOSPHOINOSITIDE METABOLISM IN BRAIN IN VIVO.

EFFECT OF STRESS ON NOREPINEPHRINE STIMULATED CYCLIC-AMP FORMATION IN BRAIN SLICES.

LACK OF ENHANCEMENT OF DIMETHYLTRYPTAMINE FORMATION IN RAT BRAIN AND RABBIT LUNG IN VIVO BY METHIONINE OR S ADENOSYLMETHIONINE.

003102 04-03
EFFECTS OF MAZINDOL ON RAT BRAIN SYNAPTOSOMAL MONOAMINE

RELEASE OF ENDOGENOUS CATECHOLAMINES FROM ISOLATED RAT BRAIN TISSUE BY FENFLURAMINE AND N ETHYLAMPHETAMINE

FFFECTS OF PARGYLINE 003111 04-03

H3-SPIROPERIDOL BINDING AND DOPAMINE STIMULATED ADENYLATE-CYCLASE: EVIDENCE FOR MULTIPLE CLASSES OF RECEPTORS IN PRIMATE BRAIN REGIONS. H3-APOMORPHINE INTERACTIONS WITH DOPAMINE RECEPTORS IN CALF

TRICYCLIC ANTIDEPRESSANTS: THERAPEUTIC PROPERTIES AND AFFINITY FOR ALPHA-NORADRENERGIC RECEPTOR BINDING SITES IN THE BRAIN. 003118 04-03 H3-CATECHOLAMINE BINDING TO ALPHA-RECEPTORS IN RAT BRAIN: ENHANCEMENT BY RESERPINE.

ADRENERGIC ALPHA-RECEPTORS AND BETA-RECEPTORS EXPRESSED BY THE SAME CELL TYPE IN PRIMARY CULTURE OF PERINATAL MOUSE

POSSIBLE ROLE OF BRAIN SEROTONIN IN THE CENTRAL EFFECTS OF KETAMINE KETAMINE.

003123 04-03 EFFECT OF RESERPINE ON THE MONOAMINE-OXIDASE (MAO) ACTIVITY IN RAT LIVER AND BRAIN.

THE EFFECT OF GAMMA-AMINOBUTYRIC-ACID ON H3-FLUNITRAZEPAM BINDING IN RAT BRAIN.

002132 04-03 INHIBITION OF CA45 MOVEMENTS BY LOWERED TEMPERATURE OR LANTHANUM IN RAT BRAIN SLICES.

RADIOIMMUNOASSAY OF ENKEPHALINS: REGIONAL DISTRIBUTION IN RAT BRAIN AFTER MORPHINE TREATMENT AND HYPOPHYSECTOMY 003136 04-03 CLOZAPINE CONCENTRATIONS IN BRAIN REGIONS: RELATIONSHIP TO DOPAMINE METABOLITE INCREASE.

THE IN VIVO BINDING OF H3-DESIPRAMINE AND H3-CHLORPROMAZINE TO AREAS IN THE RAT BRAIN.

003145 04-03 EFFECTS OF N METHYLAMINOETHANOL, AND N, N
DIMETHYLAMINOETHANOL IN THE DIET OF PREGNANT RATS ON
NEONATAL RAT BRAIN CHOLINERGIC AND PHOSPHOLIPID PROFILE

BRAIN MECHANISMS OF AMPHETAMINE-INDUCED ANOREXIA, LOCOMOTION, AND STEREOTYPY: A REVIEW. 003189 04-04

OPIOIDS AND REWARDING BRAIN STIMULATION 003216 04-04 **NEUROLEPTIC-INDUCED ATTENUATION OF BRAIN STIMULATION REWARD**

THE EFFECTS OF D ALA2-MET5-ENKEPHALINAMIDE ON BEHAVIORAL ACTIVITY AND CYCLIC-NUCLEOTIDES IN THE RAT BRAIN. (PH.D. DISSERTATION).

INHIBITION OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND BRAIN STIMULATED REWARD.

CIRCADIAN SUSCEPTIBILITY RHYTHM TO APOMORPHINE IN THE BRAIN CATECHOLAMINE LEVELS IN THE WHOLE BRAIN AND THE PROBABILITY OF MEMORY FORMATION ARE NOT RELATED.

THE RELATIONSHIP BETWEEN PIPRADROL-INDUCED RESPONDING FOR ELECTRICAL BRAIN STIMULATION, STEREOTYPED BEHAVIOUR AND LOCOMOTOR ACTIVITY.

003347 04-04

EFFECTS OF SODIUM PHENOBARBITAL ON BRAIN STIMULATION
BEHAVIOR, BEHAVIORAL SEIZURES, AND EEG SEIZURE ACTIVITY 003355 04-04

003355

EXPERIMENTAL LEAD ENCEPHALOPATHY IN THE SUCKLING RAT:
CONCENTRATION OF LEAD IN CELLULAR FRACTIONS ENRICHED IN
BRAIN CAPILLARIES.

003420 04-05 LITHIUM NEUROTOXICITY. I. THE CONCENTRATION OF LITHIUM IN DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS ATOMIC ABSORPTION SPECTROPHOTOMETRY.

ROUTINE MEASUREMENT OF HOMOVANILLIC-ACID IN RAT BRAIN BY GAS-LIQUID-CHROMATOGRAPHY.

BIOCHEMICAL EFFECTS IN MAN AND RAT OF THREE DRUGS WHICH CAN INCREASE BRAIN GABA CONTENT.

003604 04-13 DOCTORS DEBATE BRAIN HORMONE DILEMMAS.

003718 04-17

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES: MESCALINE-DEMETHYLASE ACTIVITY OF BRAIN-CORTEX SOLUBLE

000090 01-03 MAGNIFICATION OF SOME ENZYMATIC ACTIVITIES OF BRAIN-CORTEX

003127 04-03 BRAIN-DAMAGED P-CHLOROPHENYLALANINE PRODUCED EFFECTS ON BEHAVIOR IN INTACT AND BRAIN-DAMAGED RATS.

000421 01-04 EFFECT OF PIRACETAM ON BRAIN-DAMAGED, LEARNING-DISABLED

CHILDREN. 000785 01-14

CATECHOLAMINE AND OCTOPAMINE CONCENTRATIONS IN BRAINS OF PATIENTS WITH REYE SYNDROME. 000712 01-13

BRAINSTEM STEREOSPECIFIC ACTIONS OF MORPHINE ON SINGLE NEURONES IN THE BRAINSTEM OF THE RAT.

000060 01-03 EFFECTS OF RETICULAR STIMULATION, D AMPHETAMINE AND SCOPOLAMINE ON ACETYLCHOLINE RELEASE FROM THE HIPPOCAMPUS OF BRAINSTEM TRANSECTED CATS.

000098 01-03 MAO ACTIVITY IN RAT BRAINSTEM AND CEREBRAL-CORTEX FOLLOWING ACUTE AND CHRONIC TREATMENT WITH L-DOPA AND ETHANOL L-DOPA.

EFFECTS OF D AMPHETAMINE ON CONCURRENT SELF-STIMULATION OF FOREBRAIN AND BRAINSTEM LOCI.

THE EFFECT OF ABLATION OF SEROTONIN OR NOREPINEPHRINE BRAINSTEM AREAS ON HALOTHANE AND CYCLOPROPANE MAC IN RATS. (UNPUBLISHED PAPER). 001229 02-03

OLUME 10, SUBJECT INDEX	
EFFECTS OF CENTRALLY ACTING DRUGS ON BRAINSTEM	AUDITORY
RESPONSES.	002598 03-13
CLINICAL VALUE OF THE BRAINSTEM EVOKED RESPONSE	002650 03-15
EFFECTS OF MORPHINE ON BRAINSTEM NEURONES IN N. CHRONIC MORPHINE TREATED RATS, AND EFFECTS OF	AIVE AND
RATTLEBORO	
TIME-COURSE OF LITHIUM-INDUCED ALTERATIONS IN RE ENDOCRINE FUNCTION IN NORMAL AND BRATTLEBOR HYPOTHALAMIC DIABETES-INSIPIDUS.	O RATS WITH
REAKDOWN	000048 01-03
BREAKDOWN OF ENKEPHALIN AND ENDORPHIN ANALOGE EXTRACTS.	GS BY BRAIN
STUDIES ON THE INHIBITION OF PHOSPHODIESTERASE C. CYCLIC-AMP AND CYCLIC-GMP BREAKDOWN AND RE CANINE TRACHEAL SMOOTH MUSCLE.	LAXATION OF
NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHO OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGI SYMPATHETIC DENERVATION AND IN VIVO ELECTRIC OF THE SYMPATHETIC NERVE OF THE EYE.	002129 03-03 DSPHOINOSITIDE ICAL AL STIMULATION
	002802 04-03
PHOTODYNAMIC ACTION OF CHLORPROMAZINE ON ADI REPAIRABLE DAMAGE AND SINGLE STRAND BREAKS.	ENOVIRUS 5:
	000821 01-15
PRIOR PSYCHIATRIC TREATMENT AND THE DEVELOPME CANCER.	NT OF BREAST
PROLACTIN AND BREAST CANCER.	002691 03-15
PRIOR PSYCHIATRIC TREATMENT AND THE DEVELOPME	002697 03-15 NT OF BREAST
CANCER.	003674 04-15
DOSE-RESPONSE EFFECTS OF ALCOHOL UPON RAT STRA	INS BRED FOR
DIFFERENCES IN REACTIVITY TO ALCOHOL.	001498 02-04
DIFFERENTIAL TOLERANCE TO PENTOBARBITAL IN RATS DIFFERENCES IN ALCOHOL SENSITIVITY.	003338 04-04
BRIGHTNESS	
EFFECT OF SCOPOLAMINE ON RETENTION OF A SHOCK A BRIGHTNESS DISCRIMINATION IN RATS.	MOTIVATED
	001487 02-04
BRL-13776 BRL-13776: A NOVEL ANTIHYPERTENSIVE AGENT WITH MONOAMINE DEPLETING PROPERTIES.	INTERESTING
	001007 02-01
PILOT OPEN-LABEL STUDY OF BROFOXINE IN ANXIETY.	002479 03-10
BETA-ADRENERGIC RECEPTOR MEDIATED CYCLIC-AMP S	
BROKEN-CELL HOMOGENATES OF RAT BRAIN.	002033 03-03
BROMAZEPAM	002033 03-03
ALTERATIONS IN BRAIN 5 HYDROXYTRYPTAMINE META THE WITHDRAWAL PHASE AFTER CHRONIC TREATME DIAZEPAM AND BROMAZEPAM.	NT WITH
A PLACEBO-CONTROLLED STUDY OF BROMAZEPAM AN ANXIETY NEUROSIS.	000038 01-03 D DIAZEPAM IN
BROMCARBAMIDES	003542 04-10
INCORPORATION OF RADIOACTIVE LABELLED CHOLINE A INTO LUNG LECITHIN OF RABBITS TREATED WITH HIG BROMCARBAMIDES, BARBITURATES AND DIAZEPAN	SH DOSES OF
	001282 02-03
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF BROW	AIDE PSYCHOSIS. 000800 01-15
ON PSYCHOLOGICAL SYMPTOMS IN BROMIDE INTOXIC OF HIGH DOSE, LONG-TERM BROMIDE INTOXICATION HALLUCINATION AND DELUSION SYMPTOMS.	ATION ONE CASE
HALLUCINATION AND DELUSION SYMPTOMS.	000880 01-15

BROMIDE INTOXICATION IN THE ELDERLY.

BROMOCRIPTINE AND LERGOTRILE.

DIFFERENTIAL EFFECTS OF THREE DOPAMINE AGONISTS: APOMORPHINE,

THE EFFECT OF BROMOCRIPTINE ON LOCOMOTOR ACTIVITY AND CEREBRAL CATECHOLAMINES IN RODENTS.

BROMOCRIPTINE AND GASTRIC ACID OUTPUT. 001761 02-15 EVIDENCE FOR SELECTIVE AND LONG-LASTING STIMULATION OF REGULATORY DOPAMINE RECEPTORS BY BROMOCRIPTINE (CB-154).

002002 03-03
BROMOCRIPTINE: EFFECT ON SERUM PROLACTIN AND GROWTH HORMONE IN PSYCHOGERIATRIC HOSPITAL PATIENTS. BROMOCRIPTINE, DIHYDROERGOTOXINE, METHYSERGIDE, D LSD, CF-25-397, AND CF-29-712: EFFECTS ON THE METABOLISM OF BIOGENIC AMINES IN THE BRAIN OF THE RAT. THE EFFECT OF BROMOCRIPTINE ON RAT STRIATAL ADENYLATE-CYCLASE AND RAT BRAIN MONOAMINE METABOLISM. DIFFERENCES IN THE DOPAMINERGIC EFFECTS OF THE ERGOT
DERIVATIVES BROMOCEUTINE ALEXANDER AND THE ERGOT DERIVATIVES BROMOCRIPTINE, LISURIDE AND D LSD AS COMPARED WITH APOMORPHINE. BROMODIMETHOXYAMPHETAMINE
A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHOXYAMPHETAMINE
(DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), PMETHOXYAMPHETAMINE (PMA), D AMPHETAMINE (A), AND LSD IN
NONTOLERANT AND LSD TOLERANT CHRONIC SPINAL DOGS. 001273 02-03 BROMOLYSERGIC-ACID-DIETHYLAMIDE THE EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND 2
BROMOLYSERGIC-ACID-DIETHYLAMIDE (BOL) ON THE STRIATAL DOPA
ACCUMULATION: INFLUENCE OF CENTRAL 5 HYDROXYTRYPTAMINERGIC PATHWAYS 002125 03-03 IMPERIOD.

DOUBLE-BLIND COMPARISON OF BROMPERIOD. AND PERPHENAZINE.

003476 04-08 PROLIXIN-DECANOATE: BIG BROTHER BY INJECTION?. 001940 02-17 THE ROLE OF SEROTONIN ANTAGONISM IN THE TREMORGENIC ACTION OF BLIFOTENINE IN MICE BULB EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) ON SLEEP IN OLFACTORY BULB LESIONED RATS 000032 01-02 OLFACTORY BULB ABLATION IN THE RAT: BEHAVIOURAL CHANGES AND THEIR REVERSAL BY ANTIDEPRESSANT DRUGS. 000466 01-04 CONTROL OF THE RAT OLFACTORY BULB ACTIVITY INDUCED BY BIOLOGICALLY SIGNIFICANT ODORS. 001324 02-04 BUILDAD CNS SITE OF CLONIDINE-INDUCED HYPOTENSION: A MICROIONTOPHORETIC STUDY OF BULBAR CARDIOVASCULAR **NEURONS** 003086 04-03 CONDITIONED TASTE AVERSIONS: GENOTYPE BY OLFACTORY BULBECTOMY INTERACTION. 002334 03-04 BULLFROG POSTSYNAPTIC POTENTIATION OF THE SLOW MUSCARINIC EXCITATORY RESPONSE BY TETRAETHYLAMMONIUM-CHLORIDE IN THE BULLFROG SYMPATHETIC GANGLION CELLS. BUNDLE ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5 MEODMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR 000086 01-03 ROLE OF THE DORSAL NORADRENERGIC BUNDLE IN BEHAVIOUR CONTROL 000407 01-04 NEONATAL SYSTEMIC 6 HYDROXYDOPAMINE AND DORSAL TEGMENTAL BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEFHRINE AND THE POSTDECAPITATION REFLEX. PARAMETERS OF THE DORSAL BUNDLE EXTINCTION EFFECT: PREVIOUS EXTINCTION EXPERIENCE. 003289 04-04 RUPEFNORPHINE AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT. 000018 01-02 BUPROPION-HCL
A DOUBLE-BLIND CLINICAL TRIAL OF BUPROPION-HCL -- A NOVEL

003676 04-15

000451 01-04

001346 02-04

Psychopharmacology Abstracts

BUPROFION-HYDROCHLORIDE			
BUPROPION-HYDROCHLORIDE	((/-)	ALPHA-1	-BUTYLAM
CHLOROPROPIOPHENONE H	(1). 4	NOVEL	ANTIDEPRE

CHLOROPROPIOPHENONE HCL): A NOVEL ANTIDEPRESSANT AGENT. 001038 02-02 DUBLE-BLIND PLACEBO-CONTROLLED STUDY OF BUPPROPIOR

DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF BUPROPION-HYDROCHLORIDE (WELLBATRIN) IN THE TREATMENT OF DEPRESSED INPATIENTS. 002430 03-09

- CANT

THE EFFECT OF MELPERONE (BURONIL(R)) AND ITS METABOLITE FG-5155
ON THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM COMPARED TO SOME
OTHER NEUROLEPTICS.

001081 02-03

BURST FIRING OF CEREBELLAR PURKINJE NEURONES INDUCED BY BENZODIAZEPINES.

001061 02-03

BUTACLAMOL

EVALUATION OF BUTACLAMOL IN CHRONIC SCHIZOPHRENIC PATIENTS. 10

001649 02-13

BUTACLAMOL IN THE TREATMENT OF SCHIZOPHRENIA. A STANDARD-

BUTACLAMOL IN THE TREATMENT OF SCHIZOPHRENIA. A STANDARD-CONTROLLED CLINICAL TRIAL. 003465 04-08

THE PHARMACOKINETICS OF RED BLOOD CELL AND PLASMA BUTAPERAZINE CLINICAL RESPONSE AND SIDE-EFFECTS.

PLASMA BUTAPERAZINE LEVELS IN LONG-TERM CHRONIC NONRESPONDING SCHIZOPHRENICS.

BUTRIPTYLINE 001569 02-08

A NEW ANTIDEPRESSANT BUTRIPTYLINE: PLASMA LEVELS AND CLINICAL RESPONSE. 002423 03-09

BUTTON
TRITERPENES FROM THE BUTTON CACTUS, EPITHELANTHA-MICROMERIS.
001018 02-01

ANTIPSYCHOTIC EFFECTS, SIDE-EFFECTS AND EFFECTIVE DOSES OF THE BUTYROPHENONE LENPERONE (ANR-2277).

FEEDING AND DRINKING INTERACTIONS AFTER ACUTE BUTYROPHENONE

BUTYROPHENONES 001446 02-0

EFFECTS OF BUTYROPHENONES ON THE SYMPATHETIC NERVES OF THE ISOLATED RABBIT HEART AND ON THE POSTSYNAPTIC ALPHA-ADRENOCEPTORS OF THE ISOLATED RABBIT AORTA.

002026 03-03

MUSCARINIC REGULATION OF C-AMP IN MOUSE NEUROBLASTOMA.
000058 01-03

THE INFLUENCE OF CAFFEINE AND THEOBROMINE ON LOCOMOTIVE ACTIVITY AND THE BRAIN C-GMP/C-AMP RATIO IN WHITE MICE.

000275 01-03

EFFECT OF VASOACTIVE INTESTINAL PEPTIDE (VIP) AND OTHER PEPTIDES ON C-AMP ACCUMULATION IN RAT BRAIN.

C-AMP-PHOSPHODIESTERASE

CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF

DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN

STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF

C-AMP-PHOSPHODIESTERASE.

C-AMP-PHOSPHODIESTERASE.

002023 03-03

GAMMA-ENDORPHIN, ALPHA-ENDORPHIN AND MET-ENKEPHALIN ARE FORMED EXTRACELLULARLY FROM LIPOTROPIN C-FRAGMENT. 001963 03-03

THE INFLUENCE OF CAFFEINE AND THEOBROMINE ON LOCOMOTIVE ACTIVITY AND THE BRAIN C-GMP/C-AMP RATIO IN WHITE MICE. 000275 01-03

PHARMACOLOGICAL EVIDENCE FOR A LINK BETWEEN THE CEREBELLAR CONTENT OF C-GMP AND THAT OF AN ENDOGENOUS PROTEIN KINASE INHIBITOR.

O02031 03-03
ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING

ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY BENZODIAZEPINES.

002326 03-04

C-TERMINAL
SOME BEHAVIORAL EFFECTS OF SP6-11 HEXAPEPTIDE C-TERMINAL OF
SUBSTANCE-P INJECTED INTO THE CEREBRAL VENTRICLES IN RATS.
002267 03-04
BIOLOGICAL ACTIVITY OF NEUROTENSIN AND ITS C-TERMINAL PARTIAL
SEQUENCES

C-49802-B-BA
SELECTIVE INHIBITION OF NORADRENALINE AND SEROTONIN UPTAKE BY
C-49802-B-BA AND CGP-6085-A.
001960 03-02

CILIOINHIBITORY EFFECT OF PHENOTHIAZINES IN VITRO AND ITS ANTAGONISM BY CA.

EFFECTS OF NA, K, MG AND CA ON THE SATURABLE BINDING OF (3H)DHYDROMORPHINE AND (3H)NALOXONE IN VITRO.

BLOCKADE OF SYNAPTOSOMAL CA UPTAKE BY OPIATES IN VITRO. 001075 02-03

EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON SYNAPTOSOMAL CA UPTAKE.

CACTUS ALKALOIDS XXXIII: BETA-PHENETHYLAMINES FROM THE GUATEMALAN CACTUS PILOSOCEREUS-MAXONII.

001011 02-01
TRITERPENES FROM THE BUTTON CACTUS, EPITHELANTHA-MICROMERIS.
001018 02-01

THE INFLUENCE OF CAFFEINE AND THEOBROMINE ON LOCOMOTIVE ACTIVITY AND THE BRAIN C-GMP/C-AMP RATIO IN WHITE MICE. 000275 01-03

CAFFEINE RESTORES FEEDING RESPONSE TO 2 DEOXY-D-GLUCOSE IN 6
HYDROXYDOPAMINE TREATED RATS.
000277 01-03

CAFFEINE POTENTIATION OF AMPHETAMINE: IMPLICATIONS FOR HYPERKINESIS THERAPY.

EVIDENCE FOR WITHDRAWAL FROM CAFFEINE BY RATS.

STIMULATION OF CAFFEINE METABOLISM IN THE RAT BY 3
METHYLCHOLANTHRENE.

CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT RHESUS MONKEYS.

001296 02-04
CAFFEINE AND INATTENTIVENESS IN READING-DISABLED CHILDREN.
001721 02-14

COMPARATIVE TOXICITY OF CAFFEINE AND AMINOPHYLLINE IN YOUNG AND ADULT RATS.

THE INFLUENCE OF CAFFEINE ON THE PREVALENCE OF ALPHA RHYTHM.

002550 03-13

CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT
RHESUS MONKEYS.

003152 04-04
THE EFFECTS OF CAFFEINE AND METHYLPHENIDATE ON HYPERACTIVE CHILDREN

003626 04-14

BRAIN CALCIUM AND MORPHINE ACTION.

O00253 01-03

EFFECTS OF BETA-BUNGAROTOXIN, DIPHENYLHYDANTOIN AND
METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT
CATIONS AND HIGH-ENERGY PHOSPHATE CONTENTS OF BRAIN SLICES.

O00278 01-03

ACTIVATION OF TRYPTOPHAN-HYDROXYLASE BY DEPOLARIZATION: ROLE
OF CALCIUM.

O01060 02-03

CALCIUM CONTENT AND BINDING IN SYNAPTOSOMAL SUBFRACTIONS
DURING CHRONIC MORPHINE TREATMENT.

ROLE OF CALCIUM IN THE AMPHETAMINE-INDUCED STIMULATION OF CATECHOL FORMATION IN THE STRIATUM.

001268 02-03
REDUCED RENAL CALCIUM EXCRETION DURING LITHIUM THERAPY.
001597 02-09

A NEW MECHANISM OF TRICYCLIC ANTIDEPRESSANT ACTION. BLOCKADE OF PROSTAGLANDIN DEPENDENT CALCIUM MOVEMENTS.

002043 03-03

EFFECTS OF CHLORPROMAZINE AND DL-AMPHETAMINE ON CALCIUM UPTAKE BY ADRENAL CHROMAFFIN CELL MEMBRANE. 002075 03-03

ACETYLCHOLINE ANTIRELEASE EFFECT OF MORPHINE AND ITS MODIFICATION BY CALCIUM. 002143 03-03

CALCIUM METABOLISM IN LITHIUM TREATED PATIENTS: RELATION TO UNIPOLAR DICHOTOMY. 002420 03-09

ANTAGONISM OF MORPHINE ACTION ON BRAIN ACETYLCHOLINE RELEASE BY METHYLXANTHINES AND CALCIUM. 002966 04-03

THE ROLE OF CALCIUM IN THE REGULATION OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN SLICES OF RAT AND GUINEA-PIG.

003079 04-03

002973 04-03

001999 03-03

ø	0	Δ		я	g.
ъ	ø	м	м	a	۰

H3-APOMORPHINE INTERACTIONS WITH DOPAMINE RECEPTORS IN CALE

CALORIC

003113 04-03

FENFLURAMINE AND FLUOXETINE SPARE PROTEIN CONSUMPTION WHILE SUPPRESSING CALORIC INTAKE BY RATS.

002184 03-03

THE RESULTS OF A CAMPAIGN TO EDUCATE PHYSICIANS IN ANTIPSYCHOTIC DRUG USAGE.

002761 03-17

CANADA HOW CANADA HOLDS DOWN DRUG COSTS

001895 02-17

CANADIAN NOMIFENSIN IN THE TREATMENT OF DEPRESSION: A REPORT ON THE CANADIAN PART OF A TRANSCULTURAL STUDY. 002414 03-09

CANCER

THE PEAK EXPERIENCE VARIABLE IN OPT ASSISTED PSYCHOTHERAPY WITH CANCER PATIENTS

000679 01-12 DIPROPYLTRYPTAMINE (DPT) AS AN ADJUNCT IN THE COUNSELING OF CANCER PATIENTS.

PRIOR PSYCHIATRIC TREATMENT AND THE DEVELOPMENT OF BREAST CANCER

PROLACTIN AND RREAST CANCER

002691 03-15 002697 03-15

PRIOR PSYCHIATRIC TREATMENT AND THE DEVELOPMENT OF BREAST CANCER 003674 04-15

STUDIES ON THE INHIBITION OF PHOSPHODIESTERASE CATALYZED CYCLIC-AMP AND CYCLIC-GMP BREAKDOWN AND RELAXATION OF CANINE TRACHEAL SMOOTH MUSCLE.

002129 03-03 EFFECTS OF CLONIDINE ON VULNERABILITY TO FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE VENTRICLE.

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON A MG2-ATPASE OF SYNAPTIC VESICLES PREPARED FROM RAT CEREBRAL-

CORTEX 000123 01-03 ANTICONVULSANT INTERACTION OF CANNABIDIOL AND ETHOSUXIMIDE IN RATS

000339 01-04 THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, AND CANNABINOL ON THE ANESTHESIA INDUCED BY VARIOUS ANESTHETIC AGENTS IN MICE.

HYPNOTIC-LIKE EFFECTS OF CANNABIDIOL IN THE RAT.

002284 03-04 EFFECTS OF MARIJUANA EXTRACT DISTILLATE AND CANNABIDIOL ON VARIABLE INTERVAL PERFORMANCE AS A FUNCTION OF FOOD DEPRIVATION.

003308 04-04

002015 03-03

CANNABINOID

HYPOTHERMIA IN RATS PRODUCED BY NABILONE, A SYNTHETIC CANNARINGID

000213 01-03 INTRAOCULAR PRESSURE LOWERING PROPERTIES OF ABBOTT-43981 CANNABINOID DERIVED HETEROCYCLIC BENZOPYRAN WITH MINIMAL CNS ACTIVITIES.

001025 02-02 SOLID DISPERSION APPROACH FOR OVERCOMING BIOAVAILABILITY PROBLEMS DUE TO POLYMORPHISM OF NABILONE, A CANNABINOID DERIVATIVE

001539 02-06 EVIDENCE FOR THE EXISTENCE OF SPECIFIC CANNABINOID BINDING SITES 002034 03-03

CANNABINOID EFFECTS ON PLASMA CORTICOSTERONE AND UPTAKE OF H3-CORTICOSTERONE BY MOUSE BRAIN. 002051 03-03

NABILONE, A CANNABINOID, IN THE TREATMENT OF ANXIETY: AN OPEN-LABEL AND DOUBLE-BLIND STUDY. 003538 04-10

CANNABINOIDS

ISOLATION AND CHARACTERIZATION OF () CANNABITRIOL AND (-) 10 ETHOXY-9-HYDROXY-DELTA6A-TETRAHYDROCANNABINOL: TWO NEW CANNABINOIDS FROM CANNABIS-SATIVA L. EXTRACT. 000004 01-01

EFFECT OF CANNABINOIDS ON NEUROTRANSMITTER UPTAKE, ATPASE ACTIVITY AND MORPHOLOGY OF MOUSE BRAIN SYNAPTOSOMES. 000143 01-03

SEPARATION OF CANNABINOIDS

001013 02-01

MASS SPECTROMETRY OF CANNABINOIDS.

001016 02-01 CANNABINOIDS. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY
OF 8 SUBSTITUTED HYDROXY-DIMETHYLBENZOPYRANOPYRIDINE AND

001034 02-02 EFFECTS OF CANNABINOIDS ON L1210 MURINE LEUKEMIA: 1. INHIBITION OF DNA SYNTHESIS

001266 02-03 EFFECTS OF CANNABINOIDS ON UNLEARNED BEHAVIOR ANIMALS 001955 03-02

CANNABINOIDS INHIBIT TESTOSTERONE SECRETION BY MOUSE TESTES IN VITRO

TIME-COURSE OF THE EFFECTS OF NATURALLY OCCURRING CANNABINOIDS ON MORPHINE ABSTINENCE SYNDROME

002196 03-04 FFFECT OF CANNARINOIDS ON THE UPTAKE OF SEROTONIN IN HUMAN PLATELETS.

002603 03-13 THE EFFECTS OF CANNABINOIDS ON BODY TEMPERATURE AND BRAIN CATECHOLAMINE SYNTHESIS.

PROSTAGLANDINS AND CANNABIS -- VI. RELEASE OF ARACHIDONIC-ACID FROM HELA CELLS BY DELTA1-TETRAHYDROCANNABINOL AND OTHER

002850 04-03 GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF DELTA9-TETRAHYDROCANNABINOL TO CANNABINOIDS WITH THERAPEUTIC POTENTIAL

CANNABINGE PHYSIOLOGIC DISPOSITION OF NABILONE, A CANNABINOL DERIVATIVE.

IN MAN. 000735 01-13 ANTIEMETIC ACTIVITY OF NABILONE, A CANNABINOL DERIVATIVE, REVERSED BY NALOXONE IN AWAKE CATS.

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, AND CANNABINOL ON THE ANESTHESIA INDUCED BY VARIOUS ANESTHETIC AGENTS IN MICE

002015 03-03 DIRECT AND PITUITARY MEDIATED EFFECTS OF DELTA9-THC AND CANNABINOL ON THE TESTIS.

002881 04-03

003392 04-04

CANNABIS

HISTORICAL AND CULTURAL FACTORS INFLUENCING CANNABIS USE AMONG INDIANS IN SOUTH-AFRICA

000675 01-12 WITHDRAWAL FROM CANNABIS: PSYCHOPHYSIOLOGIC 000688 01-13

PSYCHOPHYSIOLOGICAL EFFECTS OF ACUTE CANNABIS INHALATION 000711 01-13 ACUTE EEG EFFECTS OF CANNABIS PREPARATIONS IN LONG-TERM

HASHISH USERS 000744 01-13 WITHDRAWAL FROM CANNABIS: LABORATORY TESTS AND CLINICAL **OBSERVATIONS**

000748 01-14 ACUTE EFFECTS OF CANNABIS ON COGNITIVE, PERCEPTUAL, AND MOTOR PERFORMANCE IN CHRONIC HASHISH USERS

000759 01-14 WITHDRAWAL FROM CANNABIS: PSYCHOLOGICAL TEST PERFORMANCE 000760 01-14

SUBJECTIVE EXPERIENCES OF CANNABIS USE IN LONG-TERM USERS 000776 01-14 ADVERSE EFFECTS OF INTRAVENOUS CANNABIS TEA

000866 01-15 PSEUDOCATATONIA ASSOCIATED WITH ABUSE OF AMPHETAMINE AND CANNABIS.

000909 01-15 CANNABIS, CATECHOLAMINES, RAPID EYE MOVEMENT SLEEP AND AGGRESSIVE BEHAVIOUR.

001320 02-04 MEASUREMENTS OF WEIGHT AND ACTIVITY IN MALE MICE FOLLOWING INHALATION OF CANNABIS SMOKE IN A CONTROLLED SMOKE EXPOSURE CHAMBER

001524 02-05 PROSTAGLANDINS AND CANNABIS -- VI. RELEASE OF ARACHIDONIC-ACID FROM HELA CELLS BY DELTA 1-TETRAHYDROCANNABINOL AND OTHER CANNABINOIDS.

002850 04-03 CANNABIS INTERFERES WITH NEST-BUILDING BEHAVIOR IN MICE 003306 04-04 FACTORS CONTRIBUTING TO CANNABIS INTOXICATION AND DEPENDENCE.

(PH.D. DISSERTATION). 003583 04-12

CANNABIS-SATIVA
ISOLATION AND CHARACTERIZATION OF () CANNABITRIOL AND (-) 10
ETHOXY-9-HYDROXY-DELTA6A-TETRAHYDROCANNABINOL: TWO NEW
CANNABINOIDS FROM CANNABIS-SATIVA L. EXTRACT.
000004 01-0

THE EFFECTS OF CANNABIS-SATIVA ON THE BEHAVIOR OF ADULT FEMALE CHACMA BABOONS (PAPIO-URSINUS) IN CAPTIVITY.

CANNABITRIOL
ISOLATION AND CHARACTERIZATION OF () CANNABITRIOL AND (-) 10
ETHOXY-9-HYDROXY-DELTAGA-TETRAHYDROCANNABINOL: TWO NEW
CANNABINOIDS FROM CANNABIS-SATIVA L. EXTRACT.

000004 01-01 IMPROVED POLYETHYLENE INTRACEREBROVENTRICULAR CANNULAS FOR RATS.

003440 04-06 NULATED

A NEW CHRONICALLY CANNULATED CAROTID ARTERY PREPARATION FOR DETERMINATION OF DRUG HALF-LIVES IN THE GUINEA-PIG.

001531 02-06

CANNULATION
ESOPHAGEAL CANNULATION FOR INTRAGASTRIC DELIVERY OF FLUIDS TO
UNRESTRAINED DOGS.
003436 04-06

003436 04-06 CAPACITANCE
THE EFFECT OF CHLORPROMAZINE ON CELL MEMBRANE RESISTANCE AND
CAPACITANCE.
001247 02-03

STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT BRAIN TISSUE SLICES.

001145 02-03 STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAMINE (DA) AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES.

EFFECT OF PSYCHOTROPIC AGENTS ON THE PHYSICAL PERFORMANCE CAPACITY OF ANIMALS EXPOSED TO HEAT AND COLD.

ANGIOTENSIN BINDING AFFINITY AND CAPACITY IN THE MIDBRAIN AREA OF SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS.

RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS: ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT LEARNING WITH D AMPPHETAMINE TREATMENTS.

CAPILLARIES EXPERIMENTAL LEAD ENCEPHALOPATHY IN THE SUCKLING RAT: CONCENTRATION OF LEAD IN CELLULAR FRACTIONS ENRICHED IN BRAIN CAPILLARIES. 003420 04-05

GUANYLYLIMIDODIPHOSPHATE ACTIONS ON ADENYLATE-CYCLASE IN HOMOGENATES OF RAT CEREBRAL-CORTEX PLUS NEURONAL AND CAPILLARY FRACTIONS.

003038 04-03 CAPSAICIN-INDUCED
CAPSAICIN-INDUCED DEPLETION OF SUBSTANCE-P FROM PRIMARY SENSORY NEURONS.

002965 04-03 THE EFFECTS OF CANNABIS-SATIVA ON THE BEHAVIOR OF ADULT FEMALE CHACMA BABOONS (PAPIO-URSINUS) IN CAPTIVITY.

000402 01-04 CAPTURE
SIMULTANEOUS DETERMINATION OF CODEINE AND MORPHINE IN
BIOLOGICAL SAMPLES BY GAS-CHROMATOGRAPHY WITH ELECTRON
CAPTURE DETECTION.

001527 02-06

EFFECTS OF CARBACHOL AND NICOTINE INJECTED INTO THE CEREBRAL VENTRICLES ON ELECTROMYOGRAM OF CONSCIOUS CATS. 000052 01-03

CARBACHOL ELICITED MOUSE-KILLING IN THE RAT: ANIMALS ATTACKED AND WOUND LOCATION. 000349 01-04 LEARNED AVERSIONS TO INTRACERERRAL CARRACHOL

001424 02-04 ATONIA AFTER CARBACHOL MICROINJECTIONS NEAR THE LOCUS-COERULEUS IN CATS.

LACK OF EFFECT OF CLONAZEPAM ON SERUM LEVELS OF DIPHENYLHYDANTOIN, PHENOBARBITAL AND CARBAMAZEPINE 000705 01-13 PSYCHOTROPIC EFFECTS OF CARBAMAZEPINE IN EPILEPSY: A DOUBLE-BLIND COMPARISON WITH PHENYTOIN.

Psychopharmacology Abstracts

003481 04-09

000487 01-05

EFFECTS OF CARBAMAZEPINE ON MUSCLE SPINDLE DISCHARGES. 002037 03-03 STUDIES ON THE CONCOMITANT USE OF CARBAMAZEPINE AND CLOMIPRAMINE FOR THE RELIEF OF POSTHERPETIC NEURALGIA

002555 03-13 SEIZURE SUSCEPTIBILITY AND ANTICONVULSANT ACTIVITY OF CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES.

THERAPEUTIC EFFECTS OF CARBAMAZEPINE IN AFFECTIVE-ILLNESS: A PRELIMINARY REPORT.

BAMYLCHOLINE
ONSET AND OFFSET OF CHLORPROMAZINE BLOCKADE OF
PHENYLEPHRINE, CARBAMYLCHOLINE AND HISTAMINE ON RABBIT

001234 02-03 CARBIDOPA
TREATMENT OF PARKINSONS DISEASE WITH THE COMBINATION L-DOPA/
L CARBIDOPA.

CARBOHYDRATE
THE EFFECT OF PENTOBARBITAL ON THE CARBOHYDRATE METABOLISM
OF GLIAL CELLS IN CULTURE.
DOQ484 01-

000484 01-05 CARBON-DIOXIDE
URINARY CARBON-DIOXIDE TENSION IN LITHIUM-CARBONATE TREATED

000882 01-15 CARBON-TETRACHLORIDE
THE EFFECT OF PHENOBARBITAL AND CARBON-TETRACHLORIDE ON
FATTY-ACID CONTENT AND COMPOSITION OF PHOSPHOLIPIDS FROM
THE ENDOPLASMIC RETICULUM OF RAT LIVER.

002888 04-03 CARBON-14
STUDIES OF EXCRETION IN RABBIT MILK AFTER ADMINISTRATION OF
CARBON-14 LABELLED AMITRIPTYLINE AND NORTRIPTYLINE.
000037 0 000037 01-03

CARBROMAL INTOXICATION — HEMODIALYSIS OR HEMOPERFUSION? 001800 02-15

CARCINOGENS
COMMON DRUGS SEEN AS POTENTIAL CARCINOGENS. 003416 04-05

CARDIAC
PLASMA NORTRIPTYLINE AND CARDIAC RESPONSES IN YOUNG AND OLD PATS

000479 01-05 THE EFFECTS OF BEHAVIORALLY RELEVANT DOSES OF CHLORPROMAZINE AND MOLINDONE ON CARDIAC ADENYLATE-CYCLASE AND ON MYOCARDIAL CONTRACTILITY.

CARDIAC ARRHYTHMIA AND HYPOPOTASSEMIA IN ASSOCIATION WITH LITHIUM-CARBONATE OVERDOSE.

CARDIAC TOXICITY WITH THIORIDAZINE TRICYCLIC ANTIDEPRESSANT

000846 01-15 CARDIAC EFFECTS OF AMITRIPTYLINE OVERDOSAGE 000893 01-15 EFFECT OF LITHIUM-CHLORIDE ON CERTAIN INDICES OF CARDIAC

001521 02-05

TRICYCLIC ANTIDEPRESSANT DRUGS AND CARDIAC CONDUCTION 001751 02-15

EFFECTS OF PRESYNAPTIC MODULATORS ON CA2-INDUCED NORADRENALINE RELEASE FROM CARDIAC SYMPATHETIC NERVES 002025 03-03

THE INFLUENCE OF COCAINE AND DESIPRAMINE ON THE CARDIAC RESPONSES TO EXOGENOUS AND ENDOGENOUS NOREPINEPHRINE 002077 03-03

CARDIOLOGICAL
CARDIOLOGICAL EFFECTS OF NOMIFENSINE, A NEW ANTIDEPRESSANT. 003645 04-15

CARDIOMYOPATHIC
CARDIOMYOPATHIC FINDINGS ASSOCIATED WITH METHYLPHENIDATE 000833 01-15

AN EVALUATION OF THE CARDIOPULMONARY SAFETY AND EFFICACY OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS ORAL HYPNOTIC AGENTS. 000854 01-15

CARDIORESPIRATORY
COMPARATIVE EFFECTS OF COCAINE AND PSEUDOCOCAINE ON EEG
ACTIVITIES, CARDIORESPIRATORY FUNCTIONS, AND SELFADMINISTRATION BEHAVIOR IN THE RHESUS MONKEY. 003292 04-04

CARDIOTOXIC
PLASMA CONCENTRATIONS AND CARDIOTOXIC EFFECTS OF DESIPRAMINE
AND PROTRIPTYLINE IN THE RAT.

000478 01-05

003381 04-04

001706 02-14

CARDIOTOXIC DRUGS, WITH SPECIAL ATTENTION TO PHENOTHIAZINES

PROSTAGLANDINS AND THE CARDIOTOXIC EFFECT OF DOXEPIN IN RABBITS AND GUINEA-PIGS.

001518 02-05

CARDIOVASCULAR

CARDIOVASCULAR EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN CONSCIOUS AND ANESTHETIZED DOGS.

000109 01-03

CENTRAL CARDIOVASCULAR EFFECTS OF MORPHINOMIMETIC PEPTIDES IN

001399 02-04

ANTAGONISM BY MIANSERIN AND CLASSICAL ALPHA-ADRENOCEPTOR BLOCKING DRUGS OF SOME CARDIOVASCULAR AND BEHAVIORAL EFFECTS OF CLONIDINE.

STRESS AND THE HEART: INTERACTIONS OF THE CARDIOVASCULAR SYSTEM, BEHAVIORAL STATE, AND PSYCHOTROPIC DRUGS.

EFFECTS OF CENTRAL GABA RECEPTOR AGONISM AND ANTAGONISM ON EVOKED DIENCEPHALIC CARDIOVASCULAR RESPONSES.

CENTRAL ADRENOCEPTORS AND CHOLINOCEPTORS IN CARDIOVASCULAR

CONTROL 002823 04-03

CARDIOVASCULAR RESPONSE TO INTRACEREBROVENTRICULAR ADMINISTRATION OF ACETYLCHOLINE IN RATS. 002982 04-03

CNS SITE OF CLONIDINE-INDUCED HYPOTENSION: A MICROIONTOPHORETIC STUDY OF BULBAR CARDIOVASCULAR

CARE

003086 04-03

SOME CONTINGENCIES AFFECTING THE UTILIZATION OF TRANQUILIZERS IN LONG-TERM CARE OF THE ELDERLY.

000649 01-11 MULTIPLE DRUG THERAPY - IS THERE A STANDARD OF CARE?

000954 01-17 DELIBERATE POISONING WITH TRICYCLIC ANTIDEPRESSANTS TREATED IN AN INTENSIVE CARE UNIT.

001758 02-15
EFFECTS OF PROLACTIN, DEXAMETHASONE, AND CORTICOSTERONE ON
MATERNAL AGGRESSION AND INFANT CARE.

CARIES

RAMPANT DENTAL CARIES IN THE TREATMENT OF DEPRESSION 002648 03-15

CAROTID

A NEW CHRONICALLY CANNULATED CAROTID ARTERY PREPARATION FOR DETERMINATION OF DRUG HALF-LIVES IN THE GUINEA-PIG. 001531 02-06

CARRIER LITHIUM AND ERYTHROCYTE MEMBRANE CATION CARRIER STUDIES IN

NORMAL AND MANIC-DEPRESSIVE SUBJECTS.

FACILITATION OF MOUNTING BEHAVIOR BY DIHYDROTESTOSTERONE-PROPIONATE IN CASTRATED ESTRADIOL-BENZOATE TREATED MALE RATS FOLLOWING PUDENDECTOMY.

000403 01-04 DIFFERENTIAL EFFECTS OF THE ANTIANDROGEN FLUTAMIDE ON ASPECTS OF SEXUAL BEHAVIOR IN CASTRATED, ANDROGEN TREATED MALE RATS

002237 03-04

EVIDENCE FOR AN INTRASTRIATAL GABAERGIC INFLUENCE ON DOPAMINE NEURONES OF THE CAT.

000050 01-03 INTERACTION OF GABA, DOPAMINE, AND ACETYLCHOLINE IN CAT STRIATUM: PHARMACOLOGICAL CONSIDERATIONS.

000051 01-03

ELECTROCORTICAL CHANGES INDUCED BY THE PERFUSION OF NORADRENALINE, ACETYLCHOLINE AND THEIR ANTAGONISTS DIRECTLY INTO THE DORSAL RAPHE NUCLEUS OF THE CAT. 000164 01-03

PHENOBARBITAL ACTIONS IN VIVO: EFFECTS OF EXTRACELLULAR POTASSIUM ACTIVITY AND OXIDATIVE METABOLISM IN CAT CEREBRAL-CORTEX

000176 01-03 EFFECTS OF SYSTEMIC MUSCIMOL AND GABA IN THE SPINAL CORD AND SUPERIOR CERVICAL GANGLION OF THE CAT. 000226 01-03

EFFECT OF ETHANOL ON (3H)OUABAIN BINDING TO DIFFERENT REGIONS OF THE CAT BRAIN.

EFFECTS OF DEAFENING AND BLINDFOLDING ON AMPHETAMINE-INDUCED STEREOTYPY IN THE CAT. 000456 01-04 CEREBELLAR UNIT ACTIVITY DURING GENERALIZED PENICILLIN EPILEPSY

PHENOBARBITAL AND PHENYTOIN EFFECTS ON SOMATOSENSORY EVOKED-POTENTIALS AND SPONTANEOUS EEG IN NORMAL CAT BRAIN 001032 02-02

ANALGESIC BRAIN STIMULATION IN THE CAT: EFFECT OF INTRAVENTRICULAR SEROTONIN, NOREPINEPHRINE, AND DOPAMINE. 001101 02-03

THE EFFECT OF NALOXONE ON THE EXCITATION OF DORSAL-HORN NEURONES OF THE CAT BY NOXIOUS AND NONNOXIOUS CUTANEOUS

001102 02-03 PROPERTIES OF THE PERIPHERAL OPIATE RECEPTORS IN THE CAT

001113 02-03 EFFECTS OF D AMPHETAMINE ON A MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE OF FOOD REINFORCEMENT IN THE CAT

001374 02-04 COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON BEHAVIOR OF

001383 02-04 EVALUATION OF SUBSTITUTED AMPHETAMINE HALLUCINOGENS USING THE CAT LIMB FLICK MODEL

001449 02-04 EFFECT OF DEXAMETHASONE ON CEREBRAL EDEMA FROM CRANIAL IMPACT IN THE CAT.

DIFFERENTIAL EXCITATORY AND INHIBITORY EFFECTS OF OPIATES ON NONNOCICEPTIVE AND NOCICEPTIVE NEURONES IN THE SPINAL CORD

SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL CORRELATES.

001974 03-03 TOLERANCE TO COCAINE-INDUCED CONVULSIONS IN THE CAT

BLOCKADE OF THE PICROTOXIN-INDUCED IN VIVO RELEASE OF DOPAMINE IN THE CAT CAUDATE NUCLEUS BY DIAZEPAM.

STIMULANT ACTION OF THYROTROPIN-RELEASING HORMONE ON CAT

THE INFLUENCE OF DIHYDROERGOTOXINE-MESYLATE ON THE LOW-KM PHOSPHODIESTERASE OF CAT AND RAT BRAIN IN VITRO.

002008 03-03 EFFECTS OF MORPHINE ON ELECTRICAL ACTIVITY OF SINGLE MYENTERIC NEURONS IN CAT SMALL BOWEL.

002009 03-03 INCORPORATION, AFTER SINGLE AND REPEATED APPLICATION OF RADIOACTIVE LABELLED DH-ERGOT ALKALOIDS IN DIFFERENT ORGANS OF THE CAT, WITH SPECIAL REFERENCE TO THE BRAIN. 002047 03-03

THE RELATIONSHIP BETWEEN CORTICAL RECRUITING RESPONSES AND PONTO-GENICULO-OCCIPITAL (PGO) WAVES DURING PARADOXICAL SLEEP AND AFTER THE ADMINISTRATION OF RESERPINE IN THE CAT

EFFECTS OF INTRAVENOUS KAINIC-ACID, N METHYL-D-ASPARTATE, AND (-) NUCIFERENE ON THE CAT SPINAL CORD.

THE IONTOPHORESIS OF DIAZEPAM IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT.

THE ROLE OF DIAZEPAM AS COMPARED TO GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT. (PH.D. DISSERTATION).

002131 03-03 EFFECT OF DIHYDROERGOTOXINE ON THALAMIC AND PYRAMIDAL EVOKED RESPONSES IN THE CAT UNDER TRANSIENT ISCHEMIA. 002201 03-04

SELECTIVE REDUCTION BY NORADRENALINE AND 5
HYDROXYTRYPTAMINE OF NOCICEPTIVE RESPONSES OF CAT DORSAL-HORN NEURONES

002246 03-04 SOME PHYSIOLOGIC CHARACTERISTICS OF THE ELECTRODERMAL REFLEX IN THE CAT

002819 04-03 STIMULATION OF PRESYNAPTIC BETA-ADRENOCEPTORS ENHANCES H3-NORADRENALINE RELEASE DURING NERVE STIMULATION IN THE PERFLISED CAT SPLEEN

002855 04-03 RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D

002862 04-03
HYPERTHERMIC RESPONSES TO CENTRAL AND PERIPHERAL INJECTIONS OF MORPHINE-SULPHATE IN THE CAT.

003425 04-06

PHARMACOLOGICAL AND ELECTROPHYSIOLOGICAL STUDIES OF MORPHINE AND ENKEPHALIN ON RAT SUPRASPINAL NEURONES AND CAT SPINAL NEURONES.

002883 04-03
INFLUENCE OF VINCAMINE AND PIRACETAM ON SLEEP-WAKING PATTERN

002925 04-03 THE RELEASE OF ACETYLCHOLINE IN THE PERFUSED CAT SPINAL CORD IN 002969 04-03

DEPRESSANT ACTIONS OF METHIONINE-ENKEPHALIN AND SOMATOSTATIN IN CAT DORSAL-HORN NEURONES ACTIVATED BY NOXIOUS STIMULI.

O03059 04-03

EFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY
THE RESPONSES OF THE MUSCLE SPINOLE OF THE TRICEPS SURAE
MUSCLE OF THE DECEREBRATE CAT TO THE MUSCLE STRETCH.

POSSIBLE PHYSIOLOGICAL SIGNIFICANCE OF THE INITIAL STEP IN THE CATABOLISM OF NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.

IMPORTANCE OF TRYPTOPHAN-PYRROLASE AND AROMATIC-AMINO-ACID-DECARBOXYLASE IN THE CATABOLISM OF TRYPTOPHAN. 003147 04-03

POSSIBLE IMPORTANCE OF 5 HYDROXYTRYPTAMINE IN NEUROLEPTIC-INDUCED CATALEPSY IN RATS. 000068 01

000068 01-03 TOLERANCE TO HALOPERIDOL CATALEPSY.

001506 02-05
ROLE OF BRAIN NOREPINEPHRINE IN NEUROLEPTIC-INDUCED CATALEPSY IN RATS.

CATALEPSY INDUCED BY INTRASTRIATAL INJECTIONS OF DELTA9-THC AND 11 OH-DELTA9-THC IN THE RAT.

002027 03-03 THE ROLE OF THE CORPUS-STRIATUM IN NEUROLEPTIC-INDUCED AND NARCOTIC-INDUCED CATALEPSY.

INCREASED HALOPERIDOL-INDUCED CATALEPSY AFTER CHRONIC COCAINE

THE EFFECT OF BACLOFEN ON ALPHA-FLUPENTHIXOL-INDUCED CATALEPSY IN THE RAT 003203 04-04

MOVEMENT INDUCED IN CATALEPTIC RATS: DIFFERENTIAL EFFECTS
PRODUCED BY ELECTRICAL STIMULATION OF THE LATERAL
HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FORMATION

CATALEPTOGENIC PROPERTIES OF BETA-ENDORPHIN

EFFECTS ON STRIATAL AND MESOLIMBIC DOPAMINE SYSTEMS OF A NEW POTENTIAL ANTIPSYCHOTIC DRUG -- MEZILAMINE -- WITH WEAK CATALEPTOGENIC PROPERTIES.

RAT STRIATAL METHIONINE-ENKEPHALIN CONTENT AFTER CHRONIC TREATMENT WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTISCHIZOPHRENIC DRUGS.

TURNOVER RATES OF GAMMA-AMINOBUTYRIC-ACID IN SUBSTANTIA-NIGRA, NUCLEUS-CAUDATUS, GLOBUS-PALLIDUS AND NUCLEUS-ACCUMBENS OF RATS INJECTED WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS.

002996 04-03 STUDIES ON THE INHIBITION OF PHOSPHODIESTERASE CATALYZED CYCLIC-AMP AND CYCLIC-GMP BREAKDOWN AND RELAXATION OF CANINE TRACHEAL SMOOTH MUSCLE.

002129 03-03 CATARACTS
ON CATARACTS SEEN DURING PSYCHOTROPIC DRUG THERAPY

001793 02-15 CATATONIA AND MALIGNANT SYNDROME: A POSSIBLE COMPLICATION OF NEUROLEPTIC ADMINISTRATION. REPORT OF A CASE INVOLVING HALDPERIDOL.

000910 01-15 CATATONIA

LITHIUM IN THE TREATMENT OF PERIODIC CATATONIA: A CASE REPORT. 003530 04-09 SINGLE CASE STUDY. CATATONIA ASSOCIATED WITH DISULFIRAM

003677 04-15

CATATONIC CATATONIC REACTIONS TO HIGH-POTENCY NEUROLEPTIC DRUGS.

000835 01-15

CATECHO A PHARMACOLOGICAL STUDY OF THE SPONTANEOUS CONVULSIVE ACTIVITY INDUCED BY 1,2 DIHYDROXYBENZENE (CATECHOL) IN THE ANESTHETIZED MOUSE

001046 02-03 ROLE OF CALCIUM IN THE AMPHETAMINE-INDUCED STIMULATION OF CATECHOL FORMATION IN THE STRIATUM.

001268 02-03 EFFECTS OF CATECHOL ESTROGENS ON SEXUAL DIFFERENTIATION IN NEONATAL FEMALE RATS.

002293 03-04 CATECHOL-O-METHYL-TRANSFERASE
DIRECT EXTRACTION RADIOASSAY FOR CATECHOL-O-METHYLTRANSFERASE ACTIVITY.

CATECHOLAMINE
REGULATION OF CATECHOLAMINE BIOSYNTHESIS IN A TRANSPLANTABLE
RAT PHEOCHROMOCYTOMA.

KINETICS OF CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN MOUSE BRAIN SYNAPTOSOMES.

STIMULUS EFFECTS OF DELTA9-THC AND ITS INTERACTION WITH NALTREXONE AND CATECHOLAMINE BLOCKERS IN RATS.

CATECHOLAMINE SYNTHESIS IN RAT BRAIN AFTER AXOTOMY: INTERACTION BETWEEN APOMORPHINE AND HALOPERIDOL.

ANTIDEPRESSIVE EFFECTS ON CENTRAL CATECHOLAMINE RECEPTORS 000202 01-03

EFFECTS OF PHENCYCLIDINE ON (3H)CATECHOLAMINE AND
(3H)SEROTONIN UPTAKE IN SYNAPTOSOMAL PREPARATIONS FROM
RAT BRAIN.

UNILATERAL CATECHOLAMINE DEPLETION OF THE CORPUS-STRIATUM AND AMPHETAMINE-INDUCED TURNING: AN ONTOGENETIC STUDY.

CATECHOLAMINE AND OCTOPAMINE CONCENTRATIONS IN BRAINS OF PATIENTS WITH REYE SYNDROME.

SLEEP AND BEHAVIORAL CHANGES POSSIBLY REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN.

000916 01-16 CATECHOLAMINE SENSITIVE ATPASE ACTIVITIES IN BRAIN SYNAPTOSOMES OF MORPHINIZED MICE.

001096 02-03 AGE-RELATED EFFECTS OF RESERPINE ON BEHAVIOR AND ON REGIONAL CATECHOLAMINE UPTAKE AND RELEASE IN THE RAT. (PH.D. DISSERTATION).

001098 02-03 THE EFFECT OF DIPHENYLHYDANTOIN ON CENTRAL CATECHOLAMINE

CONTAINING NEURONAL SYSTEMS. 001112 02-03 **ACTION OF AZABUTYRONE AND ITS ANALOGS ON CATECHOLAMINE**

METABOLISM IN RAT BRAIN. 001218 02-03 TEMPORAL EFFECTS OF P-CHLOROAMPHETAMINE ON CATECHOLAMINE

SYNTHESIS. 001251 02-03 EFFECT OF D AMPHETAMINE ON THE INHIBITION OF BRAIN CATECHOLAMINE TURNOVER INDUCED BY CYCLOHEXIMIDE

001279 02-03 CATECHOLAMINE INVOLVEMENT IN THE NARCOTIC CUE. 001332 02-04

CLINICAL STUDIES WITH MAPROTILINE AND THE REVERSED CATECHOLAMINE HYPOTHESIS OF DEPRESSION.

001642 02-13 THE EFFECTS OF SUBHYPNOTIC DOSES OF ETHANOL ON REGIONAL CATECHOLAMINE TURNOVER.

EFFECT OF THYMOANALEPTIC AGENTS ON THE COURSE OF EXPERIMENTAL ARTERIAL HYPERTENSION AND CATECHOLAMINE CONTENT IN TISSUES AND URINE

001970 03-03 STUDIES ON THE ROLE OF FOREBRAIN CATECHOLAMINE NEURONS IN EXPLORATORY BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).

002012 03-03 CHANGES IN MOUSE BRAIN CATECHOLAMINE CONTENT AND TYROSINE-HYDROXYLASE ACTIVITY DURING CHRONIC AMPHETAMINE ADMINISTRATION.

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D AMPHETAMINE ON SELF-STIMULATION OF THE SUBSTANTIA-NIGRA AND LOCUS-COERULEUS

002218 03-04 TOLERANCE TO P-CHLOROAMPHETAMINES EFFECTS ON SIDMAN
AVOIDANCE PERFORMANCE AND CATECHOLAMINE METABOLISM 002314 03-04

003297 04-04

VOLUME 16, SUBJECT INDEX

Subject Index

CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE-ILLNESS: PARADOXICAL DRUG EFFECTS. 002610 03-

CENTRAL CATECHOLAMINE NEUROTRANSMITTERS AND PSYCHOACTIVE DRUGS.

002731 03-17
THE CURRENT STATUS OF RESEARCH IN THE CATECHOLAMINE THEORIES

OF AFFECTIVE-DISORDERS.

002733 03-17

CENTRAL CATECHOLAMINE METABOLISM IN PSYCHOSIS. 002764 03-17

THE EFFECTS OF CANNABINOIDS ON BODY TEMPERATURE AND BRAIN CATECHOLAMINE SYNTHESIS. 002835 04-03

AMPHETAMINE-INDUCED INCREASE IN RAT CEREBRAL BLOOD FLOW; APPARENT LACK OF CATECHOLAMINE INVOLVEMENT. 003031 04-03

EFFECTS OF LSD AND BOL ON THE CATECHOLAMINE SYNTHESIS AND TURNOVER IN VARIOUS BRAIN REGIONS.

003043 04-03
DIURNAL VARIATIONS IN THE MOTOR ACTIVITY OF THE RAT: EFFECTS OF

INHIBITORS OF THE CATECHOLAMINE SYNTHESIS.

003274 04-04
6 HYDROXYDOPAMINE-INDUCED CATECHOLAMINE DEPLETION AND

PASSIVE AVOIDANCE LEARNING IN RATS.

O03322 04-04
CATECHOLAMINE LEVELS IN THE WHOLE BRAIN AND THE PROBABILITY OF

MEMORY FORMATION ARE NOT RELATED.

003328 04-04

DRUGS AND REINFORCEMENT MECHANISMS: A CRITICAL REVIEW OF THE

CATECHOLAMINE THEORY. 003625 04-14

ATECHOLAMINERGIC

TIME-DEPENDENT CHANGES IN ACTIVITY, REACTIVITY, AND
RESPONSIVITY DURING SHOCK: EFFECTS OF CHOLINERGIC AND
CATECHOLAMINERGIC MANIPULATIONS.

ON THE ROLE OF ASCENDING CATECHOLAMINERGIC PROJECTIONS IN INTRACRANIAL SELF-STIMULATION OF THE SUBSTANTIA-NIGRA.

D00336 01-04
EFFECTS OF CATECHOLAMINERGIC DRUGS UPON MEMORY STORAGE
PROCESSES IN MICE.

000377 01-04

EVALUATION OF THE EFFECT OF P-CHLOROAMPHETAMINE ON INDIVIDUAL
CATECHOLAMINERGIC NUCLEI IN THE RAT BRAIN.

O03003 04-03
THE EFFECTS OF INORGANIC LEAD ON THE CENTRAL CATECHOLAMINERGIC
SYSTEM OF THE RODENT WITH EMPHASIS ON POSTNATALLY EXPOSED
RATS AND MICE. (PH.D. DISSERTATION).

PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT
OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC
AND CATECHOLAMINERGIC MECHANISMS BY 6 HYDROXYDOPAMINE
AND 5,6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D.

DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: A VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIATION OF CATECHOLAMINERGIC AND SEROTONINERGIC TERMINALS IN RAT CEREBRAL STRUCTURES.

003423 04-06

CATECHOLAMINES

THE ACCUMULATION OF P-HYDROXYAMPHETAMINE BY BRAIN
HOMOGENATES AND ITS ROLE IN THE RELEASE OF CATECHOLAMINES.

RELATIVE CONCENTRATIONS OF ZWITTERIONIC AND UNCHARGED SPECIES IN CATECHOLAMINES AND THE EFFECT OF N SUBSTITUENTS.

000117 01-03

THE ACTIONS OF CHOLINOMIMETICS AND CATECHOLAMINES ON RAT SUBSTANTIA-NIGRA NEURONES.

O00163 01-03
CATECHOLAMINES AND BIOCHEMICALLY-INDUCED ABNORMAL
BEHAVIOUR IN RATS.

000356 01-04

NONCONTINGENT DISPLACEMENT OF CATECHOLAMINES BY
INTRAVENTRICULAR TYRAMINE: BIPHASIC DOSE-RESPONSE EFFECTS ON
SELF-STIMULIATION.

000364 01-04
COCAINE-INDUCED CENTRALLY MEDIATED RELEASE OF CATECHOLAMINES
INTO BLOOD OF UNDISTURBED RATS. (UNPUBLISHED PAPER).
001079 02-03

PLASMA CONCENTRATIONS OF SOME ACIDIC AND ALCOHOLIC METABOLITES DERIVED FROM M- AND P-TYRAMINE, OCTOPAMINE AND CATECHOLAMINES IN HUMANS.

001158 02-03

CANNABIS, CATECHOLAMINES, RAPID EYE MOVEMENT SLEEP AND AGGRESSIVE BEHAVIOUR. 001320 02-04

THE EFFECT OF BROMOCRIPTINE ON LOCOMOTOR ACTIVITY AND CEREBRAL CATECHOLAMINES IN RODENTS.

001346 02-04

PERIPHERAL CATECHOLAMINES RELEASED BY OXOTREMORINE MODULATE TREMOR IN THE RAT. (UNPUBLISHED PAPER).

001486 02-0EFFECT OF SYNTHESIS INHIBITION ON THE LEVELS OF BRAIN
CATECHOLAMINES IN BARBITAL DEPENDENT RATS.

THE EFFECTS OF PICROTOXIN AND PENTYLENETETRAZOL IN THE DIURNAL RHYTHMS OF CATECHOLAMINES AND SEROTONIN IN THE RAT BRAIN. 002123 03-03

ALTERATIONS IN MORPHINE ANALGESIA PRODUCED BY CHRONIC DEFICITS OF BRAIN CATECHOLAMINES OR SEROTONIN: ROLE OF ANALGESIMETRIC PROCEDURE.

MEMORIZATION AND CENTRAL CATECHOLAMINES AFTER A CRANIOCERVICAL INJURY CARRIED OUT IN RATS: INFLUENCE OF IMIPRAMINE ADMINISTRATION.

O02197 03-04

EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DEPLETIONS OF BRAIN
CATECHOLAMINES OR DOPAMINE ON MEPERIDINE ANTINOCICEPTION
IN PATS

PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF NA CHANNELS
IN THE RELEASE OF CATECHOLAMINES FROM PERFUSED ADRENAL
GLANDS

002960 04-03
RELEASE OF ENDOGENOUS CATECHOLAMINES FROM ISOLATED RAT
BRAIN TISSUE BY FENFLURAMINE AND N ETHYLAMPHETAMINE —
EFFECTS OF PARGYLINE.

003111 04-03
INFLUENCE OF CATECHOLAMINES ON DEXAMPHETAMINE-INDUCED
CHANGES IN LOCOMOTOR ACTIVITY.

MODIFICATION OF THE RADIOENZYMATIC ASSAY FOR THE CATECHOLAMINES.

003431 04-06
CATION
LITHIUM AND ERYTHROCYTE MEMBRANE CATION CARRIER STUDIES IN

LITHIUM AND ERYTHROCYTE MEMBRANE CATION CARRIER STUDIES IN NORMAL AND MANIC-DEPRESSIVE SUBJECTS.

000717 01-13

LIPIDOSIS INDUCED BY AMPHIPHILIC CATIONIC DRUGS.

ATIONS

EFFECTS OF BETA-BUNGAROTOXIN, DIPHENYLHYDANTOIN AND

METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT
CATIONS AND HIGH-ENERGY PHOSPHATE CONTENTS OF BRAIN SLICES.
000278 01-03

ALKALI-METAL CATIONS: EFFECTS ON ISOLATION-INDUCED AGGRESSION IN THE MOUSE.

CATS

EFFECTS OF CARBACHOL AND NICOTINE INJECTED INTO THE CEREBRAL

VENTRICLES ON ELECTROMYOGRAM OF CONSCIOUS CATS.

000052 01-03
CENTRALLY ACTIVE DRUGS AND THE SYMPATHETIC NERVOUS SYSTEM
OF RABBITS AND CATS.

EFFECTS OF RETICULAR STIMULATION, D AMPHETAMINE AND SCOPOLAMINE ON ACETYLCHOLINE RELEASE FROM THE HIPPOCAMPUS OF BRAINSTEM TRANSECTED CATS.

SOME EFFECTS OF MUSCIMOL IN MICE, RATS AND CATS.

KINETICS OF DISTRIBUTION OF AMPHETAMINE IN CATS.

000173 01-03

AMINERGIC AND THERMOREGULATORY MECHANISMS IN
HYPOTHALAMIC REGULATION OF GROWTH HORMONE IN CATS.

000249 01-03
ANTAGONISM BY CHOLINERGIC DRUGS OF REHAVIOURAL EFFECTS IN

ANTAGONISM BY CHOLINERGIC DRUGS OF BEHAVIOURAL EFFECTS IN CATS OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC DRUG AND ENHANCEMENT BY NICOTINE.

000404 D1-04

ROLE OF GLUCOCORTICOIDS IN AN ABNORMAL GROOMING BEHAVIOR IN CATS WITH PONTILE OR FRONTAL NEOCORTICAL LESIONS.

EFFECT OF NEUROTROPIC DRUGS ON SLEEP DISTURBANCES CAUSED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS. 000795 01-14

EFFECTS OF BENZODIAZEPINES ON PGO FIRINGS AND MULTIPLE UNIT ACTIVITY IN THE MIDBRAIN RETICULAR FORMATION IN CATS. O01265 02-03 ADRENERGIC MODULATION OF A CHOLINERGIC EMOTIONAL REACTION IN

THE CATS THALAMUS.

001344 02-0

EFFECTS OF L 5 HYDROXYTRYPTOPHAN ON SLEEP-WAKEFULNESS CYCLES

EFFECTS OF L 5 HYDROXYTRYPTOPHAN ON SLEEP-WAKEFULNESS CYCLES IN CATS. 001382 02-0

001382 02-04
BRAIN STIMULATION PROVOKED EMOTIONAL REACTIONS OF CATS IN A
SOCIAL SITUATION.
001395 02-04

5-75

ANTIEMETIC ACTIVITY OF NABILONE, A CANNABINOL DERIVATIVE, REVERSED BY NALOXONE IN AWAKE CATS. 001416 02-04 SIMILAR EFFECTS OF TRYPTOPHAN AND SLEEP ON CISTERNAL CREEROSPINAL FLUID 5 HYDROXYINDOLEACETIC AND HOMOVANILLICACIDS IN CATS. PSYCHOTROPIC DRUG EFFECTS ON THE EMOTIONAL STATE OF CATS IN A SOCIAL SITUATION. 001480 02-04
EFFECT OF ANTICONVULSANTS ON THALAMIC AFTER-DISCHARGE IN RATS 002046 03-03 EFFECTS OF DOPAMINE AGONISTS ON NEURONES IN THE CAUDATE NUCLEUS AND CEREBRAL-CORTEX OF CATS CHRONICALLY TREATED WITH NEUROLEPTICS. SUPPRESSION BY NITROUS-OXIDE OF VISUAL RESPONSES IN THE CEREBELLAR VERMIS AND SUPERIOR COLLICULUS OF CATS ANESTHETIZED WITH CHLORALOSE. COCAINE AND PSEUDOCOCAINE: COMPARATIVE EFFECTS ON ELECTRICAL AFTER-DISCHARGE IN THE LIMBIC SYSTEM OF CATS. PHARMACOLOGICAL STUDIES OF CENTRAL ACTION OF L 5
HYDROXYTRYPTOPHAN IN INTACT OR TETRABENAZINE PRETREATED
CATS. 603144 04-03 EFFECTS OF PROPYLBENZILYLCHOLINE MUSTARD ON INJECTION INTO THE LIQUOR SPACE OF CATS. 003168 04-04 LSD AND TRYPTAMINE EFFECTS ON SLEEP-WAKEFULNESS AND ELECTROCORTICOGRAM PATTERNS IN INTACT CATS. 003256 04-04 EFFECT OF METERGOLINE, P-CHLOROPHENYLALANINE AND DOPA ON DELAYED RESPONSE IN CATS AND THE RELATIONSHIP BETWEEN THE MESOLIMBIC AND NIGROSTRIATAL NEURONS. 003339 04-04 ATONIA AFTER CARBACHOL MICROINJECTIONS NEAR THE LOCUS-COERULEUS IN CATS. 003381 04-04 REPEATED SUSTAINED-RELEASE LITHIUM-CARBONATE ADMINISTRATION TO CATS 5-HT AND MORPHINE INTERACTION, EFFECTS ON SENSORY INPUT IN CAUDATE NUCLEUS AND SUBSTANTIA-NIGRA. 000089 01-03 MORPHINE AND ITS BIPHASIC INFLUENCE UPON PHARMACOLOGICALLY DISTINCT DOPAMINERGIC SYSTEMS WITHIN THE FELINE CAUDATE NUCLEUS: A BEHAVIOURAL STUDY. SUPPRESSION OF CAUDATE NEURON ACTIVITIES BY MORPHINE AND THE INVOLVEMENT OF DOPAMINERGIC NEUROTRANSMISSION.

BLOCKADE OF THE PICROTOXIN-INDUCED IN VIVO RELEASE OF DOPAMINE IN THE CAT CAUDATE NUCLEUS BY DIAZEPAM.

FACILITATORY AND DEPRESSANT EFFECTS OF DOPAMINE IN THE FELINE CAUDATE NUCLEUS.

002116 03-03 MORPHINE INCREASES AND D AMPHETAMINE DECREASES THE RATIO OF DOPAC: HVA IN PUSH-PULL PERFUSATE OF RAT CAUDATE NUCLEUS.

STIMULATION OF DOPAMINE SYNTHESIS IN CAUDATE NUCLEUS BY INTRASTRIATAL ENKEPHALINS AND ANTAGONISM BY NALOXONE

EFFECTS OF DOPAMINE AGONISTS ON NEURONES IN THE CAUDATE NUCLEUS AND CEREBRAL-CORTEX OF CATS CHRONICALLY TREATED WITH NEUROLEPTICS.

NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND L-DOPA TO RATS.

THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE OF THE RAT CAUDATE NUCLEUS — 3. THE EFFECT OF APORPHINES AND PROTOBERBERINES. 003089 04-03 HIGH-AFFINITY H3-SEROTONIN BINDING TO CAUDATE: INHIBITION BY HALLUCINOGENS AND SEROTONINERGIC DRUGS.

003138 04-03 CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE FOR AN INTERACTIONIST POSITION.

000620 01-11

000620 01-11 AMPHETAMINE AND CHICK BEHAVIOUR: A ROLE FOR MONOAMINES IN THE CAUSATION OF VOCALIZATIONS AND EMOTIONS.

CAUTIONARY TIONARY IATROGENIC EXTRAPYRAMIDAL SYNDROME — A CAUTIONARY TALE. 000834 01-15

A CASE OF LITHIUM POISONING? A CAUTIONARY TALE 003653 04-15

CAVIAR

MONOAMINE-OXIDASE INHIBITORS AND CAVIAR. 000848 01-15

DELTA9-TETRAHYDROCANNABINOL AND THE HIPPOCAMPUS: EFFECTS ON CA1 FIELD POTENTIALS IN RATS. 000287 01-03

CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF C-AMP-PHOSPHODIESTERASE. 002023 03-03

CA2-DEPENDENT
STRIATAL CONTENT OF CA2-DEPENDENT REGULATOR PROTEIN AND
DOPAMINERGIC RECEPTOR FUNCTION.

002000

CA2-INDUCED

EFFECTS OF PRESYNAPTIC MODULATORS ON CA2-INDUCED

NORADRENALINE RELEASE FROM CARDIAC SYMPATHETIC NERVES 002025 03-03

INHIBITION OF CA45 MOVEMENTS BY LOWERED TEMPERATURE OR LANTHANUM IN RAT BRAIN SLICES.

EVIDENCE FOR SELECTIVE AND LONG-LASTING STIMULATION OF REGULATORY DOPAMINE RECEPTORS BY BROMOCRIPTINE (CB-154) 002002 03-03

COMPARATIVE EFFECTS OF DIHYDROERGOTOXINE (DHET) ON CBF AND METABOLISM CHANGES PRODUCED BY EXPERIMENTAL CEREBRAL EDEMA, HYPOXIA AND HYPERTENSION.

001979 03-03 CDP-CHOLINE EFFECT OF CDP-CHOLINE ADMINISTERED INTRATHECALLY ON DISTURBANCE OF CONSCIOUSNESS.

002635 03-14

EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT BRAIN: A QUANTITATIVE HISTOLOGICAL STUDY.

000184 01-03 EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT BRAIN: A BIOCHEMICAL STUDY.

000216 01-03

EQUAL SUPPRESSION OF CEREBELLAR PURKINJE CELL ACTIVITY BY AMPHETAMINE STEREOISOMERS. 000299 01-03

PHARMACOGENETIC ASPECT OF RED BLOOD CELL LITHIUM INDEX IN MANIC-DEPRESSIVE PSYCHOSIS. 000736 01-13

CHLORDIAZEPOXIDE SELECTIVELY AUGMENTS GABA ACTION IN SPINAL CORD CELL CULTURES.

001080 02-03 BIOCHEMICAL DIFFERENTIATION OF AGGREGATING CELL CULTURES OF DIFFERENT FETAL RAT BRAIN REGIONS.

001148 02-03 THE EFFECT OF CHLORPROMAZINE ON CELL MEMBRANE RESISTANCE AND CAPACITANCE.

001247 02-03 DO DRUGS ACTING ON THE NERVOUS SYSTEM AFFECT CELL PROLIFERATION IN THE DEVELOPING BRAIN?

001512 02-05

THE PHARMACOKINETICS OF RED BLOOD CELL AND PLASMA BUTAPERAZINE CLINICAL RESPONSE AND SIDE-EFFECTS. 001561 02-08

EFFECTS OF CHLORPROMAZINE AND DL-AMPHETAMINE ON CALCIUM UPTAKE BY ADRENAL CHROMAFFIN CELL MEMBRANE. 002075 03-03 LITHIUM TRANSPORT ACROSS THE RED BLOOD CELL MEMBRANE

NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. I. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE IN EXPONENTIAL GROWTH PHASE.

002836 04-03 THE EFFECT OF MORPHINE-TOLERANCE AND DEPENDENCE ON CELL FREE PROTEIN SYNTHESIS.

002876 04-03
INDUCTION OF SULFOGALACTOSYLCERAMIDE (SULFATIDE) SYNTHESIS BY
HYDROCORTISONE (CORTISOL) IN MOUSE G-26 OLIGODENDROGLIOMA

002886 04-03 SELECTIVE ENZYME INDUCTION IN A NERVE GROWTH FACTOR RESPONSIVE PHEOCHROMOCYTOMA CELL LINE (PC-12). 002899 04-03

003420 04-05

PHENOBARBITAL EFFECT ON GLIAL CELL RESPIRATION IN THE PRESENCE OF A HIGH CONCENTRATION OF POTASSIUM.

002946 04-03

NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. II. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE TREATED WITH DIBUTYRYL-CYCLIC-AMP.

003026 04-03

EVIDENCE FOR CELL LOSS IN CORPUS-STRIATUM AFTER LONG-TERM
TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN RATS.

ADRENERGIC ALPHA-RECEPTORS AND BETA-RECEPTORS EXPRESSED BY
THE SAME CELL TYPE IN PRIMARY CULTURE OF PERINATAL MOUSE
BRAIN:

O03121 04-03
STRIATAL CELL SUPERSENSITIVITY TO APOMORPHINE IN DOPAMINE
LESIONED RATS CORRELATED TO BEHAVIOUR.

O03356 04-04
NGF-INDUCED ALTERATIONS IN PROTEIN SECRETION AND SUBSTRATE
ATTACHED MATERIAL OF A CLONAL NERVE CELL LINE.

003607 04-13

CELLS

ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE NEUROBLASTOMA CELLS.

O00241 01-03
THE EFFECT OF PENTOBARBITAL ON THE CARBOHYDRATE METABOLISM
OF GLIAL CELLS IN CULTURE.

000484 01-05
LITHIUM TRANSPORT IN RED BLOOD CELLS OF MANIC-DEPRESSIVE

PATIENTS.

000724 01-13
THE RELATIONSHIP BETWEEN EXTRACELLULAR AND INTRACELLULAR

LITHIUM CONCENTRATION IN HUMAN RED BLOOD CELLS: AN IN VITRO STUDY. 000731 01-1:

POSTSYNAPTIC POTENTIATION OF THE SLOW MUSCARINIC EXCITATORY RESPONSE BY TETRAETHYLAMMONIUM-CHLORIDE IN THE BULLFROG SYMPATHETIC GANGLION CELLS.

BLOCKADE BY PSYCHOTROPIC DRUGS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR IN CULTURED NERVE CELLS.

001223 02-03
IN VITRO EFFECTS OF CHLORPROMAZINE ON MICROTUBULES AND THE
GOLGI COMPLEX IN EMBRYONIC CHICK SPINAL GANGLION CELLS: AN
ELECTRON MICROSCOPIC STUDY.

001258 02-03 LITHIUM SODIUM COUNTERTRANSPORT IN HUMAN RED CELLS AND IN VIVO LITHIUM DISTRIBUTION BETWEEN RED CELLS AND PLASMA.

ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

DIHYDROERGOTOXINE-INDUCED MODULATION OF SPONTANEOUS ACTIVITY OF CULTURED RAT PURKINJE CELLS.

ACTIVITY OF COLORED RAT FORKING CEELS.

002020 03-03
ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR
MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE
NEUROBLASTOMA CELLS.

CHARACTERISTICS OF LI-TRANSPORT IN HUMAN RED CELLS.

002591 03-13
INTERACTION OF PENTOBARBITONE AND GAMMA-AMINOBUTYRIC-ACID
ON MAMMALIAN SYMPATHETIC GANGLION CELLS.

PROSTAGLANDINS AND CANNABIS — VI. RELEASE OF ARACHIDONIC-ACID FROM HELA CELLS BY DELTA1-TETRAHYDROCANNABINOL AND OTHER

ACTIVATION OF TYROSINE-3-MONOOXYGENASE IN PHEOCHROMOCYTOMA CELLS BY LASALOCID.

CANNABINOIDS

O02857 04-03
PHARMACOLOGIC RESPONSES OF CELLS OF A NEUROBLASTOMA-X
GLIOMA HYBRID CLONE AND MODULATION OF SYNAPSES BETWEEN
HYBRID CELLS AND MOUSE MYOTUBES.

MODIFICATION OF NUCLEAR RETENTION OF H3-ESTRADIOL BY CELLS OF THE HYPOTHALAMUS AS A FUNCTION OF EARLY HORMONE EXPERIENCE

MONOAMINE-OXIDASE-A AND MONOAMINE-OXIDASE-B IN CULTURED CELLS.

002941 04-03

MUSCARINIC RECEPTOR MEDIATED CYCLIC-GMP FORMATION BY
CULTURED NERVE CELLS — IONIC DEPENDENCE AND EFFECTS OF LOCAL
ANESTHETICS.

003064 04-03

EFFECTS OF LITHIUM ON THE MEMBRANE-BOUND MAGNESIUM

DEPENDENT ATPASE OF MOUSE NEUROBLASTOMA CELLS.

003087 04-03

CONCOMITANT ELEVATION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY CYCLIC-AMP IN CULTURED MOUSE NEIJRORIA STOMA CFLIS

HYDROLYSIS OF ENKEPHALIN BY CULTURED HUMAN ENDOTHELIAL CELLS AND BY PURIFIED PEPTIDYL DIPEPTIDASE. 003593 04-13

CELLULAR

CELLULAR LOCALIZATION OF H3-DIAZEPAM RECEPTORS.

002943 04-03
INVESTIGATIONS CONCERNING THE CELLULAR ORIGIN OF DOPAMINE
RECEPTORS

O02944 04-03

EXPERIMENTAL LEAD ENCEPHALOPATHY IN THE SUCKLING RAT:

CONCENTRATION OF LEAD IN CELLULAR FRACTIONS ENRICHED IN

BRAIN CAPILLARIES.

CENTRAL

CENTRAL TRYPTAMINERGIC EFFECTS OF 26-059. A NOVEL SEROTONIN DERIVATIVE.

LEVELS OF CHLORPROMAZINE AND ITS ACTIVE MATABOLITES IN RAT BRAIN AND THE RELATIONSHIP TO CENTRAL MONOAMINE METABOLISM AND PROLACTIN SECRETION.

FLA-136: SELECTIVE AGONIST AT CENTRAL ALPHA-ADRENORECEPTORS MEDIATING CHANGES IN THE TURNOVER OF NORADRENALINE.

ACTION OF S-1432, A NEW PSYCHOTROPIC DRUG, ON THE CENTRAL CHOLINERGIC SYSTEM.

OOO080 01-03
AN EXCITATORY ACTION OF IONTOPHORETICALLY ADMINISTERED
LITHIUM ON MAMMALIAN CENTRAL NEURONES.

00135 01-03
DIFFERENTIAL EFFECT OF VARIOUS 6 HYDROXYDOPA TREATMENTS ON
THE DEVELOPMENT OF CENTRAL AND PERIPHERAL NORADRENERGIC

000155 01-03
ANTIPODAL CENTRAL EFFECTS OF DOPAMINE AND APOMORPHINE.
000168 01-03

CENTRAL SITES AND MECHANISMS OF THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF THE NARCOTIC ANALGESIC AGENT EFENTANCE.

TYROSINE-HYDROXYLASE: DELAYED ACTIVATION IN CENTRAL NORADRENERGIC NEURONS AND INDUCTION IN ADRENAL MEDULLA ELICITED BY STIMULATION OF CENTRAL CHOLINERGIC RECEPTORS.

ODO183 01-03

POSSIBLE INVOLVEMENT OF THE CENTRAL DOPAMINERGIC SYSTEM IN THE ANTIRESERPINE EFFECT OF LSD.

O00198 01-03
ANTIDEPRESSIVE EFFECTS ON CENTRAL CATECHOLAMINE RECEPTORS.
O00202 01-03
INHIBITION OF THE CENTRAL HYPOTENSIVE EFFECT OF CLONDINE BY

TRAZODONE, A NOVEL ANTIDEPRESSANT.

O00286 01-03
CENTRAL TRANSMITTER INVOLVEMENT IN LON-954-INDUCED

TREMOROGENESIS. 000342 01-04

THE ROLE OF ASCENDING AND DESCENDING 5 HYDROXYTRYPTAMINE NEURONES IN CENTRAL CONTROL OF PAIN SENSITIVITY.

CO0380 01-04
BEHAVIORAL SENSITIVITY TO LSD: DEPENDENCY UPON THE PATTERN OF

CENTRAL 5-HT DEPLETION.

O00388 01-04

EFFECT OF BENZODIAZEPINES ON CENTRAL SEROTONERGIC NEURON

SYSTEMS.

000418 01-04

BLOCKADE OF INTRACRANIAL SELF-STIMULATION BY ANTIPSYCHOTIC

DRUGS: FAILURE TO CORRELATE WITH CENTRAL ALPHA
NORADRENERGIC BLOCKADE.

SLEEP AND BEHAVIORAL CHANGES POSSIBLY REFLECTING CENTRAL
RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS

MODE OF ACTION OF: ANTIDEPRESSANTS AND CENTRAL STIMULANTS.
(UNPUBLISHED PAPER).

MAO INHIBITORS AND CENTRAL MONOAMINE METABOLISM.

CENTRAL PHARMACOLOGY OF A NEW ANTIDEPRESSANT. 001063 02-03

A ROLE FOR CENTRAL SEROTONERGIC SYSTEMS IN THE PATTERN AND INTENSITY OF THE CONVULSIVE RESPONSE OF RATS TO ELECTROSHOCK.

THE EFFECT OF DIPHENYLHYDANTOIN ON CENTRAL CATECHOLAMINE CONTAINING NEURONAL SYSTEMS.

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIAT...) CONTROL OF NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF

CLOZAPINE AND PHENOXYBENZAMINE (PBZ) ALTERATION OF CENTRAL PHENYLETHYLAMINE (PEA) TURNOVER.

INVOLVEMENT OF CENTRAL NORADRENERGIC SYSTEM IN THE MEDIATION OF BEHAVIORAL SUPPRESSANT EFFECTS OF DIAZEPAM IN HYPERTHYROID RATS.

001220 02-03 ON THE MODE OF ACTION OF CENTRAL STIMULATORY AGENTS 001232 02-03

CENTRAL ANTAGONISM OF TYRAMINE-INDUCED SYSTEMIC HYPOTENSION BY MESCALINE

URINARY 3 METHOXY-4-HYDROXYPHENYLGLYCOL, AN INDEX OF PERIPHERAL RATHER THAN CENTRAL ADRENERGIC ACTIVITY IN THE RAT.

001277 02-03 EFFECTS OF THE ISOMERIC FORMS OF PROPRANOLOL ON CENTRAL MONOAMINE METABOLISM IN REGIONS OF RAT BRAIN.

WET-DOG SNAKE BEHAVIOUR IN THE RAT: A POSSIBLE QUANTITATIVE MODEL OF CENTRAL 5 HYDROXYTRYPTAMINE ACTIVITY.

CENTRAL CARDIOVASCULAR EFFECTS OF MORPHINOMIMETIC PEPTIDES IN

CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE ANTIPSYCHOTIC DRUGS

O01526 02-06
ANTIDEPRESSANT AGENTS. 9.3,3 DIPHENYLCYCLOBUTYLAMINES, A NEW
CLASS OF CENTRAL STIMULANTS.

001943 03-01 NEUROCHEMICAL MECHANISMS OF CENTRAL ACTION OF MORPHINE ON FUNCTIONS OF SINGLE NEURONS IN THE MIDBRAIN RETICULAR FORMATION.

DIRECT INTERACTION OF LSD WITH CENTRAL BETA-ADRENERGIC

POSSIBLE CENTRAL DOPAMINERGIC MODULATION OF THE RISE IN PLASMA CONCENTRATION OF NONESTERIFIED FATTY-ACIDS PRODUCED IN THE MOUSE BY (-)TRANS DELTA9-TETRAHYDROCANNABINOL.

002085 03-03 THE EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND 2
BROMOLYSERGIC-ACID-DIETHYLAMIDE (BOL) ON THE STRIATAL DOPA
ACCUMULATION: INFLUENCE OF CENTRAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS.

MEMORIZATION AND CENTRAL CATECHOLAMINES AFTER A
CRANIOCERVICAL INJURY CARRIED OUT IN RATS: INFLUENCE OF
IMIPRAMINE ADMINISTRATION.

002197 03-04 CENTRAL DRUG AND LESION STUDIES OF FEEDING.

002270 03-04 THE EFFECT OF CHRONIC ETHANOL TREATMENT ON BEHAVIOUR AND CENTRAL MONOAMINES IN THE RAT.

CENTRAL NERVOUS EFFECTS OF THE HYPNOTIC ETOMIDATE IN MAN. 002580 03-13 CENTRAL CATECHOLAMINE NEUROTRANSMITTERS AND PSYCHOACTIVE

DRUGS 002731 03-17 CENTRAL CATECHOLAMINE METABOLISM IN PSYCHOSIS

002764 03-17 THE CENTRAL EFFECTS OF A NOVEL DOPAMINE AGONIST.

002798 04-02 CENTRAL EFFECT OF SOMATOSTATIN ON THE SECRETION OF GROWTH HORMONE IN THE ANESTHETIZED RAT.

EFFECTS OF CENTRAL GABA RECEPTOR AGONISM AND ANTAGONISM ON EVOKED DIENCEPHALIC CARDIOVASCULAR RESPONSES.

002811 04-03 CENTRAL ADRENOCEPTORS AND CHOLINOCEPTORS IN CARDIOVASCULAR

002823 04-03 HYPERTHERMIC RESPONSES TO CENTRAL AND PERIPHERAL INJECTIONS OF MORPHINE-SULPHATE IN THE CAT. 002864 04-03

PHARMACOLOGICAL DIFFERENTIATION OF THE CENTRAL 5
HYDROXYTEYPTAMINE-LIKE ACTIONS OF AK-212 (6 CHLORO-2-1PIPERAZINYL-PYRAZINE), P-METHOXYAMPHETAMINE AND
FENFLIRAMINE IN AN IN VIVO MODEL SYSTEM. 002868 04-03 PHARMACOLOGICAL CHARACTERIZATION OF THE EXCITATORY CHOLINERGIC RECEPTORS OF RAT CENTRAL NEURONES.

003006 04-03

CENTRAL MECHANISMS OF DRUGS AS DISCRIMINATIVE STIMULI: INVOLVEMENT OF SEROTONIN PATHWAYS.

THE EFFECTS OF INORGANIC LEAD ON THE CENTRAL CATECHOLAMINERGIC SYSTEM OF THE RODENT WITH EMPHASIS ON POSTNATALLY EXPOSED RATS AND MICE. (PH.D. DISSERTATION).

003078 04-03 LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO P-CHLOROAMPHETAMINE ON CENTRAL SEROTONERGIC MECHANISMS IN

003098 04-03 POSSIBLE ROLE OF BRAIN SEROTONIN IN THE CENTRAL EFFECTS OF KETAMINE.

PHARMACOLOGICAL STUDIES OF CENTRAL ACTION OF L 5
HYDROXYTRYPTOPHAN IN INTACT OR TETRABENAZINE PRETREATED
CATS. 003123 04-03

003144 04-03 THE CENTRAL ANTISEROTONERGIC ACTION OF MIANSERIN

003281 04-04 CENTRAL AND PERIPHERAL NORADRENALINE AND RESISTANCE TO

003290 04-04 LACK OF BLOCKADE OF CENTRAL DOPAMINERGIC RECEPTORS BY NARCOTICS: COMPARISON WITH CHLORPROMAZINE.

003354 04-04 CHANGES IN THE BEHAVIORAL RESPONSE TO A NOVEL ENVIRONMENT FOLLOWING LESIONING OF THE CENTRAL DOPAMINERGIC SYSTEM IN RAT PUPS.

003368 04-04 CENTRAL MECHANISMS OF REWARD AND THE NARCOTIC CUE

003369 04-04 CENTRAL AND PERIPHERAL ACTION OF TESTOSTERONE-PROPIONATE ON SCENT GLAND MORPHOLOGY AND MARKING BEHAVIOUR IN THE MONGOLIAN GERBIL.

003370 04-04 L 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS IN GUINEA-PIGS: A MODEL FOR THE STUDY OF CENTRAL SEROTONIN DOPAMINE INTERACTIONS.

PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT
OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC
AND CATECHOLAMIREGIC MECHANISMS BY 6 HYDROXYDOPAMINE
AND 5.6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH. D.

003407 04-05 PERIPHERAL ALPHA-ADRENORECEPTOR AND CENTRAL DOPAMINE RECEPTOR ACTIVITY IN DEPRESSIVE PATIENTS.

A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS. 003608 04-13

CENTRAL-NERVOUS-SYSTEM
SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM EVALUATION OF SOME 5
ALKOXY-3H-1,4 BENZODIAZEPINES.

000021 01-02 DOPAMINE RECEPTOR BLOCKING ACTIVITY OF THE SULPIRIDE IN THE CENTRAL-NERVOUS-SYSTEM.

SYNTHESIS OF SPIROISOBENZOFURANPIPERIDINES AS POTENTIAL CENTRAL-NERVOUS-SYSTEM AGENTS. 2. COMPOUNDS CONTAINING A HETERCOATOM ATTACHED TO NITROGEN.

000167 01-03 DIFFERENTIAL EFFECTS OF OPIATES ON THE INCORPORATION OF C14-THIAMINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT

000201 01-03 3 AMINOTETRAHYDROCARBAZOLES AS A NEW SERIES OF CENTRAL-NERVOUS-SYSTEM AGENTS.

000203 01-03 DIRECT EFFECTS OF ETHANOL ON CENTRAL-NERVOUS-SYSTEM CULTURES: AN ELECTROPHYSIOLOGICAL AND MORPHOLOGICAL STUDY.

NOREPINEPHRINE ALPHA RECEPTOR BINDING IN MAMMALIAN CENTRAL-NERVOUS-SYSTEM: DIFFERENTIAL LABELING WITH AGONIST AND

000283 01-03 EFFECT OF CHLORPROMAZINE ON CENTRAL-NERVOUS-SYSTEM CONCENTRATIONS OF MANGANESE, IRON, AND COPPER.

000295 01-03 THE EFFECTS OF CENTRAL-NERVOUS-SYSTEM STIMULANTS ON TOURETTE

000629 01-11 CENTRAL-NERVOUS-SYSTEM ACTIVITY OF A NOVEL CLASS OF ANNELATED 1,4 BENZODIAZEPINES, AMINOMETHYLENE-IMIDAZOBENZODIAZEPINONES.

CANNABINOIDS. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY OF 8 SUBSTITUTED HYDROXY-DIMETHYLBENZOPYRANOPYRIDINE AND

001034 02-02 POSSIBLE PHYSIOLOGICAL SIGNIFICANCE OF THE INITIAL STEP IN THE CATABOLISM OF NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM

BENZODIAZEPINE RECEPTOR: DEMONSTRATION IN THE CENTRAL-

001198 02-03 FURTHER OBSERVATION ON THE LACK OF ACTIVE UPTAKE SYSTEM FOR

SUBSTANCE-P IN THE CENTRAL-NERVOUS-SYSTEM 001238 02-03

EFFECTS OF ANTIESTROGENS ON EATING, FEMALE SEXUAL BEHAVIOR, AND THE UPTAKE OF H3-ESTRADIOL IN THE CENTRAL-NERVOUS-SYSTEM IN RATS. (PH.D. DISSERTATION).

001447 02-04 THE EFFECTS OF PSYCHOPHARMACOLOGICAL AGENTS ON CENTRAL-NERVOUS-SYSTEM AMINE METABOLISM IN MAN

001671 02-13 CENTRAL-NERVOUS-SYSTEM EFFECTS OF PEPTIDES FOUND IN BRAIN AND INTESTINES.

001953 03-02 EFFECT OF 1 AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID (CYCLOLEUCINE)
ON DEVELOPING RAT CENTRAL-NERVOUS-SYSTEM PHOSPHOLIPIDS.

002136 03-03 GUANOSINE-MONOPHOSPHATE: A CENTRAL-NERVOUS-SYSTEM REGULATOR OF ANALGESIA.

002215 03-04 NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY EFFECTS OF DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF

002362 03-06 NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY THE EFFECTS OF DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF

002363 03-06 DOPAMINE RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM

002779 03-17 DRUGS AFFECTING THE CENTRAL-NERVOUS-SYSTEM: EFFECTS OF PEMOLINE, AND TRICYCLIC ANTIDEPRESSANTS ON NERVE TERMINAL ADENOSINE-TRIPHOSPHATASE ACTIVITIES AND NEUROTRANSMITTER

STUDIES OF THE PHYSIOLOGICAL ROLES OF PROSTAGLANDINS IN THE CENTRAL-NERVOUS-SYSTEM

002924 04-03 SOME OBSERVATIONS ON THE BINDING PATTERNS OF ALPHA-BUNGAROTOXIN IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT. 002956 04-03

EFFECT OF HYPOCHOLESTEROLEMIC AGENTS ON CENTRAL-NERVOUS-SYSTEM CHOLESTEROL BIOSYNTHESIS. III. ZUCLOMIPHENE IN COMBINATION WITH AY9944 AND TRIPARANOL.

ENTRY OF BETA-N-OXALYL-L-ALPHA-BETA-DIAMINOPROPIONIC-ACID, THE LATHYRUS-SATIVUS NEUROTOXIN INTO THE CENTRAL-NERVOUS-SYSTEM OF THE ADULT RAT, CHICK AND THE RHESUS MONKEY

003061 04-03 INTERACTION OF PHENCYCLIDINES WITH THE MUSCARINIC AND OPIATE RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM.

003128 04-03 A ROLE OF THE POLYSYNAPTIC SYSTEM OF SUBSTANTIA-NIGRA IN THE CHOLINERGIC DOPAMINERGIC EQUILIBRIUM IN THE CENTRAL-NERVOUS-

003397 04-04 CONTEMPORARY VIEWS ON THE ROLE OF NEUROLEPTICS IN THE TREATMENT OF SCHIZOPHRENIA AND THEIR ACTION IN THE CENTRAL-NERVOUS-SYSTEM.

003464 04-08 A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF TSTAMANDS OF PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR. 003657 04-15

TRACE AMINES AND ALTERNATIVE NEUROTRANSMITTERS IN THE CENTRAL-NERVOUS-SYSTEM 003698 04-17

CENTRALLY ACTIVE DRUGS AND THE SYMPATHETIC NERVOUS SYSTEM OF RABBITS AND CATS

STRESS-INDUCED ALTERATIONS OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN: EFFECTS OF CENTRALLY ACTING DRUGS.

TYRAMINE BINDING BY SYNAPTOSOMES FROM RAT BRAIN: EFFECT OF CENTRALLY ACTIVE DRUGS. 000285 01-03 ALTERATION OF THE NEURONAL RESPONSE TO AMPHETAMINE IN THE NEOSTRIATUM BY PRETREATMENT WITH A CENTRALLY ACTING ANTICHOLINERGIC

THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE HUMAN BRAIN AS AN OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING DRINGS

000747 01-14 MODIFICATION OF THE TIME-COURSE OF DMPEA TOXICITY IN THE MOUSE BY CENTRALLY ACTING DRUGS.

COCAINE-INDUCED CENTRALLY MEDIATED RELEASE OF CATECHOLAMINES INTO BLOOD OF UNDISTURBED RATS. (UNPUBLISHED PAPER).
001079 02-03

STEREOSELECTIVE, DOSE-DEPENDENT MODIFICATION OF INTRACRANIAL SELF-STIMULATION (ICSS) BY CENTRALLY ADMINISTERED LEVORPHANOL AND DEXTRORPHAN.

EFFECT OF SOME CENTRALLY ACTIVE COMPOUNDS ON AGGRESSIVE BEHAVIOUR IN SEPTAL RATS.

001376 02-04 6 HYDROXYDOPAMINE INHIBITS SOME EFFECTS OF MESCALINE CENTRALLY ADMINISTERED TO RABBITS.

002231 03-04
EFFECTS OF CENTRALLY ACTING DRUGS ON BRAINSTEM AUDITORY RESPONSES

002598 03-13 DIFFERENTIAL EFFECTS ON CONDITIONED TASTE AVERSION LEARNING
WITH PERIPHERALLY AND CENTRALLY ADMINISTERED ACETALDEHYDE 003178 04-04

NEURONAL LIPOFUSCIN IN CENTROPHENOXINE TREATED RATS 000303 01-03

CENTROPHENOXINE: EFFECTS ON AGING MAMMALIAN BRAIN 002287 03-04

CEPHALGIA RHEOENCEPHALOGRAPHIC DATA IN MIGRAINE CEPHALGIA AND THEIR CHANGES DURING STUGERON TREATMENT.

000515 01-07 CEREBULLA DNA SYNTHETIC ABILITY IN CEREBELLA FROM TEMPERATURE AND

HANDLING STRESSED NEONATAL RATS. 002934 04-03

ON THE MECHANISM OF THE DECREASE IN CEREBELLAR CYCLIC-GMP CONTENT ELICITED BY OPIATE RECEPTOR AGONISTS.

INFLUENCE OF DIAZEPAM, L-DOPA AND DOPAMINE ON THE CEREBELLAR AND SPINAL ELECTRICAL PATTERNS INDUCED BY HARMINE IN THE

000091 01-03 EFFECTS OF N METHYLAMINO-ACIDS AND CONVULSANTS ON SPONTANEOUS ACTION POTENTIALS IN GUINEA-PIG CEREBELLAR

000209 01-03 EQUAL SUPPRESSION OF CEREBELLAR PURKINJE CELL ACTIVITY BY AMPHETAMINE STEREOISOMERS.

000299 01-03 CEREBELLAR UNIT ACTIVITY DURING GENERALIZED PENICILLIN EPILEPSY IN THE AWAKE CAT.

001028 02-02 BURST FIRING OF CEREBELLAR PURKINJE NEURONES INDUCED BY BENZODIAZEPINES.

CEREBELLAR CGMP SYSTEM: A MODEL TO STUDY DRUG RECEPTOR INTERACTION. (UNPUBLISHED PAPER).

CEREBELLAR ATROPHY IN PHENYTOIN TREATED MENTALLY RETARDED

001622 02-11 PHARMACOLOGICAL EVIDENCE FOR A LINK BETWEEN THE CEREBELLAR CONTENT OF C-GMP AND THAT OF AN ENDOGENOUS PROTEIN KINASE

MORPHINE REDUCES CEREBELLAR CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT AND ELEVATES CEREBROSPINAL FLUID CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT IN RHESUS MONKEY.

002057 03-03 EFFECTS OF ANESTHETICS ON CEREBELLAR NEURONS RECORDED CHRONICALLY AFTER HARMALINE.

002260 03-04 DISAPPEARANCE OF CEREBELLAR CYCLIC-GMP-INDUCED BY KAINIC-ACID. 002826 04-03

SUPPRESSION BY NITROUS-OXIDE OF VISUAL RESPONSES IN THE CEREBELLAR VERMIS AND SUPERIOR COLLICULUS OF CATS ANESTHETIZED WITH CHLORALOSE.

EFFECT OF ACUTE MORPHINE ADMINISTRATION ON THE CEREBELLAR CYCLIC-GMP LEVEL IN TWO STRAINS OF MICE.

THE EFFECT OF DRUGS WHICH ALTER GABAERGIC FUNCTION ON CEREBELLAR GUANOSINE-MONOPHOSPHATE CONTENT.

EVIDENCE AGAINST CHRONIC DEPOLARIZATION AS A MECHANISM OF KAINIC-ACID TOXICITY IN MOUSE CEREBELLAR CULTURES.

CEREBELLAR-CORTEX
THE IONTOPHORESIS OF DIAZEPAM IN THE CUNEATE NUCLEUS AND
CEREBELLAR-CORTEX OF THE CAT.

THE ROLE OF DIAZEPAM AS COMPARED TO GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT. (PH.D. DISSERTATION).

EFFECT OF CHRONIC TREATMENT WITH NEUROLEPTICS ON THE CONTENT OF 3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE IN CEREBELLAR-CORTEX OF RATS. 002827 04-03

BICYCLIC PHOSPHORUS ESTERS INCREASE THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM.

EVIDENCE FOR FUNCTIONAL SYNAPSES BETWEEN MIXED CULTURES OF INFERIOR OLIVE AND CEREBELLUM.

THE EFFECT OF MELPERONE (BURONIL(R)) AND ITS METABOLITE FG-5155 ON THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM COMPARED TO SOME OTHER NEUROLEPTICS.

001081 02-03 CYCLIC-GMP AND GABA LEVELS IN RAT STRIATUM AND CEREBELLUM DURING MORPHINE WITHDRAWAL: EFFECT OF APOMORPHINE.

3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE LEVELS IN RAT CEREBELLUM: EFFECTS OF MORPHINE, KETAMINE, HARMALINE AND ISONIAZID. 002056 03-03

DECREASE OF CYCLIC-GMP IN CEREBELLUM BY INTRASTRIATAL D ALA2-MET-ENKEPHALINAMIDE.

DO2828 04-03
STUDIES ON THE MECHANISM OF SPROUTING OF NORADRENERGIC
TERMINALS IN RAT AND MOUSE CEREBELLUM AFTER NEONATAL 6 **AGODYXOBOXH**

002980 04-03 CYCLIC-NUCLEOTIDE LEVELS IN THE RAT STRIATUM AND CEREBELLUM IN VIVO EFFECTS OF DOPAMINE AND ACETYLCHOLINE RECEPTOR AGONISTS AND ANTAGONISTS.

003051 04-03

CEREBRAL

EFFECTS OF CARBACHOL AND NICOTINE INJECTED INTO THE CEREBRAL

VENTRICLES ON ELECTROMYOGRAM OF CONSCIOUS CATS.

000052 01-03

INTERACTIONS OF SUBSTITUTED BENZAMIDE DRUGS WITH CEREBRAL DOPAMINE PATHWAYS.

000077 01-03 PHARMACOLOGICAL TREATMENT FOLLOWING EXPERIMENTAL CEREBRAL INFARCTION: IMPLICATIONS FOR UNDERSTANDING PSYCHOLOGICAL SYMPTOMS OF HUMAN STROKE.

000243 01-03 ANTAGONISM OF BIOGENIC AMINE-INDUCED DEPRESSION OF CEREBRAL CORTICAL NEURONES BY NA-K-ATPASE INHIBITORS.

000254 01-03
CEREBRAL METABOLISM OF INTRAVENTRICULAR (3H) FENFLURAMINE. 000266 01-03

CEREBRAL METABOLISM OF (3H) P-CHLOROAMPHETAMINE 000267 01-03 SUBSTITUTED BENZAMIDES AS CEREBRAL DOPAMINE ANTAGONISTS IN

RODENTS 000355 01-04

EFFECTS OF REDUCED CEREBRAL SEROTONIN ON LEARNING 000422 01-04
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF BROMIDE PSYCHOSIS.

ELECTRON MICROSCOPIC STUDIES ON THE CEREBRAL LESIONS OF RATS IN EXPERIMENTAL CHRONIC DISULFIRAM POISONING. CLASSIFICATION AND DETERMINATION OF CEREBRAL BIOAVAILABILITY

OF PSYCHOTROPIC DRUGS BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS (STUDIES WITH AX-A411-BS). 000931 01-16

A BENZOQUINOLIZINE DERIVATIVE WITH A NEUROLEPTIC-LIKE ACTION ON CEREBRAL MONOAMINE TURNOVER.

001037 02-02 EVIDENCE FOR A DOUBLE CHOLINERGIC MECHANISM CAPABLE OF REDUCING THE TONE OF CEREBRAL ARTERIES.

001049 02-03 BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF CHRONIC REDUCTION OF CEREBRAL NORADRENALINE RECEPTOR STIMULATION.

001099 02-03 CEREBRAL CIRCULATION IS ALTERED BY A POTENT ACTH4-9 ANALOG ORG-2766. 001135 02-03 INDIRECT SYMPATHOMIMETICS AND CEREBRAL BLOOD FLOW AND METABOLISM.

THE EFFECT OF STEROID HORMONES ON CEREBRAL BLOOD FLOW BEFORE AND AFTER INTRACAROTID INFUSION OF 5 HYDROXYTRYPTAMINE.

001193 02-03 E INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LOCAL CEREBRAL GLUCOSE UTILISATION OF THE RAT.

001206 02-03 NONPARTICIPATION OF CHOLINERGIC MECHANISM IN CHEMICAL CONTROL OF CEREBRAL VASOMOTOR ACTIVITY.

001243 02-03 THE EFFECT OF BROMOCRIPTINE ON LOCOMOTOR ACTIVITY AND CEREBRAL CATECHOLAMINES IN RODENTS.

001346 02-04 ABSENCE OF DRUG-INDUCED BETA-ACTIVITY IN THE ELECTROENCEPHALOGRAM: A SIGN OF SEVERE CEREBRAL IMPAIRMENT.

001676 02-13 REGIONAL CHANGES OF CEREBRAL BLOOD FLOW DURING HALOPERIDOL THERAPY IN PATIENTS WITH PARANOID SYMPTOMS.

THE EFFECT OF SALICYLATE ON CEREBRAL BLOOD FLOW IN MAN. 001681 02-13 001677 02-13

DRUG IMPROVING CEREBRAL METABOLISM IN DEMENTIA 001695 02-13 EFFECT OF DEXAMETHASONE ON CEREBRAL EDEMA FROM CRANIAL IMPACT IN THE CAT.

001958 03-02 MEASURING CHANGES IN CEREBRAL GLUTAMATE AND GABA METABOLISM PRIOR TO CONVULSIONS INDUCED BY 3 MERCAPTOPROPIONATE.

001961 03-03 COMPARATIVE EFFECTS OF DIHYDROERGOTOXINE (DHET) ON CBF AND METABOLISM CHANGES PRODUCED BY EXPERIMENTAL CEREBRAL EDEMA, HYPOXIA AND HYPERTENSION.

001979 03-03 EFFECT OF PAPAVERINE AND DIHYDROERGOTOXINE-MESYLATE ON CEREBRAL MICROFLOW, EEG, AND PO2 IN OLIGEMIC HYPOTENSION

002032 03-03 SYNAPTIC CONNEXIONS AND RELATED POSTSYNAPTIC PHARMACOLOGY STUDIED IN THE CEREBRAL GANGLION OF APLYSIA.

002041 03-03 INDIRECT SYMPATHOMIMETIC AGENTS AND CEREBRAL BLOOD FLOW AND METABOLISM.

SOME BEHAVIORAL EFFECTS OF SP6-11 HEXAPEPTIDE C-TERMINAL OF SUBSTANCE-P INJECTED INTO THE CEREBRAL VENTRICLES IN RATS. 002267 03-04

EFFECTS OF PIRACETAM ON REGIONAL CEREBRAL BLOOD FLOW AND MENTAL FUNCTIONS IN PATIENTS WITH ORGANIC DEMENTIA. 002512 03-11

LITHIUM-CARBONATE AND BRAIN FUNCTION: 1. CEREBRAL EVOKED-POTENTIALS, EEG, AND SYMPTOM CHANGES DURING LITHIUM-CARBONATE TREATMENT.

002560 03-13 REGIONAL CHANGES IN CEREBRAL GABA CONCENTRATION AND CONVULSIONS PRODUCED BY D AND BY L ALLYLGLYCINE.

THE EFFECT OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF AMPHETAMINE ON CEREBRAL DOPAMINE RECEPTOR SENSITIVITY 002964 04-03

AMPHETAMINE-INDUCED INCREASE IN RAT CEREBRAL BLOOD FLOW; APPARENT LACK OF CATECHOLAMINE INVOLVEMENT.

003031 04-03 REGIONAL CHANGES IN THE CONCENTRATIONS OF CEREBRAL MONOAMINES AND THEIR METABOLITES AFTER ETHANOLAMINE-O-SULPHATE-INDUCED ELEVATION OF BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS

003053 04-03 LOCAL CEREBRAL GLUCOSE UTILIZATION FOLLOWING INJECTION OF BETA-ENDORPHIN INTO PERIAQUEDUCTAL GRAY MATTER IN THE RAT.

003073 04-03 DOPAMINE RECEPTORS LOCALISED ON CEREBRAL CORTICAL AFFERENTS TO RAT CORPUS-STRIATUM.

DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: A
VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIATION OF
CATECHOLAMINERGIC AND SEROTONINERGIC TERMINALS IN RAT CEREBRAL STRUCTURES.

CEREBRAL-CORTEX
THE ROLE OF THE SEPTAL NUCLEI IN THE RELEASE OF ACETYLCHOLINE
FROM THE RABBIT CEREBRAL-CORTEX AND DORSAL HIPPOCAMPUS AND THE EFFECT OF ATROPINE

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON A MG2-ATPASE OF SYNAPTIC VESICLES PREPARED FROM RAT CEREBRAL-CORTEX.

PHENOBARBITAL ACTIONS IN VIVO: EFFECTS OF EXTRACELLULAR POTASSIUM ACTIVITY AND OXIDATIVE METABOLISM IN CAT

000176 01-03 MAO ACTIVITY IN RAT BRAINSTEM AND CEREBRAL-CORTEX FOLLOWING ACUTE AND CHRONIC TREATMENT WITH L-DOPA AND ETHANOL L-DOPA.

000239 01-03 EFFECT OF DOPAMINERGIC AGONISTS UPON OXYGEN AVAILABILITY FOR

001064 02-03 INFLUENCE OF CHLORPROMAZINE AND TRIFLUOPERAZINE ON NEURONS OF AN ISOLATED SLAB OF RABBIT CEREBRAL-CORTEX.

001205 02-03 THE EFFECT OF DIHYDROERGOTOXINE ON THE ADENYLATE-CYCLASE **ACTIVITY IN HOMOGENATES OF RAT CEREBRAL-CORTEX.** 001254 02-03

EFFECT OF DIAZEPAM ON PULSE ACTIVITY OF NEURONS OF THE SENSORIMOTOR AND OPTIC AREAS OF THE RAT CEREBRAL-CORTEX 001978 03-03 STUDIES ON THE SUBSYNAPTOSOMAL DISTRIBUTION OF PSYCHOTROPIC

DRUGS IN RAT CEREBRAL-CORTEX. 002045 03-03

EFFECT OF DIHYDROERGOTOXINE ON CYCLIC-AMP GENERATING SYSTEMS IN RAT CEREBRAL-CORTEX SLICES. 002088 03-03

EFFECTS OF DOPAMINE AGONISTS ON NEURONES IN THE CAUDATE NUCLEUS AND CEREBRAL-CORTEX OF CATS CHRONICALLY TREATED WITH NEUROLEPTICS.

MODIFICATION OF ADENYLATE-CYCLASE SYSTEMS IN MOUSE CEREBRAL-CORTEX BY CHLORPROMAZINE AND RESPECTIVE 7 HDROXY ANALOGS.

002875 04-03 BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101 BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN RAT CEREBRAL-CORTEX.

002885 04-03 5 GUANYLYLIMIDODIPHOSPHATE ACTIONS ON ADENYLATE-CYCLASE IN HOMOGENATES OF RAT CEREBRAL-CORTEX PLUS NEURONAL AND CAPILLARY FRACTIONS.

003038 04-03 INTERACTIONS BETWEEN GUANINE DERIVATIVES AND NOREPINEPHRINE ON NEURONES OF THE MAMMALIAN CEREBRAL-CORTEX.

SHORT-TERM AND LONG-TERM EFFECTS OF CEREBROLYSINE ON EVOKED CORTICAL POTENTIALS IN RATS.

THE EFFECT OF CEREBROLYSINE ON CORTICAL EVOKED-POTENTIALS IN RATS WITH EARLY MALNUTRITION.

CEREBROSPINAL

EFFECTS OF AMPHETAMINE AND CHLORDIAZEPOXIDE ON PROBENECID-INDUCED ACCUMULATION OF ACIDIC METABOLITES IN THE CEREBROSPINAL FLUID OF THE DOG.

000092 01-03 CONCENTRATION OF CLONAZEPAM IN SERUM AND CEREBROSPINAL

000215 01-03 THE EFFECT OF L TRYPTOPHAN ADMINISTRATION ON THE CONCENTRATION OF PROBENECID IN PLASMA AND CEREBROSPINAL

EFFECT OF CHLORPROMAZINE TREATMENT ON MONOAMINE METABOLITE LEVELS IN CEREBROSPINAL FLUID OF PSYCHOTIC PATIENTS 000591 01-09

CEREBROSPINAL FLUID HOMOVANILLIC-ACID IN MALE ALCOHOLICS:

000645 01-11

PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS 000742 01-13 SIMILAR EFFECTS OF TRYPTOPHAN AND SLEEP ON CISTERNAL

CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC AND HOMOVANILLIC-ACIDS IN CATS 001440 02-04

LITHIUM: CLINICAL EFFECTS AND CEREBROSPINAL FLUID ACID MONOAMINE METABOLITES

001577 02-09 NEUROTRANSMITTER METABOLITES IN THE CEREBROSPINAL FLUID OF MAN FOLLOWING PHYSOSTIGMINE.

001653 02-13 ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS.

001672 02-13 CYCLIC-AMP IN CEREBROSPINAL FLUID OF MANIC AND DEPRESSIVE

001683 02-13

003101 04-03

003069 04-03

EFFECT OF CHLORPROMAZINE TREATMENT ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC PATIENTS.

MORPHINE REDUCES CEREBELLAR CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT AND ELEVATES CEREBROSPINAL FLUID CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT IN RHESUS MONKEY.

CLINICAL AND BIOCHEMICAL EFFECTS OF CHLORPROMAZINE IN PSYCHOTIC PATIENTS: RELATIONS TO CHLORPROMAZINE CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID.

ALTERATIONS OF CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC-ACID, AND TOTAL BLOOD SEROTONIN CONTENT DURING CLOZAPINE TREATMENT.

EFFECTS OF MELPERONE AND THIOTHIXENE ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC WOMEN.

ASPECTS OF INFLUX AND EFFLUX OF HOMOVANILLIC-ACID OF RAT CEREBROSPINAL FLUID.

002807 04-03 LITHILIAN TRANSPORT FROM CEREBROSPINAL FLUID.

002947 04-03 IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLETHANOL (MOPET) IN HUMAN CEREBROSPINAL FLUID AND RAT BRAIN BY MEANS OF GAS-CHROMATOGRAPHY -- MASS-SPECTROMETRY

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLLACTIC-ACID (VLA) IN CEREBROSPINAL FLUID AND 3 METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN THE URINE OF PARKINSONIAN PATIENTS TREATED WITH L-DOPA.

003602 04-13 CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED DOSES OF CHLORPROMAZINE

A COMPARISON BETWEEN FLUOROMETRIC AND MASS FRAGMENTOGRAPHIC DETERMINATIONS OF HOMOVANILLIC-ACID AND 5 HYDROXYINDOLEACETIC-ACID IN HUMAN CEREBROSPINAL FLUID. 003694 04-16

LIPOPROTEIN POTENTIATION OF THE CEREBROVASCULAR RESPONSE TO INTRAARTERIAL 5 HYDROXYTRYPTAMINE.

AMPHETAMINE-INDUCED INCREASE OF THE CEREBROVASCULAR PERMEABILITY TO PROTEIN.

O01153 02-03
THE CEREBROVASCULAR PERMEABILITY TO PROTEIN AFTER BICUCULLINE

AND AMPHETAMINE ADMINISTRATION IN SPONTANEOUSLY HYPERTENSIVE RATS. 002050 03-03

CEREBROVENTRICLE
SYNTHESIS AND TURNOVER OF H3-5-HYDROXYTRYPTAMINE IN THE
LATERAL CEREBROVENTRICLE.

002054 03-03 CEREBROVENTRICULAR ANALGESIC EFFECT OF CEREBROVENTRICULAR ADMINISTRATION OF SOMATOSTATIN (SRIF).

RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D

AMPHETAMINE. 002862 04-03 CERUCAL

EXTRAPYRAMIDAL SIDE-EFFECTS OF METOCLOPRAMIDE (CERUCAL) USED IN COMBINATION WITH AN ANTIDEPRESSANT. 000832 01-15

EFFECTS OF SYSTEMIC MUSCIMOL AND GABA IN THE SPINAL CORD AND SUPERIOR CERVICAL GANGLION OF THE CAT.

GAS-CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY OF SEROTONIN IN RAT SUPERIOR CERVICAL GANGLIA: EFFECTS OF NERVE GROWTH FACTOR AND 6 HYDROXYDOPAMINE.

THE EFFECTS OF HORMONES AND MORPHINE ON BOTH ANALGESIA AND THE LORDOSIS RESPONSE PRODUCED BY CERVICAL PROBING IN THE FEMALE RAT.

001445 02-04 THE EFFECT OF PANCURONIUM AND GALLAMINE ON MUSCARINIC TRANSMISSION IN THE SUPERIOR CERVICAL GANGLION.

002021 03-03 BETA-ADRENOCEPTORS MODULATE NORADRENALINE RELEASE FROM AXONAL SPROUTS IN CULTURED RAT SUPERIOR CERVICAL GANGLIA. 002179 03-03

EFFECT OF RUBIDIUM, LITHIUM AND CESIUM ON BRAIN ATPASE AND PROTEIN KINASES. 001172 02-03

CF-25-397
BROMOCRIPTINE, DIHYDROERGOTOXINE, METHYSERGIDE, D LSD, CF-25-397, AND CF-29-712: EFFECTS ON THE METABOLISM OF BIOGENIC AMINES IN THE BRAIN OF THE RAT.

002849 04-0:

CF-29-712
BROMOCRIPTINE, DIHYDROERGOTOXINF, METHYSERGIDE, D LSD, CF-25-397, AND CF-29-712: EFFECTS ON THE METABOLISM OF BIOGENIC AMINES IN THE BRAIN OF THE RAT.

002849 04-0:

002849 04-03

CEREBELLAR CGMP SYSTEM: A MODEL TO STUDY DRUG RECEPTOR INTERACTION. (UNPUBLISHED PAPER). 001139 02-03

CGP-6085-A

SELECTIVE INHIBITION OF NORADRENALINE AND SEROTONIN UPTAKE BY C-49802-B-BA AND CGP-6085-A.

001960 03-0 001960 03-02

THE EFFECTS OF CANNABIS-SATIVA ON THE BEHAVIOR OF ADULT FEMALE CHACMA BABOONS (PAPIO-URSINUS) IN CAPTIVITY. 000402 01-04

CHAMBER
MEASUREMENTS OF WEIGHT AND ACTIVITY IN MALE MICE FOLLOWING INHALATION OF CANNABIS SMOKE IN A CONTROLLED SMOKE EXPOSURE CHAMBER.

001524 02-4

CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE FOR AN INTERACTIONIST POSITION.

MOOD CHANGE AND MAGNESIUM: A POSSIBLE INTERACTION BETWEEN MAGNESIUM AND LITHIUM?

HOW SCHIZOPHRENIC PATIENTS CHANGE DURING 3 YEARS TREATMENT WITH DEPOT NEUROLEPTICS.

WEIGHT LOSS AND A CONCOMITANT CHANGE IN PLASMA TRICYCLIC LEVELS.

002441 03-09

FLA-136: SELECTIVE AGONIST AT CENTRAL ALPHA-ADRENORECEPTORS MEDIATING CHANGES IN THE TURNOVER OF NORADRENALINE. 000043 01-03

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES:
MESCALINE-DEMETHYLASE ACTIVITY OF BRAIN-CORTEX SOLUBLE
SUPERNATANT.

000090 01-03 ELECTROCORTICAL CHANGES INDUCED BY THE PERFUSION OF NORADRENALINE, ACETYLCHOLINE AND THEIR ANTAGONISTS DIRECTLY INTO THE DORSAL RAPHE NUCLEUS OF THE CAT.

DRUG-INDUCED CHANGES IN BRAIN TYROSINE-HYDROXYLASE ACTIVITY

CHANGES IN HIPPOCAMPAL EVOKED RESPONSES TO AFFERENT STAULATION DURING CONDITIONING.

000260 01-03 BARBITURATE-INDUCED CHANGES IN TRANSMITTER RELEASE
INC. SPENDENT OF TERMINAL SPIKE CONFIGURATION IN THE FROG
NE. ROMUSCULAR JUNCTION.

000294 01-03 TIME-DEPENDENT CHANGES IN ACTIVITY, REACTIVITY, AND RESPONSIVITY DURING SHOCK: EFFECTS OF CHOLINERGIC AND CATECHOLAMINERGIC MANIPULATIONS.

BARBITAL-INDUCED CHANGES IN SENSITIVITY TO THE BEHAVIORAL EFFECTS OF NARCOTICS.

ROLE OF TRYPTAMINE IN THE BEHAVIOURAL CHANGES CAUSED BY A MONOAMINE-OXIDASE INHIBITOR AND L TRYPTOPHAN.

LONG-TERM BEHAVIORAL CHANGES IN THE RHESUS MONKEY AFTER MULTIPLE DAILY INJECTIONS OF D METHYLAMPHETAMINE.

DRUG-INDUCED CHANGES IN THE MATERNAL BEHAVIOR OF RATS.

O00366 01-04
CHANGES IN THE RATE INCREASING EFFECTS OF D AMPHETAMINE AND
PENTOBARBITAL BY RESPONSE CONSEQUENCES.

OCC452 01-04
OLFACTORY BULB ABLATION IN THE RAT: BEHAVIOURAL CHANGES AND
THEIR REVERSAL BY ANTIDEPRESSANT DRUGS.

000466 01-04
RHEOENCEPHALOGRAPHIC DATA IN MIGRAINE CEPHALGIA AND THEIR
CHANGES DURING STUGERON TREATMENT. 000515 01-07

THE FUNCTION OF DRUG RITUALS IN HUMAN SOCIETY: CONTINUITIES AND CHANGES. 000674 01-12

Psychopharmacology Abstracts

WITHDRAWAL FROM CANNABIS: PSYCHOPHYSIOLOGICAL CHANGES. 000688 01-13 EFFECT OF DIPROPYLACETATE (CONVULEX) ON PERSONALITY CHANGES IN EPILEPTICS: PRELIMINARY REPORT.

000757 01-14 BETA-ENDORPHIN-INDUCED CHANGES IN SCHIZOPHRENIC AND DEPRESSED PATIENTS.

EEG PROFILE AND BEHAVIORAL CHANGES AFTER A SINGLE DOSE OF CLOZAPINE IN NORMALS AND SCHIZOPHRENICS.

SLEEP AND BEHAVIORAL CHANGES POSSIBLY REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAIN.

EFFECTS OF PHENOBARBITAL AND DIAZEPAM ON IMIPRAMINE-INDUCED CHANGES IN BLOOD PRESSURE, HEART RATE AND RECTAL TEMPERATURE OF RATS.

001070 02-03 CHANGES IN LIVER FUNCTION IN ACUTE POISONING BY BARBITURATE, RESERVINE AND AMPHETAMINE.

LONG-TERM CHANGES IN THE SENSITIVITY OF PRE- AND POSTSYNAPTIC DOPAMINE RECEPTORS IN MOUSE STRIATUM EVIDENCED BY BEHAVIORAL AND BIOCHEMICAL STUDIES.

ANTAGONISM OF PENTOBARBITAL-INDUCED HORMONAL CHANGES BY TRH IN RATS.

001255 02-03 INFLUENCE OF NEUROTROPIC DRUGS ON CHANGES OF EVOKED-POTENTIALS AMPLITUDES AFTER STIMULATION OF THE HYPOTHALAMUS.

DYNAMICS OF BLOOD NEUROTRANSMITTER LEVEL AS EVIDENCE OF HIGHER NERVOUS ACTIVITY CHANGES DURING CHRONIC ADMINISTRATION OF SEDUXEN.

001338 02-04

EFFECTS OF THYROTROPIN-RELEASING HORMONE ON BEHAVIORAL AND HORMONAL CHANGES INDUCED BY BETA-ENDORPHIN. 001471 02-04

FLICKER VALUES AND CHANGES IN STATES OF DEPRESSION REGIONAL CHANGES OF CEREBRAL BLOOD FLOW DURING HALOPERIDOL THERAPY IN PATIENTS WITH PARANOID SYMPTOMS.

DRUG-PRODUCED CHANGES IN HUMAN SOCIAL BEHAVIOR: FACILITATION BY D AMPHETAMINE.

001715 02-14 COMPUTER OCULOGRAPHIC DOUBLE-BLIND STUDY OF CHANGES IN VIGILANCE: ALPRENOLOL VERSUS DIAZEPAM.

001746 02-15 DAILY CHANGES IN THE BLOOD SERUM LEVELS OF DIPHENYLHYDANTOIN (DPH) AND PHENOBARBITAL.

001830 02-15 CHLORPROMAZINE-INDUCED CHANGES IN BLOOD
ADENOSINEPHOSPHORIC-ACIDS: TO THEIR DIAGNOSTIC SIGNIFICANCE
IN PSYCHIATRY.

001861 02-16 MEASURING CHANGES IN CEREBRAL GLUTAMATE AND GABA METABOLISM PRIOR TO CONVULSIONS INDUCED BY 3 MERCAPTOPROPIONATE.

001961 03-03 OMPARATIVE EFFECTS OF DIHYDROERGOTOXINE (DHET) ON CBF AND METABOLISM CHANGES PRODUCED BY EXPERIMENTAL CEREBRAL EDEMA, HYPOXIA AND HYPERTENSION.

ELECTROENCEPHALOGRAM AND SOMATOSENSORY EVOKED-POTENTIAL CHANGES AFTER ADMINISTRATION OF SIX CONVULSANT DRUGS.

CHANGES IN MOUSE BRAIN CATECHOLAMINE CONTENT AND TYROSINE HYDROXYLASE ACTIVITY DURING CHRONIC AMPHETAMINE ADMINISTRATION.

SLEEP CHANGES INDUCED BY CHRONIC ADMINISTRATION OF S-1694 (SURVECTOR).

002194 03-04 CHANGES IN THE RAT ELECTROCORTICOGRAM FOLLOWING
ADMINISTRATION OF TWO DIHYDROGENATED ERGOT DERIVATIVES 002207 03-04

CHANGES IN PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECTS OF PREMEDICATION WITH CYSTAMINE ON DYNAMICS AND KINETICS OF THIORIDAZINE.

002332 03-04 RELIABILITY OF TWO ACTIVITY BOXES COMMONLY USED TO ASSESS DRUG-INDUCED BEHAVIOURAL CHANGES.

002368 03-06 CLINICAL AND BIOCHEMICAL CHANGES IN PSYCHOTIC WOMEN TREATED WITH MELPERONE OR THIOTHIXENE.

A

n

LITHIUM-CARBONATE AND BRAIN FUNCTION: I. CEREBRAL EVOKED-POTENTIALS, EEG, AND SYMPTOM CHANGES DURING LITHIUM-CARBONATE TREATMENT.

002560 03-13

TIME-COURSE OF CHANGES IN EEG AND POWER SPECTRA DURING TREATMENT WITH NEUROLEPTICS.

002570 03-13 ASSESSMENT OF SPONTANEOUS AND DRUG-INDUCED CHANGES IN VIGILANCE BY MEANS OF A NEW MODIFICATION OF THE SHORT TIME SPECTRAL ANALYSIS OF THE EEG.

002627 03-14 RESPONSES OF THE PITUITARY ADRENAL SYSTEM OF THE PIG TO ENVIRONMENTAL CHANGES AND DRUGS

002833 04-03 EFFECT OF NALOXONE ON MORPHINE-INDUCED CHANGES IN ACTH. CORTICOSTERONE AND CYCLIC-NUCLEOTIDES

002949 04-03 CHANGES IN SYNAPTIC FUNCTION INDUCED BY BLOCKAGE OF AXONAL TRANSPORT IN THE RABBIT OPTIC PATHWAY.

REGIONAL CHANGES IN CEREBRAL GABA CONCENTRATION AND CONVULSIONS PRODUCED BY D AND BY L ALLYLGLYCINE

002954 04-03 CLONIDINE-INDUCED BODY TEMPERATURE CHANGES IN RATS WITH ANTERIOR OR POSTERIOR CORTICAL DAMAGE.

002959 04-03 CHANGES OF TAURINE CONTENT IN THE BRAIN TISSUE OF BARBITURATE DEPENDENT RATS.

002961 04-03 CHANGES IN BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS FOLLOWING ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION AND DURING POST AMPHETAMINE DEPRESSION.

002992 04-03 CHANGES IN BRAIN TRYPTOPHAN AND TYROSINE FOLLOWING ACUTE AND CHRONIC MORPHINE ADMINISTRATION.

003012 04-03 DELTA9-TETRAHYDROCANNABINOL-INDUCED CHANGES IN BRAIN RIBOSOMES

003047 04-03 REGIONAL CHANGES IN THE CONCENTRATIONS OF CEREBRAL MONOAMINES AND THEIR METABOLITES AFTER ETHANOLAMINE-O-

SULPHATE-INDUCED ELEVATION OF BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS 003053 04-03

CHANGES IN BRAIN FREE FATTY-ACIDS AFTER PAINFUL PERIPHERAL STIMULATION (EFFECT OF PROTHIADEN). 003094 04-03

CHANGES OF SENSITIVITY TO THE CUING PROPERTIES OF NARCOTIC DRUGS AS EVIDENCED BY GENERALIZATION AND CROSS-GENERALIZATION EXPERIMENTS. 003194 04-04

CHANGES IN MORPHINE SELF-ADMINISTRATION AFTER TEL-DIENCEPHALIC LESIONS IN RATS.

003228 04-04 INFLUENCE OF CATECHOLAMINES ON DEXAMPHETAMINE-INDUCED CHANGES IN LOCOMOTOR ACTIVITY.

003239 04-04 BEHAVIORAL CHANGES AND MERCURY CONCENTRATIONS IN TISSUES OF RATS EXPOSED TO MERCURY VAPOR.

003258 04-04 PSYCHOTROPIC DRUGS AND SIDMAN AVOIDANCE IN RATS: IRT

DISTRIBUTION CHANGES 003269 04-04 TOLERANCE TO MORPHINE ANALGESIA AND IMMOBILITY MEASURED IN

RATS BY CHANGES IN LOG-DOSE-RESPONSE CURVES 003307 04-04 PARALLEL CHANGES IN BEHAVIOR AND HIPPOCAMPAL MONOAMINE METABOLISM IN RATS AFTER ADMINISTRATION OF ACTH ANALOGUES

003335 04-04 CHANGES IN THE BEHAVIORAL RESPONSE TO A NOVEL ENVIRONMENT FOLLOWING LESIONING OF THE CENTRAL DOPAMINERGIC SYSTEM IN RAT PUPS

003368 04-04 CHANGES IN LOCOMOTOR ACTIVITY AND NALOXONE-INDUCED JUMPING IN MICE PRODUCED BY WIN-35197-2 (ETHYLKETAZOCINE) AND

003376 04-04 BEHAVIORAL CHANGES INDUCED BY 2,5 DIMETHOXY-

METHYLAMPHETAMINE (DOM, STP) IN PRIMATE DYADS 003380 04-04 ALOSTERIC CHANGES IN PLASMA PROTEINS IN HEALTHY VOLUNTEERS AFTER ADMINISTRATION OF LYSERGAMIDE

003584 04-12

TARDIVE-DYSKINESIA AND CHANGING CONCEPTS OF ANTIPSYCHOTIC DRUG USE: A NURSING PROSPECTIVE. 000919 01-16 CHANNELS

PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF NA CHANNELS IN THE RELEASE OF CATECHOLAMINES FROM PERFUSED ADRENAL

000256 01-03

CHARACTER

DIRECTIONAL LIPOPHILIC CHARACTER IN A SERIES OF PSYCHOTOMIMETIC PHENETHYLAMINE DERIVATIVES. 001009 02-01

CHARACTERISATION

NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN SLICES OF MOUSE LIMBIC FOREBRAIN: CHARACTERISATION AND EFFECT OF DOPAMINERGIC AGONISTS

CHARACTERISTICS

CHARACTERISTICS OF BETA-PHENETHYLAMINE SELF-ADMINISTRATION BY

BEHAVIORAL AND PSYCHOPHARMACOLOGICAL CHARACTERISTICS OF RATS RAISED IN HIGH POPULATION DENSITY.

001472 02-04 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. II. TOI FRANCE CHARACTERISTICS

001972 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 1. KINETICS AND CHARACTERISTICS OF IN VITRO BINDING.

002079 03-03 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL.

III. WITHDRAWAL CHARACTERISTICS. 002199 03-04

CHARACTERISTICS OF TILIDEN-HCL (VALORON) INTOXICATION 002377 03-07 CLINICAL AND PLASMA LEVEL CHARACTERISTICS OF INTRAMUSCULAR AND ORAL LOXAPINE.

002407 03-08 CHARACTERISTICS OF LI-TRANSPORT IN HUMAN RED CELLS

002591 03-13 WORD ASSOCIATION TIMES, FELT EFFECTS, AND PERSONALITY CHARACTERISTICS OF SCIENCE STUDENTS GIVEN A PLACEBO

002611 03-14 THE ROLE OF SUBSTRATE LIPOPHILICITY IN DETERMINING TYPE MICROSOMAL P450 BINDING CHARACTERISTICS.

SOME PHYSIOLOGIC CHARACTERISTICS OF THE ELECTRODERMAL REFLEX

IN THE CAT. CHARACTERISTICS OF MONOAMINE-OXIDASES IN BRAIN AND OTHER

ORGANS OF THE GOLDEN HAMSTER.

NARCOTIC CUING AND ANALGESIC ACTIVITY OF NARCOTIC ANALGESICS: ASSOCIATIVE AND DISSOCIATIVE CHARACTERISTICS. 003192 04-04

CHARACTERIZATION ISOLATION AND CHARACTERIZATION OF () CANNABITRIOL AND (-) 10 ETHOXY-9-HYDROXY-DELTAGA-TETRAHYDROCANNABINOL: TWO NEW CANNABINOIDS FROM CANNABIS-SATIVA L. EXTRACT. 000004 01-01

PHARMACOLOGICAL CHARACTERIZATION OF TARDIVE-DYSKINESIA 001754 02-15

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. I. TOLERANCE TO PHENCYCLIDINE DERIVATIVES IN MICE: PHARMACOLOGICAL CHARACTERIZATION.

002127 03-03 CHARACTERIZATION OF ENKEPHALIN-LIKE MATERIAL EXTRACTED FROM SYMPATHETIC GANGLIA.

002788 04-01 NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. I. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE IN EXPONENTIAL GROWTH PHASE

002836 04-03 CHARACTERIZATION OF SPECIFIC IN VIVO BINDING OF NEUROLEPTIC DRUGS IN RAT BRAIN.

002985 04-03 PHARMACOLOGICAL CHARACTERIZATION OF THE EXCITATORY CHOLINERGIC RECEPTORS OF RAT CENTRAL NEUPONES.

003006 04-03
NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED
INCREASES IN CYCLIC-AMP. II. CHARACTERIZATION OF A CULTURED
NEURONAL CELL LINE TREATED WITH DIBUTYRYL-CYCLIC-AMP. 003026 04-03

CHARACTERIZATION OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS IN MEMBRANES PREPARED FROM THE RABBIT IRIS BEFORE AND AFTER DEVELOPMENT OF SUPERSENSITIVITY.

003035 04-03 CHARACTERIZATION OF DISCRIMINATIVE STIMULUS PROPERTIES OF PSYCHOMOTOR STIMULANTS.

C

Psychopharmacology Abstracts

~	poleci index	
ж	IARCOAL	
	LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUS	SION IN
	LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUS	
	IMIPRAMINE POISONING. AN IN-VITRO AND IN-VIV	0 STUDY. 001503 02-05
	EFFECT OF ACTIVATED CHARCOAL ON ABSORPTION OF	
	THE ROLE OF CHARCOAL HEMOPERFUSION IN THE ACTI OF POISONING.	IVE MANAGEMENT
	CHARCOAL HEMOPERFUSION AND ANTIDEPRESSANT O	001842 02-15
	CHARCOAL HEMOFERFOSION AND ANTIDEFRESSANT O	002774 03-17
CH.	THE SUBCELLULAR DISTRIBUTION OF PARTICLE-BOUND CHARGES IN RAT BRAIN.	NEGATIVE
		000492 01-06
H	THE USE OF A CHECKLIST IN OBTAINING INFORMED-CO	INSENT FOR
		002778 03-17
H	DEPRENYL ADMINISTRATION IN MAN: A SELECTIVE M	ONOAMINE-

DEPRENYL ADMINISTRATION IN MAN: A SELECTIVE MOI OXIDASE B INHIBITOR WITHOUT THE CHEESE EFFECT.	NOAMINE-
	003652 04-15
6-OHDA AND ITS ANALOGUES: CHEMICAL MECHANISM	OF

EMICAL
6-OHDA AND ITS ANALOGUES: CHEMICAL MECHANISM OF NEUROTOXICITY, STUDY OF THE OXIDATION OF ORTHO-SUBSTITUTED
DOPAMINES.
THE ROTANICAL AND CHEMICAL DISTRIBUTION OF HALLICINGGENS

THE BOTANICAL AND CHEMICAL DISTRIBUTION OF HALLUC	
THE CHEMICAL CONSTITUENTS OF GINSENG PLANTS	000680 01-12

THE CHEMICAL CONSTITUTION OF SHOULD FEATING	
	001003 02-01
NONPARTICIPATION OF CHOLINERGIC MECHANISM	IN CHEMICAL
CONTROL OF CEREBRAL MACCAMOTOR ACTIVITY	

001243	02-03
NUTRITION AND CHEMICAL BIOTRANSFORMATIONS IN MAN.	
001651	02-13
QUANTITATIVE ANALYSIS OF METHADONE IN BIOLOGICAL FLUIDS U	

QUANTITATIVE ANALYSIS OF METHADONE	IN BIOLOGICAL	FLUIDS USING
DEUTERIUM-LABELED METHADONE AND	GLC CHEMICAL	IONIZATION
MASS SPECTROMETRY.		
		001862 02-16

		001862 02-16
QUANTUM CHEMICAL	STUDIES OF N SUBSTITUENT	VARIATION IN THE
OXYMORPHONE SE	RIES OF OPIATE NARCOTICS.	
	mile or or mile immediates.	001044 02 01

MALTAIS AND CHE	MICAL CUNIK	JL UF NEGAT	IVE APPECT.		
				00047	00 04
			U	02367	03-00
HLORPROMAZINE	EXCRETION II	IMPROVED 1	TIC PROCEDIII	DES FOR	3
EDACTIONATING	THE HIDINARY I	ADUC CONTE	MT INTO CUEL	ALCAL	

SUBGROUPS OF CPZ METABOLITES.	NOT THE OWNER.	
	003690 04-16	
IEMICALLY		

	ACTIVATION OF P-CH METABOLITE.	LOROAMPHETAMINE	TO A CHEMICALLY
			000476 01-0
ROTOMETER	FOR RECORDING ROT	TATION IN CHEMICALL	Y OR

ELECTRICALLY STIMULATED RATS.	
	002373 03-06
	002575 05-01

TEMILUMINESCENCE
CHEMILUMINESCENCE RESULTING FROM AN INTERACTION BETWEEN
IMIPRAMINE AND HUMAN POLYMORPHONUCLEAR LEUKOCYTES.
001263 02-0

HEMISTRY							00126	3 02-
FROM JOY	TO	DEPRESSION:	NEW	INSIGHTS	INTO	THE	CHEMISTRY	OF
MOODS								

						000001 01 17
						000981 01-17
THE CHEMISTRY	OF	DOPAMINE	RECEPTOR	s in	THE	MEDIAN EMINENCE.
						001085 02-03

CHEMOTHERAPY IN PSYCHIATRY.	
CHEMOTIEM THE CHEMICA	001880 02-1

BETA-BLOCKING SUBSTANCES IN PSYCHIATRIC CHEMOTHERAPY.
002462 03-09
ON THE TREATMENT OF NEURODERMATITIS WITH A MONOAMINE-
OXIDASE INHIBITOR: THE CHEMOTHERAPY OF PSYCHOSOMATIC
MINESS THROUGH A DEM SUPPRESSION

CHEMOTHERAPY IN MENTAL DISORDERS IN CHILDHOO	002480 03-10 D AND
--	-----------------------

	000705 00 17
***************************************	002735 03-17
CHEMOTHERAPY-INDUCED	
LITHRIBA CARRONATE ATTENNATION OF CUESAOTHER	A BOLL INIBILIZED

CHEMOTHERAPY-INDUCED	LITHIUM-CARBONATE NEUTROPENIA
	NEUTKOFENIA.

		000898 01-15
LITHIUM-CARBONATE II	N CHEMOTHERAPY-INDUCED	NEUTROPENIA.
The second second		001809 02-15

ARE YOU GOING TO LEARN TO CHEW COCA LIKE US?. 000683 01-12 RETROGRADE AXONAL TRANSPORT OF NERVE GROWTH FACTOR IN THE CILIARY GANGLION OF THE CHICK AND THE RAT. 003005 04-03

IN VITRO EFFECTS OF CHLORPROMAZINE ON MICROTUBULES AND THE GOLGI COMPLEX IN EMBRYONIC CHICK SPINAL GANGLION CELLS: AN ELECTRON MICROSCOPIC STUDY.

AMPHETAMINE AND CHICK BEHAVIOUR: A ROLE FOR MONOAMINES IN THE CAUSATION OF VOCALIZATIONS AND EMOTIONS.

ENTRY OF BETA-N-OXALYL-L-ALPHA-BETA-DIAMINOPROPIONIC-ACID, THE LATHYRUS-SATIVUS NEUROTOXIN INTO THE CENTRAL-NERVOUS-SYSTEM OF THE ADULT RAT, CHICK AND THE RHESUS MONKEY. 003061 04-03

CHICKENS
THE EFFECT OF EPINEPHRINE ON TONIC IMMOBILITY (ANIMAL HYPNOSIS) IN CHICKENS.

000460 01-04 CHLORPROMAZINE ENHANCES MEMORY IN CHICKS.

001341 02-04 RETROACTIVE AMNESIA INDUCED IN CHICKS BY THE PROLINE ANALOG L BAIKIAIN, WITHOUT EEG SEIZURES OR DEPRESSION.

003205 04-04 LITHIUM IN CHILD AND ADOLESCENT PSYCHIATRY. (UNPUBLISHED

000657 01-11 COMPARING TREATMENT TACTICS WITH A HYPERACTIVE PRESCHOOL CHILD: STIMULANT MEDICATION AND PROGRAMMED TEACHER INTERVENTION.

000660 01-11 THE RELATIVE EFFICACY OF METHYLPHENIDATE (RITALIN) AND BEHAVIOR MODIFICATION TECHNIQUES IN THE TREATMENT OF A HYPERACTIVE CHILD

000671 01-11 IMPROVEMENT WITH L-DOPA IN A HYPERKINETIC CHILD. 000769 01-14

WITHDRAWAL OF A STIMULANT DRUG AND CONCURRENT BEHAVIORAL INTERVENTION IN THE TREATMENT OF A HYPERACTIVE CHILD. 000780 01-14

LITHIUM IN THE TREATMENT OF A CHILD ABUSER 001598 02-09 CLINICAL USE OF HALOPERIDOL (SERENACE) IN CHILD PSYCHIATRY

001725 02-14 PSYCHOTROPIC DRUGS IN CHILD AND ADOLESCENT PSYCHIATR' 001939 02-17

EPILEPSY IN CHILD PSYCHIATRY. EFFECTS OF TREATMENT BY DIPROPYLACETIC-ACID.

002517 03-11

THE THERAPY OF CHILDHOOD SCHIZOPHRENIA. 000525 01-08 PEDIATRIC PSYCHOPHARMACOLOGY AND CHILDHOOD DEPRESSION.

000611 01-10 DEPRESSION IN CHILDHOOD: DIAGNOSIS, TREATMENT, AND CONCEPTUAL MODELS.

PSYCHOTROPIC AND ANTICONVULSANT DRUG USAGE IN EARLY CHILDHOOD SPECIAL EDUCATION PROGRAMS III. A PRELIMINARY REPORT: PARENT INTERVIEWS ABOUT DRUG TREATMENT

000627 01-11 MANIA IN CHILDHOOD. II. THERAPEUTIC TRIAL OF LITHIUM-CARBONATE AND FURTHER DESCRIPTION OF MANIC-DEPRESSIVE ILLNESS IN

001578 02-09 CHEMOTHERAPY IN MENTAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.

002735 03-17 CHILDREN REPORT OF SUBCOMMITTEE ON THE TREATMENT OF DEPRESSION IN

CHILDREN 000610 01-10

CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE FOR AN INTERACTIONIST POSITION. 000620 01-11

METHYLPHENIDATE THERAPY FOR INATTENTIVENESS IN SELECTED SCHOOL CHILDREN.

000623 01-11 REPORT FROM CLINICAL PRACTICE: THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG TREATMENT OF HYPERACTIVE CHILDREN. (UNPUBLISHED PAPER). 000656 01-11

THE USE OF PSYCHOTROPIC DRUGS IN CHILDREN. 000665 01-11

THE USE OF PSYCHEDELIC DRUGS IN THE TREATMENT OF SEVERELY DISTURBED CHILDREN: A REVIEW. 000678 01-12 PHARMACOPSYCHOLOGICAL INVESTIGATION OF THE EFFECT OF SEDATIVES ON MEMORY AND LEARNING PERFORMANCE IN CHILDREN AND ADOLESCENTS 000751 01-14 EFFECT OF PIRACETAM ON BRAIN-DAMAGED, LEARNING-DISABLED CHILDREN. 000785 01-14 A REVIEW OF STIMULANT DRUG RESEARCH WITH HYPERACTIVE CHILDREN THE EFFECTS OF AN ANTIPSYCHOTIC MEDICATION ON THE CLASSROOM BEHAVIOR OF FOUR SCHIZOPHRENIC MALE CHILDREN. 001568 02-08
MANIA IN CHILDHOOD. II. THERAPEUTIC TRIAL OF LITHIUM-CARBONATE AND FURTHER DESCRIPTION OF MANIC-DEPRESSIVE ILLNESS IN THE PREDICTION OF DIFFERENTIAL RESPONSIVENESS OF HYPERKINETIC CHILDREN TO METHYLPHENIDATE. (PH.D. DISSERTATION). THE EFFECTS OF METHYLPHENIDATE ON VARIOUS TYPES OF ACTIVITY LEVEL AND ATTENTION IN HYPERKINETIC CHILDREN A DEVELOPMENTAL STUDY OF SELECTIVE ATTENTION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION) 001709 02-14 CAFFEINE AND INATTENTIVENESS IN READING-DISABLED CHILDREN. 001721 02-14 METHYLPHENIDATE IN HYPERKINETIC CHILDREN: DIFFERENCES IN DOSE EFFECTS ON LEARNING AND SOCIAL BEHAVIOR 001732 02-14 PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS THERAPEUTIC APPLICATION 001737 02-14 TOWARD AN EGO-ORIENTED APPROACH TO THE STUDY OF THE EFFECTS OF PSYCHOACTIVE MEDICATION IN THE TREATMENT OF CHILDREN PSYCHOPHARMACOTHERAPY IN CHILDREN. 001934 02-17 LITHIUM-CARBONATE USE IN CHILDREN AND ADOLESCENTS: A SURVEY OF THE LITERATURE. 002471 03-09 AZAPHEN IN THE TREATMENT OF ENURESIS IN CHILDREN. 002513 03-11 ELECTROPHYSIOLOGICAL STUDIES AND AMPHETAMINE METABOLISM IN HYPERACTIVE CHILDREN. EFFECT OF THIORIDAZINE (MELLARIL-SANDOZ) ON PSYCHOMOTOR FUNCTION, CONCENTRATION, AND REACTIVITY IN CHILDREN WITH BEHAVIOR DISORDERS. 002527 03-11 PSYCHOPHARMACOTHERAPY IN CHILDREN 002533 03-11 TIME-RESPONSE ANALYSIS OF THE EFFECT OF STIMULANT MEDICATION ON THE LEARNING ABILITY OF CHILDREN REFERRED FOR HYPERACTIVITY 002534 03-11 NEUROCHEMISTRY OF WITHDRAWAL EMERGENT SYMPTOMS IN CHILDREN 002602 03-13 EFFECTS OF LORAZEPAM ON HYPERACTIVITY IN RETARDED CHILDREN 002643 03-14 EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE ON BEHAVIOR OF HYPERACTIVE CHILDREN. 002645 03-14 EKG EFFECTS OF IMIPRAMINE TREATMENT IN CHILDREN. 002696 03-15 INVESTIGATIONS OF CHILDREN OF MOTHERS TREATED IN PREGNANCY WITH ANTICONVULSANTS. 002701 03-15 PEDIATRIC PSYCHOPHARMACOLOGY: THE USE OF BEHAVIOR MODIFYING DRUGS IN CHILDREN. 002784 03-17 GROWTH OF HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE.
003562 04-11 BEHAVIOR THERAPY AND WITHDRAWAL OF STIMULANT MEDICATION IN HYPERACTIVE CHILDREN. 003566 04-11 GROWTH HORMONE, PROLACTIN AND CORTISOL RESPONSES AND GROWTH PATTERNS IN HYPERKINETIC CHILDREN TREATED WITH DEXTROAMPHETAMINE. PRELIMINARY FINDINGS.

EFFECTS OF L 5 HYDROXYTRYPTOPHAN IN AUTISTIC CHILDREN.

THE BEHAVIORAL SYMPTOMS OF HYPERKINFTIC CHILDREN WHO SUCCESSFULLY RESPONDED TO STIMULANT DRUG TREATMENT

A CONTROLLED STUDY OF LISURID IN HYPERACTIVE CHILDREN

NOW YOU DON'T CHILDREN. DRUG TREATMENT. CHLORALOSE CHLORAZEPATE CHLORAZEPATE. CHLORDIAZEPOXIDE RATS TERMINATION

BEHAVIOR OBSERVATIONS OF HYPERACTIVE CHILDREN AND METHYLPHENIDATE (RITALIN) EFFECTS IN SYSTEMATICALLY STRUCTURED CLASSROOM ENVIRONMENTS: NOW YOU SEE THEM, 003581 04-11 THE EFFECTS OF CAFFEINE AND METHYLPHENIDATE ON HYPERACTIVE DEXTROAMPHETAMINE AND PLACEBO PRACTICE EFFECTS ON SELECTIVE ATTENTION IN HYPERACTIVE CHILDREN. 003627 04-14 EFFECTS OF METHYLPHENIDATE ALONE AND IN COMBINATION WITH BEHAVIOR MODIFICATION PROCEDURES ON THE BEHAVIOR AND ACADEMIC PERFORMANCE OF HYPERACTIVE CHILDREN. 003640 04-14 THE MEDICATION CLINIC IN THE SPECTRUM OF CHILDRENS SERVICES. 000955 01-17 HYPERACTIVE AND NONHYPERACTIVE CHILDRENS SELF-DETERMINED LEVELS OF STIMULATION, (PH.D. DISSERTATION). 001717 02-14 HYPERACTIVE CHILDRENS UNDERUSE OF LEARNING TIME: CORRECTION BY STIMULANT TREATMENT 002614 03-14 HYPERACTIVE CHILDRENS KNOWLEDGE AND ATTITUDES CONCERNING 003553 04-11 3,4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3 AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND ANTICONVULSANT ACTIVITIES. 000035 01-02 SUPPRESSION BY NITROUS-OXIDE OF VISUAL RESPONSES IN THE CEREBELLAR VERMIS AND SUPERIOR COLLICULUS OF CATS ANESTHETIZED WITH CHLORALOSE. 002897 04-03 PHARMACOKINETICS OF N DESMETHYLDIAZEPAM IN HEALTHY VOLUNTEERS AFTER SINGLE DAILY DOSES OF DIPOTASSIUM 000728 01-13 ON THE HYPNOGENIC AND ANTICONVULSANT ACTIVITIES OF DEMETHYLDIAZEPAM AND CHLORDEMETHYLDIAZEPAM: TIME EFFECT 000462 01-04 CHLORDESMETHYLDIAZEPAM
SINGLE-BLIND EVALUATION OF HYPNOTIC ACTIVITY OF
CHLORDESMETHYLDIAZEPAM IN NO-PLACEBO REACTOR MEDICAL 002379 03-07 EFFECT OF CHLORDIAZEPOXIDE ADMINISTERED EARLY IN EXTINCTION ON SUBSEQUENT EXTINCTION OF A CONDITIONED EMOTIONAL RESPONSE IN RATS: IMPLICATIONS FOR HUMAN CLINICAL USE. EFFECTS OF AMPHETAMINE AND CHLORDIAZEPOXIDE ON PROBENECID-INDUCED ACCUMULATION OF ACIDIC METABOLITES IN THE CEREBROSPINAL FLUID OF THE DOG. 000092 01-03 EFFECTS OF CHLORDIAZEPOXIDE ON TAIL PINCH-INDUCED EATING IN 000442 01-04 DOXEPIN IN THE TREATMENT OF NEUROSES: A COMPARATIVE CLINICAL STUDY OF DOXEPIN, CHLORDIAZEPOXIDE, HYDROXYZINE, MEPROBAMATE, AND PHENOBARBITAL. RATE OF ABSORPTION AND CLINICAL RESPONSE TO SINGLE ORAL DOSES OF CHI ORDIAZEPOXIDE PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS CHLORDIAZEPOXIDE SELECTIVELY AUGMENTS GABA ACTION IN SPINAL CORD CELL CULTURES. EFFECTS OF D AMPHETAMINE, CHLORDIAZEPOXIDE AND PROMAZINE ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION AND STIMULUS SHOCK 001305 02-04 INCENTIVE CONTRAST UNDIMINISHED BY EXTENDED TESTING IMPRAMINE, OR CHLORDIAZEPOXIDE. EFFECTS OF CHLORDIAZEPOXIDE ON PUNISHED AND UNPUNISHED
RESPONDING BEFORE AND DURING CHLORDIAZEPOXIDE DRINKING 001417 02-04

003569 04-11

003578 04-11

003579 04-11

INTERACTIONS OF DELTA9-TETRAHYDROCANNABINOL WITH PHENOBARBITAL, ETHANOL AND CHLORDIAZEPOXIDE.

001436 02-04 EFFECT OF CHLORDIAZEPOXIDE ON THE PARTIAL REINFORCEMENT EXTINCTION EFFECT.

001491 02-04 FACTORS INFLUENCING BLOOD CONCENTRATIONS OF CHLORDIAZEPOXIDE: A USE OF MULTIPLE REGRESSION ANALYSIS.

KINETICS OF INTRAVENOUS CHLORDIAZEPOXIDE: SEX DIFFERENCES IN DRUG DISTRIBUTION.

001665 02-13 YOUNG AND ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN ELDERLY MALE VOLUNTEERS.

001689 02-13 EFFECTS OF CHLORDIAZEPOXIDE AND OXAZEPAM ADMINISTRATION ON VERBAL HOSTILITY

001720 02-14

CONTROLLED COMPARISON OF TRIFLUOPERAZINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY.

EFFECTS OF CHLORDIAZEPOXIDE, OXAZEPAM, CHLORPROMAZINE, AND D AMPHETAMINE ON SEXUAL RESPONSES IN MALE AND FEMALE HAMSTERS.

002208 03-04 SOME EFFECTS OF CHLORDIAZEPOXIDE AND D AMPHETAMINE ON RESPONSE FORCE DURING PUNISHED RESPONDING IN RATS.

002234 03-04 ETHANOL, PENTOBARBITAL, AND CHLORDIAZEPOXIDE EFFECTS IN SQUIRREL-MONKEYS RESPONDING UNDER FIXED-RATIO FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION SCHEDULES. 002254 03-04

EFFECTS OF D AMPHETAMINE AND CHLORDIAZEPOXIDE ON POSITIVE CONDITIONED SUPPRESSION.

002295 03-04 CONFLICT BEHAVIOR IN THE SQUIRREL-MONKEY: EFFECTS OF CHLORDIAZEPOXIDE, DIAZEPAM AND N DESMETHYLDIAZEPAM

002303 03-04 ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY BENZODIAZEPINES

002326 03-04 COGNITIVE AND PSYCHOPHYSIOLOGIC RESPONSE TO DOXEPIN AND CHLORDIAZEPOXIDE.

002457 03-09 RESIDUAL EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE TREATMENTS FOR ALCOHOL WITHDRAWAL.

002617 03-14 DISCRIMINATIVE PROPERTIES OF CHLORDIAZEPOXIDE: A NEW METHOD

OF ANALYSIS. 002905 04-03 INSTINCTIVE PREDATORY BEHAVIOR OF THE FERRET (PUTORIUS-PUTORIUS-FURO L.) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE (LIBRIUM).

003161 04-04 SIMILARITIES AND DIFFERENCES IN DISCRIMINATIVE STIMULUS EFFECTS OF CHLORDIAZEPOXIDE, PENTOBARBITAL, ETHANOL, AND OTHER

003163 04-04 ENHANCED CHOICE OF FAMILIAR FOOD IN A FOOD PREFERENCE TEST AFTER CHLORDIAZEPOXIDE ADMINISTRATION.

003199 04-04 CHLORDIAZEPOXIDE FLUOXETINE INTERACTIONS ON FOOD INTAKE IN

FREE-FEEDING RATS 003217 04-04 THE EFFECTS OF CHLORDIAZEPOXIDE ON A DELAYED PAIR COMPARISON TASK IN PIGEONS.

003348 04-04

FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON LOCOMOTOR ACTIVITY AND AVOIDANCE BEHAVIOUR OF RESERPINIZED MICE. 003351 04-04 EFFECTS OF CHLORDIAZEPOXIDE, AMITRIPTYLINE, IMIPRAMINE, AND THEIR COMBINATIONS ON AVOIDANCE BEHAVIOUR IN MICE.

003352 04-04

FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON THE PERFORMANCE OF MICE IN AN INHIBITORY AVOIDANCE TASK. 003353 04-04

A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-DUMMY TECHNIQUE.

003537 04-10 CHLORDIMEFORM
COMPARISON OF THE BEHAVIORAL EFFECTS OF P-CHLOROAMPHETAMINE,
CHLORDIMEFORM, QUIPAZINE, AND INTRAVENTRICULAR SEROTONIN

IN THE RAT. 003331 04-04 ORIMIPRAMINE

EFFECTS OF ORG-6582, CHLORIMIPRAMINE AND DESMETHYLIMIPRAMINE

ON THE DEPLETION OF BIOGENIC AMINES FROM THE RAT BRAIN IN

VIVO.

000159 01-03 INHIBITION OF BOTH MAO-A AND MAO-B REQUIRED FOR THE PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

000398 01-04 INTRAVENOUS COMBINED ADMINISTRATION OF CHLORIMIPRAMINE AND SULPIRIDE IN DEPRESSION.

EFFECTS OF MAZINDOL, FENFLURAMINE AND CHLORIMIPRAMINE ON THE 5 HYDROXYTRYPTAMINE UPTAKE AND STORAGE MECHANISMS IN RAT BRAIN: SIMILARITIES AND DIFFERENCES.

001983 03-03 IMPORTANCE OF DURATION OF DRUG ACTION IN THE ANTAGONISM OF P-CHLOROAMPHETAMINE DEPLETION OF BRAIN SEROTONIN — COMPARISON OF FLUOXETINE AND CHLORIMIPRAMINE.

002017 03-03 BLOCKADE OF P-METHOXYAMPHETAMINE-INDUCED SEROTONERGIC EFFECTS BY CHLORIMIPRAMINE.

002166 03-03 CHLORIMIPRAMINE INHIBITION OF MURICIDE: THE ROLE OF THE ASCENDING 5-HT PROJECTION.

003284 04-04

PLACE OF CHLORMETHIAZOLE IN TREATMENT OF ALCOHOLICS 001621 02-11

CHLORMETHIAZOLE (HEMINEURIN). 001750 02-15

EFFECTS OF CHLORMETHIAZOLE (HEMINEVRIN) ON DRUG DISCRIMINATION AND OPEN-FIELD BEHAVIOR IN GERBILS

TEMAZEPAM (EUHYPNOS) AND CHLORMETHIAZOLE: A COMPARATIVE STUDY IN GERIATRIC PATIENTS.

003634 04-14 CHLORO-2-AMINOTETEALIN
COMPARISON OF THE EFFECTS OF 6 CHLORO-2-AMINOTETRALIN AND OF
ORG-6582, A RELATED CHLOROAMPHETAMINE ANALOG, ON BRAIN
SEROTONIN METABOLISM IN RATS.

000114 01-03 CHLORO-2-PIPERAZINYLPYRAZINE
ANOREXIGENIC AND ANCILLARY ACTIONS OF MK-212 (6 CHLORO-2-PIPERAZINYLPYRAZINE; CPP).

002213 03-04

CHLORO-2-1-PIPERAZINYL-PYEAZINE
PHARMACOLOGICAL DIFFERENTIATION OF THE CENTRAL 5
HYDROXYTRYPTAMINE-LIKE ACTIONS OF MK-212 (6 CHLORO-2-1-PIPERAZINYL-PYRAZINE), P-METHOXYAMPHETAMINE AND FENFLURAMINE IN AN IN VIVO MODEL SYSTEM.

002868 04-03

CHLOROAMPHITAMINE
COMPARISON OF THE EFFECTS OF 6 CHLORO-2-AMINOTETRALIN AND OF
ORG-6582, A RELATED CHLOROAMPHETAMINE ANALOG, ON BRAIN
SEROTONIN METABOLISM IN RATS.

000114 01-0 000114 01-03

CHLOROPHENOXYACETIC-ACIDS
SUBSTANTIAL INCREASE IN THE LEVELS OF CHLOROPHENOXYACETIC-ACIDS IN THE CNS OF RATS AS A RESULT OF SEVERE INTOXICATION

CHLOROPHENYL-PIPERAZINE
BIPHASIC EFFECTS OF M CHLOROPHENYL-PIPERAZINE IN 3,4
DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN RAT BRAIN 000113 01-03

CHLOROQUINE
BEHAVIORAL TOXICITY AND EQUIVOCAL SUICIDE ASSOCIATED WITH
CHLOROQUINE AND ITS DERIVATIVES.

000839 01-15 CHLOROQUINE POTENTIATION OF THIORIDAZINE EFFECTS IN RATS AND DRUG RESISTANT SCHIZOPHRENIC PATIENTS: A PRELIMINARY REPORT 001571 02-08

CHLOROTHIAZIDE FACTORS AFFECTING THE BIOAVAILABILITY OF CHLOROTHIAZIDE IN 001674 02-13

CHLORPROMAZINE LEVELS OF CHLORPROMAZINE AND ITS ACTIVE MATABOLITES IN RAT BRAIN AND THE RELATIONSHIP TO CENTRAL MONOAMINE METABOLISM AND PROLACTIN SECRETION.

MEMBRANE LIPIDS AS INTRACELLULAR BINDERS OF CHLORPROMAZINE AND RELATED DRUGS.

000095 01-03 CHLORPROMAZINE INDUCES POPULATION INCREASE OF SYNAPTIC VESICLES IN THE RAT HYPOTHALAMIC VENTROMEDIAL NUCLEUS

000160 01-03 EFFECT OF CHLORPROMAZINE ON CENTRAL-NERVOUS-SYSTEM CONCENTRATIONS OF MANGANESE, IRON, AND COPPER.

000295 01-03

001288 02-03

PRIMATE INFORMATION PROCESSING UNDER SODIUM PENTOBARBITAL AND CHLORPROMAZINE: DIFFERENTIAL DRUG EFFECTS WITH TACHISTOSCOPICALLY PRESENTED DISCRIMINATIVE STIMUL.

600318 01-04
EFFECTS OF CLOZAPINE, CHLORPROMAZINE AND DIAZEPAM UPON
ADJUNCTIVE AND SCHEDULE-CONTROLLED BEHAVIORS.

EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN TWO INBRED STRAINS OF MICE.

SUPPRESSION OF NEOPHOBIA BY CHLORPROMAZINE IN WILD RATS. 000415 01-04

THE EFFECTS OF HALOPERIDOL, CHLORPROMAZINE AND PROPRANOLOL ON ACUTE AMPHETAMINE POISONING IN THE CONSCIOUS DOG. 000480 01-05

CHLORPROMAZINE: A POTENTIAL PHYSIOLOGICAL TERATOGEN.

DO0486 01-05
THE EFFECTS OF BEHAVIORALLY RELEVANT DOSES OF CHLORPROMAZINE

THE EFFECTS OF BEHAVIORALLY RELEVANT DOSES OF CHLORPROMAZINE AND MOLINDONE ON CARDIAC ADENYLATE-CYCLASE AND ON MYOCARDIAL CONTRACTILITY.

000487 01-05

EFFECT OF CHLORPROMAZINE ON L METHIONINE TRANSPORT IN THE RAT INTESTINE.

CLOZAPINE (LEPONEX) VS CHLORPROMAZINE (LARGACTIL) IN ACUTE SCHIZOPHRENIA (A DOUBLE-BLIND CONTROLLED STUDY).

SCHIZOPHRENIA (A DOUBLE-BLIND CONTROLLED STUDY).

000527 01-08
REPLY TO DAVIS AND HURT CONCERNING METHODOLOGICAL ISSUES IN
PSYCHOPHARMACOLOGICAL RESEARCH WITH CHLORPROMAZINE.

000538 01-08
EFFECTS OF CHLORPROMAZINE ON PLASMA PROLACTIN AND
CHLORPROMAZINE LEVELS.

O00540 01-08
PARENTERAL HALOPERIDOL IN PSYCHIATRIC EMERGENCIES: DOUBLEBLIND COMPARISON WITH CHLORPROMAZINE.

000566 01-09

EFFECT OF CHLORPROMAZINE TREATMENT ON MONOAMINE METABOLITE
LEVELS IN CEREBROSPINAL FLUID OF PSYCHOTIC PATIENTS.

CLINICAL EFFECTS OF TREATMENT WITH CHLORPROMAZINE AND THE PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS.

THE EFFECT OF DIAZEPAM, CHLORPROMAZINE AND AMOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION.

O00708 01-13
CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND ITS
METABOLITES AND CLINICAL RATINGS IN PATIENTS WITH ACUTE
RELAPSE OF SCHIZOPHRENIC AND PARANOID PSYCHOSIS.

PLASMA LEVELS OF CHLORPROMAZINE: EFFECT OF AGE, CHRONICITY OF DISEASE. AND DURATION OF TREATMENT.

O00732 01-13
PHOTODYNAMIC ACTION OF CHLORPROMAZINE ON ADENOVIRUS 5:
REPAIRABLE DAMAGE AND SINGLE STRAND BREAKS.

MASKING OF TARDIVE-DYSKINESIA WITH FOUR TIMES-A-DAY
ADMINISTRATION OF CHIORPROMAZINE

NEUROLEPTIC SIDE-EFFECTS OF CHLORPROMAZINE IN PSYCHOPHARMACOLOGICAL RESEARCH.

000895 01-15
SIDE-EFFECTS OF CHLORPROMAZINE IN RELATION TO CIGARETTE

SMOKING. 000902 01-15

EXTRAPYRAMIDAL SIDE-EFFECTS IN CHLORPROMAZINE RECIPIENTS. 000903 01-15 EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. I. CHLORPROMAZINE AND PROMETHAZINE. 001068 02-03

ANTAGONISM OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) LETHALITY BY CHLORPROMAZINE IN THE CONSCIOUS DOG. 001072 02-03

DIFFERENTIAL ANTAGONISM BY CHLORPROMAZINE AND DIAZEPAM OF FROG MOTONEURONE DEPOLARIZATION INDUCED BY GLUTAMATE RELATED AMINO-ACIDS.

PROFOUND HYPOTHERMIA IN MAMMALS TREATED WITH
TETRAHYDROCANNABINOLS, MORPHINE, OR CHLORPROMAZINE.
001140 02-03

INFLUENCE OF CHLORPROMAZINE AND TRIFLUOPERAZINE ON NEURONS OF AN ISOLATED SLAB OF RABBIT CEREBRAL-CORTEX. 001205 02-03

IN VITRO AUTONOMIC EFFECTS OF FOUR NEUROLEPTICS; CHLORPROMAZINE, HALOPERIDOL, MELPERONE AND THIORIDAZINE. 001212 02-03

ONSET AND OFFSET OF CHLORPROMAZINE BLOCKADE OF PHENYLEPHRINE, CARBAMYLCHOLINE AND HISTAMINE ON RABBIT STOMACH STRIPS.

001234 02-03

REGIONAL LOCALIZATION OF C14-MESCALINE IN RABBIT BRAIN AFTER INTRAVENTRICULAR ADMINISTRATION: EFFECTS OF CHLORPROMAZINE AND IPRONIAZIO PRETREATMENT.

O01240 02-03
THE EFFECT OF CHLORPROMAZINE ON CELL MEMBRANE RESISTANCE AND CAPACITANCE.

IN VITRO EFFECTS OF CHLORPROMAZINE ON MICROTUBULES AND THE GOLGI COMPLEX IN EMBRYONIC CHICK SPINAL GANGLION CELLS: AN ELECTRON MICROSCOPIC STUDY.

CIRCADIAN VARIATIONS IN RESPONSES TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT.

CHLORPROMAZINE ENHANCES MEMORY IN CHICKS.

EFFECT OF CHLORPROMAZINE ON ELABORATION AND EXTINCTION OF AN INSTRUMENTAL ALIMENTARY REFLEX IN PUPPIES.

DISRUPTION OF LEARNING PERFORMANCE BY CHRONIC CHLORPROMAZINE ADMINISTRATION IN THE BABOON.

DISCRETE-TRIAL CONTROL OF COCAINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF MORPHINE, NALOXONE, AND CHLORPBOMAZINE

DISCRETE-TRIAL CONTROL OF MORPHINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF NALOXONE, MORPHINE, AND CHIORPROMAZINE.

ADVERSE EFFECTS OF CHLORPROMAZINE METABOLITES ON ISOLATED

001502 02-05
LYSERGIC-ACID-DIETHYLAMIDE ANTAGONISM BY CHLORPROMAZINE,
HALOPERIDOL, DIAZEPAM, AND PENTOBARBITAL IN THE RABBIT.
001504 02-05

OFFECT OF CHLORPROMAZINE TREATMENT ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC PATIENTS.

CHLORPROMAZINE PLUS THIORIDAZINE POISONING AND TREATMENT WITH EXTRACORPOREAL DIALYSIS.

001806 02-15
RELATIONSHIPS AMONG CLINICAL RESPONSE, EXTRAPYRAMIDAL
SYNDROME AND PLASMA CHLORPROMAZINE AND METABOLITE

001827 02-15
H3-HALOPERIDOL BINDING TO DOPAMINE RECEPTORS IN RAT CORPUSSTRIATUM: INFLUENCE OF CHLORPROMAZINE METABOLITES AND
DERIVATIVES

001995 03-03

EFFECTS OF CHLORPROMAZINE AND DL-AMPHETAMINE ON CALCIUM
UPTAKE BY ADRENAL CHROMAFFIN CELL MEMBRANE.

THE ACUTE EFFECTS OF AMPHETAMINE, CHLORPROMAZINE,
AMITRIPTYLINE AND LITHIUM ON ADENOSINE-S-TRIPHOSPHATASE
ACTIVITY IN THE CORTEX OF THE RAT BRAIN.

CIRCADIAN VARIATIONS IN RESPONSE TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT.

O02182 03-03

EFFECTS OF CHLORDIAZEPOXIDE, OXAZEPAM, CHLORPROMAZINE, AND D

AMPHETAMINE ON SEXUAL RESPONSES IN MALE AND FEMALE

002208 03-04
INHIBITION OF FLAVIN SYNTHESIS BY CHLORPROMAZINE IN EUTHYROID
AND HYPERTHYROID RATS.

CLINICAL AND BIOCHEMICAL EFFECTS OF CHLORPROMAZINE IN PSYCHOTIC PATIENTS: RELATIONS TO CHLORPROMAZINE CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID.

O02538 03-11
AN EEG COMPUTER ANALYSIS OF CHLORPROMAZINE EFFECTS IN
PSYCHOTIC SUBJECTS.

ELEVATED MELATONIN SERUM CONCENTRATIONS IN PSYCHIATRIC PATIENTS TREATED WITH CHLORPROMAZINE.

002595 03-13
BEHAVIOURAL ANTAGONISM BETWEEN CHLORPROMAZINE AND NOISE IN MAN.

MODIFICATION OF ADENYLATE-CYCLASE SYSTEMS IN MOUSE CEREBRAL-CORTEX BY CHLORPROMAZINE AND RESPECTIVE 7 HDROXY ANALOGS. 002875 04-03

EFFECTS OF MATERNAL CHLORPROMAZINE ON OFFSPRING NERVOUS SYSTEM DEVELOPMENT.

002880 04-0

002880 04-03
BIPHASIC EFFECT OF CHLORPROMAZINE ON RAT PARADOXICAL SLEEP: A
STUDY OF DOSE-RELATED MECHANISMS.
003253 04-04

EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE DETECTION OF

THE BEHAVIORAL EFFECTS OF D AMPHETAMINE AND CHLORPROMAZINE IN RATS; COMBINATIONS WITH ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE. (PH.D. DISSERTATION).

003278 04-04 LACK OF BLOCKADE OF CENTRAL DOPAMINERGIC RECEPTORS BY NARCOTICS: COMPARISON WITH CHLORPROMAZINE.

INOTROPIC ACTION OF HYDROXYLATED CHLORPROMAZINE METABOLITES AND RELATED COMPOUNDS.

THE EFFECTS OF CHRONIC CHLORPROMAZINE ADMINISTRATION ON THE ALBINO RAT RETINA.

MEASUREMENT OF PLASMA AND ERYTHROCYTE CHLORPROMAZINE AND N MONODESMETHYLCHLORPROMAZINE LEVELS BY GASCHROMATOGRAPHY WITH A NITROGEN SENSITIVE DETECTOR.

A COMPARISON OF THE RELATIVE EFFICACY OF SERENACE AND CHLORPROMAZINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS. 003470 04-08

DISAPPEARANCE OF CHLORPROMAZINE FROM PLASMA FOLLOWING DRUG WITHDRAWAL.

THE EFFECT OF CHLORPROMAZINE, SOME TRICYCLIC ANTIDERESSANTS AND INSULIN ON THE ACTION OF CYCLIC-AMP AND ADENOSINE METABOLISM.

003606 04-13 CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED DOSES OF CHLORPROMAZINE.

PARADOXICAL EFFECTS IN SLEEP AND PERFORMANCE OF TWO DOSES OF CHLORPROMAZINE.

003629 04-14

CHLORPROMAZINE AND PLATELET FUNCTION. CHLORPROMAZINE EXCRETION. II. IMPROVED TLC PROCEDURES FOR FRACTIONATING THE URINARY DRUG CONTENT INTO CHEMICAL SUBGROUPS OF CPZ METABOLITES.

003690 04-16

CHLORPROMAZINE-INDUCED
CHLORPROMAZINE-INDUCED HEMOLYTIC ANEMIA IN ANOREXIA-NERVOSA

000847 01-15 CHLORPROMAZINE-INDUCED CHANGES IN BLOOD
ADENOSINEPHOSPHORIC-ACIDS: TO THEIR DIAGNOSTIC SIGNIFICANCE
IN PSYCHIATRY.

001861 02-16 CHOICE
THE EFFECTS OF PHARMACOLOGICAL AND ENVIRONMENTAL VARIABLES
ON DRUG CHOICE IN RHESUS MONKEYS.

000386 01-0

000386 01-04 CHOICE OF MEDICAL TREATMENT IN SCHIZOPHRENIA.

001564 02-08 CHOICE OF ANTIDEPRESSANTS

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS: 3
SUBCELLULAR DISTRIBUTION OF NEUROLEPTIC DRUGS AND THEIR
RECEPTORS IN VARIOUS RAT BRAIN AREAS.

002067 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 2.
REGIONAL DISTRIBUTION AND IN VIVO DISPLACEMENT OF NEUROLEPTIC DRUGS.

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 1.
KINETICS AND CHARACTERISTICS OF IN VITRO BINDING.

002079 03-03 CHOICE BEHAVIOR IN RHESUS MONKEYS: COCAINE VERSUS FOOD 003155 04-04

ENHANCED CHOICE OF FAMILIAR FOOD IN A FOOD PREFERENCE TEST AFTER CHLORDIAZEPOXIDE ADMINISTRATION. 003199 04-04

CHOLECYSTOKININ

EFFECT OF CHOLECYSTOKININ ON MEAL SIZE AND INTERMEAL INTERVAL
IN THE SHAM-FEEDING RAT. 003264 04-04

EFFECTS OF DISULFIRAM AND PYRIDOXINE ON SERUM CHOLESTEROI 002519 03-11

EFFECT OF HYPOCHOLESTEROLEMIC AGENTS ON CENTRAL-NERVOUS-SYSTEM CHOLESTEROL BIOSYNTHESIS. III. ZUCLOMIPHENE IN COMBINATION WITH AY9944 AND TRIPARANOL. 003058 04-03

CHOLINE
INFLUENCE OF CHRONIC PENTOBARBITAL OR MORPHINE TREATMENT ON
THE INCORPORATION OF P32-PHOSPHORIC-ACID AND 3H CHOLINE INTO
RAT SYNAPTIC PLASMA MEMBRANES.

000147 01-03

Psychopharmacology Abstracts

ACETYLCHOLINE AND CHOLINE IN MOUSE BRAIN -- INFLUENCE OF PERIPHERALLY ACTING CHOLINERGIC DRUGS.

000187 01-03 FORMATION OF BRAIN ACETYLCHOLINE FROM DIETARY CHOLINE AND THE EFFECT OF BARBITURATE ANESTHESIA ON THIS PROCESS.

INCORPORATION OF RADIOACTIVE LABELLED CHOLINE AND PALMITATE INTO LUNG LECITHIN OF RABBITS TREATED WITH HIGH DOSES OF BROMCARBAMIDES, BARBITURATES AND DIAZEPAM.

ENHANCEMENT BY CHOLINE OF THE INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE BY PHENOXYBENZAMINE, & HYDROXYDOPAMINE, INSULIN OR EXPOSURE TO COLD.

CHOLINE-ACETYLTRANSFERASE AND THE HIGH AFFINITY UPTAKE OF CHOLINE IN CORPUS-STRIATUM OF RESERPINISED RATS.

ESTIMATION OF DEANOL AND CHOLINE BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY.

EFFECTS OF 2 DIMETHYLAMINOETHANOL (DEANOL) ON THE METABOLISM OF CHOLINE IN PLASMA. 003589 04-13

CHOLINE-ACETYLTRANSFERASE
CHOLINE-ACETYLTRANSFERASE AND THE HIGH AFFINITY UPTAKE OF
CHOLINE IN CORPUS-STRIATUM OF RESERPINISED RATS.

002847 04-03 CHOLINE-CHLORIDE

THE EFFECT OF CHOLINE-CHLORIDE ON AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR. 002330 03-04

ACTION OF S-1432, A NEW PSYCHOTROPIC DRUG, ON THE CENTRAL CHOLINERGIC SYSTEM.

INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT.

000124 01-03 REGIONAL DIFFERENCES IN THE SENSITIVITY OF CHOLINERGIC NEURONS TO DOPAMINERGIC DRUGS AND QUIPAZINE IN THE RAT STRIATUM. 000134 01-03

TYROSINE-HYDROXYLASE: DELAYED ACTIVATION IN CENTRAL NORADRENERGIC NEURONS AND INDUCTION IN ADRENAL MEDULLA ELICITED BY STIMULATION OF CENTRAL CHOLINERGIC RECEPTORS.

000183 01-03 ACETYLCHOLINE AND CHOLINE IN MOUSE BRAIN — INFLUENCE OF PERIPHERALLY ACTING CHOLINERGIC DRUGS.

000187 01-03 ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM — IV. TOLERANCE TO OXOTREMORINE IN MICE: IN VIVO AND IN VITRO STUDIES.

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM -- III. TOLERANCE TO PHENCYCLIDINE DERIVATIVES: IN VIVO AND IN VITRO STUDIES. 000224 01-03

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON PENTOBARBITAL-INDUCED DECREASE IN CHOLINERGIC NEURONAL

000259 01-03 TIME-DEPENDENT CHANGES IN ACTIVITY, REACTIVITY, AND RESPONSIVITY DURING SHOCK: EFFECTS OF CHOLINERGIC AND CATECHOLAMINERGIC MANIPULATIONS.

000313 01-04 ANTAGONISM BY CHOLINERGIC DRUGS OF BEHAVIOURAL EFFECTS IN CATS OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC DRUG AND ENHANCEMENT BY NICOTINE.

000404 01-04 MEMORY AND COGNITIVE FUNCTION IN MAN: DOES THE CHOLINERGIC SYSTEM HAVE A SPECIFIC ROLE?

000761 01-14 **CHOLINERGIC INFLUENCES IN TARDIVE-DYSKINESIA**

000904 01-15 EVIDENCE FOR A DOUBLE CHOLINERGIC MECHANISM CAPABLE OF REDUCING THE TONE OF CEREBRAL ARTERIES.

001049 02-03 CHOLINERGIC INHIBITION OF MORPHINE-INDUCED HYPOTHERMIA 001066 02-03

EFFECT OF QUIPAZINE, A SEROTONIN-LIKE DRUG, ON STRIATAL CHOLINERGIC INTERNEURONES.

001114 02-03 NONPARTICIPATION OF CHOLINERGIC MECHANISM IN CHEMICAL CONTROL OF CEREBRAL VASOMOTOR ACTIVITY.

001243 02-03 CHOLINERGIC MODIFICATION OF THE INHIBITION OF DOPAMINE-INDUCED HYPERACTIVITY BY NEUROLEPTICS.

002455 03-09

EATING FOLLOWING CHOLINERGIC STIMULATION OF THE HYPOTHALAMUS.

ADRENERGIC MODULATION OF A CHOLINERGIC EMOTIONAL REACTION IN THE CATS THALAMUS.

CHOLINERGIC MECHANISMS INVOLVED IN HEAD-SHAKING OF INFANT

A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND BIOELECTRIC CORRELATES OF EMOTIONAL REACTIONS ELICITED BY CHOLINERGIC STIMULATION OF THE HYPOTHALAMUS AND THE VENTRAL

STIMULATION OF THE HYPOTHALAMUS AND THE VENTRAL TEGMENTUM.

O01390 02-04
ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS
SYSTEM. II. CROSS-TOLERANCE BETWEEN PHENCYCLIDINE
DERIVATIVES AND CHOLINERGIC DRUGS.

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. J. TOLERANCE TO PHENCYCLIDINE DERIVATIVES IN MICE: PHARMACOLOGICAL CHARACTERIZATION.

CHOLINERGIC INHIBITION OF METHYLPHENIDATE-INDUCED STEREOTYPY: OXOTREMORINE.

002223 03-04
EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AGONISTS AND
ANTAGONISTS INTO THE AMYGDALA ON RETENTION OF PASSIVE
AVOIDANCE TRAINING IN RATS. (PH.D. DISSERTATION).

PHARMACOLOGICAL INVESTIGATIONS OF THE CHOLINERGIC IMBALANCE HYPOTHESES OF MOVEMENT DISORDERS AND PSYCHOSIS.

SUPERSENSITIVITY OF THE CHOLINERGIC RESPONSE TO APOMORPHINE IN THE STRIATUM FOLLOWING DENERVATION OR DISUSE SUPERSENSITIVITY OF DOPAMINERGIC RECEPTORS IN THE RAT.

002872 04-03
ALPHA-BUNGAROTOXIN BLOCKS REVERSIBLY CHOLINERGIC INHIBITION IN THE COCHLEA

PHARMACOLOGICAL CHARACTERIZATION OF THE EXCITATORY
CHOLINERGIC RECEPTORS OF RAT CENTRAL NEURONES.

003006 04-03

EVIDENCE OF AN INTERACTION BETWEEN SEROTONINERGIC AND
CHOLINERGIC NEURONS IN THE CORPUS-STRIATUM AND HIPPOCAMPUS

CHOLINERGIC STIMULATION OF POLYPHOSPHOINOSITIDE METABOLISM IN

BRAIN IN VIVO.

O03097 04-03

THE ROLE OF THE CHOLINERGIC SYSTEM IN THE DEVELOPMENT OF

INCREASED NALOXONE POTENCY IN MICE. 003140 04-03

EFFECTS OF N METHYLAMINOETHANOL, AND N, N
DIMETHYLAMINOETHANOL IN THE DIET OF PREGNANT RATS ON
NEONATAL RAT BRAIN CHOLINERGIC AND PHOSPHOLIPID PROFILE.
003149 04-03

STEREOTYPED BEHAVIOR AFTER CHOLINERGIC, BUT NOT DOPAMINERGIC, STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.

TACRINE AND ITS DERIVATIVES ANTAGONIZE CHOLINERGIC PSYCHOTOMIMETICS: BEHAVIORAL STUDY IN RATS.

EMERGING CHOLINERGIC MECHANISMS AND ONTOGENY OF RESPONSE INHIBITION IN THE MOUSE. 003336 04-04

CHOLINERGIC CONDUCTANCE AS A COMPONENT OF MNEMONIC PROCESSES. (PH.D. DISSERTATION).

A ROLE OF THE POLYSYNAPTIC SYSTEM OF SUBSTANTIA-NIGRA IN THE CHOLINERGIC DOPAMINERGIC EQUILIBRIUM IN THE CENTRAL-NERVOUS-SYSTEM.

003397 04-04

THERAPEUTIC ANTAGONISM BETWEEN ANTICHOLINERGICS AND NEUROLEPTICS: POSSIBLE INVOLVEMENT OF CHOLINERGIC MECHANISMS IN SCHIZOPHRENIA.

003473 04-08
MEMORY CONSOLIDATION AND CHOLINERGIC STATE-DEPENDENT
LEARNING IN MAN.

CHOLINERGIC INVOLVEMENT IN MENTAL DISORDERS. 003612 04-13

CHOLINESTERASE

EFFECTS OF ANTICHOLINERGIC AND CHOLINESTERASE BLOCKING DRUGS
ON APPETITIVE BEHAVIOR UNDER DIFFERENT DEPRIVATION
CONDITIONS.

CHOLINOCEPTORS

CENTRAL ADRENOCEPTORS AND CHOLINOCEPTORS IN CARDIOVASCULAR
CONTROL.

CHOLINOLYTIC

CYANOCYPROHEPTADINE: ROLE OF CHOLINOLYTIC PROPERTIES IN

MODULATING NEUROLEPTIC-INDUCED ELEVATION OF STRIATAL

HOMOVANILLIC-ACID (HVA).

CHOLINOMIMETIC
EFFECTS OF CHOLINOMIMETIC DRUGS AND THEIR ANTAGONISTS INJECTED
INTO VERTEBRAL ARTERY OF UNANAESTHETIZED DOGS.

THE ACTIONS OF CHOLINOMIMETICS AND CATECHOLAMINES ON RAT SUBSTANTIA-NIGRA NEURONES. 000163 01-03

CHOOSING AN ANTIDEPRESSANT.

TREATMENT OF DYSKINETIC AND CHOREATIC MOVEMENT DISORDERS IN ADULTS.

002776 03-17

METHYLPHENIDATE-INDUCED CHOREOATHETOSIS. 002660 03-15

EFFECTS OF CHLORPROMAZINE AND DL-AMPHETAMINE ON CALCIUM UPTAKE BY ADRENAL CHROMAFFIN CELL MEMBRANE.

CHROMATOGRAPHIC
HIGH-PRESSURE LIQUID CHROMATOGRAPHIC MASS SPECTROMETRIC
DETERMINATION OF DELTA9-TETRAHYDROCANNABINOL IN HUMAN
PLASMA FOLLOWING MARJUJANA SMOKING.

HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF DOTHIEPIN AND NORTHIADEN IN HUMAN PLASMA AND SERUM. 001858 02-16

RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D

CHROMATOGRAPHY
THE PURIFICATION OF ANTIMORPHINE ANTIBODIES BY AFFINITY
CHROMATOGRAPHY.

THE EXTRACTION AND ANALYSIS OF BENZODIAZEPINES IN TISSUES BY ENZYMIC DIGESTION AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY

MEASUREMENT OF PLASMA ANTIDEPRESSANT LEVELS BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY.

BIOANALYSIS AND PHARMACOKINETICS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN MAN BY MEANS OF LIQUID

CHROMATOGRAPHY. 002728 03-16

ALTERATIONS IN BRAIN 5 HYDROXYTRYPTAMINE METABOLISM DURING THE WITHDRAWAL PHASE AFTER CHRONIC TREATMENT WITH DIAZEPAM AND BROMAZEPAM.

THE METABOLIC FATE OF C14-PHENOBARBITONE IN THE RAT AND THE EFFECT OF CHRONIC ADMINISTRATION AND DOSE SIZE.

ACUTE AND CHRONIC EFFECTS OF TETRAHYDROCANNABINOLS ON MONDAMINE-OXIDASE ACTIVITY: POSSIBLE VEHICLE/
TETRAHYDROCANNABINOL INTERACTIONS.

DOPAMINERGIC MECHANISMS INVOLVED IN THE ACUTE AND CHRONIC EFFECT OF AMPHETAMINE.

O00129 01-03
INFLUENCE OF CHRONIC PENTOBARBITAL OR MORPHINE TREATMENT ON
THE INCORPORATION OF P32-PHOSPHORIC-ACID AND 3H CHOLINE INTO
RAT SYNAPTIC PLASMA MEMBRANES.

MOTILITY RESPONSE TO MORPHINE AND AMPHETAMINE DURING
CHRONIC INHIBITION OF TYROSINE-HYDROXYLASE OR DOPAMINEBETA-HYDROXYLASE.

000166 01-03

LACK OF EFFECT OF CHRONIC HALOPERIDOL ADMINISTRATION ON THE PROLACTIN LOWERING ACTIONS OF PIRIBEDIL.

MAO ACTIVITY IN RAT BRAINSTEM AND CEREBRAL-CORTEX FOLLOWING ACUTE AND CHRONIC TREATMENT WITH L-DOPA AND ETHANOL L-

ALTERED RECEPTOR SENSITIVITY FOLLOWING CHRONIC DRUG
ADMINISTRATION IN MAN: THE TARDIVE-DYSKINESIA MODEL.

ACTIONS OF AMPHETAMINE AND ANTAGONISTS ON PUPIL DIAMETER IN THE CHRONIC SYMPATHECTOMIZED DOG. 000265 01-03

000306 01-04

- EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON SEROTONIN UPTAKE INTO RAT HYPOTHALAMIC SYNAPTOSOMES.
- 000293 01-03 DIENTIATION OF THE BEHAVIORAL AND CONVULSANT EFFECTS OF COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.
- MOVEMENT DISORDERS INDUCED IN MONKEYS BY CHRONIC HALOPERIDOL TREATMENT.
- EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON PREGNANT RATS AND THEIR OFFSPRING.
- EVALUATIONS OF SOCIAL FUNCTIONING IN A 3-YEAR DOUBLE-BLIND INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.
- BACLOFEN TREATMENT IN CHRONIC SCHIZOPHRENIA: A CLINICAL TRIAL.
 000521 01-08
- COMPARISON OF PIMOZIDE AND TRIFLUOPERAZINE AS THERAPY IN CHRONIC SCHIZOPHRENIC OUTPATIENTS ONCE-DAILY 000537 01-08
- HIGH DOSAGE HALOPERIDOL IN CHRONIC SCHIZOPHRENIA
- 000539 01-08 INHIBITION OF DOPAMINE SYNTHESIS IN CHRONIC SCHIZOPHRENIA: CLINICAL INEFFECTIVENESS OF METYROSINE.
- 000542 01-08 PHENOTHIAZINE EFFECTS ON PSYCHOLOGICAL AND PSYCHOPHYSIOLOGICAL DYSFUNCTION IN CHRONIC SCHIZOPHRENICS. 000549 01-08
- NALOXONE IN CHRONIC SCHIZOPHRENIA
- 000552 01-08 A DOUBLE-BLIND CROSS-OVER STUDY: APOMORPHINE/PLACEBO IN CHRONIC ALCOHOLICS.
- 000621 01-11
- LITHIUM PROPHYLAXIS FOR CHRONIC CLUSTER HEADACHE. 000641 01-11 METHADONE MAINTENANCE: EFFECT OF URINARY PH ON RENAL CLEARANCE IN CHRONIC HIGH AND LOW DOSES.
- PLASMA L-ALPHA-ACETYLMETHADOL (LAAM) AFTER ACUTE AND CHRONIC ADMINISTRATION.
- 000704 01-13 VISUAL EVOKED REPONSES IN CHRONIC HASHISH USERS.
- 000722 01-13 ACUTE VERSUS CHRONIC EFFECTS OF MONOAMINE-OXIDASE INHIBITORS IN DEPRESSED PATIENTS: TIME-COURSE OF MAO INHIBITORS.
- 000733 01-13 ACUTE EFFECTS OF CANNABIS ON COGNITIVE, PERCEPTUAL, AND MOTOR PERFORMANCE IN CHRONIC HASHISH USERS.
- 000759 01-14 BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC CORRELATES OF THE CHRONIC USE OF MARIJUANA -- A REVIEW.
- PERSONALITY MODIFICATIONS DUE TO LONG-TERM
 PSYCHOPHARMACOTHERAPY: IN CASE OF CHRONIC SCHIZOPHRENIA.
 000773 01-14
- PHENCYCLIDINE HYDROCHLORIDE: PHARMACOLOGIC, ACUTE, AND CHRONIC EFFECTS.
- STUDY OF NIGHT SLEEP DURING LONG-TERM GRADUAL REDUCTION IN NEUROLEPTIC THERAPY IN CHRONIC SCHIZOPHRENICS.
- DRUG DEPENDENCY IN PATIENTS WITH CHRONIC HEADACHES.
 000863 01-15
- ELECTRON MICROSCOPIC STUDIES ON THE CEREBRAL LESIONS OF RATS IN EXPERIMENTAL CHRONIC DISULFIRAM POISONING.
- 000906 01-15 PROGRAMMED FEEDING AS A MODEL OF CHRONIC ALCOHOLISM IN THE
- 001087 02-03 BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF CHRONIC REDUCTION OF CEREBRAL NORADRENALINE RECEPTOR STIMULATION.
- EFFECT OF CHRONIC LEVODOPA ON VITAMIN-B6 METABOLISM IN DISCRETE REGIONS OF RAT BRAIN
- BRAIN DISTRIBUTION OF LITHIUM AND INDOLEAMINE METABOLISM IN DOGS AFTER CHRONIC LITHIUM ADMINISTRATION.
- EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON SYNAPTOSOMAL CA UPTAKE.
- 001138 02-03 ALTERATIONS IN DOPAMINE RECEPTOR SENSITIVITY BY CHRONIC ETHANOL TREATMENT.
- EFFECTS OF ACUTE AND CHRONIC MORPHINE AND NARCOTIC ANTAGONISTS ON BRAIN ENERGY METABOLISM.
- EFFECT OF CHRONIC NEUROLEPTIC OR L-DOPA ADMINISTRATION ON GABA LEVELS IN THE RAT SUBSTANTIA-NIGRA. 001181 02-03

- THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE NOREPINEPHRINE TURNOVER IN RAT BRAIN REGIONS.
- 001227 02-03 THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS ON MHPG-SO4 IN RAT BRAIN.
- 001228 02-03 CALCIUM CONTENT AND BINDING IN SYNAPTOSOMAL SUBFRACTIONS DURING CHRONIC MORPHINE TREATMENT.
- THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDROCANNABINOL (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HORMONE (FSH) AND LUTEINIZING HORMONE (LH) IN THE OVARIECTOMIZED RHESUS
- 001245 02-03 A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHOXYAMPHETAMINE (DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), P-METHOXYAMPHETAMINE (PMA), D AMPHETAMINE (A), AND LSD IN NONTOLERANT AND LSD TOLERANT CHRONIC SPINAL DOGS.

 001273 02-03
- DYNAMICS OF BLOOD NEUROTRANSMITTER LEVEL AS EVIDENCE OF HIGHER NERVOUS ACTIVITY CHANGES DURING CHRONIC ADMINISTRATION OF SEDUXEN.
- 001338 02-04 EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION: AMPHETAMINE LEVELS AND EFFECTS UPON SOME ARYLALKYLAMINES IN RAT BRAIN.
- 001339 02-04 ACUTE AND CHRONIC EFFECTS OF GENERAL CNS DEPRESSANTS ON SEVERAL BEHAVIORAL TESTS IN RATS.
- 001356 02-04 A BIOCHEMICAL AND BEHAVIORAL ANALYSIS OF CHRONIC ALCOHOL CONSUMPTION BY RATS.
- 001362 02-04 EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE INTOXICATION ON EXPLORATORY AND STEREOTYPED BEHAVIORS IN THE RAT.
- 001379 02-04 CHRONIC AND ACUTE EFFECTS OF BARBITAL AND AMPHETAMINE IN DOPAMINE DEPLETED RATS.
- 001389 02-04 EFFECTS OF CHRONIC LITHIUM AND RUBIDIUM ADMINISTRATION UPON EXPERIMENTALLY-INDUCED CONFLICT BEHAVIOR.
- 001391 02-04 CHRONIC AND ACUTELY INDUCED DYSKINESIAS: A PHARMACOLOGIC
- 001410 02-04 PHYSICAL DEPENDENCE ASSOCIATED WITH CHRONIC METHAQUALONE
- 001428 02-04 TOLERANCE AND CROSS-TOLERANCE TO CNS DEPRESSANTS AFTER CHRONIC PENTOBARBITAL.
- 001442 02-04 DISRUPTION OF LEARNING PERFORMANCE BY CHRONIC CHLORPROMAZINE ADMINISTRATION IN THE BABOON.
- 001465 02-04 FENFLURAMINE: CUMULATIVE NEUROTOXICITY AFTER CHRONIC
- TREATMENT WITH LOW DOSAGES IN THE RAT. 001508 02-05 A SLOW-RELEASE SILICONE PELLET FOR CHRONIC AMPHETAMINE
- 001529 02-06 TREATMENT OF CHRONIC SCHIZOPHRENICS WITH THE ORAL LONG-TERM
- NEUROLEPTIC PENFLURIDOL IN AN OPEN STUDY. 001563 02-08 PLASMA BUTAPERAZINE LEVELS IN LONG-TERM CHRONIC
- NONRESPONDING SCHIZOPHRENICS. 001569 02-08
- PROPRANOLOL IN CHRONIC SCHIZOPHRENIA 001611 02-09 **EVALUATION OF BUTACLAMOL IN CHRONIC SCHIZOPHRENIC PATIENTS**
- 001649 02-13 URINARY EXCRETION OF A QUATERNARY AMMONIUM GLUCURONIDE METABOLITE OF CYPROHEPTADINE IN HUMANS UNDERGOING CHRONIC DRUG THERAPY.
- 001667 02-13 CYCLIC-AMP IN THE PLASMA OF CHRONIC SCHIZOPHRENICS, BEFORE AND AFTER TREATMENT.
- 001690 02-13 MODIFICATION OF SLEEP INDUCED IN ACUTE AND CHRONIC ADMINISTRATION OF LITHIUM.
- MAINTENANCE ANTIPSYCHOTIC PHARMACOTHERAPY, RELAPSE, AND LENGTH OF STAY OUT OF THE HOSPITAL IN CHRONIC SCHIZOPHRENICS
- 001911 02-17 PHENOBARBITAL METABOLISM DURING CHRONIC ADMINISTRATION IN
- 002007 03-03 THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON DOPAMINE METABOLISM IN RAT STRIATUM.

SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION.
002052 03-03

BRAIN NEUROTRANSMITTER RECEPTORS AND CHRONIC ANTIPSYCHOTIC DRUG TREATMENT: A MODEL FOR TARDIVE-DYSKINESIA.

O02061 03-03
CHRONIC TREATMENT WITH DESIPRAMINE CAUSED A SUSTAINED
DECREASE OF 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE AND TOTAL 3
METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT BRAIN.

A PHARMACOLOGIC COMPARISON OF 3,4
METHYLENEDIOXYAMPHETAMINE AND LSD IN THE CHRONIC SPINAL

002121 03-03

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS. 002148 03-03

METABOLISM OF 5 HYDROXYTRYPTAMINE AND LEVELS OF TRICYCLIC
ANTIDEPRESSANT DRUGS IN RAT BRAIN AFTER ACUTE AND CHRONIC
TREATMENT.

CHANGES IN MOUSE BRAIN CATECHOLAMINE CONTENT AND TYROSINE-HYDROXYLASE ACTIVITY DURING CHRONIC AMPHETAMINE ADMINISTRATION.

ALTERATIONS IN MORPHINE ANALGESIA PRODUCED BY CHRONIC DEFICITS OF BRAIN CATECHOLAMINES OR SEROTONIN: ROLE OF ANALGESIMETRIC PROCEDURE.

002186 03-03
SLEEP CHANGES INDUCED BY CHRONIC ADMINISTRATION OF \$-1694
(SURVECTOR).

002194 03-04
EFFECTS OF CHRONIC IMIPRAMINE AND CLOMIPRAMINE ORAL
ADMINISTRATION ON MATERNAL BEHAVIOR AND LITTER

002202 03-04
THE EFFECTS OF ACUTE AND CHRONIC PHENCYCLIDINE ON SCHEDULECONTROLLED BEHAVIOR IN THE SQUIRREL-MONKEY.

002209 03-04
BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC/
ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH
NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA.

NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA.

002220 03-04

BEHAVIOURAL SPECIFIC TOLERANCE FOLLOWING CHRONIC D OR L

HYDROXYNOREPHEDRINE. 002261 03-04
A BEHAVIORAL AND AUTONOMIC NERVOUS SYSTEM STUDY OF CHRONIC

AMPHETAMINE TREATMENT: LACK OF INVOLVEMENT OF P-

IMIPRAMINE ADMINISTRATION TO CONSCIOUS DOGS.

002263 03-04
THE EFFECT OF CHRONIC ETHANOL TREATMENT ON BEHAVIOUR AND

CENTRAL MONOAMINES IN THE RAT. 002271 03-04

TOLERANCE AND DEPENDENCE AFTER CHRONIC ADMINISTRATION OF CLONIDINE TO THE RAT. 002283 03-04

RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDROXYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN
ACUTE AND CHRONIC SPINAL RATS.

002289 03-04

ENHANCED ANALGESIC EFFECTS OF MORPHINE AFTER CHRONIC ADMINISTRATION OF NALOXONE IN THE RAT.

002319 03-04
INCREASED HALOPERIDOL-INDUCED CATALEPSY AFTER CHRONIC COCAINE
TREATMENT

GRADUAL REDUCTION OF NEUROLEPTIC DRUGS AMONG CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY.

002401 03-08 CHRONIC NEUROLEPTIC USE AND PERIPHERAL MOTOR NEURON DAMAGE. 002671 03-15

ASSESSMENT OF DRUG THERAPY IN CHRONIC BRAIN FAILURE. 002719 03-16 RESEARCH FINDINGS ON CHRONIC MENTAL ILLNESS: A MODEL FOR

CONTINUING-CARE IN THE HEALTH MAINTENANCE ORGANIZATION.
002777 03-17
REGIONAL SENSITIVITY OF PRIMATE BRAIN DOPAMINERGIC NEURONS TO HALOPERIDOL: ALTERATIONS FOLLOWING CHRONIC TREATMENT.

002812 04-03

EFFECT OF CHRONIC TREATMENT WITH NEUROLEPTICS ON THE CONTENT
OF 3.5 CYCLIC-GUANOSINE-MONOPHOSPHATE IN CEREBELLAR-CORTEX
OF RATS

002827 04-03

EFFECTS OF MORPHINE ON BRAINSTEM NEURONES IN NAIVE AND
CHRONIC MORPHINE TREATED RATS, AND EFFECTS OF PCPA.
002841 04-03

RAT STRIATAL METHIONINE-ENKEPHALIN CONTENT AFTER CHRONIC TREATMENT WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTISCHIZOPHRENIC DRUGS.

THE EFFECT OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF AMPHETAMINE ON CEREBRAL DOPAMINE RECEPTOR SENSITIVITY. 002964 04-03

CHRONIC NALOXONE RESULTS IN PROLONGED INCREASES IN OPIATE
BINDING SITES IN BRAIN.

CHANGES IN BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS FOLLOWING ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION AND DURING POST AMPHETAMINE DEPRESSION.

CHANGES IN BRAIN TRYPTOPHAN AND TYROSINE FOLLOWING ACUTE AND CHRONIC MORPHINE ADMINISTRATION.

DOPAMINE RECEPTOR FUNCTION AFTER CHRONIC INGESTION OF ETHANOL.

O03106 04-03

ALTERATIONS IN RECEPTORS CONTROLLING DOPAMINE SYNTHESIS AFTER
CHRONIC ETHANOL INGESTION.

BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION OF LEVO-ALPHA-ACETYLMETHADOL IN THE RAT.

BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC NARCOTIC TREATMENT IN THE GUINEA-PIG.

DIMINISHED TASTE REACTIVITY TO SACCHARIN FOLLOWING CHRONIC ADMINISTRATION OF THEOPHYLLINE IN RATS.

EFFECTS OF CHRONIC INGESTION AND WITHDRAWAL OF SODIUM
BARBITONE ON LEARNING IN RATS.

THE BEHAVIORAL EFFECTS OF D AMPHETAMINE AND CHLORPROMAZINE IN RATS; COMBINATIONS WITH ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE. (PH. D. DISSERTATION).

O03278 04-04
ACUTE AND CHRONIC EFFECTS OF COCAINE ON EXTINCTION-INDUCED
AGGRESSION.

BEHAVIORAL EFFECTS OF CHRONIC NARCOTIC ANTAGONIST
ADMINISTRATION TO INFANT RATS.

003329 04-04
EFFECT OF CHRONIC COCAINE TREATMENT ON LIMITED ACCESS FOOD
CONSUMPTION.

003395 04-04
THE EFFECTS OF CHRONIC CHLORPROMAZINE ADMINISTRATION ON THE
ALBINO RAT RETINA.

O03408 04-0:
EVIDENCE AGAINST CHRONIC DEPOLARIZATION AS A MECHANISM OF
KAINIC-ACID TOXICITY IN MOUSE CEREBELLAR CULTURES.

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. A STUDY WITH THE LONG-ACTING THIOXANTHENE DERIVATIVE, CISCLOPENTHIXOL-DECANOATE SORDINOL DEPOT.

DOUBLE-BLIND THERAPEUTIC EVALUATION OF FLUSPIRILENE COMPARED WITH FLUPHENAZINE-DECANOATE IN CHRONIC SCHIZOPHRENICS.

003454 04-08

OUTPATIENT MAINTENANCE OF CHRONIC SCHIZOPHRENIC PATIENTS WITH FLUPHENAZINE-DECANOATE (MODECATE): IBADAN EXPERIENCE. 003466 04-08

A COMPARISON OF THE RELATIVE EFFICACY OF SERENACE AND CHLORPROMAZINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS. 003470 04-08

STANDARD AND LONG-ACTING DEPOT NEUROLEPTICS IN CHRONIC SCHIZOPHRENICS: AN 18-MONTH OPEN MULTICENTRIC STUDY. 003471 04-08

A CONTROLLED CLINICAL STUDY OF TRAZODONE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH PRONOUNCED DEPRESSIVE SYMPTOMATOLOGY.

03472 04-08
CIS-CLOPENTHIXOL AND CLOPENTHIXOL (SORDINOL) IN CHRONIC
PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL INVESTIGATION.
03496 04-09
ACUTE AND CHRONIC EFFECTS OF LITHIUM-CHLORIDE ON PHYSIOLOGICAL

AND PSYCHOLOGICAL MEASURES IN NORMALS.

O03600 04-13

CHRONICALLY
DISESPRATIAL TO EPANCE TO INHIBITORY ACTION OF VARIOUS

DIFFERENTIAL TOLERANCE TO INHIBITORY ACTION OF VARIOUS
NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS
CHRONICALLY TREATED WITH HALOPERIDOL.

O01398 02-04
A NEW CHRONICALLY CANNULATED CAROTID ARTERY PREPARATION FOR

A NEW CHRONICALLY CANNULATED CAROTID ARTERY PREPARATION FOR DETERMINATION OF DRUG HALF-LIVES IN THE GUINEA-PIG. 001531 02-06 EFFECTS OF ANESTHETICS ON CEREBELLAR NEURONS RECORDED

FECTS OF ANESTHETICS ON CEREBELLAR NEURONS RECORDED CHRONICALLY AFTER HARMALINE. 002260 03-04

Psychopharmacology Abstracts

PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. I. CHRONICALLY EQUIVALENT DOSING METHOD. EFFECTS OF DOPAMINE AGONISTS ON NEURONES IN THE CAUDATE NUCLEUS AND CEREBRAL-CORTEX OF CATS CHRONICALLY TREATED WITH NEUROLEPTICS.

MOTILITY EFFECTS OF METHAMPHETAMINE IN RATS CHRONICALLY TREATED WITH MORPHINE

003162 04-04 BEHAVIORAL EFFECTS OF PSYCHOTHERAPEUTIC AGENTS IN RATS CHRONICALLY DOSED WITH ALPHA-ACETYLMETHADOL.

LOW PLASMA LEVELS OF CPZ IN PATIENTS CHRONICALLY TREATED WITH NEUROLEPTICS

003469 04-08

CHRONICITY
PLASMA LEVELS OF CHLORPROMAZINE: EFFECT OF AGE, CHRONICITY OF
DISEASE, AND DURATION OF TREATMENT.

000732 01-1. 000732 01-13

CIA RESEARCH WITH LSD-25.

001638 02-12 CICLAZINDOL
ANTIDEPRESSANT ACTIVITY AND PHARMACOLOGICAL INTERACTIONS OF CICLAZINDOL.

003493 04-09 CIGARETTE
SIDE-EFFECTS OF CHLORPROMAZINE IN RELATION TO CIGARETTE

000902 01-15 CAN CIGARETTE SIZE AND NICOTINE CONTENT INFLUENCE SMOKING AND

PUFFING RATES? 003631 04-14

RETROGRADE AXONAL TRANSPORT OF NERVE GROWTH FACTOR IN THE CILIARY GANGLION OF THE CHICK AND THE RAT.

003005 04-03

CILIOINHIBITORY
CILIOINHIBITORY EFFECT OF PHENOTHIAZINES IN VITRO AND ITS
ANTAGONISM BY CA.
0000 000040 01-03

CIMETIDINE AND MENTAL CONFUSION.

001810 02-15 MISLEADING RESPONSE OF MALIGNANT GASTRIC ULCERS TO CIMETIDINE

002704 03-15 CIMS A GC/CIMS ASSAY FOR THE CIS AND TRANS ISOMERS OF THIOTHIXENE

IN HUMAN PLASMA. 001857 02-16

CINANSENIN

MORPHINE AND ETHANOL AS DISCRIMINATIVE STIMULI: ABSENCE OF ANTAGONISM BY P-CHLOROPHENYLALANINE-METHYL-ESTER, CINANSENIN, OR BC-105.

000473 01-04

ACTIVATION OF AN IHHIBITORY NORADRENERGIC PATHWAY PROJECTING FROM THE LOCUS-COERULEUS TO THE CINGULATE CORTEX OF THE RAT. 002895 04-03

CIRCADIAN VARIATIONS IN RESPONSES TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT. 001288 02-03

CIRCADIAN VARIATION IN AN AMPHETAMINE-INDUCED MOTOR 001479 02-04

CIRCADIAN SUSCEPTIBILITY RHYTHM TO NEUROLEPTICS: TETRARENAZINE

002108 03-03 CIRCADIAN VARIATIONS IN RESPONSE TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT.

002182 03-03 CIRCADIAN RHYTHM OF LITHIUM TOXICITY IN MICE

O02344 03-05 CIRCADIAN SUSCEPTIBILITY RHYTHM TO APOMORPHINE IN THE BRAIN. 003311 04-04 CIRCADIAN RHYTHM DISORDERS IN MANIC-DEPRESSIVES

003505 04-09 CIRCLING BEHAVIOR AND STEREOTYPY INDUCED BY INTRANIGRAL OPIATE MICROINJECTIONS. 000385

000385 01-04 THE EFFECTS OF OXOTREMORINE AND PHYSOSTIGMINE ON MORPHINE INDUCED CIRCLING IN THE MOUSE.

PHARMACOLOGICAL INTERACTIONS WITH CIRCLING BEHAVIOUR INDUCED BY THE PIPERIDINYL INDOLE DERIVATIVE RU-23686 002200 03-04 COMPARATIVE EFFECTS OF PENFLURIDOL ON CIRCLING BEHAVIOR AND STRIATAL DOPAC AND SERUM PROLACTIN CONCENTRATIONS IN THE

THE EFFECTS OF HALOPERIDOL AND CLOZAPINE ON CIRCLING INDUCED BY ELECTRICAL STIMULATION OF THE SUBSTANTIA-NIGRA AND THE VENTROMEDIAL TEGMENTUM.

CIRCLING BEHAVIOUR IN THE RAT FOLLOWING UNILATERAL INJECTIONS OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE INTO THE SUBSTANTIA-NIGRA.

003375 04-04 CIRCULATION
CEREBRAL CIRCULATION IS ALTERED BY A POTENT ACTH4-9 ANALOG --

ORG-2766. THE ENTEROHEPATIC CIRCULATION OF OXAZEPAM-O-GLUCURONIDE IN

002820 04-03

HYPOTONIC CIRCULATORY DISORDERS UNDER
PSYCHOPHARMACOTHERAPY -- TREATMENT WITH 9ALPHAFLUOROHYDROCORTISONE.

002710 03-15

CIS-CLOPENTHIXOL
CIS-CLOPENTHIXOL AND CLOPENTHIXOL (SORDINOL) IN CHRONIC
PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL INVESTIGATION
002404

CIS-CLOPENTHIXOL-DECANOATE

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. A
STUDY WITH THE LONG-ACTING THIOXANTHENE DERIVATIVE, CISCLOPENTHIXOL-DECANOATE SORDINOL DEPOT.

003454 04-08

CISTERNAL SIMILAR EFFECTS OF TRYPTOPHAN AND SLEEP ON CISTERNAL CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC AND HOMOVANILLICACIDS IN CATS.

RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D AMPHETAMINE

002862 04-03

A NEW CLASS OF GABA-AGONIST.

000026 01-02 CENTRAL-NERVOUS-SYSTEM ACTIVITY OF A NOVEL CLASS OF ANNELATED 1,4 BENZODIAZEPINES, AMINOMETHYLENE-IMIDAZOBENZODIAZEPINONES.

001000 02-01 STEREOSPECIFIC AND NONSTEREOSPECIFIC EFFECTS OF ()- AN MORPHINE: EVIDENCE FOR A NEW CLASS OF RECEPTORS?

001031 02-02 1-3 PHENOTHIAZINYLPROPYL-PIPERIDINYLPHENYLMETHANONES, A NOVEL CLASS OF LONG-ACTING NEUROLEPTIC AGENTS.

001942 03-01 ANTIDEPRESSANT AGENTS. 9.3,3 DIPHENYLCYCLOBUTYLAMINES, A NEW CLASS OF CENTRAL STIMULANTS.

001943 03-01

OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINES IN L-DOPA TREATED PARKINSONIAN PATIENTS. 001994 03-03

OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINE ALKALOIDS IN L-DOPA TREATED PARKINSONIAN PATIENTS. 002655 03-15

MEDICATION CLASSES FOR THE EMOTIONALLY ILL.

000984 01-17 MULTIPLE CLASSES OF OPIATE RECEPTORS IN C57BL/6J AND DBA/2J MOUSE BRAIN.

001991 03-03 EFFECT OF AN ANTIPSYCHOTIC AND OTHER CLASSES OF DRUGS ON SPONTANEOUS LOCOMOTOR ACTIVITY AND NEUROTOXICITY IN MICE 002369 03-06

H3-SPIROPERIDOL BINDING AND DOPAMINE STIMULATED ADENYLATE-CYCLASE: EVIDENCE FOR MULTIPLE CLASSES OF RECEPTORS IN PRIMATE BRAIN REGIONS.

CLASSICAL
ANTAGONISM BY MIANSERIN AND CLASSICAL ALPHA-ADRENOCEPTOR
BLOCKING DRUGS OF SOME CARDIOVASCULAR AND BEHAVIORAL
EFFECTS OF CLONIDINE.
002138 03-

BENZAMIDES AND CLASSICAL NEUROLEPTICS: COMPARISON OF THEIR ACTIONS USING 6 APOMORPHINE-INDUCED EFFECTS. 003333 04-04

CLASSIFICATION AND DETERMINATION OF CEREBRAL BIOAVAILABILITY OF PSYCHOTROPIC DRUGS BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS (STUDIES WITH AX-A411-BS).

PSYCHOACTIVE DRUG RESPONDER SUBGROUPS -- POSSIBLE CONTRIBUTIONS TO PSYCHIATRIC CLASSIFICATION. (UNPUBLISHED

000968 01-17

CLASSROOM

THE EFFECTS OF AN ANTIPSYCHOTIC MEDICATION ON THE CLASSROOM BEHAVIOR OF FOUR SCHIZOPHRENIC MALE CHILDREN.

001568 02-08

BEHAVIOR OBSERVATIONS OF HYPERACTIVE CHILDREN AND METHYLPHENIDATE (RITALIN) EFFECTS IN SYSTEMATICALLY STRUCTURED CLASSROOM ENVIRONMENTS: NOW YOU SEE THEM, NOW YOU DONT.

003581 04-11

003019 04-03

LITHIUM ABSORPTION, DISTRIBUTION AND CLEARANCE AND BODY TEMPERATURE IN RATS GIVEN LITHIUM PLUS HALOPERIDOL. 000488 01-05

METHADONE MAINTENANCE: EFFECT OF URINARY PH ON RENAL CLEARANCE IN CHRONIC HIGH AND LOW DOSES.

000687 01-13 METABOLIC CLEARANCE RATE OF ADRENOCORTICOTROPIN IN THE RAT 002070 03-03

CLEARANCE AND ANALGESIC ACTIVITY OF THE QUATERNIZED OPIATE, N METHYLMORPHINE (6-H3) ADMINISTERED INTRACISTERNALLY TO THE

CLIMATIC

EFFECTIVENESS OF PSYCHOTROPIC DRUGS IN PATIENTS IN A STATE OF MALNUTRITION OR EXPOSED TO EXTREME CLIMATIC CONDITIONS.

A GRADUAL SCORE TO EVALUATE THE CLIMBING BEHAVIOUR ELICITED BY APOMORPHINE IN MICE. 002350 03-05

CLINIC

THE MEDICATION CLINIC IN THE SPECTRUM OF CHILDRENS SERVICES. 000955 01-17 CLINIC ATTENDANCE AND OPIATE PRESCRIPTION STATUS OF HEROIN

ADDICTS OVER A SIX-YEAR PERIOD. 000989 01-17

DRUG MONITORING AT AN AUSTRALIAN DEPOT PHENOTHIAZINE CLINIC 002402 03-08

CLINICAL

EFFECT OF CHLORDIAZEPOXIDE ADMINISTERED EARLY IN EXTINCTION ON SUBSEQUENT EXTINCTION OF A CONDITIONED EMOTIONAL RESPONSE IN RATS: IMPLICATIONS FOR HUMAN CLINICAL USE.

000022 01-02 **EVALUATION OF NALOXONE IN LABORATORY TESTS PREDICTIVE OF** CLINICAL ANTIPSYCHOTIC ACTIVITY

000029 01-02 A DOUBLE-BLIND CLINICAL TRIAL OF BUPROPION-HCL -- A NOVEL ANTIDEPRESSANT

000510 01-07 CLINICAL EXAMINATION OF THE NEW ANTIPSYCHOTIC CLOZAPINE

000514 01-07 CLINICAL AND EXPERIMENTAL EXPERIENCE WITH MAPROTILINE CLOMIPRAMINE, SYDNOCARB, AND MEFEXAMINE IN PSYCHIATRIC

PATIENTS AND NORMAL SUBJECTS 000517 01-07 BACLOFEN TREATMENT IN CHRONIC SCHIZOPHRENIA: A CLINICAL TRIAL

000521 01-08 SOME METHODOLOGICAL CONSIDERATIONS FOR THE CLINICAL **EVALUATION OF NEUROLEPTICS -- COMPARATIVE EFFECTS OF**

CLOZAPINE AND HALOPERIDOL ON SCHIZOPHRENICS. 000531 01-08 INHIBITION OF DOPAMINE SYNTHESIS IN CHRONIC SCHIZOPHRENIA

CLINICAL INEFFECTIVENESS OF METYROSINE. 000542 01-08 METHODOLOGICAL EXPERIENCE WITH A DOUBLE-BLIND MULTICENTRIC,

MONITORED CLINICAL TRIAL (MMCT) WITH SINTAMIL. 000568 01-09 WIN-27147-2 IN THE TREATMENT OF DEPRESSION: AN UNCONTROLLED

CLINICAL STUDY. 000577 01-09 MAO INHIBITORS IN CLINICAL PRACTICE: PRINCIPLES BASED ON RECENT

000578 01-09 ROLES OF MONOAMINES, PARTICULARLY DOPAMINE, IN CLINICAL DEPRESSION AND IN THE REGULATION OF MOOD.

000583 01-09 A COMPARATIVE CLINICAL STUDY FOR THE EVALUATION OF ANTIANXIETY AGENTS. (LORAZEPAM, DIAZEPAM AND PLACEBO), IN

000599 01-10 ANTIANXIETY DRUGS: CLINICAL PHARMACOLOGY AND THERAPEUTIC USE

000603 01-10

DOXEPIN IN THE TREATMENT OF NEUROSES: A COMPARATIVE CLINICAL STUDY OF DOXEPIN, CHLORDIAZEPOXIDE, HYDROXYZINE, MEPROBAMATE, AND PHENOBARBITAL.

A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY ON ANTIEPILEPTIC ACTIVITY OF CLONAZEPAM — RELATIONSHIP BETWEEN CLINICAL EFFECTS OF ORAL ADMINISTRATION AND ELECTROENCEPHALOGRAPHIC EFFECTS OF LINEAL ADMINISTRATION AND ELECTROENCEPHALOGRAPHIC EFFECTS OF INTRAVENOUS ADMINISTRATION

000639 01-11
REPORT FROM CLINICAL PRACTICE: THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG TREATMENT OF HYPERACTIVE CHILDREN. (LINPUBLISHED PAPER)

000656 01-11 LITHIUM TREATMENT OF HUNTINGTONS-CHOREA: A PLACEBO CONTROLLED CLINICAL TRIAL

CLINICAL EFFECTS OF TREATMENT WITH CHLORPROMAZINE AND THE PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS. 000670 01-11

PHENELZINE IN DEPRESSED PATIENTS: EFFECTS ON URINARY MHPG **EXCRETION IN RELATION TO CLINICAL RESPONSE**

000686 01-13 RATE OF ABSORPTION AND CLINICAL RESPONSE TO SINGLE ORAL DOSES OF CHLORDIAZEPOXIDE

000702 01-13 SALIVA LITHIUM LEVELS: CLINICAL APPLICATIONS.

II. CLINICAL ELECTROENCEPHALOGRAPHY AND ECHOENCEPHALOGRAPHY IN LONG-TERM HASHISH USERS

000723 01-13 CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND ITS METABOLITES AND CLINICAL RATINGS IN PATIENTS WITH ACUTE RELAPSE OF SCHIZOPHRENIC AND PARANOID PSYCHOSIS.

000726 01-13 CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO PSYCHOTROPIC DRUGS

000729 01-13 PILOT STUDY. THIORIDAZINE METABOLISM AND CLINICAL RESPONSE: A 000737 01-13

WITHDRAWAL FROM CANNABIS: LABORATORY TESTS AND CLINICAL **OBSERVATIONS**

000748 01-14 DRUG ANALYSIS IN THE OVERDOSED PATIENT: ITS APPLICATION TO CLINICAL TOXICOLOGY

000802 01-15 ACUTE HYPOKALEMIC MYOPATHY IN ALCOHOLISM: A CLINICAL ENTITY.
000888 01-15

CONTROLLING RATER SPECIFIC INTERFERENCE FACTORS IN CLINICAL TRIALS 000917 01-16

GENERAL METHODOLOGICAL PROBLEMS OF CLINICAL PSYCHOTROPIC DRUG TRIALS

000924 01-16 DIFFICULTIES ENCOUNTERED BY THE CLINICAL RESEARCHER IN PLANNING PSYCHOTROPIC DRUG TRIALS 000935 01-16

THE PLACEBO IN CLINICAL PSYCHOPHARMACOLOGY.

000942 01-17 CLINICAL RESEARCH TECHNIQUES IN TARDIVE-DYSKINESIA

000948 01-17 EXPERIENCE WITH A CLINICAL PHARMACOLOGICAL SERVICE IN A TEACHING HOSPITAL.

000957 01-17 THE USE OF PROLACTIN RESPONSE IN CLINICAL PSYCHOPHARMACOLOGY

000980 01-17 CLINICAL IMPLICATIONS OF BENZODIAZEPINE PHARMACOKINETICS 000985 01-17

S ADENOSYL-L-METHIONINE (SAME) TREATMENT IN GERONTOPSYCHIATRY: A CONTROLLED CLINICAL STUDY IN DEPRESSED AGED PATIENTS 001045 02-03

DIFFERENTIAL ATTENUATION BY ATROPINE AND D AMPHETAMINE ON HYPERACTIVITY: POSSIBLE CLINICAL IMPLICATIONS

001347 02-04 ARGININE-PYROGLUTAMATE (G-278): A CLINICAL EXPERIMENT. 001546 02-07

FLUVOXAMINE (DU-23001), A NEW ANTIDEPRESSANT. QUANTITATIVE PHARMACO-ELECTROENCEPHALOGRAPHY AND PILOT CLINICAL TRIALS. 001548 02-07

RELATIONSHIPS BETWEEN CLINICAL AND BIOCHEMICAL EFFECTS OF MELPERONE AND THIOTHIXENE IN PSYCHOTIC WOMEN 001557 02-08

THE PHARMACOKINETICS OF RED BLOOD CELL AND PLASMA BUTAPERAZINE CLINICAL RESPONSE AND SIDE-EFFECTS.

001561 02-08 LITHIUM: CLINICAL EFFECTS AND CEREBROSPINAL FLUID ACID MONOAMINE METABOLITES.

001577 02-09 CLINICAL AND PHARMACOKINETIC STUDY OF DIBENZEPINE (ECATRIL): COMPARISON BETWEEN THE NORMAL AND RETARD FORMS. 001581 02-09

ubject index		Psychopharmacology	Abstracts
AMITRIPTYLINE PLASMA LEVELS AND CLINICAL	RESPONSE IN PRIMARY	CLINICAL TRIAL OF FLUVOXAMINE: A NEW SEROTONERGI	c
DEPRESSION. A DOUBLE-BLIND CLINICAL COMPARISON OF AN	MOXAPINE, IMIPRAMINE,	CLINICAL EXPERIENCE IN THE TREATMENT OF OBSESSIONA	002470 03-09 AL STATES (1).
AND PLACEBO IN THE TREATMENT OF DEPRE	SSION. 001609 02-09	CLINICAL EXPERIENCE IN THE TREATMENT OF PHOBIC DISC	002477 03-10 ORDERS.
CLINICAL REPORT OF THE DRUG TRANXENE (CLI DIPOTASSIUM).	ORAZEPATE-	CLINICAL EXPERIENCE IN THE TREATMENT OF OBSESSIONA	
CLINICAL PHARMACOLOGY OF PHENCYCLIDINE		A PRELIMINARY REPORT ON CLINICAL RESPONSE AND PL	002489 03-10 ASMA LEVELS
CLINICAL STUDIES WITH MAPROTILINE AND THE CATECHOLAMINE HYPOTHESIS OF DEPRESSIO		OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN COMPULSIVE NEUROSIS.	002493 03-10
CLINICAL PHARMACOKINETICS OF LORAZEPAM INJECTION. PRELIMINARY RESULTS.	001642 02-13	A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF LOX. DIAZEPAM, AND PLACEBO IN HOSPITALIZED PATIENTS STATES OF ANXIETY.	APINE,
CLINICAL PHARMACOKINETICS OF LORAZEPAM ADMINISTRATION	001662 02-13 I. IV. LONG-TERM ORAL	A CLINICAL TRIAL OF CLOMIPRAMINE AND DIAZEPAM IN TREATMENT OF PHOBIC AND OBSESSIONAL ILLNESS.	002496 03-10 THE
CLINICAL BIOCHEMICAL ASSESSMENT OF DRUG (UNPUBLISHED PAPER).	001664 02-13 ACTION IN PATIENTS. 001668 02-13	CLINICAL AND BIOCHEMICAL EFFECTS OF CHLORPROMAZIN PSYCHOTIC PATIENTS: RELATIONS TO CHLORPROMAZIN CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FL	NE
NALOXONE (NARCAN) TREATMENT IN DEPRESS OBSERVATIONS AND EFFECTS ON CSF ENDOR	ION: CLINICAL	COCAINE IN CLINICAL MEDICINE.	002538 03-11
METABOLITES. EVALUATION OF THE COMBINATION OF TRYPTO TREATMENT OF DEPRESSION: 1. CLINICAL AN		FLUNITRAZEPAM (ROHYPNOL) COMPARED WITH NITRAZE (MOGADON) AND APROBARBITAL AS EVENING PREME TO ANESTHESIA: A CONTROLLED CLINICAL TRIAL.	EPAM DICATION PRIOR
CLINICAL USE OF HALOPERIDOL (SERENACE) IN	001704 02-14	CLINICAL VALUE OF THE BRAINSTEM EVOKED RESPONSE	
ABOUT A NONFATAL MASSIVE INTOXICATION V		ANTIPSYCHOTIC DRUGS: CLINICAL PHARMACOLOGY AND USE. PART II.	
PHARMACOKINETICS AND CLINICAL EFFECTS OF INDUCED EXTRAPYRAMIDAL SYMPTOMS.	001752 02-15 FAMANTADINE IN DRUG-	CLINICAL LABORATORY STUDIES WITH SPECIAL REGARD 1 METABOLISM IN SCHIZOPHRENICS ON OUTPATIENT LOW NEUROLEPTIC MEDICATION.	
RELATIONSHIPS AMONG CLINICAL RESPONSE, E SYNDROME AND PLASMA CHLORPROMAZINI RATIOS.		EXTENSION OF ANIMAL MODELS TO CLINICAL EVALUATIO ANTIANXIETY AGENTS.	
PHARMACOLOGICAL, BIOCHEMICAL AND CLINIC DIMETHYLAMINOETHANOL (DEANOL): A CRIT		BI AND MULTIVARIATE ANALYSIS OF EEG DATA IN CLINIC PSYCHOPHARMACOLOGY.	
CLINICAL STUDY OF ANTIPARKINSON DRUGS US PSYCHOTROPIC DRUGS.	001928 02-17	COMPREHENSIVE CLINICAL STUDIES OF PSYCHOTROPIC DE	002756 03-17
ANIMAL TEST MODELS FOR PREDICTION OF CLIP	001936 02-17 NICAL ANTIDEPRESSANT	A COOPERATIVE CLINICAL STUDY OF METHADYL-ACETATE TIMES-A-WEEK REGIMEN.	002757 03-17
ACTIVITY. VILOXAZINE IN THE TREATMENT OF DEPRESSION MEASURES AND CLINICAL RESPONSE.	002372 03-06 N: PSYCHOPHYSICAL	CLINICAL EVALUATION OF NALTREXONE TREATMENT OF C DEPENDENT INDIVIDUALS: REPORT OF THE NATIONAL R COUNCIL COMMITTEE ON CLINICAL EVALUATION OF NA	OPIATE- RESEARCH
CLINICAL TRIAL OF BUPROPION-HCL IN TREATM	002375 03-07	ANTAGONISTS.	002768 03-17
CLINICAL AND BIOCHEMICAL CHANGES IN PSYC	002381 03-07	INTERNATIONAL GUIDELINES FOR CLINICAL TRIALS OF PSY DRUGS.	002769 03-17
WITH MELPERONE OR THIOTHIXENE. EFFECTS OF FLUPENTHIXOL ON THE CLINICAL ST.	002388 03-08	ANTAGONISM OF ETHANOL EVOKED RESPONSES BY AMA POSSIBLE CLINICAL APPLICATION.	NTADINE: A
SCHIZOPHRENICS.	002395 03-08	CLINICAL PARABLE: MIRTHLESS MERRY-GO-ROUND.	002797 04-02
CLINICAL AND PLASMA LEVEL CHARACTERISTIC AND ORAL LOXAPINE.	S OF INTRAMUSCULAR	BUTACLAMOL IN THE TREATMENT OF SCHIZOPHRENIA. A CONTROLLED CLINICAL TRIAL.	
NOMIFENSIN IN THE TREATMENT OF DEPRESSIO CONTROLLED CLINICAL STUDY.		A CONTROLLED CLINICAL STUDY OF TRAZODONE IN CHRO SCHIZOPHRENIC PATIENTS WITH PRONOUNCED DEPRES	
DOXEPIN AND IMIPRAMINE IN THE TREATMENT DOUBLE-BLIND CROSS-OVER CLINICAL STUDY	WITH EKG RECORDINGS.	SYMPTOMATOLOGY. CLINICAL CORRELATES OF LOW PLATELET MONOAMINE-O	003472 04-08 XIDASE IN
CLOMIPRAMINE PLASMA LEVEL AND CLINICAL	002416 03-09 RESPONSE. 002422 03-09	SCHIZOPHRENIC PATIENTS.	003477 04-08
A NEW ANTIDEPRESSANT BUTRIPTYLINE: PLAS/ RESPONSE.	MA LEVELS AND CLINICAL	CUNICAL STUDY OF MAPROTILINE IN THE TREATMENT OF CONDITIONS IN OUTPATIENT PRACTICE.	003479 04-09
AMITRIPTYLINE PLASMA CONCENTRATION AND WORLD HEALTH ORGANIZATION COLLABORA	ATIVE STUDY.	RELATIONSHIP BETWEEN SERUM CONCENTRATIONS OF TH AND ITS MAIN NONCONJUGATED METABOLITES AND T RESPONSE IN THIORIDAZINE TREATED PATIENTS.	HE CLINICAL
CLINICAL EVALUATION OF TRAZODON.	002426 03-09	CIS-CLOPENTHIXOL AND CLOPENTHIXOL (SORDINOL) IN CI	
CLINICAL EFFECTS AND PLASMA LEVELS OF CLO DEPRESSED BARBADIANS.	002427 03-09 DMIPRAMINE IN	PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL INVE	003496 04-09
CLINICAL RESPONSE IN DEPRESSED PATIENTS IN LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND	002449 03-09 N RELATION TO PLASMA D TYRAMINE PRESSOR	CLINICAL IMPORTANCE OF DOXEPIN ANTIDEPRESSANT PL TRICYCLIC ANTIDEPRESSANTS IN THE TREATMENT OF DEP DOUBLE-BLIND CLINICAL COMPARISON OF CLOMIPRAM	003497 04-09 PRESSIONS: A
RESPONSE.	002453 03-09	(ANAFRANIL) AND AMITRIPTYLINE.	003501 04-09
SEASON ASSESS CLIMICAL PROPERTY AND DILAMANA	COMMENCE AND ALLERS AND ADDRESS OF THE PARTY	at accompany and the property and the pr	

A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE (SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS

IMIPRAMINE: CLINICAL EFFECTS AND PHARMACOKINETIC VARIABILITY. 002460 03-09

(SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE

003508 04-09 A COMPARATIVE CLINICAL TRIAL OF MIANSERIN (NORVAL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION IN GENERAL

003514 04-09 CLINICAL CORRELATES OF TRICYCLIC ANTIDEPRESSANT MEDIATED INHIBITION OF PLATELET MONOAMINE-OXIDASE.

003524 04-09 ANTIDEPRESSANT DRUG LEVELS AND CLINICAL RESPONSE.

003545 04-10 EXPERIMENTAL AND CLINICAL EVIDENCE OF THE ANTIDEPRESSANT EFFECT OF A BETA-ADRENERGIC STIMULANT.

SODIUM VALPROATE IN THE TREATMENT OF INTRACTABLE SEIZURE DISORDERS: A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY 003550 04-11

MEDICATION IN RESIDENTIAL TREATMENT: ADMINISTRATION AND CLINICAL EXPERIENCES.

003561 04-11 TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDROME WITH EMD-21657. A DERIVATIVE OF A PYRITINOL METABOLITE: DOUBLE-BLIND CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STUDIES. 003571 04-11

THE PROLACTIN RESPONSE IN CLINICAL PSYCHIATRY 003597 04-13

PLASMA LEVELS OF NEUROLEPTICS VS CLINICAL RESPONSES 003601 04-13

CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED DOSES OF CHLORPROMAZINE

TRICYCLIC ANTIDEPRESSANTS: PLASMA LEVELS AND CLINICAL FINDINGS IN OVERDOSE

003643 04-15 VALIDITY AND CLINICAL UTILITY OF NEUROLEPTIC FACILITATED ELECTROPHICEPHALOGRAPHY IN PSYCHOTIC PATIENTS.

003669 04-15

CUNICALLY THE EFFECT OF ANTIPSYCHOTIC DRUGS AND THEIR CLINICALLY INACTIVE ANALOGS ON DOPAMINE METABOLISM. 001250 02-03

CLINICOTHERAPEUTIC GILLES-DE-LA-TOURETTE SYNDROME: A NEW CLINICOTHERAPEUTIC APPROACH

003532 04-09

A DOUBLE-BLIND CONTROLLED STUDY OF CLOBAZAM FOR THE TREATMENT OF ANXIETY IN PSYCHIATRIC OUTPATIENTS.

000508 01-07 EFFECT OF A NEW BENZODIAZEPINE DERIVATE, CLOBAZAM, IN ANXIOUS PATIENTS WITH GASTROINTESTINAL DISORDERS

000604 01-10

DEVELOPMENT

THE EFFECT OF CLOFIBRATE ON TOTAL AND FREE PLASMA TRYPTOPHAN IN DEPRESSED PATIENTS.

CLOMIPRAMINE CLINICAL AND EXPERIMENTAL EXPERIENCE WITH MAPROTILINE CLOMIPRAMINE, SYDNOCARB, AND MEFEXAMINE IN PSYCHIATRIC PATIENTS AND NORMAL SUBJECTS.

000517 01-07 PLASMA LEVELS DURING TREATMENT WITH IMIPRAMINE, CLOMIPRAMINE. AND IMIPRAMINE-N-OXIDE

000576 01-09 THE DEMETHYLATION OF IMIPRAMINE AND CLOMIPRAMINE AS APPARENT FROM THEIR PLASMA KINETICS

THE EFFECTS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE ON THE IN VITRO UPTAKE OF RADIOLABELLED 5-HT AND NORADRENALINE

INTO RAT BRAIN CORTICAL SLICES. 001257 02-03 THE EFFECT OF CLOMIPRAMINE AND OTHER AMINE UPTAKE INHIBITORS

ON MORPHINE ANALGESIA IN LABORATORY ANIMALS. 002072 03-03 EFFECTS OF CHRONIC IMIPRAMINE AND CLOMIPRAMINE ORAL ADMINISTRATION ON MATERNAL BEHAVIOR AND LITTER

002202 03-04 EFFECTS OF CLOMIPRAMINE AND OTHER INHIBITORS OF MONOAMINE UPTAKE ON THE SEXUAL BEHAVIOUR OF FEMALE RATS AND RHESUS MONKEYS.

THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORMONE FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MALE CLOMIPRAMINE PLASMA LEVEL AND CLINICAL RESPONSE.

002422 03-09 PLASMA LEVEL STUDIES OF CLOMIPRAMINE AND
DESMETHYLCLOMIPRAMINE FOLLOWING INTRAVENOUS INFUSIONS OF CLOMIPRAMINE IN DEPRESSIVE PATIENTS

002448 03-09 CLINICAL EFFECTS AND PLASMA LEVELS OF CLOMIPRAMINE IN DEPRESSED BARBADIANS

002449 03-09 CLOMIPRAMINE (ANAFRANIL) AND BEHAVIOUR THERAPY IN OBSESSIVE-COMPULSIVE AND PHOBIC DISORDERS

002473 03-10 TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH CLOMIPRAMINE (ANAFRANII)

002474 03-10 A LARGE OPEN MULTICENTRE TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE MANAGEMENT OF PHOBIC DISORDERS.

002475 03-10 AN UNCONTROLLED TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF PHOBIC AND OBSESSIONAL STATES IN GENERAL

002481 03-10 CLOMIPRAMINE (ANAFRANIL) IN DEPRESSIVE PATIENTS WITH OBSESSIVE NEUROSIS

A COMPARISON OF CLOMIPRAMINE HYDROCHLORIDE (ANAFRANIL) AND BEHAVIOUR THERAPY IN THE TREATMENT OF OBSESSIVE NEUROSIS

O02492 03-10

A PRELIMINARY REPORT ON CLINICAL RESPONSE AND PLASMA LEVELS
OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN OBSESSIVE-COMPULSIVE NEUROSIS.

002493 03-10 A CLINICAL TRIAL OF CLOMIPRAMINE AND DIAZEPAM IN THE TREATMENT OF PHOBIC AND OBSESSIONAL ILLNESS.

002497 03-10 STUDIES ON THE CONCOMITANT USE OF CARBAMAZEPINE AND CLOMIPRAMINE FOR THE RELIEF OF POSTHERPETIC NEURALGIA

002555 03-13 LUTEINIZING HORMONE RELEASING HORMONE AND THYROTROPIN-RELEASING HORMONE STIMULATION STUDIES IN PATIENTS GIVEN CLOMIPRAMINE OR DEPOT NEUROLEPTICS.

002563 03-13 PLASMA PROLACTIN CONCENTRATIONS IN NORMAL SUBJECTS AND DEPRESSIVE PATIENTS FOLLOWING ORAL CLOMIPRAMINE.

002567 03-13

PLASMA CONCENTRATIONS OF CLOMIPRAMINE AND ITS N DESMETHYL
METABOLITE IN DEPRESSIVE PATIENTS FOLLOWING TREATMENT WITH VARIOUS DOSAGE REGIMES OF CLOMIPRAMINE

002568 03-13 CLOMIPRAMINE AND SLEEP: A PRELIMINARY COMMUNICATION. 002571 03-13

THE IMPACT OF CLOMIPRAMINE AND ITS WITHDRAWAL ON SOME NOCTURNAL HORMONE PROFILES -- A PRELIMINARY REPORT.

002572 03-13
EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DEPRESSIVE PATIENTS RECEIVING CLOMIPRAMINE THERAPY

002577 03-13 SECOND-GENERATION ANTIDEPRESSANTS AS RESEARCH TOOLS -- SOME PRELIMINARY FINDINGS WITH CLOMIPRAMINE AND MAPROTILINE. 002587 03-13

CLOMIPRAMINE AND MAPROTILINE ON HUMAN PLATELET UPTAKE OF 5 HYDROXYTRYPTAMINE AND DOPAMINE IN VITRO: WHAT RELEVANCE TO THEIR ANTIDEPRESSIVE AND OTHER ACTIONS?

DIFFERENCES IN THE EFFECTS OF CLOMIPRAMINE ON ENGLISH AND ASIAN VOLUNTEERS. PRELIMINARY REPORT ON A PILOT STUDY.

A SIMPLE METHOD FOR THE DETERMINATION OF THERAPEUTIC LEVELS OF CLOMIPRAMINE, IMIPRAMINE AND DESIPRAMINE.

002717 03-16 A SPECIFIC RADIOIMMUNOASSAY PROCEDURE FOR PLASMA CLOMIPRAMINE

002723 03-16
BIOANALYSIS AND PHARMACOKINETICS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN MAN BY MEANS OF LIQUID CHROMATOGRAPHY

002728 03-16 TRICYCLIC ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CLINICAL COMPARISON OF CLOMIPRAMINE (ANAFRANIL) AND AMITRIPTYLINE.

003501 04-09 CLONAL NGF-INDUCED ALTERATIONS IN PROTEIN SECRETION AND SUBSTRATE ATTACHED MATERIAL OF A CLONAL NERVE CELL LINE

003607 04-13 CLONAZEPAM CONCENTRATION OF CLONAZEPAM IN SERUM AND CEREBROSPINAL FLUID OF THE SHEEP 000215 01-03 A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY ON ANTIEPILEPTIC ACTIVITY OF CLONAZEPAM — RELATIONSHIP BETWEEN CLINICAL EFFECTS OF ORAL ADMINISTRATION AND ELECTROENCEPHALOGRAPHIC EFFECTS OF INTRAVENOUS ADMINISTRATION.

000639 01-11

LACK OF EFFECT OF CLONAZEPAM ON SERUM LEVELS OF
DIPHENYLHYDANTOIN, PHENOBARBITAL AND CARBAMAZEPINI 000705 01-13
CLONAZEPAM AND 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONIC

001281 02-03

CLONAZEPAM AND DOPAMINE RELATED STEREOTYPED BEHAVIOR. CLONAZEPAM IN THE TREATMENT OF EPILEPSY IN HANDICAPPED PATIENTS

002503 03-11

CAN PHENYTOIN BE GRADUALLY WITHDRAWN IN PATIENTS WITH MAJOR MOTOR EPILEPSY MAINTAINED ON CLONAZEPAM AND PHENOBARBITAL?.

002504 03-11 THE STABILITY AND RELIABILITY OF RADIOIMMUNOASSAYS FOR CLONAZEPAM, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN BLOOD, SERUM OR PLASMA.

PHARMACOLOGIC RESPONSES OF CELLS OF A NEUROBLASTOMA-X GLIOMA HYBRID CLONE AND MODULATION OF SYNAPSES BETWEEN HYBRID CELLS AND MOUSE MYOTUBES. 002863 04-03

CLONIDINE

EFFECTS OF APOMORPHINE AND CLONIDINE ON RAT PLASMA GROWTH
HORMONE AFTER PRETREATMENT WITH RESERPINE AND
ELECTROCONVULSIVE SHOCKS.

000102 014

000102 01-03 INHIBITION OF THE CENTRAL HYPOTENSIVE EFFECT OF CLONIDINE BY TRAZODONE. A NOVEL ANTIDEPRESSANT.

000286 01-03 THE INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT BEHAVIOUR IN RODENTS.

CLONIDINE SELF-ADMINISTRATION IN THE RAT: A COMPARISON WITH FENTANYL SELF-ADMINISTRATION.

001462 02-04 HISTAMINE H2-RECEPTORS IN THE BRAIN AND SLEEP PRODUCED BY

INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS.

ANTAGONISM BY MIANSERIN AND CLASSICAL ALPHA-ADRENOCEPTOR BLOCKING DRUGS OF SOME CARDIOVASCULAR AND BEHAVIORAL EFFECTS OF CLONIDINE.

002138 03-03 EFFECTS OF CLONIDINE ON VULNERABILITY TO FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE VENTRICLE.

NEUROCHEMICAL AND BEHAVIORAL EFFECTS OF CLONIDINE AND RELATED IMIDAZOLINES: INTERACTION WITH ALPHA-ADRENOCEPTORS.

002156 03-03

PIPEROXANE REDUCES THE EFFECTS OF CLONIDINE ON AGGRESSION IN MICE AND ON NORADRENALINE DEPENDENT HYPERMOTILITY IN RATS. 002205 03-04

FACILITATION OF LORDOSIS BEHAVIOR BY CLONIDINE IN FEMALE **GUINEA-PIGS.** 002222 03-04

TOLERANCE AND DEPENDENCE AFTER CHRONIC ADMINISTRATION OF CLONIDINE TO THE RAT.

002283 03-04 INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A
METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS.

002801 04-02 CLONIDINE BLOCKS ACUTE OPIATE WITHDRAWAL SYMPTOMS 003628 04-14

CLONIDINE-INDUCED
CLONIDINE-INDUCED BODY TEMPERATURE CHANGES IN RATS WITH ANTERIOR OR POSTERIOR CORTICAL DAMAGE.

002959 04-03

CNS SITE OF CLONIDINE-INDUCED HYPOTENSION: A MICROIONTOPHORETIC STUDY OF BULBAR CARDIOVASCULAR NEURONS. 003086 04-03

CLOPENTHIXOL
CIS-CLOPENTHIXOL AND CLOPENTHIXOL (SORDINOL) IN CHRONIC
PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL INVESTIGATION 003496 04-09

EFFECT OF ANTACIDS ON ABSORPTION OF CLORAZEPATE.

001647 02-13 A CONTROLLED COMPARATIVE TRIAL OF CLORAZEPATE (TRANXENE) AND DIAZEPAM (VALIUM) FOR ANXIETY. 002476 03-10 CLORAZEPATE-DIPOTASSIUM
CLINICAL REPORT OF THE DRUG TRANXENE (CLORAZEPATE-DIPOTASSIUM).

001612 02-10 CLORGYLINE
INHIBITION OF MONOAMINE OXIDATION IN SUBFRACTIONS OF CRUDE
MITOCHONDRIA OF RAT BRAIN BY CLORGYLINE AND LILLY-51641.
003020 04-03

CLOTHIAPINE IN MANAGEMENT OF SCHIZOPHRENIA.

000522 01-08

CLOZAPINE

EFFECTS OF CLOZAPINE, CHLORPROMAZINE AND DIAZEPAM UPON
ADJUNCTIVE AND SCHEDULE-CONTROLLED BEHAVIORS.

000330 01-04 CAL EXAMINATION OF THE NEW ANTIPSYCHOTIC CLOZAPINE (LEPONEX)

000514 01-07 CLOZAPINE (LEPONEX) VS CHLORPROMAZINE (LARGACTIL) IN ACUTE SCHIZOPHRENIA (A DOUBLE-BLIND CONTROLLED STUDY).

000527 01-08 SOME METHODOLOGICAL CONSIDERATIONS FOR THE CLINICAL EVALUATION OF NEUROLEPTICS -- COMPARATIVE EFFECTS OF CLOZAPINE AND HALOPERIDOL ON SCHIZOPHRENICS.

000531 01-08 TREATMENT OF MANIC PSYCHOSIS WITH CLOZAPINE

EEG PROFILE AND BEHAVIORAL CHANGES AFTER A SINGLE DOSE OF CLOZAPINE IN NORMALS AND SCHIZOPHRENICS.

000787 01-14 DISTRIBUTION OF CLOZAPINE IN THE RAT: EVIDENCE FOR ACTIVE TRANSPORT IN LUNG.

001129 02-03 CLOZAPINE AND PHENOXYBENZAMINE (PBZ) ALTERATION OF CENTRAL PHENYLETHYLAMINE (PEA) TURNOVER.

001177 02-03 HALOPERIDOL AND CLOZAPINE: SPECIFICITY OF ACTION ON GABA IN THE NIGROSTRIATAL SYSTEM.

001184 02-03 CLOZAPINE INDUCES HYPERPHAGIA IN UNDEPRIVED RATS.

001301 02-04 A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE SHORT-TERM EFFECTS OF CLOZAPINE UPON SLEEP PARAMETERS OF NORMAL YOUNG

AGRANULOCYTOSIS IN PATIENTS TREATED WITH CLOZAPINE: A STUDY OF THE FINNISH EPIDEMIC.

001742 02-15 EFFECT OF CLOZAPINE ON THE SLEEP PATTERN IN THE RAT

ALTERATIONS OF CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC-ACID, AND TOTAL BLOOD SEROTONIN CONTENT DURING CLOZAPINE TREATMENT.

A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE LONG-TERM EFFECTS OF CLOZAPINE UPON SLEEP PATTERNS OF NORMAL YOUNG ADULTS

002640 03-14 CLOZAPINE IN TARDIVE-DYSKINESIA

CLOZAPINE CONCENTRATIONS IN BRAIN REGIONS: RELATIONSHIP TO DOPAMINE METABOLITE INCREASE.

THE EFFECTS OF HALOPERIDOL AND CLOZAPINE ON CIRCLING INDUCED BY ELECTRICAL STIMULATION OF THE SUBSTANTIA-NIGRA AND THE VENTROMEDIAL TEGMENTUM.

003343 04-04 TARDIVE-DYSKINESIA DURING AND FOLLOWING TREATMENT WITH HALOPERIDOL, HALOPERIDOL BIPERIDEN, THIORIDAZINE, AND

003656 04-15

CLOZAPINE-INDUCED
POSSIBLE SIGNIFICANCE OF CLOZAPINE-INDUCED INCREASE IN BRAIN
DOPAMINE. 000120 01-03

REVERSAL BY PHYSOSTIGMINE OF CLOZAPINE-INDUCED DELIRIUM 001828 02-15

LITHIUM PROPHYLAXIS FOR CHRONIC CLUSTER HEADACHE.

000641 01-11

STUDIES IN THE HETEROCYCLIC SERIES. XIII. NEW CNS DEPRESSANTS DERIVED FROM 1,9 DIAZAPHENOXAZINE AND TWO ISOMERIC TRIAZAPHENOTHIAZINE RING SYSTEMS. 000030 01-02

HIGH-AFFINITY BINDING OF H3-GLYCINE AND C14-BETA-ALANINE TO SYNAPTOSOMAL MITOCHONDRIAL FRACTIONS OF RAT CNS REGIONS; EFFECTS OF STRYCHNINE. 000211 01-03

USE OF DRL IN DIFFERENTIATING ANXIOLYTIC AND NEUROLEPTIC PROPERTIES OF CNS DRUGS.

000329 01-04

INTRAOCULAR PRESSURE LOWERING PROPERTIES OF ABBOTT-43981, A CANNABINOID DERIVED HETEROCYCLIC BENZOPYRAN WITH MINIMAL 001025 02-02 PHENYLETHYLAMINES AS MEDIATORS OF THE CNS EFFECTS OF

001199 02-03 ACUTE AND CHRONIC EFFECTS OF GENERAL CNS DEPRESSANTS ON SEVERAL BEHAVIORAL TESTS IN RATS.

001356 02-04 TOLERANCE AND CROSS-TOLERANCE TO CNS DEPRESSANTS AFTER CHRONIC PENTOBARBITAL

001442 02-04 BARBITAL-INDUCED TOLERANCE AND CROSS-TOLERANCE TO VARIOUS CNS DEPRESSANTS ON RAT OPERANT BEHAVIOR

001481 02-04 SUBSTANTIAL INCREASE IN THE LEVELS OF CHLOROPHENOXYACETIC-ACIDS IN THE CNS OF RATS AS A RESULT OF SEVERE INTOXICATION

001505 02-05 TRYPTOPHAN AND 5 HYDROXYINDOLES IN DIFFERENT CNS REGIONS FOLLOWING ACUTE MORPHINE.

002097 03-03 APPRAISAL OF THE EFFECT OF IV NICOTINE ON THE CNS.

002579 03-13 THE ACTION OF CNS DRUGS ON AN ISOLATED SYMPATHETIC NERVE PREPARATION OF RABBIT.

002869 04-03 EFFECTS OF PSYCHOTROPIC DRUGS ON DEAMINASE IN CNS

002904 04-03 NEONATAL SYSTEMIC 6 HYDROXYDOPAMINE AND DORSAL TEGMENTAL BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEPHRINE AND THE POSTDECAPITATION REFLEX.

003039 04-03 CNS SITE OF CLONIDINE-INDUCED HYPOTENSION: A MICROIONTOPHORETIC STUDY OF BULBAR CARDIOVASCULAR

NEURONS 003086 04-03

THE USE OF THE CNV (CONTINGENT NEGATIVE VARIATION) IN THE DETERMINATION OF RESIDUAL EFFECTS OF FIVE HYPNOTIC DRUGS 002713 03-16

MULTICLINIC CROSS-OVER COMPARISON OF TRIAZOLAM (HALCION) AND PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND

ANXIETY IN ANXIOUS OUTPATIENTS 000762 01-14

COCA

ARE YOU GOING TO LEARN TO CHEW COCA LIKE US?

000683 01-12 COCA PROPOSED AS PRESCRIPTION DRUG

003444 04-07 COCAINE EVIDENCE FOR MULTIPHASIC PRESYNAPTIC ADAPTATION: STUDIES WITH

COCAINE AND LITHIUM 000191 01-03 POTENTIATION BY COCAINE OF THE STIMULUS-INDUCED INCREASE IN

DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL SYNAPTOSOMES. 000217 01-03 EFFECTS OF AMPHETAMINE, METHYLPHENIDATE AND COCAINE ON SERUM PROLACTIN CONCENTRATIONS IN THE MALE RAT

000234 01-03 EFFECT OF COCAINE AND DESMETHYLIMIPRAMINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-5-HYDROXYTRYPTAMINE IN RAT **BRAIN SLICES**

000305 01-03 FIXED-INTERVAL RESPONDING UNDER SECOND-ORDER SCHEDULES OF FOOD PRESENTATION OR COCAINE INJECTION.

000391 01-04 POTENTIATION OF THE BEHAVIORAL AND CONVULSANT EFFECTS OF COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.

000458 01-04 DEVELOPMENT OF TOLERANCE TO THE DISRUPTIVE AFFECTS OF COCAINE ON REPEATED ACQUISITION AND PERFORMANCE OF RESPONSE **SEQUENCES**

000459 01-04 COMPETITIVE BINDING BETWEEN COCAINE AND VARIOUS DRUGS TO SYNTHETIC LEVODOPA MELANIN.

001051 02-03 PHYSIOLOGICAL EFFECTS OF COCAINE IN THE SQUIRREL-MONKEY 001136 02-03

COCAINE AND METABOLITES: RELATIONSHIP BETWEEN PHARMACOLOGICAL ACTIVITY AND INHIBITORY ACTION ON DOPAMINE UPTAKE INTO STRIATAL SYNAPTOSOMES.

001286 02-03 COMPARISON OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE AND AMPHETAMINE IN RATS

001337 02-04 COMPARISON OF THE CONVULSANT EFFECTS OF COCAINE AND PSEUDOCOCAINE IN THE RHESUS MONKEY.

001415 02-04

EFFECTS OF L-DOPA, D AMPHETAMINE AND COCAINE ON INTRUDER-EVOKED AGGRESSION IN RATS AND MICE.

DISCRETE-TRIAL CONTROL OF COCAINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF MORPHINE, NALOXONE, AND CHLORPROMAZINE

001469 02-04 EFFECTS OF COCAINE AND FENFLURAMINE ON PROGRESSIVE RATIO PERFORMANCE

DEVELOPMENT OF BEHAVIORAL TOLERANCE TO COCAINE.

001474 02-04 THE EFFECT OF COCAINE AND D AMPHETAMINE ON PUNISHED PESPONDING

001492 02-04 INTRAVENOUS COCAINE SELF-ADMINISTRATION IN THE RABBI 001528 02-06

VALUE OF COCAINE IN OPIATE CONTAINING ELIXIRS 001628 02-11 THE INFLUENCE OF COCAINE AND DESIPRAMINE ON THE CARDIAC

RESPONSES TO EXOGENOUS AND ENDOGENOUS NOREPINEPHRINE. 002077 03-03
ALTERATIONS OF EEG ACTIVITIES AND COCAINE-INDUCED CONVULSIONS FOLLOWING PROLONGED COCAINE TREATMENT IN THE RHESUS

BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE.

002224 03-04 D AMPHETAMINE EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D AMPHETAMINE
AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY
AND SHOCK AVOIDANCE IN RHESUS MONKEYS.

002251 03-04
INDUCED TOLERANCE TO THE DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE

002280 03-04 BEHAVIOR EFFECTS OF COCAINE IN ANIMALS

002333 03-04 INCREASED HALOPERIDOL-INDUCED CATALEPSY AFTER CHRONIC COCAINE TREATMENT

002341 03-05 COCAINE IN CLINICAL MEDICINE 002546 03-13

WHAT ARE THE EFFECTS OF COCAINE IN MAN?. 002549 03-13 COCAINE: THE MATERIAL

002559 03-13 COCAINE: RECREATIONAL USE AND INTOXICATION. 002594 03-13

COCAINE HALLUCINATIONS 002698 03-15

RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D

OO2862 04-03
COCAINE AND PSEUDOCOCAINE: COMPARATIVE EFFECTS ON ELECTRICAL AFTER-DISCHARGE IN THE LIMBIC SYSTEM OF CATS

CHOICE BEHAVIOR IN RHESUS MONKEYS: COCAINE VERSUS FOOD.
003155 04-04

THE DISCRIMINATIVE STIMULUS PROPERTIES OF INTRAVENOUSLY ADMINISTERED COCAINE IN RHESUS MONKEYS.

003160 04-04 DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE AND D AMPHETAMINE; AND ANTAGONISM BY HALOPERIDOL: A COMPARATIVE STUDY

003191 04-04 NEUROLEPTIC INTERFERENCE WITH THE COCAINE CUE: INTERNAL STIMULUS CONTROL OF BEHAVIOR AND PSYCHOSIS.

003193 04-04 COCAINE AS A DISCRIMINATIVE CUE IN RATS: INTERACTIONS WITH NEUROLEPTICS AND OTHER DRUGS.

COMPARATIVE EFFECTS OF COCAINE AND PSEUDOCOCAINE ON EEG ACTIVITIES, CARDIORESPIRATORY FUNCTIONS, AND SELF-ADMINISTRATION BEHAVIOR IN THE RHESUS MONKEY.

ACUTE AND CHRONIC EFFECTS OF COCAINE ON EXTINCTION-INDUCED AGGRESSION

003303 04-04 THE EFFECTS OF HALOPERIDOL ON DISCRIMINATIVE RESPONDING CONTROLLED BY THE COCAINE CUE

003318 04-04 BEHAVIOURAL AND NEUROCHEMICAL EFFECTS OF REPEATED ADMINISTRATION OF COCAINE IN RATS.

EFFECT OF CHRONIC COCAINE TREATMENT ON LIMITED ACCESS FOOD CONSUMPTION

COCAINE AS DISCRIMINATIVE STIMULUS FOR RESPONDING MAINTAINED BY FOOD IN SQUIRREL-MONKEYS. MORTALITY. COCAINE-INDUCED CENTRALLY MEDIATED RELEASE OF CATECHOLAMINES INTO BLOOD OF UNDISTURBED RATS. (UNPUBLISHED PAPER). TOLERANCE TO COCAINE-INDUCED CONVULSIONS IN THE CAT COCAINE-INDUCED CONDITIONED TASTE AVERSIONS IN RATS EFFECT OF A COCKTAIL ON DIAZEPAM ABSORPTION. CODEINE PREPARATION OF SPIN-LABELED OPIATES: MORPHINE AND CODEINE SIMULTANEOUS DETERMINATION OF CODEINE AND MORPHINE IN BIOLOGICAL SAMPLES BY GAS-CHROMATOGRAPHY WITH ELECTRON CAPTURE DETECTION COENZYME-A
COENZYME-A IS A PURINE NUCLEOTIDE MODULATOR OF ACETYLCHOLINE 002874 04-03 COERCIVE LSD IN A COERCIVE MILIEU THERAPY PROGRAM. 001631 02-12 HEADACHES AND COFFEE. 000873 01-15 COGNITIVE MEMORY AND COGNITIVE FUNCTION IN MAN: DOES THE CHOLINERGIC SYSTEM HAVE A SPECIFIC ROLE?. COGNITIVE AND PSYCHOPHYSIOLOGIC RESPONSE TO DOXEPIN AND CHLORDIAZEPOXIDE. METHYLPHENIDATE EFFECT ON ATTENTIONAL AND COGNITIVE BEHAVIOR IN SIX- THROUGH TWELVE-YEAR-OLD MALES.

THE EFFECTS OF DAILY COCAINE ADMINISTRATION ON COCAINE-INDUCED 003421 04-05 001079 02-03 ALTERATIONS OF EEG ACTIVITIES AND COCAINE-INDUCED CONVULSIONS FOLLOWING PROLONGED COCAINE TREATMENT IN THE RHESUS MONKEY. 002091 03-03 THE EFFECTS OF DAILY COCAINE ADMINISTRATION ON COCAINE-INDUCED 003421 04-05 ALPHA-BUNGAROTOXIN BLOCKS REVERSIBLY CHOLINERGIC INHIBITION IN THE COCHLEA. 002908 04-03 003596 04-13 000494 01-06
BINDING OF CODEINE, MORPHINE, AND METHADONE TO HUMAN SERUM 000706 01-13 001527 02-06 ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: INTERACTIVE EFFECTS ON HUMAN PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS. II. 000673 01-12 ACUTE EFFECTS OF CANNABIS ON COGNITIVE, PERCEPTUAL, AND MOTOR PERFORMANCE IN CHRONIC HASHISH USERS. 000759 01-14 000761 01-14 002457 03-09 002618 03-14 THE COMPARATIVE EFFICACY OF COGNITIVE THERAPY AND PHARMACOTHERAPY IN THE TREATMENT OF DEPRESSIONS 003701 04-17 DEPRESSION: MUST PHARMACOTHERAPY FAIL FOR COGNITIVE THERAPY TO SUCCEED?. 003726 04-17

HE EFFECT OF METHYLPHENIDATE ON TEST PERFORMANCE IN THE COGNITIVELY IMPAIRED AGED. 000622 01-11 COLCHICINE
COLCHICINE BLOCKS NEUROTROPIC REGULATION OF THE RESTING
MEMBRANE POTENTIAL IN REINNERVATING SKELETAL MUSCLE
00024 THE DECREASE OF MONOAMINE-OXIDASE ACTIVITY FOLLOWING THE INTRAOCULAR INJECTION OF COLCHICINE IN THE SUPERIOR COLLICULUS OF THE RAT. 003120 04-03 ENHANCEMENT BY CHOLINE OF THE INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE BY PHENOXYBENZAMINE, 6 HYDROXYDOPAMINE, INSULIN OR EXPOSURE TO COLD. 002167 03-03 EFFECT OF PSYCHOTROPIC AGENTS ON THE PHYSICAL PERFORMANCE CAPACITY OF ANIMALS EXPOSED TO HEAT AND COLD.

Psychopharmacology Abstracts DATA ANALYSIS: COLLABORATIVE OUTPATIENT SCHIZOPHRENIA STUDY 000528 01-08 **COLLABORATIVE STUDIES IN PRIVATE PRACTICE.** 000923 01-16 AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL EFFECT: A WORLD HEALTH ORGANIZATION COLLABORATIVE STUDY. 002426 03-09 EVALUATION OF A NEW IMMUNOASSAY FOR DETERMINATION OF PHENYTOIN AND PHENOBARBITAL: RESULTS OF A EUROPEAN COLLABORATIVE CONTROL STUDY. 002529 03-11 EVIDENCE FOR NOREPINEPHRINE MEDIATED COLLATERAL INHIBITION OF LOCUS-COERULEUS NEURONS. 000039 01-03 ANTIDROMICALLY IDENTIFIED SEROTONERGIC NEURONS IN THE RAT MIDBRAIN RAPHE: EVIDENCE FOR COLLATERAL INHIBITION. 000292 01-03 THE BIOCHEMISTRY OF BRAIN DEVELOPMENT AND MENTAL
RETARDATION: THE ELEVENTH BLAKE MARSH LECTURE DELIVERED
BEFORE THE ROYAL COLLEGE OF PSYCHIATRISTS, 7 FEBRUARY, 1977.
002000 03-03 COLLEGE SUPPRESSION BY NITROUS-OXIDE OF VISUAL RESPONSES IN THE CEREBELLAR VERMIS AND SUPERIOR COLLICULUS OF CATS ANESTHETIZED WITH CHLORALOSE. THE DECREASE OF MONOAMINE-OXIDASE ACTIVITY FOLLOWING THE INTRAOCULAR INJECTION OF COLCHICINE IN THE SUPERIOR COLLICULUS OF THE RAT. 003120 04-03 THE NEUROLOGICAL BASIS OF MOTOR ASYMMETRY FOLLOWING UNILATERAL NIGROSTRIATAL LESIONS IN THE RAT: THE EFFECT OF SECONDARY SUPERIOR COLLICULUS LESIONS. 003200 04-04 COLOMBIA
A NEW HALLUCINOGEN FROM ANDEAN COLOMBIA: IOCHROMAFUCHSIOIDES. 000983 01-17 COLON IRRITABLE COLON AND DEPRESSION. 003498 04-09 COLONIES A REFILLABLE SYSTEM FOR CONTINUOUS AMPHETAMINE ADMINISTRATION: EFFECTS UPON SOCIAL BEHAVIOR IN RAT 003215 04-04 LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR BLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE IN THE FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE 000619 01-11 THE EFFECTS OF FOUR ANTIHYPERTENSIVE AGENTS ON THE STROOP COLOUR WORD TEST IN NORMAL MALE VOLUNTEER SUBJECTS. 000771 01-14 COMA A SEVEN YEAR REVIEW OF COMA PATIENTS ADMITTED TO THE REGIONAL POISONING TREATMENT CENTRE, ROYAL INFIRMARY, EDINBURGH. 001821 02-15 CLINICAL VALUE OF THE BRAINSTEM EVOKED RESPONSE IN COMA. 002650 03-15 ALPHA AND BETA COMA IN DRUG INTOXICATION 002653 03-15 AMANITA MUSHROOM POISONING WITH RECOVERY FROM COMA: A CASE REPORT 002705 03-15 ANTICONVULSANT ACTIVITY OF PHENOBARBITAL AND PHENYTOIN IN COMBINATION. METABOLIC BASIS FOR THE SUPRA-ADDITIVE EFFECT OF THE ETHANOL DIAZEPAM COMBINATION IN MICE.

OXAZEPAM (ADUMBRAN): A DOUBLE-BLIND TRIAL WITH OPIPRAMOL (INSIDON) IN DEPRESSIVE SYNDROME. 000597 01-10 TREATMENT OF PARKINSONS DISEASE WITH THE COMBINATION L-DOPA/ L CARBIDOPA.

EXTRAPYRAMIDAL SIDE-EFFECTS OF METOCLOPRAMIDE (CERUCAL) USED IN COMBINATION WITH AN ANTIDEPRESSANT. 000832 01-15

002273 03-04

001813 02-15

002531 03-11

CARDIAC TOXICITY WITH THIORIDAZINE TRICYCLIC ANTIDEPRESSANT COMBINATION.

PHARMACOLOGICAL INVESTIGATIONS CONCERNING COMBINATION EFFECTS OF ALCOHOL AND OXAZEPAM IN THE REACTIVITY PATTERN. 000897 01-15

TRICYCLIC ANTIDEPRESSANT AND MONOAMINE-OXIDASE INHIBITOR

000976 01-17

EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 2. BIOCHEMICAL ANALYSIS. 001652 02-13

EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 1. CLINICAL ANALYSIS.

EFFECT OF HYPOCHOLESTEROLEMIC AGENTS ON CENTRAL-NERVOUS-SYSTEM CHOLESTEROL BIOSYNTHESIS. III. ZUCLOMIPHENE IN COMBINATION WITH AY9944 AND TRIPARANOL.

TRYPTOPHAN NICOTINAMIDE COMBINATION IN THE TREATMENT OF NEWLY ADMITTED DEPRESSED PATIENTS.

OXYPERTINE IN COMBINATION WITH IMIPRAMINE: A CONTROLLED

EFFECTS OF METHYLPHENIDATE ALONE AND IN COMBINATION WITH BEHAVIOR MODIFICATION PROCEDURES ON THE BEHAVIOR AND ACADEMIC PERFORMANCE OF HYPERACTIVE CHILDREN.

COMBINATIONS
SELECTED COMBINATIONS OF AMITRIPTYLINE AND ANTIPSYCHOTIC
DRUGS AND COMPLEX LEARNING.

DRUGS AND COMPLEX LEARNING.

002434 03-09
AN EXPERIMENTAL STUDY OF THE EFFECTS OF AMITRIPTYLINE
PERPHENAZINE AND AMITRIPTYLINE HALOPERIDOL COMBINATIONS ON
INTERPESONAL LEARNING.

002511 03-11
LITHIUM INTOXICATION MASKED BY NEUROLEPTIC DRUGS WHEN
LITHIUM DIURETIC COMBINATIONS ARE USED.

O02682 03-15
TERATOLOGICAL EVALUATION OF ETHANOL, PENTOBARBITAL, AND
COMBINATIONS OF THESE. IN THE RAT.

THE BEHAVIORAL EFFECTS OF D AMPHETAMINE AND CHLORPROMAZINE IN RATS, COMBINATIONS WITH ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE. (PH.D. DISSERTATION).

003278 04-04

EFFECTS OF CHLORDIAZEPOXIDE, AMITRIPTYLINE, IMIPRAMINE, AND
THEIR COMBINATIONS ON AVOIDANCE BEHAVIOUR IN MICE.
003352 04-04

PROFOUND HYPOTHERMIA ON COMBINED LITHIUM-CARBONATE AND

DIAZEPAM TREATMENT.

O00870 01-15

COMBINED EFFECT OF LITHIUM AND FLUPENTHIXOL ON STRIATAL

INTRAVENOUS COMBINED ADMINISTRATION OF CHLORIMIPRAMINE AND SULPIRIDE IN DEPRESSION.

ON LONG-TERM MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY: THE COMBINED ADMINISTRATION OF ANTIPARKINSONS DRUGS.

OO1865 02-16 COMBINED SEMINAR ON THE USE OF DRUGS IN RENAL FAILURE. 001902 02-17

COMBINED TRICYCLIC MAOI THERAPY FOR REFRACTORY DEPRESSION: A
REVIEW, WITH GUIDELINES FOR APPROPRIATE USAGE.
002437 03-05

O02437 03-09

COMBINED HALOPERIDOL AND LITHIUM-CARBONATE IN TREATING MANIC PATIENTS.

COMBINED TREATMENT WITH L-DOPA AND PARCOPAN IN PARKINSONS DISEASE.

MARIJUANA, ALCOHOL, AND COMBINED DRUG EFFECTS ON THE TIME COURSE OF GLARE RECOVERY.

COMBINED EFFECTS OF ETHANOL AND DIAZEPAM ON PERFORMANCE AND ACQUISITION OF SERIAL POSITION SEQUENCES BY PIGEONS.

A CASE OF DEPRESSION SHOWING IMPROVEMENT IN TRH TEST BY COMBINED TREATMENT BY DIMETACRINE-TARTRATE AND THYROID HORMONE.

TRICYCLIC OVERDOSE IN A PATIENT GIVEN COMBINED TRICYCLIC MAOI TREATMENT.

STIMULUS PROPERTIES OF DOM: COMMONALITY WITH OTHER HALL LICENOGENS

003359 04-04

003640 04-14

COMMUNICATION

ON THE INFLUENCE OF MOBILETTEN ON THE EFFECT OF ALCOHOL IN THE HUMAN: SECOND COMMUNICATION: INFLUENCE ON THE EFFICIENCY UNDER ALCOHOL STRESS.

CLOMIPRAMINE AND SLEEP: A PRELIMINARY COMMUNICATION. 002571 03-13

DRUG THERAPY OF SCHIZOPHRENIAS IN THE COMMUNITY

THE CONTRIBUTION OF PRESCRIBED DRUGS TO THE INCIDENCE OF ACCIDENTAL AND DELIBERATE POISONING IN THE COMMUNITY. 001896 02-17

INITIAL RESPONSE TO DRUGS IN DEPRESSIVE ILLNESS AND PSYCHIATRIC
AND COMMUNITY ADJUSTMENT A YEAR LATER.

NEW APPROACH TO THE REHABILITATION OF THE HARD CORE DRUG ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY STUDY

COMPACTA

EFFECTS OF LERGOTRILE (LER), AN ERGOT DERIVATIVE, ON ACTIVITY OF
SUBSTANTIA-NIGRA PARS COMPACTA DOPAMINE (DA) NEURONS.
001278 02-03

COMPARABLE EFFICACY OF IMIPRAMINE HCL AND IMIPRAMINE-PAMOATE: A POOLED STATISTICAL REPORT.

003526 04-09

COMPARED
THE EFFECT OF MELPERONE (BURONIL(R)) AND ITS METABOLITE FG-5155
ON THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM COMPARED TO SOME

OTHER NEUROLEPTICS.

001081 02-03
PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. II.

TOLERANCE CHARACTERISTICS.

O01972 03-03

THE ROLE OF DIAZEPAM AS COMPARED TO GAMMA-AMINOBUTYRICACID (GABA) IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF
THE CAT. (PH.D. DISSERTATION).

STIMULUS PROPERTIES OF D AMPHETAMINE AS COMPARED TO L

PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL.
IV. INFLUENCE OF ELIMINATION KINETICS.

O02198 03-04
PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL.
III. WITHDRAWAL CHARACTERISTICS.

O02199 03-04
THE REINFORCING PROPERTIES OF PROCAINE AND D AMPHETAMINE
COMPARED IN RHESUS MONKEYS.

002239 03-04
PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. I.
CHRONICALLY EQUIVALENT DOSING METHOD.

O02360 03-06
FLUNITRAZEPAM (ROHYPNOL) COMPARED WITH NITRAZEPAM
(MOGADON) AND APROBARBITAL AS EVENING PREMEDICATION PRIOR
TO ANSTHESIA: A CONTROLLED CLINICAL TRIAL.

DIFFERENCES IN THE DOPAMINERGIC EFFECTS OF THE ERGOT
DERIVATIVES BROMOCRIPTINE, LISURIDE AND D LSD AS COMPARED
WITH APOMORPHINE

003244 04-04
DOUBLE-BLIND THERAPEUTIC EVALUATION OF FLUSPIRILENE COMPARED
WITH FLUPHENAZINE-DECANOATE IN CHRONIC SCHIZOPHRENICS.
003456 04-08

COMPARING
COMPARING TREATMENT TACTICS WITH A HYPERACTIVE PRESCHOOL
CHILD: STIMULANT MEDICATION AND PROGRAMMED TEACHER
INTERVENTION

THE TREATMENT OF DEPRESSION COMPARING DIVIDED AND SINGLE DOSES OF MAPROTILINE (LUDIOMIL).

O02467 03-09

A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE
(SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS
(SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH
SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE
AND NOTRIPTYLINE.

O03508 04-09

A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-DUMMY TECHNIQUE.

003537 04-10

COMPARISON

COMPARISON OF THYROTROPIN-RELEASING HORMONE WITH
MELANOCYTE-STIMULATING HORMONE RELEASE INHIBITING FACTOR
AS PENTOBARBITAL ANTAGONISTS IN MONKEYS.

000087 01-03

001787 02-15

- COMPARISON OF THE EFFECTS OF 6 CHLORO-2-AMINOTETRALIN AND OF ORG-6582, A RELATED CHLOROAMPHETAMINE ANALOG, ON BRAIN SEROTONIN METABOLISM IN RATS.
- A COMPARISON OF THE EFFECTS OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE STRIATUM, OLFACTORY TUBERCLE AND MEDIAN
- 000131 01-03 A COMPARISON IN RABBIT ISOLATED HEARTS OF THE DYSRHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE, MAPR AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK MAPROTILINE
- GABA-LIKE PROPERTIES OF FLURAZEPAM AND BACLOFEN SUGGESTED BY ROTATIONAL BEHAVIOUR FOLLOWING UNILATERAL INTRANIGRAL INJECTION: A COMPARISON WITH THE GABA-AGONIST MUSCIMOL.
- 000290 01-03 COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMOTOR ACTIVITY ANALGESIA AND PRIMARY AND PROTRACTED PHYSICAL DEPENDENCE IN SIX MOUSE STRAINS.
- 000323 01-04 COMPARISON OF THE REGULATION OF ROTATIONAL BEHAVIOR BY HYPOTHALAMIC OLIGOPEPTIDES.
- COMPARISON OF ETHANOL, PENTOBARBITAL, AND PHENOBARBITAL USING DRUG VS. DRUG DISCRIMINATION TRAINING.
- COMPARISON OF PIMOZIDE AND TRIFLUOPERAZINE AS ONCE-DAILY THERAPY IN CHRONIC SCHIZOPHRENIC OUTPATIENTS.
- CONTROLLED TRIAL OF A NEW ANTIDEPRESSIVE, AMOXAPINE, IN COMPARISON WITH AMITRIPTYLINE.
- 000555 01-09 PARENTERAL HALOPERIDOL IN PSYCHIATRIC EMERGENCIES: DOUBLE-BLIND COMPARISON WITH CHLORPROMAZINE.
- COMPARISON BETWEEN PLACEBO, PIZOTIFEN AND 1 ISOPROPYL-3-HYDROXY 5 SEMICARBAZONO-6-OXOTETRAHYDROINDOL (FIVASCAN) IN MIGRAINE PROPHYLAXIS.
- COMPARISON OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTICS IN GERIATRIC PATIENTS WITH INSOMNIA.
- SEDATIVE PROPERTIES OF DOXEPIN IN COMPARISON WITH DIAZEPAM
- 000703 01-13 MULTICLINIC CROSS-OVER COMPARISON OF TRIAZOLAM (HALCION) AND PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND ANXIETY IN ANXIOUS OUTPATIENTS.
- A COMPARISON OF PIRIBEDIL, PROCYCLIDINE AND PLACEBO IN THE CONTROL OF PHENOTHIAZINE-INDUCED PARKINSONISM.
- SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT AND NEWBORN RATS.
- A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHOXYAMPHETAMINE (DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), P-METHOXYAMPHETAMINE (PMA), D AMPHETAMINE (A), AND LSD IN MONTOLERANT AND LSD TOLERANT CHRONIC SPINAL DOGS.
- A COMPARISON OF THE EFFECTS OF INTRAVENTRICULAR MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON OPERANT BEHAVIOR IN
- 001323 02-04 COMPARISON OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE AND AMPHETAMINE IN RATS.
- 001337 02-04 A COMPARISON OF THALIDOMIDE AND PENTOBARBITAL METHODS FOR IDENTIFYING NOVEL HYPNOTIC DRUGS.
- 001359 02-04 COMPARISON OF THE CONVULSANT EFFECTS OF COCAINE AND PSEUDOCOCAINE IN THE RHESUS MONKEY.
- 001415 02-04 CLONIDINE SELF-ADMINISTRATION IN THE RAT: A COMPARISON WITH FENTANYL SELF-ADMINISTRATION.
- 001462 02-04 COMPARISON OF BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE AFTER FLUPHENAZINE-DIHYDROCHLORIDE AND FLUPHENAZINE-DECANOATE TREATMENT IN RATS.
- CLINICAL AND PHARMACOKINETIC STUDY OF DIBENZEPINE (ECATRIL)
 COMPARISON BETWEEN THE NORMAL AND RETARD FORMS.
- 001581 02-09 DOUBLE-BLIND PLACEBO-CONTROLLED COMPARISON OF AMOXAPINE AND IMIPRAMINE IN DEPRESSED OUTPATIENTS.
- 001585 02-09 A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF DOTHIEPIN AND ITS THERAPEUTIC EFFECTIVENESS.

- A DOUBLE-BLIND CLINICAL COMPARISON OF AMOXAPINE, IMIPRAMINE, AND PLACEBO IN THE TREATMENT OF DEPRESSION.
- 001609 02-09 PSYCHOTROPIC EFFECTS OF CARBAMAZEPINE IN EPILEPSY: A DOUBLE-BLIND COMPARISON WITH PHENYTOIN.
- 001706 02-14 EFFECTS OF TRITHIOZINE ON PSYCHOMOTOR SKILLS RELATED TO DRIVING: A COMPARISON WITH DIAZEPAM AND INTERACTIONS WITH ALCOHOL.
- COMPARISON OF THE EFFECTS OF NOCTRAN-10 ON HOSPITALIZED PATIENTS AND PATIENTS TREATED AT HOME.
- 001724 02-14 A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE
 DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON
 SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR
 PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION.
- CONTROLLED COMPARISON OF TRIFLUOPERAZINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY
- 001848 02-15 DESIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF DIVIDED VS SINGLE DOSE ADMINISTRATION.
- 001855 02-16 THE COMPARISON OF PSYCHOPHYSIOLOGICAL THERAPY WITH DRUG THERAPY
- 001882 02-17 RATIONALITY OF APPEALS USED IN THE PROMOTION OF PSYCHOTROPIC DRUGS. A COMPARISON OF MALE AND FEMALE MODELS.
- 001932 02-17 A COMPARISON OF FOOD INTAKE SUPPRESSION PRODUCED BY GIVING AMPHETAMINE AS AN AVERSION TREATMENT VERSUS AS AN ANOREXIC TREATMENT.
- 001981 03-03 IMPORTANCE OF DURATION OF DRUG ACTION IN THE ANTAGONISM OF P-CHLOROAMPHETAMINE DEPLETION OF BRAIN SEROTONIN --COMPARISON OF FLUOXETINE AND CHLORIMIPRAMINE
- NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: I. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY.
- 002096 03-03 COMPARISON OF THE EFFECTS OF METHAMPHETAMINE AND NEUROLEPTIC AGENTS ON TYROSINE-HYDROXYLASE ACTIVITY IN THE NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM.
- 002102 03-03 A PHARMACOLOGIC COMPARISON OF 3,4
 METHYLENEDIOXYAMPHETAMINE AND LSD IN THE CHRONIC SPINAL
- COMPARISON OF THE EFFECTS OF 5 HYDROXYTRYPTAMINE, DIMETHYLTRYPTAMINE, AND 5 METHOXY-DIMETHYLTRYPTAMINE ON RECTAL TEMPERATURE IN THE MOUSE.
- 002154 03-03 A COMPARISON OF THE EFFECTS OF SEIZURES AND TWO ANTICONVULSANT MEDICATIONS ON LEARNING IN THE PAPIO-PAPIO BABOON. (PH.D. DISSERTATION).
- 002329 03-04 A DOSE RATIO COMPARISON OF THE INTERACTION BETWEEN MORPHINE AND CYCLAZOCINE WITH NALOXONE IN RHESUS MONKEYS ON THE SHOCK TITRATION TASK.
- COMPARISON OF THE EFFECTS OF PIPOTHIAZINE-PALMITATE AND FLUPHENAZINE-DECANOATE IN A MULTICENTER DOUBLE-BLIND TRIAL
- 002412 03-08
- A COMPARISON OF DESIPRAMINE AND AMITRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE. 002417 03-09
- A COMPARISON OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE (1). 002428 03-09
- COMPARISON OF HIGH AND LOW DOSAGE REGIMES OF MAPROTILINE (LUDIOMIL). 002429 03-09
- COMPARISON OF MAPROTILINE (LUDIOMIL) AND SLOW-RELEASE AMITRIPTYLINE (TRYPTIZOL-SR)
- 002450 03-09 A COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE (2) 002452 03-09 A COMPARISON OF LUDIOMIL, TRYPTIZOL, AND LENTIZOL
- TRIMIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF SINGLE VS. DIVIDED DOSE ADMINISTRATION.
- A COMPARISON OF CLOMIPRAMINE HYDROCHLORIDE (ANAFRANIL) AND BEHAVIOUR THERAPY IN THE TREATMENT OF OBSESSIVE NEUROSIS.
- 002492 03-10 MAPROTILINE AND DOXEPIN IN THE TREATMENT OF DEPRESSION: A DOUBLE-BLIND MULTICENTRE COMPARISON.

COMPARISON OF TRIAZOLAM .25 MG AND FLURAZEPAM 15 MG IN TREATING GERIATRIC INSOMNIACS.

002524 03-11

A COMPARISON OF THE ANALGESIC EFFECT OF INTRAMUSCULAR NALBUPHINE AND MORPHINE IN PATIENTS WITH POSTOPERATIVE PAIN.

002607 03-14

DRUG UTILIZATION AND ADVERSE DRUG REACTIONS IN MEDICAL
PATIENTS: COMPARISON OF TWO PERIODS, 1969-72 AND 1973-76.
002684 03-15

A MODEL FOR EVALUATION OF ANTIANXIETY DRUGS WITH THE USE OF EXPERIMENTALLY-INDUCED STRESS: COMPARISON OF NABILONE AND DIAZEPAM.

002721 03-16
RADIOIMMUNOASSAYS FOR BETA-ENDORPHIN: COMPARISON OF PROPERTIES OF TWO ANTISERA.

002724 03-16
APPLICATION OF LIFE TABLE METHOD TO NATURALISTIC DESIGNS — A
COMPARISON OF EFFICACY OF TRICYCLIC ANTIDEPRESSANTS AND

BENZODIAZEPINES IN AMBULATORY DEPRESSIVES.

O02783 03-17

COMPARISON OF THE RESPONSES OF SINGLE CORTICAL NEURONES TO TYRAMINE AND NORADRENALINE. EFFECTS OF DESIPRAMINE.

A COMPARISON OF SOME PHARMACOLOGICAL ACTIONS OF MORPHINE AND DELTA9-TETRAHYDROCANNABINOL IN THE MOUSE.

002834 04-03
BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101
BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP
ACCUMULATION IN RAT CEREBRAL-CORTEX

002885 04-03

EPILEPTIC PROPERTIES OF LEUCINE-ENKEPHALIN AND METHIONINEENKEPHALIN: COMPARISON WITH MORPHINE AND REVERSIBILITY BY
NALOYOME

002916 04-03

A COMPARISON OF THE VASCULAR DOPAMINE RECEPTOR WITH OTHER DOPAMINE RECEPTORS.

O02927 04-03

A BEHAVIOURAL AND BIOCHEMICAL COMPARISON OF DOPAMINE
RECEPTOR BLOCKAGE PRODUCED BY HALOPERIDOL WITH THAT
PRODUCED BY SUBSTITUTED BENZAMIDE DRUGS.

O02963 04-03

A COMPARISON OF THE EFFECTS OF ANTIPSYCHOTIC DRUGS ON PITUITARY, STRIATAL AND LIMBIC SYSTEM POSTSYNAPTIC DOPAMINE RECEPTORS.

003009 04-03

NEONATAL SYSTEMIC 6 HYDROXYDDPAMINE AND DORSAL TEGMENTAL
BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEPHRINE
AND THE POSTDECAPITATION REFLEX.

O03039 04-03
IN VIVO COMPARISON OF THE RECEPTOR POPULATIONS ACTED UPON IN
THE SPINAL CORD BY MORPHINE AND PENTAPEPTIDES IN THE
PRODUCTION OF ANALGESIA.

O03143 04-03

A COMPARISON OF DISCRIMINATIVE STIMULI PRODUCED BY NALOXONE, CYCLAZOCINE AND MORPHINE IN THE RAT.

003270 04-04

COMPARISON OF THE BEHAVIORAL EFFECTS OF P-CHLOROAMPHETAMINE,
CHLORDIMEFORM, QUIPAZINE, AND INTRAVENTRICULAR SEROTONIN

003331 04-04
BENZAMIDES AND CLASSICAL NEUROLEPTICS: COMPARISON OF THEIR
ACTIONS USING 6 APOMORPHINE-INDUCED EFFECTS.

THE EFFECTS OF CHLORDIAZEPOXIDE ON A DELAYED PAIR COMPARISON

TASK IN PIGEONS.

003348 04-04

LACK OF BLOCKADE OF CENTRAL DOPAMINERGIC RECEPTORS BY

NARCOTICS: COMPARISON WITH CHLORPROMAZINE. 003354 04-04 LSD-INDUCED STIMULUS CONTROL: A COMPARISON OF SCH-12679,

FENFLURAMINE, P-METHOXYAMPHETAMINE, AND BL-3912.

003396 04-04

COMPARISON OF THE EFFECT OF SOME BENZODIAZEPINES WITH THE STAIRCASE METHOD.

COMPARISON OF THE ELECTROPHYSIOLOGICAL EFFECTS OF TWO

NEUROLEPTICS, MELPERONE AND THIORIDAZINE, ON ISOLATED RAT ATRIA.

003417 04-05

LONG-ACTING ORAL VS INJECTABLE ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENICS: A ONE-YEAR DOUBLE-BLIND COMPARISON IN MULTIPLE EPISODE SCHIZOPHRENICS.

A COMPARISON OF THE RELATIVE EFFICACY OF SERENACE AND CHLORPROMAZINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS. 003470 04-08

TRICYCLIC ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CLINICAL COMPARISON OF CLOMIPRAMINE (ANAFRANIL) AND AMITERPTYLINE

O03501 04-09

A DOUBLE-BLIND COMPARISON OF LEVODOPA, MADOPA, AND SINEMET IN PARKINSON DISEASE.

COMPARISON OF ORAL AND INTRAVENOUS METHYLPHENIDATE.

O03559 04-11
A COMPARISON OF THE EFFICACY AND ACCEPTABILITY OF TWO
FORMULATIONS OF INJECTABLE SERENACE IN THE TREATMENT OF
STATES OF EXCITEMENT

A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS. 003608 04-13

DELIRIUM-TREMENS: A DOUBLE-BLIND COMPARISON OF DIAZEPAM AND BARBITAL TREATMENT.

A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR. 003657 04-15

A PHARMACOLOGICAL AND THEORETICAL COMPARISON OF HIGH AND LOW POTENCY NEUROLEPTICS.

HOMOVANILLIC-ACID IN HUMAN CSF: COMPARISON OF FLUOROMETRY
AND GAS-CHROMATOGRAPHY MASS-SPECTROMETRY.

003691 04-16

A COMPARISON BETWEEN FLUOROMETRIC AND MASS FRAGMENTOGRAPHIC DETERMINATIONS OF HOMOVANILLIC-ACID AND 5 HYDROXYINDOLEACETIC-ACID IN HUMAN CEREBROSPINAL FLUID. 003694 04-16

THE EFFECTS OF OBSTETRICAL MEDICATION ON THE BEHAVIOR OF ISRAELI NEWBORN INFANTS AND SOME COMPARISONS WITH URUGUAYAN

AND AMERICAN INFANTS. 002673 03-15

OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF
REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR
OPERANT DRUG DISCRIMINATIONS.

003434 04-04

COMPARTMENTATION

CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. THE IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2-METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED ANALOGS OF METHAMPHETAMINE.

002141 03-03

EFFECTS OF SODIUM THIOPENTAL ON THE TRICARBOXYLIC-ACID CYCLE
METABOLISM IN MOUSE BRAIN: CO2 FIXATION AND METABOLIC
COMPARTMENTATION.

002860 04-03
METABOLISM OF GAMMA-HYDROXYBUTYRATE BY RAT BRAIN:
RELATIONSHIP TO THE KREBS-CYCLE AND METABOLIC
COMPARTMENTATION OF AMINO-ACIDS.

COMPENSATION

TOLERANCE TO THE BEHAVIOURAL EFFECTS OF PHYSOSTIGMINE IN RATS:
LACK OF IMPORTANCE OF BEHAVIOURAL COMPENSATION.

003326 04-04

COMPETITION
DIET AND UPTAKE OF ALDOMET BY THE BRAIN: COMPETITION WITH
NATURAL LARGE NEUTRAL AMINO-ACIDS.

001185 02-03
RATE-DEPENDENT EFFECTS OF AMPHETAMINE RESULTING FROM
BEHAVIORAL COMPETITION.

001368 02-04

EFFECTS OF DIAZEPAM AND D AMPHETAMINE ON FOOD COMPETITION IN
RHESUS MONKEY.

AGGRESSION INCREASE AND WATER COMPETITION DECREASE IN SQUIRREL-MONKEYS GIVEN PHYSOSTIGMINE INJECTIONS.

COMPETITIVE

COMPETITIVE BINDING BETWEEN COCAINE AND VARIOUS DRUGS TO

SYNTHETIC LEVODOPA MELANIN.

DEMONSTRATION OF AN ENDOGENOUS, COMPETITIVE INHIBITOR(S) OF H3-DIAZEPAM BINDING IN BOVINE BRAIN.

STUDIES ON DIGITAL PLETHYSMOGRAPHIC PATTERNS IN FEMALE PATIENTS WITH NONSPECIFIC COMPLAINTS.

000626 01-11

THE EFFECTS OF PHENOTHIAZINES ON COMPLEX LEARNING

000767 01-14 IN VITRO EFFECTS OF CHLORPROMAZINE ON MICROTUBULES AND THE GOLGI COMPLEX IN EMBRYONIC CHICK SPINAL GANGLION CELLS: AN ELECTRON MICROSCOPIC STUDY.

SELECTED COMBINATIONS OF AMITRIPTYLINE AND ANTIPSYCHOTIC DRUGS AND COMPLEX LEARNING.

002434 03-09 A RELIABLE, FACIAL NOCICEPTION DEVICE FOR UNRESTRAINED, AWAKE ANIMALS: EFFECTS OF MORPHINE AND TRIGEMINAL COMPLEX LESIONS.

THE EFFECTS OF APPROPRIATENESS OF ATTRIBUTED AROUSAL SOURCE AND TEST ANXIETY ON COMPLEX TEST PERFORMANCE AND REPORTED ANXIETY DURING TEST-TAKING. (PH.D. DISSERTATION).

COMPLIANCE
SOME OBSERVATIONS ON PATIENT COMPLIANCE IN AN ANTIDEPRESSIVE 002469 03-09

DRUG THERAPY: ALLIANCE AND COMPLIANCE.

002749 03-17

002888 04-03

002592 03-13

FACTORS INFLUENCING WILLINGNESS TO COMPLY AND ACTUAL COMPLIANCE WITH MEDICATION REGIMENS. (PH.D. DISSERTATION) 003722 04-17

HYPERTHYROIDISM AND A PARATHYROID ADENOMA COMPLICATING LITHIUM TREATMENT.

002686 03-15 HYPEROSMOLALITY COMPLICATING RECOVERY FROM LITHIUM TOXICITY.
003665 04-15

CATATONIA AND MALIGNANT SYNDROME: A POSSIBLE COMPLICATION OF NEUROLEPTIC ADMINISTRATION, REPORT OF A CASE INVOLVING

000910 01-15

RELATIONSHIP BETWEEN PHYSICAL FINDINGS AND RELATED SUBJECTIVE SYMPTOMS IN NEUROPSYCHIATRIC PATIENTS WITH SOMATIC COMPLICATIONS — WITH SPECIAL REFERENCE TO OPHTHALMOLOGIC 001678 02-13

RESPIRATORY COMPLICATIONS IN PATIENTS WITH INTOXICATION. 001767 02-15 IATROGENIC COMPLICATIONS OF DRUG OVERDOSAGE AND POISONING 001824 02-15

FACTORS INFLUENCING WILLINGNESS TO COMPLY AND ACTUAL COMPLIANCE WITH MEDICATION REGIMENS. (PH.D. DISSERTATION) 003722 04-17

COMPOSITION

THE EFFECT OF PHENOBARBITAL AND CARBON-TETRACHLORIDE ON FATTY-ACID CONTENT AND COMPOSITION OF PHOSPHOLIPIDS FROM THE ENDOPLASMIC RETICULUM OF RAT LIVER.

COMPREHENSIVE CLINICAL STUDIES OF PSYCHOTROPIC DRUGS 002756 03-17

COMPULSIONS, AGGRESSION, AND SELF-MUTILATION: A HYPOTHALAMIC DISORDER?

003641 04-14

MODULATION OF DEXAMPHETAMINE-INDUCED COMPULSIVE GNAWING INCLUDING THE POSSIBLE INVOLVEMENT OF PRESYNAPTIC ALPHA-ADRENORECEPTORS. 002322 03-04

COMPUTER OCULOGRAPHIC DOUBLE-BLIND STUDY OF CHANGES IN VIGILANCE: ALPRENOLOL VERSUS DIAZEPAM.

001746 02-15 COMPUTER SIMULATION OF THE MOVEMENT OF LITHIUM ACROSS ERYTHROCYTE MEMBRANES IN VITRO.

001869 02-16 DEVELOPMENT OF AN ALCOHOL-BLOCKER, USING COMPUTER ANALYZED

002564 03-13 AN EEG COMPUTER ANALYSIS OF CHLORPROMAZINE EFFECTS IN PSYCHOTIC SUBJECTS.

COMPUTERIZED

RAPID IDENTIFICATION OF HYPNOTICS IN EMERGENCY CASES BY COMPUTERIZED GAS-CHROMATOGRAPHY MASS SPECTROMETRY 001841 02-15

EVALUATION OF LOXAPINE HYDROCHLORIDE ORAL CONCENTRATE (LOXITANE C) IN ACUTE SCHIZOPHRENIA. 002411 03-08

CONCENTEATION
LOWERING OF EPINEPHRINE CONCENTRATION IN RAT BRAIN BY 2,3
DICHLORO-ALPHA-METHYL-BENZYLAMINE, AN INHIBITOR OF
NOREPINEPHRINE-N-METHYLTRANSFERASE.

000112 000112 01-03

BIPHASIC EFFECTS OF M CHLOROPHENYL-PIPERAZINE IN 3,4
DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN RAT BRAIN 000113 01-03

CONCENTRATION OF CLONAZEPAM IN SERUM AND CEREBROSPINAL FLUID OF THE SHEEP.

THE EFFECT OF L TRYPTOPHAN ADMINISTRATION ON THE CONCENTRATION OF PROBENECID IN PLASMA AND CEREBROSPINAL FLUID IN PATIENTS.

000564 01-09 ASMA CONCENTRATION AND THE ANTIDEPRESSANT EFFECT OF IMPRAMINE TREATMENT.

000567 01-09 THE RELATIONSHIP BETWEEN EXTRACELLULAR AND INTRACELLULAR LITHIUM CONCENTRATION IN HUMAN RED BLOOD CELLS: AN IN VITRO

THE INCREASE IN S ADENOSYL-L-METHIONINE (SAME) CONCENTRATION IN RAT BRAIN AFTER ITS SYSTEMATIC ADMINISTRATION.

001253 02-03 DEPENDENCE OF THE INFLUENCE OF EPINEPHRINE ON THE EXCITABILITY OF GIANT NEURONS ON ITS CONCENTRATION.

TIME-COURSE OF AUDIOGENIC SEIZURE SUSCEPTIBILITY AND PLASMA PENTOBARBITAL CONCENTRATION DURING WITHDRAWAL.

001977 03-03 POSSIBLE CENTRAL DOPAMINERGIC MODULATION OF THE RISE IN PLASMA CONCENTRATION OF NONESTERIFIED FATTY-ACIDS PRODUCED IN THE MOUSE BY (-)TRANS DELTA9-TETRAHYDROCANNABINOL.

002085 03-03 AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL EFFECT: A WORLD HEALTH ORGANIZATION COLLABORATIVE STUDY.

002426 03-09 EFFECT OF THIORIDAZINE (MELLARIL-SANDOZ) ON PSYCHOMOTOR FUNCTION, CONCENTRATION, AND REACTIVITY IN CHILDREN WITH BEHAVIOR DISORDERS.

002527 03-11 COMPARATIVE EFFECTS OF PEMOLINE, AMFONELIC-ACID AND
AMPHETAMINE ON DOPAMINE UPTAKE AND RELEASE IN VITRO AND
ON BRAIN 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN SPIPERONE-TREATED RATS.

NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND L-DOPA TO RATS.

PHENOBARBITAL EFFECT ON GLIAL CELL RESPIRATION IN THE PRESENCE OF A HIGH CONCENTRATION OF POTASSIUM.

REGIONAL CHANGES IN CEREBRAL GABA CONCENTRATION AND CONVULSIONS PRODUCED BY D AND BY L ALLYLGLYCINE.

002954 04-03 EXPERIMENTAL LEAD ENCEPHALOPATHY IN THE SUCKLING RAT: CONCENTRATION OF LEAD IN CELLULAR FRACTIONS ENRICHED IN BRAIN CAPILLARIES.

003420 04-05 LITHIUM NEUROTOXICITY. I. THE CONCENTRATION OF LITHIUM IN DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS ATOMIC ABSORPTION SPECTROPHOTOMETRY.

003432 04-06 PLASMA RENIN CONCENTRATION DURING LITHIUM THERAPY

003503 04-09 PREDICTION OF STEADY-STATE PLASMA CONCENTRATION OF IMIPRAMINE

003516 04-09 BINDING OF PHENYTOIN, L TRYPTOPHAN AND O METHYL-RED TO ALBUMIN. UNEXPECTED EFFECT OF ALBUMIN CONCENTRATION ON THE BINDING OF PHENYTOIN AND L TRYPTOPHAN. 003588 04-13

DRUGS ALTERING INSULIN SECRETION: EFFECTS ON PLASMA AND BRAIN CONCENTRATIONS OF AROMATIC-AMINO-ACIDS AND ON BRAIN 5 HYDROXYTRYPTAMINE TURNOVER.

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON BODY
TEMPERATURE AND BRAIN AMINE CONCENTRATIONS IN THE RAT AT
DIFFERENT AMBIENT TEMPERATURES.

RELATIVE CONCENTRATIONS OF ZWITTERIONIC AND UNCHARGED SPECIES IN CATECHOLAMINES AND THE EFFECT OF N SUBSTITUENTS.

000117 01-03 ROLE OF LIVER CYTOSOLIC ALDEHYDE-DEHYDROGENASE ISOZYMES IN CONTROL OF BLOOD ACETALDEHYDE CONCENTRATIONS.

000222 01-03

EFFECTS OF AMPHETAMINE, METHYLPHENIDATE AND COCAINE ON SERUM PROLACTIN CONCENTRATIONS IN THE MALE RAT.

000234 01-03 THE EFFECTS OF ETHER STRESS AND BETAMETHASONE TREATMENT ON THE CONCENTRATIONS OF NORADRENALINE AND DOPAMINE IN VARIOUS REGIONS OF THE RAT BRAIN.

EFFECT OF CHLORPROMAZINE ON CENTRAL-NERVOUS-SYSTEM CONCENTRATIONS OF MANGANESE, IRON, AND COPPER

000295 01-03
PLASMA CONCENTRATIONS AND CARDIOTOXIC EFFECTS OF DESIPRAMINE AND PROTRIPTYLINE IN THE RAT.

000478 01-05 PLASMA CONCENTRATIONS OF PERPHENAZINE AND ITS SULPHOXIDE METABOLITE DURING CONTINUOUS ORAL TREATMENT.

000631 01-11 PLASMA ANTICONVULSANT CONCENTRATIONS DURING PREGNANCY. 000642 01-11

CATECHOLAMINE AND OCTOPAMINE CONCENTRATIONS IN BRAINS OF PATIENTS WITH REYE SYNDROME 000712 01-13

PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS 000742 01-13

THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS.

001150 02-03 PLASMA CONCENTRATIONS OF SOME ACIDIC AND ALCOHOLIC METABOLITES DERIVED FROM M- AND P-TYRAMINE, OCTOPAMINE AND CATECHOLAMINES IN HUMANS 001158 02-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON SERUM THYROXINE CONCENTRATIONS IN THE RAT. 001204 02-03

COMPARATIVE BRAIN/PLASMA CONCENTRATIONS OF AMPHETAMINE ISOMERS IN MICE.

EFFECTS THE HYPNOTICS AND ANTIANXIETY DRUGS ON ACETYLCHOLINE (ACH) CONCENTRATIONS IN DISCRETE AREAS OF THE RAT BRAIN. 001239 02-03

AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOUR AND BRAIN CONCENTRATIONS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN MICE

001316 02-04 THE METABOLISM AND PLASMA CONCENTRATIONS OF L-ALPHA-ACETYLMETHADOL AND ITS METABOLITES IN MAN. (PH.D.

FACTORS INFLUENCING BLOOD CONCENTRATIONS OF CHLORDIAZEPOXIDE: A USE OF MULTIPLE REGRESSION ANALYSIS.

STEADY-STATE SERUM CONCENTRATIONS OF DOTHIEPIN AND NORTHIADEN AFTER TWO DOSAGE REGIMENS OF DOTHIEPIN

HYDROCHLORIDE (PROTHIADEN). 001675 02-13 THE EFFECTS OF ETORPHINE, FENTANYL AND MORPHINE ON

NORADRENALINE AND DOPAMINE CONCENTRATIONS IN THE STRIATUM OF RAT 002321 03-04

CLINICAL AND BIOCHEMICAL EFFECTS OF CHLORPROMAZINE IN PSYCHOTIC PATIENTS: RELATIONS TO CHLORPROMAZINE CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID 002538 03-11

PLASMA PROLACTIN CONCENTRATIONS IN NORMAL SUBJECTS AND DEPRESSIVE PATIENTS FOLLOWING ORAL CLOMIPRAMINE 002567 03-13

PLASMA CONCENTRATIONS OF CLOMIPRAMINE AND ITS N DESMETHYL METABOLITE IN DEPRESSIVE PATIENTS FOLLOWING TREATMENT WITH VARIOUS DOSAGE REGIMES OF CLOMIPRAMINE.

002568 03-13 **ELEVATED MELATONIN SERUM CONCENTRATIONS IN PSYCHIATRIC** PATIENTS TREATED WITH CHLORPROMAZINE.

002595 03-13 COMPARATIVE EFFECTS OF PENFLURIDOL ON CIRCLING BEHAVIOR AND STRIATAL DOPAC AND SERUM PROLACTIN CONCENTRATIONS IN THE

THE ANTAGONISM OF THE ANALGESIC EFFECT OF DIPYRONE BY L-DOPA AND ITS RELATION TO BRAIN AMINE CONCENTRATIONS.

002977 04-03 CHANGES IN BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS FOLLOWING ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION AND DURING POST AMPHETAMINE DEPRESSION.

002992 04-03 REGIONAL CHANGES IN THE CONCENTRATIONS OF CEREBRAL MONOAMINES AND THEIR METABOLITES AFTER ETHANOLAMINE-O-SULPHATE-INDUCED ELEVATION OF BRAIN GAMMA-AMINOBUTYRIC-003053 04-03 CLOZAPINE CONCENTRATIONS IN BRAIN REGIONS: RELATIONSHIP TO DOPAMINE METABOLITE INCREASE.

003139 04-03 BIMODAL DISTRIBUTIONS OF HIGHEST ETHANOL ACCEPTANCE CONCENTRATIONS IN TWO STRAINS OF RATS.

BEHAVIORAL CHANGES AND MERCURY CONCENTRATIONS IN TISSUES OF RATS EXPOSED TO MERCURY VAPOR.

RELATIONSHIP BETWEEN SERUM CONCENTRATIONS OF THIORIDAZINE
AND ITS MAIN NONCONJUGATED METABOLITES AND THE CLINICAL RESPONSE IN THIORIDAZINE TREATED PATIENTS

PLASMA FLUPHENAZINE CONCENTRATIONS AFTER INJECTION OF LONG **ACTING ESTERS**

CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA AND
CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED DOSES OF CHLORPROMAZINE 003614 04-13

CONCEPTS
CURRENT THERAPEUTIC CONCEPTS: CONTEMPORARY DRUGS IN THE MANAGEMENT OF ANXIETY.

TARDIVE-DYSKINESIA AND CHANGING CONCEPTS OF ANTIPSYCHOTIC DRUG USE: A NURSING PROSPECTIVE.

000919 01-16 AMINE NEUROTRANSMITTER STUDIES AND PSYCHIATRIC ILLNESS: TOWARD MORE MEANINGFUL DIAGNOSTIC CONCEPTS. (UNPUBLISHED

001893 02-17 CONCEPTUAL DEPRESSION IN CHILDHOOD: DIAGNOSIS, TREATMENT, AND CONCEPTUAL

MODELS. 000613 01-10

EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DEPRESSIVE PATIENTS RECEIVING CLOMIPRAMINE THERAPY.

CONDITIONED

EFFECT OF CHLORDIAZEPOXIDE ADMINISTERED EARLY IN EXTINCTION ON SUBSEQUENT EXTINCTION OF A CONDITIONED EMOTIONAL RESPONSE IN RATS: IMPLICATIONS FOR HUMAN CLINICAL USE.

THE EFFECT OF ANESTHESIA ON ACQUISITION AND EXTINCTION OF CONDITIONED TASTE AVERSION.

CONDITIONED TASTE AVERSION: A FIELD APPLICATION TO COYOTE

000354 01-04 FAILURE TO ELICIT CONDITIONED TASTE AVERSION BY SEVERE

000382 01-04

(-) HYDROXYCITRATE AND CONDITIONED AVERSIONS. 000428 01-04 THE EFFECTS OF PSYCHOTOMIMETIC DRUGS ON THE CONDITIONED

EMOTIONAL RESPONSE. 001308 02-04 INTRACEREBRAL NEUROTRANSMITTERS AND CONDITIONED REFLEX

PERFORMANCE 001343 02-04

GENERALIZATION OF THE CONDITIONED STIMULUS IN TASTE AVERSION. 001405 02-04 EFFECT OF PANAX GINSENG ROOT ON CONDITIONED AVOIDANCE RESPONSE IN RATS.

001451 02-04 EFFECT OF PSYCHOTROPIC DRUGS ON THE DEVELOPMENT OF DEFENSE CONDITIONED REFLEX DURING EXPERIMENTAL NEUROSIS

002204 03-04 EFFECT OF NEUROLEPTIC DRUGS ON THE CONDITIONED BEHAVIOR AFTER
PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLAL ANINE

002290 03-04 EFFECTS OF D AMPHETAMINE AND CHLORDIAZEPOXIDE ON POSITIVE CONDITIONED SUPPRESSION

002295 03-04
LESIONS OF THE DORSAL NORADRENERGIC PROJECTION ATTENUATE
MORPHINE-INDUCED BUT NOT AMPHETAMINE-INDUCED CONDITIONED TASTE AVERSION.

002299 03-04 CONDITIONED TASTE AVERSIONS: GENOTYPE BY OLFACTORY BUILBECTOMY INTERACTION.

DIFFERENTIAL EFFECTS ON CONDITIONED TASTE AVERSION LEARNING WITH PERIPHERALLY AND CENTRALLY ADMINISTERED ACETALDEHYDE. 003178 04-04

EFFECTS OF ATROPINE ON CONDITIONED TASTE AVERSION. 003209 04-04

COCAINE-INDUCED CONDITIONED TASTE AVERSIONS IN RAT 003232 04-04

METHYLPHENIDATE-INDUCED CONDITIONED TASTE AVERSIONS: AN INDEX 003337 04-04

CONDITIONING
CHANGES IN HIPPOCAMPAL EVOKED RESPONSES TO AFFERENT
STIMULATION DURING CONDITIONING.
000

000260 01-03

SUBCUTANEOUS INJECTIONS OF APOMORPHINE, STIMULUS
GENERALIZATION AND CONDITIONING: SERIOUS PITFALLS FOR THE
EXAMINER USING APOMORPHINE AS A TOOL.

A BEHAVIORAL TREATMENT OF DEPRESSION WITH ALCOHOLICS RECEIVING PHARMACOLOGICAL AVERSIVE CONDITIONING. (PH.D. DISSERTATION).

002539 03-11

THE ROLE OF PAVLOVIAN CONDITIONING IN MORPHINE-TOLERANCE.

003090 04-03
CONDITIONING FACTORS INFLUENCE TOLERANCE DEVELOPMENT TO LOW BUT NOT HIGH DOSES OF MORPHINE.

EFFECTS OF DEXAMETHASONE ON DISCRIMINATIVE CONDITIONING IN

INTERNAL STIMULUS CONDITIONING TO DISCRIMINATIVE EXTERNAL STIMULI.

003390 04-04 CONDITIONS

EFFECTS OF ANTICHOLINERGIC AND CHOLINESTERASE BLOCKING DRUGS ON APPETITIVE BEHAVIOR UNDER DIFFERENT DEPRIVATION

EFFECTIVENESS OF PSYCHOTROPIC DRUGS IN PATIENTS IN A STATE OF MALNUTRITION OR EXPOSED TO EXTREME CLIMATIC CONDITIONS. 000721 01-13

REDUCTION OF HEROIN SELF-ADMINISTRATION IN BABOONS BY MANIPULATION OF BEHAVIORAL AND PHARMACOLOGICAL CONDITIONS.

THE EFFECT OF LITHIUM ON SEROTONIN METABOLISM IN THE BRAIN OF RATS WITH PARTICULAR ATTENTION TO ITS EFFECT UNDER THE MONOAMINE ALTERED CONDITIONS.

VIGILANCE AND HUMAN ATTENTION UNDER CONDITIONS OF METHYLPHENIOATE AND SECOBARBITAL INTOXICATION: AN ASSESSMENT USING BRAIN POTENTIALS.

CLINICAL STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE CONDITIONS IN OUTPATIENT PRACTICE.

THE PRACTICAL SIGNIFICANCE OF NORTRIPTYLINE PLASMA CONTROL. A PROSPECTIVE EVALUATION UNDER ROUTINE CONDITIONS IN ENDOGENOUS DEPRESSION.

003522 04-09 CONDUCTANCE ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

-- A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND
QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

CHOLINERGIC CONDUCTANCE AS A COMPONENT OF MNEMONIC PROCESSES. (PH.D. DISSERTATION).

003344 04-04

CONDUCTION

EFFECT OF NARCOTICS ON CONDUCTION OF AFFERENT VISCERAL IMPULSES.

TRICYCLIC ANTIDEPRESSANT DRUGS AND CARDIAC CONDUCTION.
001751 02-15

CONFIGURATION
BARBITURATE-INDUCED CHANGES IN TRANSMITTER RELEASE
INDEPENDENT OF TERMINAL SPIKE CONFIGURATION IN THE FROG
NEUROMUSCULAR JUNCTION.
000294

000294 01-03

EFFECTS OF CHRONIC LITHIUM AND RUBIDIUM ADMINISTRATION UPON EXPERIMENTALLY-INDUCED CONFLICT BEHAVIOR. 001391 02-04 CONFLICT BEHAVIOR IN THE SQUIRREL-MONKEY: EFFECTS OF CHLORDIAZEPOXIDE, DIAZEPAM AND N DESMETHYLDIAZEPAM

002303 03-04 SQUIRREL-MONKEY ACTIVE CONFLICT TEST.

CONFORMATION

ON THE CONFORMATION OF NEUROLEPTIC DRUGS IN THE THREE AGGREGATION STATES AND THEIR CONFORMATIONAL RESEMBLANCE TO DOPAMINE.

000990 01-17 CONFORMATIONAL

DOPAMINE RECEPTORS IN RAT STRIATUM AND NUCLEUS-ACCUMBENS;
CONFORMATIONAL STUDIES USING RIGID ANALOGUES OF DOPAMINE.

000301 01-03

Psychopharmacology Abstracts

ON THE CONFORMATION OF NEUROLEPTIC DRUGS IN THE THREE AGGREGATION STATES AND THEIR CONFORMATIONAL RESEMBLANCE

000990 01-17

002141 03-03

CONFORMATIONALLY
CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. THE
IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF
NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED
ANALOGS OF METHAMPHETAMINE.

002141 03-03

CONFUSION CIMETIDINE AND MENTAL CONFUSION.

001810 02-15

TOLERANCE TO ETHANOL: EFFECT OF CONGENERS PRESENT IN BOURBON 000370 01-04

MATERNAL DRUG HISTORIES AND CONGENITAL ABNORMALITIES 001780 02-15

CONNECTIVITY
STRUCTURE-ACTIVITY STUDIES ON HALLUCINOGENIC AMPHETAMINES
USING MOLECULAR CONNECTIVITY. 001530 02-06

CONNEXIONS SYNAPTIC CONNEXIONS AND RELATED POSTSYNAPTIC PHARMACOLOGY STUDIED IN THE CEREBRAL GANGLION OF APLYSIA.

002041 03-03 EFFECTS OF CARBACHOL AND NICOTINE INJECTED INTO THE CEREBRAL VENTRICLES ON ELECTROMYOGRAM OF CONSCIOUS CATS.

000052 01-03 CARDIOVASCULAR EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN CONSCIOUS AND ANESTHETIZED DOGS.

000109 01-03 THE EFFECTS OF HALOPERIDOL, CHLORPROMAZINE AND PROPRANOLOL ON ACUTE AMPHETAMINE POISONING IN THE CONSCIOUS DOG.

000480 01-05 ANTAGONISM OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA)
LETHALITY BY CHLORPROMAZINE IN THE CONSCIOUS DOG.

001072 02-03 DELTA9-TETRAHYDROCANNABINOL AND DIMETHYLHEPTYLPYRAN INDUCED TACHYCARDIA IN THE CONSCIOUS RAT.

001516 02-05 A BEHAVIORAL AND AUTONOMIC NERVOUS SYSTEM STUDY OF CHRONIC IMIPRAMINE ADMINISTRATION TO CONSCIOUS DOGS.

002263 03-04 THE EFFECTS OF INTRAVENTRICULAR INJECTION OF GAMMA-AMINOBUTYRIC-ACID (GABA) ON PROLACTIN AND GONADOTROPIN RELEASE IN CONSCIOUS FEMALE RATS.

003126 04-03

CONSCIOUSNESS
THREE EXPERIENCES THAT CAN ALTER THE STATE OF CONSCIOUSNESS EFFECT OF CDP-CHOLINE ADMINISTERED INTRATHECALLY ON DISTURBANCE OF CONSCIOUSNESS.

002635 03-14

CONSECUTIVE
FATAL POISONING WITH PROPOXYPHENE: REPORT FROM 100
CONSECUTIVE CASES. 001788 02-15

CONSENTING
NEW DRUG TESTING IN THE CONSENTING ADULT. 000509 01-07

CONSEQUENCE
REPRESSION OF A LITHIUM PUMP AS A CONSEQUENCE OF LITHIUM
INGESTION BY MANIC-DEPRESSIVE SUBJECTS.

000714 01-13 A CASE OF CONSERVATIVELY MANAGED LITHIUM INTOXICATION 001811 02-15

EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN TWO INBRED STRAINS OF MICE.

000333 01-04 OXYTOCIN, VASOPRESSIN AND MEMORY: OPPOSITE EFFECTS ON CONSOLIDATION AND RETRIEVAL PROCESSES. 003174 04-04

EFFECTS OF MESCALINE AND PSILOCIN ON ACQUISITION, CONSOLIDATION, AND PERFORMANCE OF LIGHT-DARK DISCRIMINATION IN TWO INBRED STRAINS OF MICE.

003184 04-04 SUBAMNESIC CYCLOHEXIMIDE TREATMENT DELAYS CONSOLIDATION IN

003334 04-04 MEMORY CONSOLIDATION AND CHOLINERGIC STATE-DEPENDENT

001354 02-04

CO	19.5	-	**	-

FLURAZEPAM EFFECTS ON SLOW-WAVE SLEEP: STAGE-4 SUPPRESSED BUT NUMBER OF DELTA-WAVES CONSTANT.

001708 02-14

001362 02-04

CONSTITUENTS

THE CHEMICAL CONSTITUENTS OF GINSENG PLANTS.

INTERACTIONS OF ADRENERGIC COMPOUNDS WITH BRAIN MEMBRANE CONSTITUENTS.

CONSUMPTION 0029

PRENATAL ALCOHOL CONSUMPTION AND OPEN-FIELD BEHAVIOUR IN RATS: EFFECTS OF AGE AT TIME OF TESTING. 000321 01-04

EFFECTS OF PCPA ON THE CONSUMPTION OF ALCOHOL, WATER AND OTHER SOLUTIONS. 000469 01-04

AD LIBITUM CONSUMPTION AND ABSTINENCE.

A BIOCHEMICAL AND BEHAVIORAL ANALYSIS OF CHRONIC ALCOHOL CONSUMPTION BY RATS.

BARBITURATES AND ALCOHOL CONSUMPTION.

O0.1386 02-04
THE EFFECTS OF VARIOUS NARCOTIC AGONISTS AND ANTAGONISTS ON DEPRIVATION-INDUCED FLUID CONSUMPTION.

DRUG INTERACTIONS AS MEASURED BY DEPRIVATION-INDUCED FLUID

CONSUMPTION OF MEDICATION AND RISK OF DEVIANCE AMONG

ADULESCENTS.

O01888 02-17
FENFLURAMINE AND FLUOXETINE SPARE PROTEIN CONSUMPTION WHILE

SUPPRESSING CALORIC INTAKE BY RATS.

002184 03-03

EFFECT OF DIAZEPAM ON FOOD CONSUMPTION IN RATS. 002252 03-04

THE EFFECTS OF DL-5-HYDROXYTRYPTOPHAN ON ETHANOL CONSUMPTION BY RATS.

ALCOHOL CONSUMPTION IN RATS TREATED WITH LITHIUM-CARBONATE OR RUBIDIUM-CHLORIDE.

EFFECT OF CHRONIC COCAINE TREATMENT ON LIMITED ACCESS FOOD CONSUMPTION. 003395 04-04

CONTINGENCIES
SOME CONTINGENCIES AFFECTING THE UTILIZATION OF TRANQUILIZERS
IN LONG-TERM CARE OF THE ELDERLY.

000649 01-11

DRUG EFFECTS ON RESPONDING MAINTAINED BY STIMULUS REINFORCER
AND RESPONSE REINFORCER CONTINGENCIES.

CONTINGENT
THE EFFECT OF DIAZEPAM, CHLORPROMAZINE AND AMOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION.

000708 01-13
THE USE OF THE CNV (CONTINGENT NEGATIVE VARIATION) IN THE DETERMINATION OF RESIDUAL EFFECTS OF FIVE HYPNOTIC DRUGS. 002713 03-16

A COMPARATIVE CONTROLLED TRIAL OF PIMOZIDE AND FLUPHENAZINE-DECANOATE IN THE CONTINUATION THERAPY OF SCHIZOPHRENIA.

THE SOCIAL OUTCOME OF PATIENTS IN A TRIAL OF LONG-TERM CONTINUATION THERAPY IN SCHIZOPHRENIA: PIMOZIDE VS. FLUPHENAZINE.

003455 04-08 CONTINUATION THERAPY WITH AMITRIPTYLINE IN DEPRESSION. 003488 04-09

CONTINUING-CARE
THE USE OF FLUPHENAZINES IN A CONTINUING-CARE PROGRAM.
D02406 03-08

RESEARCH FINDINGS ON CHRONIC MENTAL ILLNESS: A MODEL FOR CONTINUING-CARE IN THE HEALTH MAINTENANCE ORGANIZATION. 002777 03-17

CONTINUITIES

THE FUNCTION OF DRUG RITUALS IN HUMAN SOCIETY: CONTINUITIES

AND CHANGES.

CONTRACTILITY
THE EFFECTS OF BEHAVIORALLY RELEVANT DOSES OF CHLORPROMAZINE

THE EFFECTS OF BEHAVIORALLY RELEVANT DOSES OF CHLORPROMAZINE AND MOLINDONE ON CARDIAC ADENYLATE-CYCLASE AND ON MYOCARDIAL CONTRACTILITY. 000487 01-05

RELAXATION OF SMOOTH MUSCLE FOLLOWING CONTRACTION ELICITED
BY SYMPATHETIC NERVE STIMULATION IN VIVO.

001106 02-03

CONTRAST

INCENTIVE CONTRAST UNDIMINISHED BY EXTENDED TESTING, IMPRAMINE, OR CHLORDIAZEPOXIDE.

CONTRIBUTING

FACTORS CONTRIBUTING TO CANNABIS INTOXICATION AND DEPENDENCE.
(PH.D. DISSERTATION).

003583 04-12 SITUATIONAL FACTORS CONTRIBUTING TO THE PLACEBO EFFECT. 003714 04-17

CONTROL

ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEDDMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR.

000086 01-03
INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC
AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS
RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS
IN THE RAT.

CONTROL OF THE RELEASE OF NEWLY SYNTHESIZED H3-5HYDROXYTRYPTAMINE BY NICOTINIC AND MUSCARINIC RECEPTORS IN
RAT HYPOTHALAMIC SLICES.

ROLE OF LIVER CYTOSOLIC ALDEHYDE-DEHYDROGENASE ISOZYMES IN CONTROL OF BLOOD ACETALDEHYDE CONCENTRATIONS.

000222 01-03

MATERNAL FETAL DISTRIBUTION OF METHAQUALONE IN CONTROL AND
SKF-525-A PRETREATED PREGNANT MICE.

O00263 01-03
THE ROLE OF ASCENDING AND DESCENDING 5 HYDROXYTRYPTAMINE
NEURONES IN CENTRAL CONTROL OF PAIN SENSITIVITY.

ROLE OF THE DORSAL NORADRENERGIC BUNDLE IN BEHAVIOUR

000407 01-04
NEOSTRIATAL ADMINISTRATION OF SOMATOSTATIN: DIFFERENTIAL
EFFECT OF SMALL AND LARGE DOSES ON BEHAVIOR AND MOTOR
CONTROL

CONTROL.

O00437 01-04

INTERINDIVIDUAL VARIABILITY IN DIAZEPAM METABOLISM:
PRELIMINARY EVIDENCE OF AN ABSENCE OF GENETIC CONTROL.

A COMPARISON OF PIRIBEDIL, PROCYCLIDINE AND PLACEBO IN THE CONTROL OF PHENOTHIAZINE-INDUCED PARKINSONISM.

CONTROL OF PHENOTHIAZINE-INDUCED PARKINSONISM.

000867 01-15

000932 01-16

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF
NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH
POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF

POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF THE RAT. 001118 02-03 NONPARTICIPATION OF CHOLINERGIC MECHANISM IN CHEMICAL CONTROL OF CEREBRAL VASOMOTOR ACTIVITY.

001243 02-03
CONTROL OF THE RAT OLFACTORY BULB ACTIVITY INDUCED BY
BIOLOGICALLY SIGNIFICANT ODORS.

THE EFFECTS OF SCOPOLAMINE ON THE TEMPORAL CONTROL OF

DISCRETE-TRIAL CONTROL OF COCAINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF MORPHINE, NALOXONE, AND CHLORPROMAZINE.

DISCRETE-TRIAL CONTROL OF MORPHINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF NALOXONE, MORPHINE, AND CHLORPROMAZINE.

O01470 02-04
THE HUMAN EEG IN SEVERELY POISONED PATIENTS -- INDICATION AND
CONTROL OF HEMODIALYSIS OR HEMOPERFUSION.

DENTIFICATION OF DOPAMINERGIC RECEPTORS IN ANTERIOR PITUITARY:
CORRELATION WITH THE DOPAMINERGIC CONTROL OF PROLACTIN
DELEASE

001982 03-03
RATE-DEPENDENT AND STIMULUS CONTROL EFFECT OF DRUGS.
002266 03-04

ANALYSIS AND CHEMICAL CONTROL OF NEGATIVE AFFECT.

002367 03-06

EVALUATION OF A NEW IMMUNOASSAY FOR DETERMINATION OF PHENYTOIN AND PHENOBARBITAL: RESULTS OF A EUROPEAN COLLABORATIVE CONTROL STUDY.

002529 03-11
CENTRAL ADRENOCEPTORS AND CHOLINOCEPTORS IN CARDIOVASCULAR
CONTROL.

NEUROLEPTIC INTERFERENCE WITH THE COCAINE CUE: INTERNAL STIMULUS CONTROL OF BEHAVIOR AND PSYCHOSIS.

ROLE OF HYPOTHALAMIC SEROTONERGIC RECEPTORS IN THE CONTROL OF LORDOSIS BEHAVIOR IN THE FEMALE RAT.

LSD-INDUCED STIMULUS CONTROL: A COMPARISON OF SCH-12679, FENFLURAMINE, P-METHOXYAMPHETAMINE, AND BL-3912.

ERYTHROCYTE ACCUMULATION OF THE LITHIUM-ION IN CONTROL SUBJECTS AND PATIENTS WITH PRIMARY AFFECTIVE-DISORDER

THE PRACTICAL SIGNIFICANCE OF NORTRIPTYLINE PLASMA CONTROL. A PROSPECTIVE EVALUATION UNDER ROUTINE CONDITIONS IN ENDOGENOUS DEPRESSION.

ELECTROENCEPHALOGRAPHIC CONTROL WITH FREQUENCY ANALYSIS IN DEPRESSED PATIENTS TREATED WITH SAME.

A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-DUMMY TECHNIQUE.

SELF-REPORTED ALCOHOL AND NICOTINE USE AND THE ABILITY TO CONTROL OCCIPITAL EEG IN A BIOFEEDBACK SITUATION.

003622 04-14 A DOUBLE-BLIND CONTROLLED STUDY OF CLOBAZAM FOR THE TREATMENT OF ANXIETY IN PSYCHIATRIC OUTPATIENTS.

CLOZAPINE (LEPONEX) VS CHLORPROMAZINE (LARGACTIL) IN ACUTE SCHIZOPHRENIA (A DOUBLE-BLIND CONTROLLED STUDY).

000527 01-08 MOLINDONE: A CONTROLLED EVALUATION OF THE INTRAMUSCULAR

ANTIPSYCHOTIC PREPARATION. 000541 01-08

CONTROLLED TRIAL OF A NEW ANTIDEPRESSIVE, AMOXAPINE, IN COMPARISON WITH AMITRIPTYLINE. 000555 01-09

VALPROATE-SODIUM: EVALUATION OF SO-CALLED PSYCHOTROPIC EFFECT. A CONTROLLED STUDY.

000791 01-14 NALTREXONE AND CYCLAZOCINE: A CONTROLLED TREAT/ MENT STUDY 000804 01-15

A CONTROLLED TRIAL OF METOCLOPRAMIDE IN SYMPTOMATIC GASTROESOPHAGEAL REFLUX.

000862 01-15 S ADENOSYL-L-METHIONINE (SAME) TREATMENT IN GERONTOPSYCHIATRY: A CONTROLLED CLINICAL STUDY IN DEPRESSED AGED PATIENTS.

001045 02-03 MEASUREMENTS OF WEIGHT AND ACTIVITY IN MALE MICE FOLLOWING INHALATION OF CANNABIS SMOKE IN A CONTROLLED SMOKE EXPOSURE CHAMBER.

001524 02-05 A CONTROLLED STUDY OF WIN-27147-2 IN THE TREATMENT OF

THE EFFECT OF CYCLANDELATE IN DEPRESSED AND DEMENTED PATIENTS: A CONTROLLED STUDY IN PSYCHOGERIATRIC PATIENTS.

001617 02-11 CONTROLLED COMPARISON OF TRIFLUOPERAZINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY.

A DOUBLE-BLIND CONTROLLED STUDY OF PIPOTHIAZINE-PALMITATE IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS.

O02390 03-08

A COMPARATIVE CONTROLLED TRIAL OF PIMOZIDE AND FLUPHENAZINEDECANOATE IN THE CONTINUATION THERAPY OF SCHIZOPHRENIA. 002396 03-08

GRADUAL REDUCTION OF NEUROLEPTIC DRUGS AMONG CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY.

002401 03-08 A DOUBLE-BLIND CONTROLLED COMPARATIVE STUDY OF NOMIFENSINE IN DEPRESSION.

002419 03-09 A CONTROLLED COMPARATIVE TRIAL OF CLORAZEPATE (TRANXENE) AND DIAZEPAM (VALIUM) FOR ANXIETY.

002476 03-10 DOUBLE-BLIND CONTROLLED STUDY IN PHOBIAS AND OBSESSIONS. 002483 03-10

LOXAPINE IN NEUROTIC ANXIETY: A CONTROLLED TRIAL

002490 03-10 FLUNITRAZEPAM (ROHYPNOL) COMPARED WITH NITRAZEPAM (MOGADON) AND APROBARBITAL AS EVENING PREMEDICATION PRIOR TO ANESTHESIA: A CONTROLLED CLINICAL TRIAL.

002616 03-14 THE EFFECTS OF HALOPERIDOL ON DISCRIMINATIVE RESPONDING CONTROLLED BY THE COCAINE CUE.

Psychopharmacology Abstracts

DIFFERENTIAL RESPONDING CONTROLLED BY THE DISCRIMINATIVE STIMULI PRODUCED BY CONVULSANT DRUGS IN THE RAT.

003358 04-04 A CONTROLLED STUDY OF TRYPTOPHAN BENSERAZIDE IN SCHIZOPHRENIA.

003451 04-08 CONTROLLED CLINICAL STUDY OF TRAZODONE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH PRONOUNCED DEPRESSIVE SYMPTOMATOLOGY.

VILOXAZINE AND AMITRIPTYLINE IN DEPRESSIVE ILLNESS: A DOUBLE-BLIND CONTROLLED TRIAL IN GENERAL PRACTICE.

OXYPERTINE IN COMBINATION WITH IMPRAMINE: A CONTROLLED

003521 04-09

A CONTROLLED TRIAL OF A NEW ANTIDEPRESSANT, WIN-27147-2.
003523 04-09
A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-

003537 04-10 A CONTROLLED STUDY OF TRANCOPAL IN THE TREATMENT OF SLEEP DISTURBANCES DUE TO ANXIETY.

003548 04-10 A CONTROLLED STUDY OF LISURID IN HYPERACTIVE CHILDREN.

003580 04-11 A CONTROLLED STUDY OF TRANCOPAL IN SLEEP DISTURBANCES DUE TO RHEUMATIC DISEASE.

003621 04-14

CONTROLLING CONTROLLING RATER SPECIFIC INTERFERENCE FACTORS IN CLINICAL

000917 01-16 **ALTERATIONS IN RECEPTORS CONTROLLING DOPAMINE SYNTHESIS AFTER** CHRONIC ETHANOL INGESTION

003107 04-03 INTRANIGRAL KAINIC-ACID: EVIDENCE FOR NIGRAL NONDOPAMINERGIC NEURONS CONTROLLING POSTURE AND BEHAVIOR IN A MANNER OPPOSITE TO THE DOPAMINERGIC ONES.

CONTROLS

EXCRETION OF 3,4 DIMETHOXYPHENETHYLAMINE (DMPEA) BY ACUTE SCHIZOPHRENICS AND CONTROLS. 000698 01-13

CONTROVERSY
ANIMAL HYPNOSIS AND HUMAN HYPNOSIS: NEW EXPERIMENTAL
EVIDENCE RELATING TO AN OLD CONTROVERSY.

001711 02-14 IN VIVO CONVERSION OF MESORIDAZINE TO THIORIDAZINE

003591 04-13 CONVERTING

INHIBITION OF BRAIN ANGIOTENSIN-I CONVERTING ENZYME BY BOTHROPS-JARARACA NONAPEPTIDE (SQ-20881) AND A PROLYL ANALOG (SQ-14225). 002818 04-03

EFFECT OF DIPROPYLACETATE (CONVULEX) ON PERSONALITY CHANGES IN EPILEPTICS: PRELIMINARY REPORT. 000757 01-14

CONVULSANT

EFFECT OF CONVULSANT AND ANTICONVULSANT AGENTS ON LEVEL AND

METABOLISM OF GAMMA-AMINOBUTYRIC-ACID IN MOUSE BRAIN.

00186 01-03 000186 01-03

POTENTIATION OF THE BEHAVIORAL AND CONVULSANT EFFECTS OF COCAINE BY CHRONIC ADMINISTRATION IN THE RAT. 000458 01-04

COMPARISON OF THE CONVULSANT EFFECTS OF COCAINE AND PSEUDOCOCAINE IN THE RHESUS MONKEY.

001415 02-04 NALOXONE AS A GABA-ANTAGONIST: EVIDENCE FROM IONTOPHORETIC, RECEPTOR BINDING AND CONVULSANT STUDIES. 002003 03-03

ELECTROENCEPHALOGRAM AND SOMATOSENSORY EVOKED-POTENTIAL CHANGES AFTER ADMINISTRATION OF SIX CONVULSANT DRUGS. 002055 03-03

REPEATED EXPOSURE OF RATS TO THE CONVULSANT AGENT FLUROTHYL ENHANCES 5 HYDROXYTRYPTAMINE AND DOPAMINE MEDIATED BEHAVIOURAL RESPONSES.

003234 04-04 DIFFERENTIAL RESPONDING CONTROLLED BY THE DISCRIMINATIVE STIMULI PRODUCED BY CONVULSANT DRUGS IN THE RAT. 003358 04-04

EFFECTS OF N METHYLAMINO-ACIDS AND CONVULSANTS ON SPONTANEOUS ACTION POTENTIALS IN GUINEA-PIG CEREBELLAR SLICES.

VOLUME 16, SUBJECT INDEX

DIFFERENTIAL EFFECTS OF CONVULSANTS ON VISUALLY EVOKED RESPONSES IN THE ALBINO RAT.

003171 04-04 CONVULSIONS

THE EFFECT OF 5.6 DIHYDROXYTRYPTAMINE ON POST DECAPITATION 001202 02-03

PHENOBARBITAL IN THE ACUTE MANAGEMENT OF FEBRILE CONVULSIONS

001555 02-07 MEASURING CHANGES IN CEREBRAL GLUTAMATE AND GABA METABOLISM PRIOR TO CONVULSIONS INDUCED BY 3

MERCAPTOPROPIONATE. 001961 03-03

INHIBITION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS IN RATS BY PROSTAGLANDIN-E1: ROLE OF BRAIN MONOAMINES. 001968 03-03

TOLERANCE TO COCAINE-INDUCED CONVULSIONS IN THE CAT 001984 03-03 EFFECT OF SUBACUTE DIAZEPAM ADMINISTRATION IN MICE ON THE

SUBSEQUENT ABILITY OF DIAZEPAM TO PROTECT AGAINST METRAZOL AND BICUCULLINE-INDUCED CONVULSIONS. 002053 03-03

ALTERATIONS OF EEG ACTIVITIES AND COCAINE-INDUCED CONVULSIONS FOLLOWING PROLONGED COCAINE TREATMENT IN THE RHESUS 002091 03-03

EFFECT OF ALPHA-METHYL-P-TYROSINE ON THE INCIDENCE OF SPONTANEOUS CONVULSIONS OBSERVED FOLLOWING BARBITAL

002104 03-03 REGIONAL CHANGES IN CEREBRAL GABA CONCENTRATION AND CONVULSIONS PRODUCED BY D AND BY L ALLYLGLYCINE.

002954 04-03 THE EFFECTS OF ATROPINE ON THE TOLERANCE AND THE CONVULSIONS SEEN AFTER WITHDRAWAL FROM FORCED BARBITAL DRINKING IN THE

003389 04-04 CONVULSIVE THE RELATIONSHIP BETWEEN MAGNITUDE OF ELECTROSHOCK

STIMULATION AND THE EFFECTS OF DIGITOXIGENIN PENTYLENETETRAZOL AND BRAIN MONOAMINE REDUCTION ON ELECTROSHOCK CONVULSIVE THRESHOLDS.

CONVULSIVE SEIZURES AND VILOXAZINE.

000826 01-15 A PHARMACOLOGICAL STUDY OF THE SPONTANEOUS CONVULSIVE ACTIVITY INDUCED BY 1,2 DIHYDROXYBENZENE (CATECHOL) IN THE ANESTHETIZED MOUSE.

000066 01-03

000295 01-03

000635 01-11

000412 01-04

A ROLE FOR CENTRAL SEROTONERGIC SYSTEMS IN THE PATTERN AND INTENSITY OF THE CONVULSIVE RESPONSE OF RATS TO ELECTROSHOCK

001067 02-03 COOLING

THE EFFECTS OF ALCOHOL UPON COOLING RATES OF HUMANS IMMERSED IN 7.5 DEGREES C WATER 002541 03-12

COPPER EFFECT OF CHLORPROMAZINE ON CENTRAL-NERVOUS-SYSTEM CONCENTRATIONS OF MANGANESE, IRON, AND COPPER.

COPROPORPHYRIA HEREDITARY COPROPORPHYRIA AND EPILEPSY.

COPULATION

5 HYDROXYTRYPTAMINE DEPLETION WITH P-CHLOROPHENYLALANINE EFFECTS ON EATING, DRINKING, IRRITABILITY, MURICIDE, AND COPULATION

000429 01-04 THE EFFECTS OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE FEMALE RAT.

000353 01-04 A COMPARATIVE STUDY OF DIFFERENT AMPHETAMINES ON COPULATORY BEHAVIOR AND STEREOTYPE ACTIVITY IN THE FEMALE

THE INFLUENCE OF PROGESTERONE ON THE INHIBITORY EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE FEMALE RAT 001463 02-04

CORD EFFECTS OF SYSTEMIC MUSCIMOL AND GABA IN THE SPINAL CORD AND SUPERIOR CERVICAL GANGLION OF THE CAT.

CHLORDIAZEPOXIDE SELECTIVELY AUGMENTS GABA ACTION IN SPINAL CORD CELL CULTURES. 001080 02-03 Subject Index

SELECTIVE OPIATE DEPRESSION OF SENSORY EVOKED SYNAPTIC NETWORKS IN DORSAL-HORN REGIONS OF SPINAL CORD CULTURES 001088 02-03 EFFECTS OF 4 AMINOPYRIDINE ON TRANSMISSION IN EXCITATORY AND

INHIBITORY SYNAPSES IN THE SPINAL CORD. 001384 02-04

DIFFERENTIAL EXCITATORY AND INHIBITORY EFFECTS OF OPIATES ON NONNOCICEPTIVE AND NOCICEPTIVE NEURONES IN THE SPINAL CORD

STIMULANT ACTION OF THYROTROPIN-RELEASING HORMONE ON CAT SPINAL CORD

OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG

002040 03-03 EFFECTS OF FLURAZEPAM ON AMINO-ACID EVOKED RESPONSES RECORDED FROM THE LOBSTER MUSCLE AND THE FROG SPINAL CORD. 002115 03-03 EFFECTS OF INTRAVENOUS KAINIC-ACID, N METHYL-D-ASPARTATE, AND (-) NUCIFERENE ON THE CAT SPINAL CORD.

MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF

FROG AND IMMATURE RAT THE RELEASE OF ACETYLCHOLINE IN THE PERFUSED CAT SPINAL CORD IN

MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID
AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE
ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE CORRELATES WITH ANALGESIC ACTION OF MORPHINE

STRYCHNINE BINDING ASSOCIATED WITH SYNAPTIC GLYCINE RECEPTORS IN RAT SPINAL CORD MEMBRANES: IONIC INFLUENCES.

IN VIVO COMPARISON OF THE RECEPTOR POPULATIONS ACTED UPON IN THE SPINAL CORD BY MORPHINE AND PENTAPEPTIDES IN THE PRODUCTION OF ANALGESIA.

003143 04-03 DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION

CORE RESTRAINT ALTERS THE EFFECTS OF MORPHINE AND HEROIN ON CORE TEMPERATURE IN THE RAT.

001186 02-03 NEW APPROACH TO THE REHABILITATION OF THE HARD CORE DRUG

ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY 002531 03-11

UNILATERAL CATECHOLAMINE DEPLETION OF THE CORPUS-STRIATUM
AND AMPHETAMINE-INDUCED TURNING: AN ONTOGENETIC STUDY

000471 01-04

EFFECT OF LOCAL APPLICATION OF APOMORPHINE TO THE CORPUSSTRIATUM AND TO THE NUCLEUS-ACCUMBENS ON THE RESERPINE-INDUCED RIGIDITY IN RATS.

001021 02-02 SPECIFIC RELEASE BY NALOXONE OF H3-MORPHINE FROM SUPERFUSED SLICES OF CORPUS-STRIATUM OF MICE.

EFFECTS ON HYPOTHALAMIC SELF-STIMULATION OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION INJECTED INTO NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM OF RATS.

APOMORPHINE INCREASES GLUCOSE UTILIZATION IN THE SUBSTANTIA-NIGRA, SUBTHALAMIC NUCLEUS AND CORPUS-STRIATUM OF RAT. 001976 03-03

H3-HALOPERIDOL BINDING TO DOPAMINE RECEPTORS IN RAT CORPUS-STRIATUM: INFLUENCE OF CHLORPROMAZINE METABOLITES AND

001995 03-03 THE ROLE OF THE CORPUS-STRIATUM IN NEUROLEPTIC-INDUCED AND NARCOTIC-INDUCED CATALEPSY.

002062 03-03 COMPARISON OF THE EFFECTS OF METHAMPHETAMINE AND NEUROLEPTIC AGENTS ON TYROSINE-HYDROXYLASE ACTIVITY IN THE NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM.

CHOLINE-ACETYLTRANSFERASE AND THE HIGH AFFINITY UPTAKE OF CHOLINE IN CORPUS-STRIATUM OF RESERPINISED RATS.

002847 04-03 FFFECT OF ALPHA-METHYLDOPA ON DOPAMINERGIC TRANSMISSION IN THE CORPUS-STRIATUM.

002873 04-03

EVIDENCE FOR CELL LOSS IN CORPUS-STRIATUM AFTER LONG-TERM TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN RATS. 003030 04-03

H3-SPIROPERIDOL BINDING TO TWO RECEPTOR SITES IN BOTH THE CORPUS-STRIATUM AND FRONTAL CORTEX OF RAT BRAIN.

EVIDENCE OF AN INTERACTION BETWEEN SEROTONINERGIC AND CHOLINERGIC NEURONS IN THE CORPUS-STRIATUM AND HIPPOCAMPUS OF THE RAT BRAIN.

003074 04-03
DPAMINE RECEPTORS LOCALISED ON CEREBRAL CORTICAL AFFERENTS
TO RAT CORPUS-STRIATUM. 003080 04-03

THE BLOOD (SERUM AND CORPUSCLE) DYNAMICS OF TRICYCLIC ANTIDEPRESSANTS

000556 01-09 CORRECTION
HYPERACTIVE CHILDRENS UNDERUSE OF LEARNING TIME: CORRECTION
BY STIMULANT TREATMENT.

002614 03-14

CORRELATE
BLOCKADE OF INTRACRANIAL SELF-STIMULATION BY ANTIPSYCHOTIC
DRUGS: FAILURE TO CORRELATE WITH CENTRAL ALPHANORADRENERGIC BLOCKADE.
000475 0

000475 01-04

CORRELATED

CORRELATED EFFECT OF CORTICOSTERONE ON HYPOTHALAMIC

SEROTONIN AND AVOIDANCE BEHAVIOUR IN RATS. 001394 02-04

STRIATAL CELL SUPERSENSITIVITY TO APOMORPHINE IN DOPAMINE LESIONED RATS CORRELATED TO BEHAVIOUR. 003356 04-04

CORRELATES
MEMORY IMPAIRMENT CORRELATES CLOSELY WITH CYCLOHEXIMIDE
DOSE AND DEGREE OF INHIBITION OF PROTEIN SYNTHESIS.
000436 0

000436 01-04 BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC CORRELATES OF THE CHRONIC USE OF MARIJUANA -- A REVIEW.

000766 01-14 A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND BIOELECTRIC CORRELATES OF EMOTIONAL REACTIONS ELICITED BY CHOLINERGIC STIMULATION OF THE HYPOTHALAMUS AND THE VENTRAL

SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL CORRELATES.

001974 03-03 BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC/ ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA. 002220 03-04

EEG SLEEP CORRELATES OF DEPRESSION IN MAN

002625 03-14 MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE CORRELATES WITH ANALGESIC ACTION OF MORPHINE.

002984 04-03 CLINICAL CORRELATES OF LOW PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIC PATIENTS.

003477 04-08 CLINICAL CORRELATES OF TRICYCLIC ANTIDEPRESSANT MEDIATED INHIBITION OF PLATELET MONOAMINE-OXIDASE.

CORRELATION

MULTIPLE ORAL DOSES OF DIAZEPAM, OXAZEPAM AND PHENOBARBITAL TO DOGS — BEHAVIOURAL EFFECTS AND CORRELATION WITH ANTIPYRINE HALF-LIFE.

000308 01-04 EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH MORPHOLOGY AND HORMONE PLASMA LEVELS.

000315 01-04 CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND ITS METABOLITES AND CLINICAL RATINGS IN PATIENTS WITH ACUTE RELAPSE OF SCHIZOPHRENIC AND PARANOID PSYCHOSIS.

000726 01-13 COMPARATIVE BIOAVAILABILITY OF ORAL DOSAGE FORMS OF OXAZEPAM — CORRELATION WITH IN VITRO DISSOLUTION RATE 000727 01-13

PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EMBRYOPATHIC EFFECT AND COVALENT BINDING OF PUTATIVE ARENE OXIDE METABOLITE IN GESTATIONAL TISSUE.

CORRELATION BETWEEN EXTRAPYRAMIDAL AND THERAPEUTIC EFFECTS OF NEUROLEPTICS.

Psychopharmacology Abstracts

IDENTIFICATION OF DOPAMINERGIC RECEPTORS IN ANTERIOR PITUITARY: CORRELATION WITH THE DOPAMINERGIC CONTROL OF PROLACTIN RELEASE.

CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF C-AMP-PHOSPHODIESTERASE.

CORRELATION OF URINARY EXCRETION OF METHADONE METABOLITES WITH METHADONE METABOLISM AND ANALGESIA IN THE RAT. 002080 03-03

CORRELATION OF PHENOBARBITAL-INDUCED AND SKF-525-A-INDUCED MODIFICATION OF PENTOBARBITAL HYPNOSIS WITH ALTERATION OF IN VIVO AND IN VITRO PENTOBARBITAL METABOLISM IN THE RAT.

SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION: A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL MEMBRANES FROM MATURE RAT BRAIN.

000230 01-03 SPECIFIC EFFECT OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE FRONTAL CORTEX.

EFFECTS OF IFC-45, A NEW BENZONAPHTYRIDONE DERIVATIVE WITH ANTIDEPRESSIVE ACTION, ON ACTIVITY OF THE RAT SUPRARENAL GLAND CORTEX.

SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL

THE ACUTE EFFECTS OF AMPHETAMINE, CHLORPROMAZINE,
AMITRIPTYLINE AND LITHIUM ON ADENOSINE-5-TRIPHOSPHATASE
ACTIVITY IN THE CORTEX OF THE RAT BRAIN.

002094 03-03 STIMULATION OF ADENYLATE-CYCLASE ACTIVITY IN MONKEY ANTERIOR LIMBIC CORTEX BY SEROTONIN.

ACTIVATION OF AN IHHIBITORY NORADRENERGIC PATHWAY PROJECTING FROM THE LOCUS-COERULEUS TO THE CINGULATE CORTEX OF THE RAT.

EFFECT OF SOMATOSTATIN (SRIF) AND L GLUTAMATE ON NEURONS OF THE SENSORIMOTOR CORTEX IN AWAKE HABITUATED RABBITS. 002958 04-03

AFFERENT AND EFFERENT SUBCORTICAL PROJECTIONS OF BEHAVIORALLY DEFINED SECTORS OF PREFRONTAL GRANULAR CORTEX. 002962 04-03

H3-SPIROPERIDOL BINDING TO TWO RECEPTOR SITES IN BOTH THE CORPUS-STRIATUM AND FRONTAL CORTEX OF RAT BRAIN.
003041 04-03

CORTICAL
EFFECTS OF OROTIC-ACID AND PIRAZETAM ON CORTICAL BIOELECTRICAL **ACTIVITY IN RABBITS.**

000171 01-03 ANTAGONISM OF BIOGENIC AMINE-INDUCED DEPRESSION OF CEREBRAL

CORTICAL NEURONES BY NA-K-ATPASE INHIBITORS. THE EFFECT OF BARBITURATE AND PROCAINE ON GLIAL AND NEURONAL CONTRIBUTIONS TO EVOKE CORTICAL STEADY POTENTIAL SHIFTS. 001219 02-03

THE EFFECTS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE ON THE IN VITRO UPTAKE OF RADIOLABELLED 5-HT AND NORADRENALINE INTO RAT BRAIN CORTICAL SLICES.

THE INFLUENCE OF PENTOBARBITAL UPON A CORTICAL EPILEPTOGENIC

DIFFERENTIATION OF HYPNOTIC ACTION OF NITRAZEPAM AND ESTAZOLAM AND EFFECTS ON BEHAVIOR AND CORTICAL ACTIVITY 001549 02-07

HIGH DENSITIES OF BENZODIAZEPINE RECEPTORS IN HUMAN CORTICAL 001645 02-13

THE RELATIONSHIP BETWEEN CORTICAL RECRUITING RESPONSES AND PONTO-GENICULO-OCCIPITAL (PGO) WAVES DURING PARADOXICAL SLEEP AND AFTER THE ADMINISTRATION OF RESERPINE IN THE CAT 002069 03-03

DIFFERENTIAL EFFECTS OF SUBCORTICAL LYSERGIC-ACID-DIETHYLAMIDE AND SEROTONIN ON VISUAL CORTICAL EVOKED-POTENTIALS. 002163 03-03

COMPARISON OF THE RESPONSES OF SINGLE CORTICAL NEURONES TO TYRAMINE AND NORADRENALINE: EFFECTS OF DESIPRAMINE. 002821 04-03

RESPONSES OF SINGLE CORTICAL NEURONES TO NORADRENALINE AND DOPAMINE. 002822 04-03

SHORT-TERM AND LONG-TERM EFFECTS OF CEREBROLYSINE ON EVOKED CORTICAL POTENTIALS IN RATS.

002858 04-03

000354 01-04

VOLUME 16, SUBJECT INDEX

CLONIDINE-INDUCED BODY TEMPERATURE CHANGES IN RATS WITH ANTERIOR OR POSTERIOR CORTICAL DAMAGE.

002959 04-03 LOCAL PERFUSION OF NORADRENALINE MAINTAINS VISUAL CORTICAL

003045 04-03 THE EFFECT OF CEREBROLYSINE ON CORTICAL EVOKED-POTENTIALS IN RATS WITH FARLY MAINITRITION

003069 04-03 DOPAMINE RECEPTORS LOCALISED ON CEREBRAL CORTICAL AFFERENTS TO RAT CORPUS-STRIATUM

003080 04-03

CORTICOSTEROIDOGENESIS
THE AMNESTIC EFFECT OF PROTEIN SYNTHESIS INHIBITORS IS NOT DUE
TO THE INHIBITION OF ADRENAL CORTICOSTEROIDOGENESIS. 000352 01-04

CORTICOSTEROIDS MEMORY FACILITATING AND ANTIAMNESIC EFFECTS OF CORTICOSTEROIDS.

002233 03-04 CORTICOSTERONE

CORRELATED EFFECT OF CORTICOSTERONE ON HYPOTHALAMIC SEROTONIN AND AVOIDANCE BEHAVIOUR IN RATS. 001394 02-04

CANNABINOID EFFECTS ON PLASMA CORTICOSTERONE AND UPTAKE OF H3-CORTICOSTERONE BY MOUSE BRAIN. 002051 03-03

EFFECTS OF PROLACTIN, DEXAMETHASONE, AND CORTICOSTERONE ON MATERNAL AGGRESSION AND INFANT CARE.

002240 03-04 MOUSE BRAIN TYROSINE-HYDROXYLASE AND GLUTAMIC-ACID-DECARBOXYLASE FOLLOWING TREATMENT WITH ADRENOCORTICOTROPHIC HORMONE, VASOPRESSIN OR CORTICOSTERONE

002898 04-03 EFFECT OF NALOXONE ON MORPHINE-INDUCED CHANGES IN ACTH, CORTICOSTERONE AND CYCLIC-NUCLEOTIDES

002949 04-03 ACTH EFFECTS ON RESPONSE SUPPRESSION AND PLASMA

CORTICOSTERONE IN THE MOUSE. 003363 04-04

INDUCTION OF SULFOGALACTOSYLCERAMIDE (SULFATIDE) SYNTHESIS BY HYDROCORTISONE (CORTISOL) IN MOUSE G-26 OLIGODENDROGLIOMA **CELL STRAINS**

002886 04-03 GROWTH HORMONE, PROLACTIN AND CORTISOL RESPONSES AND GROWTH PATTERNS IN HYPERKINETIC CHILDREN TREATED WITH DEXTROAMPHETAMINE. PRELIMINARY FINDINGS.

003569 04-11 CORTISONE

SEXUAL DIFFERENTIATION OF OFFSPRING OF MOTHERS TREATED WITH CORTISONE DURING PREGNANCY. 002879 04-03

COST THE HIDDEN COST OF MIND MEDICINES.

COUPLES

002674 03-15 COSTS HOW CANADA HOLDS DOWN DRUG COSTS.

001895 02-17 COUNSELING DIPROPYLTRYPTAMINE (DPT) AS AN ADJUNCT IN THE COUNSELING OF CANCER PATIENTS.

000978 01-17

COUNTERACTIVE EFFECTS OF NOREPINEPHRINE AND AMPHETAMINE ON OUABAIN-INDUCED AMNESIA. 000122 01-03

COUNTERTRANSPORT
LITHIUM SODIUM COUNTERTRANSPORT IN HUMAN RED CELLS AND IN VIVO LITHIUM DISTRIBUTION BETWEEN RED CELLS AND PLASMA 001679 02-13

ROLE OF SEROTONIN REUPTAKE INHIBITION IN THE DEVELOPMENT OF SUBSENSITIVITY OF THE NOREPINEPHRINE (NE) RECEPTOR COUPLED

ADENYLATE-CYCLASE SYSTEM. 003017 04-03

COUPLES GROUP THERAPY AS AN ADJUNCT TO LITHIUM MAINTENANCE OF THE MANIC PATIENT. 000562 01-09

INVOLUNTARY ADMINISTRATION OF PSYCHOTROPIC DRUGS — GROUNDS FOR SUIT. SOUDER V. MCGUIRE, 423 F. SUPP. 830, (PENNSYLVANIA). M.D. DISTRICT COURT. DECEMBER 9, 1976.

COURTSHIP ROLES OF THE VOMERONASAL AND OLFACTORY SYSTEMS IN COURTSHIP BEHAVIOR OF MALE GARTER SNAKES.

COVALENT

PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EMBRYOPATHIC EFFECT AND COVALENT BINDING OF PUTATIVE ARENE OXIDE METABOLITE IN GESTATIONAL TISSUE.

001515 02-05 CONDITIONED TASTE AVERSION: A FIELD APPLICATION TO COYOTE

CO2

EFFECTS OF SODIUM THIOPENTAL ON THE TRICARBOXYLIC-ACID CYCLE METABOLISM IN MOUSE BRAIN: CO2 FIXATION AND METABOLIC COMPARTMENTATION.

002860 04-03 ANOREXIGENIC AND ANCILLARY ACTIONS OF MK-212 (6 CHLORO-2-PIPERAZINYLPYRAZINE: CPP).

002213 03-04 LOW PLASMA LEVELS OF CPZ IN PATIENTS CHRONICALLY TREATED WITH

CHLORPROMAZINE EXCRETION. II. IMPROVED TLC PROCEDURES FOR FRACTIONATING THE URINARY DRUG CONTENT INTO CHEMICAL SUBGROUPS OF CPZ METABOLITES. 003690 04-16

CRANIAL EFFECT OF DEXAMETHASONE ON CEREBRAL EDEMA FROM CRANIAL IMPACT IN THE CAT.

001958 03-02 MEMORIZATION AND CENTRAL CATECHOLAMINES AFTER A
CRANIOCERVICAL INJURY CARRIED OUT IN RATS: INFLUENCE OF

IMIPRAMINE ADMINISTRATION. 002197 03-04 CREATIVITY

CREATIVITY IN NEW DRUG DEVELOPMENT: AN ACADEMIC CHALLENGE 002745 03-17

PSYCHEDELIC DRUG CRISES: TOXICITY AND THERAPEUTICS 000861 01-15

LITHIUM AND CRISIS INTERVENTION: DAMPING AFFECTIVE OVERLOAD 003717 04-17

DEPRESSION IN THE ELDERLY. II. POSSIBLE DRUG ETIOLOGIES; DIFFERENTIAL DIAGNOSTIC CRITERIA.

BENZODIAZEPINE ACTIVITY: IS INTERACTION WITH THE GLYCINE RECEPTOR, AS EVIDENCED BY DISPLACEMENT OF STRYCHNINE

BINDING, A USEFUL CRITERION?. 000151 01-03

CROSS-GENERALIZATION CHANGES OF SENSITIVITY TO THE CUING PROPERTIES OF NARCOTIC DRUGS AS EVIDENCED BY GENERALIZATION AND CROSS-GENERALIZATION EXPERIMENTS.

003194 04-04

A DOUBLE-BLIND CROSS-OVER STUDY: APOMORPHINE/PLACEBO IN 000621 01-11

CYCLOBENZAPRINE AND BENZOTROPINE METHANESULFONATE IN PARKINSONS DISEASE: A RANDOMIZED DOUBLE-BLIND CROSS-OVER

000654 01-11 MULTICLINIC CROSS-OVER COMPARISON OF TRIAZOLAM (HALCION) AND PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND ANXIETY IN ANXIOUS OUTPATIENTS

000762 01-14 DOXEPIN AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION: A DOUBLE-BLIND CROSS-OVER CLINICAL STUDY WITH EKG RECORDINGS 002416 03-09

ENDORPHIN RELEASE: CROSS-TOLERANCE TO MORPHINE.

FOOTSHOCK INDUCED ANALGESIA IN MICE: ITS REVERSAL BY NALOXONE AND CROSS-TOLERANCE WITH MORPHINE.

001078 02-03 EFFECT OF P-CHLOROPHENYLALANINE ON DEVELOPMENT OF CROSS-TOLERANCE BETWEEN PENTOBARBITAL AND ETHANOL. 001123 02-03

TOLERANCE AND CROSS-TOLERANCE TO CNS DEPRESSANTS AFFER CHRONIC PENTOBARBITAL. 001442 02-04

BARBITAL-INDUCED TOLERANCE AND CROSS-TOLERANCE TO VARIOUS CNS DEPRESSANTS ON RAT OPERANT BEHAVIOR. 001481 02-04

001916 02-17

ON THE INTERACTION OF DRUGS WITH THE CHOLINLIGIC NERVOUS SYSTEM. II. CROSS-TOLERANCE BETWEEN PHENCYCLIDINE DERIVATIVES AND CHOLINERGIC DRUGS.

METHADONE DOSE, PLASMA LEVEL, AND CROSS-TOLERANCE TO HEROIN

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL TOLERANCE AND CROSS-TOLERANCE TO MORPHINE AND METHADONE IN THE RAT.

HIBITION OF MONOAMINE OXIDATION IN SUBFRACTIONS OF CRUDE MITOCHONDRIA OF RAT BRAIN BY CLORGYLINE AND LILLY-51641.

NALOXONE (NARCAN) TREATMENT IN DEPRESSION: CLINICAL OBSERVATIONS AND EFFECTS ON CSF ENDORPHINS AND MONOAMINE METABOLITES.

001692 02-13 BRAIN: SERUM AND CSF: SERUM RATIOS AFTER A SINGLE DOSE OF DIPROPYLACETIC-ACID (DPA).

PROBENECID-INDUCED NOREPINEPHRINE ELEVATIONS IN PLASMA AND

002573 03-13 THE EFFECT OF L-DOPA AND PROPRANOLOL ON HUMAN CSF CYCLIC-NUCLEOTIDES.

HOMOVANILLIC-ACID IN HUMAN CSF: COMPARISON OF FLUOROMETRY AND GAS-CHROMATOGRAPHY MASS-SPECTROMETRY.

BIBLIOGRAPHY ON TARDIVE-DYSKINESIA SINCE CTB-TDN, VOLUME 2,

NO. 1. 000811 01-15

CUE EFFECTS OF ALPHA-METHYL-P-TYROSINE, ADRENOLYTIC COMPOUNDS, PIMOZIDE AND OTHER NEUROLEPTICS, ON THE NARCOTIC CUE. 000338 01-04

DISCRIMINATIVE STIMULUS PROPERTIES OF FENFLURAMINE IN AN OPERANT TASK: AN ANALYSIS OF ITS CUE FUNCTION.

000369 01-04 CATECHOLAMINE INVOLVEMENT IN THE NARCOTIC CUE

001332 02-04
DIFFERENTIAL CUE ATTENTIVENESS AND PLACEBO RESPONSIVITY. (PH.D. DISSERTATION)

002740 03-17 BETA-ENDORPHIN AND THE NARCOTIC CUE.

003179 04-04 NEUROLEPTIC INTERFERENCE WITH THE COCAINE CUE: INTERNAL STIMULUS CONTROL OF BEHAVIOR AND PSYCHOSIS.

003193 04-04 MORPHINE AS A DISCRIMINATIVE CUE IN GERBILS: DRUG

GENERALIZATION AND ANTAGONISM. 003249 04-04 COCAINE AS A DISCRIMINATIVE CUE IN RATS: INTERACTIONS WITH

NEUROLEPTICS AND OTHER DRUGS. 003250 04-04 THE EFFECTS OF HALOPERIDOL ON DISCRIMINATIVE RESPONDING CONTROLLED BY THE COCAINE CUE.

003318 04-04 CENTRAL MECHANISMS OF REWARD AND THE NARCOTIC CUE.

003369 04-04
REINFORCING AND AVERSIVE PROPERTIES OF THE NARCOTIC CUE.

003372 04-04 NARCOTIC CUE, NARCOTIC ANALGESIA, AND THE TOLERANCE PROBLEM. 003707 04-17

CUE-TO-CONSEQUENCE
THE ATTENUATION OF A SPECIFIC CUE-TO-CONSEQUENCE ASSOCIATION BY
ANTIEMETIC AGENTS. 001992 03-03

NARCOTIC CUEING PROPERTIES OF INTRAVENTRICULARLY ADMINISTERED SUFENTANIL, FENTANYL, MORPHINE AND MET-ENKEPHALIN.

002217 03-04

DRUG CUES, DRUG STATES, AND INFANTILE AMNESIA. 003196 04-04

NARCOTIC CUING AND ANALGESIC ACTIVITY OF NARCOTIC ANALGESICS: ASSOCIATIVE AND DISSOCIATIVE CHARACTERISTICS. 003192 04-04

CHANGES OF SENSITIVITY TO THE CUING PROPERTIES OF NARCOTIC DRUGS AS EVIDENCED BY GENERALIZATION AND CROSS-GENERALIZATION EXPERIMENTS. 003194 04-04

HISTORICAL AND CULTURAL FACTORS INFLUENCING CANNABIS USE AMONG INDIANS IN SOUTH-AFRICA.

Psychopharmacology Abstracts

CULTURE THE EFFECT OF PENTOBARBITAL ON THE CARBOHYDRATE METABOLISM OF GLIAL CELLS IN CULTURE.

000484 01-05 HIGH STATES IN CUITURE HISTORICAL PERSPECTIVE

000676 01-12 **EFFECTS OF LITHIUM ON GRANULOPOIESIS IN CULTURE**

002105 03-03 ADRENERGIC ALPHA-RECEPTORS AND BETA-RECEPTORS EXPRESSED BY THE SAME CELL TYPE IN PRIMARY CULTURE OF PERINATAL MOUSE BRAIN.

CUILTUR-D ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE NEUROBLASTOMA CELLS.

000241 01-03 BLOCKADE BY PSYCHOTROPIC DRUGS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR IN CULTURED NERVE CELLS.

ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002004 03-03

DIHYDROERGOTOXINE-INDUCED MODULATION OF SPONTANEOUS ACTIVITY OF CULTURED RAT PURKINJE CELLS.

ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002137 03-03 TA-ADRENOCEPTORS MODULATE NORADRENALINE RELEASE FROM AXONAL SPROUTS IN CULTURED RAT SUPERIOR CERVICAL GANGLIA

002179 03-03 MULTIPLE MEMBRANE ACTIONS OF ENKEPHALIN REVEALED USING CULTURED SPINAL NEURONS.

002816 04-03 NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. I. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE IN EXPONENTIAL GROWTH PHASE.

002836 04-03 MONOAMINE-OXIDASE-A AND MONOAMINE-OXIDASE-B IN CULTURED

NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. II. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE TREATED WITH DIBUTYRYL-CYCLIC-AMP.

003026 04-03 MUSCARINIC RECEPTOR MEDIATED CYCLIC-GMP FORMATION BY CULTURED NERVE CELLS -- IONIC DEPENDENCE AND EFFECTS OF LOCAL ANESTHETICS.

CONCOMITANT ELEVATION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY CYCLIC-AMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

HYDROLYSIS OF ENKEPHALIN BY CULTURED HUMAN ENDOTHELIAL CELLS AND BY PURIFIED PEPTIDYL DIPEPTIDASE.

003593 04-13

DIRECT EFFECTS OF ETHANOL ON CENTRAL-NERVOUS-SYSTEM CULTURES: AN ELECTROPHYSIOLOGICAL AND MORPHOLOGICAL STUDY.

EVIDENCE FOR FUNCTIONAL SYNAPSES BETWEEN MIXED CULTURES OF INFERIOR OLIVE AND CEREBELLUM.

000497 01-06 CHLORDIAZEPOXIDE SELECTIVELY AUGMENTS GABA ACTION IN SPINAL CORD CELL CULTURES.

SELECTIVE OPIATE DEPRESSION OF SENSORY EVOKED SYNAPTIC
NETWORKS IN DORSAL-HORN REGIONS OF SPINAL CORD CULTURES

001088 02-03 BIOCHEMICAL DIFFERENTIATION OF AGGREGATING CELL CULTURES OF DIFFERENT FETAL RAT BRAIN REGIONS.

001148 02-03 OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG NEURITES.

EVIDENCE AGAINST CHRONIC DEPOLARIZATION AS A MECHANISM OF KAINIC-ACID TOXICITY IN MOUSE CEREBELLAR CULTURES.

003418 04-05

FENFLURAMINE: CUMULATIVE NEUROTOXICITY AFTER CHRONIC TREATMENT WITH LOW DOSAGES IN THE RAT. 001508 02-05

THE IONTOPHORESIS OF DIAZEPAM IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT.

002130 03-03

VOLUME 16, SUBJECT INDEX

THE ROLE OF DIAZEPAM AS COMPARED TO GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT. (PH.D. DISSERTATION).

002131 03-03

EFFECT OF CURCUMEN-LONGA ON EMOTIONALITY AND LEARNING. 001441 02-04

THANATOPHARMACOLOGY IN THE MEDICAL SCHOOL CURRICULUM. 001910 02-17

THE TRIPHASIC AMPHETAMINE LETHAL DOSE CURVE IN MICE AND ITS POSSIBLE RELATIONSHIP TO DRUG METABOLISM.

003410 04-05

CURVES
MORPHINE ANALGESIA DOSE RESPONSE CURVES IN TOLERANT RATS:
MODIFICATION BY NALOXONE.

TOLERANCE TO MORPHINE ANALGESIA AND IMMOBILITY MEASURED IN RATS BY CHANGES IN LOG-DOSE-RESPONSE CURVES.

CUSHINGOID

CYPROHEPTADINE IN BIPOLAR AFFECTIVE-ILLNESS WITH CUSHINGOID
FEATURES.

TANEOUS

THE EFFECT OF NALOXONE ON THE EXCITATION OF DORSAL-HORN
NEURONES OF THE CAT BY NOXIOUS AND NONNOXIOUS CUTANEOUS
STIMULI.

STIMULI. 001102 02
CYANOCYPROHEPTADINE

CYANOCYPROHEPTADINE: ROLE OF CHOLINOLYTIC PROPERTIES IN

MODULATING NEUROLEPTIC-INDUCED ELEVATION OF STRIATAL HOMOVANILLIC-ACID (HVA).

O01226 02-03

CYCLANDELATE

THE EFFECT OF CYCLANDELATE IN DEPRESSED AND DEMENTED PATIENTS:

A CONTROLLED STUDY IN PSYCHOGERIATRIC PATIENTS.

001617 02-11

NALTREXONE AND CYCLAZOCINE: A CONTROLLED TREATMENT STUDY. 000804 01-15 PENTAZOCINE, CYCLAZOCINE, AND NALORPHINE AS DISCRIMINATIVE

001378 02-04
INDUCTION OF PHYSICAL DEPENDENCE ON CYCLAZOCINE AND
PENTAZOCINE IN THE RAT.

A DOSE RATIO COMPARISON OF THE INTERACTION BETWEEN MORPHINE AND CYCLACOLINE WITH NALOXONE IN RHESUS MONKEYS ON THE SHOCK TITRATION TASK.

A COMPARISON OF DISCRIMINATIVE STIMULI PRODUCED BY NALOXONE, CYCLAZOCINE AND MORPHINE IN THE RAT.

EFFECTS OF SODIUM THIOPENTAL ON THE TRICARBOXYLIC-ACID CYCLE METABOLISM IN MOUSE BRAIN: CO2 FIXATION AND METABOLIC COMPARTMENTATION

ALTERATION OF TRICARBOXYLIC-ACID CYCLE METABOLISM IN RAT BRAIN SLICES BY HALOTHANE.

ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

003272 04-04

EFFECTS OF L 5 HYDROXYTRYPTOPHAN ON SLEEP-WAKEFULNESS CYCLES
IN CATS.

TRICYCLIC ANTIDEPRESSANTS ACCELERATE MANIC-DEPRESSIVE CYCLES.
(UNPUBLISHED PAPER).

002468 03-09

CYCLIC-ADENOSINE-MONOPHOSPHATE

AGONIST EFFECTS OF BETA-PHENYLETHYLAMINES ON THE
NORADRENERGIC CYCLIC-ADENOSINE-MONOPHOSPHATE GENERATING
SYSTEM IN RAT LIMBIC FOREBRAIN. 3,5-MONOPHOSPHATE
GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. STEREOISOMERS OF

STSTEM IN KAT LIMBIC FOREBRAIN. 3,3-MUNOPHOSPHATE
GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. STEREOISOMERS OF
P-HYDROXYNOREPHEDRINE.

000272 01-03
PROSTAGLANDIN-E2, CYCLIC-ADENOSINE-MONOPHOSPHATE AND
MORPHINE ANALGESIA.

CYCLIC-ADENOSINE-MONOPHOSPHATE METABOLISM IN PATIENTS WITH SEVERE DEPRESSIVE ILLNESS.

SEVERE DEPRESSIVE ILLNESS. 000570 01-09

CYCLIC-AMP AND THE POSITIVE INTROPIC EFFECT OF NOREPINEPHRINE AND PHENYLEPHRINE. 000195 01-03 Subject Index

INFLUENCE OF INJECTED PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE BRAIN AND LUNG FOLLOWING MICROWAVE IRRADIATION. 000214 01-03

INVOLVEMENT OF BRAIN CYCLIC-AMP IN MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE. (PH.D. DISSERTATION).

URINARY CYCLIC-AMP EXCRETION BY METHADONE SUBJECTS DURING GRADUAL AND ACUTE WITHDRAWAL.

THE MOOD RESPONSE AND PLASMA CYCLIC-AMP RESPONSE TO INTRAVENOUS METHYLPHENIDATE.

CYCLIC-AMP IN CEREBROSPINAL FLUID OF MANIC AND DEPRESSIVE

CYCLIC-AMP IN THE PLASMA OF CHRONIC SCHIZOPHRENICS, BEFORE AND AFTER TREATMENT.

001690 02-13

POSSIBLE INVOLVEMENT OF CYCLIC-AMP IN INFLAMMATION INDUCED BY
A SURFACTANT.

BETA-ADRENERGIC RECEPTOR MEDIATED CYCLIC-AMP SYNTHESIS IN BROKEN-CELL HOMOGENATES OF RAT BRAIN.

O02033 03-03
FURTHER EVIDENCE OF CYCLIC-AMP MEDIATED HYPERTROPHY AS A
PREREQUISITE OF DRUG SPECIFIC ENZYME INDUCTION.

EFFECT OF DIHYDROERGOTOXINE ON CYCLIC-AMP GENERATING SYSTEMS
IN RAT CEREBRAL-CORTEX SLICES.

OO2088 03-0:
MODIFICATION OF THE NORADRENERGIC CYCLIC-AMP GENERATING
SYSTEM IN THE RAT LIMBIC FOREBRAIN BY AMPHETAMINE (A) AND
ITS HYDROXYLATED METABOLITES.

STUDIES ON THE INHIBITION OF PHOSPHODIESTERASE CATALYZED CYCLIC-AMP AND CYCLIC-GMP BREAKDOWN AND RELAXATION OF CANINE TRACHEAL SMOOTH MUSCLE.

O21129 03-0
NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN
SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC
ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS.

DOPAMINE-MIMETIC ACTIVITY OF ERGOT DERIVATIVES, AS MEASURED BY THE PRODUCTION OF CYCLIC-AMP IN ISOLATED RETINAE OF THE

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALL FULL TO THE PRESSION.

O02164 03-03

NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. I. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE IN EXPONENTIAL GROWTH PHASE.

BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101
BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP
ACCUMULATION IN RAT CEREBRAL-CORTEX.

OC2885 04-03
NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE
INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION
PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND LDOPA TO RATS.

002942 04-03

NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. II. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE TREATED WITH DIBUTYRYL-CYCLIC-AMP.

THE DIFFERENTIAL EFFECT OF LITHIUM ON NORADRENALINE AND DOPAMINE SENSITIVE ACCUMULATION OF CYCLIC-AMP IN GUINEA-PIG BRAIN.

003063 04-03
EFFECT OF STRESS ON NOREPINEPHRINE STIMULATED CYCLIC-AMP
FORMATION IN BRAIN SLICES.

CONCOMITANT ELEVATION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY CYCLIC-AMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

O03133 04-03
THE EFFECT OF CHLORPROMAZINE, SOME TRICYCLIC ANTIDEPRESSANTS
AND INSULIN ON THE ACTION OF CYCLIC-AMP AND ADENOSINE
METABOLISM.

O03606 04-13

EYCLIC-GMP

BICYCLIC PHOSPHORUS ESTERS INCREASE THE CYCLIC-GMP LEVEL IN RAT

ON THE MECHANISM OF THE DECREASE IN CEREBELLAR CYCLIC-GMP
CONTENT ELICITED BY OPIATE RECEPTOR AGONISTS.

000654 01-11

ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE NEUROBLASTOMA CELLS.

THE EFFECT OF MELPERONE (BURONIL(R)) AND ITS METABOLITE FG-5155 ON THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM COMPARED TO SOME OTHER NEUROLEPTICS.

CYCLIC-GMP AND GABA LEVELS IN RAT STRIATUM AND CEREBELLUM DURING MORPHINE WITHDRAWAL: EFFECT OF APOMORPHINE.

ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

02004 03-03 STUDIES ON THE INHIBITION OF PHOSPHODIESTERASE CATALYZED CYCLIC-AMP AND CYCLIC-GMP BREAKDOWN AND RELAXATION OF CANINE TRACHEAL SMOOTH MUSCLE.

ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

DECREASE OF CYCLIC-GMP IN CEREBELLUM BY INTRASTRIATAL D ALA2-MET-ENKEPHALINAMIDE.

002828 04-03 EFFECT OF ACUTE MORPHINE ADMINISTRATION ON THE CEREBELLAR CYCLIC-GMP LEVEL IN TWO STRAINS OF MICE.

002975 04-03 MUSCARINIC RECEPTOR MEDIATED CYCLIC-GMP FORMATION BY CULTURED NERVE CELLS -- IONIC DEPENDENCE AND EFFECTS OF LOCAL

003064 04-03

CYCLIC-GMP-INDUCED
DISAPPEARANCE OF CEREBELLAR CYCLIC-GMP-INDUCED BY KAINIC-ACID.
002826 04-03

CYCLIC-GUANOSINE-MONOPHOSPHATE

3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE LEVELS IN RAT CEREBELLUM:
EFFECTS OF MORPHINE, KETAMINE, HARMALINE AND ISONIAZID.

MORPHINE REDUCES CEREBELLAR CYCLIC-GUANOSINE-MONOPHOSPHATE
CONTENT AND ELEVATES CEREBROSPINAL FLUID CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT IN RHESUS MONKEY.

EFFECT OF CHRONIC TREATMENT WITH NEUROLEPTICS ON THE CONTENT OF 3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE IN CEREBELLAR-CORTEX OF RATS.

REGULATION OF CYCLIC-GUANOSINE-MONOPHOSPHATE IN THE RAT PINEAL AND POSTERIOR PITUITARY GLANDS.

CYCLIC-NUCLEOTIDE
STRESS-INDUCED ALTERATIONS OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN:
EFFECTS OF CENTRALLY ACTING DRUGS.

000097 01-03

000097 01-03 SPECIFICITY OF BINDING OF ANTIPSYCHOTICS TO THE ACTIVATOR OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE.

001178 02-03 BINDING OF ANTIPSYCHOTIC AGENTS TO THE CYCLIC-NUCLEOTIDE ACTIVATOR.

CYCLIC-NUCLEOTIDE LEVELS IN THE RAT STRIATUM AND CEREBELLUM —
IN VIVO EFFECTS OF DOPAMINE AND ACETYLCHOLINE RECEPTOR
AGONISTS AND ANTAGONISTS.

THE ROLE OF CALCIUM IN THE REGULATION OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN SLICES OF RAT AND GUINEA-PIG.

CYCLIC-NUCLEOTIDES

EFFECT OF NALOXONE ON MORPHINE-INDUCED CHANGES IN ACTH,
CORTICOSTERONE AND CYCLIC-NUCLEOTIDES.

002949 04-03 THE EFFECTS OF D ALA2-METS-ENKEPHALINAMIDE ON BEHAVIORAL ACTIVITY AND CYCLIC-NUCLEOTIDES IN THE RAT BRAIN. (PH.D. DISSERTATION).

003240 04-04 THE EFFECT OF L-DOPA AND PROPRANOLOL ON HUMAN CSF CYCLIC-NUCLEOTIDES.

003587 04-13 LITHIUM TREATMENT OF CYCLICAL VOMITING IN A MENTALLY DEFECTIVE

PATIENT. 000977 01-17

CYCLING
RAPID CYCLING MANIC-DEPRESSIVE PATIENTS. 001583 02-09

CYCLIZATION
ENZYMIC DEALKYLATION OF A SUBSTITUTED
AMINOACETAMIDOBENZOPHENONE AND CYCLIZATION TO THE
CORRESPONDING BENZODIAZEPINE IN VITRO.

00015

THE METABOLISM OF A SUBSTITUTED AMINOACETAMIDOBENZOPHENONE AND CYCLIZATION TO THE CORRESPONDING BENZODIAZEPINE IN THE RAT IN VIVO. 000242 01-03

QUINAZOLINES AND 1,4 BENZODIAZEPINES. 81. S TRIAZOLOBENZODIAZEPINES BY OXIDATIVE CYCLIZATION OF HYDRAZONES. 001017 02-01

CYCLOBENZAPRINE
CYCLOBENZAPRINE AND BENZOTROPINE METHANESULFONATE IN
PARKINSONS DISEASE: A RANDOMIZED DOUBLE-BLIND CROSS-OVER
STUDY.

CYCLOHEXIMIDE
STUDIES ON TOLERANCE. II. THE EFFECT OF TIMING ON INHIBITION OF
TOLERANCE TO MORPHINE BY CYCLOHEMMIDE.

ENHANCEMENT OF LEARNING BY CYCLOHEXIMIDE AND DDC: A FUNCTION OF RESPONSE STRENGTH.

THE EFFECT OF INTRACEREBRAL INJECTION OF CYCLOHEXIMIDE ON BRAIN PROTEIN SYNTHESIS AND ON THE HYPERACTIVITY SYNDROME PRODUCED BY A MONOAMINE-OXIDASE INHIBITOR AND TRYPTOPHAN. 000410 01-04 MEMORY IMPAIRMENT CORRELATES CLOSELY WITH CYCLOHEXIMIDE DOSE AND DEGREE OF INHIBITION OF PROTEIN SYNTHESIS.

000436 01-04

EFFECT OF D AMPHETAMINE ON THE INHIBITION OF BRAIN
CATECHOLAMINE TURNOVER INDUCED BY CYCLOHEXIMIDE 001279 02-03

EFFECTS OF D AMPHETAMINE AND STRYCHNINE ON CYCLOHEXIMIDE -AND DIETHYLDITHIOCARBAMATE-INDUCED AMNESIA IN MICE. 001438 02-04

SUBAMNESIC CYCLOHEXIMIDE TREATMENT DELAYS CONSOLIDATION IN MICE.

003334 04-04 INHIBITION OF 5,7 DIHYDROXYTRYPTAMINE-INDUCED SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN MICE BY TREATMENT WITH CYCLOHEXIMIDE.

003366 04-04 MORBIDITY SUPPRESSIVE EFFECT OF LITHIUM-CARBONATE IN CYCLOID

PSYCHOSIS.

CYCLOLEUCINE EFFECT OF 1 AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID (CYCLOLEUCINE)
ON DEVELOPING RAT CENTRAL-NERVOUS-SYSTEM PHOSPHOLIPIDS.
002136 03-03

CYCLOPROPANE
THE EFFECT OF ABLATION OF SEROTONIN OR NOREPINEPHRINE
BRAINSTEM AREAS ON HALOTHANE AND CYCLOPROPANE MAC IN
RATS. (UNPUBLISHED PAPER).

001229 02-03 CYCLOPROPANIC
CYCLOPROPANIC PYRIDINE ALCOHOLS.

000003 01-01

CYCLOPROPYL
FURTHER STUDIES ON THE EFFECTS OF N CYCLOPROPYL PCHLOROAMPHETAMINE IN RAT BRAIN.

000111 01-03 CYCLOTHYMIA

LITHIUM PROPHYLAXIS IN THE TREATMENT OF CYCLOTHYMIA IN
TEENAGERS.

()- AND (-) 3 METHOXYCYPROHEPTADINE. A COMPARATIVE EVALUATION OF THE ANTISEROTONIN, ANTIHISTAMINIC, ANTICHOLINERGIC, AND OREXIGENIC PROPERTIES WITH

URINARY EXCRETION OF A QUATERNARY AMMONIUM GLUCURONIDE METABOLITE OF CYPROHEPTADINE IN HUMANS UNDERGOING CHRONIC DRUG THERAPY.

001667 02-13 CYPROHEPTADINE IN BIPOLAR AFFECTIVE-ILLNESS WITH CUSHINGOID

THE EFFECTS OF P-CHLOROPHENYLALANINE, RESERPINE, METHYSERGIDE
AND CYPROHEPTADINE ON THE DOPA-INDUCED EEG SYNCHRONIZATION
IN THE RAT.

003022 04-03 CYPROTERONE-ACETATE
CYPROTERONE-ACETATE EXPOSURE DURING GESTATION IN MICE
RETARDS FETAL GROWTH.

003129 04-03 PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: THE EFFECT OF PREMEDICATION WITH CYSTAMINE ON PHARMACODYNAMICS AND PHARMACOKINETICS OF NITRAZEPAM.

002317 03-04

000152 01-03

CHANGES IN PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECTS OF PERMEDICATION WITH CYSTAMINE ON DYNAMICS AND KINETICS OF THIORIDAZINE.

002332 03-

CYTOCHROME-P-450
QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE
ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3
METHYCHOLANTHENE.

THE DEVELOPMENT OF SEX DIFFERENCES IN THE DEMETHYLATION OF ETHYLMORPHINE AND IN ITS INTERACTION WITH COMPONENTS OF THE HEPATIC MICROSOMAL CYTOCHROME-P-450 SYSTEM IN MICE. 003122 04-03

CYTOLOGY

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON UTERINE AND VAGINAL CYTOLOGY OF OVARIECTOMIZED RATS.

CYTOPLASMIC

AROMATIC AMINOTRANSFERASE ACTIVITY OF RAT BRAIN CYTOPLASMIC

AND MITOCHONDRIAL ASPARTATE AMINOTRANSFERASES.

INDUCIBLE ALDEHYDE-DEHYDROGENASES IN THE HEPATIC CYTOSOL OF THE RAT.

CYTOSOLIC

ROLE OF LIVER CYTOSOLIC ALDEHYDE-DEHYDROGENASE ISOZYMES IN CONTROL OF BLOOD ACETALDEHYDE CONCENTRATIONS.

C11-OCTYLAMINE

EVALUATION OF RADIORESPIROMETRY FOR THE DETERMINATION OF

MONOAMINE-OXIDASE ACTIVITY IN VIVO UTILIZING C11-OCTYLAMINE

AS A SUBSTRATE.

T4-BETA-ALANINE
HIGH-AFFINITY BINDING OF H3-GLYCINE AND C14-BETA-ALANINE TO
SYNAPTOSOMAL MITOCHONDRIAL FRACTIONS OF RAT CNS REGIONS;

SYNAPTOSOMAL MITOCHONDRIAL FRACTIONS OF RAT CNS REGIONS; EFFECTS OF STRYCHNINE. 000211 01-03

C14-DISULFIRAM

PHARMACOKINETIC STUDIES OF TETRAETHYL-L-C14-THIURAMDISULFIDE
(C14-DISULFIRAM). A PRELIMINARY STUDY.

000634 01-11

GLUCOSE
STIMULATION BY LITHIUM-IONS OF THE INCORPORATION OF C14GLUCOSE INTO GLYCOGEN IN RAT BRAIN SLICES.

003015 04-03

C14-IMIPRAMINE
FIRST-PASS ELIMINATION OF C14-IMIPRAMINE IN ISOLATED PERFUSED

RAT LIVER. 001052 02-03

PILOT STUDY ON THE DISTRIBUTION OF C14-LABELED METHAQUALONE IN THE RAT BRAIN.

C14-MESCALINE

REGIONAL LOCALIZATION OF C14-MESCALINE IN RABBIT BRAIN AFTER
INTRAVENTRICULAR ADMINISTRATION: EFFECTS OF CHLORPROMAZINE
AND IPRONIAZIO PRETREATMENT.

C14-METHAQUALONE
SUBCELLULAR LOCALIZATION OF C14-METHAQUALONE IN MOUSE BRAIN:
EFFECTS OF HEPATIC MICROSOMAL ENZYME INHIBITION.
002983 04-03

C14-NITRAZEPAM
TISSUE DISTRIBUTION OF RADIOACTIVITY AFTER INJECTION OF C14NITRAZEPAM IN YOUNG AND OLD RATS.

002948 04-03

C14-PHENOBARBITONE
THE METABOLIC FATE OF C14-PHENOBARBITONE IN THE RAT AND THE
EFFECT OF CHRONIC ADMINISTRATION AND DOSE SIZE.

000067 01-03

DIFFERENTIAL EFFECTS OF OPIATES ON THE INCORPORATION OF C14-THIAMINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT. 000201 01-03

C14-5
EFFECT OF TWO NON TRICYCLIC ANTIDEPRESSANT DRUGS ON C14-5
HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.
001283 02-03

C14-5-HYDROXYTRYPTAMINE
INTERFERENCE BY FENFLURAMINE WITH THE STORAGE OF C14-5-HYDROXYTRYPTAMINE IN RAT PLATELETS.

000297 01-03

EXPERIMENTAL BARBITURATE DEPENDENCE. I. BARBITURATE DEPENDENCE DEVELOPMENT IN RATS BY DRUG ADMIXED FOOD (DAF) METHOD. 003373 04-04

DAILY
LONG-TERM BEHAVIORAL CHANGES IN THE RHESUS MONKEY AFTER
MULTIPLE DAILY INJECTIONS OF D METHYLAMPHETAMINE.
000359 01-04
PHARMACOKINETICS OF N DESMETHYLDIAZEPAM IN HEALTHY

PHARMACOKINETICS OF N DESMETHYLDIAZEPAM IN HEALTHY VOLUNTEERS AFTER SINGLE DAILY DOSES OF DIPOTASSIUM CHLORAZEPATE.

DAILY 1 DELTA9-TETRAHYDROCANNABINOL AND PRESSING FOR HYPOTHALAMIC STIMULATION.

DAILY CHANGES IN THE BLOOD SERUM LEVELS OF DIPHENYLHYDANTOIN
(DPH) AND PHENOBARBITAL.

001830 02-15

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE, SELF-STIMULATION, AND PARAMETERS OF ICS. 002320 03-04

THE EFFECTS OF DAILY COCAINE ADMINISTRATION ON COCAINE-INDUCED MORTALITY. 003421 04-05

A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-DUMMY TECHNIQUE.

003537 04-10

DAMAGE
PHOTODYNAMIC ACTION OF CHLORPROMAZINE ON ADENOVIRUS 5:
REPAIRABLE DAMAGE AND SINGLE STRAND BREAKS.

QUANTITATIVE DETERMINATION OF STRESS-INDUCED MYOCARDIAL DAMAGE IN RATS.

THE PROBLEM OF PRENATAL DAMAGE FROM LONG-TERM ANTIEPILEPTIC DRUG TREATMENT.

002659 03-15
CHRONIC NEUROLEPTIC USE AND PERIPHERAL MOTOR NEURON DAMAGE.
002671 03-15
CLONIDINE-INDUCED BODY TEMPERATURE CHANGES IN RATS WITH

ANTERIOR OR POSTERIOR CORTICAL DAMAGE.

LITHIUM AND CRISIS INTERVENTION: DAMPING AFFECTIVE OVERLOAD. 003717 04-17

THE LACK OF EFFECT OF SYNTHETIC SCOTOPHOBIN ON DARKNESS
AVOIDANCE IN MICE.

001496 02-04

PROPOXYPHENE-NAPSYLATE (DARVON-N OR PN) IN THE TREATMENT OF HEROIN DEPENDENCE.

THE EFFECTS OF DARVON-N ON RETENTION OF SPECIFIC LEARNING TASKS DURING HEROIN DETOXIFICATION. (PH.D. DISSERTATION).

001703 02-14

DATA
RHEGENCEPHALOGRAPHIC DATA IN MIGRAINE CEPHALGIA AND THEIR
CHANGES DURING STUGERON TREATMENT.

DATA ANALYSIS: COLLABORATIVE OUTPATIENT SCHIZOPHRENIA STUDY.
000528 01-08

FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN TREATMENT OF REMITTED SCHIZOPHRENICS: II. RATING SCALE DATA. 000544 01-01 QUANTIFICATION AND STATISTICAL ANALYSIS OF ORDINAL SCALE DATA

IN PSYCHIATRY.

000913 01-16
RATIO DATA AND THE QUANTIFICATION OF DRUG EFFECTS.

EFFICACY OF NEUROLEPTICS AND ANTIDEPRESSANTS IN THE TEST OF APOMORPHINE HYPOTHERMIA AND SOME DATA CONCERNING NEUROCHEMICAL MECHANISMS OF THE TEST.

APOMORPHINE HYPOTHERMIA AND SOME DATA CONCERNING
NEUROCHEMICAL MECHANISMS OF THE TEST.

002147 03-03
LOSS OF INFORMATION INDUCED BY REDUCTION OF DATA IN THE
LABORATORY LANGUAGE METHOD.

BI AND MULTIVARIATE ANALYSIS OF EEG DATA IN CLINICAL PSYCHOPHARMACOLOGY.

DATS
THE EFFECT OF DIHYDROXY-2-AMINOTETRALINS (DATS) ON DOPAMINE

AND BETA TYPE ADENYLATE-CYCLASES.

DATURA-SUAVEOLENS
PSYCHOSIS INDUCED BY DATURA-SUAVEOLENS: HALLUCINOSIS AND
ANTICHOLINERGIC DELIRIUM.

REPLY TO DAVIS AND HURT CONCERNING METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGICAL RESEARCH WITH CHLORPROMAZINE.

POLYGRAPHIC EVALUATION OF ETHCHLORVYNOL (14 DAYS). 002679 03-15 SLEEP-INDUCING EFFECT OF A VASOPRESSIN ANALOG, DEAMINO-6-CARBA-ORNITHINE-8-VASOPRESSIN (DCOV) IN RATS. 003265 04-04 DDAVP AND LITHIUM-INDUCED POLYURIA/POLYDIPSIA. 001851 02-15 ENHANCEMENT OF LEARNING BY CYCLOHEXIMIDE AND DDC: A FUNCTION OF RESPONSE STRENGTH. 000374 01-04 FLUPHENAZINE DEPOT (LYORODIN DEPOT) -- SOON IN PRODUCTION IN 002400 03-08 DEAFENING

EFFECTS OF DEAFENING AND BLINDFOLDING ON AMPHETAMINE-INDUCED

STEREOTYPY IN THE CAT.

000456 01-0-000456 01-04 DEAFFERENTATION
THE EFFECTS OF HYPOTHALAMIC DEAFFERENTATION ON THE
HALOPERIDOL-INDUCED ACTIVATION OF TUBEROINFUNDIBULAR DOPAMINE NEURONS. EFFECTS OF COMPLETE HYPOTHALAMIC DEAFFERENTATION AND 5,7 DIHYDROXYTRYPTAMINE ON SEVERAL PARAMETERS OF PROLACTIN RELEASE. 001047 02-03 001990 03-03 LITHIUM AND AGGRESSIVE BEHAVIOR IN PATIENTS WITH EARLY TOTAL DEAFNESS. 000618 01-11 DEALKYLATION ENZYMIC DEALKYLATION OF A SUBSTITUTED

AMINOACETAMIDOBENZOPHENONE AND CYCLIZATION TO THE

CORRESPONDING BENZODIAZEPINE IN VITRO. 000152 01-03 EFFECTS OF PSYCHOTROPIC DRUGS ON DEAMINASE IN CNS. 002904 04-03 DEAMINATION EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE. 000127 01-03 METHYLHISTAMINE: EVIDENCE FOR SELECTIVE DEAMINATION BY MAO-B IN THE RAT BRAIN IN VIVO. 002172 03-03 PHENYLETHYLAMINE -- DEAMINATION BY MULTIPLE TYPES O MONOAMINE-OXIDASE. 002803 04.03 MINO-6-CARRA-ORNITHINE-8-VASOPRESSIN
SLEEP-INDUCING EFFECT OF A VASOPRESSIN ANALOG, DEAMINO-6CARBA-ORNITHINE-8-VASOPRESSIN (DCOV) IN RATS. 003265 04-04 DEANOL ACETAMIDOBENZOATE (DEANER) IN TARDIVE-DYSKINESIA 001935 02-17 DEANOL IN THE TREATMENT OF TARDIVE-DYSKINESIA. 000588 01-09 SENILE-DEMENTIA. TREATMENT WITH DEANOL 000624 01-11 **DEANOL IN TARDIVE-DYSKINESIA** 000820 01-15 IS DEANOL A PRECURSOR OF ACETYLCHOLINE?. 001134 02-03 DEANOL EFFECTS ON PERFORMANCE AND AVERAGE EVOKED-001412 02-04 DEANOL IN THE MANAGEMENT OF INVOLUNTARY MOVEMENT DISORDERS: A REVIEW. 001886 02-17 DEANOL IN MINIMAL-BRAIN-DYSFUNCTION 001909 02-17 PEDIATRIC PSYCHOPHARMACOLOGY: A REVIEW WITH SPECIAL REFERENCE TO DEANOL. PHARMACOLOGICAL, BIOCHEMICAL AND CLINICAL EFFECTS OF 2 DIMETHYLAMINOETHANOL (DEANOL): A CRITICAL REVIEW.

DEANOL ACETAMIDOBENZOATE (DEANER) IN TARDIVE-DYSKINESIA

DEANOL, LITHIUM AND PLACEBO IN THE TREATMENT OF TARDIVE

Psychopharmacology Abstracts

ESTIMATION OF DEANOL AND CHOLINE BY GAS-CHROMATOGRAPHY
MASS-SPECTROMETRY.

003426 04-06
EFFECTS OF 2 DIMETHYLAMINOETHANOL (DEANOL) ON THE METABOLISM
OF CHOLINE IN PLASMA.

003589 04-13

THE INVESTIGATION OF PHENOBARBITONE, PHENYTOIN AND PRIMIDONE IN THE DEATH OF EPILEPTICS.

000806 01-15
SUDDEN DEATH OF PATIENTS USING PSYCHOTROPIC MEDICATION.
001796 02-15
INTRAVENOUS PROPYLHEXEDRINE AND SUDDEN DEATH.
001850 02-15

DEATHS DEATHS AFTER OVERDOSES OF ORPHENADRINE.

DEATHS AFTER OVERDOSES OF ORPHENADRINE.

000865 01-15
001766 02-15

POLYAMINE BIOSYNTHESIS IN RAT PROSTATE. SUBSTRATE AND INHIBITOR PROPERTIES OF 7 DEAZA ANALOGUES OF DECARBOXYLATED S ADENOSYLMETHIONINE AND 5 METHYLTHIOADENOSINE.

000001 01-01

A DEBATE ON MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY—
REFLECTIONS ON THE SO-CALLED LONG-TERM SATURATION
ADMINISTRATIONS.

001872 02-16

DOCTORS DEBATE BRAIN HORMONE DILEMMAS.

003718 04-17

DECAPITATION

THE EFFECT OF 5,6 DIHYDROXYTRYPTAMINE ON POST DECAPITATION CONVULSIONS.

CONVULSIONS.

001202 02-03

DECAPITATION-INDUCED

EFFECT OF GENERAL ANESTHETICS ON HANDLING-INDUCED AND

DECAPITATION-INDUCED INCREASES IN SYMPATHOADRENAL

DISCHARGE. 002139 03-03

DECARBOXYLASE
SOMATOSENSORY EVOKED-POTENTIALS IN PATIENTS WITH PARKINSONS
SYNDROME DURING TREATMENT WITH L-DOPA AND DECARBOXYLASE
INHIBITOR.

POLYAMINE BIOSYNTHESIS IN RAT PROSTATE. SUBSTRATE AND INHIBITOR PROPERTIES OF 7 DEAZA ANALOGUES OF DECARBOXYLATED S ADENOSYLMETHIONINE AND 5 METHYLTHIOADENOSINE.

000001 01-01

DECARBOXYLATION
INHIBITION OF DOPA DECARBOXYLATION BY ANALOGUES OF TRYPTOPHAN.

DECERBRATE
TRANSCALLOSALLY EVOKED-POTENTIALS AND THE EEG IN THE
DECERBRATE DOG: ACTIONS OF TRYPTAMINERGIC, DOPAMINERGIC
AND ADRENERGIC AGONISTS.
Q00223 01-03

THE EFFECT OF D AMPHETAMINE ON GAMMA EFFERENT ACTIVITY IN THE ACUTE DECEREBRATE RAT. 002311 03-04

EFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY THE RESPONSES OF THE MUSCLE SPINDLE OF THE TRICEPS SURAE MUSCLE OF THE DECEREBRATE CAT TO THE MUSCLE STRETCH.

003109 04-03

DECISION
THE USE OF PSYCHOTROPIC DRUGS IN STATE HOSPITALS: A LEGAL OR
MEDICAL DECISION?.
002730 03-17

DECLINING
DECLINING DIAZEPAM DESENSITIZATION THERAPY.

DECORTICATE

RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS.

ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT

LEARNING WITH D AMPPHETAMINE TREATMENTS.

001614 02-10

DECREASING
ATTENUATION OF THE RATE DECREASING EFFECTS OF AMPHETAMINE ON
FIXED-RATIO RESPONDING IN RATS BY HIPPOCAMPAL LESIONS.
000474 01-04

AN ATTEMPT TO PREDICT THE DURATION OF PENTOBARBITAL NARCOSIS
ON THE BASIS OF EXPLORATORY ACTIVITY, DEFECATION RATE AND
BODY WEIGHT OF RATS.

DEFECTIVE
LITHIUM TREATMENT OF CYCLICAL VOMITING IN A MENTALLY DEFECTIVE
PATIENT.

000977 01-17

001928 02-17

001935 02-17

002677 03-15

VOLUME 16, SUBJECT INDEX

Subject Index

003348 04-04

003334 04-04

	EN		

COMPARATIVE EFFECTS OF APOMORPHINE AND NALOXONE IN ACUTELY DEFENDENT MORPHINIZED RATS AND MICE.

003379 04-04

000413 01-04

EFFECT OF PSYCHOTROPIC DRUGS ON THE DEVELOPMENT OF DEFENSE CONDITIONED REFLEX DURING EXPERIMENTAL NEUROSIS. 002204 03-04

DEFENSIVE
EFFECTS OF ALCOHOL ON ATTACK AND DEFENSIVE SUBMISSIVE REACTIONS IN RATS.

SCHIZOPHRENIA AS A PROSTAGLANDIN DEFICIENCY DISEASE 000794 01-14

DOPAMINE SUPERSENSITIVITY, ENDORPHIN EXCESS, AND PROSTAGLANDIN-ET DEFICIENCY: THREE ASPECTS OF THE SAME SCHIZOPHRENIC ELEPHANT.

003458 04-08 A DISORDER OF BIOGENIC AMINES IN DIHYDROPTERIDINE-REDUCTASE 003554 04-11

SCHIZOPHRENIA AS A DOPAMINE DEFICIENCY DISEASE. 003705 04-17

DEFICIENT

NEW EVIDENCE OF SEROTONIN DEFICIENT DEPRESSIONS 000743 01-13

DEFICITS IN PASSIVE AVOIDANCE LEARNING FOLLOWING ATROPINE IN

THE DEVELOPING RAT. 000320 01-04

SPECIFICITY OF LEARNING DEFICITS PRODUCED BY MICROINJECTIONS OF 6-OHDA INTO THE NIGROSTRIATAL SYSTEM OF THE RAT. 000346 01-04

SLEEP-DEPRIVATION DEFICITS AND THEIR REVERSAL BY D AMPHETAMINE AND L AMPHETAMINE.

000770 01-14 EFFECTS OF 6 HYDROXYDDPAMINE ON BODY WEIGHT: FEEDING DEFICITS OR SENSORY-MOTOR IMPAIRMENTS?.

ALTERATIONS IN MORPHINE ANALGESIA PRODUCED BY CHRONIC DEFICITS OF BRAIN CATECHOLAMINES OR SEROTONIN: ROLE OF ANALGESIMETRIC PROCEDURE 002186 03-03

DEFINED

THE REVOLUTION DEFINED: IT IS PHARMACOLOGIC

000949 01-17

002962 04-03

002238 03-04

001089 02-03

001432 02-04

CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. THE IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2-METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED ANALOGS OF METHAMPHETAMINE

AFFERENT AND EFFERENT SUBCORTICAL PROJECTIONS OF BEHAVIORALLY DEFINED SECTORS OF PREFRONTAL GRANULAR CORTEX.

DEGRADATION
PSYCHOPHARMACOLOGICAL STUDIES ON (-) NUCIFERINE AND ITS HOFMANN DEGRADATION PRODUCT ATHEROSPERMININE 002824 04-03

DEGRADED PROTEIN CONTAINING FOOD AND MONOAMINE-OXIDASE INHIBITORS. 001804 02-15

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL

ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE MEMORY IMPAIRMENT CORRELATES CLOSELY WITH CYCLOHEXIMIDE DOSE AND DEGREE OF INHIBITION OF PROTEIN SYNTHESIS

000436 01-04 RECOVERY AS A FUNCTION OF THE DEGREE OF AMNESIA DUE TO PROTEIN SYNTHESIS INHIBITION. 003204 04-04

DEHYDRATED

MONOAMINERGIC INFLUENCES ON THE INCORPORATION OF \$35 IN THE HYPOTHALAMIC AND NEUROHYPOPHYSIAL PROTEINS FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF \$35-CYSTEINE IN DEHYDRATED RATS.

TYROSINE-HYDROXYLASE: DELAYED ACTIVATION IN CENTRAL NORADRENERGIC NEURONS AND INDUCTION IN ADRENAL MEDULLA ELICITED BY STIMULATION OF CENTRAL CHOLINERGIC RECEPTORS. 000183 01-03 DELAYED ONSET OF SINGLE DOSE TOLFRANCE TO MORPHINE ANALGESIA

TREATMENT OF PATIENTS WITH DELAYED NEUROLEPTICS.

001921 02-17 EFFECT OF METERGOLINE, P-CHLOROPHENYLALANINE AND DOPA ON DELAYED RESPONSE IN CATS AND THE RELATIONSHIP BETWEEN THE MESOLIMBIC AND NIGROSTRIATAL NEURONS.

THE EFFECTS OF CHLORDIAZEPOXIDE ON A DELAYED PAIR COMPARISON

SUBAMNESIC CYCLOHEXIMIDE TREATMENT DELAYS CONSOLIDATION IN MICE.

DELIBERATE TOXIC DELIRIUM INDUCED BY DELIBERATE INGESTION OF JIMSON-WEED

DELIBERATE POISONING WITH TRICYCLIC ANTIDEPRESSANTS TREATED IN AN INTENSIVE CARE UNIT

001758 02-15 THE CONTRIBUTION OF PRESCRIBED DRUGS TO THE INCIDENCE OF ACCIDENTAL AND DELIBERATE POISONING IN THE COMMUNITY 001896 02-17

DELIMITATION
DELIMITATION OF NEURONAL SUBSTRATES NECESSARY FOR THE ANALGESIC ACTION OF BACLOFEN AND MORPHINE 002132 03-03

THE VALUE OF THE MMPI FOR DELINEATING SYMPTOMS UNIQUE TO POSITIVE LITHIUM RESPONDERS: A DRUG RESPONSE AND DIAGNOSTIC STUDY. (PH.D. DISSERTATION).

002638 03-14 TOXIC DELIRIUM INDUCED BY DELIBERATE INGESTION OF JIMSON-WEED

EEG OBSERVATION OF NOCTURNAL DELIRIUM IN A PATIENT TAKING ANTIDEPRESSANTS AND ANTIPARKINSONS DRUGS. 001773 02-15 PSYCHOSIS INDUCED BY DATURA-SUAVEOLENS: HALLUCINOSIS AND

ANTICHOLINERGIC DELIRIUM. 001782 02-15

REVERSAL BY PHYSOSTIGMINE OF CLOZAPINE-INDUCED DELIRIUM. 001828 02-15 ANTICHOLINERGIC DELIRIUM IN A CASE OF MUNCHAUSEN SYNDROME 003658 04-15

DIGITALIS DELIRIUM: PSYCHIATRIC CONSIDERATIONS

003727 04-17

DELIRIUM-TREMENS: A DOUBLE-BLIND COMPARISON OF DIAZEPAM AND BARBITAL TREATMENT. 003632 04-14 DELIVERY

EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D AMPHETAMINE AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY AND SHOCK AVOIDANCE IN RHESUS MONKEYS.

002251 03-04
ESOPHAGEAL CANNULATION FOR INTRAGASTRIC DELIVERY OF FLUIDS TO UNRESTRAINED DOGS. 003436 04-06

DELTA-WAVES

FLURAZEPAM EFFECTS ON SLOW-WAVE SLEEP: STAGE-4 SUPPRESSED BUT NUMBER OF DELTA-WAVES CONSTANT. 001708 02-14

DELTA 1-TETRAHYDROCANNABINOL
PROSTAGLANDINS AND CANNABIS -- VI. RELEASE OF ARACHIDONIC-ACID

FROM HELA CELLS BY DELTA1-TETRAHYDROCANNABINGL AND OTHER CANNARIMOIDS 002850 04-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON BODY

TEMPERATURE AND BRAIN AMINE CONCENTRATIONS IN THE RAT AT FFERENT AMBIENT TEMPERATURES 000105 01-03

CARDIOVASCULAR EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN CONSCIOUS AND ANESTHETIZED DOGS.

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON HEPATIC FUNCTIONS.

OO0119 01-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON A

MG2-ATPASE OF SYNAPTIC VESICLES PREPARED FROM RAT CEREBRAL-CORTEX.

000123 01-03 INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL AND D AMPHETAMINE 000139 01-03

IS DELTA9-TETRAHYDROCANNABINOL ESTROGENIC?

000210 01-03 INFLUENCE OF FASTING ON THE ABSORPTION AND EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AFTER ORAL ADMINISTRATION IN SESAME-OIL 000228 01-03

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON UTERINE AND VAGINAL CYTOLOGY OF OVARIECTOMIZED RATS. 000274 01-03

DELTA9-TETRAHYDROCANNABINOL AND THE HIPPOCAMPUS. EFFECTS ON CA1 FIELD POTENTIALS IN RATS.

000287 01-03 KINETIC STUDIES OF FOOD INTAKE AND SUCROSE SOLUTION PREFERENCE BY RATS TREATED WITH LOW DOSES OF DELTA9-TETRAHYDROCANNABINOL.

FURTHER STUDIES OF THE AGGRESSIVE BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN REM SLEEP-DEPRIVED RATS.

000331 01-04 ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: INTERACTIVE EFFECTS ON HUMAN PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS. II. 000673 01-12

HIGH-PRESSURE LIQUID CHROMATOGRAPHIC MASS SPECTROMETRIC DETERMINATION OF DELTA9-TETRAHYDROCANNABINOL IN HUMAN PLASMA FOLLOWING MARIJUANA SMOKING.

000682 01-12 NORMAL LYMPHOCYTE FUNCTION IN THE PRESENCE OF DELTA9-TETRAHYDROCANNABINOL.

000730 01-13 DAILY 1 DELTA9-TETRAHYDROCANNABINOL AND PRESSING FOR HYPOTHALAMIC STIMULATION.

001053 02-03 EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON SERUM THYROXINE CONCENTRATIONS IN THE RAT.

001204 02-03 A BEHAVIORAL ANALYSIS OF AGGRESSIVE BEHAVIORS INDUCED AND MODULATED BY DELTA9-TETRAHYDROCANNABINOL, PILOCARPINE, D AMPHETAMINE AND L-DOPA.

001419 02-04 INTERACTIONS OF DELTA9-TETRAHYDROCANNABINOL WITH PHENOBARBITAL, ETHANOL AND CHLORDIAZEPOXIDE.

001436 02-04 DELTA9-TETRAHYDROCANNABINOL AND THE EXTRAPYRAMIDAL SYSTEM. 001507 02-05

DELTA9-TETRAHYDROCANNABINOL AND DIMETHYLHEPTYLPYRAN INDUCED TACHYCARDIA IN THE CONSCIOUS RAT.

001516 02-05 FLUCTUATING DENTAL ASYMMETRY AS AN INDICATOR OF THE STRESSFUL PRENATAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN THE LABORATORY RAT.

001520 02-05 EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DRUG DISTRIBUTION AND METABOLISM: ANTIPYRENE, PENTOBARBITAL, AND ETHANOL.

001643 02-13 THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, AND CANNABINOL ON THE ANESTHESIA INDUCED BY VARIOUS ANESTHETIC AGENTS IN MICE.

002015 03-03 IMMUNOSUPPRESSION OF MICE BY DELTA9-TETRAHYDROCANNABINOL 002073 03-03

POSSIBLE CENTRAL DOPAMINERGIC MODULATION OF THE RISE IN PLASMA CONCENTRATION OF NONESTERIFIED FATTY-ACIDS PRODUCED IN THE MOUSE BY (-)TRANS DELTA9-TETRAHYDROCANNABINOL. 002085 03-03

A COMPARISON OF SOME PHARMACOLOGICAL ACTIONS OF MORPHINE AND DELTA9-TETRAHYDROCANNABINOL IN THE MOUSE. 002834 04-03

MURICIDE INDUCED BY SINGLE INJECTION OF DELTAS-TETRAHYDROCANNABINOL.

003226 04-04 DELTA9-TETRAHYDROCANNABINOL ENHANCEMENT OF LORDOSIS BEHAVIOR IN ESTROGEN TREATED FEMALE RATS.

003230 04-04 GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF DELTAS-TETRAHYDROCANNABINOL TO CANNABINOIDS WITH THERAPEUTIC POTENTIAL.

003392 04-04

DELTA9-TETRAHYDROCANNABINOL-INDUCED
DELTA9-TETRAHYDROCANNABINOL-INDUCED CHANGES IN BRAIN RIBOSOMES. 003047 04-03

DELTA9-TETRAHYDROCANNABINOL-TOLERANT
NALOXONE-INDUCED OR POSTWITHDRAWAL ABSTINENCE SIGNS IN
DELTA9-TETRAHYDROCANNABINOL-TOLERANT RATS.

STIMULUS EFFECTS OF DELTA9-THC AND ITS INTERACTION WITH NALTREXONE AND CATECHOLAMINE BLOCKERS IN RATS.

000157 01-03 DELTA9-THC AND 11 OH-DELTA9-THC: BEHAVIORAL EFFECTS AND RELATIONSHIP TO PLASMA AND BRAIN LEVELS.

000361 01-04 THE LACK OF AN EFFECT OF DELTA9-THC ON PULMONARY SMOOTH MUSCLE FUNCTION IN THE GUINEA-PIG. 001041 02-03

Psychopharmacology Abstracts

ALCOHOL-DISCRIMINATION IN GERBILS: INTERACTIONS WITH BEMEGRIDE, DH-524, AMPHETAMINE, AND DELTA9-THC.

001385 02-04 CATALEPSY INDUCED BY INTRASTRIATAL INJECTIONS OF DELTA9-THC AND 11 OH-DELTA9-THC IN THE RAT.

DIRECT AND PITUITARY MEDIATED EFFECTS OF DELTA9-THC AND CANNABINOL ON THE TESTIS.

002881 04-03 ON PSYCHOLOGICAL SYMPTOMS IN BROMIDE INTOXICATION — ONE CASE OF HIGH DOSE, LONG-TERM BROMIDE INTOXICATION WHICH SHOWED HALLUCINATION AND DELUSION SYMPTOMS.

000880 01-15 TWO CASES OF DELUSION OF WORM INFESTATION. 002487 03-10

PROPOXYPHENE ON DEMAND: ANALGESIC SEEKING BEHAVIOR IN PSYCHIATRIC INPATIENTS. 00173.

001736 02-14 THE EFFECT OF CYCLANDELATE IN DEPRESSED AND DEMENTED PATIENTS: A CONTROLLED STUDY IN PSYCHOGERIATRIC PATIENTS.

001617 02-11

DEMENTIA

NEUROTRANSMITTER PRECURSOR AMINO-ACIDS IN THE TREATMENT OF
MULTIINFARCT DEMENTIA AND ALZHEIMERS DISEASE. 000647 01-11

DRUG IMPROVING CEREBRAL METABOLISM IN DEMENTIA 001695 02-13

EFFECTS OF PIRACETAM ON REGIONAL CEREBRAL BLOOD FLOW AND MENTAL FUNCTIONS IN PATIENTS WITH ORGANIC DEMENTIA. 002512 03-11

RHEOENCEPHALOGRAPHIC AND OTHER STUDIES OF BETAHISTINE IN HUMANS. IV. PROLONGED ADMINISTRATION WITH IMPROVEMENT IN ARTERIOSCLEROTIC DEMENTIA.

002530 03-11

DEMETHYLATION
THE DEMETHYLATION OF IMIPRAMINE AND CLOMIPRAMINE AS
APPARENT FROM THEIR PLASMA KINETICS.
0007 000716 01-13

IN VIVO METABOLIC O DEMETHYLATION OF 3,4
DIMETHOXYAMPHETAMINE IN DOG AND MONKEY. MONKEY

THE DEVELOPMENT OF SEX DIFFERENCES IN THE DEMETHYLATION OF ETHYLMORPHINE AND IN ITS INTERACTION WITH COMPONENTS OF THE HEPATIC MICROSOMAL CYTOCHROME-P-450 SYSTEM IN MICE.

DEMETHYLDIAZEPAM
ON THE HYPNOGENIC AND ANTICONVULSANT ACTIVITIES OF
DEMETHYLDIAZEPAM AND CHLORDEMETHYLDIAZEPAM: TIME EFFECT 000462 01-04

DEMONSTRATED AMPHETAMINE-INDUCED TASTE AVERSION DEMONSTRATED WITH OPERANT BEHAVIOUR.

002315 03-04 DEMONSTRATION
THE DEMONSTRATION IN VIVO OF SPECIFIC BINDING SITES FOR NEUROLEPTIC DRUGS IN MOUSE BRAIN.

BENZODIAZEPINE RECEPTOR: DEMONSTRATION IN THE CENTRAL-NERVOUS-SYSTEM.

OSMOTIC MINIPUMPS FOR ADMINISTRATION OF BARBITAL TO MICE: DEMONSTRATION OF FUNCTIONAL TOLERANCE AND PHYSICAL DEPENDENCE.

002374 03-06 DEMONSTRATION OF NEUROLEPTIC RECEPTOR SITES IN MOUSE BRAIN BY AUTORADIOGRAPHY.

DEMONSTRATION OF AN ENDOGENOUS, COMPETITIVE INHIBITOR(S) OF H3-DIAZEPAM BINDING IN BOVINE BRAIN.

RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS:
ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT
LEARNING WITH D AMPPHETAMINE TREATMENTS.

003167 04-04 ELECTRICAL STIMULATION OF DENERVATED MUSCLES REDUCES INCORPORATION OF METHIONINE INTO THE ACH RECEPTOR. 000136 01-03

DEVELOPMENT OF DENERVATION ALTERATIONS IN SURFACE MEMBRANES
OF MAMMALIAN SKELETAL MUSCLE.

001246 02-03 NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION OF THE SYMPATHETIC NERVE OF THE EYE. 002802 04-03

VOLUME 16, SUBJECT INDEX

SUPERSENSITIVITY OF THE CHOLINERGIC RESPONSE TO APOMORPHINE IN THE STRIATUM FOLLOWING DENERVATION OR DISUSE SUPERSENSITIVITY OF DOPAMINERGIC RECEPTORS IN THE RAT 002872 04-03

DENSITIES

HIGH DENSITIES OF BENZODIAZEPINE RECEPTORS IN HUMAN CORTICAL AREAS

DENSITY

001645 02-13

001472 02-04

RELATIONSHIP BETWEEN THE UPTAKE OF 3H-(PLUS OR MINUS)
METARAMINOL AND THE DENSITY OF ADRENERGIC INNERVATION IN 000142 01-03

BEHAVIORAL AND PSYCHOPHARMACOLOGICAL CHARACTERISTICS OF RATS RAISED IN HIGH POPULATION DENSITY.

DENTAL

FLUCTUATING DENTAL ASYMMETRY AS AN INDICATOR OF THE STRESSFUL PRENATAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN THE LABORATORY RAT.

001520 02-05 RAMPANT DENTAL CARIES IN THE TREATMENT OF DEPRESSION 002648 03-15

DEOXY-D-GLUCOSE

CAFFEINE RESTORES FEEDING RESPONSE TO 2 DEOXY-D-GLUCOSE IN 6 HYDROXYDOPAMINE TREATED RATS.

000277 01-03 EFFECTS OF INSULIN AND 2 DEOXY-D-GLUCOSE ON FEEDING IN

HAMSTERS AND GERBILS 003345 04-04

DEOXYGLUCOSE

EFFECTS OF ANTIMYCIN A PLUS 2 DEOXYGLUCOSE ON UPTAKE AND VESICULAR STORAGE OF SEROTONIN IN HUMAN PLATELETS. (UNPUBLISHED PAPER).

000694 01-13

DIETARY EFFECTS UPON FOOD AND WATER INTAKE AND RESPONSIVENESS TO ESTROGEN, 2 DEOXYGLUCOSE AND GLUCOSE IN FEMALE RATS

003402 04-04

DEOXYPIPRADIOL

MFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3-CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN. 001119 02-03

AN ANIMAL SCREENING TEST FOR DRUGS THAT PREDICTS THE LIKELIHOOD OF HUMAN PHYSICAL DEPENDENCE.

000028 01-02 BRAIN SEROTONIN TURNOVER AND MORPHINE-TOLERANCE DEPENDENCE INDUCED BY MULTIPLE INJECTIONS IN THE RAT.

000055 01-03 THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS OF MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE. 000169 01-03

SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF PHYSICAL DEPENDENCE IN RATS: III. AUTORADIOGRAPHIC STUDIES 000177 01-03

THE EFFECTS OF 6 HYDROXYDOPAMINE ON TOLERANCE TO AND DEPENDENCE ON ETHANOL.

COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMOTOR ACTIVITY, ANALGESIA AND PRIMARY AND PROTRACTED PHYSICAL DEPENDENCE

000323 01-04 PROPOXYPHENE-NAPSYLATE (DARVON-N OR PN) IN THE TREATMENT OF HEROIN DEPENDENCE.

000979 01-17 STUDIES OF A PHARMACOLOGICAL MODEL OF ETHANOL DEPENDENCE IN THE RAT. (PH.D. DISSERTATION).

REGIONAL DISTRIBUTION OF BARBITAL IN THE BRAIN OF MICE DURING THE DEVELOPMENT OF TOLERANCE AND PHYSICAL DEPENDENCE 001180 02-03

INVOLVEMENT OF BRAIN CYCLIC-AMP IN MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE. (PH.D. DISSERTATION).

001241 02-03
HEAD-SHAKE DISTRIBUTIONS DURING SELF-MAINTAINED DEPENDENCE ON MORPHINE, METHADONE, AND L-ALPHA-ACETYLMETHADOL (LAAM) IN THE RAT

001328 02-04 PHYSICAL DEPENDENCE ASSOCIATED WITH CHRONIC METHAQUALONE **ADMINISTRATION**

PHARMACOTHERAPY OF NARCOTIC DEPENDENCE

001428 02-04

001125 02-03

001634 02-12
DEPENDENCE OF THE INFLUENCE OF EPINEPHRINE ON THE EXCITABILITY OF GIANT NEURONS ON ITS CONCENTRATION. 001967 03-03

Subject Index

PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. II TOLERANCE CHARACTERISTICS.

001972 03-03 INDUCTION OF PHYSICAL DEPENDENCE ON CYCLAZOCINE AND PENTAZOCINE IN THE RAT

INFLUENCE OF IMMUNE STIMULATION AND SUPPRESSION ON MORPHINE PHYSICAL DEPENDENCE AND TOLERANCE.

002095 03-03 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. IV. INFLUENCE OF ELIMINATION KINETICS.

002198 03-04
PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. WITHDRAWAL CHARACTERISTICS

002199 03-04 TOLERANCE AND DEPENDENCE AFTER CHRONIC ADMINISTRATION OF

002283 03-04 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. I. CHRONICALLY FOUNVALENT DOSING METHOD

002360 03-06 OSMOTIC MINIPUMPS FOR ADMINISTRATION OF BARBITAL TO MICE: DEMONSTRATION OF FUNCTIONAL TOLERANCE AND PHYSICAL

DRUG DEPENDENCE IN PROPRANOLOL TREATMENT OF MIGRAINE.
002678 03-15

WHO EXPERT COMMITTEE ON DRUG DEPENDENCE. TWENTY-FIRST

THE EFFECT OF MORPHINE-TOLERANCE AND DEPENDENCE ON CELL FREE PROTEIN SYNTHESIS.

002876 04-03 MUSCARINIC RECEPTOR MEDIATED CYCLIC-GMP FORMATION BY CULTURED NERVE CELLS — IONIC DEPENDENCE AND EFFECTS OF LOCAL ANESTHETICS.

003064 04-03 THE EFFECTS OF NALTREXONE ON THE DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE.

003170 04-04 MARIHUANA: EFFECT ON NONVERBAL FREE RECALL AS A FUNCTION OF FIELD DEPENDENCE

003300 04-04 EXPERIMENTAL BARBITURATE DEPENDENCE. I. BARBITURATE
DEPENDENCE DEVELOPMENT IN RATS BY DRUG ADMIXED FOOD (DAF)

THE PRODUCTION OF MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE THE ORAL ROUTE IN THE RAT.

FACTORS CONTRIBUTING TO CANNABIS INTOXICATION AND DEPENDENCE. (PH.D. DISSERTATION).

DEPENDENCY PUNISHMENT SPECIFIC EFFECTS OF PENTOBARBITAL: DEPENDENCY ON THE TYPE OF PUNISHER.

000322 01-04 BEHAVIORAL SENSITIVITY TO LSD: DEPENDENCY UPON THE PATTERN OF CENTRAL 5-HT DEPLETION.

000388 01-04 DRUG DEPENDENCY IN PATIENTS WITH CHRONIC HEADACHES 000863 01-15

ABSENCE OF FORMATION OF BRAIN SALSOLINOL IN ETHANOL DEPENDENT

000208 01-03 THE INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT

BEHAVIOUR IN RODENTS. 000435 01-04 RESPONSES TO INTRAVENOUS HEROIN IN DEPENDENT AND NONDEPENDENT VOLUNTEERS.

000792 01-14
NALOXONE PRECIPITATED WITHDRAWAL REVEALS SENSITIZATION TO

NEUROTRANSMITTERS IN MORPHINE-TOLERANT/DEPENDENT RATS.

O01456 02-04

DEVELOPMENT AND APPLICATION OF METHODS FOR DETERMINING THE

BIOLOGICAL TRANSMETHIOLATIONS DEPENDENT ON S ADENOSYL-L-METHIONINE

001641 02-13 CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF C-AMP-PHOSPHODIESTERASE

002023 03-03 A NEW MECHANISM OF TRICYCLIC ANTIDEPRESSANT ACTION. BLOCKADE OF PROSTAGLANDIN DEPENDENT CALCIUM MOVEMENTS. 002043 03-03

EFFECT OF SYNTHESIS INHIBITION ON THE LEVELS OF BRAIN CATECHOLAMINES IN BARBITAL DEPENDENT RATS.

002103 03-03

PIPEROXANE REDUCES THE EFFECTS OF CLONIDINE ON AGGRESSION IN MICE AND ON NORADRENALINE DEPENDENT HYPERMOTILITY IN RATS. 002205 03-04

CHANGES OF TAURINE CONTENT IN THE BRAIN TISSUE OF BARBITURATE DEPENDENT RATS.

EFFECTS OF LITHIUM ON THE MEMBRANE-BOUND MAGNESIUM DEPENDENT ATPASE OF MOUSE NEUROBLASTOMA CELLS.

POTENTIATION OF HEXOBARBITAL AND AMPHETAMINE EFFECTS IN MALE AND FEMALE RATS PHYSICALLY DEPENDENT ON MORPHINE. 003275 04-04

DEPLETED

CHRONIC AND ACUTE EFFECTS OF BARBITAL AND AMPHETAMINE IN DOPAMINE DEPLETED RATS.

DEPLETING
BRI-13776: A NOVEL ANTIHYPERTENSIVE AGENT WITH INTERESTING
MONOAMINE DEPLETING PROPERTIES.
001007 0

001007 02-01 EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D AMPHETATION SELF-STIMULATION OF THE SUBSTANTIA-NIGRA AND LOCUS-COERULEUS. 002218 03-04

EFFECTS OF ORG-6582, CHLORIMIPRAMINE AND DESMETHYLIMIPRAMINE ON THE DEPLETION OF BIOGENIC AMINES FROM THE RAT BRAIN IN

BEHAVIORAL SENSITIVITY TO LSD: DEPENDENCY UPON THE PATTERN OF CENTRAL 5-HT DEPLETION.

5 HYDROXYTRYPTAMINE DEPLETION WITH P-CHLOROPHENYLALANINE: EFFECTS ON EATING, DRINKING, IRRITABILITY, MURICIDE, AND COPULATION.

UNILATERAL CATECHOLAMINE DEPLETION OF THE CORPUS-STRIATUM AND AMPHETAMINE-INDUCED TURNING: AN ONTOGENETIC STUDY.

IMPORTANCE OF DURATION OF DRUG ACTION IN THE ANTAGONISM OF P-CHLOROAMPHETAMINE DEPLETION OF BRAIN SEROTONIN — COMPARISON OF FLUOXETINE AND CHLORIMIPRAMINE.

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS.

002148 03-03 LETHALITY OF PENTYLENETETRAZOL IN RATS AFTER DEPLETION OF BRAIN

002337 03-05 HORMONE RESPONSES TO METHYLAMPHETAMINE IN DEPRESSION: A NEW APPROACH TO THE NORADRENALINE DEPLETION HYPOTHESIS. 002424 03-09

INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA:
EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION.

002890 04-03 CAPSAICIN-INDUCED DEPLETION OF SUBSTANCE-P FROM PRIMARY SENSORY NEURONS

002965 04-03 EPINEPHRINE IN RAT HYPOTHALAMUS: ANTAGONISM BY OF 6 HYDROXYDOPAMINE-INDUCED DEPLETION.

003110 04-03 INCREASED TILT-CAGE ACTIVITY AFTER SEROTONIN DEPLETION BY 5,7 DIHYDROXYTRYPTAMINE.

003279 04-04

6 HYDROXYDOPAMINE-INDUCED CATECHOLAMINE DEPLETION AND PASSIVE AVOIDANCE LEARNING IN RATS.

EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DEPLETIONS OF BRAIN CATECHOLAMINES OR DOPAMINE ON MEPERIDINE ANTINOCICEPTION

002227 03-04 SEIZURE SUSCEPTIBILITY AND ANTICONVULSANT ACTIVITY OF CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES.

003055 04-03

DEPOLARIZATION ACTIVATION OF TRYPTOPHAN-HYDROXYLASE BY DEPOLARIZATION: ROLE OF CALCIUM.

DIFFERENTIAL ANTAGONISM BY CHLORPROMAZINE AND DIAZEPAM OF FROG MOTONEURONE DEPOLARIZATION INDUCED BY GLUTAMATE RELATED AMINO-ACIDS.

O01116 02-03

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF
NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH
POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF 001118 02-03

Psychopharmacology Abstracts

EVIDENCE AGAINST CHRONIC DEPOLARIZATION AS A MECHANISM OF KAINIC-ACID TOXICITY IN MOUSE CEREBELLAR CULTURES.

DEPOLARIZATION-INDUCED
ADENOSINE MODULATES DEPOLARIZATION-INDUCED RELEASE OF H3NORADRENALINE FROM SLICES OF RAT BRAIN NEOCORTEX.

PRACTICAL CONSIDERATIONS IN THE USE OF DEPOT NEUROLEPTICS FOR THE TREATMENT OF SCHIZOPHRENIA. 000534 01-08

DEPOT NEUROLEPTICS IN ACUTE PSYCHOSES.

001890 02-17

HOW SCHIZOPHRENIC PATIENTS CHANGE DURING 3 YEARS TREATMENT WITH DEPOT NEUROLEPTICS.

FLUPHENAZINE DEPOT (LYORODIN DEPOT) - SOON IN PRODUCTION IN THE DOR?

002400 03-08 DRUG MONITORING AT AN AUSTRALIAN DEPOT PHENOTHIAZINE CLINIC

002402 03-08 USE OF DEPOT TRANQUILLISERS IN PSYCHIATRIC DISORDERS. 002535 03-11

LUTEINIZING HORMONE RELEASING HORMONE AND THYROTROPIN-RELEASING HORMONE STIMULATION STUDIES IN PATIENTS GIVEN CLOMIPRAMINE OR DEPOT NEUROLEPTICS.

002563 03-13 MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. A STUDY WITH THE LONG-ACTING THIOXANTHENE DERIVATIVE, CISCLOPENTHIXOL-DECANOATE SORDINOL DEPOT.

003454 04-08 STANDARD AND LONG-ACTING DEPOT NEUROLEPTICS IN CHRONIC SCHIZOPHRENICS: AN 18-MONTH OPEN MULTICENTRIC STUDY.

003471 04-08

DEPRENIL: LOSS OF SELECTIVITY FOR INHIBITION OF B-TYPE MAO AFTER REPEATED TREATMENT. 003131 04-0

DEPRENYL ADMINISTRATION IN MAN: A SELECTIVE MONOAMINE-OXIDASE B INHIBITOR WITHOUT THE CHEESE EFFECT. 003652

003652 04-15

FACILITATORY AND DEPRESSANT EFFECTS OF DOPAMINE IN THE FELINE CAUDATE NUCLEUS.

002116 03-03 COMPARATIVE STUDY OF THE ANTAGONISM OF BEMEGRIDE AND PICROTOXIN ON BEHAVIOURAL DEPRESSANT EFFECTS OF DIAZEPAM IN RATS AND MICE.

DEPRESSANT ACTIONS OF METHIONINE-ENKEPHALIN AND SOMATOSTATIN IN CAT DORSAL-HORN NEURONES ACTIVATED BY NOXIOUS STIMULI. 003059 04-03

STUDIES IN THE HETEROCYCLIC SERIES. XIII. NEW CNS DEPRESSANTS DERIVED FROM 1,9 DIAZAPHENOXAZINE AND TWO ISOMERIC TRIAZAPHENOTHIAZINE RING SYSTEMS.

THE EFFECT OF STIMULANTS, DEPRESSANTS, AND PROTEIN SYNTHESIS INHIBITION ON RETENTION.

ACUTE AND CHRONIC EFFECTS OF GENERAL CNS DEPRESSANTS ON SEVERAL BEHAVIORAL TESTS IN RATS.

001356 02-04 TOLERANCE AND CROSS-TOLERANCE TO CNS DEPRESSANTS AFTER CHRONIC PENTOBARBITAL.

BARBITAL-INDUCED TOLERANCE AND CROSS-TOLERANCE TO VARIOUS CNS DEPRESSANTS ON RAT OPERANT BEHAVIOR.

001481 02-04 MEMORY: MODIFICATION OF ANISOMYCIN-INDUCED AMNESIA BY STIMULANTS AND DEPRESSANTS.

002232 03-04 INTERACTIONS BETWEEN DEPRESSANTS (ALCOHOL-TYPE) AND STIMULANTS (AMPHETAMINE-TYPE).

002297 03-04 ACTIVATING AND ANESTHETIC EFFECTS OF GENERAL DEPRESSANTS. 002301 03-04

A SEQUENTIAL TRIAL OF VILOXAZINE (VIVALAN) AND IMIPRAMINE IN MODERATELY DEPRESSED PATIENTS.

PHENELZINE IN DEPRESSED PATIENTS: EFFECTS ON URINARY MHPG EXCRETION IN RELATION TO CLINICAL RESPONSE.

ACUTE VERSUS CHRONIC EFFECTS OF MONOAMINE-OXIDASE INHIBITORS IN DEPRESSED PATIENTS: TIME-COURSE OF MAD INHIBITORS.

000733 01-13

DE

DE

001652 02-13

001692 02-13

	BETA-ENDORPHIN-INDUCED CHANGES IN SCHIZOPHRENIC A	AND DEPRESSED	TREA
	S ADENOSYL-L-METHIONINE (SAME) TREATMENT IN GERONTOPSYCHIATRY: A CONTROLLED CLINICAL STUDY	000775 01-14	REPO
	AGED PATIENTS.	III DEI NEGGED	PEDI
	DOUBLE-BLIND PLACEBO-CONTROLLED COMPARISON OF AVIMIPRAMINE IN DEPRESSED OUTPATIENTS.	001045 02-03 MOXAPINE AND	DEPR
	WHICH TRICYCLIC FOR DEPRESSED OUTPATIENTS, IMIPRA	001585 02-09 MINE PAMOATE	EFFE
	OR AMITRIPTYLINE?. HORMONE RELEASE IN DEPRESSED PATIENTS BEFORE AND	001589 02-09 AFTER	EFFE:
	RECOVERY.		P/
	THE EFFECT OF CYCLANDELATE IN DEPRESSED AND DEMEN A CONTROLLED STUDY IN PSYCHOGERIATRIC PATIENTS.	001590 02-09 TED PATIENTS:	ROU
	DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF BUPROPIC		DIAZ
	HYDROCHLORIDE (WELLBATRIN) IN THE TREATMENT OF INPATIENTS.		UNW
		002430 03-09	-
	A COMPARATIVE STUDY OF MAPROTILINE (LUDIOMIL) AN IN THE MANAGEMENT OF DEPRESSED PATIENTS IN GENI PRACTICE.	ERAL	UNV
	CLINICAL EFFECTS AND PLASMA LEVELS OF CLOMIPRAMIN	002447 03-09 IE IN	STUI
	DEPRESSED BARBADIANS.	000440 00 00	EN
	CLINICAL RESPONSE IN DEPRESSED PATIENTS IN RELATION LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND TYRAMIN	TO PLASMA IE PRESSOR	SUB
	RESPONSE.	000450 00 00	FRO
	TRIMIPRAMINE IN THE TREATMENT OF ANXIOUS DEPRESS OUTPATIENTS.	002453 03-09 ED	M
	DOXEPIN OR DIAZEPAM FOR ANXIOUS AND ANXIOUS DEP OUTPATIENTS?	002456 03-09 RESSED	ELEC LS TH
	OUT ATILITIES.	002482 03-10	
	TRYPTOPHAN NICOTINAMIDE COMBINATION IN THE TREAT NEWLY ADMITTED DEPRESSED PATIENTS.		SELE
	A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMIT (SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLIN (SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS W	E TABLETS	LACI
	SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AND NORTRIPTYLINE.	AMITRIPTYLINE	THE RI (P
	THE EFFECT OF CLOFIBRATE ON TOTAL AND FREE PLASMA	003508 04-09	(1
	IN DEPRESSED PATIENTS.		SING
	ELECTROENCEPHALOGRAPHIC CONTROL WITH FREQUENCY DEPRESSED PATIENTS TREATED WITH SAME.	003532 04-09 ANALYSIS IN	A CO
	The state of the s	003536 04-10	
2	HALOPERIDOL DEPRESSES THE ACCUMULATION OF APOMO	RPHINE IN THE	THE
	STRIATUM OF THE RAT.		INTR
	PRESSION	003384 04-04	SI
	UPTAKE INHIBITION OF BIOGENIC AMINES BY NEWER ANT DRUGS: RELEVANCE TO THE DOPAMINE HYPOTHESIS OF	DEPRESSION.	ANT
	ANTA CONTEST OF BIOCENIC ATTINE INDUCED DEBRECCION	000232 01-03	FLIC
	ANTAGONISM OF BIOGENIC AMINE-INDUCED DEPRESSION CORTICAL NEURONES BY NA-K-ATPASE INHIBITORS.	000254 01-03	DEPI
	THE EFFICACY OF ELECTROCONVULSIVE THERAPY AND ANT IN DEPRESSION.	TIDEPRESSANTS	AMI
	A REASSESSMENT OF TRICYCLICS AND ECT IN DEPRESSION		DRU
		000571 01-09	
	MAPROTILINE A DOUBLE-BLIND STUDY OF A NEW TETRA ANTIDEPRESSANT IN SEVERE DEPRESSION.	000574 01-09	THY
	WIN-27147-2 IN THE TREATMENT OF DEPRESSION: AN UN CLINICAL STUDY.	CONTROLLED	EFFE
		000577 01-09	
	TREATMENT OF DEPRESSION.	000579 01-09	A DO
	UP FROM DEPRESSION WITH A SYNTHETIC MALE HORMON	Œ.	

ROLES OF MONOAMINES, PARTICULARLY DOPAMINE, IN CLINICAL

PSYCHOENDOCRINOLOGICAL AND THERAPEUTIC EFFECTS OF TRH IN

THE INDOLEAMINE HYPOTHESIS OF DEPRESSION: AN OVERVIEW AND

DEPRESSION AND IN THE REGULATION OF MOOD.

DEPRESSION

PILOT STUDY.

ATING THE HEADACHE BY TREATING THE DEPRESSION. 000606 01-10 ORT OF SUBCOMMITTEE ON THE TREATMENT OF DEPRESSION IN HILDREN. 000610 01-10 ATRIC PSYCHOPHARMACOLOGY AND CHILDHOOD DEPRESSION.
000611 01-10 RESSION IN CHILDHOOD: DIAGNOSIS, TREATMENT, AND CONCEPTUAL ODELS CTS OF NALOXONE ON PETHIDINE-INDUCED NEONATAL DEPRESSION: ART I -- INTRAVENOUS NALOXONE CTS OF NALOXONE ON PETHIDINE-INDUCED NEONATAL DEPRESSION: ART II - INTRAMUSCULAR NALOXONE 000669 01-11 TINE NORTRIPTYLINE LEVELS IN TREATMENT OF DEPRESS 000715 01-13 ZEPAM-INDUCED HOSTILITY IN DEPRESSION. (UNPUBLISHED PAPER) 000815 01-15 ANTED EFFECTS OF PSYCHOTROPIC DRUGS: 1. EPRESSION 000825 01-15 ANTED EFFECTS OF PSYCHOTROPIC DRUGS: III. -- DRUGS FOR **EPRESSION** 000827 01-15 DIES ON THE INFLUENCE OF BIOGENIC AMINES AND PSYCHOACTIVE RUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMULATION TEST IN IDOGENOUS DEPRESSION. 000926 01-16
TYPES OF DEPRESSION -- DIAGNOSIS AND MEDICAL MANAGEMENT. 000938 01-17 M JOY TO DEPRESSION: NEW INSIGHTS INTO THE CHEMISTRY OF COODS TROPHYSIOLOGICAL EVIDENCE FOR A DOPAMINERGIC ACTION OF SD: DEPRESSION OF UNIT ACTIVITY IN THE SUBSTANTIA-NIGRA OF 001082 02-03
ECTIVE OPIATE DEPRESSION OF SENSORY EVOKED SYNAPTIC
ETWORKS IN DORSAL-HORN REGIONS OF SPINAL CORD CULTURES. 001088 02-03 K OF TOLERANCE TO THE DEPRESSION OF RAPHE UNIT ACTIVITY BY SERGIC-ACID-DIETHYLAMIDE. 001262 02-03 EFFECTS OF STIMULATION AND DEPRESSION OF THE ETICULOENDOTHELIAL SYSTEM ON SIDMAN AVOIDANCE BEHAVIOR. H.D. DISSERTATION). 001468 02-04 GLE VERSUS DIVIDED DOSES OF SINTAMIL IN DEPRESSION 001543 02-07 ONTROLLED STUDY OF WIN-27147-2 IN THE TREATMENT OF **EPRESSION** 001544 02-07 NEUROPHARMACOLOGY OF DEPRESSION. 001573 02-09 AVENOUS COMBINED ADMINISTRATION OF CHLORIMIPRAMINE AND JLPIRIDE IN DEPRESSION. 001575 02-09 IDEPRESSANT DRUG THERAPY IN PSYCHOTIC DEPRESS 001580 02-09 KER VALUES AND CHANGES IN STATES OF DEPRESSION 001592 02-09 RESSION -- THE SILENT SCREAM 001593 02-09
ITRIPTYLINE PLASMA LEVELS AND CLINICAL RESPONSE IN PRIMARY EPRESSION. 001594 02-09 IGS AND DEPRESSION: DOSAGE AND BLOOD LEVEL MONITORING. 001595 02-09 ROID FUNCTION AND GROWTH HORMONE SECRETION IN MITRIPTYLINE TREATED DEPRESSION. O01596 02-09
CCT OF EXOGENOUS ESTROGENS ON DEPRESSION IN MENOPAUSAL OUBLE-BLIND CLINICAL COMPARISON OF AMOXAPINE, IMIPRAMINE, ND PLACEBO IN THE TREATMENT OF DEPRESSION. 001609 02-09 CLINICAL STUDIES WITH MAPROTILINE AND THE REVERSED CATECHOLAMINE HYPOTHESIS OF DEPRESSION. 001642 02-13 EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 2. BIOCHEMICAL ANALYSIS

NALOXONE (NARCAN) TREATMENT IN DEPRESSION: CLINICAL OBSERVATIONS AND EFFECTS ON CSF ENDORPHINS AND MONOAMINE METABOLITES.

000581 01-09

000583 01-09

000590 01-09

000592 01-09

EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 1. CLINICAL ANALYSIS. TIMING AND RISK OF BONE MARROW DEPRESSION BY PSYCHOTROPIC 001770 02-15 DRUG-INDUCED DEPRESSION. 001816 02-15 DESIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF DIVIDED VS SINGLE DOSE ADMINISTRATION. THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN; A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION. VILOXAZINE IN THE TREATMENT OF DEPRESSION: PSYCHOPHYSICAL MEASURES AND CLINICAL RESPONSE. R-806-003-01 IN THE TREATMENT OF DEPRESSION: PLASMA LEVELS AND THERAPEUTIC RESPONSE. 002376 03-07 CLINICAL TRIAL OF BUPROPION-HCL IN TREATMENT OF DEPRESSION.

002381 03-07

NOMIFENSIN IN THE TREATMENT OF DEPRESSION: A REPORT ON THE CANADIAN PART OF A TRANSCULTURAL STUDY. 002414 03-09 NOMIFENSIN IN THE TREATMENT OF DEPRESSION: A STANDARD-CONTROLLED CLINICAL STUDY. DOXEPIN AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION: A DOUBLE-BLIND CROSS-OVER CLINICAL STUDY WITH EKG RECORDINGS. A DOUBLE-BLIND CONTROLLED COMPARATIVE STUDY OF NOMIFENSINE IN DEPRESSION. 002419 03-09 DRUG-INDUCED DEPRESSION AND ATTEMPTED SUICIDE. 002421 03-09 HORMONE RESPONSES TO METHYLAMPHETAMINE IN DEPRESSION: A NEW APPROACH TO THE NORADRENALINE DEPLETION HYPOTHESIS. 002424 03-09 DEPRESSION: BIOLOGY, PSYCHODYNAMICS, AND TREATMENT.
002425 03-09
MAPROTILINE (LUDIOMIL) IN DEPRESSION: A MULTICENTRE ASSESSMENT
0F ONSET OF ACTION, EFFICACY AND TOLERABILITY. MAPROTILINE (LUDIOMIL) IN DEPRESSION: A REPORT OF A MONITORED RELEASE STUDY IN GENERAL PRACTICE. 002433 03-09 THE EFFECT OF DEPRESSION AND ITS TREATMENT ON SERUM 002436 03-09 COMBINED TRICYCLIC MAOI THERAPY FOR REFRACTORY DEPRESSION: A
REVIEW. WITH GUIDELINES FOR APPROPRIATE USAGE. 002437 03-09 DIFFERENTIAL EFFECTS OF A SINGLE DOSE OF IMIPRAMINE AND LOPRAMINE IN HEALTHY SUBJECTS VARYING IN THEIR LEVEL OF INTRAPSYCHIC AND FAMILY DYNAMIC PROCESSES IN AN ENDOGENOUS DEPRESSION PRECEDING MANIFESTATION OF THE ILLNESS AND LITHIUM THERAPY. 002461 03-09 A PILOT ENDOCRINE STUDY IN DEPRESSION. TRIMIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF SINGLE VS. DIVIDED DOSE ADMINISTRATION. 002465 03-09 THE TREATMENT OF DEPRESSION COMPARING DIVIDED AND SINGLE DOSES OF MAPROTILINE (LUDIOMIL). 002467 03-09

MAPROTILINE AND DOXEPIN IN THE TREATMENT OF DEPRESSION: A
DOUBLE-BLIND MULTICENTRE COMPARISON.

A BEHAVIORAL TREATMENT OF DEPRESSION WITH ALCOHOLICS RECEIVING PHARMACOLOGICAL AVERSIVE CONDITIONING. (PH.D. DISSERTATION).

L TRYPTOPHAN AND 5 HYDROXYTRYPTOPHAN IN THE TREATMENT OF DEPRESSION: A REVIEW.

A REVIEW OF THE RELATIONSHIP BETWEEN ENDOCRINOPATHY AND DEPRESSION OR ANTIDEPRESSANT DRUGS, WITH PARTICULAR RESPECT TO NOVEL THEORIES INVOLVING THE OPIATE RECEPTOR.

EEG SLEEP CORRELATES OF DEPRESSION IN MAN.

THE BIOCHEMISTRY OF DEPRESSION

RAMPANT DENTAL CARIES IN THE TREATMENT OF DEPRESSION

Psychopharmacology Abstracts

CHANGES IN BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS FOLLOWING ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION AND DURING POST AMPHETAMINE DEPRESSION.

ANIMAL MODEL OF DEPRESSION: III. MECHANISM OF ACTION OF TETRABENAZINE. TETRABENAZINE. 003106 04-03
OPIATE RECEPTORS FOR BEHAVIORAL ANALGESIA RESEMBLE THOSE RELATED TO THE DEPRESSION OF SPINAL NOCICEPTIVE NEURONS. 003142 04-03

RETROACTIVE AMNESIA INDUCED IN CHICKS BY THE PROLINE ANALOG BAIKIAIN, WITHOUT EEG SEIZURES OR DEPRESSION.

003205 04-04 DEPRESSION OF PRIMATE SPINOTHALAMIC TRACT NEURONS BY IONTOPHORETIC APPLICATION OF 5 HYDROXYTRYPTAMINE.

003251 04-04 LITHIUM RESPONSIVE DEPRESSION.

003484 04-09 CONTINUATION THERAPY WITH AMITRIPTYLINE IN DEPRESSION. 003488 04-09

PSYCHOPHARMACOLOGIC TREATMENT OF DEPRESSION IN PRIVATE

003494 04-09 IRRITABLE COLON AND DEPRESSION

003498 04-09 TREATMENT OF DEPRESSION WITH DRUGS.

003500 04-09 TREATMENT OF ENDOGENOUS DEPRESSION WITH ORAL THYROTROPIN RELEASING HORMONE AND AMITRIPTYLINE.

TREATMENT OF IMIPRAMINE RESISTANT DEPRESSION AND LITHIUM REFRACTORY MANIA THROUGH DRUG INTERACTIONS.

003512 04-09 A COMPARATIVE CLINICAL TRIAL OF MIANSERIN (NORVAL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.

003514 04-09 DISTURBANCE OF HOMEOSTATIC REGULATION OF ADRENAL FUNCTION IN PATIENTS WITH ENDOGENOUS DEPRESSION.

003515 04-09

DEPRESSION IN THE ELDERLY. II. POSSIBLE DRUG ETIOLOGIES; DIFFERENTIAL DIAGNOSTIC CRITERIA.

THE PRACTICAL SIGNIFICANCE OF NORTRIPTYLINE PLASMA CONTROL. A PROSPECTIVE EVALUATION UNDER ROUTINE CONDITIONS IN ENDOGENOUS DEPRESSION.

003522 04-09 A CASE OF DEPRESSION SHOWING IMPROVEMENT IN TRH TEST BY COMBINED TREATMENT BY DIMETACRINE-TARTRATE AND THYROID

003527 04-09

DRUGS AND DEPRESSION

003531 04-09 ANTIHYPERTENSIVE DRUGS AND DEPRESSION: A REAPPRAISAL 003534 04-10

DEPRESSION - A GOOD APPROACH FOR THE NONPSYCHIATRIST: III --

003719 04-17 DEPRESSION: MUST PHARMACOTHERAPY FAIL FOR COGNITIVE THERAPY TO SUCCEED?.

003726 04-17

DEPRESSION-INDUCED
THERAPEUTIC EFFECT OF BRAIN HYDROLYSATES IN DEPRESSION-INDUCED
DISTURBANCES OF INTELLIGENCE.

002380 03-07

PSYCHOTHERAPY IN COMBINATION WITH ANTIDEPRESSANT DRUGS IN PATIENTS WITH SEVERE MASKED DEPRESSIONS. 000572 01-09

TRAZODONE BY INTRAVENOUS INFUSION IN DEPRESSIONS SECONDARY TO ORGANIC DISEASE. 000585 01-09

NEW EVIDENCE OF SEROTONIN DEFICIENT DEPRESSIONS 000743 01-13

THE INFLUENCE OF PYRIDOXINE ON THE PSYCHOPATHOLOGY AND PATHOCHEMISTRY OF DEPRESSIONS OF INVOLUTIONAL AGE. 003485 04-09

TRICYCLIC ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CLINICAL COMPARISON OF CLOMIPRAMINE (ANAFRANIL) AND AMITRIPTYLINE.

003501 04-09 TRANYLCYPROMINE (PARNATE) - A STUDY OF 1000 PATIENTS WITH SEVERE AGITATED DEPRESSIONS.

003507 04-09

THE COMPARATIVE EFFICACY OF COGNITIVE THERAPY AND PHARMACOTHERAPY IN THE TREATMENT OF DEPRESSIONS 003701 04-17

DEPRESSIVE
CYCLIC-ADENOSINE-MONOPHOSPHATE METABOLISM IN PATIENTS WITH
SEVERE DEPRESSIVE ILLNESS.
000570 014 000570 01-09

002495 03-10

002552 03-13

002557 03-13

002625 03-14

002648 03-15

002747 03-17

COMBINATION OF PHENYLPYRROLIDINOPENTANE (KATOVIT) WITH OXAZEPAM (ADUMBRAN): A DOUBLE-BLIND TRIAL WITH OPIPRAMOL (INSIDON) IN DEPRESSIVE SYNDROME.

000597 01-10

VIDEOTAPE METHODS FOR IDENTIFICATION OF NONVERBAL BEHAVIOR PARAMETERS IN DEPRESSIVE SYNDROMES.

NORADRENALINE, DEPRESSIVE ILLNESS, AND THE ACTION OF AMITRIPTYLINE.

CYCLIC-AMP IN CEREBROSPINAL FLUID OF MANIC AND DEPRESSIVE

O01683 02-13
PROLACTIN SECRETION DURING AND AFTER NOVERIL INFUSIONS TO DEPRESSIVE PATIENTS.

002438 03-09
TREATMENT OF DEPRESSIVE SYNDROME WITH NOVERIL INFUSIONS.

PLASMA LEVEL STUDIES OF CLOMIPRAMINE AND
DESMETHYLCLOMIPRAMINE FOLLOWING INTRAVENOUS INFUSIONS OF
CLOMIPRAMINE IN DEPRESSIVE PATIENTS.

INITIAL RESPONSE TO DRUGS IN DEPRESSIVE ILLNESS AND PSYCHIATRIC AND COMMUNITY ADJUSTMENT A YEAR LATER.

CLOMIPRAMINE (ANAFRANIL) IN DEPRESSIVE PATIENTS WITH OBSESSIVE NEUROSIS

DOSAGE EFFECTS OF IMIPRAMINE ON THE PSYCHOPATHOLOGIC AND BIOLOGIC INDICES OF ENDOGENOUS DEPRESSIVE SYNDROMES.

PLASMA PROLACTIN CONCENTRATIONS IN NORMAL SUBJECTS AND DEPRESSIVE PATIENTS FOLLOWING ORAL CLOMIPRAMINE.

PLASMA CONCENTRATIONS OF CLOMIPRAMINE AND ITS N DESMETHYL METABOLITE IN DEPRESSIVE PATIENTS FOLLOWING TREATMENT WITH VARIOUS DOSAGE REGIMES OF CLOMIPRAMINE.

EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DEPRESSIVE PATIENTS RECEIVING CLOMIPRAMINE THERAPY.

002577 03-13
INFLUENCE OF TRYPTOPHAN ON MEMORY FUNCTIONS IN DEPRESSIVE PATIENTS TREATED WITH UNILATERAL ECT.

PIRROXAN IN THE TREATMENT OF THE NEUROVEGETATIVE COMPONENT OF THE DEPRESSIVE SYNDROME.

O03443 04-07
A CONTROLLED CLINICAL STUDY OF TRAZODONE IN CHRONIC
SCHIZOPHRENIC PATIENTS WITH PRONOUNCED DEPRESSIVE
SYMPTOMATOLOGY.

003472 04-01
CLINICAL STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE CONDITIONS IN OUTPATIENT PRACTICE.

O03479 04-09
A STUDY OF THE RELATIONSHIP BETWEEN URINARY 5 HYDROXYINDOLES
AND DEPRESSIVE STATES

O03482 04-09
PERIPHERAL ALPHA-ADRENORECEPTOR AND CENTRAL DOPAMINE
RECEPTOR ACTIVITY IN DEPRESSIVE PATIENTS.

O03489 04-09
VILOXAZINE AND AMITRIPTYLINE IN DEPRESSIVE ILLNESS: A DOUBLE-BLIND CONTROLLED TRIAL IN GENERAL PRACTICE.

003506 04-09
THE FREQUENCY AND PERSISTENCE OF DEPRESSIVE SYMPTOMS IN THE ALCOHOL ABUSER.
003567 04-11

DEPRESSIVES

APPLICATION OF LIFE TABLE METHOD TO NATURALISTIC DESIGNS — A
COMPARISON OF EFFICACY OF TRICYCLIC ANTIDEPRESSANTS AND
BENZODIAZEPINES IN AMBULATORY DEPRESSIVES.

WHERE ARE THE UNTREATED DEPRESSIVES?. 002783 03-17

003721 04-17
DEPRESSOR
RELATIVE INFLUENCE OF ANAESTHETICS ON DEPRESSOR EFFECTS OF

INTRAVENOUS PROSTAGLANDINS E2 AND A2.

O00110 01-03

EFFECTS OF ANTICHOLINERGIC AND CHOLINESTERASE BLOCKING DRUGS ON APPETITIVE BEHAVIOR UNDER DIFFERENT DEPRIVATION CONDITIONS.

000306 01-04
DIFFERENTIAL TOLERANCE TO INHIBITORY ACTION OF VARIOUS
NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS
CHRONICALLY TREATED WITH HALOPERIDOL.

O01398 02-04
EFFECTS OF MARIJUANA EXTRACT DISTILLATE AND CANNABIDIOL ON
VARIABLE INTERVAL PERFORMANCE AS A FUNCTION OF FOOD
DEPRIVATION.

003308 04-04

DEPRIVATION-INDUCED

THE EFFECTS OF VARIOUS NARCOTIC AGONISTS AND ANTAGONISTS ON DEPRIVATION-INDUCED FLUID CONSUMPTION.

DRUG INTERACTIONS AS MEASURED BY DEPRIVATION-INDUCED FLUID CONSUMPTION. 001501 02-04

DERIVATE

EFFECT OF A NEW BENZODIAZEPINE DERIVATE, CLOBAZAM, IN ANXIOUS

PATIENTS WITH GASTROINTESTINAL DISORDERS.

000604 01-10

DERIVATIVE

CENTRAL TRYPTAMINERGIC EFFECTS OF 26-059. A NOVEL SEROTONIN
DERIVATIVE.

THE PRODUCTION OF AN ALTERNATIVE LABORATORY MODEL OF THE PARKINSON SYNDROME USING A NEW BENZYLIMIDOYLUREA DERIVATIVE LON-954.

O00083 01-03

VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF 2

AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF NAD: NADH AND
NORELEAGNINE A BETA-CARBOLINE DERIVATIVE.

PHARMACOTHERAPY FOR ORGANIC-BRAIN-SYNDROME IN LATE LIFE: EVALUATION OF AN ERGOT DERIVATIVE VS PLACEBO.

PHYSIOLOGIC DISPOSITION OF NABILONE, A CANNABINOL DERIVATIVE, IN MAN.

000735 01-13

A BENZOQUINOLIZINE DERIVATIVE WITH A NEUROLEPTIC-LIKE ACTION ON CEREBRAL MONOAMINE TURNOVER.

001037 02-02

EFFECTS OF LERGOTRILE (LER), AN ERGOT DERIVATIVE, ON ACTIVITY OF

SUBSTANTIA-NIGRA PARS COMPACTA DOPAMINE (DA) NEURONS.

001278 02-03

O01278 02-03
ANTIEMETIC ACTIVITY OF NABILONE, A CANNABINOL DERIVATIVE,
REVERSED BY NALOXONE IN AWAKE CATS.

001416 02-04

EFFECTS OF IFC-45, A NEW BENZONAPHTYRIDONE DERIVATIVE WITH
ANTIDEPRESSIVE ACTION, ON ACTIVITY OF THE RAT SUPRARENAL
GLAND CORTEX.

SOLID DISPERSION APPROACH FOR OVERCOMING BIOAVAILABILITY
PROBLEMS DUE TO POLYMORPHISM OF NABILONE, A CANNABINO'D
DERIVATIVE.

001539 02-06
DOPAMINE RECEPTORS AND ERGOT DRUGS. EVIDENCE THAT AN
ERGOLENE DERIVATIVE IS A DIFFERENTIAL AGONIST AT SUBCORTICAL
LIMBIC DOPAMINE RECEPTORS.

THE EFFECTS OF SP-111, A WATER-SOLUBLE THC DERIVATIVE, ON NEURONAL ACTIVITY IN THE RAT BRAIN.

PHARMACOLOGICAL INTERACTIONS WITH CIRCLING BEHAVIOUR INDUCED
BY THE PIPERIDINYL INDOLE DERIVATIVE RU-23686.

O02200 03-04
PHARMACOLOGICAL STUDY OF AMOXAPINE, A DIBENZOXAZEPINE
DERIVATIVE.

002307 03-04

THE PSYCHOPHARMACOLOGICAL PROPERTIES OF PINAZEPAM, A NEW
BENZODIAZEPINE DERIVATIVE.

THE TREATMENT OF ANXIETY WITH A POLYFLUORINATED BENZODIAZEPINE DERIVATIVE.

O03445 04-07

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. A

STUDY WITH THE LONG-ACTING THIOXANTHENE DERIVATIVE, CISCLOPENTHIXOL-DECANOATE SORDINOL DEPOT.

TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDROME WITH EMD-21657. A DERIVATIVE OF A PYRITINOL METABOLITE: DOUBLE-BLIND CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STUDIES.

THE EFFECTS OF A NEW BENZODIAZEPINE DERIVATIVE, ID-540, ON THE AVERAGED PHOTOPALPEBRAL REFLEX IN MAN.

003610 04-13

DERIVATIVES
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS OF BIOLOGICALLY
ACTIVE INDOLE, 1 METHYLINDOLE AND BENZO-B-THIOPHENE

DERIVATIVES.

000006 01-01

IMIPRAMINE DERIVATIVES: AMINOMETHYLATION OF DIPHENYLAMINE

AND IMINODIBENZYL.

000011 01-01
5 ARYL-DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES AS ANTIANXIETY

000013 01-01
NEW N 2 HYDROXYALKYL-BENZOMORPHAN DERIVATIVES: SYNTHESIS
AND PRELIMINARY PHARMACOLOGY.

000031 01-02

EFFECTS OF 3,4 DIMETHOXYPHENETHYLAMINE DERIVATIVES ON MONDAMINE-OXIDASE

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM — III. TOLERANCE TO PHENCYCLIDINE DERIVATIVES: IN VIVO AND IN VITRO STUDIES.

A COMPARATIVE STUDY OF DIHYDROXYLATED PHENOTHIAZINE DERIVATIVES AS MITOCHONDRIAL INHIBITORS.

INTERACTIONS OF NARCOTICS AND THEIR ANTAGONISTS WITH HUMAN SERUM ESTERASE. VI: THE BEHAVIOR OF 14 HYDROXYLATED MORPHINE DERIVATIVES.

BEHAVIORAL TOXICITY AND EQUIVOCAL SUICIDE ASSOCIATED WITH CHLOROQUINE AND ITS DERIVATIVES.

CARDIOTOXIC DRUGS, WITH SPECIAL ATTENTION TO PHENOTHIAZINES AND IMIPRAMINE DERIVATIVES.

000868 01-15 STEREOCHEMICAL STUDIES ON MEDICINAL AGENTS. 23. SYNTHESIS AND BIOLOGICAL EVALUATION OF 6 AMINO DERIVATIVES OF NALOXONE AND NALTREXONE.

DIRECTIONAL LIPOPHILIC CHARACTER IN A SERIES OF PSYCHOTOMIMETIC PHENETHYLAMINE DERIVATIVES.

001009 02-01 PIPERIDINE DERIVATIVES: SYNTHESIS OF POTENTIAL ANALGESICS IN 3 SUBSTITUTED 4 PHENYLPIPERIDINE SERIES.

CANNABINOIDS. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY OF 8 SUBSTITUTED HYDROXY-DIMETHYLBENZOPYRANOPYRIDINE AND DERIVATIVES.

ACTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND ITS DERIVATIVES ON 5 HYDROXYTRYPTAMINE RECEPTORS IN THE ISOLATED UTERINE SMOOTH MUSCLE OF THE RAT.

SUBSTITUTED AMPHETAMINE DERIVATIVES. I. EFFECT ON UPTAKE AND RELEASE OF BIOGENIC MONOAMINES AND ON MONOAMINE-OXIDASE IN THE MOUSE BRAIN. 001233 02-03

FFERENTIAL ACTIVATION BY SOME 2 AMINOTETRALIN DERIVATIVES OF THE RECEPTOR MECHANISMS IN THE NUCLEUS-ACCUMBENS OF RAT WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITING.

SUBSTITUTED AMPHETAMINE DERIVATIVES. II. BEHAVIOURAL EFFECTS IN MICE RELATED TO MONOAMINERGIC NEURONES.

PROTEIN AND ENZYME RELEASE FROM HUMAN LEUKOCYTES: INFLUENCE OF PHENOTHIAZINE DERIVATIVES.

A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE
DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON
SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR
PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION.

001787 02-15 H3-HALOPERIDOL BINDING TO DOPAMINE RECEPTORS IN RAT CORPUS-STRIATUM: INFLUENCE OF CHLORPROMAZINE METABOLITES AND DERIVATIVES.

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. II. CROSS-TOLERANCE BETWEEN PHENCYCLIDINE DERIVATIVES AND CHOLINERGIC DRUGS.

002126 03-03 ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. I. TOLERANCE TO PHENCYCLIDINE DERIVATIVES IN MICE: PHARMACOLOGICAL CHARACTERIZATION.

DOPAMINE-MIMETIC ACTIVITY OF ERGOT DERIVATIVES, AS MEASURE BY THE PRODUCTION OF CYCLIC-AMP IN ISOLATED RETINAE OF THE RABBIT. AS MEASURED

CHANGES IN THE RAT ELECTROCORTICOGRAM FOLLOWING
ADMINISTRATION OF TWO DIHYDROGENATED ERGOT DERIVATIVES.
002207 03-04

STRUCTURE-ACTIVITY RELATIONS FOR THE NEUROTOXICITY OF KAINIC-ACID DERIVATIVES AND GLUTAMATE ANALOGUES.

EFFECTS OF SOME DERIVATIVES OF 2 AMINOTETRALIN ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE AND ON THE BINDING OF H3-HALOPERIDOL TO NEUROLEPTIC RECEPTORS IN RAT STRIATUM.

002853 04-03

NHIBITION BY BARBITURIC-ACID AND ITS DERIVATIVES OF THE ENZYMES
IN RAT BRAIN WHICH PARTICIPATE IN THE SYNTHESIS OF PYRIMIDINE
RIBOTIDES.

003049 04-03 INTERACTIONS BETWEEN GUANINE DERIVATIVES AND NOREPINEPHRINE ON NEURONES OF THE MAMMALIAN CEREBRAL-CORTEX.

DIFFERENCES IN THE DOPAMINERGIC EFFECTS OF THE ERGOT DERIVATIVES BROMOCRIPTINE, LISURIDE AND D LSD AS COMPARED WITH APOMORPHINE.

003244 04-04 TACRINE AND ITS DERIVATIVES ANTAGONIZE CHOLINERGIC PSYCHOTOMIMETICS: BEHAVIORAL STUDY IN RATS.

003262 04-04 STUDIES IN THE HETEROCYCLIC SERIES. XIII. NEW CNS DEPRESSANTS DERIVED FROM 1,9 DIAZAPHENOXAZINE AND TWO ISOMERIC TRIAZAPHENOTHIAZINE RING SYSTEMS.

INTRAOCULAR PRESSURE LOWERING PROPERTIES OF ABBOTT-43981, A
CANNABINOID DERIVED HETEROCYCLIC BENZOPYRAN WITH MINIMAL
CNS ACTIVITIES.

PLASMA CONCENTRATIONS OF SOME ACIDIC AND ALCOHOLIC METABOLITES DERIVED FROM M- AND P-TYRAMINE, OCTOPAMINE AND CATECHOLAMINES IN HUMANS. 001158 02-03

THE ROLE OF ASCENDING AND DESCENDING 5 HYDROXYTRYPTAMINE NEURONES IN CENTRAL CONTROL OF PAIN SENSITIVITY. 000380 01-04

DESENSITIZATION
DECLINING DIAZEPAM DESENSITIZATION THERAPY.

001614 02-10

ILLNESS-INDUCED AVERSION LEARNING IN A DESERT SPECIES OF RODENT (ACOMYS-CAHIRINUS). 001350 02-04

DESIGN
OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF
REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR
OPERANT DRUG DISCRIMINATIONS.
003434 04

003434 04-06 STATISTICAL ASPECTS OF PSYCHOTROPIC DRUG TRIAL DESIGNS. 000922 01-16

APPLICATION OF LIFE TABLE METHOD TO NATURALISTIC DESIGNS — A COMPARISON OF EFFICACY OF TRICYCLIC ANTIDEPRESSANTS AND BENZODIAZEPINES IN AMBULATORY DEPRESSIVES.

DESIPRAMINE
PLASMA CONCENTRATIONS AND CARDIOTOXIC EFFECTS OF DESIPRAMINE
AND PROTRIPTYLINE IN THE RAT.

000478 01-05

000478 01-05 IMPURITIES IN DRUGS I: IMIPRAMINE, DESIPRAMINE, AND THEIR FORMULATIONS.

DESIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF DIVIDED VS SINGLE DOSE ADMINISTRATION.

THE INFLUENCE OF COCAINE AND DESIPRAMINE ON THE CARDIAC RESPONSES TO EXOGENOUS AND ENDOGENOUS NOREPINEPHRINE 002077 03-03

CHRONIC TREATMENT WITH DESIPRAMINE CAUSED A SUSTAINED DECREASE OF 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE AND TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT BRAIN. 002113 03-03

DESIPRAMINE AND SOME OTHER ANTIDEPRESSANT DRUGS DECREASE THE MAJOR NOREPINEPHRINE METABOLITE 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE IN THE RAT BRAIN.

002114 03-03 A COMPARISON OF DESIPRAMINE AND AMITRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.

002417 03-09 DESIPRAMINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.

A SIMPLE METHOD FOR THE DETERMINATION OF THERAPEUTIC LEVELS OF CLOMIPRAMINE, IMIPRAMINE AND DESIPRAMINE.

EFFECTS OF SINGLE AND MULTIPLE DOSES OF DESIPRAMINE (DMI) ON ENDOGENOUS LEVELS OF 3 METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE (MOPEG-SO4) IN RAT BRAIN.

COMPARISON OF THE RESPONSES OF SINGLE CORTICAL NEURONES TO TYRAMINE AND NORADRENALINE: EFFECTS OF DESIPRAMINE. 002821 04-03

EPINEPHRINE IN RAT HYPOTHALAMUS: ANTAGONISM BY DESIPRAMINE OF 6 HYDROXYDOPAMINE-INDUCED DEPLETION.

ANTICHOLINERGIC ACTIVITY OF THE TRICYCLIC ANTIDEPRESSANTS
DESIPRAMINE AND DOXEPIN IN NONDEPRESSED VOLUNTEERS.
003447 04-07

PLASMA CONCENTRATIONS OF CLOMIPRAMINE AND ITS N DESMETHYL METABOLITE IN DEPRESSIVE PATIENTS FOLLOWING TREATMENT WITH VARIOUS DOSAGE REGIMES OF CLOMIPRAMINE.

002568 03-1 002568 03-13

IMIPRAMINE, ITS N DESMETHYL AND HYDROXY METABOLITES IN PLASMA: MICRO DETERMINATION BY ALKALINE FLAME-IONIZATION GAS-CHROMATOGRAPHY (AFID-GC).

002597 03-13

DESMETHYLCLOMIPRAMINE

THE EFFECTS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE ON THE IN VITRO UPTAKE OF RADIOLABELLED 5-HT AND NORADRENALINE INTO RAT BRAIN CORTICAL SLICES.

001257 02-03

PLASMA LEVEL STUDIES OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE FOLLOWING INTRAVENOUS INFUSIONS OF CLOMIPRAMINE IN DEPRESSIVE PATIENTS.

002448 03-0

A PRELIMINARY REPORT ON CLINICAL RESPONSE AND PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN OBSESSIVE-COMPULSIVE NEUROSIS.

002493 03-10

EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DEPRESSIVE PATIENTS RECEIVING CLOMIPRAMINE THERAPY.

002577 03-13

BIOANALYSIS AND PHARMACOKINETICS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN MAN BY MEANS OF LIQUID CHROMATOGRAPHY.

002728 03-16

DESMETHYLDIAZEPAM

PHARMACOKINETICS OF N DESMETHYLDIAZEPAM IN HEALTHY VOLUNTEERS AFTER SINGLE DAILY DOSES OF DIPOTASSIUM CHLORAZEPATE.

000728 01-13

CONFLICT BEHAVIOR IN THE SQUIRREL-MONKEY: EFFECTS OF CHLORDIAZEPOXIDE, DIAZEPAM AND N DESMETHYLDIAZEPAM.

002303 03-04

PRAZEPAM, A PRECURSOR OF DESMETHYLDIAZEPAM.

002382 03-07

DESMETHYLIMIPRAMINE

EFFECTS OF ORG-6582, CHLORIMIPRAMINE AND DESMETHYLIMIPRAMINE ON THE DEPLETION OF BIOGENIC AMINES FROM THE RAT BRAIN IN VIVO.

EFFECT OF COCAINE AND DESMETHYLIMIPRAMINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-5-HYDROXYTRYPTAMINE IN RAT

RETENTION AND METABOLISM OF H3-5-HYDROXYTRYPTAMINE IN RA' BRAIN SLICES.

000305 01-03
INCREASE CAUSED BY DESMETHYLIMIPRAMINE IN THE PRODUCTION OF H3-MELATONIN BY ISOLATED PINEAL GLANDS.

001217 02-03
IN VITRO EFFECTS OF DESMETHYLIMIPRAMINE ON THE UPTAKE AND
METABOLISM OF H3-NOREPINEPHRINE IN RAT BRAIN SLICES.

001997 03-03
INFLUENCE OF PHENOBARBITAL ON THE DISTRIBUTION AND ELIMINATION OF DESMETHYLIMIPRAMINE IN THE RAT.

002842 04-03

DESPAIR

BEHAVIOURAL DESPAIR IN RATS: A NEW MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.

002370 03-06

DESTRUCTION

HALOPERIDOL INCREASES AND APOMORPHINE DECREASES STRIATAL DOPAMINE METABOLISM AFTER DESTRUCTION OF STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASE BY KAINIC-ACID.

000094 01-03
MESOLIMBIC DOPAMINE NEURONS: EFFECTS OF 6 HYDROXYDDPAMINEINDUCED DESTRUCTION AND RECEPTOR BLOCKADE ON DRUG-INDUCED
ROTATION OF RATS

PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT
OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC
AND CATECHOLAMINERGIC MECHANISMS BY 6 HYDROXYDDPAMINE
AND 5,6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D.
DISSERTATION).
003407 04-05

DESYNCHRONIZATION

A PRESYNAPTIC SITE OF ACTION WITHIN THE MESENCEPHALIC RETICULAR FORMATION FOR () AMPHETAMINE-INDUCED ELECTROCORTICAL DESYNCHRONIZATION.

001069 02-03

DETECTED

DISULFIRAM ALTERS DOPAMINE METABOLISM AT SITES IN RATS FOREBRAIN AS DETECTED BY PUSH-PULL PERFUSIONS.

003134 04-03

DETECTING

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

001535 02-06

DETECTION

SIMULTANEOUS DETERMINATION OF CODEINE AND MORPHINE IN BIOLOGICAL SAMPLES BY GAS-CHROMATOGRAPHY WITH ELECTRON CAPTURE DETECTION.

001527 02-06
DETECTION OF TWO ENDORPHIN-LIKE PEPTIDES IN NUCLEUS-CAUDATUS.
002790 04-01
EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE DETECTION OF

EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE DETECTION SHOCK.

MORPHINE AND SHOCK DETECTION: EFFECTS ON SHOCK INTENSITY.
003332 04-04

DETECTOR

MEASUREMENT OF PLASMA AND ERYTHROCYTE CHLORPROMAZINE AND N MONODESMETHYLCHLORPROMAZINE LEVELS BY GAS-CHROMATOGRAPHY WITH A NITROGEN SENSITIVE DETECTOR. 003429 04-06

DETECTORS

BLOOD LEVEL MONITORING OF BENZODIAZEPINES BY GLC USING NITROGEN SENSITIVE DETECTORS.

001860 02-16

DETERMINANT

BEHAVIORAL HISTORY AS A DETERMINANT OF THE EFFECTS OF D
AMPHETAMINE ON PUNISHED BEHAVIOR.

001306 02-04

DETERMINANTS

MOLECULAR DETERMINANTS FOR THE ACTION OF TRYPTAMINES ON AN LSD RECEPTOR.

DETERMINATION OF PADIODES

EVALUATION OF RADIORESPIROMETRY FOR THE DETERMINATION OF MONOAMINE-OXIDASE ACTIVITY IN VIVO UTILIZING C11-OCTYLAMINE AS A SUBSTRATE.

A RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION
OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF
BIOLOGICAL FLUID OR TISSUE.

HIGH-PRESSURE LIQUID CHROMATOGRAPHIC MASS SPECTROMETRIC
DETERMINATION OF DELTA9-TETRAHYDROCANNABINOL IN HUMAN
PLASMA FOLLOWING MARIJUANA SMOKING.

O00682 01-12
THIN-LAYER AND GAS-LIQUID-CHROMATOGRAPHIC PROCEDURES FOR THE
DETERMINATION OF PERAZINE AND ITS METABOLITES IN HUMAN
BODY FLUIDS.

CLASSIFICATION AND DETERMINATION OF CEREBRAL BIOAVAILABILITY
OF PSYCHOTROPIC DRUGS BY QUANTITATIVE PHARMACO-EEG AND
PSYCHOMETRIC INVESTIGATIONS (STUDIES WITH AX-A411-BS).
000931 01-16

SIMULTANEOUS DETERMINATION OF CODEINE AND MORPHINE IN
BIOLOGICAL SAMPLES BY GAS-CHROMATOGRAPHY WITH ELECTRON
CAPTURE DETECTION

O01527 02-06

A NEW CHRONICALLY CANNULATED CAROTID ARTERY PREPARATION FOR DETERMINATION OF DRUG HALF-LIVES IN THE GUINEA-PIG.

QUANTITATIVE DETERMINATION OF STRESS-INDUCED MYOCARDIAL DAMAGE IN RATS.

HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF DOTHIEPIN AND NORTHIADEN IN HUMAN PLASMA AND SERUM.

O01858 02-16 EVALUATION OF A NEW IMMUNOASSAY FOR DETERMINATION OF

EVALUATION OF A NEW IMMUNOASSAY FOR DETERMINATION OF PHENYTOIN AND PHENOBARBITAL: RESULTS OF A EUROPEAN COLLABORATIVE CONTROL STUDY.

O02529 03-1
IMIPRAMINE, ITS N DESMETHYL AND HYDROXY METABOLITES IN
PLASMA: MICRO DETERMINATION BY ALKALINE FLAME-IONIZATION
GAS-CHROMATOGRAPHY (AFID-GC).

O02597 03-13
THE USE OF THE CNV (CONTINGENT NEGATIVE VARIATION) IN THE
DETERMINATION OF RESIDUAL EFFECTS OF FIVE HYPNOTIC DRUGS.

A SIMPLE METHOD FOR THE DETERMINATION OF THERAPEUTIC LEVELS OF CLOMIFRAMINE, IMIPRAMINE AND DESIPRAMINE.

002717 03-16
THE FLUOROMETRIC DETERMINATION OF 5 METHOXYTRYPTAMINE IN MAMMALIAN TISSUES AND FLUIDS.

A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE (SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS (SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE AND MORTIPTYLINE

DETERMINATIONS

A COMPARISON BETWEEN FLUOROMETRIC AND MASS FRAGMENTOGRAPHIC DETERMINATIONS OF HOMOVANILLIC-ACID AND 5 HYDROXYINDOLEACETIC-ACID IN HUMAN CEREBROSPINAL FLUID. 003694 04-16

GENOTYPE AND TEST EXPERIENCE DETERMINE RESPONSIVENESS TO MORPHINE

002216 03-04

DETERMINED

LITHIUM NEUROTOXICITY. 1. THE CONCENTRATION OF LITHIUM IN

DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS

ATOMIC ABSORPTION SPECTROPHOTOMETRY.

DIFFERENT BEHAVIOURAL PATTERNS INDUCED BY APOMORPHINE: EVIDENCE THAT THE METHOD OF ADMINISTRATION DETERMINES THE BEHAVIOURAL RESPONSE TO THE DRUG.

DETOXIFICATION
THE EFFECTS OF DARVON-N ON RETENTION OF SPECIFIC LEARNING TASKS DURING HEROIN DETOXIFICATION. (PH.D. DISSERTATION).
001703 02-14

001833 02-15

DEUTAN
LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR
BLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE IN THE
FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE

HALOPERIDOL IN BARBITURATE DETOXIFICATION.

000619 01-11

DELITERIUM-LABELED

QUANTITATIVE ANALYSIS OF METHADONE IN BIOLOGICAL FLUIDS USING DEUTERIUM-LABELED METHADONE AND GLC CHEMICAL IONIZATION MASS SPECTROMETRY.

001862 02-16

DEVELOPING

EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT

BRAIN: A QUANTITATIVE HISTOLOGICAL STUDY.

000184 01-6

000184 01-03

EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT
BRAIN: A BIOCHEMICAL STUDY.

000216 01-03
DEFICITS IN PASSIVE AVOIDANCE LEARNING FOLLOWING ATROPINE IN

THE DEVELOPING RAT. 000320 01-04

DO DRUGS ACTING ON THE NERVOUS SYSTEM AFFECT CELL PROLIFERATION IN THE DEVELOPING BRAIN?.

EFFECT OF 1 AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID (CYCLOLEUCINE)
ON DEVELOPING RAT CENTRAL-NERVOUS-SYSTEM PHOSPHOLIPIDS.
002136 03-03
BIOCHEMICAL AND MORPHOLOGICAL FFFECTS OF TESTOSTEPONE

BIOCHEMICAL AND MORPHOLOGICAL EFFECTS OF TESTOSTERONE TREATMENT ON DEVELOPING SYMPATHETIC NEURONS. 002894 04-03

MUSCARINIC HYPOSENSITIVITY IN THE DEVELOPING RAT PRETREATED WITH 6 HYDROXYDOPA.

DEVELOPMENT OF BETA-ADRENERGIC RECEPTOR SUBSENSITIVITY BY ANTIDEPRESSANTS. 000049 (

003320 04-04

THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN THE RAT. 000106 01-03

DIFFERENTIAL EFFECT OF VARIOUS 6 HYDROXYDOPA TREATMENTS ON THE DEVELOPMENT OF CENTRAL AND PERIPHERAL NORADRENERGIC

THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS OF MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE.

000169 01-03

SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF PHYSICAL DEPENDENCE IN RATS: III. AUTORADIOGRAPHIC STUDIES

DEVELOPMENT AND DISAPPEARANCE OF SUBSENSITIVITY TO PILOCARPINE FOLLOWING A SINGLE ADMINISTRATION OF THE IRREVERSIBLE ANTICHOLINESTERASE AGENT, DFP.

000212 01-03 OPEN-FIELD BEHAVIOR AND GROSS MOTOR DEVELOPMENT IN OFFSPRING OF NURSING RAT MOTHERS GIVEN PENFLURIDOL.

000307 01-04 EFFECT OF IN-UTERO ADMINISTRATION OF MORPHINE ON THE SUBSEQUENT DEVELOPMENT OF SELF-ADMINISTRATION BEHAVIOR 000368 01-04

DEVELOPMENT OF TOLERANCE TO THE DISRUPTIVE AFFECTS OF COCAINE ON REPEATED ACQUISITION AND PERFORMANCE OF RESPONSE SEQUENCES.

000459 01-04 THE EFFECT OF MATERNALLY ADMINISTERED METHADONE ON BRAIN DEVELOPMENT IN THE OFFSPRING.

000483 01-05 TIME-COURSE AND DEVELOPMENT OF ELECTROCLINICAL FEATURES IN RELATION TO PENTYLENETETRAZOL THRESHOLDS IN MONKEYS WITH FOCAL SEIZURES.

EFFECT OF P-CHLOROPHENYLALANINE ON DEVELOPMENT OF CROSS-TOLERANCE BETWEEN PENTOBARBITAL AND ETHANOL.

001123 02-03 REGIONAL DISTRIBUTION OF BARBITAL IN THE BRAIN OF MICE DURING THE DEVELOPMENT OF TOLERANCE AND PHYSICAL DEPENDENCE.

001180 02-03 DEVELOPMENT OF DENERVATION ALTERATIONS IN SURFACE MEMBRANES OF MAMMALIAN SKELETAL MUSCLE.

001246 02-03 DEVELOPMENT OF BEHAVIORAL TOLERANCE TO COCAINE.

001474 02-04 DEVELOPMENT OF DRUG THERAPY FOR THE MENTALLY ILL

001551 02-07 DEVELOPMENT AND APPLICATION OF METHODS FOR DETERMINING THE BIOLOGICAL TRANSMETHIOLATIONS DEPENDENT ON S ADENOSYL-L-METHIONINE.

THE BIOCHEMISTRY OF BRAIN DEVELOPMENT AND MENTAL RETARDATION: THE ELEVENTH BLAKE MARSH LECTURE DELIVERED BEFORE THE ROYAL COLLEGE OF PSYCHIATRISTS, 7 FEBRUARY, 1977. 002000 03-03

ME-DEPENDENT DISRUPTIVE EFFECTS OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE ON DEVELOPMENT OF MORPHINE TOLERANCE. 002058 03-03

PRESYNAPTIC DOPAMINE RECEPTORS: DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING TREATMENT WITH FLUPHENAZINE-DECANOATE.

002120 03-03 DIFFERENTIAL REGIONAL DEVELOPMENT OF TOLERANCE TO INCREASE IN DOPAMINE TURNOVER UPON REPEATED NEUROLEPTIC ADMINISTRATION.

002144 03-03 ONTOGENETIC DEVELOPMENT OF PENTOBARBITAL EFFECTS ON ELECTROCORTICOGRAM IN RATS.

002161 03-03

EFFECTS OF CHRONIC IMIPRAMINE AND CLOMIPRAMINE ORAL ADMINISTRATION ON MATERNAL BEHAVIOR AND LITTER DEVELOPMENT. 002202 03-04

BEHAVIORAL EFFECTS OF APOMORPHINE DURING DEVELOPMENT OF

002203 03-04 EFFECT OF PSYCHOTROPIC DRUGS ON THE DEVELOPMENT OF DEFENSE CONDITIONED REFLEX DURING EXPERIMENTAL NEUROSIS.

002204 03-04 EVIDENCE FOR PARALLEL DEVELOPMENT OF TOLERANCE TO THE HYPERACTIVATING AND DISCOORDINATING EFFECTS OF ETHANOL

002249 03-04 PRENATAL MORPHINE ADMINISTRATION ALTERS BEHAVIORAL DEVELOPMENT IN THE RAT.

002308 03-04 DEVELOPMENT OF AN ALCOHOL-BLOCKER, USING COMPUTER ANALYZED

002564 03-13

PRIOR PSYCHIATRIC TREATMENT AND THE DEVELOPMENT OF BREAST CANCER

002691 03-15 CREATIVITY IN NEW DRUG DEVELOPMENT: AN ACADEMIC CHALLENGE 002745 03-17 ONTOGENETIC DEVELOPMENT OF BENZODIAZEPINE RECEPTORS IN THE

RAT BRAIN. 002840 04-03 BENEFICIAL EFFECT OF ISOLEUCINE ON FETAL BRAIN DEVELOPMENT IN

INDUCED PHENYLKETONURIA. 002846 04-03 EFFECTS OF MATERNAL CHLORPROMAZINE ON OFFSPRING NERVOUS SYSTEM DEVELOPMENT.

002880 04-03 ROLE OF SEROTONIN REUPTAKE INHIBITION IN THE DEVELOPMENT OF SUBSENSITIVITY OF THE NOREPINEPHRINE (NE) RECEPTOR COUPLED ADENYLATE-CYCLASE SYSTEM.

003017 04-03 CHARACTERIZATION OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS IN MEMBRANES PREPARED FROM THE RABBIT IRIS BEFORE AND AFTER DEVELOPMENT OF SUPERSENSITIVITY.

003035 04-03 THE DEVELOPMENT OF SEX DIFFERENCES IN THE DEMETHYLATION OF ETHYLMORPHINE AND IN ITS INTERACTION WITH COMPONENTS OF THE HEPATIC MICROSOMAL CYTOCHROME-P-450 SYSTEM IN MICE.

003122 04-03 THE ROLE OF THE CHOLINERGIC SYSTEM IN THE DEVELOPMENT OF INCREASED NALOXONE POTENCY IN MICE.

003140 04-03 THE EFFECTS OF NALTREXONE ON THE DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE

003170 04-04 NOCICEPTIVE STIMULATION PREVENTS DEVELOPMENT OF TOLERANCE TO NARCOTIC ANALGESIA. 003195 04-04

001092 02-03

CONDITIONING FACTORS INFLUENCE TOLERANCE DEVELOPMENT TO LOW BUT NOT HIGH DOSES OF MORPHINE. 003198 04-04 EXPERIMENTAL BARBITURATE DEPENDENCE. I. BARBITURATE DEPENDENCE DEVELOPMENT IN RATS BY DRUG ADMIXED FOOD (DAF) 003373 04-04 INTEROCEPTIVE DISCRIMINATIVE STIMULI AS TOOLS IN DRUG DEVELOPMENT. 003428 04-06 DEVELOPMENT OF A SPECIFIC RADIOIMMUNOASSAY FOR ACETYLCHOLINE. 003438 04-06 PRIOR PSYCHIATRIC TREATMENT AND THE DEVELOPMENT OF BREAST 003674 04-15 DEVELOPMENTAL THE DEVELOPMENTAL EFFECTS OF MORPHINE-SULFATE AND NALOXONE HYDROCHLORIDE IN THE RAT. 001510 02-05 A DEVELOPMENTAL STUDY OF SELECTIVE ATTENTION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION). DHET 001709 02-14 DEVIANCE CONSUMPTION OF MEDICATION AND RISK OF DEVIANCE AMONG ADOLESCENTS. 001888 02-17 DI-N-PROFYLACETIC-ACID PHARMACOLOGICAL TREATMENT OF DEVIANT SEXUAL BEHAVIOUR 003552 04-11 A RELIABLE, FACIAL NOCICEPTION DEVICE FOR UNRESTRAINED, AWAKE ANIMALS: EFFECTS OF MORPHINE AND TRIGEMINAL COMPLEX **I ESIONS** 003435 04-06 DEXAMETHASONE A TWO-DOSE DEXAMETHASONE SUPPRESSION TEST IN PATIENTS WITH PSYCHIATRIC ILLNESS. 001691 02-13 DIABETES-INSIPIDUS EFFECT OF DEXAMETHASONE ON CEREBRAL EDEMA FROM CRANIAL IMPACT IN THE CAT. 001958 03-02 EFFECTS OF PROLACTIN, DEXAMETHASONE, AND CORTICOSTERONE ON MATERNAL AGGRESSION AND INFANT CARE. **DIABETES-MELLITUS** 002240 03-04 EFFECTS OF DEXAMETHASONE ON DISCRIMINATIVE CONDITIONING IN PIGS 003304 04-04 DEXAMPHETAMINE-INDUCED FLUPHENAZINE MODULATION OF DEXAMPHETAMINE-INDUCED COMPULSIVE GNAWING --INCLUDING THE POSSIBLE INVOLVEMENT OF PRESYNAPTIC ALPHA-ADDENOBECEPTORS 002322 03-04 INFLUENCE OF CATECHOLAMINES ON DEXAMPHETAMINE-INDUCED CHANGES IN LOCOMOTOR ACTIVITY. 003239 04-04 DEXTRAN EFFECT OF DRUGS ON HUMAN ERYTHROCYTES -- 4. PROTECTING EFFECT OF DEXTRAN ON DRUG-INDUCED HEMOLYSIS. 003603 04-13 HYPERSENSITIVITY TO METHYLPHENIDATE AND DEXTROAMPHETAMINE: A REPORT OF TWO CASES 000901 01-15 DEXTROAMPHETAMINE AND MEASURES OF INTELLIGENCE. 001716 02-14 EFFECT OF DEXTROAMPHETAMINE ON SOMATIC EVOKED-POTENTIAL COMPONENTS IN MAN WITH SPECIAL REFERENCE TO TALK RELEVANCE AND SELECTIVE ATTENTION 001735 02-14 EFFECT OF PSYCHOTOMIMETICS (LSD AND DEXTROAMPHETAMINE) ON THE USE OF PRIMARY AND SECONDARY PROCESS LANGUAGE 002542 03-12 DEXTROAMPHETAMINE AND L AMPHETAMINE ARE EQUIPOTENT IN

STEREOSELECTIVE, DOSE-DEPENDENT MODIFICATION OF INTRACRANIAL SELF-STIMULATION (ICSS) BY CENTRALLY ADMINISTERED LEVORPHANOL AND DEXTRORPHAN. 001280 02-03 DEVELOPMENT AND DISAPPEARANCE OF SUBSENSITIVITY TO PILOCARPINE FOLLOWING A SINGLE ADMINISTRATION OF THE IRREVERSIBLE ANTICHOLINESTERASE AGENT, DFP. 000212 01-03 THE EFFECT OF DFP AND PENTOBARBITAL ON THE TURNOVER OF ACETYLCHOLINE IN THE MOUSE BRAIN 001170 02-03 INCORPORATION, AFTER SINGLE AND REPEATED APPLICATION OF RADIOACTIVE LABELLED DH-ERGOT ALKALOIDS IN DIFFERENT ORGANS OF THE CAT, WITH SPECIAL REFERENCE TO THE BRAIN. ALCOHOL-DISCRIMINATION IN GERBILS: INTERACTIONS WITH BEMEGRIDE, DH-524, AMPHETAMINE, AND DELTA9-THO 001385 02-04 COMPARATIVE EFFECTS OF DIHYDROERGOTOXINE (DHET) ON CBF AND METABOLISM CHANGES PRODUCED BY EXPERIMENTAL CEREBRAL EDEMA, HYPOXIA AND HYPERTENSION. 001979 03-03 GAMMA-AMINOBUTYRIC-ACID (GABA) AND SLEEP: THE INFLUENCE OF DI-N-PROPYLACETIC-ACID ON SLEEP IN MAN. 001730 02-14 METABOLIC RESPONSES TO ISOPROTERENOL AND EPINEPHRINE IN THE RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES AND PRETREATMENT WITH PROPRANOLOL.

000227 01-0 SYNDROME MALIN SYMPTOMS THOUGHT TO BE DUE TO INTERACTION BETWEEN NEUROLEPTICS AND ORAL DIABETES DRUGS. 001854 02-15 TIME-COURSE OF LITHIUM-INDUCED ALTERATIONS IN RENAL AND ENDOCRINE FUNCTION IN NORMAL AND BRATTLEBORO RATS WITH HYPOTHALAMIC DIABETES-INSIPIDUS. 000048 01-03 DIABETES-MELLITUS IN PATIENTS ON LITHIUM. 001792 02-15 PERIPHERAL DIABETIC NEUROPATHY TREATED WITH AMITRIPTYLINE AND 001705 02-14 RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION WITH A HIGH FAT/PROTEIN DIET. 002278 03-04 FOOD RELATED INTRAVENOUS INSULIN SELF-ADMINISTRATION IN NORMAL AND DIABETIC RATS. 003252 04-04 DEPRESSION IN CHILDHOOD: DIAGNOSIS, TREATMENT, AND CONCEPTUAL 000613 01-10
DIPHENHYDRAMINE IN THE DIFFERENTIAL DIAGNOSIS OF NEUROLEPTIC-INDUCED ORAL FACIAL DYSKINESIA. 000798 01-15 THE DIAGNOSIS AND TREATMENT OF LITHIUM TOXICITY. 000838 01-15 AKATHISIA DIAGNOSIS: AN OBJECTIVE TEST. SUBTYPES OF DEPRESSION — DIAGNOSIS AND MEDICAL MANAGEMENT.
000938 01-17
TARDIVE-DYSKINESIA: IS IT OR IS IT NOT? A REVIEW OF THE PROBLEMS IN DIAGNOSIS AND A CASE STUDY 001747 02-15 ON THE PREVALENCE, DIAGNOSIS AND MANAGEMENT OF LITHIUM-INDUCED HYPOTHYROIDISM IN PSYCHIATRIC PATIENTS. NARCOLEPSY: DIAGNOSIS AND TREATMENT. (UNPUBLISHED PAPER). 002522 03-11 001805 02-15

RETROSPECTIVE DIAGNOSIS OF HYPOMANIA FOLLOWIN

NARCOANALYSIS: THE FORGOTTEN DIAGNOSTIC AID

TREATMENT OF EPISODIC VIOLENCE WITH LITHIUM: A CASE REPORT PSYCHIATRIC DIAGNOSIS: EXPLORATION OF BIOLOGICAL PREDICTORS.
003551 04-11

A DIAGNOSTIC TREATMENT MODEL FOR EFFECTIVE GROUP TREATMENT

SUCCESSFUL

000753 01-14

000950 01-17

DEXTROAMPHETAMINE AND PLACEBO PRACTICE EFFECTS ON SELECTIVE ATTENTION IN HYPERACTIVE CHILDREN.

THE EFFECTS OF DEXTROAMPHETAMINE ON KINESTHETIC FIGURAL

ACUTE PSYCHOLOGIC AND NEUROENDOCRINE EFFECTS OF

DEXTROAMPHETAMINE AND METHYLPHENIDATE

RELEASING HUMAN GROWTH HORMONE

003627 04-14

002576 03-13

002620 03-14

002786 04-01

DIAGNOSTIC

OF DRUG ABUSERS.

CHLORPROMAZINE-INDUCED CHANGES IN BLOOD ADENOSINEPHOSPHORIC-ACIDS: TO THEIR DIAGNOSTIC SIGNIFICANCE IN PSYCHIATRY.

AMINE NEUROTRANSMITTER STUDIES AND PSYCHIATRIC ILLNESS: TOWARD MORE MEANINGFUL DIAGNOSTIC CONCEPTS. (UNPUBLISHED PAPER).

O01893 02-17
THE VALUE OF THE MMPI FOR DELINEATING SYMPTOMS UNIQUE TO POSITIVE LITHIUM RESPONDERS: A DRUG RESPONSE AND DIAGNOSTIC STUDY. (PH.D. DISSERTATION).

002638 03-14 DEPRESSION IN THE ELDERLY. II. POSSIBLE DRUG ETIOLOGIES; DIFFERENTIAL DIAGNOSTIC CRITERIA.

003520 04-09

CHLORPROMAZINE PLUS THIORIDAZINE POISONING AND TREATMENT WITH EXTRACORPOREAL DIALYSIS. 001806 02-15

DIAMETER
ACTIONS OF AMPHETAMINE AND ANTAGONISTS ON PUPIL DIAMETER IN
THE CHRONIC SYMPATHECTOMIZED DOG.

000265 01-03

EVALUATION OF PURE DIASTEREOMERS OF N SEC ALKYLMORPHINOIDS 001040 02-02

STUDIES IN THE HETEROCYCLIC SERIES. XIII. NEW CNS DEPRESSANTS DERIVED FROM 1,9 DIAZAPHENOXAZINE AND TWO ISOMERIC TRIAZAPHENOTHIAZINE RING SYSTEMS. 000030 01-02

DIAZEPAM

ALTERATIONS IN BRAIN 5 HYDROXYTRYPTAMINE METABOLISM DURING
THE WITHDRAWAL PHASE AFTER CHRONIC TREATMENT WITH
DIAZEPAM AND BROMAZEPAM.

INFLUENCE OF DIAZEPAM, L-DOPA AND DOPAMINE ON THE CEREBELLAR AND SPINAL ELECTRICAL PATTERNS INDUCED BY HARMINE IN THE RABBIT.

000091 01-03 METABOLIC BASIS FOR THE SUPRA-ADDITIVE EFFECT OF THE ETHANOL DIAZEPAM COMBINATION IN MICE.

MULTIPLE ORAL DOSES OF DIAZEPAM, OXAZEPAM AND PHENOBARBITAL TO DOGS — BEHAVIOURAL EFFECTS AND CORRELATION WITH ANTIPYRINE HALF-LIFE.

000308 01-04 EFFECTS OF CLOZAPINE, CHLORPROMAZINE AND DIAZEPAM UPON ADJUNCTIVE AND SCHEDULE-CONTROLLED BEHAVIORS.

000330 01-04 A COMPARATIVE CLINICAL STUDY FOR THE EVALUATION OF ANTIANXIETY AGENTS, (LORAZEPAM, DIAZEPAM AND PLACEBO), IN NEUROSIS.

A DOUBLE-BLIND STUDY OF THE EFFECTIVE ANTIHALLUCINATORY DOSES OF DIAZEPAM PRIOR TO KETAMINE ANESTHESIA.

INTERINDIVIDUAL VARIABILITY IN DIAZEPAM METABOLISM:
PRELIMINARY EVIDENCE OF AN ABSENCE OF GENETIC CONTROL 000696 01-13 SEDATIVE PROPERTIES OF DOXEPIN IN COMPARISON WITH DIAZEPAM. 000703 01-13

THE EFFECT OF DIAZEPAM, CHLORPROMAZINE AND AMOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION. 000708 01-13

FLOPPY INFANT SYNDROME AND MATERNAL DIAZEPAM. 000837 01-15 HAZARDS OF INTRAARTERIAL DIAZEPAM

000840 01-15

APNEA AFTER INTRAVENOUS DIAZEPAM THERAPY. 000844 01-15

FLOPPY INFANT SYNDROME AND MATERNAL DIAZEPAM. 000845 01-15 PROFOUND HYPOTHERMIA ON COMBINED LITHIUM-CARBONATE AND DIAZEPAM TREATMENT.

000870 01-15 ADDICTION TO DIAZEPAM

DIAZEPAM: EFFICACY AND TOXICITY AS REVEALED BY A SMALL SAMPLE RESEARCH STRATEGY

EFFECTS OF PHENOBARBITAL AND DIAZEPAM ON IMIPRAMINE-INDUCED CHANGES IN BLOOD PRESSURE, HEART RATE AND RECTAL TEMPERATURE OF RATS.

001070 02-03 DIFFERENTIAL ANTAGONISM BY CHLORPROMAZINE AND DIAZEPAM FROG MOTONEURONE DEPOLARIZATION INDUCED BY GLUTAMATE RELATED AMINO-ACIDS. 001116 02-03

Psychopharmacology Abstracts

NEGATIVE EFFECTS OF BICUCULLINE AND THIOSEMICARBAZIDE ON THE TRANQUILLIZING ACTION OF DIAZEPAM.

INVOLVEMENT OF CENTRAL NORADRENERGIC SYSTEM IN THE MEDIATION OF BEHAVIORAL SUPPRESSANT EFFECTS OF DIAZEPAM IN HYPERTHYROID RATS.

DIAZEPAM BLOCKADE OF REPETITIVE ACTION POTENTIALS IN SKELETAL MUSCLE FIBRES: A MODEL OF ITS MEMBRANE ACTION.

INCORPORATION OF RADIOACTIVE LABELLED CHOLINE AND PALMITATE INTO LUNG LECITHIN OF RABBITS TREATED WITH HIGH DOSES OF BROMCARBAMIDES, BARBITURATES AND DIAZEPAM.

001282 02-03 BEHAVIOURAL AND PHARMACOKINETIC STUDIES IN THE MONKEY (MACACA-MULATTA) WITH DIAZEPAM, NORDIAZEPAM AND RELATED 1,4 BENZODIAZEPINES.

001336 02-04 DIAZEPAM MAINTENANCE OF ALCOHOL PREFERENCE DURING ALCOHOL WITHDRAWAL.

001345 02-04 EFFECTS OF DIAZEPAM AND D AMPHETAMINE ON FOOD COMPETITION IN RHESUS MONKEY. 001370 02-04

LYSERGIC-ACID-DIETHYLAMIDE ANTAGONISM BY CHLORPROMAZINE, HALOPERIDOL, DIAZEPAM, AND PENTOBARBITAL IN THE RABBIT. 001504 02-05

DECLINING DIAZEPAM DESENSITIZATION THERAPY. 001614 02-10

EFFECTS OF DIAZEPAM ON UTERINE ACTIVITY DURING LABOR 001627 02-11

COMPARATIVE AVAILABILITY OF DIAZEPAM (D) IN HUMAN PLASMA (P), PAROTID SALIVA (PS) AND MIXED SALIVA (MS) AND ITS RELATIONSHIP TO PLASMA PROTEIN BINDING. 001682 02-13

EFFECTS OF TRITHIOZINE ON PSYCHOMOTOR SKILLS RELATED TO DRIVING: A COMPARISON WITH DIAZEPAM AND INTERACTIONS WITH ALCOHOL.

001723 02-14 COMPUTER OCULOGRAPHIC DOUBLE-BLIND STUDY OF CHANGES IN VIGILANCE: ALPRENOLOL VERSUS DIAZEPAM.

001746 02-15 SEQUELAE AFTER THE INTRAVENOUS INJECTION OF THREE
BENZODIAZEPINES -- DIAZEPAM, LORAZEPAM, AND FLUNITRAZEPAM 001785 02-15

PHENYTOIN INTOXICATION DURING CONCURRENT DIAZEPAM THERAPY 001826 02-15

FLOPPY-INFANT SYNDROME AND MATERNAL DIAZEPAM AND/OR NITRAZEPAM.

001835 02-15 EFFECT OF DIAZEPAM ON PULSE ACTIVITY OF NEURONS OF THE SENSORIMOTOR AND OPTIC AREAS OF THE RAT CEREBRAL-CORTEX

001978 03-03 BLOCKADE OF THE PICROTOXIN-INDUCED IN VIVO RELEASE OF DOPAMINE IN THE CAT CAUDATE NUCLEUS BY DIAZEPAM.

EFFECT OF SUBACUTE DIAZEPAM ADMINISTRATION IN MICE ON THE SUBSEQUENT ABILITY OF DIAZEPAM TO PROTECT AGAINST METRAZOL AND BICUCULLINE-INDUCED CONVULSIONS.

002053 03-03 EFFECTS OF DIAZEPAM ON DOPAMINE TURNOVER IN NEOSTRIATAL AND LIMBIC REGIONS OF THE RAT BRAIN.

002060 03-03 EFFECT OF DIAZEPAM AND PENTOBARBITAL ON AMINOOXYACETIC-ACID-INDUCED ACCUMULATION OF GABA.

002124 03-03 THE IONTOPHORESIS OF DIAZEPAM IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT.

002130 03-03 THE ROLE OF DIAZEPAM AS COMPARED TO GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT. (PH.D. DISSERTATION).

EFFECT OF EARLY EXPERIENCE, PYRITHIOXIN AND DIAZEPAM ON UC14-GLUCOSE UTILIZATION IN RAT BRAIN DURING EMOTIONAL STRESS.

002152 03-03 EFFECT OF DIAZEPAM ON THE FROG NEUROMUSCULAR JUNCTION. 002171 03-03

REDUCTION OF VMH LESION-INDUCED HYPEREMOTIONALITY AND ANTINOCICEPTION BY DIAZEPAM.

002211 03-04 **EFFECT OF DIAZEPAM ON FOOD CONSUMPTION IN RATS** 002252 03-04

CONFLICT BEHAVIOR IN THE SQUIRREL-MONKEY: EFFECTS OF CHLORDIAZEPOXIDE, DIAZEPAM AND N DESMETHYLDIAZEPAM 002303 03-04

COMPARATIVE STUDY OF THE ANTAGONISM OF BEMEGRIDE AND PICROTOXIN ON BEHAVIOURAL DEPRESSANT EFFECTS OF DIAZEPAM IN RATS AND MICE.

DICHLORO-ALPHA-METHYL-BENZYLAMINE

DICHLORO-ALPHA-METHYLBENZYLAMINE

AGENT

2.3 DICHLORO-ALPHA-METHYLBENZYLAMINE.

DICHLORO-2-IMIDAZOLINYLTHIOACETOPHENONE-HBR PRECLINICAL EVALUATION OF DITA DICHLORO-2-

STERIC INFLUENCE ON INHIBITION OF MONOAMINE-OXIDASE FORMS BY

IMIDAZOLINYLTHIOACETOPHENONE-HBR: A NEW ANOREXIGENIC

DOES DIAZEPAM MAINTAIN ALCOHOLISM?. DICHOTOMY 002351 03-05 A CONTROLLED COMPARATIVE TRIAL OF CLORAZEPATE (TRANXENE) AND DIAZEPAM (VALIUM) FOR ANXIETY. 002476 03-10 DOXEPIN OR DIAZEPAM FOR ANXIOUS AND ANXIOUS DEPRESSED **OUTPATIENTS?** 002482 03-10 A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF LOXAPINE, DIAZEPAM, AND PLACEBO IN HOSPITALIZED PATIENTS WITH VARIOUS STATES OF ANXIETY. 002496 03-10 A CLINICAL TRIAL OF CLOMIPRAMINE AND DIAZEPAM IN THE TREATMENT OF PHOBIC AND OBSESSIONAL ILLNESS. 002497 03-10 EFFECTS OF DIAZEPAM ON PHOBIC AVOIDANCE BEHAVIOR AND PHOBIC ANXIETY 002498 03-10 ALLERGY TO DIAZEPAM. 002681 03-15 PROTEIN DIET A MODEL FOR EVALUATION OF ANTIANXIETY DRUGS WITH THE USE OF EXPERIMENTALLY-INDUCED STRESS: COMPARISON OF NABILONE AND DIAZEPAM 002721 03-16 CONCERNING THE USE OF VALIUM (DIAZEPAM). 002741 03-17 THE ACTIONS OF DIAZEPAM AND PHENYTOIN ON A LOW DOSE PENICILLIN EPILEPTIFORM FOCUS IN THE ANESTHETISED RAT. 002921 04-03 EFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY THE RESPONSES OF THE MUSCLE SPINDLE OF THE TRICEPS SURAE MUSCLE OF THE DECEREBRATE CAT TO THE MUSCLE STRETCH 003109 04-03 COMBINED EFFECTS OF ETHANOL AND DIAZEPAM ON PERFORMANCE AND ACQUISITION OF SERIAL POSITION SEQUENCES BY PIGEONS FEMALE RATS. 003164 04-04 A PLACEBO-CONTROLLED STUDY OF BROMAZEPAM AND DIAZEPAM IN ANXIETY NEUROSIS. 003542 04-10 FFFFCT OF A COCKTAIL ON DIAZEPAM ARSORPTION 003596 04-13 DELIRIUM-TREMENS: A DOUBLE-BLIND COMPARISON OF DIAZEPAM AND BARBITAL TREATMENT. 003632 04-14 DIAZEPAM-INDUCED DIAZEPAM-INDUCED HOSTILITY IN DEPRESSION. (UNPUBLISHED PAPER) 000815 01-15 DIAZEPINES EFFECTS OF DIAZEPINES AND BARBITURATES ON HIPPOCAMPAL RECURRENT INHIBITION 002181 03-03 DIETHYLPROPION ANTIMUSCARINIC PROPERTIES OF ANTIDEPRESSANTS: DIBENZEPIN (NOVERIL) 001221 02-03 EXPERIENCES WITH USING THE ANTIDEPRESSANT DIBENZEPIN: NOVERIL, ON NEUROLOGY OUTPATIENTS 001615 02-10 DIETING CLINICAL AND PHARMACOKINETIC STUDY OF DIBENZEPINE (ECATRIL): COMPARISON BETWEEN THE NORMAL AND RETARD FORMS. 001581 02-09 INTENSIVE ANTIDEPRESSIVE THERAPY BY 48 HOUR SLOW-DRIP INFUSION WITH HIGH DOSES DIBENZEPINE. 001602 02-09 DIBENZOXAZEPINE PHARMACOLOGICAL STUDY OF AMOXAPINE, A DIBENZOXAZEPINE DERIVATIVE. 002307 03-04 DIBUTYRYL-CYCLIC-AMP NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. II. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE TREATED WITH DIBUTYRYL-CYCLIC-AMP.

DIETHYLDITHIOCARBAMATE MORPHINE IN THE MOUSE. LOWERING OF EPINEPHRINE CONCENTRATION IN RAT BRAIN BY 2,3 DICHLORO-ALPHA-METHYL-BENZYLAMINE, AN INHIBITOR OF NOREPINEPHRINE-N-METHYLTRANSFERASE. 000112 01-03

Subject Index CALCIUM METABOLISM IN LITHIUM TREATED PATIENTS: RELATION TO UNIPOLAR DICHOTOMY 002420 03-09 DIENCEPHALIC

EFFECTS OF CENTRAL GABA RECEPTOR AGONISM AND ANTAGONISM ON EVOKED DIENCEPHALIC CARDIOVASCULAR RESPONSES. 002811 04-03 HYDROLYSIS OF DIESTER PRODRUGS OF APOMORPHINE 000047 01-03 DIET AND UPTAKE OF ALDOMET BY THE BRAIN: COMPETITION WITH NATURAL LARGE NEUTRAL AMINO-ACIDS. 001185 02-03 RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION WITH A HIGH FAT/PROTEIN DIET. ACUTE LITHIUM-INDUCED PARKINSONISM PRECIPITATED BY LIQUID EFFECTS OF N METHYLAMINOETHANOL, AND N,N
DIMETHYLAMINOETHANOL IN THE DIET OF PREGNANT RATS ON
NEONATAL RAT BRAIN CHOLINERGIC AND PHOSPHOLIPID PROFILE.
003149 04-03 DIETARY TRYPTOPHAN EFFECTS ON THE SLEEP OF NORMAL SUBJECTS.
000505 01-07
FORMATION OF BRAIN ACETYLCHOLINE FROM DIETARY CHOLINE AND NRMATION OF BRAIN ACETYLCHOLUNE TRAVIA DISTRIBUTION OF BARBITURATE ANESTHESIA ON THIS PROCESS.
001074 02-03 EFFECT OF DIETARY FACTORS ON DRUG ACTION 001749 02-15 DIETARY EFFECTS UPON FOOD AND WATER INTAKE AND RESPONSIVENESS TO ESTROGEN, 2 DEOXYGLUCOSE AND GLUCOSE IN 003402 04-04 IMPAIRMENT OF RETENTION OF AVOIDANCE RESPONSES IN RATS BY POSTTRAINING DIETHYLDITHIOCARBAMATE. EFFECTS OF DIETHYLDITHIOCARBAMATE ON BRAIN MONOAMINE AND PROTEIN CONTENT IN NEONATAL RATS. 002063 03-03 NOREPINEPHRINE ATTENUATION OF AMNESIA PRODUCED BY 003294 04-04 EFFECTS OF D AMPHETAMINE AND STRYCHNINE ON CYCLOHEXIMIDE -AND DIETHYLDITHIOCARBAMATE-INDUCED AMNESIA IN MICE.
001438 02-04 THE SOCIOPHARMACOLOGY OF FENFLURAMINE (FM), METHYLPHENIDATE (MP), AND DIETHYLPROPION (DP) IN MACAQUE ARCTOIDES. EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D AMPHETAMINE AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY AND SHOCK AVOIDANCE IN RHESUS MONKEYS. TING
LITHIUM INTOXICATION INDUCED BY DIETING AND SAUNAS.
001839 02-15 A SEX DIFFERENCE IN THE INTERACTION BETWEEN PROMETHAZINE AND DIFFERENTIATING
USE OF DRL IN DIFFERENTIATING ANXIOLYTIC AND NEUROLEPTIC PROPERTIES OF CNS DRUGS. 000329 01-04 BIOCHEMICAL DIFFERENTIATION OF AMPHETAMINE VS METHYLPHENIDATE AND NOMIFENSINE IN RATS. 000061 01-03 PRESYNAPTIC AND POSTSYNAPTIC ACTIONS OF APOMORPHINE:
DIFFERENTIATION BY ROTARY EFFECTS IN NORMAL RATS.
BIOCHEMICAL DIFFERENTIATION OF AGGREGATING CELL CULTURES OF DIFFERENT FETAL RAT BRAIN REGIONS. 001148 02-03 DIFFFRENTIATION BETWEEN OPIOID PEPTIDES BY NALTREXONE 001230 02-03 DIFFERENTIATION OF HYPNOTIC ACTION OF NITRAZEPAM AND ESTAZOLAM AND EFFECTS ON BEHAVIOR AND CORTICAL ACTIVITY.

67 CATECHOL ESTROGENS ON SEXUAL DIFFERENTIATION IN

NEONATAL FEMALE RATS.

PHARMACOLOGICAL DIFFERENTIATION OF THE CENTRAL 5

HYDROXYTRYPTAMINE-LIKE ACTIONS OF MK-212 (6 CHLORO-2-1-

002293 03-04

002918 04-03

001020 02-02

PIPERAZINYL-PYRAZINE), P-METHOXYAMPHETAMINE AND FENELURAMINE IN AN IN VIVO MODEL SYSTEM.

SEXUAL DIFFERENTIATION OF OFFSPRING OF MOTHERS TREATED WITH CORTISONE DURING PREGNANCY.

DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: A VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIATION OF CATECHOLAMINERGIC AND SEROTONINERGIC TERMINALS IN RAT CREERAL STRUCTURES.

BIOCHEMICAL AND PHARMACOLOGICAL DIFFERENTIATION OF AFFECTIVE-DISORDERS: AN OVERVIEW. 003495 04-09

SPECTRAL ANALYSIS OF THE DIFFERING EEG EFFECTS OF BENZODIAZEPINES, MEPROBAMATE, GLUTETHIMIDE AND AMOBARBITAL IN MACACA-MULATTA.

DIFFERING ACTIONS OF AMFONELIC-ACID (AFA) AND AMPHETAMINE (AMPH) ON STRIATAL DOPAMINE (DA).

001196 02-03 BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC/ ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA. 002220 03-04

DIFFICULTIES
DIFFICULTIES ENCOUNTERED BY THE CLINICAL RESEARCHER IN PLANNING
PSYCHOTROPIC DRUG TRIALS.

000935 01-16 THE DIFFICULTIES OF OLD PEOPLE TAKING DRUGS. 001878 02-17

DIGESTION THE EXTRACTION AND ANALYSIS OF BENZODIAZEPINES IN TISSUES BY ENZYMIC DIGESTION AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY.

000928 01-16

STUDIES ON DIGITAL PLETHYSMOGRAPHIC PATTERNS IN FEMALE PATIENTS WITH NONSPECIFIC COMPLAINTS. 000626 01-11

DIGITALIS DELIRIUM: PSYCHIATRIC CONSIDERATIONS. 003727 04-17

THE RELATIONSHIP BETWEEN MAGNITUDE OF ELECTROSHOCK STIMULATION AND THE EFFECTS OF DIGITOXIGENIN, PENTYLENETETRAZOL AND BRAIN MONOAMINE REDUCTION ON ELECTROSHOCK CONVULSIVE THRESHOLDS.

000066 01-03

DIGOXIN LITHIUM DRUG INTERACTION. PSYCHOSIS: A RARE MANIFESTATION OF DIGOXIN INTOXICATION. 002700 03-15 001853 02-15

THE EFFECT OF DIHYDROERGOTOXINE ON THE ADENYLATE-CYCLASE ACTIVITY IN HOMOGENATES OF RAT CEREBRAL-CORTEX.

COMPARATIVE EFFECTS OF DIHYDROERGOTOXINE (DHET) ON CBF AND METABOLISM CHANGES PRODUCED BY EXPERIMENTAL CEREBRAL EDEMA, HYPOXIA AND HYPERTENSION.

EFFECT OF DIHYDROERGOTOXINE ON CYCLIC-AMP GENERATING SYSTEMS IN RAT CEREBRAL-CORTEX SLICES.

002088 03-03 EFFECT OF DIHYDROERGOTOXINE ON THALAMIC AND PYRAMIDAL EVOKED RESPONSES IN THE CAT UNDER TRANSIENT ISCHEMIA. 002201 03-04

BROMOCRIPTINE, DIHYDROERGOTOXINE, METHYSERGIDE, D LSD, CF-25 397, AND CF-29-712: EFFECTS ON THE METABOLISM OF BIOGENIC AMINES IN THE BRAIN OF THE RAT.

002849 04-03 DIHYDROERGOTOXINE-INDUCED
DIHYDROERGOTOXINE-INDUCED MODULATION OF SPONTANEOUS
ACTIVITY OF CULTURED RAT PURKINJE CELLS.

002020 03-03

DIHYDROERGOTOXINE-MESYLATE
THE INFLUENCE OF DIHYDROERGOTOXINE-MESYLATE ON THE LOW-KM
PHOSPHODIESTERASE OF CAT AND RAT BRAIN IN VITRO.

PHOSPHODIESTERASE OF CAT AND RAT BRAIN IN VITRO.

002008 03-03

EFFECT OF PAPAVERINE AND DIHYDROERGOTOXINE-MESYLATE OF CEREBRAL MICROFLOW, EEG, AND PO2 IN OLIGEMIC HYPOTENSION.

002032 03-03 EFFECTS OF DIHYDROERGOTOXINE-MESYLATE ON AGING NEURONS IN

VITRO. 002112 03-03

DIHYDROGENATED
CHANGES IN THE RAT ELECTROCORTICOGRAM FOLLOWING
ADMINISTRATION OF TWO DIHYDROGENATED ERGOT DERIVATIVES 002207 03-04

Psychopharmacology Abstracts

003088 04-03

002919 04-03

DIHYDROMORPHINE

EFFECTS OF NA, K, MG AND CA ON THE SATURABLE BINDING OF

(3H)DIHYDROMORPHINE AND (3H)NALOXONE IN VITRO. 000180 01-03

INFLUENCE OF NEUROLEPTICS ON THE BINDING OF MET-ENKEPHALIN, MORPHINE AND DIHYDROMORPHINE TO SYNAPTOSOME ENRICHED FRACTIONS OF RAT BRAIN.

003096 04-03

DIHYDROOXAZINOINDOLES

EFFECTS OF 3.4 DIHYDROOXAZINOINDOLES, POTENTIAL
ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS AND
RELATED ACTIVITIES. 000027 01-02

DIHYDROPTERIDINE-REDUCTASE

A DISORDER OF BIOGENIC AMINES IN DIHYDROPTERIDINE-REDUCTASE
DEFICIENCY.

003554 04-11 DIHYDROTESTOSTERONE-PROPIONATE
FACILITATION OF MOUNTING BEHAVIOR BY DIHYDROTESTOSTERONEPROPIONATE IN CASTRATED ESTRADIOL-BENZOATE TREATED MALE
RATS FOLLOWING PUDENDECTOMY.

000403 01-04 DHYDROXY-2-AMINOTETRALINS
THE EFFECT OF DIHYDROXY-2-AMINOTETRALINS (DATS) ON DOPAMINE AND BETA TYPE ADENYLATE-CYCLASES.

DIHYDROXYBENZENE
A PHARMACOLOGICAL STUDY OF THE SPONTANEOUS CONVULSIVE
ACTIVITY INDUCED BY 1,2 DIHYDROXYBENZENE (CATECHOL) IN THE
ANESTHETIZED MOUSE.

001046 02-03 A COMPARATIVE STUDY OF DIHYDROXYLATED PHENOTHIAZINE DERIVATIVES AS MITOCHONDRIAL INHIBITORS.

000282 01-03

DIHYDROXYPHENYL-CYCLOPROPYLAMINE-HYDROCHLORIDE
(-)-(E) 3,4 DIHYDROXYPHENYL-CYCLOPROPYLAMINE-HYDROCHLORIDE
(ASL-7003): A RIGID ANALOGUE OF DOPAMINE. 002793 04-02

DIHYDROXYPHENYLACETIC-ACID
BIPHASIC EFFECTS OF M CHLOROPHENYL-PIPERAZINE IN 3,4
DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN RAT BRAIN 000113 01-03

EFFECT OF PSYCHOTROPIC DRUGS ON 3,4 DIHYDROXYPHENYLACETIC-ACID (DOPAC) CONTENT IN THE MEDIAL BASAL HYPOTHALAMUS. 001962 03-03

FAILURE OF MORPHINE TO INCREASE STRIATAL 3,4
DIHYDROXYPHENYLACETIC-ACID IN FASTED RATS.

002001 03-03 COMPARATIVE EFFECTS OF PEMOLINE, AMFONELIC-ACID AND AMPHETAMINE ON DOPAMINE UPTAKE AND RELEASE IN VITRO AND ON BRAIN 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN SPIPERONE-TREATED RATS.

DIHYDROXYPHENYLALANINE

EFFECTS OF L DIHYDROXYPHENYLALANINE (L-DOPA) AND DL,5

HYDROXYTRYPTOPHAN (DL,5-HTP) ON RESERPINE-INDUCED AMNESIA.

000427 01-04

DIHYDROXYPHENYLGLYCOL-SULFATE
CHRONIC TREATMENT WITH DESIFRAMINE CAUSED A SUSTAINED
DECREASE OF 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE AND TOTAL 3
METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT BRAIN. 002113 03-03

DESIPRAMINE AND SOME OTHER ANTIDEPRESSANT DRUGS DECREASE THE MAJOR NOREPINEPHRINE METABOLITE 3,4
DIHYDROXYPHENYLGLYCOL-SULFATE IN THE RAT BRAIN. 002114 03-03

DIHYDROXYTRYPTAMINE

5,7 DIHYDROXYTRYPTAMINE LESIONS: EFFECTS ON BODY WEIGHT,
IRRITABILITY, AND MURICIDE.

AMPHETAMINE-LIKE EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE ON SOCIAL BEHAVIOUR IN THE MOUSE.

000433 01-04 THE EFFECT OF 5,6 DIHYDROXYTRYPTAMINE ON POST DECAPITATION CONVULSIONS.

EFFECTS OF COMPLETE HYPOTHALAMIC DEAFFERENTATION AND 5,7
DIHYDROXYTRYPTAMINE ON SEVERAL PARAMETERS OF PROLACTIN

001990 03-03 INCREASED TILT-CAGE ACTIVITY AFTER SEROTONIN DEPLETION BY 5,7 DIHYDROXYTRYPTAMINE.

PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC AND CATECHOLAMINERGIC MECHANISMS BY 6 HYDROXYDOPAMINE AND 5,6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D. DISSERTATION)

VOLUME 16, SUBJECT INDEX

DIHYDROXYTRYPTAMINE-INDUCED
INHIBITION OF 5,7 DIHYDROXYTRYPTAMINE-INDUCED SUPERSENSITIVITY
TO 5 HYDROXYTRYPTOPHAN IN MICE BY TREATMENT WITH

003366 04-04

DIISOBUTYRYLAPOMORPHINE

BEHAVIORAL EFFECTS OF APOMORPHINE AND
DISOBUTYRYLAPOMORPHINE IN THE MOUSE.

000314 01-04

DIISOPROPYL-PHOSPHOFLUORIDATE
THE BEHAVIORAL EFFECTS OF DIISOPROPYL-PHOSPHOFLUORIDATE:
INTERACTIONS WITH MORPHINE AND NALOXONE IN RATS.
001169 02-03

EFFECTS OF MYSOLINE AND DILANTIN ON THE EEG DURING SMR BIOFEEDBACK TRAINING OF A PSYCHOMOTOR EPILEPTIC: SINGLE CASE

001657 02-13

DILATATION

A CASE OF ACUTE GASTRIC DILATATION IN ANOREXIA-NERVOSA 000602 01-10

DOCTORS DEBATE BRAIN HORMONE DILEMMAS.

003718 04-17

DIMETACRINE-TARTRATE

A CASE OF DEPRESSION SHOWING IMPROVEMENT IN TRH TEST BY COMBINED TREATMENT BY DIMETACRINE-TARTRATE AND THYROID

003527 04-09

DIMETHOXY-4-METHYLAMPHETAMINE

BEHAVIORAL CHANGES INDUCED BY 2,5 DIMETHOXY-4 METHYLAMPHETAMINE (DOM, STP) IN PRIMATE DYADS

003380 04-04

DIMETHOXY-4-METHYLPHENYLAMINOPROPANE
STEREOSELECTIVE EFFECTS OF DIMETHOXY-4METHYLPHENYLAMINOPROPANE (DOM) ON SCHEDULE-CONTROLLED

BEHAVIOR 001372 02-04

DIMETHOXYAMPHETAMINE
IN VIVO METABOLIC O DEMETHYLATION OF 3,4
DIMETHOXYAMPHETAMINE IN DOG AND MONKEY. MONKEY

001149 02-03 DIMETHOXYPHENETHYLAMINE

EFFECTS OF 3,4 DIMETHOXYPHENETHYLAMINE DERIVATIVES ON MONOAMINE-OXIDASE.

000162 01-03 EXCRETION OF 3.4 DIMETHOXYPHENETHYLAMINE (DMPEA) BY ACUTE

SCHIZOPHRENICS AND CONTROLS. 000698 01-13

DIMETHYL-M-TYRAMINE

EVIDENCE FOR NORADRENERGIC MECHANISM IN THE GROOMING PRODUCED BY () AMPHETAMINE AND 4, GAMMA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.

INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETINE ON HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE (PCA) AND 4, ALPHA DIMETHYL-M-TYRAMINE (H-77-77) 003271 04-04

DIMETHYLAMINOETHANOL

PHARMACOLOGICAL, BIOCHEMICAL AND CLINICAL EFFECTS OF 2 DIMETHYLAMINOETHANOL (DEANOL): A CRITICAL REVIEW.

EFFECTS OF N METHYLAMINOETHANOL, AND N, N
DIMETHYLAMINOETHANOL IN THE DIET OF PREGNANT RATS ON
NEONATAL RAT BRAIN CHOLINERGIC AND PHOSPHOLIPID PROFILE. 003149 04-03

EFFECTS OF 2 DIMETHYLAMINOETHANOL (DEANOL) ON THE METABOLISM OF CHOLINE IN PLASMA. 003589 04-13

DIMETHYLHEPTYLPYRAN
DELTA9-TETRAHYDROCANNABINOL AND DIMETHYLHEPTYLPYRAN INDUCED TACHYCARDIA IN THE CONSCIOUS RAT. 001516 02-05

DIMETHYLMETHYLAMINOPROPYL-1-PHENYLINDAN

NEUROCHEMICAL PROPERTIES OF DIMETHYLMETHYLAMINOPROPYL-1-PHENYLINDAN HCL (LU-3-049) AND SELECTED TRICYCLIC ANTIDEPRESSANTS. 000251 01-03

DIMETHYLTRYFTAMINE

EFFECTS OF VARIOUS NEUROLEPTICS ON RABBIT HYPERTHERMIA INDUCED BY N,N DIMETHYLTRYPTAMINE (DMT) AND D

000099 01-03 N,N DIMETHYLTRYPTAMINE LOWERS RAT BRAIN ACETYLCHOLINE AND

000140 01-03 DOSE-RESPONSE AND TIME-COURSE EFFECTS OF N.N
DIMETHYLTRYPTAMINE ON DISRUPTION OF RAT SHUTTLE-BOX

000457 01-04

THE ELECTRONIC AND SEROTONIN RECEPTOR BINDING AFFINITY PROPERTIES OF N,N DIMETHYLTRYPTAMINE ANALOGS.

001002 02-01

003102 04-03

003259 04-04

001943 03-01

INCREASED SYNTHESIS OF STRIATAL DOPAMINE BY N.N. DIMETHYLTRYPTAMINE

001248 02-03 COMPARISON OF THE EFFECTS OF 5 HYDROXYTRYPTAMINE, DIMETHYLTRYPTAMINE, AND 5 METHOXY-DIMETHYLTRYPTAMINE ON RECTAL TEMPERATURE IN THE MOUSE.

602154 03-03

EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) ON PSYCHOTICISM

LACK OF ENHANCEMENT OF DIMETHYLTRYPTAMINE FORMATION IN RAT BRAIN AND RABBIT LUNG IN VIVO BY METHIONINE OR S ADENOSYLMETHIONINE.

DIMINISHED TASTE REACTIVITY TO SACCHARIN FOLLOWING CHRONIC ADMINISTRATION OF THEOPHYLLINE IN RATS.

DIMOXAMINE NEUROCHEMICAL PROPERTIES OF DIMOXAMINE (D), A NEW

PSYCHOTHERAPEUTIC AGENT. 001073 02-03

HYDROLYSIS OF ENKEPHALIN BY CULTURED HUMAN ENDOTHELIAL CELLS AND BY PURIFIED PEPTIDYL DIPEPTIDASE. 003593 04-13

DIPHENHYDRAMINE IN THE DIFFERENTIAL DIAGNOSIS OF NEUROLEPTIC-INDUCED ORAL FACIAL DYSKINESIA. 000798 01-15

SIMULTANEOUS IDENTIFICATION AND QUANTITATION OF DIPHENHYDRAMINE AND METHAQUALONE.

000925 01-16

HYPNOTIC ACTIVITY OF DIPHENHYDRAMINE, METHAPYRILENE, AND

003638 04-14 DIPHENYLAMINE
IMIPRAMINE DERIVATIVES: AMINOMETHYLATION OF DIPHENYLAMINE

AND IMINODIBENZYL. 000011 01-01

DIPHENYLCYCLOBUTYLAMINES ANTIDEPRESSANT AGENTS. 9.3,3 DIPHENYLCYCLOBUTYLAMINES, A NEW CLASS OF CENTRAL STIMULANTS.

EFFECTS OF BETA-BUNGAROTOXIN, DIPHENYLHYDANTOIN AND METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT CATIONS AND HIGH-ENERGY PHOSPHATE CONTENTS OF BRAIN SLICES. 000278 01-03

LACK OF EFFECT OF CLONAZEPAM ON SERUM LEVELS OF DIPHENYLHYDANTOIN, PHENOBARBITAL AND CARBAMAZEPINE 000705 01-13

THE EFFECT OF DIPHENYLHYDANTOIN ON CENTRAL CATECHOLAMINE CONTAINING NEURONAL SYSTEMS. 001112 02-03

ONE AUTOPSY CASE OF DIPHENYLHYDANTOIN INTOXICATION

DAILY CHANGES IN THE BLOOD SERUM LEVELS OF DIPHENYLHYDANTOIN (DPH) AND PHENOBARBITAL.

001830 02-15 SEIZURE SUSCEPTIBILITY AND ANTICONVULSANT ACTIVITY OF CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES

THE STABILITY AND RELIABILITY OF RADIOIMMUNOASSAYS FOR CLONAZEPAM, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN BLOOD, SERUM OR PLASMA. 003439 04-06

PHARMACOKINETICS OF N DESMETHYLDIAZEPAM IN HEALTHY VOLUNTEERS AFTER SINGLE DAILY DOSES OF DIPOTASSIUM CHLORAZEPATE.

000728 01-13

EFFECT OF DIPROPYLACETATE (CONVULEX) ON PERSONALITY CHANGES IN EPILEPTICS: PRELIMINARY REPORT.

EFFECTS OF DIPROPYLACETATE ON WAKEFULNESS AND SLEEP IN HUMAN

002632 03-14
TIME-COURSE OF THE INCREASE IN GABA LEVEL IN DIFFERENT MICE
BRAIN REGIONS FOLLOWING N DIPROPYLACETATE TREATMENT. 003091 04-03

BRAIN:SERUM AND CSF:SERUM RATIOS AFTER A SINGLE DOSE OF DIPROPYLACETIC-ACID (DPA),

002168 03-03

EPILEPSY IN CHILD PSYCHIATRY. EFFECTS OF TREATMENT BY DIPROPYLACETIC-ACID.

002517 03-11

OPYLAMINO-DIHYDROXYTETRALIN
INVESTIGATIONS INTO THE NATURE OF THE PERIORAL MOVEMENTS
INDUCED BY DIPROPYLAMINO-DIHYDROXYTETRALIN.

001334 02-04

003446 04-07

002035 03-03

DIPROPYLTRYPTAMINE (DPT) AS AN ADJUNCT IN THE COUNSELING OF CANCER PATIENTS.

000978 01-17

DIPSOGENIC
LOCALIZATION OF RECEPTORS FOR THE DIPSOGENIC ACTION OF
ANGIOTENSIN-II IN THE SUBFORNICAL ORGAN OF RAT. 003361 04-04

DIPYRONE
THE ANTAGONISM OF THE ANALGESIC EFFECT OF DIPYRONE BY L-DOPA
AND ITS RELATION TO BRAIN AMINE CONCENTRATIONS.
002977 04-6 002977 04-03

DIRECT EVIDENCE FOR AN INTERACTION OF BETA-ADRENERGIC BLOCKERS
WITH THE 5-HT RECEPTOR.

000010 01-01 DIRECT EFFECTS OF ETHANOL ON CENTRAL-NERVOUS-SYSTEM CULTURES: AN ELECTROPHYSIOLOGICAL AND MORPHOLOGICAL STUDY.

000261 01-03

CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIVITY TO THE DIRECT APPLICATION OF MORPHINE AND FOCAL ELECTRICAL STIMULATION IN THE PRODUCTION OF ANTINOCICEPTION IN THE RAT. 001291 02-03

DIRECT INTERACTION OF LSD WITH CENTRAL BETA-ADRENERGIC RECEPTORS.

002005 03-03 DIRECT AND PITUITARY MEDIATED EFFECTS OF DELTA9-THC AND CANNABINOL ON THE TESTIS.

002881 04-03 DIRECT EXTRACTION RADIOASSAY FOR CATECHOL-O-METHYL TRANSFERASE ACTIVITY.

003425 04-06 CONTRIBUTION OF THE USE OF 1035MD IN A PSYCHIATRIC WARD FOR ADULTS, ITS ACTIVITY ON THE DIRECT AND SIDE-EFFECTS OF

DIRECTED

3 HYDROXY-17-ARALKYLMORPHINANS AS POTENTIAL OPIATE RECEPTOR SITE DIRECTED AKLYLATING AGENTS. 001010 02-01

NEW DIRECTION TO THE AMINE HYPOTHESIS.

000739 01-13

DIRECTIONAL

DIRECTIONAL LIPOPHILIC CHARACTER IN A SERIES OF PSYCHOTOMIMETIC

PHENETHYLAMINE DERIVATIVES. 001009 02-01

DISAGGREGATION

DISAGGREGATION OF BRAIN POLYSOMES AFTER D LYSERGIC-ACID-DIETHYLAMIDE ADMINISTRATION IN VIVO: MECHANISM AND EFFECT OF AGE AND ENVIRONMENT.

000149 01-03 ANTIPSYCHOTIC DRUGS BLOCK LSD-INDUCED DISAGGREGATION OF BRAIN POLYSOMES.

001147 02-03 STRESS ACCENTUATION OF THE LSD-INDUCED DISAGGREGATION OF BRAIN POLYSOMES.

EFFECT OF GENERAL ANESTHETICS ON HANDLING-INDUCED AND DECAPITATION-INDUCED INCREASES IN SYMPATHOADRENAL

002139 03-03 EFFECTS OF ACETYLCHOLINE, SODIUM-GLUTAMATE AND GABA ON THE DISCHARGE OF SUPRAOPTIC NEURONS IN THE RAT. 002830 04-03

DISCHARGED

PENFLURIDOL IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS NEWLY DISCHARGED FROM A BRIEF THERAPY 002391 03-08

EFFECTS OF CARBAMAZEPINE ON MUSCLE SPINDLE DISCHARGES 002037 03-03

A STUDY OF PHYSICIAN DRUG PRESCRIBING ADOPTION AND DISCONTINUATION BEHAVIORS. (PH.D. DISSERTATION). 001889 02-17

EVIDENCE FOR PARALLEL DEVELOPMENT OF TOLERANCE TO THE HYPERACTIVATING AND DISCOORDINATING EFFECTS OF ETHANOL 002249 03-04 Psychopharmacology Abstracts

DISCRETE-TRIAL CONTROL OF COCAINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF MORPHINE, MALOXONE, AND

DISCRETE-TRIAL CONTROL OF MORPHINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF NALOXONE, MORPHINE, AND CHLORPROMAZINE.

001470 02-04

THE DISCRIMINABILITY OF NALOXONE IN RATS DEPENDS ON CONCOMITANT MORPHINE TREATMENT.

003393 04-04

DISCRIMINABLE EFFECTS OF ANTIMUSCARINICS: DOSE-RESPONSE AND SUBSTITUTION TEST STUDIES. 000426 01-04

DRUG VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS.

001777 02-15

PAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS UNDER LONG-TERM TRAINING.

000034 01-02

INFLUENCE OF THE SUSPENSION OF CONTINUED TREATMENT WITH FLURAZEPAM AND AMOBARBITAL ON TWO DISCRIMINATION LEARNING SCHEDULES.

000328 01-04 EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN TWO INBRED STRAINS OF MICE.

000333 01-04 AMPHETAMINE EFFECTS ON BRAIN SLOW POTENTIALS ASSOCIATED WITH DISCRIMINATION IN THE RAT.

000432 01-04 DIFFERENTIAL HALOPERIDOL EFFECT ON TWO INDICES OF FENTANYL SALINE DISCRIMINATION.

000495 01-06 COMPARISON OF ETHANOL, PENTOBARBITAL, AND PHENOBARBITAL USING DRUG VS. DRUG DISCRIMINATION TRAINING.

000503 01-06

EFFECTS OF METHYLPHENIDATE ON ACQUISITION AND SUBSEQUENT PERFORMANCE OF SUCCESSIVE DISCRIMINATION REVERSALS. 001371 02-04 EFFECTS OF MAGNESIUM PEMOLINE ON PATTERN DISCRIMINATION LEARNING IN YOUNG RATS.

001425 02-04 EFFECT OF SCOPOLAMINE ON RETENTION OF A SHOCK MOTIVATED BRIGHTNESS DISCRIMINATION IN RATS.

001487 02-04

DRUG DISCRIMINATION AND GENERALIZATION IN PIGEONS 001532 02-06

DRUG DISCRIMINATION AND STATE-DEPENDENT LEARNING 002753 03-17

EFFECTS OF MESCALINE AND PSILOCIN ON ACQUISITION, CONSOLIDATION, AND PERFORMANCE OF LIGHT-DARK DISCRIMINATION IN TWO INBRED STRAINS OF MICE.

003184 04-04 METHODOLOGICAL ISSUES IN DRUG DISCRIMINATION RESEARCH. 003202 04-04 THE EFFECTS OF METHYLPHENIDATE ON REPEATED ACQUISITION OF

SERIAL DISCRIMINATION REVERSALS. 003238 04-04 SOME FAILURES OF THE DRUG DISCRIMINATION HYPOTHESIS OF STATE-

DEPENDENT LEARNING 003317 04-04 EFFECTS OF D AMPHETAMINE ON TEMPORAL AND SPATIAL DISCRIMINATION IN RATS.

003349 04-04

EFFECTS OF CHLORMETHIAZOLE (HEMINEVRIN) ON DRUG DISCRIMINATION AND OPEN-FIELD BEHAVIOR IN GERBILS

003371 04-04 DORSOMEDIAL THALAMIC LESIONS AND AMPHETAMINE: ACQUISITION AND RETENTION OF A VISUAL PATTERN DISCRIMINATION ESCAPE TASK.

003399 04-04 DRUG DISCRIMINATION PARADIGMS: PROBLEMS OF TOLERANCE AND BEHAVIORAL DISRUPTION.

OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR OPERANT DRUG DISCRIMINATIONS.

003499 04-09 AND SINEMET

003556 04-11

	RIMINATIVE PRIMATE INFORMATION PROCESSING UNDER SODIUM PEN	TODADDITAL
i	AND CHLORPROMAZINE: DIFFERENTIAL DRUG EFFECTS V	VITH
	TACHISTOSCOPICALLY PRESENTED DISCRIMINATIVE STIM	
		000318 01-04
	DISCRIMINATIVE STIMULUS PROPERTIES OF FENFLURAMIN OPERANT TASK: AN ANALYSIS OF ITS CUE FUNCTION.	E IN AN
		000369 01-04
	DISCRIMINATIVE EFFECTS OF NARCOTIC AGONISTS AND A THE RAT AND SQUIRREL-MONKEY.	NTAGONISTS IN
	***************************************	000381 01-04
	TOLERANCE TO MORPHINE PRODUCED DISCRIMINATIVE ST ANALGESIA.	IMULI AND
	711111222011	000414 01-04
	MORPHINE AND ETHANOL AS DISCRIMINATIVE STIMULI: A ANTAGONISM BY P-CHLOROPHENYLALANINE-METHYL-E CINANSENIN, OR BC-105.	
	CHAMBENIN, OR BC-103.	000473 01-04
	COMPARISON OF THE DISCRIMINATIVE STIMULUS PROPER COCAINE AND AMPHETAMINE IN RATS.	
	COUNTE PHILIPPINE IN RAIS.	001337 02-04
	PENTAZOCINE, CYCLAZOCINE, AND NALORPHINE AS DISCI	
		001378 02-04
	DISCRIMINATIVE PROPERTIES OF PENTOBARBITAL AFTER I NONCONTINGENT EXPOSURE IN GERBILS.	
		001387 02-04
	DISCRIMINATIVE PENTOBARBITAL EFFECT MEASURED BY I MOVEMENTS IN RESTRAINED RATS.	HEAD
		001396 02-04
	DISCRIMINATIVE STIMULUS PROPERTIES OF QUIPAZINE.	
	BUILD DECERTOR MEDIATION OF THE DISCOVERY	001489 02-04
	DUAL RECEPTOR MEDIATION OF THE DISCRIMINATIVE STIL PROPERTIES OF PENTAZOCINE.	
		002191 03-04
	PHARMACOLOGY OF DISCRIMINATIVE DRUG STIMULI.	
		002195 03-04
	ATTRIBUTES OF DISCRIMINATIVE PENTOBARBITAL STIMUL IMMEDIATELY AFTER INTRAVENOUS INJECTION.	.05
	MINISTER ACIEN INTERPRETATION INSECTION.	002265 03-04
	INDUCED TOLERANCE TO THE DISCRIMINATIVE STIMULUS	
	COCAINE.	000000 00 04
	DISCRIMINATIVE PROPERTIES OF L AMPHETAMINE: STIMI	002280 03-04 JLUS
	GENERALIZATION.	000001 00 0
	DISCRIMINATIVE PROPERTIES OF CHLORDIAZEPOXIDE: A	002331 03-04 NEW METHOD
	OF ANALYSIS.	55550C 0 4 00
	CONTRAL MECHANISMS OF BRUCE AS DISCRIMINATIONS	002905 04-03
	CENTRAL MECHANISMS OF DRUGS AS DISCRIMINATIVE S INVOLVEMENT OF SEROTONIN PATHWAYS.	IIMULI:
	INVOLVEMENT OF SERVIONIN PAINWATS.	003070 04-03
	CHARACTERIZATION OF DISCRIMINATIVE STIMULUS PROF	
	PSYCHOMOTOR STIMULANTS.	EKTIES OF
		003150 04-04
	THE DISCRIMINATIVE STIMULUS PROPERTIES OF INTRAVE	NOUSLY
	ADMINISTERED COCAINE IN RHESUS MONKEYS.	
		003160 04-04
	SIMILARITIES AND DIFFERENCES IN DISCRIMINATIVE STIN OF CHLORDIAZEPOXIDE, PENTOBARBITAL, ETHANOL, A SEDATIVES.	
		003163 04-04
	POTENTIAL ROLES OF ENDOGENOUS PEPTIDES IN THE DISC PROPERTIES OF DRUGS.	
		003187 04-04
	DISCRIMINATIVE STIMULUS PROPERTIES OF NARCOTIC AP DRUGS.	
		003190 04-04

DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE AND D AMPHETAMINE; AND ANTAGONISM BY HALOPERIDOL: A COMPARATIVE STUDY.

DISCRIMINATIVE STIMULUS PROPERTIES OF ANTIDEPRESSANTS.

COCAINE AS A DISCRIMINATIVE CUE IN RATS: INTERACTIONS WITH

ANTAGONISM OF PENTOBARBITAL DISCRIMINATIVE STIMULUS BY BEMEGRIDE IN IMMOBILIZED RATS.

DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE: ORGANIC MOLECULAR MECHANISMS AND NEUROCHEMICAL EVENTS.

MORPHINE AS A DISCRIMINATIVE CUE IN GERBILS: DRUG GENERALIZATION AND ANTAGONISM.

NEUROLEPTICS AND OTHER DRUGS.

REINFORCING, DISCRIMINATIVE, AND/OR ACTIVATION PROPERTIES OF AMPHETAMINE.

	CYCLAZOCINE AND MORPHINE IN THE RAT.	
	EFFECTS OF DEXAMETHASONE ON DISCRIMINATIVE CONDIT	003270 04-04 FIONING IN
	THE EFFECTS OF HALOPERIDOL ON DISCRIMINATIVE RESPO!	003304 04-04 NDING
	DIFFERENTIAL RESPONDING CONTROLLED BY THE DISCRIMI STIMULI PRODUCED BY CONVULSANT DRUGS IN THE RA	T.
	INTERNAL STIMULUS CONDITIONING TO DISCRIMINATIVE E	003358 04-04 EXTERNAL
	GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PROI DELTA9-TETRAHYDROCANNABINOL TO CANNABINOIDS N THERAPEUTIC POTENTIAL.	
	COCAINE AS DISCRIMINATIVE STIMULUS FOR RESPONDING BY FOOD IN SQUIRREL-MONKEYS.	003392 04-04 MAINTAINED
	INTEROCEPTIVE DISCRIMINATIVE STIMULI AS TOOLS IN DR DEVELOPMENT.	
	THE USE OF DRUGS AS DISCRIMINATIVE STIMULI IN BEHAT	003428 04-06 VIORAL
DIE	EASE	003695 04-17
art di	TRAZODONE BY INTRAVENOUS INFUSION IN DEPRESSIONS TO ORGANIC DISEASE.	SECONDARY
	TREATMENT OF PARKINSONS DISEASE WITH THE COMBINAL CARBIDOPA.	000585 01-09 ATION L-DOPA/
	NEUROTRANSMITTER PRECURSOR AMINO-ACIDS IN THE TI MULTIINFARCT DEMENTIA AND ALZHEIMERS DISEASE.	000633 01-11 REATMENT OF
	CYCLOBENZAPRINE AND BENZOTROPINE METHANESULFON PARKINSONS DISEASE: A RANDOMIZED DOUBLE-BLIND	
	STUDY. THE OFF-ON PHENOMENON DURING TREATMENT OF PARK DISEASE WITH LEVODOPA.	000654 01-11 INSONS
	PLASMA LEVELS OF CHLORPROMAZINE: EFFECT OF AGE, ODISEASE, AND DURATION OF TREATMENT.	000664 01-11 CHRONICITY OF
	INFLUENCE OF DISULFIRAM AND DISEASE ON BENZODIAZE DISPOSITION.	000732 01-13 PINE
	SCHIZOPHRENIA AS A PROSTAGLANDIN DEFICIENCY DISEA	000738 01-13 ASE. 000794 01-14
	HALOPERIDOL-INDUCED LIVER DISEASE.	
	PHARMACODYNAMICS AND PHARMACOKINETICS OF PSY DRUGS IN THE COURSE OF RADIATION DISEASE: THE EF PREMEDICATION WITH CYSTAMINE ON PHARMACODYN PHARMACOKINETICS OF NITRAZEPAM.	FECT OF
	CHANGES IN PHARMACODYNAMICS AND PHARMACOKIN PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION D EFFECTS OF PREMEDICATION WITH CYSTAMINE ON DYN KINETICS OF THIORIDAZINE.	ISEASE:
	PHARMACODYNAMICS AND PHARMACOKINETICS OF PSY DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT PREMEDICATION WITH METANABOL ON DYNAMICS AN	OF
	THIORIDAZINE. PHARMACODYNAMICS AND PHARMACOKINETICS OF PSY	
	DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT PREMEDICATION WITH METANABOL ON DYNAMICS AN NITRAZEPAM.	D KINETICS OF
	COMBINED TREATMENT WITH L-DOPA AND PARCOPAN IN DISEASE.	
	DRUGS THAT MAY INDUCE PULMONARY DISEASE.	002518 03-11
	LEVODOPA IN PARKINSON DISEASE: A LONG-TERM APPRIMORTALITY.	
	DOPAMINERGIC MECHANISMS IN SCHIZOPHRENIA: THE A EFFECT AND THE DISEASE PROCESS.	002755 03-17 INTIPSYCHOTIC
	SPIRONOLACTONE PROPHYLAXIS IN MANIC-DEPRESSIVE D	003452 04-08 DISEASE.

A DOUBLE-BLIND COMPARISON OF LEVODOPA, MADOPA, IN PARKINSON DISEASE.

A COMPARISON OF DISCRIMINATIVE STIMULI PRODUCED BY NALOXONE,

003231 04-04

003246 04-04

003249 04-04

RACLOFEN IN PARKINSONS DISEASE 003560 04-11 POSSIBLE BIOCHEMICAL BASIS OF MEMORY DISORDER IN ALZHEIMER DISFASE STUDY OF THE TREATMENT OF VASCULAR PARKINSONS DISEASE WITH METAMIZYL. 003599 04-13 A CONTROLLED STUDY OF TRANCOPAL IN SLEEP DISTURBANCES DUE TO RHEUMATIC DISEASE. 003621 04-14 SCHIZOPHRENIA AS A DOPAMINE DEFICIENCY DISEASE. 003705 04-17 EFFECTS OF TWO ANXIOLYTICS ON DISTRACTION, HABITUATION AND DISHABITUATION. 001353 02-04 DISORDER LITHIUM AND EMOTIONAL DISORDER. 000573 01-09 THOUGHT DISORDER IN SCHIZOPHRENIA: A THEORETICAL A USING AN ANALYSIS OF SPEECH. (PH.D. DISSERTATION) APPROACH 001566 02-08 BIPOLAR MANIC-DEPRESSIVE DISORDER: A REASSESSMENT OF COURSE AND OUTCOME. 001608 02-09 A DISORDER OF BIOGENIC AMINES IN DIHYDROPTERIDINE-REDUCTASE DEFICIENCY 003554 04-11
POSSIBLE BIOCHEMICAL BASIS OF MEMORY DISORDER IN ALZHEIMER DISEASE 003575 04-11 COMPULSIONS, AGGRESSION, AND SELF-MUTILATION: A HYPOTHALAMIC DISORDER? 003641 04-14 DISORDERS MOVEMENT DISORDERS INDUCED IN MONKEYS BY CHRONIC HALOPERIDOL TREATMENT. 000490 01-05 THE IMPACT OF LITHIUM ON THE TREATMENT OF MANIC-DEPRESSIVE DISORDERS. EFFECT OF A NEW BENZODIAZEPINE DERIVATE, CLOBAZAM, IN ANXIOUS PATIENTS WITH GASTROINTESTINAL DISORDERS. 000604 01-10 LORAZEPAM IN ANXIETY WITH GLDISORDERS. 000612 01-10 URINARY MONOAMINE METABOLITE EXCRETION IN DISORDERS OF MOVEMENT 000710 01-13 IATROGENIC EXTRAPYRAMIDAL DISORDERS 000859 01-15 DOPAMINE, THE PSYCHE, AND EXTRAPYRAMIDAL DISORDERS 000864 01-15 L TRYPTOPHAN IN OBSESSIVE-COMPULSIVE DISORDERS 001616 02-10 LITHIUM THERAPY OF EXTRAPYRAMIDAL MOVEMENT DISORDERS 001774 02-15 PERSPECTIVES IN THE TREATMENT OF THE PSYCHONEUROLOGICAL DISORDERS: AFFECTIVE-DISORDERS. (UNPUBLISHED PAPER). 001870 02-16 **DEANOL IN THE MANAGEMENT OF INVOLUNTARY MOVEMENT** DISORDERS: A REVIEW 001886 02-17 EFFECTS OF IMIPRAMINE TREATMENT OF SEPARATION-INDUCED SOCIAL DISORDERS IN RHESUS MONKEYS. 002316 03-04 CLOMIPRAMINE (ANAFRANIL) AND BEHAVIOUR THERAPY IN OBSESSIVE-COMPULSIVE AND PHOBIC DISORDERS. 002473 03-10 A LARGE OPEN MULTICENTRE TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE MANAGEMENT OF PHOBIC DISORDERS.

CLINICAL EXPERIENCE IN THE TREATMENT OF PHOBIC DISORDERS

THE MANAGEMENT OF PHOBIC DISORDERS IN GENERAL PRACTICE

PHARMACOLOGICAL INVESTIGATIONS OF THE CHOLINERGIC IMBALANCE HYPOTHESES OF MOVEMENT DISORDERS AND PSYCHOSIS.

EFFECT OF THIORIDAZINE (MELLARIL-SANDOZ) ON PSYCHOMOTOR FUNCTION, CONCENTRATION, AND REACTIVITY IN CHILDREN WITH BEHAVIOR DISORDERS.

AMANTADINE IN THE TREATMENT OF BENZTROPINE REFRACTORY
EXTRAPYRAMIDAL DISORDERS INDUCED BY ANTIPSYCHOTIC DRUGS

USE OF DEPOT TRANQUILLISERS IN PSYCHIATRIC DISORDERS.

Psychopharmacology Abstracts

HYPOTONIC CIRCULATORY DISORDERS UNDER PSYCHOPHARMACOTHERAPY -- TREATMENT WITH 9ALPHA-FLUOROHYDROCORTISONE

002710 03-15 CHEMOTHERAPY IN MENTAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.

002735 03-17 CLOSING REMARKS AT A SYMPOSIUM ON OBSESSIVE-COMPULSIVE NEUROSES AND PHOBIC DISORDERS.

002760 03-17 TREATMENT OF DYSKINETIC AND CHOREATIC MOVEMENT DISORDERS IN ADULTS. 002776 03-17

BIOCHEMISTRY OF MENTAL DISORDERS: NEW VISTAS. 002781 03-17 LEAD-INDUCED BEHAVIORAL DISORDERS IN THE RAT: EFFECTS OF

003261 04-04 CIRCADIAN RHYTHM DISORDERS IN MANIC-DEPRESSIVES

003505 04-09 SODIUM VALPROATE IN THE TREATMENT OF INTRACTABLE SEIZURE DISORDERS: A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY 003550 04-11

SOMATOSTATIN IN THE TREATMENT OF PATIENTS WITH EXTRAPYRAMIDAL DISORDERS AND PATIENTS WITH EEG ABNORMALITIES.

003557 04-11 MINOR TRANQUILLIZERS IN SOMATIC DISORDERS. IATROGENIC CAUSES OF NEUROLOGIC DISORDERS: PART 2. DRUG-

RELATED DYSFUNCTIONS 003644 04-15 CHOLINERGIC INVOLVEMENT IN MENTAL DISORDERS.

003710 04-17

SOLID DISPERSION APPROACH FOR OVERCOMING BIOAVAILABILITY PROBLEMS DUE TO POLYMORPHISM OF NABILONE, A CANNABINOID DERIVATIVE. 001539 02-06

DISPLACEMENT BENZODIAZEPINE ACTIVITY: IS INTERACTION WITH THE GLYCINE RECEPTOR, AS EVIDENCED BY DISPLACEMENT OF STRYCHNINE BINDING, A USEFUL CRITERION?.

000151 01-03 NONCONTINGENT DISPLACEMENT OF CATECHOLAMINES BY INTRAVENTRICULAR TYRAMINE: BIPHASIC DOSE-RESPONSE EFFECTS ON

SELF-STIMULATION.

002068 03-03

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 2.
REGIONAL DISTRIBUTION AND IN VIVO DISPLACEMENT OF NEUROLEPTIC DRUGS.

ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS.

001672 02-13 HETEROGENEITY OF LSD DISPLACING FACTORS AND MULTIPLE TYPES OF HIGH AFFINITY LSD BINDING SITES.

003099 04-03

DISPOSITION PHARMACOKINETIC OBSERVATIONS OF PHENYTOIN DISPOSITION IN THE **NEWBORN AND YOUNG INFANT** 000644 01-11

OXAZEPAM DISPOSITION IN UREMIC PATIENTS 000720 01-13

PHYSIOLOGIC DISPOSITION OF NABILONE, A CANNABINOL DERIVATIVE. 000735 01-13

INFLUENCE OF DISULFIRAM AND DISEASE ON BENZODIAZEPINE 000738 01-13

DISPOSITION OF THREE BENZODIAZEPINES AFTER SINGLE ORAL ADMINISTRATION IN MAN.

ALPHA-METHYLDOPAMINE — A METABOLITE AND KEY INTERMEDIATE IN THE METABOLIC DISPOSITION OF 3.4 METHYLENEDIOXYAMPHETAMINE (MDA) IN DOG AND MONKEY.

001195 02-03 DISPOSITION OF KETAZOLAM, A NEW ANXIOLYTIC AGENT, IN MAN 001655 02-13 **EFFECT OF PHENOBARBITAL ON THE DISPOSITION OF INTRAVENOUS** THEOPHYLLINE

001680 02-13 ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN YOUNG AND ELDERLY MALE VOLUNTEERS.

001689 02-13 ETHANOL AND DISPOSITION OF AMYLOBARBITONE: EFFECT OF DOSE AND SIGNIFICANCE AS A MECHANISM FOR INCREASED TOXICITY 003114 04-03

002475 03-10

002485 03-10

002499 03-10

002509 03-11

002527 03-11

002535 03-11

002664 03-15

DISTURTING

INTERACTIONS OF PARTIAL LSD ANALOGS WITH BEHAVIORAL DISRUPTING EFFECTS OF LSD AND DMT IN THE RAT.

002264 03-04

000457 01-04

003692 04-16

003192 04-04

000932 01-16

DISEUPTION

DOSE-RESPONSE AND TIME-COURSE EFFECTS OF N,N

DIMETHYLTRYPTAMINE ON DISRUPTION OF RAT SHUTTLE-BOX

THE DISRUPTION OF MARIJUANA INTOXICATION.

DISRUPTION OF LEARNING PERFORMANCE BY CHRONIC CHLORPROMAZINE ADMINISTRATION IN THE BABOON.

DISRUPTION OF LATENT INHIBITION FOLLOWING SYSTEMIC ADMINISTRATION OF P-CHLOROPHENYLALANINE (PCPA).

DRUG DISCRIMINATION PARADIGMS: PROBLEMS OF TOLERANCE AND BEHAVIORAL DISRUPTION.

DEVELOPMENT OF TOLERANCE TO THE DISRUPTIVE AFFECTS OF COCAINE

ON REPEATED ACQUISITION AND PERFORMANCE OF RESPONSE SEQUENCES. 000459 01-04

TIME-DEPENDENT DISRUPTIVE EFFECTS OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE ON DEVELOPMENT OF MORPHINE TOLERANCE. 002058 03-03

P-CHLOROPHENYLALANINE PRODUCES DISSOCIATED EFFECTS ON AGGRESSION EMOTIONALITY AND MOTOR ACTIVITY.

003293 04-04

BEHAVIOURAL DISSOCIATION OF THE ENKEPHALINERGIC SYSTEMS OF NUCLEUS-ACCUMBENS AND NUCLEUS-CAUDATUS.

000096 01-03
PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATIENTS DURING LONGTERM ADMINISTRATION OF PSYCHOTROPIC DRUGS: DISSOCIATION
BETWEEN LIGHT AND NEAR VISION REACTIONS.

DISSOCIATIVE

NARCOTIC CUING AND ANALGESIC ACTIVITY OF NARCOTIC ANALGESICS:
ASSOCIATIVE AND DISSOCIATIVE CHARACTERISTICS.

COMPARATIVE BIOAVAILABILITY OF ORAL DOSAGE FORMS OF OXAZEPAM -- CORRELATION WITH IN VITRO DISSOLUTION RATE.

DISTILLATE

EFFECTS OF MARIJUANA EXTRACT DISTILLATE AND CANNABIDIOL ON

VARIABLE INTERVAL PERFORMANCE AS A FUNCTION OF FOOD

DEPRIVATION. 003308 04-04

DISTINCT DOPAMINERGIC MECHANISMS WITHIN THE NUCLEUS-ACCUMBENS OF RATS AND BEHAVIOUR.

000340 01-04

MORPHINE AND ITS BIPHASIC INFLUENCE UPON PHARMACOLOGICALLY
DISTINCT DOPAMINERGIC SYSTEMS WITHIN THE FELINE CAUDATE

NUCLEUS: A BEHAVIOURAL STUDY.

001954 03-02
SHORT-TERM MEMORY: A NEUROPHARMACOLOGICALLY DISTINCT

PROCESS.

O02189 03-04

EVIDENCE FOR DISTINCT SPINAL LOCOMOTION GENERATORS SUPPLYING
RESPECTIVELY FORELIMBS AND HINDLIMBS IN THE RABBIT.

003124 04-03 DISTINCT DOPAMINERGIC SYSTEMS IN ACTH-INDUCED GROOMING. 003197 04-04

CONTROL OF DISTORTING FACTORS.

RACTION
EFFECTS OF TWO ANXIOLYTICS ON DISTRACTION, HABITUATION AND

DISHABITUATION. 001353 02-04

DISTRANEURIN
TREATMENT OF SENILE PSYCHOSES WITH DISTRANEURIN MIXTURE.
000749 01-14

FETAL DISTRIBUTION OF NEUROPSYCHOPHARMACOLOGICAL AGENTS. 000069 01-03 KINETICS OF DISTRIBUTION OF AMPHETAMINE IN CATS.

000178 01-03
H3-DELTA9-TETRAHYDROCANNABINOL DISTRIBUTION IN PREGNANT DOGS AND THEIR FETUSES.

000194 01-03

EFFECT OF ALTERATION OF METABOLISM ON THE ANALGESIC ACTIVITY,
TOXICITY, DISTRIBUTION AND EXCRETION OF L-ALPHAACETYLMETHADOL IN THE RAT.
000245 01-03

MATERNAL FETAL DISTRIBUTION OF METHAQUALONE IN CONTROL AND SKF-525-A PRETREATED PREGNANT MICE.

000263 01-03
LITHIUM ABSORPTION, DISTRIBUTION AND CLEARANCE AND BODY
TEMPERATURE IN RATS GIVEN LITHIUM PLUS HALOPERIDOL.

OOO488 01-05
THE SUBCELLULAR DISTRIBUTION OF PARTICLE-BOUND NEGATIVE
CHARGES IN RAT BRAIN.

O00492 01-06
THE BOTANICAL AND CHEMICAL DISTRIBUTION OF HALLUCINOGENS.
ON THE DISTRIBUTION OF DRUGS IN SALIVA AND BLOOD PLASMA.

ALTERATIONS INDUCED IN DISTRIBUTION AND IN VIVO METABOLISM OF IMPRAMINE BY PREGNENOLONE-16ALPHA-CARBONITRIE.

BRAIN DISTRIBUTION OF LITHIUM AND INDOLEAMINE METABOLISM IN DOGS AFTER CHRONIC LITHIUM ADMINISTRATION.

O01108 02-03

EFFECTS OF PERINATAL 6 HYDROXYDOPAMINE TREATMENT ON OPIATE
RECEPTOR DISTRIBUTION IN ADULT BRAIN.

DISTRIBUTION OF CLOZAPINE IN THE RAT: EVIDENCE FOR ACTIVE
TRANSPORT IN LUNG.

THE DISTRIBUTION BETWEEN PLASMA AND BRAIN OF GLUTETHIMIDE AND 4 HYDROXYGLUTETHIMIDE FOLLOWING THEIR ADMINISTRATION TO MICE.

001160 02-03
DISTRIBUTION AND METABOLISM OF 4 HYDROXYPHENOBARBITAL IN THE MOUSE.

OO1171 02-C REGIONAL DISTRIBUTION OF BARBITAL IN THE BRAIN OF MICE DURING THE DEVELOPMENT OF TOLERANCE AND PHYSICAL DEPENDENCE.

OO 180 02-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DRUG DISTRIBUTION
AND METABOLISM: ANTIPYRENE, PENTOBARBITAL, AND ETHANOL.

001643 02-13
KINETICS OF INTRAVENOUS CHLORDIAZEPOXIDE: SEX DIFFERENCES IN DRUG DISTRIBUTION.

LITHIUM SODIUM COUNTERTRANSPORT IN HUMAN RED CELLS AND IN VIVO LITHIUM DISTRIBUTION BETWEEN RED CELLS AND PLASMA.

001679 02-13
STUDIES ON THE SUBSYNAPTOSOMAL DISTRIBUTION OF PSYCHOTROPIC

DRUGS IN RAT CEREBRAL-CORTEX.

O02045 03-03

ACTION OF NOREPINEPHRINE ON MICROCIRCULATION AND PO2

DISTRIBUTION IN THE ISOLATED PERFUSED RAT LIVER.

002059 03-03

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS: 3.

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS: 3.
SUBCELLULAR DISTRIBUTION OF NEUROLEPTIC DRUGS AND THEIR
RECEPTORS IN VARIOUS RAT BRAIN AREAS.

002067 03-03

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 2.
REGIONAL DISTRIBUTION AND IN VIVO DISPLACEMENT OF
NEUROLEPTIC DRUGS.

ABSORPTION AND DISTRIBUTION OF SODIUM BARBITAL IN TISSUES OF NORMAL AND DYSTROPHIC MICE.

INFLUENCE OF PHENOBARBITAL ON THE DISTRIBUTION AND ELIMINATION OF DESMETHYLIMIPRAMINE IN THE RAT.

002842 04-03
SUBCELLULAR DISTRIBUTION OF ETORPHINE IN RAT BRAIN AND EVIDENCE FOR IN VIVO STEREOSPECIFIC BINDING.

002856 04-03
PILOT STUDY ON THE DISTRIBUTION OF C14-LABELED METHAQUALONE IN THE RAT BRAIN.

002865 04-03

DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RETINA -- SUBCELLULAR DISTRIBUTION.

002867 04-03
TISSUE DISTRIBUTION OF RADIOACTIVITY AFTER INJECTION OF C14NITRAZEPAM IN YOUNG AND OLD RATS.

RADIOIMMUNOASSAY OF ENKEPHALINS: REGIONAL DISTRIBUTION IN RAT BRAIN AFTER MORPHINE TREATMENT AND HYPOPHYSECTOMY. 003136 04-03

PSYCHOTROPIC DRUGS AND SIDMAN AVOIDANCE IN RATS: IRT DISTRIBUTION CHANGES. 003269 04-04

EFFECTS OF KAINIC-ACID ON ION DISTRIBUTION AND ATP LEVELS OF STRIATAL SLICES INCUBATED IN VITRO.

DISTRIBUTIONS

HEAD-SHAKE DISTRIBUTIONS DURING SELF-MAINTAINED DEPENDENCE ON MORPHINE, METHADONE, AND L-ALPHA-ACETYLMETHADOL (LAAM) IN THE RAT.

001328 02-04

BIMODAL DISTRIBUTIONS OF HIGHEST ETHANOL ACCEPTANCE CONCENTRATIONS IN TWO STRAINS OF RATS. 003229 04-04

DISTURBANCE

EFFECT OF CDP-CHOLINE ADMINISTERED INTRATHECALLY ON DISTURBANCE OF CONSCIOUSNESS

002635 03-14 DISTURBANCE OF HOMEOSTATIC REGULATION OF ADRENAL FUNCTION IN PATIENTS WITH ENDOGENOUS DEPRESSION.

003515 04-09 BEHAVIOR DISTURBANCE, PHENOBARBITAL, AND FEBRILE SEIZURES 003582 04-11

DISTURBANCES

EFFECT OF NEUROTROPIC DRUGS ON SLEEP DISTURBANCES CAUSED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS. 000795 01-14

NEUROLOGICAL DISTURBANCES, NIGROSTRIATE SYNAPSES, AND IONTOPHORETIC DOPAMINE AND APOMORPHINE AFTER HALOPERIDO

001293 02-03 RECEPTOR SENSITIVITY MODIFICATION (RSM) — A NEW PARADIGM FOR THE POTENTIAL TREATMENT OF SOME HORMONAL AND TRANSMITTER

001659 02-13 INFLUENCE OF EXTRAPYRAMIDAL DISTURBANCES DUE TO HALOPERIDOL ON PHENAMINE STEREOTYPY AND THE EFFECTS OF SCHIZOPHRENIC BLOOD SERUM (EXPERIMENTAL STUDIES).

THERAPEUTIC EFFECT OF BRAIN HYDROLYSATES IN DEPRESSION-INDUCED DISTURBANCES OF INTELLIGENCE.

A CONTROLLED STUDY OF TRANCOPAL IN THE TREATMENT OF SLEEP DISTURBANCES DUE TO ANXIETY.

A CONTROLLED STUDY OF TRANCOPAL IN SLEEP DISTURBANCES DUE TO RHELIMATIC DISEASE

THE USE OF PSYCHEDELIC DRUGS IN THE TREATMENT OF SEVERELY DISTURBED CHILDREN: A REVIEW. 000678 01-12

NEUROTRANSMISSION AND DISTURBED BEHAVIOR. 002782 03-17

A RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF BIOLOGICAL FLUID OR TISSUE.

000496 01-06 CEREBROSPINAL FLUID HOMOVANILLIC-ACID IN MALE ALCOHOLICS: EFFECTS OF DISULFIRAM.

000645 01-11 DISULFIRAM ETHANOL REACTION. 000707 01-13

INFLUENCE OF DISULFIRAM AND DISEASE ON BENZODIAZEPINE DISPOSITION

000738 01-13 DISULFIRAM HEPATOTOXICITY

ELECTRON MICROSCOPIC STUDIES ON THE CEREBRAL LESIONS OF RATS IN EXPERIMENTAL CHRONIC DISULFIRAM POISONING.

000906 01-15 EFFECTS OF DISULFIRAM ON PHARMACOLOGICAL ACTIVITY, TOXICITY AND FATE OF MORPHINE IN RATS.

001111 02-03

LIMB REDUCTION ANOMALIES IN INFANTS BORN TO DISULFIRAM
TREATED ALCOHOLIC MOTHERS. 001817 02-15

EFFECTS OF DISULFIRAM AND PYRIDOXINE ON SERUM CHOLESTEROL 002519 03-11 DISULFIRAM ALTERS DOPAMINE METABOLISM AT SITES IN RATS FOREBRAIN AS DETECTED BY PUSH-PULL PERFUSIONS.

003134 04-03 SINGLE CASE STUDY. CATATONIA ASSOCIATED WITH DISULFIRAM

003677 04-15

DISULFIRAM-INDUCED
DISULFIRAM-INDUCED HYPOTHERMIA IN THE NORMAL RAT; ITS
ATTENUATION BY PIMOZIDE. 003085 04-03

DISUSE SUPERSENSITIVITY OF THE CHOLINERGIC RESPONSE TO APOMORPHINE IN THE STRIATUM FOLLOWING DENERVATION OR DISUSE SUPERSENSITIVITY OF DOPAMINERGIC RECEPTORS IN THE RAT. 002872 04-03

PRECLINICAL EVALUATION OF DITA DICHLORO-2-IMIDAZOLINYLTHIOACETOPHENONE-HBR: A NEW ANOREXIGENIC 001020 02-02 **Psychopharmacology Abstracts**

STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT BRAIN TISSUE SLICES.

001145 02-03 STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAMINE (DA) AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES. 002036 03-03

DIURETIC

LITHIUM USED WITH A DIURETIC

001757 02-15

003169 04-04

LITHIUM INTOXICATION MASKED BY NEUROLEPTIC DRUGS WHEN LITHIUM DIURETIC COMBINATIONS ARE USED. 002682 03-15

HYPERALGESIA INDUCED BY NALOXONE FOLLOWS DIURNAL RHYTHM IN RESPONSIVITY TO PAINFUL STIMULI

001124 02-03

THE EFFECTS OF PICROTOXIN AND PENTYLENETETRAZOL IN THE DIURNAL RHYTHMS OF CATECHOLAMINES AND SEROTONIN IN THE RAT BRAIN. 002123 03-03 DIURNAL VARIATIONS IN THE MOTOR ACTIVITY OF THE RAT: EFFECTS OF INHIBITORS OF THE CATECHOLAMINE SYNTHESIS.

003274 04-04

THE EFFECTS OF DIVALENT IONS ON MORPHINE ANALGESIA AND
ABSTINENCE SYNDROME IN MORPHINE-TOLERANT AND MORPHINE-DEPENDENT MICE.

003621 04-14

SINGLE AND DIVIDED DOSE OF IMIPRAMINE.

000595 01-10 SINGLE VERSUS DIVIDED DOSES OF SINTAMIL IN DEPRESSION

001543 02-07 A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF DOTHIEPIN AND ITS THERAPEUTIC EFFECTIVENESS.

001604 02-09 DESIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF DIVIDED VS SINGLE DOSE ADMINISTRATION.

001855 02-16 TRIMIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF SINGLE VS. DIVIDED DOSE ADMINISTRATION.

002465 03-09 THE TREATMENT OF DEPRESSION COMPARING DIVIDED AND SINGLE DOSES OF MAPROTILINE (LUDIOMIL).

002467 03-09

AMPHETAMINE EFFECTS OF CHLORPROMAZINE AND DL-AMPHETAMINE ON CALCIUM UPTAKE BY ADRENAL CHROMAFFIN CELL MEMBRANE.

002075 03-03

DL-METHADONE
THE METABOLISM OF D-, L- AND DL-METHADONE IN THE ISOLATED PERFUSED RAT LIVER

000118 01-03

DL-P-CHLOROPHENYLALANINE
THE EFFECTS OF DL-P-CHLOROPHENYLALANINE ON LEARNED
HELPLESSNESS IN THE RAT.

000311 01-04

DL-S-HYDROXYTRYPTOPHAN
THE EFFECTS OF DL-5-HYDROXYTRYPTOPHAN ON ETHANOL
CONSUMPTION BY RATS.

003148 04-03

EFFECTS OF SINGLE AND MULTIPLE DOSES OF DESIPRAMINE (DMI) ON ENDOGENOUS LEVELS OF 3 METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE (MOPEG-SO4) IN RAT BRAIN.

002814 04-03

EXCRETION OF 3,4 DIMETHOXYPHENETHYLAMINE (DMPEA) BY ACUTE SCHIZOPHRENICS AND CONTROLS.

MODIFICATION OF THE TIME-COURSE OF DMPEA TOXICITY IN THE MOUSE BY CENTRALLY ACTING DRUGS.

EFFECTS OF VARIOUS NEUROLEPTICS ON RABBIT HYPERTHERMIA INDUCED BY N,N DIMETHYLTRYPTAMINE (DMT) AND D AMPHETAMINE.

000099 01-03

INTERACTIONS OF PARTIAL LSD ANALOGS WITH BEHAVIORAL DISRUPTING EFFECTS OF LSD AND DMT IN THE RAT. 002264 03-04

EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) ON PSYCHOTICISM TESTS

002540 03-12 EFFECTS OF CANNABINOIDS ON L1210 MURINE LEUKEMIA: 1. INHIBITION OF DNA SYNTHESIS.

001266 02-03

003436 04-06

DNA SYNTHETIC ABILITY IN CEREBELLA FROM TEMPERATURE AND HANDLING STRESSED NEONATAL RATS.

002934 04-03

DOB

A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHOXYAMPHETAMINE (DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), P-METHOXYAMPHETAMINE (PMA), D AMPHETAMINE (A), AND LSD IN NONTOLERANT AND LSD TOLERANT CHRONIC SPINAL DOGS. 001273 02-03

DOCTOR

PSYCHOSIS IN YOUNG DOCTORS.

003709 04-17

DOCTORS DEBATE BRAIN HORMONE DILEMMAS.

003718 04-17

DOG

EFFECTS OF AMPHETAMINE AND CHLORDIAZEPOXIDE ON PROBENECID-INDUCED ACCUMULATION OF ACIDIC METABOLITES IN THE CEREBROSPINAL FLUID OF THE DOG.

000092 01-03

TRANSCALLOSALLY EVOKED-POTENTIALS AND THE EEG IN THE DECEREBRATE DOG: ACTIONS OF TRYPTAMINERGIC, DOPAMINERGIC AND ADRENERGIC AGONISTS.

000223 01-03

ACTIONS OF AMPHETAMINE AND ANTAGONISTS ON PUPIL DIAMETER IN THE CHRONIC SYMPATHECTOMIZED DOG.

000265 01-03

EFFECTS OF METHADONE AND MORPHINE MAINTENANCE ON DRUGSEFKING REHAVIOR IN THE DOG.

000387 01-04 CHARACTERISTICS OF BETA-PHENETHYLAMINE SELF-ADMINISTRATION BY

DOG. 000439 01-04

THE EFFECTS OF HALOPERIDOL, CHLORPROMAZINE AND PROPRANCIOL ON ACUTE AMPHETAMINE POISONING IN THE CONSCIOUS DOG. 000480 01-05

ANTAGONISM OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) LETHALITY BY CHLORPROMAZINE IN THE CONSCIOUS DOG. 001072 02-03

IN VIVO METABOLIC O DEMETHYLATION OF 3,4
DIMETHOXYAMPHETAMINE IN DOG AND MONKEY. MONKEY.
001149 02-03

PLASMA KINETICS OF NALTREXONE AND ITS GLUCURONIDE IN THE DOG.
001149 02-03

ALPHA-METHYLDOPAMINE — A METABOLITE AND KEY INTERMEDIATE IN THE METABOLIC DISPOSITION OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) IN DOG AND MONKEY.

001195 02-03
SLEEP SUPPRESSION INDUCED BY INTRAVENOUS AND INTRAVENTRICULAR
INFUSIONS OF METHOXAMINE IN THE DOG.

INFUSIONS OF METHOXAMINE IN THE DOG.
001434 02-0-

A PHARMACOLOGIC COMPARISON OF 3,4
METHYLENEDIOXYAMPHETAMINE AND LSD IN THE CHRONIC SPINAL
DOG.

BRAIN AND RETINA UPTAKE OF A RADIOIODINE LABELED PSYCHOTOMIMETIC IN DOG AND MONKEY.

nogs

003075 04-03

CARDIOVASCULAR EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN CONSCIOUS AND ANESTHETIZED DOGS.

000109 01-03
H3-DELTA9-TETRAHYDROCANNABINOL DISTRIBUTION IN PREGNANT DOGS

000194 01-03

MULTIPLE ORAL DOSES OF DIAZEPAM, OXAZEPAM AND PHENOBARBITAL
TO DOGS — BEHAVIOURAL EFFECTS AND CORRELATION WITH
ANTIPYRINE HALF-LIFE.

O00308 01-04

EFFECTS OF CHOLINOMIMETIC DRUGS AND THEIR ANTAGONISTS INJECTED
INTO VERTEBRAL ARTERY OF UNANAESTHETIZED DOGS.

BRAIN DISTRIBUTION OF LITHIUM AND INDOLEAMINE METABOLISM IN DOGS AFTER CHRONIC LITHIUM ADMINISTRATION.

A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHOXYAMPHETAMINE (DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), P. METHOXYAMPHETAMINE (PMA), D. AMPHETAMINE (A), AND LSD IN MONTOLERANT AND LSD TOLERANT CHRONIC SPINAL DOGS.

CENTRAL CARDIOVASCULAR EFFECTS OF MORPHINOMIMETIC PEPTIDES IN

001399 02-04
ELECTROENCEPHALOGRAPHIC STUDY OF THE SHORT-ACTING HYPNOTICS
FTOMIDATE AND METHOREXITAL IN DOGS.

A BEHAVIORAL AND AUTONOMIC NERVOUS SYSTEM STUDY OF CHRONIC IMIPRAMINE ADMINISTRATION TO CONSCIOUS DOGS.

SELECTIVE BLOCKADE OF DOPAMINE-INDUCED VASODILATION BY ERGONOVINE-MALEATE IN THE VASCULATURES OF DOGS AND PARBITS.

ESOPHAGEAL CANNULATION FOR INTRAGASTRIC DELIVERY OF FLUIDS TO UNRESTRAINED DOGS.

DOMESTIC

EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH MORPHOLOGY AND HORMONE PLASMA LEVELS.

EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: 1. BEHAVIOURAL EFFECTS OF INTRAMUSCULAR INJECTIONS.

DOMINANCE

ON THE ROLE OF HEMISPHERIC DOMINANCE IN SCHIZOPHRENIA AS MEASURED BY EXTRAPYRAMIDAL SIDE-EFFECTS OF NEUROLEPTICS. 003675 04-15

DOPA

EFFECT OF NEUROLEPTICS, MYDANTHAN, AND DOPA ON APOMORPHINE-INDUCED STEREOTYPY IN RATS.

O01155 02-03

ALTERATION OF L-DOPA EFFECT ON BRAIN DOPA AND DOPAMINE LEVELS
WITH NICOTINIC-ACID AND N METHYL NICOTINAMIDE. (PH.D.
DISSERTATION).

THE EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND 2
BROMOLYSERGIC-ACID-DIETHYLAMIDE (BOL) ON THE STRIATAL DOPA
ACCUMULATION: INFLUENCE OF CENTRAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS.

INHIBITION OF DOPA DECARBOXYLATION BY ANALOGUES OF TRYPTOPHAN.

002837 04-03

EFFECT OF METERGOLINE, P-CHLOROPHENYLALANINE AND DOPA ON
DELAYED RESPONSE IN CATS AND THE RELATIONSHIP BETWEEN THE
MESOLIMBIC AND NIGROSTRIATAL NEURONS.

DOPA-INDUCED
THE EFFECTS OF P-CHLOROPHENYLALANINE, RESERPINE, METHYSERGIDE
AND CYPROHEPTADINE ON THE DOPA-INDUCED EEG SYNCHRONIZATION

AND CYPROHEPTADINE ON THE DOPA-INDUCED EEG SYNCHRONIZATION IN THE RAT.

003022 04-03

DOPAC

EFFECT OF PSYCHOTROPIC DRUGS ON 3,4 DIHYDROXYPHENYLACETIC-ACID (DOPAC) CONTENT IN THE MEDIAL BASAL HYPOTHALAMUS. 001962 03-03 MORPHINE INCREASES AND D AMPHETAMINE DECREASES THE RATIO OF

MORPHINE INCREASES AND D AMPHETAMINE DECREASES THE RATIO OF DOPAC: HVA IN PUSH-PULL PERFUSATE OF RAT CAUDATE NUCLEUS. 002158 03-03 COMPARATIVE EFFECTS OF PENFLURIDOL ON CIRCLING BEHAVIOR AND

STRIATAL DOPAC AND SERUM PROLACTIN CONCENTRATIONS IN THE RAT.

DOPAMINE
DOPAMINE RECEPTOR BLOCKING ACTIVITY OF THE SULPIRIDE IN THE

CENTRAL-NERVOUS-SYSTEM.

O00024 01-02
INCREASE IN THE TURNOVER OF BRAIN DOPAMINE BY STIMULATION OF
MUSCARINIC RECEPTORS OUTSIDE THE DOPAMINE NERVE TERMINALS.

EXCITATORY ACTION OF THE MESOLIMBIC DOPAMINE SYSTEM ON SEPTAL NEURONES.

000045 01-03

EVIDENCE FOR AN INTRASTRIATAL GABAERGIC INFLUENCE ON DOPAMINE
NEURONES OF THE CAT.

000050 01-03
INTERACTION OF GABA, DOPAMINE, AND ACETYLCHOLINE IN CAT
STRIATUM: PHARMACOLOGICAL CONSIDERATIONS.

000051 01-03
INTERACTIONS OF SUBSTITUTED BENZAMIDE DRUGS WITH CEREBRAL
DOPAMINE PATHWAYS.

5-HT ANTAGONISTS INHIBIT NEUROLEPTIC AND MORPHINE ANTAGONISM OF THE HYPERACTIVITY INDUCED BY DOPAMINE FROM THE NUCLEUSACCULARENS

000082 01-03

DOPAMINE RECEPTOR BINDING ENHANCEMENT ACCOMPANIES LESIONINDUCED BEHAVIORAL SUPERSENSITIVITY.

INFLUENCE OF DIAZEPAM, L-DOPA AND DOPAMINE ON THE CEREBELLAR AND SPINAL ELECTRICAL PATTERNS INDUCED BY HARMINE IN THE

000091 01-03

HALOPERIDOL INCREASES AND APOMORPHINE DECREASES STRIATAL
DOPAMINE METABOLISM AFTER DESTRUCTION OF STRIATAL
DOPAMINE SENSITIVE ADENYLATE-CYCLASE BY KAINIC-ACID.
000094 01-03

EFFECTS OF DOPAMINE ON INTRACRANIAL PRESSURE 000103 01-03 RECEPTORS. 000107 01-03 LITHIUM INHIBITION OF NOREPINEPHRINE AND DOPAMINE

POSSIBLE SIGNIFICANCE OF CLOZAPINE-INDUCED INCREASE IN DOPAMINE.

OO0120 01-03
INCREASE IN MOUSE BRAIN DOPAMINE CONTENT BY BACLOFEN: EFFECTS
OF APOMORPHINE AND NEUROLEPTICS.

000121 01-0
INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC
AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS
RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS
IN THE RAT.

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE.

A COMPARISON OF THE EFFECTS OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE STRIATUM, OLFACTORY TUBERCLE AND MEDIAN EMINENCE.

000131 01-03 N,N DIMETHYLTRYPTAMINE LOWERS RAT BRAIN ACETYLCHOLINE AND DOPAMINE.

O00140 01-03
THE SELECTIVE INHIBITION OF DOPAMINE UPTAKE BY A TRICYCLIC IMINE.
000141 01-03

INVOLVEMENT OF THE DOPAMINE NIGROSTRIATAL SYSTEM IN THE PICROTOXIN EFFECT ON STRIATAL ACETYLCHOLINE LEVELS.

ANTIPODAL CENTRAL EFFECTS OF DOPAMINE AND APOMORPHINE.

000168 01-03
DIFFERENTIAL EFFECTS OF RESERPINE AND TETRABENAZINE ON RAT
STRIATAL SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS AND
SYNAPTOSOMAL DOPAMINE POOLS.

SPECIFIC EFFECT OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE FRONTAL CORTEX.

000175 01-03 POTENTIATION BY COCAINE OF THE STIMULUS-INDUCED INCREASE IN DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL SYNAPTOSOMES.

000217 01-03

UPTAKE INHIBITION OF BIOGENIC AMINES BY NEWER ANTIDEPRESSANT DRUGS: RELEVANCE TO THE DOPAMINE HYPOTHESIS OF DEPRESSION. 000232 01-03 DOPAMINE SELECTIVELY INCREASES H3-GABA RELEASE FROM SLICES OF RAT SUBSTANTIA-NIGRA IN VITRO.

POTENTIATION BY RESERPINE OF THE INHIBITION BY AMPHETAMINE OF (3H)DOPAMINE ACCUMULATION IN THE RAT STRIATUM. 000246 01-03

ACTION OF THE PALMITIC ESTER OF PIPOTIAZINE ON DOPAMINE METABOLISM IN THE NIGROSTRIATAL, MESOLIMBIC AND MESOCORTICAL SYSTEMS.

THE EFFECTS OF ETHER STRESS AND BETAMETHASONE TREATMENT ON THE CONCENTRATIONS OF NORADRENALINE AND DOPAMINE IN VARIOUS REGIONS OF THE RAT BRAIN.

HALLUCINOGEN BINDING TO DOPAMINE/NEUROLEPTIC RECEPTORS.

DOPAMINE RECEPTORS IN RAT STRIATUM AND NUCLEUS-ACCUMBENS; CONFORMATIONAL STUDIES USING RIGID ANALOGUES OF DOPAMINE. 000301 01-03

SUBSTITUTED BENZAMIDES AS CEREBRAL DOPAMINE ANTAGONISTS IN

000355 01-04 LEVODOPA-INDUCED DOPAMINE RECEPTOR HYPERSENSITIVITY

000392 01-04 THE INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT BEHAVIOUR IN RODENTS.

000435 01-04 ATTENUATION OF MORPHINE ANALGESIA IN RATS BY INTRA-AMYGDALOID INJECTION OF DOPAMINE.

DIFFERENTIAL EFFECTS OF THREE DOPAMINE AGONISTS: APOMORPHINE, BROMOCRIPTINE AND LERGOTRILE.

HALOPERIDOL: EFFECT OF LONG-TERM TREATMENT ON RAT STRIATAL DOPAMINE SYNTHESIS AND TURNOVER.

000481 01-05 INHIBITION OF DOPAMINE SYNTHESIS IN CHRONIC SCHIZOPHRENIA: CLINICAL INEFFECTIVENESS OF METYROSINE.

000542 01-08 ROLES OF MONOAMINES, PARTICULARLY DOPAMINE, IN CLINICAL DEPRESSION AND IN THE REGULATION OF MOOD.

000583 01-09 DOPAMINE IS A MONOAMINE-OXIDASE B SUBSTRATE IN MAN 000677 01-12 PARADOXICAL RESPONSE TO DOPAMINE AGONISTS IN TARDIVE-DYSKINESIA.

000809 01-15 DOPAMINE, THE PSYCHE, AND EXTRAPYRAMIDAL DISORDERS 000864 01-15

EFFECTS OF DOPAMINE AGONISTS IN TARDIVE-DYSKINESIA

000896 01-15 ON THE CONFORMATION OF NEUROLEPTIC DRUGS IN THE THREE AGGREGATION STATES AND THEIR CONFORMATIONAL RESEMBLANCE TO DOPAMINE.

000990 01-17 THE EFFECTS OF HYPOTHALAMIC DEAFFERENTATION ON THE HALOPERIDOL-INDUCED ACTIVATION OF TUBEROINFUNDIBULAR DOPAMINE NEURONS.

001047 02-03 IN VIVO BINDING OF H3-PIMOZIDE IN MOUSE STRIATUM: EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS.

001050 02-03 THE CHEMISTRY OF DOPAMINE RECEPTORS IN THE MEDIAN EMINENCE. 001085 02-03

ANALGESIC BRAIN STIMULATION IN THE CAT: EFFECT OF INTRAVENTRICULAR SEROTONIN, NOREPINEPHRINE, AND DOPAMINE

001101 02-03 ACTION OF DOPAMINE AGONISTS ON BRAIN VESSELS IN VITRO AND AFTER IN VIVO MICROAPPLICATION.

001107 02-03 EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE CONTENT AND METABOLISM OF DOPAMINE IN THE RAT STRIATUM.

001133 02-03 ALTERATIONS IN DOPAMINE RECEPTOR SENSITIVITY BY CHRONIC

001146 02-03 LERGOTRILE-MESYLATE: AN IN VIVO DOPAMINE AGONIST WHICH BLOCKS DOPAMINE RECEPTORS IN VITRO.

001159 02-03 LONG-TERM CHANGES IN THE SENSITIVITY OF PRE- AND POSTSYNAPTIC DOPAMINE RECEPTORS IN MOUSE STRIATUM EVIDENCED BY BEHAVIORAL AND BIOCHEMICAL STUDIES.

001187 02-03 THE RELATIVE FUNCTIONAL AVAILABILITY OF BRAIN NORADRENALINE AND DOPAMINE STORAGE POOLS.

001191 02-03 LYSERGIC-ACID-DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF PITUITARY DOPAMINE RECEPTORS.

001192 02-03 DIFFERING ACTIONS OF AMFONELIC-ACID (AFA) AND AMPHETAMINE (AMPH) ON STRIATAL DOPAMINE (DA).

001196 02-03 BRAIN NEUROTRANSMITTER RECEPTORS AFTER LONG-TERM HALOPERIDOL: DOPAMINE, ACETYLCHOLINE, SEROTONIN, ALPHANORADRENERGIC AND NALOXONE RECEPTORS.

REGIONAL EFFECTS OF NEUROLEPTICS ON DOPAMINE METABOLISM AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE ACTIVITY. INCREASED SYNTHESIS OF STRIATAL DOPAMINE BY N.N.

DIMETHYLTRYPTAMINE. 001248 02-03

THE EFFECT OF ANTIPSYCHOTIC DRUGS AND THEIR CLINICALLY INACTIVE ANALOGS ON DOPAMINE METABOLISM.

001250 02-03

EFFECT OF BETA-ENDORPHIN ON STRIATAL DOPAMINE METABOLISM. 001269 02-03

EFFECTS OF LERGOTRILE (LER), AN ERGOT DERIVATIVE, ON ACTIVITY OF SUBSTANTIA-NIGRA PARS COMPACTA DOPAMINE (DA) NEURONS. 001278 02-03

COCAINE AND METABOLITES: RELATIONSHIP BETWEEN
PHARMACOLOGICAL ACTIVITY AND INHIBITORY ACTION ON
DOPAMINE UPTAKE INTO STRIATAL SYNAPTOSOMES.

001286 02-03 NEUROLOGICAL DISTURBANCES, NIGROSTRIATE SYNAPSES, AND IONTOPHORETIC DOPAMINE AND APOMORPHINE AFTER HALOPERIDOL. 001293 02-03

EFFECTS OF DOPAMINE SUPERSENSITIVITY ON LATERAL HYPOTHALAMIC SELF-STIMULATION IN RATS.

001351 02-04 CHRONIC AND ACUTE EFFECTS OF BARBITAL AND AMPHETAMINE IN DOPAMINE DEPLETED RATS.

001389 02-04 DRUGS AFFECTING DOPAMINE NEURONS AND YAWNING BEHAVIOR 001422 02-04 TWO DOPAMINE RECEPTORS: SUPPORTIVE EVIDENCE WITH THE RAT ROTATIONAL MODEL.

001478 02-04 CLONAZEPAM AND DOPAMINE RELATED STEREOTYPED BEHAVIOR 001485 02-04 ACTH-INDUCED EXCESSIVE GROOMING INVOLVES BRAIN DOPAMINE

001490 02-04 BRAIN DOPAMINE TURNOVER AND THE RELIEF OF PARKINSONISM 001685 02-13

ALTERATION OF L-DOPA EFFECT ON BRAIN DOPA AND DOPAMINE LEVELS WITH NICOTINIC-ACID AND N METHYL NICOTINAMIDE. (PH.D. DISSERTATION).

001969 03-03

DIFFERENT EFFECTS OF METHIONINE-ENKEPHALIN AND D ALA2-METHIONINE-ENKEPHALINAMIDE ON THE METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN: FACT OR ARTIFACT?.

BLOCKADE OF THE PICROTOXIN-INDUCED IN VIVO RELEASE OF DOPAMINE IN THE CAT CAUDATE NUCLEUS BY DIAZEPAM.

H3-HALOPERIDOL BINDING TO DOPAMINE RECEPTORS IN RAT CORPUS-STRIATUM: INFLUENCE OF CHLORPROMAZINE METABOLITES AND DERIVATIVES.

H3-SPIROPERIDOL LABELS DOPAMINE RECEPTORS IN PITUITARY AND
HBAIN

001996 03-03

EVIDENCE FOR SELECTIVE AND LONG-LASTING STIMULATION OF

REGULATORY DOPAMINE RECEPTORS BY BROMOCRIPTINE (CB-154).

002002 03-03

DOPAMINE RECEPTORS AND ERGOT DRUGS. EVIDENCE THAT AN ERGOLENE DERIVATIVE IS A DIFFERENTIAL AGONIST AT SUBCORTICAL LIMBIC DOPAMINE RECEPTORS.

D02019 03-03

CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF C-AMP-PHOSPHODIESTERASE.

THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON DOPAMINE METABOLISM IN RAT STRIATUM.

002039 03-03

EFFECT OF MORPHINE ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE
ACTIVITY OR NUCLEUS-ACCUMBENS.

EFFECTS OF DIAZEPAM ON DOPAMINE TURNOVER IN NEOSTRIATAL AND LIMBIC REGIONS OF THE RAT BRAIN.

LIMBIC REGIONS OF THE RAT BRAIN.

002060 03-03

BIPHASIC FFFECTS OF AMPHETAMINE ON STRIATAL DOPAMINE

DYNAMICS. 002064 03-03

EFFECT OF ERGOT ALKALOIDS AND OF NEUROLEPTICS ON BINDING TO PUTATIVE DOPAMINE AND ALPHA RECEPTORS.

THE EFFECT OF L-DOPA ON PERIPHERAL SYMPATHETIC NERVE FUNCTION: ROLE OF PRESYNAPTIC DOPAMINE RECEPTORS.

002081 03-03 APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE RELEASE: ROLE OF DOPAMINERGIC RECEPTORS IN SUBSTANTIA-NIGRA. 002084 03-03

FACILITATORY AND DEPRESSANT EFFECTS OF DOPAMINE IN THE FELINE CAUDATE NUCLEUS.

O02116 03-03
PRESYNAPTIC DOPAMINE RECEPTORS: DEVELOPMENT OF
SUPERSENSITIVITY FOLLOWING TREATMENT WITH FLUPHENAZINEDECANOATE

002120 03-03
DIFFERENTIAL REGIONAL DEVELOPMENT OF TOLERANCE TO INCREASE IN
DOPAMINE TURNOVER UPON REPEATED NEUROLEPTIC
ADMINISTRATION

002144 03-03

EFFECTS OF BACLOFEN ON DOPAMINE METABOLISM AND INTERACTION
WITH NEUROLEPTIC EFFECTS.

TOLERANCE TO HYPOKINESIA ELICITED BY DOPAMINE AGONISTS IN MICE: HYPOSENSITIZATION OF AUTORECEPTORS?.

002221 03-04
BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE
RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC
BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE.

CO2224 03-04

EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DEPLETIONS OF BRAIN
CATECHOLAMINES OR DOPAMINE ON MEPERIDINE ANTINOCICEPTION

MESOLIMBIC DOPAMINE NEURONS: EFFECTS OF 6 HYDROXYDDPAMINE-INDUCED DESTRUCTION AND RECEPTOR BLOCKADE ON DRUG-INDUCED ROTATION OF RATS. 002258 03-04

THE INFLUENCE OF HISTAMINE ON METABOLISM OF DOPAMINE AND SEROTONIN IN THE RAT STRIATUM.

THE EFFECTS OF ETORPHINE, FENTANYL AND MORPHINE ON NORADRENALINE AND DOPAMINE CONCENTRATIONS IN THE STRIATUM OF RAT.

DOPAMINE BINDING FOLLOWING PROLONGED HALOPERIDOL PRETREATMENT.

INHIBITION BY LITHIUM OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT BRAIN.

DOES DOPAMINE HAVE A ROLE IN SCHIZOPHRENIA?. 002357 03-05

DOPAMINE AND SCHIZOPHRENIA. 002389 03-08

002405 03-08

DOPAMINERGIC FACTORS IN HUMAN PROLACTIN REGULATION: EFFECTS

OF NEUROLEPTICS AND DOPAMINE.

NEUROENDOCRINE STUDIES WITH DOPAMINE AGONISTS IN

PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS: AN APPROACH TO THE STUDY OF BRAIN DOPAMINE BLOCKADE IN HUMANS.

CLOMIPRAMINE AND MAPROTILINE ON HUMAN PLATELET UPTAKE OF 5
HYDROXYTRYPTAMINE AND DOPAMINE IN VITRO: WHAT RELEVANCE
TO THEIR ANTIDEPRESSIVE AND OTHER ACTIONS?.

BIOCHEMICAL ACTIONS OF NEUROLEPTIC DRUGS: FOCUS ON THE DOPAMINE RECEPTOR.

002738 03-17
DOPAMINE RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM.

(-)-(E) 3.4 DIHYDROXYPHENYL-CYCLOPROPYLAMINE-HYDROCHLORIDE (ASL-7003): A RIGID ANALOGUE OF DOPAMINE.

THE CENTRAL EFFECTS OF A NOVEL DOPAMINE AGONIST.

EFFECTS ON STRIATAL AND MESOLIMBIC DOPAMINE SYSTEMS OF A NEW POTENTIAL ANTIPSYCHOTIC DRUG — MEZILAMINE — WITH WEAK CATALEPTOGENIC PROPERTIES.

O02800 04-02

EFFECT OF MECAMYLAMINE ON THE FATE OF DOPAMINE IN STRIATAL
AND MESOLIMBIC AREAS OF RAT BRAIN; INTERACTION WITH
MORPHINE AND HALOPERIDOL

DOPAMINE TURNOVER IN THE INTACT RABBIT BRAIN: EFFECT OF PENTOBARBITAL OR HALOPERIDOL.

002815 04-03
RESPONSES OF SINGLE CORTICAL NEURONES TO NORADRENALINE AND
DOPAMINE.

STIMULATION OF DOPAMINE SYNTHESIS IN CAUDATE NUCLEUS BY INTRASTRIATAL ENKEPHALINS AND ANTAGONISM BY NALOXONE.

002825 04-03

EFFECTS OF DOPAMINE AGONISTS ON NEURONES IN THE CAUDATE
NUCLEUS AND CEREBRAL-CORTEX OF CATS CHRONICALLY TREATED
WITH NEUROLEPTICS.

002829 04-03

HISTOCHEMICAL EFFECTS OF KAINIC-ACID ON NEOSTRIATAL DOPAMINE
AND ACETYLCHOLINESTERASE.

O02851 04-03

EFFECTS OF SOME DERIVATIVES OF 2 AMINOTETRALIN ON DOPAMINE
SENSITIVE ADENYLATE-CYCLASE AND ON THE BINDING OF H3HALOPERIDOL TO NEUROLEPTIC RECEPTORS IN RAT STRIATUM.

RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D AMPHETAMINE

O02862 04-03

DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RETINA - SUBCELLULAR
DISTRIBUTION

DOPAMINE RECEPTOR BINDING OF H3-ADTN (2
AMINODIHYDROXYTETRAHYDRONAPHTHALENE) REGULATED BY

GUANYL-NUCLEOTIDES.

O02877 04-03

COMPARATIVE EFFECTS OF PEMOLINE, AMFONELIC-ACID AND AMPHETAMINE ON DOPAMINE UPTAKE AND RELEASE IN VITRO AND ON BRAIN 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN SPIPERONE-TREATED RATS.

002919 04-03
INFLUENCE OF LITHIUM ON DOPAMINE STIMULATED ADENYLATE-CYCLASE
ACTIVITY IN RAT BRAIN.

A COMPARISON OF THE VASCULAR DOPAMINE RECEPTOR WITH OTHER DOPAMINE RECEPTORS.

5 HYDROXYTRYPTAMINE AND DOPAMINE TRANSPORT BY RAT AND HUMAN BLOOD PLATELETS.

INVESTIGATIONS CONCERNING THE CELLULAR ORIGIN OF DOPAMINE

002944 04-03

BLOCKADE OF BOTH PILOCARPINE AND AMPHETAMINE-INDUCED HEADSHAKING WITH DOPAMINE RECEPTOR ANTAGONISTS.

002951 04-03

002345 03-05

A BEHAVIOURAL AND BIOCHEMICAL COMPARISON OF DOPAMINE RECEPTOR BLOCKAGE PRODUCED BY HALOPERIDOL WITH THAT PRODUCED BY SUBSTITUTED BENZAMIDE DRUGS.

THE EFFECT OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF AMPHETAMINE ON CEREBRAL DOPAMINE RECEPTOR SENSITIVITY.

THE EFFECT OF VILOXAZINE HYDROCHLORIDE ON THE TRANSPORT OF NORADRENALINE, DOPAMINE, 5 HYDROXYTRYPTAMINE AND GAMMA-AMINOBUTYRIC-ACID IN RAT BRAIN TISSUE.

003001 04-03 A COMPARISON OF THE EFFECTS OF ANTIPSYCHOTIC DRUGS ON PITUITARY, STRIATAL AND LIMBIC SYSTEM POSTSYNAPTIC DOPAMINE RECEPTORS.

INHIBITION OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RAT STRIATUM BY NEUROLEPTIC DRUGS ADMINISTERED IN VIVO.

THE EFFECT OF GAMMA-ACETYLENIC-GABA, AN ENZYME ACTIVATED IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE, ON DOPAMINE PATHWAYS OF THE EXTRAPYRAMIDAL AND LIMBIC SYSTEMS.

CYCLIC-NUCLEOTIDE LEVELS IN THE RAT STRIATUM AND CEREBELLUM IN VIVO EFFECTS OF DOPAMINE AND ACETYLCHOLINE RECEPTOR AGONISTS AND ANTAGONISTS.

DOPAMINE ANTAGONIST BINDING: A SIGNIFICANT DECREASE WITH MORPHINE-DEPENDENCE IN THE RAT STRIATUM.

EVIDENCE FOR THE ROLE OF ADRENOCORTICAL HORMONES IN THE REGULATION OF NORADRENALINE AND DOPAMINE METABOLISM IN CERTAIN BRAIN AREAS.

THE DIFFERENTIAL EFFECT OF LITHIUM ON NORADRENALINE AND DOPAMINE SENSITIVE ACCUMULATION OF CYCLIC-AMP IN GUINEA-PIG

AFFINITIES OF DRUGS FOR THE AGONIST AND ANTAGONIST STATES OF THE DOPAMINE RECEPTOR.

003065 04-03 DOPAMINE RECEPTORS LOCALISED ON CEREBRAL CORTICAL AFFERENTS TO RAT CORPUS-STRIATUM.

003080 04-03 THE EFFECT OF DIHYDROXY-2-AMINOTETRALINS (DATS) ON DOPAMINE AND BETA TYPE ADENYLATE-CYCLASES.

O03088 04-03
THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE OF THE RAT CAUDATE NUCLEUS — 3. THE EFFECT OF APORPHINES AND PROTOBERBERINES.

DOPAMINE RECEPTOR FUNCTION AFTER CHRONIC INGESTION OF ETHANOL.

003106 04-03 ALTERATIONS IN RECEPTORS CONTROLLING DOPAMINE SYNTHESIS AFTER CHRONIC ETHANOL INGESTION.

003107 04-03 H3-SPIROPERIDOL BINDING AND DOPAMINE STIMULATED ADENYLATE-CYCLASE: EVIDENCE FOR MULTIPLE CLASSES OF RECEPTORS IN PRIMATE BRAIN REGIONS.

03312 04-03
H3-APOMORPHINE INTERACTIONS WITH DOPAMINE RECEPTORS IN CALF

DOPAMINE SYNTHESIS AND TYROSINE-HYDROXYLASE ARE REGULATED BY INDEPENDENT DA RECEPTOR MEDIATED MECHANISMS.

INCREASED DOPAMINE METABOLISM IN RAT STRIATUM AFTER INFUSIONS OF SUBSTANCE-P INTO THE SUBSTANTIA-NIGRA.

003130 04-03 DISULFIRAM ALTERS DOPAMINE METABOLISM AT SITES IN RATS FOREBRAIN AS DETECTED BY PUSH-PULL PERFUSIONS.

CLOZAPINE CONCENTRATIONS IN BRAIN REGIONS: RELATIONSHIP TO DOPAMINE METABOLITE INCREASE.

REPEATED EXPOSURE OF RATS TO THE CONVULSANT AGENT FLUROTHYL ENHANCES 5 HYDROXYTRYPTAMINE AND DOPAMINE MEDIATED BEHAVIOURAL RESPONSES.

EVIDENCE FOR A ROLE FOR DOPAMINE IN SELF-STIMULATION OF THE NUCLEUS-ACCUMBENS OF THE RAT.

003341 04-04 STRIATAL CELL SUPERSENSITIVITY TO APOMORPHINE IN DOPAMINE LESIONED RATS CORRELATED TO BEHAVIOUR.

BEHAVIORAL EFFECTS OF DOPAMINE AGONISTS INCREASE WITH AGE. 003362 04-04

L 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS IN GUINEA-PIGS: A MODEL FOR THE STUDY OF CENTRAL SEROTONIN DOPAMINE INTERACTIONS.

DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: A VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIATION OF CATECHOLAMINERGIC AND SEROTONINERGIC TERMINALS IN RAT CEREBRAL STRUCTURES.

003423 04-06 DOPAMINE SUPERSENSITIVITY, ENDORPHIN EXCESS, AND PROSTAGLANDIN-E1 DEFICIENCY: THREE ASPECTS OF THE SAME SCHIZOPHRENIC ELEPHANT.

Psychopharmacology Abstracts

PERIPHERAL ALPHA-ADRENORECEPTOR AND CENTRAL DOPAMINE RECEPTOR ACTIVITY IN DEPRESSIVE PATIENTS.

003489 04-09 SCHIZOPHRENIA AS A DOPAMINE DEFICIENCY DISEASE. 003705 04-17

FAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS UNDER LONG-TERM TRAINING.

000034 01-02 INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY ANTITHYROID AGENTS, METHIMAZOLE AND PROPYLTHIOURACIL.

000145 01-03 MOTILITY RESPONSE TO MORPHINE AND AMPHETAMINE DURING CHRONIC INHIBITION OF TYROSINE-HYDROXYLASE OR DOPAMINE-BETA-HYDROXYLASE.

000166 01-03 EFFECT OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION ON EPINEPHRINE LEVELS IN THE BRAIN.

000255 01-03 LOW LEVELS OF DOPAMINE-BETA-HYDROXYLASE AND PSYCHOSIS 000831 01-15

SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT AND NEWBORN RATS.

CONCOMITANT ELEVATION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY CYCLIC-AMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

D03133 04-03 DOPAMINE-BETA-HYDROXYLASE RELEASE FOLLOWING ACUTE SELECTIVE SYMPATHETIC NERVE STIMULATION OF THE HEART, SPLEEN AND MESENTERY

003422 04-06

CHOLINERGIC MODIFICATION OF THE INHIBITION OF DOPAMINE-INDUCED HYPERACTIVITY BY NEUROLEPTICS.

001271 02-03 DOPAMINE-INDUCED HYPOTHERMIA IN MORPHINE-DEPENDENT RATS DD2988 04-03

SELECTIVE BLOCKADE OF DOPAMINE-INDUCED VASODILATION BY ERGONOVINE-MALEATE IN THE VASCULATURES OF DOGS AND

003067 04-03 EFFECT OF MORPHINE ON THE BASAL AND THE DOPAMINE-INDUCED RELEASE OF LHRH FROM MEDIOBASAL HYPOTHALAMIC FRAGMENTS

DOPAMINE-MIMETIC ACTIVITY OF ERGOT DERIVATIVES, AS MEASURED BY THE PRODUCTION OF CYCLIC-AMP IN ISOLATED RETINAE OF THE RABBIT.

002149 03-03

ADENYLATE-CYCLASE FROM VARIOUS DOPAMINERGIC AREAS OF THE BRAIN AND THE ACTION OF ANTIPSYCHOTIC DRUGS.

000076 01-03 REGULATION OF NIGROSTRIATAL DOPAMINERGIC NEUROTRANSMISSION IN THE RAT.

INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS

000124 01-03 DOPAMINERGIC MECHANISMS INVOLVED IN THE ACUTE AND CHRONIC EFFECT OF AMPHETAMINE.

REGIONAL DIFFERENCES IN THE SENSITIVITY OF CHOLINERGIC NEURONS TO DOPAMINERGIC DRUGS AND QUIPAZINE IN THE RAT STRIATUM. 000134 01-03

POSSIBLE INVOLVEMENT OF THE CENTRAL DOPAMINERGIC SYSTEM IN THE ANTIRESERPINE EFFECT OF LSD.

000198 01-03 TRANSCALLOSALLY EVOKED-POTENTIALS AND THE EEG IN THE DECEREBRATE DOG: ACTIONS OF TRYPTAMINERGIC, DOPAMINERGIC AND ADRENERGIC AGONISTS.

000223 01-03

NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN SLICES OF MOUSE LIMBIC FOREBRAIN: CHARACTERISATION AND EFFECT OF DOPAMINERGIC AGONISTS

000256 01-03 A DOPAMINERGIC BASIS FOR THE EFFECTS OF AMPHETAMINE ON A MOUSE PREADOLESCENT HYPERKINETIC MODEL.

000310 01-04 MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND NORADRENERGIC NEURONS IN NORMAL AND BRAIN LESIONED RATS.

000312 01-04 DISTINCT DOPAMINERGIC MECHANISMS WITHIN THE NUCLEUS-ACCUMBENS OF RATS AND BEHAVIOUR.

000340 01-04 EFFECTS OF BACLOFEN AND MUSCIMOL ON NIGROSTRIATAL DOPAMINERGIC FUNCTIONS.

000347 01-04 EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON FEEDING IN INTACT AND 6 HYDROXYDOPAMINE TREATED RATS

000378 01-04 FURTHER EVIDENCES ON THE BEHAVIOURAL EFFECTS OF SELECTIVE A-10 DOPAMINERGIC MESENCEPHALO-CORTICO-LIMBIC GROUP LESION IN

EVIDENCE FOR INCREASED APOMORPHINE SENSITIVE DOPAMINERGIC EFFECTS AFTER ACUTE TREATMENT WITH MORPHINE

000449 01-04 MODELS TO STUDY DRUG EFFECTS ON THE INTEGRATED FUNCTION OF GABAERGIC, PEPTIDERGIC (SUBSTANCE-P) AND DOPAMINERGIC NEURONS. (UNPUBLISHED PAPER).

000499 01-06 EFFECT OF DOPAMINERGIC AGONISTS UPON OXYGEN AVAILABILITY FOR CEREBRAL-CORTEX.

001064 02-03 ELECTROPHYSIOLOGICAL EVIDENCE FOR A DOPAMINERGIC ACTION OF LSD: DEPRESSION OF UNIT ACTIVITY IN THE SUBSTANTIA-NIGRA OF

001082 02-03 EFFECTS ON HYPOTHALAMIC SELF-STIMULATION OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION INJECTED INTO NUCLEUS ACCUMBENS AND CORPUS-STRIATUM OF RATS.

001466 02-04 CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE

001526 02-06 THE PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS. A TEST OF

DOPAMINERGIC BLOCKADE: NEUROENDOCRINE STUDIES IN NORMAL 001867 02-16

MORPHINE AND ITS BIPHASIC INFLUENCE UPON PHARMACOLOGICALLY DISTINCT DOPAMINERGIC SYSTEMS WITHIN THE FELINE CAUDATE NUCLEUS: A BEHAVIOURAL STUDY. 001954 03-02

STUDY OF A DOPAMINERGIC POTENTIAL ANTIPARKINSON COMPOUND IN INTACT AND NIGRA-LESIONED RATS: N-N PROPYLBUTYLDIHYDROXYPHENYLETHYLAMINE HCL

001957 03-02 IDENTIFICATION OF DOPAMINERGIC RECEPTORS IN ANTERIOR PITUITARY: CORRELATION WITH THE DOPAMINERGIC CONTROL OF PROLACTIN

SUPPRESSION OF CAUDATE NEURON ACTIVITIES BY MORPHINE AND THE INVOLVEMENT OF DOPAMINERGIC NEUROTRANSMISSION.

001985 03-03 APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE RELEASE: ROLE OF DOPAMINERGIC RECEPTORS IN SUBSTANTIA-NIGRA.

002084 03-03 POSSIBLE CENTRAL DOPAMINERGIC MODULATION OF THE RISE IN PLASMA CONCENTRATION OF NONESTERIFIED FATTY-ACIDS PRODUCED IN THE MOUSE BY (-)TRANS DELTA9-TETRAHYDROCANNABINO 002085 03-03

PHARMACOLOGICAL MANIPULATIONS OF THE SEPTAL IRRITABILITY SYNDROME: ROLE OF DOPAMINERGIC MECHANISMS IN RECOVERY OF FUNCTION. (PH.D. DISSERTATION)

INTERACTION OF ERGOT ALKALOIDS WITH DOPAMINERGIC RECEPTORS IN THE RAT STRATUM AND NUCLEUS-ACCUMBENS.

002157 03-03 BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC/ ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA

002220 03-04 EFFECT OF BACLOFEN (BF) (LIORESAL (R) ON DOPAMINERGIC SINGLE UNITS AND SIDMAN AVOIDANCE BEHAVIOR

002300 03-04 DOPAMINERGIC AGONIST PROPERTIES OF EPHEDRINE -- THEORETICAL **IMPLICATIONS**

SCREENING FOR THE EFFECTS OF DOPAMINERGIC AND ANTIDOPAMINERGIC DRUGS ON SERUM PROLACTIN LEVELS BY RADIOIMMINOASSAY

002340 03-05 DOPAMINERGIC FACTORS IN HUMAN PROLACTIN REGULATION: EFFECTS OF NEUROLEPTICS AND DOPAMINE.

002574 03-13 THE HUMAN PLATELET AS A MODEL FOR THE DOPAMINERGIC NEURON:
KINETIC AND PHARMACOLOGIC PROPERTIES AND THE ROLE OF AMINE
STORAGE GRANULES.

002596 03-13 MODIFICATION OF DREAM CONTENT AFTER PREFERENTIAL BLOCKADE OF MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS. 002619 03-14

REGIONAL SENSITIVITY OF PRIMATE BRAIN DOPAMINERGIC NEURONS TO HALOPERIDOL: ALTERATIONS FOLLOWING CHRONIC TREATMENT.

SUPERSENSITIVITY OF THE CHOLINERGIC RESPONSE TO APOMORPHINE IN THE STRIATUM FOLLOWING DENERVATION OR DISUSE SUPERSENSITIVITY OF DOPAMINERGIC RECEPTORS IN THE RAT.

002872 04-03 EFFECT OF ALPHA-METHYLDOPA ON DOPAMINERGIC TRANSMISSION IN THE CORPUS-STRIATUM.

LOSS OF STRIATAL DOPAMINERGIC RECEPTORS AFTER INTRASTRIATAL KAINIC-ACID INJECTION.

STRIATAL CONTENT OF CA2-DEPENDENT REGULATOR PROTEIN AND DOPAMINERGIC RECEPTOR FUNCTION.

IDENTIFICATION OF A SUBREGION WITHIN RAT NEOSTRIATUM FOR THE DOPAMINERGIC MODULATION OF LATERAL HYPOTHALAMIC SELI STIMULATION.

003028 04-03 PHARMACOLOGICAL EVIDENCE FOR DOPAMINERGIC PALLIDOSTRIATAL INTERACTION.

003137 04-03 DISTINCT DOPAMINERGIC SYSTEMS IN ACTH-INDUCED GROOMING 003197 04-04 STEREOTYPED BEHAVIOR AFTER CHOLINERGIC, BUT NOT DOPAMINERGIC,

STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS 003208 04-04

DIFFERENCES IN THE DOPAMINERGIC EFFECTS OF THE ERGOT
DERIVATIVES BROMOCRIPTINE, LISURIDE AND D LSD AS COMPARED WITH APOMORPHINE 003244 04-04

ANATOMICAL SPECIFICITY WITHIN RAT STRIATUM FOR THE DOPAMINERGIC MODULATION OF DRL RESPONDING AND ACTIVITY

INTRANIGRAL KAINIC-ACID: EVIDENCE FOR NIGRAL NONDOPAMINERGIC NEURONS CONTROLLING POSTURE AND BEHAVIOR IN A MANNER OPPOSITE TO THE DOPAMINERGIC ONES. 003324 04-04

THE STRIATAL DOPAMINERGIC FUNCTION IS MEDIATED BY THE INHIBITION OF A NIGRAL, NONDOPAMINERGIC NEURONAL SYSTEM VIA A STRIO-NIGRAL GABAERGIC PATHWAY.

LACK OF BLOCKADE OF CENTRAL DOPAMINERGIC RECEPTORS BY NARCOTICS: COMPARISON WITH CHLORPROMAZINE.

CHANGES IN THE BEHAVIORAL RESPONSE TO A NOVEL ENVIRONMENT FOLLOWING LESIONING OF THE CENTRAL DOPAMINERGIC SYSTEM IN

A ROLE OF THE POLYSYNAPTIC SYSTEM OF SUBSTANTIA-NIGRA IN THE CHOLINERGIC DOPAMINERGIC EQUILIBRIUM IN THE CENTRAL-NERVOUS-

003397 04-04 AMPHETAMINE-TYPE REINFORCEMENT BY DOPAMINERGIC AGONISTS IN THE RAT

003400 04-04 LITHIUM NEUROTOXICITY. I. THE CONCENTRATION OF LITHIUM IN DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS ATOMIC ABSORPTION SPECTROPHOTOMETRY.

DOPAMINERGIC MECHANISMS IN SCHIZOPHRENIA: THE ANTIPSYCHOTIC EFFECT AND THE DISEASE PROCESS.

NORADRENERGIC AND DOPAMINERGIC MECHANISMS IN GILLES-DE-LA TOURFTTF SYNDROME

003609 04-13 POSSIBLE INDICATION OF DOPAMINERGIC BLOCKADE IN MAN BY FLECTRORETINOGRAPHY 003689 04-16

DOPAMINES 6-OHDA AND ITS ANALOGUES: CHEMICAL MECHANISM OF NEUROTOXICITY. STUDY OF THE OXIDATION OF ORTHO-SUBSTITUTED DOPAMINES 000059 01-03

002338 03-05

THE ROLE OF THE SEPTAL NUCLEI IN THE RELEASE OF ACETYLCHOLINE FROM THE RABBIT CEREBRAL-CORTEX AND DORSAL HIPPOCAMPUS AND THE EFFECT OF ATROPINE.

O00101 01

ELECTROCORTICAL CHANGES INDUCED BY THE PERFUSION OF NORADREMALINE, ACETYLCHOLINE AND THEIR ANTAGONISTS DIRECTLY INTO THE DORSAL RAPHE NUCLEUS OF THE CAT. 000164 01-03

EFFECTS OF APOMORPHINE ON SELF-STIMULATION BEHAVIOUR IN DORSAL AND VENTRAL AREA OF LATERAL HYPOTHALAMUS IN MICE. 000334 01-04

ROLE OF THE DORSAL NORADRENERGIC BUNDLE IN BEHAVIOUR CONTROL

000407 01-04 EFFECTS OF ANTINOCICEPTIVE DRUGS ON THE DORSAL ROOT POTENTIAL IN THE RAT.

OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG

002040 03-03 LESIONS OF THE DORSAL NORADRENERGIC PROJECTION ATTENUATE MORPHINE-INDUCED BUT NOT AMPHETAMINE-INDUCED CONDITIONED

NEONATAL SYSTEMIC 6 HYDROXYDOPAMINE AND DORSAL TEGMENTAL BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEPHRINE AND THE POSTDECAPITATION REFLEX.

PARAMETERS OF THE DORSAL BUNDLE EXTINCTION EFFECT: PREVIOUS EXTINCTION EXPERIENCE

003289 04-04

DORSAL-HORN

SELECTIVE OPIATE DEPRESSION OF SENSORY EVOKED SYNAPTIC

NETWORKS IN DORSAL-HORN REGIONS OF SPINAL CORD CULTURES

001088 0 001088 02-03

THE EFFECT OF NALOXONE ON THE EXCITATION OF DORSAL-HORN NEURONES OF THE CAT BY NOXIOUS AND NONNOXIOUS CUTANEOUS 001102 02-03

SELECTIVE REDUCTION BY NORADRENALINE AND 5
HYDROXYTRYPTAMINE OF NOCICEPTIVE RESPONSES OF CAT DORSAL-002246 03-04

DEPRESSANT ACTIONS OF METHIONINE-ENKEPHALIN AND SOMATOSTATIN IN CAT DORSAL-HORN NEURONES ACTIVATED BY NOXIOUS STIMULI.

003059 04-03

DORSOMEDIAL

DORSOMEDIAL THALAMIC LESIONS AND AMPHETAMINE: ACQUISITION

AND RETENTION OF A VISUAL PATTERN DISCRIMINATION ESCAPE TASK

DOSAGE HIGH DOSAGE HALOPERIDOL IN CHRONIC SCHIZOPHRENIA

000539 01-08 AMITRIPTYLINE DOSAGE SCHEDULE, SAMPLING TIME AND TRICYCLIC PLASMA LEVELS.

000593 01-09 PREDICTING THE OPTIMAL LITHIUM DOSAGE.

000693 01-13 COMPARATIVE BIOAVAILABILITY OF ORAL DOSAGE FORMS OF OXAZEPAM — CORRELATION WITH IN VITRO DISSOLUTION RATE

000727 01-13 EFFECTS OF REPEATED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS ON ADIPOSE TISSUE LIPOLYTIC ACTIVITY IN THE RAT.

PASSIVE AVOIDANCE LEARNING IN THE RAT AS FUNCTIONS OF D AMPHETAMINE DOSAGE AND SHOCK INTENSITY.

001458 02-04 DRUGS AND DEPRESSION: DOSAGE AND BLOOD LEVEL MONITORING 001595 02-09

STEADY-STATE SERUM CONCENTRATIONS OF DOTHIEPIN AND NORTHIADEN AFTER TWO DOSAGE REGIMENS OF DOTHIEPIN HYDROCHLORIDE (PROTHIADEN).

001675 02-13 INDIVIDUALISED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS

001863 02-16 A COMPARISON OF HIGH AND LOW DOSAGE REGIMES OF MAPROTILINE

DOSAGE EFFECTS OF IMIPRAMINE ON THE PSYCHOPATHOLOGIC AND BIOLOGIC INDICES OF ENDOGENOUS DEPRESSIVE SYNDROMES. 002494 03-10

PLASMA CONCENTRATIONS OF CLOMIPRAMINE AND ITS N DESMETHYL METABOLITE IN DEPRESSIVE PATIENTS FOLLOWING TREATMENT WITH VARIOUS DOSAGE REGIMES OF CLOMIPRAMINE.

002568 03-13 PREDICTION OF INDIVIDUAL DOSAGE OF NORTRIPTYLINE 002714 03-16 Psychopharmacology Abstracts

003528 04-09

THE EFFECTS OF EXTENDED INSULIN DOSAGE ON TARGET-DIRECTED ATTACK AND BITING ELICITED BY TAILSHOCK.

THE USE OF PENFLURIDOL ACCORDING TO A NEW DOSAGE REGIMEN IN THE ACUTE, STABILIZATION AND MAINTENANCE PHASES OF

PSYCHOSIS 003491 04-09 LITHIUM DOSAGE AND AGE OF PATIENTS

DOSAGES FENFLURAMINE: CUMULATIVE NEUROTOXICITY AFTER CHRONIC TREATMENT WITH LOW DOSAGES IN THE RAT.

001508 02-05 PAPILLEDEMA FOLLOWING THERAPEUTIC DOSAGES OF LITHIUM-CARBONATE.

003662 04-15

DOSE THE METABOLIC FATE OF C14-PHENOBARBITONE IN THE RAT AND THE EFFECT OF CHRONIC ADMINISTRATION AND DOSE SIZE.

000067 01-03 MEMORY IMPAIRMENT CORRELATES CLOSELY WITH CYCLOHEXIMIDE DOSE AND DEGREE OF INHIBITION OF PROTEIN SYNTHESIS. 000436 01-04

SINGLE AND DIVIDED DOSE OF IMIPRAMINE. 000595 01-10

EXPERIENCE WITH SINEQUAN IN A SINGLE EVENING DOSE.

000609 01-10 DOSE PREFERENCE DURING PENTOBARBITAL SELF-ADMINISTRATION BY

000781 01-14 EEG PROFILE AND BEHAVIORAL CHANGES AFTER A SINGLE DOSE OF CLOZAPINE IN NORMALS AND SCHIZOPHRENICS.

000787 01-14 ON PSYCHOLOGICAL SYMPTOMS IN BROMIDE INTOXICATION — ONE CASE OF HIGH DOSE, LONG-TERM BROMIDE INTOXICATION WHICH SHOWED HALLUCIMATION AND DELUSION SYMPTOMS.

000880 01-15 ADJUSTMENT OF LITHIUM DOSE DURING LITHIUM-CHLOROTHIAZIDE THERAPY.

000956 01-17 DELAYED ONSET OF SINGLE DOSE TOLERANCE TO MORPHINE ANALGESIA. 001089 02-03

TRIPHASIC DOSE LETHALITY RELATIONSHIPS FOR AMPHETAMINE CERTAIN RING-SUBSTITUTED AMPHETAMINES IN ISOLATED OR AGGREGATED MICE.

001093 02-03 MORPHINE ANALGESIA DOSE RESPONSE CURVES IN TOLERANT RATS: MODIFICATION BY NALOXONE.

001143 02-03 LOW DOSE LEVODOPA IN SCHIZOPHRENIA

001558 02-08 A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF DOTHIEPIN AND ITS THERAPEUTIC EFFECTIVENESS.

001604 02-09 METHYLPHENIDATE IN HYPERKINETIC CHILDREN: DIFFERENCES IN DOSE EFFECTS ON LEARNING AND SOCIAL BEHAVIOR.

001732 02-14 A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE
DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON
SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR
PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION.
001787 02-15

DESIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF DIVIDED VS SINGLE DOSE ADMINISTRATION. 001855 02-16

PREDICTION OF PLASMA LEVELS OF IMIPRAMINE FROM
PHARMACOKINETICS OF AN INITIAL DOSE. (UNPUBLISHED PAPER) 001876 02-16

BRAIN: SERUM AND CSF: SERUM RATIOS AFTER A SINGLE DOSE OF DIPROPYLACETIC-ACID (DPA) 002168 03-03

A DOSE RATIO COMPARISON OF THE INTERACTION BETWEEN MORPHINE AND CYCLAZOCINE WITH NALOXONE IN RHESUS MONKEYS ON THE SHOCK TITRATION TASK.

NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY EFFECTS OF DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF

002362 03-06 NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY THE EFFECTS OF DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF PENTOBARBITAL.

002363 03-06 DIFFERENTIAL EFFECTS OF A SINGLE DOSE OF IMIPRAMINE AND LOPRAMINE IN HEALTHY SUBJECTS VARYING IN THEIR LEVEL OF DEPRESSION.

TRIMIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF SINGLE VS. DIVIDED DOSE ADMINISTRATION. 002465 03-09

METHADONE DOSE, PLASMA LEVEL, AND CROSS-TOLERANCE TO HEROIN

002642 03-14 THE ACTIONS OF DIAZEPAM AND PHENYTOIN ON A LOW DOSE PENICILLIN EPILEPTIFORM FOCUS IN THE ANESTHETISED RAT.

002921 04-03 ETHANOL AND DISPOSITION OF AMYLOBARBITONE: EFFECT OF DOSE AND SIGNIFICANCE AS A MECHANISM FOR INCREASED TOXICITY.

003114 04-03 ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

003272 04-04 THE TRIPHASIC AMPHETAMINE LETHAL DOSE CURVE IN MICE AND ITS POSSIBLE RELATIONSHIP TO DRUG METABOLISM.

003410 04-05 A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-

003537 04-10 IMPLICATIONS OF DOSE REGIMEN AND PROTEIN BINDING FOR PLASMA NORTRIPTYLINE ESTIMATIONS.

003547 04-10 A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR 003657 04-15

DOSE-DEPENDENT

STEREOSELECTIVE, DOSE-DEPENDENT MODIFICATION OF INTRACRANIAL SELF-STIMULATION (ICSS) BY CENTRALLY ADMINISTERED LEVORPHANOL AND DEXTRORPHAN.

BETA-ENDORPHIN: DOSE-DEPENDENT SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR.

DOSE-RELATED

BIPHASIC EFFECT OF CHLORPROMAZINE ON RAT PARADOXICAL SLEEP: A STUDY OF DOSE-RELATED MECHANISMS.

001402 02-04

003253 04-04

PSILOCYBIN: BIPHASIC DOSE-RESPONSE EFFECTS ON THE ACOUSTIC STARTLE REFLEX IN THE RAT. NONCONTINGENT DISPLACEMENT OF CATECHOLAMINES BY INTRAVENTRICULAR TYRAMINE: BIPHASIC DOSE-RESPONSE EFFECTS ON

000364 01-04

DISCRIMINABLE EFFECTS OF ANTIMUSCARINICS: DOSE-RESPONSE AND SUBSTITUTION TEST STUDIES 000426 01-04

DOSE-RESPONSE AND TIME-COURSE EFFECTS OF N,N DIMETHYLTRYPTAMINE ON DISRUPTION OF RAT SHUTTLE-BOX

000457 01-04 MARIJUANA: DOSE-RESPONSE EFFECTS ON PULSE RATE, SUBJECTIVE ESTIMATES OF POTENCY, PLEASANTNESS, AND RECOGNITION

000648 01-11 DOSE-RESPONSE EFFECTS OF ALCOHOL UPON RAT STRAINS BRED FOR DIFFERENCES IN REACTIVITY TO ALCOHOL.

001498 02-04 EFFECTS OF THE ACUTE ADMINISTRATION OF ETHANOL ON THE SLEEP OF THE RAT: A DOSE-RESPONSE STUDY. 003296 04-04

DOSED BEHAVIORAL EFFECTS OF PSYCHOTHERAPEUTIC AGENTS IN RATS CHRONICALLY DOSED WITH ALPHA-ACETYLMETHADOL.

DOSES MULTIPLE ORAL DOSES OF DIAZEPAM, OXAZEPAM AND PHENOBARBITAL TO DOGS — BEHAVIOURAL EFFECTS AND CORRELATION WITH ANTIPYRINE HALF-LIFE.

000308 01-04 KINETIC STUDIES OF FOOD INTAKE AND SUCROSE SOLUTION PREFERENCE BY RATS TREATED WITH LOW DOSES OF DELTA9-

TETRAHYDROCANNABINOL 000324 01-04

NEOSTRIATAL ADMINISTRATION OF SOMATOSTATIN: DIFFERENTIAL EFFECT OF SMALL AND LARGE DOSES ON BEHAVIOR AND MOTOR

000437 01-04 THE EFFECTS OF BEHAVIORALLY RELEVANT DOSES OF CHLORPROMAZINE AND MOLINDONE ON CARDIAC ADENYLATE-CYCLASE AND ON MYOCARDIAL CONTRACTILITY.

ANTIPSYCHOTIC EFFECTS, SIDE-EFFECTS AND EFFECTIVE DOSES OF THE BUTYROPHENONE LENPERONE (AHR-2277). 000553 01-08 A DOUBLE-BLIND STUDY OF THE EFFECTIVE ANTIHALLUCINATORY DOSES OF DIAZEPAM PRIOR TO KETAMINE ANESTHESIA.

000640 01-11 METHADONE MAINTENANCE: EFFECT OF URINARY PH ON RENAL CLEARANCE IN CHRONIC HIGH AND LOW DOSES.

RATE OF ABSORPTION AND CLINICAL RESPONSE TO SINGLE ORAL DOSES OF CHLORDIAZEPOXIDE.

000702 01-13 PHARMACOKINETICS OF N DESMETHYLDIAZEPAM IN HEALTHY VOLUNTEERS AFTER SINGLE DAILY DOSES OF DIPOTASSIUM CHLORAZEPATE

INCORPORATION OF RADIOACTIVE LABELLED CHOLINE AND PALMITATE INTO LUNG LECITHIN OF RABBITS TREATED WITH HIGH DOSES OF BROMCARBAMIDES, BARBITURATES AND DIAZEPAM.

SINGLE VERSUS DIVIDED DOSES OF SINTAMIL IN DEPRESSION

INTENSIVE ANTIDEPRESSIVE THERAPY BY 48 HOUR SLOW-DRIP INFUSION WITH HIGH DOSES DIBENZEPINE.

001602 02-09 HEMODYNAMIC EFFECTS FOLLOWING TOXIC DOSES OF TRICYCLIC

THE EFFECTS OF SUBHYPNOTIC DOSES OF ETHANOL ON REGIONAL CATECHOLAMINE TURNOVER

001964 03-03 THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MALE

002343 03-05 TOLERANCE TO HIGH DOSES OF MORPHINE: LACK OF EVIDENCE OF LEARNING

THE TREATMENT OF DEPRESSION COMPARING DIVIDED AND SINGLE DOSES OF MAPROTILINE (LUDIOMIL).

THE EFFECTS OF ONE-DAY TREATMENT OF ANXIETY WITH HIGH DOSES OF HALAZEPAM

EFFECTS OF SINGLE AND MULTIPLE DOSES OF DESIPRAMINE (DMI) ON ENDOGENOUS LEVELS OF 3 METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE (MOPEG-SO4) IN RAT BRAIN.

CONDITIONING FACTORS INFLUENCE TOLERANCE DEVELOPMENT TO LOW BUT NOT HIGH DOSES OF MORPHINE.

HIGH DOSES OF FLUPHENAZINE-ENANTHATE IN SCHIZOPHRENIA.
003453 04-08

EFFECTS OF SINGLE DOSES OF TRANYLCYPROMINE ON PLATELET MAD AND AMINE UPTAKE IN NORMAL SUBJECTS.

CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED DOSES OF CHLORPROMAZINE

003614 04-13
PARADOXICAL EFFECTS IN SLEEP AND PERFORMANCE OF TWO DOSES OF CHI ORPROMAZINE 003629 04-14

DOSING PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. I.

CHRONICALLY EQUIVALENT DOSING METHOD. 002360 03-06

A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF DOTHIEPIN AND ITS THERAPEUTIC EFFECTIVENESS. 001604 02-09 STEADY-STATE SERUM CONCENTRATIONS OF DOTHIEPIN AND NORTHIADEN AFTER TWO DOSAGE REGIMENS OF DOTHIEPIN

HYDROCHLORIDE (PROTHIADEN). 001675 02-13
HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF

GH PERFORMANCE LIQUID CHROMATOGKAFTIL DETERMINED SERUM.

DOTHIEPIN AND NORTHIADEN IN HUMAN PLASMA AND SERUM.

001858 02-16 DOUBLE

EVIDENCE FOR A DOUBLE CHOLINERGIC MECHANISM CAPABLE OF REDUCING THE TONE OF CEREBRAL ARTERIES. 001049 02-03

A DOUBLE-BLIND CONTROLLED STUDY OF CLOBAZAM FOR THE TREATMENT OF ANXIETY IN PSYCHIATRIC OUTPATIENTS 000508 01-07

A DOUBLE-BLIND CLINICAL TRIAL OF BUPROPION-HCL - A NOVEL ANTIDEPRESSANT 000510 01-07

EVALUATIONS OF SOCIAL FUNCTIONING IN A 3-YEAR DOUBLE-BLIND INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE IN CHRONIC

CLOZAPINE (LEPONEX) VS CHLORPROMAZINE (LAX .ACTIL) IN ACUTE SCHIZOPHRENIA (A DOUBLE-BLIND CONTROLLED STUDY).

PARENTERAL HALOPERIDOL IN PSYCHIATRIC EMERGENCIES: DOUBLE-BLIND COMPARISON WITH CHLORPROMAZINE.

METHODOLOGICAL EXPERIENCE WITH A DOUBLE-BLIND MULTICENTRIC, MONITORED CLINICAL TRIAL (MMCT) WITH SINTAMIL.

MAPROTILINE — A DOUBLE-BLIND STUDY OF A NEW TETRACYCLIC ANTIDEPRESSANT IN SEVERE DEPRESSION.

000574 01-09 COMBINATION OF PHENYLPYRROLIDINOPENTANE (KATOVIT) WITH OXAZEPAM (ADUMBRAN): A DOUBLE-BLIND TRIAL WITH OPIPRAMOL (INSIDON) IN DEPRESSIVE SYNDROME.

DOUBLE-BLIND TRIALS OF A NEW TRICYCLIC ANTIDEPRESSANT (MAPROTILINE).

A DOUBLE-BLIND CROSS-OVER STUDY: APOMORPHINE/PLACEBO IN CHRONIC ALCOHOLICS.

000621 01-11 A DOUBLE-BLIND STUDY OF THE EFFECTIVE ANTIHALLUCINATORY DOSES OF DIAZEPAM PRIOR TO KETAMINE ANESTHESIA.

000640 01-11 CYCLOBENZAPRINE AND BENZOTROPINE METHANESULFONATE IN PARKINSONS DISEASE: A RANDOMIZED DOUBLE-BLIND CROSS-OVER

000654 01-11 DROPERIDOL IN ACUTELY AGITATED PATIENTS: A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY.

000662 01-11 TREATMENT OF SPASMODIC TORTICOLLIS WITH AMANTADINE: A DOUBLE-BLIND STUDY.

DOUBLE-BLIND PLACEBO-CONTROLLED COMPARISON OF AMOXAPINE AND IMIPRAMINE IN DEPRESSED OUTPATIENTS.

A DOUBLE-BLIND CLINICAL COMPARISON OF AMOXAPINE, IMIPRAMINE, AND PLACEBO IN THE TREATMENT OF DEPRESSION.

001609 02-09 PSYCHOTROPIC EFFECTS OF CARBAMAZEPINE IN EPILEPSY: A DOUBLE-BLIND COMPARISON WITH PHENYTOIN.

001706 02-14 LOXAPINE VERSUS HALOPERIDOL PARENTERALLY IN ACUTE PSYCHOSIS WITH AGITATION: A DOUBLE-BLIND STUDY.

001710 02-14

COMPUTER OCULOGRAPHIC DOUBLE-BLIND STUDY OF CHANGES IN VIGILANCE: ALPRENOLOL VERSUS DIAZEPAM.

001746 02-15 A DOUBLE-BLIND CONTROLLED STUDY OF PIPOTHIAZINE-PALMITATE IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS. 002390 03-08

GRADUAL REDUCTION OF NEUROLEPTIC DRUGS AMONG CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY.

002401 03-08 COMPARISON OF THE EFFECTS OF PIPOTHIAZINE-PALMITATE AND FLUPHENAZINE-DECANOATE IN A MULTICENTER DOUBLE-BLIND TRIAL

002412 03-08 DOXEPIN AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION: A
DOUBLE-BLIND CROSS-OVER CLINICAL STUDY WITH EKG RECORDINGS

A DOUBLE-BLIND CONTROLLED COMPARATIVE STUDY OF NOMIFENSINE IN

002419 03-09 DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF BUPROPION-HYDROCHLORIDE (WELLBATRIN) IN THE TREATMENT OF DEPRESSED

DOUBLE-BLIND CONTROLLED STUDY IN PHOBIAS AND OBSESSIONS. 002483 03-10

MAPROTILINE AND DOXEPIN IN THE TREATMENT OF DEPRESSION: A DOUBLE-BLIND MULTICENTRE COMPARISON.

002495 03-10 A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF LOXAPINE, DIAZEPAM, AND PLACEBO IN HOSPITALIZED PATIENTS WITH VARIOUS STATES OF ANXIETY.

002496 03-10 A DOUBLE-BLIND INVESTIGATION OF PIRACETAM (NOOTROPIL) VERSUS PLACEBO IN THE MEMORY OF GERIATRIC INPATIENTS.

002502 03-11 A PSYCHOLOGICAL PERSPECTIVE FOR DOUBLE-BLIND TRIALS

DOUBLE-BLIND THERAPEUTIC EVALUATION OF FLUSPIRILENE COMPARED WITH FLUPHENAZINE-DECANOATE IN CHRONIC SCHIZOPHRENICS.
003456 04-08

LONG-ACTING ORAL VS INJECTABLE ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENICS: A ONE-YEAR DOUBLE-BLIND COMPARISON IN MULTIPLE EPISODE SCHIZOPHRENICS.

003467 04-08

DOUBLE-BLIND COMPARISON OF BROMPERIDOL AND PERPHENAZINE CIS-CLOPENTHIXOL AND CLOPENTHIXOL (SORDINOL) IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL INVESTIGATION.

TRICYCLIC ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIONS: A DOUBLE-BLIND CLINICAL COMPARISON OF CLOMIPRAMINE (ANAFRANIL) AND AMITRIPTYLINE.

003501 04-09 VILOXAZINE AND AMITRIPTYLINE IN DEPRESSIVE ILLNESS: A DOUBLE-BLIND CONTROLLED TRIAL IN GENERAL PRACTICE.

003506 04-09 DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF KETAZOLAM IN

003535 04-10 A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-DUMMY TECHNIQUE.

NABILONE, A CANNABINOID, IN THE TREATMENT OF ANXIETY: AN OPEN-LABEL AND DOUBLE-BLIND STUDY.

A DOUBLE-BLIND COMPARISON OF LEVODOPA, MADOPA, AND SINEMET IN PARKINSON DISEASE.

TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDROME WITH EMD-21657. A DERIVATIVE OF A PYRITINOL METABOLITE: DOUBLE-BLIND CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STUDIES.

DELIRIUM-TREMENS: A DOUBLE-BLIND COMPARISON OF DIAZEPAM AND BARBITAL TREATMENT.

003632 04-14

A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-DUMMY TECHNIQUE.

003537 04-10

COURSE AND PROGNOSIS OF THE SYNDROME OF DOUBLES. 002507 03-11

DOXEPIN

DOXEPIN IN THE TREATMENT OF NEUROSES: A COMPARATIVE CLINICAL
STUDY OF DOXEPIN, CHLORDIAZEPOXIDE, HYDROXYZINE,
MEPROBAMATE, AND PHENOBARBITAL.

000614 01-1

SEDATIVE PROPERTIES OF DOXEPIN IN COMPARISON WITH DIAZEPAM.
000703 01-13

DOXEPIN OVERDOSE: SUCCESS WITH PHYSOSTIGMINE AND FAILURE
WITH NEOSTIGMINE IN REVERSING TOXICITY

000772 01-14 PROSTAGLANDINS AND THE CARDIOTOXIC EFFECT OF DOXEPIN IN RABBITS AND GUINEA-PIGS.

DOXEPIN AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION: A DOUBLE-BLIND CROSS-OVER CLINICAL STUDY WITH EKG RECORDINGS 002416 03-09

COGNITIVE AND PSYCHOPHYSIOLOGIC RESPONSE TO DOXEPIN AND CHLORDIAZEPOXIDE.

002457 03-09 DOXEPIN OR DIAZEPAM FOR ANXIOUS AND ANXIOUS DEPRESSED OUTPATIENTS?.

002482 03-10 MAPROTILINE AND DOXEPIN IN THE TREATMENT OF DEPRESSION: A DOUBLE-BLIND MULTICENTRE COMPARISON.

002495 03-10 NTICHOLINERGIC ACTIVITY OF THE TRICYCLIC ANTIDEPRESSANTS
DESIPRAMINE AND DOXEPIN IN NONDEPRESSED VOLUNTEERS.
003447 04-07

CLINICAL IMPORTANCE OF DOXEPIN ANTIDEPRESSANT PLASMA LEVELS. 003497 04-09

BRAIN: SERUM AND CSF: SERUM RATIOS AFTER A SINGLE DOSE OF DIPROPYLACETIC-ACID (DPA), 002168 03-03

DAILY CHANGES IN THE BLOOD SERUM LEVELS OF DIPHENYLHYDANTOIN (DPH) AND PHENOBARBITAL.

001830 02-15

THE PEAK EXPERIENCE VARIABLE IN DPT ASSISTED PSYCHOTHERAPY WITH CANCER PATIENTS. 000679 01-12 DIPROPYLTRYPTAMINE (DPT) AS AN ADJUNCT IN THE COUNSELING OF CANCER PATIENTS.

000978 01-17 MODIFICATION OF DREAM CONTENT AFTER PREFERENTIAL BLOCKADE OF MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS.

002619 03-14

OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG

002040 03-03

VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF 2 AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF NAD:NADH AND NORELEAGNINE A BETA-CARBOLINE DERIVATIVE. 000200 01-03

EFFECTS OF MONOSODIUM-GLUTAMATE ON EATING AND DRINKING

000423 01-04 5 HYDROXYTRYPTAMINE DEPLETION WITH P-CHLOROPHENYLALANINE EFFECTS ON EATING, DRINKING, IRRITABILITY, MURICIDE, AND COPULATION

INHIBITION OF DRINKING BY INTRAHYPOTHALAMIC ADMINISTRATION OF

001325 02-04 DRINKING BEHAVIOUR INDUCED BY INTRACRANIAL INJECTIONS OF ELEDOISIN AND SUBSTANCE-P IN THE PIGEON

001352 02-04 EFFECTS OF CHLORDIAZEPOXIDE ON PUNISHED AND UNPUNISHED RESPONDING BEFORE AND DURING CHLORDIAZEPOXIDE DRINKING. 001417 02-04

FEEDING AND DRINKING INTERACTIONS AFTER ACUTE BUTYROPHENONE ADMINISTRATION.

D AMPHETAMINE AND ADJUNCTIVE DRINKING IN RATS

001453 02-04 PARAVENTRICULAR NUCLEUS: A PRIMARY SITE MEDIATING ADRENERGIC STIMULATION OF FEEDING AND DRINKING

ESTABLISHMENT OF ETONITAZENE AS A REINFORCER FOR RATS BY USE OF SCHEDULE-INDUCED DRINKING.

STRIATAL NONDOPAMINERGIC NEURONS: POSSIBLE INVOLVEMENT IN FEEDING AND DRINKING BEHAVIOR

003330 04-04 THE EFFECTS OF D AMPHETAMINE AND SCOPOLAMINE ON DRINKING

INDUCED BY A MULTIPLE SCHEDULE. 003350 04-04

AGIOTENSIN-INDUCED DRINKING: SEXUAL DIFFERENCES 003385 04-04 THE EFFECTS OF ATROPINE ON THE TOLERANCE AND THE CONVULSIONS

SEEN AFTER WITHDRAWAL FROM FORCED BARBITAL DRINKING IN THE

003389 04-04 DRIVEN

STRENGTH DURATION PROPERTIES OF SINGLE UNITS DRIVEN BY ELECTRICAL STIMULATION OF THE LATERAL HYPOTHALAMUS IN RATS 002763 03-17 DRIVING

EFFECTS OF TRITHIOZINE ON PSYCHOMOTOR SKILLS RELATED TO DRIVING: A COMPARISON WITH DIAZEPAM AND INTERACTIONS WITH

001723 02-14 THE EFFECTS OF TWO ANTIDEPRESSANTS, IMPRAMINE AND VILOXAZINE, UPON DRIVING PERFORMANCE.

DRL USE OF DRL IN DIFFERENTIATING ANXIOLYTIC AND NEUROLEPTIC PROPERTIES OF CNS DRUGS

000329 01-04 EFFECTS OF SODIUM-NITRITE ON DRL PERFORMANCE IN THE RAT 002325 03-04

ANATOMICAL SPECIFICITY WITHIN RAT STRIATUM FOR THE DOPAMINERGIC MODULATION OF DRL RESPONDING AND ACTIVITY 003316 04-04

DROPERIDOL
DROPERIDOL IN ACUTELY AGITATED PATIENTS: A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY.

000662 01-11 DROPERIDOL-INDUCED NEUROPHYSIOLOGICAL PARAMETERS OF DROPERIDOL-INDUCED

PSYCHOSES. 001636 02-12 DROFS

TRICYCLIC NEED DROPS WITH AGE.

000580 01-09 DRUG

ABSORPTION AND METABOLISM OF THE PHENOTHIAZINE DRUG PERAZINE IN THE RAT INTESTINAL LOOP 000063 01-03

ACTION OF S-1432, A NEW PSYCHOTROPIC DRUG, ON THE CENTRAL CHOLINERGIC SYSTEM

000080 01-03 PSYCHOACTIVE DRUG EFFECTS AND SUBSTRATE SPECIFICITY IN INTACT MITOCHONDRIAL MONOAMINE-OXIDASE FROM BRAIN. 000115 01-03

NEUROLEPTIC DRUG INTERACTIONS WITH NOREPINEPHRINE ALPHA RECEPTOR BINDING SITES IN RAT BRAIN. 000219 01-03

ALTERED RECEPTOR SENSITIVITY FOLLOWING CHRONIC DRUG ADMINISTRATION IN MAN: THE TARDIVE-DYSKINESIA MODE 000248 01-03

PRIMATE INFORMATION PROCESSING UNDER SODIUM PENTOBARBITAL AND CHLORPROMAZINE: DIFFERENTIAL DRUG EFFECTS WITH TACHISTOSCOPICALLY PRESENTED DISCRIMINATIVE STIMULI.

DRUG EFFECTS UPON FORCE AND DURATION OF RESPONSE DURING FIXED-RATIO PERFORMANCE IN RATS.

THE EFFECTS OF PHARMACOLOGICAL AND ENVIRONMENTAL VARIABLES ON DRUG CHOICE IN RHESUS MONKEYS

000386 01-04 ANTAGONISM BY CHOLINERGIC DRUGS OF BEHAVIOURAL EFFECTS IN CATS OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC DRUG AND ENHANCEMENT BY NICOTINE.

000404 01-04 ANIMAL MODELS OF ORAL DRUG SELF-ADMINISTRATION.

000408 01-04 LONG-TERM BEHAVIOURAL AND BIOCHEMICAL EFFECTS FOLLOWING PROLONGED TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL)

000420 01-04 MODELS TO STUDY DRUG EFFECTS ON THE INTEGRATED FUNCTION OF GABAERGIC, PEPTIDERGIC (SUBSTANCE-P) AND DOPAMINERGIC NEURONS. (UNPUBLISHED PAPER).

COMPARISON OF ETHANOL, PENTOBARBITAL, AND PHENOBARBITAL USING DRUG VS. DRUG DISCRIMINATION TRAINING.

NEW DRUG TESTING IN THE CONSENTING ADULT.

POSTTRAUMATIC PSYCHONEUROSIS: EVALUATION OF DRUG THERAPY.
000615 01-10
PSYCHOTROPIC AND ANTICONVULSANT DRUG USAGE IN EARLY
CHILDHOOD SPECIAL EDUCATION PROCESSAGE IN EARLY CHILDHOOD SPECIAL EDUCATION PROGRAMS III. A PRELIMINARY REPORT: PARENT INTERVIEWS ABOUT DRUG TREATMENT

REPORT FROM CLINICAL PRACTICE: THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG TREATMENT OF HYPERACTIVE CHILDREN. (UNPUBLISHED PAPER).

THE FUNCTION OF DRUG RITUALS IN HUMAN SOCIETY: CONTINUITIES AND CHANGES

000674 01-12 FLUNITRAZEPAM, AN INVESTIGATIONAL HYPNOTIC DRUG: SLEEP LABORATORY EVALUATIONS.

000750 01-14 WITHDRAWAL OF A STIMULANT DRUG AND CONCURRENT BEHAVIORAL INTERVENTION IN THE TREATMENT OF A HYPERACTIVE CHILD.

000780 01-14 DRUG AND ALCOHOL-INDUCED PSYCHIATRIC SYNDROMES

000796 01-15 DRUG ANALYSIS IN THE OVERDOSED PATIENT: ITS APPLICATION TO CLINICAL TOXICOLOGY

000802 01-15 PSYCHEDELIC DRUG CRISES: TOXICITY AND THERAPEUTICS 000861 01-15

DRUG DEPENDENCY IN PATIENTS WITH CHRONIC HEADACH 000863 01-15 ADVERSE DRUG REACTIONS.

000876 01-15 DRUG TREATMENT IN THE ELDERLY

000907 01-15 RATIO DATA AND THE QUANTIFICATION OF DRUG EFFECTS 000914 01-16

TAXONOMY AND EVALUATION OF PSYCHOLOGICAL TEST METHODS IN PSYCHOTROPIC DRUG TRIALS

THEORETICAL AND METHODOLOGICAL ASPECTS OF PSYCHOTROPIC DRUG TRIALS USING HEALTHY SUBJECTS 000918 01-16

TARDIVE-DYSKINESIA AND CHANGING CONCEPTS OF ANTIPSYCHOTIC DRUG USE: A NURSING PROSPECTIVE. 000919 01-16

STATISTICAL ASPECTS OF PSYCHOTROPIC DRUG TRIAL DESIGNS 000922 01-16 GENERAL METHODOLOGICAL PROBLEMS OF CLINICAL PSYCHOTROPIC

DRUG TRIALS. BEING A PATIENT IN A DRUG TRIAL: DO YOU LOSE SOMETHING?

000929 01-16
DIFFICULTIES ENCOUNTERED BY THE CLINICAL RESEARCHER IN PLANNING PSYCHOTROPIC DRUG TRIALS.

000935 01-16 A REVIEW OF STIMULANT DRUG RESEARCH WITH HYPERACTIVE CHILDREN

002612 03-14

nplect rugex	Psychopharmacology Abstracts
DRUG INTERACTIONS. 000945 01-17	AN AUTOMATED SYSTEM FOR THE PREDICTION AND PREVENTION OF ADVERSE DRUG REACTIONS. (PH.D. DISSERTATION).
A DIAGNOSTIC TREATMENT MODEL FOR EFFECTIVE GROUP TREATMENT OF DRUG ABUSERS. 000950 01-17	DRUG VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS.
SUBJECTIVE PHENOMENA IN DRUG TRIALS. 000951 01-17	MATERNAL DRUG HISTORIES AND CONGENITAL ABNORMALITIES.
MULTIPLE DRUG THERAPY IS THERE A STANDARD OF CARE?. 000954 01-17	001780 02-15 ON CATARACTS SEEN DURING PSYCHOTROPIC DRUG THERAPY.
PATTERNS OF ANTIPSYCHOTIC DRUG USE IN FOUR SOUTHEASTERN STATE	DRUG THERAPY OF SCHIZOPHRENIAS IN THE COMMUNITY.
HOSPITALS. 000963 01-17	001813 02-15
PSYCHOACTIVE DRUG RESPONDER SUBGROUPS — POSSIBLE CONTRIBUTIONS TO PSYCHIATRIC CLASSIFICATION. (UNPUBLISHED PAPER).	IATROGENIC COMPLICATIONS OF DRUG OVERDOSAGE AND POISONING. 001824 02-15 A POTENTIALLY TOXIC DRUG INTERACTION BETWEEN PETHIDINE
000968 01-17 EVALUATION OF THE PRISON INMATE AS A SUBJECT IN DRUG	(MEPERIDINE) AND PHENOBARBITONE. 001836 02-15
ASSESSMENT. 000982 01-17	HAZARDS OF ANTIPSYCHOTIC DRUG USE IN NONPSYCHOTIC PATIENTS. 001847 02-15
EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE	DIGOXIN LITHIUM DRUG INTERACTION. 001853 02-15
DRUG RECEPTOR MEDIATED EFFECTS. 001103 02-03	LOOKING TOWARD A REEXAMINATION OF DRUG THERAPY EXPERIENCE. 001856 02-16
EFFECT OF QUIPAZINE, A SEROTONIN-LIKE DRUG, ON STRIATAL CHOLINERGIC INTERNEURONES.	ON LONG-TERM MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY: THE COMBINED ADMINISTRATION OF ANTIPARKINSONS DRUGS. 001865 02-16
O01114 02-03 CEREBELLAR CGMP SYSTEM: A MODEL TO STUDY DRUG RECEPTOR INTERACTION. (UNPUBLISHED PAPER). 001139 02-03	A DEBATE ON MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY— REFLECTIONS ON THE SO-CALLED LONG-TERM SATURATION ADMINISTRATIONS.
THE EFFECT OF NONCONTINGENT AMPHETAMINE INJECTIONS ON THE EXTINCTION OF FOOD AND DRUG REINFORCED LEVER PRESSING IN RATS.	A REEXAMINATION OF USING ANTIPARKINSONS DRUGS WITH PSYCHOTROPIC DRUG THERAPY — A SURVEY OF OUTPATIENTS.
001404 02-04 NEUROMETABOLIC AND BEHAVIOURAL EFFECTS OF HALOPERIDOL IN RELATION TO DRUG LEVELS IN SERUM AND BRAIN.	THE COMPARISON OF PSYCHOPHYSIOLOGICAL THERAPY WITH DRUG THERAPY.
O01430 02-04 SECOND-ORDER SCHEDULES OF INTRAVENOUS DRUG SELF- ADMINISTRATION IN RHESUS MONKEYS.	A STUDY OF PHYSICIAN DRUG PRESCRIBING ADOPTION AND DISCONTINUATION BEHAVIORS. (PH.D. DISSERTATION).
PSYCHOTROPIC DRUG EFFECTS ON THE EMOTIONAL STATE OF CATS IN A	HOW CANADA HOLDS DOWN DRUG COSTS.
SOCIAL SITUATION. 001480 02-04	PRISONER SUBJECTS AND DRUG TESTING.
DRUG INTERACTIONS AS MEASURED BY DEPRIVATION-INDUCED FLUID CONSUMPTION.	PHYSICIANS DRUG INNOVATION AND RELINQUISHMENT.
001501 02-04 A NEW CHRONICALLY CANNULATED CAROTID ARTERY PREPARATION FOR	DRUG INTERACTIONS AND MULTIPLE DRUG ADMINISTRATION. 001913 02-17
DETERMINATION OF DRUG HALF-LIVES IN THE GUINEA-PIG. 001531 02-06	DRUG INTERACTIONS. 001923 02-17
DRUG DISCRIMINATION AND GENERALIZATION IN PIGEONS. 001532 02-06	BEHAVIORAL MECHANISMS OF DRUG ACTION IN SCHIZOPHRENIA.
DIFFERENT BEHAVIOURAL PATTERNS INDUCED BY APOMORPHINE. EVIDENCE THAT THE METHOD OF ADMINISTRATION DETERMINES THE BEHAVIOURAL RESPONSE TO THE DRUG.	O01933 02-17 IMPORTANCE OF DURATION OF DRUG ACTION IN THE ANTAGONISM OF P-CHLOROAMPHETAMINE DEPLETION OF BRAIN SEROTONIN — COMPARISON OF FLUOXETINE AND CHLORIMIPRAMINE.
DEVELOPMENT OF DRUG THERAPY FOR THE MENTALLY ILL. 001551 02-07	BRAIN NEUROTRANSMITTER RECEPTORS AND CHRONIC ANTIPSYCHOTIC
ANTIPARKINSONIAN DRUG ADMINISTRATION AND PLASMA LEVELS OF PENFLURIDOL, A NEW LONG-ACTING NEUROLEPTIC.	DRUG TREATMENT: A MODEL FOR TARDIVE-DYSKINESIA. 002061 03-03 FURTHER EVIDENCE OF CYCLIC-AMP MEDIATED HYPERTROPHY AS A
CHLOROQUINE POTENTIATION OF THIORIDAZINE EFFECTS IN RATS AND	PREREQUISITE OF DRUG SPECIFIC ENZYME INDUCTION.
DRUG RESISTANT SCHIZOPHRENIC PATIENTS: A PRELIMINARY REPORT. 001571 02-08	PHARMACOLOGY OF DISCRIMINATIVE DRUG STIMULI.
ANTIDEPRESSANT DRUG THERAPY IN PSYCHOTIC DEPRESSION.	CENTRAL DRUG AND LESION STUDIES OF FEEDING.
001580 02-09 LONG-TERM MAINTENANCE DRUG THERAPY IN RECURRENT AFFECTIVE- ILLNESS: CURRENT STATUS AND ISSUES.	DRUG MONITORING AT AN AUSTRALIAN DEPOT PHENOTHALINE CLINIC. 002402 03-08
CLINICAL REPORT OF THE DRUG TRANXENE (CLORAZEPATE- DIPOTASSIUM).	NEW APPROACH TO THE REHABILITATION OF THE HARD CORE DRUG ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY STUDY.
001612 02-10 EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DRUG DISTRIBUTION AND METABOLISM: ANTIPYRENE, PENTOBARBITAL, AND ETHANOL. 001643 02-13	MARIJUANA, ALCOHOL, AND COMBINED DRUG EFFECTS ON THE TIME COURSE OF GLARE RECOVERY.
KINETICS OF INTRAVENOUS CHLORDIAZEPOXIDE: SEX DIFFERENCES IN DRUG DISTRIBUTION.	CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE- ILINESS: PARADOXICAL DRUG EFFECTS.
URINARY EXCRETION OF A QUATERNARY AMMONIUM GLUCURONIDE METABOLITE OF CYPROHEPTADINE IN HUMANS UNDERGOING CHRONIC DRUG THERAPY.	EFFECTS OF ANTIANXIETY DRUG AND PERSONALITY ON STRESS-INDUCING PSYCHOMOTOR PERFORMANCE TEST.
CLINICAL BIOCHEMICAL ASSESSMENT OF DRUG ACTION IN PATIENTS. (UNPUBLISHED PAPER).	THE VALUE OF THE MMPI FOR DELINEATING SYMPTOMS UNIQUE TO POSITIVE LITHIUM RESPONDERS: A DRUG RESPONSE AND DIAGNOSTIC STUDY. (PH.D. DISSERTATION).
DRING HARDOWING CEREBRAL METABOLISM IN DEMENTIA	002638 03-14

Psychopharmacology Abstracts

002653 03-15

002656 03-15

EMOTIONAL PREDISPOSITION TO PSYCHOTROPIC DRUG EFFECTS.

002648 03-14

ALPHA AND BETA COMA IN DRUG INTOXICATION.

HEMOPERFUSION IN TREATMENT OF DRUG INTOXICATION.

001695 02-13

001743 02-15

001749 02-15

DRUG IMPROVING CEREBRAL METABOLISM IN DEMENTIA.

SEX DIFFERENCES IN RESPONSE TO DRUG TREATMENT.

EFFECT OF DIETARY FACTORS ON DRUG ACTION.

THE PROBLEM OF PRENATAL DAMAGE FROM LONG-TERM ANTIEPILEPTIC DRUG TREATMENT 002659 03-15 DRUG DEPENDENCE IN PROPRANOLOL TREATMENT OF MIGRAINE 002678 03-15 DRUG UTILIZATION AND ADVERSE DRUG REACTIONS IN MEDICAL PATIENTS: COMPARISON OF TWO PERIODS, 1969-72 AND 1973-76 002684 03-15 ELECTROENCEPHALOGRAPHIC PECULIARITIES DURING ACUTE DRUG INTOXICATIONS IN EPILEPTIC PATIENTS. 002689 03-15 DRUG REFUSAL IN SCHIZOPHRENIA: CAUSES AND PRESCRIBING HINTS 002709 03-15 ASSESSMENT OF DRUG THERAPY IN CHRONIC BRAIN FAILURE 002719 03-16 CREATIVITY IN NEW DRUG DEVELOPMENT: AN ACADEMIC CHALLENGE 002745 03-17 THE BIOLOGY OF AFFECTIVE-ILLNESS: AMINE NEUROTRANSMITTERS AND DRUG RESPONSE 002746 03-17 DRUG THERAPY: ALLIANCE AND COMPLIANCE 002749 03-17 DRUG DISCRIMINATION AND STATE-DEPENDENT LEARNING 002753 03-17 IMPOTENCE: ROLE OF DRUG AND HORMONAL TREATMENT 002759 03-17 THE RESULTS OF A CAMPAIGN TO EDUCATE PHYSICIANS IN ANTIPSYCHOTIC DRUG USAGE. 002761 03-17 WHO EXPERT COMMITTEE ON DRUG DEPENDENCE: TWENTY-FIRST REPORT EFFECTS ON STRIATAL AND MESOLIMBIC DOPAMINE SYSTEMS OF A NEW POTENTIAL ANTIPSYCHOTIC DRUG — MEZILAMINE — WITH WEAK CATALEPTOGENIC PROPERTIES. 002800 04-02 PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6 TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH KINETICS OF AMINOPYRINE-N-DEMETHYLATION PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — I. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS. 002931 04-03 PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM -- II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH. EVIDENCE FOR CELL LOSS IN CORPUS-STRIATUM AFTER LONG-TERM TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN RATS 003030 04-03 TRYPTAMINE-INDUCED DRUG EFFECTS INSENSITIVE TO SEROTONINERGIC ANTAGONISTS: EVIDENCE OF SPECIFIC TRYPTAMINERGIC RECEPTOR STIMULATION? 003057 04-03 DRUG CUES, DRUG STATES, AND INFANTILE AMNESIA 003196 04-04 METHODOLOGICAL ISSUES IN DRUG DISCRIMINATION RESEARCH 003202 04-04 MORPHINE AS A DISCRIMINATIVE CUE IN GERBILS: DRUG GENERALIZATION AND ANTAGONISM. 003249 04-04 ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE 003272 04-04 SOME FAILURES OF THE DRUG DISCRIMINATION HYPOTHESIS OF STATE-DEPENDENT LEARNING. 003317 04-04 DRUG EFFECTS ON RESPONDING MAINTAINED BY STIMULUS REINFORCER AND RESPONSE REINFORCER CONTINGENCIES. 003365 04-04 EFFECTS OF CHLORMETHIAZOLE (HEMINEVRIN) ON DRUG DISCRIMINATION AND OPEN-FIELD BEHAVIOR IN GERBILS 003371 04-04 EXPERIMENTAL BARBITURATE DEPENDENCE. I. BARBITURATE DEPENDENCE DEVELOPMENT IN RATS BY DRUG ADMIXED FOOD (DAF) METHOD INTERACTION BETWEEN D AMPHETAMINE AND ETHANOL WITH RESPECT TO LOCOMOTION, STEREOTYPIES, ETHANOL SLEEPING TIME, AND THE KINETICS OF DRUG ELIMINATION. 003378 04-04 THE TRIPHASIC AMPHETAMINE LETHAL DOSE CURVE IN MICE AND ITS POSSIBLE RELATIONSHIP TO DRUG METABOLISM. 003410 04-05

LIDOCAINE AND PENTOBARBITAL: A POTENTIALLY LETHAL DRUG DRUG

INTERACTION.

INTEROCEPTIVE DISCRIMINATIVE STIMULI AS TOOLS IN DRUG DEVELOPMENT OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR OPERANT DRUG DISCRIMINATIONS 003434 04-06 COCA PROPOSED AS PRESCRIPTION DRUG. DO ANTICHOLINERGICS ANTAGONIZE ANTIPSYCHOTIC DRUG ACTION?.
003478 04-08 TREATMENT OF IMIPRAMINE RESISTANT DEPRESSION AND LITHIUM REFRACTORY MANIA THROUGH DRUG INTERACTIONS. THE IMPLICATIONS OF PSYCHEDELIC DRUG RESEARCH FOR INTEGRATION AND SEALING OVER AS RECOVERY STYLES FROM ACUTE PSYCHOSIS.
003517 04-09 DEPRESSION IN THE ELDERLY. II. POSSIBLE DRUG ETIOLOGIES: DIFFERENTIAL DIAGNOSTIC CRITERIA. 003520 04-09 ANTIDEPRESSANT DRUG LEVELS AND CLINICAL RESPONSE. 003545 04-10 HYPERACTIVE CHILDRENS KNOWLEDGE AND ATTITUDES CONCERNING DRUG TREATMENT 003553 04-11 PROPHYLACTIC LITHIUM TREATMENT OF DRUG ABUSE. 903564 04-11 FOR NOCTURNAL TRIAL OF AN ALPHA-ADRENOLYTIC DRUG (INDORAMIN) 003573 04-11 THE BEHAVIORAL SYMPTOMS OF HYPERKINETIC CHILDREN WHO IE BEHAVIORAL SYMPTOMS OF HYPERKINETIC CHILDREN WITC SUCCESSFULLY RESPONDED TO STIMULANT DRUG TREATMENT. 003579 04-11 DISAPPEARANCE OF CHLORPROMAZINE FROM PLASMA FOLLOWING DRUG WITHDRAWAL 003605 04-13 CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED DOSES OF CHLORPROMAZINE. SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE (SIADH) SECONDARY TO ANTIPSYCHOTIC DRUG THERAPY. 003647 04-15 TARDIVE-DYSKINESIA AND PSYCHOTROPIC DRUG HISTORY 003680 04-15 DRUG HISTORY AND TARDIVE-DYSKINESIA 003682 04-15 BEHAVIORAL TOXICITY: THE PSYCHOLOGY OF DRUG POLLUTION.

003684 04-15
MULTIVARIATE ANALYSIS OF DRUG EFFECTS ON ELECTROPHYSIOLOGICAL SIGNALS IN MAN. CHLORPROMAZINE EXCRETION. II. IMPROVED TLC PROCEDURES FOR FRACTIONATING THE URINARY DRUG CONTENT INTO CHEMICAL SUBGROUPS OF CP7 METABOLITES 003690 04-16 DRUG DISCRIMINATION PARADIGMS: PROBLEMS OF TOLERANCE AND REHAVIORAL DISRUPTION 003692 04-16 DRUG TREATMENT OF MIGRAINE AND ITS VARIANTS 003696 04-17 PROGRAM. **EVALUATION OF A PATIENT DRUG SELF-ADMINISTRATION** (PH.D. DISSERTATION). 003700 04-17 DRUG INTERACTIONS 003713 04-17 PSYCHOTROPIC AND ANTIPARKINSONIAN DRUG USE: AN EXAMINATION OF PRESCRIPTION PRACTICES. 003723 04-17 DRUG-FREE A DRUG-FREE WEEK AFTER ADMISSION 001883 02-17 DRUG-INDUCED DRUG-INDUCED CHANGES IN BRAIN TYROSINE-HYDROXYLASE ACTIVITY IN VIVO 000181 01-03 OF RATS. 000366 01-04 DRUG-INDUCED CHANGES IN THE MATERNAL BEHAVIOR EFFECTS OF LERGOTRILE ON SCHIZOPHRENIA AND DRUG-INDUCED PARKINSONISM 000548 01-08 ABSENCE OF DRUG-INDUCED BETA-ACTIVITY IN THE ELECTROENCEPHALOGRAM: A SIGN OF SEVERE CEREBRAL IMPAIRMENT PHARMACOKINETICS AND CLINICAL EFFECTS OF AMANTADINE IN DRUG-

INDUCED EXTRAPYRAMIDAL SYMPTOMS

DRUG-INDUCED DEPRESSION

001781 02-15

001816 02-15

CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF C-AMP-PHOSPHODIESTERASE.

002023 03-03 MESOLIMBIC DOPAMINE NEURONS: EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DESTRUCTION AND RECEPTOR BLOCKADE ON DRUG-INDUCED ROTATION OF RATS.

RELIABILITY OF TWO ACTIVITY BOXES COMMONLY USED TO ASSESS DRUG-INDUCED BEHAVIOURAL CHANGES.

002368 03-06

003388 04-04

DRUG-INDUCED DEPRESSION AND ATTEMPTED SUICIDE

002421 03-09 ASSESSMENT OF SPONTANEOUS AND DRUG-INDUCED CHANGES IN VIGILANCE BY MEANS OF A NEW MODIFICATION OF THE SHORT TIME SPECTRAL ANALYSIS OF THE EEG.

002627 03-14 DRUG-INDUCED SYSTEMIC LUPUS-ERYTHEMATOSUS.

002676 03-15 PRESCRIPTION DRUG-INDUCED ORGANIC-BRAIN-SYNDROME

METHODOLOGICAL PROBLEMS IN THE MEASUREMENT OF DRUG-INDUCED ROTATIONAL BEHAVIOUR: CONTINUOUS RECORDING REVEALS TIME-COURSE DIFFERENCES UNDETECTED BY PREVIOUS TECHNIQUES.

DRUG-INDUCED DYSKINESIA: A CRITICAL REVIEW

003586 04-13

OF DEXTRAN ON DRUG-INDUCED HEMOLYSIS.

003586 04-13

PSYCHOLOGICAL FACTORS IN SUSCEPTIBILITY TO DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS.

003660 04-15 PREVENTING DRUG-INDUCED DYSKINESIA.

003671 04-15

DRUG-MODULATED
DRUG-MODULATED BEHAVIOURAL RESPONSES TO ENVIRONMENTAL
ENRICHMENT.

003201 04-04 DRUG-PRODUCED CHANGES IN HUMAN SOCIAL BEHAVIOR: FACILITATION BY D AMPHETAMINE.

001715 02-14

DRUG-RELATED

IATROGENIC CAUSES OF NEUROLOGIC DISORDERS: PART 2. DRUGRELATED DYSFUNCTIONS.

003644 04-15

DRUG-SEEKING
EFFECTS OF METHADONE AND MORPHINE MAINTENANCE ON DRUGSEEKING BEHAVIOR IN THE DOG.

000387 01-04

AN ANIMAL SCREENING TEST FOR DRUGS THAT PREDICTS THE LIKELIHOOD OF HUMAN PHYSICAL DEPENDENCE.

SPECIFIC LOCALIZATION OF DRUGS AT THE HYPOPHYSIS LEVEL AND SIDE-EFFECTS: THE CASE OF NEUROLEPTICS.

ADENYLATE-CYCLASE FROM VARIOUS DOPAMINERGIC AREAS OF THE BRAIN AND THE ACTION OF ANTIPSYCHOTIC DRUGS.

INTERACTIONS OF SUBSTITUTED BENZAMIDE DRUGS WITH CEREBRAL DOPAMINE PATHWAYS.

000077 01-03 CENTRALLY ACTIVE DRUGS AND THE SYMPATHETIC NERVOUS SYSTEM OF RABBITS AND CATS.

000078 01-03 THE NUCLEUS-ACCUMBENS -- POSSIBLE SITE OF ANTIPSYCHOTIC ACTION OF NEUROLEPTIC DRUGS?

000085 01-03 DRUGS ALTERING INSULIN SECRETION: EFFECTS ON PLASMA AND BRAIN CONCENTRATIONS OF AROMATIC-AMINO-ACIDS AND ON BRAIN 5 HYDROXYTRYPTAMINE TURNOVER.

000088 01-03 MEMBRANE LIPIDS AS INTRACELLULAR BINDERS OF CHLORPROMAZINE AND RELATED DRUGS.

000095 01-03 STRESS-INDUCED ALTERATIONS OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN: EFFECTS OF CENTRALLY ACTING DRUGS.

000097 01-03 TRICYCLIC ANTIDEPRESSANT DRUGS BLOCK HISTAMINE H2 RECEPTOR IN

000128 01-03 REGIONAL DIFFERENCES IN THE SENSITIVITY OF CHOLINERGIC NEURONS TO DOPAMINERGIC DRUGS AND QUIPAZINE IN THE RAT STRIATUM. 000134 01-03

THE DEMONSTRATION IN VIVO OF SPECIFIC BINDING SITES FOR NEUROLEPTIC DRUGS IN MOUSE BRAIN. 000150 01-03 Psychopharmacology Abstracts

ACETYLCHOLINE AND CHOLINE IN MOUSE BRAIN -- INFLUENCE OF PERIPHERALLY ACTING CHOLINERGIC DRUGS.

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM — IV. TOLERANCE TO OXOTREMORINE IN MICE: IN VIVO AND IN VITRO STUDIES.

INFLUENCE OF INJECTED PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE BRAIN AND LUNG FOLLOWING MICROWAVE IRRADIATION. 000214 01-03

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM — III. TOLERANCE TO PHENCYCLIDINE DERIVATIVES: IN VIVO AND IN VITRO STUDIES.

000224 01-03 EFFECTS OF PSYCHOTROPIC DRUGS ON NEUROTUBULE ASSEMBLY 000225 01-03

UPTAKE INHIBITION OF BIOGENIC AMINES BY NEWER ANTIDEPRESSANT DRUGS: RELEVANCE TO THE DOPAMINE HYPOTHESIS OF DEPRESSION. 000232 01-03

TRICYCLIC ANTIDEPRESSANTS AS ANTIMUSCARINIC DRUGS: IN VIVO AND IN VITRO STUDIES. 000235 01-03

GRANULAR AND EXTRAGRANULAR ACTION OF PSYCHOTROPIC DRUGS ON MONOAMINERGIC NEURONS. 000252 01-03

INHIBITION OF PROSTAGLANDIN SYNTHETASE SYSTEM IN THE RABBIT RENAL MEDULLA BY PSYCHOTROPIC DRUGS. 000281 01-03

TYRAMINE BINDING BY SYNAPTOSOMES FROM RAT BRAIN: EFFECT OF CENTRALLY ACTIVE DRUGS.

EFFECTS OF ANTICHOLINERGIC AND CHOLINESTERASE BLOCKING DRUGS ON APPETITIVE BEHAVIOR UNDER DIFFERENT DEPRIVATION CONDITIONS.

MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND MORADRENERGIC NEURONS IN NORMAL AND BRAIN LESIONED RATS.

000312 01-04

USE OF DIL IN DIFFERENTIATING ANXIOLYTIC AND NEUROLEPTIC PROPERTIES OF CNS DRUGS. EFFECTS OF CHOLINOMIMETIC DRUGS AND THEIR ANTAGONISTS INJECTED INTO VERTEBRAL ARTERY OF UNANAESTHETIZED DOGS.

000375 01-04 EFFECTS OF CATECHOLAMINERGIC DRUGS UPON MEMORY STORAGE PROCESSES IN MICE.

ANTAGONISM BY CHOLINERGIC DRUGS OF BEHAVIOURAL EFFECTS IN CATS OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC DRUG AND ENHANCEMENT BY NICOTINE. 000404 01-04

REWARD ENHANCEMENT BY PSYCHOMOTOR STIMULANT DRUGS.
000440 01-04 POTENTIATION OF BRAIN REWARD MECHANISMS BY PSYCHOMOTOR STIMULANT DRUGS.

000441 01-04 OLFACTO BULB ABLATION IN THE RAT: BEHAVIOURAL CHANGES AND THEIR REVERSAL BY ANTIDEPRESSANT DRUGS.

000466 01-04 BLOCKADE OF INTRACRANIAL SELF-STIMULATION BY ANTIPSYCHOTIC DRUGS: FAILURE TO CORRELATE WITH CENTRAL ALPHA-NORADRENERGIC BLOCKADE.

000475 01-04 INTERACTION OF DRUGS WITH APOMORPHINE, TRYPTAMINE AND NOREPINEPHRINE. A NEW IN VIVO APPROACH: THE ATN-TEST IN RATS.

000502 01-06 ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND RELATED DRUGS ON THE TREATMENT OF SCHIZOPHRENIA.

ANTISCHIZOPHRENIC DRUGS -- MEMBRANE RECEPTOR SITES OF ACTION.
000547 01-08

PSYCHOTHERAPY IN COMBINATION WITH ANTIDEPRESSANT DRUGS IN PATIENTS WITH SEVERE MASKED DEPRESSIONS.

000572 01-09 CURRENT THERAPEUTIC CONCEPTS: CONTEMPORARY DRUGS IN THE MANAGEMENT OF ANXIETY.

000600 01-10 ANTIANXIETY DRUGS: CLINICAL PHARMACOLOGY AND THERAPEUTIC

000603 01-10 THE USE OF PSYCHOTROPIC DRUGS IN CHILDREN.

PSYCHOSES PRECIPITATED BY PSYCHOTOMIMETIC DRUGS: A FOLLOW-UP

THE USE OF PSYCHEDELIC DRUGS IN THE TREATMENT OF SEVERELY DISTURBED CHILDREN: A REVIEW.

000678 01-12

001386 02-04

001461 02-04

PROFILES OF PSYCHEDELIC DRUGS: 4. HARMALINE.	000/81 01 10
PSYCHOTROPIC DRUGS: INFLUENCE ON RESPIRATORY FUN	
ON THE DISTRIBUTION OF DRUGS IN SALIVA AND BLOOD	000692 01-13 PLASMA.
INFLUENCE OF THE ANTIPARKINSONIAN DRUGS ON THE PL OF NEUROLEPTICS.	
EFFECTIVENESS OF PSYCHOTROPIC DRUGS IN PATIENTS IN MALNUTRITION OR EXPOSED TO EXTREME CLIMATIC CO	000700 01-13 A STATE OF ONDITIONS. 000721 01-13
CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO PSYCHOTROPIC DRUGS.	0
THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE HI AS AN OBJECTIVE METHOD TO STUDY THE EFFECTS OF ACTING DRUGS.	000729 01-13 JMAN BRAIN CENTRALLY
LONG-TERM TREATMENT WITH NEUROLEPTIC DRUGS.	000747 01-14
EFFECT OF NEUROTROPIC DRUGS ON SLEEP DISTURBANCES ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN (CATS.
UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: I DRUGERESSION.	
UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: III DRI DEPRESSION.	100000000000000000000000000000000000000
UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: II DRU SCHIZOPHRENIA.	
UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: IV DR ANXIETY.	
UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: V OTH TREATMENT AND PREVENTION.	000829 01-15 IER DRUGS,
CATATONIC REACTIONS TO HIGH-POTENCY NEUROLEPTIC I	
THE RISKS OF SEX HORMONES AS DRUGS.	000835 01-15
DRUGS AND THE OLD.	000850 01-15
ABUSE OF ANTIPARKINSONIAN DRUGS BY PSYCHIATRIC P	000855 01-15 ATIENTS.
POISONING WITH TRICYCLIC ANTIDEPRESSANT DRUGS.	000856 01-15
CARDIOTOXIC DRUGS, WITH SPECIAL ATTENTION TO PHEN AND IMIPRAMINE DERIVATIVES.	000860 01-15 IOTHIAZINES
PSYCHOTROPIC DRUGS AND INTESTINAL PARALYSIS.	000868 01-15
THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUINEPORT) EFFECTS ON PUPIL FUNCTIONING.	
THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUINEPORT).	
EPILEPTIC SEIZURES INDUCED BY PSYCHOTROPIC DRUGS.	000878 01-15
STUDIES ON THE INFLUENCE OF BIOGENIC AMINES AND PS DRUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMU	
ENDOGENOUS DEPRESSION. CLASSIFICATION AND DETERMINATION OF CEREBRAL BIOA	000926 01-16
OF PSYCHOTROPIC DRUGS BY QUANTITATIVE PHARMAI PSYCHOMETRIC INVESTIGATIONS (STUDIES WITH AX-A	
PSYCHIATRIC DRUGS IN MEDICAL PRACTICE.	000946 01-17
PSYCHIATRIC DRUGS FOR THE NONMEDICAL MENTAL HEAT IMPURITIES IN DRUGS I: IMIPRAMINE, DESIPRAMINE, AN	LTH WORKER. 000953 01-17
FORMULATIONS.	000964 01-17
NOTES ON EXPERIMENTS WITH DRUGS IN PSYCHIATRY.	000971 01-17
PSYCHOTROPIC DRUGS AND ROAD ACCIDENTS.	000988 01-17
ON THE CONFORMATION OF NEUROLEPTIC DRUGS IN THE AGGREGATION STATES AND THEIR CONFORMATIONAL TO DOPAMINE.	THREE
RATIONAL PRESCRIBING OF DRUGS.	000990 01-17
TOTAL I RESCRIBITO OF BROOM.	000993 01-17

INCREASED PRESCRIBING OF VALIUM, LIBRIUM, AND OTHER DRUGS — AN EXAMPLE OF THE INFLUENCE OF ECONOMIC AND SOCIAL FACTORS ON THE PRACTICE OF MEDICINE. MODIFICATION OF THE TIME-COURSE OF DMPEA TOXICITY IN THE MOUSE BY CENTRALLY ACTING DRUGS. COMPETITIVE BINDING BETWEEN COCAINE AND VARIOUS DRUGS TO SYNTHETIC LEVODOPA MELANIN EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. I. CHLORPROMAZINE AND PROMETHAZINE. 001068 02-03 EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS. OO1103 02-03
ANTIPSYCHOTIC DRUGS BLOCK LSD-INDUCED DISAGGREGATION OF BRAIN POLYSOMES. 001147 02-03 THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS. BIOCHEMICAL INTERACTION BETWEEN ANORECTIC DRUGS AND PIRIBEDIL. 001154 02-03 SELECTIVITY OF H3-BIOGENIC AMINE RELEASE BY D.L AMPHETAMINE AND DRUGS THAT INTERACT WITH SEROTONERGIC NEURONS. EFFECT OF PSYCHOTROPIC DRUGS ON ATPASE TRANSPORT OF THE SARCOPLASMIC RETICULUM IN RABBIT SKELETAL MUSCLES. 001174 02-03 THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LOCAL CEREBRAL GLUCOSE UTILISATION OF THE RAT. MONOSYNAPTIC ACTIVATION OF FASCIA-DENTATA IN UNRESTRAINED RATS: RESPONSE MODIFICATION BY SYNAPTICALLY ACTIVE DRUGS BLOCKADE BY PSYCHOTROPIC DRUGS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR IN CULTURED NERVE CELLS. EFFECT OF NOMIFENSINE AND OTHER ANTIDEPRESSANT DRUGS ON ACETYLCHOLINE TURNOVER IN VARIOUS AREAS OF RAT BRAIN 001225 02-03 EFFECTS THE HYPNOTICS AND ANTIANXIETY DRUGS ON ACETYLCHOLINE (ACH) CONCENTRATIONS IN DISCRETE AREAS OF THE RAT BRAIN 001239 02-03 THE EFFECT OF ANTIPSYCHOTIC DRUGS AND THEIR CLINICALLY INACTIVE ANALOGS ON DOPAMINE METABOLISM 001250 02-03 EFFECT OF TWO NON TRICYCLIC ANTIDEPRESSANT DRUGS ON C14-5 HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS. 001283 02-03 EFFECTS OF ANTINOCICEPTIVE DRUGS ON THE DORSAL ROOT POTENTIAL IN THE RAT DRUGS AND THE PRODUCTION OF TEMPORAL INTERVALS IN THE RAT. 001299 02-04 001285 02-03 SENSITIVITY TO PSYCHOACTIVE DRUGS AND THE SEROTONERGIC NEURONAL SYSTEM. 001302 02-04 EFFECTS OF ANTIPSYCHOTIC AND ANTIANXIETY DRUGS ON THE MORPHINE ABSTINENCE SYNDROME IN RATS. 001303 02-04 THE EFFECTS OF PSYCHOTOMIMETIC DRUGS ON THE CONDITIONED EMOTIONAL RESPONSE. 001308 02-04 INFLUENCE OF NEUROTROPIC DRUGS ON CHANGES OF EVOKED-POTENTIALS AMPLITUDES AFTER STIMULATION OF THE HYPOTHALAMUS. 001318 02-04 INFLUENCE OF SOME NEUROPSYCHOTROPIC DRUGS ON THE BEHAVIOURAL MODIFICATIONS INDUCED BY 3 ACETYLPYRIDINE IN 001358 02-04 A COMPARISON OF THALIDOMIDE AND PENTOBARBITA METHODS FOR IDENTIFYING NOVEL HYPNOTIC DRUGS. 001359 02-04 COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON BEHAVIOR OF INTERACTIONS BETWEEN ALCOHOL AND OTHER DRUGS ON OPEN-FIELD AND TEMPERATURE MEASUREMENTS IN GERBILS.

DRUGS AFFECTING DOPAMINE NEURONS AND YAWNING BEHAVIOR. 001422 02-04 TRICYCLIC ANTIDEPRESSANT DRUGS: ANTAGONISM OF EFFECT OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON SHOCK ELICITED

AGGRESSION.

EFFECTS ON HYPOTHALAMIC SELF-STIMULATION OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION INJECTED INTO NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM OF RATS. COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON ROTATIONAL BEHAVIOR IN RATS WITH UNILATERAL 6 HYDROXYDOPAMINE LESIONS. 001477 02-04 DO DRUGS ACTING ON THE NERVOUS SYSTEM AFFECT CELL PROLIFERATION IN THE DEVELOPING BRAIN? 001512 02-05 CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO
ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC
EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE
ANTIPSYCHOTIC DRUGS. 001526 02-06 THE HIPPOCAMPAL SLICE: A SYSTEM FOR STUDYING THE PHARMACOLOGY OF SEIZURES AND FOR SCREENING ANTICONVULSANT 001538 02-06 SOME PROBLEMS CONCERNING THE TECHNIQUES OF STUDYING THE EFFECTIVENESS OF PSYCHOTROPIC DRUGS. 001540 02-06 THE PNEUMATIC SYRINGE: A SIMPLE APPARATUS FOR SELF-ADMINISTRATION OF DRUGS BY RATS. 001541 02-06 NEW ANTIPSYCHOTIC DRUGS 001562 02-08 EXPERIENCES WITH THE CONTINUED USE OF PSYCHOTROP DRUGS. 001567 02-08 DRUGS AND DEPRESSION: DOSAGE AND BLOOD LEVEL MONITORING 001595 02-09 STUDIES OF APPLICATION OF STATISTICS TO THE METHODOLOGY OF DRUGS ACTING ON THE BRAIN. 001620 02-11 PSYCHOTROPIC DRUGS: MECHANISM OF ACTION AT THE NEUROTRANSMITTER LEVEL. 001684 02-13 TRICYCLIC ANTIDEPRESSANT DRUGS AND CARDIAC CONDUCTION. 001751 02-15 TIMING AND RISK OF BONE MARROW DEPRESSION BY PSYCHOTROPIC DRUGS. 001770 02-15

EEG OBSERVATION OF NOCTURNAL DELIRIUM IN A PATIENT TAKING ANTIDEPRESSANTS AND ANTIPARKINSONS DRUGS. 001773 02-15 OBESITY RELATED TO THE USE OF PSYCHOTROPIC DRUGS, CONSIDERED IN ITS PSYCHODYNAMIC ASPECT.

OD1802 02-15
OBESITY RELATED TO THE USE OF PSYCHOTROPIC DRUGS. CONSIDERED IN ITS ORGANIC ASPECT.

001803 02-15 INFLUENCES OF ANTIANXIETY DRUGS ON PERCEPTION.

SYNDROME MALIN SYMPTOMS THOUGHT TO BE DUE TO INTERACTION BETWEEN NEUROLEPTICS AND ORAL DIABETES DRUGS. 001854 02-15

ON LONG-TERM MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY: THE COMBINED ADMINISTRATION OF ANTIPARKINSONS DRUGS.

001865 02-16 GUIDELINES FOR NURSES: THE ADMINISTRATION OF INTRAVENOUS DRUGS THROUGH AN ESTABLISHED INTRAVENOUS PATHWAY.

001866 02-16 THE PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS. A TEST OF DOPAMINERGIC BLOCKADE: NEUROENDOCRINE STUDIES IN NORMAL

001867 02-16 A REEXAMINATION OF USING ANTIPARKINSONS DRUGS WITH PSYCHOTROPIC DRUG THERAPY -- A SURVEY OF OUTPATIENTS

001874 02-16 STIMULANT DRUGS AND LEARNING PROBLEMS.

001877 02-17 THE DIFFICULTIES OF OLD PEOPLE TAKING DRUGS. 001878 02-17

THE CONTRIBUTION OF PRESCRIBED DRUGS TO THE INCIDENCE OF ACCIDENTAL AND DELIBERATE POISONING IN THE COMMUNITY 001896 02-17

NOOTROPIC DRUGS. 001899 02-17

COMBINED SEMINAR ON THE USE OF DRUGS IN RENAL FAILURE. 001902 02-17

NOW RCA ATTACKS MEMORY AID DRUGS. INVOLUNTARY ADMINISTRATION OF PSYCHOTROPIC DRUGS — GROUNDS FOR SUIT. SOUDER V. MCGUIRE, 423 F. SUPP. 830, (PENNSYLVANIA). M.D. DISTRICT COURT. DECEMBER 9, 1976.

001916 02-17 **GUIDELINES TO REDUCE MISUSE OF DRUGS** 001917 02-17

BETA-ADRENOCEPTOR BLOCKING DRUGS 001925 02-17

Psychopharmacology Abstracts

PSYCHOTROPIC DRUGS IN PSYCHIATRY.

001931 02-17

RATIONALITY OF APPEALS USED IN THE PROMOTION OF PSYCHOTROPIC DRUGS. A COMPARISON OF MALE AND FEMALE MODELS. 001932 02-17 CLINICAL STUDY OF ANTIPARKINSON DRUGS USED TOGETHER WITH PSYCHOTROPIC DRUGS.

001936 02-17 RURAL URBAN DIFFERENCES IN THE USE OF STRESS ALLEVIATIVE DRUGS 001938 02-17

PSYCHOTROPIC DRUGS IN CHILD AND ADOLESCENT PSYCHIATRY 001939 02-17 INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A
METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS.

001959 03-02 EFFECT OF PSYCHOTROPIC DRUGS ON 3,4 DIHYDROXYPHENYLACETIC-ACID (DOPAC) CONTENT IN THE MEDIAL BASAL HYPOTHALAMUS.

001962 03-03 SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL CORRELATES.

ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

EFFECT OF ANTIPARKINSONISM DRUGS ON GASTRIC EMPTYING AND INTESTINAL TRANSIT IN THE RAT.

DOPAMINE RECEPTORS AND ERGOT DRUGS. EVIDENCE THAT AN ERGOLENE DERIVATIVE IS A DIFFERENTIAL AGONIST AT SUBCORTICAL LIMBIC DOPAMINE RECEPTORS.

002019 03-03 STUDIES ON THE SUBSYNAPTOSOMAL DISTRIBUTION OF PSYCHOTROPIC DRUGS IN RAT CEREBRAL-CORTEX.

002045 03-03 ELECTROENCEPHALOGRAM AND SOMATOSENSORY EVOKED-POTENTIAL CHANGES AFTER ADMINISTRATION OF SIX CONVULSANT DRUGS.

002055 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS: 3 SUBCELLULAR DISTRIBUTION OF NEUROLEPTIC DRUGS AND THEIR RECEPTORS IN VARIOUS RAT BRAIN AREAS.

002067 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 2. REGIONAL DISTRIBUTION AND IN VIVO DISPLACEMENT OF NEUROLEPTIC DRUGS.

DESIPRAMINE AND SOME OTHER ANTIDEPRESSANT DRUGS DECREASE THE MAJOR NOREPINEPHRINE METABOLITE 3,4
DIHYDROXYPHENYLGLYCOL-SULFATE IN THE RAT BRAIN.

002114 03-03 EFFECTS OF DRUGS ON GAMMA-AMINOBUTYRIC-ACID RECEPTORS, UPTAKE, RELEASE AND SYNTHESIS IN VITRO.

002122 03-03 ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. II. CROSS-TOLERANCE BETWEEN PHENCYCLIDINE DERIVATIVES AND CHOLINERGIC DRUGS.

002126 03-03 ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. I. TOLERANCE TO PHENCYCLIDINE DERIVATIVES IN MICE: PHARMACOLOGICAL CHARACTERIZATION.

ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002137 03-03 ANTAGONISM BY MIANSERIN AND CLASSICAL ALPHA-ADRENOCEPTOR BLOCKING DRUGS OF SOME CARDIOVASCULAR AND BEHAVIORAL EFFECTS OF CLONIDINE.

002138 03-03 EFFECTS OF BIOGENIC AMINES AND PSYCHOTROPIC DRUGS ON ENDOGENOUS PROSTAGLANDIN BIOSYNTHESIS IN THE RAT BRAIN

RECEPTOR AFFINITY AND PHARMACOLOGICAL POTENCY OF A SERIES OF NARCOTIC ANALGESIC, ANTIDIARRHEAL AND NEUROLEPTIC DRUGS.

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION.

002164 03-03 METABOLISM OF 5 HYDROXYTRYPTAMINE AND LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS IN RAT BRAIN AFTER ACUTE AND CHRONIC TREATMENT.

EFFECT OF PSYCHOTROPIC DRUGS ON THE DEVELOPMENT OF DEFENSE CONDITIONED REFLEX DURING EXPERIMENTAL NEUROSIS. 002204 03-04

002658 03-15

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D AMPHETAMINE ON SELF-STIMULATION OF THE SUBSTANTIA-NIGRA AND LOCUS-COERULEUS.

002218 03-04
EFFECTS OF STIMULANTS, ANORECTICS, AND RELATED DRUGS ON
SCHEDULE-CONTROLLED BEHAVIOR.

002243 03-04
RATE-DEPENDENT AND STIMULUS CONTROL EFFECT OF DRUGS.
002246 03-04

THE EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY AND STEREOTYPED BEHAVIOUR OF RATS STUDIED ON A HOLE-BOARD. 02274 03-04

EFFECT OF NEUROLEPTIC DRUGS ON THE CONDITIONED BEHAVIOR AFTER PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: THE EFFECT OF PREMEDICATION WITH CYSTAMINE ON PHARMACODYNAMICS AND PHARMACOKINETICS OF NITRAZEPAM.

002317 03-04
INTRAVENOUS SELF-ADMINISTRATION OF DRUGS IN RATS.

CHANGES IN PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECTS OF PREMEDICATION WITH CYSTAMINE ON DYNAMICS AND KINETICS OF THIORIDAZINE.

SCREENING FOR THE EFFECTS OF DOPAMINERGIC AND ANTIDOPAMINERGIC DRUGS ON SERUM PROLACTIN LEVELS BY RADIOIMMUNOASSAY.

002340 03-05

A METHOD FOR MECHANOGRAPHICAL RECORDING OF MUSCLE TONE IN
THE RAT: THE EFFECT OF SOME ANTIPARKINSONIAN DRUGS ON
RIGIDITY INDUCED BY RESERPINE.

O02346 03-05
PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC
DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF
PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF
THIORIDAZINE.

O02348 03-05
PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC
DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF
PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF
NITRAZEPAM.

O02358 03-0: SCREENING HALLUCINOGENIC DRUGS. II. SYSTEMATIC STUDY OF TWO BEHAVIORAL TESTS.

002361 03-06
NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY EFFECTS OF
DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF
KETAMINE

002362 03-06
NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY THE EFFECTS OF
DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF
PENTOBARBITAL.

002363 03-06
EFFECT OF AN ANTIPSYCHOTIC AND OTHER CLASSES OF DRUGS ON SPONTANEOUS LOCOMOTOR ACTIVITY AND NEUROTOXICITY IN MICE.

O02369 03-06
A VARIABLE-INTERVAL PUNISHMENT PROCEDURE FOR ASSESSING
ANXIOLYTIC EFFECTS OF DRUGS.

GRADUAL REDUCTION OF NEUROLEPTIC DRUGS AMONG CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY.

SELECTED COMBINATIONS OF AMITRIPTYLINE AND ANTIPSYCHOTIC DRUGS AND COMPLEX LEARNING.

002434 03-09
BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS: ASSAY
PROCEDURES, REPRODUCIBILITY AND RELATIONSHIP TO THERAPEUTIC
OUTCOME AND SIDE-EFFECTS.

002440 03-09
INITIAL RESPONSE TO DRUGS IN DEPRESSIVE ILLNESS AND PSYCHIATRIC
AND COMMUNITY ADJUSTMENT A YEAR LATER.

MODE OF ACTION OF ANTIDEPRESSANT DRUGS. 002459 03-09

O02466 03-09
A REVIEW OF THE RELATIONSHIP BETWEEN ENDOCRINOPATHY AND DEPRESSION OR ANTIDEPRESSANT DRUGS, WITH PARTICULAR RESPECT

A REVIEW OF THE RELATIONSHIP BETWEEN ENDOCKIND/AITHY AND DEPRESSION OR ANTIDEPRESSANT DRUGS, WITH PARTICULAR RESPECT TO NOVEL THEORIES INVOLVING THE OPIATE RECEPTOR.

PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS IN NORMAL AND

SCHIZOPHRENIC SUBJECTS.

002575 03-13

EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON PLASMA LEVELS
OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DEPRESSIVE
PATIENTS RECEIVING CLOMIPRAMINE THERAPY.

PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS: AN APPROACH TO THE STUDY OF BRAIN DOPAMINE BLOCKADE IN HUMANS.

EFFECTS OF CENTRALLY ACTING DRUGS ON BRAINSTEM AUDITORY
RESPONSES.

O02598 03-13
ON THE ACUTE EFFECT OF SOME DRUGS ON HIGHER NERVOUS ACTIVITY
IN MAN FOLLOWED UP BY THE LABORATORY LANGUAGE METHOD.
002623 03-14

ACUTE POISONINGS DUE TO DRUGS IN THE POLISH PROVINCE OF OLSZTYN FROM 1971 TO 1974.

ANTIPSYCHOTIC DRUGS: CLINICAL PHARMACOLOGY AND THERAPEUTIC USE PART II.

WITHDRAWAL PSYCHOSIS AFTER DRUGS.

O02663 03-15

AMANTADINE IN THE TREATMENT OF BENZTROPINE REFRACTORY
EXTRAPYRAMIDAL DISORDERS INDUCED BY ANTIPSYCHOTIC DRUGS.
002664 03-15

LITHIUM INTOXICATION MASKED BY NEUROLEPTIC DRUGS WHEN LITHIUM DIURETIC COMBINATIONS ARE USED. 002682 03-15

RETENTION OF URINE IN THE NEONATE POSSIBLY DUE TO ANTICONVULSANT DRUGS.

O02683 03-15
AUTONOMOUS NERVOUS FUNCTION OF LONG-TERM USERS OF
PSYCHOTROPIC DRUGS, THIRD REPORT -- PUPILOGRAM
OBSERVATIONS.

DRUGS THAT MAY INDUCE PULMONARY DISEASE. 002690 03-15

O02694 03-15
STRESS AND THE HEART: INTERACTIONS OF THE CARDIOVASCULAR
SYSTEM, BEHAVIORAL STATE, AND PSYCHOTROPIC DRUGS.

THE USE OF THE CNV (CONTINGENT NEGATIVE VARIATION) IN THE DETERMINATION OF RESIDUAL EFFECTS OF FIVE HYPNOTIC DRUGS. 002713 03-16

A SIMPLE AND SENSITIVE RADIORECEPTOR ASSAY FOR ANTISCHIZOPHRENIC DRUGS IN BLOOD.

O02715 03-16

A MODEL FOR EVALUATION OF ANTIANXIETY DRUGS WITH THE USE OF
EXPERIMENTALLY-INDUCED STRESS: COMPARISON OF NABILONE AND

PROFILES OF PROLACTIN RESPONSE TO ANTIPSYCHOTIC DRUGS: SOME METHODOLOGIC CONSIDERATIONS.

THE USE OF PSYCHOTROPIC DRUGS IN STATE HOSPITALS: A LEGAL OR AMEDICAL DECISION?

002730 03-17
CENTRAL CATECHOLAMINE NEUROTRANSMITTERS AND PSYCHOACTIVE DRUGS.

PSYCHOACTIVE DRUGS AND SOCIETY. 002731 03-17

002734 03-17
ANTIPSYCHOTIC DRUGS, NEUROTRANSMITTERS, AND SCHIZOPHRENIA.
002736 03-17
BIOCHEMICAL ACTIONS OF NEUROLEPTIC DRUGS: FOCUS ON THE

DOPAMINE RECEPTOR. 002738 03-17

COMPREHENSIVE CLINICAL STUDIES OF PSYCHOTROPIC DRUGS.

002756 03-17
INTERNATIONAL GUIDELINES FOR CLINICAL TRIALS OF PSYCHOTROPIC

PSYCHOACTIVE DRUGS. 002769 03-17

USE OF MOOD-ALTERING DRUGS IN TREATING SEXUAL PROBLEMS.

002780 03-17
PEDIATRIC PSYCHOPHARMACOLOGY: THE USE OF BEHAVIOR MODIFYING DRUGS IN CHILDREN.

USE OF PSYCHOTROPIC DRUGS TO ALTER PSYCHIC STATES.

002784 03-17

INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A
METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS.
002801 04-02

RESPONSES OF THE PITUITARY ADRENAL SYSTEM OF THE PIG TO ENVIRONMENTAL CHANGES AND DRUGS.

O02833 04-03
REVERSAL OF THE ACTION OF AMINO-ACID ANTAGONISTS BY

BARBITURATES AND OTHER HYPNOTIC DRUGS.

O02838 04-03
THE ACTION OF CNS DRUGS ON AN ISOLATED SYMPATHETIC NERVE

PREPARATION OF RABBIT. 002869 04-03

EFFECTS OF PSYCHOTROPIC DRUGS ON DEAMINASE IN CNS.
002904 04-03

DRUGS AFFECTING THE CENTRAL-NERVOUS-SYSTEM: EFFECTS OF PEMOLINE, AND TRICYCLIC ANTIDEPRESSANTS ON NERVE TERMINAL

002577 03-13

ADENOSINE-TRIPHOSPHATASE ACTIVITIES AND NEUROTRANSMITTER 002923 04-03 NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND L-002942 04-03 RAT STRIATAL METHIONINE-ENKEPHALIN CONTENT AFTER CHRONIC TREATMENT WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTISCHIZOPHRENIC DRUGS. A BEHAVIOURAL AND BIOCHEMICAL COMPARISON OF DOPAMINE RECEPTOR BLOCKAGE PRODUCED BY HALOPERIDOL WITH THAT PRODUCED BY SUBSTITUTED BENZAMIDE DRUGS. EFFECTS OF ESTROGEN AND AMINERGIC DRUGS ON THRESHOLDS OF MEDIAL BASAL HYPOTHALAMIC AXONS IN THE MEDIAN EMINENCE OF 002974 04-03 CHARACTERIZATION OF SPECIFIC IN VIVO BINDING OF NEUROLEPTIC DRUGS IN RAT BRAIN. 002985 04-03 THE EFFECT OF DRUGS WHICH ALTER GABAERGIC FUNCTION ON CEREBELLAR GUANOSINE-MONOPHOSPHATE CONTENT. 002993 04-03 A COMPARISON OF THE EFFECTS OF ANTIPSYCHOTIC DRUGS ON PITUITARY, STRIATAL AND LIMBIC SYSTEM POSTSYNAPTIC DOPAMINE RECEPTORS. 003009 04-03 EFFECT OF SUBSTITUTED BENZAMIDE DRUGS ON RAT STRIATAL TYROSINE-HYDROXYLASE. 003018 04-03 INHIBITION OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RAT STRIATUM BY NEUROLEPTIC DRUGS ADMINISTERED IN VIVO. 003027 04-03 AFFINITIES OF DRUGS FOR THE AGONIST AND ANTAGONIST STATES OF THE DOPAMINE RECEPTOR. 003065 04-03 CENTRAL MECHANISMS OF DRUGS AS DISCRIMINATIVE STIMULI: INVOLVEMENT OF SEROTONIN PATHWAYS. 003070 04-03 HIGH-AFFINITY H3-SEROTONIN BINDING TO CAUDATE: INHIBITION BY HALLUCINGENS AND SEROTONINERGIC DRUGS. 003138 04-03 POTENTIAL ROLES OF ENDOGENOUS PEPTIDES IN THE DISCRIMINATIVE PROPERTIES OF DRUGS. DISCRIMINATIVE STIMULUS PROPERTIES OF NARCOTIC ANALGESIC

003187 04-04 DRUGS 003190 04-04 CHANGES OF SENSITIVITY TO THE CUING PROPERTIES OF NARCOTIC DRUGS AS EVIDENCED BY GENERALIZATION AND CROSS-GENERALIZATION EXPERIMENTS. 003194 04-04

EXPLORATION IN IMMATURE RATS: EFFECTS OF DRUGS. 003218 04-04 RELATIONSHIP BETWEEN ANORECTIC AND REINFORCING PROPERTIES OF APPETITE SUPPRESSANT DRUGS: IMPLICATIONS FOR ASSESSMENT OF 003236 04-04

COCAINE AS A DISCRIMINATIVE CUE IN RATS: INTERACTIONS WITH NEUROLEPTICS AND OTHER DRUGS. 003250 04-04 PSYCHOTROPIC DRUGS AND SIDMAN AVOIDANCE IN RATS: IRT

DISTRIBUTION CHANGES. 003269 04-04

DIFFERENTIAL RESPONDING CONTROLLED BY THE DISCRIMINATIVE STIMULI PRODUCED BY CONVULSANT DRUGS IN THE RAT.

MOTOR ACTIVITY OF RATS FOLLOWING INTRACEREBRAL INJECTIONS OF DRUGS INFLUENCING GABA MECHANISMS. 003387 04-04

COMMON DRUGS SEEN AS POTENTIAL CARCINOGENS 003416 04-05

LONG-ACTING ORAL VS INJECTABLE ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENICS: A ONE-YEAR DOUBLE-BLIND COMPARISON IN MULTIPLE EPISODE SCHIZOPHRENICS.

003467 04-08 TREATMENT OF DEPRESSION WITH DRUGS 003500 04-09

THE PERILS OF PRESCRIBING PSYCHOTROPIC DRUGS 003504 04-09 DRUGS AND DEPRESSION

003531 04-09 ANTIHYPERTENSIVE DRUGS AND DEPRESSION: A REAPP

003534 04-10 TREATMENT OF ALCOHOLISM WITH PSYCHOTOMIMETIC DRUGS. A FOLLOW-UP STUDY. 003570 04-11

Psychopharmacology Abstracts

003625 04-14

EFFECT OF DRUGS ON HUMAN ERYTHROCYTES — 4. PROTECTING EFFECT OF DEXTRAN ON DRUG-INDUCED HEMOLYSIS.

003603 04-13 BIOCHEMICAL EFFECTS IN MAN AND RAT OF THREE DRUGS WHICH CAN INCREASE BRAIN GABA CONTENT. 003604 04-13

STIMULUS ATTRIBUTES OF DRUGS

DRUGS AND REINFORCEMENT MECHANISMS: A CRITICAL REVIEW OF THE CATECHOLAMINE THEORY.

PHARMACOKINETICS AND PSYCHOTROPIC DRUGS.

003649 04-15 WITHDRAWAL SYNDROMES ASSOCIATED WITH ANTIPSYCHOTIC DRUGS. 003655 04-15

LIPIDOSIS INDUCED BY AMPHIPHILIC CATIONIC DRUGS

003664 04-15
PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATIENTS DURING LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS: DISSOCIATION BETWEEN LIGHT AND NEAR VISION REACTIONS.

003673 04-15 THE USE OF DRUGS AS DISCRIMINATIVE STIMULI IN BEHAVIORAL PHARMACODYNAMICS.

003695 04-17 **AGGREGATION OF ANTIDEPRESSANT DRUGS IN AQUEOUS SOLUTION** 003697 04-17

PSYCHOTROPIC DRUGS IN PREGNANCY: MORPHOLOGICAL AND PSYCHOLOGICAL ADVERSE EFFECTS ON OFFSPRING.

003708 04-17 THE USE OF PRESCRIPTION DRUGS IN TREATMENT OF FIRST-TIME PSYCHIATRIC ADMISSIONS TO UNIVERSITY HOSPITAL, SASKATOON 003712 04-17

NEUROLEPTIC DRUGS AND NEUROTRANSMITTER RECEPTORS 003728 04-17

DEUNKENNESS

THE PSILOCYBIN-INDUCED STATE OF DRUNKENNESS IN NORMAL VOLUNTEERS AND SCHIZOPHRENICS.

001726 02-14

A TREATMENT FOR DRY MOUTH IN PSYCHIATRIC PATIENTS 002661 03-15

FLUVOXAMINE (DU-23001), A NEW ANTIDEPRESSANT. QUANTITATIVE PHARMACO-ELECTROENCEPHALOGRAPHY AND PILOT CLINICAL TRIALS. 001548 02-07

DUAL RECEPTOR MEDIATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF PENTAZOCINE. 002191 03-04

EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH MORPHOLOGY AND HORMONE PLASMA LEVELS.

000315 01-04 EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: I. BEHAVIOURAL EFFECTS OF INTRAMUSCULAR INJECTIONS.

000316 01-04

QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P-450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3 METHYCHOLANTHRENE.

002083 03-03

DRUG EFFECTS UPON FORCE AND DURATION OF RESPONSE DURING FIXED-RATIO PERFORMANCE IN RATS. 000363 01-04

PLASMA LEVELS OF CHLORPROMAZINE: EFFECT OF AGE, CHRONICITY OF DISEASE, AND DURATION OF TREATMENT.

THE EFFECTS OF SOME PHARMACOLOGICAL AGENTS ON THE DURATION OF IMMOBILITY SHOWN BY RABBITS PLACED IN VARIOUS POSTURES 001355 02-04

AN ATTEMPT TO PREDICT THE DURATION OF PENTOBARBITAL NARCOSIS ON THE BASIS OF EXPLORATORY ACTIVITY, DEFECATION RATE AND BODY WEIGHT OF RATS.

001435 02-04 IMPORTANCE OF DURATION OF DRUG ACTION IN THE ANTAGONISM OF P-CHLOROAMPHETAMINE DEPLETION OF BRAIN SEROTONIN — COMPARISON OF FLUOXETINE AND CHLORIMIPRAMINE. 002017 03-03

STRENGTH DURATION PROPERTIES OF SINGLE UNITS DRIVEN BY
ELECTRICAL STIMULATION OF THE LATERAL HYPOTHALAMUS IN RATS 002763 03-17

BEHAVIORAL CHANGES INDUCED BY 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) IN PRIMATE DYADS

ш			

INTRAPSYCHIC AND FAMILY DYNAMIC PROCESSES IN AN ENDOGENOUS DEPRESSION PRECEDING MANIFESTATION OF THE ILLNESS AND

002461 03-09

002358 03-05

THE BLOOD (SERUM AND CORPUSCLE) DYNAMICS OF TRICYCLIC ANTIDEPRESSANTS.

DYNAMICS OF BLOOD NEUROTRANSMITTER LEVEL AS EVIDENCE OF HIGHER NERVOUS ACTIVITY CHANGES DURING CHRONIC ADMINISTRATION OF SEDUXEN.

001338 02-04 BIPHASIC EFFECTS OF AMPHETAMINE ON STRIATAL DOPAMINE DYNAMICS.

002064 03-03 CHANGES IN PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECTS OF PREMEDICATION WITH CYSTAMINE ON DYNAMICS AND KINETICS OF THIORIDAZINE

002332 03-04 PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF THIORIDAZINE.

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF

DYSARTHRIA: AN UNUSUAL SIDE-EFFECT OF TRICYCLIC ANTIDEPRESSANTS.

000885 01-15 DYSCONTROL

VIOLENT DYSCONTROL RESPONSIVE TO D AMPHETAMINE. 002528 03-11

PHENOTHIAZINE EFFECTS ON PSYCHOLOGICAL AND
PSYCHOPHYSIOLOGICAL DYSFUNCTION IN CHRONIC SCHIZOPHRENICS

000549 01-08
PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD

RESISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWAR SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS THERAPEUTIC APPLICATION. 001737 02-14

PHARMACOLOGICAL AGENTS CAUSING SEXUAL DYSFUNCTION 001829 02-15 BLOOD-BRAIN BARRIER DYSFUNCTION AFTER AMPHETAMINE ADMINISTRATION IN RATS.

002854 04-03

DYSFUNCTIONS

IATROGENIC CAUSES OF NEUROLOGIC DISORDERS: PART 2. DRUG-RELATED DYSFUNCTIONS. 003644 04-15

DYSKINESIA WITH THIOTHIXENE. 000519 01-08 DIPHENHYDRAMINE IN THE DIFFERENTIAL DIAGNOSIS OF NEUROLEPTIC-

INDUCED ORAL FACIAL DYSKINESIA. 000798 01-15

A CASE OF ORAL DYSKINESIA ASSOCIATED WITH IMIPRAMINE TREATMENT. 001768 02-15

MORTALITY OF PATIENTS WITH TARDIVE-DYSKINESIA. DYSKINESIA 002688 03-15 SODIUM VALPROATE IN THE TREATMENT OF LEVODOPA-INDUCED

DYSKINESIA. 003568 04-11

DRUG-INDUCED DYSKINESIA: A CRITICAL REVIEW. 003586 04-13

PREVENTING DRUG-INDUCED DYSKINESIA 003671 04-15

CHRONIC AND ACUTELY INDUCED DYSKINESIAS: A PHARMACOLOGIC DISTINCTION.

001410 02-04 DYSKINESIAS EVOKED IN MONKEYS BY WEEKLY ADMINISTRATION OF

DYSKINETIC TREATMENT OF DYSKINETIC AND CHOREATIC MOVEMENT DISORDERS IN ADULTS. 002776 03-17

A COMPARISON IN RABBIT ISOLATED HEARTS OF THE DYSRHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE. AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK NORADRENALINE UPTAKE

DYSTONIA
ACUTE DYSTONIA AS AN IDIOSYNCRATIC RESPONSE TO NEUROLEPTICS IN

000409 01-04

LARYNGEAL PHARYNGEAL DYSTONIA AS A POSSIBLE CAUSE OF ASPHYXIA WITH HALOPERIDOL TREATMENT. 003654 04-15

DYSTROPHIC

ABSORPTION AND DISTRIBUTION OF SODIUM BARBITAL IN TISSUES OF NORMAL AND DYSTROPHIC MICE.

002162 03-03

EATING

EFFECTS OF MONOSODIUM-GLUTAMATE ON EATING AND DRINKING REHAVIOR IN RATS

000423 01-04 5 HYDROXYTRYPTAMINE DEPLETION WITH P-CHLOROPHENYLALANINE: EFFECTS ON EATING, DRINKING, IRRITABILITY, MURICIDE, AND COPULATION.

000429 01-04 EFFECTS OF CHLORDIAZEPOXIDE ON TAIL PINCH-INDUCED EATING IN

000442 01-04 EATING FOLLOWING CHOLINERGIC STIMULATION OF THE HYPOTHALAMUS.

001326 02-04 THE EFFECTS OF D AMPHETAMINE ON PREY KILLING AND PREY EATING IN THE RAT AND MOUSE.

001361 02-04 EFFECTS OF ANTIESTROGENS ON EATING, FEMALE SEXUAL BEHAVIOR, AND THE UPTAKE OF H3-ESTRADIOL IN THE CENTRAL-NERVOUS-SYSTEM IN RATS. (PH.D. DISSERTATION).

001447 02-04 **ECATRIC** CLINICAL AND PHARMACOKINETIC STUDY OF DIBENZEPINE (ECATRIL):

COMPARISON BETWEEN THE NORMAL AND RETARD FORM 001581 02-09

ECG

PHENOTHIAZINE-INDUCED ECG ABNORMALITIES.

000812 01-15

000723 01-13

ECHOENCEPHALOGRAPHY II. CLINICAL ELECTROENCEPHALOGRAPHY AND ECHOENCEPHALOGRAPHY IN LONG-TERM HASHISH USERS.

ECOG THE EFFECT OF NORADRENALINE ON THE ECOG OF THE PREPARATION

ENCEPHALE ISOLE OF RATS. 001475 02-04 SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT

SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL CORRELATES.

INCREASED PRESCRIBING OF VALIUM, LIBRIUM, AND OTHER DRUGS --AN EXAMPLE OF THE INFLUENCE OF ECONOMIC AND SOCIAL FACTORS ON THE PRACTICE OF MEDICINE.

000995 01-17

A LONG-TERM FOLLOW-UP OF SCHIZOPHRENICS TREATED WITH REGRESSIVE ECT.

000526 01-08 A REASSESSMENT OF TRICYCLICS AND ECT IN DEPRESSION 000571 01-09

EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 2. BIOCHEMICAL ANALYSIS.

001652 02-13 EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 1. CLINICAL ANALYSIS. 001704 02-14

INFLUENCE OF TRYPTOPHAN ON MEMORY FUNCTIONS IN DEPRESSIVE PATIENTS TREATED WITH UNILATERAL ECT. 002613 03-14

PENICILLIN IN THE PYRAMIDAL TRACT: ECTOPIC ACTION POTENTIAL

GENERATION. 002082 03-03

EDEMA EFFECT OF DEXAMETHASONE ON CEREBRAL EDEMA FROM CRANIAL IMPACT IN THE CAT.

001958 03-02 COMPARATIVE EFFECTS OF DIHYDROERGOTOXINE (DHET) ON CBF AND METABOLISM CHANGES PRODUCED BY EXPERIMENTAL CEREBRAL EDEMA, HYPOXIA AND HYPERTENSION.

EDINBURGH

A SEVEN YEAR REVIEW OF COMA PATIENTS ADMITTED TO THE REGIONAL POISONING TREATMENT CENTRE, ROYAL INFIRMARY, EDINBURGH.

001821 02-15

001979 03-03

003391 04-04

000138 01-03

VIDEO EDITING AND MEDICATION TO PRODUCE A THERAPEUTIC SELF-

001707 02-14

THE RESULTS OF A CAMPAIGN TO EDUCATE PHYSICIANS IN ANTIPSYCHOTIC DRUG USAGE.

002761 03-17

EDUCATION

PSYCHOTROPIC AND ANTICONVULSANT DRUG USAGE IN EARLY CHILDHOOD SPECIAL EDUCATION PROGRAMS III. A PRELIMINARY REPORT: PARENT INTERVIEWS ABOUT DRUG TREATMENT.

000627 01-11

TRANSCALLOSALLY EVOKED-POTENTIALS AND THE EEG IN THE DECEREBRATE DOG: ACTIONS OF TRYPTAMINERGIC, DOPAMINERGIC AND ADRENERGIC AGONISTS. 000223 01-03

EEG AND BLOOD PRESSURE EFFECTS OF TRH IN RABBITS.

000319 01-04

ACUTE EEG EFFECTS OF CANNABIS PREPARATIONS IN LONG-TERM HASHISH USERS. 000744 01-13

EEG PROFILE AND BEHAVIORAL CHANGES AFTER A SINGLE DOSE OF CLOZAPINE IN NORMALS AND SCHIZOPHRENICS.

000787 01-14 PHENOBARBITAL AND PHENYTOIN EFFECTS ON SOMATOSENSORY
EVOKED-POTENTIALS AND SPONTANEOUS EEG IN NORMAL CAT BRAIN 001032 02-02

SPECTRAL ANALYSIS OF THE DIFFERING EEG EFFECTS OF BENZODIAZEPINES, MEPROBAMATE, GLUTETHIMIDE AND AMOBARBITAL IN MACACA-MULATTA.

001130 02-03 EEG AND BEHAVIORAL EFFECTS OF D ALA2-MET-ENKEPHALINAMIDE IN THE RAT.

EEG, BLOOD LEVEL, AND BEHAVIORAL EFFECTS OF THE ANTIDEPRESSANT MIANSERIN (ORG-GB-94).

001545 02-07 EFFECTS OF MYSOLINE AND DILANTIN ON THE EEG DURING SMR BIOFEEDBACK TRAINING OF A PSYCHOMOTOR EPILEPTIC: SINGLE CASE

001657 02-13

EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS. 001712 02-14

EEG OBSERVATION OF NOCTURNAL DELIRIUM IN A PATIENT TAKING ANTIDEPRESSANTS AND ANTIPARKINSONS DRUGS.

001773 02-15 THE HUMAN EEG IN SEVERELY POISONED PATIENTS — INDICATION AND CONTROL OF HEMODIALYSIS OR HEMOPERFUSION.

001795 02-15 THE B-MITTEN EEG PATTERN AND TARDIVE-DYSKINESIA: A POSSIBLE ASSOCIATION.

EFFECT OF PAPAVERINE AND DIHYDROERGOTOXINE-MESYLATE ON CEREBRAL MICROFLOW, EEG, AND PO2 IN OLIGEMIC HYPOTENSION 002032 03-03

ALTERATIONS OF EEG ACTIVITIES AND COCAINE-INDUCED CONVULSIONS FOLLOWING PROLONGED COCAINE TREATMENT IN THE RHESUS

002091 03-03 EEG RECORDS AND THE EFFECTS OF PHENOTHIAZINE TREATMENT IN PATIENTS WITH PARANOID SCHIZOPHRENIA.

002394 03-08 EFFECTS OF FLUPENTHIXOL ON THE CLINICAL STATE AND EEG OF SCHIZOPHRENICS.

002395 03-08 LITHIUM-CARBONATE AND BRAIN FUNCTION: I. CEREBRAL EVOKED-POTENTIALS, EEG, AND SYMPTOM CHANGES DURING LITHIUM-CARBONATE TREATMENT.

002560 03-13 DEVELOPMENT OF AN ALCOHOL-BLOCKER, USING COMPUTER ANALYZED

002564 03-13 TIME-COURSE OF CHANGES IN EEG AND POWER SPECTRA DURING TREATMENT WITH NEUROLEPTICS.

002570 03-13 QUANTITATIVE EEG ANALYSIS OF THE PUTATIVE ANTIDEPRESSANT COMPOUND F1-6654.

002588 03-13 AN EEG COMPUTER ANALYSIS OF CHLORPROMAZINE EFFECTS IN PSYCHOTIC SUBJECTS.

002592 03-13 PRIMATE EEG SPECTRA BEFORE AND DURING OPIOID ADMINISTRATION. 002601 03-13

EEG SLEEP CORRELATES OF DEPRESSION IN MAN. 002625 03-14 **Psychopharmacology Abstracts**

ASSESSMENT OF SPONTANEOUS AND DRUG-INDUCED CHANGES IN VIGILANCE BY MEANS OF A NEW MODIFICATION OF THE SHORT TIME SPECTRAL ANALYSIS OF THE EEG.

002627 03-14 INFLUENCE OF LYSINE VASOPRESSIN ON THE EEG IN MAN.

002639 03-14 PHARMACODYNAMIC INVESTIGATIONS IN PSYCHOPHARMACOLOGY BY QUANTITATIVE EEG AND PSYCHOMETRIC METHODS.

002726 03-16 BI AND MULTIVARIATE ANALYSIS OF EEG DATA IN CLINICAL PSYCHOPHARMACOLOGY.

THE EFFECTS OF P-CHLOROPHENYLALANINE, RESERPINE, METHYSERGIDE AND CYPROHEPTADINE ON THE DOPA-INDUCED EEG SYNCHRONIZATION IN THE RAT.

003022 04-03 RETROACTIVE AMNESIA INDUCED IN CHICKS BY THE PROLINE ANALOG L BAIKIAIN, WITHOUT EEG SEIZURES OR DEPRESSION.

003205 04-04 COMPARATIVE EFFECTS OF COCAINE AND PSEUDOCOCAINE ON EEG ACTIVITIES, CARDIORESPIRATORY FUNCTIONS, AND SELF-ADMINISTRATION BEHAVIOR IN THE RHESUS MONKEY.

003292 04-04 EFFECTS OF SODIUM PHENOBARBITAL ON BRAIN STIMULATION BEHAVIOR, BEHAVIORAL SEIZURES, AND EEG SEIZURE ACTIVITY 003355 04-04

SOMATOSTATIN IN THE TREATMENT OF PATIENTS WITH EXTRAPYRAMIDAL DISORDERS AND PATIENTS WITH EEG ABNORMALITIES.

TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDROME WITH EMD-21657. A DERIVATIVE OF A PYRITINOL METABOLITE: DOUBLE-BLIND CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STUDIES. 003571 04-11

SELF-REPORTED ALCOHOL AND NICOTINE USE AND THE ABILITY TO CONTROL OCCIPITAL EEG IN A BIOFEEDBACK SITUATION.

003622 04-14

GENERATION OF ELECTRONIC EXCITED STATES (EES) BY TRICYCLIC ANTIDEPRESSANTS: MOLECULAR ASPECTS.

001693 02-13

EFFECTIVENESS OF PSYCHOTROPIC DRUGS IN PATIENTS IN A STATE OF MALNUTRITION OR EXPOSED TO EXTREME CLIMATIC CONDITIONS. 000721 01-13

SOME PROBLEMS CONCERNING THE TECHNIQUES OF STUDYING THE EFFECTIVENESS OF PSYCHOTROPIC DRUGS.

001540 02-06 FFFECTIVENESS OF RACIOFEN IN SCHIZOPHRENIA

001572 02-08 A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF DOTHIEPIN AND ITS THERAPEUTIC EFFECTIVENESS.

001604 02-09 EFFECTIVENESS OF TEMAZEPAM WITH SHORT-TERM, INTERMEDIATE-TERM, AND LONG-TERM USE: SLEEP LABORATORY EVALUATION. 002608 03-14

EFFECTIVENESS OF SCH-12679, A BENZAZEPINE, IN THE TREATMENT OF ANXIETY NEUROSIS. 003541 04-10

HYPNOTIC EFFECTIVENESS OF SODIUM SALICYLAMIDE WITH SHORT-TERM USE: SLEEP LABORATORY STUDIES.

003637 04-14

THE EFFECT OF D AMPHETAMINE ON GAMMA EFFERENT ACTIVITY IN THE ACUTE DECEREBRATE RAT.

AFFERENT AND EFFERENT SUBCORTICAL PROJECTIONS OF BEHAVIORALLY DEFINED SECTORS OF PREFRONTAL GRANULAR CORTEX.

EFFICIENCY ON THE INFLUENCE OF MOBILETTEN ON THE EFFECT OF ALCOHOL IN THE HUMAN: SECOND COMMUNICATION: INFLUENCE ON THE EFFICIENCY

UNDER ALCOHOL STRESS. 001623 02-11

STEREOSELECTIVITY IN THE METABOLISM OF H3-NORADRENALINE DURING UPTAKE INTO AND EFFLUX FROM THE ISOLATED RAT VAS-

002028 03-03 ASPECTS OF INFLUX AND EFFLUX OF HOMOVANILLIC-ACID OF RAT CEREBROSPINAL FLUID.

002807 04-03 LITHIUM EFFLUX FROM ERYTHROCYTES INCUBATED IN VITRO DURING LITHIUM-CARBONATE ADMINISTRATION.

003518 04-09 ORIENTED APPROACH TO THE STUDY OF THE EFFECTS OF PSYCHOACTIVE MEDICATION IN THE TREATMENT OF CHILDREN. 001875 02-16

VOLUME 16, SUBJECT INDEX

Subject Index

APOMORPHINE AND L-DOPA LOWER EJACULATION THR MALE RAT.	ESHOLD IN THE	STRENGTH DURATION PROPERTIES OF SINGLE UNITS DRIVEN BY ELECTRICAL STIMULATION OF THE LATERAL HYPOTHALAMUS 002	
INHIBITION OF EJACULATION BY AMITRIPTYLINE.	003327 04-04	NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOIN OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL	NOSITIDE
EKG	003670 04-15	SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIM OF THE SYMPATHETIC NERVE OF THE EYE.	AULATION
DOXEPIN AND IMIPRAMINE IN THE TREATMENT OF DEP DOUBLE-BLIND CROSS-OVER CLINICAL STUDY WITH E		THE NEURONAL ORIGIN OF PROSTAGLANDIN RELEASED FROM	2802 04-03 THE
EKG EFFECTS OF IMIPRAMINE TREATMENT IN CHILDREN	1.	RABBIT PORTAL VEIN IN RESPONSE TO ELECTRICAL STIMULA 002	2933 04-03
ELABORATION	002696 03-15	COCAINE AND PSEUDOCOCAINE: COMPARATIVE EFFECTS ON EL AFTER-DISCHARGE IN THE LIMBIC SYSTEM OF CATS.	ECTRICAL
EFFECT OF CHLORPROMAZINE ON ELABORATION AND E INSTRUMENTAL ALIMENTARY REFLEX IN PUPPIES.	O01407 02-04	EFFECTS OF PAIN ATTENUATING BRAIN STIMULATION AND MO	3004 04-03 ORPHINE ON
ELDERLY	001407 02-04	ELECTRICAL ACTIVITY IN THE RAPHE NUCLEI OF THE AWAKE	RAT. 3034 04-03
TOXICITY OF HIGH-DOSE FLURAZEPAM IN THE ELDERLY	000630 01-11	MOVEMENT INDUCED IN CATALEPTIC RATS: DIFFERENTIAL EFFI PRODUCED BY ELECTRICAL STIMULATION OF THE LATERAL	ECTS
SOME CONTINGENCIES AFFECTING THE UTILIZATION OF IN LONG-TERM CARE OF THE ELDERLY.		HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FOI	RMATION. 3297 04-04
INCREASED STEADY-STATE PLASMA LEVELS AND PROL OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY.		THE EFFECTS OF HALOPERIDOL AND CLOZAPINE ON CIRCLING I ELECTRICAL STIMULATION OF THE SUBSTANTIA-MIGRA AND VENTROMEDIAL TEGMENTUM.	NDUCED BY THE
THE DIFFERENTIAL EFFECTS OF MECLOFENOXATE ON MI	000734 01-13 EMORY LOSS IN	THE RELATIONSHIP BETWEEN PIPRADROL-INDUCED RESPONDIN	3343 04-04 IG FOR
DRUG TREATMENT IN THE ELDERLY.	000777 01-14	ELECTRICAL BRAIN STIMULATION, STEREOTYPED BEHAVIOU LOCOMOTOR ACTIVITY.	
	000907 01-15	ELECTRICALLY	3347 04-04
L TRYPTOPHAN ADMINISTRATION IN L-DOPA-INDUCED IN ELDERLY PARKINSONIAN PATIENTS.		ROTOMETER FOR RECORDING ROTATION IN CHEMICALLY OR ELECTRICALLY STIMULATED RATS.	
ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDI	001624 02-11 F IN YOUNG AND	00	2373 03-06
ELDERLY MALE VOLUNTEERS.	001689 02-13	ELECTROCARDIOGRAPHIC FINDINGS IN PATIENTS UNDERGOING	,
HIGH-POTENCY AND LOW-POTENCY NEUROLEPTICS IN I PSYCHIATRIC PATIENTS.			0912 01-15
DEPRESSION IN THE ELDERLY. II. POSSIBLE DRUG ETION DIFFERENTIAL DIAGNOSTIC CRITERIA.	003450 04-08 LOGIES;	TIME-COURSE AND DEVELOPMENT OF ELECTROCLINICAL FEATL RELATION TO PENTYLENETETRAZOL THRESHOLDS IN MONKE	
BROMIDE INTOXICATION IN THE ELDERLY.	003520 04-09	FOCAL SEIZURES.	1092 02-03
DROWIDE INTOXICATION IN THE ELDERLY.	003676 04-15	ELECTROCONVULSIVE	CROWEN
FURTHER STUDIES ON BL-3912A: EFFECTS ON AVOIDAL RATS WITH LOW BASELINES AND ON REACTION THE		EFFECTS OF APOMORPHINE AND CLONIDINE ON RAT PLASMA HORMONE AFTER PRETREATMENT WITH RESERPINE AND ELECTROCONVULSIVE SHOCKS.	
ELECTRIC FOOTSHOCK.	000461 01-04	THE EFFICACY OF ELECTROCONVULSIVE THERAPY AND ANTIDE IN DEPRESSION.	0102 01-03 EPRESSANTS
EFFECTS OF D AMPHETAMINE ON RESPONDING SIMULT	TANEOUSLY		0557 01-09
MAINTAINED AND PUNISHED BY PRESENTATION OF	ELECTRIC-SHOCK. 000317 01-04	ELECTROCORTICAL ELECTROCORTICAL CHANGES INDUCED BY THE PERFUSION OF	
SCHEDULE-INDUCED BITING UNDER FIXED-INTERVAL SC OR ELECTRIC-SHOCK PRESENTATION.	HEDULES OF FOOD	NORADRENALINE, ACETYLCHOLINE AND THEIR ANTAGONIS' INTO THE DORSAL RAPHE NUCLEUS OF THE CAT.	
EFFECTS OF MORPHINE, METHADONE, NALORPHINE AN RESPONDING UNDER SCHEDULES OF ELECTRIC-SHOCK	000348 01-04 ND NALOXONE ON C TITRATION. 000453 01-04	A PRESYNAPTIC SITE OF ACTION WITHIN THE MESENCEPHALIC FORMATION FOR () AMPHETAMINE-INDUCED ELECTROCORT DESYNCHRONIZATION.	0164 01-03 C RETICULAR TICAL
ELECTRICAL	000455 01-04	00	1069 02-03
INFLUENCE OF DIAZEPAM, L-DOPA AND DOPAMINE OF AND SPINAL ELECTRICAL PATTERNS INDUCED BY HA	THE CEREBELLAR	BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE AFTER INTRACEREBRAL INFUSION OF TRH IN FOWLS.	EFFECTS 03319 04-04
RABBIT.	000091 01-03	ELECTROCORTICOGRAM	3317 04-04
ELECTRICAL STIMULATION OF DENERVATED MUSCLES INCORPORATION OF METHIONINE INTO THE ACH RE	REDUCES	ONTOGENETIC DEVELOPMENT OF PENTOBARBITAL EFFECTS ON ELECTROCORTICOGRAM IN RATS.	No. 1958
EFFECTS OF MORPHINE AND HALOPERIDOL ON THE ELE OF RAT NIGROSTRIATAL NEURONS.	000136 01-03	OC CHANGES IN THE RAT ELECTROCORTICOGRAM FOLLOWING ADMINISTRATION OF TWO DIHYDROGENATED ERGOT DERIV)2161 03-03 VATIVES.
	000154 01-03	LSD AND TRYPTAMINE EFFECTS ON SLEEP-WAKEFULNESS AND	2207 03-04
EFFECT OF NEUROTROPIC DRUGS ON SLEEP DISTURBAN ELECTRICAL STIMULATION OF THE HYPOTHALAMUS	IN CATS.	ELECTROCORTICOGRAM PATTERNS IN INTACT CATS.))3256 04-04
DECREASE IN NEOSTRIATAL BLOOD FLOW AFTER D AN	000795 01-14 APHETAMINE	ELECTRODE	
ADMINISTRATION OR ELECTRICAL STIMULATION OF NIGRA.	THE SUBSTANTIA-	REWARD VERSUS PERFORMANCE IN SELF-STIMULATION: ELEC SPECIFIC EFFECTS OF ALPHA-METHYL-P-TYROSINE ON REWA	TRODE ARD IN THE
CONCURRENT MADRING OF BRAIN SITES FOR SENSITIV	001175 02-03	RAT.	2225 03-04
CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIV APPLICATION OF MORPHINE AND FOCAL ELECTRICAL THE PRODUCTION OF ANTINOCICEPTION IN THE RAT	L STIMULATION IN	ELECTRODERMAL SOME PHYSIOLOGIC CHARACTERISTICS OF THE ELECTRODERM	

ERIVATIVES. 002207 03-04 AND 003256 04-04 ELECTRODE EWARD IN THE 002225 03-04 SOME PHYSIOLOGIC CHARACTERISTICS OF THE ELECTRODERMAL REFLEX IN THE CAT. 002819 04-03 ELECTROENCEPHALOGRAM

ABSENCE OF DRUG-INDUCED BETA-ACTIVITY IN THE
ELECTROENCEPHALOGRAM: A SIGN OF SEVERE CEREBRAL
IMPAIRMENT. ELECTROENCEPHALOGRAM AND SOMATOSENSORY EVOKED-POTENTIAL CHANGES AFTER ADMINISTRATION OF SIX CONVULSANT DRUGS.
001676 02-13

001291 02-03

001314 02-04

002009 03-03

THE INFLUENCE OF ELECTRICAL STIMULATION ON THE HIPPOCAMPAL UNITS ACTIVITY OF THE RABBIT.

ANALGESIA FOLLOWING TRANSCUTANEOUS ELECTRICAL STIMULATION AND ITS PARTIAL REVERSAL BY A NARCOTIC ANTAGONIST.

EFFECTS OF MORPHINE ON ELECTRICAL ACTIVITY OF SINGLE MYENTERIC NEURONS IN CAT SMALL BOWEL.

EFFECTS OF BRAIN LESIONS AND ATROPINE ON HIPPOCAMPAL AND NEOCORTICAL ELECTROENCEPHALOGRAMS IN THE RAT. 001033 02-02

ELECTROENCEPHALOGRAPHIC

A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY ON ANTIEPILEPTIC
ACTIVITY OF CLONAZEPAM — RELATIONSHIP BETWEEN CLINICAL
EFFECTS OF ORAL ADMINISTRATION AND ELECTROENCEPHALOGRAPHIC
EFFECTS OF INTRAVENOUS ADMINISTRATION.

000639 01-11

BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC CORRELATES OF THE CHRONIC USE OF MARIJUANA — A REVIEW.

ELECTROENCEPHALOGRAPHIC STUDIES WITH I.V. METHAQUALONE IN MAN.

ELECTROENCEPHALOGRAPHIC STUDY OF THE SHORT-ACTING HYPNOTICS ETOMIDATE AND METHOHEXITAL IN DOGS.

ELECTROENCEPHALOGRAPHIC PECULIARITIES DURING ACUTE DRUG INTOXICATIONS IN EPILEPTIC PATIENTS.

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL TOLERANCE AND CROSS-TOLERANCE TO MORPHINE AND METHADONE IN THE RAT. 003010 04-03

ELECTROENCEPHALOGRAPHIC CONTROL WITH FREQUENCY ANALYSIS IN DEPRESSED PATIENTS TREATED WITH SAME.

SODIUM VALPROATE IN THE TREATMENT OF INTRACTABLE SEIZURE DISORDERS: A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY

ELECTROENCEPHALOGRAPHY
II. CLINICAL ELECTROENCEPHALOGRAPHY AND ECHOENCEPHALOGRAPHY
IN LONG-TERM HASHISH USERS.

000723 01-13 VALIDITY AND CLINICAL UTILITY OF NEUROLEPTIC FACILITATED ELECTROENCEPHALOGRAPHY IN PSYCHOTIC PATIENTS.

003669 04-15

EFFECTS OF CARBACHOL AND NICOTINE INJECTED INTO THE CEREBRAL VENTRICLES ON ELECTROMYOGRAM OF CONSCIOUS CATS.

000052 01-03

ELECTRON
ELECTRON MICROSCOPIC STUDIES ON THE CEREBRAL LESIONS OF RATS IN EXPERIMENTAL CHRONIC DISULFIRAM POISONING.

IN VITRO EFFECTS OF CHLORPROMAZINE ON MICROTUBULES AND THE GOLGI COMPLEX IN EMBRYONIC CHICK SPINAL GANGLION CELLS: AN ELECTRON MICROSCOPIC STUDY.

001258 02-03 SIMULTANEOUS DETERMINATION OF CODEINE AND MORPHINE IN BIOLOGICAL SAMPLES BY GAS-CHROMATOGRAPHY WITH ELECTRON CAPTURE DETECTION.

SOMATOSTATIN: ELECTRON MICROSCOPE IMMUNOHISTOCHEMICAL LOCALIZATION IN SECRETORY NEURONS OF RAT HYPOTHALAMUS 001948 03-01

ELECTRONIC FACTORS IN THE STRUCTURE-ACTIVITY RELATIONSHIP OF SOME 1.4 BENZODIAZEPIN-2-ONES.

000939 01-17 THE ELECTRONIC AND SEROTONIN RECEPTOR BINDING AFFINITY PROPERTIES OF N,N DIMETHYLTRYPTAMINE ANALOGS.

001002 02-01 GENERATION OF ELECTRONIC EXCITED STATES (EES) BY TRICYCLIC ANTIDEPRESSANTS: MOLECULAR ASPECTS.

ELECTROPHORETIC
ELECTROPHORETIC ANALYSES OF PROTEINS TRANSPORTED TO THE RAT
POSTERIOR PITUITARY.

002920 04-03

DIRECT EFFECTS OF ETHANOL ON CENTRAL-NERVOUS-SYSTEM CULTURES: AN ELECTROPHYSIOLOGICAL AND MORPHOLOGICAL STUDY. 000261 01-03

ELECTROPHYSIOLOGICAL (H-REFLEX) STUDIES OF PATIENTS WITH TARDIVE-DYSKINESIA.

ELECTROPHYSIOLOGICAL EVIDENCE FOR A DOPAMINERGIC ACTION OF LSD: DEPRESSION OF UNIT ACTIVITY IN THE SUBSTANTIA-NIGRA OF 001082 02-03

CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE

001526 02-06 ELECTROPHYSIOLOGICAL STUDIES AND AMPHETAMINE METABOLISM IN HYPERACTIVE CHILDREN. 002520 03-11

Psychopharmacology Abstracts

PHARMACOLOGICAL AND ELECTROPHYSIOLOGICAL STUDIES OF MORPHINE AND ENKEPHALIN ON RAT SUPRASPINAL NEURONES AND CAT SPINAL NEURONES.

THE EFFECTS OF ETHANOLAMINE-O-SULPHATE INJECTION INTO THE RAT SUBSTANTIA-NIGRA: ELECTROPHYSIOLOGICAL STUDIES. 003033 04-03

COMPARISON OF THE ELECTROPHYSIOLOGICAL EFFECTS OF TWO NEUROLEPTICS, MELPERONE AND THIORIDAZINE, ON ISOLATED RAT ATRIA.

003417 04-05
MULTIVARIATE ANALYSIS OF DRUG EFFECTS ON ELECTROPHYSIOLOGICAL SIGNALS IN MAN. 003688 04-16

ELECTRORETINOGRAM
EFFECT OF STRYCHNINE ON THE RAT ELECTRORETINOGRAM.
003048 04-03

POSSIBLE INDICATION OF DOPAMINERGIC BLOCKADE IN MAN BY ELECTRORETINOGRAPHY. 003689 04-16

THE RELATIONSHIP BETWEEN MAGNITUDE OF ELECTROSHOCK STIMULATION AND THE EFFECTS OF DIGITOXIGENIN, PENTYLENETETRAZOL AND BRAIN MONOAMINE REDUCTION ON ELECTROSHOCK CONVULSIVE THRESHOLDS.

MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND NORADRENERGIC NEURONS IN NORMAL AND BRAIN LESIONED RATS.

A ROLE FOR CENTRAL SEROTONERGIC SYSTEMS IN THE PATTERN AND INTENSITY OF THE CONVULSIVE RESPONSE OF RATS TO ELECTROSHOCK.

ELECTROSHOCK ANTICONVULSANT ACTIVITY AND BRAIN ACETYLCHOLINE ALTERATIONS IN MICE TREATED WITH SELECT BENZODIAZEPINES. 001210 02-03

DRINKING BEHAVIOUR INDUCED BY INTRACRANIAL INJECTIONS OF ELEDOISIN AND SUBSTANCE-P IN THE PIGEON.

001352 02-04 DOPAMINE SUPERSENSITIVITY, ENDORPHIN EXCESS, AND PROSTAGLANDIN-E1 DEFICIENCY: THREE ASPECTS OF THE SAME SCHIZOPHRENIC ELEPHANT. 003458

003458 04-08

ELEVATED MELATONIN SERUM CONCENTRATIONS IN PSYCHIATRIC PATIENTS TREATED WITH CHLORPROMAZINE. 002595 03-13

MORPHINE REDUCES CEREBELLAR CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT AND ELEVATES CEREBROSPINAL FLUID CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT IN RHESUS MONKEY.

002057 03-0

002057 03-03 THE EFFECTS OF ELEVATING GAMMA-AMINOBUTYRATE CONTENT IN THE SUBSTANTIA-NIGRA ON THE BEHAVIOUR OF RATS.

003291 04-04 ELEVATION OF AVERSIVE THRESHOLD IN RATS BY INTRA-AMYGDALOID INJECTION OF MORPHINE-SULPHATE.

000444 01-04 EFFECTS OF LITHIUM ON THE ELEVATION OF FOREBRAIN 5
HYDROXYINDOLES BY TRYPTOPHAN.

001086 02-03

CYANOCYPROHEPTADINE: ROLE OF CHOLINOLYTIC PROPERTIES IN MODULATING NEUROLEPTIC-INDUCED ELEVATION OF STRIATAL HOMOVANILLIC-ACID (HVA). 001226 02-03 MOOD FLEVATION AND MEDICATION

REGIONAL CHANGES IN THE CONCENTRATIONS OF CEREBRAL MONOAMINES AND THEIR METABOLITES AFTER ETHANOLAMINE-O-SULPHATE-INDUCED ELEVATION OF BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS

003053 04-03 CONCOMITANT ELEVATION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY CYCLIC-AMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

ELEVATIONS
PROBENECID-INDUCED NOREPINEPHRINE ELEVATIONS IN PLASMA AND 002573 03-13

ENKEPHALIN ANALOGUES ELICITING ANALGESIA AFTER INTRAVENOUS INJECTION.

AGGRESSION PROMOTING AND AGGRESSION ELICITING PROPERTIES OF ESTROGEN IN MALE MICE. 003360 04-04

FINIMATION
FIRST-PASS ELIMINATION OF C14-IMIPRAMINE IN ISOLATED PERFUSED
RAT LIVER.

001052 02-03 LONG-TERM ELIMINATION OF VIOLENT BEHAVIOUR BY THE INTERACTION OF PSYCHOPHARMACOLOGIC AND PSYCHOSOCIAL THERAPY. 001333 02-04

001333 02-4
PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL.
IV. INFLUENCE OF ELIMINATION KINETICS.

002198 03-04
INFLUENCE OF PHENOBARBITAL ON THE DISTRIBUTION AND ELIMINATION
OF DESMETHYLIMIPRAMINE IN THE RAT.

002842 04-03
INTERACTION BETWEEN D AMPHETAMINE AND ETHANOL WITH RESPECT
TO LOCOMOTION, STEREOTYPIES, ETHANOL SLEEPING TIME, AND THE
KINETICS OF DRUG ELIMINATION.
003378 04-04

VALUE OF COCAINE IN OPIATE CONTAINING ELIXIRS.

EMBRYOPATHIC

MARYONIC ON ANCHOROPODA A ZINE ON ANCROTURIUS AND THE

IN VITRO EFFECTS OF CHLORPROMAZINE ON MICROTUBULES AND THE GOLGI COMPLEX IN EMBRYONIC CHICK SPINAL GANGLION CELLS: AN ELECTRON MICROSCOPIC STUDY.

001258 02-03

PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EMBRYOPATHIC EFFECT AND COVALENT BINDING OF PUTATIVE ARENE OXIDE METABOLITE IN GESTATIONAL TISSUE.

METABOLITE IN GESTATIONAL TISSUE.

001515 02-05

EMBRYOPATHIES INDUCED BY TERATOGENIC AGENTS.

000857 01-15

PRODUCTION OF UNDERWEIGHT EMBRYOS IN RATS TREATED WITH BARBITURATES DURING PREGNANCY.

EMD-21657
TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDROME WITH EMD-21657. A DERIVATIVE OF A PYRITINOL METRABOLITE: DOUBLE-BLIND CLINICAL, QUANTITATIVE EEG. AND PSYCHOMETRIC STUDIES.

21657. A DERIVATIVE OF A PYRITINOL METABOLITE: DOUBLE-BLIND CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STUDIES.
003571 04-11

EMERGENCIES
PARENTERAL HALOPERIDOL IN PSYCHIATRIC EMERGENCIES: DOUBLE-BLIND COMPARISON WITH CHLORPROMAZINE.

000566 01-09

RELATIVE EFFICACY OF PARENTERAL HALOPERIDOL AND THIOTHIXENE
FOR THE EMERGENCY TREATMENT OF ACUTELY EXCITED AND

AGITATED PATIENTS. 001626 02-11
RAPID IDENTIFICATION OF HYPNOTICS IN EMERGENCY CASES BY

RAPID IDENTIFICATION OF HYPNOTICS IN EMERGENCY CASES BY COMPUTERIZED GAS-CHROMATOGRAPHY MASS SPECTROMETRY. 001841 02-15

MERGENT
NEUROCHEMISTRY OF WITHDRAWAL EMERGENT SYMPTOMS IN
CHILDREN.
002602 03-13

EMERGING
EMERGING CHOLINERGIC MECHANISMS AND ONTOGENY OF RESPONSE INHIBITION IN THE MOUSE.

EMINENCE

A COMPARISON OF THE EFFECTS OF HALOPERIDOL ON DOPAMINE
TURNOVER IN THE STRIATUM, OLFACTORY TUBERCLE AND MEDIAN
FAMILIENCE

THE CHEMISTRY OF DOPAMINE RECEPTORS IN THE MEDIAN EMINENCE.
001085 02-03

EFFECTS OF ESTROGEN AND AMINERGIC DRUGS ON THRESHOLDS OF MEDIAL BASAL HYPOTHALAMIC AXONS IN THE MEDIAN EMINENCE OF THE RAT.

002974 04-03

EMOTIONAL

EFFECT OF CHLORDIAZEPOXIDE ADMINISTERED EARLY IN EXTINCTION ON
SUBSEQUENT EXTINCTION OF A CONDITIONED EMOTIONAL RESPONSE
IN RATS: IMPLICATIONS FOR HUMAN CLINICAL USE.

IN RATS: IMPLICATIONS FOR HUMAN CLINICAL USE.

000022 01-02

LITHIUM AND EMOTIONAL DISORDER.

000573 01-09
THE EFFECTS OF PSYCHOTOMIMETIC DRUGS ON THE CONDITIONED EMOTIONAL RESPONSE.

ADRENERGIC MODULATION OF A CHOLINERGIC EMOTIONAL REACTION IN THE CATS THALAMUS.

ROLE OF THE BRAIN MONOAMINE SYSTEM IN LEARNING ON VARIOUS EMOTIONAL REINFORCEMENTS.

A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND BIOELECTRIC CORRELATES OF EMOTIONAL REACTIONS ELICITED BY CHOLINERGIC STIMULATION OF THE HYPOTHALAMUS AND THE VENTRAL TEGMENTIAN

001390 02-04
BRAIN STIMULATION PROVOKED EMOTIONAL REACTIONS OF CATS IN A
SOCIAL SITUATION.

PSYCHOTROPIC DRUG EFFECTS ON THE EMOTIONAL STATE OF CATS IN A SOCIAL SITUATION.

001480 02-04
EFFECT OF EARLY EXPERIENCE, PYRITHIOXIN AND DIAZEPAM ON UC14GLUCOSE UTILIZATION IN RAT BRAIN DURING EMOTIONAL STRESS.
002152 03-03
EMOTIONAL PREDISPOSITION TO PSYCHOTROPIC DRUG EFFECTS.

EMOTIONALITY

EFFECT OF CURCUMEN-LONGA ON EMOTIONALITY AND LEARNING.

001441 02-04

P-CHLOROPHENYLALANINE PRODUCES DISSOCIATED EFFECTS ON

AGGRESSION EMOTIONALITY AND MOTOR ACTIVITY. 003293 04-04

000984 01-17

EMOTIONS

AMPHETAMINE AND CHICK BEHAVIOUR: A ROLE FOR MONOAMINES IN THE CAUSATION OF VOCALIZATIONS AND EMOTIONS.

MEDICATION CLASSES FOR THE EMOTIONALLY ILL.

THE EFFECTS OF INORGANIC LEAD ON THE CENTRAL CATECHOLAMINERGIC
SYSTEM OF THE RODENT WITH EMPHASIS ON POSTNATALLY EXPOSED
RATS AND MICE. (PH.D. DISSERTATION).

EMPIRIC

AMP SYSTEM: LONGITUDINAL COURSE STUDIES OF PSYCHOPATHOLOGIC

AND SOMATIC SYMPTOMS. AN EMPIRIC INVESTIGATION OF THE

PROBLEM OF SIDE-EFFECTS.

000797 01-1

EMPTY
PRIMARY EMPTY SELLA SYNDROME AND BIPOLAR AFFECTIVE-ILLNESS:

CASE REPORT.

003511 04-09

EMPTYING

EFFECT OF ANTIPARKINSONISM DRUGS ON GASTRIC EMPTYING AND

INTESTINAL TRANSIT IN THE RAT. 002010 03-03

ENANTIOMORPHS
ON THE PHARMACOLOGY OF THE KETAMINE ENANTIOMORPHS IN THE
RAT.

ENCEPHALE
THE EFFECT OF NORADRENALINE ON THE ECOG OF THE PREPARATION

ENCEPHALE ISOLE OF RATS.

O01475 02-04

IATROGENIC ENCEPHALOPATHIES. 000890 01-15

THE USE OF LACTULOSE IN PORTAL SYSTEMIC ENCEPHALOPATHY.

002762 03-17

EXPERIMENTAL LEAD ENCEPHALOPATHY IN THE SUCKLING RAT:

CONCENTRATION OF LEAD IN CELLULAR FRACTIONS ENRICHED IN
BRAIN CAPILLARIES.

O03420 04-05

DIFFICULTIES ENCOUNTERED BY THE CLINICAL RESEARCHER IN PLANNING
PSYCHOTROPIC DRUG TRIALS.

000935 01-16

GLUTAMINE -- A MAJOR SUBSTRATE FOR NERVE ENDINGS.

ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE

CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. THE IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2-METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED ANALOGS OF METHAMPHETAMINE.

ENDOCRINE

TIME-COURSE OF LITHIUM-INDUCED ALTERATIONS IN RENAL AND ENDOCRINE FUNCTION IN NORMAL AND BRATTLEBORO RATS WITH HYPOTHALAMIC DIABETES-INSIPIOUS.

A PILOT ENDOCRINE STUDY IN DEPRESSION. 000048 01-03 002463 03-09

MODIFICATION OF THE 5 HYDROXYTRYPTOPHAN-INDUCED HEAD-TWITCH RESPONSE BY EXOGENOUS ENDOCRINE AGENTS.

ENDOCRINES AND AGGRESSION.

003177 04-04 000965 01-17

A REVIEW OF THE RELATIONSHIP BETWEEN ENDOCRINOPATHY AND DEPRESSION OR ANTIDEPRESSANT DRUGS, WITH PARTICULAR RESPECT TO NOVEL THEORIES INVOLVING THE OPIATE RECEPTOR. 002557 03-13

NDOGENOUS
ENDOGENOUS MODULATORS OF ACETYLCHOLINE TURNOVER RATE.
(UNPUBLISHED PAPER).

STUDIES ON THE INFLUENCE OF BIOGENIC AMINES AND PSYCHOACTIVE DRUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMULATION TEST IN ENDOGENOUS DEPRESSION.

ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS.

PHARMACOLOGICAL EVIDENCE FOR A LINK BETWEEN THE CEREBELLAR CONTENT OF C-GMP AND THAT OF AN ENDOGENOUS PROTEIN KINASE

THE INFLUENCE OF COCAINE AND DESIPRAMINE ON THE CARDIAC RESPONSES TO EXOGENOUS AND ENDOGENOUS NOREPINEPHRINE 002077 03-03

EFFECTS OF BIOGENIC AMINES AND PSYCHOTROPIC DRUGS ON ENDOGENOUS PROSTAGLANDIN BIOSYNTHESIS IN THE RAT BRAIN HOMOGENATES.

INTRAPSYCHIC AND FAMILY DYNAMIC PROCESSES IN AN ENDOGENOUS DEPRESSION PRECEDING MANIFESTATION OF THE ILLNESS AND LITHIUM THERAPY.

DOSAGE EFFECTS OF IMIPRAMINE ON THE PSYCHOPATHOLOGIC AND BIOLOGIC INDICES OF ENDOGENOUS DEPRESSIVE SYNDROMES.

002494 03-10 EFFECTS OF MSH/ACTH4-10 ON MEMORY, ATTENTION, AND ENDOGENOUS HORMONE LEVELS IN WOMEN.

002641 03-14 POSSIBLE WITHDRAWAL FROM ENDOGENOUS OPIATES IN SCHIZOPHRENICS.

002666 03-15 EVIDENCE FOR AN ENDOGENOUS FACTOR INTERFERING WITH H3-DIAZEPAM BINDING TO RAT BRAIN MEMBRANES.

002789 04-01 EFFECTS OF SINGLE AND MULTIPLE DOSES OF DESIPRAMINE (DMI) ON ENDOGENOUS LEVELS OF 3 METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE (MOPEG-SO4) IN RAT BRAIN.

INCREASE IN SERUM PROLACTIN BY EXOGENOUS AND ENDOGENOUS OPIATES: EVIDENCE FOR ANTIDOPAMINE AND ANTIPSYCHOTIC EFFECTS. 002926 04-03

DEMONSTRATION OF AN ENDOGENOUS, COMPETITIVE INHIBITOR(S) OF H3-DIAZEPAM BINDING IN BOVINE BRAIN.

002995 04-03 RELEASE OF ENDOGENOUS CATECHOLAMINES FROM ISOLATED RAT BRAIN TISSUE BY FENFLURAMINE AND N ETHYLAMPHETAMINE -EFFECTS OF PARGYLINE.

003111 04-03 POTENTIAL ROLES OF ENDOGENOUS PEPTIDES IN THE DISCRIMINATIVE PROPERTIES OF DRUGS.

003187 04-04 TREATMENT OF ENDOGENOUS DEPRESSION WITH ORAL THYROTROPIN-RELEASING HORMONE AND AMITRIPTYLINE.

DISTURBANCE OF HOMEOSTATIC REGULATION OF ADRENAL FUNCTION IN PATIENTS WITH ENDOGENOUS DEPRESSION.

THE PRACTICAL SIGNIFICANCE OF NORTRIPTYLINE PLASMA CONTROL. A PROSPECTIVE EVALUATION UNDER ROUTINE CONDITIONS IN ENDOGENOUS DEPRESSION.

003522 04-09 ENDOGENOUSLY

A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE
(SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS
(SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH
SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE

003508 04-09

EFFECTS OF PROSTAGLANDIN-E2 AND A PROSTAGLANDIN ENDOPEROXIDE ANALOGUE ON NEUROEFFECTOR TRANSMISSION IN THE RAT ANOCOCCYGEUS MUSCLE.

002888 04-03

003593 04-13

ENDOPLASMIC
THE EFFECT OF PHENOBARBITAL AND CARBON-TETRACHLORIDE ON FATTY-ACID CONTENT AND COMPOSITION OF PHOSPHOLIPIDS FROM THE ENDOPLASMIC RETICULUM OF RAT LIVER.

ENDORPHIN RELEASE: CROSS-TOLERANCE TO MORPHINE.

000229 01-03 BREAKDOWN OF ENKEPHALIN AND ENDORPHIN ANALOGS BY BRAIN

001137 02-03 FECT OF ENKEPHALIN AND ENDORPHIN ANALOGS ON RECEPTORS IN THE MOUSE VAS-DEFERENS.

DOPAMINE SUPERSENSITIVITY, ENDORPHIN EXCESS, AND PROSTAGLANDIN-E1 DEFICIENCY: THREE ASPECTS OF THE SAME SCHIZOPHRENIC ELEPHANT.

003458 04-08 DETECTION OF TWO ENDORPHIN-LIKE PEPTIDES IN NUCLEUS-CAUDATUS. 002790 04-01

EVIDENCE AGAINST INVOLVEMENT OF ENDORPHINS IN SEXUAL AROUSAL AND ORGASM IN MAN.

000701 01-13 NALOXONE (NARCAN) TREATMENT IN DEPRESSION: CLINICAL OBSERVATIONS AND EFFECTS ON CSF ENDORPHINS AND MONOAMINE METABOLITES.

001692 02-13 ENDORPHINS: NALOXONE FAILS TO ALTER EXPERIMENTAL PAIN OR MOOD IN HUMANS.

002383 03-07 WHAT USE ARE ENDORPHINS?

002488 03-10 SYSTEMIC ADMINISTRATION OF ENDORPHINS SELECTIVELY ALTERS OPEN-FIELD BEHAVIOR OF RATS.

ENDORPHINS IN PSYCHIATRY: AN OVERVIEW AND A HYPOTHESIS 003730 04-17

ENDOTHELIAL
HYDROLYSIS OF ENKEPHALIN BY CULTURED HUMAN ENDOTHELIAL CELLS
AND BY PURIFIED PEPTIDYL DIPEPTIDASE.

003693 04 1/2

ACTIONS OF ATROPINE AND SCOPOLAMINE ON THE ENDPLATE CURRENT OF THE FROG SARTORIUS MUSCLE. (PH.D. DISSERTATION).

ENDURANCE

EFECTS OF AMPHETAMINE ON ENDURANCE PERFORMANCE AND MUSCLE

WEAKNESS IN RATS.

001363 02-04

WORD ASSOCIATION TIMES, FELT EFFECTS, AND PERSONALITY CHARACTERISTICS OF SCIENCE STUDENTS GIVEN A PLACEBO ENERGIZER

002611 03-14 ENERGY EFFECTS OF ACUTE AND CHRONIC MORPHINE AND NARCOTIC ANTAGONISTS ON BRAIN ENERGY METABOLISM.

001163 02-03 ENERGY UTILIZATION IN THE INDUCED RELEASE OF GAMMA-AMINOBUTYRIC-ACID FROM SYNAPTOSOMES.

003029 04-03 PROBLEMS ENGENDERED BY ADMINISTRATION OF LONG-ACTION

NEUROLEPTICS. 001922 02-17

TREATMENT OF PRISONERS IN ENGLANDS JAILS. 000997 01-17

DIFFERENCES IN THE EFFECTS OF CLOMIPRAMINE ON ENGLISH AND ASIAN VOLUNTEERS. PRELIMINARY REPORT ON A PILOT STUDY. 002646 03-15

ENHANCEMENT
DOPAMINE RECEPTOR BINDING ENHANCEMENT ACCOMPANIES LESIONINDUCED BEHAVIORAL SUPERSENSITIVITY.
000084 01-

000084 01-03 ENHANCEMENT OF LEARNING BY CYCLOHEXIMIDE AND DDC: A FUNCTION OF RESPONSE STRENGTH.

000374 01-04 ANTAGONISM BY CHOLINERGIC DRUGS OF BEHAVIOURAL EFFECTS IN CATS OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC DRUG AND ENHANCEMENT BY NICOTINE.

000404 01-04 **REWARD ENHANCEMENT BY PSYCHOMOTOR STIMULANT DRUGS** 000440 01-04

ENHANCEMENT OF SEXUAL BEHAVIOR IN THE FEMALE RAT BY NICOTINE. 001360 02-04 ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

-- A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

ENHANCEMENT BY CHOLINE OF THE INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE BY PHENOXYBENZAMINE, 6 HYDROXYDOPAMINE, INSULIN OR EXPOSURE TO COLD.

ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY BENZODIAZEPINES.

ENHANCEMENT OF THE ANTIDEPRESSANT RESPONSE TO L TRYPTOPHAN BY A LIVER PYRROLASE INHIBITOR: A RATIONAL TREATMENT

002464 03-09 LACK OF ENHANCEMENT OF DIMETHYLTRYPTAMINE FORMATION IN RAT BRAIN AND RABBIT LUNG IN VIVO BY METHIONINE OR S ADENOSYI METHIONINE

003102 04-03 H3-CATECHOLAMINE BINDING TO ALPHA-RECEPTORS IN RAT BRAIN: ENHANCEMENT BY DESERBINE

003119 04-03 RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS: ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT LEARNING WITH D AMPPHETAMINE TREATMENTS.

003167 04-04 DELTA9-TETRAHYDROCANNABINOL ENHANCEMENT OF LORDOSIS BEHAVIOR IN ESTROGEN TREATED FEMALE RATS. 003230 04-04

ENHANCES CHLORPROMAZINE ENHANCES MEMORY IN CHICKS

001341 02-04 LEAD ENHANCES LITHIUM-INDUCED POLYDIPSIA

001409 02-04 STIMULATION OF PRESYNAPTIC BETA-ADRENOCEPTORS ENHANCES H3-

NORADRENALINE RELEASE DURING NERVE STIMULATION IN THE PERFLISED CAT SPLEEN

REPEATED EXPOSURE OF RATS TO THE CONVULSANT AGENT FLUROTHYL ENHANCES 5 HYDROXYTRYPTAMINE AND DOPAMINE MEDIATED BEHAVIOURAL RESPONSES.

003234 04-04

ENKEPHALIN **ENKEPHALIN ANALOGUES ELICITING ANALGESIA AFTER INTRAVENOUS**

001024 02-02 A SYNTHETIC ENKEPHALIN ANALOGUE WITH PROLONGED PARENTERAL

AND ORAL ANALGESIC ACTIVITY. 001036 02-02 BREAKDOWN OF ENKEPHALIN AND ENDORPHIN ANALOGS BY BRAIN

001137 02-03 **ENKEPHALIN EFFECTS ON RELEASE OF BRAIN ACETYLCHOLINE**

001152 02-03 MORPHINE AND ENKEPHALIN: ANALGESIC AND EPILEPTIC PROPERTIES 001267 02-03

INTERACTION OF IODINATED ENKEPHALIN ANALOGUES WITH OPIATE RECEPTORS 001947 03-01

BEHAVIORAL AND BIOCHEMICAL EFFECTS OF FK33-824, A PARENTERALLY AND ORALLY ACTIVE ENKEPHALIN ANALOGUE (UNPUBLISHED PAPER). 002744 03-17

SYNTHESIS OF TWO ENZYME RESISTANT ENKEPHALIN ANALOGS POSSESSING ENHANCED ANALGESIC ACTIVITY. 002787 04-01

RELEASE OF VASOPRESSIN BY ENKEPHALIN

002792 04-02 EFFECT OF ENKEPHALIN AND ENDORPHIN ANALOGS ON RECEPTORS IN THE MOUSE VAS-DEFERENS.

002794 04-02 MULTIPLE MEMBRANE ACTIONS OF ENKEPHALIN REVEALED USING CULTURED SPINAL NEURONS.

002816 04-03 PHARMACOLOGICAL AND ELECTROPHYSIOLOGICAL STUDIES OF MORPHINE AND ENKEPHALIN ON RAT SUPRASPINAL NEURONES AND CAT SPINAL NEURONES.

002883 04-03 DIFFERENT BRAIN AREAS MEDIATE THE ANALGESIC AND EPILEPTIC PROPERTIES OF ENKEPHALIN.

002915 04-03 HYDROLYSIS OF ENKEPHALIN BY CULTURED HUMAN ENDOTHELIAL CELLS AND BY PURIFIED PEPTIDYL DIPEPTIDASE.

003593 04-13 CHARACTERIZATION OF ENKEPHALIN-LIKE MATERIAL EXTRACTED FROM

SYMPATHETIC GANGLIA. 002788 04-01

ENKEPHALINERGIC

BEHAVIOURAL DISSOCIATION OF THE ENKEPHALINERGIC SYSTEMS OF NUCLEUS-ACCUMBENS AND NUCLEUS-CAUDATUS. 000096 01-03

FAILURE OF NALOXONE TO PREVENT REDUCTION OF AMNESIA BY **ENKEPHALINS**

COMPARATIVE INHIBITORY EFFECTS OF SYNTHETIC ENKEPHALINS ON THE STEREOSPECIFIC BINDING OF H3-DIHYDROMORPHINE AND H3-

A COMPARISON OF THE EFFECTS OF INTRAVENTRICULAR MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON OPERANT BEHAVIOR IN

001323 02-04

THE ENKEPHALINS AND OPIATES: STRUCTURE-ACTIVITY RELATIONS.

001901 02-17

EFFECTS OF MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON SCHEDULE-CONTROLLED RESPONDING IN THE RAT.

ANALGESIC ACTIVITY OF ENKEPHALINS FOLLOWING INTRACEREBRAL ADMINISTRATION IN THE RAT.

002275 03-04 STIMULATION OF DOPAMINE SYNTHESIS IN CAUDATE NUCLEUS BY INTRASTRIATAL ENKEPHALINS AND ANTAGONISM BY NALOXONE

RADIOIMMUNOASSAY OF ENKEPHALINS: REGIONAL DISTRIBUTION IN RAT BRAIN AFTER MORPHINE TREATMENT AND HYPOPHYSECTOMY ANALGESIA AND MOTOR ACTIVITY ELICITED BY MORPHINE AND

ENKEPHALINS IN TWO INBRED STRAINS OF MICE. 003225 04-04

ANALGESIA BY ENKEPHALINS INJECTED INTO THE NUCLEUS RETICULARIS

GIGANTOCELLULARIS OF RAT MEDULLA-OBLONGATA 003374 04-04

INFLUENCE OF NEUROLEPTICS ON THE BINDING OF MET-ENKEPHALIN, MORPHINE AND DIHYDROMORPHINE TO SYNAPTOSOME ENRICHED

FRACTIONS OF RAT BRAIN. EXPERIMENTAL LEAD ENCEPHALOPATHY IN THE SUCKLING RAT: CONCENTRATION OF LEAD IN CELLULAR FRACTIONS ENRICHED IN

BRAIN CAPILLARIES 003420 04-05 ENRICHMENT

DRUG-MODULATED BEHAVIOURAL RESPONSES TO ENVIRONMENTAL **ENRICHMENT**

003201 04-04 THE ENTEROHEPATIC CIRCULATION OF OXAZEPAM-O-GLUCURONIDE IN

GUINEA-PIGS 002820 04-03

ACUTE HYPOKALEMIC MYOPATHY IN ALCOHOLISM: A CLINICAL ENTITY 000888 01-15

ENTRY OF BETA-N-OXALYL-L-ALPHA-BETA-DIAMINOPROPIONIC-ACID, THE LATHYRUS-SAITUVS NEUROTOXIN INTO THE CENTRAL-NERVOUS-SYSTEM OF THE ADULT RAT, CHICK AND THE RHESUS MONKEY.

003061 04-03 AZAPHEN IN THE TREATMENT OF ENURESIS IN CHILDREN.

O02513 03-11
TRIAL OF AN ALPHA-ADRENOLYTIC DRUG (INDORAMIN) FOR NOCTURNAL **ENURESIS** 003573 04-11

ENURETIC RETIC

EFFECTS OF IMIPRAMINE ON ENURETIC FREQUENCY AND SLEEP STAGES.

001719 02-14

DISAGGREGATION OF BRAIN POLYSOMES AFTER D LYSERGIC-ACID-DIETHYLAMIDE ADMINISTRATION IN VIVO: MECHANISM AND EFFECT OF AGE AND ENVIRONMENT.

000149 01-03 CHANGES IN THE BEHAVIORAL RESPONSE TO A NOVEL ENVIRON FOLLOWING LESIONING OF THE CENTRAL DOPAMINERGIC SYSTEM IN RAT PUPS

THE EFFECTS OF PHARMACOLOGICAL AND ENVIRONMENTAL VARIABLES
ON DRUG CHOICE IN RHESUS MONKEYS. 000386 01-04

PREVENTION OF ENVIRONMENTAL STRESS IMPACT ON RAT 002296 03-04 RESPONSES OF THE PITUITARY ADRENAL SYSTEM OF THE PIG TO

ENVIRONMENTAL CHANGES AND DRUGS DRUG-MODULATED BEHAVIOURAL RESPONSES TO ENVIRONMENTAL **ENRICHMENT**

BEHAVIORAL AND PHYSIOLOGICAL STUDIES OF NONNARCOTIC ANALGESIA IN THE RAT ELICITED BY CERTAIN ENVIRONMENTAL STIMULI.

003242 04-04

003127 04-03

003049 04-03

BEHAVIOR OBSERVATIONS OF HYPERACTIVE CHILDREN AND METHYLPHENIDATE (RITALIN) EFFECTS IN SYSTEMATICALLY STRUCTURED CLASSROOM ENVIRONMENTS: NOW YOU SEE THEM, NOW YOU DONT. 003581 04-11

MAGNIFICATION OF SOME ENZYMATIC ACTIVITIES OF BRAIN-CORTEX SUBFRACTIONS.

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE.

000127 01-03 A COMPARISON OF THE EFFECTS OF INTRAVENTRICULAR MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON OPERANT BEHAVIOR IN

001323 02-04

PROTEIN AND ENZYME RELEASE FROM HUMAN LEUKOCYTES: INFLUENCE 001669 02-13

FURTHER EVIDENCE OF CYCLIC-AMP MEDIATED HYPERTROPHY AS A PREREQUISITE OF DRUG SPECIFIC ENZYME INDUCTION. 002086 03-03

EFFECTS OF MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON SCHEDULE-CONTROLLED RESPONDING IN THE RAT.

002206 03-04 SYNTHESIS OF TWO ENZYME RESISTANT ENKEPHALIN ANALOGS POSSESSING ENHANCED ANALGESIC ACTIVITY.

002787 04-01 INHIBITION OF BRAIN ANGIOTENSIN-I CONVERTING ENZYME BY BOTHROPS-JARARACA NONAPEPTIDE (SQ-20881) AND A PROLYL ANALOG (SQ-14225).

002818 04-03 SELECTIVE ENZYME INDUCTION IN A NERVE GROWTH FACTOR RESPONSIVE PHEOCHROMOCYTOMA CELL LINE (PC-12).

002899 04-03 SUBCELLULAR LOCALIZATION OF C14-METHAQUALONE IN MOUSE BRAIN: EFFECTS OF HEPATIC MICROSOMAL ENZYME INHIBITION.

THE EFFECT OF GAMMA-ACETYLENIC-GABA, AN ENZYME ACTIVATED IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE, ON DOPAMINE PATHWAYS OF THE EXTRAPYRAMIDAL AND LIMBIC SYSTEMS. 003037 04-03

ONSPECIFIC INHIBITION OF SOME RAT LIVER MEMBRANE-BOUND ENZYMES BY AN ADENYLATE-CYCLASE INHIBITOR, RMI-12330-A. 002936 04-03

THE EFFECT OF SODIUM PENTOBARBITAL ON SOME MITOCHONDRIAL ENZYMES.

INHIBITION BY BARBITURIC-ACID AND ITS DERIVATIVES OF THE ENZYMES IN RAT BRAIN WHICH PARTICIPATE IN THE SYNTHESIS OF PYRIMIDINE RIBOTIDES.

EMTYMIC

ENZYMIC DEALKYLATION OF A SUBSTITUTED

AMINOACETAMIDOBENZOPHENONE AND CYCLIZATION TO THE

CORRESPONDING BENZODIAZEPINE IN VITRO.

000152 01-03 THE EXTRACTION AND ANALYSIS OF BENZODIAZEPINES IN ENZYMIC DIGESTION AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY. TISSUES BY

000928 01-16

EOSINOPHILIA
PROVEN ASYMPTOMATIC EOSINOPHILIA WITH IMIPRAMINE 001765 02-15

EPHEDRINE DOPAMINERGIC AGONIST PROPERTIES OF EPHEDRINE -- THEORETICAL **IMPLICATIONS**

REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF L-DOPA, AMINOPHYLLINE, AND EPHEDRINE.

AGRANULOCYTOSIS IN PATIENTS TREATED WITH CLOZAPINE: A STUDY OF THE FINNISH EPIDEMIC.

001742 02-15

EPIDEMIOLOGY
THE EPIDEMIOLOGY OF ACUTE POISONING. 001937 02-17 **EPIDEMIOLOGY OF MARIHUANA LISE**

Psychopharmacology Abstracts

003611 04-13

HEREDITARY COPROPORPHYRIA AND EPILEPSY.

CEREBELLAR UNIT ACTIVITY DURING GENERALIZED PENICILLIN EPILEPSY IN THE AWAKE CAT.

SLOW-WAVE SLEEP AND A STATE RESEMBLING ABSENCE EPILEPSY INDUCED IN THE RAT BY GAMMA-HYDROXYBUTYRATE.

001366 02-04 PSYCHOTROPIC EFFECTS OF CARBAMAZEPINE IN EPILEPSY: A DOUBLE-BLIND COMPARISON WITH PHENYTOIN.

CLONAZEPAM IN THE TREATMENT OF EPILEPSY IN HANDICAPPED PATIENTS.

002503 03-11 CAN PHENYTOIN BE GRADUALLY WITHDRAWN IN PATIENTS WITH MAJOR MOTOR EPILEPSY MAINTAINED ON CLONAZEPAM AND PHENOBARBITAL?

002504 03-11 EPILEPSY IN CHILD PSYCHIATRY. EFFECTS OF TREATMENT BY DIPROPYLACETIC-ACID.

NONMONOAMINE-OXIDASE INHIBITOR ANTIDEPRESSANTS AND EPILEPSY: A REVIEW.

EPILEPTIC SEIZURES INDUCED BY PSYCHOTROPIC DRUGS.

000905 01-15 MORPHINE AND ENKEPHALIN: ANALGESIC AND EPILEPTIC PROPERTIES

001267 02-03 EFFECTS OF MYSOLINE AND DILANTIN ON THE EEG DURING SMR BIOFEEDBACK TRAINING OF A PSYCHOMOTOR EPILEPTIC: SINGLE CASE

001657 02-13 ELECTROENCEPHALOGRAPHIC PECULIARITIES DURING ACUTE DRUG INTOXICATIONS IN EPILEPTIC PATIENTS.

002689 03-15 DIFFERENT BRAIN AREAS MEDIATE THE ANALGESIC AND EPILEPTIC PROPERTIES OF ENKEPHALIN.

002015 04-03 EPILEPTIC PROPERTIES OF LEUCINE-ENKEPHALIN AND METHIONINE-ENKEPHALIN: COMPARISON WITH MORPHINE AND REVERSIBILITY BY NALOXONE.

002916 04-03

EPILEPTICS

EFFECT OF DIPROPYLACETATE (CONVULEX) ON PERSONALITY CHANGES IN
EPILEPTICS: PRELIMINARY REPORT.

000757 01-14

THE INVESTIGATION OF PHENOBARBITONE, PHENYTOIN AND PRIMIDONE IN THE DEATH OF EPILEPTICS. 000806 01-15

CEREBELLAR ATROPHY IN PHENYTOIN TREATED MENTALLY RETARDED EPILEPTICS. 001622 02-11
ALERTNESS IN EPILEPTICS: PHARMACOLOGICAL AND PSYCHOMETRIC

STUDY. 002526 03-11

THE IMPORTANCE OF TELEMETRIC RECORDING IN THE STUDY OF NEUROPSYCHOLOGICAL FUNCTION IN EPILEPTICS.

002606 03-14

THE ACTIONS OF DIAZEPAM AND PHENYTOIN ON A LOW DOSE PENICILLIN EPILEPTIFORM FOCUS IN THE ANESTHETISED RAT. 002921 04-03 EPILEPTOGENIC
THE INFLUENCE OF PENTOBARBITAL UPON A CORTICAL EPILEPTOGENIC

001411 02-04

POTENTIATION OF THE EPILEPTOGENIC EFFECT OF PENICILLIN-G BY MARIHUANA SMOKING. 002066 03-03

LOWERING OF EPINEPHRINE CONCENTRATION IN RAT BRAIN BY 2,3 DICHLORO-ALPHA-METHYL-BENZYLAMINE, AN INHIBITOR OF NOREPINEPHRINE-N-METHYLTRANSFERASE.

METABOLIC RESPONSES TO ISOPROTERENOL AND EPINEPHRINE IN THE RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES AND PRETREATMENT WITH PROPRANOLOL.

000227 01-03 EFFECT OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION ON EPINEPHRINE LEVELS IN THE BRAIN.

THE EFFECT OF EPINEPHRINE ON TONIC IMMOBILITY (ANIMAL HYPNOSIS)

DEPENDENCE OF THE INFLUENCE OF EPINEPHRINE ON THE EXCITABILITY OF GIANT NEURONS ON ITS CONCENTRATION.

001967 03-03

002765 03-17

EPINEPHRINE IN RAT HYPOTHALAMUS: ANTAGONISM BY DESIPRAMINE OF 6 HYDROXYDDPAMINE-INDUCED DEPLETION. 003110 04-03

EPISODE

LONG-ACTING ORAL VS INJECTABLE ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENICS: A ONE-YEAR DOUBLE-BLIND COMPARISON IN MULTIPLE EPISODE SCHIZOPHRENICS.

003467 04-08

RETROSPECTIVE DIAGNOSIS OF HYPOMANIA FOLLOWING SUCCESSFUL TREATMENT OF EPISODIC VIOLENCE WITH LITHIUM: A CASE REPORT 003490 04-09 EPITHELANTHA-MICROMERIS
TRITERPENES FROM THE BUTTON CACTUS, EPITHELANTHA-MICROMERIS

001018 02-01 A NEW NEUROMODULATOR OF THE EXTRAPYRAMIDAL SYSTEM (EPS)

EQUAL

EQUAL SUPPRESSION OF CEREBELLAR PURKINJE CELL ACTIVITY BY AMPHETAMINE STEREOISOMERS.

A ROLE OF THE POLYSYNAPTIC SYSTEM OF SUBSTANTIA-NIGRA IN THE CHOLINERGIC DOPAMINERGIC EQUILIBRIUM IN THE CENTRAL-NERVOUS-

EQUIPOTENT

DEXTROAMPHETAMINE AND L AMPHETAMINE ARE EQUIPOTENT IN RELEASING HUMAN GROWTH HORMONE. 002576 03-13

LEARNING RATE EQUIVALENCY OF TWO NARCOTIC GASES

001701 02-14

002269 03-04

001952 03-02

000299 01-03

003397 04-04

PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. I. CHRONICALLY EQUIVALENT DOSING METHOD. 002360 03-06

EQUIVOCAL

BEHAVIORAL TOXICITY AND EQUIVOCAL SUICIDE ASSOCIATED WITH CHLOROQUINE AND ITS DERIVATIVES.

000839 01-15 EFFECTS OF NEUROLEPTICS ON MORPHINE-INDUCED TAIL ERECTION IN

001400 02-04 MORPHINE-INDUCED TAIL ERECTION: SITE OF ACTION.

ERGOLENE

DOPAMINE RECEPTORS AND ERGOT DRUGS. EVIDENCE THAT AN ERGOLENE DERIVATIVE IS A DIFFERENTIAL AGONIST AT SUBCORTICAL LIMBIC DOPAMINE RECEPTORS.

ERGONOVINE-MALEATE

SELECTIVE BLOCKADE OF DOPAMINE-INDUCED VASODILATION BY ERGONOVINE-MALEATE IN THE VASCULATURES OF DOGS AND

FRGOT

003067 04-03 PHARMACOTHERAPY FOR ORGANIC-BRAIN-SYNDROME IN LATE LIFE: EVALUATION OF AN ERGOT DERIVATIVE VS PLACEBO.

000628 01-11 EFFECTS OF LERGOTRILE (LER), AN ERGOT DERIVATIVE, ON ACTIVITY OF SUBSTANTIA-NIGRA PARS COMPACTA DOPAMINE (DA) NEURONS.

001278 02-03 BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF HYPOXIC HYPOXIA IN RATS: STUDY OF THE PROTECTION AFFORDED BY ERGOT ALKALOIDS 001971 03-03

DOPAMINE RECEPTORS AND ERGOT DRUGS. EVIDENCE THAT AN ERGOLENE DERIVATIVE IS A DIFFERENTIAL AGONIST AT SUBCORTICAL LIAARIC DOPAMINE RECEPTORS

002019 03-03 BINDING INTERACTIONS OF ERGOT ALKALOIDS WITH MONOAMINERGIC RECEPTORS IN THE BRAIN.

002024 03-03 EFFECT OF ERGOT ALKALOIDS AND OF NEUROLEPTICS ON BINDING TO PUTATIVE DOPAMINE AND ALPHA RECEPTORS

002078 03-03 AS MEASURED DOPAMINE-MIMETIC ACTIVITY OF ERGOT DERIVATIVES, BY THE PRODUCTION OF CYCLIC-AMP IN ISOLATED RETINAE OF THE

002149 03-03 INTERACTION OF ERGOT ALKALOIDS WITH DOPAMINERGIC RECEPTORS IN THE RAT STRATUM AND NUCLEUS-ACCUMBENS.

002157 03-03 CHANGES IN THE RAT ELECTROCORTICOGRAM FOLLOWING
ADMINISTRATION OF TWO DIHYDROGENATED ERGOT DERIVATIVES

DIFFERENCES IN THE DOPAMINERGIC EFFECTS OF THE ERGOT
DERIVATIVES BROMOCRIPTINE, LISURIDE AND D LSD AS COMPARED WITH APOMORPHINE 003244 04-04

ERYTHROCYTE

ERYTHROCYTE/PLASMA LITHIUM RATIOS.

000586 01-09 LITHIUM AND ERYTHROCYTE MEMBRANE CATION CARRIER STUDIES IN NORMAL AND MANIC-DEPRESSIVE SUBJECTS.

000717 01-13 MEMBRANE. 001658 02-13 TRANSFER OF LITHIUM-IONS ACROSS THE ERYTHROCYTE

COMPUTER SIMULATION OF THE MOVEMENT OF LITHIUM ACROSS ERYTHROCYTE MEMBRANES IN VITRO.

001869 02-16 LITHIUM ERYTHROCYTE/PLASMA RATIO AS A PREDICTOR OF RESPONSE.

002431 03-09

LITHIUM ERYTHROCYTE:PLASMA RATIO IN PRIMARY AFFECTIVE DISCIPLIER

002445 03-09 MEASUREMENT OF PLASMA AND ERYTHROCYTE CHLORPROMAZINE AND N MONODESMETHYLCHLORPROMAZINE LEVELS BY GAS-CHROMATOGRAPHY WITH A NITROGEN SENSITIVE DETECTOR. 003429 04-06

ERYTHROCYTE ACCUMULATION OF THE LITHIUM-ION IN CONTROL SUBJECTS AND PATIENTS WITH PRIMARY AFFECTIVE-DISORDER 003519 04-09

LOWERED ERYTHROCYTE SEDIMENTATION RATE WITH SODIUM VALPROATE

LITHIUM EFFLUX FROM ERYTHROCYTES INCUBATED IN VITRO DURING LITHIUM-CARBONATE ADMINISTRATION.

EFFECT OF DRUGS ON HUMAN ERYTHROCYTES -- 4. PROTECTING EFFECT OF DEXTRAN ON DRUG-INDUCED HEMOLYSIS.

003603 04-13

003672 04-15

PECAPE

AN INVESTIGATION OF NALORPHINE AND PERPHENAZINE AS NEGATIVE REINFORCERS IN AN ESCAPE PARADIGM. 000389 01-04

THE EFFECT OF ETHANOL ON SUPPRESSION OF THE NALOXONE PRECIPITATED ESCAPE RESPONSE IN MORPHINE-DEPENDENT MICE 002230 03-04

DORSOMEDIAL THALAMIC LESIONS AND AMPHETAMINE: ACQUISITION AND RETENTION OF A VISUAL PATTERN DISCRIMINATION ESCAPE TASK. 003399 04-04

ESOPHAGEAU

ESOPHAGEAL CANNULATION FOR INTRAGASTRIC DELIVERY OF FLUIDS TO UNRESTRAINED DOGS. 003436 04-06

ESTABLISH

OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR OPERANT DRUG DISCRIMINATIONS. 003434 04-06

ESTABLISHMENT OF ETONITAZENE AS A REINFORCER FOR RATS BY USE OF SCHEDULE-INDUCED DRINKING. 002281 03-04

ESTAZOLAM

DIFFERENTIATION OF HYPNOTIC ACTION OF NITRAZEPAM AND ESTAZOLAM AND EFFECTS ON BEHAVIOR AND CORTICAL ACTIVITY

ACTION OF THE PALMITIC ESTER OF PIPOTIAZINE ON DOPAMINE METABOLISM IN THE NIGROSTRIATAL, MESOLIMBIC AND MESOCORTICAL SYSTEMS

SYNTHESIS AND PRELIMINARY PHARMACOLOGICAL ACTIVITY OF AMINOALKOXY ISOSTERES OF GLYCOLATE ESTER ANTICHOLINERGICS

INTERACTIONS OF NARCOTICS AND THEIR ANTAGONISTS WITH HUMAN SERUM ESTERASE. VI: THE BEHAVIOR OF 14 HYDROXYLATED MORPHINE DERIVATIVES.

000690 01-13

BICYCLIC PHOSPHORUS ESTERS INCREASE THE CYCLIC-GMP LEVEL IN RAT

PLASMA FLUPHENAZINE CONCENTRATIONS AFTER INJECTION OF LONG-ACTING ESTERS.

003590 04-13

PSTIMATES

MARIJUANA: DOSE-RESPONSE EFFECTS ON PULSE RATE, SUBJECTIVE ESTIMATES OF POTENCY, PLEASANTNESS, AND RECOGNITION MEMORY.

000648 01-11

ESTIMATION
ESTIMATION OF DEANOL AND CHOLINE BY GAS-CHROMATOGRAPHY
MASS-SPECTROMETRY.
003426 (

003426 04-06

THE SYNTHESIS AND URINARY ESTIMATION OF N

003595 04-13

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — I. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS. 002931 04-03

IMPLICATIONS OF DOSE REGIMEN AND PROTEIN BINDING FOR PLASMA NORTRIPTYLINE ESTIMATIONS.

FACILITATION OF MOUNTING BEHAVIOR BY DIHYDROTESTOSTERONE-PROPIONATE IN CASTRATED ESTRADIOL-BENZOATE TREATED MALE RATS FOLLOWING PUDENDECTOMY.

000403 01-04

ROLE OF NOREPINEPHRINE IN THE RELEASE OF PROLACTIN INDUCED BY SUCKLING AND ESTROGEN.

001071 02-03 LORDOSIS REFLEX, SEXUAL RECEPTIVITY, AND FEEDING: ESTROGEN RESPONSIVITY IN MALE AND FEMALE RATS.

EFFECTS OF ESTROGEN AND AMINERGIC DRUGS ON THRESHOLDS OF MEDIAL BASAL HYPOTHALAMIC AXONS IN THE MEDIAN EMINENCE OF THE RAT.

002974 04-03 DELTA9-TETRAHYDROCANNABINOL ENHANCEMENT OF LORDOSIS BEHAVIOR IN ESTROGEN TREATED FEMALE RATS.

EFFECTS OF THE PROSTAGLANDIN SYNTHESIS INHIBITOR, INDOMETHACIN ON ESTROGEN AND ESTROGEN PLUS PROGESTERONE-INDUCED SEXUAL RECEPTIVITY IN OVARIECTOMIZED RATS.

003237 04-04
SIMILAR EFFECTS OF ESTROGEN AND LATERAL HYPOTHALAMIC LESIONS
ON FEEDING BEHAVIOR OF FEMALE RATS.

AGGRESSION PROMOTING AND AGGRESSION ELICITING PROPERTIES OF ESTROGEN IN MALE MICE.

003360 04-04

DIETARY EFFECTS UPON FOOD AND WATER INTAKE AND RESPONSIVENESS TO ESTROGEN, 2 DEOXYGLUCOSE AND GLUCOSE IN FEMALE RATS. 003402 04-04

ROGEN-INDUCED

DOES PROLACTIN PLAY A ROLE IN ESTROGEN-INDUCED MATERNAL BEHAVIOR IN RATS: APOMORPHINE REDUCTION OF PROLACTIN RELEASE. 000445 01-04

IS DELTA9-TETRAHYDROCANNABINOL ESTROGENIC?.

000210 01-03 EFFECT OF EXOGENOUS ESTROGENS ON DEPRESSION IN MENOPAUSAL

001603 02-09 EFFECTS OF CATECHOL ESTROGENS ON SEXUAL DIFFERENTIATION IN NEONATAL FEMALE RATS.

002293 03-04 ESTROGENS: THEIR FUNCTIONS, USES AND HAZARDS: PART 2 002706 03-15

VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF 2
AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF NAD:NADH AND
NORELEAGNINE A BETA-CARBOLINE DERIVATIVE.

000200 01-03 ABSENCE OF FORMATION OF BRAIN SALSOLINOL IN ETHANOL DEPENDENT

000208 01-03 METABOLIC BASIS FOR THE SUPRA-ADDITIVE EFFECT OF THE ETHANOL DIAZEPAM COMBINATION IN MICE.

000218 01-03 MAO ACTIVITY IN RAT BRAINSTEM AND CEREBRAL-CORTEX FOLLOWING ACUTE AND CHRONIC TREATMENT WITH L-DOPA AND ETHANOL L-DOPA.

DIRECT EFFECTS OF ETHANOL ON CENTRAL-NERVOUS-SYSTEM CULTURES: AN ELECTROPHYSIOLOGICAL AND MORPHOLOGICAL STUDY.

000261 01-03 EFFECT OF ETHANOL ON (3H)OUABAIN BINDING TO DIFFERENT REGIONS OF THE CAT BRAIN.

THE EFFECTS OF 6 HYDROXYDOPAMINE ON TOLERANCE TO AND DEPENDENCE ON ETHANOL.

000280 01-03

Psychopharmacology Abstracts

TIME ACTION AND BEHAVIORAL EFFECTS OF AMPHETAMINE, ETHANOL, AND ACETYLMETHADOL.

000350 01-04 TOLERANCE TO ETHANOL: EFFECT OF CONGENERS PRESENT IN BOURBON.

EFFECTS OF THREE MONOAMINE-OXIDASE INHIBITORS ON PREFERENCE IN MICE.

000447 01-04 ORPHINE AND ETHANOL AS DISCRIMINATIVE STIMULI: ABSENCE OF ANTAGONISM BY P-CHLOROPHENYLALANINE-METHYL-ESTER, CINANSENIN, OR BC-105.

COMPARISON OF ETHANOL, PENTOBARBITAL, AND PHENOBARBITAL USING DRUG VS. DRUG DISCRIMINATION TRAINING.

ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: INTERACTIVE EFFECTS ON HUMAN PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS. II. 000673 01-12

DISULFIRAM ETHANOL REACTION. 000707 01-13

EFFECT OF P-CHLOROPHENYLALANINE ON DEVELOPMENT OF CROSS-TOLERANCE BETWEEN PENTOBARBITAL AND ETHANOL.

001123 02-03 STUDIES OF A PHARMACOLOGICAL MODEL OF ETHANOL DEPENDENCE IN THE RAT. (PH.D. DISSERTATION).

001125 02-03 ALTERATIONS IN DOPAMINE RECEPTOR SENSITIVITY BY CHRONIC ETHANOL TREATMENT.

001146 02-03 INTERACTIONS OF DELTA9-TETRAHYDROCANNABINOL WITH PHENOBARBITAL, ETHANOL AND CHLORDIAZEPOXIDE.

001436 02-04 ETHANOL -- ITS NEPHROTOXIC EFFECT IN THE RAT

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DRUG DISTRIBUTION AND METABOLISM: ANTIPYRENE, PENTOBARBITAL, AND ETHANOI 001643 02-13

THE EFFECTS OF SUBHYPNOTIC DOSES OF ETHANOL ON REGIONAL CATECHOLAMINE TURNOVER.

001964 03-03 EFFECT OF P-CHLOROPHENYLALANINE ON THE LOSS AND MAINTENANCE OF TOLERANCE TO ETHANOL.

002014 03-03 THE EFFECT OF ETHANOL ON SUPPRESSION OF THE NALOXONE
PRECIPITATED ESCAPE RESPONSE IN MORPHINE-DEPENDENT MICE

002230 03-04 EFFECTS OF ETHANOL: ALTERATION BY INORGANIC IONS AND NALOXONE.

002242 03-04 STEREOTYPY AND HYPERACTIVITY IN RATS RECEIVING ETHANOL AND A MONOAMINE-OXIDASE INHIBITOR.

002248 03-04 EVIDENCE FOR PARALLEL DEVELOPMENT OF TOLERANCE TO THE HYPERACTIVATING AND DISCOORDINATING EFFECTS OF ETHANOL

002249 03-04 ETHANOL, PENTOBARBITAL, AND CHLORDIAZEPOXIDE EFFECTS IN SQUIRREL-MONKEYS RESPONDING UNDER FIXED-RATIO FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION SCHEDULES

002254 03-04 EFFECTS OF D AMPHETAMINE AND ETHANOL ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION.

002255 03-04 THE EFFECT OF CHRONIC ETHANOL TREATMENT ON BEHAVIOUR AND CENTRAL MONOAMINES IN THE RAT.

INTOXICATING EFFECTS OF THREE ALIPHATIC ALCOHOLS AND BARBITAL ON TWO RAT STRAINS GENETICALLY SELECTED FOR THEIR ETHANOL INTAKE.

002276 03-04 AMANTADINE-HYDROCHLORIDE (AMN): ANTAGONISM TO ETHANOL (ETOH) MEDIATED RESPONSES IN RODENTS.

REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF L-DOPA, AMINOPHYLLINE, AND EPHEDRINE.

002544 03-13 APOMORPHINE AND AMANTADINE: INTERACTION WITH ETHANOL IN HUMANS.

002605 03-14 RESIDUAL EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE TREATMENTS FOR ALCOHOL WITHDRAWAL.

002617 03-14 ANTAGONISM OF ETHANOL EVOKED RESPONSES BY AMANTADINE: A POSSIBLE CLINICAL APPLICATION.

002797 04-02 TERATOLOGICAL EVALUATION OF ETHANOL, PENTOBARBITAL, AND COMBINATIONS OF THESE, IN THE RAT.

002976 04-03 EFFECTS OF ETHANOL WITHDRAWAL, STRESS AND AMPHETAMINE ON RAT BRAIN NA-K-ATPASE.

DOPAMINE RECEPTOR FUNCTION AFTER CHRONIC INGESTION OF

003106 04-03

ALTERATIONS IN RECEPTORS CONTROLLING DOPAMINE SYNTHESIS AFTER CHRONIC ETHANOL INGESTION.

003107 04-03
ETHANOL AND DISPOSITION OF AMYLOBARBITONE: EFFECT OF DOSE AND SIGNIFICANCE AS A MECHANISM FOR INCREASED TOXICITY.

003114 04-03
INTERACTION OF ETHANOL WITH AMYLOBARBITONE, PHENOBARBITONE
AND METHAQUALONE.

THE EFFECTS OF DL-5-HYDROXYTRYPTOPHAN ON ETHANOL

CONSUMPTION BY RATS.

O03148 04-03

EFFECTS OF ETHANOL AND PENTOBARBITAL IN MICE OF DIFFERENT AGES.
O03151 04-04

SIMILARITIES AND DIFFERENCES IN DISCRIMINATIVE STIMULUS EFFECTS
OF CHLORDIAZEPOXIDE, PENTOBARBITAL, ETHANOL, AND OTHER
SEDATIVES.

O03163 04-04
COMBINED EFFECTS OF ETHANOL AND DIAZEPAM ON PERFORMANCE
AND ACQUISITION OF SERIAL POSITION SEQUENCES BY PIGEONS.
003164 04-04

ANTAGONISM OF NALOXONE HYPERALGESIA BY ETHANOL. 003165 04-04

BIMODAL DISTRIBUTIONS OF HIGHEST ETHANOL ACCEPTANCE CONCENTRATIONS IN TWO STRAINS OF RATS.

003229 04-04

EFFECTS OF THE ACUTE ADMINISTRATION OF ETHANOL ON THE SLEEP OF THE RAT: A DOSE-RESPONSE STUDY.

INTERACTION BETWEEN D AMPHETAMINE AND ETHANOL WITH RESPECT TO LOCOMOTION, STEREOTYPIES, ETHANOL SLEEPING TIME, AND THE KINETICS OF DRUG ELIMINATION.

THANOLAMINE O SULFATE

ETHANOLAMINE-O-SULFATE

SPONTANEOUS AND AMPHETAMINE-INDUCED BEHAVIOR AFTER
BILATERAL INJECTION OF ETHANOLAMINE-O-SULFATE INTO THE
SURSTANTIA-NIGRA

ETHANGLAMINE-O-SULPHATE 002262 03-04

THE EFFECTS OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE IN AN ANIMAL TEST OF ANXIETY.

001121 02-0

THE EFFECTS OF ETHANOLAMINE-O-SULPHATE INJECTION INTO THE RAT SUBSTANTIA-NIGRA: ELECTROPHYSIOLOGICAL STUDIES.

003033 04-03

CIRCLING BEHAVIOUR IN THE RAT FOLLOWING UNILATERAL INJECTIONS OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE INTO THE SUBSTANTIA-NIGRA.

ETHANOLAMINE-O-SULPHATE-INDUCED

REGIONAL CHANGES IN THE CONCENTRATIONS OF CEREBRAL MONOAMINES AND THEIR METABOLITES AFTER ETHANOLAMINE-O-SULPHATE-INDUCED ELEVATION OF BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS

ETHCHLORVYNOL

ETHCHLORVYNOL INTOXICATION.

001849 02-15
POLYGRAPHIC EVALUATION OF ETHCHLORVYNOL (14 DAYS).

002679 03-15

ETHER

THE EFFECTS OF ETHER STRESS AND BETAMETHASONE TREATMENT ON THE CONCENTRATIONS OF NORADRENALINE AND DOPAMINE IN VARIOUS REGIONS OF THE RAT BRAIN.

000288 01-03

ETHINYL-ESTRADIOL

QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P-450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3 METHYCHOLANTHRENE.

002083 03-03

ETHNOPHARMACOLOGY OF SACRED PSYCHOACTIVE PLANTS USED BY THE INDIANS OF MEXICO. 001894 02-17

PETHOLOGICALLY

PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD
SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A
HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS
THERAPPUTICA PPLICATION.

ETHOSUXIMIDE

ANTICONVULSANT INTERACTION OF CANNABIDIOL AND ETHOSUXIMIDE
IN RATS.

000339 01-04

ETHOXY-9-HYDROXY-DELTA6A-TETRAHYDROCANNABINOL ISOLATION AND CHARACTERIZATION OF () CANNABITRIOL AND (-) 10 ETHOXY-9-HYDROXY-DELTA6A-TETRAHYDROCANNABINOL: TWO NEW CANNABINOIDS FROM CANNABIS-SATIVA L. EXTRACT.

ETHYL-5-HYDROXY-1-METHYLBUTYLBARBITURIC-ACID
THE ANTAGONISTIC EFFECTS OF 5 ETHYL-5-HYDROXY-1METHYLBUTYLBARBITURIC-ACID ON PENTOBARBITAL NARCOSIS IN
BOTH NAIVE AND TOLERANT MICE.

002336 03-04

HYLAMPHETAMINE
RELEASE OF ENDOGENOUS CATECHOLAMINES FROM ISOLATED RAT
BRAIN TISSUE BY FENFLURAMINE AND N ETHYLAMPHETAMINE —
EFFECTS OF PARGYLINE.

ETHYLKETAZOCINE
CHANGES IN LOCOMOTOR ACTIVITY AND NALOXONE-INDUCED JUMPING
IN MICE PRODUCED BY WIN-35197-2 (ETHYLKETAZOCINE) AND
MORPHINE.
003376 04-04

DEPRESSION IN THE ELDERLY. II. POSSIBLE DRUG ETIOLOGIES;
DIFFERENTIAL DIAGNOSTIC CRITERIA.

003520 04-09

DRUG VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA
APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS.

001777 02-15

AMANTADINE-HYDROCHLORIDE (AMN): ANTAGONISM TO ETHANOL
(ETOH) MEDIATED RESPONSES IN RODENTS.

002282 03-04

ELECTROENCEPHALOGRAPHIC STUDY OF THE SHORT-ACTING HYPNOTICS ETOMIDATE AND METHOMEXITAL IN DOGS. 002177 03-03

CENTRAL NERVOUS EFFECTS OF THE HYPNOTIC ETOMIDATE IN MAN.
002580 03-13

DIFFERENTIAL MOTOR EFFECTS OF INTRAVENTRICULAR INFUSION OF MORPHINE AND ETONITAZENE.

ESTABLISHMENT OF ETONITAZENE AS A REINFORCER FOR RATS BY USE OF SCHEDULE-INDUCED DRINKING.

PHARMACOLOGICAL INVESTIGATIONS ON ETOPERIDONE, A NEW PSYCHOTROPIC AGENT. 003720 04-17

ETORPHINE AND SHUTTLE-BOX SELF-STIMULATION IN THE RAT.
001304 02-04
THE EFFECTS OF ETORPHINE, FENTANYL AND MORPHINE ON
NORADRENALINE AND DOPAMINE CONCENTRATIONS IN THE STRIATUM
OF RAT.

SUBCELLULAR DISTRIBUTION OF ETORPHINE IN RAT BRAIN AND EVIDENCE FOR IN VIVO STEREOSPECIFIC BINDING.

EUHYPNOS
TEMAZEPAM (EUHYPNOS) AS A HYPNOTIC: A TWELVE-WEEK TRIAL IN
GENERAL PRACTICE.

000763 01-14
TEMAZEPAM (EUHYPNOS) AS A HYPNOTIC: A MULTICENTRE TRIAL IN
GENERAL PRACTICE.

000764 01-14
TEMAZEPAM (EUHYPNOS) AND CHLORMETHIAZOLE: A COMPARATIVE
STUDY IN GERIATRIC PATIENTS.
003634 04-14

MORPHINE AND SHUTTLE-BOX SELF-STIMULATION IN THE RAT: A MODEL FOR EUPHORIA.

EUROPEAN
EVALUATION OF A NEW IMMUNOASSAY FOR DETERMINATION OF
PHENYTOIN AND PHENOBARBITAL: RESULTS OF A EUROPEAN
COLLABORATIVE CONTROL STUDY.

002529 03-11

BUTHYROID
INHIBITION OF FLAVIN SYNTHESIS BY CHLORPROMAZINE IN EUTHYROID

AND HYPERTHYROID RATS. 002352 03-05
EVALUATE

A GRADUAL SCORE TO EVALUATE THE CLIMBING BEHAVIOUR ELICITED BY APOMORPHINE IN MICE. 002350 03-05

001737 02-14

A METHOD FOR EVALUATING ANXIOLYTIC SEDATIVES.

000616 01-10 EVALUATING ANTIANXIETY AGENT IN HUMANS: EXPERIMENTAL PARADIGMS.

000661 01-11

SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM EVALUATION OF SOME 5
ALKOXY-3H-1.4 BENZODIAZEPINES.

EVALUATION OF NALOXONE IN LABORATORY TESTS PREDICTIVE OF CLINICAL ANTIPSYCHOTIC ACTIVITY.

ANTIPSYCHOTIC PREPARATION.

EVALUATION OF RADIORESPIROMETRY FOR THE DETERMINATION OF MONOAMINE-OXIDASE ACTIVITY IN VIVO UTILIZING C11-OCTYLAMINE AS A SUBSTRATE.

SULPIRIDE: EVALUATION OF ANTIPSYCHOTIC ACTIVITY IN SCHIZOPHRENIC **PATIENTS** 000512 01-07

SOME METHODOLOGICAL CONSIDERATIONS FOR THE CLINICAL EVALUATION OF NEUROLEPTICS -- COMPARATIVE EFFECTS OF CLOZAPINE AND HALOPERIDOL ON SCHIZOPHRENICS.

000531 01-08 MOLINDONE: A CONTROLLED EVALUATION OF THE INTRAMUSCULAR

000541 01-08 A COMPARATIVE CLINICAL STUDY FOR THE EVALUATION OF ANTIANXIETY AGENTS, (LORAZEPAM, DIAZEPAM AND PLACEBO), IN NEUROSIS.

ANXIETY STATES IN FAMILY PRACTICE: AN EVALUATION OF THE NEED FOR ANTIDEPRESSANT AS WELL AS ANXIOLYTIC THERAPY.

POSTTRAUMATIC PSYCHONEUROSIS: EVALUATION OF DRUG THERAPY. 000615 01-10

PHARMACOTHERAPY FOR ORGANIC-BRAIN-SYNDROME IN LATE LIFE: EVALUATION OF AN ERGOT DERIVATIVE VS PLACEBO.

EVALUATION OF LITHIUM-CARBONATE IN THE MANAGEMENT OF GILLES-DE-LA-TOURETTES SYNDROME.

000646 01-11 VALPROATE-SODIUM: EVALUATION OF SO-CALLED PSYCHOTROPIC EFFECT. A CONTROLLED STUDY.

AN EVALUATION OF THE CARDIOPULMONARY SAFETY AND EFFICACY OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS ORAL HYPNOTIC

TAXONOMY AND EVALUATION OF PSYCHOLOGICAL TEST METHODS IN PSYCHOTROPIC DRUG TRIALS.

000915 01-16 EVALUATION OF THE PRISON INMATE AS A SUBJECT IN DRUG

ASSESSMENT 000982 01-17 STEREOCHEMICAL STUDIES ON MEDICINAL AGENTS. 23. SYNTHESIS AND BIOLOGICAL EVALUATION OF 6 AMINO DERIVATIVES OF NALOXONE AND NALTREXONE.

()- AND (-) 3 METHOXYCYPROHEPTADINE. A COMPARATIVE EVALUATION OF THE ANTISEROTONIN, ANTIHISTAMINIC, ANTICHOLINERGIC, AND OREXIGENIC PROPERTIES WITH CYPROHEPTADINE.

001012 02-01

PRECLINICAL EVALUATION OF DITA DICHLORO-2-IMIDAZOLINYLTHIOACETOPHENONE-HBR: A NEW ANOREXIGENIC

001020 02-02 EVALUATION OF PURE DIASTEREOMERS OF N SEC ALKYLMORPHINOIDS. 001040 02-02 PHENYTOIN: AN EVALUATION OF SEVERAL POTENTIAL TERATOGENIC MECHANISMS.

001097 02-03 BENZHYDRYL PIPERAZINES: A NEUROPHARMACOLOGICAL AND PSYCHOPHARMACOLOGICAL EVALUATION. (PH.D. DISSERTATION)

EVALUATION OF SUBSTITUTED AMPHETAMINE HALLUCINOGENS USING THE CAT LIMB FLICK MODEL.

AN EVALUATION OF A UNIQUE NEW ANTIPSYCHOTIC AGENT, SULPIRIDE: EFFECTS ON SERUM PROLACTIN AND GROWTH HORMONE LEVELS. 001554 02-07

EVALUATION OF BUTACLAMOL IN CHRONIC SCHIZOPHRENIC PATIENTS 001649 02-13 EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 2. BIOCHEMICAL ANALYSIS.

001652 02-13 EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 1. CLINICAL ANALYSIS.

Psychopharmacology Abstracts

STATISTICAL EVALUATION: PRESUMPTION AND METHODS.

EVALUATION OF DIFFERENT TREATMENTS IN MINIMAL-CEREBRAL-001920 02-17

SINGLE-BLIND EVALUATION OF HYPNOTIC ACTIVITY OF CHLORDESMETHYLDIAZEPAM IN NO-PLACEBO REACTOR MEDICAL PATIENTS.

002379 03-07 EVALUATION OF LOXAPINE HYDROCHLORIDE ORAL CONCENTRATE (LOXITANE C) IN ACUTE SCHIZOPHRENIA. 002411 03-08

CLINICAL EVALUATION OF TRAZODON

002427 03-09 EVALUATION OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTIC AGENTS IN PRESURGICAL PATIENTS.

EVALUATION OF A NEW IMMUNOASSAY FOR DETERMINATION OF PHENYTOIN AND PHENOBARBITAL: RESULTS OF A EUROPEAN COLLABORATIVE CONTROL STUDY.

002529 03-11 EFFECTIVENESS OF TEMAZEPAM WITH SHORT-TERM, INTERMEDIATE-TERM, AND LONG-TERM USE: SLEEP LABORATORY EVALUATION.

002608 03-14 THE EFFECT OF NITRAZEPAM ON MANUAL SKILL, GRIP STRENGTH, AND REACTION TIME WITH SPECIAL REFERENCE TO SUBJECTIVE EVALUATION OF EFFECTS ON SLEEP.

002626 03-14 POLYGRAPHIC EVALUATION OF ETHCHLORVYNOL (14 DAYS)

002679 03-15 EXTENSION OF ANIMAL MODELS TO CLINICAL EVALUATION OF ANTIANXIETY AGENTS.

002716 03-16 MODEL FOR EVALUATION OF ANTIANXIETY DRUGS WITH THE USE OF EXPERIMENTALLY-INDUCED STRESS; COMPARISON OF NABILONE AND

CLINICAL EVALUATION OF NALTREXONE TREATMENT OF OPIATE-DEPENDENT INDIVIDUALS: REPORT OF THE NATIONAL RESEARCH COUNCIL COMMITTEE ON CLINICAL EVALUATION OF NARCOTIC ANTAGONISTS

002768 03-17 TERATOLOGICAL EVALUATION OF ETHANOL, PENTOBARBITAL, AND COMBINATIONS OF THESE, IN THE RAT.

002976 04-03 EVALUATION OF THE EFFECT OF P-CHLOROAMPHETAMINE ON INDIVIDUAL CATECHOLAMINERGIC NUCLEI IN THE RAT BRAIN.

003003 04-03 NEUROPHARMACOLOGICAL AND BEHAVIORAL EVALUATION OF PROSTAGLANDIN-E2 AND 11 THIOL-11-DESOXYPROSTAGLANDIN-E2 IN THE MOUSE AND RAT.

003173 04-04 ON THE OBJECTIVE EVALUATION OF HALOPERIDOL EFFECTS IN MAN: A

PILOT STUDY 003442 04-07

DOUBLE-BLIND THERAPEUTIC EVALUATION OF FLUSPIRILENE COMPARED WITH FLUPHENAZINE-DECANOATE IN CHRONIC SCHIZOPHRENICS. 003456 04-08

THE PRACTICAL SIGNIFICANCE OF NORTRIPTYLINE PLASMA CONTROL. A PROSPECTIVE EVALUATION UNDER ROUTINE CONDITIONS IN ENDOGENOUS DEPRESSION.

003522 04-09 COMPARATIVE EVALUATION OF HYPNOTIC EFFICACY OF FLUNITRAZEPAM IN PSYCHIATRIC PATIENTS.

003574 04-11 EVALUATION OF A PATIENT DRUG SELF-ADMINISTRATION PROGRAM.
(PH.D. DISSERTATION).

003700 04-17

EVALUATIONS OF SOCIAL FUNCTIONING IN A 3-YEAR DOUBLE-BLIND INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.

000518 01-08 FLUNITRAZEPAM, AN INVESTIGATIONAL HYPNOTIC DRUG: SLEEP LABORATORY EVALUATIONS.

000750 01-14 EXPERIENCE WITH SINEQUAN IN A SINGLE EVENING DOSE.

000609 01-10 FLUNITRAZEPAM (ROHYPNOL) COMPARED WITH NITRAZEPAM (MOGADON) AND APROBARBITAL AS EVENING PREMEDICATION PRIOR TO ANESTHESIA: A CONTROLLED CLINICAL TRIAL.

EVENT-RELATED THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE HUMAN BRAIN AS AN OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING DRUGS.

000747 01-14

EVENTS

DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE: ORGANIC MOLECULAR MECHANISMS AND NEUROCHEMICAL EVENTS 003254 04-04

DIRECT EVIDENCE FOR AN INTERACTION OF BETA-ADRENERGIC BLOCKERS

WITH THE 5-HT RECEPTOR. EVIDENCE FOR NOREPINEPHRINE MEDIATED COLLATERAL INHIBITION OF LOCUS-COERULEUS NEURONS.

EVIDENCE FOR AN INTRASTRIATAL GABAERGIC INFLUENCE ON DOPAMINE NEURONES OF THE CAT.

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE

000127 01-03 EVIDENCE FOR MULTIPHASIC PRESYNAPTIC ADAPTATION: STUDIES WITH COCAINE AND LITHIUM

000191 01-03 ANTIDROMICALLY IDENTIFIED SEROTONERGIC NEURONS IN THE RAT MIDBRAIN RAPHE: EVIDENCE FOR COLLATERAL INHIBITION

000292 01-03 EVIDENCE FOR NORADRENERGIC MECHANISM IN THE GROOMING PRODUCED BY () AMPHETAMINE AND 4, GAMMA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.

EVIDENCE FOR INCREASED APOMORPHINE SENSITIVE DOPAMINERGIC EFFECTS AFTER ACUTE TREATMENT WITH MORPHINE.

000449 01-04 EVIDENCE FOR WITHDRAWAL FROM CAFFEINE BY RATS

000467 01-04 EVIDENCE FOR FUNCTIONAL SYNAPSES BETWEEN MIXED CULTURES OF INFERIOR OLIVE AND CEREBELLUM

000497 01-06 CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE FOR AN INTERACTIONIST POSITION.

INTERINDIVIDUAL VARIABILITY IN DIAZEPAM METABOLISM PRELIMINARY EVIDENCE OF AN ABSENCE OF GENETIC CONTROL

000696 01-13 EVIDENCE AGAINST INVOLVEMENT OF ENDORPHINS IN SEXUAL AROUSAL AND ORGASM IN MAN

000701 01-13 CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO

PSYCHOTROPIC DRUGS.

000729 01-13

NEW EVIDENCE OF SEROTONIN DEFICIENT DEPRESSIONS 000743 01-13 EVIDENCE FOR A NONCOVALENT INTERMOLECULAR INTERACTION OF

OPIATES WITH THIAMINE. 001008 02-01 ANIMAL PROLACTIN EVIDENCE FOR ANTIPSYCHOTIC ACTIVITY OF

PIPEROXANE 001027 02-02 STEREOSPECIFIC AND NONSTEREOSPECIFIC EFFECTS OF ()- AND (-)

MORPHINE: EVIDENCE FOR A NEW CLASS OF RECEPTORS? 001031 02-02 EVIDENCE FOR A DOUBLE CHOLINERGIC MECHANISM CAPABLE OF REDUCING THE TONE OF CEREBRAL ARTERIES.

001049 02-03 ELECTROPHYSIOLOGICAL EVIDENCE FOR A DOPAMINERGIC ACTION OF LSD: DEPRESSION OF UNIT ACTIVITY IN THE SUBSTANTIA-NIGRA OF THE RAT

001082 02-03 EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF

001118 02-03 DISTRIBUTION OF CLOZAPINE IN THE RAT: EVIDENCE FOR ACTIVE TRANSPORT IN LUNG

001129 02-03 LYSERGIC-ACID-DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF PITUITARY DOPAMINE RECEPTORS.

001192 02-03
AUTORADIOGRAPHIC EVIDENCE FOR THE SELECTIVE ACCUMULATION OF

H3-5-HT BY SUPRAEPENDYMAL NERVE TERMINALS 001222 02-03 DYNAMICS OF BLOOD NEUROTRANSMITTER LEVEL AS EVIDENCE OF HIGHER NERVOUS ACTIVITY CHANGES DURING CHRONIC ADMINISTRATION OF SEDUXEN.

001338 02-04 TWO DOPAMINE RECEPTORS: SUPPORTIVE EVIDENCE WITH THE RAT ROTATIONAL MODEL

DIFFERENT BEHAVIOURAL PATTERNS INDUCED BY APOMORPHINE: EVIDENCE THAT THE METHOD OF ADMINISTRATION DETERMINES THE BEHAVIOURAL RESPONSE TO THE DRUG.

001533 02-06 ANIMAL HYPNOSIS AND HUMAN HYPNOSIS: NEW EXPERIMENTAL EVIDENCE RELATING TO AN OLD CONTROVERSY.

EVIDENCE FOR SELECTIVE AND LONG-LASTING STIMULATION OF REGULATORY DOPAMINE RECEPTORS BY BROMOCRIPTINE (CB-154) 002002 03-03

NALOXONE AS A GABA-ANTAGONIST: EVIDENCE FROM IONTOPHORETIC, RECEPTOR BINDING AND CONVULSANT STUDIES.

002003 03-03 DOPAMINE RECEPTORS AND ERGOT DRUGS. EVIDENCE THAT AN ERGOLENE DERIVATIVE IS A DIFFERENTIAL AGONIST AT SUBCORTICAL LIMBIC DOPAMINE RECEPTORS.

002019 03-03 PHARMACOLOGICAL EVIDENCE FOR A LINK BETWEEN THE CEREBELLAR CONTENT OF C-GMP AND THAT OF AN ENDOGENOUS PROTEIN KINASE

002031 03-03
EVIDENCE FOR THE EXISTENCE OF SPECIFIC CANNABINOID BINDING SITES.
002034 03-03 FURTHER EVIDENCE OF CYCLIC-AMP MEDIATED HYPERTROPHY AS A PREREQUISITE OF DRUG SPECIFIC ENZYME INDUCTION.

002086 03-03
METHYLHISTAMINE: EVIDENCE FOR SELECTIVE DEAMINATION BY MAD-B IN THE RAT BRAIN IN VIVO

002172 03-03 EVIDENCE FOR PARALLEL DEVELOPMENT OF TOLERANCE TO THE HYPERACTIVATING AND DISCOORDINATING EFFECTS OF ETHANOL 002249 03-04

MORPHINE AND SELF-STIMULATION: EVIDENCE FOR ACTION ON A COMMON NEURAL SUBSTRATE.

002277 03-04 ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY

TOLERANCE TO HIGH DOSES OF MORPHINE: LACK OF EVIDENCE OF

002356 03-05 EVIDENCE FOR AN ENDOGENOUS FACTOR INTERFERING WITH H3-DIAZEPAM BINDING TO RAT BRAIN MEMBRANES

002789 04-01 SUBCELLULAR DISTRIBUTION OF ETORPHINE IN RAT BRAIN AND EVIDENCE FOR IN VIVO STEREOSPECIFIC BINDING.

002856 04-03 INCREASE IN SERUM PROLACTIN BY EXOGENOUS AND ENDOGENOUS OPIATES: EVIDENCE FOR ANTIDOPAMINE AND ANTIPSYCHOTIC

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH.

DO2932 04-03
PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF NA CHANNELS IN THE RELEASE OF CATECHOLAMINES FROM PERFUSED ADRENAL

EVIDENCE FOR CELL LOSS IN CORPUS-STRIATUM AFTER LONG-TERM
TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN RATS.

TRYPTAMINE-INDUCED DRUG EFFECTS INSENSITIVE TO SEROTONINERGIC ANTAGONISTS: EVIDENCE OF SPECIFIC TRYPTAMINERGIC RECEPTOR STIMULATION?.

003057 04-03 EVIDENCE FOR THE ROLE OF ADRENOCORTICAL HORMONES IN THE REGULATION OF NORADRENALINE AND DOPAMINE METABOLISM IN CERTAIN BRAIN AREAS

003062 04-03 EVIDENCE OF AN INTERACTION BETWEEN SEROTONINERGIC AND CHOLINERGIC NEURONS IN THE CORPUS-STRIATUM AND HIPPOCAMPUS OF THE RAT BRAIN

H3-SPIROPERIDOL BINDING AND DOPAMINE STIMULATED ADENYLATE-CYCLASE: EVIDENCE FOR MULTIPLE CLASSES OF RECEPTORS IN PRIMATE BRAIN REGIONS.

EVIDENCE FOR DISTINCT SPINAL LOCOMOTION GENERATORS SUPPLYING RESPECTIVELY FORELIMBS AND HINDLIMBS IN THE RABBIT

003124 04-03 PHARMACOLOGICAL EVIDENCE FOR DOPAMINERGIC PALLIDOSTRIATAL INTERACTION

003137 04-03 DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION 003241 04-04

INTRANIGRAL KAINIC-ACID: EVIDENCE FOR NIGRAL NONDOPAMINERGIC NEURONS CONTROLLING POSTURE AND BEHAVIOR IN A MANNER OPPOSITE TO THE DOPAMINERGIC ONES.

EVIDENCE FOR A ROLE FOR DOPAMINE IN SELF-STIMULATION OF THE NUCLEUS-ACCUMBENS OF THE RAT.

EVIDENCE AGAINST CHRONIC DEPOLARIZATION AS A MECHANISM OF KAINIC-ACID TOXICITY IN MOUSE CEREBELLAR CULTURES.

EXPERIMENTAL AND CLINICAL EVIDENCE OF THE ANTIDEPRESSANT EFFECT OF A BETA-ADRENERGIC STIMULANT. 003546 04-10

BENZODIAZEPINE ACTIVITY: IS INTERACTION WITH THE GLYCINE RECEPTOR, AS EVIDENCED BY DISPLACEMENT OF STRYCHNINE BINDING, A USEFUL CRITERION?.

000151 01-03 LONG-TERM CHANGES IN THE SENSITIVITY OF PRE- AND POSTSYNAPTIC DOPAMINE RECEPTORS IN MOUSE STRIATUM EVIDENCED BY BEHAVIORAL AND BIOCHEMICAL STUDIES.

CHANGES OF SENSITIVITY TO THE CUING PROPERTIES OF NARCOTIC DRUGS AS EVIDENCED BY GENERALIZATION AND CROSS-GENERALIZATION EXPERIMENTS.

FURTHER EVIDENCES ON THE BEHAVIOURAL EFFECTS OF SELECTIVE A-10 DOPAMINERGIC MESENCEPHALO-CORTICO-LIMBIC GROUP LESION IN THE RAT

EVOKE

THE EFFECT OF BARBITURATE AND PROCAINE ON GLIAL AND NEURONAL CONTRIBUTIONS TO EVOKE CORTICAL STEADY POTENTIAL SHIFTS. 001219 02-03

EVOKED

CHANGES IN HIPPOCAMPAL EVOKED RESPONSES TO AFFERENT STIMULATION DURING CONDITIONING.

000260 01-03 VISUAL EVOKED REPONSES IN CHRONIC HASHISH USERS.

SELECTIVE OPIATE DEPRESSION OF SENSORY EVOKED SYNAPTIC
NETWORKS IN DORSAL-HORN REGIONS OF SPINAL CORD CULTURES.
001088 02-03

NEUROPHYSIOLOGY, NEUROPHARMACOLOGY AND BEHAVIORAL RELATIONSHIPS OF VISUAL SYSTEM EVOKED AFTER-DISCHARGES: A REVIEW.

001885 02-17 HYPOTHERMIA EVOKED BY THE INTRACEREBRAL INJECTION OF MORPHINE-SULPHATE IN THE RAT: THE EFFECT OF RESTRAINT

002090 03-03 EFFECTS OF FLURAZEPAM ON AMINO-ACID EVOKED RESPONSES
RECORDED FROM THE LOBSTER MUSCLE AND THE FROG SPINAL CORD.

002115 03-03 EFFECT OF DIHYDROERGOTOXINE ON THALAMIC AND PYRAMIDAL EVOKED RESPONSES IN THE CAT UNDER TRANSIENT ISCHEMIA.

002201 03-04 EFFECT OF P-CHLOROPHENYLALANINE (PCPA) AND PHENYLALANINE (PHE) TREATMENT ON EARLY AUDITORY EVOKED RESPONSES IN RATS. 002304 03-04

CLINICAL VALUE OF THE BRAINSTEM EVOKED RESPONSE IN COMA. 002650 03-15

ANTAGONISM OF ETHANOL EVOKED RESPONSES BY AMANTADINE: A POSSIBLE CLINICAL APPLICATION.

002797 04-02 EFFECTS OF CENTRAL GABA RECEPTOR AGONISM AND ANTAGONISM ON EVOKED DIENCEPHALIC CARDIOVASCULAR RESPONSES.

002811 04-03 SHORT-TERM AND LONG-TERM EFFECTS OF CEREBROLYSINE ON EVOKED CORTICAL POTENTIALS IN RATS.

002858 04-03 DIFFERENTIAL EFFECTS OF CONVULSANTS ON VISUALLY EVOKED RESPONSES IN THE ALBINO RAT.

003171 04-04 DYSKINESIAS EVOKED IN MONKEYS BY WEEKLY ADMINISTRATION OF HAL OPERIDOL

EVOKED-POTENTIAL

THE EVOKED-POTENTIAL IN PHARMACOPSYCHIATRY.

001729 02-14 EFFECT OF DEXTROAMPHETAMINE ON SOMATIC EVOKED-POTENTIAL COMPONENTS IN MAN WITH SPECIAL REFERENCE TO TALK RELEVANCE AND SELECTIVE ATTENTION.

001735 02-14 ELECTROENCEPHALOGRAM AND SOMATOSENSORY EVOKED-POTENTIAL CHANGES AFTER ADMINISTRATION OF SIX CONVULSANT DRUGS. 002055 03-03 Psychopharmacology Abstracts

EVOKED-POTENTIALS
TRANSCALLOSALLY EVOKED-POTENTIALS AND THE EEG IN THE
DECEREBRATE DOG: ACTIONS OF TRYPTAMINERGIC, DOPAMINERGIC
AND ADRENERGIC AGONISTS.

PHENOBARBITAL AND PHENYTOIN EFFECTS ON SOMATOSENSORY
EVOKED-POTENTIALS AND SPONTANEOUS EEG IN NORMAL CAT BRAIN. 001032 02-02

INFLUENCE OF NEUROTROPIC DRUGS ON CHANGES OF EVOKED-POTENTIALS AMPLITUDES AFTER STIMULATION OF THE HYPOTHALAMUS.

DEANOL EFFECTS ON PERFORMANCE AND AVERAGE EVOKED-POTENTIALS.

001412 02-04 DIFFERENTIAL EFFECTS OF SUBCORTICAL LYSERGIC-ACID-DIETHYLAMIDE AND SEROTONIN ON VISUAL CORTICAL EVOKED-POTENTIALS.

THE EFFECTS OF PHENCYCLIDINE ON VISUALLY EVOKED-POTENTIALS OF RHESUS MONKEYS.

SOMATOSENSORY EVOKED-POTENTIALS IN PATIENTS WITH PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND DECARBOXYLASE INHIBITOR.

LITHIUM-CARBONATE AND BRAIN FUNCTION: 1. CEREBRAL EVOKED-POTENTIALS, EEG, AND SYMPTOM CHANGES DURING LITHIUM-CARBONATE TREATMENT.

THE EFFECT OF CEREBROLYSINE ON CORTICAL EVOKED-POTENTIALS IN RATS WITH EARLY MALNUTRITION.

003069 04-03 HEMISPHERIC ASYMMETRY OF VISUAL EVOKED-POTENTIALS WITH MOTOR IMBALANCE IN RATS.

003310 04-04

EXACERBATIONS
PORPHYRIAS: NEUROLOGIC ASPECTS AND THE TREATMENT OF
EXACERBATIONS.

000659 01-11

EXAMINATION MONOAMINE-OXIDASE: EXAMINATION OF MULTIPLE FORMS. 000156 01-03

CLINICAL EXAMINATION OF THE NEW ANTIPSYCHOTIC CLOZAPINE (LEPONEX)

000514 01-07 PSYCHOTROPIC AND ANTIPARKINSONIAN DRUG USE: AN EXAMINATION OF PRESCRIPTION PRACTICES.

003723 04-17

003194 04-04

000399 01-04

SUBCUTANEOUS INJECTIONS OF APOMORPHINE, STIMULUS GENERALIZATION AND CONDITIONING: SERIOUS PITFALLS FOR THE EXAMINER USING APOMORPHINE AS A TOOL.

000341 01-04

EXAMPLE
INCREASED PRESCRIBING OF VALIUM, LIBRIUM, AND OTHER DRUGS —
AN EXAMPLE OF THE INFLUENCE OF ECONOMIC AND SOCIAL FACTORS
ON THE PRACTICE OF MEDICINE.

000995 01-1

000995 01-17

DOPAMINE SUPERSENSITIVITY, ENDORPHIN EXCESS, AND PROSTAGLANDIN-ET DEFICIENCY: THREE ASPECTS OF THE SAME SCHIZOPHRENIC ELEPHANT.

003458 04-08

ACTH-INDUCED EXCESSIVE GROOMING IN THE RAT: LATENT ACTIVITY OF ACTH4-10

000472 01-04 ACTH-INDUCED EXCESSIVE GROOMING INVOLVES BRAIN DOPAMINE. 001490 02-04

EXCITABILITY

MOTONEURON EXCITABILITY IN PSYCHIATRIC PATIENTS.

000754 01-14 DEPENDENCE OF THE INFLUENCE OF EPINEPHRINE ON THE EXCITABILITY OF GIANT NEURONS ON ITS CONCENTRATION.

MORPHINE AND MET-ENKEPHALIN EFFECTS ON SURAL-ADELTA AFFERENT TERMINAL EXCITABILITY.

003076 04-03

EXCITATION

THE EFFECT OF NALOXONE ON THE EXCITATION OF DORSAL-HORN NEURONES OF THE CAT BY NOXIOUS AND NONNOXIOUS CUTANEOUS

001102 02-03 D ALPHA-AMINOADIPATE, ALPHA-EPSILON-DIAMINOPIMELIC-ACID AND H-966 AS ANTAGONISTS OF AMINO-ACID-INDUCED AND SYNAPTIC EXCITATION OF MAMMALIAN SPINAL NEURONES IN VIVO. 002831 04-03

EXCITATORY

EXCITATORY ACTION OF THE MESOLIMBIC DOPAMINE SYSTEM ON SEPTAL NEURONES.

000045 01-03

002141 03-03

AN EXCITATORY ACTION OF IONTOPHORETICALLY ADMINISTERED LITHIUM ON MAMMALIAN CENTRAL NEURONES.

POSTSYNAPTIC POTENTIATION OF THE SLOW MUSCARINIC EXCITATORY RESPONSE BY TETRAETHYLAMMONIUM-CHLORIDE IN THE BULLFROG SYMPATHETIC GANGLION CELLS.

001173 02-03 EFFECTS OF 4 AMINOPYRIDINE ON TRANSMISSION IN EXCITATORY AND INHIBITORY SYNAPSES IN THE SPINAL CORD.

001384 02-04 DIFFERENTIAL EXCITATORY AND INHIBITORY EFFECTS OF OPIATES ON NONNOCICEPTIVE AND NOCICEPTIVE NEURONES IN THE SPINAL CORD OF THE CAT.

MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMATURE RAT

PHARMACOLOGICAL CHARACTERIZATION OF THE EXCITATORY CHOLINERGIC RECEPTORS OF RAT CENTRAL NEURONES.

EXCITED

RELATIVE EFFICACY OF PARENTERAL HALOPERIDOL AND THIOTHIXENE FOR THE EMERGENCY TREATMENT OF ACUTELY EXCITED AND AGITATED PATIENTS. 001626 02-11

GENERATION OF ELECTRONIC EXCITED STATES (EES) BY TRICYCLIC ANTIDEPRESSANTS: MOLECULAR ASPECTS. 001693 02-13

A COMPARISON OF THE EFFICACY AND ACCEPTABILITY OF TWO FORMULATIONS OF INJECTABLE SERENACE IN THE TREATMENT OF STATES OF EXCITEMENT.

003576 04-11

003006 04-03

EXCRETION

STUDIES OF EXCRETION IN RABBIT MILK AFTER ADMINISTRATION OF CARBON-14 LABELLED AMITRIPTYLINE AND NORTRIPTYLINE 000037 01-03

EFFECT OF ALTERATION OF METABOLISM ON THE ANALGESIC ACTIVITY, TOXICITY, DISTRIBUTION AND EXCRETION OF L-ALPHA-ACETYLMETHADOL IN THE RAT.

000245 01-03 PHENELZINE IN DEPRESSED PATIENTS: EFFECTS ON URINARY MHPG **EXCRETION IN RELATION TO CLINICAL RESPONSE**

EXCRETION OF 3,4 DIMETHOXYPHENETHYLAMINE (DMPEA) BY ACUTE SCHIZOPHRENICS AND CONTROLS

000698 01-13 URINARY MONOAMINE METABOLITE EXCRETION IN DISORDERS OF

SPECIES VARIATION WITH RESPECT TO THE METABOLISM AND EXCRETION OF D AMPHETAMINE AND D,L N HYDROXYAMPHETAMINE.

001091 02-03 REDUCED RENAL CALCIUM EXCRETION DURING LITHIUM THERAPY

001597 02-09 URINARY CYCLIC-AMP EXCRETION BY METHADONE SUBJECTS DURING GRADUAL AND ACUTE WITHDRAWAL.

URINARY EXCRETION OF A QUATERNARY AMMONIUM GLUCURONIDE METABOLITE OF CYPROHEPTADINE IN HUMANS UNDERGOING CHRONIC DRUG THERAPY. 001667 02-13

URINARY EXCRETION OF PHENOLIC METABOLITES OF PROPYLAMPHETAMINE IN MAN.

001892 02-17 CORRELATION OF URINARY EXCRETION OF METHADONE METABOLITES WITH METHADONE METABOLISM AND ANALGESIA IN THE RAT 002080 03-03

CHLORPROMAZINE EXCRETION. II. IMPROVED TLC PROCEDURES FOR FRACTIONATING THE URINARY DRUG CONTENT INTO CHEMICAL SUBGROUPS OF CPZ METABOLITES. 003690 04-16

EXHIBITIONISM

SEX HORMONES AND EXHIBITIONISM.

000788 01-14

CASE REPORT: AMPHETAMINE ABSTINENCE PSYCHOSIS -- DOES IT 000899 01-15

EXISTENCE EVIDENCE FOR THE EXISTENCE OF SPECIFIC CANNABINOID BINDING SITES 002034 03-03

EXO-2-METHYLAMINOBENZOBICYCLOOCTENE CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. THE IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED ANALOGS OF METHAMPHETAMINE.

EXOGENOUS

EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH MORPHOLOGY AND HORMONE PLASMA LEVELS.

EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: I. BEHAVIOURAL EFFECTS OF INTRAMUSCULAR INJECTIONS.

000316 01-04
EFFECT OF EXOGENOUS ESTROGENS ON DEPRESSION IN MENOPAUSAL

001603 02-09 THE INFLUENCE OF COCAINE AND DESIPRAMINE ON THE CARDIAC RESPONSES TO EXOGENOUS AND ENDOGENOUS NOREPINEPHRINE. 002077 03-03

INCREASE IN SERUM PROLACTIN BY EXOGENOUS AND ENDOGENOUS OPIATES: EVIDENCE FOR ANTIDOPAMINE AND ANTIPSYCHOTIC

MODIFICATION OF THE 5 HYDROXYTRYPTOPHAN-INDUCED HEAD-TWITCH RESPONSE BY EXOGENOUS ENDOCRINE AGENTS. 003177 04-04

EXPERIENCE

BEHAVIORAL EFFECTS OF PEPTIDES IN ANIMALS: FURTHER EXPERIENCE WITH PENTOBARBITAL ANTAGONISM.

000434 01-04 CLINICAL AND EXPERIMENTAL EXPERIENCE WITH MAPROTILINE, CLOMIPRAMINE, SYDNOCARB, AND MEFEXAMINE IN PSYCHIATRIC PATIENTS AND NORMAL SUBJECTS.

METHODOLOGICAL EXPERIENCE WITH A DOUBLE-BLIND MULTICENTRIC, MONITORED CLINICAL TRIAL (MMCT) WITH SINTAMIL. 000568 01-09

EXPERIENCE WITH SINEQUAN IN A SINGLE EVENING DOSE.

000609 01-10 THE PEAK EXPERIENCE VARIABLE IN DPT ASSISTED PSYCHOTHERAPY WITH CANCER PATIENTS.

000679 01-12 EXPERIENCE WITH A CLINICAL PHARMACOLOGICAL SERVICE IN A TEACHING HOSPITAL.

000957 01-17 EFFECTS ON RETENTION OF POSTTRAINING AMPHETAMINE INJECTIONS IN MICE: INTERACTION WITH PRETRAINING EXPERIENCE.

001375 02-04 LOOKING TOWARD A REEXAMINATION OF DRUG THERAPY EXPERIENCE. 001856 02-16

EFFECT OF EARLY EXPERIENCE, PYRITHIOXIN AND DIAZEPAM ON UC14-GLUCOSE UTILIZATION IN RAT BRAIN DURING EMOTIONAL STRESS. 002152 03-03

GENOTYPE AND TEST EXPERIENCE DETERMINE RESPONSIVENESS TO

002216 03-04 CLINICAL EXPERIENCE IN THE TREATMENT OF OBSESSIONAL STATES (1). 002477 03-10 CLINICAL EXPERIENCE IN THE TREATMENT OF PHOBIC DISORDERS.

002485 03-10 CLINICAL EXPERIENCE IN THE TREATMENT OF OBSESSIONAL STATES (2).
002489 03-10

MODIFICATION OF NUCLEAR RETENTION OF H3-ESTRADIOL BY CELLS OF THE HYPOTHALAMUS AS A FUNCTION OF EARLY HORMONE

002891 04-03 PARAMETERS OF THE DORSAL BUNDLE EXTINCTION EFFECT: PREVIOUS EXTINCTION EXPERIENCE.

003289 04-04 **OUTPATIENT MAINTENANCE OF CHRONIC SCHIZOPHRENIC PATIENTS WITH** FLUPHENAZINE-DECANOATE (MODECATE): IBADAN EXPERIENCE 003466 04-08

THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (SECOND REPORT) - EFFECTS ON PUPIL FUNCTIONING.

THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (FIRST REPORT)

THREE EXPERIENCES THAT CAN ALTER THE STATE OF CONSCIOUSNESS 000684 01-12 SUBJECTIVE EXPERIENCES OF CANNABIS USE IN LONG-TERM USERS 000776 01-14

EXPERIENCES WITH THE CONTINUED USE OF PSYCHOTROPIC DRUGS. 001567 02-08

EXPERIENCES WITH USING THE ANTIDEPRESSANT DIBENZEPIN: NOVERIL. ON NEUROLOGY OUTPATIENTS.

001615 02-10

000878 01-15

EXPERIENCES WITH PHYSOSTIGMINESALICYLATE IN TRICYCLIC ANTIDEPRESSANT POISONING.

001820 02-15 MEDICATION IN RESIDENTIAL TREATMENT: ADMINISTRATION AND CLINICAL EXPEDIENCES

003561 04-11

METABOLIC AND EXPERIENTIAL FACTORS IN THE BEHAVIORAL RESPONSE TO REPEATED AMPHETAMINE. 000325 01-04

EXPERIMENT
INFLUENCE OF PHARMACOLOGICAL AGENTS ON AVOIDANCE REFLEXES IN A GROUP EXPERIMENT ON RATS.

001317 02-04 ARGININE-PYROGLUTAMATE (G-278): A CLINICAL EXPERIMENT

PHARMACOLOGICAL TREATMENT FOLLOWING EXPERIMENTAL CEREBRAL INFARCTION: IMPLICATIONS FOR UNDERSTANDING PSYCHOLOGICAL SYMPTOMS OF HUMAN STROKE.

CLINICAL AND EXPERIMENTAL EXPERIENCE WITH MAPROTILINE, CLOMIPRAMINE, SYDNOCARB, AND MEFEXAMINE IN PSYCHIATRIC PATIENTS AND NORMAL SUBJECTS.

000517 01-07 EFFECTS OF INTRAVENOUS TETRAHYDROCANNABINOL ON EXPERIMENTAL AND SURGICAL PAIN.

000655 01-11 EVALUATING ANTIANXIETY AGENT IN HUMANS: EXPERIMENTAL PARADIGMS.

000661 01-11 ELECTRON MICROSCOPIC STUDIES ON THE CEREBRAL LESIONS OF RATS IN EXPERIMENTAL CHRONIC DISULFIRAM POISONING.

000906 01-15

ANIMAL HYPNOSIS AND HUMAN HYPNOSIS: NEW EXPERIMENTAL EVIDENCE RELATING TO AN OLD CONTROVERSY. 001711 02-14 SYSTEM APPROACH IN EXPERIMENTAL PSYCHOPHARMACOLOGY AND MEMORY.

001924 02-17

EFFECT OF THYMOANALEPTIC AGENTS ON THE COURSE OF EXPERIMENTAL
ARTERIAL HYPERTENSION AND CATECHOLAMINE CONTENT IN TISSUES

AND URINE 001970 03-03

COMPARATIVE EFFECTS OF DIHYDROERGOTOXINE (DHET) ON CBF AND METABOLISM CHANGES PRODUCED BY EXPERIMENTAL CEREBRAL EDEMA, HYPOXIA AND HYPERTENSION.

EFFECT OF PSYCHOTROPIC DRUGS ON THE DEVELOPMENT. OF DEFENSE CONDITIONED REFLEX DURING EXPERIMENTAL NEUROSIS.

INFLUENCE OF EXTRAPYRAMIDAL DISTURBANCES DUE TO HALOPERIDOL ON PHENAMINE STEREOTYPY AND THE EFFECTS OF SCHIZOPHRENIC BLOOD SERUM (EXPERIMENTAL STUDIES).

002339 03-05 **ENDORPHINS: NALOXONE FAILS TO ALTER EXPERIMENTAL PAIN OR**

002383 03-07 AN EXPERIMENTAL STUDY OF THE EFFECTS OF AMITRIPTYLINE PERPHENAZINE AND AMITRIPTYLINE HALOPERIDOL COMBINATIONS ON INTERPERSONAL LEARNING.

002511 03-11 EXPERIMENTAL BARBITURATE DEPENDENCE. I. BARBITURATE DEPENDENCE DEVELOPMENT IN RATS BY DRUG ADMIXED FOOD (DAF) METHOD.

003373 04-04 EXPERIMENTAL LEAD ENCEPHALOPATHY IN THE SUCKLING RAT: CONCENTRATION OF LEAD IN CELLULAR FRACTIONS ENRICHED IN

BRAIN CAPILLARIES. 003420 04-05 EXPERIMENTAL AND CLINICAL EVIDENCE OF THE ANTIDEPRESSANT EFFECT OF A BETA-ADRENERGIC STIMULANT.

003546 04-10

EXPERIMENTALLY-INDUCED

EFFECTS OF CHRONIC LITHIUM AND RUBIDIUM ADMINISTRATION UPON EXPERIMENTALLY-INDUCED CONFLICT BEHAVIOR.

001391 024

001391 02-04 A MODEL FOR EVALUATION OF ANTIANXIETY DRUGS WITH THE USE OF EXPERIMENTALLY-INDUCED STRESS: COMPARISON OF NABILONE AND

002721 03-16 EXPERIMENTS
METHODS OF ACUTE INHALATION EXPERIMENTS.

000920 01-16 NOTES ON EXPERIMENTS WITH DRUGS IN PSYCHIATRY

000971 01-17 EFFECT OF GINSENG ON THE BRAIN BIOGENIC MONOAMINES AND 3,5 AMP SYSTEM: EXPERIMENTS ON RATS.

Psychopharmacology Abstracts

003551 04-11

CHANGES OF SENSITIVITY TO THE CUING PROPERTIES OF NARCOTIC DRUGS AS EVIDENCED BY GENERALIZATION AND CROSS-GENERALIZATION EXPERIMENTS.

003194 04-04

THE OPIATE ANOMALIES -- ANOTHER POSSIBLE EXPLANATION? 001660 02-13

EXPLORATION
RAISED BRAIN GABA LEVELS, MOTOR ACTIVITY AND EXPLORATION IN THE RAT.

000358 01-04 EFFECTS OF AMPHETAMINE AND NEMBUTAL ON SOCIAL EXPLORATION IN THE MONGOLIAN GERBIL.

001414 02-04 **EXPLORATION IN IMMATURE RATS: EFFECTS OF DRUGS.** 003218 04-04 **PSYCHIATRIC DIAGNOSIS: EXPLORATION OF BIOLOGICAL PREDICTORS**

EFFECTS OF APOMORPHINE AND HALOPERIDOL ON EXPLORATORY
BEHAVIOR AND LATENT LEARNING IN MICE.

001297 02-04 EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE INTOXICATION ON EXPLORATORY AND STEREOTYPED BEHAVIORS IN THE RAT.

001379 02-04 INFLUENCE OF BETA-ENDORPHIN ON EXPLORATORY, SOCIAL AND SEXUAL BEHAVIOUR IN THE MALE RAT.

AN ATTEMPT TO PREDICT THE DURATION OF PENTOBARBITAL NARCOSIS ON THE BASIS OF EXPLORATORY ACTIVITY, DEFECATION RATE AND BODY WEIGHT OF RATS.

001435 02-04

STUDIES ON THE ROLE OF FOREBRAIN CATECHOLAMINE NEURONS IN EXPLORATORY BEHAVIOR IN THE RAT. (PH.D. DISSERTATION). 002012 03-03

THE EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY AND STEREOTYPED BEHAVIOUR OF RATS STUDIED ON A HOLE-BOARD 002274 03-04

EXPONENTIAL

NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED

INCREASES IN CYCLIC-AMP. I. CHARACTERIZATION OF A CULTURED

NEURONAL CELL LINE IN EXPONENTIAL GROWTH PHASE.

EFFECTIVENESS OF PSYCHOTROPIC DRUGS IN PATIENTS IN A STATE OF MALNUTRITION OR EXPOSED TO EXTREME CLIMATIC CONDITIONS.

000721 01-13 EFFECT OF PSYCHOTROPIC AGENTS ON THE PHYSICAL PERFORMANCE CAPACITY OF ANIMALS EXPOSED TO HEAT AND COLD.

002273 03-04 THE EFFECTS OF INORGANIC LEAD ON THE CENTRAL CATECHOLAMINERGIC SYSTEM OF THE RODENT WITH EMPHASIS ON POSTNATALLY EXPOSED RATS AND MICE. (PH.D. DISSERTATION).

003078 04-03 BEHAVIORAL CHANGES AND MERCURY CONCENTRATIONS IN TISSUES OF RATS EXPOSED TO MERCURY VAPOR.

003258 04-04

EXPOSURE EFFECTS OF EXPOSURE TO LEAD ON SOCIAL BEHAVIOUR IN THE LABORATORY MOUSE.

000344 01-04 THE INFLUENCE OF PROPRANOLOL ON THE EXPOSURE IN VIVO OF AGORAPHOBICS.

000598 01-10 THE PHARMACOLOGICAL EFFECTS OF FETAL AND NEONATAL EXPOSURE TO NALTREXONE IN THE RAT.

001373 02-04 DISCRIMINATIVE PROPERTIES OF PENTOBARBITAL AFTER REPEATED NONCONTINGENT EXPOSURE IN GERBILS.

001387 02-04 MEASUREMENTS OF WEIGHT AND ACTIVITY IN MALE MICE FOLLOWING INHALATION OF CANNABIS SMOKE IN A CONTROLLED SMOKE EXPOSURE CHAMBER.

ENHANCEMENT BY CHOLINE OF THE INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE BY PHENOXYBENZAMINE, 6 HYDROXYDOPAMINE, INSULIN OR EXPOSURE TO COLD.

002167 03-03 PRENATAL EXPOSURE TO MEDROXYPROGESTERONE-ACETATE (MPA) IN

002615 03-14 LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO P-CHLOROAMPHETAMINE ON CENTRAL SEROTONERGIC MECHANISMS IN

003098 04-03 CYPROTERONE-ACETATE EXPOSURE DURING GESTATION IN MICE RETARDS FETAL GROWTH.

003129 04-03

REPEATED EXPOSURE OF RATS TO THE CONVULSANT AGENT FLUROTHYL ENHANCES 5 HYDROXYTRYPTAMINE AND DOPAMINE MEDIATED BEHAVIOURAL RESPONSES. 003234 04-04

EXTENSION OF ANIMAL MODELS TO CLINICAL EVALUATION OF ANTIANXIETY AGENTS.

002716 03-16 INTERNAL STIMULUS CONDITIONING TO DISCRIMINATIVE EXTERNAL STIMULI.

EXTINCTION

EFFECT OF CHLORDIAZEPOXIDE ADMINISTERED EARLY IN EXTINCTION ON SUBSEQUENT EXTINCTION OF A CONDITIONED EMOTIONAL RESPONSE IN RATS: IMPLICATIONS FOR HUMAN CLINICAL USE.

THE EFFECT OF ANESTHESIA ON ACQUISITION AND EXTINCTION OF CONDITIONED TASTE AVERSION.

000326 01-04 EFFECTS OF PIMOZIDE ON THE ACQUISITION, MAINTENANCE, AND EXTINCTION OF AN AMPHETAMINE-INDUCED TASTE AVERSION. 000373 01-04

ACQUISITION AND EXTINCTION OF OPERANT RESPONDING FOR INTRAVENOUS INJECTIONS OF FENTANYL IN THE RAT. 001397 02-04 THE EFFECT OF NONCONTINGENT AMPHETAMINE INJECTIONS ON THE

EXTINCTION OF FOOD AND DRUG REINFORCED LEVER PRESSING IN RATS

EFFECT OF CHLORPROMAZINE ON ELABORATION AND EXTINCTION OF AN INSTRUMENTAL ALIMENTARY REFLEX IN PUPPIES. 001407 02-04

EFFECT OF CHLORDIAZEPOXIDE ON THE PARTIAL REINFORCEMENT **EXTINCTION EFFECT** 001491 02-04

PARAMETERS OF THE DORSAL BUNDLE EXTINCTION EFFECT: PREVIOUS EXTINCTION EXPERIENCE. 003289 04-04

CENTRAL AND PERIPHERAL NORADRENALINE AND RESISTANCE TO EXTINCTION. 003290 04-04

THE EFFECT OF MORPHINE ON FEAR EXTINCTION IN RATS. 003305 04-04

EXTINCTION-INDUCED ACUTE AND CHRONIC EFFECTS OF COCAINE ON EXTINCTION-INDUCED 003303 04-04

EXTRACELLULAR PHENOBARBITAL ACTIONS IN VIVO: EFFECTS OF EXTRACELLULAR POTASSIUM ACTIVITY AND OXIDATIVE METABOLISM IN CAT CEREBRAL-CORTEX.

000176 01-03 THE RELATIONSHIP BETWEEN EXTRACELLULAR AND INTRACELLULAR LITHIUM CONCENTRATION IN HUMAN RED BLOOD CELLS: AN IN VITRO

000731 01-13 GAMMA-ENDORPHIN, ALPHA-ENDORPHIN AND MET-ENKEPHALIN ARE FORMED EXTRACELLULARLY FROM LIPOTROPIN C-FRAGMENT.

001963 03-03 EXTRACORPOREAL CHLORPROMAZINE PLUS THIORIDAZINE POISONING AND TREATMENT

WITH EXTRACORPOREAL DIALYSIS. 001806 02-15 EXTRACT ISOLATION AND CHARACTERIZATION OF () CANNABITRIOL AND (-) 10

ETHOXY-9-HYDROXY-DELTA6A-TETRAHYDROCANNABINOL: TWO NEW CANNABINOIDS FROM CANNABIS-SATIVA L. EXTRACT. EFFECTS OF MARIJUANA EXTRACT DISTILLATE AND CANNABIDIOL ON

VARIABLE INTERVAL PERFORMANCE AS A FUNCTION OF FOOD DEPRIVATION. 003308 04-04

CHARACTERIZATION OF ENKEPHALIN-LIKE MATERIAL EXTRACTED FROM SYMPATHETIC GANGLIA. 002788 04-01

EXTRACTION THE EXTRACTION AND ANALYSIS OF BENZODIAZEPINES IN TISSUES BY ENZYMIC DIGESTION AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY

000928 01-16 DIRECT EXTRACTION RADIOASSAY FOR CATECHOL-O-METHYL-

TRANSFERASE ACTIVITY. 003425 04-06 EXTRACTS

BREAKDOWN OF ENKEPHALIN AND ENDORPHIN ANALOGS BY BRAIN EXTRACTS. 001137 02-03 EXTRAGRANULAR

GRANULAR AND EXTRAGRANULAR ACTION OF PSYCHOTROPIC DRUGS ON MONOAMINERGIC NEURONS. 000252 01-03

EXTRAPYRAMIDAL SIDE-EFFECTS OF METOCLOPRAMIDE (CERUCAL) USED IN COMBINATION WITH AN ANTIDEPRESSANT.

000832 01-15 IATROGENIC EXTRAPYRAMIDAL SYNDROME -- A CAUTIONARY TALE 000834 01-15

IATROGENIC EXTRAPYRAMIDAL DISORDERS. 000859 01-15

DOPAMINE, THE PSYCHE, AND EXTRAPYRAMIDAL DISORDERS. 000864 01-15

EXTRAPYRAMIDAL SIDE-EFFECTS IN CHLORPROMAZINE RECIPIENTS.
000903 01-15 MIDAL SYSTEM. 001507 02-05 DELTA9-TETRAHYDROCANNABINOL AND THE EXTRAPYRA

CORRELATION BETWEEN EXTRAPYRAMIDAL AND THERAPEUTIC EFFECTS OF NEUROLEPTICS. 001741 02-15

LITHIUM THERAPY OF EXTRAPYRAMIDAL MOVEMENT DISORDERS. 001774 02-15 PHARMACOKINETICS AND CLINICAL EFFECTS OF AMANTADINE IN DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS

RELATIONSHIPS AMONG CLINICAL RESPONSE, EXTRAPYRAMIDAL SYNDROME AND PLASMA CHLORPROMAZINE AND METABOLITE PATIOS.

001827 02-15 A NEW NEUROMODULATOR OF THE EXTRAPYRAMIDAL SYSTEM (EPS).

001952 03-02 INFLUENCE OF EXTRAPYRAMIDAL DISTURBANCES DUE TO HALOPERIDOL ON PHENAMINE STEREOTYPY AND THE EFFECTS OF SCHIZOPHRENIC BLOOD SERUM (EXPERIMENTAL STUDIES)

002339 03-05 EXTRAPYRAMIDAL REACTIONS IN ADOLESCENTS TREATED WITH HIGH-POTENCY ANTIPSYCHOTICS.

AMANTADINE IN THE TREATMENT OF BENZTROPINE REFRACTORY EXTRAPYRAMIDAL DISORDERS INDUCED BY ANTIPSYCHOTIC DRUGS 002664 03-15

THE EFFECT OF GAMMA-ACETYLENIC-GABA, AN ENZYME ACTIVATED IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE, ON DOPAMINE PATHWAYS OF THE EXTRAPYRAMIDAL AND LIMBIC SYSTEMS. 003037 04-03

SOMATOSTATIN IN THE TREATMENT OF PATIENTS WITH EXTRAPYRAMIDAL DISORDERS AND PATIENTS WITH EEG ABNORMALITIES

003557 04-11 PSYCHOLOGICAL FACTORS IN SUSCEPTIBILITY TO DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS.

003660 04-15 ON THE ROLE OF HEMISPHERIC DOMINANCE IN SCHIZOPHRENIA AS MEASURED BY EXTRAPYRAMIDAL SIDE-EFFECTS OF NEUROLEPTICS 003675 04-15

EYE ACTIVITY OF VESTIBULO-OCULOMOTOR NEURONES DURING SACCADIC EYE MOVEMENTS INDUCED BY RESERPINE

000199 01-03 CANNABIS, CATECHOLAMINES, RAPID EYE MOVEMENT SLEEP AND AGGRESSIVE BEHAVIOUR

001320 02-04 EYE MOVEMENT, AN INDICATOR OF BRAIN FUNCTION

002637 03-14 EYE BLINK AND SCHIZOPHRENIA: PSYCHOSIS OR TARDIVE-DYSKINESIA? 002703 03-15

NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION OF THE SYMPATHETIC NERVE OF THE EYE.

002802 04-03 F-2ALPHA EFFECTS OF D AMPHETAMINE (D-A), PROSTAGLANDIN-E1 AND F-2ALPHA ON H3-2-DOPAMINE (H3-DA) METABOLISM, FIXED-INTERVAL (FI) BEHAVIOR AND RECTAL TEMPERATURE.

001207 02-03 FACIAL DIPHENHYDRAMINE IN THE DIFFERENTIAL DIAGNOSIS OF NEUROLEPTIC-

INDUCED ORAL FACIAL DYSKINESIA

A RELIABLE, FACIAL NOCICEPTION DEVICE FOR UNRESTRAINED, AWAKE ANIMALS: EFFECTS OF MORPHINE AND TRIGEMINAL COMPLEX LESIONS.

003435 04-06 **FACILITATED** VALIDITY AND CLINICAL UTILITY OF NEUROLEPTIC FACILITATED ELECTROENCEPHALOGRAPHY IN PSYCHOTIC PATIENTS. 003669 04-15

Psychopharmacology Abstracts

galest tool (Life	
Subject Index	
FACILITATING MEMORY FACILITATING AND ANTIAMNESIC EFFECTS OF CORTICOSTEROIDS.	MACHANIA MAC
FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON LOCOMO AND AVOIDANCE BEHAVIOUR OF RESERPINIZED MICE.	002233 03-04 TOR ACTIVITY
FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON THE PER	003351 04-04 FORMANCE OF
	003353 04-04
FACILITATION FACILITATION OF MOUNTING BEHAVIOR BY DIHYDROTEST PROPIONATE IN CASTRATED ESTRADIOL-BENZOATE TREA RATS FOLLOWING PUDENDECTOMY.	
FACILITATION BY RESERPINE OF RETENTION IN AN INHIBITO	000403 01-04 DRY
FACILITATION OF SIDMAN AVOIDANCE PERFORMANCE BY CHLOROAMPHETAMINE: ROLE OF BIOGENIC AMINES.	000406 01-04 P-
DRUG-PRODUCED CHANGES IN HUMAN SOCIAL BEHAVIOR:	001467 02-04 FACILITATION
TOLERANCE TO AMPHETAMINES FACILITATION OF SELF-STI	001715 02-14 MULATION
FACILITATION OF LORDOSIS BEHAVIOR BY CLONIDINE IN FI	002190 03-04 EMALE GUINEA-
FACILITATION OF BENZODIAZEPINE BINDING BY SODIUM-C	002222 03-04 HLORIDE AND
	003002 04-03
FACILITATORY FACILITATORY AND DEPRESSANT EFFECTS OF DOPAMINE IN CAUDATE NUCLEUS.	THE FELINE
FACT	002116 03-03

FACT	
DIFFERENT EFFECTS OF METHIONINE-ENKEPHA METHIONINE-ENKEPHALINAMIDE ON THE N AND NOREPINEPHRINE IN RAT BRAIN: FAC	METABOLISM OF DOPAMINE T OR ARTIFACT?.
	001980 03-03
DEPRESSION: MUST PHARMACOTHERAPY FA TO SUCCEED?.	IL FOR COGNITIVE THERAPY
FAUS	003726 04-17

ENDORPHINS: NALOXONE FAILS TO ALTER EXPERIMENTAL PAIN OR

MOOD IN HUMANS

FA	LURE
	FAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS UNDER LONG-TERM TRAINING.
	000034 01-0
	FAILURE TO ELICIT CONDITIONED TASTE AVERSION BY SEVERE POISONING.
	000382 01-0
	FAILURE OF NALOXONE TO PREVENT REDUCTION OF AMNESIA BY

000438 01-04 BLOCKADE OF INTRACRANIAL SELF-STIMULATION BY ANTIPSYCHOTIC DRUGS: FAILURE TO CORRELATE WITH CENTRAL ALPHANORADRENERGIC BLOCKADE. 000475 01-04 FAILURE OF NALOXONE TO AFFECT HUMAN SLEEP 000756 01-14

DOXEPIN OVERDOSE: SUCCESS WITH PHYSOSTIGMINE AND FAILURE WITH NEOSTIGMINE IN REVERSING TOXICITY. 000772 01-14 FAILURE OF METHADONE AND LEVOMETHADYL-ACETATE (LEVO-ALPHA-ACETYLMETHADOL, LAAM) MAINTENANCE TO AFFECT MEMORY.

000841 01-15 COMBINED SEMINAR ON THE USE OF DRUGS IN RENAL FAILURE 001902 02-17 FAILURE OF MORPHINE TO INCREASE STRIATAL 3,4
DIHYDROXYPHENYLACETIC-ACID IN FASTED RATS.

NALOXONE REVERSAL OF MORPHINE ANALGESIA BUT FAILURE TO ALTER REACTIVITY TO PAIN IN THE FORMALIN TEST. 002117 03-03

ASSESSMENT OF DRUG THERAPY IN CHRONIC BRAIN FAILURE 002719 03-16 FAILURES

SCOPOLAMINE-INDUCED LEARNING FAILURES IN MAN. SOME FAILURES OF THE DRUG DISCRIMINATION HYPOTHESIS OF STATE-DEPENDENT LEARNING. 003317 04-04

GILLES-DE-LA-TOURETTES SYNDROME: FAMILIAL OCCUP	RENCE AND
PRECIPITATION BY METHYLPHENIDATE THERAPY.	001823 02-15

ENHANCED CHOICE OF FAMILIAR FOOD IN A FOOD PREFERENCE TEST AFTER CHLORDIAZEPOXIDE ADMINISTRATION. 003199 04-04

PAMILY
ANXIETY STATES IN FAMILY PRACTICE: AN EVALUATION OF THE NEED
FOR ANTIDEPRESSANT AS WELL AS ANXIOLYTIC THERAPY.
000605 01-10

LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR BLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE IN THE FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE PROBAND.

INTRAPSYCHIC AND FAMILY DYNAMIC PROCESSES IN AN ENDOGENOUS DEPRESSION PRECEDING MANIFESTATION OF THE ILLNESS AND LITHIUM THERAPY.

FANTASIES
TREATMENT OF OBSESSIVE HOMOSEXUAL PEDOPHILIC FANTASIES WITH MEDROXYPROGESTERONE-ACETATE. 003543 04-10

FASCIA-DENTATA
MONOSYNAPTIC ACTIVATION OF FASCIA-DENTATA IN UNRESTRAINED
RATS: RESPONSE MODIFICATION BY SYNAPTICALLY ACTIVE DRUGS

PASTED FAILURE OF MORPHINE TO INCREASE STRIATAL 3,4
DIHYDROXYPHENYLACETIC-ACID IN FASTED RATS.

002001 03-03 INFLUENCE OF FASTING ON THE ABSORPTION AND EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AFTER ORAL ADMINISTRATION IN SESAME-

RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION WITH A HIGH FAT/PROTEIN DIET. 002278 03-04

FATAL A CASE OF FATAL IMIPRAMINE POISONING IN AN INFANT. 000879 01-15 FATAL POISONING WITH PROPOXYPHENE: REPORT FROM 100 CONSECUTIVE CASES.

001788 02-15 FATE THE METABOLIC FATE OF C14-PHENOBARBITONE IN THE RAT AND THE EFFECT OF CHRONIC ADMINISTRATION AND DOSE SIZE.

000067 01-03 EFFECTS OF DISULFIRAM ON PHARMACOLOGICAL ACTIVITY, TOXICITY AND FATE OF MORPHINE IN RATS.

001111 02-03 EFFECT OF MECAMYLAMINE ON THE FATE OF DOPAMINE IN STRIATAL AND MESOLIMBIC AREAS OF RAT BRAIN; INTERACTION WITH MORPHINE AND HALOPERIDOL.

002806 04-03

THE EFFECT OF PHENOBARBITAL AND CARBON-TETRACHLORIDE ON FATTY-ACID CONTENT AND COMPOSITION OF PHOSPHOLIPIDS FROM THE ENDOPLASMIC RETICULUM OF RAT LIVER.

FATTY-ACIDS

POSSIBLE CENTRAL DOPAMINERGIC MODULATION OF THE RISE IN
PLASMA CONCENTRATION OF NONESTERIFIED FATTY-ACIDS PRODUCED
IN THE MOUSE BY (-)TRANS DELTA9-TETRAHYDROCANNABINOL. 002085 03-03 CHANGES IN BRAIN FREE FATTY-ACIDS AFTER PAINFUL PERIPHERAL STIMULATION (EFFECT OF PROTHIADEN).

003094 04-03 FEAR THE EFFECT OF MORPHINE ON FEAR EXTINCTION IN RATS.

003305 04-04 PHENOBARBITAL IN THE ACUTE MANAGEMENT OF FEBRILE CONVULSIONS.

001555 02-07 BEHAVIOR DISTURBANCE, PHENOBARBITAL, AND FEBRILE SEIZURES 003582 04-11

SULFATES AND GLUCURONIDES OF P-HYDROXYPHENOBARBITAL IN RAT FECES. 002165 03-03

CAFFEINE RESTORES FEEDING RESPONSE TO 2 DEOXY-D-GLUCOSE IN 6
HYDROXYDOPAMINE TREATED RATS. 000277 01-03

002383 03-07

EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON FEEDING IN INTACT AND 6 HYDROXYDOPAMINE TREATED RATS.

PROGRAMMED FEEDING AS A MODEL OF CHRONIC ALCOHOLISM IN THE RAT.

LORDOSIS REFLEX, SEXUAL RECEPTIVITY, AND FEEDING: ESTROGEN RESPONSIVITY IN MALE AND FEMALE RATS.

001327 02-04

EFFECTS OF 6 HYDROXYDOPAMINE ON BODY WEIGHT: FEEDING DEFICITS
OR SENSORY-MOTOR IMPAIRMENTS?.

FEEDING AND DRINKING INTERACTIONS AFTER ACUTE BUTYROPHENONE ADMINISTRATION.

001446 02-04
DECREASED FEEDING IN RATS FOLLOWING HEPATIC PORTAL INFUSION OF
GLUCAGON.

OO1514 02-02
PARAVENTRICULAR NUCLEUS: A PRIMARY SITE MEDIATING ADRENERGIC
STIMULATION OF FEEDING AND DRINKING.

FEEDING BEHAVIOR OF SHEEP FOLLOWING INTRAVENOUS INJECTION OF IMIDAZOBENZODIAZEPINES.

CENTRAL DRUG AND LESION STUDIES OF FEEDING. 002193 03-04

O02270 03-04
FORMAMIDINE-INDUCED FEEDING AND BEHAVIORAL ALTERATION IN THE

O02294 03-04
SIMILAR EFFECTS OF ESTROGEN AND LATERAL HYPOTHALAMIC LESIONS
ON FEEDING BEHAVIOR OF FEMALE RATS.

O03314 04-04
STRIATAL NONDOPAMINERGIC NEURONS: POSSIBLE INVOLVEMENT IN
FEEDING AND DRINKING BEHAVIOR.

D03330 04-04
EFFECTS OF INSULIN AND 2 DEOXY-D-GLUCOSE ON FEEDING IN
HAMSTERS AND GERBILS

FEELINGS

VILOXAZINE, SLEEP, AND SUBJECTIVE FEELINGS. 002609 03-14

003345 04-04

003007 04-03

FELINE
MORPHINE AND ITS BIPHASIC INFLUENCE UPON PHARMACOLOGICALLY
DISTINCT DOPAMINERGIC SYSTEMS WITHIN THE FELINE CAUDATE

NUCLEUS: A BEHAVIOURAL STUDY.

001954 03-0:
FACILITATORY AND DEPRESSANT EFFECTS OF DOPAMINE IN THE FELINE

602116 03-0:
EFFECTS OF PENTYLENETETRAZOLE AND TRIMETHADIONE ON FELINE
BRAIN MONOAMINE METABOLISM.

WORD ASSOCIATION TIMES, FELT EFFECTS, AND PERSONALITY
CHARACTERISTICS OF SCIENCE STUDENTS GIVEN A PLACEBO

ENERGIZER: 002611 03-14

IMALII

THE EFFECTS OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY

BEHAVIOUR IN THE FEMALE RAT.

000353 01-04
THE EFFECTS OF CANNABIS-SATIVA ON THE BEHAVIOR OF ADULT FEMALE

CHACMA BABOONS (PAPIO-URSINUS) IN CAPTIVITY.

O00402 01-04

A COMPARATIVE STUDY OF DIFFERENT AMPHETAMINES ON
COPULATORY BEHAVIOR AND STEREOTYPE ACTIVITY IN THE FEMALE

RAT. 000412 01-04
STUDIES ON DIGITAL PLETHYSMOGRAPHIC PATTERNS IN FEMALE

PATIENTS WITH NONSPECIFIC COMPLAINTS.

DOG626 01-11

LORDOSIS REFLEX, SEXUAL RECEPTIVITY, AND FEEDING: ESTROGEN

RESPONSIVITY IN MALE AND FEMALE RATS.

001327 02-04
ENHANCEMENT OF SEXUAL BEHAVIOR IN THE FEMALE RAT BY NICOTINE.

THE EFFECTS OF HORMONES AND MORPHINE ON BOTH ANALGESIA AND THE LORDOSIS RESPONSE PRODUCED BY CERVICAL PROBING IN THE FEMALE RAT

001445 02-04

EFFECTS OF ANTIESTROGENS ON EATING, FEMALE SEXUAL BEHAVIOR,
AND THE UPTAKE OF H3-ESTRADIOL IN THE CENTRAL-NERVOUSSYSTEM IN RATS. (PH.D. DISSERTATION).

THE INFLUENCE OF PROGESTERONE ON THE INHIBITORY EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE FEMALE RAT.

001463 02-04
RATIONALITY OF APPEALS USED IN THE PROMOTION OF PSYCHOTROPIC
DRUGS. A COMPARISON OF MALE AND FEMALE MODELS.
001932 02-17

EFFECTS OF CHLORDIAZEPOXIDE, OXAZEPAM, CHLORPROMAZINE, AND D AMPHETAMINE ON SEXUAL RESPONSES IN MALE AND FEMALE HAMSTERS.

FACILITATION OF LORDOSIS BEHAVIOR BY CLONIDINE IN FEMALE GUINEA-PIGS.

O02222 03-04

EFFECTS OF CLOMIPRAMINE AND OTHER INHIBITORS OF MONOAMINE

UPTAKE ON THE SEXUAL BEHAVIOUR OF FEMALE RATS AND RHESUS

MONKEYS.

002228 03-04
EFFECTS OF CATECHOL ESTROGENS ON SEXUAL DIFFERENTIATION IN
NEONATAL FEMALE RATS.

THE EFFECTS OF INTRAVENTRICULAR INJECTION OF GAMMA-AMINOBUTYRIC-ACID (GABA) ON PROLACTIN AND GONADOTROPIN RELEASE IN CONSCIOUS FEMALE RATS.

003126 04-03

ROLE OF HYPOTHALAMIC SEROTONERGIC RECEPTORS IN THE CONTROL OF LORDOSIS BEHAVIOR IN THE FEMALE RAT.

D03220 04-04
DELTA9-TETRAHYDROCANNABINOL ENHANCEMENT OF LORDOSIS
BEHAVIOR IN ESTROGEN TREATED FEMALE RATS.

POTENTIATION OF HEXOBARBITAL AND AMPHETAMINE EFFECTS IN MALE AND FEMALE RATS PHYSICALLY DEPENDENT ON MORPHINE. 003275 04-04

O03275 04-04
SIMILAR EFFECTS OF ESTROGEN AND LATERAL HYPOTHALAMIC LESIONS
ON FEEDING BEHAVIOR OF FEMALE RATS.

O03314 04-04
DIETARY EFFECTS UPON FOOD AND WATER INTAKE AND
RESPONSIVENESS TO ESTROGEN, 2 DEOXYGLUCOSE AND GLUCOSE IN
FFMALE RATS

FEMOXETINE
INHIBITION OF BOTH MAO-A AND MAO-B REQUIRED FOR THE
PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE

PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

000398 01-04

THE SYMPATHOMIMETIC ACTIVITY OF FENFLURAMINE HYDROCHLORIDE ON RAT VAS-DEFERENS. 000205 01-0:

CEREBRAL METABOLISM OF INTRAVENTRICULAR (3H) FENFLURAMINE.

000266 01-03

INTERFERENCE BY FENFLURAMINE WITH THE STORAGE OF C14-5-

HYDROXYTRYPTAMINE IN RAT PLATELETS.

000297 01-03

DISCRIMINATIVE STIMULUS PROPERTIES OF FENFLURAMINE IN AN OPERANT TASK: AN ANALYSIS OF ITS CUE FUNCTION.

000369 01-04

METABOLISM OF FENFLURAMINE TO M
TRIFLUOROMETHYLBENZOYLGLYCINE IN RAT BRAIN.

THE SOCIOPHARMACOLOGY OF FENFLURAMINE (FM), METHYLPHENIDATE (MP), AND DIETHYLPROPION (DP) IN MACAQUE ARCTOIDES. 001311 02-04

EFFECTS OF COCAINE AND FENFLURAMINE ON PROGRESSIVE RATIO PERFORMANCE.

001473 02-04
FENFLURAMINE: CUMULATIVE NEUROTOXICITY AFTER CHRONIC
TREATMENT WITH LOW DOSAGES IN THE RAT.

PLASMA FENFLURAMINE LEVELS, WEIGHT LOSS, AND SIDE-EFFECTS. 001790 02-15

EFFECTS OF MAZINDOL, FENFLURAMINE AND CHLORIMIPRAMINE ON THE 5 HYDROXYTRYPTAMINE UPTAKE AND STORAGE MECHANISMS IN RAT BRAIN: SIMILARITIES AND DIFFERENCES.

DO1983 03-03
BLOCKAGE OF PROGESTERONE-INDUCED RELEASE OF LUTEINIZING
HORMONE AND PROLACTIN BY D AMPHETAMINE AND FENFLURAMINE
IN RATS.

002006 03-03

EFFECTS OF FENFLURAMINE AND NORFENFLURAMINE ON BRAIN
SEROTONIN METABOLISM IN RATS.

002016 03-03

FENFLURAMINE AND FLUOXETINE SPARE PROTEIN CONSUMPTION WHILE
SUPPRESSING CALORIC INTAKE BY RATS.

PHARMACOLOGICAL DIFFERENTIATION OF THE CENTRAL 5
HYDROXYTRYPTAMINE-LIKE ACTIONS OF MK-212 (6 CHLORO-2-1PIPERAZINYL-PYRAZINE), P-METHOXYAMPHETAMINE AND
FENFLURAMINE IN AN IN VIVO MODEL SYSTEM.

RELEASE OF ENDOGENOUS CATECHOLAMINES FROM ISOLATED RAT BRAIN TISSUE BY FENFLURAMINE AND N ETHYLAMPHETAMINE --EFFECTS OF PARGYLINE.

003111 04-03
LSD-INDUCED STIMULUS CONTROL: A COMPARISON OF SCH-12679,
FENFLURAMINE, P-METHOXYAMPHETAMINE, AND BL-3912.
003396 04-04

FENTANYL
CENTRAL SITES AND MECHANISMS OF THE HYPOTENSIVE AND
BRADYCARDIC EFFECTS OF THE NARCOTIC ANALGESIC AGENT

DIFFERENTIAL HALOPERIDOL EFFECT ON TWO INDICES OF FENTANYL SALINE DISCRIMINATION.

000495 01-06 ACQUISITION AND EXTINCTION OF OPERANT RESPONDING FOR INTRAVENOUS INJECTIONS OF FENTANYL IN THE RAT.

CLONIDINE SELF-ADMINISTRATION IN THE RAT: A COMPARISON WITH FENTANYL SELF-ADMINISTRATION.

001462 02-04
NARCOTIC CUEING PROPERTIES OF INTRAVENTRICULARLY ADMINISTERED
SUFENTANIL, FENTANYL, MORPHINE AND MET-ENKEPHALIN.

002217 03-04 THE EFFECTS OF ETORPHINE, FENTANYL AND MORPHINE ON NORADRENALINE AND DOPAMINE CONCENTRATIONS IN THE STRIATUM OF RAT. 002321 03-04

INSTINCTIVE PREDATORY BEHAVIOR OF THE FERRET (PUTORIUS-PUTORIUS-FURO L.) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE (LIBRIUM).

003161 04-04

FETAL DISTRIBUTION OF NEUROPSYCHOPHARMACOLOGICAL AGENTS. 000069 01-03 MATERNAL FETAL DISTRIBUTION OF METHAQUALONE IN CONTROL AND SKF-525-A PRETREATED PREGNANT MICE.

BIOCHEMICAL DIFFERENTIATION OF AGGREGATING CELL CULTURES OF DIFFERENT FETAL RAT BRAIN REGIONS.

THE PHARMACOLOGICAL EFFECTS OF FETAL AND NEONATAL EXPOSURE

001373 02-04 EFFECT OF MATERNAL MORPHINE ADMINISTRATION ON FETAL AND NEONATAL RAT LIVER TYROSINE-AA INOTRANSFERASE. 002011 03-03

OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG NEURITES.

002040 03-03
BENEFICIAL EFFECT OF ISOLEUCINE ON FETAL BRAIN DEVELOPMENT IN INDUCED PHENYLKETONURIA.

002846 04-03 CYPROTERONE-ACETATE EXPOSURE DURING GESTATION IN MICE RETARDS FETAL GROWTH.

003129 04-03 H3-DELTA9-TETRAHYDROCANNABINOL DISTRIBUTION IN PREGNANT DOGS

AND THEIR FETUSES. 000194 01-03 MALIGNANT FEVER IS NOW AN OFFICE PROBLEM TOO.

003565 04-11

THE EFFECT OF MELPERONE (BURONIL(R)) AND ITS METABOLITE FG-5155 ON THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM COMPARED TO SOME OTHER NEUROLEPTICS. 001081 02-03

DIAZEPAM BLOCKADE OF REPETITIVE ACTION POTENTIALS IN SKELETAL MUSCLE FIBRES: A MODEL OF ITS MEMBRANE ACTION. 001275 02-03

EFFECTS OF CLONIDINE ON VULNERABILITY TO FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE VENTRICLE. 002140 03-03

MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND NORADRENERGIC NEURONS IN NORMAL AND BRAIN LESIONED RATS.

000312 01-

000312 01-04 EFFECTS OF BENZAZEPINE (SCH-12679) ON SHOCK-INDUCED FIGHTING AND LOCOMOTOR BEHAVIOR IN RATS.

003166 04-04 BLOCKADE OF TESTOSTERONE MAINTAINED INTERMALE FIGHTING IN ALBINO LABORATORY MICE BY AN AROMATIZATION INHIBITOR. 003176 04-04

INHIBITION OF FIGHTING IN ISOLATED MICE FOLLOWING REPEATED ADMINISTRATION OF LITHIUM-CHLORIDE. 003282 04-04

THYROTROPIN-RELEASING HORMONE (TRH): LACK OF EFFECT ON SHOCK-ELICITED FIGHTING (SEF) IN RATS. PITUITARY ADRENOCORTICAL AXIS AND SHOCK-INDUCED FIGHTING IN

003342 04-04

Psychopharmacology Abstracts

THE EFFECTS OF DEXTROAMPHETAMINE ON KINESTHETIC FIGURAL AFTEREFFECTS.

002620 03-14 PILICIDA

FILICIDE DURING PSYCHOTROPIC-INDUCED SOMNAMBULISM: A CASE 003663 04-15

FURTHER STUDIES ON THE FINE STRUCTURE OF THE ADRENERGIC INNERVATION OF THE HYPOTHALAMUS.

003105 04-03

AGRANULOCYTOSIS IN PATIENTS TREATED WITH CLOZAPINE: A STUDY OF THE FINNISH EPIDEMIC. 001742 02-15

BURST FIRING OF CEREBELLAR PURKINJE NEURONES INDUCED BY BENZODIAZEPINES. 001061 02-03

FIRINGS

EFFECTS OF BENZODIAZEPINES ON PGO FIRINGS AND MULTIPLE UNIT ACTIVITY IN THE MIDBRAIN RETICULAR FORMATION IN CATS. 001265 02-03

FIRST-PASS EFFECT OF NALORPHINE IN RATS. 000153 01-03 FIRST-PASS ELIMINATION OF C14-IMIPRAMINE IN ISOLATED PERFUSED 001052 02-03

FIRST-PASS EFFECT OF NALORPHINE IN RATS. 001166 02-03

T-TIME
THE USE OF PRESCRIPTION DRUGS IN TREATMENT OF FIRST-TIME
PSYCHIATRIC ADMISSIONS TO UNIVERSITY HOSPITAL, SASKATOON.
003712 04-17

A COMPARISON BETWEEN PLACEBO, PIZOTIFEN AND 1 ISOPROPYL-3-HYDROXY 5 SEMICARBAZONO-6-OXOTETRAHYDROINDOL (FIVASCAN) IN MIGRAINE PROPHYLAXIS. 000653 01-11

L.FECTS OF SODIUM THIOPENTAL ON THE TRICARBOXYLIC-ACID CYCLE METABOLISM IN MOUSE BRAIN: CO2 FIXATION AND METABOLIC COMPARTMENTATION.

002860 04-03 FIXED CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED DOSES OF CHLORPROMAZINE.

003614 04-13

FIXED-INTERVAL
SCHEDULE-INDUCED BITING UNDER FIXED-INTERVAL SCHEDULES OF FOOD
OR ELECTRIC-SHOCK PRESENTATION. 000348 01-04

FIXED-INTERVAL RESPONDING UNDER SECOND-ORDER SCHEDULES OF FOOD PRESENTATION OR COCAINE INJECTION. 000391 01-04 LSD AND D AMPHETAMINE EFFECTS ON FIXED-INTERVAL RESPONDING IN THE RAT.

EFFECTS OF D AMPHETAMINE (D-A), PROSTAGLANDIN-E1 AND F-ZALPHA ON H3-2-DOPAMINE (H3-DA) METABOLISM, FIXED-INTERVAL (FI) BEHAVIOR AND RECTAL TEMPERATURE.

001207 02-03

EFFECTS OF D AMPHETAMINE, CHLORDIAZEPOXIDE AND PROMAZINE ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION AND STIMULUS SHOCK TERMINATION. 001305 02-04

EFFECTS OF D AMPHETAMINE ON A MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE OF FOOD REINFORCEMENT IN THE CAT. 001374 02-04 DECREASED RESPONSE INHIBITION DURING FIXED-INTERVAL RESPONDING IN PIGEONS FOLLOWING ATROPINE ADMINISTRATION.

002305 03-04 COMPARATIVE VALIDITY OF RANDOM-INTERVAL AND FIXED-INTERVAL URINALYSIS SCHEDULES.

EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ, ANGIOTENSIN-II, AND SUBSTANCE-P ON MULTIPLE FIXED-INTERVAL FIXED-RATIO RESPONDING IN RABBITS.

003233 04-04

DRUG EFFECTS UPON FORCE AND DURATION OF RESPONSE DURING FIXED-RATIO PERFORMANCE IN RATS.

000363 01-04 ATTENUATION OF THE RATE DECREASING EFFECTS OF AMPHETAMINE ON FIXED-RATIO RESPONDING IN RATS BY HIPPOCAMPAL LESIONS. 000474 01-04 DIFFERENTIAL EFFECT OF NALOXONE ON FIXED-RATIO OPERANT BEHAVIOR IN STRESSED AND NONSTRESSED RATS.

EFFECTS OF D AMPHETAMINE ON A MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE OF FOOD REINFORCEMENT IN THE CAT. 001374 02-04

BETA-ENDORPHIN: DOSE-DEPENDENT SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR. 001402 02-04

ETHANOL, PENTOBARBITAL, AND CHLORDIAZEPOXIDE EFFECTS IN SQUIRREL-MONKEYS RESPONDING UNDER FIXED-RATIO FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION SCHEDULES.

002254 03-04

EFFECTS OF D AMPHETAMINE AND ETHANOL ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION. 002255 03-04

EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ, ANGIOTENSIN-II, AND SUBSTANCE-P ON MULTIPLE FIXED-INTERVAL FIXED-RATIO RESPONDING IN RABBITS.

003233 04-04

EFFECTS OF METHADONE ON BEHAVIOR MAINTAINED BY FIXED-RATIO
REINFORCEMENT SCHEDULES.

003299 04-04

001443 02-04

000845 01-15

001835 02-15

FK33-824

BEHAVIORAL AND BIOCHEMICAL EFFECTS OF FK33-824, A PARENTERALLY AND ORALLY ACTIVE ENKEPHALIN ANALOGUE (UNPUBLISHED PAPER).

002744 03-17

A-136 FLA-136: SELECTIVE AGONIST AT CENTRAL ALPHA-ADRENORECEPTORS MEDIATING CHANGES IN THE TURNOVER OF NORADRENALINE. 000043 01-03

MODIFICATION OF THE AMPHETAMINE-INDUCED STEREOTYPY IN RATS FOLLOWING INHIBITION OF THE NORADRENALINE RELEASE BY FLA-136.

FLAME-IONIZATION
IMIPRAMINE, ITS N DESMETHYL AND HYDROXY METABOLITES IN
PLASMA: MICRO DETERMINATION BY ALKALINE FLAME-IONIZATION
GAS-CHROMATOGRAPHY (AFID-GC).

002597 03-13

LITHIUM NEUROTOXICITY. I. THE CONCENTRATION OF LITHIUM IN DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS

ATOMIC ABSORPTION SPECTROPHOTOMETRY.

003432 04-06

NORMAL AND AMPHETAMINE-INDUCED ROTATION OF RATS ON A FLAT SURFACE.

001365 02-04

LAVIN
INHIBITION OF FLAVIN SYNTHESIS BY CHLORPROMAZINE IN EUTHYROID
AND HYPERTHYROID RATS.

FLAVOR

LOCATION PREFERENCE AND FLAVOR AVERSION REINFORCED BY

AMPHETAMINE IN RATS.

FLEXOR

RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDROXYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN
ACUTE AND CHRONIC SPINAL RATS.

ACUTE AND CHRONIC SPINAL RATS.

002289 03-04

EVALUATION OF SUBSTITUTED AMPHETAMINE HALLUCINOGENS USING THE CAT LIMB FLICK MODEL. 001449 02-04

FLICKER VALUES AND CHANGES IN STATES OF DEPRESSION.
001592 02-09

USE OF THE FLINCH-JUMP TECHNIQUE TO STUDY NARCOTIC ANALGESIA
IN THE RAT.

003403 04-04

FLOPPY INFANT SYNDROME AND MATERNAL DIAZEPAM.

000837 01-15
FLOPPY INFANT SYNDROME AND MATERNAL DIAZEPAM.

FLOPPY-INFANT
FLOPPY-INFANT SYNDROME: IS OXAZEPAM THE ANSWER?.

001619 02-11
FLOPPY-INFANT SYNDROME AND MATERNAL DIAZEPAM AND/OR
NITE A 7 FPAM

PLOW REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF BROMIDE PSYCHOSIS. 000800 01-15 DECREASE IN NEOSTRIATAL BLOOD FLOW AFTER D AMPHETAMINE ADMINISTRATION OR ELECTRICAL STIMULATION OF THE SUBSTANTIA-

001175 02-03
INDIRECT SYMPATHOMIMETICS AND CEREBRAL BLOOD FLOW AND
METABOLISM.

THE EFFECT OF STEROID HORMONES ON CEREBRAL BLOOD FLOW BEFORE AND AFTER INTRACAROTID INFUSION OF 5 HYDROXYTRYPTAMINE.

REGIONAL CHANGES OF CEREBRAL BLOOD FLOW DURING HALOPERIDOL THERAPY IN PATIENTS WITH PARANOID SYMPTOMS. 001677 02-13

THE EFFECT OF SALICYLATE ON CEREBRAL BLOOD FLOW IN MAN.
001681 02-13
INDIRECT SYMPATHOMIMETIC AGENTS AND CEREBRAL BLOOD FLOW

AND METABOLISM.

002092 03-03

EFFECTS OF PIRACETAM ON REGIONAL CEREBRAL BLOOD FLOW AND MENTAL FUNCTIONS IN PATIENTS WITH ORGANIC DEMENTIA.

AMPHETAMINE-INDUCED INCREASE IN RAT CEREBRAL BLOOD FLOW; APPARENT LACK OF CATECHOLAMINE INVOLVEMENT. 003031 04-03

FLUCTUATING
FLUCTUATING DENTAL ASYMMETRY AS AN INDICATOR OF THE
STRESSFUL PRENATAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL
IN THE LABORATORY RAT.

FLUCTUATION 001520 02-05

MIOSIS AND FLUCTUATION IN THE RABBIT PUPIL: EFFECTS OF MORPHINE AND NALOXONE.

FLUDIAZEPAM

EFFECT OF FLUDIAZEPAM ON TURNOVER OF SEROTONIN IN MOUSE

BRAIN.

002111 03-03

EFFECTS OF AMPHETAMINE AND CHLORDIAZEPOXIDE ON PROBENECID-INDUCED ACCUMULATION OF ACIDIC METABOLITES IN THE CEREBROSPINAL FLUID OF THE DOG.

CONCENTRATION OF CLONAZEPAM IN SERUM AND CEREBROSPINAL FLUID OF THE SHEEP.

O00215 01-03

A RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION
OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF
BIOLOGICAL FLUID OR TISSUE.

THE EFFECT OF L TRYPTOPHAN ADMINISTRATION ON THE CONCENTRATION OF PROBENECID IN PLASMA AND CEREBROSPINAL ELIJID IN PATIENTS

000564 01-09

EFFECT OF CHLORPROMAZINE TREATMENT ON MONOAMINE METABOLITE

LEVELS IN CEREBROSPINAL FLUID OF PSYCHOTIC PATIENTS.

000591 01-09
CEREBROSPINAL FLUID HOMOVANILLIC-ACID IN MALE ALCOHOLICS:
EFFECTS OF DISULFIRAM.

000645 01-11
PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF
CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS.
000742 01-13

THE EFFECTS OF VARIOUS NARCOTIC AGONISTS AND ANTAGONISTS ON DEPRIVATION-INDUCED FLUID CONSUMPTION.

O01408 02-04

SIMILAR EFFECTS OF TRYPTOPHAN AND SLEEP ON CISTERNAL
CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC AND HOMOVANILLICACIDS IN CATS.

O01440 02-04

DRUG INTERACTIONS AS MEASURED BY DEPRIVATION-INDUCED FLUID

CONSUMPTION.

001501 02-04
LITHIUM: CLINICAL EFFECTS AND CEREBROSPINAL FLUID ACID
MONOAMINE METABOLITES.

001577 02-09
NEUROTRANSMITTER METABOLITES IN THE CEREBROSPINAL FLUID OF
MAN FOLLOWING PHYSOSTIGMINE.

O01653 02-1
ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN
THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING
FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS.

CYCLIC-AMP IN CEREBROSPINAL FLUID OF MANIC AND DEPRESSIVE PATIENTS. 001683 02-13

EFFECT OF CHLORPROMAZINE TREATMENT ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC PATIENTS. 001694 02-13

MORPHINE REDUCES CEREBELLAR CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT AND ELEVATES CEREBROSPINAL FLUID CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT IN RHESUS MONKEY.

002057 03-03

CLINICAL AND BIOCHEMICAL EFFECTS OF CHLORPROMAZINE IN PSYCHOTIC PATIENTS: RELATIONS TO CHLORPROMAZINE CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID.

002538 03-11 ALTERATIONS OF CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC-ACID, AND TOTAL BLOOD SEROTONIN CONTENT DURING CLOZAPINE TREATMENT.

EFFECTS OF MELPERONE AND THIOTHIXENE ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC WOMEN.

ASPECTS OF INFLUX AND EFFLUX OF HOMOVANILLIC-ACID OF RAT CEREBROSPINAL FLUID.

LITHIUM TRANSPORT FROM CEREBROSPINAL FLUID

002807 04-03 002947 04-03

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLETHANOL (MOPET) IN HUMAN CEREBROSPINAL FLUID AND RAT BRAIN BY MEANS OF GAS-CHROMATOGRAPHY — MASS-

003025 04-03

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLLACTIC-ACID (VLA) IN CEREBROSPINAL FLUID AND 3 METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN THE URINE OF PARKINSONIAN PATIENTS TREATED WITH L-DOPA.

003602 04-13

CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED DOSES OF CHLORPROMAZINE.

003614 04-13 A COMPARISON BETWEEN FLUOROMETRIC AND MASS
FRAGMENTOGRAPHIC DETERMINATIONS OF HOMOVANILLIC-ACID AND
5 HYDROXYINDOLEACETIC-ACID IN HUMAN CEREBROSPINAL FLUID. 003694 04-16

THIN-LAYER AND GAS-LIQUID-CHROMATOGRAPHIC PROCEDURES FOR THE DETERMINATION OF PERAZINE AND ITS METABOLITES IN HUMAN

QUANTITATIVE ANALYSIS OF METHADONE IN BIOLOGICAL FLUIDS USING DEUTERIUM-LABELED METHADONE AND GLC CHEMICAL IONIZATION MASS SPECTROMETRY.

001862 02-16 THE FLUOROMETRIC DETERMINATION OF 5 METHOXYTRYPTAMINE IN MAMMALIAN TISSUES AND FLUIDS.

003050 04-03 **ESOPHAGEAL CANNULATION FOR INTRAGASTRIC DELIVERY OF FLUIDS TO** UNRESTRAINED DOGS.

003436 04-06 FLUNITRAZEPAM

FLUNITRAZEPAM, LUNITRAZEPAM, AN INVESTIGATIONAL HYPNOTIC DRUG: SLEEP LABORATORY EVALUATIONS.

000750 01-14 SEQUELAE AFTER THE INTRAVENOUS INJECTION OF THREE BENZODIAZEPINES -- DIAZEPAM, LORAZEPAM, AND FLUNITRAZEPAM

001785 02-15 A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE DERIVATIVES (INITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION.

001787 02-15 FLUNITRAZEPAM (ROHYPNOL) COMPARED WITH NITRAZEPAM (MOGADON) AND APROBARBITAL AS EVENING PREMEDICATION PRIOR TO ANESTHESIA: A CONTROLLED CLINICAL TRIAL.

COMPARATIVE EVALUATION OF HYPNOTIC EFFICACY OF FLUNITRAZEPAM IN PSYCHIATRIC PATIENTS.

003574 04-11

THE FLUOROMETRIC DETERMINATION OF 5 METHOXYTRYPTAMINE IN MAMMALIAN TISSUES AND FLUIDS.

003050 04-03 A COMPARISON BETWEEN FLUOROMETRIC AND MASS
FRAGMENTOGRAPHIC DETERMINATIONS OF HOMOVANILLIC-ACID AND
5 HYDROXYINDOLEACETIC-ACID IN HUMAN CEREBROSPINAL FLUID. 003694 04-16

FLUOROMETRY
HOMOVANILLIC-ACID IN HUMAN CSF: COMPARISON OF FLUOROMETRY
AND GAS-CHROMATOGRAPHY MASS-SPECTROMETRY.
003691 04-

FLUOROPHENYL-METHOXYPHENYL-PIPERAZINOETHYLOXAZOLINONE
PHARMACOLOGICAL PROFILE OF A NEW PSYCHOTHERAPEUTIC AGENT: 4P FLUOROPHENYL-METHOXYPHENYL-PIPERAZINOETHYLOXAZOLINONE 001956 03-02 PLUOXETINE FLUOXETINE, A SEROTONIN UPTAKE INHIBITOR, IN NORMAL HUMAN

O01686 02-13

IMPORTANCE OF DURATION OF DRUG ACTION IN THE ANTAGONISM OF P-CHLOROAMPHETAMINE DEPLETION OF BRAIN SEROTONIN — COMPARISON OF FLUOXETINE AND CHLORIMIPRAMINE.

FENFLURAMINE AND FLUOXETINE SPARE PROTEIN CONSUMPTION WHILE SUPPRESSING CALORIC INTAKE BY RATS.

002184 03-03 INHIBITION OF REM SLEEP BY FLUOXETINE, A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.

003095 04-03 CHLORDIAZEPOXIDE FLUOXETINE INTERACTIONS ON FOOD INTAKE IN FREE-FEEDING RATS.

003217 04-04 FLUPENTHIXOL
LONG-TERM BEHAVIOURAL AND BIOCHEMICAL EFFECTS FOLLOWING
PROLONGED TRE-TIMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL)

000420 01-04 COMBINED EFFECT OF LITHIUM AND FLUPENTHIXOL ON STRIATAL ADENYLATE-CYCLASE.

001131 02-03 EFFECTS OF FLUPENTHIXOL ON THE CLINICAL STATE AND EEG OF SCHIZOPHRENICS.

002395 03-08 EVIDENCE FOR CELL LOSS IN CORPUS-STRIATUM AFTER LONG-TERM TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN RATS 003030 04-03

FLUPHENAZINE

EVALUATIONS OF SOCIAL FUNCTIONING IN A 3-YEAR DOUBLE-BLIND INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.

FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN TREATMENT OF REMITTED SCHIZOPHRENICS: II, RATING SCALE DATA

000544 01-08 PERIPHERAL DIABETIC NEUROPATHY TREATED WITH AMITRIPTYLINE AND FLUPHENAZINE.

PLASMA ASSAY OF FLUPHENAZINE.

FLUPHENAZINE DEPOT (LYORODIN DEPOT) -- SOON IN PRODUCTION IN

001705 02-14

002400 03-08 THE SOCIAL OUTCOME OF PATIENTS IN A TRIAL OF LONG-TERM CONTINUATION THERAPY IN SCHIZOPHRENIA: PIMOZIDE VS. FLUPHENAZINE.

PLASMA FLUPHENAZINE CONCENTRATIONS AFTER INJECTION OF LONG-ACTING ESTERS.

THE EFFECT OF L-DOPA AND LERGOTRILE-MESYLATE ON THE INTERACTION OF FLUPHENAZINE-DECANOATE AND AMPHETAMINE-INDUCED STEREOTYPY AND MORTALITY.

000401 01-04 FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN TREATMENT OF REMITTED SCHIZOPHRENICS: II. RATING SCALE DATA

FLUPHENAZINE-DECANOATE, FLUPHENAZINE-HYDROCHLORIDE GIVEN
ORALLY, AND PLACEBO IN REMITTED SCHIZOPHRENICS: I. RELAPSE
RATES AFTER ONE YEAR.

000545 01-0R FLUPHENAZINE-DECANOATE DURING PREGNANCY.

COMPARISON OF BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE AFTER FLUPHENAZINE-DIHYDROCHLORIDE AND FLUPHENAZINE-DECANOATE TREATMENT IN RATS.

001484 02-04 PRESYNAPTIC DOPAMINE RECEPTORS: DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING TREATMENT WITH FLUPHENAZINE-DECANOATE.

A COMPARATIVE CONTROLLED TRIAL OF PIMOZIDE AND FLUPHENAZINE-DECANOATE IN THE CONTINUATION THERAPY OF SCHIZOPHRENIA.

002396 03-08
COMPARISON OF THE EFFECTS OF PIPOTHIAZINE-PALMITATE AND
FLUPHENAZINE-DECANOATE IN A MULTICENTER DOUBLE-BLIND TRIAL.

002412 03-08

DOUBLE-BLIND THERAPEUTIC EVALUATION OF FLUSPIRILENE COMPARED WITH FLUPHENAZINE-DECANOATE IN CHRONIC SCHIZOPHRENICS. 003456 04-08

A LONG-TERM COMPARATIVE TRIAL OF PENFLURIDOL AND FLUPHENAZINE-DECANOATE IN SCHIZOPHRENIC OUTPATIENTS

003459 04-08
OUTPATIENT MAINTENANCE OF CHRONIC SCHIZOPHRENIC PATIENTS WITH
FLUPHENAZINE-DECANOATE (MODECATE): IBADAN EXPERIENCE. 003466 04-08

002343 03-05

FLUPHENAZINE-DIHYDROCHLORIDE

COMPARISON OF BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE AFTER FLUPHENAZINE-DIHYDROCHLORIDE AND FLUPHENAZINE-DECANOATE TREATMENT IN RATS

001484 02-04

FLUFHENAZINE-ENANTHATE
HIGH DOSES OF FLUPHENAZINE-ENANTHATE IN SCHIZOPHRENIA 003453 04-08

FLUPHENAZINE-HYDROCHLORIDE FLUPHENAZINE-DECANOATE, FLUPHENAZINE-HYDROCHLORIDE GIVEN ORALLY, AND PLACEBO IN REMITTED SCHIZOPHRENICS: I. RELAPSE RATES AFTER ONE YEAR.

000545 01-08

000328 01-04

002524 03-11

002237 03-04

FLUPHENAZINES

THE USE OF FLUPHENAZINES IN A CONTINUING-CARE PROGRAM. 002406 03-08

FLURAZEPAM

GABA-LIKE PROPERTIES OF FLURAZEPAM AND BACLOFEN SUGGESTED BY ROTATIONAL BEHAVIOUR FOLLOWING UNILATERAL INTRANIGRAL INJECTION: A COMPARISON WITH THE GABA-AGONIST MUSCIMOL.

INFLUENCE OF THE SUSPENSION OF CONTINUED TREATMENT WITH FLURAZEPAM AND AMOBARBITAL ON TWO DISCRIMINATION LEARNING SCHEDULES

TOXICITY OF HIGH-DOSE FLURAZEPAM IN THE ELDERLY.

000630 01-11 LONG-TERM EFFICACY AND SAFETY OF TRIAZOLAM AND FLURAZEPAM. 000643 01-11

COMPARISON OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTICS IN GERIATRIC PATIENTS WITH INSOMNIA. 000658 01-11

METABOLISM OF FLURAZEPAM BY THE SMALL INTESTINE.

000713 01-13 AN EVALUATION OF THE CARDIOPULMONARY SAFETY AND EFFICACY OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS ORAL HYPNOTIC

000854 01-15 FLURAZEPAM EFFECTS ON SLOW-WAVE SLEEP: STAGE-4 SUPPRESSED BUT NUMBER OF DELTA-WAVES CONSTANT.

001708 02-14

A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION. 001787 02-15

POTENTIAL UNTOWARD EFFECTS OF LONG-TERM USE OF FLURAZEPAM IN

001807 02-15 EFFECTS OF FLURAZEPAM ON AMINO-ACID EVOKED RESPONSES
RECORDED FROM THE LOBSTER MUSCLE AND THE FROG SPINAL CORD 002115 03-03

EVALUATION OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTIC AGENTS IN PRESURGICAL PATIENTS.

002514 03-11 COMPARISON OF TRIAZOLAM .25 MG AND FLURAZEPAM 15 MG IN TREATING GERIATRIC INSOMNIACS.

FLUROTHYL

REPEATED EXPOSURE OF RATS TO THE CONVULSANT AGENT FLUROTHYL ENHANCES 5 HYDROXYTRYPTAMINE AND DOPAMINE MEDIATED BEHAVIOURAL RESPONSES.

003234 04-04

DOUBLE-BLIND THERAPEUTIC EVALUATION OF FLUSPIRILENE COMPARED WITH FLUPHENAZINE-DECANOATE IN CHRONIC SCHIZOPHRENICS. 003456 04-08

FLUTAMIDE

DIFFERENTIAL EFFECTS OF THE ANTIANDROGEN FLUTAMIDE ON ASPECTS OF SEXUAL BEHAVIOR IN CASTRATED, ANDROGEN TREATED MALE RATS

FLUVOXAMINE

FLUVOXAMINE, A SPECIFIC 5 HYDROXYTRYPTAMINE UPTAKE INHIBITOR 000017 01-02

FLUVOXAMINE (DU-23001), A NEW ANTIDEPRESSANT. QUANTITATIVE PHARMACO-ELECTROENCEPHALOGRAPHY AND PILOT CLINICAL TRIALS 001548 02-07 CLINICAL TRIAL OF FLUVOXAMINE: A NEW SEROTONERGIC

ANTIDEPRESSANT. 002470 03-09

TIME-COURSE AND DEVELOPMENT OF ELECTROCLINICAL FEATURES IN RELATION TO PENTYLENETETRAZOL THRESHOLDS IN MONKEYS WITH FOCAL SFIZURES

001092 02-03 CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIVITY TO THE DIRECT APPLICATION OF MORPHINE AND FOCAL ELECTRICAL STIMULATION IN THE PRODUCTION OF ANTINOCICEPTION IN THE RAT. 001291 02-03 **FOCUS**

BRAIN MECHANISMS ASSOCIATED WITH THERAPEUTIC ACTIONS OF BENZODIAZEPINES: FOCUS ON NEUROTRANSMITTERS.

000741 01-13 THE INFLUENCE OF PENTOBARBITAL UPON A CORTICAL EPILEPTOGENIC FOCUS IN RATS.

001411 02-04 BIOCHEMICAL ACTIONS OF NEUROLEPTIC DRUGS: FOCUS ON THE DOPAMINE RECEPTOR

THE ACTIONS OF DIAZEPAM AND PHENYTOIN ON A LOW DOSE PENICILLIN EPILEPTIFORM FOCUS IN THE ANESTHETISED RAT.

FOLLICLE-STIMULATING

THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDROCANNABINOL (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HORMONE (FSH) AND LUTEINIZING HORMONE (LH) IN THE OVARIECTOMIZED RHESUS

THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORI FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MALE

POLLOW-UP

A LONG-TERM FOLLOW-UP OF SCHIZOPHRENICS TREATED WITH

000526 01-08 PSYCHOSES PRECIPITATED BY PSYCHOTOMIMETIC DRUGS: A FOLLOW-UP

000672 01-12 PURCHASES OF HYPNOTICS, SEDATIVES AND MINOR TRANQUILLIZERS AMONG 2,566 INDIVIDUALS IN THE COUNTY OF JAMTLAND, SWEDEN: A 6-YEAR FOLLOW-UP.

000940 01-17 TARDIVE-DYSKINESIA IN PSYCHOGERIATRIC PATIENTS: A FIVE-YEAR

001808 02-15 TREATMENT OF ALCOHOLISM WITH PSYCHOTOMIMETIC DRUGS. A FOLLOW-UP STUDY

003570 04-11

FOLLOWS HYPERALGESIA INDUCED BY NALOXONE FOLLOWS DIURNAL RHYTHM IN RESPONSIVITY TO PAINFUL STIMULI. 001124 02-03

STIMULATION OF FOOD INTAKE BY MUSCIMOL AND BETA-ENDORPHIN 000023 01-02 KINETIC STUDIES OF FOOD INTAKE AND SUCROSE SOLUTION PREFERENCE BY RATS TREATED WITH LOW DOSES OF DELTA9-

TETRAHYDROCANNABINOL. SCHEDULE-INDUCED BITING UNDER FIXED-INTERVAL SCHEDULES OF FOOD

OR ELECTRIC-SHOCK PRESENTATION. 000348 01-04 FIXED-INTERVAL RESPONDING UNDER SECOND-ORDER SCHEDULES OF FOOD PRESENTATION OR COCAINE INJECTION.

000391 01-04 DECREASE OF FOOD INTAKE BY QUIPAZINE IN THE RAT: RELATION TO SEROTONINERGIC RECEPTOR STIMULATION.

CO1235 02-03

EFFECTS OF D AMPHETAMINE, CHLORDIAZEPOXIDE AND PROMAZINE ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION AND STIMULUS SHOCK TERMINATION TERMINATION.

EFFECTS OF DIAZEPAM AND D AMPHETAMINE ON FOOD COMPETITION IN RHESUS MONKEY

EFFECTS OF D AMPHETAMINE ON A MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE OF FOOD REINFORCEMENT IN THE CAT.

001374 02-04 DIFFERENTIAL TOLERANCE TO :NHIBITORY ACTION OF VARIOUS NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS CHRONICALLY TREATED WITH HALOPERIDOL.

001398 02-04 THE EFFECT OF NONCONTINGENT AMPHETAMINE INJECTIONS ON THE EXTINCTION OF FOOD AND DRUG REINFORCED LEVER PRESSING IN

BIOAVAILABILITY OF OXAZEPAM: ABSENCE OF INFLUENCE OF FOOD

DEGRADED PROTEIN CONTAINING FOOD AND MONOAMINE-OXIDASE INHIRITORS

A COMPARISON OF FOOD INTAKE SUPPRESSION PRODUCED BY GIVIN AMPHETAMINE AS AN AVERSION TREATMENT VERSUS AS AN ANOREXIC TREATMENT.

001981 03-03

EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D AMPHETAMINE AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY AND SHOCK AVOIDANCE IN RHESUS MONKEYS.

002251 03-04

EFFECT OF DIAZEPAM ON FOOD CONSUMPTION IN RATS.

002252 03-04

003398 04-04

ETHANOL, PENTOBARBITAL, AND CHLORDIAZEPOXIDE EFFECTS IN SQUIRREL-MONKEYS RESPONDING UNDER FIXED-RATIO FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION SCHEDULES 002254 03-04

EFFECTS OF D AMPHETAMINE AND ETHANOL ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION.

CHOICE BEHAVIOR IN RHESUS MONKEYS: COCAINE VERSUS FOOD. 003155 04-04 ENHANCED CHOICE OF FAMILIAR FOOD IN A FOOD PREFERENCE TEST AFTER CHLORDIAZEPOXIDE ADMINISTRATION.

003199 04-04

CHLORDIAZEPOXIDE FLUOXETINE INTERACTIONS ON FOOD INTAKE IN FREE-FEEDING RATS. 003217 04-04

FOOD RELATED INTRAVENOUS INSULIN SELF-ADMINISTRATION IN NORMAL AND DIABETIC RATS. 003252 04-04

EFFECTS OF MARIJUANA EXTRACT DISTILLATE AND CANNABIDIOL ON VARIABLE INTERVAL PERFORMANCE AS A FUNCTION OF FOOD DEPRIVATION.

003308 04-04 EXPERIMENTAL BARBITURATE DEPENDENCE. I. BARBITURATE DEPENDENCE DEVELOPMENT IN RATS BY DRUG ADMIXED FOOD (DAF)

003373 04-04 EFFECT OF CHRONIC COCAINE TREATMENT ON LIMITED ACCESS FOOD

003395 04-04 COCAINE AS DISCRIMINATIVE STIMULUS FOR RESPONDING MAINTAINED BY FOOD IN SQUIRREL-MONKEYS.

DIETARY EFFECTS UPON FOOD AND WATER INTAKE AND RESPONSIVENESS TO ESTROGEN, 2 DEOXYGLUCOSE AND GLUCOSE IN FEMALE RATS.

003402 04-04

POOTDROP
NEUROPATHY ASSOCIATED WITH AMITRIPTYLINE: BILATERAL FOOTDROP 001753 02-15

FOOTSHOCK
FURTHER STUDIES ON BL-3912A: EFFECTS ON AVOIDANCE BEHAVIOR OF
RATS WITH LOW BASELINES AND ON REACTION THRESHOLDS TO
ELECTRIC FOOTSHOCK.

FOOTSHOCK INDUCED ANALGESIA IN MICE: ITS REVERSAL BY NALOXONE AND CROSS-TOLERANCE WITH MORPHINE.

DRUG EFFECTS UPON FORCE AND DURATION OF RESPONSE DURING FIXED-RATIO PERFORMANCE IN RATS.

000363 01-04 PROGRESSIVE FORCE SCHEDULES IN THE SQUIRREL-MONKEY: EFFECTS OF INCREMENT SIZE, AMPHETAMINE, AND HALOPERIDOL. (PH.D. DISSERTATION)

SOME EFFECTS OF CHLORDIAZEPOXIDE AND D AMPHETAMINE ON RESPONSE FORCE DURING PUNISHED RESPONDING IN RATS.

THE EFFECTS OF ATROPINE ON THE TOLERANCE AND THE CONVULSIONS SEEN AFTER WITHDRAWAL FROM FORCED BARBITAL DRINKING IN THE RAT.

003389 04-04

FOREBRAIN

ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5MEDIAN FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN
FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF
ROTATIONAL BEHAVIOUR.

DO0086 01-0

000086 01-03 NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN SLICES OF MOUSE LIMBIC FOREBRAIN: CHARACTERISATION AND EFFECT OF DOPAMINERGIC AGONISTS.

AGONIST EFFECTS OF BETA-PHENYLETHYLAMINES ON THE NORADRENERGIC CYCLIC-ADENOSINE-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. 3,5-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. STEREOISOMERS OF P-HYDROXYNOREPHEDRINE.

EFFECTS OF D AMPHETAMINE ON CONCURRENT SELF-STIMULATION OF FOREBRAIN AND BRAINSTEM LOCI. 000393 01-04

EFFECTS OF LITHIUM ON THE ELEVATION OF FOREBRAIN 5
HYDROXYINDOLES BY TRYPTOPHAN.

001086 02-03 STUDIES ON THE ROLE OF FOREBRAIN CATECHOLAMINE NEURONS IN EXPLORATORY BEHAVIOR IN THE RAT. (PH.D. DISSERTATION). 002012 03-03

MODIFICATION OF THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN BY AMPHETAMINE (A) AND ITS HYDROXYLATED METABOLITES.

002100 03-03 THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION. 002164 03-03

THE EFFECT OF LITHIUM ON THE INCREASE IN FOREBRAIN 5
HYDROXYINDOLEACETIC-ACID PRODUCED BY RAPHE STIMULATION. 002871 04-03

DISULFIRAM ALTERS DOPAMINE METABOLISM AT SITES IN RATS FOREBRAIN AS DETECTED BY PUSH-PULL PERFUSIONS. 003134 04-03

EVIDENCE FOR DISTINCT SPINAL LOCOMOTION GENERATORS SUPPLYING RESPECTIVELY FORELIMBS AND HINDLIMBS IN THE RABBIT.

003124 04-03

NALOXONE REVERSAL OF MORPHINE ANALGESIA BUT FAILURE TO ALTER REACTIVITY TO PAIN IN THE FORMALIN TEST. 002117 03-03

FORMAMIDINE-INDUCED FEEDING AND BEHAVIORAL ALTERATION IN THE

FORMATION

ABSENCE OF FORMATION OF BRAIN SALSOLINOL IN ETHANOL DEPENDENT

ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE NEUROBLASTOMA CELLS.

A PRESYNAPTIC SITE OF ACTION WITHIN THE MESENCEPHALIC RETICULAR FORMATION FOR () AMPHETAMINE-INDUCED ELECTROCORTICAL DESYNCHRONIZATION.

001069 02-03 FORMATION OF BRAIN ACETYLCHOLINE FROM DIETARY CHOLINE AND THE EFFECT OF BARBITURATE ANESTHESIA ON THIS PROCESS.

001074 02-03 EFFECTS OF BENZODIAZEPINES ON PGO FIRINGS AND MULTIPLE UNIT ACTIVITY IN THE MIDBRAIN RETICULAR FORMATION IN CATS.

001265 02-03 ROLE OF CALCIUM IN THE AMPHETAMINE-INDUCED STIMULATION OF CATECHOL FORMATION IN THE STRIATUM.

001268 02-03 NEUROCHEMICAL MECHANISMS OF CENTRAL ACTION OF MORPHINE ON FUNCTIONS OF SINGLE NEURONS IN THE MIDBRAIN RETICULAR FORMATION.

001973 03-03

ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS. 002137 03-03

MUSCARINIC RECEPTOR MEDIATED CYCLIC-GMP FORMATION BY
CULTURED NERVE CELLS -- IONIC DEPENDENCE AND EFFECTS OF LOCAL 003064 04-03

EFFECT OF STRESS ON NOREPINEPHRINE STIMULATED CYCLIC-AMP FORMATION IN BRAIN SLICES.

LACK OF ENHANCEMENT OF DIMETHYLTRYPTAMINE FORMATION IN RAT BRAIN AND RABBIT LUNG IN VIVO BY METHIONINE OR S ADENOSYLMETHIONINE.

003102 04-03 MOVEMENT INDUCED IN CATALEPTIC RATS: DIFFERENTIAL EFFECTS
PRODUCED BY ELECTRICAL STIMULATION OF THE LATERAL
HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FORMATION. 003297 04-04

CATECHOLAMINE LEVELS IN THE WHOLE BRAIN AND THE PROBABILITY OF MEMORY FORMATION ARE NOT RELATED.

FORMULATIONS
IMPURITIES IN DRUGS I: IMIPRAMINE, DESIPRAMINE, AND THEIR
FORMULATIONS.

000964 01-17

A COMPARISON OF THE EFFICACY AND ACCEPTABILITY OF TWO FORMULATIONS OF INJECTABLE SERENACE IN THE TREATMENT OF STATES OF EXCITEMENT.

003576 04-11

FOWLS

BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE EFFECTS
AFTER INTRACEREBRAL INFUSION OF TRH IN FOWLS.

003319 04-04

FRACTIONATING

CHLORPROMAZINE EXCRETION. II. IMPROVED TLC PROCEDURES FOR FRACTIONATING THE URINARY DRUG CONTENT INTO CHEMICAL SUBGROUPS OF CPZ METABOLITES.

003690 04-16

HIGH-AFFINITY BINDING OF H3-GLYCINE AND C14-BETA-ALANINE TO SYNAPTOSOMAL MITOCHONDRIAL FRACTIONS OF RAT CNS REGIONS: EFFECTS OF STRYCHNINE.

000211 01-03 THE EFFECTS OF LITHIUM ON ATPASE ACTIVITY IN SUBCELLULAR FRACTIONS FROM RAT BRAIN.

002038 03-03 H3-GABA RELEASE IN SYNAPTOSOMAL FRACTIONS AFTER INTRACRANIAL ADMINISTRATION OF RUTHENIUM-RED.

003013 04-03 5 GUANYLYLIMIDODIPHOSPHATE ACTIONS ON ADENYLATE-CYCLASE IN HOMOGENATES OF RAT CEREBRAL-CORTEX PLUS NEURONAL AND CAPILLARY FRACTIONS.

003038 04-03 INFLUENCE OF NEUROLEPTICS ON THE BINDING OF MET-ENKEPHALIN MORPHINE AND DIHYDROMORPHINE TO SYNAPTOSOME ENRICHED FRACTIONS OF RAT BRAIN.

EXPERIMENTAL LEAD ENCEPHALOPATHY IN THE SUCKLING RAT: CONCENTRATION OF LEAD IN CELLULAR FRACTIONS ENRICHED IN

BRAIN CAPILLARIES. 003420 04-05

FRAGMENTOGRAPHIC

A COMPARISON BETWEEN FLUOROMETRIC AND MASS FRAGMENTOGRAPHIC DETERMINATIONS OF HOMOVANILLIC-ACID AND 5 HYDROXYINDOLEACETIC-ACID IN HUMAN CEREBROSPINAL FLUID. 003694 04-16

FRAGMENTS

SYNTHESIS OF BRADYKININ FRAGMENTS AND THEIR EFFECT ON PENTOBARBITAL SLEEPING TIME IN MOUSE.

000424 01-04 POSSIBLE SIGNIFICANCE OF ACTH FRAGMENTS FOR HUMAN MENTAL PERFORMANCE.

000465 01-04 EFFECT OF MORPHINE ON THE BASAL AND THE DOPAMINE-INDUCED RELEASE OF LHRH FROM MEDIOBASAL HYPOTHALAMIC FRAGMENTS

IN VITRO 003072 04-03

THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS OF MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINI 000169 01-03

MARIJUANA: EFFECTS ON FREE RECALL AND SUBJECTIVE ORGANIZATION OF PICTURES AND WORDS.

002629 03-14 THE EFFECT OF MORPHINE-TOLERANCE AND DEPENDENCE ON CELL FREE PROTEIN SYNTHESIS.

002876 04-03 CHANGES IN BRAIN FREE FATTY-ACIDS AFTER PAINFUL PERIPHERAL STIMULATION (EFFECT OF PROTHIADEN).

003094 04-03 MARIHUANA: EFFECT ON NONVERBAL FREE RECALL AS A FUNCTION OF FIELD DEPENDENCE.

003300 04-04 THE EFFECT OF CLOFIBRATE ON TOTAL AND FREE PLASMA TRYPTOPHAN IN DEPRESSED PATIENTS.

003532 04-09 FREE_FEEDING

CHLORDIAZEPOXIDE FLUOXETINE INTERACTIONS ON FOOD INTAKE IN FREE-FEEDING RATS. 003217 04-04

FREEDOM SUBJECTS RIGHTS, FREEDOM OF INQUIRY, AND THE FUTURE OF RESEARCH IN THE ADDICTIONS.

000966 01-17

EFFECTS OF IMIPRAMINE ON ENURETIC FREQUENCY AND SLEEP STAGES 001719 02-14

ELECTROENCEPHALOGRAPHIC CONTROL WITH FREQUENCY ANALYSIS IN DEPRESSED PATIENTS TREATED WITH SAME.

THE FREQUENCY AND PERSISTENCE OF DEPRESSIVE SYMPTOMS IN THE ALCOHOL ABUSER. 003567 04-11 FROG

BARBITURATE-INDUCED CHANGES IN TRANSMITTER RELEASE INDEPENDENT OF TERMINAL SPIKE CONFIGURATION IN THE FROG NEUROMUSCULAR JUNCTION.

ACTIONS OF ATROPINE AND SCOPOLAMINE ON THE ENDPLATE CURRENT OF THE FROG SARTORIUS MUSCLE. (PH.D. DISSERTATION).

DIFFERENTIAL ANTAGONISM BY CHLORPROMAZINE AND DIAZEPAM OF FROG MOTONEURONE DEPOLARIZATION INDUCED BY GLUTAMATE RELATED AMINO-ACIDS.

EFFECTS OF FLURAZEPAM ON AMINO-ACID EVOKED RESPONSES
RECORDED FROM THE LOBSTER MUSCLE AND THE FROG SPINAL 002115 03-03

EFFECT OF DIAZEPAM ON THE FROG NEUROMUSCULAR JUNCTION 002171 03-03 MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID

INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMATURE RAT.

FRONTAL

SPECIFIC EFFECT OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE FRONTAL CORTEX.

ROLE OF GLUCOCORTICOIDS IN AN ABNORMAL GROOMING BEHAVIOR IN CATS WITH PONTILE OR FRONTAL NEOCORTICAL LESIONS.

H3-SPIROPERIDOL BINDING TO TWO RECEPTOR SITES IN BOTH THE CORPUS-STRIATUM AND FRONTAL CORTEX OF RAT BRAIN.

FSH

THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDROCANNABINOL (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HORMONE (FSH) AND LUTEINIZING HORMONE (LH) IN THE OVARIECTOMIZED RHESUS

001245 02-03

003041 04-03

002901 04-03

TIME-COURSE OF LITHIUM-INDUCED ALTERATIONS IN RENAL AND ENDOCRINE FUNCTION IN NORMAL AND BRATTLEBORO RATS WITH HYPOTHALAMIC DIABETES-INSIPIDUS.

000048 01-03 NALOXONE PRECIPITATED WITHDRAWAL AS A FUNCTION OF THE MORPHINE NALOXONE INTERVAL.

000185 01-03 DISCRIMINATIVE STIMULUS PROPERTIES OF FENFLURAMINE IN AN OPERANT TASK: AN ANALYSIS OF ITS CUE FUNCTION.

000369 01-04
ENHANCEMENT OF LEARNING BY CYCLOHEXIMIDE AND DDC: A FUNCTION OF RESPONSE STRENGTH.

MODELS TO STUDY DRUG EFFECTS ON THE INTEGRATED FUNCTION OF GABAERGIC, PEPTIDERGIC (SUBSTANCE-P) AND DOPAMINERGIC NEURONS. (UNPUBLISHED PAPER).

000499 01-06 THE FUNCTION OF DRUG RITUALS IN HUMAN SOCIETY: CONTINUITIES

AND CHANGES 000674 01-12 PSYCHOTROPIC DRUGS: INFLUENCE ON RESPIRATORY FUNCTION. 000692 01-13

NORMAL LYMPHOCYTE FUNCTION IN THE PRESENCE OF DELTAP TETP AHYDROCANNARIMOL

MEMORY AND COGNITIVE FUNCTION IN MAN: DOES THE CHOLINERGIC SYSTEM HAVE A SPECIFIC ROLE?

000761 01-14 AFFECTIVE-ILLNESS TREATED WITH LITHIUM: EFFECTS ON THYROID FUNCTION AND PSYCHIC STATUS.

000774 01-14 THE LACK OF AN EFFECT OF DELTA9-THC ON PULMONARY SMOOTH MUSCLE FUNCTION IN THE GUINEA-PIG.

CHANGES IN LIVER FUNCTION IN ACUTE POISONING BY BARBITURATE, RESERPINE AND AMPHETAMINE

001094 02-03 EFFECT OF LITHIUM-CHLORIDE ON CERTAIN INDICES OF CARDIAC

001521 02-05 THYROID FUNCTION AND GROWTH HORMONE SECRETION IN AMITRIPTYLINE TREATED DEPRESSION.

001596 02-09 DRUG VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS.

001777 02-15 EFFECT OF LITHIUM-CHLORIDE ON ADRENOCORTICAL FUNCTION IN THE

THE EFFECT OF L-DOPA ON PERIPHERAL SYMPATHETIC NERVE FUNCTION: ROLE OF PRESYNAPTIC DOPAMINE RECEPTORS.

PHARMACOLOGICAL MANIPULATIONS OF THE SEPTAL IRRITABILITY SYNDROME: ROLE OF DOPAMINERGIC MECHANISMS IN RECOVERY OF FUNCTION. (PH.D. DISSERTATION).

ALTERATIONS IN THE FUNCTION OF THE NUCLEUS LOCUS-COERULEUS: A POSSIBLE MODEL FOR STUDIES OF ANXIETY.

002298 03-04 ADULT BEHAVIOR AND ADRENOCORTICAL FUNCTION FOLLOWING NEONATAL MORPHINE TREATMENT IN RATS.

002310 03-04 EFFECT OF THIORIDAZINE (MELLARIL-SANDOZ) ON PSYCHOMOTOR FUNCTION, CONCENTRATION, AND REACTIVITY IN CHILDREN WITH BEHAVIOR DISORDERS.

02527 03-11 LITHIUM-CARBONATE AND BRAIN FUNCTION: I. CEREBRAL EVOKED-POTENTIALS, EEG, AND SYMPTOM CHANGES DURING LITHIUM-CARBONATE TREATMENT.

002560 03-13 IE IMPORTANCE OF TELEMETRIC RECORDING IN THE STUDY NEUROPSYCHOLOGICAL FUNCTION IN EPILEPTICS.

002606 03-14 EYE MOVEMENT, AN INDICATOR OF BRAIN FUNCTION. 002637 03-14

AUTONOMOUS NERVOUS FUNCTION OF LONG-TERM USERS OF PSYCHOTROPIC DRUGS, THIRD REPORT -- PUPILOGRAM OBSERVATIONS.

MODIFICATION OF NUCLEAR RETENTION OF H3-ESTRADIOL BY CELLS OF THE HYPOTHALAMUS AS A FUNCTION OF EARLY HORMONE EXPERIENCE.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL.
DRUG METABOLISM — I. FACTORS THAT INFLUENCE NADPH KINETIC
ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS.
002931 04-03
CHANGES IN SYNAPTIC FUNCTION INDUCED BY BLOCKAGE OF AXONAL
TRANSPORT IN THE RABBIT OPTIC PATHWAY.

002952 04-03 STRIATAL CONTENT OF CA2-DEPENDENT REGULATOR PROTEIN AND DOPAMINERGIC RECEPTOR FUNCTION.

002990 04-03 THE EFFECT OF DRUGS WHICH ALTER GABAERGIC FUNCTION ON CEREBELLAR GUANOSINE-MONOPHOSPHATE CONTENT.

002993 04-03 DOPAMINE RECEPTOR FUNCTION AFTER CHRONIC INGESTION OF

SENSITIVITY TO APOMORPHINE IN THE GUINEA-PIG AS A FUNCTION OF AGE AND BODY WEIGHT.

003182 04-04 RECOVERY AS A FUNCTION OF THE DEGREE OF AMNESIA DUE TO PROTEIN SYNTHESIS INHIBITION.

ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

003272 04-04 MARIHUANA: EFFECT ON NONVERBAL FREE RECALL AS A FUNCTION OF

003300 04-04 EFFECTS OF MARIJUANA EXTRACT DISTILLATE AND CANNABIDIOL ON VARIABLE INTERVAL PERFORMANCE AS A FUNCTION OF FOOD DEPRIVATION

003308 04-04 THE STRIATAL DOPAMINERGIC FUNCTION IS MEDIATED BY THE INHIBITION OF A NIGRAL, NONDOPAMINERGIC NEURONAL SYSTEM VIA A STRIO-NIGRAL GABAERGIC PATHWAY.

003325 04-04 DISTURBANCE OF HOMEOSTATIC REGULATION OF ADRENAL FUNCTION IN PATIENTS WITH ENDOGENOUS DEPRESSION.

003515 04-09 NEUROTRANSMITTER MECHANISMS DURING MENTAL ILLNESS INDUCED BY ALTERATIONS IN THYROID FUNCTION.

003636 04-14 CHLORPROMAZINE AND PLATELET FUNCTION.

003686 04-15

FUNCTIONAL

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B

MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE

OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL

ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE.

000127 01-03 EVIDENCE FOR FUNCTIONAL SYNAPSES BETWEEN MIXED CULTURES OF INFERIOR OLIVE AND CEREBELLUM.

000497 01-06 THE RELATIVE FUNCTIONAL AVAILABILITY OF BRAIN NORADRENALINE AND DOPAMINE STORAGE POOLS.

001191 02-03 THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE

RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION.

OSMOTIC MINIPUMPS FOR ADMINISTRATION OF BARBITAL TO MICE DEMONSTRATION OF FUNCTIONAL TOLERANCE AND PHYSICAL

002374 03-06

001629 02-11

FUNCTIONING
EVALUATIONS OF SOCIAL FUNCTIONING IN A 3-YEAR DOUBLE-BLIND
INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE IN CHRONIC
SCHIZOPHRENIA.

000518 (

000518 01-08 HE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (SECOND REPORT) — EFFECTS ON PUPIL FUNCTIONING.

THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (FIRST REPORT).

000878 01-15

FUNCTIONS

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON HEPATIC FUNCTIONS.

000119 01-03 EFFECTS OF BACLOFEN AND MUSCIMOL ON NIGROSTRIATAL DOPAMINERGIC FUNCTIONS.

000347 01-04 ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: INTERACTIVE EFFECTS ON HUMAN PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS. II.

PASSIVE AVOIDANCE LEARNING IN THE RAT AS FUNCTIONS OF D AMPHETAMINE DOSAGE AND SHOCK INTENSITY.

MARIJUANA: DIFFERENTIAL EFFECTS ON RIGHT AND LEFT HEMISPHERE FUNCTIONS IN MAN.

NEUROCHEMICAL MECHANISMS OF CENTRAL ACTION OF MORPHINE ON FUNCTIONS OF SINGLE NEURONS IN THE MIDBRAIN RETICULAR FORMATION.

EFFECTS OF PIRACETAM ON REGIONAL CEREBRAL BLOOD FLOW AND MENTAL FUNCTIONS IN PATIENTS WITH ORGANIC DEMENTIA.

002512 03-11 INFLUENCE OF TRYPTOPHAN ON MEMORY FUNCTIONS IN DEPRESSIVE PATIENTS TREATED WITH UNILATERAL ECT.

002613 03-14

ESTROGENS: THEIR FUNCTIONS, USES AND HAZARDS: PART 2.

002706 03-15

COMPARATIVE EFFECTS OF COCAINE AND PSEUDOCOCAINE ON EEG
ACTIVITIES, CARDIORESPIRATORY FUNCTIONS, AND SELFADMINISTRATION BEHAVIOR IN THE RHESUS MONKEY.

003292 04-04

EFFECT OF FUSARIC-ACID ON TARDIVE-DYSKINESIA AND MENTAL STATE IN PSYCHOGERIATRIC PATIENTS: A PILOT STUDY.

QUANTITATIVE EEG ANALYSIS OF THE PUTATIVE ANTIDEPRESSANT COMPOUND F1-6654.

002588 03-13

INDUCTION OF SULFOGALACTOSYLCERAMIDE (SULFATIDE) SYNTHESIS BY HYDROCORTISONE (CORTISOL) IN MOUSE G-26 OLIGODENDROGLIOMA CELL STRAINS. 002886 04-03

ARGININE-PYROGLUTAMATE (G-278): A CLINICAL EXPERIMENT

001546 02-07 INTERACTION OF GABA, DOPAMINE, AND ACETYLCHOLINE IN CAT STRIATUM: PHARMACOLOGICAL CONSIDERATIONS.

000051 01-03 REGULATORY ROLE OF GABA NEURONS ON THE ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE BY HALOPERIDOL. (UNPUBLISHED PAPER).

EFFECTS OF SYSTEMIC MUSCIMOL AND GABA IN THE SPINAL CORD AND SUPERIOR CERVICAL GANGLION OF THE CAT.

RAISED BRAIN GABA LEVELS, MOTOR ACTIVITY AND EXPLORATION IN

000358 01-04 CHLORDIAZEPOXIDE SELECTIVELY AUGMENTS GABA ACTION IN SPINAL CORD CELL CULTURES

001080 02-03 EFFECT OF CHRONIC NEUROLEPTIC OR L-DOPA ADMINISTRATION ON GABA LEVELS IN THE RAT SUBSTANTIA-NIGRA.

001181 02-03 HALOPERIDOL AND CLOZAPINE: SPECIFICITY OF ACTION ON GABA IN THE 001184 02-03

003325 04-04

CYCLIC-GMP AND GABA LEVELS IN RAT STRIATUM AND CEREBELLUM DURING MORPHINE WITHDRAWAL: EFFECT OF APOMORPHINE

001274 02-03 GAMMA-AMINOBUTYRIC-ACID (GABA) AND SLEEP: THE INFLUENCE OF DI-N-PROPYLACETIC-ACID ON SLEEP IN MAN.

001730 02-14 MEASURING CHANGES IN CEREBRAL GLUTAMATE AND GABA METABOLISM PRIOR TO CONVULSIONS INDUCED BY 3

001961 03-03 EFFECT OF DIAZEPAM AND PENTOBARBITAL ON AMINOOXYACETIC-ACID-INDUCED ACCUMULATION OF GABA.

002124 03-03 THE ROLE OF DIAZEPAM AS COMPARED TO GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT. (PH.D. DISSERTATION)

002131 03-03 ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY

002326 03-04 EFFECTS OF CENTRAL GABA RECEPTOR AGONISM AND ANTAGONISM ON EVOKED DIENCEPHALIC CARDIOVASCULAR RESPONSES

002811 04-03 EFFECTS OF ACETYLCHOLINE, SODIUM-GLUTAMATE AND GABA ON THE DISCHARGE OF SUPRAOPTIC NEURONS IN THE RAT.

002830 04-03 POTENTIATION BY NEUROLEPTIC AGENTS OF THE INHIBITORY ACTION OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE.

002832 04-03 GABA, PICROTOXIN AND RETINAL SENSITIVITY.

VERTEBRATE GABA RECEPTORS. 002892 04-03

REGIONAL CHANGES IN CEREBRAL GABA CONCENTRATION AND CONVULSIONS PRODUCED BY D AND BY L ALLYLGLYCINE 002954 04-03

STRUCTURE-ACTIVITY STUDIES ON THE INHIBITION OF GABA BINDING TO RAT BRAIN MEMBRANES BY MUSCIMOL AND RELATED COMPOUNDS 002981 04-03

THE EFFECTS OF ALLYLGLYCINE ON GABA SYNTHESIS IN VIVO 002997 04-03

FACILITATION OF BENZODIAZEPINE BINDING BY SODIUM-CHLORIDE AND

003002 04-03 POSTMORTEM AND AMINOOXYACETIC-ACID-INDUCED ACCUMULATION OF GABA: EFFECT OF GAMMA-BUTYROLACTONE AND PICROTOXIN. 003042 04-03

IS GABA INVOLVED IN ANALGESIA?.

003084 04-03 TIME-COURSE OF THE INCREASE IN GABA LEVEL IN DIFFERENT MICE BRAIN REGIONS FOLLOWING N DIPROPYLACETATE TREATMENT

003091 04-03 THE EFFECTS OF INTRAVENTRICULAR INJECTION OF GAMMA-AMINOBUTYRIC-ACID (GABA) ON PROLACTIN AND GONADOTROPIN RELEASE IN CONSCIOUS FEMALE RATS.

003126 04-03 EFFECT OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE.

003172 04-04 MOTOR ACTIVITY OF RATS FOLLOWING INTRACEREBRAL INJECTIONS OF DRUGS INFLUENCING GABA MECHANISMS

003387 04-04 BIOCHEMICAL EFFECTS IN MAN AND RAT OF THREE DRUGS WHICH CAN INCREASE BRAIN GABA CONTENT

GABA-AGONIST

A NEW CLASS OF GABA-AGONIST.

GABA-LIKE PROPERTIES OF FLURAZEPAM AND BACLOFEN SUGGESTED BY ROTATIONAL BEHAVIOUR FOLLOWING UNILATERAL INTRANIGRAL INJECTION: A COMPARISON WITH THE GABA-AGONIST MUSCIMOL

MUSCIMOL A GABA-AGONIST INJECTED INTO THE NUCLEUS-ACCUMBENS INCREASES APOMORPHINE STEREOTYPY AND DECREASES THE

001454 02-04 MUSCIMOL: GABA-AGONIST THERAPY IN SCHIZOPHRENIA. 003475 04-08

NALOXONE AS A GABA-ANTAGONIST: EVIDENCE FROM IONTOPHORETIC, RECEPTOR BINDING AND CONVULSANT STUDIES.

ARE BENZODIAZEPINES GABA-ANTAGONISTS?.

002003 03-03 000170 01-03

003604 04-13

000290 01-03

GARA-LIKE

GABA-LIKE PROPERTIES OF FLURAZEPAM AND BACLOFEN SUGGESTED BY ROTATIONAL BEHAVIOUR FOLLOWING UNILATERAL INTRANIGRAL INJECTION: A COMPARISON WITH THE GABA-AGONIST MUSCIMOL. 000290 01-03

GARA-TEANSAMINASE

THE EFFECT OF GAMMA-ACETYLENIC-GABA, AN ENZYME ACTIVATED IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE, ON DOPAMINE PATHWAYS OF THE EXTRAPYRAMIDAL AND LIMBIC SYSTEMS. 003037 04-03

EVIDENCE FOR AN INTRASTRIATAL GABAERGIC INFLUENCE ON DOPAMINE NEURONES OF THE CAT.

SECOND MESSENGER RESPONSES AND REGULATION OF HIGH AFFINITY
RECEPTOR BINDING TO STUDY PHARMACOLOGICAL MODIFICATION OF GABAERGIC TRANSMISSION. (UNPUBLISHED PAPER)

MODELS TO STUDY DRUG EFFECTS ON THE INTEGRATED FUNCTION OF GABAERGIC, PEPTIDERGIC (SUBSTANCE-P) AND DOPAMINERGIC NEURONS. (UNPUBLISHED PAPER).

000499 01-06 THE EFFECT OF DRUGS WHICH ALTER GABAERGIC FUNCTION ON CEREBELLAR GUANOSINE-MONOPHOSPHATE CONTENT.

002993 04-03 THE STRIATAL DOPAMINERGIC FUNCTION IS MEDIATED BY THE INHIBITION OF A NIGRAL, NONDOPAMINERGIC NEURONAL SYSTEM VIA A STRIO-NIGRAL GABAERGIC PATHWAY.

002889 04-03

THE EFFECT OF PANCURONIUM AND GALLAMINE ON MUSCARINIC TRANSMISSION IN THE SUPERIOR CERVICAL GANGLION.

002021 03-03

THE EFFECT OF GAMMA-ACETYLENIC-GABA, AN ENZYME ACTIVATED IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE, ON DOPAMINE PATHWAYS OF THE EXTRAPYRAMIDAL AND LIMBIC SYSTEMS. 003037 04-03

GAMMA-AMINOBUTYRATE THE EFFECTS OF ELEVATING GAMMA-AMINOBUTYRATE CONTENT IN THE SUBSTANTIA-NIGRA ON THE BEHAVIOUR OF RATS 003291 04-04

GAMMA-AMINOBUTYRIC-ACID EFFECT OF CONVULSANT AND ANTICONVULSANT AGENTS ON LEVEL AND METABOLISM OF GAMMA-AMINOBUTYRIC-ACID IN MOUSE BRAIN.

000186 01-03 THE TURNOVER RATE OF GAMMA-AMINOBUTYRIC-ACID IN THE NUCLEI OF TELENCEPHALON: IMPLICATIONS IN THE PHARMACOLOGY OF ANTIPSYCHOTICS AND OF A MINOR TRANQUILIZER.

000192 01-03 GAMMA-AMINOBUTYRIC-ACID (GABA) AND SLEEP: THE INFLUENCE OF DI-N-PROPYLACETIC-ACID ON SLEEP IN MAN.

001730 02-14 EFFECTS OF DRUGS ON GAMMA-AMINOBUTYRIC-ACID RECEPTORS. UPTAKE, RELEASE AND SYNTHESIS IN VITRO.

002122 03-03 THE ROLE OF DIAZEPAM AS COMPARED TO GAMMA-AMINOBUTYRIC ACID (GABA) IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT. (PH.D. DISSERTATION)

002131 03-03 INTERACTION OF PENTOBARBITONE AND GAMMA-AMINOBUTYRIC-ACID ON MAMMALIAN SYMPATHETIC GANGLION CELLS.

MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID
AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE
ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE
CORRELATES WITH ANALGESIC ACTION OF MORPHINE.

002984 04-03 CHANGES IN BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS FOLLOWING ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION AND DURING POST AMPHETAMINE DEPRESSION.

TURNOVER RATES OF GAMMA-AMINOBUTYRIC-ACID IN SUBSTANTIA-NIGRA, NUCLEUS-CAUDATUS, GLOBUS-PALLIDUS AND NUCLEUS-ACCUMBENS OF RATS INJECTED WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS 002996 04-03

THE EFFECT OF VILOXAZINE HYDROCHLORIDE ON THE TRANSPORT OF NORADRENALINE, DOPAMINE, 5 HYDROXYTRYPTAMINE AND GAMMA-AMINOBUTYRIC-ACID IN RAT BRAIN TISSUE. 003001 04-03

ENERGY UTILIZATION IN THE INDUCED RELEASE OF GAMMA AMINOBUTYRIC-ACID FROM SYNAPTOSOMES.

REGIONAL CHANGES IN THE CONCENTRATIONS OF CEREBRAL MONOAMINES AND THEIR METABOLITES AFTER ETHANOLAMINE-O-SULPHATE-INDUCED ELEVATION OF BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS.

THE EFFECTS OF INTRAVENTRICULAR INJECTION OF GAMMA-AMINOBUTYRIC-ACID (GABA) ON PROLACTIN AND GONADOTROPIN RELEASE IN CONSCIOUS FEMALE RATS.

THE EFFECT OF GAMMA-AMINOBUTYRIC-ACID ON H3-FLUNITRAZEPAM BINDING IN RAT BRAIN.

GAMMA-BUTYROLACTONE

POSTMORTEM AND AMINOOXYACETIC-ACID-INDUCED ACCUMULATION

OF GABA: EFFECT OF GAMMA-BUTYROLACTONE AND PICROTOXIN. 003042 04-03

GAMMA-ENDORPHIN
GAMMA-ENDORPHIN, ALPHA-ENDORPHIN AND MET-ENKEPHALIN ARE
FORMED EXTRACELLULARLY FROM LIPOTROPIN C-FRAGMENT.
201943 03 001963 03-03

GAMMA-HYDROXYBUTYRATE GAMMA-HYDROXYBUTYRATE.

000740 01-13

SLOW-WAVE SLEEP AND A STATE RESEMBLING ABSENCE EPILEPSY INDUCED IN THE RAT BY GAMMA-HYDROXYBUTYRATE. 001366 02-04

LACK OF EFFECT OF GAMMA-HYDROXYBUTYRATE IN HUNTINGTONS-

001553 02-07 METABOLISM OF GAMMA-HYDROXYBUTYRATE BY RAT BRAIN: RELATIONSHIP TO THE KREBS-CYCLE AND METABOLIC COMPARTMENTATION OF AMINO-ACIDS.

003132 04-03

002896 04-03

GAMMA-MOTONEURON
THE EFFECT OF SEROTONIN PRECURSORS ON ALPHA-MOTONEURON AND
GAMMA-MOTONEURON ACTIVITY. 002107 03-03

ACETYLCHOLINE STIMULATION OF THE SYMPATHETIC GANGLIA: EFFECTS OF TAURINE AND NICOTINIC AND MUSCARINIC GANGLION BLOCK. 000146 01-03

GAS-CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY OF SEROTONIN IN RAT SUPERIOR CERVICAL GANGLIA: EFFECTS OF NERVE GROWTH FACTOR AND 6 HYDROXYDDPAMINE.

SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT

001215 02-03 OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT GANGLIA (DRG) AND SPINAL CURD: PREDOMINANCE IN DRG

002040 03-03 BETA-ADRENOCEPTORS MODULATE NORADRENALINE RELEASE FROM AXONAL SPROUTS IN CULTURED RAT SUPERIOR CERVICAL GANGLIA 002179 03-03

CHARACTERIZATION OF ENKEPHALIN-LIKE MATERIAL EXTRACTED FROM SYMPATHETIC GANGLIA. 002788 04-01

GANGLION

ACETYLCHOLINE STIMULATION OF THE SYMPATHETIC GANGLIA: EFFECTS OF TAURINE AND NICOTINIC AND MUSCARINIC GANGLION BLOCK.

000146 01-03 EFFECTS OF SYSTEMIC MUSCIMOL AND GABA IN THE SPINAL CORD AND SUPERIOR CERVICAL GANGLION OF THE CAT.

000226 01-03 POSTSYNAPTIC POTENTIATION OF THE SLOW MUSCARINIC EXCITATORY RESPONSE BY TETRAETHYLAMMONIUM-CHLORIDE IN THE BULLFROG SYMPATHETIC GANGLION CELLS.

001173 02-03 IN VITRO EFFECTS OF CHLORPROMAZINE ON MICROTUBULES AND THE GOLGI COMPLEX IN EMBRYONIC CHICK SPINAL GANGLION CELLS: AN ELECTRON MICROSCOPIC STUDY.

001258 02-03 THE EFFECT OF PANCURONIUM AND GALLAMINE ON MUSCARINIC TRANSMISSION IN THE SUPERIOR CERVICAL GANGLION.

002021 03-03 SYNAPTIC CONNEXIONS AND RELATED POSTSYNAPTIC PHARMACOLOGY STUDIED IN THE CEREBRAL GANGLION OF APLYSIA.

002041 03-03
INTERACTION OF PENTOBARBITONE AND GAMMA-AMINOBUTYRIC-ACID
ON MAMMALIAN SYMPATHETIC GANGLION CELLS.

002844 04-03
RETROGRADE AXONAL TRANSPORT OF NERVE GROWTH FACTOR IN THE
CILIARY GANGLION OF THE CHICK AND THE RAT.

GAS-CHROMATOGRAPHIC
GAS-CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY OF SEROTONIN
IN RAT SUPERIOR CERVICAL GANGLIA: EFFECTS OF NERVE GROWTH
FACTOR AND 6 HYDROXYDOPAMINE.

Psychopharmacology Abstracts

CHROMATOGRAPHY
SIMULTANEOUS DETERMINATION OF CODEINE AND MORPHINE IN
BIOLOGICAL SAMPLES BY GAS-CHROMATOGRAPHY WITH ELECTRON
CAPTURE DETECTION.

RAPID IDENTIFICATION OF HYPNOTICS IN EMERGENCY CASES BY COMPUTERIZED GAS-CHROMATOGRAPHY MASS SPECTROMETRY.

001841 02-15 IMIPRAMINE, ITS N DESMETHYL AND HYDROXY METABOLITES IN PLASMA: MICRO DETERMINATION BY ALKALINE FLAME-IONIZATION GAS-CHROMATOGRAPHY (AFID-GC).

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4HYDROXYPHENYLETHANOL (MOPET) IN HUMAN CEREBROSPINAL FLUID
AND RAT BRAIN BY MEANS OF GAS-CHROMATOGRAPHY — MASSSPECTROMETRY.

ESTIMATION OF DEANOL AND CHOLINE BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY.

MEASUREMENT OF PLASMA AND ERYTHROCYTE CHLORPROMAZINE AND N MONODESMETHYLCHLORPROMAZINE LEVELS BY GASCHROMATOGRAPHY WITH A NITROGEN SENSITIVE DETECTOR.

HOMOVANILLIC-ACID IN HUMAN CSF: COMPARISON OF FLUOROMETRY AND GAS-CHROMATOGRAPHY MASS-SPECTROMETRY.

GAS-LIQUID-CHROMATOGRAPHIC
THIN-LAYER AND GAS-LIQUID-CHROMATOGRAPHIC PROCEDURES FOR THE
DETERMINATION OF PERAZINE AND ITS METABOLITES IN HUMAN BODY FLUIDS.

000927 01-16

GAS-LIQUID-CHROMATOGRAPHY
ROUTINE MEASUREMENT OF HOMOVANILLIC-ACID IN RAT BRAIN BY
GAS-LIQUID-CHROMATOGRAPHY.

003441 04-06 QASES
LEARNING RATE EQUIVALENCY OF TWO NARCOTIC GASES.

001701 02-14

GASOLINE SNIFFING: A REVIEW.

A CASE OF ACUTE GASTRIC DILATATION IN ANOREXIA-NERVOSA.
000602 01-10

BROMOCRIPTINE AND GASTRIC ACID OUTPUT.

001761 02-15

EFFECT OF ANTIPARKINSONISM DRUGS ON GASTRIC EMPTYING AND INTESTINAL TRANSIT IN THE RAT.

002010 03-03 MISLEADING RESPONSE OF MALIGNANT GASTRIC ULCERS TO CIMETIDINE.

002704 03-15

GASTROESOPHAGEAL
A CONTROLLED TRIAL OF METOCLOPRAMIDE IN SYMPTOMATIC
GASTROESOPHAGEAL REFLUX. 000862 01-15

EFFECT OF A NEW BENZODIAZEPINE DERIVATE, CLOBAZAM, IN ANXIOUS PATIENTS WITH GASTROINTESTINAL DISORDERS. 000604 01-10

THE EFFECT OF HOUSING AND GENDER ON MORPHINE SELF-ADMINISTRATION IN RATS.

003158 04-04

SUBCUTANEOUS INJECTIONS OF APOMORPHINE, STIMULUS GENERALIZATION AND CONDITIONING: SERIOUS PITFALLS FOR THE EXAMINER USING APOMORPHINE AS A TOOL.

GENERALIZATION OF THE CONDITIONED STIMULUS IN TASTE AVERSION 001405 02-04 DRUG DISCRIMINATION AND GENERALIZATION IN PIGEONS

001532 02-06 A DESCRIPTION OF THE NICOTINE STIMULUS AND TESTS OF ITS GENERALIZATION TO AMPHETAMINE.

002210 03-04 DISCRIMINATIVE PROPERTIES OF L AMPHETAMINE: STIMULUS GENERALIZATION.

CHANGES OF SENSITIVITY TO THE CUING PROPERTIES OF NARCOTIC DRUGS AS EVIDENCED BY GENERALIZATION AND CROSS-GENERALIZATION EXPERIMENTS. 003194 04-04

MORPHINE AS A DISCRIMINATIVE CUE IN GERBILS: DRUG GENERALIZATION AND ANTAGONISM.

003249 04-04 GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF DELTAS-TETRAHYDROCANNABINOL TO CANNABINOIDS WITH THERAPEUTIC POTENTIAL.

003392 04-04

000975 01-17

003005 04-03

VOLUME 16, SUBJECT INDEX

Subject Index

EN			

CEREBELLAR UNIT ACTIVITY DURING GENERALIZED PENICILLIN EPILEPSY IN THE AWAKE CAT.

GENERATING

AGONIST EFFECTS OF BETA-PHENYLETHYLAMINES ON THE NORADRENERGIC CYCLIC-ADENOSINE-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. 3,5-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. STERFOISOMERS OF P-HYDROXYNOREPHEDRINE

000272 01-03

003411 04-05

002334 03-04

001028 02-02

EFFECT OF DIHYDROERGOTOXINE ON CYCLIC-AMP GENERATING SYSTEMS IN RAT CEREBRAL-CORTEX SLICES.

MODIFICATION OF THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN BY AMPHETAMINE (A) AND ITS HYDROXYLATED METABOLITES.

002100 03-03 THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION.

002164 03-03

GENERATION OF ELECTRONIC EXCITED STATES (EES) BY TRICYCLIC ANTIDEPRESSANTS: MOLECULAR ASPECTS. 001693 02-13

PENICILLIN IN THE PYRAMIDAL TRACT: ECTOPIC ACTION POTENTIAL GENERATION. 002082 03-03

GENERATORS
EVIDENCE FOR DISTINCT SPINAL LOCOMOTION GENERATORS SUPPLYING RESPECTIVELY FORELIMBS AND HINDLIMBS IN THE RABBIT 003124 04-03

GENETIC ANALYSIS OF THE BEHAVIORAL RESPONSE TO D AMPHETAMINE IN MICE.

INTERINDIVIDUAL VARIABILITY IN DIAZEPAM METABOLISM:
PRELIMINARY EVIDENCE OF AN ABSENCE OF GENETIC CONTROL

000696 01-13 PROPHYLACTIC VALUE OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS -

000952 01-17 TASK-DEPENDENT GENETIC INFLUENCES ON BEHAVIORAL RESPONSE OF MICE (MUS-MUSCULUS) TO ACETALDEHYDE.

003211 04-04 A GENETIC ANALYSIS OF THE HYPERTHERMIC RESPONSE TO D AMPHETAMINE IN TWO INBRED STRAINS OF MICE.

GENETICALLY

INTOXICATING EFFECTS OF THREE ALIPHATIC ALCOHOLS AND BARBITAL ON TWO RAT STRAINS GENETICALLY SELECTED FOR THEIR ETHANOL INTAKE.

002276 03-04

INFLUENCES OF GENOTYPE AND SEX ON BEHAVIORAL TOLERANCE TO NICOTINE IN MICE

000376 01-04 GENOTYPE AND TEST EXPERIENCE DETERMINE RESPONSIVENESS TO

002216 03-04 CONDITIONED TASTE AVERSIONS: GENOTYPE BY OLFACTORY BULBECTOMY INTERACTION.

ACUTE ORGANIC-BRAIN-SYNDROME ASSOCIATED WITH GENTAMICIN THERAPY.

000808 01-15 GERBIL

EFFECTS OF PCPA ON MARKING BEHAVIOUR IN THE MALE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).

001307 02-04 EFFECTS OF AMPHETAMINE AND NEMBUTAL ON SOCIAL EXPLORATION IN THE MONGOLIAN GERBIL 001414 02-04

AMPHETAMINE EFFECTS ON STIMULUS ELICITED INVESTIGATION IN THE 003186 04-04

EFFECTS OF SPIPERONE ON SELF-STIMULATION AND OTHER ACTIVITIES OF THE MONGOLIAN GERRIL 003222 04-04

CENTRAL AND PERIPHERAL ACTION OF TESTOSTERONE-PROPIONATE ON SCENT GLAND MORPHOLOGY AND MARKING BEHAVIOUR IN THE MONGOLIAN GERBIL.

003370 04-04 **GERBILS**

ALCOHOL-DISCRIMINATION IN GERBILS: INTERACTIONS WITH BEMEGRIDE, DH-524, AMPHETAMINE, AND DELTA9-THC 001385 02-04 INTERACTIONS BETWEEN ALCOHOL AND OTHER DRUGS ON OPEN-FIELD AND TEMPERATURE MEASUREMENTS IN GERBILS.

001386 02-04 DISCRIMINATIVE PROPERTIES OF PENTOBARBITAL AFTER REPEATED NONCONTINGENT EXPOSURE IN GERBILS

001387 02-04 MORPHINE AS A DISCRIMINATIVE CUE IN GERBILS: DRUG GENERALIZATION AND ANTAGONISM.

003249 04-04 EFFECTS OF INSULIN AND 2 DEOXY-D-GLUCOSE ON FEEDING IN HAMSTERS AND GERBILS.

003345 04-04 EFFECTS OF CHLORMETHIAZOLE (HEMINEVRIN) ON DRUG DISCRIMINATION AND OPEN-FIELD BEHAVIOR IN GERBILS

003371 04-04 COMPARISON OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS
HYPNOTICS IN GERIATRIC PATIENTS WITH INSOMNIA.

POTENTIAL UNTOWARD EFFECTS OF LONG-TERM USE OF FLURAZEPAM IN

GERIATRIC PATIENTS. A DOUBLE-BLIND INVESTIGATION OF PIRACETAM (NOOTROPIL) VERSUS PLACEBO IN THE MEMORY OF GERIATRIC INPATIENTS.

COMPARISON OF TRIAZOLAM .25 MG AND FLURAZEPAM 15 MG IN

TREATING GERIATRIC INSOMNIACS. 002524 03-11

THE EFFECTS OF ACTH4-10 VERSUS PLACEBO IN THE MEMORY OF SYMPTOMATIC GERIATRIC VOLUNTEERS.

002537 03-11 IS THERE A BIOLOGICAL BASIS FOR GERIATRIC PHARMACOTHERAPY?. 002742 03-17
TEMAZEPAM (EUHYPNOS) AND CHLORMETHIAZOLE: A COMPARATIVE

STUDY IN GERIATRIC PATIENTS. 003634 04-14 GERONTOPSYCHIATRY

S ADENOSYL-L-METHIONINE (SAME) TREATMENT IN GERONTOPSYCHIATRY: A CONTROLLED CLINICAL STUDY IN DEPRESSED AGED PATIENTS.

GESTATION CYPROTERONE-ACETATE EXPOSURE DURING GESTATION IN MICE RETARDS FETAL GROWTH. 003129 04-03

PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EMBRYOPATHIC EFFECT AND COVALENT BINDING OF PUTATIVE ARENE OXIDE

METABOLITE IN GESTATIONAL TISSUE. 001515 02-05

PENTOBARBITAL: PRESYNAPTIC EFFECT IN THE SQUID GIANT SYNAPSE 000204 01-03 DEPENDENCE OF THE INFLUENCE OF EPINEPHRINE ON THE EXCITABILITY OF GIANT NEURONS ON ITS CONCENTRATION. 001967 03-03

MORPHINE SANS THE GIFT OF MORPHEUS.

000992 01-17 **GIGANTOCELLULAR!!** THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF THE MEDULLA-OBLONGATA IS A HIGHLY SENSITIVE SITE IN THE PRODUCTION OF

MORPHINE ANALGESIA IN THE RAT. ANALGESIA BY ENKEPHALINS INJECTED INTO THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF RAT MEDULLA-OBLONGATA. 003374 04-04

GILLES-DE-LA-TOURETTE GILLES-DE-LA-TOURETTE SYNDROME: A NEW CLINICOTHERAPEUTIC APPROACH

001630 02-11 NORADRENERGIC AND DOPAMINERGIC MECHANISMS IN GILLES-DE-LA-TOURFITE SYNDROME

003609 04-13 GILLES-DE-LA-TOURETTES
EVALUATION OF LITHIUM-CARBONATE IN THE MANAGEMENT OF GILLES-DE-LA-TOURETTES SYNDROME.

GILLES-DE-LA-TOURETTES SYNDROME: FAMILIAL OCCURRENCE AND PRECIPITATION BY METHYLPHENIDATE THERAPY

001823 02-15 GILLES-DE-LA-TOURETTES SYNDROME, TARDIVE-DYSKINESIA, AND PSYCHOSIS IN AN ADOLESCENT. 002651 03-15

THE CHEMICAL CONSTITUENTS OF GINSENG PLANTS. 001003 02-01 EFFECT OF PANAX GINSENG ROOT ON CONDITIONED AVOIDANCE RESPONSE IN RATS.

EFFECT OF GINSENG ON THE BRAIN BIOGENIC MONOAMINES AND 3,5 AMP SYSTEM: EXPERIMENTS ON RATS. 003044 04-03

PRENATAL EXPOSURE TO MEDROXYPROGESTERONE-ACETATE (MPA) IN

002615 03-14

GLAND

N ACETYLTRANSFERASE ACTIVITY IN PINEAL GLAND OF RATS TREATED
WITH PARGYLINE.

000046 01-

000046 01-03 EFFECTS OF IFC-45, A NEW BENZONAPHTYRIDONE DERIVATIVE WITH ANTIDERESSIVE ACTION, ON ACTIVITY OF THE RAT SUPRARENAL GLAND CORTEX.

CENTRAL AND PERIPHERAL ACTION OF TESTOSTERONE-PROPIONATE ON SCENT GLAND MORPHOLOGY AND MARKING BEHAVIOUR IN THE MONGOLIAN GERBIL.

003370 04-04 GLANDS
INCREASE CAUSED BY DESMETHYLIMIPRAMINE IN THE PRODUCTION OF
H3-MELATONIN BY ISOLATED PINEAL GLANDS.

PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF NA CHANNELS IN THE RELEASE OF CATECHOLAMINES FROM PERFUSED ADRENAL GLANDS.

REGULATION OF CYCLIC-GUANOSINE-MONOPHOSPHATE IN THE RAT PINEAL AND POSTERIOR PITUITARY GLANDS.

003032 04-03

MARIJUANA, ALCOHOL, AND COMBINED DRUG EFFECTS ON THE TIME COURSE OF GLARE RECOVERY. 002604 03-14

GLC PHARMACOKINETICS OF METHYLPHENIDATE IN THE RAT USING SINGLE ION MONITORING GLC MASS SPECTROMETRY.

000498 01-06 BLOOD LEVEL MONITORING OF BENZODIAZEPINES BY GLC USING NITROGEN SENSITIVE DETECTORS.

001860 02-16 QUANTITATIVE ANALYSIS OF METHADONE IN BIOLOGICAL FLUIDS USING DEUTERIUM-LABELED METHADONE AND GLC CHEMICAL IONIZATION MASS SPECTROMETRY.

001862 02-16 GUA THE EFFECTS OF NORTRIPTYLINE AND MESORIDAZINE ON NEURONS AND

GLIA IN VITRO. 000130 01-03

THE EFFECT OF PENTOBARBITAL ON THE CARBOHYDRATE METABOLISM OF GLIAL CELLS IN CULTURE. 000484 01-05

THE EFFECT OF BARBITURATE AND PROCAINE ON GLIAL AND NEURO CONTRIBUTIONS TO EVOKE CORTICAL STEADY POTENTIAL SHIFTS AND NEURONAL 001219 02-03 PHENOBARBITAL EFFECT ON GLIAL CELL RESPIRATION IN THE PRESENCE OF A HIGH CONCENTRATION OF POTASSIUM.

002946 04-03

OLIOMA

PHARMACOLOGIC RESPONSES OF CELLS OF A NEUROBLASTOMA-X
GLIOMA HYBRID CLONE AND MODULATION OF SYNAPSES BETWEEN
HYBRID CELLS AND MOUSE MYOTUBES.

002863 04 002863 04-03

TURNOVER RATES OF GAMMA-AMINOBUTYRIC-ACID IN SUBSTANTIA-NIGRA, NUCLEUS-CAUDATUS, GLOBUS-PALLIDUS AND NUCLEUS-ACCUMBENS OF RATS INJECTED WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS.

002996 04-03 GLUCAGON DECREASED FEEDING IN RATS FOLLOWING HEPATIC PORTAL INFUSION OF GLUCAGON.

001514 02-05 GLUCOCORTICOID SELECTIVE PURIFICATION OF A SINGLE POPULATION OF GLUCOCORTICOID RECEPTORS FROM RAT BRAIN.

GLUCOCORTICOIDS

ROLE OF GLUCOCORTICOIDS IN AN ABNORMAL GROOMING BEHAVIOR IN CATS WITH PONTILE OR FRONTAL NEOCORTICAL LESIONS. 000463 01-04

EFFECTS OF RESERPINE AND SEROTONIN ON ADENINE-NUCLEOTIDE METABOLISM AND GLUCOSE OXIDATION OF WASHED RABBIT

000237 01-03 THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LOCAL CEREBRAL GLUCOSE UTILISATION OF THE RAT.

Psychopharmacology Abstracts

APOMORPHINE INCREASES GLUCOSE UTILIZATION IN THE SUBSTANTIA-NIGRA, SUBTHALAMIC NUCLEUS AND CORPUS-STRIATUM OF RAT. 001976 03-03

LITHIUM EFFECTS ON RAT BRAIN GLUCOSE METABOLISM IN LONG-TERM LITHIUM TREATED RATS STUDIED IN VIVO.

003046 04-03 LOCAL CEREBRAL GLUCOSE UTILIZATION FOLLOWING INJECTION OF BETA-ENDORPHIN INTO PERIAQUEDUCTAL GRAY MATTER IN THE RAT. 003073 04-03

A CONTRIBUTION TO THE NEUROCHEMICAL BASIS OF THE PYRITHIOXIN EFFECT ON THE BRAIN GLUCOSE UTILISATION DURING RELATIVE BRAIN HYPOGLYCAEMIA INDUCED BY ANTICIPATION STRESS. 003083 04-03

DIETARY EFFECTS UPON FOOD AND WATER INTAKE AND RESPONSIVENESS TO ESTROGEN, 2 DEOXYGLUCOSE AND GLUCOSE IN

003402 04-04 OLUCOSIDE
INHIBITION OF MONOAMINE-OXIDASE BY ISOGENTISIN AND ITS 3 0
GLUCOSIDE.
003104 (

003104 04-03 GLUCURONIDE
PLASMA KINETICS OF NALTREXONE AND ITS GLUCURONIDE IN THE DOG

URINARY EXCRETION OF A QUATERNARY AMMONIUM GLUCURONIDE METABOLITE OF CYPROHEPTADINE IN HUMANS UNDERGOING CHRONIC

001667 02-13 GLUCURONIDES
SULFATES AND GLUCURONIDES OF P-HYDROXYPHENOBARBITAL IN RAT

002165 03-03 DIFFERENTIAL ANTAGONISM BY CHLORPROMAZINE AND DIAZEPAM OF FROG MOTONEURONE DEPOLARIZATION INDUCED BY GLUTAMATE RELATED AMINO-ACIDS.

001116 02-03 MEASURING CHANGES IN CEREBRAL GLUTAMATE AND GABA METABOLISM PRIOR TO CONVULSIONS INDUCED BY 3 MERCAPTOPROPIONATE.

001961 03-03 STRUCTURE-ACTIVITY RELATIONS FOR THE NEUROTOXICITY OF KAINIC-ACID DERIVATIVES AND GLUTAMATE ANALOGUES.

002355 03-05 REGIONAL BRAIN ATROPHY AND REDUCTIONS IN GLUTAMATE RELEASE AND UPTAKE AFTER INTRASTRIATAL KAINIC-ACID.

EFFECT OF SOMATOSTATIN (SRIF) AND L GLUTAMATE ON NEURONS OF THE SENSORIMOTOR CORTEX IN AWAKE HABITUATED RABBITS.

002958 04-03 EFFECTS OF L GLUTAMATE AND RELATED AMINO-ACIDS UPON THE RELEASE OF H3-DOPAMINE FROM RAT STRIATAL SLICES.

003340 04-04

GLUTAMATE-DECARBOXYLASE
MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID
AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE
ACTIVITY IN RAT SPINAL CORD AND THALAMUS. POSSIBLE
CORRELATES WITH ANALGESIC ACTION OF MORPHINE. 002984 04-03

GLUTAMIC-ACID-DECARBOXYLASE MOUSE BRAIN TYROSINE-HYDROXYLASE AND GLUTAMIC-ACID-DECARBOXYLASE FOLLOWING TREATMENT WITH ADRENOCORTICOTROPHIC HORMONE, VASOPRESSIN OR

CORTICOSTERONE. 002898 04-03 **GLUTAMINE -- A MAJOR SUBSTRATE FOR NERVE ENDINGS**

002839 04-03

SPECTRAL ANALYSIS OF THE DIFFERING EEG EFFECTS OF BENZODIAZEPINES, MEPROBAMATE, GLUTETHIMIDE AND AMOBARBITAL IN MACACA-MULATTA.

THE DISTRIBUTION BETWEEN PLASMA AND BRAIN OF GLUTETHIMIDE AND 4 HYDROXYGLUTETHIMIDE FOLLOWING THEIR ADMINISTRATION TO MICE.

001160 02-03 **GLYCERYL-TRINITRATE** IMPOTENCE RESPONSIVE TO GLYCERYL-TRINITRATE. TRINITRATE 000650 01-11

GLYCINE BENZODIAZEPINE ACTIVITY: IS INTERACTION WITH THE GLYCINE RECEPTOR, AS EVIDENCED BY DISPLACEMENT OF STRYCHNINE BINDING, A USEFUL CRITERION?.

000151 01-03 STRYCHNINE BINDING ASSOCIATED WITH SYNAPTIC GLYCINE RECEPTORS IN RAT SPINAL CORD MEMBRANES: IONIC INFLUENCES.

003024 04-03

002887 04-03

003197 04-04

001916 02-17

STIMULATION BY LITHIUM-IONS OF THE INCORPORATION OF C14-GLUCOSE INTO GLYCOGEN IN RAT BRAIN SLICES. 003015 04-03

SYNTHESIS AND PRELIMINARY PHARMACOLOGICAL ACTIVITY OF AMINOALKOXY ISOSTERES OF GLYCOLATE ESTER ANTICHOLINERGICS 001026 02-02

MODULATION OF DEXAMPHETAMINE-INDUCED COMPULSIVE GNAWING INCLUDING THE POSSIBLE INVOLVEMENT OF PRESYNAPTIC ALPHA-ADRENORECEPTORS

COITER

LITHIUM-CARBONATE INTAKE DURING PREGNANCY LEADING TO LARGE GOITER IN A PREMATURE INFANT. 000869 01-15

GOLDFISH THE EFFECTS OF AMPHETAMINE ON MAZE LEARNING BY GOLDFISH.

IN VITRO EFFECTS OF CHLORPROMAZINE ON MICROTUBULES AND THE GOLGI COMPLEX IN EMBRYONIC CHICK SPINAL GANGLION CELLS: AN **ELECTRON MICROSCOPIC STUDY.**

001258 02-03

GONADAL MORPHOLOGY IN SCHIZOPHRENIC PATIENTS UNDER PSYCHOTROPIC TREATMENT. 001832 02-15

GONADOTROPIN SERUM GONADOTROPIN AND TSH LEVELS AFTER TRICYCLIC

ANTIDEPRESSANTS IN HEALTHY MALES. 001670 02-13

THE EFFECTS OF INTRAVENTRICULAR INJECTION OF GAMMA AMINOBUTYRIC-ACID (GABA) ON PROLACTIN AND GONADOTROPIN RELEASE IN CONSCIOUS FEMALE RATS.

GONADOTROPINS

INHIBITORY EFFECT OF MORPHINE ON SERUM GONADOTROPINS AND PROLACTIN OF PROESTROUS RATS.

000206 01-03 GRANULAR

GRANULAR AND EXTRAGRANULAR ACTION OF PSYCHOTROPIC DRUGS ON MONOAMINERGIC NEURONS.

000252 01-03

AFFERENT AND EFFERENT SUBCORTICAL PROJECTIONS OF BEHAVIORALLY DEFINED SECTORS OF PREFRONTAL GRANULAR CORTEX.

GRANULES

QUANTITATION OF BINDING OF H3-CHLORPROMAZINE TO SYNTHETIC

THE HUMAN PLATELET AS A MODEL FOR THE DOPAMINERGIC NEURON: KINETIC AND PHARMACOLOGIC PROPERTIES AND THE ROLE OF AMINE STORAGE GRANULES.

002596 03-13 A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS. 003608 04-13

EFFECTS OF LITHIUM ON GRANULOPOIESIS IN CULTURE.

002105 03-03

003126 04-03

LITHIUM STIMULATION OF GRANULOPOIESIS.

002695 03-15

EFFECT OF MORPHINE INJECTED IN PERIADUEDUCTAL GRAY ON THE ACTIVITY OF SINGLE UNITS IN NUCLEUS RAPHE MAGNUS OF THE RAT 002817 04-03

LOCAL CEREBRAL GLUCOSE UTILIZATION FOLLOWING INJECTION OF BETA-ENDORPHIN INTO PERIAQUEDUCTAL GRAY MATTER IN THE RAT 003073 04-03

GREECE STUDY OF LONG-TERM HASHISH USERS IN GREECE: SUMMARY AND DISCUSSION

000625 01-11 MAINTENANCE ANTIPSYCHOTIC PHARMACOTHERAPY, RELAPSE, AND LENGTH OF STAY OUT OF THE HOSPITAL IN CHRONIC SCHIZOPHRENICS IN GREECE.

GREY

INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5 HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA: EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION.

THE EFFECT OF NITRAZEPAM ON MANUAL SKILL, GRIP STRENGTH, AND REACTION TIME WITH SPECIAL REFERENCE TO SUBJECTIVE **EVALUATION OF EFFECTS ON SLEEP**

002626 03-14

авоомина

EVIDENCE FOR NORADRENERGIC MECHANISM IN THE GROOMING PRODUCED BY () AMPHETAMINE AND 4,GAMMA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.

ROLE OF GLUCOCORTICOIDS IN AN ABNORMAL GROOMING BEHAVIOR IN CATS WITH PONTILE OR FRONTAL NEOCORTICAL LESIONS.

ACTH-INDUCED EXCESSIVE GROOMING IN THE RAT: LATENT ACTIVITY OF ACTH4-10.

ACTH-INDUCED EXCESSIVE GROOMING INVOLVES BRAIN DOPAMINE 001490 02-04
DISTINCT DOPAMINERGIC SYSTEMS IN ACTH-INDUCED GROOMING.

INVOLUNTARY ADMINISTRATION OF PSYCHOTROPIC DRUGS -- GROUNDS FOR SUIT. SOUDER V. MCGUIRE, 423 F.SUPP. 830, (PENNSYLVANIA). M.D. DISTRICT COURT. DECEMBER 9, 1976.

FURTHER EVIDENCES ON THE BEHAVIOURAL EFFECTS OF SELECTIVE A-10 DOPAMINERGIC MESENCEPHALO-CORTICO-LIMBIC GROUP LESION IN THE RAT.

COUPLES GROUP THERAPY AS AN ADJUNCT TO LITHIUM MAINTENANCE OF THE MANIC PATIENT.

A DIAGNOSTIC TREATMENT MODEL FOR EFFECTIVE GROUP TREATMENT OF DRUG ABUSERS.

INFLUENCE OF PHARMACOLOGICAL AGENTS ON AVOIDANCE REFLEXES IN A GROUP EXPERIMENT ON RATS.

GROUPED MORPHINE ACTION IN GROUPED AND ISOLATED RATS AND MICE 000394 01-04

POTENT PROLACTIN AND GROWTH HORMONE RELEASING ACTIVITY OF MORE ANALOGUES OF MET-ENKEPHALIN.

EFFECTS OF APOMORPHINE AND CLONIDINE ON RAT PLASMA GROWTH HORMONE AFTER PRETREATMENT WITH RESERPINE AND ELECTROCONVULSIVE SHOCKS.

000102 01-03 AMINERGIC AND THERMOREGULATORY MECHANISMS IN HYPOTHALAMIC REGULATION OF GROWTH HORMONE IN CATS. 000249 01-03

INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH D.I. METHADONE.

000270 01-03 GAS-CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY OF SEROTONIN IN RAT SUPERIOR CERVICAL GANGLIA: EFFECTS OF NERVE GROWTH FACTOR AND 6 HYDROXYDOPAMINE

001006 02-01 SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT AND NEWBORN RATS.

O01215 02-03
AN EVALUATION OF A UNIQUE NEW ANTIPSYCHOTIC AGENT, SULPIRIDE:
EFFECTS ON SERUM PROLACTIN AND GROWTH HORMONE LEVELS.

001554 02-07 THYROID FUNCTION AND GROWTH HORMONE SECRETION IN AMITRIPTYLINE TREATED DEPRESSION.

001596 02-09 BROMOCRIPTINE: EFFECT ON SERUM PROLACTIN AND GROWTH HORMONE IN PSYCHOGERIATRIC HOSPITAL PATIENTS.

002561 03-13 DEXTROAMPHETAMINE AND L AMPHETAMINE ARE EQUIPOTENT IN RELEASING HUMAN GROWTH HORMONE.

CENTRAL EFFECT OF SOMATOSTATIN ON THE SECRETION OF GROWTH HORMONE IN THE ANESTHETIZED RAT.

002803 04-03 NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. I. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE IN EXPONENTIAL GROWTH PHASE.

002836 04-03 SELECTIVE ENZYME INDUCTION IN A NERVE GROWTH FACTOR RESPONSIVE PHEOCHROMOCYTOMA CELL LINE (PC-12).

RETROGRADE AXONAL TRANSPORT OF NERVE GROWTH FACTOR IN THE CILIARY GANGLION OF THE CHICK AND THE RAT.

CYPROTERONE-ACETATE EXPOSURE DURING GESTATION IN MICE RETARDS FETAL GROWTH.

003129 04-03 GROWTH OF HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE. 003562 04-11

GROWTH HORMONE, PROLACTIN AND CORTISOL RESPONSES AND GROWTH PATTERNS IN HYPERKINETIC CHILDREN TREATED WITH DEXTROAMPHETAMINE. PRELIMINARY FINDINGS. 003569 04-11

GUANETHIDINE

EFFECT OF PRETRIAL AND POSTTRIAL TYRAMINE AND GUANETHIDINE
INJECTIONS ON AN APPETITIVE TASK IN RATS.

001439 0

001439 02-04

QUANINE
INTERACTIONS BETWEEN GUANINE DERIVATIVES AND NOREPINEPHRINE
ON NEURONES OF THE MAMMALIAN CEREBRAL-CORTEX.
003101 04-03 GUANOSINE-MONOPHOSPHATE
GUANOSINE-MONOPHOSPHATE: A CENTRAL-NERVOUS-SYSTEM
REGULATOR OF ANALGESIA.

002215 03-04

THE EFFECT OF DRUGS WHICH ALTER GABAERGIC FUNCTION ON CEREBELLAR GUANOSINE-MONOPHOSPHATE CONTENT. 002993 04-03

GUANYL-NUCLEOTIDES

DOPAMINE RECEPTOR BINDING OF H3-ADTN (2

AMINODIHYDROXYTETRAHYDRONAPHTHALENE) REGULATED BY
GUANYL-NUCLEOTIDES. 002877 04-03

GUANYLYLIMIDODIPHOSPHATE
5 GUANYLYLIMIDODIPHOSPHATE ACTIONS ON ADENYLATE-CYCLASE IN
HOMOGENATES OF RAT CEREBRAL-CORTEX PLUS NEURONAL AND
CAPILLARY FRACTIONS.

003038 04-03 CACTUS ALKALOIDS XXXIII: BETA-PHENETHYLAMINES FROM THE GUATEMALAN CACTUS PILOSOCEREUS-MAXONII.

001011 02-01

GUIDELINES FOR NURSES: THE ADMINISTRATION OF INTRAVENOUS DRUGS THROUGH AN ESTABLISHED INTRAVENOUS PATHWAY. 001866 02-16

GUIDELINES TO REDUCE MISUSE OF DRUGS.

COMBINED TRICYCLIC MAOI THERAPY FOR REFRACTORY DEPRESSION: A REVIEW, WITH GUIDELINES FOR APPROPRIATE USAGE. 002437 03-09

GUIDELINES FOR AGENTS USED IN THE TREATMENT OF POISONINGS 002652 03-15 INTERNATIONAL GUIDELINES FOR CLINICAL TRIALS OF PSYCHOTROPIC

002769 03-17

GUINEA-PIG EFFECTS OF N METHYLAMINO-ACIDS AND CONVULSANTS ON SPONTANEOUS ACTION POTENTIALS IN GUINEA-PIG CEREBELLAR

000209 01-03 THE LACK OF AN EFFECT OF DELTA9-THC ON PULMONARY SMOOTH MUSCLE FUNCTION IN THE GUINEA-PIG.

001041 02-03 A NEW CHRONICALLY CANNULATED CAROTID ARTERY PREPARATION FOR DETERMINATION OF DRUG HALF-LIVES IN THE GUINEA-PIG.

001531 02-06 SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE
MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE
GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION. 002052 03-03

THE DIFFERENTIAL EFFECT OF LITHIUM ON NORADRENALINE AND DOPAMINE SENSITIVE ACCUMULATION OF CYCLIC-AMP IN GUINEA-PIG BRAIN.

THE ROLE OF CALCIUM IN THE REGULATION OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN SLICES OF RAT AND GUINEA-PIG.

SENSITIVITY TO APOMORPHINE IN THE GUINEA-PIG AS A FUNCTION OF AGE AND BODY WEIGHT

003182 04-04
BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC NARCOTIC TREATMENT IN THE GUINEA-PIG.

GUINEA-PIOS
PROSTAGLANDINS AND THE CARDIOTOXIC EFFECT OF DOXEPIN IN

RABBITS AND GUINEA-PIGS. 001518 02-05

FACILITATION OF LORDOSIS BEHAVIOR BY CLONIDINE IN FEMALE GUINEA-

002222 03-04 THE ENTEROHEPATIC CIRCULATION OF OXAZEPAM-O-GLUCURONIDE IN GUINEA-PIGS.

L 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS IN GUINEA-PIGS: A
MODEL FOR THE STUDY OF CENTRAL SEROTONIN DOPAMINE INTERACTIONS 003386 04-04 **Psychopharmacology Abstracts**

000817 01-15

ELECTROPHYSIOLOGICAL (H-REFLEX) STUDIES OF PATIENTS WITH TARDIVE-DYSKINESIA.

EVIDENCE FOR NORADRENERGIC MECHANISM IN THE GROOMING PRODUCED BY () AMPHETAMINE AND 4, GAMMA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.

INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETINE ON HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE (PCA) AND 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77).

003271 04-04

D ALPHA-AMINOADIPATE, ALPHA-EPSILON-DIAMINOPIMELIC-ACID AND H-966 AS ANTAGONISTS OF AMINO-ACID-INDUCED AND SYNAPTIC EXCITATION OF MAMMALIAN SPINAL NEURONES IN VIVO. 002831 04-03

HA-966
MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACIDINDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D
ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF
FROG AND IMMATURE RAT.

002901 04

002901 04-03 HYPOTHESIZED ADRENERGIC/NORADRENERGIC SUBSTITUTION IN HABITUAL INFANTILE MASTURBATION: TWO CASES. 001702 02-14

HABITUATED

EFFECT OF SOMATOSTATIN (SRIF) AND L GLUTAMATE ON NEURONS OF
THE SENSORIMOTOR CORTEX IN AWAKE HABITUATED RABBITS.

002958 04-03

PHARMACOLOGICAL APPROACHES TO HABITUATION OF THE ACOUSTIC STARTLE RESPONSE IN RATS. 000425 01-EFFECTS OF TWO ANXIOLYTICS ON DISTRACTION, HABITUATION AND DISHABITUATION.

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

THE EFFECTS OF ONE-DAY TREATMENT OF ANXIETY WITH HIGH DOSES OF HALAZEPAM. 002718 03-16

EFFICACY OF HALAZEPAM (SCH-12041) AS AN ANXIOLYTI 003549 04-10

PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND ANXIETY IN ANXIOUS OUTPATIENTS.

000762 01-14

MULTIPLE ORAL DOSES OF DIAZEPAM, OXAZEPAM AND PHENOBARBITAL TO DOGS -- BEHAVIOURAL EFFECTS AND CORRELATION WITH ANTIPYRINE HALF-LIFE. 000308 01-04

HALF-LIVES
INCREASED STEADY-STATE PLASMA LEVELS AND PROLONGED HALF-LIVES
OF TRICYCLIC ANTIDEPRESSANTS I™ THE ELDERLY.

000734 01-13

A NEW CHRONICALLY CANNULATED CAROTID ARTERY PREPARATION FOR DETERMINATION OF DRUG HALF-LIVES IN THE GUINEA-PIG. 001531 02-06

HALLUCINATION
ON PSYCHOLOGICAL SYMPTOMS IN BROMIDE INTOXICATION — ONE CASE
OF HIGH DOSE, LONG-TERM BROMIDE INTOXICATION WHICH SHOWED
HALLUCINATION AND DELUSION SYMPTOMS.

000880 01-15 HALLUCINATIONS

L TRYPTOPHAN ADMINISTRATION IN L-DOPA-INDUCED HALLUCINATIONS
IN ELDERLY PARKINSONIAN PATIENTS.

001624-02-1 001624 02-11

COCAINE HALLUCINATIONS. 002698 03-15

EFFECTS OF NALOXONE ON SCHIZOPHRENIA: REDUCTION IN HALLUCINATIONS IN A SUBPOPULATION OF SUBJECTS. 003639 04-14

WAKING STAGE-1 REM OBSERVED IN PARANOID HALLUCINATORY STATES OF NARCOLEPSY. 002675 03-15

HALLUCINOGEN BINDING TO DOPAMINE/NEUROLEPTIC RECEPTORS 000296 01-03 A NEW HALLUCINOGEN FROM ANDEAN COLOMBIA: IOCHROMA-

000983 01-17

THE EFFECT OF A HALLUCINOGEN, 5 METHOXYDIMETHYLTRYPTAMINE, ON PRIMATE SOCIAL BEHAVIOR.

001455 02-04

002361 03-06

COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON BEHAVIOR OF

COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON ROTATIONAL BEHAVIOR IN RATS WITH UNILATERAL 6 HYDROXYDOPAMINE

001477 02-04 STRUCTURE-ACTIVITY STUDIES ON HALLUCINOGENIC AMPHETAMINES USING MOLECULAR CONNECTIVITY.

001530 02-06 SCREENING HALLUCINOGENIC DRUGS. II. SYSTEMATIC STUDY OF TWO BEHAVIORAL TESTS.

THE BOTANICAL AND CHEMICAL DISTRIBUTION OF HALLUCINOGENS 000680 01-12

EVALUATION OF SUBSTITUTED AMPHETAMINE HALLUCINOGENS USING THE CAT LIMB FLICK MODEL.

001449 02-04 WHY BAN HALLUCINOGENS?.

001632 02-12 STIMULUS PROPERTIES OF PHENETHYLAMINE HALLUCINOGENS AND LYSERGIC-ACID-DIETHYLAMIDE: THE ROLE OF 5 HYDROXYTRYPTAMINE

002180 03-03 EFFECTS OF D AMPHETAMINE, MONOMETHOXYAMPHETAMINES AND HALLUCINOGENS ON SCHEDULE-CONTROLLED BEHAVIOR

002244 03-04 HIGH-AFFINITY H3-SEROTONIN BINDING TO CAUDATE: INHIBITION BY HALLUCINOGENS AND SEROTONINERGIC DRUGS.

003138 04-03 STIMULUS PROPERTIES OF DOM: COMMONALITY WITH OTHER HALLUCINOGENS.

003359 04-04 HALLUCINOSIS PSYCHOSIS INDUCED BY DATURA-SUAVEOLENS: HALLUCINOSIS AND

ANTICHOLINERGIC DELIRIUM 001782 02-15

REGIONAL LOCALIZATION OF HALOPEMIDE, A NEW PSYCHOTROPIC AGENT, IN THE RAT BRAIN. 002989 04-03

HALOPERIDOL

HALOPERIDOL INCREASES AND APOMORPHINE DECREASES STRIATAL DOPAMINE METABOLISM AFTER DESTRUCTION OF STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASE BY KAINIC-ACID

000094 01-03 A COMPARISON OF THE EFFECTS OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE STRIATUM, OLFACTORY TUBERCLE AND MEDIAN

REGULATORY ROLE OF GABA NEURONS ON THE ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE BY HALOPERIDOL. (UNPUBLISHED PAPER)

000132 01-03 REINFORCING PROPERTIES OF PERPHENAZINE, HALOPERIDOL AND AMITRIPTYLINE IN RHESUS MONKEYS.

000148 01-03 EFFECTS OF MORPHINE AND HALOPERIDOL ON THE ELECTRICAL ACTIVITY OF RAT NIGROSTRIATAL NEURONS. 000154 01-03

CATECHOLAMINE SYNTHESIS IN RAT BRAIN AFTER AXOTOMY: INTERACTION BETWEEN APOMORPHINE AND HALOPERIDOI 000161 01-03

SPECIFIC EFFECT OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE FRONTAL CORTEX.

000175 01-03 LACK OF EFFECT OF CHRONIC HALOPERIDOL ADMINISTRATION ON THE PROLACTIN LOWERING ACTIONS OF PIRIBEDIL.

000233 01-03 SCHEDULE-INDUCED WATER AND SACCHARIN POLYDIPSIA UNDER HALOPERIDOL.

000390 01-04 THE EFFECTS OF HALOPERIDOL, CHLORPROMAZINE AND PROPRANOLOL ON ACUTE AMPHETAMINE POISONING IN THE CONSCIOUS DOG

000480 01-05 HALOPERIDOL: EFFECT OF LONG-TERM TREATMENT ON RAT STRIATAL DOPAMINE SYNTHESIS AND TURNOVER.

000481 01-05 LITHIUM ABSORPTION, DISTRIBUTION AND CLEARANCE AND BODY TEMPERATURE IN RATS GIVEN LITHIUM PLUS HALOPERIDOL 000488 01-05

MOVEMENT DISORDERS INDUCED IN MONKEYS BY CHRONIC HALOPERIDOL TREATMENT.

DIFFERENTIAL HALOPERIDOL EFFECT ON TWO INDICES OF FENTANYL SALINE DISCRIMINATION.

SOME METHODOLOGICAL CONSIDERATIONS FOR THE CLINICAL EVALUATION OF NEUROLEPTICS — COMPARATIVE EFFECTS OF CLOZAPINE AND HALOPERIDOL ON SCHIZOPHRENICS.

HIGH DOSAGE HALOPERIDOL IN CHRONIC SCHIZOPHRENIA

000539 01-08 PARENTERAL HALOPERIDOL IN PSYCHIATRIC EMERGENCIES: DOUBLE-BLIND COMPARISON WITH CHLORPROMAZINE.

000566 01-09 CONCOMITANT ADMINISTRATION OF HALOPERIDOL AND LITHIUM-CARBONATE IN ACUTE MANIA.

000638 01-11 HALOPERIDOL IN THE TREATMENT OF STUTTERING

1000651 01-11 INDIVIDUAL VARIATIONS IN RESPONSE OF HUMAN REM SLEEP TO AMITRIPTYLINE AND HALOPERIDOL

000779 01-14 CATATONIA AND MALIGNANT SYNDROME: A POSSIBLE COMPLICATION OF NEUROLEPTIC ADMINISTRATION. REPORT OF A CASE INVOLVING

000910 01-15 EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS.

001103 02-03 HALOPERIDOL AND CLOZAPINE: SPECIFICITY OF ACTION ON GABA IN THE NIGROSTRIATAL SYSTEM.

001184 02-03 ALTERATIONS IN BRAIN HISTAMINE AND HISTIDINE-DECARBOXYLASE ACTIVITY AFTER HALOPERIDOL AND IMIPRAMINE

001188 02-03 BRAIN NEUROTRANSMITTER RECEPTORS AFTER LONG-TERM
HALOPERIDOL: DOPAMINE, ACETYLCHOLINE, SEROTONIN, ALPHA-NORADRENERGIC AND NALOXONE RECEPTORS

001200 02-03 IN VITRO AUTONOMIC EFFECTS OF FOUR NEUROLEPTICS CHLORPROMAZINE, HALOPERIDOL, MELPERONE AND THIORIDAZINE 001212 02-03

NEUROLOGICAL DISTURBANCES, NIGROSTRIATE SYNAPSES, AND IONTOPHORETIC DOPAMINE AND APOMORPHINE AFTER HALOPERIDO 001293 02-03

EFFECTS OF APOMORPHINE AND HALOPERIDOL ON EXPLORATORY BEHAVIOR AND LATENT LEARNING IN MICE.

001297 02-04 DIFFERENTIAL TOLERANCE TO INHIBITORY ACTION OF VARIOUS NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS CHRONICALLY TREATED WITH HALOPERIDOL.

NEUROMETABOLIC AND BEHAVIOURAL EFFECTS OF HALOPERIDOL IN RELATION TO DRUG LEVELS IN SERUM AND BRAIN.

001430 02-04 PROGRESSIVE FORCE SCHEDULES IN THE SQUIRREL-MONKEY: EFFECTS OF INCREMENT SIZE, AMPHETAMINE, AND HALOPERIDOL. (PH.D.

001459 02-04 LYSERGIC-ACID-DIETHYLAMIDE ANTAGONISM BY CHLORPROMAZINE, HALOPERIDOL, DIAZEPAM, AND PENTOBARBITAL IN THE RABBIT. 001504 02-05

TOLERANCE TO HALOPERIDOL CATALEPSY. 001506 02-05

HALOPERIDOL AND ANALGESIA. CASE REPORTS

RELATIVE EFFICACY OF PARENTERAL HALOPERIDOL AND THIOTHIXENE FOR THE EMERGENCY TREATMENT OF ACUTELY EXCITED AND AGITATED PATIENTS.

REGIONAL CHANGES OF CEREBRAL BLOOD FLOW DURING HALOPERIDOL THERAPY IN PATIENTS WITH PARANOID SYMPTOMS.

001677 02-13
LOXAPINE VERSUS HALOPERIDOL PARENTERALLY IN ACUTE PSYCHOSIS WITH AGITATION: A DOUBLE-BLIND STUDY.

001710 02-14 CLINICAL USE OF HALOPERIDOL (SERENACE) IN CHILD PSY

001725 02-14 HALOPERIDOL IN BARBITURATE DETOXIFICATION

O01833 02-15
INFLUENCE OF EXTRAPYRAMIDAL DISTURBANCES DUE TO HALOPERIDOL
ON PHENAMINE STEREOTYPY AND THE EFFECTS OF SCHIZOPHRENIC
BLOOD SERUM (EXPERIMENTAL STUDIES).

DOPAMINE BINDING FOLLOWING PROLONGED HALOPERIDOL PRETREATMENT

002345 03-05 AN EXPERIMENTAL STUDY OF THE EFFECTS OF AMITRIPTYLIN PERPHENAZINE AND AMITRIPTYLINE HALOPERIDOL COMBINATIONS ON INTERPERSONAL LEARNING.

000490 01-05

COMBINED HALOPERIDOL AND LITHIUM-CARBONATE IN TREATING MANIC PATIENTS.

EFFECT OF MECAMYLAMINE ON THE FATE OF DOPAMINE IN STRIATAL AND MESOLIMBIC AREAS OF RAT BRAIN; INTERACTION WITH MORPHINE AND HALOPERIDOL.

002806 04-03
REGIONAL SENSITIVITY OF PRIMATE BRAIN DOPAMINERGIC NEURONS TO HALOPERIDOL: ALTERATIONS FOLLOWING CHRONIC TREATMENT. 002812 04-03

DOPAMINE TURNOVER IN THE INTACT RABBIT BRAIN: EFFECT OF PENTOBARBITAL OR HALOPERIDOL.

002815 04-03 A BEHAVIOURAL AND BIOCHEMICAL COMPARISON OF DOPAMINE RECEPTOR BLOCKAGE PRODUCED BY HALDPERIDOL WITH THAT PRODUCED BY SUBSTITUTED BENZAMIDE DRUGS. 002963 04-03

DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE AND D AMPHETAMINE; AND ANTAGONISM BY HALOPERIDOL: A COMPARATIVE STUDY.

003191 04-04 THE EFFECTS OF HALOPERIDOL ON DISCRIMINATIVE RESPONDING CONTROLLED BY THE COCAINE CUE.

THE EFFECTS OF HALOPERIDOL AND CLOZAPINE ON CIRCLING INDUCED BY ELECTRICAL STIMULATION OF THE SUBSTANTIA-NIGRA AND THE VENTROMEDIAL TEGMENTUM.

HALOPERIDOL DEPRESSES THE ACCUMULATION OF APOMORPHINE IN THE STRIATUM OF THE RAT.

DYSKINESIAS EVOKED IN MONKEYS BY WEEKLY ADMINISTRATION OF HALOPERIDOL.

ON THE OBJECTIVE EVALUATION OF HALOPERIDOL EFFECTS IN MAN: A PILOT STUDY

003442 04-07 HALOPERIDOL AND LITHIUM BLOCKING OF THE MOOD RESPONSE TO INTRAVENOUS METHYLPHENIDATE.

003529 04-09 HE ACUTE EFFECT OF HALOPERIDOL AND APOMORPHINE ON THE SEVERITY OF STUTTERING.

003619 04-14 PARKINSONISM BY HALOPERIDOL AND PIRIBEDIL.

003648 04-15 LARYNGEAL PHARYNGEAL DYSTONIA AS A POSSIBLE CAUSE OF ASPHYXIA WITH HALOPERIDOL TREATMENT.

003654 04-15 TARDIVE-DYSKINESIA DURING AND FOLLOWING TREATMENT WITH HALOPERIDOL, HALOPERIDOL BIPERIDEN, THIORIDAZINE, AND CLOZAPINE.

003656 04-15 HALOPERIDOL-INDUCED
THE EFFECTS OF HYPOTHALAMIC DEAFFERENTATION ON THE
HALOPERIDOL-INDUCED ACTIVATION OF TUBEROINFUNDIBULAR
DOPAMINE NEURONS.

001047 02-03 HALOPERIDOL-INDUCED LIVER DISEASE.

001776 02-15 INCREASED HALOPERIDOL-INDUCED CATALEPSY AFTER CHRONIC COCAINE

O02341 03-05
ON THE RELATION BETWEEN HALOPERIDOL-INDUCED ALTERATIONS IN DA
RELEASE AND DA METABOLISM IN RAT STRIATUM.

THE EFFECT OF ABLATION OF SEROTONIN OR NOREPINEPHRINE BRAINSTEM AREAS ON HALOTHANE AND CYCLOPROPANE MAC IN RATS. (UNPUBLISHED PAPER).

ALTERATION OF TRICARBOXYLIC-ACID CYCLE METABOLISM IN RAT BRAIN SLICES BY HALOTHANE.

002861 04-03 POISON AVERSION AND SEXUAL BEHAVIOR IN THE GOLDEN HAMSTER 001357 02-04 CHARACTERISTICS OF MONOAMINE-OXIDASES IN BRAIN AND OTHER ORGANS OF THE GOLDEN HAMSTER.

002900 04-03 EFFECTS OF CHLORDIAZEPOXIDE, OXAZEPAM, CHLORPROMAZINE, AND D AMPHETAMINE ON SEXUAL RESPONSES IN MALE AND FEMALE

002208 03-04

EFFECTS OF INSULIN AND 2 DEOXY-D-GLUCOSE ON FEEDING IN HAMSTERS AND GERBILS. 003345 04-04

HANDBOOK OF PSYCHOPHARMACOLOGY. VOL. 11. STIMULANTS 003715 04-17

Psychopharmacology Abstracts

002139 03-03

HANDICAPPED CLONAZEPAM IN THE TREATMENT OF EPILEPSY IN HANDICAPPED PATIENTS. 002503 03-11

HANDLING
THE EFFECTS OF PROLONGED HANDLING, SCOPOLAMINE, AND
PHYSOSTIGMINE ON THE ACTIVITY OF ISOLATED AND SOCIALLY REARED RATS

002285 03-04 DNA SYNTHETIC ABILITY IN CEREBELLA FROM TEMPERATURE AND HANDLING STRESSED NEONATAL RATS.

002934 04-03

EFFECT OF GENERAL ANESTHETICS ON HANDLING-INDUCED AND DECAPITATION-INDUCED INCREASES IN SYMPATHOADRENAL

PROFILES OF PSYCHEDELIC DRUGS: 4. HARMALINE.

000681 01-12 3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE LEVELS IN RAT CEREBELLUM: EFFECTS OF MORPHINE, KETAMINE, HARMALINE AND ISONIAZID. 002056 03-03

EFFECTS OF ANESTHETICS ON CEREBELLAR NEURONS RECORDED CHRONICALLY AFTER HARMALINE.

002260 03-04

HARMALINE-INDUCED
THE INDOLAMINERGIC INNERVATION OF THE INFERIOR OLIVE. 2.
RELATION TO HARMALINE-INDUCED TREMOR.

000269 01-03

INFLUENCE OF DIAZEPAM, L-DOPA AND DOPAMINE ON THE CEREBELLAR AND SPINAL ELECTRICAL PATTERNS INDUCED BY HARMINE IN THE

HASHISH STUDY OF LONG-TERM HASHISH USERS IN GREECE: SUMMARY AND DISCUSSION.

000625 01-11 INTERCORRELATIONS BETWEEN PHYSIOLOGICAL AND PSYCHOLOGICAL
EFFECTS OF MARIJUANA, HASHISH, AND THC-DELTAP IN LONG-TERM
HASHISH USERS.

000695 01-13 VISUAL EVOKED REPONSES IN CHRONIC HASHISH USERS.

000722 01-13 II. CLINICAL ELECTROENCEPHALOGRAPHY AND ECHOENCEPHALOGRAPHY IN LONG-TERM HASHISH USERS.

000723 01-13

ACUTE EEG EFFECTS OF CANNABIS PREPARATIONS IN LONG-TERM HASHISH USERS.

000744 01-13 ACUTE EFFECTS OF CANNABIS ON COGNITIVE, PERCEPTUAL, AND MOTOR PERFORMANCE IN CHRONIC HASHISH USERS.

000759 01-14 HAZARDS

HAZARDS OF INTRAARTERIAL DIAZEPAM. 000840 01-15 THE AMPHETAMINES: MEDICAL USES AND HEALTH HAZARDS 000842 01-15

HAZARDS OF ANTIPSYCHOTIC DRUG USE IN NONPSYCHOT IC PATIENTS 001847 02-15 ESTROGENS: THEIR FUNCTIONS, USES AND HAZARDS: PART 2 002706 03-15

MODIFICATION OF ADENYLATE-CYCLASE SYSTEMS IN MOUSE CEREBRAL-CORTEX BY CHLORPROMAZINE AND RESPECTIVE 7 HDROXY ANALOGS

002875 04-03

POST HEAD TRAUMA SYNDROME IN AN ADOLESCENT TREATED WITH LITHIUM-CARBONATE -- CASE REPORT. 000560 01-09

DISCRIMINATIVE PENTOBARBITAL EFFECT MEASURED BY HEAD MOVEMENTS IN RESTRAINED RATS.

001396 02-04 HEAD-SHAKE
HEAD-SHAKE DISTRIBUTIONS DURING SELF-MAINTAINED DEPENDENCE ON
MORPHINE, METHADONE, AND L-ALPHA-ACETYLMETHADOL (LAAM) IN

001328 02-04

CHOLINERGIC MECHANISMS INVOLVED IN HEAD-SHAKING OF INFANT 001380 02-04 BLOCKADE OF BOTH PILOCARPINE AND AMPHETAMINE-INDUCED HEAD-SHAKING WITH DOPAMINE RECEPTOR ANTAGONISTS.

002951 04-03

HEAD-TWITCH
QUIPAZINE-INDUCED HEAD-TWITCH IN MICE.

000189 01-03

003021 04-03

VOLUME 16, SUBJECT INDEX		Subject Index
MODIFICATION OF THE 5 HYDROXYTRYPTOPHAN-INDUCED RESPONSE BY EXOGENOUS ENDOCRINE AGENTS.	HEAD-TWITCH 003177 04-04	HELPLESSNESS THE EFFECTS OF DL-P-CHLOROPHENYLALANINE ON LEARNED HELPLESSNESS IN THE RAT.
HEADACHE TREATING THE HEADACHE BY TREATING THE DEPRESSION.		HEMIEALLISM 000311 01-04
LITHIUM PROPHYLAXIS FOR CHRONIC CLUSTER HEADACHE	000606 01-10	TREATMENT OF VASCULAR HEMIBALLISM AND HEMICHOREA. 000637 01-11
NEW TREATMENT FOR HEADACHE: PATHOPHYSIOLOGIC CONSIDERATIONS.	000641 01-11	TREATMENT OF VASCULAR HEMIBALLISM AND HEMICHOREA. 000637 01-11
HEADACHES	000961 01-17	HEMINEURIN CHLORMETHIAZOLE (HEMINEURIN).
DRUG DEPENDENCY IN PATIENTS WITH CHRONIC HEADACI	HES. 000863 01-15	HEMINEVEIN 001750 02-15
HEADACHES AND COFFEE.	000873 01-15	EFFECTS OF CHLORMETHIAZOLE (HEMINEVRIN) ON DRUG DISCRIMINATION AND OPEN-FIELD BEHAVIOR IN GERBILS. 003371 04-04
THE AMPHETAMINES: MEDICAL USES AND HEALTH HAZA	000842 01-15	MARIJUANA: DIFFERENTIAL EFFECTS ON RIGHT AND LEFT HEMISPHERE
PSYCHIATRIC DRUGS FOR THE NONMEDICAL MENTAL HEA	000953 01-17	FUNCTIONS IN MAN. 001733 02-14
AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL WORLD HEALTH ORGANIZATION COLLABORATIVE STUD		MEMISPHERIC HEMISPHERIC ASYMMETRY OF VISUAL EVOKED-POTENTIALS WITH MOTOR IMBALANCE IN RATS.
RESEARCH FINDINGS ON CHRONIC MENTAL ILLNESS: A M CONTINUING-CARE IN THE HEALTH MAINTENANCE ORG.	ODEL FOR	O03310 04-04 ON THE ROLE OF HEMISPHERIC DOMINANCE IN SCHIZOPHRENIA AS MEASURED BY EXTRAPYRAMIDAL SIDE-EFFECTS OF NEUROLEPTICS.
PHARMACOKINETICS OF OXAZEPAM IN HEALTHY VOLUNT	TEERS. 000685 01-13	HEMODIALYSIS 003675 04-15
PHARMACOKINETICS OF N DESMETHYLDIAZEPAM IN HEA VOLUNTEERS AFTER SINGLE DAILY DOSES OF DIPOTASS	LTHY	LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUSION IN IMIPRAMINE POISONING. 000477 01-05
CHLORAZEPATE. THEORETICAL AND METHODOLOGICAL ASPECTS OF PSYCH	000728 01-13 OTROPIC DRUG	MANIA DURING MAINTENANCE HEMODIALYSIS SUCCESSFULLY TREATED WITH ORAL LITHIUM-CARBONATE. 000582 01-09
TRIALS USING HEALTHY SUBJECTS. SERUM GONADOTROPIN AND TSH LEVELS AFTER TRICYCL	000918 01-16 IC	LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUSION IN IMPRAMINE POISONING. AN IN-VITRO AND IN-VIVO STUDY. 001503 02-05
ANTIDEPRESSANTS IN HEALTHY MALES. DIFFERENTIAL EFFECTS OF A SINGLE DOSE OF IMIPRAMINE		THE HUMAN EEG IN SEVERELY POISONED PATIENTS INDICATION AND CONTROL OF HEMODIALYSIS OR HEMOPERFUSION. 001795 02-15
LOPRAMINE IN HEALTHY SUBJECTS VARYING IN THEIR DEPRESSION.	002446 03-09	CARBROMAL INTOXICATION — HEMODIALYSIS OR HEMOPERFUSION?. 001800 02-15
EFFECTS OF LITHIUM IN HEALTHY TEST PERSONS.	002647 03-15	PSYCHOLOGICAL SEQUELAE TO HEMODIALYSIS. 003661 04-15
ALOSTERIC CHANGES IN PLASMA PROTEINS IN HEALTHY AFTER ADMINISTRATION OF LYSERGAMIDE.	VOLUNTEERS	HEMODYNAMIC HEMODYNAMIC EFFECTS FOLLOWING TOXIC DOSES OF TRICYCLIC ANTIDEPRESSANTS.
EART	003584 04-12	001838 02-15 HEMODYNAMICS
EFFECTS OF PHENOBARBITAL AND DIAZEPAM ON IMIPRAL CHANGES IN BLOOD PRESSURE, HEART RATE AND RECT TEMPERATURE OF RATS.	TAL	EFFECTS OF METHADONE ON RESPIRATION AND HEMODYNAMICS OF PREGNANT WOMEN. 002628 03-14
TOLERANCE TO MARIJUANA: HEART RATE AND SUBJECTI		HEMOLYSIS
EFFECTS OF BUTYROPHENONES ON THE SYMPATHETIC NEI ISOLATED RABBIT HEART AND ON THE POSTSYNAPTIC		EFFECT OF DRUGS ON HUMAN ERYTHROCYTES — 4. PROTECTING EFFECT OF DEXTRAN ON DRUG-INDUCED HEMOLYSIS. 003603 04-13
ADRENOCEPTORS OF THE ISOLATED RABBIT AORTA.	002026 03-03	HEMOLYTIC CHLORPROMAZINE-INDUCED HEMOLYTIC ANEMIA IN ANOREXIA-
STRESS AND THE HEART: INTERACTIONS OF THE CARDION SYSTEM, BEHAVIORAL STATE, AND PSYCHOTROPIC DR	/ASCULAR	NERVOSA. 000847 01-15
EFFECT OF () AMPHETAMINE ON THE RETENTION OF H3-	002711 03-15	HEMOPERFUSION LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUSION IN
CATECHOLAMINES IN SLICES OF NORMAL AND RESERPI BRAIN AND HEART.	003071 04-03	IMIPRAMINE POISONING. 000477 01-05 LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUSION IN
DOPAMINE-BETA-HYDROXYLASE RELEASE FOLLOWING AC SYMPATHETIC NERVE STIMULATION OF THE HEART, SP MESENTERY.	PLEEN AND	IMIPRAMINE POISONING. AN IN-VITRO AND IN-VIVO STUDY. 001503 02-05 SEVERE MEPROBAMATE POISONING: SUCCESSFUL TREATMENT WITH
HEARTRATE	003422 04-06	HEMOPERFUSION. 001764 02-15
PROPRANOLOL: HEARTRATE AND REFLEXES DURING A TA	NSK. 002548 03-13	THE HUMAN EEG IN SEVERELY POISONED PATIENTS — INDICATION AND CONTROL OF HEMODIALYSIS OR HEMOPERFUSION. 001795 02-15
A COMPARISON IN RABBIT ISOLATED HEARTS OF THE		CARBROMAL INTOXICATION — HEMODIALYSIS OR HEMOPERFUSION?. 001800 02-15
DYSZHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE, M AND MIANSERIN IN RELATION TO THEIR ABILITY TO BL NORADRENALINE UPTAKE.	.OCK	THE ROLE OF CHARCOAL HEMOPERFUSION IN THE ACTIVE MANAGEMENT OF POISONING.
IEAT	000138 01-03	HEMOPERFUSION IN TREATMENT OF DRUG INTOXICATION.
EFFECT OF PSYCHOTROPIC AGENTS ON THE PHYSICAL PER CAPACITY OF ANIMALS EXPOSED TO HEAT AND COLD.	002273 03-04	O02656 03-15 CHARCOAL HEMOPERFUSION AND ANTIDEPRESSANT OVERDOSE. 002774 03-17
HEAT ILLNESS SYNDROME AND LITHIUM INTOXICATION.	002669 03-15	HEPATIC EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON
PROSTAGLANDINS AND CANNABIS VI. RELEASE OF AR. FROM HELA CELLS BY DELTA1-TETRAHYDROCANNABIN		HEPATIC FUNCTIONS. 000119 01-03 INDUCIBLE ALDEHYDE-DEHYDROGENASES IN THE HEPATIC CYTOSOL OF
CANNABINOIDS.	002850 04-03	THE RAT. 001261 02-03

DECREASED FEEDING IN RATS FOLLOWING HEPATIC PORTAL INFUSION OF GLUCAGON.

QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P-450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3 METHYCHOLANTHRENE.

CLINICAL LABORATORY STUDIES WITH SPECIAL REGARD TO HEPATIC METABOLISM IN SCHIZOPHRENICS ON OUTPATIENT LONG-TERM NEUROLEPTIC MEDICATION.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — III. THE INFLUENCE OF THE 1, 4, 5, 6 TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — I. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM -- II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH.

SUBCELLULAR LOCALIZATION OF C14-METHAQUALONE IN MOUSE BRAIN: EFFECTS OF HEPATIC MICROSOMAL ENZYME INHIBITION.

THE DEVELOPMENT OF SEX DIFFERENCES IN THE DEMETHYLATION OF ETHYLMORPHINE AND IN ITS INTERACTION WITH COMPONENTS OF THE HEPATIC MICROSOMAL CYTOCHROME-P-450 SYSTEM IN MICE. 003122 04-03

HEPATITIS NECROTIZING ANGIITIS AND HEPATITIS IN AN AMPHETAMINE ABUSER. 000887 01-15

HEPATOCYTES

ADVERSE EFFECTS OF CHLORPROMAZINE METABOLITES ON ISOLATED HEPATOCYTES.

O01502 0 001502 02-05

DISULFIRAM HEPATOTOXICITY.

000886 01-15 HEREDITARY COPROPORPHYRIA AND EPILEPSY.

000635 01-11 VARIABLES IN THE PROLONGED PREFERENCE OF HEROIN OR

000778 01-14

RESPONSES TO INTRAVENOUS HEROIN IN DEPENDENT AND NONDEPENDENT VOLUNTEERS. 000792 01-14

HEROIN IN THE TREATMENT OF MORPHINE ADDICTION

PROPOXYPHENE-NAPSYLATE (DARVON-N OR PN) IN THE TREATMENT OF HEROIN DEPENDENCE.

000979 01-17 CLINIC ATTENDANCE AND OPIATE PRESCRIPTION STATUS OF HEROIN ADDICTS OVER A SIX-YEAR PERIOD.

000989 01-17 RESTRAINT ALTERS THE EFFECTS OF MORPHINE AND HEROIN ON CORE TEMPERATURE IN THE RAT. 001186 02-03

REDUCTION OF HEROIN SELF-ADMINISTRATION IN BABOONS BY MANIPULATION OF BEHAVIORAL AND PHARMACOLOGICAL CONDITIONS. 001499 02-04

THE EFFECTS OF DARVON-N ON RETENTION OF SPECIFIC LEARNING TASKS DURING HEROIN DETOXIFICATION. (PH.D. DISSERTATION). 001703 02-14

EFFECT OF MATERNALLY ADMINISTERED HEROIN ON THE MOTOR ACTIVITY OF RAT OFFSPRING.

NEW APPROACH TO THE REHABILITATION OF THE HARD CORE DRUG ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY STUDY.

002531 03-11 METHADONE DOSE, PLASMA LEVEL, AND CROSS-TOLERANCE TO HEROIN

002642 03-14 SCHEDULE-INDUCED SELF-INJECTION OF NICOTINE, METHADONE AND HEROIN BY NAIVE ANIMALS.

003321 04-04 HEROIN AND OTHER HUMANISTIC TREATMENT FOR THE TERMINALLY ILL 003703 04-17

HETERCOATOM SYNTHESIS OF SPIROISOBENZOFURANPIPERIDINES AS POTENTIAL
CENTRAL-NERVOUS-SYSTEM AGENTS. 2. COMPOUNDS CONTAINING A
HETERCOATOM ATTACHED TO NITROGEN. 000167 01-03 HETEROCYCLIC
STUDIES IN THE HETEROCYCLIC SERIES. XIII. NEW CNS DEPRESSANTS
DERIVED FROM 1,9 DIAZAPHENOXAZINE AND TWO ISOMERIC
TRIAZAPHENOTHIAZINE RING SYSTEMS.

INTRAOCULAR PRESSURE LOWERING PROPERTIES OF ABBOTT-43981, A CANNABINOID DERIVED HETEROCYCLIC BENZOPYRAN WITH MINIMAL CNS ACTIVITIES.

001025 02-02 HETEROGENEITY
HETEROGENEITY OF LSD DISPLACING FACTORS AND MULTIPLE TYPES OF
HIGH AFFINITY LSD BINDING SITES.
003099 04-0 003099 04-03

SOME BEHAVIORAL EFFECTS OF SP6-11 HEXAPEPTIDE C-TERMINAL OF SUBSTANCE-P INJECTED INTO THE CEREBRAL VENTRICLES IN RATS. 002267 03-04

HEXOBARBITAL
PHARMACOKINETICS OF HEXOBARBITAL IN THE PREGNANT AND
NONPREGNANT STUMPTAILED MONKEY.

001104 02-03 HEXOBARBITAL-EPOXIDE: A POSSIBLE INTERMEDIATE IN THE METABOLISM OF HEXOBARBITAL.

POTENTIATION OF HEXOBARBITAL AND AMPHETAMINE EFFECTS IN MALE AND FEMALE RATS PHYSICALLY DEPENDENT ON MORPHINE. 003275 04-04

HEXOBARBITAL-EPOXIDE
HEXOBARBITAL-EPOXIDE: A POSSIBLE INTERMEDIATE IN THE
METABOLISM OF HEXOBARBITAL.

THE EFFECT OF ANESTHESIA ON BRAIN MITOCHONDRIAL HEXOKINASE.

001058 02-03

THE HIDDEN COST OF MIND MEDICINES.

HIGH-AFFINITY
HIGH-AFFINITY BINDING OF H3-GLYCINE AND C14-BETA-ALANINE TO
SYNAPTOSOMAL MITOCHONDRIAL FRACTIONS OF RAT CNS REGIONS; EFFECTS OF STRYCHNINE.

000211 01-03 HIGH-AFFINITY H3-SEROTONIN BINDING TO CAUDATE: INHIBITION BY HALLUCINGGENS AND SEROTONINERGIC DRUGS.

003138 04-03

HIGH-DOSE TOXICITY OF HIGH-DOSE FLURAZEPAM IN THE ELDERLY.

000630 01-11

H-ENERGY

EFFECTS OF BETA-BUNGAROTOXIN, DIPHENYLHYDANTOIN AND

METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT
CATIONS AND HIGH-ENERGY PHOSPHATE CONTENTS OF BRAIN SLICES.

000278 01-03

HIGH-PERFORMANCE
THE EXTRACTION AND ANALYSIS OF BENZODIAZEPINES IN TISSUES BY ENZYMIC DIGESTION AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY. 000928 01-16

MEASUREMENT OF PLASMA ANTIDEPRESSANT LEVELS BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY. 002720 03-16

H-POTENCY
CATATONIC REACTIONS TO HIGH-POTENCY NEUROLEPTIC DRUGS.
000835 01-15 EXTRAPYRAMIDAL REACTIONS IN ADOLESCENTS TREATED WITH HIGH-POTENCY ANTIPSYCHOTICS.

002654 03-15 HIGH-POTENCY AND LOW-POTENCY NEUROLEPTICS IN ELDERLY PSYCHIATRIC PATIENTS.

003450 04-08 HIGH-PRESSURE LIQUID CHROMATOGRAPHIC MASS SPECTROMETRIC DETERMINATION OF DELTA9-TETRAHYDROCANNABINOL IN HUMAN

PLASMA FOLLOWING MARIJUANA SMOKING. 000682 01-12

IMODAL DISTRIBUTIONS OF HIGHEST ETHANOL ACCEPTANCE CONCENTRATIONS IN TWO STRAINS OF RATS. 003229 04-04

EVIDENCE FOR DISTINCT SPINAL LOCOMOTION GENERATORS SUPPLYING RESPECTIVELY FORELIMBS AND HINDLIMBS IN THE RABBIT. 003124 04-03

DRUG REFUSAL IN SCHIZOPHRENIA: CAUSES AND PRESCRIBING HINTS 002709 03-15

ACTIONS OF IONTOPHORETIC PHENYTOIN AND MEDAZEPAM ON HIPPOCAMPAL NEURONS.

000196 01-03

002170 03-03

002674 03-15

	HIPPOCAMPA			TO	AFFERENT
STIMULAT	ION DURING	CONDITION	ING.		000260 01-03

BENZODIAZEPINES, BARBITURATES, AND HIPPOCAMPAL INHIBITION. 000300 01-03 ATTENUATION OF THE RATE DECREASING EFFECTS OF AMPHETAMINE ON

FIXED-RATIO RESPONDING IN RATS BY HIPPOCAMPAL LESIONS. 000474 01-04 EFFECTS OF BRAIN LESIONS AND ATROPINE ON HIPPOCAMPAL AND

NEOCORTICAL ELECTROENCEPHALOGRAMS IN THE RAT.

00 1033 02-02
THE INFLUENCE OF ELECTRICAL STIMULATION ON THE HIPPOCAMPAL UNITS ACTIVITY OF THE RABBIT.

INITS ACTIVITY OF THE RABBIT. 001314 02-04

THE HIPPOCAMPAL SLICE: A SYSTEM FOR STUDYING THE PHARMACOLOGY OF SEIZURES AND FOR SCREENING ANTICONVULSANT DRUGS.

001538 02-06
EFFECTS OF DIAZEPINES AND BARBITURATES ON HIPPOCAMPAL
RECURRENT IMMIBITION.

OO2181 03-03
INCREASE OF HIPPOCAMPAL ACETYLCHOLINE TURNOVER RATE AND THE
STRETCHING YAWNING SYNDROME ELICITED BY ALPHA-MSH AND
ACTH.

EFFECTS OF URETHANE ON HIPPOCAMPAL UNIT ACTIVITY IN THE RAT.
003011 04-03

PARALLEL CHANGES IN BEHAVIOR AND HIPPOCAMPAL MONOAMINE METABOLISM IN RATS AFTER ADMINISTRATION OF ACTH ANALOGUES. 003335 04-04

HIPPOCAMPUS

EFFECTS OF RETICULAR STIMULATION, D AMPHETAMINE AND

SCOPOLAMINE ON ACETYLCHOLINE RELEASE FROM THE HIPPOCAMPUS
OF BRAINSTEM TRANSECTED CATS.

000098 01-03
THE ROLE OF THE SEPTAL NUCLEI IN THE RELEASE OF ACETYLCHOLINE
FROM THE RABBIT CEREBRAL-CORTEX AND DORSAL HIPPOCAMPUS
AND THE EFFECT OF ATROPINE.

000101 01-03
DELTA9-TETRAHYDROCANNABINOL AND THE HIPPOCAMPUS: EFFECTS ON CA1 FIELD POTENTIALS IN RATS.

O00287 01-03
THE EFFECT OF INTRAHIPPOCAMPAL KAINIC-ACID INJECTIONS AND SURGICAL LESIONS ON NEUROTRANSMITTERS IN HIPPOCAMPUS AND

SURGICAL LESIONS ON NEUROTRANSMITTERS IN HIPPOCAMPUS AND SEPTUM.

002911 04-03

EVIDENCE OF AN INTERACTION BETWEEN SEROTONINERGIC AND

CHOLINERGIC NEURONS IN THE CORPUS-STRIATUM AND HIPPOCAMPUS
OF THE RAT BRAIN.

003074 04-03

MICROINJECTION OF KAINIC-ACID INTO THE RAT HIPPOCAMPUS.

033081 04-03
THE ACETYLCHOLINE RECEPTOR IN THE RAT HIPPOCAMPUS; NICOTINIC,

MUSCARINIC OR BOTH?. 003082 04-03

AMINE
TRICYCLIC ANTIDEPRESSANT DRUGS BLOCK HISTAMINE H2 RECEPTOR IN

000128 01-03

ALTERATIONS IN BRAIN HISTAMINE AND HISTIDINE-DECARBOXYLASE
ACTIVITY AFTER HALOPERIDOL AND IMPRAMINE.

HISTAMINE STIMULATED ADENYLATE-CYCLASE: BLOCKADE BY
IMIPRAMINE AND ITS ANALOGUES.

IMIPRAMINE AND ITS ANALOGUES.

ONSET AND OFFSET OF CHLORPROMAZINE BLOCKADE OF

PHENYLEPHRINE, CARBAMYLCHOLINE AND HISTAMINE ON RABBIT STOMACH STRIPS.

001234 02-03

HISTAMINE H2-RECEPTORS IN THE BRAIN AND SLEEP PRODUCED BY CLONIDINE.

001483 02-04
THE INFLUENCE OF HISTAMINE ON METABOLISM OF DOPAMINE AND
SEROTOMIN IN THE RAT STRIATUM.

002288 03-04 HISTAMINE H2-RECEPTOR BINDING WITH H3-CIMETIDINE IN BRAIN. 002848 04-03

HISTIDINE-DECARBOXYLASE
ALTERATIONS IN BRAIN HISTAMINE AND HISTIDINE-DECARBOXYLASE
ACTIVITY AFTER HALOPERIDOL AND IMIPRAMINE.

HISTOCHEMICAL 001188 02-03

HISTOCHEMICAL EFFECTS OF KAINIC-ACID ON NEOSTRIATAL DOPAMINE AND ACETYLCHOLINESTERASE. 002851 04-03 DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: A

DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: A VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIATION OF CATECHOLAMINERGIC AND SEROTONINERGIC TERMINALS IN RAT CEREBRAL STRUCTURES.

003423 04-06

HISTOCOMPATIBILITY
HISTOCOMPATIBILITY ANTIGENS IN LITHIUM TREATED MANICDEPRESSIVE PATIENTS.

HISTOFLUORESCENCE
HISTOFLUORESCENCE OF KAINIC-ÁCID-INDUCED STRIATAL LESIONS.
003433 04-06

EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT BRAIN: A QUANTITATIVE HISTOLOGICAL STUDY.

000184 01-03

HISTORICAL
HISTORICAL AND CULTURAL FACTORS INFLUENCING CANNABIS USE
AMONG INDIANS IN SOUTH-AFRICA.

HIGH STATES IN CULTURE HISTORICAL PERSPECTIVE. 000675 01-12

MATERNAL DRUG HISTORIES AND CONGENITAL ABNORMALITIES.
001780 02-15

001780 02-1

MISTORY
BEHAVIORAL HISTORY AS A DETERMINANT OF THE EFFECTS OF D

AMPHETAMINE ON PUNISHED BEHAVIOR.

001306 02-04

THE AMYTAL INTERVIEW: HISTORY AND CURRENT USES.

TARDIVE-DYSKINESIA AND PSYCHOTROPIC DRUG HISTORY

002767 03-17

DRUG HISTORY AND TARDIVE-DYSKINESIA. 003680 04-15

PHARMACOLOGICAL MANIPULATION OF HOARDING: FURTHER ANALYSIS
OF AMPHETAMINE ISOMERS AND PIMOZIDE.

001312 02-04

HOE-984

EFFECTS OF NOMIFENSINE (HOE-984) UPON PSYCHOMOTOR ACTIVITY

AND INTRACRANIAL SELF-STIMULATION IN THE RAT.

HOFMANN
PSYCHOPHARMACOLOGICAL STUDIES ON (-) NUCIFERINE AND ITS
HOFMANN DEGRADATION PRODUCT ATHEROSPERMININE.

HOPMANN DEGRADATION PRODUCT ATHEROSPERMININE.

002824 04-03

HOLDS
HOW CANADA HOLDS DOWN DRIIG COSTS.

HOLE-BOARD
THE EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY AND
STEREOTYPED BEHAVIOUR OF RATS STUDIED ON A HOLE-BOARD.

STEREOTYPED BEHAVIOUR OF RATS STUDIED ON A HOLE-BOARD.
002274 03-04

COMPARISON OF THE EFFECTS OF NOCTRAN-10 ON HOSPITALIZED

PATIENTS AND PATIENTS TREATED AT HOME.

O01724 02-14

HOMEOSTATIC
DISTURBANCE OF HOMEOSTATIC REGULATION OF ADDENAL FUNCTION IN

DISTURBANCE OF HOMEOSTATIC REGULATION OF ADRENAL FUNCTION IN
PATIENTS WITH ENDOGENOUS DEPRESSION.

003515 04-09

THE ACCUMULATION OF P-HYDROXYAMPHETAMINE BY BRAIN HOMOGENATES AND ITS ROLE IN THE RELEASE OF CATECHOLAMINES. 000074 01-03

THE EFFECT OF DIHYDROERGOTOXINE ON THE ADENYLATE-CYCLASE ACTIVITY IN HOMOGENATES OF RAT CEREBRAL-CORTEX.

O01254 02-03
BETA-ADRENERGIC RECEPTOR MEDIATED CYCLIC-AMP SYNTHESIS IN BROKEN-CELL HOMOGENATES OF RAT BRAIN.

O02033 03-03

EFFECTS OF BIOGENIC AMINES AND PSYCHOTROPIC DRUGS ON

ENDOGENOUS PROSTAGLANDIN BIOSYNTHESIS IN THE RAT BRAIN
HOMOGENATES.

5 GUANYLYLIMIDODIPHOSPHATE ACTIONS ON ADENYLATE-CYCLASE IN HOMOGENATES OF RAT CEREBRAL-CORTEX PLUS NEURONAL AND CAPILLARY FRACTIONS.

HOMOLOGOUS
PHARMACOKINETICS OF SOME HOMOLOGOUS SERIES OF BARBITURATES
IN THE INTACT RAT AND IN THE ISOLATED PERFUSED RAT LIVER.
001292 02-03

HOMOSEXUAL
TREATMENT OF OBSESSIVE HOMOSEXUAL PEDOPHILIC FANTASIES WITH
MEDROXYPROGESTERONE-ACETATE.

HOMOVANILLIC-ACID

CEREBROSPINAL FLUID HOMOVANILLIC-ACID IN MALE ALCOHOLICS:
EFFECTS OF DISULFIRAM.

O00645 01-11
CYANOCYPROHEPTADINE: ROLE OF CHOLINOLYTIC PROPERTIES IN
MODULATING NEUROLEPTIC-INDUCED ELEVATION OF STRIATAL
HOMOVANILLIC-ACID (HVA).
001226 02-03

TOLERANCE TO STEREOTYPED BEHAVIOUR AND TO DECREASE IN STRIATAL HOMOVANILLIC-ACID LEVELS AFTER REPEATED TREATMENT WITH APOMORPHINE-DIPIVALOYL-ESTER.

ASPECTS OF INFLUX AND EFFLUX OF HOMOVANILLIC-ACID OF RAT CEREBROSPINAL FLUID.

002807 04-03 ROUTINE MEASUREMENT OF HOMOVANILLIC-ACID IN RAT BRAIN BY GAS-LIQUID-CHROMATOGRAPHY

HOMOVANILLIC-ACID IN HUMAN CSF: COMPARISON OF FLUOROMETRY AND GAS-CHROMATOGRAPHY MASS-SPECTROMETRY.

A COMPARISON BETWEEN FLUOROMETRIC AND MASS
FRAGMENTOGRAPHIC DETERMINATIONS OF HOMOVANILLIC-ACID AND
5 HYDROXYINDOLEACETIC-ACID IN HUMAN CEREBROSPINAL FLUID.
003694 04-16

HOMOVANILLIC-ACIDS
SIMILAR EFFECTS OF TRYPTOPHAN AND SLEEP ON CISTERNAL
CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC AND HOMOVANILLIC-001440 02-04

HORMONAL
ANTAGONISM OF PENTOBARBITAL-INDUCED HORMONAL CHANGES BY TRH IN RATS.

EFFECTS OF THYROTROPIN-RELEASING HORMONE ON BEHAVIORAL AND HORMONAL CHANGES INDUCED BY BETA-ENDORPHIN.

MORPHINE-LIKE PEPTIDES OF BRAIN AND THEIR RELATION TO HORMONAL NEUROTRANSMITTERS.

RECEPTOR SENSITIVITY MODIFICATION (RSM) — A NEW PARADIGM FOR THE POTENTIAL TREATMENT OF SOME HORMONAL AND TRANSMITTER DISTURBANCES.

001659 02-13 A NEW APPROACH TO THE HORMONAL TREATMENT OF IMPOTENTIA-ERECTIONIS.

002386 03-07 IMPOTENCE: ROLE OF DRUG AND HORMONAL TREATMENT 002759 03-17

POTENT PROLACTIN AND GROWTH HORMONE RELEASING ACTIVITY OF MORE ANALOGUES OF MET-ENKEPHALIN.

000019 01-02 COMPARISON OF THYROTROPIN-RELEASING HORMONE WITH MELANOCYTE-STIMULATING HORMONE RELEASE INHIBITING FACTOR AS PENTOBARBITAL ANTAGONISTS IN MONKEYS.

EFFECTS OF APOMORPHINE AND CLONIDINE ON RAT PLASMA GROWTH HORMONE AFTER PRETREATMENT WITH RESERPINE AND ELECTROCONVULSIVE SHOCKS.

000102 01-03 AMINERGIC AND THERMOREGULATORY MECHANISMS IN HYPOTHALAMIC REGULATION OF GROWTH HORMONE IN CATS 000249 01-03

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON PENTOBARBITAL-INDUCED DECREASE IN CHOLINERGIC NEURONAL

EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH MORPHOLOGY AND HORMONE PLASMA LEVELS.

000315 01-04 UP FROM DEPRESSION WITH A SYNTHETIC MALE HORMONE

000581 01-09 MORPHINE DECREASES LUTEINIZING HORMONE BY AN ACTION ON THE HYPOTHALAMIC PITUITARY AXIS.

THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDROCANNABINOL (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HORMONE (FSH) AND LUTEINIZING HORMONE (IH) IN THE OVARIECTOMIZED RHESUS MONKEY.

001245 02-03 EFFECTS OF THYROTROPIN-RELEASING HORMONE ON BEHAVIORAL AND HORMONAL CHANGES INDUCED BY BETA-ENDORPHIN.

AN EVALUATION OF A UNIQUE NEW ANTIPSYCHOTIC AGENT, SULPIRIDE: EFFECTS ON SERUM PROLACTIN AND GROWTH HORMONE LEVELS. HORMONE RELEASE IN DEPRESSED PATIENTS BEFORE AND AFTER

RECOVERY 001590 02-09

THYROID FUNCTION AND GROWTH HORMONE SECRETION IN AMITRIPTYLINE TREATED DEPRESSION.

001596 02-09 THE EFFECT OF LITHIUM ON LUTEINIZING HORMONE AND TESTOSTERONE IN MAN

PITUITARY HORMONE RELEASE IN VITRO BY MORPHINE-LIKE PEPTIDES. 001975 03-03

Psychopharmacology Abstracts

STIMULANT ACTION OF THYROTROPIN-RELEASING HORMONE ON CAT SPINAL CORD.

BLOCKAGE OF PROGESTERONE-INDUCED RELEASE OF LUTEINIZING HORMONE AND PROLACTIN BY D AMPHETAMINE AND FENFLURAMINE IN RATS.

STUDIES ON THE NEUROPHARMACOLOGY OF THYROTROPIN-RELEASING HORMONE (TRH) AND A NEW TRH ANALOG.

THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MALE

002343 03-05 HORMONE RESPONSES TO METHYLAMPHETAMINE IN DEPRESSION: A NEW APPROACH TO THE NORADRENALINE DEPLETION HYPOTHESIS.

002424 03-09 BROMOCRIPTINE: EFFECT ON SERUM PROLACTIN AND GROWTH HORMONE IN PSYCHOGERIATRIC HOSPITAL PATIENTS.

LUTEINIZING HORMONE RELEASING HORMONE AND THYROTROPIN-RELEASING HORMONE STIMULATION STUDIES IN PATIENTS GIVEN CLOMIPRAMINE OR DEPOT NEUROLEPTICS.

002563 03-13 THE IMPACT OF CLOMIPRAMINE AND ITS WITHDRAWAL ON SOME NOCTURNAL HORMONE PROFILES -- A PRELIMINARY REPORT.

002572 03-13 DEXTROAMPHETAMINE AND L AMPHETAMINE ARE EQUIPOTENT IN RELEASING HUMAN GROWTH HORMONE.

002576 03-13 EFFECTS OF MSH/ACTH4-10 ON MEMORY, ATTENTION, AND ENDOGENOUS HORMONE LEVELS IN WOMEN.

002641 03-14 CENTRAL EFFECT OF SOMATOSTATIN ON THE SECRETION OF GROWTH HORMONE IN THE ANESTHETIZED RAT.

002803 04-03 MODIFICATION OF NUCLEAR RETENTION OF H3-ESTRADIOL BY CELLS OF THE HYPOTHALAMUS AS A FUNCTION OF EARLY HORMONE

002891 04-03

MOUSE BRAIN TYROSINE-HYDROXYLASE AND GLUTAMIC-ACID-DECARBOXYLASE FOLLOWING TREATMENT WITH ADRENOCORTICOTROPHIC HORMONE, VASOPRESSIN OR CORTICOSTERONE

MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II.

002994 04-03 THYROTROPIN-RELEASING HORMONE (TRH): LACK OF EFFECT ON SHOCK-ELICITED FIGHTING (SEF) IN RATS.

TREATMENT OF ENDOGENOUS DEPRESSION WITH ORAL THYROTROPIN-RELEASING HORMONE AND AMITRIPTYLINE.

A CASE OF DEPRESSION SHOWING IMPROVEMENT IN TRH TEST BY COMBINED TREATMENT BY DIMETACRINE-TARTRATE AND THYROID

003527 04-09 GROWTH HORMONE, PROLACTIN AND CORTISOL RESPONSES AND GROWTH PATTERNS IN HYPERKINETIC CHILDREN TREATED WITH DEXTROAMPHETAMINE. PRELIMINARY FINDINGS.

003569 04-11 SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE (SIADH) SECONDARY TO ANTIPSYCHOTIC DRUG THERAPY

003647 04-15 **DOCTORS DEBATE BRAIN HORMONE DILEMMAS**

003718 04-17

OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH MORPHOLOGY AND HORMONE PLASMA LEVELS.

000315 01-04 EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: I. BEHAVIOURAL EFFECTS OF INTRAMUSCULAR INJECTIONS.

000316 01-04 SEX HORMONES AND EXHIBITIONISM 000788 01-14

THE RISKS OF SEX HORMONES AS DRUGS.

000850 01-15 THE EFFECT OF STEROID HORMONES ON CEREBRAL BLOOD FLOW BEFORE AND AFTER INTRACAROTID INFUSION OF 5 HYDROXYTRYPTAMINE.

001193 02-03 THE EFFECTS OF HORMONES AND MORPHINE ON BOTH ANALGESIA AN THE LORDOSIS RESPONSE PRODUCED BY CERVICAL PROBING IN THE

IMPACT OF AGE ON ANTERIOR PITUITARY HORMONES IN ADULT MALES. 001687 02-13 QUANTITATIVE PHARMACO-EEG WITH STEROIDAL HORMONES 002566 03-13

EVIDENCE FOR THE ROLE OF ADRENOCORTICAL HORMONES IN THE REGULATION OF NORADRENALINE AND DOPAMINE METABOLISM IN CERTAIN BRAIN AREAS.

HOSPITAL

EXPERIENCE WITH A CLINICAL PHARMACOLOGICAL SERVICE IN A TEACHING HOSPITAL 000957 01-17

MAINTENANCE ANTIPSYCHOTIC PHARMACOTHERAPY, RELAPSE, AND LENGTH OF STAY OUT OF THE HOSPITAL IN CHRONIC SCHIZOPHRENICS

001911 02-17 BROMOCRIPTINE: EFFECT ON SERUM PROLACTIN AND GROWTH HORMONE IN PSYCHOGERIATRIC HOSPITAL PATIENTS.

002561 03-13 THE USE OF PRESCRIPTION DRUGS IN TREATMENT OF FIRST-TIME PSYCHIATRIC ADMISSIONS TO UNIVERSITY HOSPITAL, SASKATOON. 003712 04-17

COMPARISON OF THE EFFECTS OF NOCTRAN-10 ON HOSPITALIZED PATIENTS AND PATIENTS TREATED AT HOME.

001724 02-14 A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF LOXAPINE DIAZEPAM, AND PLACEBO IN HOSPITALIZED PATIENTS WITH VARIOUS STATES OF ANXIETY

002496 03-10 TARDIVE-DYSKINESIA: AGE AND SEX DIFFERENCES IN HOSPITALIZED SCHIZOPHRENICS.

003681 04-15 HOSPITALS

PATTERNS OF ANTIPSYCHOTIC DRUG USE IN FOUR SOUTHEASTERN STATE HOSPITALS 000963 01-17

THE USE OF PSYCHOTROPIC DRUGS IN STATE HOSPITALS: A LEGAL OR MEDICAL DECISION?. 002730 03-17

HOSTILITY DIAZEPAM-INDUCED HOSTILITY IN DEPRESSION. (UNPUBLISHED PAPER) EFFECTS OF CHLORDIAZEPOXIDE AND OXAZEPAM ADMINISTRATION ON

VERBAL HOSTILITY. 001720 02-14

HOUSING THE EFFECT OF HOUSING AND GENDER ON MORPHINE SELF-ADMINISTRATION IN RATS

003158 04-04

STUDIES OF SEROTONIN TURNOVER IN DISCRETE NUCLEI USING HPLC. (UNPUBLISHED PAPER). 000500 01-06

HUMAN EFFECT OF CHLORDIAZEPOXIDE ADMINISTERED EARLY IN EXTINCTION ON SUBSEQUENT EXTINCTION OF A CONDITIONED EMOTIONAL RESPONSE IN RATS: IMPLICATIONS FOR HUMAN CLINICAL USE.

000022 01-02 AN ANIMAL SCREENING TEST FOR DRUGS THAT PREDICTS THE

LIKELIHOOD OF HUMAN PHYSICAL DEPENDENCE 000028 01-02 EFFECTS OF RESERPINE AND IMIPRAMINE ON VESICULAR SEROTONIN UPTAKE AND STORAGE IN INTACT HUMAN PLATELETS

000081 01-03 PHARMACOLOGICAL TREATMENT FOLLOWING EXPERIMENTAL CEREBRAL INFARCTION: IMPLICATIONS FOR UNDERSTANDING PSYCHOLOGICAL SYMPTOMS OF HUMAN STROKE.

000243 01-03 POSSIBLE SIGNIFICANCE OF ACTH FRAGMENTS FOR HUMAN MENTAL

000465 01-04 ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: INTERACTIVE EFFECTS ON HUMAN PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS. II.

000673 01-12 THE FUNCTION OF DRUG RITUALS IN HUMAN SOCIETY: CONTINUITIES AND CHANGES

000674 01-12 HIGH-PRESSURE LIQUID CHROMATOGRAPHIC MASS SPECTROMETRIC DETERMINATION OF DELTA9-TETRAHYDROCANNABINOL IN HUMAN PLASMA FOLLOWING MARLIUANA SMOKING

INTERACTIONS OF NARCOTICS AND THEIR ANTAGONISTS WITH HUMAN SERUM ESTERASE. VI: THE BEHAVIOR OF 14 HYDROXYLATED MORPHINE DERIVATIVES.

000690 01-13 EFFECTS OF ANTIMYCIN A PLUS 2 DEOXYGLUCOSE ON UPTAKE AND VESICULAR STORAGE OF SEROTONIN IN HUMAN PLATELETS.

000694 01-13 IN VITRO EFFECTS OF IMIPRAMINE ON PROLIFERATION OF HUMAN LEUKOCYTES. 000699 01-13

(UNPUBLISHED PAPER)

BINDING OF CODEINE, MORPHINE, AND METHADONE TO HUMAN SERUM

THE RELATIONSHIP BETWEEN EXTRACELLULAR AND INTRACELLULAR LITHIUM CONCENTRATION IN HUMAN RED BLOOD CELLS: AN IN VITRO

THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE HUMAN BRAIN AS AN OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING DRINGS 000747 01-14

FAILURE OF NALOYONE TO AFFECT HUMAN SLEEP

100756 01-14
INDIVIDUAL VARIATIONS IN RESPONSE OF HUMAN REM SLEEP TO
AMITRIPTYLINE AND HALOPERIDOL.

THE INFLUENCE OF ALCOHOL ON THE PERSISTENT EFFECTS ON HUMAN PERFORMANCE OF THE HYPNOTICS MANDRAX AND NITRAZEPAM. 000784 01-14

AGGRESSION. 000789 01-14 ASPECTS OF THE PSYCHOPHARMACOLOGY OF HUMAN THIN-LAYER AND GAS-LIQUID-CHROMATOGRAPHIC PROCEDURES FOR THE

DETERMINATION OF PERAZINE AND ITS METABOLITES IN HUMAN BODY FLUIDS PHARMACOKINETICS OF NITRAZEPAM IN HUMAN PLASMA AND SALIVA. 001156 02-03

CHEMILUMINESCENCE RESULTING FROM AN INTERACTION BETWEEN IMIPRAMINE AND HUMAN POLYMORPHONUCLEAR LEUKOCYTES. 001263 02-03 ON THE INFLUENCE OF MOBILETTEN ON THE EFFECT OF ALCOHOL IN THE HUMAN: SECOND COMMUNICATION: INFLUENCE ON THE EFFICIENCY UNDER ALCOHOL STRESS.

HIGH DENSITIES OF BENZODIAZEPINE RECEPTORS IN HUMAN CORTICAL

PROTEIN AND ENZYME RELEASE FROM HUMAN LEUKOCYTES: INFLUENCE OF PHENOTHIAZINE DERIVATIVES.

LITHIUM SODIUM COUNTERTRANSPORT IN HUMAN RED CELLS AND IN VIVO LITHIUM DISTRIBUTION BETWEEN RED CELLS AND PLASMA.

O01679 02-13

COMPARATIVE AVAILABILITY OF DIAZEPAM (D) IN HUMAN PLASMA (P), PAROTID SALIVA (PS) AND MIXED SALIVA (MS) AND ITS RELATIONSHIP TO PLASMA PROTEIN BINDING.

001682 02-13 FLUOXETINE, A SEROTONIN UPTAKE INHIBITOR, IN NORMAL HUMAN SUBJECTS

001686 02-13 ANIMAL HYPNOSIS AND HUMAN HYPNOSIS: NEW EXPERIMENTAL EVIDENCE RELATING TO AN OLD CONTROVERSY.

DRUG-PRODUCED CHANGES IN HUMAN SOCIAL BEHAVIOR: FACILITATION BY D AMPHETAMINE

PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS THERAPEUTIC APPLICATION.

001737 02-14 THE HUMAN EEG IN SEVERELY POISONED PATIENTS - INDICATION AND CONTROL OF HEMODIALYSIS OR HEMOPERFUSION.

001795 02-15 A GC/CIMS ASSAY FOR THE CIS AND TRANS ISOMERS OF THIOTHIXENE IN HUMAN PLASMA.

001857 02-16 HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF DOTHIEPIN AND NORTHIADEN IN HUMAN PLASMA AND SERUM. 001858 02-16 TREATMENT OF HUMAN AGGRESSIVE BEHAVIOR: FOUR CASE STUDIES OF

THE EFFECT OF LITHIUM. 002532 03-11

DOPAMINERGIC FACTORS IN HUMAN PROLACTIN REGULATION: EFFECTS OF NEUROLEPTICS AND DOPAMINE 002574 03-13

DEXTROAMPHETAMINE AND L AMPHETAMINE ARE EQUIPOTENT IN RELEASING HUMAN GROWTH HORMONE.

BIOCHEMICAL IDENTIFICATION OF THE SITE OF ACTION OF BENZODIAZEPINES IN HUMAN BRAIN BY H3-DIAZEPAM BINDING. 002583 03-13 EFFECT OF ANTIDEPRESSANTS ON THE ABSORPTION OF SEROTONIN BY

HUMAN THROMBOCYTES. 002586 03-13 CHARACTERISTICS OF LI-TRANSPORT IN HUMAN RED CELLS

002591 03-13 THE HUMAN PLATELET AS A MODEL FOR THE DOPAMINERGIC NEURON:
KINETIC AND PHARMACOLOGIC PROPERTIES AND THE ROLE OF AMINE STORAGE GRANULES. 002594 03-13

CLOMIPRAMINE AND MAPROTILINE ON HUMAN PLATELET UPTAKE OF 5 HYDROXYTRYPTAMINE AND DOPAMINE IN VITRO: WHAT RELEVANCE TO THEIR ANTIDEPRESSIVE AND OTHER ACTIONS?

EFFECT OF CANNABINOIDS ON THE UPTAKE OF SEROTONIN IN HUMAN PLATELETS.

VIGILANCE AND HUMAN ATTENTION UNDER CONDITIONS OF METHYLPHENIDATE AND SECOBARBITAL INTOXICATION: AN ASSESSMENT USING BRAIN POTENTIALS.

602622 03-14

EFFECTS OF DIPROPYLACETATE ON WAKEFULNESS AND SLEEP IN HUMAN NEONATES.

002632 03.14

HUMAN STATE-DEPENDENT LEARNING. 002727 03-16

MARIJUANA AND HUMAN PERFORMANCE: AN ANNOTATED BIBLIOGRAPHY (1970-1975). 002773 03-17

5 HYDROXYTRYPTAMINE AND DOPAMINE TRANSPORT BY RAT AND HUMAN BLOOD PLATELETS. 002928 04-03 IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLETHANOL (MOPET) IN HUMAN CEREBROSPINAL FLUID AND RAT BRAIN BY MEANS OF GAS-CHROMATOGRAPHY — MASS-

SPECTROMETRY 003025 04-03

PSYCHIATRIC ILLNESS AND HUMAN RENAL TRANSPLANTATIO 003510 04-09

PHARMACOLOGIC MANAGEMENT OF HUMAN VIOLENCE. STABILITY OF LOW BLOOD PLATELET MONOAMINE-OXIDASE ACTIVITY IN HUMAN ALCOHOLICS.

THE EFFECT OF L-DOPA AND PROPRANOLOL ON HUMAN CSF CYCLIC-NUCLEOTIDES.

HYDROLYSIS OF ENKEPHALIN BY CULTURED HUMAN ENDOTHELIAL CELLS AND BY PURIFIED PEPTIDYL DIPEPTIDASE.

003593 04-13

THE ANALGESIC ACTIVITY OF HUMAN BETA-ENDORPHIN IN MAN. 003598 04-13 EFFECT OF DRUGS ON HUMAN ERYTHROCYTES -- 4. PROTECTING EFFECT OF DEXTRAN ON DRUG-INDUCED HEMOLYSIS.

003603 04-13 A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS.

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON HUMAN PLASMA LEVELS OF TSH, GH AND PROLACTIN.

003613 04-13 EFFECT OF APOMORPHINE ON HUMAN SLEEP.

003620 04-14 HOMOVANILLIC-ACID IN HUMAN CSF: COMPARISON OF FLUOROMETRY AND GAS-CHROMATOGRAPHY MASS-SPECTROMETRY.

A COMPARISON BETWEEN FLUOROMETRIC AND MASS FRAGMENTOGRAPHIC DETERMINATIONS OF HOMOVANILLIC-ACID AND 5 HYDROXYINDOLEACETIC-ACID IN HUMAN CEREBROSPINAL FLUID. 003694 04-16

HUMANISTIC
HEROIN AND OTHER HUMANISTIC TREATMENT FOR THE TERMINALLY ILL 003703 04-17

EVALUATING ANTIANXIETY AGENT IN HUMANS: EXPERIMENTAL PARADIGMS. 000661 01-11 DOSE PREFERENCE DURING PENTOBARBITAL SELF-ADMINISTRATION BY HUMANS.

PLASMA CONCENTRATIONS OF SOME ACIDIC AND ALCOHOLIC METABOLITES DERIVED FROM M- AND P-TYRAMINE, OCTOPAMINE AND CATECHOLAMINES IN HUMANS. 001158 02-03

URINARY EXCRETION OF A QUATERNARY AMMONIUM GLUCURONIDE METABOLITE OF CYPROHEPTADINE IN HUMANS UNDERGOING CHRONIC DRUG THERAPY.

001667 02-13 ENDORPHINS: NALOXONE FAILS TO ALTER EXPERIMENTAL PAIN OR MOOD IN HUMANS.

RHEOENCEPHALOGRAPHIC AND OTHER STUDIES OF BETAHISTINE IN HUMANS. IV. PROLONGED ADMINISTRATION WITH IMPROVEMENT IN ARTERIOSCLEROTIC DEMENTIA.

THE EFFECTS OF ALCOHOL UPON COOLING RATES OF HUMANS IMMERSED IN 7.5 DEGREES C WATER. 002541 03-12 **Psychopharmacology Abstracts**

REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF L-DOPA, AMINOPHYLLINE, AND EPHEDRINE. 002544 03-13 ROLACTIN RESPONSES TO NEUROLEPTIC DRUGS: AN APPROACH TO THE STUDY OF BRAIN DOPAMINE BLOCKADE IN HUMANS.

APOMORPHINE AND AMANTADINE: INTERACTION WITH ETHANOL IN HUMANS.

002605 03-14 LITHIUM TREATMENT OF HUNTINGTONS-CHOREA: A PLACEBO-CONTROLLED CLINICAL TRIAL.

LACK OF EFFECT OF GAMMA-HYDROXYBUTYRATE IN HUNTINGTONS-CHOREA

APOMORPHINE-HYDROCHLORIDE-INDUCED IMPROVEMENT IN HUNTINGTONS-CHOREA. 002508 03-11

REPLY TO DAVIS AND HURT CONCERNING METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGICAL RESEARCH WITH CHLORPROMAZINE. 000538 01-08

CYANOCYPROHEPTADINE: ROLE OF CHOLINOLYTIC PROPERTIES IN MODULATING NEUROLEPTIC-INDUCED ELEVATION OF STRIATAL HOMOVANILLIC-ACID (HVA). 00122

001226 02-03 MORPHINE INCREASES AND D AMPHETAMINE DECREASES THE RATIO OF DOPAC: HVA IN PUSH-PULL PERFUSATE OF RAT CAUDATE NUCLEUS. 002158 03-03

PHARMACOLOGIC RESPONSES OF CELLS OF A NEUROBLASTOMA-X GLIOMA HYBRID CLONE AND MODULATION OF SYNAPSES BETWEEN HYBRID CELLS AND MOUSE MYOTUBES.

002863 04-03 QUINAZOLINES AND 1,4 BENZODIAZEPINES. 81. S TRIAZOLOBENZODIAZEPINES BY OXIDATIVE CYCLIZATION OF

001017 02-01

HYDROCORTISONE
INDUCTION OF SULFOGALACTOSYLCERAMIDE (SULFATIDE) SYNTHESIS BY
HYDROCORTISONE (CORTISOL) IN MOUSE G-26 OLIGODENDROGLIOMA

ATTENUATION OF AMNESIA BY HYDROCORTISONE IN THE MOUSE 003313 04-04

HYDROCORTISONE-SUCCINATE
SUPPRESSION OF THE HYPOTHALAMIC PITUITARY ADRENAL AXIS AFTER
ORAL HYDROCORTISONE-SUCCINATE INGESTION IN RATS. 002098 03-03

THERAPEUTIC EFFECT OF BRAIN HYDROLYSATES IN DEPRESSION-INDUCED DISTURBANCES OF INTELLIGENCE.

002380 03-07

HYDROLYSIS
HYDROLYSIS OF DIESTER PRODRUGS OF APOMORPHINE.

KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES
III: NITRAZEPAM.

H3-GLYCOGEN HYDROLYSIS IN BRAIN SLICES: RESPONSES TO NEUROTRANSMITTERS AND MODULATION OF NORADRENALINE RECEPTORS.

HYDROLYSIS OF ENKEPHALIN BY CULTURED HUMAN ENDOTHELIAL CELLS AND BY PURIFIED PEPTIDYL DIPEPTIDASE. 003593 04-13

HYDROXY IMIPRAMINE, ITS N DESMETHYL AND HYDROXY METABOLITES IN PLASMA: MICRO DETERMINATION BY ALKALINE FLAME-IONIZATION GAS-CHROMATOGRAPHY (AFID-GC).

002597 03-13 HYDROXY-DIMETHYLBENZOPYRAMOPYRIDINE
CANNABINOIDS. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY
OF 8 SUBSTITUTED HYDROXY-DIMETHYLBENZOPYRANOPYRIDINE AND

001034 02-02 HYDROXY-17-ARALKYLMORPHINANS
3 HYDROXY-17-ARALKYLMORPHINANS AS POTENTIAL OPIATE RECEPTOR SITE DIRECTED AKLYLATING AGENTS.

001010 02-01 HYDROXYALKYL-BENZOMORPHAN
NEW N 2 HYDROXYALKYL-BENZOMORPHAN DERIVATIVES: SYNTHESIS
AND PRELIMINARY PHARMACOLOGY.

000031 01-02 HYDROXYAMPHETAMINE
IDENTIFICATION OF M HYDROXYAMPHETAMINE AS A METABOLITE OF
AMPHETAMINE IN THE RAT.

VOLUME 16, SUBJECT INDEX

Subject Index

003322 04-04

001944 03-01

SPECIES VARIATION WITH RESPECT TO THE METABOLISM AND EXCRETION OF D AMPHETAMINE AND D.L. N HYDROXYAMPHETAMINE.

HYDROXYAPROBARBITONE THE SYNTHESIS AND URINARY ESTIMATION OF N HYDROXYAPROBARBITONE

003595 04-13

001091 02-03

000428 01-04

HYDROXYCITRATE

(--) HYDROXYCITRATE AND CONDITIONED AVERSIONS.

HYDROXYDOPA
DIFFERENTIAL EFFECT OF VARIOUS 6 HYDROXYDOPA TREATMENTS ON
THE DEVELOPMENT OF CENTRAL AND PERIPHERAL NORADRENERGIC

STUDIES ON THE MECHANISM OF SPROUTING OF NORADRENERGIC TERMINALS IN RAT AND MOUSE CEREBELLUM AFTER NEONATAL 6

002980 04-03 MUSCARINIC HYPOSENSITIVITY IN THE DEVELOPING RAT PRETREATED WITH 6 HYDROXYDOPA.

003320 04-04

HYDROXYDOPAMINE
ISOLATION AND IDENTIFICATION OF AN IN VIVO REACTION PRODUCT OF 6 HYDROXYDOPAMINE.

CAFFEINE RESTORES FEEDING RESPONSE TO 2 DEOXY-D-GLUCOSE IN 6
HYDROXYDOPAMINE TREATED RATS.

000277 01-03 THE EFFECTS OF 6 HYDROXYDOPAMINE ON TOLERANCE TO AND DEPENDENCE ON ETHANOL.

000280 01-03 EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON FEEDING IN INTACT AND 6 HYDROXYDOPAMINE TREATED RATS.

000378 01-04 GAS-CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY OF SEROTONIN IN RAT SUPERIOR CERVICAL GANGLIA: EFFECTS OF NERVE GROWTH FACTOR AND A HYDROXYDOPAMINE

001006 02-01 EFFECTS OF PERINATAL 6 HYDROXYDOPAMINE TREATMENT ON OPIATE RECEPTOR DISTRIBUTION IN ADULT BRAIN.

001128 02-03 DIFFERENT BEHAVIORAL RESPONSES TO L-DOPA AFTER ANTEROLATERAL OR POSTEROLATERAL HYPOTHALAMIC INJECTIONS OF 6 HYDROXYDOPAMINE.

001349 02-04 EFFECTS OF 6 HYDROXYDOPAMINE ON BODY WEIGHT: FEEDING DEFICITS OR SENSORY-MOTOR IMPAIRMENTS?

001432 02-04 COMPARATIVE FFFECTS OF HALLUCINOGENIC DRUGS ON ROTATIONAL BEHAVIOR IN RATS WITH UNILATERAL 6 HYDROXYDOPAMINE ESIONS

001477 02-04 ENHANCEMENT BY CHOLINE OF THE INDUCTION OF ADRENAL TYROSINE HYDROXYLASE BY PHENOXYBENZAMINE, 6 HYDROXYDOPAMINE, INSULIN OR EXPOSURE TO COLD.

002167 03-03 6 HYDROXYDOPAMINE INHIBITS SOME EFFECTS OF MESCALINE CENTRALLY ADMINISTERED TO RABBITS.

002231 03-04 ANTAGONISM OF THE ANTICONVULSANT ACTION OF PHENYTOIN,
PHENOBARBITAL, AND ACETAZOLAMIDE BY 6 HYDROXYDOPAMINE 002845 04-03

NEONATAL SYSTEMIC 6 HYDROXYDOPAMINE AND DORSAL TEGMENTAL BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEPHRINE AND THE POSTDECAPITATION REFLEX.

003039 04-03 BEHAVIOURAL EFFECTS OF METHYLPHENIDATE IN 6 HYDROXYDOPAMINE TREATED NEONATAL RATS

003212 04-04 SCHIZOPHRENIC-LIKE TENDENCIES IN RATS NEONATALLY TREATED WITH 6 HYDROXYDOPAMINE. (PH.D. DISSERTATION)

003323 04-04 , BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC AND CATECHOLAMINERGIC MECHANISMS BY 6 HYDROXYDOPAMINE AND 5.6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D. DISSERTATION).

HYDROXYDOPAMINE-INDUCED

EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DEPLETIONS OF BRAIN CATECHOLAMINES OR DOPAMINE ON MEPERIDINE ANTINOCICEPTION IN RATS

002227 03-04 MESOLIMBIC DOPAMINE NEURONS: EFFECTS OF 6 HYDROXYDOPAM INDUCED DESTRUCTION AND RECEPTOR BLOCKADE ON DRUG-INDUCED ROTATION OF RATS.

EPINEPHRINE IN RAT HYPOTHALAMUS: ANTAGONISM BY DESIPRAMINE OF 6 HYDROXYDOPAMINE-INDUCED DEPLETION.

003110 04-03 6 HYDROXYDOPAMINE-INDUCED CATECHOLAMINE DEPLETION AND PASSIVE AVOIDANCE LEARNING IN RATS.

HYDROXYGLUTETHIMIDE
THE DISTRIBUTION BETWEEN PLASMA AND BRAIN OF GLUTETHIMIDE
AND 4 HYDROXYGLUTETHIMIDE FOLLOWING THEIR ADMINISTRATION TO MICE 001160 02-03

HYDROXYIMIDAZOLIDINEDIONES
SYNTHESIS AND COMPARATIVE SKELETAL MUSCLE RELAXANT ACTIVITY
OF SOME 2,4 IMIDAZOLIDINEDIONES AND THEIR CORRESPONDING 5 HYDROXYIAIDAZOLIDINEDIONES.

HYDROXYINDOLEACETIC
SIMILAR EFFECTS OF TRYPTOPHAN AND SLEEP ON CISTERNAL
CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC AND HOMOVANILLIC-ACIDS IN CATS.

PERSISTENT EFFECTS OF REPEATED INJECTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE ON RAT BRAIN 5 HYDROXYTRYPTAMINE AND 5 HYDROXYINDOLEACETIC-ACID LEVELS.

ALTERATIONS OF CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC-ACID, AND TOTAL BLOOD SEROTONIN CONTENT DURING CLOZAPINE TREATMENT.

002545 03-13 THE EFFECT OF LITHIUM ON THE INCREASE IN FOREBRAIN 5 HYDROXYINDOLEACETIC-ACID PRODUCED BY RAPHE STIMULATION

A COMPARISON BETWEEN FLUOROMETRIC AND MASS FRAGMENTOGRAPHIC DETERMINATIONS OF HOMOVANILLIC-ACID AND 5 HYDROXYINDOLEACETIC-ACID IN HUMAN CEREBROSPINAL FLUID. 003694 04-16

HYDROXYINDOLES EFFECTS OF P-CHLOROPHENYLALANINE AND ALPHA-METHYLTRYPTOPHAN ON BEHAVIOUR AND BRAIN 5 HYDROXYINDOLES.

000405 01-04 EFFECTS OF LITHIUM ON THE ELEVATION OF FOREBRAIN 5
HYDROXYINDOLES BY TRYPTOPHAN.

TRYPTOPHAN AND 5 HYDROXYINDOLES IN DIFFERENT CNS REGIONS FOLLOWING ACUTE MORPHINE.

002097 03-03 A STUDY OF THE RELATIONSHIP BETWEEN URINARY 5 HYDROXYINDOLES AND DEPRESSIVE STATES.

003482 04-09

003405 04-05

HYDROXYLATED INTERACTIONS OF NARCOTICS AND THEIR ANTAGONISTS WITH HUMAN SERUM ESTERASE, VI. THE BEHAVIOR OF 14 HYDROXYLATED MORPHINE DERIVATIVES.

000690 01-13 AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOUR AND BRAIN CONCENTRATIONS OF AMPHETAMINE AND ITS HYDROXYLATED MARTAROLITES IN MICE

001316 02-04 MODIFICATION OF THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN BY AMPHETAMINE (A) AND ITS HYDROXYLATED METABOLITES.

002100 03-03
INOTROPIC ACTION OF HYDROXYLATED CHLORPROMAZINE METABOLITES AND RELATED COMPOUNDS.

HYDROXYLATION HYDROXYLATION OF THREE BENZODIAZEPINES IN VITRO.

001201 02-03

METABOLISM OF LERGOTRILE TO 13 HYDROXYLERGOTRILE, A POTENT INHIBITOR OF PROLACTIN RELEASE IN VITRO.

003040 04-03 MYDROXYMETHYL-3-M-TOLYLOXAZOLIDIN-2-ONE
MONOAMINE-OXIDASE INHIBITORY PROPERTIES OF 5 HYDROXYMETHYL3-M-TOLYLOXAZOLIDIN-2-ONE (TOLOXATONE).

002971 04-03 DISTRIBUTION AND METABOLISM OF 4 HYDROXYPHENOBARBITAL IN THE

MOUSE. 001171 02-03 **HYDROXYTRYPTAMINE**

FLUVOXAMINE, A SPECIFIC 5 HYDROXYTRYPTAMINE UPTAKE INHIBITOR. 000017 01-02 ALTERATIONS IN BRAIN 5 HYDROXYTRYPTAMINE METABOLISM DURING THE WITHDRAWAL PHASE AFTER CHRONIC TREATMENT WITH DIAZEPAM AND BROMAZEPAM.

000038 01-03 MORPHINE AND 5 HYDROXYTRYPTAMINE INTERACTIONS IN RAT HYPOTHALAMUS AND PINEAL BODY.

000065 01-03

003407 04-05

POSSIBLE IMPORTANCE OF 5 HYDROXYTRYPTAMINE IN NEUROLEPTIC-INDUCED CATALEPSY IN RATS.

DRUGS ALTERING INSULIN SECRETION: EFFECTS ON PLASMA AND BRAIN CONCENTRATIONS OF AROMATIC-AMINO-ACIDS AND ON BRAIN 5 HYDROXYTRYPTAMINE TURNOVER.

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE.

PERSISTENT EFFECTS OF REPEATED INJECTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE ON RAT BRAIN 5 HYDROXYTRYPTAMINE AND 5 HYDROXYINDOLEACETIC-ACID LEVELS. 000221 01-03

5 HYDROXYTRYPTAMINE AND SEXUAL REHAVIOUR

THE ROLE OF ASCENDING AND DESCENDING 5 HYDROXYTRYPTAMINE NEURONES IN CENTRAL CONTROL OF PAIN SENSITIVITY.

5 HYDROXYTRYPTAMINE DEPLETION WITH P-CHLOROPHENYLALANINE: EFFECTS ON EATING, DRINKING, IRRITABILITY, MURICIDE, AND COPULATION.

LIPOPROTEIN POTENTIATION OF THE CEREBROVASCULAR RESPONSE TO INTRAARTERIAL 5 HYDROXYTRYPTAMINE.

001109 02-03 ACTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND ITS DERIVATIVES ON 5 HYDROXYTRYPTAMINE RECEPTORS IN THE ISOLATED UTERINE SMOOTH MUSCLE OF THE RAT.

001144 02-03 THE EFFECT OF STEROID HORMONES ON CEREBRAL BLOOD FLOW BEFORE AND AFTER INTRACAROTID INFUSION OF 5 HYDROXYTRYPTAMINE.

001193 02-03 EFFECT OF TWO NON TRICYCLIC ANTIDEPRESSANT DRUGS ON C14-5
HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.

WET-DOG SNAKE BEHAVIOUR IN THE RAT: A POSSIBLE QUANTITATIVE MODEL OF CENTRAL 5 HYDROXYTRYPTAMINE ACTIVITY.

EFFECTS OF MAZINDOL, FENFLURAMINE AND CHLORIMIPRAMINE ON THE 5 HYDROXYTRYPTAMINE UPTAKE AND STORAGE MECHANISMS IN RAT BRAIN: SIMILARITIES AND DIFFERENCES.

A LITHIUM-CARBONATE-INDUCED INCREASE IN THE MOUSE BRAIN 5
HYDROXYTRYPTAMINE METABOLISM.

COMPARISON OF THE EFFECTS OF 5 HYDROXYTRYPTAMINE, DIMETHYLTRYPTAMINE, AND 5 METHOXY-DIMETHYLTRYPTAMINE ON RECTAL TEMPERATURE IN THE MOUSE.

METABOLISM OF 5 HYDROXYTRYPTAMINE AND LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS IN RAT BRAIN AFTER ACUTE AND CHRONIC TREATMENT.

002169 03-03 STIMULUS PROPERTIES OF PHENETHYLAMINE HALLUCINOGENS AND LYSERGIC-ACID-DIETHYLAMIDE: THE ROLE OF 5 HYDROXYTRYPTAMINE.

002180 03-03 SELECTIVE REDUCTION BY NORADRENALINE AND 5
HYDROXYTRYPTAMINE OF NOCICEPTIVE RESPONSES OF CAT DORSAL-HORN NEURONES.

002246 03-04 CLOMIPRAMINE AND MAPROTILINE ON HUMAN PLATELET UPTAKE OF 5 HYDROXYTRYPTAMINE AND DOPAMINE IN VITRO: WHAT RELEVANCE TO THEIR ANTIDEPRESSIVE AND OTHER ACTIONS?

002599 03-13 5 HYDROXYTRYPTAMINE: THE EFFECTS OF IMPAIRED SYNTHESIS ON ITS METABOLISM AND RELEASE IN RAT.

002878 04-03 INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA:
EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION.

002890 04-03 5 HYDROXYTRYPTAMINE AND DOPAMINE TRANSPORT BY RAT AND HUMAN BLOOD PLATELETS.

THE EFFECT OF VILOXAZINE HYDROCHLORIDE ON THE TRANSPORT OF NORADRENALINE, DOPAMINE, 5 HYDROXYTRYPTAMINE AND GAMMA-AMINOBUTYRIC-ACID IN RAT BRAIN TISSUE.

003001 04-03 REPEATED EXPOSURE OF RATS TO THE CONVULSANT AGENT FLUROTHYL ENHANCES 5 HYDROXYTRYPTAMINE AND DOPAMINE MEDIATED BEHAVIOURAL RESPONSES.

003234 04-04
DEPRESSION OF PRIMATE SPINOTHALAMIC TRACT NEURONS BY
IONTOPHORETIC APPLICATION OF 5 HYDROXYTRYPTAMINE. 003251 04-04 A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS. 003608 04-13

HYDROXYTEYPTAMINE-LIKE
PHARMACOLOGICAL DIFFERENTIATION OF THE CENTRAL 5
HYDROXYTRYPTAMINE-LIKE ACTIONS OF MK-212 (6 CHLORO-2-1PIPERAZINYL-PYRAZINE), P-METHOXYAMPHETAMINE AND
FENFLURAMINE IN AN IN VIVO MODEL SYSTEM.

002868 0 002868 04-03

HYDROXYTRYPTAMINERGIC
THE EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND 2
BROMOLYSERGIC-ACID-DIETHYLAMIDE (BOL) ON THE STRIATAL DOPA
ACCUMULATION: INFLUENCE OF CENTRAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS.

002125 03-0

002125 03-03 INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA:
EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION. 002890 04-03

HYDROXYTRYPTOLINE
TOXICITY OF 5 HYDROXYTRYPTOLINE IN RATS.

003409 04-05

HYDROXYTRYPTOPHAN

EFFECTS OF L DIHYDROXYPHENYLALANINE (L-DOPA) AND DL,5

HYDROXYTRYPTOPHAN (DL,5-HTP) ON RESERPINE-INDUCED AMNESIA

EFFECTS OF L 5 HYDROXYTRYPTOPHAN ON SLEEP-WAKEFULNESS CYCLES IN CATS.

RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDRO YYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN
ACUTE AND CHRONIC SPINAL RATS.

002289 03-04 L TRYPTOPHAN AND 5 HYDROXYTRYPTOPHAN IN THE TREATMENT OF DEPRESSION: A REVIEW.

002552 03-13 PHARMACOLOGICAL STUDIES OF CENTRAL ACTION OF L 5
HYDROXYTRYPTOPHAN IN INTACT OR TETRABENAZINE PRETREATED
CATS.

INHIBITION OF 5,7 DIHYDROXYTRYPTAMINE-INDUCED SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN MICE BY TREATMENT WITH CYCLOHEXIMIDE.

003366 04-04 EFFECTS OF L 5 HYDROXYTRYPTOPHAN IN AUTISTIC CHILDREN. 003578 04-11

HYDROXYTRYPTOPHAN-INDUCED
CLONAZEPAM AND 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONIC STEREOTYPY.

MODIFICATION OF THE 5 HYDROXYTRYPTOPHAN-INDUCED HEAD-TWITCH RESPONSE BY EXOGENOUS ENDOCRINE AGENTS.

L 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS IN GUINEA-PIGS: A MODEL FOR THE STUDY OF CENTRAL SEROTONIN DOPAMINE INTERACTIONS.

HYDROXYZINE DOXEPIN IN THE TREATMENT OF NEUROSES: A COMPARATIVE CLINICAL STUDY OF DOXEPIN, CHLORDIAZEPOXIDE, HYDROXYZINE, MEPROBAMATE, AND PHENOBARBITAL.

000614 01-10 NEONATAL WITHDRAWAL SYNDROME ASSOCIATED WITH HYDROXYZINE HYDROCHI ORIDE

000884 01-15

HYPEPINEPHRIA IN CASES OF STRONG INTOXICATION. 001837 02-15

HYPERACTIVATING
EVIDENCE FOR PARALLEL DEVELOPMENT OF TOLERANCE TO THE
HYPERACTIVATING AND DISCOORDINATING EFFECTS OF ETHANOL 002249 03-04

HYPERACTIVE
CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL
ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE
FOR AN INTERACTIONIST POSITION.

000620 01-11 REPORT FROM CLINICAL PRACTICE: THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG TREATMENT OF HYPERACTIVE CHILDREN. (UNPUBLISHED PAPER).

COMPARING TREATMENT TACTICS WITH A HYPERACTIVE PRESCHOOL CHILD: STIMULANT MEDICATION AND PROGRAMMED TEACHER INTERVENTION.

THE RELATIVE EFFICACY OF METHYLPHENIDATE (RITALIN) AND BEHAVIOR MODIFICATION TECHNIQUES IN THE TREATMENT OF A HYPERACTIVE CHILD.

000671 01-11

WITHDRAWAL OF A STIMULANT DRUG AND CONCURRENT BEHAVIORAL INTERVENTION IN THE TREATMENT OF A HYPERACTIVE CHILD. 000780 01-14 A REVIEW OF STIMULANT DRUG RESEARCH WITH HYPERACTIVE CHILDREN.

A DEVELOPMENTAL STUDY OF SELECTIVE ATTENTION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).

LITHIUM-CARBONATE IN THE MANAGEMENT OF HYPERACTIVE AGGRESSIVE BEHAVIOR OF THE MENTALLY RETARDED.

HYPERACTIVE AND NONHYPERACTIVE CHILDRENS SELF-DETERMINED LEVELS OF STIMULATION. (PH.D. DISSERTATION).

001717 02-14
ELECTROPHYSIOLOGICAL STUDIES AND AMPHETAMINE METABOLISM IN
HYPERACTIVE CHILDREN.

002520 03-11
HYPERACTIVE CHILDRENS UNDERUSE OF LEARNING TIME: CORRECTION
BY STIMULANT TREATMENT.

002614 03-14 EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE ON BEHAVIOR OF HYPERACTIVE CHILDREN.

HYPERACTIVE CHILDRENS KNOWLEDGE AND ATTITUDES CONCERNING DRUG TREATMENT.

GROWTH OF HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE.

BEHAVIOR THERAPY AND WITHDRAWAL OF STIMULANT MEDICATION IN HYPERACTIVE CHILDREN. 003546 04-11

A CONTROLLED STUDY OF LISURID IN HYPERACTIVE CHILDREN.
003580 04-11

BEHAVIOR OBSERVATIONS OF HYPERACTIVE CHILDREN AND METHYLPHENIDATE (RITALIN) EFFECTS IN SYSTEMATICALLY STRUCTURED CLASSROOM ENVIRONMENTS: NOW YOU SEE THEM, NOW YOU DONT.

O03581 04-11
THE EFFECTS OF CAFFEINE AND METHYLPHENIDATE ON HYPERACTIVE
CHILDREN.

003626 04-14
DEXTROAMPHETAMINE AND PLACEBO PRACTICE EFFECTS ON SELECTIVE ATTENTION IN HYPERACTIVE CHILDREN.

EFFECTS OF METHYLPHENIDATE ALONE AND IN COMBINATION WITH BEHAVIOR MODIFICATION PROCEDURES ON THE BEHAVIOR AND ACADEMIC PERFORMANCE OF HYPERACTIVE CHILDREN.

HYPERACTIVITY
5-HT ANTAGONISTS INHIBIT NEUROLEPTIC AND MORPHINE ANTAGONISM

OF THE HYPERACTIVITY INDUCED BY DOPAMINE FROM THE NUCLEUS-ACCUMBENS.

OOO082 01-03
THE EFFECT OF INTRACEREBRAL INJECTION OF CYCLOHEXIMIDE ON BRAIN

THE EFFECT OF INTRACEREBRAL INJECTION OF CYCLOHEXIMIDE ON BRAIN PROTEIN SYNTHESIS AND ON THE HYPERACTIVITY SYNDROME PRODUCED BY A MONDAMINE-OXIDASE INHIBITOR AND TRYPTOPHAN. 000410 01-04

AUTONOMIC IMBALANCE: A SUBSTRATE OF HYPERACTIVITY.

000783 01-14
CHOLINERGIC MODIFICATION OF THE INHIBITION OF DOPAMINE-INDUCED
HYPERACTIVITY BY NEUROLEPTICS.

DIFFERENTIAL ACTIVATION BY SOME 2 AMINOTETRALIN DERIVATIVES OF THE RECEPTOR MECHANISMS IN THE NUCLEUS-ACCUMBENS OF RAT WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITING.

WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITMS.

001335 02-04

DIFFERENTIAL ATTENUATION BY ATROPINE AND D AMPHETAMINE ON HYPERACTIVITY: POSSIBLE CLINICAL IMPLICATIONS.

001347 02-04
THE STRUCTURE OF BEHAVIOR OF RATS DURING MORPHINE-INDUCED HYPERACTIVITY.

STEREOTYPY AND HYPERACTIVITY IN RATS RECEIVING ETHANOL AND A MONOAMINE-OXIDASE INHIBITOR. 002248 03-04

DECREASED LOCOMOTOR ACTIVITY AND ATTENUATION OF AMPHETAMINE HYPERACTIVITY WITH INTRAVENTRICULAR INFUSION OF SEROTOMIN IN THE RAT.

002328 03-04
TIME-RESPONSE ANALYSIS OF THE EFFECT OF STIMULANT MEDICATION
ON THE LEARNING ABILITY OF CHILDREN REFERRED FOR
HYPERACTIVITY.

002534 03-11
EFFECTS OF LORAZEPAM ON HYPERACTIVITY IN RETARDED CHILDREN.
002643 03-14

NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND L-DOPA TO RATS.

TESTOSTERONE ATTENUATED STEREOTYPY AND HYPERACTIVITY INDUCED BY BETA-PHENYLETHYLAMINE IN PARGYLINE PRETREATED RATS. 03224 04-04

HYPERALGESIA INDUCED BY NALOXONE FOLLOWS DIURNAL RHYTHM IN RESPONSIVITY TO PAINFUL STIMULI.

001124 02-03

ANTAGONISM OF NALOXONE HYPERALGESIA BY ETHANOL.
003165 04-04

HYPEICALCEMIA LITHIUM-CARBONATE-INDUCED HYPERCALCEMIA

ERDOPAMINERGIC 001755 02-15

L-DOPA REVERSAL OF HYPERDOPAMINERGIC BEHAVIOUR.

002229 03-04

HYPEREMOTIONALITY
REDUCTION OF VAMALESION-INDUCED HYPEREMOTIONALITY AND

REDUCTION OF VMH LESION-INDUCED HYPEREMOTIONALITY AND ANTINOCICEPTION BY DIAZEPAM.

002211 03-04

HYPERKINESIS

CAFFEINE POTENTIATION OF AMPHETAMINE: IMPLICATIONS FOR

HYPERKINESIS THERAPY. 000448 01-04
ANIMAL MODEL FOR STUDY OF HYPERKINESIS AND AGGRESSION. 002302 03-04

MYPERKINETIC

A DOPAMINERGIC BASIS FOR THE EFFECTS OF AMPHETAMINE ON A
MOUSE PREADOLESCENT HYPERKINETIC MODEL.

MENTALLY RETARDED, HYPERKINETIC, AND PSYCHOTIC. 000310 01-04

IMPROVEMENT WITH L-DOPA IN A HYPERKINETIC CHILD. 000584 01-09

MANAGEMENT OF THE HYPERKINETIC SYNDROME WITH METHYLPHENIDATE AND SMR BIOFEEDBACK TRAINING.

THE PREDICTION OF DIFFERENTIAL RESPONSIVENESS OF HYPERKINETIC

CHILDREN TO METHYLPHENIDATE. (PH.D. DISSERTATION).

001697 02-14
THE EFFECTS OF METHYLPHENIDATE ON VARIOUS TYPES OF ACTIVITY
LEVEL AND ATTENTION IN HYPERKINETIC CHILDREN.

METHYLPHENIDATE IN HYPERKINETIC CHILDREN: DIFFERENCES IN DOSE EFFECTS ON LEARNING AND SOCIAL BEHAVIOR.

GROWTH HORMONE, PROLACTIN AND CORTISOL RESPONSES AND GROWTH PATTERNS IN HYPERKINETIC CHILDREN TREATED WITH DEXTROAMPHETAMINE. PRELIMINARY FINDINGS.

003569 04-11
THE BEHAVIORAL SYMPTOMS OF HYPERKINETIC CHILDREN WHO
SUCCESSFULLY RESPONDED TO STIMULANT DRUG TREATMENT.
003579 04-11

INHIBITION OF BOTH MAO-A AND MAO-B REQUIRED FOR THE PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

PIPEROXANE REDUCES THE EFFECTS OF CLONIDINE ON AGGRESSION IN MICE AND ON NORADRENALINE DEPENDENT HYPERMOTILITY IN RATS. 002205 03-04

INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETINE ON HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE (PCA) AND 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77).

HYPEROSMOLALITY
HYPEROSMOLALITY COMPLICATING RECOVERY FROM LITHIUM TOXICITY.
003465 04-15

A NEW ANOREXIGEN ASSAY: STRESS-INDUCED HYPERPHAGIA IN RATS.

CLOZAPINE INDUCES HYPERPHAGIA IN UNDEPRIVED RATS.

001301 02-04

HYPERREACTIVITY
INTERANIMAL AGGRESSION AND HYPERREACTIVITY FOLLOWING
HYPOTHALAMIC INFUSION OF LOCAL ANESTHETIC IN THE RAT.
003157 04-04

HYPERRESPONSIVENESS
PHARMACOLOGICAL INFLUENCES ON STARVATION-INDUCED
HYPERRESPONSIVENESS IN THE RAT. (PH.D. DISSERTATION).
002212 03-04

LEVODOPA-INDUCED DOPAMINE RECEPTOR HYPERSENSITIVITY.

000392 01-04

HYPERSENSITIVITY OF RATS TO ANORECTIC AGENTS AFTER LESIONS IN
THE VENTROMEDIAL HYPOTHALAMUS.

HYPERSENSITIVITY TO METHYLPHENIDATE AND DEXTROAMPHETAMINE:
A REPORT OF TWO CASES.

000901 01-15

HYPERTHYROID

SLEEP AND BEHAVIORAL CHANGES POSSIBLY REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN.

THE SPECIFICITY OF NEUROLEPTIC-INDUCED AND METHYSERGIDE-INDUCED BEHAVIORAL HYPERSENSITIVITY.

002259 03-04

000936 01-17

003411 04-05

ERSOMNIA LITHIUM PROPHYLAXIS OF PERIODIC HYPERSOMNIA.

HYPERTENSION
WHY PHYSICIANS PRESCRIBE BENZODIAZEPINES IN ESSENTIAL
HYPERTENSION: A PHASE IV STUDY.

000667 01-11

EFFECT OF THYMOANALEPTIC AGENTS ON THE COURSE OF EXPERIMENTAL ARTERIAL HYPERTENSION AND CATECHOLAMINE CONTENT IN TISSUES AND URINE.

001970 03-03 COMPARATIVE EFFECTS OF DIHYDROERGOTOXINE (DHET) ON CBF AND METABOLISM CHANGES PRODUCED BY EXPERIMENTAL CEREBRAL EDEMA, HYPOXIA AND HYPERTENSION.

001979 03-03 HYPERTENSIVE

APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR, LOCOMOTOR STIMULATION AND HYPOTHERMIA IN SPONTANEOUS HYPERTENSIVE RATS AND NORMOTENSIVE WISTAR RATS.

001413 02-

001413 02-04 THE CEREBROVASCULAR PERMEABILITY TO PROTEIN AFTER BICUCULLINE AND AMPHETAMINE ADMINISTRATION IN SPONTANEOUSLY HYPERTENSIVE RATS.

002050 03-03 ANGIOTENSIN BINDING AFFINITY AND CAPACITY IN THE MIDBRAIN AREA OF SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS. 002870 04-03

HYPERTHERMIA

EFFECTS OF VARIOUS NEUROLEPTICS ON RABBIT HYPERTHERMIA
INDUCED BY N, N DIMETHYLTRYPTAMINE (DMT) AND D
AMPHETAMINE.

000099 01-03 THE POTENTIATING EFFECT OF NALOXONE UPON APOMORPHINE-INDUCED

000231 01-03

HYPERTHERMIC EFFECTS OF SUPRACORTICALLY APPLIED
PROSTAGLANDINS AFTER SYSTEMIC PRETREATMENT WITH INHIBITORS
OF PROSTAGLANDIN TRANSPORT AND SYNTHESIS.

002174 03-03 HYPERTHERMIC RESPONSES TO CENTRAL AND PERIPHERAL INJECTIONS OF MORPHINE-SULPHATE IN THE CAT.

002864 04-03 A GENETIC ANALYSIS OF THE HYPERTHERMIC RESPONSE TO D
AMPHETAMINE IN TWO INBRED STRAINS OF MICE.

INVOLVEMENT OF CENTRAL NORADRENERGIC SYSTEM IN THE MEDIATION OF BEHAVIORAL SUPPRESSANT EFFECTS OF DIAZEPAM IN HYPERTHYROID RATS.

INHIBITION OF FLAVIN SYNTHESIS BY CHLORPROMAZINE IN EUTHYROID AND HYPERTHYROID RATS.

002352 03-05 HYPERTHYROIDISM
HYPERTHYROIDISM AND A PARATHYROID ADENOMA COMPLICATING
LITHIUM TREATMENT.

002686 03-15 HYPERTONIC

HYPERTONIC SODIUM-CHLORIDE AND LIDOCAINE IN A CASE OF IMPRAMINE INTOXICATION. 001769 02-15

FURTHER EVIDENCE OF CYCLIC-AMP MEDIATED HYPERTROPHY AS A PREREQUISITE OF DRUG SPECIFIC ENZYME INDUCTION. 002086 03-03

HYPNOGENIC
ON THE HYPNOGENIC AND ANTICONVULSANT ACTIVITIES OF
DEMETHYLDIAZEPAM AND CHLORDEMETHYLDIAZEPAM: TIME EFFECT 000462 01-04

THE EFFECT OF EPINEPHRINE ON TONIC IMMOBILITY (ANIMAL HYPNOSIS) IN CHICKENS.

000460 01-04 ANIMAL HYPNOSIS AND HUMAN HYPNOSIS: NEW EXPERIMENTAL EVIDENCE RELATING TO AN OLD CONTROVERSY. 001711 02-14

CORRELATION OF PHENOBARBITAL-INDUCED AND SKF-525-A-INDUCED MODIFICATION OF PENTOBARBITAL HYPNOSIS WITH ALTERATION OF IN VIVO AND IN VITRO PENTOBARBITAL METABOLISM IN THE RAT. 003008 04-03

L TRYPTOPHANE AS AN HYPNOTIC AGENT: A REVIEW.

000511 01-07 FLUNITRAZEPAM, AN INVESTIGATIONAL HYPNOTIC DRUG: SLEEP LABORATORY EVALUATIONS.

TEMAZEPAM (EUHYPNOS) AS A HYPNOTIC: A TWELVE-WEEK TRIAL IN

000763 01-14 TEMAZEPAM (EUHYPNOS) AS A HYPNOTIC: A MULTICENTRE TRIAL IN

000764 01-14 AN EVALUATION OF THE CARDIOPULMONARY SAFETY AND EFFICACY OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS ORAL HYPNOTIC

000854 01-15 A COMPARISON OF THALIDOMIDE AND PENTOBARBITAL -METHODS FOR IDENTIFYING NOVEL HYPNOTIC DRUGS.

001359 02-04 DIFFERENTIATION OF HYPNOTIC ACTION OF NITRAZEPAM AND ESTAZOLAM AND EFFECTS ON BEHAVIOR AND CORTICAL ACTIVITY 001549 02-07

L TRYPTOPHAN: AN EFFECTIVE HYPNOTIC.

A SUBJECTIVE AND OBJECTIVE METHOD ASSESSING THE EFFICACY OF HYPNOTIC MEDICATIONS IN INSOMNIACS.

001873 02-16 SINGLE-BLIND EVALUATION OF HYPNOTIC ACTIVITY OF CHLORDESMETHYLDIAZEPAM IN NO-PLACEBO REACTOR MEDICAL PATIENTS.

002379 03-07 EVALUATION OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTIC AGENTS IN PRESURGICAL PATIENTS.

002514 03-11 CENTRAL NERVOUS EFFECTS OF THE HYPNOTIC ETOMIDATE IN MAN. 002580 03-13

THE USE OF THE CNV (CONTINGENT NEGATIVE VARIATION) IN THE DETERMINATION OF RESIDUAL EFFECTS OF FIVE HYPNOTIC DRUGS

002713 03-16 REVERSAL OF THE ACTION OF AMINO-ACID ANTAGONISTS BY BARBITURATES AND OTHER HYPNOTIC DRUGS.

002838 04-03 COMPARATIVE EVALUATION OF HYPNOTIC EFFICACY OF FLUNITRAZEPAM IN PSYCHIATRIC PATIENTS.

003574 04-11 HYPNOTIC EFFECTIVENESS OF SODIUM SALICYLAMIDE WITH SHORT-TERM USE: SLEEP LABORATORY STUDIES.

003637 04-14 HYPNOTIC ACTIVITY OF DIPHENHYDRAMINE, METHAPYRILENE, AND PLACEBO.

002284 03-04

003638 04-14 HYPNOTIC-LIKE HYPNOTIC-LIKE EFFECTS OF CANNABIDIOL IN THE RAT.

HYPNOTICS

COMPARISON OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTICS IN GERIATRIC PATIENTS WITH INSOMNIA.

000658 01-11 THE INFLUENCE OF ALCOHOL ON THE PERSISTENT EFFECTS ON HUMAN PERFORMANCE OF THE HYPNOTICS MANDRAX AND NITRAZEPAM. 000784 01-14

PURCHASES OF HYPNOTICS, SEDATIVES AND MINOR TRANQUILLIZERS AMONG 2,566 INDIVIDUALS IN THE COUNTY OF JAMTLAND, SWEDEN: A 6-YEAR FOLLOW-UP.

EFFECTS THE HYPNOTICS AND ANTIANXIETY DRUGS ON ACETYLCHOLINE (ACH) CONCENTRATIONS IN DISCRETE AREAS OF THE RAT BRAIN. 001239 02-03

RAPID IDENTIFICATION OF HYPNOTICS IN EMERGENCY CASES BY COMPUTERIZED GAS-CHROMATOGRAPHY MASS SPECTROMETRY 001841 02-15

ELECTROENCEPHALOGRAPHIC STUDY OF THE SHORT-ACTING HYPNOTICS ETOMIDATE AND METHOHEXITAL IN DOGS. TOLERANCE TO SEDATIVE HYPNOTICS, MEMORY AND NORADRENERGIC (NE) SYSTEMS.

PHARMACOKINETIC STUDIES ON TOLERANCE TO SEDATIVE HYPNOTICS IN A POLYDRUG ABUSE POPULATION: 1. SECOBARBITAL. 002662 03-15

HYPOCHOLESTEROLEMIC

EFFECT OF HYPOCHOLESTEROLEMIC AGENTS ON CENTRAL-NERVOUSSYSTEM CHOLESTEROL BIOSYNTHESIS. III. ZUCLOMIPHENE IN

COMBINATION WITH AY9944 AND TRIPARANOL. 003058 04-03

HYPOGASTRIC
SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE
MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE
GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION. 002052 03-03

A CONTRIBUTION TO THE NEUROCHEMICAL BASIS OF THE PYRITHIOXIN EFFECT ON THE BRAIN GLUCOSE UTILISATION DURING RELATIVE BRAIN HYPOGLYCAEMIA INDUCED BY ANTICIPATION STRESS.

ACUTE HYPOKALEMIC MYOPATHY IN ALCOHOLISM: A CLINICAL ENTITY 000888 01-15

HYPOKINESIA

TOLERANCE TO HYPOKINESIA ELICITED BY DOPAMINE AGONISTS IN MICE: HYPOSENSITIZATION OF AUTORECEPTORS?.

002221 03-04

HYPOMANIA
RETROSPECTIVE DIAGNOSIS OF HYPOMANIA FOLLOWING SUCCESSFUL
TREATMENT OF EPISODIC VIOLENCE WITH LITHIUM: A CASE REPORT 003490 04-09

HYPOPHYSECTOMY
RADIOIMMUNOASSAY OF ENKEPHALINS: REGIONAL DISTRIBUTION IN RAT BRAIN AFTER MORPHINE TREATMENT AND HYPOPHYSECTOMY 003136 04-03

HYPOPHYSIS

SPECIFIC LOCALIZATION OF DRUGS AT THE HYPOPHYSIS LEVEL AND SIDE **EFFECTS: THE CASE OF NEUROLEPTICS.** 000053 01-03

HYPOPOTASSEMIA
CARDIAC ARRHYTHMIA AND HYPOPOTASSEMIA IN ASSOCIATION WITH LITHIUM-CARBONATE OVERDOSE.

MUSCARINIC HYPOSENSITIVITY IN THE DEVELOPING RAT PRETREATED WITH 6 HYDROXYDOPA.

003320 04-04

000843 01-15

HYPOSENSITIZATION
TOLERANCE TO HYPOKINESIA ELICITED BY DOPAMINE AGONISTS IN MICE: HYPOSENSITIZATION OF AUTORECEPTORS?.

002221 03-04

HYPOTENSION
CENTRAL ANTAGONISM OF TYRAMINE-INDUCED SYSTEMIC HYPOTENSION BY MESCALINE.

001252 02-03 EFFECT OF PAPAVERINE AND DIHYDROERGOTOXINE-MESYLATE ON CEREBRAL MICROFLOW, EEG, AND PO2 IN OLIGEMIC HYPOTENSION

002032 03-03 HYPOTENSION AND HYPOTHALAMIC AMINE METABOLISM AFTER LONG-TERM ALPHA-METHYLDOPA INFUSIONS.

002914 04-03

CNS SITE OF CLONIDINE-INDUCED HYPOTENSION: A MICROIONTOPHORETIC STUDY OF BULBAR CARDIOVASCULAR NEURONS.

003086 04-03 HYPOTENSION AND THIRST IN RATS AFTER ISOPROTERENOL TREATMENT.

HYPOTENSIVE

CENTRAL SITES AND MECHANISMS OF THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF THE NARCOTIC ANALGESIC AGENT

000179 01-03 INHIBITION OF THE CENTRAL HYPOTENSIVE EFFECT OF CLONIDINE BY TRAZODONE, A NOVEL ANTIDEPRESSANT.

TIME-COURSE OF LITHIUM-INDUCED ALTERATIONS IN RENAL AND ENDOCRINE FUNCTION IN NORMAL AND BRATTLEBORO RATS WITH HYPOTHALAMIC DIABETES-INSIPIDUS.

000048 01-03

000286 01-03

CONTROL OF THE RELEASE OF NEWLY SYNTHESIZED H3-5-HYDROXYTRYPTAMINE BY NICOTINIC AND MUSCARINIC RECEPTORS IN RAT HYPOTHALAMIC SLICES.

CHLORPROMAZINE INDUCES POPULATION INCREASE OF SYNAPTIC VESICLES IN THE RAT HYPOTHALAMIC VENTROMEDIAL NUCLEUS 000160 01-03

AMINERGIC AND THERMOREGULATORY MECHANISMS IN HYPOTHALAMIC REGULATION OF GROWTH HORMONE IN CATS

000249 01-03
EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON SEROTONIN UPTAKE INTO RAT HYPOTHALAMIC SYNAPTOSOMES.

000293 01-03 COMPARISON OF THE REGULATION OF ROTATIONAL BEHAVIOR BY HYPOTHALAMIC OLIGOPEPTIDES.

000337 01-04 THE EFFECTS OF HYPOTHALAMIC DEAFFERENTATION ON THE HALOPERIDOL-INDUCED ACTIVATION OF TUBEROINFUNDIBULAR

DOPAMINE NEURONS. 001047 02-03 DAILY 1 DELTA9-TETRAHYDROCANNABINOL AND PRESSING FOR

HYPOTHALAMIC STIMULATION. MORPHINE DECREASES LUTEINIZING HORMONE BY AN ACTION ON THE

HYPOTHALAMIC PITUITARY AXIS. 001084 02-03

THE ROLE OF HYPOTHALAMIC SEROTONIN (5-HT) BEFORE OVULATION IN IMMATURE RATS TREATED WITH PREGNANT MARE SERUM (PMS). 001287 02-03 DIFFERENT BEHAVIORAL RESPONSES TO L-DOPA AFTER ANTEROLATERAL OR POSTEROLATERAL HYPOTHALAMIC INJECTIONS OF 6

601349 02-04
EFFECTS OF DOPAMINE SUPERSENSITIVITY ON LATERAL HYPOTHALAMIC SELF-STIMULATION IN RATS.

CORRELATED EFFECT OF CORTICOSTERONE ON HYPOTHALAMIC SEROTONIN AND AVOIDANCE BEHAVIOUR IN RATS.

EFFECTS ON HYPOTHALAMIC SELF-STIMULATION OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION INJECTED INTO NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM OF RATS.

EFFECTS OF PARGYLINE ON HYPOTHALAMIC BIOGENIC AMINES AND SERUM PROLACTIN (PRL), LH AND TSH IN MALE RATS.

001988 03-03 EFFECTS OF COMPLETE HYPOTHALAMIC DEAFFERENTATION AND 5,7
DIHYDROXYTRYPTAMINE ON SEVERAL PARAMETERS OF PROLACTIN

SUPPRESSION OF THE HYPOTHALAMIC PITUITARY ADRENAL AXIS AFTER ORAL HYDROCORTISONE-SUCCINATE INGESTION IN RATS.

MONOAMINERGIC INFLUENCES ON THE INCORPORATION OF \$35 IN THE HYPOTHALAMIC AND NEUROHYPOPHYSIAL PROTEINS FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF \$35-CYSTEINE IN DEHYDRATED RATS

002238 03-04 INTERACTION BETWEEN MORPHINE AND REINFORCING LATERAL HYPOTHALAMIC STIMULATION.

HYPOTENSION AND HYPOTHALAMIC AMINE METABOLISM AFTER LONG TERM ALPHA-METHYLDOPA INFUSIONS.

EFFECTS OF ESTROGEN AND AMINERGIC DRUGS ON THRESHOLDS OF MEDIAL BASAL HYPOTHALAMIC AXONS IN THE MEDIAN EMINENCE OF

IDENTIFICATION OF A SUBREGION WITHIN RAT NEOSTRIATUM FOR THE DOPAMINERGIC MODULATION OF LATERAL HYPOTHALAMIC SELF-STIMULATION.

EFFECT OF MORPHINE ON THE BASAL AND THE DOPAMINE-INDUCED RELEASE OF LHRH FROM MEDIOBASAL HYPOTHALAMIC FRAGMENTS IN VITRO.

INTERANIMAL AGGRESSION AND HYPERREACTIVITY FOLLOWING
HYPOTHALAMIC INFUSION OF LOCAL ANESTHETIC IN THE RAT.

O03157 04-04
ROLE OF HYPOTHALAMIC SEROTONERGIC RECEPTORS IN THE CONTROL OF
LORDOSIS BEHAVIOR IN THE FEMALE RAT.

003220 04-04 SIMILAR EFFECTS OF ESTROGEN AND LATERAL HYPOTHALAMIC LESIONS ON FEEDING BEHAVIOR OF FEMALE RATS.

COMPULSIONS, AGGRESSION, AND SELF-MUTILATION: A HYPOTHALAMIC DISORDER? 003641 04-14

THE BEHAVIOURAL ACTIONS OF THE HYPOTHALAMIC PEPTIDES: A REVIEW 003651 04-15

HYPOTHALAMUS

MORPHINE AND 5 HYDROXYTRYPTAMINE INTERACTIONS IN RAT HYPOTHALAMUS AND PINEAL BODY.

000065 01-03 EFFECTS OF APOMORPHINE ON SELF-STIMULATION BEHAVIOUR IN DORSAL AND VENTRAL AREA OF LATERAL HYPOTHALAMUS IN MICE. 000334 01-04

HYPERSENSITIVITY OF RATS TO ANORECTIC AGENTS AFTER LESIONS IN THE VENTROMEDIAL HYPOTHALAMUS.

EFFECT OF NEUROTROPIC DRUGS ON SLEEP DISTURBANCES CAUSED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS.

EFFECTS ON TEMPERATURE OF MORPHINE INJECTED INTO THE PREOPTIC/ ANTERIOR HYPOTHALAMUS, MEDULLA-OBLONGATA, AND PERIPHERALLY IN UNRESTRAINED AND RESTRAINED RATS. 001264 02-03

INFLUENCE OF NEUROTROPIC DRUGS ON CHANGES OF EVOKED-POTENTIALS AMPLITUDES AFTER STIMULATION OF THE HYPOTHALAMUS

001318 02-04

EATING FOLLOWING CHOLINERGIC STIMULATION OF THE HYPOTHALAMUS

A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND BIOELECTRIC CORRELATES OF EMOTIONAL REACTIONS ELICITED BY CHOLINERGIC

STIMULATION OF THE HYPOTHALAMUS AND THE VENTRAL TEGMENTUM. 001390 02-04 EFFECT OF LITHIUM-CHLORIDE ON THE NEUROSECRETORY SYSTEM OF THE RAT HYPOTHALAMUS. SOMATOSTATIN: ELECTRON MICROSCOPE IMMUNOHISTOCHEMICAL LOCALIZATION IN SECRETORY NEURONS OF RAT HYPOTHALAMUS. EFFECT OF PSYCHOTROPIC DRUGS ON 3.4 DIHYDROXYPHENYLACETIC ACID (DOPAC) CONTENT IN THE MEDIAL BASAL HYPOTHALAMUS. 001962 03-03 STRENGTH DURATION PROPERTIES OF SINGLE UNITS DRIVEN BY ELECTRICAL STIMULATION OF THE LATERAL HYPOTHALAMUS IN RATS MODIFICATION OF NUCLEAR RETENTION OF H3-ESTRADIOL BY CELLS OF THE HYPOTHALAMUS AS A FUNCTION OF EARLY HORMONE EXPERIENCE FURTHER STUDIES ON THE FINE STRUCTURE OF THE ADRENERGIC INNERVATION OF THE HYPOTHALAMUS. EPINEPHRINE IN RAT HYPOTHALAMUS: ANTAGONISM BY DESIPRAMINE OF 6 HYDROXYDOPAMINE-INDUCED DEPLETION. MOVEMENT INDUCED IN CATALEPTIC RATS: DIFFERENTIAL EFFECTS
PRODUCED BY ELECTRICAL STIMULATION OF THE LATERAL
HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FORMATION.
003297 04-04 HYPOTHERMIA
HYPOTHERMIA IN RATS PRODUCED BY NABILONE, A SYNTHETIC
CANNABINOID. 000213 01-03 PROFOUND HYPOTHERMIA ON COMBINED LITHIUM-CARBONATE AND DIAZEPAM TREATMENT. 000870 01-15 CHOLINERGIC INHIBITION OF MORPHINE-INDUCED HYPOTHERMIA 001066 02-03 PROFOUND HYPOTHERMIA IN MAMMALS TREATED WITH
TETRAHYDROCANNABINOLS, MORPHINE, OR CHLORPROMAZINE 001140 02-03 MECHANISMS OF AMITRIPTYLINE-INDUCED HYPOTHERMIA IN THE RAT. 001176 02-03 ASCORBATE ATTENUATES APOMORPHINE-INDUCED HYPOTHERMIA IN 001260 02-03 APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR, LOCOMOTOR STIMULATION AND HYPOTHERMIA IN SPONTANEOUS HYPERTENSIVE RATS AND NORMOTENSIVE WISTAR RATS. 001413 02-04 HYPOTHERMIA EVOKED BY THE INTRACEREBRAL INJECTION OF MORPHINE-SULPHATE IN THE RAT: THE EFFECT OF RESTRAINT 002090 03-03 IMIPRAMINE ANTAGONISM OF APOMORPHINE-INDUCED HYPOTHERMIA: A NONDOPAMINERGIC INTERACTION. EFFICACY OF NEUROLEPTICS AND ANTIDEPRESSANTS IN THE TEST OF APOMORPHINE HYPOTHERMIA AND SOME DATA CONCERNING NEUROCHEMICAL MECHANISMS OF THE TEST. 002147 03-03 DOPAMINE-INDUCED HYPOTHERMIA IN MORPHINE-DEPENDENT RATS 002988 04-03 DISULFIRAM-INDUCED HYPOTHERMIA IN THE NORMAL RAT; ITS ATTENUATION BY PIMOZIDE. 003085 04-03 HYPOTHERMIC

EFFECT OF P-CHLOROPHENYLALANINE ON THE ACQUISITION OF
TOLERANCE TO THE HYPOTHERMIC EFFECTS OF ALCOHOL. 002913 04-03 HYPOTHESES

PHARMACOLOGICAL INVESTIGATIONS OF THE CHOLINERGIC IMBALANCE
HYPOTHESES OF MOVEMENT DISORDERS AND PSYCHOSIS. UPTAKE INHIBITION OF BIOGENIC AMINES BY NEWER ANTIDEPRESSANT DRUGS: RELEVANCE TO THE DOPAMINE HYPOTHESIS OF DEPRESSION 000232 01-03 THE INDOLEAMINE HYPOTHESIS OF DEPRESSION: AN OVERVIEW AND 000592 01-09 NEW DIRECTION TO THE AMINE HYPOTHESIS. 000739 01-13 CLINICAL STUDIES WITH MAPROTILINE AND THE REVERSED CATECHOLAMINE HYPOTHESIS OF DEPRESSION. 001642 02-13

TRANSMETHYLATION HYPOTHESIS: A REVIEW OF PROGRESS

NICOTINIC-ACID.

TRANSMETHYLATION HYPOTHESIS OF SCHIZOPHRENIA: METHIONINE AND

HORMONE RESPONSES TO METHYLAMPHETAMINE IN DEPRESSION: A NEW APPROACH TO THE NORADRENALINE DEPLETION HYPOTHESIS. 002424 03-09 CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE-ILINESS: PARADOXICAL DRUG EFFECTS. 002610 03-14 SOME FAILURES OF THE DRUG DISCRIMINATION HYPOTHESIS OF STATE-DEPENDENT LEARNING. 003317 04-04 ENDORPHINS IN PSYCHIATRY: AN OVERVIEW AND A HYPOTHESIS 003730 04-17 HYPOTHESIZED HYPOTHESIZED ADRENERGIC/NORADRENERGIC SUBSTITUTION IN HABITUAL INFANTILE MASTURBATION: TWO CASES. 001702 02-14 ON THE PREVALENCE, DIAGNOSIS AND MANAGEMENT OF LITHIUM-INDUCED HYPOTHYROIDISM IN PSYCHIATRIC PATIENTS. 001805 02-15 LITHIUM-INDUCED HYPOTHYROIDISM 002712 03-15 HYPOTONIC CIRCULATORY DISORDERS UNDER PSYCHOPHARMACOTHERAPY — TREATMENT WITH 9ALPHA-FLUOROHYDROCORTISONE. 002710 03-15 HYPOXIA BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF HYPOXIC HYPOXIA IN RATS: STUDY OF THE PROTECTION AFFORDED BY ERGOT ALKALOIDS 001971 03-03 COMPARATIVE EFFECTS OF DIHYDROERGOTOXINE (DHET) ON CBF AND METABOLISM CHANGES PRODUCED BY EXPERIMENTAL CEREBRAL EDEMA, HYPOXIA AND HYPERTENSION. 001979 03-03 BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF HYPOXIC HYPOXIA IN RATS: STUDY OF THE PROTECTION AFFORDED BY ERGOT ALKALOIDS 001971 03-03 ROLE OF NARCOSUGGESTIONS IN HYSTERIA. 003540 04-10 HISTAMINE H2-RECEPTOR BINDING WITH H3-CIMETIDINE IN BRAIN 002848 04-03 HISTAMINE H2-RECEPTORS IN THE BRAIN AND SLEEP PRODUCED BY CLONIDINE 001483 02-04 H3-ADTN
DOPAMINE RECEPTOR BINDING OF H3-ADTN (2
AMINODIHYDROXYTETRAHYDRONAPHTHALENE) REGULATED BY
GUANYL-NUCLEOTIDES.
002877 002877 04-03 H3-AGONISTS

ALPHA-NORADRENERGIC RECEPTORS IN THE BRAIN: DIFFERENTIAL EFFECTS OF SODIUM ON BINDING OF H3-AGONISTS AND H3-ANTAGONISTS. 002029 03-03 H3-ANTAGONISTS ALPHA-NORADRENERGIC RECEPTORS IN THE BRAIN: DIFFERENTIAL EFFECTS OF SODIUM ON BINDING OF H3-AGONISTS AND H3-H3-APOMORPHINE
H3-APOMORPHINE INTERACTIONS WITH DOPAMINE RECEPTORS IN CALF SELECTIVE LABELING OF PRESYNAPTIC RECEPTORS BY H3-DOPAMINE, H3-APOMORPHINE AND H3-CLONIDINE; LABELING OF POSTSYNAPTIC SITES BY H3-NEUROLEPTICS. 003117 04-03 STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT BRAIN TISSUE SLICES.

SELECTIVITY OF H3-BIOGENIC AMINE RELEASE BY D.L. AMPHETAMINE AND DRUGS THAT INTERACT WITH SEROTONERGIC NEURONS. 001161 02-03

H3-CATECHOLAMINE
H3-CATECHOLAMINE BINDING TO ALPHA-RECEPTORS IN RAT BRAIN:
ENHANCEMENT BY RESERPINE. 003119 04-03

H3-CATECHOLAMINES INFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3-CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN. 001119 02-03

002397 03-08

002403 03-08

EFFECT OF () AMPHETAMINE ON THE RETENTION OF H3-CATECHOLAMINES IN SLICES OF NORMAL AND RESERPINIZED RAT BRAIN AND HEART.

003071 04-03

QUANTITATION OF BINDING OF H3-CHLORPROMAZINE TO SYNTHETIC MELANINS AND MELANIN GRANULES.

002354 03-05

THE IN VIVO BINDING OF H3-DESIPRAMINE AND H3-CHLORPROMAZINE TO AREAS IN THE RAT BRAIN.

003145 04-03

002940 04-03

H3-CIMETIDINE HISTAMINE H2-RECEPTOR BINDING WITH H3-CIMETIDINE IN BRAIN 002848 04-03

H3-CIS-FLUPENTHIXOL

EFFECTS OF NEUROLEPTICS ON H3-HALOPERIDOL AND H3-CISFLUPENTHIXOL BINDING AND ON ADENYLATE-CYCLASE ACTIVITY IN

002957 04-03 SELECTIVE LABELING OF PRESYNAPTIC RECEPTORS BY H3-DOPAMINE, H3-APOMORPHINE AND H3-CLONIDINE; LABELING OF POSTSYNAPTIC SITES BY H3-NEUROLEPTICS.

003117 04-03

H3-CLOZAPINE BINDING TO RAT BRAIN MEMBRANES.

CANNABINOID EFFECTS ON PLASMA CORTICOSTERONE AND UPTAKE OF H3-CORTICOSTERONE BY MOUSE BRAIN. 002051 03-03

EFFECTS OF D AMPHETAMINE (D-A), PROSTAGLANDIN-E1 AND F-2ALPHA ON H3-2-DOPAMINE (H3-DA) METABOLISM, FIXED-INTERVAL (FI)

BEHAVIOR AND RECTAL TEMPERATURE. 001207 02-03 H3-DELTA9-TETRAHYDROCANNABINOL

H3-DELTA9-TETRAHYDROCANNABINOL DISTRIBUTION IN PREGNANT DOGS AND THEIR FETUSES. 000194 01-03

THE IN VIVO BINDING OF H3-DESIPRAMINE AND H3-CHLORPROMAZINE TO AREAS IN THE RAT BRAIN.

003145 04-03 H3-DIAZEPAM BIOCHEMICAL IDENTIFICATION OF THE SITE OF ACTION OF BENZODIAZEPINES IN HUMAN BRAIN BY H3-DIAZEPAM BINDING

002583 03-13 EVIDENCE FOR AN ENDOGENOUS FACTOR INTERFERING WITH H3-DIAZEPAM BINDING TO RAT BRAIN MEMBRANES.

002789 04-01 CELLULAR LOCALIZATION OF H3-DIAZEPAM RECEPTORS.

002943 04-03 DEMONSTRATION OF AN ENDOGENOUS, COMPETITIVE INHIBITOR(S) OF

H3-DIAZEPAM BINDING IN BOVINE BRAIN. 002995 04-03

COMPARATIVE INHIBITORY EFFECTS OF SYNTHETIC ENKEPHALINS ON THE STEREOSPECIFIC BINDING OF H3-DIHYDROMORPHINE AND H3-001076 02-03

H3-DOPAMINE STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAMINE (DA) AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES.

SELECTIVE LABELING OF PRESYNAPTIC RECEPTORS BY H3-DOPAMINE, H3-APOMORPHINE AND H3-CLONIDINE; LABELING OF POSTSYNAPTIC SITES

EFFECTS OF L GLUTAMATE AND RELATED AMINO-ACIDS UPON THE RELEASE OF H3-DOPAMINE FROM RAT STRIATAL SLICES.

003340 04-04 H3-ESTRADIOL

EFFECTS OF ANTIESTROGENS ON EATING, FEMALE SEXUAL BEHAVIOR, AND THE UPTAKE OF H3-ESTRADIOL IN THE CENTRAL-NERVOUS-SYSTEM IN RATS. (PH.D. DISSERTATION).

MODIFICATION OF NUCLEAR RETENTION OF H3-ESTRADIOL BY CELLS OF THE HYPOTHALAMUS AS A FUNCTION OF EARLY HORMONE 002891 04-03

H3-FLUNITRAZEPAM THE EFFECT OF GAMMA-AMINOBUTYRIC-ACID ON H3-FLUNITRAZEPAM BINDING IN RAT BRAIN. 003132 04-03

DOPAMINE SELECTIVELY INCREASES H3-GABA RELEASE FROM SLICES OF RAT SUBSTANTIA-NIGRA IN VITRO.

INHIBITION BY NEUROLEPTICS OF UPTAKE OF H3-GABA INTO RAT BRAIN

H3-GABA RELEASE IN SYNAPTOSOMAL FRACTIONS AFTER INTRACRANIAL ADMINISTRATION OF RUTHENIUM-RED.

HIGH-AFFINITY BINDING OF H3-GLYCINE AND C14-BETA-ALANINE TO SYNAPTOSOMAL MITOCHONDRIAL FRACTIONS OF RAT CNS REGIONS; EFFECTS OF STRYCHNINE.

000211 01-03 H3-GLYCOGEN H3-GLYCOGEN HYDROLYSIS IN BRAIN SLICES: RESPONSES TO NEUROTRANSMITTERS AND MODULATION OF NORADRENALINE

003054 04-03 H3-HALOPERIDOL H3-HALOPERIDOL BINDING TO DOPAMINE RECEPTORS IN RAT CORPUS-STRIATUM: INFLUENCE OF CHLORPROMAZINE METABOLITES AND DERIVATIVES.

O01995 03-03

EFFECTS OF SOME DERIVATIVES OF 2 AMINOTETRALIN ON DOPAMINE
SENSITIVE ADENYLATE-CYCLASE AND ON THE BINDING OF H3HALOPERIDOL TO NEUROLEPTIC RECEPTORS IN RAT STRIATUM.

EFFECTS OF NEUROLEPTICS ON H3-HALOPERIDOL AND H3-CIS FLUPENTHIXOL BINDING AND ON ADENYLATE-CYCLASE ACTIVITY IN 002957 04-03

H3-HISTAMINE HIGH AFFINITY BINDING OF H3-HISTAMINE IN RAT BRAIN.

003036 04-03 H3-LYSINE STRAIN DIFFERENCES IN THE RESPONSE TO MORPHINE OF INCORPORATION OF H3-LYSINE INTO RAT BRAIN PROTEIN

000108 01-03 INCREASE CAUSED BY DESMETHYLIMIPRAMINE IN THE PRODUCTION OF H3-MELATONIN BY ISOLATED PINEAL GLANDS.

001217 02-03 H3-METHIONINE-ENKEPHALIN
THE OPIATE RECEPTOR BINDING INTERACTIONS OF H3-METHIONINEENKEPHALIN, AN OPIOID PEPTIDE.

002155 03-03 H3-MORPHINE

SPECIFIC RELEASE BY NALOXONE OF H3-MORPHINE FROM SUPERFUSED SLICES OF CORPUS-STRIATUM OF MICE. 001164 02-03

COMPARATIVE INHIBITORY EFFECTS OF SYNTHETIC ENKEPHALINS ON THE STEREOSPECIFIC BINDING OF H3-DIHYDROMORPHINE AND H3-

001076 02-03 SELECTIVE LABELING OF PRESYNAPTIC RECEPTORS BY H3-DOPAMINE, H3-APOMORPHINE AND H3-CLONIDINE; LABELING OF POSTSYNAPTIC SITES

BY H3-NEUROLEPTICS. 003117 04-03

STEREOSELECTIVITY IN THE METABOLISM OF H3-NORADRENALINE DURING UPTAKE INTO AND EFFLUX FROM THE ISOLATED RAT VAS-

002028 03-03 STIMULATION OF PRESYNAPTIC BETA-ADRENOCEPTORS ENHANCES H3-NORADRENALINE RELEASE DURING NERVE STIMULATION IN THE PERFUSED CAT SPLEEN.

002855 04-03 ADENOSINE MODULATES DEPOLARIZATION-INDUCED RELEASE OF H3-NORADRENALINE FROM SLICES OF RAT BRAIN NEOCORTEX. 002938 04-03

IN VITRO EFFECTS OF DESMETHYLIMIPRAMINE ON THE UPTAKE AND METABOLISM OF H3-NOREPINEPHRINE IN RAT BRAIN SLICES. 001997 03-03

STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAMINE (DA) AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES. 002036 03-03 EFFECT OF BETA ADRENERGIC RECEPTOR ANTAGONISTS ON D

AMPHETAMINE AND POTASSIUM-INDUCED RELEASE OF H3 NOREPINEPHRINE FROM RAT BRAIN IN VITRO. 002187 03-03

H3-PIMOZIDE IN VIVO BINDING OF H3-PIMOZIDE IN MOUSE STRIATUM: EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS. 001050 02-03

AUTORADIOGRAPHIC LOCALIZATION OF H3-RESERPINE BINDING SITES IN 002106 03-03

000240 01-03

H3-NOREPINEPHRINE

H3-SEROTONIN
HIGH-AFFINITY H3-SEROTONIN BINDING TO CAUDATE: INHIBITION BY
HALLUCINGENS AND SEROTONINERGIC DRUGS.

003138 0 003138 04-03

H3-SPIPERONE SOLUBILIZATION OF H3-SPIPERONE BINDING SITES FROM RAT BRAIN. 002929 04-03

H3-SPIROPERIDOL
H3-SPIROPERIDOL LABELS DOPAMINE RECEPTORS IN PITUITARY AND
BRAIN.

001996 03-03 TWO BINDING SITES FOR H3-SPIROPERIDOL ON RAT STRIATAL MEMBRANES.

THE EFFECTS OF STANDARD NEUROLEPTIC COMPOUNDS ON THE BINDING OF H3-SPIROPERIDOL IN THE STRIATUM AND MESOLIMBIC SYSTEM OF THE RAT IN VITRO.

H3-SPIROPERIDOL BINDING TO TWO RECEPTOR SITES IN BOTH THE CORPUS-STRIATUM AND FRONTAL CORTEX OF RAT BRAIN.

H3-SPIROPERIDOL BINDING AND DOPAMINE STIMULATED ADENYLATE-CYCLASE: EVIDENCE FOR MULTIPLE CLASSES OF RECEPTORS IN PRIMATE BRAIN REGIONS.

003112 04-03 H3-WE-4101
BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101
BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP
ACCUMULATION IN RAT CEREBRAL-CORTEX.
002885 04-4

002885 04-03

E-DOPAMINE

EFFECTS OF D AMPHETAMINE (D-A), PROSTAGLANDIN-E1 AND F-2ALPHA
ON H3-2-DOPAMINE (H3-DA) METABOLISM, FIXED-INTERVAL (FI)
BEHAVIOR AND RECTAL TEMPERATURE.

001207 02-03

001207 02-03

AUTORADIOGRAPHIC EVIDENCE FOR THE SELECTIVE ACCUMULATION OF H3-5-HT BY SUPRAEPENDYMAL NERVE TERMINALS.

ACTIVE UPTAKE OF H3-5-HT BY SYNAPTIC VESICLES FROM RAT BRAIN.
001222 02-03
001222 02-03
001222 02-03

H3-S-HYDROXYTRYPTAMINE
CONTROL OF THE RELEASE OF NEWLY SYNTHESIZED H3-SHYDROXYTRYPTAMINE BY NICOTINIC AND MUSCARINIC RECEPTORS IN
RAT HYPOTHALAMIC SLICES.

EFFECT OF COCAINE AND DESMETHYLIMIPRAMINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-5-HYDROXYTRYPTAMINE IN RAT BRAIN SLICES.

000305 01-03 SYNTHESIS AND TURNOVER OF H3-5-HYDROXYTRYPTAMINE IN THE LATERAL CEREBROVENTRICLE.

002054 03-03 IATROGENIC EXTRAPYRAMIDAL SYNDROME -- A CAUTIONARY TALE. 000834 01-15

IATROGENIC EXTRAPYRAMIDAL DISORDERS 000859 01-15 IATROGENIC ENCEPHALOPATHIES 000890 01-15

IATROGENIC COMPLICATIONS OF DRUG OVERDOSAGE AND POISONING 001824 02-15 IATROGENIC CAUSES OF NEUROLOGIC DISORDERS: PART 2. DRUG-RELATED DYSFUNCTIONS.

003644 04-15 OUTPATIENT MAINTENANCE OF CHRONIC SCHIZOPHRENIC PATIENTS WITH FLUPHENAZINE-DECANOATE (MODECATE): IBADAN EXPERIENCE.

003466 04-08 ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): NALOXONE BLOCKS MORPHINES ACCELERATION OR PRESSING FOR ICS. 001313 02-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): PRESSING FOR ICS BEFORE AND AFTER SELF-ADMINISTRATION OF SWEETENED MORPHINE SOLUTIONS.

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE, SELF-STIMULATION, AND PARAMETERS OF ICS.

002320 03-04 STEREOSELECTIVE, DOSE-DEPENDENT MODIFICATION OF INTRACRANIAL SELF-STIMULATION (ICSS) BY CENTRALLY ADMINISTERED LEVORPHANOL AND DEXTRORPHAN.

001280 02-03 EFFECTS OF ID-540 ON AVERAGED PHOTOPALPEBRAL REFLEX IN MAN THE EFFECTS OF A NEW BENZODIAZEPINE DERIVATIVE, ID-540, ON THE AVERAGED PHOTOPALPEBRAL REFLEX IN MAN. 003610 04-13

REPORT FROM CUNICAL PRACTICE: THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG TREATMENT OF HYPERACTIVE CHILDREN. (UNPUBLISHED PAPER).

000656 01-11

IDENTIFICATION
ISOLATION AND IDENTIFICATION OF AN IN VIVO REACTION PRODUCT OF
6 HYDROXYDOPAMINE.

SIMULTANEOUS IDENTIFICATION AND QUANTITATION OF DIPHENHYDRAMINE AND METHAQUALONE. 000925 01-16

VIDEOTAPE METHODS FOR IDENTIFICATION OF NONVERBAL BEHAVIOR PARAMETERS IN DEPRESSIVE SYNDROMES.

IDENTIFICATION OF M HYDROXYAMPHETAMINE AS A METABOLITE OF AMPHETAMINE IN THE RAT. 001005 02-01

IDENTIFICATION OF THE IN VITRO N OXIDIZED METABOLITES OF ()- AND (-) N BENZYLAMPHETAMINE. 001054 02-03

IDENTIFICATION OF SHORT TIME INTERVALS UNDER LSD-25 AND MESCALINE.

001635 02-12 RAPID IDENTIFICATION OF HYPNOTICS IN EMERGENCY CASES BY COMPUTERIZED GAS-CHROMATOGRAPHY MASS SPECTROMETRY 001841 02-15

IDENTIFICATION OF DOPAMINERGIC RECEPTORS IN ANTERIOR PITUITARY:
CORRELATION WITH THE DOPAMINERGIC CONTROL OF PROLACTIN
RELEASE.

MONOAMINE-OXIDASE IN RAT RETICULOCYTES: SUBCELLULAR LOCALIZATION AND IDENTIFICATION OF ISOENZYMES.

002134 03-03 BIOCHEMICAL IDENTIFICATION OF THE SITE OF ACTION OF BENZODIAZEPINES IN HUMAN BRAIN BY H3-DIAZEPAM BINDING

002583 03-13

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4HYDROXYPHENYLETHANOL (MOPET) IN HUMAN CEREBROSPINAL FLUID
AND RAT BRAIN BY MEANS OF GAS-CHROMATOGRAPHY -- MASS-

IDENTIFICATION OF A SUBREGION WITHIN RAT NEOSTRIATUM FOR THE DOPAMINERGIC MODULATION OF LATERAL HYPOTHALAMIC SELF-STIMULATION.

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLLACTIC-ACID (VLA) IN CEREBROSPINAL FLUID AND 3 METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN THE URINE OF PARKINSONIAN PATIENTS TREATED WITH L-DOPA.

003602 04-13

IDENTIFIED
ANTIDROMICALLY IDENTIFIED SEROTONERGIC NEURONS IN THE RAT MIDBRAIN RAPHE: EVIDENCE FOR COLLATERAL INHIBITION

000292 01-03

IDENTIFYING
A COMPARISON OF THALIDOMIDE AND PENTOBARBITAL — NEW
METHODS FOR IDENTIFYING NOVEL HYPNOTIC DRUGS.
0013

INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A
METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS.

001959 03-02
INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A
METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS. 002801 04-02

IDIOSYNCRATIC ACUTE DYSTONIA AS AN IDIOSYNCRATIC RESPONSE TO NEUROLEPTICS IN RABOONS.

IFC-45

EFFECTS OF IFC-45, A NEW BENZONAPHTYRIDONE DERIVATIVE WITH ANTIDEPRESSIVE ACTION, ON ACTIVITY OF THE RAT SUPRARENAL GLAND CORTEX.

001522 0

001522 02-05 IHHIBITORY
ACTIVATION OF AN IHHIBITORY NORADRENERGIC PATHWAY PROJECTING
FROM THE LOCUS-COERULEUS TO THE CINGULATE CORTEX OF THE RAT.
002895 04-03

SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION. 002052 03-03

MORPHINE IN BRAIN AND ILEUM. 000247 01-03 MEDICATION CLASSES FOR THE EMOTIONALLY ILL.

000984 01-17 DEVELOPMENT OF DRUG THERAPY FOR THE MENTALLY ILL 001551 02-07

HEROIN AND OTHER HUMANISTIC TREATMENT FOR THE TERMINALLY ILL 003703 04-17 LITHIUM AND THE TREATMENT OF ADOLESCENT MANIC-DEPRESSIVE **HINESS** 000569 01-09 CYCLIC-ADENOSINE-MONOPHOSPHATE METABOLISM IN PATIENTS WITH SEVERE DEPRESSIVE ILLNESS MANIA IN CHILDHOOD. II. THERAPEUTIC TRIAL OF LITHIUM-CARBONATE
AND FURTHER DESCRIPTION OF MANIC-DEPRESSIVE ILLNESS IN 001578 02-09 NORADRENALINE, DEPRESSIVE ILLNESS, AND THE ACTION OF 001588 02-09 PLATELET MONOAMINE-OXIDASE ACTIVITY PREDICTS RESPONSE TO LITHIUM IN MANIC-DEPRESSIVE ILLNESS. 001607 02-09 A TWO-DOSE DEXAMETHASONE SUPPRESSION TEST IN PATIENTS WITH PSYCHIATRIC ILLNESS. 001691 02-13 AMINE NEUROTRANSMITTER STUDIES AND PSYCHIATRIC ILLNESS: TOWARD MORE MEANINGFUL DIAGNOSTIC CONCEPTS. (UNPUBLISHED PAPER) 001893 02-17 MANIC-DEPRESSIVE ILLNESS AND NEUROTRANSMITTERS. 002253 03-04 INITIAL RESPONSE TO DRUGS IN DEPRESSIVE ILLNESS AND PSYCHIATRIC AND COMMUNITY ADJUSTMENT A YEAR LATER. 002459 03-09 INTRAPSYCHIC AND FAMILY DYNAMIC PROCESSES IN AN ENDOGENOUS DEPRESSION PRECEDING MANIFESTATION OF THE ILLNESS AND LITHIUM THERAPY 002461 03-09 ON THE TREATMENT OF NEURODERMATITIS WITH A MONOAMINE-OXIDASE INHIBITOR: THE CHEMOTHERAPY OF PSYCHOSOMATIC ILLNESS THROUGH A-REM SUPPRESSION. 002480 03-10 A CLINICAL TRIAL OF CLOMIPRAMINE AND DIAZEPAM IN THE TREATMENT OF PHOBIC AND OBSESSIONAL ILLNESS. 002497 03-10 HEAT ILLNESS SYNDROME AND LITHIUM INTOXICATION 002669 03-15 RESEARCH FINDINGS ON CHRONIC MENTAL ILLNESS: MODEL FOR CONTINUING-CARE IN THE HEALTH MAINTENANCE ORGANIZATION 002777 03-17 VILOXAZINE AND AMITRIPTYLINE IN DEPRESSIVE ILLNESS: A DOUBLE-BLIND CONTROLLED TRIAL IN GENERAL PRACTICE. 003506 04-09 PSYCHIATRIC ILLNESS AND HUMAN RENAL TRANSPLANTATION 003510 04-09 MEDICAL TREATMENT OF MENTAL ILLNESS 003618 04-14 NEUROTRANSMITTER MECHANISMS DURING MENTAL ILLNESS INDUCED BY ALTERATIONS IN THYROID FUNCTION. 003636 04-14 ILLNESS-INDUCED ILLNESS-INDUCED AVERSION LEARNING IN A DESERT SPECIES OF RODENT (ACOMYS-CAHIRINUS). 001350 02-04 IMBALANCE AUTONOMIC IMBALANCE: A SUBSTRATE OF HYPERACTIVITY 000783 01-14 PHARMACOLOGICAL INVESTIGATIONS OF THE CHOLINERGIC IMBALANCE HYPOTHESES OF MOVEMENT DISORDERS AND PSYCHOSIS. 002509 03-11 HEMISPHERIC ASYMMETRY OF VISUAL EVOKED-POTENTIALS WITH MOTOR IMBALANCE IN RATS. 003310 04-04 IMIDAZORENZODIAZEPINE IN VITRO METABOLISM OF AN IMIDAZOBENZODIAZEPINE 001289 02-03 IMIDAZOBENZODIAZEPINES
FEEDING BEHAVIOR OF SHEEP FOLLOWING INTRAVENOUS INJECTION OF IMIDAZOBENZODIAZEPINES. 002193 03-04 SYNTHESIS AND COMPARATIVE SKELETAL MUSCLE RELAXANT ACTIVITY OF SOME 2.4 IMIDAZOLIDINEDIONES AND THEIR CORRESPONDING 5 HYDROXYIMIDAZOLIDINEDIONES.

NEUROCHEMICAL AND BEHAVIORAL EFFECTS OF CLONIDINE AND RELATED

THE SELECTIVE INHIBITION OF DOPAMINE LIPTAKE BY A TRICYCLIC IMINE

IMIDAZOLINES: INTERACTION WITH ALPHA-ADRENOCEPTORS

IMIDAZOLINES

IMIPRAMINE DERIVATIVES: AMINOMETHYLATION OF DIPHENYLAMINE 000011 01-01 IMIPRAMINE DERIVATIVES: AMINOMETHYLATION OF DIPHENYLAMINE AND IMINODIRENZYL EFFECTS OF RESERPINE AND IMIPRAMINE ON VESICULAR SEROTONIN
UPTAKE AND STORAGE IN INTACT HUMAN PLATELETS. SEROTONIN TRANSPORT AND STORAGE IN RABBIT BLOOD PLATELETS
THE EFFECTS OF RESERPINE AND IMPRAMINE. EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN TWO INBRED STRAINS OF MICE. 000333 01-04 LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUSION II IMIFRAMINE POISONING 000477 01-05 A SEQUENTIAL TRIAL OF VILOXAZINE (VIVALAN) AND IMIPRAMINE IN MODERATELY DEPRESSED PATIENTS. 000563 01-09 PLASMA CONCENTRATION AND THE ANTIDEPRESSANT EFFECT OF IMIPRAMINE TREATMENT. 000567 01-09 PLASMA LEVELS DURING TREATMENT WITH IMIPRAMINE. CLOMIPRAMINE, AND IMIPRAMINE-N-OXIDE. 000574 01-09 SINGLE AND DIVIDED DOSE OF IMIPRAMINE. 000595 01-10 SUCCESSFUL TREATMENT OF ANOREXIA-NERVOSA WITH 000617 01-10 IN VITRO EFFECTS OF IMIPRAMINE ON PROLIFERATION OF HUMAN LEUKOCYTES. 000699 01-13 THE DEMETHYLATION OF IMIPRAMINE AND CLOMIPRAMINE AS APPARENT FROM THEIR PLASMA KINETICS. CARDIOTOXIC DRUGS, WITH SPECIAL ATTENTION TO PHENOTHIAZINES AND IMPRAMINE DERIVATIVES. 000868 01-15 A CASE OF FATAL IMIPRAMINE POISONING IN AN INFANT 000879 01-15 IMPURITIES IN DRUGS I: IMIPRAMINE, DESIPRAMINE, AND THEIR FORMULATIONS. ALTERATIONS INDUCED IN DISTRIBUTION AND IN VIVO METABOLISM OF IMIPRAMINE BY PREGNENOLONE-16ALPHA-CARBONITRILE. 001065 02-03 ALTERATIONS IN BRAIN HISTAMINE AND HISTIDINE-DECARBOXYLASE ACTIVITY AFTER HALOPERIDOL AND IMPRAMINE. 001188 02-03 HISTAMINE STIMULATED ADENYLATE-CYCLASE: BLOCKADE BY IMIPRAMINE AND ITS ANALOGUES. 001216 02-03 CHEMILUMINESCENCE RESULTING FROM AN INTERACTION BETWEEN IMPRAMINE AND HUMAN POLYMORPHONUCLEAR LEUKOCYTES. 001263 02-03 INCENTIVE CONTRAST UNDIMINISHED BY EXTENDED TESTING IMIPRAMINE, OR CHLORDIAZEPOXIDE. 001354 02-04 LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUSION IN IMIPRAMINE POISONING. AN IN-VITRO AND IN-VIVO STUD 001503 02-05 IO AS A PREDICTOR OF ANTIDEPRESSANT RESPONSES TO IMIPRAMIN 001582 02-09 DOUBLE-BLIND PLACEBO-CONTROLLED COMPARISON OF AMOXAPINE AND IMIPRAMINE IN DEPRESSED OUTPATIENTS. WHICH TRICYCLIC FOR DEPRESSED OUTPATIENTS, IMIPRAMINE PAMOATE OR AMITRIPTYLINE?. O01589 02-09
A DOUBLE-BLIND CLINICAL COMPARISON OF AMOXAPINE, IMIPRAMINE. AND PLACEBO IN THE TREATMENT OF DEPRESSION 001609 02-09 EFFECTS OF IMIPRAMINE ON ENURETIC FREQUENCY AND SLEEP STAGES.
001719 02-14 PROVEN ASYMPTOMATIC EOSINOPHILIA WITH IMIPRA 001765 02-15 A CASE OF ORAL DYSKINESIA ASSOCIATED WITH IMIPRAMI TREATMENT. 001768 02-15 HYPERTONIC SODIUM-CHLORIDE AND LIDOCAINE IN A CASE OF IMIPRAMINE INTOXICATION. 001769 02-15 PREDICTION OF PLASMA LEVELS OF IMIPRAMINE FROM
PHARMACOKINETICS OF AN INITIAL DOSE. (UNPUBLISHED PAPER) 001876 02-16

IMINODIBENZYU

001944 03-01

002156 03-03

000141 01-03

IMIPRAMINE ANTAGONISM OF APOMORPHINE-INDUCED HYPOTHERMIA: A NONDOPAMINERGIC INTERACTION.

EFFECTS OF P-CHLOROAMPHETAMINE ON BRAIN SEROTONIN IN IMMATURE RATS.

MEMORIZATION AND CENTRAL CATECHOLAMINES AFTER CRANIOCERVICAL INJURY CARRIED OUT IN RATS: INFI	LUENCE OF	MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMI INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIME ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPIN FROG AND IMMATURE RAT.	ELIC-ACID, D
EFFECTS OF CHRONIC IMIPRAMINE AND CLOMIPRAMINE ADMINISTRATION ON MATERNAL BEHAVIOR AND LITT		EXPLORATION IN IMMATURE RATS: EFFECTS OF DRUGS.	002901 04-03
DEVELOPMENT.	002202 03-04	IMMERSED	003218 04-04
A BEHAVIORAL AND AUTONOMIC NERVOUS SYSTEM STI IMIPRAMINE ADMINISTRATION TO CONSCIOUS DOGS.	UDY OF CHRONIC	THE EFFECTS OF ALCOHOL UPON COOLING RATES OF HUM IN 7.5 DEGREES C WATER.	
EFFECTS OF IMIPRAMINE TREATMENT OF SEPARATION-IN DISORDERS IN RHESUS MONKEYS.	002263 03-04 NDUCED SOCIAL	IMMOBILITY A SEROTONERGIC, MIDBRAIN RAPHE MODEL OF TONIC IN	002541 03-12 AMOBILITY.
DOXEPIN AND IMIPRAMINE IN THE TREATMENT OF DEPR DOUBLE-BLIND CROSS-OVER CLINICAL STUDY WITH EX		THE EFFECT OF EPINEPHRINE ON TONIC IMMOBILITY (ANI/ IN CHICKENS.	
DIFFERENTIAL EFFECTS OF A SINGLE DOSE OF IMIPRAMIN LOPRAMINE IN HEALTHY SUBJECTS VARYING IN THEIR	002416 03-09 NE AND	THE PSYCHOPHARMACOLOGY OF MORPHINE EFFECTS ON IMMOBILITY, (PH.D. DISSERTATION).	000460 01-04 TONIC
DEPRESSION.		THE EFFECTS OF SOME PHARMACOLOGICAL AGENTS ON T	001276 02-03
IMIPRAMINE: CLINICAL EFFECTS AND PHARMACOKINETI	002446 03-09	OF IMMOBILITY SHOWN BY RABBITS PLACED IN VARIO	OUS POSTURES.
DOSAGE EFFECTS OF IMIPRAMINE ON THE PSYCHOPATHI	002460 03-09 OLOGIC AND	TOLERANCE TO MORPHINE ANALGESIA AND IMMOBILITY RATS BY CHANGES IN LOG-DOSE-RESPONSE CURVES.	001355 02-04 MEASURED IN
BIOLOGIC INDICES OF ENDOGENOUS DEPRESSIVE SYND	OROMES. 002494 03-10		003307 04-04
BEHAVIOR THERAPY, SUPPORTIVE PSYCHOTHERAPY, IMPHOBIAS.	IPRAMINE, AND	IMMOBILIZED ANTAGONISM OF PENTOBARBITAL DISCRIMINATIVE STIM BEMEGRIDE IN IMMOBILIZED RATS.	ULUS BY
STEADY-STATE KINETICS OF IMIPRAMINE IN PATIENTS.	002501 03-10		003266 04-04
	002556 03-13	INFLUENCE OF IMMUNE STIMULATION AND SUPPRESSION	ON MORPHINE
IMIPRAMINE, ITS N DESMETHYL AND HYDROXY METAB PLASMA: MICRO DETERMINATION BY ALKALINE FLAN		PHYSICAL DEPENDENCE AND TOLERANCE.	002095 03-03
GAS-CHROMATOGRAPHY (AFID-GC).	002597 03-13	IMMUNOASSAY	
THE EFFECTS OF TWO ANTIDEPRESSANTS, IMIPRAMINE A VILOXAZINE, UPON DRIVING PERFORMANCE.		EVALUATION OF A NEW IMMUNOASSAY FOR DETERMINA PHENYTOIN AND PHENOBARBITAL: RESULTS OF A EURO COLLABORATIVE CONTROL STUDY.	
EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE ON BE	002612 03-14		002529 03-11
HYPERACTIVE CHILDREN.	002645 03-14	IMMUNOHISTOCHEMICAL SOMATOSTATIN: ELECTRON MICROSCOPE IMMUNOHISTO LOCALIZATION IN SECRETORY NEURONS OF RAT HYPO'	
EKG EFFECTS OF IMIPRAMINE TREATMENT IN CHILDREN.	002696 03-15	IMMUNOSUPPRESSION	001948 03-01
A SIMPLE METHOD FOR THE DETERMINATION OF THERA CLOMIPRAMINE, IMIPRAMINE AND DESIPRAMINE.	PEUTIC LEVELS OF	IMMUNOSUPPRESSION OF MICE BY DELTA9-TETRAHYDRO	OCANNABINOL. 002073 03-03
INTERACTION OF IMIPRAMINE AND 3 QUINUCLIDYL-BEN.	002717 03-16 711 ATE WITH 9	ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND REL	ATED DOUGE ON
AMINO-7-METHOXYTETRAHYDROACRIDINE ON THE AI IN THE LIMBIC SYSTEM.		THE TREATMENT OF SCHIZOPHRENIA.	000536 01-08
EFFECTS OF CHLORDIAZEPOXIDE, AMITRIPTYLINE, IMIPR THEIR COMBINATIONS ON AVOIDANCE BEHAVIOUR IN	002945 04-03 AMINE, AND	THE IMPACT OF LITHIUM ON THE TREATMENT OF MANIC DISORDERS.	-DEPRESSIVE
	003352 04-04	IMPACT OF AGE ON ANTERIOR PITUITARY HORMONES IN	
TREATMENT OF IMIPRAMINE RESISTANT DEPRESSION AI REFRACTORY MANIA THROUGH DRUG INTERACTIONS	003512 04-09	EFFECT OF DEXAMETHASONE ON CEREBRAL EDEMA FROM	001687 02-13 A CRANIAL
PREDICTION OF STEADY-STATE PLASMA CONCENTRATIO		IMPACT IN THE CAT.	001958 03-02
IMIPRAMINE.	003516 04-09	PREVENTION OF ENVIRONMENTAL STRESS IMPACT ON RA	ATS. 002296 03-04
OXYPERTINE IN COMBINATION WITH IMPRAMINE: A CO TRIAL.	ONTROLLED	THE IMPACT OF CLOMIPRAMINE AND ITS WITHDRAWAL NOCTURNAL HORMONE PROFILES — A PRELIMINARY R	ON SOME
COMPARABLE EFFICACY OF IMIPRAMINE HCL AND IMIP	003521 04-09	IMPAIRED	002572 03-13
PAMOATE: A POOLED STATISTICAL REPORT.		THE EFFECT OF METHYLPHENIDATE ON TEST PERFORMAN	CE IN THE
PRAMINE-INDUCED	003526 04-09	COGNITIVELY IMPAIRED AGED.	000622 01-11
EFFECTS OF PHENOBARBITAL AND DIAZEPAM ON IMIPR. CHANGES IN BLOOD PRESSURE, HEART RATE AND RE		5 HYDROXYTRYPTAMINE: THE EFFECTS OF IMPAIRED SYL METABOLISM AND RELEASE IN RAT.	NTHESIS ON ITS
TEMPERATURE OF RATS.	001070 02-03	IMPAIRMENT	002878 04-03
IPRAMINE-N-OXIDE		MEMORY IMPAIRMENT CORRELATES CLOSELY WITH CYC	
PLASMA LEVELS DURING TREATMENT WITH IMPRAMIN CLOMIPRAMINE, AND IMPRAMINE-N-OXIDE.	lt,	DOSE AND DEGREE OF INHIBITION OF PROTEIN SYNTHE	SIS. 000436 01-04
THE KINETICS OF IMIPRAMINE-N-OXIDE IN RATS.	000576 01-09	IMPAIRMENT OF RETENTION OF AVOIDANCE RESPONSES POSTTRAINING DIETHYLDITHIOCARBAMATE.	IN RATS BY
THE KINETICS OF IMIPRAMINE-N-OXIDE IN MAN.	002109 03-03	ABSENCE OF DRUG-INDUCED BETA-ACTIVITY IN THE	000454 01-04
	002585 03-13	ELECTROENCEPHALOGRAM: A SIGN OF SEVERE CEREBR	AL
COMPARABLE EFFICACY OF IMPRAMINE HCL AND IMP	RAMINE-	IMPAIRMENT.	001676 02-13
PAMOATE: A POOLED STATISTICAL REPORT.	1000	ORGANIC IMPAIRMENT IN POLYDRUG USERS: RISK FACT	ORS.
MATURE	003526 04-09	IMPAIRMENTS	002670 03-15
THE ROLE OF HYPOTHALAMIC SEROTONIN (5-HT) BEFOR IMMATURE RATS TREATED WITH PREGNANT MARE S	ERUM (PMS).	OR SENSORY-MOTOR IMPAIRMENTS?.	
	001287 02-03		001432 02-04

IMPLANTAT	HOI
SENSITI	VITI
MYE	NTER

ES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE RIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION. 002052 03-03

IMPLICATION

MONOAMINERGIC IMPLICATION IN DIFFERENT ELEMENTS OF SEXUAL BEHAVIOUR

000411 01-04 SENESCENT BRAIN: CURRENT STATUS AND IMPLICATION IN NEUROPSYCHOPHARMACOLOGY.

001905 02-17

002759 03-17

003287 04-04

IMPOTENCE

IMPOTENCE RESPONSIVE TO GLYCERYL-TRINITRATE. TRINITRATE 000650 01-11 IMPOTENCE: ROLE OF DRUG AND HORMONAL TREATMENT.

IMPOTENTIA-EXECTIONIS

THE APPROACH RESPONSE.

A NEW APPROACH TO THE HORMONAL TREATMENT OF IMPOTENTIA-002386 03-07

IMPRINTING

IMPRINTING BEHAVIOR: PITUITARY ADRENOCORTICAL MODULATION OF

SCHIZOPHRENIC SYMPTOMS IMPROVE WITH APOMORPHINE 003474 04-08

IMPROVEMENT WITH L-DOPA IN A HYPERKINETIC CHILD.

000769 01-14 APOMORPHINE-HYDROCHLORIDE-INDUCED IMPROVEMENT IN

HUNTINGTONS-CHOREA 002508 03-11

RHEOENCEPHALOGRAPHIC AND OTHER STUDIES OF BETAHISTINE IN HUMANS. IV. PROLONGED ADMINISTRATION WITH IMPROVEMENT IN ARTERIOSCLEROTIC DEMENTIA.

002530 03-11 EFFECT OF PIMOZIDE ON THE IMPROVEMENT IN LEARNING PRODUCED BY SELF-STIMULATION AND BY WATER REINFORCEMENT.

A CASE OF DEPRESSION SHOWING IMPROVEMENT IN TRH TEST BY
COMBINED TREATMENT BY DIMETACRINE-TARTRATE AND THYROID 003527 04-09

IMPROVING

DRUG IMPROVING CEREBRAL METABOLISM IN DEMENTIA

001695 02-13

IMPULSES

EFFECT OF NARCOTICS ON CONDUCTION OF AFFERENT VISCERAL IMPULSES. 001083 02-03

IMPURITIES

IMPURITIES IN DRUGS I: IMIPRAMINE, DESIPRAMINE, AND THEIR FORMULATIONS. 000964 01-17

IN-UTERO

EFFECT OF IN-UTERO ADMINISTRATION OF MORPHINE ON THE SUBSEQUENT DEVELOPMENT OF SELF-ADMINISTRATION BEHAVIOR 000368 01-04

INACTIVE

THE EFFECT OF ANTIPSYCHOTIC DRUGS AND THEIR CLINICALLY INACTIVE ANALOGS ON DOPAMINE METABOLISM. 001250 02-03

INATTENTIVENESS

METHYLPHENIDATE THERAPY FOR INATTENTIVENESS IN SELECTED SCHOOL CHILDREN

000623 01-11 CAFFEINE AND INATTENTIVENESS IN READING-DISABLED CHILDREN 001721 02-14

EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN TWO INBRED STRAINS OF MICE. 000333 01-04

EFFECTS OF MESCALINE AND PSILOCIN ON ACQUISITION. CONSOLIDATION, AND PERFORMANCE OF LIGHT-DARK DISCRIMINATION IN TWO INBRED STRAINS OF MICE.

003184 04-04 ANALGESIA AND MOTOR ACTIVITY ELICITED BY MORPHINE AND ENKEPHALINS IN TWO INBRED STRAINS OF MICE.

003225 04-04 A GENETIC ANALYSIS OF THE HYPERTHERMIC RESPONSE TO D AMPHETAMINE IN TWO INBRED STRAINS OF MICE.

INCENTIVE CONTRAST UNDIMINISHED BY EXTENDED TESTING, IMIPRAMINE, OR CHLORDIAZEPOXIDE. 001354 02-04 INCIDENCE

TRICYCLIC ANTIDEPRESSANT OVERDOSE: INCIDENCE OF SYMPTOMS

THE CONTRIBUTION OF PRESCRIBED DRUGS TO THE INCIDENCE OF ACCIDENTAL AND DELIBERATE POISONING IN THE COMMUNITY.

001896 02-17

EFFECT OF ALPHA-METHYL-P-TYROSINE ON THE INCIDENCE OF
SPONTANEOUS CONVULSIONS OBSERVED FOLLOWING BARBITAL
MITTUPS AUG. WITHDRAWAL

002104 03-03

PHARMACOLOGICAL INCOMPATIBILITY OF NEUROLEPTICS AND TRANQUILIZERS WITH OTHER PREPARATIONS.

002680 03-15

DISSERTATION)

CHANGES IN THE RATE INCREASING EFFECTS OF D AMPHETAMINE AND PENTOBARBITAL BY RESPONSE CONSEQUENCES. 000452 01-04

THE INCREASING ABUSE OF PHENCYCLIDINE

000892 01-15

001459 02-04

000675 01-12

PROGRESSIVE FORCE SCHEDULES IN THE SQUIRREL-MONKEY: EFFECTS OF INCREMENT SIZE, AMPHETAMINE, AND HALOPERIDOL. (PH.D.

INCUBATED

EFFECTS OF KAINIC-ACID ON ION DISTRIBUTION AND ATP LEVELS OF

STRIATAL SLICES INCUBATED IN VITRO. LITHIUM EFFLUX FROM ERYTHROCYTES INCUBATED IN VITRO DURING

LITHIUM-CARBONATE ADMINISTRATION. 003518 04-09

BARBITURATE-INDUCED CHANGES IN TRANSMITTER RELEASE INDEPENDENT OF TERMINAL SPIKE CONFIGURATION IN THE FROG NEUROMUSCULAR JUNCTION

000294 01-03 PIMOZIDE (ORAP-ETHNOR): AN INDEPENDENT REPORT.

ANALGESIA INDUCED BY VAGINAL STIMULATION IN RATS IS
APPARENTLY INDEPENDENT OF A MORPHINE SENSITIVE PROCESS.
00.1090 02-03

DOPAMINE SYNTHESIS AND TYROSINE-HYDROXYLASE ARE REGULATED BY INDEPENDENT DA RECEPTOR MEDIATED MECHANISMS.

003116 04-03

INDIANS
HISTORICAL AND CULTURAL FACTORS INFLUENCING CANNABIS USE AMONG INDIANS IN SOUTH-AFRICA.

ETHNOPHARMACOLOGY OF SACRED PSYCHOACTIVE PLANTS USED BY THE INDIANS OF MEXICO. 001894 02-17

INDICATED

EFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY THE RESPONSES OF THE MUSCLE SPINDLE OF THE TRICEPS SURAE MUSCLE OF THE DECEREBRATE CAT TO THE MUSCLE STRETCH.

003109 04-03 INDICATION THE HUMAN EEG IN SEVERELY POISONED PATIENTS — INDICATION AND CONTROL OF HEMODIALYSIS OR HEMOPERFUSION.

001795 02-15 POSSIBLE INDICATION OF DOPAMINERGIC BLOCKADE IN MAN BY ELECTRORETINOGRAPHY.

003689 04-16

INDICATOR FLUCTUATING DENTAL ASYMMETRY AS AN INDICATOR OF THE STRESSFUL PRENATAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN THE LABORATORY RAT.

001520 02-05 EYE MOVEMENT, AN INDICATOR OF BRAIN FUNCTION. 002637 03-14

DIFFERENTIAL HALOPERIDOL EFFECT ON TWO INDICES OF FENTANYL

SALINE DISCRIMINATION. 000495 01-06 LYSERGIC-ACID-DIETHYLAMIDE. PHOTOELECTRON IONIZATION

POTENTIALS AS INDICES OF BEHAVIORAL ACTIVITY. 001100 02-03 EFFECT OF LITHIUM-CHLORIDE ON CERTAIN INDICES OF CARDIAC

FUNCTION. 001521 02-05 DOSAGE EFFECTS OF IMIPRAMINE ON THE PSYCHOPATHOLOGIC AND BIOLOGIC INDICES OF ENDOGENOUS DEPRESSIVE SYNDROMES. 002494 03-10

INDIRECT SYMPATHOMIMETICS AND CEREBRAL BLOOD FLOW AND METABOLISM

001189 02-03 INDIRECT SYMPATHOMIMETIC AGENTS AND CEREBRAL BLOOD FLOW AND METABOLISM.

002092 03-03

003411 04-05

INDIVIDUAL VARIATIONS IN RESPONSE OF HUMAN REM SLEEP TO AMITRIPTYLINE AND HALOPERIDOL.

000779 01-14

PREDICTION OF INDIVIDUAL DOSAGE OF NORTRIPTYLINE

002714 03-16 ON INDIVIDUAL EVALUATION OF THE EFFECT OF P-CHLOROAMPHETAMINE CATECHOLAMINERGIC NUCLEI IN THE RAT BRAIN. 003003 04-03

002768 03-17

000269 01-03

INDIVIDUALISED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS

001863 02-16

PURCHASES OF HYPNOTICS, SEDATIVES AND MINOR TRANQUILLIZERS AMONG 2,566 INDIVIDUALS IN THE COUNTY OF JAMTLAND, SWEDEN: A 6-YEAR FOLLOW-UP.

CLINICAL EVALUATION OF NALTREXONE TREATMENT OF OPIATE-DEPENDENT INDIVIDUALS: REPORT OF THE NATIONAL RESEARCH COUNCIL COMMITTEE ON CLINICAL EVALUATION OF NARCOTIC

NDOLAMINEROIC
THE INDOLAMINERGIC INNERVATION OF THE INFERIOR OLIVE. 2.
RELATION TO HARMALINE-INDUCED TREMOR.
0002:

QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS OF BIOLOGICALLY
ACTIVE INDOLE, 1 METHYLINDOLE AND BENZO-B-THIOPHENE
DERIVATIVES.

000006 01-01 PHARMACOLOGICAL INTERACTIONS WITH CIRCLING BEHAVIOUR INDUCED BY THE PIPERIDINYL INDOLE DERIVATIVE RU-23686. 002200 03-04

THE INDOLEAMINE HYPOTHESIS OF DEPRESSION: AN OVERVIEW AND PILOT STUDY

BRAIN DISTRIBUTION OF LITHIUM AND INDOLEAMINE METABOLISM IN DOGS AFTER CHRONIC LITHIUM ADMINISTRATION. 001108 02-03

THEORETICAL AND THERAPEUTIC POTENTIAL OF INDOLEAMINE PRECURSORS IN AFFECTIVE-DISORDERS.

001610 02-09

INDOMETHACIN

EFFECTS OF THE PROSTAGLANDIN SYNTHESIS INHIBITOR, INDOMETHACIN
ON ESTROGEN AND ESTROGEN PLUS PROGESTERONE-INDUCED SEXUAL
RECEPTIVITY IN OVARIECTOMIZED RATS. 003237 04-04

TRIAL OF AN ALPHA-ADRENOLYTIC DRUG (INDORAMIN) FOR NOCTURNAL ENURESIS.

003573 04-11

DRUGS THAT MAY INDUCE PULMONARY DISEASE.

002694 03-15

BRAIN SEROTONIN TURNOVER AND MORPHINE-TOLERANCE DEPENDENCE INDUCED BY MULTIPLE INJECTIONS IN THE RAT.

5-HT ANTAGONISTS INHIBIT NEUROLEPTIC AND MORPHINE ANTAGONISM OF THE HYPERACTIVITY INDUCED BY DOPAMINE FROM THE NUCLEUS-ACCUMBENS.

INFLUENCE OF DIAZEPAM, L-DOPA AND DOPAMINE ON THE CEREBELLAR AND SPINAL ELECTRICAL PATTERNS INDUCED BY HARMINE IN THE

000091 01-03

EFFECTS OF VARIOUS NEUROLEPTICS ON RABBIT HYPERTHERMIA INDUCED BY N.N DIMETHYLTRYPTAMINE (DMT) AND D AMPHETAMINE. 000099 01-03

ELECTROCORTICAL CHANGES INDUCED BY THE PERFUSION OF NORADRENALINE, ACETYLCHOLINE AND THEIR ANTAGONISTS DIRECTLY INTO THE DORSAL RAPHE NUCLEUS OF THE CAT. 000164 01-03

ACTIVITY OF VESTIBULO-OCULOMOTOR NEURONES DURING SACCADIC EYE MOVEMENTS INDUCED BY RESERPINE.

FURTHER STUDIES OF THE AGGRESSIVE BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN REM SLEEP-DEPRIVED RATS. 000331 01-04

CIRCLING BEHAVIOR AND STEREOTYPY INDUCED BY INTRANIGRAL OPIATE MICROINJECTIONS.

000385 01-04 EFFECTS OF ANGIOTENSIN-II ON SCHEDULE-DEPENDENT AND INDUCED BEHAVIOR AT RECOVERED BODY WEIGHT.

000470 01-04 MOVEMENT DISORDERS INDUCED IN MONKEYS BY CHRONIC HALOPERIDOL TREATMENT.

Psychopharmacology Abstracts

EFFECTS OF KETAMINE ON PATIENT RESPONSIVENESS DURING THE VARIOUS PHASES OF A SINGLE INDUCED ANXIETY SESSION. 000513 01-07

EMBRYOPATHIES INDUCED BY TERATOGENIC AGENTS

000857 01-15 EPILEPTIC SEIZURES INDUCED BY PSYCHOTROPIC DRUGS.

000905 01-15 A PHARMACOLOGICAL STUDY OF THE SPONTANEOUS CONVULSIVE ACTIVITY INDUCED BY 1,2 DIHYDROXYBENZENE (CATECHOL) IN THE ANESTHETIZED MOUSE.

001046 02-03 BURST FIRING OF CEREBELLAR PURKINJE NEURONES INDUCED BY BENZODIAZEPINES.

001061 02-03 ALTERATIONS INDUCED IN DISTRIBUTION AND IN VIVO METABOLISM OF IMPRAMINE BY PREGNENOLONE-16ALPHA-CARBONITRILE.

ROLE OF NOREPINEPHRINE IN THE RELEASE OF PROLACTIN INDUCED BY SUCKLING AND ESTROGEN.

001071 02-03 FOOTSHOCK INDUCED ANALGESIA IN MICE: ITS REVERSAL BY NALOXONE AND CROSS-TOLERANCE WITH MORPHINE.

001078 02-03 ANALGESIA INDUCED BY VAGINAL STIMULATION IN RATS IS
APPARENTLY INDEPENDENT OF A MORPHINE SENSITIVE PROCESS 001090 02-03

FFERENTIAL ANTAGONISM BY CHLORPROMAZINE AND DIAZEPAM OF FROG MOTONEURONE DEPOLARIZATION INDUCED BY GLUTAMATE RELATED AMINO-ACIDS.

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF

HYPERALGESIA INDUCED BY NALOXONE FOLLOWS DIURNAL RHYTHM IN RESPONSIVITY TO PAINFUL STIMULI.

001124 02-03 SOME PHARMACOLOGICAL OBERVATIONS ON THE ANALGESIA INDUCED BY ACUPUNCTURE IN RABBITS

EFFECT OF D AMPHETAMINE ON THE INHIBITION OF BRAIN
CATECHOLAMINE TURNOVER INDUCED BY CYCLOHEXIMIDE.
001279 02-03

CONTROL OF THE RAT OLFACTORY BULB ACTIVITY INDUCED BY BIOLOGICALLY SIGNIFICANT ODORS.

001324 02-04 INVESTIGATIONS INTO THE NATURE OF THE PERIORAL MOVEMENTS INDUCED BY DIPROPYLAMINO-DIHYDROXYTETRALIN.

001334 02-04 DRINKING BEHAVIOUR INDUCED BY INTRACRANIAL INJECTIONS OF ELEDDISIN AND SUBSTANCE-P IN THE PIGEON.

001352 02-04 INFLUENCE OF SOME NEUROPSYCHOTROPIC DRUGS ON THE BEHAVIOURAL MODIFICATIONS INDUCED BY 3 ACETYLPYRIDINE IN RATS.

001358 02-04

SLOW-WAVE SLEEP AND A STATE RESEMBLING ABSENCE EPILEPSY INDUCED IN THE RAT BY GAMMA-HYDROXYBUTYRATE. 001366 02-04

CHRONIC AND ACUTELY INDUCED DYSKINESIAS: A PHARMACOLOGIC DISTINCTION.

A BEHAVIORAL ANALYSIS OF AGGRESSIVE BEHAVIORS INDUCED AND MODULATED BY DELTA9-TETRAHYDROCANNABINOL, PILOCARPINE, D AMPHETAMINE AND L-DOPA

001419 02-04 SLEEP SUPPRESSION INDUCED BY INTRAVENOUS AND INTRAVENTRICULAR INFUSIONS OF METHOXAMINE IN THE DOG.

EFFECTS OF THYROTROPIN-RELEASING HORMONE ON BEHAVIORAL AND HORMONAL CHANGES INDUCED BY BETA-ENDORPHIN

001471 02-04 DELTA9-TETRAHYDROCANNABINOL AND DIMETHYLHEPTYLPYRAN INDUCED TACHYCARDIA IN THE CONSCIOUS RAT.

DIFFERENT BEHAVIOURAL PATTERNS INDUCED BY APOMORPHINE: EVIDENCE THAT THE METHOD OF ADMINISTRATION DETERMINES THE BEHAVIOURAL RESPONSE TO THE DRUG.

001533 02-06 TOXIC DELIRIUM INDUCED BY DELIBERATE INGESTION OF JIMSON-WEED

001633 02-12 MODIFICATION OF SLEEP INDUCED IN ACUTE AND CHRONIC ADMINISTRATION OF LITHIUM.

EFFECT OF ALPHA-METHYLTYROSINE (MT) PRETREATMENT ON D
AMPHETAMINE (A) AND MORPHINE (M) INDUCED MOOD IN MAN.
001714 02-14

PSYCHOSIS INDUCED BY DATURA-SUAVEOLENS: HALLUCINOSIS AND ANTICHOLINERGIC DELIRIUM.

001782 02-15

000490 01-05

WITH A HIGH FAT/PROTEIN DIET.

MEASURING CHANGES IN CEREBRAL GLUTAMATE AND GABA
METABOLISM PRIOR TO CONVULSIONS INDUCED BY 3
MERCAPTOPROPIONATE.

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, AND CANNABINOL ON THE ANESTHESIA INDUCED BY VARIOUS ANESTHETIC

AGENTS IN MICE.

002015 03-03

POSSIBLE INVOLVEMENT OF CYCLIC-AMP IN INFLAMMATION INDUCED BY

A SURFACTANT.

002018 03-03

CATALEPSY INDUCED BY INTRASTRIATAL INJECTIONS OF DELTA9-THC

AND 11 OH-DELTA9-THC IN THE RAT.

O02027 03-0:
SLEEP CHANGES INDUCED BY CHRONIC ADMINISTRATION OF S-1694
(SURVECTOR)

O02194 03-04
PHARMACOLOGICAL INTERACTIONS WITH CIRCLING BEHAVIOUR INDUCED
BY THE PIPERIDINYL INDOLE DERIVATIVE RU-23686.

002200 03-04
RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL
ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION

002278 03-04
INDUCED TOLERANCE TO THE DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE

A METHOD FOR MECHANOGRAPHICAL RECORDING OF MUSICE TONE IN THE RAT: THE EFFECT OF SOME ANTIPARKINSONIAN DRUGS ON

RIGIDITY INDUCED BY RESERPINE.

D02346 03-05
LOSS OF INFORMATION INDUCED BY REDUCTION OF DATA IN THE
LABORATORY LANGUAGE METHOD.

002624 03-14

AMANTADINE IN THE TREATMENT OF BENZTROPINE REFRACTORY
EXTRAPYRAMIDAL DISORDERS INDUCED BY ANTIPSYCHOTIC DRUGS.

O02664 03-15
BENEFICIAL EFFECT OF ISOLEUCINE ON FETAL BRAIN DEVELOPMENT IN
INDUCED PHENYLKETONURIA.

CHANGES IN SYNAPTIC FUNCTION INDUCED BY BLOCKAGE OF AXONAL

TRANSPORT IN THE RABBIT OPTIC PATHWAY.

002952 04-03

ENERGY UTILIZATION IN THE INDUCED RELEASE OF GAMMA-AMINOBUTYRIC-ACID FROM SYNAPTOSOMES.

Q03029 04-03

A CONTRIBUTION TO THE NEUROCHEMICAL BASIS OF THE PYRITHIOXIN EFFECT ON THE BRAIN GLUCOSE UTILISATION DURING RELATIVE BRAIN HYPOGLYCAEMIA INDUCED BY ANTICIPATION STRESS.

003083 04-03

RETROACTIVE AMNESIA INDUCED IN CHICKS BY THE PROLINE ANALOG L
BAIKIAIN. WITHOUT EEG SEIZURES OR DEPRESSION.

003205 04-04
TESTOSTERONE ATTENUATED STEREOTYPY AND HYPERACTIVITY INDUCED
BY BETA-PHENYLETHYLAMINE IN PARGYLINE PRETREATED RATS.
003224 04-04

MURICIDE INDUCED BY SINGLE INJECTION OF DELTA9-TETRAHYDROCANNABINOL.

MOVEMENT INDUCED IN CATALEPTIC RATS: DIFFERENTIAL EFFECTS
PRODUCED BY ELECTRICAL STIMULATION OF THE LATERAL
HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FORMATION.

HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FORMATION.
003297 04-04
NONREPRODUCIBILITY OF THE BEHAVIOURAL EFFECTS INDUCED BY
SCOTOPHORIN

O03301 04-04
THE EFFECTS OF HALOPERIDOL AND CLOZAPINE ON CIRCLING INDUCED BY
ELECTRICAL STIMULATION OF THE SUBSTANTIA-NIGRA AND THE
VENTROMEDIAL TEGRAFATIMA

003343 04-04
THE EFFECTS OF D AMPHETAMINE AND SCOPOLAMINE ON DRINKING INDUCED BY A MULTIPLE SCHEDULE.

BEHAVIORAL CHANGES INDUCED BY 2.5 DIMETHOXY-4-

METHYLAMPHETAMINE (DOM, STP) IN PRIMATE DYADS.

O03380 04-04
NEUROTRANSMITTER MECHANISMS DURING MENTAL ILLNESS INDUCED
BY ALTERATIONS IN THYROID FUNCTION.

LIPIDOSIS INDUCED BY AMPHIPHILIC CATIONIC DRUGS. 003654 04-15

INDUCES
CHLORPROMAZINE INDUCES POPULATION INCREASE OF SYNAPTIC
VESICLES IN THE RAT HYPOTHALAMIC VENTROMEDIAL NUCLEUS.

AMPHETAMINE INDUCES ANOREXIA EVEN AFTER INHIBITION OF NORADRENALINE SYNTHESIS. 000365 01-04

CLOZAPINE INDUCES HYPERPHAGIA IN UNDEPRIVED RATS.

001301 02-04

001261 02-03

INDUCIBLE
INDUCIBLE ALDEHYDE-DEHYDROGENASES IN THE HEPATIC CYTOSOL OF
THE RAT.

INDUCTION

TYROSINE-HYDROXYLASE: DELAYED ACTIVATION IN CENTRAL NORADRENERGIC NEURONS AND INDUCTION IN ADRENAL MEDULLA ELICITED BY STIMULATION OF CENTRAL CHOLINERGIC RECEPTORS. 000183 01-03

TRANS-SYNAPTIC INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE FOLLOWING AMPHETAMINE TREATMENT IN THE RAT.

REACTIVITY AND AGGRESSION IN THE RAT: INDUCTION BY ALPHA-ADRENERGIC BLOCKING AGENTS INJECTED VENTRAL TO ANTERIOR SEPTUM BUT NOT INTO LATERAL SEPTUM.

000309 01-04

NACL AND LICL EFFICACY IN THE INDUCTION OF AVERSION FOR QUININE
AND SACCHARIN SOLUTIONS IMMEDIATELY FOLLOWING INJECTION.
000396 01-04

SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT AND NEWBORN RATS.

001215 02
INDUCTION OF PHYSICAL DEPENDENCE ON CYCLAZOCINE AND
PENTAZOCINE IN THE RAT

002071 03-0:
FURTHER EVIDENCE OF CYCLIC-AMP MEDIATED HYPERTROPHY AS A
PREREQUISITE OF DRUG SPECIFIC ENZYME INDUCTION.

OO2086 03-03

ENHANCEMENT BY CHOLINE OF THE INDUCTION OF ADRENAL TYROSINEHYDROXYLASE BY PHENOXYBENZAMINE, 6 HYDROXYDOPAMINE,
INSULIN OR EXPOSURE TO COLD.

OO2167 03-03
INDUCTION OF SULFOGALACTOSYLCERAMIDE (SULFATIDE) SYNTHESIS BY
HYDROCORTISONE (CORTISOL) IN MOUSE G-26 OLIGODENDROGLIOMA

002886 04-03
SELECTIVE ENZYME INDUCTION IN A NERVE GROWTH FACTOR
RESPONSIVE PHEOCHROMOCYTOMA CELL LINE (PC-12).

NESPONSIVE PREUCHRUMUCTIOMA CELL LINE (PC-12).

002899 04-03

INHIBITION OF DOPAMINE SYNTHESIS IN CHRONIC SCHIZOPHRENIA: CLINICAL INEFFECTIVENESS OF METYROSINE.

INFANT
PHARMACOKINETIC OBSERVATIONS OF PHENYTOIN DISPOSITION IN THE
NEWBORN AND YOUNG INFANT.

FLOPPY INFANT SYNDROME AND MATERNAL DIAZEPAM.

FLOPPY INFANT SYNDROME AND MATERNAL DIAZEPAM.

000837 01-15

000845 01-15
LITHIUM-CARBONATE INTAKE DURING PREGNANCY LEADING TO LARGE
GOITER IN A PREMATURE INFANT.

A CASE OF FATAL IMIPRAMINE POISONING IN AN INFANT.

CHOLINERGIC MECHANISMS INVOLVED IN HEAD-SHAKING OF INFANT RATS

O01380 02-04
EFFECTS OF PROLACTIN, DEXAMETHASONE, AND CORTICOSTERONE ON
MATERNAL AGGRESSION AND INFANT CARE.

002240 03-04

BEHAVIORAL EFFECTS OF CHRONIC NARCOTIC ANTAGONIST
ADMINISTRATION TO INFANT RATS.

003329 04-04

INFANTILE
HYPOTHESIZED ADRENERGIC/NORADRENERGIC SUBSTITUTION IN
HABITUAL INFANTILE MASTURBATION: TWO CASES.

O01702 02-14
PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD
SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A
HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS
THEPAPFILITE APPLICATION

DRUG CUES, DRUG STATES, AND INFANTILE AMNESIA.

INFANTS
LIMB REDUCTION ANOMALIES IN INFANTS BORN TO DISULFIRAM

TREATED ALCOHOLIC MOTHERS.

O01817 02-15
THE EFFECTS OF OBSTETRICAL MEDICATION ON THE BEHAVIOR OF ISRAEL

THE EFFECTS OF OBSTETRICAL MEDICATION ON THE BEHAVIOR OF ISRAELI NEWBORN INFANTS AND SOME COMPARISONS WITH URUGUAYAN AND AMERICAN INFANTS. 002673 03-15

INFARCTION
PHARMACOLOGICAL TREATMENT FOLLOWING EXPERIMENTAL CEREBRAL
PHARMACTION: IMPLICATIONS FOR UNDERSTANDING PSYCHOLOGICAL
SYMPTOMS OF HUMAN STROKE.

000243 01-03

THE INDOLAMINERGIC INNERVATION OF THE INFERIOR OLIVE. 2. RELATION TO HARMALINE-INDUCED TREMOR.

000269 01-03 EVIDENCE FOR FUNCTIONAL SYNAPSES BETWEEN MIXED CULTURES OF INFERIOR OLIVE AND CEREBELLUM. 000497 01-06

TWO CASES OF DELUSION OF WORM INFESTATION.

002487 03-10

A SEVEN YEAR REVIEW OF COMA PATIENTS ADMITTED TO THE REGIONAL POISONING TREATMENT CENTRE, ROYAL INFIRMARY.

001821 02-15

INFLAMMATION
POSSIBLE INVOLVEMENT OF CYCLIC-AMP IN INFLAMMATION INDUCED BY
A SURFACTANT.
002018 03-03

002018 03-03

EVIDENCE FOR AN INTRASTRIATAL GABAERGIC INFLUENCE ON DOPAMINE NEURONES OF THE CAT.

INFLUENCE OF DIAZEPAM, L-DOPA AND DOPAMINE ON THE CEREBELLAR AND SPINAL ELECTRICAL PATTERNS INDUCED BY HARMINE IN THE RABBIT.

000091 01-03

RELATIVE INFLUENCE OF ANAESTHETICS ON DEPRESSOR EFFECTS OF INTRAVENOUS PROSTAGLANDINS E2 AND A2. 000110 01-03

INFLUENCE OF CHRONIC PENTOBARBITAL OR MORPHINE TREATMENT ON THE INCORPORATION OF P32-PHOSPHORIC-ACID AND 3H CHOLINE INTO RAT SYNAPTIC PLASMA MEMBRANES.

000147 01-03 NEW ASPECTS CONCERNING THE MECHANISM OF ACTION OF TRANQUILIZERS. THE INFLUENCE OF SOME TRANQUILIZERS ON PROTEIN AND NUCLEIC-ACID SYNTHESES.

000165 01-03 ACETYLCHOLINE AND CHOLINE IN MOUSE BRAIN - INFLUENCE OF PERIPHERALLY ACTING CHOLINERGIC DRUGS.

INFLUENCE OF INJECTED PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE BRAIN AND LUNG FOLLOWING MICROWAVE IRRADIATION.

000214 01-03 METABOLIC RESPONSES TO ISOPROTERENOL AND EPINEPHRINE IN THE RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES AND PRETREATMENT WITH PROPRANOLOL.

INFLUENCE OF FASTING ON THE ABSORPTION AND EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AFTER ORAL ADMINISTRATION IN SESAME-

THE INFLUENCE OF CAFFEINE AND THEOBROMINE ON LOCOMOTIVE ACTIVITY AND THE BRAIN C-GMP/C-AMP RATIO IN WHITE MICE.

INFLUENCE OF THE SUSPENSION OF CONTINUED TREATMENT WITH FLURAZEPAM AND AMOBARBITAL ON TWO DISCRIMINATION LEARNING SCHEDULES.

THE INFLUENCE OF PROPRANOLOL ON THE EXPOSURE IN VIVO OF

000598 01-10 PSYCHOTROPIC DRUGS: INFLUENCE ON RESPIRATORY FUNCTION. 000692 01-13

INFLUENCE OF THE ANTIPARKINSONIAN DRUGS ON THE PLASMA LEVEL OF NEUROLEPTICS. 000700 01-13

INFLUENCE OF DISULFIRAM AND DISEASE ON BENZODIAZEPINI DISPOSITION. 000738 01-13

THE INFLUENCE OF PYRITHIOXINE ON CERTAIN FACTORS OF INTELLIGENCE.

000752 01-14 THE INFLUENCE OF ALCOHOL ON THE PERSISTENT EFFECTS ON HUMAN PERFORMANCE OF THE HYPNOTICS MANDRAX AND NITRAZEPAM.

STUDIES ON THE INFLUENCE OF BIOGENIC AMINES AND PSYCHOACTIVE DRUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMULATION TEST IN ENDOGENOUS DEPRESSION.

INCREASED PRESCRIBING OF VALIUM, LIBRIUM, AND OTHER DRUGS—
AN EXAMPLE OF THE INFLUENCE OF ECONOMIC AND SOCIAL FACTORS
ON THE PRACTICE OF MEDICINE. 000995 01-17 Psychopharmacology Abstracts

INFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3-CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN.

001119 02-03 NEUROLEPTIC INFLUENCE ON VARIOUS NEUROTRANSMITTER

PENTOBARBITAL DOES NOT INFLUENCE THE ANTINOCICEPTIVE EFFECTS OF MORPHINE IN NAIVE OR MORPHINE-TOLERANT RATS.

INFLUENCE OF CHLORPROMAZINE AND TRIFLUOPERAZINE ON NEURONS OF AN ISOLATED SLAB OF RABBIT CEREBRAL-CORTEX.

001205 02-03 THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LOCAL CEREBRAL GLUCOSE UTILISATION OF THE RAT.

001206 02-03 THE INFLUENCE OF ELECTRICAL STIMULATION ON THE HIPPOCAMPAL UNITS ACTIVITY OF THE RABBIT.

INFLUENCE OF PHARMACOLOGICAL AGENTS ON AVOIDANCE REFLEXES IN A GROUP EXPERIMENT ON RATS. 001317 02-04

INFLUENCE OF NEUROTROPIC DRUGS ON CHANGES OF EVOKED-POTENTIALS AMPLITUDES AFTER STIMULATION OF THE HYPOTHALAMUS.

001318 02-04

INFLUENCE OF SOME NEUROPSYCHOTROPIC DRUGS ON THE BEHAVIOURAL MODIFICATIONS INDUCED BY 3 ACETYLPYRIDINE IN RATS.

THE INFLUENCE OF PENTOBARBITAL UPON A CORTICAL EPILEPTOGENIC FOCUS IN RATS.

INFLUENCE OF BETA-ENDORPHIN ON EXPLORATORY, SOCIAL AND SEXUAL BEHAVIOUR IN THE MALE RAT.

THE INFLUENCE OF PROGESTERONE ON THE INHIBITORY EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE FEMALE RAT.

On the influence of mobiletten on the effect of Alcohol in the Human: Second Communication: Influence on the efficiency under Alcohol Stress.

PROTEIN AND ENZYME RELEASE FROM HUMAN LEUKOCYTES: INFLUENCE OF PHENOTHIAZINE DERIVATIVES.

BIOAVAILABILITY OF OXAZEPAM: ABSENCE OF INFLUENCE OF FOOD

GAMMA-AMINOBUTYRIC-ACID (GABA) AND SLEEP: THE INFLUENCE OF DI-N-PROPYLACETIC-ACID ON SLEEP IN MAN.

POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES (N) ON OPIOID
ABSTINENCE SYNDROMES.

MORPHINE AND ITS BIPHASIC INFLUENCE UPON PHARMACOLOGICALLY DISTINCT DOPAMINERGIC SYSTEMS WITHIN THE FELINE CAUDATE NUCLEUS: A BEHAVIOURAL STUDY.

001954 03-02

DEPENDENCE OF THE INFLUENCE OF EPINEPHRINE ON THE EXCITABILITY OF GIANT NEURONS ON ITS CONCENTRATION. 001967 03-03

H3-HALOPERIDOL BINDING TO DOPAMINE RECEPTORS IN RAT CORPUS-STRIATUM: INFLUENCE OF CHLORPROMAZINE METABOLITES AND

THE INFLUENCE OF DIHYDROERGOTOXINE-MESYLATE ON THE LOW-KM PHOSPHODIESTERASE OF CAT AND RAT BRAIN IN VITRO. 002006 03-03

THE INFLUENCE OF COCAINE AND DESIPRAMINE ON THE CARDIAC RESPONSES TO EXOGENOUS AND ENDOGENOUS NOREPINEPHRINE 002077 03-03 INFLUENCE OF IMMUNE STIMULATION AND SUPPRESSION ON MORPHINE PHYSICAL DEPENDENCE AND TOLERANCE

INVESTIGATIONS INTO THE MECHANISM OF THE INFLUENCE OF KININS ON THE ACTION OF AMPHETAMINE.

INFLUENCE OF TRIODOTHYRONINE (T3) ON THE RENAL ACTION OF LITHIUM.

THE EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND 2

BROMOLYSERGIC-ACID-DIETHYLAMIDE (BOL) ON THE STRIATAL DOPA
ACCUMULATION: INFLUENCE OF CENTRAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS.

002125 03-03 MEMORIZATION AND CENTRAL CATECHOLAMINES AFTER A CRANIOCERVICAL INJURY CARRIED OUT IN RATS: INFLUENCE OF IMPRAMINE ADMINISTRATION.

002197 03-04

PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL.

IV. INFLUENCE OF ELIMINATION KINETICS.

002198 03THE INFLUENCE OF HISTAMINE ON METABOLISM OF DOPAMINE AND SEROTONIN IN THE RAT STRIATUM.

002288 03-04
INFLUENCE OF EXTRAPYRAMIDAL DISTURBANCES DUE TO HALOPERIDOL
ON PHENAMINE STEREOTYPY AND THE EFFECTS OF SCHIZOPHRENIC
BLOOD SERUM (EXPERIMENTAL STUDIES).

002339 03-05
INFLUENCE OF VASOPRESSIN ON LEARNING AND MEMORY.

002385 03-07
THE INFLUENCE OF CAFFEINE ON THE PREVALENCE OF ALPHA RHYTHM.

O02550 03-13
INFLUENCE OF TRYPTOPHAN ON MEMORY FUNCTIONS IN DEPRESSIVE PATIENTS TREATED WITH UNILATERAL ECT.

002613 03-14
INFLUENCE OF LYSINE VASOPRESSIN ON THE EEG IN MAN.

002639 03-14
INFLUENCE OF PHENOBARBITAL ON THE DISTRIBUTION AND ELIMINATION
OF DESMETHYLIMIPRAMINE IN THE RAT.

002842 04-03
INFLUENCE OF TRANSIENT ISCHEMIA ON MONOAMINE METABOLISM IN
THE RAT BRAIN DURING NITROUS-OXIDE AND PHENOBARBITONE
ANESTHESIA.

O02852 04-03
STERIC INFLUENCE ON INHIBITION OF MONOAMINE-OXIDASE FORMS BY
2,3 DICHLORO-ALPHA-METHYLBENZYLAMINE.

002918 04-03
INFLUENCE OF LITHIUM ON DOPAMINE STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT BRAIN.

002922 04-03
INFLUENCE OF VINCAMINE AND PIRACETAM ON SLEEP-WAKING PATTERN

OF THE CAT. 002925 04-03
PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL

DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6
TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH
KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

002930 04-03
PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — 1. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS.

002931 04-03

INFLUENCE OF NEUROLEPTICS ON THE BINDING OF MET-ENKEPHALIN,
MORPHINE AND DIHYDROMORPHINE TO SYNAPTOSOME ENRICHED
FRACTIONS OF RAT BRAIN

003096 04-03
CONDITIONING FACTORS INFLUENCE TOLERANCE DEVELOPMENT TO LOW
BUT NOT HIGH DOSES OF MORPHINE

003198 04-04
INFLUENCE OF CATECHOLAMINES ON DEXAMPHETAMINE-INDUCED

CHANGES IN LOCOMOTOR ACTIVITY.

003239 04-04

INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETINE ON
HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE

(PCA) AND 4, ALPHA DIMETHYL-M-TYRAMINE (H-77-77).

O03271 04-04

THE INFLUENCE OF PYRIDOXINE ON THE PSYCHOPATHOLOGY AND PATHOCHEMISTRY OF DEPRESSIONS OF INVOLUTIONAL AGE.

O3485 04-09
STUDY OF THE INFLUENCE OF VITAMIN SUPPLEMENTS ON THE BEHAVIOR
OF PSYCHIATRIC PATIENTS

CAN CIGARETTE SIZE AND NICOTINE CONTENT INFLUENCE SMOKING AND PUFFING RATES?

003631 04-14
INFLUENCES
INFLUENCES OF GENOTYPE AND SEX ON BEHAVIORAL TOLERANCE TO

NICOTINE IN MICE. 000376 01-04

CHOLINERGIC INFLUENCES IN TARDIVE-DYSKINESIA. 000904 01-15

INFLUENCES OF ANTIANXIETY DRUGS ON PERCEPTION. 001840 02-15

PHARMACOLOGICAL INFLUENCES ON STARVATION-INDUCED HYPERRESPONSIVENESS IN THE RAT. (PH.D. DISSERTATION). 002212 03-04 MONOAMINERGIC INFLUENCES ON THE INCORPORATION OF \$35 IN THE

HYPOTHALAMIC AND NEUROHYPOPHYSIAL PROTEINS FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF \$35-CYSTEINE IN DEHYDRATED RATS. 002238 03-04

STRYCHNINE BINDING ASSOCIATED WITH SYNAPTIC GLYCINE RECEPTORS IN RAT SPINAL CORD MEMBRANES: IONIC INFLUENCES.

O03024 04-03

TASK DEBSIDENT CENETIC INCLUENCES ON BEHAVIORAL RESPONSE OF

TASK-DEPENDENT GENETIC INFLUENCES ON BEHAVIORAL RESPONSE OF MICE (MUS-MUSCULUS) TO ACETALDEHYDE.

003211 04-04

INFLUENCING

HISTORICAL AND CULTURAL FACTORS INFLUENCING CANNABIS USE AMONG INDIANS IN SOUTH-AFRICA.

O00675 01-12

EFFECTS ON HYPOTHALAMIC SELF-STIMULATION OF DRUGS INFLUENCING
DOPAMINERGIC NEUROTRANSMISSION INJECTED INTO NUCLEUSACCUMBENS AND CORPUS-STRIATUM OF RATS.

901466 02-04

FACTORS INFLUENCING BLOOD CONCENTRATIONS OF CHLORDIAZEPOXIDE:
A USE OF MULTIPLE REGRESSION ANALYSIS.

MOTOR ACTIVITY OF RATS FOLLOWING INTRACEREBRAL INJECTIONS OF DRUGS INFLUENCING GABA MECHANISMS.

FACTORS INFLUENCING WILLINGNESS TO COMPLY AND ACTUAL COMPLIANCE WITH MEDICATION REGIMENS. (PH.D. DISSERTATION). 003722 04-17

INFLUX

ASPECTS OF INFLUX AND EFFLUX OF HOMOVANILLIC-ACID OF RAT CEREBROSPINAL FLUID.

INFORMATION PROCESSING UNDER SODIUM PENTOBARBITAL

AND CHLORPROMAZINE: DIFFERENTIAL DRUG EFFECTS WITH TACHISTOSCOPICALLY PRESENTED DISCRIMINATIVE STIMULI. 000318 01-0

CONTEXT EFFECTS IN THE STORAGE AND RETRIEVAL OF INFORMATION IN MAN.

LOSS OF INFORMATION INDUCED BY REDUCTION OF DATA IN THE

LABORATORY LANGUAGE METHOD. 002624 03-14

SECOBARBITAL AND INFORMATION PROCESSING.

003635 04-14

STATE-DEPENDENT RETRIEVAL OF ITEM, ASSOCIATIVE, AND SERIAL ORDER INFORMATION.

INFORMED-CONSENT
THE USE OF A CHECKLIST IN OBTAINING INFORMED-CONSENT FOR

TREATMENT WITH MEDICATION.

002778 03-17

TARDIVE-DYSKINESIA AND INFORMED-CONSENT. 003683 04-15

INFUSION
DIFFERENTIAL MOTOR EFFECTS OF INTRAVENTRICULAR INFUSION OF
MORPHINE AND FTONITAZENE.

TRAZODONE BY INTRAVENOUS INFUSION IN DEPRESSIONS SECONDARY TO ORGANIC DISEASE.

O00585 01-09
THE EFFECT OF STEROID HORMONES ON CEREBRAL BLOOD FLOW BEFORE
AND AFTER INTRACAROTID INFUSION OF 5 HYDROXYTRYPTAMINE.

001193 02-03
DECREASED FEEDING IN RATS FOLLOWING HEPATIC PORTAL INFUSION OF
GLUCAGON

001514 02-05
INTENSIVE ANTIDEPRESSIVE THERAPY BY 48 HOUR SLOW-DRIP INFUSION

WITH HIGH DOSES DIBENZEPINE. 001602 02-09

DECREASED LOCOMOTOR ACTIVITY AND ATTENUATION OF AMPHETAMINE HYPERACTIVITY WITH INTRAVENTRICULAR INFUSION OF SEROTONIN IN THE RAT.

002328 03-04
INTERANIMAL AGGRESSION AND HYPERREACTIVITY FOLLOWING
HYPOTHALAMIC INFUSION OF LOCAL ANESTHETIC IN THE RAT.

003157 04-04
BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE EFFECTS
AFTER INTRACEREBRAL INFUSION OF TRH IN FOWLS.

003319 04-04

SLEEP SUPPRESSION INDUCED BY INTRAVENOUS AND INTRAVENTRICULAR INFUSIONS OF METHOXAMINE IN THE DOG. 001434 02-04

PROLACTIN SECRETION DURING AND AFTER NOVERIL INFUSIONS TO DEPRESSIVE PATIENTS.

TREATMENT OF DEPRESSIVE SYNDROME WITH NOVERIL INFUSIONS.
002439 03-09

PLASMA LEVEL STUDIES OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE FOLLOWING INTRAVENOUS INFUSIONS OF CLOMIPRAMINE IN DEPRESSIVE PATIENTS.

002448 03-09
HYPOTENSION AND HYPOTHALAMIC AMINE METABOLISM AFTER LONGTERM ALPHA-METHYLDOPA INFUSIONS.

TERM ALPHA-METHYLDOPA INFUSIONS.

002914 04-0
INCREASED DOPAMINE METABOLISM IN RAT STRIATUM AFTER

INCREASED DOPAMINE METABOLISM IN RAT STRIATUM AFTER INFUSIONS OF SUBSTANCE-P INTO THE SUBSTANTIA-NIGRA. 003130 04-03

INCESTION

REPRESSION OF A LITHIUM PUMP AS A CONSEQUENCE OF LITHIUM INGESTION BY MANIC-DEPRESSIVE SUBJECTS.

000714 01-13 IIMSON-WEED. 001633 02-12 TOXIC DELIRIUM INDUCED BY DELIBERATE INGESTION OF

STATUS-EPILEPTICUS OR REPETITIVE SEIZURES FOLLOWING TOXIC INGESTION.

SUPPRESSION OF THE HYPOTHALAMIC PITUITARY ADRENAL AXIS AFTER ORAL HYDROCORTISONE-SUCCINATE INGESTION IN RATS.

DOPAMINE RECEPTOR FUNCTION AFTER CHRONIC INGESTION OF ETHANOL.

ALTERATIONS IN RECEPTORS CONTROLLING DOPAMINE SYNTHESIS AFTER CHRONIC ETHANOL INGESTION.

003107 04-03 EFFECTS OF CHRONIC INGESTION AND WITHDRAWAL OF SODIUM BARBITONE ON LEARNING IN RATS.

INGESTIVE

003273 04-04

ANALYSIS OF THE ROLE PLAYED BY THE SUBSTANTIA-NIGRA IN THE MEDIATION OF INGESTIVE, LOCOMOTOR, AND ROTATIONAL BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL MANIPULATIONS. (PH.D. DISSERTATION).

ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

003272 04-04

PSYCHOPHYSIOLOGICAL EFFECTS OF ACUTE CANNABIS INHALATION. 000711 01-13

METHODS OF ACUTE INHALATION EXPERIMENTS.

MEASUREMENTS OF WEIGHT AND ACTIVITY IN MALE MICE FOLLOWING INHALATION OF CANNABIS SMOKE IN A CONTROLLED SMOKE EXPOSURE CHAMBER.

001524 02-05

5-HT ANTAGONISTS INHIBIT NEUROLEPTIC AND MORPHINE ANTAGONISM
OF THE HYPERACTIVITY INDUCED BY DOPAMINE FROM THE NUCLEUS-

000082 01-03 CANNABINOIDS INHIBIT TESTOSTERONE SECRETION BY MOUSE TESTES IN VITRO.

001999 03-03 INHIBITING

COMPARISON OF THYROTROPIN-RELEASING HORMONE WITH MELANOCYTE-STIMULATING HORMONE RELEASE INHIBITING FACTOR AS PENTOBARBITAL ANTAGONISTS IN MONKEYS.

000087 01-03 THE BEHAVIORAL TOXICITY OF MONOAMINE-OXIDASE INHIBITING ANTIDEPRESSANTS.

000967 01-17

INHIBITION

EVIDENCE FOR NOREPINEPHRINE MEDIATED COLLATERAL INHIBITION OF
LOCUS-COERULEUS NEURONS.

000039 01-03 MONOAMINE-OXIDASE INHIBITION IN BRAIN AND LIVER PRODUCED BY BETA-CARBOLINES: STRUCTURE-ACTIVITY RELATIONSHIPS AND SUBSTRATE SPECIFICITY.

STUDIES ON TOLERANCE. II. THE EFFECT OF TIMING ON INHIBITION OF TOLERANCE TO MORPHINE BY CYCLOHEXIMIDE.

000104 01-03 LITHIUM INHIBITION OF NOREPINEPHRINE AND DOPAMINE RECEPTORS.

000107 01-03 EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE.

000127 01-03 THE SELECTIVE INHIBITION OF DOPAMINE UPTAKE BY A RICYCLIC IMINE 000141 01-03

INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY ANTITHYROID AGENTS, METHIMAZOLE AND PROPYLTHIOURACIL. 000145 01-03 MOTILITY RESPONSE TO MORPHINE AND AMPHETAMINE DURING CHRONIC INHIBITION OF TYROSINE-HYDROXYLASE OR DOPAMINE-BETA-HYDROXYLASE.

000166 01-03 UPTAKE INHIBITION OF BIOGENIC AMINES BY NEWER ANTIDEPRESSANT DRUGS: RELEVANCE TO THE DOPAMINE HYPOTHESIS OF DEPRESSION. 000232 01-03

POTENTIATION BY RESERPINE OF THE INHIBITION BY AMPHETAMINE OF (3H)DOPAMINE ACCUMULATION IN THE RAT STRIATUM.

000246 01-03

Psychopharmacology Abstracts

EFFECT OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION ON EPINEPHRINE LEVELS IN THE BRAIN.

000255 01-03

INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH D,L METHADONE

000270 01-03 INHIBITION OF PROSTAGLANDIN SYNTHETASE SYSTEM IN THE RABBIT RENAL MEDULLA BY PSYCHOTROPIC DRUGS.

000281 01-03 INHIBITION OF THE CENTRAL HYPOTENSIVE EFFECT OF CLONIDINE BY TRAZODONE, A NOVEL ANTIDEPRESSANT.

000286 01-03 ANTIDROMICALLY IDENTIFIED SEROTONERGIC NEURONS IN THE RAT MIDBRAIN RAPHE: EVIDENCE FOR COLLATERAL INHIBITION.

000292 01-03 BENZODIAZEPINES, BARBITURATES, AND HIPPOCAMPAL INHIBITION.

000300 01-03 THE AMNESTIC EFFECT OF PROTEIN SYNTHESIS INHIBITORS IS NOT DUE TO THE INHIBITION OF ADRENAL CORTICOSTEROIDOGENESIS.

000352 01-04 THE EFFECT OF STIMULANTS, DEPRESSANTS, AND PROTEIN SYNTHESIS INHIBITION ON RETENTION.

000360 01-04 AMPHETAMINE INDUCES ANOREXIA EVEN AFTER INHIBITION OF

NORADRENALINE SYNTHESIS. 000365 01-04 INHIBITION OF BOTH MAO-A AND MAO-B REQUIRED FOR THE PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

000398 01-04

MEMORY IMPAIRMENT CORRELATES CLOSELY WITH CYCLOHEXIMIDE DOSE AND DEGREE OF INHIBITION OF PROTEIN SYNTHESIS 000436 01-04

INHIBITION OF DOPAMINE SYNTHESIS IN CHRONIC SCHIZOPHRENIA: CLINICAL INEFFECTIVENESS OF METYROSINE

000542 01-08 D AMPHETAMINE INHIBITION OF PLATELET MAD FROM SCHIZOPHRENIC

000543 01-08 SLEEP AND BEHAVIORAL CHANGES POSSIBLY REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN.

000916 01-16 CHOLINERGIC INHIBITION OF MORPHINE-INDUCED HYPOTHERMIA

001066 02-03 POTENTIATION OF MORPHINE ANALGESIA IN MICE AFTER INHIBITION OF BRAIN TYPE-B MONOAMINE-OXIDASE.

001126 02-03 EFFECTS OF CANNABINOIDS ON L1210 MURINE LEUKEMIA: 1. INHIBITION OF DNA SYNTHESIS

001266 02-03 CHOLINERGIC MODIFICATION OF THE INHIBITION OF DOPAMINE-INDUCED PERACTIVITY BY NEUROLEPTICS

001271 02-03 EFFECT OF D AMPHETAMINE ON THE INHIBITION OF BRAIN CATECHOLAMINE TURNOVER INDUCED BY CYCLOHEXIMIDE

001279 02-03

INHIBITION OF DRINKING BY INTRAHYPOTHALAMIC ADMINISTRATION OF 001325 02-04

MODIFICATION OF THE AMPHETAMINE-INDUCED STEREOTYPY IN RATS FOLLOWING INHIBITION OF THE NORADRENALINE RELEASE BY FLA-136 001367 02-04 SELECTIVE INHIBITION OF NORADRENALINE AND SEROTONIN UPTAKE BY

C-49802-B-BA AND CGP-6085-A 001960 03-02 INHIBITION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS IN RATS BY

ROSTAGLANDIN-E1: ROLE OF BRAIN MONOAMINES. 001968 03-03 INHIBITION BY NEUROLEPTICS OF LIPTAKE OF H3-GABA INTO RAT BRAIN

002013 03-03

FURTHER STUDIES ON THE INHIBITION OF MONOAMINE OXIDATION BY MONOAMINE-OXIDASE INHIBITORS. 002022 03-03

RAT BRAIN ARYLACYLAMIDASE: MULTIPLE FORMS AND INHIBITION EFFECTS OF LSD, SEROTONIN AND RELATED COMPOUNDS.

002044 03-03 APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE RELEASE: ROLE OF DOPAMINERGIC RECEPTORS IN SUBSTANTIA-NIGRA. 002084 03-03

EFFECT OF SYNTHESIS INHIBITION ON THE LEVELS OF BRAIN CATECHOLAMINES IN BARBITAL DEPENDENT RATS.

002103 03-03 STUDIES ON THE INHIBITION OF PHOSPHODIESTERASE CATALYZED CYCLIC-AMP AND CYCLIC-GMP BREAKDOWN AND RELAXATION OF CANINE TRACHEAL SMOOTH MUSCLE.

002129 03-03

EFFECTS OF DIAZEPINES AND BARBITURATES ON HIPPOCAMPAL RECURRENT INHIBITION.

CHOLINERGIC INHIBITION OF METHYLPHENIDATE-INDUCED STEREOTYPY: OXOTREMORINE.

DECREASED RESPONSE INHIBITION DURING FIXED-INTERVAL RESPONDING IN PIGEONS FOLLOWING ATROPINE ADMINISTRATION. 002305 03-04

DISRUPTION OF LATENT INHIBITION FOLLOWING SYSTEMIC ADMINISTRATION OF P-CHLOROPHENYLALANINE (PCPA).

002309 03-04
INHIBITION OF FLAVIN SYNTHESIS BY CHLORPROMAZINE IN EUTHYROID
AND HYPERTHYROID RATS.

002352 03-0:
INHIBITION BY LITHIUM OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE
IN THE RAT BRAIN.

INHIBITION OF MONOAMINE-OXIDASE BY N PHENACYL-CYCLOPROPYLAMINE.

INHIBITION OF BRAIN ANGIOTENSIN-I CONVERTING ENZYME BY BOTHROPS-JARARACA NONAPEPTIDE (SQ-20881) AND A PROLYL ANALOG (SQ-14225).

INHIBITION OF DOPA DECARBOXYLATION BY ANALOGUES OF

002837 04-03
ALPHA-BUNGAROTOXIN BLOCKS REVERSIBLY CHOLINERGIC INHIBITION IN THE COCHLEA.

D0290B 04-03
STERIC INFLUENCE ON INHIBITION OF MONOAMINE-OXIDASE FORMS BY
2.3 DICHLORO-ALPHA-METHYLBENZYLAMINE.

NONSPECIFIC INHIBITION OF SOME RAT LIVER MEMBRANE-BOUND ENZYMES BY AN ADENYLATE-CYCLASE INHIBITOR, RMI-12330-A.

STRUCTURE-ACTIVITY STUDIES ON THE INHIBITION OF GABA BINDING TO RAT BRAIN MEMBRANES BY MUSCIMOL AND RELATED COMPOUNDS. 002981 04-03

SUBCELLULAR LOCALIZATION OF C14-METHAQUALONE IN MOUSE BRAIN: EFFECTS OF HEPATIC MICROSOMAL ENZYME INHIBITION.

IN VITRO INHIBITION OF MONOAMINE-OXIDASE TYPES A AND B BY D
AMPHETAMINE AND L AMPHETAMINE.

O03016 04-03

ROLE OF SEROTONIN REUPTAKE INHIBITION IN THE DEVELOPMENT OF
SUBSENSITIVITY OF THE NOREPINEPHRINE (NE) RECEPTOR COUPLED
ADENYLATE-CYCLASE SYSTEM.

003017 04-03
INHIBITION OF MONOAMINE OXIDATION IN SUBFRACTIONS OF CRUDE
MITOCHONDRIA OF RAT BRAIN BY CLORGYLINE AND LILLY-51641.
003020 04-03

INHIBITION OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RAT STRIATUM BY NEUROLEPTIC DRUGS ADMINISTERED IN VIVO.

003027 04-03
INHIBITION BY BARBITURIC-ACID AND ITS DERIVATIVES OF THE ENZYMES
IN RAT BRAIN WHICH PARTICIPATE IN THE SYNTHESIS OF PYRIMIDINE

003049 04-03
INHIBITION OF REM SLEEP BY FLUOXETINE, A SPECIFIC INHIBITOR OF
SEROTONIN UPTAKE.

NHIBITION OF MONOAMINE-OXIDASE BY ISOGENTISIN AND ITS 3 O GLUCOSIDE.

003104 04-03
DEPRENIL: LOSS OF SELECTIVITY FOR INHIBITION OF B-TYPE MAO AFTER REPEATED TREATMENT.

003131 04-03
INHIBITION OF CA45 MOVEMENTS BY LOWERED TEMPERATURE OR
LANTHANUM IN RAT BRAIN SLICES.

HIGH-AFFINITY H3-SEROTONIN BINDING TO CAUDATE: INHIBITION BY

HALLUCINOGENS AND SEROTONINERGIC DRUGS.

003138 04-03
RECOVERY AS A FUNCTION OF THE DEGREE OF AMNESIA DUE TO

RECOVERY AS A FUNCTION OF THE DEGREE OF AMNESIA DUE TO PROTEIN SYNTHESIS INHIBITION.

003204 04-04 INHIBITION OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND

BRAIN STIMULATED REWARD.

003255 04-04
INHIBITION OF FIGHTING IN ISOLATED MICE FOLLOWING REPEATED

ADMINISTRATION OF LITHIUM-CHLORIDE.

003282 04-04
CHLORIMIPRAMINE INHIBITION OF MURICIDE: THE ROLE OF THE

ASCENDING 5-HT PROJECTION.

O03284 04-04

THE STRIATAL DOPAMINERGIC FUNCTION IS MEDIATED BY THE INHIBITION OF A NIGRAL, NONDOPAMINERGIC NEURONAL SYSTEM VIA A STRIO-NIGRAL GABAERGIC PATHWAY.

EMERGING CHOLINERGIC MECHANISMS AND ONTOGENY OF RESPONSE INHIBITION IN THE MOUSE.

003336 04-04
INHIBITION OF 5,7 DIHYDROXYTRYPTAMINE-INDUCED SUPERSENSITIVITY
TO 5 HYDROXYTRYPTOPHAN IN MICE BY TREATMENT WITH
CYCLOHEXIMIDE.

003366 04-04
INHIBITION OR WET SHAKES DURING MORPHINE ABSTINENCE BY AN
ANTAGONIST OF OPIATE ANALGESIA.

CLINICAL CORRELATES OF TRICYCLIC ANTIDEPRESSANT MEDIATED INHIBITION OF PLATELET MONOAMINE-OXIDASE.

INHIBITION OF EJACULATION BY AMITRIPTYLINE. 003524 04-09

INHIBITOR

002357 03-05

POLYAMINE BIOSYNTHESIS IN RAT PROSTATE. SUBSTRATE AND INHIBITOR PROPERTIES OF 7 DEAZA ANALOGUES OF DECARBOXYLATED S ADENOSYLMETHIONINE AND 5 METHYLTHIOADENOSINE.

FLUVOXAMINE, A SPECIFIC 5 HYDROXYTRYPTAMINE UPTAKE INHIBITOR. 000017 01-02

FAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS UNDER LONG-TERM TRAINING.

000034 01-02
LOWERING OF EPINEPHRINE CONCENTRATION IN RAT BRAIN BY 2,3
DICHLORO-ALPHA-METHYL-BENZYLAMINE, AN INHIBITOR OF
NOREPINEPHRINE-N-METHYLTRANSFERASE.

ROLE OF TRYPTAMINE IN THE BEHAVIOURAL CHANGES CAUSED BY A MONOAMINE-OXIDASE INHIBITOR AND L TRYPTOPHAN.

THE EFFECT OF INTRACEREBRAL INJECTION OF CYCLOHEXIMIDE ON BRAIN PROTEIN SYNTHESIS AND ON THE HYPERACTIVITY SYNDROME PRODUCED BY A MONOAMINE-OXIDASE INHIBITOR AND TRYPTOPHAN.

TRICYCLIC ANTIDEPRESSANT AND MONOAMINE-OXIDASE INHIBITOR COMBINATION THERAPY.

000976 01-17
FLUOXETINE, A SEROTONIN UPTAKE INHIBITOR, IN NORMAL HUMAN
SUBJECTS

O01686 02-13
PHARMACOLOGICAL EVIDENCE FOR A LINK BETWEEN THE CEREBELLAR
CONTENT OF C-GMP AND THAT OF AN ENDOGENOUS PROTEIN KINASE
INHIBITOR

STEREOTYPY AND HYPERACTIVITY IN RATS RECEIVING ETHANOL AND A MONDAMINE-DXIDASE INHIBITOR.

7, N, N TRIMETHYLTRYPTAMINE: A SELECTIVE INHIBITOR OF SYNAPTOSOMAL SEROTONIN UPTAKE.

ENHANCEMENT OF THE ANTIDEPRESSANT RESPONSE TO L. TRYPTOPHAN BY A LIVER PYRROLASE INHIBITOR: A RATIONAL TREATMENT APPROJACH.

O02464 03-09
ON THE TREATMENT OF NEURODERMATITIS WITH A MONOAMINEOXIDASE INHIBITOR: THE CHEMOTHERAPY OF PSYCHOSOMATIC
ILLNESS THROUGH A-REM SUPPRESSION.

O02480 03-10

SOMATOSENSORY EVOKED-POTENTIALS IN PATIENTS WITH PARKINSONS
SYNDROME DURING TREATMENT WITH L-DOPA AND DECARBOXYLASE
INHIBITOR.

002515 03-11

NONSPECIFIC INHIBITION OF SOME RAT LIVER MEMBRANE-BOUND
ENZYMES BY AN ADENYLATE-CYCLASE INHIBITOR, RMI-12330-A.
002936 04-03

DEMONSTRATION OF AN ENDOGENOUS, COMPETITIVE INHIBITOR(S) OF H3-DIAZEPAM BINDING IN BOVINE BRAIN.

002995 04-03

THE EFFECT OF GAMMA-ACETYLENIC-GABA, AN ENZYME ACTIVATED IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE, ON DOPAMINE PATHWAYS OF THE EXTRAPYRAMIDAL AND LIMBIC SYSTEMS.

METABOLISM OF LERGOTRILE TO 13 HYDROXYLERGOTRILE, A POTENT INHIBITOR OF PROLACTIN RELEASE IN VITRO.

1NHIBITION OF REM SLEEP BY FLUOXETINE, A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.

D03095 04-03
BLOCKADE OF TESTOSTERONE MAINTAINED INTERMALE FIGHTING IN
ALBINO LABORATORY MICE BY AN AROMATIZATION INHIBITOR.
003176 04-04

EFFECTS OF THE PROSTAGLANDIN SYNTHESIS INHIBITOR, INDOMETHACIN
ON ESTROGEN AND ESTROGEN PLUS PROGESTERONE-INDUCED SEXUAL
RECEPTIVITY IN OVARIECTOMIZED RATS.

003237 04-04

003325 04-04

INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETINE ON HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE (PCA) AND 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77).

003271 04-04 NONMONOAMINE-OXIDASE INHIBITOR ANTIDEPRESSANTS AND EPILEPSY A REVIEW

003611 04-13 DEPRENYL ADMINISTRATION IN MAN: A SELECTIVE MONOAMINE OXIDASE B INHIBITOR WITHOUT THE CHEESE EFFECT.

003652 04-15

QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS IN A SERIES OF SELECTIVE 5-HT UPTAKE INHIBITORS. 000057 01-03

ANTAGONISM OF BIOGENIC AMINE-INDUCED DEPRESSION OF CEREBRAL CORTICAL NEURONES BY NA-K-ATPASE INHIBITORS. 000254 01-03

THE BLOCKADE OF SEROTONIN UPTAKE INTO SYNAPTOSOMES: RELATIONSHIP TO AN INTERACTION WITH MONOAMINE-OXIDASE INHIBITORS.

EFFECTS OF BETA-BUNGAROTOXIN, DIPHENYLHYDANTOIN AND METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT CATIONS AND HIGH-ENERGY PHOSPHATE CONTENTS OF BRAIN SLICES. 000278 01-03

A COMPARATIVE STUDY OF DIHYDROXYLATED PHENOTHIAZIN DERIVATIVES AS MITOCHONDRIAL INHIBITORS. 000282 01-03

THE AMNESTIC EFFECT OF PROTEIN SYNTHESIS INHIBITORS IS NOT DUE TO THE INHIBITION OF ADRENAL CORTICOSTEROIDOGENESIS. 000352 01-04

INHIBITION OF BOTH MAO-A AND MAO-B REQUIRED FOR THE PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

000398 01-04 EFFECTS OF THREE MONOAMINE-OXIDASE INHIBITORS ON ETHANOL PREFERENCE IN MICE.

MAO INHIBITORS IN CLINICAL PRACTICE: PRINCIPLES BASED ON RECENT

000578 01-09 ACUTE VERSUS CHRONIC EFFECTS OF MONOAMINE-OXIDASE INHIBITORS IN DEPRESSED PATIENTS: TIME-COURSE OF MAO INHIBITORS.

000733 01-13 MONOAMINE-OXIDASE INHIBITORS AND CAVIAR

000848 01-15 MAO INHIBITORS AND CENTRAL MONOAMINE METABOLISM

000991 01-17 STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT BRAIN TISSUE SLICES

001145 02-03 PHENOTHIAZINE METABOLITES AS MITOCHONDRIAL INHIBITORS. 001259 02-03

DEGRADED PROTEIN CONTAINING FOOD AND MONOAMINE-OXIDASE

001804 02-15 SELECTIVE MONOAMINE-OXIDASE INHIBITORS. 1. COMPOUNDS RELATED TO 4 AMINOPHENETHYLAMINE.

001945 03-01 FURTHER STUDIES ON THE INHIBITION OF MONOAMINE OXIDATION BY MONOAMINE-OXIDASE INHIBITORS.

002022 03-03 STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAMINE (DA) AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES.

THE EFFECT OF CLOMIPRAMINE AND OTHER AMINE UPTAKE INHIBITORS ON MORPHINE ANALGESIA IN LABORATORY ANIMALS.

002072 03-03 MPHETAMINE-

EFFECT OF METABOLIC INHIBITORS AND QUABAIN ON AMPHETAMINE-INDUCED AND POTASSIUM-INDUCED RELEASE OF BIOGENIC AMINES FROM ISOLATED BRAIN TISSUE. 002142 03-03

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS. 002148 03-03

HYPERTHERMIC EFFECTS OF SUPRACORTICALLY APPLIED PROSTAGLANDINS AFTER SYSTEMIC PRETREATMENT WITH INHIBITORS OF PROSTAGLANDIN TRANSPORT AND SYNTHESIS.

EFFECTS OF CLOMIPRAMINE AND OTHER INHIBITORS OF MONOAMINE UPTAKE ON THE SEXUAL BEHAVIOUR OF FEMALE RATS AND RHESUS MONKEYS.

THE BINDING OF INHIBITORS OF SEROTONIN UPTAKE TO BIOLOGICAL

Psychopharmacology Abstracts

DIURNAL VARIATIONS IN THE MOTOR ACTIVITY OF THE RAT: EFFECTS OF INHIBITORS OF THE CATECHOLAMINE SYNTHESIS.

INHIBITORY EFFECT OF MORPHINE ON SERUM GONADOTROPINS AND PROLACTIN OF PROESTROUS RATS.

PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, BRAIN SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION INTO BRAIN PROTEINS OF DIFFERENT MOUSE STRAINS.

000384 01-04 FACILITATION BY RESERPINE OF RETENTION IN AN INHIBITORY AVOIDANCE TASK IN MICE.

000406 01-04 COMPARATIVE INHIBITORY EFFECTS OF SYNTHETIC ENKEPHALINS ON THE STEREOSPECIFIC BINDING OF H3-DIHYDROMORPHINE AND H3-NALOXONE.

001076 02-03

COCAINE AND METABOLITES: RELATIONSHIP BETWEEN
PHARMACOLOGICAL ACTIVITY AND INHIBITORY ACTION ON
DOPAMINE UPTAKE INTO STRIATAL SYNAPTOSOMES.

001286 02-03 EFFECTS OF 4 AMINOPYRIDINE ON TRANSMISSION IN EXCITATORY AND INHIBITORY SYNAPSES IN THE SPINAL CORD.

001384 02-04 DIFFERENTIAL TOLERANCE TO INHIBITORY ACTION OF VARIOUS NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS CHRONICALLY TREATED WITH HALOPERIDOL.

001398 02-04 THE INFLUENCE OF PROGESTERONE ON THE INHIBITORY EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE FEMALE RAT.

001463 02-04 DIFFERENTIAL EXCITATORY AND INHIBITORY EFFECTS OF OPIATES ON NONNOCICEPTIVE AND NOCICEPTIVE NEURONES IN THE SPINAL CORD OF THE CAT.

DIFFERENCES IN THE INHIBITORY EFFECTS OF NORMORPHINE AND OPIOID PEPTIDES ON THE RESPONSES OF THE VASA-DEFERENTIA OF TWO STRAINS OF MICE.

POTENTIATION BY NEUROLEPTIC AGENTS OF THE INHIBITORY ACTION OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE.

NEUROPHARMACOLOGY OF AMINO-ACID INHIBITORY TRANSMITTERS. 002967 04-03

MONOAMINE-OXIDASE INHIBITORY PROPERTIES OF 5 HYDROXYMETHYL-3-M-TOLYLOXAZOLIDIN-2-ONE (TOLOXATONE).

002971 04-03 METHYLENE-BLUE ALTERS RETENTION OF INHIBITORY AVOIDANCE RESPONSES.

003288 04-04 FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON THE PERFORMANCE OF MICE IN AN INHIBITORY AVOIDANCE TASK.

BETA-ENDORPHIN INHIBITS ACH TURNOVER IN NUCLEI OF RAT BRAIN. 000012 01-01

NEUROTENSIN ADMINISTERED INTRACISTERNALLY INHIBITS
RESPONSIVENESS OF MICE TO NOXIOUS STIMULI. 002214 03-04

6 HYDROXYDOPAMINE INHIBITS SOME EFFECTS OF MESCALINE CENTRALLY ADMINISTERED TO RABBITS. 002231 03-04

POSSIBLE PHYSIOLOGICAL SIGNIFICANCE OF THE INITIAL STEP IN THE CATABOLISM OF NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM

001117 02-03 PREDICTION OF PLASMA LEVELS OF IMIPRAMINE FROM
PHARMACOKINETICS OF AN INITIAL DOSE. (UNPUBLISHED PAPER)

001876 02-16 INITIAL RESPONSE TO DRUGS IN DEPRESSIVE ILLNESS AND PSYCHIATRIC AND COMMUNITY ADJUSTMENT A YEAR LATER. 002459 03-09

INJECTABLE

LONG-ACTING ORAL VS INJECTABLE ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENICS: A ONE-YEAR DOUBLE-BLIND COMPARISON IN MULTIPLE EPISODE SCHIZOPHRENICS. 003467 04-08

A COMPARISON OF THE EFFICACY AND ACCEPTABILITY OF TWO FORMULATIONS OF INJECTABLE SERENACE IN THE TREATMENT OF STATES OF EXCITEMENT.

003576 04-11 EFFECTS OF CARBACHOL AND NICOTINE INJECTED INTO THE CEREBRAL VENTRICLES ON ELECTROMYOGRAM OF CONSCIOUS CATS.

000052 01-03

002562 03-13

INFLUENCE OF INJECTED PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE BRAIN AND LUNG FOLLOWING MICROWAVE IRRADIATION 000214 01-03

ACETYLCHOLINE TURNOVER IN SPECIFIC BRAIN AREAS OF RATS INJECTED WITH VARIOUS ANTIDEPRESSANTS. (UNPUBLISHED PAPER). 000244 01-03

REACTIVITY AND AGGRESSION IN THE RAT: INDUCTION BY ALPHA-ADRENERGIC BLOCKING AGENTS INJECTED VENTRAL TO ANTERIOR SEPTUM BUT NOT INTO LATERAL SEPTUM.

000309 01-04 EFFECTS OF CHOLINOMIMETIC DRUGS AND THEIR ANTAGONISTS INJECTED INTO VERTEBRAL ARTERY OF UNANAESTHETIZED DOGS.

000375 01-04 EFFECTS ON TEMPERATURE OF MORPHINE INJECTED INTO THE PREOPTIC/ ANTERIOR HYPOTHALAMUS, MEDULLA-OBLONGATA, AND PERIPHERALLY IN UNRESTRAINED AND RESTRAINED RATS

MUSCIMOL A GABA-AGONIST INJECTED INTO THE NUCLEUS-ACCUMBENS INCREASES APOMORPHINE STEREOTYPY AND DECREASES THE

EFFECTS ON HYPOTHALAMIC SELF-STIMULATION OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION INJECTED INTO NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM OF RATS.

SOME BEHAVIORAL EFFECTS OF SP6-11 HEXAPEPTIDE C-TERMINAL OF SUBSTANCE-P INJECTED INTO THE CEREBRAL VENTRICLES IN RATS. 002267 03-04

EFFECT OF MORPHINE INJECTED IN PERIAQUEDUCTAL GRAY ON THE ACTIVITY OF SINGLE UNITS IN NUCLEUS RAPHE MAGNUS OF THE RAT 002817 04-03

TURNOVER RATES OF GAMMA-AMINOBUTYRIC-ACID IN SUBSTANTIA-NIGRA, NUCLEUS-CAUDATUS, GLOBUS-PALLIDUS AND NUCLEUS-ACCUMBENS OF RATS INJECTED WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS

ANALGESIA BY ENKEPHALINS INJECTED INTO THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF RAT MEDULLA-OBLONGATA

003374 04-04

GABA-LIKE PROPERTIES OF FLURAZEPAM AND BACLOFEN SUGGESTED BY ROTATIONAL BEHAVIOUR FOLLOWING UNILATERAL INTRANIGRAL INJECTION: A COMPARISON WITH THE GABA-AGONIST MUSCIMOL 000290 01-03

FIXED-INTERVAL RESPONDING UNDER SECOND-ORDER SCHEDULES OF FOOD PRESENTATION OR COCAINE INJECTION.

000391 01-04 NACL AND LICL EFFICACY IN THE INDUCTION OF AVERSION FOR QUININE AND SACCHARIN SOLUTIONS IMMEDIATELY FOLLOWING INJECTION

000396 01-04 THE EFFECT OF INTRACEREBRAL INJECTION OF CYCLOHEXIMIDE ON BRAIN PROTEIN SYNTHESIS AND ON THE HYPERACTIVITY SYNDROME PRODUCED BY A MONOAMINE-OXIDASE INHIBITOR AND TRYPTOPHAN. 000410 01-04

ATTENUATION OF MORPHINE ANALGESIA IN RATS BY INTRA-AMYGDALOID INJECTION OF DOPAMINE 000443 01-04

ELEVATION OF AVERSIVE THRESHOLD IN RATS BY INTRA-AMYGDALOID INJECTION OF MORPHINE-SULPHATE

000444 01-04 **ENKEPHALIN ANALOGUES ELICITING ANALGESIA AFTER INTRAVENOUS**

001024 02-02 CLINICAL PHARMACOKINETICS OF LORAZEPAM. III. INTRAVENOUS INJECTION, PRELIMINARY RESULTS

001662 02-13 SEQUELAE AFTER THE INTRAVENOUS INJECTION OF THREE BENZODIAZEPINES - DIAZEPAM, LORAZEPAM, AND FLUNITRAZEPAM 001785 02-15

PROLIXIN-DECANOATE: BIG BROTHER BY INJECTION?. 001940 02-17

HYPOTHERMIA EVOKED BY THE INTRACEREBRAL INJECTION OF MORPHINE-SULPHATE IN THE RAT: THE EFFECT OF RESTRAINT 002090 03-03

FEEDING BEHAVIOR OF SHEEP FOLLOWING INTRAVENOUS INJECTION OF **IMIDAZOBENZODIAZEPINES** 002193 03-04

MONOAMINERGIC INFLUENCES ON THE INCORPORATION OF \$35 IN THE HYPOTHALAMIC AND NEUROHYPOPHYSIAL PROTEINS FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF \$35-CYSTEINE IN DEHYDRATED RATS

002238 03-04 SPONTANEOUS AND AMPHETAMINE-INDUCED BEHAVIOR AFTER BILATERAL INJECTION OF ETHANOLAMINE-O-SULFATE INTO THE SUBSTANTIA-NIGRA

002262 03-04 ATTRIBUTES OF DISCRIMINATIVE PENTOBARBITAL STIMULUS IMMEDIATELY AFTER INTRAVENOUS INJECTION.

002265 03-04

EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AGONISTS AND ANTAGONISTS INTO THE AMYGDALA ON RETENTION OF PASSIVE AVOIDANCE TRAINING IN RATS. (PH.D. DISSERTATION).

002323 03-04 LOSS OF STRIATAL DOPAMINERGIC RECEPTORS AFTER INTRASTRIATAL KAINIC-ACID INJECTION.

002909 04-03 TISSUE DISTRIBUTION OF RADIOACTIVITY AFTER INJECTION OF C14-NITRAZEPAM IN YOUNG AND OLD RATS.

THE EFFECTS OF ETHANOLAMINE-O-SULPHATE INJECTION INTO THE RAT SUBSTANTIA-NIGRA: ELECTROPHYSIOLOGICAL STUDIES.

LOCAL CEREBRAL GLUCOSE UTILIZATION FOLLOWING INJECTION OF BETA-ENDORPHIN INTO PERIAQUEDUCTAL GRAY MATTER IN THE RAT.

THE DECREASE OF MONOAMINE-OXIDASE ACTIVITY FOLLOWING THE INTRAOCULAR INJECTION OF COLCHICINE IN THE SUPERIOR COLLICULUS OF THE RAT 003120 04-03

THE EFFECTS OF INTRAVENTRICULAR INJECTION OF GAMM AMINOBUTYRIC-ACID (GABA) ON PROLACTIN AND GONADOTROPIN
RELEASE IN CONSCIOUS FEMALE RATS

EFFECTS OF PROPYLBENZILYLCHOLINE MUSTARD ON INJECTION INTO THE LIQUOR SPACE OF CATS

003168 04-04 MURICIDE INDUCED BY SINGLE INJECTION OF DELTA9-TETRAHYDROCANNABINOL.

003226 04-04 RETROGRADE AMNESIA PRODUCED BY POSTTRIAL INJECTION OF SUBSTANCE-P INTO SUBSTANTIA-NIGRA

ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

003272 04-04 PLASMA FLUPHENAZINE CONCENTRATIONS AFTER INJECTION OF LONG-ACTING ESTERS.

003590 04-13 INJECTIONS BRAIN SEROTONIN TURNOVER AND MORPHINE-TOLERANCE DEPENDENCE INDUCED BY MULTIPLE INJECTIONS IN THE RAT.

O00055 01-03
PERSISTENT EFFECTS OF REPEATED INJECTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE ON RAT BRAIN 5 HYDROXYTRYPTAMINE AND 5
HYDROXYINDOLFACETIC-ACID LEVELS.

EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: I. BEHAVIOURAL EFFECTS OF INTRAMUSCULAR INJECTIONS.

000316 01-04

SUBCUTANEOUS INJECTIONS OF APOMORPHINE, STIMULUS
GENERALIZATION AND CONDITIONING: SERIOUS PITFALLS FOR THE
EXAMINER USING APOMORPHINE AS A TOOL. 000341 01-04 LONG-TERM BEHAVIORAL CHANGES IN THE RHESUS MONKEY AFTER MULTIPLE DAILY INJECTIONS OF D METHYLAMPHETAMINE.

THE EFFECTS OF NEONATAL INJECTIONS OF ALPHA-MSH ON THE OPEN-FIELD BEHAVIOR OF JUVENILE AND ADULT RATS.

EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION: AMPHETAMINE LEVELS AND EFFECTS UPON SOME ARYLALKYLAMINES IN RAT BRAIN.

DIFFERENT BEHAVIORAL RESPONSES TO L-DOPA AFTER ANTEROLATERAL OR POSTEROLATERAL HYPOTHALAMIC INJECTIONS OF 6

O01349 02-04
DRINKING BEHAVIOUR INDUCED BY INTRACRANIAL INJECTIONS OF
ELEDOISIN AND SUBSTANCE-P IN THE PIGEON.

HYDROXYDOPAMINE

001352 02-04 EFFECTS ON RETENTION OF POSTTRAINING AMPHETAMINE INJECTIONS IN MICE: INTERACTION WITH PRETRAINING EXPERIENCE.

001375 02-04 ACQUISITION AND EXTINCTION OF OPERANT RESPONDING FOR INTRAVENOUS INJECTIONS OF FENTANYL IN THE RAT.

001397 02-04 THE EFFECT OF NONCONTINGENT AMPHETAMINE INJECTIONS ON THE EXTINCTION OF FOOD AND DRUG REINFORCED LEVER PRESSING IN

001404 02-04 EFFECT OF PRETRIAL AND POSTTRIAL TYRAMINE AND GUANETHIDINE INJECTIONS ON AN APPETITIVE TASK IN RATS.

CATALEPSY INDUCED BY INTRASTRIATAL INJECTIONS OF DELTA9-THC AND 11 OH-DELTA9-THC IN THE RAT.

HYPERTHERMIC RESPONSES TO CENTRAL AND PERIPHERAL INJECTIONS OF MORPHINE-SULPHATE IN THE CAT.

002864 04-03 THE EFFECT OF INTRAHIPPOCAMPAL KAINIC-ACID INJECTIONS AND SURGICAL LESIONS ON NEUROTRANSMITTERS IN HIPPOCAMPUS AND SEPTUM.

MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II. 002994 04-03

BEHAVIORAL AND ANATOMICAL CONSEQUENCES OF SMALL INTRASTRIATAL INJECTIONS OF KAINIC-ACID IN THE RAT.

003210 04-04 CIRCLING BEHAVIOUR IN THE RAT FOLLOWING UNILATERAL INJECTIONS OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE INTO THE SUBSTANTIA-NIGRA.

003375 04-04 AGGRESSION INCREASE AND WATER COMPETITION DECREASE IN SQUIRREL-MONKEYS GIVEN PHYSOSTIGMINE INJECTIONS.

003377 04-04 MOTOR ACTIVITY OF RATS FOLLOWING INTRACEREBRAL INJECTIONS OF DRUGS INFLUENCING GABA MECHANISMS. 003387 04-04

EFFECTS OF PERPHENAZINE-ENANTHATE INJECTIONS ON PROLACTIN LEVELS IN PLASMA FROM SCHIZOPHRENIC WOMEN AND MEN. 003462 04-08

MEMORIZATION AND CENTRAL CATECHOLAMINES AFTER A CRANIOCERVICAL INJURY CARRIED OUT IN RATS: INFLUENCE OF IMIPRAMINE ADMINISTRATION.

002197 03-04 INMATE

EVALUATION OF THE PRISON INMATE AS A SUBJECT IN DRUG ASSESSMENT. 000982 01-17

RELATIONSHIP BETWEEN THE UPTAKE OF 3H-(PLUS OR MINUS)
METARAMINOL AND THE DENSITY OF ADRENERGIC INNERVATION IN
ISOLATED RAT TISSUES.

000142 01-03 THE INDOLAMINERGIC INNERVATION OF THE INFERIOR OLIVE. 2. RELATION TO HARMALINE-INDUCED TREMOR.

000269 01-03 FURTHER STUDIES ON THE FINE STRUCTURE OF THE ADRENERGIC INNERVATION OF THE HYPOTHALAMUS.

INNOVATION
PHYSICIANS DRUG INNOVATION AND RELINQUISHMENT.

003105 04-03 001912 02-17

003405 04-05

INORGANIC EFFECTS OF ETHANOL: ALTERATION BY INORGANIC IONS AND

THE EFFECTS OF INORGANIC LEAD ON THE CENTRAL CATECHOLAMINERGIC SYSTEM OF THE RODENT WITH EMPHASIS ON POSTNATALLY EXPOSED RATS AND MICE. (PH.D. DISSERTATION).

003078 04-03 INOTROPIC ACTION OF HYDROXYLATED CHLORPROMAZINE METABOLITES AND RELATED COMPOUNDS.

INPATIENTS
PROPOXYPHENE ON DEMAND: ANALGESIC SEEKING BEHAVIOR IN
PSYCHIATRIC INPATIENTS.

ADVERSE REACTIONS TO MEDICATION IN PSYCHIATRIC INPATIENTS: THEIR MEANING, UTILITY AND PROBLEMS.

001744 02-15 DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF BUPROPION-HYDROCHLORIDE (WELLBATRIN) IN THE TREATMENT OF DEPRESSED

A DOUBLE-BLIND INVESTIGATION OF PIRACETAM (NOOTROPIL) VERSUS PLACEBO IN THE MEMORY OF GERIATRIC INPATIENTS.

5-HT AND MORPHINE INTERACTION, EFFECTS ON SENSORY INPUT IN CAUDATE NUCLEUS AND SUBSTANTIA-NIGRA.

000089 01-03

NQUIRY
SUBJECTS RIGHTS, FREEDOM OF INQUIRY, AND THE FUTURE OF
RESEARCH IN THE ADDICTIONS. 000966 01-17

INSENSITIVE TYPTAMINE-INDUCED DRUG EFFECTS INSENSITIVE TO SEROTONINERGIC ANTAGONISTS: EVIDENCE OF SPECIFIC TRYPTAMINERGIC RECEPTOR STIMULATION?

Psychopharmacology Abstracts

COMBINATION OF PHENYLPYRROLIDINOPENTANE (KATOVIT) WITH OXAZEPAM (ADUMBRAN): A DOUBLE-BLIND TRIAL WITH OPIPRAMOL (INSIDON) IN DEPRESSIVE SYNDROME.

000597 01-10

000597 01-10 FROM JOY TO DEPRESSION: NEW INSIGHTS INTO THE CHEMISTRY OF MOODS. 000981 01-17

THE INSOMNIA OF SLEEPING IN A STRANGE PLACE: EFFECTS OF L TRYPTOPHANE.

000632 01-11 COMPARISON OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTICS IN GERIATRIC PATIENTS WITH INSOMNIA.

000658 01-11 MULTICLINIC CROSS-OVER COMPARISON OF TRIAZOLAM (HALCION) AND PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND ANXIETY IN ANXIOUS OUTPATIENTS.

000762 01-14 TRIAZOLAM IN INSOMNIA: A STANDARD-CONTROLLED TRIAL 002523 03-11

INSOMNIACS

A SUBJECTIVE AND OBJECTIVE METHOD ASSESSING THE EFFICACY OF HYPNOTIC MEDICATIONS IN INSOMNIACS.

DO1973.0:

COMPARISON OF TRIAZOLAM .25 MG AND FLURAZEPAM 15 MG IN TREATING GERIATRIC INSOMNIACS.

INSTINCTIVE PREDATORY BEHAVIOR OF THE FERRET (PUTORIUS-PUTORIUS-FURO L.) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE (LIBRIUM).

003161 04-04

EFFECT OF CHLORPROMAZINE ON ELABORATION AND EXTINCTION OF AN INSTRUMENTAL ALIMENTARY REFLEX IN PUPPIES. 001407 02-04

DRIGS ALTERING INSULIN SECRETION: EFFECTS ON PLASMA AND BRAIN CONCENTRATIONS OF AROMATIC-AMINO-ACIDS AND ON BRAIN 5 HYDROXYTRYPTAMINE TURNOVER.

000088 01-03 ENHANCEMENT BY CHOLINE OF THE INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE BY PHENOXYBENZAMINE, 6 HYDROXYDOPAMINE, INSULIN OR EXPOSURE TO COLD.

002167 03-03 THE EFFECTS OF EXTENDED INSULIN DOSAGE ON TARGET-DIRECTED ATTACK AND BITING ELICITED BY TAILSHOCK.

003206 04-04 FOOD RELATED INTRAVENOUS INSULIN SELF-ADMINISTRATION IN NORMAL AND DIABETIC RATS.

003252 04-04 EFFECTS OF INSULIN AND 2 DEOXY-D-GLUCOSE ON FEEDING IN HAMSTERS AND GERBILS.

THE EFFECT OF CHLORPROMAZINE, SOME TRICYCLIC ANTIDEPRESSANTS AND INSULIN ON THE ACTION OF CYCLIC-AMP AND ADENOSINE METABOLISM.

003606 04-13 INTACT

EFFECTS OF RESERPINE AND IMIPRAMINE ON VESICULAR SEROTONIN UPTAKE AND STORAGE IN INTACT HUMAN PLATELETS. 000081 01-03

PSYCHOACTIVE DRUG EFFECTS AND SUBSTRATE SPECIFICITY IN INTACT MITOCHONDRIAL MONOAMINE-OXIDASE FROM BRAIN. 000115 01-03

EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON FEEDING IN INTACT AND 6 HYDROXYDOPAMINE TREATED RATS. 000378 01-04

P-CHLOROPHENYLALANINE PRODUCED EFFECTS ON BEHAVIOR IN INTACT AND BRAIN-DAMAGED RATS. 000421 01-04

BETA ADRENERGIC RECEPTOR LABELING IN INTACT ANIMALS WITH 1125-HYDROXYBENZYLPINDOLOL. 000493 01-06

PHARMACOKINETICS OF SOME HOMOLOGOUS SERIES OF BARBITURATES IN THE INTACT RAT AND IN THE ISOLATED PERFUSED RAT LIVER. 001292 02-03

STUDY OF A DOPAMINERGIC POTENTIAL ANTIPARKINSON COMPOUND IN INTACT AND NIGRA-LESIONED RATS: N-N PROPYLBUTYLDIHYDROXYPHENYLETHYLAMINE HCL.

001957 03-02 DOPAMINE TURNOVER IN THE INTACT RABBIT BRAIN: EFFECT OF PENTOBARBITAL OR HALOPERIDOL.

PHARMACOLOGICAL STUDIES OF CENTRAL ACTION OF L. 5 HYDROXYTRYPTOPHAN IN INTACT OR TETRABENAZINE PRETREATED CATS. 002815 04-03

003144 04-03

002524 03-11

003057 04-03

LSD AND TRYPTAMINE EFFECTS ON SLEEP-WAKEFULNESS AND ELECTROCORTICOGRAM PATTERNS IN INTACT CATS.

003256 04-04

STIMULATION OF FOOD INTAKE BY MUSCIMOL AND BETA-ENDORPHIN.

000023 01-02
KINETIC STUDIES OF FOOD INTAKE AND SUCROSE SOLUTION PREFERENCE
BY RATS TREATED WITH LOW DOSES OF DELTA9TETRAHYDROCANNABINOL.

UTHIUM-CARBONATE INTAKE DURING PREGNANCY LEADING TO LARGE GOITER IN A PREMATURE INFANT.

DOOB69 01-15
DECREASE OF FOOD INTAKE BY QUIPAZINE IN THE RAT: RELATION TO SEROTOMINERGIC RECEPTOR STIMULATION.

001235 02-03
DIFFERENTIAL TOLERANCE TO INHIBITORY ACTION OF VARIOUS
NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS
CHRONICALLY TREATED WITH HALOPERIDOL.

BIOAVAILABILITY OF OXAZEPAM: ABSENCE OF INFLUENCE OF FOOD INTAKE.

A COMPARISON OF FOOD INTAKE SUPPRESSION PRODUCED BY GIVING AMPHETAMINE AS AN AVERSION TREATMENT VERSUS AS AN ANOREXIC TREATMENT.

FENFLURAMINE AND FLUOXETINE SPARE PROTEIN CONSUMPTION WHILE SUPPRESSING CALORIC INTAKE BY RATS.

ODZ 184 03-0:
INTOXICATING EFFECTS OF THREE ALIPHATIC ALCOHOLS AND BARBITAL
ON TWO RAT STRAINS GENETICALLY SELECTED FOR THEIR ETHANOL
INTAKE

O02276 03-04
CHLORDIAZEPOXIDE FLUOXETINE INTERACTIONS ON FOOD INTAKE IN FREE-FEEDING RATS.

DIETARY EFFECTS UPON FOOD AND WATER INTAKE AND
RESPONSIVENESS TO ESTROGEN, 2 DEOXYGLUCOSE AND GLUCOSE IN

003402 04-04

MODELS TO STUDY DRUG EFFECTS ON THE INTEGRATED FUNCTION OF GABAERGIC, PEPTIDERGIC (SUBSTANCE-P) AND DOPAMINERGIC NEURONS. (UNPUBLISHED PAPER).

INTEGRATION
THE IMPLICATIONS OF PSYCHEDELIC DRUG RESEARCH FOR INTEGRATION
AND SEALING OVER AS RECOVERY STYLES FROM ACUTE PSYCHOSIS.
003517 04-09

000499 01-06

INTELLIGENCE
THE INFLUENCE OF PYRITHIOXINE ON CERTAIN FACTORS OF INTELLIGENCE.

DEXTROAMPHETAMINE AND MEASURES OF INTELLIGENCE. 001716 02-14

THERAPEUTIC EFFECT OF BRAIN HYDROLYSATES IN DEPRESSION-INDUCED DISTURBANCES OF INTELLIGENCE.

002380 03-07

INTENSITY

A ROLE FOR CENTRAL SEROTONERGIC SYSTEMS IN THE PATTERN AND INTENSITY OF THE CONVULSIVE RESPONSE OF RATS TO

PASSIVE AVOIDANCE LEARNING IN THE RAT AS FUNCTIONS OF D
AMPHETAMINE DOSAGE AND SHOCK INTENSITY.

MORPHINE AND SHOCK DETECTION: EFFECTS ON SHOCK INTENSITY.

003332 04-04

INTENSIVE ANTIDEPRESSIVE THERAPY BY 48 HOUR SLOW-DRIP INFUSION WITH HIGH DOSES DIBENZEPINE.

001602 02-09
DELIBERATE POISONING WITH TRICYCLIC ANTIDEPRESSANTS TREATED IN

AN INTENSIVE CARE UNIT. 001758 02-15

MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND NORADRENERGIC NEURONS IN NORMAL AND BRAIN LESIONED RATS.

SELECTIVITY OF H3-BIOGENIC AMINE RELEASE BY D.L AMPHETAMINE AND DRUGS THAT INTERACT WITH SEROTONERGIC NEURONS. 001161 02-03

DIRECT EVIDENCE FOR AN INTERACTION OF BETA-ADRENERGIC BLOCKERS WITH THE 5-HT RECEPTOR.

INTERACTION OF GABA, DOPAMINE, AND ACETYLCHOLINE IN CAT STRIATUM: PHARMACOLOGICAL CONSIDERATIONS. 5-HT AND MORPHINE INTERACTION, EFFECTS ON SENSORY INPUT IN CAUDATE NUCLEUS AND SUBSTANTIA-NIGRA.

INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL AND D
AMPHETAMINE.

BENZODIAZEPINE ACTIVITY: IS INTERACTION WITH THE GLYCINE RECEPTOR, AS EVIDENCED BY DISPLACEMENT OF STRYCHNINE BINDING. A LISEFIL CRITERION?

O00151 01-03
STIMULUS EFFECTS OF DELTA9-THC AND ITS INTERACTION WITH
NALTREXONE AND CATECHOLAMINE BLOCKERS IN RATS.

O00157 01-03
CATECHOLAMINE SYNTHESIS IN RAT BRAIN AFTER AXOTOMY:
INTERACTION BETWEEN APOMORPHINE AND HALOPERIDOL.

O00161 01-03
ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC MERVOUS
SYSTEM — IV. TOLERANCE TO OXOTPEMORINE IN MICE: IN VIVO AND
IN VITRO STUDIES.

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM — III. TOLERANCE TO PHENCYCLIDINE DERIVATIVES: IN VIVO AND IN VITRO STUDIES.

THE BLOCKADE OF SEROTONIN UPTAKE INTO SYNAPTOSOMES:
RELATIONSHIP TO AN INTERACTION WITH MONOAMINE-OXIDASE INHIBITORS.

O00268 01-03
ANTICONVULSANT INTERACTION OF CANNABIDIOL AND ETHOSUXIMIDE

O00339 01-04
THE EFFECT OF L-DOPA AND LERGOTRILE-MESYLATE ON THE INTERACTION
OF FLUPHENAZINE-DECANOATE AND AMPHETAMINE-INDUCED
STREOTYPY AND MORTALITY

THE INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT
REHAVIOUR IN RODENTS.

O00435 01-04
INTERACTION OF DRUGS WITH APOMORPHINE, TRYPTAMINE AND
NOREPINEPHRINE. A NEW IN VIVO APPROACH: THE ATN-TEST IN

000502 01-06
LITHIUM-CARBONATE AND METHYLDOPA: APPARENT INTERACTION IN
MAN.

000807 01-15
EVIDENCE FOR A NONCOVALENT INTERMOLECULAR INTERACTION OF
OPIATES WITH THIAMINE.

OPIATES WITH THIAMINE.

001008 02-01
INTERACTION OF AMITRIPTYLINE AND MORPHINE IN MORPHINETOLERANT AND NONTOLERANT RATS.

INTERACTION BETWEEN NARCOTIC ANTAGONIST (NALOXONE) AND LYSERGIC-ACID-DIETHYLAMIDE (LSD) IN THE RAT.

CEREBELLAR CGMP SYSTEM: A MODEL TO STUDY DRUG RECEPTOR INTERACTION. (UMPUBLISHED PAPER).

BIOCHEMICAL INTERACTION BETWEEN ANORECTIC DRUGS AND PRIBEOIL.
001154 02-03
A SEX DIFFERENCE IN THE INTERACTION BETWEEN PROMETHAZINE AND

MORPHINE IN THE MOUSE.

O01242 02-03

CHEMILUMINESCENCE RESULTING FROM AN INTERACTION BETWEEN
IMIPRAMINE AND HUMAN POLYMORPHONUCLEAR LEUKOCYTES.
001263 02-03
THE THERMAL EFFECTS OF INTERACTION RETWEEN D AMPHETAMINE AND

THE THERMAL EFFECTS OF INTERACTION BETWEEN D AMPHETAMINE AND ANTIDEPRESSANTS AMONG RATS KEPT AT VARIOUS AMBIENT TEMPERATURES. 001290 02-03

INTERACTION OF ARENA SIZE WITH DIFFERENT MEASURES OF AMPHETAMINE EFFECTS.

LONG-TERM ELIMINATION OF VIOLENT BEHAVIOUR BY THE INTERACTION OF PSYCHOPHARMACOLOGIC AND PSYCHOSOCIAL THERAPY.

O01333 02-04

EFFECTS ON RETENTION OF POSTTRAINING AMPHETAMINE INJECTIONS IN
MICE: INTERACTION WITH PRETRAINING EXPERIENCE.

001375 02-04
NALOXONE INTERACTION WITH NEUROLEPTIC-INDUCED SUPPRESSION OF
NARCOTIC WITHDRAWAL.

MOOD CHANGE AND MAGNESIUM: A POSSIBLE INTERACTION BETWEEN MAGNESIUM AND LITHIUM?

A POTENTIALLY TOXIC DRUG INTERACTION BETWEEN PETHIDINE
(MEPERIDINE) AND PHENOBARBITONE.

001836 02-15

DIGOXIN LITHIUM DRUG INTERACTION.

000312 01-04

0000010 01-01

SYNDROME MALIN SYMPTOMS THOUGHT TO BE DUE TO INTERACTION BETWEEN NEUROLEPTICS AND ORAL DIABETES DRUGS.

001854 02-15 INTERACTION OF IODINATED ENKEPHALIN ANALOGUES WITH OPIATE

001947 03-01 DIRECT INTERACTION OF LSD WITH CENTRAL BETA-ADRENERGIC RECEPTORS

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. II. CROSS-TOLERANCE BETWEEN PHENCYCLIDINE DERIVATIVES AND CHOLINERGIC DRUGS.

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. I. TOLERANCE TO PHENCYCLIDINE DERIVATIVES IN MICE. PHARMACOLOGICAL CHARACTERIZATION.

002127 03-03 IMIPRAMINE ANTAGONISM OF APOMORPHINE-INDUCED HYPOTHERMIA: A NONDOPAMINERGIC INTERACTION.

NEUROCHEMICAL AND BEHAVIORAL EFFECTS OF CLONIDINE AND RELATED IMIDAZOLINES: INTERACTION WITH ALPHA-ADRENOCEPTORS.

TERACTION OF ERGOT ALKALOIDS WITH DOPAMINERGIC RECEPTORS IN THE RAT STRATUM AND NUCLEUS-ACCUMBENS.

002157 03-03 EFFECTS OF BACLOFEN ON DOPAMINE METABOLISM AND INTERACTION WITH NEUROLEPTIC EFFECTS.

002173 03-03 INTERACTION BETWEEN MORPHINE AND REINFORCING LATERAL HYPOTHALAMIC STIMULATION.

002291 03-04

CONDITIONED TASTE AVERSIONS: GENOTYPE BY OLFACTORY BULBECTOMY INTERACTION.

A DOSE RATIO COMPARISON OF THE INTERACTION BETWEEN MORPHINE AND CYCLAZOCINE WITH NALOXONE IN RHESUS MONKEYS ON THE SHOCK TITRATION TASK.

APOMORPHINE AND AMANTADINE: INTERACTION WITH ETHANOL IN

EFFECT OF MECAMYLAMINE ON THE FATE OF DOPAMINE IN STRIATAL AND MESOLIMBIC AREAS OF RAT BRAIN; INTERACTION WITH MORPHINE AND HALOPERIDOL.

002806 04-03 INTERACTION OF PENTOBARBITONE AND GAMMA-AMINOBUTYRIC-ACID ON MAMMALIAN SYMPATHETIC GANGLION CELLS.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH,

INTERACTION OF IMIPRAMINE AND 3 QUINUCLIDYL-BENZILATE WITH 9
AMINO-7-METHOXYTETRAHYDROACRIDINE ON THE AFTER-DISCHARGES
IN THE LIMBIC SYSTEM.

EVIDENCE OF AN INTERACTION BETWEEN SEROTONINERGIC AND CHOLINERGIC NEURONS IN THE CORPUS-STRIATUM AND HIPPOCAMPUS OF THE RAT BRAIN

INTERACTION OF ETHANOL WITH AMYLOBARBITONE, PHENOBARBITONE AND METHAQUALONE.

003115 04-03 THE DEVELOPMENT OF SEX DIFFERENCES IN THE DEMETHYLATION OF ETHYLMORPHINE AND IN ITS INTERACTION WITH COMPONENTS OF THE HEPATIC MICROSOMAL CYTOCHROME-P-450 SYSTEM IN MICE.

003122 04-03 INTERACTION OF PHENCYCLIDINES WITH THE MUSCARINIC AND OPIATE RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM.

PHARMACOLOGICAL EVIDENCE FOR DOPAMINERGIC PALLIDOSTRIATAL INTERACTION

003137 04-03 INTERACTION BETWEEN PHENCYCLIDINE AND PENTOBARBITAL IN SEVERAL SPECIES OF LABORATORY ANIMALS.

003185 04-04 CAN SOCIAL INTERACTION BE USED TO MEASURE ANXIETY?

003219 04-04 INTERACTION BETWEEN D AMPHETAMINE AND ETHANOL WITH RESPECT TO LOCOMOTION, STEREOTYPIES, ETHANOL SLEEPING TIME, AND THE KINETICS OF DRUG ELIMINATION.

003378 04-04 LIDOCAINE AND PENTOBARBITAL: A POTENTIALLY LETHAL DRUG DRUG

003412 04-05 PHARMACOKINETIC INTERACTION BETWEEN AMITRIPTYLINE AND NEUROLEPTICS.

003461 04-08 LITHIUM-CARBONATE AND TETRACYCLINE INTERACTION. 003667 04-15

INTERACTIONIST
CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL
ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE
FOR AN INTERACTIONIST POSITION.

INTERACTIONS
MORPHINE AND 5 HYDROXYTRYPTAMINE INTERACTIONS IN RAT
HYPOTHALAMUS AND PINEAL BODY.
D00000

000065 01-03 ACUTE AND CHRONIC EFFECTS OF TETRAHYDROCANNABINOLS ON MONOAMINE-OXIDASE ACTIVITY: POSSIBLE VEHICLE/ TETRAHYDROCANNABINOL INTERACTIONS.

000075 01-03 INTERACTIONS OF SUBSTITUTED BENZAMIDE DRUGS WITH CEREBRAL

000077 01-03 NEUROLEPTIC DRUG INTERACTIONS WITH NOREPINEPHRINE ALPHA

RECEPTOR BINDING SITES IN RAT BRAIN 000219 01-03

SOME OBSERVATIONS ON THE MECHANISM OF BENZODIAZEPINE BARBITURATE INTERACTIONS IN THE MOUSE. 000335 01-04

INTERACTIONS OF NARCOTICS AND THEIR ANTAGONISTS WITH HUMAN SERUM ESTERASE. VI: THE BEHAVIOR OF 14 HYDROXYLATED MORPHINE DERIVATIVES.

000690 01-13 DRUG INTERACTIONS.

000945 01-17 THE BEHAVIORAL EFFECTS OF DIISOPROPYL-PHOSPHOFLUORIDATE: INTERACTIONS WITH MORPHINE AND NALOXONE IN RATS.

INTERACTIONS OF LEUCINE AND METHIONINE-ENKEPHALIN WITH MORPHINE IN VITRO AND IN VIVO.

001272 02-03 ALCOHOL-DISCRIMINATION IN GERBILS: INTERACTIONS WITH BEMEGRIDE, DH-524, AMPHETAMINE, AND DELTA9-THC.

001385 02-04 INTERACTIONS BETWEEN ALCOHOL AND OTHER DRUGS ON OPEN-FIELD AND TEMPERATURE MEASUREMENTS IN GERBILS.

001386 02-04 INTERACTIONS OF DELTA9-TETRAHYDROCANNABINOL WITH PHENOBARBITAL, ETHANOL AND CHLORDIAZEPOXIDE.

001436 02-04 FEEDING AND DRINKING INTERACTIONS AFTER ACUTE BUTYROPHENONE ADMINISTRATION.

001446 02-04 DRUG INTERACTIONS AS MEASURED BY DEPRIVATION-INDUCED FLUID

001501 02-04 TOXIC INTERACTIONS OF STIMULANTS, NARCOTICS AND NARCOTIC

ANTAGONISTS. 001511 02-05

EFFECTS OF TRITHIOZINE ON PSYCHOMOTOR SKILLS RELATED TO DRIVING: A COMPARISON WITH DIAZEPAM AND INTERACTIONS WITH ALCOHOL.

001723 02-14 DRUG INTERACTIONS AND MULTIPLE DRUG ADMINISTRATION 001913 02-17

INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS. 001959 03-02

BINDING INTERACTIONS OF ERGOT ALKALOIDS WITH MONOAMINERGIC RECEPTORS IN THE BRAIN.

THE OPIATE RECEPTOR BINDING INTERACTIONS OF H3-METHIONINE-ENKEPHALIN, AN OPIOID PEPTIDE.

PHARMACOLOGICAL INTERACTIONS WITH CIRCLING BEHAVIOUR INDUCED BY THE PIPERIDINYL INDOLE DERIVATIVE RU-23686.

002200 03-04 INTERACTIONS OF PARTIAL LSD ANALOGS WITH BEHAVIORAL DISRUPTING EFFECTS OF LSD AND DMT IN THE RAT.

002264 03-04 INTERACTIONS BETWEEN DEPRESSANTS (ALCOHOL-TYPE) AND STIMULANTS (AMPHETAMINE-TYPE).

STRESS AND THE HEART: INTERACTIONS OF THE CARDIOVASCULAR

SYSTEM, BEHAVIORAL STATE, AND PSYCHOTROPIC DRUGS 002711 03-15

INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS. 002801 04-02

INTERACTIONS OF ADRENERGIC COMPOUNDS WITH BRAIN MEMBRANE

INTERACTIONS BETWEEN GUANINE DERIVATIVES AND NOREPINEPHRINE ON NEURONES OF THE MAMMALIAN CEREBRAL-CORTEX. 003101 04-03

VOLUME 16, SUBJECT INDEX

Subject Index

H3-APOMORPHINE INTERACTIONS WITH DOPAMINE RECEPTORS IN CALF BRAIN.

003113 04-03

A NEW ANIMAL MODEL FOR SCHIZOPHRENIA: INTERACTIONS WITH ADRENERGIC MECHANISMS.

003175 04-04

CHLORDIAZEPOXIDE FLUOXETINE INTERACTIONS ON FOOD INTAKE IN FREE-FEEDING RATS. 003217 04-04

COCAINE AS A DISCRIMINATIVE CUE IN RATS: INTERACTIONS WITH NEUROLEPTICS AND OTHER DRUGS.

L 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS IN GUINEA-PIGS: A MODEL FOR THE STUDY OF CENTRAL SEROTONIN DOPAMINE INTERACTIONS.

D03386 04-04
ANTIDEPRESSANT ACTIVITY AND PHARMACOLOGICAL INTERACTIONS OF
CICLAZINDOL.
D03493 04-09

TREATMENT OF IMIPRAMINE RESISTANT DEPRESSION AND LITHIUM REFRACTORY MANIA THROUGH DRUG INTERACTIONS.

003512 04-09

DRUG INTERACTIONS. 003713 04-17

INTERACTIVE
ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: INTERACTIVE EFFECTS
ON HUMAN PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS. II.

NTERANIMAL
INTERANIMAL
INTERANIMAL AGGRESSION AND HYPERREACTIVITY FOLLOWING
HYPOTHALAMIC INFUSION OF LOCAL ANESTHETIC IN THE RAT.

INTERCORRELATIONS
INTERCORRELATIONS BETWEEN PHYSIOLOGICAL AND PSYCHOLOGICAL
EFFECTS OF MARIJUANA, HASHISH, AND THC-DELTA9 IN LONG-TERM
HASHISH USERS.

000695 01-13

INTERDEPENDENCE BETWEEN SOCIAL PROCESSES AND NEUROCHEMICAL OPERATIONS.

INTERFERENCE
INTERFERENCE BY FENFLURAMINE WITH THE STORAGE OF C14-5-

HYDROXYTRYPTAMINE IN RAT PLATELETS.

O00297 01-03

CONTROLLING RATER SPECIFIC INTERFERENCE FACTORS IN CLINICAL

TRIALS. 000917 01-16

NEUROLEPTIC INTERFERENCE WITH THE COCAINE CUE: INTERNAL STIMULUS CONTROL OF BEHAVIOR AND PSYCHOSIS.

O03193 04-04

INTERFERES

CANNABIS INTERFERES WITH NEST-BUILDING BEHAVIOR IN MICE.

003306 04-04

INTERFERING
EVIDENCE FOR AN ENDOGENOUS FACTOR INTERFERING WITH H3DIAZEPAM BINDING TO RAT BRAIN MEMBRANES.

002789 04-01
INTERINDIVIDUAL VARIABILITY IN DIAZEPAM METABOLISM:

PRELIMINARY EVIDENCE OF AN ABSENCE OF GENETIC CONTROL.
000696 01-13

BLOCKADE OF TESTOSTERONE MAINTAINED INTERMALE FIGHTING IN ALBINO LABORATORY MICE BY AN AROMATIZATION INHIBITOR. 003176 04-04

INTERMEAL

EFFECT OF CHOLECYSTOKININ ON MEAL SIZE AND INTERMEAL INTERVAL
IN THE SHAM-FEEDING RAT.

INTERMEDIATE

ALPHA-METHYLDOPAMINE — A METABOLITE AND KEY INTERMEDIATE IN
THE METABOLIC DISPOSITION OF 3,4 METHYLENEDIOXYAMPHETAMINE
(MDA) IN DOG AND MONKEY.

(MDA) IN DOG AND MONKEY.

001195 02-03

HEXOBARBITAL-EPOXIDE: A POSSIBLE INTERMEDIATE IN THE METABOLISM OF HEXOBARBITAL.

METABOLISM OF HEXOBARBITAL. 002170 03-03

EFFECTIVENESS OF TEMAZEPAM WITH SHORT-TERM, INTERMEDIATE-TERM, AND LONG-TERM USE: SLEEP LABORATORY EVALUATION. 002608 03-14

EVIDENCE FOR A NONCOVALENT INTERMOLECULAR INTERACTION OF OPIATES WITH THIAMINE.

INTERMOLECULAR

INTERNAL
NEUROLEPTIC INTERFERENCE WITH THE COCAINE CUE: INTERNAL
STIMULUS CONTROL OF BEHAVIOR AND PSYCHOSIS.

INTERNAL STIMULUS CONDITIONING TO DISCRIMINATIVE EXTERNAL STIMULI.

003390 04-04
INTERNATIONAL GUIDELINES FOR CLINICAL TRIALS OF PSYCHOTROPIC

002769 03-17
INTERNEURONES
EFFECT OF QUIPAZINE, A SEROTONIN-LIKE DRUG, ON STRIATAL
CHOLINERGIC INTERNEURONES.

CHOLINERGIC INTERNEURONES. 001114 02-03

INTEROCEPTIVE DISCRIMINATIVE STIMULI AS TOOLS IN DRUG
DEVELOPMENT. 003428 04-06
HTERPERSONAL

INTERPERSONAL

AN EXPERIMENTAL STUDY OF THE EFFECTS OF AMITRIPTYLINE
PERPHENAZINE AND AMITRIPTYLINE HALOPERIDOL COMBINATIONS ON
INTERPERSONAL LEARNING.

002511 03-11

PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS THERAPEUTIC APPLICATION.

INTERVAL

NALOXONE PRECIPITATED WITHDRAWAL AS A FUNCTION OF THE
MORPHINE NALOXONE INTERVAL

000185 01-03

EFFECT OF CHOLECYSTOKININ ON MEAL SIZE AND INTERMEAL INTERVAL
IN THE SHAM-FEEDING RAT.

003264 04-04
EFFECTS OF MARLJUANA EXTRACT DISTILLATE AND CANNABIDIOL ON
VARIABLE INTERVAL PERFORMANCE AS A FUNCTION OF FOOD
DEPONDATION

O03308 04-04

DRUGS AND THE PRODUCTION OF TEMPORAL INTERVALS IN THE RAT.

001299 02-04

IDENTIFICATION OF SHORT TIME INTERVALS UNDER LSD-25 AND

INTERVENTION

COMPARING TREATMENT TACTICS WITH A HYPERACTIVE PRESCHOOL
CHILD: STIMULANT MEDICATION AND PROGRAMMED TEACHER

WITHDRAWAL OF A STIMULANT DRUG AND CONCURRENT BEHAVIORAL INTERVENTION IN THE TREATMENT OF A HYPERACTIVE CHILD. 000780 01-1. LITHIUM AND CRISIS INTERVENTION: DAMPING AFFECTIVE OVERLOAD.

INTERVIEW
THE AMYTAL INTERVIEW: HISTORY AND CURRENT USES.

INTERVENTION.

002767 03-17
PSYCHOTROPIC AND ANTICONVULSANT DRUG USAGE IN EARLY
CHILDHOOD SPECIAL EDUCATION PROGRAMS III. A PRELIMINARY

REPORT: PARENT INTERVIEWS ABOUT DRUG TREATMENT.

000627 01-11

NTESTINAL

ABSORPTION AND METABOLISM OF THE PHENOTHIAZINE DRUG PERAZINE
IN THE RAT INTESTINAL LOOP.

O00063 01-03
PSYCHOTROPIC DRUGS AND INTESTINAL PARALYSIS.

PSYCHOTROPIC DRUGS AND INTESTINAL PARALYSIS.

000875 01-15
EFFECT OF ANTIPARKINSONISM DRUGS ON GASTRIC EMPTYING AND
INTESTINAL TRANSIT IN THE RAT.

O02010 03-03

EFFECT OF VASOACTIVE INTESTINAL PEPTIDE (VIP) AND OTHER PEPTIDES
ON C-AMP ACCUMULATION IN RAT BRAIN.

003056 04-03

INTESTINE

EFFECT OF CHLORPROMAZINE ON L METHIONINE TRANSPORT IN THE RAT

INTESTINE.

O00489 01-05
METABOLISM OF FLURAZEPAM BY THE SMALL INTESTINE.

METABOLISM OF FLURAZEPAM BY THE SMALL INTESTINE.
000713 01-13

CENTRAL-NERVOUS-SYSTEM EFFECTS OF PEPTIDES FOUND IN BRAIN AND INTESTINES. 001953 03-02

INTOXICATING
INTOXICATING EFFECTS OF THREE ALIPHATIC ALCOHOLS AND BARBITAL
ON TWO RAT STRAINS GENETICALLY SELECTED FOR THEIR ETHANOL
INTAKE

INTOXICATION
THE DISRUPTION OF MARIJUANA INTOXICATION.

002276 03-04
000782 01-14

and constant	1 Tythophaniatology Abstracts
ON PSYCHOLOGICAL SYMPTOMS IN BROMIDE INTOXICATION — OF HIGH DOSE, LONG-TERM BROMIDE INTOXICATION WHICH SY	
HALLUCINATION AND DELUSION SYMPTOMS.	THE RELATIONSHIP BETWEEN EXTRACELLULAR AND INTRACELLULAR ID 01-15 LITHIUM CONCENTRATION IN HUMAN RED BLOOD CELLS: AN IN VITRO
ON EXPLORATORY AND STEREOTYPED BEHAVIORS IN THE RAT.	000731 01-13
SUBSTANTIAL INCREASE IN THE LEVELS OF CHLOROPHENOXYACET ACIDS IN THE CNS OF RATS AS A RESULT OF SEVERE INTOXICA	TIC- THE EFFECT OF INTRACEREBRAL INJECTION OF CYCLOHEXIMIDE ON BRAIN TION. PROTEIN SYNTHESIS AND ON THE HYPERACTIVITY SYNDROME
INTOXICATION BY ORPHENADRINE HCL; MECHANISM AND THERA	PY. 000410 01-04
ABOUT A NONFATAL MASSIVE INTOXICATION WITH SUSTAINED-R THIORIDAZINE. CLINICAL AND THERAPEUTIC PROBLEMS.	001343 02-04
RESPIRATORY COMPLICATIONS IN PATIENTS WITH INTOXICATION.	2 02-15 LEARNED AVERSIONS TO INTRACEREBRAL CARBACHOL. 001424 02-04
00176 HYPERTONIC SODIUM-CHLORIDE AND LIDOCAINE IN A CASE OF IMIPRAMINE INTOXICATION.	7 02-15 HYPOTHERMIA EVOKED BY THE INTRACEREBRAL INJECTION OF MORPHINE-SULPHATE IN THE RAT: THE EFFECT OF RESTRAINT. 002090 03-03
PARTICULARITIES OF LITHIUM INTOXICATION IN ADVANCED AGE.	ANALGESIC ACTIVITY OF ENKEPHALINS FOLLOWING INTRACEREBRAL ADMINISTRATION IN THE RAT.
CARBROMAL INTOXICATION HEMODIALYSIS OR HEMOPERFUSION	2 02-15 002-15 BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE EFFECTS 0 02-15 AFTER INTRACEREBRAL INFUSION OF TRH IN FOWLS.
A CASE OF CONSERVATIVELY MANAGED LITHIUM INTOXICATION.	003319 04-04
ONE AUTOPSY CASE OF DIPHENYLHYDANTOIN INTOXICATION.	DRUGS INFLUENCING GABA MECHANISMS.
PHENYTOIN INTOXICATION DURING CONCURRENT DIAZEPAM THE	RAPY. HATRACEREBRALLY 003387 04-04
HYPEPINEPHRIA IN CASES OF STRONG INTOXICATION.	PHARMACOLOGICAL ACTIONS OF INTRACEREBRALLY ADMINISTERED POLYAMINES IN MICE.
LITHIUM INTOXICATION INDUCED BY DIETING AND SAUNAS.	000033 01-02
ETHCHLORVYNOL INTOXICATION.	MONOAMINERGIC INFLUENCES ON THE INCORPORATION OF \$35 IN THE
CHARACTERISTICS OF TILIDEN-HCL (VALORON) INTOXICATION.	INTRACEREBROVENTRICULAR INJECTION OF S35-CYSTEINE IN
REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSM THE EFFICACY OF L-DOPA, AMINOPHYLLINE, AND EPHEDRINE.	AENT OF CARDIOVASCULAR RESPONSE TO INTRACEREBROVENTRICULAR
COCAINE: RECREATIONAL USE AND INTOXICATION.	002982 04-03
VIGILANCE AND HUMAN ATTENTION UNDER CONDITIONS OF METHYLPHENIDATE AND SECOBARBITAL INTOXICATION: AN	4 03-13 EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ, ANGIOTENSIN-II, AND SUBSTANCE-P ON MULTIPLE FIXED-INTERVAL FIXED-RATIO RESPONDING IN RABBITS.
ASSESSMENT USING BRAIN POTENTIALS. 00262	003233 04-04 IMPROVED POLYETHYLENE INTRACEREBROVENTRICULAR CANNULAS FOR
ALPHA AND BETA COMA IN DRUG INTOXICATION. 00265	3 03-15 RATS. 003440 04-06
HEMOPERFUSION IN TREATMENT OF DRUG INTOXICATION. O0265	6 03-15 NEUROTENSIN ADMINISTERED INTRACISTERNALLY INHIBITS
HEAT ILLNESS SYNDROME AND LITHIUM INTOXICATION.	9 03-15 RESPONSIVENESS OF MICE TO NOXIOUS STIMULI. 002214 03-04
LITHIUM INTOXICATION MASKED BY NEUROLEPTIC DRUGS WHEN LITHIUM DIURETIC COMBINATIONS ARE USED.	CLEARANCE AND ANALGESIC ACTIVITY OF THE QUATERNIZED OPIATE, N METHYLMORPHINE (6-H3) ADMINISTERED INTRACISTERNALLY TO THE
PSYCHOSIS: A RARE MANIFESTATION OF DIGOXIN INTOXICATION.	003019 04-03
FACTORS CONTRIBUTING TO CANNABIS INTOXICATION AND DEPER (PH.D. DISSERTATION).	10 03-15 INTRACRANIAL EFFECTS OF DOPAMINE ON INTRACRANIAL PRESSURE. 000103 01-03
PENTOBARBITAL INTOXICATION IN THE PREGNANT RAT.	ON THE ROLE OF ASCENDING CATECHOLAMINERGIC PROJECTIONS IN
	9 04-15 INTRACRANIAL SELF-STIMULATION OF THE SUBSTANTIA-NIGRA. 000336 01-04
THE EFFECT OF MARIHUANA INTOXICATION ON BLOOD PRESSURE.	
TOXICATIONS	000475 01-04
ELECTROENCEPHALOGRAPHIC PECULIARITIES DURING ACUTE DRUG INTOXICATIONS IN EPILEPTIC PATIENTS.	SELF-STIMULATION (ICSS) BY CENTRALLY ADMINISTERED LEVORPHANOL AND DEXTRORPHAN.
ATTENUATION OF MORPHINE ANALGESIA IN RATS BY INTRA-	ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): NALOXONE
AMYGDALOID INJECTION OF DOPAMINE.	BLOCKS MORPHINES ACCELERATION OR PRESSING FOR ICS.
ELEVATION OF AVERSIVE THRESHOLD IN RATS BY INTRA-AMYGD. INJECTION OF MORPHINE-SULPHATE.	ALOID THE EFFECT OF AMPHETAMINE AND L-DOPA ON TETRABENAZINE-INDUCED SUPPRESSION OF INTRACRANIAL SELF-STIMULATION IN THE RAT.
TRAARTERIAL	4 01-04 ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): PRESSING
	FOR ICS BEFORE AND AFTER SELF-ADMINISTRATION OF SWEETENED MORPHINE SOLUTIONS.
LIPOPROTEIN POTENTIATION OF THE CEREBROVASCULAR RESPONS INTRAARTERIAL 5 HYDROXYTRYPTAMINE.	SE TO 001331 02-04 EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON
ITRACAROTID	EFFECTS UPON SOME ARYLALKYLAMINES IN RAT BRAIN.
THE EFFECT OF STEROID HORMONES ON CEREBRAL BLOOD FLOW I	BEFORE 001339 02-04

000095 01-03

DRINKING BEHAVIOUR INDUCED BY INTRACRANIAL INJECTIONS OF ELEDOISIN AND SUBSTANCE-P IN THE PIGEON.

CONCURRENT INTRACRANIAL SELF-STIMULATION AND AMPHETAMINE SELF-ADMINISTRATION IN RATS.

001495 02-04

INTRACAROTID
THE EFFECT OF STEROID HORMONES ON CEREBRAL BLOOD FLOW BEFORE
AND AFTER INTRACAROTID INFUSION OF 5 HYDROXYTRYPTAMINE.
001193 02-03

INTRACELLULAR
MEMBRANE LIPIDS AS INTRACELLULAR BINDERS OF CHLORPROMAZINE
AND RELATED DRUGS.

000095 01-1

VOLUME 16, SUBJECT INDEX

Subject Index

EFFECTS OF NOMIFENSINE (HOE-984) UPON PSYCHOMOTOR ACTIVITY AND INTRACRANIAL SELF-STIMULATION IN THE RAT. 002256 03-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE, SELF-STIMULATION, AND PARAMETERS OF ICS. 002320 03-04

H3-GABA RELEASE IN SYNAPTOSOMAL FRACTIONS AFTER INTRACRANIAL ADMINISTRATION OF RUTHENIUM-RED.

003013 04-03 INTRACTABLE

SODIUM VALPROATE IN THE TREATMENT OF INTRACTABLE SEIZURE DISORDERS: A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY. 003550 04-11

ESOPHAGEAL CANNULATION FOR INTRAGASTRIC DELIVERY OF FLUIDS TO UNRESTRAINED DOGS.

003436 04-06
THE EFFECTS OF INTRAGASTRIC MORPHINE SELF-ADMINISTRATION IN THE RAT. (PH.D. DISSERTATION). 003437 04-06

INTRAHIPPOCAMPAL
THE EFFECT OF INTRAHIPPOCAMPAL KAINIC-ACID INJECTIONS AND
SURGICAL LESIONS ON NEUROTRANSMITTERS IN HIPPOCAMPUS AND

002911 04-03 INTRAHYPOTHALAMIC

INHIBITION OF DRINKING BY INTRAHYPOTHALAMIC ADMINISTRATION OF

MORPHINE 001325 02-04 INTRAMUSCULAR EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: I. BEHAVIOURAL EFFECTS OF

INTRAMUSCULAR INJECTIONS 000316 01-04

MOLINDONE: A CONTROLLED EVALUATION OF THE INTRAMUSCULAR ANTIPSYCHOTIC PREPARATION 000541 01-08

EFFECTS OF NALOXONE ON PETHIDINE-INDUCED NEONATAL DEPRESSION: PART II - INTRAMUSCULAR NALOXONE.

000669 01-11 CLINICAL AND PLASMA LEVEL CHARACTERISTICS OF INTRAMUSCULAR AND ORAL LOXAPINE

002407 03-08 EFFICACY OF LOXAPINE HYDROCHLORIDE INTRAMUSCULAR (LOXITANE-IM) IN ACUTE SCHIZOPHRENIA

002410 03-08 BIOAVAILABILITY OF ORAL AND INTRAMUSCULAR PHENOBARBITAL 002600 03-13

A COMPARISON OF THE ANALGESIC EFFECT OF INTRAMUSCULAR NALBUPHINE AND MORPHINE IN PATIENTS WITH POSTOPERATIVE PAIN

002607 03-14

INTRANIGRAL GABA-LIKE PROPERTIES OF FLURAZEPAM AND BACLOFEN SUGGESTED BY ROTATIONAL BEHAVIOUR FOLLOWING UNILATERAL INTRANIGRAL INJECTION: A COMPARISON WITH THE GABA-AGONIST MUSCIMOL 000290 01-03

CIRCLING BEHAVIOR AND STEREOTYPY INDUCED BY INTRANIGRAL OPIATE MICROINJECTIONS. 000385 01-04

INTRANIGRAL KAINIC-ACID: EVIDENCE FOR NIGRAL NONDOPAMINERGIC NEURONS CONTROLLING POSTURE AND BEHAVIOR IN A MANNER OPPOSITE TO THE DOPAMINERGIC ONES.

003324 04-04 INTRACCULAR INTRAOCULAR PRESSURE LOWERING PROPERTIES OF ABBOTT-43981 CANNABINOID DERIVED HETEROCYCLIC BENZOPYRAN WITH MINIMAL

CNS ACTIVITIES 001025 02-02 THE DECREASE OF MONOAMINE-OXIDASE ACTIVITY FOLLOWING THE INTRAOCULAR INJECTION OF COLCHICINE IN THE SUPERIOR COLLICULUS

OF THE RAT. 003120 04-03 INTRAPERITONEALLY POTENTIATION BY NEUROLEPTIC AGENTS OF THE INHIBITORY ACTION OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR

ACTIVITY OF MICE. 002832 04-03

EFFECT OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE. 003172 04-04

INTRAPSYCHIC INTRAPSYCHIC AND FAMILY DYNAMIC PROCESSES IN AN ENDOGENOUS DEPRESSION PRECEDING MANIFESTATION OF THE ILLNESS AND LITHILIAN THERAPY 002461 03-09

EVIDENCE FOR AN INTRASTRIATAL GABAERGIC INFLUENCE ON DOPAMINE NEURONES OF THE CAT. 000050 01-03 CATALEPSY INDUCED BY INTRASTRIATAL INJECTIONS OF DELTA9-THC AND 11 OH-DELTA9-THC IN THE RAT.

STIMULATION OF DOPAMINE SYNTHESIS IN CAUDATE NUCLEUS BY INTRASTRIATAL ENKEPHALINS AND ANTAGONISM BY NALOXONE

DECREASE OF CYCLIC-GMP IN CEREBELLUM BY INTRASTRIATAL D ALA2-MET-ENKEPHALINAMIDE

002828 04-03
LOSS OF STRIATAL DOPAMINERGIC RECEPTORS AFTER INTRASTRIATAL KAINIC-ACID INJECTION.

REGIONAL BRAIN ATROPHY AND REDUCTIONS IN GLUTAMATE RELEASE AND UPTAKE AFTER INTRASTRIATAL KAINIC-ACID.

BEHAVIORAL AND ANATOMICAL CONSEQUENCES OF SMALL INTRASTRIATAL INJECTIONS OF KAINIC-ACID IN THE RAT. 003210 04-04

EFFECT OF CDP-CHOLINE ADMINISTERED INTRATHECALLY ON DISTURBANCE OF CONSCIOUSNESS.

002635 03-14 INTRAVENOUS RELATIVE INFLUENCE OF ANAESTHETICS ON DEPRESSOR EFFECTS OF

INTRAVENOUS PROSTAGLANDINS E2 AND A2. 000110 01-03 REINFORCING PROPERTIES OF INTRAVENOUS PROCAINE IN RHESUS MONKEYS.

000362 01-04 TRAZODONE BY INTRAVENOUS INFUSION IN DEPRESSIONS SECONDARY TO ORGANIC DISEASE.

A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY ON ANTIEPILEPTIC ACTIVITY OF CLONAZEPAM — RELATIONSHIP BETWEEN CLINICAL EFFECTS OF ORAL ADMINISTRATION AND ELECTROENCEPHALOGRAPHIC EFFECTS OF INTRAVENOUS ADMINISTRATION.

000639 01-11 EFFECTS OF INTRAVENOUS TETRAHYDROCANNABINOL ON EXPERIMENTAL AND SURGICAL PAIN

000655 01-11 EFFECTS OF NALOXONE ON PETHIDINE-INDUCED NEONATAL DEPRESSION: PART I -- INTRAVENOUS NALOXONE

000668 01-11 RESPONSES TO INTRAVENOUS HEROIN IN DEPENDENT AND NONDEPENDENT VOLUNTEERS

000792 01-14 APNEA AFTER INTRAVENOUS DIAZEPAM THERAPY.

000844 01-15 ADVERSE EFFECTS OF INTRAVENOUS CANNABIS TEA

000866 01-15
ENKEPHALIN ANALOGUES ELICITING ANALGESIA AFTER INTRAVENOUS

NARCOTIC BLOCKADE, LENGTH OF ADDICTION, AND PERSISTENCE OF INTRAVENOUS MORPHINE SELF-ADMINISTRATION IN RATS.

ACQUISITION AND EXTINCTION OF OPERANT RESPONDING FOR INTRAVENOUS INJECTIONS OF FENTANYL IN THE RAT.

001397 02-04
SLEEP SUPPRESSION INDUCED BY INTRAVENOUS AND INTRAVENTRICULAR INFUSIONS OF METHOXAMINE IN THE DOG

001434 02-04 SECOND-ORDER SCHEDULES OF INTRAVENOUS DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS.

001452 02-04 INTRAVENOUS COCAINE SELF-ADMINISTRATION IN THE 001528 02-06

INTRAVENOUS NALOXONE ADMINISTRATION IN SCHIZOPHRENIA AND

001560 02-08
INTRAVENOUS COMBINED ADMINISTRATION OF CHLORIMIPRAMINE AND SULPIRIDE IN DEPRESSION.

CLINICAL PHARMACOKINETICS OF LORAZEPAM. III. INTRAVENOUS INJECTION. PRELIMINARY RESULTS.

001662 02-13
KINETICS OF INTRAVENOUS CHLORDIAZEPOXIDE: SEX DIFFERENCES IN DRUG DISTRIBUTION.

001665 02-13 THE MOOD RESPONSE AND PLASMA CYCLIC-AMP RESPONSE TO INTRAVENOUS METHYLPHENIDATE

001666 02-13
EFFECT OF PHENOBARBITAL ON THE DISPOSITION OF INTRAVENOUS THEOPHYLLINE.

SEQUELAE AFTER THE INTRAVENOUS INJECTION OF THREE BENZODIAZEPINES — DIAZEPAM, LORAZEPAM, AND FLUNITRAZEPAM. 001785 02-15

INTRAVENOUS PROPYLHEXEDRINE AND SUDDEN DEATH. 001850 02-15

GUIDELINES FOR NURSES: THE ADMINISTRATION OF INTRAVENOUS DRUGS THROUGH AN ESTABLISHED INTRAVENOUS PATHWAY.
001866 02-16

EFFECTS OF INTRAVENOUS KAINIC-ACID, N METHYL-D-ASPARTATE, AND (-) NUCIFERENE ON THE CAT SPINAL CORD.

FEEDING BEHAVIOR OF SHEEP FOLLOWING INTRAVENOUS INJECTION OF IMIDAZOBENZODIAZEPINES.

002193 03-04 CONTINUOUS INTRAVENOUS NALTREXONE EFFECTS ON MORPHINE SELF-ADMINISTRATION IN RHESUS MONKEYS.

002241 03-04 EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D AMPHETAMINE AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY AND SHOCK AVOIDANCE IN RHESUS MONKEYS.

002251 03-04 ATTRIBUTES OF DISCRIMINATIVE PENTOBARBITAL STIMULUS IMMEDIATELY AFTER INTRAVENOUS INJECTION.

OPEN-FIELD BEHAVIOR AFTER INTRAVENOUS AMPHETAMINE ANALOGUES IN RATS.

002272 03-04 INTRAVENOUS SELF-ADMINISTRATION OF DRUGS IN RATS

002324 03-04 PLASMA LEVEL STUDIES OF CLOMIPRAMINE AND
DESMETHYLCLOMIPRAMINE FOLLOWING INTRAVENOUS INFUSIONS OF
CLOMIPRAMINE IN DEPRESSIVE PATIENTS.

002448 03-09 FOOD RELATED INTRAVENOUS INSULIN SELF-ADMINISTRATION IN NORMAL AND DIABETIC RATS.

003252 04-04 HALOPERIDOL AND LITHIUM BLOCKING OF THE MOOD RESPONSE TO INTRAVENOUS METHYLPHENIDATE.

COMPARISON OF ORAL AND INTRAVENOUS METHYLPHENIDATE.
003559 04-11

INTRAVENOUSLY
STUDIES OF THE REINFORCING PROPERTIES OF INTRAVENOUSLY SELFADMINISTERED COMPOUNDS IN RHESUS MONKEYS. (PH.D.

002188 03-04 THE DISCRIMINATIVE STIMULUS PROPERTIES OF INTRAVENOUSLY ADMINISTERED COCAINE IN RHESUS MONKEYS.

003160 04-04

CEREBRAL METABOLISM OF INTRAVENTRICULAR (3H) FENFLURAMINE 000266 01-03

NONCONTINGENT DISPLACEMENT OF CATECHOLAMINES BY INTRAVENTRICULAR TYRAMINE: BIPHASIC DOSE-RESPONSE EFFECTS ON SELF-STIMULATION.

000364 01-04 DIFFERENTIAL MOTOR EFFECTS OF INTRAVENTRICULAR INFUSION OF MORPHINE AND ETONITAZENE.

000450 01-04 ANALGESIC BRAIN STIMULATION IN THE CAT: EFFECT OF INTRAVENTRICULAR SEROTONIN, NOREPINEPHRINE, AND DOPAMINE

001101 02-03 REGIONAL LOCALIZATION OF C14-MESCALINE IN RABBIT BRAIN AFTER INTRAVENTRICULAR ADMINISTRATION: EFFECTS OF CHLORPROMAZINE AND IPRONIAZIO PRETREATMENT.

A COMPARISON OF THE EFFECTS OF INTRAVENTRICULAR MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON OPERANT BEHAVIOR IN THE RAT. 001240 02-03

001323 02-04 SLEEP SUPPRESSION INDUCED BY INTRAVENOUS AND INTRAVENTRICULAR INFUSIONS OF METHOXAMINE IN THE DOG.

001434 02-04

DECREASED LOCOMOTOR ACTIVITY AND ATTENUATION OF AMPHETAMINE HYPERACTIVITY WITH INTRAVENTRICULAR INFUSION OF SEROTONIN IN THE RAT.

MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II.

002994 04-03 THE EFFECTS OF INTRAVENTRICULAR INJECTION OF GAMMA-AMINOBUTYRIC-ACID (GABA) ON PROLACTIN AND GONADOTROPIN RELEASE IN CONSCIOUS FEMALE RATS.

COMPARISON OF THE BEHAVIORAL EFFECTS OF P-CHLOROAMPHETAMINE, CHLORDIMEFORM, QUIPAZINE, AND INTRAVENTRICULAR SEROTONIN IN THE RAT

INTRAVENTRICULARLY

UPTAKE AND METABOLISM OF INTRAVENTRICULARLY ADMINISTERED PIPERIDINE AND ITS EFFECTS ON SLEEP AND WAKEFULNESS IN THE RAT. 001208 02-03 Psychopharmacology Abstracts

NARCOTIC CUEING PROPERTIES OF INTRAVENTRICULARLY ADMINISTERED SUFENTANIL, FENTANYL, MORPHINE AND MET-ENKEPHALIN.

002217 03-04

EFFECTS OF INTRAVENTRICULARLY ADMINISTERED MONOAMINES ON SEIZURE SUSCEPTIBILITY AND BODY TEMPERATURE IN RATS.

003180 04-04

INTROPIC
CYCLIC-AMP AND THE POSITIVE INTROPIC EFFECT OF NOREPINEPHRINE
AND PHENYLEPHRINE.
000195 01

000195 01-03 INTRUDER-EVOKED

EFFECTS OF L-DOPA, D AMPHETAMINE AND COCAINE ON INTRUDEREVOKED AGGRESSION IN RATS AND MICE.

001420 02-04 INTRUDER-EVOKED AGGRESSION IN ISOLATED AND NONISOLATED MICE: EFFECTS OF PSYCHOMOTOR STIMULANTS AND L-DOPA.

003298 04-04

MARIJUANA AND MEMORY INTRUSIONS.

001727 02-14

INVESTIGATION
AN INVESTIGATION OF SOPHORA-SECUNDIFLORA SEEDS (MESCALBEANS) 0000007 01-01

AN INVESTIGATION OF NALORPHINE AND PERPHENAZINE AS NEGATIVE REINFORCERS IN AN ESCAPE PARADIGM. 000389 01-04

EVALUATIONS OF SOCIAL FUNCTIONING IN A 3-YEAR DOUBLE-BLIND INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE IN CHRONIC SCHIZOPHRENIA.

PHARMACOPSYCHOLOGICAL INVESTIGATION OF THE EFFECT OF SEDATIVES ON MEMORY AND LEARNING PERFORMANCE IN CHILDREN AND ADOLESCENTS.

000751 01-14 AMP SYSTEM: LONGITUDINAL COURSE STUDIES OF PSYCHOPATHOLOGIC AND SOMATIC SYMPTOMS. AN EMPIRIC INVESTIGATION OF THE PROBLEM OF SIDE-EFFECTS.

THE INVESTIGATION OF PHENOBARBITONE, PHENYTOIN AND PRIMIDONE IN THE DEATH OF EPILEPTICS.

A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE SHORT-TERM EFFECTS OF CLOZAPINE UPON SLEEP PARAMETERS OF NORMAL YOUNG ADULTS.

001734 02-14 DOUBLE-BLIND INVESTIGATION OF PIRACETAM (NOOTROPIL) VERSUS PLACEBO IN THE MEMORY OF GERIATRIC INPATIENTS.

002502 03-11 PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE LONG-TERM EFFECTS OF CLOZAPINE UPON SLEEP PATTERNS OF NORMAL YOUNG ADULTS.

002640 03-14 AMPHETAMINE EFFECTS ON STIMULUS ELICITED INVESTIGATION IN THE MONGOLIAN GERBIL.

003186 04-04 CIS-CLOPENTHIXOL AND CLOPENTHIXOL (SORDINOL) IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL INVESTIGATION 003496 04-09

INVESTIGATIONAL FLUNITRAZEPAM, AN INVESTIGATIONAL HYPNOTIC DRUG: SLEEP LABORATORY EVALUATIONS.

000750 01-14

INVESTIGATIONS 3.4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3 AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF DOTESTIA ANTIPENCENT ANTIPENCENT ANTIPENCENT ANTIPENCENT POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND ANTICONVULSANT ACTIVITIES

000035 01-02 INVESTIGATIONS OF THE ANALGESIC AND MORPHINE-LIKE PROPERTIES

PHARMACOLOGICAL INVESTIGATIONS CONCERNING COMBINATION EFFECTS OF ALCOHOL AND OXAZEPAM IN THE REACTIVITY PATTERN 000897 01-15

CLASSIFICATION AND DETERMINATION OF CEREBRAL BIOAVAILABILITY OF PSYCHOTROPIC DRUGS BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS (STUDIES WITH AX-A411-BS).

000931 01-16 INVESTIGATIONS INTO THE NATURE OF THE PERIORAL MOVEMENTS INDUCED BY DIPROPYLAMINO-DIHYDROXYTETRALIN.

001334 02-04 INVESTIGATIONS INTO THE MECHANISM OF THE INFLUENCE OF KININS ON THE ACTION OF AMPHETAMINE.

002101 03-03 PHARMACOLOGICAL INVESTIGATIONS OF THE CHOLINERGIC IMBALANCE HYPOTHESES OF MOVEMENT DISORDERS AND PSYCHOSIS.

002509 03-11 INVESTIGATIONS OF CHILDREN OF MOTHERS TREATED IN PREGNANCY WITH ANTICONVULSANTS.

002701 03-15

VOLUME 16, SUBJECT INDEX

Subject Index

PHARMACODYNAMIC INVESTIGATIONS IN PSYCHOPHARMACOLOGY BY QUANTITATIVE EEG AND PSYCHOMETRIC METHODS.

002726 03-16 INVESTIGATIONS CONCERNING THE CELLULAR ORIGIN OF DOPAMINE RECEPTORS

002944 04-03 PHARMACOLOGICAL INVESTIGATIONS ON ETOPERIDONE, A NEW PSYCHOTROPIC AGENT.

003720 04-17

DEANOL IN THE MANAGEMENT OF INVOLUNTARY MOVEMENT DISORDERS: A REVIEW.

001886 02-17 INVOLUNTARY ADMINISTRATION OF PSYCHOTROPIC DRUGS — GROUNDS FOR SUIT. SOUDER V. MCGUIRE, 423 F. SUPP. 830, (PENNSYLVANIA). M.D. DISTRICT COURT. DECEMBER 9, 1976.

001916 02-17

LISURID (LYSENYL-SPOFA) IN THE TREATMENT OF ORGANIC PSYCHOSYNDROME IN INVOLUTION

003563 04-11

THE INFLUENCE OF PYRIDOXINE ON THE PSYCHOPATHOLOGY AND PATHOCHEMISTRY OF DEPRESSIONS OF INVOLUTIONAL AGE.

003485 04-09 INVOLVED DOPAMINERGIC MECHANISMS INVOLVED IN THE ACUTE AND CHRONIC

EFFECT OF AMPHETAMINE. 000129 01-03 SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF PHYSICAL DEPENDENCE IN RATS: III. AUTORADIOGRAPHIC STUDIES

000177 01-03 NATURE OF RECEPTORS INVOLVED IN APOMORPHINE RESPONSES IN **PIGEONS**

POSSIBLE MECHANISMS INVOLVED IN THE STEREOTYPED BEHAVIOR **ELICITED BY AMPHETAMINE**

MULTIPLE BRAIN SITES INVOLVED IN MORPHINE ANTINOCICEPTION. 001270 02-03

CHOLINERGIC MECHANISMS INVOLVED IN HEAD-SHAKING OF INFANT 001380 02-04

IS GABA INVOLVED IN ANALGESIA?. 003084 04-03

INVOLVEMENT

INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT

000124 01-03 INVOLVEMENT OF THE DOPAMINE NIGROSTRIATAL SYSTEM IN THE PICROTOXIN EFFECT ON STRIATAL ACETYLCHOLINE LEVELS. 000158 01-03

POSSIBLE INVOLVEMENT OF THE CENTRAL DOPAMINERGIC SYSTEM IN THE ANTIRESERPINE EFFECT OF LSD.

000198 01-03 CENTRAL TRANSMITTER INVOLVEMENT IN LON-954-INDUCED TREMOROGENESIS

000342 01-04 EVIDENCE AGAINST INVOLVEMENT OF ENDORPHINS IN SEXUAL AROUSAL AND ORGASM IN MAN

000701 01-13 INVOLVEMENT OF CENTRAL NORADRENERGIC SYSTEM IN THE MEDIATION OF BEHAVIORAL SUPPRESSANT EFFECTS OF DIAZEPAM IN HYPERTHYROID RATS

001220 02-03 INVOLVEMENT OF BRAIN CYCLIC-AMP IN MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE. (PH.D. DISSERTATION).

001241 02-03 CATECHOLAMINE INVOLVEMENT IN THE NARCOTIC CUE.

001332 02-04 SUPPRESSION OF CAUDATE NEURON ACTIVITIES BY MORPHINE AND THE INVOLVEMENT OF DOPAMINERGIC NEUROTRANSMISSION.

001985 03-03 POSSIBLE INVOLVEMENT OF CYCLIC-AMP IN INFLAMMATION INDUCED BY A SURFACTANT.

BEHAVIOURAL SPECIFIC TOLERANCE FOLLOWING CHRONIC D OR L AMPHETAMINE TREATMENT: LACK OF INVOLVEMENT OF P-HYDROXYNOREPHEDRINE

002261 03-04 MODULATION OF DEXAMPHETAMINE-INDUCED COMPULSIVE GNAWING INCLUDING THE POSSIBLE INVOLVEMENT OF PRESYNAPTIC ALPHA-ADRENORECEPTORS.

INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA: EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION 002890 04-03 PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — III. THE INFLUENCE OF THE 1, 4, 5, 6 TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — I. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH.

PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF NA CHANNELS IN THE RELEASE OF CATECHOLAMINES FROM PERFUSED ADRENAL CLAMPE **GLANDS**

002960 04-03 AMPHETAMINE-INDUCED INCREASE IN RAT CEREBRAL BLOOD FLOW, APPARENT LACK OF CATECHOLAMINE INVOLVEMENT.

CENTRAL MECHANISMS OF DRUGS AS DISCRIMINATIVE STIMULI: INVOLVEMENT OF SEROTONIN PATHWAYS.

STRIATAL NONDOPAMINERGIC NEURONS: POSSIBLE INVOLVEMENT IN FEEDING AND DRINKING BEHAVIOR.

THERAPEUTIC ANTAGONISM BETWEEN ANTICHOLINERGICS AND NEUROLEPTICS: POSSIBLE INVOLVEMENT OF CHOLINERGIC MECHANISMS IN SCHIZOPHRENIA.

003473 04-08 CHOLINERGIC INVOLVEMENT IN MENTAL DISORDERS

003710 04-17

ACTH-INDUCED EXCESSIVE GROOMING INVOLVES BRAIN DOPAMINE 001490 02-04 **IOCHROMA-FUCHSIOIDES**

A NEW HALLUCINOGEN FROM ANDEAN COLOMBIA: IOCHROMA-**FUCHSIOIDES** 000983 01-17

IODINATED INTERACTION OF IODINATED ENKEPHALIN ANALOGUES WITH OPIATE

RECEPTORS. 001947 03-01

PHARMACOKINETICS OF METHYLPHENIDATE IN THE RAT USING SINGLE ION MONITORING GLC MASS SPECTROMETRY. 000498 01-06 EFFECTS OF KAINIC-ACID ON ION DISTRIBUTION AND ATP LEVELS OF

STRIATAL SLICES INCUBATED IN VITRO. 003406 04-05

STRYCHNINE BINDING ASSOCIATED WITH SYNAPTIC GLYCINE RECEPTORS IN RAT SPINAL CORD MEMBRANES: IONIC INFLUENCES

003024 04-03 MUSCARINIC RECEPTOR MEDIATED CYCLIC-GMP FORMATION BY CULTURED NERVE CELLS — IONIC DEPENDENCE AND EFFECTS OF LOCAL ANESTHETICS. 003064 04-03

IONIZATION LYSERGIC-ACID-DIETHYLAMIDE. PHOTOELECTRON IONIZATION POTENTIALS AS INDICES OF BEHAVIORAL ACTIVITY

001100 02-03 QUANTITATIVE ANALYSIS OF METHADONE IN BIOLOGICAL FLUIDS USING DEUTERIUM-LABELED METHADONE AND GLC CHEMICAL IONIZATION MASS SPECTROMETRY.

IONS

EFFECTS OF ETHANOL: ALTERATION BY INORGANIC IONS AND

002242 03-04 THE EFFECTS OF DIVALENT IONS ON MORPHINE ANALGESIA AND
ABSTINENCE SYNDROME IN MORPHINE-TOLERANT AND MORPHINE-DEPENDENT MICE

003169 04-04 IONTOPHORESIS

IONTOPHORESIS OF METHIONINE-ENKEPHALIN IN THE LOCUS-COERULEUS 000304 01-03

THE IONTOPHORESIS OF DIAZEPAM IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT. 002130 03-03

IONTOPHORETIC

ACTIONS OF IONTOPHORETIC PHENYTOIN AND MEDAZEPAM ON HIPPOCAMPAL NEURONS.

PREFERENTIAL ACTION OF 5 METHOXYTRYPTAMINE AND 5 METHOXYDIMETHYLTRYPTAMINE ON PRESYNAPTIC SEROTONIN RECEPTORS: A COMPARATIVE IONTOPHORETIC STUDY WITH LSD AND

001862 02-16

NEUROLOGICAL DISTURBANCES, NIGROSTRIATE SYNAPSES, AND IONTOPHORETIC DOPAMINE AND APOMORPHINE AFTER HALOPERIDOL. 001293 02-03

NALOXONE AS A GABA-ANTAGONIST: EVIDENCE FROM IONTOPHORETIC, RECEPTOR BINDING AND CONVULSANT STUDIES. 002003 03-03

DEPRESSION OF PRIMATE SPINOTHALAMIC TRACT NEURONS BY IONTOPHORETIC APPLICATION OF 5 HYDROXYTRYPTAMINE. 003251 04-04

IONTOPHORETICALLY
AN EXCITATORY ACTION OF IONTOPHORETICALLY ADMINISTERED
LITHIUM ON MAMMALIAN CENTRAL NEURONES. 000135 01-03

PRONIAZID

REGIONAL LOCALIZATION OF C14-MESCALINE IN RABBIT BRAIN AFTER INTRAVENTRICULAR ADMINISTRATION: EFFECTS OF CHLORPROMAZINE AND IPRONIAZID PRETREATMENT.

001240 02-03

001240 02-03

002089 03-03

NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION OF THE SYMPATHETIC MERVE OF THE EYE.

CHARACTERIZATION OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS IN MEMBRANES PREPARED FROM THE RABBIT IRIS BEFORE AND AFTER DEVELOPMENT OF SUPERSENSITIVITY.

EFFECT OF CHLORPROMAZINE ON CENTRAL-NERVOUS-SYSTEM CONCENTRATIONS OF MANGANESE, IRON, AND COPPER. 000295 01-03

IRRADIATION
INFLUENCE OF INJECTED PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS
IN MOUSE BRAIN AND LUNG FOLLOWING MICROWAVE IRRADIATION.
000214 01-03

DEVELOPMENT AND DISAPPEARANCE OF SUBSENSITIVITY TO PILOCARPINE FOLLOWING A SINGLE ADMINISTRATION OF THE IRREVERSIBLE ANTICHOLINESTERASE AGENT, DFP.

000212 01-03 REVERSIBLE AND IRREVERSIBLE EFFECTS OF P-CHLOROAMPHETAMINE ON BRAIN SEROTONIN IN MICE.

000276 01-03 THE EFFECT OF GAMMA-ACETYLENIC-GABA, AN ENZYME ACTIVATED IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE, ON DOPAMINE PATHWAYS OF THE EXTRAPYRAMIDAL AND LIMBIC SYSTEMS. 003037 04-03

IRRITABILITY 5 HYDROXYTRYPTAMINE DEPLETION WITH P-CHLOROPHENYLALANINE: EFFECTS ON EATING, DRINKING, IRRITABILITY, MURICIDE, AND COPULATION.

5,7 DIHYDROXYTRYPTAMINE LESIONS: EFFECTS ON BODY WEIGHT, IRRITABILITY, AND MURICIDE.

000430 01-04 PHARMACOLOGICAL MANIPULATIONS OF THE SEPTAL IRRITABILITY SYNDROME: ROLE OF DOPAMINERGIC MECHANISMS IN RECOVERY OF FUNCTION. (PH.D. DISSERTATION).

RRITABLE IRRITABLE COLON AND DEPRESSION.

003498 04-09

PSYCHOTROPIC DRUGS AND SIDMAN AVOIDANCE IN RATS: IRT DISTRIBUTION CHANGES. 003269 04-04

ISCHEMIA

EFFECT OF DIHYDROERGOTOXINE ON THALAMIC AND PYRAMIDAL

EVOKED RESPONSES IN THE CAT UNDER TRANSIENT ISCHEMIA. 002201 03-04

INFLUENCE OF TRANSIENT ISCHEMIA ON MONOAMINE METABOLISM IN THE RAT BRAIN DURING NITROUS-OXIDE AND PHENOBARBITONE ANESTHESIA. 002852 04-03

EFFECTS OF CLONIDINE ON VULNERABILITY TO FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE VENTRICLE. 002140 03-03

ISOENZYMES

MONOAMINE-OXIDASE IN RAT REFICULOCYTES: SUBCELLULAR
LOCALIZATION AND IDENTIFICATION OF ISOENZYMES.

002134 03-03
EFFECTS OF MORPHINE ON ISOENZYMES OF PYRUVATE KINASE AND
TYROSINE-AMINOTRANSFERASE IN RAT.

003141 04-03 INHIBITION OF MONOAMINE-OXIDASE BY ISOGENTISIN AND ITS 3 O 003104 04-03

THE METABOLISM OF D-, L- AND DL-METHADONE IN THE ISOLATED PERFUSED RAT LIVER. 000118 000118 01-03

A COMPARISON IN RABBIT ISOLATED HEARTS OF THE DYSRHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE, MAPROTILINE AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK NORADREMALINE UPTAKE.

RELATIONSHIP BETWEEN THE UPTAKE OF 3H-(PLUS OR MINUS)
METARAMINOL AND THE DENSITY OF ADRENERGIC INNERVATION IN
ISOLATED RAT TISSUES.

SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION: A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL MEMBRANES FROM MATURE RAT BRAIN.

MORPHINE ACTION IN GROUPED AND ISOLATED RATS AND MICE.
000394 01-04 FIRST-PASS ELIMINATION OF C14-IMIPRAMINE IN ISOLATED PERFUSED RAT LIVER.

TRIPHASIC DOSE LETHALITY RELATIONSHIPS FOR AMPHETAMINE AND CERTAIN RING-SUBSTITUTED AMPHETAMINES IN ISOLATED OR AGGREGATED MICE.

001093 02-03 ACTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND ITS DERIVATIVES ON 5 HYDROXYTRYPTAMINE RECEPTORS IN THE ISOLATED UTERINE SMOOTH MUSCLE OF THE RAT.

O01144 02-03

AND AGGREGATED RATS.

O01144 02-03

O01144 02-03

001182 02-03 INFLUENCE OF CHLORPROMAZINE AND TRIFLUOPERAZINE ON NEURONS OF AN ISOLATED SLAB OF RABBIT CFREBRAL-CORTEX.

001205 02-03 INCREASE CAUSED BY DESMETHYLIMIPRAMINE IN THE PRODUCTION OF H3-MELATONIN BY ISOLATED PINEAL GLANDS.

PHARMACOKINETICS OF SOME HOMOLOGOUS SERIES OF BARBITURATES IN THE INTACT RAT AND IN THE ISOLATED PERFUSED RAT LIVER. 001292 02-03

ADVERSE EFFECTS OF CHLORPROMAZINE METABOLITES ON ISOLATED HEPATOCYTES.

001502 02-05 EFFECTS OF BUTYROPHENONES ON THE SYMPATHETIC NERVES OF THE ISOLATED RABBIT HEART AND ON THE POSTSYNAPTIC ALPHA-ADRENOCEPTORS OF THE ISOLATED RABBIT AORTA.

STEREOSELECTIVITY IN THE METABOLISM OF H3-NORADREMALINE DURING UPTAKE INTO AND EFFLUX FROM THE ISOLATED RAT VAS-

002028 03-03 SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION. 002052 03-03

ACTION OF NOREPINEPHRINE ON MICROCIRCULATION AND PO2
DISTRIBUTION IN THE ISOLATED PERFUSED RAT LIVER.

EFFECT OF METABOLIC INHIBITORS AND OUABAIN ON AMPHETAMINE-INDUCED AND POTASSIUM-INDUCED RELEASE OF BIOGENIC AMINES FROM ISOLATED BRAIN TISSUE.

DOPAMINE-MIMETIC ACTIVITY OF ERGOT DERIVATIVES, AS MEASURED BY THE PRODUCTION OF CYCLIC-AMP IN ISOLATED RETINAE OF THE RABBIT.

002149 03-03 THE EFFECTS OF PROLONGED HANDLING, SCOPOLAMINE, AND PHYSOSTIGMINE ON THE ACTIVITY OF ISOLATED AND SOCIALLY REARED RATS.

THE ACTION OF CNS DRUGS ON AN ISOLATED SYMPATHETIC NERVE PREPARATION OF RABBIT.

MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMATURE RAT.

RELEASE OF ENDOGENOUS CATECHOLAMINES FROM ISOLATED RAT BRAIN TISSUE BY FENFLURAMINE AND N ETHYLAMPHETAMINE — EFFECTS OF PARGYLINE.

003111 04-03 INHIBITION OF FIGHTING IN ISOLATED MICE FOLLOWING REPEATED ADMINISTRATION OF LITHIUM-CHLORIDE.

INTRUDER-EVOKED AGGRESSION IN ISOLATED AND NONISOLATED MICE: EFFECTS OF PSYCHOMOTOR STIMULANTS AND L-DOPA. 003298 04-04

VOLUME 16, SUBJECT INDEX

ISOMERS

Subject Index

COMPARISON OF THE ELECTROPHYSIOLOGICAL EFFECTS OF TWO NEUROLEPTICS, MELPERONE AND THIORIDAZINE, ON ISOLATED RAT ATRIA.

003417 04-05

ISR AFLI

ISOLATION AND CHARACTERIZATION OF () CANNABITRIOL AND (-) 10 ETHOXY-9-HYDROXY-DELTA6A-TETRAHYDROCANNABINOL: TWO NEW CANNABINOIDS FROM CANNABIS-SATIVA L. EXTRACT.

00004 01-01
ISOLATION AND IDENTIFICATION OF AN IN VIVO REACTION PRODUCT OF
6 HYDROXYDOPAMINE.

SOLATION-INDUCED 000008 01-01

ALKALI-METAL CATIONS: EFFECTS ON ISOLATION-INDUCED AGGRESSION IN THE MOUSE. 001348 02-04

THE EFFECT OF NORADRENALINE ON THE ECOG OF THE PREPARATION ENCEPHALE ISOLE OF RATS.

001475 02-04

ISOLEUCINE
BENEFICIAL EFFECT OF ISOLEUCINE ON FETAL BRAIN DEVELOPMENT IN

INDUCED PHENYLKETONURIA. 002846 04-03

STUDIES IN THE HETEROCYCLIC SERIES. XIII. NEW CNS DEPRESSANTS DERIVED FROM 1.9 DIAZAPHENOXAZINE AND TWO ISOMERIC TRIAZAPHENOTHIAZINE RING SYSTEMS.

000030 01-0

EFFECTS OF THE ISOMERIC FORMS OF PROPRANOLOL ON CENTRAL MONOAMINE METABOLISM IN REGIONS OF RAT BRAIN.

PHARMACOLOGICAL AND BIOCHEMICAL PROPERTIES OF ISOMERIC YOHIMBINE ALKALOIDS.

002987 04-03

INFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3-CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN.

001119 02-03

COMPARATIVE BRAIN/PLASMA CONCENTRATIONS OF AMPHETAMINE ISOMERS IN MICE.

PHARMACOLOGICAL MANIPULATION OF HOARDING: FURTHER ANALYSIS OF AMPHETAMINE ISOMERS AND PIMOZIDE.

A GC/CIMS ASSAY FOR THE CIS AND TRANS ISOMERS OF THIOTHIXENE IN HUMAN PLASMA.

THE EFFECTS OF AMPHETAMINE ISOMERS ON ROTAROD PERFORMANCE.
002235 03-04

PHARMACOLOGICAL AND TOXICOLOGICAL EFFECTS OF BETA 3.4
METHYLENEDIOXYAMPHETAMINE ISOMERS.

SONIAZID 003285 04-04

3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE LEVELS IN RAT CEREBELLUM: EFFECTS OF MORPHINE, KETAMINE, HARMALINE AND ISONIAZID. 002056 03-03

A COMPARISON BETWEEN PLACEBO, PIZOTIFEN AND 1 ISOPROPYL-3-HYDROXY 5 SEMICARBAZONO-6-OXOTETRAHYDROINDOL (FIVASCAN) IN MIGRAINE PROPHYLAXIS.

ISOPROPYLIDENEDIOXYPHENYL

3,4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND
BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCLINIMIDES AND 3
AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF
POTENTIAL ANTIPARKINSONIAL ANTIPSYCHOTIC AND

AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND ANTICONVULSANT ACTIVITIES.

000035 01-02

METABOLIC RESPONSES TO ISOPROTERENOL AND EPINEPHRINE IN THE RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES AND PRETREATMENT WITH PROPRANOLOL.

D00227 01-03
HYPOTENSION AND THIRST IN RATS AFTER ISOPROTERENOL TREATMENT
003245 04-04

ISOSTERES

SYNTHESIS AND PRELIMINARY PHARMACOLOGICAL ACTIVITY OF
AMINOALKOXY ISOSTERES OF GLYCOLATE ESTER ANTICHOLINERGICS.

001026 02-02

USE OF STABLE ISOTOPES IN STUDIES ON THE METABOLISM OF AMPHETAMINE. 002970 04-03

ROLE OF LIVER CYTOSOLIC ALDEHYDE-DEHYDROGENASE ISOZYMES IN CONTROL OF BLOOD ACETALDEHYDE CONCENTRATIONS.

THE EFFECTS OF OBSTETRICAL MEDICATION ON THE BEHAVIOR OF ISRAELI NEWBORN INFANTS AND SOME COMPARISONS WITH URUGUAYAN AND AMERICAN INFANTS.

STATE-DEPENDENT RETRIEVAL OF ITEM, ASSOCIATIVE, AND SERIAL ORDER INFORMATION.

ITERATIVE

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

IT25-HYDROXYBENZYLPINDOLOL

BETA ADRENERGIC RECEPTOR LABELING IN INTACT ANIMALS WITH IT25HYDROXYBENZYLPINDOLOL.

000493 01-06

TREATMENT OF PRISONERS IN ENGLANDS JAILS.

000997 01-17

PURCHASES OF HYPNOTICS, SEDATIVES AND MINOR TRANQUILLIZERS
AMONG 2,566 INDIVIDUALS IN THE COUNTY OF JAMTLAND, SWEDEN!
A 6-YEAR FOLLOW-UP.

JIMSON-WEED
TOXIC DELIRIUM INDUCED BY DELIBERATE INGESTION OF JIMSON-WEED.
001633 02-12

FROM JOY TO DEPRESSION: NEW INSIGHTS INTO THE CHEMISTRY OF MOODS. 000981 01-17

CHANGES IN LOCOMOTOR ACTIVITY AND NALOXONE-INDUCED JUMPING
IN MICE PRODUCED BY WIN-35197-2 (ETHYLKETAZOCINE) AND

JUNCTION
BARBITURATE-INDUCED CHANGES IN TRANSMITTER RELEASE

INDEPENDENT OF TERMINAL SPIKE CONFIGURATION IN THE FROG NEUROMUSCULAR JUNCTION. 000294 01-03 EFFECT OF DIAZEPAM ON THE FROG NEUROMUSCULAR JUNCTION.

EFFECT OF DIAZEPAM ON THE FROG NEUROMUSCULAR JUNCTION. 002171 03-03

THE EFFECTS OF NEONATAL INJECTIONS OF ALPHA-MSH ON THE OPEN-FIELD BEHAVIOR OF JUVENILE AND ADULT RATS.

001309 02-04

JUXTAVESICULAR

VESICULAR AND JUXTAVESICULAR SEROTONIN: EFFECTS OF LYSERGIC
ACID-DIETHYLAMIDE AND RESERPINE.

001141 02-03

HALOPERIDOL INCREASES AND APOMORPHINE DECREASES STRIATAL DOPAMINE METABOLISM AFTER DESTRUCTION OF STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASE BY KAINIC-ACID. 000094 01-03

EFFECTS OF INTRAVENOUS KAINIC-ACID, N METHYL-D-ASPARTATE, AND

(-) NUCIFERENE ON THE CAT SPINAL CORD.

AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY AND STEREOTYPY AFTER KAINIC-ACID LESIONS OF THE STRIATUM.

STRUCTURE-ACTIVITY RELATIONS FOR THE NEUROTOXICITY OF KAINIC-ACID DERIVATIVES AND GLUTAMATE ANALOGUES.

002355 03-05
DISAPPEARANCE OF CEREBELLAR CYCLIC-GMP-INDUCED BY KAINIC-ACID.
002826 04-03
HISTOCHEMICAL EFFECTS OF KAINIC-ACID ON NEOSTRIATAL DOPAMINE

002851 04-03
LOSS OF STRIATAL DOPAMINERGIC RECEPTORS AFTER INTRASTRIATAL
KAINIC-ACID INJECTION.

AND ACETYLCHOLINESTERASE

THE EFFECT OF INTRAHIPPOCAMPAL KAINIC-ACID INJECTIONS AND SURGICAL LESIONS ON NEUROTRANSMITTERS IN HIPPOCAMPUS AND SEPTIM.

O02911 04-0:
REGIONAL BRAIN ATROPHY AND REDUCTIONS IN GLUTAMATE RELEASE
AND UPTAKE AFTER INTRASTRIATAL KAINIC-ACID.

MICROINJECTION OF KAINIC-ACID INTO THE RAT HIPPOCAMPUS.

0030B1 04-03
BEHAVIORAL AND ANATOMICAL CONSEQUENCES OF SMALL

INTRASTRIATAL INJECTIONS OF KAINIC-ACID IN THE RAT.

INTRANIGRAL KAINIC-ACID: EVIDENCE FOR NIGRAL NONDOPAMINERGIC NEURONS CONTROLLING POSTURE AND BEHAVIOR IN A MANNER OPPOSITE TO THE DOPAMINERGIC ONES.

EFFECTS OF KAINIC-ACID ON ION DISTRIBUTION AND ATP LEVELS OF STRIATAL SLICES INCUBATED IN VITRO. EVIDENCE AGAINST CHRONIC DEPOLARIZATION AS A MECHANISM OF KAINIC-ACID TOXICITY IN MOUSE CEREBELLAR CULTURES.

003418 04-05

KAINIC-ACID-INDUCED
HISTOFLUORESCENCE OF KAINIC-ACID-INDUCED STRIATAL LESIONS

003433 04-06

COMBINATION OF PHENYLPYRROLIDINOPENTANE (KATOVIT) WITH OXAZEPAM (ADUMBRAN): A DOUBLE-BLIND TRIAL WITH OPIPRAMOL (INSIDON) IN DEPRESSIVE SYNDROME. 000597 01-10

ON THE PHARMACOLOGY OF THE KETAMINE ENANTIOMORPHS IN THE RAT. 000193 01 000193 01-03

KETAMINE SELF-ADMINISTRATION BY THE RHESUS MONKEY

EFFECTS OF KETAMINE ON PATIENT RESPONSIVENESS DURING THE VARIOUS PHASES OF A SINGLE INDUCED ANXIETY SESSION.

DOUBLE-BLIND STUDY OF THE EFFECTIVE ANTIHALLUCINATORY DOSES OF DIAZEPAM PRIOR TO KETAMINE ANESTHESIA.

3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE LEVELS IN RAT CEREBELLUM: EFFECTS OF MORPHINE, KETAMINE, HARMALINE AND ISONIAZID.

NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY EFFECTS OF DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF KETAMINE.

002362 03-06 POSSIBLE ROLE OF BRAIN SEROTONIN IN THE CENTRAL EFFECTS OF

003123 04-03

DIFFERENTIAL EFFECTS OF KETAMINE ON SCHEDULE-CONTROLLED
RESPONDING AND MOTILITY. 003295 04-04

DISPOSITION OF KETAZOLAM, A NEW ANXIOLYTIC AGENT, IN MAN. 001655 02-13 DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF KETAZOLAM IN

003535 04-10

O-DIHYDROBENZOTHIAZEPINES

A NEW SYNTHESIS OF 5 KETO-DIHYDROBENZOTHIAZEPINES AND A
PRELIMINARY STUDY OF THEIR BIOLOGICAL PROPERTIES. 000016 01-02

KILLING
THE EFFECTS OF D AMPHETAMINE ON PREY KILLING AND PREY EATING
IN THE RAT AND MOUSE.
001361 02-

PHARMACOLOGICAL EVIDENCE FOR A LINK BETWEEN THE CEREBELLAR CONTENT OF C-GMP AND THAT OF AN ENDOGENOUS PROTEIN KINASE

002031 03-03 EFFECTS OF MORPHINE ON ISOENZYMES OF PYRUVATE KINASE AND TYROSINE-AMINOTRANSFERASE IN RAT. 003141 04-03

KINASES

EFFECT OF RUBIDIUM, LITHIUM AND CESIUM ON BRAIN ATPASE AND PROTEIN KINASES. 001172 02-03

LEVODOPA-INDUCED PSYCHOSIS: A KINDLING PHENOMENON

003668 04-15 KINESTHETIC

THE EFFECTS OF DEXTROAMPHETAMINE ON KINESTHETIC FIGURAL AFTEREFFECTS.

002620 03-14 KINETIC STUDIES OF FOOD INTAKE AND SUCROSE SOLUTION PREFERENCE BY RATS TREATED WITH LOW DOSES OF DELTA9-TETRAHYDROCANNABINOL.

THE HUMAN PLATELET AS A MODEL FOR THE DOPAMINERGIC NEURON:
KINETIC AND PHARMACOLOGIC PROPERTIES AND THE ROLE OF AMINE
STORAGE GRANULES.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — I. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS. 002931 04-03

Psychopharmacology Abstracts

A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS. 003608 04-13

KINETICS OF CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN MOUSE BRAIN SYNAPTOSOMES.

000093

000093 01-03 KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES III: NITRAZEPAM.

KINETICS OF DISTRIBUTION OF AMPHETAMINE IN CATS.

000178 01-03

000137 01-03

000716 01-13

002358 03-05

002556 03-13

003378 04-04

THE DEMETHYLATION OF IMPRAMINE AND CLOMIPRAMINE AS APPARENT FROM THEIR PLASMA KINETICS.

OXIDATION KINETICS OF PHENOTHIAZINE AND 10
METHYLPHENOTHIAZINE IN ACIDIC MEDIUM.

001015 02-01 PLASMA KINETICS OF NALTREXONE AND ITS GLUCURONIDE IN THE DOG. 001183 02-03

KINETICS OF INTRAVENOUS CHLORDIAZEPOXIDE: SEX DIFFERENCES IN DRUG DISTRIBUTION.

001665 02-13 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 1.
KINETICS AND CHARACTERISTICS OF IN VITRO BINDING.

002079 03-03 THE KINETICS OF IMIPRAMINE-N-OXIDE IN RATS

002109 03-03 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL.

IV. INFLUENCE OF ELIMINATION KINETICS.

CHANGES IN PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECTS OF PREMEDICATION WITH CYSTAMINE ON DYNAMICS AND KINETICS OF THIORIDAZINE.

002332 03-04 PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF THIORIDAZINE

002348 03-05 PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF

STEADY-STATE KINETICS OF IMPRAMINE IN PATIENTS.

THE KINETICS OF IMIPRAMINE-N-OXIDE IN MAN.

002585 03-13 PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6 TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

002930 04-03 INTERACTION BETWEEN D AMPHETAMINE AND ETHANOL WITH RESPECT TO LOCOMOTION, STEREOTYPIES, ETHANOL SLEEPING TIME, AND THE KINETICS OF DRUG ELIMINATION.

KININS

INVESTIGATIONS INTO THE MECHANISM OF THE INFLUENCE OF KININS ON THE ACTION OF AMPHETAMINE. 002101 03-03

KLINEFELTERS SYNDROME AND BIPOLAR AFFECTIVE-ILLNESS: A CASE REPORT 003486 04-09

KNOWLEDGE
HYPERACTIVE CHILDRENS KNOWLEDGE AND ATTITUDES CONCERNING
DRUG TREATMENT. 003553 04-11

METABOLISM OF GAMMA-HYDROXYBUTYRATE BY RAT BRAIN: RELATIONSHIP TO THE KREBS-CYCLE AND METABOLIC COMPARTMENTATION OF AMINO-ACIDS. 002896 04-03

-ALPHA-ACETYLMETHADOL

EFFECT OF ALTERATION OF METABOLISM ON THE ANALGESIC ACTIVITY,
TOXICITY, DISTRIBUTION AND EXCRETION OF L-ALPHAACETYLMETHADOL IN THE RAT.

000245 01-03 PLASMA L-ALPHA-ACETYLMETHADOL (LAAM) AFTER ACUTE AND CHRONIC ADMINISTRATION.

HEAD-SHAKE DISTRIBUTIONS DURING SELF-MAINTAINED DEPENDENCE ON MORPHINE, METHADONE, AND L-ALPHA-ACETYLMETHADOL (LAAM) IN THE RAT.

001328 02-04

THE METABOLISM AND PLASMA CONCENTRATIONS OF L-ALPHA-ACETYLMETHADOL AND ITS METABOLITES IN MAN. (PH.D.

001656 02-13 L-DOPA INFLUENCE OF DIAZEPAM, L-DOPA AND DOPAMINE ON THE CEREBELLAR AND SPINAL ELECTRICAL PATTERNS INDUCED BY HARMINE IN THE

000091 01-03 MAO ACTIVITY IN RAT BRAINSTEM AND CEREBRAL-CORTEX FOLLOWING ACUTE AND CHRONIC TREATMENT WITH L-DOPA AND ETHANOL L-

000239 01-03 THE EFFECT OF L-DOPA AND LERGOTRILE-MESYLATE ON THE INTERACTION OF FLUPHENAZINE-DECANOATE AND AMPHETAMINE-INDUCED STEREOTYPY AND MORTALITY.

000401 01-04 EFFECTS OF L DIHYDROXYPHENYLALANINE (L-DOPA) AND DL,5 HYDROXYTRYPTOPHAN (DL,5-HTP) ON RESERPINE-INDUCED AMNESIA 000427 01-04

TREATMENT OF PARKINSONS DISEASE WITH THE COMBINATION L-DOPA/

000633 01-11 IMPROVEMENT WITH L-DOPA IN A HYPERKINETIC CHILD. 000769 01-14

PAROSMIA AND AROMATIC ANOSMIA UNDER L-DOPA THERAPY 000871 01-15

EFFECT OF CHRONIC NEUROLEPTIC OR L-DOPA ADMINISTRATION ON GABA LEVELS IN THE RAT SUBSTANTIA-NIGRA. 001181 02-03

ANTAGONISM BETWEEN THE EFFECTS OF L-DOPA AND APOMORPHINE ON THE BEHAVIOR OF RATS.

001298 02-04 LOCOMOTOR STIMULATION BY L-DOPA: RELATIVE IMPORTANCE OF NORADRENALINE RECEPTOR ACTIVATION.

001300 02-04 THE EFFECT OF AMPHETAMINE AND L-DOPA ON TETRABENAZINE-INDUCED SUPPRESSION OF INTRACRANIAL SELF-STIMULATION IN THE RAT.

001321 02-04 DIFFERENT BEHAVIORAL RESPONSES TO L-DOPA AFTER ANTEROLATERAL OR POSTEROLATERAL HYPOTHALAMIC INJECTIONS OF 6

HYDROXYDOPAMINE 001349 02-04 A BEHAVIORAL ANALYSIS OF AGGRESSIVE BEHAVIORS INDUCED AND MODULATED BY DELTA9-TETRAHYDROCANNABINOL, PILOCARPINE, D

AMPHETAMINE AND L-DOPA 001419 02-04 EFFECTS OF L-DOPA, D AMPHETAMINE AND COCAINE ON INTRUDER-

EVOKED AGGRESSION IN RATS AND MICE 001420 02-04 PSYCHOLOGICAL SIDE-EFFECTS OF L-DOPA AND ANTICONVULSANT

001801 02-15

ALTERATION OF L-DOPA EFFECT ON BRAIN DOPA AND DOPAMINE LEVELS WITH NICOTINIC-ACID AND N METHYL NICOTINAMIDE. (PH.D. DISSERTATION)

001969 03-03 OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINES IN L-DOPA TREATED PARKINSONIAN PATIENTS.

001994 03-03 THE EFFECT OF L-DOPA ON PERIPHERAL SYMPATHETIC NERVE FUNCTION:
ROLE OF PRESYNAPTIC DOPAMINE RECEPTORS.

002081 03-03 L-DOPA REVERSAL OF HYPERDOPAMINERGIC BEHAVIOUR

002229 03-04 SOMATOSENSORY EVOKED-POTENTIALS IN PATIENTS WITH PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND DECARBOXYLASE INHIBITOR

002515 03-11 COMBINED TREATMENT WITH L-DOPA AND PARCOPAN IN PARKINSONS

002518 03-11 REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF L-DOPA, AMINOPHYLLINE, AND EPHEDRINE.

002544 03-13 OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINE ALKALOIDS IN L-DOPA TREATED PARKINSONIAN PATIENTS.

002655 03-15 NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND L-DOPA TO RATS

002942 04-03 THE ANTAGONISM OF THE ANALGESIC EFFECT OF DIPYRONE BY L-DOPA AND ITS RELATION TO BRAIN AMINE CONCENTRATIONS.

002977 04-03 EFFECT OF L-DOPA PRETREATMENT ON IN VIVO PROTEIN SYNTHESIS IN VARIOUS RAT BRAIN REGIONS 003048 04-03 INTRUDER-EVOKED AGGRESSION IN ISOLATED AND NONISOLATED MICE: EFFECTS OF PSYCHOMOTOR STIMULANTS AND L-DOPA.

APOMORPHINE AND L-DOPA LOWER EJACULATION THRESHOLD IN THE MALE RAT

003327 04-04 PARADOXICAL REACTION TO L-DOPA IN SCHIZOPHRENIC PATIENTS.
003449 04-08 L-DOPA TREATMENT OF REACTIVE STUPOROUS STATES.

003513 04-09 THE EFFECT OF L-DOPA AND PROPRANOLOL ON HUMAN CSF CYCLIC-NUCLEOTIDES

003587 04-13 IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLLACTIC-ACID (VLA) IN CEREBROSPINAL FLUID AND 3 METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN THE URINE OF PARKINSONIAN PATIENTS TREATED WITH L-DOPA

003602 04-13 RESPONSE TO LITHIUM IN A CASE OF L-DOPA-INDUCED PSYCHOSIS L TRYPTOPHAN ADMINISTRATION IN L-DOPA-INDUCED HALLUCINATIONS

IN ELDERLY PARKINSONIAN PATIENTS. 001624 02-11

PLASMA L-ALPHA-ACETYLMETHADOL (LAAM) AFTER ACUTE AND CHRONIC ADMINISTRATION

000704 01-13 FAILURE OF METHADONE AND LEVOMETHADYL-ACETATE (LEVO-ALPHA-ACETYLMETHADOL, LAAM) MAINTENANCE TO AFFECT MEMORY. 000841 01-15

HEAD-SHAKE DISTRIBUTIONS DURING SELF-MAINTAINED DEPENDENCE ON MORPHINE, METHADONE, AND L-ALPHA-ACETYLMETHADOL (LAAM) IN

LABELED BRAIN AND RETINA UPTAKE OF A RADIOIODINE LABELED PSYCHOTOMIMETIC IN DOG AND MONKEY.

003075 04-03

LABELING NOREPINEPHRINE ALPHA RECEPTOR BINDING IN MAMMALIAN CENTRAL-NERVOUS-SYSTEM: DIFFERENTIAL LABELING WITH AGONIST AND ANTAGONIST

BETA ADRENERGIC RECEPTOR LABELING IN INTACT ANIMALS WITH 1125-HYDROXYBENZYLPINDOLOL.

SELECTIVE LABELING OF PRESYNAPTIC RECEPTORS BY H3-DOPAMINE, H3-APOMORPHINE AND H3-CLONIDINE; LABELING OF POSTSYNAPTIC SITES BY H3-NEUROLEPTICS.

003117 04-03

STUDIES OF EXCRETION IN RABBIT MILK AFTER ADMINISTRATION OF CARBON-14 LABELLED AMITRIPTYLINE AND NORTRIPTYLINE.

O00037 01-03
INCORPORATION OF RADIOACTIVE LABELLED CHOLINE AND PALMITATE INTO LUNG LECITHIN OF RABBITS TREATED WITH HIGH DOSES OF BROMCARBAMIDES, BARBITURATES AND DIAZEPAM.

INCORPORATION, AFTER SINGLE AND REPEATED APPLICATION OF RADIOACTIVE LABELLED DH-ERGOT ALKALOIDS IN DIFFERENT ORGANS OF THE CAT, WITH SPECIAL REFERENCE TO THE BRAIN. 002047 03-03

H3-SPIROPERIDOL LABELS DOPAMINE RECEPTORS IN PITUITARY AND BRAIN.

EFFECTS OF DIAZEPAM ON UTERINE ACTIVITY DURING LABOR

001627 02-11

EVALUATION OF NALOXONE IN LABORATORY TESTS PREDICTIVE OF CLINICAL ANTIPSYCHOTIC ACTIVITY. 000029 01-02 THE PRODUCTION OF AN ALTERNATIVE LABORATORY MODEL OF THE

PARKINSON SYNDROME USING A NEW BENZYLIMIDOYLUREA DERIVATIVE LON-954 000083 01-03
EFFECTS OF EXPOSURE TO LEAD ON SOCIAL BEHAVIOUR IN THE
LABORATORY MOUSE

LABORATORY MOUSE. WITHDRAWAL FROM CANNABIS: LABORATORY TESTS AND CLINICAL

OBSERVATIONS. 000748 01-14 FLUNITRAZEPAM, AN INVESTIGATIONAL HYPNOTIC DRUG: SLEET

LABORATORY EVALUATIONS. 000750 01-14

FLUCTUATING DENTAL ASYMMETRY AS AN INDICATOR OF THE STRESSFUL PRENATAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN THE LABORATORY RAT.

001520 02-05

001996 03-03

THE EFFECT OF CLOMIPRAMINE AND OTHER AMINE UPTAKE INHIBITORS ON MORPHINE ANALGESIA IN LABORATORY ANIMALS.

002072 03-03 THE EFFECT OF NEUROLEPTICS AND ALPHA-METHYL-P-TYROSINE ON SERUM PROLACTIN LEVELS IN LABORATORY ANIMALS AND MAN 002582 03-13

EFFECTIVENESS OF TEMAZEPAM WITH SHORT-TERM, INTERMEDIATE-TERM, AND LONG-TERM USE: SLEEP LABORATORY EVALUATION. 002608 03-14

ON THE ACUTE EFFECT OF SOME DRUGS ON HIGHER NERVOUS ACTIVITY IN MAN FOLLOWED UP BY THE LABORATORY LANGUAGE METHOD. 002623 03-14

LOSS OF INFORMATION INDUCED BY REDUCTION OF DATA IN THE LABORATORY LANGUAGE METHOD.

002624 03-14 CLINICAL LABORATORY STUDIES WITH SPECIAL REGARD TO HEPATIC METABOLISM IN SCHIZOPHRENICS ON OUTPATIENT LONG-TERM NEUROLEPTIC MEDICATION.

BLOCKADE OF TESTOSTERONE MAINTAINED INTERMALE FIGHTING IN ALBINO LABORATORY MICE BY AN AROMATIZATION INHIBITOR.

003176 04-04 INTERACTION BETWEEN PHENCYCLIDINE AND PENTOBARBITAL IN SEVERAL SPECIES OF LABORATORY ANIMALS.

003185 04-04
HYPNOTIC EFFECTIVENESS OF SODIUM SALICYLAMIDE WITH SHORT-TERM USE: SLEEP LABORATORY STUDIES.

LACTULOSE

THE USE OF LACTULOSE IN PORTAL SYSTEMIC ENCEPHALOPATHY 002762 03-17

EFFECT OF PSYCHOTOMIMETICS (LSD AND DEXTROAMPHETAMINE) ON THE USE OF PRIMARY AND SECONDARY PROCESS LANGUAGE.

O02542 03-12
ON THE ACUTE EFFECT OF SOME DRUGS ON HIGHER NERVOUS ACTIVITY
IN MAN FOLLOWED UP BY THE LABORATORY LANGUAGE METHOD. 002623 03-14

LOSS OF INFORMATION INDUCED BY REDUCTION OF DATA IN THE LABORATORY LANGUAGE METHOD. 002624 03-14

INHIBITION OF CA45 MOVEMENTS BY LOWERED TEMPERATURE OR LANTHANUM IN RAT BRAIN SLICES.

003135 04-03

CLOZAPINE (LEPONEX) VS CHLORPROMAZINE (LARGACTIL) IN ACUTE SCHIZOPHRENIA (A DOUBLE-BLIND CONTROLLED STUDY). 000527 01-08

LARYNGEAL PHARYNGEAL DYSTONIA AS A POSSIBLE CAUSE OF ASPHYXIA WITH HALOPERIDOL TREATMENT.

ACTIVATION OF TYROSINE-3-MONOOXYGENASE IN PHEOCHROMOCYTOMA CELLS BY LASALOCID.

OPEN-FIELD AND LASHLEY III MAZE BEHAVIOUR OF THE OFFSPRING OF AMPHETAMINE TREATED RATS.

003315 04-04

ACTH-INDUCED EXCESSIVE GROOMING IN THE RAT: LATENT ACTIVITY OF

000472 01-04 EFFECTS OF APOMORPHINE AND HALOPERIDOL ON EXPLORATORY BEHAVIOR AND LATENT LEARNING IN MICE.

001297 02-04 DISRUPTION OF LATENT INHIBITION FOLLOWING SYSTEMIC ADMINISTRATION OF P-CHLOROPHENYLALANINE (PCPA).

RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS: ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT LEARNING WITH D AMPPHETAMINE TREATMENTS.

003167 04-04 REACTIVITY AND AGGRESSION IN THE RAT: INDUCTION BY ALPHA-ADRENERGIC BLOCKING AGENTS INJECTED VENTRAL TO ANTERIOR SEPTUM BUT NOT INTO LATERAL SEPTUM.

000309 0

EFFECTS OF APOMORPHINE ON SELF-STIMULATION BEHAVIOUR IN DORSAL AND VENTRAL AREA OF LATERAL HYPOTHALAMUS IN MICE

000334 01-04 EFFECTS OF DOPAMINE SUPERSENSITIVITY ON LATERAL HYPOTHALAMIC SELF-STIMULATION IN RATS.

SYNTHESIS AND TURNOVER OF H3-5-HYDROXYTRYPTAMINE IN THE LATERAL CEREBROVENTRICLE. 002054 03-03

Psychopharmacology Abstracts

INTERACTION BETWEEN MORPHINE AND REINFORCING LATERAL HYPOTHALAMIC STIMULATION.

002291 03-04 STRENGTH DURATION PROPERTIES OF SINGLE UNITS DRIVEN BY ELECTRICAL STIMULATION OF THE LATERAL HYPOTHALAMUS IN RATS

IDENTIFICATION OF A SUBREGION WITHIN RAT NEOSTRIATUM FOR THE DOPAMINERGIC MODULATION OF LATERAL HYPOTHALAMIC SELF-STIMULATION.

MOVEMENT INDUCED IN CATALEPTIC RATS: DIFFERENTIAL EFFECTS
PRODUCED BY ELECTRICAL STIMULATION OF THE LATERAL
HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FORMATION.
003297 04-04

SIMILAR EFFECTS OF ESTROGEN AND LATERAL HYPOTHALAMIC LESIONS ON FEEDING BEHAVIOR OF FEMALE RATS.

LATHYRUS-SATIVUS
ENTRY OF BETA-N-OXALYL-L-ALPHA-BETA-DIAMINOPROPIONIC-ACID, THE
LATHYRUS-SATIVUS NEUROTOXIN INTO THE CENTRAL-NERVOUSSYSTEM OF THE ADULT RAT, CHICK AND THE RHESUS MONKEY.

003061 04-03

003637 04-14

003654 04-15

002857 04-03

ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS.

EFFECT OF AGE AND ROUTE OF ADMINISTRATION ON LD50 OF LITHIUM-CHLORIDE IN THE RAT.

001517 02-05

EFFECTS OF EXPOSURE TO LEAD ON SOCIAL BEHAVIOUR IN THE LABORATORY MOUSE.

000344 01-04 EFFECT OF D AMPHETAMINE ON LOCOMOTOR ACTIVITY OF LEAD FED RABBIT NEONATES.

001406 02-04 LEAD ENHANCES LITHIUM-INDUCED POLYDIPSIA.

001409 02-04 THE EFFECTS OF INORGANIC LEAD ON THE CENTRAL CATECHOLAMINERGIC SYSTEM OF THE RODENT WITH EMPHASIS ON POSTNATALLY EXPOSED RATS AND MICE. (PH.D. DISSERTATION).

003078 04-03

EXPERIMENTAL LEAD ENCEPHALOPATHY IN THE SUCKLING RAT: CONCENTRATION OF LEAD IN CELLULAR FRACTIONS ENRICHED IN BRAIN CAPILLARIES.

003420 04-05

LEAD-INDUCED BEHAVIORAL DISORDERS IN THE RAT: EFFECTS OF AMPHETAMINE. 003261 04-04

ARE YOU GOING TO LEARN TO CHEW COCA LIKE US?.

000683 01-12

000333 01-04

THE EFFECTS OF DL-P-CHLOROPHENYLALANINE ON LEARNED HELPLESSNESS IN THE RAT.

EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN TWO INBRED STRAINS OF MICE.

LEARNED AVERSIONS TO INTRACEREBRAL CARBACHOL. 001424 02-04

EFFECTS OF METHYLPHENIDATE ON AVOIDANCE LEARNING IN THE AGED

000020 01-02 FAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS UNDER LONG-TERM TRAINING.

DEFICITS IN PASSIVE AVOIDANCE LEARNING FOLLOWING ATROPINE IN THE DEVELOPING RAT.

INFLUENCE OF THE SUSPENSION OF CONTINUED TREATMENT WITH FLURAZEPAM AND AMOBARBITAL ON TWO DISCRIMINATION LEARNING SCHEDULES.

000328 01-04 EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN TWO INBRED STRAINS OF MICE.

SPECIFICITY OF LEARNING DEFICITS PRODUCED BY MICROINJECTIONS OF 6-OHDA INTO THE NIGROSTRIATAL SYSTEM OF THE RAT.

000346 01-04 ENHANCEMENT OF LEARNING BY CYCLOHEXIMIDE AND DDC: A FUNCTION OF RESPONSE STRENGTH.

000374 01-04

EFFECTS OF REDUCED CEREBRAL SEROTONIN ON LEARNING. O00422 01-04 THE EFFECTS OF AMPHETAMINE ON MAZE LEARNING BY GOLDFISH. O00446 01-04 PHARMACOPSYCHOLOGICAL INVESTIGATION OF THE EFFECT OF SEDATIVES ON MEMORY AND LEARNING PERFORMANCE IN CHILDREN AND ADOLESCENTS. O00751 01 14	003317 04-04 INE DEPLETION AND 003322 04-04 I LEARNING PRODUCED BY
THE EFFECTS OF AMPHETAMINE ON MAZE LEARNING BY GOLDFISH. 000446 01-04 PHARMACOPSYCHOLOGICAL INVESTIGATION OF THE EFFECT OF SEDATIVES ON MEMORY AND LEARNING PERFORMANCE IN CHILDREN AND ADOLESCENTS. 6 HYDROXYDOPAMINE-INDUCED CATECHOLAMI PASSIVE AVOIDANCE LEARNING IN RATS. 6 FFECT OF PIMOZIDE ON THE IMPROVEMENT IN	INE DEPLETION AND 003322 04-04 I LEARNING PRODUCED BY
PHARMACOPSYCHOLOGICAL INVESTIGATION OF THE EFFECT OF SEDATIVES ON MEMORY AND LEARNING PERFORMANCE IN CHILDREN AND ADOLESCENTS. PASSIVE AVOIDANCE LEARNING IN RATS. EFFECT OF PIMOZIDE ON THE IMPROVEMENT IN	003322 04-04 LEARNING PRODUCED BY
THE EFFECTS OF PHENOTHIAZINES ON COMPLEX LEARNING. O00751 01-14 SELF-STIMULATION AND BY WATER REINFOR	CEMENT. 003394 04-04
MAJOR THEORIES OF STATE-DEPENDENT LEARNING. 000767 01-14 MOOD STATE-DEPENDENT LEARNING.	
SCOPOLAMINE-INDUCED LEARNING FAILURES IN MAN. 000970 01-17 MEMORY CONSOLIDATION AND CHOLINERGIC S	003585 04-12 STATE-DEPENDENT
EFFECTS OF APOMORPHINE AND HALOPERIDOL ON EXPLORATORY	003612 04-13
BEHAVIOR AND LATENT LEARNING IN MICE. 001297 02-04 ILLNESS-INDUCED AVERSION LEARNING IN A DESERT SPECIES OF RODENT CHILDREN.	EARNING-DISABLED
(ACOMYS-CAHIRINUS). O01350 02-04 LECITHIN	000785 01-14
ROLE OF THE BRAIN MONOAMINE SYSTEM IN LEARNING ON VARIOUS EMOTIONAL REINFORCEMENTS. OO1369 02-04 BROMCARBAMIDES, BARBITITRATES AND DIA BROMCARBAMIDES, BARBITITRATES AND DIA	VITH HIGH DOSES OF
EFFECTS OF MAGNESIUM PEMOLINE ON PATTERN DISCRIMINATION LEARNING IN YOUNG RATS. LECTURE	001282 02-03
O01425 02-04 EFFECT OF CURCUMEN-LONGA ON EMOTIONALITY AND LEARNING. THE BIOCHEMISTRY OF BRAIN DEVELOPMENT A RETARDATION: THE ELEVENTH BLAKE MARSI	
ODOR AVERSION LEARNING IN NEONATAL RATS. O01441 02-04 BEFORE THE ROYAL COLLEGE OF PSYCHIATRIC	
PASSIVE AVOIDANCE LEARNING IN THE RAT AS FUNCTIONS OF D OUT 448 02-04 MARIJUANA: DIFFERENTIAL EFFECTS ON RIGHT	AND LEFT HEMISPHERE
AMPHETAMINE DOSAGE AND SHOCK INTENSITY. 001458 02-04 FUNCTIONS IN MAN.	001733 02-14
DISRUPTION OF LEARNING PERFORMANCE BY CHRONIC CHLORPROMAZINE ADMINISTRATION IN THE BABOON. THE USE OF PSYCHOTROPIC DRUGS IN STATE H	S. NOV. OF BOOK AS A SECOND
LEARNING RATE EQUIVALENCY OF TWO NARCOTIC GASES. O01465 02-04 MEDICAL DECISION?	002730 03-17
O0.1701 02-14 THE EFFECTS OF DARVON-N ON RETENTION OF SPECIFIC LEARNING TASKS DURING HEROIN DETOXIFICATION. (PH.D. DISSERTATION)	AND PERSISTENCE OF
METHYLPHENIDATE IN HYPERKINETIC CHILDREN: DIFFERENCES IN DOSE EFFECTS ON LEARNING AND SOCIAL BEHAVIOR. MAINTENANCE ANTIPSYCHOTIC PHARMACOTH AND SOCIAL BEHAVIOR.	OO1322 02-04 ERAPY, RELAPSE, AND
STIMULANT DRUGS AND LEARNING PROBLEMS.	001911 02-17
BASIC MECHANISMS OF STATE-DEPENDENT LEARNING. 001877 02-17 LENPERONE ANTIPSYCHOTIC EFFECTS, SIDE-EFFECTS AND EF	
A COMPARISON OF THE EFFECTS OF SEIZURES AND TWO BUTYROPHENONE LENPERONE (AHR-2277).	000553 01-06
ANTICONVULSANT MEDICATIONS ON LEARNING IN THE PAPIO-PAPIO BABOON. (PH.D. DISSERTATION). 002329 03-04 A COMPARISON OF LUDIOMIL, TRYPTIZOL, AN	0.30.10.10.10.10.90.00
TOLERANCE TO HIGH DOSES OF MORPHINE: LACK OF EVIDENCE OF LEARNING.	002454 03-09
O02356 03-05 INFLUENCE OF VASOPRESSIN ON LEARNING AND MEMORY. O02356 03-05 CLINICAL EXAMINATION OF THE NEW ANTIPSY (LEPONEX).	CHOTIC CLOZAPINE
O2385 03-07 SELECTED COMBINATIONS OF AMITRIPTYLINE AND ANTIPSYCHOTIC DRUGS AND COMPLEX LEARNING. CLOZAPINE (LEPONEX) VS CHLORPROMAZINE (SCHIZOPHRENIA (A DOUBLE-BLIND CONTROL	
AN EXPERIMENTAL STUDY OF THE EFFECTS OF AMITRIPTYLINE	000527 01-08
PERPHENAZINE AND AMITRIPTYLINE HALOPERIDOL COMBINATIONS ON EFFECTS OF LERGOTRILE (LER), AN ERGOT DERI INTERPERSONAL LEARNING. SUBSTANTIA-NIGRA PARS COMPACTA DOPA	MINE (DA) NEURONS.
002511 03-11 TIME-RESPONSE ANALYSIS OF THE EFFECT OF STIMULANT MEDICATION ON THE LEARNING ABILITY OF CHILDREN REFERRED FOR DIFFERENTIAL EFFECTS OF THREE DOPAMINE AC	001278 02-03
HYPERACTIVITY. 002534 03-11 BROMOCRIPTINE AND LERGOTRILE.	000451 01-04
HYPERACTIVE CHILDRENS UNDERUSE OF LEARNING TIME: CORRECTION BY STIMULANT TREATMENT. O02614 03-14 FARKINSONISM.	ND DRUG-INDUCED
HUMAN STATE-DEPENDENT LEARNING. DOCTOR OF LERGOTRILE (LER), AN ERGOT DERI	
DRUG DISCRIMINATION AND STATE-DEPENDENT LEARNING.	001278 02-03
MAJOR THEORIES OF STATE-DEPENDENT LEARNING. 002772 03-17 METABOLISM OF LERGOTRILE TO 13 HYDROXY INHIBITOR OF PROLACTIN RELEASE IN VITRO	46 1/20 0000
EFFECTS OF ADRENALECTOMY ON TASTE AVERSION LEARNING.	003040 04-03
RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS: ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT LEARNING WITH D AMPPHETAMINE TREATMENTS. THE FFFECT OF L-DOPA AND LERGOTRILE-MESY. OF FLUPHENAZINE-DECANOATE AND AMPHET STEREOTYPY AND MORTALITY.	TATE ON THE INTERACTION TAMINE-INDUCED
DIFFERENTIAL EFFECTS ON CONDITIONED TASTE AVERSION LEARNING WITH PERIPHERALLY AND CENTRALLY ADMINISTERED ACETALDEHYDE. U03167 04-04 LERGOTRILE-MESYLATE: AN IN VIVO DOPAMIN BLOCKS DOPAMINE RECEPTORS IN VITRO.	000401 01-04 NE AGONIST WHICH
OO3178 04-04 EFFECTS OF CHRONIC INGESTION AND WITHDRAWAL OF SODIUM LESION	001159 02-03
BARBITONE ON LEARNING IN RATS. O03273 04-04 FURTHER EVIDENCES ON THE BEHAVIOURAL EF	FECTS OF SELECTIVE A-10 MBIC GROUP LESION IN
PHYSIOLOGICAL SUBSTRATES OF STATE-DEPENDENT LEARNING. 003302 04-04	000399 01-0

BEHAVIORAL EFFECTS OF NEUROLEPTICS, APOMORPHINE AND AMPHETAMINE AFTER BILATERAL LESION OF THE LOCUS-COERULEUS IN RATS.

CENTRAL DRUG AND LESION STUDIES OF FEEDING.

001393 02-04

NEONATAL SYSTEMIC 6 HYDROXYDOPAMINE AND DORSAL TEGMENTAL BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEPHRINE AND THE POSTDECAPITATION REFLEX.

DOPAMINE RECEPTOR BINDING ENHANCEMENT ACCOMPANIES LESION-INDUCED BEHAVIORAL SUPERSENSITIVITY.

000084 01-03

003039 04-03

REDUCTION OF VMH LESION-INDUCED HYPEREMOTIONALITY AND ANTINOCICEPTION BY DIAZEPAM. 002211 03-04

EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) ON SLEEP IN OLFACTORY BULB LESIONED RATS. 000032 01-02

MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND NORADRENERGIC NEURONS IN NORMAL AND BRAIN LESIONED RATS.

000312 01-04 STRIATAL CELL SUPERSENSITIVITY TO APOMORPHINE IN DOPAMINE LESIONED RATS CORRELATED TO BEHAVIOUR. 003356 04-04

LESIONING
CHANGES IN THE BEHAVIORAL RESPONSE TO A NOVEL ENVIRONMENT
FOLLOWING LESIONING OF THE CENTRAL DOPAMINERGIC SYSTEM IN
RAT PUPS.
D03368 04-

ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEDOMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR.

5,7 DIHYDROXYTRYPTAMINE LESIONS: EFFECTS ON BODY WEIGHT, IRRITABILITY, AND MURICIDE.

000430 01-04 HYPERSENSITIVITY OF RATS TO ANORECTIC AGENTS AFTER LESIONS IN

ROLE OF GLUCOCORTICOIDS IN AN ABNORMAL GROOMING BEHAVIOR IN CATS WITH PONTILE OR FRONTAL NEOCORTICAL LESIONS. 000463 01-04

ATTENUATION OF THE RATE DECREASING EFFECTS OF AMPHETAMINE ON FIXED-RATIO RESPONDING IN RATS BY HIPPOCAMPAL LESIONS. 000474 01-04

ELECTRON MICROSCOPIC STUDIES ON THE CEREBRAL LESIONS OF RATS IN EXPERIMENTAL CHRONIC DISULFIRAM POISONING.

000906 01-15 EFFECTS OF BRAIN LESIONS AND ATROPINE ON HIPPOCAMPAL AND NEOCORTICAL ELECTROENCEPHALOGRAMS IN THE RAT.

001033 02-02 POTENTIATION OF MORPHINE ANALGESIA BY LESIONS OF THE NUCLEUS LOCUS-COFRUITUS

VARIOUS EFFECTS OF D AMPHETAMINE IN RATS WITH SELECTIVE LESIONS OF BRAIN NORADRENALINE CONTAINING NEURONS OR TREATED WITH PENFLURIDOL.

001437 02-04 COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON ROTATIONAL BEHAVIOR IN RATS WITH UNILATERAL 6 HYDROXYDOPAMINE

EFFECTS OF MEDIAL RAPHE AND RAPHE MAGNUS LESIONS ON THE ANALGESIC ACTIVITY OF MORPHINE AND METHADONE.

AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY AND STEREOTYPY AFTER KAINIC-ACID LESIONS OF THE STRIATUM.

LESIONS OF THE DORSAL NORADRENERGIC PROJECTION ATTENUATE MORPHINE-INDUCED BUT NOT AMPHETAMINE-INDUCED CONDITIONED TASTE AVERSION.

INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA:
EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION. 002890 04-03

THE EFFECT OF INTRAHIPPOCAMPAL KAINIC-ACID INJECTIONS AND SURGICAL LESIONS ON NEUROTRANSMITTERS IN HIPPOCAMPUS AND

STUDIES ON THE EFFECT OF LESIONS OF THE VENTRAL NORADRENERGIC TRACT ON THE ANTINOCICEPTIVE ACTION OF MORPHINE. 002979 04-03 Psychopharmacology Abstracts

THE NEUROLOGICAL BASIS OF MOTOR ASYMMETRY FOLLOWING UNILATERAL NIGROSTRIATAL LESIONS IN THE RAT: THE EFFECT OF SECONDARY SUPERIOR COLLICULUS LESIONS.

003200 04-04 CHANGES IN MORPHINE SELF-ADMINISTRATION AFTER TEL-DIENCEPHALIC

DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION.

MILAR EFFECTS OF ESTROGEN AND LATERAL HYPOTHALAMIC LESIONS ON FEEDING BEHAVIOR OF FEMALE RATS.

003314 04-04 DORSOMEDIAL THALAMIC LESIONS AND AMPHETAMINE: ACQUISITION AND RETENTION OF A VISUAL PATTERN DISCRIMINATION ESCAPE TASK.

HISTOFLUORESCENCE OF KAINIC-ACID-INDUCED STRIATAL LESIONS 003433 04-06

A RELIABLE, FACIAL NOCICEPTION DEVICE FOR UNRESTRAINED, AWAKE ANIMALS: EFFECTS OF MORPHINE AND TRIGEMINAL COMPLEX LESIONS.

003435 04-06

003412 04-05

LETHAL EFFECTS OF PHYSOSTIGMINE PLUS LITHIUM IN RATS

000485 01-05 THE TRIPHASIC AMPHETAMINE LETHAL DOSE CURVE IN MICE AND ITS POSSIBLE RELATIONSHIP TO DRUG METABOLISM.

LIDOCAINE AND PENTOBARBITAL: A POTENTIALLY LETHAL DRUG DRUG

LETHALITY

ANTAGONISM OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA)
LETHALITY BY CHLORPROMAZINE IN THE CONSCIOUS DOG.

001072 02-03 TRIPHASIC DOSE LETHALITY RELATIONSHIPS FOR AMPHETAMINE AND CERTAIN RING-SUBSTITUTED AMPHETAMINES IN ISOLATED OR AGGREGATED MICE.

001093 02-03 AMPHETAMINE LETHALITY IN MICE. (PH.D. DISSERTATION). 001151 02-03

PHARMACOLOGICAL MODIFICATION OF SHOCK POTENTIATED AMPHETAMINE LETHALITY.

001494 02-04 LETHALITY OF PENTYLENETETRAZOL IN RATS AFTER DEPLETION OF BRAIN NOREPINEPHRINE.

002337 03-05

LEUCINE

INTERACTIONS OF LEUCINE AND METHIONINE-ENKEPHALIN WITH MORPHINE IN VITRO AND IN VIVO.

EPILEPTIC PROPERTIES OF LEUCINE-ENKEPHALIN AND METHIONINE-ENKEPHALIN: COMPARISON WITH MORPHINE AND REVERSIBILITY BY NALOXONE

002916 04-03

EFFECTS OF CANNABINOIDS ON L1210 MURINE LEUKEMIA: 1. INHIBITION OF DNA SYNTHESIS. 001266 02-03

IN VITRO EFFECTS OF IMIPRAMINE ON PROLIFERATION OF HUMAN

CHEMILUMINESCENCE RESULTING FROM AN INTERACTION BETWEEN IMPRAMINE AND HUMAN POLYMORPHONUCLEAR LEUKOCYTES.

PROTEIN AND ENZYME RELEASE FROM HUMAN LEUKOCYTES: INFLUENCE OF PHENOTHIAZINE DERIVATIVES. 001669 02-13

LEUKOPENIA
TREATMENT OF LEUKOPENIA WITH LITHIUM-CARBONATE: A
PRELIMINARY REPORT.

003448 04-07 LEVEL BICYCLIC PHOSPHORUS ESTERS INCREASE THE CYCLIC-GMP LEVEL IN RAT

CEREBELLUM 000009 01-01

SPECIFIC LOCALIZATION OF DRUGS AT THE HYPOPHYSIS LEVEL AND SIDE-EFFECTS: THE CASE OF NEUROLEPTICS. 000053 01-03

EFFECT OF CONVULSANT AND ANTICONVULSANT AGENTS ON LEVEL AND METABOLISM OF GAMMA-AMINOBUTYRIC-ACID IN MOUSE BRAIN. 000186 01-03 INFLUENCE OF THE ANTIPARKINSONIAN DRUGS ON THE PLASMA LEVEL

OF NEUROLEPTICS. 000700 01-13 THE EFFECT OF MELPERONE (BURONIL(R)) AND ITS METABOLITE FG-5155 ON THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM COMPARED TO SOME OTHER NEUROLEPTICS.

001081 02-03

DYNAMICS OF BLOOD NEUROTRANSMITTER LEVEL AS EVIDENCE OF HIGHER NERVOUS ACTIVITY CHANGES DURING CHRONIC ADMINISTRATION OF SEDUXEN.

EEG, BLOOD LEVEL, AND BEHAVIORAL EFFECTS OF THE ANTIDEPRESSANT MIANSERIN (ORG-GB-94).

DRUGS AND DEPRESSION: DOSAGE AND BLOOD LEVEL MONITORING. 001595 02-09

ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS

001672 02-13 PSYCHOTROPIC DRUGS: MECHANISM OF ACTION AT THE NEUROTRANSMITTER LEVEL

001684 02-13 THE EFFECTS OF METHYLPHENIDATE ON VARIOUS TYPES OF ACTIVITY LEVEL AND ATTENTION IN HYPERKINETIC CHILDREN.

001698 02-14 BLOOD LEVEL MONITORING OF BENZODIAZEPINES BY GLC USING NITROGEN SENSITIVE DETECTORS.

001860 02-16 CLINICAL AND PLASMA LEVEL CHARACTERISTICS OF INTRAMUSCULAR AND ORAL LOXAPINE.

002407 03-08 CLOMIPRAMINE PLASMA LEVEL AND CLINICAL RESPONSE

002422 03-09 DIFFERENTIAL EFFECTS OF A SINGLE DOSE OF IMIPRAMINE AND LOPRAMINE IN HEALTHY SUBJECTS VARYING IN THEIR LEVEL OF

002446 03-09 PLASMA LEVEL STUDIES OF CLOMIPRAMINE AND

DESMETHYLCLOMIPRAMINE FOLLOWING INTRAVENOUS INFUSIONS OF CLOMIPRAMINE IN DEPRESSIVE PATIENTS. 002448 03-09

THE THIORIDAZINE LEVEL IN THE BLOOD SERUM AND SYMPTOMS OF THE PARANOID SYNDROME. 002543 03-13

METHADONE DOSE, PLASMA LEVEL, AND CROSS-TOLERANCE TO HEROIN IN MAN.

002642 03-14 EFFECT OF ACUTE MORPHINE ADMINISTRATION ON THE CEREBELLAR CYCLIC-GMP LEVEL IN TWO STRAINS OF MICE.

002975 04-03 TIME-COURSE OF THE INCREASE IN GABA LEVEL IN DIFFERENT MICE BRAIN REGIONS FOLLOWING N DIPROPYLACETATE TREATMENT. 003091 04-03

LEVELS

LEVELS OF CHLORPROMAZINE AND ITS ACTIVE MATABOLITES IN RAT BRAIN AND THE RELATIONSHIP TO CENTRAL MONOAMINE METABOLISM AND PROLACTIN SECRETION

000041 01-03 STRESS-INDUCED ALTERATIONS OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN: **EFFECTS OF CENTRALLY ACTING DRUGS**

000097 01-03 INVOLVEMENT OF THE DOPAMINE NIGROSTRIATAL SYSTEM IN THE

PICROTOXIN EFFECT ON STRIATAL ACETYLCHOLINE LEVELS 000158 01-03 THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS OF MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT
OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE.

INFLUENCE OF INJECTED PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE BRAIN AND LUNG FOLLOWING MICROWAVE IRRADIATION. 000214 01-03

PERSISTENT EFFECTS OF REPEATED INJECTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE ON RAT BRAIN 5 HYDROXYTRYPTAMINE AND 5 HYDROXYINDOLEACETIC-ACID LEVELS.

000221 01-03 EFFECT OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION ON EPINEPHRINE LEVELS IN THE RRAIN

000255 01-03 EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH MORPHOLOGY AND HORMONE PLASMA LEVELS.

000315 01-04 RAISED BRAIN GABA LEVELS, MOTOR ACTIVITY AND EXPLORATION IN

000358 01-04 DELTA9-THC AND 11 OH-DELTA9-THC: BEHAVIORAL EFFECTS AND RELATIONSHIP TO PLASMA AND BRAIN LEVELS.

EFFECTS OF CHLORPROMAZINE ON PLASMA PROLACTIN AND CHLORPROMAZINE LEVELS. 000540 01-08 PLASMA LEVELS DURING TREATMENT WITH IMIPRAMINE, CLOMIPRAMINE, AND IMIPRAMINE-N-OXIDE

EFFECT OF CHLORPROMAZINE TREATMENT ON MONOAMINE METABOLITE LEVELS IN CEREBROSPINAL FLUID OF PSYCHOTIC PATIENTS.

AMITRIPTYLINE DOSAGE SCHEDULE, SAMPLING TIME AND TRICYCLIC PLASMA LEVELS

000593 01-09
RELATIONSHIP BETWEEN AGE AND TRICYCLIC ANTIDEPRESSANT PLASMA

000652 01-11 LACK OF EFFECT OF CLONAZEPAM ON SERUM LEVELS OF DIPHENYLHYDANTOIN, PHENOBARBITAL AND CARBAMAZEPINE

000705 01-13 POLITIME MODIFICIAL INFORMATION OF DEPRESSION

000715 01-13 SALIVA LITHIUM LEVELS: CLINICAL APPLICATIONS

000718 01-13 SMA LEVELS OF CHLORPROMAZINE: EFFECT OF AGE, CHRONICITY OF DISEASE, AND DURATION OF TREATMENT.

INCREASED STEADY-STATE PLASMA LEVELS AND PROLONGED HALF-LIVES OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY.

LOW LEVELS OF DOPAMINE-BETA-HYDROXYLASE AND PSYCHOSIS. 000831 01-15

TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS AND ADVERSE EFFECTS AFTER OVERDOSE

000883 01-15 EFFECT OF CHRONIC NEUROLEPTIC OR L-DOPA ADMINISTRATION ON GABA LEVELS IN THE RAT SUBSTANTIA-NIGRA.

CYCLIC-GMP AND GABA LEVELS IN RAT STRIATUM AND CEREBELLUM DURING MORPHINE WITHDRAWAL: EFFECT OF APOMORPHINE.

001274 02-03 EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION: AMPHETAMINE LEVELS AND EFFECTS UPON SOME ARYLALKYLAMINES IN RAT BRAIN.

001339 02-04 NEUROMETABOLIC AND BEHAVIOURAL EFFECTS OF HALOPERIDOL IN RELATION TO DRUG LEVELS IN SERUM AND BRAIN.

001430 02-04 TOLERANCE TO STEREOTYPED BEHAVIOUR AND TO DECREASE IN STRIATAL HOMOVANILLIC-ACID LEVELS AFTER REPEATED TREATMENT WITH APOMORPHINE-DIPIVALOYL-ESTER.

SUBSTANTIAL INCREASE IN THE LEVELS OF CHLOROPHENOXYACETIC-ACIDS IN THE CNS OF RATS AS A RESULT OF SEVERE INTOXICATION 001505 02-05

AN EVALUATION OF A UNIQUE NEW ANTIPSYCHOTIC AGENT, SULPIRIDE: EFFECTS ON SERUM PROLACTIN AND GROWTH HORMONE LEVELS. ANTIPARKINSONIAN DRUG ADMINISTRATION AND PLASMA LEVELS OF

PENFLURIDOL, A NEW LONG-ACTING NEUROLEPTIC 001559 02-08 PLASMA BUTAPERAZINE LEVELS IN LONG-TERM CHRONIC

NONRESPONDING SCHIZOPHRENICS.

PROTRIPTYLINE PLASMA LEVELS AND ANTIDEPRESSANT RESPONSE. 001576 02-09 AMITRIPTYLINE BLOOD LEVELS AND RELAPSE.

O01587 02-09

AMITRIPTYLINE PLASMA LEVELS AND CLINICAL RESPONSE IN PRIMARY

001594 02-09 SERUM GONADOTROPIN AND TSH LEVELS AFTER TRICYCLIC ANTIDEPRESSANTS IN HEALTHY MALES.

001670 02-13 EFFECT OF CHLORPROMAZINE TREATMENT ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC PATIENTS.

001694 02-13
HYPERACTIVE AND NONHYPERACTIVE CHILDRENS SELF-DETERMINED LEVELS OF STIMULATION. (PH.D. DISSERTATION) 001717 02-14

PLASMA FENFLURAMINE LEVELS, WEIGHT LOSS, AND SIDE-EFFECTS. 001790 02-15 DAILY CHANGES IN THE BLOOD SERUM LEVELS OF DIPHENYLHYDANTOIN

(DPH) AND PHENOBARBITAL. 001830 02-15 REDUCED LEVELS OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA FROM

VACUTAINERS 001859 02-16 PREDICTION OF PLASMA LEVELS OF IMIPRAMINE FROM
PHARMACOKINETICS OF AN INITIAL DOSE. (UNPUBLISHED PAPER)

O01876 02-16

ALTERATION OF L-DOPA EFFECT ON BRAIN DOPA AND DOPAMINE LEVELS
WITH NICOTINIC-ACID AND N METHYL NICOTINAMIDE. (PH.D.

001969 03-03

000361 01-04

3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE LEVELS IN RAT CEREBELLUM: EFFECTS OF MORPHINE, KETAMINE, HARMALINE AND ISONIAZID. 002056 03-03 EFFECT OF SYNTHESIS INHIBITION ON THE LEVELS OF BRAIN CATECHOLAMINES IN BARBITAL DEPENDENT RATS.

METABOLISM OF 5 HYDROXYTRYPTAMINE AND LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS IN RAT BRAIN AFTER ACUTE AND CHRONIC TREATMENT. 002169 03-03

SCREENING FOR THE EFFECTS OF DOPAMINERGIC AND ANTIDOPAMINERGIC DRUGS ON SERUM PROLACTIN LEVELS BY RADIOIMMUNOASSAY.

R-806-003-01 IN THE TREATMENT OF DEPRESSION: PLASMA LEVELS AND THERAPEUTIC RESPONSE.

002376 03-07 A COMPARISON OF DESIPRAMINE AND AMITRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.

02417 03-09 A NEW ANTIDEPRESSANT BUTRIPTYLINE: PLASMA LEVELS AND CLINICAL

002423 03-09 BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS: ASSAY PROCEDURES, REPRODUCIBILITY AND RELATIONSHIP TO THERAPEUTIC OUTCOME AND SIDE-EFFECTS.

002440 03-09 WEIGHT LOSS AND A CONCOMITANT CHANGE IN PLASMA TRICYCLIC

002441 03-09 DESIPRAMINE PLASMA LEVELS AND THERAPEUTIC RESPONSE

002443 03-09 CLINICAL EFFECTS AND PLASMA LEVELS OF CLOMIPRAMINE IN DEPRESSED BARBADIANS.

EFFICACY, SIDE-EFFECTS, PLASMA AND BLOOD LEVELS OF MAPROTILINE (LUDIOMIL).

CLINICAL RESPONSE IN DEPRESSED PATIENTS IN RELATION TO PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND TYRAMINE PRESSOR RESPONSE.

TRICYCLIC PLASMA LEVELS: EFFECT OF AGE, RACE, SEX, AND SMOKING. 002472 03-09

A PRELIMINARY REPORT ON CLINICAL RESPONSE AND PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN OBSESSIVE-COMPULSIVE NEUROSIS.

002493 03-10

EFFECTS OF MELPERONE AND THIOTHIXENE ON PROLACTIN LEVELS IN

CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC WOMEN.

002547 03-13 LACK OF EFFECTS OF L TRYPTOPHAN ON BASAL AND TRH STIMULATED TSH AND PROLACTIN LEVELS.

EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DEPRESSIVE PATIENTS RECEIVING CLOMIPRAMINE THERAPY.

002577 03-13

THE EFFECT OF NEUROLEPTICS AND ALPHA-METHYL-P-TYROSINE ON SERUM PROLACTIN LEVELS IN LABORATORY ANIMALS AND MAN 002582 03-13

TYRAMINE PRESSOR RESPONSES AND PLASMA LEVELS DURING
TRICYCLIC ANTIDEPRESSANT THERAPY 002584 03-13

MOTIVATION LEVELS AND THE MARIHUANA HIGH.

002633 03-14 EFFECTS OF MSH/ACTH4-10 ON MEMORY, ATTENTION, AND ENDOGENOUS HORMONE LEVELS IN WOMEN.

002641 03-14 USE OF TRICYCLIC ANTIDEPRESSANT BLOOD LEVELS

A SIMPLE METHOD FOR THE DETERMINATION OF THERAPEUTIC LEVELS OF CLOMIPRAMINE, IMIPRAMINE AND DESIPRAMINE.

002717 03-16 MEASUREMENT OF PLASMA ANTIDEPRESSANT LEVELS BY PERFORMANCE LIQUID CHROMATOGRAPHY.

002720 03-16
EFFECTS OF SINGLE AND MULTIPLE DOSES OF DESIPRAMINE (DMI) ON ENDOGENOUS LEVELS OF 3 METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE (MOPEG-SO4) IN RAT BRAIN.

002814 04-03 EFFECT OF 6 METHOXYTETRAHYDRO-BETA-CARBOLINE ON SERUM PROLACTIN LEVELS OF MALE RATS.

002903 04-03 CYCLIC-NUCLEOTIDE LEVELS IN THE RAT STRIATUM AND CEREBELLUM IN VIVO EFFECTS OF DOPAMINE AND ACETYLCHOLINE RECEPTOR AGONISTS AND ANTAGONISTS.

003051 04-03 THE ROLE OF CALCIUM IN THE REGULATION OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN SLICES OF RAT AND GUINEA-PIG. 003079 04-03 CATECHOLAMINE LEVELS IN THE WHOLE BRAIN AND THE PROBABILITY OF MEMORY FORMATION ARE NOT RELATED.

003328 04-04 EFFECTS OF KAINIC-ACID ON ION DISTRIBUTION AND ATP LEVELS OF STRIATAL SLICES INCUBATED IN VITRO.

003406 04-05 MEASUREMENT OF PLASMA AND ERYTHROCYTE CHLORPROMAZINE AND N MONODESMETHYLCHLORPROMAZINE LEVELS BY GAS-CHROMATOGRAPHY WITH A NITROGEN SENSITIVE DETECTOR.

003429 04-06 EFFECTS OF PERPHENAZINE-ENANTHATE INJECTIONS ON PROLACTIN LEVELS IN PLASMA FROM SCHIZOPHRENIC WOMEN AND MEN.

003462 04-08 LOW PLASMA LEVELS OF CPZ IN PATIENTS CHRONICALLY TREATED WITH NEUROLEPTICS.

CLINICAL IMPORTANCE OF DOXEPIN ANTIDEPRESSANT PLASMA LEVELS 003497 04-09

A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE (SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS
(SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH
SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE AND NORTRIPTYLINE

003508 04-09 ANTIDEPRESSANT DRUG LEVELS AND CLINICAL RESPONSE.

003545 04-10 PLASMA LEVELS OF NEUROLEPTICS VS CLINICAL RESPONSES

003601 04-13 EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON HUMAN PLASMA LEVELS OF TSH, GH AND PROLACTIN.

003613 04-13 TRICYCLIC ANTIDEPRESSANTS: PLASMA LEVELS AND CLINICAL FINDINGS IN OVERDOSE.

003643 04-15 THYROID AUTOANTIBODY LEVELS DURING LITHIUM THERAPY

003650 04-15 LEVER

THE EFFECT OF NONCONTINGENT AMPHETAMINE INJECTIONS ON THE EXTINCTION OF FOOD AND DRUG REINFORCED LEVER PRESSING IN RATS. 001404 02-04

FAILURE OF METHADONE AND LEVOMETHADYL-ACETATE (LEVO-ALPHA-ACETYLMETHADON, LAAM) MAINTENANCE TO AFFECT MEMORY. 000841 01-15

BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION OF LEVO-ALPHA-ACETYLMETHADOL IN THE RAT. 003154 04-04

VO-ALPHA-ACETYLMETHADOL AND METABOLITES: SOME EFFECTS ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT. 003156 04-04

THE OFF-ON PHENOMENON DURING TREATMENT OF PARKINSONS DISEASE WITH LEVODOPA.

000664 01-11 COMPETITIVE BINDING BETWEEN COCAINE AND VARIOUS DRUGS TO SYNTHETIC LEVODOPA MELANIN.

001051 02-03 EFFECT OF CHRONIC LEVODOPA ON VITAMIN-B6 METABOLISM IN DISCRETE REGIONS OF RAT BRAIN.

001105 02-03 LEVODOPA IN SUBACUTE SCLEROSING PANENCEPHALITIS.

001547 02-07 LOW DOSE LEVODOPA IN SCHIZOPHRENIA 001558 02-08

NEUROENDOCRINE RESPONSES TO LEVODOPA IN AFFECTIVE-ILLNESS 002435 03-09

FOUR-YEAR TREATMENT OF PATIENTS WITH PARKINSONISM USING AMANTADINE ALONE OR WITH LEVODOPA. 002707 03-15

LEVODOPA IN PARKINSON DISEASE: A LONG-TERM APPRAISAL OF MORTALITY.

002755 03-17 A DOUBLE-BLIND COMPARISON OF LEVODOPA, MADOPA, AND SINEMET IN PARKINSON DISEASE.

003556 04-11

LEVODOPA-INDUCED

LEVODOPA-INDUCED DOPAMINE RECEPTOR HYPERSENSITIVITY 000392 01-04 SODIUM VALPROATE IN THE TREATMENT OF LEVODOPA-INDUCED

003568 04-11 LEVODOPA-INDUCED PSYCHOSIS: A KINDLING PHENOMENON. 003668 04-15

LEVOMETHADYL-ACETATE FAILURE OF METHADONE AND LEVOMETHADYL-ACETATE (LEVO-ALPHA-ACETYLMETHADOL, LAAM) MAINTENANCE TO AFFECT MEMORY. 000841 01-15

VOLUME 16. SUBJECT INDEX

STEREOSELECTIVE, DOSE-DEPENDENT MODIFICATION OF INTRACRANIAL SELF-STIMULATION (ICSS) BY CENTRALLY ADMINISTERED LEVORPHANOL AND DEXTRORPHAN.

001280 02-03

LEVORPHANOL-TARTRATE

EFFECTS OF NALOXONE FOLLOWING A SINGLE ADMINISTRATION OF LEVORPHANOL-TARTRATE IN THE NAIVE RAT.

001110 02-03

EFFECT OF MORPHINE ON THE BASAL AND THE DOPAMINE-INDUCED
RELEASE OF LHRH FROM MEDIOBASAL HYPOTHALAMIC FRAGMENTS

003072 04-03

U-TRANSPORT

CHARACTERISTICS OF LI-TRANSPORT IN HUMAN RED CELLS

002591 03-13

RELATIONSHIP BETWEEN ANORECTIC AND REINFORCING PROPERTIES OF APPETITE SUPPRESSANT DRUGS: IMPLICATIONS FOR ASSESSMENT OF

003236 04-04

INCREASED PRESCRIBING OF VALIUM, LIBRIUM, AND OTHER DRUGS --AN EXAMPLE OF THE INFLUENCE OF ECONOMIC AND SOCIAL FACTORS ON THE PRACTICE OF MEDICINE.

INSTINCTIVE PREDATORY BEHAVIOR OF THE FERRET (PUTORIUS-PUTORIUS-FURO L.) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE (LIBRIUM).

003161 04-04

NACL AND LICL EFFICACY IN THE INDUCTION OF AVERSION FOR QUININE AND SACCHARIN SOLUTIONS IMMEDIATELY FOLLOWING INJECTION. 000396 01-04

LIDOCAINE

HYPERTONIC SODIUM-CHLORIDE AND LIDOCAINE IN A CASE OF IMPRAMINE INTOXICATION.

001769 02-15 LIDOCAINE AND PENTOBARBITAL: A POTENTIALLY LETHAL DRUG DRUG

003412 04-05

LIFE

SEROTONIN REDUCTION EARLY IN LIFE AND ITS EFFECTS ON BEHAVIOR 000383 01-04 PHARMACOTHERAPY FOR ORGANIC-BRAIN-SYNDROME IN LATE LIFE:

EVALUATION OF AN ERGOT DERIVATIVE VS PLACEBO.

000628 01-11 APPLICATION OF LIFE TABLE METHOD TO NATURALISTIC DESIGNS - A COMPARISON OF EFFICACY OF TRICYCLIC ANTIDEPRESSANTS AND BENZODIAZEPINES IN AMBULATORY DEPRESSIVES.

002783 03-17

LIFELONG

SERVICES FOR SCHIZOPHRENICS: A LIFELONG APPROACH TO

TREATMENT.

002398 03-08

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS: 3. SUBCELLULAR DISTRIBUTION OF NEUROLEPTIC DRUGS AND THEIR RECEPTORS IN VARIOUS RAT BRAIN AREAS.

002067 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 2. REGIONAL DISTRIBUTION AND IN VIVO DISPLACEMENT OF NEUROLEPTIC DRUGS.

002068 03-03

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 1. KINETICS AND CHARACTERISTICS OF IN VITRO BINDING.

ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS.

LIGATION

QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P-450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3 METHYCHOLANTHRENE

LIGHT

PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATIENTS DURING LONG TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS: DISSOCIATION BETWEEN LIGHT AND NEAR VISION REACTIONS. 003673 04-15

LIGHT-DARK

EFFECTS OF MESCALINE AND PSILOCIN ON ACQUISITION, CONSOLIDATION, AND PERFORMANCE OF LIGHT-DARK DISCRIMINATION IN TWO INBRED STRAINS OF MICE.

003184 04-04

001672 02-13

002083 03-03

Subject Index

ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

003272 04-04

LILLY-51641 INHIBITION OF MONOAMINE OXIDATION IN SUBFRACTIONS OF CRUDE MITOCHONDRIA OF RAT BRAIN BY CLORGYLINE AND LILLY-51641.

003020 04-03

EVALUATION OF SUBSTITUTED AMPHETAMINE HALLUCINOGENS USING THE CAT LIMB FLICK MODEL

LIMB REDUCTION ANOMALIES IN INFANTS BORN TO DISULFIRAM TREATED ALCOHOLIC MOTHERS.

001817 02-15

LIMBIC

NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN SLICES OF MOUSE LIMBIC FOREBRAIN: CHARACTERISATION AND EFFECT OF DOPAMINERGIC AGONISTS

000256 01-03

AGONIST EFFECTS OF BETA-PHENYLETHYLAMINES ON THE NORADRENERGIC CYCLIC-ADENOSINE-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. 3,5-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. STEREOISOMERS OF P-HYDROXYNOREPHEDRINE.

DOPAMINE RECEPTORS AND ERGOT DRUGS. EVIDENCE THAT AN ERGOLENE DERIVATIVE IS A DIFFERENTIAL AGONIST AT SUBCORTICAL LIMBIC DOPAMINE RECEPTORS.

EFFECTS OF DIAZEPAM ON DOPAMINE TURNOVER IN NEOSTRIATAL AND LIMBIC REGIONS OF THE RAT BRAIN.

MODIFICATION OF THE NORADRENERGIC CYCLIC-AMP GENERATING
SYSTEM IN THE RAT LIMBIC FOREBRAIN BY AMPHETAMINE (A) AND ITS HYDROXYLATED METABOLITES.

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION

STIMULATION OF ADENYLATE-CYCLASE ACTIVITY IN MONKEY ANTERIOR LIMBIC CORTEX BY SEROTONIN.

INTERACTION OF IMIPRAMINE AND 3 QUINUCLIDYL-BENZILATE WITH 9
AMINO-7-METHOXYTETRAHYDROACRIDINE ON THE AFTER-DISCHARGES
IN THE LIMBIC SYSTEM.

COCAINE AND PSEUDOCOCAINE: COMPARATIVE EFFECTS ON ELECTRICAL AFTER-DISCHARGE IN THE LIMBIC SYSTEM OF CATS.

A COMPARISON OF THE EFFECTS OF ANTIPSYCHOTIC DRUGS ON PITUITARY, STRIATAL AND LIMBIC SYSTEM POSTSYNAPTIC DOPAMINE RECEPTORS.

THE EFFECT OF GAMMA-ACETYLENIC-GABA, AN ENZYME ACTIVATED IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE, ON DOPAMINE PATHWAYS OF THE EXTRAPYRAMIDAL AND LIMBIC SYSTEMS.

LIN-1418

STUDY OF SULTOPRIDE (LIN-1418) IN AGITATED STATES.

001722 02-14

PHARMACOLOGICAL EVIDENCE FOR A LINK BETWEEN THE CEREBELLAR CONTENT OF C-GMP AND THAT OF AN ENDOGENOUS PROTEIN KINASE

002031 03-03 LINKAGE

LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR BLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE IN THE FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE PROBAND

000619 01-11

EFFECT OF BACLOFEN (BF) (LIORESAL (R) ON DOPAMINERGIC SINGLE UNITS AND SIDMAN AVOIDANCE BEHAVIOR. 002300 03-04

LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUSION IN IMIPRAMINE POISONING 000477 01-05

LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUSION IN IMPRAMINE POISONING. AN IN-VITRO AND IN-VIVO STUDY 001503 02-05 EFFECT OF MITOCHONDRIAL LIPID PEROXIDATION ON MONOAMINE

OXIDASE.

002813 04-03

LIPIDOSIS INDUCED BY AMPHIPHILIC CATIONIC DRUGS.

003664 04-15

WALL STREET	
MEMBRANE LIPIDS AS INTRACELLULAR BINDERS OF CHLORPROMAZINE AND RELATED DRUGS.	CC
UPOFUSCIN 000095 01-03	TH
NEURONAL LIPOFUSCIN IN CENTROPHENOXINE TREATED RATS. 000303 01-03	LIT
EFFECTS OF REPEATED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS ON ADIPOSE TISSUE LIPOLYTIC ACTIVITY IN THE RAT.	LIT
IPOPHILIC 001179 02-03	ER
DIRECTIONAL LIPOPHILIC CHARACTER IN A SERIES OF PSYCHOTOMIMETIC PHENETHYLAMINE DERIVATIVES.	LIT
1POPHILICITY 001009 02-01	
THE ROLE OF SUBSTRATE LIPOPHILICITY IN DETERMINING TYPE 1 MICROSOMAL P450 BINDING CHARACTERISTICS.	LIT
IPOPROTEIN 002809 04-03	LIT
LIPOPROTEIN POTENTIATION OF THE CEREBROVASCULAR RESPONSE TO INTRAARTERIAL 5 HYDROXYTRYPTAMINE.	LIT
JPOTROPIN 001109 02-03	
GAMMA-ENDORPHIN, ALPHA-ENDORPHIN AND MET-ENKEPHALIN ARE FORMED EXTRACELLULARLY FROM LIPOTROPIN C-FRAGMENT. 001963 03-03	LIT
HIGH-PRESSURE LIQUID CHROMATOGRAPHIC MASS SPECTROMETRIC	IN
DETERMINATION OF DELTA9-TETRAHYDROCANNABINOL IN HUMAN PLASMA FOLLOWING MARIJUANA SMOKING.	PR
THE EXTRACTION AND ANALYSIS OF BENZODIAZEPINES IN TISSUES BY	TH
ENZYMIC DIGESTION AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY. 000928 01-16	RE
HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF DOTHIEPIN AND NORTHIADEN IN HUMAN PLASMA AND SERUM.	LIT
O01858 02-16 ACUTE LITHIUM-INDUCED PARKINSONISM PRECIPITATED BY LIQUID PROTEIN DIET.	SA
002685 03-15 MEASUREMENT OF PLASMA ANTIDEPRESSANT LEVELS BY HIGH- PERFORMANCE LIQUID CHROMATOGRAPHY.	PL
BIOANALYSIS AND PHARMACOKINETICS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN MAN BY MEANS OF LIQUID CHROMATOGRAPHY.	PL
002728 03-16	
IQUOR EFFECTS OF PROPYLBENZILYLCHOLINE MUSTARD ON INJECTION INTO THE LIQUOR SPACE OF CATS.	TH
003168 04-04	PH
LISURID (LYSENYL-SPOFA) IN THE TREATMENT OF ORGANIC PSYCHOSYNDROME IN INVOLUTION.	
A CONTROLLED STUDY OF LISURID IN HYPERACTIVE CHILDREN. 003580 04-11	AF
ISURIDE DIFFERENCES IN THE DOPAMINERGIC EFFECTS OF THE ERGOT	TH
DERIVATIVES BROMOCRIPTINE, LISURIDE AND D LSD AS COMPARED WITH APOMORPHINE.	Al
ACUTE EFFECTS OF LISURIDE (0.1 MG), AMANTADINE (100 MG) AND TRIHEXYPHENIDYL (5 MG) ON VERBAL ASSOCIATIONS.	PR
003630 04-14	Li
ADVERSE REACTIONS LITERATURE: A BIBLIOMETRIC ANALYSIS. 000999 01-17	PF
UTHIUM-CARBONATE USE IN CHILDREN AND ADOLESCENTS: A SURVEY OF THE LITERATURE. 002471 03-09	A
LITHIUM INHIBITION OF NOREPINEPHRINE AND DOPAMINE RECEPTORS.	LI
AN EXCITATORY ACTION OF IONTOPHORETICALLY ADMINISTERED LITHIUM ON MAMMALIAN CENTRAL NEURONES.	Al
EVIDENCE FOR MULTIPHASIC PRESYNAPTIC ADAPTATION: STUDIES WITH COCAINE AND LITHIUM.	
LETHAL EFFECTS OF PHYSOSTIGMINE PLUS LITHIUM IN RATS.	EF
000485 01-05 LITHIUM ABSORPTION, DISTRIBUTION AND CLEARANCE AND BODY TEMPERATURE IN RATS GIVEN LITHIUM PLUS HALOPERIDOL.	BR
RESPONSE TO LITHIUM IN A CASE OF L-DOPA-INDUCED PSYCHOSIS.	CC
000559 01-09	

Psychopharmacology Abstracts

COUPLES GROUP THERAPY AS AN ADJUNCT TO LITHIUM NOT THE MANIC PATIENT.	MAINTENANCE
THE IMPACT OF LITHIUM ON THE TREATMENT OF MANIC-EDISORDERS.	000562 01-09 DEPRESSIVE
LITHIUM AND THE TREATMENT OF ADOLESCENT MANIC-DE	000565 01-09 PRESSIVE
ILLNESS.	000569 01-09
LITHIUM AND EMOTIONAL DISORDER.	000573 01-09
ERYTHROCYTE/PLASMA LITHIUM RATIOS.	000586 01-09
LITHIUM PROPHYLAXIS IN THE TREATMENT OF CYCLOTHYM TEENAGERS.	MIA IN 000601 01-10
LITHIUM AND AGGRESSIVE BEHAVIOR IN PATIENTS WITH DEAFNESS.	EARLY TOTAL
LITHIUM PROPHYLAXIS FOR CHRONIC CLUSTER HEADACHE	
LITHIUM IN CHILD AND ADOLESCENT PSYCHIATRY. (UNPUT PAPER).	000641 01-11 BLISHED
LITHIUM TREATMENT OF HUNTINGTONS-CHOREA: A PLACE CONTROLLED CLINICAL TRIAL.	000657 01-11 BO-
INTRACELLULAR LITHIUM.	000663 01-11
PREDICTING THE OPTIMAL LITHIUM DOSAGE.	000691 01-13
THE SYSTEMIC EFFECTS OF LITHIUM.	000693 01-13
REPRESSION OF A LITHIUM PUMP AS A CONSEQUENCE OF	000709 01-13
INGESTION BY MANIC-DEPRESSIVE SUBJECTS.	
LITHIUM AND ERYTHROCYTE MEMBRANE CATION CARRIES NORMAL AND MANIC-DEPRESSIVE SUBJECTS.	
SALIVA LITHIUM LEVELS: CLINICAL APPLICATIONS.	000717 01-13
PLASMA PROLACTIN DURING LITHIUM TREATMENT.	000718 01-13
LITHIUM TRANSPORT IN RED BLOOD CELLS OF MANIC-DEPL PATIENTS.	000719 01-13 RESSIVE
PLASMA ALDOSTERONE AND MAGNESIUM IN SERUM AND DURING LITHIUM TREATMENT.	000724 01-13 URINE
THE RELATIONSHIP BETWEEN EXTRACELLULAR AND INTRA- LITHIUM CONCENTRATION IN HUMAN RED BLOOD CELLS STUDY.	000725 01-13 CELLULAR :: AN IN VITRO
PHARMACOGENETIC ASPECT OF RED BLOOD CELL LITHIUM MANIC-DEPRESSIVE PSYCHOSIS.	000731 01-13 INDEX IN
AFFECTIVE-ILLNESS TREATED WITH LITHIUM: EFFECTS ON 1 FUNCTION AND PSYCHIC STATUS.	000736 01-13 HYROID
THE DIAGNOSIS AND TREATMENT OF LITHIUM TOXICITY.	000774 01-14
ADVERSE EFFECTS OF LITHIUM TREATMENT.	000838 01-15
PREDICTION OF THE LITHIUM RATIO IN MAN BY MEANS O	000874 01-15 F AN IN VITRO
	000930 01-16
LITHIUM PROPHYLAXIS OF PERIODIC HYPERSOMNIA. PROPHYLACTIC VALUE OF LITHIUM IN MANIC-DEPRESSIVE	000936 01-17 PSYCHOSIS
GENETIC ASPECTS. ADJUSTMENT OF LITHIUM DOSE DURING LITHIUM-CHLORO	000952 01-17 THIAZIDE
THERAPY. LITHIUM TREATMENT OF CYCLICAL VOMITING IN A MENTA	000956 01-17 ALLY DEFECTIVE
PATIENT. ANALYSIS OF A SCHOOL OF THOUGHT ON THE EFFECTS OF	000977 01-17 LITHIUM ON
BEHAVIOR. EFFECTS OF LITHIUM ON THE ELEVATION OF FOREBRAIN 5 HYDROXYINDOLES BY TRYPTOPHAN.	000987 01-17
BRAIN DISTRIBUTION OF LITHIUM AND INDOLEAMINE MET DOGS AFTER CHRONIC LITHIUM ADMINISTRATION.	001086 02-03 ABOLISM IN
COMBINED EFFECT OF LITHIUM AND FLUPENTHIXOL ON STU- ADENYLATE-CYCLASE.	001108 02-03 RIATAL
The state of the s	001131 02-03

PREDICTION OF LITHIUM RESPONSE IN AFFECTIVE-DISORDERS THE EFFECT OF LITHIUM ON AN ANIMAL MODEL OF TARDIVE-DYSKINESIA 001167 02-03 EFFECT OF RUBIDIUM, LITHIUM AND CESIUM ON BRAIN ATPASE AND UNIPOLAR DICHOTOMY PROTEIN KINASES EFFECTS OF LITHIUM ON SEIZURE SUSCEPTIBILITY IN ALCOHOLIZED AND NONALCOHOLIZED RATS 001315 02-04 DISCIPLIER EFFECTS OF CHRONIC LITHIUM AND RUBIDIUM ADMINISTRATION UPON EXPERIMENTALLY-INDUCED CONFLICT BEHAVIOR 001391 02-04 LITHIUM: CLINICAL EFFECTS AND CEREBROSPINAL FLUID ACID MONOAMINE METABOLITES 001577 02-09 MOOD CHANGE AND MAGNESIUM: A POSSIBLE INTERACTION BETWEEN THE EFFECT OF LITHIUM MAGNESIUM AND LITHIUM? 001591 02-09 REDUCED RENAL CALCIUM EXCRETION DURING LITHIUM THERAPY 001597 02-09 LITHIUM IN THE TREATMENT OF A CHILD ABUSER 001598 02-09 PLASMA ALDOSTERONE DURING LITHIUM TREATMENT 001599 02-09 PLATELET MONOAMINE-OXIDASE ACTIVITY PREDICTS RESPONSE TO LITHIUM IN MANIC-DEPRESSIVE ILLNESS. 001607 02-09 ADDENDUM CONCERNING A PROPOSED MODEL FOR THE ACTION OF LITHILIAA 001640 02-13 LITHIUM THERAPY AND ALKALINE-EARTH METAL METABOLISM: A **BIOCHEMICAL SCREENING STUDY** 001644 02-13 DYSKINESIA A PROPOSED MODEL FOR THE ACTION OF LITHIUM 001648 02-13 LITHIUM SODIUM COUNTERTRANSPORT IN HUMAN RED CELLS AND IN VIVO LITHIUM DISTRIBUTION BETWEEN RED CELLS AND PLASMA. 001679 02-13 LITHIUM TREATMENT MODIFICATION OF SLEEP INDUCED IN ACUTE AND CHRONIC ADMINISTRATION OF LITHIUM. 001699 02-14 THE EFFECT OF LITHIUM ON LUTEINIZING HORMONE AND TESTOSTERONE IN MAN 001731 02-14 STIMULATION. LITHIUM USED WITH A DIURETIC 001757 02-15 LITHIUM 001760 02-15 PARTICULARITIES OF LITHIUM INTOXICATION IN ADVANCED AC 001772 02-15 ACTIVITY IN RAT BRAIN LITHIUM THERAPY OF EXTRAPYRAMIDAL MOVEMENT DISORDER 001774 02-15 ON THE SAFETY OF LONG-TERM TREATMENT WITH LITHIUM 001775 02-15 DIABETES-MELLITUS IN PATIENTS ON LITHIUM 001792 02-15 MERCURY CONTENT OF MEDICINAL LITHIUM PREPARATIONS 001797 02-15 A CASE OF CONSERVATIVELY MANAGED LITHIUM INTOXICATION 001811 02-15 LITHIUM INTOXICATION INDUCED BY DIETING AND SAUNAS 001839 02-15 DIGOXIN LITHIUM DRUG INTERACTION 001853 02-15 COMPUTER SIMULATION OF THE MOVEMENT OF LITHIUM ACROSS **ERYTHROCYTE MEMBRANES IN VITRO.** 001869 02-16 THE EFFECTS OF LITHIUM ON ATPASE ACTIVITY IN SUBCELLULAR FRACTIONS FROM RAT BRAIN 002038 03-03 THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON DOPAMINE METABOLISM IN RAT STRIATUM. 002039 03-03 THE ACUTE EFFECTS OF AMPHETAMINE, CHLORPROMAZINE AMITRIPTYLINE AND LITHIUM ON ADENOSINE-5-TRIPHOSPHATASE ACTIVITY IN THE CORTEX OF THE RAT BRAIN. 002094 03-03 EFFECTS OF LITHIUM ON GRANULOPOIESIS IN CULTURE 002105 03-03 THE EFFECT OF LITHIUM ON SEROTONIN METABOLISM IN THE BRAIN OF RATS WITH PARTICULAR ATTENTION TO ITS EFFECT UNDER THE MONOAMINE ALTERED CONDITIONS. 002110 03-03

INFLUENCE OF TRIIODOTHYRONINE (T3) ON THE RENAL ACTION OF

INHIBITION BY LITHIUM OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE

CIRCADIAN RHYTHM OF LITHIUM TOXICITY IN MICE

LITHIUM.

IN THE RAT BRAIN.

CALCIUM METABOLISM IN LITHIUM TREATED PATIENTS: RELATION TO 002420 03-09 OF RESPONSE. 002431 03-09 LITHIUM ERYTHROCYTE/PLASMA RATIO AS A PREDICTOR LITHIUM ERYTHROCYTE: PLASMA RATIO IN PRIMARY INTRAPSYCHIC AND FAMILY DYNAMIC PROCESSES IN AN ENDOGENOUS DEPRESSION PRECEDING MANIFESTATION OF THE ILLNESS AND TREATMENT OF HUMAN AGGRESSIVE BEHAVIOR: FOUR CASE STUDIES OF 002532 03-11 LITHIUM TRANSPORT ACROSS THE RED BLOOD CELL 002553 03-13 PLASMA RENIN SUBSTRATE DURING LITHIUM TREATMENT 002569 03-13 LITHIUM EFFECT ON TEMPERATURE RHYTHM IN PSYCHIATRIC PATIENTS.
002581 03-13
THE VALUE OF THE MMPI FOR DELINEATING SYMPTOMS UNIQUE TO POSITIVE LITHIUM RESPONDERS: A DRUG RESPONSE AND DIAGNOSTIC STUDY. (PH.D. DISSERTATION). 002638 03-14 EFFECTS OF LITHIUM IN HEALTHY TEST PERSONS. 002647 03-15 HEAT ILLNESS SYNDROME AND LITHIUM INTOXICATION 002669 03-15 DEANOL, LITHIUM AND PLACEBO IN THE TREATMENT OF TARDIVE-002677 03-15 LITHIUM INTOXICATION MASKED BY NEUROLEPTIC DRUGS WHEN LITHIUM DIURETIC COMBINATIONS ARE USED. 002682 03-15 HYPERTHYROIDISM AND A PARATHYROID ADENOMA COMPLICATING 002686 03-15 LITHIUM STIMULATION OF GRANULOPOIESIS. THE EFFECT OF LITHIUM ON AMPHETAMINE-INDUCED LOCOMOTOR 002791 04-02 THE EFFECT OF LITHIUM ON THE INCREASE IN FOREBRAIN 5
HYDROXYINDOLEACETIC-ACID PRODUCED BY RAPHE STIMULATION INFLUENCE OF LITHIUM ON DOPAMINE STIMULATED ADENYLATE-CYCLASE 002922 04-03 LITHIUM TRANSPORT FROM CEREBROSPINAL FLUID 002947 04-03 LITHIUM EFFECTS ON RAT BRAIN GLUCOSE METABOLISM IN LONG-TERM LITHIUM TREATED RATS STUDIED IN VIVO. THE DIFFERENTIAL EFFECT OF LITHIUM ON NORADRENALINE AND DOPAMINE SENSITIVE ACCUMULATION OF CYCLIC-AMP IN GUINEA-PIG 003063 04-03 EFFECTS OF LITHIUM ON THE MEMBRANE-BOUND MAGNESIUM DEPENDENT ATPASE OF MOUSE NEUROBLASTOMA CELLS 003087 04-03 MYOCARDIAL PHARMACOKINETICS OF LITHIUM IN VITRO 003414 04-05 MYOCARDIAL EFFECTS OF LITHIUM IN VITRO. LITHIUM NEUROTOXICITY. I. THE CONCENTRATION OF LITHIUM IN DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS ATOMIC ABSORPTION SPECTROPHOTOMETRY. 003432 04-06 LITHIUM RESPONSIVE DEPRESSION 003484 04-09 RETROSPECTIVE DIAGNOSIS OF HYPOMANIA FOLLOWING SUCCESSFUL
TREATMENT OF EPISODIC VIOLENCE WITH LITHIUM: A CASE REPORT.
003490 04-09 IQ AS A PREDICTOR OF ANTIDEPRESSANT RESPONSES TO LITHIUM 003492 04-09 PLASMA RENIN CONCENTRATION DURING LITHIUM THERAPY 003503 04-09 TREATMENT OF IMPRAMINE RESISTANT DEPRESSION AND LITHIUM REFRACTORY MANIA THROUGH DRUG INTERACTIONS. 003512 04-09 LITHIUM FEFLUX FROM FRYTHROCYTES INCUBATED IN VITRO DURING LITHIUM-CARBONATE ADMINISTRATION. 003518 04-09 LITHIUM DOSAGE AND AGE OF PATIENTS. 003528 04-09 HALOPERIDOL AND LITHIUM BLOCKING OF THE MOOD RESPONSE TO INTRAVENOUS METHYLPHENIDATE. 003529 04-09

002119 03-03

002344 03-05

002357 03-05

LITHIUM IN THE TREATMENT OF PERIODIC CATATONIA: A CASE REPORT. 003530 04-09 HISTOCOMPATIBILITY ANTIGENS IN LITHIUM TREATED MANIC-DEPRESSIVE PATIENTS. 003533 04-09 PROPHYLACTIC LITHIUM TREATMENT OF DRUG ABUSE 003564 04-11 THYROID AUTOANTIBODY LEVELS DURING LITHIUM THERA 003650 04-15 A CASE OF LITHIUM POISONING? A CAUTIONARY TALE HYPEROSMOLALITY COMPLICATING RECOVERY FROM LITHIUM TOXICITY. 003665 04-15 LITHIUM FOR STEROID-INDUCED PSYCHOSIS 003679 04-15 LITHIUM AND CRISIS INTERVENTION: DAMPING AFFECTIVE OVERLOAD. 003717 04-17 LITHIUM-CARBONATE

POST HEAD TRAUMA SYNDROME IN AN ADOLESCENT TREATED WITH

LITHIUM-CARBONATE -- CASE REPORT.

DODGEO D. 000560 01-09 MANIA DURING MAINTENANCE HEMODIALYSIS SUCCESSFULLY TREATED WITH ORAL LITHIUM-CARBONATE. 000582 01-09 LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR BUNDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE IN THE FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE 000619 01-11 CONCOMITANT ADMINISTRATION OF HALOPERIDOL AND LITHIUM-CARBONATE IN ACUTE MANIA. EVALUATION OF LITHIUM-CARBONATE IN THE MANAGEMENT OF GILLES-DE-LA-TOURETTES SYNDROME. UTHIUM-CARBONATE AND METHYLDOPA: APPARENT INTERACTION IN CARDIAC ARRHYTHMIA AND HYPOPOTASSEMIA IN ASSOCIATION WITH LITHIUM-CARBONATE OVERDOSE. 000843 01-15 LITHIUM-CARBONATE INTAKE DURING PREGNANCY LEADING TO LARGE GOITER IN A PREMATURE INFANT. 000869 01-15 PROFOUND HYPOTHERMIA ON COMBINED LITHIUM-CARBONATE AND DIAZEPAM TREATMENT. 000870 01-15 URINARY CARBON-DIOXIDE TENSION IN LITHIUM-CARBONATE TREATED PATIENTS 000882 01-15 LITHIUM-CARBONATE ATTENUATION OF CHEMOTHERAPY-INDUCED NEUTROPENIA 000898 01-15 THE EFFECT OF SUBCHRONIC ADMINISTRATION OF LITHIUM-CARBONATE ON THE PHARMACOLOGICAL ACTIVITY OF D AMPHETAMINE. 001295 02-04 MANIA IN CHILDHOOD. II. THERAPEUTIC TRIAL OF LITHIUM-CARBONATE AND FURTHER DESCRIPTION OF MANIC-DEPRESSIVE ILLNESS IN 001578 02-09 LITHIUM-CARBONATE IN THE MANAGEMENT OF HYPERACTIVE AGGRESSIVE BEHAVIOR OF THE MENTALLY RETARDED. 001713 02-14 LITHIUM-CARBONATE IN CHEMOTHERAPY-INDUCED NEUTROPENIA. 001809 02-15 USE OF LITHIUM-CARBONATE WITH RETARDED ACTION (MICALITE) IN PATIENTS WITH AFFECTIVE-PSYCHOSES. 002444 03-09 LITHIUM-CARBONATE USE IN CHILDREN AND ADOLESCENTS: A SURVEY OF THE LITERATURE.

COMBINED HALOPERIDOL AND LITHIUM-CARBONATE IN TREATING MANIC

MORBIDITY SUPPRESSIVE EFFECT OF LITHIUM-CARBONATE IN CYCLOID

LITHIUM-CARBONATE AND BRAIN FUNCTION: I. CEREBRAL EVOKED-POTENTIALS, EEG, AND SYMPTOM CHANGES DURING LITHIUM-CARBONATE TREATMENT.

ALCOHOL CONSUMPTION IN RATS TREATED WITH LITHIUM-CARBONATE OR RUBIDIUM-CHLORIDE.

REPEATED SUSTAINED-RELEASE LITHIUM-CARBONATE ADMINISTRATION TO CATS.

TREATMENT OF LEUKOPENIA WITH LITHIUM-CARBONATE: PRELIMINARY REPORT.

	Psychopharmacology	Abstracts
	LITHIUM EFFLUX FROM ERYTHROCYTES INCUBATED IN VIT	RO DURING
	PAPILLEDEMA FOLLOWING THERAPEUTIC DOSAGES OF LITTICARBONATE.	003518 04-09 HIUM-
	LITHIUM-CARBONATE AND TETRACYCLINE INTERACTION.	003662 04-15
17	HIUM-CARSONATE-INDUCED	003667 04-15
	LITHIUM-CARBONATE-INDUCED HYPERCALCEMIA. A LITHIUM-CARBONATE-INDUCED INCREASE IN THE MOUS	001755 02-15
	HYDROXYTRYPTAMINE METABOLISM.	002153 03-03
IT	HIUM-CHLORIDE EFFECT OF AGE AND ROUTE OF ADMINISTRATION ON LD50 CHLORIDE IN THE RAT.	OF LITHIUM-
	EFFECT OF LITHIUM-CHLORIDE ON CERTAIN INDICES OF CA	001517 02-05 RDIAC
	EFFECT OF LITHIUM-CHLORIDE ON THE NEUROSECRETORY S RAT HYPOTHALAMUS.	001521 02-05 SYSTEM OF THE
	EFFECT OF LITHIUM-CHLORIDE ON ADRENOCORTICAL FUNC	001525 02-05 TION IN THE
	INHIBITION OF FIGHTING IN ISOLATED MICE FOLLOWING R ADMINISTRATION OF LITHIUM-CHLORIDE.	002049 03-03 EPEATED
	ACUTE AND CHRONIC EFFECTS OF LITHIUM-CHLORIDE ON I	003282 04-04 PHYSIOLOGICAL
IT	HIUM-CHLOROTHIAZIDE	003600 04-13
	ADJUSTMENT OF LITHIUM DOSE DURING LITHIUM-CHLORG THERAPY.	
IT	HIUM-INDUCED TIME-COURSE OF LITHIUM-INDUCED ALTERATIONS IN REN.	000956 01-17
	ENDOCRINE FUNCTION IN NORMAL AND BRATTLEBORO HYPOTHALAMIC DIABETES-INSIPIDUS.	
	LITHIUM-INDUCED AGGRAVATION OF TARDIVE-DYSKINESI	000048 01-03 A.
	LEAD ENHANCES LITHIUM-INDUCED POLYDIPSIA.	000818 01-15
	PATHOGENESIS OF LITHIUM-INDUCED POLYURIA.	001409 02-04
	ON THE PREVALENCE, DIAGNOSIS AND MANAGEMENT OF INDUCED HYPOTHYROIDISM IN PSYCHIATRIC PATIENTS.	
	DDAVP AND LITHIUM-INDUCED POLYURIA/POLYDIPSIA.	001805 02-15
	ACUTE LITHIUM-INDUCED PARKINSONISM PRECIPITATED B	001851 02-15 Y LIQUID
	LITHIUM-INDUCED HYPOTHYROIDISM.	002685 03-15
	WIIIM ION	002712 03-15

ERYTHROCYTE ACCUMULATION OF THE LITHIUM-ION IN CONTROL SUBJECTS AND PATIENTS WITH PRIMARY AFFECTIVE-DISORDER 003519 04-09

LITHIUM-IONS
TRANSFER OF LITHIUM-IONS ACROSS THE ERYTHROCYTE MEMBRANE 001658 02-13 STIMULATION BY LITHIUM-IONS OF THE INCORPORATION OF C14-GLUCOSE INTO GLYCOGEN IN RAT BRAIN SLICES.

EFFECTS OF LITHIUM-SALTS ON MEMORY.

SUBSTRATE SPECIFICITY

003015 04-03 001798 02-15

002471 03-09

002525 03-11

002560 03-13

003159 04-04

003413 04-05

LITTER EFFECTS OF CHRONIC IMIPRAMINE AND CLOMIPRAMINE ORAL ADMINISTRATION ON MATERNAL BEHAVIOR AND LITTER DEVELOPMENT.

002202 03-04 MONOAMINE-OXIDASE INHIBITION IN BRAIN AND LIVER PRODUCED BY BETA-CARBOLINES: STRUCTURE-ACTIVITY RELATIONSHIPS AND

000064 01-03 THE METABOLISM OF D-, L- AND DL-METHADONE IN THE ISOLATED

PERFUSED RAT LIVER. 000118 01-03 ROLE OF LIVER CYTOSOLIC ALDEHYDE-DEHYDROGENASE ISOZYMES IN CONTROL OF BLOOD ACETALDEHYDE CONCENTRATIONS.

000222 01-03 FIRST-PASS ELIMINATION OF C14-IMIPRAMINE IN ISOLATED PERFUSED RAT LIVER

001052 02-03

003448 04-07

CHANGES IN LIVER FUNCTION IN ACUTE POISONING BY BARBITURATE, PESEDDINE AND AMPHETAMINE 001094 02-03 PHARMACOKINETICS OF SOME HOMOLOGOUS SERIES OF BARBITURATES IN THE INTACT RAT AND IN THE ISOLATED PERFUSED RAT LIVER. 001292 02-03 HALOPERIDOL-INDUCED LIVER DISEASE 001776 02-15 LOCI EFFECT OF MATERNAL MORPHINE ADMINISTRATION ON FETAL AND NEONATAL RAT LIVER TYROSINE-AMINOTRANSFERASE. 002011 03-03 ACTION OF NOREPINEPHRINE ON MICROCIRCULATION AND PO2 DISTRIBUTION IN THE ISOLATED PERFUSED RAT LIVER. 002059 03-03
ENHANCEMENT OF THE ANTIDEPRESSANT RESPONSE TO L TRYPTOPHAN BY A LIVER PYRROLASE INHIBITOR: A RATIONAL TREATMENT APPROACH. 002464 03-09 THE EFFECT OF PHENOBARBITAL AND CARBON-TETRACHLORIDE ON FATTY-ACID CONTENT AND COMPOSITION OF PHOSPHOLIPIDS FROM THE ENDOPLASMIC RETICULUM OF RAT LIVER. 002888 04-03 SUBSTRATE SELECTIVE ACTIVATION OF RAT LIVER MITOCHONDRIAL MONOAMINE-OXIDASE BY OXYGEN. 002912 04-03 NONSPECIFIC INHIBITION OF SOME RAT LIVER MEMBRANE-BOUND ENZYMES BY AN ADENYLATE-CYCLASE INHIBITOR, RMI-12330-A EFFECT OF RESERPINE ON THE MONOAMINE-OXIDASE (MAO) ACTIVITY IN RAT LIVER AND BRAIN. 003125 04-03 LOBSTER EFFECTS OF FLURAZEPAM ON AMINO-ACID EVOKED RESPONSES RECORDED FROM THE LOBSTER MUSCLE AND THE FROG SPINAL CORD 002115 03-03 EFFECT OF LOCAL APPLICATION OF APOMORPHINE TO THE CORPUS STRIATUM AND TO THE NUCLEUS-ACCUMBENS ON THE RESERPINE-INDUCED PIGIDITY IN PATS 001021 02-02 THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LOCAL CEREBRAL GLUCOSE UTILISATION OF THE RAT. LOCAL PERFUSION OF NORADRENALINE MAINTAINS VISUAL CORTICAL

003045 04-03 MUSCARINIC RECEPTOR MEDIATED CYCLIC-GMP FORMATION BY CULTURED NERVE CELLS -- IONIC DEPENDENCE AND EFFECTS OF LOCAL

003064 04-03 LOCAL CEREBRAL GLUCOSE UTILIZATION FOLLOWING INJECTION OF BETA-ENDORPHIN INTO PERIAQUEDUCTAL GRAY MATTER IN THE RAT. INTERANIMAL AGGRESSION AND HYPERREACTIVITY FOLLOWING HYPOTHALAMIC INFUSION OF LOCAL ANESTHETIC IN THE RAT. 003157 04-04

LOCALISED DOPAMINE RECEPTORS LOCALISED ON CEREBRAL CORTICAL AFFERENTS TO RAT CORPUS-STRIATUM 003080 04-03

BRAIN. III. THE TELENCEPHALON.

SPECIFIC LOCALIZATION OF DRUGS AT THE HYPOPHYSIS LEVEL AND SIDE-EFFECTS: THE CASE OF NEUROLEPTICS. 000053 01-03 AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT

001048 02-03 REGIONAL LOCALIZATION OF C14-MESCALINE IN RABBIT BRAIN AFTER INTRAVENTRICULAR ADMINISTRATION: EFFECTS OF CHLORPROMAZINE AND IPRONIAZID PRETREATMENT

001240 02-03 SOMATOSTATIN: ELECTRON MICROSCOPE IMMUNOHISTOCHEMICAL LOCALIZATION IN SECRETORY NEURONS OF RAT HYPOTHALAMUS. 001948 03-01 AUTORADIOGRAPHIC LOCALIZATION OF H3-RESERPINE BINDING SITES IN

RAT BRAIN. MONOAMINE-OXIDASE IN RAT RETICULOCYTES: SUBCELLULAR LOCALIZATION AND IDENTIFICATION OF ISOENZYMES.

002134 03-03 CELLULAR LOCALIZATION OF H3-DIAZERAM RECEPTORS

002943 04-03 SUBCELLULAR LOCALIZATION OF C14-METHAQUALONE IN MOUSE BRAIN: EFFECTS OF HEPATIC MICROSOMAL ENZYME INHIBITION.

REGIONAL LOCALIZATION OF HALOPEMIDE, A NEW PSYCHOTROPIC AGENT. IN THE RAT BRAIN. 002989 04-03

LOCALIZATION OF RECEPTORS FOR THE DIPSOGENIC ACTION OF ANGIOTENSIN-II IN THE SUBFORNICAL ORGAN OF RAT. 003361 04-04 LOCATION

CARBACHOL ELICITED MOUSE-KILLING IN THE RAT: ANIMALS ATTACKED AND WOUND LOCATION. 000349 01-04

LOCATION PREFERENCE AND FLAVOR AVERSION REINFORCED BY AMPHETAMINE IN RATS. 001443 02-04

EFFECTS OF D AMPHETAMINE ON CONCURRENT SELF-STIMULATION OF FOREBRAIN AND BRAINSTEM LOCI.

EVIDENCE FOR DISTINCT SPINAL LOCOMOTION GENERATORS SUPPLYING RESPECTIVELY FORELIMBS AND HINDLIMBS IN THE RABBIT. 003124 04-03

BRAIN MECHANISMS OF AMPHETAMINE-INDUCED ANOREXIA LOCOMOTION, AND STEREOTYPY: A REVIEW.

003189 04-04 INTERACTION BETWEEN D AMPHETAMINE AND ETHANOL WITH RESPECT TO LOCOMOTION, STEREOTYPIES, ETHANOL SLEEPING TIME, AND THE KINETICS OF DRUG ELIMINATION.

LOCOMOTIVE THE INFLUENCE OF CAFFEINE AND THEOBROMINE ON LOCOMOTIVE ACTIVITY AND THE BRAIN C-GMP/C-AMP RATIO IN WHITE MICE 000275 01-03

LOCOMOTOR COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMOTOR ACTIVITY, ANALGESIA AND PRIMARY AND PROTRACTED PHYSICAL DEPENDENCE IN SIX MOUSE STRAINS.

LOCOMOTOR STIMULATION BY L-DOPA: RELATIVE IMPORTANCE OF NORADRENALINE RECEPTOR ACTIVATION

001300 02-04 THE EFFECT OF BROMOCRIPTINE ON LOCOMOTOR ACTIVITY AND CEREBRAL CATECHOLAMINES IN RODENTS

001346 02-04 EFFECT OF D AMPHETAMINE ON LOCOMOTOR ACTIVITY OF LEAD FED RABBIT NEONATES

001406 02-04 APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR, LOCOMOTOR STIMULATION AND HYPOTHERMIA IN SPONTANEOUS HYPERTENSIVE RATS AND NORMOTENSIVE WISTAR RATS.

001413 02-04 BIPHASIC EFFECTS OF APOMORPHINE ON LOCOMOTOR ACTIVITY IN RATS

ANALYSIS OF THE ROLE PLAYED BY THE SUBSTANTIA-NIGRA IN THE MEDIATION OF INGESTIVE, LOCOMOTOR, AND ROTATIONAL BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL MANIPULATIONS. (PH.D. DISSERTATION)

002247 03-04 AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY AND STEREOTYPY AFTER KAINIC-ACID LESIONS OF THE STRIATUM.

002279 03-04 DECREASED LOCOMOTOR ACTIVITY AND ATTENUATION OF AMPHETAMINE HYPERACTIVITY WITH INTRAVENTRICULAR INFUSION OF SEROTONIN IN THE RAT

002328 03-04 EFFECT OF AN ANTIPSYCHOTIC AND OTHER CLASSES OF DRUGS ON SPONTANEOUS LOCOMOTOR ACTIVITY AND NEUROTOXICITY IN MICE 002369 03-06

THE EFFECT OF LITHIUM ON AMPHETAMINE-INDUCED LOCOMOTOR

POTENTIATION BY NEUROLEPTIC AGENTS OF THE INHIBITORY ACTION OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE

002832 04-03 EFFECTS OF BENZAZEPINE (SCH-12679) ON SHOCK-INDUCED FIGHTING AND LOCOMOTOR BEHAVIOR IN RATS.

003166 04-04 EFFECT OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE.

003172 04-04 INFLUENCE OF CATECHOLAMINES ON DEXAMPHETAMINE-INDUCED CHANGES IN LOCOMOTOR ACTIVITY.

003239 04-04
SUPPRESSION OF LOCOMOTOR ACTIVITY IN SPARROWS BY TREATMENT

003243 04-04 THE RELATIONSHIP BETWEEN PIPRADROL-INDUCED RESPONDING FOR ELECTRICAL BRAIN STIMULATION, STEREOTYPED BEHAVIOUR AND LOCOMOTOR ACTIVITY

003347 04-04 FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON LOCOMOTOR ACTIVITY AND AVOIDANCE BEHAVIOUR OF RESERPINIZED MICE. 003351 04-04

CHANGES IN LOCOMOTOR ACTIVITY AND NALOXONE-INDUCED JUMPING IN MICE PRODUCED BY WIN-35197-2 (ETHYLKETAZOCINE) AND 003376 04-04

EVIDENCE FOR NOREPINEPHRINE MEDIATED COLLATERAL INHIBITION OF LOCUS-COERULEUS NEURONS.

IONTOPHORESIS OF METHIONINE-ENKEPHALIN IN THE LOCUS-COERULEUS

POTENTIATION OF MORPHINE ANALGESIA BY LESIONS OF THE NUCLEUS LOCUS-COERULEUS.

001142 02-03 BEHAVIORAL EFFECTS OF NEUROLEPTICS, APOMORPHINE AND
AMPHETAMINE AFTER BILATERAL LESION OF THE LOCUS-COERULEUS IN

601393 02-04
EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D AMPHETAMINE
ON SELF-STIMULATION OF THE SUBSTANTIA-NIGRA AND LOCUS-

002218 03-04 ALTERATIONS IN THE FUNCTION OF THE NUCLEUS LOCUS-COERULEUS: A
POSSIBLE MODEL FOR STUDIES OF ANXIETY.

ACTIVATION OF AN IHHIBITORY NORADRENERGIC PATHWAY PROJECTING FROM THE LOCUS-COERULEUS TO THE CINGULATE CORTEX OF THE RAT. 002895 04-03

ATONIA AFTER CARBACHOL MICROINJECTIONS NEAR THE LOCUS-COERULEUS IN CATS. 003381 04-04

LOFEPRAMIN
DOUBLE-BUIND TRIALS OF A NEW TRICYCLIC ANTIDEPRESSANT
(LOFEPRAMIN) AND A TETRACYCLIC ANTIDEPRESSANT (MAPROTILINE).
000607 01-10

TOLERANCE TO MORPHINE ANALGESIA AND IMMOBILITY MEASURED IN RATS BY CHANGES IN LOG-DOSE-RESPONSE CURVES.

003307 04-04 THE PRODUCTION OF AN ALTERNATIVE LABORATORY MODEL OF THE PARKINSON SYNDROME USING A NEW BENZYLIMIDOYLUREA DERIVATIVE LON-954.

000083 01-03

CENTRAL TRANSMITTER INVOLVEMENT IN LON-954-INDUCED TREMOROGENESIS.

000342 01-04 THE PHARMACOLOGY OF A NEW POTENT, LONG-ACTING NEUROLEPTIC,

PIFLUTIXOL 001035 02-02 ANTIPARKINSONIAN DRUG ADMINISTRATION AND PLASMA LEVELS OF PENFLURIDOL, A NEW LONG-ACTING NEUROLEPTIC.

001559 02-08 1-3 PHENOTHIAZINYLPROPYL-PIPERIDINYLPHENYLMETHANONES, A NOVEL CLASS OF LONG-ACTING NEUROLEPTIC AGENTS.

001942 03-01 MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. A STUDY WITH THE LONG-ACTING THIOXANTHENE DERIVATIVE, CIS-CLOPENTHIXOL-DECANOATE SORDINOL DEPOT.

LONG-ACTING ORAL VS INJECTABLE ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENICS: A ONE-YEAR DOUBLE-BLIND COMPARISON IN MULTIPLE EPISODE SCHIZOPHRENICS.

003467 04-08 STANDARD AND LONG-ACTING DEPOT NEUROLEPTICS IN CHRONIC SCHIZOPHRENICS: AN 18-MONTH OPEN MULTICENTRIC STUDY PLASMA FLUPHENAZINE CONCENTRATIONS AFTER INJECTION OF LONG

ACTING ESTERS. 003590 04-13 ASSESSMENT OF LONG-ACTING NEUROLEPTICS METHODS AND

PROBLEMS. 003693 04-16

PROBLEMS ENGENDERED BY ADMINISTRATION OF LONG-ACTION NEUROLEPTICS. 001922 02-17

LONG-LASTING EVIDENCE FOR SELECTIVE AND LONG-LASTING STIMULATION OF REGULATORY DOPAMINE RECEPTORS BY BROMOCRIPTINE (CB-154) 002002 03-03

FAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS UNDER LONG-TERM TRAINING. 000034 01-

LONG-TERM BEHAVIORAL CHANGES IN THE RHESUS MONKEY AFTER MULTIPLE DAILY INJECTIONS OF D METHYLAMPHETAMINE. 000359 01-04

Psychopharmacology Abstracts

LONG-TERM BEHAVIOURAL AND BIOCHEMICAL EFFECTS FOLLOWING PROLONGED TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN RATS.

000420 01-04 HALOPERIDOL: EFFECT OF LONG-TERM TREATMENT ON RAT STRIATAL DOPAMINE SYNTHESIS AND TURNOVER.

000481 01-05 A LONG-TERM FOLLOW-UP OF SCHIZOPHRENICS TREATED WITH REGRESSIVE ECT.

000526 01-08 LONG-TERM TREATMENT OF SCHIZOPHRENIA IN MEDICAL PRACTICE. 000529 01-08 STUDY OF LONG-TERM HASHISH USERS IN GREECE: SUMMARY AND DISCUSSION.

LONG-TERM EFFICACY AND SAFETY OF TRIAZOLAM AND FLURAZEPAM. 000643 01-11

SOME CONTINGENCIES AFFECTING THE UTILIZATION OF TRANQUILIZERS IN LONG-TERM CARE OF THE ELDERLY.

000649 01-11 INTERCORRELATIONS BETWEEN PHYSIOLOGICAL AND PSYCHOLOGICAL
EFFECTS OF MARIJUANA, HASHISH, AND THC-DELTA9 IN LONG-TERM
HASHISH USERS.

000695 01-13 II. CLINICAL ELECTROENCEPHALOGRAPHY AND ECHOENCEPHALOGRAPHY IN LONG-TERM HASHISH USERS.

000723 01-13 ACUTE EEG EFFECTS OF CANNABIS PREPARATIONS IN LONG-TERM

000744 01-13 MARIJUANA EFFECTS ON LONG-TERM MEMORY ASSESSMENT AND

000755 01-14 LONG-TERM TREATMENT WITH NEUROLEPTIC DRUGS.

000768 01-14 PERSONALITY MODIFICATIONS DUE TO LONG-TERM
PSYCHOPHARMACOTHERAPY: IN CASE OF CHRONIC SCHIZOPHRENIA

000773 01-14 SUBJECTIVE EXPERIENCES OF CANNABIS USE IN LONG-TERM USERS 000776 01-14

STUDY OF NIGHT SLEEP DURING LONG-TERM GRADUAL REDUCTION IN NEUROLEPTIC THERAPY IN CHRONIC SCHIZOPHRENICS. 000852 01-15

THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (SECOND REPORT) — EFFECTS ON PUPIL FUNCTIONING. 000877 01-15

THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (FIRST REPORT).

000878 01-15 ON PSYCHOLOGICAL SYMPTOMS IN BROMIDE INTOXICATION — ONE CASE OF HIGH DOSE, LONG-TERM BROMIDE INTOXICATION WHICH SHOWED HALLUCINATION AND DELUSION SYMPTOMS.

000880 01-15 LONG-TERM CHANGES IN THE SENSITIVITY OF PRE- AND POSTSYNAPTIC DOPAMINE RECEPTORS IN MOUSE STRIATUM EVIDENCED BY BEHAVIORAL AND BIOCHEMICAL STUDIES.

001187 02-03 BRAIN NEUROTRANSMITTER RECEPTORS AFTER LONG-TERM HALOPERIDOL: DOPAMINE, ACETYLCHOLINE, SEROTONIN, ALPHA NORADRENERGIC AND NALOXONE RECEPTORS.

001200 02-03 LONG-TERM ELIMINATION OF VIOLENT BEHAVIOUR BY THE INTERACTION OF PSYCHOPHARMACOLOGIC AND PSYCHOSOCIAL THERAPY.

001333 02-04 TREATMENT OF CHRONIC SCHIZOPHRENICS WITH THE ORAL LONG-TERM NEUROLEPTIC PENFLURIDOL IN AN OPEN STUDY.

001563 02-08 LONG-TERM TREATMENT OF SCHIZOPHRENIA WITH PENFLURIDOL

001565 02-08 PLASMA BUTAPERAZINE LEVELS IN LONG-TERM CHRONIC NONRESPONDING SCHIZOPHRENICS.

001569 02-08 LONG-TERM MAINTENANCE DRUG THERAPY IN RECURRENT AFFECTIVE-ILLNESS: CURRENT STATUS AND ISSUES.

001600 02-09 CLINICAL PHARMACOKINETICS OF LORAZEPAM. IV. LONG-TERM ORAL ADMINISTRATION.

001664 02-13 ON THE SAFETY OF LONG-TERM TREATMENT WITH LITHIUM

001775 02-15 POTENTIAL UNTOWARD EFFECTS OF LONG-TERM USE OF FLURAZEPAM IN

ON LONG-TERM MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY: THE COMBINED ADMINISTRATION OF ANTIPARKINSONS DRUGS.

001879 02-17

A DEBATE ON MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY --REFLECTIONS ON THE SO-CALLED LONG-TERM SATURATION DOES LONG-TERM TREATMENT WITH AMITRIPTYLINE ALTER THE MONOAMINE-DYIDASE OF BAT TRANSPORTED TO THE THE MONOAMINE-DYIDASE OF BAT TRANSPORTED TO THE 002042 03-03 THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MALE EFFECTIVENESS OF TEMAZEPAM WITH SHORT-TERM, INTERMEDIATE-TERM, AND LONG-TERM USE: SLEEP LABORATORY EVALUATION. 002608 03-14 A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE LONG-TERM EFFECTS OF CLOZAPINE UPON SLEEP PATTERNS OF NORMAL YOUNG ADULTS. 002640 03-14 THE PROBLEM OF PRENATAL DAMAGE FROM LONG-TERM ANTIEPILEPTIC DRUG TREATMENT CLINICAL LABORATORY STUDIES WITH SPECIAL REGARD TO HEPATIC METABOLISM IN SCHIZOPHRENICS ON OUTPATIENT LONG-TERM NEUROLEPTIC MEDICATION. 002667 03-15 AUTONOMOUS NERVOUS FUNCTION OF LONG-TERM USERS OF PSYCHOTROPIC DRUGS, THIRD REPORT -- PUPILOGRAM **OBSERVATIONS** LEVODOPA IN PARKINSON DISEASE: A LONG-TERM APPRAISAL OF MORTALITY SHORT-TERM AND LONG-TERM EFFECTS OF CEREBROLYSINE ON EVOKED CORTICAL POTENTIALS IN RATS. 002858 04-03 HYPOTENSION AND HYPOTHALAMIC AMINE METABOLISM AFTER LONG-TERM ALPHA-METHYLDOPA INFUSIONS. 002014 04-03 EVIDENCE FOR CELL LOSS IN CORPUS-STRIATUM AFTER LONG-TERM TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) 003030 04-03 LITHIUM EFFECTS ON RAT BRAIN GLUCOSE METABOLISM IN LONG-TERM LITHIUM TREATED RATS STUDIED IN VIVO. 003046 04-03 LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO P CHLOROAMPHETAMINE ON CENTRAL SEROTONERGIC MECHANISMS IN MICE 003098 04-03 THE SOCIAL OUTCOME OF PATIENTS IN A TRIAL OF LONG-TERM CONTINUATION THERAPY IN SCHIZOPHRENIA: PIMOZIDE VS. 003455 04-08 A LONG-TERM COMPARATIVE TRIAL OF PENFLURIDOL AND FLUPHENAZINE-DECANOATE IN SCHIZOPHRENIC OUTPATIENTS 003459 04-08 PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATIENTS DURING LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS: DISSOCIATION BETWEEN LIGHT AND NEAR VISION REACTIONS. AMP SYSTEM: LONGITUDINAL COURSE STUDIES OF PSYCHOPATHOLOGIC AND SOMATIC SYMPTOMS. AN EMPIRIC INVESTIGATION OF THE ROBLEM OF SIDE-EFFECTS. 000797 01-15 SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION. 002052 03-03 ABSORPTION AND METABOLISM OF THE PHENOTHIAZINE DRUG PERAZINE IN THE RAT INTESTINAL LOOP. 000063 01-03 DIFFERENTIAL EFFECTS OF A SINGLE DOSE OF IMIPRAMINE AND LOPRAMINE IN HEALTHY SUBJECTS VARYING IN THEIR LEVEL OF DEPRESSION. 002446 03-09

A COMPARATIVE CLINICAL STUDY FOR THE EVALUATION OF ANTIANXIETY AGENTS, (LORAZEPAM, DIAZEPAM AND PLACEBO), IN

CLINICAL PHARMACOKINETICS OF LORAZEPAM. III. INTRAVENOUS

CLINICAL PHARMACOKINETICS OF LORAZEPAM. IV. LONG-TERM ORAL

LORAZEPAM IN ANXIETY WITH GI DISORDERS.

INJECTION. PRELIMINARY RESULTS.

NEUROSIS

ADMINISTRATION

SEQUELAE AFTER THE INTRAVENOUS INJECTION OF THREE BENZODIAZEPINES -- DIAZEPAM, LORAZEPAM, AND FLUNITRAZEPAM 001785 02-15 A STUDY OF THE MANAGEMENT OF ANXIETY WITH LORAZEPAM EFFECTS OF LORAZEPAM ON HYPERACTIVITY IN RETARDED CHILDREN.
002643 03-14 MANAGEMENT OF ACUTE ANXIETY SYNDROME WITH PARENTERALLY ADMINISTERED LORAZEPAM. 003539 04-10 LORDOSIS LORDOSIS REFLEX, SEXUAL RECEPTIVITY, AND FEEDING: ESTROGEN RESPONSIVITY IN MALE AND FEMALE RATS. THE EFFECTS OF HORMONES AND MORPHINE ON BOTH ANALGESIA AND THE LORDOSIS RESPONSE PRODUCED BY CERVICAL PROBING IN THE 001445 02-04 FACILITATION OF LORDOSIS BEHAVIOR BY CLONIDINE IN FEMALE ROLE OF HYPOTHALAMIC SEROTONERGIC RECEPTORS IN THE CONTROL OF LORDOSIS BEHAVIOR IN THE FEMALE RAT. 003220 04-04 DELTA9-TETRAHYDROCANNABINOL ENHANCEMENT OF LORDOSIS
BEHAVIOR IN ESTROGEN TREATED FEMALE RATS. 003230 04-04 LOSE BEING A PATIENT IN A DRUG TRIAL: DO YOU LOSE SOMETHING? 000929 01-16 LOSS THE DIFFERENTIAL EFFECTS OF MECLOFENOXATE ON MEMORY LOSS IN THE ELDERLY. PLASMA FENFLURAMINE LEVELS, WEIGHT LOSS, AND SIDE-EFFECTS. 001790 02-15 EFFECT OF P-CHLOROPHENYLALANINE ON THE LOSS AND MAINTENANCE OF TOLERANCE TO ETHANOL. 002014 03-03 WEIGHT LOSS AND A CONCOMITANT CHANGE IN PLASMA TRICYCLIC LEVELS. 002441 03-09 LOSS OF INFORMATION INDUCED BY REDUCTION OF DATA IN THE LABORATORY LANGUAGE METHOD. 002624 03-14 LOSS OF STRIATAL DOPAMINERGIC RECEPTORS AFTER INTRASTRIATAL KAINIC-ACID INJECTION. EVIDENCE FOR CELL LOSS IN CORPUS-STRIATUM AFTER LONG-TERM TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN RATS 003030 04-03 DEPRENIL: LOSS OF SELECTIVITY FOR INHIBITION OF B-TYPE MAO AFTER REPEATED TREATMENT 003131 04-03 THE INFLUENCE OF DIHYDROERGOTOXINE-MESYLATE ON THE LOW-KM
PHOSPHODIESTERASE OF CAT AND RAT BRAIN IN VITRO. 002008 03-03 HIGH-POTENCY AND LOW-POTENCY NEUROLEPTICS IN ELDERLY PSYCHIATRIC PATIENTS. 003450 04-08 LOWERED INHIBITION OF CA45 MOVEMENTS BY LOWERED TEMPERATURE OR LANTHANUM IN RAT BRAIN SLICES. 003135 04-03 LOWERED ERYTHROCYTE SEDIMENTATION RATE WITH SODIUM 003672 04-15 LOWERING LOWERING OF EPINEPHRINE CONCENTRATION IN RAT BRAIN BY 2,3 DICHLORO-ALPHA-METHYL-BENZYLAMINE, AN INHIBITOR OF NOREPINEPHRINE-N-METHYLTRANSFERASE. 000112 01-03 LACK OF EFFECT OF CHRONIC HALOPERIDOL ADMINISTRATION ON THE PROLACTIN LOWERING ACTIONS OF PIRIBEDIL. 000233 01-03 INTRAOCULAR PRESSURE LOWERING PROPERTIES OF ABBOTT-43981, A
CANNABINOID DERIVED HETEROCYCLIC BENZOPYRAN WITH MINIMAL CNS ACTIVITIES 001025 02-02 LOWERS N,N DIMETHYLTRYPTAMINE LOWERS RAT BRAIN ACETYLCHOLINE AND 000140 01-03 LOXAPINE LOXAPINE VERSUS HALOPERIDOL PARENTERALLY IN ACUTE PSYCHOSIS WITH AGITATION: A DOUBLE-BLIND STUDY. 001710 02-14

LOXAPINE UPDATE: 1966-1976

000599 01-10

000612 01-10

001662 02-13

PARENTERAL LOXAPINE IN ACUTE SCHIZOPHRENIA. CLINICAL AND PLASMA LEVEL CHARACTERISTICS OF INTRAMUSCULAR AND ORAL LOXAPINE. 002407 03-08

EFFICACY OF LOXAPINE HYDROCHLORIDE INTRAMUSCULAR (LOXITANE-IM) IN ACUTE SCHIZOPHRENIA. 002410 03-08 EVALUATION OF LOXAPINE HYDROCHLORIDE ORAL CONCENTRATE (LOXITANE C) IN ACUTE SCHIZOPHRENIA. 002411 03-08 LOXAPINE IN NEUROTIC ANXIETY: A CONTROLLED TRIAL. 002490 03-10 A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF LOXAPINE, DIAZEPAM, AND PLACEBO IN HOSPITALIZED PATIENTS WITH VARIOUS STATES OF ANXIETY. LOXAPINE IN NEUROTIC ANXIETY: SOME MODIFIERS OF TREATMENT RESPONSE. 003544 04-10 EVALUATION OF LOXAPINE HYDROCHLORIDE ORAL CONCENTRATE (LOXITANE C) IN ACUTE SCHIZOPHRENIA. 002411 03-08 LOXITANE-IM

EFFICACY OF LOXAPINE HYDROCHLORIDE INTRAMUSCULAR (LOXITANE-IM) IN ACUTE SCHIZOPHRENIA.

002410 03-PHARMACOLOGICAL PROFILE OF A NEW PSYCHOTHERAPEUTIC AGENT: 4P FLUOROPHENYL-METHOXYPHENYL-PIPERAZINOETHYLOXAZOLINONE (LR-511). POSSIBLE INVOLVEMENT OF THE CENTRAL DOPAMINERGIC SYSTEM IN THE ANTIRESERPINE EFFECT OF LSD. BEHAVIORAL SENSITIVITY TO LSD: DEPENDENCY UPON THE PATTERN OF CENTRAL 5-HT DEPLETION. 000388 01-04 LSD AND D AMPHETAMINE EFFECTS ON FIXED-INTERVAL RESPONDING IN A NEW VIEW OF THE STRUCTURAL RELATIONSHIP BETWEEN LSD AND MESCALINE. ELECTROPHYSIOLOGICAL EVIDENCE FOR A DOPAMINERGIC ACTION OF LSD: DEPRESSION OF UNIT ACTIVITY IN THE SUBSTANTIA-NIGRA OF THE PAT. 001082 02-03 PREFERENTIAL ACTION OF 5 METHOXYTRYPTAMINE AND 5
METHOXYDIMETHYLTRYPTAMINE ON PRESYNAPTIC SEROTONIN
RECEPTORS: A COMPARATIVE IONTOPHORETIC STUDY WITH LSD AND 001095 02-03 INTERACTION BETWEEN NARCOTIC ANTAGONIST (NALOXONE) AND LYSERGIC-ACID-DIETHYLAMIDE (LSD) IN THE RAT. 001120 02-03 ACTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND ITS DERIVATIVES ON 5 HYDROXYTRYPTAMINE RECEPTORS IN THE ISOLATED UTERINE SMOOTH MUSCLE OF THE RAT. THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS.

A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHOXYAMPHETAMINE (DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), P-METHOXYAMPHETAMINE (PMA), DAMPHETAMINE (A), AND LSD IN NONTOLERANT AND LSD TOLERANT CHRONIC SPINAL DOGS.

O01273 02-03

TRICYCLIC ANTIDEORESSANT DRICS: ANTIGONISM OF EFFECT OF 0.

TRICYCLIC ANTIDEPRESSANT DRUGS: ANTAGONISM OF EFFECT OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON SHOCK ELICITED AGGRESSION.

LSD IN A COERCIVE MILIEU THERAPY PROGRAM

ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS. 001672 02-13

DIRECT INTERACTION OF LSD WITH CENTRAL BETA-ADRENERGIC RAT BRAIN ARYLACYLAMIDASE: MULTIPLE FORMS AND INHIBITION EFFECTS OF LSD, SEROTONIN AND RELATED COMPOUNDS.

A PHARMACOLOGIC COMPARISON OF 3,4
METHYLENEDIOXYAMPHETAMINE AND LSD IN THE CHRONIC SPINAL
DOG.

Psychopharmacology Abstracts

THE EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND 2
BROMOLYSERGIC-ACID-DIETHYLAMIDE (BOL) ON THE STRIATAL DOPA
ACCUMULATION: INFLUENCE OF CENTRAL 5
HYDROXYTEYPTAMINERGIC PATHWAYS.

002125 03-03 MOLECULAR DETERMINANTS FOR THE ACTION OF TRYPTAMINES ON AN

002178 03-03 INTERACTIONS OF PARTIAL LSD ANALOGS WITH BEHAVIORAL DISRUPTING EFFECTS OF LSD AND DMT IN THE RAT.

002264 03-04

HARMACOLOGICAL AND BEHAVIORAL COMPONENTS OF TOLERANCE TO LSD AND MESCALINE IN RATS.

002286 03-04 RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDROXYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN
ACUTE AND CHRONIC SPINAL RATS.

EFFECT OF PSYCHOTOMIMETICS (LSD AND DEXTROAMPHETAMINE) ON THE USE OF PRIMARY AND SECONDARY PROCESS LANGUAGE. 002542 03-12

BROMOCRIPTINE, DIHYDROERGOTOXINE, METHYSERGIDE, D LSD, CF-25-397, AND CF-29-712: EFFECTS ON THE METABOLISM OF BIOGENIC AMINES IN THE BRAIN OF THE RAT.

002849 04-03 EFFECTS OF LSD AND BOL ON THE CATECHOLAMINE SYNTHESIS AND TURNOVER IN VARIOUS BRAIN REGIONS.

HETEROGENEITY OF LSD DISPLACING FACTORS AND MULTIPLE TYPES OF HIGH AFFINITY LSD BINDING SITES. 003099 04-03

DIFFERENCES IN THE DOPAMINERGIC EFFECTS OF THE ERGOT
DERIVATIVES BROMOCRIPTINE, LISURIDE AND D LSD AS COMPARED

003244 04-04 LSD AND TRYPTAMINE EFFECTS ON SLEEP-WAKEFULNESS AND ELECTROCORTICOGRAM PATTERNS IN INTACT CATS.

003256 04-04 ANTIPSYCHOTIC DRUGS BLOCK LSD-INDUCED DISAGGREGATION OF BRAIN POLYSOMES.

STRESS ACCENTUATION OF THE LSD-INDUCED DISAGGREGATION OF BRAIN POLYSOMES.

LSD-INDUCED STIMULUS CONTROL: A COMPARISON OF SCH-12679, FENFLURAMINE, P-METHOXYAMPHETAMINE, AND BL-3912. 003396 04-04

IDENTIFICATION OF SHORT TIME INTERVALS UNDER LSD-25 AND

001635 02-12 CIA RESEARCH WITH LSD-25.

001638 02-12 ANIMAL MODELS OF SCHIZOPHRENIA: THE CASE FOR LSD-25 003706 04-17

LU-3-049

NEUROCHEMICAL PROPERTIES OF DIMETHYLMETHYLAMINOPROPYL-1PHENYLINDAN HCL (LU-3-049) AND SELECTED TRICYCLIC
ANTIDEPRESSANTS.

000251 01

000251 01-03

A COMPARISON OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE (1). 002428 03-09 A COMPARISON OF HIGH AND LOW DOSAGE REGIMES OF MAPROTILINE (LUDIOMIL).

002429 03-09 MAPROTILINE (LUDIOMIL) IN DEPRESSION: A MULTICENTRE ASSESSMENT OF ONSET OF ACTION, EFFICACY AND TOLERABILITY. 002432 03-09

MAPROTILINE (LUDIOMIL) IN DEPRESSION: A REPORT OF A MONITORED RELEASE STUDY IN GENERAL PRACTICE.

002433 03-09 A COMPARATIVE STUDY OF MAPROTILINE (LUDIOMIL) AND VILOXAZINE IN THE MANAGEMENT OF DEPRESSED PATIENTS IN GENERAL PRACTICE.

A COMPARISON OF MAPROTILINE (LUDIOMIL) AND SLOW-RELEASE AMITRIPTYLINE (TRYPTIZOL-SR).

EFFICACY, SIDE-EFFECTS, PLASMA AND BLOOD LEVELS OF MAPROTILINE (LUDIOMIL).

002451 03-09 A COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE (2)

A COMPARISON OF LUDIOMIL, TRYPTIZOL, AND LENTIZOL 002454 03-09 THE TREATMENT OF DEPRESSION COMPARING DIVIDED AND SINGLE DOSES OF MAPROTILINE (LUDIOMIL).

002467 03-09

002121 03-03

VOLUME 16, SUBJECT INDEX

ACTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND ITS DERIVATIVES ON 5 HYDROXYTRYPTAMINE RECEPTORS IN THE ISOLATED UTERINE SMOOTH MUSCLE OF THE RAT.

PRACTICAL CONSIDERATIONS IN THE USE OF MAPROTILINE (LUDIOMIL) IN 002758 03-17

001144 02-03 LYSERGIC-ACID-DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF PITUITARY DOPAMINE RECEPTORS

Subject Index

002180 03-03

000384 01-04

LUMINAL THE STUDY OF THE MUTAGENIC ACTIVITY OF LUMINAL AND PYRAZIDAL

001192 02-03 LACK OF TOLERANCE TO THE DEPRESSION OF RAPHE UNIT ACTIVITY BY

LUNG INFLUENCE OF INJECTED PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS

LYSERGIC-ACID-DIETHYLAMIDE 001262 02-03

IN MOUSE BRAIN AND LUNG FOLLOWING MICROWAVE IRRADIATION 000214 01-03 DISTRIBUTION OF CLOZAPINE IN THE RAT: EVIDENCE FOR ACTIVE TRANSPORT IN LUNG.

TRICYCLIC ANTIDEPRESSANT DRUGS: ANTAGONISM OF EFFECT OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON SHOCK ELICITED AGGRESSION.

001129 02-03 INCORPORATION OF RADIOACTIVE LABELLED CHOLINE AND PALMITATE INTO LUNG LECITHIN OF RABBITS TREATED WITH HIGH DOSES OF BROMCARBAMIDES, BARBITURATES AND DIAZEPAM.

THE INFLUENCE OF PROGESTERONE ON THE INHIBITORY EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE FEMALE PART FEMALE RAT.

001282 02-03 LACK OF ENHANCEMENT OF DIMETHYLTRYPTAMINE FORMATION IN RAT BRAIN AND RABBIT LUNG IN VIVO BY METHIONINE OR S ADENOSYLMETHIONINE

003102 04-03

001463 02-04
LYSERGIC-ACID-DIETHYLAMIDE ANTAGONISM BY CHLORPROMAZINE. HALOPERIDOL, DIAZEPAM, AND PENTOBARBITAL IN THE RABBIT 001504 02-05

LUPUS-ERYTHEMATOSUS DRUG-INDUCED SYSTEMIC LUPUS-ERYTHEMATOSUS.

HYPOTHALAMIC PITUITARY AXIS.

LYSENYL-SPOFA

THE EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND 2
BROMOLYSERGIC-ACID-DIETHYLAMIDE (BOL) ON THE STRIATAL DOPA
ACCUMULATION: INFLUENCE OF CENTRAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS.

002676 03-15 LUTEINIZING MORPHINE DECREASES LUTEINIZING HORMONE BY AN ACTION ON THE

DIFFERENTIAL EFFECTS OF SUBCORTICAL LYSERGIC-ACID-DIETHYLAMIDE AND SEROTONIN ON VISUAL CORTICAL EVOKED-POTENTIALS.

001084 02-03 THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDROCANNABINOL (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HORMONE (FSH) AND LUTEINIZING HORMONE (LH) IN THE OVARIECTOMIZED RHESUS

STIMULUS PROPERTIES OF PHENETHYLAMINE HALLUCINOGENS AND LYSERGIC-ACID-DIETHYLAMIDE: THE ROLE OF 5 HYDROXYTRYPTAMINE.

THE EFFECT OF LITHIUM ON LUTEINIZING HORMONE AND TESTOSTERONE

LYSINE PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, BRAIN SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION INTO BRAIN PROTEINS OF DIFFERENT MOUSE STRAINS.

001731 02-14 BLOCKAGE OF PROGESTERONE-INDUCED RELEASE OF LUTEINIZING HORMONE AND PROLACTIN BY D AMPHETAMINE AND FENFLURAMINE

INFLUENCE OF LYSINE VASOPRESSIN ON THE EEG IN MAN 002639 03-14

THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MALE

EFFECTS OF CANNABINOIDS ON L1210 MURINE LEUKEMIA: 1. INHIBITION OF DNA SYNTHESIS. 001266 02-03

002343 03-05

THE EFFECT OF ABLATION OF SEROTONIN OR NOREPINEPHRINE BRAINSTEM AREAS ON HALOTHANE AND CYCLOPROPANE MAC IN RATS. (UNPUBLISHED PAPER). 001229 02-03

LUTEINIZING HORMONE RELEASING HORMONE AND THYROTROPIN-RELEASING HORMONE STIMULATION STUDIES IN PATIENTS GIVEN CLOMIPRAMINE OR DEPOT NEUROLEPTICS.

MACACA-MULATTA SPECTRAL ANALYSIS OF THE DIFFERING EEG EFFECTS OF BENZODIAZEPINES, MEPROBAMATE, GLUTETHIMIDE AND AMOBARBITAL IN MACACA-MULATTA.

NORMAL LYMPHOCYTE FUNCTION IN THE PRESENCE OF DELTA9-TETRAHYDROCANNABINOL.

> 001130 02-03 BEHAVIOURAL AND PHARMACOKINETIC STUDIES IN THE MONKEY
> (MACACA-MULATTA) WITH DIAZEPAM, NORDIAZEPAM AND RELATED 1,4 BENZODIAZEPINES 001336 02-04

000730 01-13 LYORODIN TREATMENT OF SCHIZOPHRENIC PSYCHOSES WITH LYORODIN

> MACAQUE THE SOCIOPHARMACOLOGY OF FENFLURAMINE (FM), METHYLPHENIDATE (MP), AND DIETHYLPROPION (DP) IN MACAQUE ARCTOIDES. 001311 02-04

000546 01-08 FLUPHENAZINE DEPOT (LYORODIN DEPOT) - SOON IN PRODUCTION IN THE DDR?. 002400 03-08

> SOCIOPHARMACOLOGY OF D AMPHETAMINE IN MACAQUE ARCTOIDES II. 001493 02-04 MACAQUES EFFECTS OF AMPHETAMINE ON SOCIAL BEHAVIORS OF RHESUS

LISURID (LYSENYL-SPOFA) IN THE TREATMENT OF ORGANIC PSYCHOSYNDROME IN INVOLUTION. 003563 04-11 LYSERGAMIDE
ALOSTERIC CHANGES IN PLASMA PROTEINS IN HEALTHY VOLUNTEERS

AFTER ADMINISTRATION OF LYSERGAMIDE.

MACAQUES: AN ANIMAL MODEL OF PARANOIA. 002365 03-06 MACROPHAGES MONOAMINE-OXIDASE ACTIVITY OF MACROPHAGES AT REST AND DURING PHAGOCYTOSIS.

003584 04-12 LYSERGIC-ACID-DIETHYLAMIDE DISAGGREGATION OF BRAIN POLYSOMES AFTER D LYSERGIC-ACID-DIETHYLAMIDE ADMINISTRATION IN VIVO: MECHANISM AND EFFECT OF AGE AND ENVIRONMENT

002902 04-03

PERSISTENT EFFECTS OF REPEATED INJECTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE ON RAT BRAIN 5 HYDROXYTRYPTAMINE AND 5 HYDROXYINDOLEACETIC-ACID LEVELS.

A DOUBLE-BLIND COMPARISON OF LEVODOPA, MADOPA, AND SINEMET IN PARKINSON DISEASE. 003556 04-11

000221 01-03 THE EFFECTS OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE FEMALE RAT.

MAGNESIUM PLASMA ALDOSTERONE AND MAGNESIUM IN SERUM AND URINE DURING LITHIUM TREATMENT.

000353 01-04

000725 01-13 EFFECTS OF MAGNESIUM PEMOLINE ON PATTERN DISCRIMINATION LEARNING IN YOUNG RATS.

LYSERGIC-ACID-DIETHYLAMIDE. PHOTOELECTRON IONIZATION POTENTIALS AS INDICES OF BEHAVIORAL ACTIVITY. 001100 02-03 INTERACTION BETWEEN NARCOTIC ANTAGONIST (NALOXONE) AND LYSERGIC-ACID-DIETHYLAMIDE (LSD) IN THE RAT.

001425 02-04 MOOD CHANGE AND MAGNESIUM: A POSSIBLE INTERACTION BETWEEN MAGNESIUM AND LITHIUM?

001120 02-03 VESICULAR AND JUXTAVESICULAR SEROTONIN: EFFECTS OF LYSERGIC-ACID-DIETHYLAMIDE AND RESERPINE.

001591 02-09 EFFECTS OF LITHIUM ON THE MEMBRANE-BOUND MAGNESIUM DEPENDENT ATPASE OF MOUSE NEUROBLASTOMA CELLS. 003087 04-03

MAGNIFICATION
MAGNIFICATION OF SOME ENZYMATIC ACTIVITIES OF BRAIN-CORTEX SUBFRACTIONS.

003127 04-03

MAGNITUDE

THE RELATIONSHIP BETWEEN MAGNITUDE OF ELECTROSHOCK
STIMULATION AND THE EFFECTS OF DIGITOXIGENIN,
PENTYLENETERAZOL AND BRAIN MONOAMINE REDUCTION ON
ELECTROSHOCK CONVULSIVE THRESHOLDS.

000066 01-03

MAGNUS

EFFECTS OF MEDIAL RAPHE AND RAPHE MAGNUS LESIONS ON THE

ANALGESIC ACTIVITY OF MORPHINE AND METHADONE.

001986 03-03 EFFECT OF MORPHINE INJECTED IN PERIAQUEDUCTAL GRAY ON THE ACTIVITY OF SINGLE UNITS IN NUCLEUS RAPHE MAGNUS OF THE RAT. 002817 04-03

MAINTAIN
DOES DIAZEPAM MAINTAIN ALCOHOLISM?

002351 03-05

003401 04-04

MAINTAINED

EFFECTS OF D AMPHETAMINE ON RESPONDING SIMULTANEOUSLY
MAINTAINED AND PUNISHED BY PRESENTATION OF ELECTRICS

FFECTS OF D AMPHETAMINE, CHLORDIAZEPOXIDE AND PROMAZINE ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION AND STIMULUS SHOCK

EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D AMPHETAMINE AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY AND SHOCK AVOIDANCE IN RHESUS MONKEYS.

EFFECTS OF D AMPHETAMINE AND ETHANOL ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION. 002255 03-04

CAN PHENYTOIN BE GRADUALLY WITHDRAWN IN PATIENTS WITH MAJOR MOTOR EPILEPSY MAINTAINED ON CLONAZEPAM AND PHENOBARBITAL?

002504 03-11 BLOCKADE OF TESTOSTERONE MAINTAINED INTERMALE FIGHTING IN ALBINO LABORATORY MICE BY AN AROMATIZATION INHIBITOR. 003176 04-04

EFFECTS OF METHADONE ON BEHAVIOR MAINTAINED BY FIXED-RATIO REINFORCEMENT SCHEDULES.

003299 04-04 DRUG EFFECTS ON RESPONDING MAINTAINED BY STIMULUS REINFORCER AND RESPONSE REINFORCER CONTINGENCIES.

003365 04-04 COCAINE AS DISCRIMINATIVE STIMULUS FOR RESPONDING MAINTAINED BY FOOD IN SQUIRREL-MONKEYS.

003398 04-04 EFFECTS OF NALOXONE ON SCHEDULE-CONTROLLED BEHAVIOR IN MORPHINE MAINTAINED PIGEONS.

LOCAL PERFUSION OF NORADRENALINE MAINTAINS VISUAL CORTICAL PLASTICITY.

003045 04-03 MAINTENANCE
EFFECTS OF PIMOZIDE ON THE ACQUISITION, MAINTENANCE, ANI
EXTINCTION OF AN AMPHETAMINE-INDUCED TASTE AVERSION

000373 01-04 EFFECTS OF METHADONE AND MORPHINE MAINTENANCE ON DRUG SEEKING BEHAVIOR IN THE DOG.

000387 01-04 COUPLES GROUP THERAPY AS AN ADJUNCT TO LITHIUM MAINTENANCE OF THE MANIC PATIENT.

000562 01-09 MANIA DURING MAINTENANCE HEMODIALYSIS SUCCESSFULLY TREATED WITH ORAL LITHIUM-CARBONATE.

000582 01-09 METHADONE MAINTENANCE: EFFECT OF URINARY PH ON RENAL CLEARANCE IN CHRONIC HIGH AND LOW DOSES.

000687 01-13

MEDICAL SCREENING OF PATIENTS ON MAINTENANCE NEUROLEPTICS. 000822 01-15 FAILURE OF METHADONE AND LEVOMETHADYL-ACETATE (LEVO-ALPHA-ACETYLMETHADOL, LAAM) MAINTENANCE TO AFFECT MEMORY.

000841 01-15

DIAZEPAM MAINTENANCE OF ALCOHOL PREFERENCE DURING ALCOHOL WITHDRAWAL

001345 02-04 LONG-TERM MAINTENANCE DRUG THERAPY IN RECURRENT AFFECTIVE-ILLNESS: CURRENT STATUS AND ISSUES.

ON LONG-TERM MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY: THE COMBINED ADMINISTRATION OF ANTIPARKINSONS DRUGS. 001865 02-16

Psychopharmacology Abstracts

A DEBATE ON MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY — REFLECTIONS ON THE SO-CALLED LONG-TERM SATURATION ADMINISTRATIONS.

001872 02-16 MAINTENANCE ANTIPSYCHOTIC PHARMACOTHERAPY, RELAPSE, AND LENGTH OF STAY OUT OF THE HOSPITAL IN CHRONIC SCHIZOPHRENICS IN GREECE.

EFFECT OF P-CHLOROPHENYLALANINE ON THE LOSS AND MAINTENANCE OF TOLERANCE TO ETHANOL.

A DOUBLE-BLIND CONTROLLED STUDY OF PIPOTHIAZINE-PALMITATE IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS.

002390 03-08 PENFLURIDOL IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS NEWLY DISCHARGED FROM A BRIEF THERAPY UNIT. 002391 03-08

THREE YEARS MAINTENANCE NEUROLEPTIC TREATMENT IN SCHIZOPHRENIA -- BEFORE AND BEYOND.

RESEARCH FINDINGS ON CHRONIC MENTAL ILLNESS: A MODEL FOR CONTINUING-CARE IN THE HEALTH MAINTENANCE ORGANIZATION 002777 03-17

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. A STUDY WITH THE LONG-ACTING THIOXANTHENE DERIVATIVE, CIS-CLOPENTHIXOL-DECANOATE SORDINOL DEPOT.

003454 04-08 OUTPATIENT MAINTENANCE OF CHRONIC SCHIZOPHRENIC PATIENTS WITH FLUPHENAZINE-DECANOATE (MODECATE): IBADAN EXPERIENCE. 003466 04-08

THE USE OF PENFLURIDOL ACCORDING TO A NEW DOSAGE REGIMEN IN THE ACUTE, STABILIZATION AND MAINTENANCE PHASES OF **PSYCHOSIS**

MAJOR THEORIES OF STATE-DEPENDENT LEARNING

000970 01-17 DESIPRAMINE AND SOME OTHER ANTIDEPRESSANT DRUGS DECREASE THE MAJOR NOREPINEPHRINE METABOLITE 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE IN THE RAT BRAIN.

CAN PHENYTOIN BE GRADUALLY WITHDRAWN IN PATIENTS WITH MAJOR MOTOR EPILEPSY MAINTAINED ON CLONAZEPAM AND PHENOBARBITAL?.

MAJOR THEORIES OF STATE-DEPENDENT LEARNING.

002772 03-17

002504 03-11

003491 04-09

GLUTAMINE -- A MAJOR SUBSTRATE FOR NERVE ENDINGS 002839 04-03

EFFECTS OF AMPHETAMINE, METHYLPHENIDATE AND COCAINE ON SERUM PROLACTIN CONCENTRATIONS IN THE MALE RAT.

000234 01-03 EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH MORPHOLOGY AND HORMONE PLASMA LEVELS.

000315 01-04 EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: I. BEHAVIOURAL EFFECTS OF INTRAMUSCULAR INJECTIONS.

000316 01-04 FACILITATION OF MOUNTING BEHAVIOR BY DIHYDROTESTOSTERONE-PROPIONATE IN CASTRATED ESTRADIOL-BENZOATE TREATED MALE RATS FOLLOWING PUDENECTOMY.

000403 01-04 UP FROM DEPRESSION WITH A SYNTHETIC MALE HORMONE.

000581 01-09 CEREBROSPINAL FLUID HOMOVANILLIC-ACID IN MALE ALCOHOLICS: EFFECTS OF DISULFIRAM.

THE EFFECTS OF FOUR ANTIHYPERTENSIVE AGENTS ON THE STROOP COLOUR WORD TEST IN NORMAL MALE VOLUNTEER SUBJECTS.

000771 01-14 EFFECTS OF PCPA ON MARKING BEHAVIOUR IN THE MALE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).

LORDOSIS REFLEX, SEXUAL RECEPTIVITY, AND FEEDING: ESTROGEN RESPONSIVITY IN MALE AND FEMALE RATS.

EFFECTS OF MORPHINE AND NALTREXONE ON SEXUAL BEHAVIOUR ON THE MALE RAT.

INFLUENCE OF BETA-ENDORPHIN ON EXPLORATORY, SOCIAL AND SEXUAL BEHAVIOUR IN THE MALE RAT.

001418 02-04 MEASUREMENTS OF WEIGHT AND ACTIVITY IN MALE MICE FOLLOWING INHALATION OF CANNABIS SMOKE IN A CONTROLLED SMOKE EXPOSURE CHAMBER.

THE EFFECTS OF AN ANTIPSYCHOTIC MEDICATION ON THE CLASSROOM BEHAVIOR OF FOUR SCHIZOPHRENIC MALE CHILDREN.

ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN YOUNG AND ELDERLY MALE VOLUNTEERS.

RATIONALITY OF APPEALS USED IN THE PROMOTION OF PSYCHOTROPIC DRUGS. A COMPARISON OF MALE AND FEMALE MODELS.

EFFECTS OF PARGYLINE ON HYPOTHALAMIC BIOGENIC AMINES AND SERUM PROLACTIN (PRL), LH AND TSH IN MALE RATS

001988 03-03 EFFECTS OF CHLORDIAZEPOXIDE, OXAZEPAM, CHLORPROMAZINE, AND D AMPHETAMINE ON SEXUAL RESPONSES IN MALE AND FEMALE HAMSTERS.

DIFFERENTIAL EFFECTS OF THE ANTIANDROGEN FLUTAMIDE ON ASPECTS OF SEXUAL BEHAVIOR IN CASTRATED, ANDROGEN TREATED MALE

THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MALE

002343 03-05 EFFECT OF 6 METHOXYTETRAHYDRO-BETA-CARBOLINE ON SERUM PROLACTIN LEVELS OF MALE RATS.

ROLES OF THE VOMERONASAL AND OLFACTORY SYSTEMS IN COURTSHIP BEHAVIOR OF MALE GARTER SNAKES.

POTENTIATION OF HEXOBARBITAL AND AMPHETAMINE EFFECTS IN MALE AND FEMALE RATS PHYSICALLY DEPENDENT ON MORPHINE.

APOMORPHINE AND L-DOPA LOWER EJACULATION THRESHOLD IN THE MALE RAT. 003327 04-04

AGGRESSION PROMOTING AND AGGRESSION ELICITING PROPERTIES OF ESTROGEN IN MALE MICE. 003360 04-04

SERUM GONADOTROPIN AND TSH LEVELS AFTER TRICYCLIC ANTIDEPRESSANTS IN HEALTHY MALES

001670 02-13
IMPACT OF AGE ON ANTERIOR PITUITARY HORMONES IN ADULT MALES. 001687 02-13 METHYLPHENIDATE EFFECT ON ATTENTIONAL AND COGNITIVE BEHAVIOR

IN SIX- THROUGH TWELVE-YEAR-OLD MALES. 002618 03-14

CATATONIA AND MALIGNANT SYNDROME: A POSSIBLE COMPLICATION OF NEUROLEPTIC ADMINISTRATION. REPORT OF A CASE INVOLVING

000910 01-15 MISLEADING RESPONSE OF MALIGNANT GASTRIC ULCERS TO

002704 03-15 MALIGNANT FEVER IS NOW AN OFFICE PROBLEM TOO. 003565 04-11

FOUR CASES OF SYNDROME MALIN.

001783 02-15 SYNDROME MALIN SYMPTOMS THOUGHT TO BE DUE TO INTERACTION BETWEEN NEUROLEPTICS AND ORAL DIABETES DRUGS.

EFFECTIVENESS OF PSYCHOTROPIC DRUGS IN PATIENTS IN A STATE OF MALNUTRITION OR EXPOSED TO EXTREME CLIMATIC CONDITIONS 000721 01-13

THE EFFECT OF CEREBROLYSINE ON CORTICAL EVOKED-POTENTIALS IN RATS WITH EARLY MALNUTRITION.

ANTISERUMS TO NEURONS AND TO OLIGODENDROGLIA FROM MAMMALIAN BRAIN

000014 01-01 AN EXCITATORY ACTION OF IONTOPHORETICALLY ADMINISTERED LITHIUM ON MAMMALIAN CENTRAL NEURONES

000135 01-03 A MORPHINE-LIKE FACTOR IN MAMMALIAN BRAIN: ANALGESIC **ACTIVITY IN RATS**

000220 01-03 NOREPINEPHRINE ALPHA RECEPTOR BINDING IN MAMMALIAN CENTRAL-NERVOUS-SYSTEM: DIFFERENTIAL LABELING WITH AGONIST AND

000283 01-03 DEVELOPMENT OF DENERVATION ALTERATIONS IN SURFACE MEMBRANES OF MAMMALIAN SKELETAL MUSCLE.

001246 02-03 CENTROPHENOXINE: EFFECTS ON AGING MAMMALIAN BRAIN 002287 03-04 D ALPHA-AMINOADIPATE, ALPHA-EPSILON-DIAMINOPIMELIC-ACID AND H-966 AS ANTAGONISTS OF AMINO-ACID-INDUCED AND SYNAPTIC EXCITATION OF MAMMALIAN SPINAL NEURONES IN VIVO.

INTERACTION OF PENTOBARBITONE AND GAMMA-AMINOBUTYRIC-ACID ON MAMMALIAN SYMPATHETIC GANGLION CELLS.

THE FLUOROMETRIC DETERMINATION OF 5 METHOXYTRYPTAMINE IN MAMMALIAN TISSUES AND FLUIDS

INTERACTIONS BETWEEN GUANINE DERIVATIVES AND NOREPINEPHRINE ON NEURONES OF THE MAMMALIAN CEREBRAL-CORTEX. 003101 04-03

PROFOUND HYPOTHERMIA IN MAMMALS TREATED WITH OFOUND HYPOTHERMIA IN MAMMALS INCALED TO THE TETRAHYDROCANNABINOLS, MORPHINE, OR CHLORPROMAZINE. 001140 02-03

ALTERED RECEPTOR SENSITIVITY FOLLOWING CHRONIC DRUG ADMINISTRATION IN MAN: THE TARDIVE-DYSKINESIA MODE 000248 01-03

PHARMACOLOGIC ACTIVITY OF BETA-ENDORPHIN IN MAN 000507 01-07 DOPAMINE IS A MONOAMINE-OXIDASE B SUBSTRATE IN

000677 01-12
EVIDENCE AGAINST INVOLVEMENT OF ENDORPHINS IN SEXUAL AROUSAL AND ORGASM IN MAN.

PHYSIOLOGIC DISPOSITION OF NABILONE, A CANNABINOL DERIVATIVE. IN MAN

000735 01-13 DISPOSITION OF THREE BENZODIAZEPINES AFTER SINGLE ORAL ADMINISTRATION IN MAN

000745 01-13 MEMORY AND COGNITIVE FUNCTION IN MAN: DOES THE CHOLINERGIC SYSTEM HAVE A SPECIFIC ROLE?.

COMPARATIVE EFFECTS OF D AMPHETAMINE, L AMPHETAMINE, AND METHYLPHENIDATE ON MOOD IN MAN.

000790 01-14
CONTEXT EFFECTS IN THE STORAGE AND RETRIEVAL OF INFORMATION IN

000793 01-14
LITHIUM-CARBONATE AND METHYLDOPA: APPARENT INTERACTION IN MAN

000807 01-15 SLEEP AND BEHAVIORAL CHANGES POSSIBLY REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN

PREDICTION OF THE LITHIUM RATIO IN MAN BY MEANS OF AN IN VITRO TEST

000930 01-16 SCOPOLAMINE-INDUCED LEARNING FAILURES IN MAN

000972 01-17 NEFOPAM (N), MORPHINE (M), AND D AMPHETAMINE (A) IN MAN: SUBJECTIVE, BEHAVIORAL, AND PHYSIOLOGIC EFFECTS.

EFFECTS OF ID-540 ON AVERAGED PHOTOPALPEBRAL REFLEX IN MAN. 001556 02-07

NUTRITION AND CHEMICAL BIOTRANSFORMATIONS IN MAN.

001651 02-13
NEUROTRANSMITTER METABOLITES IN THE CEREBROSPINAL FLUID OF MAN FOLLOWING PHYSOSTIGMINE

001653 02-13 DISPOSITION OF KETAZOLAM, A NEW ANXIOLYTIC AGENT, IN MAN. 001655 02-13

THE METABOLISM AND PLASMA CONCENTRATIONS OF L-ALPHA-ACETYLMETHADOL AND ITS METABOLITES IN MAN. (PH.D. DISSERTATION)

THE EFFECTS OF PSYCHOPHARMACOLOGICAL AGENTS ON CENTRAL-NERVOUS-SYSTEM AMINE METABOLISM IN MAN.

001671 02-13 FACTORS AFFECTING THE BIOAVAILABILITY OF CHLOROTHIAZIDE IN 001674 02-13

THE EFFECT OF SALICYLATE ON CEREBRAL BLOOD FLOW IN MAN ELECTROENCEPHALOGRAPHIC STUDIES WITH I.V. METHAQUALONE IN

EFFECT OF ALPHA-METHYLTYROSINE (MT) PRETREATMENT ON D
AMPHETAMINE (A) AND MORPHINE (M) INDUCED MOOD IN MAN.
001714 02-14
GAMMA-AMINOBUTYRIC-ACID (GABA) AND SLEEP: THE INFLUENCE OF
DI-N-PROPYLACETIC-ACID ON SLEEP IN MAN.

THE EFFECT OF LITHIUM ON LUTEINIZING HORMONE AND TESTOSTERONE

001731 02-14

001854 02-15

003069 04-03

Su	bject Index		
	MARIJUANA: DIFFERENTIAL EFFECTS ON RIGHT AND LEFT FUNCTIONS IN MAN.		LITHIUM-CARBONATE AGGRESSIVE BEHA
	EFFECT OF DEXTROAMPHETAMINE ON SOMATIC EVOKED-I COMPONENTS IN MAN WITH SPECIAL REFERENCE TO TA AND SELECTIVE ATTENTION.	001733 02-14 POTENTIAL ALK RELEVANCE	ON THE PREVALENCE INDUCED HYPOTHY
	URINARY EXCRETION OF PHENOLIC METABOLITES OF PROPYLAMPHETAMINE IN MAN.	001735 02-14	THE ROLE OF CHARCO
	WHAT ARE THE EFFECTS OF COCAINE IN MAN?	001892 02-17	DEANOL IN THE MAN DISORDERS: A REV
	CENTRAL NERVOUS EFFECTS OF THE HYPNOTIC ETOMIDAT	002549 03-13 E IN MAN.	A COMPARATIVE STI
	THE EFFECT OF NEUROLEPTICS AND ALPHA-METHYL-P-TYR SERUM PROLACTIN LEVELS IN LABORATORY ANIMALS	002580 03-13 OSINE ON	IN THE MANAGEM PRACTICE.
	THE KINETICS OF IMIPRAMINE-N-OXIDE IN MAN.	002582 03-13	A LARGE OPEN MULT THE MANAGEMEN
	BEHAVIOURAL ANTAGONISM BETWEEN CHLORPROMAZIN	002585 03-13 E AND NOISE IN	A STUDY OF THE MA
		002621 03-14 OUS ACTIVITY	THE MANAGEMENT
	ON THE ACUTE EFFECT OF SOME DRUGS ON HIGHER NERV IN MAN FOLLOWED UP BY THE LABORATORY LANGUAGE	GE METHOD. 002623 03-14	CONSIDERATIONS IN
	EEG SLEEP CORRELATES OF DEPRESSION IN MAN.	002625 03-14	MANAGEMENT OF A
	INFLUENCE OF LYSINE VASOPRESSIN ON THE EEG IN MAN.	002639 03-14	PHARMACOLOGIC M
	METHADONE DOSE, PLASMA LEVEL, AND CROSS-TOLERAN IN MAN.		ALCOHOLISM: PRACT
	AN APOMORPHINE-INDUCED VOMITING MODEL FOR ANTI-	002642 03-14 EMETIC STUDIES	MANDIBULOGRAM MANDIBULOGRAM A
	BIOANALYSIS AND PHARMACOKINETICS OF CLOMIPRAMII DESMETHYLCLOMIPRAMINE IN MAN BY MEANS OF LIQ CHROMATOGRAPHY.	002722 03-16 NE AND UID	RAT.
	ON THE OBJECTIVE EVALUATION OF HALOPERIDOL EFFECTS	002728 03-16 IN MAN: A	THE INFLUENCE OF AI
	PILOT STUDY.	003442 04-07	MANGANESE EFFECT OF CHLORPRO
	THE ANALGESIC ACTIVITY OF HUMAN BETA-ENDORPHIN II BIOCHEMICAL EFFECTS IN MAN AND RAT OF THREE DRUG	003598 04-13	CONCENTRATIONS
	INCREASE BRAIN GABA CONTENT.	003604 04-13	ANIMAL MODELS FO
	THE EFFECTS OF A NEW BENZODIAZEPINE DERIVATIVE, ID- AVERAGED PHOTOPALPEBRAL REFLEX IN MAN.	-540, ON THE 003610 04-13	MANIA DURING MAI WITH ORAL LITHIU
	MEMORY CONSOLIDATION AND CHOLINERGIC STATE-DEPELEARNING IN MAN.	NDENT	CONCOMITANT ADM CARBONATE IN AC
	DEPRENYL ADMINISTRATION IN MAN: A SELECTIVE MONO OXIDASE B INHIBITOR WITHOUT THE CHEESE EFFECT.	003612 04-13 DAMINE-	MANIA IN CHILDHOO
	MULTIVARIATE ANALYSIS OF DRUG EFFECTS ON ELECTROI	003652 04-15 PHYSIOLOGICAL	AND FURTHER DES
	SIGNALS IN MAN.	003688 04-16	ANIMAL MODELS FO
	POSSIBLE INDICATION OF DOPAMINERGIC BLOCKADE IN N ELECTRORETINOGRAPHY.	003689 04-16	TREATMENT OF IMIP
MA	NAGED A CASE OF CONSERVATIVELY MANAGED LITHIUM INTOXIC		MANIC
MA	NAGEMENT	001811 02-15	OF THE MANIC PA
	EFFICACY OF SCH-12679 IN THE MANAGEMENT OF AGGR RETARDATES.		TREATMENT OF MAN
	CLOTHIAPINE IN MANAGEMENT OF SCHIZOPHRENIA.	000506 01-07	CYCLIC-AMP IN CERE PATIENTS.
	CURRENT THERAPEUTIC CONCEPTS: CONTEMPORARY DRU MANAGEMENT OF ANXIETY.		COMBINED HALOPER
	EVALUATION OF LITHIUM-CARBONATE IN THE MANAGEM	000600 01-10 ENT OF GILLES-	PATIENTS.
	DE-LA-TOURETTES SYNDROME. REPORT FROM CLINICAL PRACTICE: THE REAL AND IDEAL OF STIMULANT DRUG TREATMENT OF HYPERACTIVE CH	000646 01-11 MANAGEMENT	MANIC-DEPRESSIVE THE IMPACT OF LITH DISORDERS.
	(UNPUBLISHED PAPER).	000656 01-11	LITHIUM AND THE TE

SUBTYPES OF DEPRESSION - DIAGNUSIS AND MEDICAL MANAGEMENT. 000938 01-17

PHENOBARBITAL IN THE ACUTE MANAGEMENT OF FEBRILE CONVULSIONS.

THE PRACTICAL MANAGEMENT OF AFFECTIVE-DISORDERS.

MANAGEMENT OF THE HYPERKINETIC SYNDROME WITH METHYLPHENIDATE AND SMR BIOFEEDBACK TRAINING.

Psychopharmacology	Abstracts
LITHIUM-CARBONATE IN THE MANAGEMENT OF HYPERAC AGGRESSIVE BEHAVIOR OF THE MENTALLY RETARDED.	TIVE
ON THE PREVALENCE, DIAGNOSIS AND MANAGEMENT OF INDUCED HYPOTHYROIDISM IN PSYCHIATRIC PATIENTS	001713 02-14 LITHIUM-
THE ROLE OF CHARCOAL HEMOPERFUSION IN THE ACTIVE OF POISONING.	001805 02-15
DEANOL IN THE MANAGEMENT OF INVOLUNTARY MOVE	001842 02-15 MENT
DISORDERS: A REVIEW. A COMPARATIVE STUDY OF MAPROTILINE (LUDIOMIL) AI IN THE MANAGEMENT OF DEPRESSED PATIENTS IN GEN	001886 02-17 ND VILOXAZINE IERAL
PRACTICE. A LARGE OPEN MULTICENTRE TRIAL OF CLOMIPRAMINE (THE MANAGEMENT OF PHOBIC DISORDERS.	002447 03-09 ANAFRANIL) IN
A STUDY OF THE MANAGEMENT OF ANXIETY WITH LORA	002475 03-10 ZEPAM
THE MANAGEMENT OF PHOBIC DISORDERS IN GENERAL P	002478 03-10
CONSIDERATIONS IN THE MANAGEMENT OF PARKINSONII	002499 03-10
MANAGEMENT OF ACUTE ANXIETY SYNDROME WITH PAI	002510 03-1
ADMINISTERED LORAZEPAM.	003539 04-1
PHARMACOLOGIC MANAGEMENT OF HUMAN VIOLENCE.	003558 04-1
ALCOHOLISM: PRACTICAL ASPECTS OF MANAGEMENT.	003572 04-1
IDIBULOGRAM MANDIBULOGRAM AS A MEASURE OF STEREOTYPED BEH	AVIOR IN THE
RAT.	003427 04-0
IDRAX THE INFLUENCE OF ALCOHOL ON THE PERSISTENT EFFECTS PERFORMANCE OF THE HYPNOTICS MANDRAX AND NI IGANESE EFFECT OF CHLORPROMAZINE ON CENTRAL-NERVOUS-SYS	000784 01-1
CONCENTRATIONS OF MANGANESE, IRON, AND COPPE	
ANIMAL MODELS FOR MANIA. (UNPUBLISHED PAPER).	
MANIA DURING MAINTENANCE HEMODIALYSIS SUCCESSI WITH ORAL LITHIUM-CARBONATE.	000501 01-0 FULLY TREATED
CONCOMITANT ADMINISTRATION OF HALOPERIDOL AND CARBONATE IN ACUTE MANIA.	000582 01-0 LITHIUM-
MANIA IN CHILDHOOD. II. THERAPEUTIC TRIAL OF LITHIU AND FURTHER DESCRIPTION OF MANIC-DEPRESSIVE ILL CHILDREN.	000638 01-1 M-CARBONATE NESS IN
ANIMAL MODELS FOR MANIA.	001578 02-0
TREATMENT OF IMIPRAMINE RESISTANT DEPRESSION AN REFRACTORY MANIA THROUGH DRUG INTERACTIONS.	002766 03-1 D LITHIUM
IC	003512 04-0
OF THE MANIC PATIENT.	MAINTENANCE
TREATMENT OF MANIC PSYCHOSIS WITH CLOZAPINE.	000562 01-0
CYCLIC-AMP IN CEREBROSPINAL FLUID OF MANIC AND DI	000575 01-0 EPRESSIVE
PATIENTS. COMBINED HALOPERIDOL AND LITHIUM-CARBONATE IN T	001683 02-1 REATING MANI
PATIENTS.	002516 03-1
HC-DEPRESSIVE THE IMPACT OF LITHIUM ON THE TREATMENT OF MANIC- DISORDERS.	
LITHIUM AND THE TREATMENT OF ADOLESCENT MANIC-D	000565 01-0 DEPRESSIVE

000714 01-13

LITHIUM AND ERYTHROCYTE MEMBRANE CATION CARRIER STUDIES IN NORMAL AND MANIC-DEPRESSIVE SUBJECTS.

LITHIUM TRANSPORT IN RED BLOOD CELLS OF MANIC-DEPRESSIVE PATIENTS.

000724 01-13

5-238

001555 02-07

VOLUME 16. SUBJECT INDEX

LITHIUM THERAPY

Subject Index

002172 03-03

PHARMACOGENETIC ASPECT OF RED BLOOD CELL LITHIUM INDEX IN MANIC-DEPRESSIVE PSYCHOSIS.

000736 01-13 PROPHYLACTIC VALUE OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS GENETIC ASPECTS.

000952 01-17
MANIA IN CHILDHOOD. II. THERAPEUTIC TRIAL OF LITHIUM-CARBONATE AND FURTHER DESCRIPTION OF MANIC-DEPRESSIVE ILLNESS IN

001578 02-09 RAPID CYCLING MANIC-DEPRESSIVE PATIENTS.

001583 02-09 MANIC-DEPRESSIVE PSYCHOSES.

001586 02-09 PLATELET MONOAMINE-OXIDASE ACTIVITY PREDICTS RESPONSE TO LITHIUM IN MANIC-DEPRESSIVE ILLNESS.

001607 02-09 BIPOLAR MANIC-DEPRESSIVE DISORDER: A REASSESSMENT OF COURSE AND OUTCOME.

001608 02-09 MANIC-DEPRESSIVE ILLNESS AND NEUROTRANSMITTERS.

002253 03-04 TRICYCLIC ANTIDEPRESSANTS ACCELERATE MANIC-DEPRESSIVE CYCLES. (UNPUBLISHED PAPER).

002468 03-09 SPIRONOLACTONE PROPHYLAXIS IN MANIC-DEPRESSIVE DISEASE 003499 04-09

HISTOCOMPATIBILITY ANTIGENS IN LITHIUM TREATED MANIC-

003533 04-09 MANIC-DEPRESSIVES

CIRCADIAN RHYTHM DISORDERS IN MANIC-DEPRESSIVES. 003505 04-09

INTRAPSYCHIC AND FAMILY DYNAMIC PROCESSES IN AN ENDOGENOUS DEPRESSION PRECEDING MANIFESTATION OF THE ILLNESS AND

002461 03-09 PSYCHOSIS: A RARE MANIFESTATION OF DIGOXIN INTOXICATION 002700 03-15

MANIPULATION PHARMACOLOGICAL MANIPULATION OF HOARDING: FURTHER ANALYSIS OF AMPHETAMINE ISOMERS AND PIMOZIDE.

REDUCTION OF HEROIN SELF-ADMINISTRATION IN BABOONS BY MANIPULATION OF BEHAVIORAL AND PHARMACOLOGICAL

001499 02-04 ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING

MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY BENZODIAZEPINES. 002326 03-04

MANIPULATIONS TIME-DEPENDENT CHANGES IN ACTIVITY, REACTIVITY, AND

RESPONSIVITY DURING SHOCK: EFFECTS OF CHOLINERGIC AND CATECHOLAMINERGIC MANIPULATIONS. PHARMACOLOGICAL MANIPULATIONS OF THE SEPTAL IRRITABILITY

SYNDROME: ROLE OF DOPAMINERGIC MECHANISMS IN RECOVERY OF FUNCTION. (PH.D. DISSERTATION). 002089 03-03

ANALYSIS OF THE ROLE PLAYED BY THE SUBSTANTIA-NIGRA IN THE MEDIATION OF INGESTIVE, LOCOMOTOR, AND ROTATIONAL BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL MANIPULATIONS. (PH.D. DISSERTATION). 002247 03-04

THE EFFECT OF NITRAZEPAM ON MANUAL SKILL, GRIP STRENGTH, AND REACTION TIME WITH SPECIAL REFERENCE TO SUBJECTIVE **EVALUATION OF EFFECTS ON SLEEP**

MAO ACTIVITY IN RAT BRAINSTEM AND CEREBRAL-CORTEX FOLLOWING ACUTE AND CHRONIC TREATMENT WITH L-DOPA AND ETHANOL L-

000239 01-03 D AMPHETAMINE INHIBITION OF PLATELET MAO FROM SCHIZOPHRENIC

000543 01-08 MAO INHIBITORS IN CLINICAL PRACTICE: PRINCIPLES BASED ON RECENT

RESEARCH 000578 01-09 ACUTE VERSUS CHRONIC EFFECTS OF MONOAMINE-OXIDASE INHIBITORS

IN DEPRESSED PATIENTS: TIME-COURSE OF MAO INHIBITORS 000733 01-13

MAO INHIBITORS AND CENTRAL MONOAMINE METABOLISM 000991 01-17 EFFECT OF RESERPINE ON THE MONOAMINE-OXIDASE (MAO) ACTIVITY IN RAT LIVER AND BRAIN 003125 04-03 DEPRENIL: LOSS OF SELECTIVITY FOR INHIBITION OF B-TYPE MAO AFTER REPEATED TREATMENT

EFFECTS OF SINGLE DOSES OF TRANYLCYPROMINE ON PLATELET MAD AMINE UPTAKE IN NORMAL SUBJECTS. 003594 04-13

MAG-A
INHIBITION OF BOTH MAC-A AND MAC-B REQUIRED FOR THE
PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE
INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

000398 0 000398 01-04

MAO-B

INHIBITION OF BOTH MAO-A AND MAO-B REQUIRED FOR THE PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

000398 01-04 METHYLHISTAMINE: EVIDENCE FOR SELECTIVE DEAMINATION BY MAO-B IN THE RAT BRAIN IN VIVO.

MAOI

COMBINED TRICYCLIC MAOI THERAPY FOR REFRACTORY DEPRESSION: A REVIEW, WITH GUIDELINES FOR APPROPRIATE USAGE

002437 03-09
TRICYCLIC OVERDOSE IN A PATIENT GIVEN COMBINED TRICYCLIC MAOI TREATMENT

CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIVITY TO THE DIRECT APPLICATION OF MORPHINE AND FOCAL ELECTRICAL STIMULATION IN THE PRODUCTION OF ANTINOCICEPTION IN THE RAT. 001291 02-03

MAPROTILINE

A COMPARISON IN RABBIT ISOLATED HEARTS OF THE COMPARISON IN RABBI TO SOCIALED HEARTS OF THE APPLY THE MAPR AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK NORADRENALINE UPTAKE.

000138 01-03 CLINICAL AND EXPERIMENTAL EXPERIENCE WITH MAPROTILINE, CLOMIPRAMINE, SYDNOCARB, AND MEFEXAMINE IN PSYCHIATRIC PATIENTS AND NORMAL SUBJECTS

000517 01-07 MAPROTILINE -- A DOUBLE-BLIND STUDY OF A NEW TETRACYCLIC ANTIDEPRESSANT IN SEVERE DEPRESSION.

000574 01-09 DOUBLE-BLIND TRIALS OF A NEW TRICYCLIC ANTIDEPRESSANT (LOFEPRAMIN) AND A TETRACYCLIC ANTIDEPRESSANT (MAPROTILINE). 000607 01-10

POISONING WITH MAPROTILINE AND MIANSERIN

000819 01-15 ACUTE POISONING WITH MAPROTILINE HYDROCHLORIDE.

000881 01-15 CLINICAL STUDIES WITH MAPROTILINE AND THE REVERSED CATECHOLAMINE HYPOTHESIS OF DEPRESSION.

O01642 02-13
A COMPARISON OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE (1).
002428 03-09

A COMPARISON OF HIGH AND LOW DOSAGE REGIMES OF MAPROTILINE (LUDIOMIL).

MAPROTILINE (LUDIOMIL) IN DEPRESSION: A MULTICENTRE ASSESSMENT OF ONSET OF ACTION, EFFICACY AND TOLERABILITY.

MAPROTILINE (LUDIOMIL) IN DEPRESSION: A REPORT OF A MONITORED RELEASE STUDY IN GENERAL PRACTICE.

A COMPARATIVE STUDY OF MAPROTILINE (LUDIOMIL) AND VILOXAZINE IN THE MANAGEMENT OF DEPRESSED PATIENTS IN GENERAL

002447 03-09 A COMPARISON OF MAPROTILINE (LUDIOMIL) AND SLOW-RELEASE AMITRIPTYLINE (TRYPTIZOL-SR).

002450 03-09 EFFICACY, SIDE-EFFECTS, PLASMA AND BLOOD LEVELS OF MAPROTILINE (LUDIOMIL).

002451 03-09 A COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE (2) 002452 03-09 THE TREATMENT OF DEPRESSION COMPARING DIVIDED AND SINGLE

DOSES OF MAPROTILINE (LUDIOMIL) 002467 03-09 MAPROTILINE AND DOXEPIN IN THE TREATMENT OF DEPRESSION: A DOUBLE-BLIND MULTICENTRE COMPARISON.

002495 03-10 SECOND-GENERATION ANTIDEPRESSANTS AS RESEARCH TOOLS — SOME PRELIMINARY FINDINGS WITH CLOMIPRAMINE AND MAPROTILINE. 002587 03-13

CLOMIPRAMINE AND MAPROTILINE ON HUMAN PLATELET UPTAKE OF S HYDROXYTRYPTAMINE AND DOPAMINE IN VITRO: TO THEIR ANTIDEPRESSIVE AND OTHER ACTIONS? WHAT RELEVANCE

PRACTICAL CONSIDERATIONS IN THE USE OF MAPROTILINE (LUDIOMIL) IN GENERAL PRACTICE.

CLINICAL STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE CONDITIONS IN OUTPATIENT PRACTICE.

THE ROLE OF HYPOTHALAMIC SEROTONIN (5-HT) BEFORE OVULATION IN IMMATURE RATS TREATED WITH PREGNANT MARE SERUM (PMS). 001287 02-03

POTENTIATION OF THE EPILEPTOGENIC EFFECT OF PENICILLIN-G BY MARIHUANA SMOKING.

002066 03-03 TOXICOLOGICAL AND PHARMACOLOGICAL EFFECTS OF MARIHUANA 002347 03-05

MOTIVATION LEVELS AND THE MARIHUANA HIGH. 002633 03-14

EPIDEMIOLOGY OF MARIHUANA USE.

MARIHUANA: EFFECT ON NONVERBAL FREE RECALL AS A FUNCTION OF FIELD DEPENDENCE.

003300 04-04 THE EFFECT OF MARIHUANA INTOXICATION ON BLOOD PRESSURE. 003724 04-17

MARIJUANA: DOSE-RESPONSE EFFECTS ON PULSE RATE, SUBJECTIVE ESTIMATES OF POTENCY, PLEASANTNESS, AND RECOGNITION MEMORY.

000648 (

000648 01-11 HIGH-PRESSURE LIQUID CHROMATOGRAPHIC MASS SPECTROMETRIC DETERMINATION OF DELTA9-TETRAHYDROCANNABINOL IN HUMAN PLASMA FOLLOWING MARIJUANA SMOKING.

000682 01-12 INTERCORRELATIONS BETWEEN PHYSIOLOGICAL AND PSYCHOLOGICAL EFFECTS OF MARIJUANA, HASHISH, AND THC-DELTA9 IN LONG-TERM

MARIJUANA EFFECTS ON LONG-TERM MEMORY ASSESSMENT AND RETRIEVAL.

000755 01-14 BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC CORRELATES OF THE CHRONIC USE OF MARIJUANA -- A REVIEW.

000766 01-14

THE DISRUPTION OF MARLUUANA INTOXICATION 000782 01-14 WHAT THE PRACTICING PHYSICIAN SHOULD KNOW ABOUT MARIJUANA

000851 01-15 SIDE-EFFECTS OF SIMULTANEOUS ALCOHOL AND MARIJUANA USE 000900 01-15

MARUUANA AND MEMORY INTRUSIONS 001727 02-14

MARUUANA: DIFFERENTIAL EFFECTS ON RIGHT AND LEFT HEMISPHERE FUNCTIONS IN MAN.

001733 02-14 TOLERANCE TO MARIJUANA: HEART RATE AND SUBJECTIVE HIGH. 001818 02-15

MARIJUANA, ALCOHOL, AND COMBINED DRUG EFFECTS ON THE TIME COURSE OF GLARE RECOVERY. 002604 03-14

MARIJUANA: EFFECTS ON FREE RECALL AND SUBJECTIVE ORGANIZATION
OF PICTURES AND WORDS.

002629 03-14

MARIJUANA AND HUMAN PERFORMANCE: AN ANNOTATED BIBLIOGRAPHY (1970-1975).

EFFECTS OF MARIJUANA EXTRACT DISTILLATE AND CANNABIDIOL ON VARIABLE INTERVAL PERFORMANCE AS A FUNCTION OF FOOD DEPRIVATION. 003308 04-04

LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR BLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE IN THE FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE PROBAND

000619 01-11

EFFECTS OF PCPA ON MARKING BEHAVIOUR IN THE MALE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).

CENTRAL AND PERIPHERAL ACTION OF TESTOSTERONE-PROPIONATE ON SCENT GLAND MORPHOLOGY AND MARKING BEHAVIOUR IN THE MONGOLIAN GERBIL.

TIMING AND RISK OF BONE MARROW DEPRESSION BY PSYCHOTROPIC DRUGS.

001770 02-15

003370 04-04

Psychopharmacology Abstracts

MARSH
THE BIOCHEMISTRY OF BRAIN DEVELOPMENT AND MENTAL
RETARDATION: THE ELEVENTH BLAKE MARSH LECTURE DELIVERED
BEFORE THE ROYAL COLLEGE OF PSYCHIATRISTS, 7 FEBRUARY, 1977
002000 03-4 002000 03-03

MASKED PSYCHOTHERAPY IN COMBINATION WITH ANTIDEPRESSANT DRUGS IN PATIENTS WITH SEVERE MASKED DEPRESSIONS.

000572 01-09 LITHIUM INTOXICATION MASKED BY NEUROLEPTIC DRUGS WHEN LITHIUM DIURETIC COMBINATIONS ARE USED.

002682 03-15

MASKING OF TARDIVE-DYSKINESIA WITH FOUR TIMES-A-DAY ADMINISTRATION OF CHLORPROMAZINE.

SS-SPECTROMETRY

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4HYDROXYPHENYLETHANOL (MOPET) IN HUMAN CEREBROSPINAL FLUID
AND RAT BRAIN BY MEANS OF GAS-CHROMATOGRAPHY — MASSSPECTROMETRY.

ESTIMATION OF DEANOL AND CHOLINE BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY.

003426 04-06 HOMOVANILLIC-ACID IN HUMAN CSF: COMPARISON OF FLUOROMETRY AND GAS-CHROMATOGRAPHY MASS-SPECTROMETRY.

ABOUT A NONFATAL MASSIVE INTOXICATION WITH SUSTAINED-RELEASE THIORIDAZINE, CLINICAL AND THERAPEUTIC PROBLEMS.

001752 02-15

003691 04-16

000849 01-15

MASTURBATION
HYPOTHESIZED ADRENERGIC/NORADRENERGIC SUBSTITUTION IN
HABITUAL INFANTILE MASTURBATION: TWO CASES.

001702 02-14

LEVELS OF CHLORPROMAZINE AND ITS ACTIVE MATABOLITES IN RAT BRAIN AND THE RELATIONSHIP TO CENTRAL MONOAMINE METABOLISM AND PROLACTIN SECRETION.

000041 01-03

MATCHING
EFFECTS OF SODIUM PENTOBARBITAL ON SYMBOLIC MATCHING AND
SYMBOLIC ODDITY PERFORMANCE. 003213 04-04

MATERNAL FETAL DISTRIBUTION OF METHAQUALONE IN CONTROL AND SKF-525-A PRETREATED PREGNANT MICE.

000263 01-03 DRUG-INDUCED CHANGES IN THE MATERNAL BEHAVIOR OF RATS 000366 01-04

DOES PROLACTIN PLAY A ROLE IN ESTROGEN-INDUCED MATERNAL BEHAVIOR IN RATS: APOMORPHINE REDUCTION OF PROLACTIN RELEASE.

000445 01-04 FLOPPY INFANT SYNDROME AND MATERNAL DIAZEPAM.

000837 01-15 FLOPPY INFANT SYNDROME AND MATERNAL DIAZEPAM.

000845 01-15 MATERNAL DRUG HISTORIES AND CONGENITAL ABNORMALITIES. 001780 02-15

FLOPPY-INFANT SYNDROME AND MATERNAL DIAZEPAM AND/OR NITRAZEPAM 001835 02-15

EFFECT OF MATERNAL MORPHINE ADMINISTRATION ON FETAL AND NEONATAL RAT LIVER TYROSINE-AMINOTRANSFERASE. 002011 03-03

EFFECTS OF CHRONIC IMIPRAMINE AND CLOMIPRAMINE ORAL ADMINISTRATION ON MATERNAL BEHAVIOR AND LITTER DEVELOPMENT.

EFFECTS OF PROLACTIN, DEXAMETHASONE, AND CORTICOSTERONE ON MATERNAL AGGRESSION AND INFANT CARE.

002240 03-04 EFFECTS OF MATERNAL CHLORPROMAZINE ON OFFSPRING NERVOUS SYSTEM DEVELOPMENT. 002880 04-03

MATERNALLY
THE EFFECT OF MATERNALLY ADMINISTERED METHADONE ON BRAIN
DEVELOPMENT IN THE OFFSPRING.

000483 01-05 EFFECT OF MATERNALLY ADMINISTERED HEROIN ON THE MOTOR ACTIVITY OF RAT OFFSPRING.

INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA:
EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION. 002890 04-03

VOLUME 16, SUBJECT INDEX

Subject Index

LOCAL CEREBRAL GLUCOSE UTILIZATION FOLLOWING INJECTION OF BETA-ENDORPHIN INTO PERIAQUEDUCTAL GRAY MATTER IN THE RAT

SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION: A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL MEMBRANES FROM MATURE RAT BRAIN. 000230 01-03

MAUDSLEY

DIFFERENCES IN BENZODIAZEPINE RECEPTOR BINDING IN MAUDSLEY REACTIVE AND MAUDSLEY NONREACTIVE RATS. 003066 04-03

THE EFFECTS OF AMPHETAMINE ON MAZE LEARNING BY GOLDFISH 000446 01-04 OPEN-FIELD AND LASHLEY III MAZE BEHAVIOUR OF THE OFFSPRING OF AMPHETAMINE TREATED RATS.

MAZINDOL

STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT BRAIN TISSUE SLICES

EFFECTS OF MAZINDOL, FENFLURAMINE AND CHLORIMIPRAMINE ON THE 5 HYDROXYTRYPTAMINE UPTAKE AND STORAGE MECHANISMS IN RAT BRAIN: SIMILARITIES AND DIFFERENCES

001983 03-03 STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAMINE (DA) AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES. 002036 03-03

MAZINDOL EFFECTS ON SCHEDULE-CONTROLLED RESPONDING OF THE

002268 03-04 EFFECTS OF MAZINDOL ON RAT BRAIN SYNAPTOSOMAL MONOAMINE

INVOLUNTARY ADMINISTRATION OF PSYCHOTROPIC DRUGS — GROUNDS FOR SUIT. SOUDER V. MCGUIRE, 423 F.SUPP. 830, (PENNSYLVANIA). M.D. DISTRICT COURT. DECEMBER 9, 1976. 001916 02-17

ANTAGONISM OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA)
LETHALITY BY CHLORPROMAZINE IN THE CONSCIOUS DOG.

O01072 02-03

ALPHA-METHYLDOPAMINE -- A METABOLITE AND KEY INTERMEDIATE IN
THE METABOLIC DISPOSITION OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) IN DOG AND MONKEY

001195 02-03

EFFECT OF CHOLECYSTOKININ ON MEAL SIZE AND INTERMEAL INTERVAL IN THE SHAM-FEEDING RAT. 003264 04-04

CAN SOCIAL INTERACTION BE USED TO MEASURE ANXIETY?

003219 04-04 MANDIBULOGRAM AS A MEASURE OF STEREOTYPED BEHAVIOR IN THE

MEASURED DISCRIMINATIVE PENTOBARBITAL EFFECT MEASURED BY HEAD MOVEMENTS IN RESTRAINED RATS.

DRUG INTERACTIONS AS MEASURED BY DEPRIVATION-INDUCED FLUID CONSUMPTION.

DOPAMINE-MIMETIC ACTIVITY OF ERGOT DERIVATIVES, AS MEASURE BY THE PRODUCTION OF CYCLIC-AMP IN ISOLATED RETINAE OF THE AS MEASURED

002149 03-03 TOLERANCE TO MORPHINE ANALGESIA AND IMMOBILITY MEASURED IN RATS BY CHANGES IN LOG-DOSE-RESPONSE CURVES.

003307 04-04 ON THE ROLE OF HEMISPHERIC DOMINANCE IN SCHIZOPHRENIA AS MEASURED BY EXTRAPYRAMIDAL SIDE-EFFECTS OF NEUROLEPTICS 003675 04-15

MEASUREMENT OF PLASMA ANTIDEPRESSANT LEVELS BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY.

002720 03-16

MEASUREMENT OF PROTEIN TURNOVER IN RAT BRAIN.

METHODOLOGICAL PROBLEMS IN THE MEASUREMENT OF DRUG-INDUCED ROTATIONAL BEHAVIOUR: CONTINUOUS RECORDING REVEALS TIME-COURSE DIFFERENCES UNDETECTED BY PREVIOUS TECHNIQUES 003388 04-04 MEASUREMENT OF PLASMA AND ERYTHROCYTE CHLORPROMAZINE AND

N MONODESMETHYLCHLORPROMAZINE LEVELS BY GAS-CHROMATOGRAPHY WITH A NITROGEN SENSITIVE DETECTOR 003429 04-06 ROUTINE MEASUREMENT OF HOMOVANILLIC-ACID IN RAT BRAIN BY GAS-LIQUID-CHROMATOGRAPHY. 003441 04-06

PHARMACOLOGICAL IMPLICATIONS OF BRAIN ACETYLCHOLINE TURNOVER MEASUREMENTS IN RAT BRAIN NUCLEI.

INTERACTIONS BETWEEN ALCOHOL AND OTHER DRUGS ON OPEN-FIELD AND TEMPERATURE MEASUREMENTS IN GERBILS.

MEASUREMENTS OF WEIGHT AND ACTIVITY IN MALE MICE FOLLOWING
INHALATION OF CANNABIS SMOKE IN A CONTROLLED SMOKE EXPOSURE CHAMBER.

001524 02-05 MEASURES
INTERACTION OF ARENA SIZE WITH DIFFERENT MEASURES OF

003315 04-04

003103 04-03

003427 04-06

AMPHETAMINE EFFECTS. 001329 02-04

DEXTROAMPHETAMINE AND MEASURES OF INTELLIGENCE. 001716 02-14

A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE REPEATED DOSE COMPARISON OF THREE BENZUDIAGETHE DEPENDANCES (INTRAZEPAM, FURAZEPAM AND FLUNITRAZEPAM) ON SUBJECTIVE APPRAISALS OF SLEEP AND ALEASURES OF PSYCHOMOTOR PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION.

001787 02-15

VILOXAZINE IN THE TREATMENT OF DEPRESSION: PSYCHOPHYSICAL MEASURES AND CLINICAL RESPONSE.

ACUTE AND CHRONIC EFFECTS OF LITHIUM-CHLORIDE ON PHYSIOLOGICAL AND PSYCHOLOGICAL MEASURES IN NORMALS. 003600 04-13

MEASURING

MEASURING CHANGES IN CEREBRAL GLUTAMATE AND GABA METABOLISM PRIOR TO CONVULSIONS INDUCED BY 3

001961 03-03

MECAMYLAMINE EFFECT OF MECAMYLAMINE ON THE FATE OF DOPAMINE IN STRIATAL AND MESOLIMBIC AREAS OF RAT BRAIN; INTERACTION WITH MORPHINE AND HALOPERIDOL.

ON THE MECHANISM OF THE DECREASE IN CEREBELLAR CYCLIC-GMP CONTENT ELICITED BY OPIATE RECEPTOR AGONISTS. 6-OHDA AND ITS ANALOGUES: CHEMICAL MECHANISM OF NEUROTOXICITY. STUDY OF THE OXIDATION OF ORTHO-SUBSTITUTED

DOPAMINES. 000059 01-03

DISAGGREGATION OF BRAIN POLYSOMES AFTER D LYSERGIC-ACID-DIETHYLAMIDE ADMINISTRATION IN VIVO: MECHANISM AND EFFECT OF AGE AND ENVIRONMENT.

NEW ASPECTS CONCERNING THE MECHANISM OF ACTION OF TRANQUILIZERS. THE INFLUENCE OF SOME TRANQUILIZERS ON PROTEIN AND NUCLEIC-ACID SYNTHESES. 000165 01-03

SOME OBSERVATIONS ON THE MECHANISM OF BENZODIAZEPINE BARBITURATE INTERACTIONS IN THE MOUSE

000335 01-04 EVIDENCE FOR NORADRENERGIC MECHANISM IN THE GROOMING PRODUCED BY () AMPHETAMINE AND 4,GAMMA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.

000397 01-04 MECHANISM FOR PHENOTHIAZINE OXIDATION

001014 02-01 EVIDENCE FOR A DOUBLE CHOLINERGIC MECHANISM CAPABLE OF REDUCING THE TONE OF CEREBRAL ARTERIES

001049 02-03 NONPARTICIPATION OF CHOLINERGIC MECHANISM IN CHEMICAL CONTROL OF CEREBRAL VASOMOTOR ACTIVITY.

001243 02-03 INTOXICATION BY ORPHENADRINE HCL; MECHANISM AND THERAPY. 001519 02-05

PSYCHOTROPIC DRUGS: MECHANISM OF ACTION AT THE NEUROTRANSMITTER LEVEL.

A NEW MECHANISM OF TRICYCLIC ANTIDEPRESSANT ACTION. BLOCKADE OF PROSTAGLANDIN DEPENDENT CALCIUM MOVEMENTS.

INVESTIGATIONS INTO THE MECHANISM OF THE INFLUENCE OF KININS ON THE ACTION OF AMPHETAMINE.

002101 03-03 STUDIES ON THE MECHANISM OF SPROUTING OF NORADRENERGIC TERMINALS IN RAT AND MOUSE CEREBELLUM AFTER NEONATAL 6 HYDROXYDOPA

ANIMAL MODEL OF DEPRESSION: III. MECHANISM OF ACTION OF TETRABENAZINE 003108 04-03

ETHANOL AND DISPOSITION OF AMYLOBARBITONE: EFFECT OF DOSE AND SIGNIFICANCE AS A MECHANISM FOR INCREASED TOXICITY.

A POSSIBLE PHYSIOLOGICAL MECHANISM FOR SHORT-TERM MEMORY.
003114 04-03
A POSSIBLE PHYSIOLOGICAL MECHANISM FOR SHORT-TERM MEMORY.
003227 04-04 EVIDENCE AGAINST CHRONIC DEPOLARIZATION AS A MECH KAINIC-ACID TOXICITY IN MOUSE CEREBELLAR CULTURES. MECHANISM OF

003418 04-05 MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA.

EFFECTS OF 3,4 DIHYDROOXAZINOINDOLES, POTENTIAL
ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS AND
RELATED ACTIVITIES. 000027 01-02

003460 04-08

DOPAMINERGIC MECHANISMS INVOLVED IN THE ACUTE AND CHRONIC EFFECT OF AMPHETAMINE.

KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES III: NITRAZEPAM.

CENTRAL SITES AND MECHANISMS OF THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF THE NARCOTIC ANALGESIC AGENT FENTANYL.

000179 01-03 AMINERGIC AND THERMOREGULATORY MECHANISMS IN HYPOTHALAMIC REGULATION OF GROWTH HORMONE IN CATS. DO BENZODIAZEPINES AFFECT MOTOR OR SENSORY MECHANISMS?

000250 01-03 DISTINCT DOPAMINERGIC MECHANISMS WITHIN THE NUCLEUS ACCUMBENS OF RATS AND BEHAVIOUR.

000340 01-04 POSSIBLE MECHANISMS INVOLVED IN THE STEREOTYPED BEHAVIOR ELICITED BY AMPHETAMINE.

000372 01-04 POTENTIATION OF BRAIN REWARD MECHANISMS BY PSYCHOMOTOR STIMULANT DRUGS.

000441 01-04 ECHANISMS. 000455 01-04 BENZODIAZEPINES: BEHAVIORAL AND NEUROCHEMICAL A

NEURAL MECHANISMS OF BENZODIAZEPINE ACTIONS

BRAIN MECHANISMS ASSOCIATED WITH THERAPEUTIC ACTIONS OF BENZODIAZEPINES: FOCUS ON NEUROTRANSMITTERS.

MECHANISMS OF SUPERSENSITIVITY. (UNPUBLISHED PAPER) 000746 01-13

PHENYTOIN: AN EVALUATION OF SEVERAL POTENTIAL TERATOGENIC MECHANISMS.

001097 02-03 MECHANISMS OF AMITRIPTYLINE-INDUCED HYPOTHERMIA IN THE RAT. 001176 02-03

DIFFERENTIAL ACTIVATION BY SOME 2 AMINOTETRALIN DERIVATIVES OF THE RECEPTOR MECHANISMS IN THE NUCLEUS-ACCUMBENS OF RAT WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITING.

001335 02-04
CHOLINERGIC MECHANISMS INVOLVED IN HEAD-SHAKING OF INFANT

001380 02-04 EFFECTS OF OPIATES AND OPIOID PEPTIDES ON MOTOR BEHAVIORS: SITES AND MECHANISMS OF ACTION. (UNPUBLISHED PAPER). 001433 02-04

BEHAVIORAL MECHANISMS OF DRUG ACTION IN SCHIZOPHRENIA

NEUROCHEMICAL MECHANISMS OF CENTRAL ACTION OF MORPHINE ON FUNCTIONS OF SINGLE NEURONS IN THE MIDBRAIN RETICULAR FORMATION.

001973 03-03 EFFECTS OF MAZINDOL, FENFLURAMINE AND CHLORIMIPRAMINE ON THE 5 HYDROXYTRYPTAMINE UPTAKE AND STORAGE MECHANISMS IN RAT BRAIN: SIMILARITIES AND DIFFERENCES.

001983 03-03 CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF C-AMP-PHOSPHODIESTERASE.

002023 03-03 PHARMACOLOGICAL MANIPULATIONS OF THE SEPTAL IRRITABILITY SYNDROME: ROLE OF DOPAMINERGIC MECHANISMS IN RECOVERY OF FUNCTION. (PH.D. DISSERTATION).

002089 03-03 EFFICACY OF NEUROLEPTICS AND ANTIDEPRESSANTS IN THE TEST OF APOMORPHINE HYPOTHERMIA AND SOME DATA CONCERNING NEUROCHEMICAL MECHANISMS OF THE TEST.

METRAZOL-INDUCED PETIT-MAL: THE ROLE PLAYED BY MONOAMINERGIC MECHANISMS AND STRIATUM. 002192 03-04

Psychopharmacology Abstracts

BASIC MECHANISMS OF STATE-DEPENDENT LEARNING

002292 03-04

ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY BENZODIAZEPINES.

002326 03-04 CENTRAL MECHANISMS OF DRUGS AS DISCRIMINATIVE STIMULI: INVOLVEMENT OF SEROTONIN PATHWAYS.

003070 04-03

LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO P-CHLOROAMPHETAMINE ON CENTRAL SEROTONERGIC MECHANISMS IN MICE

003098 04-03 DOPAMINE SYNTHESIS AND TYROSINE-HYDROXYLASE ARE REGULATED BY INDEPENDENT DA RECEPTOR MEDIATED MECHANISMS.

003116 04-03 A NEW ANIMAL MODEL FOR SCHIZOPHRENIA: INTERACTIONS WITH ADRENERGIC MECHANISMS.

003175 04-04 BRAIN MECHANISMS OF AMPHETAMINE-INDUCED ANOREXIA, LOCOMOTION, AND STEREOTYPY: A REVIEW.

003189 04-04 BIPHASIC EFFECT OF CHLORPROMAZINE ON RAT PARADOXICAL SLEEP: A STUDY OF DOSE-RELATED MECHANISMS.

003253 04-04 DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE: ORGANIC MOLECULAR MECHANISMS AND NEUROCHEMICAL EVENTS.

003254 04-04 EMERGING CHOLINERGIC MECHANISMS AND ONTOGENY OF RESPONSE INHIBITION IN THE MOUSE.

003336 04-04 CENTRAL MECHANISMS OF REWARD AND THE NARCOTIC CUE

003369 04-04 MOTOR ACTIVITY OF RATS FOLLOWING INTRACEREBRAL INJECTIONS OF DRUGS INFLUENCING GABA MECHANISMS.

PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT
OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC
AND CATECHOLAMINERGIC MECHANISMS BY 6 HYDROXYDOPAMINE
AND 5.6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D.

003407 04-05 DOPAMINERGIC MECHANISMS IN SCHIZOPHRENIA: THE ANTIPSYCHOTIC EFFECT AND THE DISEASE PROCESS.

003452 04-08 THERAPEUTIC ANTAGONISM BETWEEN ANTICHOLINERGICS AND NEUROLEPTICS: POSSIBLE INVOLVEMENT OF CHOLINERGIC MECHANISMS IN SCHIZOPHRENIA.

003473 04-08 NORADRENERGIC AND DOPAMINERGIC MECHANISMS IN GILLES-DE-LA-TOURETTE SYNDROME.

003609 04-13 DRUGS AND REINFORCEMENT MECHANISMS: A CRITICAL REVIEW OF THE CATECHOLAMINE THEORY.

003625 04-14 NEUROTRANSMITTER MECHANISMS DURING MENTAL ILLNESS INDUCED BY ALTERATIONS IN THYROID FUNCTION.

MECHANOGRAPHICAL

A METHOD FOR MECHANOGRAPHICAL RECORDING OF MUSCLE TONE IN
THE RAT: THE EFFECT OF SOME ANTIPARKINSONIAN DRUGS ON
RIGIDITY INDUCED BY RESERVINE.

002346 03-05

THE DIFFERENTIAL EFFECTS OF MECLOFENOXATE ON MEMORY LOSS IN THE ELDERLY. 000777 01-14

MIDAZEPAM
ACTIONS OF IONTOPHORETIC PHENYTOIN AND MEDAZEPAM ON
HIPPOCAMPAL NEURONS. 000196 01-03

EFFECT OF PSYCHOTROPIC DRUGS ON 3,4 DIHYDROXYPHENYLACETIC-ACID (DOPAC) CONTENT IN THE MEDIAL BASAL HYPOTHALAMUS.

001962 03-03 EFFECTS OF MEDIAL RAPHE AND RAPHE MAGNUS LESIONS ON THE ANALGESIC ACTIVITY OF MORPHINE AND METHADONE.

001986 03-03 EFFECTS OF ESTROGEN AND AMINERGIC DRUGS ON THRESHOLDS OF MEDIAL BASAL HYPOTHALAMIC AXONS IN THE MEDIAN EMINENCE OF THE RAT.

002974 04-03

MOTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEDOMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FORBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR. 000086 01-03

VOLUME 16, SUBJECT INDEX

A COMPARISON OF THE EFFECTS OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE STRIATUM, OLFACTORY TUBERCLE AND MEDIAN

000131 01-03 THE CHEMISTRY OF DOPAMINE RECEPTORS IN THE MEDIAN EMINENCE 001085 02-03 SEROTONERGIC BASIS OF REWARD IN MEDIAN RAPHE OF THE RAT

001421 02-04 EFFECTS OF ESTROGEN AND AMINERGIC DRUGS ON THRESHOLDS OF MEDIAL BASAL HYPOTHALAMIC AXONS IN THE MEDIAN EMINENCE OF

002974 04-03

MEDIATE DIFFERENTIAL ACTIVATION BY SOME 2 AMINOTETRALIN DERIVATIVES OF THE RECEPTOR MECHANISMS IN THE NUCLEUS-ACCUMBENS OF RAT WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITING.

001335 02-04 DIFFERENT BRAIN AREAS MEDIATE THE ANALGESIC AND EPILEPTIC PROPERTIES OF ENKEPHALIN.

002915 04-03 MEDIATED

EVIDENCE FOR NOREPINEPHRINE MEDIATED COLLATERAL INHIBITION OF LOCUS-COERULEUS NEURONS.

ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE NEUROBLASTOMA CELLS.

000241 01-03 COCAINE-INDUCED CENTRALLY MEDIATED RELEASE OF CATECHOLAMINES INTO BLOOD OF UNDISTURBED RATS. (UNPUBLISHED PAPER) 001079 02-03

EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS.

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF

001118 02-03 ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002004 03-03 BETA-ADRENERGIC RECEPTOR MEDIATED CYCLIC-AMP SYNTHESIS IN BROKEN-CELL HOMOGENATES OF RAT BRAIN.

002033 03-03 FURTHER EVIDENCE OF CYCLIC-AMP MEDIATED HYPERTROPHY AS A PREREQUISITE OF DRUG SPECIFIC ENZYME INDUCTION.

002086 03-03 ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS

002137 03-03 AMANTADINE-HYDROCHLORIDE (AMN): ANTAGONISM TO ETHANOL (ETOH) MEDIATED RESPONSES IN RODENTS.

002282 03-04 DIRECT AND PITUITARY MEDIATED EFFECTS OF DELTA9-THC AND

CANNABINOL ON THE TESTIS 002881 04-03 MUSCARINIC RECEPTOR MEDIATED CYCLIC-GMP FORMATION BY
CULTURED NERVE CELLS — IONIC DEPENDENCE AND EFFECTS OF LOCAL

003064 04-03 DOPAMINE SYNTHESIS AND TYROSINE-HYDROXYLASE ARE REGULATED BY INDEPENDENT DA RECEPTOR MEDIATED MECHANISMS

003116 04-03 REPEATED EXPOSURE OF RATS TO THE CONVULSANT AGENT FLUROTHYL ENHANCES 5 HYDROXYTRYPTAMINE AND DOPAMINE MEDIATED BEHAVIOURAL RESPONSES

003234 04-04 THE STRIATAL DOPAMINERGIC FUNCTION IS MEDIATED BY THE INHIBITION OF A NIGRAL, NONDOPAMINERGIC NEURONAL SYSTEM VIA A STRIO-NIGRAL GABAERGIC PATHWAY.

003325 04-04 CLINICAL CORRELATES OF TRICYCLIC ANTIDEPRESSANT MEDIATED INHIBITION OF PLATELET MONOAMINE-OXIDASE.

003524 04-09 MEDIATING FLA-136: SELECTIVE AGONIST AT CENTRAL ALPHA-ADRENORECEPTORS

MEDIATING CHANGES IN THE TURNOVER OF NORADRENALINE 000043 01-03 PARAVENTRICULAR NUCLEUS: A PRIMARY SITE MEDIATING ADRENERGIC STIMULATION OF FEEDING AND DRINKING. 002074 03-03

MEDIATION INVOLVEMENT OF CENTRAL NORADRENERGIC SYSTEM IN THE MEDIATION OF BEHAVIORAL SUPPRESSANT EFFECTS OF DIAZEPAM IN HYPERTHYROID RATS

Subject Index

001199 02-03

A POSSIBLE ROLE OF THE PAG IN THE MEDIATION OF SUBJECTIVE EFFECTS OF MORPHINE

DUAL RECEPTOR MEDIATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF PENTAZOCINE.

002191 03-04 ANALYSIS OF THE ROLE PLAYED BY THE SUBSTANTIA-NIGRA IN THE MEDIATION OF INGESTIVE, LOCOMOTOR, AND ROTATIONAL BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL MANIPULATIONS. (PH.D. DISSERTATION).

002247 03-04 MEDIATORS PHENYLETHYLAMINES AS MEDIATORS OF THE CNS EFFECTS OF **AMPHETAMINE**

MEDICAL LONG-TERM TREATMENT OF SCHIZOPHRENIA IN MEDICAL PRACTICE 000529 01-08
MEDICAL SCREENING OF PATIENTS ON MAINTENANCE NEUROLEPTICS.

THE AMPHETAMINES: MEDICAL USES AND HEALTH HAZARDS.
000842 01-15

MANAGEMENT. 000938 01-17 SUBTYPES OF DEPRESSION -- DIAGNOSIS AND MEDICAL

PSYCHIATRIC DRUGS IN MEDICAL PRACTICE.

000946 01-17
THE ROLE OF BENZODIAZEPINES IN NONPSYCHIATRIC MEDICAL PRACTICE.
000960 01-17

CHOICE OF MEDICAL TREATMENT IN SCHIZOPHRENIA 001564 02-08
THANATOPHARMACOLOGY IN THE MEDICAL SCHOOL CURRICULUM.

001910 02-17 SINGLE-BLIND EVALUATION OF HYPNOTIC ACTIVITY OF CHLORDESMETHYLDIAZEPAM IN NO-PLACEBO REACTOR MEDICAL

PATIENTS DRUG UTILIZATION AND ADVERSE DRUG REACTIONS IN MEDICAL PATIENTS: COMPARISON OF TWO PERIODS, 1969-72 AND 1973-76.
002684 03-15

THE USE OF PSYCHOTROPIC DRUGS IN STATE HOSPITALS: MEDICAL DECISION?.

002730 03-17 MEDICAL TREATMENT OF MENTAL ILLNESS.

003618 04-14

COMPARING TREATMENT TACTICS WITH A HYPERACTIVE PRESCHOOL CHILD: STIMULANT MEDICATION AND PROGRAMMED TEACHER INTERVENTION

000660 01-11 TREATING BLURRED VISION ASSOCIATED WITH ANTIPSYCHOTIC MEDICATION.

000810 01-15 THE MEDICATION CLINIC IN THE SPECTRUM OF CHILDRENS 000955 01-17

MEDICATION CLASSES FOR THE EMOTIONALLY ILL

THE EFFECTS OF AN ANTIPSYCHOTIC MEDICATION ON THE CLASSROOM BEHAVIOR OF FOUR SCHIZOPHRENIC MALE CHILDREN.

VIDEO EDITING AND MEDICATION TO PRODUCE A THERAPEUTIC SELF-001707 02-14

ADVERSE REACTIONS TO MEDICATION IN PSYCHIATRIC INPATIENTS: THEIR MEANING, UTILITY AND PROBLEMS. 001744 02-15

MOOD ELEVATION AND MEDICATION

A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE
DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON
SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR
PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION.
001787 02-15

SUDDEN DEATH OF PATIENTS USING PSYCHOTROPIC MEDICATION 001796 02-15
PSYCHOLOGICAL SIDE-EFFECTS OF L-DOPA AND ANTICONVULSANT MEDICATION.

TOWARD AN EGO-ORIENTED APPROACH TO THE STUDY OF THE EFFECTS
OF PSYCHOACTIVE MEDICATION IN THE TREATMENT OF CHILDREN.
001875 02-16

CONSUMPTION OF MEDICATION AND RISK OF DEVIANCE AMONG TIME-RESPONSE ANALYSIS OF THE EFFECT OF STIMULANT MEDICATION

ON THE LEARNING ABILITY OF CHILDREN REFERRED FOR HYPERACTIVITY

CLINICAL LABORATORY STUDIES WITH SPECIAL REGARD TO HEPATIC METABOLISM IN SCHIZOPHRENICS ON OUTPATIENT LONG-TERM NEUROLEPTIC MEDICATION.

THE EFFECTS OF OBSTETRICAL MEDICATION ON THE BEHAVIOR OF ISRAELI NEWBORN INFANTS AND SOME COMPARISONS WITH URUGUAYAN AND AMERICAN INFANTS.

002673 03-15 WHAT IS AN ADEQUATE THERAPEUTIC TRIAL OF PSYCHOTROPIC MEDICATION?.

002775 03-17

THE USE OF A CHECKLIST IN OBTAINING INFORMED-CONSENT FOR TREATMENT WITH MEDICATION.

002778 03-17 MEDICATION IN RESIDENTIAL TREATMENT: ADMINISTRATION AND CLINICAL EXPERIENCES.

003561 04-11 BEHAVIOR THERAPY AND WITHDRAWAL OF STIMULANT HYPERACTIVE CHILDREN. MEDICATION IN

003566 04-11 FACTORS INFLUENCING WILLINGNESS TO COMPLY AND ACTUAL COMPLIANCE WITH MEDICATION REGIMENS. (PH.D. DISSERTATION) 003722 04-17

ON PRESCRIBING MEDICATIONS FOR RECOVERING ALCOHOLIC PATIENTS. A SUBJECTIVE AND OBJECTIVE METHOD ASSESSING THE EFFICACY OF HYPNOTIC MEDICATIONS IN INSOMNIACS.

A COMPARISON OF THE EFFECTS OF SEIZURES AND TWO ANTICONVULSANT MEDICATIONS ON LEARNING IN THE PAPIO-PAPIO BABOON. (PH.D. DISSERTATION). 002329 03-04

STEREOCHEMICAL STUDIES ON MEDICINAL AGENTS. 23. SYNTHESIS AND BIOLOGICAL EVALUATION OF 6 AMINO DERIVATIVES OF NALOXONE AND NALTREXONE. 001004 02-01

MERCURY CONTENT OF MEDICINAL LITHIUM PREPARATIONS 001797 02-15

MEDICINE
PLACEBO AND ITS IMPORTANCE IN MEDICINE.

000994 01-17 INCREASED PRESCRIBING OF VALIUM, LIBRIUM, AND OTHER DRUGS —
AN EXAMPLE OF THE INFLUENCE OF ECONOMIC AND SOCIAL FACTORS
ON THE PRACTICE OF MEDICINE.

000995 01-17 PSYCHOPHARMACOLOGY IN THE PRACTICE OF MEDICINE. 001904 02-17 **HOW I PRACTICE MEDICINE**

001907 02-17 COCAINE IN CLINICAL MEDICINE

002546 03-13 PSYCHOSOMATIC MEDICINE TODAY: AN OVERVIEW.

THE HIDDEN COST OF MIND MEDICINES. 002674 03-15

EFFECT OF MORPHINE ON THE BASAL AND THE DOPAMINE-INDUCED RELEASE OF LHRH FROM MEDIOBASAL HYPOTHALAMIC FRAGMENTS

003072 04-03

002748 03-17

001015 02-01

OXIDATION KINETICS OF PHENOTHIAZINE AND 10 METHYLPHENOTHIAZINE IN ACIDIC MEDIUM.

MEDROXYPROGESTERONE-ACETATE
PRENATAL EXPOSURE TO MEDROXYPROGESTERONE-ACETATE (MPA) IN

002615 03-14 TREATMENT OF OBSESSIVE HOMOSEXUAL PEDOPHILIC FANTASIES WITH MEDROXYPROGESTERONE-ACETATE.

003543 04-10

TYROSINE-HYDROXYLASE: DELAYED ACTIVATION IN CENTRAL NORADRENERGIC NEURONS AND INDUCTION IN ADRENAL MEDULLA ELICITED BY STIMULATION OF CENTRAL CHOLINERGIC RECEPTORS. 000183 01-03

INHIBITION OF PROSTAGLANDIN SYNTHETASE SYSTEM IN THE RABBIT RENAL MEDULLA BY PSYCHOTROPIC DRUGS.

SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT AND NEWBORN RATS.

THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF THE MEDULLA-OBLONGATA IS A HIGHLY SENSITIVE SITE IN THE PRODUCTION OF MORPHINE ANALGESIA IN THE RAT.

001256 02-03

001215 02-03

Psychopharmacology Abstracts

EFFECTS ON TEMPERATURE OF MORPHINE INJECTED INTO THE PREOPTIC/ ANTERIOR HYPOTHALAMUS, MEDULLA-OBLONGATA, AND PERIPHERALLY IN UNRESTRAINED AND RESTRAINED RATS.

ANALGESIA BY ENKEPHALINS INJECTED INTO THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF RAT MEDULLA-OBLONGATA.

CLINICAL AND EXPERIMENTAL EXPERIENCE WITH MAPROTILINE, CLOMIPRAMINE, SYDNOCARB, AND MEFEXAMINE IN PSYCHIATRIC PATIENTS AND NORMAL SUBJECTS.

000517 01

000517 01-07

ANIN
COMPETITIVE BINDING BETWEEN COCAINE AND VARIOUS DRUGS TO SYNTHETIC LEVODOPA MELANIN.

QUANTITATION OF BINDING OF H3-CHLORPROMAZINE TO SYNTHETIC MELANINS AND MELANIN GRANULES. 002354 03-05

MELANINS

QUANTITATION OF BINDING OF H3-CHLORPROMAZINE TO SYNTHETIC

MELANINS AND MELANIN GRANULES.

002254.0 002354 03-05

MELANOCYTE-STIMULATING
COMPARISON OF THYROTROPIN-RELEASING HORMONE WITH
MELANOCYTE-STIMULATING HORMONE RELEASE INHIBITING FACTOR
AS PENTOBARBITAL ANTAGONISTS IN MONKEYS.

AELATONIN

ELEVATED MELATONIN SERUM CONCENTRATIONS IN PSYCHIATRIC
PATIENTS TREATED WITH CHLORPROMAZINE.

002595 03-13 SUPPRESSION OF LOCOMOTOR ACTIVITY IN SPARROWS BY TREATMENT WITH MELATONIN.

000087 01-03

MELLARIL-SANDOZ

EFFECT OF THIORIDAZINE (MELLARIL-SANDOZ) ON PSYCHOMOTOR
FUNCTION, CONCENTRATION, AND REACTIVITY IN CHILDREN WITH
BEHAVIOR DISORDERS.

002527 03-11

THE EFFECT OF MELPERONE (BURONIL(R)) AND ITS METABOLITE FG-5155
ON THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM COMPARED TO SOME
OTHER NEUROLEPTICS.

001081 02-03 IN VITRO AUTONOMIC EFFECTS OF FOUR NEUROLEPTICS: CHLORPROMAZINE, HALOPERIDOL, MELPERONE AND THIORIDAZINE

001212 02-03 RELATIONSHIPS BETWEEN CLINICAL AND BIOCHEMICAL EFFECTS OF MELPERONE AND THIOTHIXENE IN PSYCHOTIC WOMEN.

001557 02-08

CLINICAL AND BIOCHEMICAL CHANGES IN PSYCHOTIC WOMEN TREATED WITH MELPERONE OR THIOTHIXENE. 002388 03-08

EFFECTS OF MELPERONE AND THIOTHIXENE ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC WOMEN. 002547 03-13

COMPARISON OF THE ELECTROPHYSIOLOGICAL EFFECTS OF TWO NEUROLEPTICS, MELPERONE AND THIORIDAZINE, ON ISOLATED RAT ATRIA 003417 04-05

MEMBRANE LIPIDS AS INTRACELLULAR BINDERS OF CHLORPROMAZINE AND RELATED DRUGS.

000095 01-

000095 01-03 COLCHICINE BLOCKS NEUROTROPIC REGULATION OF THE RESTING MEMBRANE POTENTIAL IN REINNERVATING SKELETAL MUSCLE

000262 01-03 ANTISCHIZOPHRENIC DRUGS -- MEMBRANE RECEPTOR SITES OF ACTION 000547 01-08

LITHIUM AND ERYTHROCYTE MEMBRANE CATION CARRIER STUDIES IN NORMAL AND MANIC-DEPRESSIVE SUBJECTS.

000717 01-13 PROPERTIES OF THE PERIPHERAL OPIATE RECEPTORS IN THE CAT NICITATING MEMBRANE.

001113 02-03 THE EFFECT OF CHLORPROMAZINE ON CELL MEMBRANE RESISTANCE AND CAPACITANCE.

001247 02-03 DIAZEPAM BLOCKADE OF REPETITIVE ACTION POTENTIALS IN SKELETAL MUSCLE FIBRES: A MODEL OF ITS MEMBRANE ACTION.

001275 02-03 TRANSFER OF LITHIUM-IONS ACROSS THE ERYTHROCYTE MEMBRANE

EFFECTS OF CHLORPROMAZINE AND DL-AMPHETAMINE ON CALCIUM UPTAKE BY ADRENAL CHROMAFFIN CELL MEMBRANE.

LITHIUM TRANSPORT ACROSS THE RED BLOOD CELL MEMBRANE 002553 03-13 MULTIPLE MEMBRANE ACTIONS OF ENKEPHALIN REVEALED USING CULTURED SPINAL NEURONS. 02816 04-03

INTERACTIONS OF ADRENERGIC COMPOUNDS WITH BRAIN MEMBRANE 002939 04-03

MEMBRANE-BOUND
NONSPECIFIC INHIBITION OF SOME RAT LIVER MEMBRANE-BOUND ONSPECIFIC INHIBITION OF SOME RAT LEVER MILITARY RMI-12330-A.
ENZYMES BY AN ADENYLATE-CYCLASE INHIBITOR, RMI-12330-A.
002936 04-03

EFFECTS OF LITHIUM ON THE MEMBRANE-BOUND MAGNESIUM DEPENDENT ATPASE OF MOUSE NEUROBLASTOMA CELLS 003087 04-03

ROLE OF PHOSPHOLIPIDS IN MUSCARINIC BINDING BY NEURAL

INFLUENCE OF CHRONIC PENTOBARBITAL OR MORPHINE TREATMENT ON THE INCORPORATION OF P32-PHOSPHORIC-ACID AND 3H CHOLINE INTO RAT SYNAPTIC PLASMA MEMBRANES.

000147 01-03 SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION: A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL MEMBRANES FROM MATURE RAT BRAIN.

000230 01-03 THE EFFECT OF PH ON STEREOSPECIFIC OPIATE BINDING TO MOUSE BRAIN MEMBRANES

000271 01-03 **DEVELOPMENT OF DENERVATION ALTERATIONS IN SURFACE MEMBRANES** OF MAMMALIAN SKELETAL MUSCLE.

001246 02-03 COMPUTER SIMULATION OF THE MOVEMENT OF LITHIUM ACROSS ERYTHROCYTE MEMBRANES IN VITRO.

001869 02-16 EVIDENCE FOR AN ENDOGENOUS FACTOR INTERFERING WITH H3-DIAZEPAM BINDING TO RAT BRAIN MEMBRANES

002789 04-01 TWO BINDING SITES FOR H3-SPIROPERIDOL ON RAT STRIATAL

MEMBRANES 002843 04-03

H3-CLOZAPINE BINDING TO RAT BRAIN MEMBRANES. 002940 04-03 STRUCTURE-ACTIVITY STUDIES ON THE INHIBITION OF GABA BINDING TO

RAT BRAIN MEMBRANES BY MUSCIMOL AND RELATED COMPOUNDS 002981 04-03 STRYCHNINE BINDING ASSOCIATED WITH SYNAPTIC GLYCINE RECEPTORS

IN RAT SPINAL CORD MEMBRANES: IONIC INFLUENCES. 003024 04-03 CHARACTERIZATION OF ALPHA-ADRENERGIC AND BETA-ADRENERG

RECEPTORS IN MEMBRANES PREPARED FROM THE RABBIT IRIS BEFORE AND AFTER DEVELOPMENT OF SUPERSENSITIVITY. 003035 04-03

MEMORIZATION

MEMORIZATION AND CENTRAL CATECHOLAMINES AFTER A CRANIOCERVICAL INJURY CARRIED OUT IN RATS: INFLUENCE OF IMPRAMINE ADMINISTRATION. 002197 03-04

EFFECTS OF CATECHOLAMINERGIC DRUGS UPON MEMORY STORAGE PROCESSES IN MICE

MEMORY IMPAIRMENT CORRELATES CLOSELY WITH CYCLOHEXIMIDE DOSE AND DEGREE OF INHIBITION OF PROTEIN SYNTHESIS

000436 01-04 MARIJUANA: DOSE-RESPONSE EFFECTS ON PULSE RATE, SUBJECTIVE ESTIMATES OF POTENCY, PLEASANTNESS, AND RECOGNITION MEMORY

000648 01-11 PHARMACOPSYCHOLOGICAL INVESTIGATION OF THE EFFECT OF SEDATIVES ON MEMORY AND LEARNING PERFORMANCE IN CHILDREN AND ADOLESCENTS

000751 01-14 MARIJUANA EFFECTS ON LONG-TERM MEMORY ASSESSMENT AND RETRIEVAL

000755 01-14 MEMORY AND COGNITIVE FUNCTION IN MAN: DOES THE CHOLINERGIC SYSTEM HAVE A SPECIFIC ROLE?

000761 01-14 THE DIFFERENTIAL EFFECTS OF MECLOFENOXATE ON MEMORY LOSS IN THE ELDERLY.

000777 01-14 FAILURE OF METHADONE AND LEVOMETHADYL-ACETATE (LEVO-ALPHA-ACETYLMETHADOL, LAAM) MAINTENANCE TO AFFECT MEMORY

000841 01-15 CHLORPROMAZINE ENHANCES MEMORY IN CHICKS 001341 02-04

MARIJUANA AND MEMORY INTRUSIONS. 001727 02-14 EFFECTS OF LITHIUM-SALTS ON MEMORY. 001798 02-15

001915 02-17 SYSTEM APPROACH IN EXPERIMENTAL PSYCHOPHARMACOLOGY AND MEMORY

001924 02-17 SHORT-TERM MEMORY: A NEUROPHARMACOLOGICALLY DISTINCT PROCESS

MEMORY: MODIFICATION OF ANISOMYCIN-INDUCED AMNESIA BY STIMULANTS AND DEPRESSANTS 002232 03-04

MEMORY FACILITATING AND ANTIAMNESIC EFFECTS OF CORTICOSTEROIDS

NOW RCA ATTACKS MEMORY AID DRUGS

TOLERANCE TO SEDATIVE HYPNOTICS, MEMORY AND NORADRENERGIC (NE) SYSTEMS

002318 03-04 INFLUENCE OF VASOPRESSIN ON LEARNING AND MEMORY

002385 03-07 A DOUBLE-BLIND INVESTIGATION OF PIRACETAM (NOOTROPIL) VERSUS PLACEBO IN THE MEMORY OF GERIATRIC INPATIENTS.

002502 03-11 THE EFFECTS OF ACTH4-10 VERSUS PLACEBO IN THE MEMORY OF SYMPTOMATIC GERIATRIC VOLUNTEERS.

INFLUENCE OF TRYPTOPHAN ON MEMORY FUNCTIONS IN DEPRESSIVE PATIENTS TREATED WITH UNILATERAL ECT.

002613 03-14 EFFECTS OF MSH/ACTH4-10 ON MEMORY, ATTENTION, AND ENDOGENOUS HORMONE LEVELS IN WOMEN.

OXYTOCIN, VASOPRESSIN AND MEMORY: OPPOSITE EFFECTS ON CONSOLIDATION AND RETRIEVAL PROCESSES

O03174 04-04
A POSSIBLE PHYSIOLOGICAL MECHANISM FOR SHORT-TERM MEMORY.
003227 04-04 CATECHOLAMINE LEVELS IN THE WHOLE BRAIN AND THE PROBABILITY OF

MEMORY FORMATION ARE NOT RELATED. 003328 04-04 POSSIBLE BIOCHEMICAL BASIS OF MEMORY DISORDER IN ALZHEIMER

DISEASE 003575 04-11 MEMORY CONSOLIDATION AND CHOLINERGIC STATE-DEPENDENT LEARNING IN MAN.

003612 04-13 AAFM

THE PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS. A TEST OF DOPAMINERGIC BLOCKADE: NEUROENDOCRINE STUDIES IN NORMAL

001867 02-16
EFFECTS OF PERPHENAZINE-ENANTHATE INJECTIONS ON PROLACTIN LEVELS IN PLASMA FROM SCHIZOPHRENIC WOMEN AND MEN 003462 04-08

MEMORAUKAI EFFECT OF EXOGENOUS ESTROGENS ON DEPRESSION IN MENOPAUSAL WOMEN

001603 02-09 MENTAL

POSSIBLE SIGNIFICANCE OF ACTH FRAGMENTS FOR HUMAN MENTAL PERFORMANCE 000465 01-04 EFFICACY OF SCH-12679 IN THE MANAGEMENT OF AGGRESSIVE MENTAL

RETARDATES 000506 01-07
PSYCHIATRIC DRUGS FOR THE NONMEDICAL MENTAL HEALTH WORKER.
000953 01-17

EFFECT OF FUSARIC-ACID ON TARDIVE-DYSKINESIA AND MENTAL STATE IN PSYCHOGERIATRIC PATIENTS: A PILOT STUDY.

001629 02-11 CIMETIDINE AND MENTAL CONFUSION 001810 02-15

THE BIOCHEMISTRY OF BRAIN DEVELOPMENT AND MENTAL
RETARDATION: THE ELEVENTH BLAKE MARSH LECTURE DELIVERED BEFORE THE ROYAL COLLEGE OF PSYCHIATRISTS, 7 FEBRUARY, 1977. 002000 03-03

EFFECTS OF PIRACETAM ON REGIONAL CEREBRAL BLOOD FLOW AND MENTAL FUNCTIONS IN PATIENTS WITH ORGANIC DEMENTIA 002512 03-11 CHEMOTHERAPY IN MENTAL DISORDERS IN CHILDHOOD AND

ADOLESCENCE. 002735 03-17 RESEARCH FINDINGS ON CHRONIC MENTAL ILLNESS: A MODEL FOR CONTINUING-CARE IN THE HEALTH MAINTENANCE ORGANIZATION

002777 03-17

BIOCHEMISTRY OF MENTAL DISORDERS: NEW VISTAS. 002781 03-17 MEDICAL TREATMENT OF MENTAL ILLNESS.

003618 04-14
NEUROTRANSMITTER MECHANISMS DURING MENTAL ILLNESS INDUCED BY ALTERATIONS IN THYROID FUNCTION. 003636 04-14

Subject Index CHOLINERGIC INVOLVEMENT IN MENTAL DISORDERS. 003710 04-17 MENTALLY RETARDED, HYPERKINETIC, AND PSYCHOTIC. 000584 01-09 LITHIUM TREATMENT OF CYCLICAL VOMITING IN A MENTALLY DEFECTIVE PATIENT. 000977 01-17 DEVELOPMENT OF DRUG THERAPY FOR THE MENTALLY ILL 001551 02-07 CEREBELLAR ATROPHY IN PHENYTOIN TREATED MENTALLY RETARDED EPILEPTICS. 001622 02-11 LITHIUM-CARBONATE IN THE MANAGEMENT OF HYPERACTIVE AGGRESSIVE BEHAVIOR OF THE MENTALLY RETARDED. 001713 02-14 WEO-TETRAHYDRO-BETA-CARBOLINE

UPTAKE OF 5 METHOXYTRYPTOLINE (6 MEO-TETRAHYDRO-BETA-CARBOLINE) BY BLOOD PLATELETS AND ITS EFFECT ON 5-HT UPTAKE AND RELEASE. 001043 02-03 ERIDINE
MEPERIDINE EFFECTS ON SCHEDULE-CONTROLLED RESPONDING.
000400 01-04 A POTENTIALLY TOXIC DRUG INTERACTION BETWEEN PETHIDINE (MEPERIDINE) AND PHENOBARBITONE. 001836 02-15 EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DEPLETIONS OF BRAIN CATECHOLAMINES OR DOPAMINE ON MEPERIDINE ANTINOCICEPTION IN RATS. 002227 03-04 DOXEPIN IN THE TREATMENT OF NEUROSES: A COMPARATIVE CLINICAL STUDY OF DOXEPIN, CHLORDIAZEPOXIDE, HYDROXYZINE, MEPROBAMATE, AND PHENOBARBITAL. 000614 01-10 SPECTRAL ANALYSIS OF THE DIFFERING EEG EFFECTS OF BENZODIAZEPINES, MEPROBAMATE, GLUTETHIMIDE AND AMOBARBITAL IN MACACA-MULATTA. 001130 02-03 SEVERE MEPROBAMATE POISONING: SUCCESSFUL TREATMENT WITH HEMOPERFUSION. 001764 02-15 MERCAPTOPROPIONATE

MEASURING CHANGES IN CEREBRAL GLUTAMATE AND GABA

METABOLISM PRIOR TO CONVULSIONS INDUCED BY 3

MERCAPTOPROPIONATE. 001961 03-03 MERCURY CONTENT OF MEDICINAL LITHIUM PREPARATIONS 001797 02-15 BEHAVIORAL CHANGES AND MERCURY CONCENTRATIONS IN TISSUES OF RATS EXPOSED TO MERCURY VAPOR. 003258 04-04 MERIONES-UNGUICULATUS

EFFECTS OF PCPA ON MARKING BEHAVIOUR IN THE MALE MONGOLIAN
GERBIL (MERIONES-UNGUICULATUS). 001307 02-04

MERRY-GO-ROUND
CLINICAL PARABLE: MIRTHLESS MERRY-GO-ROUND. 003463 04-08 AN INVESTIGATION OF SOPHORA-SECUNDIFLORA SEEDS (MESCALBEANS) 000007 01-01 MESCALINE

A NEW VIEW OF THE STRUCTURAL RELATIONSHIP BETWEEN LSD AND MESCALINE. 000419 01-04

NTRAL ANTAGONISM OF TYRAMINE-INDUCED SYSTEMIC HYPOTENSION BY MESCALINE.

IDENTIFICATION OF SHORT TIME INTERVALS UNDER LSD-25 AND

6 HYDROXYDOPAMINE INHIBITS SOME EFFECTS OF MESCALINE CENTRALLY ADMINISTERED TO RABBITS.

PHARMACOLOGICAL AND BEHAVIORAL COMPONENTS OF LSD AND MESCALINE IN RATS.

EFFECTS OF MESCALINE AND PSILOCIN ON ACQUISITION, CONSOLIDATION, AND PERFORMANCE OF LIGHT-DARK DISCRIMINATION IN TWO INBRED STRAINS OF MICE.

MESCALINE-DEMETHYLASE

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES:

MESCALINE-DEMETHYLASE ACTIVITY OF BRAIN-CORTEX SOLUBLE

MESCALINE.

SUPERNATANT

Psychopharmacology Abstracts MESCALINE-INDUCED

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES:
MESCALINE-DEMETHYLASE ACTIVITY OF BRAIN-CORTEX SOLUBLE SUPERNATANT.

000090 A PRESYNAPTIC SITE OF ACTION WITHIN THE MESENCEPHALIC RETICULAR FORMATION FOR () AMPHETAMINE-INDUCED ELECTROCORTICAL DESYNCHRONIZATION. 001069 02-03 MESENCEPHALO-CORTICO-LIMBIC

FURTHER EVIDENCES ON THE BEHAVIOURAL EFFECTS OF SELECTIVE A-10

DOPAMINERGIC MESENCEPHALO-CORTICO-LIMBIC GROUP LESION IN THE RAT. 000399 01-04 DOPAMINE-BETA-HYDROXYLASE RELEASE FOLLOWING ACUTE SELECTIVE SYMPATHETIC NERVE STIMULATION OF THE HEART, SPLEEN AND MESENTERY. 003422 04-06 MESOCORTICAL

ACTION OF THE PALMITIC ESTER OF PIPOTIAZINE ON DOPAMINE
METABOLISM IN THE NIGROSTRIATAL, MESOLIMBIC AND
MESOCORTICAL SYSTEMS. 000258 01-03 MODIFICATION OF DREAM CONTENT AFTER PREFERENTIAL BLOCKADE OF MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS. 002619 03-14 MESOLIMBIC

EXCITATORY ACTION OF THE MESOLIMBIC DOPAMINE SYSTEM ON SEPTAL NEURONES.

000045 000045 01-03 ACTION OF THE PALMITIC ESTER OF PIPOTIAZINE ON DOPAMINE METABOLISM IN THE NIGROSTRIATAL, MESOLIMBIC AND MESOCORTICAL SYSTEMS. 000258 01-03 MESOLIMBIC DOPAMINE NEURONS: EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DESTRUCTION AND RECEPTOR BLOCKADE ON DRUG-INDUCED ROTATION OF RATS. 002258 03-04 MODIFICATION OF DREAM CONTENT AFTER PREFERENTIAL BLOCKADE OF MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS. 002619 03-14 EFFECTS ON STRIATAL AND MESOLIMBIC DOPAMINE SYSTEMS OF A NEW POTENTIAL ANTIPSYCHOTIC DRUG -- MEZILAMINE -- WITH WEAK CATALEPTOGENIC PROPERTIES. 002800 04-02 EFFECT OF MECAMYLAMINE ON THE FATE OF DOPAMINE IN STRIATAL AND MESOLIMBIC AREAS OF RAT BRAIN; INTERACTION WITH MORPHINE AND HALOPERIDOL. 002806 04-03 THE EFFECTS OF STANDARD NEUROLEPTIC COMPOUNDS ON THE BINDING OF H3-SPIROPERIDOL IN THE STRIATUM AND MESOLIMBIC SYSTEM OF THE RAT IN VITRO. EFFECT OF METERGOLINE, P-CHLOROPHENYLALANINE AND DOPA ON DELAYED RESPONSE IN CATS AND THE RELATIONSHIP BETWEEN THE MESOLIMBIC AND NIGROSTRIATAL NEURONS. 003339 04-04 MESORIDAZINE
THE EFFECTS OF NORTRIPTYLINE AND MESORIDAZINE ON NEURONS AND 000130 01-03 SUCCESSFUL SUICIDES WITH THIORIDAZINE AND MESORIDAZINE 000823 01-15 IN VIVO CONVERSION OF MESORIDAZINE TO THIORIDAZINE 003591 04-13 SECOND MESSENGER RESPONSES AND REGULATION OF HIGH AFFINITY RECEPTOR BINDING TO STUDY PHARMACOLOGICAL MODIFICATION OF GABAERGIC TRANSMISSION. (UNPUBLISHED PAPER). 000133 01-03 MET-ENKEPHALIN
POTENT PROLACTIN AND GROWTH HORMONE RELEASING ACTIVITY OF MORE ANALOGUES OF MET-ENKEPHALIN. 000019 01-02 GAMMA-ENDORPHIN, ALPHA-ENDORPHIN AND MET-ENKEPHALIN ARE FORMED EXTRACELLULARLY FROM LIPOTROPIN C-FRAGMENT. 001963 03-03 NARCOTIC CUEING PROPERTIES OF INTRAVENTRICULARLY ADMINISTERED SUFENTANIL, FENTANYL, MORPHINE AND MET-ENKEPHALIN. 002217 03-04 EFFECTS OF MET-ENKEPHALIN ON BODY TEMPERATURE OF NORMAL AND MORPHINE-TOLERANT RATS.

MORPHINE AND MET-ENKEPHALIN EFFECTS ON SURAL-ADELTA AFFERENT TERMINAL EXCITABILITY.

003076 04-03

001252 02-03

001635 02-12

002231 03-04

003184 04-04

TOLFRANCE TO 002286 03-04

001108 02-03

001289 02-03

INFLUENCE OF NEUROLEPTICS ON THE BINDING OF MET-ENKEPHALIN, MORPHINE AND DIHYDROMORPHINE TO SYNAPTOSOME ENRICHED FRACTIONS OF RAT BRAIN.

003096 04-03

THE METABOLIC FATE OF C14-PHENOBARBITONE IN THE RAT AND THE EFFECT OF CHRONIC ADMINISTRATION AND DOSE SIZE.

METABOLIC BASIS FOR THE SUPRA-ADDITIVE EFFECT OF THE ETHANOL DIAZEPAM COMBINATION IN MICE.

000218 01-03
METABOLIC RESPONSES TO ISOPROTERENOL AND EPINEPHRINE IN THE
RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES
AND PRETREATMENT WITH PROPRANOLOL.

EFFECTS OF BETA-BUNGAROTOXIN, DIPHENYLHYDANTOIN AND METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT CATIONS AND HIGH-ENERGY PHOSPHATE CONTENTS OF BRAIN SLICES. 000278 01-03

METABOLIC AND EXPERIENTIAL FACTORS IN THE BEHAVIORAL RESPONSE TO REPEATED AMPHETAMINE.

METABOLIC ACTIVATION OF P-CHLOROAMPHETAMINE TO A CHEMICALLY REACTIVE METABOLITE.

IN VIVO METABOLIC O DEMETHYLATION OF 3,4
DIMETHOXYAMPHETAMINE IN DOG AND MONKEY. MONKEY.

001149 02-03

ALPHA-METHYLDOPAMINE — A METABOLITE AND KEY INTERMEDIATE IN
THE METABOLIC DISPOSITION OF 3,4 METHYLENEDIOXYAMPHETAMINE
(MDA) IN DOG AND MONKEY

METABOLIC CLEARANCE RATE OF ADRENOCORTICOTROPIN IN THE RAT. 002070 03-03

EFFECT OF METABOLIC INHIBITORS AND OUABAIN ON AMPHETAMINE-INDUCED AND POTASSIUM-INDUCED RELEASE OF BIOGENIC AMINES FROM ISOLATED BRAIN TISSUE.

EFFECTS OF SODIUM THIOPENTAL ON THE TRICARBOXYLIC-ACID CYCLE
METABOLISM IN MOUSE BRAIN: CO2 FIXATION AND METABOLIC
COMPARTMENTATION

002860 04-03
METABOLISM OF GAMMA-HYDROXYBUTYRATE BY RAT BRAIN:
RELATIONSHIP TO THE KREBS-CYCLE AND METABOLIC

COMPARTMENTATION OF AMINO-ACIDS. 002896 04-0

ALTERATIONS IN BRAIN 5 HYDROXYTRYPTAMINE METABOLISM DURING THE WITHDRAWAL PHASE AFTER CHRONIC TREATMENT WITH DIAZEPAM AND BROMAZEPAM.

LEVELS OF CHLORPROMAZINE AND ITS ACTIVE MATABOLITES IN RAT BRAIN AND THE RELATIONSHIP TO CENTRAL MONOAMINE METABOLISM AND PROLACTIN SECRETION.

METABOLISM AND PROLACTIN SECRETION.

000041 01-03

EFFECTS OF BENSERAZIDE ON TRYPTOPHAN METABOLISM IN THE MOUSE.
000054 01-03

ABSORPTION AND METABOLISM OF THE PHENOTHIAZINE DRUG PERAZINE IN THE RAT INTESTINAL LOOP. 000063 01-03

HALOPERIDOL INCREASES AND APOMORPHINE DECREASES STRIATAL DOPAMINE METABOLISM AFTER DESTRUCTION OF STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASE BY KAINIC-ACID.

000094 01-03
COMPARISON OF THE EFFECTS OF 6 CHLORO-2-AMINOTETRALIN AND OF ORG-6582, A RELATED CHLOROAMPHETAMINE ANALOG, ON BRAIN SEROTONIN METABOLISM IN RATS.

000114 01-03

THE METABOLISM OF D-, L- AND DL-METHADONE IN THE ISOLATED PREFUSED RAT LIVER.

O00118 01-03
PHENOBARBITAL ACTIONS IN VIVO: EFFECTS OF EXTRACELLULAR
POTASSIUM ACTIVITY AND OXIDATIVE METABOLISM IN CAT
CEREBRAL-CORTEX.

CEREBRAL-CORTEX.

000176 01-03

EFFECT OF CONVULSANT AND ANTICONVULSANT AGENTS ON LEVEL AND
METABOLISM OF GAMMA-AMINOBUTYRIC-ACID IN MOUSE BRAIN.

000186 01-03

EFFECTS OF RESERPINE AND SEROTONIN ON ADENINE-NUCLEOTIDE

METABOLISM AND GLUCOSE OXIDATION OF WASHED RABBIT
PLATELETS.

000237 01-03

EFFECT OF RESERPINE ON ADENOSINE UPTAKE AND METABOLISM, AND
SUBCELLULAR TRANSPORT OF PLATELET ADENOSINE-TRIPHOSPHATE IN
WASHED RABBIT PLATELETS.

THE METABOLISM OF A SUBSTITUTED AMINOACETAMIDOBENZOPHENONE AND CYCLIZATION TO THE CORRESPONDING BENZODIAZEPINE IN THE RAT IN VIVO. 000242 01-03

EFFECT OF ALTERATION OF METABOLISM ON THE ANALGESIC ACTIVITY, TOXICITY, DISTRIBUTION AND EXCRETION OF L-ALPHA-ACETYLMETHADOL IN THE RAT.

ACTION OF THE PALMITIC ESTER OF PIPOTIAZINE ON DOPAMINE METABOLISM IN THE NIGROSTRIATAL, MESOLIMBIC AND MESOCORTICAL SYSTEMS.

CEREBRAL METABOLISM OF INTRAVENTRICULAR (3H) FENFLURAMINE.
000266 01-03

CEREBRAL METABOLISM OF (3H) P-CHLOROAMPHETAMINE.

EFFECT OF COCAINE AND DESMETHYLIMIPRAMINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-5-HYDROXYTRYPTAMINE IN RAT BRAIN SLICES.

O00305 01-03
THE EFFECT OF PENTOBARBITAL ON THE CARBOHYDRATE METABOLISM
OF GLIAL CELLS IN CULTURE.

CYCLIC-ADENOSINE-MONOPHOSPHATE METABOLISM IN PATIENTS WITH SEVERE DEPRESSIVE ILLNESS. 000570 01-09

INTERINDIVIDUAL VARIABILITY IN DIAZEPAM METABOLISM: PRELIMINARY EVIDENCE OF AN ABSENCE OF GENETIC CONTROL. 000696 01-13

METABOLISM OF FLURAZEPAM BY THE SMALL INTESTINE.

000713 01-13
THIORIDAZINE METABOLISM AND CLINICAL RESPONSE: A PILOT STUDY.
000737 01-13

MAO INHIBITORS AND CENTRAL MONOAMINE METABOLISM.

000991 01-17
STIMULATION OF CAFFEINF METABOLISM IN THE RAT BY 3

METHYLCHOLANTHRENE.

001044 02-03

ALTERATIONS INDUCED IN DISTRIBUTION AND IN VIVO METABOLISM OF IMIPRAMINE BY PREGNENOLONE-16ALPHA-CARBONITRILE.

SPECIES VARIATION WITH RESPECT TO THE METABOLISM AND EXCRETION OF D AMPHETAMINE AND D, L N HYDROXYAMPHETAMINE-SUCCINATE

001091 02-03

EFFECT OF CHRONIC LEVODOPA ON VITAMIN-B6 METABOLISM IN
DISCRETE REGIONS OF RAT BRAIN.

001105 02-03
BRAIN DISTRIBUTION OF LITHIUM AND INDOLEAMINE METABOLISM IN
DOGS AFTER CHRONIC LITHIUM ADMINISTRATION.

METABOLISM OF FENFLURAMINE TO M
TRIFLUOROMETHYLBENZOYLGLYCINE IN RAT BRAIN.

001127 02-03

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE CONTENT AND
METABOLISM OF DOPAMINE IN THE RAT STRIATUM.

EFFECT OF ATROPINE ON ACETYLCHOLINE METABOLISM IN THE MOUSE

001157 02-03
EFFECTS OF ACUTE AND CHRONIC MORPHINE AND NARCOTIC
ANTAGONISTS ON BRAIN ENERGY METABOLISM.

001163 02-03
DISTRIBUTION AND METABOLISM OF 4 HYDROXYPHENOBARBITAL IN THE MOUSE.

001171 02-03
INDIRECT SYMPATHOMIMETICS AND CEREBRAL BLOOD FLOW AND
METABOLISM.

O01189 02-03
EFFECTS OF D AMPHETAMINE (D-A), PROSTAGLANDIN-E1 AND F-2ALPHA
ON H3-2-DOPAMINE (H3-DA) METABOLISM, FIXED-INTERVAL (FI)
BEHAVIOR AND RECTAL TEMPERATURE.

UPTAKE AND METABOLISM OF INTRAVENTRICULARLY ADMINISTERED PIPERIOINE AND ITS EFFECTS ON SLEEP AND WAKEFULNESS IN THE DAT

O01208 02-03
ACTION OF AZABUTYRONE AND ITS ANALOGS ON CATECHOLAMINE
METABOLISM IN RAT BRAIN.

001218 02-03
REGIONAL EFFECTS OF NEUROLEPTICS ON DOPAMINE METABOLISM AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE ACTIVITY.

THE EFFECT OF ANTIPSYCHOTIC DRUGS AND THEIR CLINICALLY INACTIVE ANALOGS ON DOPAMINE METABOLISM.

001250 02-03

EFFECT OF BETA-ENDORPHIN ON STRIATAL DOPAMINE METABOLISM.
001269 02-03

EFFECTS OF THE ISOMERIC FORMS OF PROPRANOLOL ON CENTRAL MONOAMINE METABOLISM IN REGIONS OF RAT BRAIN.

001284 02-03
IN VITRO METABOLISM OF AN IMIDAZOBENZODIAZEPINE.

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DRUG DISTRIBUTION AND METABOLISM: ANTIPYRENE, PENTOBARBITAL, AND ETHANOL. 001643 02-13

LITHIUM THERAPY AND ALKALINE-EARTH METAL METABOLISM: A BIOCHEMICAL SCREENING STUDY.

THE METABOLISM AND PLASMA CONCENTRATIONS OF L-ALPHA-ACETYLMETHADOL AND ITS METABOLITES IN MAN. (PH.D. DISSERTATION).

THE EFFECTS OF PSYCHOPHARMACOLOGICAL AGENTS ON CENTRAL-NERVOUS-SYSTEM AMINE METABOLISM IN MAN.

001671 02-13 DRUG IMPROVING CEREBRAL METABOLISM IN DEMENTIA

001695 02-13 MEASURING CHANGES IN CEREBRAL GLUTAMATE AND GABA METABOLISM PRIOR TO CONVULSIONS INDUCED BY 3 MERCAPTOPROPIONATE.

COMPARATIVE EFFECTS OF DIHYDROERGOTOXINE (DHET) ON CBF AND METABOLISM CHANGES PRODUCED BY EXPERIMENTAL CEREBRAL EDEMA, HYPOXIA AND HYPERTENSION.

001979 03-03 DIFFERENT EFFECTS OF METHIONINE-ENKEPHALIN AND D ALA2-METHIONINE-ENKEPHALINAMIDE ON THE METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN: FACT OR ARTIFACT?.

IN VITRO EFFECTS OF DESMETHYLIMIPRAMINE ON THE UPTAKE AND METABOLISM OF H3-NOREPINEPHRINE IN RAT BRAIN SLICES.

001997 03-03 PHENOBARBITAL METABOLISM DURING CHRONIC ADMINISTRATION IN

002007 03-03 EFFECTS OF FENFLURAMINE AND NORFENFLURAMINE ON BRAIN SEROTONIN METABOLISM IN RATS.

002016 03-03

STEREOSELECTIVITY IN THE METABOLISM OF H3-NORADRENALINE DURING UPTAKE INTO AND EFFLUX FROM THE ISOLATED RAT VAS-DEFERENS. 002028 03-03

THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON DOPAMINE METABOLISM IN RAT STRIATUM.

002039 03-03 METABOLISM OF AMPHETAMINE BY RAT BRAIN TISSUE.

002065 03-03 CORRELATION OF URINARY EXCRETION OF METHADONE A WITH METHADONE METABOLISM AND ANALGESIA IN T METABOLITES THE RAT. 002080 03-03

INDIRECT SYMPATHOMIMETIC AGENTS AND CEREBRAL BLOOD FLOW AND METABOLISM.

002092 03-03 THE EFFECT OF LITHIUM ON SEROTONIN METABOLISM IN THE BRAIN OF RATS WITH PARTICULAR ATTENTION TO ITS EFFECT UNDER THE MONOAMINE ALTERED CONDITIONS.

002110 03-03 A LITHIUM-CARBONATE-INDUCED INCREASE IN THE MOUSE BRAIN 5
HYDROXYTRYPTAMINE METABOLISM.

METABOLISM OF 5 HYDROXYTRYPTAMINE AND LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS IN RAT BRAIN AFTER ACUTE AND CHRONIC TREATMENT. 002153 03-03

002169 03-03 HEXOBARBITAL-EPOXIDE: A POSSIBLE INTERMEDIATE IN THE METABOLISM OF HEXOBARBITAL.

002170 03-03 EFFECTS OF BACLOFEN ON DOPAMINE METABOLISM AND WITH NEUROLEPTIC EFFECTS.

002173 03-03 THE INFLUENCE OF HISTAMINE ON METABOLISM OF DOPAMINE AND SEROTONIN IN THE RAT STRIATUM.

002288 03-04 TOLERANCE TO P-CHLOROAMPHETAMINES EFFECTS ON SIDMAN AVOIDANCE PERFORMANCE AND CATECHOLAMINE METABOLISM

002314 03-04 CALCIUM METABOLISM IN LITHIUM TREATED PATIENTS: RELATION TO UNIPOLAR DICHOTOMY.

ELECTROPHYSIOLOGICAL STUDIES AND AMPHETAMINE METABOLISM IN HYPERACTIVE CHILDREN.

002520 03-11 CLINICAL LABORATORY STUDIES WITH SPECIAL REGARD TO HEPATIC METABOLISM IN SCHIZOPHRENICS ON OUTPATIENT LONG-TERM NEUROLEPTIC MEDICATION.

002667 03-15 CENTRAL CATECHOLAMINE METABOLISM IN PSYCHOSIS.

002764 03-17 BROMOCRIPTINE, DIHYDROERGOTOXINE, METHYSERGIDE, D LSD, CF-25-397, AND CF-29-712: EFFECTS ON THE METABOLISM OF BIOGENIC AMINES IN THE BRAIN OF THE RAT.

INFLUENCE OF TRANSIENT ISCHEMIA ON MONOAMINE METABOLISM IN THE RAT BRAIN DURING NITROUS-OXIDE AND PHENOBARBITONE ANESTHESIA.

EFFECTS OF SODIUM THIOPENTAL ON THE TRICARBOXYLIC-ACID CYCLE METABOLISM IN MOUSE BRAIN: CO2 FIXATION AND METABOLIC COMPARTMENTATION.

002860 04-03 ALTERATION OF TRICARBOXYLIC-ACID CYCLE METABOLISM IN RAT BRAIN SLICES BY HALOTHANE.

002861 04-03 5 HYDROXYTRYPTAMINE: THE EFFECTS OF IMPAIRED SYNTHESIS ON ITS METABOLISM AND RELEASE IN RAT.

002878 04-03 METABOLISM OF GAMMA-HYDROXYBUTYRATE BY RAT BRAIN: RELATIONSHIP TO THE KREBS-CYCLE AND METABOLIC COMPARTMENTATION OF AMINO-ACIDS.

002896 04-03 HYPOTENSION AND HYPOTHALAMIC AMINE METABOLISM AFTER LONG TERM ALPHA-METHYLDOPA INFUSIONS.

002914 04-03 PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6 TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH KINETICS OF AMINOPYRINE—DEMETHYLATION.

002930 04-03 PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — I. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS. 002931 04-03

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM -- II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH.

002932 04-03 USE OF STABLE ISOTOPES IN STUDIES ON THE METABOLISM OF

THE EFFECT OF BROMOCRIPTINE ON RAT STRIATAL ADENYLATE-CYCLASE AND RAT BRAIN MONOAMINE METABOLISM.

METABOLISM OF BETA 3.4 METHYLENEDIOXYAMPHETAMINE IN THE

003000 04-03 EFFECTS OF PENTYLENETETRAZOLE AND TRIMETHADIONE ON FELINE BRAIN MONOAMINE METABOLISM.

CORRELATION OF PHENOBARBITAL-INDUCED AND SKF-525-A-INDUCED MODIFICATION OF PENTOBARBITAL HYPNOSIS WITH ALTERATION OF IN VIVO AND IN VITRO PENTOBARBITAL METABOLISM IN THE RAT. 003008 04-03

ON THE RELATION BETWEEN HALOPERIDOL-INDUCED ALTERATIONS IN DA RELEASE AND DA METABOLISM IN RAT STRIATUM.

003021 04-03 METABOLISM OF LERGOTRILE TO 13 HYDROXYLERGOTRILE, A POTENT INHIBITOR OF PROLACTIN RELEASE IN VITRO.

003040 04-03 LITHIUM EFFECTS ON RAT BRAIN GLUCOSE METABOLISM IN LONG-TERM LITHIUM TREATED RATS STUDIED IN VIVO.

003046 04-03 EVIDENCE FOR THE ROLE OF ADRENOCORTICAL HORMONES IN THE REGULATION OF NORADRENALINE AND DOPAMINE METABOLISM IN CERTAIN BRAIN AREAS. 003062 04-03

CHOLINERGIC STIMULATION OF POLYPHOSPHOINOSITIDE METABOLISM IN BRAIN IN VIVO. 003097 04-03

INCREASED DOPAMINE METABOLISM IN RAT STRIATUM AFTER INFUSIONS OF SUBSTANCE-P INTO THE SUBSTANTIA-NIGRA. 003130 04-03

DISULFIRAM ALTERS DOPAMINE METABOLISM AT SITES IN RATS FOREBRAIN AS DETECTED BY PUSH-PULL PERFUSIONS.

003134 04-03 ARALLEL CHANGES IN BEHAVIOR AND HIPPOCAMPAL MONOAMINE METABOLISM IN RATS AFTER ADMINISTRATION OF ACTH ANALOGUES 003335 04-04 THE TRIPHASIC AMPHETAMINE LETHAL DOSE CURVE IN MICE AND ITS POSSIBLE RELATIONSHIP TO DRUG METABOLISM.

003410 04-05 EFFECTS OF 2 DIMETHYLAMINOETHANOL (DEANOL) ON THE METABOLISM OF CHOLINE IN PLASMA.

003589 04-13 THE EFFECT OF CHLORPROMAZINE, SOME TRICYCLIC ANTIDEPRESSANTS AND INSULIN ON THE ACTION OF CYCLIC-AMP AND ADENOSINE METABOLISM.

000476 01-05

003606 04-13 METABOLIC ACTIVATION OF P-CHLOROAMPHETAMINE TO A CHEMICALLY REACTIVE METABOLITE. 000476 01-05

002849 04-03

001692 02-13

EFFECT OF CHLORPROMAZINE TREATMENT ON MONOAMINE METABOLITE LEVELS IN CEREBROSPINAL FLUID OF PSYCHOTIC PATIENTS.

000591 01-09
PLASMA CONCENTRATIONS OF PERPHENAZINE AND ITS SULPHOXIDE METABOLITE DURING CONTINUOUS ORAL TREATMENT.

URINARY MONOAMINE METABOLITE EXCRETION IN DISORDERS OF MOVEMENT

000710 01-13 IDENTIFICATION OF M HYDROXYAMPHETAMINE AS A METABOLITE OF AMPHETAMINE IN THE RAT

001005 02-01 THE EFFECT OF MELPERONE (BURONIL(R)) AND ITS METABOLITE FG-5155 ON THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM COMPARED TO SOME OTHER NEUROLEPTICS.

ALPHA-METHYLDOPAMINE -- A METABOLITE AND KEY INTERMEDIATE IN THE METABOLIC DISPOSITION OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) IN DOG AND MONKEY

001195 02-03 PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EMBRYOPATHIC EFFECT AND COVALENT BINDING OF PUTATIVE ARENE OXIDE METABOLITE IN GESTATIONAL TISSUE.

URINARY EXCRETION OF A QUATERNARY AMMONIUM GLUCURONIDE METABOLITE OF CYPROHEPTADINE IN HUMANS UNDERGOING CHRONIC DRUG THERAPY

001667 02-13 RELATIONSHIPS AMONG CLINICAL RESPONSE, EXTRAPYRAMIDAL SYNDROME AND PLASMA CHLORPROMAZINE AND METABOLITE

DESIPRAMINE AND SOME OTHER ANTIDEPRESSANT DRUGS DECREASE THE MAJOR NOREPINEPHRINE METABOLITE 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE IN THE RAT BRAIN

002114 03-03 PLASMA CONCENTRATIONS OF CLOMIPRAMINE AND ITS N DESMETHYL METABOLITE IN DEPRESSIVE PATIENTS FOLLOWING TREATMENT WITH VARIOUS DOSAGE REGIMES OF CLOMIPRAMINE.

002568 03-13 CLOZAPINE CONCENTRATIONS IN BRAIN REGIONS: RELATIONSHIP TO DOPAMINE METABOLITE INCREASE.

003139 04-03
TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDROME WITH EMD-21657. A DERIVATIVE OF A PYRITINOL METABOLITE: DOUBLE-BLIND CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STUDIES 003571 04-11

EFFECTS OF AMPHETAMINE AND CHLORDIAZEPOXIDE ON PROBENECID-INDUCED ACCUMULATION OF ACIDIC METABOLITES IN THE CEREBROSPINAL FLUID OF THE DOG.

000092 01-03
A RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF BIOLOGICAL FLUID OR TISSUE

000496 01-06 CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND ITS METABOLITES AND CLINICAL RATINGS IN PATIENTS WITH ACUTE RELAPSE OF SCHIZOPHRENIC AND PARANOID PSYCHOSIS.

000726 01-13 PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS

000742 01-13 THIN-LAYER AND GAS-LIQUID-CHROMATOGRAPHIC PROCEDURES FOR THE DETERMINATION OF PERAZINE AND ITS METABOLITES IN HUMAN **BODY FLUIDS**

000927 01-16 IDENTIFICATION OF THE IN VITRO N OXIDIZED METABOLITES OF ()- AND (-) N BENZYLAMPHETAMINE.

001054 02-03 PLASMA CONCENTRATIONS OF SOME ACIDIC AND ALCOHOLIC METABOLITES DERIVED FROM M- AND P-TYRAMINE, OCTOPAMINE AND CATECHOLAMINES IN HUMANS.

001158 02-03 PHENOTHIAZINE METABOLITES AS MITOCHONDRIAL INHIBITORS. 001259 02-03

COCAINE AND METABOLITES: RELATIONSHIP BETWEEN PHARMACOLOGICAL ACTIVITY AND INHIBITORY ACTION ON DOPAMINE UPTAKE INTO STRIATAL SYNAPTOSOMES.

001286 02-03 AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOUR AND BRAIN CONCENTRATIONS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN MICE

001316 02-04 ADVERSE EFFECTS OF CHLORPROMAZINE METABOLITES ON ISOLATED **HEPATOCYTES**

001502 02-05 LITHIUM: CLINICAL EFFECTS AND CEREBROSPINAL FLUID ACID MONOAMINE METABOLITES.

NEUROTRANSMITTER METABOLITES IN THE CEREBROSPINAL FLUID OF MAN FOLLOWING PHYSOSTIGMINE.

THE METABOLISM AND PLASMA CONCENTRATIONS OF L-ALPHA-ACETYLMETHADOL AND ITS METABOLITES IN MAN. (PH.D. DISSERTATION).

001656 02-13 NALOXONE (NARCAN) TREATMENT IN DEPRESSION: CLINICAL
OBSERVATIONS AND EFFECTS ON CSF ENDORPHINS AND MONOAMINE METABOLITES.

URINARY EXCRETION OF PHENOLIC METABOLITES OF PROPYLAMPHETAMINE IN MAN.

H3-HALOPERIDOL BINDING TO DOPAMINE RECEPTORS IN RAT CORPUS-STRIATUM: INFLUENCE OF CHLORPROMAZINE METABOLITES AND DERIVATIVES.

CORRELATION OF URINARY EXCRETION OF METHADONE METABOLITES WITH METHADONE METABOLISM AND ANALGESIA IN THE RAT.

MODIFICATION OF THE NORADRENERGIC CYCLIC-AMP GENERATING
SYSTEM IN THE RAT LIMBIC FOREBRAIN BY AMPHETAMINE (A) AND
ITS HYDROXYLATED METABOLITES.

002100 03-03 IMIPRAMINE, ITS N DESMETHYL AND HYDROXY METABOLITES IN PLASMA: MICRO DETERMINATION BY ALKALINE FLAME-IONIZATION GAS-CHROMATOGRAPHY (AFID-GC).

REGIONAL CHANGES IN THE CONCENTRATIONS OF CEREBRAL MONOAMINES AND THEIR METABOLITES AFTER ETHANOLAMINE-O-SULPHATE-INDUCED ELEVATION OF BRAIN GAMMA-AMINOBUTYRIC-**ACID CONCENTRATIONS**

LEVO-ALPHA-ACETYLMETHADOL AND METABOLITES: SOME EFFECTS ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT.

INOTROPIC ACTION OF HYDROXYLATED CHLORPROMAZINE METABOLITES AND RELATED COMPOUNDS.

O03405 04-05
RELATIONSHIP BETWEEN SERUM CONCENTRATIONS OF THIORIDAZINE
AND ITS MAIN NONCONJUGATED METABOLITES AND THE CLINICAL
RESPONSE IN THIORIDAZINE TREATED PATIENTS.

003480 04-09 CHLORPROMAZINE EXCRETION. II. IMPROVED TLC PROCEDURES FOR FRACTIONATING THE URINARY DRUG CONTENT INTO CHEMICAL SUBGROUPS OF CPZ METABOLITES.

003690 04-16

METAI LITHIUM THERAPY AND ALKALINE-EARTH METAL METABOLISM: A BIOCHEMICAL SCREENING STUDY.

001644 02-13 METAMIZYL

STUDY OF THE TREATMENT OF VASCULAR PARKINSONS DISEASE WITH METAMIZYL 003599 04-13

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF THIORIDAZINE

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF NITRAZEPAM.

METARAMINOL RELATIONSHIP BETWEEN THE UPTAKE OF 3H-(PLUS OR MINUS)
METARAMINOL AND THE DENSITY OF ADRENERGIC INNERVATION IN ISOLATED RAT TISSUES.

MEYERGOLINE EFFECT OF METERGOLINE, P-CHLOROPHENYLALANINE AND DOPA ON DELAYED RESPONSE IN CATS AND THE RELATIONSHIP BETWEEN THE MESOLIMBIC AND NIGROSTRIATAL NEURONS.

003339 04-04

METHADONE INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH D,L METHADONE

000270 01-03 EFFECTS OF METHADONE AND MORPHINE MAINTENANCE ON DRUG SEEKING BEHAVIOR IN THE DOG.

O00387 01-04
EFFECTS OF MORPHINE, METHADONE, NALORPHINE AND NALOXONE ON
RESPONDING UNDER SCHEDULES OF ELECTRIC-SHOCK TITRATION. 453 01-04

THE EFFECT OF MATERNALLY ADMINISTERED METHADONE ON BRAIN DEVELOPMENT IN THE OFFSPRING.

000483 01-05

002358 03-05

METHADONE MAINTENANCE: EFFECT OF URINARY PH ON RENAL CLEARANCE IN CHRONIC HIGH AND LOW DOSES.

BINDING OF CODEINE, MORPHINE, AND METHADONE TO HUMAN SERUM PROTEINS. 000706 01-13

RIFAMPICIN AND METHADONE WITHDRAWAL

FAILURE OF METHADONE AND LEVOMETHADYL-ACETATE (LEVO-ALPHA-ACETYLMETHADOL, LAAM) MAINTENANCE TO AFFECT MEMORY.

000841 01-15

O00841 01-15
HEAD-SHAKE DISTRIBUTIONS DURING SELF-MAINTAINED DEPENDENCE ON MORPHINE, METHADONE, AND L-ALPHA-ACETYLMETHADOL (LAAM) IN THE RAT.

URINARY CYCLIC-AMP EXCRETION BY METHADONE SUBJECTS DURING GRADUAL AND ACUTE WITHDRAWAL.

LATE WITHDRAWAL SYMPTOMS IN BABIES BORN TO METHADONE ADDICTS.

QUANTITATIVE ANALYSIS OF METHADONE IN BIOLOGICAL FLUIDS USING DEUTERIUM-LABELED METHADONE AND GLC CHEMICAL IONIZATION MASS SPECTROMETRY.

EFFECTS OF MEDIAL RAPHE AND RAPHE MAGNUS LESIONS ON THE ANALGESIC ACTIVITY OF MORPHINE AND METHADONE.

CORRELATION OF URINARY EXCRETION OF METHADONE METABOLITES WITH METHADONE METABOLISM AND ANALGESIA IN THE RAT. 002080 03-03

METHADONE IN SCHIZOPHRENIC RAGE: A CASE STUDY. 002387 03-08

NEW APPROACH TO THE REHABILITATION OF THE HARD CORE DRUG

ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY

STUDY

602531 03-11 PREGNANT WOMEN. 002531 03-11

METHADONE DOSE, PLASMA LEVEL, AND CROSS-TOLERANCE TO HEROIN IN MAN.

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL TOLERANCE AND CROSS-TOLERANCE TO MORPHINE AND METHADONE IN THE RAT.

AVERSIVENESS OF ORAL METHADONE IN RATS

EFFECTS OF METHADONE ON BEHAVIOR MAINTAINED BY FIXED-RATIO REINFORCEMENT SCHEDULES.

003299 04-04 SCHEDULE-INDUCED SELF-INJECTION OF NICOTINE, METHADONE AND HEROIN BY NAIVE ANIMALS.

003321 04-04 PSYCHOANALYTIC AND BEHAVIORAL CONSIDERATIONS IN ANTAGONIST AND METHADONE PROGRAMS.

003704 04-17

METHADYL-ACETATE A COOPERATIVE CLINICAL STUDY OF METHADYL-ACETATE. I. THREE-TIMES-A-WEEK REGIMEN.

002757 03-17 METHAMPHETAMINE
ON THE COURSE OF METHAMPHETAMINE (PHILOPON) PSYCHOSIS 001794 02-15

COMPARISON OF THE EFFECTS OF METHAMPHETAMINE AND NEUROLEPTIC AGENTS ON TYROSINE-HYDROXYLASE ACTIVITY IN THE NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM.

002102 03-03 CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. THE IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2-METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED ANALOGS OF METHAMPHETAMINE. 002141 03-03

MOTILITY EFFECTS OF METHAMPHETAMINE IN RATS CHRONICALLY TREATED WITH MORPHINE. 003162 04-04

METHANESULFONATE
CYCLOBENZAPRINE AND BENZOTROPINE METHANESULFONATE IN
PARKINSONS DISEASE: A RANDOMIZED DOUBLE-BLIND CROSS-OVER

STUDY. 000654 01-11

METHAPYRILENE HYPNOTIC ACTIVITY OF DIPHENHYDRAMINE, METHAPYRILENE, AND PLACEBO. 003638 04-14

HAQUALONE
MATERNAL FETAL DISTRIBUTION OF METHAQUALONE IN CONTROL AND
SKF-525-A PRETREATED PREGNANT MICE.
000263 01-000263 01-03 SIMULTANEOUS IDENTIFICATION AND QUANTITATION OF DIPHENHYDRAMINE AND METHAQUALONE.

000925 01-16

003102 04-03

THE EFFECTS OF METHAQUALONE ON THE SEIZURE SUSCEPTIBILITY OF 001062 02-03

THE EFFECTS OF METHAQUALONE ON PITUITARY ADRENOCORTICAL ACTIVITY IN MICE. 001194 02-03

PHYSICAL DEPENDENCE ASSOCIATED WITH CHRONIC METHAQUALONE ADMINISTRATION.

001428 02-04 ELECTROENCEPHALOGRAPHIC STUDIES WITH I.V. METHAQUALONE IN MAN.

001688 02-13 PILOT STUDY ON THE DISTRIBUTION OF C14-LABELED METHAQUALONE IN THE RAT BRAIN.

002865 04-03 INTERACTION OF ETHANOL WITH AMYLOBARBITONE, PHENOBARBITONE AND METHAQUALONE. 003115 04-03

METHIMAZOLE
INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY ANTITHYROID
AGENTS, METHIMAZOLE AND PROPYLTHIOURACIL.

000145 01-03

ELECTRICAL STIMULATION OF DENERVATED MUSCLES REDUCES INCORPORATION OF METHIONINE INTO THE ACH RECEPTOR.

000136 01-03 EFFECT OF CHLORPROMAZINE ON L METHIONINE TRANSPORT IN THE RAT INTESTINE.

TRANSMETHYLATION HYPOTHESIS OF SCHIZOPHRENIA: METHIONINE AND NICOTINIC-ACID.

LACK OF ENHANCEMENT OF DIMETHYLTRYPTAMINE FORMATION IN RAT BRAIN AND RABBIT LUNG IN VIVO BY METHIONINE OR S ADENOSYLMETHIONINE.

METHIONINE-ENKEPHALIN
IONTOPHOREIS OF METHIONINE-ENKEPHALIN IN THE LOCUS-COERULEUS
AREA.

000304 01-03 INTERACTIONS OF LEUCINE AND METHIONINE-ENKEPHALIN WITH MORPHINE IN VITRO AND IN VIVO.

001272 02-03 DIFFERENT EFFECTS OF METHIONINE-ENKEPHALIN AND D ALA2-METHIONINE-ENKEPHALINAMIDE ON THE METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN: FACT OR ARTIFACT?.

001980 03-03 EPILEPTIC PROPERTIES OF LEUCINE-ENKEPHALIN AND METHIONINE-ENKEPHALIN: COMPARISON WITH MORPHINE AND REVERSIBILITY BY NALOXONE.

RAT STRIATAL METHIONINE-ENKEPHALIN CONTENT AFTER CHRONIC TREATMENT WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTISCHIZOPHRENIC DRUGS.

002953 04-03 DEPRESSANT ACTIONS OF METHIONINE-ENKEPHALIN AND
SOMATOSTATIN IN CAT DORSAL-HORN NEURONES ACTIVATED BY

NOXIOUS STIMULI.

A RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF BIOLOGICAL FLUID OR TISSUE.

A METHOD FOR EVALUATING ANXIOLYTIC SEDATIVES. 000616 01-10

THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE HUMAN BRAIN AS AN OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING DRUGS.

000747 01-14 DIFFERENT BEHAVIOURAL PATTERNS INDUCED BY APOMORPHINE: EVIDENCE THAT THE METHOD OF ADMINISTRATION DETERMINES THE BEHAVIOURAL RESPONSE TO THE DRUG.

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

001535 02-06 A SUBJECTIVE AND OBJECTIVE METHOD ASSESSING THE EFFICACY OF HYPNOTIC MEDICATIONS IN INSOMNIACS.

001873 02-16 INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS. 001959 03-02

002289 03-04

003025 04-03

003602 04-13

001043 02-03

A METHOD FOR MECHANOGRAPHICAL RECORDING OF MUSCLE TONE IN THE RAT: THE EFFECT OF SOME ANTIPARKINSONIAN DRUGS ON RIGIDITY INDUCED BY RESERPINE.

002346 03-05 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. I. CHRONICALLY EQUIVALENT DOSING METHOD.

002360 03-06 ON THE ACUTE EFFECT OF SOME DRUGS ON HIGHER NERVOUS ACTIVITY IN MAN FOLLOWED UP BY THE LABORATORY LANGUAGE METHOD. 002623 03-14

LOSS OF INFORMATION INDUCED BY REDUCTION OF DATA IN THE LABORATORY LANGUAGE METHOD.

002624 03-14 A SIMPLE METHOD FOR THE DETERMINATION OF THERAPEUTIC LEVELS OF CLOMIPRAMINE. IMIPRAMINE AND DESIPRAMINE.

002717 03-16 APPLICATION OF LIFE TABLE METHOD TO NATURALISTIC DESIGNS — COMPARISON OF EFFICACY OF TRICYCLIC ANTIDEPRESSANTS AND BENZODIAZEPINES IN AMBULATORY DEPRESSIVES.

002783 03-17 INTERACTIONS BETWEEN CLONIDINE AND ANTIDEPRESSANT DRUGS: A METHOD FOR IDENTIFYING ANTIDEPRESSANT-LIKE AGENTS

002801 04-02 DISCRIMINATIVE PROPERTIES OF CHI ORDIAZEPOXIDE: A NEW METHOD OF ANALYSIS.

002905 04-03 EXPERIMENTAL BARBITURATE DEPENDENCE. I. BARBITURATE DEPENDENCE DEVELOPMENT IN RATS BY DRUG ADMIXED FOOD (DAF)

003373 04-04 COMPARISON OF THE EFFECT OF SOME BENZODIAZEPINES WITH THE

STAIRCASE METHOD. 003404 04-04 METHODOLOGIC

PROFILES OF PROLACTIN RESPONSE TO ANTIPSYCHOTIC DRUGS: SOME METHODOLOGIC CONSIDERATIONS. 002725 03-16

METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGICAL RESEARCH 000523 01-08

SOME METHODOLOGICAL CONSIDERATIONS FOR THE CLINICAL EVALUATION OF NEUROLEPTICS — COMPARATIVE EFFECTS OF CLOZAPINE AND HALOPERIDOL ON SCHIZOPHRENICS.

000531 01-08 REPLY TO DAVIS AND HURT CONCERNING METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGICAL RESEARCH WITH CHLORPROMAZINE. 000538 01-08

METHODOLOGICAL EXPERIENCE WITH A DOUBLE-BLIND MULTICENTRIC, MONITORED CLINICAL TRIAL (MMCT) WITH SINTAMIL. 000568 01-09

THEORETICAL AND METHODOLOGICAL ASPECTS OF PSYCHOTROPIC DRUG TRIALS USING HEALTHY SUBJECTS.

000918 01-16 GENERAL METHODOLOGICAL PROBLEMS OF CLINICAL PSYCHOTROPIC DRUG TRIALS.

000924 01-16 METHODOLOGICAL ISSUES IN DRUG DISCRIMINATION RESEARCH.
003202 04-04

METHODOLOGICAL PROBLEMS IN THE MEASUREMENT OF DRUG-INDUCED ROTATIONAL BEHAVIOUR: CONTINUOUS RECORDING REVEALS TIME-COURSE DIFFERENCES UNDETECTED BY PREVIOUS TECHNIQUES.

0033BB 04-04 METHODOLOGY APPLICATION OF STATISTICS TO THE METHODOLOGY OF STUDIES OF

DRUGS ACTING ON THE BRAIN. 001620 02-11

METHODS TAXONOMY AND EVALUATION OF PSYCHOLOGICAL TEST METHODS IN PSYCHOTROPIC DRUG TRIALS. 000915 01-16

METHODS OF ACUTE INHALATION EXPERIMENTS. 000920 01-16

METHODS OF WITHDRAWAL STUDY. 000921 01-16

VIDEOTAPE METHODS FOR IDENTIFICATION OF NONVERBAL BEHAVIOR PARAMETERS IN DEPRESSIVE SYNDROMES.

000934 01-16 A COMPARISON OF THALIDOMIDE AND PENTOBARBITAL METHODS FOR IDENTIFYING NOVEL HYPNOTIC DRUGS. NEW

001359 02-04 DEVELOPMENT AND APPLICATION OF METHODS FOR DETERMINING THE BIOLOGICAL TRANSMETHIOLATIONS DEPENDENT ON S ADENOSYL-L-

001641 02-13 STATISTICAL EVALUATION: PRESUMPTION AND METHODS

001864 02-16
PHARMACODYNAMIC INVESTIGATIONS IN PSYCHOPHARMACOLOGY BY QUANTITATIVE EEG AND PSYCHOMETRIC METHODS 002726 03-16 ASSESSMENT OF LONG-ACTING NEUROLEPTICS. METHODS AND PROBLEMS

INFUSIONS OF METHOXAMINE IN THE DOG.

003693 04-16 ELECTROENCEPHALOGRAPHIC STUDY OF THE SHORT-ACTING HYPNOTICS ETOMIDATE AND METHOHEXITAL IN DOGS.

002177 03-03 METHOXAMINE SLEEP SUPPRESSION INDUCED BY INTRAVENOUS AND INTRAVENTRICULAR

001434 02-04 RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDROXYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN ACUTE AND CHRONIC SPINAL RATS.

METHOXY-DIMETHYLTRYPTAMINE
COMPARISON OF THE EFFECTS OF 5 HYDROXYTRYPTAMINE,
DIMETHYLTRYPTAMINE, AND 5 METHOXY-DIMETHYLTRYPTAMINE ON
RECTAL TEMPERATURE IN THE MOUSE.

002154 03-03 METHOXY-4-HYDROXYPHENYLETHANOL IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLETHANOL (MOPET) IN HUMAN CEREBROSPINAL FLUID AND RAT BRAIN BY MEANS OF GAS-CHROMATOGRAPHY — MASS-**SPECTROMETRY**

METHOXY-4-HYDEOXYPHENYLGLYCOL URINARY 3 METHOXY-4-HYDROXYPHENYLGLYCOL, AN INDEX OF PERIPHERAL RATHER THAN CENTRAL ADRENERGIC ACTIVITY IN THE

CHRONIC TREATMENT WITH DESIPRAMINE CAUSED A SUSTAINED DECREASE OF 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE AND TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT BRAIN. 002113 03-03

ON THE ORIGIN OF VANILLYLMANDELIC-ACID AND 3 METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT BRAIN. 002804 04-03

METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE

EFFECTS OF SINGLE AND MULTIPLE DOSES OF DESIPRAMINE (DMI) ON

ENDOGENOUS LEVELS OF 3 METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE (MOPEG-SO4) IN RAT BRAIN. 002814 04-03

METMOXY-4-MYDROXYPHENYLLACTIC-ACID

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4HYDROXYPHENYLLACTIC-ACID (VIA) IN CEREBROSPINAL FLUID AND 3
METHOXY-4-HYDROXYPHENYLPYRVIVIC-ACID (VPA) IN THE URINE OF
PARKINSONIAN PATIENTS TREATED WITH L-DOPA. 003602 04-13

METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID
IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4HYDROXYPHENYLLACTIC-ACID (VIA) IN CEREBROSPINAL FLUID AND 3
METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN THE URINE OF PARKINSONIAN PATIENTS TREATED WITH L-DOPA.

METHOXYCYPROHEPTADINE ()- AND (-) 3 METHOXYCYPROHEPTADINE. A COMPARATIVE EVALUATION OF THE ANTISEROTONIN, ANTIHISTAMINIC, ANTICHOLINERGIC, AND OREXIGENIC PROPERTIES WITH

CYPROHEPTADINE

001012 02-01 METHOXYDIMETHYLTRYPTAMINE
PREFERENTIAL ACTION OF 5 METHOXYTRYPTAMINE AND 5
METHOXYDIMETHYLTRYPTAMINE ON PRESYNAPTIC SEROTONIN
RECEPTORS: A COMPARATIVE IONTOPHORETIC STUDY WITH LSD AND

THE EFFECT OF A HALLUCINOGEN, 5 METHOXYDIMETHYLTRYPTAMINE, ON PRIMATE SOCIAL BEHAVIOR

001455 02-04 METHOXYTETRAHYDRO-BETA-CARBOLINE EFFECT OF 6 METHOXYTETRAHYDRO-BETA-CARBOLINE ON SERUM PROLACTIN LEVELS OF MALE RATS.

002903 04-03

METHOXYTRYPTAMINE
PREFERENTIAL ACTION OF 5 METHOXYTRYPTAMINE AND 5
METHOXYDIMETHYLTRYPTAMINE ON PRESYNAPTIC SEROTONIN
RECEPTORS: A COMPARATIVE IONTOPHORETIC STUDY WITH LSD AND

001095 02-03
THE FLUOROMETRIC DETERMINATION OF 5 METHOXYTRYPTAMINE IN MAMMALIAN TISSUES AND FLUIDS. 003050 04-03

METHOXYTRYPTOLINE UPTAKE OF 5 METHOXYTRYPTOLINE (6 MEO-TETRAHYDRO-BETA-CARBOLINE) BY BLOOD PLATELETS AND ITS EFFECT ON 5-HT UPTAKE

QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P-450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE

Psychopharmacology Abstracts

000020 01-02

000061 01-03

ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3
METHYCHOLANTHRENE

ALTERATION OF L-DOPA EFFECT ON BRAIN DOPA AND DOPAMINE LEVELS WITH NICOTINIC-ACID AND N METHYL NICOTINAMIDE. (PH.D. DISSERTATION).

001040 03.03

003588 04-13

METHYL-D-ASPARTATE

EFFECTS OF INTRAVENOUS KAINIC-ACID, N METHYL-D-ASPARTATE, AND

(-) NUCIFERENE ON THE CAT SPINAL CORD.

METHYL-RED
BINDING OF PHENYTOIN, L TRYPTOPHAN AND O METHYL-RED TO
ALBUMIN. UNEXPECTED EFFECT OF ALBUMIN CONCENTRATION ON THE
BINDING OF PHENYTOIN AND L TRYPTOPHAN.

003588 04-13

METHYLAMINO-ACIDS

EFFECTS OF N METHYLAMINO-ACIDS AND CONVULSANTS ON SPONTANEOUS ACTION POTENTIALS IN GUINEA-PIG CEREBELLAR 000209 01-03

METHYLAMINOETHANOL

EFFECTS OF IN METHYLAMINOETHANOL, AND N, N

DIMETHYLAMINOETHANOL IN THE DIET OF PREGNANT RATS ON

NEONATAL RAT BRAIN CHOLINERGIC AND PHOSPHOLIPID PROFILE

METHYLAMPHETAMINE
LONG-TERM BEHAVIORAL CHANGES IN THE RHESUS MONKEY AFTER
MULTIPLE DAILY INJECTIONS OF D METHYLAMPHETAMINE. 000359 01-04

HORMONE RESPONSES TO METHYLAMPHETAMINE IN DEPRESSION: A NEW APPROACH TO THE NORADRENALINE DEPLETION HYPOTHESIS. 002424 03-09

METHYLCHOLANTHRENE
STIMULATION OF CAFFEINE METABOLISM IN THE RAT BY 3
METHYLCHOLANTHRENE.

001044 02-03

METHYLDOPA

LITHIUM-CARBONATE AND METHYLDOPA: APPARENT INTERACTION IN

MAN.

000807 01-15 METHYLENE-BLUE ALTERS RETENTION OF INHIBITORY AVOIDANCE

003288 04-04

METHYLENEDIOXYAMPHETAMINE
ANTAGONISM OF 3.4 METHYLENEDIOXYAMPHETAMINE (MDA)
LETHALITY BY CHLORPROMAZINE IN THE CONSCIOUS DOG. 001072 02-03 ALPHA-METHYLDOPAMINE — A METABOLITE AND KEY INTERMEDIATE IN THE METABOLIC DISPOSITION OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA) IN DOG AND MONKEY.

001195 02-03 A PHARMACOLOGIC COMPARISON OF 3,4
METHYLENEDIOXYAMPHETAMINE AND LSD IN THE CHRONIC SPINAL

EFFECTS OF RACEMIC, (S)- AND (R) METHYLENEDIOXYAMPHETAMINE ON SYNAPTOSOMAL UPTAKE AND RELEASE OF TRITIATED NOREPINEPHRINE

002999 04-03
METABOLISM OF BETA 3,4 METHYLENEDIOXYAMPHETAMINE IN THE

003000 04-03 PHARMACOLOGICAL AND TOXICOLOGICAL EFFECTS OF BETA 3,4
METHYLENEDIOXYAMPHETAMINE ISOMERS. 003285 04-04

AETHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND SENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3 AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND ANTICONVULSANT ACTIVITIES.

000035 01-02 METHYLHISTAMINE METHYLHISTAMINE: EVIDENCE FOR SELECTIVE DEAMINATION BY MAC-B IN THE RAT BRAIN IN VIVO.

002172 03-03 QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS OF BIOLOGICALLY ACTIVE INDOLE, 1 METHYLINDOLE AND BENZO-B-THIOPHENE

CLEARANCE AND ANALGESIC ACTIVITY OF THE QUATERNIZED OPIATE, N METHYLMORPHINE (6-H3) ADMINISTERED INTRACISTERNALLY TO THE 003019 04-03 AETHYLPHENIDATE

EFFECTS OF METHYLPHENIDATE ON AVOIDANCE LEARNING IN THE AGED

BIOCHEMICAL DIFFERENTIATION OF AMPHETAMINE VS METHYLPHENIDATE AND NOMIFENSINE IN RATS.

EFFECTS OF AMPHETAMINE, METHYLPHENIDATE AND COCAINE ON SERUM PROLACTIN CONCENTRATIONS IN THE MALE RAT. 000234 01-03

PHARMACOKINETICS OF METHYLPHENIDATE IN THE RAT USING SINGLE ION MONITORING GLC MASS SPECTROMETRY. 000408 01-04

PSYCHODIAGNOSTIC USE OF METHYLPHENIDATE 000530 01-08

THE EFFECT OF METHYLPHENIDATE ON TEST PERFORMANCE IN THE COGNITIVELY IMPAIRED AGED. 000622 01-11

METHYLPHENIDATE THERAPY FOR INATTENTIVENESS IN SELECTED SCHOOL CHILDREN.

THE RELATIVE EFFICACY OF METHYLPHENIDATE (RITALIN) AND BEHAVIOR MODIFICATION TECHNIQUES IN THE TREATMENT OF A HYPERACTIVE CHILD.

PSYCHOLOGIC AND NEUROENDOCRINE RESPONSE TO METHYLPHENIDATE. 000689 01-13 COMPARATIVE EFFECTS OF D AMPHETAMINE, L AMPHETAMINE, AND METHYLPHENIDATE ON MOOD IN MAN.

CARDIOMYOPATHIC FINDINGS ASSOCIATED WITH METHYLPHENIDATE.
000833 01-15 HYPERSENSITIVITY TO METHYLPHENIDATE AND DEXTROAMPHETAMINE: A REPORT OF TWO CASES.

INFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3-CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN.

001119 02-03 THE SOCIOPHARMACOLOGY OF FENFLURAMINE (FM), METHYLPHENIDATE (MP), AND DIETHYLPROPION (DP) IN MACAQUE ARCTOIDES.

001311 02-04 EFFECTS OF METHYLPHENIDATE ON ACQUISITION AND SUBSEQUENT PERFORMANCE OF SUCCESSIVE DISCRIMINATION REVERSALS.

001371 02-04 EFFECTS OF METHYLPHENIDATE (M) ON ACTIVITY OF WHIRLER MICE

001450 02-04 METHYLPHENIDATE, AMYGDALECTOMY AND ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.

001500 02-04 MANAGEMENT OF THE HYPERKINETIC SYNDROME WITH
METHYLPHENIDATE AND SMR BIOFEEDBACK TRAINING

001625 02-11 THE MOOD RESPONSE AND PLASMA CYCLIC-AMP RESPONSE TO INTRAVENOUS METHYLPHENIDATE

001666 02-13 THE PREDICTION OF DIFFERENTIAL RESPONSIVENESS OF HYPERKINETIC CHILDREN TO METHYLPHENIDATE. (PH.D. DISSERTATION). 001697 02-14

THE EFFECTS OF METHYLPHENIDATE ON VARIOUS TYPES OF ACTIVITY I EVEL AND ATTENTION IN HYPERKINETIC CHILDREN

001698 02-14 METHYLPHENIDATE IN HYPERKINETIC CHILDREN: DIFFERENCES IN DOSE EFFECTS ON LEARNING AND SOCIAL BEHAVIOR. 001732 02-14

METHYLPHENIDATE (RITALIN) ABUSE 001738 02-15

GILLES-DE-LA-TOURETTES SYNDROME: FAMILIAL OCCURRENCE AND PRECIPITATION BY METHYLPHENIDATE THERAPY.

001823 02-15 METHYLPHENIDATE EFFECT ON ATTENTIONAL AND COGNITIVE BEHAVIOR IN SIX- THROUGH TWELVE-YEAR-OLD MALES.

002618 03-14 VIGILANCE AND HUMAN ATTENTION UNDER CONDITIONS OF METHYLPHENIDATE AND SECOBARBITAL INTOXICATION: AN ASSESSMENT USING BRAIN POTENTIALS.

002622 03-14 EFFECTS OF IMIPRAMINE AND METHYLPHENIDATE ON BEHAVIOR OF HYPERACTIVE CHILDREN.

002645 03-14 ACUTE PSYCHOLOGIC AND NEUROENDOCRINE EFFECTS OF DEXTROAMPHETAMINE AND METHYLPHENIDATE.

BEHAVIOURAL EFFECTS OF METHYLPHENIDATE IN 6 HYDROXYDOPAMINE TREATED NEONATAL RATS.

003212 04-04 ACTIVITY ANALYSIS OF OPERANT BEHAVIOR FOLLOWING METHYLPHENIDATE ADMINISTRATION.

003223 04-04

THE EFFECTS OF METHYLPHENIDATE ON REPEATED ACQUISITION OF 003238 04.04 HALOPERIDOL AND LITHIUM BLOCKING OF THE MOOD RESPONSE TO INTRAVENOUS METHYLPHENIDATE 003520 04.00 COMPARISON OF ORAL AND INTRAVENOUS METHYLPHENIDATE 003559 04-11 GROWTH OF HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE 003562 04-11 BEHAVIOR OBSERVATIONS OF HYPERACTIVE CHILDREN AND METHYLPHENIDATE (RITALIN) EFFECTS IN SYSTEMATICALLY STRUCTURED CLASSROOM ENVIRONMENTS: NOW YOU SEE THEM NOW YOU DON'T 003581 04-11 THE EFFECTS OF CAFFEINE AND METHYLPHENIDATE ON HYPERACTIVE CHIEDDEN EFFECTS OF METHYLPHENIDATE ALONE AND IN COMBINATION WITH BEHAVIOR MODIFICATION PROCEDURES ON THE BEHAVIOR AND ACADEMIC PERFORMANCE OF HYPERACTIVE CHILDREN 003640 04-14 METHYLPHENIDATE-INDUCED
CHOLINERGIC INHIBITION OF METHYLPHENIDATE-INDUCED STEREOTYPY:
OXOTREMORINE. 002223 03-04 METHYL PHENIDATE-INDUCED CHOREDATHETOSIS 002660 03-15 METHYLPHENIDATE-INDUCED CONDITIONED TASTE AVERSIONS: AN INDEX OF TOXICITY 003337 04-04 METHYLPHENOTHIAZINE
OXIDATION KINETICS OF PHENOTHIAZINE AND 10 METHYLPHENOTHIAZINE IN ACIDIC MEDIUM. 001015 02-01 METHYLPURINE ASSOCIATION OF SOME PSYCHOTOMIMETIC COMPOUNDS WITH 6 METHYLPURINE IN AQUEOUS SOLUTIONS. 001950 03-01 POLYAMINE BIOSYNTHESIS IN RAT PROSTATE. SUBSTRATE AND INHIBITOR PROPERTIES OF 7 DEAZA ANALOGUES OF DECARBOXYLATED S ADENOSYLMETHIONINE AND 5 METHYLTHIOADENOSINE 000001 01-01 ANTAGONISM OF MORPHINE ACTION ON BRAIN ACETYLCHOLINE RELEASE BY METHYLXANTHINES AND CALCIUM. BROMOCRIPTINE, DIHYDROERGOTOXINE, METHYSERGIDE, D LSD, CF-25-397, AND CF-29-712: EFFECTS ON THE METABOLISM OF BIOGENIC AMINES IN THE BRAIN OF THE RAT 002849 04-03 THE EFFECTS OF P-CHLOROPHENYLALANINE, RESERPINE, METHYSERGIDE AND CYPROHEPTADINE ON THE DOPA-INDUCED EEG SYNCHRONIZATION IN THE RAT. 003022 04-03 METHYREROIDE, INDUCED THE SPECIFICITY OF NEUROLEPTIC-INDUCED AND METHYSERGIDE-INDUCED BEHAVIORAL HYPERSENSITIVITY. 002259 03-04 METOCLOPRAMIDE EXTRAPYRAMIDAL SIDE-EFFECTS OF METOCLOPRAMIDE (CERUCAL) USED IN COMBINATION WITH AN ANTIDEPRESSANT. 000832 01-15 A CONTROLLED TRIAL OF METOCLOPRAMIDE IN SYMPTOMATIC GASTROESOPHAGEAL REFLUX. 000862 01-15 METRAZOL

EFFECT OF SUBACUTE DIAZEPAM ADMINISTRATION IN MICE ON THE SUBSEQUENT ABILITY OF DIAZEPAM TO PROTECT AGAINST METRAZOL AND BICUCULLINE-INDUCED CONVULSIONS 002053 03-03 METRAZOL-INDUCED PETIT-MAL: THE ROLE PLAYED BY MONOAMINERGIC

MECHANISMS AND STRIATUM.

CLINICAL INEFFECTIVENESS OF METYROSINE.

INHIBITION OF DOPAMINE SYNTHESIS IN CHRONIC SCHIZOPHRENIA:

ETHNOPHARMACOLOGY OF SACRED PSYCHOACTIVE PLANTS USED BY THE INDIANS OF MEXICO.

EFFECTS ON STRIATAL AND MESOLIMBIC DOPAMINE SYSTEMS OF A NEW POTENTIAL ANTIPSYCHOTIC DRUG — MEZILAMINE — WITH WEAK CATALEPTOGENIC PROPERTIES.

METYPOSINE

METHAMINE

EFFECTS OF NA, K, MG AND CA ON THE SATURABLE BINDING OF
(3H)DIHYDROMORPHINE AND (3H)NALOXONE IN VITRO. EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON A
MG2-ATPASE OF SYNAPTIC VESICLES PREPARED FROM RAT CEREBRAL-CORTEX 000123 01-03 MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMANATURE PAT 002001 04-03 PHENELZINE IN DEPRESSED PATIENTS: EFFECTS ON URINARY MHPG
EXCRETION IN RELATION TO CLINICAL RESPONSE. 000686 01-13 THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF TRICYCLIC
ANTIDEPRESSANTS ON MAPG-SO4 IN RAT BRAIN. 001228 02-03 MIAMSERIN

EFFECTS OF MIANSERIN, A NEW ANTIDEPRESSANT, ON THE IN VITRO

AND IN VIVO UPTAKE OF MONOAMINES. 000124 01-03 A COMPARISON IN RABBIT ISOLATED HEARTS OF THE DYSRHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE, MAPR.
AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK MAPROTILINE NORADRENALINE UPTAKE. 000138 01-03
MIANSERIN IN THE PROPHYLACTIC TREATMENT OF BIPOLAR AFFECTIVE-000561 01-09 POISONING WITH MAPROTILINE AND MIANSERIN. 000819 01-15 EFFECT OF MIANSERIN ON RRAIN SEROTONIN TURNOVER IN MICE 001057 02-03 EEG, BLOOD LEVEL, AND BEHAVIORAL EFFECTS OF THE ANTIDEPRESSANT MIANSERIN (ORG-GB-94). ANTAGONISM BY MIANSERIN AND CLASSICAL ALPHA-ADRENOCEPTOR
BLOCKING DRUGS OF SOME CARDIOVASCULAR AND BEHAVIORAL 002138 03-03 THE CENTRAL ANTISEROTONERGIC ACTION OF MIANSERIN 003281 04-04 A COMPARATIVE CLINICAL TRIAL OF MIANSERIN (NORVAL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION IN GENERAL 003514 04-09 MIANSERINE BLOCKADE OF PRESYNAPTIC ALPHA-RECEPTORS AND OF AMINE UPTAKE
IN THE RAT BRAIN BY THE ANTIDEPRESSANT MIANSERINE. 001965 03-03 USE OF LITHIUM-CARBONATE WITH RETARDED ACTION (MICALITE) IN PATIENTS WITH AFFECTIVE-PSYCHOSES. 002444 03-09 MANCE PHARMACOLOGICAL ACTIONS OF INTRACEREBRALLY ADMINISTERED POLYAMINES IN MICE 000033 01-02 SOME EFFECTS OF MUSCIMOL IN MICE, RATS AND CATS. 000173 01-03 ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM - IV. TOLERANCE TO OXOTREMORINE IN MICE: IN VIVO AND IN VITRO STUDIES. 000188 01-03 QUIPAZINE-INDUCED HEAD-TWITCH IN MICE. ABSENCE OF FORMATION OF BRAIN SALSOLINOL IN ETHANOL DEPENDENT MICE 000208 01-03 METABOLIC BASIS FOR THE SUPRA-ADDITIVE EFFECT OF THE ETHANOL DIAZEPAM COMBINATION IN MICE. 000218 01-03 MATERNAL FETAL DISTRIBUTION OF METHAQUALONE IN CONTROL AND SKF-525-A PRETREATED PREGNANT MICE. 000263 01-03 INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH D.L METHADONE THE INFLUENCE OF CAFFEINE AND THEOBROMINE ON LOCOMOTIVE ACTIVITY AND THE BRAIN C-GMP/C-AMP RATIO IN WHITE MICE 000275 01-03 REVERSIBLE AND IRREVERSIBLE EFFECTS OF P-CHLOROAMPHETAMINE ON BRAIN SEROTONIN IN MICE. 000276 01-03

002192 03-04

000542 01-08

EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN TWO INBRED STRAINS OF MICE.

000333 01-04 EFFECTS OF APOMORPHINE ON SELF-STIMULATION BEHAVIOUR IN DORSAL AND VENTRAL AREA OF LATERAL HYPOTHALAMUS IN MICE. 000334 01-04

INFLUENCES OF GENOTYPE AND SEX ON BEHAVIORAL TOLERANCE TO NICOTINE IN MICE.

000376 01-04 EFFECTS OF CATECHOLAMINERGIC DRUGS UPON MEMORY STORAGE PROCESSES IN MICE. 000377 01-04

MORPHINE ACTION IN GROUPED AND ISOLATED RATS AND MICE 000394 01-04

INHIBITION OF BOTH MAO-A AND MAO-B REQUIRED FOR THE PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

000398 01-04 FACILITATION BY RESERPINE OF RETENTION IN AN INHIBITORY AVOIDANCE TASK IN MICE.

000406 01-04 EFFECTS OF THREE MONOAMINE-OXIDASE INHIBITORS ON ETHANOL PREFERENCE IN MICE.

000447 01-04 GENETIC ANALYSIS OF THE BEHAVIORAL RESPONSE TO D AMPHETAMINE

000482 01-05 EFFECT OF MIANSERIN ON BRAIN SEROTONIN TURNOVER IN MICE. 001057 02-03

THE EFFECTS OF METHAQUALONE ON THE SEIZURE SUSCEPTIBILITY OF

001062 02-03 FOOTSHOCK INDUCED ANALGESIA IN MICE: ITS REVERSAL BY NALOXONE AND CROSS-TOLERANCE WITH MORPHINE.

001078 02-03 TRIPHASIC DOSE LETHALITY RELATIONSHIPS FOR AMPHETAMINE AND CERTAIN RING-SUBSTITUTED AMPHETAMINES IN ISOLATED OR AGGREGATED MICE.

001093 02-03 CATECHOLAMINE SENSITIVE ATPASE ACTIVITIES IN BRAIN SYNAPTOSOMES OF MORPHINIZED MICE.

POTENTIATION OF MORPHINE ANALGESIA IN MICE AFTER INHIBITION OF BRAIN TYPE-B MONOAMINE-OXIDASE.

001126 02-03 AMPHETAMINE LETHALITY IN MICE. (PH.D. DISSERTATION).

001151 02-03 THE DISTRIBUTION BETWEEN PLASMA AND BRAIN OF GLUTETHIMIDE AND 4 HYDROXYGLUTETHIMIDE FOLLOWING THEIR ADMINISTRATION TO MICE.

SPECIFIC RELEASE BY NALOXONE OF H3-MORPHINE FROM SUPERFUSED SLICES OF CORPUS-STRIATUM OF MICE.

O01164 02-03 ENHANCED AFFINITY OF OPIATE RECEPTORS FOR NALOXONE IN STRIATAL SLICES OF MORPHINE-DEPENDENT MICE.

001165 02-03
REGIONAL DISTRIBUTION OF BARBITAL IN THE BRAIN OF MICE DURING
THE DEVELOPMENT OF TOLERANCE AND PHYSICAL DEPENDENCE. 001180 02-03

THE EFFECTS OF METHAQUALONE ON PITUITARY ADRENOCORTICAL ACTIVITY IN MICE.

001194 02-03 ELECTROSHOCK ANTICONVULSANT ACTIVITY AND BRAIN ACETYLCHOLINE ALTERATIONS IN MICE TREATED WITH SELECT BENZODIAZEPINES. 001210 02-03

COMPARATIVE BRAIN/PLASMA CONCENTRATIONS OF AMPHETAMINE ISOMERS IN MICE. 001224 02-03

EFFECTS OF APOMORPHINE AND HALOPERIDOL ON EXPLORATORY BEHAVIOR AND LATENT LEARNING IN MICE. 001297 02-04

AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOUR AND BRAIN CONCENTRATIONS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN MICE.

001316 02-04 EFFECTS ON RETENTION OF POSTTRAINING AMPHETAMINE INJECTIONS IN MICE: INTERACTION WITH PRETRAINING EXPERIENCE.

001375 02-04 EFFECTS OF NEUROLEPTICS ON MORPHINE-INDUCED TAIL ERECTION IN MICE

001400 02-04 EFFECTS OF L-DOPA, D AMPHETAMINE AND COCAINE ON INTRUDER-EVOKED AGGRESSION IN RATS AND MICE.

001420 02-04 SUBSTITUTED AMPHETAMINE DERIVATIVES. II. BEHAVIOURAL EFFECTS IN MICE RELATED TO MONOAMINERGIC NEURONES.

EFFECTS OF D AMPHETAMINE AND STRYCHNINE ON CYCLOHEXIMIDE —
AND DIETHYLDITHIOCARBAMATE-INDUCED AMNESIA IN MICE.
001438 02-04

EFFECTS OF METHYLPHENIDATE (M) ON ACTIVITY OF WHIRLER MICE

001450 02-04 THE LACK OF EFFECT OF SYNTHETIC SCOTOPHOBIN ON DARKNESS AVOIDANCE IN MICE.

001496 02-04 MEASUREMENTS OF WEIGHT AND ACTIVITY IN MALE MICE FOLLOWING INHALATION OF CANNABIS SMOKE IN A CONTROLLED SMOKE EXPOSURE CHAMBER.

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL, CANNABIDIOL, AND CANNABINOL ON THE ANESTHESIA INDUCED BY VARIOUS ANESTHETIC AGENTS IN MICE.

EFFECT OF SUBACUTE DIAZEPAM ADMINISTRATION IN MICE ON THE SUBSEQUENT ABILITY OF DIAZEPAM TO PROTECT AGAINST METRAZOL AND BICUCULLINE-INDUCED CONVULSIONS.

002053 03-03 IMMUNOSUPPRESSION OF MICE BY DELTA9-TETRAHYDROCANNABINO

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. I. TOLERANCE TO PHENCYCLIDINE DERIVATIVES IN MICE: PHARMACOLOGICAL CHARACTERIZATION.

ABSORPTION AND DISTRIBUTION OF SODIUM BARBITAL IN TISSUES OF NORMAL AND DYSTROPHIC MICE.

DIFFERENCES IN THE INHIBITORY EFFECTS OF NORMORPHINE AND OPIOID PEPTIDES ON THE RESPONSES OF THE VASA-DEFERENTIA OF TWO STRAINS OF MICE.

002176 03-03 INCREASED ANTAGONIST POTENCY OF NALOXONE CAUSED BY MORPHINE PRETREATMENT IN MICE.

002183 03-03 PIPEROXANE REDUCES THE EFFECTS OF CLONIDINE ON AGGRESSION IN MICE AND ON NORADRENALINE DEPENDENT HYPERMOTILITY IN RATS 002205 03-04

NEUROTENSIN ADMINISTERED INTRACISTERNALLY INHIBITS RESPONSIVENESS OF MICE TO NOXIOUS STIMULI.

002214 03-04 TOLERANCE TO HYPOKINESIA ELICITED BY DOPAMINE AGONISTS IN MICE: HYPOSENSITIZATION OF AUTORECEPTORS?.

002221 03-04 THE EFFECT OF ETHANOL ON SUPPRESSION OF THE NALOXONE PRECIPITATED ESCAPE RESPONSE IN MORPHINE-DEPENDENT MICE

002230 03-04 THE ROLE OF SEROTONIN ANTAGONISM IN THE TREMORGENIC ACTION OF

002236 03-04 COMPARATIVE STUDY OF THE ANTAGONISM OF BEMEGRIDE AND PICROTOXIN ON BEHAVIOURAL DEPRESSANT EFFECTS OF DIAZEPAM IN RATS AND MICE.

002312 03-04 THE ANTAGONISTIC EFFECTS OF 5 ETHYL-5-HYDROXY-1METHYLBUTYLBARBITURIC-ACID ON PENTOBARBITAL NARCOSIS IN
BOTH NAIVE AND TOLERANT MICE.

002336 03-04 CIRCADIAN RHYTHM OF LITHIUM TOXICITY IN MICE.

002344 03-05 A GRADUAL SCORE TO EVALUATE THE CLIMBING BEHAVIOUR ELICITED BY APOMORPHINE IN MICE.

002350 03-05 EFFECT OF AN ANTIPSYCHOTIC AND OTHER CLASSES OF DRUGS ON SPONTANEOUS LOCOMOTOR ACTIVITY AND NEUROTOXICITY IN MICE

OSMOTIC MINIPUMPS FOR ADMINISTRATION OF BARBITAL TO MICE: DEMONSTRATION OF FUNCTIONAL TOLERANCE AND PHYSICAL

POTENTIATION BY NEUROLEPTIC AGENTS OF THE INHIBITORY ACTION OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE.

002832 04-03 EFFECT OF ACUTE MORPHINE ADMINISTRATION ON THE CEREBELLAR CYCLIC-GMP LEVEL IN TWO STRAINS OF MICE.

THE EFFECTS OF INORGANIC LEAD ON THE CENTRAL CATECHOLAMINERGIC SYSTEM OF THE RODENT WITH EMPHASIS ON POSTNATALLY EXPOSED RATS AND MICE. (PH.D. DISSERTATION).

003078 04-03 TIME-COURSE OF THE INCREASE IN GABA LEVEL IN DIFFERENT MICE BRAIN REGIONS FOLLOWING N DIPROPYLACETATE TREATMENT. 003091 04-03

003086 04-03

LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO P-CHLOROAMPHETAMINE ON CENTRAL SEROTONERGIC MECHANISMS IN

THE DEVELOPMENT OF SEX DIFFERENCES IN THE DEMETHYLATION OF EFFYLMORPHINE AND IN ITS INTERACTION WITH COMPONENTS OF THE HEPATIC MICROSOMAL CYTOCHROME-P-450 SYSTEM IN MICE. 003122 04-03

CYPROTERONE-ACETATE EXPOSURE DURING GESTATION IN MICE RETARDS FETAL GROWTH.

THE ROLE OF THE CHOLINERGIC SYSTEM IN THE DEVELOPMENT OF INCREASED NALOXONE POTENCY IN MICE.

603140 04-03
EFFECTS OF ETHANOL AND PENTOBARBITAL IN MICE OF DIFFERENT AGES.
603151 04-04

THE EFFECTS OF DIVALENT IONS ON MORPHINE ANALGESIA AND ABSTINENCE SYNDROME IN MORPHINE-TOLERANT AND MORPHINE-DEPENDENT MICE

003169 04-04 EFFECT OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE.

003172 04-04 BLOCKADE OF TESTOSTERONE MAINTAINED INTERMALE FIGHTING IN ALBINO LABORATORY MICE BY AN AROMATIZATION INHIBITOR. 003176 04-04

EFFECTS OF MESCALINE AND PSILOCIN ON ACQUISITION CONSOLIDATION, AND PERFORMANCE OF LIGHT-DARK DISCRIMINATION IN TWO INBRED STRAINS OF MICE.

003184 04-04 TASK-DEPENDENT GENETIC INFLUENCES ON BEHAVIORAL RESPONSE OF MICE (MUS-MUSCULUS) TO ACETALDEHYDE.

ANALGESIA AND MOTOR ACTIVITY ELICITED BY MORPHINE AND ENKEPHALINS IN TWO INBRED STRAINS OF MICE.

003225 04-04
INHIBITION OF FIGHTING IN ISOLATED MICE FOLLOWING REPEATED ADMINISTRATION OF LITHIUM-CHLORIDE

003282 04-04 INTRUDER-EVOKED AGGRESSION IN ISOLATED AND NONISOLATED MICE: EFFECTS OF PSYCHOMOTOR STIMULANTS AND L-DOPA.

003298 04-04 CANNABIS INTERFERES WITH NEST-BUILDING BEHAVIOR IN MICE.
003306 04-04

SUBAMNESIC CYCLOHEXIMIDE TREATMENT DELAYS CONSOLIDATION IN MICE

FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON LOCOMOTOR ACTIVITY AND AVOIDANCE BEHAVIOUR OF RESERPINIZED MICE

EFFECTS OF CHLORDIAZEPOXIDE, AMITRIPTYLINE, IMIPRAMINE, AND THEIR COMBINATIONS ON AVOIDANCE BEHAVIOUR IN MICE.

FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON THE PERFORMANCE OF MICE IN AN INHIBITORY AVOIDANCE TASK.

AGGRESSION PROMOTING AND AGGRESSION ELICITING PROPERTIES OF ESTROGEN IN MALE MICE

INHIBITION OF 5.7 DIHYDROXYTRYPTAMINE-INDUCED SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN MICE BY TREATMENT WITH CYCLOHEXIMIDE.

003366 04-04 CHANGES IN LOCOMOTOR ACTIVITY AND NALOXONE-INDUCED JUMPING IN MICE PRODUCED BY WIN-35197-2 (ETHYLKETAZOCINE) AND

003376 04-04
COMPARATIVE EFFECTS OF APOMORPHINE AND NALOXONE IN ACUTELY DEFENDENT MORPHINIZED RATS AND MICE.

003379 04-04 THE TRIPHASIC AMPHETAMINE LETHAL DOSE CURVE IN MICE AND ITS POSSIBLE RELATIONSHIP TO DRUG METABOLISM. 003410 04-05

A GENETIC ANALYSIS OF THE HYPERTHERMIC RESPONSE TO D AMPHETAMINE IN TWO INBRED STRAINS OF MICE. 003411 04-05

ACTION OF DOPAMINE AGONISTS ON BRAIN VESSELS IN VITRO AND AFTER IN VIVO MICROAPPLICATION.

001107 02-03 MICROCIRCULATION ACTION OF NOREPINEPHRINE ON MICROCIRCULATION AND PO2

DISTRIBUTION IN THE ISOLATED PERFUSED RAT LIVER. 002059 03-03

EFFECT OF PAPAVERINE AND DIHYDROERGOTOXINE-MESYLATE ON CEREBRAL MICROFLOW, EEG. AND PO2 IN OLIGEMIC HYPOTENSION 002032 03-03

MICROINJECTION MICROINJECTION OF KAINIC-ACID INTO THE RAT HIPPOCAMPUS 003081 04-03 MICROINJECTIONS

SPECIFICITY OF LEARNING DEFICITS PRODUCED BY MICROINJECTIONS OF 6-OHDA INTO THE NIGROSTRIATAL SYSTEM OF THE RAT. 000346 01-04

CIRCLING BEHAVIOR AND STEREOTYPY INDUCED BY INTRANIGRAL OPIATE MICROINJECTIONS. 000385 01-04

ATONIA AFTER CARBACHOL MICROINJECTIONS NEAR THE LOCUS-COFRUITEUS IN CATS 003381 04-04

MICROIONTOPHORETIC

CNS SITE OF CLONIDINE-INDUCED HYPOTENSION: A
MICROIONTOPHORETIC STUDY OF BULBAR CARDIOVASCULAR

MICROSCOPE

SOMATOSTATIN: ELECTRON MICROSCOPE IMMUNOHISTOCHEMICAL LOCALIZATION IN SECRETORY NEURONS OF RAT HYPOTHALAMUS 001948 03-01

MICROSCOPIC ELECTRON MICROSCOPIC STUDIES ON THE CEREBRAL LESIONS OF RATS IN EXPERIMENTAL CHRONIC DISULFIRAM POISONING.

000906 01-15 IN VITRO EFFECTS OF CHLORPROMAZINE ON MICROTUBULES GOLGI COMPLEX IN EMBRYONIC CHICK SPINAL GANGLION CELLS: AN ELECTRON MICROSCOPIC STUDY.

001258 02-03

MICROSOMAL QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P-450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3

AAETHYCHOL ANTHRENE 002083 03-03

THE ROLE OF SUBSTRATE LIPOPHILICITY IN DETERMINING TYPE 1
MICROSOMAL P450 BINDING CHARACTERISTICS. 002809 04-03

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6
TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — I. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOM DRUG METABOLISM — II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH.

002932 04-03 SUBCELLULAR LOCALIZATION OF C14-METHAQUALONE IN MOUSE BRAIN: EFFECTS OF HEPATIC MICROSOMAL ENZYME INHIBITION.

002983 04-03 THE DEVELOPMENT OF SEX DIFFERENCES IN THE DEMETHYLATION OF ETHYLMORPHINE AND IN ITS INTERACTION WITH COMPONENTS OF THE HEPATIC MICROSOMAL CYTOCHROME-P-450 SYSTEM IN MICE.

IN VITRO EFFECTS OF CHLORPROMAZINE ON MICROTUBULES AND THE GOLGI COMPLEX IN EMBRYONIC CHICK SPINAL GANGLION CELLS: AN **ELECTRON MICROSCOPIC STUDY**

001258 02-03 MICROWAVE INFLUENCE OF INJECTED PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE BRAIN AND LUNG FOLLOWING MICROWAVE IRRADIATION.

A SEROTONERGIC, MIDBRAIN RAPHE MODEL OF TONIC IMMOBILITY 000291 01-03 ANTIDROMICALLY IDENTIFIED SEROTONERGIC NEURONS IN THE RAT MIDBRAIN RAPHE: EVIDENCE FOR COLLATERAL INHIBITION 000292 01-03

EFFECTS OF BENZODIAZEPINES ON PGO FIRINGS AND MULTIPLE UNIT ACTIVITY IN THE MIDBRAIN RETICULAR FORMATION IN CATS. 001265 02-03

DIFFERENTIAL EFFECTS OF MORPHINE AND D AMPHETAMINE ON SELF-STIMULATION FROM CLOSELY ADJACENT REGIONS IN RAT MIDBRAIN 001403 02-04

NEUROCHEMICAL MECHANISMS OF CENTRAL ACTION OF MORPHINE ON FUNCTIONS OF SINGLE NEURONS IN THE MIDBRAIN RETICULAR FORMATION.

001973 03-03 ANGIOTENSIN BINDING AFFINITY AND CAPACITY IN THE MIDBRAIN AREA OF SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS. 002870 04-03

MIGRAINE RHEOENCEPHALOGRAPHIC DATA IN MIGRAINE CEPHALGIA AND THEIR CHANGES DURING STUGERON TREATMENT.

000515 01-07

A COMPARISON BETWEEN PLACEBO, PIZOTIFEN AND 1 ISOPROPYL-3-HYDROXY 5 SEMICARBAZONO-6-OXOTETRAHYDROINDOL (FIVASCAN) IN MIGRAINE PROPHYLAXIS. 000653 01-11 DRUG DEPENDENCE IN PROPRANCIOL TREATMENT OF MIGRAIN 002678 03-15 DRUG TREATMENT OF MIGRAINE AND ITS VARIANTS 003696 04-17 LSD IN A COERCIVE MILIEU THERAPY PROGRAM 001631 02-12 STUDIES OF EXCRETION IN RABBIT MILK AFTER ADMINISTRATION OF CARBON-14 LABELLED AMITRIPTYLINE AND NORTRIPTYLINE. 000037 01-03 THE HIDDEN COST OF MIND MEDICINES. 002674 03-15 INTRACCULAR PRESSURE LOWERING PROPERTIES OF ABBOTT-43981, A CANNABINOID DERIVED HETEROCYCLIC BENZOPYRAN WITH MINIMAL CNS ACTIVITIES. 001025 02-02 MIMAL-BRAIN-DYSFUNCTION MINIMAL-BRAIN-DYSFUNCTION. 000973 01-17 DEANOL IN MINIMAL-BRAIN-DYSFUNCTION. 001909 02-17 EVALUATION OF DIFFERENT TREATMENTS IN MINIMAL-CEREBRAL-DAMAGE. 001920 02-17 OSMOTIC MINIPUMPS FOR ADMINISTRATION OF BARBITAL TO MICE: DEMONSTRATION OF FUNCTIONAL TOLERANCE AND PHYSICAL 002374 03-06 THE TURNOVER RATE OF GAMMA-AMINOBUTYRIC-ACID IN THE NUCLEI OF TELENCEPHALON: IMPLICATIONS IN THE PHARMACOLOGY OF ANTIPSYCHOTICS AND OF A MINOR TRANQUILIZER. PURCHASES OF HYPNOTICS, SEDATIVES AND MINOR TRANQUILLIZERS AMONG 2,566 INDIVIDUALS IN THE COUNTY OF JAMTLAND, SWEDEN: A 6-YEAR FOLLOW-UP. 000940 01-17 MINOR TRANQUILLIZERS IN SOMATIC DISORDERS. 003633 04-14 MIOSIS MIOSIS AND FLUCTUATION IN THE RABBIT PUPIL: EFFECTS OF MORPHINE AND NALOXONE. 000504 01-06 MIRTHLESS CLINICAL PARABLE: MIRTHLESS MERRY-GO-ROUND. 003463 04-08 GUIDELINES TO REDUCE MISUSE OF DRUGS. 001917 02-17 MITOCHONDRIA MITOCHONDRIA OF MONOAMINE OXIDATION IN SUBFRACTIONS OF CRUDE MITOCHONDRIA OF RAT BRAIN BY CLORGYLINE AND LILLY-51641. 003020 04-03

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — I. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS. MK-212 ANOREXIGENIC AND ANCILLARY ACTIONS OF MK-212 (6 CHLORO-2-PIPERAZINYLPYRAZINE; CPP). PHARMACOLOGICAL DIFFERENTIATION OF THE CENTRAL 5
HYDROXYTEYPTAMINE-LIKE ACTIONS OF MK-212 (6 CHLORO-2-1PIPERAZINYL-PYRAZINE), P-METHOXYAMPHETAMINE AND
FENFLURAMINE IN AN IN VIVO MODEL SYSTEM. MNEMONIC
CHOLINERGIC CONDUCTANCE AS A COMPONENT OF MNEMONIC
PROCESSES. (PH.D. DISSERTATION).
0033 MOBILETTEN
ON THE INFLUENCE OF MOBILETTEN ON THE EFFECT OF ALCOHOL IN THE HUMAN: SECOND COMMUNICATION: INFLUENCE ON THE EFFICIENCY UNDER ALCOHOL STRESS.

001623 02-MODE (UNPUBLISHED PAPER) MODE OF ACTION OF ANTIDEPRESSANT DRUGS. DERIVATIVE LON-954 ALTERED RECEPTOR SENSITIVITY FOLLOWING CHRONIC DRUG MITOCHONDRIAL
PSYCHOACTIVE DRUG EFFECTS AND SUBSTRATE SPECIFICITY IN INTACT
MITOCHONDRIAL MONOAMINE-OXIDASE FROM BRAIN.
000115 01-MOUSE PREADOLESCENT HYPERKINETIC MODEL. A DIAGNOSTIC TREATMENT MODEL FOR EFFECTIVE GROUP TREATMENT OF DRUG ABUSERS. 000115 01-03 HIGH-AFFINITY BINDING OF H3-GLYCINE AND C14-BETA-ALANINE TO SYNAPTOSOMAL MITOCHONDRIAL FRACTIONS OF RAT CNS REGIONS; EFFECTS OF STRYCHNINE. 000211 01-03 RAT A COMPARATIVE STUDY OF DIHYDROXYLATED PHENOTHIAZINE DERIVATIVES AS MITOCHONDRIAL INHIBITORS.

MIXED

THE EFFECT OF ANESTHESIA ON BRAIN MITOCHONDRIAL HEXOKINASE. 001058 02-03 NHIBITORS. 001259 02-03 PHENOTHIAZINE METABOLITES AS MITOCHONDRIAL II EFFECT OF MITOCHONDRIAL LIPID PEROXIDATION ON MONOAMINE-002813 04-03 SUBSTRATE SELECTIVE ACTIVATION OF RAT LIVER MITOCHONDRIAL MONOAMINE-OXIDASE BY OXYGEN.

AROMATIC AMINOTRANSFERASE ACTIVITY OF RAT BRAIN CYTOPLASMIC AND MITOCHONDRIAL ASPARTATE AMINOTRANSFERASES.

002978 04-03 THE EFFECT OF SODIUM PENTOBARBITAL ON SOME MITOCHONDRIAL 003014 04-03 COMPARATIVE AVAILABILITY OF DIAZEPAM (D) IN HUMAN PLASMA
(P), PAROTID SALIVA (PS) AND MIXED SALIVA (MS) AND ITS
RELATIONSHIP TO PLASMA PROTEIN BINDING.

EVIDENCE FOR FUNCTIONAL SYNAPSES BETWEEN MIXED CULTURES OF INFERIOR OLIVE AND CEREBELLUM.

TREATMENT OF SENILE PSYCHOSES WITH DISTRANEURIN MIXTURE. 000749 01-14

002213 03-04

002868 04-03

METHODOLOGICAL EXPERIENCE WITH A DOUBLE-BLIND MULTICENTRIC, MONITORED CLINICAL TRIAL (MMCT) WITH SINTAMIL. 000568 01-09

THE VALUE OF THE MMPI FOR DELINEATING SYMPTOMS UNIQUE TO POSITIVE LITHIUM RESPONDERS: A DRUG RESPONSE AND DIAGNOSTIC STUDY. (PH.D. DISSERTATION). 002638 03-14

003344 04-04

001623 02-11 MODE OF ACTION OF: ANTIDEPRESSANTS AND CENTRAL STIMULANTS.

000958 01-17 ON THE MODE OF ACTION OF CENTRAL STIMULATORY AGENTS 001232 02-03

002466 03-09 MODECATE
OUTPATIENT MAINTENANCE OF CHRONIC SCHIZOPHRENIC PATIENTS WITH
FLUPHENAZINE-DECANOATE (MODECATE): IBADAN EXPERIENCE. 003466 04-08

THE PRODUCTION OF AN ALTERNATIVE LABORATORY MODEL OF THE PARKINSON SYNDROME USING A NEW BENZYLIMIDOYLUREA

ADMINISTRATION IN MAN: THE TARDIVE-DYSKINESIA MODE 000248 01-03 A SEROTONERGIC, MIDBRAIN RAPHE MODEL OF TONIC IMMOBILITY

000083 01-03

000291 01-03 A DOPAMINERGIC BASIS FOR THE EFFECTS OF AMPHETAMINE ON A

000950 01-17 PROGRAMMED FEEDING AS A MODEL OF CHRONIC ALCOHOLISM IN THE 001087 02-03

STUDIES OF A PHARMACOLOGICAL MODEL OF ETHANOL DEPENDENCE IN THE RAT. (PH.D. DISSERTATION). 001125 02-03

CEREBELLAR CGMP SYSTEM: A MODEL TO STUDY DRUG RECEPTOR INTERACTION. (UNPUBLISHED PAPER). 001139 02-03

THE EFFECT OF LITHIUM ON AN ANIMAL MODEL OF TARDIVE DYSKINESIA

001167 02-03 DIAZEPAM BLOCKADE OF REPETITIVE ACTION POTENTIALS IN SKELETAL MUSCLE FIBRES: A MODEL OF ITS MEMBRANE ACTION.

WET-DOG SNAKE BEHAVIOUR IN THE RAT: A POSSIBLE QUANTITATIVE MODEL OF CENTRAL 5 HYDROXYTRYPTAMINE ACTIVITY. 001310 02-04 MORPHINE AND SHUTTLE-BOX SELF-STIMULATION IN THE RAT: A MODEL FOR EUPHORIA.

001401 02-04

000282 01-03

SCHIZOPHRENIA?

000563 01-09

EVALUATION OF SUBSTITUTED AMPHETAMINE HALLUCINOGENS USING THE CAT LIMB FLICK MODEL

001449 02-04 TWO DOPAMINE RECEPTORS: SUPPORTIVE EVIDENCE WITH THE RAT

ROTATIONAL MODEL. 001478 02-04 ADDENDUM CONCERNING A PROPOSED MODEL FOR THE ACTION OF

LITHIUM 001640 02-13

A PROPOSED MODEL FOR THE ACTION OF LITHIUM.

001648 02-13 BRAIN NEUROTRANSMITTER RECEPTORS AND CHRONIC ANTIPSYCHOTIC

DRUG TREATMENT: A MODEL FOR TARDIVE-DYSKINESIA NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: 1. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY.

002096 03-03

ALTERATIONS IN THE FUNCTION OF THE NUCLEUS LOCUS-COERULEUS: A POSSIBLE MODEL FOR STUDIES OF ANXIETY 002298 03-04

ANIMAL MODEL FOR STUDY OF HYPERKINESIS AND AGGRESSION. 002302 03-04 TAILS OF STRESS RELATED BEHAVIOR: A NEUROPHARMACOLOGICAL

MODEL. 002359 03-06

EFFECTS OF AMPHETAMINE ON SOCIAL BEHAVIORS OF RHESUS MACAQUES: AN ANIMAL MODEL OF PARANOIA.

002365 03-06 BEHAVIOURAL DESPAIR IN RATS: A NEW MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.

002370 03-06 AMPHETAMINE PSYCHOSIS -- A MODEL FOR PARANOID

002413 03-08 THE HUMAN PLATELET AS A MODEL FOR THE DOPAMINERGIC NEURON:
KINETIC AND PHARMACOLOGIC PROPERTIES AND THE ROLE OF AMINE STORAGE GRANULES.

A MODEL FOR EVALUATION OF ANTIANXIETY DRUGS WITH THE USE OF EXPERIMENTALLY-INDUCED STRESS: COMPARISON OF NABILONE AND

002721 03-16 AN APOMORPHINE-INDUCED VOMITING MODEL FOR ANTIEMETIC STUDIES

002722 03-16 RESEARCH FINDINGS ON CHRONIC MENTAL ILLNESS: A MODEL FOR CONTINUING-CARE IN THE HEALTH MAINTENANCE ORGANIZATION

002777 03-17 PHARMACOLOGICAL DIFFERENTIATION OF THE CENTRAL 5

HYDROXYTRYPTAMINE-LIKE ACTIONS OF MK-212 (6 CHLORO-2-1-PIPERAZINYL-PYRAZINE), P-METHOXYAMPHETAMINE AND FENFLURAMINE IN AN IN VIVO MODEL SYSTEM. 002868 04-03 ANIMAL MODEL OF DEPRESSION: III. MECHANISM OF ACTION OF

003108 04-03 A NEW ANIMAL MODEL FOR SCHIZOPHRENIA: INTERACTIONS WITH ADRENERGIC MECHANISMS.

L 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS IN GUINEA-PIGS: A MODEL FOR THE STUDY OF CENTRAL SEROTONIN DOPAMINE

MODELS

ANIMAL MODELS OF ORAL DRUG SELF-ADMINISTRATION.

000408 01-04 MODELS TO STUDY DRUG EFFECTS ON THE INTEGRATED FUNCTION OF GABAERGIC, PEPTIDERGIC (SUBSTANCE-P) AND DOPAMINERGIC NEURONS. (UNPUBLISHED PAPER).

000499 01-06 ANIMAL MODELS FOR MANIA. (UNPUBLISHED PAPER).

000501 01-06 DEPRESSION IN CHILDHOOD: DIAGNOSIS, TREATMENT, AND CONCEPTUAL

000613 01-10 CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE ANTIPSYCHOTIC DRUGS

RATIONALITY OF APPEALS USED IN THE PROMOTION OF PSYCHOTROPIC DRUGS. A COMPARISON OF MALE AND FEMALE MODELS 001932 02-17

ANIMAL MODELS IN PSYCHIATRY AND NEUROLOGY

002366 03-06 ANIMAL TEST MODELS FOR PREDICTION OF CLINICAL ANTIDEPRESSANT ACTIVITY. 002372 03-06 EXTENSION OF ANIMAL MODELS TO CLINICAL EVALUATION OF ANTIANXIETY AGENTS.

002716 03-16 ANIMAL MODELS FOR MANIA. 002766 03-17

ANIMAL MODELS OF SCHIZOPHRENIA: THE CASE FOR LSD-003706 04-17

MODERATELY A SEQUENTIAL TRIAL OF VILOXAZINE (VIVALAN) AND IMIPRAMINE IN MODERATELY DEPRESSED PATIENTS

SECOND MESSENGER RESPONSES AND REGULATION OF HIGH AFFINITY
RECEPTOR BINDING TO STUDY PHARMACOLOGICAL MODIFICATION OF GABAERGIC TRANSMISSION. (UNPUBLISHED PAPER).

000133 01-03 MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND NORADRENERGIC NEURONS IN NORMAL AND BRAIN LESIONED RATS.

THE RELATIVE EFFICACY OF METHYLPHENIDATE (RITALIN) AND BEHAVIOR MODIFICATION TECHNIQUES IN THE TREATMENT OF A HYPERACTIVE

MODIFICATION OF THE TIME-COURSE OF DMPEA TOXICITY IN THE MOUSE BY CENTRALLY ACTING DRUGS.

001039 02-02 MORPHINE ANALGESIA DOSE RESPONSE CURVES IN TOLERANT RATS: MODIFICATION BY NALOXONE

MONOSYNAPTIC ACTIVATION OF FASCIA-DENTATA IN UNRESTRAINED RATS: RESPONSE MODIFICATION BY SYNAPTICALLY ACTIVE DRUGS.

CHOLINERGIC MODIFICATION OF THE INHIBITION OF DOPAMINE-INDUCED HYPERACTIVITY BY NEUROLEPTICS.

STEREOSELECTIVE, DOSE-DEPENDENT MODIFICATION OF INTRACRANIAL SELF-STIMULATION (ICSS) BY CENTRALLY ADMINISTERED LEVORPHANOL AND DEXTRORPHAN

MODIFICATION OF THE AMPHETAMINE-INDUCED STEREOTYPY IN RATS FOLLOWING INHIBITION OF THE NORADRENALINE RELEASE BY FLA-136. 001367 02-04

PHARMACOLOGICAL MODIFICATION OF SHOCK POTENTIATED AMPHETAMINE LETHALITY

RECEPTOR SENSITIVITY MODIFICATION (RSM) — A NEW PARADIGM FOR THE POTENTIAL TREATMENT OF SOME HORMONAL AND TRANSMITTER 001659 02-13

MODIFICATION OF SLEEP INDUCED IN ACUTE AND CHRONIC ADMINISTRATION OF LITHIUM.

SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL CORRELATES

001974 03-03 MODIFICATION OF THE NORADRENERGIC CYCLIC-AMP GENERATING
SYSTEM IN THE RAT LIMBIC FOREBRAIN BY AMPHETAMINE (A) AND ITS HYDROXYLATED METABOLITES

002100 03-03 ACETYLCHOLINE ANTIRELEASE EFFECT OF MORPHINE AND ITS MODIFICATION BY CALCIUM.

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION.

002164 03-03 MEMORY: MODIFICATION OF ANISOMYCIN-INDUCED AMNESIA BY STIMULANTS AND DEPRESSANTS.

002232 03-04 MODIFICATION OF DREAM CONTENT AFTER PREFERENTIAL BLOCKADE OF MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS. 002619 03-14

ASSESSMENT OF SPONTANEOUS AND DRUG-INDUCED CHANGES IN VIGILANCE BY MEANS OF A NEW MODIFICATION OF THE SHORT TIME SPECTRAL ANALYSIS OF THE EEG.

MODIFICATION OF ADENYLATE-CYCLASE SYSTEMS IN MOUSE CEREBRAL-CORTEX BY CHLORPROMAZINE AND RESPECTIVE 7 HDROXY ANALOGS. 002875 04-03

MODIFICATION OF NUCLEAR RETENTION OF H3-ESTRADIOL BY CELLS OF THE HYPOTHALAMUS AS A FUNCTION OF EARLY HORMONE

002891 04-03 CORRELATION OF PHENOBARBITAL-INDUCED AND SKF-525-A-INDUCED MODIFICATION OF PENTOBARBITAL HYPNOSIS WITH ALTERATION OF IN VIVO AND IN VITRO PENTOBARBITAL METABOLISM IN THE RAT. 003008 04-03

003386 04-04

MODIFICATION OF THE 5 HYDROXYTRYPTOPHAN-INDUCED HEAD-TWITCH RESPONSE BY EXOGENOUS ENDOCRINE AGENTS. 003177 04-04

MODIFICATION OF THE RADIOENZYMATIC ASSAY FOR THE CATECHOLAMINES.

003431 04-06 EFFECTS OF METHYLPHENIDATE ALONE AND IN COMBINATION WITH BEHAVIOR MODIFICATION PROCEDURES ON THE BEHAVIOR AND ACADEMIC PERFORMANCE OF HYPERACTIVE CHILDREN. 003640 04-14

PERSONALITY MODIFICATIONS DUE TO LONG-TERM
PSYCHOPHARMACOTHERAPY: IN CASE OF CHRONIC SCHIZOPHRENIA.
000773 01-14

INFLUENCE OF SOME NEUROPSYCHOTROPIC DRUGS ON THE BEHAVIOURAL MODIFICATIONS INDUCED BY 3 ACETYLPYRIDINE IN RATS. 001358 02-04

MODIFIED

BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC/
ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH
NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA.

002220 03-04 002220 03-04

INSTINCTIVE PREDATORY BEHAVIOR OF THE FERRET (PUTORIUS-PUTORIUS-FURO L.) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE (LIBRIUM). 003161 04-04

VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF 2
AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF NAD:NADH AND
NORELEAGNINE A BETA-CARBOLINE DERIVATIVE.

000200 01-03

MODIFIERS
LOXAPINE IN NEUROTIC ANXIETY: SOME MODIFIERS OF TREATMENT

003544 04-10 MODIFYING

PEDIATRIC PSYCHOPHARMACOLOGY: THE USE OF BEHAVIOR MODIFYING DRUGS IN CHILDREN. 002784 03-17

PERIPHERAL CATECHOLAMINES RELEASED BY OXOTREMORINE MODULATE TREMOR IN THE RAT. (UNPUBLISHED PAPER).

001486 02-04 BETA-ADRENOCEPTORS MODULATE NORADRENALINE RELEASE FROM AXONAL SPROUTS IN CULTURED RAT SUPERIOR CERVICAL GANGLIA 002179 03-03

MODULATED

A BEHAVIORAL ANALYSIS OF AGGRESSIVE BEHAVIORS INDUCED AND MODULATED BY DELTA9-TETRAHYDROCANNABINOL, PILOCARPINE, D AMPHETAMINE AND L-DOPA. 001419 02-04

MODULATES

ADENOSINE MODULATES DEPOLARIZATION-INDUCED RELEASE OF H3NORADRENALINE FROM SLICES OF RAT BRAIN NEOCORTEX.

002938 (

002938 04-03 MODULATING

CYANOCYPROHEPTADINE: ROLE OF CHOLINOLYTIC PROPERTIES IN MODULATING NEUROLEPTIC-INDUCED ELEVATION OF STRIATAL HOMOVANILLIC-ACID (HVA). 001226 02-03

MODULATION OF BRAIN TRYPTOPHAN-HYDROXYLASE ACTIVITY BY BRAIN TRYPTOPHAN CONTENT.

000207 01-03 MODULATION OF ACETYLCHOLINE TURNOVER IN BRAIN REGIONS AND HIGH AFFINITY UPTAKE.

001209 02-03 ADRENERGIC MODULATION OF A CHOLINERGIC EMOTIONAL REACTION IN

THE CATS THALAMUS. 001344 02-04 DIHYDROERGOTOXINE-INDUCED MODULATION OF SPONTANEOUS ACTIVITY OF CULTURED RAT PURKINJE CELLS.

002020 03-03 POSSIBLE CENTRAL DOPAMINERGIC MODULATION OF THE RISE IN PLASMA CONCENTRATION OF NONESTERIFIED FATTY-ACIDS PRODUCED IN THE MOUSE BY (-)TRANS DELTA9-TETRAHYDROCANNABINOL.

MODULATION OF DEXAMPHETAMINE-INDUCED COMPUSIVE GNAWING — INCLUDING THE POSSIBLE INVOLVEMENT OF PRESYNAPTIC ALPHA-ADRENORECEPTORS.

002322 03-04 NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. I. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE IN EXPONENTIAL GROWTH PHASE.

PHARMACOLOGIC RESPONSES OF CELLS OF A NEUROBLASTOMA-X GLIOMA HYBRID CLONE AND MODULATION OF SYNAPSES BETWEEN HYBRID CELLS AND MOUSE MYOTUBES. 002863 04-03 MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II.

NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. II. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE TREATED WITH DIBUTYRYL-CYCLIC-AMP.

IDENTIFICATION OF A SUBREGION WITHIN RAT NEOSTRIATUM FOR THE DOPAMINERGIC MODULATION OF LATERAL HYPOTHALAMIC SELF-STIMULATION.

H3-GLYCOGEN HYDROLYSIS IN BRAIN SLICES: RESPONSES TO NEUROTRANSMITTERS AND MODULATION OF NORADRENALINE RECEPTORS.

003054 04-03 DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION. 003241 04-04

IMPRINTING BEHAVIOR: PITUITARY ADRENOCORTICAL MODULATION OF THE APPROACH RESPONSE.

ANATOMICAL SPECIFICITY WITHIN RAT STRIATUM FOR THE DOPAMINERGIC MODULATION OF DRL RESPONDING AND ACTIVITY 003316 04-04

MODULATOR
COENZYME-A IS A PURINE NUCLEOTIDE MODULATOR OF ACETYLCHOLINE OUTPUT. 002874 04-03

MODULATORS ENDOGENOUS MODULATORS OF ACETYLCHOLINE TURNOVER RATE.
(UNPUBLISHED PAPER).

000073 01-03 EFFECTS OF PRESYNAPTIC MODULATORS ON CA2-INDUCED NORADRENALINE RELEASE FROM CARDIAC SYMPATHETIC NERVES

002025 03-03

FLUNITRAZEPAM (ROHYPNOL) COMPARED WITH NITRAZEPAM (MOGADON) AND APROBARBITAL AS EVENING PREMEDICATION PRIOR TO ANESTHESIA: A CONTROLLED CLINICAL TRIAL.

002616 03-14 MOLECULAR

STRUCTURE-ACTIVITY STUDIES ON HALLUCINOGENIC AMPHETAMINES USING MOLECULAR CONNECTIVITY. 001530 02-06

GENERATION OF ELECTRONIC EXCITED STATES (EES) BY TRICYCLIC ANTIDEPRESSANTS: MOLECULAR ASPECTS.

001693 02-13 MOLECULAR DETERMINANTS FOR THE ACTION OF TRYPTAMINES ON AN

DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE: ORGANIC MOLECULAR MECHANISMS AND NEUROCHEMICAL EVENTS.

003254 04-04 MOLINDONE THE EFFECTS OF BEHAV'ORALLY RELEVANT DOSES OF CHLORPROMAZINE AND MOUNDONE G.1 CARDIAC ADENYLATE-CYCLASE AND ON MYOCARDIAL CONTRACTILITY.

000487 01-05 MOLINDONE: A CONTROLLED EVALUATION OF THE INTRAMUSCULAR ANTIPSYCHOTIC PREPARATION.

000541 01-08 MOLINDONE: AN APOMORPHINE ANTAGONIST IN THE RABBIT 001056 02-03

MONGOLIAN EFFECTS OF PCPA ON MARKING BEHAVIOUR IN THE MALE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).

001307 02-04 EFFECTS OF AMPHETAMINE AND NEMBUTAL ON SOCIAL EXPLORATION IN

THE MONGOLIAN GERBIL 001414 02-04 AMPHETAMINE EFFECTS ON STIMULUS ELICITED INVESTIGATION IN THE

003186 04-04 EFFECTS OF SPIPERONE ON SELF-STIMULATION AND OTHER ACTIVITIES OF THE MONGOLIAN GERBIL

CENTRAL AND PERIPHERAL ACTION OF TESTOSTERONE-PROPIONATE ON SCENT GLAND MORPHOLOGY AND MARKING BEHAVIOUR IN THE MONGOLIAN GERBIL.

003370 04-04

MONITORED
METHODOLOGICAL EXPERIENCE WITH A DOUBLE-BLIND MULTICENTRIC,
MONITORED CLINICAL TRIAL (MMCT) WITH SINTAMIL.
D00568-01

THE EFFECT OF A NEW BENZODIAZEPINE ON THE POLYGRAPHICALLY MONITORED SLEEP OF NORMAL VOLUNTEERS.

000765 01-14

MAPROTILINE (LUDIOMIL) IN DEPRESSION: A REPORT OF A MONITORED RELEASE STUDY IN GENERAL PRACTICE.

002433 03-09

PHARMACOKINETICS OF METHYLPHENIDATE IN THE RAT USING SINGLE ION MONITORING GLC MASS SPECTROMETRY. 000498 01-06

DRUGS AND DEPRESSION: DOSAGE AND BLOOD LEVEL MONITORING. 001595 02-09 BLOOD LEVEL MONITORING OF BENZODIAZEPINES BY GLC USING

NITROGEN SENSITIVE DETECTORS.

001860 02-16

DRUG MONITORING AT AN AUSTRALIAN DEPOT PHENOTHIAZINE CLINIC.
002402 03-08

MONKEY

LONG-TERM BEHAVIORAL CHANGES IN THE RHESUS MONKEY AFTER

MULTIPLE DAILY INJECTIONS OF D. METHYLAMPHETAMINE.

000359 01-04
KETAMINE SELF-ADMINISTRATION BY THE RHESUS MONKEY.
000417 01-04

PHARMACOKINETICS OF HEXOBARBITAL IN THE PREGNANT AND NONPREGNANT STUMPTAILED MONKEY. 001104 02-03

IN VIVO METABOLIC O DEMETHYLATION OF 3,4
DIMETHOXYAMPHETAMINE IN DOG AND MONKEY. MONKEY.

O01149 02-03

ALPHA-METHYLDOPAMINE — A METABOLITE AND KEY INTERMEDIATE IN
THE METABOLIC DISPOSITION OF 3,4 METHYLENEDIOXYAMPHETAMINE
(MDA) IN DOG AND MONKEY

THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDROCANNABINOL (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HORMONE (FSH) AND LUTEINIZING HORMONE (LH) IN THE OVARIECTOMIZED RHESUS MONKEY

BEHAVIOURAL AND PHARMACOKINETIC STUDIES IN THE MONKEY (MACACA-MULATTA) WITH DIAZEPAM, NORDIAZEPAM AND RELATED 1.4 BENZODIAZEPINES.

001336 02-04

EFFECTS OF DIAZEPAM AND D AMPHETAMINE ON FOOD COMPETITION IN RHESUS MONKEY.

COMPARISON OF THE CONVULSANT EFFECTS OF COCAINE AND PSEUDOCOCAINE IN THE RHESUS MONKEY.

001415 02-04

MORPHINE REDUCES CEREBELLAR CYCLIC-GUANOSINE-MONOPHOSPHATE
CONTENT AND ELEVATES CEREBROSPINAL FLUID CYCLIC-GUANOSINEMONOPHOSPHATE CONTENT IN RHESUS MONKEY.

ALTERATIONS OF EEG ACTIVITIES AND COCAINE-INDUCED CONVULSIONS FOLLOWING PROLONGED COCAINE TREATMENT IN THE RHESUS MONKEY

002091 03-03
STIMULATION OF ADENYLATE-CYCLASE ACTIVITY IN MONKEY ANTERIOR
LIMBIC CORTEX BY SEROTONIN

O02805 04-03
ENTRY OF BETA-N-OXALYL-L-ALPHA-BETA-DIAMINOPROPIONIC-ACID, THE LATHYRUS-SATIVUS NEUROTOXIN INTO THE CENTRAL-NERVOUS-SYSTEM OF THE ADULT RAT, CHICK AND THE RHESUS MONKEY.
03061 04-03

BRAIN AND RETINA UPTAKE OF A RADIOIODINE LABELED PSYCHOTOMIMETIC IN DOG AND MONKEY.

COMPARATIVE EFFECTS OF COCAINE AND PSEUDOCOCAINE ON EEG ACTIVITIES, CARDIORESPIRATORY FUNCTIONS, AND SELF-ADMINISTRATION BEHAVIOR IN THE RHESUS MONKEY.

MONKEYS
COMPARISON OF THYROTROPIN-RELEASING HORMONE WITH

MELANOCYTE-STIMULATING HORMONE RELEASE INHIBITING FACTOR
AS PENTOBARBITAL ANTAGONISTS IN MONKEYS.

000087 01-0.

REINFORCING PROPERTIES OF PERPHENAZINE, HALOPERIDOL AND AMITRIPTYLINE IN RHESUS MONKEYS.

000148 01-03

REINFORCING PROPERTIES OF INTRAVENOUS PROCAINE IN RHESUS MONKEYS.

THE EFFECTS OF PHARMACOLOGICAL AND ENVIRONMENTAL VARIABLES ON DRUG CHOICE IN RHESUS MONKEYS.

000386 01-04

MOVEMENT DISORDERS INDUCED IN MONKEYS BY CHRONIC HALOPERIDOL TREATMENT.

000490 01-05

TIME-COURSE AND DEVELOPMENT OF ELECTROCLINICAL FEATURES IN
RELATION TO PENTYLENETETRAZOL THRESHOLDS IN MONKEYS WITH
FOCAL SEIZURES.

001092 02-03
CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT
RHESUS MONKEYS.
001296 02-04

SECOND-ORDER SCHEDULES OF INTRAVENOUS DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS.

O01452 02-04
STUDIES OF THE REINFORCING PROPERTIES OF INTRAVENOUSLY SELFADMINISTERED COMPOUNDS IN RHESUS MONKEYS. (PH.D.
DISSERTATION).

EFFECTS OF CLOMIPRAMINE AND OTHER INHIBITORS OF MONOAMINE
UPTAKE ON THE SEXUAL BEHAVIOUR OF FEMALE RATS AND RHESUS
MONKEYS.

O02228 03-04
THE REINFORCING PROPERTIES OF PROCAINE AND D AMPHETAMINE
COMPARED IN RIESUS MONKEYS.

Q02239 03-04
CONTINUOUS INTRAVENOUS NALTREXONE EFFECTS ON MORPHINE SELFADMINISTRATION IN RHESUS MONKEYS.

O02241 03-04

EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D AMPHETAMINE
AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY
AND SHOCK AVOIDANCE IN RHESUS MONKEYS.

THE EFFECTS OF PHENCYCLIDINE ON VISUALLY EVOKED-POTENTIALS OF RHESUS MONKEYS

002306 03-04

EFFECTS OF IMIPRAMINE TREATMENT OF SEPARATION-INDUCED SOCIAL
DISORDERS IN RHESUS MONKEYS.

A DOSE RATIO COMPARISON OF THE INTERACTION BETWEEN MORPHINE AND CYCLAZOCINE WITH NALOXONE IN RHESUS MONKEYS ON THE SHOCK TITRATION TASK.

O02335 03-04
CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT
RHESUS MONKEYS.

CHOICE BEHAVIOR IN RHESUS MONKEYS: COCAINE VERSUS FOOD. 003155 04-04

THE DISCRIMINATIVE STIMULUS PROPERTIES OF INTRAVENOUSLY ADMINISTERED COCAINE IN RHESUS MONKEYS.

DYSKINESIAS EVOKED IN MONKEYS BY WEEKLY ADMINISTRATION OF HALOPERIDOL.

MONOAMINE
LEVELS OF CHLORPROMAZINE AND ITS ACTIVE MATABOLITES IN RAT
BRAIN AND THE RELATIONSHIP TO CENTRAL MONOAMINE
METABOLISM AND PROLACTIN SECRETION.

THE RELATIONSHIP BETWEEN MAGNITUDE OF ELECTROSHOCK
STIMULATION AND THE EFFECTS OF DIGITOXIGENIN,
PENTYLENETETRAZOL AND BRAIN MONOAMINE REDUCTION ON
ELECTROSHOCK CONVULSIVE THRESHOLDS.

000066 01-03

EFFECT OF CHLORPROMAZINE TREATMENT ON MONOAMINE METABOLITE
LEVELS IN CEREBROSPINAL FLUID OF PSYCHOTIC PATIENTS.
000591 01-09

URINARY MONOAMINE METABOLITE EXCRETION IN DISORDERS OF MOVEMENT.

MAO INHIBITORS AND CENTRAL MONOAMINE METABOLISM.

000991 01-17
BRL-13776: A NOVEL ANTIHYPERTENSIVE AGENT WITH INTERESTING
MONOAMINE DEPLETING PROPERTIES.

O 1007 02-01

A BENZOQUINOLIZINE DERIVATIVE WITH A NEUROLEPTIC-LIKE ACTION ON CEREBRAL MONOAMINE TURNOVER.

001037 02-02

EFFECTS OF THE ISOMERIC FORMS OF PROPRANOLOL ON CENTRAL
MONOAMINE METABOLISM IN REGIONS OF RAT BRAIN.

001284 02-03
ROLE OF THE BRAIN MONOAMINE SYSTEM IN LEARNING ON VARIOUS
EMOTIONAL REINFORCEMENTS.

001369 02-04
LITHIUM: CLINICAL EFFECTS AND CEREBROSPINAL FLUID ACID
MONOAMINE METABOLITES.

001577 02-09
NALOXONE (NARCAN) TREATMENT IN DEPRESSION: CLINICAL
OBSERVATIONS AND EFFECTS ON CSF ENDORPHINS AND MONOAMINE
METABOLITES.

001692 02-13

FURTHER STUDIES ON THE INHIBITION OF MONOAMINE OXIDATION BY
MONOAMINE-OXIDASE INHIBITORS.

002022 03-03

EFFECTS OF DIETHYLDITHIOCARBAMATE ON BRAIN MONOAMINE AND PROTEIN CONTENT IN NEONATAL RATS.

THE EFFECT OF LITHIUM ON SEROTONIN METABOLISM IN THE BRAIN OF RATS WITH PARTICULAR ATTENTION TO ITS EFFECT UNDER THE MONOAMINE ALTERED CONDITIONS.

002480 03-10

EFFECTS OF CLOMIPRAMINE AND OTHER INHIBITORS OF MONOAMINE UPTAKE ON THE SEXUAL BEHAVIOUR OF FEMALE RATS AND RHESUS

002228 03-04 INFLUENCE OF TRANSIENT ISCHEMIA ON MONOAMINE METABOLISM IN THE RAT BRAIN DURING NITROUS-OXIDE AND PHENOBARBITONE ANESTHESIA.

002852 04-03 THE EFFECT OF BROMOCRIPTINE ON RAT STRIATAL ADENYLATE-CYCLASE AND RAT BRAIN MONOAMINE METABOLISM.

EFFECTS OF PENTYLENETETRAZOLE AND TRIMETHADIONE ON FELINE BRAIN MONOAMINE METABOLISM.

003007 04-03
INHIBITION OF MONOAMINE OXIDATION IN SUBFRACTIONS OF CRUDE
MITOCHONDRIA OF RAT BRAIN BY CLORGYLINE AND LILLY-51641. 003020 04-03 EFFECTS OF MAZINDOL ON RAT BRAIN SYNAPTOSOMAL MONOAMINE

003103 04-03 PARALLEL CHANGES IN BEHAVIOR AND HIPPOCAMPAL MONOAMINE METABOLISM IN RATS AFTER ADMINISTRATION OF ACTH ANALOGUES 003335 04-04

MONOAMINE-OXIDASE
MONOAMINE-OXIDASE INHIBITION IN BRAIN AND LIVER PRODUCED BY
BETA-CARBOLINES: STRUCTURE-ACTIVITY RELATIONSHIPS AND SUBSTRATE SPECIFICITY

000064 01-03 ACUTE AND CHRONIC EFFECTS OF TETRAHYDROCANNABINOLS ON MONOAMINE-OXIDASE ACTIVITY: POSSIBLE VEHICLE/TETRAHYDROCANNABINOL INTERACTIONS.

000075 01-03 PSYCHOACTIVE DRUG EFFECTS AND SUBSTRATE SPECIFICITY IN INTACT MITOCHONDRIAL MONOAMINE-OXIDASE FROM BRAIN.

000115 01-03 EVALUATION OF RADIORESPIROMETRY FOR THE DETERMINATION OF MONOAMINE-OXIDASE ACTIVITY IN VIVO UTILIZING C11-OCTYLAMINE

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE.

000127 01-03 MONOAMINE-OXIDASE: EXAMINATION OF MULTIPLE FORMS

000156 01-03 EFFECTS OF 3.4 DIMETHOXYPHENETHYLAMINE DERIVATIVES ON MONOAMINE-OXIDASE.

000162 01-03 THE BLOCKADE OF SEROTONIN UPTAKE INTO SYNAPTOSOMES: RELATIONSHIP TO AN INTERACTION WITH MONOAMINE-OXIDASE INHIBITORS

ROLE OF TRYPTAMINE IN THE BEHAVIOURAL CHANGES CAUSED BY A MONOAMINE-OXIDASE INHIBITOR AND L TRYPTOPHAN.

000343 01-04 THE EFFECT OF INTRACEREBRAL INJECTION OF CYCLOHEXIMIDE ON BRAIN PROTEIN SYNTHESIS AND ON THE HYPERACTIVITY SYNDROME PRODUCED BY A MONOAMINE-OXIDASE INHIBITOR AND TRYPTOPHAN.

000410 01-04 EFFECTS OF THREE MONOAMINE-OXIDASE INHIBITORS ON ETHANOL PREFERENCE IN MICE.

000447 01-04 DOPAMINE IS A MONOAMINE-OXIDASE B SUBSTRATE IN MAN

000677 01-12 ACUTE VERSUS CHRONIC EFFECTS OF MONOAMINE-OXIDASE INHIBITORS IN DEPRESSED PATIENTS: TIME-COURSE OF MAQ INHIBITORS. 000733 01-13

MONOAMINE-OXIDASE INHIBITORS AND CAVIAR. 000848 01-15 THE BEHAVIORAL TOXICITY OF MONOAMINE-OXIDASE INHIBITING ANTIDEPRESSANTS.

000967 01-17 TRICYCLIC ANTIDEPRESSANT AND MONOAMINE-OXIDASE INHIBITOR COMBINATION THERAPY.

POTENTIATION OF MORPHINE ANALGESIA IN MICE AFTER INHIBITION OF BRAIN TYPE-B MONOAMINE-OXIDASE.

SUBSTITUTED AMPHETAMINE DERIVATIVES. I. EFFECT ON UPTAKE AND RELEASE OF BIOGENIC MONOAMINES AND ON MONOAMINE-OXIDASE IN THE MOUSE BRAIN.

001233 02-03 PLATELET MONOAMINE-OXIDASE ACTIVITY PREDICTS RESPONSE TO LITHIUM IN MANIC-DEPRESSIVE ILLNESS.

001607 02-09 DEGRADED PROTEIN CONTAINING FOOD AND MONOAMINE-OXIDASE INHIBITORS 001804 02-15 SELECTIVE MONOAMINE-OXIDASE INHIBITORS. 1. COMPOUNDS RELATED TO 4 AMINOPHENETHYLAMINE.

FURTHER STUDIES ON THE INHIBITION OF MONOAMINE OXIDATION BY MONOAMINE-OXIDASE INHIBITORS.

DOES LONG-TERM TREATMENT WITH AMITRIPTYLINE ALTER THE MONOAMINE-OXIDASE OF RAT BRAIN?. 002042 03-03

MONOAMINE-OXIDASE IN RAT RETICULOCYTES: SUBCELLULAR LOCALIZATION AND IDENTIFICATION OF ISOENZYMES.

002134 03-03 STEREOTYPY AND HYPERACTIVITY IN RATS RECEIVING ETHANOL AND A MONOAMINE-OXIDASE INHIBITOR.

002248 03-04 ON THE TREATMENT OF NEURODERMATITIS WITH A MONOAMINE-OXIDASE INHIBITOR: THE CHEMOTHERAPY OF PSYCHOSOMATIC ILLNESS THROUGH A-REM SUPPRESSION.

INHIBITION OF MONOAMINE-OXIDASE BY N PHENACYL-CYCLOPROPYLAMINE.

002796 04-02 EFFECT OF MITOCHONDRIAL LIPID PEROXIDATION ON MONOAMINE OXIDASE

002813 04-03 PHENYLETHYLAMINE -- DEAMINATION BY MULTIPLE TYPES OF MONOAMINE-OXIDASE.

002893 04-03 MONOAMINE-OXIDASE ACTIVITY OF MACROPHAGES AT REST AND DURING PHAGOCYTOSIS.

002902 04-03 SUBSTRATE SELECTIVE ACTIVATION OF RAT LIVER MITOCHONDRIAL MONOAMINE-OXIDASE BY OXYGEN.

002912 04-03 STERIC INFLUENCE ON INHIBITION OF MONOAMINE-OXIDASE FORMS BY 2.3 DICHLORO-ALPHA-METHYLBENZYLAMINE.

002918 04-03 MONOAMINE-OXIDASE INHIBITORY PROPERTIES OF 5 HYDROXYMETHYL 3-M-TOLYLOXAZOLIDIN-2-ONE (TOLOXATONE).

002971 04-03 IN VITRO INHIBITION OF MONOAMINE-OXIDASE TYPES A AND B BY D
AMPHETAMINE AND L AMPHETAMINE.

003016 04-03 INHIBITION OF MONOAMINE-OXIDASE BY ISOGENTISIN AND ITS 3 O GLUCOSIDE.

003104 04-03 THE DECREASE OF MONOAMINE-OXIDASE ACTIVITY FOLLOWING THE INTRAOCULAR INJECTION OF COLCHICINE IN THE SUPERIOR COLLICULUS

EFFECT OF RESERPINE ON THE MONOAMINE-OXIDASE (MAO) ACTIVITY IN RAT LIVER AND BRAIN.

003125 04-03 CLINICAL CORRELATES OF LOW PLATELET MONOAMINE-OXIDASE IN

003477 04-08 CLINICAL CORRELATES OF TRICYCLIC ANTIDEPRESSANT MEDIATED INHIBITION OF PLATELET MONOAMINE-OXIDASE.

003524 04-09

STABILITY OF LOW BLOOD PLATELET MONOAMINE-OXIDASE ACTIVITY IN

003577 04-11 **DEPRENYL ADMINISTRATION IN MAN: A SELECTIVE MONOAMINE-**OXIDASE B INHIBITOR WITHOUT THE CHEESE EFFECT

003652 04-15

MONOAMINE-OXIDASE-A
MONOAMINE-OXIDASE-B IN CULTURED CFLLS 002941 04-03

MONOAMINE-OXIDASE-8
MONOAMINE-OXIDASE-A AND MONOAMINE-OXIDASE-B IN CULTURED 002941 04-03

MONOAMINE-OXIDASES CHARACTERISTICS OF MONOAMINE-OXIDASES IN BRAIN AND OTHER ORGANS OF THE GOLDEN HAMSTER.

002900 04-03

MONOAMINERGIC
GRANULAR AND EXTRAGRANULAR ACTION OF PSYCHOTROPIC DRUGS
ON MONOAMINERGIC NEURONS. 000252 01-03

MONOAMINERGIC IMPLICATION IN DIFFERENT ELEMENTS OF SEXUAL BEHAVIOUR. 000411 01-04

SUBSTITUTED AMPHETAMINE DERIVATIVES. II. BEHAVIOURAL EFFECTS IN MICE RELATED TO MONOAMINERGIC NEURONES.

001429 02-04 BINDING INTERACTIONS OF ERGOT ALKALOIDS WITH MONOAMINERGIC RECEPTORS IN THE BRAIN.

002024 03-03

METRAZOL-INDUCED PETIT-MAL: THE ROLE PLAYED BY MONOAMINERGIC MECHANISMS AND STRIATUM.

002192 03-04
MONOAMINERGIC INFLUENCES ON THE INCORPORATION OF 535 IN THE
HYPOTHALAMIC AND NEUROHYPOPHYSIAL PROTEINS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF 535-CYSTEINE IN DEHYDRATED RATS

002238 03-04

MONOAMINES

EFFECTS OF MIANSERIN, A NEW ANTIDEPRESSANT, ON THE IN VITRO
AND IN VIVO UPTAKE OF MONOAMINES.

OOD126 O.

THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS OF MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE. 000169 01-03

ROLES OF MONOAMINES, PARTICULARLY DOPAMINE, IN CLINICAL DEPRESSION AND IN THE REGULATION OF MOOD.

SUBSTITUTED AMPHETAMINE DERIVATIVES. I. EFFECT ON UPTAKE AND RELEASE OF BIOGENIC MONOAMINES AND ON MONOAMINE-OXIDASE IN THE MOUSE BRAIN

001233 02-03 AMPHETAMINE AND CHICK BEHAVIOUR: A ROLE FOR MONOAMINES IN THE CAUSATION OF VOCALIZATIONS AND EMOTIONS.

001342 02-04 INHIBITION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS IN RATS BY PROSTAGLANDIN-E1: ROLE OF BRAIN MONOAMINES.

001968 03-03 THE EFFECT OF CHRONIC ETHANOL TREATMENT ON BEHAVIOUR AND CENTRAL MONOAMINES IN THE RAT.

002271 03-04 EFFECT OF GINSENG ON THE BRAIN BIOGENIC MONOAMINES AND 3.5 AMP SYSTEM: EXPERIMENTS ON RATS.

003044 04-03 REGIONAL CHANGES IN THE CONCENTRATIONS OF CEREBRAL MONOAMINES AND THEIR METABOLITES AFTER ETHANOLAMINE-O-SULPHATE-INDUCED ELEVATION OF BRAIN GAMMA-AMINOBUTYRIC-

ACID CONCENTRATIONS. 003053 04-03 SEIZURE SUSCEPTIBILITY AND ANTICONVULSANT ACTIVITY OF

CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES. EFFECTS OF INTRAVENTRICULARLY ADMINISTERED MONOAMINES ON SEIZURE SUSCEPTIBILITY AND BODY TEMPERATURE IN RATS.

003180 04-04

MONODESMETHYLCHLORPROMAZINE
MEASUREMENT OF PLASMA AND ERYTHROCYTE CHLORPROMAZINE AND
N MONODESMETHYLCHLORPROMAZINE LEVELS BY GASCHROMATOGRAPHY WITH A NITROGEN SENSITIVE DETECTOR. 003429 04-06

MONOMETHOXYAMPHETAMINES

EFFECTS OF D AMPHETAMINE, MONOMETHOXYAMPHETAMINES AND
HALLUCINOGENS ON SCHEDULE-CONTROLLED BEHAVIOR. 002244 03-04

MONOMETHYLTHIO ANALOGUES OF 1 TRIMETHOXYPHENYL-2-

AMINOPROPANE. 001030 02-02 MONOSODIUM-GLUTAMATE

EFFECTS OF MONOSODIUM-GLUTAMATE ON EATING AND DRINKING

BEHAVIOR IN RATS. 000423 01-04

MONOSYNAPTIC ACTIVATION OF FASCIA-DENTATA IN UNRESTRAINED RATS: RESPONSE MODIFICATION BY SYNAPTICALLY ACTIVE DRUGS 001214 02-03

MONOVALENT
EFFECTS OF BETA-BUNGAROTOXIN, DIPHENYLHYDANTOIN AND METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT CATIONS AND HIGH-ENERGY PHOSPHATE CONTENTS OF BRAIN SLICES. 000278 01-03

ROLES OF MONOAMINES, PARTICULARLY DOPAMINE, IN CLINICAL DEPRESSION AND IN THE REGULATION OF MOOD

000583 01-09 COMPARATIVE EFFECTS OF D AMPHETAMINE, L AMPHETAMINE, AND METHYLPHENIDATE ON MOOD IN MAN.

000790 01-14 MOOD CHANGE AND MAGNESIUM: A POSSIBLE INTERACTION BETWEEN MAGNESIUM AND LITHIUM? 001591 02-09

THE MOOD RESPONSE AND PLASMA CYCLIC-AMP RESPONSE TO INTRAVENOUS METHYLPHENIDATE 001666 02-13

EFFECT OF ALPHA-METHYLTYROSINE (MT) PRETREATMENT ON D
AMPHETAMINE (A) AND MORPHINE (M) INDUCED MOOD IN MAN 001714 02-14

MOOD ELEVATION AND MEDICATION. 001771 02-15 ENDORPHINS: NALOXONE FAILS TO ALTER EXPERIMENTAL PAIN OR MOOD IN HUMANS

002383 03-07 HALOPERIDOL AND LITHIUM BLOCKING OF THE MOOD RESPONSE TO INTRAVENOUS METHYLPHENIDATE. 003529 04-09

MOOD STATE-DEPENDENT LEARNING

003585 04-12

002525 03-11

MOOD-ALTERING USE OF MOOD-ALTERING DRUGS IN TREATING SEXUAL PROBLEMS 002780 03-17

FROM JOY TO DEPRESSION: NEW INSIGHTS INTO THE CHEMISTRY OF

0000981 01-17

EFFECTS OF SINGLE AND MULTIPLE DOSES OF DESIPRAMINE (DMI) ON ENDOGENOUS LEVELS OF 3 METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE (MOPEG-SO4) IN RAT BRAIN.

002814 04-03 MOPET

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLETHANOL (MOPET) IN HUMAN CEREBROSPINAL FLUID AND RAT BRAIN BY MEANS OF GAS-CHROMATOGRAPHY -- MASS-SPECTROMETRY 003025 04-03

MORBIDITY SUPPRESSIVE EFFECT OF LITHIUM-CARBONATE IN CYCLOID PSYCHOSIS.

A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE
DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON
SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR
PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION. 001787 02-15

A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR
PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND
SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR 003657 04-15

MORPHEUS MORPHINE SANS THE GIFT OF MORPHEUS. 000992 01-17

STEREOSPECIFIC ACTIONS OF MORPHINE ON SINGLE NEURONES IN THE

000060 01-03 EFFECTS OF REPEATED ADMINISTRATION OF MORPHINE ON TYROSINE-HYDROXYLASE IN THE RAT BRAIN.

000062 01-03 MORPHINE AND 5 HYDROXYTRYPTAMINE INTERACTIONS IN RAT HYPOTHALAMUS AND PINEAL BODY

000065 01-03 5-HT ANTAGONISTS INHIBIT NEUROLEPTIC AND MORPHINE ANTAGONISM OF THE HYPERACTIVITY INDUCED BY DOPAMINE FROM THE NUCLEUS-ACCUMBENS. 000082 01-03

5-HT AND MORPHINE INTERACTION, EFFECTS ON SENSORY INPUT IN CAUDATE NUCLEUS AND SUBSTANTIA-NIGRA.

STUDIES ON TOLERANCE. II. THE EFFECT OF TIMING ON INHIBITION OF TOLERANCE TO MORPHINE BY CYCLOHEXIMIDE. 000104 01-03

THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN THE RAT 000106 01-03

STRAIN DIFFERENCES IN THE RESPONSE TO MORPHINE ON INCORPORATION OF H3-LYSINE INTO RAT BRAIN PROTEIN

INFLUENCE OF CHRONIC PENTOBARBITAL OR MORPHINE TREATMENT ON THE INCORPORATION OF P32-PHOSPHORIC-ACID AND 3H CHOLINE INTO RAT SYNAPTIC PLASMA MEMBRANES.

000147 01-03 EFFECTS OF MORPHINE AND HALOPERIDOL ON THE ELECTRICAL ACTIVITY OF RAT NIGROSTRIATAL NEURONS.

000154 01-03 MOTILITY RESPONSE TO MORPHINE AND AMPHETAMINE DURING CHRONIC INHIBITION OF TYROSINE-HYDROXYLASE OR DOPAMINE-BETA-HYDROXYLASE

THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS OF MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE.

O00169 01-03

SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF PHYSICAL DEPENDENCE IN RATS: III. AUTORADIOGRAPHIC STUDIES.

000177 01-03 NALOXONE PRECIPITATED WITHDRAWAL AS A FUNCTION OF THE MORPHINE NALOXONE INTERVAL.

000185 01-03

PENTOBARBITAL DOES NOT INFLUENCE THE ANTINOCICEPTIVE EFFECTS OF MORPHINE IN NAIVE OR MORPHINE-TOLERANT RATS. EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON SYNAPTOSOMAL CA UPTAKE.

PROFOUND HYPOTHERMIA IN MAMMALS TREATED WITH TETRAHYDROCANNABINOLS, MORPHINE, OR CHLORPROMAZINE. 001140 02-03
POTENTIATION OF MORPHINE ANALGESIA BY LESIONS OF THE NUCLUS LOCUS-COERULEUS.

MORPHINE ANALGESIA DOSE RESPONSE CURVES IN TOLERANT RATS: MODIFICATION BY NALOXONE.

Subject Index
INHIBITORY EFFECT OF PROLACTIN OF PROE
ENDORPHIN RELEASE:
MORPHINE IN BRAIN A
BRAIN CALCIUM AND
PROSTAGLANDIN-E2, C MORPHINE ANALGES
EFFECT OF ACUTE AND UPTAKE INTO RAT H
COMPARISON OF THE I ANALGESIA AND PR IN SIX MOUSE STRA
EFFECT OF APOMORPH MORPHINE.
EFFECT OF IN-UTERO ALL SUBSEQUENT DEVELO
EFFECTS OF METHADOR SEEKING BEHAVIOR
MORPHINE ACTION IN
TOLERANCE TO MORPH ANALGESIA.
ATTENUATION OF MOR
EVIDENCE FOR INCREASEFFECTS AFTER ACUT
DIFFERENTIAL MOTOR MORPHINE AND ETG
EFFECTS OF MORPHINE RESPONDING UNDER
MORPHINE AND ETHAI ANTAGONISM BY P- CINANSENIN, OR BC
EFFECTS OF CHRONIC A AND THEIR OFFSPRII
PREPARATION OF SPIN
MIOSIS AND FLUCTUA' AND NALOXONE.
INTERACTIONS OF NAF SERUM ESTERASE. \ MORPHINE DERIVAT
BINDING OF CODEINE, PROTEINS.
HEROIN IN THE TREAT
MORPHINE SANS THE
STEREOSPECIFIC AND I
FOOTSHOCK INDUCED AND CROSS-TOLERA
MORPHINE DECREASES HYPOTHALAMIC PIT
DELAYED ONSET OF SI

WILLIAM .	
bject Index	
INHIBITORY EFFECT OF MORPHINE ON SERUM GONADOTR PROLACTIN OF PROESTROUS RATS.	OPINS AND
ENDORPHIN RELEASE: CROSS-TOLERANCE TO MORPHINE.	000206 01-03
	000229 01-03
MORPHINE IN BRAIN AND ILEUM.	000247 01-03
BRAIN CALCIUM AND MORPHINE ACTION. PROSTAGLANDIN-E2, CYCLIC-ADENOSINE-MONOPHOSPHA	000253 01-03
MORPHINE ANALGESIA.	
EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT UPTAKE INTO RAT HYPOTHALAMIC SYNAPTOSOMES.	
COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMO ANALGESIA AND PRIMARY AND PROTRACTED PHYSICA IN SIX MOUSE STRAINS.	000293 01-03 OTOR ACTIVITY, NL DEPENDENCE
	000323 01-04
EFFECT OF APOMORPHINE ON THE ANTINOCICEPTIVE ACTI MORPHINE.	VITY OF
EFFECT OF IN-UTERO ADMINISTRATION OF MORPHINE ON SUBSEQUENT DEVELOPMENT OF SELF-ADMINISTRATION	000351 01-04 THE BEHAVIOR.
EFFECTS OF METHADONE AND MORPHINE MAINTENANCE SEEKING BEHAVIOR IN THE DOG.	000368 01-04
MORPHINE ACTION IN GROUPED AND ISOLATED RATS AN	000387 01-04 D MICE.
TOLERANCE TO MORPHINE PRODUCED DISCRIMINATIVE S ANALGESIA.	000394 01-04 TIMULI AND
ATTENUATION OF MORPHINE ANALGESIA IN RATS BY INT	000414 01-04
AMYGDALOID INJECTION OF DOPAMINE.	000443 01-04
EVIDENCE FOR INCREASED APOMORPHINE SENSITIVE DOP EFFECTS AFTER ACUTE TREATMENT WITH MORPHINE.	AMINERGIC 000449 01-04
DIFFERENTIAL MOTOR EFFECTS OF INTRAVENTRICULAR IN MORPHINE AND ETONITAZENE.	FUSION OF
EFFECTS OF MORPHINE, METHADONE, NALORPHINE AND RESPONDING UNDER SCHEDULES OF ELECTRIC-SHOCK T	000450 01-04 NALOXONE ON ITRATION. 000453 01-04
MORPHINE AND ETHANOL AS DISCRIMINATIVE STIMULI: ANTAGONISM BY P-CHLOROPHENYLALANINE-METHYL-E CINANSENIN, OR BC-105.	ABSENCE OF
EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON PI AND THEIR OFFSPRING.	000473 01-04 REGNANT RATS
PREPARATION OF SPIN-LABELED OPIATES: MORPHINE AN	000491 01-05
MIOSIS AND FLUCTUATION IN THE RABBIT PUPIL: EFFECTS	000494 01-06
AND NALOXONE. INTERACTIONS OF NARCOTICS AND THEIR ANTAGONISTS SERUM ESTERASE. VI: THE BEHAVIOR OF 14 HYDROXY MORPHINE DERIVATIVES.	000504 01-06 WITH HUMAN (LATED
BINDING OF CODEINE, MORPHINE, AND METHADONE TO PROTEINS.	000690 01-13 HUMAN SERUM
	000706 01-13
HEROIN IN THE TREATMENT OF MORPHINE ADDICTION.	000959 01-17
MORPHINE SANS THE GIFT OF MORPHEUS.	000002 01.17

UPTAKE INTO RAT HYPOTHALAMIC SYNAPTOSOMES.	ON SERVICIONIA	MODIFICATION BY NALOXONE.
COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMO ANALGESIA AND PRIMARY AND PROTRACTED PHYSICA		001143 02-03 EFFECTS OF ACUTE AND CHRONIC MORPHINE AND NARCOTIC ANTAGONISTS ON BRAIN ENERGY METABOLISM.
IN SIX MOUSE STRAINS. EFFECT OF APOMORPHINE ON THE ANTINOCICEPTIVE ACTIV	000323 01-04 VITY OF	THE BEHAVIORAL EFFECTS OF DIISOPROPYL-PHOSPHOFLIORIDATE: INTERACTIONS WITH MORPHINE AND NALOXONE IN RATS.
MORPHINE. EFFECT OF IN-UTERO ADMINISTRATION OF MORPHINE ON	000351 01-04 THE	001169 02-03 RESTRAINT ALTERS THE EFFECTS OF MORPHINE AND HEROIN ON CORE TEMPERATURE IN THE RAT.
SUBSEQUENT DEVELOPMENT OF SELF-ADMINISTRATION EFFECTS OF METHADONE AND MORPHINE MAINTENANCE	000368 01-04	THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE NOREPINEPHRINE TURNOVER IN RAT BRAIN REGIONS.
SEEKING BEHAVIOR IN THE DOG. MORPHINE ACTION IN GROUPED AND ISOLATED RATS AN	000387 01-04 D MICE.	001227 02-03 CALCIUM CONTENT AND BINDING IN SYNAPTOSOMAL SUBFRACTIONS DURING CHRONIC MORPHINE TREATMENT.
TOLERANCE TO MORPHINE PRODUCED DISCRIMINATIVE ST ANALGESIA.	000394 01-04 TIMULI AND	A SEX DIFFERENCE IN THE INTERACTION BETWEEN PROMETHAZINE AND MORPHINE IN THE MOUSE.
ATTENUATION OF MORPHINE ANALGESIA IN RATS BY INT AMYGDALOID INJECTION OF DOPAMINE.		001242 02-03 THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF THE MEDULLA- OBLONGATA IS A HIGHLY SENSITIVE SITE IN THE PRODUCTION OF
EVIDENCE FOR INCREASED APOMORPHINE SENSITIVE DOP. EFFECTS AFTER ACUTE TREATMENT WITH MORPHINE.		MORPHINE ANALGESIA IN THE RAT. 001256 02-03 EFFECTS ON TEMPERATURE OF MORPHINE INJECTED INTO THE PREOPTIC/
DIFFERENTIAL MOTOR EFFECTS OF INTRAVENTRICULAR INIMORPHINE AND ETONITAZENE.		ANTERIOR HYPOTHALAMUS, MEDULLA-OBLONGATA, AND PERIPHERALLY IN UNRESTRAINED AND RESTRAINED RATS. 001264 02-03
EFFECTS OF MORPHINE, METHADONE, NALORPHINE AND RESPONDING UNDER SCHEDULES OF ELECTRIC-SHOCK TI	000450 01-04 NALOXONE ON	MORPHINE AND ENKEPHALIN: ANALGESIC AND EPILEPTIC PROPERTIES. 001267 02-03 MULTIPLE BRAIN SITES INVOLVED IN MORPHINE ANTINOCICEPTION.
MORPHINE AND ETHANOL AS DISCRIMINATIVE STIMULI: ANTAGONISM BY P-CHLOROPHENYLALANINE-METHYL-E	000453 01-04 ABSENCE OF	INTERACTIONS OF LEUCINE AND METHIONINE-ENKEPHALIN WITH MORPHINE IN VITRO AND IN VIVO.
CINANSENIN, OR BC-105. EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON PR	000473 01-04 EGNANT RATS	001272 02-03 CYCLIC-GMP AND GABA LEVELS IN RAT STRIATUM AND CEREBELLUM DURING MORPHINE WITHDRAWAL: EFFECT OF APOMORPHINE.
AND THEIR OFFSPRING. PREPARATION OF SPIN-LABELED OPIATES: MORPHINE AND	000491 01-05 CODEINE.	THE PSYCHOPHARMACOLOGY OF MORPHINE EFFECTS ON TONIC IMMOBILITY. (PH.D. DISSERTATION).
MIOSIS AND FLUCTUATION IN THE RABBIT PUPIL: EFFECTS AND NALOXONE.		001276 02-03 CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIVITY TO THE DIRECT APPLICATION OF MORPHINE AND FOCAL ELECTRICAL STIMULATION IN
INTERACTIONS OF NARCOTICS AND THEIR ANTAGONISTS SERUM ESTERASE. VI: THE BEHAVIOR OF 14 HYDROXY MORPHINE DERIVATIVES.	LATED	THE PRODUCTION OF ANTINOCICEPTION IN THE RAT. D01291 02-03 EFFECTS OF ANTIPSYCHOTIC AND ANTIANXIETY DRUGS ON THE MORPHINE ABSTINENCE SYNDROME IN RATS.
BINDING OF CODEINE, MORPHINE, AND METHADONE TO PROTEINS.		001303 02-04 NARCOTIC BLOCKADE, LENGTH OF ADDICTION, AND PERSISTENCE OF INTRAVENOUS MORPHINE SELF-ADMINISTRATION IN RATS.
HEROIN IN THE TREATMENT OF MORPHINE ADDICTION.	000706 01-13	A COMPARISON OF THE EFFECTS OF INTRAVENTRICULAR MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON OPERANT BEHAVIOR IN
MORPHINE SANS THE GIFT OF MORPHEUS. STEREOSPECIFIC AND NONSTEREOSPECIFIC EFFECTS OF ()-	000992 01-17 AND (-)	THE RAT. 001323 02-04 INHIBITION OF DRINKING BY INTRAHYPOTHALAMIC ADMINISTRATION OF
MORPHINE: EVIDENCE FOR A NEW CLASS OF RECEPTOR FOOTSHOCK INDUCED ANALGESIA IN MICE: ITS REVERSAL AND CROSS-TOLERANCE WITH MORPHINE.	001031 02-02	MORPHINE. 001325 02-04 HEAD-SHAKE DISTRIBUTIONS DURING SELF-MAINTAINED DEPENDENCE ON MORPHINE, METHADONE, AND L-ALPHA-ACETYLMETHADOL (LAAM) IN
MORPHINE DECREASES LUTEINIZING HORMONE BY AN ACH HYPOTHALAMIC PITUITARY AXIS.	001078 02-03 CTION ON THE	THE RAT. O01328 02-04 ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): PRESSING
DELAYED ONSET OF SINGLE DOSE TOLERANCE TO MORPH	001084 02-03 INE ANALGESIA.	FOR ICS BEFORE AND AFTER SELF-ADMINISTRATION OF SWEETENED MORPHINE SOLUTIONS.
ANALGESIA INDUCED BY VAGINAL STIMULATION IN RATS APPARENTLY INDEPENDENT OF A MORPHINE SENSITIVE	PROCESS.	001331 02-04 EFFECTS OF MORPHINE AND NALTREXONE ON SEXUAL BEHAVIOUR ON THE MALE RAT.
EFFECTS OF DISULFIRAM ON PHARMACOLOGICAL ACTIVITY AND FATE OF MORPHINE IN RATS.		MORPHINE AND SHUTTLE-BOX SELF-STIMULATION IN THE RAT: A MODEL FOR EUPHORIA.
INTERACTION OF AMITRIPTYLINE AND MORPHINE IN MOI TOLERANT AND NONTOLERANT RATS.		001401 02-04 DIFFERENTIAL EFFECTS OF MORPHINE AND D AMPHETAMINE ON SELF- STIMULATION FROM CLOSELY ADJACENT REGIONS IN RAT MIDBRAIN.
POTENTIATION OF MORPHINE ANALGESIA IN MICE AFTER BRAIN TYPE-B MONOAMINE-OXIDASE.	001115 02-03 INHIBITION OF	A POSSIBLE ROLE OF THE PAG IN THE MEDIATION OF SUBJECTIVE EFFECTS OF MORPHINE.
The state of the s	001126 02-03	001444 02-04

THE EFFECTS OF HORMONES AND MORPHINE ON BOTH ANALGESIA AND THE LORDOSIS RESPONSE PRODUCED BY CERVICAL PROBING IN THE FEMALE RAT

DISCRETE-TRIAL CONTROL OF COCAINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF MORPHINE, NALOXONE, AND

001469 02-04
DISCRETE-TRIAL CONTROL OF MORPHINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF NALOXONE, MORPHINE, AND

SIMULTANEOUS DETERMINATION OF CODEINE AND MORPHINE IN
BIOLOGICAL SAMPLES BY GAS-CHROMATOGRAPHY WITH ELECTRON

001527 02-06 NEFOPAM (N), MORPHINE (M), AND D AMPHETAMINE (A) IN MAN: SUBJECTIVE, BEHAVIORAL, AND PHYSIOLOGIC EFFECTS.

001550 02-07

EFFECT OF ALPHA-METHYLTYROSINE (MT) PRETREATMENT ON D

AMPHETAMINE (A) AND MORPHINE (M) INDUCED MOOD IN MAN.

MORPHINE AND ITS BIPHASIC INFLUENCE UPON PHARMACOLOGICALLY DISTINCT DOPAMINERGIC SYSTEMS WITHIN THE FELINE CAUDATE NUCLEUS: A BEHAVIOURAL STUDY

001954 03-02 NEUROCHEMICAL MECHANISMS OF CENTRAL ACTION OF MORPHINE ON FUNCTIONS OF SINGLE NEURONS IN THE MIDBRAIN RETICULAR

001973 03-03 SUPPRESSION OF CAUDATE NEURON ACTIVITIES BY MORPHINE AND THE INVOLVEMENT OF DOPAMINERGIC NEUROTRANSMISSION.

001985 03.03 EFFECTS OF MEDIAL RAPHE AND RAPHE MAGNUS LESIONS ON THE ANALGESIC ACTIVITY OF MORPHINE AND METHADONE

001986 03-03

DIHYDROXYPHENYLACETIC-ACID IN FASTED RATS

002001 03-03 EFFECTS OF MORPHINE ON ELECTRICAL ACTIVITY OF SINGLE MYENTERIC NEURONS IN CAT SMALL BOWEL.

002009 03-03 EFFECT OF MATERNAL MORPHINE ADMINISTRATION ON FETAL AND NEONATAL RAT LIVER TYROSINE-AMINOTRANSFERASE

002011 03-03 EFFECT OF MORPHINE ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE **ACTIVITY OR NUCLEUS-ACCUMBENS**

002048 03-03 SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION.

002052 03-03
3.5 CYCLIC-GUANOSINE-MONOPHOSPHATE LEVELS IN RAT CEREBELLUM: EFFECTS OF MORPHINE, KETAMINE, HARMALINE AND ISONIAZID 002056 03-03

MORPHINE REDUCES CEREBELLAR CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT AND ELEVATES CEREBROSPINAL FLUID CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT IN RHESUS MONKEY.

TIME-DEPENDENT DISRUPTIVE EFFECTS OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE ON DEVELOPMENT OF MORPHINE TOLERANCE. 002058 03-03 THE FFFFCT OF CLOSAIPRAMINE AND OTHER AMINE UPTAKE INHIBITORS

ON MORPHINE ANALGESIA IN LABORATORY ANIMALS. 002072 03-03 EFFECTS OF MORPHINE ON AXONAL TRANSPORT IN NIGROSTRIATAL

002093 03-03
INFLUENCE OF IMMUNE STIMULATION AND SUPPRESSION ON MORPHINE

PHYSICAL DEPENDENCE AND TOLERANCE. 002095 03-03 TRYPTOPHAN AND 5 HYDROXYINDOLES IN DIFFERENT CNS REGIONS

FOLLOWING ACUTE MORPHINE. 002097 03-03

NALOXONE REVERSAL OF MORPHINE ANALGESIA BUT FAILURE TO ALTER REACTIVITY TO PAIN IN THE FORMALIN TEST.

DELIMITATION OF NEURONAL SUBSTRATES NECESSARY FOR THE ANALGESIC ACTION OF BACLOFEN AND MORPHINE. 002132 03-03

ACETYLCHOLINE ANTIRELEASE EFFECT OF MORPHINE AND ITS MODIFICATION BY CALCIUM.

MORPHINE INCREASES AND D AMPHETAMINE DECREASES THE RATIO OF DOPAC: HVA IN PUSH-PULL PERFUSATE OF RAT CAUDATE NUCLEUS 002158 03-03 EFFECT OF AGE ON ACUTE MORPHINE RESPONSE IN THE RAT

002159 03-03 INCREASED ANTAGONIST POTENCY OF NALOXONE CAUSED BY MORPHINE PRETREATMENT IN MICE.

ALTERATIONS IN MORPHINE ANALGESIA PRODUCED BY CHRONIC DEFICITS OF BRAIN CATECHOLAMINES OR SEROTONIN: ROLE OF ANALGESIMETRIC PROCEDURE

002186 03-03 TIME-COURSE OF THE EFFECTS OF NATURALLY OCCURRING CANNABINOIDS ON MORPHINE ABSTINENCE SYNDROME

EFFECTS OF MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON SCHEDULE-CONTROLLED RESPONDING IN THE RAT.

GENOTYPE AND TEST EXPERIENCE DETERMINE RESPONSIVENESS TO

NARCOTIC CUEING PROPERTIES OF INTRAVENTRICULARLY ADMINISTERED SUFENTANIL, FENTANYL, MORPHINE AND MET-ENKEPHALIN. 002217 03-04

CONTINUOUS INTRAVENOUS NALTREXONE EFFECTS ON MORPHINE SELF-ADMINISTRATION IN RHESUS MONKEYS

002241 03-04 MORPHINE AND SELF-STIMULATION: EVIDENCE FOR ACTION ON A COMMON NEURAL SUBSTRATE.

002277 03-04 INTERACTION BETWEEN MORPHINE AND REINFORCING LATERAL HYPOTHALAMIC STIMULATION.

002291 03-04 PRENATAL MORPHINE ADMINISTRATION ALTERS BEHAVIORAL DEVELOPMENT IN THE RAT.

002308 03-04 ADULT BEHAVIOR AND ADRENOCORTICAL FUNCTION FOLLOWING NEONATAL MORPHINE TREATMENT IN RATS.

002310 03-04 ENHANCED ANALGESIC EFFECTS OF MORPHINE AFTER CHRONIC ADMINISTRATION OF NALOXONE IN THE RAT.

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE, SELF-STIMULATION, AND PARAMETERS OF

002320 03-04 THE EFFECTS OF ETORPHINE, FENTANYL AND MORPHINE ON NORADRENALINE AND DOPAMINE CONCENTRATIONS IN THE STRIATUM

A DOSE RATIO COMPARISON OF THE INTERACTION BETWEEN MORPHINE
AND CYCLAZOCINE WITH NALOXONE IN RHESUS MONKEYS ON THE SHOCK TITRATION TASK

002335 03-04 TOLERANCE TO HIGH DOSES OF MORPHINE: LACK OF EVIDENCE OF **LEARNING**

A COMPARISON OF THE ANALGESIC EFFECT OF INTRAMUSCULAR
NALBUPHINE AND MORPHINE IN PATIENTS WITH POSTOPERATIVE

EFFECT OF MECAMYLAMINE ON THE FATE OF DOPAMINE IN STRIATAL AND MESOLIMBIC AREAS OF RAT BRAIN; INTERACTION WITH MORPHINE AND HALOPERIDOL.

O02806 04-03

EFFECT OF MORPHINE INJECTED IN PERIAQUEDUCTAL GRAY ON THE
ACTIVITY OF SINGLE UNITS IN NUCLEUS RAPHE MAGNUS OF THE RAT.
O02817 04-03

A COMPARISON OF SOME PHARMACOLOGICAL ACTIONS OF MORPHINE

AND DELTA9-TETRAHYDROCANNABINOL IN THE MOUSE.

EFFECTS OF MORPHINE ON BRAINSTEM NEURONES IN NAIVE AND FECTS OF MORPHINE ON BRAINSTEM NEURONES IN 1997.
CHRONIC MORPHINE TREATED RATS, AND EFFECTS OF PCPA.
002841 04-03

PHARMACOLOGICAL AND ELECTROPHYSIOLOGICAL STUDIES OF MORPHINE AND ENKEPHALIN ON RAT SUPRASPINAL NEURONES AND CAT SPINAL NEURONES.

INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA:
EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION.

002890 04-03 EPILEPTIC PROPERTIES OF LEUCINE-ENKEPHALIN AND METHIONIN ENKEPHALIN: COMPARISON WITH MORPHINE AND REVERSIBILITY BY

ANTAGONISM OF MORPHINE ACTION ON BRAIN ACETYLCHOLINE RELEASE BY METHYLXANTHINES AND CALCIUM.

EFFECT OF ACUTE MORPHINE ADMINISTRATION ON THE CEREBELLAR CYCLIC-GMP LEVEL IN TWO STRAINS OF MICE

STUDIES ON THE EFFECT OF LESIONS OF THE VENTRAL NORADRENERGIC TRACT ON THE ANTINOCICEPTIVE ACTION OF MORPHINE.

MORPHINE-INDUCED ALTERATIONS OF GAMMA -AMINOBUTYRIC-ACID ORPHINE-INDUCED ALIERATIONS OF GAMMA-AMINOBUTYRIC-A
AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE
ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE
CORRELATES WITH ANALGESIC ACTION OF MORPHINE. 002984 04-03

002183 03-03

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL TOLERANCE AND CROSS-TOLERANCE TO MORPHINE AND METHADONE IN THE RAT. 003010 04-03

CHANGES IN BRAIN TRYPTOPHAN AND TYROSINE FOLLOWING ACUTE AND CHRONIC MORPHINE ADMINISTRATION.

003012 04-03

EFFECTS OF PAIN ATTENUATING BRAIN STIMULATION AND MORPHINE ON
ELECTRICAL ACTIVITY IN THE RAPHE NUCLEI OF THE AWAKE RAT.

EFFECT OF MORPHINE ON THE BASAL AND THE DOPAMINE-INDUCED RELEASE OF LHRH FROM MEDIOBASAL HYPOTHALAMIC FRAGMENTS IN VITRO.

MORPHINE AND MET-ENKEPHALIN EFFECTS ON SURAL-ADELTA AFFERENT TERMINAL EXCITABILITY.

003076 04-03 EFFECT OF ACUTE MORPHINE ADMINISTRATION ON REGIONAL ACETYLCHOLINE TURNOVER IN THE RAT.

INFLUENCE OF NEUROLEPTICS ON THE BINDING OF MET-ENCEPHALIN, MORPHINE AND DIHYDROMORPHINE TO SYNAPTOSOME ENRICHED FRACTIONS OF RAT BRAIN.

003096 04-03
RADIOIMMUNOASSAY OF ENKEPHALINS: REGIONAL DISTRIBUTION IN
RAT BRAIN AFTER MORPHINE TREATMENT AND HYPOPHYSECTOMY.

EFFECTS OF MORPHINE ON ISOENZYMES OF PYRUVATE KINASE AND TYROSINE-AMINOTRANSFERASE IN RAT.

IN VIVO COMPARISON OF THE RECEPTOR POPULATIONS ACTED UPON IN THE SPINAL CORD BY MORPHINE AND PENTAPEPTIDES IN THE PRODUCTION OF ANALGESIA.

003143 04-03 THE EFFECT OF HOUSING AND GENDER ON MORPHINE SELF-ADMINISTRATION IN RATS.

MOTILITY EFFECTS OF METHAMPHETAMINE IN RATS CHRONICALLY TREATED WITH MORPHINE.

003162 04-04 THE EFFECTS OF DIVALENT IONS ON MORPHINE ANALGESIA AND
ABSTINENCE SYNDROME IN MORPHINE-TOLERANT AND MORPHINEDEPENDENT MICE.

THE EFFECTS OF NALTREXONE ON THE DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE.

CONDITIONING FACTORS INFLUENCE TOLERANCE DEVELOPMENT TO LOW BUT NOT HIGH DOSES OF MORPHINE.

003198 04-04 ANALGESIA AND MOTOR ACTIVITY ELICITED BY MORPHINE AND ENKEPHALINS IN TWO INBRED STRAINS OF MICE.

CHANGES IN MORPHINE SELF-ADMINISTRATION AFTER TEL-DIENCEPHALIC LESIONS IN RATS.

003228 04-04 MORPHINE AS A DISCRIMINATIVE CUE IN GERBILS: DRUG GENERALIZATION AND ANTAGONISM.

003249 04-04 A COMPARISON OF DISCRIMINATIVE STIMULI PRODUCED BY NALOXONE, CYCLAZOCINE AND MORPHINE IN THE RAT.

POTENTIATION OF HEXOBARBITAL AND AMPHETAMINE EFFECTS IN MALE AND FEMALE RATS PHYSICALLY DEPENDENT ON MORPHINE.

003275 04-04
EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE DETECTION OF

THE BEHAVIORAL EFFECTS OF D AMPHETAMINE AND CHLORPROMAZINE IN RATS; COMBINATIONS WITH ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE. (PH.D. DISSERTATION).

THE EFFECT OF MORPHINE ON FEAR EXTINCTION IN RATS

003305 04-04 MEASURED IN TOLERANCE TO MORPHINE ANALGESIA AND IMMOBILITY RATS BY CHANGES IN LOG-DOSE-RESPONSE CURVES.

003307 04-04 MORPHINE AND SHOCK DETECTION: EFFECTS ON SHOCK INTENSITY

CHANGES IN LOCOMOTOR ACTIVITY AND NALOXONE-INDUCED JUMPING IN MICE PRODUCED BY WIN-35197-2 (ETHYLKETAZOCINE) AND MORPHINE.

003376 04-04 INHIBITION OR WET SHAKES DURING MORPHINE ABSTINENCE BY AN ANTAGONIST OF OPIATE ANALGESIA.

003383 04-04 THE DISCRIMINABILITY OF NALOXONE IN RATS DEPENDS ON CONCOMITANT MORPHINE TREATMENT.

003393 04-04 EFFECTS OF NALOXONE ON SCHEDULE-CONTROLLED BEHAVIOR IN MORPHINE MAINTAINED PIGEONS. 003401 04-04 A RELIABLE, FACIAL NOCICEPTION DEVICE FOR UNRESTRAINED, AWAKE ANIMALS: EFFECTS OF MORPHINE AND TRIGEMINAL COMPLEX LESIONS.

THE EFFECTS OF INTRAGASTRIC MORPHINE SELF-ADMINISTRATION IN THE RAT. (PH.D. DISSERTATION). 003437 04-06

MORPHINE-DEPENDENCE
DOPAMINE ANTAGONIST BINDING: A SIGNIFICANT DECREASE WITH
MORPHINE-DEPENDENCE IN THE RAT STRIATUM.

003052 04-03 MORPHINE-DEPENDENT
ENHANCED AFFINITY OF OPIATE RECEPTORS FOR NALOXONE IN STRIATAL
SLICES OF MORPHINE-DEPENDENT MICE.

001165 02-03

001165 02-03 CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT

RHESUS MONKEYS 001296 02-04 THE EFFECT OF ETHANOL ON SUPPRESSION OF THE NALOXONE PRECIPITATED ESCAPE RESPONSE IN MORPHINE-DEPENDENT MICE

002230 03-04 DOPAMINE-INDUCED HYPOTHERMIA IN MORPHINE-DEPENDENT RATS 002988 04-03

CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT RHESUS MONKEYS. 003152 04-04

THE EFFECTS OF DIVALENT IONS ON MORPHINE ANALGESIA AND
ABSTINENCE SYNDROME IN MORPHINE-TOLERANT AND MORPHINEDEPENDENT MICE.

003169 04-04 MORPHINE-INDUCED
CHOLINERGIC INHIBITION OF MORPHINE-INDUCED HYPOTHERMIA NALTREXONE BLOCKADE OF MORPHINE-INDUCED ANTIDIURESIS IN THE

001162 02-03 EFFECTS OF NEUROLEPTICS ON MORPHINE-INDUCED TAIL ERECTION IN

001400 02-04 THE STRUCTURE OF BEHAVIOR OF RATS DURING MORPHINE-INDUCED HYPERACTIVITY.

001426 02-04

THE EFFECTS OF OXOTREMORINE AND PHYSOSTIGMINE ON MORPHINE-INDUCED CIRCLING IN THE MOUSE. 001457 02-04

MORPHINE-INDUCED TAIL ERECTION: SITE OF ACTION.

002269 03-04 LESIONS OF THE DORSAL NORADRENERGIC PROJECTION ATTENUATE MORPHINE-INDUCED BUT NOT AMPHETAMINE-INDUCED CONDITIONED TASTE AVERSION.

002299 03-04 EFFECT OF NALOXONE ON MORPHINE-INDUCED CHANGES IN ACTH, CORTICOSTERONE AND CYCLIC-NUCLEOTIDES.

002949 04-03 MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE CORRELATES WITH ANALGESIC ACTION OF MORPHINE.

MORPHINE-LIKE FACTOR IN MAMMALIAN BRAIN: ANALGESIC ACTIVITY IN RATS. 0002:

1000220 01-03

INVESTIGATIONS OF THE ANALGESIC AND MORPHINE-LIKE PROPERTIES OF AZIDOMORPHINE.

002984 04-03

000379 01-04 MORPHINE-LIKE PEPTIDES OF BRAIN AND THEIR RELATION TO HORMONAL NEUROTRANSMITTERS.

001650 02-13 PITUITARY HORMONE RELEASE IN VITRO BY MORPHINE-LIKE PEPTIDES 001975 03-03

MORPHINE-SULFATE
EFFECTS OF MORPHINE-SULFATE ON RENAL TRANSPORT PROCESSES

001055 02-03 THE DEVELOPMENTAL EFFECTS OF MORPHINE-SULFATE AND NALOXONE-HYDROCHLORIDE IN THE RAT. 001510 02-05

MORPHINE-SULPHATE
ELEVATION OF AVERSIVE THRESHOLD IN RATS BY INTRA-AMYGDALOID
INJECTION OF MORPHINE-SULPHATE.

HYPOTHERMIA EVOKED BY THE INTRACEREBRAL INJECTION OF MORPHINE-SULPHATE IN THE RAT: THE EFFECT OF RESTRAINT

002090 03-03 HYPERTHERAIC RESPONSES TO CENTRAL AND PERIPHERAL INJECTIONS OF MORPHINE-SULPHATE IN THE CAT.

002864 04-03 MORPHINE-TOLERANCE
BRAIN SEROTONIN TURNOVER AND MORPHINE-TOLERANCE DEPENDENCE
INDUCED BY MULTIPLE INJECTIONS IN THE RAT. 000055 01-03

VOLUME 16, SUBJECT INDEX

SEXUAL DIFFERENTIATION OF OFFSPRING OF MOTHERS TREATED WITH

Subject Index

INVOLVEMENT OF BRAIN CYCLIC-AMP IN MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE. (PH.D. DISSERTATION). THE EFFECT OF MORPHINE-TOLERANCE AND DEPENDENCE ON CELL FREE PROTEIN SYNTHESIS

002876 04-03

THE ROLE OF PAVLOVIAN CONDITIONING IN MORPHINE-TOLERANCE.
003090 04-03 THE PRODUCTION OF MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE BY THE ORAL ROUTE IN THE RAT.

003424 04-06

MORPHINE-TOLERANT
INTERACTION OF AMITRIPTYLINE AND MORPHINE IN MORPHINE-TOLERANT AND NONTOLERANT RATS.

001115 02-03 PENTOBARBITAL DOES NOT INFLUENCE THE ANTINOCICEPTIVE EFFECTS OF MORPHINE IN NAIVE OR MORPHINE-TOLERANT RATS.

NALOXONE PRECIPITATED WITHDRAWAL REVEALS SENSITIZATION TO NEUROTRANSMITTERS IN MORPHINE-TOLERANT/DEPENDENT RATS

EFFECTS OF MET-ENKEPHALIN ON BODY TEMPERATURE OF NORMAL AND MORPHINE-TOLERANT RATS.

THE EFFECTS OF DIVALENT IONS ON MORPHINE ANALGESIA AND ABSTINENCE SYNDROME IN MORPHINE-TOLERANT AND MORPHINE-DEPENDENT MICE

003169 04-04

MORPHINES
ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): NALOXONE BLOCKS MORPHINES ACCELERATION OR PRESSING FOR IC 001313 02-04

CATECHOLAMINE SENSITIVE ATPASE ACTIVITIES IN BRAIN SYNAPTOSOMES OF MORPHINIZED MICE.

COMPARATIVE EFFECTS OF APOMORPHINE AND NALOXONE IN ACUTELY

DEFENDENT MORPHINIZED RATS AND MICE. 003379 04-04 MORPHINOMIMETIC

CENTRAL CARDIOVASCULAR EFFECTS OF MORPHINOMIMETIC PEPTIDES IN DOGS. 001399 02-04

MORPHOLOGICAL DIRECT EFFECTS OF ETHANOL ON CENTRAL-NERVOUS-SYSTEM CULTURES: AN ELECTROPHYSIOLOGICAL AND MORPHOLOGICAL STUDY 000261 01-03

BIOCHEMICAL AND MORPHOLOGICAL EFFECTS OF TESTOSTERONE TREATMENT ON DEVELOPING SYMPATHETIC NEURONS 002894 04-03

PSYCHOTROPIC DRUGS IN PREGNANCY: MORPHOLOGICAL AND PSYCHOLOGICAL ADVERSE EFFECTS ON OFFSPRING. 003708 04-17

EFFECT OF CANNABINOIDS ON NEUROTRANSMITTER UPTAKE, ATPASE ACTIVITY AND MORPHOLOGY OF MOUSE BRAIN SYNAPTOSOMES.

000143 01-03 EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH MORPHOLOGY AND HORMONE PLASMA LEVELS.

000315 01-04 **GONADAL MORPHOLOGY IN SCHIZOPHRENIC PATIENTS UNDER** PSYCHOTROPIC TREATMENT.

001832 02-15 CENTRAL AND PERIPHERAL ACTION OF TESTOSTERONE-PROPIONATE ON SCENT GLAND MORPHOLOGY AND MARKING BEHAVIOUR IN THE

MONGOLIAN GERBIL 003370 04-04 MORTALITY

THE EFFECT OF L-DOPA AND LERGOTRILE-MESYLATE ON THE INTERACTION OF FLUPHENAZINE-DECANOATE AND AMPHETAMINE-INDUCED STEREOTYPY AND MORTALITY.

000401 01-04 MORTALITY OF PATIENTS WITH TARDIVE-DYSKINESIA DYSKINESIA

002688 03-15 LEVODOPA IN PARKINSON DISEASE: A LONG-TERM APPRAISAL OF MORTALITY

002755 03-17 THE EFFECTS OF DAILY COCAINE ADMINISTRATION ON COCAINE-INDUCED MORTALITY. 003421 04-05

MOTHERS OPEN-FIELD BEHAVIOR AND GROSS MOTOR DEVELOPMENT IN OFFSPRING

OF NURSING RAT MOTHERS GIVEN PENFLURIDOL 000307 01-04 LIMB REDUCTION ANOMALIES IN INFANTS BORN TO DISULFIRAM

TREATED ALCOHOLIC MOTHERS INVESTIGATIONS OF CHILDREN OF MOTHERS TREATED IN PREGNANCY WITH ANTICONVULSANTS.

001817 02-15 002701 03-15 CORTISONE DURING PREGNANCY. 002879 04-03

MOTILITY MOTILITY RESPONSE TO MORPHINE AND AMPHETAMINE DURING CHRONIC INHIBITION OF TYROSINE-HYDROXYLASE OR DOPAMINE-

000166 01-03

MUSCIMOL A GABA-AGONIST INJECTED INTO THE NUCLEUS-ACCUMBENS
INCREASES APOMORPHINE STEREOTYPY AND DECREASES THE MOTILITY.

001454 02-04 MOTILITY EFFECTS OF METHAMPHETAMINE IN RATS CHRONICALLY TREATED WITH MORPHINE.

003162 04-04 DIFFERENTIAL EFFECTS OF KETAMINE ON SCHEDULE-CONTROLLED RESPONDING AND MOTILITY.

003295 04-04 MOTIVATED EFFECT OF SCOPOLAMINE ON RETENTION OF A SHOCK MOTIVATED BRIGHTNESS DISCRIMINATION IN RATS.

PSYCHOPHARMACOLOGY OF AVERSIVELY MOTIVATED BEHAVIOR. 003615 04-14 001487 02-04

MOTIVATION LEVELS AND THE MARIHUANA HIGH.

002633 03-14

CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE FOR AN INTERACTIONIST POSITION

000620 01-11 MOTONEURON EXCITABILITY IN PSYCHIATRIC PATIENTS.

000754 01-14 DIFFERENTIAL ANTAGONISM BY CHLORPROMAZINE AND DIAZEPAM OF FROG MOTONEURONE DEPOLARIZATION INDUCED BY GLUTAMATE

RELATED AMINO-ACIDS 001116 02-03 MOTOR

DO BENZODIAZEPINES AFFECT MOTOR OR SENSORY MECHANISMS? 000250 01-03 OPEN-FIELD BEHAVIOR AND GROSS MOTOR DEVELOPMENT IN OFFSPRING OF NURSING RAT MOTHERS GIVEN PENFLURIDOL.

000307 01-04 RAISED BRAIN GABA LEVELS, MOTOR ACTIVITY AND EXPLORATION IN THE RAT.

000358 01-04 NEOSTRIATAL ADMINISTRATION OF SOMATOSTATIN: DIFFERENTIAL EFFECT OF SMALL AND LARGE DOSES ON BEHAVIOR AND MOTOR CONTROL

000437 01-04 DIFFERENTIAL MOTOR EFFECTS OF INTRAVENTRICULAR INFUSION OF MORPHINE AND ETONITAZENE.

000450 01-04 ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: INTERACTIVE EFFECTS ON HUMAN PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS. II. ACUTE EFFECTS OF CANNABIS ON COGNITIVE, PERCEPTUAL, AND MOTOR PERFORMANCE IN CHRONIC HASHISH USERS.

000759 01-14
EFFECTS OF OPIATES AND OPIOID PEPTIDES ON MOTOR BEHAVIORS:

SITES AND MECHANISMS OF ACTION. (UNPUBLISHED PAPER) 001433 02-04 CIRCADIAN VARIATION IN AN AMPHETAMINE-INDUCED MOTOR

RESPONSE. 001479 02-04 THE STUDY OF SEQUENCES OF MOTOR BEHAVIOR.

001537 02-06 RAPID TOLERANCE TO THE MOTOR EFFECTS OF P-CHLOROAMPHETAMINE IN RATS.

002226 03-04 EFFECT OF MATERNALLY ADMINISTERED HEROIN ON THE MOTOR ACTIVITY OF RAT OFFSPRING.

002349 03-05 CAN PHENYTOIN BE GRADUALLY WITHDRAWN IN PATIENTS WITH MAJOR MOTOR EPILEPSY MAINTAINED ON CLONAZEPAM AND PHENOBARBITAL?

002504 03-11 CHRONIC NEUROLEPTIC USE AND PERIPHERAL MOTOR NEURON DAMAGE 002671 03-15

EFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY THE RESPONSES OF THE MUSCLE SPINDLE OF THE TRICEPS SURAE MUSCLE OF THE DECEREBRATE CAT TO THE MUSCLE STRETCH. 003109 04-03

THE NEUROLOGICAL BASIS OF MOTOR ASYMMETRY FOLLOWING UNILATERAL NIGROSTRIATAL LESIONS IN THE RAT: THE EFFECT OF SECONDARY SUPERIOR COLLICULUS LESIONS. 003200 04-04

ANALGESIA AND MOTOR ACTIVITY ELICITED BY MORPHINE AND ENKEPHALINS IN TWO INBRED STRAINS OF MICE.

003225 04-04 DIURNAL VARIATIONS IN THE MOTOR ACTIVITY OF THE RAT: EFFECTS OF INHIBITORS OF THE CATECHOLAMINE SYNTHESIS.

003274 04-04 P-CHLOROPHENYLALANINE PRODUCES DISSOCIATED EFFECTS ON AGGRESSION EMOTIONALITY AND MOTOR ACTIVITY.

003293 04-04 HEMISPHERIC ASYMMETRY OF VISUAL EVOKED-POTENTIALS WITH MOTOR IMBALANCE IN RATS.

MOTOR ACTIVITY OF RATS FOLLOWING INTRACEREBRAL INJECTIONS OF DRUGS INFLUENCING GABA MECHANISMS.

MOUNTING
FACILITATION OF MOUNTING BEHAVIOR BY DIHYDROTESTOSTERONEPROPIONATE IN CASTRATED ESTRADIOL-BENZOATE TREATED MALE
RATS FOLLOWING PUDENDECTOMY.

000403 0

EFFECTS OF BENSERAZIDE ON TRYPTOPHAN METABOLISM IN THE MOUSE. 000054 01-03

ASTOMA MUSCARINIC REGULATION OF C-AMP IN MOUSE NEUROB 000058 01-03 KINETICS OF CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN MOUSE BRAIN SYNAPTOSOMES.

000093 01-03

INCREASE IN MOUSE BRAIN DOPAMINE CONTENT BY BACLOFEN: EFFECTS OF APOMORPHINE AND NEUROLEPTICS.

000121 01-03 EFFECT OF CANNABINOIDS ON NEUROTRANSMITTER UPTAKE, ATPASE ACTIVITY AND MORPHOLOGY OF MOUSE BRAIN SYNAPTOSOMES.

000143 01-03 THE DEMONSTRATION IN VIVO OF SPECIFIC BINDING SITES FOR NEUROLEPTIC DRUGS IN MOUSE BRAIN.

000150 01-03 EFFECT OF CONVULSANT AND ANTICONVULSANT AGENTS ON LEVEL AND METABOLISM OF GAMMA-AMINOBUTYRIC-ACID IN MOUSE BRAIN. 000186 01-03

ACETYLCHOLINE AND CHOLINE IN MOUSE BRAIN -- INFLUENCE OF PERIPHERALLY ACTING CHOLINERGIC DRUGS.

000187 01-03 INFLUENCE OF INJECTED PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE BRAIN AND LUNG FOLLOWING MICROWAVE IRRADIATION. 000214 01-03

ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE NEUROBLASTOMA CELLS.

000241 01-03 NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN SLICES OF MOUSE LIMBIC FOREBRAIN: CHARACTERISATION AND EFFECT OF DOPAMINERGIC AGONISTS.

000256 01-03 THE EFFECT OF PH ON STEREOSPECIFIC OPIATE BINDING TO MOUSE BRAIN MEMBRANES.

000271 01-03 A DOPAMINERGIC BASIS FOR THE EFFECTS OF AMPHETAMINE ON A MOUSE PREADOLESCENT HYPERKINETIC MODEL.

BEHAVIORAL EFFECTS OF APOMORPHINE AND DIISOBUTYRYLAPOMORPHINE IN THE MOUSE.

000314 01-04 COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMOTOR ACTIVITY, ANALGESIA AND PRIMARY AND PROTRACTED PHYSICAL DEPENDENCE IN SIX MOUSE STRAINS.

000323 01-04 SOME OBSERVATIONS ON THE MECHANISM OF BENZODIAZEPINE BARBITURATE INTERACTIONS IN THE MOUSE.

000335 01-04 EFFECTS OF EXPOSURE TO LEAD ON SOCIAL BEHAVIOUR IN THE LABORATORY MOUSE.

000344 01-04 SOME EFFECTS OF NALOXONE ON BEHAVIOR IN THE MOUSE

000371 01-04 PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, BRAIN SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION INTO BRAIN PROTEINS OF DIFFERENT MOUSE STRAINS.

000384 01-04 SYNTHESIS OF BRADYKININ FRAGMENTS AND THEIR EFFECT ON PENTOBARBITAL SLEEPING TIME IN MOUSE.

000424 01-04 AMPHETAMINE-LIKE EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE ON SOCIAL BEHAVIOUR IN THE MOUSE.

MODIFICATION OF THE TIME-COURSE OF DMPEA TOXICITY IN THE MOUSE BY CENTRALLY ACTING DRUGS. 001039 02-02

Psychopharmacology Abstracts

A PHARMACOLOGICAL STUDY OF THE SPONTANEOUS CONVULSIVE ACTIVITY INDUCED BY 1,2 DIHYDROXYBENZENE (CATECHOL) IN THE ANESTHETIZED MOUSE.

001046 02-03 IN VIVO BINDING OF H3-PIMOZIDE IN MOUSE STRIATUM: EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS.

001050 02-03 EFFECT OF ATROPINE ON ACETYLCHOLINE METABOLISM IN THE MOUSE

001157 02-03 THE EFFECT OF DFP AND PENTOBARBITAL ON THE TURNOVER OF ACETYLCHOLINE IN THE MOUSE BRAIN.

001170 02-03 DISTRIBUTION AND METABOLISM OF 4 HYDROXYPHENOBARBITAL IN THE MOUSE.

001171 02-03 LONG-TERM CHANGES IN THE SENSITIVITY OF PRE- AND POSTSYNAPTIC DOPAMINE RECEPTORS IN MOUSE STRIATUM EVIDENCED BY BEHAVIORAL AND BIOCHEMICAL STUDIES.

001187 02-03 THE EFFECT OF NICOTINE ON THE ACETYLCHOLINE CONTENT IN MOUSE

SUBSTITUTED AMPHETAMINE DERIVATIVES. I. EFFECT ON UPTAKE AND RELEASE OF BIOGENIC MONOAMINES AND ON MONOAMINE-OXIDASE IN THE MOUSE BRAIN.

001233 02-03 A SEX DIFFERENCE IN THE INTERACTION BETWEEN PROMETHAZINE AND MORPHINE IN THE MOUSE.

001242 02-03 ALKALI-METAL CATIONS: EFFECTS ON ISOLATION-INDUCED AGGRESSION IN THE MOUSE.

001348 02-04 THE EFFECTS OF D AMPHETAMINE ON PREY KILLING AND PREY EATING IN THE RAT AND MOUSE.

001361 02-04 THE EFFECTS OF OXOTREMORINE AND PHYSOSTIGMINE ON MORPHINE-INDUCED CIRCLING IN THE MOUSE.

001457 02-04 MULTIPLE CLASSES OF OPIATE RECEPTORS IN C57BL/6J AND DBA/2J MOUSE BRAIN.

001991 03-03 CANNABINOIDS INHIBIT TESTOSTERONE SECRETION BY MOUSE TESTES IN

ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002004 03-03 OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG

002040 03-03 CANNABINOID EFFECTS ON PLASMA CORTICOSTERONE AND UPTAKE OF H3-CORTICOSTERONE BY MOUSE BRAIN.

002051 03-03 POSSIBLE CENTRAL DOPAMINERGIC MODULATION OF THE RISE IN PLASMA CONCENTRATION OF NONESTERIFIED FATTY-ACIDS PRODUCED IN THE MOUSE BY (-)TRANS DELTA9-TETRAHYDROCANNABINOL.

002085 03-03 EFFECT OF FLUDIAZEPAM ON TURNOVER OF SEROTONIN IN MOUSE

002111 03-03 ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002137 03-03 A LITHIUM-CARBONATE-INDUCED INCREASE IN THE MOUSE BRAIN 5
HYDROXYTRYPTAMINE METABOLISM.

002153 03-03 COMPARISON OF THE EFFECTS OF 5 HYDROXYTRYPTAMINE, DIMETHYLTRYPTAMINE, AND 5 METHOXY-DIMETHYLTRYPTAMINE ON RECTAL TEMPERATURE IN THE MOUSE.

002154 03-03 CHANGES IN MOUSE BRAIN CATECHOLAMINE CONTENT AND TYROSINE-HYDROXYLASE ACTIVITY DURING CHRONIC AMPHETAMINE ADMINISTRATION.

002175 03-03 EFFECT OF ENKEPHALIN AND ENDORPHIN ANALOGS ON RECEPTORS IN THE MOUSE VAS-DEFERENS

A COMPARISON OF SOME PHARMACOLOGICAL ACTIONS OF MORPHINE AND DELTA9-TETRAHYDROCANNABINOL IN THE MOUSE.

002834 04-03 EFFECTS OF SODIUM THIOPENTAL ON THE TRICARBOXYLIC-ACID CYCLE METABOLISM IN MOUSE BRAIN: CO2 FIXATION AND METABOLIC COMPARTMENTATION.

002860 04-03

000310 01-04

PHARMACOLOGIC RESPONSES OF CELLS OF A NEUROBLASTOMA-X GLIOMA HYBRID CLONE AND MODULATION OF SYNAPSES BETWEEN HYBRID CELLS AND MOUSE MYOTUBES.

002863 04-03 MODIFICATION OF ADENYLATE-CYCLASE SYSTEMS IN MOUSE CEREBRAL-CORTEX BY CHLORPROMAZINE AND RESPECTIVE 7 HDROXY ANALOGS

O02875 04-03
INDUCTION OF SULFOGALACTOSYLCERAMIDE (SULFATIDE) SYNTHESIS BY
HYDROCORTISONE (CORTISOL) IN MOUSE G-26 OLIGODENDROGLIOMA CELL STRAINS

002886 04-03 MOUSE BRAIN TYROSINE-HYDROXYLASE AND GLUTAMIC-ACID DECARBOXYLASE FOLLOWING TREATMENT WITH ADRENOCORTICOTROPHIC HORMONE, VASOPRESSIN OF CORTICOSTERONE

002898 04-03 DEMONSTRATION OF NEUROLEPTIC RECEPTOR SITES IN MOUSE BRAIN BY AUTORADIOGRAPHY

002950 04-03 STUDIES ON THE MECHANISM OF SPROUTING OF NORADRENERGIC TERMINALS IN RAT AND MOUSE CEREBELLUM AFTER NEONATAL 6 HYDROXYDOPA.

002980 04-03
SUBCELLULAR LOCALIZATION OF C14-METHAQUALONE IN MOUSE BRAIN: EFFECTS OF HEPATIC MICROSOMAL ENZYME INHIBITION.

002983 04-03 EFFECTS OF LITHIUM ON THE MEMBRANE-BOUND MAGNESIUM DEPENDENT ATPASE OF MOUSE NEUROBLASTOMA CELLS.

003087 04-03 ADRENERGIC ALPHA-RECEPTORS AND BETA-RECEPTORS EXPRESSED BY
THE SAME CELL TYPE IN PRIMARY CULTURE OF PERINATAL MOUSE

003121 04-03 CONCOMITANT ELEVATION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY CYCLIC-AMP IN CULTURED MOUSE NEUROBLASTOMA CELLS

003133 04-03 NEUROPHARMACOLOGICAL AND BEHAVIORAL EVALUATION OF PROSTAGLANDIN-E2 AND 11 THIOL-11-DESOXYPROSTAGLANDIN-E2 IN THE MOUSE AND RAT.

003173 04-04 ATTENUATION OF AMNESIA BY HYDROCORTISONE IN THE MOUSE 003313 04-04 EMERGING CHOLINERGIC MECHANISMS AND ONTOGENY OF RESPONSE

INHIBITION IN THE MOUSE. 003336 04-04

ACTH EFFECTS ON RESPONSE SUPPRESSION AND PLASMA CORTICOSTERONE IN THE MOUSE.

PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC AND CATECHOLAMINERGIC MECHANISMS BY 6 HYDROXYDOPAMINE AND 5,6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D. DISSERTATION).

EVIDENCE AGAINST CHRONIC DEPOLARIZATION AS A MECHANISM OF KAINIC-ACID TOXICITY IN MOUSE CEREBELLAR CULTURES. 003418 04-05

MOUSE-KILLING CARBACHOL ELICITED MOUSE-KILLING IN THE RAT: ANIMALS ATTACKED AND WOUND LOCATION

000349 01-04

A TREATMENT FOR DRY MOUTH IN PSYCHIATRIC PATIENTS 002661 03-15 MOVEMENT

MOVEMENT DISORDERS INDUCED IN MONKEYS BY CHRONIC HALOPERIDOL TREATMENT.

000490 01-05 URINARY MONOAMINE METABOLITE EXCRETION IN DISORDERS OF MOVEMENT

000710 01-13 CANNABIS, CATECHOLAMINES, RAPID EYE MOVEMENT SLEEP AND AGGRESSIVE BEHAVIOUR.

001320 02-04 LITHIUM THERAPY OF EXTRAPYRAMIDAL MOVEMENT DISORDERS. 001774 02-15 COMPUTER SIMULATION OF THE MOVEMENT OF LITHIUM ACROSS

ERYTHROCYTE MEMBRANES IN VITRO 001869 02-16 DEANOL IN THE MANAGEMENT OF INVOLUNTARY MOVEMENT

DISORDERS: A REVIEW PHARMACOLOGICAL INVESTIGATIONS OF THE CHOLINERGIC IMBALANCE

HYPOTHESES OF MOVEMENT DISORDERS AND PSYCHOSIS 002509 03-11

EYE MOVEMENT, AN INDICATOR OF BRAIN FUNCTION. 002637 03-14 TREATMENT OF DYSKINETIC AND CHOREATIC MOVEMENT DISORDERS IN ADULTS.

MOVEMENT INDUCED IN CATALEPTIC RATS: DIFFERENTIAL EFFECTS
PRODUCED BY ELECTRICAL STIMULATION OF THE LATERAL
HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FORMATION.
03297 04-04

ACTIVITY OF VESTIBULO-OCULOMOTOR NEURONES DURING SACCADIC EYE MOVEMENTS INDUCED BY RESERPINE

000199 01-03
INVESTIGATIONS INTO THE NATURE OF THE PERIORAL MOVEMENTS INDUCED BY DIPROPYLAMINO-DIHYDROXYTETRALIN.

001334 02-04 DISCRIMINATIVE PENTOBARBITAL EFFECT MEASURED BY HEAD MOVEMENTS IN RESTRAINED RATS

A NEW MECHANISM OF TRICYCLIC ANTIDEPRESSANT ACTION. BLOCKADE OF PROSTAGLANDIN DEPENDENT CALCIUM MOVEMENTS.

INHIBITION OF CA45 MOVEMENTS BY LOWERED TEMPERATURE OR LANTHANUM IN RAT BRAIN SLICES. 003135 04-03

PRENATAL EXPOSURE TO MEDROXYPROGESTERONE-ACETATE (MPA) IN GIRLS

002615 03-14

EFFECTS OF MSH/ACTH4-10 ON MEMORY, ATTENTION, AND ENDOGENOUS HORMONE LEVELS IN WOMEN. 002641 03-14

COMPARISON OF THE EFFECTS OF PIPOTHIAZINE-PALMITATE AND FLUPHENAZINE-DECANDATE IN A MULTICENTER DOUBLE-BLIND TRIAL 002412 03-08

MULTICENTRE TEMAZEPAM (EUHYPNOS) AS A HYPNOTIC: A MULTICENTRE TRIAL IN GENERAL PRACTICE.

MAPROTILINE (LUDIOMIL) IN DEPRESSION: A MULTICENTRE ASSESSMENT OF ONSET OF ACTION, EFFICACY AND TOLERABILITY.

002432 03-09 A LARGE OPEN MULTICENTRE TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE MANAGEMENT OF PHOBIC DISORDERS.

002475 03-10 MAPROTILINE AND DOXEPIN IN THE TREATMENT OF DEPRESSION: A DOUBLE-BLIND MULTICENTRE COMPARISON. 002495 03-10

MULTICENTRIC METHODOLOGICAL EXPERIENCE WITH A DOUBLE-BLIND MULTICENTRIC, MONITORED CLINICAL TRIAL (MMCT) WITH SINTAMIL.

STANDARD AND LONG-ACTING DEPOT NEUROLEPTICS IN CHRONIC SCHIZOPHRENICS: AN 18-MONTH OPEN MULTICENTRIC STUDY. 003471 04-08

MULTICLINIC PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND ANXIETY IN ANXIOUS OUTPATIENTS.

000762 01-14 NEUROTRANSMITTER PRECURSOR AMINO-ACIDS IN THE TREATMENT OF MULTIINFARCT DEMENTIA AND ALZHEIMERS DISEASE

000647 01-11

EVIDENCE FOR MULTIPHASIC PRESYNAPTIC ADAPTATION: STUDIES WITH COCAINE AND LITHIUM. 000191 01-03 MULTIPLE

BRAIN SEROTONIN TURNOVER AND MORPHINE-TOLERANCE DEPENDENCE INDUCED BY MULTIPLE INJECTIONS IN THE RAT. 000055 01-03

MONOAMINE-OXIDASE: EXAMINATION OF MULTIPLE FORMS

MULTIPLE ORAL DOSES OF DIAZEPAM, OXAZEPAM AND PHENOBARBITAL TO DOGS — BEHAVIOURAL EFFECTS AND CORRELATION WITH ANTIPYRINE HALF-LIFE.

LONG-TERM BEHAVIORAL CHANGES IN THE RHESUS MONKEY AFTER MULTIPLE DAILY INJECTIONS OF D METHYLAMPHETAMINE. 000359 01-04 MULTIPLE DRUG THERAPY -- IS THERE A STANDARD OF CARE?

EFFECTS OF BENZODIAZEPINES ON PGO FIRINGS AND MULTIPLE UNIT ACTIVITY IN THE MIDBRAIN RETICULAR FORMATION IN CATS. MULTIPLE BRAIN SITES INVOLVED IN MORPHINE ANTINOCICEPTION.

001270 02-03

EFFECTS OF D AMPHETAMINE ON A MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE OF FOOD REINFORCEMENT IN THE CAT. 001374 02-04

FACTORS INFLUENCING BLOOD CONCENTRATIONS OF CHLORDIAZEPOXIDE: A USE OF MULTIPLE REGRESSION ANALYSIS. 001663 02-13

002776 03-17

DRUG INTERACTIONS AND MULTIPLE DRUG ADMINISTRATION 001913 02-17 MULTIPLE CLASSES OF OPIATE RECEPTORS IN C57BL/6J AND DBA/2J MOUSE BRAIN.

RAT BRAIN ARYLACYLAMIDASE: MULTIPLE FORMS AND INHIBITION EFFECTS OF LSD, SEROTONIN AND RELATED COMPOUNDS.

002044 03-03

EFFECTS OF SALSOLINOL, A TETRAHYDROISOQUINOLINE ALKALOID, ON MULTIPLE SCHEDULE PERFORMANCE IN RATS.

EFFECTS OF SINGLE AND MULTIPLE DOSES OF DESIPRAMINE (DMI) ON ENDOGENOUS LEVELS OF 3 METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE (MOPEG-SO4) IN RAT BRAIN.

MULTIPLE MEMBRANE ACTIONS OF ENKEPHALIN REVEALED USING CULTURED SPINAL NEURONS.

002816 04-03 PHENYLETHYLAMINE — DEAMINATION BY MULTIPLE TYPES OF MONOAMINE-DXIDASE.

002893 04-03

HETEROGENEITY OF LSD DISPLACING FACTORS AND MULTIPLE TYPES OF
HIGH AFFINITY LSD BINDING SITES.

H3-SPIROPERIDOL BINDING AND DOPAMINE STIMULATED ADENYLATE-CYCLASE: EVIDENCE FOR MULTIPLE CLASSES OF RECEPTORS IN PRIMATE BRAIN REGIONS.

003112 04-03 EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ, ANGIOTENSIN-II, AND SUBSTANCE-P ON MULTIPLE FIXED-INTERVAL FIXED-RATIO RESPONDING IN RABBITS.

PENTOBARBITAL, PROMAZINE, D AMPHETAMINE, AND SCOPOLAMINE EFFECTS ON BEHAVIOR UNDER MULTIPLE AND PRIMED SCHEDULES OF REINFORCEMENT.

003267 04-04 THE EFFECTS OF D AMPHETAMINE AND SCOPOLAMINE ON DRINKING INDUCED BY A MULTIPLE SCHEDULE.

003350 04-04 LONG-ACTING ORAL VS INJECTABLE ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENICS: A ONE-YEAR DOUBLE-BLIND COMPARISON IN MULTIPLE EPISODE SCHIZOPHRENICS.

003467 04-08 DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION 003241 04-0

003241 04-04 MULTIVARIATE
BI AND MULTIVARIATE ANALYSIS OF EEG DATA IN CLINICAL
PSYCHOPHARMACOLOGY.

002743 03-17 MULTIVARIATE ANALYSIS OF DRUG EFFECTS ON ELECTROPHYSIOLOGICAL

003688 04-16

ANTICHOLINERGIC DELIRIUM IN A CASE OF MUNCHAUSEN SYNDROME. 003658 04-15

5 HYDROXYTRYPTAMINE DEPLETION WITH P-CHLOROPHENYLALANINE: EFFECTS ON EATING, DRINKING, IRRITABILITY, MURICIDE, AND COPULATION.

000429 01-04 WEIGHT. 5,7 DIHYDROXYTRYPTAMINE LESIONS: EFFECTS ON BODY IRRITABILITY, AND MURICIDE.

000430 01-04 MURICIDE INDUCED BY SINGLE INJECTION OF DELTA9-TETRAHYDROCANNABINOL.

003226 04-04 CHLORIMIPRAMINE INHIBITION OF MURICIDE: THE ROLE OF THE ASCENDING 5-HT PROJECTION.

EFFECTS OF CANNABINOIDS ON L1210 MURINE LEUKEMIA: 1. INHIBITION OF DNA SYNTHESIS.

001266 02-03 TASK-DEPENDENT GENETIC INFLUENCES ON BEHAVIORAL RESPONSE OF MICE (MUS-MUSCULUS) TO ACETALDEHYDE.

003211 04-04

MUSCASE IN THE TURNOVER OF BRAIN DOPAMINE BY STIMULATION OF MUSCARINIC RECEPTORS OUTSIDE THE DOPAMINE NERVE TERMINALS 000042 01-03

ROLE OF PHOSPHOLIPIDS IN MUSCARINIC BINDING BY NEURAL MEMBRANES. 000044 01-03

MUSCARINIC REGULATION OF C-AMP IN MOUSE NEUROBLASTOMA.

000058 01-03
INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC
AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS

Psychopharmacology Abstracts

RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT.

000124 01-03

CONTROL OF THE RELEASE OF NEWLY SYNTHESIZED H3-5-HYDROXYTRYPTAMINE BY NICOTINIC AND MUSCARINIC RECEPTORS IN RAT HYPOTHALAMIC SLICES.

000144 01-03 ACETYLCHOLINE STIMULATION OF THE SYMPATHETIC GANGLIA: EFFECTS OF TAURINE AND NICOTINIC AND MUSCARINIC GANGLION BLOCK. 000146 01-03

ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE NEUROBLASTOMA CELLS.

POSTSYNAPTIC POTENTIATION OF THE SLOW MUSCARINIC EXCITATORY RESPONSE BY TETRAETHYLAMMONIUM-CHLORIDE IN THE BULLFROG SYMPATHETIC GANGLION CELLS.

001173 02-03 BLOCKADE BY PSYCHOTROPIC DRUGS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR IN CULTURED NERVE CELLS.

ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002004 03-03 THE EFFECT OF PANCURONIUM AND GALLAMINE ON MUSCARINIC TRANSMISSION IN THE SUPERIOR CERVICAL GANGLION.

002021 03-03 ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

MUSCARINIC RECEPTOR MEDIATED CYCLIC-GMP FORMATION BY CULTURED NERVE CELLS -- IONIC DEPENDENCE AND EFFECTS OF LOCAL ANESTHETICS

003064 04-03 THE ACETYLCHOLINE RECEPTOR IN THE RAT HIPPOCAMPUS; NICOTINIC, MUSCARINIC OR BOTH?.

003082 04-03 INTERACTION OF PHENCYCLIDINES WITH THE MUSCARINIC AND OPIATE RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM.

003128 04-03 MUSCARINIC HYPOSENSITIVITY IN THE DEVELOPING RAT PRETREATED

WITH 6 HYDROXYDOPA. 003320 04-04

MUSCIMOL STIMULATION OF FOOD INTAKE BY MUSCIMOL AND BETA-ENDORPHIN 000023 01-02

SOME EFFECTS OF MUSCIMOL IN MICE, RATS AND CATS. 000173 01-03 EFFECTS OF SYSTEMIC MUSCIMOL AND GABA IN THE SPINAL CORD AND SUPERIOR CERVICAL GANGLION OF THE CAT.

GABA-LIKE PROPERTIES OF FLURAZEPAM AND BACLOFEN SUGGESTED BY ROTATIONAL BEHAVIOUR FOLLOWING UNILATERAL INTRANIGRAL INJECTION: A COMPARISON WITH THE GABA-AGONIST MUSCIMOL.

000290 01-03 EFFECTS OF BACLOFEN AND MUSCIMOL ON NIGROSTRIATAL DOPAMINERGIC FUNCTIONS.

000347 01-04 MUSCIMOL A GABA-AGONIST INJECTED INTO THE NUCLEUS-ACCUMBENS INCREASES APOMORPHINE STEREOTYPY AND DECREASES THE MOTILITY.

001454 02-04 STRUCTURE-ACTIVITY STUDIES ON THE INHIBITION OF GABA BINDING TO RAT BRAIN MEMBRANES BY MUSCIMOL AND RELATED COMPOUNDS. 002981 04-03

MUSCIMOL: GABA-AGONIST THERAPY IN SCHIZOPHRENIA 003475 04-08

MUSCLE COLCHICINE BLOCKS NEUROTROPIC REGULATION OF THE RESTING MEMBRANE POTENTIAL IN REINNERVATING SKELETAL MUSCLE 000262 01-03

THE LACK OF AN EFFECT OF DELTA9-THC ON PULMONARY SMOOTH MUSCLE FUNCTION IN THE GUINEA-PIG. 001041 02-03

ACTIONS OF ATROPINE AND SCOPOLAMINE ON THE ENDPLATE CURRENT OF THE FROG SARTORIUS MUSCLE. (PH.D. DISSERTATION). 001042 02-03

EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. I. CHLORPROMAZINE AND PROMETHAZINE.

EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS.

001103 02-03 RELAXATION OF SMOOTH MUSCLE FOLLOWING CONTRACTION ELICITED BY SYMPATHETIC NERVE STIMULATION IN VIVO.

001106 02-03

003284 04-04

002960 04-03

ACTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND ITS DERIVATIVES ON 5 HYDROXYTRYPTAMINE RECEPTORS IN THE ISOLATED UTERINE SMOOTH MUSCLE OF THE RAT.

DEVELOPMENT OF DENERVATION ALTERATIONS IN SURFACE MEMBRANES OF MAMMALIAN SKELETAL MUSCLE.

DIAZEPAM BLOCKADE OF REPETITIVE ACTION POTENTIALS IN SKELETAL MUSCLE FIBRES: A MODEL OF ITS MEMBRANE ACTION.

EFFECTS OF AMPHETAMINE ON ENDURANCE PERFORMANCE AND MUSCLE

SYNTHESIS AND COMPARATIVE SKELETAL MUSCLE RELAXANT ACTIVITY OF SOME 2,4 IMIDAZOLIDINEDIONES AND THEIR CORRESPONDING 5 HYDROXYIMIDAZOLIDINEDIONES.

001944 03-01 EFFECTS OF CARBAMAZEPINE ON MUSCLE SPINDLE DISCHARGES. 002037 03-03

SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION.

EFFECTS OF FLURAZEPAM ON AMINO-ACID EVOKED RESPONSES
RECORDED FROM THE LOBSTER MUSCLE AND THE FROG SPINAL CORD.
002115 03-03

STUDIES ON THE INHIBITION OF PHOSPHODIESTERASE CATALYZED CYCLIC-AMP AND CYCLIC-GMP BREAKDOWN AND RELAXATION OF CANINE TRACHEAL SMOOTH MUSCLE.

002129 03-03 A METHOD FOR MECHANOGRAPHICAL RECORDING OF MUSCLE TONE IN THE RAT: THE EFFECT OF SOME ANTIPARKINSONIAN DRUGS ON RIGIDITY INDUCED BY RESERPINE.

002346 03-05 NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION OF THE SYMPATHETIC NERVE OF THE EYE.

002802 04-03 EFFECTS OF PROSTAGLANDIN-E2 AND A PROSTAGLANDIN ENDOPEROXIDE ANALOGUE ON NEUROEFFECTOR TRANSMISSION IN THE RAT ANOCOCCYGEUS MUSCLE.

002808 04-03 EFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY THE RESPONSES OF THE MUSCLE SPINDLE OF THE TRICEPS SURAE MUSCLE OF THE DECEREBRATE CAT TO THE MUSCLE STRETCH.

003109 04-03 MUSCLES **ELECTRICAL STIMULATION OF DENERVATED MUSCLES REDUCES** INCORPORATION OF METHIONINE INTO THE ACH RECEPTOR

000136 01-03 EFFECT OF PSYCHOTROPIC DRUGS ON ATPASE TRANSPORT OF THE SARCOPLASMIC RETICULUM IN RABBIT SKELETAL MUSCLES 001174 02-03

AMANITA MUSHROOM POISONING WITH RECOVERY FROM COMA: A

CASE REPORT. 002705 03-15

MUSICIANS EFFECT OF OXPRENOLOL ON STAGE-FRIGHT IN MUSICIANS. 001718 02-14

MUSTARD EFFECTS OF PROPYLBENZILYLCHOLINE MUSTARD ON INJECTION INTO THE LIQUOR SPACE OF CATS. 003168 04-04

THE STUDY OF THE MUTAGENIC ACTIVITY OF LUMINAL AND PYRAZIDAL 002353 03-05

EFFECT OF NEUROLEPTICS, MYDANTHAN, AND DOPA ON APOMORPHINE-INDUCED STEREOTYPY IN RATS. 001155 02-03

EFFECTS OF MORPHINE ON ELECTRICAL ACTIVITY OF SINGLE MYENTERIC NEURONS IN CAT SMALL BOWEL.

002009 03-03 SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION. 002052 03-03

OPIATE WITHDRAWAL SIGNS IN SINGLE MYENTERIC NEURONES 002118 03-03

MYOCARDIAL THE EFFECTS OF BEHAVIORALLY RELEVANT DOSES OF CHLORPROMAZINE AND MOLINDONE ON CARDIAC ADENYLATE-CYCLASE AND ON MYOCARDIAL CONTRACTILITY.

QUANTITATIVE DETERMINATION OF STRESS-INDUCED MYOCARDIAL DAMAGE IN RATS. 001536 02-06 MYOCARDIAL PHARMACOKINETICS OF LITHIUM IN VITRO.

003414 04-05 MYOCARDIAL EFFECTS OF LITHIUM IN VITRO. 003415 04-05

MYOCLONIC CLONAZEPAM AND 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONIC STEREOTYPY

001281 02-03 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS IN GUINEA-PIGS: A MODEL FOR THE STUDY OF CENTRAL SEROTONIN DOPAMINE

003386 04-04 PATHY
ACUTE HYPOKALEMIC MYOPATHY IN ALCOHOLISM: A CLINICAL ENTITY.
000888 01-15

MYOTONIN POSSIBLE PROPRANOLOL MYOTONIN ASSOCIATION. 000889 01-15

MYOTUBES PHARMACOLOGIC RESPONSES OF CELLS OF A NEUROBLASTOMA-X
GLIOMA HYBRID CLONE AND MODULATION OF SYNAPSES BETWEEN HYBRID CELLS AND MOUSE MYOTUBES.

002863 04-03 EFFECTS OF MYSOLINE AND DILANTIN ON THE EEG DURING SMR BIOFEEDBACK TRAINING OF A PSYCHOMOTOR EPILEPTIC: SINGLE CASE STUDY.

001657 02-13 **MYTHS** MYTHS, THEORIES AND TREATMENT OF SCHIZOPHRENIA.

000520 01-08

EFFECTS OF NA, K, MG AND CA ON THE SATURABLE BINDING OF (3H)DIHYDROMORPHINE AND (3H)NALOXONE IN VITRO. 000180 01-03 THE EFFECT OF AMIZYL AND ARECOLINE ON THE ACTIVITY OF NA-K-ATPASE AND THE CONTENT OF NA AND K IN RAT BRAIN.

PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF NA CHANNELS IN THE RELEASE OF CATECHOLAMINES FROM PERFUSED ADRENAL

NA-K-ATPASE KINETICS OF CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN MOUSE BRAIN SYNAPTOSOMES

000093 01-03 ANTAGONISM OF BIOGENIC AMINE-INDUCED DEPRESSION OF CEREBRAL CORTICAL NEURONES BY NA-K-ATPASE INHIBITORS.

THE EFFECT OF AMIZYL AND ARECOLINE ON THE ACTIVITY OF NA-K-ATPASE AND THE CONTENT OF NA AND K IN RAT BRAIN. 002151 03-03

EFFECTS OF ETHANOL WITHDRAWAL, STRESS AND AMPHETAMINE ON RAT BRAIN NA-K-ATPASE. 003060 04-03

NABILONE HYPOTHERMIA IN RATS PRODUCED BY NABILONE, A SYNTHETIC CANNABINOID 000213 01-03 PHYSIOLOGIC DISPOSITION OF NABILONE, A CANNABINOL DERIVATIVE,

ANTIEMETIC ACTIVITY OF NABILONE, A CANNABINOL DERIVATIVE REVERSED BY NALOXONE IN AWAKE CATS. 001416 02-04

SOLID DISPERSION APPROACH FOR OVERCOMING BIOAVAILABILITY PROBLEMS DUE TO POLYMORPHISM OF NABILONE, A CANNABINOID

A MODEL FOR EVALUATION OF ANTIANXIETY DRUGS WITH THE USE OF EXPERIMENTALLY-INDUCED STRESS: COMPARISON OF NABILONE AND DIAZEPAM

NABILONE, A CANNABINOID, IN THE TREATMENT OF ANXIETY: AN OPEN-LABEL AND DOUBLE-BLIND STUDY. 203538 04-10

NACL AND LICL EFFICACY IN THE INDUCTION OF AVERSION FOR QUININE AND SACCHARIN SOLUTIONS IMMEDIATELY FOLLOWING INJECTION. 000396 01-04

VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF 2
AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF NAD:NADH AND
NORELEAGNINE A BETA-CARBOLINE DERIVATIVE. 000200 01-03

NADH VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF 2
AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF NAD:NADH AND
NORELEAGNINE A BETA-CARBOLINE DERIVATIVE. 000200 01-03

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6 TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

002930 04-03 PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH. 002932 04-03

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — III. THE INFLUENCE OF THE 1, 4, 5, 6 TETRAHYDRONICOTIONAMIDE ANALOGUE OF NADH ON THE NADPH KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — I. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS. 002931 04-03

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM -- II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH. 002932 04-03

EFFECTS OF NALOXONE FOLLOWING A SINGLE ADMINISTRATION OF LEVORPHANOL-TARTRATE IN THE NAIVE RAT.

001110 02-03 PENTOBARBITAL DOES NOT INFLUENCE THE ANTINOCICEPTIVE EFFECTS OF MORPHINE IN NAIVE OR MORPHINE-TOLERANT RATS.

001132 02-03 THE ANTAGONISTIC EFFECTS OF 5 ETHYL-5-HYDROXY-1-METHYLBUTYLBARBITURIC-ACID ON PENTOBARBITAL NARCOSIS IN BOTH NAIVE AND TOLERANT MICE.

002336 03-04 EFFECTS OF MORPHINE ON BRAINSTEM NEURONES IN NAIVE AND CHRONIC MORPHINE TREATED RATS, AND EFFECTS OF PCPA.

SCHEDULE-INDUCED SELF-INJECTION OF NICOTINE, METHADONE AND HEROIN BY NAIVE ANIMALS.

003321 04-04

A COMPARISON OF THE ANALGESIC EFFECT OF INTRAMUSCULAR NALBUPHINE AND MORPHINE IN PATIENTS WITH POSTOPERATIVE

002607 03-14 NALORPHINE FIRST-PASS EFFECT OF NALORPHINE IN RATS.

000153 01-03 AN INVESTIGATION OF NALORPHINE AND PERPHENAZINE AS NEGATIVE REINFORCERS IN AN ESCAPE PARADIGM.

000389 01-04 EFFECTS OF MORPHINE, METHADONE, NALORPHINE AND NALOXONE ON RESPONDING UNDER SCHEDULES OF ELECTRIC-SHOCK TITRATION.

000453 01-04

FIRST-PASS EFFECT OF NALORPHINE IN RATS 001166 02-03 PENTAZOCINE, CYCLAZOCINE, AND NALORPHINE AS DISCRIMINATIVE

001378 02-04

EVALUATION OF NALOXONE IN LABORATORY TESTS PREDICTIVE OF CUNICAL ANTIPSYCHOTIC ACTIVITY.

000029 01-02 EFFECTS OF NA, K, MG AND CA ON THE SATURABLE BINDING OF (3H)DIHYDROMORPHINE AND (3H)NALOXONE IN VITRO.

000180 01-03 NALOXONE PRECIPITATED WITHDRAWAL AS A FUNCTION OF THE MORPHINE NALOXONE INTERVAL.

000185 01-03 THE POTENTIATING EFFECT OF NALOXONE UPON APOMORPHINE-INDUCED HYPERTHERMIA.

000231 01-03 SOME EFFECTS OF NALOXONE ON BEHAVIOR IN THE MOUSE

000371 01-04 FAILURE OF NALOXONE TO PREVENT REDUCTION OF AMNESIA BY ENKEPHALINS

000438 01-04 EFFECTS OF MORPHINE, METHADONE, NALORPHINE AND NALOXONE ON RESPONDING UNDER SCHEDULES OF ELECTRIC-SHOCK TITRATION.

MIOSIS AND FLUCTUATION IN THE RABBIT PUPIL: EFFECTS OF MORPHINE AND NALOXONE.

000504 01-06 **NEGATIVE NALOXONE EFFECTS IN SCHIZOPHRENIC PATIENTS** 000532 01-08 LACK OF EFFECT OF NALOXONE ON SCHIZOPHRENIC SYMPTOMS

000533 01-08 NALOXONE IN CHRONIC SCHIZOPHRENIA 000552 01-08

Psychopharmacology Abstracts

EFFECTS OF NALOXONE ON PETHIDINE-INDUCED NEONATAL DEPRESSION: PART I -- INTRAVENOUS NALOXONE.

000668 01-11 EFFECTS OF NALOXONE ON PETHIDINE-INDUCED NEONATAL DEPRESSION: PART II - INTRAMUSCULAR NALOXONE.

000669 01-11 **FAILURE OF NALOXONE TO AFFECT HUMAN SLEEP**

000756 01-14 STEREOCHEMICAL STUDIES ON MEDICINAL AGENTS. 23. SYNTHESIS AND BIOLOGICAL EVALUATION OF 6 AMINO DERIVATIVES OF NALOXONE AND NALTREXONE.

001004 02-01 FOOTSHOCK INDUCED ANALGESIA IN MICE: ITS REVERSAL BY NALOXONE AND CROSS-TOLERANCE WITH MORPHINE.

001078 02-03 THE EFFECT OF NALOXONE ON THE EXCITATION OF DORSAL-HORN NEURONES OF THE CAT BY NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULI.

001102 02-03 EFFECTS OF NALOXONE FOLLOWING A SINGLE ADMINISTRATION OF LEVORPHANOL-TARTRATE IN THE NAIVE RAT.

001110 02-03 INTERACTION BETWEEN NARCOTIC ANTAGONIST (NALOXONE) AND LYSERGIC-ACID-DIETHYLAMIDE (LSD) IN THE RAT.

001120 02-03 HYPERALGESIA INDUCED BY NALOXONE FOLLOWS DIURNAL RHYTHM IN RESPONSIVITY TO PAINFUL STIMULI.

001124 02-03 MORPHINE ANALGESIA DOSE RESPONSE CURVES IN TOLERANT RATS: MODIFICATION BY NALOXONE.

001143 02-03 SPECIFIC RELEASE BY NALOXONE OF H3-MORPHINE FROM SUPERFUSED SLICES OF CORPUS-STRIATUM OF MICE.

001164 02-03 ENHANCED AFFINITY OF OPIATE RECEPTORS FOR NALOXONE IN STRIATAL SLICES OF MORPHINE-DEPENDENT MICE.

001165 02-03 THE BEHAVIORAL EFFECTS OF DIISOPROPYL-PHOSPHOFLUORIDATE: INTERACTIONS WITH MORPHINE AND NALOXONE IN RATS.

001169 02-03 BRAIN NEUROTRANSMITTER RECEPTORS AFTER LONG-TERM
HALOPERIDOL: DOPAMINE, ACETYLCHOLINE, SEROTONIN, ALPHANORADRENERGIC AND NALOXONE RECEPTORS.

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): NALOXONE BLOCKS MORPHINES ACCELERATION OR PRESSING FOR ICS.

001313 02-04 DIFFERENTIAL EFFECT OF NALOXONE ON FIXED-RATIO OPERANT BEHAVIOR IN STRESSED AND NONSTRESSED RATS.

001330 02-04 NALOXONE INTERACTION WITH NEUROLEPTIC-INDUCED SUPPRESSION OF NARCOTIC WITHDRAWAL.

ANTIEMETIC ACTIVITY OF NABILONE, A CANNABINOL DERIVATIVE, REVERSED BY NALOXONE IN AWAKE CATS.

NALOXONE PRECIPITATED WITHDRAWAL REVEALS SENSITIZATION TO NEUROTRANSMITTERS IN MORPHINE-TOLERANT/DEPENDENT RATS. 001456 02-04

DISCRETE-TRIAL CONTROL OF COCAINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF MORPHINE, NALOXONE, AND CHLORPROMAZINE.

DISCRETE-TRIAL CONTROL OF MORPHINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF NALOXONE, MORPHINE, AND CHLORPROMAZINE.

001470 02-04 INTRAVENOUS NALOXONE ADMINISTRATION IN SCHIZOPHRENIA AND AFFECTIVE-ILLNESS.

001560 02-08 NALOXONE (NARCAN) TREATMENT IN DEPRESSION: CLINICAL OBSERVATIONS AND EFFECTS ON CSF ENDORPHINS AND MONOAMINE

NALOXONE AS A GABA-ANTAGONIST: EVIDENCE FROM IONTOPHORETIC, RECEPTOR BINDING AND CONVULSANT STUDIES.

NALOXONE REVERSAL OF MORPHINE ANALGESIA BUT FAILURE TO ALTER REACTIVITY TO PAIN IN THE FORMALIN TEST.

002117 03-03 INCREASED ANTAGONIST POTENCY OF NALOXONE CAUSED BY MORPHINE PRETREATMENT IN MICE.

002183 03-03 THE EFFECT OF ETHANOL ON SUPPRESSION OF THE NALOXONE PRECIPITATED ESCAPE RESPONSE IN MORPHINE-DEPENDENT MICE

002230 03-04 EFFECTS OF ETHANOL: ALTERATION BY INORGANIC IONS AND

002242 03-04

ENHANCED ANALGESIC EFFECTS OF MORPHINE AFTER CHRONIC ADMINISTRATION OF NALOXONE IN THE RAT

002319 03-04

A DOSE RATIO COMPARISON OF THE INTERACTION BETWEEN MORPHINE AND CYCLAZOCINE WITH NALOXONE IN RHESUS MONKEYS ON THE SHOCK TITRATION TASK

002335 03-04

ENDORPHINS: NALOXONE FAILS TO ALTER EXPERIMENTAL PAIN OR MOOD IN HUMANS

002383 03-07

STIMULATION OF DOPAMINE SYNTHESIS IN CAUDATE NUCLEUS BY INTRASTRIATAL ENKEPHALINS AND ANTAGONISM BY NALOXONE 002825 04-03 EPILEPTIC PROPERTIES OF LEUCINE-ENKEPHALIN AND METHION

ENKEPHALIN: COMPARISON WITH MORPHINE AND REVERSIBILITY BY NALOXONE.

002916 04-03 EFFECT OF NALOXONE ON MORPHINE-INDUCED CHANGES IN ACTH, CORTICOSTERONE AND CYCLIC-NUCLEOTIDES.

002949 04-03 CHRONIC NALOXONE RESULTS IN PROLONGED INCREASES IN OPIATE BINDING SITES IN BRAIN.

002986 04-03 THE ROLE OF THE CHOLINERGIC SYSTEM IN THE DEVELOPMENT OF INCREASED NALOXONE POTENCY IN MICE.

003140 04-03 ANTAGONISM OF NALOXONE HYPERALGESIA BY ETHANOL

003165 04-04 A COMPARISON OF DISCRIMINATIVE STIMULI PRODUCED BY NALOXONE,

CYCLAZOCINE AND MORPHINE IN THE RAT. 003270 04-04 COMPARATIVE EFFECTS OF APOMORPHINE AND NALOXONE IN ACUTELY

DEFENDENT MORPHINIZED RATS AND MICE. 003379 04-04 THE DISCRIMINABILITY OF NALOXONE IN RATS DEPENDS ON

CONCOMITANT MORPHINE TREATMENT. 003393 04-04 EFFECTS OF NALOXONE ON SCHEDULE-CONTROLLED BEHAVIOR IN

MORPHINE MAINTAINED PIGEONS. 003401 04-04

EFFECTS OF NALOXONE ON SCHIZOPHRENIA: REDUCTION IN HALLUCINATIONS IN A SUBPOPULATION OF SUBJECTS

003639 04-14 NALOXONE-HYDROCHLORIDE

THE DEVELOPMENTAL EFFECTS OF MORPHINE-SULFATE AND NALOXONE-HYDROCHLORIDE IN THE RAT.

001510 02-05 NALOXONE-INDUCED NALOXONE-INDUCED OR POSTWITHDRAWAL ABSTINENCE SIGNS IN

DELTA9-TETRAHYDROCANNABINOL-TOLERANT RATS. 002257 03-04 CHANGES IN LOCOMOTOR ACTIVITY AND NALOXONE-INDUCED JUMPING

IN MICE PRODUCED BY WIN-35197-2 (ETHYLKETAZOCINE) AND MORPHINE 003376 04-04

STIMULUS EFFECTS OF DELTA9-THC AND ITS INTERACTION WITH NALTREXONE AND CATECHOLAMINE BLOCKERS IN RATS.

NALTREXONE AND CYCLAZOCINE: A CONTROLLED TREATMENT STUDY

000804 01-15 STEREOCHEMICAL STUDIES ON MEDICINAL AGENTS. SYNTHESIS AND BIOLOGICAL EVALUATION OF 6 AMINO DERIVATIVES OF NALOXONE AND NALTREXONE

001004 02-01 NALTREXONE BLOCKADE OF MORPHINE-INDUCED ANTIDIURESIS IN THE RAT

001162 02-03 PLASMA KINETICS OF NALTREXONE AND ITS GLUCURONIDE IN THE DOG 001183 02-03

DIFFERENTIATION BETWEEN OPIOID PEPTIDES BY NALTREXONE 001230 02-03 THE PHARMACOLOGICAL EFFECTS OF FETAL AND NEONATAL EXPOSURE

TO NALTREXONE IN THE RAT. 001373 02-04

EFFECTS OF MORPHINE AND NALTREXONE ON SEXUAL BEHAVIOUR ON THE MALE RAT 001377 02-04

CONTINUOUS INTRAVENOUS NALTREXONE EFFECTS ON MORPHINE SELF-ADMINISTRATION IN RHESUS MONKEYS. 002241 03-04

CLINICAL EVALUATION OF NALTREXONE TREATMENT OF OPIATE-DEPENDENT INDIVIDUALS: REPORT OF THE NATIONAL RESEARCH COUNCIL COMMITTEE ON CLINICAL EVALUATION OF NARCOTIC ANTAGONISTS

002768 03-17 THE EFFECTS OF NALTREXONE ON THE DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE. 003170 04-04 NARCAN

NALOXONE (NARCAN) TREATMENT IN DEPRESSION: CLINICAL OBSERVATIONS AND EFFECTS ON CSF ENDORPHINS AND MONOAMINE

001692 02-13

MARCOANALYSIS

NARCOANALYSIS: THE FORGOTTEN DIAGNOSTIC AID.

000753 01-14

NARCOLEPSY NARCOLEPSY: DIAGNOSIS AND TREATMENT. (UNPUBLISHED PAPER) 002522 03-11 WAKING STAGE-1 REM OBSERVED IN PARANOID HALLUCINATORY

STATES OF NARCOLEPSY 002675 03-15

NARCOSIS

AN ATTEMPT TO PREDICT THE DURATION OF PENTOBARBITAL NARCOSIS ON THE BASIS OF EXPLORATORY ACTIVITY, DEFECATION RATE AND BODY WEIGHT OF RATS.

001435 02-04 THE ANTAGONISTIC EFFECTS OF 5 ETHYL-5-HYDROXY-1-METHYLBUTYLBARBITURIC-ACID ON PENTOBARBITAL NARCOSIS IN BOTH NAIVE AND TOLERANT MICE.

NARCOSUGGESTIONS

ROLE OF NARCOSUGGESTIONS IN HYSTERIA

002336 03-04 003540 04-10

CENTRAL SITES AND MECHANISMS OF THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF THE NARCOTIC ANALGESIC AGENT

000179 01-03

EFFECTS OF ALPHA-METHYL-P-TYROSINE, ADRENOLYTIC COMPOUNDS, PIMOZIDE AND OTHER NEUROLEPTICS, ON THE NARCOTIC CUE. 000338 01-04 DISCRIMINATIVE EFFECTS OF NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT AND SQUIRREL-MONKEY.

000381 01-04 INTERACTION BETWEEN NARCOTIC ANTAGONIST (NALOXONE) AND LYSERGIC-ACID-DIETHYLAMIDE (LSD) IN THE RAT

001120 02-03 EFFECTS OF ACUTE AND CHRONIC MORPHINE AND NARCOTIC ANTAGONISTS ON BRAIN ENERGY METABOLISM

001163 02-03 NARCOTIC BLOCKADE, LENGTH OF ADDICTION, AND PERSISTENCE OF INTRAVENOUS MORPHINE SELF-ADMINISTRATION IN RATS.

001322 02-04 CATECHOLAMINE INVOLVEMENT IN THE NARCOTIC CUE

001332 02-04
NALOXONE INTERACTION WITH NEUROLEPTIC-INDUCED SUPPRESSION OF

001381 02-04 THE EFFECTS OF VARIOUS NARCOTIC AGONISTS AND ANTAGONISTS ON DEPRIVATION-INDUCED FLUID CONSUMPTION.

001408 02-04 TOXIC INTERACTIONS OF STIMULANTS, NARCOTICS AND NARCOTIC

001511 02-05 PHARMACOTHERAPY OF NARCOTIC DEPENDENCE.

001634 02-12
ANALGESIA FOLLOWING TRANSCUTANEOUS ELECTRICAL STIMULATION AND ITS PARTIAL REVERSAL BY A NARCOTIC ANTAGONIST 001646 02-13

LEARNING RATE EQUIVALENCY OF TWO NARCOTIC GASES. 001701 02-14

PRODOPAMINERGIC EFFECT OF NARCOTIC ANTAGONISTS IN RABBITS PRETREATED WITH ANTIDOPAMINERGIC OR ANTISEROTONERGIC

002135 03-03 RECEPTOR AFFINITY AND PHARMACOLOGICAL POTENCY OF A SERIES OF NARCOTIC ANALGESIC, ANTIDIARRHEAL AND NEUROLEPTIC DRUGS. 002160 03-03

NARCOTIC CUEING PROPERTIES OF INTRAVENTRICULARLY ADMINISTERED SUFENTANIL, FENTANYL, MORPHINE AND MET-ENKEPHALIN.

CLINICAL EVALUATION OF NALTREXONE TREATMENT OF OPIATE-DEPENDENT INDIVIDUALS: REPORT OF THE NATIONAL RESEARCH COUNCIL COMMITTEE ON CLINICAL EVALUATION OF NARCOTIC

002768 03-17 BETA-ENDORPHIN AND THE NARCOTIC CUE.

003179 04-04 BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC NARCOTIC TREATMENT IN THE GUINEA-PIG

003183 04-04 DISCRIMINATIVE STIMULUS PROPERTIES OF NARCOTIC ANALGESIC

NARCOTIC CUING AND ANALGESIC ACTIVITY OF NARCOTIC ANALGESICS:
ASSOCIATIVE AND DISSOCIATIVE CHARACTERISTICS.

CHANGES OF SENSITIVITY TO THE CUING PROPERTIES OF NARCOTIC DRUGS AS EVIDENCED BY GENERALIZATION AND CROSS-GENERALIZATION EXPERIMENTS.

NOCICEPTIVE STIMULATION PREVENTS DEVELOPMENT OF TOLERANCE TO NARCOTIC ANALGESIA.

DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION. 003241 04-04

BEHAVIORAL EFFECTS OF CHRONIC NARCOTIC ANTAGONIST ADMINISTRATION TO INFANT RATS.

003329 04-04 **AVERSIVE PROPERTIES OF NARCOTIC ANTAGONISTS IN RATS**

003367 04-04 CENTRAL MECHANISMS OF REWARD AND THE NARCOTIC CUE

REINFORCING AND AVERSIVE PROPERTIES OF THE NARCOTIC CUE. USE OF THE FLINCH-JUMP TECHNIQUE TO STUDY NARCOTIC ANALGESIA IN THE RAT.

NARCOTIC CUE, NARCOTIC ANALGESIA, AND THE TOLERANCE PROBLEM. 003707 04-17 003403 04-04

NARCOTIC-INDUCED
THE ROLE OF THE CORPUS-STRIATUM IN NEUROLEPTIC-INDUCED AND NARCOTIC-INDUCED CATALEPSY.

002062 0

002062 03-03 NARCOTICS
SPECIFIC ACTION OF NARCOTICS ON REFLEX ACTIVATION OF RAT ALPHA-

BARBITAL-INDUCED CHANGES IN SENSITIVITY TO THE BEHAVIORAL EFFECTS OF NARCOTICS.

000332 01-04 INTERACTIONS OF NARCOTICS AND THEIR ANTAGONISTS WITH HUMAN SERUM ESTERASE. VI: THE BEHAVIOR OF 14 HYDROXYLATED MORPHINE DERIVATIVES.

000690 01-13 EFFECT OF NARCOTICS ON CONDUCTION OF AFFERENT VISCERAL

TOXIC INTERACTIONS OF STIMULANTS, NARCOTICS AND NARCOTIC

ANTAGONISTS

QUANTUM CHEMICAL STUDIES OF N SUBSTITUENT VARIATION IN THE OXYMORPHONE SERIES OF OPIATE NARCOTICS. 001946 03-01

LACK OF BLOCKADE OF CENTRAL DOPAMINERGIC RECEPTORS BY NARCOTICS: COMPARISON WITH CHLORPROMAZINE.

003354 04-04 CLINICAL EVALUATION OF NALTREXONE TREATMENT OF OPIATE-DEPENDENT INDIVIDUALS: REPORT OF THE NATIONAL RESEARC COUNCIL COMMITTEE ON CLINICAL EVALUATION OF NARCOTIC

002768 03-17

DIET AND UPTAKE OF ALDOMET BY THE BRAIN: COMPETITION WITH NATURAL LARGE NEUTRAL AMINO-ACIDS. 001185 02-03

MATURALISTIC

APPLICATION OF LIFE TABLE METHOD TO NATURALISTIC DESIGNS -- A

COMPARISON OF EFFICACY OF TRICYCLIC ANTIDERESSANTS AND
BENZODIAZEPINES IN AMBULATORY DEPRESSIVES.

002783 03

002783 03-17 NATURE OF RECEPTORS INVOLVED IN APOMORPHINE RESPONSES IN

INVESTIGATIONS INTO THE NATURE OF THE PERIORAL MOVEMENTS INDUCED BY DIPROPYLAMINO-DIHYDROXYTETRALIN. 001334 02-04

NECROTIZING ANGIITIS AND HEPATITIS IN AN AMPHETAMINE ABUSER. 000887 01-15

TRICYCLIC NEED DROPS WITH AGE.

000580 01-09 ANXIETY STATES IN FAMILY PRACTICE: AN EVALUATION OF THE NEED FOR ANTIDEPRESSANT AS WELL AS ANXIOLYTIC THERAPY. 000605 01-10

NEFOPAM
NEFOPAM (N), MORPHINE (M), AND D AMPHETAMINE (A) IN MAN:
SUBJECTIVE, BEHAVIORAL, AND PHYSIOLOGIC EFFECTS.

NEGATIVE
AN INVESTIGATION OF NALORPHINE AND PERPHENAZINE AS NEGATIVE
REINFORCERS IN AN ESCAPE PARADIGM. 000389 01-04

Psychopharmacology Abstracts

THE SUBCELLULAR DISTRIBUTION OF PARTICLE-BOUND NEGATIVE CHARGES IN RAT BRAIN.

000492 01-06 **NEGATIVE NALOXONE EFFECTS IN SCHIZOPHRENIC PATIENT**

THE EFFECT OF DIAZEPAM, CHLORPROMAZINE AND AMOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION.

NEGATIVE EFFECTS OF BICUCULLINE AND THIOSEMICARBAZIDE ON THE TRANQUILLIZING ACTION OF DIAZEPAM.

001213 02-03 ANALYSIS AND CHEMICAL CONTROL OF NEGATIVE AFFECT

THE USE OF THE CNV (CONTINGENT NEGATIVE VARIATION) IN THE DETERMINATION OF RESIDUAL EFFECTS OF FIVE HYPNOTIC DRUGS. 002713 03-16

IEMBUTAL

EFFECTS OF AMPHETAMINE AND NEMBUTAL ON SOCIAL EXPLORATION IN
THE MONGOLIAN GERBIL. 001414 02-04

NEOCORTEX
ADENOSINE MODULATES DEPOLARIZATION-INDUCED RELEASE OF H3NORADRENALINE FROM SLICES OF RAT BRAIN NEOCORTEX.
002938 0

ROLE OF GLUCOCORTICOIDS IN AN ABNORMAL GROOMING BEHAVIOR IN CATS WITH PONTILE OR FRONTAL NEOCORTICAL LESIONS.

000463 01-04 EFFECTS OF BRAIN LESIONS AND ATROPINE ON HIPPOCAMPAL AND NEOCORTICAL ELECTROENCEPHALOGRAMS IN THE RAT. 001033 02-02

NEOMYCIN
THE EFFECTS OF NEOMYCIN UPON TRANSMITTER RELEASE AND ACTION.
000302 01-03

EFFECTS OF NALOXONE ON PETHIDINE-INDUCED NEONATAL DEPRESSION: PART I -- INTRAVENOUS NALOXONE.

000668 01-11 EFFECTS OF NALOXONE ON PETHIDINE-INDUCED NEONATAL DEPRESSION: PART II - INTRAMUSCULAR NALOXONE.

000669 01-11 NEONATAL WITHDRAWAL SYNDROME ASSOCIATED WITH HYDROXYZINE HYDROCHLORIDE.

000884 01-15 THE EFFECTS OF NEONATAL INJECTIONS OF ALPHA-MSH ON THE OPEN-FIELD BEHAVIOR OF JUVENILE AND ADULT RATS.

001309 02-04 THE PHARMACOLOGICAL EFFECTS OF FETAL AND NEONATAL EXPOSURE TO NALTREXONE IN THE RAT

001373 02-04 ODOR AVERSION LEARNING IN NEONATAL RATS.

001448 02-04 EFFECT OF MATERNAL MORPHINE ADMINISTRATION ON FETAL AND NEONATAL RAT LIVER TYROSINE-AMINOTRANSFERASE.

002011 03-03 EFFECTS OF DIETHYLDITHIOCARBAMATE ON BRAIN MONOAMINE AND PROTEIN CONTENT IN NEONATAL RATS.

002063 03-03 EFFECTS OF CATECHOL ESTROGENS ON SEXUAL DIFFERENTIATION IN NEONATAL FEMALE RATS.

002293 03-04 ADULT BEHAVIOR AND ADRENOCORTICAL FUNCTION FOLLOWING NEONATAL MORPHINE TREATMENT IN RATS.

002310 03-04 DNA SYNTHETIC ABILITY IN CEREBELLA FROM TEMPERATURE AND HANDLING STRESSED NEONATAL RATS.

STUDIES ON THE MECHANISM OF SPROUTING OF NORADRENERGIC TERMINALS IN RAT AND MOUSE CEREBELLUM AFTER NEONATAL 6 HYDROXYDOPA.

NEONATAL SYSTEMIC 6 HYDROXYDOPAMINE AND DORSAL TEGMENTAL BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEPHRINE AND THE POSTDECAPITATION REFLEX.

003039 04-03 EFFECTS OF N METHYLAMINOETHANOL, AND N,N
DIMETHYLAMINOETHANOL IN THE DIET OF PREGNANT RATS ON
NEONATAL RAT BRAIN CHOLINERGIC AND PHOSPHOLIPID PROFILE.

BEHAVIOURAL EFFECTS OF METHYLPHENIDATE IN 6 HYDROXYDOPAMINE TREATED NEONATAL RATS. 003212 04-04

SCHIZOPHRENIC-LIKE TENDENCIES IN RATS NEONATALLY TREATED WITH 6 HYDROXYDOPAMINE. (PH.D. DISSERTATION). 003323 04-04

RETENTION OF URINE IN THE NEONATE POSSIBLY DUE TO ANTICONVULSANT DRUGS.

002683 03-15

001550 02-07

002026 03-03

NEONATES
EFFECT OF D AMPHETAMINE ON LOCOMOTOR ACTIVITY OF LEAD FED RABBIT NEONATES

EFFECTS OF DIPROPYLACETATE ON WAKEFULNESS AND SLEEP IN HUMAN

002632 03-14 NEOPHOBIA

SUPPRESSION OF NEOPHOBIA BY CHLORPROMAZINE IN WILD RATS. 000415 01-04

DOXEPIN OVERDOSE: SUCCESS WITH PHYSOSTIGMINE AND FAILURE WITH NEOSTIGMINE IN REVERSING TOXICITY. 000772 01-14

NEOSTRIATAL NEOSTRIATAL ADMINISTRATION OF SOMATOSTATIN: DIFFERENTIAL EFFECT OF SMALL AND LARGE DOSES ON BEHAVIOR AND MOTOR

DECREASE IN NEOSTRIATAL BLOOD FLOW AFTER D AMPHETAMINE ADMINISTRATION OR ELECTRICAL STIMULATION OF THE SUBSTANTIA-

EFFECTS OF DIAZEPAM ON DOPAMINE TURNOVER IN NEOSTRIATAL AND LIMBIC REGIONS OF THE RAT BRAIN.

002060 03-03 HISTOCHEMICAL EFFECTS OF KAINIC-ACID ON NEOSTRIATAL DOPAMINE AND ACETYLCHOLINESTERASE.

ALTERATION OF THE NEURONAL RESPONSE TO AMPHETAMINE IN THE NEOSTRIATUM BY PRETREATMENT WITH A CENTRALLY ACTING

IDENTIFICATION OF A SUBREGION WITHIN RAT NEOSTRIATUM FOR THE DOPAMINERGIC MODULATION OF LATERAL HYPOTHALAMIC SELF-STIMULATION.

NEPHROTOXIC

ETHANOL - ITS NEPHROTOXIC EFFECT IN THE RAT. 001523 02-05

INCREASE IN THE TURNOVER OF BRAIN DOPAMINE BY STIMULATION OF MUSCARINIC RECEPTORS OUTSIDE THE DOPAMINE NERVE TERMINALS 000042 01-03

GAS-CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY OF SEROTONIN IN RAT SUPERIOR CERVICAL GANGLIA: EFFECTS OF NERVE GROWTH FACTOR AND 6 HYDROXYDOPAMINE.

001006 02-01 RELAXATION OF SMOOTH MUSCLE FOLLOWING CONTRACTION ELICITED BY SYMPATHETIC NERVE STIMULATION IN VIVO

001106 02-03 SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT AND NEWBORN RATS

001215 02-03 AUTORADIOGRAPHIC EVIDENCE FOR THE SELECTIVE ACCUMULATION OF H3-5-HT BY SUPRAEPENDYMAL NERVE TERMINALS.

001222 02-03 BLOCKADE BY PSYCHOTROPIC DRUGS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR IN CULTURED NERVE CELLS.

001223 02-03 SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION.

002052 03-03 THE EFFECT OF L-DOPA ON PERIPHERAL SYMPATHETIC NERVE FUNCTION: ROLE OF PRESYNAPTIC DOPAMINE RECEPTORS.

002081 03-03 NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION OF THE SYMPATHETIC NERVE OF THE EYE.

002802 04-03 **GLUTAMINE -- A MAJOR SUBSTRATE FOR NERVE ENDINGS**

002839 04-03 STIMULATION OF PRESYNAPTIC BETA-ADRENOCEPTORS ENHANCES H3-NORADRENALINE RELEASE DURING NERVE STIMULATION IN THE PERFUSED CAT SPLEEN.

002855 04-03 THE ACTION OF CNS DRUGS ON AN ISOLATED SYMPATHETIC NERVE PREPARATION OF RABBIT 002869 04-03

THE UPTAKE AND RELEASE OF H3-2 AMINO-6-7-DIHYDROXYTETRAHYDRONAPHTHALENE (ADTN) BY STRIATAL NERVE

002884 04-03 SELECTIVE ENZYME INDUCTION IN A NERVE GROWTH FACTOR RESPONSIVE PHEOCHROMOCYTOMA CELL LINE (PC-12). 002899 04-03

DRUGS AFFECTING THE CENTRAL-NERVOUS-SYSTEM: EFFECTS OF PEMOLINE, AND TRICYCLIC ANTIDEPRESSANTS ON NERVE TERMINAL ADENOSINE-TRIPHOSPHATASE ACTIVITIES AND NEUROTRANSMITTER

RETROGRADE AXONAL TRANSPORT OF NERVE GROWTH FACTOR IN THE CILIARY GANGLION OF THE CHICK AND THE RAT.

003005 04-03 MUSCARINIC RECEPTOR MEDIATED CYCLIC-GMP FORMATION BY
CULTURED NERVE CELLS -- IONIC DEPENDENCE AND EFFECTS OF LOCAL

003064 04-03 PREFERENCE BEHAVIOR AND TASTE NERVE RESPONSES IN D PENICILLAMINE TREATED RATS.

DOPAMINE-BETA-HYDROXYLASE RELEASE FOLLOWING ACUTE SELECTIVE SYMPATHETIC NERVE STIMULATION OF THE HEART, SPLEEN AND

003422 04-04 NGF-INDUCED ALTERATIONS IN PROTEIN SECRETION AND SUBSTRATE ATTACHED MATERIAL OF A CLONAL NERVE CELL LINE. 003607 04-13

NERVES

002851 04-03

003028 04-03

EFFECTS OF PRESYNAPTIC MODULATORS ON CA2-INDUCED NORADRENALINE RELEASE FROM CARDIAC SYMPATHETIC NERVES 002025 03-03
EFFECTS OF BUTYROPHENONES ON THE SYMPATHETIC NERVES OF THE

ISOLATED RABBIT HEART AND ON THE POSTSYNAPTIC ALPHA-ADRENOCEPTORS OF THE ISOLATED RABBIT AORTA.

NERVOUS

CENTRALLY ACTIVE DRUGS AND THE SYMPATHETIC NERVOUS SYSTEM
OF RABBITS AND CATS.

000078 01-03 ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM — IV. TOLERANCE TO OXOTREMORINE IN MICE: IN VIVO AND IN VITRO STUDIES.

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM — III. TOLERANCE TO PHENCYCLIDINE DERIVATIVES: IN VIVO AND IN VITRO STUDIES.

THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (SECOND REPORT) -- EFFECTS ON PUPIL FUNCTIONING.

THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (FIRST REPORT).

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF

001118 02-03 DYNAMICS OF BLOOD NEUROTRANSMITTER LEVEL AS EVIDENCE OF HIGHER NERVOUS ACTIVITY CHANGES DURING CHRONIC ADMINISTRATION OF SEDUXEN.

001338 02-04 DO DRUGS ACTING ON THE NERVOUS SYSTEM AFFECT CELL

PROLIFERATION IN THE DEVELOPING BRAIN? 001512 02-05 ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. II. CROSS-TOLERANCE BETWEEN PHENCYCLIDINE DERIVATIVES AND CHOLINERGIC DRUGS.

002126 03-03 ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. I. TOLERANCE TO PHENCYCLIDINE DERIVATIVES IN MICE: PHARMACOLOGICAL CHARACTERIZATION.

002127 03-03 A BEHAVIORAL AND AUTONOMIC NERVOUS SYSTEM STUDY OF CHRONIC IMIPRAMINE ADMINISTRATION TO CONSCIOUS DOGS.

002263 03-04 CENTRAL NERVOUS EFFECTS OF THE HYPNOTIC ETOMIDATE IN MAN. 002580 03-13

ON THE ACUTE EFFECT OF SOME DRUGS ON HIGHER NERVOUS ACTIVITY IN MAN FOLLOWED UP BY THE LABORATORY LANGUAGE METHOD 002623 03-14

AUTONOMOUS NERVOUS FUNCTION OF LONG-TERM USERS OF PSYCHOTROPIC DRUGS, THIRD REPORT -- PUPILOGRAM

002690 03-15 EFFECTS OF MATERNAL CHLORPROMAZINE ON OFFSPRING NERVOUS SYSTEM DEVELOPMENT.

002880 04-03

CANNABIS INTERFERES WITH NEST-BUILDING BEHAVIOR IN MICE. 003306 04-04

NETWORKS

SELECTIVE OPIATE DEPRESSION OF SENSORY EVOKED SYNAPTIC NETWORKS IN DORSAL-HORN REGIONS OF SPINAL CORD CULTURES

ROLE OF PHOSPHOLIPIDS IN MUSCARINIC BINDING BY NEURAL 000044 01-03

NEURAL MECHANISMS OF BENZODIAZEPINE ACTIONS.

000594 01-10

MORPHINE AND SELF-STIMULATION: EVIDENCE FOR ACTION ON A COMMON NEURAL SUBSTRATE.

002277 03-04

IRALGIA
STUDIES ON THE CONCOMITANT USE OF CARBAMAZEPINE AND
CLOMIPRAMINE FOR THE RELIEF OF POSTHERPETIC NEURALGIA.
002555 03-13

003133 04-03

002863 04-03

NEURITES
OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT
GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG 002040 03-03

NEUROBLASTOMA MUSCARINIC REGULATION OF C-AMP IN MOUSE NEUROBLASTOMA. 000058 01-03

ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE NEUROBLASTOMA CELLS.

ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002137 03-03 EFFECTS OF LITHIUM ON THE MEMBRANE-BOUND MAGNESIUM DEPENDENT ATPASE OF MOUSE NEUROBLASTOMA CELLS.

003087 04-03

CONCOMITANT ELEVATION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY CYCLIC-AMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

NEUROBLASTOMA-X
PHARMACOLOGIC RESPONSES OF CELLS OF A NEUROBLASTOMA-X
GLIOMA HYBRID CLONE AND MODULATION OF SYNAPSES BETWEEN
HYBRID CELLS AND MOUSE MYOTUBES.

NEUROCHEMICAL
NEUROCHEMICAL PROPERTIES OF DIMETHYLMETHYLAMINOPROPYL-1PHENYLINDAN HCL (LU-3-049) AND SELECTED TRICYCLIC
ANTIDEPRESSANTS.
000251 01

DO0251 01-03
BENZODIAZEPINES: BEHAVIORAL AND NEUROCHEMICAL MECHANISMS. 000455 01-04

CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO PSYCHOTROPIC DRUGS.

000729 01-13 NEUROCHEMICAL STUDIES OF AGGRESSION IN ANIMALS.

000947 01-17 NEUROCHEMICAL PROPERTIES OF DIMOXAMINE (D), A NEW PSYCHOTHERAPEUTIC AGENT.

NEUROCHEMICAL MECHANISMS OF CENTRAL ACTION OF MORPHINE ON FUNCTIONS OF SINGLE NEURONS IN THE MIDBRAIN RETICULAR FORMATION.

EFFICACY OF NEUROLEPTICS AND ANTIDEPRESSANTS IN THE TEST OF APOMORPHINE HYPOTHERMIA AND SOME DATA CONCERNING NEUROCHEMICAL MECHANISMS OF THE TEST.

NEUROCHEMICAL AND BEHAVIORAL EFFECTS OF CLONIDINE AND RELATED IMIDAZOLINES: INTERACTION WITH ALPHA-ADRENOCEPTORS.

A CONTRIBUTION TO THE NEUROCHEMICAL BASIS OF THE PYRITHIOXIN EFFECT ON THE BRAIN GLUCOSE UTILISATION DURING RELATIVE BRAIN HYPOGLYCAEMIA INDUCED BY ANTICIPATION STRESS.

DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE: ORGANIC MOLECULAR MECHANISMS AND NEUROCHEMICAL EVENTS. 003254 04-04

BEHAVIOURAL AND NEUROCHEMICAL EFFECTS OF REPEATED ADMINISTRATION OF COCAINE IN RATS.

PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT
OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC
AND CATECHOLAMINERGIC MECHANISMS BY 6 HYDROXYDDPAMINE
AND 5.6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D.
DISSERTATION).

Psychopharmacology Abstracts

INTERDEPENDENCE BETWEEN SOCIAL PROCESSES AND NEUROCHEMICAL OPERATIONS. 003623 04-14

NEUROCHEMISTRY
NEUROCHEMISTRY OF WITHDRAWAL EMERGENT SYMPTOMS IN
CHILDREN.

002602 03-13 PHARMACOLOGY AND NEUROCHEMISTRY OF APOMORPHINE

003592 04-13 BEHAVIORAL NEUROCHEMISTRY: NEUROREGULATORS AND BEHAVIORAL STATES.

NODERMATITIS
ON THE TREATMENT OF NEURODERMATITIS WITH A MONOAMINEOXIDASE INHIBITOR: THE CHEMOTHERAPY OF PSYCHOSOMATIC
ILLNESS THROUGH A-REM SUPPRESSION.

EUROEFFECTOR

EFFECTS OF PROSTAGLANDIN-E2 AND A PROSTAGLANDIN ENDOPEROXIDE

ANALOGUE ON NEUROEFFECTOR TRANSMISSION IN THE RAT

ANOCOCCYGEUS MUSCLE.

002808 04-03

PSYCHOLOGIC AND NEUROENDOCRINE RESPONSE TO METHYLPHENIDATE

THE PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS. A TEST OF DOPAMINERGIC BLOCKADE: NEUROENDOCRINE STUDIES IN NORMAL MEN.

001867 02-16 NEUROENDOCRINE RESPONSES TO LEVODOPA IN AFFECTIVE-ILLNESS 002435 03-09

NEUROENDOCRINE STUDIES WITH DOPAMINE AGONISTS IN

ACUTE PSYCHOLOGIC AND NEUROENDOCRINE EFFECTS OF DEXTROAMPHETAMINE AND METHYLPHENIDATE.

002589 03-13 002786 04-01

002238 03-04

NEUROHYPOPHYSIAL
MONOAMINERGIC INFLUENCES ON THE INCORPORATION OF \$35 IN THE
HYPOTHALAMIC AND NEUROHYPOPHYSIAL PROTEINS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF \$35-CYSTEINE IN DEHYDRATED RATS

NOUROLEPTIC

5-HT ANTAGONISTS INHIBIT NEUROLEPTIC AND MORPHINE ANTAGONISM
OF THE HYPERACTIVITY INDUCED BY DOPAMINE FROM THE NUCLEUSACCUMBENS.

000082 01-03

THE NUCLEUS-ACCUMBENS — POSSIBLE SITE OF ANTIPSYCHOTIC ACTION OF NEUROLEPTIC DRUGS?.

000085 01-03 THE DEMONSTRATION IN VIVO OF SPECIFIC BINDING SITES FOR NEUROLEPTIC DRUGS IN MOUSE BRAIN.

000150 01-03 NEUROLEPTIC DRUG INTERACTIONS WITH NOREPINEPHRINE ALPHA RECEPTOR BINDING SITES IN RAT BRAIN.

000219 01-03 HALLUCINOGEN BINDING TO DOPAMINE/NEUROLEPTIC RECEPTORS

000296 01-03 USE OF DRL IN DIFFERENTIATING ANXIOLYTIC AND NEUROLEPTIC PROPERTIES OF CNS DRUGS.

000329 01-04 LONG-TERM BEHAVIOURAL AND BIOCHEMICAL EFFECTS FOLLOWING
PROLONGED TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL)

000420 01-04

LONG-TERM TREATMENT WITH NEUROLEPTIC DRUGS. 000768 01-14

CATATONIC REACTIONS TO HIGH-POTENCY NEUROLEPTIC DRUGS. 000835 01-15 STUDY OF NIGHT SLEEP DURING LONG-TERM GRADUAL REDUCTION IN NEUROLEPTIC THERAPY IN CHRONIC SCHIZOPHRENICS.

000852 01-15 NEUROLEPTIC SIDE-EFFECTS OF CHLORPROMAZINE IN PSYCHOPHARMACOLOGICAL RESEARCH.

CATATONIA AND MALIGNANT SYNDROME: A POSSIBLE COMPLICATION OF NEUROLEPTIC ADMINISTRATION. REPORT OF A CASE INVOLVING HALOPERIDOL.

000910 01-15 ON THE CONFORMATION OF NEUROLEPTIC DRUGS IN THE THREE AGGREGATION STATES AND THEIR CONFORMATIONAL RESEMBLANCE TO DOPAMINE.

000990 01-17 THE PHARMACOLOGY OF A NEW POTENT, LONG-ACTING NEUROLEPTIC. PIFLUTIXOL

001035 02-02 NEUROLEPTIC INFLUENCE ON VARIOUS NEUROTRANSMITTER SUBSTANCES.

001122 02-03

THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS.

001150 02-03 EFFECT OF CHRONIC NEUROLEPTIC OR L-DOPA ADMINISTRATION ON GABA LEVELS IN THE RAT SUBSTANTIA-NIGRA.

001181 02-03 ANTIPARKINSONIAN DRUG ADMINISTRATION AND PLASMA LEVELS OF PENFLURIDOL. A NEW LONG-ACTING NEUROLEPTIC.

001559 02-08 TREATMENT OF CHRONIC SCHIZOPHRENICS WITH THE ORAL LONG-TERM NEUROLEPTIC PENFLURIDOL IN AN OPEN STUDY.

001563 02-08 THE PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS. A TEST OF DOPAMINERGIC BLOCKADE: NEUROENDOCRINE STUDIES IN NORMAL

001867 02-16 1-3 PHENOTHIAZINYLPROPYL-PIPERIDINYLPHENYLMETHANONES, A NOVEL CLASS OF LONG-ACTING NEUROLEPTIC AGENTS.

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS: 3
SUBCELLULAR DISTRIBUTION OF NEUROLEPTIC DRUGS AND THEIR RECEPTORS IN VARIOUS RAT BRAIN AREAS.

002067 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 2. REGIONAL DISTRIBUTION AND IN VIVO DISPLACEMENT OF NEUROLEPTIC DRUGS.

002068 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 1. KINETICS AND CHARACTERISTICS OF IN VITRO BINDING.

002079 03-03 NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: I. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY

002096 03-03 COMPARISON OF THE EFFECTS OF METHAMPHETAMINE AND NEUROLEPTIC AGENTS ON TYROSINE-HYDROXYLASE ACTIVITY IN THE NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM.

002102 03-03 DIFFERENTIAL REGIONAL DEVELOPMENT OF TOLERANCE TO INCREASE IN DOPAMINE TURNOVER UPON REPEATED NEUROLEPTIC ADMINISTRATION.

RECEPTOR AFFINITY AND PHARMACOLOGICAL POTENCY OF A SERIES OF NARCOTIC ANALGESIC, ANTIDIARRHEAL AND NEUROLEPTIC DRUGS. 002160 03-03

EFFECTS OF BACLOFEN ON DOPAMINE METABOLISM AND INTERACTION WITH NEUROLEPTIC EFFECTS.

002173 03-03 BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC, ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA.

002220 03-04 EFFECT OF NEUROLEPTIC DRUGS ON THE CONDITIONED BEHAVIOR AFTER PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE.

002290 03-04 THREE YEARS MAINTENANCE NEUROLEPTIC TREATMENT IN SCHIZOPHRENIA - BEFORE AND BEYOND.

002392 03-08 GRADUAL REDUCTION OF NEUROLEPTIC DRUGS AMONG CHRONIC

SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY 002401 03-08

WHEN IS A NEUROLEPTIC APPROPRIATE IN PSYCHONEUROSIS 002486 03-10 PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS IN NORMAL AND

SCHIZOPHRENIC SUBJECTS. 002575 03-13 PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS: AN APPROACH TO THE STUDY OF BRAIN DOPAMINE BLOCKADE IN HUMANS.

002590 03-13 CLINICAL LABORATORY STUDIES WITH SPECIAL REGARD TO HEPATIC METABOLISM IN SCHIZOPHRENICS ON OUTPATIENT LONG-TERM

NEUROLEPTIC MEDICATION. 002667 03-15 CHRONIC NEUROLEPTIC USE AND PERIPHERAL MOTOR NEURON DAMAGE

002671 03-15 LITHIUM INTOXICATION MASKED BY NEUROLEPTIC DRUGS WHEN LITHIUM DIURETIC COMBINATIONS ARE USED.

002682 03-15 BIOCHEMICAL ACTIONS OF NEUROLEPTIC DRUGS: FOCUS ON THE DOPAMINE RECEPTOR.

002738 03-17
POTENTIATION BY NEUROLEPTIC AGENTS OF THE INHIBITORY ACTION OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE. 002832 04-03

EFFECTS OF SOME DERIVATIVES OF 2 AMINOTETRALIN ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE AND ON THE BINDING OF H3-HALOPERIDOL TO NEUROLEPTIC RECEPTORS IN RAT STRIATUM. 002853 04-03 NEUROLEPTIC BLOCKADE OF THE EFFECT OF VARIOUS NEUROTRANSMITTER SUBSTANCES.

NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND L-DOPA TO RATS.

DEMONSTRATION OF NEUROLEPTIC RECEPTOR SITES IN MOUSE BRAIN BY AUTORADIOGRAPHY.

THE EFFECTS OF STANDARD NEUROLEPTIC COMPOUNDS ON THE BINDING OF H3-SPIROPERIDOL IN THE STRIATUM AND MESOLIMBIC SYSTEM OF THE RAT IN VITRO.

CHARACTERIZATION OF SPECIFIC IN VIVO BINDING OF NEUROLEPTIC DRUGS IN RAT BRAIN.

002985 04-03
INHIBITION OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RAT
STRIATUM BY NEUROLEPTIC DRUGS ADMINISTERED IN VIVO.

EVIDENCE FOR CELL LOSS IN CORPUS-STRIATUM AFTER LONG-TERM TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN RATS. 003030 04-03

NEUROLEPTIC INTERFERENCE WITH THE COCAINE CUE: INTERNAL STIMULUS CONTROL OF BEHAVIOR AND PSYCHOSIS. VALIDITY AND CLINICAL UTILITY OF NEUROLEPTIC FACILITATED ELECTROENCEPHALOGRAPHY IN PSYCHOTIC PATIENTS.

NEUROLEPTIC DRUGS AND NEUROTRANSMITTER RECEPTORS 003728 04-17

NEUROLEPTIC-INDUCED
POSSIBLE IMPORTANCE OF 5 HYDROXYTRYPTAMINE IN NEUROLEPTIC-INDUCED CATALEPSY IN RATS.

DIPHENHYDRAMINE IN THE DIFFERENTIAL DIAGNOSIS OF NEUROLEPTIC-INDUCED ORAL FACIAL DYSKINESIA.

000798 01-15 CYANOCYPROHEPTADINE: ROLE OF CHOLINOLYTIC PROPERTIES IN MODULATING NEUROLEPTIC-INDUCED ELEVATION OF STRIATAL

NALOXONE INTERACTION WITH NEUROLEPTIC-INDUCED SUPPRESSION OF NARCOTIC WITHDRAWAL

001381 02-04
ROLE OF BRAIN NOREPINEPHRINE IN NEUROLEPTIC-INDUCED CATALEPSY

001509 02-05 THE ROLE OF THE CORPUS-STRIATUM IN NEUROLEPTIC-INDUCED AND NARCOTIC-INDUCED CATALEPSY

THE SPECIFICITY OF NEUROLEPTIC-INDUCED AND METHYSERGIDE-INDUCED BEHAVIORAL HYPERSENSITIVITY.

002259 03-04
NEUROLEPTIC-INDUCED ATTENUATION OF BRAIN STIMULATION REWARD IN RATS

003221 04-04 NEUROLEPTIC-INDUCED SUPERSENSITIVITY PSYCHOSIS 003646 04-15

A BENZOQUINOLIZINE DERIVATIVE WITH A NEUROLEPTIC-LIKE ACTION ON CEREBRAL MONOAMINE TURNOVER.

001037 02-02 NEUROLEPTICS

SPECIFIC LOCALIZATION OF DRUGS AT THE HYPOPHYSIS LEVEL AND SIDE-EFFECTS: THE CASE OF NEUROLEPTICS. EFFECTS OF VARIOUS NEUROLEPTICS ON RABBIT HYPERTHERMIA INDUCED BY N,N DIMETHYLTRYPTAMINE (DMT) AND D

INCREASE IN MOUSE BRAIN DOPAMINE CONTENT BY BACLOFEN: EFFECTS
OF APOMORPHINE AND MELIDIAL ENTURY. OF APOMORPHINE AND NEUROLEPTICS.

EFFECTS OF ALPHA-METHYL-P-TYROSINE, ADRENOLYTIC COMPOUNDS, PIMOZIDE AND OTHER NEUROLEPTICS, ON THE NARCOTIC CUE. 000338 01-04 ACUTE DYSTONIA AS AN IDIOSYNCRATIC RESPONSE TO NEUROLEPTICS IN BABIOONS.

000409 01-04

SOME METHODOLOGICAL CONSIDERATIONS FOR THE CLINICAL EVALUATION OF NEUROLEPTICS -- COMPARATIVE EFFECTS OF CLOZAPINE AND HALOPERIDOL ON SCHIZOPHRENICS.

PRACTICAL CONSIDERATIONS IN THE USE OF DEPOT NEUROLEPTICS FOR THE TREATMENT OF SCHIZOPHRENIA.

THE PREDICTIVE VALUE OF THE BIOCHEMICAL ACTION PROFILE OF NEUROLEPTICS. 000551 01-08

INFLUENCE OF THE ANTIPARKINSONIAN DRUGS ON THE PLASMA LEVEL MEDICAL SCREENING OF PATIENTS ON MAINTENANCE NEUROLEPTICS.

THE EFFECT OF MELPERONE (BURONIL(R)) AND ITS METABOLITE FG-5155
ON THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM COMPARED TO SOME
OTHER NEUROLEPTICS.

EFFECT OF NEUROLEPTICS, MYDANTHAN, AND DOPA ON APOMORPHINE-INDUCED STEREOTYPY IN RATS.

001155 02-03

IN VITRO AUTONOMIC EFFECTS OF FOUR NEUROLEPTICS:
CHLORPROMAZINE, HALOPERIDOL, MELPERONE AND THIORIDAZINE.
001212 02-03
REGIONAL EFFECTS OF NEUROLEPTICS ON DOPAMINE METABOLISM AND
DOPAMINE SENSITIVE ADENYLATE-CYCLASE ACTIVITY.

CHOLINERGIC MODIFICATION OF THE INHIBITION OF DOPAMINE-INDUCED HYPERACTIVITY BY NEUROLEPTICS. 001271 02-03

BEHAVIORAL EFFECTS OF NEUROLEPTICS, APOMORPHINE AND AMPHETAMINE AFTER BILATERAL LESION OF THE LOCUS-COERULEUS IN RATS.

001393 02-04 DIFFERENTIAL TOLERANCE TO INHIBITORY ACTION OF VARIOUS NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS CHRONICALLY TREATED WITH HALOPERIDOL.

EFFECTS OF NEUROLEPTICS ON MORPHINE-INDUCED TAIL ERECTION IN

001400 02-04 CORRELATION BETWEEN EXTRAPYRAMIDAL AND THERAPEUTIC EFFECTS OF NEUROLEPTICS.

001741 02-15 ADVERSE RESPONSE TO NEUROLEPTICS IN SCHIZOPHRENIA

001814 02-15 SYNDROME MALIN SYMPTOMS THOUGHT TO BE DUE TO INTERACTION BETWEEN NEUROLEPTICS AND ORAL DIABETES DRUGS.

001854 02-15 **DEPOT NEUROLEPTICS IN ACUTE PSYCHOSES**

001890 02-17 TREATMENT OF PATIENTS WITH DELAYED NEUROLEPTICS.

001921 02-17 PROBLEMS ENGENDERED BY ADMINISTRATION OF LONG-ACTION

NEUROLEPTICS. 001922 02-17

INHIBITION BY NEUROLEPTICS OF UPTAKE OF H3-GABA INTO RAT BRAIN SYNAPTOSOMES. 002013 03-03

EFFECT OF ERGOT ALKALOIDS AND OF NEUROLEPTICS ON BINDING TO PUTATIVE DOPAMINE AND ALPHA RECEPTORS. 002078 03-03

CIRCADIAN SUSCEPTIBILITY RHYTHM TO NEUROLEPTICS: TETRABENAZINE.

002108 03-03 EFFICACY OF NEUROLEPTICS AND ANTIDEPRESSANTS IN THE TEST OF APOMORPHINE HYPOTHERMIA AND SOME DATA CONCERNING NEUROCHEMICAL MECHANISMS OF THE TEST.

HOW SCHIZOPHRENIC PATIENTS CHANGE DURING 3 YEARS TREATMENT WITH DEPOT NEUROLEPTICS.

002393 03-08 NEUROLEPTICS AND SCHIZOPHRENIA.

002399 03-08 LUTEINIZING HORMONE RELEASING HORMONE AND THYROTROPIN-RELEASING HORMONE STIMULATION STUDIES IN PATIENTS GIVEN CLOMIPRAMINE OR DEPOT NEUROLEPTICS.

TIME-COURSE OF CHANGES IN EEG AND POWER SPECTRA DURING TREATMENT WITH NEUROLEPTICS.

DOPAMINERGIC FACTORS IN HUMAN PROLACTIN REGULATION: EFFECTS OF NEUROLEPTICS AND DOPAMINE.

THE EFFECT OF NEUROLEPTICS AND ALPHA-METHYL-P-TYROSINE ON SERUM PROLACTIN LEVELS IN LABORATORY ANIMALS AND MAN

002582 03-13 PHARMACOLOGICAL INCOMPATIBILITY OF NEUROLEPTICS AND TRANQUILIZERS WITH OTHER PREPARATIONS.

002680 03-1: EFFECT OF CHRONIC TREATMENT WITH NEUROLEPTICS ON THE CONTENT OF 3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE IN CEREBELLAR-CORTEX OF RATS.

002827 04-03 EFFECTS OF DOPAMINE AGONISTS ON NEURONES IN THE CAUDATE
NUCLEUS AND CEREBRAL-CORTEX OF CATS CHRONICALLY TREATED 002829 04-03

Psychopharmacology Abstracts

EFFECTS OF NEUROLEPTICS ON H3-HALOPERIDOL AND H3-CIS-FLUPENTHIXOL BINDING AND ON ADENYLATE-CYCLASE ACTIVITY IN

002957 04-03 INFLUENCE OF NEUROLEPTICS ON THE BINDING OF MET-ENKEPHALIN, MORPHINE AND DIHYDROMORPHINE TO SYNAPTOSOME ENRICHED FRACTIONS OF RAT BRAIN.

003096 04-03 COCAINE AS A DISCRIMINATIVE CUE IN RATS: INTERACTIONS WITH NEUROLEPTICS AND OTHER DRUGS.

003250 04-04 BENZAMIDES AND CLASSICAL NEUROLEPTICS: COMPARISON OF THEIR ACTIONS USING 6 APOMORPHINE-INDUCED EFFECTS.

003333 04-04 COMPARISON OF THE ELECTROPHYSIOLOGICAL EFFECTS OF TWO NEUROLEPTICS, MELPERONE AND THIORIDAZINE, ON ISOLATED RAT ATRIA.

EFFECTS OF SOME OF THE NEUROLEPTICS ON THE REPRODUCTIVE ORGANS

003419 04-05 CONTRIBUTION OF THE USE OF 1035MD IN A PSYCHIATRIC WARD FOR ADULTS, ITS ACTIVITY ON THE DIRECT AND SIDE-EFFECTS OF NEUROLEPTICS.

003446 04-07 HIGH-POTENCY AND LOW-POTENCY NEUROLEPTICS IN ELDERLY PSYCHIATRIC PATIENTS.

003450 04-08 PHARMACOKINETIC INTERACTION BETWEEN AMITRIPTYLINE AND NEUROLEPTICS.

003461 04-08 CONTEMPORARY VIEWS ON THE ROLE OF NEUROLEPTICS IN THE TREATMENT OF SCHIZOPHRENIA AND THEIR ACTION IN THE CENTRAL-NERVOUS-SYSTEM

003464 04-08 LOW PLASMA LEVELS OF CPZ IN PATIENTS CHRONICALLY TREATED WITH NEUROLEPTICS.

STANDARD AND LONG-ACTING DEPOT NEUROLEPTICS IN CHRONIC SCHIZOPHRENICS: AN 18-MONTH OPEN MULTICENTRIC STUDY. 003471 04-08

THERAPEUTIC ANTAGONISM BETWEEN ANTICHOLINERGICS AND NEUROLEPTICS: POSSIBLE INVOLVEMENT OF CHOLINERGIC MECHANISMS IN SCHIZOPHRENIA.

003473 04-08 PLASMA LEVELS OF NEUROLEPTICS VS CLINICAL RESPONSES. 003601 04-13

ON THE ROLE OF HEMISPHERIC DOMINANCE IN SCHIZOPHRENIA AS MEASURED BY EXTRAPYRAMIDAL SIDE-EFFECTS OF NEUROLEPTICS

003675 04-15 PHARMACOLOGICAL AND THEORETICAL COMPARISON OF HIGH AND LOW POTENCY NEUROLEPTICS.

003687 04-15 ASSESSMENT OF LONG-ACTING NEUROLEPTICS. METHODS AND PROBLEMS.

003693 04-16

PORPHYRIAS: NEUROLOGIC ASPECTS AND THE TREATMENT OF EXACERBATIONS.

IATROGENIC CAUSES OF NEUROLOGIC DISORDERS: PART 2. DRUG-RELATED DYSFUNCTIONS.

003644 04-15 NEUROLOGICAL

PSYCHIATRIC AND NEUROLOGICAL APPLICATIONS OF BETA-BLOCKING

000596 01-10 NEUROLOGICAL DISTURBANCES, NIGROSTRIATE SYNAPSES, AND IONTOPHORETIC DOPAMINE AND APOMORPHINE AFTER HALOPERIDOL 001293 02-03

CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO
ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC
EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE
ANTIPSYCHOTIC DRUGS.

001526 02-06 THE NEUROLOGICAL BASIS OF MOTOR ASYMMETRY FOLLOWING UNILATERAL NIGROSTRIATAL LESIONS IN THE RAT: THE EFFECT OF SECONDARY SUPERIOR COLLICULUS LESIONS.

003200 04-04 NEUROLOGY EXPERIENCES WITH USING THE ANTIDEPRESSANT DIBENZEPIN: NOVERIL, ON NEUROLOGY OUTPATIENTS.

001615 02-10 ANIMAL MODELS IN PSYCHIATRY AND NEUROLOGY.

002366 03-06

NEUROMETABOLIC NEUROMETABOLIC AND BEHAVIOURAL EFFECTS OF HALOPERIDOL IN RELATION TO DRUG LEVELS IN SERUM AND BRAIN. 001430 02-04

NEUROMODULATOR

A NEW NEUROMODULATOR OF THE EXTRAPYRAMIDAL SYSTEM (EPS) 001952 03-02

NEUROMUSCULAR

BARBITURATE-INDUCED CHANGES IN TRANSMITTER RELEASE INDEPENDENT OF TERMINAL SPIKE CONFIGURATION IN THE FROG NEUROMUSCULAR JUNCTION.

000294 01-03 EFFECT OF DIAZEPAM ON THE FROG NEUROMUSCULAR JUNCTION 002171 03-03

EFFECTS OF 4 AMINOPYRIDINE ON NEUROMUSCULAR TRANSMISSION 002991 04-03

MEURON

EFFECT OF BENZODIAZEPINES ON CENTRAL SEROTONERGIC NEURON SYSTEMS.

000418 01-04 SUPPRESSION OF CAUDATE NEURON ACTIVITIES BY MORPHINE AND THE INVOLVEMENT OF DOPAMINERGIC NEUROTRANSMISSION

001985 03-03 THE HUMAN PLATELET AS A MODEL FOR THE DOPAMINERGIC NEURON: KINETIC AND PHARMACOLOGIC PROPERTIES AND THE ROLE OF AMINE STORAGE GRANULES.

002596 03-13 CHRONIC NEUROLEPTIC USE AND PERIPHERAL MOTOR NEURON DAMAGE 002671 03-15

NEURONAL

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON PENTOBARBITAL-INDUCED DECREASE IN CHOLINERGIC NEURONAL

000259 01-03 ALTERATION OF THE NEURONAL RESPONSE TO AMPHETAMINE IN THE NEOSTRIATUM BY PRETREATMENT WITH A CENTRALLY ACTING

000298 01-03 NEURONAL LIPOFUSCIN IN CENTROPHENOXINE TREATED RATS. 000303 01-03

THE EFFECT OF DIPHENYLHYDANTOIN ON CENTRAL CATECHOLAMINE CONTAINING NEURONAL SYSTEMS.

THE EFFECT OF BARBITURATE AND PROCAINE ON GLIAL AND NEURONAL CONTRIBUTIONS TO EVOKE CORTICAL STEADY POTENTIAL SHIFTS. 001219 02-03

SENSITIVITY TO PSYCHOACTIVE DRUGS AND THE SEROTONERGIC NEURONAL SYSTEM.

001302 02-04 DELIMITATION OF NEURONAL SUBSTRATES NECESSARY FOR THE ANALGESIC ACTION OF BACLOFEN AND MORPHINE.

002132 03-03 THE EFFECTS OF SP-111, A WATER-SOLUBLE THC DERIVATIVE, ON NEURONAL ACTIVITY IN THE RAT BRAIN.

002150 03-03

NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-ET STIMULATED INCREASES IN CYCLIC-AMP. I. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE IN EXPONENTIAL GROWTH PHASE.

002836 04-03 THE NEURONAL ORIGIN OF PROSTAGLANDIN RELEASED FROM THE RABBIT PORTAL VEIN IN RESPONSE TO ELECTRICAL STIMULATION 002933 04-03

NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. II. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE TREATED WITH DIBUTYRYL-CYCLIC-AMP. 003026 04-03

5 GUANYLYLIMIDODIPHOSPHATE ACTIONS ON ADENYLATE-CYCLASE IN HOMOGENATES OF RAT CEREBRAL-CORTEX PLUS NEURONAL AND CAPILLARY FRACTIONS

003038 04-03 THE STRIATAL DOPAMINERGIC FUNCTION IS MEDIATED BY THE INHIBITION OF A NIGRAL, NONDOPAMINERGIC NEURONAL SYSTEM VIA A STRIO-NIGRAL GABAERGIC PATHWAY.

NEURONES

EXCITATORY ACTION OF THE MESOLIMBIC DOPAMINE SYSTEM ON

000045 01-03 EVIDENCE FOR AN INTRASTRIATAL GABAERGIC INFLUENCE ON DOPAMINE

000050 01-03 STEREOSPECIFIC ACTIONS OF MORPHINE ON SINGLE NEURONES IN THE BRAINSTEM OF THE RAT.

000060 01-03 AN EXCITATORY ACTION OF IONTOPHORETICALLY ADMINISTERED LITHIUM ON MAMMALIAN CENTRAL NEURONES

000135 01-03 THE ACTIONS OF CHOLINOMIMETICS AND CATECHOLAMINES ON RAT SUBSTANTIA-NIGRA NEURONES

ACTIVITY OF VESTIBULO-OCULOMOTOR NEURONES DURING SACCADIC EYE MOVEMENTS INDUCED BY RESERPINE. 000199 01-03 ANTAGONISM OF BIOGENIC AMINE-INDUCED DEPRESSION OF CEREBRAL CORTICAL NEURONES BY NA-K-ATPASE INHIBITORS.

THE ROLE OF ASCENDING AND DESCENDING 5 HYDROXYTRYPTAMINE NEURONES IN CENTRAL CONTROL OF PAIN SENSITIVITY.

BURST FIRING OF CEREBELLAR PURKINJE NEURONES INDUCED BY **BENZODIAZEPINES**

001061 02-03 THE EFFECT OF NALOXONE ON THE EXCITATION OF DORSAL-HORN
NEURONES OF THE CAT BY NOXIOUS AND NONNOXIOUS CUTANEOUS

O01102 02-03
SUBSTITUTED AMPHETAMINE DERIVATIVES, II. BEHAVIOURAL EFFECTS IN MICE RELATED TO MONOAMINERGIC NEURONES

DIFFERENTIAL EXCITATORY AND INHIBITORY EFFECTS OF OPIATES ON MONNOCICEPTIVE AND NOCICEPTIVE NEURONES IN THE SPINAL CORD THE CAT.

001966 03-03 OPIATE WITHDRAWAL SIGNS IN SINGLE MYENTERIC NEURONE 002118 03-03

SELECTIVE REDUCTION BY NORADRENALINE AND 5
HYDROXYTRYPTAMINE OF NOCICEPTIVE RESPONSES OF CAT DORSAL-HORN NEURONES

002246 03-04 COMPARISON OF THE RESPONSES OF SINGLE CORTICAL NEURONES TO TYRAMINE AND NORADRENALINE: EFFECTS OF DESIPRAMINE.

RESPONSES OF SINGLE CORTICAL NEURONES TO NORADRENALINE AND DOPAMINE.

EFFECTS OF DOPAMINE AGONISTS ON NEURONES IN THE CAUDATE NUCLEUS AND CEREBRAL-CORTEX OF CATS CHRONICALLY TREATED

002829 04-03 D ALPHA-AMINOADIPATE, ALPHA-EPSILON-DIAMINOPIMELIC-ACID AN H-966 AS ANTAGONISTS OF AMINO-ACID-INDUCED AND SYNAPTIC EXCITATION OF MAMMALIAN SPINAL NEURONES IN VIVO.

EFFECTS OF MORPHINE ON BRAINSTEM NEURONES IN NAIVE AND CHRONIC MORPHINE TREATED RATS, AND EFFECTS OF PCPA.
002841 04-03

PHARMACOLOGICAL AND ELECTROPHYSIOLOGICAL STUDIES OF MORPHINE AND ENKEPHALIN ON RAT SUPRASPINAL NEURONES AND CAT SPINAL NEURONES

O02883 04-03
ANGIOTENSIN RECEPTIVE NEURONES IN THE SUBFORNICAL ORGAN.
STRUCTURE-ACTIVITY RELATIONS.

002906 04-03 PHARMACOLOGICAL CHARACTERIZATION OF THE EXCITATORY CHOLINERGIC RECEPTORS OF RAT CENTRAL NEURONES.

003006 04-03 DEPRESSANT ACTIONS OF METHIONINE-ENKEPHALIN AND SOMATOSTATIN IN CAT DORSAL-HORN NEURONES ACTIVATED BY NOXIOUS STIMULI

003059 04-03 INTERACTIONS BETWEEN GUANINE DERIVATIVES AND NOREPINEPHRINE ON NEURONES OF THE MAMMALIAN CEREBRAL-CORTEX. 003101 04-03

NEURONS ANTISERUMS TO NEURONS AND TO OLIGODENDROGLIA FROM MAMMALIAN BRAIN.

000014 01-01 EVIDENCE FOR NOREPINEPHRINE MEDIATED COLLATERAL INHIBITION OF LOCUS-COERULEUS NEURONS.

THE EFFECTS OF NORTRIPTYLINE AND MESORIDAZINE ON NEURONS AND GLIA IN VITRO.

000130 01-03 REGULATORY ROLE OF GABA NEURONS ON THE ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE BY HALOPERIDOL. (UNPUBLISHED

000132 01-03 REGIONAL DIFFERENCES IN THE SENSITIVITY OF CHOLINERGIC NEURONS TO DOPAMINERGIC DRUGS AND QUIPAZINE IN THE RAT STRIATUM. 000134 01-03

EFFECTS OF MORPHINE AND HALOPERIDOL ON THE ELECTRICAL ACTIVITY OF RAT NIGROSTRIATAL NEURONS.

000154 01-03 DIFFERENTIAL EFFECT OF VARIOUS 6 HYDROXYDOPA TREATMENTS ON THE DEVELOPMENT OF CENTRAL AND PERIPHERAL NORADRENERGIC MEURONS

TYROSINE-HYDROXYLASE: DELAYED ACTIVATION IN CENTRAL MORADRENERGIC NEURONS AND INDUCTION IN ADRENAL MEDULLA ELICITED BY STIMULATION OF CENTRAL CHOLINERGIC RECEPTORS.

000183 01-03

ACTIONS OF IONTOPHORETIC PHENYTOIN AND MEDAZEPAM ON HIPPOCAMPAL NEURONS.

003325 04-04

GRANULAR AND EXTRAGRANULAR ACTION OF PSYCHOTROPIC DRUGS ON MONOAMINERGIC NEURONS.

000252 01-03 ANTIDROMICALLY IDENTIFIED SEROTONERGIC NEURONS IN THE RAT MIDBRAIN RAPHE: EVIDENCE FOR COLLATERAL INHIBITION.

MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND NORADRENERGIC NEURONS IN NORMAL AND BRAIN LESIONED RATS.

MODELS TO STUDY DRUG EFFECTS ON THE INTEGRATED FUNCTION OF GABAERGIC, PEPTIDERGIC (SUBSTANCE-P) AND DOPAMINERGIC NEURONS. (UNPUBLISHED PAPER).

000499 01-06 THE EFFECTS OF HYPOTHALAMIC DEAFFERENTATION ON THE HALOPERIDOL-INDUCED ACTIVATION OF TUBEROINFUNDIBULAR DOPAMINE NEURONS.

SELECTIVITY OF H3-BIOGENIC AMINE RELEASE BY D.L. AMPHETAMINE AND DRUGS THAT INTERACT WITH SEROTONERGIC NEURONS.

001161 02-03 INFLUENCE OF CHLORPROMAZINE AND TRIFLUOPERAZINE ON NEURONS OF AN ISOLATED SLAB OF RABBIT CEREBRAL-CORTEX.

001205 02-03 THE ACTION OF BACLOFEN ON NEURONS OF THE SUBSTANTIA-NIGRA AND OF THE VENTRAL TEGMENTAL AREA.

EFFECTS OF LERGOTRILE (LER), AN ERGOT DERIVATIVE, ON ACTIVITY OF SUBSTANTIA-NIGRA PARS COMPACTA DOPAMINE (DA) NEURONS. 001278 02-03

DRUGS AFFECTING DOPAMINE NEURONS AND YAWNING BEHAVIOR 001422 02-04

VARIOUS EFFECTS OF D AMPHETAMINE IN RATS WITH SELECTIVE LESIONS OF BRAIN NORADRENALINE CONTAINING NEURONS OR TREATED WITH PENFLURIDOL.

001437 02-04 SOMATOSTATIN: ELECTRON MICROSCOPE IMMUNOHISTOCHEMICAL LOCALIZATION IN SECRETORY NEURONS OF RAT HYPOTHALAMUS

001948 03-01 DEPENDENCE OF THE INFLUENCE OF EPINEPHRINE ON THE EXCITABILITY OF GIANT NEURONS ON ITS CONCENTRATION.

001967 03-03 NEUROCHEMICAL MECHANISMS OF CENTRAL ACTION OF MORPHINE ON FUNCTIONS OF SINGLE NEURONS IN THE MIDBRAIN RETICULAR FORMATION.

001973 03-03 EFFECT OF DIAZEPAM ON PULSE ACTIVITY OF NEURONS OF THE SENSORIMOTOR AND OPTIC AREAS OF THE RAT CEREBRAL-CORTEX

001978 03-03 EFFECTS OF MORPHINE ON ELECTRICAL ACTIVITY OF SINGLE MYENTERIC NEURONS IN CAT SMALL BOWEL.

STUDIES ON THE ROLE OF FOREBRAIN CATECHOLAMINE NEURONS IN EXPLORATORY BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).

002012 03-03 EFFECTS OF MORPHINE ON AXONAL TRANSPORT IN NIGROSTRIATAL NEURONS.

002093 03-03 EFFECTS OF DIHYDROERGOTOXINE-MESYLATE ON AGING NEURONS IN

002112 03-03 MESOLIMBIC DOPAMINE NEURONS: EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DESTRUCTION AND RECEPTOR BLOCKADE ON DRUG-INDUCED

002258 03-04 EFFECTS OF ANESTHETICS ON CEREBELLAR NEURONS RECORDED CHRONICALLY AFTER HARMALINE.

REGIONAL SENSITIVITY OF PRIMATE BRAIN DOPAMINERGIC NEURONS TO HALOPERIDOL: ALTERATIONS FOLLOWING CHRONIC TREATMENT.

002812 04-03 MULTIPLE MEMBRANE ACTIONS OF ENKEPHALIN REVEALED USING CULTURED SPINAL NEURONS.

002816 04-03 EFFECTS OF ACETYLCHOLINE, SODIUM-GLUTAMATE AND GABA ON THE DISCHARGE OF SUPRAOPTIC NEURONS IN THE RAT.

002830 04-03 BIOCHEMICAL AND MORPHOLOGICAL EFFECTS OF TESTOSTERONE TREATMENT ON DEVELOPING SYMPATHETIC NEURONS.

002894 04-03 EFFECTS OF ANGIOTENSIN-II AND ACETYLCHOLINE ON NEURONS IN THE PREOPTIC AREA.

002935 04-03 EFFECT OF SOMATOSTATIN (SRIF) AND L GLUTAMATE ON NEURONS OF THE SENSORIMOTOR CORTEX IN AWAKE HABITUATED RABBITS. 002958 04-03
CAPSAICIN-INDUCED DEPLETION OF SUBSTANCE-P FROM PRIMARY

SENSORY NEURONS. 002965 04-03 EVIDENCE OF AN INTERACTION BETWEEN SEROTONINERGIC AND CHOLINERGIC NEURONS IN THE CORPUS-STRIATUM AND HIPPOCAMPUS OF THE RAT BRAIN.

003074 04-03

CNS SITE OF CLONIDINE-INDUCED HYPOTENSION: A MICROIONTOPHORETIC STUDY OF BULBAR CARDIOVASCULAR NEURONS.

003086 04-03 OPIATE RECEPTORS FOR BEHAVIORAL ANALGESIA RESEMBLE THOSE RELATED TO THE DEPRESSION OF SPINAL NOCICEPTIVE NEURONS. 003142 04-03

DEPRESSION OF PRIMATE SPINOTHALAMIC TRACT NEURONS BY IONTOPHORETIC APPLICATION OF 5 HYDROXYTRYPTAMINE.

003251 04-04 TRANIGRAL KAINIC-ACID: EVIDENCE FOR NIGRAL NONDOPAMINERGIC NEURONS CONTROLLING POSTURE AND BEHAVIOR IN A MANNER OPPOSITE TO THE DOPAMINERGIC ONES.

STRIATAL NONDOPAMINERGIC NEURONS: POSSIBLE INVOLVEMENT IN FEEDING AND DRINKING BEHAVIOR.

EFFECT OF METERGOLINE, P-CHLOROPHENYLALANINE AND DOPA ON DELAYED RESPONSE IN CATS AND THE RELATIONSHIP BETWEEN THE MESOLIMBIC AND NIGROSTRIATAL NEURONS.

003339 04-04 A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS. 003608 04-13

PERIPHERAL DIABETIC NEUROPATHY TREATED WITH AMITRIPTYLINE AND FLUPHENAZINE.

001705 02-14 NEUROPATHY ASSOCIATED WITH AMITRIPTYLINE: BILATERAL FOOTDROP 001753 02-15

NEUROPHARMACOLOGICAL
BENZHYDRYL PIPERAZINES: A NEUROPHARMACOLOGICAL AND
PSYCHOPHARMACOLOGICAL EVALUATION. (PH.D. DISSERTATION) 001427 02-04 TAILS OF STRESS RELATED BEHAVIOR: A NEUROPHARMACOLOGICAL

002359 03-06

NEUROPHARMACOLOGICAL STUDIES ON THE NIGROSTRIATAL AND RAPHE STRIATAL SYSTEM IN THE RAT. 002882 04-03

NEUROPHARMACOLOGICAL AND BEHAVIORAL EVALUATION OF PROSTAGLANDIN-E2 AND 11 THIOL-11-DESOXYPROSTAGLANDIN-E2 IN THE MOUSE AND RAT. 003173 04-04

THE NEUROPHARMACOLOGICAL ACTIONS OF AMOXAPINE.

003235 04-04

NEUROPHARMACOLOGICALLY
SHORT-TERM MEMORY: A NEUROPHARMACOLOGICALLY DISTINCT
PROCESS.

002189 03-04

NEUROPHARMACOLOGY THE NEUROPHARMACOLOGY OF DEPRESSION.

001573 02-09 NEUROPHYSIOLOGY, NEUROPHARMACOLOGY AND BEHAVIORAL RELATIONSHIPS OF VISUAL SYSTEM EVOKED AFTER-DISCHARGES: A REVIEW.

STUDIES ON THE NEUROPHARMACOLOGY OF THYROTROPIN-RELEASING HORMONE (TRH) AND A NEW TRH ANALOG. 002185 03-03

NEUROPHARMACOLOGY AND BEHAVIOR.

002750 03-17 NEUROPHARMACOLOGY OF AMINO-ACID INHIBITORY TRANSMITTERS

002967 04-03 NEUROPHYSIOLOGICAL PARAMETERS OF DROPERIDOL-INDUCED PSYCHOSES. NEUROPHYSIOLOGICAL

001636 02-12

NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY EFFECTS OF DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF KETAMINE.

NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY THE EFFECTS OF DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF 002363 03-06

NEUROPHYSIOLOGY, NEUROPHARMACOLOGY AND BEHAVIORAL RELATIONSHIPS OF VISUAL SYSTEM EVOKED AFTER-DISCHARGES: A

COMPLICATIONS -- WITH SPECIAL REFERENCE TO OPHTHALMOLOGIC OBSERVATIONS. 001678 02-13

NEUROPSYCHOLOGICAL ACTH4-10 IN THE AMELIORATION OF NEUROPSYCHOLOGICAL SYMPTOMATOLOGY ASSOCIATED WITH SENILE ORGANIC-BRAIN-

002505 03-11 THE IMPORTANCE OF TELEMETRIC RECORDING IN THE STUDY OF NEUROPSYCHOLOGICAL FUNCTION IN EPILEPTICS.

002606 03-14

002760 03-17

003542 04-10

NEUROPSYCHOPHARMACOLOGICAL FETAL DISTRIBUTION OF NEUROPSYCHOPHARMACOLOGICAL **AGENTS** 000069 01-03

SENESCENT BRAIN: CURRENT STATUS AND IMPLICATION IN NEUROPSYCHOPHARMACOLOGY.

001905 02-17 NEUROPSYCHOTROPIC
INFLUENCE OF SOME NEUROPSYCHOTROPIC DRUGS ON THE BEHAVIOURAL MODIFICATIONS INDUCED BY 3 ACETYLPYRIDINE IN

001358 02-04 NEUROREGULATORS BEHAVIORAL NEUROCHEMISTRY: NEUROREGULATORS AND BEHAVIORAL STATES. 003616 04-14

NEUROSECRETORY
EFFECT OF LITHIUM-CHLORIDE ON THE NEUROSECRETORY SYSTEM OF THE RAT HYPOTHALAMUS. 001525 02-05

NEUROSES DOXEPIN IN THE TREATMENT OF NEUROSES: A COMPARATIVE CLINICAL STUDY OF DOXEPIN, CHLORDIAZEPOXIDE, HYDROXYZINE, MEPROBAMATE, AND PHENOBARBITAL.

000614 01-10 CLOSING REMARKS AT A SYMPOSIUM ON OBSESSIVE-COMPULSIVE NEUROSES AND PHOBIC DISORDERS.

A COMPARATIVE CLINICAL STUDY FOR THE EVALUATION OF ANTIANXIETY AGENTS, (LORAZEPAM, DIAZEPAM AND PLACEBO), IN

000599 01-10 EFFECT OF PSYCHOTROPIC DRUGS ON THE DEVELOPMENT OF DEFENSE CONDITIONED REFLEX DURING EXPERIMENTAL NEUROSIS

002204 03-04 TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH CLOMIPRAMINE (ANAFRANIL).

002474 03-10 CLOMIPRAMINE (ANAFRANIL) IN DEPRESSIVE PATIENTS WITH OBSESSIVE

NEUROSIS. 002491 03-10 A COMPARISON OF CLOMIPRAMINE HYDROCHLORIDE (ANAFRANIL) AND BEHAVIOUR THERAPY IN THE TREATMENT OF OBSESSIVE NEUROSIS.

A PRELIMINARY REPORT ON CLINICAL RESPONSE AND PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN OBSESSIVE-COMPULSIVE NEUROSIS.

002493 03-10 EFFECTIVENESS OF SCH-12679, A BENZAZEPINE, IN THE TREATMENT OF ANXIETY NEUROSIS.

003541 04-10 A PLACEBO-CONTROLLED STUDY OF BROMAZEPAM AND DIAZEPAM IN ANXIETY NEUROSIS.

NEUROTENSIN ADMINISTERED INTRACISTERNALLY INHIBITS RESPONSIVENESS OF MICE TO NOXIOUS STIMULI.

002214 03-04 BIOLOGICAL ACTIVITY OF NEUROTENSIN AND ITS C-TERMINAL PARTIAL

MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING

HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II. 002994 04-03

LOXAPINE IN NEUROTIC ANXIETY: A CONTROLLED TRIAL 002490 03-10 LOXAPINE IN NEUROTIC ANXIETY: SOME MODIFIERS OF TREATMENT RESPONSE

NEUROTOXICITY 6-OHDA AND ITS ANALOGUES: CHEMICAL MECHANISM OF NEUROTOXICITY. STUDY OF THE OXIDATION OF ORTHO-SUBSTITUTED DOPAMINES 000059 01-03

FENFLURAMINE: CUMULATIVE NEUROTOXICITY AFTER CHRONIC TREATMENT WITH LOW DOSAGES IN THE RAT.

STRUCTURE-ACTIVITY RELATIONS FOR THE NEUROTOXICITY OF KAINIC-ACID DERIVATIVES AND GLUTAMATE ANALOGUES.

EFFECT OF AN ANTIPSYCHOTIC AND OTHER CLASSES OF DRUGS ON SPONTANEOUS LOCOMOTOR ACTIVITY AND NEUROTOXICITY IN MICE

LITHIUM NEUROTOXICITY. 1. THE CONCENTRATION OF LITHIUM IN DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS ATOMIC ABSORPTION SPECTROPHOTOMETRY.

NEUROTOXIN ENTRY OF BETA-N-OXALYL-L-ALPHA-BETA-DIAMINOPROPIONIC-ACID, THE TTRY OF BETA-N-OXALYL-L-ALPHA-BETA-DIAMETERAL-NERVOUS-LATHYRUS-SATIVUS NEUROTOXIN INTO THE CENTRAL-NERVOUS-SYSTEM OF THE ADULT RAT, CHICK AND THE RHESUS MONKEY. 003061 04-03

NEUROTRANEMISSION
REGULATION OF NIGROSTRIATAL DOPAMINERGIC NEUROTRANSMISSION

EFFECTS ON HYPOTHALAMIC SELF-STIMULATION OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION INJECTED INTO NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM OF RATS.

SUPPRESSION OF CAUDATE NEURON ACTIVITIES BY MORPHINE AND THE INVOLVEMENT OF DOPAMINERGIC NEUROTRANSMISSION.

NEUROTRANSMISSION AND DISTURBED BEHAVIOR. 002782 03-17

NEUROTRANSMITTER
EFFECT OF CANNABINOIDS ON NEUROTRANSMITTER UPTAKE, ATPASE ACTIVITY AND MORPHOLOGY OF MOUSE BRAIN SYNAPTOSOMES. 000143 01-03

NEUROTRANSMITTER PRECURSOR AMINO-ACIDS IN THE TREATMENT OF MULTIINFARCT DEMENTIA AND ALZHEIMERS DISEASE. 000647 01-11

NEUROLEPTIC INFLUENCE ON VARIOUS NEUROTRANSMITTER

BRAIN NEUROTRANSMITTER RECEPTORS AFTER LONG-TERM HALOPERIDOL: DOPAMINE, ACETYLCHOLINE, SEROTONIN, ALPHANORADRENERGIC AND NALOXONE RECEPTORS.

001200 02-03 DYNAMICS OF BLOOD NEUROTRANSMITTER LEVEL AS EVIDENCE OF HIGHER NERVOUS ACTIVITY CHANGES DURING CHRONIC ADMINISTRATION OF SEDUXEN.

NEUROTRANSMITTER METABOLITES IN THE CEREBROSPINAL FLUID OF

MAN FOLLOWING PHYSOSTIGMINE. 001653 02-13 PSYCHOTROPIC DRUGS: MECHANISM OF ACTION AT THE

NEUROTRANSMITTER LEVEL. 001684 02-13 AMINE NEUROTRANSMITTER STUDIES AND PSYCHIATRIC ILLNESS: TOWARD MORE MEANINGFUL DIAGNOSTIC CONCEPTS. (UNPUBLISHED

001893 02-17 BRAIN NEUROTRANSMITTER RECEPTORS AND CHRONIC ANTIPSYCHOTIC DRUG TREATMENT: A MODEL FOR TARDIVE-DYSKINESIA.

002061 03-03
NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. I. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE IN EXPONENTIAL GROWTH PHASE.

002836 04-03 NEUROLEPTIC BLOCKADE OF THE EFFECT OF VARIOUS **NEUROTRANSMITTER SUBSTANCES.**

002910 04-03 DRUGS AFFECTING THE CENTRAL-NERVOUS-SYSTEM: EFFECTS OF PEMOLINE, AND TRICYCLIC ANTIDEPRESSANTS ON NERVE TERMINAL ADENOSINE-TRIPHOSPHATASE ACTIVITIES AND NEUROTRANSMITTER

002923 04-03
NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED
INCREASES IN CYCLIC-AMP. II. CHARACTERIZATION OF A CULTURED
NEURONAL CELL LINE TREATED WITH DIBUTYRYL-CYCLIC-AMP.

NEUROTRANSMITTER MECHANISMS DURING MENTAL ILLNESS INDUCED BY ALTERATIONS IN THYROID FUNCTION.

003636 04-14 NEUROTRANSMITTER THEORY AND ORTHOMOLECULAR PRACTICE 003725 04-17

NEUROLEPTIC DRUGS AND NEUROTRANSMITTER RECEPTORS 003728 04-17

NEUROTRANSMITTERS NEUROTRANSMITTERS AND RESPONSE SUPPRESSION

000464 01-04 BRAIN MECHANISMS ASSOCIATED WITH THERAPEUTIC ACTIONS OF BENZODIAZEPINES: FOCUS ON NEUROTRANSMITTERS.

000741 01-13 INTRACEREBRAL NEUROTRANSMITTERS AND CONDITIONED REFLEX PERFORMANCE.

001508 02-05

NALOXONE PRECIPITATED WITHDRAWAL REVEALS SENSITIZATION TO NEUROTRANSMITTERS IN MORPHINE-TOLERANT/DEPENDENT RATS. MORPHINE-LIKE PEPTIDES OF BRAIN AND THEIR RELATION TO HORMONAL NEUROTRANSMITTERS. 001650 02-13 MANIC-DEPRESSIVE ILLNESS AND NEUROTRANSMITTERS. CENTRAL CATECHOLAMINE NEUROTRANSMITTERS AND PSYCHOACTIVE 002731 03-17 ANTIPSYCHOTIC DRUGS, NEUROTRANSMITTERS, AND SCHIZOPHRENIA.
002736 03-17
THE BIOLOGY OF AFFECTIVE-ILLNESS: AMINE NEUROTRANSMITTERS AND 002746 03-17 THE EFFECT OF INTRAHIPPOCAMPAL KAINIC-ACID INJECTIONS AND SURGICAL LESIONS ON NEUROTRANSMITTERS IN HIPPOCAMPUS AND 002911 04-03 H3-GLYCOGEN HYDROLYSIS IN BRAIN SLICES: RESPONSES TO NEUROTRANSMITTERS AND MODULATION OF NORADRENALINE RECEPTORS 003054 04-03 TRACE AMINES AND ALTERNATIVE NEUROTRANSMITTERS IN THE CENTRAL-NERVOUS-SYSTEM. 003698 04-17 NEUROTROPIC
COLCHICINE BLOCKS NEUROTROPIC REGULATION OF THE RESTING
MEMBRANE POTENTIAL IN REINNERVATING SKELETAL MUSCLE
2002 000262 01-03 EFFECT OF NEUROTROPIC DRUGS ON SLEEP DISTURBANCES CAUSED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS. 000795 01-14 INFLUENCE OF NEUROTROPIC DRUGS ON CHANGES OF EVOKED-POTENTIALS AMPLITUDES AFTER STIMULATION OF THE HYPOTHALAMUS. 001318 02-04 NEUROTUBULE
EFFECTS OF PSYCHOTROPIC DRUGS ON NEUROTUBULE ASSEMBLY
0002: 000225 01-03 PIRROXAN IN THE TREATMENT OF THE NEUROVEGETATIVE COMPONENT
OF THE DEPRESSIVE SYNDROME. 003443 04-07 NEUTRAL
DIET AND UPTAKE OF ALDOMET BY THE BRAIN: COMPETITION WITH
NATURAL LARGE NEUTRAL AMINO-ACIDS.

001185 (001185 02-03 NEUTROPENIA
LITHIUM-CARBONATE ATTENUATION OF CHEMOTHERAPY-INDUCED LITHIUM-CARBONATE IN CHEMOTHERAPY-INDUCED NEUTROPENIA. 001809 02-15 ISOLATION AND CHARACTERIZATION OF () CANNABITRIOL AND (-) 10 ETHOXY-9-HYDROXY-DELTA6A-TETRAHYDROCANNABINOL: TWO NEW CANNABINOIDS FROM CANNABIS-SATIVA L. EXTRACT. 000004 01-01 A NEW SYNTHESIS OF 5 KETO-DIHYDROBENZOTHIAZEPINES AND A PRELIMINARY STUDY OF THEIR BIOLOGICAL PROPERTIES. 000016 01-02 AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT.

Psychopharmacology Abstracts 3 AMINOTETRAHYDROCARBAZOLES AS A NEW SERIES OF CENTRAL-NERVOUS-SYSTEM AGENTS. 000203 01-03 A NEW VIEW OF THE STRUCTURAL RELATIONSHIP BETWEEN LSD AND MESCALINE. A NEW ANOREXIGEN ASSAY: STRESS-INDUCED HYPERPHAGIA IN RATS. DO0468-01-04 INTERACTION OF DRUGS WITH APOMORPHINE, TRYPTAMINE AND NOREPINEPHRINE. A NEW IN VIVO APPROACH: THE ATN-TEST IN RATS. 000502 01-06 NEW DRUG TESTING IN THE CONSENTING ADULT. 000509 01-07 CLINICAL EXAMINATION OF THE NEW ANTIPSYCHOTIC CLOZAPINE 000514 01-07 CONTROLLED TRIAL OF A NEW ANTIGEPRESSIVE, AMOXAPINE, IN COMPARISON WITH AMITRIPTYLINE. 000555 01-09 MAPROTILINE -- A DOUBLE-BLIND STUDY OF A NEW TETRACYCLIC ANTIDEPRESSANT IN SEVERE DEPRESSION. 000574 01-09 EFFECT OF A NEW BENZODIAZEPINE DERIVATE, CLOBAZAM, IN ANXIOUS PATIENTS WITH GASTROINTESTINAL DISORDERS. 000604 01-10 DOUBLE-BLIND TRIALS OF A NEW TRICYCLIC ANTIDEPRESSANT (LOFEPRAMIN) AND A TETRACYCLIC ANTIDEPRESSANT (MAPROTILINE) 000607 01-10 **NEW DIRECTION TO THE AMINE HYPOTHESIS.** 000739 01-13 **NEW EVIDENCE OF SEROTONIN DEFICIENT DEPRESSIONS** 000743 01-13 THE EFFECT OF A NEW BENZODIAZEPINE ON THE POLYGRAPHICALLY MONITORED SLEEP OF NORMAL VOLUNTEERS. 000765 01-14 000943 01-17 NEW TREATMENT FOR HEADACHE: PATHOPHYSIOLOGIC CONSIDERATIONS. 000961 01-17 FROM JOY TO DEPRESSION: NEW INSIGHTS INTO THE CHEMISTRY OF MOODS. 000981 01-17 A NEW HALLUCINOGEN FROM ANDEAN COLOMBIA: IOCHROMA-FUCHSIOIDES. 000983 01-17 PRECLINICAL EVALUATION OF DITA DICHLORO-2-IMIDAZOLINYLTHIOACETOPHENONE-HBR: A NEW ANDREXIGENIC 001020 02-02 STEREOSPECIFIC AND NONSTEREOSPECIFIC EFFECTS OF ()- AN MORPHINE: EVIDENCE FOR A NEW CLASS OF RECEPTORS? AND (-) 001031 02-02 THE PHARMACOLOGY OF A NEW POTENT, LONG-ACTING NEUROLEPTIC, PIELLITIXOL 001035 02-02 CENTRAL PHARMACOLOGY OF A NEW ANTIDEPRESSANT. 001063 02-03 NEUROCHEMICAL PROPERTIES OF DIMOXAMINE (D), A NEW PSYCHOTHERAPEUTIC AGENT. 001073 02-03 A COMPARISON OF THALIDOMIDE AND PENTOBARBITAL METHODS FOR IDENTIFYING NOVEL HYPNOTIC DRUGS 001359 02-04 EFFECTS OF IFC-45, A NEW BENZONAPHTYRIDONE DERIVATIVE WITH ANTIDEPRESSIVE ACTION, ON ACTIVITY OF THE RAT SUPRARENAL GLAND CORTEX. 001522 02-05 A NEW CHRONICALLY CANNULATED CAROTID ARTERY PREPARATION FOR DETERMINATION OF DRUG HALF-LIVES IN THE GUINEA-PIG. 001531 02-06 ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST - A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY. FLUVOXAMINE (DU-23001), A NEW ANTIDEPRESSANT. QUANTITATIVE PHARMACO-ELECTROENCEPHALOGRAPHY AND PILOT CLINICAL TRIALS. 001548 02-07 AN EVALUATION OF A UNIQUE NEW ANTIPSYCHOTIC AGENT, SULPRIDE: EFFECTS ON SERUM PROLACTIN AND GROWTH HORMONE LEVELS. 001554 02-07 ANTIPARKINSONIAN DRUG ADMINISTRATION AND PLASMA LEVELS OF PENFLURIDOL, A NEW LONG-ACTING NEUROLEPTIC. 001559 02-08 NEW ANTIPSYCHOTIC DRUGS.

GILLES-DE-LA-TOURETTE SYNDROME: A NEW CLINICOTHERAPEUTIC

001562 02-08

001630 02-11

000018 01-02

000031 01-02

000080 01-03

000126 01-03

NEW ASPECTS CONCERNING THE MECHANISM OF ACTION OF TRANQUILIZERS. THE INFLUENCE OF SOME TRANQUILIZERS ON PROTEIN AND NUCLEIC-ACID SYNTHESES. 000165 01-03 SOME OLD AND NEW THEORIES IN BIOCHEMICAL PSYCHIATR 000190 01-03

STUDIES IN THE HETEROCYCLIC SERIES. XIII. NEW CNS DEPRESSANTS DERIVED FROM 1,9 DIAZAPHENOXAZINE AND TWO ISOMERIC TRIAZAPHENOTHIAZINE RING SYSTEMS.

ACTION OF S-1432, A NEW PSYCHOTROPIC DRUG, ON THE CENTRAL CHOLINERGIC SYSTEM.

THE PRODUCTION OF AN ALTERNATIVE LABORATORY MODEL OF THE PARKINSON SYNDROME USING A NEW BENZYLIMIDOYLUREA DERIVATIVE LON-954.

EFFECTS OF MIANSERIN, A NEW ANTIDEPRESSANT, ON THE IN VITRO AND IN VIVO UPTAKE OF MONOAMINES.

NEW N 2 HYDROXYALKYL-BENZOMORPHAN DERIVATIVES: SYNTHESIS AND PRELIMINARY PHARMACOLOGY.

A NEW CLASS OF GABA-AGONIST.

DISPOSITION OF KETAZOLAM, A NEW ANXIOLYTIC AGENT, IN MAN. 001655 02-13

RECEPTOR SENSITIVITY MODIFICATION (RSM) — A NEW PARADIGM FOR THE POTENTIAL TREATMENT OF SOME HORMONAL AND TRANSMITTER DISTURBANCES.

O01659 02-13

ANIMAL HYPNOSIS AND HUMAN HYPNOSIS: NEW EXPERIMENTAL
EVIDENCE RELATING TO AN OLD CONTROVERSY.

001711 02-14
ANTIDEPRESSANT AGENTS. 9.3,3 DIPHENYLCYCLOBUTYLAMINES, A NEW
CLASS OF CENTRAL STIMULANTS.

A NEW NEUROMODULATOR OF THE EXTRAPYRAMIDAL SYSTEM (EPS).

PHARMACOLOGICAL PROFILE OF A NEW PSYCHOTHERAPEUTIC AGENT: 4-P FLUOROPHENYL-METHOXYPHENYL-PIPERAZINOETHYLOXAZOLINONE

OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINES IN L-DOPA TREATED PARKINSONIAN PATIENTS.

001994 03-03

A NEW MECHANISM OF TRICYCLIC ANTIDEPRESSANT ACTION. BLOCKADE
OF PROSTAGLANDIN DEPENDENT CALCIUM MOVEMENTS.

002043 03-03
STUDIES ON THE NEUROPHARMACOLOGY OF THYROTROPIN-RELEASING
HORMONE (TRH) AND A NEW TRH ANALOG.

D02185 03-03
BEHAVIOURAL DESPAIR IN RATS: A NEW MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.

A NEW APPROACH TO THE HORMONAL TREATMENT OF IMPOTENTIA-

D02386 03-07 A NEW ANTIDEPRESSANT BUTRIPTYLINE: PLASMA LEVELS AND CLINICAL

002423 03-09
HORMONE RESPONSES TO METHYLAMPHETAMINE IN DEPRESSION: A
NEW APPROACH TO THE NORADRENALINE DEPLETION HYPOTHESIS.
002424 03-09

CLINICAL TRIAL OF FLUVOXAMINE: A NEW SEROTONERGIC ANTIDEPRESSANT.

002470 03-09

EVALUATION OF A NEW IMMUNOASSAY FOR DETERMINATION OF PHENYTOIN AND PHENOBARBITAL: RESULTS OF A EUROPEAN COLLABORATIVE CONTROL STUDY.

COLLABORATIVE CONTROL STUDY.

O02529 03-11

NEW APPROACH TO THE REHABILITATION OF THE HARD CORE DRUG
ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY

STUDY.

O02531 03-1

ASSESSMENT OF SPONTANEOUS AND DRUG-INDUCED CHANGES IN VIGILANCE BY MEANS OF A NEW MODIFICATION OF THE SHORT TIME SPECTRAL ANALYSIS OF THE EEG.

SPECTRAL ANALYSIS OF THE EEG.

O02627 03-14

OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINE

ALKALOIDS IN L-DOPA TREATED PARKINSONIAN PATIENTS. 002655 03-15
CREATIVITY IN NEW DRUG DEVELOPMENT: AN ACADEMIC CHALLENGE. 002745 03-17

BIOCHEMISTRY OF MENTAL DISORDERS: NEW VISTAS.

EFFECTS ON STRIATAL AND MESOLIMBIC DOPAMINE SYSTEMS OF A NEW POTENTIAL ANTIPSYCHOTIC DRUG -- MEZILAMINE -- WITH WEAK

DISCRIMINATIVE PROPERTIES OF CHLORDIAZEPOXIDE: A NEW METHOD

002905 04-03
REGIONAL LOCALIZATION OF HALOPEMIDE, A NEW PSYCHOTROPIC
AGENT. IN THE RAT BRAIN.

A NEW ANIMAL MODEL FOR SCHIZOPHRENIA: INTERACTIONS WITH

ADRENERGIC MECHANISMS.

003175 04-04
PHYSALAEMIN, A NEW POTENT ANTIDIPSOGEN IN THE RAT.

003207 04-04
INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETINE ON
HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE
(PCA) AND 4, ALPHA DIMETHYL-M-TYRAMINE (H-77-77).

003271 04-04
THE PSYCHOPHARMACOLOGICAL PROPERTIES OF PINAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.

THE USE OF PENFLURIDOL ACCORDING TO A NEW DOSAGE REGIMEN IN THE ACUTE, STABILIZATION AND MAINTENANCE PHASES OF PSYCHOSIS.

003491 04-09 A CONTROLLED TRIAL OF A NEW ANTIDEPRESSANT, WIN-27147-2. 003523 04-09 THE EFFECTS OF A NEW BENZODIAZEPINE DERIVATIVE, ID-540, ON THE AVERAGED PHOTOPALPERRAL REFLEX IN MAN.

O03610 04-13
CARDIOLOGICAL EFFECTS OF NOMIFENSINE, A NEW ANTIDEPRESSANT.
003645 04-15

PHARMACOLOGICAL INVESTIGATIONS ON ETOPERIDONE, A NEW PSYCHOTROPIC AGENT. 003720 04-17

NEWBORN

PHARMACOKINETIC OBSERVATIONS OF PHENYTOIN DISPOSITION IN THE NEWBORN AND YOUNG INFANT.

SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT AND NEWBORN RATS.

THE EFFECTS OF OBSTETRICAL MEDICATION ON THE BEHAVIOR OF ISRAELI NEWBORN INFANTS. AND SOME COMPARISONS WITH URUGUAYAN AND AMERICAN INFANTS.

002673 03-15

NGF-INDUCED

NGF-INDUCED ALTERATIONS IN PROTEIN SECRETION AND SUBSTRATE

ATTACHED MATERIAL OF A CLONAL NERVE CELL LINE.

PROPERTIES OF THE PERIPHERAL OPIATE RECEPTORS IN THE CAT
NICITATING MEMBRANE.

O01113 02-03

NICOTINAMIDE

ALTERATION OF L-DOPA EFFECT ON BRAIN DOPA AND DOPAMINE LEVELS

WITH NICOTINIC-ACID AND N METHYL NICOTINAMIDE. (PH.D.

DISSERTATION).

O01969 03-03
TRYPTOPHAN NICOTINAMIDE COMBINATION IN THE TREATMENT OF NEWLY ADMITTED DEPRESSED PATIENTS.

NICOTINE
EFFECTS OF CARBACHOL AND NICOTINE INJECTED INTO THE CEREBRAL

FFECTS OF CARBACHOL AND NICOTINE INJECTED INTO CATS.
VENTRICLES ON ELECTROMYOGRAM OF CONSCIOUS CATS.
000052 01-03
INFLUENCES OF GENOTYPE AND SEX ON BEHAVIORAL TOLERANCE TO

NICOTINE IN MICE.

000376 01-04

ANTAGONISM BY CHOLINERGIC DRUGS OF BEHAVIOURAL EFFECTS IN
CATS OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC DRUG AND

CATS OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC DRUG AND ENHANCEMENT BY NICOTINE.

O00404 01-04
THE EFFECT OF NICOTINE ON THE ACETYLCHOLINE CONTENT IN MOUSE

THE EFFECT OF NICOTINE ON THE ACETYLCHOLINE CONTENT IN MOUSE BRAIN REGIONS.

001197 02-03

ENHANCEMENT OF SEXUAL BEHAVIOR IN THE FEMALE RAT BY NICOTINE.

O01360 02-04

A DESCRIPTION OF THE NICOTINE STIMULUS AND TESTS OF ITS

GENERALIZATION TO AMPHETAMINE. 002210 03-04

APPRAISAL OF THE EFFECT OF IV NICOTINE ON THE CNS.

002579 03-13
DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE: ORGANIC

DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE: ORGANIC MOLECULAR MECHANISMS AND NEUROCHEMICAL EVENTS.

003254 04-04

SCHEDULE-INDUCED SELF-INJECTION OF NICOTINE, METHADONE AND HEROIN BY NAIVE ANIMALS.

SELF-REPORTED ALCOHOL AND NICOTINE USE AND THE ABILITY TO CONTROL OCCIPITAL EEG IN A BIOFEEDBACK SITUATION.

CAN CIGARETTE SIZE AND NICOTINE CONTENT INFLUENCE SMOKING AND PUFFING RATES?.

003631 04-14

INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE PAT

CONTROL OF THE RELEASE OF NEWLY SYNTHESIZED H3-5-HYDROXYTRYPTAMINE BY NICOTINIC AND MUSCARINIC RECEPTORS IN RAT HYPOTHALAMIC SLICES.

ACETYLCHOLINE STIMULATION OF THE SYMPATHETIC GANGLIA: EFFECTS
OF TAURINE AND NICOTINIC AND MUSCARINIC GANGLION BLOCK.
000146 01-03

THE ACETYLCHOLINE RECEPTOR IN THE RAT HIPPOCAMPUS, NICOTINIC, MUSCARINIC OR BOTH?.

NICOTINIC-ACID

ALTERATION OF L-DOPA EFFECT ON BRAIN DOPA AND DOPAMINE LEVELS

WITH NICOTINIC-ACID AND N METHYL NICOTINAMIDE. (PH.D.

001969 03-03

TRANSMETHYLATION HYPOTHESIS OF SCHIZOPHRENIA: METHIONINE AND

STUDY OF NIGHT SLEEP DURING LONG-TERM GRADUAL REDUCTION IN NEUROLEPTIC THERAPY IN CHRONIC SCHIZOPHRENICS. 000852 01-15

HT-TIME
A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE
DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON
SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR
PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION.
001787 02-15

A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-DUMMY TECHNIQUE. 003537 04-10

RA-LESIONED
STUDY OF A DOPAMINERGIC POTENTIAL ANTIPARKINSON COMPOUND IN
INTACT AND NIGRA-LESIONED RATS: N-N
PROPYLBUTYLDIHYDROXYPHENYLETHYLAMINE HCL. 001957 03-02

ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY BENZODIAZEPINES.

INTRANIGRAL KAINIC-ACID: EVIDENCE FOR NIGRAL NONDOPAMINERGIC NEURONS CONTROLLING POSTURE AND BEHAVIOR IN A MANNER OPPOSITE TO THE DOPAMINERGIC ONES.

THE STRIATAL DOPAMINERGIC FUNCTION IS MEDIATED BY THE INHIBITION OF A NIGRAL, NONDOPAMINERGIC NEURONAL SYSTEM VIA A STRIO-NIGRAL GABAERGIC PATHWAY.

003325 04-04

NIGROSTRIATAL
REGULATION OF NIGROSTRIATAL DOPAMINERGIC NEUROTRANSMISSION

000100 01-03 EFFECTS OF MORPHINE AND HALOPERIDOL ON THE ELECTRICAL ACTIVITY OF RAT NIGROSTRIATAL NEURONS.

000154 01-03 INVOLVEMENT OF THE DOPAMINE NIGROSTRIATAL SYSTEM IN THE PICROTOXIN EFFECT ON STRIATAL ACETYLCHOLINE LEVELS. 000158 01-03

ACTION OF THE PALMITIC ESTER OF PIPOTIAZINE ON DOPAMINE METABOLISM IN THE NIGROSTRIATAL, MESOLIMBIC AND MESOCORTICAL SYSTEMS.

000258 01-03

SPECIFICITY OF LEARNING DEFICITS PRODUCED BY MICROINJECTIONS OF 6-OHDA INTO THE NIGROSTRIATAL SYSTEM OF THE RAT. 000346 01-04

EFFECTS OF BACLOFEN AND MUSCIMOL ON NIGROSTRIATAL DOPAMINERGIC FUNCTIONS.

000347 01-04 HALOPERIDOL AND CLOZAPINE: SPECIFICITY OF ACTION ON GABA IN THE NIGROSTRIATAL SYSTEM.

001184 02-03 EFFECTS OF MORPHINE ON AXONAL TRANSPORT IN NIGROSTRIATAL NEURONS.

002093 03-03 NEUROPHARMACOLOGICAL STUDIES ON THE NIGROSTRIATAL AND RAPHE STRIATAL SYSTEM IN THE RAT.

002882 04-03 THE NEUROLOGICAL BASIS OF MOTOR ASYMMETRY FOLLOWING
UNILATERAL NIGROSTRIATAL LESIONS IN THE RAT: THE EFFECT OF
SECONDARY SUPERIOR COLLICULUS LESIONS.

EFFECT OF METERGOLINE, P-CHLOROPHENYLALANINE AND DOPA ON DELAYED RESPONSE IN CATS AND THE RELATIONSHIP BETWEEN THE MESOLIMBIC AND NIGROSTRIATAL NEURONS.

003339 04-04 NIGROSTRIATE

NEUROLOGICAL DISTURBANCES, NIGROSTRIATE SYNAPSES, AND IONTOPHORETIC DOPAMINE AND APOMORPHINE AFTER HALOPERIDO. 001293 02-03

NITRAZEPAM

KINETICS AND MECHANISMS OF HYDROLYSIS OF 1,4 BENZODIAZEPINES

III: NITRAZEPAM.

THE INFLUENCE OF ALCOHOL ON THE PERSISTENT EFFECTS ON HUMAN PERFORMANCE OF THE HYPNOTICS MANDRAX AND NITRAZEPAM.

000784 01-14
PHARMACOKINETICS OF NITRAZEPAM IN HUMAN PLASMA AND SALIVA. 001156 02-03

DIFFERENTIATION OF HYPNOTIC ACTION OF NITRAZEPAM AND ESTAZOLAM AND EFFECTS ON BEHAVIOR AND CORTICAL ACTIVITY 001549 02-07

Psychopharmacology Abstracts

A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE
DERIVATIVES (INTRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON
SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR
PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION.
001787 02-15

FLOPPY-INFANT SYNDROME AND MATERNAL DIAZEPAM AND/OR

001835 02-15 PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: THE EFFECT OF PREMEDICATION WITH CYSTAMINE ON PHARMACODYNAMICS AND PHARMACOKINETICS OF NITRAZEPAM.

002317 03-04 PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC
DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF
PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF NITRAZEPAM

002358 03-05 FLUNITRAZEPAM (ROHYPNOL) COMPARED WITH NITRAZEPAM (MOGADON) AND APROBARBITAL AS EVENING PREMEDICATION PRIOR TO ANESTHESIA: A CONTROLLED CLINICAL TRIAL.

THE EFFECT OF NITRAZEPAM ON MANUAL SKILL, GRIP STRENGTH, AND REACTION TIME WITH SPECIAL REFERENCE TO SUBJECTIVE EVALUATION OF EFFECTS ON SLEEP.

002626 03-14

NITROGEN
SYNTHESIS OF SPIROISOBENZOFURANPIPERIDINES AS POTENTIAL
CENTRAL-NERVOUS-SYSTEM AGENTS. 2. COMPOUNDS CONTAINING A
HETERCOATOM ATTACHED TO NITROGEN.

000167 01-03 000167 01-03

BLOOD LEVEL MONITORING OF BENZODIAZEPINES BY GLC USING NITROGEN SENSITIVE DETECTORS. 001860 02-16

MEASUREMENT OF PLASMA AND ERYTHROCYTE CHLORPROMAZINE AND N MONODESMETHYLCHLORPROMAZINE LEVELS BY GAS-CHROMATOGRAPHY WITH A NITROGEN SENSITIVE DETECTOR. 003429 04-06

NITROUS-OXIDE INFLUENCE OF TRANSIENT ISCHEMIA ON MONOAMINE METABOLISM IN THE RAT BRAIN DURING NITROUS-OXIDE AND PHENOBARBITONE

SUPPRESSION BY NITROUS-OXIDE OF VISUAL RESPONSES IN THE CEREBELLAR VERMIS AND SUPERIOR COLLICULUS OF CATS ANESTHETIZED WITH CHLORALOSE.

002897 04-03 NO-PLACEBO
SINGLE-BLIND EVALUATION OF HYPNOTIC ACTIVITY OF
CHLORDESMETHYLDIAZEPAM IN NO-PLACEBO REACTOR MEDICAL

PATIENTS. 002379 03-07

NOCICEPTION
A RELIABLE, FACIAL NOCICEPTION DEVICE FOR UNRESTRAINED, AWAKE
ANIMALS: EFFECTS OF MORPHINE AND TRIGEMINAL COMPLEX

DIFFERENTIAL EXCITATORY AND INHIBITORY EFFECTS OF OPIATES ON NONNOCICEPTIVE AND NOCICEPTIVE NEURONES IN THE SPINAL CORD OF THE CAT.

001966 03-03 SELECTIVE REDUCTION BY NORADRENALINE AND 5
HYDROXYTRYPTAMINE OF NOCICEPTIVE RESPONSES OF CAT DORSAL-HORN NEURONES. 002246 03-04

OPIATE RECEPTORS FOR BEHAVIORAL ANALGESIA RESEMBLE THOSE RELATED TO THE DEPRESSION OF SPINAL NOCICEPTIVE NEURONS. 003142 04-03 NOCICEPTIVE STIMULATION PREVENTS DEVELOPMENT OF TOLERANCE TO NARCOTIC ANALGESIA.

003195 04-04

DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION 003241 04-04

NOCTRAN-10 COMPARISON OF THE EFFECTS OF NOCTRAN-10 ON HOSPITALIZED PATIENTS AND PATIENTS TREATED AT HOME.

001724 001724 02-14

NOCTURNAL

EEG OBSERVATION OF NOCTURNAL DELIRIUM IN A PATIENT TAKING

ANTIDEPRESSANTS AND ANTIPARKINSONS DRUGS.

001773 02-15 THE IMPACT OF CLOMIPRAMINE AND ITS WITHDRAWAL ON SOME NOCTURNAL HORMONE PROFILES -- A PRELIMINARY REPORT. 002572 03-13

TRIAL OF AN ALPHA-ADRENOLYTIC DRUG (INDORAMIN) FOR NOCTURNAL **ENURESIS**

003573 04-11

VOLUME 16, SUBJECT INDEX

Subject Index

003330 04-04

	UR		

PAVOR NOCTURNUS IN A SCHIZOPHRENIC PATIENT: A REVIEW AND CASE STUDY.

002521 03-11

NOISE

BEHAVIOURAL ANTAGONISM BETWEEN CHLORPROMAZINE AND NOISE IN MAN. 002621 03-14

NOMIFENSIN

NOMIFENSIN IN THE TREATMENT OF DEPRESSION: A REPORT ON THE CANADIAN PART OF A TRANSCULTURAL STUDY.

NOMIFENSIN IN THE TREATMENT OF DEPRESSION: A STANDARD-CONTROLLED CLINICAL STUDY.

002415 03-09

NOMIFENSINE

BIOCHEMICAL DIFFERENTIATION OF AMPHETAMINE VS METHYLPHENIDATE AND NOMIFENSINE IN RATS.

000061 01-03

EFFECT OF NOMIFENSINE AND OTHER ANTIDEPRESSANT DRUGS ON
ACETYLCHOLINE TURNOVER IN VARIOUS AREAS OF RAT BRAIN.
001225 02-03

EFFECTS OF NOMIFENSINE (HOE-984) UPON PSYCHOMOTOR ACTIVITY AND INTRACRANIAL SELF-STIMULATION IN THE RAT.

A DOUBLE-BLIND CONTROLLED COMPARATIVE STUDY OF NOMIFENSINE IN DEPRESSION

002419 03-09 CARDIOLOGICAL EFFECTS OF NOMIFENSINE, A NEW ANTIDEPRESSANT. 003645 04-15

NONADDICTING
THE SEARCH FOR A NONADDICTING ANALGESIC: HAS IT BEEN WORTH

IT?. 000025 01-02

PERFORMANCE DIFFERENCES BETWEEN ADDICTS AND NONADDICTS.

000786 01-14

PONALCOHOLIZED

EFFECTS OF LITHIUM ON SEIZURE SUSCEPTIBILITY IN ALCOHOLIZED AND

NONALCOHOLIZED RATS. 001315 02-04

NONAPEPTIDE
INHIBITION OF BRAIN ANGIOTENSIN-I CONVERTING ENZYME BY
BOTHROPS-JARARACA NONAPEPTIDE (SQ-20881) AND A PROLYL
ANALOG (SQ-14225).

NONCATALEPTOGENIC 002818 04-03

RAT STRIATAL METHIONINE-ENKEPHALIN CONTENT AFTER CHRONIC TREATMENT WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTISCHIZOPHRENIC DRUGS.

TURNOVER RATES OF GAMMA-AMINOBUTYRIC-ACID IN SUBSTANTIA-NIGRA, NUCLEUS-CAUDATUS, GLOBUS-PALLIDUS AND NUCLEUS-ACCUMBENS OF RATS INJECTED WITH CATALEPTOGENIC AND NONCATALEPTOGENIC AMPREYCHOTICS.

NONCATALEPTOGENIC ANTIPSYCHOTICS.

002996 04-03

RELATIONSHIP BETWEEN SERUM CONCENTRATIONS OF THIORIDAZINE
AND ITS MAIN NONCONJUGATED METABOLITES AND THE CLINICAL
RESPONSE IN THIORIDAZINE TREATED PATIENTS.

NONCONTINGENT
NONCONTINGENT DISPLACEMENT OF CATECHOLAMINES BY
INTRAVENTRICULAR TYRAMINE: BIPHASIC DOSE-RESPONSE EFFECTS ON
SELF-STIMULATION

DISCRIMINATIVE PROPERTIES OF PENTOBARBITAL AFTER REPEATED NONCONTINGENT EXPOSURE IN GERBILS.

THE EFFECT OF NONCONTINGENT AMPHETAMINE INJECTIONS ON THE EXTINCTION OF FOOD AND DRUG REINFORCED LEVER PRESSING IN

RATS. 001404 02-04
NONCOVALENT

EVIDENCE FOR A NONCOVALENT INTERMOLECULAR INTERACTION OF OPIATES WITH THIAMINE. 001008 02-01

RESPONSES TO INTRAVENOUS HEROIN IN DEPENDENT AND NONDEPENDENT VOLUNTEERS. 000792 01-14

NONDEPRESSED

ANTICHOLINERGIC ACTIVITY OF THE TRICYCLIC ANTIDEPRESSANTS

DESIPRAMINE AND DOXEPIN IN NONDEPRESSED VOLUNTEERS.

003447 04-07

NONDOPAMINERGIC
IMIPRAMINE ANTAGONISM OF APOMORPHINE-INDUCED HYPOTHERMIA:
A NONDOPAMINERGIC INTERACTION.
002133 03-03

INTRANIGRAL KAINIC-ACID: EVIDENCE FOR NIGRAL NONDOPAMINERGIC NEURONS CONTROLLING POSTURE AND BEHAVIOR IN A MANNER OPPOSITE TO THE DOPAMINERGIC ONES.

O03324 04-04
THE STRIATAL DOPAMINERGIC FUNCTION IS MEDIATED BY THE
INHIBITION OF A NIGRAL, NONDOPAMINERGIC NEURONAL SYSTEM
VIA A STRIO-NIGRAL GABAERGIC PATHWAY.

O03325 04-04
STRIATAL NONDOPAMINERGIC NEURONS: POSSIBLE INVOLVEMENT IN
FEEDING AND DRINKING BEHAVIOR

NONESTERIFIED
POSSIBLE CENTRAL DOPAMINERGIC MODULATION OF THE RISE IN
PLASMA CONCENTRATION OF NONESTERIFIED FATTY-ACIDS PRODUCED

PLASMA CONCENTRATION OF NONESTERIFIED FATTY-ACIDS PRODUCED IN THE MOUSE BY (-)TRANS DELTA9-TETRAHYDROCANNABINOL. 002085 03-03

ABOUT A NONFATAL MASSIVE INTOXICATION WITH SUSTAINED-RELEASE THIORIDAZINE. CLINICAL AND THERAPEUTIC PROBLEMS.

MONHYPERACTIVE
HYPERACTIVE AND NONHYPERACTIVE CHILDRENS SELF-DETERMINED
LEVELS OF STIMULATION. (PH.D. DISSERTATION).

NONISOLATED
INTRUDER-EVOKED AGGRESSION IN ISOLATED AND NONISOLATED MICE:
EFFECTS OF PSYCHOMOTOR STIMULANTS AND L-DOPA.

NOHMEDICAL 003298 04-04

PSYCHIATRIC DRUGS FOR THE NONMEDICAL MENTAL HEALTH WORKER.
000953 01-17

NONMONOAMINE-OXIDASE INHIBITOR ANTIDEPRESSANTS AND EPILEPSY: A REVIEW.

NONMARCOTIC

DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND
NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER
EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION.
003241 04-04

BEHAVIORAL AND PHYSIOLOGICAL STUDIES OF NONNARCOTIC ANALGESIA IN THE RAT ELICITED BY CERTAIN ENVIRONMENTAL STIMULI.

DIFFERENTIAL EXCITATORY AND INHIBITORY EFFECTS OF OPIATES ON NONNOCICEPTIVE AND NOCICEPTIVE NEURONES IN THE SPINAL CORD OF THE CAT.

NONNOXIOUS
THE EFFECT OF NALOXONE ON THE EXCITATION OF DORSAL-HORN
NEURONES OF THE CAT BY NOXIOUS AND NONNOXIOUS CUTANEOUS

STIMULI. 001102 02-03

NONPARTICIPATION
NONPARTICIPATION OF CHOLINERGIC MECHANISM IN CHEMICAL
CONTROL OF CEREBRAL VASOMOTOR ACTIVITY.

001243 02-03

PHARMACOKINETICS OF HEXOBARBITAL IN THE PREGNANT AND NONPREGNANT STUMPTAILED MONKEY.

001104 02-03

NONPSYCHIATRIC
THE ROLE OF BENZODIAZEPINES IN NONPSYCHIATRIC MEDICAL PRACTICE.

HONPSYCHIATRIST
DEPRESSION — A GOOD APPROACH FOR THE NONPSYCHIATRIST: III --

HOW TO USE THE TRICYCLICS. 003719 04-17
NONPSYCHIATRISTS

PSYCHOPHARMACOLOGIC AGENTS: PRESCRIPTION PATTERNS OF NONPSYCHIATRISTS. 001927 02-17

HAZARDS OF ANTIPSYCHOTIC DRUG USE IN NONPSYCHOTIC PATIENTS.
001847 02-15

NONBEACTIVE
DIFFERENCES IN BENZODIAZEPINE RECEPTOR BINDING IN MAUDSLEY
REACTIVE AND MAUDSLEY NONREACTIVE RATS.

NONRIPRODUCIBILITY NUNREACTIVE RATS. 003066 04-03

NONREPRODUCIBILITY OF THE BEHAVIOURAL EFFECTS INDUCED BY SCOTOPHOBIN.

NONEESPONDING

PLASMA BUTAPERAZINE LEVELS IN LONG-TERM CHRONIC NONRESPONDING SCHIZOPHRENICS.

001569 02-08

STUDIES ON DIGITAL PLETHYSMOGRAPHIC PATTERNS IN FEMALE PATIENTS WITH NONSPECIFIC COMPLAINTS.

000626 01-11 EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS.

001103 02-03 NONSPECIFIC INHIBITION OF SOME RAT LIVER MEMBRANE-BOUND ENZYMES BY AN ADENYLATE-CYCLASE INHIBITOR, RMI-12330-A 002936 04-03

NONSTEREOSPECIFIC
STEREOSPECIFIC AND NONSTEREOSPECIFIC EFFECTS OF ()- AND (-)
MORPHINE: EVIDENCE FOR A NEW CLASS OF RECEPTORS? 001031 02-02

NONSTRESSED

DIFFERENTIAL EFFECT OF NALOXONE ON FIXED-RATIO OPERANT BEHAVIOR IN STRESSED AND NONSTRESSED RATS. 001330 02-04

NONTOLERANT INTERACTION OF AMITRIPTYLINE AND MORPHINE IN MORPHINE-TOLERANT AND NONTOLERANT RATS.

A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHOXYAMPHETAMINE (DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), P-METHOXYAMPHETAMINE (PMA), D AMPHETAMINE (A), AND LSD IN NONTOLERANT AND LSD TOLERANT CHRONIC SPINAL DOGS.

VIDEOTAPE METHODS FOR IDENTIFICATION OF NONVERBAL BEHAVIOR PARAMETERS IN DEPRESSIVE SYNDROMES.

000934 01-16 MARIHUANA: EFFECT ON NONVERBAL FREE RECALL AS A FUNCTION OF

NOOTROPIC DRUGS.

003300 04-04 001899 02-17

ON THE EFFECT OF NOOTROPIL AN ATP AND ATPASE IN BRAIN OF RATS.

A DOUBLE-BLIND INVESTIGATION OF PIRACETAM (NOOTROPIL) VERSUS PLACEBO IN THE MEMORY OF GERIATRIC INPATIENTS.

NORADRENALINE
FLA-136: SELECTIVE AGONIST AT CENTRAL ALPHA-ADRENORECEPTORS
MEDIATING CHANGES IN THE TURNOVER OF NORADRENALINE. 000043 01-03

A COMPARISON IN RABBIT ISOLATED HEARTS OF THE DYSRHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE, MAPROTILINE AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK NORADREMALINE UPTAKE.

000138 01-03 ELECTROCORTICAL CHANGES INDUCED BY THE PERFUSION OF NORADRENALINE, ACETYLCHOLINE AND THEIR ANTAGONISTS DIRECTLY INTO THE DORSAL RAPHE NUCLEUS OF THE CAT.

NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN SLICES OF MOUSE LIMBIC FOREBRAIN: CHARACTERISATION AND EFFECT OF DOPAMINERGIC AGONISTS.

000256 01-03 THE EFFECTS OF ETHER STRESS AND BETAMETHASONE TREATMENT ON THE CONCENTRATIONS OF NORADRENALINE AND DOPAMINE IN VARIOUS REGIONS OF THE RAT BRAIN.

000288 01-03 AMPHETAMINE INDUCES ANOREXIA EVEN AFTER INHIBITION OF NORADRENALINE SYNTHESIS.

BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF CHRONIC REDUCTION OF CEREBRAL NORADRENALINE RECEPTOR STIMULATION.

POSSIBLE PHYSIOLOGICAL SIGNIFICANCE OF THE INITIAL STEP IN THE CATABOLISM OF NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.

001117 02-03 THE RELATIVE FUNCTIONAL AVAILABILITY OF BRAIN NORADRENALINE AND DOPAMINE STORAGE POOLS.

THE EFFECTS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE ON THE IN VITRO UPTAKE OF RADIOLABELLED 5-HT AND NORADRENALINE INTO RAT BRAIN CORTICAL SLICES.

001257 02-03 LOCOMOTOR STIMULATION BY L-DOPA: RELATIVE IMPORTANCE OF NORADRENALINE RECEPTOR ACTIVATION.

MODIFICATION OF THE AMPHETAMINE-INDUCED STEREOTYPY IN RATS FOLLOWING INHIBITION OF THE NORADRENALINE RELEASE BY FLA-136 001367 02-04 VARIOUS EFFECTS OF D AMPHETAMINE IN RATS WITH SELECTIVE LESIONS OF BRAIN NORADRENALINE CONTAINING NEURONS OR TREATED WITH PENFLURIDOL.

THE EFFECT OF NORADRENALINE ON THE ECOG OF THE PREPARATION ENCEPHALE ISOLE OF RATS.

001475 02-04 NORADRENALINE, DEPRESSIVE ILLNESS, AND THE ACTION OF

001588 02-09 SELECTIVE INHIBITION OF NORADRENALINE AND SEROTONIN UPTAKE BY C-49802-B-BA AND CGP-6085-A.

EFFECTS OF PRESYNAPTIC MODULATORS ON CA2-INDUCED
NORADRENALINE RELEASE FROM CARDIAC SYMPATHETIC NERVES

002025 03-03
BETA-ADRENOCEPTORS MODULATE NORADRENALINE RELEASE FROM
AXONAL SPROUTS IN CULTURED RAT SUPERIOR CERVICAL GANGLIA. 002179 03-03

PIPEROXANE REDUCES THE EFFECTS OF CLONIDINE ON AGGRESSION IN MICE AND ON NORADRENALINE DEPENDENT HYPERMOTILITY IN RATS 002205 03-04

SELECTIVE REDUCTION BY NORADRENALINE AND 5
HYDROXYTRYPTAMINE OF NOCICEPTIVE RESPONSES OF CAT DORSALHORN NEURONES.

002246 03-04 THE EFFECTS OF ETORPHINE, FENTANYL AND MORPHINE ON NORADRENALINE AND DOPAMINE CONCENTRATIONS IN THE STRIATUM OF RAT.

HORMONE RESPONSES TO METHYLAMPHETAMINE IN DEPRESSION: A NEW APPROACH TO THE NORADRENALINE DEPLETION HYPOTHESIS. 002424 03-09 002321 03-04

COMPARISON OF THE RESPONSES OF SINGLE CORTICAL NEURONES TO TYRAMINE AND NORADRENALINE: EFFECTS OF DESIPRAMINE.

RESPONSES OF SINGLE CORTICAL NEURONES TO NORADRENALINE AND DOPAMINE.

O02822 04-03
THE EFFECT OF VILOXAZINE HYDROCHLORIDE ON THE TRANSPORT OF NORADREMALINE, DOPAMINE, 5 HYDROXYTRYPTAMINE AND GAMMA-AMINOBUTYRIC-ACID IN RAT BRAIN TISSUE.

003001 04-03 LOCAL PERFUSION OF NORADRENALINE MAINTAINS VISUAL CORTICAL PLASTICITY.

H3-GLYCOGEN HYDROLYSIS IN BRAIN SLICES: RESPONSES TO NEUROTRANSMITTERS AND MODULATION OF NORADRENALINE REFERENCES.

EVIDENCE FOR THE ROLE OF ADRENOCORTICAL HORMONES IN THE REGULATION OF NORADRENALINE AND DOPAMINE METABOLISM IN CERTAIN BRAIN AREAS.

003062 04-03 THE DIFFERENTIAL EFFECT OF LITHIUM ON NORADRENALINE AND DOPAMINE SENSITIVE ACCUMULATION OF CYCLIC-AMP IN GUINEA-PIG

003063 04-03 CENTRAL AND PERIPHERAL NORADREN. LINE AND RESISTANCE TO EXTINCTION.

DIFFERENTIAL EFFECT OF VARIOUS 6 HYDROXYDOPA TREATMENTS ON THE DEVELOPMENT OF CENTRAL AND PERIPHERAL NORADRENERGIC

TYROSINE-HYDROXYLASE: DELAYED ACTIVATION IN CENTRAL NORADRENERGIC NEURONS AND INDUCTION IN ADRENAL MEDULLA ELICITED BY STIMULATION OF CENTRAL CHOLINERGIC RECEPTORS. 000183 01-03

AGONIST EFFECTS OF BETA-PHENYLETHYLAMINES ON THE NORADRENERGIC CYCLIC-ADENOSINE-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. 3,5-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. STEREOISOMERS OF P-HYDROXYNOREPHEDRINE.

MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND NORADRENERGIC NEURONS IN NORMAL AND BRAIN LESIONED RATS.

EVIDENCE FOR NORADRENERGIC MECHANISM IN THE GROOMING PRODUCED BY () AMPHETAMINE AND 4, GAMMA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.

000397 01-04 ROLE OF THE DORSAL NORADRENERGIC BUNDLE IN BEHAVIOUR

INVOLVEMENT OF CENTRAL NORADRENERGIC SYSTEM IN THE MEDIATION OF BEHAVIORAL SUPPRESSANT EFFECTS OF DIAZEPAM IN HYPERTHYROID RATS.

001220 02-03

HYPOTHESIZED ADRENERGIC/NORADRENERGIC SUBSTITUTION IN HABITUAL INFANTILE MASTURBATION: TWO CASES.

001702 02-14
MODIFICATION OF THE NORADRENERGIC CYCLIC-AMP GENERATING
SYSTEM IN THE RAT LIMBIC FOREBRAIN BY AMPHETAMINE (A) AND
ITS HYDROXYLATED METABOLITES.

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION.

BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE.

002224 03-04
LESIONS OF THE DORSAL NORADRENERGIC PROJECTION ATTENUATE
MORPHINE-INDUCED BUT NOT AMPHETAMINE-INDUCED CONDITIONED
TASTE AVERSION.

TOLERANCE TO SEDATIVE HYPNOTICS, MEMORY AND NORADRENERGIC

O02318 03-04
ACTIVATION OF AN IHHIBITORY NORADRENERGIC PATHWAY PROJECTING
FROM THE LOCUS-COERULEUS TO THE CINGULATE CORTEX OF THE RAT.
002895 04.03

STUDIES ON THE EFFECT OF LESIONS OF THE VENTRAL NORADRENERGIC TRACT ON THE ANTINOCICEPTIVE ACTION OF MORPHINE.

002979 04-03

STUDIES ON THE MECHANISM OF SPROUTING OF NORADRENERGIC TERMINALS IN RAT AND MOUSE CEREBELLUM AFTER NEONATAL 6 HYDROXYDOPA.

NORADRENERGIC AND DOPAMINERGIC MECHANISMS IN GILLES-DE-LA-TOURETTE SYNDROME.

003609 04-

BEHAVIOURAL AND PHARMACOKINETIC STUDIES IN THE MONKEY (MACACA-MULATTA) WITH DIAZEPAM, NORDIAZEPAM AND RELATED 1,4 BENZODIAZEPINES. 001336 02-04

ELEAGNINE
VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF 2
AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF NAD:NADH AND
NORELEAGNINE A BETA-CARBOLINE DERIVATIVE.

000200 01-03

NOREPINEPHRINE
EVIDENCE FOR NOREPINEPHRINE MEDIATED COLLATERAL INHIBITION OF

LOCUS-COERULEUS NEURONS.

000039 01-03

LITHIUM INHIBITION OF NOREPINEPHRINE AND DOPAMINE RECEPTORS.
000107 01-03

O00107 01-03
COUNTERACTIVE EFFECTS OF NOREPINEPHRINE AND AMPHETAMINE ON OUABAIN-INDUCED AMNESIA.

OG0122 01-03

CYCLIC-AMP AND THE POSITIVE INTROPIC EFFECT OF NOREPINEPHRINE
AND PHENYLEPHRINE.

000195 01-03
NEUROLEPTIC DRUG INTERACTIONS WITH NOREPINEPHRINE ALPHA
RECEPTOR BINDING SITES IN RAT BRAIN.

NOREPINEPHRINE ALPHA RECEPTOR BINDING IN MAMMALIAN CENTRAL-NERVOUS-SYSTEM: DIFFERENTIAL LABELING WITH AGONIST AND ANTAGONIST.

000283 01-03
INTERACTION OF DRUGS WITH APOMORPHINE, TRYPTAMINE AND
NOREPINEPHRINE. A NEW IN VIVO APPROACH: THE ATN-TEST IN

ROLE OF NOREPINEPHRINE IN THE RELEASE OF PROLACTIN INDUCED BY SUCKLING AND ESTROGEN.

O01071 02-03

ANALGESIC BRAIN STIMULATION IN THE CAT: EFFECT OF
INTRAVENTRICULAR SEROTONIN, NOREPINEPHRINE, AND DOPAMINE.
001101 02-03

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF THE RAT.

O01118 02-03
THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE NOREPINEPHRINE TURNOVER IN RAT BRAIN REGIONS.

O01227 02-03
THE EFFECT OF ABLATION OF SEROTONIN OR NOREPINEPHRINE
BRAINSTEM AREAS ON HALOTHANE AND CYCLOPROPANE MAC IN
RATS. (UNPUBLISHED PAPER).

SPECIFICITY OF AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE AND SEROTONIN FROM RAT BRAIN IN VITRO.

ROLE OF BRAIN NOREPINEPHRINE IN NEUROLEPTIC-INDUCED CATALEPSY IN RATS.

DIFFERENT EFFECTS OF METHIONINE-ENKEPHALIN AND D ALA2-METHIONINE-ENKEPHALINAMIDE ON THE METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN: FACT OR ARTIFACT?.

ACTION OF NOREPINEPHRINE ON MICROCIRCULATION AND PO2
DISTRIBUTION IN THE ISOLATED PERFUSED RAT LIVER.

THE INFLUENCE OF COCAINE AND DESIPRAMINE ON THE CARDIAC RESPONSES TO EXOGENOUS AND ENDOGENOUS NOREPINEPHRINE. 002077 03-03

DESIPRAMINE AND SOME OTHER ANTIDEPRESSANT DRUGS DECREASE THE MAJOR NOREPINEPHRINE METABOLITE 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE IN THE RAT BRAIN.

002114 03-03

CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. THE IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2-METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED ANALOGS OF METHAMPHETAMINE.

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS.

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION.

002164 03-03
LETHALITY OF PENTYLENETETRAZOL IN RATS AFTER DEPLETION OF BRAIN
MOREPINEPHRINE

PROBENECID-INDUCED NOREPINEPHRINE ELEVATIONS IN PLASMA AND

002573 03-1.

NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE

OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL

SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION
OF THE SYMPATHETIC NERVE OF THE EYE.

O02802 04-03

RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE
AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL
PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D
AMPHETAMINE

BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101 BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN RAT CEREBRAL-CORTEX.

002885 04-03

EFFECTS OF RACEMIC, (S)- AND (R) METHYLENEDIOXYAMPHETAMINE ON SYNAPTOSOMAL UPTAKE AND RELEASE OF TRITIATED MODEPHINEPHINE

ROLE OF SEROTONIN REUPTAKE INHIBITION IN THE DEVELOPMENT OF SUBSENSITIVITY OF THE NOREPINEPHRINE (NE) RECEPTOR COUPLED ADENYLATE-CYCLASE SYSTEM.

003017 04-03
NEONATAL SYSTEMIC 6 HYDROXYDOPAMINE AND DORSAL TEGMENTAL
BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEPHRINE
AND THE POSTDECAPITATION REFLEX.

003039 04-03
EFFECT OF STRESS ON NOREPINEPHRINE STIMULATED CYCLIC-AMP
FORMATION IN BRAIN SLICES.

003100 04-03
INTERACTIONS BETWEEN GUANINE DERIVATIVES AND NOREPINEPHRINE
ON NEURONES OF THE MAMMALIAN CEREBRAL-CORTEX.
003101 04-03

003294 04-04

NOREPINEPHRINE ATTENUATION OF AMNESIA PRODUCED BY DIETHYLDITHIOCARBAMATE.

NOREPINEPHRINE-M-METHYLTRANSFERASE
LOWERING OF EPINEPHRINE CONCENTRATION IN RAT BRAIN BY 2,3
DICHLORO-ALPHA-METHYL-BENZYLAMINE, AN INHIBITOR OF
NOREPINEPHRINE-M-METHYLTRANSFERASE.

NOREPINEPHRINE-N-METHYLTRANSFERASE.

000112 01-03

MORFENFLURAMINE

EFFECTS OF FENFLURAMINE AND NORFENFLURAMINE ON BRAIN SEROTONIN METABOLISM IN RATS.

TIME-COURSE OF LITHIUM-INDUCED ALTERATIONS IN RENAL AND ENDOCRINE FUNCTION IN NORMAL AND BRATTLEBORD RATS WITH HYPOTHALAMIC DIABETES-INSIPIDUS.

000048 01-03

002176 03-03

MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND NORADRENERGIC NEURONS IN NORMAL AND BRAIN LESIONED RATS.

000312 01-04

PRESYNAPTIC AND POSTSYNAPTIC ACTIONS OF APOMORPHINE DIFFERENTIATION BY ROTARY EFFECTS IN NORMAL RATS.

000367 01-04 SUBJECTS. 000505 01-07 DIETARY TRYPTOPHAN EFFECTS ON THE SLEEP OF NORMAL

CLINICAL AND EXPERIMENTAL EXPERIENCE WITH MAPROTILLINE, CLOMIPRAMINE, SYDNOCARB, AND MEFEXAMINE IN PSYCHIATRIC PATIENTS AND NORMAL SUBJECTS.

LITHIUM AND ERYTHROCYTE MEMBRANE CATION CARRIER STUDIES IN NORMAL AND MANIC-DEPRESSIVE SUBJECTS.

NORMAL LYMPHOCYTE FUNCTION IN THE PRESENCE OF DELTAS TETRAHYDROCANNABINOL.

THE EFFECT OF A NEW BENZODIAZEPINE ON THE POLYGRAPHICALLY MONITORED SLEEP OF NORMAL VOLUNTEERS.

THE EFFECTS OF FOUR ANTIHYPERTENSIVE AGENTS ON THE STROOP COLOUR WORD TEST IN NORMAL MALE VOLUNTEER SUBJECTS.

PHENOBARBITAL AND PHENYTOIN EFFECTS ON SOMATOSENSORY
EVOKED-POTENTIALS AND SPONTANEOUS EEG IN NORMAL CAT BRAIN.
001032 02-02 NORMAL AND AMPHETAMINE-INDUCED ROTATION OF RATS ON A FLAT

001365 02-04

UNICAL AND PHARMACOKINETIC STUDY OF DIBENZEPINE (ECATRIL): COMPARISON BETWEEN THE NORMAL AND RETARD FORMS. 001581 02-09

FLUOXETINE, A SEROTONIN UPTAKE INHIBITOR, IN NORMAL HUMAN

THE PSYCHOTROPIC EFFECTS OF ATENOLOL IN NORMAL SUBJECTS:
PRELIMINARY FINDINGS.

THE PSILOCYBIN-INDUCED STATE OF DRUNKENNESS IN NORMAL VOLUNTEERS AND SCHIZOPHRENICS.

A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE SHORT-TERM EFFECTS OF CLOZAPINE UPON SLEEP PARAMETERS OF NORMAL YOUNG ADULTS.

THE PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS. A TEST OF DOPAMINERGIC BLOCKADE: NEUROENDOCRINE STUDIES IN NORMAL

001867 02-16 EFFECTS OF CLONIDINE ON VULNERABILITY TO FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE VENTRICLE.

ABSORPTION AND DISTRIBUTION OF SODIUM BARBITAL IN TISSUES OF NORMAL AND DYSTROPHIC MICE.

PLASMA PROLACTIN CONCENTRATIONS IN NORMAL SUBJECTS AND DEPRESSIVE PATIENTS FOLLOWING ORAL CLOMIPRAMINE.

PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS IN NORMAL AND SCHIZOPHRENIC SUBJECTS.

A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE LONG-TERM EFFECTS OF CLOZAPINE UPON SLEEP PATTERNS OF NORMAL YOUNG ADULTS. 002640 03-14

EFFECTS OF MET-ENKEPHALIN ON BODY TEMPERATURE OF NORMAL AND MORPHINE-TOLERANT RATS.

002907 04-03 EFFECT OF () AMPHETAMINE ON THE RETENTION OF H3-CATECHOLAMINES IN SLICES OF NORMAL AND RESERPINIZED RAT BRAIN AND HEART.

003071 04-03 DISULFIRAM-INDUCED HYPOTHERMIA IN THE NORMAL RAT; ITS ATTENUATION BY PIMOZIDE.

003085 04-03 FOOD RELATED INTRAVENOUS INSULIN SELF-ADMINISTRATION IN NORMAL AND DIABETIC RATS.

EFFECTS OF SINGLE DOSES OF TRANYLCYPROMINE ON PLATELET MAO AND AMINE UPTAKE IN NORMAL SUBJECTS. 003594 04-13

PLACEBO AND SLEEP PATTERNS OF NORMAL YOUNG ADULTS 003729 04-17

EEG PROFILE AND BEHAVIORAL CHANGES AFTER A SINGLE DOSE OF CLOZAPINE IN NORMALS AND SCHIZOPHRENICS.

000787 01-14 ACUTE AND CHRONIC EFFECTS OF LITHIUM-CHLORIDE ON PHYSIOLOGICAL AND PSYCHOLOGICAL MEASURES IN NORMALS.

NORMETABOLITES
POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES (N) ON OPIOID
ABSTINENCE SYNDROMES.

00189

001897 02-17

DIFFERENCES IN THE INHIBITORY EFFECTS OF NORMORPHINE AND OPIOID PEPTIDES ON THE RESPONSES OF THE VASA-DEFERENTIA OF TWO STRAINS OF MICE.

APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR, LOCOMOTOR STIMULATION AND HYPOTHERMIA IN SPONTANEOUS HYPERTENSIVE RATS AND NORMOTENSIVE WISTAR RATS.

ANGIOTENSIN BINDING AFFINITY AND CAPACITY IN THE MIDBRAIN AREA OF SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS.

NORTHIADEN
STEADY-STATE SERUM CONCENTRATIONS OF DOTHIEPIN AND
NORTHIADEN AFTER TWO DOSAGE REGIMENS OF DOTHIEPIN
HYDROCHLORIDE (PROTHIADEN).

HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF DOTHIEPIN AND NORTHIADEN IN HUMAN PLASMA AND SERUM. 001858 02-16

NORTRIPTYLINE
STUDIES OF EXCRETION IN RABBIT MILK AFTER ADMINISTRATION OF
CARBON-14 LABELLED AMITRIPTYLINE AND NORTRIPTYLINE.
000037 01-03

THE EFFECTS OF NORTRIPTYLINE AND MESORIDAZINE ON NEURONS AND GLIA IN VITRO.

000130 01-03 PLASMA NORTRIPTYLINE AND CARDIAC RESPONSES IN YOUNG AND OLD

000479 01-05 ROUTINE NORTRIPTYLINE LEVELS IN TREATMENT OF DEPRESSION.

SPECIFIC RADIOIMMUNOASSAY FOR AMITRIPTYLINE AND NORTRIPTYLINE IN PLASMA.

EFFECT OF ACTIVATED CHARCOAL ON ABSORPTION OF NORTRIPTYLINE 001763 02-15

PREDICTION OF INDIVIDUAL DOSAGE OF NORTRIPTYLINE. 002714 03-16

A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE (SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS (SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE

003508 04-09 THE PRACTICAL SIGNIFICANCE OF NORTRIPTYLINE PLASMA CONTROL. A PROSPECTIVE EVALUATION UNDER ROUTINE CONDITIONS IN ENDOGENOUS DEPRESSION.

003522 04-09 IMPLICATIONS OF DOSE REGIMEN AND PROTEIN BINDING FOR PLASMA NORTRIPTYLINE ESTIMATIONS.

003547 04-10

A COMPARATIVE CLINICAL TRIAL OF MIANSERIN (NORVAL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.

003514 04-09

NOURISHMENT
METABOLIC RESPONSES TO ISOPROTERENOL AND EPINEPHRINE IN THE
RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES
AND PRETREATMENT WITH PROPRANOLOL.

000227 01-0 000227 01-03

ANTIMUSCARINIC PROPERTIES OF ANTIDEPRESSANTS: DIBENZEPIN

001221 02-03 EXPERIENCES WITH USING THE ANTIDEPRESSANT DIBENZEPIN: NOVERIL, ON NEUROLOGY OUTPATIENTS.

PROLACTIN SECRETION DURING AND AFTER NOVERIL INFUSIONS TO DEPRESSIVE PATIENTS.

TREATMENT OF DEPRESSIVE SYNDROME WITH NOVERIL INFUSIONS. 002439 03.09

NOXIOUS THE EFFECT OF NALOXONE ON THE EXCITATION OF DORSAL-HORN NEURONES OF THE CAT BY NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULI.

001102 02-03 NEUROTENSIN ADMINISTERED INTRACISTERNALLY INHIBITS RESPONSIVENESS OF MICE TO NOXIOUS STIMULI.

002214 03-04 DEPRESSANT ACTIONS OF METHIONINE-ENKEPHALIN AND SOMATOSTATIN IN CAT DORSAL-HORN NEURONES ACTIVATED BY NOXIOUS STIMULI.

003059 04-03

003600 04-13

NUCIFERENE

EFFECTS OF INTRAVENOUS KAINIC-ACID, N METHYL-D-ASPARTATE, AND (-) NUCIFERENE ON THE CAT SPINAL CORD.

002128 03-03

PSYCHOPHARMACOLOGICAL STUDIES ON (-) NUCIFERINE AND ITS HOFMANN DEGRADATION PRODUCT ATHEROSPERMININE. 002824 04-03

MODIFICATION OF NUCLEAR RETENTION OF H3-ESTRADIOL BY CELLS OF THE HYPOTHALAMUS AS A FUNCTION OF EARLY HORMONE EXPERIENCE

002891 04-03

BETA-ENDORPHIN INHIBITS ACH TURNOVER IN NUCLEI OF RAT BRAIN 000012 01-01

THE ROLE OF THE SEPTAL NUCLEI IN THE RELEASE OF ACETYLCHOLINE FROM THE RABBIT CEREBRAL-CORTEX AND DORSAL HIPPOCAMPUS AND THE EFFECT OF ATROPINE.

000101 01-03 THE TURNOVER RATE OF GAMMA-AMINOBUTYRIC-ACID IN THE NUCLEI OF TELENCEPHALON: IMPLICATIONS IN THE PHARMACOLOGY OF ANTIPSYCHOTICS AND OF A MINOR TRANQUILIZER

000192 01-03 STUDIES OF SEROTONIN TURNOVER IN DISCRETE NUCLEI USING HPLC. (UNPUBLISHED PAPER).

000500 01-06

PHARMACOLOGICAL IMPLICATIONS OF BRAIN ACETYLCHOLINE TURNOVER MEASUREMENTS IN RAT BRAIN NUCLEI.

001077 02-03 EVALUATION OF THE EFFECT OF P-CHLOROAMPHETAMINE ON INDIVIDUAL CATECHOLAMINERGIC NUCLEI IN THE RAT BRAIN.

003003 04-03 EFFECTS OF PAIN ATTENUATING BRAIN STIMULATION AND MORPHINE ON ELECTRICAL ACTIVITY IN THE RAPHE NUCLEI OF THE AWAKE RAT 003034 04-03

NUCLFIC-ACID

NEW ASPECTS CONCERNING THE MECHANISM OF ACTION OF TRANQUILIZERS. THE INFLUENCE OF SOME TRANQUILIZERS ON PROTEIN AND NUCLEIC-ACID SYNTHESES.

000165 01-03

NUCLEOTIDE COENZYME-A IS A PURINE NUCLEOTIDE MODULATOR OF ACETYLCHOLINE

002874 04-03

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6 TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

002930 04-03 PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM -- I. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS. 002931 04-03

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH 002932 04-03

5-HT AND MORPHINE INTERACTION, EFFECTS ON SENSORY INPUT IN CAUDATE NUCLEUS AND SUBSTANTIA-NIGRA.

CHLORPROMAZINE INDUCES POPULATION INCREASE OF SYNAPTIC VESICLES IN THE RAT HYPOTHALAMIC VENTROMEDIAL NUCLEUS

000160 01-03 ELECTROCORTICAL CHANGES INDUCED BY THE PERFUSION OF NORADRENALINE, ACETYLCHOLINE AND THEIR ANTAGONISTS DIRECTLY INTO THE DORSAL RAPHE NUCLEUS OF THE CAT.

000164 01-03
POTENTIATION OF MORPHINE ANALGESIA BY LESIONS OF THE NUCLEUS LOCUS-COERULEUS.

001142 02-03 THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF THE MEDULLA-OBLONGATA IS A HIGHLY SENSITIVE SITE IN THE PRODUCTION OF MORPHINE ANALGESIA IN THE RAT.

001256 02-03 MORPHINE AND ITS BIPHASIC INFLUENCE UPON PHARMACOLOGICALLY DISTINCT DOPAMINERGIC SYSTEMS WITHIN THE FELINE CAUDATE NUCLEUS: A BEHAVIOURAL STUDY.

001954 03-02 APOMORPHINE INCREASES GLUCOSE UTILIZATION IN THE SUBSTANTIA-NIGRA, SUBTHALAMIC NUCLEUS AND CORPUS-STRIATUM OF RAT.

001976 03-03 BLOCKADE OF THE PICROTOXIN-INDUCED IN VIVO RELEASE OF DOPAMINE IN THE CAT CAUDATE NUCLEUS BY DIAZEPAM.

001989 03-03 PARAVENTRICULAR NUCLEUS: A PRIMARY SITE MEDIATING ADRENERGIC STIMULATION OF FEEDING AND DRINKING.

002074 03-03

FACILITATORY AND DEPRESSANT EFFECTS OF DOPAMINE IN THE FELINE CAUDATE NUCLEUS.

002116 03-03 THE IONTOPHORESIS OF DIAZEPAM IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT.

002130 03-03 THE ROLE OF DIAZEPAM AS COMPARED TO GAMMA AMINOBUTYRIC ACID (GABA) IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT. (PH.D. DISSERTATION)

002131 03-03 MORPHINE INCREASES AND D AMPHETAMINE DECREASES THE RATIO OF DOPAC:HVA IN PUSH-PULL PERFUSATE OF RAT CAUDATE NUCLEUS. 002158 03-03

ALTERATIONS IN THE FUNCTION OF THE NUCLEUS LOCUS-COERULEUS: A POSSIBLE MODEL FOR STUDIES OF ANXIETY

002298 03-04 EFFECT OF MORPHINE INJECTED IN PERIAQUEDUCTAL GRAY ON THE ACTIVITY OF SINGLE UNITS IN NUCLEUS RAPHE MAGNUS OF THE RAT. 002817 04-03 STIMULATION OF DOPAMINE SYNTHESIS IN CAUDATE NUCLEUS BY

INTRASTRIATAL ENKEPHALINS AND ANTAGONISM BY NALOXONE 002825 04-03 EFFECTS OF DOPAMINE AGONISTS ON NEURONES IN THE CAUDATE
NUCLEUS AND CEREBRAL-CORTEX OF CATS CHRONICALLY TREATED
WITH NEUROLEPTICS.

NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND L

THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE OF THE RAT CAUDATE NUCLEUS — 3. THE EFFECT OF APORPHINES AND PROTOBERBERINES.

ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

003272 04-04 ANALGESIA BY ENKEPHALINS INJECTED INTO THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF RAT MEDULLA-OBLONGATA. 003374 04-04

NUCLEUS-ACCUMBENS

5-HT ANTAGONISTS INHIBIT NEUROLEPTIC AND MORPHINE ANTAGONISM OF THE HYPERACTIVITY INDUCED BY DOPAMINE FROM THE NUCLEUS-

THE NUCLEUS-ACCUMBENS -- POSSIBLE SITE OF ANTIPSYCHOTIC ACTION OF NEUROLEPTIC DRUGS?

000085 01-03 BEHAVIOURAL DISSOCIATION OF THE ENKEPHALINERGIC SYSTEMS OF NUCLEUS-ACCUMBENS AND NUCLEUS-CAUDATUS.

DOPAMINE RECEPTORS IN RAT STRIATUM AND NUCLEUS-ACCUMBENS; CONFORMATIONAL STUDIES USING RIGID ANALOGUES OF DOPAMINE 000301 01-03

DISTINCT DOPAMINERGIC MECHANISMS WITHIN THE NUCLEUS-ACCUMBENS OF RATS AND BEHAVIOUR.

000340 01-04 EFFECT OF LOCAL APPLICATION OF APOMORPHINE TO THE CORPUS-STRIATUM AND TO THE NUCLEUS-ACCUMBENS ON THE RESERPINE-INDUCED RIGIDITY IN RATS.

001021 02-02 DIFFERENTIAL ACTIVATION BY SOME 2 AMINOTETRALIN DERIVATIVES OF THE RECEPTOR MECHANISMS IN THE NUCLEUS-ACCUMBENS OF RAT WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITING

001335 02-04 MUSCIMOL A GABA-AGONIST INJECTED INTO THE NUCLEUS-ACCUMBENS INCREASES APOMORPHINE STEREOTYPY AND DECREASES THE MOTILITY.

EFFECTS ON HYPOTHALAMIC SELF-STIMULATION OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION INJECTED INTO NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM OF RATS.

EFFECT OF MORPHINE ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE ACTIVITY OR NUCLEUS-ACCUMBENS. 002048 03-03

COMPARISON OF THE EFFECTS OF METHAMPHETAMINE AND NEUROLEPTIC AGENTS ON TYROSINE-HYDROXYLASE ACTIVITY IN THE NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM.

002102 03-03 INTERACTION OF ERGOT ALKALOIDS WITH DOPAMINERGIC RECEPTORS IN THE RAT STRATUM AND NUCLEUS-ACCUMBENS.

002157 03-03 TURNOVER RATES OF GAMMA-AMINOBUTYRIC-ACID IN SUBSTANTIA-NIGRA, NUCLEUS-CAUDATUS, GLOBUS-PALLIDUS AND NUCLEUS-ACCUMBENS OF RATS INJECTED WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS.

002996 04-03

EVIDENCE FOR A ROLE FOR DOPAMINE IN SELF-STIMULATION OF THE NUCLEUS-ACCUMBENS OF THE RAT. 003341 04-04

NUCLEUS-CAUDATUS
BEHAVIOURAL DISSOCIATION OF THE ENKEPHALINERGIC SYSTEMS OF
NUCLEUS-ACCUMBENS AND NUCLEUS-CAUDATUS.

DETECTION OF TWO ENDORPHIN-LIKE PEPTIDES IN NUCLEUS-CAUDATUS.

002790 04-01

TURNOVER RATES OF GAMMA-AMINOBUTYRIC-ACID IN SUBSTANTIANIGRA, NUCLEUS-CAUDATUS, GLOBUS-PALLIDUS AND NUCLEUSACCUMBENS OF RATS INJECTED WITH CATALEPTOGENIC AND
NONCATALEPTOGENIC ANTIPSYCHOTICS.

GUIDELINES FOR NURSES: THE ADMINISTRATION OF INTRAVENOUS DRUGS THROUGH AN ESTABLISHED INTRAVENOUS PATHWAY.

001866 02-16

002996 04-03

NURSING
OPEN-FIELD BEHAVIOR AND GROSS MOTOR DEVELOPMENT IN OFFSPRING
OF NURSING RAT MOTHERS GIVEN PENFLURIDOL.
000307 01-04

TARDIVE-DYSKINESIA AND CHANGING CONCEPTS OF ANTIPSYCHOTIC DRUG USE: A NURSING PROSPECTIVE.

NUTRITION AND CHEMICAL BIOTRANSFORMATIONS IN MAN 001651 02-13

OBERVATIONS
SOME PHARMACOLOGICAL OBERVATIONS ON THE ANALGESIA INDUCED
BY ACUPUNCTURE IN RABBITS. 001190 02-03

OBESITY RELATED TO THE USE OF PSYCHOTROPIC DRUGS, CONSIDERED IN ITS PSYCHODYNAMIC ASPECT.

ODESITY RELATED TO THE USE OF PSYCHOTROPIC DRUGS, CONSIDERED IN ITS ORGANIC ASPECT.

THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE HUMAN BRAIN AS AN OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING DRUGS.

000747 01-14 AKATHISIA DIAGNOSIS: AN OBJECTIVE TEST.

000858 01-15 A SUBJECTIVE AND OBJECTIVE METHOD ASSESSING THE EFFICACY OF HYPNOTIC MEDICATIONS IN INSOMNIACS.

001873 02-16 ON THE OBJECTIVE EVALUATION OF HALOPERIDOL EFFECTS IN MAN: A

REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR

003657 04-15 FURTHER OBSERVATION ON THE LACK OF ACTIVE UPTAKE SYSTEM FOR SUBSTANCE-P IN THE CENTRAL-NERVOUS-SYSTEM.

001238 02-03

EEG OBSERVATION OF NOCTURNAL DELIRIUM IN A PATIENT TAKING ANTIDEPRESSANTS AND ANTIPARKINSONS DRUGS. 001773 02-15

OBSERVATIONS
SOME OBSERVATIONS ON THE MECHANISM OF BENZODIAZEPINE
BARBITURATE INTERACTIONS IN THE MOUSE.

00033

PHARMACOKINETIC OBSERVATIONS OF PHENYTOIN DISPOSITION IN THE NEWBORN AND YOUNG INFANT

WITHDRAWAL FROM CANNABIS: LABORATORY TESTS AND CLINICAL OBSERVATIONS.

000748 01-14 P-METHOXYPHENYLETHYLAMINE (PMPEA): SOME BEHAVIORAL OBSERVATIONS IN RATS.

001319 02-04 RELATIONSHIP BETWEEN PHYSICAL FINDINGS AND RELATED SUBJECTIVE SYMPTOMS IN NEUROPSYCHIATRIC PATIENTS WITH SOMATIC COMPLICATIONS — WITH SPECIAL REFERENCE TO OPHTHALMOLOGIC OBSERVATIONS.

001678 02-13 NALOXONE (NARCAN) TREATMENT IN DEPRESSION: CLINICAL OBSERVATIONS AND EFFECTS ON CSF ENDORPHINS AND MONDAMINE METABOLITES.

OBSERVATIONS ON THE TREATMENT OF PHENCYCLIDINE (PCP)

001745 02-15 **OBSERVATIONS ON THE CONTINUOUS USE OF TRIOXAZINE.** 002384 03-07

Psychopharmacology Abstracts

SOME OBSERVATIONS ON PATIENT COMPLIANCE IN AN ANTIDEPRESSIVE

002469 03-09 AUTONOMOUS NERVOUS FUNCTION OF LONG-TERM USERS OF PSYCHOTROPIC DRUGS, THIRD REPORT -- PUPILOGRAM OBSERVATIONS.

002690 03-15 SOME OBSERVATIONS ON THE BINDING PATTERNS OF ALPHA-BUNGAROTOXIN IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT 002956 04-03

BEHAVIOR OBSERVATIONS OF HYPERACTIVE CHILDREN AND METHYLPHENIDATE (RITALIN) EFFECTS IN SYSTEMATICALLY STRUCTURED CLASSROOM ENVIRONMENTS: NOW YOU SEE THEM,

003581 04-11

OBSERVED EFFECT OF ALPHA-METHYL-P-TYROSINE ON THE INCIDENCE OF SPONTANEOUS CONVULSIONS OBSERVED FOLLOWING BARBITAL WITHDRAWAL.

002104 03-03 WAKING STAGE-1 REM OBSERVED IN PARANOID HALLUCINATORY STATES OF NARCOLEPSY.

002675 03-15 OBSESSIONAL
CLINICAL EXPERIENCE IN THE TREATMENT OF OBSESSIONAL STATES (1)
002477 03-

002477 03-10 AN UNCONTROLLED TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF PHOBIC AND OBSESSIONAL STATES IN GENERAL

PRACTICE 002481 03-10

CLINICAL EXPERIENCE IN THE TREATMENT OF OBSESSIONAL STATES (2). 002489 03-10 A CLINICAL TRIAL OF CLOMIPRAMINE AND DIAZEPAM IN THE TREATMENT OF PHOBIC AND OBSESSIONAL ILLNESS.

002497 03-10 OBSESSIONS

DOUBLE-BLIND CONTROLLED STUDY IN PHOBIAS AND OBSESSIONS. 002483 03-10 RECENT RESULTS OF BEHAVIOURAL TREATMENTS OF PHOBIAS AND OBSESSIONS.

OBSESSIVE CLOMIPRAMINE (ANAFRANIL) IN DEPRESSIVE PATIENTS WITH OBSESSIVE NEUROSIS. 002491 03-10

A COMPARISON OF CLOMIPRAMINE HYDROCHLORIDE (ANAFRANIL) AND BEHAVIOUR THERAPY IN THE TREATMENT OF OBSESSIVE NEUROSIS.

002484 03-10

000712 01-13

002492 03-10 TREATMENT OF OBSESSIVE HOMOSEXUAL PEDOPHILIC FANTASIES WITH MEDROXYPROGESTERONE-ACETATE.

003543 04-10

OBSESSIVE-COMPULSIVE
L TRYPTOPHAN IN OBSESSIVE-COMPULSIVE DISORDERS

001616 02-10 CLOMIPRAMINE (ANAFRANIL) AND BEHAVIOUR THERAPY IN OBSESSIVE-COMPULSIVE AND PHOBIC DISORDERS.

002473 03-10 TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH CLOMIPRAMINE (ANAFRANIL).

002474 03-10 A PRELIMINARY REPORT ON CLINICAL RESPONSE AND PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN OBSESSIVE-COMPULSIVE NEUROSIS.

002493 03-10 CLOSING REMARKS AT A SYMPOSIUM ON OBSESSIVE-COMPULSIVE NEUROSES AND PHOBIC DISORDERS.

002760 03-17 THE EFFECTS OF OBSTETRICAL MEDICATION ON THE BEHAVIOR OF ISRAELI NEWBORN INFANTS AND SOME COMPARISONS WITH URUGUAYAN AND AMERICAN INFANTS.

002673 03-15 **OBSTRUCTION**

ANGIOTENSIN-INDUCED THIRST: EFFECTS OF THIRD VENTRICLE OBSTRUCTION AND PERIVENTRICULAR ABLATION.

003181 04-04 OBTAINING
THE USE OF A CHECKLIST IN OBTAINING INFORMED-CONSENT FOR TREATMENT WITH MEDICATION.

00277

002778 03-17

SELF-REPORTED ALCOHOL AND NICOTINE USE AND THE ABILITY TO CONTROL OCCIPITAL EEG IN A BIOFEEDBACK SITUATION. 003622 04-14

OCTOPAMINE
CATECHOLAMINE AND OCTOPAMINE CONCENTRATIONS IN BRAINS OF
PATIENTS WITH REYE SYNDROME.

000712 01

000014 01-01

VOLUME 16, SUBJECT INDEX PLASMA CONCENTRATIONS OF SOME ACIDIC AND ALCOHOLIC METABOLITES DERIVED FROM M- AND P-TYRAMINE, OCTOPAMINE AND CATECHOLAMINES IN HUMANS. 001158 02-03 OCTOPUS-VULGARIS
A BRAIN SPECIFIC PROTEIN FROM OCTOPUS-VULGARIS, LAM 000125 01-03 COMPUTER OCULOGRAPHIC DOUBLE-BLIND STUDY OF CHANGES IN VIGILANCE: ALPRENOLOL VERSUS DIAZEPAM. 001746 02-15 EFFECTS OF SODIUM PENTOBARBITAL ON SYMBOLIC MATCHING AND SYMBOLIC ODDITY PERFORMANCE. 003213 04-04 ODOR ODOR AVERSION LEARNING IN NEONATAL RATS. 001448 02-04 CONTROL OF THE RAT OLFACTORY BULB ACTIVITY INDUCED BY BIOLOGICALLY SIGNIFICANT ODORS. 001324 02-04 THE OFF-ON PHENOMENON DURING TREATMENT OF PARKINSONS DISEASE WITH LEVODOPA. 000664 01-11 OFFICE MALIGNANT FEVER IS NOW AN OFFICE PROBLEM TOO. ONCE-DAILY 003565 04-11 OFFSET ONSET AND OFFSET OF CHLORPROMAZINE BLOCKADE OF PHENYLEPHRINE, CARBAMYLCHOLINE AND HISTAMINE ON RABBIT STOMACH STRIPS. 001234 02-03 **OFFSPRING** OPEN-FIELD BEHAVIOR AND GROSS MOTOR DEVELOPMENT IN OFFSPRING OF NURSING RAT MOTHERS GIVEN PENFLURIDOL. 000307 01-04 THE EFFECT OF MATERNALLY ADMINISTERED METHADONE ON BRAIN DEVELOPMENT IN THE OFFSPRING 000483 01-05 EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON PREGNANT RATS

AND THEIR OFFSPRING 000491 01-05 EFFECT OF MATERNALLY ADMINISTERED HEROIN ON THE MOTOR ACTIVITY OF RAT OFFSPRING

002349 03-05 SEXUAL DIFFERENTIATION OF OFFSPRING OF MOTHERS TREATED WITH CORTISONE DURING PREGNANCY

EFFECTS OF MATERNAL CHLORPROMAZINE ON OFFSPRING NERVOUS SYSTEM DEVELOPMENT.

002880 04-03 OPEN-FIELD AND LASHLEY III MAZE BEHAVIOUR OF THE OFFSPRING OF AMPHETAMINE TREATED RATS.

003315 04-04 PSYCHOTROPIC DRUGS IN PREGNANCY: MORPHOLOGICAL AND PSYCHOLOGICAL ADVERSE EFFECTS ON OFFSPRING.

003708 04-17 DELTA9-THC AND 11 OH-DELTA9-THC: BEHAVIORAL EFFECTS AND

RELATIONSHIP TO PLASMA AND BRAIN LEVELS 000361 01-04

CATALEPSY INDUCED BY INTRASTRIATAL INJECTIONS OF DELTA9-THC AND 11 OH-DELTA9-THC IN THE RAT. 002027 03-03

OLFACTORY EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) ON SLEEP IN OLFACTORY BULB LESIONED RATS.

000032 01-02 A COMPARISON OF THE EFFECTS OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE STRIATUM, OLFACTORY TUBERCLE AND MEDIAN

000131 01-03 OLFACTORY BULB ABLATION IN THE RAT: BEHAVIOURAL CHANGES AND THEIR REVERSAL BY ANTIDEPRESSANT DRUGS 000466 01-04

CONTROL OF THE RAT OLFACTORY BULB ACTIVITY INDUCED BY BIOLOGICALLY SIGNIFICANT ODORS. 001324 02-04

CONDITIONED TASTE AVERSIONS: GENOTYPE BY OLFACTORY

002334 03-04 ROLES OF THE VOMERONASAL AND OLFACTORY SYSTEMS IN COURTSHIP BEHAVIOR OF MALE GARTER SNAKES.

003268 04-04 EFFECT OF PAPAVERINE AND DIHYDROERGOTOXINE-MESYLATE ON CEREBRAL MICROFLOW, EEG, AND PO2 IN OLIGEMIC HYPOTENSION 002032 03-03 OLIGODENDROGLIA
ANTISERUMS TO NEURONS AND TO OLIGODENDROGLIA FROM
MAMMALIAN BRAIN.

OLIGODENDROGLIOMA
INDUCTION OF SULFOGALACTOSYLCERAMIDE (SULFATIDE) SYNTHESIS BY
HYDROCORTISONE (CORTISOL) IN MOUSE G-26 OLIGODENDROGLIOMA CELL STRAINS.

OLIGOPEPTIDES

COMPARISON OF THE REGULATION OF ROTATIONAL BEHAVIOR BY
HYPOTHALAMIC OLIGOPEPTIDES. 000337 01-04

THE INDOLAMINERGIC INNERVATION OF THE INFERIOR OLIVE. 2. RELATION TO HARMALINE-INDUCED TREMOR.

EVIDENCE FOR FUNCTIONAL SYNAPSES BETWEEN MIXED CULTURES OF INFERIOR OLIVE AND CEREBELLUM. 000497 01-06

ACUTE POISONINGS DUE TO DRUGS IN THE POLISH PROVINCE OF OLSZTYN FROM 1971 TO 1974. 002657 03-15

OMISSION
BENZODIAZEPINES AND BEHAVIORAL EFFECTS OF REWARD (WATER) OMISSION IN THE RAT.

COMPARISON OF PIMOZIDE AND TRIFLUOPERAZINE AS ONCE-DAILY THERAPY IN CHRONIC SCHIZOPHRENIC OUTPATIENTS 000537 01-08

THE EFFECTS OF ONE-DAY TREATMENT OF ANXIETY WITH HIGH DOSES OF HALAZEPAM. 002718 03-16

ONTOGENETIC UNILATERAL CATECHOLAMINE DEPLETION OF THE CORPUS-STRIATUM

AND AMPHETAMINE-INDUCED TURNING: AN ONTOGENETIC STUDY.

ONTOGENETIC DEVELOPMENT OF PENTOBARBITAL EFFECTS ON
ELECTROCORTICOGRAM IN RATS.

ONTOGENETIC DEVELOPMENT OF BENZODIAZEPINE RECEPTORS IN THE RAT BRAIN. 002840 04-03

ONTOGENY
EMERGING CHOLINERGIC MECHANISMS AND ONTOGENY OF RESPONSE INHIBITION IN THE MOUSE.

003336 04-04 TREATMENT OF CHRONIC SCHIZOPHRENICS WITH THE ORAL LONG-TERM NEUROLEPTIC PENFLURIDOL IN AN OPEN STUDY.

O01563 02-08
A LARGE OPEN MULTICENTRE TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE MANAGEMENT OF PHOBIC DISORDERS. 002475 03-10

STANDARD AND LONG-ACTING DEPOT NEUROLEPTICS IN CHRONIC SCHIZOPHRENICS: AN 18-MONTH OPEN MULTICENTRIC STUDY 003471 04-08

OPEN-FIELD BEHAVIOR AND GROSS MOTOR DEVELOPMENT IN OFFSPRING OF NURSING RAT MOTHERS GIVEN PENFLURIDOL.

000307 01-04 PRENATAL ALCOHOL CONSUMPTION AND OPEN-FIELD BEHAVIOUR IN RATS: EFFECTS OF AGE AT TIME OF TESTING.

000321 01-04 THE EFFECTS OF NEONATAL INJECTIONS OF ALPHA-MSH ON THE OPEN-FIELD BEHAVIOR OF JUVENILE AND ADULT RATS.

INTERACTIONS BETWEEN ALCOHOL AND OTHER DRUGS ON OPEN-FIELD AND TEMPERATURE MEASUREMENTS IN GERBILS.

EFFECTS OF PCPA AND SELECTIVE REM SLEEP-DEPRIVATION ON ROTOROD PERFORMANCE AND OPEN-FIELD BEHAVIOR IN THE RAT. 002219 03-04

OPEN-FIELD BEHAVIOR AFTER INTRAVENOUS AMPHETAMINE ANALOGUES IN RATS OPEN-FIELD AND LASHLEY III MAZE BEHAVIOUR OF THE OFFSPRING OF

EFFECTS OF CHLORMETHIAZOLE (HEMINEVRIN) ON DRUG DISCRIMINATION AND OPEN-FIELD BEHAVIOR IN GERBILS SYSTEMIC ADMINISTRATION OF ENDORPHINS SELECTIVELY ALTERS OPEN-FIELD BEHAVIOR OF RATS.

003382 04-04

PILOT OPEN-LABEL STUDY OF BROFOXINE IN ANXIETY. 002479 03-10

NABILONE, A CANNABINOID, IN THE TREATMENT OF ANXIETY: AN OPEN-LABEL AND DOUBLE-BLIND STUDY. 003538 04-10

OPERANT
DISCRIMINATIVE STIMULUS PROPERTIES OF FENFLURAMINE IN AN
OPERANT TASK: AN ANALYSIS OF ITS CUE FUNCTION.
00036

000369 01-04 A COMPARISON OF THE EFFECTS OF INTRAVENTRICULAR MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON OPERANT BEHAVIOR IN THE RAT.

001323 02-04 DIFFERENTIAL EFFECT OF NALOXONE ON FIXED-RATIO OPERANT BEHAVIOR IN STRESSED AND NONSTRESSED RATS.

001330 02-04 ACQUISITION AND EXTINCTION OF OPERANT RESPONDING FOR INTRAVENOUS INJECTIONS OF FENTANYL IN THE RAT.

001397 02-04

BETA-ENDORPHIN: DOSE-DEPENDENT SUPPRESSION OF FIXED-RATIO OPERANT BEHAVIOR

001402 02-04 EFFECTS OF PHENCYCLIDINE ON OPERANT BEHAVIOR IN RATS

001423 02-04 BARBITAL-INDUCED TOLERANCE AND CROSS-TOLERANCE CNS DEPRESSANTS ON RAT OPERANT BEHAVIOR. TO VARIOUS

001481 02-04 AMPHETAMINE-INDUCED TASTE AVERSION DEMONSTRATED WITH OPERANT BEHAVIOUR.

002315 03-04

ACTIVITY ANALYSIS OF OPERANT BEHAVIOR FOLLOWING METHYLPHENIDATE ADMINISTRATION. 003223 04-04

OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR OPERANT DRUG DISCRIMINATIONS.

003434 04-06 INTERDEPENDENCE BETWEEN SOCIAL PROCESSES AND NEUROCHEMICAL OPERATIONS.

003623 04-14 OPHTHALMOLOGIC

RELATIONSHIP BETWEEN PHYSICAL FINDINGS AND RELATED SUBJECTIVE SYMPTOMS IN NEUROPSYCHIATRIC PATIENTS WITH SOMATIC COMPLICATIONS -- WITH SPECIAL REFERENCE TO OPHTHALMOLOGIC

OBSERVATIONS. 001678 02-13

OPLATE ON THE MECHANISM OF THE DECREASE IN CEREBELLAR CYCLIC-GMP CONTENT ELICITED BY OPIATE RECEPTOR AGONISTS.

THE EFFECT OF PH ON STEREOSPECIFIC OPIATE BINDING TO MOUSE BRAIN MEMBRANES.

000271 01-03 CIRCLING BEHAVIOR AND STEREOTYPY INDUCED BY INTRANIGRAL OPIATE MICROINJECTIONS.

000385 01-04 CLINIC ATTENDANCE AND OPIATE PRESCRIPTION STATUS OF HEROIN ADDICTS OVER A SIX-YEAR PERIOD.

3 HYDROXY-17-ARALKYLMORPHINANS AS POTENTIAL OPIATE RECEPTOR SITE DIRECTED AKLYLATING AGENTS.

001010 02-01 AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. III. THE TELENCEPHALON.

001048 02-03 SELECTIVE OPIATE DEPRESSION OF SENSORY EVOKED SYNAPTIC NETWORKS IN DORSAL-HORN REGIONS OF SPINAL CORD CULTURES

EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS.

001103 02-03 PROPERTIES OF THE PERIPHERAL OPIATE RECEPTORS IN THE CAT NICITATING MEMBRANE.

001113 02-03 EFFECTS OF PERINATAL 6 HYDROXYDOPAMINE TREATMENT ON OPIATE RECEPTOR DISTRIBUTION IN ADULT BRAIN.

001128 02-03 ENHANCED AFFINITY OF OPIATE RECEPTORS FOR NALOXONE IN STRIATAL SLICES OF MORPHINE-DEPENDENT MICE.

001165 02-03 SOME STRUCTURAL FEATURES GOVERNING OPIATE ACTION (UNPUBLISHED PAPER

001168 02-03 VALUE OF COCAINE IN OPIATE CONTAINING ELIXIRS

001628 02-11 THE OPIATE ANOMALIES -- ANOTHER POSSIBLE EXPLANAT 001660 02-13

ANTIPSYCHOTIC EFFECT OF OPIATE AGONISTS. 001661 02-13

Psychopharmacology Abstracts

QUANTUM CHEMICAL STUDIES OF N SUBSTITUENT VARIATION IN THE OXYMORPHONE SERIES OF OPIATE NARCOTICS.

INTERACTION OF IODINATED ENKEPHALIN ANALOGUES WITH OPIATE RECEPTORS.

3 BENZAZOCINE-AMIDINIUM-NITRONATES. AN UNUSUAL TYPE OF OPIATE ANTAGONIST.

MULTIPLE CLASSES OF OPIATE RECEPTORS IN C57BL/6J AND DBA/2J MOUSE BRAIN

001991 03-03 OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG

002040 03-03 OPIATE WITHDRAWAL SIGNS IN SINGLE MYENTERIC NEURONES. 002118 03-03

THE OPIATE RECEPTOR BINDING INTERACTIONS OF H3-METHIONINE ENKEPHALIN, AN OPIOID PEPTIDE.

A REVIEW OF THE RELATIONSHIP BETWEEN ENDOCRINOPATHY AND DEPRESSION OR ANTIDEPRESSANT DRUGS, WITH PARTICULAR RESPECT TO NOVEL THEORIES INVOLVING THE OPIATE RECEPTOR.

002557 03-13 CHRONIC NALOXONE RESULTS IN PROLONGED INCREASES IN OPIATE

CLEARANCE AND ANALGESIC ACTIVITY OF THE QUATERNIZED OPIATE, N
METHYLMORPHINE (6-H3) ADMINISTERED INTRACISTERNALLY TO THE

003019 04-03 THE OPIATE RECEPTORS

003092 04-03 INTERACTION OF PHENCYCLIDINES WITH THE MUSCARINIC AND OPIATE RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM.

OPIATE RECEPTORS FOR BEHAVIORAL ANALGESIA RESEMBLE THOSE
RELATED TO THE DEPRESSION OF SPINAL NOCICEPTIVE NEURONS.

003142 04-03 INHIBITION OR WET SHAKES DURING MORPHINE ABSTINENCE BY AN ANTAGONIST OF OPIATE ANALGESIA.

003383 04-04 **CLONIDINE BLOCKS ACUTE OPIATE WITHDRAWAL SYMPTOMS** 003628 04-14

CLINICAL EVALUATION OF NALTREXONE TREATMENT OF OPIATE-DEPENDENT INDIVIDUALS: REPORT OF THE NATIONAL RESEARCH COUNCIL COMMITTEE ON CLINICAL EVALUATION OF NARCOTIC ANTAGONISTS 002768 03-17

DIFFERENTIAL EFFECTS OF OPIATES ON THE INCORPORATION OF C14-THIAMINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.

000201 01-03 PREPARATION OF SPIN-LABELED OPIATES: MORPHINE AND CODEINE. 000494 01-06

EVIDENCE FOR A NONCOVALENT INTERMOLECULAR INTERACTION OF OPIATES WITH THIAMINE.

001008 02-01 BLOCKADE OF SYNAPTOSOMAL CA UPTAKE BY OPIATES IN VITRO. 001075 02-03

EFFECTS OF OPIATES AND OPIOID PEPTIDES ON MOTOR BEHAVIORS: SITES AND MECHANISMS OF ACTION. (UNPUBLISHED PAPER). 001433 02-04

THE ENKEPHALINS AND OPIATES: STRUCTURE-ACTIVITY RELATIONS 001901 02-17

DIFFERENTIAL EXCITATORY AND INHIBITORY EFFECTS OF OPIATES ON NONNOCICEPTIVE AND NOCICEPTIVE NEURONES IN THE SPINAL CORD OF THE CAT. 001966 03-03

POSSIBLE WITHDRAWAL FROM ENDOGENOUS OPIATES IN SCHIZOPHRENICS.

INCREASE IN SERUM PROLACTIN BY EXOGENOUS AND ENDOGENOUS OPIATES: EVIDENCE FOR ANTIDOPAMINE AND ANTIPSYCHOTIC **EFFECTS**

002926 04-03

DIFFERENTIATION BETWEEN OPIOID PEPTIDES BY NALTREXONE 001230 02-03 EFFECTS OF OPIATES AND OPIOID PEPTIDES ON MOTOR BEHAVIORS: SITES AND MECHANISMS OF ACTION. (UNPUBLISHED PAPER).

001433 02-04 POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES (N) ON OPIOID ABSTINENCE SYNDROMES.

001897 02-17 THE OPIATE RECEPTOR BINDING INTERACTIONS OF H3-METHIONINE-ENKEPHALIN, AN OPIOID PEPTIDE.

002155 03-03

DIFFERENCES IN THE INHIBITORY EFFECTS OF NORMORPHINE AND OPIOID PEPTIDES ON THE RESPONSES OF THE VASA-DEFERENTIA OF TWO

002176 03-03 PRIMATE EEG SPECTRA BEFORE AND DURING OPIOID ADMINISTRATION IN VITRO PROFILE OF SOME OPIOID PENTAPEPTIDE ANALOGUES.

OPIOIDS

OPIOIDS AND REWARDING BRAIN STIMULATION.

003216 04-04

002799 04-02

COMBINATION OF PHENYLPYRROLIDINOPENTANE (KATOVIT) WITH OXAZEPAM (ADUMBRAN): A DOUBLE-BLIND TRIAL WITH OPIPRAMOL (INSIDON) IN DEPRESSIVE SYNDROME.

000597 01-10

OXYTOCIN, VASOPRESSIN AND MEMORY: OPPOSITE EFFECTS ON CONSOLIDATION AND RETRIEVAL PROCESSES.

003174 04-04 OPPOSITE ACTION OF OXYTOCIN TO VASOPRESSIN IN PASSIVE

AVOIDANCE BEHAVIOR IN RATS.

003263 04-04 INTRANIGRAL KAINIC-ACID: EVIDENCE FOR NIGRAL NONDOPAMINERGIC NEURONS CONTROLLING POSTURE AND BEHAVIOR IN A MANNER OPPOSITE TO THE DOPAMINERGIC ONES.

EFFECT OF DIAZEPAM ON PULSE ACTIVITY OF NEURONS OF THE SENSORIMOTOR AND OPTIC AREAS OF THE RAT CEREBRAL-CORTEX. 001978 03-03

CHANGES IN SYNAPTIC FUNCTION INDUCED BY BLOCKAGE OF AXONAL TRANSPORT IN THE RABBIT OPTIC PATHWAY. 002952 04-03

OPTIMAL

PREDICTING THE OPTIMAL LITHIUM DOSAGE.

000693 01-13

003324 04-04

OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR OPERANT DRUG DISCRIMINATIONS.

003434 04-06

INFLUENCE OF FASTING ON THE ABSORPTION AND EFFECTS OF DELTAS TETRAHYDROCANNABINOL AFTER ORAL ADMINISTRATION IN SESAME-

MULTIPLE ORAL DOSES OF DIAZEPAM, OXAZEPAM AND PHENOBARBITAL TO DOGS -- BEHAVIOURAL EFFECTS AND CORRELATION WITH ANTIPYRINE HALF-LIFE.

000308 01-04 ANIMAL MODELS OF ORAL DRUG SELF-ADMINISTRATION.

000408 01-04 FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN TREATMENT OF REMITTED SCHIZOPHRENICS: II. RATING SCALE DATA

000544 01-08 MANIA DURING MAINTENANCE HEMODIALYSIS SUCCESSFULLY TREATED WITH ORAL LITHIUM-CARBONATE.

000582 01-09 PLASMA CONCENTRATIONS OF PERPHENAZINE AND ITS SULPHOXIDE METABOLITE DURING CONTINUOUS ORAL TREATMENT.

000631-01-11 A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY ON ANTIEPILEPTIC ACTIVITY OF CLONAZEPAM -- RELATIONSHIP BETWEEN CLINICAL EFFECTS OF ORAL ADMINISTRATION AND ELECTROENCEPHALOGRAPHIC EFFECTS OF INTRAVENOUS ADMINISTRATION

000639 01-11 RATE OF ABSORPTION AND CLINICAL RESPONSE TO SINGLE ORAL DOSES OF CHLORDIAZEPOXIDE

000702 01-13 COMPARATIVE BIOAVAILABILITY OF ORAL DOSAGE FORMS OF OXAZEPAM - CORRELATION WITH IN VITRO DISSOLUTION RATE 000727 01-13

DISPOSITION OF THREE BENZODIAZEPINES AFTER SINGLE ORAL ADMINISTRATION IN MAIN 000745 01-13

DIPHENHYDRAMINE IN THE DIFFERENTIAL DIAGNOSIS OF NEUROLEPTIC-INDUCED ORAL FACIAL DYSKINESIA.

AN EVALUATION OF THE CARDIOPULMONARY SAFETY AND EFFICACY OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS ORAL HYPNOTIC

000854 01-15 A SYNTHETIC ENKEPHALIN ANALOGUE WITH PROLONGED PARENTERAL AND ORAL ANALGESIC ACTIVITY

001036 02-02 TREATMENT OF CHRONIC SCHIZOPHRENICS WITH THE ORAL LONG-TERM NEUROLEPTIC PENELURIDOL IN AN OPEN STUDY

001563 02-08 CLINICAL PHARMACOKINETICS OF LORAZEPAM, IV. LONG-TERM ORAL ADMINISTRATION.

A CASE OF ORAL DYSKINESIA ASSOCIATED WITH IMIPRAMINE TREATMENT. SYNDROME MALIN SYMPTOMS THOUGHT TO BE DUE TO INTERACTION BETWEEN NEUROLEPTICS AND ORAL DIABETES DRUGS.

001854 02-15
SUPPRESSION OF THE HYPOTHALAMIC PITUITARY ADRENAL AXIS AFTER ORAL HYDROCORTISONE-SUCCINATE INGESTION IN RATS

002098 03-03 EFFECTS OF CHRONIC IMIPRAMINE AND CLOMIPRAMINE ORAL ADMINISTRATION ON MATERNAL BEHAVIOR AND LITTER DEVELOPMENT.

002202 03-04
CLINICAL AND PLASMA LEVEL CHARACTERISTICS OF INTRAMUSCULAR AND ORAL LOXAPINE

EVALUATION OF LOXAPINE HYDROCHLORIDE ORAL CONCENTRATE (LOXITANE C) IN ACUTE SCHIZOPHRENIA.

002411 03-08 PLASMA PROLACTIN CONCENTRATIONS IN NORMAL SUBJECTS AND DEPRESSIVE PATIENTS FOLLOWING ORAL CLOMIPRAMINE.

002567 03-13
BIOAVAILABILITY OF ORAL AND INTRAMUSCULAR PHENOBARBITAL.

002600 03-13 BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION OF LEVO-ALPHA-ACETYLMETHADOL IN THE RAT.

003154 04-04 AVERSIVENESS OF ORAL METHADONE IN RATS.

THE PRODUCTION OF MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE BY THE ORAL ROUTE IN THE RAT.

LONG-ACTING ORAL VS INJECTABLE ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENICS: A ONE-YEAR DOUBLE-BLIND COMPARISON IN MULTIPLE EPISODE SCHIZOPHRENICS.

003467 04-08 TREATMENT OF ENDOGENOUS DEPRESSION WITH ORAL THYROTROPIN
RELEASING HORMONE AND AMITRIPTYLINE.

003502 04-09 COMPARISON OF ORAL AND INTRAVENOUS METHYLPHENIDATE 003559 04-11

FLUPHENAZINE-DECANOATE, FLUPHENAZINE-HYDROCHLORIDE GIVEN ORALLY, AND PLACEBO IN REMITTED SCHIZOPHRENICS: I. RELAPSE RATES AFTER ONE YEAR.

000545 01-08 BEHAVIORAL AND BIOCHEMICAL EFFECTS OF FK33-824, A
PARENTERALLY AND ORALLY ACTIVE ENKEPHALIN ANALOGUE

(UNPUBLISHED PAPER). 002744 03-17

ORAP-ETHNOR

PIMOZIDE (ORAP-ETHNOR): AN INDEPENDENT REPORT. 000974 01-17

STATE-DEPENDENT RETRIEVAL OF ITEM, ASSOCIATIVE, AND SERIAL ORDER INFORMATION.

003711 04-17 ORDINAL QUANTIFICATION AND STATISTICAL ANALYSIS OF ORDINAL SCALE DATA

IN PSYCHIATRY. 000913 01-16 OREXIGENIC

()- AND (-) 3 METHOXYCYPROHEPTADINE. A COMPARATIVE EVALUATION OF THE ANTISEROTONIN, ANTIHISTAMINIC, ANTICHOLINERGIC, AND OREXIGENIC PROPERTIES WITH CYPROHEPTADINE 001012 02-01

ORG-GB-94
EEG, BLOOD LEVEL, AND BEHAVIORAL EFFECTS OF THE ANTIDEPRESSANT
MIANSERIN (ORG-GB-94). 001545 02-07

ORG-2766 CEREBRAL CIRCULATION IS ALTERED BY A POTENT ACTH4-9 ANALOG --ORG-2766

ORG-6582

COMPARISON OF THE EFFECTS OF 6 CHLORO-2-AMINOTETRALIN AND OF ORG-6582, A RELATED CHLOROAMPHETAMINE ANALOG, ON BRAIN SEROTONIN METABOLISM IN RATS.

EFFECTS OF ORG-6582, CHLORIMIPRAMINE AND DESMETHYLIMIPRAMINE ON THE DEPLETION OF BIOGENIC AMINES FROM THE RAT BRAIN IN VIVO.

000159 01-03 ORGAN

ANGIOTENSIN RECEPTIVE NEURONES IN THE SUBFORNICAL ORGAN STRUCTURE-ACTIVITY RELATIONS.

LOCALIZATION OF RECEPTORS FOR THE DIPSOGENIC ACTION OF ANGIOTENSIN-II IN THE SUBFORNICAL ORGAN OF RAT.

Psychopharmacology Abstracts

001766 02-15

Subject Ind
TRAZODONI TO ORGA
OBESITY RE
EFFECTS OF MENTAL
ORGANIC IA
DISCRIMINA
LISURID (LY PSYCHOS
ORGANIC-BRAI PHARMACO EVALUAT
ACUTE ORG THERAPY
PERSPECTIV AND ORG
ACTH4-10 I SYMPTON SYNDROM
PRESCRIPTIO
TREATMENT 21657. A CLINICAL
ORGANIZATION AMITRIPTYN WORLD H
MARIJUAN/ OF PICTU
RESEARCH I
AN ULTRAS ON SYNA

	bject Index	
	GANIC	CECONDARY
	TRAZODONE BY INTRAVENOUS INFUSION IN DEPRESSIONS TO ORGANIC DISEASE.	
	OBESITY RELATED TO THE USE OF PSYCHOTROPIC DRUGS, ITS ORGANIC ASPECT.	000585 01-09 CONSIDERED IN
	EFFECTS OF PIRACETAM ON REGIONAL CEREBRAL BLOOD F	001803 02-15
	MENTAL FUNCTIONS IN PATIENTS WITH ORGANIC DEME	
	ORGANIC IMPAIRMENT IN POLYDRUG USERS: RISK FACTO	RS.
	DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE: OR	
	MOLECULAR MECHANISMS AND NEUROCHEMICAL EVEN	TS. 003254 04-04
	LISURID (LYSENYL-SPOFA) IN THE TREATMENT OF ORGANI PSYCHOSYNDROME IN INVOLUTION.	
_		003563 04-11
	GANIC-BRAIN-SYNDROME PHARMACOTHERAPY FOR ORGANIC-BRAIN-SYNDROME IN EVALUATION OF AN ERGOT DERIVATIVE VS PLACEBO.	LATE LIFE:
	ACUTE ORGANIC-BRAIN-SYNDROME ASSOCIATED WITH G	000628 01-11
	THERAPY.	
	PERSPECTIVES IN BIOLOGICAL PSYCHIATRY, PART 3: SCHI	000808 01-15
	AND ORGANIC-BRAIN-SYNDROME.	
	ACTH4-10 IN THE AMELIORATION OF NEUROPSYCHOLOGIC	001696 02-14
	SYMPTOMATOLOGY ASSOCIATED WITH SENILE ORGANI SYNDROME.	
	STAUKOME.	002505 03-11
	PRESCRIPTION DRUG-INDUCED ORGANIC-BRAIN-SYNDROM	
	TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDRO 21657. A DERIVATIVE OF A PYRITINOL METABOLITE: D CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STI	OUBLE-BLIND
	CLINICAL, QUANTITATIVE EEG, AND PSTCHOMETRIC ST	003571 04-11
	GANIZATION AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL WORLD HEALTH ORGANIZATION COLLABORATIVE STUD	
		002426 03-09
	MARIJUANA: EFFECTS ON FREE RECALL AND SUBJECTIVE (OF PICTURES AND WORDS.	
		002629 03-14

PTIC ORGANIZATION. 002968 04-03 INCORPORATION, AFTER SINGLE AND REPEATED APPLICATION OF RADIOACTIVE LABELLED DH-ERGOT ALKALOIDS IN DIFFERENT ORGANS OF THE CAT, WITH SPECIAL REFERENCE TO THE BRAIN. 002047 03-03 CHARACTERISTICS OF MONOAMINE-OXIDASES IN BRAIN AND OTHER ORGANS OF THE GOLDEN HAMSTER.

TRUCTURAL STUDY INTO THE EFFECTS OF PENTOBARBITONE

002900 04-03 EFFECTS OF SOME OF THE NEUROLEPTICS ON THE REPRODUCTIVE ORGANS OF RATS. 003419 04-05

ORGASM
EVIDENCE AGAINST INVOLVEMENT OF ENDORPHINS IN SEXUAL AROUSAL
AND ORGASM IN MAN.

PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS THERAPEUTIC APPLICATION.

001737 02-14 ORIGIN

ON THE ORIGIN OF VANILLYLMANDELIC-ACID AND 3 METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT BRAIN. THE NEURONAL ORIGIN OF PROSTAGLANDIN RELEASED FROM THE RABBIT PORTAL VEIN IN RESPONSE TO ELECTRICAL STIMULATION 002804 04-03 002933 04-03

INVESTIGATIONS CONCERNING THE CELLULAR ORIGIN OF DOPAMINE 002944 04-03

OPIGINS ORIGINS AND FUTURE OF BEHAVIORAL PHARMACOLOGY 002739 03-17

OROTIC-ACID
EFFECTS OF OROTIC-ACID AND PIRAZETAM ON CORTICAL BIOELECTRICAL **ACTIVITY IN RABBITS.** 000171 01-03 DEATHS AFTER OVERDOSES OF ORPHENADRINE.

000865 01-15 INTOXICATION BY ORPHENADRINE HCL; MECHANISM AND THERAPY. 001519 02-05 TWO CASES OF SEVERE ORPHENADRINE POISONING WITH ATYPICAL 001748 02-15

DEATHS AFTER OVERDOSES OF ORPHENADRINE.

ORTHO-SUBSTITUTED
6-OHDA AND ITS ANALOGUES: CHEMICAL MECHANISM OF
NEUROTOXICITY. STUDY OF THE OXIDATION OF ORTHO-SUBSTITUTED 000059 01-03

ORTHOMOLECULAR
NEUROTRANSMITTER THEORY AND ORTHOMOLECULAR PRACTICE 003725 04-17

OSMOTIC OSMOTIC MINIPUMPS FOR ADMINISTRATION OF BARBITAL TO MICE: DEMONSTRATION OF FUNCTIONAL TOLERANCE AND PHYSICAL DEPENDENCE. 002374 03-06

EFFECT OF ETHANOL ON (3H)OUABAIN BINDING TO DIFFERENT REGIONS OF THE CAT BRAIN. 000264 01-03

EFFECT OF METABOLIC INHIBITORS AND OUABAIN ON AMPHETAMINE-INDUCED AND POTASSIUM-INDUCED RELEASE OF BIOGENIC AMINES FROM ISOLATED BRAIN TISSUE. 002142 03-03

COUNTERACTIVE EFFECTS OF NOREPINEPHRINE AND AMPHETAMINE ON OUABAIN-INDUCED AMNESIA. 000122 01-03

OUTCOME BIPOLAR MANIC-DEPRESSIVE DISORDER: A REASSESSMENT OF COURSE 001608 02-09

BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS: ASSAY PROCEDURES, REPRODUCIBILITY AND RELATIONSHIP TO THERAPEUTIC OUTCOME AND SIDE-EFFECTS.

THE SOCIAL OUTCOME OF PATIENTS IN A TRIAL OF LONG-TERM CONTINUATION THERAPY IN SCHIZOPHRENIA: PIMOZIDE VS. FLUPHENAZINE.

003455 04-08 DATA ANALYSIS: COLLABORATIVE OUTPATIENT SCHIZOPHRENIA STUDY 000528 01-08

TRICYCLIC ANTIDEPRESSANTS IN OUTPATIENT THERAPY

CLINICAL LABORATORY STUDIES WITH SPECIAL REGARD TO HEPATIC METABOLISM IN SCHIZOPHRENICS ON OUTPATIENT LONG-TERM NEUROLEPTIC MEDICATION.

OUTPATIENT MAINTENANCE OF CHRONIC SCHIZOPHRENIC PATIENTS WITH FLUPHENAZINE-DECANOATE (MODECATE): IBADAN EXPERIENCE.

CLINICAL STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE CONDITIONS IN OUTPATIENT PRACTICE. 003479 04-09

OUTPATIENTS
A DOUBLE-BLIND CONTROLLED STUDY OF CLOBAZAM FOR THE TREATMENT OF ANXIETY IN PSYCHIATRIC OUTPATIENTS.

000508 01-07 COMPARISON OF PIMOZIDE AND TRIFLUOPERAZINE AS ONCE-DAILY THERAPY IN CHRONIC SCHIZOPHRENIC OUTPATIENTS.

000537 01-08 MULTICLINIC CROSS-OVER COMPARISON OF TRIAZOLAM (HALCION) AND PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND ANXIETY IN ANXIOUS OUTPATIENTS.

DOUBLE-BLIND PLACEBO-CONTROLLED COMPARISON OF AMOXAPINE AND IMPRAMINE IN DEPRESSED OUTPATIENTS.

WHICH TRICYCLIC FOR DEPRESSED OUTPATIENTS, IMIPRAMINE PAMOATE OR AMITRIPTYLINE?

O01589 02-09

EXPERIENCES WITH USING THE ANTIDEPRESSANT DIBENZEPIN: NOVERIL,
ON NEUROLOGY OUTPATIENTS.

001615 02-10 REEXAMINATION OF USING ANTIPARKINSONS DRUGS WITH PSYCHOTROPIC DRUG THERAPY -- A SURVEY OF OUTPATIENTS 001874 02-16

A DOUBLE-BLIND CONTROLLED STUDY OF PIPOTHIAZINE-PALMITATE IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS. 002390 03-08

TRIMIPRAMINE IN THE TREATMENT OF ANXIOUS DEPRESSED OUTPATIENTS.

	DOXEPIN OR DIAZEPAM FOR ANXIOUS AND ANXIOUS DEPR OUTPATIENTS?	ESSED
	A LONG-TERM COMPARATIVE TRIAL OF PENFLURIDOL AND FLUPHENAZINE-DECANOATE IN SCHIZOPHRENIC OUTPATIE	
οu	TPUT	003459 04-08
	BROMOCRIPTINE AND GASTRIC ACID OUTPUT. COENZYME-A IS A PURINE NUCLEOTIDE MODULATOR OF AC	001761 02-15 ETYLCHOLINE
	OUTPUT.	002874 04-03
ov	ARIECTOMIZED EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON UTERINE CYTOLOGY OF OVARIECTOMIZED RATS.	
	THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDRI (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HOI AND LUTEINIZING HORMONE (LH) IN THE OVARIECTOMIZ MONKEY.	RMONE (FSH)
	EFFECTS OF THE PROSTAGLANDIN SYNTHESIS INHIBITOR, IN ON ESTROGEN AND ESTROGEN PLUS PROGESTERONE-IND RECEPTIVITY IN OVARIECTOMIZED RATS.	UCED SEXUAL
ov	FERDOSAGE	003237 04-04
	CARDIAC EFFECTS OF AMITRIPTYLINE OVERDOSAGE.	000893 01-15
	IATROGENIC COMPLICATIONS OF DRUG OVERDOSAGE AND	POISONING. 001824 02-15
-		OSTIGMINE. 001844 02-15
U	PREDOSE DOXEPIN OVERDOSE: SUCCESS WITH PHYSOSTIGMINE AND WITH NEOSTIGMINE IN REVERSING TOXICITY.	
	TRICYCLIC ANTIDEPRESSANT OVERDOSE: INCIDENCE OF SY	000772 01-14 MPTOMS. 000801 01-15
	CARDIAC ARRHYTHMIA AND HYPOPOTASSEMIA IN ASSOC LITHIUM-CARBONATE OVERDOSE.	IATION WITH
	TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS AND ADVERSAFTER OVERDOSE.	000843 01-15 SE EFFECTS
	THE BARBITURATE OVERDOSE.	000883 01-15
	CHARCOAL HEMOPERFUSION AND ANTIDEPRESSANT OVER	001778 02-15 DOSE.
	TRICYCLIC ANTIDEPRESSANTS: PLASMA LEVELS AND CLINI IN OVERDOSE.	002774 03-17 CAL FINDINGS
	TRICYCLIC OVERDOSE IN A PATIENT GIVEN COMBINED TRIC	003643 04-15 CYCLIC MAOI
-	TREATMENT.	003685 04-15
O	PRUG ANALYSIS IN THE OVERDOSED PATIENT: ITS APPLICATION CLINICAL TOXICOLOGY.	ATION TO
	THE TRICYCLIC ANTIDEPRESSANT OVERDOSED PATIENT.	000802 01-15
OV	/ERDOSES	001852 02-15
	DEATHS AFTER OVERDOSES OF ORPHENADRINE.	000865 01-15
	DEATHS AFTER OVERDOSES OF ORPHENADRINE.	001766 02-15
-		PATIENTS. 001822 02-15
01	LITHIUM AND CRISIS INTERVENTION: DAMPING AFFECTIVE	OVERLOAD. 003717 04-17
01	THE INDOLEAMINE HYPOTHESIS OF DEPRESSION: AN OVER PILOT STUDY.	
	PHARMACOLOGICAL RESEARCH AND THE PSYCHOSES: AN	000592 01-09 OVERVIEW. 001868 02-16
	PSYCHOSOMATIC MEDICINE TODAY: AN OVERVIEW.	
	BIOCHEMICAL AND PHARMACOLOGICAL DIFFERENTIATION DISORDERS: AN OVERVIEW.	
	ENDORPHINS IN PSYCHIATRY: AN OVERVIEW AND A HYPO	003495 04-09 THESIS. 003730 04-17
	THE ROLE OF HYPOTHALAMIC SEROTONIN (5-HT) BEFORE IMMATURE RATS TREATED WITH PREGNANT MARE SER	
0)	MULTIPLE ORAL DOSES OF DIAZEPAM, OXAZEPAM AND P TO DOGS — BEHAVIOURAL EFFECTS AND CORRELATION ANTIPYRINE HALF-LIFE.	HENOBARBITAL WITH

COMBINATION OF PHENYLPYRROLIDINOPENTANE (KATO OXAZEPAM (ADUMBRAN): A DOUBLE-BLIND TRIAL ((INSIDON) IN DEPRESSIVE SYNDROME.	
PHARMACOKINETICS OF OXAZEPAM IN HEALTHY VOLU	000597 01-10 INTEERS.
OXAZEPAM DISPOSITION IN UREMIC PATIENTS.	000685 01-13
COMPARATIVE BIOAVAILABILITY OF ORAL DOSAGE FO	
OXAZEPAM — CORRELATION WITH IN VITRO DISSOL PHARMACOLOGICAL INVESTIGATIONS CONCERNING CO EFFECTS OF ALCOHOL AND OXAZEPAM IN THE REACH	000727 01-13 OMBINATION
FLOPPY-INFANT SYNDROME: IS OXAZEPAM THE ANSW	000897 01-15
BIOAVAILABILITY OF OXAZEPAM: ABSENCE OF INFLUE	001619 02-11
EFFECTS OF CHLORDIAZEPOXIDE AND OXAZEPAM ADN VERBAL HOSTILITY.	001673 02-13 AINISTRATION ON
EFFECTS OF CHLORDIAZEPOXIDE, OXAZEPAM, CHLORP AMPHETAMINE ON SEXUAL RESPONSES IN MALE AN	001720 02-14 ROMAZINE, AND D ND FEMALE
HAMSTERS.	002208 03-04
SAFETY OF OXAZEPAM.	002702 03-15
THE ENTEROHEPATIC CIRCULATION OF OXAZEPAM-O-G	LUCURONIDE IN
GUINEA-PIGS.	002820 04-03
OXIDASE PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC DRUG METABOLISM — I. FACTORS THAT INFLUENCE ESTIMATIONS DURING MIXED FUNCTION OXIDASE R	NADPH KINETIC REACTIONS.
OXIDATION	002931 04-03
6-OHDA AND ITS ANALOGUES: CHEMICAL MECHANISM NEUROTOXICITY. STUDY OF THE OXIDATION OF ORT DOPAMINES.	THO-SUBSTITUTED
EFFECTS OF RESERPINE AND SEROTONIN ON ADENINE- METABOLISM AND GLUCOSE OXIDATION OF WASHE	
PLATELETS.	000237 01-03
MECHANISM FOR PHENOTHIAZINE OXIDATION. OXIDATION KINETICS OF PHENOTHIAZINE AND 10	001014 02-01
METHYLPHENOTHIAZINE IN ACIDIC MEDIUM. EFFECTS OF ADENINE-NUCLEOTIDES ON OXIDATION OF	001015 02-01 PHENOTHIAZINE
TRANQUILIZERS. FURTHER STUDIES ON THE INHIBITION OF MONOAMIN	001059 02-03 E OXIDATION BY
MONOAMINE-OXIDASE INHIBITORS.	002022 03-03
INHIBITION OF MONOAMINE OXIDATION IN SUBFRACT MITOCHONDRIA OF RAT BRAIN BY CLORGYLINE AN	TIONS OF CRUDE
PHENOBARBITAL ACTIONS IN VIVO: EFFECTS OF EXTR. POTASSIUM ACTIVITY AND OXIDATIVE METABOLIS CEREBRAL-CORTEX.	
QUINAZOLINES AND 1.4 BENZODIAZEPINES, 81. \$	000176 01-03
TRIAZOLOBENZODIAZEPINES BY OXIDATIVE CYCLIZ. HYDRAZONES.	ATION OF
OXIDE	001017 02-01
PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EFFECT AND COVALENT BINDING OF PUTATIVE ARE METABOLITE IN GESTATIONAL TISSUE.	
OXIDIZED	001515 02-05
IDENTIFICATION OF THE IN VITRO N OXIDIZED METAB (-) N BENZYLAMPHETAMINE.	OLITES OF ()- AND
OXOTREMORINE	001054 02-03
ON THE INTERACTION OF DRUGS WITH THE CHOLINER SYSTEM – IV. TOLERANCE TO OXOTREMORINE IN A IN VITRO STUDIES.	GIC NERVOUS MICE: IN VIVO AND
THE EFFECTS OF OXOTREMORINE AND PHYSOSTIGMIN	000188 01-03 IE ON MORPHINE-
INDUCED CIRCLING IN THE MOUSE.	001457 02-04

PERIPHERAL CATECHOLAMINES RELEASED BY OXOTREMORINE MODULATE TREMOR IN THE RAT. (UNPUBLISHED PAPER).

001486 02-04

000308 01-04

CHOLINERGIC INHIBITION OF METHYLPHENIDATE-INDUCED STEREOTYPY: OXOTREMORINE. 002223 03-04

OXPRENOLOL
EFFECT OF OXPRENOLOL ON STAGE-FRIGHT IN MUSICIANS.

001718 02-14 OXPRENOLOL (TRASICOR) POISONING

OXYGEN

EFFECT OF DOPAMINERGIC AGONISTS UPON OXYGEN AVAILABILITY FOR CEREBRAL-CORTEX.

001819 02-15

003263 04-04

SUBSTRATE SELECTIVE ACTIVATION OF RAT LIVER MITOCHONDRIAL MONOAMINE-OXIDASE BY OXYGEN. 002912 04-03

OXYMORPHONE
QUANTUM CHEMICAL STUDIES OF N SUBSTITUENT VARIATION IN THE
OXYMORPHONE SERIES OF OPIATE NARCOTICS. 001946 03-01

OXYPERTINE IN COMBINATION WITH IMPRAMINE: A CONTROLLED TRIAL.

003521 04-09

OXYTOCIN

OXYTOCIN, VASOPRESSIN AND MEMORY: OPPOSITE EFFECTS ON CONSOLIDATION AND RETRIEVAL PROCESSES.

003174 04-04 OPPOSITE ACTION OF OXYTOCIN TO VASOPRESSIN IN PASSIVE AVOIDANCE BEHAVIOR IN RATS.

P-BROMOMETHAMPHETAMINE
THE EFFECT OF P-BROMOMETHAMPHETAMINE ON AGGRESSIVE

001392 02-04

P-CHLOROAMPHETAMINE
FURTHER STUDIES ON THE EFFECTS OF N CYCLOPROPYL PCHLOROAMPHETAMINE IN RAT BRAIN.

000111 01-03

CEREBRAL METABOLISM OF (3H) P-CHLOROAMPHETAMINE

000267 01-03 REVERSIBLE AND IRREVERSIBLE EFFECTS OF P-CHLOROAMPHETAMINE ON BRAIN SEROTONIN IN MICE.

METABOLIC ACTIVATION OF P-CHLOROAMPHETAMINE TO A CHEMICALLY REACTIVE METABOLITE.

000476 01-05
TEMPORAL EFFECTS OF P-CHLOROAMPHETAMINE ON CATECHOLAMINE

001251 02-03

FACILITATION OF SIDMAN AVOIDANCE PERFORMANCE BY I CHLOROAMPHETAMINE: ROLE OF BIOGENIC AMINES.

001467 02-04 IMPORTANCE OF DURATION OF DRUG ACTION IN THE ANTAGONISM OF P-CHLOROAMPHETAMINE DEPLETION OF BRAIN SEROTONIN --COMPARISON OF FLUOXETINE AND CHLORIMIPRAMINE.

002017 03-03
RAPID TOLERANCE TO THE MOTOR EFFECTS OF P-CHLOROAMPHETAMINE IN RATS.

002226 03-04 EFFECTS OF P-CHLOROAMPHETAMINE ON BRAIN SEROTONIN IN

IMMATURE RATS.

O02866 04-03 EVALUATION OF THE EFFECT OF P-CHLOROAMPHETAMINE ON INDIVIDUAL CATECHOLAMINERGIC NUCLEI IN THE RAT BRAIN.

LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO P-CHLOROAMPHETAMINE ON CENTRAL SEROTONERGIC MECHANISMS IN

INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETINE ON HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE (PCA) AND 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77).

003271 04-04

COMPARISON OF THE BEHAVIORAL EFFECTS OF P-CHLOROAMPHETAMINE, CHLORDIMEFORM, QUIPAZINE, AND INTRAVENTRICULAR SEROTONIN

P-CHLOROAMPHETAMINES
TOLERANCE TO P-CHLOROAMPHETAMINES EFFECTS ON SIDMAN
AVOIDANCE PERFORMANCE AND CATECHOLAMINE METABOLISM.
002314 03-04

P-CHLOROPHENYL-GABA
BACLOFEN (P-CHLOROPHENYL-GABA) IN SCHIZOPHRENIA.

002378 03-07

P-CHLOROPHENYLALANINE

EFECTS OF P-CHLOROPHENYLALANINE (PCPA) ON SLEEP IN OLFACTORY
BUILB LESIONED RATS. 000032 01-02

EFFECTS OF P-CHLOROPHENYLALANINE AND ALPHA-METHYLTRYPTOPHAN ON BEHAVIOUR AND BRAIN 5 HYDROXYINDOLES. 000405 01-04 Psychopharmacology Abstracts

P-CHLOROPHENYLALANINE PRODUCED EFFECTS ON BEHAVIOR IN INTACT AND BRAIN-DAMAGED RATS.

000421 01-04 5 HYDROXYTRYPTAMINE DEPLETION WITH P-CHLOROPHENYLALANINE: EFFECTS ON EATING, DRINKING, IRRITABILITY, MURICIDE, AND COPULATION.

000429 01-04 THE EFFECTS OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE IN AN ANIMAL TEST OF ANXIETY.

001121 02-03 EFFECT OF P-CHLOROPHENYLALANINE ON DEVELOPMENT OF CROSS-TOLERANCE BETWEEN PENTOBARBITAL AND ETHANOL.

O01123 02-03

OF TOLERANCE TO ETHANOL.

OF TOLERANCE TO ETHANOL.

EFFECT OF NEUROLEPTIC DRUGS ON THE CONDITIONED BEHAVIOR AFTER PRETREATMENT WITH ALPHA-METHYLTYROSINE OR P-CHLOROPHENYLALANINE. 002290 03-04

EFFECT OF P-CHLOROPHENYLALANINE (PCPA) AND PHENYLALANINE (PHE)
TREATMENT ON EARLY AUDITORY EVOKED RESPONSES IN RATS. 002304 03-04

DISRUPTION OF LATENT INHIBITION FOLLOWING SYSTEMIC ADMINISTRATION OF P-CHLOROPHENYLALANINE (PCPA).

002309 03-04 EFFECT OF P-CHLOROPHENYLALANINE ON THE ACQUISITION OF TOLERANCE TO THE HYPOTHERMIC EFFECTS OF ALCOHOL.

002913 04-03 THE EFFECTS OF P-CHLOROPHENYLALANINE, RESERPINE, METHYSERGIDE AND CYPROHEPTADINE ON THE DOPA-INDUCED EEG SYNCHRONIZATION IN THE RAT.

003022 04-03 P-CHLOROPHENYLALANINE PRODUCES DISSOCIATED EFFECTS ON AGGRESSION EMOTIONALITY AND MOTOR ACTIVITY.

003293 04-04

EFFECT OF METERGOLINE, P-CHLOROPHENYLALANINE AND DOPA ON DELAYED RESPONSE IN CATS AND THE RELATIONSHIP BETWEEN THE MESOLIMBIC AND NIGROSTRIATAL NEURONS. 003339 04-04

CIRCLING BEHAVIOUR IN THE RAT FOLLOWING UNILATERAL INJECTIONS OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE INTO THE SUBSTANTIA-NIGRA.

003375 04-04

P-CHLOROPHENYLALANINE-METHYL-ESTER
MORPHINE AND ETHANOL AS DISCRIMINATIVE STIMULI: ABSENCE OF
ANTAGONISM BY P-CHLOROPHENYLALANINE-METHYL-ESTER,
CINANSENIN, OR BC-105.

000473 01-04

P-HYDROXYAMPHETAMINE
THE ACCUMULATION OF P-HYDROXYAMPHETAMINE BY BRAIN
HOMOGENATES AND ITS ROLE IN THE RELEASE OF CATECHOLAMINES.

000074 01-03 P-HYDROXYNOREPHEDRINE

AGONIST EFFECTS OF BETA-PHENYLETHYLAMINES ON THE NORADRENERGIC CYCLIC-ADENOSINE-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. 3,5-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. STEREOISOMERS OF P-HYDROXYNOREPHEDRINE

000272 01-03 BEHAVIOURAL SPECIFIC TOLERANCE FOLLOWING CHRONIC D OR L AMPHETAMINE TREATMENT: LACK OF INVOLVEMENT OF P-HYDROXYNOREPHEDRINE.

002261 03-04 P-HYDROXYPHENOBARBITAL
SULFATES AND GLUCURONIDES OF P-HYDROXYPHENOBARBITAL IN RAT

FECES. 002165 03-03

P-METHOXYAMPHETAMINE
A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHOXYAMPHETAMINE
(DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), PMETHOXYAMPHETAMINE (PMA), D AMPHETAMINE (A), AND LSD IN
NONTOLERANT AND LSD TOLERANT CHRONIC SPINAL DOGS.

001273 02-03 PHARMACOLOGICAL DIFFERENTIATION OF THE CENTRAL 5
HYDROXYTRYPTAMINE-LIKE ACTIONS OF MK-212 (6 CHLORO-2-1PIPERAZINYL-PYRAZINE), P-METHOXYAMPHETAMINE AND
FENFLURAMINE IN AN IN VIVO MODEL SYSTEM.

LSD-INDUCED STIMULUS CONTROL: A COMPARISON OF SCH-12679, FENFLURAMINE, P-METHOXYAMPHETAMINE, AND BL-3912. 003396 04-04

P-METHOXYAMPHETAMINE-INDUCED
BLOCKADE OF P-METHOXYAMPHETAMINE-INDUCED SEROTONERGIC
EFFECTS BY CHLORIMIPRAMINE.

002166 03-03

P-METHOXYPHENYLETHYLAMINE
P-METHOXYPHENYLETHYLAMINE (PMPEA): SOME BEHAVIORAL **OBSERVATIONS IN RATS.**

001319 02-04

VOLUME 16, SUBJECT INDEX

Subject Index

P-TYRAMINE PLASMA CONCENTRATIONS OF SOME ACIDIC AND ALCOHOLIC METABOLITES DERIVED FROM M- AND P-TYRAMINE, OCTOPAMINE AND CATECHOLAMINES IN HUMANS.

001158 02-03

A POSSIBLE ROLE OF THE PAG IN THE MEDIATION OF SUBJECTIVE EFFECTS

001444 02-04

PAIN

THE ROLE OF ASCENDING AND DESCENDING 5 HYDROXYTRYPTAMINE NEURONES IN CENTRAL CONTROL OF PAIN SENSITIVITY. 000380 01-04

EFFECTS OF INTRAVENOUS TETRAHYDROCANNABINOL ON EXPERIMENTAL AND SURGICAL PAIN. 000655 01-11

THE NEW WAR ON PAIN.

000943 01-17 NALOXONE REVERSAL OF MORPHINE ANALGESIA BUT FAILURE TO ALTER REACTIVITY TO PAIN IN THE FORMALIN TEST.

ENDORPHINS: NALOXONE FAILS TO ALTER EXPERIMENTAL PAIN OR MOOD IN HUMANS

002383 03-07 A COMPARISON OF THE ANALGESIC EFFECT OF INTRAMUSCULAR NALBUPHINE AND MORPHINE IN PATIENTS WITH POSTOPERATIVE

EFFECTS OF PAIN ATTENUATING BRAIN STIMULATION AND MORPHINE ON ELECTRICAL ACTIVITY IN THE RAPHE NUCLEI OF THE AWAKE RAT.

DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION 003241 04-04

PAINFUL

HYPERALGESIA INDUCED BY NALOXONE FOLLOWS DIURNAL RHYTHM IN RESPONSIVITY TO PAINFUL STIMULI. 001124 02-03

CHANGES IN BRAIN FREE FATTY-ACIDS AFTER PAINFUL PERIPHERAL STIMULATION (EFFECT OF PROTHIADEN). 003094 04-03

PAIR

PAMOATE

THE EFFECTS OF CHLORDIAZEPOXIDE ON A DELAYED PAIR COMPARISON TASK IN PIGEONS.

003348 04-04

PALLIDOSTRIATAL PHARMACOLOGICAL EVIDENCE FOR DOPAMINERGIC PALLIDOSTRIATAL INTERACTION

003137 04-03

INCORPORATION OF RADIOACTIVE LABELLED CHOLINE AND PALMITATE INTO LUNG LECITHIN OF RABBITS TREATED WITH HIGH DOSES OF BROMCARBAMIDES, BARBITURATES AND DIAZEPAM.

PALMITIC ACTION OF THE PALMITIC ESTER OF PIPOTIAZINE ON DOPAMINE METABOLISM IN THE NIGROSTRIATAL, MESOLIMBIC AND

MESOCORTICAL SYSTEMS. 000258 01-03

WHICH TRICYCLIC FOR DEPRESSED OUTPATIENTS, IMIPRAMINE PAMOATE OR AMITRIPTYLINE?.

PANAY EFFECT OF PANAX GINSENG ROOT ON CONDITIONED AVOIDANCE RESPONSE IN RATS.

001451 02-04 PANCURONIUM

THE EFFECT OF PANCURONIUM AND GALLAMINE ON MUSCARINIC TRANSMISSION IN THE SUPERIOR CERVICAL GANGLION. 002021 03-03 **PANENCEPHALITIS**

LEVODOPA IN SUBACUTE SCLEROSING PANENCEPHALITIS. 001547 02-07

EFFECT OF PAPAVERINE AND DIHYDROERGOTOXINE-MESYLATE ON CEREBRAL MICROFLOW, EEG, AND PO2 IN OLIGEMIC HYPOTENSION 002032 03-03

PAPILLEDEMA PAPILLEDEMA FOLLOWING THERAPEUTIC DOSAGES OF LITHIUM-CARBONATE. 003662 04-15

A COMPARISON OF THE EFFECTS OF SEIZURES AND TWO
ANTICONVULSANT MEDICATIONS ON LEARNING IN THE PAPIO-PAPIO BABOON. (PH.D. DISSERTATION). 002329 03-04 PAPIO-URSINUS

THE EFFECTS OF CANNABIS-SATIVA ON THE BEHAVIOR OF ADULT FEMALE CHACMA BABOONS (PAPIO-URSINUS) IN CAPTIVITY. 000402 01-04

CLINICAL PARABLE: MIRTHLESS MERRY-GO-ROUND.

003463 04-08

PARACETAMOL
ANOTHER PARACETAMOL TRAGEDY.

PARADIGM

000853 01-15 AN INVESTIGATION OF NALORPHINE AND PERPHENAZINE AS NEGATIVE

REINFORCERS IN AN ESCAPE PARADIGM. RECEPTOR SENSITIVITY MODIFICATION (RSM) -- A NEW PARADIGM FOR THE POTENTIAL TREATMENT OF SOME HORMONAL AND TRANSMITTER

001659 02-13

EVALUATING ANTIANXIETY AGENT IN HUMANS: EXPERIMENTAL PARADIGMS.

000661 01-11 DRUG DISCRIMINATION PARADIGMS: PROBLEMS OF TOLERANCE AND BEHAVIORAL DISRUPTION.

003692 04-16 PARADOXICAL PARADOXICAL EFFECTS OF AMPHETAMINE ON PREWEANLING AND

POSTWEANLING RATS. 000327 01-04

PARADOXICAL RESPONSE TO DOPAMINE AGONISTS IN TARDIVE-DYSKINESIA

000809 01-15 THE RELATIONSHIP BETWEEN CORTICAL RECRUITING RESPONSES AND PONTO-GENICULO-OCCIPITAL (PGO) WAVES DURING PARADOXICAL SLEEP AND AFTER THE ADMINISTRATION OF RESERPINE IN THE CAT. 9 03-03

CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE-ILLNESS: PARADOXICAL DRUG EFFECTS. 002610 03-14

BIPHASIC EFFECT OF CHLORPROMAZINE ON RAT PARADOXICAL SLEEP: A STUDY OF DOSE-RELATED MECHANISMS 003253 04-04

PARADOXICAL REACTION TO L-DOPA IN SCHIZOPHRENIC PATIENTS PARADOXICAL EFFECTS IN SLEEP AND PERFORMANCE OF TWO DOSES OF CHLORPROMAZINE

003629 04-14 PARALLEL

EVIDENCE FOR PARALLEL DEVELOPMENT OF TOLERANCE TO THE HYPERACTIVATING AND DISCOORDINATING EFFECTS OF ETHANOL

PARALLEL CHANGES IN BEHAVIOR AND HIPPOCAMPAL MONOAMINE METABOLISM IN RATS AFTER ADMINISTRATION OF ACTH ANALOGUES. 003335 04-04

PARALYSIS PSYCHOTROPIC DRUGS AND INTESTINAL PARALYSIS.

000875 01-15

PARAMETERS CLINICAL EFFECTS OF TREATMENT WITH CHLORPROMAZINE AND THE PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS. 000670 01-11

VIDEOTAPE METHODS FOR IDENTIFICATION OF NONVERBAL BEHAVIOR PARAMETERS IN DEPRESSIVE SYNDROMES. NEUROPHYSIOLOGICAL PARAMETERS OF DROPERIDOL-INDUCED

PSYCHOSES. A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE SHORT-TERM EFFECTS OF CLOZAPINE UPON SLEEP PARAMETERS OF NORMAL YOUNG

ADULTS 001734 02-14 EFFECTS OF COMPLETE HYPOTHALAMIC DEAFFERENTATION AND 5,7
DIHYDROXYTRYPTAMINE ON SEVERAL PARAMETERS OF PROLACTIN

RELEASE. 001990 03-03 ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE, SELF-STIMULATION, AND PARAMETERS OF ICS.

002320 03-04 PARAMETERS OF THE DORSAL BUNDLE EXTINCTION EFFECT: PREVIOUS EXTINCTION EXPERIENCE.

003289 04-04

PARANCIA
EFFECTS OF AMPHETAMINE ON SOCIAL BEHAVIORS OF RHESUS MACAQUES: AN ANIMAL MODEL OF PARANOIA. 002365 03-06

CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND ITS METABOLITES AND CLINICAL RATINGS IN PATIENTS WITH ACUTE RELAPSE OF SCHIZOPHRENIC AND PARANOID PSYCHOSIS. 000726 01-13

REGIONAL CHANGES OF CEREBRAL BLOOD FLOW DURING HALOPERIDOL THERAPY IN PATIENTS WITH PARANOID SYMPTOMS.

001677 02-13 EEG RECORDS AND THE EFFECTS OF PHENOTHIAZINE TREATMENT IN PATIENTS WITH PARANOID SCHIZOPHRENIA.

AMPHETAMINE PSYCHOSIS -- A MODEL FOR PARANOID SCHIZOPHRENIA?

THE THIORIDAZINE LEVEL IN THE BLOOD SERUM AND SYMPTOMS OF THE PARANOID SYNDROME.

WAKING STAGE-1 REM OBSERVED IN PARANOID HALLUCINATORY STATES OF NARCOLEPSY.

002675 03-15

FARATHYROID

HYPERTHYROIDISM AND A PARATHYROID ADENOMA COMPLICATING LITHIUM TREATMENT. 002686 03-15

PARAVENTRICULAR

PARAVENTRICULAR NUCLEUS: A PRIMARY SITE MEDIATING ADRENERGIC STIMULATION OF FEEDING AND DRINKING.

002074 03-03 ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

003272 04-04

COMBINED TREATMENT WITH L-DOPA AND PARCOPAN IN PARKINSONS DISEASE.

002518 03-11 PARENT

PSYCHOTROPIC AND ANTICONVULSANT DRUG USAGE IN EARLY CHILDHOOD SPECIAL EDUCATION PROGRAMS III. A PRELIMINARY REPORT: PARENT INTERVIEWS ABOUT DRUG TREATMENT. 000627 01-11

PARENTERAL

PARENTERAL HALOPERIDOL IN PSYCHIATRIC EMERGENCIES: DOUBLE-BLIND COMPARISON WITH CHLORPROMAZINE.

000566 01-09 A SYNTHETIC ENKEPHALIN ANALOGUE WITH PROLONGED PARENTERAL AND ORAL ANALGESIC ACTIVITY.

RELATIVE EFFICACY OF PARENTERAL HALOPERIDOL AND THIOTHIXENE FOR THE EMERGENCY TREATMENT OF ACUTELY EXCITED AND AGITATED PATIENTS.

001626 02-11 PARENTERAL LOXAPINE IN ACUTE SCHIZOPHRENIA.

PARENTERALLY

LOXAPINE VERSUS HALOPERIDOL PARENTERALLY IN ACUTE PSYCHOSIS WITH AGITATION: A DOUBLE-BLIND STUDY.

001710 02-14 BEHAVIORAL AND BIOCHEMICAL EFFECTS OF FK33-824, A PARENTERALLY AND ORALLY ACTIVE ENKEPHALIN ANALOGUE (UNPUBLISHED PAPER).

MANAGEMENT OF ACUTE ANXIETY SYNDROME WITH PARENTERALLY ADMINISTERED LORAZEPAM.

003539 04-10 PARGYLINE

N ACETYLTRANSFERASE ACTIVITY IN PINEAL GLAND OF RATS TREATED
WITH PARGYLINE.

000046 01-03 EFFECTS OF TRANYLCYPROMINE AND PARGYLINE ON BRAIN TRYPTAMINE.

000279 01-03

EFFECTS OF PARGYLINE ON HYPOTHALAMIC BIOGENIC AMINES AND SERUM PROLACTIN (PRL), LH AND TSH IN MALE RATS.

001988 03-03 RELEASE OF ENDOGENOUS CATECHOLAMINES FROM ISOLATED RAT BRAIN TISSUE BY FENFLURAMINE AND N ETHYLAMPHETAMINE — EFFECTS OF PARGYLINE.

003111 04-03 TESTOSTERONE ATTENUATED STEREOTYPY AND HYPERACTIVITY INDUCED BY BETA-PHENYLETHYLAMINE IN PARGYLINE PRETREATED RATS. 003224 04-04

THE PRODUCTION OF AN ALTERNATIVE LABORATORY MODEL OF THE PARKINSON SYNDROME USING A NEW BENZYLIMIDOYLUREA DERIVATIVE LON-954.

000083 01-03 LEVODOPA IN PARKINSON DISEASE: A LONG-TERM APPRAISAL OF MORTALITY

A DOUBLE-BLIND COMPARISON OF LEVODOPA, MADOPA, AND SINEMET IN PARKINSON DISEASE. 003556 04-11 Psychopharmacology Abstracts

002394 03-08

002404 03-08

PARKINSONIAN
L TRYPTOPHAN ADMINISTRATION IN L-DOPA-INDUCED HALLUCINATIONS IN ELDERLY PARKINSONIAN PATIENTS.

OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINES IN L-DOPA TREATED PARKINSONIAN PATIENTS.

OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINE ALKALOIDS IN L-DOPA TREATED PARKINSONIAN PATIENTS. 002655 03-15

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLLACTIC-ACID (VLA) IN CEREBROSPINAL FLUID AND 3 METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN THE URINE OF PARKINSONIAN PATIENTS TREATED WITH L-DOPA.

003602 04-13 PARKINSONISM

EFFECTS OF LERGOTRILE ON SCHIZOPHRENIA AND DRUG-INDUCED PARKINSONISM.

000548 01-08 THE RELATIONSHIP BETWEEN PARKINSONISM AND TARDIVE-DYSKINESIA 000836 01-15

A COMPARISON OF PIRIBEDIL, PROCYCLIDINE AND PLACEBO IN THE CONTROL OF PHENOTHIAZINE-INDUCED PARKINSONISM.

BRAIN DOPAMINE TURNOVER AND THE RELIEF OF PARKINSONISM 001685 02-13 THERAPY OF PARKINSONISM

001887 02-17

CONSIDERATIONS IN THE MANAGEMENT OF PARKINSONISM.
002510 03-11 ACUTE LITHIUM-INDUCED PARKINSONISM PRECIPITATED BY LIQUID

PROTEIN DIET 002685 03-15 FOUR-YEAR TREATMENT OF PATIENTS WITH PARKINSONISM USING AMANTADINE ALONE OR WITH LEVODOPA.

002707 03-15

PARKINSONISM BY HALOPERIDOL AND PIRIBEDIL.

003648 04-15

PARKINSONS
TREATMENT OF PARKINSONS DISEASE WITH THE COMBINATION L-DOPA/

000633 01-11 CYCLOBENZAPRINE AND BENZOTROPINE METHANESULFONATE IN PARKINSONS DISEASE: A RANDOMIZED DOUBLE-BLIND CROSS-OVER STUDY.

000654 01-11 THE OFF-ON PHENOMENON DURING TREATMENT OF PARKINSONS DISEASE WITH LEVODOPA.

SOMATOSENSORY EVOKED-POTENTIALS IN PATIENTS WITH PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND DECARBOXYLASE INHIBITOR.

COMBINED TREATMENT WITH L-DOPA AND PARCOPAN IN PARKINSONS DISEASE.

002518 03-11 BACLOFEN IN PARKINSONS DISEASE.

003560 04-11 STUDY OF THE TREATMENT OF VASCULAR PARKINSONS DISEASE WITH METAMIZYL.

003599 04-13 TRANYLCYPROMINE (PARNATE) -- A STUDY OF 1000 PATIENTS WITH SEVERE AGITATED DEPRESSIONS.

003507 04-09

PAROSMIA AND AROMATIC ANOSMIA UNDER L-DOPA THERAPY. 000871 01-15

PAROTID
COMPARATIVE AVAILABILITY OF DIAZEPAM (D) IN HUMAN PLASMA
(P), PAROTID SALIVA (PS) AND MIXED SALIVA (MS) AND ITS
RELATIONSHIP TO PLASMA PROTEIN BINDING.

PAROXETINE

OXETINE
INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETINE CN
HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE
(PCA) AND 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77).
003271 04-04

EFFECT OF CHLORDIAZEPOXIDE ON THE PARTIAL REINFORCEMENT EXTINCTION EFFECT.

001491 02-04 ANALGESIA FOLLOWING TRANSCUTANEOUS ELECTRICAL STIMULATION AND ITS PARTIAL REVERSAL BY A NARCOTIC ANTAGONIST. 001646 02-13

INTERACTIONS OF PARTIAL LSD ANALOGS WITH BEHAVIORAL DISRUPTING EFFECTS OF LSD AND DMT IN THE RAT. 002264 03-04 RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION WITH A HIGH FAT/PROTEIN DIET.

BIOLOGICAL ACTIVITY OF NEUROTENSIN AND ITS C-TERMINAL PARTIAL SEQUENCES.

PARTICIPATE
O02973 04-03
INHIBITION BY BARBITURIC-ACID AND ITS DERIVATIVES OF THE ENZYMES
IN RAT BRAIN WHICH PARTICIPATE IN THE SYNTHESIS OF PYRIMIDINE

IN RAT BRAIN WHICH PARTICIPATE IN THE SYNTHESIS OF PYRIMIDINE RIBOTIDES. 003049 04-03

PARTICLE-BOUND
THE SUBCELLULAR DISTRIBUTION OF PARTICLE-BOUND NEGATIVE
CHARGES IN RAT BRAIN.

000492 01-06

PARTICULARITIES OF LITHIUM INTOXICATION IN ADVANCED AGE.
001772 02-15

PASSIVE
DEFICITS IN PASSIVE AVOIDANCE LEARNING FOLLOWING ATROPINE IN
THE DEVELOPING RAT.

PASSIVE AVOIDANCE LEARNING IN THE RAT AS FUNCTIONS OF D
AMPHETAMINE DOSAGE AND SHOCK INTENSITY.

EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AGONISTS AND ANTAGONISTS INTO THE AMYGDALA ON RETENTION OF PASSIVE AVOIDANCE TRAINING IN RATS. (PH.D. DISSERTATION).

TIME-DEPENDENT EFFECTS OF RESERPINE ON RETENTION OF PASSIVE AVOIDANCE.

OPPOSITE ACTION OF OXYTOCIN TO VASOPRESSIN IN PASSIVE AVOIDANCE BEHAVIOR IN RATS.

6 HYDROXYDOPAMINE-INDUCED CATECHOLAMINE DEPLETION AND PASSIVE AVOIDANCE LEARNING IN RATS.

PATHOCHEMISTRY
THE INFLUENCE OF PYRIDOXINE ON THE PSYCHOPATHOLOGY AND
PATHOCHEMISTRY OF DEPRESSIONS OF INVOLUTIONAL AGE.
003485 04-09

PATHOGENESIS

PA

PATHOPHYSIOLOGIC

NEW TREATMENT FOR HEADACHE: PATHOPHYSIOLOGIC

CONSIDERATIONS

Q00961 01-17

GUIDELINES FOR NURSES: THE ADMINISTRATION OF INTRAVENOUS
DRUGS THROUGH AN ESTABLISHED INTRAVENOUS PATHWAY.

001866 02-16
ACTIVATION OF AN IHHIBITORY NORADRENERGIC PATHWAY PROJECTING
FROM THE LOCUS-COERULEUS TO THE CINGULATE CORTEX OF THE RAT.
002895 04-03

CHANGES IN SYNAPTIC FUNCTION INDUCED BY BLOCKAGE OF AXONAL TRANSPORT IN THE RABBIT OPTIC PATHWAY. 002952 04-03

THE STRIATAL DOPAMINERGIC FUNCTION IS MEDIATED BY THE INHIBITION OF A NIGRAL, NONDOPAMINERGIC NEURONAL SYSTEM VIA A STRIO-NIGRAL GABAERGIC PATHWAY.

003325 04-04

PATHWAYS
INTERACTIONS OF SUBSTITUTED BENZAMIDE DRUGS WITH CEREBRAL
DOPAMINE PATHWAYS.

THE EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND 2
BROMOLYSERGIC-ACID-DIETHYLAMIDE (BOL) ON THE STRIATAL DOPA
ACCUMULATION: INFLUENCE OF CENTRAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS.

002125 03-03
INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA:
EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION.
002890 04-03

THE EFFECT OF GAMMA-ACETYLENIC-GABA, AN ENZYME ACTIVATED IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE, ON DOPAMINE PATHWAYS OF THE EXTRAPYRAMIDAL AND LIMBIC SYSTEMS. 003037 04-03

CENTRAL MECHANISMS OF DRUGS AS DISCRIMINATIVE STIMULI: INVOLVEMENT OF SEROTONIN PATHWAYS.

PATIENT

EFFECTS OF KETAMINE ON PATIENT RESPONSIVENESS DURING THE

VARIOUS PHASES OF A SINGLE INDUCED ANXIETY SESSION.

000513 01-C

COUPLES GROUP THERAPY AS AN ADJUNCT TO LITHIUM MAINTENANCE
OF THE MANIC PATIENT.

A PSYCHOSOMATIC TRIAD IN A BIPOLAR PATIENT.

O00589 01-09
DRUG ANALYSIS IN THE OVERDOSED PATIENT: ITS APPLICATION TO

CLINICAL TOXICOLOGY. 000802 01-15

BEING A PATIENT IN A DRUG TRIAL: DO YOU LOSE SOMETHING?. 000929 01-16 LITHIUM TREATMENT OF CYCLICAL VOMITING IN A MENTALLY DEFECTIVE PATIENT.

EEG OBSERVATION OF NOCTURNAL DELIRIUM IN A PATIENT TAKING ANTIDEPRESSANTS AND ANTIPARKINSONS DRUGS.

THE TRICYCLIC ANTIDEPRESSANT OVERDOSED PATIENT. 001773 02-15

SOME OBSERVATIONS ON PATIENT COMPLIANCE IN AN ANTIDEPRESSIVE TRIAL

PAVOR NOCTURNUS IN A SCHIZOPHRENIC PATIENT: A REVIEW AND CASE STUDY.

THE SLEEPY PATIENT. 002521 03-1

TRICYCLIC OVERDOSE IN A PATIENT GIVEN COMBINED TRICYCLIC MAOI

EVALUATION OF A PATIENT DRUG SELF-ADMINISTRATION PROGRAM.
(PH.D. DISSERTATION).

PATIENTS
SULPIRIDE: EVALUATION OF ANTIPSYCHOTIC ACTIVITY IN SCHIZOPHRENIC

PATIENTS. 000512 01-07

CLINICAL AND EXPERIMENTAL EXPERIENCE WITH MAPROTILINE, CLOMIPRAMINE, SYDNOCARB, AND MEFEXAMINE IN PSYCHIATRIC PATIENTS AND NORMAL SUBJECTS.

NEGATIVE NALOXONE EFFECTS IN SCHIZOPHRENIC PATIENTS.

D AMPHETAMINE INHIBITION OF PLATELET MAO FROM SCHIZOPHRENIC PATIENTS.

A SEQUENTIAL TRIAL OF VILOXAZINE (VIVALAN) AND IMIPRAMINE IN MODERATELY DEPRESSED PATIENTS.

THE EFFECT OF L TRYPTOPHAN ADMINISTRATION ON THE CONCENTRATION OF PROBENECID IN PLASMA AND CEREBROSPINAL FILLID IN PATIENTS.

000564 01-09
CYCLIC-ADENOSINE-MONOPHOSPHATE METABOLISM IN PATIENTS WITH
SEVERE DEPRESSIVE ILLNESS.

SEVERE DEPRESSIVE ILLNESS.

000570 01-09
PSYCHOTHERAPY IN COMBINATION WITH ANTIDEPRESSANT DRUGS IN
PATIENTS WITH SEVERE MASKED DEPRESSIONS.

O00572 01-09

EFFECT OF CHLORPROMAZINE TREATMENT ON MONOAMINE METABOLITE
LEVELS IN CEREBROSPINAL FLUID OF PSYCHOTIC PATIENTS.

EFFECT OF A NEW BENZODIAZEJINE DERIVATE, CLOBAZAM, IN ANXIOUS PATIENTS WITH GASTROINTESTINAL DISORDERS.

LITHIUM AND AGGRESSIVE BEHAVIOR IN PATIENTS WITH EARLY TOTAL

STUDIES ON DIGITAL PLETHYSMOGRAPHIC PATTERNS IN FEMALE

PATIENTS WITH NONSPECIFIC COMPLAINTS.

000626 01-11

COMPARISON OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS
HYPNOTICS IN GERIATRIC PATIENTS WITH INSOMNIA.

HYPNOTICS IN GERIATRIC PATIENTS WITH INSOMNIA.

OO0658 01-11

DROPERIDOL IN ACUTELY AGITATED PATIENTS: A DOUBLE-BLIND

PLACEBO-CONTROLLED STUDY.

000662 01-11
THE PEAK EXPERIENCE VARIABLE IN DPT ASSISTED PSYCHOTHERAPY
WITH CANCER PATIENTS.

PHENELZINE IN DEPRESSED PATIENTS: EFFECTS ON URINARY MHPG EXCRETION IN RELATION TO CLINICAL RESPONSE.

O00686 01-13
CATECHOLAMINE AND OCTOPAMINE CONCENTRATIONS IN BRAINS OF PATIENTS WITH REYE SYNDROME.

OXAZEPAM DISPOSITION IN UREMIC PATIENTS.

O00720 01-13

EFFECTIVENESS OF PSYCHOTROPIC DRUGS IN PATIENTS IN A STATE OF
MALNUTRITION OR EXPOSED TO EXTREME CLIMATIC CONDITIONS.

UITHIUM TRANSPORT IN RED BLOOD CELLS OF MANIC-DEPRESSIVE PATIENTS.

003070 04-03

000562 01-09

001694 02-13

001712 02-14

001724 02-14

001742 02-15

001767 02-15

001792 02-15

001795 02-15

001805 02-15

001807 02-15

001808 02-15

INDICATION AND

CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND ITS METABOLITES AND CLINICAL RATINGS IN PATIENTS WITH ACUTE RELAPSE OF SCHIZOPHRENIC AND PARANOID PSYCHOSIS. MOTONEURON EXCITABILITY IN PSYCHIATRIC PATIENTS. DRUG DEPENDENCY IN PATIENTS WITH CHRONIC HEADACHES PATIENTS ELECTROCARDIOGRAPHIC FINDINGS IN PATIENTS UNDERGOIN AMITRIPTYLINE TREATMENT.

EFFECT OF CHLORPROMAZINE TREATMENT ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC PATIENTS. ACUTE VERSUS CHRONIC EFFECTS OF MONDAMINE-OXIDASE INHIBITORS IN DEPRESSED PATIENTS: TIME-COURSE OF MAO INHIBITORS. 000733 01-13 EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS. ASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS. 000742 01-13 BETA-ENDORPHIN-INDUCED CHANGES IN SCHIZOPHRENIC AND DEPRESSED PATIENTS. 000775 01-14 ELECTROPHYSIOLOGICAL (H-REFLEX) STUDIES OF PATIENTS WITH TARDIVE-DYSKINESIA. 000817 01-15 MEDICAL SCREENING OF PATIENTS ON MAINTENANCE NEUROLEPTICS. 000822 01-15 ABUSE OF ANTIPARKINSONIAN DRUGS BY PSYCHIATRIC PATIENTS.
000856 01-15 000863 01-15 ON PRESCRIBING MEDICATIONS FOR RECOVERING ALCOHOLIC PATIENTS.

O00872 01-15
THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (SECOND REPORT) — EFFECTS ON PUPIL FUNCTIONING. THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (FIRST REPORT). URINARY CARBON-DIOXIDE TENSION IN LITHIUM-CARBONATE TREATED 000882 01-15 DIPROPYLTRYPTAMINE (DPT) AS AN ADJUNCT IN THE COUNSELING OF CANCER PATIENTS. 000978 01-17 S ADENOSYL-L-METHIONINE (SAME) TREATMENT IN
GERONTOPSYCHIATRY: A CONTROLLED CUNICAL STUDY IN DEPRESSED 001045 02-03 CHLOROQUINE POTENTIATION OF THIORIDAZINE EFFECTS IN RATS AND DRUG RESISTANT SCHIZOPHRENIC PATIENTS: A PRELIMINARY REPORT. 001571 02-08 RAPID CYCLING MANIC-DEPRESSIVE PATIENTS 001583 02-09 HORMONE RELEASE IN DEPRESSED PATIENTS BEFORE AND AFTER RECOVERY THE EFFECT OF CYCLANDELATE IN DEPRESSED AND DEMENTED PATIENTS: A CONTROLLED STUDY IN PSYCHOGERIATRIC PATIENTS. L TRYPTOPHAN ADMINISTRATION IN L-DOPA-INDUCED HALLUCINATIONS IN ELDERLY PARKINSONIAN PATIENTS. 001624 02-11 RELATIVE EFFICACY OF PARENTERAL HALOPERIDOL AND THIOTHIXENE FOR THE EMERGENCY TREATMENT OF ACUTELY EXCITED AND AGITATED PATIENTS. O01626 02-11

EFFECT OF FUSARIC-ACID ON TARDIVE-DYSKINESIA AND MENTAL STATE
IN PSYCHOGERIATRIC PATIENTS: A PILOT STUDY.

COMPARISON OF THE EFFECTS OF NOCTRAN-10 ON HOSPITALIZED PATIENTS AND PATIENTS TREATED AT HOME. AGRANULOCYTOSIS IN PATIENTS TREATED WITH CLOZAPINE: A STUDY OF THE FINNISH EPIDEMIC. RESPIRATORY COMPLICATIONS IN PATIENTS WITH INTOXICATION DIABETES-MELLITUS IN PATIENTS ON LITHIUM. THE HUMAN EEG IN SEVERELY POISONED PATIENTS -CONTROL OF HEMODIALYSIS OR HEMOPERFUSION. SUDDEN DEATH OF PATIENTS USING PSYCHOTROPIC MEDICATION. 001796 02-15 ON THE PREVALENCE, DIAGNOSIS AND MANAGEMENT OF LITHIUM-INDUCED HYPOTHYROIDISM IN PSYCHIATRIC PATIENTS. POTENTIAL UNTOWARD EFFECTS OF LONG-TERM USE OF FLURAZEPAM IN GERIATRIC PATIENTS. TARDIVE-DYSKINESIA IN PSYCHOGERIATRIC PATIENTS: A FIVE-YEAR FOLLOW-UP. A SEVEN YEAR REVIEW OF COMA PATIENTS ADMITTED TO THE REGIONAL POISONING TREATMENT CENTRE, ROYAL INFIRMARY, EDINBURGH. WITH DEPOT NEUROLEPTICS.

(UNPUBLISHED PAPER). ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS. 001672 02-13 REGIONAL CHANGES OF CEREBRAL BLOOD FLOW DURING HALOPERIDOL THERAPY IN PATIENTS WITH PARANOID SYMPTOMS. RELATIONSHIP BETWEEN PHYSICAL FINDINGS AND RELATED SUBJECTIVE SYMPTOMS IN NEUROPSYCHIATRIC PATIENTS WITH SOMATIC COMPLICATIONS -- WITH SPECIAL REFERENCE TO OPHTHALMOLOGIC OBSERVATIONS. 001678 02-13 CYCLIC-AMP IN CEREBROSPINAL FLUID OF MANIC AND DEPRESSIVE PATIENTS. 001683 02-13 A TWO-DOSE DEXAMETHASONE SUPPRESSION TEST IN PATIENTS WITH PSYCHIATRIC ILLNESS. 001691 02-13

EVALUATION OF BUTACLAMOL IN CHRONIC SCHIZOPHRENIC PATIENTS. 001649 02-13 CLINICAL BIOCHEMICAL ASSESSMENT OF DRUG ACTION IN PATIENTS.

001821 02-15 TRICYCLIC ANTIDEPRESSANT OVERDOSES IN ADOLESCENT PATIENTS. 001822 02-15 GONADAL MORPHOLOGY IN SCHIZOPHRENIC PATIENTS UNDER PSYCHOTROPIC TREATMENT. 001832 02-15 HAZARDS OF ANTIPSYCHOTIC DRUG USE IN NONPSYCHOTIC PATIENTS 001847 02-15 POLYPHARMACY AMONG PSYCHIATRIC PATIENTS. 001900 02-17 TREATMENT OF PATIENTS WITH DELAYED NEUROLEPTICS. 001921 02-17 OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINES IN L-DOPA TREATED PARKINSONIAN PATIENTS. 001994 03-03 SINGLE-BLIND EVALUATION OF HYPNOTIC ACTIVITY OF CHLORDESMETHYLDIAZEPAM IN NO-PLACEBO REACTOR MEDICAL PATIENTS. 002379 03-07 PATIENTS NEWLY DISCHARGED FROM A BRIEF THERAPY UNIT. 002391 03-08 PENFLURIDOL IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC **HOW SCHIZOPHRENIC PATIENTS CHANGE DURING 3 YEARS TREATMENT** 002393 03-08 EEG RECORDS AND THE EFFECTS OF PHENOTHIAZINE TREATMENT IN PATIENTS WITH PARANOID SCHIZOPHRENIA. 002394 03-08 CALCIUM METABOLISM IN LITHIUM TREATED PATIENTS: RELATION TO UNIPOLAR DICHOTOMY. 002420 03-09 PROLACTIN SECRETION DURING AND AFTER NOVERIL INFUSIONS TO DEPRESSIVE PATIENTS. 002438 03-09 USE OF LITHIUM-CARBONATE WITH RETARDED ACTION (MICALITE) IN PATIENTS WITH AFFECTIVE-PSYCHOSES. 002444 03-09 A COMPARATIVE STUDY OF MAPROTILINE (LUDIOMIL) AND VILOXAZINE IN THE MANAGEMENT OF DEPRESSED PATIENTS IN GENERAL 002447 03-09 PLASMA LEVEL STUDIES OF CLOMIPRAMINE AND
DESMETHYLCLOMIPRAMINE FOLLOWING INTRAVENOUS INFUSIONS OF
CLOMIPRAMINE IN DEPRESSIVE PATIENTS. 002448 03-09 CLINICAL RESPONSE IN DEPRESSED PATIENTS IN RELATION TO PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND TYRAMINE PRESSOR RESPONSE. 002453 03-09 CLOMIPRAMINE (ANAFRANIL) IN DEPRESSIVE PATIENTS WITH OBSESSIVE A DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF LOXAPINE, DIAZEPAM, AND PLACEBO IN HOSPITALIZED PATIENTS WITH VARIOUS STATES OF ANXIETY. 002491 03-10 002496 03-10

CLONAZEPAM IN THE TREATMENT OF EPILEPSY IN HANDICAPPED PATIENTS.

002503 03-11

CAN PHENYTOIN BE GRADUALLY WITHDRAWN IN PATIENTS WITH MAJOR MOTOR EPILEPSY MAINTAINED ON CLONAZEPAM AND PHENOBARBITAL?.

002504 03-11

EFFECTS OF PIRACETAM ON REGIONAL CEREBRAL BLOOD FLOW AND
MENTAL FUNCTIONS IN PATIENTS WITH ORGANIC DEMENTIA.
002512 03-11

EVALUATION OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTIC AGENTS IN PRESURGICAL PATIENTS.

002514 03-11
SOMATOSENSORY EVOKED-POTENTIALS IN PATIENTS WITH PARKINSONS
SYNDROME DURING TREATMENT WITH L-DOPA AND DECARBOXYLASE
INHIBITOR.

O02515 03-11
COMBINED HALOPERIDOL AND LITHIUM-CARBONATE IN TREATING MANIC PATIENTS.

002516 03-11
CLINICAL AND BIOCHEMICAL EFFECTS OF CHLORPROMAZINE IN
PSYCHOTIC PATIENTS: RELATIONS TO CHLORPROMAZINE

CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID. 002538 03-11

STEADY-STATE KINETICS OF IMIPRAMINE IN PATIENTS. 002556 03-13

BROMOCRIPTINE: EFFECT ON SERUM PROLACTIN AND GROWTH HORMONE IN PSYCHOGERIATRIC HOSPITAL PATIENTS.

002561 03-13
LUTEINIZING HORMONE RELEASING HORMONE AND THYROTROPINRELEASING HORMONE STIMULATION STUDIES IN PATIENTS GIVEN
CLOMIPRAMINE OR DEPOT NEUROLEPTICS.

002563 03-13
PLASMA PROLACTIN CONCENTRATIONS IN NORMAL SUBJECTS AND
DEPRESSIVE PATIENTS FOLLOWING ORAL CLOMIPRAMINE.

002567 03-13

PLASMA CONCENTRATIONS OF CLOMIPRAMINE AND ITS N DESMETHYL

METABOLITE IN DEPRESSIVE PATIENTS FOLLOWING TREATMENT WITH

VARIOUS DOSAGE REGIMES OF CLOMIPRAMINE.

002568 03-13
EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON PLASMA LEVELS
OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DEPRESSIVE

PATIENTS RECEIVING CLOMIPRAMINE THERAPY. 002577 03-13

LITHIUM EFFECT ON TEMPERATURE RHYTHM IN PSYCHIATRIC PATIENTS. 002581 03-13 ELEVATED MELATONIN SERUM CONCENTRATIONS IN PSYCHIATRIC

PATIENTS TREATED WITH CHLORPROMAZINE. 002595 03-13

A COMPARISON OF THE ANALGESIC EFFECT OF INTRAMUSCULAR NALBUPHINE AND MORPHINE IN PATIENTS WITH POSTOPERATIVE PAIN. 002607 03-14

INFLUENCE OF TRYPTOPHAN ON MEMORY FUNCTIONS IN DEPRESSIVE PATIENTS TREATED WITH UNILATERAL ECT. 002613 03-14

THE ALPHA SPECTRUM IN SCHIZOPHRENIC PATIENTS DUE TO PSYCHOPHARMACOLOGICAL TREATMENT AND DIFFERENT SOCIOCULTURAL SETTINGS.

OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINE
ALKALOIDS IN 1-DOPA TREATED PARKINSONIAN PATIENTS.

A TREATMENT FOR DRY MOUTH IN PSYCHIATRIC PATIENTS.

O02661 03-15
DRUG UTILIZATION AND ADVERSE DRUG REACTIONS IN MEDICAL

PATIENTS: COMPARISON OF TWO PERIODS, 1969-72 AND 1973-76. 002684 03-15

MORTALITY OF PATIENTS WITH TARDIVE-DYSKINESIA. DYSKINESIA. 002688 03-15

ELECTROENCEPHALOGRAPHIC PECULIARITIES DURING ACUTE DRUG INTOXICATIONS IN EPILEPTIC PATIENTS. 002689 03-15 FOUR-YEAR TREATMENT OF PATIENTS WITH PARKINSONISM USING

AMANTADINE ALONE OR WITH LEVODOPA. 002707 03-15

PARADOXICAL REACTION TO L-DOPA IN SCHIZOPHRENIC PATIENTS.
003449 04-08
HIGH-POTENCY AND LOW-POTENCY NEUROLEPTICS IN ELDERLY

PSYCHIATRIC PATIENTS. 003450 04-08

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. A STUDY WITH THE LONG-ACTING THIOXANTHENE DERIVATIVE, CIS-CLOPENTHIXOL-DECANOATE SORDINOL DEPOT. 003454 04-08

THE SOCIAL OUTCOME OF PATIENTS IN A TRIAL OF LONG-TERM CONTINUATION THERAPY IN SCHIZOPHRENIA: PIMOZIDE VS. FLUPHENAZINE. 003455 04-08

OUTPATIENT MAINTENANCE OF CHRONIC SCHIZOPHRENIC PATIENTS WITH FLUPHENAZINE-DECANOATE (MODECATE): IBADAN EXPERIENCE. 003466 04-08

LOW PLASMA LEVELS OF CPZ IN PATIENTS CHRONICALLY TREATED WITH NEUROLEPTICS.

A CONTROLLED CLINICAL STUDY OF TRAZODONE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH PRONOUNCED DEPRESSIVE

003472 04-08
CLINICAL CORRELATES OF LOW PLATELET MONOAMINE-OXIDASE IN
SCHIZOPHRENIC PATIENTS.

003477 04-01

RELATIONSHIP BETWEEN SERUM CONCENTRATIONS OF THIORIDAZINE
AND ITS MAIN NONCONJUGATED METABOLITES AND THE CLINICAL
RESPONSE IN THIORIDAZINE TREATED PATIENTS.

TRYPTOPHAN NICOTINAMIDE COMBINATION IN THE TREATMENT OF NEWLY ADMITTED DEPRESSED PATIENTS.

003487 04-09
PERIPHERAL ALPHA-ADRENORECEPTOR AND CENTRAL DOPAMINE
RECEPTOR ACTIVITY IN DEPRESSIVE PATIENTS.

003489 04-09
CIS-CLOPENTHIXOL AND CLOPENTHIXOL (SORDINOL) IN CHRONIC
PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL INVESTIGATION.
003496 04-09

TRANYLCYPROMINE (PARNATE) - A STUDY OF 1000 PATIENTS WITH SEVERE AGITATED DEPRESSIONS.

O03507 04-09

A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE
(SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS
(SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH
SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE
AND NOBTRIPTYLINE

003508 04-09
DISTURBANCE OF HOMEOSTATIC REGULATION OF ADRENAL FUNCTION IN
PATIENTS WITH ENDOGENOUS DEPRESSION.

003515 04-09
ERYTHROCYTE ACCUMULATION OF THE LITHIUM-ION IN CONTROL
SUBJECTS AND PATIENTS WITH PRIMARY AFFECTIVE-DISORDER.
003519 04-09

LITHIUM DOSAGE AND AGE OF PATIENTS.

003528 04-09
THE EFFECT OF CLOFIBRATE ON TOTAL AND FREE PLASMA TRYPTOPHAN IN DEPRESSED PATIENTS.

003532 04-09
HISTOCOMPATIBILITY ANTIGENS IN LITHIUM TREATED MANICDEPRESSIVE PATIENTS.

ELECTROENCEPHALOGRAPHIC CONTROL WITH FREQUENCY ANALYSIS IN DEPRESSED PATIENTS TREATED WITH SAME.

SOMATOSTATIN IN THE TREATMENT OF PATIENTS WITH EXTRAPYRAMIDAL DISORDERS AND PATIENTS WITH EEG ARNORMALITIES

COMPARATIVE EVALUATION OF HYPNOTIC EFFICACY OF FLUNITRAZEPAM IN PSYCHIATRIC PATIENTS. 003574 04-11

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLLACTIC-ACID (VLA) IN CEREBROSPINAL FLUID AND 3 METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN THE URINE OF PARKINSONIAN PATIENTS TREATED WITH 1-DOPA.

003602 04-13

CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA AND

CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED

DOSES OF CHLORPROMAZINE.

003614 04-13
STUDY OF THE INFLUENCE OF VITAMIN SUPPLEMENTS ON THE BEHAVIOR
OF PSYCHIATRIC PATIENTS.

TEMAZEPAM (EUHYPNOS) AND CHLORMETHIAZOLE: A COMPARATIVE STUDY IN GERIATRIC PATIENTS.

003634 04-14
VALIDITY AND CLINICAL UTILITY OF NEUROLEPTIC FACILITATED
ELECTROENCEPHALOGRAPHY IN PSYCHOTIC PATIENTS.

PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATIENTS DURING LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS: DISSOCIATION BETWEEN LIGHT AND NEAR VISION REACTIONS.

003673 04-15

PATTERN

BEHAVIORAL SENSITIVITY TO LSD: DEPENDENCY UPON THE PATTERN OF CENTRAL 5-HT DEPLETION.

000388 01-04
PHARMACOLOGICAL INVESTIGATIONS CONCERNING COMBINATION
EFFECTS OF ALCOHOL AND OXAZEPAM IN THE REACTIVITY PATTERN.
000897 01-15

A ROLE FOR CENTRAL SEROTONERGIC SYSTEMS IN THE PATTERN AND INTENSITY OF THE CONVULSIVE RESPONSE OF RATS TO ELECTROSHOCK. 001067 02-03 EFFECTS OF MAGNESIUM PEMOLINE ON PATTERN DISCRIMINATION LEARNING IN YOUNG RATS.

001425 02-04 PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS

001737 02-14 THE B-MITTEN EEG PATTERN AND TARDIVE-DYSKINESIA: A POSSIBLE ASSOCIATION. 001846 02-15

EFFECT OF CLOZAPINE ON THE SLEEP PATTERN IN THE RAT 002313 03-04 INFLUENCE OF VINCAMINE AND PIRACETAM ON SLEEP-WAKING PATTERN

DORSOMEDIAL THALAMIC LESIONS AND AMPHETAMINE: ACQUISITE
AND RETENTION OF A VISUAL PATTERN DISCRIMINATION ESCAPE

INFLUENCE OF DIAZEPAM, L-DOPA AND DOPAMINE ON THE CEREBELLAR AND SPINAL ELECTRICAL PATTERNS INDUCED BY HARMINE IN THE

000091 01-03 STUDIES ON DIGITAL PLETHYSMOGRAPHIC PATTERNS IN FEMALE PATIENTS WITH NONSPECIFIC COMPLAINTS.

PATTERNS OF ANTIPSYCHOTIC DRUG USE IN FOUR SOUTHEASTERN STATE HOSPITALS

000963 01-17 PSYCHOTHERAPEUTIC PRESCRIBING PATTERNS IN GENERAL PRACTICE

000998 01-17 DIFFERENT BEHAVIOURAL PATTERNS INDUCED BY APOMORPHINE: EVIDENCE THAT THE METHOD OF ADMINISTRATION DETERMINES THE BEHAVIOURAL RESPONSE TO THE DRUG.

001533 02-06 EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS.

001712 02-14 PSYCHOPHARMACOLOGIC AGENTS: PRESCRIPTION PATTERNS OF NONPSYCHIATRISTS.

A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE LONG-TERM EFFECTS OF CLOZAPINE UPON SLEEP PATTERNS OF NORMAL YOUNG ADULTS.

002640 03-14 PATTERNS OF THE USE OF BENZODIAZEPINES IN AUSTRALIA 002737 03-17

SOME OBSERVATIONS ON THE BINDING PATTERNS OF ALPHA-BUNGAROTOXIN IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT

002956 04-03 LSD AND TRYPTAMINE EFFECTS ON SLEEP-WAKEFULNESS AND ELECTROCORTICOGRAM PATTERNS IN INTACT CATS.

003256 04-04 GROWTH HORMONE, PROLACTIN AND CORTISOL RESPONSES AND GROWTH PATTERNS IN HYPERKINETIC CHILDREN TREATED WITH DEXTROAMPHETAMINE. PRELIMINARY FINDINGS.

003569 04-11 PLACEBO AND SLEEP PATTERNS OF NORMAL YOUNG ADULTS. 003729 04-17

PAVLOVIAN THE ROLE OF PAVLOVIAN CONDITIONING IN MORPHINE-TOLERANCE 003090 04-03

PAVOR

PAVOR NOCTURNUS IN A SCHIZOPHRENIC PATIENT: A REVIEW AND CASE

002521 03-11 SELECTIVE ENZYME INDUCTION IN A NERVE GROWTH FACTOR RESPONSIVE PHEOCHROMOCYTOMA CELL LINE (PC-12).

002899 04-03 INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETINE ON HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE (PCA) AND 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77).

003271 04-04 PHENCYCLIDINE (PCP) ABUSE.

000803 01-15 OBSERVATIONS ON THE TREATMENT OF PHENCYCLIDINE (PCP)

001745 02-15 MORE ABOUT POISONING BY PHENCYCLIDINE (PCP, ANGEL-DUST) 001786 02-15 EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) ON SLEEP IN OLFACTORY
BULB LESIONED RATS.

EFFECTS OF PCPA ON THE CONSUMPTION OF ALCOHOL, WATER AND OTHER SOLUTIONS.

000469 01-04 EFFECTS OF PCPA ON MARKING BEHAVIOUR IN THE MALE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).

EFFECTS OF PCPA AND SELECTIVE REM SLEEP-DEPRIVATION ON ROTOROD PERFORMANCE AND OPEN-FIELD BEHAVIOR IN THE RAT.

EFFECT OF P-CHLOROPHENYLALANINE (PCPA) AND PHENYLALANINE (PHE)
TREATMENT ON EARLY AUDITORY EVOKED RESPONSES IN RATS.
002304 03-04

DISRUPTION OF LATENT INHIBITION FOLLOWING SYSTEMIC ADMINISTRATION OF P-CHLOROPHENYLALANINE (PCPA)

EFFECTS OF MORPHINE ON BRAINSTEM NEURONES IN NAIVE AND CHRONIC MORPHINE TREATED RATS, AND EFFECTS OF PCPA.
002841 04-03

THE PEAK EXPERIENCE VARIABLE IN DPT ASSISTED PSYCHOTHERAPY WITH CANCER PATIENTS. 000679 01-12

ELECTROENCEPHALOGRAPHIC PECULIARITIES DURING ACUTE DRUG INTOXICATIONS IN EPILEPTIC PATIENTS.

002689 03-15 PEDIATRIC PEDIATRIC PSYCHOPHARMACOLOGY AND CHILDHOOD DEPRESSION.

000611 01-10 PEDIATRIC PSYCHOPHARMACOLOGY: A REVIEW WITH SPECIAL REFERENCE TO DEANOL.

001918 02-17 PEDIATRIC PSYCHOPHARMACOLOGY: THE USE OF BEHAVIOR MODIFYING DRUGS IN CHILDREN.

002784 03-17

PEDOPHILIC
TREATMENT OF OBSESSIVE HOMOSEXUAL PEDOPHILIC FANTASIES WITH
MEDROXYPROGESTERONE-ACETATE.
003543 04-1 003543 04-10

A SLOW-RELEASE SILICONE PELLET FOR CHRONIC AMPHETAMINE ADMINISTRATION

SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION. 002052 03-03

PEMOUNE EFFECTS OF MAGNESIUM PEMOLINE ON PATTERN DISCRIMINATION LEARNING IN YOUNG RATS.

COMPARATIVE EFFECTS OF PEMOLINE, AMFONELIC-ACID AND AMPHETAMINE ON DOPAMINE UPTAKE AND RELEASE IN VITRO AND ON BRAIN 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN SPIPERONE-TREATED RATS.

DRUGS AFFECTING THE CENTRAL-NERVOUS-SYSTEM: EFFECTS OF PEMOLINE, AND TRICYCLIC ANTIDEPRESSANTS ON NERVE TERMINAL ADENOSINE-TRIPHOSPHATASE ACTIVITIES AND NEUROTRANSMITTER

002923 04-03 OPEN-FIELD BEHAVIOR AND GROSS MOTOR DEVELOPMENT IN OFFSPRING OF NURSING RAT MOTHERS GIVEN PENFLURIDOL.

000307 01-04 VARIOUS EFFECTS OF D AMPHETAMINE IN RATS WITH SELECTIVE LESIONS OF BRAIN NORADRENALINE CONTAINING NEURONS OR TREATED WITH PENFLURIDOL.

001437 02-04 ANTIPARKINSONIAN DRUG ADMINISTRATION AND PLASMA LEVELS OF PENFLURIDOL, A NEW LONG-ACTING NEUROLEPTIC.

001559 02-08 TREATMENT OF CHRONIC SCHIZOPHRENICS WITH THE ORAL LONG-TERM NEUROLEPTIC PENFLURIDOL IN AN OPEN STUDY.

001563 02-08 LONG-TERM TREATMENT OF SCHIZOPHRENIA WITH PENFLURIDOL. 001565 02-08

THE TREATMENT OF TARDIVE-DYSKINESIA WITH PENFLURIDO 001618 02-11 PENFLURIDOL IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC

PATIENTS NEWLY DISCHARGED FROM A BRIEF THERAPY UNIT 002391 03-08 COMPARATIVE EFFECTS OF PENFLURIDOL ON CIRCLING BEHAVIOR AND

STRIATAL DOPAC AND SERUM PROLACTIN CONCENTRATIONS IN THE

A LONG-TERM COMPARATIVE TRIAL OF PENFLURIDOL AND FLUPHENAZINE-DECANOATE IN SCHIZOPHRENIC OUTPATIENTS

003459 04-08 THE USE OF PENFLURIDOL ACCORDING TO A NEW DOSAGE REGIMEN IN THE ACUTE, STABILIZATION AND MAINTENANCE PHASES OF PSYCHOSIS.

003491 04-09

002191 03-04

PREFERENCE BEHAVIOR AND TASTE NERVE RESPONSES IN D PENICILLAMINE TREATED RATS. 003248 04-04

CEREBELLAR UNIT ACTIVITY DURING GENERALIZED PENICILLIN EPILEPSY IN THE AWAKE CAT.

001028 02-02 PENICILLIN IN THE PYRAMIDAL TRACT: ECTOPIC ACTION POTENTIAL

002082 03-03 THE ACTIONS OF DIAZEPAM AND PHENYTOIN ON A LOW DOSE PENICILLIN EPILEPTIFORM FOCUS IN THE ANESTHETISED RAT 002921 04-03

POTENTIATION OF THE EPILEPTOGENIC EFFECT OF PENICILLIN-G BY MARIHUANA SMOKING.

002066 03-03 PENNSYLVANIA
INVOLUNTARY ADMINISTRATION OF PSYCHOTROPIC DRUGS -- GROUNDS

FOR SUIT. SOUDER V. MCGUIRE, 423 F.SUPP. 830, (PENNSYLVANIA). M.D. DISTRICT COURT. DECEMBER 9, 1976. 001916 02-17

IN VITRO PROFILE OF SOME OPIOID PENTAPEPTIDE ANALOGUES 002799 04-02

IN VIVO COMPARISON OF THE RECEPTOR POPULATIONS ACTED UPON IN THE SPINAL CORD BY MORPHINE AND PENTAPEPTIDES IN THE PRODUCTION OF ANALGESIA

003143 04-03 PENTAZOCINE, CYCLAZOCINE, AND NALORPHINE AS DISCRIMINATIVE

STIMULI. 001378 02-04

INDUCTION OF PHYSICAL DEPENDENCE ON CYCLAZOCINE AND PENTAZOCINE IN THE RAT. 002071 03-03

DUAL RECEPTOR MEDIATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF PENTAZOCINE.

PENTORABBITAL

COMPARISON OF THYROTROPIN-RELEASING HORMONE WITH MELANOCYTE-STIMULATING HORMONE RELEASE INHIBITING FACTOR AS PENTOBARRITAL ANTAGONISTS IN MONKEYS

INFLUENCE OF CHRONIC PENTOBARBITAL OR MORPHINE TREATMENT ON THE INCORPORATION OF P32-PHOSPHORIC-ACID AND 3H CHOLINE INTO RAT SYNAPTIC PLASMA MEMBRANES.

000147 01-03 PENTOBARBITAL: PRESYNAPTIC EFFECT IN THE SQUID GIANT SYNAPSE. 000204 01-03

PRIMATE INFORMATION PROCESSING UNDER SODIUM PENTOBARBITAL AND CHLORPROMAZINE: DIFFERENTIAL DRUG EFFECTS WITH TACHISTOSCOPICALLY PRESENTED DISCRIMINATIVE STIMULI

000318 01-04 PUNISHMENT SPECIFIC EFFECTS OF PENTOBARBITAL: DEPENDENCY ON THE TYPE OF PUNISHER

000322 01-04 SYNTHESIS OF BRADYKININ FRAGMENTS AND THEIR EFFECT ON

PENTOBARBITAL SLEEPING TIME IN MOUSE. 000424 01-04 BEHAVIORAL EFFECTS OF PEPTIDES IN ANIMALS: FURTHER EXPERIENCE WITH PENTOBARBITAL ANTAGONISM.

000434 01-04 CHANGES IN THE RATE INCREASING EFFECTS OF D AMPHETAMINE AND PENTOBARBITAL BY RESPONSE CONSEQUENCES.

000452 01-04 THE EFFECT OF PENTOBARBITAL ON THE CARBOHYDRATE METABOLISM OF GLIAL CELLS IN CULTURE

000484 01-05 COMPARISON OF ETHANOL, PENTOBARBITAL, AND PHENOBARBITAL USING DRUG VS. DRUG DISCRIMINATION TRAINING.

000503 01-06 DOSE PREFERENCE DURING PENTOBARBITAL SELF-ADMINISTRATION BY HUMANS.

EFFECT OF P-CHLOROPHENYLALANINE ON DEVELOPMENT OF CROSS-TOLERANCE BETWEEN PENTOBARBITAL AND ETHANOL 001123 02-03

PENTOBARBITAL DOES NOT INFLUENCE THE ANTINOCICEPTIVE EFFECTS OF MORPHINE IN NAIVE OR MORPHINE-TOLERANT RATS. 001132 02-03 THE EFFECT OF DFP AND PENTOBARBITAL ON THE TURNOVER OF ACETYLCHOLINE IN THE MOUSE BRAIN.

001170 02-03 EFFECT OF PENTOBARBITAL ON REGIONAL BRAIN PHOSPHOLIPID SYNTHESIS.

001203 02-03 A COMPARISON OF THALIDOMIDE AND PENTOBARBITA METHODS FOR IDENTIFYING NOVEL HYPNOTIC DRUGS

001359 02-04 DISCRIMINATIVE PROPERTIES OF PENTOBARBITAL AFTER REPEATED NONCONTINGENT EXPOSURE IN GERBILS.

001387 02-04 DISCRIMINATIVE PENTOBARBITAL EFFECT MEASURED BY HEAD MOVEMENTS IN RESTRAINED RATS.

001396 02-04 THE INFLUENCE OF PENTOBARBITAL UPON A CORTICAL EPILEPTOGENIC **FOCUS IN RATS**

001411 02-04 AN ATTEMPT TO PREDICT THE DURATION OF PENTOBARBITAL NARCOSIS

ON THE BASIS OF EXPLORATORY ACTIVITY, DEFECATION RATE AND BODY WEIGHT OF RATS. 001435 02-04

TOLERANCE AND CROSS-TOLERANCE TO CNS DEPRESSANTS AFTER CHRONIC PENTOBARBITAL 001442 02-04

LYSERGIC-ACID-DIETHYLAMIDE ANTAGONISM BY CHLORPROMAZINE, HALOPERIDOL, DIAZEPAM, AND PENTOBARBITAL IN THE RABBIT. 001504 02-05

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DRUG DISTRIBUTION AND METABOLISM: ANTIPYRENE, PENTOBARBITAL, AND ETHANOL. PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. II

TOLERANCE CHARACTERISTICS

TIME-COURSE OF AUDIOGENIC SEIZURE SUSCEPTIBILITY AND PLASMA PENTOBARBITAL CONCENTRATION DURING WITHDRAWAL. EFFECT OF DIAZEPAM AND PENTOBARBITAL ON AMINOOXYACETIC-ACID-

INDUCED ACCUMULATION OF GARA 002124 03-03

ONTOGENETIC DEVELOPMENT OF PENTOBARBITAL EFFECTS ON FLECTROCORTICOGRAM IN RATS 002161 03-03

PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. IV INFLUENCE OF FLIMINATION KINETICS. 002198 03-04

PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. III. WITHDRAWAL CHARACTERISTICS

ETHANOL, PENTOBARBITAL, AND CHLORDIAZEPOXIDE EFFECTS IN SQUIRREL-MONKEYS RESPONDING UNDER FIXED-RATIO FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION SCHEDULES 002254 03-04

ATTRIBUTES OF DISCRIMINATIVE PENTOBARBITAL STIMULUS
IMMEDIATELY AFTER INTRAVENOUS INJECTION. 002265 03-04

THE ANTAGONISTIC EFFECTS OF 5 ETHYL-5-HYDROXY-1-METHYLBUTYLBARBITURIC-ACID ON PENTOBARBITAL NARCOSIS IN BOTH NAIVE AND TOLERANT MICE. 002336 03-04

PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. I. CHRONICALLY EQUIVALENT DOSING METHOD. 002360 03-06

NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY THE EFFECTS OF DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFECT OF DENTORADRITAL 002363 03-06

DOPAMINE TURNOVER IN THE INTACT RABBIT BRAIN: EFFECT OF PENTOBARBITAL OR HALOPERIDOL 002815 04-03

TERATOLOGICAL EVALUATION OF ETHANOL, PENTOBARBITAL, AND COMBINATIONS OF THESE. IN THE RAT. 002976 04-03

CORRELATION OF PHENOBARBITAL-INDUCED AND SKF-525-A-INDUCED MODIFICATION OF PENTOBARBITAL HYPNOSIS WITH ALTERATION OF IN VIVO AND IN VITRO PENTOBARBITAL METABOLISM IN THE RAT.

003008 04-03 THE EFFECT OF SODIUM PENTOBARBITAL ON SOME MITOCHONDRIAL **ENZYMES**

003014 04-03 EFFECTS OF ETHANOL AND PENTOBARBITAL IN MICE OF DIFFERENT AGES.
003151 04-04

SIMILARITIES AND DIFFERENCES IN DISCRIMINATIVE STIMULUS EFFECTS OF CHLORDIAZEPOXIDE, PENTOBARBITAL, ETHANOL, AND OTHER SEDATIVES

003163 04-04 INTERACTION BETWEEN PHENCYCLIDINE AND PENTOBARBITAL IN SEVERAL SPECIES OF LABORATORY ANIMALS. 003185 04-04

000781 01-14

EFFECTS OF SODIUM PENTOBARBITAL ON SYMBOLIC MATCHING AND SYMBOLIC ODDITY PERFORMANCE.

003213 04-04

ANTAGONISM OF PENTOBARBITAL DISCRIMINATIVE STIMULUS BY BEMEGRIDE IN IMMOBILIZED RATS. PENTOBARBITAL, PROMAZINE, D AMPHETAMINE, AND SCOPOLAMINE EFFECTS ON BÉHAVIOR UNDER MULTIPLE AND PRIMED SCHEDULES OF REINFORCEMENT.

003267 04-04 DIFFERENTIAL TOLERANCE TO PENTOBARBITAL IN RATS BRED FOR DIFFERENCES IN ALCOHOL SENSITIVITY.

003338 04-04 DRUG DRUG LIDOCAINE AND PENTOBARBITAL: A POTENTIALLY LETHAL INTERACTION. 003412 04-05

PENTOBARBITAL INTOXICATION IN THE PREGNANT RAT. 003659 04-15

PENTOBARBITAL-INDUCED

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON
PENTOBARBITAL-INDUCED DECREASE IN CHOLINERGIC NEURONAL

ANTAGONISM OF PENTOBARBITAL-INDUCED HORMONAL CHANGES BY TRH IN RATS.

001255 02-03 PENTOBARBITONE
INTERACTION OF PENTOBARBITONE AND GAMMA-AMINOBUTYRIC-ACID
ON MAMMALIAN SYMPATHETIC GANGLION CELLS.
D02844 04-0

002844 04-03 AN ULTRASTRUCTURAL STUDY INTO THE EFFECTS OF PENTOBARBITONE ON SYNAPTIC ORGANIZATION.

002968 04-03

THE RELATIONSHIP BETWEEN MAGNITUDE OF ELECTROSHOCK STIMULATION AND THE EFFECTS OF DIGITOXIGENIN, PENTYLENETETRAZOL AND BRAIN MONOAMINE REDUCTION ON ELECTROSHOCK CONVULSIVE TIRESHOLDS.

000066 01-03 PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, BRAIN SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION INTO BRAIN PROTEINS OF DIFFERENT MOUSE STRAINS.

TIME-COURSE AND DEVELOPMENT OF ELECTROCLINICAL FEATURES IN RELATION TO PENTYLENETETRAZOL THRESHOLDS IN MONKEYS WITH FOCAL SEIZURES

001092 02-03 EFFECT OF BARBITURATE WITHDRAWAL ON PENTYLENETETRAZOL SEIZURE THRESHOLD

001364 02-04 THE EFFECTS OF PICROTOXIN AND PENTYLENETETRAZOL IN THE DIURNAL RHYTHMS OF CATECHOLAMINES AND SEROTONIN IN THE RAT BRAIN.

LETHALITY OF PENTYLENETETRAZOL IN RATS AFTER DEPLETION OF BRAIN NOREPINEPHRINE.

002337 03-05 PENTYLENETETAZOL-INDUCED
INHIBITION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS IN RATS BY
PROSTAGLANDIN-E1: ROLE OF BRAIN MONOAMINES.

001968 03-03 PENTYLENETETRAZOLE

EFFECTS OF PENTYLENETETRAZOLE AND TRIMETHADIONE ON FELINE

BRAIN MONOAMINE METABOLISM.

003007 04-03 PEOPLE THE DIFFICULTIES OF OLD PEOPLE TAKING DRUGS.

001878 02-17 THE OPIATE RECEPTOR BINDING INTERACTIONS OF H3-METHIONINE-ENKEPHALIN, AN OPIOID PEPTIDE.

002155 03-03 EFFECT OF VASOACTIVE INTESTINAL PEPTIDE (VIP) AND OTHER PEPTIDES ON C-AMP ACCUMULATION IN RAT BRAIN.

003056 04-03 PEPTIDERGIC

MODELS TO STUDY DRUG EFFECTS ON THE INTEGRATED FUNCTION OF GABAERGIC, PEPTIDERGIC (SUBSTANCE-P) AND DOPAMINERGIC NEURONS. (UNPUBLISHED PAPER). 000499 01-06

BEHAVIORAL EFFECTS OF PEPTIDES IN ANIMALS: FURTHER EXPERIENCE WITH PENTOBARBITAL ANTAGONISM.

000434 01-04 DIFFERENTIATION BETWEEN OPIOID PEPTIDES BY NALTREXONE 001230 02-03

CENTRAL CARDIOVASCULAR EFFECTS OF MORPHINOMIMETIC PEPTIDES IN DOGS

EFFECTS OF OPIATES AND OPIOID PEPTIDES ON MOTOR BEHAVIORS:
SITES AND MECHANISMS OF ACTION. (UNPUBLISHED PAPER).
001433 02-04

Psychopharmacology Abstracts

003651 04-15

MORPHINE-LIKE PEPTIDES OF BRAIN AND THEIR RELATION TO HORMONAL NEUROTRANSMITTERS.

001650 02-13 CENTRAL-NERVOUS-SYSTEM EFFECTS OF PEPTIDES FOUND IN BRAIN AND INTESTINES.

PITUITARY HORMONE RELEASE IN VITRO BY MORPHINE-LIKE PEPTIDES.
001975 03-03
DIFFERENCES IN THE INHIBITORY EFFECTS OF NORMORPHINE AND OPIOID
PEPTIDES ON THE RESPONSES OF THE VASA-DEFERENTIA OF TWO
STRAINS OF MICE.

DETECTION OF TWO ENDORPHIN-LIKE PEPTIDES IN NUCLEUS-CAUDATUS 002790 04-01

FFFECT OF VASOACTIVE INTESTINAL PEPTIDE (VIP) AND OTHER PEPTIDES
ON C-AMP ACCUMULATION IN RAT BRAIN.

POTENTIAL ROLES OF ENDOGENOUS PEPTIDES IN THE DISCRIMINATIVE PROPERTIES OF DRUGS. 003187 04-04

THE BEHAVIOURAL ACTIONS OF THE HYPOTHALAMIC PEPTIDES: A REVIEW

PEPTIDYL
HYDROLYSIS OF ENKEPHALIN BY CULTURED HUMAN ENDOTHELIAL CELLS
AND BY PURIFIED PEPTIDYL DIPEPTIDASE.

003593 04 12

003593 04-13

PERAZINE

ABSORPTION AND METABOLISM OF THE PHENOTHIAZINE DRUG PERAZINE
IN THE RAT INTESTINAL LOOP.

THIN-LAYER AND GAS-LIQUID-CHROMATOGRAPHIC PROCEDURES FOR THE DETERMINATION OF PERAZINE AND ITS METABOLITES IN HUMAN BODY FLUIDS. 000927 01-16

PERCEPTION
INFLUENCES OF ANTIANXIETY DRUGS ON PERCEPTION.

001840 02-15

ETHANOL AND DELTA9-TETRAHYDROCANNABINOL: INTERACTIVE EFFECTS ON HUMAN PERCEPTUAL, COGNITIVE AND MOTOR FUNCTIONS. II. 000673 01-12 ACUTE EFFECTS OF CANNABIS ON COGNITIVE, PERCEPTUAL, AND MOTOR PERFORMANCE IN CHRONIC HASHISH USERS.

000759 01-14

PERFORMANCE
DRUG EFFECTS UPON FORCE AND DURATION OF RESPONSE DURING
FIXED-RATIO PERFORMANCE IN RATS.

000263

000363 01-04 DEVELOPMENT OF TOLERANCE TO THE DISRUPTIVE AFFECTS OF COCAINE ON REPEATED ACQUISITION AND PERFORMANCE OF RESPONSE SEQUENCES.

000459 01-04 POSSIBLE SIGNIFICANCE OF ACTH FRAGMENTS FOR HUMAN MENTAL PERFORMANCE.

000465 01-04 THE EFFECT OF METHYLPHENIDATE ON TEST PERFORMANCE IN THE COGNITIVELY IMPAIRED AGED.

000622 01-11 PHARMACOPSYCHOLOGICAL INVESTIGATION OF THE EFFECT OF SEDATIVES ON MEMORY AND LEARNING PERFORMANCE IN CHILDREN AND ADOLESCENTS.

000751 01-14 ACUTE EFFECTS OF CANNABIS ON COGNITIVE, PERCEPTUAL, AND MOTOR PERFORMANCE IN CHRONIC HASHISH USERS.

000759 01-14 WITHDRAWAL FROM CANNABIS: PSYCHOLOGICAL TEST PERFORMANCE 000760 01-14

THE INFLUENCE OF ALCOHOL ON THE PERSISTENT EFFECTS ON HUMAN PERFORMANCE OF THE HYPNOTICS MANDRAX AND NITRAZEPAM. 000784 01-14

PERFORMANCE DIFFERENCES BETWEEN ADDICTS AND NONADDICTS 000786 01-14 INTRACEREBRAL NEUROTRANSMITTERS AND CONDITIONED REFLEX PERFORMANCE.

001343 02-04 EFFECTS OF AMPHETAMINE ON ENDURANCE PERFORMANCE AND MUSCLE WEAKNESS IN RATS.

001363 02-04 EFFECTS OF METHYLPHENIDATE ON ACQUISITION AND SUBSEQUENT PERFORMANCE OF SUCCESSIVE DISCRIMINATION REVERSALS.

001371 02-04 DEANOL EFFECTS ON PERFORMANCE AND AVERAGE EVOKED-POTENTIALS.

001412 02-04

DISRUPTION OF LEARNING PERFORMANCE BY CHRONIC CHLORPROMAZINE ADMINISTRATION IN THE BABOON.

001465 02-04 FACILITATION OF SIDMAN AVOIDANCE PERFORMANCE BY CHLOROAMPHETAMINE: ROLE OF BIOGENIC AMINES.

EFFECTS OF COCAINE AND FENFLURAMINE ON PROGRESSIVE RATIO PERFORMANCE.

METHYLPHENIDATE, AMYGDALECTOMY AND ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.

O01500 02-04

A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE
DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON
SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR
PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION.

HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF DOTHIEPIN AND NORTHIADEN IN HUMAN PLASMA AND SERUM.

001858 02-16
EFFECTS OF PCPA AND SELECTIVE REM SLEEP-DEPRIVATION ON ROTOROD
PERFORMANCE AND OPEN-FIELD BEHAVIOR IN THE RAT.

REWARD VERSUS PERFORMANCE IN SELF-STIMULATION. ELECTRODE SPECIFIC EFFECTS OF ALPHA-METHYL-P-TYROSINE ON REWARD IN THE RAT.

THE EFFECTS OF AMPHETAMINE ISOMERS ON ROTARDD PERFORMANCE.

002235 03-04

EFFECTS OF SALSOLINOL, A TETRAHYDROISOQUINOLINE ALKALOID, ON MULTIPLE SCHEDULE PERFORMANCE IN RATS. 002250 03-04

EFFECT OF PSYCHOTROPIC AGENTS ON THE PHYSICAL PERFORMANCE CAPACITY OF ANIMALS EXPOSED TO HEAT AND COLD.

002273 03-04
TOLERANCE TO P-CHLOROAMPHETAMINES EFFECTS ON SIDMAN
AVOIDANCE PERFORMANCE AND CATECHOLAMINE METABOLISM.
002314 03-04

EFFECTS OF SODIUM-NITRITE ON DRL PERFORMANCE IN THE RAT.

002325 03-04
THE EFFECTS OF TWO ANTIDEPRESSANTS. IMIPRAMINE AND

VILOXAZINE, UPON DRIVING PERFORMANCE. 002612 03-14

EFFECTS OF ANTIANXIETY DRUG AND PERSONALITY ON STRESS-INDUCING PSYCHOMOTOR PERFORMANCE TEST. 002630 03-14

MARIJUANA AND HUMAN PERFORMANCE: AN ANNOTATED BIBLIOGRAPHY (1970-1975).

O02773 03-17
COMBINED EFFECTS OF ETHANOL AND DIAZEPAM ON PERFORMANCE
AND ACQUISITION OF SERIAL POSITION SEQUENCES BY PIGEONS.

RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS: ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT LEARNING WITH D AMPPHETAMINE TREATMENTS.

003167 04-04

EFFECTS OF MESCALINE AND PSILOCIN ON ACQUISITION, CONSOLIDATION, AND PERFORMANCE OF LIGHT-DARK DISCRIMINATION IN TWO INBRED STRAINS OF MICE.

O03184 04-04
EFFECTS OF SODIUM PENTOBARBITAL ON SYMBOLIC MATCHING AND
SYMBOLIC ODDITY PERFORMANCE.

003213 04-04
EFFECTS OF MARIJUANA EXTRACT DISTILLATE AND CANNABIDIOL ON
VARIABLE INTERVAL PERFORMANCE AS A FUNCTION OF FOOD
DEPRIVATION

O03308 04-04

FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON THE PERFORMANCE OF MICE IN AN IMHIBITORY AVOIDANCE TASK.

PARADOXICAL EFFECTS IN SLEEP AND PERFORMANCE OF TWO DOSES OF CHLORPROMAZINE.

003629 04-14

EFFECTS OF METHYLPHENIDATE ALONE AND IN COMBINATION WITH

BEHAVIOR MODIFICATION PROCEDURES ON THE BEHAVIOR AND

ACADEMIC PERFORMANCE OF HYPERACTIVE CHILDREN.

A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR.

THE EFFECTS OF APPROPRIATENESS OF ATTRIBUTED AROUSAL SOURCE AND TEST ANXIETY ON COMPLEX TEST PERFORMANCE AND REPORTED ANXIETY DURING TEST-TAKING. (PH.D. DISSERTATION).

PERFUSATE

MORPHINE INCREASES AND D AMPHETAMINE DECREASES THE RATIO OF
DOPAC:HVA IN PUSH-PULL PERFUSATE OF RAT CAUDATE NUCLEUS.

RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D AMPHETAMINE. 002862 04-03 PERFUSED

THE METABOLISM OF D-, L- AND DL-METHADONE IN THE ISOLATED PERFUSED RAT LIVER.

FIRST-PASS ELIMINATION OF C14-IMIPRAMINE IN ISOLATED PERFUSED

PHARMACOKINETICS OF SOME HOMOLOGOUS SERIES OF BARBITURATES IN THE INTACT RAT AND IN THE ISOLATED PERFUSED RAT LIVER. 001292 02-03

ACTION OF NOREPINEPHRINE ON MICROCIRCULATION AND PO2
DISTRIBUTION IN THE ISOLATED PERFUSED RAT LIVER.

STIMULATION OF PRESYNAPTIC BETA-ADRENCEPTORS ENHANCES H3-NORADRENALINE RELEASE DURING NERVE STIMULATION IN THE PERFUSED CAT SPIFEN

PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF NA CHANNELS IN THE RELEASE OF CATECHOLAMINES FROM PERFUSED ADRENAL GLANDS.

THE RELEASE OF ACETYLCHOLINE IN THE PERFUSED CAT SPINAL CORD IN VIVO.

PERFUSION
ELECTROCORTICAL CHANGES INDUCED BY THE PERFUSION OF
NORADRENALINE, ACETYLCHOLINE AND THEIR ANTAGONISTS DIRECTLY
INTO THE DOBSAL RAPHE NUCLEUS OF THE CAT.

LOCAL PERFUSION OF NORADRENALINE MAINTAINS VISUAL CORTICAL
PLASTICITY.

003045 04-03

DISULFIRAM ALTERS DOPAMINE METABOLISM AT SITES IN RATS FOREBRAIN AS DETECTED BY PUSH-PULL PERFUSIONS.

003134 04-03

REAQUEDUCTAL

EFFECT OF MORPHINE INJECTED IN PERIAQUEDUCTAL GRAY ON THE

ACTIVITY OF SINGLE UNITS IN NUCLEUS RAPHE MAGNUS OF THE RAT.

002817 04-03

INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA:
EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION.

LOCAL CEREBRAL GLUCOSE UTILIZATION FOLLOWING INJECTION OF BETA-ENDORPHIN INTO PERIAQUEDUCTAL GRAY MATTER IN THE RAT.

PERILS
THE PERILS OF PRESCRIBING PSYCHOTROPIC DRUGS

003504 04-09

PERIMATAL

EFFECTS OF PERIMATAL 6 HYDROXYDOPAMINE TREATMENT ON OPIATE
RECEPTOR DISTRIBUTION IN ADULT BRAIN.

ADRENERGIC ALPHA-RECEPTORS AND BETA-RECEPTORS EXPRESSED BY
THE SAME CELL TYPE IN PRIMARY CULTURE OF PERINATAL MOUSE

003121 04-03

LITHIUM PROPHYLAXIS OF PERIODIC HYPERSOMNIA.

000936 01-17

LITHIUM IN THE TREATMENT OF PERIODIC CATATONIA: A CASE REPORT.
003530 04-09

INVESTIGATIONS INTO THE NATURE OF THE PERIORAL MOVEMENTS
INDUCED BY DIPROPYLAMINO-DIHYDROXYTETRALIN.

001334 02-04

PERIPHERAL

FAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO
AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS
UNDER LONG-TERM TRAINING.

DIFFERENTIAL EFFECT OF VARIOUS 6 HYDROXYDDPA TREATMENTS ON THE DEVELOPMENT OF CENTRAL AND PERIPHERAL NORADRENERGIC MEURONS.

O00155 01-03
PROPERTIES OF THE PERIPHERAL OPIATE RECEPTORS IN THE CAT
NICITATING MEMBRANE.

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF THE PAT.

O01118 02-03
URINARY 3 METHOXY-4-HYDROXYPHENYLGLYCOL, AN INDEX OF
PERIPHERAL RATHER THAN CENTRAL ADRENERGIC ACTIVITY IN THE
DAT

PERIPHERAL CATECHOLAMINES RELEASED BY OXOTREMORINE MODULATE TREMOR IN THE RAT. (UNPUBLISHED PAPER).

001486 02-04

PERIPHERAL DIABETIC NEUROPATHY TREATED WITH AMITRIPTYLINE AND FLUPHENAZINE. THE EFFECT OF L-DOPA ON PERIPHERAL SYMPATHETIC NERVE FUNCTION: ROLE OF PRESYNAPTIC DOPAMINE RECEPTORS.

CHRONIC NEUROLEPTIC USE AND PERIPHERAL MOTOR NEURON DAMAGE.

HYPERTHERMIC RESPONSES TO CENTRAL AND PERIPHERAL INJECTIONS
OF MORPHINE-SULPHATE IN THE CAT.

CHANGES IN BRAIN FREE FATTY-ACIDS AFTER PAINFUL PERIPHERAL STIMULATION (EFFECT OF PROTHIADEN).

003094 04-03 CENTRAL AND PERIPHERAL NORADRENALINE AND RESISTANCE TO EXTINCTION.

CENTRAL AND PERIPHERAL ACTION OF TESTOSTERONE-PROPIONATE ON SCENT GLAND MORPHOLOGY AND MARKING BEHAVIOUR IN THE MONGOLIAN GERBIL.

003370 04-04 PERIPHERAL ALPHA-ADRENORECEPTOR AND CENTRAL DOPAMINE RECEPTOR ACTIVITY IN DEPRESSIVE PATIENTS. 003489 04-09

PERIPHERALLY

ACETYLCHOLINE AND CHOLINE IN MOUSE BRAIN — INFLUENCE OF PERIPHERALLY ACTING CHOLINERGIC DRUGS.

EFFECTS ON TEMPERATURE OF MORPHINE INJECTED INTO THE PREOPTIC/ ANTERIOR HYPOTHALAMUS, MEDULLA-OBLONGATA, AND PERIPHERALLY IN UNRESTRAINED AND RESTRAINED RATS.

DIFFERENTIAL EFFECTS ON CONDITIONED TASTE AVERSION LEARNING
WITH PERIPHERALLY AND CENTRALLY ADMINISTERED ACETALDEHYDE.
003178 04-04

003181 04-04

PERIVENTRICULAR
ANGIOTENSIN-INDUCED THIRST: EFFECTS OF THIRD VENTRICLE
OBSTRUCTION AND PERIVENTRICULAR ABLATION.

PERLAPINE: RELATIONSHIP BETWEEN STIMULATION OF PROLACTIN SECRETION AND ANTIPSYCHOTIC ACTIVITY.

000197 01-03

AMPHETAMINE-INDUCED INCREASE OF THE CEREBROVASCULAR PERMEABILITY TO PROTEIN. 001153 02-03

THE CEREBROVASCULAR PERMEABILITY TO PROTEIN AFTER BICUCULLINE AND AMPHETAMINE ADMINISTRATION IN SPONTANEOUSLY HYPERTENSIVE RATS. 002050 03-03

PEROXIDATION
EFFECT OF MITOCHONDRIAL LIPID PEROXIDATION ON MONOAMINE-OXIDASE.

002813 04-03 PERPHENAZINE
REINFORCING PROPERTIES OF PERPHENAZINE, HALOPERIDOL AND
AMITRIPTYLINE IN RHESUS MONKEYS.

AN INVESTIGATION OF NALORPHINE AND PERPHENAZINE AS NEGATIVE REINFORCERS IN AN ESCAPE PARADIGM.

000389 01-04 PLASMA CONCENTRATIONS OF PERPHENAZINE AND ITS SULPHOXIDE METABOLITE DURING CONTINUOUS ORAL TREATMENT.

000631 01-11 EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D. AMPHETAMINE AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY AND SHOCK AVOIDANCE IN RHESUS MONKEYS.

002251 03-04 AN EXPERIMENTAL STUDY OF THE EFFECTS OF AMITRIPTYLINE
PERPHENAZINE AND AMITRIPTYLINE HALOPERIDOL COMBINATIONS ON
INTERPERSONAL LEARNING.

002511 03-11 DOUBLE-BLIND COMPARISON OF BROMPERIDOL AND PERPHENAZINE. 003476 04-08

PERPHENAZINE-ENANTHATE

EFFECTS OF PERPHENAZINE-ENANTHATE INJECTIONS ON PROLACTIN

LEVELS IN PLASMA FROM SCHIZOPHRENIC WOMEN AND MEN.

003462 04-08

ABATEMENT OF STIMULUS PERSERVATION FOLLOWING REPEATED D AMPHETAMINE TREATMENT: ABSENCE OF BEHAVIORALLY AUGMENTED TOLERANCE.

PERSISTENCE ARCOTIC BLOCKADE, LENGTH OF ADDICTION, AND PERSISTENCE OF INTRAVENOUS MORPHINE SELF-ADMINISTRATION IN RATS.

001322 02-04 THE FREQUENCY AND PERSISTENCE OF DEPRESSIVE SYMPTOMS IN THE ALCOHOL ABUSER. 003567 04-11

PERSISTENT
PERSISTENT EFFECTS OF REPEATED INJECTIONS OF D LYSERGIC-ACIDDIETHYLAMIDE ON RAT BRAIN 5 HYDROXYTRYPTAMINE AND 5
HYDROXYINDOLEACETIC-ACID LEVELS.

000221 (

000221 01-03 THE INFLUENCE OF ALCOHOL ON THE PERSISTENT EFFECTS ON HUMAN PERFORMANCE OF THE HYPNOTICS MANDRAX AND NITRAZEPAM.

PERSISTING
PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD
SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A
HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS
THERAPEUTIC APPLICATION.
001737 001737 02-14

EFFECT OF DIPROPYLACETATE (CONVULEX) ON PERSONALITY CHANGES IN EPILEPTICS: PRELIMINARY REPORT.

000757 01-14 PERSONALITY MODIFICATIONS DUE TO LONG-TERM
PSYCHOPHARMACOTHERAPY: IN CASE OF CHRONIC SCHIZOPHRENIA.

000773 01-14 WORD ASSOCIATION TIMES, FELT EFFECTS, AND PERSONALITY CHARACTERISTICS OF SCIENCE STUDENTS GIVEN A PLACEBO ENERGIZER.

002611 03-14 EFFECTS OF ANTIANXIETY DRUG AND PERSONALITY ON STRESS-INDUCING PSYCHOMOTOR PERFORMANCE TEST.

002630 03-14 PERSONS

EFFECTS OF LITHIUM IN HEALTHY TEST PERSONS.

002647 03-15

HIGH STATES IN CULTURE HISTORICAL PERSPECTIVE. 000676 01-12 PHARMACOLOGIC PERSPECTIVE.

000891 01-15 A PSYCHOLOGICAL PERSPECTIVE FOR DOUBLE-BLIND TRIALS

002729 03-16 **PERSPECTIVES**

PERSPECTIVES IN BIOLOGICAL PSYCHIATRY. PART 2: AFFECTIVE-DISORDERS. 000558 01-09 PERSPECTIVES IN BIOLOGICAL PSYCHIATRY. PART 3: SCHIZOPHRENIA
AND ORGANIC-BRAIN-SYNDROME.

001696 02-14

PERSPECTIVES IN THE TREATMENT OF THE PSYCHONEUROLOGICAL DISORDERS: AFFECTIVE-DISORDERS. (UNPUBLISHED PAPER). 001870 02-16

A POTENTIALLY TOXIC DRUG INTERACTION BETWEEN PETHIDINE (MEPERIDINE) AND PHENOBARBITONE.

001836 02-15

HIDINE-INDUCED

EFFECTS OF NALOXONE ON PETHIDINE-INDUCED NEONATAL DEPRESSION:
PART I -- INTRAVENOUS NALOXONE.

000668 01-11 EFFECTS OF NALOXONE ON PETHIDINE-INDUCED NEONATAL DEPRESSION:
PART II - INTRAMUSCULAR NALOXONE. 000669 01-11

METRAZOL-INDUCED PETIT-MAL: THE ROLE PLAYED BY MONOAMINERGIC MECHANISMS AND STRIATUM.

002192 03-04 EFFECTS OF BENZODIAZEPINES ON PGO FIRINGS AND MULTIPLE UNIT ACTIVITY IN THE MIDBRAIN RETICULAR FORMATION IN CATS.

001265 02-03 THE RELATIONSHIP BETWEEN CORTICAL RECRUITING RESPONSES AND PONTO-GENICULO-OCCIPITAL (PGO) WAVES DURING PARADOXICAL SLEEP AND AFTER THE ADMINISTRATION OF RESERPINE IN THE CAT 002069 03-03

PHAGOCYTOSIS

MONOAMINE-OXIDASE ACTIVITY OF MACROPHAGES AT REST AND DURING PHAGOCYTOSIS.

002902 002902 04-03

PHARMACO-EEO
CLASSIFICATION AND DETERMINATION OF CEREBRAL BIOAVAILABILITY
OF PSYCHOTROPIC DRUGS BY QUANTITATIVE PHARMACO-EEG AND
PSYCHOMETRIC INVESTIGATIONS (STUDIES WITH AX-A411-BS).

000931 01-16 QUANTITATIVE PHARMACO-EEG WITH ANTIMIGRAINE COMPOUNDS 002565 03-13 QUANTITATIVE PHARMACO-EEG WITH STEROIDAL HORMONES

002566 03-13

PHARMACO-ELECTROENCEPHALOGRAPHY
FLUVOXAMINE (DU-23001), A NEW ANTIDEPRESSANT. QUANTITATIVE
PHARMACO-ELECTROENCEPHALOGRAPHY AND PILOT CLINICAL TRIALS 001548 02-07

VOLUME 16, SUBJECT INDEX

Subject Index

000891 01-15

PHA			

CLINICAL EFFECTS OF TREATMENT WITH CHLORPROMAZINE AND THE PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS. 000670 01-11

PHARMACODYNAMIC INVESTIGATIONS IN PSYCHOPHARMACOLOGY BY QUANTITATIVE EEG AND PSYCHOMETRIC METHODS.

003695 04-17

000736 01-13

PHARMACODYNAMICS

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: THE EFFECT OF PREMEDICATION WITH CYSTAMINE ON PHARMACODYNAMICS AND PHARMACOKINETICS OF NITRAZEPAM.

002317 03-04 CHANGES IN PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECTS OF PREMEDICATION WITH CYSTAMINE ON DYNAMICS AND KINETICS OF THIORIDAZINE

002332 03-04 PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF

002348 03-05 PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF

002358 03-05 THE USE OF DRUGS AS DISCRIMINATIVE STIMULI IN BEHAVIORAL PHARMACODYNAMICS.

FHARMACOGENETIC PHARMACOGENETIC ASPECT OF RED BLOOD CELL LITHIUM INDEX IN MANIC-DEPRESSIVE PSYCHOSIS.

PHARMACOKINETIC

PHARMACOKINETIC STUDIES OF TETRAETHYL-L-C14-THIURAMDISULFIDE (C14-DISULFIRAM). A PRELIMINARY STUDY.

000634 01-11 PHARMACOKINETIC OBSERVATIONS OF PHENYTOIN DISPOSITION IN THE NEWBORN AND YOUNG INFANT

000644 01-11 CLINICAL EFFECTS OF TREATMENT WITH CHLORPROMAZINE AND THE PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS

000670 01-11 BEHAVIOURAL AND PHARMACOKINETIC STUDIES IN THE MONKEY (MACACA-MULATTA) WITH DIAZEPAM, NORDIAZEPAM AND RELATED 1 4 BENZODIAZEPINES

001336 02-04 CLINICAL AND PHARMACOKINETIC STUDY OF DIBENZEPINE (ECATRIL):

COMPARISON BETWEEN THE NORMAL AND RETARD FORMS. 001581 02-09 IMIPRAMINE: CLINICAL EFFECTS AND PHARMACOKINETIC VARIABILITY 002460 03-09

PHARMACOKINETIC STUDIES ON TOLERANCE TO SEDATIVE HYPNOTICS IN A POLYDRUG ABUSE POPULATION: I. SECOBARBITAL 002662 03-15

PHARMACOKINETIC INTERACTION BETWEEN AMITRIPTYLINE AND NEUROLEPTICS. 003461 04-08

THE PHARMACOKINETIC ASPECTS OF THERAPY WITH PSYCHOTROPIC AGENTS. 003716 04-17

PHARMACOKINETICS

PHARMACOKINETICS OF METHYLPHENIDATE IN THE RAT USING SINGLE ION MONITORING GLC MASS SPECTROMETRY 000498 01-06

PHARMACOKINETICS OF OXAZEPAM IN HEALTHY VOLUNTEERS 000685 01-13

PHARMACOKINETICS OF N DESMETHYLDIAZEPAM IN HEALTHY VOLUNTEERS AFTER SINGLE DAILY DOSES OF DIPOTASSIUM CHLORAZEPATE

000728 01-13 CLINICAL IMPLICATIONS OF BENZODIAZEPINE PHARMACOKINETICS

000985 01-17 PHARMACOKINETICS OF HEXOBARBITAL IN THE PREGNANT AND NONPREGNANT STUMPTAILED MONKEY.

PHARMACOKINETICS OF NITRAZEPAM IN HUMAN PLASMA AND SALIVA. 001156 02-03

PHARMACOKINETICS OF SOME HOMOLOGOUS SERIES OF BARBITURATES IN THE INTACT RAT AND IN THE ISOLATED PERFUSED RAT LIVER. 001292 02-03

THE PHARMACOKINETICS OF RED BLOOD CELL AND PLASMA BUTAPERAZINE CLINICAL RESPONSE AND SIDE-EFFECTS. 001561 02-08

CLINICAL PHARMACOKINETICS OF LORAZEPAM. III. INTRAVENOUS INJECTION. PRELIMINARY RESULTS. 001662 02-13 CLINICAL PHARMACOKINETICS OF LORAZEPAM. IV. LONG-TERM ORAL ADMINISTRATION.

PHARMACOKINETICS AND CLINICAL EFFECTS OF AMANTADINE IN DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS

001781 02-15 PREDICTION OF PLASMA LEVELS OF IMIPRAMINE FROM PHARMACOKINETICS OF AN INITIAL DOSE. (UNPUBLISHED PAPER) 001876 02-16

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE. THE EFFECT OF PREMEDICATION WITH CYSTAMINE ON PHARMACODYNAMICS AND PHARMACOKINETICS OF NITRAZEPAM.

CHANGES IN PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECTS OF PREMEDICATION WITH CYSTAMINE ON DYNAMICS AND KINETICS OF THIORIDAZINE.

002332 03-04 PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF THIORIDAZINE.

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF NITRAZEPAM

002358 03-05 BIOANALYSIS AND PHARMACOKINETICS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN MAN BY MEANS OF LIQUID

CHROMATOGRAPHY 002728 03-16 MYOCARDIAL PHARMACOKINETICS OF LITHIUM IN VITRO

003414 04-05 PHARMACOKINETICS AND PSYCHOTROPIC DRUGS. 003649 04-15

PHARMACOLOGIC

SYNTHESIS AND PHARMACOLOGIC STUDY OF 1 **OXODIHYDROBENZODIAZEPINES**

000005 01-01 PHARMACOLOGIC ACTIVITY OF BETA-ENDORPHIN IN MAN

000507 01-07 PHENCYCLIDINE HYDROCHLORIDE: PHARMACOLOGIC, ACUTE, AND CHRONIC EFFECTS.

000814 01-15 PHARMACOLOGIC PERSPECTIVE.

THE REVOLUTION DEFINED: IT IS PHARMACOLOGIC.

000949 01-17 CHRONIC AND ACUTELY INDUCED DYSKINESIAS: A PHARMACOLOGIC DISTINCTION.

001410 02-04 A PHARMACOLOGIC COMPARISON OF 3,4
METHYLENEDIOXYAMPHETAMINE AND LSD IN THE CHRONIC SPINAL

002121 03-03 THE HUMAN PLATELET AS A MODEL FOR THE DOPAMINERGIC NEURON KINETIC AND PHARMACOLOGIC PROPERTIES AND THE ROLE OF AMINE

STORAGE GRANIILES 002596 03-13

PHARMACOLOGIC RESPONSES OF CELLS OF A NEUROBLASTOMA-X GLIOMA HYBRID CLONE AND MODULATION OF SYNAPSES BETWEEN HYBRID CELLS AND MOUSE MYOTUBES. 002863 04-03

PHARMACOLOGIC MANAGEMENT OF HUMAN VIOLENCE. 003558 04-11

A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS 003608 04-13

PHARMACOLOGICAL PHARMACOLOGICAL ACTIONS OF INTRACEREBRALLY ADMINISTERED POLYAMINES IN MICE.

000033 01-02 INTERACTION OF GABA, DOPAMINE, AND ACETYLCHOLINE IN CAT STRIATUM: PHARMACOLOGICAL CONSIDERATIONS.

000051 01-03 SECOND MESSENGER RESPONSES AND REGULATION OF HIGH AFFINITY
RECEPTOR BINDING TO STUDY PHARMACOLOGICAL MODIFICATION OF GABAERGIC TRANSMISSION. (UNPUBLISHED PAPER)

000133 01-03 PHARMACOLOGICAL TREATMENT FOLLOWING EXPERIMENTAL CEREBRAL INFARCTION: IMPLICATIONS FOR UNDERSTANDING PSYCHOLOGICAL SYMPTOMS OF HUMAN STROKE

THE EFFECTS OF PHARMACOLOGICAL AND ENVIRONMENTAL VARIABLES ON DRUG CHOICE IN RHESUS MONKEYS. 000386 01-04 PHARMACOLOGICAL APPROACHES TO HABITUATION OF THE ACOUSTIC STARTLE RESPONSE IN RATS.

PHARMACOLOGICAL INVESTIGATIONS CONCERNING COMBINATION EFFECTS OF ALCOHOL AND OXAZEPAM IN THE REACTIVITY PATTERN.
000897 01-15

EXPERIENCE WITH A CLINICAL PHARMACOLOGICAL SERVICE IN A TEACHING HOSPITAL.

SYNTHESIS AND PRELIMINARY PHARMACOLOGICAL ACTIVITY OF AMINOALKOXY ISOSTERES OF GLYCOLATE ESTER ANTICHOLINERGICS. 001026 02-02

A PHARMACOLOGICAL STUDY OF THE SPONTANEOUS CONVULSIVE ACTIVITY INDUCED BY 1,2 DIHYDROXYBENZENE (CATECHOL) IN THE ANESTHETIZED MOUSE.

PHARMACOLOGICAL IMPLICATIONS OF BRAIN ACETYLCHOLINE TURNOVER MEASUREMENTS IN RAT BRAIN NUCLEI.

EFFECTS OF DISULFIRAM ON PHARMACOLOGICAL ACTIVITY, TOXICITY AND FATE OF MORPHINE IN RATS.

STUDIES OF A PHARMACOLOGICAL MODEL OF ETHANOL DEPENDENCE IN THE RAT. (PH.D. DISSERTATION).

SOME PHARMACOLOGICAL OBERVATIONS ON THE ANALGESIA INDUCED BY ACUPUNCTURE IN RABBITS.

001190 02-03 BIOCHEMICAL AND PHARMACOLOGICAL STUDIES ON AMINEPTINE (S-1694) AND () AMPHETAMINE IN THE RAT.

001236 02-03 COCAINE AND METABOLITES: RELATIONSHIP BETWEEN
PHARMACOLOGICAL ACTIVITY AND INHIBITORY ACTION ON
DOPAMINE UPTAKE INTO STRIATAL SYNAPTOSOMES.

THE EFFECT OF SUBCHRONIC ADMINISTRATION OF LITHIUM-CARBONATE ON THE PHARMACOLOGICAL ACTIVITY OF D AMPHETAMINE.

PHARMACOLOGICAL MANIPULATION OF HOARDING: FURTHER ANALYSIS OF AMPHETAMINE ISOMERS AND PIMOZIDE.

INFLUENCE OF PHARMACOLOGICAL AGENTS ON AVOIDANCE REFLEXES IN A GROUP EXPERIMENT ON RATS.

THE EFFECTS OF SOME PHARMACOLOGICAL AGENTS ON THE DURATION OF IMMOBILITY SHOWN BY RABBITS PLACED IN VARIOUS POSTURES. 001355 02-04

THE PHARMACOLOGICAL EFFECTS OF FETAL AND NEONATAL EXPOSURE TO NALTREXONE IN THE RAT.

001373 02-04 PHARMACOLOGICAL MODIFICATION OF SHOCK POTENTIATED AMPHETAMINE LETHALITY.

001494 02-04 REDUCTION OF HEROIN SELF-ADMINISTRATION IN BABOONS BY MANIPULATION OF BEHAVIORAL AND PHARMACOLOGICAL

PHARMACOLOGICAL CHARACTERIZATION OF TARDIVE-DYSKINESIA. 001754 02-15

PHARMACOLOGICAL AGENTS CAUSING SEXUAL DYSFUNCTION 001829 02-15

PHARMACOLOGICAL RESEARCH AND THE PSYCHOSES: AN OVERVIEW.

001868 02-16
PHARMACOLOGICAL, BIOCHEMICAL AND CLINICAL EFFECTS OF 2
DIMETHYLAMINOETHANOL (DEANOL): A CRITICAL REVIEW.

001928 02-17
PHARMACOLOGICAL PROFILE OF A NEW PSYCHOTHERAPEUTIC AGENT: 4P FLUOROPHENYL-METHOXYPHENYL-PIPERAZINOETHYLOXAZOLINONE (LR-511).

PHARMACOLOGICAL EVIDENCE FOR A LINK BETWEEN THE CEREBELLAR CONTENT OF C-GMP AND THAT OF AN ENDOGENOUS PROTEIN KINASE NHIBITOR

PHARMACOLOGICAL MANIPULATIONS OF THE SEPTAL IRRITABILITY SYNDROME: ROLE OF DOPAMINERGIC MECHANISMS IN RECOVERY OF FUNCTION. (PH.D. DISSERTATION).

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. I. TOLERANCE TO PHENCYCLIDINE DERIVATIVES IN MICE: PHARMACOLOGICAL CHARACTERIZATION.

002127 03-03 RECEPTOR AFFINITY AND PHARMACOLOGICAL POTENCY OF A SERIES OF NARCOTIC ANALGESIC, ANTIDIARRHEAL AND NEUROLEPTIC DRUGS. 002160 03-03

PHARMACOLOGICAL INTERACTIONS WITH CIRCLING BEHAVIOUR INDUCED BY THE PIPERIDINYL INDOLE DERIVATIVE RU-23686. 002200 03-04

PHARMACOLOGICAL INFLUENCES ON STARVATION-INDUCED
HYPERRESPONSIVENESS IN THE RAT. (PH.D. DISSERTATION) 002212 03-04 ANALYSIS OF THE ROLE PLAYED BY THE SUBSTANTIA-NIGRA IN THE MEDIATION OF INGESTIVE, LOCOMOTOR, AND ROTATIONAL BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL MANIPULATIONS. (PH. D. DISSERTATION).

002247 03-04 HARMACOLOGICAL AND BEHAVIORAL COMPONENTS OF TOLERANCE TO LSD AND MESCALINE IN RATS.

002286 03-04 RMACOLOGICAL STUDY OF AMOXAPINE, A DIBENZOXAZEPINE DERIVATIVE

002307 03-04 TOXICOLOGICAL AND PHARMACOLOGICAL EFFECTS OF MARIHUANA.

PHARMACOLOGICAL INVESTIGATIONS OF THE CHOLINERGIC IMBALANCE HYPOTHESES OF MOVEMENT DISORDERS AND PSYCHOSIS.

002509 03-11 ALERTNESS IN EPILEPTICS: PHARMACOLOGICAL AND PSYCHOMETRIC STUDY.

002526 03-11 A BEHAVIORAL TREATMENT OF DEPRESSION WITH ALCOHOLICS RECEIVING PHARMACOLOGICAL AVERSIVE CONDITIONING. (PH.D. DISSERTATION).

002539 03-11 PHARMACOLOGICAL INCOMPATIBILITY OF NEUROLEPTICS AND TRANQUILIZERS WITH OTHER PREPARATIONS.

A COMPARISON OF SOME PHARMACOLOGICAL ACTIONS OF MORPHINE AND DELTA9-TETRAHYDROCANNABINOL IN THE MOUSE.

PHARMACOLOGICAL DIFFERENTIATION OF THE CENTRAL 5
HYDROXYTEYPTAMINE-LIKE ACTIONS OF MK-212 (6 CHLORO-2-1PIPERAZINYL-PYRAZINE), P-METHOXYAMPHETAMINE AND
FENFLURAMINE IN AN IN VIVO MODEL SYSTEM.

002868 04-03 PHARMACOLOGICAL AND ELECTROPHYSIOLOGICAL STUDIES OF MORPHINE AND ENKEPHALIN ON RAT SUPRASPINAL NEURONES AND CAT SPINAL NEURONES.

002883 04-03 PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF NA CHANNELS IN THE RELEASE OF CATECHOLAMINES FROM PERFUSED ADRENAL GLANDS.

002960 04-03 PHARMACOLOGICAL AND BIOCHEMICAL PROPERTIES OF ISOMERIC YOHIMBINE ALKALOIDS.

002987 04-03 PHARMACOLOGICAL CHARACTERIZATION OF THE EXCITATORY CHOLINERGIC RECEPTORS OF RAT CENTRAL NEURONES.

003006 04-03 PHARMACOLOGICAL EVIDENCE FOR DOPAMINERGIC PALLIDOSTRIATAL

INTERACTION. 003137 04-03

PHARMACOLOGICAL STUDIES OF CENTRAL ACTION OF L 5
HYDROXYTRYPTOPHAN IN INTACT OR TETRABENAZINE PRETREATED
CATS.

003144 04-03 PHARMACOLOGICAL AND TOXICOLOGICAL EFFECTS OF BETA 3,4
METHYLENEDIOXYAMPHETAMINE ISOMERS.

PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT
OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC
AND CATECHOLAMINERGIC MECHANISMS BY 6 HYDROXYDDPAMINE
AND 5,6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D.
DISSERTATION).

003407 04-05 ANTIDEPRESSANT ACTIVITY AND PHARMACOLOGICAL INTERACTIONS OF

003493 04-09 BIOCHEMICAL AND PHARMACOLOGICAL DIFFERENTIATION OF AFFECTIVE-DISORDERS: AN OVERVIEW.

003495 04-09 **BIOCHEMICAL AND PHARMACOLOGICAL PREDICTORS.** 003509 04-09

PHARMACOLOGICAL TREATMENT OF DEVIANT SEXUAL BEHAVIOUR 003552 04-11 PHARMACOLOGICAL AND THEORETICAL COMPARISON OF HIGH AND LOW POTENCY NEUROLEPTICS.

003687 04-15 PHARMACOLOGICAL INVESTIGATIONS ON ETOPERIDONE, A NEW PSYCHOTROPIC AGENT.

003720 04-17 PHARMACOLOGICALLY
MORPHINE AND ITS BIPHASIC INFLUENCE UPON PHARMACOLOGICALLY
DISTINCT DOPAMINERGIC SYSTEMS WITHIN THE FELINE CAUDATE
NUCLEUS: A BEHAVIOURAL STUDY.

001954 03-02 NEW N 2 HYDROXYALKYL-BENZOMORPHAN DERIVATIVES: SYNTHESIS AND PRELIMINARY PHARMACOLOGY.

000031 01-02

	THE TURNOVER RATE OF GAMMA-AMINOBUTYRIC-ACID IN OF TELENCEPHALON: IMPLICATIONS IN THE PHARMACOI ANTIPSYCHOTICS AND OF A MINOR TRANQUILIZER.	
	ON THE PHARMACOLOGY OF THE KETAMINE ENANTIOMOR	000192 01-03 PHS IN THE
	RAT. ANTIANXIETY DRUGS: CLINICAL PHARMACOLOGY AND TH	000193 01-03 ERAPEUTIC
	USE.	000603 01-10
	THE PHARMACOLOGY OF ANOREXIGENESIS. THE PHARMACOLOGY OF A NEW POTENT, LONG-ACTING N	000962 01-17 IEUROLEPTIC,
	PIFLUTIXOL.	001035 02-02
	CENTRAL PHARMACOLOGY OF A NEW ANTIDEPRESSANT.	001063 02-03
	THE HIPPOCAMPAL SLICE: A SYSTEM FOR STUDYING THE PHARMACOLOGY OF SEIZURES AND FOR SCREENING AN DRUGS.	
	CLINICAL PHARMACOLOGY OF PHENCYCLIDINE TOXICITY.	001538 02-06
	SYNAPTIC CONNEXIONS AND RELATED POSTSYNAPTIC PHA	001637 02-12 RMACOLOGY
	STUDIED IN THE CEREBRAL GANGLION OF APLYSIA.	002041 03-03
	PHARMACOLOGY OF DISCRIMINATIVE DRUG STIMULI.	002195 03-04
	ANTIPSYCHOTIC DRUGS: CLINICAL PHARMACOLOGY AND USE. PART II.	
	ORIGINS AND FUTURE OF BEHAVIORAL PHARMACOLOGY.	002658 03-15
	PHARMACOLOGY AND NEUROCHEMISTRY OF APOMORPHI	002739 03-17 NE.
H	ARMACOPSYCHIATRY	003592 04-13
	THE EVOKED-POTENTIAL IN PHARMACOPSYCHIATRY.	001729 02-14
H	ARMACOPSYCHOLOGICAL	
	PHARMACOPSYCHOLOGICAL INVESTIGATION OF THE EFFEC SEDATIVES ON MEMORY AND LEARNING PERFORMANCI AND ADOLESCENTS.	E IN CHILDREN
H	ARMACOTHERAPY	000751 01-14
	PHARMACOTHERAPY FOR ORGANIC-BRAIN-SYNDROME IN EVALUATION OF AN ERGOT DERIVATIVE VS PLACEBO.	LATE LIFE:
	PHARMACOTHERAPY OF NARCOTIC DEPENDENCE.	000628 01-11
	MAINTENANCE ANTIPSYCHOTIC PHARMACOTHERAPY, REL LENGTH OF STAY OUT OF THE HOSPITAL IN CHRONIC SC	001634 02-12 APSE, AND HIZOPHRENICS
	IN GREECE.	001911 02-17
	ON PHARMACOTHERAPY FOR THE AGED.	001919 02-17
	IS THERE A BIOLOGICAL BASIS FOR GERIATRIC PHARMACO	
	PHARMACOTHERAPY.	003555 04-11
	THE COMPARATIVE EFFICACY OF COGNITIVE THERAPY AND PHARMACOTHERAPY IN THE TREATMENT OF DEPRESSION	NS. 003701 04-17
	DEPRESSION: MUST PHARMACOTHERAPY FAIL FOR COGNITO SUCCEED?.	TIVE THERAPY
11/	ARYNGEAL	003726 04-17
	LARYNGEAL PHARYNGEAL DYSTONIA AS A POSSIBLE CAU ASPHYXIA WITH HALOPERIDOL TREATMENT.	
H	ASES	003654 04-15
	EFFECTS OF KETAMINE ON PATIENT RESPONSIVENESS DUR VARIOUS PHASES OF A SINGLE INDUCED ANXIETY SESSI	
	THE USE OF PENFLURIDOL ACCORDING TO A NEW DOSAGE THE ACUTE, STABILIZATION AND MAINTENANCE PHASE PSYCHOSIS.	REGIMEN IN
16.2	ASIC	003491 04-09
993	PHASIC ACTIVITY IN THE RAT.	000070 01 02
111	ENACYL-CYCLOPROPYLAMINE	000070 01-03
	INHIBITION OF MONOAMINE-OXIDASE BY N PHENACYL- CYCLOPROPYLAMINE.	
H	ENAMINE	002796 04-02
	INFLUENCE OF EXTRAPYRAMIDAL DISTURBANCES DUE TO	HALOPERIDOL

LUME 16, SUBJECT INDEX		Subject Index
THE TURNOVER RATE OF GAMMA-AMINOBUTYRIC-ACID I OF TELENCEPHALON: IMPLICATIONS IN THE PHARMACO ANTIPSYCHOTICS AND OF A MINOR TRANQUILIZER.	DLOGY OF	PHENCYCLIDINE ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM — III. TOLERANCE TO PHENCYCLIDINE DERIVATIVES: IN VIVO
ON THE PHARMACOLOGY OF THE KETAMINE ENANTIOMO	000192 01-03 RPHS IN THE	AND IN VITRO STUDIES. O000224 01-03 EFFECTS OF PHENCYCLIDINE ON (3H)CATECHOLAMINE AND
ANTIANXIETY DRUGS: CLINICAL PHARMACOLOGY AND TI	000193 01-03 HERAPEUTIC	(3H) SEROTONIN UPTAKE IN SYNAPTOSOMAL PREPARATIONS FROM RAT BRAIN.
USE. THE PHARMACOLOGY OF ANOREXIGENESIS.	000603 01-10	PHENCYCLIDINE (PCP) ABUSE. 000803 01-15
THE PHARMACOLOGY OF A NEW POTENT, LONG-ACTING	000962 01-17 NEUROLEPTIC,	PHENCYCLIDINE HYDROCHLORIDE: PHARMACOLOGIC, ACUTE, AND CHRONIC EFFECTS.
PIFLUTIXOL.	001035 02-02	THE INCREASING ABUSE OF PHENCYCLIDINE.
CENTRAL PHARMACOLOGY OF A NEW ANTIDEPRESSANT.	001063 02-03	000892 01-15 EFFECTS OF PHENCYCLIDINE ON OPERANT BEHAVIOR IN RATS.
THE HIPPOCAMPAL SLICE: A SYSTEM FOR STUDYING THE PHARMACOLOGY OF SEIZURES AND FOR SCREENING AI DRUGS.	NTICONVULSANT	CLINICAL PHARMACOLOGY OF PHENCYCLIDINE TOXICITY. 001637 02-12
CLINICAL PHARMACOLOGY OF PHENCYCLIDINE TOXICITY.	001538 02-06	OBSERVATIONS ON THE TREATMENT OF PHENCYCLIDINE (PCP) POISONING.
SYNAPTIC CONNEXIONS AND RELATED POSTSYNAPTIC PH	001637 02-12 ARMACOLOGY	MORE ABOUT POISONING BY PHENCYCLIDINE (PCP, ANGEL-DUST).
STUDIED IN THE CEREBRAL GANGLION OF APLYSIA.	002041 03-03	ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS
Pharmacology of discriminative drug stimuli. Antipsychotic drugs: Clinical Pharmacology and	002195 03-04	SYSTEM. II. CROSS-TOLERANCE BETWEEN PHENCYCLIDINE DERIVATIVES AND CHOLINERGIC DRUGS. 002126 03-03
USE. PART II.	002658 03-15	ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. I. TOLERANCE TO PHENCYCLIDINE DERIVATIVES IN MICE:
ORIGINS AND FUTURE OF BEHAVIORAL PHARMACOLOGY.	002739 03-17	PHARMACOLOGICAL CHARACTERIZATION. 002127 03-03
PHARMACOLOGY AND NEUROCHEMISTRY OF APOMORPH	INE. 003592 04-13	THE EFFECTS OF ACUTE AND CHRONIC PHENCYCLIDINE ON SCHEDULE- CONTROLLED BEHAVIOR IN THE SQUIRREL-MONKEY.
HE EVOKED-POTENTIAL IN PHARMACOPSYCHIATRY.	001729 02-14	002209 03-04 THE EFFECTS OF PHENCYCLIDINE ON VISUALLY EVOKED-POTENTIALS OF RHESUS MONKEYS.
PHARMACOPSYCHOLOGICAL PHARMACOPSYCHOLOGICAL INVESTIGATION OF THE EFFE SEDATIVES ON MEMORY AND LEARNING PERFORMANCE SEDATIVES ON MEMORY AND LEARNING PERFORMANCE OF THE SEPERATURE OF THE SEPTIME OF THE	CT OF	002306 03-04 INTERACTION BETWEEN PHENCYCLIDINE AND PENTOBARBITAL IN SEVERAL SPECIES OF LABORATORY ANIMALS.
AND ADOLESCENTS.	000751 01-14	O03185 04-04 PHENCYCLIDINE: A BIBLIOGRAPHY OF BIOMEDICAL AND BEHAVIORAL RESEARCH.
PHARMACOTHERAPY FOR ORGANIC-BRAIN-SYNDROME IN EVALUATION OF AN ERGOT DERIVATIVE VS PLACEBO.	LATE LIFE:	PHENCYCLIDINES 003699 04-17
PHARMACOTHERAPY OF NARCOTIC DEPENDENCE.	000628 01-11	INTERACTION OF PHENCYCLIDINES WITH THE MUSCARINIC AND OPIATE RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM.
MAINTENANCE ANTIPSYCHOTIC PHARMACOTHERAPY, RE	001634 02-12 LAPSE, AND	PHENELZINE 003128 04-03
LENGTH OF STAY OUT OF THE HOSPITAL IN CHRONIC SO IN GREECE.		PHENELZINE IN DEPRESSED PATIENTS: EFFECTS ON URINARY MHPG EXCRETION IN RELATION TO CLINICAL RESPONSE.
ON PHARMACOTHERAPY FOR THE AGED.	001911 02-17	PHENELZINE-INDUCED 000686 01-13
S THERE A BIOLOGICAL BASIS FOR GERIATRIC PHARMAC	001919 02-17 OTHERAPY?.	PHENELZINE-INDUCED PSYCHOSIS. 003678 04-15
PHARMACOTHERAPY.	002742 03-17	PHENETHYLAMINE DIRECTIONAL LIPOPHILIC CHARACTER IN A SERIES OF PSYCHOTOMIMETIC
THE COMPARATIVE EFFICACY OF COGNITIVE THERAPY AN	003555 04-11	PHENETHYLAMINE DERIVATIVES. 001009 02-01
PHARMACOTHERAPY IN THE TREATMENT OF DEPRESSION	003701 04-17	STIMULUS PROPERTIES OF PHENETHYLAMINE HALLUCINOGENS AND LYSERGIC-ACID-DIETHYLAMIDE: THE ROLE OF 5
DEPRESSION: MUST PHARMACOTHERAPY FAIL FOR COGN TO SUCCEED?.		HYDROXYTRYPTAMINE. 002180 03-03
TYNGEAL PURISH DUCTONIA AS A POSSIBLE CAL	003726 04-17	PHENOBARBITAL PHENOBARBITAL ACTIONS IN VIVO: EFFECTS OF EXTRACELLULAR POTASSIUM ACTIVITY AND OXIDATIVE METABOLISM IN CAT
ARYNGEAL PHARYNGEAL DYSTONIA AS A POSSIBLE CAL ASPHYXIA WITH HALOPERIDOL TREATMENT.	003654 04-15	CEREBRAL-CORTEX. 000176 01-03
IES FFFECTS OF KETAMINE ON PATIENT RESPONSIVENESS DUI VARIOUS PHASES OF A SINGLE INDUCED ANXIETY SESS	RING THE	ANTICONVULSANT ACTIVITY OF PHENOBARBITAL AND PHENYTOIN IN COMBINATION. 000182 01-03
THE USE OF PENFLURIDOL ACCORDING TO A NEW DOSAG THE ACUTE, STABILIZATION AND MAINTENANCE PHASE	000513 01-07 E REGIMEN IN	MULTIPLE ORAL DOSES OF DIAZEPAM, OXAZEPAM AND PHENOBARBITAL TO DOGS — BEHAVIOURAL EFFECTS AND CORRELATION WITH ANTIPYRINE HALF-LIFE.
PSYCHOSIS.	003491 04-09	COMPARISON OF ETHANOL, PENTOBARBITAL, AND PHENOBARBITAL
PHASIC ACTIVITY IN THE RAT.	000070 01-03	USING DRUG VS. DRUG DISCRIMINATION TRAINING. 000503 01-06 DOXEPIN IN THE TREATMENT OF NEUROSES: A COMPARATIVE CLINICAL
HACYL-CYCLOPROPYLAMINE NHIBITION OF MONOAMINE-OXIDASE BY N PHENACYL- CYCLOPROPYLAMINE	30070 01-03	STUDY OF DOXEPIN, CHIORDIAZEPOXIDE, HYDROXYZINE, MEPROBAMATE, AND PHENOBARBITAL. 000614 01-10
CYCLOPROPYLAMINE.	002796 04-02	LACK OF EFFECT OF CLONAZEPAM ON SERUM LEVELS OF DIPHENYLHYDANTOIN, PHENOBARBITAL AND CARBAMAZEPINE.
NFLUENCE OF EXTRAPYRAMIDAL DISTURBANCES DUE TO ON PHENAMINE STEREOTYPY AND THE EFFECTS OF SCH		000705 01-13 PHENOBARBITAL AND PHENYTOIN EFFECTS ON SOMATOSENSORY
BLOOD SERUM (EXPERIMENTAL STUDIES).	002339 03-05	EVOKED-POTENTIALS AND SPONTANEOUS EEG IN NORMAL CAT BRAIN. 001032 02-02

EFFECTS OF PHENOBARBITAL AND DIAZEPAM ON IMIPRAMINE-INDUCED CHANGES IN BLOOD PRESSURE, HEART RATE AND RECTAL TEMPERATURE OF RATS. 001070 02-03

INTERACTIONS OF DELTA9-TETRAHYDROCANNABINOL WITH PHENOBARBITAL, ETHANOL AND CHLORDIAZEPOXIDE. 001436 02-04

PHENOBARBITAL IN THE ACUTE MANAGEMENT OF FEBRILE CONVULSIONS

001555 02-07 EFFECT OF PHENOBARBITAL ON THE DISPOSITION OF INTRAVENOUS THEOPHYLLINE.

DAILY CHANGES IN THE BLOOD SERUM LEVELS OF DIPHENYLHYDANTOIN (DPH) AND PHENOBARBITAL.

001830 02-15 PHENOBARBITAL METABOLISM DURING CHRONIC ADMINISTRATION IN RATS

002007 03-03 QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P.
450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE
ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3 METHYCHOLANTHRENE

002083 03-03 CAN PHENYTOIN BE GRADUALLY WITHDRAWN IN PATIENTS WITH MAJOR MOTOR EPILEPSY MAINTAINED ON CLONAZEPAM AND PHENOBARBITAL?

002504 03-11 EVALUATION OF A NEW IMMUNOASSAY FOR DETERMINATION OF PHENYTOIN AND PHENOBARBITAL: RESULTS OF A EUROPEAN COLLABORATIVE CONTROL STUDY.

BIOAVAILABILITY OF ORAL AND INTRAMUSCULAR PHENOBARBITAL 002600 03-13

INFLUENCE OF PHENOBARBITAL ON THE DISTRIBUTION AND ELIMINATION OF DESMETHYLIMIPRAMINE IN THE RAT. 002842 04-03

ANTAGONISM OF THE ANTICONVULSANT ACTION OF PHENYTOIN, PHENOBARBITAL, AND ACETAZOLAMIDE BY 6 HYDROXYDOPAMINI 002845 04-03

THE EFFECT OF PHENOBARBITAL AND CARBON-TETRACHLORIDE ON FATTY-ACID CONTENT AND COMPOSITION OF PHOSPHOLIPIDS FROM THE ENDOPLASMIC RETICULUM OF RAT LIVER.

002888 04-03 PHENOBARBITAL EFFECT ON GLIAL CELL RESPIRATION IN THE PRESENCE OF A HIGH CONCENTRATION OF POTASSIUM.

002946 04-03 SEIZURE SUSCEPTIBILITY AND ANTICONVULSANT ACTIVITY OF CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBIT RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES

003055 04-03

EFFECTS OF SODIUM PHENOBARBITAL ON BRAIN STIMULATION
BEHAVIOR, BEHAVIORAL SEIZURES, AND EEG SEIZURE ACTIVITY 003355 04-04

THE STABILITY AND RELIABILITY OF RADIOIMMUNOASSAYS FOR CLONAZEPAM, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN BLOOD, SERUM OR PLASMA. 003439 04-06

BEHAVIOR DISTURBANCE, PHENOBARBITAL, AND FEBRILE SEIZURES 003582 04-11

PHENOBARBITAL-INDUCED

CORRELATION OF PHENOBARBITAL-INDUCED AND SKF-525-A-INDUCED MODIFICATION OF PENTOBARBITAL HYPNOSIS WITH ALTERATION OF IN VIVO AND IN VITRO PENTOBARBITAL METABOLISM IN THE RAT. 003008 04-03

PHENOBARBITONE
THE INVESTIGATION OF PHENOBARBITONE, PHENYTOIN AND PRIMIDONE
IN THE DEATH OF EPILEPTICS.

000806 01-15 PHENOBARBITONE TERATOGENICITY: A CASE REPORT. 001799 02-15

A POTENTIALLY TOXIC DRUG INTERACTION BETWEEN PETHIDINE (MEPERIDINE) AND PHENOBARBITONE.

001836 02-15 INFLUENCE OF TRANSIENT ISCHEMIA ON MONOAMINE METABOLISM IN THE RAT BRAIN DURING NITROUS-OXIDE AND PHENOBARBITONE ANESTHESIA.

002852 04-03
INTERACTION OF ETHANOL WITH AMYLOBARBITONE, PHENOBARBITONE
AND METHAQUALONE.

003115 04-03 URINARY EXCRETION OF PHENOLIC METABOLITES OF PROPYLAMPHETAMINE IN MAN.

SUBJECTIVE PHENOMENA IN DRUG TRIALS.

000951 01-17

001892 02-17

Psychopharmacology Abstracts

PHENOTHIAZINE
ABSORPTION AND METABOLISM OF THE PHENOTHIAZINE DRUG PERAZINE
IN THE RAT INTESTINAL LOOP.
000063 01-03

A COMPARATIVE STUDY OF DIHYDROXYLATED PHENOTHIAZINE DERIVATIVES AS MITOCHONDRIAL INHIBITORS.

000282 01-03 PHENOTHIAZINE EFFECTS ON PSYCHOLOGICAL AND PSYCHOPHYSIOLOGICAL DYSFUNCTION IN CHRONIC SCHIZOPHRENICS 000549 01-08

MECHANISM FOR PHENOTHIAZINE OXIDATION 001014 02-01

OXIDATION KINETICS OF PHENOTHIAZINE AND 10
METHYLPHENOTHIAZINE IN ACIDIC MEDIUM.

001015 02-01 EFFECTS OF ADENINE-NUCLEOTIDES ON OXIDATION OF PHENOTHIAZINE TRANQUILIZERS.

001059 02-03 PHENOTHIAZINE METABOLITES AS MITOCHONDRIAL INHIBITORS 001259 02-03

PROTEIN AND ENZYME RELEASE FROM HUMAN LEUKOCYTES: INFLUENCE OF PHENOTHIAZINE DERIVATIVES. 001669 02-13

TREATMENT OF PHENOTHIAZINE OVERDOSAGE WITH PHYSOSTIGMINE. 001844 02-15

EEG RECORDS AND THE EFFECTS OF PHENOTHIAZINE TREATMENT IN PATIENTS WITH PARANOID SCHIZOPHRENIA. 002394 03-08 DRUG MONITORING AT AN AUSTRALIAN DEPOT PHENOTHIAZINE CLINIC

002402 03-08

PHENOTHIAZINE-INDUCED PHENOTHIAZINE-INDUCED ECG ABNORMALITIES. 000812 01-15

A COMPARISON OF PIRIBEDIL, PROCYCLIDINE AND PLACEBO IN THE CONTROL OF PHENOTHIAZINE-INDUCED PARKINSONISM. 000867 01-15

PHENOTHIAZINE-INDUCED PRIAPISM: A CASE REPORT. 001779 02-15

PHENOTHIAZINES
CILIOINHIBITORY EFFECT OF PHENOTHIAZINES IN VITRO AND ITS
ANTAGONISM BY CA.
0000

000040 01-03 ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND RELATED DRUGS ON THE TREATMENT OF SCHIZOPHRENIA

000536 01-08 THE EFFECTS OF PHENOTHIAZINES ON COMPLEX LEARNING 000767 01-14

CARDIOTOXIC DRUGS, WITH SPECIAL ATTENTION TO PHENOTHIAZINES AND IMPRAMINE DERIVATIVES.

000868 01-15 PRESCRIBING PHENOTHIAZINES 000894 01-15

PHENOTHIAZINYLPROPYL-PIPERIDINYLPHENYLMETHANONES

1-3 PHENOTHIAZINYLPROPYL-PIPERIDINYLPHENYLMETHANONES, A
NOVE. CLASS OF LONG-ACTING NEUROLEPTIC AGENTS.

001942 03-01

PHENOY BENZAMINE
CLOZAPINE AND PHENOXYBENZAMINE (PBZ) ALTERATION OF CENTRAL
PHENYLETHYLAMINE (PEA) TURNOVER.

ENHANCEMENT BY CHOLINE OF THE INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE BY PHENOXYBENZAMINE, 6 HYDROXYDOPAMINE, INSULIN OR EXPOSURE TO COLD.

002167 03-03 BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE.

THE EFFECTS OF PIMOZIDE AND PHENOXYBENZAMINE PRETREATMENTS ON AMPHETAMINE AND APOMORPHINE POTENTIATION OF THE ACOUSTIC STARTLE RESPONSE IN RATS.

BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE.

002224 03-04 PHENYLALANINE

EFFECT OF P-CHLOROPHENYLALANINE (PCPA) AND PHENYLALANINE (PHE)

TREATMENT ON EARLY AUDITORY EVOKED RESPONSES IN RATS.

002304 03-04 PHENYLEPHRINE

CYCLIC-AMP AND THE POSITIVE INTROPIC EFFECT OF NOREPINEPHRINE

AND PHENYLEPHRINE.

000195 01

000195 01-03 ONSET AND OFFSET OF CHLORPROMAZINE BLOCKADE OF PHENYLEPHRINE, CARBAMYLCHOLINE AND HISTAMINE ON RABBIT STOMACH STRIPS.

001234 02-03

001794 02-15

PHENYLETHANOLAMINE-N-METHYLTRANSFERASE
EFFECT OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND

DOPAMINE-BETA-HYDROXYLASE INHIBITION ON EPINEPHRINE LEVELS

INHIBITION OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND BRAIN STIMULATED REWARD.

003255 04-04 FHENYLETHYLAMINE
CLOZAPINE AND PHENOXYBENZAMINE (PBZ) ALTERATION OF CENTRAL

PHENYLETHYLAMINE (PEA) TURNOVER.

001177 02-03 PHENYLETHYLAMINE -- DEAMINATION BY MULTIPLE TYPES OF MONOAMINE OXIDASE

002893 04-03

PHENYLETHYLAMINES
PHENYLETHYLAMINES AS MEDIATORS OF THE CNS EFFECTS OF AMPHETAMINE. 001199 02-03

PHENYLKETONURIA BENEFICIAL EFFECT OF ISOLEUCINE ON FETAL BRAIN DEVELOPMENT IN INDUCED PHENYLKETONURIA.

002846 04-03 PHENYLPIPERIDINE PIPERIDINE DERIVATIVES: SYNTHESIS OF POTENTIAL ANALGESICS IN 3 SUBSTITUTED 4 PHENYLPIPERIDINE SERIES.

PHENYLPYRROLIDINOPENTANE COMBINATION OF PHENYLPYRROLIDINOPENTANE (KATOVIT) WITH OXAZEPAM (ADUMBRAN): A DOUBLE-BLIND TRIAL WITH OPIPRAMOL

(INSIDON) IN DEPRESSIVE SYNDROME.

PHENYTOIN
ANTICONVULSANT ACTIVITY OF PHENOBARBITAL AND PHENYTOIN IN COMBINATION. 000182 01-03

ACTIONS OF IONTOPHORETIC PHENYTOIN AND MEDAZEPAM ON HIPPOCAMPAL NEURONS.

000196 01-03 PHARMACOKINETIC OBSERVATIONS OF PHENYTOIN DISPOSITION IN THE NEWBORN AND YOUNG INFANT.

000644 01-11 THE INVESTIGATION OF PHENOBARBITONE, PHENYTOIN AND PRIMIDONE

IN THE DEATH OF EPILEPTICS. 000806 01-15 PHENOBARBITAL AND PHENYTOIN EFFECTS ON SOMATOSENSORY

EVOKED-POTENTIALS AND SPONTANEOUS EEG IN NORMAL CAT BRAIN. 001032 02-02 PHENYTOIN: AN EVALUATION OF SEVERAL POTENTIAL TERATOGENIC

PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EMBRYOPATHIC EFFECT AND COVALENT BINDING OF PUTATIVE ARENE OXIDE

METABOLITE IN GESTATIONAL TISSUE. 001515 02-05 CEREBELLAR ATROPHY IN PHENYTOIN TREATED MENTALLY RETARDED

EPILEPTICS 001622 02-11 PSYCHOTROPIC EFFECTS OF CARBAMAZEPINE IN EPILEPSY: A DOUBLE

BLIND COMPARISON WITH PHENYTOIN 001706 02-14 PHENYTOIN INTOXICATION DURING CONCURRENT DIAZEPAM THERAP

001826 02-15 CAN PHENYTOIN BE GRADUALLY WITHDRAWN IN PATIENTS WITH MAJOR MOTOR EPILEPSY MAINTAINED ON CLONAZEPAM AND

PHENOBARBITAL?

EVALUATION OF A NEW IMMUNOASSAY FOR DETERMINATION OF PHENYTOIN AND PHENOBARBITAL: RESULTS OF A EUROPEAN COLLABORATIVE CONTROL STUDY

002529 03-11 ANTAGONISM OF THE ANTICONVULSANT ACTION OF PHENYTOIN, PHENOBARBITAL, AND ACETAZOLAMIDE BY 6 HYDROXYDOPAMINE 002845 04-03

THE ACTIONS OF DIAZEPAM AND PHENYTOIN ON A LOW DOSE PENICILLIN EPILEPTIFORM FOCUS IN THE ANESTHETISED RAT. 002921 04-03

BINDING OF PHENYTOIN, L TRYPTOPHAN AND O METHYL-RED TO ALBUMIN. UNEXPECTED EFFECT OF ALBUMIN CONCENTRATION ON THE BINDING OF PHENYTOIN AND L TRYPTOPHAN. 003588 04-13

PHEOCHROMOCYTOMA
REGULATION OF CATECHOLAMINE BIOSYNTHESIS IN A TRANSPLANTABLE
RAT PHEOCHROMOCYTOMA.

000071 01-03 **ACTIVATION OF TYROSINE-3-MONOOXYGENASE IN** PHEOCHROMOCYTOMA CELLS BY LASALOCID.

002857 04-03 SELECTIVE ENZYME INDUCTION IN A NERVE GROWTH FACTOR RESPONSIVE PHEOCHROMOCYTOMA CELL LINE (PC-12). 002899 04-03 PHOBIAS

DOUBLE-BLIND CONTROLLED STUDY IN PHOBIAS AND OBSESSIONS 002483 03-10 RECENT RESULTS OF BEHAVIOURAL TREATMENTS OF PHOBIAS AND

PHILOPON
ON THE COURSE OF METHAMPHETAMINE (PHILOPON) PSYCHOSIS

BEHAVIOR THERAPY, SUPPORTIVE PSYCHOTHERAPY, IMIPRAMINE, AND 002501 03-10

PHOBIC CLOMIPRAMINE (ANAFRANIL) AND BEHAVIOUR THERAPY IN OBSESSIVE-COMPULSIVE AND PHOBIC DISORDERS.

A LARGE OPEN MULTICENTRE TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE MANAGEMENT OF PHOBIC DISORDERS.

AN UNCONTROLLED TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF PHOBIC AND OBSESSIONAL STATES IN GENERAL PRACTICE

002481 03-10 CLINICAL EXPERIENCE IN THE TREATMENT OF PHOBIC DISORDERS 002485 03-10

A CLINICAL TRIAL OF CLOMIPRAMINE AND DIAZEPAM IN THE TREATMENT OF PHOBIC AND OBSESSIONAL ILLNESS. 002497 03-10

FFFECTS OF DIAZEPAM ON PHORIC AVOIDANCE BEHAVIOR AND PHORIC ANXIFTY 002498 03-10

THE MANAGEMENT OF PHORIC DISORDERS IN GENERAL PRACTICE 002499 03-10 CLOSING REMARKS AT A SYMPOSIUM ON OBSESSIVE-COMPULSIVE

NEUROSES AND PHORIC DISORDERS 002760 03-17

EFFECTS OF BETA-BUNGAROTOX!N, DIPHENYLHYDANTOIN AND METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT CATIONS AND HIGH-ENERGY PHOSPHATE CONTENTS OF

000278 01-03 PHOSPHODIESTERASE SPECIFICITY OF BINDING OF ANTIPSYCHOTICS TO THE ACTIVATOR OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE

001178 02-03 THE INFLUENCE OF DIHYDROERGOTOXINE-MESYLATE ON THE LOW-KM PHOSPHODIESTERASE OF CAT AND RAT BRAIN IN VITRO.

002008 03-03 STUDIES ON THE INHIBITION OF PHOSPHODIESTERASE CATALYZED CYCLIC-AMP AND CYCLIC-GMP BREAKDOWN AND RELAXATION OF CANINE TRACHEAL SMOOTH MUSCLE. 002129 03-03

PHOSPHOLIPID

EFFECT OF PENTOBARBITAL ON REGIONAL BRAIN PHOSPHOLIPID SYNTHESIS.

001203 02-03 EFFECTS OF N METHYLAMINOETHANOL, AND N, N
DIMETHYLAMINOETHANOL IN THE DIET OF PREGNANT RATS ON NEONATAL RAT BRAIN CHOLINERGIC AND PHOSPHOLIPID PROFILE 003149 04-03

PHOSPHOLIPIDS ROLE OF PHOSPHOLIPIDS IN MUSCARINIC BINDING BY NEURAL MEMBRANES

000044 01-03 EFFECT OF 1 AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID (CYCLOLEUCINE)
ON DEVELOPING RAT CENTRAL-NERVOUS-SYSTEM PHOSPHOLIPIDS. 002136 03-03

THE EFFECT OF PHENOBARBITAL AND CARBON-TETRACHLORIDE ON FATTY-ACID CONTENT AND COMPOSITION OF PHOSPHOLIPIDS FROM THE ENDOPLASMIC RETICULUM OF RAT LIVER. 002888 04-03

BICYCLIC PHOSPHORUS ESTERS INCREASE THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM.

000009 01-01 PHOTODYNAMIC PHOTODYNAMIC ACTION OF CHLORPROMAZINE ON ADENOVIRUS 5: REPAIRABLE DAMAGE AND SINGLE STRAND BREAKS.

000821 01-15 PHOTOELECTRON LYSERGIC-ACID-DIETHYLAMIDE. PHOTOELECTRON IONIZATION POTENTIALS AS INDICES OF BEHAVIORAL ACTIVITY.

001100 02-03 EFFECTS OF ID-540 ON AVERAGED PHOTOPALPEBRAL REFLEX IN MAN THE EFFECTS OF A NEW BENZODIAZEPINE DERIVATIVE, ID-540, ON THE AVERAGED PHOTOPALPEBRAL REFLEX IN MAN.

Psychopharmacology Abstracts

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

001535 02-06

PHYSALAEMIN, A NEW POTENT ANTIDIPSOGEN IN THE RAT 003207 04-04

AN ANIMAL SCREENING TEST FOR DRUGS THAT PREDICTS THE LIKELIHOOD OF HUMAN PHYSICAL DEPENDENCE.

000028 01-02 THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS OF MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE. 000169 01-03

SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF PHYSICAL DEPENDENCE IN RATS: III. AUTORADIOGRAPHIC STUDIES 000177 01-03

COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMOTOR ACTIVITY, ANALGESIA AND PRIMARY AND PROTRACTED PHYSICAL DEPENDENCE IN SIX MOUSE STRAINS.

REGIONAL DISTRIBUTION OF BARBITAL IN THE BRAIN OF MICE DURING THE DEVELOPMENT OF TOLERANCE AND PHYSICAL DEPENDENCE. 001180 02-03

INVOLVEMENT OF BRAIN CYCLIC-AMP IN MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE. (PH.D. DISSERTATION). 001241 02-03

PHYSICAL DEPENDENCE ASSOCIATED WITH CHRONIC METHAQUALONE ADMINISTRATION.

001428 02-04 RELATIONSHIP BETWEEN PHYSICAL FINDINGS AND RELATED SUBJECTIVE SYMPTOMS IN NEUROPSYCHIATRIC PATIENTS WITH SOMATIC COMPLICATIONS — WITH SPECIAL REFERENCE TO OPHTHALMOLOGIC

001678 02-13 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. II. TOLERANCE CHARACTERISTICS.

001972 03-03 INDUCTION OF PHYSICAL DEPENDENCE ON CYCLAZOCINE AND PENTAZOCINE IN THE RAT.

002071 03-03 INFLUENCE OF IMMUNE STIMULATION AND SUPPRESSION ON MORPHINE PHYSICAL DEPENDENCE AND TOLERANCE.

002095 03-03

PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL.

IV. INFLUENCE OF ELIMINATION KINETICS. 002198 03-04

PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL.
III. WITHDRAWAL CHARACTERISTICS. 002199 03-04

EFFECT OF PSYCHOTROPIC AGENTS ON THE PHYSICAL PERFORMANCE CAPACITY OF ANIMALS EXPOSED TO HEAT AND COLD.

002273 03-04 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. I. CHRONICALLY EQUIVALENT DOSING METHOD.

OSMOTIC MINIPUMPS FOR ADMINISTRATION OF BARBITAL TO MICE: DEMONSTRATION OF FUNCTIONAL TOLERANCE AND PHYSICAL DEPENDENCE

002374 03-06 THE EFFECTS OF NALTREXONE ON THE DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE.

003170 04-04 THE PRODUCTION OF MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE BY THE ORAL ROUTE IN THE RAT.

003424 04-06 PHYSICALLY

POTENTIATION OF HEXOBARBITAL AND AMPHETAMINE EFFECTS IN MALE AND FEMALE RATS PHYSICALLY DEPENDENT ON MORPHINE

003275 04-04 WHAT THE PRACTICING PHYSICIAN SHOULD KNOW ABOUT MARIJUANA

000851 01-15 A STUDY OF PHYSICIAN DRUG PRESCRIBING ADOPTION AND DISCONTINUATION BEHAVIORS. (PH.D. DISSERTATION).

001889 02-17

WHY PHYSICIANS PRESCRIBE BENZODIAZEPINES IN ESSENTIAL HYPERTENSION: A PHASE IV STUDY

000667 01-11 PHYSICIANS DRUG INNOVATION AND RELINQUISHMENT

THE RESULTS OF A CAMPAIGN TO EDUCATE PHYSICIANS IN ANTIPSYCHOTIC DRUG USAGE.

001912 02-17 002761 03-17

PHYSIOLOGIC
PHYSIOLOGIC DISPOSITION OF NABILONE. A CANNABINOL DERIVATIVE.

000735 01-13

NEFOPAM (N), MORPHINE (M), AND D AMPHETAMINE (A) IN MAN: SUBJECTIVE, BEHAVIORAL, AND PHYSIOLOGIC EFFECTS. 001550 02-07

SOME PHYSIOLOGIC CHARACTERISTICS OF THE ELECTRODERMAL REFLEX IN THE CAT.

DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION. 003241 04-04

CHLORPROMAZINE: A POTENTIAL PHYSIOLOGICAL TERATOGEN

000486 01-05 INTERCORRELATIONS BETWEEN PHYSIOLOGICAL AND PSYCHOLOGICAL EFFECTS OF MARIUUANA, HASHISH, AND THC-DELTA9 IN LONG-TERM HASHISH USERS.

000695 01-13 POSSIBLE PHYSIOLOGICAL SIGNIFICANCE OF THE INITIAL STEP IN THE CATABOLISM OF NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM

001117 02-03 PHYSIOLOGICAL EFFECTS OF COCAINE IN THE SQUIRREL-MONKEY

001136 02-03 STUDIES OF THE PHYSIOLOGICAL ROLES OF PROSTAGLANDINS IN THE CENTRAL-NERVOUS-SYSTEM.

002924 04-03 A POSSIBLE PHYSIOLOGICAL MECHANISM FOR SHORT-TERM MEMORY 003227 04-04

BEHAVIORAL AND PHYSIOLOGICAL STUDIES OF NONNARCOTIC
ANALGESIA IN THE RAT ELICITED BY CERTAIN ENVIRONMENTAL
STIMULI.

003242 04-04 PHYSIOLOGICAL SUBSTRATES OF STATE-DEPENDENT LEARNING. 003302 04-04

ACUTE AND CHRONIC EFFECTS OF LITHIUM-CHLORIDE ON PHYSIOLOGICAL AND PSYCHOLOGICAL MEASURES IN NORMALS.

LETHAL EFFECTS OF PHYSOSTIGMINE PLUS LITHIUM IN RATS

000485 01-05 DOXEPIN OVERDOSE: SUCCESS WITH PHYSOSTIGMINE AND FAILURE WITH NEOSTIGMINE IN REVERSING TOXICITY.

000772 01-14 THE EFFECTS OF OXOTREMORINE AND PHYSOSTIGMINE ON MORPHINE-

INDUCED CIRCLING IN THE MOUSE 001457 02-04

NEUROTRANSMITTER METABOLITES IN THE CEREBROSPINAL FLUID OF MAN FOLLOWING PHYSOSTIGMINE 001653 02-13

REVERSAL BY PHYSOSTIGMINE OF CLOZAPINE-INDUCED DELIRIUM 001828 02-15

PHYSOSTIGMINE TREATMENT OF ANTICHOLINERGIC POISONING 001843 02-15

TREATMENT OF PHENOTHIAZINE OVERDOSAGE WITH PHYSOSTIGMINE 001844 02-15 THE EFFECTS OF PROLONGED HANDLING, SCOPOLAMINE, AND PHYSOSTIGMINE ON THE ACTIVITY OF ISOLATED AND SOCIALLY

REARED RATS. 002285 03-04 TOLERANCE TO THE BEHAVIOURAL EFFECTS OF PHYSOSTIGMINE IN RATS: LACK OF IMPORTANCE OF BEHAVIOURAL COMPENSATION.

003326 04-04 AGGRESSION INCREASE AND WATER COMPETITION DECREASE IN SQUIRREL-MONKEYS GIVEN PHYSOSTIGMINE INJECTIONS.

003377 04-04 EXPERIENCES WITH PHYSOSTIGMINESALICYLATE IN TRICYCLIC ANTIDEPRESSANT POISONING.

001820 02-15 PICROTOXIN

INVOLVEMENT OF THE DOPAMINE NIGROSTRIATAL SYSTEM IN THE PICROTOXIN EFFECT ON STRIATAL ACETYLCHOLINE LEVELS.

000158 01-03 THE EFFECTS OF PICROTOXIN AND PENTYLENETETRAZOL IN THE DIURNAL RHYTHMS OF CATECHOLAMINES AND SEROTONIN IN THE RAT BRAIN. 002123 03-03

COMPARATIVE STUDY OF THE ANTAGONISM OF BEMEGRIDE AND PICROTOXIN ON BEHAVIOURAL DEPRESSANT EFFECTS OF DIAZEPAM IN RATS AND MICE 002312 03-04

GABA, PICROTOXIN AND RETINAL SENSITIVITY.

002889 04-03 POSTMORTEM AND AMINOOXYACETIC-ACID-INDUCED ACCUMULATION OF GABA: EFFECT OF GAMMA-BUTYROLACTONE AND PICROTOXIN. 003042 04-03

PILOT

PILOT STUDY.

THE RAT BRAIN.

PILOT STUDY.

000373 01-04

000518 01-08

001027 02-02

BLOCKADE OF THE PICROTOXIN-INDUCED IN VIVO R	ELEASE OF DOPAMINE
IN THE CAT CAUDATE NUCLEUS BY DIAZEPAM.	001989 03-03
MARIJUANA: EFFECTS ON FREE RECALL AND SUBJECTION OF PICTURES AND WORDS.	CTIVE ORGANIZATION
	002629 03-14
THE PHARMACOLOGY OF A NEW POTENT, LONG-AC PIFLUTIXOL.	TING NEUROLEPTIC,
	001035 02-02
RESPONSES OF THE PITUITARY ADRENAL SYSTEM O ENVIRONMENTAL CHANGES AND DRUGS.	
MGEON	002833 04-03
DRINKING BEHAVIOUR INDUCED BY INTRACRANIAL ELEDOISIN AND SUBSTANCE-P IN THE PIGEON.	
MAZINDOL EFFECTS ON SCHEDULE-CONTROLLED RES	001352 02-04 SPONDING OF THE
	002268 03-04
PIGEONS NATURE OF RECEPTORS INVOLVED IN APOMORPHIN PIGEONS.	NE RESPONSES IN
DRUG DISCRIMINATION AND GENERALIZATION IN F	
DECREASED RESPONSE INHIBITION DURING FIXED-IN IN PIGEONS FOLLOWING ATROPINE ADMINISTRA	
COMBINED EFFECTS OF ETHANOL AND DIAZEPAM C AND ACQUISITION OF SERIAL POSITION SEQUENCE	ES BY PIGEONS.
THE EFFECTS OF CHLORDIAZEPOXIDE ON A DELAYER TASK IN PIGEONS.	
EFFECTS OF NALOXONE ON SCHEDULE-CONTROLLED MORPHINE MAINTAINED PIGEONS.	003348 04-04 BEHAVIOR IN
	003401 04-04
FFECTS OF DEXAMETHASONE ON DISCRIMINATIVE PIGS.	CONDITIONING IN
	003304 04-04
PILOCARPINE DEVELOPMENT AND DISAPPEARANCE OF SUBSENSI PILOCARPINE FOLLOWING A SINGLE ADMINISTRA IRREVERSIBLE ANTICHOLINESTERASE AGENT. DF	ATION OF THE
A BEHAVIORAL ANALYSIS OF AGGRESSIVE BEHAVI MODULATED BY DELTA9-TETRAHYDROCANNABIN AMPHETAMINE AND L-DOPA.	000212 01-03 ORS INDUCED AND NOL, PILOCARPINE, D
BLOCKADE OF BOTH PILOCARPINE AND AMPHETAN SHAKING WITH DOPAMINE RECEPTOR ANTAGON	
PILOSOCEREUS-MAXONII	002951 04-03
CACTUS ALKALOIDS XXXIII: BETA-PHENETHYLAMIN	IES FROM THE

THE INDOLEAMINE HYPOTHESIS OF DEPRESSION: AN OVERVIEW AND

THIORIDAZINE METABOLISM AND CLINICAL RESPONSE: A PILOT STUDY

FLUVOXAMINE (DU-23001), A NEW ANTIDEPRESSANT. QUANTITATIVE PHARMACO-ELECTROENCEPHALOGRAPHY AND PILOT CLINICAL TRIALS. 001548 02-07

EFFECT OF FUSARIC-ACID ON TARDIVE-DYSKINESIA AND MENTAL STATE

NEW APPROACH TO THE REHABILITATION OF THE HARD CORE DRUG ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY

VOLUNTEERS. PRELIMINARY REPORT ON A PILOT STUDY

DIFFERENCES IN THE EFFECTS OF CLOMIPRAMINE ON ENGLISH AND ASIAN

PILOT STUDY ON THE DISTRIBUTION OF C14-LABELED METHAQUALONE IN

ON THE OBJECTIVE EVALUATION OF HALOPERIDOL EFFECTS IN MAN: A

IN PSYCHOGERIATRIC PATIENTS: A PILOT STUDY

PILOT OPEN-LABEL STUDY OF BROFOXINE IN ANXIETY.

A PILOT ENDOCRINE STUDY IN DEPRESSION.

COMPARISON OF PIMOZIDE AND TRIFLUOPERAZINE AS ONCE-DAILY THERAPY IN CHRONIC SCHIZOPHRENIC OUTPATIENTS. 000537 01-08 PIMOZIDE IN TREATMENT OF ANOREXIA-NERVOSA. 000608 01-10 PIMOZIDE (ORAP-ETHNOR): AN INDEPENDENT REPORT. 000974 01-17 PHARMACOLOGICAL MANIPULATION OF HOARDING: FURTHER ANALYSIS OF AMPHETAMINE ISOMERS AND PIMOZIDE. 001312 02-04 EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS. 001712 02-14 BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE. O02224 03-04

A COMPARATIVE CONTROLLED TRIAL OF PIMOZIDE AND FLUPHENAZINEDECANOATE IN THE CONTINUATION THERAPY OF SCHIZOPHRENIA. SERUM PROLACTIN AND ANTIPSYCHOTIC RESPONSES TO PIMOZIDE IN SCH17OPHRENIA 002408 03-08 DISULFIRAM-INDUCED HYPOTHERMIA IN THE NORMAL RAT; ITS ATTENUATION BY PIACOZIDE THE EFFECTS OF PIMOZIDE AND PHENOXYBENZAMINE PRETREATMENTS ON AMPHETAMINE AND APOMORPHINE POTENTIATION OF THE ACOUSTIC STARTLE RESPONSE IN RATS. EFFECT OF PIMOZIDE ON THE IMPROVEMENT IN LEARNING PRODUCED BY SELF-STIMULATION AND BY WATER REINFORCEMENT. THE SOCIAL OUTCOME OF PATIENTS IN A TRIAL OF LONG-TERM CONTINUATION THERAPY IN SCHIZOPHRENIA: PIMOZIDE VS. FLUPHENAZINE. 003455 04-08 THE PSYCHOPHARMACOLOGICAL PROPERTIES OF PINAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE. 003357 04-04 PINCH-INDUCED EFFECTS OF CHLORDIAZEPOXIDE ON TAIL PINCH-INDUCED EATING IN 000442 01-04 PINEAL N ACETYLTRANSFERASE ACTIVITY IN PINEAL GLAND OF RATS TREATED WITH PARGYLINE. 000046 01-03 MORPHINE AND 5 HYDROXYTRYPTAMINE INTERACTIONS IN RAT HYPOTHALAMUS AND PINEAL BODY. 000065 01-03 INCREASE CAUSED BY DESMETHYLIMIPRAMINE IN THE PRODUCTION OF H3-MELATONIN BY ISOLATED PINEAL GLANDS. 001217 02-03 REGULATION OF CYCLIC-GUANOSINE-MONOPHOSPHATE IN THE RAT PINEAL AND POSTERIOR PITUITARY GLANDS. 003032 04-03 BENZHYDRYL PIPERAZINES: A NEUROPHARMACOLOGICAL AND PSYCHOPHARMACOLOGICAL EVALUATION. (PH.D. DISSERTATION) 001427 02-04 PIPERIDINE
PIPERIDINE DERIVATIVES: SYNTHESIS OF POTENTIAL ANALGESICS IN 3 SUBSTITUTED 4 PHENYLPIPERIDINE SERIES. 001019 02-02 UPTAKE AND METABOLISM OF INTRAVENTRICULARLY ADMINISTERED PIPERIDINE AND ITS EFFECTS ON SLEEP AND WAKEFULNESS IN THE RAT 001208 02-03 PHARMACOLOGICAL INTERACTIONS WITH CIRCLING BEHAVIOUR INDUCED BY THE PIPERIDINYL INDOLE DERIVATIVE RU-23686. 002200 03-04

PIMOZIDE

EFFECTS OF ALPHA-METHYL-P-TYROSINE, ADRENOLYTIC COMPOUNDS,
PIMOZIDE AND OTHER NEUROLEPTICS, ON THE NARCOTIC CUE.

000338 01

EFFECTS OF PIMOZIDE ON THE ACQUISITION, MAINTENANCE, AND
EXTINCTION OF AN AMPHETAMINE-INDUCED TASTE AVERSION.

EVALUATIONS OF SOCIAL FUNCTIONING IN A 3-YEAR DOUBLE-BLIND INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE IN CHRONIC

001011 02-01

000592 01-09

000737 01-13

001629 02-11

002463 03-09

002479 03-10

002531 03-11

002646 03-15

002865 04-03

PIPEROXANE REDUCES THE EFFECTS OF CLONIDINE ON AGGRESSION IN MICE AND ON NORADRENALINE DEPENDENT HYPERMOTILITY IN RAT

PIPOTHIAZINE-PALMITATE

A DOUBLE-BLIND CONTROLLED STUDY OF PIPOTHIAZINE-PALMITATE IN
THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS. 002390 03-08

COMPARISON OF THE EFFECTS OF PIPOTHIAZINE-PALMITATE AND FLUPHENAZINE-DECANOATE IN A MULTICENTER DOUBLE-BLIND TRIA 002412 03-08

000258 01-03

003347 04-04

003648 04-15

PIPOTIAZINE
ACTION OF THE PALMITIC ESTER OF PIPOTIAZINE ON DOPAMINE
METABOLISM IN THE NIGROSTRIATAL, MESOLIMBIC AND
MESOCORTICAL SYSTEMS.

PIPRADROL-INDUCED
THE RELATIONSHIP BETWEEN PIPRADROL-INDUCED RESPONDING FOR
ELECTRICAL BRAIN STIMULATION, STEREOTYPED BEHAVIOUR AND
LOCOMOTOR ACTIVITY.

EFFECT OF PIRACETAM ON BRAIN-DAMAGED, LEARNING-DISABLED CHILDREN.

000785 01-14 A DOUBLE-BLIND INVESTIGATION OF PIRACETAM (NOOTROPIL) VERSUS PLACEBO IN THE MEMORY OF GERIATRIC INPATIENTS.

EFFECTS OF PIRACETAM ON REGIONAL CEREBRAL BLOOD FLOW AND MENTAL FUNCTIONS IN PATIENTS WITH ORGANIC DEMENTIA. 002512 03-11
INFLUENCE OF VINCAMINE AND PIRACETAM ON SLEEP-WAKING PATTERN

OF THE CAT. 002925 04-03

PIRAZETAM

EFFECTS OF OROTIC-ACID AND PIRAZETAM ON CORTICAL BIOELECTRICAL **ACTIVITY IN RABBITS.** 000171 01-03

LACK OF EFFECT OF CHRONIC HALOPERIDOL ADMINISTRATION ON THE PROLACTIN LOWERING ACTIONS OF PIRIBEDIL.

000233 01-03 A COMPARISON OF PIRIBEDIL, PROCYCLIDINE AND PLACEBO IN THE CONTROL OF PHENOTHIAZINE-INDUCED PARKINSONISM.

000867 01-15 BIOCHEMICAL INTERACTION BETWEEN ANORECTIC DRUGS AND PIRIBEDIL. 001154 02-03

PARKINSONISM BY HALOPERIDOL AND PIRIBEDIL

PIRROXAN IN THE TREATMENT OF THE NEUROVEGETATIVE COMPONENT OF THE DEPRESSIVE SYNDROME.

003443 04-07

SUBCUTANEOUS INJECTIONS OF APOMORPHINE, STIMULUS
GENERALIZATION AND CONDITIONING: SERIOUS PITFALLS FOR THE
EXAMINER USING APOMORPHINE AS A TOOL.

000341 0

000341 01-04 MORPHINE DECREASES LUTEINIZING HORMONE BY AN ACTION ON THE HYPOTHALAMIC PITUITARY AXIS.

001084 02-03 LYSERGIC-ACID-DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF PITUITARY DOPAMINE RECEPTORS.

001192 02-03 THE EFFECTS OF METHAQUALONE ON PITUITARY ADRENOCORTICAL ACTIVITY IN MICE.

IMPACT OF AGE ON ANTERIOR PITUITARY HORMONES IN ADULT MALES

001687 02-13 PITUITARY HORMONE RELEASE IN VITRO BY MORPHINE-LIKE PEPTIDES. 001975 03-03

IDENTIFICATION OF DOPAMINERGIC RECEPTORS IN ANTERIOR PITUITARY: CORRELATION WITH THE DOPAMINERGIC CONTROL OF PROLACTIN 001982 03-03

H3-SPIROPERIDOL LABELS DOPAMINE RECEPTORS IN PITUITARY AND BRAIN.

SUPPRESSION OF THE HYPOTHALAMIC PITUITARY ADRENAL AXIS AFTER ORAL HYDROCORTISONE-SUCCINATE INGESTION IN RATS.

RESPONSES OF THE PITUITARY ADRENAL SYSTEM OF THE PIG TO ENVIRONMENTAL CHANGES AND DRUGS.

DIRECT AND PITUITARY MEDIATED EFFECTS OF DELTA9-THC AND CANNABINOL ON THE TESTIS. ELECTROPHORETIC ANALYSES OF PROTEINS TRANSPORTED TO THE RAT

POSTERIOR PITUITARY.

002920 04-03

Psychopharmacology Abstracts

A COMPARISON OF THE EFFECTS OF ANTIPSYCHOTIC DRUGS ON PITUITARY, STRIATAL AND LIMBIC SYSTEM POSTSYNAPTIC DOPAMINE RECEPTORS.

003009 04-03 REGULATION OF CYCLIC-GUANOSINE-MONOPHOSPHATE IN THE RAT PINEAL AND POSTERIOR PITUITARY GLANDS.

IMPRINTING BEHAVIOR: PITUITARY ADRENOCORTICAL MODULATION OF THE APPROACH RESPONSE.

003287 04-04 PITUITARY ADRENOCORTICAL AXIS AND SHOCK-INDUCED FIGHTING IN RATS 003342 04-04

PIZOTIFEN
A COMPARISON BETWEEN PLACEBO, PIZOTIFEN AND 1 ISOPROPYL-3-HYDROXY 5 SEMICARBAZONO-6-OXOTETRAHYDROINDOL (FIVASCAN) IN MIGRAINE PROPHYLAXIS. 000653 01-1

PIZOTIFEN AS AN ANTIDEPRESSANT.

000653 01-11 001606 02-09

FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN TREATMENT OF REMITTED SCHIZOPHRENICS: II. RATING SCALE DATA. 000544, 01-08

FLUPHENAZINE-DECANOATE, FLUPHENAZINE-HYDROCHLORIDE GIVEN ORALLY, AND PLACEBO IN REMITTED SCHIZOPHRENICS: I. RELAPSE RATES AFTER ONE YEAR.

A COMPARATIVE CLINICAL STUDY FOR THE EVALUATION OF ANTIANXIETY AGENTS, (LORAZEPAM, DIAZEPAM AND PLACEBO), IN NEUROSIS.

000599 01-10 DOUBLE-BLIND CROSS-OVER STUDY: APOMORPHINE/PLACEBO IN CHRONIC ALCOHOLICS.

000621 01-11 PHARMACOTHERAPY FOR ORGANIC-BRAIN-SYNDROME IN LATE LIFE: EVALUATION OF AN ERGOT DERIVATIVE VS PLACEBO.

A COMPARISON BETWEEN PLACEBO, PIZOTIFEN AND 1 ISOPROPYL-3-HYDROXY 5 SEMICARBAZONO-6-OXOTETRAHYDROINDOL (FIVASCAN) IN MIGRAINE PROPHYLAXIS.

000653 01-11 COMPARISON OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTICS IN GERIATRIC PATIENTS WITH INSOMNIA.

000658 01-11 MULTICLINIC CROSS-OVER COMPARISON OF TRIAZOLAM (HALCION) AND PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND ANXIETY IN ANXIOUS OUTPATIENTS.

AN EVALUATION OF THE CARDIOPULMONARY SAFETY AND EFFICACY OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS ORAL HYPNOTIC

000854 01-15 A COMPARISON OF PIRIBEDIL, PROCYCLIDINE AND PLACEBO IN THE CONTROL OF PHENOTHIAZINE-INDUCED PARKINSONISM.

000867 01-15 THE PLACEBO IN CLINICAL PSYCHOPHARMACOLOGY.

000942 01-17 THE PLACEBO EFFECT. 000969 01-17

PLACEBO AND ITS IMPORTANCE IN MEDICINE.

A DOUBLE-BLIND CLINICAL COMPARISON OF AMOXAPINE, IMIPRAMINE, AND PLACEBO IN THE TREATMENT OF DEPRESSION.

DOUBLE-BLIND COMPARATIVE CLINICAL STUDY OF LOXAPINE, DIAZEPAM, AND PLACEBO IN HOSPITALIZED PATIENTS WITH VARIOUS STATES OF ANXIETY.

A DOUBLE-BLIND INVESTIGATION OF PIRACETAM (NOOTROPIL) VERSUS PLACEBO IN THE MEMORY OF GERIATRIC INPATIENTS.

002502 03-11 EVALUATION OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTIC AGENTS IN PRESURGICAL PATIENTS.

THE EFFECTS OF ACTH4-10 VERSUS PLACEBO IN THE MEMORY OF SYMPTOMATIC GERIATRIC VOLUNTEERS.

002537 03-11 WORD ASSOCIATION TIMES, FELT EFFECTS, AND PERSONALITY CHARACTERISTICS OF SCIENCE STUDENTS GIVEN A PLACEBO ENERGIZER.

002611 03-14 DEANOL, LITHIUM AND PLACEBO IN THE TREATMENT OF TARDIVE DYSKINESIA.

DIFFERENTIAL CUE ATTENTIVENESS AND PLACEBO RESPONSIVITY. (PH.D. DISSERTATION).

002740 03-17 DEXTROAMPHETAMINE AND PLACEBO PRACTICE EFFECTS ON SELECTIVE ATTENTION IN HYPERACTIVE CHILDREN.

HYPNOTIC ACTIVITY OF DIPHENHYDRAMINE, METHAPYRILENE, AND PLACEBO.

SITUATIONAL FACTORS CONTRIBUTING TO THE PLACEBO EFFECT. 003714 04-17

PLACEBO AND SLEEP PATTERNS OF NORMAL YOUNG ADULTS. 003729 04-17

PLACEBO-CONTROLLED
DROPERIDOL IN ACUTELY AGITATED PATIENTS: A DOUBLE-BLIND
PLACEBO-CONTROLLED STUDY.

000662 01-11
LITHIUM TREATMENT OF HUNTINGTONS-CHOREA: A PLACEBOCONTROLLED CLINICAL TRIAL.

000663 01-11

DOUBLE-BLIND PLACEBO-CONTROLLED COMPARISON OF AMOXAPINE AND IMIPRAMINE IN DEPRESSED OUTPATIENTS.

O01585 02-09

DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF BUPROPIONHYDROCHLORIDE (WELLBATRIN) IN THE TREATMENT OF DEPRESSED
INPATIENTS.

O02430 03-09
DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF KETAZOLAM IN
ANXIETY.

A PLACEBO-CONTROLLED STUDY OF BROMAZEPAM AND DIAZEPAM IN ANXIETY NEUROSIS.

PLACEBOS

PLACEBOS IN PSYCHIATRIC THERAPY.

003542 04-10

PLANNING
DIFFICULTIES ENCOUNTERED BY THE CLINICAL RESEARCHER IN PLANNING
PSYCHOTROPIC DRUG TRIALS.

000935 01-16

PLANTS
THE CHEMICAL CONSTITUENTS OF GINSENG PLANTS.

001003 02-01
ETHNOPHARMACOLOGY OF SACRED PSYCHOACTIVE PLANTS USED BY
THE INDIANS OF MEXICO.

001894 02-17

PLASMA

DRUGS ALTERING INSULIN SECRETION: EFFECTS ON PLASMA AND BRAIN CONCENTRATIONS OF AROMATIC-AMINO-ACIDS AND ON BRAIN 5 HYDROXYTRYPTAMINE TURNOYER.

000088 01-03

EFFECTS OF APOMORPHINE AND CLONIDINE ON RAT PLASMA GROWTH

HORMONE AFTER PRETREATMENT WITH RESERPINE AND ELECTROCONVULSIVE SHOCKS.

INFLUENCE OF CHRONIC PENTOBARBITAL OR MORPHINE TREATMENT ON THE INCORPORATION OF P32-PHOSPHORIC-ACID AND 3H CHOLINE INTO RAT SYNAPTIC PLASMA MEMBRANES.

O00147 01-03

EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR
OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH
MORPHOLOGY AND HORMONE PLASMA LEVELS.

000315 01-04
DELTA9-THC AND 11 OH-DELTA9-THC: BEHAVIORAL EFFECTS AND
RELATIONSHIP TO PLASMA AND BRAIN LEVELS.

PLASMA CONCENTRATIONS AND CARDIOTOXIC EFFECTS OF DESIPRAMINE AND PROTRIPTYLINE IN THE RAT.

000478 01-05

PLASMA NORTRIPTYLINE AND CARDIAC RESPONSES IN YOUNG AND OLD RATS.

000479 01-05
EFFECTS OF CHLORPROMAZINE ON PLASMA PROLACTIN AND
CHLORPROMAZINE LEVELS.

THE EFFECT OF L TRYPTOPHAN ADMINISTRATION ON THE CONCENTRATION OF PROBENECID IN PLASMA AND CEREBROSPINAL FILLID IN PATIENTS

000564 01-09
PLASMA CONCENTRATION AND THE ANTIDEPRESSANT EFFECT OF
IMIPRAMINE TREATMENT.

PLASMA LEVELS DURING TREATMENT WITH IMIPRAMINE,

CLOMIPRAMINE, AND IMIPRAMINE-N-OXIDE. 000576 01-09 ERYTHROCYTE/PLASMA LITHIUM RATIOS.

O00586 01-09

AMITRIPTYLINE DOSAGE SCHEDULE, SAMPLING TIME AND TRICYCLIC
PLASMA LEVELS.

O00593 01-09
PLASMA CONCENTRATIONS OF PERPHENAZINE AND ITS SULPHOXIDE
METABOLITE DURING CONTINUOUS ORAL TREATMENT.

000631 01-11

PLASMA ANTICONVULSANT CONCENTRATIONS DURING PREGNANCY. 000642 01-11 RELATIONSHIP BETWEEN AGE AND TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS.

000652 01-11
HIGH-PRESSURE LIQUID CHROMATOGRAPHIC MASS SPECTROMETRIC
DETERMINATION OF DELTAP-TETRAHYDROCANNABINOL IN HUMAN
PLASMA FOLLOWING MARIJUANA SMOKING.

O00682 01-12
ON THE DISTRIBUTION OF DRUGS IN SALIVA AND BLOOD PLASMA.
000697 01-13
INFLUENCE OF THE ANTIPARKINSONIAN DRUGS ON THE PLASMA LEVEL

OF NEUROLEPTICS.

O00700 01-13

PLASMA 1-ALPHA-ACETYLMETHADOL (LAAM) AFTER ACUTE AND

PLASMA L-ALPHA-ACETYLMETHADOL (LAAM) AFTER ACUTE AND CHRONIC ADMINISTRATION.

000704 01-13
THE DEMETHYLATION OF IMIPRAMINE AND CLOMIPRAMINE AS

APPARENT FROM THEIR PLASMA KINETICS.

000716 01-13

PLASMA PROLACTIN DURING LITHIUM TREATMENT. 000719 01-13

PLASMA ALDOSTERONE AND MAGNESIUM IN SERUM AND URINE DURING LITHIUM TREATMENT. 000725 01-13

CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND ITS
METABOLITES AND CLINICAL RATINGS IN PATIENTS WITH ACUTE
RELAPSE OF SCHIZOPHRENIC AND PARANOID PSYCHOSIS.

O00726 01-13
PLASMA LEVELS OF CHLORPROMAZINE: EFFECT OF AGE, CHRONICITY OF DISEASE, AND DURATION OF TREATMENT.

000732 01-13
INCREASED STEADY-STATE PLASMA LEVELS AND PROLONGED HALF-LIVES
OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY.

O00734 01-13
PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF
CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS.
000742 01-13

TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS AND ADVERSE EFFECTS
AFTER OVERDOSE.

PHARMACOKINETICS OF NITRAZEPAM IN HUMAN PLASMA AND SALIVA. 001156 02-03

PLASMA CONCENTRATIONS OF SOME ACIDIC AND ALCOHOLIC METABOLITES DERIVED FROM M- AND P-TYRAMINE, OCTOPAMINE AND CATECHOLAMINES IN HUMANS.

THE DISTRIBUTION BETWEEN PLASMA AND BRAIN OF GLUTETHIMDE
AND 4 HYDROXYGLUTETHIMIDE FOLLOWING THEIR ADMINISTRATION
TO MICE

001160 02-03
PLASMA KINETICS OF NALTREXONE AND ITS GLUCURONIDE IN THE DOG.
001183 02-03
COMPARATIVE BRAIN/PLASMA CONCENTRATIONS OF AMPHETAMINE

ISOMERS IN MICE.

O01224 02-03

SPECIFIC RADIOIMMUNOASSAY FOR AMITRIPTYLINE AND NORTRIPTYLINE
IN PLASMA.

O01534 02-06
ANTIPARKINSONIAN DRUG ADMINISTRATION AND PLASMA LEVELS OF
PENFLURIDOL, A NEW LONG-ACTING NEUROLEPTIC.

THE PHARMACOKINETICS OF RED BLOOD CELL AND PLASMA BUTAPERAZINE CLINICAL RESPONSE AND SIDE-EFFECTS. 001561 02-08

PLASMA BUTAPERAZINE LEVELS IN LONG-TERM CHRONIC NONRESPONDING SCHIZOPHRENICS.

001569 02-08
PROTRIPTYLINE PLASMA LEVELS AND ANTIDEPRESSANT RESPONSE.
001576 02-09
AMITRIPTYLINE PLASMA LEVELS AND CLINICAL RESPONSE IN PRIMARY

PLASMA ALDOSTERONE DURING LITHIUM TREATMENT.

001599 02-09
THE METABOLISM AND PLASMA CONCENTRATIONS OF L-ALPHAACETYLMETHADOL AND ITS METABOLITES IN MAN. (PH.D.

001656 02-13
THE MOOD RESPONSE AND PLASMA CYCLIC-AMP RESPONSE TO
INTRAVENOUS METHYLPHENIDATE.

001666 02-13
LITHIUM SODIUM COUNTERTRANSPORT IN HUMAN RED CELLS AND IN
VIVO LITHIUM DISTRIBUTION BETWEEN RED CELLS AND PLASMA.
001679 02-13

COMPARATIVE AVAILABILITY OF DIAZEPAM (D) IN HUMAN PLASMA.
(P), PAROTID SALIVA (PS) AND MIXED SALIVA (MS) AND ITS
RELATIONSHIP TO PLASMA PROTEIN BINDING.

001A82 02-13

CYCLIC-AMP IN THE PLASMA OF CHRONIC SCHIZOPHRENICS, BEFORE AND AFTER TREATMENT.

001690 02-13

EFFECT OF CHLORPROMAZINE TREATMENT ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC PATIENTS. 001694 02-13 PLASMA FENFLURAMINE LEVELS, WEIGHT LOSS, AND SIDE-EFFECTS RELATIONSHIPS AMONG CLINICAL RESPONSE, EXTRAPYRAMIDAL SYNDROME AND PLASMA CHLORPROMAZINE AND METABOLITE RATIOS.

001827 02-15 A GC/CIMS ASSAY FOR THE CIS AND TRANS ISOMERS OF THIOTHIXENE IN HUMAN PLASMA.

001857 02-16 HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF DOTHIEPIN AND NORTHIADEN IN HUMAN PLASMA AND SERUM. 001858 02-16 REDUCED LEVELS OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA FROM

VACUTAINERS 001859 02-16

PLASMA ASSAY OF FLUPHENAZINE.

001871 02-16

PREDICTION OF PLASMA LEVELS OF IMIPRAMINE FROM
PHARMACOKINETICS OF AN INITIAL DOSE. (UNPUBLISHED PAPER)

TIME-COURSE OF AUDIOGENIC SEIZURE SUSCEPTIBILITY AND PLASMA PENTOBARBITAL CONCENTRATION DURING WITHDRAWAL. 001977 03-03

CANNABINOID EFFECTS ON PLASMA CORTICOSTERONE AND UPTAKE OF H3-CORTICOSTERONE BY MOUSE BRAIN. 002051 03-03

POSSIBLE CENTRAL DOPAMINERGIC MODULATION OF THE RISE IN PLASMA CONCENTRATION OF NONESTERIFIED FATTY-ACIDS PRODUCED IN THE MOUSE BY (-)TRANS DELTA9-TETRAHYDROCANNABINOL. 002085 03-03

THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MALE

002343 03-05 R-806-003-01 IN THE TREATMENT OF DEPRESSION: PLASMA LEVELS AND THERAPEUTIC RESPONSE.

002376 03-07 CLINICAL AND PLASMA LEVEL CHARACTERISTICS OF INTRAMUSCULAR AND ORAL LOXAPINE.

002407 03-08 A COMPARISON OF DESIPRAMINE AND AMITRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.

002417 03-09 CLOMIPRAMINE PLASMA LEVEL AND CLINICAL RESPONSE

002422 03-09 A NEW ANTIDEPRESSANT BUTRIPTYLINE: PLASMA LEVELS AND CLINICAL RESPONSE.

002423 03-09 AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL EFFECT: A WORLD HEALTH ORGANIZATION COLLABORATIVE STUDY.

002426 03-09 LITHIUM ERYTHROCYTE/PLASMA RATIO AS A PREDICTOR OF RESPONSE.
002431 03-09
WEIGHT LOSS AND A CONCOMITANT CHANGE IN PLASMA TRICYCLIC

LEVELS 002441 03-09

DESIPRAMINE PLASMA LEVELS AND THERAPEUTIC RESPONSE 002443 03-09 LITHIUM ERYTHROCYTE: PLASMA RATIO IN PRIMARY AFFECTIVE-DISORDER

002445 03-09 PLASMA LEVEL STUDIES OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE FOLLOWING INTRAVENOUS INFUSIONS OF CLOMIPRAMINE IN DEPRESSIVE PATIENTS.

002448 03-09 CLINICAL EFFECTS AND PLASMA LEVELS OF CLOMIPRAMINE IN DEPRESSED BARBADIANS.

002449 03-09 EFFICACY, SIDE-EFFECTS, PLASMA AND BLOOD LEVELS OF MAPROTILINE (LUDIOMIL).

002451 03-09 CLINICAL RESPONSE IN DEPRESSED PATIENTS IN RELATION TO PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND TYRAMINE PRESSOR

TRICYCLIC PLASMA LEVELS: EFFECT OF AGE, RACE, SEX, AND SMOKING.
002472 03-09

A PRELIMINARY REPORT ON CLINICAL RESPONSE AND PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN OBSESSIVE-COMPULSIVE NEUROSIS.

002493 03-10 CLINICAL AND BIOCHEMICAL EFFECTS OF CHLORPROMAZINE IN PSYCHOTIC PATIENTS: RELATIONS TO CHLORPROMAZINE CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID. 002538 03-11 EFFECTS OF MELPERONE AND THIOTHIXENE ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC WOMEN.

ASMA PROLACTIN CONCENTRATIONS IN NORMAL SUBJECTS AND DEPRESSIVE PATIENTS FOLLOWING ORAL CLOMIPRAMINE.

PLASMA CONCENTRATIONS OF CLOMIPRAMINE AND ITS N DESMETHYL METABOLITE IN DEPRESSIVE PATIENTS FOLLOWING TREATMENT WITH VARIOUS DOSAGE REGIMES OF CLOMIPRAMINE.

PLASMA RENIN SUBSTRATE DURING LITHIUM TREATMENT

002569 03-13 PROBENECID-INDUCED NOREPINEPHRINE ELEVATIONS IN PLASMA AND

EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DEPRESSIVE PATIENTS RECEIVING CLOMIPRAMINE THERAPY.

TYRAMINE PRESSOR RESPONSES AND PLASMA LEVELS DURING TRICYCLIC ANTIDEPRESSANT THERAPY.

IMIPRAMINE, ITS N DESMETHYL AND HYDROXY METABOLITES IN PLASMA: MICRO DETERMINATION BY ALKALINE FLAME-IONIZATION GAS-CHROMATOGRAPHY (AFID-GC).

002597 03-13 METHADONE DOSE, PLASMA LEVEL, AND CROSS-TOLERANCE TO HEROIN IN MAN

002642 03-14 MEASUREMENT OF PLASMA ANTIDEPRESSANT LEVELS BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY.

002720 03-16 SPECIFIC RADIOIMMUNOASSAY PROCEDURE FOR PLASMA CLOMIPRAMINE.

002723 03-16 ACTH EFFECTS ON RESPONSE SUPPRESSION AND PLASMA CORTICOSTERONE IN THE MOUSE.

003363 04-04 MEASUREMENT OF PLASMA AND ERYTHROCYTE CHLORPROMAZINE AND N MONODESMETHYLCHLORPROMAZINE LEVELS BY GAS-CHROMATOGRAPHY WITH A NITROGEN SENSITIVE DETECTOR.

THE STABILITY AND RELIABILITY OF RADIOIMMUNOASSAYS FOR CLONAZEPAM, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN BLOOD, SERUM OR PLASMA.

003439 04-06 EFFECTS OF PERPHENAZINE-ENANTHATE INJECTIONS ON PROLACTIN LEVELS IN PLASMA FROM SCHIZOPHRENIC WOMEN AND MEN. 003462 04-08

LOW PLASMA LEVELS OF CPZ IN PATIENTS CHRONICALLY TREATED WITH NEUROLEPTICS

003469 04-08 CLINICAL IMPORTANCE OF DOXEPIN ANTIDEPRESSANT PLASMA LEVELS 003497 04-09 PLASMA RENIN CONCENTRATION DURING LITHIUM THERAPY

003503 04-09 PREDICTION OF STEADY-STATE PLASMA CONCENTRATION OF IMIPRAMINE.

THE PRACTICAL SIGNIFICANCE OF NORTRIPTYLINE PLASMA CONTROL. A PROSPECTIVE EVALUATION UNDER ROUTINE CONDITIONS IN ENDOGENOUS DEPRESSION.

003522 04-09 THE EFFECT OF CLOFIBRATE ON TOTAL AND FREE PLASMA TRYPTOPHAN IN DEPRESSED PATIENTS

003532 04-09 IMPLICATIONS OF DOSE REGIMEN AND PROTEIN BINDING FOR PLASMA NORTRIPTYLINE ESTIMATIONS

003547 04-10 ALOSTERIC CHANGES IN PLASMA PROTEINS IN HEALTHY VOLUNTEERS AFTER ADMINISTRATION OF LYSERGAMIDE

003584 04-12 EFFECTS OF 2 DIMETHYLAMINOETHANOL (DEANOL) ON THE METABOLISM OF CHOLINE IN PLASMA

003589 04-13 SMA FLUPHENAZINE CONCENTRATIONS AFTER INJECTION OF LONG-

003590 04-13 PLASMA LEVELS OF NEUROLEPTICS VS CLINICAL RESPONSES.

003601 04-13 DISAPPEARANCE OF CHLORPROMAZINE FROM PLASMA FOLLOWING DRUG WITHDRAWAL.

003605 04-13 EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON HUMAN PLASMA LEVELS OF TSH, GH AND PROLACTIN.

003613 04-13 CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED DOSES OF CHLORPROMAZINE.

000626 01-11

TRICYCLIC ANTIDEPRESSANTS: PLASMA LEVELS AND CLINICAL FINDINGS IN OVERDOSE. 003643 04-15

PLASTICITY SUBSTRATES OF ELEMENTARY BEHAVIORAL PLASTICITY.

LOCAL PERFUSION OF NORADRENALINE MAINTAINS VISUAL CORTICAL PLASTICITY.

PLATELET EFFECT OF RESERPINE ON ADENOSINE UPTAKE AND METABOLISM, AND SUBCELLULAR TRANSPORT OF PLATELET ADENOSINE-TRIPHOSPHATE IN WASHED RABBIT PLATELETS.

000238 01-03 D AMPHETAMINE INHIBITION OF PLATELET MAO FROM SCHIZOPHRENIC PATIENTS.

000543 01-08 PLATELET MONOAMINE-OXIDASE ACTIVITY PREDICTS RESPONSE TO LITHIUM IN MANIC-DEPRESSIVE ILLNESS

THE HUMAN PLATELET AS A MODEL FOR THE DOPAMINERGIC NEURON:
KINETIC AND PHARMACOLOGIC PROPERTIES AND THE ROLE OF AMINE STORAGE GRANULES

CLOMIPRAMINE AND MAPROTILINE ON HUMAN PLATELET UPTAKE OF 5 HYDROXYTRYPTAMINE AND DOPAMINE IN VITRO: WHAT RELEVANCE TO THEIR ANTIDEPRESSIVE AND OTHER ACTIONS?

002599 03-13 CLINICAL CORRELATES OF LOW PLATELET MONOAMINE-OXIDASE IN SCHIZOPHRENIC PATIENTS.

003477 04-08 CLINICAL CORRELATES OF TRICYCLIC ANTIDEPRESSANT MEDIATED INHIBITION OF PLATELET MONOAMINE-OXIDASE.

003524 04-09
STABILITY OF LOW BLOOD PLATELET MONDAMINE-OXIDASE ACTIVITY IN HUMAN ALCOHOLICS.

003577 04-11 EFFECTS OF SINGLE DOSES OF TRANYLCYPROMINE ON PLATELET MAD AND AMINE UPTAKE IN NORMAL SUBJECTS.

003594 04-13 A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS 003608 04-13

CHLORPROMAZINE AND PLATELET FUNCTION

003686 04-15

PLATELETS EFFECTS OF RESERPINE AND IMIPRAMINE ON VESICULAR SEROTONIN UPTAKE AND STORAGE IN INTACT HUMAN PLATELETS

EFFECTS OF RESERPINE AND SEROTONIN ON ADENINE-NUCLEOTIDE

INTERFERENCE BY FENFLURAMINE WITH THE STORAGE OF C14-5-

000081 01-03 SEROTONIN TRANSPORT AND STORAGE IN RABBIT BLOOD PLATELETS THE EFFECTS OF RESERPINE AND IMPRAMINE.

000236 01-03

METABOLISM AND GLUCOSE OXIDATION OF WASHED RABBIT PLATFLETS

EFFECT OF RESERPINE ON ADENOSINE UPTAKE AND METABOLISM, AND SUBCELLULAR TRANSPORT OF PLATELET ADENOSINE-TRIPHOSPHATE IN WASHED RABBIT PLATELETS. 000238 01-03

HYDROXYTRYPTAMINE IN RAT PLATELETS. 000297 01-03 EFFECTS OF ANTIMYCIN A PLUS 2 DEOXYGLUCOSE ON UPTAKE AND VESICULAR STORAGE OF SEROTONIN IN HUMAN PLATELETS.

(UNPUBLISHED PAPER) UPTAKE OF 5 METHOXYTRYPTOLINE (6 MEO-TETRAHYDRO-BETA-CARBOLINE) BY BLOOD PLATELETS AND ITS EFFECT ON 5-HT UPTAKE

001043 02-03 EFFECT OF TWO NON TRICYCLIC ANTIDEPRESSANT DRUGS ON C14-5 HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.

001283 02-03 EFFECT OF CANNABINOIDS ON THE UPTAKE OF SEROTONIN IN HUMAN

002603 03-13 5 HYDROXYTRYPTAMINE AND DOPAMINE TRANSPORT BY RAT AND HUMAN BLOOD PLATELETS.

002928 04-03 A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS. 003608 04-13

DOES PROLACTIN PLAY A ROLE IN ESTROGEN-INDUCED MATERNAL BEHAVIOR IN RATS: APOMORPHINE REDUCTION OF PROLACTIN RELEASE 000445 01-04 PLEASANTNESS

MARJUANA: DOSE-RESPONSE EFFECTS ON PULSE RATE, SUBJECTIVE ESTIMATES OF POTENCY, PLEASANTNESS, AND RECOGNITION MEMORY

000648 01-11 STUDIES ON DIGITAL PLETHYSMOGRAPHIC PATTERNS IN FEMALE PATIENTS WITH NONSPECIFIC COMPLAINTS.

PLEXUS

SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION. 002052 03-03

PMPEA

P-METHOXYPHENYLETHYLAMINE (PMPEA): SOME BEHAVIORAL **OBSERVATIONS IN RATS** 001319 02-04

PNEUMATIC

THE PNEUMATIC SYRINGE: A SIMPLE APPARATUS FOR SELF-ADMINISTRATION OF DRUGS BY RATS. 001541 02-06

POISON AVERSION AND SEXUAL BEHAVIOR IN THE GOLDEN HAMSTER. 001357 02-04

THE HUMAN EEG IN SEVERELY POISONED PATIENTS -- INDICATION AND CONTROL OF HEMODIALYSIS OR HEMOPERFUSION

001795 02-15 FAILURE TO ELICIT CONDITIONED TASTE AVERSION BY SEVERE

POISONING 000382 01-04 LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUSION IN IMPRAMINE POISONING.

000477 01-05

THE EFFECTS OF HALOPERIDOL, CHLORPROMAZINE AND PROPRANOLOL ON ACUTE AMPHETAMINE POISONING IN THE CONSCIOUS DOG. 000480 01-05

POISONING WITH ANTIDEPRESSANTS 000805 01-15 POISONING WITH MAPROTILINE AND MIANSERIN

000819 01-15 POISONING WITH TRICYCLIC ANTIDEPRESSANT DRUGS

000860 01-15 A CASE OF FATAL IMIPRAMINE POISONING IN AN INFANT 000879 01-15

ACUTE POISONING WITH MAPROTILINE HYDROCHLORIDE ELECTRON MICROSCOPIC STUDIES ON THE CEREBRAL LESIONS OF RATS IN EXPERIMENTAL CHRONIC DISULFIRAM POISONING.

CHANGES IN LIVER FUNCTION IN ACUTE POISONING BY BARBITURATE.

RESERPINE AND AMPHETAMINE. 001094 02-03

LIPID HEMODIALYSIS VERSUS CHARCOAL HEMOPERFUSION IN IMIPRAMINE POISONING. AN IN-VITRO AND IN-VIVO STUDY 001503 02-05 OBSERVATIONS ON THE TREATMENT OF PHENCYCLIDINE (PCP)

001745 02-15 TWO CASES OF SEVERE ORPHENADRINE POISONING WITH ATYPICAL

001748 02-15 DELIBERATE POISONING WITH TRICYCLIC ANTIDEPRESSANTS TREATED IN

AN INTENSIVE CARE UNIT 001758 02-15 SEVERE MEPROBAMATE POISONING: SUCCESSFUL TREATMENT WITH

HEMOPERFUSION 001764 02-15 MORE ABOUT POISONING BY PHENCYCLIDINE (PCP, ANGEL-DUST). 001786 02-15

FATAL POISONING WITH PROPOXYPHENE: REPORT FROM 100 CONSECUTIVE CASES. 001788 02-15

POISONING WITH ANTIDEPRESSANTS 001791 02-15 CHLORPROMAZINE PLUS THIORIDAZINE POISONING AND TREATMENT

WITH EXTRACORPOREAL DIALYSIS. 001806 02-15

OXPRENOLOL (TRASICOR) POISONING 001819 02-15 EXPERIENCES WITH PHYSOSTIGMINESALICYLATE IN TRICYCLIC ANTIDEPRESSANT POISONING

001820 02-15 A SEVEN YEAR REVIEW OF COMA PATIENTS ADMITTED TO THE REGIONAL POISONING TREATMENT CENTRE, ROYAL INFIRMARY, FDINBURGH

IATROGENIC COMPLICATIONS OF DRUG OVERDOSAGE AND POISONING. 001824 02-15

THE ROLE OF CHARCOAL HEMOPERFUSION IN THE ACTIVE MANAGEMENT 001842 02-15 PHYSOSTIGMINE TREATMENT OF ANTICHOLINERGIC POISON 001843 02-15

THE CONTRIBUTION OF PRESCRIBED DRUGS TO THE INCIDENCE OF ACCIDENTAL AND DELIBERATE POISONING IN THE COMMUNITY

001896 02-17 THE EPIDEMIOLOGY OF ACUTE POISONING

O01937 02-17
ANITA MUSHROOM POISONING WITH RECOVERY FROM COMA: A CASE REPORT.

002705 03-15 A CASE OF LITHIUM POISONING? A CAUTIONARY TALE. 003653 04-15

POISONINGS
GUIDELINES FOR AGENTS USED IN THE TREATMENT OF POISONINGS 002652 03-15

ACUTE POISONINGS DUE TO DRUGS IN THE POLISH PROVINCE OF OLSZTYN FROM 1971 TO 1974. 002657 03-15

POLISH
ACUTE POISONINGS DUE TO DRUGS IN THE POLISH PROVINCE OF OLSZTYN FROM 1971 TO 1974.

0026: 002657 03-15 POLLUTION

BEHAVIORAL TOXICITY: THE PSYCHOLOGY OF DRUG POLLUTION.
003684 04-15

POLYAMINE BIOSYNTHESIS IN RAT PROSTATE. SUBSTRATE AND INHIBITOR PROPERTIES OF 7 DEAZA ANALOGUES OF DECARBOXYLATED S ADENOSYLMETHIONINE AND 5 METHYLTHIOADENOSINE. 000001 01-01

POLYAMINES
PHARMACOLOGICAL ACTIONS OF INTRACEREBRALLY ADMINISTERED
POLYAMINES IN MICE. 000033 01-02

POLYDIPSIA
SCHEDULE-INDUCED WATER AND SACCHARIN POLYDIPSIA UNDER
HALOPERIDOL. 000390 01-04

LEAD ENHANCES LITHIUM-INDUCED POLYDIPSIA 001409 02-04 DDAVP AND LITHIUM-INDUCED POLYURIA/POLYDIPSIA. 001851 02-15

POLYDRUG
PHARMACOKINETIC STUDIES ON TOLERANCE TO SEDATIVE HYPNOTICS IN
A POLYDRUG ABUSE POPULATION: 1. SECOBARBITAL.
002662 03-15 002662 03-15

ORGANIC IMPAIRMENT IN POLYDRUG USERS: RISK FACTOR 002670 03-15

IMPROVED POLYETHYLENE INTRACEREBROVENTRICULAR CANNULAS FOR RATS. POLYETHYLENE 003440 04-06

THE TREATMENT OF ANXIETY WITH A POLYFLUORINATED BENZODIAZEPINE DERIVATIVE. 003445 04-07

POLYGRAPH
PSYCHOPHARMACOLOGIC AGENTS IN POLYGRAPH TESTING

001926 02-17

POLYGRAPHIC POLYGRAPHIC EVALUATION OF ETHCHLORVYNOL (14 DAYS). 002679 03-15 POLYGRAPHICALLY

THE EFFECT OF A NEW BENZODIAZEPINE ON THE POLYGRAPHICALLY MONITORED SLEEP OF NORMAL VOLUNTEERS. 000765 01-14

SOLID DISPERSION APPROACH FOR OVERCOMING BIOAVAILABILITY PROBLEMS DUE TO POLYMORPHISM OF NABILONE, A CANNABINOID DERIVATIVE.

POLYMORPHONUCLEAR
CHEMILUMINESCENCE RESULTING FROM AN INTERACTION BETWEEN
IMIPRAMINE AND HUMAN POLYMORPHONUCLEAR LEUKOCYTES.
001263 02-03 001539 02-06

POLYPHARMACY AMONG PSYCHIATRIC PATIENTS.

001900 02-17 POLYPHOSPHOINOSITIDE CHOLINERGIC STIMULATION OF POLYPHOSPHOINOSITIDE METABOLISM IN BRAIN IN VIVO.

003097 04-03 POLYSOMES DISAGGREGATION OF BRAIN POLYSOMES AFTER D LYSERGIC-ACID-DIETHYLAMIDE ADMINISTRATION IN VIVO: MECHANISM AND EFFECT OF AGE AND ENVIRONMENT.

Psychopharmacology Abstracts

ANTIPSYCHOTIC DRUGS BLOCK LSD-INDUCED DISAGGREGATION OF BRAIN POLYSOMES. 001147 02-03

STRESS ACCENTUATION OF THE LSD-INDUCED DISAGGREGATION OF BRAIN POLYSOMES.

002035 03-03

A ROLE OF THE POLYSYNAPTIC SYSTEM OF SUBSTANTIA-NIGRA IN THE CHOLINERGIC DOPAMINERGIC EQUILIBRIUM IN THE CENTRAL-NERVOUS-003397 04-04

PATHOGENESIS OF LITHIUM-INDUCED POLYURIA.

001513 02-05 DDAVP AND LITHIUM-INDUCED POLYURIA/POLYDIPSIA 001851 02-15

PONTILE
ROLE OF GLUCOCORTICOIDS IN AN ABNORMAL GROOMING BEHAVIOR IN
CATS WITH PONTILE OR FRONTAL NEOCORTICAL LESIONS.
000463 01-04 000463 01-04

PONTO-GENICULO-OCCIPITAL
THE RELATIONSHIP BETWEEN CORTICAL RECRUITING RESPONSES AND
PONTO-GENICULO-OCCIPITAL (PGO) WAVES DURING PARADOXICAL
SLEEP AND AFTER THE ADMINISTRATION OF RESERPINE IN THE CAT 002069 03-03

COMPARABLE EFFICACY OF IMIPRAMINE HCL AND IMIPRAMINE-PAMOATE: A POOLED STATISTICAL REPORT. 0035

POOLS DIFFERENTIAL EFFECTS OF RESERPINE AND TETRABENAZINE ON RAT STRIATAL SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS AND SYNAPTOSOMAL DOPAMINE POOLS.

000172 01-03 THE RELATIVE FUNCTIONAL AVAILABILITY OF BRAIN NORADRENALINE AND DOPAMINE STORAGE POOLS.

001191 02-03

POPULATION
CHLORPROMAZINE INDUCES POPULATION INCREASE OF SYNAPTIC
VESICLES IN THE RAT HYPOTHALAMIC VENTROMEDIAL NUCLEUS. 000160 01-03

BEHAVIORAL AND PSYCHOPHARMACOLOGICAL CHARACTERISTICS OF RATS RAISED IN HIGH POPULATION DENSITY. 001472 02-04

PHARMACOKINETIC STUDIES ON TOLERANCE TO SEDATIVE HYPNOTICS IN A POLYDRUG ABUSE POPULATION: 1. SECOBARBITAL. 002662 03-15

SELECTIVE PURIFICATION OF A SINGLE POPULATION OF GLUCOCORTICOID RECEPTORS FROM RAT BRAIN.

002887 04-03

THE USE BENZODIAZEPINES IN PRISON POPULATIONS

002506 03-11 IN VIVO COMPARISON OF THE RECEPTOR POPULATIONS ACTED UPON IN THE SPINAL CORD BY MORPHINE AND PENTAPEPTIDES IN THE PRODUCTION OF ANALGESIA. 003143 04-03

PORPHYRIAS PORPHYRIAS: NEUROLOGIC ASPECTS AND THE TREATMENT OF **EXACERBATIONS**

000659 01-11 PORTAL DECREASED FEEDING IN RATS FOLLOWING HEPATIC PORTAL INFUSION OF

001514 02-05

THE USE OF LACTULOSE IN PORTAL SYSTEMIC ENCEPHALOPATHY 002762 03-17 THE NEURONAL ORIGIN OF PROSTAGLANDIN RELEASED FROM THE RABBIT PORTAL VEIN IN RESPONSE TO ELECTRICAL STIMULATION

002933 04-03

POSITION
CAUSAL ATTRIBUTIONS OF HYPERACTIVE CHILDREN AND MOTIVATIONAL
ASSUMPTIONS OF TWO BEHAVIOR CHANGE APPROACHES: EVIDENCE
FOR AN INTERACTIONIST POSITION.

000620 01-11

COMBINED EFFECTS OF ETHANOL AND DIAZEPAM ON PERFORMANCE AND ACQUISITION OF SERIAL POSITION SEQUENCES BY PIGEONS. 003164 04-04

POSITIVE

CYCLIC-AMP AND THE POSITIVE INTROPIC EFFECT OF NOREPINEPHRINE

AND PHENYLEPHRINE.

000195 01-03 EFFECTS OF D AMPHETAMINE AND CHLORDIAZEPOXIDE ON POSITIVE CONDITIONED SUPPRESSION.

THE VALUE OF THE MMPI FOR DELINEATING SYMPTOMS UNIQUE TO POSITIVE LITHIUM RESPONDERS: A DRUG RESPONSE AND DIAGNOSTIC STUDY. (PH.D. DISSERTATION).

002638 03-14

003526 04-09

000149 01-03

SYNTHESIS OF TWO ENZYME RESISTANT ENKEPHALIN ANALOGS POSSESSING ENHANCED ANALGESIC ACTIVITY.

POST HEAD TRAUMA SYNDROME IN AN ADOLESCENT TREATED WITH LITHIUM-CARBONATE - CASE REPORT.

000560 01-09 THE EFFECT OF 5.6 DIHYDROXYTRYPTAMINE ON POST DECAPITATION

001202 02-03 CHANGES IN BRAIN GAMMA-AMINOBUTYRIC-ACID CONCENTRATIONS FOLLOWING ACUTE AND CHRONIC AMPHETAMINE ADMINISTRATION AND DURING POST AMPHETAMINE DEPRESSION.

POSTDECAPITATION

NEONATAL SYSTEMIC 6 HYDROXYDOPAMINE AND DORSAL TEGMENTAL BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEPHRINE AND THE POSTDECAPITATION REFLEX. 003039 04-03

POSTERIOR

ELECTROPHORETIC ANALYSES OF PROTEINS TRANSPORTED TO THE RAT POSTERIOR PITUITARY

002920 04-03 CLONIDINE-INDUCED BODY TEMPERATURE CHANGES IN RATS WITH ANTERIOR OR POSTERIOR CORTICAL DAMAGE

002959 04-03 REGULATION OF CYCLIC-GUANOSINE-MONOPHOSPHATE IN THE RAT PINEAL AND POSTERIOR PITUITARY GLANDS.

003032 04-03

POSTEROLATERAL DIFFERENT BEHAVIORAL RESPONSES TO L-DOPA AFTER ANTEROLATERAL

OR POSTEROLATERAL HYPOTHALAMIC INJECTIONS OF 6 HYDROXYDOPAMINE

001349 02-04 POSTHERPETIC

STUDIES ON THE CONCOMITANT USE OF CARBAMAZEPINE AND CLOMIPRAMINE FOR THE RELIEF OF POSTHERPETIC NEURALGIA 002555 03-13

POSTMORTEM
POSTMORTEM AND AMINOOXYACETIC-ACID-INDUCED ACCUMULATION OF GABA: EFFECT OF GAMMA-BUTYROLACTONE AND PICROTOXIN.

THE EFFECTS OF INORGANIC LEAD ON THE CENTRAL CATECHOLAMINERGIC SYSTEM OF THE RODENT WITH EMPHASIS ON POSTNATALLY EXPOSED RATS AND MICE. (PH.D. DISSERTATION). 003078 04-03

POSTOPERATIVE

COMPARISON OF THE ANALGESIC EFFECT OF INTRAMUSCULAR NALBUPHINE AND MORPHINE IN PATIENTS WITH POSTOPERATIVE

002607 03-14

POSTSYNAPTIC

PRESYNAPTIC AND POSTSYNAPTIC ACTIONS OF APOMORPHINE: DIFFERENTIATION BY ROTARY EFFECTS IN NORMAL RATS.

000367 01-04 POSTSYNAPTIC POTENTIATION OF THE SLOW MUSCARINIC EXCITATORY RESPONSE BY TETRAETHYLAMMONIUM-CHLORIDE IN THE BULLFROG SYMPATHETIC GANGLION CELLS.

001173 02-03
LONG-TERM CHANGES IN THE SENSITIVITY OF PRE- AND POSTSYNAPTIC DOPAMINE RECEPTORS IN MOUSE STRIATUM EVIDENCED BY BEHAVIORAL AND BIOCHEMICAL STUDIES.

001187 02-03 EFFECTS OF BUTYROPHENONES ON THE SYMPATHETIC NERVES OF THE ISOLATED RABBIT HEART AND ON THE POSTSYNAPTIC ALPHA-ADRENOCEPTORS OF THE ISOLATED RABBIT AORTA.

002026 03-03
SYNAPTIC CONNEXIONS AND RELATED POSTSYNAPTIC PHARMACOLOGY STUDIED IN THE CEREBRAL GANGLION OF APLYSIA.

002041 03-03 PRESYNAPTIC AND POSTSYNAPTIC EFFECTS OF SULPIRIDE AND OTHER SUBSTITUTED BENZAMIDES.

002099 03-03
THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION.

002164 03-03 A COMPARATIVE STUDY ON THE PRESYNAPTIC AND POSTSYNAPTIC ALPHA BLOCKING ACTIVITY OF A SERIES OF BENZODIOXANES

002972 04-03 A COMPARISON OF THE EFFECTS OF ANTIPSYCHOTIC DRUGS ON PITUITARY, STRIATAL AND LIMBIC SYSTEM POSTSYNAPTIC DOPAMINE RECEPTORS.

SELECTIVE LABELING OF PRESYNAPTIC RECEPTORS BY H3-DOPAMINE, H3-APOMORPHINE AND H3-CLONIDINE; LABELING OF POSTSYNAPTIC SITES BY H3-NEUROLEPTICS.

FOSTTRAINING

002787 04-01

ADMINISTRATION OF D AMPHETAMINE IN THE RAT.

000416 01-04 IMPAIRMENT OF RETENTION OF AVOIDANCE RESPONSES IN RATS BY POSTTRAINING DIETHYLDITHIOCARBAMATE.

EFFECTS ON RETENTION OF POSTTRAINING AMPHETAMINE INJECTIONS IN MICE: INTERACTION WITH PRETRAINING EXPERIENCE.

001375 02-04 EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AGONISTS AND ANTAGONISTS INTO THE AMYGDALA ON RETENTION OF PASSIVE AVOIDANCE TRAINING IN RATS. (PH.D. DISSERTATION). 002323 03-04

POSTTRAUMATIC PSYCHONEUROSIS: EVALUATION OF DRUG THERAPY.
000615 01-10

EFFECT OF PRETRIAL AND POSTTRIAL TYRAMINE AND GUANETHIDINE INJECTIONS ON AN APPETITIVE TASK IN RATS.

001439 02-04 RETROGRADE AMNESIA PRODUCED BY POSTTRIAL INJECTION OF SUBSTANCE-P INTO SUBSTANTIA-NIGRA.

INTRANIGRAL KAINIC-ACID: EVIDENCE FOR NIGRAL NONDOPAMINERGIC NEURONS CONTROLLING POSTURE AND BEHAVIOR IN A MANNER OPPOSITE TO THE DOPAMINERGIC ONES. 003324 04-04

POSTURES

THE EFFECTS OF SOME PHARMACOLOGICAL AGENTS ON THE DURATION OF IMMOBILITY SHOWN BY RABBITS PLACED IN VARIOUS POSTURES. 001355 02-04

PARADOXICAL EFFECTS OF AMPHETAMINE ON PREWEANLING AND POSTWEANLING RATS.

POSTWITHDRAWAL
NALOXONE-INDUCED OR POSTWITHDRAWAL ABSTINENCE SIGNS IN DELTA9-TETRAHYDROCANNABINOL-TOLERANT RATS.

002257 03-04

000327 01-04

003247 04-04

POTASSIUM PHENOBARBITAL ACTIONS IN VIVO: EFFECTS OF EXTRACELLULA POTASSIUM ACTIVITY AND OXIDATIVE METABOLISM IN CAT CEREBRAL-CORTEX.

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF

001118 02-03 PHENOBARBITAL EFFECT ON GLIAL CELL RESPIRATION IN THE PRESENCE OF A HIGH CONCENTRATION OF POTASSIUM.

002946 04-03

EFFECT OF METABOLIC INHIBITORS AND QUABAIN ON AMPHETAMINE-INDUCED AND POTASSIUM-INDUCED RELEASE OF BIOGENIC AMINES FROM ISOLATED BRAIN TISSUE 002142 03-03

EFFECT OF BETA ADRENERGIC RECEPTOR ANTAGONISTS ON D AMPHETAMINE AND POTASSIUM-INDUCED RELEASE OF H3-NOREPINEPHRINE FROM RAT BRAIN IN VITRO. 002187 03-03

MARIJUANA: DOSE-RESPONSE EFFECTS ON PULSE RATE, SUBJECTIVE ESTIMATES OF POTENCY, PLEASANTNESS, AND RECOGNITION MEMORY

RECEPTOR AFFINITY AND PHARMACOLOGICAL POTENCY OF A SERIES OF NARCOTIC ANALGESIC, ANTIDIARRHEAL AND NEUROLEPTIC DRUGS. 002160 03-03

INCREASED ANTAGONIST POTENCY OF NALOXONE CAUSED BY MORPHINE PRETREATMENT IN MICE. 002183 03-03

THE ROLE OF THE CHOLINERGIC SYSTEM IN THE DEVELOPMENT OF INCREASED NALOXONE POTENCY IN MICE.

A PHARMACOLOGICAL AND THEORETICAL COMPARISON OF HIGH AND LOW POTENCY NEUROLEPTICS. 003687 04-15

POTENT PROLACTIN AND GROWTH HORMONE RELEASING ACTIVITY OF MORE ANALOGUES OF MET-ENKEPHALIN.

000019 01-02 THE PHARMACOLOGY OF A NEW POTENT, LONG-ACTING NEUROLEPTIC,

001035 02-02 CEREBRAL CIRCULATION IS ALTERED BY A POTENT ACTH4-9 ANALOG --ORG-2766.

001135 02-03

METABOLISM OF LERGOTRILE TO 13 HYDROXYLERGOTRILE, A POTENT INHIBITOR OF PROLACTIN RELEASE IN VITRO. 003040 04-03

PHYSALAEMIN, A NEW POTENT ANTIDIPSOGEN IN THE RAT 003207 04-04

POTENTIAL

EFFECTS OF 3,4 DIHYDROOXAZINOINDOLES, POTENTIAL ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS AND RELATED ACTIVITIES.

000027 01-02 3.4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3 AMINOPYRROLIDINES, STREOSELECTIVE INVESTIGATIONS OF POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND ANTICONVULSANT ACTIVITIES.

000035 01-02 A COMPARISON IN RABBIT ISOLATED HEARTS OF THE DYSRHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE, MAPRI AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK NORADREMALINE UPTAKE. MAPROTILINE

000138 01-03 SYNTHESIS OF SPIROISOBENZOFURANPIPERIDINES AS POTENTIAL CENTRAL-NERVOUS-SYSTEM AGENTS. 2. COMPOUNDS CONTAINING A HETERCOATOM ATTACHED TO NITROGEN. 000167 01-03

COLCHICINE BLOCKS NEUROTROPIC REGULATION OF THE RESTING MEMBRANE POTENTIAL IN REINNERVATING SKELETAL MUSCLE 000262 01-03

CHLORPROMAZINE: A POTENTIAL PHYSIOLOGICAL TERATOGEN. 000486 01-05 3 HYDROXY-17-ARALKYLMORPHINANS AS POTENTIAL OPIATE RECEPTOR SITE DIRECTED AKLYLATING AGENTS.

001010 02-01

PIPERIDINE DERIVATIVES: SYNTHESIS OF POTENTIAL ANALGESICS IN 3 SUBSTITUTED 4 PHENYLPIPERIDINE SERIES.

001019 02-02 EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. I. CHLORPROMAZINE AND PROMETHAZINE.

001068 02-03 PHENYTOIN: AN EVALUATION OF SEVERAL POTENTIAL TERATOGENIC MECHANISMS.

001097 02-03 EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS.

THE EFFECT OF BARBITURATE AND PROCAINE ON GLIAL AND NEURONAL CONTRIBUTIONS TO EVOKE CORTICAL STEADY POTENTIAL SHIFTS.

001219 02-03 EFFECTS OF ANTINOCICEPTIVE DRUGS ON THE DORSAL ROOT POTENTIAL IN THE RAT.

VILOXAZINE: ASSESSMENT OF POTENTIAL RAPID ANTIDEPRESSANT ACTION.

001584 02-09 THEORETICAL AND THERAPEUTIC POTENTIAL OF INDOLEAMINE PRECURSORS IN AFFECTIVE-DISORDERS.

RECEPTOR SENSITIVITY MODIFICATION (RSM) — A NEW PARADIGM FOR THE POTENTIAL TREATMENT OF SOME HORMONAL AND TRANSMITTER

001659 02-13
POTENTIAL UNTOWARD EFFECTS OF LONG-TERM USE OF FLURAZEPAM IN

001807 02-15
STUDY OF A DOPAMINERGIC POTENTIAL ANTIPARKINSON COMPOUND IN
HTACT AND NIGRA-LESIONED RATS: N-N
PROPYLBUTYLDIHYDROXYPHENYLETHYLAMINE HCL.

001957 03-02 PENICILLIN IN THE PYRAMIDAL TRACT: ECTOPIC ACTION POTENTIAL GENERATION.

002082 03-03 EFFECTS ON STRIATAL AND MESOLIMBIC DOPAMINE SYSTEMS OF A NEW POTENTIAL ANTIPSYCHOTIC DRUG -- MEZILAMINE -- WITH WEAK CATALEPTOGENIC PROPERTIES.

POTENTIAL ROLES OF ENDOGENOUS PEPTIDES IN THE DISCRIMINATIVE PROPERTIES OF DRUGS.

GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF DELTA9-TETRAHYDROCANNABINOL TO CANNABINOIDS WITH THERAPEUTIC POTENTIAL.

003392 04-04 COMMON DRUGS SEEN AS POTENTIAL CARCINOGENS. 003416 04-05

A POTENTIALLY TOXIC DRUG INTERACTION BETWEEN PETHIDINE (MEPERIDINE) AND PHENOBARBITONE.

001836 02-15

Psychopharmacology Abstracts

LIDOCAINE AND PENTOBARBITAL: A POTENTIALLY LETHAL DRUG DRUG INTERACTION. 003412 04-05

POTENTIALS

EFFECTS OF N METHYLAMINO-ACIDS AND CONVULSANTS ON SPONTANEOUS ACTION POTENTIALS IN GUINEA-PIG CEREBELLAR

DELTA9-TETRAHYDROCANNABINOL AND THE HIPPOCAMPUS: EFFECTS ON CA1 FIELD POTENTIALS IN RATS.

AMPHETAMINE EFFECTS ON BRAIN SLOW POTENTIALS ASSOCIATED WITH DISCRIMINATION IN THE RAT.

000432 01-04 THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE HUMAN BRAIN AS AN OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING DRUGS.

000747 01-14 LYSERGIC-ACID-DIETHYLAMIDE. PHOTOELECTRON IONIZATION POTENTIALS AS INDICES OF BEHAVIORAL ACTIVITY.

001100 02-03 DIAZEPAM BLOCKADE OF REPETITIVE ACTION POTENTIALS IN SKELETAL MUSCLE FIBRES: A MODEL OF ITS MEMBRANE ACTION.

001275 02-03 VIGILANCE AND HUMAN ATTENTION UNDER CONDITIONS OF METHYLPHENIDATE AND SECOBARBITAL INTOXICATION: AN ASSESSMENT USING BRAIN POTENTIALS.

002622 03-14

SHORT-TERM AND LONG-TERM EFFECTS OF CEREBROLYSINE ON EVOKED CORTICAL POTENTIALS IN RATS. 002858 04-03

POTENTIATED

PHARMACOLOGICAL MODIFICATION OF SHOCK POTENTIATED AMPHETAMINE LETHALITY.

001494 02-04 THE POTENTIATING EFFECT OF NALOXONE UPON APOMORPHINE-INDUCED

HYPERTHERMIA 000231 01-03

POTENTIATION
POTENTIATION BY COCAINE OF THE STIMULUS-INDUCED INCREASE IN DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL SYNAPTOSOMES. 000217 01-03

POTENTIATION BY RESERPINE OF THE INHIBITION BY AMPHETAMINE OF (3H)DOPAMINE ACCUMULATION IN THE RAT STRIATUM. 000246 01-03

POTENTIATION OF BRAIN REWARD MECHANISMS BY PSYCHOMOTOR STIMULANT DRUGS.

000441 01-04 CAFFEINE POTENTIATION OF AMPHETAMINE: IMPLICATIONS FOR HYPERKINESIS THERAPY.

000448 01-04 POTENTIATION OF THE BEHAVIORAL AND CONVULSANT EFFECTS OF COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.

000458 01-04 LIPOPROTEIN POTENTIATION OF THE CEREBROVASCULAR RESPONSE TO INTRAARTERIAL 5 HYDROXYTRYPTAMINE.

001109 02-03 POTENTIATION OF MORPHINE ANALGESIA IN MICE AFTER INHIBITION OF BRAIN TYPE-B MONOAMINE-OXIDASE.

001126 02-03 POTENTIATION OF MORPHINE ANALGESIA BY LESIONS OF THE NUCLEUS LOCUS COEPULFUS

001142 02-03 POSTSYNAPTIC POTENTIATION OF THE SLOW MUSCARINIC EXCITATORY RESPONSE BY TETRAETHYLAMMONIUM-CHLORIDE IN THE BULLFROG SYMPATHETIC GANGLION CELLS.

CHLOROQUINE POTENTIATION OF THIORIDAZINE EFFECTS IN RATS AND DRUG RESISTANT SCHIZOPHRENIC PATIENTS: A PRELIMINARY REPORT.

001571 02-08 POTENTIATION OF THE EPILEPTOGENIC EFFECT OF PENICILLIN-G BY MARIHUANA SMOKING.

POTENTIATION BY NEUROLEPTIC AGENTS OF THE INHIBITORY ACTION OF INTRAPERITONEALLY ADMINISTERED GABA ON THE LOCOMOTOR ACTIVITY OF MICE.

THE EFFECTS OF PIMOZIDE AND PHENOXYBENZAMINE PRETREATMENTS ON AMPHETAMINE AND APOMORPHINE POTENTIATION OF THE ACOUSTIC STARTLE RESPONSE IN RATS.

003257 04-04 POTENTIATION OF HEXOBARBITAL AND AMPHETAMINE EFFECTS IN MALE AND FEMALE RATS PHYSICALLY DEPENDENT ON MORPHINE. 003275 04-04

POWER TIME-COURSE OF CHANGES IN EEG AND POWER SPECTRA DURING

TREATMENT WITH NEUROLEPTICS.

EFFECT OF PAPAVERINE AND DIHYDROERGOTOXINE-MESYLATE ON CEREBRAL MICROFLOW, EEG, AND PO2 IN OLIGEMIC HYPOTENSION 002032 03-03

ACTION OF NOREPINEPHRINE ON MICROCIRCULATION AND PO2
DISTRIBUTION IN THE ISOLATED PERFUSED RAT LIVER.

002059 03-03

PRACTICING WHAT THE PRACTICING PHYSICIAN SHOULD KNOW ABOUT MARIJUANA 000851 01-15

PRAZEPAM

PRAZEPAM, A PRECURSOR OF DESMETHYLDIAZEPAM

002382 03-07

PREADOLESCENT A DOPAMINERGIC BASIS FOR THE EFFECTS OF AMPHETAMINE ON A MOUSE PREADOLESCENT HYPERKINETIC MODEL.

000310 01-04

PRECEDING

INTRAPSYCHIC AND FAMILY DYNAMIC PROCESSES IN AN ENDOGENOUS DEPRESSION PRECEDING MANIFESTATION OF THE ILLNESS AND LITHIUM THERAPY

PRECIPITATE

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION.

002164 03-03

PRECIPITATED

NALOXONE PRECIPITATED WITHDRAWAL AS A FUNCTION OF THE MORPHINE NALOXONE INTERVAL.

000185 01-03 PSYCHOSES PRECIPITATED BY PSYCHOTOMIMETIC DRUGS: A FOLLOW-UP STUDY

000672 01-12 NALOXONE PRECIPITATED WITHDRAWAL REVEALS SENSITIZATION TO NEUROTRANSMITTERS IN MORPHINE-TOLERANT/DEPENDENT RATS 001456 02-04

THE EFFECT OF ETHANOL ON SUPPRESSION OF THE NALOXONE PRECIPITATED ESCAPE RESPONSE IN MORPHINE-DEPENDENT MICE 002230 03-04

ACUTE LITHIUM-INDUCED PARKINSONISM PRECIPITATED BY LIQUID PROTEIN DIFT

002685 03-15

PRECIPITATION
GILLES-DE-LA-TOURETTES SYNDROME: FAMILIAL OCCURRENCE AND PRECIPITATION BY METHYLPHENIDATE THERAPY.

001823 02-15

001020 02-02

002107 03-03

003161 04-04

001435 02-04

PRECIDICAL

PRECLINICAL EVALUATION OF DITA DICHLORO-2 IMIDAZOLINYLTHIOACETOPHENONE-HBR: A NEW ANOREXIGENIC AGENT

PRECURSOR

IS DEANOL A PRECURSOR OF ACETYLCHOLINE?.

NEUROTRANSMITTER PRECURSOR AMINO-ACIDS IN THE TREATMENT OF MULTIINFARCT DEMENTIA AND ALZHEIMERS DISEASE 000647 01-11

001134 02-03 PRAZEPAM A PRECURSOR OF DESMETHYLDIAZEPAM.

002382 03-07

PRECURSORS

THEORETICAL AND THERAPEUTIC POTENTIAL OF INDOLFAMINE PRECURSORS IN AFFECTIVE-DISORDERS.

001610 02-09 THE FFFECT OF SEROTONIN PRECURSORS ON ALPHA-MOTONEURON AND GAMMA-MOTONEURON ACTIVITY

PREDATION

CONDITIONED TASTE AVERSION: A FIELD APPLICATION TO COYOTE PREDATION ON SHEEP. 000354 01-04

INSTINCTIVE PREDATORY BEHAVIOR OF THE FERRET (PUTORIUS-PUTORIUS-FURO L.) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE (LIBRIUM).

AN ATTEMPT TO PREDICT THE DURATION OF PENTOBARBITAL NARCOSIS ON THE BASIS OF EXPLORATORY ACTIVITY, DEFECATION RATE AND BODY WEIGHT OF RATS.

PREDICTING
PREDICTING THE OPTIMAL LITHIUM DOSAGE. 000693 01-13

CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE ANTIPSYCHOTIC DRUGS. 001526 02-06 PREDICTION

PREDICTION OF THE LITHIUM RATIO IN MAN BY MEANS OF AN IN VITRO

003516 04-09

003492 04-09

THE PREDICTION OF DIFFERENTIAL RESPONSIVENESS OF HYPERKINETIC CHILDREN TO METHYLPHENIDATE. (PH.D. DISSERTATION).
001697 02-14

AN AUTOMATED SYSTEM FOR THE PREDICTION AND PREVENTION OF ADVERSE DRUG REACTIONS. (PH.D. DISSERTATION). 001759 02-15

PREDICTION OF PLASMA LEVELS OF IMIPRAMINE FROM PHARMACOKINETICS OF AN INITIAL DOSE. (UNPUBLISHED PAPER).
001876 02-16
ANIMAL TEST MODELS FOR PREDICTION OF CLINICAL ANTIDEPRESSANT

ACTIVITY 002372 03-06

PREDICTION OF LITHIUM RESPONSE IN AFFECTIVE-DISORDER 002418 03-09

PREDICTION OF INDIVIDUAL DOSAGE OF NORTRIPTYLINE 002714 03-16 PREDICTION OF STEADY-STATE PLASMA CONCENTRATION O IMIPRAMINE.

EVALUATION OF NALOXONE IN LABORATORY TESTS PREDICTIVE OF CLINICAL ANTIPSYCHOTIC ACTIVITY.

000029 01-02 THE PREDICTIVE VALUE OF THE BIOCHEMICAL ACTION PROFILE OF

000551 01-08 PREDICTOR

IQ AS A PREDICTOR OF ANTIDEPRESSANT RESPONSES TO IMIPRAMINE 001582 02-09 OF RESPONSE. LITHIUM ERYTHROCYTE/PLASMA RATIO AS A PREDICTOR 002431 03-09 IQ AS A PREDICTOR OF ANTIDEPRESSANT RESPONSES TO LITHIUM

PREDICTORS BIOCHEMICAL AND PHARMACOLOGICAL PREDICTORS.

PSYCHIATRIC DIAGNOSIS: EXPLORATION OF BIOLOGICAL PREDICTORS.
003551 04-11 003509 04-09

PREDICTS

AN ANIMAL SCREENING TEST FOR DRUGS THAT PREDICTS THE LIKELIHOOD OF HUMAN PHYSICAL DEPENDENCE.

000028 01-02 PLATELET MONOAMINE-OXIDASE ACTIVITY PREDICTS RESPONSE TO LITHIUM IN MANIC-DEPRESSIVE ILLNESS.

001607 02-09

001095 02-03

PREDISFOSITION

EMOTIONAL PREDISPOSITION TO PSYCHOTROPIC DRUG EFFECTS.
002649 03-15 PREDOMINANCE

OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG NEURITES.

002040 03-03 PREFERENCE

KINETIC STUDIES OF FOOD INTAKE AND SUCROSE SOLUTION PREFERENCE BY RATS TREATED WITH LOW DOSES OF DELTA9-TETRAHYDROCANNABINOL 000324 01-04

EFFECTS OF THREE MONOAMINE-OXIDASE INHIBITORS ON ETHANOL PREFERENCE IN MICE 000447 01-04

VARIABLES IN THE PROLONGED PREFERENCE OF HEROIN OR **AMPHETAMINES**

000778 01-14 DOSE PREFERENCE DURING PENTOBARBITAL SELF-ADMINISTRATION BY HUMANS

DIAZEPAM MAINTENANCE OF ALCOHOL PREFERENCE DURING ALCOHOL WITHDRAWAL

001345 02-04 LOCATION PREFERENCE AND FLAVOR AVERSION REINFORCED BY AMPHETAMINE IN RATS

ENHANCED CHOICE OF FAMILIAR FOOD IN A FOOD PREFERENCE TEST AFTER CHLORDIAZEPOXIDE ADMINISTRATION.

003199 04-04 PREFERENCE BEHAVIOR AND TASTE NERVE RESPONSES IN D
PENICILLAMINE TREATED RATS.

003248 04-04

PREFERENTIAL ACTION OF 5 METHOXYTRYPTAMINE AND 5
METHOXYDIMETHYLTRYPTAMINE ON PRESYNAPTIC SEROTONIN
RECEPTORS: A COMPARATIVE IONTOPHORETIC STUDY WITH LSD AND

MODIFICATION OF DREAM CONTENT AFTER PREFERENTIAL BLOCKADE OF MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS. 002619 03-14

AFFERENT AND EFFERENT SUBCORTICAL PROJECTIONS OF BEHAVIORALLY DEFINED SECTORS OF PREFRONTAL GRANULAR CORTEX.

PRODUCTION OF UNDERWEIGHT EMBRYOS IN RATS TREATED WITH BARBITURATES DURING PREGNANCY.

000072 01-03

PLASMA ANTICONVULSANT CONCENTRATIONS DURING PREGNANCY 000642 01-11

FLUPHENAZINE-DECANOATE DURING PREGNANCY

000813 01-15 LITHIUM-CARBONATE INTAKE DURING PREGNANCY LEADING TO LARGE GOITER IN A PREMATURE INFANT. 000869 01-15

INVESTIGATIONS OF CHILDREN OF MOTHERS TREATED IN PREGNANCY WITH ANTICONVULSANTS.

002701 03-15 SEXUAL DIFFERENTIATION OF OFFSPRING OF MOTHERS TREATED WITH CORTISONE DURING PREGNANCY.

002879 04-03 PSYCHOTROPIC DRUGS IN PREGNANCY: MORPHOLOGICAL AND PSYCHOLOGICAL ADVERSE EFFECTS ON OFFSPRING.

003708 04-17

PREGNANT
H3-DELTA9-TETRAHYDROCANNABINOL DISTRIBUTION IN PREGNANT DOGS
AND THEIR FETUSES.
000194 01-03

000194 01-03 MATERNAL FETAL DISTRIBUTION OF METHAQUALONE IN CONTROL AND SKF-525-A PRETREATED PREGNANT MICE.

EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON PREGNANT RATS AND THEIR OFFSPRING.

000491 01-05 PHARMACOKINETICS OF HEXOBARBITAL IN THE PREGNANT AND NONPREGNANT STUMPTAILED MONKEY.

THE ROLE OF HYPOTHALAMIC SEROTONIN (5-HT) BEFORE OVILLATION IN IMMATURE RATS TREATED WITH PREGNANT MARE SERUM (PMS).

001287 02-03 EFFECTS OF METHADONE ON RESPIRATION AND HEMODYNAMICS OF PREGNANT WOMEN.

002628 03-14

EFFECTS OF N METHYLAMINOETHANOL, AND N, N
DIMETHYLAMINOETHANOL IN THE DIET OF PREGNANT RATS ON
NEONATAL RAT BRAIN CHOLINERGIC AND PHOSPHOLIPID PROFILE 003149 04-03

PENTOBARBITAL INTOXICATION IN THE PREGNANT RAT.

PREGNEHOLONE-16ALPHA-CARBONITRILE
ALTERATIONS INDUCED IN DISTRIBUTION AND IN VIVO METABOLISM OF
IMPRAMINE BY PREGNENOLONE-16ALPHA-CARBONITRILE.

001065 02-03

LITHIUM-CARBONATE INTAKE DURING PREGNANCY LEADING TO LARGE GOITER IN A PREMATURE INFANT. 000869 01-15

PREMEDICATION
PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC
DRUGS IN THE COURSE OF RADIATION DISEASE: THE EFFECT OF
PREMEDICATION WITH CYSTAMINE ON PHARMACODYNAMICS AND
PHARMACOKINETICS OF NITRAZEPAM.

002317 03-04 CHANGES IN PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECTS OF PREMEDICATION WITH CYSTAMINE ON DYNAMICS AND KINETICS OF THIORIDAZINE.

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC
DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF
PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF THIORIDAZINE

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF

FLUNITRAZEPAM (ROHYPNOL) COMPARED WITH NITRAZEPAM (MOGADON) AND APROBARBITAL AS EVENING PREMEDICATION PRIOR TO ANESTHESIA: A CONTROLLED CLINICAL TRIAL. 002616 03-14

PRENATAL
PRENATAL ALCOHOL CONSUMPTION AND OPEN-FIELD BEHAVIOUR IN
RATS: EFFECTS OF AGE AT TIME OF TESTING.
000321 (

000321 01-04

003659 04-15

Psychopharmacology Abstracts

FLUCTUATING DENTAL ASYMMETRY AS AN INDICATOR OF THE STRESSFUL PRENATAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN THE LABORATORY RAT.

PRENATAL MORPHINE ADMINISTRATION ALTERS BEHAVIORAL DEVELOPMENT IN THE RAT.

O02308 03-04
PRENATAL EXPOSURE TO MEDROXYPROGESTERONE-ACETATE (MPA) IN

O02615 03-14
THE PROBLEM OF PRENATAL DAMAGE FROM LONG-TERM ANTIEPILEPTIC DRUG TREATMENT.

002659 03-15

PREOPTIC

EFFECTS ON TEMPERATURE OF MORPHINE INJECTED INTO THE PREOPTIC/ ANTERIOR HYPOTHALAMUS, MEDULLA-OBLONGATA, AND PERIPHERALLY IN UNRESTRAINED AND RESTRAINED RATS.

001264 02-03

EFFECTS OF ANGIOTENSIN-II AND ACETYLCHOLINE ON NEURONS IN THE PREOPTIC AREA.

002935 04-03

FURTHER EVIDENCE OF CYCLIC-AMP MEDIATED HYPERTROPHY AS A PREREQUISITE OF DRUG SPECIFIC ENZYME INDUCTION. 002086 03-03

PRESCHOOL

COMPARING TREATMENT TACTICS WITH A HYPERACTIVE PRESCHOOL
CHILD: STIMULANT MEDICATION AND PROGRAMMED TEACHER
INTERVENTION.

000660 01

000660 01-11

WHY PHYSICIANS PRESCRIBE BENZODIAZEPINES IN ESSENTIAL HYPERTENSION: A PHASE IV STUDY.

000667 01-11 THE CONTRIBUTION OF PRESCRIBED DRUGS TO THE INCIDENCE OF ACCIDENTAL AND DELIBERATE POISONING IN THE COMMUNITY

001896 02-17 ON PRESCRIBING MEDICATIONS FOR RECOVERING ALCOHOLIC PATIENTS

000872 01-15 PRESCRIBING PHENOTHIAZINES. 000894 01-15

RATIONAL PRESCRIBING OF DRUGS.

000993 01-17 INCREASED PRESCRIBING OF VALIUM, LIBRIUM, AND OTHER DRUGS —
AN EXAMPLE OF THE INFLUENCE OF ECONOMIC AND SOCIAL FACTORS
ON THE PRACTICE OF MEDICINE.

PSYCHOTHERAPEUTIC PRESCRIBING PATTERNS IN GENERAL PRACTICE. 000998 01-17 A STUDY OF PHYSICIAN DRUG PRESCRIBING ADOPTION AND

DISCONTINUATION BEHAVIORS. (PH.D. DISSERTATION) 001889 02-17

DRUG REFUSAL IN SCHIZOPHRENIA: CAUSES AND PRESCRIBING HINTS 002709 03-15 THE PERILS OF PRESCRIBING PSYCHOTROPIC DRUGS.

PRESCRIPTION CLINIC ATTENDANCE AND OPIATE PRESCRIPTION STATUS OF HEROIN ADDICTS OVER A SIX-YEAR PERIOD.

000989 01-17 **PSYCHOPHARMACOLOGIC AGENTS: PRESCRIPTION PATTERNS OF NONPSYCHIATRISTS**

PRESCRIPTION DRUG-INDUCED ORGANIC-BRAIN-SYNDROME 002687 03-15

COCA PROPOSED AS PRESCRIPTION DRUG

THE USE OF PRESCRIPTION DRUGS IN TREATMENT OF FIRST-TIME PSYCHIATRIC ADMISSIONS TO UNIVERSITY HOSPITAL, SASKATOON 003712 04-17

PSYCHOTROPIC AND ANTIPARKINSONIAN DRUG USE: AN EXAMINATION OF PRESCRIPTION PRACTICES. 003723 04-17

PRESSING
DAILY 1 DELTA9-TETRAHYDROCANNABINOL AND PRESSING FOR
HYPOTHALAMIC STIMULATION.
0010

001053 02-03 ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): NALOXONE BLOCKS MORPHINES ACCELERATION OR PRESSING FOR ICS.

001313 02-04 ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): PRESSING FOR ICS BEFORE AND AFTER SELF-ADMINISTRATION OF SWEETENED MORPHINE SOLUTIONS.

001331 02-04 THE EFFECT OF NONCONTINGENT AMPHETAMINE INJECTIONS ON THE EXTINCTION OF FOOD AND DRUG REINFORCED LEVER PRESSING IN

001404 02-04

003504 04-09

CLINICAL RESPONSE IN DEPRESSED PATIENTS IN RELATION TO PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND TYRAMINE PRESSOR RESPONSE.

002453 03-09

TYRAMINE PRESSOR RESPONSES AND PLASMA LEVELS DURING TRICYCLIC ANTIDEPRESSANT THERAPY. 002584 03-13

PRESSURE

EFFECTS OF DOPAMINE ON INTRACRANIAL PRESSURE.

000103 01-03

EEG AND BLOOD PRESSURE EFFECTS OF TRH IN RABBITS.

000319 01-04
INTRAOCULAR PRESSURE LOWERING PROPERTIES OF ABBOTT-43981, A
CANNABINOID DERIVED HETEROCYCLIC BENZOPYRAN WITH MINIMAL

001025 02-02

EFFECTS OF PHENOBARBITAL AND DIAZEPAM ON IMIPRAMINE-INDUCED CHANGES IN BLOOD PRESSURE, HEART RATE AND RECTAL TEMPERATURE OF RATS.

001070 02-03

THE EFFECT OF MARIHUANA INTOXICATION ON BLOOD PRESSURE. 003724 04-17

PRESUMPTION

STATISTICAL EVALUATION: PRESUMPTION AND METHODS.

001864 02-16

PRESURGICAL

EVALUATION OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTIC AGENTS IN PRESURGICAL PATIENTS.

002514 03-11

PRESYNAPTIC

INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT.

000124 01-03
EVIDENCE FOR MULTIPHASIC PRESYNAPTIC ADAPTATION: STUDIES WITH

COCAINE AND LITHIUM.

DO0191 01-03

PENTOBARBITAL: PRESYNAPTIC EFFECT IN THE SQUID GIANT SYNAPSE. 000204 01-03 PRESYNAPTIC AND POSTSYNAPTIC ACTIONS OF APOMORPHINE:

PRESYNAPTIC AND POSTSYNAPTIC ACTIONS OF APOMORPHINE: DIFFERENTIATION BY ROTARY EFFECTS IN NORMAL RATS. 000367 01-04

A PRESYNAPTIC SITE OF ACTION WITHIN THE MESENCEPHALIC RETICULAR FORMATION FOR () AMPHETAMINE-INDUCED ELECTROCORTICAL DESYNCHRONIZATION.

001069 02-03

PREFERENTIAL ACTION OF 5 METHOXYTRYPTAMINE AND 5
METHOXYDIMETHYLTRYPTAMINE ON PRESYNAPTIC SEROTONIN
RECEPTORS: A COMPARATIVE IONTOPHORETIC STUDY WITH LSD AND
SEROTONIN.

001095 02-03
BLOCKADE OF PRESYNAPTIC ALPHA-RECEPTORS AND OF AMINE UPTAKE
IN THE RAT BRAIN BY THE ANTIDEPRESSANT MIANSERINE.

001965 03-03

EFFECTS OF PRESYNAPTIC MODULATORS ON CA2-INDUCED
NORADREMALINE RELEASE FROM CARDIAC SYMPATHETIC NERVES.

002025 03-03
THE EFFECT OF L-DOPA ON PERIPHERAL SYMPATHETIC NERVE FUNCTION:
ROLE OF PRESYNAPTIC DOPAMINE RECEPTORS.

002081 03-03
PRESYNAPTIC AND POSTSYNAPTIC EFFECTS OF SULPIRIDE AND OTHER

SUBSTITUTED BENZAMIDES. 002099 03-03

PRESYNAPTIC DOPAMINE RECEPTORS: DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING TREATMENT WITH FLUPHENAZINE-

DECANOATE. 002120 03-03

MODULATION OF DEXAMPHETAMINE-INDUCED COMPULSIVE GNAWING --

MODULATION OF DEXAMPHETAMINE-INDUCED COMPULSIVE GNAWING — INCLUDING THE POSSIBLE INVOLVEMENT OF PRESYNAPTIC ALPHA-ADRENORECEPTORS.

O02322 03-04
STIMULATION OF PRESYNAPTIC BETA-ADRENOCEPTORS ENHANCES H3NORADRENALINE RELEASE DURING NERVE STIMULATION IN THE
PERFUSED CAT SPIEEN.

A COMPARATIVE STUDY ON THE PRESYNAPTIC AND POSTSYNAPTIC ALPHA BLOCKING ACTIVITY OF A SERIES OF BENZODIOXANES.

SELECTIVE LABELING OF PRESYNAPTIC RECEPTORS BY H3-DOPAMINE, H3-APOMORPHINE AND H3-CLONIDINE; LABELING OF POSTSYNAPTIC SITES BY H3-NEUROLEPTICS.

003117 04-03

PRETRAINING

EFECTS ON RETENTION OF POSTTRAINING AMPHETAMINE INJECTIONS IN
MICE: INTERACTION WITH PRETRAINING EXPERIENCE.

CE: INTERACTION WITH PRETRAINING EXPERIENCE.
001375 02-04

PRETREATED

MATERNAL FETAL DISTRIBUTION OF METHAQUALONE IN CONTROL AND SKF-525-A PRETREATED PREGNANT MICE.

PRODOPAMINERGIC EFFECT OF NARCOTIC ANTAGONISTS IN RABBITS
PRETREATED WITH ANTIDOPAMINERGIC OR ANTISEROTONERGIC

002135 03-03

PHARMACOLOGICAL STUDIES OF CENTRAL ACTION OF L 5
HYDROXYTRYPTOPHAN IN INTACT OR TETRABENAZINE PRETREATED
CATS.

TESTOSTERONE ATTENUATED STEREOTYPY AND HYPERACTIVITY INDUCED BY BETA-PHENYLETHYLAMINE IN PARGYLINE PRETREATED RATS. 003224 04-04

MUSCARINIC HYPOSENSITIVITY IN THE DEVELOPING RAT PRETREATED WITH 6 HYDROXYDDPA. 003320 04-04

PRETREATMENT

EFFECTS OF APOMORPHINE AND CLONIDINE ON RAT PLASMA GROWTH HORMONE AFTER PRETREATMENT WITH RESERPINE AND ELECTROCONVILLSIVE SHOCKS.

METABOLIC RESPONSES TO ISOPPOTERENOL AND EPINEPHRINE IN THE RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES AND PRETREATMENT WITH PROPRANOLOL.

ALTERATION OF THE NEURONAL RESPONSE TO AMPHETAMINE IN THE NEOSTRIATUM BY PRETREATMENT WITH A CENTRALLY ACTING ANTICHOLINERGIC.

000298 01-03
REGIONAL LOCALIZATION OF C14-MESCALINE IN RABBIT BRAIN AFTER
INTRAVENTRICULAR ADMINISTRATION: EFFECTS OF CHLORPROMAZINE
AND IPPONIAZIO PRETREATMENT

001240 02-03

EFFECT OF ALPHA-METHYLTYROSINE (MT) PRETREATMENT ON D

AMPHETAMINE (A) AND MORPHINE (M) INDUCED MOOD IN MAN.
001714 02-14

HYPERTHERMIC EFFECTS OF SUPRACORTICALLY APPLIED PROSTAGLANDINS AFTER SYSTEMIC PRETREATMENT WITH INHIBITORS OF PROSTAGLANDIN TRANSPORT AND SYNTHESIS.

002174 03-03
INCREASED ANTAGONIST POTENCY OF NALOXONE CAUSED BY MORPHINE PRETREATMENT IN MICE.

O02183 03-03

EFFECT OF NEUROLEPTIC DRUGS ON THE CONDITIONED BEHAVIOR AFTER
PRETREATMENT WITH ALPHA-METHYLTYROSINE OR PCHI OROPHENYI AL ANINE

002290 03-04
DOPAMINE BINDING FOLLOWING PROLONGED HALOPERIDOL

602345 03-05
EFFECT OF L-DOPA PRETREATMENT ON IN VIVO PROTEIN SYNTHESIS IN VARIOUS RAT BRAIN REGIONS.

003068 04-03

THE EFFECTS OF PIMOZIDE AND PHENOXYBENZAMINE PRETREATMENTS
ON AMPHETAMINE AND APOMORPHINE POTENTIATION OF THE

ACOUSTIC STARTLE RESPONSE IN RATS. 003257 04-04
PRETRIAL

EFFECT OF PRETRIAL AND POSTTRIAL TYRAMINE AND GUANETHIDINE
INJECTIONS ON AN APPETITIVE TASK IN RATS.

001439 02-04

ON THE PREVALENCE, DIAGNOSIS AND MANAGEMENT OF LITHIUM-INDUCED HYPOTHYROIDISM IN PSYCHIATRIC PATIENTS. 001805 02-15

THE INFLUENCE OF CAFFEINE ON THE PREVALENCE OF ALPHA RHYTHM.
002550 03-13

FAILURE OF NALOXONE TO PREVENT REDUCTION OF AMNESIA BY ENKEPHALINS. 000438 01-04

PREVENTING
PREVENTING DRUG-INDUCED DYSKINESIA.

003671 04-15

THE PREVENTION OF TARDIVE-DYSKINESIA.

000816 01-15
UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: V. — OTHER DRUGS,
TREATMENT AND PREVENTION.

TREATMENT AND PREVENTION.

O00830 01-15

AN AUTOMATED SYSTEM FOR THE PREDICTION AND PREVENTION OF ADVERSE DRUG REACTIONS. (PH.D. DISSERTATION).

PREVENTION OF TARDIVE-DYSKINESIA. 001762 02-15

PREVENTION OF ENVIRONMENTAL STRESS IMPACT ON RATS.

PREVENTIVE
TARDIVE-DYSKINESIA: A PREVENTIVE APPROACH.

NOCICEPTIVE STIMULATION PREVENTS DEVELOPMENT OF TOLERANCE TO NARCOTIC ANALGESIA.

001740 02-15

000327 01-04

003195 04-04 PREWEANLING
PARADOXICAL EFFECTS OF AMPHETAMINE ON PREWEANLING AND
POSTWEANLING RATS.

THE EFFECTS OF D AMPHETAMINE ON PREY KILLING AND PREY EATING IN THE RAT AND MOUSE.

001361 02-04 PRIAPISM
PHENOTHIAZINE-INDUCED PRIAPISM: A CASE REPORT. 001779 02-15

PRIMARY
COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMOTOR ACTIVITY
ANALGESIA AND PRIMARY AND PROTRACTED PHYSICAL DEPENDENCE
IN SIX MOUSE STRAINS.

000323 01-04 AMITRIPTYLINE PLASMA LEVELS AND CLINICAL RESPONSE IN PRIMARY DEPRESSION

001594 02-09 PARAVENTRICULAR NUCLEUS: A PRIMARY SITE MEDIATING ADRENERGIC STIMULATION OF FEEDING AND DRINKING.

002074 03-03 LITHIUM ERYTHROCYTE: PLASMA RATIO IN PRIMARY AFFECTIVE-DISORDER

EFFECT OF PSYCHOTOMIMETICS (LSD AND DEXTROAMPHETAMINE) ON THE USE OF PRIMARY AND SECONDARY PROCESS LANGUAGE.

CAPSAICIN-INDUCED DEPLETION OF SUBSTANCE-P FROM PRIMARY SENSORY NEURONS.

ADRENERGIC ALPHA-RECEPTORS AND BETA-RECEPTORS EXPRESSED BY THE SAME CELL TYPE IN PRIMARY CULTURE OF PERINATAL MOUSE BRAIN.

003121 04-03 PRIMARY EMPTY SELLA SYNDROME AND BIPOLAR AFFECTIVE-ILLNESS:

003511 04-09 ERYTHROCYTE ACCUMULATION OF THE LITHIUM-ION IN CONTROL
SUBJECTS AND PATIENTS WITH PRIMARY AFFECTIVE-DISORDER

003519 04-09

PRIMATE INFORMATION PROCESSING UNDER SODIUM PENTOBARBITAL AND CHLORPROMAZINE: DIFFERENTIAL DRUG EFFECTS WITH TACHISTOSCOPICALLY PRESENTED DISCRIMINATIVE STIMULI. 000318 01-04

THE EFFECT OF A HALLUCINOGEN, 5 METHOXYDIMETHYLTRYPTAMINE, ON PRIMATE SOCIAL BEHAVIOR. 001455 02-04 PRIMATE EEG SPECTRA BEFORE AND DURING OPIOID ADMINISTRATION.

002601 03-13 REGIONAL SENSITIVITY OF PRIMATE BRAIN DOPAMINERGIC NEURONS TO HALOPERIDOL: ALTERATIONS FOLLOWING CHRONIC TREATMENT.

002812 04-03 H3-SPIROPERIDOL BINDING AND DOPAMINE STIMULATED ADENYLATE-CYCLASE: EVIDENCE FOR MULTIPLE CLASSES OF RECEPTORS IN PRIMATE BRAIN REGIONS.

003112 04-03 DEPRESSION OF PRIMATE SPINOTHALAMIC TRACT NEURONS BY IONTOPHORETIC APPLICATION OF 5 HYDROXYTRYPTAMINE. 003251 04-04

BEHAVIORAL CHANGES INDUCED BY 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) IN PRIMATE DYADS.

PRIMED PENTOBARBITAL, PROMAZINE, D AMPHETAMINE, AND SCOPOLAMINE EFFECTS ON BEHAVIOR UNDER MULTIPLE AND PRIMED SCHEDULES OF

REINFORCEMENT 003267 04-04

PRIMIDONE
THE INVESTIGATION OF PHENOBARBITONE, PHENYTOIN AND PRIMIDONE
IN THE DEATH OF EPILEPTICS.

000806 01-1:

000806 01-15 PRISON EVALUATION OF THE PRISON INMATE AS A SUBJECT IN DRUG ASSESSMENT

000982 01-17 THE USE BENZODIAZEPINES IN PRISON POPULATIONS. 002506 03-11

PRISONER SUBJECTS AND DRUG TESTING.

Psychopharmacology Abstracts

000997 01-17

TREATMENT OF PRISONERS IN ENGLANDS JAILS.

PRIVATE COLLABORATIVE STUDIES IN PRIVATE PRACTICE. PSYCHOPHARMACOLOGIC TREATMENT OF DEPRESSION IN PRIVATE

003494 04-09

EFFECTS OF PARGYLINE ON HYPOTHALAMIC BIOGENIC AMINES AND SERUM PROLACTIN (PRL), LH AND TSH IN MALE RATS.

001988 03-03 PROBABILITY
CATECHOLAMINE LEVELS IN THE WHOLE BRAIN AND THE PROBABILITY OF MEMORY FORMATION ARE NOT RELATED.

003328 04-04

PROBAND
LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR
BLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE IN THE
FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE

THE EFFECT OF L TRYPTOPHAN ADMINISTRATION ON THE CONCENTRATION OF PROBENECID IN PLASMA AND CEREBROSPINAL FLUID IN PATIENTS.

EFFECTS OF AMPHETAMINE AND CHLORDIAZEPOXIDE ON PROBENECID-INDUCED ACCUMULATION OF ACIDIC METABOLITES IN THE CEREBROSPINAL FLUID OF THE DOG.

000092 01-03 PROBENECID-INDUCED NOREPINEPHRINE ELEVATIONS IN PLASMA AND

002573 03-13

PROBING
THE EFFECTS OF HORMONES AND MORPHINE ON BOTH ANALGESIA AND
THE LORDOSIS RESPONSE PRODUCED BY CERVICAL PROBING IN THE FEMALE PAT

PROBLEM

AMP SYSTEM: LONGITUDINAL COURSE STUDIES OF PSYCHOPATHOLOGIC

AND SOMATIC SYMPTOMS. AN EMPIRIC INVESTIGATION OF THE

000797 01-15 THE PROBLEM OF PRENATAL DAMAGE FROM LONG-TERM ANTIEPILEPTIC DRUG TREATMENT.

002659 03-15 MALIGNANT FEVER IS NOW AN OFFICE PROBLEM TOO.

003565 04-11 NARCOTIC CUE, NARCOTIC ANALGESIA, AND THE TOLERANCE PROBLEM 003707 04-17

PROBLEMS GENERAL METHODOLOGICAL PROBLEMS OF CLINICAL PSYCHOTROPIC

000924 01-16 SOLID DISPERSION APPROACH FOR OVERCOMING BIOAVAILABILITY PROBLEMS DUE TO POLYMORPHISM OF NABILONE, A CANNABINOID

001539 02-06 SOME PROBLEMS CONCERNING THE TECHNIQUES OF STUDYING THE EFFECTIVENESS OF PSYCHOTROPIC DRUGS.

001540 02-06 ADVERSE REACTIONS TO MEDICATION IN PSYCHIATRIC INPATIENTS: THEIR MEANING, UTILITY AND PROBLEMS.

001744 02-15 TARDIVE-DYSKINESIA: IS IT OR IS IT NOT? A REVIEW OF THE PROBLEMS IN DIAGNOSIS AND A CASE STUDY.

ABOUT A NONFATAL MASSIVE INTOXICATION WITH SUSTAINED-RELEASE THIORIDAZINE. CLINICAL AND THERAPEUTIC PROBLEMS.

001752 02-15 STIMULANT DRUGS AND LEARNING PROBLEMS.

001877 02-17 PROBLEMS ENGENDERED BY ADMINISTRATION OF LONG-ACTION NEUROI EPTICS

001922 02-17 USE OF MOOD-ALTERING DRUGS IN TREATING SEXUAL PROBLEMS

METHODOLOGICAL PROBLEMS IN THE MEASUREMENT OF DRUG-INDUCED ROTATIONAL BEHAVIOUR: CONTINUOUS RECORDING REVEALS TIME-COURSE DIFFERENCES UNDETECTED BY PREVIOUS TECHNIQUES. 003388 04-04

DRUG DISCRIMINATION PARADIGMS: PROBLEMS OF TOLERANCE AND BEHAVIORAL DISRUPTION.

003693 04-16

003692 04-16 ASSESSMENT OF LONG-ACTING NEUROLEPTICS. METHODS AND PROBLEMS.

REINFORCING PROPERTIES OF INTRAVENOUS PROCAINE IN RHESUS MONKEYS

THE EFFECT OF BARBITURATE AND PROCAINE ON GLIAL AND NEURONAL CONTRIBUTIONS TO EVOKE CORTICAL STEADY POTENTIAL SHIFTS. 001219 02-03

THE REINFORCING PROPERTIES OF PROCAINE AND D AMPHETAMINE COMPARED IN RHESUS MONKEYS.

002239 03-04 PROCEDURE

ALTERATIONS IN MORPHINE ANALGESIA PRODUCED BY CHRONIC DEFICITS OF BRAIN CATECHOLAMINES OR SEROTONIN: ROLE OF ANALGESIMETRIC PROCEDURE.

002186 03-03 A VARIABLE-INTERVAL PUNISHMENT PROCEDURE FOR ASSESSING ANXIOLYTIC EFFECTS OF DRUGS.

002371 03-06 A SPECIFIC RADIOIMMUNOASSAY PROCEDURE FOR PLASMA CLOAMIPR AMINE

PROCEDURES.

THIN-LAYER AND GAS-LIQUID-CHROMATOGRAPHIC PROCEDURES FOR THE DETERMINATION OF PERAZINE AND ITS METABOLITES IN HUMAN

BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS. ASSAY PROCEDURES, REPRODUCIBILITY AND RELATIONSHIP TO THERAPEUTIC

OUTCOME AND SIDE-EFFECTS. 002440 03-09 OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR OPERANT DRUG DISCRIMINATIONS.

EFFECTS OF METHYLPHENIDATE ALONE AND IN COMBINATION WITH BEHAVIOR MODIFICATION PROCEDURES ON THE BEHAVIOR AND

ACADEMIC PERFORMANCE OF HYPERACTIVE CHILDREN. CHLORPROMAZINE EXCRETION. II. IMPROVED TLC PROCEDURES FOR FRACTIONATING THE URINARY DRUG CONTENT INTO CHEMICAL SUBGROUPS OF CPZ METABOLITES.

003490 04-14 RIMATE INFORMATION PROCESSING UNDER SODIUM PENTOBARBITAL AND CHLORPROMAZINE: DIFFERENTIAL DRUG EFFECTS WITH TACHISTOSCOPICALLY PRESENTED DISCRIMINATIVE STIMULI.

000318 01-04 SECOBARBITAL AND INFORMATION PROCESSING.

003635 04-14 PROCYCLIDINE A COMPARISON OF PIRIBEDIL, PROCYCLIDINE AND PLACEBO IN THE

CONTROL OF PHENOTHIAZINE-INDUCED PARKINSONISM

PRODOPAMINERGIC EFFECT OF NARCOTIC ANTAGONISTS IN RABBITS PRETREATED WITH ANTIDOPAMINERGIC OR ANTISEROTONERGIC **AGENTS** 002135 03-03

HYDROLYSIS OF DIESTER PRODRUGS OF APOMORPHINE. 000047 01-03

VIDEO EDITING AND MEDICATION TO PRODUCE A THERAPEUTIC SELF-

001707 02-14 PRODUCTION PRODUCTION OF UNDERWEIGHT EMBRYOS IN RATS TREATED WITH BARRITURATES DURING PREGNANCY

THE PRODUCTION OF AN ALTERNATIVE LABORATORY MODEL OF THE PARKINSON SYNDROME USING A NEW BENZYLIMIDOYLUREA

DERIVATIVE LON-954. 000083 01-03 INHIBITION OF BOTH MAO-A AND MAO-B REQUIRED FOR THE

PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. I. CHLORPROMAZINE AND PROMETHAZINE.

EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS 001103 02-03

INCREASE CAUSED BY DESMETHYLIMIPRAMINE IN THE PRODUCTION OF H3-MELATONIN BY ISOLATED PINEAL GLANDS. 001217 02-03

THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF THE MEDULLA-OBLONGATA IS A HIGHLY SENSITIVE SITE IN THE PRODUCTION OF MORPHINE ANALGESIA IN THE RAT.

001256 02-03

CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIVITY TO THE DIRECT APPLICATION OF MORPHINE AND FOCAL ELECTRICAL STIMULATION IN THE PRODUCTION OF ANTINOCICEPTION IN THE RAT.

001291 02-03 DRUGS AND THE PRODUCTION OF TEMPORAL INTERVALS IN THE RAT.
001299 02-04

DOPAMINE-MIMETIC ACTIVITY OF ERGOT DERIVATIVES, AS MEASURED BY THE PRODUCTION OF CYCLIC-AMP IN ISOLATED RETINAE OF THE

FLUPHENAZINE DEPOT (LYORODIN DEPOT) -- SOON IN PRODUCTION IN

IN VIVO COMPARISON OF THE RECEPTOR POPULATIONS ACTED UPON IN THE SPINAL CORD BY MORPHINE AND PENTAPEPTIDES IN THE PRODUCTION OF ANALGESIA.

THE PRODUCTION OF MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE BY THE ORAL ROUTE IN THE RAT. 003424 04-06

INHIBITORY EFFECT OF MORPHINE ON SERUM GONADOTROPINS AND PROLACTIN OF PROESTROUS RATS.

000206 01-03 PROFILE THE PREDICTIVE VALUE OF THE BIOCHEMICAL ACTION PROFILE OF

NEUROLEPTICS EEG PROFILE AND BEHAVIORAL CHANGES AFTER A SINGLE DOSE OF CLOZAPINE IN NORMALS AND SCHIZOPHRENICS.

PHARMACOLOGICAL PROFILE OF A NEW PSYCHOTHERAPEUTIC AGENT: 4-P FLUOROPHENYL-METHOXYPHENYL-PIPERAZINOETHYLOXAZOLINONE (LR-511)

001956 03-02 IN VITRO PROFILE OF SOME OPIOID PENTAPEPTIDE ANALOGUE 002799 04-02

EFFECTS OF N METHYLAMINOETHANOL, AND N,N
DIMETHYLAMINOETHANOL IN THE DIET OF PREGNANT RATS ON
NEONATAL RAT BRAIN CHOLINERGIC AND PHOSPHOLIPID PROFILE 003149 04-03

PROFILES PROFILES OF PSYCHEDELIC DRUGS: 4. HARMALINE.

000681 01-12 THE IMPACT OF CLOMIPRAMINE AND ITS WITHDRAWAL ON SOME NOCTURNAL HORMONE PROFILES -- A PRELIMINARY REPORT

O02572 03-13
PROFILES OF PROLACTIN RESPONSE TO ANTIPSYCHOTIC DRUGS: SOME METHODOLOGIC CONSIDERATIONS.

THE INFLUENCE OF PROGESTERONE ON THE INHIBITORY EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE

FEMALE RAT

PROGESTEROME-INDUCED
BLOCKAGE OF PROGESTERONE-INDUCED RELEASE OF LUTEINIZING
HORMONE AND PROLACTIN BY D AMPHETAMINE AND FENFLURAMINE

EFFECTS OF THE PROSTAGLANDIN SYNTHESIS INHIBITOR, INDOMETHACIN ON ESTROGEN AND ESTROGEN PLUS PROGESTERONE-INDUCED SEXUAL RECEPTIVITY IN OVARIECTOMIZED RATS.

003237 04-04

PROGNOSIS COURSE AND PROGNOSIS OF THE SYNDROME OF DOUBLES. 002507 03-11

PROGNOSTIC STUDIES ON THE INFLUENCE OF BIOGENIC AMINES AND PSYCHOACTIVE DRUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMULATION TEST IN ENDOGENOUS DEPRESSION.

000926 01-16 PROGRAMMED COMPARING TREATMENT TACTICS WITH A HYPERACTIVE PRESCHOOL CHILD: STIMULANT MEDICATION AND PROGRAMMED TEACHER

PROGRAMMED FEEDING AS A MODEL OF CHRONIC ALCOHOLISM IN THE

RAT. 001087 02-03

PROGRAMS PSYCHOTROPIC AND ANTICONVULSANT DRUG USAGE IN EARLY CHILDHOOD SPECIAL EDUCATION PROGRAMS III. A PRELIMINARY REPORT: PARENT INTERVIEWS ABOUT DRUG TREATMENT.

000627 01-11 PSYCHOANALYTIC AND BEHAVIORAL CONSIDERATIONS IN ANTAGONIST AND METHADONE PROGRAMS.

003704 04-17 TRANSMETHYLATION HYPOTHESIS: A REVIEW OF PROGRESS 002397 03-08

PROGRESSIVE FORCE SCHEDULES IN THE SQUIRREL-MONKEY: EFFECTS OF INCREMENT SIZE, AMPHETAMINE, AND HALOPERIDOL. (PH.D.

001459 02-04 EFFECTS OF COCAINE AND FENFLURAMINE ON PROGRESSIVE RATIO PERFORMANCE.

001473 02-04

003284 04-04

000540 01-08

PROJECTING
ACTIVATION OF AN IHHIBITORY NORADRENERGIC PATHWAY PROJECTING
FROM THE LOCUS-COERULEUS TO THE CINGULATE CORTEX OF THE RAT.
002895 04-03 002895 04-03

PROJECTION
LESIONS OF THE DORSAL NORADRENERGIC PROJECTION ATTENUATE
MORPHINE-INDUCED BUT NOT AMPHETAMINE-INDUCED CONDITIONED

002299 03-04 CHLORIMIPRAMINE INHIBITION OF MURICIDE: THE ROLE OF THE ASCENDING 5-HT PROJECTION.

ON THE ROLE OF ASCENDING CATECHOLAMINERGIC PROJECTIONS IN INTRACRANIAL SELF-STIMULATION OF THE SUBSTANTIA-NIGRA.

000336 01-04 AFFERENT AND EFFERENT SUBCORTICAL PROJECTIONS OF BEHAVIORALLY DEFINED SECTORS OF PREFRONTAL GRANULAR CORTEX.

002962 04-03

PROLACTIN
POTENT PROLACTIN AND GROWTH HORMONE RELEASING ACTIVITY OF
MORE ANALOGUES OF MET-ENKEPHALIN.

000019 01-02 LEVELS OF CHLORPROMAZINE AND ITS ACTIVE MATABOLITES IN RAT BRAIN AND THE RELATIONSHIP TO CENTRAL MONOAMINE METABOLISM AND PROLACTIN SECRETION.

000041 01-03 PERLAPINE: RELATIONSHIP BETWEEN STIMULATION OF PROLACTIN SECRETION AND ANTIPSYCHOTIC ACTIVITY.

000197 01-03

INHIBITORY EFFECT OF MORPHINE ON SERUM GONADOTROPINS AND PROLACTIN OF PROESTROUS RATS. 000206 01-03

LACK OF EFFECT OF CHRONIC HALOPERIDOL ADMINISTRATION ON THE PROLACTIN LOWERING ACTIONS OF PIRIBEDIL.

000233 01-03 EFFECTS OF AMPHETAMINE, METHYLPHENIDATE AND COCAINE ON SERUM PROLACTIN CONCENTRATIONS IN THE MALE RAT.

000234 01-03 DOES PROLACTIN PLAY A ROLE IN ESTROGEN-INDUCED MATERNAL BEHAVIOR IN RATS: APOMORPHINE REDUCTION OF PROLACTIN RELEASE.

000445 01-04 EFFECTS OF CHLORPROMAZINE ON PLASMA PROLACTIN AND CHLORPROMAZINE LEVELS.

PLASMA PROLACTIN DURING LITHIUM TREATMENT

THE USE OF PROLACTIN RESPONSE IN CLINICAL PSYCHOPHARMACOLOGY. 000980 01-17

ANIMAL PROLACTIN EVIDENCE FOR ANTIPSYCHOTIC ACTIVITY OF PIPEROXANE.

001027 02-02 ROLE OF NOREPINEPHRINE IN THE RELEASE OF PROLACTIN INDUCED BY SUCKLING AND ESTROGEN.

001071 02-03 AN EVALUATION OF A UNIQUE NEW ANTIPSYCHOTIC AGENT, SULPIRIDE: EFFECTS ON SERUM PROLACTIN AND GROWTH HORMONE LEVELS. 001554 02-07

EFFECT OF CHLORPROMAZINE TREATMENT ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC PATIENTS.

001694 02-13 THE PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS. A TEST OF DOPAMINERGIC BLOCKADE: NEUROENDOCRINE STUDIES IN NORMAL

IDENTIFICATION OF DOPAMINERGIC RECEPTORS IN ANTERIOR PITUITARY: CORRELATION WITH THE DOPAMINERGIC CONTROL OF PROLACTIN RELEASE.

001982 03-03 EFFECTS OF PARGYLINE ON HYPOTHALAMIC BIOGENIC AMINES AND SERUM PROLACTIN (PRL), LH AND TSH IN MALE RATS.

001988 03-03 EFFECTS OF COMPLETE HYPOTHALAMIC DEAFFERENTATION AND 5,7
DIHYDROXYTRYPTAMINE ON SEVERAL PARAMETERS OF PROLACTIN

001990 03-03 BLOCKAGE OF PROGESTERONE-INDUCED RELEASE OF LUTEINIZING
HORMONE AND PROLACTIN BY D AMPHETAMINE AND FENFLURAMINE IN RATS

Psychopharmacology Abstracts

NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: I. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY.

EFFECTS OF PROLACTIN, DEXAMETHASONE, AND CORTICOSTERONE ON MATERNAL AGGRESSION AND INFANT CARE.

002240 03-04 SCREENING FOR THE EFFECTS OF DOPAMINERGIC AND
ANTIDOPAMINERGIC DRUGS ON SERUM PROLACTIN LEVELS BY
RADIOIMMUNOASSAY.

002340 03-05 THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MALE

002343 03-05 SERUM PROLACTIN AND ANTIPSYCHOTIC RESPONSES TO PIMOZIDE IN SCHIZOPHRENIA.

002408 03-08 PROLACTIN SECRETION DURING AND AFTER NOVERIL INFUSIONS TO DEPRESSIVE PATIENTS.

002438 03-09 EFFECTS OF MELPERONE AND THIOTHIXENE ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC WOMEN.

002547 03-13 LACK OF EFFECTS OF L TRYPTOPHAN ON BASAL AND TRH STIMULATED TSH AND PROLACTIN LEVELS.

DECREASE IN SERUM PROLACTIN AFTER PROPRANOLOL IN

002558 03-13

BROMOCRIPTINE: EFFECT ON SERUM PROLACTIN AND GROWTH HORMONE IN PSYCHOGERIATRIC HOSPITAL PATIENTS. 002561 03-13

PLASMA PROLACTIN CONCENTRATIONS IN NORMAL SUBJECTS AND **DEPRESSIVE PATIENTS FOLLOWING ORAL CLOMIPRAMINE** 002567 03-13

DOPAMINERGIC FACTORS IN HUMAN PROLACTIN REGULATION: EFFECTS OF NEUROLEPTICS AND DOPAMINE

002574 03-13 PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS IN NORMAL AND SCHIZOPHRENIC SUBJECTS.

002575 03-13 THE EFFECT OF NEUROLEPTICS AND ALPHA-METHYL-P-TYROSINE ON SERUM PROLACTIN LEVELS IN LABORATORY ANIMALS AND MAN

002582 03-13 PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS: AN APPROACH TO THE STUDY OF BRAIN DOPAMINE BLOCKADE IN HUMANS.

002590 03-13 PROLACTIN AND BREAST CANCER

PROFILES OF PROLACTIN RESPONSE TO ANTIPSYCHOTIC DRUGS: SOME METHODOLOGIC CONSIDERATIONS.

COMPARATIVE EFFECTS OF PENFLURIDOL ON CIRCLING BEHAVIOR AND STRIATAL DOPAC AND SERUM PROLACTIN CONCENTRATIONS IN THE

002810 04-03 EFFECT OF 6 METHOXYTETRAHYDRO-BETA-CARBOLINE ON SERUM PROLACTIN LEVELS OF MALE RATS.

002903 04-03 INCREASE IN SERUM PROLACTIN BY EXOGENOUS AND ENDOGENOUS CPIATES: EVIDENCE FOR ANTIDOPAMINE AND ANTIPSYCHOTIC

002926 04-03 METABOLISM OF LERGOTRILE TO 13 HYDROXYLERGOTRILE, A POTENT INHIBITOR OF PROLACTIN RELEASE IN VITRO.

003040 04-03 THE EFFECTS OF INTRAVENTRICULAR INJECTION OF GAMMA AMINOBUTYRIC-ACID (GABA) ON PROLACTIN AND GONADOTROPIN RELEASE IN CONSCIOUS FEMALE RATS.

EFFECTS OF PERPHENAZINE-ENANTHATE INJECTIONS ON PROLACTIN LEVELS IN PLASMA FROM SCHIZOPHRENIC WOMEN AND MEN.

GROWTH HORMONE, PROLACTIN AND CORTISOL RESPONSES AND GROWTH PATTERNS IN HYPERKINETIC CHILDREN TREATED WITH DEXTROAMPHETAMINE. PRELIMINARY FINDINGS.

THE PROLACTIN RESPONSE IN CLINICAL PSYCHIATRY

003597 04-13 EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON HUMAN PLASMA LEVELS

003569 04-11

OF TSH, GH AND PROLACTIN. 003613 04-13

PROLIFERATION

EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT
BRAIN: A QUANTITATIVE HISTOLOGICAL STUDY.

EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT BRAIN: A BIOCHEMICAL STUDY. 000216 01-03

002006 03-03

VOLUME 16. SUBJECT INDEX

IN VITRO EFFECTS OF IMIPRAMINE ON PROLIFERATION OF HUMAN LEUKOCYTES

000699 01-13

DO DRUGS ACTING ON THE NERVOUS SYSTEM AFFECT CELL PROLIFERATION IN THE DEVELOPING BRAIN?

001512 02-05

RETROACTIVE AMNESIA INDUCED IN CHICKS BY THE PROLINE ANALOG L BAIKIAIN, WITHOUT EEG SEIZURES OR DEPRESSION.

003205 04-04

PROLIXIN-DECANOATE

PROLIXIN-DECANOATE: BIG BROTHER BY INJECTION?. PROLIXIN-DECANOATE: A REVIEW OF THE RESEARCH.

001940 02-17 001941 02-17

LONG-TERM BEHAVIOURAL AND BIOCHEMICAL EFFECTS FOLLOWING PROLONGED TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN RATS

000420 01-04

INCREASED STEADY-STATE PLASMA LEVELS AND PROLONGED HALF-LIVES OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY.

000734 01-13 VARIABLES IN THE PROLONGED PREFERENCE OF HEROIN OR

000778 01-14 A SYNTHETIC ENKEPHALIN ANALOGUE WITH PROLONGED PARENTERAL AND ORAL ANALGESIC ACTIVITY.

001036 02-02 EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG PATTERNS IN PSYCHIATRIC PATIENTS.

001712 02-14 ALTERATIONS OF EEG ACTIVITIES AND COCAINE-INDUCED CONVULSIONS FOLLOWING PROLONGED COCAINE TREATMENT IN THE RHESUS

MONKEY 002091 03-03 THE EFFECTS OF PROLONGED HANDLING, SCOPOLAMINE, AND PHYSOSTIGMINE ON THE ACTIVITY OF ISOLATED AND SOCIALLY

REARED RATS 002285 03-04

DOPAMINE BINDING FOLLOWING PROLONGED HALOPERIDOL PRETREATMENT

RHEOENCEPHALOGRAPHIC AND OTHER STUDIES OF BETAHISTINE IN HUMANS, IV. PROLONGED ADMINISTRATION WITH IMPROVEMENT IN ARTERIOSCLEROTIC DEMENTIA

002530 03-11 CHRONIC NALOXONE RESULTS IN PROLONGED INCREASES IN OPIATE BINDING SITES IN BRAIN

002986 04-03

PROLYL

INHIBITION OF BRAIN ANGIOTENSIN-I CONVERTING ENZYME BY BOTHROPS-JARARACA NONAPEPTIDE (SQ-20881) AND A PROLYL ANALOG (SQ-14225).

002818 04-03

PROMAZINE EFFECTS OF D AMPHETAMINE, CHLORDIAZEPOXIDE AND PROMAZINE ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION AND STIMULUS SHOCK TERMINATION

001305 02-04 PENTOBARBITAL, PROMAZINE, D AMPHETAMINE, AND SCOPOLAMINE EFFECTS ON BEHAVIOR UNDER MULTIPLE AND PRIMED SCHEDULES OF

REINFORCEMENT 003267 04-04 PROMETHAZINE EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION

IN SKELETAL MUSCLE. I. CHLORPROMAZINE AND PROMETHAZINE 001068 02-03 A SEX DIFFERENCE IN THE INTERACTION BETWEEN PROMETHAZINE AND MORPHINE IN THE MOUSE.

001242 02-03

PROMOTING AGGRESSION PROMOTING AND AGGRESSION ELICITING PROPERTIES OF ESTROGEN IN MALE MICE.

003360 04-04 PROMOTION

RATIONALITY OF APPEALS USED IN THE PROMOTION OF PSYCHOTROPIC DRUGS. A COMPARISON OF MALE AND FEMALE MODELS. 001932 02-17

A CONTROLLED CLINICAL STUDY OF TRAZODONE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH PRONOUNCED DEPRESSIVE SYMPTOMATOLOGY

003472 04-08 MIANSERIN IN THE PROPHYLACTIC TREATMENT OF BIPOLAR AFFECTIVE-ILLNESS.

000561 01-09

Subject Index

000653 01-11

PROPHYLACTIC VALUE OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS GENETIC ASPECTS.

000952 01-17 PROPHYLACTIC LITHIUM TREATMENT OF DRUG ABUSE 003564 04-11

PEOPHYLAXIS

LITHIUM PROPHYLAXIS IN THE TREATMENT OF CYCLOTHYMIA IN TEENAGERS.

000601 01-10 LITHIUM PROPHYLAXIS FOR CHRONIC CLUSTER HEADACHE

A COMPARISON BETWEEN PLACEBO, PIZOTIFEN AND 1 ISOPROPYL-3-HYDROXY 5 SEMICARBAZONO-6-OXOTETRAHYDROINDOL (FIVASCAN) IN MIGRAINE PROPHYLAXIS

LITHIUM PROPHYLAXIS OF PERIODIC HYPERSOMNIA

000936 01-17 SPIRONOLACTONE PROPHYLAXIS IN MANIC-DEPRESSIVE DISEASE 003499 04-09

PROPOXYPHENE PROPOXYPHENE ON DEMAND: ANALGESIC SEEKING BEHAVIOR IN

AGORAPHOBICS

PSYCHIATRIC INPATIENTS. 001736 02-14 FATAL POISONING WITH PROPOXYPHENE: REPORT FROM 100

CONSECUTIVE CASES 001788 02-15 PROPOXYPHENE-NAPSYLATE

PROPOXYPHENE-NAPSYLATE (DARVON-N OR PN) IN THE TREATMENT OF 000979 01-17

PROPRANOLOL METABOLIC RESPONSES TO ISOPROTERENOL AND EPINEPHRINE IN THE RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES AND PRETREATMENT WITH PROPRANOLOL.

000227 01-03 THE EFFECTS OF HALOPERIDOL, CHLORPROMAZINE AND PROPRANOLOL ON ACUTE AMPHETAMINE POISONING IN THE CONSCIOUS DOG.

000480 01-05 PROPRANOLOL IN SCHIZOPHRENIA.

000550 01-08 PROPRANOLOL AS AN ADJUNCT TO THE TREATMENT OF SCHIZOPHRENIA.
000554 01-08 THE INFLUENCE OF PROPRANOLOL ON THE EXPOSURE IN VIVO OF

000598 01-10 POSSIBLE PROPRANOLOL MYOTONIN ASSOCIATION. 000889 01-15

EFFECTS OF THE ISOMERIC FORMS OF PROPRANOLOL ON CENTRAL MONOAMINE METABOLISM IN REGIONS OF RAT BRAIN. 001284 02-03 PROPRANOLOL IN CHRONIC SCHIZOPHRENIA

001611 02-09 PROPRANOLOL: HEARTRATE AND REFLEXES DURING A TASK 002548 03-13

DECREASE IN SERUM PROLACTIN AFTER PROPRANOLOL IN SCHIZOPHRENIA 002558 03-13

002672 03-15 DRUG DEPENDENCE IN PROPRANOLOL TREATMENT OF MIGRAINE 002678 03-15

ACUTE BRAIN SYNDROME AFTER PROPRANOLOL TREATMENT 002708 03-15 THE EFFECT OF L-DOPA AND PROPRANOLOL ON HUMAN CSF CYCLIC-NUCLEOTIDES.

003587 04-13

URINARY EXCRETION OF PHENOLIC METABOLITES OF PROPYLAMPHETAMINE IN MAN. 001892 02-17

ACUTE BRAIN SYNDROME AFTER PROPRANOLOL

PROPYLBENZILYLCHOLINE
EFFECTS OF PROPYLBENZILYLCHOLINE MUSTARD ON INJECTION INTO THE LIQUOR SPACE OF CATS. 003168 04-04

PROPYLBUTYLDIHYDROXYPHENYLETHYLAMINE STUDY OF A DOPAMINERGIC POTENTIAL ANTIPARKINSON COMPOUND IN
INTACT AND NIGRA-LESIONED RATS: N-N

PROPYLBUTYLDIHYDROXYPHENYLETHYLAMINE HCL 001957 03-02

001850 02-15

PROPYLHEXEDRINE INTRAVENOUS PROPYLHEXEDRINE AND SUDDEN DEATH.

PROPYLTHIOURACIL INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY ANTITHYROID AGENTS. METHIMAZOLE AND PROPYLTHIOURACIL 000145 01-03

TARDIVE-DYSKINESIA AND CHANGING CONCEPTS OF ANTIPSYCHOTIC DRUG USE: A NURSING PROSPECTIVE. 000919 01-16

THE PRACTICAL SIGNIFICANCE OF NORTRIPTYLINE PLASMA CONTROL. A PROSPECTIVE EVALUATION UNDER ROUTINE CONDITIONS IN ENDOGENOUS DEPRESSION.

003522 04-09

INHIBITION OF PROSTAGLANDIN SYNTHETASE SYSTEM IN THE RABBIT RENAL MEDULLA BY PSYCHOTROPIC DRUGS.

000281 01-03

SCHIZOPHRENIA AS A PROSTAGLANDIN DEFICIENCY DISEASE 000794 01-14

A NEW MECHANISM OF TRICYCLIC ANTIDEPRESSANT ACTION. BLOCKADE OF PROSTAGLANDIN DEPENDENT CALCIUM MOVEMENTS.

EFFECTS OF BIOGENIC AMINES AND PSYCHOTROPIC DRUGS ON ENDOGENOUS PROSTAGLANDIN BIOSYNTHESIS IN THE RAT BRAIN HOMOGENATES.

002145 03-03

HYPERTHERMIC EFFECTS OF SUPRACORTICALLY APPLIED PROSTAGLANDINS AFTER SYSTEMIC PRETREATMENT WITH INHIBITORS OF PROSTAGLANDIN TRANSPORT AND SYNTHESIS. 002174 03-03

EFFECTS OF PROSTAGLANDIN-E2 AND A PROSTAGLANDIN ENDOPEROXIDE ANALOGUE ON NEUROEFFECTOR TRANSMISSION IN THE RAT ANOCOCCYGEUS MUSCLE.

002808 04-03 THE NEURONAL ORIGIN OF PROSTAGLANDIN RELEASED FROM THE RABBIT PORTAL VEIN IN RESPONSE TO ELECTRICAL STIMULATION

002933 04-03 EFFECTS OF THE PROSTAGLANDIN SYNTHESIS INHIBITOR, INDOMETHACIN ON ESTROGEN AND ESTROGEN PLUS PROGESTERONE-INDUCED SEXUAL RECEPTIVITY IN OVARIECTOMIZED RATS.

PROSTAGLANDIN-E1

EFFECTS OF D AMPHETAMINE (D-A), PROSTAGLANDIN-E1 AND F-2ALPHA
ON H3-2-DOPAMINE (H3-DA) METABOLISM, FIXED-INTERVAL (FI)
BEHAVIOR AND RECTAL TEMPERATURE.

001207 02-03 INHIBITION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS IN RATS BY PROSTAGLANDIN-E1: ROLE OF BRAIN MONOAMINES

NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-ET STIMULATED INCREASES IN CYCLIC-AMP. I. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE IN EXPONENTIAL GROWTH PHASE.

002836 04-03 NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. II. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE TREATED WITH DIBUTYRYL-CYCLIC-AMP.

003026 04-03 DOPAMINE SUPERSENSITIVITY, ENDORPHIN EXCESS, AND PROSTAGLANDIN-E1 DEFICIENCY: THREE ASPECTS OF THE SAME

SCHIZOPHRENIC ELEPHANT. 003458 04-08

ROSTAGLANDIN-E2, CYCLIC-ADENOSINE-MONOPHOSPHATE AND MORPHINE ANALGESIA. PROSTAGLANDIN-E2.

000289 01-03 EFFECTS OF PROSTAGLANDIN-E2 AND A PROSTAGLANDIN ENDOPEROXIDE ANALOGUE ON NEUROEFFECTOR TRANSMISSION IN THE RAT ANOCOCCYGEUS MUSCLE

002808 04-03 NEUROPHARMACOLOGICAL AND BEHAVIORAL EVALUATION OF PROSTAGLANDIN-E2 AND 11 THIOL-11-DESOXYPROSTAGLANDIN-E2 IN THE MOUSE AND RAT.

RELATIVE INFLUENCE OF ANAESTHETICS ON DEPRESSOR EFFECTS OF INTRAVENOUS PROSTAGLANDINS E2 AND A2.

000110 01-03 PROSTAGLANDINS AND THE CARDIOTOXIC EFFECT OF DOXEPIN IN RABBITS AND GUINEA-PIGS.

001518 02-05 HYPERTHERMIC EFFECTS OF SUPRACORTICALLY APPLIED PROSTAGLANDINS AFTER SYSTEMIC PRETREATMENT WITH INHIBITORS OF PROSTAGLANDIN TRANSPORT AND SYNTHESIS.

002174 03-03 PROSTAGLANDINS AND CANNABIS - VI. RELEASE OF ARACHIDONIC-ACID FROM HELA CELLS BY DELTA 1-TETRAHYDROCANNABINOL AND OTHER CANNABINOIDS

002850 04-03 STUDIES OF THE PHYSIOLOGICAL ROLES OF PROSTAGLANDINS IN THE CENTRAL-NERVOUS-SYSTEM.

PROSTATE

POLYAMINE BIOSYNTHESIS IN RAT PROSTATE. SUBSTRATE AND INHIBITOR PROPERTIES OF 7 DEAZA ANALOGUES OF DECARBOXYLATED S ADENOSYLMETHIONINE AND 5 METHYLTHIOADENOSINE. 000001 01-01

Psychopharmacology Abstracts

PROTECT

EFFECT OF SUBACUTE DIAZEPAM ADMINISTRATION IN MICE ON THE SUBSEQUENT ABILITY OF DIAZEPAM TO PROTECT AGAINST METRAZOL AND BICUCULLINE-INDUCED CONVULSIONS.

002053 03-03

PROTECTING EFFECT OF DRUGS ON HUMAN ERYTHROCYTES -- 4. PROTECTING EFFECT OF DEXTRAN ON DRUG-INDUCED HEMOLYSIS.

003603 04-13

PROTECTION
BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF HYPOXIC HYPOXIA IN
RATS: STUDY OF THE PROTECTION AFFORDED BY ERGOT ALKALOIDS

STRAIN DIFFERENCES IN THE RESPONSE TO MORPHINE ON INCORPORATION OF H3-LYSINE INTO RAT BRAIN PROTEIN

000108 01-03 A BRAIN SPECIFIC PROTEIN FROM OCTOPUS-VULGARIS, LAM. 000125 01-03

NEW ASPECTS CONCERNING THE MECHANISM OF ACTION OF TRANQUILIZERS. THE INFLUENCE OF SOME TRANQUILIZERS ON PROTEIN AND NUCLEIC-ACID SYNTHESES.

THE AMNESTIC EFFECT OF PROTEIN SYNTHESIS INHIBITORS IS NOT DUE TO THE INHIBITION OF ADRENAL CORTICOSTEROIDOGENESIS.

000352 01-04 THE EFFECT OF STIMULANTS, DEPRESSANTS, AND PROTEIN SYNTHESIS INHIBITION ON RETENTION.

THE EFFECT OF INTRACEREBRAL INJECTION OF CYCLOHEXIMIDE ON BRAIN PROTEIN SYNTHESIS AND ON THE HYPERACTIVITY SYNDROME PRODUCED BY A MONOAMINE-OXIDASE INHIBITOR AND TRYPTOPHAN. 000410 01-04

MEMORY IMPAIRMENT CORRELATES CLOSELY WITH CYCLOHEXIMIDE DOSE AND DEGREE OF INHIBITION OF PROTEIN SYNTHESIS.

000436 01-04 AMPHETAMINE-INDUCED INCREASE OF THE CEREBROVASCULAR PERMEABILITY TO PROTEIN.

001153 02-03 EFFECT OF RUBIDIUM, LITHIUM AND CESIUM ON BRAIN ATPASE AND PROTEIN KINASES.

001172 02-03 PROTEIN AND ENZYME RELEASE FROM HUMAN LEUKOCYTES: INFLUENCE OF PHENOTHIAZINE DERIVATIVES.

001669 02-13 COMPARATIVE AVAILABILITY OF DIAZEPAM (D) IN HUMAN PLASMA (P), PAROTID SALIVA (PS) AND MIXED SALIVA (MS) AND ITS RELATIONSHIP TO PLASMA PROTEIN BINDING.

001682 02-13 DEGRADED PROTEIN CONTAINING FOOD AND MONOAMINE-OXIDASE

001804 02-15

CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF C-AMP-PHOSPHODIESTERASE.

PHARMACOLOGICAL EVIDENCE FOR A LINK BETWEEN THE CEREBELLAR CONTENT OF C-GMP AND THAT OF AN ENDOGENOUS PROTEIN KINASE

002031 03-03 THE CEREBROVASCULAR PERMEABILITY TO PROTEIN AFTER BICUCULLINE AND AMPHETAMINE ADMINISTRATION IN SPONTANEOUSLY HYPERTENSIVE RATS

002050 03-03 EFFECTS OF DIETHYLDITHIOCARBAMATE ON BRAIN MONOAMINE AND PROTEIN CONTENT IN NEONATAL RATS.

002063 03-03 FENFLURAMINE AND FLUOXETINE SPARE PROTEIN CONSUMPTION WHILE SUPPRESSING CALORIC INTAKE BY RATS. 002184 03-03

RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION WITH A HIGH FAT/PROTEIN DIET.

002278 03-04 ACUTE LITHIUM-INDUCED PARKINSONISM PRECIPITATED BY LIQUID

PROTEIN DIFT. 002685 03-15

MEASUREMENT OF PROTEIN TURNOVER IN RAT BRAIN 002859 04-03 THE EFFECT OF MORPHINE-TOLERANCE AND DEPENDENCE ON CELL FREE PROTEIN SYNTHESIS.

002876 04-03 STRIATAL CONTENT OF CA2-DEPENDENT REGULATOR PROTEIN AND DOPAMINERGIC RECEPTOR FUNCTION.

002990 04-03 EFFECT OF L-DOPA PRETREATMENT ON IN VIVO PROTEIN SYNTHESIS IN VARIOUS RAT BRAIN REGIONS.

003068 04-03

003173 04-04

RECOVERY AS A FUNCTION OF THE DEGREE OF AMNESIA D PROTEIN SYNTHESIS INHIBITION.	OUE TO
PROTEIN STATILESIS INHIBITION.	003204 04-04
IMPLICATIONS OF DOSE REGIMEN AND PROTEIN BINDING I NORTRIPTYLINE ESTIMATIONS.	
NGF-INDUCED ALTERATIONS IN PROTEIN SECRETION AND S ATTACHED MATERIAL OF A CLONAL NERVE CELL LINE.	003547 04-10 SUBSTRATE
PROTEINS	003607 04-13
PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION IN PROTEINS OF DIFFERENT MOUSE STRAINS.	, BRAIN ITO BRAIN
BINDING OF CODEINE, MORPHINE, AND METHADONE TO H	000384 01-04
MONOAMINERGIC INFLUENCES ON THE INCORPORATION O HYPOTHALAMIC AND NEUROHYPOPHYSIAL PROTEINS FO INTRACEREBROVENTRICULAR INJECTION OF \$35-CYSTEIN DEHYDRATED RATS.	000706 01-13 F S35 IN THE DLLOWING NE IN
ELECTROPHORETIC ANALYSES OF PROTEINS TRANSPORTED POSTERIOR PITUITARY.	002238 03-04 TO THE RAT
ALOSTERIC CHANGES IN PLASMA PROTEINS IN HEALTHY V	002920 04-03 OLUNTEERS
AFTER ADMINISTRATION OF LYSERGAMIDE.	003584 04-12
PROTHIADEN STEADY-STATE SERUM CONCENTRATIONS OF DOTHIEPIN A	ND
NORTHIADEN AFTER TWO DOSAGE REGIMENS OF DOTHI HYDROCHLORIDE (PROTHIADEN).	EPIN
CHANGES IN BRAIN FREE FATTY-ACIDS AFTER PAINFUL PER STIMULATION (EFFECT OF PROTHIADEN).	001675 02-13 RIPHERAL
	003094 04-03
PROTOBERBERINES THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE OF THE R. NUCLEUS — 3. THE EFFECT OF APORPHINES AND PROTOI	AT CAUDATE BERBERINES. 003089 04-03
PROTRACTED COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMO ANALGESIA AND PRIMARY AND PROTRACTED PHYSICA IN SIX MOUSE STRAINS.	
	000323 01-04
PROTRIPTYLINE PLASMA CONCENTRATIONS AND CARDIOTOXIC EFFECTS OF AND PROTRIPTYLINE IN THE RAT.	
PROTRIPTYLINE PLASMA LEVELS AND ANTIDEPRESSANT R	000478 01-05 ESPONSE. 001576 02-09
PROVINCE	
ACUTE POISONINGS DUE TO DRUGS IN THE POLISH PROVID OLSZTYN FROM 1971 TO 1974.	
PROVOKED	002657 03-15
BRAIN STIMULATION PROVOKED EMOTIONAL REACTIONS SOCIAL SITUATION.	OF CATS IN A
	001395 02-04
PSEUDOCATATONIA PSEUDOCATATONIA ASSOCIATED WITH ABUSE OF AMPHE	TAMINE AND
CANNABIS.	000909 01-15
PSEUDOCOCAINE COMPARISON OF THE CONVULSANT EFFECTS OF COCAINE	
PSEUDOCOCAINE IN THE RHESUS MONKEY.	
COCAINE AND PSEUDOCOCAINE: COMPARATIVE EFFECTS OF AFFER-DISCHARGE IN THE LIMBIC SYSTEM OF CATS.	
COMPARATIVE EFFECTS OF COCAINE AND PSEUDOCOCAINI ACTIVITIES, CARDIORESPIRATORY FUNCTIONS, AND SEI ADMINISTRATION BEHAVIOR IN THE RHESUS MONKEY.	LF-
PSILOCIN	003292 04-04
EFFECTS OF MESCALINE AND PSILOCIN ON ACQUISITION, CONSOLIDATION, AND PERFORMANCE OF LIGHT-DARK	
DISCRIMINATION IN TWO INBRED STRAINS OF MICE.	003184 04-04
PSILOCYBIN: BIPHASIC DOSE-RESPONSE EFFECTS ON THE A	
STARTLE REFLEX IN THE RAT.	000345 01-04
PSILOCYBIN-INDUCED THE PSILOCYBIN-INDUCED STATE OF DRUNKENNESS IN NO.	4.17.10
VOLUNTEERS AND SCHIZOPHRENICS.	

RECOVERY AS A FUNCTION OF THE DEGREE OF AMNESIA DUE TO PROTEIN SYNTHESIS INHIBITION.	PSYCHEDELIC THE USE OF PSYCHEDELIC DRUGS IN THE TREATMENT OF SEVERELY
MPLICATIONS OF DOSE REGIMEN AND PROTEIN BINDING FOR PLASM	-04 DISTURBED CHILDREN: A REVIEW.
NORTRIPTYLINE ESTIMATIONS.	PROFILES OF PSYCHEDELIC DRUGS: 4. HARMALINE.
OG3547 OA NGF-INDUCED ALTERATIONS IN PROTEIN SECRETION AND SUBSTRATE ATTACHED MATERIAL OF A CLONAL NERVE CELL LINE.	PSYCHEDELIC DRUG CRISES: TOXICITY AND THERAPEUTICS. 000861 01-15
PROTEINS 003607 04	AN INTRODUCTION TO THE PSYCHEDELIC PSYCHOTHERAPY OF SALVADOR ROQUET.
PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, BRAIN SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION INTO BRAIN PROTEINS OF DIFFERENT MOUSE STRAINS.	O01639 02-12 THE IMPLICATIONS OF PSYCHEDELIC DRUG RESEARCH FOR INTEGRATION AND SEALING OVER AS RECOVERY STYLES FROM ACUTE PSYCHOSIS.
BINDING OF CODEINE, MORPHINE, AND METHADONE TO HUMAN SER PROTEINS.	PSYCHIATRIC A DOUBLE-BLIND CONTROLLED STUDY OF CLOBAZAM FOR THE
MONOAMINERGIC INFLUENCES ON THE INCORPORATION OF \$35 IN TH HYPOTHALAMIC AND NEUROHYPOPHYSIAL PROTEINS FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF \$35-CYSTEINE IN DEHYDRATED RATS.	CLINICAL AND EXPERIMENTAL EXPERIENCE WITH MAPROTILINE, CLOMIPRAMINE, SYDNOCARB, AND MEFEXAMINE IN PSYCHIATRIC PATIENTS AND NORMAL SUBJECTS.
002238 0: ELECTROPHORETIC ANALYSES OF PROTEINS TRANSPORTED TO THE RA POSTERIOR PITUITARY.	PARENTERAL HALOPERIDOL IN PSYCHIATRIC EMERGENCIES: DOUBLE- BLIND COMPARISON WITH CHLORPROMAZINE.
D02920 O- ALOSTERIC CHANGES IN PLASMA PROTEINS IN HEALTHY VOLUNTEERS AFTER ADMINISTRATION OF LYSERGAMIDE.	PSYCHIATRIC AND NEUROLOGICAL APPLICATIONS OF BETA-BLOCKING AGENTS.
PROTHIADEN 003584 0	MOTONEURON EXCITABILITY IN PSYCHIATRIC PATIENTS. 000596 01-10
STEADY-STATE SERUM CONCENTRATIONS OF DOTHIEPIN AND NORTHIADEN AFTER TWO DOSAGE REGIMENS OF DOTHIEPIN	DRUG AND ALCOHOL-INDUCED PSYCHIATRIC SYNDROMES.
HYDROCHLORIDE (PROTHIADEN). 001675 0	ABUSE OF ANTIPARKINSONIAN DRUGS BY PSYCHIATRIC PATIENTS.
CHANGES IN BRAIN FREE FATTY-ACIDS AFTER PAINFUL PERIPHERAL	PSYCHIATRIC DRUGS IN MEDICAL PRACTICE.
STIMULATION (EFFECT OF PROTHIADEN). O03094 0- PROTOBERBERINES	PSYCHIATRIC DRUGS FOR THE NONMEDICAL MENTAL HEALTH WURKER.
THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE OF THE RAT CAUDAT NUCLEUS — 3. THE EFFECT OF APORPHINES AND PROTOBERBERINES 003089 0.	CONTRIBUTIONS TO DEVCHIATRIC CLASSIFICATION (INDIBITIONS)
PROTRACTED COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMOTOR ACTIVI ANALGESIA AND PRIMARY AND PROTRACTED PHYSICAL DEPENDEN IN SIX MOUSE STRAINS.	TY, A TWO-DOSE DEXAMETHASONE SUPPRESSION TEST IN PATIENTS WITH PSYCHIATRIC ILLNESS.
PROTRIPTYLINE 000323 0	EFFECTS OF PROLUNGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG
PLASMA CONCENTRATIONS AND CARDIOTOXIC EFFECTS OF DESIPRAN AND PROTRIPTYLINE IN THE RAT.	001712 02-14
PROTRIPTYLINE PLASMA LEVELS AND ANTIDEPRESSANT RESPONSE.	001736 02-14
PROVINCE ACUTE POISONINGS DUE TO DRUGS IN THE POLISH PROVINCE OF	ADVERSE REACTIONS TO MEDICATION IN PSYCHIATRIC INPATIENTS: THEIR MEANING, UTILITY AND PROBLEMS. 001744 02-15
OLSZTYN FROM 1971 TO 1974. 002657 0	ON THE PREVALENCE DIAGNOSIS AND MANAGEMENT OF LITHIUM-
PROVOKED BRAIN STIMULATION PROVOKED EMOTIONAL REACTIONS OF CATS IN SOCIAL SITUATION.	A AMINE NEUROTRANSMITTER STUDIES AND PSYCHIATRIC ILLNESS: TOWARD MORE MEANINGFUL DIAGNOSTIC CONCEPTS. (UNPUBLISHED)
PSEUDOCATATONIA 001395 0	2-04 PAPER). 001893 02-17
PSEUDOCATATONIA ASSOCIATED WITH ABUSE OF AMPHETAMINE AN CANNABIS.	POLYPHARMACY AMONG PSYCHIATRIC PATIENTS. 001900 02-17
PSEUDOCOCAINE 000909 0	1-15 PLACEBOS IN PSYCHIATRIC THERAPY.
COMPARISON OF THE CONVULSANT EFFECTS OF COCAINE AND	PSYCHIATRIC SEQUELAE OF AMOK. 001930 02-17
PSEUDOCOCAINE IN THE RHESUS MONKEY. O01415 O COCAINE AND PSEUDOCOCAINE: COMPARATIVE EFFECTS ON ELECTRIC	AL AND COMMUNITY ADJUSTMENT A YEAR LATER.
AFTER-DISCHARGE IN THE LIMBIC SYSTEM OF CATS. 003004 0	4-03 BETA-BLOCKING SUBSTANCES IN PSYCHIATRIC CHEMOTHERAPY.
COMPARATIVE EFFECTS OF COCAINE AND PSEUDOCOCAINE ON EEG ACTIVITIES, CARDIORESPIRATORY FUNCTIONS, AND SELF-	002462 03-09 USE OF DEPOT TRANQUILLISERS IN PSYCHIATRIC DISORDERS. 002535 03-11
ADMINISTRATION BEHAVIOR IN THE RHESUS MONKEY. 003292 0	
PSILOCIN EFFECTS OF MESCALINE AND PSILOCIN ON ACQUISITION, CONSOLIDATION, AND PERFORMANCE OF LIGHT-DARK	ELEVATED MELATONIN SERUM CONCENTRATIONS IN PSYCHIATRIC PATIENTS TREATED WITH CHLORPROMAZINE.
DISCRIMINATION IN TWO INBRED STRAINS OF MICE. 003184 0	
PSILOCYBIN PSILOCYBIN: BIPHASIC DOSE-RESPONSE EFFECTS ON THE ACOUSTIC STARTLE REFLEX IN THE RAT.	002661 03-15 PRIOR PSYCHIATRIC TREATMENT AND THE DEVELOPMENT OF BREAST CANCER.
000345 0	1-04 002691 03-15
PSILOCYBIN-INDUCED THE PSILOCYBIN-INDUCED STATE OF DRUNKENNESS IN NORMAL VOLUNTEERS AND SCHIZOPHRENICS.	CONTRIBUTION OF THE USE OF 1035MD IN A PSYCHIATRIC WARD FOR ADULTS, IT'S ACTIVITY ON THE DIRECT AND SIDE-EFFECTS OF NEUROLEPTICS.
001726 0	
DOPAMINE, THE PSYCHE, AND EXTRAPYRAMIDAL DISORDERS. 000864 0	PSYCHIATRIC PATIENTS.

Subject Index

PSYCHIATRIC ILLNESS AND HUMAN RENAL TRANSPLANTATION.
003510 04-09 COMPARATIVE EVALUATION OF HYPNOTIC EFFICACY OF FLUNITRAZEPAM IN PSYCHIATRIC PATIENTS.

003574 04-11 STUDY OF THE INFLUENCE OF VITAMIN SUPPLEMENTS ON OF PSYCHIATRIC PATIENTS.

003624 04-14 OF BREAST PRIOR PSYCHIATRIC TREATMENT AND THE DEVELOPMENT CANCER.

THE USE OF PRESCRIPTION DRUGS IN TREATMENT OF FIRST-TIME PSYCHIATRIC ADMISSIONS TO UNIVERSITY HOSPITAL, SASKATOON 003712 04-17 DIGITALIS DELIRIUM: PSYCHIATRIC CONSIDERATIONS

003727 04-17 CHATRISTS
THE BIOCHEMISTRY OF BRAIN DEVELOPMENT AND MENTAL
RETARDATION: THE ELEVENTH BLAKE MARSH LECTURE DELIVERED
BEFORE THE ROYAL COLLEGE OF PSYCHIATRISTS, 7 FEBRUARY, 1977.
002000 03-03 PSYCHIATRISTS

PSYCHIATRY SOME OLD AND NEW THEORIES IN BIOCHEMICAL PSYCHIATRY 000190 01-03 PERSPECTIVES IN BIOLOGICAL PSYCHIATRY. PART 2: AFFECTIVE-

DISORDERS 000558 01-09 LITHIUM IN CHILD AND ADOLESCENT PSYCHIATRY. (UNPUBLISHED PAPER)

QUANTIFICATION AND STATISTICAL ANALYSIS OF ORDINAL SCALE DATA

IN PSYCHIATRY 000913 01-16 NOTES ON EXPERIMENTS WITH DRUGS IN PSYCHIATRY

000971 01-17 PERSPECTIVES IN BIOLOGICAL PSYCHIATRY. PART 3: SCHIZOPHRENIA AND ORGANIC-BRAIN-SYNDROME.

001696 02-14 CLINICAL USE OF HALOPERIDOL (SERENACE) IN CHILD PSY CHIATRY. 001725 02-14 CHLORPROMAZINE-INDUCED CHANGES IN BLOOD

ADENOSINEPHOSPHORIC-ACIDS: TO THEIR DIAGNOSTIC SIGNIFICANCE IN PSYCHIATRY. 001861 02-16

CHEMOTHERAPY IN PSYCHIATRY 001880 02-17

PSYCHOTROPIC DRUGS IN PSYCHIATRY.

PSYCHOTROPIC DRUGS IN CHILD AND ADOLESCENT PSYCHIATRY. 001939 02-17 NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: 1. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY.

002096 03-03 ANIMAL MODELS IN PSYCHIATRY AND NEUROLOGY. 002366 03-06

EPILEPSY IN CHILD PSYCHIATRY. EFFECTS OF TREATMENT BY DIPROPYLACETIC-ACID. 002517 03-11

THE PROLACTIN RESPONSE IN CLINICAL PSYCHIATRY 003597 04-13 ENDORPHINS IN PSYCHIATRY: AN OVERVIEW AND A HYPOTHESIS 003730 04-17

AFFECTIVE-ILLNESS TREATED WITH LITHIUM: EFFECTS ON THYROID FUNCTION AND PSYCHIC STATUS.

000774 01-14 ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

001535 02-06 USE OF PSYCHOTROPIC DRUGS TO ALTER PSYCHIC STATES 002785 03-17

PSYCHOACTIVE
PSYCHOACTIVE DRUG EFFECTS AND SUBSTRATE SPECIFICITY IN INTACT
MITOCHONDRIAL MONOAMINE-OXIDASE FROM BRAIN.
000115 01-

INFLUENCE OF INJECTED PSYCHOACTIVE DRUGS ON CYCLIC-AMP LEVELS IN MOUSE BRAIN AND LUNG FOLLOWING MICROWAVE IRRADIATION.

STUDIES ON THE INFLUENCE OF BIOGENIC AMINES AND PSYCHOACTIVE DRUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMULATION TEST IN ENDOGENOUS DEPRESSION.

000926 01-16 PSYCHOACTIVE DRUG RESPONDER SUBGROUPS — POSSIBLE CONTRIBUTIONS TO PSYCHIATRIC CLASSIFICATION. (UNPUBLISHED

Psychopharmacology Abstracts

SENSITIVITY TO PSYCHOACTIVE DRUGS AND THE SEROTONERGIC NEURONAL SYSTEM.

TOWARD AN EGO-ORIENTED APPROACH TO THE STUDY OF THE EFFECTS OF PSYCHOACTIVE MEDICATION IN THE TREATMENT OF CHILDREN. 001875 02-16

ETHNOPHARMACOLOGY OF SACRED PSYCHOACTIVE PLANTS USED BY THE INDIANS OF MEXICO.

SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL CORRELATES

001974 03-03 CENTRAL CATECHOLAMINE NEUROTRANSMITTERS AND PSYCHOACTIVE DRUGS

002731 03-17 PSYCHOACTIVE DRUGS AND SOCIETY. 002734 03-17

PSYCHOACTIVE DRUGS. 002771 03-17

PSYCHOANALYTIC
PSYCHOANALYTIC AND BEHAVIORAL CONSIDERATIONS IN ANTAGONIST
AND METHADONE PROGRAMS.

003704 04-1

003704 04-17

PSYCHODIAGNOSTIC USE OF METHYLPHENIDATE.

000530 01-08 OBESITY RELATED TO THE USE OF PSYCHOTROPIC DRUGS, CONSIDERED IN ITS PSYCHODYNAMIC ASPECT.

001802 02-15 DEPRESSION: BIOLOGY, PSYCHODYNAMICS, AND TREATMENT

002425 03-09

PSYCHOENDOCRINOLOGICAL AND THERAPEUTIC EFFECTS OF TRH IN DEPRESSION. 000590 01-09

PSYCHOGERIATRIC
THE EFFECT OF CYCLANDELATE IN DEPRESSED AND DEMENTED PATIENTS:
A CONTROLLED STUDY IN PSYCHOGERIATRIC PATIENTS.

001617 02-11 EFFECT OF FUSARIC-ACID ON TARDIVE-DYSKINESIA AND MENTAL STATE IN PSYCHOGERIATRIC PATIENTS: A PILOT STUDY.

001629 02-11 TARDIVE-DYSKINESIA IN PSYCHOGERIATRIC PATIENTS: A FIVE-YEAR FOLLOW-UP.

001808 02-15 BROMOCRIPTINE: EFFECT ON SERUM PROLACTIN AND GROWTH HORMONE IN PSYCHOGERIATRIC HOSPITAL PATIENTS.

002561 03-13

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: THE EFFECT OF PREMEDICATION WITH CYSTAMINE ON PHARMACODYNAMICS AND PHARMACOKINETICS OF NITRAZEPAM.

CHANGES IN PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECTS OF PREMEDICATION WITH CYSTAMINE ON DYNAMICS AND KINETICS OF THIORIDAZINE.

002332 03-04 PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF

002348 03-05 PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF NITRAZEPAM

PSYCHOLOGIC AND NEUROENDOCRINE RESPONSE TO METHYLPHENIDATE 000689 01-13

ACUTE PSYCHOLOGIC AND NEUROENDOCRINE EFFECTS OF DEXTROAMPHETAMINE AND METHYLPHENIDATE.

002786 04-01

PSYCHOLOGICAL
PHARMACOLOGICAL TREATMENT FOLLOWING EXPERIMENTAL CEREBRAL
INFARCTION: IMPLICATIONS FOR UNDERSTANDING PSYCHOLOGICAL
SYMPTOMS OF HUMAN STROKE.

000243 01-0 000243 01-03

PHENOTHIAZINE EFFECTS ON PSYCHOLOGICAL AND
PSYCHOPHYSIOLOGICAL DYSFUNCTION IN CHRONIC SCHIZOPHRENICS

INTERCORRELATIONS BETWEEN PHYSIOLOGICAL AND PSYCHOLOGICAL EFFECTS OF MARIJUANA, HASHISH, AND THC-DELTA9 IN LONG-TERM HASHISH LISERS

000695 01-13

002358 03-05

WITHDRAWAL FROM CANNABIS: PSYCHOLOGICAL TEST PERFORMANCE. 000760 01-14 ON PSYCHOLOGICAL SYMPTOMS IN BROMIDE INTOXICATION — ONE CASE OF HIGH DOSE, LONG-TERM BROMIDE INTOXICATION WHICH SHOWED HALLUCINATION AND DELUSION SYMPTOMS.

TAXONOMY AND EVALUATION OF PSYCHOLOGICAL TEST METHODS IN PSYCHOTROPIC DRUG TRIALS.

000915 01-16

003660 04-15

PSYCHOLOGICAL SIDE-EFFECTS OF L-DOPA AND ANTICONVULSANT MEDICATION

001801 02-15 A PSYCHOLOGICAL PERSPECTIVE FOR DOUBLE-BLIND TRIALS

002729 03-16 ACUTE AND CHRONIC EFFECTS OF LITHIUM-CHLORIDE ON PHYSIOLOGICAL AND PSYCHOLOGICAL MEASURES IN NORMALS.

003600 04-13 PSYCHOLOGICAL FACTORS IN SUSCEPTIBILITY TO DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS.

PSYCHOLOGICAL SEQUELAE TO HEMODIALYSIS.

003661 04-15

PSYCHOTROPIC DRUGS IN PREGNANCY: MORPHOLOGICAL AND PSYCHOLOGICAL ADVERSE EFFECTS ON OFFSPRING 003708 04-17

PSYCHOLOGY

BEHAVIORAL TOXICITY: THE PSYCHOLOGY OF DRUG POLLUTION 003684 04-15

PSYCHOMETRIC CLASSIFICATION AND DETERMINATION OF CEREBRAL BIOAVAILABILITY

OF PSYCHOTROPIC DRUGS BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS (STUDIES WITH AX-A411-BS) 000931 01-16

ALERTNESS IN EPILEPTICS: PHARMACOLOGICAL AND PSYCHOMETRIC 002526 03-11

PHARMACODYNAMIC INVESTIGATIONS IN PSYCHOPHARMACOLOGY BY QUANTITATIVE EEG AND PSYCHOMETRIC METHODS.

002726 03-16
TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDROME WITH EMD-21657. A DERIVATIVE OF A PYRITINOL METABOLITE: DOUBLE-BLIND CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STUDIES. 003571 04-11

REWARD ENHANCEMENT BY PSYCHOMOTOR STIMULANT DRUGS 000440 01-04 POTENTIATION OF BRAIN REWARD MECHANISMS BY PSYCHOMOTOR STIMULANT DRUGS.

000441 01-04 EFFECTS OF MYSOLINE AND DILANTIN ON THE EEG DURING SMR BIOFEEDBACK TRAINING OF A PSYCHOMOTOR EPILEPTIC: SINGLE CASE

001657 02-13 EFFECTS OF TRITHIOZINE ON PSYCHOMOTOR SKILLS RELATED TO DRIVING: A COMPARISON WITH DIAZEPAM AND INTERACTIONS WITH

ALCOHOL. 001723 02-14 A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR

PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION 001787 02-15 EFFECTS OF NOMIFENSINE (HOF-984) LIPON PSYCHOMOTOR ACTIVITY AND INTRACRANIAL SELF-STIMULATION IN THE RAT.

002256 03-04 EFFECT OF THIORIDAZINE (MELLARIL-SANDOZ) ON PSYCHOMOTOR FUNCTION, CONCENTRATION, AND REACTIVITY IN CHILDREN WITH BEHAVIOR DISORDERS

002527 03-11 EFFECTS OF ANTIANXIETY DRUG AND PERSONALITY ON STRESS-INDUCING PSYCHOMOTOR PERFORMANCE TEST.

002630 03-14 CHARACTERIZATION OF DISCRIMINATIVE STIMULUS PROPERTIES OF PSYCHOMOTOR STIMULANTS.

003150 04-04 INTRUDER-EVOKED AGGRESSION IN ISOLATED AND NONISOLATED MICE: EFFECTS OF PSYCHOMOTOR STIMULANTS AND L-DOPA.

A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR. 003657 04-15

PSYCHONEURAL THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (SECOND REPORT) -- EFFECTS ON PUPIL FUNCTIONING.

000877 01-15

THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (FIRST REPORT)

000878 01-15

PSYCHONEUROLOGICAL

PERSPECTIVES IN THE TREATMENT OF THE PSYCHONEUROLOGICAL

DISORDERS: AFFECTIVE-DISORDERS. (UNPUBLISHED PAPER). 001870 02-16

POSTTRAUMATIC PSYCHONEUROSIS: EVALUATION OF DRUG THERAPY 000615 01-10 WHEN IS A NEUROLEPTIC APPROPRIATE IN PSYCHONEUROSIS?

002486 03-10

PSYCHOPATHOLOGIC

AMP SYSTEM: LONGITUDINAL COURSE STUDIES OF PSYCHOPATHOLOGIC

AND SOMATIC SYMPTOMS. AN EMPIRIC INVESTIGATION OF THE

PROBLEM OF SIDE-EFFECTS.

DOSAGE EFFECTS OF IMIPRAMINE ON THE PSYCHOPATHOLOGIC AND BIOLOGIC INDICES OF ENDOGENOUS DEPRESSIVE SYNDROMES. 002494 03-10

PSYCHOPATHOLOGY
THE INFLUENCE OF PYRIDOXINE ON THE PSYCHOPATHOLOGY AND PATHOCHEMISTRY OF DEPRESSIONS OF INVOLUTIONAL AG 003485 04-09

PSYCHOPHARMACEUTICALS IN EVERYDAY PRACTICE.

002752 03-17 **PSYCHOPHARMACOLOGIC** LONG-TERM FLIMINATION OF VIOLENT BEHAVIOUR BY THE INTERACTION OF PSYCHOPHARMACOLOGIC AND PSYCHOSOCIAL THERAPY 001333 02-04

PSYCHOPHARMACOLOGIC AGENTS IN POLYGRAPH TESTING 001926 02-17 PSYCHOPHARMACOLOGIC AGENTS: PRESCRIPTION PATTERNS OF

NONPSYCHIATRISTS. 001927 02-17 PSYCHOPHARMACOLOGIC TREATMENT OF DEPRESSION IN PRIVATE

PRACTICE. 003494 04-09

PSYCHOPHARMACOLOGICAL METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGICAL RESEARCH

REPLY TO DAVIS AND HURT CONCERNING METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGIGAL RESEARCH WITH CHLORPROMAZINE. 000538 01-08 NEUROLEPTIC SIDE-EFFECTS OF CHLORPROMAZINE IN PSYCHOPHARMACOLOGICAL RESEARCH.

000895 01-15 EFFECT OF CERTAIN PSYCHOPHARMACOLOGICAL AGENTS ON ADAPTATION UNDER STRESS.

001249 02-03 BENZHYDRYL PIPERAZINES: A NEUROPHARMACOLOGICAL AND PSYCHOPHARMACOLOGICAL EVALUATION. (PH.D. DISSERTATION)

001427 02-04 REHAVIORAL AND PSYCHOPHARMACOLOGICAL CHARACTERISTICS OF RATS RAISED IN HIGH POPULATION DENSITY.

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION TIAGORISM OF SAIN CONDUCTANCE RESPONSE (SCR) HABITUATION TO DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST — A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

001535 02-06 THE EFFECTS OF PSYCHOPHARMACOLOGICAL AGENTS ON CENTRAL-NERVOUS-SYSTEM AMINE METABOLISM IN MAN.

001671 02-13 THE ALPHA SPECTRUM IN SCHIZOPHRENIC PATIENTS DUE TO PSYCHOPHARMACOLOGICAL TREATMENT AND DIFFERENT SOCIOCULTURAL SETTINGS.

PSYCHOPHARMACOLOGICAL STUDIES ON (-) NUCIFERINE AND ITS HOFMANN DEGRADATION PRODUCT ATHEROSPERMININE 002824 04-03

THE PSYCHOPHARMACOLOGICAL PROPERTIES OF PINAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.

003357 04-04 PSYCHOPHARMACOLOGY

PEDIATRIC PSYCHOPHARMACOLOGY AND CHILDHOOD DEPRESSION ASPECTS OF THE PSYCHOPHARMACOLOGY OF HUMAN AGGRESSION. 000789 01-14

PSYCHOPHARMACOLOGY OF THE SWITCH PROCESS IN AFFECTIVE-ILLNESS. (UNPUBLISHED PAPER). 000941 01-17

THE PLACEBO IN CLINICAL PSYCHOPHARMACOLOGY. 000942 01-17

RESEARCH BARRIERS IN PSYCHOPHARMACOLOGY 000944 01-17

THE USE OF PROLACTIN RESPONSE IN CLINICAL PSYCHOPHARMACOLOG 000980 01-17

THE REVENORULE BLLLCALAGE OF LIABBUILD PEFFORE ON TOLIC	NAME OF THE PERSON OF THE PERS
THE PSYCHOPHARMACOLOGY OF MORPHINE EFFECTS ON TONIC IMMOBILITY. (PH.D. DISSERTATION).	RESPONSE TO LITHIUM IN A CASE OF L-DOPA-INDUCED PSYCHOSIS.
SOME CONSIDERATIONS ON THE BIOCHEMICAL BASIS OF	TREATMENT OF MANIC PSYCHOSIS WITH CLOZAPINE. 000575 01-09
PSYCHOPHARMACOLOGY. (UNPUBLISHED PAPER). 001891 02-17 TRANSCULTURAL ASPECTS OF PSYCHOPHARMACOLOGY.	CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND ITS METABOLITES AND CLINICAL RATINGS IN PATIENTS WITH ACUTE
PSYCHOPHARMACOLOGY IN THE PRACTICE OF MEDICINE. 001903 02-17	000726 01-13
001904 02-17 PEDIATRIC PSYCHOPHARMACOLOGY: A REVIEW WITH SPECIAL REFERENCE TO DEANOL.	PHARMACOGENETIC ASPECT OF RED BLOOD CELL LITHIUM INDEX IN MANIC-DEPRESSIVE PSYCHOSIS. 000736 01-13
001918 02-17 SYSTEM APPROACH IN EXPERIMENTAL PSYCHOPHARMACOLOGY AND MEMORY.	REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF BROMIDE PSYCHOSIS. 000800 01-15
PSYCHOPHARMACOLOGY: A BIOCHEMICAL AND BEHAVIORAL	CASE REPORT: AMPHETAMINE ABSTINENCE PSYCHOSIS - DOES IT
APPROACH. 001929 02-17 PHARMACODYNAMIC INVESTIGATIONS IN PSYCHOPHARMACOLOGY BY	PROPHYLACTIC VALUE OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS —
QUANTITATIVE EEG AND PSYCHOMETRIC METHODS. 002726 03-16	GENETIC ASPECTS. 000952 01-17
BI AND MULTIVARIATE ANALYSIS OF EEG DATA IN CLINICAL PSYCHOPHARMACOLOGY. 002743 03-17	LOXAPINE VERSUS HALOPERIDOL PARENTERALLY IN ACUTE PSYCHOSIS WITH AGITATION: A DOUBLE-BLIND STUDY.
PEDIATRIC PSYCHOPHARMACOLOGY: THE USE OF BEHAVIOR MODIFYING DRUGS IN CHILDREN.	PSYCHOSIS INDUCED BY DATURA-SUAVEOLENS: HALLUCINOSIS AND ANTICHOLINERGIC DELIRIUM.
PSYCHOPHARMACOLOGY OF ALCOHOL.	ON THE COLIDSE OF METHAMPHETAMINE (PHILOPON) PSYCHOSIS
PSYCHOPHARMACOLOGY OF AVERSIVELY MOTIVATED BEHAVIOR.	AMPHETAMINE PSYCHOSIS A MODEL FOR PARANOID
HANDBOOK OF PSYCHOPHARMACOLOGY, VOL. 11. STIMULANTS.	002413 03-08
PSYCHOPHARMACOTHERAPY PERSONALITY MODIFICATIONS DUE TO LONG-TERM	PHARMACOLOGICAL INVESTIGATIONS OF THE CHOLINERGIC IMBALANCE HYPOTHESES OF MOVEMENT DISORDERS AND PSYCHOSIS. 002509 03-11
PSYCHOPHARMACOTHERAPY: IN CASE OF CHRONIC SCHIZOPHRENIA. 000773 01-14	MODRIDITY SUPPRESSIVE EFFECT OF LITHHUM CARRONATE IN CYCLOID
PSYCHOPHARMACOTHERAPY IN CHILDREN. 001934 02-17	000505 00 11
PSYCHOPHARMACOTHERAPY IN CHILDREN. 002533 03-11	PSYCHOSIS IN AN ADDIESCENT
HYPOTONIC CIRCULATORY DISORDERS UNDER PSYCHOPHARMACOTHERAPY — TREATMENT WITH 9ALPHA- FLUOROHYDROCORTISONE.	WITHDRAWAL PSYCHOSIS AFTER DRUGS. 002663 03-15
002710 03-15	PSYCHOSIS: A RARE MANIFESTATION OF DIGOXIN INTOXICATION. 002700 03-15
PSYCHOPHYSICAL VILOXAZINE IN THE TREATMENT OF DEPRESSION: PSYCHOPHYSICAL MEASURES AND CLINICAL RESPONSE.	EYE BLINK AND SCHIZOPHRENIA: PSYCHOSIS OR TARDIVE-DYSKINESIA?. 002703 03-15
PSYCHOPHYSIOLOGIC 002375 03-07	CENTRAL CATECHOLAMINE METABOLISM IN PSYCHOSIS. 002764 03-17
COGNITIVE AND PSYCHOPHYSIOLOGIC RESPONSE TO DOXEPIN AND CHLORDIAZEPOXIDE.	NEUROLEPTIC INTERFERENCE WITH THE COCAINE CUE: INTERNAL STIMULUS CONTROL OF BEHAVIOR AND PSYCHOSIS.
PSYCHOPHYSIOLOGICAL PHENOTHIAZINE EFFECTS ON PSYCHOLOGICAL AND PSYCHOPHYSIOLOGICAL DYSFUNCTION IN CHRONIC SCHIZOPHRENICS.	THE USE OF PENFLURIDOL ACCORDING TO A NEW DOSAGE REGIMEN IN THE ACUTE, STABILIZATION AND MAINTENANCE PHASES OF PSYCHOSIS.
000549 01-08 WITHDRAWAL FROM CANNABIS: PSYCHOPHYSIOLOGICAL CHANGES.	THE IMPLICATIONS OF PSYCHEDELIC DRUG RESEARCH FOR INTEGRATION
PSYCHOPHYSIOLOGICAL EFFECTS OF ACUTE CANNABIS INHALATION.	003517 04-09
A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE SHORT-TERM EFFECTS	003646 04-15
OF CLOZAPINE UPON SLEEP PARAMETERS OF NORMAL YOUNG ADULTS.	003668 04-15
THE COMPARISON OF PSYCHOPHYSIOLOGICAL THERAPY WITH DRUG	003678 04-15
THERAPY. 001882 02-17	LITHIUM FOR STEROID-INDUCED PSYCHOSIS. 003679 04-15
A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE LONG-TERM EFFECTS OF CLOZAPINE UPON SLEEP PATTERNS OF NORMAL YOUNG ADULTS.	PSYCHOSIS IN YOUNG DOCTORS. 003709 04-17 PSYCHOSOCIAL
PSYCHOSES RELAPSE RATES OF SCHIZOPHRENIC PSYCHOSES. 002640 03-14	LONG-TERM ELIMINATION OF VIOLENT BEHAVIOUR BY THE INTERACTION OF PSYCHOPHARMACOLOGIC AND PSYCHOSOCIAL THERAPY.
TREATMENT OF SCHIZOPHRENIC PSYCHOSES WITH LYORODIN.	PSYCHOSOMATIC 001333 02-04
PSYCHOSES PRECIPITATED BY PSYCHOTOMIMETIC DRUGS: A FOLLOW-UP STUDY.	A PSYCHOSOMATIC TRIAD IN A BIPOLAR PATIENT. O00589 01-09 ON THE TREATMENT OF NEURODERMATITIS WITH A MONOAMINE-
TREATMENT OF SENILE PSYCHOSES WITH DISTRANEURIN MIXTURE.	
MANIC-DEPRESSIVE PSYCHOSES.	
NEUROPHYSIOLOGICAL PARAMETERS OF DROPERIDOL-INDUCED	
PSYCHOSES.	LISURID (LYSENYL-SPOFA) IN THE TREATMENT OF ORGANIC
PHARMACOLOGICAL RESEARCH AND THE PSYCHOSES: AN OVERVIEW.	003563 04-11
DEPOT NEUROLEPTICS IN ACUTE PSYCHOSES. 001868 02-16	PSYCHOTHERAPEUTIC PRESCRIBING PATTERNS IN GENERAL PRACTICE.
001890 02-17	000998 01-17

003262 04-04

VOLUME 16, SUBJECT INDEX NEUROCHEMICAL PROPERTIES OF DIMOXAMINE (D), A NEW **PSYCHOTOMIMETICS** PSYCHOTHERAPEUTIC AGENT. PHARMACOLOGICAL PROFILE OF A NEW PSYCHOTHERAPEUTIC AGENT: 4P FLUOROPHENYL-METHOXYPHENYL-PIPERAZINOETHYLOXAZOLINONE 001956 03-02 BEHAVIORAL EFFECTS OF PSYCHOTHERAPEUTIC AGENTS IN RATS CHRONICALLY DOSED WITH ALPHA-ACETYLMETHADOL 003280 04-04 PSYCHOTHERAPY
PSYCHOTHERAPY IN COMBINATION WITH ANTIDEPRESSANT DRUGS IN PATIENTS WITH SEVERE MASKED DEPRESSIONS. 000572 01-09 THE PEAK EXPERIENCE VARIABLE IN DPT ASSISTED PSYCHOTHERAPY WITH CANCER PATIENTS. 000679 01-12 AN INTRODUCTION TO THE PSYCHEDELIC PSYCHOTHERAPY OF SALVADOR ROQUET 001639 02-12 BEHAVIOR THERAPY, SUPPORTIVE PSYCHOTHERAPY, IMIPRAMINE, AND PHORIAS 002501 03-10 **PSYCHOTIC** THE USE OF PSYCHOTROPIC DRUGS IN CHILDREN MENTALLY RETARDED, HYPERKINETIC, AND PSYCHOTIC. 000584 01-09 EFFECT OF CHLORPROMAZINE TREATMENT ON MONOAMINE METABOLITE LEVELS IN CEREBROSPINAL FLUID OF PSYCHOTIC PATIENTS 000591 01-09 RELATIONSHIPS BETWEEN CLINICAL AND BIOCHEMICAL EFFECTS OF MELPERONE AND THIOTHIXENE IN PSYCHOTIC WOMEN 001557 02-08 ANTIDEPRESSANT DRUG THERAPY IN PSYCHOTIC DEPRESSION 001580 02-09 ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN EFFECT. A CONTROLLED STUDY. THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS. 001672 02-13 EFFECT OF CHLORPROMAZINE TREATMENT ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC PATIENTS. 001694 02-13 CLINICAL AND BIOCHEMICAL CHANGES IN PSYCHOTIC WOMEN TREATED WITH MELPERONE OR THIOTHIXENE. 002388 03-08 CLINICAL AND BIOCHEMICAL EFFECTS OF CHLORPROMAZINE IN PSYCHOTIC PATIENTS: RELATIONS TO CHLORPROMAZINE CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID 002538 03-11

EFFECTS OF MELPERONE AND THIOTHIXENE ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC WOMEN. 002547 03-13 AN EEG COMPUTER ANALYSIS OF CHLORPROMAZINE EFFECTS IN

PSYCHOTIC SUBJECTS. 002592 03-13 CIS-CLOPENTHIXOL AND CLOPENTHIXOL (SORDINOL) IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL INVESTIGATION 003496 04-09

CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED DOSES OF CHLORPROMAZINE 003614 04-13

VALIDITY AND CLINICAL UTILITY OF NEUROLEPTIC FACILITATED ELECTROENCEPHALOGRAPHY IN PSYCHOTIC PATIENTS. 003669 04-15

PSYCHOTICISM EFFECTS OF N.N DIMETHYLTRYPTAMINE (DMT) ON PSYCHOTICISM TESTS.

002540 03-12 **PSYCHOTOMIMETIC** ANTAGONISM BY CHOLINERGIC DRUGS OF BEHAVIOURAL EFFECTS IN CATS OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC DRUG AND ENHANCEMENT BY NICOTINE. 000404 01-04 PSYCHOSES PRECIPITATED BY PSYCHOTOMIMETIC DRUGS: A FOLLOW-UP

DIRECTIONAL LIPOPHILIC CHARACTER IN A SERIES OF PSYCHOTOMIMETIC PHENETHYLAMINE DERIVATIVES.

001009 02-01 THE EFFECTS OF PSYCHOTOMIMETIC DRUGS ON THE CONDITIONED EMOTIONAL RESPONSE. 001308 02-04

ASSOCIATION OF SOME PSYCHOTOMIMETIC COMPOUNDS WITH 6 METHYLPURINE IN AQUEOUS SOLUTIONS. 001950 03-01 BRAIN AND RETINA UPTAKE OF A RADIOIODINE LABELED

PSYCHOTOMIMETIC IN DOG AND MONKEY. 003075 04-03 TREATMENT OF ALCOHOLISM WITH PSYCHOTOMIMETIC DRUGS. A FOLLOW-UP STUDY. 003570 04-11

EFFECT OF PSYCHOTOMIMETICS (LSD AND DEXTROAMPHETAMINE) ON THE USE OF PRIMARY AND SECONDARY PROCESS LANGUAGE. 002542 03-12

TACRINE AND ITS DERIVATIVES ANTAGONIZE CHOLINERGIC PSYCHOTOMIMETICS: BEHAVIORAL STUDY IN RATS.

PSYCHOTROPIC

ACTION OF S-1432, A NEW PSYCHOTROPIC DRUG, ON THE CENTRAL CHOLINERGIC SYSTEM. 000080 01-03

EFFECTS OF PSYCHOTROPIC DRUGS ON NEUROTUBULE ASSEMBLY 000225 01-03 GRANULAR AND EXTRAGRANULAR ACTION OF PSYCHOTROPIC DRUGS ON MONOAMINERGIC NEURONS.

000252 01-03 INHIBITION OF PROSTAGLANDIN SYNTHETASE SYSTEM IN THE RABBIT RENAL MEDULLA BY PSYCHOTROPIC DRUGS

000281 01-03 PSYCHOTROPIC AND ANTICONVULSANT DRUG USAGE IN EARLY
CHILDHOOD SPECIAL EDUCATION PROGRAMS III. A PRELIMINARY REPORT: PARENT INTERVIEWS ABOUT DRUG TREATMENT 000627 01-11

000665 01-11 PSYCHOTROPIC DRUGS: INFLUENCE ON RESPIRATORY FUNCTION.

000692 01-13

EFFECTIVENESS OF PSYCHOTROPIC DRUGS IN PATIENTS IN A STATE OF
MALNUTRITION OR EXPOSED TO EXTREME CLIMATIC CONDITIONS.

000721 01-13

CLINICAL EVIDENCE FOR NEUROCHEMICAL ADAPTATION TO PSYCHOTROPIC DRUGS. 000729 01-13 VALPROATE-SODIUM: EVALUATION OF SO-CALLED PSYCHOTROPIC

000791 01-14 UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: I. -- DRUGS FOR

000825 01-15 UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: III. - DRUGS FOR

000827 01-15 UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: II. -- DRUGS FOR

000828 01-15 UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: IV. - DRUGS FOR

000829 01-15 UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: V. - OTHER DRUGS, TREATMENT AND PREVENTION. 000830 01-15

PSYCHOTROPIC DRUGS AND INTESTINAL PARALYSIS. 000875 01-15

EPILEPTIC SEIZURES INDUCED BY PSYCHOTROPIC DRUGS 000905 01-15 TAXONOMY AND EVALUATION OF PSYCHOLOGICAL TEST METHODS IN PSYCHOTROPIC DRUG TRIALS.

000915 01-16 THEORETICAL AND METHODOLOGICAL ASPECTS OF PSYCHOTROPIC DRUG TRIALS USING HEALTHY SUBJECTS

000918 01-16 STATISTICAL ASPECTS OF PSYCHOTROPIC DRUG TRIAL DESIGNS. 000922 01-16

GENERAL METHODOLOGICAL PROBLEMS OF CLINICAL PSYCHOTROPIC DRUG TRIALS.

CLASSIFICATION AND DETERMINATION OF CEREBRAL BIOAVAILABILITY OF PSYCHOTROPIC DRUGS BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS (STUDIES WITH AX-A411-BS). 000931 01-16

DIFFICULTIES ENCOUNTERED BY THE CLINICAL RESEARCHER IN PLANNING PSYCHOTROPIC DRUG TRIALS. 000935 01-16 PSYCHOTROPIC DRUGS AND ROAD ACCIDENTS

000988 01-17 EFFECT OF PSYCHOTROPIC DRUGS ON ATPASE TRANSPORT OF THE SARCOPLASMIC RETICULUM IN RABBIT SKELETAL MUSCLES. 001174 02-03

THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LOCAL CEREBRAL GLUCOSE UTILISATION OF THE RAT. 001206 02-03

BLOCKADE BY PSYCHOTROPIC DRUGS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR IN CULTURED NERVE CELLS.

001223 02-03 EFFECTS OF PSYCHOTROPIC AGENTS ON AMPHETAMINE-INDUCED REHAVIOR IN RATS

PSYCHOTROPIC DRUG EFFECTS ON THE EMOTIONAL STATE OF CATS IN A SOCIAL SITUATION. 001480 02-04

Subject Index

SOME PROBLEMS CONCERNING THE TECHNIQUES OF STUDYING THE EFFECTIVENESS OF PSYCHOTROPIC DRUGS. 001540 02-06 EXPERIENCES WITH THE CONTINUED USE OF PSYCHOTROPIC DRUGS 001567 02-08 PSYCHOTROPIC DRUGS: MECHANISM OF ACTION AT THE NEUROTRANSMITTER LEVEL. 001684 02-13 THE PSYCHOTROPIC EFFECTS OF ATENOLOL IN NORMAL SUBJECTS: PRELIMINARY FINDINGS. 001700 02-14 PSYCHOTROPIC EFFECTS OF CARBAMAZEPINE IN EPILEPSY: A DOUBLE-BLIND COMPARISON WITH PHENYTOIN. TIMING AND RISK OF BONE MARROW DEPRESSION BY PSYCHOTROPIC 001770 02-15 ON CATARACTS SEEN DURING PSYCHOTROPIC DRUG THERAPY 001793 02-15 SUDDEN DEATH OF PATIENTS USING PSYCHOTROPIC MEDICATION 001796 02-15 OBESITY RELATED TO THE USE OF PSYCHOTROPIC DRUGS, CONSIDERED IN ITS PSYCHODYNAMIC ASPECT. OBESITY RELATED TO THE USE OF PSYCHOTROPIC DRUGS, CONSIDERED IN ITS ORGANIC ASPECT. 001803 02-15 GONADAL MORPHOLOGY IN SCHIZOPHRENIC PATIENTS UNDER PSYCHOTROPIC TREATMENT. 001832 02-15 ON LONG-TERM MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY: THE COMBINED ADMINISTRATION OF ANTIPARKINSONS DRUGS. 001865 02-16 DEBATE ON MAINTENANCE OF PSYCHOTROPIC DRUG THERAP REFLECTIONS ON THE SO-CALLED LONG-TERM SATURATION ADMINISTRATIONS. 001872 02-16 A REEXAMINATION OF USING ANTIPARKINSONS DRUGS WITH PSYCHOTROPIC DRUG THERAPY — A SURVEY OF OUTPATIENTS 001874 02-16 INVOLUNTARY ADMINISTRATION OF PSYCHOTROPIC DRUGS — GROUNDS FOR SUIT. SOUDER V. MCGUIRE, 423 F. SUPP. 830, (PENNSYLVANIA). M.D. DISTRICT COURT. DECEMBER 9, 1976. PSYCHOTROPIC DRUGS IN PSYCHIATRY. 001931 02-17 RATIONALITY OF APPEALS USED IN THE PROMOTION OF PSYCHOTROPIC DRUGS. A COMPARISON OF MALE AND FEMALE MODELS. 001932 02-17 CLINICAL STUDY OF ANTIPARKINSON DRUGS USED TOGETHER WITH **PSYCHOTROPIC DRUGS** 001936 02-17 PSYCHOTROPIC DRUGS IN CHILD AND ADOLESCENT PSYCHIATRY 001939 02-17 EFFECT OF PSYCHOTROPIC DRUGS ON 3,4 DIHYDROXYPHENYLACETIC-ACID (DOPAC) CONTENT IN THE MEDIAL BASAL HYPOTHALAMUS. 001962 03-03 STUDIES ON THE SUBSYNAPTOSOMAL DISTRIBUTION OF PSYCHOTROPIC DRUGS IN RAT CEREBRAL-CORTEX. 002045 03-03 EFFECTS OF BIOGENIC AMINES AND PSYCHOTROPIC DRUGS ON ENDOGENOUS PROSTAGLANDIN BIOSYNTHESIS IN THE RAT BRAIN HOMOGENATES. 002145 03-03 EFFECT OF PSYCHOTROPIC DRUGS ON THE DEVELOPMENT OF DEFENSE CONDITIONED REFLEX DURING EXPERIMENTAL NEUROSIS. 002204 03-04 EFFECT OF PSYCHOTROPIC AGENTS ON THE PHYSICAL PERFORMANCE CAPACITY OF ANIMALS EXPOSED TO HEAT AND COLD. THE EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY AND STEREOTYPED BEHAVIOUR OF RATS STUDIED ON A HOLE-BOARD 002274 03-04 EMOTIONAL PREDISPOSITION TO PSYCHOTROPIC DRUG EFFECTS. 002649 03-15 AUTONOMOUS NERVOUS FUNCTION OF LONG-TERM USERS OF PSYCHOTROPIC DRUGS, THIRD REPORT -- PUPILOGRAM 002690 03-15 STRESS AND THE HEART: INTERACTIONS OF THE CARDIOVASCULAR SYSTEM, BEHAVIORAL STATE, AND PSYCHOTROPIC DRUGS. 002711 03-15 THE USE OF PSYCHOTROPIC DRUGS IN STATE HOSPITALS: A LEGAL OR MEDICAL DECISION? 002730 03-17 COMPREHENSIVE CLINICAL STUDIES OF PSYCHOTROPIC DRUGS 002756 03-17 INTERNATIONAL GUIDELINES FOR CLINICAL TRIALS OF PSYCHOTROPIC

Psychopharmacology Abstracts

	• • • • • • • • • • • • • • • • • • • •
WHAT IS AN ADEQUATE THERAPEUTIC TRIAL OF PSYC MEDICATION?.	CHOTROPIC
USE OF PSYCHOTROPIC DRUGS TO ALTER PSYCHIC ST	002775 03-17
EFFECTS OF PSYCHOTROPIC DRUGS ON DEAMINASE II	002785 03-17
REGIONAL LOCALIZATION OF HALOPEMIDE, A NEW P.	002904 04-03
AGENT, IN THE RAT BRAIN.	002989 04-03
PSYCHOTROPIC DRUGS AND SIDMAN AVOIDANCE IN DISTRIBUTION CHANGES.	RATS: IRT 003269 04-04
THE PERILS OF PRESCRIBING PSYCHOTROPIC DRUGS.	
PHARMACOKINETICS AND PSYCHOTROPIC DRUGS.	003504 04-09
PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATII TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS BETWEEN LIGHT AND NEAR VISION REACTIONS.	S: DISSOCIATION
TARDIVE-DYSKINESIA AND PSYCHOTROPIC DRUG HIS	
PSYCHOTROPIC DRUGS IN PREGNANCY: MORPHOLOG PSYCHOLOGICAL ADVERSE EFFECTS ON OFFSPRING.	
THE PHARMACOKINETIC ASPECTS OF THERAPY WITH AGENTS.	003708 04-17
PHARMACOLOGICAL INVESTIGATIONS ON ETOPERIDO PSYCHOTROPIC AGENT.	
PSYCHOTROPIC AND ANTIPARKINSONIAN DRUG USE: OF PRESCRIPTION PRACTICES.	003720 04-17 AN EXAMINATION
PSYCHOTROPIC-INDUCED	003723 04-17
FILICIDE DURING PSYCHOTROPIC-INDUCED SOMNAME REPORT.	
PUDENDECTOMY	003663 04-15
FACILITATION OF MOUNTING BEHAVIOR BY DIHYDRO PROPIONATE IN CASTRATED ESTRADIOL-BENZOATE RATS FOLLOWING PUDENDECTOMY.	
PUFFING	000403 01-04
CAN CIGARETTE SIZE AND NICOTINE CONTENT INFLUE PUFFING RATES?	ENCE SMOKING AND
PULMONARY	003631 04-14
THE LACK OF AN EFFECT OF DELTA9-THC ON PULMON MUSCLE FUNCTION IN THE GUINEA-PIG.	NARY SMOOTH
DRUGS THAT MAY INDUCE PULMONARY DISEASE.	001041 02-03
PULSE	002694 03-15
MARIJUANA: DOSE-RESPONSE EFFECTS ON PULSE RA ESTIMATES OF POTENCY, PLEASANTNESS, AND RE	
MEMORY. EFFECT OF DIAZEPAM ON PULSE ACTIVITY OF NEURO	000648 01-11 NS OF THE
SENSORIMOTOR AND OPTIC AREAS OF THE RAT CE	001978 03-03
REPRESSION OF A LITHIUM PUMP AS A CONSEQUENCE INGESTION BY MANIC-DEPRESSIVE SUBJECTS.	
PUNISHED	000714 01-13
EFFECTS OF D AMPHETAMINE ON RESPONDING SIMU MAINTAINED AND PUNISHED BY PRESENTATION OF	
BEHAVIORAL HISTORY AS A DETERMINANT OF THE E AMPHETAMINE ON PUNISHED BEHAVIOR.	
ANTI TELAMINE ON PONISHED BEHAVIOR.	001306 02-04

EFFECTS OF CHLORDIAZEPOXIDE ON PUNISHED AND UNPUNISHED RESPONDING BEFORE AND DURING CHLORDIAZEPOXIDE DRINKING. 001417 02-04

THE EFFECT OF COCAINE AND D AMPHETAMINE ON PUNISHED RESPONDING. 001492 02-04

SOME EFFECTS OF CHLORDIAZEPOXIDE AND D AMPHETAMINE ON RESPONSE FORCE DURING PUNISHED RESPONDING IN RATS.

002234 03-04

PUNISHER
PUNISHMENT SPECIFIC EFFECTS OF PENTOBARBITAL: DEPENDENCY ON THE
TYPE OF PUNISHER.
000322 01-04

PUNISHMENT SPECIFIC EFFECTS OF PENTOBARBITAL: DEPENDENCY ON THE TYPE OF PUNISHER. 000322 01-04

002769 03-17

A VARIABLE-INTERVAL PUNISHMENT PROCEDURE FOR ASSESSING ANXIOLYTIC EFFECTS OF DRUGS.

002371 03-06

000877 01-15

002690 03-15

PUPIL

ACTIONS OF AMPHETAMINE AND ANTAGONISTS ON PUPIL DIAMETER IN THE CHRONIC SYMPATHECTOMIZED DOG.

000265 01-03 MIOSIS AND FLUCTUATION IN THE RABBIT PUPIL: EFFECTS OF MORPHINE AND NALOXONE

000504 01-06 THE AUTONOMOUS NERVOUS FUNCTIONING OF PATIENTS WHO HAVE EXPERIENCED LONG-TERM USE OF PSYCHONEURAL DRUGS (SECOND REPORT) — EFFECTS ON PUPIL FUNCTIONING.

PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATIENTS DURING LONG-

TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS: DISSOCIATION BETWEEN LIGHT AND NEAR VISION REACTIONS. 003673 04-15

AUTONOMOUS NERVOUS FUNCTION OF LONG-TERM USERS OF PSYCHOTROPIC DRUGS, THIRD REPORT — PUPILOGRAM

PUPPIES

EFFECT OF CHLORPROMAZINE ON ELABORATION AND EXTINCTION OF AN INSTRUMENTAL ALIMENTARY REFLEX IN PUPPIES.

CHANGES IN THE BEHAVIORAL RESPONSE TO A NOVEL ENVIRONMENT FOLLOWING LESIONING OF THE CENTRAL DOPAMINERGIC SYSTEM IN 003368 04-04

PURCHASES

PURCHASES OF HYPNOTICS, SEDATIVES AND MINOR TRANQUILLIZERS AMONG 2,566 INDIVIDUALS IN THE COUNTY OF JAMTLAND, SWEDEN: A 6-YEAR FOLLOW-UP. 000940 01-17

EVALUATION OF PURE DIASTEREOMERS OF N SEC ALKYLMORPHINOIDS 001040 02-02

THE PURIFICATION OF ANTIMORPHINE ANTIBODIES BY AFFINITY

000015 01-01 SELECTIVE PURIFICATION OF A SINGLE POPULATION OF GLUCOCORTICOID 002887 04-03

PURIFIED

HYDROLYSIS OF ENKEPHALIN BY CULTURED HUMAN ENDOTHELIAL CELLS AND BY PURIFIED PEPTIDYL DIPEPTIDASE. 003593 04-13

COENZYME-A IS A PURINE NUCLEOTIDE MODULATOR OF ACETYLCHOLINE OUTPUT. 002874 04-03

EQUAL SUPPRESSION OF CEREBELLAR PURKINJE CELL ACTIVITY BY AMPHETAMINE STEREOISOMERS.

000299 01-03 BURST FIRING OF CEREBELLAR PURKINJE NEURONES INDUCED BY BENZODIAZEPINES.

001061 02-03 DIHYDROERGOTOXINE-INDUCED MODULATION OF SPONTANEOUS ACTIVITY OF CULTURED RAT PURKINJE CELLS.

PUSH-PULL

MORPHINE INCREASES AND D AMPHETAMINE DECREASES THE RATIO OF DOPAC: HVA IN PUSH-PULL PERFUSATE OF RAT CAUDATE NUCLEUS 002158 03-03

DISULFIRAM ALTERS DOPAMINE METABOLISM AT SITES IN RATS FOREBRAIN AS DETECTED BY PUSH-PULL PERFUSIONS.

PUTATIVE

ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEODMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR

000086 01-03 THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS.

PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EMBRYOPATHIC EFFECT AND COVALENT BINDING OF PUTATIVE ARENE OXIDE METABOLITE IN GESTATIONAL TISSUE.

001515 02-05 CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC

EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE ANTIPSYCHOTIC DRUGS.

ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS.

EFFECT OF ERGOT ALKALOIDS AND OF NEUROLEPTICS ON BINDING TO PUTATIVE DOPAMINE AND ALPHA RECEPTORS.

QUANTITATIVE EEG ANALYSIS OF THE PUTATIVE ANTIDEPRESSANT COMPOUND F1-6654. 002588 03-13

PUTORIUS-PUTORIUS-FURO

INSTINCTIVE PREDATORY BEHAVIOR OF THE FERRET (PUTORIUS-PUTORIUS-FURO L.) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE (LIBRIUM).

003161 04-04

PYRAMIDAL

PENICILLIN IN THE PYRAMIDAL TRACT: ECTOPIC ACTION POTENTIAL GENERATION.

002082 03-03 EFFECT OF DIHYDROERGOTOXINE ON THALAMIC AND PYRAMIDAL EVOKED RESPONSES IN THE CAT UNDER TRANSIENT ISCHEMIA. 002201 03-04

THE STUDY OF THE MUTAGENIC ACTIVITY OF LUMINAL AND PYRAZIDAL

PYRAZINYLBENZODIAZEPINES

QUINAZOLINES AND 1,4 BENZODIAZEPINES. 82. 5 PYRIMIDYL AND 5 PYRAZINYLBENZODIAZEPINES. 001022 02-02

PYRAZOLODIAZEPINES

PYRAZOLODIAZEPINES. 2.

ARYLDIALKYLDIHYDROPYRAZOLODIAZEPINONES AS ANTIANXIETY AND ANTICONVULSANT AGENTS. 001001 02-01

CYCLOPROPANIC PYRIDINE ALCOHOLS.

000003 01-01

002932 04-03

YRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6
TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — I. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS. 002931 04-03

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH.

PYRIDOXINE

EFFECTS OF DISULFIRAM AND PYRIDOXINE ON SERUM CHOLESTEROI THE INFLUENCE OF PYRIDOXINE ON THE PSYCHOPATHOLOGY AND PATHOCHEMISTRY OF DEPRESSIONS OF INVOLUTIONAL AGE.

PYRIMIDINE

INHIBITION BY BARBITURIC-ACID AND ITS DERIVATIVES OF THE ENZYMES IN RAT BRAIN WHICH PARTICIPATE IN THE SYNTHESIS OF PYRIMIDINE RIBOTIDES. 003049 04-03

PYRIMIDYL

002020 03-03

QUINAZOLINES AND 1,4 BENZODIAZEPINES. 82. 5 PYRIMIDYL AND 5 PYRAZINYLBENZODIAZEPINES. 001022 02-02

FYRITHIOXIN

EFFECT OF EARLY EXPERIENCE, PYRITHIOXIN AND DIAZEPAM ON UC14-GLUCOSE UTILIZATION IN RAT BRAIN DURING EMOTIONAL STRESS. 002152 03-03

A CONTRIBUTION TO THE NEUROCHEMICAL BASIS OF THE PYRITHIOXIN EFFECT ON THE BRAIN GLUCOSE UTILISATION DURING RELATIVE BRAIN HYPOGLYCAEMIA INDUCED BY ANTICIPATION STRESS. 003083 04-03

PYRITHIOXINE

THE INFLUENCE OF PYRITHIOXINE ON CERTAIN FACTORS OF INTELLIGENCE

TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDROME WITH EMD-21657. A DERIVATIVE OF A PYRITINOL METABOLITE: DOUBLE-BLIND CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STUDIES. 003571 04-11

PYRROLASE

ENHANCEMENT OF THE ANTIDEPRESSANT RESPONSE TO L TRYPTOPHAN BY A LIVER PYRROLASE INHIBITOR: A RATIONAL TREATMENT

002464 03-09

EFFECTS OF MORPHINE ON ISOENZYMES OF PYRUVATE KINASE AND TYROSINE-AMINOTRANSFERASE IN RAT.

PHOSPHORIC ACID
INFLUENCE OF CHRONIC PENTOBARBITAL OR MORPHINE TREATMENT ON
THE INCORPORATION OF P32-PHOSPHORIC-ACID AND 3H CHOLINE INTO
RAT SYNAPTIC PLASAYA MEMBRANES.

THE ROLE OF SUBSTRATE LIPOPHILICITY IN DETERMINING TYPE 1 MICROSOMAL P450 BINDING CHARACTERISTICS.

002809 04-03

QUALITATIVE ALTERATION IN HEPATIC MICROSOMAL CYTOCHROME-P-450 APOPROTEINS ASSOCIATED WITH BILE DUCT LIGATION, AND THE ADMINISTRATION OF ETHINYL-ESTRADIOL, PHENOBARBITAL AND 3 METHYCHOLANTHRENE

002083 03-03

QUANTIFICATION
QUANTIFICATION AND STATISTICAL ANALYSIS OF ORDINAL SCALE DATA
IN PSYCHIATRY.

000913 01-16 RATIO DATA AND THE QUANTIFICATION OF DRUG EFFECTS

000914 01-16 IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLETHANOL (MOPET) IN HUMAN CEREBROSPINAL FLUID AND RAT BRAIN BY MEANS OF GAS-CHROMATOGRAPHY — MASS-SPECTROMETRY.

003025 04-03

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLLACTIC-ACID (VLA) IN CEREBROSPINAL FLUID AND 3 METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN THE URINE OF PARKINSONIAN PATIENTS TREATED WITH L-DOPA. 003602 04-13

QUANTIFYING
ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION
DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST
— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND
QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

001535 02-0

001535 02-06

QUANTITATION
SIMULTANEOUS IDENTIFICATION AND QUANTITATION OF
DIPHENHYDRAMINE AND METHAQUALONE.

000925 01-16 QUANTITATION OF BINDING OF H3-CHLORPROMAZINE TO SYNTHETIC MELANINS AND MELANIN GRANULES.

002354 03-05

QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS OF BIOLOGICALLY ACTIVE INDOLE, 1 METHYLINDOLE AND BENZO-B-THIOPHENE

000006 01-01

QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS IN A SERIES OF SELECTIVE 5-HT UPTAKE INHIBITORS. 000057 01-03

EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT BRAIN: A QUANTITATIVE HISTOLOGICAL STUDY.

CLASSIFICATION AND DETERMINATION OF CEREBRAL BIOAVAILABILITY OF PSYCHOTROPIC DRUGS BY QUANTITATIVE PHARMACO-EEG AND PSYCHOMETRIC INVESTIGATIONS (STUDIES WITH AX-A411-BS).

000931 01-16 WET-DOG SNAKE BEHAVIOUR IN THE RAT: A POSSIBLE QUANTITATIVE MODEL OF CENTRAL 5 HYDROXYTRYPTAMINE ACTIVITY.

001310 02-04 QUANTITATIVE DETERMINATION OF STRESS-INDUCED MYOCARDIAL DAMAGE IN RATS.

FLUVOXAMINE (DU-23001), A NEW ANTIDEPRESSANT. QUANTITATIVE PHARMACO-ELECTROENCEPHALOGRAPHY AND PILOT CLINICAL TRIALS.

QUANTITATIVE ANALYSIS OF METHADONE IN BIOLOGICAL FLUIDS USING DEUTERIUM-LABELED METHADONE AND GLC CHEMICAL IONIZATION MASS SPECTROMETRY.

001862 02-16 QUANTITATIVE PHARMACO-EEG WITH ANTIMIGRAINE COMPOUNDS

002565 03-13 QUANTITATIVE PHARMACO-EEG WITH STEROIDAL HORMONES

002566 03-13 QUANTITATIVE EEG ANALYSIS OF THE PUTATIVE ANTIDEPRESSANT COMPOUND F1-6654.

002588 03-13 PHARMACODYNAMIC INVESTIGATIONS IN PSYCHOPHARMACOLOGY BY QUANTITATIVE EEG AND PSYCHOMETRIC METHODS.

002726 03-16 TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDROME WITH EMD-21657. A DERIVATIVE OF A PYRITINOL METABOLITE: DOUBLE-BLIND CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STUDIES. 003571 04-11

QUANTUM CHEMICAL STUDIES OF N SUBSTITUENT VARIATION IN THE OXYMORPHONE SERIES OF OPIATE NARCOTICS. 001946 03

URINARY EXCRETION OF A QUATERNARY AMMONIUM GLUCURONIDE METABOLITE OF CYPROHEPTADINE IN HUMANS UNDERGOING CHRONIC DRUG THERAPY

QUATERNIZED

CLEARANCE AND ANALGESIC ACTIVITY OF THE QUATERNIZED OPIATE, N
METHYLMORPHINE (6-H3) ADMINISTERED INTRACISTERNALLY TO THE
RAT.

QUINAZOLINES
QUINAZOLINES AND 1,4 BENZODIAZEPINES. 81. S
TRIAZOLOBENZODIAZEPINES BY OXIDATIVE CYCLIZATION OF HYDRAZONES

001017 02-01 QUINAZOLINES AND 1,4 BENZODIAZEPINES. 82. 5 PYRIMIDYL AND 5 PYRAZINYLBENZODIAZEPINES.

001022 02-02

NACL AND LICL EFFICACY IN THE INDUCTION OF AVERSION FOR QUININE
AND SACCHARIN SOLUTIONS IMMEDIATELY FOLLOWING INJECTION. 000396 01-04

QUINUCLIDYL-BENZILATE
INTERACTION OF IMIPRAMINE AND 3 QUINUCLIDYL-BENZILATE WITH 9
AMINO-7-METHOXYTETRAHYDROACRIDINE ON THE AFTER-DISCHARGES
IN THE LIMBIC SYSTEM.

002945 04-03

REGIONAL DIFFERENCES IN THE SENSITIVITY OF CHOLINERGIC NEURONS
TO DOPAMINERGIC DRUGS AND QUIPAZINE IN THE RAT STRIATUM.
000134 01-1

000134 01-03 EFFECT OF QUIPAZINE, A SEROTONIN-LIKE DRUG, ON STRIATAL CHOLINERGIC INTERNEURONES.

001114 02-03 DECREASE OF FOOD INTAKE BY QUIPAZINE IN THE RAT: RELATION TO SEROTONINERGIC RECEPTOR STIMULATION.

001235 02-03 DISCRIMINATIVE STIMULUS PROPERTIES OF QUIPAZINE.

001489 02-04
COMPARISON OF THE BEHAVIORAL EFFECTS OF P-CHLOROAMPHETAMINE, CHLORDIMEFORM, QUIPAZINE, AND INTRAVENTRICULAR SEROTONIN IN THE RAT

003331 04-04

QUIPAZINE-INDUCED
QUIPAZINE-INDUCED HEAD-TWITCH IN MICE.

000189 01-03

THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS.

NS-003-01
R-806-003-01 IN THE TREATMENT OF DEPRESSION: PLASMA LEVELS AND THERAPPEUTIC RESPONSE.

002376 03-07

STUDIES OF EXCRETION IN RABBIT MILK AFTER ADMINISTRATION OF CARBON-14 LABELLED AMITRIPTYLINE AND NORTRIPTYLINE.

000037 01-03 INFLUENCE OF DIAZEPAM, L-DOPA AND DOPAMINE ON THE CEREBELLAR AND SPINAL ELECTRICAL PATTERNS INDUCED BY HARMINE IN THE RABBIT.

EFFECTS OF VARIOUS NEUROLEPTICS ON RABBIT HYPERTHERMIA INDUCED BY N.N DIMETHYLTRYPTAMINE (DMT) AND D AMPHETAMINE.

THE ROLE OF THE SEPTAL NUCLEI IN THE RELEASE OF ACETYLCHOLINE FROM THE RABBIT CEREBRAL-CORTEX AND DORSAL HIPPOCAMPUS AND THE EFFECT OF ATROPINE. 000101 01-03

A COMPARISON IN RABBIT ISOLATED HEARTS OF THE DYSRHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE, MAPROTILINE AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK NORADREMALINE UPTAKE.

METABOLIC RESPONSES TO ISOPROTERENOL AND EPINEPHRINE IN THE RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES AND PRETREATMENT WITH PROPRANOLOL.

000227 01-03 SEROTONIN TRANSPORT AND STORAGE IN RABBIT BLOOD PLATELETS
THE EFFECTS OF RESERPINE AND IMPRAMINE.

000236 01-03 EFFECTS OF RESERPINE AND SEROTONIN ON ADENINE-NUCLEOTIDE METABOLISM AND GLUCOSE OXIDATION OF WASHED RABBIT PLATELETS.

002999 04-03

EFFECT OF RESERPINE ON ADENOSINE UPTAKE AND METABOLISM, AND SUBCELLULAR TRANSPORT OF PLATELET ADENOSINE-TRIPHOSPHATE IN WASHED RABBIT PLATFLETS

000238 01-03

INHIBITION OF PROSTAGLANDIN SYNTHETASE SYSTEM IN THE RABBIT RENAL MEDULLA BY PSYCHOTROPIC DRUGS. 000281 01-03 MIOSIS AND FLUCTUATION IN THE RABBIT PUPIL: EFFECTS OF MORPHINE

AND NALOXONE 000504 01-06 MOLINDONE: AN APOMORPHINE ANTAGONIST IN THE RABBIT

EFFECT OF PSYCHOTROPIC DRUGS ON ATPASE TRANSPORT OF THE SARCOPLASMIC RETICULUM IN RABBIT SKELETAL MUSCLES.

INFLUENCE OF CHLORPROMAZINE AND TRIFLUOPERAZINE ON NEURONS OF AN ISOLATED SLAB OF RABBIT CEREBRAL-CORTEX.

001205 02-03 ONSET AND OFFSET OF CHLORPROMAZINE BLOCKADE OF PHENYLEPHRINE, CARBAMYLCHOLINE AND HISTAMINE ON RABBIT STOMACH STRIPS

001234 02-03 REGIONAL LOCALIZATION OF C14-MESCALINE IN RABBIT BRAIN AFTER INTRAVENTRICULAR ADMINISTRATION: EFFECTS OF CHLORPROMAZINE

001240 02-03 THE INFLUENCE OF ELECTRICAL STIMULATION ON THE HIPPOCAMPAL UNITS ACTIVITY OF THE RABBIT.

001314 02-04 EFFECT OF D AMPHETAMINE ON LOCOMOTOR ACTIVITY OF LEAD FED RABBIT NEONATES

001406 02-04 LYSERGIC-ACID-DIETHYLAMIDE ANTAGONISM BY CHLORPROMAZINE, HALOPERIDOL, DIAZEPAM, AND PENTOBARBITAL IN THE RABBIT.

INTRAVENOUS COCAINE SELF-ADMINISTRATION IN THE RABBIT 001528 02-06 THE EFFECT OF BENZTROPINE-MESYLATE IN THE RABBIT SYNDROME AND

TARDIVE-DYSKINESIA.

EFFECTS OF BENZYDAMINE ON THE BIOELECTRIC ACTIVITY OF THE RABBIT

001998 03-03
EFFECTS OF BUTYROPHENONES ON THE SYMPATHETIC NERVES OF THE
ISOLATED RABBIT HEART AND ON THE POSTSYNAPTIC ALPHAADRENOCEPTORS OF THE ISOLATED RABBIT AORTA.

DOPAMINE-MIMETIC ACTIVITY OF ERGOT DERIVATIVES, AS MEASURE BY THE PRODUCTION OF CYCLIC-AMP IN ISOLATED RETINAE OF THE AS MEASURED

002149 03-03 NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION OF THE SYMPATHETIC NERVE OF THE EYE.

002802 04-03 DOPAMINE TURNOVER IN THE INTACT RABBIT BRAIN: EFFECT OF PENTOBARBITAL OR HALOPERIDOL.

002815 04-03 THE ACTION OF CNS DRUGS ON AN ISOLATED SYMPATHETIC NERVE PREPARATION OF RABBIT.

002869 04-03 THE NEURONAL ORIGIN OF PROSTAGLANDIN RELEASED FROM THE RABBIT PORTAL VEIN IN RESPONSE TO ELECTRICAL STIMULATION

002933 04-03 CHANGES IN SYNAPTIC FUNCTION INDUCED BY BLOCKAGE OF AXONAL TRANSPORT IN THE RABBIT OPTIC PATHWAY.

002952 04-03 CHARACTERIZATION OF ALPHA-ADRENERGIC AND BETA-ADRENERGI RECEPTORS IN MEMBRANES PREPARED FROM THE RABBIT IRIS BEFORE AND AFTER DEVELOPMENT OF SUPERSENSITIVITY.

LACK OF ENHANCEMENT OF DIMETHYLTRYPTAMINE FORMATION IN RAT BRAIN AND RABBIT LUNG IN VIVO BY METHIONINE OR S ADENOSYLMETHIONINE.

003102 04-03 EVIDENCE FOR DISTINCT SPINAL LOCOMOTION GENERATORS SUPPLYING RESPECTIVELY FORELIMBS AND HINDLIMBS IN THE RABBIT 003124 04-03

RABBITS CENTRALLY ACTIVE DRUGS AND THE SYMPATHETIC NERVOUS SYSTEM OF RABBITS AND CATS.

EFFECTS OF OROTIC-ACID AND PIRAZETAM ON CORTICAL BIOELECTRICAL **ACTIVITY IN RABBITS.**

000171 01-03 EEG AND BLOOD PRESSURE EFFECTS OF TRH IN RABBITS.

000319 01-04 SOME PHARMACOLOGICAL OBERVATIONS ON THE ANALGESIA INDUCED BY ACUPUNCTURE IN RABBITS. 001190 02-03

INCORPORATION OF RADIOACTIVE LABELLED CHOLINE AND PALMITATE INTO LUNG LECITHIN OF RABBITS TREATED WITH HIGH DOSES OF BROMCARBAMIDES, BARBITURATES AND DIAZEPAM.

001282 02-03 THE EFFECTS OF SOME PHARMACOLOGICAL AGENTS ON THE DURATION OF IMMOBILITY SHOWN BY RABBITS PLACED IN VARIOUS POSTURES 001355 02-04

PROSTAGLANDINS AND THE CARDIOTOXIC EFFECT OF DOXEPIN IN RABBITS AND GUINEA-PIGS.

PRODOPAMINERGIC EFFECT OF NARCOTIC ANTAGONISTS IN RABBITS PRETREATED WITH ANTIDOPAMINERGIC OR ANTISEROTONERGIC

002135 03-03 6 HYDROXYDOPAMINE INHIBITS SOME EFFECTS OF MESCALINE CENTRALLY ADMINISTERED TO RABBITS.

002231 03-04 EFFECT OF SOMATOSTATIN (SRIF) AND L GLUTAMATE ON NEURONS OF THE SENSORIMOTOR CORTEX IN AWAKE HABITUATED RABBITS.

SELECTIVE BLOCKADE OF DOPAMINE-INDUCED VASODILATION BY ERGONOVINE-MALEATE IN THE VASCULATURES OF DOGS AND RABBITS

003067 04-03 EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ, ANGIOTENSIN-II, AND SUBSTANCE-P ON MULTIPLE FIXED-INTERVAL FIXED-RATIO RESPONDING IN RABBITS.

003233 04-04 RACE TRICYCLIC PLASMA LEVELS: EFFECT OF AGE, RACE, SEX, AND SMOKING 002472 03-09

RACEMIC EFFECTS OF RACEMIC, (S)- AND (R) METHYLENEDIOXYAMPHETAMINE ON SYNAPTOSOMAL UPTAKE AND RELEASE OF TRITIATED

RADIATION PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: THE EFFECT OF PREMEDICATION WITH CYSTAMINE ON PHARMACODYNAMICS AND PHARMACOKINETICS OF NITRAZEPAM.

CHANGES IN PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECTS OF PREMEDICATION WITH CYSTAMINE ON DYNAMICS AND KINETICS OF THIORIDAZINE.

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC
DRUGS IN THE COURSE OF RADIATION DISEASE. EFFECT OF
PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF 002358 03-05

A RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION
OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF

INCORPORATION OF RADIOACTIVE LABELLED CHOLINE AND PALMITATE INTO LUNG LECITHIN OF RABBITS TREATED WITH HIGH DOSES OF BROMCARBAMIDES, BARBITURATES AND DIAZEPAM.

INCORPORATION, AFTER SINGLE AND REPEATED APPLICATION OF RADIOACTIVE LABELLED DH-ERGOT ALKALOIDS IN DIFFERENT ORGANS OF THE CAT, WITH SPECIAL REFERENCE TO THE BRAIN.

RADIOACTIVITY TISSUE DISTRIBUTION OF RADIOACTIVITY AFTER INJECTION OF C14-NITRAZEPAM IN YOUNG AND OLD RATS. 002948 04-03

DIRECT EXTRACTION RADIOASSAY FOR CATECHOL-O-METHYL-TRANSFERASE ACTIVITY. 003425 04-06

RADIOENZYMATIC RADIOENZYMATIC PAPER CHROMATOGRAPHIC ASSAY FOR DOPAMINE AND NOREPINEPHRINE IN CEREBROVENTRICULAR CISTERNAL PERFUSATE OF CAT FOLLOWING ADMINISTRATION OF COCAINE OR D

002862 04-03 MODIFICATION OF THE RADIOENZYMATIC ASSAY FOR THE **CATECHOLAMINES**

003431 04-06 SPECIFIC RADIOIMMUNOASSAY FOR AMITRIPTYLINE AND NORTRIPTYLINE IN PLASMA. 001534 02-06

SCREENING FOR THE EFFECTS OF DOPAMINERGIC AND	
ANTIDOPAMINERGIC DRUGS ON SERUM PROLACTIN LEY	VELS BY
RADIOIMMUNOASSAY.	

002340 03-05 A SPECIFIC RADIOIMMUNOASSAY PROCEDURE FOR PLASMA CLOMIPRAMINE.

002723 03-16 RADIOIMMUNOASSAY OF ENKEPHALINS: REGIONAL DISTRIBUTION IN RAT BRAIN AFTER MORPHINE TREATMENT AND HYPOPHYSECTOMY. 003136 04-03

003438 04-06

003439 04-06

DEVELOPMENT OF A SPECIFIC RADIOIMMUNOASSAY FOR ACETYLCHOLINE.

RADIOIMMUNOASSAYS
RADIOIMMUNOASSAYS FOR BETA-ENDORPHIN: COMPARISON OF
PROPERTIES OF TWO ANTISERA.

002724 03-16 THE STABILITY AND RELIABILITY OF RADIOIMMUNOASSAYS FOR CLONAZEPAM, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN BLOOD, SERUM OR PLASMA.

RADIOIODINE
BRAIN AND RETINA UPTAKE OF A RADIOIODINE LABELED
PSYCHOTOMIMETIC IN DOG AND MONKEY.

003075 04-03

THE EFFECTS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE ON THE IN VITRO UPTAKE OF RADIOLABELLED 5-HT AND NORADRENALINE INTO RAT BRAIN CORTICAL SLICES. 001257 02-03

A SIMPLE AND SENSITIVE RADIORECEPTOR ASSAY FOR ANTISCHIZOPHRENIC DRUGS IN BLOOD.

002715 03-16

RADIORESPIROMETRY
EVALUATION OF RADIORESPIROMETRY FOR THE DETERMINATION OF
MONOAMINE-OXIDASE ACTIVITY IN VIVO UTILIZING C11-OCTYLAMINE AS A SUBSTRATE 000116 01-03

METHADONE IN SCHIZOPHRENIC RAGE: A CASE STUDY. 002387 03-08

RAISED BRAIN GABA LEVELS, MOTOR ACTIVITY AND EXPLORATION IN THE RAT

000358 01-04 BEHAVIORAL AND PSYCHOPHARMACOLOGICAL CHARACTERISTICS OF RATS RAISED IN HIGH POPULATION DENSITY. 001472 02-04

RAMPANT
RAMPANT DENTAL CARIES IN THE TREATMENT OF DEPRESSION.
002648 03-15

RANDOM-INTERVAL
COMPARATIVE VALIDITY OF RANDOM-INTERVAL AND FIXED-INTERVAL URINALYSIS SCHEDULES.

002751 03-17 CYCLOBENZAPRINE AND BENZOTROPINE METHANESULFONATE IN PARKINSONS DISEASE: A RANDOMIZED DOUBLE-BLIND CROSS-OVER

000654 01-11 ELECTROCORTICAL CHANGES INDUCED BY THE PERFUSION OF NORADRENALINE, ACETYLCHOLINE AND THEIR ANTAGONISTS DIRECTLY INTO THE DORSAL RAPHE NUCLEUS OF THE CAT.

A SEROTONERGIC, MIDBRAIN RAPHE MODEL OF TONIC IMMOBILITY. 000291 01-03

ANTIDROMICALLY IDENTIFIED SEROTONERGIC NEURONS IN THE RAT MIDBRAIN RAPHE: EVIDENCE FOR COLLATERAL INHIBITION.

LACK OF TOLERANCE TO THE DEPRESSION OF RAPHE UNIT ACTIVITY BY LYSERGIC-ACID-DIETHYLAMIDE. 001262 02-03

SEROTONERGIC BASIS OF REWARD IN MEDIAN RAPHE OF THE RAT. 001421 02-04

EFFECTS OF MEDIAL RAPHE AND RAPHE MAGNUS LESIONS ON THE ANALGESIC ACTIVITY OF MORPHINE AND METHADONE. 001986 03-03

EFFECT OF MORPHINE INJECTED IN PERIAQUEDUCTAL GRAY ON THE ACTIVITY OF SINGLE UNITS IN NUCLEUS RAPHE MAGNUS OF THE RAT 002817 04-03 THE EFFECT OF LITHIUM ON THE INCREASE IN FOREBRAIN 5
HYDROXYINDOLEACETIC-ACID PRODUCED BY RAPHE STIMULATION

002871 04-03
NEUROPHARMACOLOGICAL STUDIES ON THE NIGROSTRIATAL AND RAPHE STRIATAL SYSTEM IN THE RAT

O02882 04-03

EFFECTS OF PAIN ATTENUATING BRAIN STIMULATION AND MORPHINE ON ELECTRICAL ACTIVITY IN THE RAPHE NUCLEI OF THE AWAKE RAT. O03034 04-03

RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF BIOLOGICAL FLUID OR TISSUE.

CANNABIS, CATECHOLAMINES, RAPID EYE MOVEMENT SLEEP AND AGGRESSIVE BEHAVIOUR. 001320 02-04

RAPID CYCLING MANIC-DEPRESSIVE PATIENTS.

VILOXAZINE: ASSESSMENT OF POTENTIAL RAPID ANTIDEPRESSANT

001584 02-09 RAPID IDENTIFICATION OF HYPNOTICS IN EMERGENCY CASES BY COMPUTERIZED GAS-CHROMATOGRAPHY MASS SPECTROMETRY

001841 02-15 RAPID TOLERANCE TO THE MOTOR EFFECTS OF P-CHLOROAMPHETAMINE 002226 03-04

PSYCHOSIS: A RARE MANIFESTATION OF DIGOXIN INTOXICATION. 002700 03-15

POLYAMINE BIOSYNTHESIS IN RAT PROSTATE. SUBSTRATE AND INHIBITOR PROPERTIES OF 7 DEAZA ANALOGUES OF DECARBOXYLATED S ADENOSYLMETHIONINE AND 5 METHYLTHIOADENOSINE.

BICYCLIC PHOSPHORUS ESTERS INCREASE THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM.

BETA-ENDORPHIN INHIBITS ACH TURNOVER IN NUCLEI OF RAT BRAIN. EFFECTS OF METHYLPHENIDATE ON AVOIDANCE LEARNING IN THE AGED

000020 01-02 LEVELS OF CHLORPROMAZINE AND ITS ACTIVE MATABOLITES IN RAT BRAIN AND THE RELATIONSHIP TO CENTRAL MONOAMINE METABOLISM AND PROLACTIN SECRETION.

000041 01-03 BRAIN SEROTONIN TURNOVER AND MORPHINE-TOLERANCE DEPENDENCE INDUCED BY MULTIPLE INJECTIONS IN THE RAT.

000055 01-03 STEREOSPECIFIC ACTIONS OF MORPHINE ON SINGLE NEURONES IN THE BRAINSTEM OF THE RAT.

000060 01-03 EFFECTS OF REPEATED ADMINISTRATION OF MORPHINE ON TYROSINE-HYDROXYLASE IN THE RAT BRAIN.

000062 01-03 ABSORPTION AND METABOLISM OF THE PHENOTHIAZINE DRUG PERAZINE IN THE RAT INTESTINAL LOOP.

000063 01-03 MORPHINE AND 5 HYDROXYTRYPTAMINE INTERACTIONS IN RAT HYPOTHALAMUS AND PINEAL BODY.

000065 01-03 THE METABOLIC FATE OF C14-PHENOBARBITONE IN THE RAT AND THE EFFECT OF CHRONIC ADMINISTRATION AND DOSE SIZE.

000067 01-03 PHASIC ACTIVITY IN THE RAT.

000070 01-03 REGULATION OF CATECHOLAMINE BIOSYNTHESIS IN A TRANSPLANTABLE RAT PHEOCHROMOCYTOMA.

000071 01-03 **REGULATION OF NIGROSTRIATAL DOPAMINERGIC NEUROTRANSMISSION**

000100 01-03 EFFECTS OF APOMORPHINE AND CLONIDINE ON RAT PLASMA GROWTH HORMONE AFTER PRETREATMENT WITH RESERPINE AND ELECTROCONVULSIVE SHOCKS.

000102 01-03 THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON BODY
TEMPERATURE AND BRAIN AMINE CONCENTRATIONS IN THE RAT AT
DIFFERENT AMBIENT TEMPERATURES.

000105 01-03 THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN THE RA 000106 01-03

STRAIN DIFFERENCES IN THE RESPONSE TO MORPHINE ON INCORPORATION OF H3-LYSINE INTO RAT BRAIN PROTEIN 000108 01-03

FURTHER STUDIES ON THE EFFECTS OF N CYCLOPROPYL P-CHLOROAMPHETAMINE IN RAT BRAIN.

LOWERING OF EPINEPHRINE CONCENTRATION IN RAT BRAIN BY 2,3 DICHLORO-ALPHA-METHYL-BENZYLAMINE, AN INHIBITOR OF NOREPINEPHRINE-N-METHYLTRANSFERASE.

000112 01-03 BIPHASIC EFFECTS OF M CHLOROPHENYL-PIPERAZINE IN 3,4
DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN RAT BRAIN

000113 01-03 THE METABOLISM OF D-, L- AND DL-METHADONE IN THE ISOLATED PERFUSED RAT LIVER.

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON A MG2-ATPASE OF SYNAPTIC VESICLES PREPARED FROM RAT CEREBRAL-

000123 01-03
INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE 000127 01-03

REGIONAL DIFFERENCES IN THE SENSITIVITY OF CHOLINERGIC NEURONS TO DOPAMINERGIC DRUGS AND QUIPAZINE IN THE RAT STRIATUM 000134 01-03 N.N DIMETHYLTRYPTAMINE LOWERS RAT BRAIN ACETYLCHOLINE AND

000140 01-03

RELATIONSHIP BETWEEN THE UPTAKE OF 3H-(PLUS OR MINUS) METARAMINOL AND THE DENSITY OF ADRENERGIC INNERVATION IN

000142 01-03

CONTROL OF THE RELEASE OF NEWLY SYNTHESIZED H3-5-HYDROXYTRYPTAMINE BY NICOTINIC AND MUSCARINIC RECEPTORS IN RAT HYPOTHALAMIC SLICES.

000144 01-03 INFLUENCE OF CHRONIC PENTOBARBITAL OR MORPHINE TREATMENT ON THE INCORPORATION OF P32-PHOSPHORIC-ACID AND 3H CHOLINE INTO RAT SYNAPTIC PLASMA MEMBRANES.

000147 01-03 EFFECTS OF MORPHINE AND HALOPERIDOL ON THE ELECTRICAL ACTIVITY

000154 01-03 EFFECTS OF ORG-6582, CHLORIMIPRAMINE AND DESMETHYLIMIPRAMINE ON THE DEPLETION OF BIOGENIC AMINES FROM THE RAT BRAIN IN

OF RAT NIGROSTRIATAL NEURONS

CHLORPROMAZINE INDUCES POPULATION INCREASE OF SYNAPTIC VESICLES IN THE RAT HYPOTHALAMIC VENTROMEDIAL NUCLEUS

000160 01-03 CATECHOLAMINE SYNTHESIS IN RAT BRAIN AFTER AXOTOMY

INTERACTION BETWEEN APOMORPHINE AND HALOPERIDOL 000161 01-03 THE ACTIONS OF CHOLINOMIMETICS AND CATECHOLAMINES ON RAT

SUBSTANTIA-NIGRA NEURONES. 000163 01-03 DIFFERENTIAL EFFECTS OF RESERPINE AND TETRABENAZINE ON RAT

STRIATAL SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS AND SYNAPTOSOMAL DOPAMINE POOLS. 000172 01-03

SPECIFIC ACTION OF NARCOTICS ON REFLEX ACTIVATION OF RAT ALPHA-MOTONEURONES

000174 01-03 EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT BRAIN: A QUANTITATIVE HISTOLOGICAL STUDY

000184 01-03 ON THE PHARMACOLOGY OF THE KETAMINE ENANTIOMORPHS IN THE

000193 01-03 VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF 2

AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF NAD:NADH AND NORELEAGNINE A BETA-CARBOLINE DERIVATIVE 000200 01-03

DIFFERENTIAL EFFECTS OF OPIATES ON THE INCORPORATION OF C14-THIAMINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT 000201 01-03

THE SYMPATHOMIMETIC ACTIVITY OF FENFLURAMINE HYDROCHLORIDE ON RAT VAS-DEFERENS

000205 01-03 HIGH-AFFINITY BINDING OF H3-GLYCINE AND C14-BETA-ALANINE TO SYNAPTOSOMAL MITOCHONDRIAL FRACTIONS OF RAT CNS REGIONS; *FFFFCTS OF STRYCHNINE*

000211 01-03 EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT BRAIN: A BIOCHEMICAL STUDY.

000216 01-03 POTENTIATION BY COCAINE OF THE STIMULUS-INDUCED INCREASE IN DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL SYNAPTOSOMES

000217 01-03 NEUROLEPTIC DRUG INTERACTIONS WITH NOREPINEPHRINE ALPHA RECEPTOR BINDING SITES IN RAT BRAIN.

000219 01-03 PERSISTENT EFFECTS OF REPEATED INJECTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE ON RAT BRAIN 5 HYDROXYTRYPTAMINE AND 5 HYDROXYINDOLFACETIC-ACID LEVELS

000221 01-03

SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION: A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL MEMBRANES FROM MATURE RAT BRAIN.

EFFECTS OF AMPHETAMINE, METHYLPHENIDATE AND COCAINE ON SERUM PROLACTIN CONCENTRATIONS IN THE MALE RAT.

000234 01-03 MAO ACTIVITY IN RAT BRAINSTEM AND CEREBRAL-CORTEX FOLLOWING ACUTE AND CHRONIC TREATMENT WITH L-DOPA AND ETHANOL L-

000239 01-03 DOPAMINE SELECTIVELY INCREASES H3-GABA RELEASE FROM SLICES OF RAT SUBSTANTIA-NIGRA IN VITRO

THE METABOLISM OF A SUBSTITUTED AMINOACETAMIDOBENZOPHENONE
AND CYCLIZATION TO THE CORRESPONDING BENZODIAZEPINE IN THE

EFFECT OF ALTERATION OF METABOLISM ON THE ANALGESIC ACTIVITY,
TOXICITY, DISTRIBUTION AND EXCRETION OF L-ALPHAACETYLMETHADOL IN THE RAT.

000245 01-03 POTENTIATION BY RESERVINE OF THE INHIBITION BY AMPHETAMINE OF (3H)DOPAMINE ACCUMULATION IN THE RAT STRIATUM.

000246 01-03 AGONIST EFFECTS OF BETA-PHENYLETHYLAMINES ON THE NORADRENERGIC CYCLIC-ADENOSINE-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. 3,5-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. STEREOISOMERS OF P-HYDROXYNOREPHEDRINE

000272 01-03 EFFECTS OF PHENCYCLIDINE ON (3H)CATECHOLAMINE AND (3H) SEROTONIN UPTAKE IN SYNAPTOSOMAL PREPARATIONS FROM

TRANS-SYNAPTIC INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE FOLLOWING AMPHETAMINE TREATMENT IN THE RAT.

TYRAMINE BINDING BY SYNAPTOSOMES FROM RAT BRAIN: EFFECT OF CENTRALLY ACTIVE DRUGS

THE EFFECTS OF ETHER STRESS AND BETAMETHASONE TREATMENT ON THE CONCENTRATIONS OF NORADRENALINE AND DOPAMINE IN VARIOUS REGIONS OF THE RAT BRAIN

000288 01-03 ANTIDROMICALLY IDENTIFIED SEROTONERGIC NEURONS IN THE RAT MIDBRAIN RAPHE: EVIDENCE FOR COLLATERAL INHIBITION.

000292 01-03 EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON SEROTONIN UPTAKE INTO RAT HYPOTHALAMIC SYNAPTOSOMES.

000293 01-03 INTERFERENCE BY FENFLURAMINE WITH THE STORAGE OF C14-5 HYDROXYTRYPTAMINE IN RAT PLATELETS.

DOPAMINE RECEPTORS IN RAT STRIATUM AND NUCLEUS-ACCUMBENS; CONFORMATIONAL STUDIES USING RIGID ANALOGUES OF DOPAMINE. 000301 01-03

EFFECT OF COCAINE AND DESMETHYLIMIPRAMINE ON THE UPTAKE, RETENTION AND METABOLISM OF H3-5-HYDROXYTRYPTAMINE IN RAT

000305 01-03 OPEN-FIELD BEHAVIOR AND GROSS MOTOR DEVELOPMENT IN OFFSPRING OF NURSING RAT MOTHERS GIVEN PENFLURIDOL

000307 01-04 REACTIVITY AND AGGRESSION IN THE RAT: INDUCTION BY ALPHA-ADRENERGIC BLOCKING AGENTS INJECTED VENTRAL TO ANTERIOR SEPTUM BUT NOT INTO LATERAL SEPTUM.

000309 01-04 THE EFFECTS OF DL-P-CHLOROPHENYLALANINE ON LEARNED

HELPLESSNESS IN THE RAT. 000311 01-04 DEFICITS IN PASSIVE AVOIDANCE LEARNING FOLLOWING ATROPINE IN THE DEVELOPING RAT.

PSILOCYBIN: BIPHASIC DOSE-RESPONSE EFFECTS ON THE ACOUSTIC STARTLE REFLEX IN THE RAT

SPECIFICITY OF LEARNING DEFICITS PRODUCED BY MICROINJECTIONS OF 6-OHDA INTO THE NIGROSTRIATAL SYSTEM OF THE RAT.

CARBACHOL ELICITED MOUSE-KILLING IN THE RAT: ANIMALS ATTACKED AND WOUND LOCATION.

000349 01-04 THE EFFECTS OF LYSERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE FEMALE RAT

000353 01-04 RAISED BRAIN GABA LEVELS, MOTOR ACTIVITY AND EXPLORATION IN THE RAT

001129 02-03

DISCRIMINATIVE EFFECTS OF NARCOTIC AGONISTS AND ANTAGONISTS IN

LSD AND D AMPHETAMINE EFFECTS ON FIXED-INTERVAL RESPONDING IN THE RAT.

FURTHER EVIDENCES ON THE BEHAVIOURAL EFFECTS OF SELECTIVE A-10 DOPAMINERGIC MESENCEPHALO-CORTICO-LIMBIC GROUP LESION IN THE RAT.

A COMPARATIVE STUDY OF DIFFERENT AMPHETAMINES ON COPULATORY BEHAVIOR AND STEREOTYPE ACTIVITY IN THE FEMALE RAT.

RECOVERY OF AMNESTIC EFFECT OF ALPHA-AMANITIN BY POSTTRAINING ADMINISTRATION OF D AMPHETAMINE IN THE RAT.

AMPHETAMINE EFFECTS ON BRAIN SLOW POTENTIALS ASSOCIATED WITH DISCRIMINATION IN THE RAT. 000432 01-04

DOSE-RESPONSE AND TIME-COURSE EFFECTS OF N,N
DIMETHYLTRYPTAMINE ON DISRUPTION OF RAT SHUTTLE-BOX
AVOIDANCE.

POTENTIATION OF THE BEHAVIORAL AND CONVULSANT EFFECTS OF COCAINE BY CHRONIC ADMINISTRATION IN THE RAT.

OLFACTORY BULB ABLATION IN THE RAT: BEHAVIOURAL CHANGES AND THEIR REVERSAL BY ANTIDEPRESSANT DRUGS.

ACTH-INDUCED EXCESSIVE GROOMING IN THE RAT: LATENT ACTIVITY OF

PLASMA CONCENTRATIONS AND CARDIOTOXIC EFFECTS OF DESIPRAMINE AND PROTRIPTYLINE IN THE RAT.

HALOPERIDOL: EFFECT OF LONG-TERM TREATMENT ON RAT STRIATAL DOPAMINE SYNTHESIS AND TURNOVER.

EFFECT OF CHLORPROMAZINE ON L METHIONINE TRANSPORT IN THE RAT

000489 01-05 THE SUBCELLULAR DISTRIBUTION OF PARTICLE-BOUND NEGATIVE CHARGES IN RAT BRAIN.

PHARMACOKINETICS OF METHYLPHENIDATE IN THE RAT USING SINGLE ION MONITORING GLC MASS SPECTROMETRY.

000498 01-06 IDENTIFICATION OF M HYDROXYAMPHETAMINE AS A METABOLITE OF AMPHETAMINE IN THE RAT.

GAS-CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY OF SEROTONIN IN RAT SUPERIOR CERVICAL GANGLIA: EFFECTS OF NERVE GROWTH FACTOR AND 6 HYDROXYDOPAMINE.

001006 02-01 EFFECTS OF BRAIN LESIONS AND ATROPINE ON HIPPOCAMPAL AND NEOCORTICAL ELECTROENCEPHALOGRAMS IN THE RAT.

001033 02-02 STIMULATION OF CAFFEINE METABOLISM IN THE RAT BY 3 METHYLCHOLANTHRENE.

001044 02-03 **AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT** BRAIN. III. THE TELENCEPHALON.

001048 02-03 FIRST-PASS ELIMINATION OF C14-IMIPRAMINE IN ISOLATED PERFUSED RAT LIVER.

001052 02-03 PHARMACOLOGICAL IMPLICATIONS OF BRAIN ACETYLCHOLINE TURNOVER MEASUREMENTS IN RAT BRAIN NUCLEI.

THE EFFECT OF MELPERONE (BURONIL(R)) AND ITS METABOLITE FG-5155 ON THE CYCLIC-GMP LEVEL IN RAT CEREBELLUM COMPARED TO SOME OTHER NEUROLEPTICS.

ELECTROPHYSIOLOGICAL EVIDENCE FOR A DOPAMINERGIC ACTION OF LSD: DEPRESSION OF UNIT ACTIVITY IN THE SUBSTANTIA-NIGRA OF THE RAT.

PROGRAMMED FEEDING AS A MODEL OF CHRONIC ALCOHOLISM IN THE

001087 02-03 AGE-RELATED EFFECTS OF RESERPINE ON BEHAVIOR AND ON REGIONAL CATECHOLAMINE UPTAKE AND RELEASE IN THE RAT. (PH.D.

EFFECT OF CHRONIC LEVODOPA ON VITAMIN-B6 METABOLISM IN DISCRETE REGIONS OF RAT BRAIN.

EFFECTS OF NALOXONE FOLLOWING A SINGLE ADMINISTRATION OF LEVORPHANOL-TARTRATE IN THE NAIVE RAT.

POSSIBLE PHYSIOLOGICAL SIGNIFICANCE OF THE INITIAL STEP IN THE CATABOLISM OF NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF THE RAT.

INFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3-CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN.

001119 02-03 INTERACTION BETWEEN NARCOTIC ANTAGONIST (NALOXONE) AND LYSERGIC-ACID-DIETHYLAMIDE (LSD) IN THE RAT.

001120 02-03 STUDIES OF A PHARMACOLOGICAL MODEL OF ETHANOL DEPENDENCE IN 001125 02-03

METABOLISM OF FENFLURAMINE TO M
TRIFLUOROMETHYLBENZOYLGLYCINE IN RAT BRAIN

001127 02-03 DISTRIBUTION OF CLOZAPINE IN THE RAT: EVIDENCE FOR ACTIVE TRANSPORT IN LUNG.

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE CONTENT AND
METABOLISM OF DOPAMINE IN THE RAT STRIATUM. 001133 02-03

ACTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND ITS DERIVATIVES ON 5 HYDROXYTRYPTAMINE RECEPTORS IN THE ISOLATED UTERINE SMOOTH MUSCLE OF THE RAT.

STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT BRAIN TISSUE SLICES.

BIOCHEMICAL DIFFERENTIATION OF AGGREGATING CELL CULTURES OF DIFFERENT FETAL RAT BRAIN REGIONS.

001148 02-03 NALTREXONE BLOCKADE OF MORPHINE-INDUCED ANTIDIURESIS IN THE

MECHANISMS OF AMITRIPTYLINE-INDUCED HYPOTHERMIA IN THE RAT. 001176 02-03

EFFECTS OF REPEATED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS ON ADIPOSE TISSUE LIPOLYTIC ACTIVITY IN THE RAT.

001179 02-03 EFFECT OF CHRONIC NEUROLEPTIC OR L-DOPA ADMINISTRATION ON GABA LEVELS IN THE RAT SUBSTANTIA-NIGRA.

001181 02-03 RESTRAINT ALTERS THE EFFECTS OF MORPHINE AND HEROIN ON CORE
TEMPERATURE IN THE RAT.

001186 02-03 EFFECTS OF DELTAY-TETRAHYDROCANNABINOL ON SERUM THYROXINE CONCENTRATIONS IN THE RAT.

001204 02-03 THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LOCAL CEREBRAL GLUCOSE UTILISATION OF THE RAT.

001206 02-03 UPTAKE AND METABOLISM OF INTRAVENTRICULARLY ADMINISTERED PIPERIDINE AND ITS EFFECTS ON SLEEP AND WAKEFULNESS IN THE RAT.

001208 02-03 ACTION OF AZABUTYRONE AND ITS ANALOGS ON CATECHOLAMINE METABOLISM IN RAT BRAIN.

001218 02-03 EFFECT OF NOMIFENSINE AND OTHER ANTIDEPRESSANT DRUGS ON ACETYLCHOLINE TURNOVER IN VARIOUS AREAS OF RAT BRAIN.

001225 02-03 THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE NOREPINEPHRINE TURNOVER IN RAT BRAIN REGIONS.

001227 02-03 THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS ON MHPG-SO4 IN RAT BRAIN.

001228 02-03 DECREASE OF FOOD INTAKE BY QUIPAZINE IN THE RAT: RELATION TO SEROTONINERGIC RECEPTOR STIMULATION.

001235 02-03 BIOCHEMICAL AND PHARMACOLOGICAL STUDIES ON AMINEPTINE (S-1694) AND () AMPHETAMINE IN THE RAT.

001236 02-03 EFFECTS THE HYPNOTICS AND ANTIANXIETY DRUGS ON ACETYLCHOLINE (ACH) CONCENTRATIONS IN DISCRETE AREAS OF THE RAT BRAIN. 001239 02-03

THE INCREASE IN S ADENOSYL-L-METHIONINE (SAME) CONCENTRATION IN RAT BRAIN AFTER ITS SYSTEMATIC ADMINISTRATION.

001253 02-03 THE EFFECT OF DIHYDROERGOTOXINE ON THE ADENYLATE-CYCLASE ACTIVITY IN HOMOGENATES OF RAT CEREBRAL-CORTEX.

001254 02-03

001110 02-03

THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF THE MEDULLA-OBLONGATA IS A HIGHLY SENSITIVE SITE IN THE PRODUCTION OF

THE EFFECTS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE ON THE IN VITRO UPTAKE OF RADIOLABELLED 5-HT AND NORADRENALINE INTO PAT BRAIN CORTICAL SLICES

001257 02-03 INDUCIBLE ALDEHYDE-DEHYDROGENASES IN THE HEPATIC CYTOSOL OF THE RAT

001261 02-03 CYCLIC-GMP AND GABA LEVELS IN RAT STRIATUM AND CEREBELLUM DURING MORPHINE WITHDRAWAL: EFFECT OF APOMORPHINE

001274 02-03 URINARY 3 METHOXY-4-HYDROXYPHENYLGLYCOL, AN INDEX OF PERIPHERAL RATHER THAN CENTRAL ADRENERGIC ACTIVITY IN THE

001277 02-03 EFFECT OF TWO NON TRICYCLIC ANTIDEPRESSANT DRUGS ON C14-5 HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS

001283 02-03 EFFECTS OF THE ISOMERIC FORMS OF PROPRANOLOL ON CENTRAL MONOAMINE METABOLISM IN REGIONS OF RAT BRAIN

001284 02-03 EFFECTS OF ANTINOCICEPTIVE DRUGS ON THE DORSAL ROOT POTENTIAL IN THE RAT

001285 02-03 CIRCADIAN VARIATIONS IN RESPONSES TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT

001288 02-03 CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIVITY TO THE DIRECT APPLICATION OF MORPHINE AND FOCAL ELECTRICAL STIMULATION IN THE PRODUCTION OF ANTINOCICEPTION IN THE RAT.

PHARMACOKINETICS OF SOME HOMOLOGOUS SERIES OF BARBITURATES IN THE INTACT RAT AND IN THE ISOLATED PERFUSED RAT LIVER.

SPECIFICITY OF AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE AND SEROTONIN FROM RAT BRAIN IN VITRO.

001294 02-03 DRUGS AND THE PRODUCTION OF TEMPORAL INTERVALS IN THE RAT. 001299 02-04

ETORPHINE AND SHUTTLE-BOX SELF-STIMULATION IN THE RAT 001304 02-04 WET-DOG SNAKE BEHAVIOUR IN THE RAT: A POSSIBLE QUANTITATIVE MODEL OF CENTRAL 5 HYDROXYTRYPTAMINE ACTIVITY.

001310 02-04 THE EFFECT OF AMPHETAMINE AND L-DOPA ON TETRABENAZINE-INDUCED SUPPRESSION OF INTRACRANIAL SELF-STIMULATION IN THE RAT.

001321 02-04 A COMPARISON OF THE EFFECTS OF INTRAVENTRICULAR MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON OPERANT BEHAVIOR IN

001323 02-04 CONTROL OF THE RAT OLFACTORY BULB ACTIVITY INDUCED BY BIOLOGICALLY SIGNIFICANT ODORS.

001324 02-04 HEAD-SHAKE DISTRIBUTIONS DURING SELF-MAINTAINED DEPENDENCE ON MORPHINE, METHADONE, AND L-ALPHA-ACETYLMETHADOL (LAAM) IN

THE RAT 001328 02-04

DIFFERENTIAL ACTIVATION BY SOME 2 AMINOTETRALIN DERIVATIVES OF THE RECEPTOR MECHANISMS IN THE NUCLEUS-ACCUMBENS OF RAT WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITING. 001335 02-04 EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION: AMPHETAMINE LEVELS AND EFFECTS UPON SOME ARYLALKYLAMINES IN RAT BRAIN.

001339 02-04 ENHANCEMENT OF SEXUAL BEHAVIOR IN THE FEMALE RAT BY NICOTINE. 001360 02-04

THE EFFECTS OF D AMPHETAMINE ON PREY KILLING AND PREY EATING 001361 02-04

SLOW-WAVE SLEEP AND A STATE RESEMBLING ABSENCE EPILEPSY INDUCED IN THE RAT BY GAMMA-HYDROXYBUTYRATE 001366 02-04

THE PHARMACOLOGICAL EFFECTS OF FETAL AND NEONATAL EXPOSURE TO NALTREXONE IN THE RAT 001373 02-04

EFFECTS OF MORPHINE AND NALTREXONE ON SEXUAL BEHAVIOUR ON

001377 02-04 EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE INTOXICATION ON EXPLORATORY AND STEREOTYPED BEHAVIORS IN THE RAT. 001379 02-04

ACQUISITION AND EXTINCTION OF OPERANT RESPONDING FOR INTRAVENOUS INJECTIONS OF FENTANYL IN THE RAT 001397 02-04 MORPHINE AND SHUTTLE-BOX SELF-STIMULATION IN THE RAT: A MODEL FOR FUPHORIA

DIFFERENTIAL EFFECTS OF MORPHINE AND D AMPHETAMINE ON SELF
STIMULATION FROM CLOSELY ADJACENT REGIONS IN RAT MIDBRA 001403 02-04

INFLUENCE OF BETA-ENDORPHIN ON EXPLORATORY, SOCIAL AND SEXUAL BEHAVIOUR IN THE MALE RAT. 001418 02-04

SEROTONERGIC BASIS OF REWARD IN MEDIAN RAPHE OF THE RAT.

O01421 02-04

THE EFFECTS OF HORMONES AND MORPHINE ON BOTH ANALGESIA AND

THE LORDOSIS RESPONSE PRODUCED BY CERVICAL PROBING IN THE

FFMAIF RAT

PASSIVE AVOIDANCE LEARNING IN THE RAT AS FUNCTIONS OF D
AMPHETAMINE DOSAGE AND SHOCK INTENSITY.

CLONIDINE SELF-ADMINISTRATION IN THE RAT: A COMPARISON WITH FENTANYL SELF-ADMINISTRATION.

THE INFLUENCE OF PROGESTERONE ON THE INHIBITORY EFFECT OF SERGIC-ACID-DIETHYLAMIDE ON COPULATORY BEHAVIOUR IN THE FEMALE RAT

001463 02-04
EEG AND BEHAVIORAL EFFECTS OF D ALA2-MET-ENKEPHALINAMIDE IN THE RAT

001476 02-04 TWO DOPAMINE RECEPTORS: SUPPORTIVE EVIDENCE WITH THE RAT ROTATIONAL MODEL.

001478 02-04
BARBITAL-INDUCED TOLERANCE AND CROSS-TOLERANCE TO VARIOUS CNS DEPRESSANTS ON RAT OPERANT BEHAVIOR

PERIPHERAL CATECHOLAMINES RELEASED BY OXOTREMORINE MODULATE TREMOR IN THE RAT. (UNPUBLISHED PAPER).

DOSE-RESPONSE EFFECTS OF ALCOHOL UPON RAT STRAINS BRED FOR DIFFERENCES IN REACTIVITY TO ALCOHOL

001498 02-04 METHYLPHENIDATE, AMYGDALECTOMY AND ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.

001500 02-04 FENFLURAMINE: CUMULATIVE NEUROTOXICITY AFTER CHRONIC TREATMENT WITH LOW DOSAGES IN THE RAT.

THE DEVELOPMENTAL EFFECTS OF MORPHINE-SULFATE AND NALOXONE-

HYDROCHLORIDE IN THE RAT. 001510 02-05 DELTA9-TETRAHYDROCANNABINOL AND DIMETHYLHEPTYLPYRAN

INDUCED TACHYCARDIA IN THE CONSCIOUS RAT.

EFFECT OF AGE AND ROUTE OF ADMINISTRATION ON LD50 OF LITHIUM-CHLORIDE IN THE RAT.

001517 02-05 FLUCTUATING DENTAL ASYMMETRY AS AN INDICATOR OF THE STRESSFUL PRENATAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL

IN THE LAROPATORY PAT EFFECTS OF IFC-45, A NEW BENZONAPHTYRIDONE DERIVATIVE WITH ANTIDEPRESSIVE ACTION, ON ACTIVITY OF THE RAT SUPRARENAL

001522 02-05 ETHANOL -- ITS NEPHROTOXIC EFFECT IN THE RAT.

001523 02-05
EFFECT OF LITHIUM-CHLORIDE ON THE NEUROSECRETORY SYSTEM OF THE RAT HYPOTHALAMUS

SOMATOSTATIN: ELECTRON MICROSCOPE IMMUNOHISTOCHEMICAL LOCALIZATION IN SECRETORY NEURONS OF RAT HYPOTHALAMUS. O01948 03-01 BLOCKADE OF PRESYNAPTIC ALPHA-RECEPTORS AND OF AMINE UPTAKE IN THE RAT BRAIN BY THE ANTIDEPRESSANT MIANSERINE.

APOMORPHINE INCREASES GLUCOSE UTILIZATION IN THE SUBSTANTIA-NIGRA, SUBTHALAMIC NUCLEUS AND CORPUS-STRIATUM OF RAT. 001976 03-03

EFFECT OF DIAZEPAM ON PULSE ACTIVITY OF NEURONS OF THE SENSORIMOTOR AND OPTIC AREAS OF THE RAT CEREBRAL-CORTEX 001978 03-03

DIFFERENT EFFECTS OF METHIONINE-ENKEPHALIN AND D ALA2-METHIONINE-ENKEPHALINAMIDE ON THE METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN: FACT OR ARTIFACT?.

EFFECTS OF MAZINDOL, FENFLURAMINE AND CHLORIMIPRAMINE ON THE 5 HYDROXYTRYPTAMINE UPTAKE AND STORAGE MECHANISMS IN RAT BRAIN: SIMILARITIES AND DIFFERENCES.

IN VIVO EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE IN RAT BRAIN

- H3-HALOPERIDOL BINDING TO DOPAMINE RECEPTORS IN RAT CORPUS-STRIATUM: INFLUENCE OF CHLORPROMAZINE METABOLITES AND DERIVATIVES.
- IN VITRO EFFECTS OF DESMETHYLIMIPRAMINE ON THE UPTAKE AND METABOLISM OF H3-NOREPINEPHRINE IN RAT BRAIN SLICES. 001997 03-03
- THE INFLUENCE OF DIHYDROERGOTOXINE-MESYLATE ON THE LOW-KM PHOSPHODIESTERASE OF CAT AND RAT BRAIN IN VITRO. 002008 03-03
- EFFECT OF ANTIPARKINSONISM DRUGS ON GASTRIC EMPTYING AND INTESTINAL TRANSIT IN THE RAT.
- 002010 03-03 EFFECT OF MATERNAL MORPHINE ADMINISTRATION ON FETAL AND NEONATAL RAT LIVER TYROSINE-AMINOTRANSFERASE.
- STUDIES ON THE ROLE OF FOREBRAIN CATECHOLAMINE NEURONS IN EXPLORATORY BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
- 002012 03-03 INHIBITION BY NEUROLEPTICS OF UPTAKE OF H3-GABA INTO RAT BRAIN SYNAPTOSOMES.
- DIHYDROERGOTOXINE-INDUCED MODULATION OF SPONTANEOUS ACTIVITY OF CULTURED RAT PURKINJE CELLS.
- CATALEPSY INDUCED BY INTRASTRIATAL INJECTIONS OF DELTA9-THC AND 11 OH-DELTA9-THC IN THE RAT.
- 002027 03-03 STEREOSELECTIVITY IN THE METABOLISM OF H3-NORADRENALINE DURING UPTAKE INTO AND EFFLUX FROM THE ISOLATED RAT VAS-
- 002028 03-03
 BETA-ADRENERGIC RECEPTOR MEDIATED CYCLIC-AMP SYNTHESIS IN
 BROKEN-CELL HOMOGENATES OF RAT BRAIN.
- STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAM AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES. DOPAMINE (DA)
- 002036 03-03 THE EFFECTS OF LITHIUM ON ATPASE ACTIVITY IN SUBCELLULAR FRACTIONS FROM RAT BRAIN.
- 002038 03-03 THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON DOPAMINE METABOLISM IN RAT STRIATUM.
- 002039 03-03 DOES LONG-TERM TREATMENT WITH AMITRIPTYLINE ALTER THE MONOAMINE-OXIDASE OF RAT BRAIN?.
- RAT BRAIN ARYLACYLAMIDASE: MULTIPLE FORMS AND INHIBITION EFFECTS OF LSD, SEROTONIN AND RELATED COMPOUNDS.
- 002044 03-03 STUDIES ON THE SUBSYNAPTOSOMAL DISTRIBUTION OF PSYCHOTROPIC DRUGS IN RAT CEREBRAL-CORTEX.
- 002045 03-03 EFFECT OF LITHIUM-CHLORIDE ON ADRENOCORTICAL FUNCTION IN THE RAT.
- 002049 03-03 3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE LEVELS IN RAT CEREBELLUM: EFFECTS OF MORPHINE, KETAMINE, HARMALINE AND ISONIAZID.
- 002056 03-03 ACTION OF NOREPINEPHRINE ON MICROCIRCULATION AND PO2 DISTRIBUTION IN THE ISOLATED PERFUSED RAT LIVER.
- 002059 03-03 EFFECTS OF DIAZEPAM ON DOPAMINE TURNOVER IN NEOSTRIATAL AND LIMBIC REGIONS OF THE RAT BRAIN.
- 002060 03-03 METABOLISM OF AMPHETAMINE BY RAT BRAIN TISSUE
- 002065 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS: 3.
 SUBCELLULAR DISTRIBUTION OF NEUROLEPTIC DRUGS AND THEIR
 RECEPTORS IN VARIOUS RAT BRAIN AREAS.
- METABOLIC CLEARANCE RATE OF ADRENOCORTICOTROPIN IN THE RAT. 002070 03-03
- INDUCTION OF PHYSICAL DEPENDENCE ON CYCLAZOCINE AND PENTAZOCINE IN THE RAT.
- CORRELATION OF URINARY EXCRETION OF METHADONE METABOLITES WITH METHADONE METABOLISM AND ANALGESIA IN THE RAT.
- EFFECT OF DIHYDROERGOTOXINE ON CYCLIC-AMP GENERATING SYSTEMS IN RAT CEREBRAL-CORTEX SLICES.
- 002088 03-03 HYPOTHERMIA EVOKED BY THE INTRACEREBRAL INJECTION OF MORPHINE-SULPHATE IN THE RAT: THE EFFECT OF RESTRAINT
- 002090 03-03 THE ACUTE EFFECTS OF AMPHETAMINE, CHLORPROMAZINE,
 AMITRIPTYLINE AND LITHIUM ON ADENOSINE-5-TRIPHOSPHATASE
 ACTIVITY IN THE CORTEX OF THE RAT BRAIN.

- NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: I. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY.
- 002096 03-03 MODIFICATION OF THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE RAT LIMBIC FOREBRAIN BY AMPHETAMINE (A) AND ITS HYDROXYLATED METABOLITES.
- 002100 03-03 AUTORADIOGRAPHIC LOCALIZATION OF H3-RESERPINE BINDING SITES IN RAT BRAIN.
- CHRONIC TREATMENT WITH DESIPRAMINE CAUSED A SUSTAINED DECREASE OF 3.4 DIHYDROXYPHENYLGLYCOL-SULFATE AND TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT BRAIN.
- 002113 03-03 DESIPRAMINE AND SOME OTHER ANTIDEPRESSANT DRUGS DECREASE THE MAJOR NOREPINEPHRINE METABOLITE 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE IN THE RAT BRAIN.
- 002114 03-03 THE EFFECTS OF PICROTOXIN AND PENTYLENETETRAZOL IN THE DIURNAL RHYTHMS OF CATECHOLAMINES AND SEROTONIN IN THE RAT BRAIN. 002123 03-03
- MONOAMINE-OXIDASE IN RAT RETICULOCYTES: SUBCELLULAR LOCALIZATION AND IDENTIFICATION OF ISOENZYMES.
- 002134 03-03 EFFECT OF 1 AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID (CYCLOLEUCINE)
 ON DEVELOPING RAT CENTRAL-NERVOUS-SYSTEM PHOSPHOLIPIDS. 002136 03-03
- CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2-METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED ANALOGS OF METHAMPHETAMINE.
- 002141 03-03 EFFECTS OF BIOGENIC AMINES AND PSYCHOTROPIC DRUGS ON ENDOGENOUS PROSTAGLANDIN BIOSYNTHESIS IN THE RAT BRAIN HOMOGENATES.
- 002145 03-03 THE EFFECTS OF SP-111, A WATER-SOLUBLE THC DERIVATIVE, ON NEURONAL ACTIVITY IN THE RAT BRAIN.
- 002150 03-03 THE EFFECT OF AMIZYL AND ARECOLINE ON THE ACTIVITY OF NA-K-ATPASE AND THE CONTENT OF NA AND K IN RAT BRAIN.
- 002151 03-03 EFFECT OF EARLY EXPERIENCE, PYRITHIOXIN AND DIAZEPAM ON UC14-GLUCOSE UTILIZATION IN RAT BRAIN DURING EMOTIONAL STRESS.
- 002152 03-03 INTERACTION OF ERGOT ALKALOIDS WITH DOPAMINERGIC RECEPTORS IN THE RAT STRATUM AND NUCLEUS-ACCUMBENS.
- 002157 03-03 MORPHINE INCREASES AND D AMPHETAMINE DECREASES THE RATIO OF DOPAC: HVA IN PUSH-PULL PERFUSATE OF RAT CAUDATE NUCLEUS.
- 002158 03-03 EFFECT OF AGE ON ACUTE MORPHINE RESPONSE IN THE RAT.
- 002159 03-03 SULFATES AND GLUCURONIDES OF P-HYDROXYPHENOBARBITAL IN RAT FECES
- 002165 03-03 METABOLISM OF 5 HYDROXYTRYPTAMINE AND LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS IN RAT BRAIN AFTER ACUTE AND CHRONIC
- 002169 03-03 METHYLHISTAMINE: EVIDENCE FOR SELECTIVE DEAMINATION BY MAO-B IN THE RAT BRAIN IN VIVO.
- 002172 03-03 BETA-ADRENOCEPTORS MODULATE NORADRENALINE RELEASE FROM AXONAL SPROUTS IN CULTURED RAT SUPERIOR CERVICAL GANGLIA. 002179 03-03
- CIRCADIAN VARIATIONS IN RESPONSE TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT. 002182 03-03
- EFFECT OF BETA ADRENERGIC RECEPTOR ANTAGONISTS ON D AMPHETAMINE AND POTASSIUM-INDUCED RELEASE OF H3-NOREPINEPHRINE FROM RAT BRAIN IN VITRO.
- 002187 03-03 EFFECTS OF MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON SCHEDULE-CONTROLLED RESPONDING IN THE RAT.
- 002206 03-04 CHANGES IN THE RAT ELECTROCORTICOGRAM FOLLOWING ADMINISTRATION OF TWO DIHYDROGENATED ERGOT DERIVATIVES
- 002207 03-04 PHARMACOLOGICAL INFLUENCES ON STARVATION-INDUCED HYPERRESPONSIVENESS IN THE RAT. (PH.D. DISSERTATION)
- 002212 03-04 EFFECTS OF PCPA AND SELECTIVE REM SLEEP-DEPRIVATION ON ROTOROD PERFORMANCE AND OPEN-FIELD BEHAVIOR IN THE RAT.

002219 03-04

002094 03-03

REWARD VERSUS PERFORMANCE IN SELF-STIMULATION: ELECTRODE SPECIFIC EFFECTS OF ALPHA-METHYL-P-TYROSINE ON REWARD IN THE RAT.

002225 03-04
EFFECTS OF NOMIFENSINE (HOE-984) UPON PSYCHOMOTOR ACTIVITY
AND INTRACRANIAL SELF-STIMULATION IN THE RAT.

002256 03-04
INTERACTIONS OF PARTIAL LSD ANALOGS WITH BEHAVIORAL
DISRUPTING EFFECTS OF LSD AND DMT IN THE RAT.

002264 03-04
THE EFFECT OF CHRONIC ETHANOL TREATMENT ON BEHAVIOUR AND
CENTRAL MONOAMINES IN THE RAT.

ANALGESIC ACTIVITY OF ENKEPHALINS FOLLOWING INTRACEREBRAL ADMINISTRATION IN THE RAT.

002275 03-04
INTOXICATING EFFECTS OF THREE ALIPHATIC ALCOHOLS AND BARBITAL
ON TWO RAT STRAINS GENETICALLY SELECTED FOR THEIR ETHANOL
INTAKE.

TOLERANCE AND DEPENDENCE AFTER CHRONIC ADMINISTRATION OF CLONIDINE TO THE RAT.

HYPNOTIC-LIKE EFFECTS OF CANNABIDIOL IN THE RAT.

THE INFLUENCE OF HISTAMINE ON METABOLISM OF DOPAMINE AND SEROTONIN IN THE RAT STRIATUM.

FORMAMIDINE-INDUCED FEEDING AND BEHAVIORAL ALTERATION IN THE

002294 03-04
PRENATAL MORPHINE ADMINISTRATION ALTERS BEHAVIORAL

DEVELOPMENT IN THE RAT.

O02308 03-04

THE EFFECT OF D AMPHETAMINE ON GAMMA EFFERENT ACTIVITY IN THE

ACUTE DECEREBRATE RAT. 002311 03-04

EFFECT OF CLOZAPINE ON THE SLEEP PATTERN IN THE RAT.

002313 03-04
ENHANCED ANALGESIC EFFECTS OF MORPHINE AFTER CHRONIC

ADMINISTRATION OF NALOXONE IN THE RAT. 002319 03-04

THE EFFECTS OF ETORPHINE, FENTANYL AND MORPHINE ON NORADRENALINE AND DOPAMINE CONCENTRATIONS IN THE STRIATUM OF RAT.

002321 03-04

EFFECTS OF SODIUM-NITRITE ON DRL PERFORMANCE IN THE RAT.
002325 03-04

DECREASED LOCOMOTOR ACTIVITY AND ATTENUATION OF AMPHETAMINE HYPERACTIVITY WITH INTRAVENTRICULAR INFUSION OF SEROTONIN IN THE RAT.

THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORMONE, FOLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MALE

002343 03-05

A METHOD FOR MECHANOGRAPHICAL RECORDING OF MUSCLE TONE IN
THE RAT: THE EFFECT OF SOME ANTIPARKINSONIAN DRUGS ON
RIGIDITY INDUCED BY RESERPINE.

602346 03-05
EFFECT OF MATERNALLY ADMINISTERED HEROIN ON THE MOTOR
ACTIVITY OF RAT OFFSPRING.

INHIBITION BY LITHIUM OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN THE RAT BRAIN.

002357 03-05
EVIDENCE FOR AN ENDOGENOUS FACTOR INTERFERING WITH H3DIAZEPAM BINDING TO RAT BRAIN MEMBRANES

002789 04-01
CENTRAL EFFECT OF SOMATOSTATIN ON THE SECRETION OF GROWTH
HORMONE IN THE ANESTHETIZED RAT.

ON THE ORIGIN OF VANILLYLMANDELIC-ACID AND 3 METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT BRAIN.

D02804 04-03

EFFECT OF MECAMYLAMINE ON THE FATE OF DOPAMINE IN STRIATAL
AND MESOLIMBIC AREAS OF RAT BRAIN; INTERACTION WITH
MORPHINE AND HALOPERIDOL.

ASPECTS OF INFLUX AND EFFLUX OF HOMOVANILLIC-ACID OF RAT CEREBROSPINAL FLUID.

002807 04-03

EFFECTS OF PROSTAGLANDIN-E2 AND A PROSTAGLANDIN ENDOPEROXIDE
ANALOGUE ON NEUROEFFECTOR TRANSMISSION IN THE RAT
ANOCOCCYGEUS MUSCLE.

COMPARATIVE EFFECTS OF PENFLURIDOL ON CIRCLING BEHAVIOR AND STRIATAL DOPAC AND SERUM PROLACTIN CONCENTRATIONS IN THE RAT.

002810 04-03

EFFECTS OF SINGLE AND MULTIPLE DOSES OF DESIPRAMINE (DMI) ON ENDOGENOUS LEVELS OF 3 METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE (MOPEG-SO4) IN RAT BRAIN.

O02814 04-03

EFFECT OF MORPHINE INJECTED IN PERIAQUEDUCTAL GRAY ON THE
ACTIVITY OF SINGLE UNITS IN NUCLEUS RAPHE MAGNUS OF THE RAT.
O02817 04-03

EFFECTS OF ACETYLCHOLINE, SODIUM-GLUTAMATE AND GABA ON THE DISCHARGE OF SUPRAOPTIC NEURONS IN THE RAT.

ONTOGENETIC DEVELOPMENT OF BENZODIAZEPINE RECEPTORS IN THE RAT BRAIN.

INFLUENCE OF PHENOBARBITAL ON THE DISTRIBUTION AND ELIMINATION OF DESMETHYLIMIPRAMINE IN THE RAT.

TWO BINDING SITES FOR H3-SPIROPERIDOL ON RAT STRIATAL

MEMBRANES

BROMOCRIPTINE, DIHYDROERGOTOXINE, METHYSERGIDE, D LSD, CF-25-397, AND CF-29-712: EFFECTS ON THE METABOLISM OF BIOGENIC AMINES IN THE BRAIN OF THE RAT.

INFLUENCE OF TRANSIENT ISCHEMIA ON MONOAMINE METABOLISM IN THE RAT BRAIN DURING NITROUS-OXIDE AND PHENOBARBITONE AMESTHESIA

ANESTRIESIA.

002852 04-03

EFFECTS OF SOME DERIVATIVES OF 2 AMINOTETRALIN ON DOPAMINE
SENSITIVE ADENYLATE-CYCLASE AND ON THE BINDING OF H3HALOPERIDOL TO NEUROLEPTIC RECEPTORS IN RAT STRIATUM.

002853 04-03

SUBCELLULAR DISTRIBUTION OF ETORPHINE IN RAT BRAIN AND EVIDENCE FOR IN VIVO STEREOSPECIFIC BINDING.

MEASUREMENT OF PROTEIN TURNOVER IN RAT BRAIN. 002856 04-03

002859 04-03
ALTERATION OF TRICARBOXYLIC-ACID CYCLE METABOLISM IN RAT
BRAIN SLICES BY HALOTHANE:

PILOT STUDY ON THE DISTRIBUTION OF C14-LABELED METHAQUALONE IN THE RAT BRAIN.

O02865 04-03
SUPERSENSITIVITY OF THE CHOLINERGIC RESPONSE TO APOMORPHINE IN
THE STRIATUM FOLLOWING DENERVATION OR DISUSE
SUPERSENSITIVITY OF DOPAMINERGIC RECEPTORS IN THE RAT.

5 HYDROXYTRYPTAMINE: THE EFFECTS OF IMPAIRED SYNTHESIS ON ITS METABOLISM AND RELEASE IN RAT.

002878 04-03
NEUROPHARMACOLOGICAL STUDIES ON THE NIGROSTRIATAL AND RAPHE STRIATAL SYSTEM IN THE RAT.

DO2882 04-03
PHARMACOLOGICAL AND ELECTROPHYSIOLOGICAL STUDIES OF
MORPHINE AND ENKEPHALIN ON RAT SUPRASPINAL NEURONES AND
CAT SPINAL NEURONES.

002883 04-03
BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101
BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP
ACCUMULATION IN RAT CEREBRAL-CORTEX.

O02885 04-03

SELECTIVE PURIFICATION OF A SINGLE POPULATION OF GLUCOCORTICOID
RECEPTORS FROM RAT BRAIN.

OO2887 04-03
THE EFFECT OF PHENOBARBITAL AND CARBON-TETRACHLORIDE ON
FATTY-ACID CONTENT AND COMPOSITION OF PHOSPHOLIPIDS FROM
THE ENDOPLASMIC RETICULUM OF RAT LIVER.

O02888 04-03

ACTIVATION OF AN IHHIBITORY NORADRENERGIC PATHWAY PROJECTING
FROM THE LOCUS-COERULEUS TO THE CINGULATE CORTEX OF THE RAT.

002895 04-03

METABOLISM OF GAMMA-HYDROXYBUTYRATE BY RAT BRAIN: RELATIONSHIP TO THE KREBS-CYCLE AND METABOLIC COMPARTMENTATION OF AMINO-ACIDS.

MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMATURE RAT.

002901 04-03
SUBSTRATE SELECTIVE ACTIVATION OF RAT LIVER MITOCHONDRIAL
MONOAMINE-OXIDASE BY OXYGEN.

002912 04-03
ELECTROPHORETIC ANALYSES OF PROTEINS TRANSPORTED TO THE RAT
POSTERIOR PITUITARY.

THE ACTIONS OF DIAZEPAM AND PHENYTOIN ON A LOW DOSE PENICILLIN EPILEPTIFORM FOCUS IN THE ANESTHETISED RAT.

INFLUENCE OF LITHIUM ON DOPAMINE STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT BRAIN. 002922 04-03

5 HYDROXYTRYPTAMINE AND DOPAMINE TRANSPORT BY RAT AND HUMAN BLOOD PLATELETS.

002928 04-03

SOLUBILIZATION OF H3-SPIPERONE BINDING SITES FROM RAT BRAIN.
002929 04-03
PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL
DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6
TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH
KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — 1. FACTORS THAT INFLUENCE NADPH KINETIC ESTIMATIONS DURING MIXED FUNCTION OXIDASE REACTIONS.

PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL DRUG METABOLISM — II. EVIDENCE FOR A COOPERATIVE INTERACTION BETWEEN NADPH AND NADH.

NONSPECIFIC INHIBITION OF SOME RAT LIVER MEMBRANE-BOUND ENZYMES BY AN ADENYLATE-CYCLASE INHIBITOR, RMI-12330-A 002936 04-03 ACTIVE UPTAKE OF H3-5-HT BY SYNAPTIC VESICLES FROM RAT BRAIN.

002937 04-03

ADENOSINE MODULATES DEPOLARIZATION-INDUCED RELEASE OF H3-NORADRENALINE FROM SLICES OF RAT BRAIN NEOCORTEX. 002938 04-03

H3-CLOZAPINE BINDING TO RAT BRAIN MEMBRANES

002940 04-03
RAT STRIATAL METHIONINE-ENKEPHALIN CONTENT AFTER CHRONIC
TREATMENT WITH CATALEPTOGENIC AND NONCATALEPTOGENIC

O02953 04-03
THE EFFECTS OF STANDARD NEUROLEPTIC COMPOUNDS ON THE BINDING OF H3-SPIROPERIDOL IN THE STRIATUM AND MESOLIMBIC SYSTEM OF THE RAT IN VITRO.

002955 04-03 SOME OBSERVATIONS ON THE BINDING PATTERNS OF ALPHA-BUNGAROTOXIN IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT

002956 04-03 EFFECTS OF ESTROGEN AND AMINERGIC DRUGS ON THRESHOLDS OF MEDIAL BASAL HYPOTHALAMIC AXONS IN THE MEDIAN EMINENCE OF

002974 04-03 TERATOLOGICAL EVALUATION OF ETHANOL, PENTOBARBITAL, AND COMBINATIONS OF THESE, IN THE RAT.

002976 04-03 AROMATIC AMINOTRANSFERASE ACTIVITY OF RAT BRAIN CYTOPLASMIC AND MITOCHONDRIAL ASPARTATE AMINOTRANSFERASES.

002978 04-03

STUDIES ON THE MECHANISM OF SPROUTING OF NORADRENERGIC TERMINALS IN RAT AND MOUSE CEREBELLUM AFTER NEONATAL 6 HYDROXYDOPA.

STRUCTURE-ACTIVITY STUDIES ON THE INHIBITION OF GABA BINDING TO RAT BRAIN MEMBRANES BY MUSCIMOL AND RELATED COMPOUNDS.

MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID
AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE
ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE
CORRELATES WITH ANALGESIC ACTION OF MORPHINE. 002984 04-03

CHARACTERIZATION OF SPECIFIC IN VIVO BINDING OF NEUROLEPTIC DRUGS IN RAT BRAIN.

REGIONAL LOCALIZATION OF HALOPEMIDE, A NEW PSYCHOTROPIC AGENT, IN THE RAT BRAIN.

MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II. 002004 04-03

THE EFFECT OF BROMOCRIPTINE ON RAT STRIATAL ADENYLATE-CYCLASE AND RAT BRAIN MONOAMINE METABOLISM.

002998 04-03 METABOLISM OF BETA 3,4 METHYLENEDIOXYAMPHETAMINE IN THE

003000 04-03 THE EFFECT OF VILOXAZINE HYDROCHLORIDE ON THE TRANSPORT OF NORADRENALINE, DOPAMINE, 5 HYDROXYTRYPTAMINE AND GAMMA-AMINOBUTYRIC-ACID IN RAT BRAIN TISSUE.

003001 04-03 EVALUATION OF THE EFFECT OF P-CHLOROAMPHETAMINE ON INDIVIDUAL CATECHOLAMINERGIC NUCLEI IN THE RAT BRAIN.

003003 04-03 RETROGRADE AXONAL TRANSPORT OF NERVE GROWTH FACTOR IN THE CILIARY GANGLION OF THE CHICK AND THE RAT.

003005 04-03 PHARMACOLOGICAL CHARACTERIZATION OF THE EXCITATORY CHOLINERGIC RECEPTORS OF RAT CENTRAL NEURONES.

CORRELATION OF PHENOBARBITAL-INDUCED AND SKF-525-A-INDUCED MODIFICATION OF PENTOBARBITAL HYPNOSIS WITH ALTERATION OF IN VIVO AND IN VITRO PENTOBARBITAL METABOLISM IN THE RAT. 003008 04-03

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL TOLERANCE AND CROSS-TOLERANCE TO MORPHINE AND METHADONE IN THE RAT.

003010 04-03 EFFECTS OF URETHANE ON HIPPOCAMPAL UNIT ACTIVITY IN THE RAT. 003011 04-03 STIMULATION BY LITHIUM-IONS OF THE INCORPORATION OF C14-GUICOSE INTO GLYCOGEN IN RAT BRAIN SLICES.

003015 04-03 EFFECT OF SUBSTITUTED BENZAMIDE DRUGS ON RAT STRIATAL TYROSINE-HYDROXYLASE.

CLEARANCE AND ANALGESIC ACTIVITY OF THE QUATERNIZED OPIATE, N
METHYLMORPHINE (6-H3) ADMINISTERED INTRACISTERNALLY TO THE
RAT.

INHIBITION OF MONOAMINE OXIDATION IN SUBFRACTIONS OF CRUDE MITOCHONDRIA OF RAT BRAIN BY CLORGYLINE AND LILLY-51641.

003020 04-03 ON THE RELATION BETWEEN HALOPERIDOL-INDUCED ALTERATIONS IN DA RELEASE AND DA METABOLISM IN RAT STRIATUM.

003021 04-03 THE EFFECTS OF P-CHLOROPHENYLALANINE, RESERPINE, METHYSERGIDE AND CYPROHEPTADINE ON THE DOPA-INDUCED EEG SYNCHRONIZATION IN THE RAT.

STRYCHNINE BINDING ASSOCIATED WITH SYNAPTIC GLYCINE RECEPTORS IN RAT SPINAL CORD MEMBRANES: IONIC INFLUENCES.

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4HYDROXYPHENYLETHANOL (MOPET) IN HUMAN CEREBROSPINAL FLUID
AND RAT BRAIN BY MEANS OF GAS-CHROMATOGRAPHY — MASSSPECTROMETRY.

INHIBITION OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RAT STRIATUM BY NEUROLEPTIC DRUGS ADMINISTERED IN VIVO.

IDENTIFICATION OF A SUBREGION WITHIN RAT NEOSTRIATUM FOR THE DOPAMINERGIC MODULATION OF LATERAL HYPOTHALAMIC SELF-STIMULATION.

003028 04-03 AMPHETAMINE-INDUCED INCREASE IN RAT CEREBRAL BLOOD FLOW; APPARENT LACK OF CATECHOLAMINE INVOLVEMENT.

003031 04-03 REGULATION OF CYCLIC-GUANOSINE-MONOPHOSPHATE IN THE RAT PINEAL AND POSTERIOR PITUITARY GLANDS.

003032 04-03 THE EFFECTS OF ETHANOLAMINE-O-SULPHATE INJECTION INTO THE RAT SUBSTANTIA-NIGRA: ELECTROPHYSIOLOGICAL STUDIES.

O03033 04-03

EFFECTS OF PAIN ATTENUATING BRAIN STIMULATION AND MORPHINE ON
ELECTRICAL ACTIVITY IN THE RAPHE NUCLEI OF THE AWAKE RAT.

003034 04-03 HIGH AFFINITY BINDING OF H3-HISTAMINE IN RAT BRAIN.

003036 04-03 5 GUANYLYLIMIDODIPHOSPHATE ACTIONS ON ADENYLATE-CYCLASE IN HOMOGENATES OF RAT CEREBRAL-CORTEX PLUS NEURONAL AND CAPILLARY FRACTIONS.

003038 04-03 H3-SPIROPERIDOL BINDING TO TWO RECEPTOR SITES IN BOTH THE CORPUS-STRIATUM AND FRONTAL CORTEX OF RAT BRAIN.

003041 04-03 LITHIUM EFFECTS ON RAT BRAIN GLUCOSE METABOLISM IN LONG-TERM LITHIUM TREATED RATS STUDIED IN VIVO.

003046 04-03 EFFECT OF STRYCHNINE ON THE RAT ELECTRORETINOGRAM

003048 04-03 INHIBITION BY BARBITURIC-ACID AND ITS DERIVATIVES OF THE ENZYMES IN RAT BRAIN WHICH PARTICIPATE IN THE SYNTHESIS OF PYRIMIDINE

003049 04-03 CYCLIC-NUCLEOTIDE LEVELS IN THE RAT STRIATUM AND CEREBELLUM IN VIVO EFFECTS OF DOPAMINE AND ACETYLCHOLINE RECEPTOR AGONISTS AND ANTAGONISTS.

DOPAMINE ANTAGONIST BINDING: A SIGNIFICANT DECREASE WITH MORPHINE-DEPENDENCE IN THE RAT STRIATUM.

003052 04-03 EFFECT OF VASOACTIVE INTESTINAL PEPTIDE (VIP) AND OTHER PEPTIDES ON C-AMP ACCUMULATION IN RAT BRAIN.

EFFECTS OF ETHANOL WITHDRAWAL, STRESS AND AMPHETAMINE ON RAT BRAIN NA-K-ATPASE.

003060 04-03 ENTRY OF BETA-N-OXALYL-L-ALPHA-BETA-DIAMINOPROPIONIC-ACID, THE LATHYRUS-SATIVUS NEUROTOXIN INTO THE CENTRAL-NERVOUS-SYSTEM OF THE ADULT RAT, CHICK AND THE RHESUS MONKEY. 003061 04-03

003006 04-03

ACETYLCHOLINE TURNOVER IN THE RAT.

EFFECT OF L-DOPA PRETREATMENT ON IN VIVO PROTEIN SYNTHESIS IN VARIOUS RAT BRAIN REGIONS.

003068 04-03

EFFECT OF () AMPHETAMINE ON THE RETENTION OF H3-CATECHOLAMINES IN SLICES OF NORMAL AND RESERPINIZED RAT BRAIN AND HEART.

LOCAL CEREBRAL GLUCOSE UTILIZATION FOLLOWING INJECTION OF BETA-ENDORPHIN INTO PERIAQUEDUCTAL GRAY MATTER IN THE RAT. 003073 04-03

EVIDENCE OF AN INTERACTION BETWEEN SEROTONINERGIC AND CHOLINERGIC NEURONS IN THE CORPUS-STRIATUM AND HIPPOCAMPUS OF THE RAT BRAIN.

003074 04-03
EFFECT OF ACUTE MORPHINE ADMINISTRATION ON REGIONAL

THE ROLE OF CALCIUM IN THE REGULATION OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN SLICES OF RAT AND GUINEA-PIG.

003079 04-03

DOPAMINE RECEPTORS LOCALISED ON CEREBRAL CORTICAL AFFERENTS
TO RAT CORPUS-STRIATUM.

MICROIN IECTION OF KAINIC-ACID INTO THE RAT HIPPOCAMPUS

THE ACETYLCHOLINE RECEPTOR IN THE RAT HIPPOCAMPUS; NICOTINIC, MUSCARINIC OR BOTH?

003082 04-03
DISULFIRAM-INDUCED HYPOTHERMIA IN THE NORMAL RAT; ITS
ATTENUATION BY PIMOZIDE.

003085 04-03
THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE OF THE RAT CAUDATE NUCLEUS — 3. THE EFFECT OF APORPHINES AND PROTOBERBERINES.
003089 04-03

INFLUENCE OF NEUROLEPTICS ON THE BINDING OF MET-ENKEPHALIN, MORPHINE AND DIHYDROMORPHINE TO SYNAPTOSOME ENRICHED FRACTIONS OF RAT BRAIN.

003096 04-03

LACK OF ENHANCEMENT OF DIMETHYLTRYPTAMINE FORMATION IN RAT
BRAIN AND RABBIT LUNG IN VIVO BY METHIONINE OR S
ADENOSYLMETHIONINE.

003102 04-03
EFFECTS OF MAZINDOL ON RAT BRAIN SYNAPTOSOMAL MONOAMINE
UPTAKE.

EPINEPHRINE IN RAT HYPOTHALAMUS: ANTAGONISM BY DESIPRAMINE OF 6 HYDROXYDOPAMINE-INDUCED DEPLETION.

O03110 04-03
RELEASE OF ENDOGENOUS CATECHOLAMINES FROM ISOLATED RAT
BRAIN TISSUE BY FENFLURAMINE AND N ETHYLAMPHETAMINE -EFFECTS OF PARGYLINE.

003111 04-03
H3-CATECHOLAMINE BINDING TO ALPHA-RECEPTORS IN RAT BRAIN:
ENHANCEMENT BY RESERVINE.

003119 04-03
THE DECREASE OF MONOAMINE-OXIDASE ACTIVITY FOLLOWING THE INTRAOCULAR INJECTION OF COLCHICINE IN THE SUPERIOR COLLICULUS

EFFECT OF RESERPINE ON THE MONOAMINE-OXIDASE (MAO) ACTIVITY IN RAT LIVER AND BRAIN.

003125 04-03
INCREASED DOPAMINE METABOLISM IN RAT STRIATUM AFFER
INFUSIONS OF SUBSTANCE-P INTO THE SUBSTANTIA-NIGRA.

O03130 04-03
THE EFFECT OF GAMMA-AMINOBUTYRIC-ACID ON H3-FLUNITRAZEPAM
BINDING IN RAT BRAIN.

003132 04-03
INHIBITION OF CA45 MOVEMENTS BY LOWERED TEMPERATURE OR
LANTHANUM IN RAT BRAIN SLICES.

RADIOIMMUNOASSAY OF ENKEPHALINS: REGIONAL DISTRIBUTION IN RAT BRAIN AFTER MORPHINE TREATMENT AND HYPOPHYSECTOMY.

EFFECTS OF MORPHINE ON ISOENZYMES OF PYRUVATE KINASE AND TYROSINE-AMINOTRANSFERASE IN RAT.

O03141 04-03
THE IN VIVO BINDING OF H3-DESIPRAMINE AND H3-CHLORPROMAZINE
TO AREAS IN THE RAT BRAIN.

603145 04-03
EFFECTS OF N METHYLAMINOETHANOL, AND N,N
DIMETHYLAMINOETHANOL IN THE DIET OF PREGNANT RATS ON
NEONATAL RAT BRAIN CHOLINERGIC AND PHOSPHOLIPID PROFILE.

003149 04-0 BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION OF LEVO-ALPHA-ACETYLMETHADOL IN THE RAT.

LEVO-ALPHA-ACETYLMETHADOL AND METABOLITES: SOME EFFECTS ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT.

INTERANIMAL AGGRESSION AND HYPERREACTIVITY FOLLOWING
HYPOTHALAMIC INFUSION OF LOCAL ANESTHETIC IN THE RAT.
003157 04-04

DIFFERENTIAL EFFECTS OF CONVULSANTS ON VISUALLY EVOKED RESPONSES IN THE ALBINO RAT.

003171 04-04
NEUROPHARMACOLOGICAL AND BEHAVIORAL EVALUATION OF
PROSTAGLANDIN-E2 AND 11 THIOL-11-DESOXYPROSTAGLANDIN-E2 IN
THE MOUSE AND RAT.

O03173 04-04
THE NEUROLOGICAL BASIS OF MOTOR ASYMMETRY FOLLOWING
UNILATERAL NIGROSTRIATAL LESIONS IN THE RAT: THE EFFECT OF
SECONDARY SUPERIOR COLLICULUS LESIONS.

THE EFFECT OF BACLOFEN ON ALPHA-FLUPENTHIXOL-INDUCED CATALEPSY IN THE RAT. 003203 04-04

PHYSALAEMIN, A NEW POTENT ANTIDIPSOGEN IN THE RAT.

003207 04-04

BEHAVIORAL AND ANATOMICAL CONSEQUENCES OF SMALL INTRASTRIATAL INJECTIONS OF KAINIC-ACID IN THE RAT.

003210 04-04
BRIEF PERIODS OF SOCIALIZATION AND LATER BEHAVIOR IN THE RAT.
003214 04-04

A REFILLABLE SYSTEM FOR CONTINUOUS AMPHETAMINE ADMINISTRATION: EFFECTS UPON SOCIAL BEHAVIOR IN RAT COLONIES.

003215 04-04
ROLE OF HYPOTHALAMIC SEROTONERGIC RECEPTORS IN THE CONTROL OF
LORDOSIS BEHAVIOR IN THE FEMALE RAT.

THE EFFECTS OF D ALA2-MET5-ENKEPHALINAMIDE ON BEHAVIORAL ACTIVITY AND CYCLIC-NUCLEOTIDES IN THE RAT BRAIN. (PH.D. DISSERTATION).

003240 04-04
BEHAVIORAL AND PHYSIOLOGICAL STUDIES OF NONNARCOTIC
ANALGESIA IN THE RAT ELICITED BY CERTAIN ENVIRONMENTAL
STIAMULT

003242 04-04
BIPHASIC EFFECT OF CHLORPROMAZINE ON RAT PARADOXICAL SLEEP: A
STUDY OF DOSE-RELATED MECHANISMS.

003253 04-04
LEAD-INDUCED BEHAVIORAL DISORDERS IN THE RAT: EFFECTS OF
AMPHITAMINE

003261 04-04

EFFECT OF CHOLECYSTOKININ ON MEAL SIZE AND INTERMEAL INTERVAL
IN THE SHAM-FEEDING RAT.

003264 04-04

A COMPARISON OF DISCRIMINATIVE STIMULI PRODUCED BY NALOXONE, CYCLAZOCINE AND MORPHINE IN THE RAT.

003270 04-04

DIURNAL VARIATIONS IN THE MOTOR ACTIVITY OF THE RAT: EFFECTS OF
INHIBITORS OF THE CATECHOLAMINE SYNTHESIS.

O03274 04-04
DIFFERENTIAL BEHAVIORAL EFFECTS OF SULPIRIDE IN THE RAT AND
SOLIBBEL-MONKEY

003276 04-04

EFFECTS OF THE ACUTE ADMINISTRATION OF ETHANOL ON THE SLEEP OF
THE RAT: A DOSE-RESPONSE STUDY.

003296 04-04

ANATOMICAL SPECIFICITY WITHIN RAT STRIATUM FOR THE
DOPAMINERGIC MODULATION OF DRL RESPONDING AND ACTIVITY.
003316 04-04

MUSCARINIC HYPOSENSITIVITY IN THE DEVELOPING RAT PRETREATED WITH 6 HYDROXYDOPA.

003320 04-04
APOMORPHINE AND L-DOPA LOWER EJACULATION THRESHOLD IN THE
MALE RAT.

COMPARISON OF THE BEHAVIORAL EFFECTS OF P-CHLOROAMPHETAMINE, CHLORDIMEFORM, QUIPAZINE, AND INTRAVENTRICULAR SEROTONIN IN THE RAT.

CO3331 04-04
EFFECTS OF L GLUTAMATE AND RELATED AMINO-ACIDS UPON THE
RELEASE OF H3-DOPAMINE FROM RAT STRIATAL SLICES.

003340 04-04

EVIDENCE FOR A ROLE FOR DOPAMINE IN SELF-STIMULATION OF THE
NUCLEUS-ACCUMBENS OF THE RAT.

DIFFERENTIAL RESPONDING CONTROLLED BY THE DISCRIMINATIVE STIMULI PRODUCED BY CONVULSANT DRUGS IN THE RAT.

O03358 04-04
LOCALIZATION OF RECEPTORS FOR THE DIPSOGENIC ACTION OF
ANGIOTENSIN-II IN THE SUBFORNICAL ORGAN OF RAT.

BENZODIAZEPINES AND BEHAVIORAL EFFECTS OF REWARD (WATER)
OAISSION IN THE RAT.

003364 04-04

003156 04-04

Subject Index

CHANGES IN THE BEHAVIORAL RESPONSE TO A NOVEL ENVIRONMENT FOLLOWING LESIONING OF THE CENTRAL DOPAMINERGIC SYSTEM IN

ANALGESIA BY ENKEPHALINS INJECTED INTO THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF RAT MEDULLA-OBLONGATA.

003374 04-04 CIRCLING BEHAVIOUR IN THE RAT FOLLOWING UNILATERAL INJECTIONS OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE INTO THE SUBSTANTIA-NIGRA.

003375 04-04 HALOPERIDOL DEPRESSES THE ACCUMULATION OF APOMORPHINE IN THE STRIATUM OF THE RAT.

THE EFFECTS OF ATROPINE ON THE TOLERANCE AND THE CONVULSIONS SEEN AFTER WITHDRAWAL FROM FORCED BARBITAL DRINKING IN THE

003389 04-04 AMPHETAMINE-TYPE REINFORCEMENT BY DOPAMINERGIC AGONISTS IN

003400 04-04 USE OF THE FLINCH-JUMP TECHNIQUE TO STUDY NARCOTIC ANALGESIA IN THE RAT. 003403 04-04

THE EFFECTS OF CHRONIC CHLORPROMAZINE ADMINISTRATION ON THE ALBINO RAT RETINA. 003408 04-05

COMPARISON OF THE ELECTROPHYSIOLOGICAL EFFECTS OF TWO
NEUROLEPTICS, MELPERONE AND THIORIDAZINE, ON ISOLATED RAT

003417 04-05 EXPERIMENTAL LEAD ENCEPHALOPATHY IN THE SUCKLING RAT: CONCENTRATION OF LEAD IN CELLULAR FRACTIONS ENRICHED IN BRAIN CAPILLARIES.

003420 04-05 DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: A
VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIATION OF
CATECHOLAMINERGIC AND SEROTONINERGIC TERMINALS IN RAT CEREBRAL STRUCTURES.

003423 04-06 THE PRODUCTION OF MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE BY THE ORAL ROUTE IN THE RAT.

MANDIBULOGRAM AS A MEASURE OF STEREOTYPED BEHAVIOR IN THE

003427 04-06 LITHIUM NEUROTOXICITY. I. THE CONCENTRATION OF LITHIUM IN DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS ATOMIC ABSORPTION SPECTROPHOTOMETRY.

003432 04-06

THE EFFECTS OF INTRAGASTRIC MORPHINE SELF-ADMINISTRATION IN THE RAT. (PH.D. DISSERTATION) 003437 04-06

ROUTINE MEASUREMENT OF HOMOVANILLIC-ACID IN RAT BRAIN BY GAS-LIQUID-CHROMATOGRAPHY.

003441 04-06 BIOCHEMICAL EFFECTS IN MAN AND RAT OF THREE DRUGS WHICH CAN INCREASE BRAIN GABA CONTENT.

003604 04-13 PENTOBARBITAL INTOXICATION IN THE PREGNANT RAT.

003659 04-15 ENDOGENOUS MODULATORS OF ACETYLCHOLINE TURNOVER RATE.

(UNPUBLISHED PAPER). 000073 01-03 THE TURNOVER RATE OF GAMMA-AMINOBUTYRIC-ACID IN THE NUCLEI OF TELENCEPHALON: IMPLICATIONS IN THE PHARMACOLOGY OF ANTIPSYCHOTICS AND OF A MINOR TRANQUILIZER.

000192 01-03 CHANGES IN THE RATE INCREASING EFFECTS OF D AMPHETAMINE AND PENTOBARBITAL BY RESPONSE CONSEQUENCES.

000452 01-04 ATTENUATION OF THE RATE DECREASING EFFECTS OF AMPHETAMINE ON FIXED-RATIO RESPONDING IN RATS BY HIPPOCAMPAL LESIONS.

000474 01-04 MARIJUANA: DOSE-RESPONSE EFFECTS ON PULSE RATE, SUBJECTIVE ESTIMATES OF POTENCY, PLEASANTNESS, AND RECOGNITION MEMORY.

RATE OF ABSORPTION AND CLINICAL RESPONSE TO SINGLE ORAL DOSES OF CHLORDIAZEPOXIDE.

000702 01-13 COMPARATIVE BIOAVAILABILITY OF ORAL DOSAGE FORMS OF OXAZEPAM -- CORRELATION WITH IN VITRO DISSOLUTION RATE. 000727 01-13

EFFECTS OF PHENOBARBITAL AND DIAZEPAM ON IMIPRAMINE-INDUCED CHANGES IN BLOOD PRESSURE, HEART RATE AND RECTAL TEMPERATURE OF RATS. 001070 02-03 Psychopharmacology Abstracts

AN ATTEMPT TO PREDICT THE DURATION OF PENTOBARBITAL NARCOSIS ON THE BASIS OF EXPLORATORY ACTIVITY, DEFECATION RATE AND BODY WEIGHT OF RATS.

001435 02-04 LEARNING RATE EQUIVALENCY OF TWO NARCOTIC GASES.

001701 02-14 TOLERANCE TO MARIJUANA: HEART RATE AND SUBJECTIVE HIGH. 001818 02-15

METABOLIC CLEARANCE RATE OF ADRENOCORTICOTROPIN 002070 03-03

INCREASE OF HIPPOCAMPAL ACETYLCHOLINE TURNOVER RATE AND THE STRETCHING YAWNING SYNDROME ELICITED BY ALPHA-MSH AND

002644 03-14 MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II 002994 04-03

LOWERED ERYTHROCYTE SEDIMENTATION RATE WITH SODIUM VALPROATE.

003672 04-15

RATE-DEPENDENT
RATE-DEPENDENT EFFECTS OF AMPHETAMINE RESULTING FROM
BEHAVIORAL COMPETITION.

001368 02-04 RATE-DEPENDENT AND STIMULUS CONTROL EFFECT OF DRUGS 002266 03-04

CONTROLLING RATER SPECIFIC INTERFERENCE FACTORS IN CLINICAL TRIALS

000917 01-16

RATES

RELAPSE RATES OF SCHIZOPHRENIC PSYCHOSES.

000524 01-08 FLUPHENAZINE-DECANOATE, FLUPHENAZINE-HYDROCHLORIDE GIVEN ORALLY, AND PLACEBO IN REMITTED SCHIZOPHRENICS: I. RELAPSE RATES AFTER ONE YEAR.

000545 01-08 EFFECTS OF D AMPHETAMINE ON DIFFERENT RATES OF AVOIDANCE BEHAVIOR IN RATS.

001488 02-04 THE EFFECTS OF ALCOHOL UPON COOLING RATES OF HUMANS IMMERSED IN 7.5 DEGREES C WATER.

002541 03-12 TURNOVER RATES OF GAMMA-AMINOBUTYRIC-ACID IN SUBSTANTIA-NIGRA, NUCLEUS-CAUDATUS, GLOBUS-PALLIDUS AND NUCLEUS-ACCUMBENS OF RATS INJECTED WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS.

002996 04-03 CAN CIGARETTE SIZE AND NICOTINE CONTENT INFLUENCE SMOKING AND PUFFING RATES?

003631 04-14

TREATMENT OF REMITTED SCHIZOPHRENICS: II. RATING SCALE DATA

CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND ITS METABOLITES AND CLINICAL RATINGS IN PATIENTS WITH ACUTE RELAPSE OF SCHIZOPHRENIC AND PARANOID PSYCHOSIS. 000726 01-13

THE INFLUENCE OF CAFFEINE AND THEOBROMINE ON LOCOMOTIVE
ACTIVITY AND THE BRAIN C-GMP/C-AMP RATIO IN WHITE MICE 000275 01-03

RATIO DATA AND THE QUANTIFICATION OF DRUG EFFECTS. 000914 01-16 PREDICTION OF THE LITHIUM RATIO IN MAN BY MEANS OF AN IN VITRO

EFFECTS OF COCAINE AND FENFLURAMINE ON PROGRESSIVE RATIO PERFORMANCE.

001473 02-04 MORPHINE INCREASES AND D AMPHETAMINE DECREASES THE RATIO OF DOPAC: HVA IN PUSH-PULL PERFUSATE OF RAT CAUDATE NUCLEUS. 002158 03-03

A DOSE RATIO COMPARISON OF THE INTERACTION BETWEEN MORPHINE AND CYCLAZOCINE WITH NALOXONE IN RHESUS MONKEYS ON THE SHOCK TITRATION TASK. 002335 03-04

LITHIUM ERYTHROCYTE/PLASMA RATIO AS A PREDICTOR OF RESPONSE 002431 03-09 LITHIUM ERYTHROCYTE: PLASMA RATIO IN PRIMARY AFFECTIVE-

RATIONAL PRESCRIBING OF DRUGS.

002445 03-09 000993 01-17

VOLUME 16. SUBJECT INDEX

ENHANCEMENT OF THE ANTIDEPRESSANT RESPONSE TO L TRYPTOPHAN BY A LIVER PYRROLASE INHIBITOR: A RATIONAL TREATMENT APPROACH

002464 03-09

PATIONALITY RATIONALITY OF APPEALS USED IN THE PROMOTION OF PSYCHOTROPIC DRUGS. A COMPARISON OF MALE AND FEMALE MODELS. 001932 02-17

RATIOS

ERYTHROCYTE/PLASMA LITHIUM RATIOS.

000586 01-09 RELATIONSHIPS AMONG CLINICAL RESPONSE, EXTRAPYRAMIDAL SYNDROME AND PLASMA CHLORPROMAZINE AND METABOLITE

001827 02-15

BRAIN: SERUM AND CSF: SERUM RATIOS AFTER A SINGLE DOSE OF DIPROPYLACETIC-ACID (DPA), 002168 03-03

PATE EFFECT OF CHLORDIAZEPOXIDE ADMINISTERED EARLY IN EXTINCTION ON SUBSEQUENT EXTINCTION OF A CONDITIONED EMOTIONAL RESPONSE IN RATS: IMPLICATIONS FOR HUMAN CLINICAL USE. 000022 01-02

EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) ON SLEEP IN OLFACTORY BULB LESIONED RATS. 000032 01-02

FAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS UNDER LONG-TERM TRAINING 000034 01-02

N ACETYLTRANSFERASE ACTIVITY IN PINEAL GLAND OF RATS TREATED WITH PARGYLINE

000046 01-03 TIME-COURSE OF LITHIUM-INDUCED ALTERATIONS IN RENAL AND ENDOCRINE FUNCTION IN NORMAL AND BRATTLEBORO RATS WITH HYPOTHALAMIC DIABETES-INSIPIDUS

000048 01-03 BIOCHEMICAL DIFFERENTIATION OF AMPHETAMINE VS METHYLPHENIDATE AND NOMIFENSINE IN RATS.

000061 01-03 POSSIBLE IMPORTANCE OF 5 HYDROXYTRYPTAMINE IN NEUROLEPTIC-

INDUCED CATALEPSY IN RATS. 000068 01-03 PRODUCTION OF UNDERWEIGHT EMBRYOS IN RATS TREATED WITH

BARBITURATES DURING PREGNANCY 000072 01-03 COMPARISON OF THE EFFECTS OF 6 CHLORO-2-AMINOTETRALIN AND OF ORG-6582, A RELATED CHLOROAMPHETAMINE ANALOG, ON BRAIN SEROTONIN METABOLISM IN RATS.

000114 01-03

FIRST-PASS EFFECT OF NALORPHINE IN RATS. 000153 01-03 STIMULUS EFFECTS OF DELTA9-THC AND ITS INTERACTION WITH

NALTREXONE AND CATECHOLAMINE BLOCKERS IN RATS 000157 01-03 SOME EFFECTS OF MUSCIMOL IN MICE. RATS AND CATS

SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF PHYSICAL DEPENDENCE IN RATS: III. AUTORADIOGRAPHIC STUDIES 000177 01-03 INHIBITORY EFFECT OF MORPHINE ON SERUM GONADOTROPINS AND

PROLACTIN OF PROESTROUS RATS. 000206 01-03 HYPOTHERMIA IN RATS PRODUCED BY NABILONE, A SYNTHETIC CANNABINOID

000213 01-03 A MORPHINE-LIKE FACTOR IN MAMMALIAN BRAIN: ANALGESIC **ACTIVITY IN RATS**

ACETYLCHOLINE TURNOVER IN SPECIFIC BRAIN AREAS OF RATS INJECTED WITH VARIOUS ANTIDEPRESSANTS. (UNPUBLISHED PAPER)

000244 01-03 EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON UTERINE AND VAGINAL CYTOLOGY OF OVARIECTOMIZED RATS.

000274 01-03 CAFFEINE RESTORES FEEDING RESPONSE TO 2 DEOXY-D-GLUCOSE IN 6 HYDROXYDOPAMINE TREATED RATS.

000277 01-03 DELTA9-TETRAHYDROCANNABINOL AND THE HIPPOCAMPUS: EFFECTS ON CA1 FIELD POTENTIALS IN RATS.

000287 01-03 NEURONAL LIPOFUSCIN IN CENTROPHENOXINE TREATED RATS 000303 01-03

MODIFICATION OF ELECTROSHOCK FIGHTING BY DRUGS KNOWN TO INTERACT WITH DOPAMINERGIC AND NORADRENERGIC NEURONS IN

000312 01-04 PRENATAL ALCOHOL CONSUMPTION AND OPEN-FIELD BEHAVIOUR IN RATS: EFFECTS OF AGE AT TIME OF TESTING. 000321 01-04 Subject Index

KINETIC STUDIES OF FOOD INTAKE AND SUCROSE SOLUTION PREFERENCE BY RATS TREATED WITH LOW DOSES OF DELTA9-TETRAHYDROCANNARINOL

000324 01-04 PARADOXICAL EFFECTS OF AMPHETAMINE ON PREWEANLING AND POSTWEANLING RATS

FURTHER STUDIES OF THE AGGRESSIVE BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN REM SLEEP-DEPRIVED RATS.

ANTICONVULSANT INTERACTION OF CANNABIDIOL AND ETHOSUXIMIDE

000339 01-04 DISTINCT DOPAMINERGIC MECHANISMS WITHIN THE NUCLEUS-ACCUMBENS OF RATS AND BEHAVIOUR

000340 01-04 CATECHOLAMINES AND BIOCHEMICALLY-INDUCED ABNORMAL REHAVIOUR IN PATS

DRUG EFFECTS UPON FORCE AND DURATION OF RESPONSE DURING FIXED-RATIO PERFORMANCE IN RATS.

000363 01-04 DRUG-INDUCED CHANGES IN THE MATERNAL BEHAVIOR OF RATS. 000366 01-04

PRESYNAPTIC AND POSTSYNAPTIC ACTIONS OF APOMORPHINE: DIFFERENTIATION BY ROTARY EFFECTS IN NORMAL RATS.

000367 01-04 EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON FEEDING IN INTACT AND 6 HYDROXYDOPAMINE TREATED RATS.

000378 01-04 MORPHINE ACTION IN GROUPED AND ISOLATED RATS AND MICE.

000394 01-04
EVIDENCE FOR NORADRENERGIC MECHANISM IN THE GROOMING

PRODUCED BY () AMPHETAMINE AND 4, GAMMA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.

000397 01-04 FACILITATION OF MOUNTING BEHAVIOR BY DIHYDROTESTOSTERONE-PROPIONATE IN CASTRATED ESTRADIOL-BENZOATE TREATED MALE RATS FOLLOWING PUDENDECTOMY

000403 01-04 EFFECTS OF ALCOHOL ON ATTACK AND DEFENSIVE SUBMISSIVE **REACTIONS IN RATS**

000413 01-04 SUPPRESSION OF NEOPHOBIA BY CHLORPROMAZINE IN WILD RATS.

LONG-TERM BEHAVIOURAL AND BIOCHEMICAL EFFECTS FOLLOWING PROLONGED TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN PATS

000420 01-04 P-CHLOROPHENYLALANINE PRODUCED EFFECTS ON BEHAVIOR IN INTACT AND BRAIN-DAMAGED RATS.

000421 01-04 EFFECTS OF MONOSODIUM-GLUTAMATE ON EATING AND DRINKING BEHAVIOR IN RATS.

000423 01-04 PHARMACOLOGICAL APPROACHES TO HABITUATION OF THE ACOUSTIC STARTLE RESPONSE IN RATS.

000425 01-04
HYPERSENSITIVITY OF RATS TO ANORECTIC AGENTS AFTER LESIONS IN THE VENTROMEDIAL HYPOTHALAMUS.

000431 01-04 EFFECTS OF CHLORDIAZEPOXIDE ON TAIL PINCH-INDUCED EATING IN RATS.

000442 01-04 ATTENUATION OF MORPHINE ANALGESIA IN RATS BY INTRA AMYGDALOID INJECTION OF DOPAMINE.

000443 01-04 ELEVATION OF AVERSIVE THRESHOLD IN RATS BY INTRA-AMYGDALOID INJECTION OF MORPHINE-SULPHATE.

DOES PROLACTIN PLAY A ROLE IN ESTROGEN-INDUCED MATERNAL BEHAVIOR IN RATS: APOMORPHINE REDUCTION OF PROLACTIN RELEASE.

000445 01-04 IMPAIRMENT OF RETENTION OF AVOIDANCE RESPONSES IN RATS BY POSTTRAINING DIETHYLDITHIOCARBAMATE.

FURTHER STUDIES ON BL-3912A: EFFECTS ON AVOIDANCE BEHAVIOR OF RATS WITH LOW BASELINES AND ON REACTION THRESHOLDS TO FLECTRIC FOOTSHOCK

EVIDENCE FOR WITHDRAWAL FROM CAFFEINE BY RATS

000467 01-04 A NEW ANOREXIGEN ASSAY: STRESS-INDUCED HYPERPHAGIA IN RATS. 000468 01-04

ATTENUATION OF THE RATE DECREASING EFFECTS OF AMPHETAMINE ON FIXED-RATIO RESPONDING IN RATS BY HIPPOCAMPAL LESIONS 000474 01-04

PLASMA NORTRIPTYLINE AND CARDIAC RESPONSES IN YOUNG AND OLD RATS

LETHAL EFFECTS OF PHYSOSTIGMINE PLUS LITHIUM IN RATS.

000485 01-05

LITHIUM ABSORPTION, DISTRIBUTION AND CLEARANCE AND BODY
TEMPERATURE IN RATS GIVEN LITHIUM PLUS HALOPERIDOL.

000488 01-05

EFFECTS OF CHRONIC MORPHINE ADMINISTRATION ON PREGNANT RATS
AND THEIR OFFSPRING.

000491 01-05 INTERACTION OF DRUGS WITH APOMORPHINE, TRYPTAMINE AND NOREPINEPHRINE. A NEW IN VIVO APPROACH: THE ATN-TEST IN RATS.

ELECTRON MICROSCOPIC STUDIES ON THE CEREBRAL LESIONS OF RATS IN EXPERIMENTAL CHRONIC DISULFIRAM POISONING.

EFFECT OF LOCAL APPLICATION OF APOMORPHINE TO THE CORPUS-STRIATUM AND TO THE NUCLEUS-ACCUMBENS ON THE RESERPINE-INDUCED RIGIDITY IN RATS.

001021 02-02 A ROLE FOR CENTRAL SEROTONERGIC SYSTEMS IN THE PATTERN AND INTENSITY OF THE CONVULSIVE RESPONSE OF RATS TO ELECTROSHOCK.

EFFECTS OF PHENOBARBITAL AND DIAZEPAM ON IMIPRAMINE-INDUCED CHANGES IN BLOOD PRESSURE, HEART RATE AND RECTAL TEMPERATURE OF RATS.

COCAINE-INDUCED CENTRALLY MEDIATED RELEASE OF CATECHOLAMINES INTO BLOOD OF UNDISTURBED RATS. (UNPUBLISHED PAPER).

AND GATE OF MANDRIBLE IN A ST. (UNIVERSISTED PAPER).

O01079 02-03

ANALGESIA INDUCED BY VAGINAL STIMULATION IN RATS IS

APPARENTLY INDEPENDENT OF A MORPHINE SENSITIVE PROCESS.

O01090 02-03

EFFECTS OF DISULFERAM ON PHARMACOLOGICAL ACTIVITY, TOXICITY

AND FATE OF MORPHINE IN RATS.

001111 02-03 INTERACTION OF AMITRIPTYLINE AND MORPHINE IN MORPHINE-TOLERANT AND NONTOLERANT RATS.

PENTOBARBITAL DOES NOT INFLUENCE THE ANTINOCICEPTIVE EFFECTS OF MORPHINE IN NAIVE OR MORPHINE-TOLERANT RATS.

001132 02-03 MORPHINE ANALGESIA DOSE RESPONSE CURVES IN TOLERANT RATS: MODIFICATION BY NALOXONE.

EFFECT OF NEUROLEPTICS, MYDANTHAN, AND DOPA ON APOMORPHINE-INDUCED STEREOTYPY IN RATS.

001155 02-03

FIRST-PASS EFFECT OF NALORPHINE IN RATS. 001166 02-03 THE BEHAVIORAL EFFECTS OF DIISOPROPYL-PHOSPHOFLUORIDATE: INTERACTIONS WITH MORPHINE AND NALOXONE IN RATS.

001169 02-03 EFFECTS OF AMPHETAMINE ON BRAIN BIOGENIC AMINES IN ISOLATED AND AGGREGATED RATS.

001182 02-03 MONOSYNAPTIC ACTIVATION OF FASCIA-DENTATA IN UNRESTRAINED RATS: RESPONSE MODIFICATION BY SYNAPTICALLY ACTIVE DRUGS

SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT AND NEWBORN RATS

INVOLVEMENT OF CENTRAL NORADRENERGIC SYSTEM IN THE MEDIATION OF BEHAVIORAL SUPPRESSANT EFFECTS OF DIAZEPAM IN HYPERTHYROID RATS.

001220 02-03 THE EFFECT OF ABLATION OF SEROTONIN OR NOREPINEPHRINE BRAINSTEM AREAS ON HALOTHANE AND CYCLOPROPANE MAC IN RATS. (UNPUBLISHED PAPER).

001229 02-03
ANTAGONISM OF PENTOBARBITAL-INDUCED HORMONAL CHANGES BY TRH IN RATS.

001255 02-03 EFFECTS ON TEMPERATURE OF MORPHINE INJECTED INTO THE PREOPTIC/ ANTERIOR HYPOTHALAMUS, MEDULLA-OBLONGATA, AND PERIPHERALLY IN UNRESTRAINED AND RESTRAINED RATS.

001264 02-03 THE ROLE OF HYPOTHALAMIC SEROTONIN (5-HT) BEFORE OVULATION IN IMMATURE RATS TREATED WITH PREGNANT MARE SERUM (PMS).

001287 02-03 THE THERMAL EFFECTS OF INTERACTION BETWEEN D AMPHETAMINE AND ANTIDEPRESSANTS AMONG RATS KEPT AT VARIOUS AMBIENT TEMPERATURES.

ANTAGONISM BETWEEN THE EFFECTS OF L-DOPA AND APOMORPHINE ON THE BEHAVIOR OF RATS.

CLOZAPINE INDUCES HYPERPHAGIA IN UNDEPRIVED RATS. 001301 02-04 EFFECTS OF ANTIPSYCHOTIC AND ANTIANXIETY DRUGS ON THE MORPHINE ABSTINENCE SYNDROME IN RATS.

001303 02-04 THE EFFECTS OF NEONATAL INJECTIONS OF ALPHA-MSH ON THE OPEN-FIELD BEHAVIOR OF JUVENILE AND ADULT RATS.

001309 02-04 EFFECTS OF LITHIUM ON SEIZURE SUSCEPTIBILITY IN ALCOHOLIZED AND NONALCOHOLIZED RATS.

INFLUENCE OF PHARMACOLOGICAL AGENTS ON AVOIDANCE REFLEXES IN A GROUP EXPERIMENT ON RATS.

001317 02-04 P-METHOXYPHENYLETHYLAMINE (PMPEA): SOME BEHAVIORAL OBSERVATIONS IN RATS.

NARCOTIC BLOCKADE, LENGTH OF ADDICTION, AND PERSISTENCE OF INTRAVENOUS MORPHINE SELF-ADMINISTRATION IN RATS.

001322 02-04 LORDOSIS REFLEX, SEXUAL RECEPTIVITY, AND FEEDING: RESPONSIVITY IN MALE AND FEMALE RATS. **ESTROGEN**

001327 02-04 DIFFERENTIAL EFFECT OF NALOXONE ON FIXED-RATIO OPERANT BEHAVIOR IN STRESSED AND NONSTRESSED RATS.

001330 02-04 COMPARISON OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE AND AMPHETAMINE IN RATS.

EFFECTS OF DOPAMINE SUPERSENSITIVITY ON LATERAL HYPOTHALAMIC SELF-STIMULATION IN RATS.

ACUTE AND CHRONIC EFFECTS OF GENERAL CNS DEPRESSANTS ON SEVERAL REMAYIONAL TESTS IN CONTROL OF THE PROPERTY OF SEVERAL BEHAVIORAL TESTS IN RATS.

001356 02-04 INFLUENCE OF SOME NEUROPSYCHOTROPIC DRUGS ON THE BEHAVIOURAL MODIFICATIONS INDUCED BY 3 ACETYLPYRIDINE IN RATS.

001358 02-04 A BIOCHEMICAL AND BEHAVIORAL ANALYSIS OF CHRONIC ALCOHOL CONSUMPTION BY RATS.

001362 02-04 EFFECTS OF AMPHETAMINE ON ENDURANCE PERFORMANCE AND MUSCLE WEAKNESS IN RATS.

001363 02-04 NORMAL AND AMPHETAMINE-INDUCED ROTATION OF RATS ON A FLAT SURFACE

001365 02-04 MODIFICATION OF THE AMPHETAMINE-INDUCED STEREOTYPY IN RATS FOLLOWING INHIBITION OF THE NORADRENALINE RELEASE BY FLA-136 001367 02-04

EFFECT OF SOME CENTRALLY ACTIVE COMPOUNDS ON AGGRESSIVE BEHAVIOUR IN SEPTAL RATS.

CHOLINERGIC MECHANISMS INVOLVED IN HEAD-SHAKING OF INFANT RATS

001380 02-04 CHRONIC AND ACUTE EFFECTS OF BARBITAL AND AMPHETAMINE IN DOPAMINE DEPLETED RATS.

001389 02-04 BEHAVIORAL EFFECTS OF NEUROLEPTICS, APOMORPHINE AND AMPHETAMINE AFTER BILATERAL LESION OF THE LOCUS-COERULEUS IN RATS.

001393 02-04 CORRELATED EFFECT OF CORTICOSTERONE ON HYPOTHALAMIC SEROTONIN AND AVOIDANCE BEHAVIOUR IN RATS.

001394 02-04 DISCRIMINATIVE PENTOBARBITAL EFFECT MEASURED BY HEAD MOVEMENTS IN RESTRAINED RATS.

DIFFERENTIAL TOLERANCE TO INHIBITORY ACTION OF VARIOUS NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS CHRONICALLY TREATED WITH HALOPERIDOL.

001398 02-04 THE EFFECT OF NONCONTINGENT AMPHETAMINE INJECTIONS ON THE EXTINCTION OF FOOD AND DRUG REINFORCED LEVER PRESSING IN RATS.

THE INFLUENCE OF PENTOBARBITAL UPON A CORTICAL EPILEPTOGENIC FOCUS IN RATS.

APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR, LOCOMOTOR STIMULATION AND HYPOTHERMIA IN SPONTANEOUS HYPERTENSIVE RATS AND NORMOTENSIVE WISTAR RATS.

001413 02-04 EFFECTS OF L-DOPA, D AMPHETAMINE AND COCAINE ON INTRUDER-EVOKED AGGRESSION IN RATS AND MICE.

001420 02-04 EFFECTS OF PHENCYCLIDINE ON OPERANT BEHAVIOR IN RATS 001423 02-04

EFFECTS OF MAGNESIUM PEMOLINE ON PATTERN DISCRIMINATION LEARNING IN YOUNG RATS.

001425 02-04

002103 03-03

THE STRUCTURE OF BEHAVIOR OF RATS DURING MORPHINE-INDUCED HYPERACTIVITY.

AN ATTEMPT TO PREDICT THE DURATION OF PENTOBARBITAL NARCOSIS ON THE BASIS OF EXPLORATORY ACTIVITY, DEFECATION RATE AND BODY WEIGHT OF RATS.

VARIOUS EFFECTS OF D AMPHETAMINE IN RATS WITH SELECTIVE LESIONS OF BRAIN NORADRENALINE CONTAINING NEURONS OR TREATED WITH PENFLURIDOL.

EFFECT OF PRETRIAL AND POSTTRIAL TYRAMINE AND GUANETHIDINE INJECTIONS ON AN APPETITIVE TASK IN RATS.

001439 02-04
LOCATION PREFERENCE AND FLAVOR AVERSION REINFORCED BY
AMPHETAMINE IN RATS

O01443 02-04

EFFECTS OF ANTIESTROGENS ON EATING, FEMALE SEXUAL BEHAVIOR,
AND THE UPTAKE OF H3-ESTRADIOL IN THE CENTRAL-NERVOUSSYSTEM IN RATS. (PH.D. DISSERTATION).

ODOR AVERSION LEARNING IN NEONATAL RATS.

001448 02-04
EFFECT OF PANAX GINSENG ROOT ON CONDITIONED AVOIDANCE
RESPONSE IN RATS.

D AMPHETAMINE AND ADJUNCTIVE DRINKING IN RATS.

001453 02-04
NALOXONE PRECIPITATED WITHDRAWAL REVEALS SENSITIZATION TO
NEUROTRANSMITTERS IN MORPHINE-TOLERANT/DEPENDENT RATS.
001456 02-04

EFFECTS OF PSYCHOTROPIC AGENTS ON AMPHETAMINE-INDUCED
BEHAVIOR IN RATS.

001460 02-04

BIPHASIC EFFECTS OF APOMORPHINE ON LOCOMOTOR ACTIVITY IN RATS.

EFFECTS ON HYPOTHALAMIC SELF-STIMULATION OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION INJECTED INTO NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM OF RATS.

001466 02-04
BEHAVIORAL AND PSYCHOPHARMACOLOGICAL CHARACTERISTICS OF
RATS RAISED IN HIGH POPULATION DENSITY.

THE EFFECT OF NORADRENALINE ON THE ECOG OF THE PREPARATION ENCEPHALE ISOLE OF RATS.

001475 02-04
COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON ROTATIONAL
BEHAVIOR IN RATS WITH UNILATERAL 6 HYDROXYDOPAMINE
LESIONS

ON THE EFFECT OF NOOTROPIL AN ATP AND ATPASE IN BRAIN OF RATS.
O01482 02-04

COMPARISON OF BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE AFTER FLUPHENAZINE-DIHYDROCHLORIDE AND FLUPHENAZINE-DECANOATE TREATMENT IN RATS.

001484 02-04
EFFECT OF SCOPOLAMINE ON RETENTION OF A SHOCK MOTIVATED
BRIGHTNESS DISCRIMINATION IN RATS.

001487 02-04
EFFECTS OF D AMPHETAMINE ON DIFFERENT RATES OF AVOIDANCE
BEHAVIOR IN RATS.

O01488 02-04
CONCURRENT INTRACRANIAL SELF-STIMULATION AND AMPHETAMINE
SELF-ADMINISTRATION IN RATS.

SUBSTANTIAL INCREASE IN THE LEVELS OF CHLOROPHENOXYACETIC-ACIDS IN THE CNS OF RATS AS A RESULT OF SEVERE INTOXICATION.

001505 02-05
ROLE OF BRAIN NOREPINEPHRINE IN NEUROLEPTIC-INDUCED CATALEPSY
IN RATS.

001509 02-05

DECREASED FEEDING IN RATS FOLLOWING HEPATIC PORTAL INFUSION OF GLUCAGON.

QUANTITATIVE DETERMINATION OF STRESS-INDUCED MYOCARDIAL DAMAGE IN RATS.

O01536 02-06
THE PNEUMATIC SYRINGE: A SIMPLE APPARATUS FOR SELFADMINISTRATION OF DRUGS BY RATS.

001541 02-06
CHLOROQUINE POTENTIATION OF THIORIDAZINE EFFECTS IN RATS AND
DRUG RESISTANT SCHIZOPHRENIC PATIENTS: A PRELIMINARY REPORT.
001571 02-08

STUDY OF A DOPAMINERGIC POTENTIAL ANTIPARKINSON COMPOUND IN INTACT AND NIGRA-LESIONED RATS: N-N PROPYLBUTYLDIHYDROXYPHENYLETHYLAMINE HCL.

001957 03-02
INHIBITION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS IN RATS BY PROSTAGLANDIN-E1: ROLE OF BRAIN MONOAMINES.

BIOCHEMICAL AND BEHAVIOURAL EFFECTS OF HYPOXIC HYPOXIA IN RATS: STUDY OF THE PROTECTION AFFORDED BY ERGOT ALKALOIDS. 001971 03-03 EFFECTS OF PARGYLINE ON HYPOTHALAMIC BIOGENIC AMINES AND

SERUM PROLACTIN (PRL), LH AND TSH IN MALE RATS.

001988 03-03

FAILURE OF MORPHINE TO INCREASE STRIATAL 3,4
DIHYDROXYPHENYLACETIC-ACID IN FASTED RATS.

BLOCKAGE OF PROGESTERONE-INDUCED RELEASE OF LUTEINIZING
HORMONE AND PROLACTIN BY D AMPHETAMINE AND FENFLURAMINE
IN RATS.

PHENOBARBITAL METABOLISM DURING CHRONIC ADMINISTRATION IN PATS

002007 03-03

EFFECTS OF FENFLURAMINE AND NORFENFLURAMINE ON BRAIN

SEROTONIN METABOLISM IN RATS.

O02016 03-03
EFFECT OF ANTICONVULSANTS ON THALAMIC AFTER-DISCHARGE IN RATS
AND CATS.

002046 03-03
THE CEREBROVASCULAR PERMEABILITY TO PROTEIN AFTER BICUCULLINE
AND AMPHETAMINE ADMINISTRATION IN SPONTANEOUSLY
HYPERTENSIVE RATS.

002050 03-03

EFFECTS OF DIETHYLDITHIOCARBAMATE ON BRAIN MONOAMINE AND PROTEIN CONTENT IN NEONATAL RATS.

002063 03-03
SUPPRESSION OF THE HYPOTHALAMIC PITUITARY ADRENAL AXIS AFTER
ORAL HYDROCORTISONE-SUCCIMATE INGESTION IN RATS.

002098 03-03

EFFECT OF SYNTHESIS INHIBITION ON THE LEVELS OF BRAIN

CATECHOLAMINES IN BARBITAL DEPENDENT RATS.

THE KINETICS OF IMIPRAMINE-N-OXIDE IN RATS.

THE EFFECT OF LITHIUM ON SEROTONIN METABOLISM IN THE BRAIN OF RATS WITH PARTICULAR ATTENTION TO ITS EFFECT UNDER THE MONOAMINE ALTERED CONDITIONS.

ONTOGENETIC DEVELOPMENT OF PENTOBARBITAL EFFECTS ON ELECTROCORTICOGRAM IN RATS.

O02161 03-03

FENFLURAMINE AND FLUOXETINE SPARE PROTEIN CONSUMPTION WHILE
SUPPRESSING CALORIC INTAKE BY RATS.

MEMORIZATION AND CENTRAL CATECHOLAMINES AFTER A
CRANIOCERVICAL INJURY CARRIED OUT IN RATS: INFLUENCE OF
IMIPRAMINE ADMINISTRATION.

BEHAVIORAL EFFECTS OF APOMORPHINE DURING DEVELOPMENT OF

O02203 03-04
PIPEROXANE REDUCES THE EFFECTS OF CLONIDINE ON AGGRESSION IN
MICE AND ON NORADRENALINE DEPENDENT HYPERMOTILITY IN RATS.
002205 03-04

BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE.

002224 03-04
RAPID TOLERANCE TO THE MOTOR EFFECTS OF P-CHLOROAMPHETAMINE
IN RATS.

O02226 03-04

EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DEPLETIONS OF BRAIN
CATECHOLAMINES OR DOPAMINE ON MEPERIDINE ANTINOCICEPTION
IN RATS.

002227 03-04

EFFECTS OF CLOMIPRAMINE AND OTHER INHIBITORS OF MONOAMINE

UPTAKE ON THE SEXUAL BEHAVIOUR OF FEMALE RATS AND RHESUS

MONKEYS.

O02228 03-04

SOME EFFECTS OF CHLORDIAZEPOXIDE AND D AMPHETAMINE ON RESPONSE FORCE DURING PUNISHED RESPONDING IN RATS.

002234 03-04
DIFFERENTIAL EFFECTS OF THE ANTIANDROGEN FLUTAMIDE ON ASPECTS
OF SEXUAL BEHAVIOR IN CASTRATED, ANDROGEN TREATED MALE
RATS

002237 03-04
MONOAMINERGIC INFLUENCES ON THE INCORPORATION OF S35 IN THE
HYPOTHALAMIC AND NEUROHYPOPHYSIAL PROTEINS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF S35-CYSTEINE IN
DELLYDLATED BATE

O02238 03-04
STEREOTYPY AND HYPERACTIVITY IN RATS RECEIVING ETHANOL AND A
MONOAMINE-OXIDASE INHIBITOR.

602248 03-04

EFFECTS OF SALSOLINOL, A TETRAHYDROISOQUINOLINE ALKALOID, ON MULTIPLE SCHEDULE PERFORMANCE IN RATS.

001968 03-03

EFFECT OF DIAZEPAM ON FOOD CONSUMPTION IN RATS.

002252 03-04 NALOXONE-INDUCED OR POSTWITHDRAWAL ABSTINENCE SIGNS IN DELTAP-TETRAHYDROCANNABINOL-TOLERANT RATS.

MESOLIMBIC DOPAMINE NEURONS: EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DESTRUCTION AND RECEPTOR BLOCKADE ON DRUG-INDUCED ROTATION OF RATS

002258 03-04 SOME BEHAVIORAL EFFECTS OF SP6-11 HEXAPEPTIDE C-TERMINAL OF SUBSTANCE-P INJECTED INTO THE CEREBRAL VENTRICLES IN RATS.

OPEN-FIELD BEHAVIOR AFTER INTRAVENOUS AMPHETAMINE ANALOGUES

THE EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY AND STEREOTYPED BEHAVIOUR OF RATS STUDIED ON A HOLE-BOARD 002274 03-04

RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION WITH A HIGH FAT/PROTEIN DIET.

ESTABLISHMENT OF ETONITAZENE AS A REINFORCER FOR RATS BY USE OF SCHEDULE-INDUCED DRINKING.

002281 03-04 THE EFFECTS OF PROLONGED HANDLING, SCOPOLAMINE, AND PHYSOSTIGMINE ON THE ACTIVITY OF ISOLATED AND SOCIALLY

PHARMACOLOGICAL AND BEHAVIORAL COMPONENTS OF TOLERANCE TO LSD AND MESCALINE IN RATS.

RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDROXYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN
ACUTE AND CHRONIC SPINAL RATS.

002289 03-04 EFFECTS OF CATECHOL ESTROGENS ON SEXUAL DIFFERENTIATION IN NEONATAL FEMALE RATS.

002293 03-04 PREVENTION OF ENVIRONMENTAL STRESS IMPACT ON RAT 002296 03-04

EFFECT OF P-CHLOROPHENYLALANINE (PCPA) AND PHENYLALANINE (PHE) TREATMENT ON EARLY AUDITORY EVOKED RESPONSES IN RATS. 002304 03-04

ADULT BEHAVIOR AND ADRENOCORTICAL FUNCTION FOLLOWING NEONATAL MORPHINE TREATMENT IN RATS.

COMPARATIVE STUDY OF THE ANTAGONISM OF BEMEGRIDE AND PICROTOXIN ON BEHAVIOURAL DEPRESSANT EFFECTS OF DIAZEPAM IN RATS AND MICE.

002312 03-04 EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AGONISTS AND ANTAGONISTS INTO THE AMYGDALA ON RETENTION OF PASSIVE AVOIDANCE TRAINING IN RATS. (PH.D. DISSERTATION).

002323 03-04 INTRAVENOUS SELF-ADMINISTRATION OF DRUGS IN RATS.

LETHALITY OF PENTYLENETETRAZOL IN RATS AFTER DEPLETION OF BRAIN NOREPINEPHRINE.

002337 03-05 COMPARATIVE TOXICITY OF CAFFEINE AND AMINOPHYLLINE IN YOUNG AND ADULT RATS.

002342 03-05
INHIBITION OF FLAVIN SYNTHESIS BY CHLORPROMAZINE IN EUTHYROID AND HYPERTHYROID RATS.

002352 03-05 BEHAVIOURAL DESPAIR IN RATS: A NEW MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.

002370 03-06 ROTOMETER FOR RECORDING ROTATION IN CHEMICALLY OF ELECTRICALLY STIMULATED RATS.

002373 03-06 STRENGTH DURATION PROPERTIES OF SINGLE UNITS DRIVEN BY ELECTRICAL STIMULATION OF THE LATERAL HYPOTHALAMUS IN RATS

002763 03-17

EFFECT OF CHRONIC TREATMENT WITH NEUROLEPTICS ON THE CONTENT
OF 3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE IN CEREBELLAR-CORTEX
OF RATS.

002827 04-03 EFFECTS OF MORPHINE ON BRAINSTEM NEURONES IN NAIVE AND CHRONIC MORPHINE TREATED RATS, AND EFFECTS OF PCPA.

002841 04-03 CHOLINE-ACETYLTRANSFERASE AND THE HIGH AFFINITY UPTAKE OF CHOLINE IN CORPUS-STRIATUM OF RESERPINISED RATS.

002847 04-03 BLOOD-BRAIN BARRIER DYSFUNCTION AFTER AMPHETAMINE ADMINISTRATION IN RATS.

002854 04-03 SHORT-TERM AND LONG-TERM EFFECTS OF CEREBROLYSINE ON EVOKED CORTICAL POTENTIALS IN RATS.

EFFECTS OF P-CHLOROAMPHETAMINE ON BRAIN SEROTONIN IN IMMATURE RATS.

O02866 04-03

ANGIOTENSIN BINDING AFFINITY AND CAPACITY IN THE MIDBRAIN AREA
OF SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS.

EFFECT OF 6 METHOXYTETRAHYDRO-BETA-CARBOLINE ON SERUM PROLACTIN LEVELS OF MALE RATS.

002903 04-03

EFFECTS OF MET-ENKEPHALIN ON BODY TEMPERATURE OF NORMAL AND MORPHINE-TOLERANT RATS.

002907 04-03 COMPARATIVE EFFECTS OF PEMOLINE, AMFONELIC-ACID AND AMPHETAMINE ON DOPAMINE UPTAKE AND RELEASE IN VITRO AND ON BRAIN 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN SPIPERONE-TREATED RATS.

002919 04-03 NA SYNTHETIC ABILITY IN CEREBELLA FROM TEMPERATURE AND HANDLING STRESSED NEONATAL RATS.

002934 04-03 NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND L-DOPA TO RATS.

002942 04-03 TISSUE DISTRIBUTION OF RADIOACTIVITY AFTER INJECTION OF C14-NITRAZEPAM IN YOUNG AND OLD RATS.

002948 04-03 CLONIDINE-INDUCED BODY TEMPERATURE CHANGES IN RATS WITH ANTERIOR OR POSTERIOR CORTICAL DAMAGE.

002959 04-03 CHANGES OF TAURINE CONTENT IN THE BRAIN TISSUE OF BARBITURATE DEPENDENT RATS.

002961 04-03 CARDIOVASCULAR RESPONSE TO INTRACEREBROVENTRICULAR ADMINISTRATION OF ACETYLCHOLINE IN RATS.

DOPAMINE-INDUCED HYPOTHERMIA IN MORPHINE-DEPENDENT RATS. 002988 04-03

TURNOVER RATES OF GAMMA-AMINOBUTYRIC-ACID IN SUBSTANTIA-NIGRA, NUCLEUS-CAUDATUS, GLOBUS-PALLIDUS AND NUCLEUS-ACCUMBENS OF RATS INJECTED WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS. 002996 04-03

EVIDENCE FOR CELL LOSS IN CORPUS-STRIATUM AFTER LONG-TERM TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN RATS 003030 04-03 EFFECT OF GINSENG ON THE BRAIN BIOGENIC MONOAMINES AND 3,5
AMP SYSTEM: EXPERIMENTS ON RATS.

003044 04-03 LITHIUM EFFECTS ON RAT BRAIN GLUCOSE METABOLISM IN LONG-TERM

LITHIUM TREATED RATS STUDIED IN VIVO. 003046 04-03

CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES.

003055 04-03 DIFFERENCES IN BENZODIAZEPINE RECEPTOR BINDING IN MAUDSLEY REACTIVE AND MAUDSLEY NONREACTIVE RATS.

003066 04-03 THE EFFECT OF CEREBROLYSINE ON CORTICAL EVOKED-POTENTIALS IN RATS WITH EARLY MALNUTRITION.

003069 04-03 THE EFFECTS OF INORGANIC LEAD ON THE CENTRAL CATECHOLAMINERGIC SYSTEM OF THE RODENT WITH EMPHASIS ON POSTNATALLY EXPOSED RATS AND MICE. (PH.D. DISSERTATION).

003078 04-03 THE EFFECTS OF INTRAVENTRICULAR INJECTION OF GAMMA-AMINOBUTYRIC-ACID (GABA) ON PROLACTIN AND GONADOTROPIN RELEASE IN CONSCIOUS FEMALE RATS.

003126 04-03 DISULFIRAM ALTERS DOPAMINE METABOLISM AT SITES IN RATS FOREBRAIN AS DETECTED BY PUSH-PULL PERFUSIONS.

003134 04-03 EFFECTS OF D AMPHETAMINE ON THE SET POINT OF THE THERMOREGULATORY SYSTEM IN RATS.

003146 04-03

THE EFFECTS OF DL-5-HYDROXYTRYPTOPHAN ON ETHANOL CONSUMPTION BY RATS.

003148 04-03 EFFECTS OF N METHYLAMINOETHANOL, AND N,N
DIMETHYLAMINOETHANOL IN THE DIET OF PREGNANT RATS ON
NEONATAL RAT BRAIN CHOLINERGIC AND PHOSPHOLIPID PROFILE 003149 04-03

THE EFFECT OF HOUSING AND GENDER ON MORPHINE SELF-ADMINISTRATION IN RATS.

003158 04-04 ALCOHOL CONSUMPTION IN RATS TREATED WITH LITHIUM-CARBONATE OR RUBIDIUM-CHLORIDE.

003159 04-04

002858 04-03

MOTILITY EFFECTS OF METHAMPHETAMINE IN RATS CHRONICALLY TREATED WITH MORPHINE.

EFFECTS OF BENZAZEPINE (SCH-12679) ON SHOCK-INDUCED FIGHTING AND LOCOMOTOR BEHAVIOR IN RATS.

RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS: ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT LEARNING WITH D AMPPHETAMINE TREATMENTS.

O03167 04-04

EFFECTS OF INTRAVENTRICULARLY ADMINISTERED MONOAMINES ON
SEIZURE SUSCEPTIBILITY AND BODY TEMPERATURE IN RATS.

AVERSIVENESS OF ORAL METHADONE IN RATS.

003180 04-04

STEREOTYPED BEHAVIOR AFTER CHOLINERGIC, BUT NOT DOPAMINERGIC, STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.

003208 04-04
BEHAVIOURAL EFFECTS OF METHYLPHENIDATE IN 6 HYDROXYDOPAMINE
TREATED NEONATAL RATS.

CHLORDIAZEPOXIDE FLUOXETINE INTERACTIONS ON FOOD INTAKE IN FREE-FEEDING RATS.

EXPLORATION IN IMMATURE RATS: EFFECTS OF DRUGS.

003218 04-04
NEUROLEPTIC-INDUCED ATTENUATION OF BRAIN STIMULATION REWARD
IN RATS

003221 04-04
TESTOSTERONE ATTENUATED STEREOTYPY AND HYPERACTIVITY INDUCED
BY BETA-PHENYLETHYLAMINE IN PARGYLINE PRETREATED RATS.
003224 04-04
CHANGES IN MORPHINE SELF-ADMINISTRATION AFTER TEL-DIENCEPHALIC

LESIONS IN RATS.

003228 04-04
BIMODAL DISTRIBUTIONS OF HIGHEST ETHANOL ACCEPTANCE

CONCENTRATIONS IN TWO STRAINS OF RATS.

003229 04-04

DELTA9-TETRAHYDROCANNABINOL ENHANCEMENT OF LORDOSIS BEHAVIOR IN ESTROGEN TREATED FEMALE RATS.

003230 04-04

COCAINE-INDUCED CONDITIONED TASTE AVERSIONS IN RATS.

003230 04-04

REPEATED EXPOSURE OF RATS TO THE CONVULSANT AGENT FLUROTHYL ENHANCES 5 HYDROXYTRYPTAMINE AND DOPAMINE MEDIATED BEHAVIOURAL RESPONSES.

EFFECTS OF THE PROSTAGLANDIN SYNTHESIS INHIBITOR, INDOMETHACIN ON ESTROGEN AND ESTROGEN PLUS PROGESTERONE-INDUCED SEXUAL RECEPTIVITY IN OVARIECTOMIZED RATS.

003237 04-04
HYPOTENSION AND THIRST IN RATS AFTER ISOPROTERENOL TREATMENT.
003245 04-04

PREFERENCE BEHAVIOR AND TASTE NERVE RESPONSES IN D PENICILLAMINE TREATED RATS. 003248 04-04

COCAINE AS A DISCRIMINATIVE CUE IN RATS: INTERACTIONS WITH NEUROLEPTICS AND OTHER DRUGS.

003250 04-04
FOOD RELATED INTRAVENOUS INSULIN SELF-ADMINISTRATION IN
NORMAL AND DIABETIC RATS.

003252 04-04
THE EFFECTS OF PIMOZIDE AND PHENOXYBENZAMINE PRETREATMENTS
ON AMPHETAMINE AND APOMORPHINE POTENTIATION OF THE
ACOUSTIC STARTLE RESPONSE IN RATS.

003257 04-04
BEHAVIORAL CHANGES AND MERCURY CONCENTRATIONS IN TISSUES OF RATS EXPOSED TO MERCURY VAPOR.

003258 04-04
DIMINISHED TASTE REACTIVITY TO SACCHARIN FOLLOWING CHRONIC
ADMINISTRATION OF THEOPHYLLINE IN RATS.

TACRINE AND ITS DERIVATIVES ANTAGONIZE CHOLINERGIC PSYCHOTOMIMETICS: BEHAVIORAL STUDY IN RATS.

O03262 04-04

OPPOSITE ACTION OF OXYTOCIN TO VASOPRESSIN IN PASSIVE
AVOIDANCE BEHAVIOR IN RATS.

AVOIDANCE BEHAVIOR IN KATS.

003263 04-04
SLEEP-INDUCING EFFECT OF A VASOPRESSIN ANALOG, DEAMINO-6-

CARBA-ORNITHINE-B-VASOPRESSIN (DCOV) IN RATS. 003265 04-04 ANTAGONISM OF PENTOBARBITAL DISCRIMINATIVE STIMULUS BY

BEMEGRIDE IN IMMOBILIZED RATS.

003266 04-04
PSYCHOTROPIC DRUGS AND SIDMAN AVOIDANCE IN RATS: IRT
DISTRIBUTION CHANGES.

003269 04-04
INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETING ON
HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE
(PCA) AND 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77).

EFFECTS OF CHRONIC INGESTION AND WITHDRAWAL OF SODIUM
BARBITONE ON LEARNING IN RATS.

O03273 04-04
POTENTIATION OF HEXOBARBITAL AND AMPHETAMINE EFFECTS IN MALE
AND FEMALE RATS PHYSICALLY DEPENDENT ON MORPHINE.
003275 04-04

THE BEHAVIORAL EFFECTS OF D AMPHETAMINE AND CHLORPROMAZINE IN RATS; COMBINATIONS WITH ACUTE AND CHRONIC ADMINISTRATION OF MORPHINE. (PH.D. DISSERTATION).

003278 04-04
BEHAVIORAL EFFECTS OF PSYCHOTHERAPEUTIC AGENTS IN RATS
CHRONICALLY DOSED WITH ALPHA-ACETYLMETHADOL.

THYROTROPIN-RELEASING HORMONE (TRH): LACK OF EFFECT ON SHOCK-ELICITED FIGHTING (SEF) IN RATS.

003283 04-04

THE CONTRIBUTION OF TRYPTAMINE TO THE BEHAVIOURAL EFFECTS OF L
TRYPTOPHAN IN TRANYLCYPROMINE TREATED RATS.

O03286 04-04
THE EFFECTS OF ELEVATING GAMMA-AMINOBUTYRATE CONTENT IN THE
SUBSTANTIA-NIGRA ON THE BEHAVIOUR OF RATS.

MOVEMENT INDUCED IN CATALEPTIC RATS: DIFFERENTIAL EFFECTS
PRODUCED BY ELECTRICAL STIMULATION OF THE LATERAL
HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FORMATION.
03297 04-04

THE EFFECT OF MORPHINE ON FEAR EXTINCTION IN RATS.

003305 04-04
TOLERANCE TO MORPHINE ANALGESIA AND IMMOBILITY MEASURED IN
RATS BY CHANGES IN LOG-DOSE-RESPONSE CURVES.

003307 04-04
HEMISPHERIC ASYMMETRY OF VISUAL EVOKED-POTENTIALS WITH
MOTOR IMBALANCE IN RATS.

003310 04-04
SIMILAR EFFECTS OF ESTROGEN AND LATERAL HYPOTHALAMIC LESIONS
ON FEEDING BEHAVIOR OF FEMALE RATS.

O03314 04-04

OPEN-FIELD AND LASHLEY III MAZE BEHAVIOUR OF THE OFFSPRING OF

AMPHETAMINE TREATED RATS.

003315 04-04
6 HYDROXYDOPAMINE-INDUCED CATECHOLAMINE DEPLETION AND
PASSIVE AVOIDANCE LEARNING IN RATS.

O03322 04-04 SCHIZOPHRENIC-LIKE TENDENCIES IN RATS NEONATALLY TREATED WITH 6 HYDROXYDDPAMINE. (PH.D. DISSERTATION).

TOLERANCE TO THE BEHAVIOURAL EFFECTS OF PHYSOSTIGMINE IN RATS: LACK OF IMPORTANCE OF BEHAVIOURAL COMPENSATION.

003326 04-04
BEHAVIORAL EFFECTS OF CHRONIC NARCOTIC ANTAGONIST
ADMINISTRATION TO INFANT RATS.

PARALLEL CHANGES IN BEHAVIOR AND HIPPOCAMPAL MONOAMINE
METABOLISM IN RATS AFTER ADMINISTRATION OF ACTH ANALOGUES.
003325 O4.04

003335 04-04
DIFFERENTIAL TOLERANCE TO PENTOBARBITAL IN RATS BRED FOR
DIFFERENCES IN ALCOHOL SENSITIVITY.

PITUITARY ADRENOCORTICAL AXIS AND SHOCK-INDUCED FIGHTING IN RATS.

003342 04-04

BEHAVIOURAL AND NEUROCHEMICAL EFFECTS OF REPEATED
ADMINISTRATION OF COCAINE IN RATS.

003346 04-04
EFFECTS OF D AMPHETAMINE ON TEMPORAL AND SPATIAL
DISCRIMINATION IN RATS

O03349 04-04
STRIATAL CELL SUPERSENSITIVITY TO APOMORPHINE IN DOPAMINE
LESIONED RATS CORRELATED TO BEHAVIOUR.

O03356 04-04

AVERSIVE PROPERTIES OF NARCOTIC ANTAGONISTS IN RATS.

EXPERIMENTAL BARBITURATE DEPENDENCE. I. BARBITURATE DEPENDENCE DEVELOPMENT IN RATS BY DRUG ADMIXED FOOD (DAF) METHOD.

COMPARATIVE EFFECTS OF APOMORPHINE AND NALOXONE IN ACUTELY DEFENDENT MORPHINIZED RATS AND MICE.

003379 04-04

SYSTEMIC ADMINISTRATION OF ENDORPHINS SELECTIVELY ALTERS OPEN-FIELD BEHAVIOR OF RATS.

003382 04-04

MOTOR ACTIVITY OF RATS FOLLOWING INTRACEREBRAL INJECTIONS OF DRUGS INFLUENCING GABA MECHANISMS.

THE DISCRIMINABILITY OF NALOXONE IN RATS DEPENDS ON CONCOMITANT MORPHINE TREATMENT.

003393 04-04

000128 01-03

Subject Index	
DIETARY EFFECTS UPON FOOD AND WATER INTAKE AND RESPONSIVENESS TO ESTROGEN, 2 DEOXYGLUCOSE AN	ID GLUCOSE IN
FEMALE RATS.	003402 04-04
TOXICITY OF 5 HYDROXYTRYPTOLINE IN RATS. EFFECTS OF SOME OF THE NEUROLEPTICS ON THE REPROD	003409 04-05
OF RATS. IMPROVED POLYETHYLENE INTRACEREBROVENTRICULAR (003419 04-05
RATS.	003440 04-06
NOW RCA ATTACKS MEMORY AID DRUGS.	001915 02-17
ISOLATION AND IDENTIFICATION OF AN IN VIVO REACTION	
6 HYDROXYDOPAMINE. FURTHER STUDIES ON BL-3912A: EFFECTS ON AVOIDANC RATS WITH LOW BASELINES AND ON REACTION THRES	000008 01-01 E BEHAVIOR OF HOLDS TO
ELECTRIC FOOTSHOCK. DISULFIRAM ETHANOL REACTION.	000461 01-04
	000707 01-13
ADRENERGIC MODULATION OF A CHOLINERGIC EMOTION. THE CATS THALAMUS.	
THE EFFECT OF NITRAZEPAM ON MANUAL SKILL, GRIP ST REACTION TIME WITH SPECIAL REFERENCE TO SUBJECT EVALUATION OF EFFECTS ON SLEEP.	001344 02-04 TRENGTH, AND IVE
PARADOXICAL REACTION TO L-DOPA IN SCHIZOPHRENIC	002626 03-14 PATIENTS.
REACTIONS	003449 04-08
EFFECTS OF ALCOHOL ON ATTACK AND DEFENSIVE SUBMI REACTIONS IN RATS.	
CATATONIC REACTIONS TO HIGH-POTENCY NEUROLEPTIC	000413 01-04 DRUGS. 000835 01-15
ADVERSE DRUG REACTIONS.	
ADVERSE REACTIONS LITERATURE: A BIBLIOMETRIC ANA	000876 01-15 LYSIS.
A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND CORRELATES OF EMOTIONAL REACTIONS ELICITED BY (STIMULATION OF THE HYPOTHALAMUS AND THE VENT TEGMENTUM.	RAL
BRAIN STIMULATION PROVOKED EMOTIONAL REACTIONS SOCIAL SITUATION.	001390 02-04 OF CATS IN A
ADVERSE REACTIONS TO MEDICATION IN PSYCHIATRIC IN THEIR MEANING, UTILITY AND PROBLEMS.	001395 02-04 NPATIENTS:
AN AUTOMATED SYSTEM FOR THE PREDICTION AND PRE	001744 02-15 VENTION OF
ADVERSE DRUG REACTIONS. (PH.D. DISSERTATION). EXTRAPYRAMIDAL REACTIONS IN ADDLESCENTS TREATER	001759 02-15 D WITH HIGH-
POTENCY ANTIPSYCHOTICS. DRUG UTILIZATION AND ADVERSE DRUG REACTIONS IN I	002654 03-15
PATIENTS: COMPARISON OF TWO PERIODS, 1969-72	AND 1973-76. 002684 03-15
PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC M DRUG METABOLISM — I. FACTORS THAT INFLUENCE N. ESTIMATIONS DURING MIXED FUNCTION OXIDASE REA	CTIONS. 002931 04-03
PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATIENT: TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS: D BETWEEN LIGHT AND NEAR VISION REACTIONS.	S DURING LONG- ISSOCIATION
REACTIVE	003673 04-15
METABOLIC ACTIVATION OF P-CHLOROAMPHETAMINE TO REACTIVE METABOLITE.	
DIFFERENCES IN BENZODIAZEPINE RECEPTOR BINDING IN REACTIVE AND MAUDSLEY NONREACTIVE RATS.	
L-DOPA TREATMENT OF REACTIVE STUPOROUS STATES.	003066 04-03

REACTIVITY

UMI

	DIETARY EFFECTS UPON FOOD A ND WATER INTAKE AND RESPONSIVENESS TO ESTROGEN, 2 DEOXYGLUCOSE AND	D GLUCOSE IN	PHARMACOLOGICAL INVESTIGATIONS CONCERNING COMBINATION EFFECTS OF ALCOHOL AND OXAZEPAM IN THE REACTIVITY PATT 000897
	FEMALE RATS. TOXICITY OF 5 HYDROXYTRYPTOLINE IN RATS.	003402 04-04	DOSE-RESPONSE EFFECTS OF ALCOHOL UPON RAT STRAINS BRED FO DIFFERENCES IN REACTIVITY TO ALCOHOL.
	TOAICHT OF S HIDROXTIKIFIOLINE IN KAIS.	003409 04-05	001498
	EFFECTS OF SOME OF THE NEUROLEPTICS ON THE REPRODI OF RATS.	UCTIVE ORGANS	NALOXONE REVERSAL OF MORPHINE ANALGESIA BUT FAILURE TO REACTIVITY TO PAIN IN THE FORMALIN TEST.
	IMPROVED POLYETHYLENE INTRACEREBROVENTRICULAR C		effect of thioridazine (Mellaril-Sandoz) on Psychomotor Function, Concentration, and Reactivity in Children wit
-		003440 04-06	BEHAVIOR DISORDERS. 002527
_	NOW RCA ATTACKS MEMORY AID DRUGS.	001915 02-17	DIMINISHED TASTE REACTIVITY TO SACCHARIN FOLLOWING CHRON ADMINISTRATION OF THEOPHYLLINE IN RATS.
U	CTION		003259
	ISOLATION AND IDENTIFICATION OF AN IN VIVO REACTION 6 HYDROXYDOPAMINE.		REACTOR SINGLE-BLIND EVALUATION OF HYPNOTIC ACTIVITY OF
	FURTHER STUDIES ON BL-3912A: EFFECTS ON AVOIDANCE RATS WITH LOW BASELINES AND ON REACTION THRES	000008 01-01 BEHAVIOR OF	CHLORDESMETHYLDIAZEPAM IN NO-PLACEBO REACTOR MEDICAL PATIENTS. 002379
	ELECTRIC FOOTSHOCK.	HOLDS TO	READING-DISABLED
	DISULFIRAM ETHANOL REACTION.	000461 01-04	CAFFEINE AND INATTENTIVENESS IN READING-DISABLED CHILDREN. 001721
		000707 01-13	REAPPRAISAL
	ADRENERGIC MODULATION OF A CHOLINERGIC EMOTIONA THE CATS THALAMUS.	AL REACTION IN	ANTIHYPERTENSIVE DRUGS AND DEPRESSION: A REAPPRAISAL. 003534
	THE CATS THALAMUS.	001344 02-04	REARED
	THE EFFECT OF NITRAZEPAM ON MANUAL SKILL, GRIP ST REACTION TIME WITH SPECIAL REFERENCE TO SUBJECTI EVALUATION OF EFFECTS ON SLEEP.	RENGTH, AND	THE EFFECTS OF PROLONGED HANDLING, SCOPOLAMINE, AND PHYSOSTIGMINE ON THE ACTIVITY OF ISOLATED AND SOCIALLY REARED RATS.
		002626 03-14	002285
	PARADOXICAL REACTION TO L-DOPA IN SCHIZOPHRENIC F	PATIENTS. 003449 04-08	A REASSESSMENT OF TRICYCLICS AND ECT IN DEPRESSION.
E/	ACTIONS		000571
	REACTIONS IN RATS.		BIPOLAR MANIC-DEPRESSIVE DISORDER: A REASSESSMENT OF COL AND OUTCOME.
	CATATOMIC DEACTIONS TO HIGH POTENCY MEUROLEPTIC	000413 01-04	001608
	CATATONIC REACTIONS TO HIGH-POTENCY NEUROLEPTIC I	000835 01-15	RECALL RETENTION, AND RITALIN.
	ADVERSE DRUG REACTIONS.		001728
	ADVERSE REACTIONS LITERATURE: A BIBLIOMETRIC ANAL		MARIJUANA: EFFECTS ON FREE RECALL AND SUBJECTIVE ORGANIZ OF PICTURES AND WORDS.
		000999 01-17	002629
	A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND CORRELATES OF EMOTIONAL REACTIONS ELICITED BY C	HOLINERGIC	MARIHUANA: EFFECT ON NONVERBAL FREE RECALL AS A FUNCTION FIELD DEPENDENCE.
	STIMULATION OF THE HYPOTHALAMUS AND THE VENTI	RAL	003300
	TEGMENTUM. BRAIN STIMULATION PROVOKED EMOTIONAL REACTIONS	001390 02-04	RECEIVING STEREOTYPY AND HYPERACTIVITY IN RATS RECEIVING ETHANOL A MONOAMINE-OXIDASE INHIBITOR.
	SOCIAL SITUATION.	OF CATS IN A	MONOAMINE-OXIDASE INFIBITOR. 002248
	ADVERSE REACTIONS TO MEDICATION IN PSYCHIATRIC IN	001395 02-04 IPATIENTS:	A BEHAVIORAL TREATMENT OF DEPRESSION WITH ALCOHOLICS RECEIVING PHARMACOLOGICAL AVERSIVE CONDITIONING. (PH.)
	THEIR MEANING, UTILITY AND PROBLEMS.	001744 02-15	DISSERTATION). 002539
	AN AUTOMATED SYSTEM FOR THE PREDICTION AND PREV ADVERSE DRUG REACTIONS. (PH.D. DISSERTATION).	VENTION OF	EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON PLASMA OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DEPRES.
	EVERABLE AND A MARKET THE ARCTIONS IN A POST COCCUSTO TREATER	001759 02-15	PATIENTS RECEIVING CLOMIPRAMINE THERAPY.
	EXTRAPYRAMIDAL REACTIONS IN ADOLESCENTS TREATED POTENCY ANTIPSYCHOTICS.	WITH HIGH-	RECEPTIVE 002577
	Totalic Filting Colonics.	002654 03-15	ANGIOTENSIN RECEPTIVE NEURONES IN THE SUBFORNICAL ORGAN.
	DRUG UTILIZATION AND ADVERSE DRUG REACTIONS IN A PATIENTS: COMPARISON OF TWO PERIODS, 1969-72 A	AEDICAL AND 1973-76.	STRUCTURE-ACTIVITY RELATIONS. 002906
		002684 03-15	RECEPTIVITY
	PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MI DRUG METABOLISM — I. FACTORS THAT INFLUENCE NA ESTIMATIONS OF THE PROPERTY O	ADPH KINETIC	LORDOSIS REFLEX, SEXUAL RECEPTIVITY, AND FEEDING: ESTROGEN RESPONSIVITY IN MALE AND FEMALE RATS.
	ESTIMATIONS DURING MIXED FUNCTION OXIDASE REAL	002931 04-03	001327 EFFECTS OF THE PROSTAGLANDIN SYNTHESIS INHIBITOR, INDOMET
	PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATIENTS TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS: DI	DURING LONG-	ON ESTROGEN AND ESTROGEN PLUS PROGESTERONE-INDUCED SI RECEPTIVITY IN OVARIECTOMIZED RATS.
	BETWEEN LIGHT AND MEAD VISION PEACTIONS		00222

REACTIVITY AND AGGRESSION IN THE RAT: INDUCTION BY ALPHA-ADRENERGIC BLOCKING AGENTS INJECTED VENTRAL TO ANTERIOR SEPTUM BUT NOT INTO LATERAL SEPTUM.

TIME-DEPENDENT CHANGES IN ACTIVITY, REACTIVITY, AND RESPONSIVITY DURING SHOCK: EFFECTS OF CHOLINERGIC AND CATECHOLAMINERGIC MANIPULATIONS.

EFFECTS OF ALCOHOL AND OXAZEPAM IN THE REACTIVE	TY PATTERN.
DOSE-RESPONSE EFFECTS OF ALCOHOL UPON RAT STRAINS DIFFERENCES IN REACTIVITY TO ALCOHOL.	
NALOXONE REVERSAL OF MORPHINE ANALGESIA BUT FAIL REACTIVITY TO PAIN IN THE FORMALIN TEST.	
EFFECT OF THIORIDAZINE (MELLARIL-SANDOZ) ON PSYCHO FUNCTION, CONCENTRATION, AND REACTIVITY IN CHILD BEHAVIOR DISORDERS.	MOTOR PREN WITH
DIMINISHED TASTE REACTIVITY TO SACCHARIN FOLLOWIN ADMINISTRATION OF THEOPHYLLINE IN RATS.	002527 03-11 G CHRONIC
REACTOR	003259 04-04
SINGLE-BLIND EVALUATION OF HYPNOTIC ACTIVITY OF CHLORDESMETHYLDIAZEPAM IN NO-PLACEBO REACTOR PATIENTS.	
READING-DISABLED	002379 03-07
CAFFEINE AND INATTENTIVENESS IN READING-DISABLED CO	HILDREN. 001721 02-14
REAPPRAISAL ANTIHYPERTENSIVE DRUGS AND DEPRESSION: A REAPPRA	ISAL. 003534 04-10
THE EFFECTS OF PROLONGED HANDLING, SCOPOLAMINE, A PHYSOSTIGMINE ON THE ACTIVITY OF ISOLATED AND S	
REARED RATS.	002285 03-04
A REASSESSMENT OF TRICYCLICS AND ECT IN DEPRESSION	
BIPOLAR MANIC-DEPRESSIVE DISORDER: A REASSESSMEN AND OUTCOME.	000571 01-09 T OF COURSE
RECALL	001608 02-09
RECALL, RETENTION, AND RITALIN.	001728 02-14
MARIJUANA: EFFECTS ON FREE RECALL AND SUBJECTIVE OF PICTURES AND WORDS.	ORGANIZATION
MARIHUANA: EFFECT ON NONVERBAL FREE RECALL AS A FIELD DEPENDENCE.	
RECEIVING	003300 04-04
STEREOTYPY AND HYPERACTIVITY IN RATS RECEIVING ET MONOAMINE-OXIDASE INHIBITOR.	
A BEHAVIORAL TREATMENT OF DEPRESSION WITH ALCOH RECEIVING PHARMACOLOGICAL AVERSIVE CONDITIONIN DISSERTATION).	
EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON F OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN	
PATIENTS RECEIVING CLOMIPRAMINE THERAPY.	002577 03-13
RECEPTIVE ANGIOTENSIN RECEPTIVE NEURONES IN THE SUBFORNICAL STRUCTURE-ACTIVITY RELATIONS.	ORGAN.
	002906 04-03
RECEPTIVITY LORDOSIS REFLEX, SEXUAL RECEPTIVITY, AND FEEDING: E RESPONSIVITY IN MALE AND FEMALE RATS.	STROGEN
EFFECTS OF THE PROSTAGLANDIN SYNTHESIS INHIBITOR, I ON ESTROGEN AND ESTROGEN PLUS PROGESTERONE-INI	
RECEPTOR	003237 04-04
DIRECT EVIDENCE FOR AN INTERACTION OF BETA-ADRENE WITH THE 5-HT RECEPTOR.	RGIC BLOCKERS
DOPAMINE RECEPTOR BLOCKING ACTIVITY OF THE SULPIR CENTRAL-NERVOUS-SYSTEM.	000010 01-01 IDE IN THE
DEVELOPMENT OF BETA-ADRENERGIC RECEPTOR SUBSENS ANTIDEPRESSANTS.	000024 01-02 ITIVITY BY
ON THE MECHANISM OF THE DECREASE IN CEREBELLAR CONTENT ELICITED BY OPIATE RECEPTOR AGONISTS.	000049 01-03 YCLIC-GMP
DOPAMINE RECEPTOR BINDING ENHANCEMENT ACCOMPA	000056 01-03 NIES LESION-
TRICYCLIC ANTIDEPRESSANT DRUGS BLOCK HISTAMINE H	000084 01-03 2 RECEPTOR IN

003673 04-15

000476 01-05

003066 04-03

003513 04-09

SECOND MESSENGER RESPONSES AND REGULATION OF HIGH AFFINITY RECEPTOR BINDING TO STUDY PHARMACOLOGICAL MODIFICATION OF GABAERGIC TRANSMISSION. (UNPUBLISHED PAPER).

000133 01-03 **ELECTRICAL STIMULATION OF DENERVATED MUSCLES REDUCES** INCORPORATION OF METHIONINE INTO THE ACH RECEPTOR

000136 01-03 BENZODIAZEPINE ACTIVITY: IS INTERACTION WITH THE GLYCINE RECEPTOR, AS EVIDENCED BY DISPLACEMENT OF STRYCHNINE BINDING, A USEFUL CRITERION?

000151 01-03 NEUROLEPTIC DRUG INTERACTIONS WITH NOREPINEPHRINE ALPHA RECEPTOR BINDING SITES IN RAT BRAIN.

000219 01-03 ANTIPSYCHOTICS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED CYCLIC-GMP FORMATION IN CULTURED MOUSE

NEUROBLASTOMA CELLS. 000241 01-03 ALTERED RECEPTOR SENSITIVITY FOLLOWING CHRONIC DRUG

ADMINISTRATION IN MAN: THE TARDIVE-DYSKINESIA MODEL 000248 01-03 NOREPINEPHRINE ALPHA RECEPTOR BINDING IN MAMMALIAN CENTRAL-NERVOUS-SYSTEM: DIFFERENTIAL LABELING WITH AGONIST AND

000283 01-03 LEVODOPA-INDUCED DOPAMINE RECEPTOR HYPERSENSITIVITY.
000392 01-04

BETA ADRENERGIC RECEPTOR LABELING IN INTACT ANIMALS WITH 1125-HYDROXYBENZYLPINDOLOL

000493 01-06 ANTISCHIZOPHRENIC DRUGS — MEMBRANE RECEPTOR SITES OF ACTION. 000547 01-08

SLEEP AND BEHAVIORAL CHANGES POSSIBLY REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN

000916 01-16 THE ELECTRONIC AND SEROTONIN RECEPTOR BINDING AFFINITY PROPERTIES OF N,N DIMETHYLTRYPTAMINE ANALOGS.

001002 02-01 3 HYDROXY-17-ARALKYLMORPHINANS AS POTENTIAL OPIATE RECEPTOR SITE DIRECTED AKLYLATING AGENTS.

001010 02-01 BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF CHRONIC REDUCTION OF CEREBRAL NORADRENALINE RECEPTOR STIMULATION.

001099 02-03 EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION

IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS. 001103 02-03 EFFECTS OF PERINATAL 6 HYDROXYDOPAMINE TREATMENT ON OPIATE

RECEPTOR DISTRIBUTION IN ADULT BRAIN. 001128 02-03 CEREBELLAR CGMP SYSTEM: A MODEL TO STUDY DRUG RECEPTOR

INTERACTION. (UNPUBLISHED PAPER). 001139 02-03

ALTERATIONS IN DOPAMINE RECEPTOR SENSITIVITY BY CHRONIC

001146 02-03 THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS.

001150 02-03 BENZODIAZEPINE RECEPTOR: DEMONSTRATION IN THE CENTRAL-

NERVOUS-SYSTEM 001198 02-03 BLOCKADE BY PSYCHOTROPIC DRUGS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR IN CULTURED NERVE CELLS.

001223 02-03 DECREASE OF FOOD INTAKE BY QUIPAZINE IN THE RAT: RELATION TO SEROTONINERGIC RECEPTOR STIMULATION.

001235 02-03 LOCOMOTOR STIMULATION BY L-DOPA: RELATIVE IMPORTANCE OF NORADRENALINE RECEPTOR ACTIVATION.

DIFFERENTIAL ACTIVATION BY SOME 2 AMINOTETRALIN DERIVATIVES OF THE RECEPTOR MECHANISMS IN THE NUCLEUS-ACCUMBENS OF RAT WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITIN

001335 02-04 RECEPTOR SENSITIVITY MODIFICATION (RSM) -- A NEW PARADIGM FOR THE POTENTIAL TREATMENT OF SOME HORMONAL AND TRANSMITTER DISTURBANCES

001659 02-13 ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS.

001672 02-13 NALOXONE AS A GABA-ANTAGONIST: EVIDENCE FROM IONTOPHORETIC, RECEPTOR BINDING AND CONVULSANT STUDIES 002003 03-03 ANTIDEPRESSANT DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS

002004 03-03 BETA-ADRENERGIC RECEPTOR MEDIATED CYCLIC-AMP SYNTHESIS IN BROKEN-CELL HOMOGENATES OF RAT BRAIN.

ANTIPSYCHOTIC DRUGS BLOCK MUSCARINIC ACETYLCHOLINE RECEPTOR MEDIATED FORMATION OF CYCLIC-GMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

002137 03-03 THE OPIATE RECEPTOR BINDING INTERACTIONS OF H3-METHIONINE ENKEPHALIN, AN OPIOID PEPTIDE.

RECEPTOR AFFINITY AND PHARMACOLOGICAL POTENCY OF A SERIES OF NARCOTIC ANALGESIC. ANTIDIARRHEAL AND NEUROLEPTIC DRUGS.

THE NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN THE LIMBIC TE NORADRENERGIC CYCLIC-AMP GENERATING STSTEM IN THE LIMBIC FOREBRAIN: A FUNCTIONAL POSTSYNAPTIC NOREPINEPHRINE RECEPTOR SYSTEM AND ITS MODIFICATION BY DRUGS WHICH EITHER PRECIPITATE OR ALLEVIATE DEPRESSION.

002164 03-03
MOLECULAR DETERMINANTS FOR THE ACTION OF TRYPTAMINES ON AN

002178 03-03 EFFECT OF BETA ADRENERGIC RECEPTOR ANTAGONISTS ON D AMPHETAMINE AND POTASSIUM-INDUCED RELEASE OF H3-NOREPINEPHRINE FROM RAT BRAIN IN VITRO.

002187 03-03 DUAL RECEPTOR MEDIATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF PENTAZOCINE

BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE.

MESOLIMBIC DOPAMINE NEURONS: EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DESTRUCTION AND RECEPTOR BLOCKADE ON DRUG-INDUCED ROTATION OF RATS.

002258 03-04 A REVIEW OF THE RELATIONSHIP BETWEEN ENDOCRINOPATHY AND DEPRESSION OR ANTIDEPRESSANT DRUGS, WITH PARTICULAR RESPECT TO NOVEL THEORIES INVOLVING THE OPIATE RECEPTOR.

002557 03-13 CATECHOLAMINE AGONIST AND RECEPTOR HYPOTHESIS OF AFFECTIVE-ILLNESS: PARADOXICAL DRUG EFFECTS.

002610 03-14 BIOCHEMICAL ACTIONS OF NEUROLEPTIC DRUGS: FOCUS ON THE

EFFECTS OF CENTRAL GABA RECEPTOR AGONISM AND ANTAGONISM ON EVOKED DIENCEPHALIC CARDIOVASCULAR RESPONSES.

DOPAMINE RECEPTOR BINDING OF H3-ADTN (2
AMINODIHYDROXYTETRAHYDRONAPHTHALENE) REGULATED BY GUANYL-NUCLEOTIDES

002877 04-03 A COMPARISON OF THE VASCULAR DOPAMINE RECEPTOR WITH OTHER DOPAMINE RECEPTORS.

DEMONSTRATION OF NEUROLEPTIC RECEPTOR SITES IN MOUSE BRAIN BY AUTORADIOGRAPHY.

002950 04-03
BLOCKADE OF BOTH PILOCARPINE AND AMPHETAMINE-INDUCED HEAD-SHAKING WITH DOPAMINE RECEPTOR ANTAGONISTS.

002951 04-03 A BEHAVIOURAL AND BIOCHEMICAL COMPARISON OF DOPAMINE RECEPTOR BLOCKAGE PRODUCED BY HALOPERIDOL WITH THAT PRODUCED BY SUBSTITUTED BENZAMIDE DRUGS.

002963 04-03 THE EFFECT OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF AMPHETAMINE ON CEREBRAL DOPAMINE RECEPTOR SENSITIVITY 002964 04-03

STRIATAL CONTENT OF CA2-DEPENDENT REGULATOR PROTEIN AND DOPAMINERGIC RECEPTOR FUNCTION. 002990 04-03 ROLE OF SEROTONIN REUPTAKE INHIBITION IN THE DEVELOPMENT OF SUBSENSITIVITY OF THE NOREPINEPHRINE (NE) RECEPTOR COUPLED

ADENYLATE-CYCLASE SYSTEM. 003017 04-03

H3-SPIROPERIDOL BINDING TO TWO RECEPTOR SITES IN BOTH THE CORPUS-STRIATUM AND FRONTAL CORTEX OF RAT BRAIN 003041 04-03

CYCLIC-NUCLEOTIDE LEVELS IN THE RAT STRIATUM AND CEREBELLUM IN VIVO EFFECTS OF DOPAMINE AND ACETYLCHOLINE RECEPTOR AGONISTS AND ANTAGONISTS.

TRYPTAMINE-INDUCED DRUG EFFECTS INSENSITIVE TO SEROTONINERGIC ANTAGONISTS: EVIDENCE OF SPECIFIC TRYPTAMINERGIC RECEPTOR STIMULATION?

LYSERGIC-ACID-DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF

PITUITARY DOPAMINE RECEPTORS

ROTATIONAL MODEL. BRAIN. RECEPTORS

BRAIN NEUROTRANSMITTER RECEPTORS AFTER LONG-TERM HALOPERIDOL: DOPAMINE, ACETYLCHOLINE, SEROTONIN, ALPHA-NORADRENERGIC AND NALOXONE RECEPTORS. 001200 02-03 TWO DOPAMINE RECEPTORS: SUPPORTIVE EVIDENCE WITH THE RAT 001478 02-04 HIGH DENSITIES OF BENZODIAZEPINE RECEPTORS IN HUMAN CORTICAL 001645 02-13 INTERACTION OF IODINATED ENKEPHALIN ANALOGUES WITH OPIATE 001947 03-01 IDENTIFICATION OF DOPAMINERGIC RECEPTORS IN ANTERIOR PITUITARY: CORRELATION WITH THE DOPAMINERGIC CONTROL OF PROLACTIN 001982 03-03 MULTIPLE CLASSES OF OPIATE RECEPTORS IN C57BL/6J AND DBA/2J MOUSE BRAIN. H3-HALOPERIDOL BINDING TO DOPAMINE RECEPTORS IN RAT CORPUS-STRIATUM: INFLUENCE OF CHLORPROMAZINE METABOLITES AND 001995 03-03 H3-SPIROPERIDOL LABELS DOPAMINE RECEPTORS IN PITUITARY AND 001996 03-03 EVIDENCE FOR SELECTIVE AND LONG-LASTING STIMULATION OF REGULATORY DOPAMINE RECEPTORS BY BROMOCRIPTINE (CB-154) 002002 03-03 DIRECT INTERACTION OF LSD WITH CENTRAL BETA-ADRENERGIC 002005 03-03 DOPAMINE RECEPTORS AND ERGOT DRUGS. EVIDENCE THAT AN ERGOLENE DERIVATIVE IS A DIFFERENTIAL AGONIST AT SUBCORTICAL 002019 03-03 BINDING INTERACTIONS OF ERGOT ALKALOIDS WITH MONOAMINERGIC ALPHA-NORADRENERGIC RECEPTORS IN THE BRAIN: DIFFERENTIAL EFFECTS OF SODIUM ON BINDING OF H3-AGONISTS AND H3-002029 03-03 OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG 002040 03-03 BRAIN NEUROTRANSMITTER RECEPTORS AND CHRONIC ANTIPSYCHOTIC DRUG TREATMENT: A MODEL FOR TARDIVE-DYSKINESIA. 002061 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS: 3.

SUBCELLULAR DISTRIBUTION OF NEUROLEPTIC DRUGS AND THEIR
RECEPTORS IN VARIOUS RAT BRAIN AREAS. 002067 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 2. REGIONAL DISTRIBUTION AND IN VIVO DISPLACEMENT OF 002068 03-03 EFFECT OF ERGOT ALKALOIDS AND OF NEUROLEPTICS ON BINDING TO PUTATIVE DOPAMINE AND ALPHA RECEPTORS. 002078 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 1. KINETICS AND CHARACTERISTICS OF IN VITRO BINDING. 002079 03-03 THE EFFECT OF L-DOPA ON PERIPHERAL SYMPATHETIC NERVE FUNCTION: ROLE OF PRESYNAPTIC DOPAMINE RECEPTORS. 002081 03-03 APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE RELEASE: ROLE OF DOPAMINERGIC RECEPTORS IN SUBSTANTIA-NIGRA. 002084 03-03 PRESYNAPTIC DOPAMINE RECEPTORS: DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING TREATMENT WITH FLUPHENAZINE-002120 03-03 EFFECTS OF DRUGS ON GAMMA-AMINOBUTYRIC-ACID RECEPTORS, UPTAKE, RELEASE AND SYNTHESIS IN VITRO. 002122 03-03 INTERACTION OF ERGOT ALKALOIDS WITH DOPAMINERGIC RECEPTORS IN THE RAT STRATUM AND NUCLEUS-ACCUMBENS. 002157 03-03 THE BINDING OF INHIBITORS OF SEROTONIN UPTAKE TO BIOLOGICAL 002562 03-13 DOPAMINE RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM 002779 03-17 EFFECT OF ENKEPHALIN AND ENDORPHIN ANALOGS ON RECEPTORS IN THE MOUSE VAS-DEFERENS. 002794 04-02

001187 02-03

001192 02-03

ONTOGENETIC DEVELOPMENT OF BENZODIAZEPINE RECEPTORS IN THE 002840 04-03

EFFECTS OF SOME DERIVATIVES OF 2 AMINOTETRALIN ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE AND ON THE BINDING OF H3-HALOPERIDOL TO NEUROLEPTIC RECEPTORS IN RAT STRIATUM 002853 04-03

SUPERSENSITIVITY OF THE CHOLINERGIC RESPONSE TO APOMORPHINE IN THE STRIATUM FOLLOWING DENERVATION OR DISUSE SUPERSENSITIVITY OF DOPAMINERGIC RECEPTORS IN THE RAT

002872 04-03 BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101 BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN RAT CEREBRAL-CORTEX.

SELECTIVE PURIFICATION OF A SINGLE POPULATION OF GLUCOCORTICOID RECEPTORS FROM RAT BRAIN.

VERTEBRATE GABA RECEPTORS

002892 04-03 LOSS OF STRIATAL DOPAMINERGIC RECEPTORS AFTER INTRASTRIATAL KAINIC-ACID INJECTION

002909 04-03 A COMPARISON OF THE VASCULAR DOPAMINE RECEPTOR WITH OTHER DOPAMINE RECEPTORS.

002927 04-03 CELLULAR LOCALIZATION OF H3-DIAZEPAM RECEPTORS.

002943 04-03 INVESTIGATIONS CONCERNING THE CELLULAR ORIGIN OF DOPAMINE

RECEPTORS 002944 04-03

PHARMACOLOGICAL CHARACTERIZATION OF THE EXCITATORY

CHOLINERGIC RECEPTORS OF RAT CENTRAL NEURONES. 003006 04-03

A COMPARISON OF THE EFFECTS OF ANTIPSYCHOTIC DRUGS ON PITUITARY, STRIATAL AND LIMBIC SYSTEM POSTSYNAPTIC DOPAMINE RECEPTORS. 003009 04-03

STRYCHNINE BINDING ASSOCIATED WITH SYNAPTIC GLYCINE RECEPTORS IN RAT SPINAL CORD MEMBRANES: IONIC INFLUENCES. 003024 04-03

CHARACTERIZATION OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS IN MEMBRANES PREPARED FROM THE RABBIT IRIS BEFORE AND AFTER DEVELOPMENT OF SUPERSENSITIVITY.

003035 04-03 H3-GLYCOGEN HYDROLYSIS IN BRAIN SLICES: RESPONSES TO NEUROTRANSMITTERS AND MODULATION OF NORADRENALINE RECEPTORS

003054 04-03 DOPAMINE RECEPTORS LOCALISED ON CEREBRAL CORTICAL AFFERENTS TO RAT CORPUS-STRIATUM.

THE OPIATE RECEPTORS.

PRIMATE BRAIN REGIONS

003092 04-03 ALTERATIONS IN RECEPTORS CONTROLLING DOPAMINE SYNTHESIS AFTER CHRONIC ETHANOL INGESTION.

003107 04-03 H3-SPIROPERIDOL BINDING AND DOPAMINE STIMULATED ADENYLATE-CYCLASE: EVIDENCE FOR MULTIPLE CLASSES OF RECEPTORS IN

003112 04-03 H3-APOMORPHINE INTERACTIONS WITH DOPAMINE RECEPTORS IN CALF BRAIN

003113 04-03 SELECTIVE LABELING OF PRESYNAPTIC RECEPTORS BY H3-DOPAMINE, H3-APOMORPHINE AND H3-CLONIDINE; LABELING OF POSTSYNAPTIC SITES BY H3-NEUROLEPTICS

INTERACTION OF PHENCYCLIDINES WITH THE MUSCARINIC AND OPIATE RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM. 003128 04-03

OPIATE RECEPTORS FOR BEHAVIORAL ANALGESIA RESEMBLE THOSE RELATED TO THE DEPRESSION OF SPINAL NOCICEPTIVE NEURONS 003142 04-03

ROLE OF HYPOTHALAMIC SEROTONERGIC RECEPTORS IN THE CONTROL OF LORDOSIS BEHAVIOR IN THE FEMALE RAT

003220 04-04 LACK OF BLOCKADE OF CENTRAL DOPAMINERGIC RECEPTORS BY NARCOTICS: COMPARISON WITH CHLORPROMAZINE

003354 04-04 LOCALIZATION OF RECEPTORS FOR THE DIPSOGENIC ACTION OF ANGIOTENSIN-II IN THE SUBFORNICAL ORGAN OF RAT

003361 04-04 NEUROLEPTIC DRUGS AND NEUROTRANSMITTER RECEPTORS.

003728 04-17 EXTRAPYRAMIDAL SIDE-EFFECTS IN CHLORPROMAZINE RECIPIENTS

RECOGNITION

MARIJUANA: DOSE-RESPONSE EFFECTS ON PULSE RATE, SUBJECTIVE ESTIMATES OF POTENCY, PLEASANTNESS, AND RECOGNITION MEMORY.

RECORDED

ORDED

EFFECTS OF FLURAZEPAM ON AMINO-ACID EVOKED RESPONSES

RECORDED FROM THE LOBSTER MUSCLE AND THE FROG SPINAL CORD.

002115 03-03

EFFECTS OF ANESTHETICS ON CEREBELLAR NEURONS RECORDED CHRONICALLY AFTER HARMALINE. 002260 03-04

RECORDING

002887 04-03

003080 04-03

A METHOD FOR MECHANOGRAPHICAL RECORDING OF MUSCLE TONE IN THE RAT: THE EFFECT OF SOME ANTIPARKINSONIAN DRUGS ON RIGIDITY INDUCED BY RESERPINE.

002346 03-05 ROTOMETER FOR RECORDING ROTATION IN CHEMICALLY OF ELECTRICALLY STIMULATED RATS.

002373 03-06 THE IMPORTANCE OF TELEMETRIC RECORDING IN THE STUDY NEUROPSYCHOLOGICAL FUNCTION IN EPILEPTICS.

002606 03-14 METHODOLOGICAL PROBLEMS IN THE MEASUREMENT OF DRUG-INDUCED ROTATIONAL BEHAVIOUR: CONTINUOUS RECORDING REVEALS TIME-COURSE DIFFERENCES UNDETECTED BY PREVIOUS TECHNIQUES.

003388 04-04

RECORDINGS DOXEPIN AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION: A
DOUBLE-BLIND CROSS-OVER CLINICAL STUDY WITH EKG RECORDINGS 002416 03-09

RECORDS EEG RECORDS AND THE EFFECTS OF PHENOTHIAZINE TREATMENT IN PATIENTS WITH PARANOID SCHIZOPHRENIA.

002394 03-08 RECOVERED

EFFECTS OF ANGIOTENSIN-II ON SCHEDULE-DEPENDENT AND INDUCED BEHAVIOR AT RECOVERED BODY WEIGHT. 000470 01-04

ON PRESCRIBING MEDICATIONS FOR RECOVERING ALCOHOLIC PATIENTS 000872 01-15

RECOVERY RECOVERY OF AMNESTIC EFFECT OF ALPHA-AMANITIN BY POSTTRAINING ADMINISTRATION OF D AMPHETAMINE IN THE RAT.

000416 01-04 HORMONE RELEASE IN DEPRESSED PATIENTS BEFORE AND AFTER

RECOVERY 001590 02-09 PHARMACOLOGICAL MANIPULATIONS OF THE SEPTAL IRRITABILITY SYNDROME: ROLE OF DOPAMINERGIC MECHANISMS IN RECOVERY OF

FUNCTION. (PH.D. DISSERTATION). 002089 03-03 MARIJUANA, ALCOHOL, AND COMBINED DRUG EFFECTS ON THE TIME COURSE OF GLARE RECOVERY.

002604 03-14 AMANITA MUSHROOM POISONING WITH RECOVERY FROM COMA: A

002705 03-15 RECOVERY AS A FUNCTION OF THE DEGREE OF AMNESIA DUE TO PROTEIN SYNTHESIS INHIBITION.

THE IMPLICATIONS OF PSYCHEDELIC DRUG RESEARCH FOR INTEGRATION AND SEALING OVER AS RECOVERY STYLES FROM ACUTE PSYCHOSIS. 003517 04-09 HYPEROSMOLALITY COMPLICATING RECOVERY FROM LITHIUM TOXICITY. 003665 04-15

RECREATIONAL

COCAINE: RECREATIONAL USE AND INTOXICATION.

002594 03-13

THE RELATIONSHIP BETWEEN CORTICAL RECRUITING RESPONSES PONTO-GENICULO-OCCIPITAL (PGO) WAVES DURING PARADOXICAL SLEEP AND AFTER THE ADMINISTRATION OF RESERVINE IN THE CAT 002069 03-03

EFFECTS OF PHENOBARBITAL AND DIAZEPAM ON IMIPRAMINE-INDUCED CHANGES IN BLOOD PRESSURE, HEART RATE AND RECTAL TEMPERATURE OF RATS

EFFECTS OF D AMPHETAMINE (D-A), PROSTAGLANDIN-E1 AND F-2ALPHA ON H3-2-DOPAMINE (H3-DA) METABOLISM, FIXED-INTERVAL (FI) BEHAVIOR AND RECTAL TEMPERATURE.

001207 02-03 COMPARISON OF THE EFFECTS OF 5 HYDROXYTRYPTAMINE, DIMETHYLTRYPTAMINE, AND 5 METHOXY-DIMETHYLTRYPTAMINE ON RECTAL TEMPERATURE IN THE MOUSE.

002154 03-03

UMI

RECURRENT
LONG-TERM MAINTENANCE DRUG THERAPY IN RECURRENT AFFECTIVEILLNESS: CURRENT STATUS AND ISSUES.

001600 02-09 EFFECTS OF DIAZEPINES AND BARBITURATES ON HIPPOCAMPAL RECURRENT INHIBITION.

002181 03-03

LITHIUM TRANSPORT IN RED BLOOD CELLS OF MANIC-DEPRESSIVE

000724 01-13 THE RELATIONSHIP BETWEEN EXTRACELLULAR AND INTRACELLULAR LITHIUM CONCENTRATION IN HUMAN RED BLOOD CELLS: AN IN VITRO

000731 01-13 PHARMACOGENETIC ASPECT OF RED BLOOD CELL LITHIUM INDEX IN MANIC-DEPRESSIVE PSYCHOSIS.

000736 01-13 THE PHARMACOKINETICS OF RED BLOOD CELL AND PLASMA BUTAPERAZINE CLINICAL RESPONSE AND SIDE-EFFECTS.

001561 02-08 LITHIUM SODIUM COUNTERTRANSPORT IN HUMAN RED CELLS AND IN VIVO LITHIUM DISTRIBUTION BETWEEN RED CELLS AND PLASMA. 001679 02-13

LITHIUM TRANSPORT ACROSS THE RED BLOOD CELL MEMBRANE 002553 03-13

CHARACTERISTICS OF LI-TRANSPORT IN HUMAN RED CELLS 002591 03-13

GUIDELINES TO REDUCE MISUSE OF DRUGS.

001917 02-17

PEDUCED EFFECTS OF REDUCED CEREBRAL SEROTONIN ON LEARNING.

000422 01-04 REDUCED RENAL CALCIUM EXCRETION DURING LITHIUM THERAPY. 001597 02-09

REDUCED LEVELS OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA FROM VACUTAINERS. 001859 02-16

PEDLICES

ELECTRICAL STIMULATION OF DENERVATED MUSCLES REDUCES INCORPORATION OF METHIONINE INTO THE ACH RECEPTOR.

MORPHINE REDUCES CEREBELLAR CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT AND ELEVATES CEREBROSPINAL FLUID CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT IN RHESUS MONKEY.

002057 03-03 PIPEROXANE REDUCES THE EFFECTS OF CLONIDINE ON AGGRESSION IN MICE AND ON NORADRENALINE DEPENDENT HYPERMOTILITY IN RATS 002205 03-04

EVIDENCE FOR A DOUBLE CHOLINERGIC MECHANISM CAPABLE OF REDUCING THE TONE OF CEREBRAL ARTERIES.

001049 02-03

REDUCTION

DCTION
THE RELATIONSHIP BETWEEN MAGNITUDE OF ELECTROSHOCK
STIMULATION AND THE EFFECTS OF DIGITOXIGENIN,
PENTYLENETETRAZOL AND BRAIN MONOAMINE REDUCTION ON
ELECTROSHOCK CONVULSIVE THRESHOLDS.

000066 01-03 SEROTONIN REDUCTION EARLY IN LIFE AND ITS EFFECTS ON BEHAVIOR. 000383 01-04

FAILURE OF NALOXONE TO PREVENT REDUCTION OF AMNESIA BY ENKEPHALINS.

000438 01-04 DOES PROLACTIN PLAY A ROLE IN ESTROGEN-INDUCED MATERNAL BEHAVIOR IN RATS: APOMORPHINE REDUCTION OF PROLACTIN

STUDY OF NIGHT SLEEP DURING LONG-TERM GRADUAL REDUCTION IN NEUROLEPTIC THERAPY IN CHRONIC SCHIZOPHRENICS.

DOO852 01-15
BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF CHRONIC REDUCTION OF
CEREBRAL NORADRENALINE RECEPTOR STIMULATION.

REDUCTION OF HEROIN SELF-ADMINISTRATION IN BABOONS BY MANIPULATION OF BEHAVIORAL AND PHARMACOLOGICAL

001499 02-04

LIMB REDUCTION ANOMALIES IN INFANTS BORN TO DISULFIRAM TREATED ALCOHOLIC MOTHERS. 001817 02-15

REDUCTION OF VMH LESION-INDUCED HYPEREMOTIONALITY AND ANTINOCICEPTION BY DIAZEPAM.

002211 03-04 SELECTIVE REDUCTION BY NORADRENALINE AND 5
HYDROXYTRYPTAMINE OF NOCICEPTIVE RESPONSES OF CAT DORSAL-

HORN NEURONES 002246 03-04 GRADUAL REDUCTION OF NEUROLEPTIC DRUGS AMONG CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY.

LOSS OF INFORMATION INDUCED BY REDUCTION OF DATA IN THE LABORATORY LANGUAGE METHOD.

EFFECTS OF NALOXONE ON SCHIZOPHRENIA: REDUCTION IN HALLUCINATIONS IN A SUBPOPULATION OF SUBJECTS.

003639 04-14

001856 02-16

RECEPTOR OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN
RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED
REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS.

001150 02-03 REGIONAL BRAIN ATROPHY AND REDUCTIONS IN GLUTAMATE RELEASE AND UPTAKE AFTER INTRASTRIATAL KAINIC-ACID.

002917 04-03 REEXAMINATION
LOOKING TOWARD A REEXAMINATION OF DRUG THERAPY EXPERIENCE

A REEXAMINATION OF USING ANTIPARKINSONS DRUGS WITH PSYCHOTROPIC DRUG THERAPY — A SURVEY OF OUTPATIENTS 001874 02-16

TIME-RESPONSE ANALYSIS OF THE EFFECT OF STIMULANT MEDICATION ON THE LEARNING ABILITY OF CHILDREN REFERRED FOR

002534 03-11

A REFILLABLE SYSTEM FOR CONTINUOUS AMPHETAMINE ADMINISTRATION: EFFECTS UPON SOCIAL BEHAVIOR IN RAT

003215 04-04 SLEEP AND BEHAVIORAL CHANGES POSSIBLY REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN.

000916 01-16

REFLEX
SPECIFIC ACTION OF NARCOTICS ON REFLEX ACTIVATION OF RAT ALPHAMOTONEURONES.
000174 01-03

000174 01-03 PSILOCYBIN: BIPHASIC DOSE-RESPONSE EFFECTS ON THE ACOUSTIC STARTLE REFLEX IN THE RAT.

000345 01-04 LORDOSIS REFLEX, SEXUAL RECEPTIVITY, AND FEEDING: ESTROGEN RESPONSIVITY IN MALE AND FEMALE RATS.

001327 02-04 INTRACEREBRAL NEUROTRANSMITTERS AND CONDITIONED REFLEX

PERFORMANCE 001343 02-04

EFFECT OF CHLORPROMAZINE ON ELABORATION AND EXTINCTION OF AN INSTRUMENTAL ALIMENTARY REFLEX IN PUPPIES.

EFFECTS OF ID-540 ON AVERAGED PHOTOPALPEBRAL REFLEX IN MAN. 001556 02-07 EFFECT OF PSYCHOTROPIC DRUGS ON THE DEVELOPMENT OF DEFENSE CONDITIONED REFLEX DURING EXPERIMENTAL NEUROSIS.

002204 03-04 RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDROXYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN
ACUTE AND CHRONIC SPINAL RATS.

002289 03-04 SOME PHYSIOLOGIC CHARACTERISTICS OF THE ELECTRODERMAL REFLEX

002819 04-03 NEONATAL SYSTEMIC 6 HYDROXYDOPAMINE AND DORSAL TEGMENTAL BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEPHRINE AND THE POSTDECAPITATION REFLEX.

003039 04-03 THE EFFECTS OF A NEW BENZODIAZEPINE DERIVATIVE, ID-540, ON THE AVERAGED PHOTOPALPEBRAL REFLEX IN MAN. 003610 04-13

INFLUENCE OF PHARMACOLOGICAL AGENTS ON AVOIDANCE REFLEXES IN A GROUP EXPERIMENT ON RATS. 001317 02-04

PROPRANOLOL: HEARTRATE AND REFLEXES DURING A TASK 002548 03-13

DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION. 003241 04-04

A CONTROLLED TRIAL OF METOCLOPRAMIDE IN SYMPTOMATIC GASTROESOPHAGEAL REFLUX.

000862 01-15 REFRACTORY
COMBINED TRICYCLIC MAOI THERAPY FOR REFRACTORY DEPRESSION: A REVIEW, WITH GUIDELINES FOR APPROPRIATE USAGE 002437 03-09

003515 04-09

002990 04-03

002531 03-11

AMANTADINE IN THE TREATMENT OF BENZTROPINE REFRACTORY EXTRAPYRAMIDAL DISORDERS INDUCED BY ANTIPSYCHOTIC DRUGS 002664 03-15

TREATMENT OF IMIPRAMINE RESISTANT DEPRESSION AND LITHIUM REFRACTORY MANIA THROUGH DRUG INTERACTIONS 003512 04-09

DRUG REFUSAL IN SCHIZOPHRENIA. CAUSES AND PRESCRIBING HINTS 002709 03-15

A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF DOTHIEPIN AND ITS THERAPEUTIC EFFECTIVENESS. 001604 02-09

REGIMEN

A COOPERATIVE CLINICAL STUDY OF METHADYL-ACETATE. I. THREE-TIMES-A-WEEK REGIMEN.

002757 03-17

THE USE OF PENFLURIDOL ACCORDING TO A NEW DOSAGE REGIMEN IN THE ACUTE, STABILIZATION AND MAINTENANCE PHASES OF

003491 04-09 IMPLICATIONS OF DOSE REGIMEN AND PROTEIN BINDING FOR PLASMA NORTRIPTYLINE ESTIMATIONS

003547 04-10

STEADY-STATE SERUM CONCENTRATIONS OF DOTHIEPIN AND
NORTHIADEN AFTER TWO DOSAGE REGIMENS OF DOTHIEPIN HYDROCHLORIDE (PROTHIADEN)

001675 02-13 FACTORS INFLUENCING WILLINGNESS TO COMPLY AND ACTUAL COMPLIANCE WITH MEDICATION REGIMENS. (PH.D. DISSERTATION) 003722 04-17

A COMPARISON OF HIGH AND LOW DOSAGE REGIMES OF MAPROTILINE (LUDIOMIL)

PLASMA CONCENTRATIONS OF CLOMIPRAMINE AND ITS N DESMETHYL METABOLITE IN DEPRESSIVE PATIENTS FOLLOWING TREATMENT WITH VARIOUS DOSAGE REGIMES OF CLOMIPRAMINE.

REGRESSION

FACTORS INFLUENCING BLOOD CONCENTRATIONS OF CHLORDIAZEPOXIDE: A USE OF MULTIPLE REGRESSION ANALYSIS.

001663 02-13

002548 03-13

A LONG-TERM FOLLOW-UP OF SCHIZOPHRENICS TREATED WITH REGRESSIVE ECT. 000526 01-08

REGULATED

CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF C-AMP-PHOSPHODIESTERASE.

DOPAMINE RECEPTOR BINDING OF H3-ADTN (2 AMINODIHYDROXYTETRAHYDRONAPHTHALENE) REGULATED BY GUANYL-NUCLEOTIDES.

002877 04-03 DOPAMINE SYNTHESIS AND TYROSINE-HYDROXYLASE ARE REGULATED BY INDEPENDENT DA RECEPTOR MEDIATED MECHANISMS 003116 04-03

REGULATION

MUSCARINIC REGULATION OF C-AMP IN MOUSE NEUROBLASTOMA 000058 01-03

REGULATION OF CATECHOLAMINE BIOSYNTHESIS IN A TRANSPLANTABLE RAT PHEOCHROMOCYTOMA.

000071 01-03 REGULATION OF NIGROSTRIATAL DOPAMINERGIC NEUROTRANSMISSION

000100 01-03 SECOND MESSENGER RESPONSES AND REGULATION OF HIGH AFFINITY RECEPTOR BINDING TO STUDY PHARMACOLOGICAL MODIFICATION OF GABAERGIC TRANSMISSION. (UNPUBLISHED PAPER). 000133 01-03

AMINERGIC AND THERMOREGULATORY MECHANISMS IN HYPOTHALAMIC REGULATION OF GROWTH HORMONE IN CATS 000249 01-03

COLCHICINE BLOCKS NEUROTROPIC REGULATION OF THE RESTING MEMBRANE POTENTIAL IN REINNERVATING SKELETAL MUSCLE 000262 01-03

COMPARISON OF THE REGULATION OF ROTATIONAL BEHAVIOR BY HYPOTHALAMIC OLIGOPEPTIDES

000337 01-04 ROLES OF MONOAMINES, PARTICULARLY DOPAMINE, IN CLINICAL DEPRESSION AND IN THE REGULATION OF MOOD.

000583 01-09 DOPAMINERGIC FACTORS IN HUMAN PROLACTIN REGULATION: EFFECTS OF NEUROLEPTICS AND DOPAMINE 002574 03-13 REGULATION OF CYCLIC-GUANOSINE-MONOPHOSPHATE IN THE RAT PINEAL AND POSTERIOR PITUITARY GLANDS

EVIDENCE FOR THE ROLE OF ADRENOCORTICAL HORMONES IN THE REGULATION OF NORADRENALINE AND DOPAMINE METABOLISM IN

THE ROLE OF CALCIUM IN THE REGULATION OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN SLICES OF RAT AND GUINEA-PIG

003079 04-03 DISTURBANCE OF HOMEOSTATIC REGULATION OF ADRENAL FUNCTION IN PATIENTS WITH ENDOGENOUS DEPRESSION.

PEGULATOR

GUANOSINE-MONOPHOSPHATE: A CENTRAL-NERVOUS-SYSTEM REGULATOR OF ANALGESIA

002215 03-04 STRIATAL CONTENT OF CA2-DEPENDENT REGULATOR PROTEIN AND DOPAMINERGIC RECEPTOR FUNCTION

REGULATORY ROLE OF GABA NEURONS ON THE ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE BY HALOPERIDOL. (UNPUBLISHED PAPERI

EVIDENCE FOR SELECTIVE AND LONG-LASTING STIMULATION OF REGULATORY DOPAMINE RECEPTORS BY BROMOCRIPTINE (CB-154) 002002 03-03

REHABILITATION
NEW APPROACH TO THE REHABILITATION OF THE HARD CORE DRUG
ADDICT (HEROIN METHADONE ADDICTS): A PILOT COMMUNITY STUDY

REINFORCED THE EFFECT OF NONCONTINGENT AMPHETAMINE INJECTIONS ON THE EXTINCTION OF FOOD AND DRUG REINFORCED LEVER PRESSING IN

001404 02-04 LOCATION PREFERENCE AND FLAVOR AVERSION REINFORCED BY AMPHETAMINE IN RATS.

001443 02-04

EFFECTS OF D AMPHETAMINE ON A MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE OF FOOD REINFORCEMENT IN THE CAT 001374 02-04

EFFECT OF CHLORDIAZEPOXIDE ON THE PARTIAL REINFORCEMENT **EXTINCTION EFFECT**

001491 02-04 BLOCKADE OF COCAINE REINFORCEMENT IN RATS WITH THE DOPAMINE RECEPTOR BLOCKER PIMOZIDE, BUT NOT WITH THE NORADRENERGIC BLOCKERS PHENTOLAMINE OR PHENOXYBENZAMINE.

002224 03-04 PENTOBARBITAL, PROMAZINE, D AMPHETAMINE, AND SCOPOLAMINE
EFFECTS ON BEHAVIOR UNDER MULTIPLE AND PRIMED SCHEDULES OF REINFORCEMENT

EFFECTS OF METHADONE ON BEHAVIOR MAINTAINED BY FIXED-RATIO REINFORCEMENT SCHEDULES

EFFECT OF PIMOZIDE ON THE IMPROVEMENT IN LEARNING PRODUCED BY SELF-STIMULATION AND BY WATER REINFORCEMENT.

AMPHETAMINE-TYPE REINFORCEMENT BY DOPAMINERGIC AGONISTS IN

003400 04-04 OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR OPERANT DRUG DISCRIMINATIONS.

DRUGS AND REINFORCEMENT MECHANISMS: A CRITICAL REVIEW OF THE CATECHOLAMINE THEORY. 003625 04-14

REINFORCEMENTS
ROLE OF THE BRAIN MONOAMINE SYSTEM IN LEARNING ON VARIOUS

EMOTIONAL REINFORCEMENTS. 001369 02-04

ESTABLISHMENT OF ETONITAZENE AS A REINFORCER FOR RATS BY USE OF SCHEDULE-INDUCED DRINKING.

002281 03-04 DRUG EFFECTS ON RESPONDING MAINTAINED BY STIMULUS REINFORCER AND RESPONSE REINFORCER CONTINGENCIES. 003365 04-04

REINFORCERS

AN INVESTIGATION OF NALORPHINE AND PERPHENAZINE AS NEGATIVE REINFORCERS IN AN ESCAPE PARADIGM. 000389 01-04

REINFORCING PROPERTIES OF PERPHENAZINE, HALOPERIDOL AND AMITRIPTYLINE IN RHESUS MONKEYS.

- REINFORCING PROPERTIES OF INTRAVENOUS PROCAINE IN RHESUS MONKEYS.
- O00362 01-04
 STUDIES OF THE REINFORCING PROPERTIES OF INTRAVENOUSLY SELFADMINISTERED COMPOUNDS IN RHESUS MONKEYS. (PH.D.
- THE REINFORCING PROPERTIES OF PROCAINE AND D AMPHETAMINE COMPARED IN RHESUS MONKEYS.
- O02239 03-04
 INTERACTION BETWEEN MORPHINE AND REINFORCING LATERAL
 HYPOTHALAMIC STIMULATION.
- 002291 03-04
 REINFORCING, DISCRIMINATIVE, AND/OR ACTIVATION PROPERTIES OF
 AMPHETAMINE.
- RELATIONSHIP BETWEEN ANORECTIC AND REINFORCING PROPERTIES OF APPETITE SUPPRESSANT DRUGS: IMPLICATIONS FOR ASSESSMENT OF ABUSE LIABILITY.
- 003236 04-04
 REINFORCING AND AVERSIVE PROPERTIES OF THE NARCOTIC CUE.
 003372 04-04
- REINNERVATING
 COLCHICINE BLOCKS NEUROTROPIC REGULATION OF THE RESTING
 MEMBRANE POTENTIAL IN REINNERVATING SKELETAL MUSCLE.
 000262 01-03
- RELAPSE
 RELAPSE RATES OF SCHIZOPHRENIC PSYCHOSES.
 - O0)524 01-08
 FLUPHENAZINE-DECANOATE, FLUPHENAZINE-HYDROCHLORIDE GIVEN
 ORALLY, AND PLACEBO IN REMITTED SCHIZOPHRENICS: I. RELAPSE
 RATES AFTER ONE YEAR.
 - CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND ITS
 METABOLITES AND CLINICAL RATINGS IN PATIENTS WITH ACUTE
 RELAPSE OF SCHIZOPHRENIC AND PARANOID PSYCHOSIS.

000545 01-08

- AMITRIPTYLINE BLOOD LEVELS AND RELAPSE. 000726 01-13 001587 02-09
- MAINTENANCE ANTIPSYCHOTIC PHARMACOTHERAPY, RELAPSE, AND LENGTH OF STAY OUT OF THE HOSPITAL IN CHRONIC SCHIZOPHRENICS IN GREECE.
- RELAXANT
 SYNTHESIS AND COMPARATIVE SKELETAL MUSCLE RELAXANT ACTIVITY
 OF SOME 2,4 IMIDAZOLIDINEDIONES AND THEIR CORRESPONDING 5
 HYDROXYIMIDAZOLIDINEDIONES.
- OF SOME 2.4 IMIDAZOLIDINEDIONES AND THEIR CORRESPONDING 5
 HYDROXYIMIDAZOLIDINEDIONES.

 001944 03-01
 RELAXATION
 - RELAXATION OF SMOOTH MUSCLE FOLLOWING CONTRACTION ELICITED BY SYMPATHETIC NERVE STIMULATION IN VIVO. 001106 02-03
 - STUDIES ON THE INHIBITION OF PHOSPHODIESTERASE CATALYZED CYCLIC-AMP AND CYCLIC-GMP BREAKDOWN AND RELAXATION OF CANINE TRACHEAL SMOOTH MUSCLE.

 002129 03-03
- RELEASE
 THE ACCUMULATION OF P-HYDROXYAMPHETAMINE BY BRAIN
 HOMOGENATES AND ITS ROLE IN THE RELEASE OF CATECHOLAMINES.
 - COMPARISON OF THYROTROPIN-RELEASING HORMONE WITH
 MELANOCYTE-STIMULATING HORMONE RELEASE INHIBITING FACTOR
 AS PENTOBARBITAL ANTAGONISTS IN MONKEYS.
 - EFFECTS OF RETICULAR STIMULATION, D AMPHETAMINE AND SCOPOLAMINE ON ACETYLCHOLINE RELEASE FROM THE HIPPOCAMPUS OF BRAINSTEM TRANSECTED CATS.
 - O00098 01-03
 THE ROLE OF THE SEPTAL NUCLEI IN THE RELEASE OF ACETYLCHOLINE
 FROM THE RABBIT CEREBRAL-CORTEX AND DORSAL HIPPOCAMPUS
 AND THE EFFECT OF ATROPINE.
 - INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE PAT
 - O00124 01-03
 CONTROL OF THE RELEASE OF NEWLY SYNTHESIZED H3-5HYDROXYTRYPTAMINE BY NICOTINIC AND MUSCARINIC RECEPTORS IN
 RAT HYPOTHALAMIC SLICES.
 - ENDORPHIN RELEASE: CROSS-TOLERANCE TO MORPHINE.
 - 000229 01-0 DOPAMINE SELECTIVELY INCREASES H3-GABA RELEASE FROM SLICES OF RAT SUBSTANTIA-NIGRA IN VITRO.

 $\mathsf{U} \mathsf{M} \mathsf{I}$

000240 01-03

BARBITURATE-INDUCED CHANGES IN TRANSMITTER RELEASE
INDEPENDENT OF TERMINAL SPIKE CONFIGURATION IN THE FROG
NEUROMUSCULAR JUNCTION.
000294 01-03

- THE EFFECTS OF NEOMYCIN UPON TRANSMITTER RELEASE AND ACTION. 000302 01-03
- DOES PROLACTIN PLAY A ROLE IN ESTROGEN-INDUCED MATERNAL BEHAVIOR IN RATS: APOMORPHINE REDUCTION OF PROLACTIN RELEASE.
- UPTAKE OF 5 METHOXYTRYPTOLINE (6 MEO-TETRAHYDRO-BETA-CARBOLINE) BY BLOOD PLATELETS AND ITS EFFECT ON 5-HT UPTAKE AND RELEASE.
- ROLE OF NOREPINEPHRINE IN THE RELEASE OF PROLACTIN INDUCED BY SUCKLING AND ESTROGEN.
- COCAINE-INDUCED CENTRALLY MEDIATED RELEASE OF CATECHOLAMINES INTO BLOOD OF UNDISTURBED RATS. (UNPUBLISHED PAPER).
 001079 02-03
- AGE-RELATED EFFECTS OF RESERPINE ON BEHAVIOR AND ON REGIONAL CATECHOLAMINE UPTAKE AND RELEASE IN THE RAT. (PH.D. DISSERTATION).
- O01098 02-03

 EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF
 MOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH
 POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF
 THE PAT
- OO1118 02-03
 INFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND
 METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN.
- 001119 02-03
 ENKEPHALIN EFFECTS ON RELEASE OF BRAIN ACETYLCHOLINE.
- SELECTIVITY OF H3-BIOGENIC AMINE RELEASE BY D.L. AMPHETAMINE
 AND DRUGS THAT INTERACT WITH SEROTONERGIC NEURONS.

 001161 02-03
- SPECIFIC RELEASE BY NALOXONE OF H3-MORPHINE FROM SUPERFUSED SLICES OF CORPUS-STRIATUM OF MICE.
- SUBSTITUTED AMPHETAMINE DERIVATIVES. I. EFFECT ON UPTAKE AND RELEASE OF BIOGENIC MONOAMINES AND ON MONOAMINE-OXIDASE IN THE MOUSE BRAIN.
- O01233 02-03

 SPECIFICITY OF AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE
 AND SEROTONIN FROM RAT BRAIN IN VITRO.
- MODIFICATION OF THE AMPHETAMINE-INDUCED STEREOTYPY IN RATS FOLLOWING INHIBITION OF THE NORADRENALINE RELEASE BY FLA-136.
- HORMONE RELEASE IN DEPRESSED PATIENTS BEFORE AND AFTER RECOVERY.
- 001590 02-09
 PROTEIN AND ENZYME RELEASE FROM HUMAN LEUKOCYTES: INFLUENCE
 OF PHENOTHIAZINE DERIVATIVES.
- OF PHENOTHIAZINE DERIVATIVES.

 001669 02-13

 PITUITARY HORMONE RELEASE IN VITRO BY MORPHINE-LIKE PEPTIDES.
- IDENTIFICATION OF DOPAMINERGIC RECEPTORS IN ANTERIOR PITUITARY: CORRELATION WITH THE DOPAMINERGIC CONTROL OF PROLACTIN
- 001982 03-03
 BLOCKADE OF THE PICROTOXIN-INDUCED IN VIVO RELEASE OF DOPAMINE
 IN THE CAT CAUDATE NUCLEUS BY DIAZEPAM.
- 001989 03-03

 EFFECTS OF COMPLETE HYPOTHALAMIC DEAFFERENTATION AND 5,7

 DIHYDROXYTRYPTAMINE ON SEVERAL PARAMETERS OF PROLACTIN
- 001990 03-03

 BLOCKAGE OF PROGESTERONE-INDUCED RELEASE OF LUTEINIZING
 HORMONE AND PROLACTIN BY D AMPHETAMINE AND FENFLURAMINE
- IN RATS.

 002006 03-03

 EFFECTS OF PRESYNAPTIC MODULATORS ON CA2-INDUCED
 NORADRENALINE RELEASE FROM CARDIAC SYMPATHETIC NERVES.
- APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE RELEASE:
 ROLE OF DOPAMINERGIC RECEPTORS IN SUBSTANTIA-NIGRA.
- EFFECTS OF DRUGS ON GAMMA-AMINOBUTYRIC-ACID RECEPTORS,
 UPTAKE, RELEASE AND SYNTHESIS IN VITRO.
- CONFORMATIONALLY DEFINED ADRENERGIC AGENTS. III. THE IMPORTANCE OF COMPARTMENTATION IN THE RELEASE OF NOREPINEPHRINE FROM RAT ATRIA BY ENDO-2-METHYLAMINOBENZOBICYCLOOCTENE, AND EXO-2-METHYLAMINOBENZOBICYCLOOCTENE, CONFORMATIONALLY DEFINED ANALOGS OF METHAMPHETAMINE.
- O2141 03-0

 EFFECT OF METABOLIC INHIBITORS AND OUABAIN ON AMPHETAMINEINDUCED AND POTASSIUM-INDUCED RELEASE OF BIOGENIC AMINES
 FROM ISOLATED BRAIN TISSUE.

002576 03-13

BETA-ADRENOCEPTORS MODULATE NORADRENALINE RELEASE FROM AXONAL SPROUTS IN CULTURED RAT SUPERIOR CERVICAL GANGLIA 002179 03-03

EFFECT OF BETA ADRENERGIC RECEPTOR ANTAGONISTS ON D AMPHETAMINE AND POTASSIUM-INDUCED RELEASE OF H3-NOREPINEPHRINE FROM RAT BRAIN IN VITRO

002187 03-03 MAPPOTILINE (LIDIOMIL) IN DEPRESSION, A REPORT OF A MONITORED RELEASE STUDY IN GENERAL PRACTICE.

002433 03-09

DELEASE OF VASOPRESSIN BY ENKEPHALIN

002792 04-02 PROSTAGLANDINS AND CANNABIS -- VI. RELEASE OF ARACHIDONIC-ACID FROM HELA CELLS BY DELTA1-TETRAHYDROCANNABINOL AND OTHER

STIMULATION OF PRESYNAPTIC BETA-ADRENOCEPTORS ENHANCES H3-NORADRENALINE RELEASE DURING NERVE STIMULATION IN THE

002855 04-03 5 HYDROXYTRYPTAMINE: THE EFFECTS OF IMPAIRED SYNTHESIS ON ITS METABOLISM AND RELEASE IN RAT. 002878 04-03

THE UPTAKE AND RELEASE OF H3-2 AMINO-6-7-DIHYDROXYTETRAHYDRONAPHTHALENE (ADTN) BY STRIATAL NERVE

002884 04-03 REGIONAL BRAIN ATROPHY AND REDUCTIONS IN GLUTAMATE RELEASE AND UPTAKE AFTER INTRASTRIATAL KAINIC-ACID.

002917 04-03 COMPARATIVE EFFECTS OF PEMOLINE, AMFONELIC-ACID AND AMPHETAMINE ON DOPAMINE UPTAKE AND RELEASE IN VITRO AND ON BRAIN 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN SPIPERONE-TREATED RATS

DRUGS AFFECTING THE CENTRAL-NERVOUS-SYSTEM: EFFECTS OF PEMOLINE, AND TRICYCLIC ANTIDERRESSANTS ON NERVE TERMINAL ADENOSINE-TRIPHOSPHATASE ACTIVITIES AND NEUROTRANSMITTER

002923 04-03 ADENOSINE MODULATES DEPOLARIZATION-INDUCED RELEASE OF H3-NORADRENALINE FROM SLICES OF RAT BRAIN NEOCORTEX

002938 04-03 PHARMACOLOGICAL EVIDENCE FOR THE INVOLVEMENT OF NA CHANNELS IN THE RELEASE OF CATECHOLAMINES FROM PERFUSED ADRENAL

002960 04-03 ANTAGONISM OF MORPHINE ACTION ON BRAIN ACETYLCHOLINE RELEASE BY METHYLXANTHINES AND CALCIUM

002966 04-03 THE RELEASE OF ACETYLCHOLINE IN THE PERFUSED CAT SPINAL CORD IN

002969 04-03 EFFECTS OF RACEMIC. (S)- AND (R) METHYLENEDIOXYAMPHETAMINE ON SYNAPTOSOMAL UPTAKE AND RELEASE OF TRITIATED

002999 04-03 H3-GABA RELEASE IN SYNAPTOSOMAL FRACTIONS AFTER INTRACRANIAL ADMINISTRATION OF RUTHENIUM-RED

003013 04-03 ON THE RELATION BETWEEN HALOPERIDOL-INDUCED ALTERATIONS IN DA RELEASE AND DA METABOLISM IN RAT STRIATUM. 003021 04-03

ENERGY UTILIZATION IN THE INDUCED RELEASE OF GAMMA-AMINOBUTYRIC-ACID FROM SYNAPTOSOMES

003029 04-03 METABOLISM OF LERGOTRILE TO 13 HYDROXYLERGOTRILE, A POTENT INHIBITOR OF PROLACTIN RELEASE IN VITRO.

EFFECT OF MORPHINE ON THE BASAL AND THE DOPAMINE-INDUCED RELEASE OF LHRH FROM MEDIOBASAL HYPOTHALAMIC FRAGMENTS

003072 04-03 RELEASE OF ENDOGENOUS CATECHOLAMINES FROM ISOLATED RAT BRAIN TISSUE BY FENFLURAMINE AND N ETHYLAMPHETAMINE --EFFECTS OF PARGYLINE.

003111 04-03 THE EFFECTS OF INTRAVENTRICULAR INJECTION OF GAMMA-AMINOBUTYRIC-ACID (GABA) ON PROLACTIN AND GONADOTROPIN RELEASE IN CONSCIOUS FEMALE RATS

003126 04-03 EFFECTS OF L GLUTAMATE AND RELATED AMINO-ACIDS UPON THE RELEASE OF H3-DOPAMINE FROM RAT STRIATAL SLICES

003340 04-04 DOPAMINE-BETA-HYDROXYLASE RELEASE FOLLOWING ACUTE SELECTIVE SYMPATHETIC NERVE STIMULATION OF THE HEART, SPLEEN AND MESENTERY 003422 04-06

RELEASED

PERIPHERAL CATECHOLAMINES RELEASED BY OXOTREMORINE MODULATE TREMOR IN THE RAT. (UNPUBLISHED PAPER).

001486 02-04 THE NEURONAL ORIGIN OF PROSTAGLANDIN RELEASED FROM THE RABBIT PORTAL VEIN IN RESPONSE TO ELECTRICAL STIMULATION 002933 04-03

POTENT PROLACTIN AND GROWTH HORMONE RELEASING ACTIVITY OF MORE ANALOGUES OF MET-ENKEPHALIN.

000019 01-02 STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT BRAIN TISSUE SLICES.

O01145 02-03
STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS
RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAMINE (DA)
AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES.

LUTEINIZING HORMONE RELEASING HORMONE AND THYROTROPIN-RELEASING HORMONE STIMULATION STUDIES IN PATIENTS GIVEN CLOMIPRAMINE OR DEPOT NEUROLEPTICS.

002563 03-13 DEXTROAMPHETAMINE AND L AMPHETAMINE ARE EQUIPOTENT IN RELEASING HUMAN GROWTH HORMONE.

RELIABILITY

RELIABILITY OF TWO ACTIVITY BOXES COMMONLY USED TO ASSESS DRUG-INDUCED BEHAVIOURAL CHANGES.

002368 03-06 THE STABILITY AND RELIABILITY OF RADIOIMMUNOASSAYS FOR CLONAZEPAM, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN BLOOD. SERUM OR PLASMA.

003439 04-06 A RELIABLE, FACIAL NOCICEPTION DEVICE FOR UNRESTRAINED, AWAKE
ANIMALS: EFFECTS OF MORPHINE AND TRIGEMINAL COMPLEX

003435 04-06

RELIEF BRAIN DOPAMINE TURNOVER AND THE RELIEF OF PARKINSONISM.
001685 02-13 STUDIES ON THE CONCOMITANT USE OF CARBAMAZEPINE AND CLOMIPRAMINE FOR THE RELIEF OF POSTHERPETIC NEURALGIA 002555 03-13

RELINQUISHMENT PHYSICIANS DRUG INNOVATION AND RELINQUISHMENT.

001912 02-17 FURTHER STUDIES OF THE AGGRESSIVE BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL IN REM SLEEP-DEPRIVED RATS.

000331 01-04 INDIVIDUAL VARIATIONS IN RESPONSE OF HUMAN REM SLEEP TO AMITRIPTYLINE AND HALOPERIDOL.

000779 01-14 EFFECTS OF PCPA AND SELECTIVE REM SLEEP-DEPRIVATION ON ROTOROD PERFORMANCE AND OPEN-FIELD BEHAVIOR IN THE RAT.

002219 03-04 WAKING STAGE-1 REM OBSERVED IN PARANOID HALLUCINATORY STATES OF NARCOLEPSY

NHIBITION OF REM SLEEP BY FLUOXETINE, A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE. 003095 04-03

REMISSION SCHIZOPHRENIC SYMPTOM REMISSION WITH APOMORPHINE 001570 02-08

FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN TREATMENT OF REMITTED SCHIZOPHRENICS: II. RATING SCALE DATA. 000544 01-08

FLUPHENAZINE-DECANOATE, FLUPHENAZINE-HYDROCHLORIDE GIVEN
ORALLY, AND PLACEBO IN REMITTED SCHIZOPHRENICS; I. RELAPSE RATES AFTER ONE YEAR. 000545 01-08

TIME-COURSE OF LITHIUM-INDUCED ALTERATIONS IN RENAL AND ENDOCRINE FUNCTION IN NORMAL AND BRATTLEBORO RATS WITH

HYPOTHALAMIC DIABETES-INSIPIDUS 000048 01-03 INHIBITION OF PROSTAGLANDIN SYNTHETASE SYSTEM IN THE RABBIT RENAL MEDULLA BY PSYCHOTROPIC DRUGS.

000281 01-03 METHADONE MAINTENANCE: EFFECT OF URINARY PH ON RENAL CLEARANCE IN CHRONIC HIGH AND LOW DOSES

000687 01-13 EFFECTS OF MORPHINE-SULFATE ON RENAL TRANSPORT REDUCED RENAL CALCIUM EXCRETION DURING LITHIUM THERAPY.
001597 02-09 001055 02-03

UMI

COMBINED SEMINAR ON THE USE OF DRUGS IN RENAL FAILURE. 001902 02-17 INFLUENCE OF TRIIODOTHYRONINE (T3) ON THE RENAL ACTION OF 002119 03-03 003510 04-09 002569 03-13 003503 04-09 000821 01-15 000062 01-03 000459 01-04 001179 02-03 001387 02-04 001497 02-04 DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION. 001787 02-15 002047 03-03 002144 03-03 003234 04-04 003238 04-04 003260 04-04 003282 04-04 003413 04-05 A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR 003657 04-15 PEPETITIVE DIAZEPAM BLOCKADE OF REPETITIVE ACTION POTENTIALS IN SKELETAL MUSCLE FIBRES: A MODEL OF ITS MEMBRANE ACTION 001275 02-03 STATUS-EPILEPTICUS OR REPETITIVE SEIZURES FOLLOWING TOXIC INGESTION

REPONSES
VISUAL EVOKED REPONSES IN CHRONIC HASHISH USERS. 000722 01-13 REPRESSION
REPRESSION OF A LITHIUM PUMP AS A CONSEQUENCE OF LITHIUM
INGESTION BY MANIC-DEPRESSIVE SUBJECTS. 000714 01-13 REPRODUCIBILITY
BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS: ASSAY
PROCEDURES, REPRODUCIBILITY AND RELATIONSHIP TO THERAPEUTIC
OUTCOME AND SIDE-EFFECTS. REPRODUCTIVE

EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR
OF ADULT MALE DOMESTIC DUCKS: II. CORRELATION WITH
MORPHOLOGY AND HORMONE PLASMA LEVELS.

000315 01-00 EFFECTS OF EXOGENOUS HORMONES ON THE REPRODUCTIVE BEHAVIOUR OF ADULT MALE DOMESTIC DUCKS: 1. BEHAVIOURAL EFFECTS OF INTRAMUSCULAR INJECTIONS. 000316 01-04 EFFECTS OF SOME OF THE NEUROLEPTICS ON THE REPRODUCTIVE ORGANS 003419 04-05 REQUIRED
INHIBITION OF BOTH MAO-A AND MAO-B REQUIRED FOR THE
PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE
INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

000398 0 000398 01-04 RESEARCH METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGICAL RESEARCH 000523 0 METHODOLOGICAL ISSUES IN PSYCHOPHARMACULUGICAL REDEABLIT.

OD 0523 01-08
REPLY TO DAVIS AND HURT CONCERNING METHODOLOGICAL ISSUES IN
PSYCHOPHARMACOLOGICAL RESEARCH WITH CHLORPROMAZINE.

000538 01-08 MAO INHIBITORS IN CLINICAL PRACTICE: PRINCIPLES BASED ON RECENT RESEARCH 000578 01-09 NEUROLEPTIC SIDE-EFFECTS OF CHLORPROMAZINE IN PSYCHOPHARMACOLOGICAL RESEARCH. 000895 01-15 DIAZEPAM: EFFICACY AND TOXICITY AS REVEALED BY A SMALL SAMPLE RESEARCH STRATEGY. 000933 01-16 A REVIEW OF STIMULANT DRUG RESEARCH WITH HYPERACTIVE CHILDREN. 000937 01-17 RESEARCH BARRIERS IN PSYCHOPHARMACOLOGY. 000944 01-17 CLINICAL RESEARCH TECHNIQUES IN TARDIVE-DYSKINESIA 000948 01-17 JECTS RIGHTS, FREEDOM OF INQUIRY, AND THE FUTURE OF RESEARCH IN THE ADDICTIONS. 000966 01-17 CIA RESEARCH WITH LSD-25 001638 02-12 PHARMACOLOGICAL RESEARCH AND THE PSYCHOSES: AN OVERVIEW 001868 02-16 PROLIXIN-DECANOATE: A REVIEW OF THE RESEARCH 001941 02-17 SECOND-GENERATION ANTIDEPRESSANTS AS RESEARCH TOOLS -- SOME PRELIMINARY FINDINGS WITH CLOMIPRAMINE AND MAPROTILINE. 002587 03-13 THE CURRENT STATUS OF RESEARCH IN THE CATECHOLAMINE THEORIES 002733 03-17 LINICAL EVALUATION OF NALTREXONE TREATMENT OF OPILATE-DEPENDENT INDIVIDUALS: REPORT OF THE NATIONAL RESEARCH COUNCIL COMMITTEE ON CLINICAL EVALUATION OF NARCOTIC 002768 03-17 RESEARCH FINDINGS ON CHRONIC MENTAL ILLNESS: A MODEL FOR CONTINUING-CARE IN THE HEALTH MAINTENANCE ORGANIZATION 002777 03-17 METHODOLOGICAL ISSUES IN DRUG DISCRIMINATION RESEARCH. 003202 04-04
THE IMPLICATIONS OF PSYCHEDELIC DRUG RESEARCH FOR INTEGRATION AND SEALING OVER AS RECOVERY STYLES FROM ACUTE PSYCHOSIS 003517 04-09 PHENCYCLIDINE: A BIBLIOGRAPHY OF BIOMEDICAL AND BEHAVIORAL RESEARCH 003699 04-17 DIFFICULTIES ENCOUNTERED BY THE CLINICAL RESEARCHER IN PLANNING PSYCHOTROPIC DRUG TRIALS. 000935 01-16 ON THE CONFORMATION OF NEUROLEPTIC DRUGS IN THE THREE AGGREGATION STATES AND THEIR CONFORMATIONAL RESEMBLANCE

000990 01-17

001845 02-15

003561 04-11

003290 04-04

OPIATE RECEPTORS FOR REHAVIORAL ANALGESIA RESEMBLE THOSE RELATED TO THE DEPRESSION OF SPINAL NOCICEPTIVE NEURONS 003142 04-03

SLOW-WAVE SLEEP AND A STATE RESEMBLING ABSENCE EPILEPSY INDUCED IN THE RAT BY GAMMA-HYDROXYBUTYRATE. 001366 02-04

EFFECTS OF RESERPINE AND IMIPRAMINE ON VESICULAR SEROTONIN UPTAKE AND STORAGE IN INTACT HUMAN PLATELETS.

000081 01-03 EFFECTS OF APOMORPHINE AND CLONIDINE ON RAT PLASMA GROWTH HORMONE AFTER PRETREATMENT WITH RESERPINE AND ELECTROCONVULSIVE SHOCKS.

000102 01-03 DIFFERENTIAL EFFECTS OF RESERPINE AND TETRABENAZINE ON RAT STRIATAL SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS AND SYNAPTOSOMAL DOPAMINE POOLS

000172 01-03 EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT BRAIN: A QUANTITATIVE HISTOLOGICAL STUDY

000184 01-03 **ACTIVITY OF VESTIBULO-OCULOMOTOR NEURONES DURING SACCADIC** EYE MOVEMENTS INDUCED BY RESERVINE

000199 01-03 EFFECT OF RESERPINE ON CELL PROLIFERATION IN THE DEVELOPING RAT BRAIN: A BIOCHEMICAL STUDY

000216 01-03 SEROTONIN TRANSPORT AND STORAGE IN RABBIT BLOOD PLATELETS --THE EFFECTS OF RESERPINE AND IMIPRAMINE

000236 01-03 EFFECTS OF RESERPINE AND SEROTONIN ON ADENINE-NUCLEOTIDE METABOLISM AND GLUCOSE OXIDATION OF WASHED RABBIT

000237 01-03 EFFECT OF RESERPINE ON ADENOSINE UPTAKE AND METABOLISM, AND SUBCELLULAR TRANSPORT OF PLATELET ADENOSINE-TRIPHOSPHATE IN WASHED RABBIT PLATELETS.

000238 01-03 POTENTIATION BY RESERPINE OF THE INHIBITION BY AMPHETAMINE OF (3H)DOPAMINE ACCUMULATION IN THE RAT STRIATUM

000246 01-03 FACILITATION BY RESERVINE OF RETENTION IN AN INHIBITORY AVOIDANCE TASK IN MICE.

000406 01-04 CHANGES IN LIVER FUNCTION IN ACUTE POISONING BY BARBITURATE, RESERPINE AND AMPHETAMINE.

001094 02-03 AGE-RELATED EFFECTS OF RESERPINE ON BEHAVIOR AND ON REGIONAL CATECHOLAMINE UPTAKE AND RELEASE IN THE RAT. (PH.D.

001098 02-03 VESICULAR AND JUXTAVESICULAR SEROTONIN: EFFECTS OF LYSERGIC-ACID-DIETHYLAMIDE AND RESERVINE

THE RELATIONSHIP BETWEEN CORTICAL RECRUITING RESPONSES AND PONTO-GENICULO-OCCIPITAL (PGO) WAVES DURING PARADOXICAL SLEEP AND AFTER THE ADMINISTRATION OF RESERVINE IN THE CAT

002069 03-03 TIME-DEPENDENT EFFECTS OF RESERPINE ON RETENTION OF PASSIVE

002327 03-04 A METHOD FOR MECHANOGRAPHICAL RECORDING OF MUSCLE TONE IN THE RAT: THE EFFECT OF SOME ANTIPARKINSONIAN DRUGS ON RIGIDITY INDUCED BY RESERPINE

002346 03-05 THE EFFECTS OF P-CHLOROPHENYLALANINE, RESERPINE, METHYSERGIDE AND CYPROHEPTADINE ON THE DOPA-INDUCED EEG SYNCHRONIZATION

003022 04-03 H3-CATECHOLAMINE BINDING TO ALPHA-RECEPTORS IN RAT BRAIN: ENHANCEMENT BY RESERPINE.

003119 04-03 EFFECT OF RESERPINE ON THE MONOAMINE-OXIDASE (MAO) ACTIVITY IN RAT LIVER AND BRAIN.

003125 04-03

PESERPINE-INDUCED

EFFECTS OF L DIHYDROXYPHENYLALANINE (L-DOPA) AND DL,5 HYDROXYTRYPTOPHAN (DL,5-HTP) ON RESERPINE-INDUCED AMNESIA 000427 01-04 EFFECT OF LOCAL APPLICATION OF APOMORPHINE TO THE CORPUS-

STRIATUM AND TO THE NUCLEUS-ACCUMBENS ON THE RESERPINE-INDUCED RIGIDITY IN RATS 001021 02-02

CHOLINE-ACETYLTRANSFERASE AND THE HIGH AFFINITY UPTAKE OF CHOLINE IN CORPUS-STRIATUM OF RESERPINISED RATS. 002847 04-03 RESERPINIZED

EFFECT OF () AMPHETAMINE ON THE RETENTION OF H3-CATECHOLAMINES IN SLICES OF NORMAL AND RESERPINIZED RAT

FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON LOCOMOTOR ACTIVITY AND AVOIDANCE BEHAVIOUR OF RESERPINIZED MICE. 003351 04-04

MEDICATION IN RESIDENTIAL TREATMENT: ADMINISTRATION AND CLINICAL EXPERIENCES.

RESIDUAL

RESIDUAL EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE TREATMENTS FOR ALCOHOL WITHDRAWAL.

THE USE OF THE CNV (CONTINGENT NEGATIVE VARIATION) IN THE DETERMINATION OF RESIDUAL EFFECTS OF FIVE HYPNOTIC DRUG 002713 03-16 RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS:

ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT
LEARNING WITH D AMPPHETAMINE TREATMENTS. 003167 04-04

THE EFFECT OF CHLORPROMAZINE ON CELL MEMBRANE RESISTANCE AND CAPACITANCE.

RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION WITH A HIGH FAT/PROTEIN DIET.

002278 03-04 CENTRAL AND PERIPHERAL NORADRENALINE AND RESISTANCE TO EXTINCTION.

A COMPARISON OF THE EFFECTS OF INTRAVENTRICULAR MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON OPERANT BEHAVIOR IN

001323 02-04 CHLOROQUINE POTENTIATION OF THIORIDAZINE EFFECTS IN RATS AND DRUG RESISTANT SCHIZOPHRENIC PATIENTS: A PRELIMINARY REPORT. 001571 02-08

EFFECTS OF MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON SCHEDULE-CONTROLLED RESPONDING IN THE RAT.

002206 03-04 SYNTHESIS OF TWO ENZYME RESISTANT ENKEPHALIN ANALOGS POSSESSING ENHANCED ANALGESIC ACTIVITY.

002787 04-01 TREATMENT OF IMIPRAMINE RESISTANT DEPRESSION AND LITHIUM REFRACTORY MANIA THROUGH DRUG INTERACTIONS.

003512 04-09

RESPECTIVE

MODIFICATION OF ADENYLATE-CYCLASE SYSTEMS IN MOUSE CEREBRAL CORTEX BY CHLORPROMAZINE AND RESPECTIVE 7 HDROXY ANALOGS. 002875 04-03

RESPIRATION EFFECTS OF METHADONE ON RESPIRATION AND HEMODYNAMICS OF PREGNANT WOMEN

PHENOBARBITAL EFFECT ON GLIAL CELL RESPIRATION IN THE PRESENCE OF A HIGH CONCENTRATION OF POTASSIUM.

002946 04-03

RESPIRATORY

PSYCHOTROPIC DRUGS: INFLUENCE ON RESPIRATORY FUNCTION 000692 01-13 RESPIRATORY COMPLICATIONS IN PATIENTS WITH INTOXICATION 001767 02-15

THE BEHAVIORAL SYMPTOMS OF HYPERKINETIC CHILDREN WHO SUCCESSFULLY RESPONDED TO STIMULANT DRUG TREATMENT 003579 04-11

PSYCHOACTIVE DRUG RESPONDER SUBGROUPS -- POSSIBLE CONTRIBUTIONS TO PSYCHIATRIC CLASSIFICATION. (UNPUBLISHED

PAPER)

THE VALUE OF THE MMPI FOR DELINEATING SYMPTOMS UNIQUE TO POSITIVE LITHIUM RESPONDERS: A DRUG RESPONSE AND DIAGNOSTIC STUDY. (PH.D. DISSERTATION). 002638 03-14

EFFECT OF CHLORDIAZEPOXIDE ADMINISTERED EARLY IN EXTINCTION ON SUBSEQUENT EXTINCTION OF A CONDITIONED EMOTIONAL RESPONSE IN RATS: IMPLICATIONS FOR HUMAN CLINICAL USE. 000022 01-02

STRAIN DIFFERENCES IN THE RESPONSE TO MORPHINE ON INCORPORATION OF H3-LYSINE INTO RAT BRAIN PROTEIN 000108 01-03

001666 02-13

UMI

MOTILITY RESPONSE TO MORPHINE AND AMPHETAMINE DURING CHRONIC INHIBITION OF TYROSINE-HYDROXYLASE OR DOPAMINE-BETA-HYDROXYLASE. 000166 01-03 CAFFEINE RESTORES FEEDING RESPONSE TO 2 DEOXY-D-GLUCOSE IN 6
HYDROXYDOPAMINE TREATED RATS. 000277 01-03 ALTERATION OF THE NEURONAL RESPONSE TO AMPHETAMINE IN THE NEOSTRIATUM BY PRETREATMENT WITH A CENTRALLY ACTING ANTICHOLINERGIC. METABOLIC AND EXPERIENTIAL FACTORS IN THE BEHAVIORAL RESPONSE TO REPEATED AMPHETAMINE. 000325 01-04 DRUG EFFECTS UPON FORCE AND DURATION OF RESPONSE DURING FIXED-RATIO PERFORMANCE IN RATS. 000363 01-04 ENHANCEMENT OF LEARNING BY CYCLOHEXIMIDE AND DDC: A FUNCTION 000374 01-04 ACUTE DYSTONIA AS AN IDIOSYNCRATIC RESPONSE TO NEUROLEPTICS IN 000409 01-04 PHARMACOLOGICAL APPROACHES TO HABITUATION OF THE ACOUSTIC 000425 01-04 CHANGES IN THE RATE INCREASING EFFECTS OF D AMPHETAMINE AND PENTOBARBITAL BY RESPONSE CONSEQUENCES. 000452 01-04 DEVELOPMENT OF TOLERANCE TO THE DISRUPTIVE AFFECTS OF COCAINE ON REPEATED ACQUISITION AND PERFORMANCE OF RESPONSE 000459 01-04 000464 01-04 GENETIC ANALYSIS OF THE BEHAVIORAL RESPONSE TO D AMPHETAMINE 000482 01-05 RESPONSE TO LITHIUM IN A CASE OF L-DOPA-INDUCED PSYCHOSIS 000559 01-09 PHENELZINE IN DEPRESSED PATIENTS: EFFECTS ON URINARY MHPG EXCRETION IN RELATION TO CLINICAL RESPONSE. 000686 01-13 PSYCHOLOGIC AND NEUROENDOCRINE RESPONSE TO METHYLPHENIDATE. RATE OF ABSORPTION AND CLINICAL RESPONSE TO SINGLE ORAL DOSES OF CHLORDIAZEPOXIDE. 000702 01-13 PILOT STUDY. THIORIDAZINE METABOLISM AND CLINICAL RESPONSE: A 000737 01-13 INDIVIDUAL VARIATIONS IN RESPONSE OF HUMAN REM SLEEP TO AMITRIPTYLINE AND HALOPERIDOL. 000779 01-14 PARADOXICAL RESPONSE TO DOPAMINE AGONISTS IN TARDIVE-000809 01-15 THE USE OF PROLACTIN RESPONSE IN CLINICAL PSYCHOPI HARMACOLOGY 000980 01-17 A ROLE FOR CENTRAL SEROTONERGIC SYSTEMS IN THE PATTERN AND INTENSITY OF THE CONVULSIVE RESPONSE OF RATS TO 001067 02-03 LIPOPROTEIN POTENTIATION OF THE CEREBROVASCULAR RESPONSE TO 001109 02-03 MORPHINE ANALGESIA DOSE RESPONSE CURVES IN TOLERANT RATS: 001143 02-03 POSTSYNAPTIC POTENTIATION OF THE SLOW MUSCARINIC EXCITATORY RESPONSE BY TETRAETHYLAMMONIUM-CHLORIDE IN THE BULLFROG SYMPATHETIC GANGLION CELLS.

THE EFFECTS OF HORMONES AND MORPHINE ON BOTH ANALGESIA AND THE LORDOSIS RESPONSE PRODUCED BY CERVICAL PROBING IN THE

EFFECT OF PANAX GINSENG ROOT ON CONDITIONED AVOIDANCE RESPONSE IN RATS.

CIRCADIAN VARIATION IN AN AMPHETAMINE-INDUCED MOTOR

001173 02-03 MONOSYNAPTIC ACTIVATION OF FASCIA-DENTATA IN UNRESTRAINED
RATS: RESPONSE MODIFICATION BY SYNAPTICALLY ACTIVE DRUGS 001214 02-03 THE EFFECTS OF PSYCHOTOMIMETIC DRUGS ON THE CONDITIONED EMOTIONAL RESPONSE. 001308 02-04

DIFFERENT BEHAVIOURAL PATTERNS INDUCED BY APOMORPHINE: EVIDENCE THAT THE METHOD OF ADMINISTRATION DETERMINES THE BEHAVIOURAL RESPONSE TO THE DRUG.

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION
DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND
QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY. 001535 02-06

THE PHARMACOKINETICS OF RED BLOOD CELL AND PLASMA BUTAPERAZINE CLINICAL RESPONSE AND SIDE-EFFECTS.

PROTRIPTYLINE PLASMA LEVELS AND ANTIDEPRESSANT RESPONSE. 001576 02-09 AMITRIPTYLINE PLASMA LEVELS AND CLINICAL RESPONSE IN PRIMARY DEPRESSION.

001594 02-09 PLATELET MONOAMINE-OXIDASE ACTIVITY PREDICTS RESPONSE TO LITHIUM IN MANIC-DEPRESSIVE ILLNESS.

001607 02-09 THE MOOD RESPONSE AND PLASMA CYCLIC-AMP RESPONSE TO INTRAVENOUS METHYLPHENIDATE.

SEX DIFFERENCES IN RESPONSE TO DRUG TREATMENT. 001743 02-15

ADVERSE RESPONSE TO NEUROLEPTICS IN SCHIZOPHRENIA 001814 02-15

RELATIONSHIPS AMONG CLINICAL RESPONSE, EXTRAPYRAMIDAL SYNDROME AND PLASMA CHLORPROMAZINE AND METABOLITE RATIOS. 001827 02-15

THE PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS. A TEST OF DOPAMINERGIC BLOCKADE: NEUROENDOCRINE STUDIES IN NORMAL

001867 02-16 EFFECT OF AGE ON ACUTE MORPHINE RESPONSE IN THE RAT. 002159 03-03

CIRCADIAN VARIATIONS IN RESPONSE TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT. 002182 03-03

THE EFFECT OF ETHANOL ON SUPPRESSION OF THE NALOXONE PRECIPITATED ESCAPE RESPONSE IN MORPHINE-DEPENDENT MICE 002230 03-04 SOME EFFECTS OF CHLORDIAZEPOXIDE AND D AMPHETAMINE ON RESPONSE FORCE DURING PUNISHED RESPONDING IN RATS.

002234 03-04 DECREASED RESPONSE INHIBITION DURING FIXED-INTERVAL RESPONDING IN PIGEONS FOLLOWING ATROPINE ADMINISTRATION.

002305 03-04 VILOXAZINE IN THE TREATMENT OF DEPRESSION: PSYCHOPHYSICAL MEASURES AND CLINICAL RESPONSE.

002375 03-07 R-806-003-01 IN THE TREATMENT OF DEPRESSION: PLASMA LEVELS AND THERAPEUTIC RESPONSE.

002376 03-07 A COMPARISON OF DESIPRAMINE AND AMITRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.

002417 03-09 PREDICTION OF LITHIUM RESPONSE IN AFFECTIVE-DISORDERS 002418 03-09

CLOMIPRAMINE PLASMA LEVEL AND CLINICAL RESPONSE 002422 03-09

A NEW ANTIDEPRESSANT BUTRIPTYLINE: PLASMA LEVELS AND CLINICAL RESPONSE 002423 03-09

LITHIUM ERYTHROCYTE/PLASMA RATIO AS A PREDICTOR OF RESPONSE 002431 03-09 DESIPRAMINE PLASMA LEVELS AND THERAPEUTIC RESPONSE

002443 03-09 CLINICAL RESPONSE IN DEPRESSED PATIENTS IN RELATION TO PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND TYRAMINE PRESSOR RESPONSE

002453 03-09 COGNITIVE AND PSYCHOPHYSIOLOGIC RESPONSE TO DOXEPIN AND CHLORDIAZEPOXIDE

002457 03-09 INITIAL RESPONSE TO DRUGS IN DEPRESSIVE ILLNESS AND PSYCHIATRIC AND COMMUNITY ADJUSTMENT A YEAR LATER.

002459 03-09 ENHANCEMENT OF THE ANTIDEPRESSANT RESPONSE TO L TRYPTOPHAN BY A LIVER PYRROLASE INHIBITOR: A RATIONAL TREATMENT APPROACH

002464 03-09 A PRELIMINARY REPORT ON CLINICAL RESPONSE AND PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN OBSESSIVE-COMPULSIVE NEUROSIS.

002493 03-10 PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS IN NORMAL AND SCHIZOPHRENIC SUBJECTS.

002575 03-13

001445 02-04

001451 02-04

001479 02-04

THE VALUE OF THE MMPI FOR DELINEATING SYMPTOMS UNIQUE TO POSITIVE LITHIUM RESPONDERS: A DRUG RESPONSE AND DIAGNOSTIC STUDY. (PH.D. DISSERTATION).

002638 03-14

CLINICAL VALUE OF THE BRAINSTEM EVOKED RESPONSE IN COMA. 002650 03-15 MISLEADING RESPONSE OF MALIGNANT GASTRIC ULCERS TO

MISLEADING RESPONSE OF MALIGNANT GASTRIC ULCERS TO CIMETIDINE.

002704 03-15
PROFILES OF PROLACTIN RESPONSE TO ANTIPSYCHOTIC DRUGS: SOME METHODOLOGIC CONSIDERATIONS.

002725 03-16
THE BIOLOGY OF AFFECTIVE-ILLNESS: AMINE NEUROTRANSMITTERS AND DRIIG RESPONSE

002746 03-17
SUPERSENSITIVITY OF THE CHOLINERGIC RESPONSE TO APOMORPHINE IN
THE STRIATUM FOLLOWING DENERVATION OR DISUSE
SUPERSENSITIVITY OF DOPAMNIREGIC RECEPTORS IN THE RAT.

002872 04-03
THE NEURONAL ORIGIN OF PROSTAGLANDIN RELEASED FROM THE
RABBIT PORTAL VEIN IN RESPONSE TO ELECTRICAL STIMULATION.

CARDIOVASCULAR RESPONSE TO INTRACEREBROVENTRICULAR ADMINISTRATION OF ACETYLCHOLINE IN RATS.

MODIFICATION OF THE 5 HYDROXYTRYPTOPHAN-INDUCED HEAD-TWITCH RESPONSE BY EXOGENOUS ENDOCRINE AGENTS.

O03177 04-04

TASK-DEPENDENT GENETIC INFLUENCES ON BEHAVIORAL RESPONSE OF MICE (MUS-MUSCULUS) TO ACETALDEHYDE.

O03211 04-04
THE EFFECTS OF PIMOZIDE AND PHENOXYBENZAMINE PRETREATMENTS
ON AMPHETAMINE AND APOMORPHINE POTENTIATION OF THE
ACOUSTIC STARTLE RESPONSE IN RATS.

003257 04-04
IMPRINTING BEHAVIOR: PITUITARY ADRENOCORTICAL MODULATION OF
THE APPROACH RESPONSE.

003287 04-04
EMERGING CHOLINERGIC MECHANISMS AND ONTOGENY OF RESPONSE
INHIBITION IN THE MOUSE.

O03336 04-04

EFFECT OF METERGOLINE, P-CHLOROPHENYLALANINE AND DOPA ON
DELAYED RESPONSE IN CATS AND THE RELATIONSHIP BETWEEN THE
MESOLIMBIC AND NIGROSTRIATAL NEURONS.

ACTH EFFECTS ON RESPONSE SUPPRESSION AND PLASMA
CORTICOSTERONE IN THE MOUSE

DRUG EFFECTS ON RESPONDING MAINTAINED BY STIMULUS REINFORCER
AND RESPONSE REINFORCER CONTINGENCIES

CHANGES IN THE BEHAVIORAL RESPONSE TO A NOVEL ENVIRONMENT FOLLOWING LESIONING OF THE CENTRAL DOPAMINERGIC SYSTEM IN RAT PUPS

A GENETIC ANALYSIS OF THE HYPERTHERMIC RESPONSE TO D

AMPHETAMINE IN TWO INBRED STRAINS OF MICE.

003411 04-05
RELATIONSHIP BETWEEN SERUM CONCENTRATIONS OF THIORIDAZINE
AND ITS MAIN NONCONJUGATED METABOLITES AND THE CLINICAL

RESPONSE IN THIORIDAZINE TREATED PATIENTS.

O03480 04-09
HALOPERIDOL AND LITHIUM BLOCKING OF THE MOOD RESPONSE TO INTRAVENOUS METHYLPHENIDATE.

LOXAPINE IN NEUROTIC ANXIETY: SOME MODIFIERS OF TREATMENT RESPONSE

003544 04-10
ANTIDEPRESSANT DRUG LEVELS AND CLINICAL RESPONSE.

THE PROLACTIN RESPONSE IN CLINICAL PSYCHIATRY. 003545 04-10 003597 04-13

RESPONSES

ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5MEDDMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN
FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF
ROTATIONAL BEHAVIOUR.

OCOORGO 01-03 SECOND MESSENGER RESPONSES AND REGULATION OF HIGH AFFINITY RECEPTOR BINDING TO STUDY PHARMACOLOGICAL MODIFICATION OF GABAERGIC TRANSMISSION. (UNPUBLISHED PAPER).

000133 01-03
METABOLIC RESPONSES TO ISOPROTERENOL AND EPINEPHRINE IN THE
RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES
AND PRETREATMENT WITH PROPRANOLOL.

NATURE OF RECEPTORS INVOLVED IN APOMORPHINE RESPONSES IN

CHANGES IN HIPPOCAMPAL EVOKED RESPONSES TO AFFERENT STIMULATION DURING CONDITIONING.

MPAIRMENT OF RETENTION OF AVOIDANCE RESPONSES IN RATS BY
POSTTRAINING DIFTHYLDITHIOCARBAMATE.

O00454 01-04
PLASMA NORTRIPTYLINE AND CARDIAC RESPONSES IN YOUNG AND OLD
RATS.

000479 01-05
RESPONSES TO INTRAVENOUS HEROIN IN DEPENDENT AND
NONDEPENDENT VOLUNTEERS.

CIRCADIAN VARIATIONS IN RESPONSES TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT.

O01288 02-03
DIFFERENT BEHAVIORAL RESPONSES TO L-DOPA AFTER ANTEROLATERAL
OR POSTEROLATERAL HYPOTHALAMIC INJECTIONS OF 6
HYDROXYDOPAMINE

IQ AS A PREDICTOR OF ANTIDEPRESSANT RESPONSES TO IMIPRAMINE.
001582 02-09

THE RELATIONSHIP BETWEEN CORTICAL RECRUITING RESPONSES AND PONTO-GENICULO-OCCIPITAL (PGO) WAVES DURING PARADOXICAL SLEEP AND AFTER THE ADMINISTRATION OF RESERPINE IN THE CAT.

THE INFLUENCE OF COCAINE AND DESIPRAMINE ON THE CARDIAC RESPONSES TO EXOGENOUS AND ENDOGENOUS NOREPINEPHRINE. 022077 03-03

EFFECTS OF FLURAZEPAM ON AMINO-ACID EVOKED RESPONSES
RECORDED FROM THE LOBSTER MUSCLE AND THE FROG SPINAL CORD.
002115 03-03

DIFFERENCES IN THE INHIBITORY EFFECTS OF NORMORPHINE AND OPIOID PEPTIDES ON THE RESPONSES OF THE VASA-DEFERENTIA OF TWO STRAINS OF MICE.

EFFECT OF DIHYDROERGOTOXINE ON THALAMIC AND PYRAMIDAL EVOKED RESPONSES IN THE CAT UNDER TRANSIENT ISCHEMIA.

O02201 03-04

EFFECTS OF CHLORDIAZEPOXIDE, OXAZEPAM, CHLORPROMAZINE, AND D

AMPHETAMINE

AMSTER

AMSTE

002208 03-04
BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC/
ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH
NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA.

SELECTIVE REDUCTION BY NORADRENALINE AND 5
HYDROXYTRYPTAMINE OF NOCICEPTIVE RESPONSES OF CAT DORSAL-

HORN NEURONES.

O02246 03-04

AMANTADINE-HYDROCHLORIDE (AMN): ANTAGONISM TO ETHANOL
(ETOH) MEDIATED RESPONSES IN RODENTS.

002282 03-04
RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDROXYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN
ACUTE AND CHRONIC SPINAL RATS.

O02289 03-04

EFFECT OF P-CHLOROPHENYLALANINE (PCPA) AND PHENYLALANINE (PHE)

TREATMENT ON EARLY AUDITORY EVOKED RESPONSES IN RATS.

O02304 03-04

ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING

MANIPULATION OF NIGRAL MECHANISMS WITH CHLOWING
EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY
BRAZORIAZEPINES:

002326 03-04
SERUM PROLACTIN AND ANTIPSYCHOTIC RESPONSES TO PIMOZIDE IN SCHIZOPHRENIA.

002408 03-08

HORMONE RESPONSES TO METHYLAMPHETAMINE IN DEPRESSION:
NEW APPROACH TO THE NORADRENALINE DEPLETION HYPOTHESIS.
002424 03-09

NEUROENDOCRINE RESPONSES TO LEVODOPA IN AFFECTIVE-ILLNESS. 002435 03-09
TYRAMINE PRESSOR RESPONSES AND PLASMA LEVELS DURING

TRICYCLIC ANTIDEPRESSANT THERAPY.

O02584 03-13

PROLACTIN RESPONSES TO NEUROLEPTIC DRUGS: AN APPROACH TO THE STUDY OF BRAIN DOPAMINE BLOCKADE IN HUMANS.

002590 03-13

EFFECTS OF CENTRALLY ACTING DRUGS ON BRAINSTEM AUDITORY
RESPONSES.

002598 03-13
ANTAGONISM OF ETHANOL EVOKED RESPONSES BY AMANTADINE: A
POSSIBLE CLINICAL APPLICATION.

002797 04-02

EFFECTS OF CENTRAL GABA RECEPTOR AGONISM AND ANTAGONISM ON
EVOKED DIENCEPHALIC CARDIOVASCULAR RESPONSES.

COMPARISON OF THE RESPONSES OF SINGLE CORTICAL NEURONES TO TYRAMINE AND NORADRENALINE: EFFECTS OF DESIPRAMINE. 002821 04-03

Subject Index

RESPONSES OF SINGLE CORTICAL NEURONES TO NORADRENALINE AND DOPAMINE

002822 04-03 RESPONSES OF THE PITUITARY ADRENAL SYSTEM OF THE PIG TO ENVIRONMENTAL CHANGES AND DRUGS.

PHARMACOLOGIC RESPONSES OF CELLS OF A NEUROBLASTOMA-X GLIOMA HYBRID CLONE AND MODULATION OF SYNAPSES BETWEEN HYBRID CELLS AND MOUSE MYOTUBES.

002863 04-03

HYPERTHERMIC RESPONSES TO CENTRAL AND PERIPHERAL INJECTIONS

OF MORPHINE-SULPHATE IN THE CAT.

002864 04-03 SUPPRESSION BY NITROUS-OXIDE OF VISUAL RESPONSES IN THE CEREBELLAR VERMIS AND SUPERIOR COLLICULUS OF CATS ANESTHETIZED WITH CHLORALOSE.

002897 04-03 MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMATURE RAT.

002901 04-03 H3-GLYCOGEN HYDROLYSIS IN BRAIN SLICES: RESPONSES TO NEUROTRANSMITTERS AND MODULATION OF NORADRENALINE RECEPTORS.

EFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY THE RESPONSES OF THE MUSCLE SPINDLE OF THE TRICEPS SURAE MUSCLE OF THE DECEREBRATE CAT TO THE MUSCLE STRETCH.

003109 04-03

DIFFERENTIAL EFFECTS OF CONVULSANTS ON VISUALLY EVOKED RESPONSES IN THE ALBINO RAT.

DRUG-MODULATED BEHAVIOURAL RESPONSES TO ENVIRONMENTAL

REPEATED EXPOSURE OF RATS TO THE CONVULSANT AGENT FLUROTHYL ENHANCES 5 HYDROXYTRYPTAMINE AND DOPAMINE MEDIATED BEHAVIOURAL RESPONSES.

003234 04-04 PREFERENCE BEHAVIOR AND TASTE NERVE RESPONSES IN D PENICILLAMINE TREATED RATS.

003248 04-04 METHYLENE-BLUE ALTERS RETENTION OF INHIBITORY AVOIDANCE RESPONSES

003288 04-04 IQ AS A PREDICTOR OF ANTIDEPRESSANT RESPONSES TO LITHIUM. 003492 04-09

GROWTH HORMONE, PROLACTIN AND CORTISOL RESPONSES AND GROWTH PATTERNS IN HYPERKINETIC CHILDREN TREATED WITH DEXTROAMPHETAMINE. PRELIMINARY FINDINGS.

003569 04-11 PLASMA LEVELS OF NEUROLEPTICS VS CLINICAL RESPONSES

RESPONSIVE
LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR
BLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE IN THE
FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE

000619 01-11 IMPOTENCE RESPONSIVE TO GLYCERYL-TRINITRATE. TRINITRATE

000650 01-11 VIOLENT DYSCONTROL RESPONSIVE TO D AMPHETAMINE.

002528 03-11 SELECTIVE ENZYME INDUCTION IN A NERVE GROWTH FACTOR RESPONSIVE PHEOCHROMOCYTOMA CELL LINE (PC-12).

002899 04-03 LITHIUM RESPONSIVE DEPRESSION

003484 04-09 RESPONSIVENESS EFFECTS OF KETAMINE ON PATIENT RESPONSIVENESS DURING THE VARIOUS PHASES OF A SINGLE INDUCED ANXIETY SESSION.

THE PREDICTION OF DIFFERENTIAL RESPONSIVENESS OF HYPERKINETIC CHILDREN TO METHYLPHENIDATE. (PH.D. DISSERTATION). 001697 02-14

NEUROTENSIN ADMINISTERED INTRACISTERNALLY INHIBITS RESPONSIVENESS OF MICE TO NOXIOUS STIMULI.

002214 03-04 GENOTYPE AND TEST EXPERIENCE DETERMINE RESPONSIVENESS TO

002216 03-04 DIETARY EFFECTS UPON FOOD AND WATER INTAKE AND
RESPONSIVENESS TO ESTROGEN, 2 DEOXYGLUCOSE AND GLUCOSE IN

FEMALE RATS. 003402 04-04

RESPONSIVITY
TIME-DEPENDENT CHANGES IN ACTIVITY, REACTIVITY, AND
RESPONSIVITY DURING SHOCK: EFFECTS OF CHOLINERGIC AND
CATECHOLAMINERGIC MANIPULATIONS. 000313 01-04

Psychopharmacology Abstracts

HYPERALGESIA INDUCED BY NALOXONE FOLLOWS DIURNAL RHYTHM IN RESPONSIVITY TO PAINFUL STIMULI.

LORDOSIS REFLEX, SEXUAL RECEPTIVITY, AND FEEDING: ESTROGEN RESPONSIVITY IN MALE AND FEMALE RATS.

001327 02-04 DIFFERENTIAL CUE ATTENTIVENESS AND PLACEBO RESPONSIVITY. (PH.D. DISSERTATION).

MONOAMINE-OXIDASE ACTIVITY OF MACROPHAGES AT REST AND DURING PHAGOCYTOSIS.

002902 04-03

RESTING
COLCHICINE BLOCKS NEUROTROPIC REGULATION OF THE RESTING
MEMBRANE POTENTIAL IN REINNERVATING SKELETAL MUSCLE
00024 000262 01-03

RESTORATION
RESISTANCE OF ALLOXAN DIABETIC RATS TO THE BEHAVIORAL
ACTIVATION INDUCED BY D AMPHETAMINE: PARTIAL RESTORATION
WITH A HIGH FAT/PROTEIN DIET.

002278 03-04 RESTORES

CAFFEINE RESTORES FEEDING RESPONSE TO 2 DEOXY-D-GLUCOSE IN 6 HYDROXYDOPAMINE TREATED RATS. 000277 01-03

RESTRAINED EFFECTS ON TEMPERATURE OF MORPHINE INJECTED INTO THE PREOPTIC/ ANTERIOR HYPOTHALAMUS, MEDULLA-OBLONGATA, AND PERIPHERALLY IN UNRESTRAINED AND RESTRAINED RATS. 001264 02-03

DISCRIMINATIVE PENTOBARBITAL EFFECT MEASURED BY HEAD MOVEMENTS IN RESTRAINED RATS. 001396 02-04

RESTRAINT
RESTRAINT ALTERS THE EFFECTS OF MORPHINE AND HEROIN ON CORE
TEMPERATURE IN THE RAT.

001186 02-03 HYPOTHERMIA EVOKED BY THE INTRACEREBRAL INJECTION OF MORPHINE-SULPHATE IN THE RAT: THE EFFECT OF RESTRAINT. 002090 03-03

RETARD CLINICAL AND PHARMACOKINETIC STUDY OF DIBENZEPINE (ECATRIL): COMPARISON BETWEEN THE NORMAL AND RETARD FORMS

001581 02-09 EFFICACY OF SCH-12679 IN THE MANAGEMENT OF AGGRESSIVE MENTAL RETARDATES.

000506 01-07 ARDATION
THE BIOCHEMISTRY OF BRAIN DEVELOPMENT AND MENTAL
RETARDATION: THE ELEVENTH BLAKE MARSH LECTURE DELIVERED
BEFORE THE ROYAL COLLEGE OF PSYCHIATRISTS, 7 FEBRUARY, 1977.
002000 03-03 RETARDATION

MENTALLY RETARDED, HYPERKINETIC, AND PSYCHOTIC.

000584 01-09 CEREBELLAR ATROPHY IN PHENYTOIN TREATED MENTALLY RETARDED

001622 02-11 LITHIUM-CARBONATE IN THE MANAGEMENT OF HYPERACTIVE AGGRESSIVE BEHAVIOR OF THE MENTALLY RETARDED.

001713 02-14 USE OF LITHIUM-CARBONATE WITH RETARDED ACTION (MICALITE) IN PATIENTS WITH AFFECTIVE-PSYCHOSES.

002444 03-09 EFFECTS OF LORAZEPAM ON HYPERACTIVITY IN RETARDED CHILDREN 002643 03-14

CYPROTERONE-ACETATE EXPOSURE DURING GESTATION IN MICE RETARDS FETAL GROWTH.

003129 04-03 RETENTION

EFFECT OF COCAINE AND DESMETHYLIMIPRAMINE ON THE UPTAKE,
RETENTION AND METABOLISM OF H3-5-HYDROXYTRYPTAMINE IN RAT
BRAIN SLICES.

000305 01-03

THE EFFECT OF STIMULANTS, DEPRESSANTS, AND PROTEIN SYNTHESIS INHIBITION ON RETENTION.

000360 01-04 FACILITATION BY RESERPINE OF RETENTION IN AN INHIBITORY
AVOIDANCE TASK IN MICE.

000406 01-04 IMPAIRMENT OF RETENTION OF AVOIDANCE RESPONSES IN RATS BY POSTTRAINING DIETHYLDITHIOCARBAMATE.

000454 01-04 EFFECTS ON RETENTION OF POSTTRAINING AMPHETAMINE INJECTIONS IN MICE: INTERACTION WITH PRETRAINING EXPERIENCE.

003601 04-13

EFFECT OF SCOPOLAMINE ON RETENTION OF A SHOCK MOTIVATED BRIGHTNESS DISCRIMINATION IN RATS.

001487 02-04 THE EFFECTS OF DARVON-N ON RETENTION OF SPECIFIC LEARNING TASKS DURING HEROIN DETOXIFICATION. (PH.D. DISSERTATION) 001703 02-14

RECALL, RETENTION, AND RITALIN.

001728 02-14

EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AGONISTS AND ANTAGONISTS INTO THE AMYGDALA ON RETENTION OF PASSIVE AVOIDANCE TRAINING IN RATS. (PH.D. DISSERTATION) 002323 03-04

TIME-DEPENDENT EFFECTS OF RESERPINE ON RETENTION OF PASSIVE 002327 03-04

RETENTION OF URINE IN THE NEONATE POSSIBLY DUE TO ANTICONVULSANT DRUGS

002683 03-15 MODIFICATION OF NUCLEAR RETENTION OF H3-ESTRADIOL BY CELLS OF THE HYPOTHALAMUS AS A FUNCTION OF EARLY HORMONE EXPERIENCE 002891 04-03

EFFECT OF () AMPHETAMINE ON THE RETENTION OF H3-CATECHOLAMINES IN SLICES OF NORMAL AND RESERPINIZED RAT RRAIN AND HEART

003071 04-03 METHYLENE-BLUE ALTERS RETENTION OF INHIBITORY AVOIDANCE

003288 04-04 DORSOMEDIAL THALAMIC LESIONS AND AMPHETAMINE: ACQUISITION AND RETENTION OF A VISUAL PATTERN DISCRIMINATION ESCAPE 003399 04-04

RETICULAR

EFFECTS OF RETICULAR STIMULATION, D AMPHETAMINE AND SCOPOLAMINE ON ACETYLCHOLINE RELEASE FROM THE HIPPOCAMPUS OF BRAINSTEM TRANSECTED CATS

000098 01-03 A PRESYNAPTIC SITE OF ACTION WITHIN THE MESENCEPHALIC RETICULAR FORMATION FOR () AMPHETAMINE-INDUCED ELECTROCORTICAL DESYNCHRONIZATION

001069 02-03 EFFECTS OF BENZODIAZEPINES ON PGO FIRINGS AND MULTIPLE UNIT ACTIVITY IN THE MIDBRAIN RETICULAR FORMATION IN CATS.

001265 02-03 NEUROCHEMICAL MECHANISMS OF CENTRAL ACTION OF MORPHINE ON FUNCTIONS OF SINGLE NEURONS IN THE MIDBRAIN RETICULAR

001973 03-03 MOVEMENT INDUCED IN CATALEPTIC RATS: DIFFERENTIAL EFFECTS PRODUCED BY ELECTRICAL STIMULATION OF THE LATERAL HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FORMATION. 003297 04-04

RETICULARIS

FORMATION

THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF THE MEDULLA-OBLONGATA IS A HIGHLY SENSITIVE SITE IN THE PRODUCTION OF MORPHINE ANALGESIA IN THE RAT.

001256 02-03 ANALGESIA BY ENKEPHALINS INJECTED INTO THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF RAT MEDULLA-OBLONGATA.

RETICULOCYTES

MONOAMINE-OXIDASE IN RAT RETICULOCYTES: SUBCELLULAR LOCALIZATION AND IDENTIFICATION OF ISOENZYMES.

002134 03-03

RETICULOENDOTHELIAL THE EFFECTS OF STIMULATION AND DEPRESSION OF THE RETICULOENDOTHELIAL SYSTEM ON SIDMAN AVOIDANCE BEHAVIOR.

(PH.D. DISSERTATION). 001468 02-04 RETICULUM

EFFECT OF PSYCHOTROPIC DRUGS ON ATPASE TRANSPORT OF THE SARCOPLASMIC RETICULUM IN RABBIT SKELETAL MUSCLES 001174 02-03 THE EFFECT OF PHENOBARBITAL AND CARBON-TETRACHLORIDE ON

FATTY-ACID CONTENT AND COMPOSITION OF PHOSPHOLIPIDS FROM THE ENDOPLASMIC RETICULUM OF RAT LIVER 002888 04-03

DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RETINA -- SUBCELLULAR

DISTRIBUTION 002867 04-03 BRAIN AND RETINA UPTAKE OF A RADIOIODINE LABELED

PSYCHOTOMIMETIC IN DOG AND MONKEY. 003075 04-03 THE EFFECTS OF CHRONIC CHLORPROMAZINE ADMINISTRATION ON THE ALBINO RAT RETINA 003408 04-05

RETINAL

DOPAMINE-MIMETIC ACTIVITY OF ERGOT DERIVATIVES, AS MEASURED BY THE PRODUCTION OF CYCLIC-AMP IN ISOLATED RETINAE OF THE

RETINAL GABA, PICROTOXIN AND RETINAL SENSITIVITY. 002149 03-03 002889 04-03

003247 04-04

003017 04-03

003238 04-04

RETRIEVAL

MARIJUANA EFFECTS ON LONG-TERM MEMORY ASSESSMENT AND RETRIEVAL

000755 01-14 CONTEXT EFFECTS IN THE STORAGE AND RETRIEVAL OF INFORMATION IN

000793 01-14 OXYTOCIN, VASOPRESSIN AND MEMORY: OPPOSITE EFFECTS ON CONSOLIDATION AND RETRIEVAL PROCESSES.

003174 04-04 STATE-DEPENDENT RETRIEVAL OF ITEM, ASSOCIATIVE, AND SERIAL ORDER INFORMATION. 003711 04-17

RETROACTIVE

RETROACTIVE AMNESIA INDUCED IN CHICKS BY THE PROLINE ANALOG L BAIKIAIN, WITHOUT EEG SEIZURES OR DEPRESSION.

003205 04-04 RETROGRADE RETROGRADE AXONAL TRANSPORT OF NERVE GROWTH FACTOR IN THE

CILIARY GANGLION OF THE CHICK AND THE RAT. 003005 04-03 RETROGRADE AMNESIA PRODUCED BY POSTTRIAL INJECTION OF SUBSTANCE-P INTO SUBSTANTIA-NIGRA.

RETROSPECTIVE DIAGNOSIS OF HYPOMANIA FOLLOWING SUCCESSFUL
TREATMENT OF EPISODIC VIOLENCE WITH LITHIUM: A CASE REPORT.
003490 04-09

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS 002148 03-03

ROLE OF SEROTONIN REUPTAKE INHIBITION IN THE DEVELOPMENT OF SUBSENSITIVITY OF THE NOREPINEPHRINE (NE) RECEPTOR COUPLED ADENYLATE-CYCLASE SYSTEM.

REVERSAL

OLFACTORY BULB ABLATION IN THE RAT: BEHAVIOURAL CHANGES AND THEIR REVERSAL BY ANTIDEPRESSANT DRUGS.

000466 01-04 SLEEP-DEPRIVATION DEFICITS AND THEIR REVERSAL BY D AMPHETAMINE AND L AMPHETAMINE

000770 01-14 FOOTSHOCK INDUCED ANALGESIA IN MICE: ITS REVERSAL BY NALOXONE

AND CROSS-TOLERANCE WITH MORPHINE. 001078 02-03 ANALGESIA FOLLOWING TRANSCUTANEOUS ELECTRICAL STIMULATION

AND ITS PARTIAL REVERSAL BY A NARCOTIC ANTAGONIST 001646 02-13 REVERSAL BY PHYSOSTIGMINE OF CLOZAPINE-INDUCED DELIRIUM.

001828 02-15 NALOXONE REVERSAL OF MORPHINE ANALGESIA BUT FAILURE TO ALTER REACTIVITY TO PAIN IN THE FORMALIN TEST.

002117 03-03 L-DOPA REVERSAL OF HYPERDOPAMINERGIC BEHAVIOUR.

002229 03-04 REVERSAL OF ETHANOL INTOXICATION IN HUMANS: AN ASSESSMENT OF THE EFFICACY OF L-DOPA, AMINOPHYLLINE, AND EPHEDRINE

002544 03-13 REVERSAL OF THE ACTION OF AMINO-ACID ANTAGONISTS BY BARBITURATES AND OTHER HYPNOTIC DRUGS.

002838 04-03 REVERSALS

EFFECTS OF METHYLPHENIDATE ON ACQUISITION AND SUBSEQUENT PERFORMANCE OF SUCCESSIVE DISCRIMINATION REVERSALS

001371 02-04 THE EFFECTS OF METHYLPHENIDATE ON REPEATED ACQUISITION OF SERIAL DISCRIMINATION REVERSALS.

REVERSED ANTIEMETIC ACTIVITY OF NABILONE, A CANNABINOL DERIVATIVE, REVERSED BY NALOXONE IN AWAKE CATS.

001416 02-04

CLINICAL STUDIES WITH MAPROTILINE AND THE REVERSED CATECHOLAMINE HYPOTHESIS OF DEPRESSION. 001642 02-13

EPILEPTIC PROPERTIES OF LEUCINE-ENKEPHALIN AND METHIONINE-ENKEPHALIN: COMPARISON WITH MORPHINE AND REVERSIBILITY BY NALOXONE. 002916 04-03

ANXIETY REVISITED.

STIMULANT DRUGS.

THE REVOLUTION DEFINED: IT IS PHARMACOLOGIC.

REWARD ENHANCEMENT BY PSYCHOMOTOR STIMULANT DRUGS

POTENTIATION OF BRAIN REWARD MECHANISMS BY PSYCHOMOTOR

REVOLUTION

REVERSIBLE AND IRREVERSIBLE EFFECTS OF P-CHLOROAMPHETAMINE ON BRAIN SEROTONIN IN MICE. 000276 01-03 REVERSIBLY
ALPHA-BUNGAROTOXIN BLOCKS REVERSIBLY CHOLINERGIC INHIBITION IN
THE COCHLEA. 002908 04-03 DOXEPIN OVERDOSE: SUCCESS WITH PHYSOSTIGMINE AND FAILURE WITH NEOSTIGMINE IN REVERSING TOXICITY. 000772 01-14 I TRYPTOPHANE AS AN HYPNOTIC AGENT. A REVIEW THE USE OF PSYCHEDELIC DRUGS IN THE TREATMENT OF SEVERELY DISTURBED CHILDREN: A REVIEW 000678 01-12 BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC CORRELATES OF THE CHRONIC USE OF MARIJUANA -- A REVIEW. 000766 01-14 A REVIEW OF STIMULANT DRUG RESEARCH WITH HYPERACTIVE 000937 01-17 GASOLINE SNIFFING: A REVIEW. 000975 01-17 BEHAVIORAL EFFECTS OF BENZODIAZEPINES: A REVIEW. TARDIVE-DYSKINESIA: IS IT OR IS IT NOT? A REVIEW OF THE PROBLEMS IN DIAGNOSIS AND A CASE STUDY. 001747 02-15 A SEVEN YEAR REVIEW OF COMA PATIENTS ADMITTED TO THE REGIONAL POISONING TREATMENT CENTRE, ROYAL INFIRMARY, 001821 02-15 NEUROPHYSIOLOGY, NEUROPHARMACOLOGY AND BEHAVIORAL RELATIONSHIPS OF VISUAL SYSTEM EVOKED AFTER-DISCHARGES: A 001885 02-17 DEANOL IN THE MANAGEMENT OF INVOLUNTARY MOVEMENT DISORDERS: A REVIEW. 001886 02-17 PEDIATRIC PSYCHOPHARMACOLOGY: A REVIEW WITH SPECIAL REFERENCE TO DEANOL. 001918 02-17 PHARMACOLOGICAL, BIOCHEMICAL AND CLINICAL EFFECTS OF 2 DIMETHYLAMINOETHANOL (DEANOL): A CRITICAL REVIEW. 001928 02-17 PROLIXIN-DECANOATE: A REVIEW OF THE RESEARCH. 001941 02-17 TRANSMETHYLATION HYPOTHESIS: A REVIEW OF PROGRESS 002397 03-08 COMBINED TRICYCLIC MAOI THERAPY FOR REFRACTORY DEPRESSION: A REVIEW, WITH GUIDELINES FOR APPROPRIATE USAGE. 002437 03-09 PAVOR NOCTURNUS IN A SCHIZOPHRENIC PATIENT: A REVIEW AND CASE L TRYPTOPHAN AND 5 HYDROXYTRYPTOPHAN IN THE TREATMENT OF DEPRESSION: A REVIEW. 002552 03-13 A REVIEW OF THE RELATIONSHIP BETWEEN ENDOCRINOPATHY AND DEPRESSION OR ANTIDEPRESSANT DRUGS, WITH PARTICULAR RESPECT TO NOVEL THEORIES INVOLVING THE OPIATE RECEPTOR. 002557 03-13 BRAIN MECHANISMS OF AMPHETAMINE-INDUCED ANOREXIA, LOCOMOTION, AND STEREOTYPY: A REVIEW. 003189 04-04 DRUG-INDUCED DYSKINESIA: A CRITICAL REVIEW 003586 04-13
NONMONOAMINE-OXIDASE INHIBITOR ANTIDEPRESSANTS AND EPILEPSY: DRUGS AND REINFORCEMENT MECHANISMS: A CRITICAL REVIEW OF THE CATECHOLAMINE THEORY. 003625 04-14 THE BEHAVIOURAL ACTIONS OF THE HYPOTHALAMIC PEPTIDES: A 003651 04-15

Psychopharmacology Abstracts

SEROTONERGIC BASIS OF REWARD IN MEDIAN RAPHE OF THE RAT. 001421 02-04
REWARD VERSUS PERFORMANCE IN SELF-STIMULATION: ELECTRODE SPECIFIC EFFECTS OF ALPHA-METHYL-P-TYROSINE ON REWARD IN THE RAT.

002225 03-04
NEUROLEPTIC-INDUCED ATTENUATION OF BRAIN STIMULATION REWARD
IN RATS.

003221 04-04
INHIBITION OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND
BRAIN STIMULATED REWARD.

BENZODIAZEPINES AND BEHAVIORAL EFFECTS OF REWARD (WATER)
OMISSION IN THE RAT.

CENTRAL MECHANISMS OF REWARD AND THE NARCOTIC CUE.
003369 04-04

REWARDING
OPIOIDS AND REWARDING BRAIN STIMULATION.

003216 04-04

CATECHOLAMINE AND OCTOPAMINE CONCENTRATIONS IN BRAINS OF PATIENTS WITH REYE SYNDROME. 000712 01-13

RHEOENCEPHALOGRAPHIC
RHEOENCEPHALOGRAPHIC DATA IN MIGRAINE CEPHALGIA AND THEIR
CHANGES DURING STUGERON TREATMENT.
000515 01-07

RHEOENCEPHALOGRAPHIC AND OTHER STUDIES OF BETAHISTINE IN HUMANS. IV. PROLONGED ADMINISTRATION WITH IMPROVEMENT IN ARTERIOSCLEROTIC DEMENTIA.

RHESUS
REINFORCING PROPERTIES OF PERPHENAZINE, HALOPERIDOL AND
AMITRIPTYLINE IN RHESUS MONKEYS.

000148 01-03

LONG-TERM BEHAVIORAL CHANGES IN THE RHESUS MONKEY AFTER
MULTIPLE DAILY INJECTIONS OF D METHYLAMPHETAMINE.

000359 01-04
REINFORCING PROPERTIES OF INTRAVENOUS PROCAINE IN RHESUS

THE EFFECTS OF PHARMACOLOGICAL AND ENVIRONMENTAL VARIABLES ON DRUG CHOICE IN RHESUS MONKEYS.

000386 01-04
KETAMINE SELF-ADMINISTRATION BY THE RHESUS MONKEY.

THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDROCANNABINOL (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HORMONE (SH) AND LUTEINIZING HORMONE (LH) IN THE OVARIECTOMIZED RHESUS

CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT RHESUS MONKEYS.

EFFECTS OF DIAZEPAM AND D AMPHETAMINE ON FOOD COMPETITION IN RHESUS MONKEY.

COMPARISON OF THE CONVULSANT EFFECTS OF COCAINE AND PSEUDOCOCAINE IN THE RHESUS MONKEY.

SECOND-ORDER SCHEDULES OF INTRAVENOUS DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS.

MORPHINE REDUCES CEREBELLAR CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT AND ELEVATES CEREBROSPINAL FLUID CYCLIC-GUANOSINE-MONOPHOSPHATE CONTENT IN RHESUS MONKEY.

ALTERATIONS OF EEG ACTIVITIES AND COCAINE-INDUCED CONVULSIONS FOLLOWING PROLONGED COCAINE TREATMENT IN THE RHESUS MONKEY.

STUDIES OF THE REINFORCING PROPERTIES OF INTRAVENOUSLY SELF-ADMINISTERED COMPOUNDS IN RHESUS MONKEYS. (PH.D.

002188 03-04

EFFECTS OF CLOMIPRAMINE AND OTHER INHIBITORS OF MONOAMINE

UPTAKE ON THE SEXUAL BEHAVIOUR OF FEMALE RATS AND RHESUS

MONKEYS.

O02228 03-04
THE REINFORCING PROPERTIES OF PROCAINE AND D AMPHETAMINE COMPARED IN RHESUS MONKEYS.

CONTINUOUS INTRAVENOUS NALTREXONE EFFECTS ON MORPHINE SELF-ADMINISTRATION IN RHESUS MONKEYS.

EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D AMPHETAMINE
AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY
AND SHOCK AVOIDANCE IN RHESUS MONKEYS.

002251 03-04

002593 03-13

000949 01-17

000440 01-04

000441 01-04

THE EFFECTS OF PHENCYCLIDINE ON VISUALLY EVOKED-POTENTIALS OF RHESUS MONKEYS. 002306 03-04 EFFECTS OF IMIPRAMINE TREATMENT OF SEPARATION-INDUCED SOCIAL DISORDERS IN RHESUS MONKEYS. A DOSE RATIO COMPARISON OF THE INTERACTION BETWEEN MORPHINE AND CYCLAZOCINE WITH NALOXONE IN RHESUS MONKEYS ON THE SHOCK TITRATION TASK 002335 03-04 EFFECTS OF AMPHETAMINE ON SOCIAL BEHAVIORS OF RHESUS MACAQUES: AN ANIMAL MODEL OF PARANDIA. ENTRY OF BETA-N-OXALYL-L-ALPHA-BETA-DIAMINOPROPIONIC-ACID, THE ITRY OF BETA-N-OXALYL-L-ALPMA-BETA-UTAMINOT FOR THE CASE, THE LATHYRUS-SATIVUS NEUROTOXIN INTO THE CENTRAL-NERVOUS-SYSTEM OF THE ADULT RAT, CHICK AND THE RHESUS MONKEY. 003061 04-03 CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT RHESUS MONKEYS 003152 04-04 CHOICE BEHAVIOR IN RHESUS MONKEYS: COCAINE VERSUS FOOD. 003155 04-04 THE DISCRIMINATIVE STIMULUS PROPERTIES OF INTRAVENOUSLY ADMINISTERED COCAINE IN RHESUS MONKEYS COMPARATIVE EFFECTS OF COCAINE AND PSEUDOCOCAINE ON EEG ACTIVITIES, CARDIORESPIRATORY FUNCTIONS, AND SELF-ADMINISTRATION BEHAVIOR IN THE RHESUS MONKEY.

003292 04-04 A CONTROLLED STUDY OF TRANCOPAL IN SLEEP DISTURBANCES DUE TO RHEUMATIC DISEASE 003621 04-14 HYPERALGESIA INDUCED BY NALOXONE FOLLOWS DIURNAL RHYTHM IN RESPONSIVITY TO PAINFUL STIMULI.

CIRCADIAN SUSCEPTIBILITY RHYTHM TO NEUROLEPTICS: TETRABENAZINE.

CIRCADIAN RHYTHM OF LITHIUM TOXICITY IN MICE. 002344 03-05 THE INFLUENCE OF CAFFEINE ON THE PREVALENCE OF ALPHA RHYTHM 002550 03-13 LITHIUM EFFECT ON TEMPERATURE RHYTHM IN PSYCHIATRIC PATIENTS 002581 03-13 CIRCADIAN SUSCEPTIBILITY RHYTHM TO APOMORPHINE IN THE BRAIN.

001124 02-03

002108 03-03

003047 04-03

000799 01-15

003311 04-04 CIRCADIAN RHYTHM DISORDERS IN MANIC-DEPRESSIVES. 003505 04-09

SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL

001974 03-03 THE EFFECTS OF PICROTOXIN AND PENTYLENETETRAZOL IN THE DIURNAL RHYTHMS OF CATECHOLAMINES AND SEROTONIN IN THE RAT BRAIN 002123 03-03

BEHAVIORAL RHYTHMS IN SCHIZOPHRENIA. DOLLAR DALOR

RIBOSOMES MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES: MESCALINE-DEMETHYLASE ACTIVITY OF BRAIN-CORTEX SOLUBLE

000090 01-03 DELTA9-TETRAHYDROCANNABINOL-INDUCED CHANGES IN BRAIN RIBOSOMES.

INHIBITION BY BARBITURIC-ACID AND ITS DERIVATIVES OF THE ENZYMES IN RAT BRAIN WHICH PARTICIPATE IN THE SYNTHESIS OF PYRIMIDINE RIBOTIDES.

003049 04-03 RIFAMPICIN RIFAMPICIN AND METHADONE WITHDRAWAL

DIGMT MARIJUANA: DIFFERENTIAL EFFECTS ON RIGHT AND LEFT HEMISPHERE FUNCTIONS IN MAN 001733 02-14

RIGHTS SUBJECTS RIGHTS, FREEDOM OF INQUIRY, AND THE FUTURE OF RESEARCH IN THE ADDICTIONS. 000966 01-17

RIGID DOPAMINE RECEPTORS IN RAT STRIATUM AND NUCLEUS-ACCUMBENS, CONFORMATIONAL STUDIES USING RIGID ANALOGUES OF DOPAMINE 000301 01-03

(-)-(E) 3,4 DIHYDROXYPHENYL-CYCLOPROPYLAMINE-HYDROCHLORIDE (ASL-7003): A RIGID ANALOGUE OF DOPAMINE. 002793 04-02 RIGIDITY

EFFECT OF LOCAL APPLICATION OF APOMORPHINE TO THE CORPUSSTRIATUM AND TO THE NUCLEUS-ACCUMBENS ON THE RESERPINE-

INDUCED RIGIDITY IN RATS

A METHOD FOR MECHANOGRAPHICAL RECORDING OF MUSCLE TONE IN THE RAT: THE EFFECT OF SOME ANTIPARKINSONIAN DRUGS ON RIGIDITY INDUCED BY RESERPINE.

002346 03-05 RING-SUBSTITUTED TRIPHASIC DOSE LETHALITY RELATIONSHIPS FOR AMPHETAMINE AND CERTAIN RING-SUBSTITUTED AMPHETAMINES IN ISOLATED OR AGGREGATED MICE.

001093 02-03 BISK TIMING AND RISK OF BONE MARROW DEPRESSION BY PSYCHOTROPIC

DRIVES 001770 02-15 CONSUMPTION OF MEDICATION AND RISK OF DEVIANCE AMONG ADOLESCENTS.

001888 02-17 ORGANIC IMPAIRMENT IN POLYDRUG USERS. RISK FACTOR 002670 03-15

THE RISKS OF SEX HORMONES AS DRUGS. 000850 01-15

THE RELATIVE EFFICACY OF METHYLPHENIDATE (RITALIN) AND BEHAVIOR MODIFICATION TECHNIQUES IN THE TREATMENT OF A HYPERACTIVE 000671 01-11

RECALL, RETENTION, AND RITALIN. 001728 02-14 METHYLPHENIDATE (RITALIN) ABUSE

001738 02-15 BEHAVIOR OBSERVATIONS OF HYPERACTIVE CHILDREN AND METHYLPHENIDATE (RITALIN) EFFECTS IN SYSTEMATICALLY

STRUCTURED CLASSROOM ENVIRONMENTS: NOW YOU SEE THEM. NOW YOU DONT. 003581 04-11

THE FUNCTION OF DRUG RITUALS IN HUMAN SOCIETY: CONTINUITIES AND CHANGES

000674 01-12 RMI-12330-A NONSPECIFIC INHIBITION OF SOME RAT LIVER MEMBRANE-BOUND ONSPECIFIC INHIBITION OF SOME RAT LIVER MEMBARIE-ENZYMES BY AN ADENYLATE-CYCLASE INHIBITOR, RMI-12330-A. 002936 04-03

ILLNESS-INDUCED AVERSION LEARNING IN A DESERT SPECIES OF RODENT

(ACOMYS-CAHIRINUS) THE EFFECTS OF INORGANIC LEAD ON THE CENTRAL CATECHOLAMINERGIC SYSTEM OF THE RODENT WITH EMPHASIS ON POSTNATALLY EXPOSED RATS AND MICE. (PH.D. DISSERTATION).

003078 04-03

RODENTS SUBSTITUTED BENZAMIDES AS CEREBRAL DOPAMINE ANTAGONISTS IN PODENTS

000355 01-04 THE INTERACTION OF CLONIDINE WITH DOPAMINE DEPENDENT BEHAVIOUR IN RODENTS.

000435 01-04 THE EFFECT OF BROMOCRIPTINE ON LOCOMOTOR ACTIVITY AND CEREBRAL CATECHOLAMINES IN RODENTS.

AMANTADINE-HYDROCHLORIDE (AMN): ANTAGONISM TO ETHANOL (ETOH) MEDIATED RESPONSES IN RODENTS.

FLUNITRAZEPAM (ROHYPNOL) COMPARED WITH NITRAZEPAM (MOGADON) AND APROBARBITAL AS EVENING PREMEDICATION PRIOR TO ANESTHESIA: A CONTROLLED CLINICAL TRIAL.

002616 03-14 ROLE ROLE OF PHOSPHOLIPIDS IN MUSCARINIC BINDING BY NEURAL

MEMBRANES THE ACCUMULATION OF P-HYDROXYAMPHETAMINE BY BRAIN HOMOGENATES AND ITS ROLE IN THE RELEASE OF CATECHOLAMINES

ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEDIAN FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR.

THE ROLE OF THE SEPTAL NUCLEI IN THE RELEASE OF ACETYLCHOLINE FROM THE RABBIT CEREBRAL-CORTEX AND DORSAL HIPPOCAMPUS AND THE EFFECT OF ATROPINE.

000101 01-03

REGULATORY ROLE OF GABA NEURONS ON THE ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE BY HALOPERIDOL. (UNPUBLISHED

000132 01-03

ROLE OF LIVER CYTOSOLIC ALDEHYDE-DEHYDROGENASE ISOZYMES IN CONTROL OF BLOOD ACETALDEHYDE CONCENTRATIONS. 000222 01-03

ON THE ROLE OF ASCENDING CATECHOLAMINERGIC PROJECTIONS IN INTRACRANIAL SELF-STIMULATION OF THE SUBSTANTIA-NIGRA.

000336 01-04 ROLE OF TRYPTAMINE IN THE BEHAVIOURAL CHANGES CAUSED BY A MONOAMINE-OXIDASE INHIBITOR AND L TRYPTOPHAN.

000343 01-04 THE ROLE OF ASCENDING AND DESCENDING 5 HYDROXYTRYPTAMINE NEURONES IN CENTRAL CONTROL OF PAIN SENSITIVITY.

000380 01-04 ROLE OF THE DORSAL NORADRENERGIC BUNDLE IN BEHAVIOUR

000407 01-04 DOES PROLACTIN PLAY A ROLE IN ESTROGEN-INDUCED MATERNAL BEHAVIOR IN RATS: APOMORPHINE REDUCTION OF PROLACTIN

000445 01-04 ROLE OF GLUCOCORTICOIDS IN AN ABNORMAL GROOMING BEHAVIOR IN CATS WITH PONTILE OR FRONTAL NEOCORTICAL LESIONS.

000463 01-04 MEMORY AND COGNITIVE FUNCTION IN MAN: DOES THE CHOLINERGIC SYSTEM HAVE A SPECIFIC ROLE?.

000761 01-14 THE ROLE OF BENZODIAZEPINES IN NONPSYCHIATRIC MEDICAL PRACTICE. 000960 01-17

ACTIVATION OF TRYPTOPHAN-HYDROXYLASE BY DEPOLARIZATION: ROLE OF CALCIUM. 001060 02-03

A ROLE FOR CENTRAL SEROTONERGIC SYSTEMS IN THE PATTERN AND INTENSITY OF THE CONVULSIVE RESPONSE OF RATS TO 001067 02-03

ROLE OF NOREPINEPHRINE IN THE RELEASE OF PROLACTIN INDUCED BY SUCKLING AND ESTROGEN. 001071 02-03

CYANOCYPROHEPTADINE: ROLE OF CHOLINOLYTIC PROPERTIES IN MODULATING NEUROLEPTIC-INDUCED ELEVATION OF STRIATAL HOMOVANILLIC-ACID (HVA).

ROLE OF CALCIUM IN THE AMPHETAMINE-INDUCED STIMULATION OF CATECHOL FORMATION IN THE STRIATUM.

THE ROLE OF HYPOTHALAMIC SEROTONIN (5-HT) BEFORE OVULATION IN IMMATURE RATS TREATED WITH PREGNANT MARE SERUM (PMS).

001287 02-03 AMPHETAMINE AND CHICK BEHAVIOUR: A ROLE FOR MONOAMINES IN THE CAUSATION OF VOCALIZATIONS AND EMOTIONS.

ROLE OF THE BRAIN MONOAMINE SYSTEM IN LEARNING ON VARIOUS EMOTIONAL REINFORCEMENTS.

A POSSIBLE ROLE OF THE PAG IN THE MEDIATION OF SUBJECTIVE EFFECTS

FACILITATION OF SIDMAN AVOIDANCE PERFORMANCE BY P. CHLOROAMPHETAMINE: ROLE OF BIOGENIC AMINES. 001467 02-04

ROLE OF BRAIN NOREPINEPHRINE IN NEUROLEPTIC-INDUCED CATALEPSY IN RATS. 001509 02-05

THE ROLE OF CHARCOAL HEMOPERFUSION IN THE ACTIVE MANAGEMENT OF POISONING.

001842 02-15 INHIBITION OF PENTYLENETETRAZOL-INDUCED CONVULSIONS IN RATS BY PROSTAGLANDIN-E1: ROLE OF BRAIN MONOAMINES.

001968 03-03 STUDIES ON THE ROLE OF FOREBRAIN CATECHOLAMINE NEURONS IN EXPLORATORY BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).

002012 03-03 THE ROLE OF THE CORPUS-STRIATUM IN NEUROLEPTIC-INDUCED AND NARCOTIC-INDUCED CATALEPSY.

002062 03-03 THE EFFECT OF L-DOPA ON PERIPHERAL SYMPATHETIC NERVE FUNCTION: ROLE OF PRESYNAPTIC DOPAMINE RECEPTORS.

002081 03-03 POMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE RELEASE: ROLE OF DOPAMINERGIC RECEPTORS IN SUBSTANTIA-NIGRA.

002084 03-03 PHARMACOLOGICAL MANIPULATIONS OF THE SEPTAL IRRITABILITY SYNDROME: ROLE OF DOPAMINERGIC MECHANISMS IN RECOVERY OF FUNCTION. (PH.D. DISSERTATION). 002089 03-03

THE ROLE OF DIAZEPAM AS COMPARED TO GAMMA-AMINOBUTYRIC-ACID (GABA) IN THE CUNEATE NUCLEUS AND CEREBELLAR-CORTEX OF THE CAT. (PH.D. DISSERTATION).

002131 03-03 STIMULUS PROPERTIES OF PHENETHYLAMINE HALLUCINOGENS AND LYSERGIC-ACID-DIETHYLAMIDE: THE ROLE OF 5 HYDROXYTRYPTAMINE.

002180 03-03 ALTERATIONS IN MORPHINE ANALGESIA PRODUCED BY CHRONIC DEFICITS OF BRAIN CATECHOLAMINES OR SEROTONIN: ROLE OF ANALGESIMETRIC PROCEDURE.

002186 03-03 METRAZOL-INDUCED PETIT-MAL: THE ROLE PLAYED BY MONOAMINERGIC MECHANISMS AND STRIATUM.

002192 03-04 THE ROLE OF SEROTONIN ANTAGONISM IN THE TREMORGENIC ACTION OF BUFOTENINE IN MICE.

ANALYSIS OF THE ROLE PLAYED BY THE SUBSTANTIA-NIGRA IN THE MEDIATION OF INGESTIVE, LOCOMOTOR, AND ROTATIONAL BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL AND PLAYER AND PLAYER OF THE PLAYER OF THE SUBSTANTIAL AND PLAYER OF THE SUBSTANTIA MANIPULATIONS (PH D DISSERTATION)

002247 03-04 DOES DOPAMINE HAVE A ROLE IN SCHIZOPHRENIA?

002389 03-08 THE HUMAN PLATELET AS A MODEL FOR THE DOPAMINERGIC NEURON:
KINETIC AND PHARMACOLOGIC PROPERTIES AND THE ROLE OF AMINE
STORAGE GRANULES.

002596 03-13 IMPOTENCE: ROLE OF DRUG AND HORMONAL TREATMENT.

002759 03-17 THE ROLE OF SUBSTRATE LIPOPHILICITY IN DETERMINING TYPE 1 MICROSOMAL P450 BINDING CHARACTERISTICS.

ROLE OF SEROTONIN REUPTAKE INHIBITION IN THE DEVELOPMENT OF SUBSENSITIVITY OF THE NOREPINEPHRINE (NE) RECEPTOR COUPLED ADENYLATE-CYCLASE SYSTEM.

003017 04-03 EVIDENCE FOR THE ROLE OF ADRENOCORTICAL HORMONES IN THE REGULATION OF NORADRENALINE AND DOPAMINE METABOLISM IN CERTAIN BRAIN AREAS.

003062 04-03 THE ROLE OF CALCIUM IN THE REGULATION OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN SLICES OF RAT AND GUINEA-PIG.

003079 04-03 THE ROLE OF PAVLOVIAN CONDITIONING IN MORPHINE-TOLERANCE 003090 04-03

POSSIBLE ROLE OF BRAIN SEROTONIN IN THE CENTRAL EFFECTS OF KETAMINE.

003123 04-03 THE ROLE OF THE CHOLINERGIC SYSTEM IN THE DEVELOPMENT OF INCREASED NALOXONE POTENCY IN MICE.

003140 04-03 ROLE OF HYPOTHALAMIC SEROTONERGIC RECEPTORS IN THE CONTROL OF LORDOSIS BEHAVIOR IN THE FEMALE RAT.

003220 04-04 CHLORIMIPRAMINE INHIBITION OF MURICIDE: THE ROLE OF THE ASCENDING 5-HT PROJECTION.

003284 04-04 EVIDENCE FOR A ROLE FOR DOPAMINE IN SELF-STIMULATION OF THE NUCLEUS-ACCUMBENS OF THE RAT.

A ROLE OF THE POLYSYNAPTIC SYSTEM OF SUBSTANTIA-NIGRA IN THE CHOLINERGIC DOPAMINERGIC EQUILIBRIUM IN THE CENTRAL-NERVOUS-SYSTEM. 003341 04-04

003397 04-04 CONTEMPORARY VIEWS ON THE ROLE OF NEUROLEPTICS IN THE TREATMENT OF SCHIZOPHRENIA AND THEIR ACTION IN THE CENTRAL-NERVOUS-SYSTEM.

003464 04-08 ROLE OF NARCOSUGGESTIONS IN HYSTERIA.

003540 04-10 ON THE ROLE OF HEMISPHERIC DOMINANCE IN SCHIZOPHRENIA AS MEASURED BY EXTRAPYRAMIDAL SIDE-EFFECTS OF NEUROLEPTICS 003675 04-15

ROLES OF MONOAMINES, PARTICULARLY DOPAMINE, IN CLINICAL DEPRESSION AND IN THE REGULATION OF MOOD.

000583 01-09 STUDIES OF THE PHYSIOLOGICAL ROLES OF PROSTAGLANDINS IN THE CENTRAL-NERVOUS-SYSTEM

POTENTIAL ROLES OF ENDOGENOUS PEPTIDES IN THE DISCRIMINATIVE

003187 04-04 ROLES OF THE VOMERONASAL AND OLFACTORY SYSTEMS IN COURTSHIP BEHAVIOR OF MALE GARTER SNAKES.

RESPONSE IN RATS.

-	 -

EFFECTS OF ANTINOCICEPTIVE DRUGS ON THE DORSAL ROOT POTENTIAL IN THE RAT.

001285 02-03
EFFECT OF PANAX GINSENG ROOT ON CONDITIONED AVOIDANCE

OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT
GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG

002040 03-03

002235 03-04

002373 03-06

ROQUET

AN INTRODUCTION TO THE PSYCHEDELIC PSYCHOTHERAPY OF SALVADOR ROQUET.

ROTAROD
THE EFFECTS OF AMPHETAMINE ISOMERS ON ROTAROD PERFORMANCE.

ROTARY

PRESYNAPTIC AND POSTSYNAPTIC ACTIONS OF APOMORPHINE:

DIFFERENTIATION BY ROTARY EFFECTS IN NORMAL RATS.

000367 01-04

NORMAL AND AMPHETAMINE-INDUCED ROTATION OF RATS ON A FLAT SURFACE. 001365 02-04

MESOLIMBIC DOPAMINE NEURONS: EFFECTS OF 6 HYDROXYDOPAMINE-INDUCED DESTRUCTION AND RECEPTOR BLOCKADE ON DRUG-INDUCED ROTATION OF RATS. 002258 03-04

ROTOMETER FOR RECORDING ROTATION IN CHEMICALLY OR FLECTRICALLY STIMULATED RATS.

ROTATIONAL

ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEDDMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL REFLAVIOUR

GABA-LIKE PROPERTIES OF FLURAZEPAM AND BACLOFEN SUGGESTED BY ROTATIONAL BEHAVIOUR FOLLOWING UNILATERAL INTRANIGRAL INJECTION: A COMPARISON WITH THE GABA-AGONIST MUSCIMOL.

O00290 01-03
COMPARISON OF THE REGULATION OF ROTATIONAL BEHAVIOR BY
HYPOTHALAMIC OLIGOPEPTIDES.

000337 01-04
COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON ROTATIONAL

COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON ROTATIONAL BEHAVIOR IN RATS WITH UNILATERAL 6 HYDROXYDOPAMINE LESIONS.

TWO DOPAMINE RECEPTORS: SUPPORTIVE EVIDENCE WITH THE RAT ROTATIONAL MODEL.

O01478 02-04

ANALYSIS OF THE ROLE PLAYED BY THE SUBSTANTIA-NIGRA IN THE
MEDIATION OF INGESTIVE, LOCOMOTOR, AND ROTATIONAL
BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL
MANIBULATIONS (BULD, DISSEPTATION).

BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL MANIPULATIONS. (PH.D. DISSERTATION). 002247 03-04 ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY

BENZODIAZEPINES.

002326 03-04
METHODOLOGICAL PROBLEMS IN THE MEASUREMENT OF DRUG-INDUCED
ROTATIONAL BEHAVIOUR: CONTINUOUS RECORDING REVEALS TIME-

ROTATIONAL BEHAVIOUR: CONTINUOUS RECORDING REVEALS TIME-COURSE DIFFERENCES UNDETECTED BY PREVIOUS TECHNIQUES. 003388 04-04

ROTOMETER FOR RECORDING ROTATION IN CHEMICALLY OR ELECTRICALLY STIMULATED RATS.

002373 03-06

EFFECTS OF PCPA AND SELECTIVE REM SLEEP-DEPRIVATION ON ROTOROD PERFORMANCE AND OPEN-FIELD BEHAVIOR IN THE RAT.

002219 03-04

EFFECT OF AGE AND ROUTE OF ADMINISTRATION ON LD50 OF LITHIUM-CHLORIDE IN THE RAT. 001517 02-05

THE PRODUCTION OF MORPHINE-TOLERANCE AND PHYSICAL DEPENDENCE BY THE ORAL ROUTE IN THE RAT.

ROUTINE
ROUTINE NORTRIPTYLINE LEVELS IN TREATMENT OF DEPRESSION.
000715 01-13

ROUTINE MEASUREMENT OF HOMOVANILLIC-ACID IN RAT BRAIN BY GAS-LIQUID-CHROMATOGRAPHY.

003441 04-06

THE PRACTICAL SIGNIFICANCE OF NORTRIPTYLINE PLASMA CONTROL. A PROSPECTIVE EVALUATION UNDER ROUTINE CONDITIONS IN ENDOGENOUS DEPESSION.

003522 04-09

RECEPTOR SENSITIVITY MODIFICATION (RSM) — A NEW PARADIGM FOR THE POTENTIAL TREATMENT OF SOME HORMONAL AND TRANSMITTER DISTURBANCES.

RU-23686

PHARMACOLOGICAL INTERACTIONS WITH CIRCLING BEHAVIOUR INDUCED
BY THE PIPERIDINYL INDOLE DERIVATIVE RU-23686.

RUBIDIUM

EFFECT OF RUBIDIUM, LITHIUM AND CESIUM ON BRAIN ATPASE AND

PROTEIN KINASES.

O01172 02-03

EFFECTS OF CHRONIC LITHIUM AND RUBIDIUM ADMINISTRATION UPON

EXPERIMENTALLY-INDUCED CONFLICT BEHAVIOR.

001391 02-04

THE EFFECT OF RUBIDIUM IN SCHIZOPHRENIA. 001542 02-07

ALCOHOL CONSUMPTION IN RATS TREATED WITH LITHIUM-CARBONATE
OR RUBIDIUM-CHLORIDE.

003159 04-04

RURAL URBAN DIFFERENCES IN THE USE OF STRESS ALLEVIATIVE DRUGS.

H3-GABA RELEASE IN SYNAPTOSOMAL FRACTIONS AFTER INTRACRANIAL ADMINISTRATION OF RUTHENIUM-RED.

S-1432
ACTION OF S-1432, A NEW PSYCHOTROPIC DRUG, ON THE CENTRAL CHOLINERGIC SYSTEM.

000080 01-0

BIOCHEMICAL AND PHARMACOLOGICAL STUDIES ON AMINEPTINE (S1694) AND () AMPHETAMINE IN THE RAT.

SLEEP CHANGES INDUCED BY CHRONIC ADMINISTRATION OF S-1694 (SURVECTOR).

SACCADIC

ACTIVITY OF VESTIBULO-OCULOMOTOR NEURONES DURING SACCADIC

EYE MOVEMENTS INDUCED BY RESERVINE.

SACCHARIN
SCHEDULE-INDUCED WATER AND SACCHARIN POLYDIPSIA UNDER

NACL AND LICL EFFICACY IN THE INDUCTION OF AVERSION FOR QUININE
AND SACCHARIN SOLUTIONS IMMEDIATELY FOLLOWING INJECTION.

DIMINISHED TASTE REACTIVITY TO SACCHARIN FOLLOWING CHRONIC
ADMINISTRATION OF THEOPHYLLINE IN RATS.

003259 04-04

SACRED
ETHNOPHARMACOLOGY OF SACRED PSYCHOACTIVE PLANTS USED BY
THE INDIANS OF MEXICO.

SPECS FOR A SAFE HIGH.

002754 03-17

001894 02-17

LONG-TERM EFFICACY AND SAFETY OF TRIAZOLAM AND FLURAZEPAM.

000643 01-11
AN EVALUATION OF THE CARDIOPULMONARY SAFETY AND EFFICACY OF
TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS ORAL HYPNOTIC
ACENTS

TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS ORAL HYPNOTIC AGENTS.

000854 01-15
ON THE SAFETY OF LONG-TERM TREATMENT WITH LITHIUM

SAFETY OF OXAZEPAM. 002702 03-15

SALBUTAMOL
ANTIDEPRESSANT EFFECT OF SALBUTAMOL.

600516 01-07

BALICYLAMIDE
HYPNOTIC EFFECTIVENESS OF SODIUM SALICYLAMIDE WITH SHORT-TERM
USE: SLEEP LABORATORY STUDIES.

003637 04-14

SALICYLATE
THE EFFECT OF SALICYLATE ON CEREBRAL BLOOD FLOW IN MAN.
001681 02-13

BALINE
DIFFERENTIAL HALOPERIDOL EFFECT ON TWO INDICES OF FENTANYL
SALINE DISCRIMINATION.

000495 01-06

SALIVA
ON THE DISTRIBUTION OF DRUGS IN SALIVA AND BLOOD PLASMA.
000697 01-13 SALIVA LITHIUM LEVELS: CLINICAL APPLICATIONS.

PHARMACOKINETICS OF NITRAZEPAM IN HUMAN PLASMA AND SALIVA.

COMPARATIVE AVAILABILITY OF DIAZEPAM (D) IN HUMAN PLASMA
(P), PAROTID SALIVA (PS) AND MIXED SALIVA (MS) AND ITS
RELATIONSHIP TO PLASMA PROTEIN BINDING.

SALSOLINOL
ABSENCE OF FORMATION OF BRAIN SALSOLINOL IN ETHANOL DEPENDENT

EFFECTS OF SALSOLINOL, A TETRAHYDROISOQUINOLINE ALKALOID, ON MULTIPLE SCHEDULE PERFORMANCE IN RATS.

000200 01-03

000593 01-09

VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF 2
AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF NAD:NADH AND
NORELEAGNINE A BETA-CARBOLINE DERIVATIVE.

A RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF BIOLOGICAL FLUID OR TISSUE.

DIAZEPAM: EFFICACY AND TOXICITY AS REVEALED BY A SMALL SAMPLE RESEARCH STRATEGY. 000933 01-16

SIMULTANEOUS DETERMINATION OF CODEINE AND MORPHINE IN BIOLOGICAL SAMPLES BY GAS-CHROMATOGRAPHY WITH ELECTRON CAPTURE DETECTION.

001527 02-06 SAMPLING

AMITRIPTYLINE DOSAGE SCHEDULE, SAMPLING TIME AND TRICYCLIC
PLASMA LEVELS.

EFFECT OF PSYCHOTROPIC DRUGS ON ATPASE TRANSPORT OF THE SARCOPLASMIC RETICULUM IN RABBIT SKELETAL MUSCLES. 001174 02-03

A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE (SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS (SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE AND NORTRIPTYLINE

003508 04-09 SAROTEN-RETARD

A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE
(SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS
(SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH
SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE

003508 04-09 TORIUS
ACTIONS OF ATROPINE AND SCOPOLAMINE ON THE ENDPLATE CURRENT
OF THE FROG SARTORIUS MUSCLE. (PH.D. DISSERTATION).
001042 02-03

THE USE OF PRESCRIPTION DRUGS IN TREATMENT OF FIRST-TIME
PSYCHIATRIC ADMISSIONS TO UNIVERSITY HOSPITAL, SASKATOON 003712 04-17

SATURABLE EFFECTS OF NA, K, MG AND CA ON THE SATURABLE BINDING OF (3H)DIHYDROMORPHINE AND (3H)NALOXONE IN VITRO. 000180 01-03

A DEBATE ON MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY REFLECTIONS ON THE SO-CALLED LONG-TERM SATURATION ADMINISTRATIONS.

001872 02-16

LITHIUM INTOXICATION INDUCED BY DIETING AND SAUNAS 001839 02-15

FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN TREATMENT OF REMITTED SCHIZOPHRENICS: II. RATING SCALE DATA. 000544 01-08 QUANTIFICATION AND STATISTICAL ANALYSIS OF ORDINAL SCALE DATA IN PSYCHIATRY.

CENTRAL AND PERIPHERAL ACTION OF TESTOSTERONE-PROPIONATE ON SCENT GLAND (NORPHOLOGY AND MARKING BEHAVIOUR IN THE MONGOLIAN GERBIL. 003370 04-04 **Psychopharmacology Abstracts**

SCH-12041
EFFICACY OF HALAZEPAM (SCH-12041) AS AN ANXIOLYTIC 003549 04-10

SCH-12679

EFFICACY OF SCH-12679 IN THE MANAGEMENT OF AGGRESSIVE MENTAL
RETARDATES.

000506 01-07

000506 01-07 EFFECTS OF BENZAZEPINE (SCH-12679) ON SHOCK-INDUCED FIGHTING AND LOCOMOTOR BEHAVIOR IN RATS.

LSD-INDUCED STIMULUS CONTROL: A COMPARISON OF SCH-12679, FENFLURAMINE, P-METHOXYAMPHETAMINE, AND BL-3912.

003396 04-04 EFFECTIVENESS OF SCH-12679, A BENZAZEPINE, IN THE TREATMENT OF ANXIETY NEUROSIS. 003541 04-10

AMITRIPTYLINE DOSAGE SCHEDULE, SAMPLING TIME AND TRICYCLIC PLASMA LEVELS. *

000593 01-09 EFFECTS OF D AMPHETAMINE ON A MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE OF FOOD REINFORCEMENT IN THE CAT.

001374 02-04 EFFECTS OF SALSOLINOL, A TETRAHYDROISOQUINOLINE ALKALOID, ON MULTIPLE SCHEDULE PERFORMANCE IN RATS.

002250 03-04 THE EFFECTS OF D AMPHETAMINE AND SCOPOLAMINE ON DRINKING INDUCED BY A MULTIPLE SCHEDULE.

003350 04-04 OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR OPERANT DRUG DISCRIMINATIONS.

003434 04-06

SCHEDULE-CONTROLLED

EFFECTS OF CLOZAPINE, CHLORPROMAZINE AND DIAZEPAM UPON
ADJUNCTIVE AND SCHEDULE-CONTROLLED BEHAVIORS.

000330 01-04 MEPERIDINE EFFECTS ON SCHEDULE-CONTROLLED RESPONDING

000400 01-04 STEREOSELECTIVE EFFECTS OF DIMETHOXY-4-METHYLPHENYLAMINOPROPANE (DOM) ON SCHEDULE-CONTROLLED BEHAVIOR.

001372 02-04 EFFECTS OF MORPHINE AND TWO ENZYME RESISTANT ENKEPHALINS ON SCHEDULE-CONTROLLED RESPONDING IN THE RAT.

002206 03-04 THE EFFECTS OF ACUTE AND CHRONIC PHENCYCLIDINE ON SCHEDULE-CONTROLLED BEHAVIOR IN THE SQUIRREL-MONKEY.

002209 03-04

EFFECTS OF STIMULANTS, ANORECTICS, AND RELATED DRUGS ON SCHEDULE-CONTROLLED BEHAVIOR. 002243 03-04

EFFECTS OF D AMPHETAMINE, MONOMETHOXYAMPHETAMINES AND HALLUCINOGENS ON SCHEDULE-CONTROLLED BEHAVIOR. 002244 03-04

MAZINDOL EFFECTS ON SCHEDULE-CONTROLLED RESPONDING OF THE

LEVO-ALPHA-ACETYLMETHADOL AND METABOLITES: SOME EFFECTS ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT.

003156 04-04 DIFFERENTIAL EFFECTS OF KETAMINE ON SCHEDULE-CONTROLLED
RESPONDING AND MOTILITY.

003295 04-04 EFFECTS OF NALOXONE ON SCHEDULE-CONTROLLED BEHAVIOR IN MORPHINE MAINTAINED PIGEONS.

003401 04-04

SCHEDULE-DEPENDENT
EFFECTS OF ANGIOTENSIN-II ON SCHEDULE-DEPENDENT AND INDUCED
BEHAVIOR AT RECOVERED BODY WEIGHT. 000470 01-04

SCHEDULE-INDUCED
SCHEDULE-INDUCED BITING UNDER FIXED-INTERVAL SCHEDULES OF FOOD
OR ELECTRIC-SHOCK PRESENTATION.

000348 01-04 SCHEDULE-INDUCED WATER AND SACCHARIN POLYDIPSIA UNDER HALOPERIDOL.

000390 01-04 ESTABLISHMENT OF ETONITAZENE AS A REINFORCER FOR RATS BY USE OF SCHEDULE-INDUCED DRINKING.

002281 03-04 SCHEDULE-INDUCED SELF-INJECTION OF NICOTINE, METHADONE AND HEROIN BY NAIVE ANIMALS.

003321 04-04 INFLUENCE OF THE SUSPENSION OF CONTINUED TREATMENT WITH FLURAZEPAM AND AMOBARBITAL ON TWO DISCRIMINATION LEARNING SCHEDULES.

000328 01-04

002268 03-04

VOLUME 16, SUBJECT INDEX

Subject Index

VOLUME 16, SUBJECT INDEX		Subject Index		
SCHEDULE-INDUCED BITING UNDER FIXED-INTERVAL SCHEDULE	S OF FOOD	SCHIZOPHRENIA AS A PROSTAGLANDIN DEFICIENCY DISEAS	SE.	
FIXED-INTERVAL RESPONDING UNDER SECOND-ORDER SCHEDU	0348 01-04 ULES OF	UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: II DRUG SCHIZOPHRENIA.		
	0391 01-04	THE EFFECT OF RUBIDIUM IN SCHIZOPHRENIA.	000828 01-15	
RESPONDING UNDER SCHEDULES OF ELECTRIC-SHOCK TITES	TION.	LOW DOSE LEVODOPA IN SCHIZOPHRENIA.	001542 02-07	
EFFECTS OF D AMPHETAMINE, CHLORDIAZEPOXIDE AND PROF RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER	FIXED-	INTRAVENOUS NALOXONE ADMINISTRATION IN SCHIZOPHI AFFECTIVE-ILLNESS.		
INTERVAL SCHEDULES OF FOOD PRESENTATION AND STIMU TERMINATION.		CHOICE OF MEDICAL TREATMENT IN SCHIZOPHRENIA.	001560 02-08	
SECOND-ORDER SCHEDULES OF INTRAVENOUS DRUG SELF-	11305 02-04	LONG-TERM TREATMENT OF SCHIZOPHRENIA WITH PENFLU		
ADMINISTRATION IN RHESUS MONKEYS. OO PROGRESSIVE FORCE SCHEDULES IN THE SQUIRREL-MONKEY: INCREMENT SIZE, AMPHETAMINE, AND HALDPERIDOL. (PH		THOUGHT DISORDER IN SCHIZOPHRENIA: A THEORETICAL A USING AN ANALYSIS OF SPEECH. (PH.D. DISSERTATION)).	
DISSERTATION).	11459 02-04	EFFECTIVENESS OF BACLOFEN IN SCHIZOPHRENIA.	001566 02-08	
ETHANOL, PENTOBARBITAL, AND CHLORDIAZEPOXIDE EFFECTS	SIN	PROPRANOLOL IN CHRONIC SCHIZOPHRENIA.	001572 02-08	
	DULES. 02254 03-04	PERSPECTIVES IN BIOLOGICAL PSYCHIATRY. PART 3: SCHI AND ORGANIC-BRAIN-SYNDROME.	001611 02-09 ZOPHRENIA	
EFFECTS OF D AMPHETAMINE AND ETHANOL ON RESPONDING SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-RATIO SCI	HEDULES OF	ADVERSE RESPONSE TO NEUROLEPTICS IN SCHIZOPHRENIA	001696 02-14	
	02255 03-04	SCHIZOPHRENIA.	001814 02-15	
COMPARATIVE VALIDITY OF RANDOM-INTERVAL AND FIXED- URINALYSIS SCHEDULES.		BEHAVIORAL MECHANISMS OF DRUG ACTION IN SCHIZOP	001881 02-17	
PENTOBARBITAL, PROMAZINE, D AMPHETAMINE, AND SCOP		BACLOFEN (P-CHLOROPHENYL-GABA) IN SCHIZOPHRENIA.	001933 02-17	
EFFECTS ON BEHAVIOR UNDER MULTIPLE AND PRIMED SCH REINFORCEMENT.	11	DOES DOPAMINE HAVE A ROLE IN SCHIZOPHRENIA?.	002378 03-07	
EFFECTS OF METHADONE ON BEHAVIOR MAINTAINED BY FIXE	03267 04-04 ED-RATIO	THREE YEARS MAINTENANCE NEUROLEPTIC TREATMENT IN	002389 03-08	
	03299 04-04	SCHIZOPHRENIA - BEFORE AND BEYOND.		
CHIZOAFFECTIVE LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN OBLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS: OCCURRENCE	CE IN THE	EEG RECORDS AND THE EFFECTS OF PHENOTHIAZINE TREA PATIENTS WITH PARANOID SCHIZOPHRENIA.		
	00619 01-11	A COMPARATIVE CONTROLLED TRIAL OF PIMOZIDE AND F DECANOATE IN THE CONTINUATION THERAPY OF SCHIZE	OPHRENIA.	
CHIZOPHRENIA EVALUATIONS OF SOCIAL FUNCTIONING IN A 3-YEAR DOUBLE-BLIND		NEUROLEPTICS AND SCHIZOPHRENIA.	002396 03-08	
INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE IN CI SCHIZOPHRENIA.		TRANSMETHYLATION HYPOTHESIS OF SCHIZOPHRENIA: M	002399 03-08 ETHIONINE AND	
MYTHS, THEORIES AND TREATMENT OF SCHIZOPHRENIA.	00518 01-08	NICOTINIC-ACID.	002403 03-08	
BACLOFEN TREATMENT IN CHRONIC SCHIZOPHRENIA: A CLINI		PARENTERAL LOXAPINE IN ACUTE SCHIZOPHRENIA.	002404 03-08	
CLOTHIAPINE IN MANAGEMENT OF SCHIZOPHRENIA.	00521 01-08	DOPAMINE AND SCHIZOPHRENIA.	002405 03-08	
THE THERAPY OF CHILDHOOD SCHIZOPHRENIA.	00522 01-08	SERUM PROLACTIN AND ANTIPSYCHOTIC RESPONSES TO P SCHIZOPHRENIA.		
CLOZAPINE (LEPONEX) VS CHLORPROMAZINE (LARGACTIL) IN SCHIZOPHRENIA (A DOUBLE-BLIND CONTROLLED STUDY).	00525 01-08 N ACUTE	EFFICACY OF LOXAPINE HYDROCHLORIDE INTRAMUSCULAI IM) IN ACUTE SCHIZOPHRENIA.	002408 03-08 R (LOXITANE-	
DATA ANALYSIS: COLLABORATIVE OUTPATIENT SCHIZOPHRE	00527 01-08 NIA STUDY. 00528 01-08	EVALUATION OF LOXAPINE HYDROCHLORIDE ORAL CONCE (LOXITANE C) IN ACUTE SCHIZOPHRENIA.	002410 03-08 NTRATE	
LONG-TERM TREATMENT OF SCHIZOPHRENIA IN MEDICAL PR		AMPHETAMINE PSYCHOSIS A MODEL FOR PARANOID	002411 03-08	
PRACTICAL CONSIDERATIONS IN THE USE OF DEPOT NEUROLE THE TREATMENT OF SCHIZOPHRENIA.	EPTICS FOR	SCHIZOPHRENIA?.	002413 03-08	
THE BIOLOGICAL SUBSTRATES OF SCHIZOPHRENIA.	00534 01-08	DECREASE IN SERUM PROLACTIN AFTER PROPRANOLOL IN SCHIZOPHRENIA.		
ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND RELATE THE TREATMENT OF SCHIZOPHRENIA.		NEUROENDOCRINE STUDIES WITH DOPAMINE AGONISTS II SCHIZOPHRENIA.		
HIGH DOSAGE HALOPERIDOL IN CHRONIC SCHIZOPHRENIA.	00536 01-08	EYE BLINK AND SCHIZOPHRENIA: PSYCHOSIS OR TARDIVE	002589 03-13 E-DYSKINESIA?.	
INHIBITION OF DOPAMINE SYNTHESIS IN CHRONIC SCHIZOPH CLINICAL INEFFECTIVENESS OF METYROSINE.	00539 01-08 IRENIA:	DRUG REFUSAL IN SCHIZOPHRENIA: CAUSES AND PRESCR	002703 03-15 IBING HINTS. 002709 03-15	
	00542 01-08	ANTIPSYCHOTIC DRUGS, NEUROTRANSMITTERS, AND SCH	HZOPHRENIA. 002736 03-17	
PARKINSONISM.	00548 01-08	A NEW ANIMAL MODEL FOR SCHIZOPHRENIA: INTERACTION ADRENERGIC MECHANISMS.		
PROPRANOLOL IN SCHIZOPHRENIA.	00550 01-08	A CONTROLLED STUDY OF TRYPTOPHAN BENSERAZIDE IN	003175 04-04	
NALOXONE IN CHRONIC SCHIZOPHRENIA.	STEELING CO. IV	SCHIZOPHRENIA.	003451 04 00	
PROPRANOLOL AS AN ADJUNCT TO THE TREATMENT OF SCH	00552 01-08 IIZOPHRENIA. 00554 01-08	DOPAMINERGIC MECHANISMS IN SCHIZOPHRENIA: THE A EFFECT AND THE DISEASE PROCESS.		
PERSONALITY MODIFICATIONS DUE TO LONG-TERM PSYCHOPHARMACOTHERAPY: IN CASE OF CHRONIC SCHIZ	OPHRENIA. 00773 01-14	HIGH DOSES OF FLUPHENAZINE-ENANTHATE IN SCHIZOPH	003452 04-08 RENIA. 003453 04-08	

Št	bject Index	
	THE SOCIAL OUTCOME OF PATIENTS IN A TRIAL OF LONG- CONTINUATION THERAPY IN SCHIZOPHRENIA: PIMOZIDI FLUPHENAZINE.	TERM VS.
	MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREAT ACUTE SCHIZOPHRENIA.	003455 04-08 MENT OF
	CONTEMPORARY VIEWS ON THE ROLE OF NEUROLEPTICS IN TREATMENT OF SCHIZOPHRENIA AND THEIR ACTION IN NERVOUS-SYSTEM.	
	BUTACLAMOL IN THE TREATMENT OF SCHIZOPHRENIA. A CONTROLLED CLINICAL TRIAL.	003464 04-08 STANDARD-
	BEHAVIORAL RHYTHMS IN SCHIZOPHRENIA.	003465 04-08
		003468 04-08 AND IC
	MUSCIMOL: GABA-AGONIST THERAPY IN SCHIZOPHRENIA	003473 04-08
	EFFECTS OF NALOXONE ON SCHIZOPHRENIA: REDUCTION II HALLUCINATIONS IN A SUBPOPULATION OF SUBJECTS.	003475 04-08
	ON THE ROLE OF HEMISPHERIC DOMINANCE IN SCHIZOPHE MEASURED BY EXTRAPYRAMIDAL SIDE-EFFECTS OF NEU	ROLEPTICS.
	SCHIZOPHRENIA AS A DOPAMINE DEFICIENCY DISEASE.	003675 04-15
	ANIMAL MODELS OF SCHIZOPHRENIA: THE CASE FOR LSD-	
iC	DRUG THERAPY OF SCHIZOPHRENIAS IN THE COMMUNITY	001813 02-15
C	HIZOPHRENIC SULPIRIDE: EVALUATION OF ANTIPSYCHOTIC ACTIVITY IN PATIENTS.	SCHIZOPHRENIC
	RELAPSE RATES OF SCHIZOPHRENIC PSYCHOSES.	000512 01-07
	NEGATIVE NALOXONE EFFECTS IN SCHIZOPHRENIC PATIENT	000524 01-08 S.
	LACK OF EFFECT OF NALOXONE ON SCHIZOPHRENIC SYMP	
	COMPARISON OF PIMOZIDE AND TRIFLUOPERAZINE AS ON THERAPY IN CHRONIC SCHIZOPHRENIC OUTPATIENTS.	
	D AMPHETAMINE INHIBITION OF PLATELET MAO FROM SC PATIENTS.	000537 01-08 HIZOPHRENIC
	TREATMENT OF SCHIZOPHRENIC PSYCHOSES WITH LYORO	000543 01-08 DIN.
	CORRELATION BETWEEN PLASMA CHLORPROMAZINE AND METABOLITES AND CLINICAL RATINGS IN PATIENTS WIT RELAPSE OF SCHIZOPHRENIC AND PARANOID PSYCHOSI	000546 01-08 ITS H ACUTE S.
	BETA-ENDORPHIN-INDUCED CHANGES IN SCHIZOPHRENIC A	000726 01-13
	THE EFFECTS OF AN ANTIPSYCHOTIC MEDICATION ON THE BEHAVIOR OF FOUR SCHIZOPHRENIC MALE CHILDREN.	000775 01-14 CLASSROOM
	SCHIZOPHRENIC SYMPTOM REMISSION WITH APOMORPH	001568 02-08 INE.
	CHLOROQUINE POTENTIATION OF THIORIDAZINE EFFECTS II DRUG RESISTANT SCHIZOPHRENIC PATIENTS: A PRELIM	
	EVALUATION OF BUTACLAMOL IN CHRONIC SCHIZOPHREN	001571 02-08 IC PATIENTS.
	GONADAL MORPHOLOGY IN SCHIZOPHRENIC PATIENTS UN PSYCHOTROPIC TREATMENT.	001649 02-13 IDER
	INFLUENCE OF EXTRAPYRAMIDAL DISTURBANCES DUE TO ON PHENAMINE STEREOTYPY AND THE EFFECTS OF SCH BLOOD SERUM (EXPERIMENTAL STUDIES).	ZOPHRENIC
	METUADONE IN CONTODURENC BACE A CASE STUDY	002339 03-05

A DOUBLE-BLIND CONTROLLED STUDY OF PIPOTHIAZINE-PALMITATE IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS. 002390 03-08
PENFLURIDOL IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS NEWLY DISCHARGED FROM A BRIEF THERAPY UNIT. 002391 03-08
HOW SCHIZOPHRENIC PATIENTS CHANGE DURING 3 YEARS TREATMENT WITH DEPOT NEUROLEPTICS.

PAVÓR NOCTURNUS IN A SCHIZOPHRENIC PATIENT: A REVIEW AND CASE STUDY.

METHADONE IN SCHIZOPHRENIC RAGE: A CASE STUDY.

200	Marketon or Alberton
Psyci	nopharmacology Abstracts
PROLACTIN RESPONSE TO NEUROL SCHIZOPHRENIC SUBJECTS.	
THE ALPHA SPECTRUM IN SCHIZO PSYCHOPHARMACOLOGICAL TR SOCIOCULTURAL SETTINGS.	002575 03-13 PHRENIC PATIENTS DUE TO EATMENT AND DIFFERENT
PARADOXICAL REACTION TO L-DO	
MAINTENANCE TREATMENT OF CH STUDY WITH THE LONG-ACTING CLOPENTHIXOL-DECANDATE SOF	003449 D4-08 IRONIC SCHIZOPHRENIC PATIENTS. A I THIOXANTHENE DERIVATIVE, CIS- IDINOL DEPOT.
DOPAMINE SUPERSENSITIVITY, EN PROSTAGLANDIN-E1 DEFICIENCY SCHIZOPHRENIC ELEPHANT.	003454 04-08 DORPHIN EXCESS, AND THREE ASPECTS OF THE SAME
A LONG-TERM COMPARATIVE TRI FLUPHENAZINE-DECANOATE IN :	
EFFECTS OF PERPHENAZINE-ENANT LEVELS IN PLASMA FROM SCHIL	003459 04-08 HATE INJECTIONS ON PROLACTIN
	HRONIC SCHIZOPHRENIC PATIENTS WITH DDECATE): IBADAN EXPERIENCE. 003466 04-08
A CONTROLLED CLINICAL STUDY O SCHIZOPHRENIC PATIENTS WITH SYMPTOMATOLOGY.	F TRAZODONE IN CHRONIC
SCHIZOPHRENIC SYMPTOMS IMPR	003472 04-08 ROVE WITH APOMORPHINE.
CLINICAL CORRELATES OF LOW PL SCHIZOPHRENIC PATIENTS.	ATELET MONOAMINE-OXIDASE IN
	CHIZOPHRENIC PATIENTS DURING LONG- YCHOTROPIC DRUGS: DISSOCIATION ION REACTIONS.
CHIZOPHRENIC-LIKE	003673 04-15
SCHIZOPHRENIC-LIKE TENDENCIES 6 HYDROXYDOPAMINE. (PH.D.	IN RATS NEONATALLY TREATED WITH DISSERTATION).
CHIZOPHRENICS	003323 04-04
A LONG-TERM FOLLOW-UP OF SCH REGRESSIVE ECT.	HIZOPHRENICS TREATED WITH
SOME METHODOLOGICAL CONSIDER EVALUATION OF NEUROLEPTICS CLOZAPINE AND HALOPERIDOL	- COMPARATIVE EFFECTS OF
FLUPHENAZINE-DECANOATE, ORA	000531 01-08 L FLUPHENAZINE, AND PLACEBO IN IZOPHRENICS: II. RATING SCALE DATA.
	000544 01-08 HENAZINE-HYDROCHLORIDE GIVEN NITTED SCHIZOPHRENICS: 1. RELAPSE
PHENOTHIAZINE EFFECTS ON PSYC	
EXCRETION OF 3,4 DIMETHOXYPH	NCTION IN CHRONIC SCHIZOPHRENICS. 000549 01-08 IENETHYLAMINE (DMPEA) BY ACUTE
SCHIZOPHRENICS AND CONTRO EEG PROFILE AND BEHAVIORAL CI	HANGES AFTER A SINGLE DOSE OF
CLOZAPINE IN NORMALS AND S STUDY OF NIGHT SLEEP DURING L	SCHIZOPHRENICS. 000787 01-14 ONG-TERM GRADUAL REDUCTION IN
TREATMENT OF CHRONIC SCHIZOI NEUROLEPTIC PENFLURIDOL IN A	DOOB52 01-15 PHRENICS WITH THE ORAL LONG-TERM
PLASMA BUTAPERAZINE LEVELS I	N LONG-TERM CHRONIC
	CHRONIC SCHIZOPHRENICS, BEFORE
THE PSILOCYBIN-INDUCED STATE VOLUNTEERS AND SCHIZOPHRE	NICS.
MAINTENANCE ANTIPSYCHOTIC P LENGTH OF STAY OUT OF THE P IN GREECE.	001726 02-14 HARMACOTHERAPY, RELAPSE, AND HOSPITAL IN CHRONIC SCHIZOPHRENICS
EFFECTS OF FLUPENTHIXOL ON TH	E CLINICAL STATE AND EEG OF

002395 03-08

002521 03-11

SCHIZOPHRENICS.

SERVICES FOR SCHIZOPHRENICS: A LIFELONG APPROACH TO 002398 03-08 GRADUAL REDUCTION OF NEUROLEPTIC DRUGS AMONG CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY 002401 03-08 POSSIBLE WITHDRAWAL FROM ENDOGENOUS OPIATES IN 002666 03-15 CLINICAL LABORATORY STUDIES WITH SPECIAL REGARD TO HEPATIC
METABOLISM IN SCHIZOPHRENICS ON OUTPATIENT LONG-TERM 002667 03-15
DOUBLE-BLIND THERAPEUTIC EVALUATION OF FLUSPIRILENE COMPARED WITH FLUPHENAZINE-DECANOATE IN CHRONIC SCHIZOPHRENIC 003456 04-08 LONG-ACTING ORAL VS INJECTABLE ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENICS: A ONE-YEAR DOUBLE-BLIND COMPARISON IN MULTIPLE EPISODE SCHIZOPHRENICS. 003467 04-08 A COMPARISON OF THE RELATIVE EFFICACY OF SERENACE AND
CHIORPROMAZINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS 003470 04-08 STANDARD AND LONG-ACTING DEPOT NEUROLEPTICS IN CHRONIC SCHIZOPHRENICS: AN 18-MONTH OPEN MULTICENTRIC STUDY. 003471 04-08 TARDIVE-DYSKINESIA. AGE AND SEX DIFFERENCES IN HOSPITALIZED 003681 04-15 SCHOOL METHYLPHENIDATE THERAPY FOR INATTENTIVENESS IN SELECTED SCHOOL CHILDREN 000623 01-11 ANALYSIS OF A SCHOOL OF THOUGHT ON THE EFFECTS OF LITHIUM ON BEHAVIOR PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS THERAPEUTIC APPLICATION 001737 02-14 THANATOPHARMACOLOGY IN THE MEDICAL SCHOOL CURRICULUM 001910 02-17 SCIENCE WORD ASSOCIATION TIMES, FELT EFFECTS, AND PERSONALITY CHARACTERISTICS OF SCIENCE STUDENTS GIVEN A PLACEBO 002611 03-14 SCLEDOSING LEVODOPA IN SUBACUTE SCLEROSING PANENCEPHALITIS. 001547 02-07 **SCOPOLAMINE** EFFECTS OF RETICULAR STIMULATION, D AMPHETAMINE AND SCOPOLAMINE ON ACETYLCHOLINE RELEASE FROM THE HIPPOCAMPUS OF BRAINSTEM TRANSECTED CATS. ACTIONS OF ATROPINE AND SCOPOLAMINE ON THE ENDPLATE CURRENT OF THE FROG SARTORIUS MUSCLE. (PH.D. DISSERTATION). 001042 02-03 THE EFFECTS OF SCOPOLAMINE ON THE TEMPORAL CONTROL OF BEHAVIOR.

001431 02-04 EFFECT OF SCOPOLAMINE ON RETENTION OF A SHOCK MOTIVATED

BRIGHTNESS DISCRIMINATION IN RATS. 001487 02-04 THE EFFECTS OF PROLONGED HANDLING, SCOPOLAMINE, AND PHYSOSTIGMINE ON THE ACTIVITY OF ISOLATED AND SOCIALLY REARED RATS 002285 03-04

PENTOBARBITAL, PROMAZINE, D AMPHETAMINE, AND SCOPOLAMINE EFFECTS ON BEHAVIOR UNDER MULTIPLE AND PRIMED SCHEDULES OF REINFORCEMENT.

THE EFFECTS OF D AMPHETAMINE AND SCOPOLAMINE ON DRINKING INDUCED BY A MULTIPLE SCHEDULE. 003350 04-04

SCOPOLAMINE-INDUCED SCOPOLAMINE-INDUCED LEARNING FAILURES IN MAN. 000972 01-17

SCORE A GRADUAL SCORE TO EVALUATE THE CLIMBING BEHAVIOUR ELICITED BY APOMORPHINE IN MICE.

002350 03-05 SCOTOPHOBIN THE LACK OF EFFECT OF SYNTHETIC SCOTOPHOBIN ON DARKNESS AVOIDANCE IN MICE.

001496 02-04 NONREPRODUCIBILITY OF THE BEHAVIOURAL EFFECTS INDUCED BY SCOTOPHOBIN 003301 04-04

SPREAM DEPRESSION -- THE SILENT SCREAM

001593 02-09

000025 01-02

SCHOOL MINIS AN ANIMAL SCREENING TEST FOR DRUGS THAT PREDICTS THE LIKELIHOOD OF HUMAN PHYSICAL DEPENDENCE.

000028 01-02 MEDICAL SCREENING OF PATIENTS ON MAINTENANCE NEUROLEPTIC 000822 01-15

THE HIPPOCAMPAL SLICE: A SYSTEM FOR STUDYING THE
PHARMACOLOGY OF SEIZURES AND FOR SCREENING ANTICONVULSANT 001538 02-06

LITHIUM THERAPY AND ALKALINE-EARTH METAL METABOLISM: A BIOCHEMICAL SCREENING STUDY 001644 02-13

SCREENING FOR THE EFFECTS OF DOPAMINERGIC AND ANTIDOPAMINERGIC DRUGS ON SERUM PROLACTIN LEVELS BY RADIOIMMUNOASSAY.

002340 03-05 SCREENING HALLUCINOGENIC DRUGS. II. SYSTEMATIC STUDY OF TWO
BEHAVIORAL TESTS.

THE IMPLICATIONS OF PSYCHEDELIC DRUG RESEARCH FOR INTEGRATION
AND SEALING OVER AS RECOVERY STYLES FROM ACUTE PSYCHOSIS. 003517 04-09

THE SEARCH FOR A NONADDICTING ANALGESIC: HAS IT BEEN WORTH

SECOBARBITAL VIGILANCE AND HUMAN ATTENTION UNDER CONDITIONS OF METHYLPHENIDATE AND SECOBARBITAL INTOXICATION: AN ASSESSMENT USING BRAIN POTENTIALS

002622 03-14 PHARMACOKINETIC STUDIES ON TOLERANCE TO SEDATIVE HYPNOTICS IN A POLYDRUG ABUSE POPULATION: 1. SECOBARBITAL.

002662 03-15 SECORAPRITAL AND INFORMATION PROCESSING

003635 04-14 SECOND-GENERATION SECOND-GENERATION ANTIDEPRESSANTS AS RESEARCH TOOLS -- SOME PRELIMINARY FINDINGS WITH CLOMIPRAMINE AND MAPROTILINE.

002587 03-13 SECOND, ORDER

FIXED-INTERVAL RESPONDING UNDER SECOND-ORDER SCHEDULES OF FOOD PRESENTATION OR COCAINE INJECTION 000391 01-04 SECOND-ORDER SCHEDULES OF INTRAVENOUS DRUG SELF-

ADMINISTRATION IN RHESUS MONKEYS. 001452 02-04

SECONDARY TRAZODONE BY INTRAVENOUS INFUSION IN DEPRESSIONS SECONDARY TO ORGANIC DISEASE

000585 01-09 EFFECT OF PSYCHOTOMIMETICS (LSD AND DEXTROAMPHETAMINE) ON THE USE OF PRIMARY AND SECONDARY PROCESS LANGUAGE. 002542 03-12

THE NEUROLOGICAL BASIS OF MOTOR ASYMMETRY FOLLOWING UNILATERAL MIGROSTRIATAL LESIONS IN THE RAT: THE EFFECT OF SECONDARY SUPERIOR COLLICULUS LESIONS.

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE (SIADH) SECONDARY TO ANTIPSYCHOTIC DRUG THERAPY.

003647 04-15 SECRETION

LEVELS OF CHLORPROMAZINE AND ITS ACTIVE MATABOLITES IN RAT BRAIN AND THE RELATIONSHIP TO CENTRAL MONOAMINE METABOLISM AND PROLACTIN SECRETION.

000041 01-03 DRUGS ALTERING INSULIN SECRETION: EFFECTS ON PLASMA AND BRAIN CONCENTRATIONS OF AROMATIC-AMINO-ACIDS AND ON BRAIN 5 HYDROXYTRYPTAMINE TURNOVER.

PERLAPINE: RELATIONSHIP BETWEEN STIMULATION OF PROLACTIN SECRETION AND ANTIPSYCHOTIC ACTIVITY.

THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDROCANNABINOL (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HORMONE (FSH) AND LUTEINIZING HORMONE (LH) IN THE OVARIECTOMIZED RHESUS

MONKEY 001245 02-03 THYROID FUNCTION AND GROWTH HORMONE SECRETION IN AMITRIPTYLINE TREATED DEPRESSION.

CANNABINOIDS INHIBIT TESTOSTERONE SECRETION BY MOUSE TESTES IN VITRO

001999 03-03

NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: 1. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY.

PROLACTIN SECRETION DURING AND AFTER NOVERIL INFUSIONS TO DEPRESSIVE PATIENTS.

002438 03-09 CENTRAL EFFECT OF SOMATOSTATIN ON THE SECRETION OF GROWTH HORMONE IN THE ANESTHETIZED RAT.

002803 04-03 NGF-INDUCED ALTERATIONS IN PROTEIN SECRETION AND SUBSTRATE ATTACHED MATERIAL OF A CLONAL NERVE CELL LINE.

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE (SIADH) SECONDARY TO ANTIPSYCHOTIC DRUG THERAPY.

SECRETORY
SOMATOSTATIN: ELECTRON MICROSCOPE IMMUNOHISTOCHEMICAL
LOCALIZATION IN SECRETORY NEURONS OF RAT HYPOTHALAMUS
001948 001948 03-01

SECTORS

AFFERENT AND EFFERENT SUBCORTICAL PROJECTIONS OF BEHAVIORALLY
DEFINED SECTORS OF PREFRONTAL GRANULAR CORTEX.

002962 04-03

SEDATIVE
SEDATIVE PROPERTIES OF DOXEPIN IN COMPARISON WITH DIAZEPAM.
000703 01-13
TOLERANCE TO SEDATIVE HYPNOTICS, MEMORY AND NORADRENERGIC
(NE) SYSTEMS.
002318 03-04

PHARMACOKINETIC STUDIES ON TOLERANCE TO SEDATIVE HYPNOTICS IN A POLYDRUG ABUSE POPULATION: I. SECOBARBITAL.

002662 03-15

SEDATIVES
A METHOD FOR EVALUATING ANXIOLYTIC SEDATIVES.

000616 01-10 PHARMACOPSYCHOLOGICAL INVESTIGATION OF THE EFFECT OF SEDATIVES ON MEMORY AND LEARNING PERFORMANCE IN CHILDREN AND ADOLESCENTS.

PURCHASES OF HYPNOTICS, SEDATIVES AND MINOR TRANQUILLIZERS AMONG 2,566 INDIVIDUALS IN THE COUNTY OF JAMTLAND, SWEDEN: A 6-YEAR FOLLOW-UP.

000940 01-17 SIMILARITIES AND DIFFERENCES IN DISCRIMINATIVE STIMULUS EFFECTS OF CHLORDIAZEPOXIDE, PENTOBARBITAL, ETHANOL, AND OTHER

003163 04-04

SEDIMENTATION
LOWERED ERYTHROCYTE SEDIMENTATION RATE WITH SODIUM
VALPROATE.

003672 04-15

DYNAMICS OF BLOOD NEUROTRANSMITTER LEVEL AS EVIDENCE OF HIGHER NERVOUS ACTIVITY CHANGES DURING CHRONIC ADMINISTRATION OF SEDUXEN.

001338 02-04 AN INVESTIGATION OF SOPHORA-SECUNDIFLORA SEEDS (MESCALBEANS). 000007 01-01

THYROTROPIN-RELEASING HORMONE (TRH): LACK OF EFFECT ON SHOCK-ELICITED FIGHTING (SEF) IN RATS.

003283 04-04 SEIZURE

PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, BRAIN SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION INTO BRAIN PROTEINS OF DIFFERENT MOUSE STRAINS.

THE EFFECTS OF METHAQUALONE ON THE SEIZURE SUSCEPTIBILITY OF

effects of Lithium on Seizure Susceptibility in Alcoholized and Nonalcoholized Rats.

001315 02-04 EFFECT OF BARBITURATE WITHDRAWAL ON PENTYLENETETRAZOL SEIZURE THRESHOLD

001364 02-04 TIME-COURSE OF AUDIOGENIC SEIZURE SUSCEPTIBILITY AND PLASMA PENTOBARBITAL CONCENTRATION DURING WITHDRAWAL.

001977 03-03 SEIZURE SUSCEPTIBILITY AND ANTICONVULSANT ACTIVITY OF CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES.

003055 04-03 EFFECTS OF INTRAVENTRICULARLY ADMINISTERED MONOAMINES ON SEIZURE SUSCEPTIBILITY AND BODY TEMPERATURE IN RATS.

003180 04-04 EFFECTS OF SODIUM PHENOBARBITAL ON BRAIN STIMULATION
BEHAVIOR, BEHAVIORAL SEIZURES, AND EEG SEIZURE ACTIVITY

Psychopharmacology Abstracts

SODIUM VALPROATE IN THE TREATMENT OF INTRACTABLE SEIZURE DISORDERS: A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY 003550 04-11

SEIZURES

CONVULSIVE SEIZURES AND VILOXAZINE.

000826 01-15

EPILEPTIC SEIZURES INDUCED BY PSYCHOTROPIC DRUGS.

000905 01-15

TIME-COURSE AND DEVELOPMENT OF ELECTROCLINICAL FEATURES IN RELATION TO PENTYLENETETRAZOL THRESHOLDS IN MONKEYS WITH

001092 02-03

THE HIPPOCAMPAL SLICE: A SYSTEM FOR STUDYING THE PHARMACOLOGY OF SEIZURES AND FOR SCREENING ANTICONVULSANT DRUGS.

001538 02-06 STATUS-EPILEPTICUS OR REPETITIVE SEIZURES FOLLOWING TOXIC INGESTION.

001845 02-15

A COMPARISON OF THE EFFECTS OF SEIZURES AND TWO ANTICONVULSANT MEDICATIONS ON LEARNING IN THE PAPIO-PAPIO BABOON. (PH.D. DISSERTATION). 002329 03-04

RETROACTIVE AMNESIA INDUCED IN CHICKS BY THE PROLINE ANALOG L BAIKIAIN, WITHOUT EEG SEIZURES OR DEPRESSION. 003205 04-04

EFFECTS OF SODIUM PHENOBARBITAL ON BRAIN STIMULATION
BEHAVIOR, BEHAVIORAL SEIZURES, AND EEG SEIZURE ACTIVITY 003355 04-04 BEHAVIOR DISTURBANCE, PHENOBARBITAL, AND FEBRILE SEIZURES

003582 04-11

SELECTION
SELECTION AMONG BENZODIAZEPINES FOR ALCOHOL WITHDRAWAL
001906 001906 02-17

FLA-136: SELECTIVE AGONIST AT CENTRAL ALPHA-ADRENORECEPTORS MEDIATING CHANGES IN THE TURNOVER OF NORADRENALINE.

000043 01-03 QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS IN A SERIES OF SELECTIVE 5-HT UPTAKE INHIBITORS.

000057 01-03 THE SELECTIVE INHIBITION OF DOPAMINE UPTAKE BY A TRICYCLIC IMINE 000141 01-03

FURTHER EVIDENCES ON THE BEHAVIOURAL EFFECTS OF SELECTIVE A-10
DOPAMINERGIC MESENCEPHALO-CORTICO-LIMBIC GROUP LESION IN

SELECTIVE OPIATE DEPRESSION OF SENSORY EVOKED SYNAPTIC NETWORKS IN DORSAL-HORN REGIONS OF SPINAL CORD CULTURES 001088 02-03

SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT

AND NEWBORN RATS.

AUTORADIOGRAPHIC EVIDENCE FOR THE SELECTIVE ACCUMULATION OF H3-5-HT BY SUPRAEPENDYMAL NERVE TERMINALS.

001222 02-03 VARIOUS EFFECTS OF D AMPHETAMINE IN RATS WITH SELECTIVE LESIONS OF BRAIN NORADRENALINE CONTAINING NEURONS OR TREATED WITH PENFLURIDOL.

001437 02-04 A DEVELOPMENTAL STUDY OF SELECTIVE ATTENTION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).

001709 02-14 EFFECT OF DEXTROAMPHETAMINE ON SOMATIC EVOKED-POTENTIAL COMPONENTS IN MAN WITH SPECIAL REFERENCE TO TALK RELEVANCE AND SELECTIVE ATTENTION.

001735 02-14 SELECTIVE MONOAMINE-OXIDASE INHIBITORS. 1. COMPOUNDS RELATED TO 4 AMINOPHENETHYLAMINE.

001945 03-01 SELECTIVE INHIBITION OF NORADRENALINE AND SEROTONIN UPTAKE BY C-49802-B-BA AND CGP-6085-A.

SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL CORRELATES.

001974 03-03 EVIDENCE FOR SELECTIVE AND LONG-LASTING STIMULATION OF REGULATORY DOPAMINE RECEPTORS BY BROMOCRIPTINE (CB-154). 002002 03-03

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS.

002148 03-03 METHYLHISTAMINE. EVIDENCE FOR SELECTIVE DEAMINATION BY MAO-B
IN THE RAT BRAIN IN VIVO.

002172 03-03

EFFECTS OF PCPA AND SELECTIVE REM SLEEP-DEPRIVATION ON ROTOROD PERFORMANCE AND OPEN-FIELD BEHAVIOR IN THE RAT.

002219 03-04

SELECTIVE REDUCTION BY NORADRENALINE AND 5
HYDROXYTRYPTAMINE OF NOCICEPTIVE RESPONSES OF CAT DORSAL-HORN NEURONES

002246 03-04

7, N, N TRIMETHYLTRYPTAMINE: A SELECTIVE INHIBITOR OF SYNAPTOSOMAL SEROTONIN UPTAKE. 002364 03-06

SELECTIVE PURIFICATION OF A SINGLE POPULATION OF GLUCOCORTICOID RECEPTORS FROM RAT BRAIN. 002887 04-03

SELECTIVE ENZYME INDUCTION IN A NERVE GROWTH FACTOR RESPONSIVE PHEOCHROMOCYTOMA CELL LINE (PC-12).

002899 04-03 MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMATURE RAT.

002901 04-03 SUBSTRATE SELECTIVE ACTIVATION OF RAT LIVER MITOCHONDRIAL MONOAMINE-OXIDASE BY OXYGEN.

002912 04-03 SEIZURE SUSCEPTIBILITY AND ANTICONVULSANT ACTIVITY OF CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES.

003055 04-03 SELECTIVE BLOCKADE OF DOPAMINE-INDUCED VASODILATION BY ERGONOVINE-MALEATE IN THE VASCULATURES OF DOGS AND

003067 04-03 SELECTIVE LABELING OF PRESYNAPTIC RECEPTORS BY H3-DOPAMINE, H3 APOMORPHINE AND H3-CLONIDINE; LABELING OF POSTSYNAPTIC SITES

DOPAMINE-BETA-HYDROXYLASE RELEASE FOLLOWING ACUTE SELECTIVE SYMPATHETIC NERVE STIMULATION OF THE HEART. SPLEEN AND MESENTERY

003422 04-06 DEXTROAMPHETAMINE AND PLACEBO PRACTICE EFFECTS ON SELECTIVE ATTENTION IN HYPERACTIVE CHILDREN. 003627 04-14

DEPRENYL ADMINISTRATION IN MAN: A SELECTIVE MONOAMINE-OXIDASE B INHIBITOR WITHOUT THE CHEESE EFFECT. 003652 04-15

SELECTIVITY

SELECTIVITY OF H3-BIOGENIC AMINE RELEASE BY D,L AMPHETAMINE AND DRUGS THAT INTERACT WITH SEROTONERGIC NEURONS 001161 02-03

DEPRENIL: LOSS OF SELECTIVITY FOR INHIBITION OF B-TYPE MAO AFTER REPEATED TREATMENT.

PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT
OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC
AND CATECHOLAMINERGIC MECHANISMS BY 6 HYDROXYDOPAMINE AND 5,6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D. DISSERTATION).

003407 04-05

STUDIES OF THE REINFORCING PROPERTIES OF INTRAVENOUSLY SELF-ADMINISTERED COMPOUNDS IN RHESUS MONKEYS. (PH.D. DISSERTATION)

002188 03-04

SELF-ADMINISTRATION EFFECT OF IN-UTERO ADMINISTRATION OF MORPHINE ON THE SUBSEQUENT DEVELOPMENT OF SELF-ADMINISTRATION BEHAVIOR 000368 01-04

ANIMAL MODELS OF ORAL DRUG SELF-ADMINISTRATION 000408 01-04

KETAMINE SELF-ADMINISTRATION BY THE RHESUS MONKEY 000417 01-04 CHARACTERISTICS OF BETA-PHENETHYLAMINE SELF-ADMINISTRATION BY

000439 01-04
DOSE PREFERENCE DURING PENTOBARBITAL SELF-ADMINISTRATION BY

000781 01-14

NARCOTIC BLOCKADE, LENGTH OF ADDICTION, AND PERSISTENCE OF INTRAVENOUS MORPHINE SELF-ADMINISTRATION IN RATS. 001322 02-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): PRESSIN FOR ICS BEFORE AND AFTER SELF-ADMINISTRATION OF SWEETENED MORPHINE SOLUTIONS. 001331 02-04

SECOND-ORDER SCHEDULES OF INTRAVENOUS DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS.

CLONIDINE SELF-ADMINISTRATION IN THE RAT: A COMPARISON WITH FENTANYL SELF-ADMINISTRATION.

CONCURRENT INTRACRANIAL SELF-STIMULATION AND AMPHETAMINE SELF-ADMINISTRATION IN RATS.

REDUCTION OF HEROIN SELF-ADMINISTRATION IN BABOONS BY MANIPULATION OF BEHAVIORAL AND PHARMACOLOGICAL CONDITIONS

001499 02-04 INTRAVENOUS COCAINE SELF-ADMINISTRATION IN THE RABBI' 001528 02-06

THE PNEUMATIC SYRINGE: A SIMPLE APPARATUS FOR SELF
ADMINISTRATION OF DRUGS BY RATS.

CONTINUOUS INTRAVENOUS NALTREXONE EFFECTS ON MORPHINE SELF-ADMINISTRATION IN RHESUS MONKEYS. 002241 03-04

INTRAVENOUS SELF-ADMINISTRATION OF DRUGS IN RATS. 002324 03-04

THE EFFECT OF HOUSING AND GENDER ON MORPHINE SELF-ADMINISTRATION IN RATS

CHANGES IN MORPHINE SELF-ADMINISTRATION AFTER TEL-DIENCEPHALIC LESIONS IN RATS

003228 04-04 FOOD RELATED INTRAVENOUS INSULIN SELF-ADMINISTRATION IN NORMAL AND DIABETIC RATS.

COMPARATIVE EFFECTS OF COCAINE AND PSEUDOCOCAINE ON EEG ACTIVITIES, CARDIORESPIRATORY FUNCTIONS, AND SELF-ADMINISTRATION BEHAVIOR IN THE RHESUS MONKEY.

THE EFFECTS OF INTRAGASTRIC MORPHINE SELF-ADMINISTRATION IN THE RAT. (PH.D. DISSERTATION).

003437 04-06
EVALUATION OF A PATIENT DRUG SELF-ADMINISTRATION PROGRAM. (PH.D. DISSERTATION).

003700 04-17 HYPERACTIVE AND NONHYPERACTIVE CHILDRENS SELF-DETERMINED LEVELS OF STIMULATION. (PH.D. DISSERTATION).

001717 02-14 SELF-INJECTION

DISCRETE-TRIAL CONTROL OF COCAINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF MORPHINE, NALOXONE, AND CHLORPROMAZINE.

DISCRETE-TRIAL CONTROL OF MORPHINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF NALOXONE, MORPHINE, AND CHIORPROMAZINE

001470 02-04 SCHEDULE-INDUCED SELF-INJECTION OF NICOTINE, METHADONE AND HEROIN BY NAIVE ANIMALS.

SELF-MAINTAINED HEAD-SHAKE DISTRIBUTIONS DURING SELF-MAINTAINED DEPENDENCE ON MORPHINE, METHADONE, AND L-ALPHA-ACETYLMETHADOL (LAAM) IN THE RAT

SELF-MODEL VIDEO EDITING AND MEDICATION TO PRODUCE A THERAPEUTIC SELF-MODEL.

001707 02-14 SELF-MUTILATION COMPULSIONS, AGGRESSION, AND SELF-MUTILATION: A HYPOTHALAMIC DISORDER?

003641 04-14 SELF-REPORTED ALCOHOL AND NICOTINE USE AND THE ABILITY TO

CONTROL OCCIPITAL EEG IN A BIOFEEDBACK SITUATION. 003622 04-14 SELF-STIMULATION

-STIMULATION

EFFECTS OF APOMORPHINE ON SELF-STIMULATION BEHAVIOUR IN

DORSAL AND VENTRAL AREA OF LATERAL HYPOTHALAMUS IN MICE.

000334 01-04 ON THE ROLE OF ASCENDING CATECHOLAMINERGIC PROJECTIONS IN INTRACRANIAL SELF-STIMULATION OF THE SUBSTANTIA-NIGRA.

000336 01-04 NONCONTINGENT DISPLACEMENT OF CATECHOLAMINES BY
INTRAVENTRICULAR TYRAMINE: BIPHASIC DOSE-RESPONSE EFFECTS ON

SELF-STIMULATION EFFECTS OF D AMPHETAMINE ON CONCURRENT SELF-STIMULATION OF

FOREBRAIN AND BRAINSTEM LOCI. 000393 01-04

BLOCKADE OF INTRACRANIAL SELF-STIMULATION BY ANTIPSYCHOTIC DRUGS: FAILURE TO CORRELATE WITH CENTRAL ALPHANORADRENERGIC BLOCKADE.

STEREOSELECTIVE, DOSE-DEPENDENT MODIFICATION OF INTRACRANIAL SELF-STIMULATION (ICSS) BY CENTRALLY ADMINISTERED LEVORPHANOL AND DEXTRORPHAN. 001280 02-03

001462 02-04

ETORPHINE AND SHUTTLE-BOX SELF-STIMULATION IN THE RAT

001304 02-04 THE EFFECT OF AMPHETAMINE AND L-DOPA ON TETRABENAZINE-INDUCED SUPPRESSION OF INTRACRANIAL SELF-STIMULATION IN THE RAT. 001321 02-04

EFFECT OF ACUTE AND CHRONIC INJECTIONS OF AMPHETAMINE ON INTRACRANIAL SELF-STIMULATION: AMPHETAMINE LEVELS AND EFFECTS UPON SOME ARYLALKYLAMINES IN RAT BRAIN.

001339 02-04 EFFECTS OF DOPAMINE SUPERSENSITIVITY ON LATERAL HYPOTHALAMIC SELF-STIMULATION IN RATS.

001351 02-04 MORPHINE AND SHUTTLE-BOX SELF-STIMULATION IN THE RAT: A MODEL FOR EUPHORIA.

001401 02-04 DIFFERENTIAL EFFECTS OF MORPHINE AND D AMPHETAMINE ON SELF-STIMULATION FROM CLOSELY ADJACENT REGIONS IN RAT MIDBRAIN 001403 02-04

EFFECTS ON HYPOTHALAMIC SELF-STIMULATION OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION INJECTED INTO NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM OF RATS.

001466 02-04 CONCURRENT INTRACRANIAL SELF-STIMULATION AND AMPHETAMINE SELF-ADMINISTRATION IN RATS.

001495 02-04 TOLERANCE TO AMPHETAMINES FACILITATION OF SELF-STIMULATION RESPONDING: ANATOMICAL SPECIFICITY.

002190 03-04 EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D AMPHETAMINE ON SELF-STIMULATION OF THE SUBSTANTIA-NIGRA AND LOCUS-

COERULEUS

REWARD VERSUS PERFORMANCE IN SELF-STIMULATION: ELECTRODE SPECIFIC EFFECTS OF ALPHA-METHYL-P-TYROSINE ON REWARD IN THE RAT. 002225 03-04

EFFECTS OF NOMIFENSINE (HOE-984) UPON PSYCHOMOTOR ACTIVITY AND INTRACRANIAL SELF-STIMULATION IN THE RAT. 002256 03-04

MORPHINE AND SELF-STIMULATION: EVIDENCE FOR ACTION ON A COMMON NEURAL SUBSTRATE

002277 03-04 ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE, SELF-STIMULATION, AND PARAMETERS OF ICS.

002320 03-04 IDENTIFICATION OF A SUBREGION WITHIN RAT NEOSTRIATUM FOR THE DOPAMINERGIC MODULATION OF LATERAL HYPOTHALAMIC SELF-STIMULATION.

003028 04-03 EFFECTS OF SPIPERONE ON SELF-STIMULATION AND OTHER ACTIVITIES OF THE MONGOLIAN GERBIL

003222 04-04 EVIDENCE FOR A ROLE FOR DOPAMINE IN SELF-STIMULATION OF THE NUCLEUS-ACCUMBENS OF THE RAT.

003341 04-04 EFFECT OF PIMOZIDE ON THE IMPROVEMENT IN LEARNING PRODUCED BY SELF-STIMULATION AND BY WATER REINFORCEMENT. 003394 04-04

SELLA PRIMARY EMPTY SELLA SYNDROME AND BIPOLAR AFFECTIVE-ILLNESS: CASE REPORT

003511 04-09

SEMICARBAZONO-6-OXOTETRAHYDROINDOL
A COMPARISON BETWEEN PLACEBO, PIZOTIFEN AND 1 ISOPROPYL-3-HYDROXY 5 SEMICARBAZONO-6-OXOTETRAHYDROINDOL (FIVASCAN) IN MIGRAINE PROPHYLAXIS. 000653 01-11

SEMINAR
COMBINED SEMINAR ON THE USE OF DRUGS IN RENAL FAILURE 001902 02-17

SENESCENT BRAIN: CURRENT STATUS AND IMPLICATION IN NEUROPSYCHOPHARMACOLOGY. 001905 02-17

TREATMENT OF SENILE PSYCHOSES WITH DISTRANEURIN MIXTURE 000749 01-14 ACTH4-10 IN THE AMELIORATION OF NEUROPSYCHOLOGICAL SYMPTOMATOLOGY ASSOCIATED WITH SENILE ORGANIC-BRAIN-SYNDROME.

002505 03-11 SENILE-DEMENTIA SENILE-DEMENTIA: TREATMENT WITH DEANOL

000624 01-11 KINETICS OF CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN MOUSE BRAIN SYNAPTOSOMES.

000093 01-03

Psychopharmacology Abstracts

HALOPERIDOL INCREASES AND APOMORPHINE DECREASES STRIATAL DOPAMINE METABOLISM AFTER DESTRUCTION OF STRIATAL DOPAMINE SENSITIVE ADENYLATE-CYCLASE BY KAINIC-ACID. 000094 01-03

NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN SLICES OF MOUSE LIMBIC FOREBRAIN: CHARACTERISATION AND EFFECT OF DOPAMINERGIC AGONISTS.

000256 01-03 EVIDENCE FOR INCREASED APOMORPHINE SENSITIVE DOPAMINERGIC EFFECTS AFTER ACUTE TREATMENT WITH MORPHINE.

000449 01-04 ANALGESIA INDUCED BY VAGINAL STIMULATION IN RATS IS
APPARENTLY INDEPENDENT OF A MORPHINE SENSITIVE PROCESS.

001090 02-03

CATECHOLAMINE SENSITIVE ATPASE ACTIVITIES IN BRAIN SYNAPTOSOMES OF MORPHINIZED MICE.

001096 02-03 REGIONAL EFFECTS OF NEUROLEPTICS ON DOPAMINE METABOLISM AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE ACTIVITY.

001237 02-03 THE NUCLEUS RETICULARIS GIGANTOCELLULARIS OF THE MEDULLA-OBLONGATA IS A HIGHLY SENSITIVE SITE IN THE PRODUCTION OF MORPHINE ANALGESIA IN THE RAT.

001256 02-03 BLOOD LEVEL MONITORING OF BENZODIAZEPINES BY GLC USING NITROGEN SENSITIVE DETECTORS.

001860 02-16 EFFECT OF MORPHINE ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE ACTIVITY OR NUCLEUS-ACCUMBENS.

INHIBITION BY LITHIUM OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE

002357 03-05 BEHAVIOURAL DESPAIR IN RATS: A NEW MODEL SENSITIVE TO ANTIDEPRESSANT TREATMENTS.

002370 03-06 A SIMPLE AND SENSITIVE RADIORECEPTOR ASSAY FOR ANTISCHIZOPHRENIC DRUGS IN BLOOD.

EFFECTS OF SOME DERIVATIVES OF 2 AMINOTETRALIN ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE AND ON THE BINDING OF H3-HALOPERIDOL TO NEUROLEPTIC RECEPTORS IN RAT STRIATUM.

002853 04-03 DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RETINA - SUBCELLULAR

002867 04-03 INHIBITION OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RAT STRIATUM BY NEUROLEPTIC DRUGS ADMINISTERED IN VIVO.

003027 04-03 THE DIFFERENTIAL EFFECT OF LITHIUM ON NORADRENALINE AND DOPAMINE SENSITIVE ACCUMULATION OF CYCLIC-AMP IN GUINEA-PIG

THE DOPAMINE SENSITIVE ADENYLATE-CYCLASE OF THE RAT CAUDATE NUCLEUS — 3. THE EFFECT OF APORPHINES AND PROTOBERBERINES. 003089 04-03

MEASUREMENT OF PLASMA AND ERYTHROCYTE CHLORPROMAZINE AND N MONODESMETHYLCHLORPROMAZINE LEVELS BY GAS-CHROMATOGRAPHY WITH A NITROGEN SENSITIVE DETECTOR 003429 04-06

SENSITIVITIES

SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION. 002052 03-03

REGIONAL DIFFERENCES IN THE SENSITIVITY OF CHOLINERGIC NEURONS TO DOPAMINERGIC DRUGS AND QUIPAZINE IN THE RAT STRIATUM.

000134 01-03 ALTERED RECEPTOR SENSITIVITY FOLLOWING CHRONIC DRUG ADMINISTRATION IN MAN: THE TARDIVE-DYSKINESIA MODEL

000248 01-03 BARBITAL-INDUCED CHANGES IN SENSITIVITY TO THE BEHAVIORAL EFFECTS OF NARCOTICS.

000332 01-04 THE ROLE OF ASCENDING AND DESCENDING 5 HYDROXYTRYPTAMINE NEURONES IN CENTRAL CONTROL OF PAIN SENSITIVITY.

000380 01-04 BEHAVIORAL SENSITIVITY TO LSD: DEPENDENCY UPON THE PATTERN OF CENTRAL 5-HT DEPLETION.

000388 01-04 ALTERATIONS IN DOPAMINE RECEPTOR SENSITIVITY BY CHRONIC ETHANOL TREATMENT.

001146 02-03 LONG-TERM CHANGES IN THE SENSITIVITY OF PRE- AND POSTSYNAPTIC DOPAMINE RECEPTORS IN MOUSE STRIATUM EVIDENCED BY BEHAVIORAL AND BIOCHEMICAL STUDIES.

001187 02-03

CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIVITY TO THE DIRECT APPLICATION OF MORPHINE AND FOCAL ELECTRICAL STIMULATION IN THE PRODUCTION OF ANTINOCICEPTION IN THE RAT.

SENSITIVITY TO PSYCHOACTIVE DRUGS AND THE SEROTONERGIC

001302 02-04
RECEPTOR SENSITIVITY MODIFICATION (RSM) — A NEW PARADIGM FOR
THE POTENTIAL TREATMENT OF SOME HORMONAL AND TRANSMITTER

001659 02-13 REGIONAL SENSITIVITY OF PRIMATE BRAIN DOPAMINERGIC NEURONS TO HALOPERIDOL: ALTERATIONS FOLLOWING CHRONIC TREATMENT

GABA, PICROTOXIN AND RETINAL SENSITIVITY.

002889 04-03

THE EFFECT OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF AMPHETAMINE ON CEREBRAL DOPAMINE RECEPTOR SENSITIVITY. 002964 04-03 SENSITIVITY TO APOMORPHINE IN THE GUINEA-PIG AS A FUNCTION OF AGE AND BODY WEIGHT.

CHANGES OF SENSITIVITY TO THE CUING PROPERTIES OF NARCOTIC DRUGS AS EVIDENCED BY GENERALIZATION AND CROSS-

GENERALIZATION EXPERIMENTS. 003194 04-04

DIFFERENTIAL TOLERANCE TO PENTOBARBITAL IN RATS BRED FOR DIFFERENCES IN ALCOHOL SENSITIVITY. 003338 04-04

NALOXONE PRECIPITATED WITHDRAWAL REVEALS SENSITIZATION TO ALOXONE PRECIPITATED WITHUKAWAL REVEALS SENSITIZATION OF NEUROTRANSMITTERS IN MORPHINE-TOLERANT/DEPENDENT RATS. 001456 02-04

SENSORIMOTOR

EFFECT OF DIAZEPAM ON PULSE ACTIVITY OF NEURONS OF THE

SENSORIMOTOR AND OPTIC AREAS OF THE RAT CEREBRAL-CORTEX

EFFECT OF SOMATOSTATIN (SRIF) AND L GLUTAMATE ON NEURONS OF THE SENSORIMOTOR CORTEX IN AWAKE HABITUATED RABBITS. 002958 04-03

SENSORY 5-HT AND MORPHINE INTERACTION, EFFECTS ON SENSORY INPUT IN CAUDATE NUCLEUS AND SUBSTANTIA-NIGRA.

000089 01-03 DO BENZODIAZEPINES AFFECT MOTOR OR SENSORY MECHANISMS? 000250 01-03 SELECTIVE OPIATE DEPRESSION OF SENSORY EVOKED SYNAPTIC

NETWORKS IN DORSAL-HORN REGIONS OF SPINAL CORD CULTURES 001088 02-03 CAPSAICIN-INDUCED DEPLETION OF SUBSTANCE-P FROM PRIMARY SENSORY NEURONS.

002965 04-03

EFFECTS OF 6 HYDROXYDOPAMINE ON BODY WEIGHT: FEEDING DEFICITS OR SENSORY-MOTOR IMPAIRMENTS?.

001432 02-04

SEPARATION

SEPARATION OF CANNABINOIDS.

001013 02-01

SEPARATION-INDUCED EFFECTS OF IMPRAMINE TREATMENT OF SEPARATION-INDUCED SOCIAL DISORDERS IN RHESUS MONKEYS.

002316 03-04 EXCITATORY ACTION OF THE MESOLIMBIC DOPAMINE SYSTEM ON

THE ROLE OF THE SEPTAL NUCLEI IN THE RELEASE OF ACETYLCHOLINE FROM THE RABBIT CEREBRAL-CORTEX AND DORSAL HIPPOCAMPUS AND THE EFFECT OF ATROPINE

000101 01-03 EFFECT OF SOME CENTRALLY ACTIVE COMPOUNDS ON AGGRESSIVE BEHAVIOUR IN SEPTAL RATS.

001376 02-04 PHARMACOLOGICAL MANIPULATIONS OF THE SEPTAL IRRITABILITY SYNDROME: ROLE OF DOPAMINERGIC MECHANISMS IN RECOVERY OF FUNCTION. (PH.D. DISSERTATION).

SEPTUM

REACTIVITY AND AGGRESSION IN THE RAT: INDUCTION BY ALPHA ADRENERGIC BLOCKING AGENTS INJECTED VENTRAL TO ANTERIOR SEPTUM BUT NOT INTO LATERAL SEPTUM.

000309 01-04 THE EFFECT OF INTRAHIPPOCAMPAL KAINIC-ACID INJECTIONS AND SURGICAL LESIONS ON NEUROTRANSMITTERS IN HIPPOCAMPUS AND SEPTUM.

002911 04-03

SEQUELAE AFTER THE INTRAVENOUS INJECTION OF THREE BENZODIAZEPINES -- DIAZEPAM, LORAZEPAM, AND FLUNITRAZEPAM 001785 02-15 PSYCHIATRIC SEQUELAE OF AMOK

PSYCHOLOGICAL SEQUELAE TO HEMODIALYSIS.

002409 03-08

003661 04-15

000459 01-04

000563 01-09

DEVELOPMENT OF TOLERANCE TO THE DISRUPTIVE AFFECTS OF COCAINE ON REPEATED ACQUISITION AND PERFORMANCE OF RESPONSE SEQUENCES

THE STUDY OF SEQUENCES OF MOTOR BEHAVIOR

001537 02-06
BIOLOGICAL ACTIVITY OF NEUROTENSIN AND ITS C-TERMINAL PARTIAL **SEQUENCES**

COMBINED EFFECTS OF ETHANOL AND DIAZEPAM ON PERFORMANCE AND ACQUISITION OF SERIAL POSITION SEQUENCES BY 003164 04-04

A SEQUENTIAL TRIAL OF VILOXAZINE (VIVALAN) AND IMIPRAMINE IN MODERATELY DEPRESSED PATIENTS.

CLINICAL USE OF HALOPERIDOL (SERENACE) IN CHILD PSYCHIATRY 001725 02-14 A COMPARISON OF THE RELATIVE EFFICACY OF SERENACE AND

CHLORPROMAZINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS. 003470 04-08

A COMPARISON OF THE EFFICACY AND ACCEPTABILITY OF TWO
FORMULATIONS OF INJECTABLE SERENACE IN THE TREATMENT OF STATES OF EXCITEMENT 003576 04-11

COMBINED EFFECTS OF ETHANOL AND DIAZEPAM ON PERFORMANCE AND ACQUISITION OF SERIAL POSITION SEQUENCES BY PIGEONS.

THE EFFECTS OF METHYLPHENIDATE ON REPEATED ACQUISITION OF SERIAL DISCRIMINATION REVERSALS.

003238 04-04 STATE-DEPENDENT RETRIEVAL OF ITEM, ASSOCIATIVE, AND SERIAL ORDER INFORMATION. 003711 04-17

SUBCUTANEOUS INJECTIONS OF APOMORPHINE, STIMULUS
GENERALIZATION AND CONDITIONING: SERIOUS PITFALLS FOR THE
EXAMINER USING APOMORPHINE AS A TOOL.

000341 01-04

SEROTOMERGIC A SEROTONERGIC, MIDBRAIN RAPHE MODEL OF TONIC IMMOBILITY

000291 01-03 ANTIDROMICALLY IDENTIFIED SEROTONERGIC NEURONS IN THE RAT MIDBRAIN RAPHE: EVIDENCE FOR COLLATERAL INHIBITION.

000292 01-03 EFFECT OF BENZODIAZEPINES ON CENTRAL SEROTONERGIC NEURON

000418 01-04 A ROLE FOR CENTRAL SEROTONERGIC SYSTEMS IN THE PATTERN AND INTENSITY OF THE CONVULSIVE RESPONSE OF RATS TO

ELECTROSHOCK. O01067 02-03
SELECTIVITY OF H3-BIOGENIC AMINE RELEASE BY D,L AMPHETAMINE

AND DRUGS THAT INTERACT WITH SEROTONERGIC NEURONS 001161 02-03 SENSITIVITY TO PSYCHOACTIVE DRUGS AND THE SEROTONERGIC NEURONAL SYSTEM.

001302 02-04 SEROTONERGIC BASIS OF REWARD IN MEDIAN RAPHE OF THE RAT 001421 02-04

BLOCKADE OF P-METHOXYAMPHETAMINE-INDUCED SEROTONERGIC EFFECTS BY CHLORIMIPRAMINE. 002166 03-03

CLINICAL TRIAL OF FLUVOXAMINE: A NEW SEROTONERGIC ANTIDEPRESSANT.

002470 03-09 LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO P-CHLOROAMPHETAMINE ON CENTRAL SEROTONERGIC MECHANISMS IN

003098 04-03 ROLE OF HYPOTHALAMIC SEROTONERGIC RECEPTORS IN THE CONTROL OF LORDOSIS BEHAVIOR IN THE FEMALE RAT

003220 04-04 PHARMACOLOGICAL, BEHAVIORAL AND NEUROCHEMICAL ASSESSMENT
OF THE SELECTIVITY OF THE DESTRUCTION OF CENTRAL SEROTONERGIC
AND CATECHOLAMIRERGIC MECHANISMS BY 6 HYDROXYDOPAMINE
AND 5,6 DIHYDROXYTRYPTAMINE IN THE MOUSE. (PH.D. DISSERTATION).

A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS.

CENTRAL TRYPTAMINERGIC EFFECTS OF 26-059. A NOVEL SEROTONIN

000036 01-02

BRAIN SEROTONIN TURNOVER AND MORPHINE-TOLERANCE DEPENDENCE INDUCED BY MULTIPLE INJECTIONS IN THE RAT. 000055 01-03 EFFECTS OF RESERPINE AND IMIPRAMINE ON VESICULAR SEROTONIN UPTAKE AND STORAGE IN INTACT HUMAN PLATELETS.

000081 01-03 ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEDOMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR.

COMPARISON OF THE EFFECTS OF 6 CHLORO-2-AMINOTETRALIN AND OF ORG-6582, A RELATED CHLOROAMPHETAMINE ANALOG, ON BRAIN SEROTONIN METABOLISM IN RATS.

000114 01-03

SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION: A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL MEMBRANES FROM MATURE RAT BRAIN. 000230 01-03

SEROTONIN TRANSPORT AND STORAGE IN RABBIT BLOOD PLATELETS THE EFFECTS OF RESERPINE AND IMIPRAMINE. 000236 01-03

EFFECTS OF RESERPINE AND SEROTONIN ON ADENINE-NUCLEOTIDE METABOLISM AND GLUCOSE OXIDATION OF WASHED RABBIT PLATELETS.

000237 01-03 THE BLOCKADE OF SEROTONIN UPTAKE INTO SYNAPTOSOMES:
RELATIONSHIP TO AN INTERACTION WITH MONOAMINE-OXIDASE INHIBITORS.

000268 01-03

000743 01-13

EFFECTS OF PHENCYCLIDINE ON (3H)CATECHOLAMINE AND (3H)SEROTONIN UPTAKE IN SYNAPTOSOMAL PREPARATIONS FROM

000273 01-03
REVERSIBLE AND IRREVERSIBLE EFFECTS OF P-CHLOROAMPHETAMINE ON BRAIN SEROTONIN IN MICE.

EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON SEROTONIN UPTAKE INTO RAT HYPOTHALAMIC SYNAPTOSOMES.

SEROTONIN REDUCTION EARLY IN LIFE AND ITS EFFECTS ON BEHAVIOR. 000383 01-04

EFFECTS OF REDUCED CEREBRAL SEROTONIN ON LEARNING

000422 01-04 STUDIES OF SEROTONIN TURNOVER IN DISCRETE NUCLEI USING HPLC.

000500 01-06 EFFECTS OF ANTIMYCIN A PLUS 2 DEOXYGLUCOSE ON UPTAKE AND VESICULAR STORAGE OF SEROTONIN IN HUMAN PLATELETS. (UNPUBLISHED PAPER).

000694 01-13

NEW EVIDENCE OF SEROTONIN DEFICIENT DEPRESSIONS.

THE ELECTRONIC AND SEROTONIN RECEPTOR BINDING AFFINITY PROPERTIES OF N,N DIMETHYLTRYPTAMINE ANALOGS

GAS-CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY OF SEROTONIN IN RAT SUPERIOR CERVICAL GANGLIA: EFFECTS OF NERVE GROWTH FACTOR AND 6 HYDROXYDDPAMINE.

001006 02-01 EFFECT OF MIANSERIN ON BRAIN SEROTONIN TURNOVER IN MICI

001057 02-03 PREFERENTIAL ACTION OF 5 METHOXYTRYPTAMINE AND 5
METHOXYDIMETHYLTRYPTAMINE ON PRESYNAPTIC SEROTONIN
RECEPTORS: A COMPARATIVE IONTOPHORETIC STUDY WITH LSD AND
SEROTONIN.

001095 02-03 ANALGESIC BRAIN STIMULATION IN THE CAT: EFFECT OF INTRAVENTRICULAR SEROTONIN, NOREPINEPHRINE, AND DOPAMINE.

001101 02-03 VESICULAR AND JUXTAVESICULAR SEROTONIN: EFFECTS OF LYSERGIC-ACID-DIETHYLAMIDE AND RESERPINE.

THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS.

001150 02-03 BRAIN NEUROTRANSMITTER RECEPTORS AFTER LONG-TERM HALOPERIDOL: DOPAMINE, ACETYLCHOLINE, SEROTONIN, ALPHA-NORADRENERGIC AND NALOXONE RECEPTORS.

001200 02-03 THE EFFECT OF ABLATION OF SEROTONIN OR NOREPINEPHRINE BRAINSTEM AREAS ON HALOTHANE AND CYCLOPROPANE MAC IN RATS. (UNPUBLISHED PAPER). 001229 02-03 THE ROLE OF HYPOTHALAMIC SEROTONIN (5-HT) BEFORE OVULATION IN IMMATURE RATS TREATED WITH PREGNANT MARE SERUM (PMS). 001287 02-03

SPECIFICITY OF AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE AND SEROTONIN FROM RAT BRAIN IN VITRO. 001294 02-03

CORRELATED EFFECT OF CORTICOSTERONE ON HYPOTHALAMIC SEROTONIN AND AVOIDANCE BEHAVIOUR IN RATS.

ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS.

001672 02-13 FLUOXETINE, A SEROTONIN UPTAKE INHIBITOR, IN NORMAL HUMAN

SELECTIVE INHIBITION OF NORADRENALINE AND SEROTONIN UPTAKE BY C-49802-B-BA AND CGP-6085-A.

001960 03-02

EFFECTS OF FENFLURAMINE AND NORFENFLURAMINE ON BRAIN SEROTONIN METABOLISM IN RATS.

002016 03-03 IMPORTANCE OF DURATION OF DRUG ACTION IN THE ANTAGONISM OF P-CHLOROAMPHETAMINE DEPLETION OF BRAIN SEROTONIN --COMPARISON OF FLUOXETINE AND CHLORIMIPRAMINE.

002017 03-03 RAT BRAIN ARYLACYLAMIDASE: MULTIPLE FORMS AND INHIBITION EFFECTS OF LSD, SEROTONIN AND RELATED COMPOUNDS

002044 03-03 THE EFFECT OF SEROTONIN PRECURSORS ON ALPHA-MOTONEURON AND GAMMA-MOTONEURON ACTIVITY.

002107 03-03 THE EFFECT OF LITHIUM ON SEROTONIN METABOLISM IN THE BRAIN OF RATS WITH PARTICULAR ATTENTION TO ITS EFFECT UNDER THE MONOAMINE ALTERED CONDITIONS.

002110 03-03 EFFECT OF FLUDIAZEPAM ON TURNOVER OF SEROTONIN IN MOUSE

THE EFFECTS OF PICROTOXIN AND PENTYLENETETRAZOL IN THE DIURNAL RHYTHMS OF CATECHOLAMINES AND SEROTONIN IN THE RAT BRAIN. 002123 03-03

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS.

DIFFERENTIAL EFFECTS OF SUBCORTICAL LYSERGIC-ACID-DIETHYLAMIDE AND SEROTONIN ON VISUAL CORTICAL EVOKED-POTENTIALS. 002163 03-03

ALTERATIONS IN MORPHINE ANALGESIA PRODUCED BY CHRONIC
DEFICITS OF BRAIN CATECHOLAMINES OR SEROTONIN: ROLE OF
ANALGESIMETRIC PROCEDURE.

THE ROLE OF SEROTONIN ANTAGONISM IN THE TREMORGENIC ACTION OF BUFOTENINE IN MICE.

002236 03-04 THE INFLUENCE OF HISTAMINE ON METABOLISM OF DOPAMINE AND SEROTONIN IN THE RAT STRIATUM.

DECREASED LOCOMOTOR ACTIVITY AND ATTENUATION OF AMPHETAMINE HYPERACTIVITY WITH INTRAVENTRICULAR INFUSION OF SEROTONIN IN THE RAT.

7, N, N TRIMETHYLTRYPTAMINE: A SELECTIVE INHIBITOR OF SYNAPTOSOMAL SEROTONIN UPTAKE.

ALTERATIONS OF CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC-ACID, AND TOTAL BLOOD SEROTONIN CONTENT DURING CLOZAPINE TREATMENT.

002545 03-13 THE BINDING OF INHIBITORS OF SEROTONIN UPTAKE TO BIOLOGICAL RECEPTORS

002562 03-13 EFFECT OF ANTIDEPRESSANTS ON THE ABSORPTION OF SEROTONIN BY HUMAN THROMBOCYTES.

002586 03-13 EFFECT OF CANNABINOIDS ON THE UPTAKE OF SEROTONIN IN HUMAN PLATELETS

002603 03-13 STIMULATION OF ADENYLATE-CYCLASE ACTIVITY IN MONKEY ANTERIOR LIMBIC CORTEX BY SEROTONIN.

002805 04-03 EFFECTS OF P-CHLOROAMPHETAMINE ON BRAIN SEROTONIN IN IMMATURE RATS.

002866 04-03 ROLE OF SEROTONIN REUPTAKE INHIBITION IN THE DEVELOPMENT OF SUBSENSITIVITY OF THE NOREPINEPHRINE (NE) RECEPTOR COUPLED ADENYLATE-CYCLASE SYSTEM.

CENTRAL MECHANISMS OF DRUGS AS DISCRIMINATIVE STIMULI:
INVOLVEMENT OF SEROTONIN PATHWAYS.

003070 04-03
INHIBITION OF REM SLEEP BY FLUOXETINE, A SPECIFIC INHIBITOR OF
SEROTONIN UPTAKE.

003095 04-03

POSSIBLE ROLE OF BRAIN SEROTONIN IN THE CENTRAL EFFECTS OF KETAMINE. 003123 04-03 INCREASED TILT-CAGE ACTIVITY AFTER SEROTONIN DEPLETION BY 5,7

DIHYDROXYTRYPTAMINE.

003279 04-04

COMPARISON OF THE BEHAVIORAL EFFECTS OF P-CHLOROAMPHETAMINE,
CHLORDIMEFORM, QUIPAZINE, AND INTRAVENTRICULAR SEROTONIN

L 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONUS IN GUINEA-PIGS: A
MODEL FOR THE STUDY OF CENTRAL SEROTONIN DOPAMINE
INTERACTIONS.

EFFECT OF QUIPAZINE, A SEROTONIN-LIKE DRUG, ON STRIATAL CHOLINERGIC INTERNEURONES.

SEROTONINERGIC

DECREASE OF FOOD INTAKE BY QUIPAZINE IN THE RAT: RELATION TO SEROTONINERGIC RECEPTOR STIMULATION.

001235 02-03
TRYPTAMINE-INDUCED DRUG EFFECTS INSENSITIVE TO SEROTONINERGIC
ANTAGONISTS: EVIDENCE OF SPECIFIC TRYPTAMINERGIC RECEPTOR
STIMULATION?

O03057 04-03

EVIDENCE OF AN INTERACTION BETWEEN SEROTONINERGIC AND
CHOLINERGIC NEURONS IN THE CORPUS-STRIATUM AND HIPPOCAMPUS
OF THE RAT BRAIN

HIGH-AFFINITY H3-SEROTONIN BINDING TO CAUDATE: INHIBITION BY HALLUCINOGENS AND SEROTONINERGIC DRUGS.

DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: A VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIATION OF CATECHOLAMINERGIC AND SEROTONINERGIC TERMINALS IN RAT CEREBRAL STRUCTURES.

SERUM

INHIBITORY EFFECT OF MORPHINE ON SERUM GONADOTROPINS AND PROLACTIN OF PROESTROUS RATS.

003423 04-06

000206 01-03
CONCENTRATION OF CLONAZEPAM IN SERUM AND CEREBROSPINAL
FLUID OF THE SHEEP

000215 01-03

EFFECTS OF AMPHETAMINE, METHYLPHENIDATE AND COCAINE ON
SERUM PROLACTIN CONCENTRATIONS IN THE MALE RAT.

THE BLOOD (SERUM AND CORPUSCLE) DYNAMICS OF TRICYCLIC ANTIDEPRESSANTS.

000556 01-09
INTERACTIONS OF NARCOTICS AND THEIR ANTAGONISTS WITH HUMAN
SERUM ESTERASE. VI: THE BEHAVIOR OF 14 HYDROXYLATED
MORPHINE DERIVATIVES.

000690 01-13
LACK OF EFFECT OF CLONAZEPAM ON SERUM LEVELS OF
DIPHENYLHYDANTOIN, PHENOBARBITAL AND CARBAMAZEPINE.

000705 01-13
BINDING OF CODEINE, MORPHINE, AND METHADONE TO HUMAN SERUM PROTEINS.

PLASMA ALDOSTERONE AND MAGNESIUM IN SERUM AND URINE DURING LITHIUM TREATMENT

000725 01-13

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON SERUM THYROXINE
CONCENTRATIONS IN THE RAT.

001204 02-03
THE ROLE OF HYPOTHALAMIC SEROTONIN (5-HT) BEFORE OVULATION IN
IMMATURE RATS TREATED WITH PREGNANT MARE SERUM (PMS).
001287 02-03

NEUROMETABOLIC AND BEHAVIOURAL EFFECTS OF HALOPERIDOL IN RELATION TO DRUG LEVELS IN SERUM AND BRAIN.

001430 02-04

AN EVALUATION OF A UNIQUE NEW ANTIPSYCHOTIC AGENT, SULPIRIDE: EFFECTS ON SERUM PROLACTIN AND GROWTH HORMONE LEVELS. 001554 02-07

SERUM GONADOTROPIN AND TSH LEVELS AFTER TRICYCLIC ANTIDEPRESSANTS IN HEALTHY MALES.

STEADY-STATE SERUM CONCENTRATIONS OF DOTHIEPIN AND NORTHIADEN AFTER TWO DOSAGE REGIMENS OF DOTHIEPIN HYDROCHLORIDE (PROTHIADEN).

DAILY CHANGES IN THE BLOOD SERUM LEVELS OF DIPHENYLHYDANTOIN (DPH) AND PHENOBARBITAL.

(DPH) AND PHENOBARBITAL.

001830 02-15
HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF
DOTHIEPIN AND NORTHIADEN IN HUMAN PLASMA AND SERUM.
001858 02-16

EFFECTS OF PARGYLINE ON HYPOTHALAMIC BIOGENIC AMINES AND SERUM PROLACTIN (PRL), LH AND TSH IN MALE RATS.

BRAIN: SERUM AND CSF: SERUM RATIOS AFTER A SINGLE DOSE OF DIPROPYLACETIC-ACID (DPA)

OO2168 03-03
INFLUENCE OF EXTRAPYRAMIDAL DISTURBANCES DUE TO HALOPERIDOL
ON PHENAMINE STEREOTYPY AND THE EFFECTS OF SCHIZOPHRENIC
BLOOD SERUM (EXPERIMENTAL STUDIES).

SCREENING FOR THE EFFECTS OF DOPAMINERGIC AND ANTIDOPAMINERGIC DRUGS ON SERUM PROLACTIN LEVELS BY RADIOIMMUNOASSAY.

SERUM PROLACTIN AND ANTIPSYCHOTIC RESPONSES TO PIMOZIDE IN

THE EFFECT OF DEPRESSION AND ITS TREATMENT ON SERUM THYROXINE.
002436 03-09
EFFECTS OF DISULFIRAM AND PYRIDOXINE ON SERUM CHOLESTEROL.

THE THIORIDAZINE LEVEL IN THE BLOOD SERUM AND SYMPTOMS OF THE PARANOID SYNDROME.

DECREASE IN SERUM PROLACTIN AFTER PROPRANOLOL IN

002558 03-13
BROMOCRIPTINE: EFFECT ON SERUM PROLACTIN AND GROWTH
HORMONE IN PSYCHOGERIATRIC HOSPITAL PATIENTS.

O02561 03-13
THE EFFECT OF NEUROLEPTICS AND ALPHA-METHYL-P-TYROSINE ON
SERUM PROLACTIN LEVELS IN LABORATORY ANIMALS AND MAN.
002582 03-13

ELEVATED MELATONIN SERUM CONCENTRATIONS IN PSYCHIATRIC PATIENTS TREATED WITH CHLORPROMAZINE.

COMPARATIVE EFFECTS OF PENFLURIDOL ON CIRCLING BEHAVIOR AND STRIATAL DOPAC AND SERUM PROLACTIN CONCENTRATIONS IN THE RAT.

EFFECT OF 6 METHOXYTETRAHYDRO-BETA-CARBOLINE ON SERUM
PROLACTIN LEVELS OF MALE RATS.

002903 04-03
INCREASE IN SERUM PROLACTIN BY EXOGENOUS AND ENDOGENOUS
OPIATES: EVIDENCE FOR ANTIDOPAMINE AND ANTIPSYCHOTIC
EFFECTS

002926 04-03
THE STABILITY AND RELIABILITY OF RADIOIMMUNOASSAYS FOR
CLONAZEPAM, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN BLOOD,
SERUIM OR PLASMA

003439 04-06
RELATIONSHIP BETWEEN SERUM CONCENTRATIONS OF THIORIDAZINE
AND ITS MAIN NONCONJUGATED METABOLITES AND THE CLINICAL
RESPONSE IN THIORIDAZINE TREATED PATIENTS.

O.33480 04-09

A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE
(SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS
(SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH
SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE
AND NORTRIPTYLINE.

SERVICES

THE MEDICATION CLINIC IN THE SPECTRUM OF CHILDRENS SERVICES.

000955 01-17

SERVICES FOR SCHIZOPHRENICS: A LIFELONG APPROACH TO

5ESAME-OIL
INFLUENCE OF FASTING ON THE ABSORPTION AND EFFECTS OF DELTA9TETRAHYDROCANNABINOL AFTER ORAL ADMINISTRATION IN SESAMEOIL

O00228 01-03
SETTINGS
THE ALPHA SPECTRUM IN SCHIZOPHRENIC PATIENTS DUE TO
PSYCHOPHARMACOLOGICAL TREATMENT AND DIFFERENT

SOCIOCULTURAL SETTINGS.

002636 03-14

SEX
INFLUENCES OF GENOTYPE AND SEX ON BEHAVIORAL TOLERANCE TO
NICOTINE IN MICE

SEX HORMONES AND EXHIBITIONISM. 000788 01-14

THE RISKS OF SEX HORMONES AS DRUGS.

002398 03-08

001675 02-13

A SEX DIFFERENCE IN THE INTERACTION BETWEEN PROMETHAZINE AND MORPHINE IN THE MOUSE. 001242 02-03 KINETICS OF INTRAVENOUS CHLORDIAZEPOXIDE: SEX DIFFERENCES IN 001665 02-13 SEX DIFFERENCES IN RESPONSE TO DRUG TREATMENT. TRICYCLIC PLASMA LEVELS: EFFECT OF AGE, RACE, SEX, AND SMOKING.
002472 03-09
THE DEVELOPMENT OF SEX DIFFERENCES IN THE DEMETHYLATION OF
ETHYLMORPHINE AND IN ITS INTERACTION WITH COMPONENTS OF THE
HEPATIC MICROSOMAL CYTOCHROME-P-450 SYSTEM IN MICE. 003122 04-03 ATTENUATION OF STEREOTYPED BEHAVIOUR BY SEX STEROIDS J03312 04-04 TARDIVE-DYSKINESIA: AGE AND SEX DIFFERENCES IN HOSPITALIZED SCHIZOPHRENICS. 003681 04-15 SEYUAL 5 HYDROXYTRYPTAMINE AND SEXUAL BEHAVIOUR 000357 01-04 MONOAMINERGIC IMPLICATION IN DIFFERENT ELEMENTS OF SEXUAL EVIDENCE AGAINST INVOLVEMENT OF ENDORPHINS IN SEXUAL AROUSAL AND ORGASM IN MAN. 000701 01-13 LORDOSIS REFLEX, SEXUAL RECEPTIVITY, AND FEEDING: ESTROGEN RESPONSIVITY IN MALE AND FEMALE RATS. 001327 02-04 POISON AVERSION AND SEXUAL BEHAVIOR IN THE GOLDEN HAMSTER. 001357 02-04 ENHANCEMENT OF SEXUAL BEHAVIOR IN THE FEMALE RAT BY NICOTINE. 001360 02-04 EFFECTS OF MORPHINE AND NALTREXONE ON SEXUAL BEHAVIOUR ON THE MALE RAT. INFLUENCE OF BETA-ENDORPHIN ON EXPLORATORY, SOCIAL AND SEXUAL BEHAVIOUR IN THE MALE RAT.

EFFECTS OF ANTIESTROGENS ON EATING, FEMALE SEXUAL BEHAVIOR, AND THE UPTAKE OF H3-ESTRADIOL IN THE CENTRAL-NERVOUS-SYSTEM IN RATS. (PH.D. DISSERTATION). 001447 02-04 PHARMACOLOGICAL AGENTS CAUSING SEXUAL DYSFUNCTION. 001829 02-15 EFFECTS OF CHLORDIAZEPOXIDE, OXAZEPAM, CHLORPROMAZINE, AND D AMPHETAMINE ON SEXUAL RESPONSES IN MALE AND FEMALE HAMSTERS.

002208 03-04

EFFECTS OF CLOMIPRAMINE AND OTHER INHIBITORS OF MONOAMINE

UPTAKE ON THE SEXUAL BEHAVIOUR OF FEMALE RATS AND RHESUS

MONKEYS. 002228 03-04 DIFFERENTIAL EFFECTS OF THE ANTIANDROGEN FLUTAMIDE ON ASPECTS
OF SEXUAL BEHAVIOR IN CASTRATED, ANDROGEN TREATED MALE

002237 03-04 EFFECTS OF CATECHOL ESTROGENS ON SEXUAL DIFFERENTIATION IN NEONATAL FEMALE RATS.

002293 03-04 PROBLEMS. USE OF MOOD-ALTERING DRUGS IN TREATING SEXUAL P

002780 03-17 SEXUAL DIFFERENTIATION OF OFFSPRING OF MOTHERS TREATED WITH CORTISONE DURING PREGNANCY.

002879 04-03 EFFECTS OF THE PROSTAGLANDIN SYNTHESIS INHIBITOR, INDOMETHACIN ON ESTROGEN AND ESTROGEN PLUS PROGESTERONE-INDUCED SEXUAL RECEPTIVITY IN OVARIECTOMIZED RATS. INDOMETHACIN

003237 04-04 AGIOTENSIN-INDUCED DRINKING: SEXUAL DIFFERENCES. 003385 04-04

PHARMACOLOGICAL TREATMENT OF DEVIANT SEXUAL BEHAVIOUR.
003552 04-11

IHIBITION OR WET SHAKES DURING MORPHINE ABSTINENCE BY AN ANTAGONIST OF OPIATE ANALGESIA. 003383 04-04

SHAM-FEEDING

EFFECT OF CHOLECYSTOKININ ON MEAL SIZE AND INTERMEAL INTERVAL
IN THE SHAM-FEEDING RAT.

003264 04-0 003264 04-04

SHAPING
OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF
REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR
OPERANT DRUG DISCRIMINATIONS.
003434 04 003434 04-06 CONCENTRATION OF CLONAZEPAM IN SERUM AND CEREBROSPINAL FLUID OF THE SHEEP.

CONDITIONED TASTE AVERSION: A FIELD APPLICATION TO COYOTE PREDATION ON SHEEP.

FEEDING BEHAVIOR OF SHEEP FOLLOWING INTRAVENOUS INJECTION OF IMIDAZOBENZODIAZEPINES.

THE UPTAKE OF S35-METHIMAZOLE BY SHEEP THYROID SLICES IN VITRO.

002193 03-04

003093 04-03

THE EFFECT OF BARBITURATE AND PROCAINE ON GLIAL AND NEURONAL CONTRIBUTIONS TO EVOKE CORTICAL STEADY POTENTIAL SHIFTS.

001219 02-03 SHOCK

TIME-DEPENDENT CHANGES IN ACTIVITY, REACTIVITY, AND RESPONSIVITY DURING SHOCK: EFFECTS OF CHOLINERGIC AND CATECHOLAMINERGIC MANIPULATIONS.

EFFECTS OF D AMPHETAMINE, CHLORDIAZEPOXIDE AND PROMAZINE ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION AND STIMULUS SHOCK TERMINATION.

PASSIVE AVOIDANCE LEARNING IN THE RAT AS FUNCTIONS OF D AMPHETAMINE DOSAGE AND SHOCK INTENSITY.

TRICYCLIC ANTIDEPRESSANT DRUGS: ANTAGONISM OF EFFECT OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON SHOCK ELICITED AGGRESSION.

001461 02-04 EFFECT OF SCOPOLAMINE ON RETENTION OF A SHOCK MOTIVATED BRIGHTNESS DISCRIMINATION IN RATS.

001487 02-04 PHARMACOLOGICAL MODIFICATION OF SHOCK POTENTIATED AMPHETAMINE LETHALITY.

EFFECTS OF INTRAVENOUS COCAINE, DIETHYLPROPION, D AMPHETAMINE AND PERPHENAZINE ON RESPONDING MAINTAINED BY FOOD DELIVERY AND SHOCK AVOIDANCE IN RHESUS MONKEYS.

A DOSE RATIO COMPARISON OF THE INTERACTION BETWEEN MORPHINE AND CYCLAZOCINE WITH NALOXONE IN RHESUS MONKEYS ON THE SHOCK TITRATION TASK.

002335 03-04

EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE DETECTION OF

003277 04-04 MORPHINE AND SHOCK DETECTION: EFFECTS ON SHOCK INTENSITY 003332 04-04

SHOCK-ELICITED
THYROTROPIN-RELEASING HORMONE (TRH): LACK OF EFFECT ON SHOCKELICITED FIGHTING (SEF) IN RATS.

003283 04-04 003283 04-04

EFFECTS OF BENZAZEPINE (SCH-12679) ON SHOCK-INDUCED FIGHTING AND LOCOMOTOR BEHAVIOR IN RATS.

PITUITARY ADRENOCORTICAL AXIS AND SHOCK-INDUCED FIGHTING IN 003342 04-04

EFFECTS OF APOMORPHINE AND CLONIDINE ON RAT PLASMA GROWTH HORMONE AFTER PRETREATMENT WITH RESERPINE AND ELECTROCONVULSIVE SHOCKS.

000102 01-03 SHORT-ACTING
ELECTROENCEPHALOGRAPHIC STUDY OF THE SHORT-ACTING HYPNOTICS
ETOMIDATE AND METHOREXITAL IN DOGS.

002177 03-03 SHORT-TERM

A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE SHORT-TERM EFFECTS OF CLOZAPINE UPON SLEEP PARAMETERS OF NORMAL YOUNG **ADULTS**

001734 02-14 SHORT-TERM MEMORY: A NEUROPHARMACOLOGICALLY DISTINCT **PROCESS**

EFFECTIVENESS OF TEMAZEPAM WITH SHORT-TERM, INTERMEDIATE-TERM. AND LONG-TERM USE: SLEEP LABORATORY EVALUATION. 002608 03-14

SHORT-TERM AND LONG-TERM EFFECTS OF CEREBROLYSINE ON EVOKED CORTICAL POTENTIALS IN RATS.

A POSSIBLE PHYSIOLOGICAL MECHANISM FOR SHORT-TERM MEMORY.
003227 04-04 HYPNOTIC EFFECTIVENESS OF SODIUM SALICYLAMIDE WITH SHORT-TERM USE: SLEEP LABORATORY STUDIES.

VOLUME 16, SUBJECT INDEX

A CASE OF DEPRESSION SHOWING IMPROVEMENT IN TRH TEST BY COMBINED TREATMENT BY DIMETACRINE-TARTRATE AND THYROID

003527 04-09

SHUTTLE-BOX DOSE-RESPONSE AND TIME-COURSE EFFECTS OF N,N
DIMETHYLTRYPTAMINE ON DISRUPTION OF RAT SHUTTLE-BOX

000457 01-04 ETORPHINE AND SHUTTLE-BOX SELF-STIMULATION IN THE RAT 001304 02-04 MORPHINE AND SHUTTLE-BOX SELF-STIMULATION IN THE RAT: A MODEL FOR EUPHORIA.

001401 02-04

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE (SIADH) SECONDARY TO ANTIPSYCHOTIC DRUG THERAPY. 003647 04-15

DYSARTHRIA: AN UNUSUAL SIDE-EFFECT OF TRICYCLIC ANTIDEPRESSANTS.

000885 01-15 SPECIFIC LOCALIZATION OF DRUGS AT THE HYPOPHYSIS LEVEL AND SIDE-**EFFECTS: THE CASE OF NEUROLEPTICS**

ANTIPSYCHOTIC EFFECTS, SIDE-EFFECTS AND EFFECTIVE DOSES OF THE BUTYROPHENONE LENPERONE (AHR-2277).

000553 01-08 AMP SYSTEM: LONGITUDINAL COURSE STUDIES OF PSYCHOPATHOLOGIC AND SOMATIC SYMPTOMS. AN EMPIRIC INVESTIGATION OF THE PROBLEM OF SIDE-EFFECTS.

000797 01-15
EXTRAPYRAMIDAL SIDE-EFFECTS OF METOCLOPRAMIDE (CERUCAL) USED IN COMBINATION WITH AN ANTIDEPRESSANT.

000832 01-15 NEUROLEPTIC SIDE-EFFECTS OF CHLORPROMAZINE IN PSYCHOPHARMACOLOGICAL RESEARCH

000895 01-15 SIDE-EFFECTS OF SIMULTANEOUS ALCOHOL AND MARIJUANA USE. 000900 01-15

SIDE-EFFECTS OF CHLORPROMAZINE IN RELATION TO CIGARETTE SMOKING

000902 01-15 EXTRAPYRAMIDAL SIDE-EFFECTS IN CHLORPROMAZINE RECIPIENTS.
000903 01-15

CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE ANTIPSYCHOTIC DRUGS

001526 02-06 THE PHARMACOKINETICS OF RED BLOOD CELL AND PLASMA BUTAPERAZINE CLINICAL RESPONSE AND SIDE-EFFECTS

001561 02-08 PLASMA FENFLURAMINE LEVELS, WEIGHT LOSS, AND SIDE-EFFECTS 001790 02-15

PSYCHOLOGICAL SIDE-EFFECTS OF L-DOPA AND ANTICONVULSANT MEDICATION.

001801 02-15 BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS: ASSAY PROCEDURES, REPRODUCIBILITY AND RELATIONSHIP TO THERAPEUTIC OUTCOME AND SIDE-EFFECTS.

EFFICACY, SIDE-EFFECTS, PLASMA AND BLOOD LEVELS OF MAPROTILINE (LUDIOMIL).

CONTRIBUTION OF THE USE OF 1035MD IN A PSYCHIATRIC WARD FOR ADULTS, ITS ACTIVITY ON THE DIRECT AND SIDE-EFFECTS OF

003446 04-07 A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR

NEUROLEPTICS

003657 04-15 ON THE ROLE OF HEMISPHERIC DOMINANCE IN SCHIZOPHRENIA AS MEASURED BY EXTRAPYRAMIDAL SIDE-EFFECTS OF NEUROLEPTICS. 003675 04-15

FAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS UNDER LONG-TERM TRAINING.

000034 01-02 FACILITATION OF SIDMAN AVOIDANCE PERFORMANCE BY CHLOROAMPHETAMINE: ROLE OF BIOGENIC AMINES.

001467 02-04 THE EFFECTS OF STIMULATION AND DEPRESSION OF THE RETICULOENDOTHELIAL SYSTEM ON SIDMAN AVOIDANCE BEHAVIOR (PH.D. DISSERTATION). 001468 02-04 Subject Index

003269 04-04

EFFECT OF BACLOFEN (BF) (LIORESAL (R) ON DOPAMINERGIC SINGLE UNITS AND SIDMAN AVOIDANCE BEHAVIOR

002300 03-04 TOLERANCE TO P-CHLOROAMPHETAMINES EFFECTS ON SIDMAN AVOIDANCE PERFORMANCE AND CATECHOLAMINE METABOLISM 002314 03-04

PSYCHOTROPIC DRUGS AND SIDMAN AVOIDANCE IN RATS: IRT DISTRIBUTION CHANGES

SIGN ABSENCE OF DRUG-INDUCED BETA-ACTIVITY IN THE

ELECTROENCEPHALOGRAM: A SIGN OF SEVERE CEREBRAL 001676 02-13

SIGNALS MULTIVARIATE ANALYSIS OF DRUG EFFECTS ON ELECTROPHYSIOLOGICAL SIGNALS IN MAN

003688 04-16 SIGNIFICANCE POSSIBLE SIGNIFICANCE OF CLOZAPINE-INDUCED INCREASE IN BRAIN DOPAMINE

POSSIBLE SIGNIFICANCE OF ACTH FRAGMENTS FOR HUMAN MENTAL PERFORMANCE.

000465 01-04 POSSIBLE PHYSIOLOGICAL SIGNIFICANCE OF THE INITIAL STEP IN THE CATABOLISM OF NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM

001117 02-03 CHLORPROMAZINE-INDUCED CHANGES IN BLOOD
ADENOSINEPHOSPHORIC-ACIDS: TO THEIR DIAGNOSTIC SIGNIFICANCE IN PSYCHIATRY

001861 02-16 ETHANOL AND DISPOSITION OF AMYLOBARBITONE: EFFECT OF DOSE AND SIGNIFICANCE AS A MECHANISM FOR INCREASED TOXICITY

003114 04-03 THE PRACTICAL SIGNIFICANCE OF NORTRIPTYLINE PLASMA CONTROL. A PROSPECTIVE EVALUATION UNDER ROUTINE CONDITIONS IN ENDOGENOUS DEPRESSION.

003522 04-09

CONTROL OF THE RAT OLFACTORY BULB ACTIVITY INDUCED BY BIOLOGICALLY SIGNIFICANT ODORS.

001324 02-04 DOPAMINE ANTAGONIST BINDING: A SIGNIFICANT DECREASE WITH MORPHINE-DEPENDENCE IN THE RAT STRIATUM.

003052 04-03 SIGNS CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT RHESUS MONKEYS

001296 02-04 OPIATE WITHDRAWAL SIGNS IN SINGLE MYENTERIC NEURONES 002118 03-03

NALOXONE-INDUCED OR POSTWITHDRAWAL ABSTINENCE SIGNS IN DELTA9-TETRAHYDROCANNABINOL-TOLERANT RATS.

002257 03-04 CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT RHESUS MONKEYS.

003152 04-04 SILENT DEPRESSION -- THE SILENT SCREAM.

001593 02-09

A SLOW-RELEASE SILICONE PELLET FOR CHRONIC AMPHETAMINE ADMINISTRATION. 001529 02-06

SIMILARITIES EFFECTS OF MAZINDOL, FENFLURAMINE AND CHLORIMIPRAMINE ON THE 5 HYDROXYTRYPTAMINE UPTAKE AND STORAGE MECHANISMS IN RAT BRAIN: SIMILARITIES AND DIFFERENCES.

SIMILARITIES AND DIFFERENCES IN DISCRIMINATIVE STIMULUS EFFECTS
OF CHLORDIAZEPOXIDE, PENTOBARBITAL, ETHANOL, AND OTHER

003163 04-04 SIMPLE

A RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF BIOLOGICAL FLUID OR TISSUE. 000496 01-06

THE PNEUMATIC SYRINGE: A SIMPLE APPARATUS FOR SELFADMINISTRATION OF DRUGS BY RATS.

001541 02-06 A SIMPLE AND SENSITIVE RADIORECEPTOR ASSAY FOR ANTISCHIZOPHRENIC DRUGS IN BLOOD

O02715 03-16
A SIMPLE METHOD FOR THE DETERMINATION OF THERAPEUTIC LEVELS OF CLOMIPRAMINE, IMIPRAMINE AND DESIPRAMINE 002717 03-16

SIMULATION

COMPUTER SIMULATION OF THE MOVEMENT OF LITHIUM ACROSS ERYTHROCYTE MEMBRANES IN VITRO. 001869 02-16

SIMULTANEOUSLY
EFFECTS OF D AMPHETAMINE ON RESPONDING SIMULTANEOUSLY
MAINTAINED AND PUNISHED BY PRESENTATION OF ELECTRIC-SHOCK 000317 01-04

A DOUBLE-BLIND COMPARISON OF LEVODOPA, MADOPA, AND SINEMET IN PARKINSON DISEASE. 003556 04-11

SINFOUAN

EXPERIENCE WITH SINEQUAN IN A SINGLE EVENING DOSE. 000609 01-10

STEREOSPECIFIC ACTIONS OF MORPHINE ON SINGLE NEURONES IN THE BRAINSTEM OF THE RAT.

000060 01-03 DEVELOPMENT AND DISAPPEARANCE OF SUBSENSITIVITY TO PILOCARPINE FOLLOWING A SINGLE ADMINISTRATION OF THE IRREVERSIBLE ANTICHOLINESTERASE AGENT, DFP.

000212 01-03 A RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF BIOLOGICAL FLUID OR TISSUE.

000496 01-06 PHARMACOKINETICS OF METHYLPHENIDATE IN THE RAT USING SINGLE ION MONITORING GLC MASS SPECTROMETRY.

000498 01-06

EFFECTS OF KETAMINE ON PATIENT RESPONSIVENESS DURING THE VARIOUS PHASES OF A SINGLE INDUCED ANXIETY SESSION. 000513 01-07

SINGLE AND DIVIDED DOSE OF IMIPRAMINE 000595 01-10

"ERIENCE WITH SINEQUAN IN A SINGLE EVENING DOSE. 000609 01-10 RATE OF ABSORPTION AND CLINICAL RESPONSE TO SINGLE ORAL DOSES

OF CHLORDIAZEPOXIDE 000702 01-13

HARMACOKINETICS OF N DESMETHYLDIAZEPAM IN HEALTHY VOLUNTEERS AFTER SINGLE DAILY DOSES OF DIPOTASSIUM CHLORAZEPATE.

000728 01-13 DISPOSITION OF THREE BENZODIAZEPINES AFTER SINGLE ORAL ADMINISTRATION IN MAN.

000745 01-13 EEG PROFILE AND BEHAVIORAL CHANGES AFTER A SINGLE DOSE OF CLOZAPINE IN NORMALS AND SCHIZOPHRENICS.

000787 01-14 PHOTODYNAMIC ACTION OF CHLORPROMAZINE ON ADENOVIRUS 5: REPAIRABLE DAMAGE AND SINGLE STRAND BREAKS.

000B21 01-15 DELAYED ONSET OF SINGLE DOSE TOLERANCE TO MORPHINE ANALGESIA

001089 02-03 EFFECTS OF NALOXONE FOLLOWING A SINGLE ADMINISTRATION OF LEVORPHANOL-TARTRATE IN THE NAIVE RAT.

001110 02-03 SINGLE VERSUS DIVIDED DOSES OF SINTAMIL IN DEPRESSION. 001543 02-07

A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF DOTHIEPIN AND ITS THERAPEUTIC EFFECTIVENESS.

001604 02-09 EFFECTS OF MYSOLINE AND DILANTIN ON THE EEG DURING SMR BIOFEEDBACK TRAINING OF A PSYCHOMOTOR EPILEPTIC: SINGLE CASE

001657 02-13 DESIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF DIVIDED VS SINGLE DOSE ADMINISTRATION.

001855 02-16 NEUROCHEMICAL MECHANISMS OF CENTRAL ACTION OF MORPHINE ON FUNCTIONS OF SINGLE NEURONS IN THE MIDBRAIN RETICULAR FORMATION

001973 03-03 EFFECTS OF MORPHINE ON ELECTRICAL ACTIVITY OF SINGLE MYENTERIC NEURONS IN CAT SMALL BOWEL.

002009 03-03 INCORPORATION, AFTER SINGLE AND REPEATED APPLICATION OF RADIOACTIVE LABELLED DH-ERGOT ALKALOIDS IN DIFFERENT ORGANS OF THE CAT, WITH SPECIAL REFERENCE TO THE BRAIN.

002047 03-03 **OPIATE WITHDRAWAL SIGNS IN SINGLE MYENTERIC NEURONES** 002118 03-03 BRAIN: SERUM AND CSF: SERUM RATIOS AFTER A SINGLE DOSE OF DIPROPYLACETIC-ACID (DPA),

002168 03-03 EFFECT OF BACLOFEN (BF) (LIORESAL (R) ON DOPAMINERGIC SINGLE UNITS AND SIDMAN AVOIDANCE BEHAVIOR.

002300 03-04

Psychopharmacology Abstracts

DIFFERENTIAL EFFECTS OF A SINGLE DOSE OF IMIPRAMINE AND LOPRAMINE IN HEALTHY SUBJECTS VARYING IN THEIR LEVEL OF DEPRESSION.

002446 03-09 TRIMIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF SINGLE VS. DIVIDED DOSE ADMINISTRATION.

THE TREATMENT OF DEPRESSION COMPARING DIVIDED AND SINGLE DOSES OF MAPROTILINE (LUDIOMIL).

002467 03-09 STRENGTH DURATION PROPERTIES OF SINGLE UNITS DRIVEN BY ELECTRICAL STIMULATION OF THE LATERAL HYPOTHALAMUS IN RATS

002763 03-17 EFFECTS OF SINGLE AND MULTIPLE DOSES OF DESIPRAMINE (DMI) ON ENDOGENOUS LEVELS OF 3 METHOXY-4-HYDROXYPHENYLGLYCOL-SULFATE (MOPEG-SO4) IN RAT BRAIN.

EFFECT OF MORPHINE INJECTED IN PERIAQUEDUCTAL GRAY ON THE ACTIVITY OF SINGLE UNITS IN NUCLEUS RAPHE MAGNUS OF THE RAT

COMPARISON OF THE RESPONSES OF SINGLE CORTICAL NEURONES TO TYRAMINE AND NORADRENALINE: EFFECTS OF DESIPRAMINE.

002821 04-03 RESPONSES OF SINGLE CORTICAL NEURONES TO NORADRENALINE AND DOPAMINE.

002822 04-03 SELECTIVE PURIFICATION OF A SINGLE POPULATION OF GLUCOCORTICOID RECEPTORS FROM RAT BRAIN.

002887 04-03 MURICIDE INDUCED BY SINGLE INJECTION OF DELTA9-TETRAHYDROCANNABINOL.

003226 04-04 A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-

003537 04-10 EFFECTS OF SINGLE DOSES OF TRANYLCYPROMINE ON PLATELET MAD AND AMINE UPTAKE IN NORMAL SUBJECTS.

003594 04-13 SINGLE CASE STUDY. CATATONIA ASSOCIATED WITH DISULFIRAM

003677 04-15

SINGLE-BLIND
SINGLE-BLIND EVALUATION OF HYPNOTIC ACTIVITY OF
CHLORDESMETHYLDIAZEPAM IN NO-PLACEBO REACTOR MEDICAL

002379 03-07

METHODOLOGICAL EXPERIENCE WITH A DOUBLE-BLIND MULTICENTRIC, MONITORED CLINICAL TRIAL (MMCT) WITH SINTAMIL.

000568 01-09 SINGLE VERSUS DIVIDED DOSES OF SINTAMIL IN DEPRESSION 001543 02-07

THE DEMONSTRATION IN VIVO OF SPECIFIC BINDING SITES FOR NEUROLEPTIC DRUGS IN MOUSE BRAIN.

SITES OF ACTION OF MORPHINE INVOLVED IN THE DEVELOPMENT OF PHYSICAL DEPENDENCE IN RATS: III. AUTORADIOGRAPHIC STUDIES 000177 01-03

CENTRAL SITES AND MECHANISMS OF THE HYPOTENSIVE AND BRADYCARDIC EFFECTS OF THE NARCOTIC ANALGESIC AGENT FENTANYI

000179 01-03 NEUROLEPTIC DRUG INTERACTIONS WITH NOREPINEPHRINE ALPHA RECEPTOR BINDING SITES IN RAT BRAIN

000219 01-03 ANTISCHIZOPHRENIC DRUGS -- MEMBRANE RECEPTOR SITES OF ACTION. 000547 01-08 MULTIPLE BRAIN SITES INVOLVED IN MORPHINE ANTIMOCICEPTION

001270 02-03 CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIVITY TO THE DIRECT APPLICATION OF MORPHINE AND FOCAL ELECTRICAL STIMULATION IN THE PRODUCTION OF ANTINOCICEPTION IN THE RAT.

EFFECTS OF OPIATES AND OPIOID PEPTIDES ON MOTOR BEHAVIORS: SITES AND MECHANISMS OF ACTION. (UNPUBLISHED PAPER).

001433 02-04 EVIDENCE FOR THE EXISTENCE OF SPECIFIC CANNABINOID BINDING SITES. 002034 03-03 **AUTORADIOGRAPHIC LOCALIZATION OF H3-RESERPINE BINDING SITES IN**

RAT BRAIN. 002106 03-03

TWO BINDING SITES FOR H3-SPIROPERIDOL ON RAT STRIATAL MEMBRANES.

002843 04-03 SOLUBILIZATION OF H3-SPIPERONE BINDING SITES FROM RAT BRAIN 002929 04-03 DEMONSTRATION OF NEUROLEPTIC RECEPTOR SITES IN MOUSE BRAIN BY AUTORADIOGRAPHY.

CHRONIC NALOXONE RESULTS IN PROLONGED INCREASES IN OPIATE
RINDING SITES IN REALN

H3-SPIROPERIDOL BINDING TO TWO RECEPTOR SITES IN BOTH THE CORPUS-STRIATUM AND FRONTAL CORTEX OF RAT BRAIN.

HETEROGENEITY OF LSD DISPLACING FACTORS AND MULTIPLE TYPES OF HIGH AFFINITY LSD BINDING SITES.

SELECTIVE LABELING OF PRESYNAPTIC RECEPTORS BY H3-ODPAMINE, H3-APOMORPHINE AND H3-CLONIDINE; LABELING OF POSTSYNAPTIC SITES BY H3-NEUROLEPTICS.

O03117 04-03
TRICYCLIC ANTIDEPRESSANTS: THERAPEUTIC PROPERTIES AND AFFINITY
FOR ALPHA-NORADRENERGIC RECEPTOR BINDING SITES IN THE BRAIN.

DISULFIRAM ALTERS DOPAMINE METABOLISM AT SITES IN RATS FOREBRAIN AS DETECTED BY PUSH-PULL PERFUSIONS.

003134 04-03

SITUATION

BRAIN STIMULATION PROVOKED EMOTIONAL REACTIONS OF CATS IN A SOCIAL SITUATION.

PSYCHOTROPIC DRUG EFFECTS ON THE EMOTIONAL STATE OF CATS IN A SOCIAL SITUATION.

SELF-REPORTED ALCOHOL AND NICOTINE USE AND THE ABILITY TO CONTROL OCCIPITAL EEG IN A BIOFEEDBACK SITUATION.

003622 04-14

SITUATIONAL FACTORS CONTRIBUTING TO THE PLACEBO EFFECT.

O03714 04-17
SIZE
THE METABOLIC FATE OF C14-PHENOBARBITONE IN THE RAT AND THE

EFFECT OF CHRONIC ADMINISTRATION AND DOSE SIZE.

000067 01-03

INTERACTION OF ARENA SIZE WITH DIFFERENT MEASURES OF
AMPHETAMINE EFFECTS.

PROGRESSIVE FORCE SCHEDULES IN THE SQUIRREL-MONKEY: EFFECTS OF INCREMENT SIZE, AMPHETAMINE, AND HALOPERIDOL. (PH.D.

001459 02-04

EFFECT OF CHOLECYSTOKININ ON MEAL SIZE AND INTERMEAL INTERVAL
IN THE SHAM-FEEDING RAT.

O03264 04-04
CAN CIGARETTE SIZE AND NICOTINE CONTENT INFLUENCE SMOKING AND PUFFING RATES?

003631 04-14

COLCHICINE BLOCKS NEUROTROPIC REGULATION OF THE RESTING MEMBRANE POTENTIAL IN REINNERVATING SKELETAL MUSCLE. 000262 01-03 EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION

EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION
IN SKELETAL MUSCLE. I. CHLORPROMAZINE AND PROMETHAZINE.
001068 02-03

EFFECTS OF ANTIPSYCHOTIC DRUGS ON ACTION POTENTIAL PRODUCTION IN SKELETAL MUSCLE. II. HALOPERIDOL: NONSPECIFIC AND OPIATE DRUG RECEPTOR MEDIATED EFFECTS.

EFFECT OF PSYCHOTROPIC DRUGS ON ATPASE TRANSPORT OF THE SARCOPLASMIC RETICULUM IN RABBIT SKELETAL MUSCLES.

001174 02-03
DEVELOPMENT OF DENERVATION ALTERATIONS IN SURFACE MEMBRANES
OF MAMMALIAN SKELETAL MUSCLE.

001246 02-03
DIAZEPAM BLOCKADE OF REPETITIVE ACTION POTENTIALS IN SKELETAL
MUSCLE FIBRES: A MODEL OF ITS MEMBRANE ACTION.
001275 02-03

SYNTHESIS AND COMPARATIVE SKELETAL MUSCLE RELAXANT ACTIVITY OF SOME 2,4 IMIDAZOLIDINEDIONES AND THEIR CORRESPONDING 5 HYDROXYIMIDAZOLIDINEDIONES. 001944 03-01

SKF-525-A

MATERNAL FETAL DISTRIBUTION OF METHAQUALONE IN CONTROL AND
SKF-525-A PRETREATED PREGNANT MICE.

000263 01-03

SKF-525-A-INDUCED

CORRELATION OF PHENOBARBITAL-INDUCED AND SKF-525-A-INDUCED

MODIFICATION OF PENTOBARBITAL HYPNOSIS WITH ALTERATION OF IN

VIVO AND IN VITRO PENTOBARBITAL METABOLISM IN THE RAT.

003008 04-03

THE EFFECT OF NITRAZEPAM ON MANUAL SKILL, GRIP STRENGTH, AND REACTION TIME WITH SPECIAL REFERENCE TO SUBJECTIVE EVALUATION OF EFFECTS ON SLEEP. 002626 03-14

EFFECTS OF TRITHIOZINE ON PSYCHOMOTOR SKILLS RELATED TO DRIVING: A COMPARISON WITH DIAZEPAM AND INTERACTIONS WITH ALCOHOL.

001723 02-14

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION
DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST

— A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND
QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

001535 02-04

INFLUENCE OF CHLORPROMAZINE AND TRIFLUOPERAZINE ON NEURONS
OF AN ISOLATED SLAB OF RABBIT CEREBRAL-CORTEX.
001205 02-03

EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) ON SLEEP IN OLFACTORY
BULB LESIONED RATS.

000032 01-02
DIETARY TRYPTOPHAN EFFECTS ON THE SLEEP OF NORMAL SUBJECTS.
000505 01-07
FLUNITRAZEPAM, AN INVESTIGATIONAL HYPNOTIC DRUG: SLEEP
LABORATORY EVALUATIONS.

000750 01-14

FAILURE OF NALOXONE TO AFFECT HUMAN SLEEP.

THE EFFECT OF A NEW BENZODIAZEPINE ON THE POLYGRAPHICALLY

MONITORED SLEEP OF NORMAL VOLUNTEERS.

O00765 01-14
INDIVIDUAL VARIATIONS IN RESPONSE OF HUMAN REM SLEEP TO
AMITRIPTYLINE AND HALOPERIDOL.

000779 01-14

EFFECT OF NEUROTROPIC DRUGS ON SLEEP DISTURBANCES CAUSED BY
ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS.

STUDY OF NIGHT SLEEP DURING LONG-TERM GRADUAL REDUCTION IN NEUROLEPTIC THERAPY IN CHRONIC SCHIZOPHRENICS.

000852 01-15
SLEEP AND BEHAVIORAL CHANGES POSSIBLY REFLECTING CENTRAL
RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS
INHIBITION IN MAN.

UPTAKE AND METABOLISM OF INTRAVENTRICULARLY ADMINISTERED PIPERIDINE AND ITS EFFECTS ON SLEEP AND WAKEFULNESS IN THE

CANNABIS, CATECHOLAMINES, RAPID EYE MOVEMENT SLEEP AND

001320 02-04
SLOW-WAVE SLEEP AND A STATE RESEMBLING ABSENCE EPILEPSY
INDUCED IN THE RAT BY GAMMA-HYDROXYBUTYRATE.

001366 02-04

SLEEP SUPPRESSION INDUCED BY INTRAVENOUS AND INTRAVENTRICULAR INFUSIONS OF METHOXAMINE IN THE DOG.

O01434 02-04
SIMILAR EFFECTS OF TRYPTOPHAN AND SLEEP ON CISTERNAL
CEREBROSPINAL FLUID 5 MYDROXYINDOLEACETIC AND HOMOVANILLICACIDS IN CATS.

HISTAMINE H2-RECEPTORS IN THE BRAIN AND SLEEP PRODUCED BY

CLONIDINE.

O01483 02-04

MODIFICATION OF SLEEP INDUCED IN ACUTE AND CHRONIC

ADMINISTRATION OF LITHIUM.

O01699 02-14

FLURAZEPAM EFFECTS ON SLOW-WAVE SLEEP: STAGE-4 SUPPRESSED

BUT NUMBER OF DELTA-WAVES CONSTANT.

O01708 02-14

EFFECTS OF PROLONGED ADMINISTRATION OF PIMOZIDE ON SLEEP EEG
PATTERNS IN PSYCHIATRIC PATIENTS.

EFFECTS OF IMIPRAMINE ON ENURETIC FREQUENCY AND SLEEP STAGES.
001712 02-14

GAMMA-AMINOBUTYRIC-ACID (GABA) AND SLEEP: THE INFLUENCE OF DI-N-PROPYLACETIC-ACID ON SLEEP IN MAN.

A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE SHORT-TERM EFFECTS OF CLOZAPINE UPON SLEEP PARAMETERS OF NORMAL YOUNG ADULTS.

ADULTS.

O01734 02-14

A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE
DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON
SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR
PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION.
001787 02-15

THE RELATIONSHIP BETWEEN CORTICAL RECRUITING RESPONSES AND PONTO-GENICULO-OCCIPITAL (PGO) WAVES DURING PARADOXICAL SLEEP AND AFTER THE ADMINISTRATION OF RESERPINE IN THE CAT. 002069 03-03

SLEEP CHANGES INDUCED BY CHRONIC ADMINISTRATION OF S-1694 (SURVECTOR).

002194 03-04

EFFECT OF CLOZAPINE ON THE SLEEP PATTERN IN THE RAT.
002313 03-04

CLOMIPRAMINE AND SLEEP: A PRELIMINARY COMMUNICATION.
002571 03-13

EFFECTIVENESS OF TEMAZEPAM WITH SHORT-TERM, INTERMEDIATETERM, AND LONG-TERM USE: SLEEP LABORATORY EVALUATION.
002608 03-14

VILOXAZINE, SLEEP, AND SUBJECTIVE FEELINGS.
002609 03-14

EEG SLEEP CORRELATES OF DEPRESSION IN MAN.
002625 03-14

THE EFFECT OF NITRAZEPAM ON MANUAL SKILL, GRIP STRENGTH, AND
REACTION TIME WITH SPECIAL REFERENCE TO SUBJECTIVE
EVALUATION OF EFFECTS ON SLEEP.
002626 03-14

EFFECTS OF DIPROPYLACETATE ON WAKEFULNESS AND SLEEP IN HUMAN NEONATES.

002632 03-14
A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE LONG-TERM EFFECTS OF CLOZAPINE UPON SLEEP PATTERNS OF NORMAL YOUNG ADULTS.
002640 03-14
INHIBITION OF REM SLEEP BY FLUOXETINE, A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
003095 04-03

BIPHASIC EFFECT OF CHLORPROMAZINE ON RAT PARADOXICAL SLEEP: A STUDY OF DOSE-RELATED MECHANISMS.

003253 04-04 EFFECTS OF THE ACUTE ADMINISTRATION OF ETHANOL ON THE SLEEP OF THE RAT: A DOSE-RESPONSE STUDY.

A CONTROLLED STUDY OF TRANCOPAL IN THE TREATMENT OF SLEEP DISTURBANCES DUE TO ANXIETY. 003548 04-10

EFFECT OF APOMORPHINE ON HUMAN SLEEP.

O03620 04-14

A CONTROLLED STUDY OF TRANCOPAL IN SLEEP DISTURBANCES DUE TO RHEUMATIC DISEASE.

PARADOXICAL EFFECTS IN SLEEP AND PERFORMANCE OF TWO DOSES OF CHLORPROMAZINE.

HYPNOTIC EFFECTIVENESS OF SODIUM SALICYLAMIDE WITH SHORT-TERM USE: SLEEP LABORATORY STUDIES.

A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF IVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR. 003657 04-15

PLACEBO AND SLEEP PATTERNS OF NORMAL YOUNG ADULTS. 003729 04-17

SLEEP-DEPRIVATION
SLEEP-DEPRIVATION DEFICITS AND THEIR REVERSAL BY D AMPHETAMINE
AND L AMPHETAMINE.
000770 01-14

EFFECTS OF PCPA AND SELECTIVE REM SLEEP-DEPRIVATION ON ROTOROD PERFORMANCE AND OPEN-FIELD BEHAVIOR IN THE RAT. 002219 03-04

SLEEP-DEPRIVED
FURTHER STUDIES OF THE AGGRESSIVE BEHAVIOR INDUCED BY DELTA9TETRAHYDROCANNABINOL IN REM SLEEP-DEPRIVED RATS.
000331 01-04

LEEP-INDUCING
SLEEP-INDUCING EFFECT OF A VASOPRESSIN ANALOG, DEAMINO-6CARBA-ORNITHINE-8-VASOPRESSIN (DCOV) IN RATS.

003265 04-04

SLEEP-WAKEFULNESS
EFFECTS OF L 5 HYDROXYTRYPTOPHAN ON SLEEP-WAKEFULNESS CYCLES IN CATS.

LSD AND TRYPTAMINE EFFECTS ON SLEEP-WAKEFULNESS AND ELECTROCORTICOGRAM PATTERNS IN INTACT CATS.

003256 04-04

INFLUENCE OF VINCAMINE AND PIRACETAM ON SLEEP-WAKING PATTERN
OF THE CAT.
002925 04-03

SLEEPING
SYNTHESIS OF BRADYKININ FRAGMENTS AND THEIR EFFECT ON
PENTOBARBITAL SLEEPING TIME IN MOUSE.

THE INSOMNIA OF SLEEPING IN A STRANGE PLACE: EFFECTS OF L TRYPTOPHANE.

000632 01-11
INTERACTION BETWEEN D AMPHETAMINE AND ETHANOL WITH RESPECT
TO LOCOMOTION, STEREOTYPIES, ETHANOL SLEEPING TIME, AND THE
KINETICS OF DRUG ELIMINATION.
003378 04-04

SLEEPLESSNESS DUE TO SOPORIFICS?

THE SLEEPY PATIENT.

001815 02-15 002692 03-15

THE HIPPOCAMPAL SLICE: A SYSTEM FOR STUDYING THE PHARMACOLOGY OF SEIZURES AND FOR SCREENING ANTICONVULSANT DRUGS.

CONTROL OF THE RELEASE OF NEWLY SYNTHESIZED H3-5HYDROXYTRYPTAMINE BY NICOTINIC AND MUSCARINIC RECEPTORS IN
RAT HYPOTHALAMIC SLICES.

000144 01-03

EFFECTS OF N METHYLAMINO-ACIDS AND CONVULSANTS ON SPONTANEOUS ACTION POTENTIALS IN GUINEA-PIG CEREBELLAR SLICES.

000209 01-03

DOPAMINE SELECTIVELY INCREASES H3-GABA RELEASE FROM SLICES OF RAT SUBSTANTIA-NIGRA IN VITRO.

NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN SLICES OF MOUSE LIMBIC FOREBRAIN: CHARACTERISATION AND EFFECT OF DOPAMINERGIC AGONISTS.

000256 01-03

EFFECTS OF BETA-BUNGAROTOXIN, DIPHENYLHYDANTOIN AND
METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT
CATIONS AND HIGH-ENERGY PHOSPHATE CONTENTS OF BRAIN SLICES.

000278 01-03

EFFECT OF COCAINE AND DESMETHYLIMIPRAMINE ON THE UPTAKE,
RETENTION AND METABOLISM OF H3-5-HYDROXYTRYPTAMINE IN RAT
BRAIN SLICES.

STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT BRAIN TISSUE SLICES.

BRAIN TISSUE SLICES.

001145 02-03

SPECIFIC RELEASE BY NALOXONE OF H3-MORPHINE FROM SUPERFUSED SLICES OF CORPUS-STRIATUM OF MICE.

O01164 02-03

ENHANCED AFFINITY OF OPIATE RECEPTORS FOR NALOXONE IN STRIATAL
SLICES OF MORPHINE-DEPENDENT MICE.

THE EFFECTS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE ON THE IN VITRO UPTAKE OF RADIOLABELLED 5-HT AND NORADRENALINE INTO RAT BRAIN CORTICAL SLICES.

001257 02-03

IN VITRO EFFECTS OF DESMETHYLIMIPRAMINE ON THE UPTAKE AND
METABOLISM OF H3-MOREPINEPHRINE IN RAT BRAIN SLICES.

STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAMINE (DA) AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES.

002036 03-03

002036 03-03

EFFECT OF DIHYDROERGOTOXINE ON CYCLIC-AMP GENERATING SYSTEMS IN RAT CEREBRAL-CORTEX SLICES.

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS.

ALTERATION OF TRICARBOXYLIC-ACID CYCLE METABOLISM IN RAT BRAIN SLICES BY HALOTHANE.

ADENOSINE MODULATES DEPOLARIZATION-INDUCED RELEASE OF H3-NORADRENALINE FROM SLICES OF RAT BRAIN NEOCORTEX. 002938 04-03

STIMULATION BY LITHIUM-IONS OF THE INCORPORATION OF C14-GLUCOSE INTO GLYCOGEN IN RAT BRAIN SLICES.

H3-GLYCOGEN HYDROLYSIS IN BRAIN SLICES: RESPONSES TO NEUROTRANSMITTERS AND MODULATION OF NORADRENALINE RECEPTORS. 003054 04-03

EFFECT OF () AMPHETAMINE ON THE RETENTION OF H3-CATECHOLAMINES IN SLICES OF NORMAL AND RESERPINIZED RAT BRAIN AND HEART.

THE ROLE OF CALCIUM IN THE REGULATION OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN SLICES OF RAT AND GUINEA-PIG.

003079 04-03

THE UPTAKE OF S35-METHIMAZOLE BY SHEEP THYROID SLICES IN VITRO.
003093 04-03

EFFECT OF STRESS ON NOREPINEPHRINE STIMULATED CYCLIC-AMP
FORMATION IN BRAIN SLICES.

003100 04-03
INHIBITION OF CA45 MOVEMENTS BY LOWERED TEMPERATURE OR
LANTHANUM IN RAT BRAIN SLICES.

THANUM IN RAT BRAIN SLICES. 003135 04-03

EFFECTS OF L GLUTAMATE AND RELATED AMINO-ACIDS UPON THE RELEASE OF H3-DOPAMINE FROM RAT STRIATAL SLICES.

EFFECTS OF KAINIC-ACID ON ION DISTRIBUTION AND ATP LEVELS OF STRIATAL SLICES INCUBATED IN VITRO.

003406 04-05

SLOW

AMPHETAMINE EFFECTS ON BRAIN SLOW POTENTIALS ASSOCIATED WITH DISCRIMINATION IN THE RAT.

THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE HUMAN BRAIN AS AN OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING DRUGS.

000747 01-14
POSTSYNAPTIC POTENTIATION OF THE SLOW MUSCARINIC EXCITATORY
RESPONSE BY TETRAETHYLAMMONIUM-CHLORIDE IN THE BULLFROG
SYMPATHETIC GANGLION CELLS.

SLOW-DRIP

INTENSIVE ANTIDEPRESSIVE THERAPY BY 48 HOUR SLOW-DRIP INFUSION WITH HIGH DOSES DIBENZEPINE.

001602 02-09

001173 02-03

002450 03-09

A SLOW-RELEASE SILICONE PELLET FOR CHRONIC AMPHETAMINE

O01529 02-06
A COMPARISON OF MAPROTILINE (LUDIOMIL) AND SLOW-RELEASE
AMITRIPTYLINE (TRYPTIZOL-SR).

SLOW-WAVE

SLOW-WAVE SLEEP AND A STATE RESEMBLING ABSENCE EPILEPSY INDUCED IN THE RAT BY GAMMA-HYDROXYBUTYRATE.

FLURAZEPAM EFFECTS ON SLOW-WAVE SLEEP: STAGE-4 SUPPRESSED BUT NUMBER OF DELTA-WAVES CONSTANT.

001708 02-14

MEASUREMENTS OF WEIGHT AND ACTIVITY IN MALE MICE FOLLOWING INHALATION OF CANNABIS SMOKE IN A CONTROLLED SMOKE EXPOSURE CHAMBER.

001524 02-05

SMOKING
HIGH-PRESSURE LIQUID CHROMATOGRAPHIC MASS SPECTROMETRIC
DETERMINATION OF DELTA9-TETRAHYDROCANNABINOL IN HUMAN
PLASMA FOLLOWING MARIJUANA SMOKING.

PLASMA FOLLOWING MARIJUANA SMOKING.

000682 01-12
SIDE-EFFECTS OF CHLORPROMAZINE IN RELATION TO CIGARETTE

000902 01-15
POTENTIATION OF THE EPILEPTOGENIC EFFECT OF PENICILLIN-G BY
MARIHJANA SMOKING

TRICYCLIC PLASMA LEVELS: EFFECT OF AGE, RACE, SEX, AND SMOKING.
002472 03-09

CAN CIGARETTE SIZE AND NICOTINE CONTENT INFLUENCE SMOKING AND PUFFING RATES?.

THE LACK OF AN EFFECT OF DELTA9-THC ON PULMONARY SMOOTH
AUSCLE FUNCTION IN THE GUINEA-PIG.

001041 02-03

RELAXATION OF SMOOTH MUSCLE FOLLOWING CONTRACTION ELICITED
BY SYMPATHETIC NERVE STIMULATION IN VIVO.

O01106 02-03
ACTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND ITS
DERIVATIVES ON 5 HYDROXYTRYPTAMINE RECEPTORS IN THE
ISOLATED UTERINE SMOOTH MUSCLE OF THE RAT.

O01144 02-03

SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE
MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE
GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION.
020252 03-03

STUDIES ON THE INHIBITION OF PHOSPHODIESTERASE CATALYZED CYCLIC-AMP AND CYCLIC-GMP BREAKDOWN AND RELAXATION OF CANINE TRACHEAL SMOOTH MUSCLE.

002129 03-03

NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINDSTIDE
OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL
SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION
OF THE SYMPATHETIC NERVE OF THE EYE.
002802 04-03

SMR

MANAGEMENT OF THE HYPERKINETIC SYNDROME WITH METHYLPHENIDATE AND SMR BIOFEEDBACK TRAINING.

O01625 02-11

EFFECTS OF MYSOLINE AND DILANTIN ON THE EEG DURING SMR
BIOFEEDBACK TRAINING OF A PSYCHOMOTOR EPILEPTIC: SINGLE CASE

001657 02-13

WET-DOG SNAKE BEHAVIOUR IN THE RAT: A POSSIBLE QUANTITATIVE MODEL OF CENTRAL 5 HYDROXYTRYPTAMINE ACTIVITY.

SNAKES 001310 02-04

ROLES OF THE VOMERONASAL AND OLFACTORY SYSTEMS IN COURTSHIP BEHAVIOR OF MALE GARTER SNAKES. 003268 04-0-

GASOLINE SNIFFING: A REVIEW.

003268 04-04

SOCIAL SEEECTS OF EXPOSUR

EFFECTS OF EXPOSURE TO LEAD ON SOCIAL BEHAVIOUR IN THE LABORATORY MOUSE.

AMPHETAMINE-LIKE EFFECTS OF 5,6 DIHYDROXYTRYPTAMINE ON SOCIAL BEHAVIOUR IN THE MOUSE.

O00433 01-04

EVALUATIONS OF SOCIAL FUNCTIONING IN A 3-YEAR DOUBLE-BLIND
INVESTIGATION OF PIMOZIDE VERSUS FLUPHENAZINE IN CHRONIC
SCHIZOPHERNIA

INCREASED PRESCRIBING OF VALIUM, LIBRIUM, AND OTHER DRUGS — AN EXAMPLE OF THE INFLUENCE OF ECONOMIC AND SOCIAL FACTORS ON THE PRACTICE OF MEDICINE.

BRAIN STIMULATION PROVOKED EMOTIONAL REACTIONS OF CATS IN A SOCIAL SITUATION.

001395 02-04

EFFECTS OF AMPHETAMINE AND NEMBUTAL ON SOCIAL EXPLORATION IN
THE MONGOLIAN GERBIL

INFLUENCE OF BETA-ENDORPHIN ON EXPLORATORY, SOCIAL AND SEXUAL BEHAVIOUR IN THE MALE RAT.

O01418 02-04
THE EFFECT OF A HALLUCINOGEN, 5 METHOXYDIMETHYLTRYPTAMINE,
ON PRIMATE SOCIAL BEHAVIOR.

PSYCHOTROPIC DRUG EFFECTS ON THE EMOTIONAL STATE OF CATS IN A

DRUG-PRODUCED CHANGES IN HUMAN SOCIAL BEHAVIOR: FACILITATION
BY D AMPHETAMINE

O01715 02-14
METHYLPHENIDATE IN HYPERKINETIC CHILDREN: DIFFERENCES IN DOSE
EFFECTS ON LEARNING AND SOCIAL BEHAVIOR.

EFFECTS OF IMIPRAMINE TREATMENT OF SEPARATION-INDUCED SOCIAL DISORDERS IN RHESUS MONKEYS.

EFFECTS OF AMPHETAMINE ON SOCIAL BEHAVIORS OF RHESUS
MACAQUES: AN ANIMAL MODEL OF PARANOIA.

A REFILLABLE SYSTEM FOR CONTINUOUS AMPHETAMINE
ADMINISTRATION: EFFECTS UPON SOCIAL BEHAVIOR IN RAT

ADMINISTRATION: EFFECTS UPON SOCIAL BEHAVIOR IN RAT COLONIES.

003215 04-04
CAN SOCIAL INTERACTION BE USED TO MEASURE ANXIETY?.

THE SOCIAL OUTCOME OF PATIENTS IN A TRIAL OF LONG-TERM
CONTINUATION THERAPY IN SCHIZOPHRENIA: PIMOZIDE VS.

003455 04-08
INTERDEPENDENCE BETWEEN SOCIAL PROCESSES AND NEUROCHEMICAL
OPERATIONS.

SOCIALIZATION
BRIEF PERIODS OF SOCIALIZATION AND LATER BEHAVIOR IN THE RAT.
003214 04-04

O03214 04

THE EFFECTS OF PROLONGED HANDLING, SCOPOLAMINE, AND
PHYSOSTIGMINE ON THE ACTIVITY OF ISOLATED AND SOCIALLY

PHYSOSTIGMINE ON THE ACTIVITY OF ISOLATED AND SOCIALLY REARED RATS.

002285 03-04

THE FUNCTION OF DRUG RITUALS IN HUMAN SOCIETY: CONTINUITIES AND CHANGES. 000674 01-12

PSYCHOACTIVE DRUGS AND SOCIETY. 002734 03-17

THE ALPHA SPECTRUM IN SCHIZOPHRENIC PATIENTS DUE TO PSYCHOPHARMACOLOGICAL TREATMENT AND DIFFERENT SOCIOCULTURAL SETTINGS. 002636 03-14

THE SOCIOPHARMACOLOGY OF FENFLURAMINE (FM), METHYLPHENIDATE (MP), AND DIETHYLPROPION (DP) IN MACAQUE ARCTOIDES. 001311 02-04

SOCIOPHARMACOLOGY OF D AMPHETAMINE IN MACAQUE ARCTOIDES II.
001493 02-04

PRIMATE INFORMATION PROCESSING UNDER SODIUM PENTOBARBITAL AND CHLORPROMAZINE: DIFFERENTIAL DRUG EFFECTS WITH TACHISTOSCOPICALLY PRESENTED DISCRIMINATIVE STIMULI.

LITHIUM SODIUM COUNTERTRANSPORT IN HUMAN RED CELLS AND IN VIVO LITHIUM DISTRIBUTION BETWEEN RED CELLS AND PLASMA. 001679 02-13

ALPHA-NORADRENERGIC RECEPTORS IN THE BRAIN: DIFFERENTIAL EFFECTS OF SODIUM ON BINDING OF H3-AGONISTS AND H3-ANTAGONISTS.

ABSORPTION AND DISTRIBUTION OF SODIUM BARBITAL IN TISSUES OF NORMAL AND DYSTROPHIC MICE.

EFFECTS OF SODIUM THIOPENTAL ON THE TRICARBOXYLIC-ACID CYCLE METABOLISM IN MOUSE BRAIN: CO2 FIXATION AND METABOLIC COMPARTMENTATION.

002860 04-03 THE EFFECT OF SODIUM PENTOBARBITAL ON SOME MITOCHONDRIAL

003014 04-03 EFFECTS OF SODIUM PENTOBARBITAL ON SYMBOLIC MATCHING AND SYMBOLIC ODDITY PERFORMANCE.

003213 04-04 EFFECTS OF CHRONIC INGESTION AND WITHDRAWAL OF SODIUM BARBITONE ON LEARNING IN RATS.

003273 04-04 EFFECTS OF SODIUM PHENOBARBITAL ON BRAIN STIMULATION BEHAVIOR, BEHAVIORAL SEIZURES, AND EEG SEIZURE ACTIVITY 003355 04-04

AN IMPROVED ASSAY OF TYROSINE-HYDROXYLASE USING SODIUM ACTIVATION

003430 04-06 SODIUM VALPROATE AND TARDIVE-DYSKINESIA.

SODIUM VALPROATE IN THE TREATMENT OF INTRACTABLE SEIZURE DISORDERS: A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY. 003550 04-11

SODIUM VALPROATE IN THE TREATMENT OF LEVODOPA-INDUCED

003568 04-11 HYPNOTIC EFFECTIVENESS OF SODIUM SALICYLAMIDE WITH SHORT-TERM USE: SLEEP LABORATORY STUDIES.

003637 04-14 LOWERED ERYTHROCYTE SEDIMENTATION RATE WITH SODIUM

003672 04-15

SODIUM-CHLORIDE HYPERTONIC SODIUM-CHLORIDE AND LIDOCAINE IN A CASE OF IMPRAMINE INTOXICATION.

901769 02-15
FACILITATION OF BENZODIAZEPINE BINDING BY SODIUM-CHLORIDE AND

GABA. 003002 04-03

EFFECTS OF ACETYLCHOLINE, SODIUM-GLUTAMATE AND GABA ON THE DISCHARGE OF SUPRAOPTIC NEURONS IN THE RAT.

002830 04-03 EFFECTS OF SODIUM-NITRITE ON DRL PERFORMANCE IN THE RAT.

002325 03-04

SOLID DISPERSION APPROACH FOR OVERCOMING BIOAVAILABILITY PROBLEMS DUE TO POLYMORPHISM OF NABILONE. A CANNABINOID 001539 02-06

SOLUBILIZATION OF H3-SPIPERONE BINDING SITES FROM RAT BRAIN 002929 04-03

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES MESCALINE-DEMETHYLASE ACTIVITY OF BRAIN-CORTEX SOLUBLE

SUPERNATANT. 000090 01-03

SOLUTION KINETIC STUDIES OF FOOD INTAKE AND SUCROSE SOLUTION PREFERENCE BY RATS TREATED WITH LOW DOSES OF DELTA9-TETRAHYDROCANNABINOL

000324 01-04 AGGREGATION OF ANTIDEPRESSANT DRUGS IN AQUEOUS SOLUTION. 003697 04-17

UTIONS
NACL AND LICL EFFICACY IN THE INDUCTION OF AVERSION FOR QUININE
AND SACCHARIN SOLUTIONS IMMEDIATELY FOLLOWING INJECTION.
000396_01-04 EFFECTS OF PCPA ON THE CONSUMPTION OF ALCOHOL, WATER AND OTHER SOLUTIONS.

000469 01-04

Psychopharmacology Abstracts

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): PRESSING FOR ICS BEFORE AND AFTER SELF-ADMINISTRATION OF SWEETENED MORPHINE SOLUTIONS.

001331 02-04 ASSOCIATION OF SOME PSYCHOTOMIMETIC COMPOUNDS WITH 6
METHYLPURINE IN AQUEOUS SOLUTIONS.

SOMATIC

AMP SYSTEM: LONGITUDINAL COURSE STUDIES OF PSYCHOPATHOLOGIC

AND SOMATIC SYMPTOMS. AN EMPIRIC INVESTIGATION OF THE PROBLEM OF SIDE-EFFECTS.

D00797 01-1.

A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND BIOELECTRIC CORRELATES OF EMOTIONAL REACTIONS ELICITED BY CHOLINERGIC STIMULATION OF THE HYPOTHALAMUS AND THE VENTRAL

001390 02-04 RELATIONSHIP BETWEEN PHYSICAL FINDINGS AND RELATED SUBJECTIVE SYMPTOMS IN NEUROPSYCHIATRIC PATIENTS WITH SOMATIC COMPLICATIONS -- WITH SPECIAL REFERENCE TO OPHTHALMOLOGIC

001678 02-13 EFFECT OF DEXTROAMPHETAMINE ON SOMATIC EVOKED-POTENTIAL COMPONENTS IN MAN WITH SPECIAL REFERENCE TO TALK RELEVANCE AND SELECTIVE ATTENTION.

MINOR TRANQUILLIZERS IN SOMATIC DISORDERS.

001735 02-14 003633 04-14

001815 02-15

001950 03-01

SOMATOSENSORY
PHENOBARBITAL AND PHENYTOIN EFFECTS ON SOMATOSENSORY
EVOKED-POTENTIALS AND SPONTANEOUS EEG IN NORMAL CAT BRAIN.
001032 02-02

ELECTROENCEPHALOGRAM AND SOMATOSENSORY EVOKED-POTENTIAL CHANGES AFTER ADMINISTRATION OF SIX CONVULSANT DRUGS. 002055 03-03

SOMATOSENSORY EVOKED-POTENTIALS IN PATIENTS WITH PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND DECARBOXYLASE INHIBITOR

NEOSTRIATAL ADMINISTRATION OF SOMATOSTATIN: DIFFERENTIAL EFFECT OF SMALL AND LARGE DOSES ON BEHAVIOR AND MOTOR

000437 01-04 SOMATOSTATIN: ELECTRON MICROSCOPE IMMUNOHISTOCHEMICAL LOCALIZATION IN SECRETORY NEURONS OF RAT HYPOTHALAMUS

001948 03-01 ANALGESIC EFFECT OF CEREBROVENTRICULAR ADMINISTRATION OF SOMATOSTATIN (SRIF).

CENTRAL EFFECT OF SOMATOSTATIN ON THE SECRETION OF GROWTH HORMONE IN THE ANESTHETIZED RAT.

EFFECT OF SOMATOSTATIN (SRIF) AND L GLUTAMATE ON NEURONS OF THE SENSORIMOTOR CORTEX IN AWAKE HABITUATED RABBITS.

MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II.

002994 04-03 DEPRESSANT ACTIONS OF METHIONINE-ENKEPHALIN AND
SOMATOSTATIN IN CAT DORSAL-HORN NEURONES ACTIVATED BY 003059 04-03

SOMATOSTATIN IN THE TREATMENT OF PATIENTS WITH EXTRAPYRAMIDAL DISORDERS AND PATIENTS WITH EEG ABNORMALITIES.

003557 04-11

SOMESTHETIC
SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT
SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL CORRELATES 001974 03-03

SOMNAMBULISM
FILICIDE DURING PSYCHOTROPIC-INDUCED SOMNAMBULISM: A CASE

003663 04-15 SOPHORA-SECUNDIFLORA
AN INVESTIGATION OF SOPHORA-SECUNDIFLORA SEEDS (MESCALBEANS)

000007 01-01

SLEEPLESSNESS DUE TO SOPORIFICS?.

SORDINOL
MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. A
STUDY WITH THE LONG-ACTING THIOXANTHENE DERIVATIVE, CISCLOPENTHIXOL-DECANOATE SORDINOL DEPOT.

003454 04

CIS-CLOPENTHIXOL AND CLOPENTHIXOL (SORDINOL) IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL INVESTIGATION 003496 04-09

VOLUME 16, SUBJECT INDEX

Subject Index

INVOLUNTARY ADMINISTRATION OF PSYCHOTROPIC DRUGS — GROUNDS FOR SUIT. SOUDER V. MCGUIRE, 423 F.SUPP. 830, (PENNSYLVANIA). M.D. DISTRICT COURT. DECEMBER 9, 1976.

SOURCE

THE EFFECTS OF APPROPRIATENESS OF ATTRIBUTED AROUSAL SOURCE AND TEST ANXIETY ON COMPLEX TEST PERFORMANCE AND REPORTED ANXIETY DURING TEST-TAKING. (PH.D. DISSERTATION).

SOUTH-AFRICA
HISTORICAL AND CULTURAL FACTORS INFLUENCING CANNABIS USE AMONG INDIANS IN SOUTH-AFRICA.

000675 01-12

003702 04-17

SOUTHFASTERN

PATTERNS OF ANTIPSYCHOTIC DRUG USE IN FOUR SOUTHEASTERN STATE HOSPITALS 000963 01-17

THE EFFECTS OF SP-111, A WATER-SOLUBLE THC DERIVATIVE, ON NEURONAL ACTIVITY IN THE RAT BRAIN.

002150 03-03

EFFECTS OF PROPYLBENZILYLCHOLINE MUSTARD ON INJECTION INTO THE LIQUOR SPACE OF CATS. 003168 04-04

SPARE

FENFLURAMINE AND FLUOXETINE SPARE PROTEIN CONSUMPTION WHILE SUPPRESSING CALORIC INTAKE BY RATS.

002184 03-03

SPARROWS SUPPRESSION OF LOCOMOTOR ACTIVITY IN SPARROWS BY TREATMENT WITH MELATONIN

003243 04-04

SPASMODIC

TREATMENT OF SPASMODIC TORTICOLLIS WITH AMANTADINE: A DOUBLE-BLIND STUDY. 000666 01-11

SPATIAL

EFFECTS OF D AMPHETAMINE ON TEMPORAL AND SPATIAL DISCRIMINATION IN RATS.

003349 04-04

SPECIES

RELATIVE CONCENTRATIONS OF ZWITTERIONIC AND UNCHARGED SPECIES IN CATECHOLAMINES AND THE EFFECT OF N SUBSTITUENTS. 000117 01-03

SPECIES VARIATION WITH RESPECT TO THE METABOLISM AND EXCRETION OF D AMPHETAMINE AND D.L. N HYDROXYAMPHETAMINE. SUCCINATE.

001091 02-03

ILLNESS-INDUCED AVERSION LEARNING IN A DESERT SPECIES OF RODENT (ACOMYS-CAHIRINUS) 001350 02-04 INTERACTION BETWEEN PHENCYCLIDINE AND PENTOBARBITAL IN SEVERAL SPECIES OF LABORATORY ANIMALS.

SPECIEIC

FLUVOXAMINE, A SPECIFIC 5 HYDROXYTRYPTAMINE UPTAKE INHIBITOR 000017 01-02

SPECIFIC LOCALIZATION OF DRUGS AT THE HYPOPHYSIS LEVEL AND SIDE-**EFFECTS: THE CASE OF NEUROLEPTICS.**

000053 01-03 A BRAIN SPECIFIC PROTEIN FROM OCTOPUS-VULGARIS, LAM

000125 01-03 THE DEMONSTRATION IN VIVO OF SPECIFIC BINDING SITES FOR NEUROLEPTIC DRUGS IN MOUSE BRAIN.

000150 01-03 SPECIFIC ACTION OF NARCOTICS ON REFLEX ACTIVATION OF RAT ALPHA-MOTONEURONES

000174 01-03 SPECIFIC EFFECT OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE FRONTAL CORTEX.

000175 01-03 SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION: A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL MEMBRANES FROM MATURE RAT BRAIN.

000230 01-03 ACETYLCHOLINE TURNOVER IN SPECIFIC BRAIN AREAS OF RATS INJECTED WITH VARIOUS ANTIDEPRESSANTS. (UNPUBLISHED PAPER)

000244 01-03 PUNISHMENT SPECIFIC EFFECTS OF PENTOBARBITAL: DEPENDENCY ON THE TYPE OF PUNISHER.

000322 01-04 MEMORY AND COGNITIVE FUNCTION IN MAN: DOES THE CHOLINERGIC SYSTEM HAVE A SPECIFIC ROLE?

000761 01-14 CONTROLLING RATER SPECIFIC INTERFERENCE FACTORS IN CLINICAL TRIALS.

SPECIFIC RELEASE BY NALOXONE OF H3-MORPHINE FROM SUPERFUSED SLICES OF CORPUS-STRIATUM OF MICE

ODI 164 02-03
SPECIFIC RADIOIMMUNOASSAY FOR AMITRIPTYLINE AND NORTRIPTYLINE

THE EFFECTS OF DARVON-N ON RETENTION OF SPECIFIC LEARNING TASKS DURING HEROIN DETOXIFICATION. (PH.D. DISSERTATION).

001703 02-14 THE ATTENUATION OF A SPECIFIC CUE-TO-CONSEQUENCE ASSOCIATION BY ANTIEMETIC AGENTS.

EVIDENCE FOR THE EXISTENCE OF SPECIFIC CANNABINOID BINDING SITES. 002034 03-03

FURTHER EVIDENCE OF CYCLIC-AMP MEDIATED HYPERTROPHY AS A PREREQUISITE OF DRUG SPECIFIC ENZYME INDUCTION

002086 03-03 REWARD VERSUS PERFORMANCE IN SELF-STIMULATION: ELECTRODE SPECIFIC EFFECTS OF ALPHA-METHYL-P-TYROSINE ON REWARD IN THE

BEHAVIOURAL SPECIFIC TOLERANCE FOLLOWING CHRONIC D OR L AMPHETAMINE TREATMENT: LACK OF INVOLVEMENT OF P-

002261 03-04 A SPECIFIC RADIOIMMUNOASSAY PROCEDURE FOR PLASMA

002723 03-16 CHARACTERIZATION OF SPECIFIC IN VIVO BINDING OF NEUROLEPTIC DRUGS IN RAT BRAIN

002985 04-03 TRYPTAMINE-INDUCED DRUG EFFECTS INSENSITIVE TO SEROTONINERGIC ANTAGONISTS: EVIDENCE OF SPECIFIC TRYPTAMINERGIC RECEPTOR STIMULATION?.

003057 04-03 INHIBITION OF REM SLEEP BY FLUOXETINE. A SPECIFIC INHIBITOR OF

SEROTONIN UPTAKE. 003095 04-03

DEVELOPMENT OF A SPECIFIC RADIOIMMUNOASSAY FOR ACETYLCHOLINE.

SPECIFICITY

MONOAMINE-OXIDASE INHIBITION IN BRAIN AND LIVER PRODUCED BY BETA-CARBOLINES: STRUCTURE-ACTIVITY RELATIONSHIPS AND SLIBSTRATE SPECIFICITY

000064 01-03 PSYCHOACTIVE DRUG EFFECTS AND SUBSTRATE SPECIFICITY IN INTACT MITOCHONDRIAL MONOAMINE-OXIDASE FROM BRAIN

000115 01-03 SPECIFICITY OF LEARNING DEFICITS PRODUCED BY MICROINJECTIONS OF 6-OHDA INTO THE NIGROSTRIATAL SYSTEM OF THE RAT

000346 01-04 SPECIFICITY OF BINDING OF ANTIPSYCHOTICS TO THE ACTIVATOR OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE.

001178 02-03 HALOPERIDOL AND CLOZAPINE: SPECIFICITY OF ACTION ON GABA IN THE 001184 02-03

SPECIFICITY OF AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE AND SEROTONIN FROM RAT BRAIN IN VITRO. 001294 02-03

TOLERANCE TO AMPHETAMINES FACILITATION OF SELF-STIMULATION RESPONDING: ANATOMICAL SPECIFICITY.

002190 03-04 THE SPECIFICITY OF NEUROLEPTIC-INDUCED AND METHYSERGIDE-INDUCED BEHAVIORAL HYPERSENSITIVITY. 002259 03-04

ANATOMICAL SPECIFICITY WITHIN RAT STRIATUM FOR THE DOPAMINERGIC MODULATION OF DRL RESPONDING AND ACTIVITY 003316 04-04

SPECS

SPECS FOR A SAFE HIGH.

002754 03-17

003438 04-06

SPECTRA

BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC/ ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA. 002220 03-04

TIME-COURSE OF CHANGES IN EEG AND POWER SPECTRA DURING TREATMENT WITH NEUROLEPTICS.

002570 03-13 PRIMATE EEG SPECTRA BEFORE AND DURING OPIOID ADMINISTRATION 002601 03-13

SPECTRAL

SPECTRAL ANALYSIS OF THE DIFFERING EEG EFFECTS OF BENZODIAZEPINES, MEPROBAMATE, GLUTETHIMIDE AND AMOBARBITAL IN MACACA-MULATTA.

001130 02-03

000917 01-16

ASSESSMENT OF SPONTANEOUS AND DRUG-INDUCED CHANGES IN VIGILANCE BY MEANS OF A NEW MODIFICATION OF THE SHORT TIME SPECTRAL ANALYSIS OF THE EEG.

002627 03-14

SPECTROMETRIC
HIGH-PRESSURE LIQUID CHROMATOGRAPHIC MASS SPECTROMETRIC
DETERMINATION OF DELTA9-TETRAHYDROCANNABINOL IN HUMAN
PLASMA FOLLOWING MARIJUANA SMOKING.

GAS-CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY OF SEROTONIN IN RAT SUPERIOR CERVICAL GANGLIA: EFFECTS OF NERVE GROWTH FACTOR AND 6 HYDROXYDOPAMINE.

001006 02-01

SPECTROMETRY
PHARMACOKINETICS OF METHYLPHENIDATE IN THE RAT USING SINGLE
ION MONITORING GLC MASS SPECTROMETRY.

000498 01-000498 01-06

MASS SPECTROMETRY OF CANNABINOIDS 001016 02-01 RAPID IDENTIFICATION OF HYPNOTICS IN EMERGENCY CASES BY COMPUTERIZED GAS-CHROMATOGRAPHY MASS SPECTROMETRY

QUANTITATIVE ANALYSIS OF METHADONE IN BIOLOGICAL FLUIDS USING DEUTERIUM-LABELED METHADONE AND GLC CHEMICAL IONIZATION MASS SPECTROMETRY.

001862 02-16

SPECTROPHOTOMETRY

LITHIUM NEUROTOXICITY. I. THE CONCENTRATION OF LITHIUM IN

DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS

ATOMIC ABSORPTION SPECTROPHOTOMETRY.

003432 04-04 003432 04-06

THE MEDICATION CLINIC IN THE SPECTRUM OF CHILDRENS SERVICES. 000955 01-17

THE ALPHA SPECTRUM IN SCHIZOPHRENIC PATIENTS DUE TO PSYCHOPHARMACOLOGICAL TREATMENT AND DIFFERENT SOCIOCULTURAL SETTINGS.

002636 03-14

THOUGHT DISORDER IN SCHIZOPHRENIA: A THEORETICAL APPROACH USING AN ANALYSIS OF SPEECH. (PH.D. DISSERTATION). 001566 02-08

BARBITURATE-INDUCED CHANGES IN TRANSMITTER RELEASE INDEPENDENT OF TERMINAL SPIKE CONFIGURATION IN THE FROG NEUROMUSCULAR JUNCTION.

000294 01-03

-LABELED PREPARATION OF SPIN-LABELED OPIATES: MORPHINE AND CODEINE. 000494 01-06

SPINAL
INFLUENCE OF DIAZEPAM, L-DOPA AND DOPAMINE ON THE CEREBELLAR
AND SPINAL ELECTRICAL PATTERNS INDUCED BY HARMINE IN THE
RABBIT.

000091 01-0

000091 01-03 EFFECTS OF SYSTEMIC MUSCIMOL AND GABA IN THE SPINAL CORD AND SUPERIOR CERVICAL GANGLION OF THE CAT.

CHLORDIAZEPOXIDE SELECTIVELY AUGMENTS GABA ACTION IN SPINAL CORD CELL CULTURES.

001080 02-03 SELECTIVE OPIATE DEPRESSION OF SENSORY EVOKED SYNAPTIC NETWORKS IN DORSAL-HORN REGIONS OF SPINAL CORD CULTURES 001088 02-03

IN VITRO EFFECTS OF CHLORPROMAZINE ON MICROTUBULES AND THE GOLGI COMPLEX IN EMBRYONIC CHICK SPINAL GANGLION CELLS: AN ELECTRON MICROSCOPIC STUDY.

001258 02-03 A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHOXYAMPHETAMINE (DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), P-METHOXYAMPHETAMINE (PMA), D AMPHETAMINE (A), AND LSD IN NONTOLERANT AND LSD TOLERANT CHRONIC SPINAL DOGS.

001273 02-03 EFFECTS OF 4 AMINOPYRIDINE ON TRANSMISSION IN EXCITATORY AND INHIBITORY SYNAPSES IN THE SPINAL CORD.

001384 02-04 DIFFERENTIAL EXCITATORY AND INHIBITORY EFFECTS OF OPIATES ON NONNOCICEPTIVE AND NOCICEPTIVE NEURONES IN THE SPINAL CORD OF THE CAT

O01966 03-03
STIMULANT ACTION OF THYROTROPIN-RELEASING HORMONE ON CAT SPINAL CORD.

OPIATE RECEPTORS IN CULTURES OF FETAL MOUSE DORSAL ROOT GANGLIA (DRG) AND SPINAL CORD: PREDOMINANCE IN DRG NEURITES.

002040 03-03 EFFECTS OF FLURAZEPAM ON AMINO-ACID EVOKED RESPONSES
RECORDED FROM THE LOBSTER MUSCLE AND THE FROG SPINAL CORD.
002115 03-03 A PHARMACOLOGIC COMPARISON OF 3,4
METHYLENEDIOXYAMPHETAMINE AND LSD IN THE CHRONIC SPINAL
DOG.

EFFECTS OF INTRAVENOUS KAINIC-ACID, N METHYL-D-ASPARTATE, AND
(-) NUCLIFERENE ON THE CAT SPINAL CORD.

002128 03-03 RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDROXYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN
ACUTE AND CHRONIC SPINAL RATS.

002289 03-04 MULTIPLE MEMBRANE ACTIONS OF ENKEPHALIN REVEALED USING CULTURED SPINAL NEURONS.

D ALPHA-AMINOADIPATE, ALPHA-EPSILON-DIAMINOPIMELIC-ACID AND H-966 AS ANTAGONISTS OF AMINO-ACID-INDUCED AND SYNAPTIC EXCITATION OF MAMMALIAN SPINAL NEURONES IN VIVO.

002831 04-03 PHARMACOLOGICAL AND ELECTROPHYSIOLOGICAL STUDIES OF MORPHINE AND ENKEPHALIN ON RAT SUPRASPINAL NEURONES AND CAT SPINAL NEURONES.

002883 04-03 INVOLVEMENT OF THE PERIAQUEDUCTAL GREY MATTER AND SPINAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS IN MORPHINE ANALGESIA:
EFFECTS OF LESIONS AND 5 HYDROXYTRYPTAMINE DEPLETION. 002890 04-03

MG2-LIKE SELECTIVE ANTAGONISM OF EXCITATORY AMINO-ACID-INDUCED RESPONSES BY ALPHA-EPSILON-DIAMINOPIMELIC-ACID, D ALPHA-AMINOADIPATE AND HA-966 IN ISOLATED SPINAL CORD OF FROG AND IMMATURE RAT.

002901 04-03 THE RELEASE OF ACETYLCHOLINE IN THE PERFUSED CAT SPINAL CORD IN

MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE CORRELATES WITH ANALGESIC ACTION OF MORPHINE.

STRYCHNINE BINDING ASSOCIATED WITH SYNAPTIC GLYCINE RECEPTORS IN RAT SPINAL CORD MEMBRANES: IONIC INFLUENCES.

003024 04-03 EVIDENCE FOR DISTINCT SPINAL LOCOMOTION GENERATORS SUPPLYING RESPECTIVELY FORELIMBS AND HINDLIMBS IN THE RABBIT.

003124 04-03 OPIATE RECEPTORS FOR BEHAVIORAL ANALGESIA RESEMBLE THOSE RELATED TO THE DEPRESSION OF SPINAL NOCICEPTIVE NEURONS.

003142 04-03 IN VIVO COMPARISON OF THE RECEPTOR POPULATIONS ACTED UPON IN THE SPINAL CORD BY MORPHINE AND PENTAPEPTIDES IN THE PRODUCTION OF ANALGESIA.

003143 04-03 DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES: FURTHER EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION.

EFFECTS OF CARBAMAZEPINE ON MUSCLE SPINDLE DISCHARGES 002037 03-03

EFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY THE RESPONSES OF THE MUSCLE SPINDLE OF THE TRICEPS SURAE MUSCLE OF THE DECEREBRATE CAT TO THE MUSCLE STRETCH. 003109 04-03

SPINOTHALAMIC

DEPRESSION OF PRIMATE SPINOTHALAMIC TRACT NEURONS BY IONTOPHORETIC APPLICATION OF 5 HYDROXYTRYPTAMINE.

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS: 3.
SUBCELLULAR DISTRIBUTION OF NEUROLEPTIC DRUGS AND THEIR
RECEPTORS IN VARIOUS RAT BRAIN AREAS.

002067 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 2.
REGIONAL DISTRIBUTION AND IN VIVO DISPLACEMENT OF
NEUROLEPTIC DRUGS.

002068 03-03 SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS. 1. KINETICS AND CHARACTERISTICS OF IN VITRO BINDING.

002079 03-03 EFFECTS OF SPIPERONE ON SELF-STIMULATION AND OTHER ACTIVITIES OF THE MONGOLIAN GERBIL.

003222 04-04 SPIPERONE-TREATED

COMPARATIVE EFFECTS OF PEMOLINE, AMFONELIC-ACID AND

AMPHETAMINE ON DOPAMINE UPTAKE AND RELEASE IN VITRO AND
ON BRAIN 3,4 DHYDROXYPHENYLACETIC-ACID CONCENTRATION IN
SPIPERONE-TREATED RATS.

SPIROISOBENZOFURANPIPERIDINES
SYNTHESIS OF SPIROISOBENZOFURANPIPERIDINES AS POTENTIAL
CENTRAL-NERVOUS-SYSTEM AGENTS. 2. COMPOUNDS CONTAINING A
HETERCOATOM ATTACHED TO NITROGEN.

000167 01-03 EFFECTS OF SUBSTITUTED SPIROISOBENZOFURANPIPERIDINES ON SYNAPTOSOMAL BIOGENIC AMINE TRANSPORT.

002087 03-03 SPIRONOLACTONE

SPIRONOLACTONE PROPHYLAXIS IN MANIC-DEPRESSIVE DISEASE 003499 04-09

STIMULATION OF PRESYNAPTIC BETA-ADRENOCEPTORS ENHANCES H3-NORADRENALINE RELEASE DURING NERVE STIMULATION IN THE

DOPAMINE-BETA-HYDROXYLASE RELEASE FOLLOWING ACUTE SELECTIVE SYMPATHETIC NERVE STIMULATION OF THE HEART, SPLEEN AND

SPONTANEOUS INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS

000124 01-03 EFFECTS OF N METHYLAMINO-ACIDS AND CONVULSANTS ON SPONTANEOUS ACTION POTENTIALS IN GUINEA-PIG CEREBELLAR

PHENOBARBITAL AND PHENYTOIN EFFECTS ON SOMATOSENSORY EVOKED-POTENTIALS AND SPONTANEOUS EEG IN NORMAL CAT BRAIN. 001032 02-02

A PHARMACOLOGICAL STUDY OF THE SPONTANEOUS CONVUISIVE ACTIVITY INDUCED BY 1,2 DIHYDROXYBENZENE (CATECHOL) IN THE ANESTHETIZED MOUSE.

001046 02-03 APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR, LOCOMOTOR STIMULATION AND HYPOTHERMIA IN SPONTANEOUS HYPERTENSIVE RATS AND NORMOTENSIVE WISTAR RATS.

001413 02-04 SELECTIVE MODIFICATION OF SPONTANEOUS ECOG RHYTHMS OF THE CAT SOMESTHETIC CORTEX BY PSYCHOACTIVE DRUGS: BEHAVIORAL

DIHYDROERGOTOXINE-INDUCED MODULATION OF SPONTANEOUS ACTIVITY OF CULTURED RAT PURKINJE CELLS. 002020 03-03

EFFECT OF ALPHA-METHYL-P-TYROSINE ON THE INCIDENCE OF SPONTANEOUS CONVULSIONS OBSERVED FOLLOWING BARBITAL 002104 03-03

SPONTANEOUS AND AMPHETAMINE-INDUCED BEHAVIOR AFTER BILATERAL INJECTION OF ETHANOLAMINE-O-SULFATE INTO THE SUBSTANTIA-NIGRA.

002262 03-04 EFFECT OF AN ANTIPSYCHOTIC AND OTHER CLASSES OF DRUGS ON SPONTANEOUS LOCOMOTOR ACTIVITY AND NEUROTOXICITY IN MICE. 002369 03-06

ASSESSMENT OF SPONTANEOUS AND DRUG-INDUCED CHANGES IN VIGILANCE BY MEANS OF A NEW MODIFICATION OF THE SHORT TIME SPECTRAL ANALYSIS OF THE EEG. 002627 03-14

SPONTANEOUSLY THE CEREBROVASCULAR PERMEABILITY TO PROTEIN AFTER BICUCULLINE AND AMPHETAMINE ADMINISTRATION IN SPONTANEOUSLY HYPERTENSIVE RATS

002050 03-03 ANGIOTENSIN BINDING AFFINITY AND CAPACITY IN THE MIDBRAIN AREA OF SPONTANEOUSLY HYPERTENSIVE AND NORMOTENSIVE RATS.

002870 04-03

STUDIES ON THE MECHANISM OF SPROUTING OF NORADRENERGIC TERMINALS IN RAT AND MOUSE CEREBELLUM AFTER NEONATAL 6 HYDROXYDOPA. 002980 04-03

SPROUTS BETA-ADRENOCEPTORS MODULATE NORADRENALINE RELEASE FROM AXONAL SPROUTS IN CULTURED RAT SUPERIOR CERVICAL GANGLIA 002179 03-03

SOME BEHAVIORAL EFFECTS OF SP6-11 HEXAPEPTIDE C-TERMINAL OF SUBSTANCE-P INJECTED INTO THE CEREBRAL VENTRICLES IN RATS. 002267 03-04

INHIBITION OF BRAIN ANGIOTENSIN-I CONVERTING ENZYME BY BOTHROPS-JARARACA NONAPEPTIDE (SQ-20881) AND A PROLYL ANALOG (SQ-14225). 002818 04-03 SQ-20881

003422 04-06

INHIBITION OF BRAIN ANGIOTENSIN-I CONVERTING ENZYME BY BOTHROPS-JARARACA NONAPEPTIDE (SQ-20881) AND A PROLYL ANALOG (SQ-14225). 002818 04-03

PENTOBARBITAL: PRESYNAPTIC EFFECT IN THE SQUID GIANT SYNAPSE 000204 01-03

SQUIRREL-MONKEY DISCRIMINATIVE EFFECTS OF NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT AND SQUIRREL-MONKEY.

000381 01-04 PHYSIOLOGICAL EFFECTS OF COCAINE IN THE SQUIRREL-MONKEY 001136 02-03

PROGRESSIVE FORCE SCHEDULES IN THE SQUIRREL-MONKEY: EFFECTS OF INCREMENT SIZE, AMPHETAMINE, AND HALOPERIDOL. (PH.D.

001459 02-04 THE EFFECTS OF ACUTE AND CHRONIC PHENCYCLIDINE ON SCHEDULE-CONTROLLED BEHAVIOR IN THE SQUIRREL-MONKEY.

002209 03-04 CONFLICT BEHAVIOR IN THE SQUIRREL-MONKEY: EFFECTS OF CHLORDIAZEPOXIDE, DIAZEPAM AND N DESMETHYLDIAZEPAM 002303 03-04

SOUIRREL-MONKEY ACTIVE CONFLICT TEST. 002795 04-02 DIFFERENTIAL BEHAVIORAL EFFECTS OF SULPIRIDE IN THE RAT AND

003276 04-04 SQUIRREL-MONKEYS EFFECTS OF D AMPHETAMINE, CHLORDIAZEPOXIDE AND PROMAZINE ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION AND STIMULUS SHOCK

SQUIRREL-MONKEY

TERMINATION

DISCRETE-TRIAL CONTROL OF COCAINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF MORPHINE, NALOXONE, AND CHLORPROMAZINE.

001469 02-04 DISCRETE-TRIAL CONTROL OF MORPHINE SELF-INJECTION BEHAVIOUR IN SQUIRREL-MONKEYS: EFFECTS OF NALOXONE, MORPHINE, AND

001470 02-04 ETHANOL, PENTOBARBITAL, AND CHLORDIAZEPOXIDE EFFECTS IN SQUIRREL-MONKEYS RESPONDING UNDER FIXED-RATIO FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION SCHEDULES

002254 03-04 EFFECTS OF D AMPHETAMINE AND ETHANOL ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION. 002255 03-04

AGGRESSION INCREASE AND WATER COMPETITION DECREASE IN SQUIRREL-MONKEYS GIVEN PHYSOSTIGMINE INJECTIONS. 003377 04-04 COCAINE AS DISCRIMINATIVE STIMULUS FOR RESPONDING MAINTAINED

BY FOOD IN SQUIRREL-MONKEYS. 003398 04-04

SRIF ANALGESIC EFFECT OF CEREBROVENTRICULAR ADMINISTRATION OF SOMATOSTATIN (SRIF).

002245 03-04 EFFECT OF SOMATOSTATIN (SRIF) AND L GLUTAMATE ON NEURONS OF THE SENSORIMOTOR CORTEX IN AWAKE HABITUATED RABBITS 002958 04-03

THE STABILITY AND RELIABILITY OF RADIOIMMUNOASSAYS FOR CLONAZEPAM, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN BLOOD, SERUM OR PLASMA.

003439 04-06 STABILITY OF LOW BLOOD PLATELET MONOAMINE-OXIDASE ACTIVITY IN HUMAN ALCOHOLICS.

003577 04-11 STABILIZATION
THE USE OF PENFLURIDOL ACCORDING TO A NEW DOSAGE REGIMEN IN
THE ACUTE, STABILIZATION AND MAINTENANCE PHASES OF PSYCHOSIS

003491 04-09 USE OF STABLE ISOTOPES IN STUDIES ON THE METABOLISM OF

AMPHETAMINE. 002970 04-03

EFFECT OF OXPRENOLOL ON STAGE-FRIGHT IN MUSICIANS. 001718 02-14

WAKING STAGE-1 REM OBSERVED IN PARANOID HALLUCINATORY STATES OF NARCOLEPSY. 002675 03-15

FLURAZEPAM EFFECTS ON SLOW-WAVE SLEEP: STAGE-4 SUPPRESSED BUT NUMBER OF DELTA-WAVES CONSTANT. 001708 02-14 EFFECTS OF IMIPRAMINE ON ENURETIC FREQUENCY AND SLEEP STAGES.
001719 02-14 STAIRCASE
COMPARISON OF THE EFFECT OF SOME BENZODIAZEPINES WITH THE
STAIRCASE METHOD. 003404 04-04 STANDARD MULTIPLE DRUG THERAPY -- IS THERE A STANDARD OF CARE? 000954 01-17 THE EFFECTS OF STANDARD NEUROLEPTIC COMPOUNDS ON THE BINDING OF H3-SPIROPERIDOL IN THE STRIATUM AND MESOLIMBIC SYSTEM OF THE PAT IN WITPO 002955 04-03 STANDARD AND LONG-ACTING DEPOT NEUROLEPTICS IN CHRONIC SCHIZOPHRENICS: AN 18-MONTH OPEN MULTICENTRIC STUDY. 003471 04-08 STANDARD-CONTROLLED

NOMIFENSIN IN THE TREATMENT OF DEPRESSION: A STANDARDCONTROLLED CLINICAL STUDY. 002415 03-09 TRIAZOLAM IN INSOMNIA: A STANDARD-CONTROLLED TRIAL 002523 03-11 BUTACLAMOL IN THE TREATMENT OF SCHIZOPHRENIA. A CONTROLLED CLINICAL TRIAL. STANDARD-003465 04-08 STARTLE SILOCYBIN: BIPHASIC DOSE-RESPONSE EFFECTS ON THE ACOUSTIC STARTLE REFLEX IN THE RAT. 000345 01-04 PHARMACOLOGICAL APPROACHES TO HABITUATION OF THE ACOUSTIC STARTLE RESPONSE IN RATS. 00425 01-04 THE EFFECTS OF PIMOZIDE AND PHENOXYBENZAMINE PRETREATMENTS ON AMPHETAMINE AND APOMORPHINE POTENTIATION OF THE ACOUSTIC STARTLE RESPONSE IN RATS. 003257 04-04 STARVATION-INDUCED
PHARMACOLOGICAL INFLUENCES ON STARVATION-INDUCED
HYPERRESPONSIVENESS IN THE RAT. (PH.D. DISSERTATION) 002212 03-04 METABOLIC RESPONSES TO ISOPROTERENOL AND EPINEPHRINE IN THE RABBIT: INFLUENCE OF STATE OF NOURISHMENT, ALLOXAN DIABETES AND PRETREATMENT WITH PROPRANOLOL. 000227 01-03 THREE EXPERIENCES THAT CAN ALTER THE STATE OF CONSCIOUSNESS 000684 01-12 EFFECTIVENESS OF PSYCHOTROPIC DRUGS IN PATIENTS IN A STATE OF MALNUTRITION OR EXPOSED TO EXTREME CLIMATIC CONDITIONS. 000721 01-13 PATTERNS OF ANTIPSYCHOTIC DRUG USE IN FOUR SOUTHEASTERN STATE 000963 01-17 SLOW-WAVE SLEEP AND A STATE RESEMBLING ABSENCE EPILEPSY INDUCED IN THE RAT BY GAMMA-HYDROXYBUTYRATE. 901366 02-04
PSYCHOTROPIC DRUG EFFECTS ON THE EMOTIONAL STATE OF CATS IN A SOCIAL SITUATION effect of Fusaric-Acid on Tardive-Dyskinesia and Mental State in Psychogeriatric Patients: A Pilot Study. 001629 02-11 THE PSILOCYBIN-INDUCED STATE OF DRUNKENNESS IN NORMAL VOLUNTEERS AND SCHIZOPHRENICS. 001726 02-14 EFFECTS OF FLUPENTHIXOL ON THE CLINICAL STATE AND EEG OF **SCHIZOPHRENICS** 002395 03-08 TRESS AND THE HEART: INTERACTIONS OF THE CARDIOVASCULAR SYSTEM, BEHAVIORAL STATE, AND PSYCHOTROPIC DRUGS. 002711 03-15 THE USE OF PSYCHOTROPIC DRUGS IN STATE HOSPITALS: A LEGAL OR MEDICAL DECISION?.

MAJOR THEORIES OF STATE-DEPENDENT LEARNING.

MAJOR THEORIES OF STATE-DEPENDENT LEARNING

HUMAN STATE-DEPENDENT LEARNING

BASIC MECHANISMS OF STATE-DEPENDENT LEARNING

DRUG DISCRIMINATION AND STATE-DEPENDENT LEARNING

Psychopharmacology Abstracts Physiological Substrates of State-Dependent Learning. 003302 04-04 Some Failures of the Drug discrimination hypothesis of State-

MOOD STATE-DEPENDENT LEARNING. 003317 04-04

MEMORY CONSOLIDATION AND CHOLINERGIC STATE-DEPENDENT LEARNING IN MAN.

003612 04-13
STATE-DEPENDENT RETRIEVAL OF ITEM, ASSOCIATIVE, AND SERIAL ORDER INFORMATION.

ORDER INFORMATION. 003711 04-17

STATE-TRAIT

STATE-TRAIT ANXIETY AND ANXIOLYTIC TREATMENT.

ATISTICAL
QUANTIFICATION AND STATISTICAL ANALYSIS OF ORDINAL SCALE DATA
IN PSYCHIATRY.

STATISTICAL ASPECTS OF PSYCHOTROPIC DRUG TRIAL DESIGNS.
000922 01-16
STATISTICAL EVALUATION: PRESUMPTION AND METHODS.

COMPARABLE EFFICACY OF IMIPRAMINE HCL AND IMIPRAMINE-PAMOATE: A POOLED STATISTICAL REPORT.

PAMOATE: A POOLED STATISTICAL REPORT.

003526 04-09

STATISTICS

APPLICATION OF STATISTICS TO THE METHODOLOGY OF STUDIES OF DRUGS ACTING ON THE BRAIN.

001620 02-11

ATUS-EPILEPTICUS
STATUS-EPILEPTICUS OR REPETITIVE SEIZURES FOLLOWING TOXIC
INGESTION.

STAY

MAINTENANCE ANTIPSYCHOTIC PHARMACOTHERAPY, RELAPSE, AND
LENGTH OF STAY OUT OF THE HOSPITAL IN CHRONIC SCHIZOPHRENICS
IN GREECE.

IN GREECE. 001911 02-17

THE FFECT OF BARBITURATE AND PROCAINE ON GLIAL AND NEURONAL CONTRIBUTIONS TO EVOKE CORTICAL STEADY POTENTIAL SHIFTS.

001219 02-03

INCREASED STEADY-STATE PLASMA LEVELS AND PROLONGED HALF-LIVES
OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY.

000734 01-13

STEADY-STATE SERUM CONCENTRATIONS OF DOTHIEPIN AND NORTHIADEN AFTER TWO DOSAGE REGIMENS OF DOTHIEPIN HYDROCHLORIDE (PROTHIADEN).

STEADY-STATE KINETICS OF IMIPRAMINE IN PATIENTS.

002556 03-13

PREDICTION OF STEADY-STATE PLASMA CONCENTRATION OF IMPRAMINE.

003516 04-09

002500 03-10

PPOSSIBLE PHYSIOLOGICAL SIGNIFICANCE OF THE INITIAL STEP IN THE CATABOLISM OF NORADRENALINE IN THE CENTRAL-NERVOUS-SYSTEM OF THE RAT.

STEREOCHEMICAL
STEREOCHEMICAL STUDIES ON MEDICINAL AGENTS. 23. SYNTHESIS AND
BIOLOGICAL EVALUATION OF 6 AMINO DERIVATIVES OF NALOXONE

AND NALTREXONE. 001004 02-01

AGONIST EFFECTS OF BETA-PHENYLETHYLAMINES ON THE NORADRENERGIC CYCLIC-ADENOSINE-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. 3,5-MONOPHOSPHATE GENERATING SYSTEM IN RAT LIMBIC FOREBRAIN. STEREOISOMERS OF P-HYDROXYNOREPHEDRINE.

000272 01-03

EQUAL SUPPRESSION OF CEREBELLAR PURKINJE CELL ACTIVITY BY AMPHETAMINE STEREOISOMERS.

000299 01-03

3.4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3 AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND ANTICONVULSANT ACTIVITIES.

00035 01-0;
STEREOSELECTIVE, DOSE-DEPENDENT MODIFICATION OF INTRACRANIAL
SELF-STIMULATION (ICSS) BY CENTRALLY ADMINISTERED
LEVORPHANOL AND DEXTROPPHAN.

001280 02-03

002730 03-17

000970 01-17

002292 03-04

002727 03-16

002753 03-17

002772 03-17

STEREOSELECTIVE EFFECTS OF DIMETHOXY-4-METHYLPHENYLAMINOPROPANE (DOM) ON SCHEDULE-CONTROLLED BEHAVIOR. 001372 02-04

STEREOSELECTIVITY
STEREOSELECTIVITY IN THE METABOLISM OF H3-NORADRENALINE
DURING UPTAKE INTO AND EFFLUX FROM THE ISOLATED RAT VAS-

STEREOSPECIFIC
STEREOSPECIFIC ACTIONS OF MORPHINE ON SINGLE NEURONES IN THE
BRAINSTEM OF THE RAT.

THE EFFECT OF PH ON STEREOSPECIFIC OPIATE BINDING TO MOUSE BRAIN

STEREOSPECIFIC AND NONSTEREOSPECIFIC EFFECTS OF ()- AND (-)
MORPHINE: EVIDENCE FOR A NEW CLASS OF RECEPTORS?.

OO1031 02-02
COMPARATIVE INHIBITORY EFFECTS OF SYNTHETIC ENKEPHALINS ON THE
STEREOSPECIFIC BINDING OF H3-DIHYDROMORPHINE AND H3HAJ OXONE

001076 02-03
SYNTHESIS AND STEREOSPECIFIC ANTIPSYCHOTIC ACTIVITY OF
BENZOCYCLOHEPTENE-PIRIDINE.

SUBCELLULAR DISTRIBUTION OF ETORPHINE IN RAT BRAIN AND EVIDENCE FOR IN VIVO STEREOSPECIFIC BINDING.

002856 04-03

STEREOTYPE
A COMPARATIVE STUDY OF DIFFERENT AMPHETAMINES ON
COPULATORY BEHAVIOR AND STEREOTYPE ACTIVITY IN THE FEMALE

ELICITED BY AMPHETAMINE. 000372 01-04

AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOUR AND BRAIN
CONCENTRATIONS OF AMPHETAMINE AND ITS HYDROXYLATED

METABOLITES IN MICE.

O01316 02-04

DIFFERENTIAL ACTIVATION BY SOME 2 AMINOTETRALIN DERIVATIVES OF THE RECEPTOR MECHANISMS IN THE NUCLEUS-ACCUMBENS OF RAT WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITING.

WHICH MEDIATE HYPERACTIVITY AND STEREOTYPED BITING.
001335 02-04
EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE INTOXICATION
ON EXPLORATORY AND STEREOTYPED BEHAVIORS IN THE RAT.

O01379 02-04

APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR, LOCOMOTOR

STIMULATION AND HYPOTHERMIA IN SPONTANEOUS HYPERTENSIVE

RATS AND NORMOTENSIVE WISTAR RATS.

001413 02-04
CIONAZEPAM AND DOPAMINE RELATED STEREOTYPED BEHAVIOR.

O01485 02-04
TOLERANCE TO STEREOTYPED BEHAVIOUR AND TO DECREASE IN
STRIATAL HOMOVANILLIC-ACID LEVELS AFTER REPEATED TREATMENT
WITH APOMORPHINE-DIPIVALOYL-ESTER.

001497 02-04
THE EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY AND
STEREOTYPED BEHAVIOUR OF RATS STUDIED ON A HOLE-BOARD.
002274 03-04

THE EFFECT OF CHOLINE-CHLORIDE ON AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR. 002330 03-04

STEREOTYPED BEHAVIOR AFTER CHOLINERGIC, BUT NOT DOPAMINERGIC, STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.

ATTENUATION OF STEREOTYPED BEHAVIOUR BY SEX STEROIDS.

THE RELATIONSHIP BETWEEN PIPRADROL-INDUCED RESPONDING FOR ELECTRICAL BRAIN STIMULATION, STEREOTYPED BEHAVIOUR AND LOCOMOTOR ACTIVITY.

MANDIBULOGRAM AS A MEASURE OF STEREOTYPED BEHAVIOR IN THE RAT.

STEREOTYPIES
INTERACTION BETWEEN D. AMPHETAMINE AND ETHANOL WITH RESPECT
TO LOCOMOTION, STEREOTYPIES, ETHANOL SLEEPING TIME, AND THE
KINETICS OF DRUG ELIMINATION.

00337B 04-04

STEREOTYPY
CIRCLING BEHAVIOR AND STEREOTYPY INDUCED BY INTRANIGRAL
OPIATE MICROINJECTIONS.

THE EFFECT OF L-DOPA AND LERGOTRILE-MESYLATE ON THE INTERACTION OF FLUPHENAZINE-DECANOATE AND AMPHETAMINE-INDUCED STEREOTYPY AND MORTALITY.

EFFECTS OF DEAFENING AND BLINDFOLDING ON AMPHETAMINE-INDUCED STEREOTYPY IN THE CAT.

OO0456 01-0

EFFECT OF NEUROLEPTICS, MYDANTHAN, AND DOPA ON APOMORPHINEINDUCED STEREOTYPY IN RATS.

CLONAZEPAM AND 5 HYDROXYTRYPTOPHAN-INDUCED MYOCLONIC

MODIFICATION OF THE AMPHETAMINE-INDUCED STEREOTYPY IN RATS FOLLOWING INHIBITION OF THE NORADRENALINE RELEASE BY FLA-136. 001367 02-04

MUSCIMOL A GABA-AGONIST INJECTED INTO THE NUCLEUS-ACCUMBENS INCREASES APOMORPHINE STEREOTYPY AND DECREASES THE MOTILITY.

CHOLINERGIC INHIBITION OF METHYLPHENIDATE-INDUCED STEREOTYPY:

OXOTREMORINE.

STEREOTYPY AND HYPERACTIVITY IN RATS RECEIVING ETHANOL AND A MONOAMINE-OXIDASE INHIBITOR.

Q02248 03-04

AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY AND STEREOTYPY AFTER
KAINIC-ACID LESIONS OF THE STRIATUM.

O02279 03-04
INFLUENCE OF EXTRAPYRAMIDAL DISTURBANCES DUE TO HALOPERIDOL
ON PHENAMINE STEREOTYPY AND THE EFFECTS OF SCHIZOPHRENIC
BLOOD SERUM (EXPERIMENTAL STUDIES).

002339 03-05
BRAIN MECHANISMS OF AMPHETAMINE-INDUCED ANOREXIA,
LOCOMOTION, AND STEREOTYPY: A REVIEW.

TESTOSTERONE ATTENUATED STEREOTYPY AND HYPERACTIVITY INDUCED BY BETA-PHENYLETHYLAMINE IN PARGYLINE PRETREATED RATS. 003224 04-04

STERIC
STERIC INFLUENCE ON INHIBITION OF MONOAMINE-OXIDASE FORMS BY
2,3 DICHLORO-ALPHA-METHYLBENZYLAMINE.

002918 04-03

THE EFFECT OF STEROID HORMONES ON CEREBRAL BLOOD FLOW BEFORE AND AFTER INTRACAROTID INFUSION OF 5 HYDROXYTRYPTAMINE.

O01193 02-03

STEROID-INDUCED
LITHIUM FOR STEROID-INDUCED PSYCHOSIS.

STEROIDAL
QUANTITATIVE PHARMACO-EEG WITH STEROIDAL HORMONES.

002566 03-13

ATTENUATION OF STEREOTYPED BEHAVIOUR BY SEX STEROIDS.
003312 04-04

REWARD ENHANCEMENT BY PSYCHOMOTOR STIMULANT DRUGS.
000440 01-04
POTENTIATION OF BRAIN REWARD MECHANISMS BY PSYCHOMOTOR

O00441 01-04
REPORT FROM CLINICAL PRACTICE: THE REAL AND IDEAL MANAGEMENT
OF STIMULANT DRUG TREATMENT OF HYPERACTIVE CHILDREN.
(IMPOURLISHED PAPER)

COMPARING TREATMENT TACTICS WITH A HYPERACTIVE PRESCHOOL CHILD: STIMULANT MEDICATION AND PROGRAMMED TEACHER INTERVENTION.

WITHDRAWAL OF A STIMULANT DRUG AND CONCURRENT BEHAVIORAL
INTERVENTION IN THE TREATMENT OF A HYPERACTIVE CHILD.
000780 01-14

A REVIEW OF STIMULANT DRUG RESEARCH WITH HYPERACTIVE CHILDREN.

O00937 01-17
STIMULANT DRUGS AND LEARNING PROBLEMS.

001877 02-17
STIMULANT ACTION OF THYROTROPIN-RELEASING HORMONE ON CAT
SPINAL CORD.

TIME-RESPONSE ANALYSIS OF THE EFFECT OF STIMULANT MEDICATION ON THE LEARNING ABILITY OF CHILDREN REFERRED FOR HYPERACTIVITY.

002534 03-11
HYPERACTIVE CHILDRENS UNDERUSE OF LEARNING TIME: CORRECTION
BY STIMULANT TREATMENT.

002614 03-14

EXPERIMENTAL AND CLINICAL EVIDENCE OF THE ANTIDEPRESSANT EFFECT
OF A BETA-ADRENERGIC STIMULANT.

003546 04-10
BEHAVIOR THERAPY AND WITHDRAWAL OF STIMULANT MEDICATION IN
HYPERACTIVE CHILDREN.

003566 04-11

THE BEHAVIORAL SYMPTOMS OF HYPERKINETIC CHILDREN WHO SUCCESSFULLY RESPONDED TO STIMULANT DRUG TREATMENT 003579 04-11

THE EFFECT OF STIMULANTS, DEPRESSANTS, AND PROTEIN SYNTHESIS INHIBITION ON RETENTION.

000360 01-04 THE EFFECTS OF CENTRAL-NERVOUS-SYSTEM STIMULANTS ON TOURETTE SYNDROME.

MODE OF ACTION OF: ANTIDEPRESSANTS AND CENTRAL STIMULANTS. (UNPUBLISHED PAPER).

000958 01-17 TOXIC INTERACTIONS OF STIMULANTS, NARCOTICS AND NARCOTIC

ANTIDEPRESSANT AGENTS. 9.3,3 DIPHENYLCYCLOBUTYLAMINES, A NEW CLASS OF CENTRAL STIMULANTS.

001943 03-01 MEMORY: MODIFICATION OF ANISOMYCIN-INDUCED AMNESIA BY STIMULANTS AND DEPRESSANTS.

002232 03-04 EFFECTS OF STIMULANTS, ANORECTICS, AND RELATED DRUGS ON SCHEDULE-CONTROLLED BEHAVIOR.

002243 03-04 INTERACTIONS BETWEEN DEPRESSANTS (ALCOHOL-TYPE) AND STIMULANTS (AMPHETAMINE-TYPE).

CHARACTERIZATION OF DISCRIMINATIVE STIMULUS PROPERTIES OF PSYCHOMOTOR STIMULANTS.

003150 04-04 INTRUDER-EVOKED AGGRESSION IN ISOLATED AND NONISOLATED MICE: EFFECTS OF PSYCHOMOTOR STIMULANTS AND L-DOPA.

HANDBOOK OF PSYCHOPHARMACOLOGY, VOL. 11. STIMULANTS. 003715 04-17 003298 04-04

STIMULATED
HISTAMINE STIMULATED ADENYLATE-CYCLASE: BLOCKADE BY
IMIPRAMINE AND ITS ANALOGUES.

DIFFERENTIAL TOLERANCE TO INHIBITORY ACTION OF VARIOUS NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS CHRONICALLY TREATED WITH HALOPERIDOL.

001398 02-04 NEUROLEPTIC STIMULATED PROLACTIN SECRETION IN THE RAT AS AN ANIMAL MODEL FOR BIOLOGICAL PSYCHIATRY: I. COMPARISON WITH ANTIPSYCHOTIC ACTIVITY.

002096 03-03

NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN BRAIN
SLICES IN VITRO AFTER SEROTONIN DEPLETION OR CHRONIC
ADMINISTRATION OF SELECTIVE AMINE REUPTAKE INHIBITORS.

002148 03-03 ROTOMETER FOR RECORDING ROTATION IN CHEMICALLY OR ELECTRICALLY STIMULATED RATS.

LACK OF EFFECTS OF L TRYPTOPHAN ON BASAL AND TRH STIMULATED TSH AND PROLACTIN LEVELS.

NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION OF THE SYMPATHETIC NERVE OF THE EYE.

NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. I. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE IN EXPONENTIAL GROWTH PHASE.

002836 04-03 BRAIN ALPHA-ADRENERGIC RECEPTORS: COMPARISON OF H3-WB-4101 BINDING WITH NOREPINEPHRINE STIMULATED CYCLIC-AMP ACCUMULATION IN RAT CEREBRAL-CORTEX.

INFLUENCE OF LITHIUM ON DOPAMINE STIMULATED ADENYLATE-CYCLASE ACTIVITY IN RAT BRAIN.

002922 04-03
NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED
INCREASES IN CYCLIC-AMP. II. CHARACTERIZATION OF A CULTURED
NEURONAL CELL LINE TREATED WITH DIBUTYRYL-CYCLIC-AMP.

003026 04-03 EFFECT OF STRESS ON NOREPINEPHRINE STIMULATED CYCLIC-AMP FORMATION IN BRAIN SLICES.

H3-SPIROPERIDOL BINDING AND DOPAMINE STIMULATED ADENYLATE-CYCLASE: EVIDENCE FOR MULTIPLE CLASSES OF RECEPTORS IN PRIMATE BRAIN REGIONS.

003112 04-03 INHIBITION OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND BRAIN STIMULATED REWARD.

003255 04-04 STIMULATION
STIMULATION OF FOOD INTAKE BY MUSCIMOL AND BETA-ENDORPHIN

Psychopharmacology Abstracts

INCREASE IN THE TURNOVER OF BRAIN DOPAMINE BY STIMULATION OF MUSCARINIC RECEPTORS OUTSIDE THE DOPAMINE NERVE TERMINALS 000042 01-03

THE RELATIONSHIP BETWEEN MAGNITUDE OF ELECTROSHOCK STIMULATION AND THE EFFECTS OF DIGITOXIGENIN, PENTYLENETETRAZOL AND BRAIN MONOAMINE REDUCTION ON ELECTROSHOCK CONVULSIVE THRESHOLDS.

000066 01-03 EFFECTS OF RETICULAR STIMULATION, D AMPHETAMINE AND SCOPOLAMINE ON ACETYLCHOLINE RELEASE FROM THE HIPPOCAMPUS OF BRAINSTEM TRANSECTED CATS.

ELECTRICAL STIMULATION OF DENERVATED MUSCLES REDUCES INCORPORATION OF METHIONINE INTO THE ACH RECEPTOR. 000136 01-03

ACETYLCHOLINE STIMULATION OF THE SYMPATHETIC GANGLIA: EFFECTS OF TAURINE AND NICOTINIC AND MUSCARINIC GANGLION BLOCK.

TYROSINE-HYDROXYLASE: DELAYED ACTIVATION IN CENTRAL NORADRENERGIC NEURONS AND INDUCTION IN ADRENAL MEDULLA ELICITED BY STIMULATION OF CENTRAL CHOLINERGIC RECEPTORS.

000183 01-03 PERLAPINE: RELATIONSHIP BETWEEN STIMULATION OF PROLACTIN SECRETION AND ANTIPSYCHOTIC ACTIVITY.

000197 01-03 SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION: A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL MEMBRANES FROM MATURE RAT BRAIN.

000230 01-03 CHANGES IN HIPPOCAMPAL EVOKED RESPONSES TO AFFERENT STIMULATION DURING CONDITIONING.

EFFECT OF NEUROTROPIC DRUGS ON SLEEP DISTURBANCES CAUSED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS IN CATS.

000795 01-14 STUDIES ON THE INFLUENCE OF BIOGENIC AMINES AND PSYCHOACTIVE DRUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMULATION TEST IN ENDOGENOUS DEPRESSION.

000926 01-16 STIMULATION OF CAFFEINE METABOLISM IN THE RAT BY 3 METHYLCHOLANTHRENE.

001044 02-03 DAILY 1 DELTA9-TETRAHYDROCANNABINOL AND PRESSING FOR HYPOTHALAMIC STIMULATION.

001053 02-03 ANALGESIA INDUCED BY VAGINAL STIMULATION IN RATS IS
APPARENTLY INDEPENDENT OF A MORPHINE SENSITIVE PROCESS 001090 02-03

BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF CHRONIC REDUCTION OF CEREBRAL NORADRENALINE RECEPTOR STIMULATION.

001099 02-03 ANALGESIC BRAIN STIMULATION IN THE CAT: EFFECT OF INTRAVENTRICULAR SEROTONIN, NOREPINEPHRINE, AND DOPAMINE

001101 02-03 RELAXATION OF SMOOTH MUSCLE FOLLOWING CONTRACTION ELICITED BY SYMPATHETIC NERVE STIMULATION IN VIVO.

001106 02-03 DECREASE IN NEOSTRIATAL BLOOD FLOW AFTER D AMPHETAMINE ADMINISTRATION OR ELECTRICAL STIMULATION OF THE SUBSTANTIA-

001175 02-03 LYSERGIC-ACID-DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF PITUITARY DOPAMINE RECEPTORS.

DECREASE OF FOOD INTAKE BY QUIPAZINE IN THE RAT: RELATION TO SEROTOMINERGIC RECEPTOR STIMULATION.

001235 02-03 ROLE OF CALCIUM IN THE AMPHETAMINE-INDUCED STIMULATION OF CATECHOL FORMATION IN THE STRIATUM.

CONCURRENT MAPPING OF BRAIN SITES FOR SENSITIVITY TO THE DIRECT APPLICATION OF MORPHINE AND FOCAL ELECTRICAL STIMULATION IN THE PRODUCTION OF ANTINOCICEPTION IN THE RAT.

001291 02-03 LOCOMOTOR STIMULATION BY L-DOPA: RELATIVE IMPORTANCE OF NORADRENALINE RECEPTOR ACTIVATION.

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): NALOXONE BLOCKS MORPHINES ACCELERATION OR PRESSING FOR ICS. 001313 02-04

THE INFLUENCE OF ELECTRICAL STIMULATION ON THE HIPPOCAMPAL UNITS ACTIVITY OF THE RABBIT.

INFLUENCE OF NEUROTROPIC DRUGS ON CHANGES OF EVOKED-POTENTIALS AMPLITUDES AFTER STIMULATION OF THE HYPOTHALAMUS.

EATING FOLLOWING CHOLINERGIC STIMULATION OF THE

HYPOTHALAMUS.

001318 02-04 001326 02-04

000023 01-02

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): PRESSING FOR ICS BEFORE AND AFTER SELF-ADMINISTRATION OF SWEETENED MORPHINE SOLUTIONS.

A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND BIOELECTRIC CORRELATES OF EMOTIONAL REACTIONS ELICITED BY CHOLINERGIC STIMULATION OF THE HYPOTHALAMUS AND THE VENTRAL TEGMENTUM.

001390 02-04

BRAIN STIMULATION PROVOKED EMOTIONAL REACTIONS OF CATS IN A SOCIAL SITUATION.

001395 02-04

APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR, LOCOMOTOR

STIMULATION AND HYPOTHERMIA IN SPONTANEOUS HYPERTENSIVE

RATS AND NORMOTENSIVE WISTAR RATS.

THE EFFECTS OF STIMULATION AND DEPRESSION OF THE RETICULOENDOTHELIAL SYSTEM ON SIDMAN AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).

O01468 02-04

ANALGESIA FOLLOWING TRANSCUTANEOUS ELECTRICAL STIMULATION
AND ITS PARTIAL REVERSAL BY A NARCOTIC ANTAGONIST.

001646 02-13

HYPERACTIVE AND NONHYPERACTIVE CHILDRENS SELF-DETERMINED LEVELS OF STIMULATION. (PH.D. DISSERTATION).

EVIDENCE FOR SELECTIVE AND LONG-LASTING STIMULATION OF REGULATORY DOPAMINE RECEPTORS BY BROMOCRIPTINE (CB-154). 002002 03-03 PARAVENTRICULAR NUCLEUS: A PRIMARY SITE MEDIATING ADRENERGIC

STIMULATION OF FEEDING AND DRINKING.

002074 03-03
INFLUENCE OF IMMUNE STIMULATION AND SUPPRESSION ON MORPHINE

PHYSICAL DEPENDENCE AND TOLERANCE. 002095 03-03
INTERACTION BETWEEN MORPHINE AND REINFORCING LATERAL

HYPOTHALAMIC STIMULATION.

002291 03-04

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): DAILY MORPHINE, SELF-STIMULATION, AND PARAMETERS OF ICS.

002320 03-04
LUTEINIZING HORMONE RELEASING HORMONE AND THYROTROPINRELEASING HORMONE STIMULATION STUDIES IN PATIENTS GIVEN
CLOMIPRAMINE OR DEPOT NEUROLEPTICS.

LITHIUM STIMULATION OF GRANULOPOIESIS.

O02695 03-15
STRENGTH DURATION PROPERTIES OF SINGLE UNITS DRIVEN BY

002563 03-13

ELECTRICAL STIMULATION OF THE LATERAL HYPOTHALAMUS IN RATS.
002763 03-17
THE EFFECT OF LITHIUM ON AMPHETAMINE-INDUCED LOCOMOTOR
STIMULATION.

002791 04-02

NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE

OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL
SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION
OF THE SYMPATHETIC NERVE OF THE EYE.

002802 04-03
STIMULATION OF ADENYLATE-CYCLASE ACTIVITY IN MONKEY ANTERIOR
LIMBIC CORTEX BY SEROTONIN

O02805 04-03
STIMULATION OF DOPAMINE SYNTHESIS IN CAUDATE NUCLEUS BY
INTRASTRIATAL ENKEPHALINS AND ANTAGONISM BY NALOXONE.
002825 04-03

STIMULATION OF PRESYNAPTIC BETA-ADRENOCEPTORS ENHANCES H3-NORADRENALINE RELEASE DURING NERVE STIMULATION IN THE PERFUSED CAT SPLEEN.

002855 04-03
THE EFFECT OF LITHIUM ON THE INCREASE IN FOREBRAIN 5
HYDROXYINDOLEACETIC-ACID PRODUCED BY RAPHE STIMULATION.
002871 04-03

THE NEURONAL ORIGIN OF PROSTAGLANDIN RELEASED FROM THE RABBIT PORTAL VEIN IN RESPONSE TO ELECTRICAL STIMULATION. 002933 04-03 STIMULATION BY LITHIUM-IONS OF THE INCORPORATION OF C14-

GLUCOSE INTO GLYCOGEN IN RAT BRAIN SLICES.

003015 04-03

EFFECTS OF PAIN ATTENUATING BRAIN STIMULATION AND MORPHINE ON ELECTRICAL ACTIVITY IN THE RAPHE NUCLEI OF THE AWAKE RAT. 03034 04-03

TRYPTAMINE-INDUCED DRUG EFFECTS INSENSITIVE TO SEROTOMINERGIC ANTAGONISTS: EVIDENCE OF SPECIFIC TRYPTAMINERGIC RECEPTOR STIMULATION?

CHANGES IN BRAIN FREE FATTY-ACIDS AFTER PAINFUL PERIPHERAL STIMULATION (EFFECT OF PROTHIADEN).

CHOLINERGIC STIMULATION OF POLYPHOSPHOINOSITIDE METABOLISM IN BRAIN IN VIVO.

NOCICEPTIVE STIMULATION PREVENTS DEVELOPMENT OF TOLERANCE TO NARCOTIC ANALGESIA.

STEREOTYPED BEHAVIOR AFTER CHOLINERGIC, BUT NOT DOPAMINERGIC, STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS.

OPIOIDS AND REWARDING BRAIN STIMULATION.

003216 04-04
NEUROLEPTIC-INDUCED ATTENUATION OF BRAIN STIMULATION REWARD
IN RATS.

O03221 04-04

ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS

EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND

TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

MOVEMENT INDUCED IN CATALEPTIC RATS: DIFFERENTIAL EFFECTS
PRODUCED BY ELECTRICAL STIMULATION OF THE LATERAL
HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FORMATION.

O03297 04-04
THE EFFECTS OF HALOPERIDOL AND CLOZAPINE ON CIRCLING INDUCED BY
ELECTRICAL STIMULATION OF THE SUBSTANTIA-NIGRA AND THE
VENTROMEDIAL TEGMENTUM.

THE RELATIONSHIP BETWEEN PIPRADROL-INDUCED RESPONDING FOR ELECTRICAL BRAIN STIMULATION, STEREOTYPED BEHAVIOUR AND LOCOMOTOR ACTIVITY

EFFECTS OF SODIUM PHENOBARBITAL ON BRAIN STIMULATION
BEHAVIOR, BEHAVIORAL SEIZURES, AND EEG SEIZURE ACTIVITY.
003355 04-04

DOPAMINE-BETA-HYDROXYLASE RELEASE FOLLOWING ACUTE SELECTIVE SYMPATHETIC NERVE STIMULATION OF THE HEART, SPLEEN AND MESENTERY. 003422 04-06

STIMULATORY
ON THE MODE OF ACTION OF CENTRAL STIMULATORY AGENTS.
001232 02-03

PRIMATE INFORMATION PROCESSING UNDER SODIUM PENTOBARBITAL
AND CHLORPROMAZINE: DIFFERENTIAL DRUG EFFECTS WITH
TACHISTOSCOPICALLY PRESENTED DISCRIMINATIVE STIMULI.

TOLERANCE TO MORPHINE PRODUCED DISCRIMINATIVE STIMULI AND ANALGESIA.

MORPHINE AND ETHANOL AS DISCRIMINATIVE STIMULI: ABSENCE OF ANTAGONISM BY P-CHLOROPHENYLALANINE-METHYL-ESTER, CINANSENIN, OR BC-105.

THE EFFECT OF NALOXONE ON THE EXCITATION OF DORSAL-HORN NEURONES OF THE CAT BY NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULI.

O01102 02-03

HYPERALGESIA INDUCED BY NALOXONE FOLLOWS DIURNAL RHYTHM IN RESPONSIVITY TO PAINFUL STIMULI.

PENTAZOCINE, CYCLAZOCINE, AND NALORPHINE AS DISCRIMINATIVE STIMULI.

PHARMACOLOGY OF DISCRIMINATIVE DRUG STIMULI. 001378 02-04

NEUROTENSIN ADMINISTERED INTRACISTERNALLY INHIBITS RESPONSIVENESS OF MICE TO NOXIOUS STIMULI. 002214 03-04

DEPRESSANT ACTIONS OF METHIONINE-ENKEPHALIN AND SOMATOSTATIN IN CAT DORSAL-HORN NEURONES ACTIVATED BY NOXIOUS STIMULI.

003059 04-03
CENTRAL MECHANISMS OF DRUGS AS DISCRIMINATIVE STIMULI:
INVOLVEMENT OF SEROTONIN PATHWAYS.

003070 04-03
BEHAVIORAL AND PHYSIOLOGICAL STUDIES OF NONNARCOTIC
ANALGESIA IN THE RAT ELICITED BY CERTAIN ENVIRONMENTAL
STIMULI.

A COMPARISON OF DISCRIMINATIVE STIMULI PRODUCED BY NALOXONE, CYCLAZOCINE AND MORPHINE IN THE RAT.

DIFFERENTIAL RESPONDING CONTROLLED BY THE DISCRIMINATIVE STIMULI PRODUCED BY CONVULSANT DRUGS IN THE RAT.

003358 04-04

INTERNAL STIMULUS CONDITIONING TO DISCRIMINATIVE EXTERNAL STIMULI.

003390 04-04
INTEROCEPTIVE DISCRIMINATIVE STIMULI AS TOOLS IN DRUG
DEVELOPMENT.

003428 04-06
THE USE OF DRUGS AS DISCRIMINATIVE STIMULI IN BEHAVIORAL PHARMACODYNAMICS.

003695 04-17

STIMULUS EFFECTS OF DELTA9-THC AND ITS INTERACTION WITH NALTREXONE AND CATECHOLAMINE BLOCKERS IN RATS. 000157 01-03 SUBCUTANEOUS INJECTIONS OF APOMORPHINE, STIMULUS
GENERALIZATION AND CONDITIONING: SERIOUS PITFALLS FOR THE
EXAMINER USING APOMORPHINE AS A TOOL. 000341 01-04 DISCRIMINATIVE STIMULUS PROPERTIES OF FENFLURAMINE IN AN OPERANT TASK: AN ANALYSIS OF ITS CUE FUNCTION. EFFECTS OF D AMPHETAMINE, CHLORDIAZEPOXIDE AND PROMAZINE ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION AND STIMULUS SHOCK TERMINATION. COMPARISON OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE AND AMPHETAMINE IN RATS. GENERALIZATION OF THE CONDITIONED STIMULUS IN TASTE AVERSION. 001405 02-04 DISCRIMINATIVE STIMULUS PROPERTIES OF QUIPAZINE. 001489 02-04 STIMULUS PROPERTIES OF D AMPHETAMINE AS COMPARED TO L
AMPHETAMINE. STIMULUS PROPERTIES OF PHENETHYLAMINE HALLUCINOGENS AND LYSERGIC-ACID-DIETHYLAMIDE: THE ROLE OF 5 HYDROXYTRYPTAMINE. 002180 03-03 DUAL RECEPTOR MEDIATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF PENTAZOCINE. 002191 03-04 A DESCRIPTION OF THE NICOTINE STIMULUS AND TESTS OF ITS GENERALIZATION TO AMPHETAMINE. 002210 03-04 ATTRIBUTES OF DISCRIMINATIVE PENTOBARBITAL STIMULUS IMMEDIATELY AFTER INTRAVENOUS INJECTION. 002265 03-04 RATE-DEPENDENT AND STIMULUS CONTROL EFFECT OF DRUGS 002266 03-04 INDUCED TOLERANCE TO THE DISCRIMINATIVE STIMULUS PROPERTIES OF DISCRIMINATIVE PROPERTIES OF L AMPHETAMINE: STIMULUS
GENERALIZATION CHARACTERIZATION OF DISCRIMINATIVE STIMULUS PROPERTIES OF PSYCHOMOTOR STIMULANTS. 003150 04-04 THE DISCRIMINATIVE STIMULUS PROPERTIES OF INTRAVENOUSLY ADMINISTERED COCAINE IN RHESUS MONKEYS. 003160 04-04
SIMILARITIES AND DIFFERENCES IN DISCRIMINATIVE STIMULUS EFFECTS
OF CHLORDIAZEPOXIDE, PENTOBARBITAL, ETHANOL, AND OTHER 003163 04-04

AMPHETAMINE EFFECTS ON STIMULUS ELICITED INVESTIGATION IN THE MONGOLIAN GERBIL DISCRIMINATIVE STIMULUS PROPERTIES OF NARCOTIC ANALGESIC 003190 04-04 DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE AND D AMPHETAMINE; AND ANTAGONISM BY HALOPERIDOL: A COMPARATIVE STUDY. 003191 04-04 NEUROLEPTIC INTERFERENCE WITH THE COCAINE CUE: INTERNAL STIMULUS CONTROL OF BEHAVIOR AND PSYCHOSIS.

DISCRIMINATIVE STIMULUS PROPERTIES OF ANTIDEPRESSANTS DISCRIMINATIVE STIMULUS PROPERTIES OF NICOTINE: ORGANIC
MOLECULAR MECHANISMS AND NEUROCHEMICAL EVENTS.

ABATEMENT OF STIMULUS PERSERVATION FOLLOWING REPEATED D
AMPHETAMINE TREATMENT: ABSENCE OF BEHAVIORALLY
AUGMENTED TOLERANCE.

DRUG EFFECTS ON RESPONDING MAINTAINED BY STIMULUS REINFORCER AND RESPONSE REINFORCER CONTINGENCIES. 003365 04-04
INTERNAL STIMULUS CONDITIONING TO DISCRIMINATIVE EXTERNAL

ANTAGONISM OF PENTOBARBITAL DISCRIMINATIVE STIMULUS BY BEMEGRIDE IN IMMOBILIZED RATS.

STIMULUS PROPERTIES OF DOM: COMMONALITY WITH OTHER HALLUCINOGENS.

STIMULI.

Psychopharmacology Abstracts

GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF DELTAS-TETRAHYDROCANNABINOL TO CANNABINOIDS WITH THERAPEUTIC POTENTIAL. 003392 04-04

LSD-INDUCED STIMULUS CONTROL: A COMPARISON OF SCH-12679, FENFLURAMINE, P-METHOXYAMPHETAMINE, AND BL-3912. 003396 04-04

COCAINE AS DISCRIMINATIVE STIMULUS FOR RESPONDING MAINTAINED BY FOOD IN SQUIRREL-MONKEYS. 003398 04-04

STIMULUS ATTRIBUTES OF DRUGS. 003617 04-14

STIMULUS-INDUCED
POTENTIATION BY COCAINE OF THE STIMULUS-INDUCED INCREASE IN
DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL SYNAPTOSOMES.
000217 0 000217 01-03

STIMULUS-SHOCK
ETHANOL, PENTOBARBITAL, AND CHLORDIAZEPOXIDE EFFECTS IN
SQUIRREL-MONKEYS RESPONDING UNDER FIXED-RATIO FOOD
PRESENTATION AND STIMULUS-SHOCK TERMINATION SCHEDULES. 002254 03-04

EFFECTS OF D AMPHETAMINE AND ETHANOL ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION. 002255 03-04

STOMACH
ONSET AND OFFSET OF CHLORPROMAZINE BLOCKADE OF
PHENYLEPHRINE, CARBAMYLCHOLINE AND HISTAMINE ON RABBIT
STOMACH STRIPS.
001234 0

EFFECTS OF RESERPINE AND IMIPRAMINE ON VESICULAR SEROTONIN UPTAKE AND STORAGE IN INTACT HUMAN PLATELETS.

000081 01-03 SEROTONIN TRANSPORT AND STORAGE IN RABBIT BLOOD PLATELETS
THE EFFECTS OF RESERPINE AND IMPRAMINE.

000236 01-03 INTERFERENCE BY FENFLURAMINE WITH THE STORAGE OF C14-5-HYDROXYTRYPTAMINE IN RAT PLATELETS.

000297 01-03 EFFECTS OF CATECHOLAMINERGIC DRUGS UPON MEMORY STORAGE PROCESSES IN MICE.

000377 01-04 EFFECTS OF ANTIMYCIN A PLUS 2 DEOXYGLUCOSE ON UPTAKE AND VESICULAR STORAGE OF SEROTONIN IN HUMAN PLATELETS. (UNPUBLISHED PAPER).

000694 01-13 CONTEXT EFFECTS IN THE STORAGE AND RETRIEVAL OF INFORMATION IN

000793 01-14 THE RELATIVE FUNCTIONAL AVAILABILITY OF BRAIN NORADRENALINE AND DOPAMINE STORAGE POOLS.

EFFECTS OF MAZINDOL, FENFLURAMINE AND CHLORIMIPRAMINE ON THE 5 HYDROXYTRYPTAMINE UPTAKE AND STORAGE MECHANISMS IN RAT BRAIN: SIMILARITIES AND DIFFERENCES.

THE HUMAN PLATELET AS A MODEL FOR THE DOPAMINERGIC NEURON:
KINETIC AND PHARMACOLOGIC PROPERTIES AND THE ROLE OF AMINE
STORAGE GRANULES.

002596 03-13 A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTRYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES: COMPARISON WITH CENTRAL SEROTONERGIC NEURONS.

BEHAVIORAL CHANGES INDUCED BY 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM, STP) IN PRIMATE DYADS. 003380 04-04

STRAIN DIFFERENCES IN THE RESPONSE TO MORPHINE ON INCORPORATION OF H3-LYSINE INTO RAT BRAIN PROTEIN 000108 01-03

COMPARISON OF THE EFFECTS OF MORPHINE ON LOCOMOTOR ACTIVITY, ANALGESIA AND PRIMARY AND PROTRACTED PHYSICAL DEPENDENCE IN SIX MOUSE STRAINS.

EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON-DISCRIMINATION LEARNING, CONSOLIDATION, AND LEARNED BEHAVIOR IN TWO INBRED STRAINS OF MICE.

000333 01-04 PENTYLENETETRAZOL: INHIBITORY AVOIDANCE BEHAVIOR, BRAIN SEIZURE ACTIVITY, AND (3H)LYSINE INCORPORATION INTO BRAIN PROTEINS OF DIFFERENT MOUSE STRAINS.

000384 01-04 DOSE-RESPONSE EFFECTS OF ALCOHOL UPON RAT STRAINS BRED FOR DIFFERENCES IN REACTIVITY TO ALCOHOL.

001234 02-03

003193 04-04

003260 04-04

003266 04-04

003359 04-04

002644 03-14

DIFFERENCES IN THE INHIBITORY EFFECTS OF NORMORPHINE AND OPIOID PEPTIDES ON THE RESPONSES OF THE VASA-DEFERENTIA OF TWO STRAINS OF MICE.

INTOXICATING EFFECTS OF THREE ALIPHATIC ALCOHOLS AND BARBITAL ON TWO RAT STRAINS GENETICALLY SELECTED FOR THEIR ETHANOL INTAKE.

INDUCTION OF SULFOGALACTOSYLCERAMIDE (SULFATIDE) SYNTHESIS BY HYDROCORTISONE (CORTISOL) IN MOUSE G-26 OLIGODENDROGLIOMA CELL STRAINS.

EFFECT OF ACUTE MORPHINE ADMINISTRATION ON THE CEREBELLAR CYCLIC-GMP LEVEL IN TWO STRAINS OF MICE.

002975 04-03

EFFECTS OF MESCALINE AND PSILOCIN ON ACQUISITION, CONSOLIDATION, AND PERFORMANCE OF LIGHT-DARK DISCRIMINATION IN TWO INBRED STRAINS OF MICE.

ANALGESIA AND MOTOR ACTIVITY ELICITED BY MORPHINE AND ENKEPHALINS IN TWO IMBRED STRAINS OF MICE.

003225 04-04
BIMODAL DISTRIBUTIONS OF HIGHEST ETHANOL ACCEPTANCE
CONCENTRATIONS IN TWO STRAINS OF RATS.

A GENETIC ANALYSIS OF THE HYPERTHERMIC RESPONSE TO D
AMPHETAMINE IN TWO INBRED STRAINS OF MICE.

O03411 04-05

PHOTODYNAMIC ACTION OF CHLORPROMAZINE ON ADENOVIRUS 5:
REPAIRABLE DAMAGE AND SINGLE STRAND BREAKS.

000821 01-15

THE INSOMNIA OF SLEEPING IN A STRANGE PLACE: EFFECTS OF L

TRYPTOPHANE. 000632 01-11

STRATEGY
DIAZEPAM: EFFICACY AND TOXICITY AS REVEALED BY A SMALL SAMPLE
RESEARCH STRATEGY.

000933 01-16

INTERACTION OF ERGOT ALKALOIDS WITH DOPAMINERGIC RECEPTORS IN THE RAT STRATUM AND NUCLEUS-ACCUMBENS.

STRENGTH

ENHANCEMENT OF LEARNING BY CYCLOHEXIMIDE AND DDC: A FUNCTION

OF RESPONSE STRENGTH.

O00374 01-04
THE EFFECT OF NITRAZEPAM ON MANUAL SKILL, GRIP STRENGTH, AND
REACTION TIME WITH SPECIAL REFERENCE TO SUBJECTIVE
EVALUATION OF EFFECTS ON SLEEP.

O02626 03-14

STRENGTH DURATION PROPERTIES OF SINGLE UNITS DRIVEN BY
ELECTRICAL STIMULATION OF THE LATERAL HYPOTHALAMUS IN RATS.
002763 03-17

STRESS
THE EFFECTS OF ETHER STRESS AND BETAMETHASONE TREATMENT ON
THE CONCENTRATIONS OF NORADRENALINE AND DOPAMINE IN
VARIOUS REGIONS OF THE RAT REALIN

O00288 01-03

EFFECT OF CERTAIN PSYCHOPHARMACOLOGICAL AGENTS ON
ADAPTATION UNDER STRESS

O01249 02-03
ON THE INFLUENCE OF MOBILETTEN ON THE EFFECT OF ALCOHOL IN THE
HUMAN: SECOND COMMUNICATION: INFLUENCE ON THE EFFICIENCY
UNDER ALCOHOL STRESS.

001623 02-11 RURAL URBAN DIFFERENCES IN THE USE OF STRESS ALLEVIATIVE DRUGS. 001938 02-17 STRESS ACCENTUATION OF THE LSD-INDUCED DISAGGREGATION OF

BKAIN POLYSOMES.

002035 03-03

EFFECT OF EARLY EXPERIENCE, PYRITHIOXIN AND DIAZEPAM ON UC14GLUCOSE UTILIZATION IN RAT BRAIN DURING EMOTIONAL STRESS.

PREVENTION OF ENVIRONMENTAL STRESS IMPACT ON RATS.

TAILS OF STRESS RELATED BEHAVIOR: A NEUROPHARMACOLOGICAL

O02359 03-06
STRESS AND THE HEART: INTERACTIONS OF THE CARDIOVASCULAR
SYSTEM, BEHAVIORAL STATE, AND PSYCHOTROPIC DRUGS.

A MODEL FOR EVALUATION OF ANTIANXIETY DRUGS WITH THE USE OF EXPERIMENTALLY-INDUCED STRESS: COMPARISON OF NABILONE AND DIAZEPAM.

002721 03-16

EFFECTS OF ETHANOL WITHDRAWAL, STRESS AND AMPHETAMINE ON
RAT BRAIN NA-K-ATPASE.

A CONTRIBUTION TO THE NEUROCHEMICAL BASIS OF THE PYRITHIOXIN EFFECT ON THE BRAIN GLUCOSE UTILISATION DURING RELATIVE BRAIN HYPOGLYCAEMIA INDUCED BY ANTICIPATION STRESS.

EFFECT OF STRESS ON NOREPINEPHRINE STIMULATED CYCLIC-AMP FORMATION IN BRAIN SLICES.

STRESS-INDUCED 003100 04-03

STRESS-INDUCED ALTERATIONS OF CYCLIC-NUCLEOTIDE LEVELS IN BRAIN: EFFECTS OF CENTRALLY ACTING DRUGS.

A NEW ANOREXIGEN ASSAY: STRESS-INDUCED HYPERPHAGIA IN RATS.
QUANTITATIVE DETERMINATION OF STRESS-INDUCED MYOCARDIAL

DAMAGE IN RATS. 001536 02-06
TRESS-INDUCING

EFFECTS OF ANTIANXIETY DRUG AND PERSONALITY ON STRESS-INDUCING PSYCHOMOTOR PERFORMANCE TEST. 002630 03-14

STRESSED
DIFFERENTIAL EFFECT OF NALOXONE ON FIXED-RATIO OPERANT
BEHAVIOR IN STRESSED AND NONSTRESSED RATS.

DNA SYNTHETIC ABILITY IN CEREBELLA FROM TEMPERATURE AND HANDLING STRESSED NEONATAL RATS.

STRESSFUL
FLUCTUATING DENTAL ASYMMETRY AS AN INDICATOR OF THE
STRESSFUL PREMATAL EFFECTS OF DELTAP-TETRAHYDROCANNABINOL
IN THE LABORATORY RAT.

RETCH

FFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY

EFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY THE RESPONSES OF THE MUSCLE SPINDLE OF THE TRICEPS SURAE MUSCLE OF THE DECEREBRATE CAT TO THE MUSCLE STRETCH.

003109 04-03

STRETCHING
INCREASE OF HIPPOCAMPAL ACETYLCHOLINE TURNOVER RATE AND THE
STRETCHING YAWNING SYNDROME ELICITED BY ALPHA-MSH AND

HALOPERIDOL INCREASES AND APOMORPHINE DECREASES STRIATAL
DOPAMINE METABOLISM AFTER DESTRUCTION OF STRIATAL
DOPAMINE SENSITIVE ADENYLATE-CYCLASE BY KAINIC-ACID.

INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT

000124 01-03
REGULATORY ROLE OF GABA NEURONS ON THE ACTIVATION OF
STRIATAL TYROSINE-HYDROXYLASE BY HALOPERIDOL. (UNPUBLISHED

000132 01-03
INVOLVEMENT OF THE DOPAMINE NIGROSTRIATAL SYSTEM IN THE
PICROTOXIN EFFECT ON STRIATAL ACETYLCHOLINE LEVELS.

OO0158 01-03
DIFFERENTIAL EFFECTS OF RESERPINE AND TETRABENAZINE ON RAT
STRIATAL SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS AND
SYNAPTOSOMAL DOPAMINE POOLS.

O00172 01-03
POTENTIATION BY COCAINE OF THE STIMULUS-INDUCED INCREASE IN
DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL SYNAPTOSOMES.
000217 01-03

HALOPERIDOL: EFFECT OF LONG-TERM TREATMENT ON RAT STRIATAL DOPAMINE SYNTHESIS AND TURNOVER. 000481 01-05

EFFECT OF QUIPAZINE, A SEROTONIN-LIKE DRUG, ON STRIATAL CHOLINERGIC INTERNEURONES.

COMBINED EFFECT OF LITHIUM AND FLUPENTHIXOL ON STRIATAL ADENYLATE-CYCLASE.

ADENYLATE-CYCLASE.

001131 02-03
ENHANCED AFFINITY OF OPIATE RECEPTORS FOR NALOXONE IN STRIATAL

SLICES OF MORPHINE-DEPENDENT MICE.

001165 02-03

DIFFERING ACTIONS OF AMFONELIC-ACID (AFA) AND AMPHETAMINE (AMPH) ON STRIATAL DOPAMINE (DA).

001196 02-03

CYANOCYPROHEPTADINE: ROLE OF CHOLINOLYTIC PROPERTIES IN MODULATING NEUROLEPTIC-INDUCED ELEVATION OF STRIATAL HOMOVANILLIC-ACID (HVA).

001226 02-03

INCREASED SYNTHESIS OF STRIATAL DOPAMINE BY N,N

001248 02-03
EFFECT OF BETA-ENDORPHIN ON STRIATAL DOPAMINE METABOLISM.
001269 02-03

COCAINE AND METABOLITES: RELATIONSHIP BETWEEN PHARMACOLOGICAL ACTIVITY AND INHIBITORY ACTION ON DOPAMINE UPTAKE INTO STRIATAL SYNAPTOSOMES.

TOLERANCE TO STEREOTYPED BEHAVIOUR AND TO DECREASE IN STRIATAL HOMOVANILLIC-ACID LEVELS AFTER REPEATED TREATMENT WITH APOMORPHINE-DIPIVALOYL-ESTER.

FAILURE OF MORPHINE TO INCREASE STRIATAL 3,4
DIHYDROXYPHENYLACETIC-ACID IN FASTED RATS.

CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF C-AMP-PHOSPHODIESTERASE.

BIPHASIC EFFECTS OF AMPHETAMINE ON STRIATAL DOPAMINE DYNAMICS.

O02064 03-03

APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE RELEASE:
ROLE OF DOPAMINERGIC RECEPTORS IN SUBSTANTIA-NIGRA.

002084 03-03 THE EFFECT OF LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND 2
BROMOLYSERGIC-ACID-DIETHYLAMIDE (BOL) ON THE STRIATAL DOPA
ACCUMULATION: INFLUENCE OF CENTRAL 5
HYDROXYTRYPTAMINERGIC PATHWAYS.

602125 03-03

EFFECTS ON STRIATAL AND MESOLIMBIC DOPAMINE SYSTEMS OF A NEW POTENTIAL ANTIPSYCHOTIC DRUG — MEZILAMINE — WITH WEAK CATALEPTOGENIC PROPERTIES.

EFFECT OF MECAMYLAMINE ON THE FATE OF DOPAMINE IN STRIATAL AND MESOLIMBIC AREAS OF RAT BRAIN; INTERACTION WITH MORPHINE AND HALOPERIDOL.

COMPARATIVE EFFECTS OF PENFLURIDOL ON CIRCLING BEHAVIOR AND STRIATAL DOPAC AND SERUM PROLACTIN CONCENTRATIONS IN THE

TWO BINDING SITES FOR H3-SPIROPERIDOL ON RAT STRIATAL MEMBRANES.

002843 04-03 NEUROPHARMACOLOGICAL STUDIES ON THE NIGROSTRIATAL AND RAPHE STRIATAL SYSTEM IN THE RAT. 002882 04-03

THE UPTAKE AND RELEASE OF H3-2 AMINO-6-7-DIHYDROXYTETRAHYDRONAPHTHALENE (ADTN) BY STRIATAL NERVE TERMINALS.

LOSS OF STRIATAL DOPAMINERGIC RECEPTORS AFTER INTRASTRIATAL

002909 04-03 RAT STRIATAL METHIONINE-ENKEPHALIN CONTENT AFTER CHRONIC TREATMENT WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTISCHIZOPHRENIC DRUGS.

\$TRIATAL CONTENT OF CA2-DEPENDENT REGULATOR PROTEIN AND DOPAMINERGIC RECEPTOR FUNCTION.

THE EFFECT OF BROMOCRIPTINE ON RAT STRIATAL ADENYLATE-CYCLASE AND RAT BRAIN MONOAMINE METABOLISM.

002998 04-03 A COMPARISON OF THE EFFECTS OF ANTIPSYCHOTIC DRUGS ON PITUITARY, STRIATAL AND LIMBIC SYSTEM POSTSYNAPTIC DOPAMINE RECEPTORS.

EFFECT OF SUBSTITUTED BENZAMIDE DRUGS ON RAT STRIATAL TYROSINE-HYDROXYLASE.

THE STRIATAL DOPAMINERGIC FUNCTION IS MEDIATED BY THE INHIBITION OF A NIGRAL, NONDOPAMINERGIC NEURONAL SYSTEM VIA A STRIO-NIGRAL GABAERGIC PATHWAY.

STRIATAL NONDOPAMINERGIC NEURONS: POSSIBLE INVOLVEMENT IN FEEDING ORINKING BEHAVIOR.

003330 04-04 EFFECTS OF L GLUTAMATE AND RELATED AMINO-ACIDS UPON THE RELEASE OF H3-DOPAMINE FROM RAT STRIATAL SLICES.

003340 04-04 STRIATAL CELL SUPERSENSITIVITY TO APOMORPHINE IN DOPAMINE LESIONED RATS CORRELATED TO BEHAVIOUR.

003356 04-04 EFFECTS OF KAINIC-ACID ON ION DISTRIBUTION AND ATP LEVELS OF STRIATAL SLICES INCUBATED IN VITRO.

003406 04-05 HISTOFLUORESCENCE OF KAINIC-ACID-INDUCED STRIATAL LESIONS 003433 04-06

STRIATUM INTERACTION OF GABA, DOPAMINE, AND ACETYLCHOLINE IN CAT STRIATUM: PHARMACOLOGICAL CONSIDERATIONS.

000051 01-03

A COMPARISON OF THE EFFECTS OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE STRIATUM, OLFACTORY TUBERCLE AND MEDIAN EMINENCE.

REGIONAL DIFFERENCES IN THE SENSITIVITY OF CHOLINERGIC NEURONS TO DOPAMINERGIC DRUGS AND QUIPAZINE IN THE RAT STRIATUM. 000134 01-03

POTENTIATION BY RESERPINE OF THE INHIBITION BY AMPHETAMINE OF (3H)DOPAMINE ACCUMULATION IN THE RAT STRIATUM.

000246 01-03 DOPAMINE RECEPTORS IN RAT STRIATUM AND NUCLEUS-ACCUMBENS; CONFORMATIONAL STUDIES USING RIGID ANALOGUES OF DOPAMINE 000301 01-03

IN VIVO BINDING OF H3-PIMOZIDE IN MOUSE STRIATUM: EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS.

001050 02-03 EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE CONTENT AND METABOLISM OF DOPAMINE IN THE RAT STRIATUM.

001133 02-03 LONG-TERM CHANGES IN THE SENSITIVITY OF PRE- AND POSTSYNAPTIC DOPAMINE RECEPTORS IN MOUSE STRIATUM EVIDENCED BY BEHAVIORAL AND BIOCHEMICAL STUDIES.

001187 02-03 ROLE OF CALCIUM IN THE AMPHETAMINE-INDUCED STIMULATION OF CATECHOL FORMATION IN THE STRIATUM.

001268 02-03 CYCLIC-GMP AND GABA LEVELS IN RAT STRIATUM AND CEREBELLUM DURING MORPHINE WITHDRAWAL: EFFECT OF APOMORPHINE.

001274 02-03 THE EFFECT OF CHRONIC LITHIUM ADMINISTRATION ON DOPAMINE METABOLISM IN RAT STRIATUM.

METRAZOL-INDUCED PETIT-MAL: THE ROLE PLAYED BY MONOAMINERGIC MECHANISMS AND STRIATUM.

002192 03-04 AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY AND STEREOTYPY AFTER KAINIC-ACID LESIONS OF THE STRIATUM.

002279 03-04 THE INFLUENCE OF HISTAMINE ON METABOLISM OF DOPAMINE AND SEROTONIN IN THE RAT STRIATUM.

002288 03-04 THE EFFECTS OF ETORPHINE, FENTANYL AND MORPHINE ON NORADREMALINE AND DOPAMINE CONCENTRATIONS IN THE STRIATUM OF RAT.

EFFECTS OF SOME DERIVATIVES OF 2 AMINOTETRALIN ON DOPAMINE SENSITIVE ADENYLATE-CYCLASE AND ON THE BINDING OF H3-HALOPERIDOL TO NEUROLEPTIC RECEPTORS IN RAT STRIATUM.

002853 04-03 SUPERSENSITIVITY OF THE CHOLINERGIC RESPONSE TO APOMORPHINE IN THE STRIATUM FOLLOWING DENERVATION OR DISUSE SUPERSENSITIVITY OF DOPAMINERGIC RECEPTORS IN THE RAT.

002872 04-03 THE EFFECTS OF STANDARD NEUROLEPTIC COMPOUNDS ON THE BINDING OF H3-SPIROPERIDOL IN THE STRIATUM AND MESOLIMBIC SYSTEM OF THE RAT IN VITRO.

ON THE RELATION BETWEEN HALOPERIDOL-INDUCED ALTERATIONS IN DA RELEASE AND DA METABOLISM IN RAT STRIATUM.

INHIBITION OF DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RAT STRIATUM BY NEUROLEPTIC DRUGS ADMINISTERED IN VIVO.

003027 04-03

CYCLIC-NUCLEOTIDE LEVELS IN THE RAT STRIATUM AND CEREBELLUM IN VIVO EFFECTS OF DOPAMINE AND ACETYLCHOLINE RECEPTOR AGONISTS AND ANTAGONISTS. 003051 04-03

DOPAMINE ANTAGONIST BINDING: A SIGNIFICANT DECREASE WITH MORPHINE-DEPENDENCE IN THE RAT STRIATUM. 003052 04-03

INCREASED DOPAMINE METABOLISM IN RAT STRIATUM AFTER INFUSIONS OF SUBSTANCE-P INTO THE SUBSTANTIA-NIGRA. 003130 04-03

ANATOMICAL SPECIFICITY WITHIN RAT STRIATUM FOR THE DOPAMINERGIC MODULATION OF DRL RESPONDING AND ACTIVITY 003316 04-04

HALOPERIDOL DEPRESSES THE ACCUMULATION OF APOMORPHINE IN THE STRIATUM OF THE RAT. 003384 04-04

STRIO-NIGRAL
THE STRIATAL DOPAMINERGIC FUNCTION IS MEDIATED BY THE
INHIBITION OF A NIGRAL, NONDOPAMINERGIC NEURONAL SYSTEM
VIA A STRIO-NIGRAL GABAERGIC PATHWAY.

003325 04 003325 04-04

ONSET AND OFFSET OF CHLORPROMAZINE BLOCKADE OF PHENYLEPHRINE, CARBAMYLCHOLINE AND HISTAMINE ON RABBIT STOMACH STRIPS.

001234 02-03

PHARMACOLOGICAL TREATMENT FOLLOWING EXPERIMENTAL CEREBRAL INFARCTION: IMPLICATIONS FOR UNDERSTANDING PSYCHOLOGICAL SYMPTOMS OF HUMAN STROKE

000243 01-03

STRONG

HYPEPINEPHRIA IN CASES OF STRONG INTOXICATION.

001837 02-15

STROOP

THE EFFECTS OF FOUR ANTIHYPERTENSIVE AGENTS ON THE STROOP COLOUR WORD TEST IN NORMAL MALE VOLUNTEER SUBJECTS 000771 01-14

A NEW VIEW OF THE STRUCTURAL RELATIONSHIP BETWEEN LSD AND MESCALINE

000419 01-04

SOME STRUCTURAL FEATURES GOVERNING OPIATE ACTION (UNPUBLISHED PAPER

001168 02-03

THE STRUCTURE OF BEHAVIOR OF RATS DURING MORPHINE-INDUCED HYPERACTIVITY. 001426 02-04

FURTHER STUDIES ON THE FINE STRUCTURE OF THE ADRENERGIC INNERVATION OF THE HYPOTHALAMUS.

003105 04-03

QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS OF BIOLOGICALLY ACTIVE INDOLE, 1 METHYLINDOLE AND BENZO-B-THIOPHENE **DERIVATIVES**

000006 01-01 QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS IN A SERIES OF SELECTIVE 5-HT UPTAKE INHIBITORS.

000057 01-03 MONOAMINE-OXIDASE INHIBITION IN BRAIN AND LIVER PRODUCED BY BETA-CARBOLINES: STRUCTURE-ACTIVITY RELATIONSHIPS AND SLIBSTRATE SPECIFICITY

000064 01-03 **ELECTRONIC FACTORS IN THE STRUCTURE-ACTIVITY RELATIONSHIP OF** SOME 1.4 BENZODIAZEPIN-2-ONES.

000939 01-17 STRUCTURE-ACTIVITY STUDIES ON HALLUCINOGENIC AMPHETAMINES

USING MOLECULAR CONNECTIVITY. 001530 02-06

THE ENKEPHALINS AND OPIATES: STRUCTURE-ACTIVITY RELATIONS 001901 02-17

STRUCTURE-ACTIVITY RELATIONS FOR THE NEUROTOXICITY OF KAINIC-ACID DERIVATIVES AND GLUTAMATE ANALOGUES.

002355 03-05 ANGIOTENSIN RECEPTIVE NEURONES IN THE SUBFORNICAL ORGAN. STRUCTURE-ACTIVITY RELATIONS.

002906 04-03 STRUCTURE-ACTIVITY STUDIES ON THE INHIBITION OF GABA BINDING TO RAT BRAIN MEMBRANES BY MUSCIMOL AND RELATED COMPOUNDS 002981 04-03

STRUCTURED

BEHAVIOR OBSERVATIONS OF HYPERACTIVE CHILDREN AND METHYLPHENIDATE (RITALIN) EFFECTS IN SYSTEMATICALLY STRUCTURED CLASSROOM ENVIRONMENTS: NOW YOU SEE THEM. NOW YOU DONT.

STRUCTURES

DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIATION OF CATECHOLAMINERGIC AND SEROTONINERGIC TERMINALS IN RAT CEREBRAL STRUCTURES

BENZODIAZEPINE ACTIVITY: IS INTERACTION WITH THE GLYCINE RECEPTOR, AS EVIDENCED BY DISPLACEMENT OF STRYCHNINE BINDING A USEFUL CRITERION?

HIGH-AFFINITY BINDING OF H3-GLYCINE AND C14-BETA-ALANINE TO SYNAPTOSOMAL MITOCHONDRIAL FRACTIONS OF RAT CNS REGIONS; EFFECTS OF STRYCHNINE.

000211 01-03 EFFECTS OF D AMPHETAMINE AND STRYCHNINE ON CYCLOHEXIMIDE -AND DIETHYLDITHIOCARBAMATE-INDUCED AMNESIA IN MICE. 001438 02-04

STRYCHNINE BINDING ASSOCIATED WITH SYNAPTIC GLYCINE RECEPTORS IN RAT SPINAL CORD MEMBRANES: IONIC INFLUENCES. 003024 04-03

EFFECT OF STRYCHNINE ON THE RAT ELECTRORETINOGRAM 003048 04-03

WORD ASSOCIATION TIMES, FELT EFFECTS, AND PERSONALITY CHARACTERISTICS OF SCIENCE STUDENTS GIVEN A PLACEBO

002611 03-14

003581 04-11

003423 04-06

THE HIPPOCAMPAL SLICE: A SYSTEM FOR STUDYING THE PHARMACOLOGY OF SEIZURES AND FOR SCREENING ANTICONVULSANT

001538 02-06 SOME PROBLEMS CONCERNING THE TECHNIQUES OF STUDYING THE EFFECTIVENESS OF PSYCHOTROPIC DRUGS. 001540 02-06

RHEOENCEPHALOGRAPHIC DATA IN MIGRAINE CEPHALGIA AND THEIR CHANGES DURING STUGERON TREATMENT. 000515 01-07

STUMPTAILED PHARMACOKINETICS OF HEXOBARBITAL IN THE PREGNANT AND NONPREGNANT STUMPTAILED MONKEY.

001104 02-03

STUPOROUS

L-DOPA TREATMENT OF REACTIVE STUPOROUS STATES.

003513 04-09

STUTTERING

HALOPERIDOL IN THE TREATMENT OF STUTTERING

000651 01-11 THE ACUTE EFFECT OF HALOPERIDOL AND APOMORPHINE ON THE

SEVERITY OF STUTTERING. 003619 04-14

THE IMPLICATIONS OF PSYCHEDELIC DRUG RESEARCH FOR INTEGRATION IE IMPLICATIONS OF PSYCHEDELIC DRUG RESEARCH TO A PSYCHOSIS.
AND SEALING OVER AS RECOVERY STYLES FROM ACUTE PSYCHOSIS.
003517 04-09

SUBACUTE

LEVODOPA IN SUBACUTE SCLEROSING PANENCEPHALITIS.

001547 02-07 EFFECT OF SUBACUTE DIAZEPAM ADMINISTRATION IN MICE ON THE SUBSEQUENT ABILITY OF DIAZEPAM TO PROTECT AGAINST METRAZOL AND BICUCULLINE-INDUCED CONVULSIONS.

002053 03-03 SUBAMNESIC SUBAMNESIC CYCLOHEXIMIDE TREATMENT DELAYS CONSOLIDATION IN

003334 04-04

MAICE

EFFECT OF RESERPINE ON ADENOSINE UPTAKE AND METABOLISM, AND SUBCELLULAR TRANSPORT OF PLATELET ADENOSINE-TRIPHOSPHATE IN WASHED RABBIT PLATELETS

000238 01-03 THE SUBCELLULAR DISTRIBUTION OF PARTICLE-BOUND NEGATIVE CHARGES IN RAT BRAIN

000492 01-06 THE EFFECTS OF LITHIUM ON ATPASE ACTIVITY IN SUBCELLULAR

FRACTIONS FROM RAT BRAIN.

SPIPERONE: A LIGAND OF CHOICE FOR NEUROLEPTIC RECEPTORS: 3. SUBCELLULAR DISTRIBUTION OF NEUROLEPTIC DRUGS AND THEIR RECEPTORS IN VARIOUS RAT BRAIN AREAS. 002067 03-03

MONOAMINE-OXIDASE IN RAT RETICULOCYTES: SUBCELLULAR LOCALIZATION AND IDENTIFICATION OF ISOENZYMES. 002134 03-03
SUBCELLULAR DISTRIBUTION OF ETORPHINE IN RAT BRAIN AND EVIDENCE

FOR IN VIVO STEREOSPECIFIC BINDING 002856 04-03

DOPAMINE SENSITIVE ADENYLATE-CYCLASE IN RETINA -- SUBCELLULAR DISTRIBUTION. 002867 04-03

SUBCELLULAR LOCALIZATION OF C14-METHAQUALONE IN MOUSE BRAIN: EFFECTS OF HEPATIC MICROSOMAL ENZYME INHIBITION. 002983 04-03

THE EFFECT OF SUBCHRONIC ADMINISTRATION OF LITHIUM-CARBONATE ON THE PHARMACOLOGICAL ACTIVITY OF D AMPHETAMINE. 001295 02-04

SUBCOMMITTEE REPORT OF SUBCOMMITTEE ON THE TREATMENT OF DEPRESSION IN CHILDREN

DOPAMINE RECEPTORS AND ERGOT DRUGS. EVIDENCE THAT AN ERGOLENE DERIVATIVE IS A DIFFERENTIAL AGONIST AT SUBCORTICAL LIMBIC DOPAMINE RECEPTORS.

002019 03-03 DIFFERENTIAL EFFECTS OF SUBCORTICAL LYSERGIC-ACID-DIETHYLAMIDE AND SEROTONIN ON VISUAL CORTICAL EVOKED-POTENTIALS

002163 03-03 AFFERENT AND EFFERENT SUBCORTICAL PROJECTIONS OF BEHAVIORALLY DEFINED SECTORS OF PREFRONTAL GRANULAR CORTEX. 002962 04-03

SUBCUTANEOUS INJECTIONS OF APOMORPHINE, STIMULUS
GENERALIZATION AND CONDITIONING: SERIOUS PITFALLS FOR THE
EXAMINER USING APOMORPHINE AS A TOOL.

000610 01-10

SUBFORNICAL
ANGIOTENSIN RECEPTIVE NEURONES IN THE SUBFORNICAL ORGAN.
STRUCTURE-ACTIVITY RELATIONS.

LOCALIZATION OF RECEPTORS FOR THE DIPSOGENIC ACTION OF ANGIOTENSIN-II IN THE SUBFORNICAL ORGAN OF RAT.

SUBFRACTIONS
CALCIUM CONTENT AND BINDING IN SYNAPTOSOMAL SUBFRACTIONS
DURING CHRONIC MORPHINE TREATMENT.
001231 02

INHIBITION OF MONOAMINE OXIDATION IN SUBFRACTIONS OF CRUDE MITOCHONDRIA OF RAT BRAIN BY CLORGYLINE AND LILLY-51641.

003020 04-03

MAGNIFICATION OF SOME ENZYMATIC ACTIVITIES OF BRAIN-CORTEX SUBFRACTIONS.

003127 04-03

SUBGROUPS
PSYCHOACTIVE DRUG RESPONDER SUBGROUPS -- POSSIBLE
CONTRIBUTIONS TO PSYCHIATRIC CLASSIFICATION. (UNPUBLISHED

000968 01-17 CHLORPROMAZINE EXCRETION. II. IMPROVED TLC PROCEDURES FOR FRACTIONATING THE URINARY DRUG CONTENT INTO CHEMICAL SUBGROUPS OF CPZ METABOLITES.

003690 04-16

SUBHYPNOTIC
THE EFFECTS OF SUBHYPNOTIC DOSES OF ETHANOL ON REGIONAL
CATECHOLAMINE TURNOVER.

O0196

001964 03-03 EVALUATION OF THE PRISON INMATE AS:A SUBJECT IN DRUG ASSESSMENT.

000982 01-17

MARIJUANA: DOSE-RESPONSE EFFECTS ON PULSE RATE, SUBJECTIVE ESTIMATES OF POTENCY, PLEASANTNESS, AND RECOGNITION

SUBJECTIVE EXPERIENCES OF CANNABIS USE IN LONG-TERM USERS. 000776 01-14 SUBJECTIVE PHENOMENA IN DRUG TRIALS.

A POSSIBLE ROLE OF THE PAG IN THE MEDIATION OF SUBJECTIVE EFFECTS OF MORPHINE

001444 02-04 NEFOPAM (N), MORPHINE (M), AND D AMPHETAMINE (A) IN MAN: SUBJECTIVE, BEHAVIORAL, AND PHYSIOLOGIC EFFECTS.

001550 02-07 RELATIONSHIP BETWEEN PHYSICAL FINDINGS AND RELATED SUBJECTIVE SYMPTOMS IN NEUROPSYCHIATRIC PATIENTS WITH SOMATIC COMPLICATIONS — WITH SPECIAL REFERENCE TO OPHTHALMOLOGIC OBSERVATIONS.

001678 02-13 A REPEATED DOSE COMPARISON OF THREE BENZODIAZEPINE DERIVATIVES (NITRAZEPAM, FLURAZEPAM AND FLUNITRAZEPAM) ON SUBJECTIVE APPRAISALS OF SLEEP AND MEASURES OF PSYCHOMOTOR PERFORMANCE THE MORNING FOLLOWING NIGHT-TIME MEDICATION.

001787 02-15 TOLERANCE TO MARIJUANA: HEART RATE AND SUBJECTIVE HIGH

A SUBJECTIVE AND OBJECTIVE METHOD ASSESSING THE EFFICACY OF HYPNOTIC MEDICATIONS IN INSOMNIACS. 001873 02-16

VILOXAZINE, SLEEP, AND SUBJECTIVE FEELINGS.

THE EFFECT OF NITRAZEPAM ON MANUAL SKILL, GRIP STRENGTH, AND REACTION TIME WITH SPECIAL REFERENCE TO SUBJECTIVE EVALUATION OF EFFECTS ON SLEEP.

002626 03-14 MARIJUANA: EFFECTS ON FREE RECALL AND SUBJECTIVE ORGANIZATION OF PICTURES AND WORDS.

A REPEATED DOSE COMPARISON OF THE SIDE-EFFECTS OF FIVE ANTIHISTAMINES ON OBJECTIVE ASSESSMENTS OF PSYCHOMOTOR PERFORMANCE, CENTRAL-NERVOUS-SYSTEM AROUSAL AND SUBJECTIVE APPRAISALS OF SLEEP AND EARLY MORNING BEHAVIOUR. 003657 04-15

SUBJECTS
DIETARY TRYPTOPHAN EFFECTS ON THE SLEEP OF NORMAL SUBJECTS
000505 0 000505 01-07

CLINICAL AND EXPERIMENTAL EXPERIENCE WITH MAPROTILINE, CLOMIPRAMINE, SYDNOCARB. AND MEFEXAMINE IN PSYCHIATRIC PATIENTS AND NORMAL SUBJECTS.

000517 01-07 REPRESSION OF A LITHIUM PUMP AS A CONSEQUENCE OF LITHIUM INGESTION BY MANIC-DEPRESSIVE SUBJECTS.

LITHIUM AND ERYTHROCYTE MEMBRANE CATION CARRIER STUDIES IN NORMAL AND MANIC-DEPRESSIVE SUBJECTS. 000717 01-13

Psychopharmacology Abstracts

THE EFFECTS OF FOUR ANTIHYPERTENSIVE AGENTS ON THE STROOP COLOUR WORD TEST IN NORMAL MALE VOLUNTEER SUBJECTS. 000771 01-14

THEORETICAL AND METHODOLOGICAL ASPECTS OF PSYCHOTROPIC DRUG TRIALS USING HEALTHY SUBJECTS.

000918 01-16 SUBJECTS RIGHTS, FREEDOM OF INQUIRY, AND THE FUTURE OF RESEARCH IN THE ADDICTIONS.

000966 01-17 URINARY CYCLIC-AMP EXCRETION BY METHADONE SUBJECTS DURING GRADUAL AND ACUTE WITHDRAWAL.

001654 02-13 FLUOXETINE, A SEROTONIN UPTAKE INHIBITOR, IN NORMAL HUMAN

001686 02-13

THE PSYCHOTROPIC EFFECTS OF ATENOLOL IN NORMAL SUBJECTS: PRELIMINARY FINDINGS. 001700 02-14

PRISONER SUBJECTS AND DRUG TESTING.

001908 02-17 DIFFERENTIAL EFFECTS OF A SINGLE DOSE OF IMIPRAMINE AND LOPRAMINE IN HEALTHY SUBJECTS VARYING IN THEIR LEVEL OF DEPRESSION.

002446 03-09 PLASMA PROLACTIN CONCENTRATIONS IN NORMAL SUBJECTS AND DEPRESSIVE PATIENTS FOLLOWING ORAL CLOMIPRAMINE.

002567 03-13 PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS IN NORMAL AND SCHIZOPHRENIC SUBJECTS.

002575 03-13 AN EEG COMPUTER ANALYSIS OF CHLORPROMAZINE EFFECTS IN PSYCHOTIC SUBJECTS.

002592 03-13 ERYTHROCYTE ACCUMULATION OF THE LITHIUM-ION IN CONTROL
SUBJECTS AND PATIENTS WITH PRIMARY AFFECTIVE-DISORDER

003519 04-09 EFFECTS OF SINGLE DOSES OF TRANYLCYPROMINE ON PLATELET MAD AND AMINE UPTAKE IN NORMAL SUBJECTS.

003594 04-13 EFFECTS OF NALOXONE ON SCHIZOPHRENIA: REDUCTION IN HALLUCINATIONS IN A SUBPOPULATION OF SUBJECTS.

003639 04-14

SUBMISSIVE EFFECTS OF ALCOHOL ON ATTACK AND DEFENSIVE SUBMISSIVE REACTIONS IN RATS. 0004 000413 01-04

SUBPOPULATION

EFFECTS OF NALOXONE ON SCHIZOPHRENIA: REDUCTION IN
HALLUCINATIONS IN A SUBPOPULATION OF SUBJECTS.

003639 04-14

IDENTIFICATION OF A SUBREGION WITHIN RAT NEOSTRIATUM FOR THE DOPAMINERGIC MODULATION OF LATERAL HYPOTHALAMIC SELF-STIMULATION.

SUBSENSITIVITY
DEVELOPMENT OF BETA-ADRENERGIC RECEPTOR SUBSENSITIVITY BY
ANTIDEPRESSANTS.
000049 0

000049 01-03 **DEVELOPMENT AND DISAPPEARANCE OF SUBSENSITIVITY TO** PILOCARPINE FOLLOWING A SINGLE ADMINISTRATION OF THE IRREVERSIBLE ANTICHOLINESTERASE AGENT, DFP.

ROLE OF SEROTONIN REUPTAKE INHIBITION IN THE DEVELOPMENT OF SUBSENSITIVITY OF THE NOREPINEPHRINE (NE) RECEPTOR COUPLED ADENYLATE-CYCLASE SYSTEM.

003017 04-03 SUBSEQUENT

EFFECT OF CHLORDIAZEPOXIDE ADMINISTERED EARLY IN EXTINCTION ON SUBSEQUENT EXTINCTION OF A CONDITIONED EMOTIONAL RESPONSE IN RATS: IMPLICATIONS FOR HUMAN CLINICAL USE.

EFFECT OF IN-UTERO ADMINISTRATION OF MORPHINE ON THE SUBSEQUENT DEVELOPMENT OF SELF-ADMINISTRATION BEHAVIOR

000368 01-04 EFFECTS OF METHYLPHENIDATE ON ACQUISITION AND SUBSEQUENT PERFORMANCE OF SUCCESSIVE DISCRIMINATION REVERSALS.

EFFECT OF SUBACUTE DIAZEPAM ADMINISTRATION IN MICE ON THE SUBSEQUENT ABILITY OF DIAZEPAM TO PROTECT AGAINST METRAZOL AND BICUCULLINE-INDUCED CONVULSIONS.

SUBSTANCE-P
MODELS TO STUDY DRUG EFFECTS ON THE INTEGRATED FUNCTION OF
GABACRGIC, PEPTIDERGIC (SUBSTANCE-P) AND DOPAMINERGIC
NEURONS. (UNPUBLISHED PAPER).

000499 0

FURTHER OBSERVATION ON THE LACK OF ACTIVE UPTAKE SYSTEM FOR SUBSTANCE-P IN THE CENTRAL-NERVOUS-SYSTEM.

001818 02-15

001946 03-01

DRINKING BEHAVIOUR INDUCED BY INTRACRANIAL INJECTIONS OF ELEDOISIN AND SUBSTANCE-P IN THE PIGEON.

001352 02-04

SOME BEHAVIORAL EFFECTS OF SP6-11 HEXAPEPTIDE C-TERMINAL OF SUBSTANCE-P INJECTED INTO THE CEREBRAL VENTRICLES IN RATS. 002267 03-04

CAPSAICIN-INDUCED DEPLETION OF SUBSTANCE-P FROM PRIMARY

002965 04-03 INCREASED DOPAMINE METABOLISM IN RAT STRIATUM AFTER INFUSIONS OF SUBSTANCE-P INTO THE SUBSTANTIA-NIGRA.

003130 04-03 EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ, ANGIOTENSIN-II, AND SUBSTANCE-P ON MULTIPLE FIXED-INTERVAL FIXED-RATIO RESPONDING IN RABBITS.

003233 04-04 RETROGRADE AMNESIA PRODUCED BY POSTTRIAL INJECTION OF SUBSTANCE-P INTO SUBSTANTIA-NIGRA.

003247 04-04

SUBSTANTIA-HIGHA
5-HT AND MORPHINE INTERACTION, EFFECTS ON SENSORY INPUT IN CAUDATE NUCLEUS AND SUBSTANTIA-NIGRA.

000089 01-03 THE ACTIONS OF CHOLINOMIMETICS AND CATECHOLAMINES ON RAT SUBSTANTIA-NIGRA NEURONES.

000163 01-03 DOPAMINE SELECTIVELY INCREASES H3-GABA RELEASE FROM SLICES OF RAT SUBSTANTIA-NIGRA IN VITRO

000240 01-03 ON THE ROLE OF ASCENDING CATECHOLAMINERGIC PROJECTIONS IN INTRACRANIAL SELF-STIMULATION OF THE SUBSTANTIA-NIGRA.

000336 01-04 ELECTROPHYSIOLOGICAL EVIDENCE FOR A DOPAMINERGIC ACTION OF LSD: DEPRESSION OF UNIT ACTIVITY IN THE SUBSTANTIA-NIGRA OF THE RAT.

DECREASE IN NEOSTRIATAL BLOOD FLOW AFTER D AMPHETAMINE
ADMINISTRATION OR ELECTRICAL STIMULATION OF THE SUBSTANTIA-

001175 02-03 EFFECT OF CHRONIC NEUROLEPTIC OR L-DOPA ADMINISTRATION ON GABA LEVELS IN THE RAT SUBSTANTIA-NIGRA.

001181 02-03 THE ACTION OF BACLOFEN ON NEURONS OF THE SUBSTANTIA-NIGRA AND OF THE VENTRAL TEGMENTAL AREA.

001211 02-03 EFFECTS OF LERGOTRILE (LER), AN ERGOT DERIVATIVE, ON ACTIVITY OF SUBSTANTIA-NIGRA PARS COMPACTA DOPAMINE (DA) NEURONS.

001278 02-03 APOMORPHINE INCREASES GLUCOSE UTILIZATION IN THE SUBSTANTIA-NIGRA, SUBTHALAMIC NUCLEUS AND CORPUS-STRIATUM OF RAT.

001976 03-03 APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE RELEASE: ROLE OF DOPAMINERGIC RECEPTORS IN SUBSTANTIA-NIGRA.

002084 03-03 EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND D AMPHETAMINE ON SELF-STIMULATION OF THE SUBSTANTIA-NIGRA AND LOCUS-

002218 03-04 ANALYSIS OF THE ROLE PLAYED BY THE SUBSTANTIA-NIGRA IN THE MEDIATION OF INGESTIVE, LOCOMOTOR, AND ROTATIONAL BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL MANIPULATIONS. (PH.D. DISSERTATION).

002247 03-04 SPONTANEOUS AND AMPHETAMINE-INDUCED BEHAVIOR AFTER BILATERAL INJECTION OF ETHANOLAMINE-O-SULFATE INTO THE

002262 03-04 TURNOVER RATES OF GAMMA-AMINOBUTYRIC-ACID IN SUBSTANTIA-NIGRA, NUCLEUS-CAUDATUS, GLOBUS-PALLIDUS AND NUCLEUS-ACCUMBENS OF RATS INJECTED WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTIPSYCHOTICS.

002996 04-03 THE EFFECTS OF ETHANOLAMINE-O-SULPHATE INJECTION INTO THE RAT SUBSTANTIA-NIGRA: ELECTROPHYSIOLOGICAL STUDIES.

003033 04-03 INCREASED DOPAMINE METABOLISM IN RAT STRIATUM AFTER INFUSIONS OF SUBSTANCE-P INTO THE SUBSTANTIA-NIGRA

003130 04-03 STEREOTYPED BEHAVIOR AFTER CHOLINERGIC, BUT NOT DOPAMINERGIC, STIMULATION OF THE SUBSTANTIA-NIGRA IN RATS

003208 04-04 RETROGRADE AMNESIA PRODUCED BY POSTTRIAL INJECTION OF SUBSTANCE-P INTO SUBSTANTIA-NIGRA

003247 04-04 THE EFFECTS OF ELEVATING GAMMA-AMINOBUTYRATE CONTENT IN THE SUBSTANTIA-NIGRA ON THE BEHAVIOUR OF RATS

MOVEMENT INDUCED IN CATALEPTIC RATS: DIFFERENTIAL EFFECTS
PRODUCED BY ELECTRICAL STIMULATION OF THE LATERAL
HYPOTHALAMUS, SUBSTANTIA-NIGRA, AND RETICULAR FORMATION.
003297 04-04

THE EFFECTS OF HALOPERIDOL AND CLOZAPINE ON CIRCLING INDUCED BY ELECTRICAL STIMULATION OF THE SUBSTANTIA-NIGRA AND THE VENTROMEDIAL TEGMENTUM.

CIRCLING BEHAVIOUR IN THE RAT FOLLOWING UNILATERAL INJECTIONS
OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE INTO THE SUBSTANTIA-NIGRA.

A ROLE OF THE POLYSYNAPTIC SYSTEM OF SUBSTANTIA-NIGRA IN THE CHOLINERGIC DOPAMINERGIC EQUILIBRIUM IN THE CENTRAL-NERVOUS-SYSTEM.

SUBSTANTIAL INCREASE IN THE LEVELS OF CHLOROPHENOXYACETIC-ACIDS IN THE CNS OF RATS AS A RESULT OF SEVERE INTOXICATION 001505 02-05

QUANTUM CHEMICAL STUDIES OF N SUBSTITUENT VARIATION IN THE OXYMORPHONE SERIES OF OPIATE NARCOTICS.

RELATIVE CONCENTRATIONS OF ZWITTERIONIC AND UNCHARGED SPECIES IN CATECHOLAMINES AND THE EFFECT OF N SUBSTITUENTS.

SUBSTITUTED TRIFLUOROMETHYLPHENYLPIPERAZINES AS ANORECTIC

3.4 METHYLENEDIOXYPHENYL, ISOPROPYLIDENEDIOXYPHENYL, AND BENZYL SUBSTITUTED CHIRAL 2 AMINOSUCCINIMIDES AND 3 AMINOPYRROLIDINES. STEREOSELECTIVE INVESTIGATIONS OF POTENTIAL ANTIPARKINSONIAN, ANTIPSYCHOTIC AND

ANTICONVULSANT ACTIVITIES. 000035 01-02 INTERACTIONS OF SUBSTITUTED BENZAMIDE DRUGS WITH CEREBRAL DOPAMINE PATHWAYS.

000077 01-03 ENZYMIC DEALKYLATION OF A SUBSTITUTED

AMINOACETAMIDOBENZOPHENONE AND CYCLIZATION TO THE
CORRESPONDING BENZODIAZEPINE IN VITRO.

000152 01-03 THE METABOLISM OF A SUBSTITUTED AMINOACETAMIDOBENZOPHENON AND CYCLIZATION TO THE CORRESPONDING BENZODIAZEPINE IN THE RAT IN VIVO.

SUBSTITUTED BENZAMIDES AS CEREBRAL DOPAMINE ANTAGONISTS IN

PIPERIDINE DERIVATIVES: SYNTHESIS OF POTENTIAL ANALGESICS IN 3 SUBSTITUTED 4 PHENYLPIPERIDINE SERIES.

CANNABINOIDS. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY
OF 8 SUBSTITUTED HYDROXY-DIMETHYLBENZOPYRANOPYRIDINE AND

SUBSTITUTED AMPHETAMINE DERIVATIVES. I. EFFECT ON UPTAKE AND RELEASE OF BIOGENIC MONOAMINES AND ON MONOAMINE-OXIDASE

IN THE MOUSE BRAIN 001233 02-03 SUBSTITUTED AMPHETAMINE DERIVATIVES. II. BEHAVIOURAL EFFECTS IN MICE RELATED TO MONOAMINERGIC NEURONES.

001429 02-04 EVALUATION OF SUBSTITUTED AMPHETAMINE HALLUCINOGENS USING THE CAT LIMB FLICK MODEL.

001449 02-04 EFFECTS OF SUBSTITUTED SPIROISOBENZOFURANPIPERIDINES ON SYNAPTOSOMAL BIOGENIC AMINE TRANSPORT.

002087 03-03 PRESYNAPTIC AND POSTSYNAPTIC EFFECTS OF SULPIRIDE AND OTHER SUBSTITUTED BENZAMIDES.

002099 03-03 A BEHAVIOURAL AND BIOCHEMICAL COMPARISON OF DOPAMINE RECEPTOR BLOCKAGE PRODUCED BY HALOPERIDOL WITH THAT PRODUCED BY SUBSTITUTED BENZAMIDE DRUGS.

002963 04-03 EFFECT OF SUBSTITUTED BENZAMIDE DRUGS ON RAT STRIATAL TYROSINE-HYDROXYLASE.

003018 04-03 DISCRIMINABLE EFFECTS OF ANTIMUSCARINICS: DOSE-RESPONSE AND

SUBSTITUTION TEST STUDIES. 000426 01-04 HYPOTHESIZED ADRENERGIC/NORADRENERGIC SUBSTITUTION IN HABITUAL INFANTILE MASTURBATION: TWO CASES.

001702 02-14

Psychopharmacology Abstracts

DOLVALUE DIOCYMPHECIC IN DAT PROCEATE CHREED ATE AND	DRUG-INDUCED DEPRESSION AND ATTEMPTED SUICIDE.
POLYAMINE BIOSYNTHESIS IN RAT PROSTATE. SUBSTRATE AND INHIBITOR PROPERTIES OF 7 DEAZA ANALOGUES OF DECARBOXYLATED S ADENOSYLMETHIONINE AND 5 METHYLTHIOADENOSINE. 000001 01-0	SUCCESSFUL SUICIDES WITH THIORIDAZINE AND MESORIDAZINE.
MONOAMINE-OXIDASE INHIBITION IN BRAIN AND LIVER PRODUCED BY BETA-CARBOLINES: STRUCTURE-ACTIVITY RELATIONSHIPS AND SUBSTRATE SPECIFICITY.	SULFATES SULFATES AND GLUCURONIDES OF P-HYDROXYPHENOBARBITAL IN RAT FECES.
PSYCHOACTIVE DRUG EFFECTS AND SUBSTRATE SPECIFICITY IN INTACT	002165 03-03
MITOCHONDRIAL MONDAMINE-OXIDASE FROM BRAIN. 000115 01-0: EVALUATION OF RADIORESPIROMETRY FOR THE DETERMINATION OF	III DROCOKIISOIL (COKIISOL) IN MIOUSE 0-20 OLIOODENDROOLIOMA
MONOAMINE-OXIDASE ACTIVITY IN VIVO UTILIZING C11-OCTYLAMINE AS A SUBSTRATE.	CHIECOCAL ACTOCYLCER A MINE
DOPAMINE IS A MONOAMINE-OXIDASE B SUBSTRATE IN MAN.	HYDROCOPTISONE (CORTISOL) IN MOUSE G-26 OLIGODENDROGLIOMA
AUTONOMIC IMBALANCE: A SUBSTRATE OF HYPERACTIVITY. 000783 01-14	CELL STRAINS.
MORPHINE AND SELF-STIMULATION: EVIDENCE FOR ACTION ON A COMMON NEURAL SUBSTRATE.	PLASMA CONCENTRATIONS OF PERPHENAZINE AND ITS SULPHOXIDE
PLASMA RENIN SUBSTRATE DURING LITHIUM TREATMENT.	000631 01-11
002569 03-13 THE ROLE OF SUBSTRATE LIPOPHILICITY IN DETERMINING TYPE 1 MICROSOMAL P450 BINDING CHARACTERISTICS.	DOPAMINE RECEPTOR BLOCKING ACTIVITY OF THE SULPIRIDE IN THE CENTRAL-NERVOUS-SYSTEM.
GLUTAMINE A MAJOR SUBSTRATE FOR NERVE ENDINGS. 002809 04-0: 002839 04-0:	SULPIRIDE: EVALUATION OF ANTIPSYCHOTIC ACTIVITY IN SCHIZOPHRENIC
SUBSTRATE SELECTIVE ACTIVATION OF RAT LIVER MITOCHONDRIAL	000512 01-07 AN EVALUATION OF A UNIQUE NEW ANTIPSYCHOTIC AGENT, SULPIRIDE:
MONOAMINE-OXIDASE BY OXYGEN. 002912 04-0: NGF-INDUCED ALTERATIONS IN PROTEIN SECRETION AND SUBSTRATE	EFFECTS ON SERUM PROLACTIN AND GROWTH HORMONE LEVELS. 001554 02-07
ATTACHED MATERIAL OF A CLONAL NERVE CELL LINE. 003607 04-1:	
THE BIOLOGICAL SUBSTRATES OF SCHIZOPHRENIA. 000535 01-01	O01575 02-09 PRESYNAPTIC AND POSTSYNAPTIC EFFECTS OF SULPIRIDE AND OTHER SUBSTITUTED BENZAMIDES.
SUBSTRATES OF ELEMENTARY BEHAVIORAL PLASTICITY. 002030 03-0: DELIMITATION OF NEURONAL SUBSTRATES NECESSARY FOR THE	002099 03-03 DIFFERENTIAL BEHAVIORAL EFFECTS OF SULPIRIDE IN THE RAT AND SQUIRREL-MONKEY.
ANALGESIC ACTION OF BACLOFEN AND MORPHINE. 002132 03-03	003276 04-04
PHYSIOLOGICAL SUBSTRATES OF STATE-DEPENDENT LEARNING. 003302 04-0-	STUDY OF SUITOPRIDE (LIN-1418) IN AGITATED STATES
SUBSYNAPTOSOMAL STUDIES ON THE SUBSYNAPTOSOMAL DISTRIBUTION OF PSYCHOTROPIC DRUGS IN RAT CEREBRAL-CORTEX.	SPECIFIC RELEASE BY NALOXONE OF H3-MORPHINE FROM SUPERFUSED SLICES OF CORPUS-STRIATUM OF MICE.
SURTHALAMIC 002045 03-0	001164 02-03
APOMORPHINE INCREASES GLUCOSE UTILIZATION IN THE SUBSTANTIA- NIGRA, SUBTHALAMIC NUCLEUS AND CORPUS-STRIATUM OF RAT. 001976 03-0.	EFFECTS OF SYSTEMIC MUSCIMOL AND GABA IN THE SPINAL CORD AND SUPERIOR CERVICAL GANGLION OF THE CAT.
SUBTYPES SUBTYPES OF DEPRESSION DIAGNOSIS AND MEDICAL MANAGEMENT. 000938 01-1:	GAS-CHROMATOGRAPHIC MASS SPECTROMETRIC ASSAY OF SEROTONIN
DEPRESSION: MUST PHARMACOTHERAPY FAIL FOR COGNITIVE THERAPY TO SUCCEED?	001006 02-01 THE EFFECT OF PANCURONIUM AND GALLAMINE ON MUSCARINIC
SUCCESSIVE 003726 04-1	7 TRANSMISSION IN THE SUPERIOR CERVICAL GANGLION. 002021 03-03
EFFECTS OF METHYLPHENIDATE ON ACQUISITION AND SUBSEQUENT PERFORMANCE OF SUCCESSIVE DISCRIMINATION REVERSALS. 001371 02-0.	BETA-ADRENOCEPTORS MODULATE NORADRENALINE RELEASE FROM AXONAL SPROUTS IN CULTURED RAT SUPERIOR CERVICAL GANGLIA. 002179 03-03
ROLE OF NOREPINEPHRINE IN THE RELEASE OF PROLACTIN INDUCED BY SUCKLING AND ESTROGEN.	SUPPRESSION BY NITROUS-OXIDE OF VISUAL RESPONSES IN THE CEREBELLAR VERMIS AND SUPERIOR COLLICULUS OF CATS ANESTHETIZED WITH CHLORALOSE.
001071 02-0	002897 04-03
EXPERIMENTAL LEAD ENCEPHALOPATHY IN THE SUCKLING RAT: CONCENTRATION OF LEAD IN CELLULAR FRACTIONS ENRICHED IN BRAIN CAPILLARIES.	THE DECREASE OF MONOAMINE-OXIDASE ACTIVITY FOLLOWING THE INTRAOCULAR INJECTION OF COLCHICINE IN THE SUPERIOR COLLICULUS OF THE RAT.
SUCROSE 003420 04-0	THE NEUROLOGICAL BASIS OF MOTOR ASYMMETRY FOLLOWING
KINETIC STUDIES OF FOOD INTAKE AND SUCROSE SOLUTION PREFERENCE BY RATS TREATED WITH LOW DOSES OF DELTA9- TETRAHYDROCANNABINOL.	UNILATERAL NIGROSTRIATAL LESIONS IN THE RAT: THE EFFECT OF SECONDARY SUPERIOR COLLICULUS LESIONS. 003200 04-04
000324 01-0	SUPERNATANT
SUDDEN SUDDEN DEATH OF PATIENTS USING PSYCHOTROPIC MEDICATION. 001796 02-1:	MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES: MESCALINE-DEMETHYLASE ACTIVITY OF BRAIN-CORTEX SOLUBLE SUPERNATANT.
INTRAVENOUS PROPYLHEXEDRINE AND SUDDEN DEATH. 001850 02-1:	000090 01-03
SUFENTANIL NARCOTIC CUEING PROPERTIES OF INTRAVENTRICULARLY ADMINISTERED	DOPAMINE RECEPTOR BINDING ENHANCEMENT ACCOMPANIES LESION-
SUFENTANIL, FENTANYL, MORPHINE AND MET-ENKEPHALIN. 002217 03-0	000084 01-03
SUICIDE BEHAVIORAL TOXICITY AND EQUIVOCAL SUICIDE ASSOCIATED WITH	000746 01-13
CHLOROQUINE AND ITS DERIVATIVES.	SELF-STIMULATION IN RATS.
000839 01-1	001351 02-04

COMPARISON OF BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE AFTER FLUPHENAZINE-DIHYDROCHLORIDE AND FLUPHENAZINE-DECANOATE TREATMENT IN RATS.

001484 02-04

CORRELATION BETWEEN DRUG-INDUCED SUPERSENSITIVITY OF DOPAMINE DEPENDENT STRIATAL MECHANISMS AND THE INCREASE IN STRIATAL CONTENT OF THE CA2 REGULATED PROTEIN ACTIVATOR OF C-AMP-PHOSPHODIESTERASE.

002023 03-

PRESYNAPTIC DOPAMINE RECEPTORS: DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING TREATMENT WITH FLUPHENAZINE DECANOATE.

O02120 03-03
SUPERSENSITIVITY OF THE CHOLINERGIC RESPONSE TO APOMORPHINE IN
THE STRIATUM FOLLOWING DENERVATION OR DISUSE
SUPERSENSITIVITY OF DOPAMINERGIC RECEPTORS IN THE RAT.
002872 04-03

CHARACTERIZATION OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS IN MEMBRANES PREPARED FROM THE RABBIT IRIS BEFORE AND AFTER DEVELOPMENT OF SUPERSENSITIVITY.

003035 04-03
BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC NARCOTIC TREATMENT IN THE GUINEA-PIG.

O03183 04-04
STRIATAL CELL SUPERSENSITIVITY TO APOMORPHINE IN DOPAMINE
LESIONED RATS CORRELATED TO BEHAVIOUR.

003356 04-0
INHIBITION OF 5,7 DIHYDROXYTRYPTAMINE-INDUCED SUPERSENSITIVITY
TO 5 HYDROXYTRYPTOPHAN IN MICE BY TREATMENT WITH
CYCLOHEVIANDE

DOPAMINE SUPERSENSITIVITY, ENDORPHIN EXCESS, AND PROSTAGLANDIN-E1 DEFICIENCY: THREE ASPECTS OF THE SAME

SCHIZOPHRENIC ELEPHANT. 003458 04-08

NEUROLEPTIC-INDUCED SUPERSENSITIVITY PSYCHOSIS.

003646 04-06

SUPPLEMENTS
STUDY OF THE INFLUENCE OF VITAMIN SUPPLEMENTS ON THE BEHAVIOR
OF PSYCHIATRIC PATIENTS.

003624 04-14

SUPPLYING

EVIDENCE FOR DISTINCT SPINAL LOCOMOTION GENERATORS SUPPLYING

RESPECTIVELY FORELIMBS AND HINDLIMBS IN THE RABBIT.

RESPECTIVELY FORELIMBS AND HINDLIMBS IN THE RABBIT.
003124 04-03

TWO DOPAMINE RECEPTORS: SUPPORTIVE EVIDENCE WITH THE RAT ROTATIONAL MODEL. 001478 02-04

BEHAVIOR THERAPY, SUPPORTIVE PSYCHOTHERAPY, IMIPRAMINE, AND PHOBIAS. 002501 03-10

SUPPRESSANT

INVOLVEMENT OF CENTRAL NORADRENERGIC SYSTEM IN THE MEDIATION OF BEHAVIORAL SUPPRESSANT EFFECTS OF DIAZEPAM IN HYPERTHYROID RATS.

001220 02-03

RELATIONSHIP BETWEEN ANORECTIC AND REINFORCING PROPERTIES OF
APPETITE SUPPRESSANT DRUGS: IMPLICATIONS FOR ASSESSMENT OF
ABUSE LIABILITY.

ADUSE LIABILITY. 003236 04-04

FLURAZEPAM EFFECTS ON SLOW-WAVE SLEEP: STAGE-4 SUPPRESSED BUT NUMBER OF DELTA-WAVES CONSTANT. 001708 02-14

FENELURAMINE AND FLUOXETINE SPARE PROTEIN CONSUMPTION WHILE

SUPPRESSING CALORIC INTAKE BY RATS. 002184 03-03

EQUAL SUPPRESSION OF CEREBELLAR PURKINJE CELL ACTIVITY BY AMPHETAMINE STEREOISOMERS.

000299 01-03

SUPPRESSION OF NEOPHOBIA BY CHLORPROMAZINE IN WILD RATS.

O00415 01-04
NEUROTRANSMITTERS AND RESPONSE SUPPRESSION.

000464 01-04
THE EFFECT OF AMPHETAMINE AND L-DOPA ON TETRABENAZINE-INDUCED
SUPPRESSION OF INTRACRANIAL SELF-STIMULATION IN THE RAT.
001321 02-04

001321 02-0
NALOXONE INTERACTION WITH NEUROLEPTIC-INDUCED SUPPRESSION OF NARCOTIC WITHDRAWAL.

DOTAS 02-04
BETA-ENDORPHIN: DOSE-DEPENDENT SUPPRESSION OF FIXED-RATIO
OPERANT BEHAVIOR.

001402 02-04

SLEEP SUPPRESSION INDUCED BY INTRAVENOUS AND INTRAVENTRICULAR INFUSIONS OF METHOXAMINE IN THE DOG.

001434 02-04

A TWO-DOSE DEXAMETHASONE SUPPRESSION TEST IN PATIENTS WITH PSYCHIATRIC ILLNESS.

A COMPARISON OF FOOD INTAKE SUPPRESSION PRODUCED BY GIVING AMPHETAMINE AS AN AVERSION TREATMENT VERSUS AS AN ANOREXIC TREATMENT.

SUPPRESSION OF CAUDATE NEURON ACTIVITIES BY MORPHINE AND THE INVOLVEMENT OF DOPAMINERGIC NEUROTRANSMISSION.

INFLUENCE OF IMMUNE STIMULATION AND SUPPRESSION ON MORPHINE PHYSICAL DEPENDENCE AND TOLERANCE.

SUPPRESSION OF THE HYPOTHALAMIC PITUITARY ADRENAL AXIS AFTER ORAL HYDROCORTISONE-SUCCINATE INGESTION IN RATS. 002098 03-03

THE EFFECT OF ETHANOL ON SUPPRESSION OF THE NALOXONE PRECIPITATED ESCAPE RESPONSE IN MORPHINE-DEPENDENT MICE. 002230 03-04

EFFECTS OF D AMPHETAMINE AND CHLORDIAZEPOXIDE ON POSITIVE CONDITIONED SUPPRESSION.

O02295 03-04
ON THE TREATMENT OF NEURODERMATITIS WITH A MONOAMINEOXIDASE INHIBITOR: THE CHEMOTHERAPY OF PSYCHOSOMATIC
ILLNESS THROUGH A-REM SUPPRESSION.

O02480 03-10
SUPPRESSION BY NITROUS-OXIDE OF VISUAL RESPONSES IN THE
CEREBELLAR VERMIS AND SUPERIOR COLLICULUS OF CATS
ANESTHETIZED WITH CHLORALOSE.

002897 04-03
DIFFERENTIAL EFFECTS OF SPINAL CORD LESIONS ON NARCOTIC AND
NONNARCOTIC SUPPRESSION OF NOCICEPTIVE REFLEXES; FURTHER
EVIDENCE FOR THE PHYSIOLOGIC MULTIPLICITY OF PAIN MODULATION.

SUPPRESSION OF LOCOMOTOR ACTIVITY IN SPARROWS BY TREATMENT WITH MELATONIN.

ACTH EFFECTS ON RESPONSE SUPPRESSION AND PLASMA CORTICOSTERONE IN THE MOUSE.

003363 04-04

MORBIDITY SUPPRESSIVE EFFECT OF LITHIUM-CARBONATE IN CYCLOID PSYCHOSIS. 002525 03-11

SUPRA-ADDITIVE

METABOLIC BASIS FOR THE SUPRA-ADDITIVE EFFECT OF THE ETHANOL

DIAZEPAM COMBINATION IN MICE.

SUPRACORTICALLY
HYPERTHERMIC EFFECTS OF SUPRACORTICALLY APPLIED
PROSTAGLANDINS AFTER SYSTEMIC PRETREATMENT WITH INHIBITORS
OF PROSTAGLANDIN TRANSPORT AND SYNTHESIS.

OF PROSTAGLANDIN TRANSPORT AND SYNTHESIS.

O02174 03-03

SUPRAEPENDYMAL

AUTORADIOGRAPHIC EVIDENCE FOR THE SELECTIVE ACCUMULATION OF

H3-5-HT BY SUPRAEPENDYMAL NERVE TERMINALS.

001222 02-03

SUPRAOPTIC

EFFECTS OF ACETYLCHOLINE, SODIUM-GLUTAMATE AND GABA ON THE DISCHARGE OF SUPRAOPTIC NEURONS IN THE RAT.

002830 04-03

SUPRAREMAL

EFFECTS OF IFC-45, A NEW BENZONAPHTYRIDONE DERIVATIVE WITH

ANTIDEPRESSIVE ACTION, ON ACTIVITY OF THE RAT SUPRARENAL

GLAND CORTEX.

001522 02-05

PHARMACOLOGICAL AND ELECTROPHYSIOLOGICAL STUDIES OF MORPHINE AND ENKEPHALIN ON RAT SUPRASPINAL NEURONES AND CAT SPINAL NEURONES. 002883 04-03

SURAE

EFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY
THE RESPONSES OF THE MUSCLE SPINDLE OF THE TRICEPS SURAE
MUSCLE OF THE DECEREBRATE CAT TO THE MUSCLE STRETCH.

003109 04-03

SURAL-ADELTA
MORPHINE AND MET-ENKEPHALIN EFFECTS ON SURAL-ADELTA AFFERENT
TERMINAL EXCITABILITY.

TERMINAL EXCITABILITY. 003076 04-03

DEVELOPMENT OF DENERVATION ALTERATIONS IN SURFACE MEMBRANES OF MAMMALIAN SKELETAL MUSCLE. 001246 02-03

NORMAL AND AMPHETAMINE-INDUCED ROTATION OF RATS ON A FLAT SURFACE. 001365 02-04

PREACTAINT
POSSIBLE INVOLVEMENT OF CYCLIC-AMP IN INFLAMMATION INDUCED BY
A SURFACTANT.
002018 03-03

EFFECTS OF INTRAVENOUS TETRAHYDROCANNABINOL ON EXPERIMENTAL AND SURGICAL PAIN.

000655 01-11

PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF CHLORDIAZEPOXIDE AND ITS METABOLITES IN SURGICAL PATIENTS

ANALYSIS OF THE ROLE PLAYED BY THE SUBSTANTIA-NIGRA IN THE MEDIATION OF INGESTIVE, LOCOMOTOR, AND ROTATIONAL BEHAVIORS AS REVEALED BY SURGICAL AND PHARMACOLOGICAL MANIPULATIONS. (PH.D. DISSERTATION).

NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION OF THE SYMPATHETIC NERVE OF THE EYE.

002R02 04-03 THE EFFECT OF INTRAHIPPOCAMPAL KAINIC-ACID INJECTIONS AND SURGICAL LESIONS ON NEUROTRANSMITTERS IN HIPPOCAMPUS AND SEPTUM.

002911 04-03 SLEEP CHANGES INDUCED BY CHRONIC ADMINISTRATION OF S-1694 (SURVECTOR).

002194 03-04

A REEXAMINATION OF USING ANTIPARKINSONS DRUGS WITH PSYCHOTROPIC DRUG THERAPY — A SURVEY OF OUTPATIENTS

001874 02-16 LITHIUM-CARBONATE USE IN CHILDREN AND ADOLESCENTS: A SURVEY OF THE LITERATURE.

002471 03-09 THE EFFECTS OF METHAQUALONE ON THE SEIZURE SUSCEPTIBILITY OF

EFFECTS OF LITHIUM ON SEIZURE SUSCEPTIBILITY IN ALCOHOLIZED AND NONALCOHOLIZED RATS.

TIME-COURSE OF AUDIOGENIC SEIZURE SUSCEPTIBILITY AND PLASMA PENTOBARBITAL CONCENTRATION DURING WITHDRAWAL. 001977 03-03

CIRCADIAN SUSCEPTIBILITY RHYTHM TO NEUROLEPTICS: TETRABENAZINE.

SEIZURE SUSCEPTIBILITY AND ANTICONVULSANT ACTIVITY OF CARBAMAZEPINE, DIPHENYLHYDANTOIN AND PHENOBARBITAL IN RATS WITH SELECTIVE DEPLETIONS OF BRAIN MONOAMINES.

EFFECTS OF INTRAVENTRICULARLY ADMINISTERED MONOAMINES ON SEIZURE SUSCEPTIBILITY AND BODY TEMPERATURE IN RATS. 003180 04-04

CIRCADIAN SUSCEPTIBILITY RHYTHM TO APOMORPHINE IN THE BRAIN 003311 04-04 PSYCHOLOGICAL FACTORS IN SUSCEPTIBILITY TO DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS.

003660 04-15

INFLUENCE OF THE SUSPENSION OF CONTINUED TREATMENT WITH FLURAZEPAM AND AMOBARBITAL ON TWO DISCRIMINATION LEARNING SCHEDULES.

000328 01-04 SUSTAINED

CHRONIC TREATMENT WITH DESIPRAMINE CAUSED A SUSTAINED DECREASE OF 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE AND TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT BRAIN.

SUSTAINED-RELEASE

ABOUT A NONFATAL MASSIVE INTOXICATION WITH SUSTAINED-RELEASE
THIORIDAZINE. CLINICAL AND THERAPEUTIC PROBLEMS.

001752 02-15

REPEATED SUSTAINED-RELEASE LITHIUM-CARBONATE ADMINISTRATION

A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE (SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS (SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE

003508 04-09 PURCHASES OF HYPNOTICS, SEDATIVES AND MINOR TRANQUILLIZERS AMONG 2,566 INDIVIDUALS IN THE COUNTY OF JAMTLAND, SWEDEN: A 6-YEAR FOLLOW-UP.

SWEETENED

ADDICTIVE AGENTS AND INTRACRANIAL STIMULATION (ICS): PRESSING FOR ICS BEFORE AND AFTER SELF-ADMINISTRATION OF SWEETENED MORPHINE SOLUTIONS.

001331 02-0 001331 02-04 PSYCHOPHARMACOLOGY OF THE SWITCH PROCESS IN AFFECTIVE-ILLNESS. (UNPUBLISHED PAPER). 000941 01-17

SYDNOCARB CLINICAL AND EXPERIMENTAL EXPERIENCE WITH MAPROTILINE, CLOMIPRAMINE, SYDNOCARB, AND MEFEXAMINE IN PSYCHIATRIC PATIENTS AND NORMAL SUBJECTS.

EFFECTS OF SODIUM PENTOBARBITAL ON SYMBOLIC MATCHING AND SYMBOLIC ODDITY PERFORMANCE.

SYMPATHECTOMIZED

ACTIONS OF AMPHETAMINE AND ANTAGONISTS ON PUPIL DIAMETER IN THE CHRONIC SYMPATHECTOMIZED DOG. 000265 01-03

SYMPATHETIC
CENTRALLY ACTIVE DRUGS AND THE SYMPATHETIC NERVOUS SYSTEM
OF RABBITS AND CATS.
000078 01-

000078 01-03 ACETYLCHOLINE STIMULATION OF THE SYMPATHETIC GANGLIA: EFFECTS OF TAURINE AND NICOTINIC AND MUSCARINIC GANGLION BLOCK. 000146 01-03

RELAXATION OF SMOOTH MUSCLE FOLLOWING CONTRACTION ELICITED BY SYMPATHETIC NERVE STIMULATION IN VIVO.

POSTSYNAPTIC POTENTIATION OF THE SLOW MUSCARINIC EXCITATORY RESPONSE BY TETRAETHYLAMMONIUM-CHLORIDE IN THE BULLFROG SYMPATHETIC GANGLION CELLS.

SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT AND NEWBORN RATS.

EFFECTS OF PRESYNAPTIC MODULATORS ON CA2-INDUCED
NORADRENALINE RELEASE FROM CARDIAC SYMPATHETIC NERVES 002025 03-03

EFFECTS OF BUTYROPHENONES ON THE SYMPATHETIC NERVES OF THE ISOLATED RABBIT HEART AND ON THE POSTSYNAPTIC ALPHA-ADRENOCEPTORS OF THE ISOLATED RABBIT AORTA.

002026 03-03 THE EFFECT OF L-DOPA ON PERIPHERAL SYMPATHETIC NERVE FUNCTION: ROLE OF PRESYNAPTIC DOPAMINE RECEPTORS.

002081 03-03 CHARACTERIZATION OF ENKEPHALIN-LIKE MATERIAL EXTRACTED FROM SYMPATHETIC GANGLIA.

002788 04-01 NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION OF THE SYMPATHETIC NERVE OF THE EYE.

002802 04-03 INTERACTION OF PENTOBARBITONE AND GAMMA-AMINOBUTYRIC-ACID ON MAMMALIAN SYMPATHETIC GANGLION CELLS.

002844 04-03 THE ACTION OF CNS DRUGS ON AN ISOLATED SYMPATHETIC NERVE PREPARATION OF RABBIT.

002869 04-03 BIOCHEMICAL AND MORPHOLOGICAL EFFECTS OF TESTOSTERONE TREATMENT ON DEVELOPING SYMPATHETIC NEURONS.

DOPAMINE-BETA-HYDROXYLASE RELEASE FOLLOWING ACUTE SELECTIVE SYMPATHETIC NERVE STIMULATION OF THE HEART, SPLEEN AND MESENTERY.

003422 04-06 SYMPATHOADRENAL

EFFECT OF GENERAL ANESTHETICS ON HANDLING-INDUCED AND DECAPITATION-INDUCED INCREASES IN SYMPATHOADRENAL DISCHARGE.

002139 03-03 SYMPATHOMIMETIC
AUTORADIOGRAPHIC STUDIES WITH SYMPATHOMIMETIC AMINES 000079 01-03

THE SYMPATHOMIMETIC ACTIVITY OF FENFLURAMINE HYDROCHLORIDE ON RAT VAS-DEFERENS. 000205 01-03

INDIRECT SYMPATHOMIMETIC AGENTS AND CEREBRAL BLOOD FLOW AND METABOLISM.

002092 03-03 INDIRECT SYMPATHOMIMETICS AND CEREBRAL BLOOD FLOW AND MFTAROLISM

001189 02-03 SCHIZOPHRENIC SYMPTOM REMISSION WITH APOMORPHINE 001570 02-08 LITHIUM-CARBONATE AND BRAIN FUNCTION: I. CEREBRAL EVOKED-POTENTIALS, EEG, AND SYMPTOM CHANGES DURING LITHIUM-CARBONATE TREATMENT.

002560 03-13

SYMPTOMATIC
A CONTROLLED TRIAL OF METOCLOPRAMIDE IN SYMPTOMATIC GASTROESOPHAGEAL REFLUX.

000862 01-15 THE EFFECTS OF ACTH4-10 VERSUS PLACEBO IN THE MEMORY OF SYMPTOMATIC GERIATRIC VOLUNTEERS.

002537 03-11

ACTH4-10 IN THE AMELIORATION OF NEUROPSYCHOLOGICAL SYMPTOMATOLOGY ASSOCIATED WITH SENILE ORGANIC-BRAIN-

002505 03-11

A CONTROLLED CLINICAL STUDY OF TRAZODONE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH PRONOUNCED DEPRESSIVE SYMPTOMATOLOGY.

003472 04-08

SYMPTOMS

PHARMACOLOGICAL TREATMENT FOLLOWING EXPERIMENTAL CEREBRAL INFARCTION: IMPLICATIONS FOR UNDERSTANDING PSYCHOLOGICAL SYMPTOMS OF HUMAN STROKE.

000243 01-03

LACK OF EFFECT OF NALOXONE ON SCHIZOPHRENIC SYMPTOMS. 000533 01-08

AMP SYSTEM: LONGITUDINAL COURSE STUDIES OF PSYCHOPATHOLOGIC AND SOMATIC SYMPTOMS. AN EMPIRIC INVESTIGATION OF THE PROBLEM OF SIDE-EFFECTS.

TRICYCLIC ANTIDEPRESSANT OVERDOSE: INCIDENCE OF SYMPTOMS. 000801 01-15 ON PSYCHOLOGICAL SYMPTOMS IN BROMIDE INTOXICATION — ONE CASE OF HIGH DOSE, LONG-TERM BROMIDE INTOXICATION WHICH SHOWED

HALLUCINATION AND DELUSION SYMPTOMS 000880 01-15

REGIONAL CHANGES OF CEREBRAL BLOOD FLOW DURING HALOPERIDOL THERAPY IN PATIENTS WITH PARANOID SYMPTOMS. 001677 02-13

RELATIONSHIP BETWEEN PHYSICAL FINDINGS AND RELATED SUBJECTIVE SYMPTOMS IN NEUROPSYCHIATRIC PATIENTS WITH SOMATIC COMPLICATIONS -- WITH SPECIAL REFERENCE TO OPHTHALMOLOGIC

001678 02-13 LATE WITHDRAWAL SYMPTOMS IN BABIES BORN TO METHADONE

001756 02-15

PHARMACOKINETICS AND CLINICAL EFFECTS OF AMANTADINE IN DRUG-INDUCED EXTRAPYRAMIDAL SYMPTOMS.

001781 02-15 SYNDROME MALIN SYMPTOMS THOUGHT TO BE DUE TO INTERACTION BETWEEN NEUROLEPTICS AND ORAL DIABETES DRUGS.

001854 02-15 THE THIORIDAZINE LEVEL IN THE BLOOD SERUM AND SYMPTOMS OF THE PARANOID SYNDROME.

002543 03-13 NEUROCHEMISTRY OF WITHDRAWAL EMERGENT SYMPTOMS IN CHILDREN

002602 03-13 THE VALUE OF THE MMPI FOR DELINEATING SYMPTOMS UNIQUE TO POSITIVE LITHIUM RESPONDERS: A DRUG RESPONSE AND DIAGNOSTIC

STUDY. (PH.D. DISSERTATION) 002638 03-14 SCHIZOPHRENIC SYMPTOMS IMPROVE WITH APOMORPHINE

003474 04-08 THE FREQUENCY AND PERSISTENCE OF DEPRESSIVE SYMPTOMS IN THE ALCOHOL ABUSER

003567 04-11 THE BEHAVIORAL SYMPTOMS OF HYPERKINETIC CHILDREN WHO SUCCESSFULLY RESPONDED TO STIMULANT DRUG TREATMENT

003579 04-11 CLONIDINE BLOCKS ACUTE OPIATE WITHDRAWAL SYMPTOMS 003628 04-14

PSYCHOLOGICAL FACTORS IN SUSCEPTIBILITY TO DRUG-INDUCED **EXTRAPYRAMIDAL SYMPTOMS** 003660 04-15

SYNAPSE PENTOBARBITAL: PRESYNAPTIC EFFECT IN THE SQUID GIANT SYNAPSE 000204 01-03

SYNAPSES EVIDENCE FOR FUNCTIONAL SYNAPSES BETWEEN MIXED CULTURES OF INFERIOR OLIVE AND CEREBELLUM.

000497 01-06 NEUROLOGICAL DISTURBANCES, NIGROSTRIATE SYNAPSES, AND IONTOPHORETIC DOPAMINE AND APOMORPHINE AFTER HALOPERIDOL 001293 02-03

EFFECTS OF 4 AMINOPYRIDINE ON TRANSMISSION IN EXCITATORY AND INHIBITORY SYNAPSES IN THE SPINAL CORD. 001384 02-04 PHARMACOLOGIC RESPONSES OF CELLS OF A NEUROBLASTOMA-X GLIOMA HYBRID CLONE AND MODULATION OF SYNAPSES BETWEEN HYBRID CELLS AND MOUSE MYOTUBES.

002863 04-03

SYNAPTIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON A MG2-ATPASE OF SYNAPTIC VESICLES PREPARED FROM RAT CEREBRAL-CORTEX.

INFLUENCE OF CHRONIC PENTOBARBITAL OR MORPHINE TREATMENT ON THE INCORPORATION OF P32-PHOSPHORIC-ACID AND 3H CHOLINE INTO RAT SYNAPTIC PLASMA MEMBRANES.

000147 01-03 CHLORPROMAZINE INDUCES POPULATION INCREASE OF SYNAPTIC VESICLES IN THE RAT HYPOTHALAMIC VENTROMEDIAL NUCLEUS

SELECTIVE OPIATE DEPRESSION OF SENSORY EVOKED SYNAPTIC
NETWORKS IN DORSAL-HORN REGIONS OF SPINAL CORD CULTURES. 001088 02-03
INFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND

METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3-CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN

SYNAPTIC CONNEXIONS AND RELATED POSTSYNAPTIC PHARMACOLOGY STUDIED IN THE CEREBRAL GANGLION OF APLYSIA.

D ALPHA-AMINOADIPATE, ALPHA-EPSILON-DIAMINOPIMELIC-ACID AND H-966 AS ANTAGONISTS OF AMINO-ACID-INDUCED AND SYNAPTIC EXCITATION OF MAMMALIAN SPINAL NEURONES IN VIVO.

ACTIVE UPTAKE OF H3-5-HT BY SYNAPTIC VESICLES FROM RAT BRAIN. 002937 04-03 002831 04-03

CHANGES IN SYNAPTIC FUNCTION INDUCED BY BLOCKAGE OF AXONAL TRANSPORT IN THE RABBIT OPTIC PATHWAY.

AN ULTRASTRUCTURAL STUDY INTO THE EFFECTS OF PENTOBARBITONE ON SYNAPTIC ORGANIZATION. 002968 04-03

STRYCHNINE BINDING ASSOCIATED WITH SYNAPTIC GLYCINE RECEPTORS IN RAT SPINAL CORD MEMBRANES: IONIC INFLUENCES. 003024 04-03

SYNAPTICALLY

MONOSYNAPTIC ACTIVATION OF FASCIA-DENTATA IN UNRESTRAINED RATS: RESPONSE MODIFICATION BY SYNAPTICALLY ACTIVE DRUGS. 001214 02-03

DIFFERENTIAL EFFECTS OF RESERPINE AND TETRABENAZINE ON RAT STRIATAL SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS AND SYNAPTOSOMAL DOPAMINE POOLS.

000172 01-03 HIGH-AFFINITY BINDING OF H3-GLYCINE AND C14-BETA-ALANINE TO SYNAPTOSOMAL MITOCHONDRIAL FRACTIONS OF RAT CNS REGIONS; EFFECTS OF STRYCHNINE

SPECIFIC SEROTONIN BINDING AND ADENYLATE-CYCLASE STIMULATION:
A CORRELATIVE STUDY USING ISOLATED SYNAPTOSOMAL
MEMBRANES FROM MATURE RAT BRAIN.

000230 01-03 EFFECTS OF PHENCYCLIDINE ON (3H)CATECHOLAMINE AND
(3H)SEROTONIN UPTAKE IN SYNAPTOSOMAL PREPARATIONS FROM

000273 01-03 BLOCKADE OF SYNAPTOSOMAL CA UPTAKE BY OPIATES IN VITRO.

001075 02-03 EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON SYNAPTOSOMAL CA UPTAKE.

CALCIUM CONTENT AND BINDING IN SYNAPTOSOMAL SUBFRACTIONS
DURING CHRONIC MORPHINE TREATMENT.

EFFECTS OF SUBSTITUTED SPIROISOBENZOFURANPIPERIDINES ON SYNAPTOSOMAL BIOGENIC AMINE TRANSPORT.

002087 03-03 7,N,N TRIMETHYLTRYPTAMINE: A SELECTIVE INHIBITOR OF SYNAPTOSOMAL SEROTONIN UPTAKE.

EFFECTS OF RACEMIC, (S)- AND (R) METHYLENEDIOXYAMPHETAMINE ON SYNAPTOSOMAL UPTAKE AND RELEASE OF TRITIATED MOREPINEPHERINE

M3-GABA RELEASE IN SYNAPTOSOMAL FRACTIONS AFTER INTRACRANIAL ADMINISTRATION OF RUTHENIUM-RED.

EFFECTS OF MAZINDOL ON RAT BRAIN SYNAPTOSOMAL MONOAMINE UPTAKE. 003103 04-03

SYNAPTOSOME

INFLUENCE OF NEUROLEPTICS ON THE BINDING OF MET-ENKEPHALIN, MORPHINE AND DIHYDROMORPHINE TO SYNAPTOSOME ENRICHED FRACTIONS OF RAT BRAIN.

003096 04-03

Subject Index
SYNAPTOSOMES KINETICS OF CATE MOUSE BRAIN
EFFECT OF CANNA ACTIVITY AND
POTENTIATION BY DOPAMINE SYN
THE BLOCKADE OF RELATIONSHIP 1 INHIBITORS.
TYRAMINE BINDIN CENTRALLY ACT
EFFECT OF ACUTE A
CATECHOLAMINE SYNAPTOSOME
COCAINE AND ME PHARMACOLOG DOPAMINE UPT
INHIBITION BY NEI
ENERGY UTILIZATI
SYNCHRONIZATION THE EFFECTS OF P- AND CYPROHEP IN THE RAT.
THE PRODUCTION PARKINSON SYNDERIVATIVE LOI
THE EFFECT OF INT PROTEIN SYNTH PRODUCED BY A
POST HEAD TRAUM
COMBINATION OF OXAZEPAM (AD (INSIDON) IN DE
THE EFFECTS OF CE SYNDROME.
EVALUATION OF LI
CATECHOLAMINE A
IATROGENIC EXTR
FLOPPY INFANT SY
FLOPPY INFANT SY
NEONATAL WITHD

Su	bject Index
SY	NAPTOSOMES KINETICS OF CAT MOUSE BRAIN
	EFFECT OF CANNA ACTIVITY AND
	POTENTIATION BY
	THE BLOCKADE O RELATIONSHIP INHIBITORS.
	TYRAMINE BINDI CENTRALLY AC
	EFFECT OF ACUTE UPTAKE INTO I
	CATECHOLAMINE SYNAPTOSOMI
	COCAINE AND MI PHARMACOLO DOPAMINE UP
	INHIBITION BY NE
	ENERGY UTILIZAT
SYI	THE EFFECTS OF P AND CYPROHEI IN THE RAT.
SYI	THE PRODUCTION PARKINSON SY DERIVATIVE LO
	THE EFFECT OF IN PROTEIN SYNTI PRODUCED BY
	POST HEAD TRAU
	COMBINATION OF OXAZEPAM (A (INSIDON) IN C
	THE EFFECTS OF C
	EVALUATION OF I
(D)	CATECHOLAMINE PATIENTS WITH
	IATROGENIC EXTE
	FLOPPY INFANT S
	FLOPPY INFANT S
	NEONATAL WITH
	OF NEUROLEPTI HALOPERIDOL.
	MORPHINE AB
	FLOPPY-INFANT S
	MANAGEMENT O METHYLPHENIC
	GILLES-DE-LA-TOU

Y	IN		

		NA-K-ATPASE	ACTIVITY IN
SYNAPTOSO	MED.		000093 01-03
RINOIDS ON	NEUROTRA	NSAAITTER UP	TAKE ATPASE

INOIDS ON NEUROTRANSMITTER UPTAKE, ATPA MORPHOLOGY OF MOUSE BRAIN SYNAPTOSOMES 000143 01-03

COCAINE OF THE STIMULUS-INDUCED INCREASE IN THESIS IN RAT BRAIN STRIATAL SYNAPTOSOMES. 000217 01-03

SEROTONIN UPTAKE INTO SYNAPTOSOMES: O AN INTERACTION WITH MONOAMINE-OXIDASE

000268 01-03 G BY SYNAPTOSOMES FROM RAT BRAIN: EFFECT OF IVE DRUGS. 000285 01-03

AND CHRONIC MORPHINE TREATMENT ON SEROTONIA
AT HYPOTHALAMIC SYNAPTOSOMES. 000293 01-03

ENSITIVE ATPASE ACTIVITIES IN BRAIN OF MORPHINIZED MICE. 001096 02-03

ABOLITES: RELATIONSHIP BETWEEN
CAL ACTIVITY AND INHIBITORY ACTION ON
AKE INTO STRIATAL SYNAPTOSOMES.

001286 02-03 ROLEPTICS OF UPTAKE OF H3-GABA INTO RAT BRAIN

002013 03-03 ON IN THE INDUCED RELEASE OF GAMMA-ACID FROM SYNAPTOSOMES.

003029 04-03

CHLOROPHENYLALANINE, RESERPINE, METHYSERGIDE FADINE ON THE DOPA-INDUCED EEG SYNCHRONIZATION 003022 04-03

OF AN ALTERNATIVE LABORATORY MODEL OF THE IDROME USING A NEW BENZYLIMIDOYLUREA

000083 01-03 RACEREBRAL INJECTION OF CYCLOHEXIMIDE ON BRAIN ISIS AND ON THE HYPERACTIVITY SYNDROME MONOAMINE-OXIDASE INHIBITOR AND TRYPTOPHAN.

000410 01-04 SYNDROME IN AN ADOLESCENT TREATED WITH

NATE - CASE REPORT 000560 01-09

PHENYLPYRROLIDINOPENTANE (KATOVIT) WITH UMBRAN): A DOUBLE-BLIND TRIAL WITH OPIPRAMOL PRESSIVE SYNDROME. 000597 01-10

NTRAL-NERVOUS-SYSTEM STIMULANTS ON TOURETTE 000629 01-11

HIUM-CARBONATE IN THE MANAGEMENT OF GILLES-S SYNDROME 000646 01-11

AND OCTOPAMINE CONCENTRATIONS IN BRAINS OF REYE SYNDROME. 000712 01-13

PYRAMIDAL SYNDROME - A CAUTIONA RY TALE 000834 01-15 NDROME AND MATERNAL DIAZEPAM

000837 01-15 NDROME AND MATERNAL DIAZEPAM.

000845 01-15 RAWAL SYNDROME ASSOCIATED WITH HYDROXYZINE

MALIGNANT SYNDROME: A POSSIBLE COMPLICATION IC ADMINISTRATION. REPORT OF A CASE INVOLVING

000910 01-15

PSYCHOTIC AND ANTIANXIETY DRUGS ON THE 001303 02-04

SYNDROME: IS OXAZEPAM THE ANSWER? 001619 02-11 THE HYPERKINETIC SYNDROME WITH

DATE AND SMR BIOFEEDBACK TRAINING 001625 02-11 A-TOURETTE SYNDROME: A NEW CLINICOTHERAPEUTIC APPROACH

FOUR CASES OF SYNDROME MALIN.

001630 02-11 001783 02-15

Psychopharmacology Abstracts

GILLES-DE-LA-TOURETTES SYNDROME: FAMILIAL OCCURRENCE AND PRECIPITATION BY METHYLPHENIDATE THERAPY.

RELATIONSHIPS AMONG CLINICAL RESPONSE, EXTRAPYRAMIDAL SYNDROME AND PLASMA CHLORPROMAZINE AND METABOLITE RATIOS.

001827 02-15 THE EFFECT OF BENZTROPINE-MESYLATE IN THE RABBIT SYNDROME AND TARDIVE-DYSKINESIA.

001834 02-15 FLOPPY-INFANT SYNDROME AND MATERNAL DIAZEPAM AND/OR

001835 02-15 SYNDROME MALIN SYMPTOMS THOUGHT TO BE DUE TO INTERACTION BETWEEN NEUROLEPTICS AND ORAL DIABETES DRUGS.

001854 02-15 PHARMACOLOGICAL MANIPULATIONS OF THE SEPTAL IRRITABILITY
SYNDROME: ROLE OF DOPAMINERGIC MECHANISMS IN RECOVERY OF
FUNCTION. (PH.D. DISSERTATION).

002089 03.03 TIME-COURSE OF THE EFFECTS OF NATURALLY OCCURRING CANNABINOIDS ON MORPHINE ABSTINENCE SYNDROME

002196 03-04 TREATMENT OF DEPRESSIVE SYNDROME WITH NOVERIL INFUSIONS 002439 03-09

COURSE AND PROGNOSIS OF THE SYNDROME OF DOUBLES 002507 03-11

SOMATOSENSORY EVOKED-POTENTIALS IN PATIENTS WITH PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND DECARBOXYLASE INHIBITOR.

002515 03-11 THE THIORIDAZINE LEVEL IN THE BLOOD SERUM AND SYMPTOMS OF THE PARANOID SYNDROME.

002543 03-13 INCREASE OF HIPPOCAMPAL ACETYLCHOLINE TURNOVER RATE AND THE STRETCHING YAWNING SYNDROME ELICITED BY ALPHA-MSH AND ACTH.

002644 03-14 GILLES-DE-LA-TOURETTES SYNDROME, TARDIVE-DYSKINESIA, AND PSYCHOSIS IN AN ADOLESCENT.

002651 03-15 THE TARDIVE-DYSKINESIA SYNDROME

002668 03-15 HEAT ILLNESS SYNDROME AND LITHIUM INTOXICATION. 002669 03-15

ACUTE BRAIN SYNDROME AFTER PROPRANOLOL 002672 03-15

ACUTE BRAIN SYNDROME AFTER PROPRANOLOL TREATMENT. 002708 03-15

THE EFFECTS OF DIVALENT IONS ON MORPHINE ANALGESIA AND ABSTINENCE SYNDROME IN MORPHINE-TOLERANT AND MORPHINE-DEPENDENT MICE. 003169 04-04

PIRROXAN IN THE TREATMENT OF THE NEUROVEGETATIVE COMPONENT OF THE DEPRESSIVE SYNDROME. 003443 04-07

KLINEFELTERS SYNDROME AND BIPOLAR AFFECTIVE-ILLNESS: A CASE REPORT. 003486 04-09

PRIMARY EMPTY SELLA SYNDROME AND BIPOLAR AFFECTIVE-ILLNESS: CASE REPORT. 003511 04-09

MANAGEMENT OF ACUTE ANXIETY SYNDROME WITH PARENTERALLY ADMINISTERED LORAZEPAM. 003539 04-10

NORADRENERGIC AND DOPAMINERGIC MECHANISMS IN GILLES-DE-LA-TOURETTE SYNDROME.

003609 04-13 SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE (SIADH) SECONDARY TO ANTIPSYCHOTIC DRUG THERAPY.

003647 04-15 ANTICHOLINERGIC DELIRIUM IN A CASE OF MUNCHAUSEN SYNDROME 003658 04-15

DRUG AND ALCOHOL-INDUCED PSYCHIATRIC SYNDROMES.

000796 01-15 VIDEOTAPE METHODS FOR IDENTIFICATION OF NONVERBAL BEHAVIOR PARAMETERS IN DEPRESSIVE SYNDROMES.

000934 01-16 POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES (N) ON OPIOID ABSTINENCE SYNDROMES.

001897 02-17 DOSAGE EFFECTS OF IMIPRAMINE ON THE PSYCHOPATHOLOGIC AND BIOLOGIC INDICES OF ENDOGENOUS DEPRESSIVE SYNDROMES.

002494 03-10 WITHDRAWAL SYNDROMES ASSOCIATED WITH ANTIPSYCHOTIC DRUGS. 003655 04-15

VOLUME 16, SUBJECT INDEX

Subject Index

NEW ASPECTS CONCERNING THE MECHANISM OF ACTION OF TRANQUILIZERS. THE INFLUENCE OF SOME TRANQUILIZERS ON PROTEIN AND NUCLEIC-ACID SYNTHESES.

000165 01-03

SYNTHESIS AND PHARMACOLOGIC STUDY OF 1 OXODIHYDROBENZODIAZEPINES.

000005 01-01

A NEW SYNTHESIS OF 5 KETO-DIHYDROBENZOTHIAZEPINES AND A PRELIMINARY STUDY OF THEIR BIOLOGICAL PROPERTIES.

000016 01-02 SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM EVALUATION OF SOME 5

ALKOXY-3H-1.4 BENZODIAZEPINES. 000021 01-02 NEW N 2 HYDROXYALKYL-BENZOMORPHAN DERIVATIVES: SYNTHESIS

000031 01-02 CATECHOLAMINE SYNTHESIS IN RAT BRAIN AFTER AXOTOMY: INTERACTION BETWEEN APOMORPHINE AND HALOPERIDOL 000161 01-03

SYNTHESIS OF SPIROISOBENZOFURANPIPERIDINES AS POTENTIAL CENTRAL-NERVOUS-SYSTEM AGENTS. 2. COMPOUNDS CONTAINING A HETERCOATOM ATTACHED TO NITROGEN.

POTENTIATION BY COCAINE OF THE STIMULUS-INDUCED INCREASE IN DOPAMINE SYNTHESIS IN RAT BRAIN STRIATAL SYNAPTOSOMES. 000217 01-03

THE AMNESTIC EFFECT OF PROTEIN SYNTHESIS INHIBITORS IS NOT DUE TO THE INHIBITION OF ADRENAL CORTICOSTEROIDOGENESIS.

000352 01-04 THE EFFECT OF STIMULANTS, DEPRESSANTS, AND PROTEIN SYNTHESIS INHIBITION ON RETENTION

000360 01-04 AMPHETAMINE INDUCES ANOREXIA EVEN AFTER INHIBITION OF

NORADRENALINE SYNTHESIS. 000365 01-04 THE EFFECT OF INTRACEREBRAL INJECTION OF CYCLOHEXIMIDE ON BRAIN

PROTEIN SYNTHESIS AND ON THE HYPERACTIVITY SYNDROME PRODUCED BY A MONOAMINE-OXIDASE INHIBITOR AND TRYPTOPHAN. 000410 01-04 SYNTHESIS OF BRADYKININ FRAGMENTS AND THEIR EFFECT ON

PENTOBARBITAL SLEEPING TIME IN MOUSE. 000424 01-04

MEMORY IMPAIRMENT CORRELATES CLOSELY WITH CYCLOHEXIMIDE DOSE AND DEGREE OF INHIBITION OF PROTEIN SYNTHESIS.

000436 01-04 HALOPERIDOL: EFFECT OF LONG-TERM TREATMENT ON RAT STRIATAL DOPAMINE SYNTHESIS AND TURNOVER.

INHIBITION OF DOPAMINE SYNTHESIS IN CHRONIC SCHIZOPHRENIA: CLINICAL INEFFECTIVENESS OF METYROSINE.

000542 01-08 SLEEP AND BEHAVIORAL CHANGES POSSIBLY REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS

000916 01-16 STEREOCHEMICAL STUDIES ON MEDICINAL AGENTS, 23, SYNTHESIS AND BIOLOGICAL EVALUATION OF 6 AMINO DERIVATIVES OF NALOXONE AND NAITREYONE

001004 02-01 PIPERIDINE DERIVATIVES: SYNTHESIS OF POTENTIAL ANALGESICS IN 3 SUBSTITUTED 4 PHENYLPIPERIDINE SERIES.

001019 02-02 SYNTHESIS AND PRELIMINARY PHARMACOLOGICAL ACTIVITY OF AMINOALKOXY ISOSTERES OF GLYCOLATE ESTER ANTICHOLINERGICS 001026 02-02

CANNABINOIDS. SYNTHESIS AND CENTRAL-NERVOUS-SYSTEM ACTIVITY OF 8 SUBSTITUTED HYDROXY-DIMETHYLBENZOPYRANOPYRIDINE AND 001034 02-02

EFFECT OF PENTOBARBITAL ON REGIONAL BRAIN PHOSPHOLIPID SYNTHESIS. 001203 02-03

INCREASED SYNTHESIS OF STRIATAL DOPAMINE BY N,N DIMETHYLTRYPTAMINE.

001248 02-03 TEMPORAL EFFECTS OF P-CHLOROAMPHETAMINE ON CATECHOLAMINE

001251 02-03 EFFECTS OF CANNABINOIDS ON L1210 MURINE LEUKEMIA: 1. INHIBITION

001266 02-03 SYNTHESIS AND COMPARATIVE SKELETAL MUSCLE RELAXANT ACTIVITY OF SOME 2,4 IMIDAZOLIDINEDIONES AND THEIR CORRESPONDING 5 HYDROXYIMIDAZOLIDINEDIONES.

001944 03-01 SYNTHESIS AND STEREOSPECIFIC ANTIPSYCHOTIC ACTIVITY OF BENZOCYCLOHEPTENE-PIRIDINE.

001949 03-01

BETA-ADRENERGIC RECEPTOR MEDIATED CYCLIC-AMP SYNTHESIS IN BROKEN-CELL HOMOGENATES OF RAT BRAIN.

002033 03-03 SYNTHESIS AND TURNOVER OF H3-5-HYDROXYTRYPTAMINE IN THE LATERAL CEREBROVENTRICLE.

002054 03-03 EFFECT OF SYNTHESIS INHIBITION ON THE LEVELS OF BRAIN CATECHOLAMINES IN BARBITAL DEPENDENT RATS.

EFFECTS OF DRUGS ON GAMMA-AMINOBUTYRIC-ACID RECEPTORS, UPTAKE, RELEASE AND SYNTHESIS IN VITRO.

002122 03-03 HYPERTHERMIC EFFECTS OF SUPRACORTICALLY APPLIED
PROSTAGLANDINS AFTER SYSTEMIC PRETREATMENT WITH INHIBITORS OF PROSTAGLANDIN TRANSPORT AND SYNTHESIS.

002174 03-03 INHIBITION OF FLAVIN SYNTHESIS BY CHLORPROMAZINE IN EUTHYROID AND HYPERTHYROID RATS

002352 03-05 SYNTHESIS OF TWO ENZYME RESISTANT ENKEPHALIN ANALOGS POSSESSING ENHANCED ANALGESIC ACTIVITY.

002787 04-01 STIMULATION OF DOPAMINE SYNTHESIS IN CAUDATE NUCLEUS BY INTRASTRIATAL ENKEPHALINS AND ANTAGONISM BY NALOXONE

THE EFFECTS OF CANNABINOIDS ON BODY TEMPERATURE AND BRAIN CATECHOLAMINE SYNTHESIS.

002835 04-03 THE EFFECT OF MORPHINE-TOLERANCE AND DEPENDENCE ON CELL FREE PROTEIN SYNTHESIS.

5 HYDROXYTRYPTAMINE: THE EFFECTS OF IMPAIRED SYNTHESIS ON ITS METABOLISM AND RELEASE IN RAT.

002878 04-03 INDUCTION OF SULFOGALACTOSYLCERAMIDE (SULFATIDE) SYNTHESIS BY HYDROCORTISONE (CORTISOL) IN MOUSE G-26 OLIGODENDROGLIOMA CELL STRAINS

002886 04-03 THE EFFECTS OF ALLYLGLYCINE ON GABA SYNTHESIS IN VIVO.
002997 04-03

EFFECTS OF LSD AND BOL ON THE CATECHOLAMINE SYNTHESIS AND TURNOVER IN VARIOUS BRAIN REGIONS

003043 04-03

INHIBITION BY BARBITURIC-ACID AND ITS DERIVATIVES OF THE ENZYMES
IN RAT BRAIN WHICH PARTICIPATE IN THE SYNTHESIS OF PYRIMIDINE
RIBOTIDES

EFFECT OF L-DOPA PRETREATMENT ON IN VIVO PROTEIN SYNTHESIS IN VARIOUS RAT BRAIN REGIONS.

ALTERATIONS IN RECEPTORS CONTROLLING DOPAMINE SYNTHESIS AFTER CHRONIC ETHANOL INGESTION.

003107 04-03 DOPAMINE SYNTHESIS AND TYROSINE-HYDROXYLASE ARE REGULATED BY INDEPENDENT DA RECEPTOR MEDIATED MECHANISMS.

003116 04-03 RECOVERY AS A FUNCTION OF THE DEGREE OF AMNESIA DUE TO PROTEIN SYNTHESIS INHIBITION.

EFFECTS OF THE PROSTAGLANDIN SYNTHESIS INHIBITOR, INDOMETHACIN ON ESTROGEN AND ESTROGEN PLUS PROGESTERONE-INDUCED SEXUAL RECEPTIVITY IN OVARIECTOMIZED RATS.

DIURNAL VARIATIONS IN THE MOTOR ACTIVITY OF THE RAT: EFFECTS OF INHIBITORS OF THE CATECHOLAMINE SYNTHESIS.

THE SYNTHESIS AND URINARY ESTIMATION OF N HYDROXYAPROBARBITONE

003595 04-13

SYNTHESIZED CONTROL OF THE RELEASE OF NEWLY SYNTHESIZED H3-5-HYDROXYTRYPTAMINE BY NICOTINIC AND MUSCARINIC RECEPTORS IN

000144 01-03

SYNTHETASE INHIBITION OF PROSTAGLANDIN SYNTHETASE SYSTEM IN THE RABBIT RENAL MEDULLA BY PSYCHOTROPIC DRUGS. 000281 01-03

SYNTHETIC HYPOTHERMIA IN RATS PRODUCED BY NABILONE, A SYNTHETIC

CANNABINOID. 000213 01-03 UP FROM DEPRESSION WITH A SYNTHETIC MALE HORMONE

000581 01-09 A SYNTHETIC ENKEPHALIN ANALOGUE WITH PROLONGED PARENTERAL AND ORAL ANALGESIC ACTIVITY.

001036 02-02 COMPETITIVE BINDING BETWEEN COCAINE AND VARIOUS DRUGS TO SYNTHETIC LEVODOPA MELANIN.

001051 02-03

COMPARATIVE INHIBITORY EFFECTS OF SYNTHETIC ENKEPHALINS ON THE STEREOSPECIFIC BINDING OF H3-DIHYDROMORPHINE AND H3-NALOXONE.

001076 02-03 THE LACK OF EFFECT OF SYNTHETIC SCOTOPHOBIN ON DARKNESS AVOIDANCE IN MICE.

QUANTITATION OF BINDING OF H3-CHLORPROMAZINE TO SYNTHETIC MELANINS AND MELANIN GRANULES.

O02354 03-05
DNA SYNTHETIC ABILITY IN CEREBELLA FROM TEMPERATURE AND
HANDLING STRESSED NEONATAL RATS.

SYRINGE

THE PNEUMATIC SYRINGE: A SIMPLE APPARATUS FOR SELF-ADMINISTRATION OF DRUGS BY RATS.

SYSTEMATIC

001541 02-06

003382 04-04

THE INCREASE IN S ADENOSYL-L-METHIONINE (SAME) CONCENTRATION IN RAT BRAIN AFTER ITS SYSTEMATIC ADMINISTRATION.

SCREENING HALLUCINGENIC DRUGS. II. SYSTEMATIC STUDY OF TWO BEHAVIORAL TESTS.

BEHAVIOR OBSERVATIONS OF HYPERACTIVE CHILDREN AND METHYLPHENIDATE (RITALIN) EFFECTS IN SYSTEMATICALLY STRUCTURED CLASSROOM ENVIRONMENTS: NOW YOU SEE THEM,

YOU DONT. 003581 04-11 EFFECTS OF SYSTEMIC MUSCIMOL AND GABA IN THE SPINAL CORD AND SUPERIOR CERVICAL GANGLION OF THE CAT.

THE SYSTEMIC EFFECTS OF LITHIUM.

000226 01-03

000709 01-13 CENTRAL ANTAGONISM OF TYRAMINE-INDUCED SYSTEMIC HYPOTENSION BY MESCALINE.

001252 02-03 HYPERTHERMIC EFFECTS OF SUPRACORTICALLY APPLIED PROSTAGLANDINS AFTER SYSTEMIC PRETREATMENT WITH INHIBITORS OF PROSTAGLANDIN TRANSPORT AND SYNTHESIS.

002174 03-03

DISRUPTION OF LATENT INHIBITION FOLLOWING SYSTEMIC ADMINISTRATION OF P-CHLOROPHENYLALANINE (PCPA). 002309 03-04

DRUG-INDUCED SYSTEMIC LUPUS-FRYTHEMATOSUS

002676 03-15 THE USE OF LACTULOSE IN PORTAL SYSTEMIC ENCEPHALOPATHY. 002762 03-17

NEONATAL SYSTEMIC 6 HYDROXYDOPAMINE AND DORSAL TEGMENTAL BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEPHRINE AND THE POSTDECAPITATION REFLEX.

003039 04-03 SYSTEMIC ADMINISTRATION OF ENDORPHINS SELECTIVELY ALTERS OPEN-FIELD BEHAVIOR OF RATS.

STUDIES IN THE HETEROCYCLIC SERIES. XIII. NEW CNS DEPRESSANTS
DERIVED FROM 1,9 DIAZAPHENOXAZINE AND TWO ISOMERIC
TRIAZAPHENOTHIAZINE RING SYSTEMS.

BEHAVIOURAL DISSOCIATION OF THE ENKEPHALINERGIC SYSTEMS OF NUCLEUS-ACCUMBENS AND NUCLEUS-CAUDATUS.

ACTION OF THE PALMITIC ESTER OF PIPOTIAZINE ON DOPAMINE METABOLISM IN THE NIGROSTRIATAL, MESOLIMBIC AND MESOCORTICAL SYSTEMS.

000258 01-03 EFFECT OF BENZODIAZEPINES ON CENTRAL SEROTONERGIC NEURON SYSTEMS.

000418 01-04 A ROLE FOR CENTRAL SEROTONERGIC SYSTEMS IN THE PATTERN AND INTENSITY OF THE CONVULSIVE RESPONSE OF RATS TO ELECTROSHOCK.

001067 02-03 THE EFFECT OF DIPHENYLHYDANTOIN ON CENTRAL CATECHOLAMINE CONTAINING NEURONAL SYSTEMS.

EVIDENCE FOR AN ALPHA-ADRENOCEPTOR MEDIATED CONTROL OF NOREPINEPHRINE (NE) RELEASE INDUCED BY DEPOLARIZATION WITH POTASSIUM IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF

001118 02-03 CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE ANTIPSYCHOTIC DRUGS 001526 02-06 Psychopharmacology Abstracts

MORPHINE AND ITS BIPHASIC INFLUENCE UPON PHARMACOLOGICALLY DISTINCT DOPAMINERGIC SYSTEMS WITHIN THE FELINE CAUDATE NUCLEUS: A BEHAVIOURAL STUDY.

EFFECT OF DIHYDROERGOTOXINE ON CYCLIC-AMP GENERATING SYSTEMS IN RAT CEREBRAL-CORTEX SLICES.

002088 03-03 TOLERANCE TO SEDATIVE HYPNOTICS, MEMORY AND NORADRENERGIC (NE) SYSTEMS.

MODIFICATION OF DREAM CONTENT AFTER PREFERENTIAL BLOCKADE OF MESOLIMBIC AND MESOCORTICAL DOPAMINERGIC SYSTEMS.

002619 03-14 EFFECTS ON STRIATAL AND MESOLIMBIC DOPAMINE SYSTEMS OF A NEW POTENTIAL ANTIPSYCHOTIC DRUG -- MEZILAMINE -- WITH WEAK CATALEPTOGENIC PROPERTIES.

MODIFICATION OF ADENYLATE-CYCLASE SYSTEMS IN MOUSE CEREBRAL-CORTEX BY CHLORPROMAZINE AND RESPECTIVE 7 HDROXY ANALOGS.

THE EFFECT OF GAMMA-ACETYLENIC-GABA, AN ENZYME ACTIVATED IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE, ON DOPAMINE PATHWAYS OF THE EXTRAPYRAMIDAL AND LIMBIC SYSTEMS.

003037 04-03 DISTINCT DOPAMINERGIC SYSTEMS IN ACTH-INDUCED GROOMING. 003197 04-04

ROLES OF THE VOMERONASAL AND OLFACTORY SYSTEMS IN COURTSHIF BEHAVIOR OF MALE GARTER SNAKES.

LITHIUM NEUROTOXICITY. I. THE CONCENTRATION OF LITHIUM IN DOPAMINERGIC SYSTEMS OF RAT BRAIN DETERMINED BY FLAMELESS ATOMIC ABSORPTION SPECTROPHOTOMETRY. 003432 04-06

MONOAMINERGIC INFLUENCES ON THE INCORPORATION OF S35 IN THE HYPOTHALAMIC AND NEUROHYPOPHYSIAL PROTEINS FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF S35-CYSTEINE IN DEHYDRATED RATS

002238 03-04 S35-CYSTEINE
MONOAMINERGIC INFLUENCES ON THE INCORPORATION OF S35 IN THE
HYPOTHALAMIC AND NEUROHYPOPHYSIAL PROTEINS FOLLOWING
INTRACEREBROVENTRICULAR INJECTION OF S35-CYSTEINE IN
DEHYDRATED RATS.

S35-METHIMAZOLE
THE UPTAKE OF S35-METHIMAZOLE BY SHEEP THYROID SLICES IN VITRO

APPLICATION OF LIFE TABLE METHOD TO NATURALISTIC DESIGNS — A COMPARISON OF EFFICACY OF TRICYCLIC ANTIDEPRESSANTS AND BENZODIAZEPINES IN AMBULATORY DEPRESSIVES.

TABLETS
A CLINICAL TRIAL COMPARING SUSTAINED-RELEASE AMITRIPTYLINE (SAROTEN-RETARD) AND CONVENTIONAL AMITRIPTYLINE TABLETS (SAROTEN) IN ENDOGENOUSLY DEPRESSED PATIENTS WITH SIMULTANEOUS DETERMINATION OF SERUM LEVELS OF AMITRIPTYLINE 003508 04-09

TACHISTOSCOPICALLY
PRIMATE INFORMATION PROCESSING UNDER SODIUM PENTOBARBITAL
AND CHLORPROMAZINE: DIFFERENTIAL DRUG EFFECTS WITH
TACHISTOSCOPICALLY PRESENTED DISCRIMINATIVE STIMULI. 000318 01-04

TACHYCARDIA

DELTA9-TETRAHYDROCANNABINOL AND DIMETHYLHEPTYLPYRAN
INDUCED TACHYCARDIA IN THE CONSCIOUS RAT.

00151

001516 02-05

TACRINE AND ITS DERIVATIVES ANTAGONIZE CHOLINERGIC PSYCHOTOMIMETICS: BEHAVIORAL STUDY IN RATS. 003262 04-04 TACTICS

COMPARING TREATMENT TACTICS WITH A HYPERACTIVE PRESCHOOL CHILD: STIMULANT MEDICATION AND PROGRAMMED TEACHER

000660 01-11

EFFECTS OF CHLORDIAZEPOXIDE ON TAIL PINCH-INDUCED EATING IN 000442 01-04 EFFECTS OF NEUROLEPTICS ON MORPHINE-INDUCED TAIL ERECTION IN

001400 02-04 MORPHINE-INDUCED TAIL ERECTION: SITE OF ACTION. 002269 03-04

TAILS OF STRESS RELATED BEHAVIOR: A NEUROPHARMACOLOGICAL MODEL. 002359 03-06

002334 03-04

and the second s			
ALSHOCK THE EFFECTS OF EXTENDED INSULIN DOSAGE ON TARGET-	DIRECTED	THE TARDIVE-DYSKINESIA SYNDROME.	002668 03-15
ATTACK AND BITING ELICITED BY TAILSHOCK.	003206 04-04	DEANOL, LITHIUM AND PLACEBO IN THE TREATMENT OF DYSKINESIA.	TARDIVE-
IATROGENIC EXTRAPYRAMIDAL SYNDROME A CAUTIO		MORTALITY OF PATIENTS WITH TARDIVE-DYSKINESIA.	
A CASE OF LITHIUM POISONING? A CAUTIONARY TALE.	000834 01-15	CLOZAPINE IN TARDIVE-DYSKINESIA.	002688 03-15
ARDIVE-DYSKINESIA	003653 04-15	EYE BLINK AND SCHIZOPHRENIA: PSYCHOSIS OR TARDI	
ALTERED RECEPTOR SENSITIVITY FOLLOWING CHRONIC DI ADMINISTRATION IN MAN: THE TARDIVE-DYSKINESIA		SODIUM VALPROATE AND TARDIVE-DYSKINESIA.	002703 03-15
DEANOL IN THE TREATMENT OF TARDIVE-DYSKINESIA.	000248 01-03	TARDIVE-DYSKINESIA DURING AND FOLLOWING TREATM	
PARADOXICAL RESPONSE TO DOPAMINE AGONISTS IN TA	000588 01-09 ARDIVE-	HALOPERIDOL, HALOPERIDOL BIPERIDEN, THIORIDAZ CLOZAPINE.	INE, AND 003656 04-15
DYSKINESIA.	000809 01-15	TARDIVE-DYSKINESIA.	003666 04-15
BIBLIOGRAPHY ON TARDIVE-DYSKINESIA SINCE CTB-TDN, NO. 1.		TARDIVE-DYSKINESIA AND PSYCHOTROPIC DRUG HISTO	
THE PREVENTION OF TARDIVE-DYSKINESIA.	000811 01-15	TARDIVE-DYSKINESIA: AGE AND SEX DIFFERENCES IN H	
ELECTROPHYSIOLOGICAL (H-REFLEX) STUDIES OF PATIENT	000816 01-15 S WITH	SCHIZOPHRENICS.	003681 04-15
TARDIVE-DYSKINESIA.	000817 01-15	DRUG HISTORY AND TARDIVE-DYSKINESIA.	003682 04-15
LITHIUM-INDUCED AGGRAVATION OF TARDIVE-DYSKINES	O00818 01-15	TARDIVE-DYSKINESIA AND INFORMED-CONSENT.	003683 04-15
DEANOL IN TARDIVE-DYSKINESIA.	000820 01-15	TARGET-DIRECTED THE EFFECTS OF EXTENDED INSULIN DOSAGE ON TARGE	T-DIRECTED
TARDIVE-DYSKINESIA.	1 55000000	ATTACK AND BITING ELICITED BY TAILSHOCK.	003206 04-04
THE RELATIONSHIP BETWEEN PARKINSONISM AND TARD		TASK DISCRIMINATIVE STIMULUS PROPERTIES OF FENFLURAN	
MASKING OF TARDIVE-DYSKINESIA WITH FOUR TIMES-A	000836 01-15 -DAY	OPERANT TASK: AN ANALYSIS OF ITS CUE FUNCTION	
ADMINISTRATION OF CHLORPROMAZINE.	000849 01-15	FACILITATION BY RESERPINE OF RETENTION IN AN INHII	BITORY
EFFECTS OF DOPAMINE AGONISTS IN TARDIVE-DYSKINES		AVOIDANCE TASK IN MICE.	000406 01-04
CHOLINERGIC INFLUENCES IN TARDIVE-DYSKINESIA.	000904 01-15	EFFECT OF PRETRIAL AND POSTTRIAL TYRAMINE AND G INJECTIONS ON AN APPETITIVE TASK IN RATS.	
TARDIVE-DYSKINESIA AND CHANGING CONCEPTS OF AN' DRUG USE: A NURSING PROSPECTIVE.		A DOSE RATIO COMPARISON OF THE INTERACTION BET AND CYCLAZOCINE WITH NALOXONE IN RHESUS MO	
CLINICAL RESEARCH TECHNIQUES IN TARDIVE-DYSKINESI		SHOCK TITRATION TASK.	002335 03-04
THE EFFECT OF LITHIUM ON AN ANIMAL MODEL OF TARE DYSKINESIA.	DIVE-	PROPRANOLOL: HEARTRATE AND REFLEXES DURING A THE EFFECTS OF CHLORDIAZEPOXIDE ON A DELAYED PA	002548 03-13
THE TREATMENT OF TARDIVE-DYSKINESIA WITH PENFLUI	001167 02-03 RIDOL.	TASK IN PIGEONS.	003348 04-0
EFFECT OF FUSARIC-ACID ON TARDIVE-DYSKINESIA AND IN PSYCHOGERIATRIC PATIENTS: A PILOT STUDY.	001618 02-11 MENTAL STATE	FACILITATING EFFECTS OF CHLORDIAZEPOXIDE ON THE MICE IN AN INHIBITORY AVOIDANCE TASK.	
BIOFEEDBACK TREATMENT OF TARDIVE-DYSKINESIA: TW		DORSOMEDIAL THALAMIC LESIONS AND AMPHETAMIN AND RETENTION OF A VISUAL PATTERN DISCRIMINA TASK.	E: ACQUISITION
TARDIVE-DYSKINESIA: A PREVENTIVE APPROACH.	001739 02-15		003399 04-04
TARDIVE-DYSKINESIA: IS IT OR IS IT NOT? A REVIEW OF IN DIAGNOSIS AND A CASE STUDY.	001740 02-15 THE PROBLEMS	TASK-DEPENDENT TASK-DEPENDENT GENETIC INFLUENCES ON BEHAVIORA MICE (MUS-MUSCULUS) TO ACETALDEHYDE.	
	001747 02-15	TASKS	003211 04-0
PHARMACOLOGICAL CHARACTERIZATION OF TARDIVE-D	001754 02-15	THE EFFECTS OF DARVON-N ON RETENTION OF SPECIFIC DURING HEROIN DETOXIFICATION. (PH.D. DISSERTAT	TION).
PREVENTION OF TARDIVE-DYSKINESIA.	001762 02-15	TASTE	001703 02-14
DRUG VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKIN APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS.	e la la contra con	THE EFFECT OF ANESTHESIA ON ACQUISITION AND EXTI CONDITIONED TASTE AVERSION.	NCTION OF
TARDIVE-DYSKINESIA IN PSYCHOGERIATRIC PATIENTS: A FOLLOW-UP.	001777 02-15 A FIVE-YEAR	CONDITIONED TASTE AVERSION: A FIELD APPLICATION PREDATION ON SHEEP.	000326 01-0 TO COYOTE
THE TREATMENT OF TARDIVE-DYSKINESIA.	001808 02-15	EFFECTS OF PIMOZIDE ON THE ACQUISITION, MAINTEN	000354 01-0 ANCE, AND
THE EFFECT OF BENZTROPINE-MESYLATE IN THE RABBIT TARDIVE-DYSKINESIA.	001831 02-15 SYNDROME AND	EXTINCTION OF AN AMPHETAMINE-INDUCED TASTE FAILURE TO ELICIT CONDITIONED TASTE AVERSION BY	AVERSION. 000373 01-0
THE B-MITTEN EEG PATTERN AND TARDIVE-DYSKINESIA:	001834 02-15 A POSSIBLE	POISONING.	000382 01-0
ASSOCIATION.	001846 02-15	GENERALIZATION OF THE CONDITIONED STIMULUS IN 1	ASTE AVERSION. 001405 02-0
DEANOL ACETAMIDOBENZOATE (DEANER) IN TARDIVE-D		LESIONS OF THE DORSAL NORADRENERGIC PROJECTION MORPHINE-INDUCED BUT NOT AMPHETAMINE-INDUCED	ATTENUATE
BRAIN NEUROTRANSMITTER RECEPTORS AND CHRONIC ADDRUG TREATMENT: A MODEL FOR TARDIVE-DYSKINES	ANTIPSYCHOTIC	TASTE AVERSION.	002299 03-0
GILLES-DE-LA-TOURETTES SYNDROME, TARDIVE-DYSKINI PSYCHOSIS IN AN ADOLESCENT.		AMPHETAMINE-INDUCED TASTE AVERSION DEMONSTR OPERANT BEHAVIOUR.	002315 03-0
EFFECT OF BACLOFEN ON TARDIVE-DYSKINESIA.	002651 03-15	CONDITIONED TASTE AVERSIONS: GENOTYPE BY OLFACE BULBECTOMY INTERACTION.	TORY
	002665 03-15	151635709	002334 03-0

EFFECTS OF ADRENALECTOMY ON TASTE AVERSION LEARNING 003153 04-04 DIFFERENTIAL EFFECTS ON CONDITIONED TASTE AVERSION LEARNING WITH PERIPHERALLY AND CENTRALLY ADMINISTERED ACETALDEHYDE. 003178 04-04

EFFECTS OF ATROPINE ON CONDITIONED TASTE AVERSION

003209 04-04

COCAINE-INDUCED CONDITIONED TASTE AVERSIONS IN RATS 003232 04-04

PREFERENCE BEHAVIOR AND TASTE NERVE RESPONSES IN D

DIMINISHED TASTE REACTIVITY TO SACCHARIN FOLLOWING CHRONIC ADMINISTRATION OF THEOPHYLLINE IN RATS.

003259 04-04
METHYLPHENIDATE-INDUCED CONDITIONED TASTE AVERSIONS: AN INDEX

ACETYLCHOLINE STIMULATION OF THE SYMPATHETIC GANGLIA: EFFECTS OF TAURINE AND NICOTINIC AND MUSCARINIC GANGLION BLOCK. 000146 01-03

EFFECTS OF TAURINE ON ALCOHOL WITHDRAWAL

000636 01-11

003337 04-04

CHANGES OF TAURINE CONTENT IN THE BRAIN TISSUE OF BARBITURATE DEPENDENT RATS.

002961 04-03 MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE CORRELATES WITH ANALGESIC ACTION OF MORPHINE. 002984 04-03

TAXONOMY
TAXONOMY AND EVALUATION OF PSYCHOLOGICAL TEST METHODS IN
PSYCHOTROPIC DRUG TRIALS.

000915 01

000915 01-16

ADVERSE EFFECTS OF INTRAVENOUS CANNABIS TEA.

000866 01-15

COMPARING TREATMENT TACTICS WITH A HYPERACTIVE PRESCHOOL CHILD: STIMULANT MEDICATION AND PROGRAMMED TEACHER INTERVENTION

000660 01-11

EXPERIENCE WITH A CLINICAL PHARMACOLOGICAL SERVICE IN A TEACHING HOSPITAL

000957 01-17

USE OF THE FLINCH-JUMP TECHNIQUE TO STUDY NARCOTIC ANALGESIA

A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-DUMMY TECHNIQUE.

003537 04-10

THE RELATIVE EFFICACY OF METHYLPHENIDATE (RITALIN) AND BEHAVIOR MODIFICATION TECHNIQUES IN THE TREATMENT OF A HYPERACTIVE

000671 01-11 CLINICAL RESEARCH TECHNIQUES IN TARDIVE-DYSKINESIA.

000948 01-17 SOME PROBLEMS CONCERNING THE TECHNIQUES OF STUDYING THE EFFECTIVENESS OF PSYCHOTROPIC DRUGS.

METHODOLOGICAL PROBLEMS IN THE MEASUREMENT OF DRUG-INDUCED ROTATIONAL BEHAVIOUR: CONTINUOUS RECORDING REVEALS TIME-COURSE DIFFERENCES UNDETECTED BY PREVIOUS TECHNIQUES. 003388 04-04

LITHIUM PROPHYLAXIS IN THE TREATMENT OF CYCLOTHYMIA IN TEENAGERS. 000601 01-10

THE ACTION OF BACLOFEN ON NEURONS OF THE SUBSTANTIA-NIGRA AND OF THE VENTRAL TEGMENTAL AREA.

NEONATAL SYSTEMIC 6 HYDROXYDOPAMINE AND DORSAL TEGMENTAL BUNDLE LESION: COMPARISON OF EFFECTS ON CNS NOREPINEPHRINE AND THE POSTDECAPITATION REFLEX.

TEGMENTUM

A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND BIOELECTRIC
CORRELATES OF EMOTIONAL REACTIONS ELICITED BY CHOLINERGIC
STIMULATION OF THE HYPOTHALAMUS AND THE VENTRAL TEGMENTUM

001390 02-04

Psychopharmacology Abstracts

THE EFFECTS OF HALOPERIDOL AND CLOZAPINE ON CIRCLING INDUCED BY ELECTRICAL STIMULATION OF THE SUBSTANTIA-NIGRA AND THE VENTROMEDIAL TEGMENTUM.

003343 04-04

TEL-DIENCEPHALIC
CHANGES IN MORPHINE SELF-ADMINISTRATION AFTER TEL-DIENCEPHALIC
LESIONS IN RATS.

003228 04-04

THE IMPORTANCE OF TELEMETRIC RECORDING IN THE STUDY OF NEUROPSYCHOLOGICAL FUNCTION IN EPILEPTICS.

002606 03-14

001048 02-03

TELENCEPHALON
THE TURNOVER RATE OF GAMMA-AMINOBUTYRIC-ACID IN THE NUCLEI OF TELENCEPHALON: IMPLICATIONS IN THE PHARMACOLOGY OF ANTIPSYCHOTICS AND OF A MINOR TRANQUILIZER.

000192 01-1

000192 01-03 AUTORADIOGRAPHIC LOCALIZATION OF OPIATE RECEPTORS IN RAT BRAIN. III. THE TELENCEPHALON.

TEMAZEPAM (EUHYPNOS) AS A HYPNOTIC: A TWELVE-WEEK TRIAL IN GENERAL PRACTICE

MAZEPAM (EUHYPNOS) AS A HYPNOTIC: A MULTICENTRE TRIAL IN GENERAL PRACTICE.

000764 01-14 EFFECTIVENESS OF TEMAZEPAM WITH SHORT-TERM, INTERMEDIATE TERM, AND LONG-TERM USE: SLEEP LABORATORY EVALUATION.

TEMAZEPAM (EUHYPNOS) AND CHLORMETHIAZOLE: A COMPARATIVE STUDY IN GERIATRIC PATIENTS.

003634 04-14

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON BODY
TEMPERATURE AND BRAIN AMINE CONCENTRATIONS IN THE RAT AT
DIFFERENT AMBIENT TEMPERATURES.

LITHIUM ABSORPTION, DISTRIBUTION AND CLEARANCE AND BODY TEMPERATURE IN RATS GIVEN LITHIUM PLUS HALOPERIDOL.

000488 01-05 EFFECTS OF PHENOBARBITAL AND DIAZEPAM ON IMIPRAMINE-INDUCED CHANGES IN BLOOD PRESSURE, HEART RATE AND RECTAL TEMPERATURE OF RATS.

RESTRAINT ALTERS THE EFFECTS OF MORPHINE AND HEROIN ON CORE TEMPERATURE IN THE RAT.

EFFECTS OF D AMPHETAMINE (D-A), PROSTAGLANDIN-E1 AND F-2ALPHA ON H3-2-DOPAMINE (H3-DA) METABOLISM, FIXED-INTERVAL (FI) BEHAVIOR AND RECTAL TEMPERATURE.

001207 02-03 EFFECTS ON TEMPERATURE OF MORPHINE INJECTED INTO THE PREOPTIC/ ANTERIOR HYPOTHALAMUS, MEDULLA-OBLONGATA, AND PERIPHERALLY IN UNRESTRAINED AND RESTRAINED RATS.

001264 02-03 INTERACTIONS BETWEEN ALCOHOL AND OTHER DRUGS ON OPEN-FIELD AND TEMPERATURE MEASUREMENTS IN GERBILS.

001386 02-04 COMPARISON OF THE EFFECTS OF 5 HYDROXYTRYPTAMINE, DIMETHYLTRYPTAMINE, AND 5 METHOXY-DIMETHYLTRYPTAMINE ON RECTAL TEMPERATURE IN THE MOUSE.

002154 03-03 LITHIUM EFFECT ON TEMPERATURE RHYTHM IN PSYCHIATRIC PATIENTS 002581 03-13

THE EFFECTS OF CANNABINOIDS ON BODY TEMPERATURE AND BRAIN CATECHOLAMINE SYNTHESIS. 002835 04-03

EFFECTS OF MET-ENKEPHALIN ON BODY TEMPERATURE OF NORMAL AND MORPHINE-TOLERANT RATS. 002907 04-03

DNA SYNTHETIC ABILITY IN CEREBELLA FROM TEMPERATURE AND HANDLING STRESSED NEONATAL RATS.

002934 04-03 CLONIDINE-INDUCED BODY TEMPERATURE CHANGES IN RATS WITH ANTERIOR OR POSTERIOR CORTICAL DAMAGE.

002959 04-03 INHIBITION OF CA45 MOVEMENTS BY LOWERED TEMPERATURE OR LANTHANUM IN RAT BRAIN SLICES.

EFFECTS OF INTRAVENTRICULARLY ADMINISTERED MONOAMINES ON SEIZURE SUSCEPTIBILITY AND BODY TEMPERATURE IN RATS.

003180 04-04 BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE EFFECTS
AFTER INTRACEREBRAL INFUSION OF TRH IN FOWLS. 003319 04-04

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON BODY
TEMPERATURE AND BRAIN AMINE CONCENTRATIONS IN THE RAT AT
DIFFERENT AMBIENT TEMPERATURES.

VOLUME 16. SUBJECT INDEX

THE THERMAL EFFECTS OF INTERACTION BETWEEN D AMPHETAMINE AND ANTIDEPRESSANTS AMONG RATS KEPT AT VARIOUS AMBIENT

001290 02-03

003349 04-04

TEMPORAL
TEMPORAL EFFECTS OF P-CHLOROAMPHETAMINE ON CATECHOLAMINE

001251 02-03
DRUGS AND THE PRODUCTION OF TEMPORAL INTERVALS IN THE RAT. THE EFFECTS OF SCOPOLAMINE ON THE TEMPORAL CONTROL OF

001431 02-04

EFFECTS OF D AMPHETAMINE ON TEMPORAL AND SPATIAL DISCRIMINATION IN RATS.

TENDENCIES

SCHIZOPHRENIC-LIKE TENDENCIES IN RATS NEONATALLY TREATED WITH 6 HYDROXYDOPAMINE. (PH.D. DISSERTATION). 003323 04-04

TENSION

URINARY CARBON-DIOXIDE TENSION IN LITHIUM-CARBONATE TREATED **PATIENTS** 000882 01-15

TERATOGEN

CHLORPROMAZINE: A POTENTIAL PHYSIOLOGICAL TERATOGEN 000486 01-05

PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EMBRYOPATHIC EFFECT AND COVALENT BINDING OF PUTATIVE ARENE OXIDE METABOLITE IN GESTATIONAL TISSUE.

001515 02-05

TERATOGENIC

EMBRYOPATHIES INDUCED BY TERATOGENIC AGENTS

000857 01-15 PHENYTOIN: AN EVALUATION OF SEVERAL POTENTIAL TERATOGENIC MECHANISMS.

001097 02-03

PHENOBARBITONE TERATOGENICITY: A CASE REPORT.

001799 02-15

003076 04-03

TERATOLOGICAL EVALUATION OF ETHANOL, PENTOBARBITAL, AND COMBINATIONS OF THESE, IN THE RAT. 002976 04-03

TERMINAL

BARBITURATE-INDUCED CHANGES IN TRANSMITTER RELEASE INDEPENDENT OF TERMINAL SPIKE CONFIGURATION IN THE FROG NEUROMUSCULAR JUNCTION.

DRUGS AFFECTING THE CENTRAL-NERVOUS-SYSTEM: EFFECTS OF PEMOLINE, AND TRICYCLIC ANTIDEPRESSANTS ON NERVE TERMINAL ADENOSINE-TRIPHOSPHATASE ACTIVITIES AND NEUROTRANSMITTER

002923 04-03 MORPHINE AND MET-ENKEPHALIN EFFECTS ON SURAL-ADELTA AFFERENT TERMINAL EXCITABILITY.

HEROIN AND OTHER HUMANISTIC TREATMENT FOR THE TERMINALLY ILL 003703 04-17

INCREASE IN THE TURNOVER OF BRAIN DOPAMINE BY STIMULATION OF MUSCARINIC RECEPTORS OUTSIDE THE DOPAMINE NERVE TERMINALS 000042 01-03

INVOLVEMENT OF CHOLINERGIC PRESYNAPTIC RECEPTORS OF NICOTINIC AND MUSCARINIC TYPES IN THE CONTROL OF THE SPONTANEOUS RELEASE OF DOPAMINE FROM STRIATAL DOPAMINERGIC TERMINALS IN THE RAT.

000124 01-03 AUTORADIOGRAPHIC EVIDENCE FOR THE SELECTIVE ACCUMULATION OF H3-5-HT BY SUPRAEPENDYMAL NERVE TERMINALS

001222 02-03 THE UPTAKE AND RELEASE OF H3-2 AMINO-6-7-DIHYDROXYTETRAHYDRONAPHTHALENE (ADTN) BY STRIATAL NERVE TERMINALS.

002884 04-03 STUDIES ON THE MECHANISM OF SPROUTING OF NORADRENERGIC TERMINALS IN RAT AND MOUSE CEREBELLUM AFTER NEONATAL 6 HYDROXYDOPA

DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: A VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIATION OF CATECHOLAMINERGIC AND SEROTONINERGIC TERMINALS IN RAT CEREBRAL STRUCTURES.

EFFECTS OF D AMPHETAMINE, CHLORDIAZEPOXIDE AND PROMAZINE ON RESPONDING OF SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-

INTERVAL SCHEDULES OF FOOD PRESENTATION AND STIMULUS SHOCK TERMINATION 001305 02-04

ETHANOL, PENTOBARBITAL, AND CHLORDIAZEPOXIDE EFFECTS IN SQUIRREL-MONKEYS RESPONDING UNDER FIXED-RATIO FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION SCHEDULES 002254 03-04

EFFECTS OF D AMPHETAMINE AND ETHANOL ON RESPONDING OF
SQUIRREL-MONKEYS MAINTAINED UNDER FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK TERMINATION 002255 03-04

AN ANIMAL SCREENING TEST FOR DRUGS THAT PREDICTS THE LIKELIHOOD OF HUMAN PHYSICAL DEPENDENCE

000028 01-02 DISCRIMINABLE EFFECTS OF ANTIMUSCARINICS: DOSE-RESPONSE AND

000426 01-04 THE EFFECT OF METHYLPHENIDATE ON TEST PERFORMANCE IN THE COGNITIVELY IMPAIRED AGED.

000622 01-11 WITHDRAWAL FROM CANNABIS: PSYCHOLOGICAL TEST PERFORMANCE 000760 01-14

THE EFFECTS OF FOUR ANTIHYPERTENSIVE AGENTS ON THE STROOP COLOUR WORD TEST IN NORMAL MALE VOLUNTEER SUBJECTS 000771 01-14

AKATHISIA DIAGNOSIS: AN OBJECTIVE TEST.

000858 01-15 TAXONOMY AND EVALUATION OF PSYCHOLOGICAL TEST METHODS IN PSYCHOTROPIC DRUG TRIALS.

000915 01-16 STUDIES ON THE INFLUENCE OF BIOGENIC AMINES AND PSYCHOACTIVE DRUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMULATION TEST IN ENDOGENOUS DEPRESSION

000926 01-16 PREDICTION OF THE LITHIUM RATIO IN MAN BY MEANS OF AN IN VITRO TEST.

000930 01-16 THE EFFECTS OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE IN AN ANIMAL TEST OF ANXIETY

O01121 02-03

ANTAGONISM OF SKIN CONDUCTANCE RESPONSE (SCR) HABITUATION DURING ITERATIVE PHOTOSTIMULATION IN MICE: HABITUATION TEST A NEW PSYCHOPHARMACOLOGICAL METHOD FOR DETECTING AND QUANTIFYING ENHANCEMENT OF PSYCHIC ACTIVITY.

A TWO-DOSE DEXAMETHASONE SUPPRESSION TEST IN PATIENTS WITH PSYCHIATRIC ILLNESS.

001691 02-13 THE PROLACTIN RESPONSE TO NEUROLEPTIC DRUGS. A TEST OF DOPAMINERGIC BLOCKADE: NEUROENDOCRINE STUDIES IN NORMAL

001867 02-16 NALOXONE REVERSAL OF MORPHINE ANALGESIA BUT FAILURE TO ALTER REACTIVITY TO PAIN IN THE FORMALIN TEST.

002117 03-03 EFFICACY OF NEUROLEPTICS AND ANTIDEPRESSANTS IN THE TEST OF APOMORPHINE HYPOTHERMIA AND SOME DATA CONCERNING NEUROCHEMICAL MECHANISMS OF THE TEST.

002147 03-03 GENOTYPE AND TEST EXPERIENCE DETERMINE RESPONSIVENESS TO

ANIMAL TEST MODELS FOR PREDICTION OF CLINICAL ANTIDEPRESSANT 002372 03-06

EFFECTS OF ANTIANXIETY DRUG AND PERSONALITY ON STRESS-INDUCING PSYCHOMOTOR PERFORMANCE TEST.

002630 03-14 EFFECTS OF LITHIUM IN HEALTHY TEST PERSONS. 002647 03-15

SQUIRREL-MONKEY ACTIVE CONFLICT TEST. 002795 04-02

ENHANCED CHOICE OF FAMILIAR FOOD IN A FOOD PREFERENCE TEST AFTER CHLORDIAZEPOXIDE ADMINISTRATION. 003199 04-04 A CASE OF DEPRESSION SHOWING IMPROVEMENT IN TRH TEST BY COMBINED TREATMENT BY DIMETACRINE-TARTRATE AND THYROID

003527 04-09 THE EFFECTS OF APPROPRIATENESS OF ATTRIBUTED AROUSAL SOURCE AND TEST ANXIETY ON COMPLEX TEST PERFORMANCE AND REPORTED ANXIETY DURING TEST-TAKING. (PH.D. DISSERTATION).

TEST-TAKING

HORMONE

THE EFFECTS OF APPROPRIATENESS OF ATTRIBUTED AROUSAL SOURCE AND TEST ANXIETY ON COMPLEX TEST PERFORMANCE AND REPORTED ANXIETY DURING TEST-TAKING. (PH.D. DISSERTATION). 003702 04-17

003702 04-17

CANNABINOIDS INHIBIT TESTOSTERONE SECRETION BY MOUSE TESTES IN VITPO

001999 03-03

TESTING
PRENATAL ALCOHOL CONSUMPTION AND OPEN-FIELD BEHAVIOUR IN
RATS: EFFECTS OF AGE AT TIME OF TESTING.
000321 0

000321 01-04

NEW DRUG TESTING IN THE CONSENTING ADULT.

000509 01-07

INCENTIVE CONTRAST UNDIMINISHED BY EXTENDED TESTING, IMPRAMINE, OR CHLORDIAZEPOXIDE. PRISONER SUBJECTS AND DRUG TESTING

001354 02-04

PSYCHOPHARMACOLOGIC AGENTS IN POLYGRAPH TESTING

001908 02-17 001926 02-17

DIRECT AND PITUITARY MEDIATED EFFECTS OF DELTA9-THC AND CANNABINOL ON THE TESTIS.

002881 04-03

TESTOSTERONE
THE EFFECT OF LITHIUM ON LUTEINIZING HORMONE AND TESTOSTERONE
IN MAN.

001731 02-14

CANNABINOIDS INHIBIT TESTOSTERONE SECRETION BY MOUSE TESTES IN

001999 03-03 THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC DOSES OF CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING HORMONE, FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE IN THE MALE

002343 03-05

BIOCHEMICAL AND MORPHOLOGICAL EFFECTS OF TESTOSTERONE TREATMENT ON DEVELOPING SYMPATHETIC NEURONS.

002894 04-03 BLOCKADE OF TESTOSTERONE MAINTAINED INTERMALE FIGHTING IN ALBINO LABORATORY MICE BY AN AROMATIZATION INHIBITOR.

003176 04-04 TESTOSTERONE ATTENUATED STEREOTYPY AND HYPERACTIVITY INDUCED BY BETA-PHENYLETHYLAMINE IN PARGYLINE PRETREATED RATS.

003224 04-04 TESTOSTERONE-PROPIONATE

CENTRAL AND PERIPHERAL ACTION OF TESTOSTERONE-PROPIONATE ON SCENT GLAND MORPHOLOGY AND MARKING BEHAVIOUR IN THE MONGOLIAN GEBBIL.

003370 04-04

EVALUATION OF NALOXONE IN LABORATORY TESTS PREDICTIVE OF CLINICAL ANTIPSYCHOTIC ACTIVITY.

WITHDRAWAL FROM CANNABIS: LABORATORY TESTS AND CLINICAL

ACUTE AND CHRONIC EFFECTS OF GENERAL CNS DEPRESSANTS ON SEVERAL BEHAVIORAL TESTS IN RATS.

001356 02-04 A DESCRIPTION OF THE NICOTINE STIMULUS AND TESTS OF ITS GENERALIZATION TO AMPHETAMINE.

SCREENING HALLUCINOGENIC DRUGS. II. SYSTEMATIC STUDY OF TWO BEHAVIORAL TESTS.

EFFECTS OF N,N DIMETHYLTRYPTAMINE (DMT) ON PSYCHOTICISM

002540 03-12

TETRABENAZINE
DIFFERNITIAL EFFECTS OF RESERPINE AND TETRABENAZINE ON RAT
STRIATAL SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS AND
SYNAPTOSOMAL DOPAMINE POOLS. 000172 01-03

CIRCADIAN SUSCEPTIBILITY RHYTHM TO NEUROLEPTICS: TETRABENAZINE.

002108 03-03 ANIMAL MODEL OF DEPRESSION: III. MECHANISM OF ACTION OF TETRABENAZINE.

003108 04-03 PHARMACOLOGICAL STUDIES OF CENTRAL ACTION OF L.5
HYDROXYTRYPTOPHAN IN INTACT OR TETRABENAZINE PRETREATED
CATS.

003144 04-03

TETRABENAZINE-INDUCED
THE EFFECT OF AMPHETAMINE AND L-DOPA ON TETRABENAZINE-INDUCED SUPPRESSION OF INTRACRANIAL SELF-STIMULATION IN THE RAT. 001321 02-04

TETRACYCLIC

MAPROTILINE -- A DOUBLE-BLIND STUDY OF A NEW TETRACYCLIC

ANTIDEPRESSANT IN SEVERE DEPRESSION. 000574 01-09

Psychopharmacology Abstracts

001173 02-03

DOUBLE-BLIND TRIALS OF A NEW TRICYCLIC ANTIDEPRESSANT (MAPROTILINE). 000607 01-10

LITHIUM-CARBONATE AND TETRACYCLINE INTERACTION.

003667 04-15

TETRAETHYL-L-C14-THIURAMDISULFIDE
PHARMACOKINETIC STUDIES OF TETRAETHYL-L-C14-THIURAMDISULFIDE
(C14-DISULFIRAM). A PRELIMINARY STUDY.

AETHYLAMMONIUM-CHLORIDE
POSTSYNAPTIC POTENTIATION OF THE SLOW MUSCARINIC EXCITATORY
RESPONSE BY TETRAETHYLAMMONIUM-CHLORIDE IN THE BULLFROG
SYMPATHETIC GANGLION CELLS.

TETRAHYDROCANNABINOL

ACUTE AND CHRONIC EFFECTS OF TETRAHYDROCANNABINOLS ON
MONOAMINE-OXIDASE ACTIVITY: POSSIBLE VEHICLE/
TETRAHYDROCANNABINOL INTERACTIONS.

EFFECTS OF INTRAVENOUS TETRAHYDROCANNABINOL ON EXPERIMENTAL

THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDROCANNABINOL (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HORMONE (FISH) AND LUTEINIZING HORMONE (LH) IN THE OVARIECTOMIZED RHESUS

001245 02-03 TETRAHYDROCANNABINOL AND ACETYLCHOLINESTERASE.

003023 04-03

TETRAHYDROCANNABINOLS

ACUTE AND CHRONIC EFFECTS OF TETRAHYDROCANNABINOLS ON MONOAMINE-OXIDASE ACTIVITY: POSSIBLE VEHICLE/
TETRAHYDROCANNABINOL INTERACTIONS. 000075 01-03

PROFOUND HYPOTHERMIA IN MAMMALS TREATED WITH TETRAHYDROCANNABINOLS, MORPHINE, OR CHLORPROMAZINE

001140 02-03 TETRAMYDROISOQUINOLINE
EFFECTS OF SALSOLINOL, A TETRAMYDROISOQUINOLINE ALKALOID, ON
MULTIPLE SCHEDULE PERFORMANCE IN RATS.

002250 03-04

OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINE ALKALOIDS IN L-DOPA TREATED PARKINSONIAN PATIENTS. 002655 03-15

TETRAHYDROISOQUINOLINES
OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINES IN LDOPA TREATED PARKINSONIAN PATIENTS.

TETRAHYDRONICOTIMAMIDE
PYRIDINE NUCLEOTIDE INVOLVEMENT IN RAT HEPATIC MICROSOMAL
DRUG METABOLISM — III. THE INFLUENCE OF THE 1,4,5,6
TETRAHYDRONICOTINAMIDE ANALOGUE OF NADH ON THE NADPH
KINETICS OF AMINOPYRINE-N-DEMETHYLATION.

002930 04-03

THALAMIC

EFFECT OF ANTICONVULSANTS ON THALAMIC AFTER-DISCHARGE IN RATS

AND CATS.

002046 03-03

EFFECT OF DIHYDROERGOTOXINE ON THALAMIC AND PYRAMIDAL EVOKED RESPONSES IN THE CAT UNDER TRANSIENT ISCHEMIA. 002201 03-04

DORSOMEDIAL THALAMIC LESIONS AND AMPHETAMINE: ACQUISITION AND RETENTION OF A VISUAL PATTERN DISCRIMINATION ESCAPE TASK. 003399 04-04

ADRENERGIC MODULATION OF A CHOLINERGIC EMOTIONAL REACTION IN THE CATS THALAMUS. 001344 02-04

MORPHINE-INDUCED ALTERATIONS OF GAMMA-AMINOBUTYRIC-ACID AND TAURINE CONTENTS AND L GLUTAMATE-DECARBOXYLASE ACTIVITY IN RAT SPINAL CORD AND THALAMUS: POSSIBLE CORRELATES WITH ANALGESIC ACTION OF MORPHINE.

002984 04-03

7: ALIDOMIDE
A COMPARISON OF THALIDOMIDE AND PENTOBARBITAL
METHODS FOR IDENTIFYING NOVEL HYPNOTIC DRUGS. 001359 02-04

THANATOPHARMACOLOGY
THANATOPHARMACOLOGY IN THE MEDICAL SCHOOL CURRICULUM 001910 02-17

THE EFFECT OF CHRONIC ADMINISTRATION OF TETRAHYDROCANNABINOL (THC) ON THE SECRETION OF FOLLICLE-STIMULATING HORMONE (FSH) AND LUTEINIZING HORMONE (LH) IN THE OVARIECTOMIZED RHESUS MONKEY.

THE EFFECTS OF SP-111, A WATER-SOLUBLE THC DERIVATIVE, ON NEURONAL ACTIVITY IN THE RAT BRAIN.

002150 03-03

INTERCORRELATIONS BETWEEN PHYSIOLOGICAL AND PSYCHOLOGICAL EFFECTS OF MARIJUANA, HASHISH, AND THC-DELTA9 IN LONG-TERM HASHISH USERS

000695 01-13

003259 04-04

002772 03-17

THE INFLUENCE OF CAFFEINE AND THEOBROMINE ON LOCOMOTIVE ACTIVITY AND THE BRAIN C-GMP/C-AMP RATIO IN WHITE MICE 000275 01-03

EFFECT OF PHENOBARBITAL ON THE DISPOSITION OF INTRAVENOUS THEOPHYLLINE.

001680 02-13 DIMINISHED TASTE REACTIVITY TO SACCHARIN FOLLOWING CHRONIC ADMINISTRATION OF THEOPHYLLINE IN RATS.

THEORETICAL AND METHODOLOGICAL ASPECTS OF PSYCHOTROPIC DRUG TRIALS USING HEALTHY SUBJECTS

000918 01-16 THOUGHT DISORDER IN SCHIZOPHRENIA: A THEORETICAL APPROACH USING AN ANALYSIS OF SPEECH. (PH.D. DISSERTATION).

001566 02-08 THEORETICAL AND THERAPEUTIC POTENTIAL OF INDOLEAMINE PRECURSORS IN AFFECTIVE-DISORDERS.

001610 02-09 DOPAMINERGIC AGONIST PROPERTIES OF EPHEDRINE -- THEORETICAL **IMPLICATIONS**

002338 03-05 A PHARMACOLOGICAL AND THEORETICAL COMPARISON OF HIGH AND LOW POTENCY NEUROLEPTICS.

003687 04-15 THEORIES

SOME OLD AND NEW THEORIES IN BIOCHEMICAL PSYCHIATRY 000190 01-03

MYTHS. THEORIES AND TREATMENT OF SCHIZOPHRENIA 000520 01-08

MAJOR THEORIES OF STATE-DEPENDENT LEARNING 000970 01-17

A REVIEW OF THE RELATIONSHIP BETWEEN ENDOCRINOPATHY AND DEPRESSION OR ANTIDEPRESSANT DRUGS, WITH PARTICULAR RESPECT TO NOVEL THEORIES INVOLVING THE OPIATE RECEPTOR

002557 03-13 THE CURRENT STATUS OF RESEARCH IN THE CATECHOLAMINE THEORIES OF AFFECTIVE-DISORDERS

002733 03-17 MAJOR THEORIES OF STATE-DEPENDENT LEARNING.

THEORY

DRUGS AND REINFORCEMENT MECHANISMS: A CRITICAL REVIEW OF THE CATECHOLAMINE THEORY.

003625 04-14 NEUROTRANSMITTER THEORY AND ORTHOMOLECULAR PRACTICE

003725 04-17 THER APPUTIC PSYCHOENDOCRINOLOGICAL AND THERAPEUTIC EFFECTS OF TRH IN

DEPRESSION 000590 01-09 CURRENT THERAPEUTIC CONCEPTS: CONTEMPORARY DRUGS IN THE

MANAGEMENT OF ANXIETY. 000600 01-10 ANTIANXIETY DRUGS: CLINICAL PHARMACOLOGY AND THERAPEUTIC

000603 01-10

BRAIN MECHANISMS ASSOCIATED WITH THERAPEUTIC ACTIONS OF BENZODIAZEPINES: FOCUS ON NEUROTRANSMITTERS. 000741 01-13

UNUSUAL THERAPEUTIC FFFECT OF AMITRIPTYLINE 000908 01-15

CENTRAL DOPAMINERGIC SYSTEMS: TWO IN VIVO ELECTROPHYSIOLOGICAL MODELS FOR PREDICTING THERAPEUTIC EFFICACY AND NEUROLOGICAL SIDE-EFFECTS OF PUTATIVE ANTIPSYCHOTIC DRUGS

001526 02-06 MANIA IN CHILDHOOD. II. THERAPEUTIC TRIAL OF LITHIUM-CARBONATE AND FURTHER DESCRIPTION OF MANIC-DEPRESSIVE ILLNESS IN CHILDREN.

001578 02-09 A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF

001604 02-09 THEORETICAL AND THERAPEUTIC POTENTIAL OF INDOLEAMINE PRECURSORS IN AFFECTIVE-DISORDERS

001610 02-09 VIDEO EDITING AND MEDICATION TO PRODUCE A THERAPEUTIC SELF-

PERSISTING INFANTILE PATTERN OF ATTENTIVENESS IN BACKWARD SCHOOL CHILDREN WITH BRAIN DYSFUNCTION. ATTEMPT OF A

HUMAN ETHOLOGICALLY ORIENTED INTERPRETATION AND ITS THERAPEUTIC APPLICATION

CORRELATION BETWEEN EXTRAPYRAMIDAL AND THERAPEUTIC EFFECTS
OF NEUROL EPTICS OF NEUROLEPTICS.

ABOUT A NONFATAL MASSIVE INTOXICATION WITH SUSTAINED-RELEASE THIORIDAZINE. CLINICAL AND THERAPEUTIC PROBLEMS.

001752 02-15 R-806-003-01 IN THE TREATMENT OF DEPRESSION: PLASMA LEVELS AND THERAPEUTIC RESPONSE.

002376 03-07 THERAPEUTIC EFFECT OF BRAIN HYDROLYSATES IN DEPRESSION-INDUCED DISTURBANCES OF INTELLIGENCE.

002380 03-07 A COMPARISON OF DESIPRAMINE AND AMITRIPTYLINE PLASMA LEVELS AND THERAPEUTIC RESPONSE.

002417 03-09 BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS: ASSAY
PROCEDURES, REPRODUCIBILITY AND RELATIONSHIP TO THERAPEUTIC OUTCOME AND SIDE-EFFECTS

002440 03-09 DESIPRAMINE PLASMA LEVELS AND THERAPEUTIC RESPONSE 002443 03-09

ANTIPSYCHOTIC DRUGS: CLINICAL PHARMACOLOGY AND THERAPEUTIC USE. PART II.

A SIMPLE METHOD FOR THE DETERMINATION OF THERAPEUTIC LEVELS OF CLOMIPRAMINE, IMIPRAMINE AND DESIPRAMINE.

002717 03-16 WHAT IS AN ADEQUATE THERAPEUTIC TRIAL OF PSYCHOTROI MEDICATION?

TRICYCLIC ANTIDEPRESSANTS: THERAPEUTIC PROPERTIES AND AFFINITY FOR ALPHA-NORADRENERGIC RECEPTOR BINDING SITES IN THE BRAIN. 003118 04-03

GENERALIZATION OF THE DISCRIMINATIVE STIMULUS PROPERTIES OF DELTA9-TETRAHYDROCANNABINOL TO CANNABINOIDS WITH THERAPEUTIC POTENTIAL

DOUBLE-BLIND THERAPEUTIC EVALUATION OF FLUSPIRILENE COMPARED WITH FLUPHENAZINE-DECANOATE IN CHRONIC SCHIZOPHRENICS.

THERAPEUTIC ANTAGONISM BETWEEN ANTICHOLINERGICS AND NEUROLEPTICS: POSSIBLE INVOLVEMENT OF CHOLINERGIC MECHANISMS IN SCHIZTOPHE PARAMETERS.

003473 04-08 THERAPEUTIC EFFECTS OF CARBAMAZEPINE IN AFFECTIVE-ILLNESS: A PRELIMINARY REPORT.

003481 04-09 PAPILLEDEMA FOLLOWING THERAPEUTIC DOSAGES OF LITHIUM CARBONATE.

003662 04-15 THERAPEUTICS

PSYCHEDELIC DRUG CRISES: TOXICITY AND THERAPEUTICS 000861 01-15

CAFFEINE POTENTIATION OF AMPHETAMINE: IMPLICATIONS FOR HYPERKINESIS THERAPY. 000448 01-04

THE THERAPY OF CHILDHOOD SCHIZOPHRENIA 000525 01-08 COMPARISON OF PIMOZIDE AND TRIFLUOPERAZINE AS ONCE-DAILY

THERAPY IN CHRONIC SCHIZOPHRENIC OUTPATIENTS.

THE EFFICACY OF ELECTROCONVULSIVE THERAPY AND ANTIDEPRESSANTS IN DEPRESSION.

COUPLES GROUP THERAPY AS AN ADJUNCT TO LITHIUM MAINTENANCE OF THE MANIC PATIENT

ANXIETY STATES IN FAMILY PRACTICE: AN EVALUATION OF THE NEED FOR ANTIDEPRESSANT AS WELL AS ANXIOLYTIC THERAPY.

POSTTRAUMATIC PSYCHONEUROSIS: EVALUATION OF DRUG THERAPY.
000615 01-10 METHYLPHENIDATE THERAPY FOR INATTENTIVENESS IN SELECTED SCHOOL CHILDREN.

ACUTE ORGANIC-BRAIN-SYNDROME ASSOCIATED WITH GENTAMICIN THERAPY.

000808 01-15 APNEA AFTER INTRAVENOUS DIAZEPAM THERAPY

STUDY OF NIGHT SLEEP DURING LONG-TERM GRADUAL REDUCTION IN NEUROLEPTIC THERAPY IN CHRONIC SCHIZOPHRENICS.

PAROSMIA AND AROMATIC ANOSMIA UNDER L-DOPA THERAPY.
000871 01-15 MULTIPLE DRUG THERAPY -- IS THERE A STANDARD OF CARE?

ADJUSTMENT OF LITHIUM DOSE DURING LITHIUM-CHLOROTHIAZIDE

000956 01-17 TRICYCLIC ANTIDEPRESSANT AND MONOAMINE-OXIDASE INHIBITOR COMBINATION THERAPY

O0976 01-17
OF PSYCHOPHARMACOLOGIC AND PSYCHOSOCIAL THERAPY.

INTOXICATION BY ORPHENADRINE HCL; MECHANISM AND THERAPY. 001519 02-05

DEVELOPMENT OF DRUG THERAPY FOR THE MENTALLY IL 001551 02-07

ANTIDEPRESSANT DRUG THERAPY IN PSYCHOTIC DEPRESSION 001580 02-09

REDUCED RENAL CALCIUM EXCRETION DURING LITHIUM THERAPY. 001597 02-09 LONG-TERM MAINTENANCE DRUG THERAPY IN RECURRENT AFFECTIVE-ILLNESS: CURRENT STATUS AND ISSUES.

001600 02-09 INTENSIVE ANTIDEPRESSIVE THERAPY BY 48 HOUR SLOW-DRIP INFUSION WITH HIGH DOSES DIBENZEPINE.

001602 02-09 AMITRIPTYLINE THERAPY IN ANOREXIA-NERVOSA

001613 02-10 DECLINING DIAZEPAM DESENSITIZATION THERAPY

001614 02-10 LSD IN A COERCIVE MILIEU THERAPY PROGRAM

001631 02-12 LITHIUM THERAPY AND ALKALINE-EARTH METAL METABOLISM: A BIOCHEMICAL SCREENING STUDY.

001644 02-13 RINARY EXCRETION OF A QUATERNARY AMMONIUM GLUCURONIDE METABOLITE OF CYPROHEPTADINE IN HUMANS UNDERGOING CHRONIC DRUG THERAPY

REGIONAL CHANGES OF CEREBRAL BLOOD FLOW DURING HALOPERIDOL THERAPY IN PATIENTS WITH PARANOID SYMPTOMS.

001677 02-13 LITHIUM THERAPY OF EXTRAPYRAMIDAL MOVEMENT DISORDERS 001774 02-15

ON CATARACTS SEEN DURING PSYCHOTROPIC DRUG THERAPY 001793 02-15

DRUG THERAPY OF SCHIZOPHRENIAS IN THE COMMUNITY 001813 02-15

GILLES-DE-LA-TOURETTES SYNDROME: FAMILIAL OCCURRENCE AND PRECIPITATION BY METHYLPHENIDATE THERAPY

001823 02-15 PHENYTOIN INTOXICATION DURING CONCURRENT DIAZEPAM THERAPY 001826 02-15 LOOKING TOWARD A REEXAMINATION OF DRUG THERAPY EXPERIENCE 001856 02-16

ON LONG-TERM MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY: THE COMBINED ADMINISTRATION OF ANTIPARKINSONS DRUGS. 001865 02-16

A DEBATE ON MAINTENANCE OF PSYCHOTROPIC DRUG THERAPY REFLECTIONS ON THE SO-CALLED LONG-TERM SATURATION ADMINISTRATIONS.

A REEXAMINATION OF USING ANTIPARKINSONS DRUGS WITH .
PSYCHOTROPIC DRUG THERAPY — A SURVEY OF OUTPATIENTS

001874 02-16 THE COMPARISON OF PSYCHOPHYSIOLOGICAL THERAPY WITH DRUG THERAPY

001882 02-17 TRICYCLIC ANTIDEPRESSANTS IN OUTPATIENT THERAPY

001884 02-17 THERAPY OF PARKINSONISM 001887 02-17

PLACEBOS IN PSYCHIATRIC THERAPY. 001930 02-17

PENFLURIDOL IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS NEWLY DISCHARGED FROM A BRIEF THERAPY UNIT

O02391 03-08

A COMPARATIVE CONTROLLED TRIAL OF PIMOZIDE AND FLUPHENAZINEDECANOATE IN THE CONTINUATION THERAPY OF SCHIZOPHRENIA. 002396 03-08
COMBINED TRICYCLIC MAOI THERAPY FOR REFRACTORY DEPRESSION: A

REVIEW, WITH GUIDELINES FOR APPROPRIATE USAGE 002437 03-09
INTRAPSYCHIC AND FAMILY DYNAMIC PROCESSES IN AN ENDOGENOUS DEPRESSION PRECEDING MANIFESTATION OF THE ILLNESS AND LITHIUM THERAPY.

002461 03-09 CLOMIPRAMINE (ANAFRANIL) AND BEHAVIOUR THERAPY IN OBSESSIVE-COMPULSIVE AND PHOBIC DISORDERS.

002473 03-10 A COMPARISON OF CLOMIPRAMINE HYDROCHLORIDE (ANAFRANIL) AND BEHAVIOUR THERAPY IN THE TREATMENT OF OBSESSIVE NEUROSIS. 002492 03-10

Psychopharmacology Abstracts

BEHAVIOR THERAPY, SUPPORTIVE PSYCHOTHERAPY, IMIPRAMINE, AND

002501 03-10 EFFECTS OF CONCOMITANTLY ADMINISTERED DRUGS ON PLASMA LEVELS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DEPRESSIVE PATIENTS RECEIVING CLOMIPRAMINE THERAPY.

002577 03-13 RAMINE PRESSOR RESPONSES AND PLASMA LEVELS DURING TRICYCLIC ANTIDEPRESSANT THERAPY.

002584 03-13

ASSESSMENT OF DRUG THERAPY IN CHRONIC BRAIN FAILURE 002719 03-16 DRUG THERAPY: ALLIANCE AND COMPLIANCE.

THE SOCIAL OUTCOME OF PATIENTS IN A TRIAL OF LONG-TERM CONTINUATION THERAPY IN SCHIZOPHRENIA: PIMOZIDE VS.

003455 04-08 MUSCIMOL: GABA-AGONIST THERAPY IN SCHIZOPHRENIA.

003475 04-08 CONTINUATION THERAPY WITH AMITRIPTYLINE IN DEPRESSION 003488 04-09

PLASMA RENIN CONCENTRATION DURING LITHIUM THERAPY 003503 04-09

BEHAVIOR THERAPY AND WITHDRAWAL OF STIMULANT MEDICATION IN HYPERACTIVE CHILDREN. 003566 04-11

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE (SIADH) SECONDARY TO ANTIPSYCHOTIC DRUG THERAPY. 003647 04-15

THYROID AUTOANTIBODY LEVELS DURING LITHIUM THERAPY 003650 04-15

SINGLE CASE STUDY. CATATONIA ASSOCIATED WITH DISULFIRAM THERAPY

003677 04-15 THE COMPARATIVE EFFICACY OF COGNITIVE THERAPY AND PHARMACOTHERAPY IN THE TREATMENT OF DEPRESSIONS

003701 04-17 THE PHARMACOKINETIC ASPECTS OF THERAPY WITH PSYCHOTROPIC

003716 04-17 DEPRESSION: MUST PHARMACOTHERAPY FAIL FOR COGNITIVE THERAPY TO SUCCEED?

003726 04-17

THE THERMAL EFFECTS OF INTERACTION BETWEEN D AMPHETAMINE AND ANTIDEPRESSANTS AMONG RATS KEPT AT VARIOUS AMBIENT

TEMPERATURES.

001290 02-03 THERMOREGULATORY

AMINERGIC AND THERMOREGULATORY MECHANISMS IN HYPOTHALAMIC REGULATION OF GROWTH HORMONE IN CATS 000249 01-03

EFFECTS OF D AMPHETAMINE ON THE SET POINT OF THE THERMOREGULATORY SYSTEM IN RATS

003146 04-03

EVIDENCE FOR A NONCOVALENT INTERMOLECULAR INTERACTION OF OPIATES WITH THIAMINE. 001008 02-01

THIN-LAYER
THIN-LAYER AND GAS-LIQUID-CHROMATOGRAPHIC PROCEDURES FOR THE
DETERMINATION OF PERAZINE AND ITS METABOLITES IN HUMAN

BODY FLUIDS 000927 01-16 THIOL-11-DESOXYPROSTAGLANDIN-E2

PROSTAGLANDIN-E2 AND 11 THIOL-11-DESOXYPROSTAGLANDIN-E2 IN THE MOUSE AND RAT. 003173 04-04

THIOPENTAL EFFECTS OF SODIUM THIOPENTAL ON THE TRICARBOXYLIC-ACID CYCLE

METABOLISM IN MOUSE BRAIN: CO2 FIXATION AND METABOLIC COMPARTMENTATION 002860 04-03

THIORIDAZINE
THIORIDAZINE METABOLISM AND CLINICAL RESPONSE: A PILOT STUDY 000737 01-13 SUCCESSFUL SUICIDES WITH THIORIDAZINE AND MESORIDAZINE

000823 01-15 CARDIAC TOXICITY WITH THIORIDAZINE TRICYCLIC ANTIDEPRESSANT COMBINATION

000846 01-15 IN VITRO AUTONOMIC EFFECTS OF FOUR NEUROLEPTICS CHLORPROMAZINE, HALOPERIDOL, MELPERONE AND THIORIDAZINE

001212 02-03 CHLOROQUINE POTENTIATION OF THIORIDAZINE EFFECTS IN RATS AND A PRELIMINARY REPORT.

O01571 02-08 ABOUT A NONFATAL MASSIVE INTOXICATION WITH SUSTAINED-RELEASE THIORIDAZINE. CLINICAL AND THERAPEUTIC PROBLEMS.

CHLORPROMAZINE PLUS THIORIDAZINE POISONING AND TREATMENT WITH EXTRACORPOREAL DIALYSIS.

O01806 02-15
CHANGES IN PHARMACODYNAMICS AND PHARMACOKINETICS OF
PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE;
EFFECTS OF PERMEDICATION WITH CYSTAMINE ON DYNAMICS AND
KINETICS OF THIORIDAZINE.

PHARMACODYNAMICS AND PHARMACOKINETICS OF PSYCHOLEPTIC DRUGS IN THE COURSE OF RADIATION DISEASE: EFFECT OF PREMEDICATION WITH METANABOL ON DYNAMICS AND KINETICS OF THIORIDAZINE.

EFFECT OF THIORIDAZINE (MELLARIL-SANDOZ) ON PSYCHOMOTOR FUNCTION, CONCENTRATION, AND REACTIVITY IN CHILDREN WITH BEHAVIOR DISORDERS.

002527 03-11
THE THIORIDAZINE LEVEL IN THE BLOOD SERUM AND SYMPTOMS OF THE PARANOID SYNDROME.

O02543 03-13
COMPARISON OF THE ELECTROPHYSIOLOGICAL EFFECTS OF TWO
NEUROLEPTICS, MELPERONE AND THIORIDAZINE, ON ISOLATED RAT
ATRIA

O03417 04-05
RELATIONSHIP BETWEEN SERUM CONCENTRATIONS OF THIORIDAZINE
AND ITS MAIN NONCONJUGATED METABOLITES AND THE CLINICAL
RESPONSE IN THIORIDAZINE TREATED PATIENTS.

IN VIVO CONVERSION OF MESORIDAZINE TO THIORIDAZINE.

TARDIVE-DYSKINESIA DURING AND FOLLOWING TREATMENT WITH HALOPERIDOL, HALOPERIDOL BIPERIDEN, THIORIDAZINE, AND CLOZAPINE. 003656 04-15

NEGATIVE EFFECTS OF BICUCULLINE AND THIOSEMICARBAZIDE ON THE TRANQUILLIZING ACTION OF DIAZEPAM.

THIOTHIXENE
DYSKINESIA WITH THIOTHIXENE.

000519 01-08
RELATIONSHIPS BETWEEN CLINICAL AND BIOCHEMICAL EFFECTS OF
MELPERONE AND THIOTHIXENE IN PSYCHOTIC WOMEN.

RELATIVE EFFICACY OF PARENTERAL HALOPERIDOL AND THIOTHIXENE FOR THE EMERGENCY TREATMENT OF ACUTELY EXCITED AND AGITATED PATIENTS.

A GC/CIMS ASSAY FOR THE CIS AND TRANS ISOMERS OF THIOTHIXENE IN HUMAN PLASMA.

O01857 02-16
CLINICAL AND BIOCHEMICAL CHANGES IN PSYCHOTIC WOMEN TREATED WITH MELPERONE OR THIOTHIXENE.

D023B8 03-08
EFFECTS OF MELPERONE AND THIOTHIXENE ON PROLACTIN LEVELS IN
CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC WOMEN.
002547 03-13

THIOXANTHENE

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. A
STUDY WITH THE LONG-ACTING THIOXANTHENE DERIVATIVE, CISCLOPENTHIXOL-DECANOATE SORDINOL DEPOT.

CLOPENTHIXOL-DECANOATE SORDINOL DEPOT.

D03454 04-08

1ST

ANGIOTENSIN-INDUCED THIRST: EFFECTS OF THIRD VENTRICLE

OBSTRUCTION AND PERIVENTRICULAR ABLATION.

003181 04-04
HYPOTENSION AND THIRST IN RATS AFTER ISOPROTERENOL TREATMENT.

THOUGHT

ANALYSIS OF A SCHOOL OF THOUGHT ON THE EFFECTS OF LITHIUM ON BEHAVIOR.

000987 01-17
THOUGHT DISORDER IN SCHIZOPHRENIA: A THEORETICAL APPROACH
USING AN ANALYSIS OF SPEECH. (PH.D. DISSERTATION).
001566 02-08

SYNDROME MALIN SYMPTOMS THOUGHT TO BE DUE TO INTERACTION BETWEEN NEUROLEPTICS AND ORAL DIABETES DRUGS.

001854 02-15

A COOPERATIVE CLINICAL STUDY OF METHADYL-ACETATE. 1. THREE-TIMES-A-WEEK REGIMEN. 002757 03-17

ELEVATION OF AVERSIVE THRESHOLD IN RATS BY INTRA-AMYGDALOID INJECTION OF MORPHINE-SULPHATE. 000444 01-04

EFFECT OF BARBITURATE WITHDRAWAL ON PENTYLENETETRAZOL SEIZURE THRESHOLD.

APOMORPHINE AND L-DOPA LOWER EJACULATION THRESHOLD IN THE MALE RAT. 003327 04-04

THRESHOLDS
THE RELATIONSHIP BETWEEN MAGNITUDE OF ELECTROSHOCK
STIMULATION AND THE EFFECTS OF DIGITOXIGENIN,
PENTYLENETETRAZOL AND BRAIN MONOAMINE REDUCTION ON
ELECTROSHOCK CONVULSIVE THRESHOLDS.

FURTHER STUDIES ON BL-3912A: EFFECTS ON AVOIDANCE BEHAVIOR OF RATS WITH LOW BASELINES AND ON REACTION THRESHOLDS TO ELECTRIC FOOTSHOCK.

TIME-COURSE AND DEVELOPMENT OF ELECTROCLINICAL FEATURES IN RELATION TO PENTYLENETETRAZOL THRESHOLDS IN MONKEYS WITH FOCAL SEIZURES

EFFECTS OF ESTROGEN AND AMINERGIC DRUGS ON THRESHOLDS OF MEDIAL BASAL HYPOTHALAMIC AXONS IN THE MEDIAN EMINENCE OF THE RAT.

002974 04-03

THROMBOCYTES

EFFECT OF ANTIDEPRESSANTS ON THE ABSORPTION OF SEROTONIN BY
HUMAN THROMBOCYTES.

002586 03-13
THYMOANALEPTIC
EFFECT OF THYMOANALEPTIC AGENTS ON THE COURSE OF EXPERIMENTAL
ARTERIAL HYPERTENSION AND CATECHOLAMINE CONTENT IN TISSUES

AND URINE. 001970 03-03

AFFECTIVE-ILLNESS TREATED WITH LITHIUM: EFFECTS ON THYROID FUNCTION AND PSYCHIC STATUS.

000774 01-14

THYROID FUNCTION AND GROWTH HORMONE SECRETION IN AMITRIPTYLINE TREATED DEPRESSION.

001596 02-09

THE UPTAKE OF \$35-METHIMAZOLE BY SHEEP THYROID SLICES IN VITRO.

003093 04-03

A CASE OF DEPRESSION SHOWING IMPROVEMENT IN TRH TEST BY

COMBINED TREATMENT BY DIMETACRINE-TARTRATE AND THYROID

COMBINED TREATMENT BY DIMETACRINE-TARTRATE AND THYROID HORMONE.

003527 04-09

NEUROTRANSMITTER MECHANISMS DURING MENTAL ILLNESS INDUCED BY ALTERATIONS IN THYROID FUNCTION. 003636 04-14 THYROID AUTOANTIBODY LEVELS DURING LITHIUM THERAPY.

THYROTEOPIN-RELEASING
COMPARISON OF THYROTROPIN-RELEASING HORMONE WITH
MELANOCYTE-STIMULATING HORMONE RELEASE INHIBITING FACTOR
AS PENTOBARBITAL ANTAGONISTS IN MONKEYS.

AS PENTOBARBITAL ANTAGONISTS IN MONKEYS.

000087 01-03

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON
PENTOBARBITAL-INDUCED DECREASE IN CHOLINERGIC NEURONAL

PENTOBARBITAL-INDUCED DECREASE IN CHOLINERGIC NEURONAL ACTIVITY.

EFFECTS OF THYROTROPIN-RELEASING HORMONE ON BEHAVIORAL AND HORMONAL CHANGES INDUCED BY BETA-ENDORPHIN. 001471 02-04

STIMULANT ACTION OF THYROTROPIN-RELEASING HORMONE ON CAT SPINAL CORD.

STUDIES ON THE NEUROPHARMACOLOGY OF THYROTROPIN-RELEASING HORMONE (TRH) AND A NEW TRH ANALOG. 002185 03-03

OO2185 03-03
LUTEINIZING HORMONE RELEASING HORMONE AND THYROTROPINRELEASING HORMONE STIMULATION STUDIES IN PATIENTS GIVEN
CLOMIPRAMINE OR DEPOT NEUROLEPTICS.

MODULATION OF THE TURNOVER RATE OF ACETYLCHOLINE IN RAT BRAIN BY INTRAVENTRICULAR INJECTIONS OF THYROTROPIN-RELEASING HORMONE, SOMATOSTATIN, NEUROTENSIN AND ANGIOTENSIN-II. 002994 04-03

THYROTROPIN-RELEASING HORMONE (TRH): LACK OF EFFECT ON SHOCK-ELICITED FIGHTING (SEF) IN RATS.

TREATMENT OF ENDOGENOUS DEPRESSION WITH ORAL THYROTROPIN-RELEASING HORMONE AND AMITRIPTYLINE.

003502 04-09

THYROXINE

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON SERUM THYROXINE

CONCENTRATIONS IN THE RAT.

THE EFFECT OF DEPRESSION AND ITS TREATMENT ON SERUM THYROXINE.
001243 03-09

TILIDEN-HCL
CHARACTERISTICS OF TILIDEN-HCL (VALORON) INTOXICATION 002377 03-07

INCREASED TILT-CAGE ACTIVITY AFTER SEROTONIN DEPLETION BY 5,7 DIHYDROXYTRYPTAMINE.

003279 04-04

PRENATAL ALCOHOL CONSUMPTION AND OPEN-FIELD BEHAVIOUR IN RATS: EFFECTS OF AGE AT TIME OF TESTING.

000321 01-04 TIME ACTION AND BEHAVIORAL EFFECTS OF AMPHETAMINE, ETHANOL, AND ACETYLMETHADOL.

000350 01-04 SYNTHESIS OF BRADYKININ FRAGMENTS AND THEIR EFFECT ON PENTOBARBITAL SLEEPING TIME IN MOUSE.

000424 01-04 ON THE HYPNOGENIC AND ANTICONVULSANT ACTIVITIES OF DEMETHYLDIAZEPAM AND CHLORDEMETHYLDIAZEPAM: TIME EFFECT

000462 01-04 AMITRIPTYLINE DOSAGE SCHEDULE, SAMPLING TIME AND TRICYCLIC PLASMA LEVELS.

000593 01-09 IDENTIFICATION OF SHORT TIME INTERVALS UNDER LSD-25 AND MESCALINE.

001635 02-12 MARIJUANA, ALCOHOL, AND COMBINED DRUG EFFECTS ON THE TIME COURSE OF GLARE RÉCOVERY.

002604 03-14 HYPERACTIVE CHILDRENS UNDERUSE OF LEARNING TIME: CORRECTION BY STIMULANT TREATMENT.

THE EFFECT OF NITRAZEPAM ON MANUAL SKILL, GRIP STRENGTH, AND REACTION TIME WITH SPECIAL REFERENCE TO SUBJECTIVE EVALUATION OF EFFECTS ON SLEEP.

002626 03-14 ASSESSMENT OF SPONTANEOUS AND DRUG-INDUCED CHANGES IN VIGILANCE BY MEANS OF A NEW MODIFICATION OF THE SHORT TIME SPECTRAL ANALYSIS OF THE EEG.

ADRENERGIC STIMULATION OF THE PARAVENTRICULAR NUCLEUS AND ITS EFFECTS ON INGESTIVE BEHAVIOR AS A FUNCTION OF DRUG DOSE AND TIME OF INJECTION IN THE LIGHT-DARK CYCLE.

INTERACTION BETWEEN D AMPHETAMINE AND ETHANOL WITH RESPECT TO LOCOMOTION, STEREOTYPIES, ETHANOL SLEEPING TIME, AND THE KINETICS OF DRUG ELIMINATION.

003378 04-04

TIME-COURSE OF LITHIUM-INDUCED ALTERATIONS IN RENAL AND ENDOCRINE FUNCTION IN NORMAL AND BRATTLEBORD RATS WITH HYPOTHALAMIC DIABETES-INSIPIDUS.

000048 01-03 DOSE-RESPONSE AND TIME-COURSE EFFECTS OF N,N
DIMETHYLTRYPTAMINE ON DISRUPTION OF RAT SHUTTLE-BOX
AVOIDANCE.

000457 01-04 ACUTE VERSUS CHRONIC EFFECTS OF MONOAMINE-OXIDASE INHIBITORS IN DEPRESSED PATIENTS: TIME-COURSE OF MAO INHIBITORS.

000733 01-13 MODIFICATION OF THE TIME-COURSE OF DMPEA TOXICITY IN THE MOUSE BY CENTRALLY ACTING DRUGS.

001039 02-02 TIME-COURSE AND DEVELOPMENT OF ELECTROCLINICAL FEATURES IN RELATION TO PENTYLENETETRAZOL THRESHOLDS IN MONKEYS WITH FOCAL SEIZURES.

TIME-COURSE OF AUDIOGENIC SEIZURE SUSCEPTIBILITY AND PLASMA PENTOBARBITAL CONCENTRATION DURING WITHDRAWAL.

TIME-COURSE OF THE EFFECTS OF NATURALLY OCCURRING CANNABINOIDS ON MORPHINE ABSTINENCE SYNDROME.

002196 03-04 TIME-COURSE OF CHANGES IN EEG AND POWER SPECTRA DURING TREATMENT WITH NEUROLEPTICS.

002570 03-13 TIME-COURSE OF THE INCREASE IN GABA LEVEL IN DIFFERENT MICE BRAIN REGIONS FOLLOWING N DIPROPYLACETATE TREATMENT.

METHODOLOGICAL PROBLEMS IN THE MEASUREMENT OF DRUG-INDUCED ROTATIONAL BEHAVIOUR: CONTINUOUS RECORDING REVEALS TIME-COURSE DIFFERENCES UNDETECTED BY PREVIOUS TECHNIQUES. 003388 04-04

"E-DEPENDENT CHANGES IN ACTIVITY, REACTIVITY, AND RESPONSIVITY DURING SHOCK: EFFECTS OF CHOLINERGIC AND CATECHOLAMINERGIC MANIPULATIONS. 000313 01-04 Psychopharmacology Abstracts

003537 04-10

TIME-DEPENDENT DISRUPTIVE EFFECTS OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE ON DEVELOPMENT OF MORPHINE TOLERANCE. 002058 03-03

TIME-DEPENDENT EFFECTS OF RESERPINE ON RETENTION OF PASSIVE AVOIDANCE.

002327 03-04

TIME-RESPONSE
TIME-RESPONSE ANALYSIS OF THE EFFECT OF STIMULANT MEDICATION
ON THE LEARNING ABILITY OF CHILDREN REFERRED FOR

002534 03-11

WORD ASSOCIATION TIMES, FELT EFFECTS, AND PERSONALITY CHARACTERISTICS OF SCIENCE STUDENTS GIVEN A PLACEBO

A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-DUMMY TECHNIQUE.

STUDIES ON TOLERANCE. II. THE EFFECT OF TIMING ON INHIBITION OF TOLERANCE TO MORPHINE BY CYCLOHEXIMIDE.

000104 01-03 TIMING AND RISK OF BONE MARROW DEPRESSION BY PSYCHOTROPIC DRIIGS

001770 02-15 TISSUE A RAPID AND SIMPLE RADIOACTIVE METHOD FOR THE DETERMINATION OF DISULFIRAM AND ITS METABOLITES FROM A SINGLE SAMPLE OF BIOLOGICAL FLUID OR TISSUE.

STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT BRAIN TISSUE SLICES. 001145 02-03

EFFECTS OF REPEATED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS ON ADIPOSE TISSUE LIPOLYTIC ACTIVITY IN THE RAT.

001179 02-03 PHENYTOIN TERATOGENESIS: CORRELATION BETWEEN EMBRYOPATHIC EFFECT AND COVALENT BINDING OF PUTATIVE ARENE OXIDE METABOLITE IN GESTATIONAL TISSUE.

001515 02-05 STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAMINE (DA) AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES.

002036 03-03 METABOLISM OF AMPHETAMINE BY RAT BRAIN TISSUE

002065 03-03 EFFECT OF METABOLIC INHIBITORS AND OUABAIN ON AMPHETAMINE-INDUCED AND POTASSIUM-INDUCED RELEASE OF BIOGENIC AMINES FROM ISOLATED BRAIN TISSUE.

TISSUE DISTRIBUTION OF RADIOACTIVITY AFTER INJECTION OF C14-NITRAZEPAM IN YOUNG AND OLD RATS.

002948 04-03 CHANGES OF TAURINE CONTENT IN THE BRAIN TISSUE OF BARBITURATE DEPENDENT RATS.

THE EFFECT OF VILOXAZINE HYDROCHLORIDE ON THE TRANSPORT OF NORADRENALINE, DOPAMINE, 5 HYDROXYTRYPTAMINE AND GAMMA-AMINOBUTYRIC-ACID IN RAT BRAIN TISSUE.

003001 04-03 RELEASE OF ENDOGENOUS CATECHOLAMINES FROM ISOLATED RAT BRAIN TISSUE BY FENFLURAMINE AND N ETHYLAMPHETAMINE — EFFECTS OF PARGYLINE.

RELATIONSHIP BETWEEN THE UPTAKE OF 3H-(PLUS OR MINUS)
METARAMINOL AND THE DENSITY OF ADRENERGIC INNERVATION IN
ISOLATED RAT TISSUES.

000142 01-03 THE EXTRACTION AND ANALYSIS OF BENZODIAZEPINES IN TISSUES BY ENZYMIC DIGESTION AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY.

EFFECT OF THYMOANALEPTIC AGENTS ON THE COURSE OF EXPERIMENTAL
ARTERIAL HYPERTENSION AND CATECHOLAMINE CONTENT IN TISSUES AND LIRINE

001970 03-03 ABSORPTION AND DISTRIBUTION OF SODIUM BARBITAL IN TISSUES OF NORMAL AND DYSTROPHIC MICE.

002162 03-03 THE FLUOROMETRIC DETERMINATION OF 5 METHOXYTRYPTAMINE IN MAMMALIAN TISSUES AND FLUIDS.

003050 04-03 BEHAVIORAL CHANGES AND MERCURY CONCENTRATIONS IN TISSUES OF RATS EXPOSED TO MERCURY VAPOR.

003258 04-04

EFFECTS OF MORPHINE, METHADONE, NALORPHINE AND NALOXONE ON RESPONDING UNDER SCHEDULES OF ELECTRIC-SHOCK TITRATION. 000453 01-04

A DOSE RATIO COMPARISON OF THE INTERACTION BETWEEN MORPHINE AND CYCLAZOCINE WITH NALOXONE IN RHESUS MONKEYS ON THE SHOCK TITRATION TASK

002335 03-04

CHLORPROMAZINE EXCRETION. II. IMPROVED TLC PROCEDURES FOR FRACTIONATING THE URINARY DRUG CONTENT INTO CHEMICAL SUBGROUPS OF CPZ METABOLITES

003690 04-16

CLINICAL STUDY OF ANTIPARKINSON DRUGS USED TOGETHER WITH PSYCHOTROPIC DRUGS. 001936 02-17

TOLERABILITY

MAPROTILINE (LUDIOMIL) IN DEPRESSION: A MULTICENTRE ASSESSMENT OF ONSET OF ACTION, EFFICACY AND TOLERABILITY

002432 03-09

TOLERANCE
STUDIES ON TOLERANCE. II. THE EFFECT OF TIMING ON INHIBITION OF
TOLERANCE TO MORPHINE BY CYCLOHEXIMIDE.

000104 01

000104 01-03

THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN THE RAT 000106 01-03

THE ANTAGONIZING EFFECT OF ASPARTIC-ACID ON THE BRAIN LEVELS OF MONOAMINES AND FREE AMINO-ACIDS DURING THE DEVELOPMENT OF TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE 000169 01-03

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM -- IV. TOLERANCE TO OXOTREMORINE IN MICE: IN VIVO AND IN VITRO STUDIES.

000188 01-03 ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM — III. TOLERANCE TO PHENCYCLIDINE DERIVATIVES: IN VIVO AND IN VITRO STUDIES.

000224 01-03 THE EFFECTS OF 6 HYDROXYDOPAMINE ON TOLERANCE TO AND DEPENDENCE ON ETHANOL

000280 01-03 TOLERANCE TO ETHANOL: EFFECT OF CONGENERS PRESENT IN BOURBON 000370 01-04

INFLUENCES OF GENOTYPE AND SEX ON BEHAVIORAL TOLERANCE TO NICOTINE IN MICE.

000376 01-04 TOLERANCE TO MORPHINE PRODUCED DISCRIMINATIVE STIMULI AND

000414 01-04 DEVELOPMENT OF TOLERANCE TO THE DISRUPTIVE AFFECTS OF COCAINE ON REPEATED ACQUISITION AND PERFORMANCE OF RESPONSE

000459 01-04 DELAYED ONSET OF SINGLE DOSE TOLERANCE TO MORPHINE ANALGESIA. 001089 02-03

REGIONAL DISTRIBUTION OF BARBITAL IN THE BRAIN OF MICE DURING THE DEVELOPMENT OF TOLERANCE AND PHYSICAL DEPENDENCE 001180 02-03

LACK OF TOLERANCE TO THE DEPRESSION OF RAPHE UNIT ACTIVITY BY LYSERGIC-ACID-DIETHYLAMIDE 001262 02-03

DIFFERENTIAL TOLERANCE TO INHIBITORY ACTION OF VARIOUS NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS CHRONICALLY TREATED WITH HALOPERIDOL 001398 02-04

TOLERANCE AND CROSS-TOLERANCE TO CNS DEPRESSANTS AFTER CHRONIC PENTOBARBITAL

001442 02-04 DEVELOPMENT OF BEHAVIORAL TOLERANCE TO COCAINE 001474 02-04

BARBITAL-INDUCED TOLERANCE AND CROSS-TOLERANCE TO VARIOUS CNS DEPRESSANTS ON RAT OPERANT BEHAVIOR 001481 02-04

TOLERANCE TO STEREOTYPED BEHAVIOUR AND TO DECREASE IN STRIATAL HOMOVANILLIC-ACID LEVELS AFTER REPEATED TREATMENT WITH APOMORPHINE-DIPIVALOYL-ESTER. 001497 02-04

TOLERANCE TO HALOPERIDOL CATALEPSY

001506 02-05 TOLERANCE TO MARIJUANA: HEART RATE AND SUBJECTIVE HIGH.

001818 02-15 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL. II. TOLERANCE CHARACTERISTICS 001972 03-03

TOLERANCE TO COCAINE-INDUCED CONVULSIONS IN THE CAT 001984 03-03

EFFECT OF P-CHLOROPHENYLALANINE ON THE LOSS AND MAINTENANCE OF TOLERANCE TO ETHANOL.

TIME-DEPENDENT DISRUPTIVE EFFECTS OF APOMORPHINE AND ALPHA-METHYL-P-TYROSINE ON DEVELOPMENT OF MORPHINE TOLERANCE. 002058 03-03

INFLUENCE OF IMMUNE STIMULATION AND SUPPRESSION ON MORPHINE PHYSICAL DEPENDENCE AND TOLERANCE. 002095 03-03

ON THE INTERACTION OF DRUGS WITH THE CHOLINERGIC NERVOUS SYSTEM. I. TOLERANCE TO PHENCYCLIDINE DERIVATIVES IN MICE: PHARMACOLOGICAL CHARACTERIZATION.

002127 03-03 DIFFERENTIAL REGIONAL DEVELOPMENT OF TOLERANCE TO INCREASE IN DOPAMINE TURNOVER UPON REPEATED NEUROLEPTIC **ADMINISTRATION**

TOLERANCE TO AMPHETAMINES FACILITATION OF SELF-STIMULATION RESPONDING: ANATOMICAL SPECIFICITY

002190 03-04 TOLERANCE TO HYPOKINESIA ELICITED BY DOPAMINE AGONISTS IN MICE: HYPOSENSITIZATION OF AUTORECEPTORS?

002221 03-04
RAPID TOLERANCE TO THE MOTOR EFFECTS OF P-CHLOROAMPHETAMINE IN RATS.

002226 03-04 EVIDENCE FOR PARALLEL DEVELOPMENT OF TOLERANCE TO THE HYPERACTIVATING AND DISCOORDINATING EFFECTS OF ETHANOL 002249 03-04

BEHAVIOURAL SPECIFIC TOLERANCE FOLLOWING CHRONIC D OR L AMPHETAMINE TREATMENT: LACK OF INVOLVEMENT OF P HYDROXYNOREPHEDRINE

002261 03-04 INDUCED TOLERANCE TO THE DISCRIMINATIVE STIMULUS PROPERTIES OF COCAINE

002280 03-04 TOLERANCE AND DEPENDENCE AFTER CHRONIC ADMINISTRATION OF

002283 03-04 PHARMACOLOGICAL AND BEHAVIORAL COMPONENTS OF TOLERANCE TO ISD AND MESCALINE IN RATS

TOLERANCE TO P-CHLOROAMPHETAMINES EFFECTS ON SIDMAN AVOIDANCE PERFORMANCE AND CATECHOLAMINE METABOLISM

002314 03-04 TOLERANCE TO SEDATIVE HYPNOTICS, MEMORY AND NORADRENERGIC (NE) SYSTEMS.

002318 03-04 TOLERANCE TO HIGH DOSES OF MORPHINE: LACK OF EVIDENCE OF LEARNING

OSMOTIC MINIPUMPS FOR ADMINISTRATION OF BARBITAL TO MICE: DEMONSTRATION OF FUNCTIONAL TOLERANCE AND PHYSICAL

002374 03-06 PHARMACOKINETIC STUDIES ON TOLERANCE TO SEDATIVE HYPNOTICS IN A POLYDRUG ABUSE POPULATION: I. SECOBARBITAL.

002662 03-15 EFFECT OF P-CHLOROPHENYLALANINE ON THE ACQUISITION OF TOLERANCE TO THE HYPOTHERMIC EFFECTS OF ALCOHOL.

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL TOLERANCE AND CROSS-TOLERANCE TO MORPHINE AND METHADONE IN THE RAT.

NOCICEPTIVE STIMULATION PREVENTS DEVELOPMENT OF TOLERANCE TO NARCOTIC ANALGESIA.

003195 04-04 CONDITIONING FACTORS INFLUENCE TOLERANCE DEVELOPMENT TO LOW BUT NOT HIGH DOSES OF MORPHINE.

003198 04-04 ABATEMENT OF STIMULUS PERSERVATION FOLLOWING REPEATED D
AMPHETAMINE TREATMENT: ABSENCE OF BEHAVIORALLY AUGMENTED TOLERANCE

003260 04-04 TOLERANCE TO MORPHINE ANALGESIA AND IMMOBILITY MEASURED IN RATS BY CHANGES IN LOG-DOSE-RESPONSE CURVES.

003307 04-04 TOLERANCE TO THE BEHAVIOURAL EFFECTS OF PHYSOSTIGMINE IN RATS: LACK OF IMPORTANCE OF BEHAVIOURAL COMPENSATION.

003326 04-04 DIFFERENTIAL TOLERANCE TO PENTOBARBITAL IN RATS BRED FOR DIFFERENCES IN ALCOHOL SENSITIVITY.

003338 04-04 THE EFFECTS OF ATROPINE ON THE TOLERANCE AND THE CONVULSIONS SEEN AFTER WITHDRAWAL FROM FORCED BARBITAL DRINKING IN THE

DRUG DISCRIMINATION PARADIGMS: PROBLEMS OF TOLERANCE AND BEHAVIORAL DISRUPTION.

003692 04-16
NARCOTIC CUE, NARCOTIC ANALGESIA, AND THE TOLERANCE PROBLEM.
003707 04-17

002014 03-03

Subject Index	
TOLERANT MORPHINE ANALGESIA DOSE RESPONSE CURVES IN TOL MODIFICATION BY NALOXONE.	ERANT RATS:
COMPANY OF A STATE OF THE STATE	001143 02-0
A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHO: (DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), P. METHOXYAMPHETAMINE (PMA), D AMPHETAMINE (NONTOLERANT AND LSD TOLERANT CHRONIC SPINAL	A), AND LSD IN
	001273 02-0
THE ANTAGONISTIC EFFECTS OF 5 ETHYL-5-HYDROXY-1- METHYLBUTYLBARBITURIC-ACID ON PENTOBARBITAL BOTH NAIVE AND TOLERANT MICE.	
BOARD STATE OF THE	002336 03-0
MONOAMINE-OXIDASE INHIBITORY PROPERTIES OF 5 HT 3-M-TOLYLOXAZOLIDIN-2-ONE (TOLOXATONE).	POROXYMETHYL
	002971 04-0
TONE EVIDENCE FOR A DOUBLE CHOLINERGIC MECHANISM CA REDUCING THE TONE OF CEREBRAL ARTERIES.	PABLE OF
REDUCING THE TONE OF CEREBRAL ARTERIES.	001049 02-0
A METHOD FOR MECHANOGRAPHICAL RECORDING OF A THE RAT: THE EFFECT OF SOME ANTIPARKINSONIAN I RIGIDITY INDUCED BY RESERPINE.	AUSCLE TONE IN
MODELL DI RESERVINE.	002346 03-0
A SEROTONERGIC. MIDBRAIN RAPHE MODEL OF TONIC	IMMORILITY
A SENSTONEROIC, MISSISSIA RATTE MOSEE OF TORICE	000291 01-0
THE EFFECT OF EPINEPHRINE ON TONIC IMMOBILITY (AN IN CHICKENS.	IMAL HYPNOSIS
THE ROYCHARD AND ACCURATE OF LIGHT HILL PROPERTY OF	000460 01-0
THE PSYCHOPHARMACOLOGY OF MORPHINE EFFECTS OF IMMOBILITY. (PH.D. DISSERTATION).	NIONIC
The second secon	001276 02-0
SUBCUTANEOUS INJECTIONS OF APOMORPHINE, STIMUL	211
GENERALIZATION AND CONDITIONING: SERIOUS PITFA EXAMINER USING APOMORPHINE AS A TOOL.	ALLS FOR THE
	000341 01-0
NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUD DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EF KETAMINE.	
	002362 03-0
NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUD' DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EF PENTOBARBITAL.	
BARALINIS LIBERTY IN STRATEGICAL CONTRACTOR OF THE STRATEGICAL CON	002363 03-0
DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENT CATECHOLAMINERGIC AND SEROTONINERGIC TERMIN CEREBRAL STRUCTURES.	IATION OF
	003423 04-0
TOOLS	

IN CHICKENS.	
	000460 01-0
THE PSYCHOPHARMACOLOGY OF MORPHINE EFFECTS ON 1 IMMOBILITY. (PH.D. DISSERTATION).	ONIC
IMMODILITE. (FR.D. DISSERIATION).	001276 02-03
TOOL	001270 02-0
SUBCUTANEOUS INJECTIONS OF APOMORPHINE, STIMULUS	
GENERALIZATION AND CONDITIONING: SERIOUS PITFALL EXAMINER USING APOMORPHINE AS A TOOL.	S FOR THE
	000341 01-04
NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY I DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFE KETAMINE.	
	002362 03-06
NEUROPHYSIOLOGICAL APPROACH AS A TOOL TO STUDY TO DRUGS ON THE CENTRAL-NERVOUS-SYSTEM: DOSE EFFE PENTOBARBITAL.	THE EFFECTS OF CT OF
	002363 03-06
DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VI	
VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIA CATECHOLAMINERGIC AND SEROTONINERGIC TERMINAL	
CEREBRAL STRUCTURES.	S IN KAI
	003423 04-06
TOOLS	
SECOND-GENERATION ANTIDEPRESSANTS AS RESEARCH TO PRELIMINARY FINDINGS WITH CLOMIPRAMINE AND MA	PROTILINE.
INTEROCEPTINE DISCRIMINATINE STRAIGHT AS TOOLS IN DESCRIPTION	002587 03-13
INTEROCEPTIVE DISCRIMINATIVE STIMULI AS TOOLS IN DR DEVELOPMENT.	
TORTICOLLIS	003428 04-0
TREATMENT OF SPASMODIC TORTICOLLIS WITH AMANTAL DOUBLE-BUND STUDY.	DINE: A
DOUBLE BEIND STODY.	000666 01-1
TOURETTE	
THE EFFECTS OF CENTRAL-NERVOUS-SYSTEM STIMULANTS SYNDROME.	ON TOURETTE
the first transfer of the state	000629 01-1
TOXIC	ABCOTIC
TOXIC INTERACTIONS OF STIMULANTS, NARCOTICS AND N ANTAGONISTS.	AKCOTIC
	001511 02-0
TOXIC DELIRIUM INDUCED BY DELIBERATE INGESTION OF J	IMSON-WEED. 001633 02-12
A POTENTIALLY TOXIC DRUG INTERACTION BETWEEN PETH (MEPERIDINE) AND PHENOBARBITONE.	IDINE
	001836 02-1
HEMODYNAMIC EFFECTS FOLLOWING TOXIC DOSES OF TRI ANTIDEPRESSANTS.	-,
CTATUS CONCOTICUS ON REPORTITUE OFFICE CO.	001838 02-1
STATUS-EPILEPTICUS OR REPETITIVE SEIZURES FOLLOWING INGESTION.	
THE SECRET OF LODIC TERMS ADMINISTRATION OF TOWN	001845 02-1
THE EFFECT OF LONG-TERM ADMINISTRATION OF TOXIC D CLOMIPRAMINE ON PLASMA PROLACTIN, LUTEINIZING FOLLICLE-STIMULATING HORMONE AND TESTOSTERONE	HORMONE.
RAT.	

Psychopharmacology	Abstracts
OXICITY	
EFFECT OF ALTERATION OF METABOLISM ON THE ANALGES TOXICITY, DISTRIBUTION AND EXCRETION OF L-ALPHA- ACETYLMETHADOL IN THE RAT.	SIC ACTIVITY,
TOXICITY OF HIGH-DOSE FLURAZEPAM IN THE ELDERLY.	000245 01-03
DOXEPIN OVERDOSE: SUCCESS WITH PHYSOSTIGMINE AND WITH NEOSTIGMINE IN REVERSING TOXICITY.	000630 01-11 FAILURE
THE DIAGNOSIS AND TREATMENT OF LITHIUM TOXICITY.	000772 01-14
BEHAVIORAL TOXICITY AND EQUIVOCAL SUICIDE ASSOCIA	000838 01-15
CHLOROQUINE AND ITS DERIVATIVES.	000839 01-15
CARDIAC TOXICITY WITH THIORIDAZINE TRICYCLIC ANTIDI COMBINATION.	
PSYCHEDELIC DRUG CRISES: TOXICITY AND THERAPEUTICS	000846 01-15
DIAZEPAM: EFFICACY AND TOXICITY AS REVEALED BY A SERVER STRATEGY.	
THE BEHAVIORAL TOXICITY OF MONOAMINE-OXIDASE INH ANTIDEPRESSANTS.	
MODIFICATION OF THE TIME-COURSE OF DMPEA TOXICITY BY CENTRALLY ACTING DRUGS.	
EFFECTS OF DISULFIRAM ON PHARMACOLOGICAL ACTIVITY AND FATE OF MORPHINE IN RATS.	001039 02-02 Y, TOXICITY
CLINICAL PHARMACOLOGY OF PHENCYCLIDINE TOXICITY.	001111 02-03
ANTABUSE TOXICITY.	001637 02-12
COMPARATIVE TOXICITY OF CAFFEINE AND AMINOPHYLLII AND ADULT RATS.	001825 02-15 NE IN YOUNG
CIRCADIAN RHYTHM OF LITHIUM TOXICITY IN MICE.	002342 03-05
ETHANOL AND DISPOSITION OF AMYLOBARBITONE: EFFECT SIGNIFICANCE AS A MECHANISM FOR INCREASED TOXIC	
METHYLPHENIDATE-INDUCED CONDITIONED TASTE AVERSION OF TOXICITY.	003114 04-03
TOXICITY OF 5 HYDROXYTRYPTOLINE IN RATS.	003337 04-04
	003409 04-05
EVIDENCE AGAINST CHRONIC DEPOLARIZATION AS A MEC KAINIC-ACID TOXICITY IN MOUSE CEREBELLAR CULTURE	S. 003418 04-05
HYPEROSMOLALITY COMPLICATING RECOVERY FROM LITH	003665 04-15
BEHAVIORAL TOXICITY: THE PSYCHOLOGY OF DRUG POLLI	O03684 04-15
TOXICOLOGICAL AND PHARMACOLOGICAL EFFECTS OF MA	RIHUANA. 002347 03-05
PHARMACOLOGICAL AND TOXICOLOGICAL EFFECTS OF BET METHYLENEDIOXYAMPHETAMINE ISOMERS.	A 3,4
OXICOLOGY	003285 04-04
DRUG ANALYSIS IN THE OVERDOSED PATIENT: ITS APPLIC CLINICAL TOXICOLOGY.	
RACE	000802 01-15
TRACE AMINES AND ALTERNATIVE NEUROTRANSMITTERS CENTRAL-NERVOUS-SYSTEM.	
RACHEAL	003698 04-17
STUDIES ON THE INHIBITION OF PHOSPHODIESTERASE CAT. CYCLIC-AMP AND CYCLIC-GMP BREAKDOWN AND RELA CANINE TRACHEAL SMOOTH MUSCLE.	
RACT	002129 03-03
PENICILLIN IN THE PYRAMIDAL TRACT: ECTOPIC ACTION P GENERATION.	
STUDIES ON THE EFFECT OF LESIONS OF THE VENTRAL NOR TRACT ON THE ANTINOCICEPTIVE ACTION OF MORPHINI	
DEPRESSION OF PRIMATE SPINOTHALAMIC TRACT NEUROI IONTOPHORETIC APPLICATION OF 5 HYDROXYTRYPTAM	INE.
PAGENY	003251 04-04

TRAGEDY
ANOTHER PARACETAMOL TRAGEDY.

002852 04-03

VOLUME 16, SUBJECT INDEX

-			×	á	×	4	×	Ŀ	*	*	
T	Е	u	Ą	а	ľ	٩	ı	P	9	u	

FAILURE OF PERIPHERAL DOPAMINE-BETA-HYDROXYLASE INHIBITOR TO AFFECT DISCRIMINATED SIDMAN AVOIDANCE LEARNING IN RATS UNDER LONG-TERM TRAINING.

000034 01-02 COMPARISON OF ETHANOL, PENTOBARBITAL, AND PHENOBARBITAL USING DRUG VS. DRUG DISCRIMINATION TRAINING.

MANAGEMENT OF THE HYPERKINETIC SYNDROME WITH METHYLPHENIDATE AND SMR BIOFEEDBACK TRAINING.

001625 02-11 EFFECTS OF MYSOLINE AND DILANTIN ON THE EEG DURING SMR BIOFEEDBACK TRAINING OF A PSYCHOMOTOR EPILEPTIC: SINGLE CASE

001657 02-13
EFFECTS OF POSTTRAINING INJECTION OF CHOLINERGIC AGONISTS AND

ANTAGONISTS INTO THE AMYGDALA ON RETENTION OF PASSIVE AVOIDANCE TRAINING IN RATS. (PH.D. DISSERTATION) 002323 03-04

OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR OPERANT DRUG DISCRIMINATIONS. 003434 04-06

TRANCOPAL

A CONTROLLED STUDY COMPARING A THREE TIMES DAILY DOSE OF CHLORDIAZEPOXIDE WITH A SINGLE NIGHT-TIME DOSE OF TRANCOPAL IN THE CONTROL OF ANXIETY, USING A DOUBLE-BLIND, DOUBLE-

003537 04-10 A CONTROLLED STUDY OF TRANCOPAL IN THE TREATMENT OF SLEEP DISTURBANCES DUE TO ANXIETY.

003548 04-10 A CONTROLLED STUDY OF TRANCOPAL IN SLEEP DISTURBANCES DUE TO RHEUMATIC DISEASE.

TRANQUILIZER THE TURNOVER RATE OF GAMMA-AMINOBUTYRIC-ACID IN THE NUCLEI OF TELENCEPHALON: IMPLICATIONS IN THE PHARMACOLOGY OF ANTIPSYCHOTICS AND OF A MINOR TRANQUILIZER.

000192 01-03

NEW ASPECTS CONCERNING THE MECHANISM OF ACTION OF TRANQUILIZERS. THE INFLUENCE OF SOME TRANQUILIZERS ON PROTEIN AND NUCLEIC-ACID SYNTHESES.

000165 01-03 SOME CONTINGENCIES AFFECTING THE UTILIZATION OF TRANQUILIZERS IN LONG-TERM CARE OF THE ELDERLY.

000649 01-11 EFFECTS OF ADENINE-NUCLEOTIDES ON OXIDATION OF PHENOTHIAZINE

TRANQUILIZERS. 001059 02-03 PHARMACOLOGICAL INCOMPATIBILITY OF NEUROLEPTICS AND

TRANQUILIZERS WITH OTHER PREPARATIONS. 002680 03-15

TRANCHILLISERS

BABIES AND TRANQUILLISERS.

002535 03-11 TRANQUILLIZERS

USE OF DEPOT TRANQUILLISERS IN PSYCHIATRIC DISORDERS

PURCHASES OF HYPNOTICS, SEDATIVES AND MINOR TRANQUILLIZERS AMONG 2.566 INDIVIDUALS IN THE COUNTY OF JAMTLAND, SWEDEN: A 6-YEAR FOLLOW-UP

000940 01-17 MINOR TRANQUILLIZERS IN SOMATIC DISORDERS. 003633 04-14

TRANQUILLIZING NEGATIVE EFFECTS OF BICUCULLINE AND THIOSEMICARBAZIDE ON THE

TRANQUILLIZING ACTION OF DIAZEPAM. 001213 02-03

TRANS-SYNAPTIC TRANS-SYNAPTIC INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE FOLLOWING AMPHETAMINE TREATMENT IN THE RAT

TRANSCALLOSALLY TRANSCALLOSALLY EVOKED-POTENTIALS AND THE EEG IN THE DECEREBRATE DOG: ACTIONS OF TRYPTAMINERGIC, DOPAMINERGIC AND ADRENERGIC AGONISTS.

000223 01-03 TRANSCULTURAL TRANSCULTURAL ASPECTS OF PSYCHOPHARMACOLOGY.

001903 02-17 NOMIFENSIN IN THE TREATMENT OF DEPRESSION: A REPORT ON THE CANADIAN PART OF A TRANSCULTURAL STUDY. 002414 03-09

TRANSCUTANEOUS ANALGESIA FOLLOWING TRANSCUTANEOUS ELECTRICAL STIMULATION AND ITS PARTIAL REVERSAL BY A NARCOTIC ANTAGONIST 001646 02-13 TRANSECTED

000503 01-06

000587 01-09

000284 01-03

EFFECTS OF RETICULAR STIMULATION, D AMPHETAMINE AND SCOPOLAMINE ON ACETYLCHOLINE RELEASE FROM THE HIPPOCAMPUS OF BRAINSTEM TRANSECTED CATS. 000098 01-03

TRANSFER TRANSFER OF LITHIUM-IONS ACROSS THE ERYTHROCYTE MEMBRANE. 001658 02-13

EFFECT OF DIHYDROERGOTOXINE ON THALAMIC AND PYRAMIDAL EVOKED RESPONSES IN THE CAT UNDER TRANSIENT ISCHEMIA INFLUENCE OF TRANSIENT ISCHEMIA ON MONOAMINE METABOLISM IN

THE RAT BRAIN DURING NITROUS-OXIDE AND PHENOBARBITONE AMESTHESIA

TRANSIT EFFECT OF ANTIPARKINSONISM DRUGS ON GASTRIC EMPTYING AND

INTESTINAL TRANSIT IN THE RAT. 002010 03-03

DEVELOPMENT AND APPLICATION OF METHODS FOR DETERMINING THE BIOLOGICAL TRANSMETHIOLATIONS DEPENDENT ON S ADENOSYL-L-001641 02-13

TRANSMETHYLATION HYPOTHESIS: A REVIEW OF PROGRESS 002397 03-08 TRANSMETHYLATION HYPOTHESIS OF SCHIZOPHRENIA METHIONINE AND

NICOTINIC-ACID 002403 03-08

TRANSMISSION SECOND MESSENGER RESPONSES AND REGULATION OF HIGH AFFINITY RECEPTOR BINDING TO STUDY PHARMACOLOGICAL MODIFICATION OF GABAERGIC TRANSMISSION. (UNPUBLISHED PAPER).

000133 01-03 FFFECTS OF A AMINOPYRIDINE ON TRANSMISSION IN EXCITATORY AND INHIBITORY SYNAPSES IN THE SPINAL CORD.

THE EFFECT OF PANCURONIUM AND GALLAMINE ON MUSCARINIC TRANSMISSION IN THE SUPERIOR CERVICAL GANGLION.

002021 03-03 ROTATIONAL BEHAVIOUR AND C-GMP RESPONSES FOLLOWING MANIPULATION OF NIGRAL MECHANISMS WITH CHLORDIAZEPOXIDE: EVIDENCE FOR ENHANCEMENT OF GABA TRANSMISSION BY BENZODIAZEPINES.

EFFECTS OF PROSTAGLANDIN-E2 AND A PROSTAGLANDIN ENDOPEROXIDE ANALOGUE ON NEUROEFFECTOR TRANSMISSION IN THE RAT ANOCOCCYGEUS MUSCI F

EFFECT OF ALPHA-METHYLDOPA ON DOPAMINERGIC TRANSMISSION IN THE CORPUS-STRIATUM

002873 04-03 EFFECTS OF 4 AMINOPYRIDINE ON NEUROMUSCULAR TRANSMISSION 002991 04-03

BARBITURATE-INDUCED CHANGES IN TRANSMITTER RELEASE INDEPENDENT OF TERMINAL SPIKE CONFIGURATION IN THE FROG

NEUROMUSCULAR JUNCTION. 000294 01-03 THE EFFECTS OF NEOMYCIN UPON TRANSMITTER RELEASE AND ACTION. 000302 01-03

CENTRAL TRANSMITTER INVOLVEMENT IN LON-954-INDUCED TREMOROGENESIS.

RECEPTOR SENSITIVITY MODIFICATION (RSM) — A NEW PARADIGM FOR THE POTENTIAL TREATMENT OF SOME HORMONAL AND TRANSMITTER DISTURBANCES

001659 02-13 TRANSMITTERS NEUROPHARMACOLOGY OF AMINO-ACID INHIBITORY TRANSMITTERS 002967 04-03

TRANSPLANTABLE
REGULATION OF CATECHOLAMINE BIOSYNTHESIS IN A TRANSPLANTABLE

RAT PHEOCHROMOCYTOMA. 000071 01-03 TRANSPLANTATION

PSYCHIATRIC ILLNESS AND HUMAN RENAL TRANSPLANTATION 003510 04-09 SEROTONIN TRANSPORT AND STORAGE IN RABBIT BLOOD PLATELETS -

THE EFFECTS OF RESERPINE AND IMIPRAMINE 000236 01-03 EFFECT OF RESERPINE ON ADENOSINE UPTAKE AND METABOLISM, AND SUBCELLULAR TRANSPORT OF PLATELET ADENOSINE-TRIPHOSPHATE IN

WASHED RABBIT PLATELETS

EFFECT OF CHLORPROMAZINE ON L METHIONINE TRANSPORT IN THE RAT INTESTINE 000489 01-05

LITHIUM TRANSPORT IN RED BLOOD CELLS OF MANIC-DEPRESSIVE **PATIENTS** EFFECTS OF MORPHINE-SULFATE ON RENAL TRANSPORT PROCESSES. DISTRIBUTION OF CLOZAPINE IN THE RAT: EVIDENCE FOR ACTIVE TRANSPORT IN LUNG. EFFECTS OF SUBSTITUTED SPIROISOBENZOFURANPIPERIDINES ON SYNAPTOSOMAL BIOGENIC AMINE TRANSPORT. 602087 03-03
EFFECTS OF MORPHINE ON AXONAL TRANSPORT IN NIGROSTRIATAL HYPERTHERMIC EFFECTS OF SUPRACORTICALLY APPLIED
PROSTAGLANDINS AFTER SYSTEMIC PRETREATMENT WITH INHIBITORS
OF PROSTAGLANDIN TRANSPORT AND SYNTHESIS. 5 HYDROXYTRYPTAMINE AND DOPAMINE TRANSPORT BY RAT AND HUMAN BLOOD PLATELETS. LITHIUM TRANSPORT FROM CEREBROSPINAL FLUID. CHANGES IN SYNAPTIC FUNCTION INDUCED BY BLOCKAGE OF AXONAL TRANSPORT IN THE RABBIT OPTIC PATHWAY. THE EFFECT OF VILOXAZINE HYDROCHLORIDE ON THE TRANSPORT OF NORADRENALINE, DOPAMINE, 5 HYDROXYTRYPTAMINE AND GAMMA-AMINOBUTYRIC-ACID IN RAT BRAIN TISSUE. A KINETIC AND PHARMACOLOGIC ANALYSIS OF 5 HYDROXYTEYPTAMINE TRANSPORT BY HUMAN PLATELETS AND PLATELET STORAGE GRANULES; COMPARISON WITH CENTRAL SEROTONERGIC NEURONS. 003608 04-13 ELECTROPHORETIC ANALYSES OF PROTEINS TRANSPORTED TO THE RAT POSTERIOR PITUITARY. TRANXENE
CLINICAL REPORT OF THE DRUG TRANXENE (CLORAZEPATE-DIPOTASSIUM) TRANXENE TRANYLCYPROMINE

EFFECTS OF TRANYLCYPROMINE AND PARGYLINE ON BRAIN
TRYPTAMINE. NEUROLEPTIC DRUGS BLOCK BOTH THE HYPERACTIVITY AND THE INCREASE IN CAUDATE NUCLEUS CYCLIC-AMP CONCENTRATION PRODUCED BY THE ADMINISTRATION OF TRANYLCYPROMINE AND L-DOPA TO RATS EFFECTS OF SINGLE DOSES OF TRANYLCYPROMINE ON PLATELET MAD AND AMINE UPTAKE IN NORMAL SUBJECTS. TRASICOR

TRAZODONE BY INTRAVENOUS INFUSION IN DEPRESSIONS TO ORGANIC DISEASE.

001055 02-03 EFFECT OF PSYCHOTROPIC DRUGS ON ATPASE TRANSPORT OF THE SARCOPLASMIC RETICULUM IN RABBIT SKELETAL MUSCLES. 002093 03-03 002174 03-03 002928 04-03 002947 04-03 RETROGRADE AXONAL TRANSPORT OF NERVE GROWTH FACTOR IN THE CILIARY GANGLION OF THE CHICK AND THE RAT. LITHIUM-CARBONATE - CASE REPORT WITH ORAL LITHIUM-CARBONATE **FUNCTION AND PSYCHIC STATUS** 002920 04-03 A CONTROLLED COMPARATIVE TRIAL OF CLORAZEPATE (TRANXENE) AND DIAZEPAM (VALIUM) FOR ANXIETY. 002578 03-13 000279 01-03 THE CONTRIBUTION OF TRYPTAMINE TO THE BEHAVIOURAL EFFECTS OF L TRYPTOPHAN IN TRANYLCYPROMINE TREATED RATS. TRANYLCYPROMINE (PARNATE) -- A STUDY OF 1000 PATIENTS WITH SEVERE AGITATED DEPRESSIONS. 003507 04-09 003594 04-13 OXPRENOLOL (TRASICOR) POISONING. 001819 02-15 POST HEAD TRAUMA SYNDROME IN AN ADOLESCENT TREATED WITH LITHIUM-CARBONATE — CASE REPORT. 000560 01-09 CLINICAL EVALUATION OF TRAZODON. 002427 03-09 TRAZODONE
INHIBITION OF THE CENTRAL HYPOTENSIVE EFFECT OF CLONIDINE BY
TRAZODONE, A NOVEL ANTIDEPRESSANT.

O00286 LIMB REDUCTION ANOMALIES IN INFANTS BORN TO DISULFIRAM TREATED ALCOHOLIC MOTHERS.

A CONTROLLED CLINICAL STUDY OF TRAZODONE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH PRONOUNCED DEPRESSIVE SYMPTOMATOLOGY. 003472 04-08 N ACETYLTRANSFERASE ACTIVITY IN PINEAL GLAND OF RATS TREATED WITH PARGYLINE. 000046 01-03 PRODUCTION OF UNDERWEIGHT EMBRYOS IN RATS TREATED WITH BARBITURATES DURING PREGNANCY. 000072 01-03 INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH D.I CAFFEINE RESTORES FEEDING RESPONSE TO 2 DEOXY-D-GLUCOSE IN 6 HYDROXYDOPAMINE TREATED RATS. 000277 01-03 NEURONAL LIPOFUSCIN IN CENTROPHENOXINE TREATED RATS 000303 01-03 KINETIC STUDIES OF FOOD INTAKE AND SUCROSE SOLUTION PREFERENCE BY RATS TREATED WITH LOW DOSES OF DELTA9-TETRAHYDROCANNABINOL. 000324 01-04 EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON FEEDING IN INTACT AND 6 HYDROXYDOPAMINE TREATED RATS. 000378 01-04 FACILITATION OF MOUNTING BEHAVIOR BY DIHYDROTESTOSTERONE-PROPIONATE IN CASTRATED ESTRADIOL-BENZOATE TREATED MALE RATS FOLLOWING PUDENDECTOMY. 000403 01-04 A LONG-TERM FOLLOW-UP OF SCHIZOPHRENICS TREATED WITH 000526 01-08 POST HEAD TRAUMA SYNDROME IN AN ADOLESCENT TREATED WITH 000560 01-09 MANIA DURING MAINTENANCE HEMODIALYSIS SUCCESSFULLY TREATED 000582 01-09 AFFECTIVE-ILLNESS TREATED WITH LITHIUM: EFFECTS ON THYROID 000774 01-14 URINARY CARBON-DIOXIDE TENSION IN LITHIUM-CARBONATE TREATED 000882 01-15 PROFOUND HYPOTHERMIA IN MAMMALS TREATED WITH TETRAHYDROCANNABINOLS, MORPHINE, OR CHLORPROMAZINE 001140 02-03 ELECTROSHOCK ANTICONVULSANT ACTIVITY AND BRAIN ACTIVICHOLINE ALTERATIONS IN MICE TREATED WITH SELECT BENZODIAZEPINES. 001210 02-03 INCORPORATION OF RADIOACTIVE LABELLED CHOLINE AND PALMITATE INTO LUNG LECITHIN OF RABBITS TREATED WITH HIGH DOSES OF BROMCARBAMIDES, BARBITURATES AND DIAZEPAM. THE ROLE OF HYPOTHALAMIC SEROTONIN (5-HT) BEFORE OVULATION IN IMMATURE RATS TREATED WITH PREGNANT MARE SERUM (PMS). 001287 02-03 DIFFERENTIAL TOLERANCE TO INHIBITORY ACTION OF VARIOUS NEUROLEPTICS ON DEPRIVATION STIMULATED FOOD INTAKE IN RATS CHRONICALLY TREATED WITH HALOPERIDOL. 001398 02-04 VARIOUS EFFECTS OF D AMPHETAMINE IN RATS WITH SELECTIVE LESIONS OF BRAIN NORADRENALINE CONTAINING NEURONS OR TREATED WITH PENFLURIDOL. 001437 02-04 THYROID FUNCTION AND GROWTH HORMONE SECRETION IN AMITRIPTYLINE TREATED DEPRESSION. 001596 02-09 CEREBELLAR ATROPHY IN PHENYTOIN TREATED MENTALLY RETARDED EPILEPTICS. 001622 02-11 PERIPHERAL DIABETIC NEUROPATHY TREATED WITH AMITRIPTYLINE AND FLUPHENAZINE. 001705 02-14 COMPARISON OF THE EFFECTS OF NOCTRAN-10 ON HOSPITALIZED PATIENTS AND PATIENTS TREATED AT HOME. 001724 02-14 AGRANULOCYTOSIS IN PATIENTS TREATED WITH CLOZAPINE: A STUDY OF THE FINNISH EPIDEMIC. 001742 02-15 DELIBERATE POISONING WITH TRICYCLIC ANTIDEPRESSANTS TREATED IN AN INTENSIVE CARE UNIT.

OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINES IN L-DOPA TREATED PARKINSONIAN PATIENTS.

001758 02-15

001817 02-15

001994 03-03

000286 01-03 SECONDARY

WITH MELPERONE OR THIOTHIXENE

DIFFERENTIAL EFFECTS OF THE ANTIANDROGEN FLUTAMIDE ON ASPECTS OF SEXUAL BEHAVIOR IN CASTRATED, ANDROGEN TREATED MALE

002237 03-04 CLINICAL AND BIOCHEMICAL CHANGES IN PSYCHOTIC WOMEN TREATED

002388 03-08 CALCIUM METABOLISM IN LITHIUM TREATED PATIENTS: RELATION TO UNIPOLAR DICHOTOMY.

002420 03-09 ELEVATED MELATONIN SERUM CONCENTRATIONS IN PSYCHIATRIC PATIENTS TREATED WITH CHLORPROMAZINE.

002595 03-13 INFLUENCE OF TRYPTOPHAN ON MEMORY FUNCTIONS IN DEPRESSIVE PATIENTS TREATED WITH UNILATERAL ECT.

002613 03-14 EXTRAPYRAMIDAL REACTIONS IN ADOLESCENTS TREATED WITH HIGH-POTENCY ANTIPSYCHOTICS.

002654 03-15 OCCURRENCE OF A NEW CLASS OF TETRAHYDROISOQUINOLINE ALKALOIDS IN L-DOPA TREATED PARKINSONIAN PATIENTS

002655 03-15 INVESTIGATIONS OF CHILDREN OF MOTHERS TREATED IN PREGNANCY WITH ANTICONVULSANTS.

002701 03-15 EFFECTS OF DOPAMINE AGONISTS ON NEURONES IN THE CAUDATE NUCLEUS AND CEREBRAL-CORTEX OF CATS CHRONICALLY TREATED WITH NEUROLEPTICS.

002829 04-03 EFFECTS OF MORPHINE ON BRAINSTEM NEURONES IN NAIVE AND CHRONIC MORPHINE TREATED RATS, AND EFFECTS OF PCPA.

002841 04-03 SEXUAL DIFFERENTIATION OF OFFSPRING OF MOTHERS TREATED WITH CORTISONE DURING PREGNANCY

002879 04-03 NEUROTRANSMITTER MODULATION OF PROSTAGLANDIN-E1 STIMULATED INCREASES IN CYCLIC-AMP. II. CHARACTERIZATION OF A CULTURED NEURONAL CELL LINE TREATED WITH DIBUTYRYL-CYCLIC-AMP.

LITHIUM EFFECTS ON RAT BRAIN GLUCOSE METABOLISM IN LONG-TERM LITHIUM TREATED RATS STUDIED IN VIVO.

ALCOHOL CONSUMPTION IN RATS TREATED WITH LITHIUM-CARBONATE OR RUBIDIUM-CHI ORIDE

MOTILITY EFFECTS OF METHAMPHETAMINE IN RATS CHRONICALLY TREATED WITH MORPHINE

003162 04-04 BEHAVIOURAL EFFECTS OF METHYLPHENIDATE IN 6 HYDROXYDOPAMINE TREATED NEONATAL RATS.

003212 04-04 DELTAS-TETRAHYDROCANNABINOL ENHANCEMENT OF LORDOSIS BEHAVIOR IN ESTROGEN TREATED FEMALE RATS.

003230 04-04 PREFERENCE BEHAVIOR AND TASTE NERVE RESPONSES IN D PENICILLAMINE TREATED RATS.

003248 04-04 THE CONTRIBUTION OF TRYPTAMINE TO THE BEHAVIOURAL EFFECTS OF L TRYPTOPHAN IN TRANYLCYPROMINE TREATED RATS.

O03286 04-04
OPEN-FIELD AND LASHLEY III MAZE BEHAVIOUR OF THE OFFSPRING OF AMPHETAMINE TREATED RATS.

003315 04-04 SCHIZOPHRENIC-LIKE TENDENCIES IN RATS NEONATALLY TREATED WITH 6 HYDROXYDOPAMINE. (PH.D. DISSERTATION).

003323 04-04 TREATED WITH LOW PLASMA LEVELS OF CPZ IN PATIENTS CHRONICALLY NEUROLEPTICS.

003469 04-08 RELATIONSHIP BETWEEN SERUM CONCENTRATIONS OF THIORIDAZINE AND ITS MAIN NONCONJUGATED METABOLITES AND THE CLINICAL RESPONSE IN THIORIDAZINE TREATED PATIENTS

003480 04-09 HISTOCOMPATIBILITY ANTIGENS IN LITHIUM TREATED MANIC-

DEPRESSIVE PATIENTS ELECTROENCEPHALOGRAPHIC CONTROL WITH FREQUENCY ANALYSIS IN DEPRESSED PATIENTS TREATED WITH SAME.

GROWTH OF HYPERACTIVE CHILDREN TREATED WITH METHYLPHENIDATE. 003562 04-11

GROWTH HORMONE, PROLACTIN AND CORTISOL RESPONSES AND GROWTH PATTERNS IN HYPERKINETIC CHILDREN TREATED WITH DEXTROAMPHETAMINE. PRELIMINARY FINDINGS.

003569 04-11 IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLLACTIC-ACID (VLA) IN CEREBROSPINAL FLUID AND 3 METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN THE URINE OF PARKINSONIAN PATIENTS TREATED WITH L-DOPA. 003602 04-13 CLINICAL EFFECTS AND DRUG CONCENTRATIONS IN PLASMA AND CEREBROSPINAL FLUID IN PSYCHOTIC PATIENTS TREATED WITH FIXED DOSES OF CHLORPROMAZINE 003614 04-13

TREATING THE HEADACHE BY TREATING THE DEPRESSION.

000606 01-10 TREATING BLURRED VISION ASSOCIATED WITH ANTIPSYCHOTIC MEDICATION.

000810 01-15 COMBINED HALOPERIDOL AND LITHIUM-CAPRONATE IN TREATING MANIC PATIENTS.

COMPARISON OF TRIAZOLAM .25 MG AND FLURAZEPAM 15 MG IN TREATING GERIATRIC INSOMNIACS.

002524 03-11 USE OF MOOD-ALTERING DRUGS IN TREATING SEXUAL P 002780 03-17

TREATMENT

ALTERATIONS IN BRAIN 5 HYDROXYTRYPTAMINE METABOLISM DURING THE WITHDRAWAL PHASE AFTER CHRONIC TREATMENT WITH DIAZEPAM AND BROMAZEPAM

INFLUENCE OF CHRONIC PENTOBARBITAL OR MORPHINE TREATMENT ON THE INCORPORATION OF P32-PHOSPHORIC-ACID AND 3H CHOLINE INTO RAT SYNAPTIC PLASMA MEMBRANES.

000147 01-03 MAO ACTIVITY IN RAT BRAINSTEM AND CEREBRAL-CORTEX FOLLOWING ACUTE AND CHRONIC TREATMENT WITH L-DOPA AND ETHANOL L-

PHARMACOLOGICAL TREATMENT FOLLOWING EXPERIMENTAL CEREBRAL INFARCTION: IMPLICATIONS FOR UNDERSTANDING PSYCHOLOGICAL SYMPTOMS OF HUMAN STROKE

000243 01-03 TRANS-SYNAPTIC INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE FOLLOWING AMPHETAMINE TREATMENT IN THE RAT.

000284 01-03 THE EFFECTS OF ETHER STRESS AND BETAMETHASONE TREATMENT ON THE CONCENTRATIONS OF NORADRENALINE AND DOPAMINE IN VARIOUS REGIONS OF THE RAT BRAIN.

EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON SEROTONIN UPTAKE INTO RAT HYPOTHALAMIC SYNAPTOSOMES.

000293 01-03 INFLUENCE OF THE SUSPENSION OF CONTINUED TREATMENT WITH FLURAZEPAM AND AMOBARBITAL ON TWO DISCRIMINATION LEARNING SCHEDULES

000328 01-04 LONG-TERM BEHAVIOURAL AND BIOCHEMICAL EFFECTS FOLLOWING PROLONGED TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL)

000420 01-04

EVIDENCE FOR INCREASED APOMORPHINE SENSITIVE DOPAMINERGIC EFFECTS AFTER ACUTE TREATMENT WITH MORPHINE.

000449 01-04 HALOPERIDOL: EFFECT OF LONG-TERM TREATMENT ON RAT STRIATAL DOPAMINE SYNTHESIS AND TURNOVER.

000481 01-05 MOVEMENT DISORDERS INDUCED IN MONKEYS BY CHRONIC HALOPERIDOL TREATMENT.

000490 01-05 A DOUBLE-BLIND CONTROLLED STUDY OF CLOBAZAM FOR THE TREATMENT OF ANXIETY IN PSYCHIATRIC OUTPATIENTS.

000508 01-07 RHEOENCEPHALOGRAPHIC DATA IN MIGRAINE CEPHALGIA AND THEIR CHANGES DURING STUGERON TREATMENT.

MYTHS THEORIES AND TREATMENT OF SCHIZOPHRENIA

BACLOFEN TREATMENT IN CHRONIC SCHIZOPHRENIA: CLINICAL TRIAL. 000521 01-08

PRACTICE. 000529 01-08 LONG-TERM TREATMENT OF SCHIZOPHRENIA IN MEDICA PRACTICAL CONSIDERATIONS IN THE USE OF DEPOT NEUROLEPTICS FOR THE TREATMENT OF SCHIZOPHRENIA

000534 01-08

ANALYSIS OF THE IMPACT OF PHENOTHIAZINES AND RELATED DRUGS ON THE TREATMENT OF SCHIZOPHRENIA

000536 01-08 FLUPHENAZINE-DECANOATE, ORAL FLUPHENAZINE, AND PLACEBO IN TREATMENT OF REMITTED SCHIZOPHRENICS: II. RATING SCALE DATA. 000544 01-08

TREATMENT OF SCHIZOPHRENIC PSYCHOSES WITH LYORODIN.

PROPRANOLOL AS AN ADJUNCT TO THE TREATMENT OF SCHIZOPHRENIA.

000554 01-08 MIANSERIN IN THE PROPHYLACTIC TREATMENT OF BIPOLAR AFFECTIVE-ILLNESS.

•	pleci maex	
	THE IMPACT OF LITHIUM ON THE TREATMENT OF MANIC-DISORDERS.	DEPRESSIVE
	PLASMA CONCENTRATION AND THE ANTIDEPRESSANT EFF	000565 01-09 ECT OF
	LITHIUM AND THE TREATMENT OF ADOLESCENT MANIC-DE	000567 01-09 PRESSIVE
	TREATMENT OF MANIC PSYCHOSIS WITH CLOZAPINE.	000569 01-09
	PLASMA LEVELS DURING TREATMENT WITH IMPRAMINE, CLOMIPRAMINE, AND IMPRAMINE-N-OXIDE.	000575 01-09
	WIN-27147-2 IN THE TREATMENT OF DEPRESSION: AN UN CLINICAL STUDY.	000576 01-09 CONTROLLED
	TREATMENT OF DEPRESSION.	000577 01-09
	DEANOL IN THE TREATMENT OF TARDIVE-DYSKINESIA.	000579 01-09
		000588 01-09
	EFFECT OF CHLORPROMAZINE TREATMENT ON MONOAMIN LEVELS IN CEREBROSPINAL FLUID OF PSYCHOTIC PATIEN	TS. 000591 01-09
	LITHIUM PROPHYLAXIS IN THE TREATMENT OF CYCLOTHY/ TEENAGERS.	
	PIMOZIDE IN TREATMENT OF ANOREXIA-NERVOSA.	000601 01-10
	REPORT OF SUBCOMMITTEE ON THE TREATMENT OF DEPRE	
	DEPRESSION IN CHILDHOOD: DIAGNOSIS, TREATMENT, AN MODELS.	
	DOXEPIN IN THE TREATMENT OF NEUROSES: A COMPARAT STUDY OF DOXEPIN, CHLORDIAZEPOXIDE, HYDROXYZIN MEPROBAMATE, AND PHENOBARBITAL.	Ε,
	SUCCESSFUL TREATMENT OF ANOREXIA-NERVOSA WITH IN	000614 01-10 MIPRAMINE.
	SENILE-DEMENTIA: TREATMENT WITH DEANOL.	000617 01-10
	PSYCHOTROPIC AND ANTICONVULSANT DRUG USAGE IN E CHILDHOOD SPECIAL EDUCATION PROGRAMS III. A PREI	LIMINARY
	REPORT: PARENT INTERVIEWS ABOUT DRUG TREATMEN PLASMA CONCENTRATIONS OF PERPHENAZINE AND ITS SU METABOLITE DURING CONTINUOUS ORAL TREATMENT.	000627 01-11
	TREATMENT OF PARKINSONS DISEASE WITH THE COMBINAL CARBIDOPA.	000631 01-11 ATION L-DOPA/
	TREATMENT OF VASCULAR HEMIBALLISM AND HEMICHOR	000633 01-11
	NEUROTRANSMITTER PRECURSOR AMINO-ACIDS IN THE TE MULTIINFARCT DEMENTIA AND ALZHEIMERS DISEASE.	000637 01-11
	HALOPERIDOL IN THE TREATMENT OF STUTTERING.	000647 01-11
	REPORT FROM CLINICAL PRACTICE: THE REAL AND IDEAL OF STIMULANT DRUG TREATMENT OF HYPERACTIVE CHI (UNPUBLISHED PAPER).	
	PORPHYRIAS: NEUROLOGIC ASPECTS AND THE TREATMEN EXACERBATIONS.	000656 01-11 T OF
	COMPARING TREATMENT TACTICS WITH A HYPERACTIVE CHILD: STIMULANT MEDICATION AND PROGRAMMED T INTERVENTION.	000659 01-11 PRESCHOOL EACHER
	LITHIUM TREATMENT OF HUNTINGTONS-CHOREA: A PLACE CONTROLLED CLINICAL TRIAL.	000660 01-11 EBO-
	THE OFF-ON PHENOMENON DURING TREATMENT OF PARKI DISEASE WITH LEVODOPA.	000663 01-11 INSONS
	TREATMENT OF SPASMODIC TORTICOLLIS WITH AMANTAI DOUBLE-BLIND STUDY.	000664 01-11 DINE: A
	CLINICAL EFFECTS OF TREATMENT WITH CHLORPROMAZIN PHARMACOKINETIC AND PHARMACODYNAMIC PARAM	ETERS.
	THE RELATIVE EFFICACY OF METHYLPHENIDATE (RITALIN) MODIFICATION TECHNIQUES IN THE TREATMENT OF A H CHILD.	000670 01-11 AND BEHAVIOR YPERACTIVE
	THE USE OF PSYCHEDELIC DRUGS IN THE TREATMENT OF S DISTURBED CHILDREN: A REVIEW.	000671 01-11 SEVERELY
		000678 01-12

Psychopharmacology Abstracts

Psychopharmacology	Abstracts
ROUTINE NORTRIPTYLINE LEVELS IN TREATMENT OF DEPRE	SSION.
PLASMA PROLACTIN DURING LITHIUM TREATMENT.	000715 01-13
PLASMA ALDOSTERONE AND MAGNESIUM IN SERUM AND DURING LITHIUM TREATMENT.	URINE
PLASMA LEVELS OF CHLORPROMAZINE: EFFECT OF AGE, C DISEASE, AND DURATION OF TREATMENT.	000725 01-13 HRONICITY OF
TREATMENT OF SENILE PSYCHOSES WITH DISTRANEURIN A	
MULTICLINIC CROSS-OVER COMPARISON OF TRIAZOLAM (PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA ANXIETY IN ANXIOUS OUTPATIENTS.	000749 01-14 HALCION) AND A AND
LONG-TERM TREATMENT WITH NEUROLEPTIC DRUGS.	000762 01-14
WITHDRAWAL OF A STIMULANT DRUG AND CONCURRENT INTERVENTION IN THE TREATMENT OF A HYPERACTIVE (
NALTREXONE AND CYCLAZOCINE: A CONTROLLED TREATM	000780 01-14
UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: V OTH TREATMENT AND PREVENTION.	000804 01-15 ER DRUGS,
THE DIAGNOSIS AND TREATMENT OF LITHIUM TOXICITY.	000830 01-15
PROFOUND HYPOTHERMIA ON COMBINED LITHIUM-CARBO DIAZEPAM TREATMENT.	000838 01-15 NATE AND
ADVERSE EFFECTS OF LITHIUM TREATMENT.	000870 01-15
DRUG TREATMENT IN THE ELDERLY.	000874 01-15
ELECTROCARDIOGRAPHIC FINDINGS IN PATIENTS UNDERGO	000907 01-15 ING
AMITRIPTYLINE TREATMENT. A DIAGNOSTIC TREATMENT MODEL FOR EFFECTIVE GROUP OF DRUG ABUSERS.	000912 01-15 TREATMENT
HEROIN IN THE TREATMENT OF MORPHINE ADDICTION.	000950 01-17
NEW TREATMENT FOR HEADACHE: PATHOPHYSIOLOGIC CONSIDERATIONS.	000959 01-17
LITHIUM TREATMENT OF CYCLICAL VOMITING IN A MENT/ PATIENT.	000961 01-17 ALLY DEFECTIVE
PROPOXYPHENE-NAPSYLATE (DARVON-N OR PN) IN THE THEROIN DEPENDENCE.	000977 01-17 REATMENT OF
TREATMENT OF PRISONERS IN ENGLANDS JAILS.	000979 01-17
S ADENOSYL-L-METHIONINE (SAME) TREATMENT IN	000997 01-17
GERONTOPSYCHIATRY: A CONTROLLED CLINICAL STUDY AGED PATIENTS.	IN DEPRESSED 001045 02-03
EFFECTS OF PERINATAL 6 HYDROXYDOPAMINE TREATMEN RECEPTOR DISTRIBUTION IN ADULT BRAIN.	T ON OPIATE
ALTERATIONS IN DOPAMINE RECEPTOR SENSITIVITY BY CHETHANOL TREATMENT.	
CALCIUM CONTENT AND BINDING IN SYNAPTOSOMAL SUBDURING CHRONIC MORPHINE TREATMENT.	
COMPARISON OF BEHAVIORAL SUPERSENSITIVITY TO APO AFTER FLUPHENAZINE-DIHYDROCHLORIDE AND FLUPHEN DECANOATE TREATMENT IN RATS.	
TOLERANCE TO STEREOTYPED BEHAVIOUR AND TO DECREASTRIATAL HOMOVANILLIC-ACID LEVELS AFTER REPEATE	001484 02-04 ASE IN D TREATMENT
WITH APOMORPHINE-DIPIVALOYL-ESTER.	001497 02-04
FENFLURAMINE: CUMULATIVE NEUROTOXICITY AFTER CHR TREATMENT WITH LOW DOSAGES IN THE RAT.	ONIC 001508 02-05
A CONTROLLED STUDY OF WIN-27147-2 IN THE TREATMENT DEPRESSION.	NT OF 001544 02-07
TREATMENT OF CHRONIC SCHIZOPHRENICS WITH THE ORAN NEUROLEPTIC PENFLURIDOL IN AN OPEN STUDY.	L LONG-TERM
CHOICE OF MEDICAL TREATMENT IN SCHIZOPHRENIA.	001563 02-08
LONG-TERM TREATMENT OF SCHIZOPHRENIA WITH PENFLU	
LITHIUM IN THE TREATMENT OF A CHILD ABUSER.	001565 02-08

PLASMA ALDOSTERONE DURING LITHIUM TREATMENT.

001599 02-09 A DOUBLE-BLIND CLINICAL COMPARISON OF AMOXAPINE. IMIPRAMINE AND PLACEBO IN THE TREATMENT OF DEPRESSION

001609 02-09 THE TREATMENT OF TARDIVE-DYSKINESIA WITH PENFLURIDOL

001618 02-11 PLACE OF CHLORMETHIAZOLE IN TREATMENT OF ALCOHOLICS

001621 02-11 RELATIVE EFFICACY OF PARENTERAL HALOPERIDOL AND THIOTHIXENE FOR THE EMERGENCY TREATMENT OF ACUTELY EXCITED AND AGITATED PATIENTS

001626 02-11 EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 2. BIOCHEMICAL ANALYSIS.

001652 02-13 RECEPTOR SENSITIVITY MODIFICATION (RSM) — A NEW PARADIGM FOR THE POTENTIAL TREATMENT OF SOME HORMONAL AND TRANSMITTER

001659 02-13 CYCLIC-AMP IN THE PLASMA OF CHRONIC SCHIZOPHRENICS. BEFORE AND AFTER TREATMENT.

001690 02-13 NALOXONE (NARCAN) TREATMENT IN DEPRESSION: CLINICAL **OBSERVATIONS AND EFFECTS ON CSF ENDORPHINS AND MONOAMINE** METAROLITES

001692 02-13 EFFECT OF CHLORPROMAZINE TREATMENT ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC PATIENTS 001694 02-13

EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 1. CLINICAL ANALYSIS

001704 02-14 BIOFEEDBACK TREATMENT OF TARDIVE-DYSKINESIA: TWO CASE REPORTS

001739 02-15 SEX DIFFERENCES IN RESPONSE TO DRUG TREATMENT

001743 02-15 OBSERVATIONS ON THE TREATMENT OF PHENCYCLIDINE (PCP) POISONING

001745 02-15 SEVERE MEPROBAMATE POISONING: SUCCESSFUL TREATMENT WITH HEMOPERFUSION

001764 02-15 A CASE OF ORAL DYSKINESIA ASSOCIATED WITH IMIPRAMINE TREATMENT.

001768 02-15 ON THE SAFETY OF LONG-TERM TREATMENT WITH LITHIUM 001775 02-15

CHLORPROMAZINE PLUS THIORIDAZINE POISONING AND TREATMENT WITH EXTRACORPOREAL DIALYSIS.

001806 02-15 A SEVEN YEAR REVIEW OF COMA PATIENTS ADMITTED TO THE REGIONAL POISONING TREATMENT CENTRE, ROYAL INFIRMARY.

001821 02-15 THE TREATMENT OF TARDIVE-DYSKINESIA.

001831 02-15 GONADAL MORPHOLOGY IN SCHIZOPHRENIC PATIENTS UNDER PSYCHOTROPIC TREATMENT.

001832 02-15 PHYSOSTIGMINE TREATMENT OF ANTICHOLINERGIC POISONING

001843 02-15 TREATMENT OF PHENOTHIAZINE OVERDOSAGE WITH PHYSOSTIGMINE 001844 02-15

CONTROLLED COMPARISON OF TRIFLUOPERAZINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY.

001848 02-15 DESIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF DIVIDED VS SINGLE DOSE ADMINISTRATION.

001855 02-16 PERSPECTIVES IN THE TREATMENT OF THE PSYCHONEUROLOGICAL DISORDERS: AFFECTIVE-DISORDERS. (UNPUBLISHED PAPER)

001870 02-16 TOWARD AN EGO-ORIENTED APPROACH TO THE STUDY OF THE EFFECTS OF PSYCHOACTIVE MEDICATION IN THE TREATMENT OF CHILDREN 001875 02-16

TREATMENT OF PATIENTS WITH DELAYED NEUROLEPTICS. 001921 02-17

A COMPARISON OF FOOD INTAKE SUPPRESSION PRODUCED BY GIVING AMPHETAMINE AS AN AVERSION TREATMENT VERSUS AS AN ANOREXIC TREATMENT

001981 03-03 DOES LONG-TERM TREATMENT WITH AMITRIPTYLINE ALTER THE MONOAMINE-OXIDASE OF RAT BRAIN?.

002042 03-03 BRAIN NEUROTRANSMITTER RECEPTORS AND CHRONIC ANTIPSYCHOTIC DRUG TREATMENT: A MODEL FOR TARDIVE-DYSKINESIA 002061 03-03 ALTERATIONS OF EEG ACTIVITIES AND COCAINE-INDUCED CONVULSIONS FOLLOWING PROLONGED COCAINE TREATMENT IN THE RHESUS MONKEY.

002091 03-03 CHRONIC TREATMENT WITH DESIPRAMINE CAUSED A SUSTAINED DECREASE OF 3,4 DIHYDROXYPHENYLGLYCOL-SULFATE AND TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT BRAIN 002113 03-03

PRESYNAPTIC DOPAMINE RECEPTORS: DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING TREATMENT WITH FLUPHENAZINE.

002120 03-03 METABOLISM OF 5 HYDROXYTRYPTAMINE AND LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS IN RAT BRAIN AFTER ACUTE AND CHRONIC

002169 03-03 BEHAVIOURAL CORRELATES OF MODIFIED DOPAMINERGIC ANTICHOLINERGIC RESPONSES FOLLOWING CHRONIC TREATMENT WITH NEUROLEPTIC AGENTS OF DIFFERING ACTIVITY SPECTRA.

BEHAVIOURAL SPECIFIC TOLERANCE FOLLOWING CHRONIC D OR L
AMPHETAMINE TREATMENT. LACK OF INDICATE OF THE CONTROL OF T AMPHETAMINE TREATMENT: LACK OF INVOLVEMENT OF HYDROXYNOREPHEDRINE.

002261 03-04 THE EFFECT OF CHRONIC ETHANOL TREATMENT ON BEHAVIOUR AND CENTRAL MONOAMINES IN THE RAT. 002271 03-04

EFFECT OF P-CHLOROPHENYLALANINE (PCPA) AND PHENYLALANINE TREATMENT ON EARLY AUDITORY EVOKED RESPONSES IN RATS 002304 03-04

ADULT BEHAVIOR AND ADRENOCORTICAL FUNCTION FOLLOWING NEONATAL MORPHINE TREATMENT IN RATS. 002310 03-04

EFFECTS OF IMIPRAMINE TREATMENT OF SEPARATION-INDUCED SOCIAL DISORDERS IN RHESUS MONKEYS.

002316 03-04
INCREASED HALOPERIDOL-INDUCED CATALEPSY AFTER CHRONIC COCAINE TREATMENT

002341 03-05 VILOXAZINE IN THE TREATMENT OF DEPRESSION: PSYCHOPHYSICAL MEASURES AND CLINICAL RESPONSE

002375 03-07 -003-01 IN THE TREATMENT OF DEPRESSION: PLASMA LEVELS AND THERAPEUTIC RESPONSE

CLINICAL TRIAL OF BUPROPION-HCL IN TREATMENT OF DEPRESSION.
002381 03-07 A NEW APPROACH TO THE HORMONAL TREATMENT OF IMPOTENTIA-

002386 03-07 A DOUBLE-BLIND CONTROLLED STUDY OF PIPOTHIAZINE-PALMITATE IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS.

002390 03-08 PENFLURIDOL IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS NEWLY DISCHARGED FROM A BRIEF THERAPY UNIT.

002391 03-08 THREE YEARS MAINTENANCE NEUROLEPTIC TREATMENT IN SCHIZOPHRENIA -- BEFORE AND BEYOND.

HOW SCHIZOPHRENIC PATIENTS CHANGE DURING 3 YEARS TREATMENT WITH DEPOT NEUROLEPTICS. 002393 03-08

EEG RECORDS AND THE EFFECTS OF PHENOTHIAZINE TREATMENT IN PATIENTS WITH PARANOID SCHIZOPHRENIA. 002394 03-08

SERVICES FOR SCHIZOPHRENICS: A LIFELONG APPROACH TO TREATMENT

002398 03-08 NOMIFENSIN IN THE TREATMENT OF DEPRESSION: A REPORT ON THE CANADIAN PART OF A TRANSCULTURAL STUDY.

002414 03-09 NOMIFENSIN IN THE TREATMENT OF DEPRESSION: A STANDARD-CONTROLLED CLINICAL STUDY.

002415 03-09 DOXEPIN AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION: A DOUBLE-BLIND CROSS-OVER CLINICAL STUDY WITH EKG RECORDIN 002416 03-09 DEPRESSION: BIOLOGY PSYCHODYNAMICS, AND TREATMENT

002425 03-09 DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF BUPROPION-HYDROCHLORIDE (WELLBATRIN) IN THE TREATMENT OF DEPRESSED

THE EFFECT OF DEPRESSION AND ITS TREATMENT ON SERUM THYROXINE.
002436 03-09 INFUSIONS. 002439 03-09 TREATMENT OF DEPRESSIVE SYNDROME WITH NOVERIL

TRIMIPRAMINE IN THE TREATMENT OF ANXIOUS DEPRESSED **OUTPATIENTS**

002456 03-09

ENHANCEMENT OF THE ANTIDEPRESSANT RESPONSE TO L TRYPTOPHAN BY A LIVER PYRROLASE INHIBITOR: A RATIONAL TREATMENT TRIMIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF SINGLE VS. DIVIDED DOSE ADMINISTRATION. THE TREATMENT OF DEPRESSION COMPARING DIVIDED AND SINGLE DOSES OF MAPROTILINE (LUDIOMIL). 002467 03-09 TREATMENT OF OBSESSIVE-COMPULSIVE NEUROSIS WITH CLOMIPRAMINE (ANAFRANIL) CLINICAL EXPERIENCE IN THE TREATMENT OF OBSESSIONAL STATES (1).

O02477 03-10
ON THE TREATMENT OF NEURODERMATITIS WITH A MONOAMINEOXIDASE INHIBITOR: THE CHEMOTHERAPY OF PSYCHOSOMATIC
ILLNESS THROUGH A-REM SUPPRESSION. AN UNCONTROLLED TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF PHOBIC AND OBSESSIONAL STATES IN GENERAL 002481 03-10 CLINICAL EXPERIENCE IN THE TREATMENT OF PHOBIC DISORDERS 002485 03-10 CLINICAL EXPERIENCE IN THE TREATMENT OF OBSESSIONAL STATES (2).
002489 03-10 A COMPARISON OF CLOMIPRAMINE HYDROCHLORIDE (ANAFRANIL) AND BEHAVIOUR THERAPY IN THE TREATMENT OF OBSESSIVE NEUROSIS. 002492 03-10 MAPROTILINE AND DOXEPIN IN THE TREATMENT OF DEPRESSION: A
DOUBLE-BLIND MULTICENTRE COMPARISON. 002495 03-10

A CLINICAL TRIAL OF CLOMIPRAMINE AND DIAZEPAM IN THE TREATMENT OF PHOBIC AND OBSESSIONAL ILLNESS. 002497 03-10 STATE-TRAIT ANXIETY AND ANXIOLYTIC TREATMENT 002500 03-10 CLONAZEPAM IN THE TREATMENT OF EPILEPSY IN HANDICAPPED PATIENTS. 002503 03-11 AZAPHEN IN THE TREATMENT OF ENURESIS IN CHILDREN

SOMATOSENSORY EVOKED-POTENTIALS IN PATIENTS WITH PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND DECARBOXYLASE

002515 03-11 EPILEPSY IN CHILD PSYCHIATRY. EFFECTS OF TREATMENT BY DIPROPYLACETIC-ACID. 002517 03-11

COMBINED TREATMENT WITH L-DOPA AND PARCOPAN IN PARKINSONS

002518 03-11 NARCOLEPSY: DIAGNOSIS AND TREATMENT. (UNPUBLISHED PAPER). 002522 03-11
TREATMENT OF HUMAN AGGRESSIVE BEHAVIOR: FOUR CASE STUDIES OF

THE EFFECT OF LITHIUM. 002532 03-11

A BEHAVIORAL TREATMENT OF DEPRESSION WITH ALCOHOLICS RECEIVING PHARMACOLOGICAL AVERSIVE CONDITIONING. (Ph.D. DISSERTATION).

ALTERATIONS OF CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC-ACID, AND TOTAL BLOOD SEROTONIN CONTENT DURING CLOZAPINE TREATMENT. L TRYPTOPHAN AND 5 HYDROXYTRYPTOPHAN IN THE TREATMENT OF DEPRESSION: A REVIEW.

002552 03-13 LITHIUM-CARBONATE AND BRAIN FUNCTION: 1. CEREBRAL EVOKED-POTENTIALS, EEG, AND SYMPTOM CHANGES DURING LITHIUM-CARBONATE TREATMENT.

002560 03-13 PLASMA CONCENTRATIONS OF CLOMIPRAMINE AND ITS N DESMETHYL METABOLITE IN DEPRESSIVE PATIENTS FOLLOWING TREATMENT WITH VARIOUS DOSAGE REGIMES OF CLOMIPRAMINE.

002568 03-13 PLASMA RENIN SUBSTRATE DURING LITHIUM TREATMENT

002569 03-13 TIME-COURSE OF CHANGES IN EEG AND POWER SPECTRA DURING TREATMENT WITH NEUROLEPTICS.

002570 03-13 HYPERACTIVE CHILDRENS UNDERUSE OF LEARNING TIME: CORRECTION BY STIMULANT TREATMENT

002614 03-14 THE ALPHA SPECTRUM IN SCHIZOPHRENIC PATIENTS DUE TO PSYCHOPHARMACOLOGICAL TREATMENT AND DIFFERENT SOCIOCULTURAL SETTINGS.

002636 03-14 RAMPANT DENTAL CARIES IN THE TREATMENT OF DEPRESSION. 002648 03-15

Psychopharmacology Abstracts

GUIDELINES FOR AGENTS USED IN THE TREATMENT OF POISONINGS 002652 03-15 HEMOPEREUSION IN TREATMENT OF DRUG INTOXICATION

002656 03-15 THE PROBLEM OF PRENATAL DAMAGE FROM LONG-TERM ANTIEPILEPTIC DRUG TREATMENT.

002659 03-15 A TREATMENT FOR DRY MOUTH IN PSYCHIATRIC PATIENTS

002661 03-15 MANTADINE IN THE TREATMENT OF BENZTROPINE REFRACTORY
EXTRAPYRAMIDAL DISORDERS INDUCED BY ANTIPSYCHOTIC DRUGS

002664 03-15 NOL, LITHIUM AND PLACEBO IN THE TREATMENT OF TARDIVE-DYSKINESIA.

002677 03-15 DRUG DEPENDENCE IN PROPRANOLOL TREATMENT OF MIGRAINE

HYPERTHYROIDISM AND A PARATHYROID ADENOMA COMPLICATING LITHIUM TREATMENT.

002686 03-15 PRIOR PSYCHIATRIC TREATMENT AND THE DEVELOPMENT OF BREAST CANCER.

002691 03-15 EKG EFFECTS OF IMIPRAMINE TREATMENT IN CHILDREN

002696 03-15 FOUR-YEAR TREATMENT OF PATIENTS WITH PARKINSONISM USING AMANTADINE ALONE OR WITH LEVODOPA.

002707 03-15 ACUTE BRAIN SYNDROME AFTER PROPRANOLOL TREATMENT 002708 03-15

HYPOTONIC CIRCULATORY DISORDERS UNDER
PSYCHOPHARMACOTHERAPY -- TREATMENT WITH 9ALPHA-**FLUOROHYDROCORTISONE**

002710 03-15 THE EFFECTS OF ONE-DAY TREATMENT OF ANXIETY WITH HIGH DOSES OF HALAZEPAM.

002718 03-16 IMPOTENCE: ROLE OF DRUG AND HORMONAL TREATMENT

002759 03-17 CLINICAL EVALUATION OF NALTREXONE TREATMENT OF OPINITE-DEPENDENT INDIVIDUALS: REPORT OF THE NATIONAL RESEARCH COUNCIL COMMITTEE ON CLINICAL EVALUATION OF NARCOTIC ANTAGONISTS.

002768 03-17 TREATMENT OF DYSKINETIC AND CHOREATIC MOVEMENT DISORDERS IN

002776 03-17 THE USE OF A CHECKLIST IN OBTAINING INFORMED-CONSENT FOR TREATMENT WITH MEDICATION

REGIONAL SENSITIVITY OF PRIMATE BRAIN DOPAMINERGIC NEURONS TO HALOPERIDOL: ALTERATIONS FOLLOWING CHRONIC TREATMENT

602812 04-00

FFECT OF CHRONIC TREATMENT WITH NEUROLEPTICS ON THE CONTENT OF 3,5 CYCLIC-GUANOSINE-MONOPHOSPHATE IN CEREBELLAR-CORTEX OF RATS. 002812 04-03

002827 04-03

BIOCHEMICAL AND MORPHOLOGICAL EFFECTS OF TESTOSTERONE TREATMENT ON DEVELOPING SYMPATHETIC NEURONS. 002894 04-03

MOUSE BRAIN TYROSINE-HYDROXYLASE AND GLUTAMIC-ACID-DECARBOXYLASE FOLLOWING TREATMENT WITH ADRENOCORTICOTROPHIC HORMONE, VASOPRESSIN OR CORTICOSTERONI

002898 04-03 RAT STRIATAL METHIONINE-ENKEPHALIN CONTENT AFTER CHRONIC TREATMENT WITH CATALEPTOGENIC AND NONCATALEPTOGENIC ANTISCHIZOPHRENIC DRUGS.

002953 04-03 EVIDENCE FOR CELL LOSS IN CORPUS-STRIATUM AFTER LONG-TERM TREATMENT WITH A NEUROLEPTIC DRUG (FLUPENTHIXOL) IN RATS 003030 04-03

TIME-COURSE OF THE INCREASE IN GABA LEVEL IN DIFFERENT MICE BRAIN REGIONS FOLLOWING N DIPROPYLACETATE TREATMENT. 003091 04-03

DEPRENIL: LOSS OF SELECTIVITY FOR INHIBITION OF B-TYPE MAO AFTER REPEATED TREATMENT.

003131 04-03 RADIOIMMUNOASSAY OF ENKEPHALINS: REGIONAL DISTRIBUTION IN RAT BRAIN AFTER MORPHINE TREATMENT AND HYPOPHYSECTOMY 003136 04-03

BEHAVIORAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC NARCOTIC TREATMENT IN THE GUINEA-PIG.

003183 04-04 SUPPRESSION OF LOCOMOTOR ACTIVITY IN SPARROWS BY TREATMENT WITH MELATONIN.

003243 04-04 HYPOTENSION AND THIRST IN RATS AFTER ISOPROTERENOL TREATMENT 003245 04-04 ABATEMENT OF STIMULUS PERSERVATION FOLLOWING REPEATED D
AMPHETAMINE TREATMENT: ABSENCE OF BEHAVIORALLY
AUGMENTED TOLERANCE.
003260 04-04

SUBAMNESIC CYCLOHEXIMIDE TREATMENT DELAYS CONSOLIDATION IN MICE.

INHIBITION OF 5,7 DIHYDROXYTRYPTAMINE-INDUCED SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN MICE BY TREATMENT WITH CYCLOHEXIMIDE.

THE DISCRIMINABILITY OF NALOXONE IN RATS DEPENDS ON CONCOMITANT MORPHINE TREATMENT

EFFECT OF CHRONIC COCAINE TREATMENT ON LIMITED ACCESS FOOD

PIRROXAN IN THE TREATMENT OF THE NEUROVEGETATIVE COMPONENT OF THE DEPRESSIVE SYNDROME.

THE TREATMENT OF ANXIETY WITH A POLYFLUORINATED BENZODIAZEPINE DERIVATIVE.

TREATMENT OF LEUKOPENIA WITH LITHIUM-CARBONATE: A
PRELIMINARY REPORT.

PRELIMINARY REPORT.

00344B 04-07

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. A

STUDY WITH THE LONG-ACTING THIOXANTHENE DERIVATIVE, CIS-

STUDY WITH THE LONG-ACTING THIOXANTHERE DERIVATIVE, CIS-CLOPENTHIXOL-DECANOATE SORDINOL DEPOT. 003454 04-08

MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA.

003460 04-08

CONTEMPORARY VIEWS ON THE ROLE OF NEUROLEPTICS IN THE TREATMENT OF SCHIZOPHRENIA AND THEIR ACTION IN THE CENTRAL-NERVOUS-SYSTEM.

BUTACLAMOL IN THE TREATMENT OF SCHIZOPHRENIA. A STANDARD-CONTROLLED CLINICAL TRIAL.

A COMPARISON OF THE RELATIVE EFFICACY OF SERENACE AND CHLORPROMAZINE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.

CLINICAL STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE CONDITIONS IN OUTPATIENT PRACTICE.

003479 04-09
TRYPTOPHAN NICOTINAMIDE COMBINATION IN THE TREATMENT OF
NEWLY ADMITTED DEPRESSED PATIENTS.

003487 04-09
RETROSPECTIVE DIAGNOSIS OF HYPOMANIA FOLLOWING SUCCESSFUL
TREATMENT OF EPISODIC VIOLENCE WITH LITHIUM: A CASE REPORT.
003490 04-09

PSYCHOPHARMACOLOGIC TREATMENT OF DEPRESSION IN PRIVATE PRACTICE.

TREATMENT OF DEPRESSION WITH DRUGS. 003494 04-09

003500 04-09
TRICYCLIC ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIONS: A
DOUBLE-BLIND CLINICAL COMPARISON OF CLOMIPRAMINE
(ANAFRANIL) AND AMITRIPTYLINE.

003501 04-09
TREATMENT OF ENDOGENOUS DEPRESSION WITH ORAL THYROTROPINRELEASING HORMONE AND AMITRIPTYLINE.

TREATMENT OF IMIPRAMINE RESISTANT DEPRESSION AND LITHIUM REFRACTORY MANIA THROUGH DRUG INTERACTIONS.

L-DOPA TREATMENT OF REACTIVE STUPOROUS STATES. 003512 04-09

O03513 04-09
A COMPARATIVE CLINICAL TRIAL OF MIANSERIN (NORVAL) AND
AMITRIPTYLINE IN THE TREATMENT OF DEPRESSION IN GENERAL
PRACTICE

A CASE OF DEPRESSION SHOWING IMPROVEMENT IN TRH TEST BY COMBINED TREATMENT BY DIMETACRINE-TARTRATE AND THYROID

003527 04-09

LITHIUM IN THE TREATMENT OF PERIODIC CATATONIA: A CASE REPORT.

003530 04-09
NABILONE, A CANNABINOID, IN THE TREATMENT OF ANXIETY: AN OPEN-LABEL AND DOUBLE-BLIND STUDY.

EFFECTIVENESS OF SCH-12679, A BENZAZEPINE, IN THE TREATMENT OF ANXIETY NEUROSIS.

TREATMENT OF OBSESSIVE HOMOSEXUAL PEDOPHILIC FANTASIES WITH MEDROXYPROGESTERONE-ACETATE. 003543 04-10

LOXAPINE IN NEUROTIC ANXIETY: SOME MODIFIERS OF TREATMENT RESPONSE.

A CONTROLLED STUDY OF TRANCOPAL IN THE TREATMENT OF SLEEP DISTURBANCES DUE TO ANXIETY.

O03548 04-10
SODIUM VALPROATE IN THE TREATMENT OF INTRACTABLE SEIZURE
DISORDERS: A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY.

003550 04-11
PHARMACOLOGICAL TREATMENT OF DEVIANT SEXUAL BEHAVIOUR.
003552 04-11
HYPERACTIVE CHILDRENS KNOWLEDGE AND ATTITUDES CONCERNING

DRUG TREATMENT.

SOMATOSTATIN IN THE TREATMENT OF PATIENTS WITH

EXTRAPYRAMIDAL DISORDERS AND PATIENTS WITH EEG ABNORMALITIES. 003557 04-11

MEDICATION IN RESIDENTIAL TREATMENT: ADMINISTRATION AND
CLINICAL EXPERIENCES.

003561 04-11

LISURID (LYSENYL-SPOFA) IN THE TREATMENT OF ORGANIC PSYCHOSYNDROME IN INVOLUTION.

PROPHYLACTIC LITHIUM TREATMENT OF DRUG ABUSE. 003563 04-11

003564 04-11 SODIUM VALPROATE IN THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA.

003568 04-11
TREATMENT OF ALCOHOLISM WITH PSYCHOTOMIMETIC DRUGS. A
FOLLOW-UP STUDY

O03570 04-11
TREATMENT OF THE ALCOHOLIC ORGANIC-BRAIN-SYNDROME WITH EMD21657. A DERIVATIVE OF A PYRITINOL METABOLITE: DOUBLE-BLIND
CLINICAL, QUANTITATIVE EEG, AND PSYCHOMETRIC STUDIES.

A COMPARISON OF THE EFFICACY AND ACCEPTABILITY OF TWO FORMULATIONS OF INJECTABLE SERENACE IN THE TREATMENT OF STATES OF SYCTEMARKET

THE BEHAVIORAL SYMPTOMS OF HYPERKINETIC CHILDREN WHO SUCCESSFULLY RESPONDED TO STIMULANT DRUG TREATMENT.

003579 04-11
STUDY OF THE TREATMENT OF VASCULAR PARKINSONS DISEASE WITH
METAMIZYL.

MEDICAL TREATMENT OF MENTAL ILLNESS.

O03618 04-14
DELIRIUM-TREMENS: A DOUBLE-BLIND COMPARISON OF DIAZEPAM AND
BARBITAL TREATMENT.

003632 04-14
LARYNGEAL PHARYNGEAL DYSTONIA AS A POSSIBLE CAUSE OF
ASPHYXIA WITH HALOPERIDOL TREATMENT.

O03654 04-15
TARDIVE-DYSKINESIA DURING AND FOLLOWING TREATMENT WITH
HALOPERIDOL, HALOPERIDOL BIPERIDEN, THIORIDAZINE, AND
CLOZAPINE

003656 04-15
PRIOR PSYCHIATRIC TREATMENT AND THE DEVELOPMENT OF BREAST
CANCER

003674 04-15
TRICYCLIC OVERDOSE IN A PATIENT GIVEN COMBINED TRICYCLIC MAOI
TREATMENT.

DRUG TREATMENT OF MIGRAINE AND ITS VARIANTS. 003695 04-17

THE COMPARATIVE EFFICACY OF COGNITIVE THERAPY AND PHARMACOTHERAPY IN THE TREATMENT OF DEPRESSIONS.

HEROIN AND OTHER HUMANISTIC TREATMENT FOR THE TERMINALLY ILL.
003703 04-17

THE USE OF PRESCRIPTION DRUGS IN TREATMENT OF FIRST-TIME PSYCHIATRIC ADMISSIONS TO UNIVERSITY HOSPITAL, SASKATOON. 003712 04-17

DIFFERENTIAL EFFECT OF VARIOUS 6 HYDROXYDOPA TREATMENTS ON THE DEVELOPMENT OF CENTRAL AND PERIPHERAL NORADRENERGIC NEURONS.

000155 01-03

EVALUATION OF DIFFERENT TREATMENTS IN MINIMAL-CEREBRALDAMAGE.

001920 02-17
BEHAVIOURAL DESPAIR IN RATS: A NEW MODEL SENSITIVE TO
ANTIDEPRESSANT TREATMENTS.

002370 03-06
RECENT RESULTS OF BEHAVIOURAL TREATMENTS OF PHOBIAS AND
OBSESSIONS.

RESIDUAL EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE TREATMENTS
FOR ALCOHOL WITHDRAWAL.

002617 03-14

003544 04-10

RESIDUAL CAPACITY FOR AVOIDANCE LEARNING IN DECORTICATE RATS: ENHANCEMENT OF PERFORMANCE AND DEMONSTRATION OF LATENT LEARNING WITH D AMPPHETAMINE TREATMENTS.

003167 04-04

THE INDOLAMINERGIC INNERVATION OF THE INFERIOR OLIVE. 2. RELATION TO HARMALINE-INDUCED TREMOR.

000269 01-03

PERIPHERAL CATECHOLAMINES RELEASED BY OXOTREMORINE MODULATE TREMOR IN THE RAT. (UNPUBLISHED PAPER).

001486 02-04

ACRESSIC
THE ROLE OF SEROTONIN ANTAGONISM IN THE TREMORGENIC ACTION OF BUFOTENINE IN MICE. 002236 03-04

TREMOROGENESIS

CENTRAL TRANSMITTER INVOLVEMENT IN LON-954-INDUCED TREMOROGENESIS.

000342 01-04

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON PENTOBARBITAL-INDUCED DECREASE IN CHOLINERGIC NEURONAL ACTIVITY.

000259 01-03

EEG AND BLOOD PRESSURE EFFECTS OF TRH IN RABBITS

000319 01-04

PSYCHOENDOCRINOLOGICAL AND THERAPEUTIC EFFECTS OF TRH IN DEPRESSION.

STUDIES ON THE INFLUENCE OF BIOGENIC AMINES AND PSYCHOACTIVE DRUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMULATION TEST IN ENDOGENOUS DEPRESSION.

000926 01-16

ANTAGONISM OF PENTOBARBITAL-INDUCED HORMONAL CHANGES BY TRH IN RATS.

STUDIES ON THE NEUROPHARMACOLOGY OF THYROTROPIN-RELEASING HORMONE (TRH) AND A NEW TRH ANALOG.

002185 03-03 LACK OF EFFECTS OF L TRYPTOPHAN ON BASAL AND TRH STIMULATED TSH AND PROLACTIN LEVELS.

002554 03-13

THYROTROPIN-RELEASING HORMONE (TRH): LACK OF EFFECT ON SHOCK-ELICITED FIGHTING (SEF) IN RATS. 003283 04-04

BEHAVIOURAL, ELECTROCORTICAL AND BODY TEMPERATURE EFFECTS
AFTER INTRACEREBRAL INFUSION OF TRH IN FOWLS.

003319 04-04 A CASE OF DEPRESSION SHOWING IMPROVEMENT IN TRH TEST BY COMBINED TREATMENT BY DIMETACRINE-TARTRATE AND THYROID HORMONE.

003527 04-09

A PSYCHOSOMATIC TRIAD IN A BIPOLAR PATIENT.

000589 01-09

TRIAZAPHENOTHIAZINE
STUDIES IN THE HETEROCYCLIC SERIES. XIII. NEW CNS DEPRESSANTS
DERIVED FROM 1,9 DIAZAPHENOXAZINE AND TWO ISOMERIC
TRIAZAPHENOTHIAZINE RING SYSTEMS.

000030 01-02

LONG-TERM EFFICACY AND SAFETY OF TRIAZOLAM AND FLURAZEPAA 000643 01-11 COMPARISON OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTICS IN GERIATRIC PATIENTS WITH INSOMNIA.

000658 01-11 MULTICLINIC CROSS-OVER COMPARISON OF TRIAZOLAM (HALCION) AND PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND ANXIETY IN ANXIOUS OUTPATIENTS.

AN EVALUATION OF THE CARDIOPULMONARY SAFETY AND EFFICACY OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS ORAL HYPNOTIC

000854 01-15 EVALUATION OF TRIAZOLAM, FLURAZEPAM, AND PLACEBO AS HYPNOTIC AGENTS IN PRESURGICAL PATIENTS.

002514 03-11 TRIAZOLAM IN INSOMNIA: A STANDARD-CONTROLLED TRIAL

002523 03-11 COMPARISON OF TRIAZOLAM .25 MG AND FLURAZEPAM 15 MG IN TREATING GERIATRIC INSOMNIACS.

002524 03-11

TRIAZOLOBENZODIAZEPINES

QUINAZOLINES AND 1,4 BENZODIAZEPINES. 81. S

TRIAZOLOBENZODIAZEPINES BY OXIDATIVE CYCLIZATION OF
HYDRAZONES.

001017 02-01

EFFECTS OF SODIUM THIOPENTAL ON THE TRICARBOXYLIC-ACID CYCLE METABOLISM IN MOUSE BRAIN: CO2 FIXATION AND METABOLIC COMPARTMENTATION.

ALTERATION OF TRICARBOXYLIC-ACID CYCLE METABOLISM IN RAT BRAIN SLICES BY HALOTHANE.

002861 04-03

TENCEPS

EFFECT OF DIAZEPAM ON THE GAMMA MOTOR SYSTEM INDICATED BY
THE RESPONSES OF THE MUSCLE SPINDLE OF THE TRICEPS SURAE
MUSCLE OF THE DECEREBRATE CAT TO THE MUSCLE STRETCH.
003109 044

TRICYCLIC ANTIDEPRESSANT DRUGS BLOCK HISTAMINE H2 RECEPTOR IN BRAIN. 000128 01-03

THE SELECTIVE INHIBITION OF DOPAMINE UPTAKE BY A TRICYCLIC IMINE. 000141 01-03

TRICYCLIC ANTIDEPRESSANTS AS ANTIMUSCARINIC DRUGS: IN VIVO AND IN VITRO STUDIES.

NEUROCHEMICAL PROPERTIES OF DIMETHYLMETHYLAMINOPROPYL-1-PHENYLINDAN HCL (LU-3-049) AND SELECTED TRICYCLIC ANTIDEPRESSANTS.

THE BLOOD (SERUM AND CORPUSCLE) DYNAMICS OF TRICYCLIC ANTIDEPRESSANTS. 000556 01-09

TRICYCLIC NEED DROPS WITH AGE.

AMITRIPTYLINE DOSAGE SCHEDULE, SAMPLING TIME AND TRICYCLIC PLASMA LEVELS.

DOUBLE-BLIND TRIALS OF A NEW TRICYCLIC ANTIDEPRESSANT (MAPROTILINE). 000607 01-10

RELATIONSHIP BETWEEN AGE AND TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS.

000652 01-11 INCREASED STEADY-STATE PLASMA LEVELS AND PROLONGED HALF-LIVES OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY.

000734 01-13 TRICYCLIC ANTIDEPRESSANT OVERDOSE: INCIDENCE OF SYMPTOMS.

000801 01-15

CARDIAC TOXICITY WITH THIORIDAZINE TRICYCLIC ANTIDEPRESSANT 000846 01-15

POISONING WITH TRICYCLIC ANTIDEPRESSANT DRUGS. 000860 01-15

TRICYCLIC ANTIDEPRESSANT PLASMA LEVELS AND ADVERSE EFFECTS AFTER OVERDOSE 000883 01-15

DYSARTHRIA: AN UNUSUAL SIDE-EFFECT OF TRICYCLIC ANTIDEPRESSANTS. 000885 01-15

TRICYCLIC ANTIDEPRESSANT AND MONOAMINE-OXIDASE INHIBITOR COMBINATION THERAPY. 000976 01-17

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE CONTENT AND METABOLISM OF DOPAMINE IN THE RAT STRIATUM. 001133 02-03

EFFECTS OF REPEATED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS ON ADIPOSE TISSUE LIPOLYTIC ACTIVITY IN THE RAT. 001179 02-03

THE EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF TRICYCLIC ANTIDEPRESSANTS ON MHPG-SO4 IN RAT BRAIN. 001228 02-03

ALPHA-ADRENOCEPTOR BLOCKADE BY TRICYCLIC ANTIDEPRESSANTS 001244 02-03 EFFECT OF TWO NON TRICYCLIC ANTIDEPRESSANT DRUGS ON C14-5
HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS.

TRICYCLIC ANTIDEPRESSANT DRUGS: ANTAGONISM OF EFFECT OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) ON SHOCK ELICITED AGGRESSION.

WHICH TRICYCLIC FOR DEPRESSED OUTPATIENTS, IMIPRAMINE PAMOATE OR AMITRIPTYLINE?.

001589 02-09 SERUM GONADOTROPIN AND TSH LEVELS AFTER TRICYCLIC ANTIDEPRESSANTS IN HEALTHY MALES.

001670 02-13 GENERATION OF ELECTRONIC EXCITED STATES (EES) BY TRICYCLIC ANTIDEPRESSANTS: MOLECULAR ASPECTS.

001693 02-13 TRICYCLIC ANTIDEPRESSANT DRUGS AND CARDIAC CONDUCTION. 001751 02-15

DELIBERATE POISONING WITH TRICYCLIC ANTIDEPRESSANTS TREATED IN AN INTENSIVE CARE UNIT.

001758 02-15

EXPERIENCES WITH PHYSOSTIGMINESALICYLATE IN TRICYCLIC ANTIDEPRESSANT POISONING. 001820 02-15 TRICYCLIC ANTIDEPRESSANT OVERDOSES IN ADOLESCENT PATIENTS 001822 02-15 HEMODYNAMIC EFFECTS FOLLOWING TOXIC DOSES OF TRICYCLIC ANTIDEPRESSANTS. 001838 02-15 THE TRICYCLIC ANTIDEPRESSANT OVERDOSED PATIENT. 001852 02-15 REDUCED LEVELS OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA FROM

001859 02-16 INDIVIDUALISED DOSAGE OF TRICYCLIC ANTIDEPRESSANTS 001863 02-16 TRICYCLIC ANTIDEPRESSANTS IN OUTPATIENT THERAP

IN VIVO EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE IN RAT BRAIN.

001987 03-03 A NEW MECHANISM OF TRICYCLIC ANTIDEPRESSANT ACTION. BLOCKADE OF PROSTAGLANDIN DEPENDENT CALCIUM MOVEMENTS 002043 03-03

METABOLISM OF 5 HYDROXYTRYPTAMINE AND LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS IN RAT BRAIN AFTER ACUTE AND CHRONIC

002169 03-03 COMBINED TRICYCLIC MAOI THERAPY FOR REFRACTORY DEPRESSION: A REVIEW, WITH GUIDELINES FOR APPROPRIATE USAGE. 002437 03-09

BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANT DRUGS: ASSAY PROCEDURES, REPRODUCIBILITY AND RELATIONSHIP TO THERAPEUTIC OUTCOME AND SIDE-EFFECTS.

WEIGHT LOSS AND A CONCOMITANT CHANGE IN PLASMA TRICYCLIC LEVELS.

002441 03-09
CLINICAL RESPONSE IN DEPRESSED PATIENTS IN RELATION TO PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND TYRAMINE PRESSOR

002453 03-09 TRICYCLIC ANTIDEPRESSANTS ACCELERATE MANIC-DEPRESSIVE CYCLES. (UNPUBLISHED PAPER)

002468 03-09 TRICYCLIC PLASMA LEVELS: EFFECT OF AGE, RACE, SEX, AND SMOKING 002472 03-09

TYRAMINE PRESSOR RESPONSES AND PLASMA LEVELS DURING TRICYCLIC ANTIDEPRESSANT THERAPY.

002584 03-13 USE OF TRICYCLIC ANTIDEPRESSANT BLOOD LEVELS

002693 03-15 APPLICATION OF LIFE TABLE METHOD TO NATURALISTIC DESIGNS COMPARISON OF EFFICACY OF TRICYCLIC ANTIDEPRESSANTS AND BENZODIAZEPINES IN AMBULATORY DEPRESSIVES.

DRUGS AFFECTING THE CENTRAL-NERVOUS-SYSTEM: EFFECTS OF PEMOLINE, AND TRICYCLIC ANTIDEPRESSANTS ON NERVE TERMINAL ADENOSINE-TRIPHOSPHATASE ACTIVITIES AND NEUROTRANSMITTER RELEASE

TRICYCLIC ANTIDEPRESSANTS: THERAPEUTIC PROPERTIES AND AFFINITY
FOR ALPHA-NORADRENERGIC RECEPTOR BINDING SITES IN THE BRAIN 003118 04-03 ANTICHOLINERGIC ACTIVITY OF THE TRICYCLIC ANTIDEPRESSANTS

DESIPRAMINE AND DOXEPIN IN NONDEPRESSED VOLUNTEERS 003447 04-07

ANTICHOLINERGIC ACTIVITY OF TWO TRICYCLIC ANTIDEPRESSANTS 003483 04-09

TRICYCLIC ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSIONS: A
DOUBLE-BLIND CLINICAL COMPARISON OF CLOMIPRAMINE (ANAFRANIL) AND AMITRIPTYLINE. 003501 04-09

CLINICAL CORRELATES OF TRICYCLIC ANTIDEPRESSANT MEDIATED INHIBITION OF PLATELET MONOAMINE-OXIDASE 003524 04-09

THE EFFECT OF CHLORPROMAZINE, SOME TRICYCLIC ANTIDERESSANTS AND INSULIN ON THE ACTION OF CYCLIC-AMP AND ADENOSINE 003606 04-13

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON HUMAN PLASMA LEVELS OF TSH. GH AND PROLACTIN.

003613 04-13 TRICYCLIC ANTIDEPRESSANTS: PLASMA LEVELS AND CLINICAL FINDINGS

003643 04-15 TRICYCLIC OVERDOSE IN A PATIENT GIVEN COMBINED TRICYCLIC MAOI TREATMENT 003685 04-15

A REASSESSMENT OF TRICYCLICS AND ECT IN DEPRESSION. 000571 01-09 AGRANULOCYTOSIS ASSOCIATED WITH TRICYCLICS

003642 04-15

DEPRESSION -- A GOOD APPROACH FOR THE NONPSYCHIATRIST: III HOW TO USE THE TRICYCLICS 003719 04-17

TRIFLUOPERAZINE
COMPARISON OF PIMOZIDE AND TRIFLUOPERAZINE AS ONCE-DAILY THERAPY IN CHRONIC SCHIZOPHRENIC OUTPATIENTS. 000537 01-08

INFLUENCE OF CHLORPROMAZINE AND TRIFLUOPERAZINE ON NEURONS OF AN ISOLATED SLAB OF RABBIT CEREBRAL-CORTEX. 001205 02-03

CONTROLLED COMPARISON OF TRIFLUOPERAZINE AND CHLORDIAZEPOXIDE IN THE TREATMENT OF ANXIETY.

001848 02-15

TRIFLUOROMETHYLBENZOYLGLYCINE METABOLISM OF FENFLURAMINE TO M

TRIFLUOROMETHYLBENZOYLGLYCINE IN RAT BRAIN.

001127 02-03

TRIFLUOROMETHYLPHENYLPIPERAZINES SUBSTITUTED TRIFLUOROMETHYLPHENYLPIPERAZINES AS ANORECTIC AGENTS.

000002 01-01 TRIGEMINAL A RELIABLE, FACIAL NOCICEPTION DEVICE FOR UNRESTRAINED, AWAKE ANIMALS: EFFECTS OF MORPHINE AND TRIGEMINAL COMPLEX

ESIONS 003435 04-06

ACUTE EFFECTS OF LISURIDE (0.1 MG), AMANTADINE (100 MG) AND TRIHEXYPHENIDYL (5 MG) ON VERBAL ASSOCIATIONS. 003630 04-14

INFLUENCE OF TRIIODOTHYRONINE (T3) ON THE RENAL ACTION OF LITHIUM. 002119 03-03

TRIMETHADIONE EFFECTS OF PENTYLENETETRAZOLE AND TRIMETHADIONE ON FELINE BRAIN MONOAMINE METABOLISM. 003007 04-03

TRIMETHOXYAMPHETAMINE A COMPARISON OF THE EFFECTS OF 4 BROMODIMETHOXYAMPHETAMINE (DOB), 3,4,5 TRIMETHOXYAMPHETAMINE (TMA), P-METHOXYAMPHETAMINE (PMA), D AMPHETAMINE (A), A NONTOLERANT AND LSD TOLERANT CHRONIC SPINAL DOG AND LSD IN

001273 02-03 TRIMETHOXYPHENYL-2-AMINOPROPANE MONOMETHYLTHIO ANALOGUES OF 1 TRIMETHOXYPHENYL-2-AMINOPROPANE.

001030 02-02 TRIMETHYLTRYPTAMINE 7, N, N TRIMETHYLTRYPTAMINE: A SELECTIVE INHIBITOR OF SYNAPTOSOMAL SEROTONIN UPTAKE.

002364 03-06 TRIMIPRAMINE IN THE TREATMENT OF ANXIOUS DEPRESSED

002456 03-09 TRIMIPRAMINE IN THE TREATMENT OF DEPRESSION: A COMPARISON OF SINGLE VS. DIVIDED DOSE ADMINISTRATION.

002465 03-09 IMPOTENCE RESPONSIVE TO GLYCERYL-TRINITRATE, TRINITRATE 000650 01-11

TRIOXAZINE OBSERVATIONS ON THE CONTINUOUS USE OF TRIOXAZINE. 002384 03-07

EFFECT OF HYPOCHOLESTEROLEMIC AGENTS ON CENTRAL-NERVOUS-SYSTEM CHOLESTEROL BIOSYNTHESIS. III. ZUCLOMIPHENE IN COMBINATION WITH AY9944 AND TRIPARANOL.

003058 04-03 TRIPHASIC DOSE LETHALITY RELATIONSHIPS FOR AMPHETAMINE AND CERTAIN RING-SUBSTITUTED AMPHETAMINES IN ISOLATED OR

AGGREGATED MICE 001093 02-03 THE TRIPHASIC AMPHETAMINE LETHAL DOSE CURVE IN MICE AND ITS POSSIBLE RELATIONSHIP TO DRUG METABOLISM.

003410 04-05 TRIPHOSPHOINOSITIDE

NOREPINEPHRINE STIMULATED BREAKDOWN OF TRIPHOSPHOINOSITIDE OF RABBIT IRIS SMOOTH MUSCLE: EFFECTS OF SURGICAL SYMPATHETIC DENERVATION AND IN VIVO ELECTRICAL STIMULATION OF THE SYMPATHETIC NERVE OF THE EYE. 002802 04-03

TRITERPENES FROM THE BUTTON CACTUS, EPITHELANTHA-MICROMERIS 001018 02-01

EFFECTS OF TRITHIOZINE ON PSYCHOMOTOR SKILLS RELATED TO DRIVING: A COMPARISON WITH DIAZEPAM AND INTERACTIONS WITH ALCOHOL.

001723 02-14

TRITIATED

EFFECTS OF RACEMIC, (S)- AND (R) METHYLENEDIOXYAMPHETAMINE ON SYNAPTOSOMAL UPTAKE AND RELEASE OF TRITIATED NOREPINEPHRINE.

002999 04-03

EFFECTS OF TRANYLCYPROMINE AND PARGYLINE ON BRAIN TRYPTAMINE.

000279 01-03 ROLE OF TRYPTAMINE IN THE BEHAVIOURAL CHANGES CAUSED BY A MONOAMINE-OXIDASE INHIBITOR AND L TRYPTOPHAN.

000343 01-04 INTERACTION OF DRUGS WITH APOMORPHINE, TRYPTAMINE AND NOREPINEPHRINE. A NEW IN VIVO APPROACH: THE ATN-TEST IN

000502 01-06

RESPONSES OF THE FLEXOR REFLEX TO LSD, TRYPTAMINE, 5
HYDROXYTRYPTOPHAN, METHOXAMINE, AND D AMPHETAMINE IN
ACUTE AND CHRONIC SPINAL RATS.

002289 03-04

LSD AND TRYPTAMINE EFFECTS ON SLEEP-WAKEFULNESS AND ELECTROCORTICOGRAM PATTERNS IN INTACT CATS.

003256 04-04 THE CONTRIBUTION OF TRYPTAMINE TO THE BEHAVIOURAL EFFECTS OF L TRYPTOPHAN IN TRANYLCYPROMINE TREATED RATS.

003286 04-04

TRYPTAMINE-INDUCED
TRYPTAMINE-INDUCED DRUG EFFECTS INSENSITIVE TO SEROTONINERGIC ANTAGONISTS: EVIDENCE OF SPECIFIC TRYPTAMINERGIC RECEPTOR STIMULATION?

003057 04-03

CENTRAL TRYPTAMINERGIC EFFECTS OF 26-059. A NOVEL SEROTONIN

000036 01-02

TRANSCALLOSALLY EVOKED-POTENTIALS AND THE EEG IN THE DECEREBRATE DOG: ACTIONS OF TRYPTAMINERGIC, DOPAMINERGIC AND ADRENERGIC AGONISTS.

000223 01-03 TRYPTAMINE-INDUCED DRUG EFFECTS INSENSITIVE TO SEROTONINERGIC ANTAGONISTS: EVIDENCE OF SPECIFIC TRYPTAMINERGIC RECEPTOR STIMULATION?.

TRYPTAMINES

MOLECULAR DETERMINANTS FOR THE ACTION OF TRYPTAMINES ON AN 002178 03-03

A COMPARISON OF LUDIOMIL, TRYPTIZOL, AND LENTIZOL

002454 03-09 TRYPTIZOL-SE

A COMPARISON OF MAPROTILINE (LUDIOMIL) AND SLOW-RELEASE AMITRIPTYLINE (TRYPTIZOL-SR).

002450 03-09 EFFECTS OF BENSERAZIDE ON TRYPTOPHAN METABOLISM IN THE MOUSE

000054 01-03 MODULATION OF BRAIN TRYPTOPHAN-HYDROXYLASE ACTIVITY BY BRAIN TRYPTOPHAN CONTENT.

000207 01-03 ROLE OF TRYPTAMINE IN THE BEHAVIOURAL CHANGES CAUSED BY A MONOAMINE-OXIDASE INHIBITOR AND L TRYPTOPHAN.

000343 01-04 THE EFFECT OF INTRACEREBRAL INJECTION OF CYCLOHEXIMOIDE ON BRAIN PROTEIN SYNTHESIS AND ON THE HYPERACTIVITY SYNDROME PRODUCED BY A MONOAMINE-OXIDASE INHIBITOR AND TRYPTOPHAN. 000410 01-04 DIETARY TRYPTOPHAN EFFECTS ON THE SLEEP OF NORMAL SUBJECTS

000505 01-07 THE EFFECT OF L TRYPTOPHAN ADMINISTRATION ON THE CONCENTRATION OF PROBENECID IN PLASMA AND CEREBROSPINAL

FLUID IN PATIENTS 000564 01-09

EFFECTS OF LITHIUM ON THE ELEVATION OF FOREBRAIN 5
HYDROXYINDOLES BY TRYPTOPHAN.

001086 02-03 SIMILAR EFFECTS OF TRYPTOPHAN AND SLEEP ON CISTERNAL CEREBROSPINAL FLUID 5 HYDROXYINDOLEACETIC AND HOMOVANILLICACIDS IN CATS. 001440 02-04

TRYPTOPHAN AND AFFECTIVE-DISORDERS. 001579 02-09

L TRYPTOPHAN IN OBSESSIVE-COMPULSIVE DISORDERS 001616 02-10

Psychopharmacology Abstracts

L TRYPTOPHAN ADMINISTRATION IN L-DOPA-INDUCED HALLUCINATIONS IN ELDERLY PARKINSONIAN PATIENTS.

EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 2. BIOCHEMICAL ANALYSIS.

001652 02-13 EVALUATION OF THE COMBINATION OF TRYPTOPHAN AND ECT IN THE TREATMENT OF DEPRESSION: 1. CLINICAL ANALYSIS.

L TRYPTOPHAN: AN EFFECTIVE HYPNOTIC.

001784 02-15

TRYPTOPHAN AND 5 HYDROXYINDOLES IN DIFFERENT CNS REGIONS FOLLOWING ACUTE MORPHINE. 002097 03-03

ENHANCEMENT OF THE ANTIDEPRESSANT RESPONSE TO L TRYPTOPHAN BY A LIVER PYRROLASE INHIBITOR: A RATIONAL TREATMENT APPROACH.

L TRYPTOPHAN AND 5 HYDROXYTRYPTOPHAN IN THE TREATMENT OF DEPRESSION: A REVIEW.

LACK OF EFFECTS OF L TRYPTOPHAN ON BASAL AND TRH STIMULATED TSH AND PROLACTIN LEVELS.

INFLUENCE OF TRYPTOPHAN ON MEMORY FUNCTIONS IN DEPRESSIVE PATIENTS TREATED WITH UNILATERAL ECT.

002613 03-14 HAS TRYPTOPHAN ANY ANTICONVULSIVE EFFECT?

002634 03-14 INHIBITION OF DOPA DECARBOXYLATION BY ANALOGUES OF

TRYPTOPHAN 002837 04-03 CHANGES IN BRAIN TRYPTOPHAN AND TYROSINE FOLLOWING ACUTE AND CHRONIC MORPHINE ADMINISTRATION.

003012 04-03 IMPORTANCE OF TRYPTOPHAN-PYRROLASE AND AROMATIC-AMINO-ACID-DECARBOXYLASE IN THE CATABOLISM OF TRYPTOPHAN. 003147 04-03

THE CONTRIBUTION OF TRYPTAMINE TO THE BEHAVIOURAL EFFECTS OF L TRYPTOPHAN IN TRANYLCYPROMINE TREATED RATS.

003286 04-04 A CONTROLLED STUDY OF TRYPTOPHAN BENSERAZIDE IN **SCHIZOPHRENIA**

003451 04-08 TRYPTOPHAN NICOTINAMIDE COMBINATION IN THE TREATMENT OF NEWLY ADMITTED DEPRESSED PATIENTS.

003487 04-09 THE EFFECT OF CLOFIBRATE ON TOTAL AND FREE PLASMA TRYPTOPHAN IN DEPRESSED PATIENTS. 003532 04-09

BINDING OF PHENYTOIN, L TRYPTOPHAN AND O METHYL-RED TO ALBUMIN. UNEXPECTED EFFECT OF ALBUMIN CONCENTRATION ON THE BINDING OF PHENYTOIN AND L TRYPTOPHAN. 003588 04-13

MODULATION OF BRAIN TRYPTOPHAN-HYDROXYLASE ACTIVITY BY BRAIN TRYPTOPHAN CONTENT.

ACTIVATION OF TRYPTOPHAN-HYDROXYLASE BY DEPOLARIZATION: ROLE OF CALCIUM. 001060 02-03

TRYPTOPHAN-PYRROLASE
IMPORTANCE OF TRYPTOPHAN-PYRROLASE AND AROMATIC-AMINO-ACID-DECARBOXYLASE IN THE CATABOLISM OF TRYPTOPHAN

003147 04-03 TRYPTOPHANE L TRYPTOPHANE AS AN HYPNOTIC AGENT: A REVIEW.

000511 01-07 THE INSOMNIA OF SLEEPING IN A STRANGE PLACE: EFFECTS OF L TRYPTOPHANE.

000632 01-11

SERUM GONADOTROPIN AND TSH LEVELS AFTER TRICYCLIC ANTIDEPRESSANTS IN HEALTHY MALES. 001670 02-13 EFFECTS OF PARGYLINE ON HYPOTHALAMIC BIOGENIC AMINES AND SERUM PROLACTIN (PRL), LH AND TSH IN MALE RATS

001988 03-03 LACK OF EFFECTS OF L TRYPTOPHAN ON BASAL AND TRH STIMULATED TSH AND PROLACTIN LEVELS.

002554 03-13 EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON HUMAN PLASMA LEVELS OF TSH, GH AND PROLACTIN.

003613 04-13

A COMPARISON OF THE EFFECTS OF HALOPERIDOL ON DOPAMINE TURNOVER IN THE STRIATUM, OLFACTORY TUBERCLE AND MEDIAN

TUBEROINFUNDIBULAR
THE EFFECTS OF HYPOTHALAMIC DEAFFERENTATION ON THE
HALOPERIDOL-INDUCED ACTIVATION OF TUBEROINFUNDIBULAR DOPAMINE NEURONS

001047 02-03

TWO-DOSE
A TWO-DOSE DEXAMETHASONE SUPPRESSION TEST IN PATIENTS WITH PSYCHIATRIC ILLNESS.

ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE

001691 02-13

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL

EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE-A AND TYPE-B MONOAMINE-OXIDASE IN RAT BRAIN IN VIVO AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5 HYDROXYTRYPTAMINE.

POTENTIATION OF MORPHINE ANALGESIA IN MICE AFTER INHIBITION OF BRAIN TYPE-B MONOAMINE-OXIDASE.

TYPICAL

MARGARET B. - A TYPICAL BELLEVUE CASE.

001126 02-03 002732 03-17

TYRAMINE

TYRAMINE BINDING BY SYNAPTOSOMES FROM RAT BRAIN: EFFECT OF CENTRALLY ACTIVE DRUGS.

000285 01-03

NONCONTINGENT DISPLACEMENT OF CATECHOLAMINES BY INTRAVENTRICULAR TYRAMINE: BIPHASIC DOSE-RESPONSE EFFECTS ON

000364 01-04

003141 04-03

EFFECT OF PRETRIAL AND POSTTRIAL TYRAMINE AND GUANETHIDINE INJECTIONS ON AN APPETITIVE TASK IN RATS. 001439 02-04

CLINICAL RESPONSE IN DEPRESSED PATIENTS IN RELATION TO PLASMA LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND TYRAMINE PRESSOR RESPONSE

002453 03-09 TYRAMINE PRESSOR RESPONSES AND PLASMA LEVELS DURING TRICYCLIC ANTIDEPRESSANT THERAPY

002584 03-13 COMPARISON OF THE RESPONSES OF SINGLE CORTICAL NEURONES TO TYRAMINE AND NORADRENALINE: EFFECTS OF DESIPRAMINE.

CENTRAL ANTAGONISM OF TYRAMINE-INDUCED SYSTEMIC HYPOTENSION BY MESCALINE. 001252 02-03

TYROSINE

CHANGES IN BRAIN TRYPTOPHAN AND TYROSINE FOLLOWING ACUTE AND CHRONIC MORPHINE ADMINISTRATION. 003012 04-03

TYROSINE-AMINOTRANSFERASE

EFFECT OF MATERNAL MORPHINE ADMINISTRATION ON FETAL AND
NEONATAL RAT LIVER TYROSINE-AMINOTRANSFERASE.

EFFECTS OF MORPHINE ON ISOENZYMES OF PYRUVATE KINASE AND TYROSINE-AMINOTRANSFERASE IN RAT.

TYROSINE-HYDROXYLASE

EFFECTS OF REPEATED ADMINISTRATION OF MORPHINE ON TYROSINE-HYDROXYLASE IN THE RAT BRAIN.

000062 01-03 REGULATORY ROLE OF GABA NEURONS ON THE ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE BY HALOPERIDOL. (UNPUBLISHED

000132 01-03 MOTILITY RESPONSE TO MORPHINE AND AMPHETAMINE DURING CHRONIC INHIBITION OF TYROSINE-HYDROXYLASE OR DOPAMINE-

000166 01-03 DRUG-INDUCED CHANGES IN BRAIN TYROSINE-HYDROXYLASE ACTIVITY IN VIVO.

000181 01-03 TYROSINE-HYDROXYLASE: DELAYED ACTIVATION IN CENTRAL NORADRENERGIC NEURONS AND INDUCTION IN ADRENAL MEDULLA ELICITED BY STIMULATION OF CENTRAL CHOLINERGIC RECEPTORS. 000183 01-03

TRANS-SYNAPTIC INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE FOLLOWING AMPHETAMINE TREATMENT IN THE RAT.

SELECTIVE INDUCTION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE GROWTH FACTOR: COMPARISON BETWEEN ADRENAL MEDULLA AND SYMPATHETIC GANGLIA OF ADULT AND NEWBORN RATS. 001215 02-03 COMPARISON OF THE EFFECTS OF METHAMPHETAMINE AND NEUROLEPTIC AGENTS ON TYROSINE-HYDROXYLASE ACTIVITY IN THE NUCLEUS-ACCUMBENS AND CORPUS-STRIATUM.

002102 03-03 ENHANCEMENT BY CHOLINE OF THE INDUCTION OF ADRENAL TYROSINE-HYDROXYLASE BY PHENOXYBENZAMINE, 6 HYDROXYDOPAMINE, INSULIN OR EXPOSURE TO COLD.

CHANGES IN MOUSE BRAIN CATECHOLAMINE CONTENT AND TYROSINE-HYDROXYLASE ACTIVITY DURING CHRONIC AMPHETAMINE **ADMINISTRATION**

002175 03-03 MOUSE BRAIN TYROSINE-HYDROXYLASE AND GLUTAMIC-ACID-DECARBOXYLASE FOLLOWING TREATMENT WITH ADRENOCORTICOTROPHIC HORMONE, VASOPRESSIN OR

002898 04-03 EFFECT OF SUBSTITUTED BENZAMIDE DRUGS ON RAT STRIATAL TYROSINE-HYDROXYI ASE

O03018 04-DOPAMINE SYNTHESIS AND TYROSINE-HYDROXYLASE ARE REGULATED BY INDEPENDENT DA RECEPTOR MEDIATED MECHANISMS.

CONCOMITANT ELEVATION OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE BY CYCLIC-AMP IN CULTURED MOUSE NEUROBLASTOMA CELLS.

AN IMPROVED ASSAY OF TYROSINE-HYDROXYLASE USING SODIUM
ACTIVATION.

003430 04-06

TYROSINE-3-MONOOXYGENASE
ACTIVATION OF TYROSINE-3-MONOOXYGENASE IN

PHEOCHROMOCYTOMA CELLS BY LASALOCID.

002857 04-03

EFFECT OF EARLY EXPERIENCE, PYRITHIOXIN AND DIAZEPAM ON UC14-GLUCOSE UTILIZATION IN RAT BRAIN DURING EMOTIONAL STRESS. 002152 03-03

ULCERS MISLEADING RESPONSE OF MALIGNANT GASTRIC ULCERS TO CLAAFTIDINE

002704 03-15

AN ULTRASTRUCTURAL STUDY INTO THE EFFECTS OF PENTOBARBITONE ON SYNAPTIC ORGANIZATION.

002968 04-03 UNAMAESTHETIZED

EFFECTS OF CHOLINOMIMETIC DRUGS AND THEIR ANTAGONISTS INJECTED

INTO VERTEBRAL ARTERY OF UNANAESTHETIZED DOGS.

000375 01-04 RELATIVE CONCENTRATIONS OF ZWITTERIONIC AND UNCHARGED SPECIES IN CATECHOLAMINES AND THE EFFECT OF N SUBSTITUENTS.

000117 01-03

WIN-27147-2 IN THE TREATMENT OF DEPRESSION: AN UNCONTROLLED CLINICAL STUDY.

000577 01-09 AN UNCONTROLLED TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF PHOBIC AND OBSESSIONAL STATES IN GENERAL

002481 03-10

DEPRIVED CLOZAPINE INDUCES HYPERPHAGIA IN UNDEPRIVED RATS. 001301 02-04

PHARMACOLOGICAL TREATMENT FOLLOWING EXPERIMENTAL CEREBRAL INFARCTION: IMPLICATIONS FOR UNDERSTANDING PSYCHOLOGICAL

SYMPTOMS OF HUMAN STROKE. 000243 01-03

HYPERACTIVE CHILDRENS UNDERUSE OF LEARNING TIME: CORRECTION BY STIMULANT TREATMENT. 002614 03-14

UNDERWEIGHT PRODUCTION OF UNDERWEIGHT EMBRYOS IN RATS TREATED WITH

BARBITURATES DURING PREGNANCY. 000072 01-03

METHODOLOGICAL PROBLEMS IN THE MEASUREMENT OF DRUG-INDUCED ETHODOLOGICAL PROBLEMS IN THE MEASUREMENT OF BOARD TRANSPORTED FOR ROTATIONAL BEHAVIOUR: CONTINUOUS RECORDING REVEALS TIME-COURSE DIFFERENCES UNDETECTED BY PREVIOUS TECHNIQUES. 003388 04-04

INCENTIVE CONTRAST UNDIMINISHED BY EXTENDED TESTING, IMPRAMINE, OR CHLORDIAZEPOXIDE.

001354 02-04 UNDISTURBED COCAINE-INDUCED CENTRALLY MEDIATED RELEASE OF CATECHOLAMINES
INTO BLOOD OF UNDISTURBED RATS. (UNPUBLISHED PAPER).
001079 02-03

Subject Index ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEDDMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR GABA-LIKE PROPERTIES OF FLURAZEPAM AND BACLOFEN SUGGESTED BY ROTATIONAL BEHAVIOUR FOLLOWING UNILATERAL INTRANIGRAL INJECTION: A COMPARISON WITH THE GABA-AGONIST MUSCIMOL. UNILATERAL CATECHOLAMINE DEPLETION OF THE CORPUS-STRIATUM AND AMPHETAMINE-INDUCED TURNING: AN ONTOGENETIC STUDY. 000471 01-04 COMPARATIVE EFFECTS OF HALLUCINOGENIC DRUGS ON ROTATIONAL BEHAVIOR IN RATS WITH UNILATERAL 6 HYDROXYDOPAMINE LESIONS. INFLUENCE OF TRYPTOPHAN ON MEMORY FUNCTIONS IN DEPRESSIVE PATIENTS TREATED WITH UNILATERAL ECT. THE NEUROLOGICAL BASIS OF MOTOR ASYMMETRY FOLLOWING UNILATERAL NIGROSTRIATAL LESIONS IN THE RAT: THE EFFECT OF SECONDARY SUPERIOR COLLICULUS LESIONS. CIRCLING BEHAVIOUR IN THE RAT FOLLOWING UNILATERAL INJECTIONS
OF P-CHLOROPHENYLALANINE AND ETHANOLAMINE-O-SULPHATE INTO
THE SUBSTANTIA-NIGRA. 003375 04-04 CALCIUM METABOLISM IN LITHIUM TREATED PATIENTS: RELATION TO UNIPOLAR DICHOTOMY. 002420 03-09 CEREBELLAR UNIT ACTIVITY DURING GENERALIZED PENICILLIN EPILEPSY IN THE AWAKE CAT.

ELECTROPHYSIOLOGICAL EVIDENCE FOR A DOPAMINERGIC ACTION OF LSD: DEPRESSION OF UNIT ACTIVITY IN THE SUBSTANTIA-NIGRA OF LACK OF TOLERANCE TO THE DEPRESSION OF RAPHE UNIT ACTIVITY BY LYSERGIC-ACID-DIETHYLAMIDE.

001262 02-03 EFFECTS OF BENZODIAZEPINES ON PGO FIRINGS AND MULTIPLE UNIT ACTIVITY IN THE MIDBRAIN RETICULAR FORMATION IN CATS. 001265 02-03 DELIBERATE POISONING WITH TRICYCLIC ANTIDEPRESSANTS TREATED IN AN INTENSIVE CARE UNIT.

PENFLURIDOL IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIC PATIENTS NEWLY DISCHARGED FROM A BRIEF THERAPY UNIT. EFFECTS OF URETHANE ON HIPPOCAMPAL UNIT ACTIVITY IN THE RAT

THE INFLUENCE OF ELECTRICAL STIMULATION ON THE HIPPOCAMPAL UNITS ACTIVITY OF THE RABBIT.

001314 02-04 EFFECT OF BACLOFEN (BF) (LIORESAL (R) ON DOPAMINERGIC SINGLE UNITS AND SIDMAN AVOIDANCE BEHAVIOR

STRENGTH DURATION PROPERTIES OF SINGLE UNITS DRIVEN BY ELECTRICAL STIMULATION OF THE LATERAL HYPOTHALAMUS IN RATS

EFFECT OF MORPHINE INJECTED IN PERIAQUEDUCTAL GRAY ON THE ACTIVITY OF SINGLE UNITS IN NUCLEUS RAPHE MAGNUS OF THE RAT. 002817 04-03

UNIVERSITY
THE USE OF PRESCRIPTION DRUGS IN TREATMENT OF FIRST-TIME
PSYCHIATRIC ADMISSIONS TO UNIVERSITY HOSPITAL, SASKATOON
003712 0 003712 04-17

EFFECTS OF CANNABINOIDS ON UNLEARNED BEHAVIOR IN ANIMALS. 001955 03-02

ENDOGENOUS LIGANDS OF A PUTATIVE LSD SEROTONIN RECEPTOR IN THE CEREBROSPINAL FLUID: HIGHER LEVEL OF LSD DISPLACING FACTORS (LDF) IN UNMEDICATED PSYCHOTIC PATIENTS. 001672 02-13

UNPUNISHED

EFFECTS OF CHLORDIAZEPOXIDE ON PUNISHED AND UNPUNISHED

RESPONDING BEFORE AND DURING CHLORDIAZEPOXIDE DRINKING

001417 0

MONOSYNAPTIC ACTIVATION OF FASCIA-DENTATA IN UNRESTRAINED RATS: RESPONSE MODIFICATION BY SYNAPTICALLY ACTIVE DRUGS 001214 02-03

EFFECTS ON TEMPERATURE OF MORPHINE INJECTED INTO THE PREOPTIC/ ANTERIOR HYPOTHALAMUS, MEDULLA-OBLONGATA, AND PERIPHERALLY IN UNRESTRAINED AND RESTRAINED RATS. 001264 02-03

Psychopharmacology Abstracts

A RELIABLE, FACIAL NOCICEPTION DEVICE FOR UNRESTRAINED, AWAKE ANIMALS: EFFECTS OF MORPHINE AND TRIGEMINAL COMPLEX LESIONS.

ESOPHAGEAL CANNULATION FOR INTRAGASTRIC DELIVERY OF FLUIDS TO UNRESTRAINED DOGS.

POTENTIAL UNTOWARD EFFECTS OF LONG-TERM USE OF FLURAZEPAM IN GERIATRIC PATIENTS. 001807 02-15

UNTREATED

WHERE ARE THE UNTREATED DEPRESSIVES?

003721 04-17

UNWANTED
UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: 1. -- DRUGS FOR

000825 01-15 UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: III. - DRUGS FOR DEPRESSION.

000827 01-15 UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: II. -- DRUGS FOR SCHIZOPHRENIA.

000828 01-15 UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: IV. -- DRUGS FOR

000829 01-15 UNWANTED EFFECTS OF PSYCHOTROPIC DRUGS: V. - OTHER DRUGS. TREATMENT AND PREVENTION.

UPDATE

LOXAPINE UPDATE: 1966-1976.

000830 01-15 001879 02-17

FLUVOXAMINE, A SPECIFIC 5 HYDROXYTRYPTAMINE UPTAKE INHIBITOR 000017 01-02

EFFECTS OF 3,4 DIHYDROOXAZINOINDOLES, POTENTIAL
ANTIDEPRESSANTS, ON BIOGENIC AMINE UPTAKE MECHANISMS AND
RELATED ACTIVITIES.

000027 01-02 QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS IN A SERIES OF SELECTIVE 5-HT UPTAKE INHIBITORS

000057 01-03 EFFECTS OF RESERPINE AND IMIPRAMINE ON VESICULAR SEROTONIN UPTAKE AND STORAGE IN INTACT HUMAN PLATELETS.

000081 01-03 EFFECTS OF MIANSERIN, A NEW ANTIDEPRESSANT, ON THE IN VITRO AND IN VIVO UPTAKE OF MONOAMINES.

000126 01-03 A COMPARISON IN RABBIT ISOLATED HEARTS OF THE DYSRHYTHMOGENIC POTENTIAL OF AMITRIPTYLINE, AND MIANSERIN IN RELATION TO THEIR ABILITY TO BLOCK NORADRENALINE UPTAKE.

THE SELECTIVE INHIBITION OF DOPAMINE UPTAKE BY A TRICYCLIC IMINE 000141 01-03

RELATIONSHIP BETWEEN THE UPTAKE OF 3H-(PLUS OR MINUS)
METARAMINOL AND THE DENSITY OF ADRENERGIC INNERVATION IN
ISOLATED RAT TISSUES.

EFFECT OF CANNABINOIDS ON NEUROTRANSMITTER UPTAKE, ATPASE ACTIVITY AND MORPHOLOGY OF MOUSE BRAIN SYNAPTOSOMES.

UPTAKE INHIBITION OF BIOGENIC AMINES BY NEWER ANTIDEPRESSANT DRUGS: RELEVANCE TO THE DOPAMINE HYPOTHESIS OF DEPRESSION

000232 01-03 EFFECT OF RESERPINE ON ADENOSINE UPTAKE AND METABOLISM, AND SUBCELLULAR TRANSPORT OF PLATELET ADENOSINE-TRIPHOSPHATE IN WASHED RABBIT PLATELETS.

000238 01-03 THE BLOCKADE OF SEROTONIN UPTAKE INTO SYNAPTOSOMES:
RELATIONSHIP TO AN INTERACTION WITH MONOAMINE-OXIDASE INHIBITORS

000268 01-03 EFFECTS OF PHENCYCLIDINE ON (3H)CATECHOLAMINE AND
(3H)SEROTONIN UPTAKE IN SYNAPTOSOMAL PREPARATIONS FROM
RAT BRAIN.

000273 01-03 EFFECTS OF BETA-BUNGAROTOXIN, DIPHENYLHYDANTOIN AND METABOLIC INHIBITORS ON CALCIUM UPTAKE AND ON MONOVALENT CATIONS AND HIGH-ENERGY PHOSPHATE CONTENTS OF BRAIN SLICES.

000278 01-03 EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON SEROTONIN UPTAKE INTO RAT HYPOTHALAMIC SYNAPTOSOMES.

000293 01-03 EFFECT OF COCAINE AND DESMETHYLIMIPRAMINE ON THE UPTAKE RETENTION AND METABOLISM OF H3-5-HYDROXYTRYPTAMINE IN RAT BRAIN SLICES.

INHIBITION OF BOTH MAO-A AND MAO-B REQUIRED FOR THE PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

000398 01-04 EFFECTS OF ANTIMYCIN A PLUS 2 DEOXYGLUCOSE ON UPTAKE AND VESICULAR STORAGE OF SEROTONIN IN HUMAN PLATELETS. (UNPUBLISHED PAPER).

000694 01-13 UPTAKE OF 5 METHOXYTRYPTOLINE (6 MEO-TETRAHYDRO-BETA-CARBOLINE) BY BLOOD PLATELETS AND ITS EFFECT ON 5-HT UPTAKE AND RELEASE.

001043 02-03

BLOCKADE OF SYNAPTOSOMAL CA UPTAKE BY OPIATES IN VITRO. 001075 02-03 AGE-RELATED EFFECTS OF RESERPINE ON BEHAVIOR AND ON REGIONAL CATECHOLAMINE UPTAKE AND RELEASE IN THE RAT. (PH.D. DISSERTATION

001098 02-03 INFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3-CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN.

001119 02-03 EFFECT OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON SYNAPTOSOMAL CA UPTAKE.

001138 02-03 STUDIES ON THE CAPACITY OF MAZINDOL AND DITA TO ACT AS UPTAKE INHIBITORS OR RELEASING AGENTS FOR H3-BIOGENIC AMINES IN RAT BRAIN TISSUE SLICES.

001145 02-03 DIET AND UPTAKE OF ALDOMET BY THE BRAIN: COMPETITION WITH NATURAL LARGE NEUTRAL AMINO-ACIDS.

001185 02-03 UPTAKE AND METABOLISM OF INTRAVENTRICULARLY ADMINISTERED PIPERIDINE AND ITS EFFECTS ON SLEEP AND WAKEFULNESS IN THE

001208 02-03 MODULATION OF ACETYLCHOLINE TURNOVER IN BRAIN REGIONS AND HIGH AFFINITY UPTAKE.

SUBSTITUTED AMPHETAMINE DERIVATIVES. I. EFFECT ON UPTAKE AND RELEASE OF BIOGENIC MONOAMINES AND ON MONOAMINE-OXIDASE IN THE MOUSE BRAIN.

001233 02-03 FURTHER OBSERVATION ON THE LACK OF ACTIVE UPTAKE SYSTEM FOR SUBSTANCE-P IN THE CENTRAL-NERVOUS-SYSTEM.

001238 02-03 THE EFFECTS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE ON THE IN VITRO UPTAKE OF RADIOLABELLED 5-HT AND NORADRENALINE INTO RAT BRAIN CORTICAL SLICES

001257 02-03 EFFECT OF TWO NON TRICYCLIC ANTIDEPRESSANT DRUGS ON C14-5 HYDROXYTRYPTAMINE UPTAKE BY RAT PLATELETS

001283 02-03 COCAINE AND METABOLITES: RELATIONSHIP BETWEEN PHARMACOLOGICAL ACTIVITY AND INHIBITORY ACTION ON DOPAMINE UPTAKE INTO STRIATAL SYNAPTOSOMES.

001286 02-03 EFFECTS OF ANTIESTROGENS ON EATING, FEMALE SEXUAL BEHAVIOR, AND THE UPTAKE OF H3-ESTRADIOL IN THE CENTRAL-NERVOUS-SYSTEM IN RATS. (PH.D. DISSERTATION).

FLUOXETINE, A SEROTONIN UPTAKE INHIBITOR, IN NORMAL HUMAN SUBJECTS

SELECTIVE INHIBITION OF NORADRENALINE AND SEROTONIN UPTAKE BY C-49802-B-BA AND CGP-6085-A

BLOCKADE OF PRESYNAPTIC ALPHA-RECEPTORS AND OF AMINE UPTAKE IN THE RAT BRAIN BY THE ANTIDEPRESSANT MIANSERINE

001965 03-03 EFFECTS OF MAZINDOL, FENFLURAMINE AND CHLORIMIPRAMINE ON THE 5 HYDROXYTRYPTAMINE UPTAKE AND STORAGE MECHANISMS IN RAT BRAIN: SIMILARITIES AND DIFFERENCES.

001983 03-03 IN VIVO EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON BIOGENIC AMINE UPTAKE IN RAT BRAIN.

001987 03-03 IN VITRO EFFECTS OF DESMETHYLIMIPRAMINE ON THE UPTAKE AND METABOLISM OF H3-NOREPINEPHRINE IN RAT BRAIN SLICES

001997 03-03 INHIBITION BY NEUROLEPTICS OF UPTAKE OF H3-GABA INTO RAT BRAIN SYNAPTOSOMES.

002013 03-03 STEREOSELECTIVITY IN THE METABOLISM OF H3-NORADRENALINE DURING UPTAKE INTO AND EFFLUX FROM THE ISOLATED RAT VAS-

002028 03-03 STUDIES ON THE CAPACITY OF DITA AND MAZINDOL TO ACT AS RELEASING AGENTS AND UPTAKE INHIBITORS FOR H3-DOPAMINE (DA) AND H3-NOREPINEPHRINE (NE) IN RAT BRAIN TISSUE SLICES. 002036 03-03

DEFERENS

CANNABINOID EFFECTS ON PLASMA CORTICOSTERONE AND UPTAKE OF H3-CORTICOSTERONE BY MOUSE BRAIN.

THE EFFECT OF CLOMIPRAMINE AND OTHER AMINE UPTAKE INHIBITORS ON MORPHINE ANALGESIA IN LABORATORY ANIMALS.

EFFECTS OF CHLORPROMAZINE AND DL-AMPHETAMINE ON CALCIUM UPTAKE BY ADRENAL CHROMAFFIN CELL MEMBRANE.

EFFECTS OF DRUGS ON GAMMA-AMINOBUTYRIC-ACID RECEPTORS. UPTAKE, RELEASE AND SYNTHESIS IN VITRO.

EFFECTS OF CLOMIPRAMINE AND OTHER INHIBITORS OF MONOAMINE UPTAKE ON THE SEXUAL BEHAVIOUR OF FEMALE RATS AND RHESUS MONKEYS. 002228 03-04

7, N, N TRIMETHYLTRYPTAMINE: A SELECTIVE INHIBITOR OF SYNAPTOSOMAL SEROTONIN UPTAKE.

THE BINDING OF INHIBITORS OF SEROTONIN UPTAKE TO BIOLOGICAL

CLOMIPRAMINE AND MAPROTILINE ON HUMAN PLATELET UPTAKE OF 5 HYDROXYTRYPTAMINE AND DOPAMINE IN VITRO: WHAT RELEVANCE TO THEIR ANTIDEPRESSIVE AND OTHER ACTIONS?.

002599 03-13
EFFECT OF CANNABINOIDS ON THE UPTAKE OF SEROTONIN IN HUMAN PLATFLETS.

002603 03-13 CHOLINE-ACETYLTRANSFERASE AND THE HIGH AFFINITY UPTAKE OF CHOLINE IN CORPUS-STRIATUM OF RESERPINISED RATS.

002847 04-03 THE UPTAKE AND RELEASE OF H3-2 AMINO-6-7-DIHYDROXYTETRAHYDRONAPHTHALENE (ADTN) BY STRIATAL NERVE

REGIONAL BRAIN ATROPHY AND REDUCTIONS IN GLUTAMATE RELEASE AND UPTAKE AFTER INTRASTRIATAL KAINIC-ACID.

002917 04-03 COMPARATIVE EFFECTS OF PEMOLINE, AMFONELIC-ACID AND AMPHETAMINE ON DOPAMINE UPTAKE AND RELEASE IN VITRO AND ON BRAIN 3,4 DIHYDROXYPHENYLACETIC-ACID CONCENTRATION IN SPIPERONE-TREATED RATS.

O02919 04-03 ACTIVE UPTAKE OF H3-5-HT BY SYNAPTIC VESICLES FROM RAT BRAIN. 002937 04-03

EFFECTS OF RACEMIC, (S)- AND (R) METHYLENEDIOXYAMPHETAMINE ON SYNAPTOSOMAL UPTAKE AND RELEASE OF TRITIATED

002999 04-03 BRAIN AND RETINA UPTAKE OF A RADIOIODINE LABELED PSYCHOTOMIMETIC IN DOG AND MONKEY.

003075 04-03
THE UPTAKE OF \$35-METHIMAZOLE BY SHEEP THYROID SLICES IN VITRO.
003093 04-03 INHIBITION OF REM SLEEP BY FLUOXETINE, A SPECIFIC INHIBITOR OF

SEROTONIN UPTAKE. 003095 04-03
EFFECTS OF MAZINDOL ON RAT BRAIN SYNAPTOSOMAL MONOAMINE

UPTAKE 003103 04-03

INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETINE ON HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE (PCA) AND 4, ALPHA DIMETHYL-M-TYRAMINE (H-77-77)

DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: A
VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIATION OF
CATECHOLAMINERGIC AND SEROTONINERGIC TERMINALS IN RAT CEREBRAL STRUCTURES. 003423 04-06

EFFECTS OF SINGLE DOSES OF TRANYLCYPROMINE ON PLATELET MAO AND AMINE UPTAKE IN NORMAL SUBJECTS. 003594 04-13

URBAN RURAL URBAN DIFFERENCES IN THE USE OF STRESS ALLEVIATIVE DRUGS 001938 02-17

OXAZEPAM DISPOSITION IN UREMIC PATIENTS 000720 01-13

EFFECTS OF URETHANE ON HIPPOCAMPAL UNIT ACTIVITY IN THE RAT.
003011 04-03

COMPARATIVE VALIDITY OF RANDOM-INTERVAL AND FIXED-INTERVAL URINALYSIS SCHEDULES. 002751 03-17

PHENELZINE IN DEPRESSED PATIENTS: EFFECTS ON URINARY MHPG EXCRETION IN RELATION TO CLINICAL RESPONSE. 000686 01-13

METHADONE MAINTENANCE: EFFECT OF URINARY PH ON RENAL CLEARANCE IN CHRONIC HIGH AND LOW DOSES.

URINARY MONOAMINE METABOLITE EXCRETION IN DISORDERS OF MOVEMENT.

URINARY CARBON-DIOXIDE TENSION IN LITHIUM-CARBONATE TREATED

000882 01-15 URINARY 3 METHOXY-4-HYDROXYPHENYLGLYCOL, AN INDEX OF PERIPHERAL RATHER THAN CENTRAL ADRENERGIC ACTIVITY IN THE

URINARY CYCLIC-AMP EXCRETION BY METHADONE SUBJECTS DURING GRADUAL AND ACUTE WITHDRAWAL.

URINARY EXCRETION OF A QUATERNARY AMMONIUM GLUCURONIDE METABOLITE OF CYPROHEPTADINE IN HUMANS UNDERGOING CHRONIC DRUG THERAPY

URINARY EXCRETION OF PHENOLIC METABOLITES OF PROPYLAMPHETAMINE IN MAN.

CORRELATION OF URINARY EXCRETION OF METHADONE METABOLITES WITH METHADONE METABOLISM AND ANALGESIA IN THE RAT. 002080 03-03 A STUDY OF THE RELATIONSHIP BETWEEN URINARY 5 HYDROXYINDOLES

AND DEPRESSIVE STATES.

THE SYNTHESIS AND URINARY ESTIMATION OF N
HYDROXYAPROBARBITONE.

003482 04-09

001667 02-13

CHLORPROMAZINE EXCRETION. II. IMPROVED TLC PROCEDURES FOR FRACTIONATING THE URINARY DRUG CONTENT INTO CHEMICAL SUBGROUPS OF CPZ METABOLITES.

003690 04-16

PLASMA ALDOSTERONE AND MAGNESIUM IN SERUM AND URINE DURING LITHIUM TREATMENT.

EFFECT OF THYMOANALEPTIC AGENTS ON THE COURSE OF EXPERIMENTAL ARTERIAL HYPERTENSION AND CATECHOLAMINE CONTENT IN TISSUES

RETENTION OF URINE IN THE NEONATE POSSIBLY DUE TO ANTICONVULSANT DRUGS.

001970 03-03 002683 03-15

IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDPOXYPHENYLLACTIC-ACID (VLA) IN CEREBROSPINAL FLUID AND 3 METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN THE URINE OF PARKINSONIAN PATIENTS TREATED WITH L-DOPA.

THE EFFECTS OF OBSTETRICAL MEDICATION ON THE BEHAVIOR OF ISRAELI NEWBORN INFANTS AND SOME COMPARISONS WITH URUGUAYAN AND AMERICAN INFANTS.

002673 03-15

PSYCHOTROPIC AND ANTICONVULSANT DRUG USAGE IN EARLY CHILDHOOD SPECIAL EDUCATION PROGRAMS III. A PRELIMINARY REPORT: PARENT INTERVIEWS ABOUT DRUG TREATMENT.

COMBINED TRICYCLIC MAOI THERAPY FOR REFRACTORY DEPRESSION: A REVIEW, WITH GUIDELINES FOR APPROPRIATE USAGE.

THE RESULTS OF A CAMPAIGN TO EDUCATE PHYSICIANS IN ANTIPSYCHOTIC DRUG USAGE.

002761 03-17 USERS

STUDY OF LONG-TERM HASHISH USERS IN GREECE: SUMMARY AND

000625 01-11 INTERCORRELATIONS BETWEEN PHYSIOLOGICAL AND PSYCHOLOGICAL EFFECTS OF MARIJUANA, HASHISH, AND THC-DELTA9 IN LONG-TERM HASHISH USERS.

000695 01-13 VISUAL EVOKED REPONSES IN CHRONIC HASHISH USERS. II. CLINICAL ELECTROENCEPHALOGRAPHY AND ECHOENCEPHALOGRAPHY IN LONG-TERM HASHISH USERS.

ACUTE EEG EFFECTS OF CANNABIS PREPARATIONS IN LONG-TERM HASHISH USERS.

ACUTE EFFECTS OF CANNABIS ON COGNITIVE, PERCEPTUAL, AND MOTOR PERFORMANCE IN CHRONIC HASHISH USERS.

000759 01-14 SUBJECTIVE EXPERIENCES OF CANNABIS USE IN LONG-TERM USERS.
000776 01-14

ORGANIC IMPAIRMENT IN POLYDRUG USERS: RISK FACTORS

Psychopharmacology Abstracts

AUTONOMOUS NERVOUS FUNCTION OF LONG-TERM USERS OF PSYCHOTROPIC DRUGS, THIRD REPORT -- PUPILOGRAM OBSERVATIONS.

002690 03-15

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON UTERINE AND VAGINAL
CYTOLOGY OF OVARIECTOMIZED RATS. 000274 01-03

ACTIONS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD) AND ITS
DERIVATIVES ON 5 HYDROXYTRYPTAMINE RECEPTORS IN THE
ISOLATED UTERINE SMOOTH MUSCLE OF THE RAT.

001144 02-03 EFFECTS OF DIAZEPAM ON UTERINE ACTIVITY DURING LABOR 001627 02-11

UTILISATION
THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LOCAL CEREBRAL GLUCOSE UTILISATION OF THE RAT.

001206

001206 02-03 A CONTRIBUTION TO THE NEUROCHEMICAL BASIS OF THE PYRITHIOXIN EFFECT ON THE BRAIN GLUCOSE UTILISATION DURING RELATIVE BRAIN HYPOGLYCAEMIA INDUCED BY ANTICIPATION STRESS. 003083 04-03

ADVERSE REACTIONS TO MEDICATION IN PSYCHIATRIC INPATIENTS: THEIR MEANING, UTILITY AND PROBLEMS. 001744 02-15

VALIDITY AND CLINICAL UTILITY OF NEUROLEPTIC FACILITATED ELECTROENCEPHALOGRAPHY IN PSYCHOTIC PATIENTS. 003669 04-15

UTILIZATION
SOME CONTINGENCIES AFFECTING THE UTILIZATION OF TRANQUILIZERS
IN LONG-TERM CARE OF THE ELDERLY.

APOMORPHINE INCREASES GLUCOSE UTILIZATION IN THE SUBSTANTIA-NIGRA, SUBTHALAMIC NUCLEUS AND CORPUS-STRIATUM OF RAT. 001976 03-03 EFFECT OF EARLY EXPERIENCE, PYRITHIOXIN AND DIAZEPAM ON UC14-GLUCOSE UTILIZATION IN RAT BRAIN DURING EMOTIONAL STRESS.

002152 03-03

DRUG UTILIZATION AND ADVERSE DRUG REACTIONS IN MEDICAL PATIENTS: COMPARISON OF TWO PERIODS, 1969-72 AND 1973-76 002684 03-15

ENERGY UTILIZATION IN THE INDUCED RELEASE OF GAMMA-AMINOBUTYRIC-ACID FROM SYNAPTOSOMES. 003029 04-03

LOCAL CEREBRAL GLUCOSE UTILIZATION FOLLOWING INJECTION OF BETA-ENDORPHIN INTO PERIAQUEDUCTAL GRAY MATTER IN THE RAT.

UTILIZING

EVALUATION OF RADIORESPIROMETRY FOR THE DETERMINATION OF MONOAMINE-OXIDASE ACTIVITY IN VIVO UTILIZING C11-OCTYLAMINE AS A SUBSTRATE.

000116 01-03 VACUTAINERS REDUCED LEVELS OF TRICYCLIC ANTIDEPRESSANTS IN PLASMA FROM VACUTAINERS.

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON UTERINE AND VAGINAL CYTOLOGY OF OVARIECTOMIZED RATS.

000274 01-03 ANALGESIA INDUCED BY VAGINAL STIMULATION IN RATS IS
APPARENTLY INDEPENDENT OF A MORPHINE SENSITIVE PROCESS 001090 02-03

001859 02-16

003669 04-15

VALIDITY
COMPARATIVE VALIDITY OF RANDOM-INTERVAL AND FIXED-INTERVAL
URINALYSIS SCHEDULES.
002751 03-

002751 03-17 VALIDITY AND CLINICAL UTILITY OF NEUROLEPTIC FACILITATED ELECTROENCEPHALOGRAPHY IN PSYCHOTIC PATIENTS.

INCREASED PRESCRIBING OF VALIUM, LIBRIUM, AND OTHER DRUGS — AN EXAMPLE OF THE INFLUENCE OF ECONOMIC AND SOCIAL FACTORS ON THE PRACTICE OF MEDICINE.

000995 01-17 A CONTROLLED COMPARATIVE TRIAL OF CLORAZEPATE (TRANXENE) AND DIAZEPAM (VALIUM) FOR ANXIETY. 002476 03-10

CONCERNING THE USE OF VALIUM (DIAZEPAM). 002741 03-17

CHARACTERISTICS OF TILIDEN-HCL (VALORON) INTOXICATION 002377 03-07 VALPROATE SODIUM VALPROATE AND TARDIVE-DYSKINESIA

003457 04-08 SODIUM VALPROATE IN THE TREATMENT OF INTRACTABLE SEIZURE DISORDERS: A CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY 003550 04-11

002670 03-15

SODIUM VALPROATE IN THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA. 003568 04-11

LOWERED ERYTHROCYTE SEDIMENTATION RATE WITH SODIUM VALPROATE. 003672 04-15

VALPROATE-SODIUM: EVALUATION OF SO-CALLED PSYCHOTROPIC EFFECT. A CONTROLLED STUDY.

000791 01-14

VALUABLE

DOPAMINE UPTAKE IN SEROTONINERGIC TERMINALS IN VITRO: A
VALUABLE TOOL FOR THE HISTOCHEMICAL DIFFERENTIATION OF
CATECHOLAMINERGIC AND SEROTONINERGIC TERMINALS IN RAT
CEREBRAL STRUCTURES.

003423 04-06

ALUE
THE PREDICTIVE VALUE OF THE BIOCHEMICAL ACTION PROFILE OF
NEUROLEPTICS.

O00551 01-08

STUDIES ON THE INFLUENCE OF BIOGENIC AMINES AND PSYCHOACTIVE
DRUGS ON THE PROGNOSTIC VALUE OF THE TRH STIMULATION TEST IN
ENDOGENOUS DEPRESSION.

PROPHYLACTIC VALUE OF LITHIUM IN MANIC-DEPRESSIVE PSYCHOSIS —
GENETIC ASPECTS. 000952 01-17

VALUE OF COCAINE IN OPIATE CONTAINING ELIXIRS.

001628 02-11

THE VALUE OF THE MMPI FOR DELINEATING SYMPTOMS UNIQUE TO POSITIVE LITHIUM RESPONDERS: A DRUG RESPONSE AND DIAGNOSTIC STUDY. (PH.D. DISSERTATION).

002638 03-14
CLINICAL VALUE OF THE BRAINSTEM EVOKED RESPONSE IN COMA.
002650 03-15

FLICKER VALUES AND CHANGES IN STATES OF DEPRESSION.
001592 02-09

YANILLYLMANDELIC-ACID
ON THE ORIGIN OF VANILLYLMANDELIC-ACID AND 3 METHOXY-4HYDROXYPHENYLGLYCOL IN THE RAT BRAIN.

HYDROXYPHENYLGLYCOL IN THE RAT BRAIN.
002804 0

BEHAVIORAL CHANGES AND MERCURY CONCENTRATIONS IN TISSUES OF RATS EXPOSED TO MERCURY VAPOR. 003258 04-04

INTERINDIVIDUAL VARIABILITY IN DIAZEPAM METABOLISM:
PRELIMINARY EVIDENCE OF AN ABSENCE OF GENETIC CONTROL.
000696 01-13
IMIPRAMINE: CLINICAL EFFECTS AND PHARMACOKINETIC VARIABILITY.

IMIPRAMINE: CLINICAL EFFECTS AND PHARMACOKINETIC VARIABILITY.
002460 03-09

/ARIABLE
THE PEAK EXPERIENCE VARIABLE IN DPT ASSISTED PSYCHOTHERAPY

WITH CANCER PATIENTS.

000679 01-12

EFFECTS OF MARIJUANA EXTRACT DISTILLATE AND CANNABIDIOL ON VARIABLE INTERVAL PERFORMANCE AS A FUNCTION OF FOOD

DEPRIVATION. 003308 04-04

VARIABLE-INTERVAL

A VARIABLE-INTERVAL PUNISHMENT PROCEDURE FOR ASSESSING

ANXIOLYTIC EFFECTS OF DRUGS.

002371 03-06

VARIABLES
THE EFFECTS OF PHARMACOLOGICAL AND ENVIRONMENTAL VARIABLES
ON DRUG CHOICE IN RHESUS MONKEYS.

000386 01-04
VARIABLES IN THE PROLONGED PREFERENCE OF HEROIN OR

DRUG VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA
APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS.

VARIANTS

DRUG TREATMENT OF MIGRAINE AND ITS VARIANTS.

O01777 02-15

VARIATION
THE EFFECT OF DIAZEPAM, CHLORPROMAZINE AND AMOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION.

SPECIES VARIATION WITH RESPECT TO THE METABOLISM AND EXCRETION OF D AMPHETAMINE AND D,L N HYDROXYAMPHETAMINE-SUCCIDATE

CIRCADIAN VARIATION IN AN AMPHETAMINE-INDUCED MOTOR RESPONSE.

QUANTUM CHEMICAL STUDIES OF N SUBSTITUENT VARIATION IN THE OXYMORPHONE SERIES OF OPIATE NARCOTICS.

THE USE OF THE CNV (CONTINGENT NEGATIVE VARIATION) IN THE DETERMINATION OF RESIDUAL EFFECTS OF FIVE HYPNOTIC DRUGS. 002713 03-16

WARIATIONS
INDIVIDUAL VARIATIONS IN RESPONSE OF HUMAN REM SLEEP TO
AMITRIPTYLINE AND HALOPERIDOL.

CIRCADIAN VARIATIONS IN RESPONSES TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT.

CIRCADIAN VARIATIONS IN RESPONSE TO AMPHETAMINE AND CHLORPROMAZINE IN THE RAT.

002182 03-03

DIURNAL VARIATIONS IN THE MOTOR ACTIVITY OF THE RAT: EFFECTS OF INHIBITORS OF THE CATECHOLAMINE SYNTHESIS.

VAS-DEFERENS
THE SYMPATHOMIMETIC ACTIVITY OF FENFLURAMINE HYDROCHLORIDE
ON RAT VAS-DEFERENS.

STEREOSELECTIVITY IN THE METABOLISM OF H3-NORADRENALINE DURING UPTAKE INTO AND EFFLUX FROM THE ISOLATED RAT VAS-

002028 03-03

SENSITIVITIES OF THE ISOLATED ILEAL LONGITUDINAL SMOOTH MUSCLE
MYENTERIC PLEXUS AND HYPOGASTRIC NERVE VAS-DEFERENS OF THE
GUINEA-PIG AFTER CHRONIC MORPHINE PELLET IMPLANTATION.

EFFECT OF ENKEPHALIN AND ENDORPHIN ANALOGS ON RECEPTORS IN THE MOUSE VAS-DEFERENS.

002794 04-02 ASA-DEFERENTIA

DIFFERENCES IN THE INHIBITORY EFFECTS OF NORMORPHINE AND OPIOID PEPTIDES ON THE RESPONSES OF THE VASA-DEFERENTIA OF TWO STRAINS OF MICE.

VASCULAR
TREATMENT OF VASCULAR HEMIBALLISM AND HEMICHOREA.
000637 01-11

A COMPARISON OF THE VASCULAR DOPAMINE RECEPTOR WITH OTHER DOPAMINE RECEPTORS. 002927 04-03

STUDY OF THE TREATMENT OF VASCULAR PARKINSONS DISEASE WITH METAMIZYL. 003599 04-13

VASCULATURES

SELECTIVE BLOCKADE OF DOPAMINE-INDUCED VASODILATION BY ERGONOVINE-MALEATE IN THE VASCULATURES OF DOGS AND RABBITS

VASOACTIVE

EFFECT OF VASOACTIVE INTESTINAL PEPTIDE (VIP) AND OTHER PEPTIDES
ON C-AMP ACCUMULATION IN RAT BRAIN.

VASODILATION
SELECTIVE BLOCKADE OF DOPAMINE-INDUCED VASODILATION BY
ERGONOVINE-MALEATE IN THE VASCULATURES OF DOGS AND

ERGONOVINE-MALEATE IN THE VASCULATURES OF DOGS AND RABBITS. 003067 04-03

NONPARTICIPATION OF CHOLINERGIC MECHANISM IN CHEMICAL CONTROL OF CEREBRAL VASOMOTOR ACTIVITY.

001243 02-03

VASOPRESSIN
INFLUENCE OF VASOPRESSIN ON LEARNING AND MEMORY.
002385 03-07

VASOPRESSIN IN AMNESIA. 002631 03-14

INFLUENCE OF LYSINE VASOPRESSIN ON THE EEG IN MAN.

002639 03-14

RELEASE OF VASOPRESSIN BY ENKEPHALIN.

O02792 04-02

MOUSE BRAIN TYROSINE-HYDROXYLASE AND GLUTAMIC-ACIDDECARBOXYLASE FOLLOWING TREATMENT WITH
ADRENOCORTICOTROPHIC HORMONE, VASOPRESSIN OR
CORTICOSTERONE.

OXYTOCIN, VASOPRESSIN AND MEMORY: OPPOSITE EFFECTS ON CONSOLIDATION AND RETRIEVAL PROCESSES.

O03174 04-04

OPPOSITE ACTION OF OXYTOCIN TO VASOPRESSIN IN PASSIVE
AVOIDANCE BEHAVIOR IN RATS.

SLEEP-INDUCING EFFECT OF A VASOPRESSIN ANALOG, DEAMINO-6-CARBA-ORNITHINE-8-VASOPRESSIN (DCOV) IN RATS. 003265 04-04

000075 01-03

VEHICLE

ACUTE AND CHRONIC EFFECTS OF TETRAHYDROCANNABINOLS ON MONOAMINE-OXIDASE ACTIVITY: POSSIBLE VEHICLE/
TETRAHYDROCANNABINOL INTERACTIONS.

THE NEURONAL ORIGIN OF PROSTAGLANDIN RELEASED FROM THE RABBIT PORTAL VEIN IN RESPONSE TO ELECTRICAL STIMULATION.
002933 04-03

THAL

REACTIVITY AND AGGRESSION IN THE RAT: INDUCTION BY ALPHAADRENERGIC BLOCKING AGENTS INJECTED VENTRAL TO ANTERIOR
SEPTUM BUT NOT INTO LATERAL SEPTUM.

000309.0

000309 01-04 EFFECTS OF APOMORPHINE ON SELF-STIMULATION BEHAVIOUR IN DORSAL AND VENTRAL AREA OF LATERAL HYPOTHALAMUS IN MICE

THE ACTION OF BACLOFEN ON NEURONS OF THE SUBSTANTIA-NIGRA AND OF THE VENTRAL TEGMENTAL AREA.

A COMPARATIVE STUDY OF AUTONOMIC, SOMATIC AND BIOELECTRIC CORRELATES OF EMOTIONAL REACTIONS ELICITED BY CHOLINERGIC STIMULATION OF THE HYPOTHALAMUS AND THE VENTRAL TEGMENTUM.

001390 02-04 STUDIES ON THE EFFECT OF LESIONS OF THE VENTRAL NORADRENERGIC TRACT ON THE ANTINOCICEPTIVE ACTION OF MORPHINE. 002979 04-03

VENTRICLE

EFFECTS OF CLONIDINE ON VULNERABILITY TO FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE VENTRICLE.

002140 03-03 ANGIOTENSIN-INDUCED THIRST: EFFECTS OF THIRD VENTRICLE OBSTRUCTION AND PERIVENTRICULAR ABLATION.

EFFECTS OF CARBACHOL AND NICOTINE INJECTED INTO THE CEREBRAL VENTRICLES ON ELECTROMYOGRAM OF CONSCIOUS CATS.

SOME BEHAVIORAL EFFECTS OF SP6-11 HEXAPEPTIDE C-TERMINAL OF SUBSTANCE-P INJECTED INTO THE CEREBRAL VENTRICLES IN RATS. 002267 03-04

PHITOMEDIAL
CHLORPROMAZINE INDUCES POPULATION INCREASE OF SYNAPTIC
VESICLES IN THE RAT HYPOTHALAMIC VENTROMEDIAL NUCLEUS.
000160 000160 01-03

HYPERSENSITIVITY OF RATS TO ANORECTIC AGENTS AFTER LESIONS IN THE VENTROMEDIAL HYPOTHALAMUS.

THE EFFECTS OF HALOPERIDOL AND CLOZAPINE ON CIRCLING INDUCED BY ELECTRICAL STIMULATION OF THE SUBSTANTIA-NIGRA AND THE VENTROMEDIAL TEGMENTUM.

EFFECTS OF CHLORDIAZEPOXIDE AND OXAZEPAM ADMINISTRATION ON VERBAL HOSTILITY.

001720 02-14 ACUTE EFFECTS OF LISURIDE (D.1 MG), AMANTADINE (100 MG) AND TRIHEXYPHENIDYL (5 MG) ON VERBAL ASSOCIATIONS.

SUPPRESSION BY NITROUS-OXIDE OF VISUAL RESPONSES IN THE CEREBELLAR VERMIS AND SUPERIOR COLLICULUS OF CATS ANESTHETIZED WITH CHLORALOSE.

002897 04-03

003343 04-04

003181 04-04

EFFECTS OF CHOLINOMIMETIC DRUGS AND THEIR ANTAGONISTS INJECTED INTO VERTEBRAL ARTERY OF UNANAESTHETIZED DOGS. 000375 01-04

VERTEBRATE
VERTEBRATE GABA RECEPTORS.

002892 04-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON A MG2-ATPASE OF SYNAPTIC VESICLES PREPARED FROM RAT CEREBRAL-CORTEX.

000123 01-03 CHLORPROMAZINE INDUCES POPULATION INCREASE OF SYNAPTIC VESICLES IN THE RAT HYPOTHALAMIC VENTROMEDIAL NUCLEUS 000160 01-03

INFLUENCE OF ISOMERS OF AMPHETAMINE, DEOXYPIPRADIOL, AND METHYLPHENIDATE ON UPTAKE AND RELEASE OF H3-CATECHOLAMINES IN SYNAPTIC VESICLES OF RAT BRAIN.

ACTIVE UPTAKE OF H3-5-HT BY SYNAPTIC VESICLES FROM RAT BRAIN.
002937 04-03

EFFECTS OF RESERPINE AND IMIPRAMINE ON VESICULAR SEROTONIN
UPTAKE AND STORAGE IN INTACT HUMAN PLATELETS.

EFFECTS OF ANTIMYCIN A PLUS 2 DEDXYGLUCOSE ON UPTAKE AND VESICULAR STORAGE OF SEROTONIN IN HUMAN PLATELETS. (UNPUBLISHED PAPER).

000694 01-13

Psychopharmacology Abstracts

VESICULAR AND JUXTAVESICULAR SEROTONIN: EFFECTS OF LYSERGIC-ACID-DIETHYLAMIDE AND RESERPINE.

001141 02-03

000934 01-16

VESSELS ACTION OF DOPAMINE AGONISTS ON BRAIN VESSELS IN VITRO AND AFTER IN VIVO MICROAPPLICATION.

001107 02-03

VESTIBULO-OCULOMOTOR

ACTIVITY OF VESTIBULO-OCULOMOTOR NEURONES DURING SACCADIC
EYE MOVEMENTS INDUCED BY RESERPINE.

VIDEO EDITING AND MEDICATION TO PRODUCE A THERAPEUTIC SELF-001707 02-14

VIDEOTAPE
VIDEOTAPE METHODS FOR IDENTIFICATION OF NONVERBAL BEHAVIOR
PARAMETERS IN DEPRESSIVE SYNDROMES.

000934 01

VIGILANCE
COMPUTER OCULOGRAPHIC DOUBLE-BLIND STUDY OF CHANGES IN
VIGILANCE: ALPRENOLOL VERSUS DIAZEPAM.

VIGILANCE AND HUMAN ATTENTION UNDER CONDITIONS OF METHYLPHENIDATE AND SECOBARBITAL INTOXICATION: AN ASSESSMENT USING BRAIN POTENTIALS.

002622 03-14 ASSESSMENT OF SPONTANEOUS AND DRUG-INDUCED CHANGES IN VIGILANCE BY MEANS OF A NEW MODIFICATION OF THE SHORT TIME SPECTRAL ANALYSIS OF THE EEG.

002627 03-14 VILOXAZINE

A SEQUENTIAL TRIAL OF VILOXAZINE (VIVALAN) AND IMIPRAMINE IN MODERATELY DEPRESSED PATIENTS. 000563 01-09

CONVULSIVE SEIZURES AND VILOXAZINE 000826 01-15

VILOXAZINE: ASSESSMENT OF POTENTIAL RAPID ANTIDEPRESSANT ACTION 001584 02-09

VILOXAZINE IN THE TREATMENT OF DEPRESSION: PSYCHOPHYSICAL MEASURES AND CLINICAL RESPONSE. 002375 03-07

A COMPARATIVE STUDY OF MAPROTILINE (LUDIOMIL) AND VILOXAZINE IN THE MANAGEMENT OF DEPRESSED PATIENTS IN GENERAL PRACTICE.

VILOXAZINE, SLEEP, AND SUBJECTIVE FEELINGS.

002447 03-09 002609 03-14

THE EFFECTS OF TWO ANTIDEPRESSANTS, IMIPRAMINE AND VILOXAZINE, UPON DRIVING PERFORMANCE.

THE EFFECT OF VILOXAZINE HYDROCHLORIDE ON THE TRANSPORT OF NORADRENALINE, DOPAMINE, 5 HYDROXYTRYPTAMINE AND GAMMA-AMINOBUTYRIC-ACID IN RAT BRAIN TISSUE.

003001 04-03 VILOXAZINE AND AMITRIPTYLINE IN DEPRESSIVE ILLNESS: A DOUBLE-BLIND CONTROLLED TRIAL IN GENERAL PRACTICE.

003506 04-09

VINCAMINE
INFLUENCE OF VINCAMINE AND PIRACETAM ON SLEEP-WAKING PATTERN
OF THE CAT. 002925 04-03

RETROSPECTIVE DIAGNOSIS OF HYPOMANIA FOLLOWING SUCCESSFUL TREATMENT OF EPISODIC VIOLENCE WITH LITHIUM: A CASE REPORT. 003490 04-09 PHARMACOLOGIC MANAGEMENT OF HUMAN VIOLENCE 003558 04-11

LONG-TERM ELIMINATION OF VIOLENT BEHAVIOUR BY THE INTERACTION OF PSYCHOPHARMACOLOGIC AND PSYCHOSOCIAL THERAPY.

001333 02-04 VIOLENT DYSCONTROL RESPONSIVE TO D AMPHETAMINE 002528 03-11

EFFECT OF VASOACTIVE INTESTINAL PEPTIDE (VIP) AND OTHER PEPTIDES ON C-AMP ACCUMULATION IN RAT BRAIN.

003056 04-03

VISCERAL

EFFECT OF NARCOTICS ON CONDUCTION OF AFFERENT VISCERAL
IMPULSES.

0010 001083 02-03

TREATING BLURRED VISION ASSOCIATED WITH ANTIPSYCHOTIC

000810 01-15 PUPILLARY ABNORMALITIES IN SCHIZOPHRENIC PATIENTS DURING LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS: DISSOCIATION BETWEEN LIGHT AND NEAR VISION REACTIONS.

003673 04-15

VOLUME 16, SUBJECT INDEX

Subject Index

002069 03-03

VISUAL	
VISUAL EVOKED REPONSES IN CHRONIC HASHISH USERS.	000700 01 10
NEUROPHYSIOLOGY, NEUROPHARMACOLOGY AND BEHAVI RELATIONSHIPS OF VISUAL SYSTEM EVOKED AFTER-DISC REVIEW.	000722 01-13 IORAL CHARGES: A
DIFFERENTIAL EFFECTS OF SUBCORTICAL LYSERGIC-ACID-DI AND SEROTONIN ON VISUAL CORTICAL EVOKED-POTENT	IALS.
SUPPRESSION BY NITROUS-OXIDE OF VISUAL RESPONSES I CEREBELLAR VERMIS AND SUPERIOR COLLICULUS OF CA ANESTHETIZED WITH CHLORALOSE.	TS
LOCAL PERFUSION OF NORADRENALINE MAINTAINS VISUA PLASTICITY.	002897 04-03 L CORTICAL
HEMISPHERIC ASYMMETRY OF VISUAL EVOKED-POTENTIAL MOTOR IMBALANCE IN RATS.	003045 04-03 LS WITH
DORSOMEDIAL THALAMIC LESIONS AND AMPHETAMINE: AND RETENTION OF A VISUAL PATTERN DISCRIMINATIO TASK.	
	003399 04-04
THE EFFECTS OF PHENCYCLIDINE ON VISUALLY EVOKED-PO	TENTIALS OF
RHESUS MONKEYS.	002306 03-04
DIFFERENTIAL EFFECTS OF CONVULSANTS ON VISUALLY EV RESPONSES IN THE ALBINO RAT.	
	003171 04-04
STUDY OF THE INFLUENCE OF VITAMIN SUPPLEMENTS ON	THE BEHAVIOR
OF PSYCHIATRIC PATIENTS.	003624 04-14
VITAMIN-96 EFFECT OF CHRONIC LEVODOPA ON VITAMIN-86 METABOL	
DISCRETE REGIONS OF RAT BRAIN.	
VIVALAN	001105 02-03
A SEQUENTIAL TRIAL OF VILOXAZINE (VIVALAN) AND IMI MODERATELY DEPRESSED PATIENTS.	
VIA	000563 01-0
IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4- HYDROXYPHENYLLACTIC-ACID (VLA) IN CEREBROSPINAI METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN ' PARKINSONIAN PATIENTS TREATED WITH L-DOPA.	THE URINE OF
VAIH	003602 04-1
REDUCTION OF VMH LESION-INDUCED HYPEREMOTIONALIT ANTINOCICEPTION BY DIAZEPAM.	Y AND
VOCALIZATIONS	002211 03-0
AMPHETAMINE AND CHICK BEHAVIOUR: A ROLE FOR MOI THE CAUSATION OF VOCALIZATIONS AND EMOTIONS.	NOAMINES IN
	001342 02-0
VOLUNTARY VOLUNTARY ETHANOL DRINKING BY THE RAT: EFFECTS OF AMINOETHYLISOTHIOURONIUM SALT, A MODIFIER OF A NORELEAGNINE A BETA-CARBOLINE DERIVATIVE.	IAD:NADH AND
VOLUNTEER	000200 01-0
THE EFFECTS OF FOUR ANTIHYPERTENSIVE AGENTS ON THI COLOUR WORD TEST IN NORMAL MALE VOLUNTEER SU	
PHARMACOKINETICS OF OXAZEPAM IN HEALTHY VOLUNT	EERS. 000685 01-1
PHARMACOKINETICS OF N DESMETHYLDIAZEPAM IN HEAI VOLUNTEERS AFTER SINGLE DAILY DOSES OF DIPOTASS CHLORAZEPATE.	IUM
THE EFFECT OF A NEW BENZODIAZEPINE ON THE POLYGRA MONITORED SLEEP OF NORMAL VOLUNTEERS.	000728 01-1 APHICALLY

RESPONSES TO INTRAVENOUS HEROIN IN DEPENDENT AND

ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN YOUNG AND

DIFFERENCES IN THE EFFECTS OF CLOMIPRAMINE ON ENGLISH AND ASIAN VOLUNTEERS. PRELIMINARY REPORT ON A PILOT STUDY.

THE PSILOCYBIN-INDUCED STATE OF DRUNKENNESS IN NORMAL

THE EFFECTS OF ACTH4-10 VERSUS PLACEBO IN THE MEMORY OF SYMPTOMATIC GERIATRIC VOLUNTEERS.

NONDEPENDENT VOLUNTEERS.

ELDERLY MALE VOLUNTEERS

VOLUNTEERS AND SCHIZOPHRENICS.

ANTICHOLINERGIC ACTIVITY OF THE TRICYCLIC ANTIDEPRESSANTS DESIPRAMINE AND DOXEPIN IN NONDEPRESSED VOLUNTEERS 003447 04-07 ALOSTERIC CHANGES IN PLASMA PROTEINS IN HEALTHY VOLUNTEERS AFTER ADMINISTRATION OF LYSERGAMIDE. 003584 04-12 VOMERONASAL ROLES OF THE VOMERONASAL AND OLFACTORY SYSTEMS IN COURTSHIP BEHAVIOR OF MALE GARTER SNAKES. 003268 04-04 VOMITING LITHIUM TREATMENT OF CYCLICAL VOMITING IN A MENTALLY DEFECTIVE PATIENT. 000977 01-17 AN APOMORPHINE-INDUCED VOMITING MODEL FOR ANTIEMETIC STUDIES 002722 03-16 IDENTIFICATION AND QUANTIFICATION OF 3 METHOXY-4-HYDROXYPHENYLLACTIC-ACID (VLA) IN CEREBROSPINAL FLUID AND 3
METHOXY-4-HYDROXYPHENYLPYRUVIC-ACID (VPA) IN THE URINE OF PARKINSONIAN PATIENTS TREATED WITH L-DOPA. 003602 04-13 VULNERABILITY EFFECTS OF CLONIDINE ON VULNERABILITY TO FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE VENTRICLE. WAKEFULNESS UPTAKE AND METABOLISM OF INTRAVENTRICULARLY ADMINISTERED PIPERIDINE AND ITS EFFECTS ON SLEEP AND WAKEFULNESS IN THE EFFECTS OF DIPROPYLACETATE ON WAKEFULNESS AND SLEEP IN HUMAN WAKING STAGE-1 REM OBSERVED IN PARANOID HALLUCINATORY STATES OF NARCOLEPSY. 002675 03-15 THE NEW WAR ON PAIN. 000943 01-17 WARD CONTRIBUTION OF THE USE OF 1035MD IN A PSYCHIATRIC WARD FOR ADULTS. ITS ACTIVITY ON THE DIRECT AND SIDE-EFFECTS OF WASHED EFFECTS OF RESERPINE AND SEROTONIN ON ADENINE-NUCLEOTIDE METABOLISM AND GLUCOSE OXIDATION OF WASHED RABBIT PLATELETS. 000237 01-03 EFFECT OF RESERPINE ON ADENOSINE UPTAKE AND METABOLISM, AND SUBCELLULAR TRANSPORT OF PLATELET ADENOSINE-TRIPHOSPHATE IN WASHED RABBIT PLATELETS. 000238 01-03 WATER SCHEDULE-INDUCED WATER AND SACCHARIN POLYDIPSIA UNDER HALOPERIDOL. 000390 01-04 EFFECTS OF PCPA ON THE CONSUMPTION OF ALCOHOL, WATER AND OTHER SOLUTIONS 000469 01-04 THE EFFECTS OF ALCOHOL UPON COOLING RATES OF HUMANS IMMERSED IN 7.5 DEGREES C WATER. 002541 03-12 BENZODIAZEPINES AND BEHAVIORAL EFFECTS OF REWARD (WATER) OMISSION IN THE RAT. 003364 04-04 AGGRESSION INCREASE AND WATER COMPETITION DECREASE IN SQUIRREL-MONKEYS GIVEN PHYSOSTIGMINE INJECTIONS. 003377 04-04 EFFECT OF PIMOZIDE ON THE IMPROVEMENT IN LEARNING PRODUCED BY SELF-STIMULATION AND BY WATER REINFORCEMENT. 003394 04-04 DIETARY EFFECTS UPON FOOD AND WATER INTAKE AND RESPONSIVENESS TO ESTROGEN, 2 DEOXYGLUCOSE AND GLUCOSE IN FEMALE RATS 003402 04-04 WATER-SOLUBLE THE EFFECTS OF SP-111, A WATER-SOLUBLE THC DERIVATIVE, ON NEURONAL ACTIVITY IN THE RAT BRAIN. 002150 03-03 THE RELATIONSHIP BETWEEN CORTICAL RECRUITING RESPONSES AND PONTO-GENICULO-OCCIPITAL (PGO) WAVES DURING PARADOXICAL SLEEP AND AFTER THE ADMINISTRATION OF RESERPINE IN THE CAT

000765 01-14

000792 01-14

001689 02-13

001726 02-14

002646 03-15

POTENTIAL ANTIPSYCHOTIC DRUG -- MEZILAMINE SYSTEMS OF A NEW POTENTIAL ANTIPSYCHOTIC DRUG -- MEZILAMINE -- WITH WEAK CATALEPTOGENIC PROPERTIES.

002800 04-02

WEAKNESS

EFFECTS OF AMPHETAMINE ON ENDURANCE PERFORMANCE AND MUSCLE
WEAKNESS IN RATS. 001363 02-04

5,7 DIHYDROXYTRYPTAMINE LESIONS: EFFECTS ON BODY WEIGHT, IRRITABILITY, AND MURICIDE.

000430 01-04 EFFECTS OF ANGIOTENSIN-II ON SCHEDULE-DEPENDENT AND INDUCED BEHAVIOR AT RECOVERED BODY WEIGHT.

000470 01-04 EFFECTS OF 6 HYDROXYDOPAMINE ON BODY WEIGHT: FEEDING DEFICITS OR SENSORY-MOTOR IMPAIRMENTS?. 001432 02-04

AN ATTEMPT TO PREDICT THE DURATION OF PENTOBARBITAL NARCOSIS ON THE BASIS OF EXPLORATORY ACTIVITY, DEFECATION RATE AND BODY WEIGHT OF RATS.

001435 02-04 MEASUREMENTS OF WEIGHT AND ACTIVITY IN MALE MICE FOLLOWING INHALATION OF CANNABIS SMOKE IN A CONTROLLED SMOKE EXPOSURE CHAMBER.

001524 02-05 PLASMA FENFLURAMINE LEVELS, WEIGHT LOSS, AND SIDE-EFFECTS 001790 02-15 WEIGHT LOSS AND A CONCOMITANT CHANGE IN PLASMA TRICYCLIC LEVELS

002441 03-09 SENSITIVITY TO APOMORPHINE IN THE GUINEA-PIG AS A FUNCTION OF AGE AND BODY WEIGHT.

003182 04-04 DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF BUPROPION-HYDROCHLORIDE (WELLBATRIN) IN THE TREATMENT OF DEPRESSED

002430 03-09

INHIBITION OR WET SHAKES DURING MORPHINE ABSTINENCE BY AN ANTAGONIST OF OPIATE ANALGESIA.

003383 04-04 WET-DOG SNAKE BEHAVIOUR IN THE RAT: A POSSIBLE QUANTITATIVE MODEL OF CENTRAL 5 HYDROXYTRYPTAMINE ACTIVITY.

001310 02:

001310 02-04

EFFECTS OF METHYLPHENIDATE (M) ON ACTIVITY OF WHIRLER MICE 001450 02-04

FACTORS INFLUENCING WILLINGNESS TO COMPLY AND ACTUAL COMPLIANCE WITH MEDICATION REGIMENS. (PH.D. DISSERTATION) 003722 04-17

WIN-27147-2 IN THE TREATMENT OF DEPRESSION: AN UNCONTROLLED CLINICAL STUDY

A CONTROLLED STUDY OF WIN-27147-2 IN THE TREATMENT OF DEPRESSION A CONTROLLED TRIAL OF A NEW ANTIDEPRESSANT, WIN-27147-2.

003523 04-09

WIN-35197-2
CHANGES IN LOCOMOTOR ACTIVITY AND NALOXONE-INDUCED JUMPING
IN MICE PRODUCED BY WIN-35197-2 (ETHYLKETAZOCINE) AND 003376 04-04

APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR, LOCOMOTOR STIMULATION AND HYPOTHERMIA IN SPONTANEOUS HYPERTENSIVE RATS AND NORMOTENSIVE WISTAR RATS. 001413 02-04

WITHDRAWAL ALTERATIONS IN BRAIN 5 HYDROXYTRYPTAMINE METABOLISM DURING THE WITHDRAWAL PHASE AFTER CHRONIC TREATMENT WITH DIAZEPAM AND BROMAZEPAM.

000038 01-03 NALOXONE PRECIPITATED WITHDRAWAL AS A FUNCTION OF THE MORPHINE NALOXONE INTERVAL. 000185 01-03

EVIDENCE FOR WITHDRAWAL FROM CAFFEINE BY RATS 000467 01-04 **EFFECTS OF TAURINE ON ALCOHOL WITHDRAWAL**

000636 01-11 WITHDRAWAL FROM CANNABIS: PSYCHOPHYSIOLOGICAL CHANGES. 000688 01-13

Psychopharmacology Abstracts

000799 01-15

WITHDRAWAL FROM CANNABIS: LABORATORY TESTS AND CLINICAL OBSERVATIONS.

000748 01-14 WITHDRAWAL FROM CANNABIS: PSYCHOLOGICAL TEST PERFORMANCE. 000760 01-14 WITHDRAWAL OF A STIMULANT DRUG AND CONCURRENT BEHAVIORAL INTERVENTION IN THE TREATMENT OF A HYPERACTIVE CHILD.

000780 01-14 RIFAMPICIN AND METHADONE WITHDRAWAL

NEONATAL WITHDRAWAL SYNDROME ASSOCIATED WITH HYDROXYZINE HYDROCHLORIDE.

000884 01-15 METHODS OF WITHDRAWAL STUDY.

000921 01-16 CYCLIC-GMP AND GABA LEVELS IN RAT STRIATUM AND CEREBELLUM DURING MORPHINE WITHDRAWAL: EFFECT OF APOMORPHINE.

001274 02-03 CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT RHESUS MONKEYS

001296 02-04 DIAZEPAM MAINTENANCE OF ALCOHOL PREFERENCE DURING ALCOHOL WITHDRAWAL

001345 02-04 EFFECT OF BARBITURATE WITHDRAWAL ON PENTYLENETETRAZOL SEIZURE THRESHOLD

001364 02-04 EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE INTOXICATION ON EXPLORATORY AND STEREOTYPED BEHAVIORS IN THE RAT.

001379 02-04 NALOXONE INTERACTION WITH NEUROLEPTIC-INDUCED SUPPRESSION OF NARCOTIC WITHDRAWAL

001381 02-04 NALOXONE PRECIPITATED WITHDRAWAL REVEALS SENSITIZATION TO NEUROTRANSMITTERS IN MORPHINE-TOLERANT/DEPENDENT RATS.

001456 02-04 URINARY CYCLIC-AMP EXCRETION BY METHADONE SUBJECTS DURING GRADUAL AND ACUTE WITHDRAWAL.

001654 02-13 LATE WITHDRAWAL SYMPTOMS IN BABIES BORN TO METHADONE **ADDICTS**

001756 02-15 SELECTION AMONG BENZODIAZEPINES FOR ALCOHOL WITHDRAWAL

001906 02-17 TIME-COURSE OF AUDIOGENIC SEIZURE SUSCEPTIBILITY AND PLASMA PENTOBARBITAL CONCENTRATION DURING WITHDRAWAL.

001977 03-03 EFFECT OF ALPHA-METHYL-P-TYROSINE ON THE INCIDENCE OF SPONTANEOUS CONVULSIONS OBSERVED FOLLOWING BARBITAL WITHDRAWAL

002104 03-03 **OPIATE WITHDRAWAL SIGNS IN SINGLE MYENTERIC NEURONES**

002118 03-03 PHYSICAL DEPENDENCE TO BARBITAL COMPARED TO PENTOBARBITAL.

III. WITHDRAWAL CHARACTERISTICS.

002199 03-04 THE IMPACT OF CLOMIPRAMINE AND ITS WITHDRAWAL ON SOME NOCTURNAL HORMONE PROFILES -- A PRELIMINARY REPORT.

002572 03-13 **NEUROCHEMISTRY OF WITHDRAWAL EMERGENT SYMPTOMS IN**

002602 03-13 RESIDUAL EFFECTS OF ETHANOL AND CHLORDIAZEPOXIDE TREATMENTS FOR ALCOHOL WITHDRAWAL

002617 03-14 WITHDRAWAL PSYCHOSIS AFTER DRUGS 002663 03-15

POSSIBLE WITHDRAWAL FROM ENDOGENOUS OPIATES IN SCHIZOPHRENICS.

002666 03-15 THE EFFECT OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF AMPHETAMINE ON CEREBRAL DOPAMINE RECEPTOR SENSITIVITY 002964 04-03

EFFECTS OF ETHANOL WITHDRAWAL, STRESS AND AMPHETAMINE ON RAT BRAIN NA-K-ATPASE.

003060 04-03 CAFFEINE ELICITED WITHDRAWAL SIGNS IN MORPHINE-DEPENDENT RHESUS MONKEYS.

003152 04-04 EFFECTS OF CHRONIC INGESTION AND WITHDRAWAL OF SODIUM BARBITONE ON LEARNING IN RATS.

003273 04-04 THE EFFECTS OF ATROPINE ON THE TOLERANCE AND THE CONVULSIONS SEEN AFTER WITHDRAWAL FROM FORCED BARBITAL DRINKING IN THE RAT.

003389 04-04 BEHAVIOR THERAPY AND WITHDRAWAL OF STIMULANT MEDICATION IN HYPERACTIVE CHILDREN.

003566 04-11

VOLUME 16, SUBJECT INDEX

DISAPPEARANCE OF CHLORPROMAZINE FROM PLASMA FOLLOWING DRUG WITHDRAWAL.

003605 04-13 CLONIDINE BLOCKS ACUTE OPIATE WITHDRAWAL SYMPTOMS 003628 04-14 WITHDRAWAL SYNDROMES ASSOCIATED WITH ANTIPSYCHOTIC DRUGS. 003655 04-15

CAN PHENYTOIN BE GRADUALLY WITHDRAWN IN PATIENTS WITH MAJOR MOTOR EPILEPSY MAINTAINED ON CLONAZEPAM AND PHENOBARBITAL?

002504 03-11

000996 01-17

RELATIONSHIPS BETWEEN CLINICAL AND BIOCHEMICAL EFFECTS OF MELPERONE AND THIOTHIXENE IN PSYCHOTIC WOMEN.

001557 02-08 EFFECT OF EXOGENOUS ESTROGENS ON DEPRESSION IN MENOPAUSAL

001603 02-09 CLINICAL AND BIOCHEMICAL CHANGES IN PSYCHOTIC WOMEN TREATED WITH MELPERONE OR THIOTHIXENE

002388 03-08 EFFECTS OF MELPERONE AND THIOTHIXENE ON PROLACTIN LEVELS IN CEREBROSPINAL FLUID AND PLASMA OF PSYCHOTIC WOMEN.

002547 03-13 EFFECTS OF METHADONE ON RESPIRATION AND HEMODYNAMICS OF PREGNANT WOMEN.

002628 03-14 EFFECTS OF MSH/ACTH4-10 ON MEMORY, ATTENTION, AND ENDOGENOUS HORMONE LEVELS IN WOMEN.

002641 03-14 EFFECTS OF PERPHENAZINE-ENANTHATE INJECTIONS ON PROLACTIN LEVELS IN PLASMA FROM SCHIZOPHRENIC WOMEN AND MEN. 003462 04-08

WORD

THE EFFECTS OF FOUR ANTIHYPERTENSIVE AGENTS ON THE STROOP COLOUR WORD TEST IN NORMAL MALE VOLUNTEER SUBJECTS. 000771 01-14

WORD ASSOCIATION TIMES, FELT EFFECTS, AND PERSONALITY CHARACTERISTICS OF SCIENCE STUDENTS GIVEN A PLACEBO

002611 03-14

MARIJUANA: EFFECTS ON FREE RECALL AND SUBJECTIVE ORGANIZATION OF PICTURES AND WORDS.

002629 03-14 WORK HOW BENZODIAZEPINES WORK

WHEN ANTIDEPRESSANTS DONT WORK.

003525 04-09 PSYCHIATRIC DRUGS FOR THE NONMEDICAL MENTAL HEALTH WORKER

000953 01-17

AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL EFFECT: A WORLD HEALTH ORGANIZATION COLLABORATIVE STUDY. 002426 03-09

TWO CASES OF DELUSION OF WORM INFESTATION. 002487 03-10

WORTH THE SEARCH FOR A NONADDICTING ANALGESIC: HAS IT BEEN WORTH

000025 01-02 WOUND CARBACHOL ELICITED MOUSE-KILLING IN THE RAT: ANIMALS ATTACKED

AND WOUND LOCATION. 000349 01-04 X-CHROMOSOME

LINKAGE BETWEEN AN X-CHROMOSOME MARKER (DEUTAN COLOR BLINDNESS) AND BIPOLAR AFFECTIVE-ILLNESS; OCCURRENCE IN THE FAMILY OF A LITHIUM-CARBONATE RESPONSIVE SCHIZOAFFECTIVE PROBAND

000619 01-11 YAWNING

DRUGS AFFECTING DOPAMINE NEURONS AND YAWNING BEHAVIOR 001422 02-04 INCREASE OF HIPPOCAMPAL ACETYLCHOLINE TURNOVER RATE AND THE STRETCHING YAWNING SYNDROME ELICITED BY ALPHA-MSH AND ACTH. 002644 03-14

YOHIMBINE PHARMACOLOGICAL AND BIOCHEMICAL PROPERTIES OF ISOMERIC YOHIMBINE ALKALOIDS. 002987 04-03

YOUNG INHIBITION OF GROWTH IN YOUNG MICE TREATED WITH D.L. METHADONE 000270 01-03 Subject Index

PLASMA NORTRIPTYLINE AND CARDIAC RESPONSES IN YOUNG AND OLD

000479 01-05
PHARMACOKINETIC OBSERVATIONS OF PHENYTOIN DISPOSITION IN THE NEWBORN AND YOUNG INFANT.

EFFECTS OF MAGNESIUM PEMOLINE ON PATTERN DISCRIMINATION LEARNING IN YOUNG RATS.

001425 02-04 ABSORPTION AND DISPOSITION OF CHLORDIAZEPOXIDE IN YOUNG AND **ELDERLY MALE VOLUNTEERS.**

A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE SHORT-TERM EFFECTS
OF CLOZAPINE UPON SLEEP PARAMETERS OF NORMAL YOUNG

COMPARATIVE TOXICITY OF CAFFEINE AND AMINOPHYLLINE IN YOUNG AND ADULT RATS

A PSYCHOPHYSIOLOGICAL INVESTIGATION OF THE LONG-TERM EFFECTS
OF CLOZAPINE UPON SLEEP PATTERNS OF NORMAL YOUNG ADULTS.
002640 03-14

TISSUE DISTRIBUTION OF RADIOACTIVITY AFTER INJECTION OF C14
NITRAZEPAM IN YOUNG AND OLD RATS. 002948 04-03

PSYCHOSIS IN YOUNG DOCTORS.

003709 04-17 PLACEBO AND SLEEP PATTERNS OF NORMAL YOUNG ADULTS 003729 04-17

EFFECT OF HYPOCHOLESTEROLEMIC AGENTS ON CENTRAL-NERVOUS SYSTEM CHOLESTEROL BIOSYNTHESIS. III. ZUCLOMIPHENE IN

COMBINATION WITH AY9944 AND TRIPARANOL 003058 04-03

RELATIVE CONCENTRATIONS OF ZWITTERIONIC AND UNCHARGED SPECIES IN CATECHOLAMINES AND THE EFFECT OF N SUBSTITUENTS. 000117 01-03

OXODIHYDROBENZODIAZEPINES
SYNTHESIS AND PHARMACOLOGIC STUDY OF 1 OXODIHYDROBENZODIAZEPINES

000005 01-01 CONTRIBUTION OF THE USE OF 1035MD IN A PSYCHIATRIC WARD FOR ADULTS, ITS ACTIVITY ON THE DIRECT AND SIDE-EFFECTS OF NEUROL EPTICS

003446 04-07 OPTIMAL TRAINING COMPARTMENT DESIGN, SCHEDULE OF

REINFORCEMENT AND SHAPING PROCEDURES TO ESTABLISH 2-BAR OPERANT DRUG DISCRIMINATIONS. 003434 04-06

CENTRAL TRYPTAMINERGIC EFFECTS OF 26-059. A NOVEL SEROTONIN DERIVATIVE. 000036 01-02

5-HIAA THE ACTIONS OF NEUROLEPTIC DRUGS AND PUTATIVE SEROTONIN RECEPTOR ANTAGONISTS ON LSD AND QUIPAZINE-INDUCED REDUCTIONS OF BRAIN 5-HIAA CONCENTRATIONS.

001150 02-03 DIRECT EVIDENCE FOR AN INTERACTION OF BETA-ADRENERGIC BLOCKERS WITH THE 5-HT RECEPTOR

000010 01-01 QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS IN A SERIES OF SELECTIVE 5-HT UPTAKE INHIBITORS.

000057 01-03 5-HT ANTAGONISTS INHIBIT NEUROLEPTIC AND MORPHINE ANTAGONISM OF THE HYPERACTIVITY INDUCED BY DOPAMINE FROM THE NUCLEUS-ACCUMBENS.

ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEDDMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR

000086 01-03 5-HT AND MORPHINE INTERACTION, EFFECTS ON SENSORY INPUT IN CAUDATE NUCLEUS AND SUBSTANTIA-NIGRA.

000089 01-03 BEHAVIORAL SENSITIVITY TO LSD: DEPENDENCY UPON THE PATTERN OF CENTRAL 5-HT DEPLETION. 000388 01-04

INHIBITION OF BOTH MAO-A AND MAO-B REQUIRED FOR THE PRODUCTION OF HYPERMOTILITY IN MICE WITH THE 5-HT UPTAKE INHIBITORS CHLORIMIPRAMINE AND FEMOXETINE.

000398 01-04 UPTAKE OF 5 METHOXYTRYPTOLINE (6 MEO-TETRAHYDRO-BETA-CARBOLINE) BY BLOOD PLATELETS AND ITS EFFECT ON 5-HT UPTAKE AND RELEASE

001043 02-03

THE EFFECTS OF CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE ON THE IN VITRO UPTAKE OF RADIOLABELLED 5-HT AND NORADRENALINE INTO RAT BRAIN CORTICAL SLICES.

001257 02-03

003284 04-04

THE ROLE OF HYPOTHALAMIC SEROTONIN (5-HT) BEFORE OVULATION IN IMMATURE RATS TREATED WITH PREGNANT MARE SERUM (PMS). 001287 02-03

INFLUENCE OF THE NEW 5-HT UPTAKE INHIBITOR PAROXETINE ON HYPERMOTILITY IN RATS PRODUCED BY P-CHLOROAMPHETAMINE (PCA) AND 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77).

003271 04-04 CHLORIMIPRAMINE INHIBITION OF MURICIDE: THE ROLE OF THE ASCENDING 5-HT PROJECTION.

EFFECTS OF L DIHYDROXYPHENYLALANINE (L-DOPA) AND DL,5 HYDROXYTRYPTOPHAN (DL,5-HTP) ON RESERPINE-INDUCED AMNESIA 000427 01-04

5-MEODMT

ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEDOM'T FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR.

000086 01-03

ROTATIONAL RESPONSES TO THE PUTATIVE SEROTONIN AGONIST 5-MEDOMT FOLLOWING UNILATERAL 5-6-DHT LESIONS OF THE MEDIAN FOREBRAIN BUNDLE: A POSSIBLE ROLE FOR 5-HT IN THE CONTROL OF ROTATIONAL BEHAVIOUR.

000086 01-03

Psychopharmacology Abstracts

CLEARANCE AND ANALGESIC ACTIVITY OF THE QUATERNIZED OPIATE, N METHYLMORPHINE (6-H3) ADMINISTERED INTRACISTERNALLY TO THE RAT.

003019 04-03

6-OHDA

6-OHDA AND ITS ANALOGUES: CHEMICAL MECHANISM OF NEUROTOXICITY. STUDY OF THE OXIDATION OF ORTHO-SUBSTITUTED DOPAMINES.

000059 01-03

SPECIFICITY OF LEARNING DEFICITS PRODUCED BY MICROINJECTIONS OF 6-OHDA INTO THE NIGROSTRIATAL SYSTEM OF THE RAT.

000346 01-04

9ALPHA-FLUOROHYDROCORTISONE
HYPOTONIC CIRCULATORY DISORDERS UNDER
PSYCHOPHARMACOTHERAPY — TREATMENT WITH 9ALPHA-FLUOROHYDROCORTISONE.

002710 03-15

PERCHOPHARMACOLDON AVERACES

The All Control of the Control of th

PSYCHOPHARMACOLOGY ABSTRACTS

Questions about Clearinghouse service should be addressed to:

Psychopharmacology Abstracts
National Clearinghouse for Mental Health Information
Alcohol, Drug Abuse, and Mental Health Administration
5600 Fishers Lane
Rockville, Maryland 20857

For information on subscriptions and the purchase of single copies of the Abstracts (Vol. 7 onward), please refer to page ii of this issue.

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE PUBLIC HEALTH SERVICE

ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION 5600 FISHERS LANE ROCKVILLE, MARYLAND 20857

> OFFICIAL BUSINESS Penalty for private use, \$300

POSTAGE AND FEES PAID U.S. DEPARTMENT OF H.E.W. HEW 389

Fourth-Class/Book



PSA SERIASOOSCISSDUEO02R SERIALS PROCESSING UNIV HICROFILMS INTL 300 N ZEEB RD ANN ARBOR HI 48106

NOTICE OF MAILING CHANGE

- ☐ Check here if you wish to discontinue receiving this type of publication.
- Check here if your address has changed and you wish to continue receiving the type of publication. (Be sure to furnish your complete address including zip code.)

Tear off cover with address label still affixed and send to:

Alcohol, Drug Abuse, and Mental Health Administration Printing and Publications Management Section 5600 Fishers Lane (Rm. 6-105) Rockville, Maryland 20657

DHEW Publication No. (ADM) 80-150 Printed 1980

